NofPmids,NofSnps,associationType,diseaseId,diseaseName,diseaseType,disease_mention,geneId,geneSymbol,gene_mention,originalSource,pmid,raw_sentence,score,sentence,source
5,0,Biomarker,C0005695,Bladder Neoplasm,disease,bladder cancer,10,NAT2,NAT2,CTD_human,10022756,"The NAT2 slow acetylator genotype is associated with bladder cancer in Taiwanese, but not in the Black Foot Disease endemic area population.",0.24587142988000799,"The <span class=""gene"" id=""10022756-0-4-8"">NAT2</span>* slow acetylator genotype is associated with <span class=""disease"" id=""10022756-0-54-68"">bladder cancer</span> in Taiwanese, but not in the Black Foot Disease endemic area population.",CTD_human
5,0,Biomarker,C0005695,Bladder Neoplasm,disease,bladder cancer,10,NAT2,NAT2,CTD_human,18505952,"Assuming a very low prior probability of 0.000001, similar to a probability assumed for a randomly selected single-nucleotide polymorphism in a genome-wide association study, and statistical power to detect an OR of 1.5, 4 associations were considered noteworthy as denoted by an FPRP value <0.2: GSTM1 null and bladder cancer (OR, 1.5; 95% CI, 1.3-1.6; P = 1.9 x 10(-14)), NAT2 slow acetylator and bladder cancer (OR, 1.46; 95% CI, 1.26-1.68; P = 2.5 x 10(-7)), MTHFR C677T and gastric cancer (OR, 1.52; 95% CI, 1.31-1.77; P = 4.9 x 10(-8)), and GSTM1 null and acute leukemia (OR, 1.20; 95% CI, 1.14-1.25; P = 8.6 x 10(-15)).",0.24587142988000799,"Assuming a very low prior probability of 0.000001, similar to a probability assumed for a randomly selected single-nucleotide polymorphism in a genome-wide association study, and statistical power to detect an OR of 1.5, 4 associations were considered noteworthy as denoted by an FPRP value &lt;0.2: GSTM1 null and <span class=""disease"" id=""18505952-10-312-326"">bladder cancer</span> (OR, 1.5; 95% CI, 1.3-1.6; P = 1.9 x 10(-14)), <span class=""gene"" id=""18505952-10-374-378"">NAT2</span> slow acetylator and <span class=""disease"" id=""18505952-10-399-413"">bladder cancer</span> (OR, 1.46; 95% CI, 1.26-1.68; P = 2.5 x 10(-7)), MTHFR C677T and gastric cancer (OR, 1.52; 95% CI, 1.31-1.77; P = 4.9 x 10(-8)), and GSTM1 null and acute leukemia (OR, 1.20; 95% CI, 1.14-1.25; P = 8.6 x 10(-15)).",CTD_human
1,0,Biomarker,C0023903,Liver neoplasms,group,liver tumors,10,NAT2,NAT2,CTD_human,19666988,Our results are consistent with the tumor target specificity of PhIP and MeIQx and with increased susceptibility to MeIQx-induced liver tumors in rapid NAT2 acetylators.,0.209628114093152,"Our results are consistent with the tumor target specificity of PhIP and MeIQx and with increased susceptibility to MeIQx-induced <span class=""disease"" id=""19666988-9-130-142"">liver tumors</span> in rapid <span class=""gene"" id=""19666988-9-152-156"">NAT2</span> acetylators.",CTD_human
1,0,Biomarker,C0027794,Neural Tube Defects,group,NTD,10,NAT2,NAT2,CTD_human,20641098,"Mothers who consumed caffeine, oxidized CYP1A2*1F quickly, and acetylized NAT2 slowly had a nonsignificantly elevated estimated risk for an NTD-affected pregnancy (OR, 3.10; 95% CI, 0.86-11.21).",0.200274726784213,"Mothers who consumed caffeine, oxidized CYP1A2*1F quickly, and acetylized <span class=""gene"" id=""20641098-8-74-78"">NAT2</span> slowly had a nonsignificantly elevated estimated risk for an <span class=""disease"" id=""20641098-8-140-143"">NTD</span>-affected pregnancy (OR, 3.10; 95% CI, 0.86-11.21).",CTD_human
1,0,Biomarker,C0345967,Malignant mesothelioma,disease,MM,10,NAT2,NAT2,CTD_human,16697254,"Combination of NAT2 fast acetylator and GSTM1 null genotype posed a significantly increased risk of MM in the Italian, but not in the Finnish study.",0.20350593566014002,"Combination of <span class=""gene"" id=""16697254-10-15-19"">NAT2</span> fast acetylator and GSTM1 null genotype posed a significantly increased risk of <span class=""disease"" id=""16697254-10-100-102"">MM</span> in the Italian, but not in the Finnish study.",CTD_human
1,0,Biomarker,C1956346,Coronary Artery Disease,disease,coronary artery disease,10,NAT2,NAT2,CTD_human,21572414,"Variants at three of these loci have previously been linked with important clinical outcomes: SLC7A9 is a risk locus for chronic kidney disease, NAT2 for coronary artery disease and genotype-dependent response to drug toxicity, and SLC6A20 for iminoglycinuria.",0.200274726784213,"Variants at three of these loci have previously been linked with important clinical outcomes: SLC7A9 is a risk locus for chronic kidney disease, <span class=""gene"" id=""21572414-5-145-149"">NAT2</span> for <span class=""disease"" id=""21572414-5-154-177"">coronary artery disease</span> and genotype-dependent response to drug toxicity, and SLC6A20 for iminoglycinuria.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,Autism,100,ADA,adenosine deaminase,CTD_human,11354825,Autism: evidence of association with adenosine deaminase genetic polymorphism.,0.208645876648242,"<span class=""disease"" id=""11354825-0-0-6"">Autism</span>: evidence of association with <span class=""gene"" id=""11354825-0-37-56"">adenosine deaminase</span> genetic polymorphism.",CTD_human
2,0,Therapeutic,C0020452,Hyperemia,disease,hyperemia,100,ADA,adenosine deaminase,CTD_human,7949234,Combining adenosine deaminase with propranolol further reduced peak conductance and the hyperemia volume compared with enzyme pretreatment alone.,0.202681755307501,"Combining <span class=""gene"" id=""7949234-7-10-29"">adenosine deaminase</span> with propranolol further reduced peak conductance and the <span class=""disease"" id=""7949234-7-88-97"">hyperemia</span> volume compared with enzyme pretreatment alone.",CTD_human
2,0,Therapeutic,C0020452,Hyperemia,disease,hyperemia,100,ADA,Adenosine deaminase,CTD_human,2502780,Adenosine deaminase completely abolished reactive hyperemia during control perfusion but only delayed it under adrenaline perfusion.,0.202681755307501,"<span class=""gene"" id=""2502780-5-0-19"">Adenosine deaminase</span> completely abolished reactive <span class=""disease"" id=""2502780-5-50-59"">hyperemia</span> during control perfusion but only delayed it under adrenaline perfusion.",CTD_human
1,1,Biomarker,C0014175,Endometriosis,disease,endometriosis,100048912,CDKN2B-AS1,CDKN2BAS,CTD_human,20601957,A genome-wide association study identifies genetic variants in the CDKN2BAS locus associated with endometriosis in Japanese.,0.201373633921065,"A genome-wide association study identifies genetic variants in the <span class=""gene"" id=""20601957-0-67-75"">CDKN2BAS</span> locus associated with <span class=""disease"" id=""20601957-0-98-111"">endometriosis</span> in Japanese.",CTD_human
1,4,Biomarker,C0017612,"Glaucoma, Open-Angle",disease,open angle glaucoma,100048912,CDKN2B-AS1,CDKN2B-AS1,CTD_human,21532571,Genome-wide association study identifies susceptibility loci for open angle glaucoma at TMCO1 and CDKN2B-AS1.,0.20082418035263896,"Genome-wide association study identifies susceptibility loci for <span class=""disease"" id=""21532571-0-65-84"">open angle glaucoma</span> at TMCO1 and <span class=""gene"" id=""21532571-0-98-108"">CDKN2B-AS1</span>.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,hepatocellular carcinoma,100124700,HOTAIR,HOTAIR,CTD_human,21327457,Overexpression of long non-coding RNA HOTAIR predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation.,0.201098907136852,"Overexpression of long non-coding RNA <span class=""gene"" id=""21327457-0-38-44"">HOTAIR</span> predicts tumor recurrence in <span class=""disease"" id=""21327457-0-74-98"">hepatocellular carcinoma</span> patients following liver transplantation.",CTD_human
1,0,Biomarker,C0031117,Peripheral Neuropathy,group,PN,100126572,GJE1,GJE1,CTD_human,21228734,"Genes associated with immune function (CTLA4, CTSS), reflexive coupling within Schwann cells (GJE1), drug binding (PSMB1), and neuron function (TCF4, DYNC1I1) associated with bortezomib-induced PN in this study.",0.200274726784213,"Genes associated with immune function (CTLA4, CTSS), reflexive coupling within Schwann cells (<span class=""gene"" id=""21228734-10-94-98"">GJE1</span>), drug binding (PSMB1), and neuron function (TCF4, DYNC1I1) associated with bortezomib-induced <span class=""disease"" id=""21228734-10-194-196"">PN</span> in this study.",CTD_human
1,7,Biomarker,C1846059,Roifman syndrome,disease,Roifman Syndrome,100151683,RNU4ATAC,RNU4ATAC,CTD_human,26522830,Compound heterozygous mutations in the noncoding RNU4ATAC cause Roifman Syndrome by disrupting minor intron splicing.,0.40027472678421294,"Compound heterozygous mutations in the noncoding <span class=""gene"" id=""26522830-0-49-57"">RNU4ATAC</span> cause <span class=""disease"" id=""26522830-0-64-80"">Roifman Syndrome</span> by disrupting minor intron splicing.",CTD_human;ORPHANET
1,8,Biomarker,C1859452,"MICROCEPHALIC OSTEODYSPLASTIC PRIMORDIAL DWARFISM, TYPE I",disease,MOPD1,100151683,RNU4ATAC,RNU4ATAC,CTD_human,26522830,"RNU4ATAC rare variants have been recently reported to cause microcephalic osteodysplastic primordial dwarfism, type I (MOPD1), whose phenotype is distinct from Roifman Syndrome.",0.201923087489492,"<span class=""gene"" id=""26522830-4-0-8"">RNU4ATAC</span> rare variants have been recently reported to cause <span class=""disease"" id=""26522830-4-60-117"">microcephalic osteodysplastic primordial dwarfism, type I</span> (<span class=""disease"" id=""26522830-4-119-124"">MOPD1</span>), whose phenotype is distinct from Roifman Syndrome.",CTD_human
1,0,Biomarker,C0024141,"Lupus Erythematosus, Systemic",disease,SLE,10019,SH2B3,SH2B3,CTD_human,19838195,"A candidate screen of alleles previously associated with other autoimmune diseases suggested five loci (P < 1 x 10(-3)) that may contribute to SLE: IFIH1, CFB, CLEC16A, IL12B and SH2B3.",0.202681755307501,"A candidate screen of alleles previously associated with other autoimmune diseases suggested five loci (P &lt; 1 x 10(-3)) that may contribute to <span class=""disease"" id=""19838195-5-143-146"">SLE</span>: IFIH1, CFB, CLEC16A, IL12B and <span class=""gene"" id=""19838195-5-179-184"">SH2B3</span>.",CTD_human
1,0,Biomarker,C0027051,Myocardial Infarction,disease,myocardial infarction,10019,SH2B3,SH2B3,CTD_human,19198610,"We also found that a nonsynonymous SNP at 12q24, in SH2B3, associated significantly (P = 8.6 x 10(-8)) with myocardial infarction in six different populations (6,650 cases and 40,621 controls).",0.40508878383078906,"We also found that a nonsynonymous SNP at 12q24, in <span class=""gene"" id=""19198610-7-52-57"">SH2B3</span>, associated significantly (P = 8.6 x 10(-8)) with <span class=""disease"" id=""19198610-7-108-129"">myocardial infarction</span> in six different populations (6,650 cases and 40,621 controls).",CTD_human;HPO
1,37,Biomarker,C1833373,"Inclusion Body Myopathy, Autosomal Recessive",disease,autosomal recessive inclusion-body myopathy,10020,GNE,GNE,CTD_human,12473780,An Italian family with autosomal recessive inclusion-body myopathy and mutations in the GNE gene.,0.201098907136852,"An Italian family with <span class=""disease"" id=""12473780-0-23-66"">autosomal recessive inclusion-body myopathy</span> and mutations in the <span class=""gene"" id=""12473780-0-88-91"">GNE</span> gene.",CTD_human
12,23,Biomarker,C1853926,NONAKA MYOPATHY,disease,Nonaka myopathy,10020,GNE,UDP-N-acetylglucosamine-2-epimerase/N-acetylmannosamine kinase,CTD_human,11916006,Nonaka myopathy is caused by mutations in the UDP-N-acetylglucosamine-2-epimerase/N-acetylmannosamine kinase gene (GNE).,0.6178572409738521,"<span class=""disease"" id=""11916006-0-0-15"">Nonaka myopathy</span> is caused by mutations in the <span class=""gene"" id=""11916006-0-46-108"">UDP-N-acetylglucosamine-2-epimerase/N-acetylmannosamine kinase</span> gene (GNE).",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C1961102,Precursor Cell Lymphoblastic Leukemia Lymphoma,disease,acute lymphoblastic leukemia,100288687,DUX4,DUX4,CTD_human,27776115,Deregulation of DUX4 and ERG in acute lymphoblastic leukemia.,0.2,"Deregulation of <span class=""gene"" id=""27776115-0-16-20"">DUX4</span> and ERG in <span class=""disease"" id=""27776115-0-32-60"">acute lymphoblastic leukemia</span>.",CTD_human
2,0,Biomarker,C0030567,Parkinson Disease,disease,PD,100359403,PARK16,PARK16,CTD_human,19915576,"By comparing results of a GWAS performed on individuals of European ancestry, we identified PARK16, SNCA and LRRK2 as shared risk loci for PD and BST1 and MAPT as loci showing population differences.",0.20845101777597602,"By comparing results of a GWAS performed on individuals of European ancestry, we identified <span class=""gene"" id=""19915576-4-92-98"">PARK16</span>, SNCA and LRRK2 as shared risk loci for <span class=""disease"" id=""19915576-4-139-141"">PD</span> and BST1 and MAPT as loci showing population differences.",CTD_human
2,0,Biomarker,C0030567,Parkinson Disease,disease,PD,100359403,PARK16,PARK16,CTD_human,19915575,"We replicated the effect of a new locus detected in the Japanese cohort (PARK16, rs823128, OR = 0.66, P = 7.29 x 10(-8)) and provide supporting evidence that common variation around LRRK2 modulates risk for PD (rs1491923, OR = 1.14, P = 1.55 x 10(-5)).",0.20845101777597602,"We replicated the effect of a new locus detected in the Japanese cohort (<span class=""gene"" id=""19915575-5-73-79"">PARK16</span>, rs823128, OR = 0.66, P = 7.29 x 10(-8)) and provide supporting evidence that common variation around LRRK2 modulates risk for <span class=""disease"" id=""19915575-5-207-209"">PD</span> (rs1491923, OR = 1.14, P = 1.55 x 10(-5)).",CTD_human
1,0,Biomarker,C0848558,Hypospadias,disease,hypospadias,10046,MAMLD1,MAMLD1,CTD_human,21559465,"Although previous studies have indicated that MAMLD1 mutations result in hypospadias primarily because of compromised testosterone production around the critical period for fetal sex development, the underlying mechanism(s) remains to be clarified.",0.210568964137734,"Although previous studies have indicated that <span class=""gene"" id=""21559465-2-46-52"">MAMLD1</span> mutations result in <span class=""disease"" id=""21559465-2-73-84"">hypospadias</span> primarily because of compromised testosterone production around the critical period for fetal sex development, the underlying mechanism(s) remains to be clarified.",CTD_human
1,0,Biomarker,C0686353,"Muscular Dystrophies, Limb-Girdle",group,limb-girdle muscular dystrophy,10049,DNAJB6,DNAJB6,CTD_human,22366786,Mutations affecting the cytoplasmic functions of the co-chaperone DNAJB6 cause limb-girdle muscular dystrophy.,0.203021994626344,"Mutations affecting the cytoplasmic functions of the co-chaperone <span class=""gene"" id=""22366786-0-66-72"">DNAJB6</span> cause <span class=""disease"" id=""22366786-0-79-109"">limb-girdle muscular dystrophy</span>.",CTD_human
1,0,Therapeutic,C0020538,Hypertensive disease,group,high blood pressure,10052,GJC1,Cx45,CTD_human,19109587,The high blood pressure of the Cx40 knockout mice was significantly reduced when Cx45 was knocked into the locus but remained mildly elevated compared to wild-type mice.,0.2,"The <span class=""disease"" id=""19109587-6-4-23"">high blood pressure</span> of the Cx40 knockout mice was significantly reduced when <span class=""gene"" id=""19109587-6-81-85"">Cx45</span> was knocked into the locus but remained mildly elevated compared to wild-type mice.",CTD_human
1,0,Biomarker,C0003873,Rheumatoid Arthritis,disease,RA,10057,ABCC5,ABCC5,CTD_human,23897011,"Concurrent with evidence of an immune-activation gene signature in MTX-naive RA patients, significant up-regulation of the folate-metabolizing enzymes ?-glutamyl hydrolase and dihydrofolate reductase, as well as the MTX/folate efflux transporters ABCC2 and ABCC5, was observed in the MTX-naive RA group compared to healthy controls.",0.200274726784213,"Concurrent with evidence of an immune-activation gene signature in MTX-naive <span class=""disease"" id=""23897011-6-77-79"">RA</span> patients, significant up-regulation of the folate-metabolizing enzymes &gamma;-glutamyl hydrolase and dihydrofolate reductase, as well as the MTX/folate efflux transporters ABCC2 and <span class=""gene"" id=""23897011-6-257-262"">ABCC5</span>, was observed in the MTX-naive <span class=""disease"" id=""23897011-6-294-296"">RA</span> group compared to healthy controls.",CTD_human
3,9,Biomarker,C0795905,Cantu syndrome,disease,Cant? syndrome,10060,ABCC9,ABCC9,CTD_human,22610116,Dominant missense mutations in ABCC9 cause Cant? syndrome.,0.602747267842131,"Dominant missense mutations in <span class=""gene"" id=""22610116-0-31-36"">ABCC9</span> cause <span class=""disease"" id=""22610116-0-43-57"">Cant? syndrome</span>.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0015695,Fatty Liver,disease,hepatic steatosis,10062,NR1H3,LXR?,CTD_human,23651738,"Liver X receptor-? (LXR?), a member of the nuclear receptor superfamily of ligand-activated transcription factors, regulates de novo fatty acid synthesis that leads to stimulate hepatic steatosis.",0.201098907136852,"<span class=""gene"" id=""23651738-1-0-18"">Liver X receptor-&alpha;</span> (<span class=""gene"" id=""23651738-1-20-24"">LXR&alpha;</span>), a member of the nuclear receptor superfamily of ligand-activated transcription factors, regulates de novo fatty acid synthesis that leads to stimulate <span class=""disease"" id=""23651738-1-178-195"">hepatic steatosis</span>.",CTD_human
1,2,Biomarker,C1850318,Omodysplasia type 1,disease,omodysplasia,10082,GPC6,GPC6,CTD_human,19481194,Mutations in the heparan-sulfate proteoglycan glypican 6 (GPC6) impair endochondral ossification and cause recessive omodysplasia.,0.40082418035263895,"Mutations in the heparan-sulfate proteoglycan <span class=""gene"" id=""19481194-0-46-56"">glypican 6</span> (<span class=""gene"" id=""19481194-0-58-62"">GPC6</span>) impair endochondral ossification and cause recessive <span class=""disease"" id=""19481194-0-117-129"">omodysplasia</span>.",CTD_human;ORPHANET
1,0,Biomarker,C0018817,Atrial Septal Defects,group,atrial septal defect,10084,PQBP1,PQBP1,CTD_human,16740914,"The clinical similarity of our family to these patients with mutations in PQBP1, particularly the presence of microcephaly, short stature, and atrial septal defect, prompted examination of this gene.",0.4,"The clinical similarity of our family to these patients with mutations in <span class=""gene"" id=""16740914-5-74-79"">PQBP1</span>, particularly the presence of microcephaly, short stature, and <span class=""disease"" id=""16740914-5-143-163"">atrial septal defect</span>, prompted examination of this gene.",CTD_human;HPO
3,0,Biomarker,C0025958,Microcephaly,disease,microcephaly,10084,PQBP1,PQBP1,CTD_human,16740914,"The clinical similarity of our family to these patients with mutations in PQBP1, particularly the presence of microcephaly, short stature, and atrial septal defect, prompted examination of this gene.",0.20383181960166602,"The clinical similarity of our family to these patients with mutations in <span class=""gene"" id=""16740914-5-74-79"">PQBP1</span>, particularly the presence of <span class=""disease"" id=""16740914-5-110-122"">microcephaly</span>, short stature, and atrial septal defect, prompted examination of this gene.",CTD_human
3,0,Biomarker,C0025958,Microcephaly,disease,microcephaly,10084,PQBP1,PQBP1,CTD_human,15024694,Novel truncating mutations in the polyglutamine tract binding protein 1 gene (PQBP1) cause Renpenning syndrome and X-linked mental retardation in another family with microcephaly.,0.20383181960166602,"Novel truncating mutations in the <span class=""gene"" id=""15024694-0-34-71"">polyglutamine tract binding protein 1</span> gene (<span class=""gene"" id=""15024694-0-78-83"">PQBP1</span>) cause Renpenning syndrome and X-linked mental retardation in another family with <span class=""disease"" id=""15024694-0-166-178"">microcephaly</span>.",CTD_human
4,8,Biomarker,C0796135,Renpenning syndrome 1,disease,Golabi-Ito-Hall syndrome,10084,PQBP1,PQBP1,CTD_human,16740914,Golabi-Ito-Hall syndrome results from a missense mutation in the WW domain of the PQBP1 gene.,0.402472541057918,"<span class=""disease"" id=""16740914-0-0-24"">Golabi-Ito-Hall syndrome</span> results from a missense mutation in the WW domain of the <span class=""gene"" id=""16740914-0-82-87"">PQBP1</span> gene.",CTD_human;UNIPROT
4,8,Biomarker,C0796135,Renpenning syndrome 1,disease,Renpenning syndrome,10084,PQBP1,PQBP1,CTD_human,15782410,"In acknowledgement of the historical importance of the original report of Renpenning syndrome [1962], we propose that the entities with PQBP1 mutations be combined under the name of Renpenning syndrome.",0.402472541057918,"In acknowledgement of the historical importance of the original report of <span class=""disease"" id=""15782410-8-74-93"">Renpenning syndrome</span> [1962], we propose that the entities with <span class=""gene"" id=""15782410-8-136-141"">PQBP1</span> mutations be combined under the name of <span class=""disease"" id=""15782410-8-182-201"">Renpenning syndrome</span>.",CTD_human;UNIPROT
4,8,Biomarker,C0796135,Renpenning syndrome 1,disease,Renpenning syndrome,10084,PQBP1,PQBP1,CTD_human,15024694,Novel truncating mutations in the polyglutamine tract binding protein 1 gene (PQBP1) cause Renpenning syndrome and X-linked mental retardation in another family with microcephaly.,0.402472541057918,"Novel truncating mutations in the <span class=""gene"" id=""15024694-0-34-71"">polyglutamine tract binding protein 1</span> gene (<span class=""gene"" id=""15024694-0-78-83"">PQBP1</span>) cause <span class=""disease"" id=""15024694-0-91-110"">Renpenning syndrome</span> and X-linked mental retardation in another family with microcephaly.",CTD_human;UNIPROT
2,0,Biomarker,C1136249,"Mental Retardation, X-Linked",disease,X-linked mental retardation,10084,PQBP1,PQBP1,CTD_human,15024694,Novel truncating mutations in the polyglutamine tract binding protein 1 gene (PQBP1) cause Renpenning syndrome and X-linked mental retardation in another family with microcephaly.,0.21149545880499804,"Novel truncating mutations in the <span class=""gene"" id=""15024694-0-34-71"">polyglutamine tract binding protein 1</span> gene (<span class=""gene"" id=""15024694-0-78-83"">PQBP1</span>) cause Renpenning syndrome and <span class=""disease"" id=""15024694-0-115-142"">X-linked mental retardation</span> in another family with microcephaly.",CTD_human
2,0,Biomarker,C1136249,"Mental Retardation, X-Linked",disease,X-linked mental retardation,10084,PQBP1,polyglutamine binding protein 1,CTD_human,14634649,Mutations in the polyglutamine binding protein 1 gene cause X-linked mental retardation.,0.21149545880499804,"Mutations in the <span class=""gene"" id=""14634649-0-17-48"">polyglutamine binding protein 1</span> gene cause <span class=""disease"" id=""14634649-0-60-87"">X-linked mental retardation</span>.",CTD_human
1,0,Biomarker,C0021831,Intestinal Diseases,group,enteropathy,10105,PPIF,CypD,CTD_human,20668000,"In conclusion, mitochondrial CypD plays a key role in NSAID-induced enteropathy, lending itself as a potentially new therapeutic target for cytoprotective intervention.",0.2,"In conclusion, mitochondrial <span class=""gene"" id=""20668000-14-29-33"">CypD</span> plays a key role in NSAID-induced <span class=""disease"" id=""20668000-14-68-79"">enteropathy</span>, lending itself as a potentially new therapeutic target for cytoprotective intervention.",CTD_human
1,0,Biomarker,C0009324,Ulcerative Colitis,disease,ulcerative colitis,10109,ARPC2,ARPC2,CTD_human,18836448,"Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility.",0.208096423079816,"Sequence variants in IL10, <span class=""gene"" id=""18836448-0-27-32"">ARPC2</span> and multiple other loci contribute to <span class=""disease"" id=""18836448-0-71-89"">ulcerative colitis</span> susceptibility.",CTD_human
1,1,Biomarker,C0004096,Asthma,disease,asthma,10111,RAD50,RAD50,CTD_human,24241537,"Four of these, GSDMB, IL33, RAD50 and IL1RL1, were previously reported as asthma susceptibility loci, but the effect sizes for these loci in our cohort were considerably larger than in the previous genome-wide association studies of asthma.",0.201923087489492,"Four of these, GSDMB, IL33, <span class=""gene"" id=""24241537-5-28-33"">RAD50</span> and IL1RL1, were previously reported as <span class=""disease"" id=""24241537-5-74-80"">asthma</span> susceptibility loci, but the effect sizes for these loci in our cohort were considerably larger than in the previous genome-wide association studies of <span class=""disease"" id=""24241537-5-233-239"">asthma</span>.",CTD_human
2,0,Biomarker,C0002452,Amelogenesis Imperfecta,disease,AI,10117,ENAM,Enam,CTD_human,15649948,Enamelin (Enam) is essential for amelogenesis: ENU-induced mouse mutants as models for different clinical subtypes of human amelogenesis imperfecta (AI).,0.413158174887594,"<span class=""gene"" id=""15649948-0-0-8"">Enamelin</span> (<span class=""gene"" id=""15649948-0-10-14"">Enam</span>) is essential for amelogenesis: ENU-induced mouse mutants as models for different clinical subtypes of human <span class=""disease"" id=""15649948-0-124-147"">amelogenesis imperfecta</span> (<span class=""disease"" id=""15649948-0-149-151"">AI</span>).",CTD_human;HPO
2,0,Biomarker,C0002452,Amelogenesis Imperfecta,disease,amelogenesis imperfecta,10117,ENAM,enamelin,CTD_human,17652207,"These results define the ATE1 mice as a model for local hypoplastic autosomal-dominant amelogenesis imperfecta (AIH2), which is caused by enamelin truncation mutations in humans.",0.413158174887594,"These results define the ATE1 mice as a model for local hypoplastic autosomal-dominant <span class=""disease"" id=""17652207-7-87-110"">amelogenesis imperfecta</span> (AIH2), which is caused by <span class=""gene"" id=""17652207-7-138-146"">enamelin</span> truncation mutations in humans.",CTD_human;HPO
1,0,Biomarker,C0004763,Barrett Esophagus,disease,BE,1012,CDH13,CDH13,CTD_human,18729198,"These findings suggest that hypermethylation of CDH13 is a common, tissue-specific event in human EAC, occurs early during BE-associated neoplastic progression, and correlates with known clinical neoplastic progression risk factors.",0.200274726784213,"These findings suggest that hypermethylation of <span class=""gene"" id=""18729198-12-48-53"">CDH13</span> is a common, tissue-specific event in human EAC, occurs early during <span class=""disease"" id=""18729198-12-123-125"">BE</span>-associated neoplastic progression, and correlates with known clinical neoplastic progression risk factors.",CTD_human
1,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,NSCLC,1012,CDH13,CDH13,CTD_human,18337602,"In a multivariate model, promoter methylation of the cyclin-dependent kinase inhibitor 2A gene p16, the H-cadherin gene CDH13, the Ras association domain family 1 gene RASSF1A, and the adenomatous polyposis coli gene APC in tumors and in histologically tumor-negative lymph nodes was associated with tumor recurrence, independently of NSCLC stage, age, sex, race, smoking history, and histologic characteristics of the tumor.",0.201923087489492,"In a multivariate model, promoter methylation of the cyclin-dependent kinase inhibitor 2A gene p16, the <span class=""gene"" id=""18337602-5-104-114"">H-cadherin</span> gene <span class=""gene"" id=""18337602-5-120-125"">CDH13</span>, the Ras association domain family 1 gene RASSF1A, and the adenomatous polyposis coli gene APC in tumors and in histologically tumor-negative lymph nodes was associated with tumor recurrence, independently of <span class=""disease"" id=""18337602-5-335-340"">NSCLC</span> stage, age, sex, race, smoking history, and histologic characteristics of the tumor.",CTD_human
2,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,1012,CDH13,T-cadherin,CTD_human,18553387,"Upon pharmacological treatment with demethylating agent 5-aza-2'-deoxycytidine or histone deacetylase inhibitor trichostatin A, T-cadherin promoter hypermethylation and/or histone deacetylation was frequently observed in HCC samples and cell lines.",0.20902291774708104,"Upon pharmacological treatment with demethylating agent 5-aza-2'-deoxycytidine or histone deacetylase inhibitor trichostatin A, <span class=""gene"" id=""18553387-7-128-138"">T-cadherin</span> promoter hypermethylation and/or histone deacetylation was frequently observed in <span class=""disease"" id=""18553387-7-221-224"">HCC</span> samples and cell lines.",CTD_human
2,0,Biomarker,C2239176,Liver carcinoma,disease,hepatoma,1012,CDH13,T-cadherin,CTD_human,18425332,"To provide a functional link between T-cadherin promoter methylation and T-cadherin growth regulation, we used the HepG2 hepatoma cell line that exhibits T-cadherin promoter methylation.",0.20902291774708104,"To provide a functional link between <span class=""gene"" id=""18425332-8-37-47"">T-cadherin</span> promoter methylation and T-cadherin growth regulation, we used the HepG2 <span class=""disease"" id=""18425332-8-121-129"">hepatoma</span> cell line that exhibits <span class=""gene"" id=""18425332-8-154-164"">T-cadherin</span> promoter methylation.",CTD_human
1,0,Biomarker,C0023467,"Leukemia, Myelocytic, Acute",disease,AML,10125,RASGRP1,Rasgrp1,CTD_human,21441929,"We identified such mutations using a Sleeping Beauty transposon, which caused rapid-onset AML in 80% of mice with Npm1c, associated with mutually exclusive integrations in Csf2, Flt3 or Rasgrp1 in 55 of 70 leukemias.",0.20082418035263896,"We identified such mutations using a Sleeping Beauty transposon, which caused rapid-onset <span class=""disease"" id=""21441929-5-90-93"">AML</span> in 80% of mice with Npm1c, associated with mutually exclusive integrations in Csf2, Flt3 or <span class=""gene"" id=""21441929-5-186-193"">Rasgrp1</span> in 55 of 70 leukemias.",CTD_human
1,7,Biomarker,C1857355,"Leigh syndrome , French Canadian type",disease,"Leigh syndrome, French-Canadian type",10128,LRPPRC,LSFC,CTD_human,12529507,"Here we illustrate how such data sets can expedite disease-gene discovery, by using them to identify the gene causing Leigh syndrome, French-Canadian type (LSFC, Online Mendelian Inheritance in Man no.",0.6019230874894921,"Here we illustrate how such data sets can expedite disease-gene discovery, by using them to identify the gene causing <span class=""disease"" id=""12529507-3-118-154"">Leigh syndrome, French-Canadian type</span> (<span class=""gene"" id=""12529507-3-156-160"">LSFC</span>, Online Mendelian Inheritance in Man no.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0029408,Degenerative polyarthritis,disease,OA,10131,TRAP1,TRAP1,CTD_human,18784066,"As possible outputs for this antioxidant deficiency, we found an increase of intracellular reactive oxygen species generation in OA chondrocytes and also verified an OA-dependent increase in the mitochondrial tumor necrosis factor-alpha receptor-associated protein 1 (TRAP1), a chaperone with a reported reactive oxygen species antagonist role.",0.2,"As possible outputs for this antioxidant deficiency, we found an increase of intracellular reactive oxygen species generation in <span class=""disease"" id=""18784066-8-129-131"">OA</span> chondrocytes and also verified an <span class=""disease"" id=""18784066-8-166-168"">OA</span>-dependent increase in the mitochondrial tumor necrosis factor-alpha receptor-associated protein 1 (<span class=""gene"" id=""18784066-8-268-273"">TRAP1</span>), a chaperone with a reported reactive oxygen species antagonist role.",CTD_human
1,1,Biomarker,C0029401,Osteitis Deformans,disease,Paget's disease of bone,10133,OPTN,OPTN,CTD_human,20436471,"Genome-wide association study identifies variants at CSF1, OPTN and TNFRSF11A as genetic risk factors for Paget's disease of bone.",0.201923087489492,"Genome-wide association study identifies variants at CSF1, <span class=""gene"" id=""20436471-0-59-63"">OPTN</span> and TNFRSF11A as genetic risk factors for <span class=""disease"" id=""20436471-0-106-129"">Paget's disease of bone</span>.",CTD_human
1,0,Biomarker,C0028754,Obesity,disease,obesity,10135,NAMPT,NAMPT,CTD_human,23834033,Elevated microRNA-34a in obesity reduces NAD+ levels and SIRT1 activity by directly targeting NAMPT.,0.21326507482255203,"Elevated microRNA-34a in <span class=""disease"" id=""23834033-0-25-32"">obesity</span> reduces NAD+ levels and SIRT1 activity by directly targeting <span class=""gene"" id=""23834033-0-94-99"">NAMPT</span>.",CTD_human
1,6,Biomarker,C0024117,Chronic Obstructive Airway Disease,disease,chronic obstructive pulmonary disease,10144,FAM13A,FAM13A,CTD_human,20173748,Variants in FAM13A are associated with chronic obstructive pulmonary disease.,0.203846174978983,"Variants in <span class=""gene"" id=""20173748-0-12-18"">FAM13A</span> are associated with <span class=""disease"" id=""20173748-0-39-76"">chronic obstructive pulmonary disease</span>.",CTD_human
1,0,Biomarker,C0029408,Degenerative polyarthritis,disease,OA,10149,ADGRG2,GPR64,CTD_human,17568789,"HOXD10, HOXD11, HOXD13, CCL8 and LIM homeobox 2 were highly and exclusively expressed in RA and CLU, sarcoglycan-gamma, GPR64, POU3F3, peroxisome proliferative activated receptor-gamma and tripartite motif-containing 2 were expressed only in OA.",0.2,"HOXD10, HOXD11, HOXD13, CCL8 and LIM homeobox 2 were highly and exclusively expressed in RA and CLU, sarcoglycan-gamma, <span class=""gene"" id=""17568789-4-120-125"">GPR64</span>, POU3F3, peroxisome proliferative activated receptor-gamma and tripartite motif-containing 2 were expressed only in <span class=""disease"" id=""17568789-4-242-244"">OA</span>.",CTD_human
1,7,Biomarker,C1863844,Adult-onset citrullinemia type 2,disease,CTLN2,10165,SLC25A13,SLC25A13,CTD_human,16449956,"The diagnosis of CTLN2 was confirmed by elevations of plasma citrulline level (384.3 nmol/mL; normal 17-43 nmol/mL) and serum pancreatic secretory trypsin inhibitor (PSTI) (110 ng/mL; normal 4.6-12.2 ng/mL), decrease in hepatic argininosuccinate synthetase activity (5.5% of control), lack of hepatic citrin protein expression and mutations in SLC25A13 gene (compound heterozygote with S225X and Ex1-1G>A).",0.41284664632338597,"The diagnosis of <span class=""disease"" id=""16449956-7-17-22"">CTLN2</span> was confirmed by elevations of plasma citrulline level (384.3 nmol/mL; normal 17-43 nmol/mL) and serum pancreatic secretory trypsin inhibitor (PSTI) (110 ng/mL; normal 4.6-12.2 ng/mL), decrease in hepatic argininosuccinate synthetase activity (5.5% of control), lack of hepatic <span class=""gene"" id=""16449956-7-301-307"">citrin</span> protein expression and mutations in <span class=""gene"" id=""16449956-7-344-352"">SLC25A13</span> gene (compound heterozygote with S225X and Ex1-1G&gt;A).",CTD_human;ORPHANET
1,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastasis,101669767,SCHLAP1,SChLAP1,CTD_human,24076601,In vitro and in vivo gain-of-function and loss-of-function experiments indicate that SChLAP1 is critical for cancer cell invasiveness and metastasis.,0.20054945356842604,"In vitro and in vivo gain-of-function and loss-of-function experiments indicate that <span class=""gene"" id=""24076601-5-85-92"">SChLAP1</span> is critical for cancer cell invasiveness and <span class=""disease"" id=""24076601-5-138-148"">metastasis</span>.",CTD_human
1,0,Biomarker,C0025202,melanoma,disease,MM,1017,CDK2,CDK2,CTD_human,21559390,"However, three SNPs in TYR, SILV/CDK2 and ADAMTS20 genes (rs17793678, rs2069398 and rs1510521 respectively) had an overall p-value<0.05 when considering the whole DNA collection (1214 MM cases and 1296 controls).",0.216180169513938,"However, three SNPs in TYR, SILV/<span class=""gene"" id=""21559390-9-33-37"">CDK2</span> and ADAMTS20 genes (rs17793678, rs2069398 and rs1510521 respectively) had an overall p-value&lt;0.05 when considering the whole DNA collection (1214 <span class=""disease"" id=""21559390-9-184-186"">MM</span> cases and 1296 controls).",CTD_human
2,0,Biomarker,C0025149,Medulloblastoma,disease,medulloblastoma,1021,CDK6,cyclin-dependent kinase 6,CTD_human,23138228,Inhibition of cyclin-dependent kinase 6 suppresses cell proliferation and enhances radiation sensitivity in medulloblastoma cells.,0.207388912419119,"Inhibition of <span class=""gene"" id=""23138228-0-14-39"">cyclin-dependent kinase 6</span> suppresses cell proliferation and enhances radiation sensitivity in <span class=""disease"" id=""23138228-0-108-123"">medulloblastoma</span> cells.",CTD_human
1,1,Biomarker,C0796095,Opitz trigonocephaly syndrome,disease,Opitz trigonocephaly) syndrome,10225,CD96,CD96,CTD_human,17847009,"Mutations in CD96, a member of the immunoglobulin superfamily, cause a form of the C (Opitz trigonocephaly) syndrome.",0.600274726784213,"Mutations in <span class=""gene"" id=""17847009-0-13-17"">CD96</span>, a member of the immunoglobulin superfamily, cause a form of the C (<span class=""disease"" id=""17847009-0-86-116"">Opitz trigonocephaly) syndrome</span>.",CTD_human;ORPHANET;UNIPROT
1,1,Biomarker,C0038868,Progressive supranuclear palsy,disease,PSP,10228,STX6,STX6,CTD_human,21685912,"We found significant previously unidentified signals (P < 5 × 10(-8)) associated with PSP risk at STX6, EIF2AK3 and MOBP.",0.20054945356842604,"We found significant previously unidentified signals (P &lt; 5 &times; 10(-8)) associated with <span class=""disease"" id=""21685912-5-86-89"">PSP</span> risk at <span class=""gene"" id=""21685912-5-98-102"">STX6</span>, EIF2AK3 and MOBP.",CTD_human
1,0,Biomarker,C0001418,Adenocarcinoma,group,adenocarcinomas,10232,MSLN,Mesothelin,CTD_human,11751476,Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE).,0.206839458850693,"<span class=""gene"" id=""11751476-0-0-10"">Mesothelin</span> is overexpressed in the vast majority of ductal <span class=""disease"" id=""11751476-0-59-74"">adenocarcinomas</span> of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE).",CTD_human
3,0,Biomarker,C0025500,Mesothelioma,disease,mesothelioma,10232,MSLN,mesothelin,CTD_human,11751476,"Using an online SAGE database (http://www.ncbi.nlm.gov/SAGE), we found the tag for mesothelin to be consistently present in the mesothelioma, ovarian cancer, and pancreatic cancer libraries but not in normal pancreas libraries.",0.22928092289226398,"Using an online SAGE database (http://www.ncbi.nlm.gov/SAGE), we found the tag for <span class=""gene"" id=""11751476-5-83-93"">mesothelin</span> to be consistently present in the <span class=""disease"" id=""11751476-5-128-140"">mesothelioma</span>, ovarian cancer, and pancreatic cancer libraries but not in normal pancreas libraries.",CTD_human
3,0,Biomarker,C0025500,Mesothelioma,disease,mesotheliomas,10232,MSLN,mesothelin,CTD_human,20933535,It has been reported that serum concentrations of megakaryocyte potentiating factor N-ERC/mesothelin become elevated in patients with mesotheliomas caused by asbestos exposure.,0.22928092289226398,"It has been reported that serum concentrations of <span class=""gene"" id=""20933535-3-50-83"">megakaryocyte potentiating factor</span> N-ERC/<span class=""gene"" id=""20933535-3-90-100"">mesothelin</span> become elevated in patients with <span class=""disease"" id=""20933535-3-134-147"">mesotheliomas</span> caused by asbestos exposure.",CTD_human
1,0,Biomarker,C0206698,Cholangiocarcinoma,disease,cholangiocarcinomas,10232,MSLN,mesothelin,CTD_human,14576474,"The mesothelin expression in about one-third of the cholangiocarcinomas, but not in hepatomas, suggests that this marker may have some utility in distinguishing between these two malignancies when they are poorly differentiated.",0.200274726784213,"The <span class=""gene"" id=""14576474-14-4-14"">mesothelin</span> expression in about one-third of the <span class=""disease"" id=""14576474-14-52-71"">cholangiocarcinomas</span>, but not in hepatomas, suggests that this marker may have some utility in distinguishing between these two malignancies when they are poorly differentiated.",CTD_human
1,1,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,T2D,10239,AP3S2,AP3S2,CTD_human,21874001,"In the combined analysis, we identified common genetic variants at six loci (GRB14, ST6GAL1, VPS26A, HMG20A, AP3S2 and HNF4A) newly associated with T2D (P = 4.1 × 10(-8) to P = 1.9 × 10(-11)).",0.20082418035263896,"In the combined analysis, we identified common genetic variants at six loci (GRB14, ST6GAL1, VPS26A, HMG20A, <span class=""gene"" id=""21874001-4-109-114"">AP3S2</span> and HNF4A) newly associated with <span class=""disease"" id=""21874001-4-148-151"">T2D</span> (P = 4.1 &times; 10(-8) to P = 1.9 &times; 10(-11)).",CTD_human
1,0,Biomarker,C0014175,Endometriosis,disease,endometriosis,10257,ABCC4,ABCC4,CTD_human,25446850,"Higher expression of PLA2G2A, PTGS2, AKR1B1, AKR1C3 and ABCC4 was seen in 22-B endometriosis cells compared to HIESC control cells.",0.200274726784213,"Higher expression of PLA2G2A, PTGS2, AKR1B1, AKR1C3 and <span class=""gene"" id=""25446850-11-56-61"">ABCC4</span> was seen in 22-B <span class=""disease"" id=""25446850-11-79-92"">endometriosis</span> cells compared to HIESC control cells.",CTD_human
2,0,Therapeutic,C0021841,Intestinal Neoplasms,group,intestinal tumor,1026,CDKN1A,Cip1,CTD_human,12468628,"Moreover, we used a combination of gene expression profiling of the response of cells in culture to sulindac and the response of the human mucosa in subjects treated with sulindac for 1 month, coupled with a mouse genetic model approach, to identify the cyclin dependent kinase inhibitor p21(WAF1/Cip1) as an important suppressor of Apc-initiated intestinal tumor formation and a necessary component for tumor inhibition by sulindac.",0.20054945356842604,"Moreover, we used a combination of gene expression profiling of the response of cells in culture to sulindac and the response of the human mucosa in subjects treated with sulindac for 1 month, coupled with a mouse genetic model approach, to identify the cyclin dependent kinase inhibitor p21(<span class=""gene"" id=""12468628-5-292-296"">WAF1</span>/<span class=""gene"" id=""12468628-5-297-301"">Cip1</span>) as an important suppressor of Apc-initiated <span class=""disease"" id=""12468628-5-347-363"">intestinal tumor</span> formation and a necessary component for tumor inhibition by sulindac.",CTD_human
2,0,Biomarker,C0021841,Intestinal Neoplasms,group,intestinal tumor,1026,CDKN1A,Cip1,CTD_human,12468628,"Moreover, we used a combination of gene expression profiling of the response of cells in culture to sulindac and the response of the human mucosa in subjects treated with sulindac for 1 month, coupled with a mouse genetic model approach, to identify the cyclin dependent kinase inhibitor p21(WAF1/Cip1) as an important suppressor of Apc-initiated intestinal tumor formation and a necessary component for tumor inhibition by sulindac.",0.20054945356842604,"Moreover, we used a combination of gene expression profiling of the response of cells in culture to sulindac and the response of the human mucosa in subjects treated with sulindac for 1 month, coupled with a mouse genetic model approach, to identify the cyclin dependent kinase inhibitor p21(<span class=""gene"" id=""12468628-5-292-296"">WAF1</span>/<span class=""gene"" id=""12468628-5-297-301"">Cip1</span>) as an important suppressor of Apc-initiated <span class=""disease"" id=""12468628-5-347-363"">intestinal tumor</span> formation and a necessary component for tumor inhibition by sulindac.",CTD_human
2,0,Biomarker,C0024121,Lung Neoplasms,group,Lung tumors,1026,CDKN1A,Cip1,CTD_human,12466968,Lung tumors were the predominant tumor type in urethane-treated mice regardless of p21(Cip1) status.,0.208473464178654,"<span class=""disease"" id=""12466968-6-0-11"">Lung tumors</span> were the predominant tumor type in urethane-treated mice regardless of p21(<span class=""gene"" id=""12466968-6-87-91"">Cip1</span>) status.",CTD_human
1,0,Biomarker,C0024121,Lung Neoplasms,group,lung tumors,10266,RAMP2,RAMP2,CTD_human,17671114,"Immunohistochemistry showed that RAMP2 was down-regulated in a majority of lung tumors, and RAMP2 down-regulation was correlated with high tumor grade.",0.202732912464814,"Immunohistochemistry showed that <span class=""gene"" id=""17671114-11-33-38"">RAMP2</span> was down-regulated in a majority of <span class=""disease"" id=""17671114-11-75-86"">lung tumors</span>, and <span class=""gene"" id=""17671114-11-92-97"">RAMP2</span> down-regulation was correlated with high tumor grade.",CTD_human
1,0,Biomarker,C0017668,Focal glomerulosclerosis,disease,Focal segmental glomerulosclerosis,10269,ZMPSTE24,ZMPSTE24,CTD_human,17152860,Focal segmental glomerulosclerosis in patients with mandibuloacral dysplasia owing to ZMPSTE24 deficiency.,0.200274726784213,"<span class=""disease"" id=""17152860-0-0-34"">Focal segmental glomerulosclerosis</span> in patients with mandibuloacral dysplasia owing to <span class=""gene"" id=""17152860-0-86-94"">ZMPSTE24</span> deficiency.",CTD_human
1,3,Biomarker,C0206754,Neuroendocrine Tumors,group,neuroendocrine tumors,1027,CDKN1B,CDKN1B,CTD_human,24185511,Somatic mutation of CDKN1B in small intestine neuroendocrine tumors.,0.203557092817453,"Somatic mutation of <span class=""gene"" id=""24185511-0-20-26"">CDKN1B</span> in small intestine <span class=""disease"" id=""24185511-0-46-67"">neuroendocrine tumors</span>.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,hepatocellular carcinoma,1027,CDKN1B,kip1,CTD_human,20698225,JAB1 expression is associated with inverse expression of p27(kip1) in hepatocellular carcinoma.,0.22622212648592396,"JAB1 expression is associated with inverse expression of p27(<span class=""gene"" id=""20698225-0-61-65"">kip1</span>) in <span class=""disease"" id=""20698225-0-70-94"">hepatocellular carcinoma</span>.",CTD_human
2,17,Biomarker,C0004903,Beckwith-Wiedemann Syndrome,disease,Beckwith-Wiedemann syndrome,1028,CDKN1C,CDKN1C,CTD_human,22634751,"All IMAGe-associated mutations clustered in the PCNA-binding domain of CDKN1C and resulted in loss of PCNA binding, distinguishing them from the mutations of CDKN1C that cause Beckwith-Wiedemann syndrome, an overgrowth syndrome.",0.42797906585778495,"All IMAGe-associated mutations clustered in the PCNA-binding domain of <span class=""gene"" id=""22634751-6-71-77"">CDKN1C</span> and resulted in loss of PCNA binding, distinguishing them from the mutations of <span class=""gene"" id=""22634751-6-158-164"">CDKN1C</span> that cause <span class=""disease"" id=""22634751-6-176-203"">Beckwith-Wiedemann syndrome</span>, an overgrowth syndrome.",CTD_human;UNIPROT
1,0,Biomarker,C0014173,Endometrial Hyperplasia,disease,endometrial hyperplasia,1028,CDKN1C,kip2,CTD_human,22064387,"In both endometrial hyperplasia and cancer, the expression of P57(kip2) protein was low.",0.2,"In both <span class=""disease"" id=""22064387-5-8-31"">endometrial hyperplasia</span> and cancer, the expression of P57(<span class=""gene"" id=""22064387-5-66-70"">kip2</span>) protein was low.",CTD_human
1,0,Biomarker,C0002736,Amyotrophic Lateral Sclerosis,disease,ALS,10280,SIGMAR1,sigma-1 receptor,CTD_human,24885036,Lack of synergistic effect of resveratrol and sigma-1 receptor agonist (PRE-084) in SOD1G?³A ALS mice: overlapping effects or limited therapeutic opportunity?,0.40219781427370505,"Lack of synergistic effect of resveratrol and <span class=""gene"" id=""24885036-0-46-62"">sigma-1 receptor</span> agonist (PRE-084) in SOD1G?³A <span class=""disease"" id=""24885036-0-93-96"">ALS</span> mice: overlapping effects or limited therapeutic opportunity?",CTD_human;HPO
1,0,Biomarker,C0001418,Adenocarcinoma,group,adenocarcinoma,1029,CDKN2A,p16,CTD_human,20135361,Implication of p16 inactivation in tumorigenic activity of respiratory epithelial cell lines and adenocarcinoma cell line established from plutonium-induced lung tumor in rat.,0.26372240650190304,"Implication of <span class=""gene"" id=""20135361-0-15-18"">p16</span> inactivation in tumorigenic activity of respiratory epithelial cell lines and <span class=""disease"" id=""20135361-0-97-111"">adenocarcinoma</span> cell line established from plutonium-induced lung tumor in rat.",CTD_human
2,0,Biomarker,C0005695,Bladder Neoplasm,disease,bladder cancer,1029,CDKN2A,INK4A,CTD_human,15987713,"We, therefore, examined, in a population-based study of human bladder cancer, the relationship between epigenetic silencing of three tumor suppressor genes, p16(INK4A), RASSF1A and PRSS3, and exposure to both tobacco and arsenic in bladder cancer.",0.23532491214495202,"We, therefore, examined, in a population-based study of human <span class=""disease"" id=""15987713-5-62-76"">bladder cancer</span>, the relationship between epigenetic silencing of three tumor suppressor genes, p16(<span class=""gene"" id=""15987713-5-161-166"">INK4A</span>), RASSF1A and PRSS3, and exposure to both tobacco and arsenic in <span class=""disease"" id=""15987713-5-232-246"">bladder cancer</span>.",CTD_human
2,0,Therapeutic,C0005695,Bladder Neoplasm,disease,bladder cancer,1029,CDKN2A,INK4A,CTD_human,15987713,"We, therefore, examined, in a population-based study of human bladder cancer, the relationship between epigenetic silencing of three tumor suppressor genes, p16(INK4A), RASSF1A and PRSS3, and exposure to both tobacco and arsenic in bladder cancer.",0.23532491214495202,"We, therefore, examined, in a population-based study of human <span class=""disease"" id=""15987713-5-62-76"">bladder cancer</span>, the relationship between epigenetic silencing of three tumor suppressor genes, p16(<span class=""gene"" id=""15987713-5-161-166"">INK4A</span>), RASSF1A and PRSS3, and exposure to both tobacco and arsenic in <span class=""disease"" id=""15987713-5-232-246"">bladder cancer</span>.",CTD_human
2,0,Biomarker,C0006118,Brain Neoplasms,group,brain tumor,1029,CDKN2A,p16,CTD_human,15144691,To study in series the p16 protein expression on the rat brain tumor induced transplacentally by ENU.,0.21615604437963698,"To study in series the <span class=""gene"" id=""15144691-1-23-26"">p16</span> protein expression on the rat <span class=""disease"" id=""15144691-1-57-68"">brain tumor</span> induced transplacentally by ENU.",CTD_human
2,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,non-small-cell lung cancer,1029,CDKN2A,p16INK4A,CTD_human,19375815,p16INK4A inactivation mechanisms in non-small-cell lung cancer patients occupationally exposed to asbestos.,0.233725881923581,"<span class=""gene"" id=""19375815-0-0-8"">p16INK4A</span> inactivation mechanisms in <span class=""disease"" id=""19375815-0-36-62"">non-small-cell lung cancer</span> patients occupationally exposed to asbestos.",CTD_human
2,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,NSCLC,1029,CDKN2A,cyclin-dependent kinase inhibitor 2A,CTD_human,18337602,"In a multivariate model, promoter methylation of the cyclin-dependent kinase inhibitor 2A gene p16, the H-cadherin gene CDH13, the Ras association domain family 1 gene RASSF1A, and the adenomatous polyposis coli gene APC in tumors and in histologically tumor-negative lymph nodes was associated with tumor recurrence, independently of NSCLC stage, age, sex, race, smoking history, and histologic characteristics of the tumor.",0.233725881923581,"In a multivariate model, promoter methylation of the <span class=""gene"" id=""18337602-5-53-89"">cyclin-dependent kinase inhibitor 2A</span> gene p16, the H-cadherin gene CDH13, the Ras association domain family 1 gene RASSF1A, and the adenomatous polyposis coli gene APC in tumors and in histologically tumor-negative lymph nodes was associated with tumor recurrence, independently of <span class=""disease"" id=""18337602-5-335-340"">NSCLC</span> stage, age, sex, race, smoking history, and histologic characteristics of the tumor.",CTD_human
1,0,Biomarker,C0017601,Glaucoma,disease,glaucoma,1029,CDKN2A,CDKN2A,CTD_human,21532571,We also show that CDKN2A and CDKN2B are upregulated in the retina of a rat model of glaucoma.,0.20082418035263896,"We also show that <span class=""gene"" id=""21532571-5-18-24"">CDKN2A</span> and CDKN2B are upregulated in the retina of a rat model of <span class=""disease"" id=""21532571-5-84-92"">glaucoma</span>.",CTD_human
2,0,Biomarker,C0017638,Glioma,disease,glioma,1029,CDKN2A,CDKN2A,CTD_human,19578367,"We identified five risk loci for glioma at 5p15.33 (rs2736100, TERT; P = 1.50 x 10(-17)), 8q24.21 (rs4295627, CCDC26; P = 2.34 x 10(-18)), 9p21.3 (rs4977756, CDKN2A-CDKN2B; P = 7.24 x 10(-15)), 20q13.33 (rs6010620, RTEL1; P = 2.52 x 10(-12)) and 11q23.3 (rs498872, PHLDB1; P = 1.07 x 10(-8)).",0.253787349464875,"We identified five risk loci for <span class=""disease"" id=""19578367-2-33-39"">glioma</span> at 5p15.33 (rs2736100, TERT; P = 1.50 x 10(-17)), 8q24.21 (rs4295627, CCDC26; P = 2.34 x 10(-18)), 9p21.3 (rs4977756, <span class=""gene"" id=""19578367-2-158-164"">CDKN2A</span>-CDKN2B; P = 7.24 x 10(-15)), 20q13.33 (rs6010620, RTEL1; P = 2.52 x 10(-12)) and 11q23.3 (rs498872, PHLDB1; P = 1.07 x 10(-8)).",CTD_human
4,0,Biomarker,C0024121,Lung Neoplasms,group,lung tumor,1029,CDKN2A,p16,CTD_human,20135361,Implication of p16 inactivation in tumorigenic activity of respiratory epithelial cell lines and adenocarcinoma cell line established from plutonium-induced lung tumor in rat.,0.24457949054429398,"Implication of <span class=""gene"" id=""20135361-0-15-18"">p16</span> inactivation in tumorigenic activity of respiratory epithelial cell lines and adenocarcinoma cell line established from plutonium-induced <span class=""disease"" id=""20135361-0-157-167"">lung tumor</span> in rat.",CTD_human
4,0,Biomarker,C0024121,Lung Neoplasms,group,lung tumors,1029,CDKN2A,INK4a,CTD_human,11872642,Aberrant CpG island methylation of the p16(INK4a) and estrogen receptor genes in rat lung tumors induced by particulate carcinogens.,0.24457949054429398,"Aberrant CpG island methylation of the p16(<span class=""gene"" id=""11872642-0-43-48"">INK4a</span>) and estrogen receptor genes in rat <span class=""disease"" id=""11872642-0-85-96"">lung tumors</span> induced by particulate carcinogens.",CTD_human
1,0,Biomarker,C0024299,Lymphoma,group,lymphomas,1029,CDKN2A,p16INK4a,CTD_human,9488045,"Inactivations of p16INK4a-alpha, p16INK4a-beta and p15INK4b genes in 2',3'-dideoxycytidine- and 1,3-butadiene-induced murine lymphomas.",0.223517924775745,"Inactivations of <span class=""gene"" id=""9488045-0-17-25"">p16INK4a</span>-alpha, <span class=""gene"" id=""9488045-0-33-41"">p16INK4a</span>-beta and p15INK4b genes in 2',3'-dideoxycytidine- and 1,3-butadiene-induced murine <span class=""disease"" id=""9488045-0-125-134"">lymphomas</span>.",CTD_human
1,0,Biomarker,C0025202,melanoma,disease,melanoma,1029,CDKN2A,CDKN2A,CTD_human,24495407,Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.,0.64,"Loss of <span class=""gene"" id=""24495407-0-8-14"">CDKN2A</span> expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in <span class=""disease"" id=""24495407-0-144-152"">melanoma</span> cell lines.",CTD_human;HPO
1,0,Biomarker,C0025500,Mesothelioma,disease,mesothelioma,1029,CDKN2A,p16INK4a,CTD_human,18379362,Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a: results of cancer and leukemia group B 159904.,0.222195448011992,"Response to the methylation inhibitor dihydro-5-azacytidine in <span class=""disease"" id=""18379362-0-63-75"">mesothelioma</span> is not associated with methylation of <span class=""gene"" id=""18379362-0-114-122"">p16INK4a</span>: results of cancer and leukemia group B 159904.",CTD_human
1,0,Biomarker,C0026764,Multiple Myeloma,disease,multiple myeloma,1029,CDKN2A,p16,CTD_human,16008847,[Hypermethylation of CpG island of p16 gene and arsenic trioxide induced p16 gene demethylation in multiple myeloma].,0.21508126237708602,"[Hypermethylation of CpG island of <span class=""gene"" id=""16008847-0-35-38"">p16</span> gene and arsenic trioxide induced <span class=""gene"" id=""16008847-0-73-76"">p16</span> gene demethylation in <span class=""disease"" id=""16008847-0-99-115"">multiple myeloma</span>].",CTD_human
1,0,Biomarker,C0027819,Neuroblastoma,disease,neuroblastoma,1029,CDKN2A,Arf,CTD_human,15814359,"Loss of heterozygosity at the Ink4a/Arf gene locus was observed in 5/5 malignant gliomas and 1/1 neuroblastoma, while the PTEN(phosphatase and tensin homologue) gene locus was unaffected by deletions.",0.208776901717502,"Loss of heterozygosity at the <span class=""gene"" id=""15814359-7-30-35"">Ink4a</span>/<span class=""gene"" id=""15814359-7-36-39"">Arf</span> gene locus was observed in 5/5 malignant gliomas and 1/1 <span class=""disease"" id=""15814359-7-97-110"">neuroblastoma</span>, while the PTEN(phosphatase and tensin homologue) gene locus was unaffected by deletions.",CTD_human
1,0,Biomarker,C0032927,Precancerous Conditions,phenotype,premalignant,1029,CDKN2A,p16,CTD_human,24991542,Promoter region hypermethylation and mRNA expression of MGMT and p16 genes in tissue and blood samples of human premalignant oral lesions and oral squamous cell carcinoma.,0.214154767709821,"Promoter region hypermethylation and mRNA expression of MGMT and <span class=""gene"" id=""24991542-0-65-68"">p16</span> genes in tissue and blood samples of human <span class=""disease"" id=""24991542-0-112-124"">premalignant</span> oral lesions and oral squamous cell carcinoma.",CTD_human
2,0,Biomarker,C0345967,Malignant mesothelioma,disease,MM,1029,CDKN2A,Ink4a,CTD_human,21526190,"Furthermore, while inactivation of Arf appears to be crucial for MM pathogenesis, the inactivation of both p16(Ink4a) and p19(Arf) cooperate to accelerate asbestos-induced tumorigenesis.",0.206318716036901,"Furthermore, while inactivation of Arf appears to be crucial for <span class=""disease"" id=""21526190-11-65-67"">MM</span> pathogenesis, the inactivation of both p16(<span class=""gene"" id=""21526190-11-111-116"">Ink4a</span>) and p19(Arf) cooperate to accelerate asbestos-induced tumorigenesis.",CTD_human
1,0,Biomarker,C0596263,Carcinogenesis,phenotype,tumorigenesis,1029,CDKN2A,Cdkn2a,CTD_human,21526190,Losses of both products of the Cdkn2a/Arf locus contribute to asbestos-induced mesothelioma development and cooperate to accelerate tumorigenesis.,0.28,"Losses of both products of the <span class=""gene"" id=""21526190-0-31-37"">Cdkn2a</span>/Arf locus contribute to asbestos-induced mesothelioma development and cooperate to accelerate <span class=""disease"" id=""21526190-0-132-145"">tumorigenesis</span>.",CTD_human
1,0,Biomarker,C1961102,Precursor Cell Lymphoblastic Leukemia Lymphoma,disease,acute lymphoblastic leukemia,1029,CDKN2A,CDKN2A,CTD_human,20453839,"Using data from a genome-wide association study of 907 individuals with childhood acute lymphoblastic leukemia (cases) and 2,398 controls and with validation in samples totaling 2,386 cases and 2,419 controls, we have shown that common variation at 9p21.3 (rs3731217, intron 1 of CDKN2A) influences acute lymphoblastic leukemia risk (odds ratio = 0.71, P = 3.01 x 10(-11)), irrespective of cell lineage.",0.227977387126161,"Using data from a genome-wide association study of 907 individuals with childhood acute lymphoblastic leukemia (cases) and 2,398 controls and with validation in samples totaling 2,386 cases and 2,419 controls, we have shown that common variation at 9p21.3 (rs3731217, intron 1 of <span class=""gene"" id=""20453839-1-280-286"">CDKN2A</span>) influences <span class=""disease"" id=""20453839-1-299-327"">acute lymphoblastic leukemia</span> risk (odds ratio = 0.71, P = 3.01 x 10(-11)), irrespective of cell lineage.",CTD_human
1,0,Biomarker,C0013336,Dwarfism,disease,primordial dwarfism,10293,TRAIP,TRAIP,CTD_human,26595769,TRAIP promotes DNA damage response during genome replication and is mutated in primordial dwarfism.,0.200274726784213,"<span class=""gene"" id=""26595769-0-0-5"">TRAIP</span> promotes DNA damage response during genome replication and is mutated in <span class=""disease"" id=""26595769-0-79-98"">primordial dwarfism</span>.",CTD_human
1,0,Biomarker,C0025958,Microcephaly,disease,microcephaly,10293,TRAIP,TRAIP,CTD_human,26595769,"TRAIP is necessary for efficient cell cycle progression and mutations in TRAIP therefore limit cellular proliferation, providing a potential mechanism for microcephaly and dwarfism phenotypes.",0.200274726784213,"<span class=""gene"" id=""26595769-4-0-5"">TRAIP</span> is necessary for efficient cell cycle progression and mutations in <span class=""gene"" id=""26595769-4-73-78"">TRAIP</span> therefore limit cellular proliferation, providing a potential mechanism for <span class=""disease"" id=""26595769-4-155-167"">microcephaly</span> and dwarfism phenotypes.",CTD_human
1,1,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,T2D,10296,MAEA,MAEA,CTD_human,22158537,"The combined analysis identified eight new T2D loci reaching genome-wide significance, which mapped in or near GLIS3, PEPD, FITM2-R3HDML-HNF4A, KCNK16, MAEA, GCC1-PAX4, PSMD6 and ZFAND3.",0.20054945356842604,"The combined analysis identified eight new <span class=""disease"" id=""22158537-3-43-46"">T2D</span> loci reaching genome-wide significance, which mapped in or near GLIS3, PEPD, FITM2-R3HDML-HNF4A, KCNK16, <span class=""gene"" id=""22158537-3-152-156"">MAEA</span>, GCC1-PAX4, PSMD6 and ZFAND3.",CTD_human
1,0,Biomarker,C0021390,Inflammatory Bowel Diseases,group,IBD,10297,APC2,APC2,CTD_human,18716850,"Moreover, methylation of APC1A, APC2, SFRP1, and SFRP2 appears to mark progression from IBD colitis to IBD-associated neoplasia, and these genes may serve as biomarkers for IBD-associated neoplasia.",0.200274726784213,"Moreover, methylation of APC1A, <span class=""gene"" id=""18716850-12-32-36"">APC2</span>, SFRP1, and SFRP2 appears to mark progression from <span class=""disease"" id=""18716850-12-88-91"">IBD</span> colitis to <span class=""disease"" id=""18716850-12-103-106"">IBD</span>-associated neoplasia, and these genes may serve as biomarkers for <span class=""disease"" id=""18716850-12-173-176"">IBD</span>-associated neoplasia.",CTD_human
1,0,Biomarker,C0796126,AICARDI-GOUTIERES SYNDROME 1,disease,Aicardi-Goutières syndrome,103,ADAR,ADAR1,CTD_human,23001123,Mutations in ADAR1 cause Aicardi-Goutières syndrome associated with a type I interferon signature.,0.201923087489492,"Mutations in <span class=""gene"" id=""23001123-0-13-18"">ADAR1</span> cause <span class=""disease"" id=""23001123-0-25-51"">Aicardi-Gouti&egrave;res syndrome</span> associated with a type I interferon signature.",CTD_human
1,0,Biomarker,C0017601,Glaucoma,disease,glaucoma,1030,CDKN2B,CDKN2B,CTD_human,21532571,We also show that CDKN2A and CDKN2B are upregulated in the retina of a rat model of glaucoma.,0.201098907136852,"We also show that CDKN2A and <span class=""gene"" id=""21532571-5-29-35"">CDKN2B</span> are upregulated in the retina of a rat model of <span class=""disease"" id=""21532571-5-84-92"">glaucoma</span>.",CTD_human
2,0,Biomarker,C0017638,Glioma,disease,glioma,1030,CDKN2B,CDKN2B,CTD_human,19578367,"We identified five risk loci for glioma at 5p15.33 (rs2736100, TERT; P = 1.50 x 10(-17)), 8q24.21 (rs4295627, CCDC26; P = 2.34 x 10(-18)), 9p21.3 (rs4977756, CDKN2A-CDKN2B; P = 7.24 x 10(-15)), 20q13.33 (rs6010620, RTEL1; P = 2.52 x 10(-12)) and 11q23.3 (rs498872, PHLDB1; P = 1.07 x 10(-8)).",0.21326507482255203,"We identified five risk loci for <span class=""disease"" id=""19578367-2-33-39"">glioma</span> at 5p15.33 (rs2736100, TERT; P = 1.50 x 10(-17)), 8q24.21 (rs4295627, CCDC26; P = 2.34 x 10(-18)), 9p21.3 (rs4977756, CDKN2A-<span class=""gene"" id=""19578367-2-165-171"">CDKN2B</span>; P = 7.24 x 10(-15)), 20q13.33 (rs6010620, RTEL1; P = 2.52 x 10(-12)) and 11q23.3 (rs498872, PHLDB1; P = 1.07 x 10(-8)).",CTD_human
2,0,Biomarker,C0017638,Glioma,disease,glioma,1030,CDKN2B,CDKN2B,CTD_human,19578366,Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility.,0.21326507482255203,"Variants in the <span class=""gene"" id=""19578366-0-16-22"">CDKN2B</span> and RTEL1 regions are associated with high-grade <span class=""disease"" id=""19578366-0-72-78"">glioma</span> susceptibility.",CTD_human
1,0,Biomarker,C0024299,Lymphoma,group,lymphomas,1030,CDKN2B,p15INK4b,CTD_human,9488045,"Inactivations of p16INK4a-alpha, p16INK4a-beta and p15INK4b genes in 2',3'-dideoxycytidine- and 1,3-butadiene-induced murine lymphomas.",0.205154296365419,"Inactivations of p16INK4a-alpha, p16INK4a-beta and <span class=""gene"" id=""9488045-0-51-59"">p15INK4b</span> genes in 2',3'-dideoxycytidine- and 1,3-butadiene-induced murine <span class=""disease"" id=""9488045-0-125-134"">lymphomas</span>.",CTD_human
1,0,Biomarker,C1956346,Coronary Artery Disease,disease,CAD,1030,CDKN2B,CDKN2B,CTD_human,23104008,"In 3 of the 14 regions, TCF7L2 (T2D), CTLA4 (Graves' disease) and CDKN2A-CDKN2B (T2D), much of the posterior probability rested on a single SNP, and, in 4 other regions (CDKN2A-CDKN2B (CAD) and CDKAL1, FTO and HHEX (T2D)), the 95% sets were small, thereby excluding most SNPs as potentially causal.",0.21478241045857102,"In 3 of the 14 regions, TCF7L2 (T2D), CTLA4 (Graves' disease) and CDKN2A-<span class=""gene"" id=""23104008-3-73-79"">CDKN2B</span> (T2D), much of the posterior probability rested on a single SNP, and, in 4 other regions (CDKN2A-<span class=""gene"" id=""23104008-3-177-183"">CDKN2B</span> (<span class=""disease"" id=""23104008-3-185-188"">CAD</span>) and CDKAL1, FTO and HHEX (T2D)), the 95% sets were small, thereby excluding most SNPs as potentially causal.",CTD_human
1,0,Biomarker,C3463824,MYELODYSPLASTIC SYNDROME,group,myelodysplastic syndromes,1030,CDKN2B,P15INK4B,CTD_human,17294728,[Methylation of P15INK4B gene in patients with myelodysplastic syndromes and demethylating effects of drugs].,0.213381744514495,"[Methylation of <span class=""gene"" id=""17294728-0-16-24"">P15INK4B</span> gene in patients with <span class=""disease"" id=""17294728-0-47-72"">myelodysplastic syndromes</span> and demethylating effects of drugs].",CTD_human
2,4,Biomarker,C0024141,"Lupus Erythematosus, Systemic",disease,systemic lupus erythematosus,10318,TNIP1,TNIP1,CTD_human,19838195,"A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus.",0.208110778457133,"A large-scale replication study identifies <span class=""gene"" id=""19838195-0-43-48"">TNIP1</span>, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for <span class=""disease"" id=""19838195-0-99-127"">systemic lupus erythematosus</span>.",CTD_human
1,2,Biomarker,C0036421,Systemic Scleroderma,disease,systemic sclerosis,10318,TNIP1,TNIP1,CTD_human,21750679,"Genome-wide scan identifies TNIP1, PSORS1C1, and RHOB as novel risk loci for systemic sclerosis.",0.20082418035263896,"Genome-wide scan identifies <span class=""gene"" id=""21750679-0-28-33"">TNIP1</span>, PSORS1C1, and RHOB as novel risk loci for <span class=""disease"" id=""21750679-0-77-95"">systemic sclerosis</span>.",CTD_human
1,0,Biomarker,C0024299,Lymphoma,group,lymphomas,10320,IKZF1,ikaros,CTD_human,11980663,Point mutations and deletions in the znfn1a1/ikaros gene in chemically induced murine lymphomas.,0.206015278498054,"Point mutations and deletions in the <span class=""gene"" id=""11980663-0-37-44"">znfn1a1</span>/<span class=""gene"" id=""11980663-0-45-51"">ikaros</span> gene in chemically induced murine <span class=""disease"" id=""11980663-0-86-95"">lymphomas</span>.",CTD_human
2,4,Biomarker,C0002395,Alzheimer's Disease,disease,Alzheimer's disease,10347,ABCA7,ABCA7,CTD_human,21460840,"Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease.",0.20796707674217998,"Common variants at <span class=""gene"" id=""21460840-0-19-24"">ABCA7</span>, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with <span class=""disease"" id=""21460840-0-83-102"">Alzheimer's disease</span>.",CTD_human
2,4,Biomarker,C0002395,Alzheimer's Disease,disease,Alzheimer's disease,10347,ABCA7,ABCA7,CTD_human,25807283,Loss-of-function variants in ABCA7 confer risk of Alzheimer's disease.,0.20796707674217998,"Loss-of-function variants in <span class=""gene"" id=""25807283-0-29-34"">ABCA7</span> confer risk of <span class=""disease"" id=""25807283-0-50-69"">Alzheimer's disease</span>.",CTD_human
1,2,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,T2D,10363,HMG20A,HMG20A,CTD_human,21874001,"In the combined analysis, we identified common genetic variants at six loci (GRB14, ST6GAL1, VPS26A, HMG20A, AP3S2 and HNF4A) newly associated with T2D (P = 4.1 × 10(-8) to P = 1.9 × 10(-11)).",0.201373633921065,"In the combined analysis, we identified common genetic variants at six loci (GRB14, ST6GAL1, VPS26A, <span class=""gene"" id=""21874001-4-101-107"">HMG20A</span>, AP3S2 and HNF4A) newly associated with <span class=""disease"" id=""21874001-4-148-151"">T2D</span> (P = 4.1 &times; 10(-8) to P = 1.9 &times; 10(-11)).",CTD_human
1,0,Biomarker,C0026650,Movement Disorders,group,movement disorder,10367,MICU1,MICU1,CTD_human,24336167,"Here we report mutations of MICU1 in individuals with a disease phenotype characterized by proximal myopathy, learning difficulties and a progressive extrapyramidal movement disorder.",0.200274726784213,"Here we report mutations of <span class=""gene"" id=""24336167-4-28-33"">MICU1</span> in individuals with a disease phenotype characterized by proximal myopathy, learning difficulties and a progressive extrapyramidal <span class=""disease"" id=""24336167-4-165-182"">movement disorder</span>.",CTD_human
1,0,Biomarker,C0026848,Myopathy,group,muscle disorder,10367,MICU1,MICU1,CTD_human,24336167,Loss-of-function mutations in MICU1 cause a brain and muscle disorder linked to primary alterations in mitochondrial calcium signaling.,0.200274726784213,"Loss-of-function mutations in <span class=""gene"" id=""24336167-0-30-35"">MICU1</span> cause a brain and <span class=""disease"" id=""24336167-0-54-69"">muscle disorder</span> linked to primary alterations in mitochondrial calcium signaling.",CTD_human
1,0,Biomarker,C0018816,Heart Septal Defects,group,septal defects,10370,CITED2,CITED2,CTD_human,16287139,"In summary, the observation of these mutations in patients with septal defects indicates that CITED2 has a causative impact in the development of CHD in humans.",0.200274726784213,"In summary, the observation of these mutations in patients with <span class=""disease"" id=""16287139-10-64-78"">septal defects</span> indicates that <span class=""gene"" id=""16287139-10-94-100"">CITED2</span> has a causative impact in the development of CHD in humans.",CTD_human
2,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastasis,10397,NDRG1,NDRG1,CTD_human,22972152,Our findings reinforce the idea that NDRG1 plays a metastasis suppressor role in oral and oropharyngeal squamous cell carcinomas and may be a useful marker for these tumors.,0.216194524891256,"Our findings reinforce the idea that <span class=""gene"" id=""22972152-7-37-42"">NDRG1</span> plays a <span class=""disease"" id=""22972152-7-51-61"">metastasis</span> suppressor role in oral and oropharyngeal squamous cell carcinomas and may be a useful marker for these tumors.",CTD_human
2,0,Therapeutic,C0027627,Neoplasm Metastasis,phenotype,metastasis,10397,NDRG1,NDRG1,CTD_human,22972152,Our findings reinforce the idea that NDRG1 plays a metastasis suppressor role in oral and oropharyngeal squamous cell carcinomas and may be a useful marker for these tumors.,0.216194524891256,"Our findings reinforce the idea that <span class=""gene"" id=""22972152-7-37-42"">NDRG1</span> plays a <span class=""disease"" id=""22972152-7-51-61"">metastasis</span> suppressor role in oral and oropharyngeal squamous cell carcinomas and may be a useful marker for these tumors.",CTD_human
1,0,Biomarker,C0024117,Chronic Obstructive Airway Disease,disease,COPD,10411,RAPGEF3,Epac1,CTD_human,22363678,"Importantly, Epac1 expression was also reduced in lung tissue from COPD patients.",0.200274726784213,"Importantly, <span class=""gene"" id=""22363678-7-13-18"">Epac1</span> expression was also reduced in lung tissue from <span class=""disease"" id=""22363678-7-67-71"">COPD</span> patients.",CTD_human
1,0,Biomarker,C0035585,Rickettsia Infections,group,rickettsioses,10411,RAPGEF3,Epac1,CTD_human,24218580,Our results demonstrate that Epac1-mediated signaling represents a mechanism for host-pathogen interactions and that Epac1 is a potential target for the prevention and treatment of fatal rickettsioses.,0.2,"Our results demonstrate that <span class=""gene"" id=""24218580-7-29-34"">Epac1</span>-mediated signaling represents a mechanism for host-pathogen interactions and that <span class=""gene"" id=""24218580-7-117-122"">Epac1</span> is a potential target for the prevention and treatment of fatal <span class=""disease"" id=""24218580-7-187-200"">rickettsioses</span>.",CTD_human
1,0,Biomarker,C0027819,Neuroblastoma,disease,neuroblastoma,10413,YAP1,YAP,CTD_human,26121086,"Recurrent alterations at relapse included mutations in the putative CHD5 neuroblastoma tumor suppressor, chromosome 9p losses, DOCK8 mutations, inactivating mutations in PTPN14 and a relapse-specific activity pattern for the PTPN14 target YAP.",0.2,"Recurrent alterations at relapse included mutations in the putative CHD5 <span class=""disease"" id=""26121086-6-73-86"">neuroblastoma</span> tumor suppressor, chromosome 9p losses, DOCK8 mutations, inactivating mutations in PTPN14 and a relapse-specific activity pattern for the PTPN14 target <span class=""gene"" id=""26121086-6-239-242"">YAP</span>.",CTD_human
1,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,10451,VAV3,Vav3,CTD_human,21115475,"We also report that Ahr- and Vav3-deficient mice display hypertension, tachypnea, and sympathoexcitation.",0.200274726784213,"We also report that Ahr- and <span class=""gene"" id=""21115475-6-29-33"">Vav3</span>-deficient mice display <span class=""disease"" id=""21115475-6-57-69"">hypertension</span>, tachypnea, and sympathoexcitation.",CTD_human
1,0,Biomarker,C0033578,Prostatic Neoplasms,group,prostate tumors,10451,VAV3,Vav3,CTD_human,17909013,"We found that prostate tumors from the Low-T mutant mice share a similar gene expression profile as androgen-independent prostate tumors from these mutant mice, which includes the deregulated expression of several genes that are up-regulated in human hormone-refractory prostate cancer, such as Vav3 and Runx1.",0.20546582492962803,"We found that <span class=""disease"" id=""17909013-3-14-29"">prostate tumors</span> from the Low-T mutant mice share a similar gene expression profile as androgen-independent <span class=""disease"" id=""17909013-3-121-136"">prostate tumors</span> from these mutant mice, which includes the deregulated expression of several genes that are up-regulated in human hormone-refractory prostate cancer, such as <span class=""gene"" id=""17909013-3-295-299"">Vav3</span> and Runx1.",CTD_human
1,2,Biomarker,C0035334,Retinitis Pigmentosa,disease,retinitis pigmentosa,10461,MERTK,MERTK,CTD_human,11062461,"Mutations in MERTK, the human orthologue of the RCS rat retinal dystrophy gene, cause retinitis pigmentosa.",0.609535569535511,"Mutations in <span class=""gene"" id=""11062461-0-13-18"">MERTK</span>, the human orthologue of the RCS rat retinal dystrophy gene, cause <span class=""disease"" id=""11062461-0-86-106"">retinitis pigmentosa</span>.",CTD_human;HPO;ORPHANET
1,0,Biomarker,C0023903,Liver neoplasms,group,liver tumors,10468,FST,Follistatin,CTD_human,12203361,Follistatin overexpression in rodent liver tumors: a possible mechanism to overcome activin growth control.,0.20054945356842604,"<span class=""gene"" id=""12203361-0-0-11"">Follistatin</span> overexpression in rodent <span class=""disease"" id=""12203361-0-37-49"">liver tumors</span>: a possible mechanism to overcome activin growth control.",CTD_human
1,0,Biomarker,C0162557,"Liver Failure, Acute",disease,acute liver failure,10468,FST,follistatin,CTD_human,12560755,Activin A and follistatin in acute liver failure.,0.2,"Activin A and <span class=""gene"" id=""12560755-0-14-25"">follistatin</span> in <span class=""disease"" id=""12560755-0-29-48"">acute liver failure</span>.",CTD_human
2,0,Biomarker,C2239176,Liver carcinoma,disease,hepatocellular carcinomas,10468,FST,Follistatin,CTD_human,12203361,Follistatin expression was also observed in cell lines derived from human hepatocellular carcinomas.,0.201098907136852,"<span class=""gene"" id=""12203361-9-0-11"">Follistatin</span> expression was also observed in cell lines derived from human <span class=""disease"" id=""12203361-9-74-99"">hepatocellular carcinomas</span>.",CTD_human
1,0,Biomarker,C0025202,melanoma,disease,melanoma,10481,HOXB13,HOXB13,CTD_human,17145863,"Reexpression of either of two of the silenced genes, HOXB13 and SYK, resulted in reduced colony formation in vitro and diminished tumor formation in vivo, indicating that these genes function as tumor suppressors in melanoma.",0.20300763924902696,"Reexpression of either of two of the silenced genes, <span class=""gene"" id=""17145863-6-53-59"">HOXB13</span> and SYK, resulted in reduced colony formation in vitro and diminished tumor formation in vivo, indicating that these genes function as tumor suppressors in <span class=""disease"" id=""17145863-6-216-224"">melanoma</span>.",CTD_human
4,0,Biomarker,C0033578,Prostatic Neoplasms,group,prostate tumor,10481,HOXB13,HOXB13,CTD_human,26457646,"Introduction of FOXA1 and HOXB13 into an immortalized prostate cell line reprogrammed the AR cistrome to resemble that of a prostate tumor, functionally linking these specific factors to AR cistrome reprogramming.",0.205740551713841,"Introduction of FOXA1 and <span class=""gene"" id=""26457646-6-26-32"">HOXB13</span> into an immortalized prostate cell line reprogrammed the AR cistrome to resemble that of a <span class=""disease"" id=""26457646-6-124-138"">prostate tumor</span>, functionally linking these specific factors to AR cistrome reprogramming.",CTD_human
1,0,Biomarker,C2931456,"Prostate cancer, familial",disease,hereditary prostate cancer,10481,HOXB13,HOXB13,CTD_human,22236224,The novel HOXB13 G84E variant is associated with a significantly increased risk of hereditary prostate cancer.,0.40219781427370505,"The novel <span class=""gene"" id=""22236224-9-10-16"">HOXB13</span> G84E variant is associated with a significantly increased risk of <span class=""disease"" id=""22236224-9-83-109"">hereditary prostate cancer</span>.",CTD_human;ORPHANET
1,0,Biomarker,C0029434,Osteogenesis Imperfecta,disease,osteogenesis imperfecta,10491,CRTAP,CRTAP,CTD_human,18566967,CRTAP and LEPRE1 mutations in recessive osteogenesis imperfecta.,0.21123508739810298,"<span class=""gene"" id=""18566967-0-0-5"">CRTAP</span> and LEPRE1 mutations in recessive <span class=""disease"" id=""18566967-0-40-63"">osteogenesis imperfecta</span>.",CTD_human
1,0,Biomarker,C0345967,Malignant mesothelioma,disease,malignant mesothelioma,10495,ENOX2,ENOX2,CTD_human,26807072,ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4-10 years in advance of clinical symptoms.,0.2,"<span class=""gene"" id=""26807072-0-0-5"">ENOX2</span>-based early detection (ONCOblot) of asbestos-induced <span class=""disease"" id=""26807072-0-59-81"">malignant mesothelioma</span> 4-10 years in advance of clinical symptoms.",CTD_human
2,0,Biomarker,C0007137,Squamous cell carcinoma,disease,squamous cell carcinomas,1050,CEBPA,C/EBP?,CTD_human,21346772,C/EBP? expression is downregulated in human nonmelanoma skin cancers and inactivation of C/EBP? confers susceptibility to UVB-induced skin squamous cell carcinomas.,0.20300763924902696,"<span class=""gene"" id=""21346772-0-0-6"">C/EBP&alpha;</span> expression is downregulated in human nonmelanoma skin cancers and inactivation of <span class=""gene"" id=""21346772-0-89-95"">C/EBP&alpha;</span> confers susceptibility to UVB-induced skin <span class=""disease"" id=""21346772-0-139-163"">squamous cell carcinomas</span>.",CTD_human
3,10,Biomarker,C0023467,"Leukemia, Myelocytic, Acute",disease,acute myeloid leukemias,1050,CEBPA,CCAAT/enhancer-binding protein alpha,CTD_human,18987666,"CCAAT/enhancer-binding protein alpha (C/EBPalpha) is mutated in 10% of acute myeloid leukemias, resulting in either a truncated protein or an altered leucine zipper (C/EBPalphaLZ) that prevents DNA binding.",0.7962970860266919,"<span class=""gene"" id=""18987666-1-0-36"">CCAAT/enhancer-binding protein alpha</span> (C/EBPalpha) is mutated in 10% of <span class=""disease"" id=""18987666-1-71-94"">acute myeloid leukemias</span>, resulting in either a truncated protein or an altered leucine zipper (C/EBPalphaLZ) that prevents DNA binding.",CTD_human;HPO;UNIPROT
2,0,Biomarker,C2239176,Liver carcinoma,disease,hepatocellular carcinoma,1050,CEBPA,CCAAT/enhancer binding protein alpha,CTD_human,16288022,CCAAT/enhancer binding protein alpha knock-in mice exhibit early liver glycogen storage and reduced susceptibility to hepatocellular carcinoma.,0.203021994626344,"<span class=""gene"" id=""16288022-0-0-36"">CCAAT/enhancer binding protein alpha</span> knock-in mice exhibit early liver glycogen storage and reduced susceptibility to <span class=""disease"" id=""16288022-0-118-142"">hepatocellular carcinoma</span>.",CTD_human
1,0,Biomarker,C0034069,Pulmonary Fibrosis,disease,pulmonary fibrosis,1051,CEBPB,CCAAT/enhancer binding protein beta,CTD_human,17177178,An essential role for CCAAT/enhancer binding protein beta in bleomycin-induced pulmonary fibrosis.,0.200274726784213,"An essential role for <span class=""gene"" id=""17177178-0-22-57"">CCAAT/enhancer binding protein beta</span> in bleomycin-induced <span class=""disease"" id=""17177178-0-79-97"">pulmonary fibrosis</span>.",CTD_human
1,0,Biomarker,C0033375,Prolactinoma,disease,prolactinoma,1052,CEBPD,CEBPD,CTD_human,21980073,CEBPD suppresses prolactin expression and prolactinoma cell proliferation.,0.200274726784213,"<span class=""gene"" id=""21980073-0-0-5"">CEBPD</span> suppresses prolactin expression and <span class=""disease"" id=""21980073-0-42-54"">prolactinoma</span> cell proliferation.",CTD_human
1,0,Therapeutic,C2239176,Liver carcinoma,disease,HCC,10553,HTATIP2,TIP30,CTD_human,16799960,TIP30 inhibits growth of HCC cell lines and inhibits HCC xenografts in mice in combination with 5-FU.,0.206029633875371,"<span class=""gene"" id=""16799960-0-0-5"">TIP30</span> inhibits growth of <span class=""disease"" id=""16799960-0-25-28"">HCC</span> cell lines and inhibits <span class=""disease"" id=""16799960-0-53-56"">HCC</span> xenografts in mice in combination with 5-FU.",CTD_human
1,0,Biomarker,C0149521,"Pancreatitis, Chronic",disease,chronic pancreatitis,1056,CEL,CEL,CTD_human,25774637,A recombined allele of the lipase gene CEL and its pseudogene CELP confers susceptibility to chronic pancreatitis.,0.20054945356842604,"A recombined allele of the lipase gene <span class=""gene"" id=""25774637-0-39-42"">CEL</span> and its pseudogene CELP confers susceptibility to <span class=""disease"" id=""25774637-0-93-113"">chronic pancreatitis</span>.",CTD_human
1,0,Biomarker,C0014175,Endometriosis,disease,endometriosis,10562,OLFM4,OLFM-4,CTD_human,21048224,The role of OLFM-4 in endometrial tissue remodeling before the secretory phase and during the predisposition and early events in endometriosis can be postulated but requires additional investigation.,0.200274726784213,"The role of <span class=""gene"" id=""21048224-11-12-18"">OLFM-4</span> in endometrial tissue remodeling before the secretory phase and during the predisposition and early events in <span class=""disease"" id=""21048224-11-129-142"">endometriosis</span> can be postulated but requires additional investigation.",CTD_human
2,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,NSCLC,10568,SLC34A2,SLC34A2,CTD_human,22617245,"We selected NSCLC cell lines--A549 (KRAS G12S), NCI-H3255 (EGFR L858R), NCI-H3122 (EML4-ALK E13;A20), and HCC78 (SLC34A2-ROS1)-to evaluate the antiproliferative effects of submicromolar concentrations of the multitargeted TKIs imatinib, sorafenib, erlotinib, and crizotinib.",0.20054945356842604,"We selected <span class=""disease"" id=""22617245-3-12-17"">NSCLC</span> cell lines--A549 (KRAS G12S), NCI-H3255 (EGFR L858R), NCI-H3122 (EML4-ALK E13;A20), and HCC78 (<span class=""gene"" id=""22617245-3-113-120"">SLC34A2</span>-ROS1)-to evaluate the antiproliferative effects of submicromolar concentrations of the multitargeted TKIs imatinib, sorafenib, erlotinib, and crizotinib.",CTD_human
1,0,Biomarker,C0149521,"Pancreatitis, Chronic",disease,chronic pancreatitis,1057,CELP,CELP,CTD_human,25774637,A recombined allele of the lipase gene CEL and its pseudogene CELP confers susceptibility to chronic pancreatitis.,0.200274726784213,"A recombined allele of the lipase gene CEL and its pseudogene <span class=""gene"" id=""25774637-0-62-66"">CELP</span> confers susceptibility to <span class=""disease"" id=""25774637-0-93-113"">chronic pancreatitis</span>.",CTD_human
1,0,Biomarker,C0339573,"Glaucoma, Primary Open Angle",disease,primary open-angle glaucoma,10587,TXNRD2,TXNRD2,CTD_human,26752265,"Genome-wide association analysis identifies TXNRD2, ATXN2 and FOXC1 as susceptibility loci for primary open-angle glaucoma.",0.200274726784213,"Genome-wide association analysis identifies <span class=""gene"" id=""26752265-0-44-50"">TXNRD2</span>, ATXN2 and FOXC1 as susceptibility loci for <span class=""disease"" id=""26752265-0-95-122"">primary open-angle glaucoma</span>.",CTD_human
5,0,Biomarker,C0026848,Myopathy,group,myopathy,10599,SLCO1B1,SLCO1B1,CTD_human,18650507,SLCO1B1 variants and statin-induced myopathy--a genomewide study.,0.214964592685143,"<span class=""gene"" id=""18650507-0-0-7"">SLCO1B1</span> variants and statin-induced <span class=""disease"" id=""18650507-0-36-44"">myopathy</span>--a genomewide study.",CTD_human
5,0,Biomarker,C0026848,Myopathy,group,myopathy,10599,SLCO1B1,SLCO1B1,CTD_human,19833260,Single nucleotide polymorphisms in cytochrome P450 enzymes impair statin metabolism; the reduced function SLCO1B1*5 allele impairs statin clearance and is associated with simvastatin-induced myopathy with creatine kinase (CK) elevation.,0.214964592685143,"Single nucleotide polymorphisms in cytochrome P450 enzymes impair statin metabolism; the reduced function <span class=""gene"" id=""19833260-3-106-113"">SLCO1B1</span>*5 allele impairs statin clearance and is associated with simvastatin-induced <span class=""disease"" id=""19833260-3-191-199"">myopathy</span> with creatine kinase (CK) elevation.",CTD_human
5,0,Biomarker,C0026848,Myopathy,group,myopathy,10599,SLCO1B1,SLCO1B1,CTD_human,15681900,A novel variant allele of OATP-C (SLCO1B1) found in a Japanese patient with pravastatin-induced myopathy.,0.214964592685143,"A novel variant allele of <span class=""gene"" id=""15681900-0-26-32"">OATP-C</span> (<span class=""gene"" id=""15681900-0-34-41"">SLCO1B1</span>) found in a Japanese patient with pravastatin-induced <span class=""disease"" id=""15681900-0-96-104"">myopathy</span>.",CTD_human
5,0,Biomarker,C0026848,Myopathy,group,myopathy,10599,SLCO1B1,SLCO1B1,CTD_human,19238167,Functional analysis of a mutation in the SLCO1B1 gene (c.1628T>G) identified in a Japanese patient with pravastatin-induced myopathy.,0.214964592685143,"Functional analysis of a mutation in the <span class=""gene"" id=""19238167-0-41-48"">SLCO1B1</span> gene (c.1628T&gt;G) identified in a Japanese patient with pravastatin-induced <span class=""disease"" id=""19238167-0-124-132"">myopathy</span>.",CTD_human
5,0,Biomarker,C0026848,Myopathy,group,myopathy,10599,SLCO1B1,SLCO1B1,CTD_human,21243006,Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin.,0.214964592685143,"Differential effect of the rs4149056 variant in <span class=""gene"" id=""21243006-0-48-55"">SLCO1B1</span> on <span class=""disease"" id=""21243006-0-59-67"">myopathy</span> associated with simvastatin and atorvastatin.",CTD_human
1,0,Biomarker,C0017661,IGA Glomerulonephritis,disease,IgA nephropathy,10610,ST6GALNAC2,ST6GALNAC2,CTD_human,17480010,Variants of the ST6GALNAC2 promoter influence transcriptional activity and contribute to genetic susceptibility to IgA nephropathy.,0.205638237399215,"Variants of the <span class=""gene"" id=""17480010-0-16-26"">ST6GALNAC2</span> promoter influence transcriptional activity and contribute to genetic susceptibility to <span class=""disease"" id=""17480010-0-115-130"">IgA nephropathy</span>.",CTD_human
1,0,Biomarker,C0011881,Diabetic Nephropathy,disease,diabetic nephropathy,10628,TXNIP,thioredoxin interacting protein,CTD_human,17582205,A possible role of thioredoxin interacting protein in the pathogenesis of streptozotocin-induced diabetic nephropathy.,0.201373633921065,"A possible role of <span class=""gene"" id=""17582205-0-19-50"">thioredoxin interacting protein</span> in the pathogenesis of streptozotocin-induced <span class=""disease"" id=""17582205-0-97-117"">diabetic nephropathy</span>.",CTD_human
1,0,Biomarker,C0079744,Diffuse Large B-Cell Lymphoma,disease,DLBCL,10628,TXNIP,VDUP1,CTD_human,16081686,"We found that patients with DLBCL with the worst prognosis, according to the outcome predictor score, had decreased expression of catalase, glutathione peroxidase, manganese superoxide dismutase, and VDUP1, a protein that inhibits thioredoxin activity.",0.2,"We found that patients with <span class=""disease"" id=""16081686-5-28-33"">DLBCL</span> with the worst prognosis, according to the outcome predictor score, had decreased expression of catalase, glutathione peroxidase, manganese superoxide dismutase, and <span class=""gene"" id=""16081686-5-200-205"">VDUP1</span>, a protein that inhibits thioredoxin activity.",CTD_human
1,0,Biomarker,C0345967,Malignant mesothelioma,disease,MM,10643,IGF2BP3,IMP3,CTD_human,23621518,These results suggest that CD146 and IMP3 are useful diagnostic and prognostic markers of MM.,0.2,"These results suggest that CD146 and <span class=""gene"" id=""23621518-10-37-41"">IMP3</span> are useful diagnostic and prognostic markers of <span class=""disease"" id=""23621518-10-90-92"">MM</span>.",CTD_human
1,0,Biomarker,C0028754,Obesity,disease,obesity,1066,CES1,CES1,CTD_human,20975297,"A dysregulation in CES1, APOE and other lipid metabolism-related genes is associated to cardiovascular risk factors linked to obesity.",0.201098907136852,"A dysregulation in <span class=""gene"" id=""20975297-0-19-23"">CES1</span>, APOE and other lipid metabolism-related genes is associated to cardiovascular risk factors linked to <span class=""disease"" id=""20975297-0-126-133"">obesity</span>.",CTD_human
1,0,Biomarker,C0006413,Burkitt Lymphoma,disease,Burkitt lymphomas,10672,GNA13,GNA13,CTD_human,23143597,"We identified 70 genes that were recurrently mutated in Burkitt lymphomas, including ID3, GNA13, RET, PIK3R1 and the SWI/SNF genes ARID1A and SMARCA4.",0.2,"We identified 70 genes that were recurrently mutated in <span class=""disease"" id=""23143597-4-56-73"">Burkitt lymphomas</span>, including ID3, <span class=""gene"" id=""23143597-4-90-95"">GNA13</span>, RET, PIK3R1 and the SWI/SNF genes ARID1A and SMARCA4.",CTD_human
1,0,Biomarker,C0003873,Rheumatoid Arthritis,disease,rheumatoid arthritis,10678,B3GNT2,B3GNT2,CTD_human,22446963,"Our study identified nine loci newly associated with rheumatoid arthritis at a threshold of P < 5.0 × 10(-8), including B3GNT2, ANXA3, CSF2, CD83, NFKBIE, ARID5B, PDE2A-ARAP1, PLD4 and PTPN2.",0.20082418035263896,"Our study identified nine loci newly associated with <span class=""disease"" id=""22446963-3-53-73"">rheumatoid arthritis</span> at a threshold of P &lt; 5.0 &times; 10(-8), including <span class=""gene"" id=""22446963-3-120-126"">B3GNT2</span>, ANXA3, CSF2, CD83, NFKBIE, ARID5B, PDE2A-ARAP1, PLD4 and PTPN2.",CTD_human
1,0,Biomarker,C0018213,Graves Disease,disease,Graves' disease,10678,B3GNT2,B3GNT2,CTD_human,22446963,"ANXA3 was also associated with susceptibility to systemic lupus erythematosus (P = 0.0040), and B3GNT2 and ARID5B were associated with Graves' disease (P = 3.5 × 10(-4) and 2.9 × 10(-4), respectively).",0.20054945356842604,"ANXA3 was also associated with susceptibility to systemic lupus erythematosus (P = 0.0040), and <span class=""gene"" id=""22446963-4-96-102"">B3GNT2</span> and ARID5B were associated with <span class=""disease"" id=""22446963-4-135-150"">Graves' disease</span> (P = 3.5 &times; 10(-4) and 2.9 &times; 10(-4), respectively).",CTD_human
1,0,Biomarker,C0000768,Congenital Abnormality,group,birth defects,10683,DLL3,Dll3,CTD_human,17849441,Dll3 and Notch1 genetic interactions model axial segmental and craniofacial malformations of human birth defects.,0.20082418035263896,"<span class=""gene"" id=""17849441-0-0-4"">Dll3</span> and Notch1 genetic interactions model axial segmental and craniofacial <span class=""disease"" id=""17849441-0-76-89"">malformations</span> of human <span class=""disease"" id=""17849441-0-99-112"">birth defects</span>.",CTD_human
1,0,Biomarker,C0020473,Hyperlipidemia,disease,hyperlipidemia,1071,CETP,CETP,CTD_human,10519734,"CETP gene expression is regulated by cholesterol, and plasma CETP level increases in patients with hyperlipidemia and with cholesterol feeding.",0.41554107827658004,"<span class=""gene"" id=""10519734-2-0-4"">CETP</span> gene expression is regulated by cholesterol, and plasma <span class=""gene"" id=""10519734-2-61-65"">CETP</span> level increases in patients with <span class=""disease"" id=""10519734-2-99-113"">hyperlipidemia</span> and with cholesterol feeding.",CTD_human;HPO
1,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,1071,CETP,CETP,CTD_human,20511482,Cholesteryl ester transfer protein (CETP) genotype and reduced CETP levels associated with decreased prevalence of hypertension.,0.21739865323144197,"<span class=""gene"" id=""20511482-0-0-34"">Cholesteryl ester transfer protein</span> (<span class=""gene"" id=""20511482-0-36-40"">CETP</span>) genotype and reduced <span class=""gene"" id=""20511482-0-63-67"">CETP</span> levels associated with decreased prevalence of <span class=""disease"" id=""20511482-0-115-127"">hypertension</span>.",CTD_human
1,0,Biomarker,C0020557,Hypertriglyceridemia,phenotype,HTG,1071,CETP,CETP,CTD_human,12754275,"Associations between CET, lipids, insulin resistance, CETP and PLTP activities, and PLTP mass were investigated in 18 HTG patients and 20 controls.",0.21215181230838298,"Associations between CET, lipids, insulin resistance, <span class=""gene"" id=""12754275-3-54-58"">CETP</span> and PLTP activities, and PLTP mass were investigated in 18 <span class=""disease"" id=""12754275-3-118-121"">HTG</span> patients and 20 controls.",CTD_human
1,1,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,10718,NRG3,NRG3,CTD_human,20713722,Common genetic variation in Neuregulin 3 (NRG3) influences risk for schizophrenia and impacts NRG3 expression in human brain.,0.209693626627782,"Common genetic variation in <span class=""gene"" id=""20713722-0-28-40"">Neuregulin 3</span> (<span class=""gene"" id=""20713722-0-42-46"">NRG3</span>) influences risk for <span class=""disease"" id=""20713722-0-68-81"">schizophrenia</span> and impacts <span class=""gene"" id=""20713722-0-94-98"">NRG3</span> expression in human brain.",CTD_human
1,0,Biomarker,C0080178,Spina Bifida,disease,spina bifida,1072,CFL1,CFL1,CTD_human,17352815,Association between CFL1 gene polymorphisms and spina bifida risk in a California population.,0.20300763924902696,"Association between <span class=""gene"" id=""17352815-0-20-24"">CFL1</span> gene polymorphisms and <span class=""disease"" id=""17352815-0-48-60"">spina bifida</span> risk in a California population.",CTD_human
1,0,Biomarker,C0025958,Microcephaly,disease,microcephaly,10733,PLK4,PLK4,CTD_human,25344692,"Mutations in PLK4, encoding a master regulator of centriole biogenesis, cause microcephaly, growth failure and retinopathy.",0.2,"Mutations in <span class=""gene"" id=""25344692-0-13-17"">PLK4</span>, encoding a master regulator of centriole biogenesis, cause <span class=""disease"" id=""25344692-0-78-90"">microcephaly</span>, growth failure and retinopathy.",CTD_human
3,0,Biomarker,C0005695,Bladder Neoplasm,disease,bladder cancer,10735,STAG2,STAG2,CTD_human,24121789,Frequent truncating mutations of STAG2 in bladder cancer.,0.201098907136852,"Frequent truncating mutations of <span class=""gene"" id=""24121789-0-33-38"">STAG2</span> in <span class=""disease"" id=""24121789-0-42-56"">bladder cancer</span>.",CTD_human
3,0,Biomarker,C0005695,Bladder Neoplasm,disease,bladder cancer,10735,STAG2,STAG2,CTD_human,24121791,Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy.,0.201098907136852,"Recurrent inactivation of <span class=""gene"" id=""24121791-0-26-31"">STAG2</span> in <span class=""disease"" id=""24121791-0-35-49"">bladder cancer</span> is not associated with aneuploidy.",CTD_human
1,0,Biomarker,C1876203,Frontonasal dysplasia,disease,frontonasal dysplasia,10736,SIX2,Six2,CTD_human,18570229,Misexpression of Six2 is associated with heritable frontonasal dysplasia and renal hypoplasia in 3H1 Br mice.,0.200274726784213,"Misexpression of <span class=""gene"" id=""18570229-0-17-21"">Six2</span> is associated with heritable <span class=""disease"" id=""18570229-0-51-72"">frontonasal dysplasia</span> and renal hypoplasia in 3H1 Br mice.",CTD_human
1,0,Biomarker,C0003469,Anxiety Disorders,group,anxiety,10743,RAI1,Rai1,CTD_human,18285828,"Data show that Rai1-transgenic mice have growth retardation, increased locomotor activity, and abnormal anxiety-related behavior compared to wild-type littermates.",0.2,"Data show that <span class=""gene"" id=""18285828-6-15-19"">Rai1</span>-transgenic mice have growth retardation, increased locomotor activity, and abnormal <span class=""disease"" id=""18285828-6-104-111"">anxiety</span>-related behavior compared to wild-type littermates.",CTD_human
2,0,Biomarker,C0028754,Obesity,disease,obesity,10743,RAI1,Rai1,CTD_human,15459175,"These results indicate that the smaller deletions contain the gene(s), most likely Rai1, causing craniofacial abnormalities and obesity.",0.4010989071368521,"These results indicate that the smaller deletions contain the gene(s), most likely <span class=""gene"" id=""15459175-8-83-87"">Rai1</span>, causing craniofacial abnormalities and <span class=""disease"" id=""15459175-8-128-135"">obesity</span>.",CTD_human;HPO
2,0,Biomarker,C0028754,Obesity,disease,obesity,10743,RAI1,Rai1,CTD_human,19116176,"Mouse models with targeted disruption of Rai1 have recapitulated overt SMS phenotypes, including craniofacial abnormalities, obesity, and neurobehavioral anomalies.",0.4010989071368521,"Mouse models with targeted disruption of <span class=""gene"" id=""19116176-3-41-45"">Rai1</span> have recapitulated overt SMS phenotypes, including craniofacial abnormalities, <span class=""disease"" id=""19116176-3-125-132"">obesity</span>, and neurobehavioral anomalies.",CTD_human;HPO
1,0,Biomarker,C0376634,Craniofacial Abnormalities,group,craniofacial abnormalities,10743,RAI1,Rai1,CTD_human,19116176,"Mouse models with targeted disruption of Rai1 have recapitulated overt SMS phenotypes, including craniofacial abnormalities, obesity, and neurobehavioral anomalies.",0.2,"Mouse models with targeted disruption of <span class=""gene"" id=""19116176-3-41-45"">Rai1</span> have recapitulated overt SMS phenotypes, including <span class=""disease"" id=""19116176-3-97-123"">craniofacial abnormalities</span>, obesity, and neurobehavioral anomalies.",CTD_human
1,0,Biomarker,C0700201,Dyssomnias,disease,sleep disturbance,10743,RAI1,RAI1,CTD_human,19752160,"Haploinsufficiency of RAI1 results in developmental delay, mental retardation, sleep disturbance, self-abusive behaviors, and most features commonly seen in SMS.",0.20054945356842604,"Haploinsufficiency of <span class=""gene"" id=""19752160-2-22-26"">RAI1</span> results in developmental delay, mental retardation, <span class=""disease"" id=""19752160-2-79-96"">sleep disturbance</span>, self-abusive behaviors, and most features commonly seen in SMS.",CTD_human
12,8,Biomarker,C0795864,Smith-Magenis syndrome,disease,Smith-Magenis syndrome,10743,RAI1,Rai1,CTD_human,15746153,Inactivation of Rai1 in mice recapitulates phenotypes observed in chromosome engineered mouse models for Smith-Magenis syndrome.,0.4898901642316721,"Inactivation of <span class=""gene"" id=""15746153-0-16-20"">Rai1</span> in mice recapitulates phenotypes observed in chromosome engineered mouse models for <span class=""disease"" id=""15746153-0-105-127"">Smith-Magenis syndrome</span>.",CTD_human;ORPHANET
12,8,Biomarker,C0795864,Smith-Magenis syndrome,disease,SMS,10743,RAI1,RAI1,CTD_human,19236431,Validation using real-time quantitative reverse transcriptase polymerase chain reaction confirmed the gene expression profile of 75% of the selected genes analyzed in both HEK293T RAI1 knockdown cells and SMS lymphoblastoid cell lines.,0.4898901642316721,"Validation using real-time quantitative reverse transcriptase polymerase chain reaction confirmed the gene expression profile of 75% of the selected genes analyzed in both HEK293T <span class=""gene"" id=""19236431-7-180-184"">RAI1</span> knockdown cells and <span class=""disease"" id=""19236431-7-205-208"">SMS</span> lymphoblastoid cell lines.",CTD_human;ORPHANET
12,8,Biomarker,C0795864,Smith-Magenis syndrome,disease,Smith-Magenis syndrome,10743,RAI1,Rai1,CTD_human,17273973,Penetrance of craniofacial anomalies in mouse models of Smith-Magenis syndrome is modified by genomic sequence surrounding Rai1: not all null alleles are alike.,0.4898901642316721,"Penetrance of craniofacial anomalies in mouse models of <span class=""disease"" id=""17273973-0-56-78"">Smith-Magenis syndrome</span> is modified by genomic sequence surrounding <span class=""gene"" id=""17273973-0-123-127"">Rai1</span>: not all null alleles are alike.",CTD_human;ORPHANET
12,8,Biomarker,C0795864,Smith-Magenis syndrome,disease,SMS,10743,RAI1,RAI1,CTD_human,16845274,"Although RAI1 is the primary gene responsible for most features of SMS, other genes within 17p11.2 contribute to the variable features and overall severity of the syndrome.",0.4898901642316721,"Although <span class=""gene"" id=""16845274-8-9-13"">RAI1</span> is the primary gene responsible for most features of <span class=""disease"" id=""16845274-8-67-70"">SMS</span>, other genes within 17p11.2 contribute to the variable features and overall severity of the syndrome.",CTD_human;ORPHANET
12,8,Biomarker,C0795864,Smith-Magenis syndrome,disease,SMS,10743,RAI1,Rai1,CTD_human,18285828,"Our results show that Rai1 dosage has major consequences on molecular processes involved in growth, development, and neurological and behavioral functions, thus providing evidence for several dosage-thresholds for phenotypic manifestations causing dup(17)(p11.2) syndrome or SMS in humans.",0.4898901642316721,"Our results show that <span class=""gene"" id=""18285828-9-22-26"">Rai1</span> dosage has major consequences on molecular processes involved in growth, development, and neurological and behavioral functions, thus providing evidence for several dosage-thresholds for phenotypic manifestations causing dup(17)(p11.2) syndrome or <span class=""disease"" id=""18285828-9-275-278"">SMS</span> in humans.",CTD_human;ORPHANET
12,8,Biomarker,C0795864,Smith-Magenis syndrome,disease,SMS,10743,RAI1,Rai1,CTD_human,19116176,"Mouse models with targeted disruption of Rai1 have recapitulated overt SMS phenotypes, including craniofacial abnormalities, obesity, and neurobehavioral anomalies.",0.4898901642316721,"Mouse models with targeted disruption of <span class=""gene"" id=""19116176-3-41-45"">Rai1</span> have recapitulated overt <span class=""disease"" id=""19116176-3-71-74"">SMS</span> phenotypes, including craniofacial abnormalities, obesity, and neurobehavioral anomalies.",CTD_human;ORPHANET
12,8,Biomarker,C0795864,Smith-Magenis syndrome,disease,SMS,10743,RAI1,RAI1,CTD_human,15459175,"RAI1 has been recently suggested as a major gene for majority of the SMS phenotypes, but its role in the full spectrum of the phenotype remains unclear.",0.4898901642316721,"<span class=""gene"" id=""15459175-3-0-4"">RAI1</span> has been recently suggested as a major gene for majority of the <span class=""disease"" id=""15459175-3-69-72"">SMS</span> phenotypes, but its role in the full spectrum of the phenotype remains unclear.",CTD_human;ORPHANET
12,8,Biomarker,C0795864,Smith-Magenis syndrome,disease,SMS,10743,RAI1,RAI1,CTD_human,19752160,"Given the phenotypic overlap between SMS and the SMS-like cases, these data may provide some insight into the function of RAI1, including the pathways in which it may be involved and the genes it may regulate.",0.4898901642316721,"Given the phenotypic overlap between <span class=""disease"" id=""19752160-9-37-40"">SMS</span> and the <span class=""disease"" id=""19752160-9-49-52"">SMS</span>-like cases, these data may provide some insight into the function of <span class=""gene"" id=""19752160-9-122-126"">RAI1</span>, including the pathways in which it may be involved and the genes it may regulate.",CTD_human;ORPHANET
12,8,Biomarker,C0795864,Smith-Magenis syndrome,disease,Smith-Magenis syndrome,10743,RAI1,RAI1,CTD_human,20691407,"Data presented here show that deletion or mutation of HDAC4 results in reduced expression of RAI1, which causes Smith-Magenis syndrome when haploinsufficient, providing a link to the overlapping findings in these disorders.",0.4898901642316721,"Data presented here show that deletion or mutation of HDAC4 results in reduced expression of <span class=""gene"" id=""20691407-8-93-97"">RAI1</span>, which causes <span class=""disease"" id=""20691407-8-112-134"">Smith-Magenis syndrome</span> when haploinsufficient, providing a link to the overlapping findings in these disorders.",CTD_human;ORPHANET
12,8,Biomarker,C0795864,Smith-Magenis syndrome,disease,Smith-Magenis syndrome,10743,RAI1,RAI1,CTD_human,15788730,RAI1 variations in Smith-Magenis syndrome patients without 17p11.2 deletions.,0.4898901642316721,"<span class=""gene"" id=""15788730-0-0-4"">RAI1</span> variations in <span class=""disease"" id=""15788730-0-19-41"">Smith-Magenis syndrome</span> patients without 17p11.2 deletions.",CTD_human;ORPHANET
12,8,Biomarker,C0795864,Smith-Magenis syndrome,disease,SMS,10743,RAI1,Rai1,CTD_human,17517686,"To determine the contribution of RAI1 in the neurobehavioral traits in SMS, we performed a battery of behavioral tests on Rai1 mutant mice and the Df(11)17-1/+ mice that have a small deletion of approximately 590 kb.",0.4898901642316721,"To determine the contribution of <span class=""gene"" id=""17517686-5-33-37"">RAI1</span> in the neurobehavioral traits in <span class=""disease"" id=""17517686-5-71-74"">SMS</span>, we performed a battery of behavioral tests on <span class=""gene"" id=""17517686-5-122-126"">Rai1</span> mutant mice and the Df(11)17-1/+ mice that have a small deletion of approximately 590 kb.",CTD_human;ORPHANET
1,0,Biomarker,C1510586,Autism Spectrum Disorders,disease,autism spectrum disorders,10743,RAI1,RAI1,CTD_human,20981775,The mechanisms by which the deletion of RAI1 and contiguous genes cause psychopathology remain unknown but they provide a solid starting point for further studies of gene-brain-behavior interactions in SMS and autism spectrum disorders.,0.20082418035263896,"The mechanisms by which the deletion of <span class=""gene"" id=""20981775-10-40-44"">RAI1</span> and contiguous genes cause psychopathology remain unknown but they provide a solid starting point for further studies of gene-brain-behavior interactions in SMS and <span class=""disease"" id=""20981775-10-210-235"">autism spectrum disorders</span>.",CTD_human
1,1,Biomarker,C3714756,Intellectual Disability,group,mental retardation,10743,RAI1,RAI1,CTD_human,19752160,"Haploinsufficiency of RAI1 results in developmental delay, mental retardation, sleep disturbance, self-abusive behaviors, and most features commonly seen in SMS.",0.40027472678421294,"Haploinsufficiency of <span class=""gene"" id=""19752160-2-22-26"">RAI1</span> results in developmental delay, <span class=""disease"" id=""19752160-2-59-77"">mental retardation</span>, sleep disturbance, self-abusive behaviors, and most features commonly seen in SMS.",CTD_human;HPO
15,18,Biomarker,C0030360,Papillon-Lefevre Disease,disease,Papillon-Lefèvre syndrome,1075,CTSC,cathepsin C,CTD_human,10662807,Haim-Munk syndrome and Papillon-Lefèvre syndrome are allelic mutations in cathepsin C.,0.635324912144952,"Haim-Munk syndrome and <span class=""disease"" id=""10662807-0-23-48"">Papillon-Lef&egrave;vre syndrome</span> are allelic mutations in <span class=""gene"" id=""10662807-0-74-85"">cathepsin C</span>.",CTD_human;ORPHANET;UNIPROT
2,1,Biomarker,C1855627,HAIM-MUNK SYNDROME,disease,Haim-Munk syndrome,1075,CTSC,cathepsin C,CTD_human,10662807,Haim-Munk syndrome and Papillon-Lefèvre syndrome are allelic mutations in cathepsin C.,0.6013736339210661,"<span class=""disease"" id=""10662807-0-0-18"">Haim-Munk syndrome</span> and Papillon-Lef&egrave;vre syndrome are allelic mutations in <span class=""gene"" id=""10662807-0-74-85"">cathepsin C</span>.",CTD_human;ORPHANET;UNIPROT
2,0,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,10752,CHL1,CHL1,CTD_human,15653271,Case-control association study of the close homologue of L1 (CHL1) gene and schizophrenia in the Chinese population.,0.20974478378509498,"Case-control association study of the close homologue of L1 (<span class=""gene"" id=""15653271-0-61-65"">CHL1</span>) gene and <span class=""disease"" id=""15653271-0-76-89"">schizophrenia</span> in the Chinese population.",CTD_human
2,0,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,10752,CHL1,CALL,CTD_human,11986985,"An association between a missense polymorphism in the close homologue of L1 (CHL1, CALL) gene and schizophrenia.",0.20974478378509498,"An association between a missense polymorphism in the close homologue of L1 (<span class=""gene"" id=""11986985-0-77-81"">CHL1</span>, <span class=""gene"" id=""11986985-0-83-87"">CALL</span>) gene and <span class=""disease"" id=""11986985-0-98-111"">schizophrenia</span>.",CTD_human
1,0,Biomarker,C3714756,Intellectual Disability,group,mental retardation,10752,CHL1,CALL,CTD_human,12812975,This suggests that the CALL gene at 3p26.3 is a prime candidate for an autosomal form of mental retardation.,0.20082418035263896,"This suggests that the <span class=""gene"" id=""12812975-12-23-27"">CALL</span> gene at 3p26.3 is a prime candidate for an autosomal form of <span class=""disease"" id=""12812975-12-89-107"">mental retardation</span>.",CTD_human
2,1,Biomarker,C0003872,"Arthritis, Psoriatic",disease,psoriatic arthritis,10758,TRAF3IP2,TRAF3IP2,CTD_human,20953186,Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis.,0.204604842796993,"Common variants at <span class=""gene"" id=""20953186-0-19-27"">TRAF3IP2</span> are associated with susceptibility to <span class=""disease"" id=""20953186-0-66-85"">psoriatic arthritis</span> and psoriasis.",CTD_human
2,1,Biomarker,C0003872,"Arthritis, Psoriatic",disease,PsA,10758,TRAF3IP2,TRAF3IP2,CTD_human,20953188,"A stratified analysis of our datasets including only PsA cases (1,922 cases compared to 8,037 controls, P = 4.57 × 10?¹² for rs33980500) suggested that TRAF3IP2 represents a shared susceptibility for PsV and PsA.",0.204604842796993,"A stratified analysis of our datasets including only <span class=""disease"" id=""20953188-5-53-56"">PsA</span> cases (1,922 cases compared to 8,037 controls, P = 4.57 &times; 10?¹² for rs33980500) suggested that <span class=""gene"" id=""20953188-5-152-160"">TRAF3IP2</span> represents a shared susceptibility for PsV and <span class=""disease"" id=""20953188-5-208-211"">PsA</span>.",CTD_human
3,3,Biomarker,C0033860,Psoriasis,disease,psoriasis,10758,TRAF3IP2,TRAF3IP2,CTD_human,20953186,Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis.,0.207561324888707,"Common variants at <span class=""gene"" id=""20953186-0-19-27"">TRAF3IP2</span> are associated with susceptibility to psoriatic arthritis and <span class=""disease"" id=""20953186-0-90-99"">psoriasis</span>.",CTD_human
3,3,Biomarker,C0033860,Psoriasis,disease,psoriasis,10758,TRAF3IP2,TRAF3IP2,CTD_human,20953188,Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2.,0.207561324888707,"Genome-wide association study identifies a <span class=""disease"" id=""20953188-0-43-52"">psoriasis</span> susceptibility locus at <span class=""gene"" id=""20953188-0-77-85"">TRAF3IP2</span>.",CTD_human
1,0,Biomarker,C0027720,Nephrosis,disease,nephrosis,10763,NES,nestin,CTD_human,16418842,"To gain insight into the role of IF proteins in podocytes, we investigated the expression of nestin, vimentin, and desmin in puromycin aminonucleoside (PAN) nephrosis.",0.2,"To gain insight into the role of IF proteins in podocytes, we investigated the expression of <span class=""gene"" id=""16418842-2-93-99"">nestin</span>, vimentin, and desmin in puromycin aminonucleoside (PAN) <span class=""disease"" id=""16418842-2-157-166"">nephrosis</span>.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,10771,ZMYND11,ZMYND11,CTD_human,25217958,"These genetic changes include haploinsufficiency of SETBP1 associated with intellectual disability and loss of expressive language and truncations of ZMYND11 in individuals with autism, aggression and complex neuropsychiatric features.",0.200274726784213,"These genetic changes include haploinsufficiency of SETBP1 associated with intellectual disability and loss of expressive language and truncations of <span class=""gene"" id=""25217958-6-150-157"">ZMYND11</span> in individuals with <span class=""disease"" id=""25217958-6-178-184"">autism</span>, aggression and complex neuropsychiatric features.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,hepatocellular carcinoma,10788,IQGAP2,IQGAP2,CTD_human,20977743,IQGAP1 and IQGAP2 are reciprocally altered in hepatocellular carcinoma.,0.281373633921066,"IQGAP1 and <span class=""gene"" id=""20977743-0-11-17"">IQGAP2</span> are reciprocally altered in <span class=""disease"" id=""20977743-0-46-70"">hepatocellular carcinoma</span>.",CTD_human
52,416,Biomarker,C0010674,Cystic Fibrosis,disease,cystic fibrosis,1080,CFTR,CFTR,CTD_human,21083385,Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation.,1.0,"Effect of VX-770 in persons with <span class=""disease"" id=""21083385-0-33-48"">cystic fibrosis</span> and the G551D-<span class=""gene"" id=""21083385-0-63-67"">CFTR</span> mutation.",CTD_human;ORPHANET;UNIPROT
52,416,Biomarker,C0010674,Cystic Fibrosis,disease,CF,1080,CFTR,CFTR,CTD_human,16463024,Thirty-seven families with F508del-CFTR homozygous siblings exhibiting extreme clinical phenotypes that had been selected from the 467 pairs of the European CF Twin and Sibling Study were genotyped at 12p13 and 16p12 markers.,1.0,"Thirty-seven families with F508del-<span class=""gene"" id=""16463024-4-35-39"">CFTR</span> homozygous siblings exhibiting extreme clinical phenotypes that had been selected from the 467 pairs of the European <span class=""disease"" id=""16463024-4-157-159"">CF</span> Twin and Sibling Study were genotyped at 12p13 and 16p12 markers.",CTD_human;ORPHANET;UNIPROT
52,416,Biomarker,C0010674,Cystic Fibrosis,disease,cystic fibrosis,1080,CFTR,cystic fibrosis transmembrane conductance regulator,CTD_human,17347447,No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations.,1.0,"No detectable improvements in <span class=""gene"" id=""17347447-0-30-81"">cystic fibrosis transmembrane conductance regulator</span> by nasal aminoglycosides in patients with <span class=""disease"" id=""17347447-0-124-139"">cystic fibrosis</span> with stop mutations.",CTD_human;ORPHANET;UNIPROT
52,416,Biomarker,C0010674,Cystic Fibrosis,disease,cystic fibrosis,1080,CFTR,CFTR,CTD_human,16763370,Cystic fibrosis (CF) is a recessive genetic disease caused by defects of the cystic fibrosis trans-membrane regulator (CFTR) gene with a median survival of less than 35 years.,1.0,"<span class=""disease"" id=""16763370-1-0-15"">Cystic fibrosis</span> (<span class=""disease"" id=""16763370-1-17-19"">CF</span>) is a recessive genetic disease caused by defects of the <span class=""disease"" id=""16763370-1-77-92"">cystic fibrosis</span> trans-membrane regulator (<span class=""gene"" id=""16763370-1-119-123"">CFTR</span>) gene with a median survival of less than 35 years.",CTD_human;ORPHANET;UNIPROT
52,416,Biomarker,C0010674,Cystic Fibrosis,disease,cystic fibrosis,1080,CFTR,CFTR,CTD_human,7560099,The most common cause of cystic fibrosis is a mutation that deletes phenylalanine 508 in cystic fibrosis transmembrane conductance regulator (CFTR).,1.0,"The most common cause of <span class=""disease"" id=""7560099-1-25-40"">cystic fibrosis</span> is a mutation that deletes phenylalanine 508 in <span class=""gene"" id=""7560099-1-89-140"">cystic fibrosis transmembrane conductance regulator</span> (<span class=""gene"" id=""7560099-1-142-146"">CFTR</span>).",CTD_human;ORPHANET;UNIPROT
52,416,Biomarker,C0010674,Cystic Fibrosis,disease,CF,1080,CFTR,CFTR,CTD_human,1718974,"We conclude that intestinal CFI-3 cells retain the CF phenotype relating to defective regulation of Cl- channels, and therefore constitute a suitable model, 1) for elucidating the function of CFTR protein, 2) developing new therapeutic agents, and 3) correcting the CF defect by gene replacement therapy in vitro.",1.0,"We conclude that intestinal CFI-3 cells retain the <span class=""disease"" id=""1718974-11-51-53"">CF</span> phenotype relating to defective regulation of Cl- channels, and therefore constitute a suitable model, 1) for elucidating the function of <span class=""gene"" id=""1718974-11-192-196"">CFTR</span> protein, 2) developing new therapeutic agents, and 3) correcting the <span class=""disease"" id=""1718974-11-266-268"">CF</span> defect by gene replacement therapy in vitro.",CTD_human;ORPHANET;UNIPROT
52,416,Biomarker,C0010674,Cystic Fibrosis,disease,cystic fibrosis,1080,CFTR,CFTR,CTD_human,11786964,Correction of CFTR malfunction and stimulation of Ca-activated Cl channels restore HCO3- secretion in cystic fibrosis bile ductular cells.,1.0,"Correction of <span class=""gene"" id=""11786964-0-14-18"">CFTR</span> malfunction and stimulation of Ca-activated Cl channels restore HCO3- secretion in <span class=""disease"" id=""11786964-0-102-117"">cystic fibrosis</span> bile ductular cells.",CTD_human;ORPHANET;UNIPROT
52,416,Biomarker,C0010674,Cystic Fibrosis,disease,CF,1080,CFTR,CFTR,CTD_human,21602569,Cystic fibrosis (CF) is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that cause loss of function of the CFTR channel on the apical surface of epithelial cells.,1.0,"<span class=""disease"" id=""21602569-1-0-15"">Cystic fibrosis</span> (<span class=""disease"" id=""21602569-1-17-19"">CF</span>) is caused by mutations in the <span class=""gene"" id=""21602569-1-51-102"">cystic fibrosis transmembrane conductance regulator</span> (<span class=""gene"" id=""21602569-1-104-108"">CFTR</span>) gene that cause loss of function of the CFTR channel on the apical surface of epithelial cells.",CTD_human;ORPHANET;UNIPROT
52,416,Biomarker,C0010674,Cystic Fibrosis,disease,Cystic fibrosis,1080,CFTR,CFTR,CTD_human,17541014,Cystic fibrosis results from mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.,1.0,"<span class=""disease"" id=""17541014-1-0-15"">Cystic fibrosis</span> results from mutations in the <span class=""gene"" id=""17541014-1-46-97"">cystic fibrosis transmembrane conductance regulator</span> (<span class=""gene"" id=""17541014-1-99-103"">CFTR</span>) gene.",CTD_human;ORPHANET;UNIPROT
52,416,Biomarker,C0010674,Cystic Fibrosis,disease,CF,1080,CFTR,CFTR,CTD_human,21303308,Several types of mutations in the cystic fibrosis transmembrane regulator (CFTR) gene lead to abnormal CFTR protein and alterations of chloride and sodium transmembrane transportation in cystic fibrosis (CF).,1.0,"Several types of mutations in the <span class=""disease"" id=""21303308-1-34-49"">cystic fibrosis</span> transmembrane regulator (CFTR) gene lead to abnormal <span class=""gene"" id=""21303308-1-103-107"">CFTR</span> protein and alterations of chloride and sodium transmembrane transportation in <span class=""disease"" id=""21303308-1-187-202"">cystic fibrosis</span> (<span class=""disease"" id=""21303308-1-204-206"">CF</span>).",CTD_human;ORPHANET;UNIPROT
2,0,Biomarker,C0021364,Male infertility,phenotype,male infertility,1080,CFTR,CFTR,CTD_human,18554162,"Thus in a very near future, for a comprehensive male infertility panel, it will be essential to include additional genetic tests, such as CFTR gene mutations, sperm mitochondrial DNA mutations, and androgen receptor gene mutations, besides the conventional chromosomal analyses, Y chromosome microdeletion detection, and sperm-FISH analyses.",0.449161288422289,"Thus in a very near future, for a comprehensive <span class=""disease"" id=""18554162-11-48-64"">male infertility</span> panel, it will be essential to include additional genetic tests, such as <span class=""gene"" id=""18554162-11-138-142"">CFTR</span> gene mutations, sperm mitochondrial DNA mutations, and androgen receptor gene mutations, besides the conventional chromosomal analyses, Y chromosome microdeletion detection, and sperm-FISH analyses.",CTD_human;HPO
2,0,Biomarker,C0030305,Pancreatitis,disease,pancreatitis,1080,CFTR,CFTR,CTD_human,23143602,"Alcohol was long thought to be the primary causative agent, but genetic contributions have been of interest since the discovery that rare PRSS1, CFTR and SPINK1 variants were associated with pancreatitis risk.",0.30593856429562605,"Alcohol was long thought to be the primary causative agent, but genetic contributions have been of interest since the discovery that rare PRSS1, <span class=""gene"" id=""23143602-2-145-149"">CFTR</span> and SPINK1 variants were associated with <span class=""disease"" id=""23143602-2-191-203"">pancreatitis</span> risk.",CTD_human
1,0,Biomarker,C0085548,Autosomal Recessive Polycystic Kidney Disease,disease,autosomal recessive polycystic kidney disease,1080,CFTR,CFTR,CTD_human,18988797,"Our data suggest that hepatic cystogenesis in autosomal recessive polycystic kidney disease may involve increased fluid accumulation because of overexpression and abnormal location of AQP1, CFTR, and AE2 in cystic cholangiocytes.",0.2,"Our data suggest that hepatic cystogenesis in <span class=""disease"" id=""18988797-8-46-91"">autosomal recessive polycystic kidney disease</span> may involve increased fluid accumulation because of overexpression and abnormal location of AQP1, <span class=""gene"" id=""18988797-8-190-194"">CFTR</span>, and AE2 in cystic cholangiocytes.",CTD_human
1,0,Biomarker,C0149521,"Pancreatitis, Chronic",disease,chronic pancreatitis,1080,CFTR,CFTR,CTD_human,18206817,"Other genes--such as the anionic trypsinogen (PRSS2), the serine protease inhibitor Kazal type 1 (SPINK1), and the cystic fibrosis transmembrane conductance regulator (CFTR)--have also been found to be associated with chronic pancreatitis (idiopathic and hereditary).",0.251485542144921,"Other genes--such as the anionic trypsinogen (PRSS2), the serine protease inhibitor Kazal type 1 (SPINK1), and the <span class=""gene"" id=""18206817-8-115-166"">cystic fibrosis transmembrane conductance regulator</span> (<span class=""gene"" id=""18206817-8-168-172"">CFTR</span>)--have also been found to be associated with <span class=""disease"" id=""18206817-8-218-238"">chronic pancreatitis</span> (idiopathic and hereditary).",CTD_human
6,24,Biomarker,C0403814,Congenital bilateral aplasia of vas deferens,disease,Congenital bilateral absence of the vas deferens,1080,CFTR,cystic fibrosis transmembrane conductance regulator,CTD_human,11119745,"Congenital bilateral absence of the vas deferens: clinical characteristics, biological parameters, cystic fibrosis transmembrane conductance regulator gene mutations, and implications for genetic counseling.",0.7115280676498771,"<span class=""disease"" id=""11119745-0-0-48"">Congenital bilateral absence of the vas deferens</span>: clinical characteristics, biological parameters, <span class=""gene"" id=""11119745-0-99-150"">cystic fibrosis transmembrane conductance regulator</span> gene mutations, and implications for genetic counseling.",CTD_human;ORPHANET;UNIPROT
6,24,Biomarker,C0403814,Congenital bilateral aplasia of vas deferens,disease,CAVD,1080,CFTR,CFTR,CTD_human,10875853,"Congenital absence of the vas deferens (CAVD) is a heterogeneous disorder, largely due to mutations in the cystic fibrosis (CFTR) gene.",0.7115280676498771,"Congenital absence of the vas deferens (<span class=""disease"" id=""10875853-1-40-44"">CAVD</span>) is a heterogeneous disorder, largely due to mutations in the cystic fibrosis (<span class=""gene"" id=""10875853-1-124-128"">CFTR</span>) gene.",CTD_human;ORPHANET;UNIPROT
3,0,Biomarker,C1319853,"Asthma, Aspirin-Induced",disease,AIA,10800,CYSLTR1,CYSLTR1,CTD_human,16502481,"Increased expression of CYSLTR1 with CYLSTR1 and CYSLTR2 polymorphisms are new findings in AIA, while the ALOX5 promoter polymorphism has been noted in AIU.",0.20054945356842604,"Increased expression of <span class=""gene"" id=""16502481-4-24-31"">CYSLTR1</span> with CYLSTR1 and CYSLTR2 polymorphisms are new findings in <span class=""disease"" id=""16502481-4-91-94"">AIA</span>, while the ALOX5 promoter polymorphism has been noted in AIU.",CTD_human
1,0,Biomarker,C0038220,Status Epilepticus,disease,status epilepticus,10803,CCR9,CCR9,CTD_human,17181556,"CCR7, CCR8, CCR9 and CCR10 in the mouse hippocampal CA1 area and the dentate gyrus during and after pilocarpine-induced status epilepticus.",0.2,"CCR7, CCR8, <span class=""gene"" id=""17181556-0-12-16"">CCR9</span> and CCR10 in the mouse hippocampal CA1 area and the dentate gyrus during and after pilocarpine-induced <span class=""disease"" id=""17181556-0-120-138"">status epilepticus</span>.",CTD_human
2,0,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,10814,CPLX2,complexin II,CTD_human,11483314,"In schizophrenia, synaptophysin mRNA was decreased, as was complexin II and its mRNA.",0.28761248204602,"In <span class=""disease"" id=""11483314-5-3-16"">schizophrenia</span>, synaptophysin mRNA was decreased, as was <span class=""gene"" id=""11483314-5-59-71"">complexin II</span> and its mRNA.",CTD_human
1,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastasis,10855,HPSE,HPA,CTD_human,22240343,"Thus, we conclude that the combination of an anti-HPA antibody and a CTL response in HPA-immunization gene therapy is enough to attenuate tumor growth and metastasis.",0.26874109217772896,"Thus, we conclude that the combination of an anti-<span class=""gene"" id=""22240343-9-50-53"">HPA</span> antibody and a CTL response in <span class=""gene"" id=""22240343-9-85-88"">HPA</span>-immunization gene therapy is enough to attenuate tumor growth and <span class=""disease"" id=""22240343-9-155-165"">metastasis</span>.",CTD_human
1,0,Biomarker,C0002395,Alzheimer's Disease,disease,Alzheimer's disease,10858,CYP46A1,CYP46A1,CTD_human,19286353,CYP46A1 variants influence Alzheimer's disease risk and brain cholesterol metabolism.,0.262723536431733,"<span class=""gene"" id=""19286353-0-0-7"">CYP46A1</span> variants influence <span class=""disease"" id=""19286353-0-27-46"">Alzheimer's disease</span> risk and brain cholesterol metabolism.",CTD_human
2,0,Biomarker,C0451641,Urolithiasis,disease,urolithiasis,10861,SLC26A1,sat-1,CTD_human,19002488,"Oxalate is then excreted by the kidneys via the basolateral sat-1 (males > females) and the apical CFEX (Slc26a6; GD unknown) in PT and eliminated in the urine (males > females), where it may contribute to the male-prevailing development of oxalate urolithiasis.",0.200274726784213,"Oxalate is then excreted by the kidneys via the basolateral <span class=""gene"" id=""19002488-9-60-65"">sat-1</span> (males &gt; females) and the apical CFEX (Slc26a6; GD unknown) in PT and eliminated in the urine (males &gt; females), where it may contribute to the male-prevailing development of oxalate <span class=""disease"" id=""19002488-9-249-261"">urolithiasis</span>.",CTD_human
1,0,Biomarker,C0020429,Hyperalgesia,phenotype,hyperalgesia,10887,PROKR1,pkr1,CTD_human,16793879,"In wild-type mice, activation of PKRs by the PKR agonist Bv8 caused hyperalgesia and sensitized to the actions of capsaicin. pkr1-null mice exhibited impaired responses to Bv8 but showed normal hyperalgesic responses to bradykinin and PGE2 (prostaglandin E2).",0.2,"In wild-type mice, activation of PKRs by the PKR agonist Bv8 caused <span class=""disease"" id=""16793879-5-68-80"">hyperalgesia</span> and sensitized to the actions of capsaicin. <span class=""gene"" id=""16793879-5-125-129"">pkr1</span>-null mice exhibited impaired responses to Bv8 but showed normal hyperalgesic responses to bradykinin and PGE2 (prostaglandin E2).",CTD_human
1,0,Biomarker,C0030193,Pain,phenotype,pain,10887,PROKR1,PKR1,CTD_human,16793879,Impaired nociception and inflammatory pain sensation in mice lacking the prokineticin receptor PKR1: focus on interaction between PKR1 and the capsaicin receptor TRPV1 in pain behavior.,0.2,"Impaired nociception and inflammatory pain sensation in mice lacking the prokineticin receptor <span class=""gene"" id=""16793879-0-95-99"">PKR1</span>: focus on interaction between <span class=""gene"" id=""16793879-0-130-134"">PKR1</span> and the capsaicin receptor TRPV1 in <span class=""disease"" id=""16793879-0-171-175"">pain</span> behavior.",CTD_human
2,0,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,NIDDM,10891,PPARGC1A,Gly482Ser,CTD_human,15592662,Common polymorphisms of the PPAR-gamma2 (Pro12Ala) and PGC-1alpha (Gly482Ser) genes are associated with the conversion from impaired glucose tolerance to type 2 diabetes in the STOP-NIDDM trial.,0.37230271272619203,"Common polymorphisms of the PPAR-gamma2 (Pro12Ala) and <span class=""gene"" id=""15592662-0-55-65"">PGC-1alpha</span> (<span class=""gene"" id=""15592662-0-67-76"">Gly482Ser</span>) genes are associated with the conversion from impaired glucose tolerance to <span class=""disease"" id=""15592662-0-154-169"">type 2 diabetes</span> in the STOP-<span class=""disease"" id=""15592662-0-182-187"">NIDDM</span> trial.",CTD_human
1,0,Biomarker,C0027051,Myocardial Infarction,disease,MI,10891,PPARGC1A,PGC-1?,CTD_human,22503866,"Herein, we reported that the relative protein levels of RIP140/PGC-1? were up-regulated in the failing hearts after chronic myocardial infarction (MI), and correlated negatively with the energy state index phosphocreatine (PCr)/ATP ratios.",0.28,"Herein, we reported that the relative protein levels of RIP140/<span class=""gene"" id=""22503866-3-63-69"">PGC-1&alpha;</span> were up-regulated in the failing hearts after chronic <span class=""disease"" id=""22503866-3-124-145"">myocardial infarction</span> (<span class=""disease"" id=""22503866-3-147-149"">MI</span>), and correlated negatively with the energy state index phosphocreatine (PCr)/ATP ratios.",CTD_human
1,0,Biomarker,C0079744,Diffuse Large B-Cell Lymphoma,disease,DLBCL,10892,MALT1,MALT1 protease,CTD_human,21173233,These results demonstrate a critical function of PI3K-PDK1 signaling upstream of MALT1 protease and NF-?B in distinct ABC DLBCL cells and provide a rationale for the pharmacologic use of PI3K inhibitors in DLBCL therapy.,0.20439562854741,"These results demonstrate a critical function of PI3K-PDK1 signaling upstream of <span class=""gene"" id=""21173233-6-81-95"">MALT1 protease</span> and NF-&kappa;B in distinct ABC DLBCL cells and provide a rationale for the pharmacologic use of PI3K inhibitors in <span class=""disease"" id=""21173233-6-206-211"">DLBCL</span> therapy.",CTD_human
1,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastasis,10893,MMP24,MMP24,CTD_human,27869830,"Inactivation of CIC relieves repression of its effector ETV4, driving ETV4-mediated upregulation of MMP24, which is necessary and sufficient for metastasis.",0.2,"Inactivation of CIC relieves repression of its effector ETV4, driving ETV4-mediated upregulation of <span class=""gene"" id=""27869830-3-100-105"">MMP24</span>, which is necessary and sufficient for <span class=""disease"" id=""27869830-3-145-155"">metastasis</span>.",CTD_human
1,0,Biomarker,C0037050,Sick Building Syndrome,disease,sick building syndrome,10908,PNPLA6,NTE,CTD_human,23418070,Association of sick building syndrome with neuropathy target esterase (NTE) activity in Japanese.,0.200274726784213,"Association of <span class=""disease"" id=""23418070-0-15-37"">sick building syndrome</span> with <span class=""gene"" id=""23418070-0-43-69"">neuropathy target esterase</span> (<span class=""gene"" id=""23418070-0-71-74"">NTE</span>) activity in Japanese.",CTD_human
2,0,Biomarker,C0085084,Motor Neuron Disease,disease,motor neuron disease,10908,PNPLA6,Neuropathy target esterase,CTD_human,18313024,Neuropathy target esterase gene mutations cause motor neuron disease.,0.20383181960166602,"<span class=""gene"" id=""18313024-0-0-26"">Neuropathy target esterase</span> gene mutations cause <span class=""disease"" id=""18313024-0-48-68"">motor neuron disease</span>.",CTD_human
2,0,Biomarker,C0085084,Motor Neuron Disease,disease,Motor neuron disease,10908,PNPLA6,neuropathy target esterase,CTD_human,20603202,Motor neuron disease due to neuropathy target esterase mutation: enzyme analysis of fibroblasts from human subjects yields insights into pathogenesis.,0.20383181960166602,"<span class=""disease"" id=""20603202-0-0-20"">Motor neuron disease</span> due to <span class=""gene"" id=""20603202-0-28-54"">neuropathy target esterase</span> mutation: enzyme analysis of fibroblasts from human subjects yields insights into pathogenesis.",CTD_human
1,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,10911,UTS2,U-II,CTD_human,16160878,Urotensin-II (U-II) receptors are widely distributed in the central nervous system.Intracerebroventricular (i.c.v.) injection of U-II causes hypertension and bradycardia and stimulates prolactin and thyrotropin secretion.,0.206238848124954,"<span class=""gene"" id=""16160878-1-0-12"">Urotensin-II</span> (<span class=""gene"" id=""16160878-1-14-18"">U-II</span>) receptors are widely distributed in the central nervous system.Intracerebroventricular (i.c.v.) injection of <span class=""gene"" id=""16160878-1-129-133"">U-II</span> causes <span class=""disease"" id=""16160878-1-141-153"">hypertension</span> and bradycardia and stimulates prolactin and thyrotropin secretion.",CTD_human
1,0,Therapeutic,C0266999,Vesicular Stomatitis,disease,Vesicular Stomatitis,10919,EHMT2,EHMT2,CTD_human,26418342,Inhibition of EHMT2 Induces a Robust Antiviral Response Against Foot-and-Mouth Disease and Vesicular Stomatitis Virus Infections in Bovine Cells.,0.2,"Inhibition of <span class=""gene"" id=""26418342-0-14-19"">EHMT2</span> Induces a Robust Antiviral Response Against Foot-and-Mouth Disease and <span class=""disease"" id=""26418342-0-91-111"">Vesicular Stomatitis</span> Virus Infections in Bovine Cells.",CTD_human
1,0,Biomarker,C0085084,Motor Neuron Disease,disease,MND,10935,PRDX3,Prx3,CTD_human,16702190,"Using quantitative real-time PCR (Q-PCR), we show that Prx3 is also downregulated in spinal motor neurons from patients with both sporadic (sMND) and SOD1-related fMND.",0.200274726784213,"Using quantitative real-time PCR (Q-PCR), we show that <span class=""gene"" id=""16702190-9-55-59"">Prx3</span> is also downregulated in spinal motor neurons from patients with both sporadic (sMND) and SOD1-related f<span class=""disease"" id=""16702190-9-164-167"">MND</span>.",CTD_human
1,0,Biomarker,C0007134,Renal Cell Carcinoma,disease,RCC,10950,BTG3,BTG3,CTD_human,19221000,This is the first report to show that BTG3 is epigenetically silenced in RCC and can be reactivated by genistein-induced promoter demethylation and active histone modification.,0.200274726784213,"This is the first report to show that <span class=""gene"" id=""19221000-11-38-42"">BTG3</span> is epigenetically silenced in <span class=""disease"" id=""19221000-11-73-76"">RCC</span> and can be reactivated by genistein-induced promoter demethylation and active histone modification.",CTD_human
1,0,Biomarker,C0005695,Bladder Neoplasm,disease,bladder cancer,10979,FERMT2,Kindlin-2,CTD_human,21624607,Kindlin-2 expression in arsenite- and cadmium-transformed bladder cancer cell lines and in archival specimens of human bladder cancer.,0.2,"<span class=""gene"" id=""21624607-0-0-9"">Kindlin-2</span> expression in arsenite- and cadmium-transformed <span class=""disease"" id=""21624607-0-58-72"">bladder cancer</span> cell lines and in archival specimens of human <span class=""disease"" id=""21624607-0-119-133"">bladder cancer</span>.",CTD_human
1,0,Biomarker,C0023343,Leprosy,disease,leprosy,10981,RAB32,RAB32,CTD_human,22019778,Identification of two new loci at IL23R and RAB32 that influence susceptibility to leprosy.,0.20054945356842604,"Identification of two new loci at IL23R and <span class=""gene"" id=""22019778-0-44-49"">RAB32</span> that influence susceptibility to <span class=""disease"" id=""22019778-0-83-90"">leprosy</span>.",CTD_human
1,5,Biomarker,C0265962,Ichthyosis linearis circumflexa,disease,Netherton syndrome,11005,SPINK5,LEKTI,CTD_human,20657595,Here we show that the membrane protease matriptase initiates Netherton syndrome in a LEKTI-deficient mouse model by premature activation of a pro-kallikrein cascade.,0.493461612426442,"Here we show that the membrane protease matriptase initiates <span class=""disease"" id=""20657595-2-61-79"">Netherton syndrome</span> in a <span class=""gene"" id=""20657595-2-85-90"">LEKTI</span>-deficient mouse model by premature activation of a pro-kallikrein cascade.",CTD_human;ORPHANET
2,0,Therapeutic,C0033578,Prostatic Neoplasms,group,prostate tumor,11009,IL24,MDA7,CTD_human,21671747,"In conclusion, ASC expressing PEDF and MDA7 could effectively reduce prostate tumor growth in vivo, suggesting ASC-cytokine therapies might have translational applications, especially the PEDF modality.",0.20054945356842604,"In conclusion, ASC expressing PEDF and <span class=""gene"" id=""21671747-11-39-43"">MDA7</span> could effectively reduce <span class=""disease"" id=""21671747-11-69-83"">prostate tumor</span> growth in vivo, suggesting ASC-cytokine therapies might have translational applications, especially the PEDF modality.",CTD_human
1,0,Biomarker,C0036572,Seizures,phenotype,seizures,1103,CHAT,choline acetyltransferase,CTD_human,19941057,Pilocarpine-induced seizures produce alterations on choline acetyltransferase and acetylcholinesterase activities and deficit memory in rats.,0.2,"Pilocarpine-induced <span class=""disease"" id=""19941057-0-20-28"">seizures</span> produce alterations on <span class=""gene"" id=""19941057-0-52-77"">choline acetyltransferase</span> and acetylcholinesterase activities and deficit memory in rats.",CTD_human
1,0,Biomarker,C0023467,"Leukemia, Myelocytic, Acute",disease,AML,11040,PIM2,Pim-2,CTD_human,19458359,We identified the Pim-2 serine/threonine kinase as mainly responsible for 4E-BP1 phosphorylation on the S(65) residue and subsequent translation control in AML.,0.201098907136852,"We identified the <span class=""gene"" id=""19458359-7-18-23"">Pim-2</span> serine/threonine kinase as mainly responsible for 4E-BP1 phosphorylation on the S(65) residue and subsequent translation control in <span class=""disease"" id=""19458359-7-156-159"">AML</span>.",CTD_human
1,0,Biomarker,C0014544,Epilepsy,disease,epileptic,1106,CHD2,CHD2,CTD_human,23708187,Targeted resequencing in epileptic encephalopathies identifies de novo mutations in CHD2 and SYNGAP1.,0.202197814273705,"Targeted resequencing in <span class=""disease"" id=""23708187-0-25-34"">epileptic</span> encephalopathies identifies de novo mutations in <span class=""gene"" id=""23708187-0-84-88"">CHD2</span> and SYNGAP1.",CTD_human
1,0,Therapeutic,C0024121,Lung Neoplasms,group,lung tumor,11063,SOX30,SOX30,CTD_human,25435374,"SOX30 was expressed in normal and peri-tumoral lung tissues in which SOX30 was unmethylated, but was silenced or downregulated in lung cancer cell lines and primary lung tumor tissues harboring a hypermethylated SOX30.",0.200274726784213,"<span class=""gene"" id=""25435374-4-0-5"">SOX30</span> was expressed in normal and peri-tumoral lung tissues in which <span class=""gene"" id=""25435374-4-69-74"">SOX30</span> was unmethylated, but was silenced or downregulated in lung cancer cell lines and primary <span class=""disease"" id=""25435374-4-165-175"">lung tumor</span> tissues harboring a hypermethylated <span class=""gene"" id=""25435374-4-212-217"">SOX30</span>.",CTD_human
2,0,Biomarker,C0005586,Bipolar Disorder,disease,bipolar disorder,1109,AKR1C4,AKR1C4,CTD_human,21570127,AKR1C4 gene variant associated with low euthymic serum progesterone and a history of mood irritability in males with bipolar disorder.,0.400549453568426,"<span class=""gene"" id=""21570127-0-0-6"">AKR1C4</span> gene variant associated with low euthymic serum progesterone and a history of mood irritability in males with <span class=""disease"" id=""21570127-0-117-133"">bipolar disorder</span>.",CTD_human;PSYGENET
1,0,Biomarker,C1456784,Paranoia,disease,paranoia,1109,AKR1C4,AKR1C4,CTD_human,22356824,"The haplotype of all 4 SNPs in the AKR1C4 gene reduced the risk of exhibiting paranoia by 80% (OR 0.19, 95% CI 0.06-0.61, p=0.05).",0.200274726784213,"The haplotype of all 4 SNPs in the <span class=""gene"" id=""22356824-6-35-41"">AKR1C4</span> gene reduced the risk of exhibiting <span class=""disease"" id=""22356824-6-78-86"">paranoia</span> by 80% (OR 0.19, 95% CI 0.06-0.61, p=0.05).",CTD_human
1,0,Biomarker,C0034155,"Purpura, Thrombotic Thrombocytopenic",disease,TTP,11093,ADAMTS13,ADAMTS13,CTD_human,12656756,"The cloning of the ADAMTS13 gene has also raised the prospect of recombinant enzyme therapy for the treatment of TTP, and this has heightened the need for a simple assay.",0.31221358455981,"The cloning of the <span class=""gene"" id=""12656756-7-19-27"">ADAMTS13</span> gene has also raised the prospect of recombinant enzyme therapy for the treatment of <span class=""disease"" id=""12656756-7-113-116"">TTP</span>, and this has heightened the need for a simple assay.",CTD_human
2,0,Biomarker,C2717961,Thrombotic Microangiopathies,group,TMA,11093,ADAMTS13,ADAMTS13,CTD_human,16388419,"As with idiopathic cases of TTP/HUS, basic science discoveries in the late 1990s now suggest that the likely mechanisms by which these agents lead to a thrombotic microangiopathy (TMA) include either an immune-mediated phenomenon involving the ADAMTS13 metalloprotease or direct endothelial toxicity.",0.20989016423167198,"As with idiopathic cases of <span class=""gene"" id=""16388419-3-28-31"">TTP</span>/HUS, basic science discoveries in the late 1990s now suggest that the likely mechanisms by which these agents lead to a <span class=""disease"" id=""16388419-3-152-178"">thrombotic microangiopathy</span> (<span class=""disease"" id=""16388419-3-180-183"">TMA</span>) include either an immune-mediated phenomenon involving the <span class=""gene"" id=""16388419-3-244-252"">ADAMTS13</span> metalloprotease or direct endothelial toxicity.",CTD_human
2,0,Biomarker,C2717961,Thrombotic Microangiopathies,group,thrombotic microangiopathy,11093,ADAMTS13,Von Willebrand factor--cleaving protease,CTD_human,14625834,Von Willebrand factor--cleaving protease activity in thrombotic microangiopathy after living donor liver transplantation: a case report.,0.20989016423167198,"<span class=""gene"" id=""14625834-0-0-40"">Von Willebrand factor--cleaving protease</span> activity in <span class=""disease"" id=""14625834-0-53-79"">thrombotic microangiopathy</span> after living donor liver transplantation: a case report.",CTD_human
2,3,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,type 2 diabetes,111,ADCY5,ADCY5,CTD_human,20081858,"We also demonstrated association of ADCY5, PROX1, GCK, GCKR and DGKB-TMEM195 with type 2 diabetes.",0.21024308019620802,"We also demonstrated association of <span class=""gene"" id=""20081858-5-36-41"">ADCY5</span>, PROX1, GCK, GCKR and DGKB-TMEM195 with <span class=""disease"" id=""20081858-5-82-97"">type 2 diabetes</span>.",CTD_human
2,3,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,type 2 diabetes,111,ADCY5,ADCY5,CTD_human,23202124,"Five of the loci are known to be associated with other phenotypes: ADCY5 and CDKAL1 with type 2 diabetes, ADRB1 with adult blood pressure and HMGA2 and LCORL with adult height.",0.21024308019620802,"Five of the loci are known to be associated with other phenotypes: <span class=""gene"" id=""23202124-4-67-72"">ADCY5</span> and CDKAL1 with <span class=""disease"" id=""23202124-4-89-104"">type 2 diabetes</span>, ADRB1 with adult blood pressure and HMGA2 and LCORL with adult height.",CTD_human
1,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,111,ADCY5,AC V,CTD_human,12717102,"To assess the contributions of hypertension, left ventricular hypertrophy (LVH), the renin-angiotensin-aldosterone system (RAS), and the sympathetic nervous system to these changes, ventricular expression of AC V mRNA was measured at different ages in spontaneously hypertensive rats (SHRs).",0.2,"To assess the contributions of <span class=""disease"" id=""12717102-4-31-43"">hypertension</span>, left ventricular hypertrophy (LVH), the renin-angiotensin-aldosterone system (RAS), and the sympathetic nervous system to these changes, ventricular expression of <span class=""gene"" id=""12717102-4-208-212"">AC V</span> mRNA was measured at different ages in spontaneously hypertensive rats (SHRs).",CTD_human
1,0,Biomarker,C0004096,Asthma,disease,asthma,11127,KIF3A,KIF3A,CTD_human,21912604,"The association between KIF3A rs7737031 and asthma was validated in 3 independent populations, further substantiating the validity of our gene selection approach.",0.20054945356842604,"The association between <span class=""gene"" id=""21912604-9-24-29"">KIF3A</span> rs7737031 and <span class=""disease"" id=""21912604-9-44-50"">asthma</span> was validated in 3 independent populations, further substantiating the validity of our gene selection approach.",CTD_human
1,0,Biomarker,C0152427,Polydactyly,disease,polydactyly,11127,KIF3A,Kif3a,CTD_human,17698054,"Here we demonstrate that conditional inactivation of the Kif3a subunit of the kinesin-2 intraflagellar transport motor in mesenchymal skeletal progenitor cells results in severe patterning defects in the craniofacial area, the formation of split sternum and the development of polydactyly.",0.2,"Here we demonstrate that conditional inactivation of the <span class=""gene"" id=""17698054-2-57-62"">Kif3a</span> subunit of the kinesin-2 intraflagellar transport motor in mesenchymal skeletal progenitor cells results in severe patterning defects in the craniofacial area, the formation of split sternum and the development of <span class=""disease"" id=""17698054-2-277-288"">polydactyly</span>.",CTD_human
1,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,NSCLC,1113,CHGA,ChrA,CTD_human,21595568,"Expression of NSE was present in 22.4%, ChrA in 15.5% and Syn in 14.8% of patients with NSCLC.",0.20082418035263896,"Expression of NSE was present in 22.4%, <span class=""gene"" id=""21595568-4-40-44"">ChrA</span> in 15.5% and Syn in 14.8% of patients with <span class=""disease"" id=""21595568-4-88-93"">NSCLC</span>.",CTD_human
1,0,Biomarker,C0031511,Pheochromocytoma,disease,pheochromocytoma,1113,CHGA,chromogranin A,CTD_human,11116123,"We conclude that plasma chromogranin A is an effective tool in the diagnosis of pheochromocytoma, and markedly elevated chromogranin A may point to malignant pheochromocytoma.",0.202472541057918,"We conclude that plasma <span class=""gene"" id=""11116123-13-24-38"">chromogranin A</span> is an effective tool in the diagnosis of <span class=""disease"" id=""11116123-13-80-96"">pheochromocytoma</span>, and markedly elevated <span class=""gene"" id=""11116123-13-120-134"">chromogranin A</span> may point to malignant pheochromocytoma.",CTD_human
1,1,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,T2DM,11132,CAPN10,CAPN-10,CTD_human,23349674,"Chronic exposure to iAs seems to be a risk factor for T2DM in humans through the reduction of beta-cell function, with an enhanced effect seen in the presence of the at-risk genotype of SNP-43 in CAPN-10.",0.328526153164498,"Chronic exposure to iAs seems to be a risk factor for <span class=""disease"" id=""23349674-10-54-58"">T2DM</span> in humans through the reduction of beta-cell function, with an enhanced effect seen in the presence of the at-risk genotype of SNP-43 in <span class=""gene"" id=""23349674-10-196-203"">CAPN-10</span>.",CTD_human
2,0,Biomarker,C0004352,Autistic Disorder,disease,autism,11141,IL1RAPL1,IL1RAPL1,CTD_human,18801879,Mutations in the calcium-related gene IL1RAPL1 are associated with autism.,0.40433011601278,"Mutations in the calcium-related gene <span class=""gene"" id=""18801879-0-38-46"">IL1RAPL1</span> are associated with <span class=""disease"" id=""18801879-0-67-73"">autism</span>.",CTD_human;HPO
2,0,Biomarker,C0004352,Autistic Disorder,disease,autism,11141,IL1RAPL1,IL1RAPL1,CTD_human,20437600,Mutations or deletions in IL1RAPL1 have been previously reported in three families with autism.,0.40433011601278,"Mutations or deletions in <span class=""gene"" id=""20437600-7-26-34"">IL1RAPL1</span> have been previously reported in three families with <span class=""disease"" id=""20437600-7-88-94"">autism</span>.",CTD_human;HPO
1,0,Biomarker,C0041296,Tuberculosis,disease,tuberculosis,11151,CORO1A,TACO,CTD_human,16040207,Recent reports have indicated that cholesterol-dependent association of tryptophan-aspartate containing coat protein (TACO) plays a crucial role in the entry/survival of Mycobacterium tuberculosis within human macrophages.,0.201098907136852,"Recent reports have indicated that cholesterol-dependent association of <span class=""gene"" id=""16040207-1-72-116"">tryptophan-aspartate containing coat protein</span> (<span class=""gene"" id=""16040207-1-118-122"">TACO</span>) plays a crucial role in the entry/survival of Mycobacterium <span class=""disease"" id=""16040207-1-184-196"">tuberculosis</span> within human macrophages.",CTD_human
1,0,Therapeutic,C0009375,Colonic Neoplasms,group,colon tumors,11156,PTP4A3,Ptp4a3,CTD_human,23555575,Ptp4a3-null mice developed 50% fewer colon tumors than wildtype mice after exposure to azoxymethane and dextran sodium sulfate.,0.20054945356842604,"<span class=""gene"" id=""23555575-10-0-6"">Ptp4a3</span>-null mice developed 50% fewer <span class=""disease"" id=""23555575-10-37-49"">colon tumors</span> than wildtype mice after exposure to azoxymethane and dextran sodium sulfate.",CTD_human
1,0,Biomarker,C0017638,Glioma,disease,glioma,1116,CHI3L1,YKL-40,CTD_human,20506295,"CHI3L1 (YKL-40) is expressed in human gliomas and regulates the invasion, growth and survival of glioma cells.",0.21177018558921198,"<span class=""gene"" id=""20506295-0-0-6"">CHI3L1</span> (<span class=""gene"" id=""20506295-0-8-14"">YKL-40</span>) is expressed in human <span class=""disease"" id=""20506295-0-38-45"">gliomas</span> and regulates the invasion, growth and survival of <span class=""disease"" id=""20506295-0-97-103"">glioma</span> cells.",CTD_human
1,0,Biomarker,C0001418,Adenocarcinoma,group,adenocarcinoma,11186,RASSF1,RASSF1,CTD_human,15639718,"Comparison of methylation in adenocarcinoma cell lines and tumors versus non-tumor lung tissue showed methylation of ESR1, PGR1 and RASSF1 to be significantly elevated in adenocarcinoma, with RASSF1 being most significant (P=0.0002).",0.217525092680369,"Comparison of methylation in <span class=""disease"" id=""15639718-8-29-43"">adenocarcinoma</span> cell lines and tumors versus non-tumor lung tissue showed methylation of ESR1, PGR1 and <span class=""gene"" id=""15639718-8-132-138"">RASSF1</span> to be significantly elevated in <span class=""disease"" id=""15639718-8-171-185"">adenocarcinoma</span>, with <span class=""gene"" id=""15639718-8-192-198"">RASSF1</span> being most significant (P=0.0002).",CTD_human
1,0,Biomarker,C0005695,Bladder Neoplasm,disease,bladder cancer,11186,RASSF1,RASSF1A,CTD_human,15987713,"We, therefore, examined, in a population-based study of human bladder cancer, the relationship between epigenetic silencing of three tumor suppressor genes, p16(INK4A), RASSF1A and PRSS3, and exposure to both tobacco and arsenic in bladder cancer.",0.212319639157638,"We, therefore, examined, in a population-based study of human <span class=""disease"" id=""15987713-5-62-76"">bladder cancer</span>, the relationship between epigenetic silencing of three tumor suppressor genes, p16(INK4A), <span class=""gene"" id=""15987713-5-169-176"">RASSF1A</span> and PRSS3, and exposure to both tobacco and arsenic in <span class=""disease"" id=""15987713-5-232-246"">bladder cancer</span>.",CTD_human
1,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,NSCLC,11186,RASSF1,RASSF1A,CTD_human,18337602,"In a multivariate model, promoter methylation of the cyclin-dependent kinase inhibitor 2A gene p16, the H-cadherin gene CDH13, the Ras association domain family 1 gene RASSF1A, and the adenomatous polyposis coli gene APC in tumors and in histologically tumor-negative lymph nodes was associated with tumor recurrence, independently of NSCLC stage, age, sex, race, smoking history, and histologic characteristics of the tumor.",0.215044460597091,"In a multivariate model, promoter methylation of the cyclin-dependent kinase inhibitor 2A gene p16, the H-cadherin gene CDH13, the Ras association domain family 1 gene <span class=""gene"" id=""18337602-5-168-175"">RASSF1A</span>, and the adenomatous polyposis coli gene APC in tumors and in histologically tumor-negative lymph nodes was associated with tumor recurrence, independently of <span class=""disease"" id=""18337602-5-335-340"">NSCLC</span> stage, age, sex, race, smoking history, and histologic characteristics of the tumor.",CTD_human
1,0,Biomarker,C0021390,Inflammatory Bowel Diseases,group,inflammatory bowel disease,11186,RASSF1,Rassf1a,CTD_human,24146755,"Rassf1a knockout mice displayed clinical symptoms of inflammatory bowel disease including: increased intestinal permeability, enhanced cytokine/chemokine production, elevated nuclear factor of kappa light polypeptide gene enhancer in B-cells (NF?B) activity, elevated colonic cell death and epithelial cell injury.",0.2,"<span class=""gene"" id=""24146755-3-0-7"">Rassf1a</span> knockout mice displayed clinical symptoms of <span class=""disease"" id=""24146755-3-53-79"">inflammatory bowel disease</span> including: increased intestinal permeability, enhanced cytokine/chemokine production, elevated nuclear factor of kappa light polypeptide gene enhancer in B-cells (NF&kappa;B) activity, elevated colonic cell death and epithelial cell injury.",CTD_human
1,0,Biomarker,C0025149,Medulloblastoma,disease,medulloblastoma,11186,RASSF1,RASSF1A,CTD_human,21880625,"On the basis of this knowledge, we demonstrate how the loss of RASSF1A function in medulloblastoma cells might be overcome using the novel BH3-only mimetic ABT-737 in combination with chemotherapeutic agents to target the BCL-2 anti-apoptotic members.",0.201923087489492,"On the basis of this knowledge, we demonstrate how the loss of <span class=""gene"" id=""21880625-6-63-70"">RASSF1A</span> function in <span class=""disease"" id=""21880625-6-83-98"">medulloblastoma</span> cells might be overcome using the novel BH3-only mimetic ABT-737 in combination with chemotherapeutic agents to target the BCL-2 anti-apoptotic members.",CTD_human
2,0,Biomarker,C0025500,Mesothelioma,disease,mesothelioma,11186,RASSF1,RASSF1A,CTD_human,12082623,"These data, together with our previous findings, support a causal relationship between SV40 infection, progressive RASSF1A methylation and its silencing, and the pathogenesis of mesothelioma.",0.20328236603324,"These data, together with our previous findings, support a causal relationship between SV40 infection, progressive <span class=""gene"" id=""12082623-10-115-122"">RASSF1A</span> methylation and its silencing, and the pathogenesis of <span class=""disease"" id=""12082623-10-178-190"">mesothelioma</span>.",CTD_human
1,0,Biomarker,C0080178,Spina Bifida,disease,spina bifida,1119,CHKA,CHKA,CTD_human,17184542,This study investigated whether single nucleotide polymorphisms (SNPs) in human choline kinase A (CHKA) gene and CTP:phosphocholine cytidylytransferase (PCYT1A) gene were risk factors for spina bifida.,0.200274726784213,"This study investigated whether single nucleotide polymorphisms (SNPs) in human <span class=""gene"" id=""17184542-6-80-94"">choline kinase</span> A (<span class=""gene"" id=""17184542-6-98-102"">CHKA</span>) gene and CTP:phosphocholine cytidylytransferase (PCYT1A) gene were risk factors for <span class=""disease"" id=""17184542-6-188-200"">spina bifida</span>.",CTD_human
1,0,Biomarker,C0009404,Colorectal Neoplasms,group,colorectal tumor,11197,WIF1,WIF-1,CTD_human,17923031,"Methylation of sFRP1, 2, 5 and WIF-1 genes might serve as biomarkers for the early detection of colorectal tumor.",0.20054945356842604,"Methylation of sFRP1, 2, 5 and <span class=""gene"" id=""17923031-16-31-36"">WIF-1</span> genes might serve as biomarkers for the early detection of <span class=""disease"" id=""17923031-16-96-112"">colorectal tumor</span>.",CTD_human
1,0,Biomarker,C0027404,Narcolepsy,disease,narcolepsy,1120,CHKB,CHKB,CTD_human,18820697,Variant between CPT1B and CHKB associated with susceptibility to narcolepsy.,0.201098907136852,"Variant between CPT1B and <span class=""gene"" id=""18820697-0-26-30"">CHKB</span> associated with susceptibility to <span class=""disease"" id=""18820697-0-65-75"">narcolepsy</span>.",CTD_human
1,0,Biomarker,C0024305,"Lymphoma, Non-Hodgkin",disease,Non-Hodgkin Lymphoma,11200,CHEK2,CHEK2,CTD_human,26506619,Association of Germline CHEK2 Gene Variants with Risk and Prognosis of Non-Hodgkin Lymphoma.,0.200274726784213,"Association of Germline <span class=""gene"" id=""26506619-0-24-29"">CHEK2</span> Gene Variants with Risk and Prognosis of <span class=""disease"" id=""26506619-0-71-91"">Non-Hodgkin Lymphoma</span>.",CTD_human
1,2,Biomarker,C0029463,Osteosarcoma,disease,osteosarcomas,11200,CHEK2,CHK2,CTD_human,11746983,"Mutations of the CHK2 gene are found in some osteosarcomas, but are rare in breast, lung, and ovarian tumors.",0.603557092817453,"Mutations of the <span class=""gene"" id=""11746983-0-17-21"">CHK2</span> gene are found in some <span class=""disease"" id=""11746983-0-45-58"">osteosarcomas</span>, but are rare in breast, lung, and ovarian tumors.",CTD_human;HPO;ORPHANET
2,0,Biomarker,C0085390,Li-Fraumeni Syndrome,disease,Li-Fraumeni Syndrome,11200,CHEK2,CHK2,CTD_human,11719428,Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni Syndrome.,0.41068563382967604,"Destabilization of <span class=""gene"" id=""11719428-0-19-23"">CHK2</span> by a missense mutation associated with <span class=""disease"" id=""11719428-0-63-83"">Li-Fraumeni Syndrome</span>.",CTD_human;ORPHANET
1,0,Biomarker,C2931456,"Prostate cancer, familial",disease,familial prostate cancer,11200,CHEK2,CHEK2,CTD_human,12533788,Additional screening for CHEK2 mutations in 149 families with familial prostate cancer revealed 11 mutations (5 unique) in nine families.,0.40082418035263895,"Additional screening for <span class=""gene"" id=""12533788-5-25-30"">CHEK2</span> mutations in 149 families with <span class=""disease"" id=""12533788-5-62-86"">familial prostate cancer</span> revealed 11 mutations (5 unique) in nine families.",CTD_human;ORPHANET
1,5,Biomarker,C0158683,Polycystic liver disease,disease,polycystic liver disease,11231,SEC63,SEC63,CTD_human,21685914,Autosomal dominant polycystic liver disease results from mutations in PRKCSH or SEC63.,0.603021994626344,"Autosomal dominant <span class=""disease"" id=""21685914-1-19-43"">polycystic liver disease</span> results from mutations in PRKCSH or <span class=""gene"" id=""21685914-1-80-85"">SEC63</span>.",CTD_human;HPO;ORPHANET
4,10,Biomarker,C1868682,Paroxysmal kinesigenic choreoathetosis,disease,paroxysmal kinesigenic dyskinesia,112476,PRRT2,PRRT2,CTD_human,22101681,Exome sequencing identifies truncating mutations in PRRT2 that cause paroxysmal kinesigenic dyskinesia.,0.615384699915934,"Exome sequencing identifies truncating mutations in <span class=""gene"" id=""22101681-0-52-57"">PRRT2</span> that cause <span class=""disease"" id=""22101681-0-69-102"">paroxysmal kinesigenic dyskinesia</span>.",CTD_human;ORPHANET;UNIPROT
1,0,Therapeutic,C0004096,Asthma,disease,Asthma,11251,PTGDR2,CRTh2,CTD_human,27103662,Preclinical Safety Profile of a Depleting Antibody against CRTh2 for Asthma: Well Tolerated Despite Unexpected CRTh2 Expression on Vascular Pericytes in the Central Nervous System and Gastric Mucosa.,0.21538302118431,"Preclinical Safety Profile of a Depleting Antibody against <span class=""gene"" id=""27103662-0-59-64"">CRTh2</span> for <span class=""disease"" id=""27103662-0-69-75"">Asthma</span>: Well Tolerated Despite Unexpected <span class=""gene"" id=""27103662-0-111-116"">CRTh2</span> Expression on Vascular Pericytes in the Central Nervous System and Gastric Mucosa.",CTD_human
1,0,Biomarker,C0002622,Amnesia,disease,amnesia,11255,HRH3,histamine H3 receptor,CTD_human,11125734,Effects of histamine H3 receptor agonists and antagonists on cognitive performance and scopolamine-induced amnesia.,0.2,"Effects of <span class=""gene"" id=""11125734-0-11-32"">histamine H3 receptor</span> agonists and antagonists on cognitive performance and scopolamine-induced <span class=""disease"" id=""11125734-0-107-114"">amnesia</span>.",CTD_human
1,1,Biomarker,C0023434,Chronic Lymphocytic Leukemia,disease,CLL,11262,SP140,SP140,CTD_human,18758461,"We identified six previously unreported CLL risk loci at 2q13 (rs17483466; P = 2.36 x 10(-10)), 2q37.1 (rs13397985, SP140; P = 5.40 x 10(-10)), 6p25.3 (rs872071, IRF4; P = 1.91 x 10(-20)), 11q24.1 (rs735665; P = 3.78 x 10(-12)), 15q23 (rs7176508; P = 4.54 x 10(-12)) and 19q13.32 (rs11083846, PRKD2; P = 3.96 x 10(-9)).",0.20591296418342803,"We identified six previously unreported <span class=""disease"" id=""18758461-2-40-43"">CLL</span> risk loci at 2q13 (rs17483466; P = 2.36 x 10(-10)), 2q37.1 (rs13397985, <span class=""gene"" id=""18758461-2-116-121"">SP140</span>; P = 5.40 x 10(-10)), 6p25.3 (rs872071, IRF4; P = 1.91 x 10(-20)), 11q24.1 (rs735665; P = 3.78 x 10(-12)), 15q23 (rs7176508; P = 4.54 x 10(-12)) and 19q13.32 (rs11083846, PRKD2; P = 3.96 x 10(-9)).",CTD_human
1,0,Biomarker,C0023269,leiomyosarcoma,disease,leiomyosarcomas,11274,USP18,USP18,CTD_human,26555296,Mice null for the deubiquitinase USP18 spontaneously develop leiomyosarcomas.,0.200274726784213,"Mice null for the deubiquitinase <span class=""gene"" id=""26555296-0-33-38"">USP18</span> spontaneously develop <span class=""disease"" id=""26555296-0-61-76"">leiomyosarcomas</span>.",CTD_human
1,0,Biomarker,C0009952,Febrile Convulsions,disease,febrile seizures,112755,STX1B,syntaxin-1B,CTD_human,25362483,"Here we report the identification of mutations in STX1B, encoding syntaxin-1B, that are associated with both febrile seizures and epilepsy.",0.20054945356842604,"Here we report the identification of mutations in <span class=""gene"" id=""25362483-3-50-55"">STX1B</span>, encoding <span class=""gene"" id=""25362483-3-66-77"">syntaxin-1B</span>, that are associated with both <span class=""disease"" id=""25362483-3-109-125"">febrile seizures</span> and epilepsy.",CTD_human
1,0,Biomarker,C0014544,Epilepsy,disease,epilepsy,112755,STX1B,STX1B,CTD_human,25362483,"Mutations in STX1B, encoding a presynaptic protein, cause fever-associated epilepsy syndromes.",0.20054945356842604,"Mutations in <span class=""gene"" id=""25362483-0-13-18"">STX1B</span>, encoding a presynaptic protein, cause fever-associated <span class=""disease"" id=""25362483-0-75-83"">epilepsy</span> syndromes.",CTD_human
2,8,Biomarker,C0024141,"Lupus Erythematosus, Systemic",disease,systemic lupus erythematosus,11277,TREX1,TREX1,CTD_human,17660818,Mutations in the gene encoding the 3'-5' DNA exonuclease TREX1 are associated with systemic lupus erythematosus.,0.4119937552161121,"Mutations in the gene encoding the 3'-5' DNA exonuclease <span class=""gene"" id=""17660818-0-57-62"">TREX1</span> are associated with <span class=""disease"" id=""17660818-0-83-111"">systemic lupus erythematosus</span>.",CTD_human;UNIPROT
3,1,Biomarker,C0024145,Chilblain lupus 1,disease,chilblain lupus,11277,TREX1,TREX1,CTD_human,27566796,Familial chilblain lupus is a monogenic form of cutaneous lupus erythematosus caused by loss-of-function mutations in the nucleases TREX1 or SAMHD1.,0.602197814273705,"Familial <span class=""disease"" id=""27566796-1-9-24"">chilblain lupus</span> is a monogenic form of cutaneous lupus erythematosus caused by loss-of-function mutations in the nucleases <span class=""gene"" id=""27566796-1-132-137"">TREX1</span> or SAMHD1.",CTD_human;ORPHANET;UNIPROT
8,22,Biomarker,C0796126,AICARDI-GOUTIERES SYNDROME 1,disease,Aicardi-Goutières syndrome,11277,TREX1,AGS1,CTD_human,16845398,Mutations in the gene encoding the 3'-5' DNA exonuclease TREX1 cause Aicardi-Goutières syndrome at the AGS1 locus.,0.48796707674218,"Mutations in the gene encoding the 3'-5' DNA exonuclease <span class=""gene"" id=""16845398-0-57-62"">TREX1</span> cause <span class=""disease"" id=""16845398-0-69-95"">Aicardi-Gouti&egrave;res syndrome</span> at the <span class=""gene"" id=""16845398-0-103-107"">AGS1</span> locus.",CTD_human;UNIPROT
1,0,Biomarker,C0025958,Microcephaly,disease,microcephaly,11284,PNKP,PNKP,CTD_human,20118933,"Mutations in PNKP cause microcephaly, seizures and defects in DNA repair.",0.200274726784213,"Mutations in <span class=""gene"" id=""20118933-0-13-17"">PNKP</span> cause <span class=""disease"" id=""20118933-0-24-36"">microcephaly</span>, seizures and defects in DNA repair.",CTD_human
1,0,Biomarker,C0036572,Seizures,phenotype,seizures,11284,PNKP,PNKP,CTD_human,20118933,"Mutations in PNKP cause microcephaly, seizures and defects in DNA repair.",0.40027472678421294,"Mutations in <span class=""gene"" id=""20118933-0-13-17"">PNKP</span> cause microcephaly, <span class=""disease"" id=""20118933-0-38-46"">seizures</span> and defects in DNA repair.",CTD_human;HPO
1,0,Biomarker,C0005686,Urinary Bladder Diseases,group,Urinary Bladder Disease,1131,CHRM3,Muscarinic Acetylcholine Receptor M3,CTD_human,22077972,Muscarinic Acetylcholine Receptor M3 Mutation Causes Urinary Bladder Disease and a Prune-Belly-like Syndrome.,0.200274726784213,"<span class=""gene"" id=""22077972-0-0-36"">Muscarinic Acetylcholine Receptor M3</span> Mutation Causes <span class=""disease"" id=""22077972-0-53-76"">Urinary Bladder Disease</span> and a Prune-Belly-like Syndrome.",CTD_human
1,1,Biomarker,C0033770,Prune Belly Syndrome,disease,Prune-Belly,1131,CHRM3,Muscarinic Acetylcholine Receptor M3,CTD_human,22077972,Muscarinic Acetylcholine Receptor M3 Mutation Causes Urinary Bladder Disease and a Prune-Belly-like Syndrome.,0.600274726784213,"<span class=""gene"" id=""22077972-0-0-36"">Muscarinic Acetylcholine Receptor M3</span> Mutation Causes Urinary Bladder Disease and a <span class=""disease"" id=""22077972-0-83-94"">Prune-Belly</span>-like Syndrome.",CTD_human;HPO;ORPHANET
1,0,Biomarker,C1853118,Severe congenital neutropenia,phenotype,congenital neutropenia,11311,VPS45,VPS45,CTD_human,23599270,The Thr224Asn mutation in the VPS45 gene is associated with the congenital neutropenia and primary myelofibrosis of infancy.,0.20054945356842604,"The Thr224Asn mutation in the <span class=""gene"" id=""23599270-0-30-35"">VPS45</span> gene is associated with the <span class=""disease"" id=""23599270-0-64-86"">congenital neutropenia</span> and primary myelofibrosis of infancy.",CTD_human
9,0,Biomarker,C0030567,Parkinson Disease,disease,Parkinson's disease,11315,PARK7,PARK7,CTD_human,23037695,"DJ-1 was first identified as an activated ras-dependent oncogene and later found to be a causative gene for a familial form of Parkinson's disease, PARK7.",0.305236237771581,"DJ-1 was first identified as an activated ras-dependent oncogene and later found to be a causative gene for a familial form of <span class=""disease"" id=""23037695-3-127-146"">Parkinson's disease</span>, <span class=""gene"" id=""23037695-3-148-153"">PARK7</span>.",CTD_human
9,0,Biomarker,C0030567,Parkinson Disease,disease,Parkinson's disease,11315,PARK7,PARK7,CTD_human,20800516,The familial Parkinson's disease gene DJ-1 (PARK7) is expressed in red cells and plays a role in protection against oxidative damage.,0.305236237771581,"The familial <span class=""disease"" id=""20800516-0-13-32"">Parkinson's disease</span> gene DJ-1 (<span class=""gene"" id=""20800516-0-44-49"">PARK7</span>) is expressed in red cells and plays a role in protection against oxidative damage.",CTD_human
9,0,Biomarker,C0030567,Parkinson Disease,disease,Parkinson disease,11315,PARK7,protein DJ-1,CTD_human,23792957,Parkinson disease protein DJ-1 binds metals and protects against metal-induced cytotoxicity.,0.305236237771581,"<span class=""disease"" id=""23792957-0-0-17"">Parkinson disease</span> <span class=""gene"" id=""23792957-0-18-30"">protein DJ-1</span> binds metals and protects against metal-induced cytotoxicity.",CTD_human
9,0,Biomarker,C0030567,Parkinson Disease,disease,PD,11315,PARK7,"protein, DJ-1",CTD_human,22898350,"Loss-of-function mutations in the gene encoding the multifunctional protein, DJ-1, have been implicated in the pathogenesis of early-onset familial Parkinson's disease (PD), suggesting that DJ-1 may act as a neuroprotectant for dopaminergic (DA) neurons.",0.305236237771581,"Loss-of-function mutations in the gene encoding the multifunctional <span class=""gene"" id=""22898350-1-68-81"">protein, DJ-1</span>, have been implicated in the pathogenesis of early-onset familial <span class=""disease"" id=""22898350-1-148-167"">Parkinson's disease</span> (<span class=""disease"" id=""22898350-1-169-171"">PD</span>), suggesting that DJ-1 may act as a neuroprotectant for dopaminergic (DA) neurons.",CTD_human
9,0,Biomarker,C0030567,Parkinson Disease,disease,Parkinson's disease,11315,PARK7,PARK7,CTD_human,15784737,Mutations of the DJ-1 (PARK7) gene are linked to familial Parkinson's disease.,0.305236237771581,"Mutations of the DJ-1 (<span class=""gene"" id=""15784737-1-23-28"">PARK7</span>) gene are linked to familial <span class=""disease"" id=""15784737-1-58-77"">Parkinson's disease</span>.",CTD_human
1,0,Biomarker,C0279626,Squamous cell carcinoma of esophagus,disease,esophageal squamous cell carcinoma,113278,SLC52A3,C20orf54,CTD_human,20729853,Genome-wide association study of esophageal squamous cell carcinoma in Chinese subjects identifies susceptibility loci at PLCE1 and C20orf54.,0.202472541057918,"Genome-wide association study of <span class=""disease"" id=""20729853-0-33-67"">esophageal squamous cell carcinoma</span> in Chinese subjects identifies susceptibility loci at PLCE1 and <span class=""gene"" id=""20729853-0-132-140"">C20orf54</span>.",CTD_human
1,0,Biomarker,C0149521,"Pancreatitis, Chronic",disease,chronic pancreatitis,11330,CTRC,CTRC,CTD_human,18059268,Chymotrypsin C (CTRC) variants that diminish activity or secretion are associated with chronic pancreatitis.,0.21407489979787397,"<span class=""gene"" id=""18059268-0-0-14"">Chymotrypsin C</span> (<span class=""gene"" id=""18059268-0-16-20"">CTRC</span>) variants that diminish activity or secretion are associated with <span class=""disease"" id=""18059268-0-87-107"">chronic pancreatitis</span>.",CTD_human
4,0,Biomarker,C0001973,"Alcoholic Intoxication, Chronic",disease,alcohol dependence,1136,CHRNA3,CHRNA3,CTD_human,18414406,"Using the family-based association test, we observed that a different group of polymorphisms, spanning CHRNA5-CHRNA3, demonstrate association with alcohol dependence defined by Diagnostic and Statistical Manual of Mental Disorders, 4th edn (DSM-IV) criteria.",0.410452294445791,"Using the family-based association test, we observed that a different group of polymorphisms, spanning CHRNA5-<span class=""gene"" id=""18414406-5-110-116"">CHRNA3</span>, demonstrate association with <span class=""disease"" id=""18414406-5-147-165"">alcohol dependence</span> defined by Diagnostic and Statistical Manual of Mental Disorders, 4th edn (DSM-IV) criteria.",CTD_human;PSYGENET
3,0,Biomarker,C0085541,"Epilepsy, Frontal Lobe",disease,frontal lobe epilepsy,1137,CHRNA4,Chrna4,CTD_human,12823585,A new Chrna4 mutation with low penetrance in nocturnal frontal lobe epilepsy.,0.215760062283148,"A new <span class=""gene"" id=""12823585-0-6-12"">Chrna4</span> mutation with low penetrance in nocturnal <span class=""disease"" id=""12823585-0-55-76"">frontal lobe epilepsy</span>.",CTD_human
5,0,Biomarker,C0001973,"Alcoholic Intoxication, Chronic",disease,alcohol dependence,1138,CHRNA5,CHRNA5,CTD_human,18414406,Genetic variation in the CHRNA5 gene affects mRNA levels and is associated with risk for alcohol dependence.,0.4134087765375061,"Genetic variation in the <span class=""gene"" id=""18414406-0-25-31"">CHRNA5</span> gene affects mRNA levels and is associated with risk for <span class=""disease"" id=""18414406-0-89-107"">alcohol dependence</span>.",CTD_human;PSYGENET
4,0,Biomarker,C0525045,Mood Disorders,group,mood disorder,114,ADCY8,Adcy8,CTD_human,19691954,Interspecies trait genetics reveals association of Adcy8 with mouse avoidance behavior and a human mood disorder.,0.40027472678421294,"Interspecies trait genetics reveals association of <span class=""gene"" id=""19691954-0-51-56"">Adcy8</span> with mouse avoidance behavior and a human <span class=""disease"" id=""19691954-0-99-112"">mood disorder</span>.",CTD_human;PSYGENET
1,0,Biomarker,C0002395,Alzheimer's Disease,disease,Alzheimer disease,1141,CHRNB2,CHRNB2,CTD_human,17192785,"In addition to identifying the epsilon4 allele of APOE and related effects, we pinpointed over a dozen potential Alzheimer disease susceptibility genes (ACE, CHRNB2, CST3, ESR1, GAPDHS, IDE, MTHFR, NCSTN, PRNP, PSEN1, TF, TFAM and TNF) with statistically significant allelic summary odds ratios (ranging from 1.11-1.38 for risk alleles and 0.92-0.67 for protective alleles).",0.22073217642199497,"In addition to identifying the epsilon4 allele of APOE and related effects, we pinpointed over a dozen potential <span class=""disease"" id=""17192785-5-113-130"">Alzheimer disease</span> susceptibility genes (ACE, <span class=""gene"" id=""17192785-5-158-164"">CHRNB2</span>, CST3, ESR1, GAPDHS, IDE, MTHFR, NCSTN, PRNP, PSEN1, TF, TFAM and TNF) with statistically significant allelic summary odds ratios (ranging from 1.11-1.38 for risk alleles and 0.92-0.67 for protective alleles).",CTD_human
1,0,Biomarker,C0010346,Crohn Disease,disease,Crohn's disease,114548,NLRP3,NLRP3,CTD_human,19098911,Common variants in the NLRP3 region contribute to Crohn's disease susceptibility.,0.21894011400176303,"Common variants in the <span class=""gene"" id=""19098911-0-23-28"">NLRP3</span> region contribute to <span class=""disease"" id=""19098911-0-50-65"">Crohn's disease</span> susceptibility.",CTD_human
1,3,Biomarker,C0035258,Restless Legs Syndrome,disease,RLS,114781,BTBD9,BTBD9,CTD_human,17637780,"In a genome-wide association study we found highly significant associations between RLS and intronic variants in the homeobox gene MEIS1, the BTBD9 gene encoding a BTB(POZ) domain as well as variants in a third locus containing the genes encoding mitogen-activated protein kinase MAP2K5 and the transcription factor LBXCOR1 on chromosomes 2p, 6p and 15q, respectively.",0.21462435336629998,"In a genome-wide association study we found highly significant associations between <span class=""disease"" id=""17637780-2-84-87"">RLS</span> and intronic variants in the homeobox gene MEIS1, the <span class=""gene"" id=""17637780-2-142-147"">BTBD9</span> gene encoding a BTB(POZ) domain as well as variants in a third locus containing the genes encoding mitogen-activated protein kinase MAP2K5 and the transcription factor LBXCOR1 on chromosomes 2p, 6p and 15q, respectively.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,114788,CSMD3,CSMD3,CTD_human,18270536,Two patients with balanced translocations and autistic disorder: CSMD3 as a candidate gene for autism found in their common 8q23 breakpoint area.,0.200274726784213,"Two patients with balanced translocations and <span class=""disease"" id=""18270536-0-46-63"">autistic disorder</span>: <span class=""gene"" id=""18270536-0-65-70"">CSMD3</span> as a candidate gene for <span class=""disease"" id=""18270536-0-95-101"">autism</span> found in their common 8q23 breakpoint area.",CTD_human
1,0,Biomarker,C0028754,Obesity,disease,obese,1149,CIDEA,CIDEA,CTD_human,20975297,"Several genes and transcripts involved in lipolysis were down-regulated, such as AKAP1, PRKAR2B, Gi and CIDEA, whereas NPY1R and CES1 were up-regulated, when comparing obese to lean subjects.",0.20487956958120604,"Several genes and transcripts involved in lipolysis were down-regulated, such as AKAP1, PRKAR2B, Gi and <span class=""gene"" id=""20975297-3-104-109"">CIDEA</span>, whereas NPY1R and CES1 were up-regulated, when comparing <span class=""disease"" id=""20975297-3-168-173"">obese</span> to lean subjects.",CTD_human
1,0,Biomarker,C0242383,Age related macular degeneration,disease,macular degeneration,114902,C1QTNF5,CTRP5,CTD_human,16123441,Late-onset macular degeneration and long anterior lens zonules result from a CTRP5 gene mutation.,0.204055389228567,"Late-onset <span class=""disease"" id=""16123441-0-11-31"">macular degeneration</span> and long anterior lens zonules result from a <span class=""gene"" id=""16123441-0-77-82"">CTRP5</span> gene mutation.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,hepatocarcinoma,114990,VASN,Vasorin,CTD_human,25826090,Vasorin is a potential serum biomarker and drug target of hepatocarcinoma screened by subtractive-EMSA-SELEX to clinic patient serum.,0.200274726784213,"<span class=""gene"" id=""25826090-0-0-7"">Vasorin</span> is a potential serum biomarker and drug target of <span class=""disease"" id=""25826090-0-58-73"">hepatocarcinoma</span> screened by subtractive-EMSA-SELEX to clinic patient serum.",CTD_human
1,0,Biomarker,C0025202,melanoma,disease,melanoma,115265,DDIT4L,DDIT4L,CTD_human,16778180,"CGIs in putative promoter regions of 34 genes (ABHD9, BARHL1, CLIC5, CNNM1, COL2A1, CPT1C, DDIT4L, DERL3, DHRS3, DPYS, EFEMP2, FAM62C, FAM78A, FLJ33790, GBX2, GPR10, GPRASP1, HOXA9, HOXD11, HOXD12, HOXD13, p14ARF, PAX6, PRDX2, PTPRG, RASD1, RAX, REC8L1, SLC27A3, TGFB2, TLX2, TMEM22, TMEM30B, and UNC5C) were found to be methylated in at least 1 of 13 melanoma cell lines but not in two cultured normal melanocytes.",0.2,"CGIs in putative promoter regions of 34 genes (ABHD9, BARHL1, CLIC5, CNNM1, COL2A1, CPT1C, <span class=""gene"" id=""16778180-3-91-97"">DDIT4L</span>, DERL3, DHRS3, DPYS, EFEMP2, FAM62C, FAM78A, FLJ33790, GBX2, GPR10, GPRASP1, HOXA9, HOXD11, HOXD12, HOXD13, p14ARF, PAX6, PRDX2, PTPRG, RASD1, RAX, REC8L1, SLC27A3, TGFB2, TLX2, TMEM22, TMEM30B, and UNC5C) were found to be methylated in at least 1 of 13 <span class=""disease"" id=""16778180-3-352-360"">melanoma</span> cell lines but not in two cultured normal melanocytes.",CTD_human
1,0,Therapeutic,C0878544,Cardiomyopathies,group,cardiomyopathy,116,ADCYAP1,pituitary adenylate cyclase-activating polypeptide,CTD_human,20378996,Cardioprotective effect of endogenous pituitary adenylate cyclase-activating polypeptide on Doxorubicin-induced cardiomyopathy in mice.,0.2,"Cardioprotective effect of endogenous <span class=""gene"" id=""20378996-0-38-88"">pituitary adenylate cyclase-activating polypeptide</span> on Doxorubicin-induced <span class=""disease"" id=""20378996-0-112-126"">cardiomyopathy</span> in mice.",CTD_human
7,10,Biomarker,C0473219,Renal hypouricemia,disease,familial renal hypouricemia,116085,SLC22A12,URAT1,CTD_human,14655203,"This is the first report of the 2 male siblings of familial renal hypouricemia complicated with exercise-induced ARF, with definite demonstration of genetic abnormality in the responsible gene (URAT1).",0.606868169605328,"This is the first report of the 2 male siblings of <span class=""disease"" id=""14655203-15-51-78"">familial renal hypouricemia</span> complicated with exercise-induced ARF, with definite demonstration of genetic abnormality in the responsible gene (<span class=""gene"" id=""14655203-15-194-199"">URAT1</span>).",CTD_human;ORPHANET;UNIPROT
7,10,Biomarker,C0473219,Renal hypouricemia,disease,renal hypouricemia,116085,SLC22A12,URAT1,CTD_human,14694169,Clinical and molecular analysis of patients with renal hypouricemia in Japan-influence of URAT1 gene on urinary urate excretion.,0.606868169605328,"Clinical and molecular analysis of patients with <span class=""disease"" id=""14694169-0-49-67"">renal hypouricemia</span> in Japan-influence of <span class=""gene"" id=""14694169-0-90-95"">URAT1</span> gene on urinary urate excretion.",CTD_human;ORPHANET;UNIPROT
2,0,Biomarker,C0009207,Cockayne Syndrome,disease,CS,1161,ERCC8,ERCC8,CTD_human,22466612,"UV(S)S comprises three groups, UV(S)S/CS-A, UV(S)S/CS-B and UV(S)S-A, caused by mutations in ERCC8, ERCC6 and an unidentified gene, respectively.",0.22097987118319698,"UV(S)S comprises three groups, UV(S)S/<span class=""disease"" id=""22466612-3-38-40"">CS</span>-A, UV(S)S/<span class=""disease"" id=""22466612-3-51-53"">CS</span>-B and UV(S)S-A, caused by mutations in <span class=""gene"" id=""22466612-3-93-98"">ERCC8</span>, ERCC6 and an unidentified gene, respectively.",CTD_human
1,0,Biomarker,C0038356,Stomach Neoplasms,group,gastric tumors,116135,LRRC3B,LRRC3B,CTD_human,18757430,Pyrosequencing analysis of the promoter region revealed that LRRC3B was significantly hypermethylated in gastric tumors.,0.20300763924902696,"Pyrosequencing analysis of the promoter region revealed that <span class=""gene"" id=""18757430-5-61-67"">LRRC3B</span> was significantly hypermethylated in <span class=""disease"" id=""18757430-5-105-119"">gastric tumors</span>.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,116442,RAB39B,RAB39B,CTD_human,20159109,"Mutations in the small GTPase gene RAB39B are responsible for X-linked mental retardation associated with autism, epilepsy, and macrocephaly.",0.200274726784213,"Mutations in the small GTPase gene <span class=""gene"" id=""20159109-0-35-41"">RAB39B</span> are responsible for X-linked mental retardation associated with <span class=""disease"" id=""20159109-0-106-112"">autism</span>, epilepsy, and macrocephaly.",CTD_human
1,0,Biomarker,C0014544,Epilepsy,disease,epilepsy,116442,RAB39B,RAB39B,CTD_human,20159109,"Mutations in the small GTPase gene RAB39B are responsible for X-linked mental retardation associated with autism, epilepsy, and macrocephaly.",0.200274726784213,"Mutations in the small GTPase gene <span class=""gene"" id=""20159109-0-35-41"">RAB39B</span> are responsible for X-linked mental retardation associated with autism, <span class=""disease"" id=""20159109-0-114-122"">epilepsy</span>, and macrocephaly.",CTD_human
1,0,Biomarker,C1136249,"Mental Retardation, X-Linked",disease,X-linked mental retardation,116442,RAB39B,RAB39B,CTD_human,20159109,"Mutations in the small GTPase gene RAB39B are responsible for X-linked mental retardation associated with autism, epilepsy, and macrocephaly.",0.200274726784213,"Mutations in the small GTPase gene <span class=""gene"" id=""20159109-0-35-41"">RAB39B</span> are responsible for <span class=""disease"" id=""20159109-0-62-89"">X-linked mental retardation</span> associated with autism, epilepsy, and macrocephaly.",CTD_human
1,0,Biomarker,C0020479,Hyperlipoproteinemia Type III,disease,type III hyperlipidemia,116519,APOA5,APOA5,CTD_human,16143024,Polymorphisms in the apolipoprotein A5 (APOA5) gene and type III hyperlipidemia.,0.203231208875927,"Polymorphisms in the <span class=""gene"" id=""16143024-0-21-38"">apolipoprotein A5</span> (<span class=""gene"" id=""16143024-0-40-45"">APOA5</span>) gene and <span class=""disease"" id=""16143024-0-56-79"">type III hyperlipidemia</span>.",CTD_human
1,0,Biomarker,C0020557,Hypertriglyceridemia,phenotype,HTG,116519,APOA5,APOA5,CTD_human,20657596,"Through GWAS, we identified common variants in APOA5, GCKR, LPL and APOB associated with HTG.",0.324716035584786,"Through GWAS, we identified common variants in <span class=""gene"" id=""20657596-5-47-52"">APOA5</span>, GCKR, LPL and APOB associated with <span class=""disease"" id=""20657596-5-89-92"">HTG</span>.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,116987,AGAP1,CENTG2,CTD_human,15892143,Evaluation of the chromosome 2q37.3 gene CENTG2 as an autism susceptibility gene.,0.20541466777231498,"Evaluation of the chromosome 2q37.3 gene <span class=""gene"" id=""15892143-0-41-47"">CENTG2</span> as an <span class=""disease"" id=""15892143-0-54-60"">autism</span> susceptibility gene.",CTD_human
1,0,Biomarker,C0004096,Asthma,disease,bronchial asthma,117,ADCYAP1R1,PAC1R,CTD_human,21059121,PAC1R agonists may represent a promising target for an anti-inflammatory therapy in airway diseases such as bronchial asthma.,0.200274726784213,"<span class=""gene"" id=""21059121-14-0-5"">PAC1R</span> agonists may represent a promising target for an anti-inflammatory therapy in airway diseases such as <span class=""disease"" id=""21059121-14-108-124"">bronchial asthma</span>.",CTD_human
1,0,Therapeutic,C2239176,Liver carcinoma,disease,HCC,117145,THEM4,carboxyl-terminal modulator protein,CTD_human,23392203,"Successful self-cleavage of 2A-peptide induced synergistic antitumor effect in the liver of H-ras12V, the HCC model mice, by simultaneous activation of LETM1 (Leucine zipper/EF hand-containing transmembrane-1) and CTMP (carboxyl-terminal modulator protein).",0.200274726784213,"Successful self-cleavage of 2A-peptide induced synergistic antitumor effect in the liver of H-ras12V, the <span class=""disease"" id=""23392203-3-106-109"">HCC</span> model mice, by simultaneous activation of LETM1 (Leucine zipper/EF hand-containing transmembrane-1) and <span class=""gene"" id=""23392203-3-214-218"">CTMP</span> (<span class=""gene"" id=""23392203-3-220-255"">carboxyl-terminal modulator protein</span>).",CTD_human
1,0,Biomarker,C0008372,Intrahepatic Cholestasis,disease,intrahepatic cholestasis,1174,AP1S1,AP1S1,CTD_human,23423674,"A Sephardic-Jewish patient, carrying a new AP1S1 homozygous mutation, showed severe perturbations of copper metabolism with hypocupremia, hypoceruloplasminemia and liver copper accumulation, along with intrahepatic cholestasis.",0.4,"A Sephardic-Jewish patient, carrying a new <span class=""gene"" id=""23423674-3-43-48"">AP1S1</span> homozygous mutation, showed severe perturbations of copper metabolism with hypocupremia, hypoceruloplasminemia and liver copper accumulation, along with <span class=""disease"" id=""23423674-3-202-226"">intrahepatic cholestasis</span>.",CTD_human;HPO
1,0,Biomarker,C1836330,ERYTHROKERATODERMIA VARIABILIS 3 (disorder),disease,MEDNIK,1174,AP1S1,AP1S1,CTD_human,23423674,"We solved the pathogenetic mechanism of MEDNIK syndrome, demonstrating that AP1S1 regulates intracellular copper machinery mediated by copper-pump proteins.",0.400549453568426,"We solved the pathogenetic mechanism of <span class=""disease"" id=""23423674-9-40-46"">MEDNIK</span> syndrome, demonstrating that <span class=""gene"" id=""23423674-9-76-81"">AP1S1</span> regulates intracellular copper machinery mediated by copper-pump proteins.",CTD_human;ORPHANET
1,29,Biomarker,C0027127,Myotonia Congenita,disease,myotonia congenita,1180,CLCN1,CLCN1,CTD_human,20399394,Novel CLCN1 mutation in carbamazepine-responsive myotonia congenita.,0.427349744377411,"Novel <span class=""gene"" id=""20399394-0-6-11"">CLCN1</span> mutation in carbamazepine-responsive <span class=""disease"" id=""20399394-0-49-67"">myotonia congenita</span>.",CTD_human;ORPHANET
1,0,Biomarker,C0017638,Glioma,disease,glioma,1181,CLCN2,ClC-2,CTD_human,12843258,We suggest that ClC-2 and ClC-3 channels are specifically upregulated in glioma membranes and endow glioma cells with an enhanced ability to transport Cl-.,0.20300763924902696,"We suggest that <span class=""gene"" id=""12843258-11-16-21"">ClC-2</span> and ClC-3 channels are specifically upregulated in <span class=""disease"" id=""12843258-11-73-79"">glioma</span> membranes and endow <span class=""disease"" id=""12843258-11-100-106"">glioma</span> cells with an enhanced ability to transport Cl-.",CTD_human
1,0,Biomarker,C0017638,Glioma,disease,glioma,1182,CLCN3,ClC-3,CTD_human,12843258,We suggest that ClC-2 and ClC-3 channels are specifically upregulated in glioma membranes and endow glioma cells with an enhanced ability to transport Cl-.,0.203557092817453,"We suggest that ClC-2 and <span class=""gene"" id=""12843258-11-26-31"">ClC-3</span> channels are specifically upregulated in <span class=""disease"" id=""12843258-11-73-79"">glioma</span> membranes and endow <span class=""disease"" id=""12843258-11-100-106"">glioma</span> cells with an enhanced ability to transport Cl-.",CTD_human
1,0,Biomarker,C2931822,Nasopharyngeal carcinoma,disease,nasopharyngeal carcinoma,1182,CLCN3,ClC-3,CTD_human,22108225,ClC-3 protein may be considered as a potential tumor marker and therapeutic target for human nasopharyngeal carcinoma.,0.202197814273705,"<span class=""gene"" id=""22108225-8-0-5"">ClC-3</span> protein may be considered as a potential tumor marker and therapeutic target for human <span class=""disease"" id=""22108225-8-93-117"">nasopharyngeal carcinoma</span>.",CTD_human
1,0,Biomarker,C0017638,Glioma,disease,glioma,1184,CLCN5,ClC-5,CTD_human,12843258,"Transcripts for ClC-2 thru ClC-7 were detected in a human glioma cell line by PCR, whereas only ClC-2, ClC-3, and ClC-5 protein could be identified by Western blot.",0.2,"Transcripts for ClC-2 thru ClC-7 were detected in a human <span class=""disease"" id=""12843258-3-58-64"">glioma</span> cell line by PCR, whereas only ClC-2, ClC-3, and <span class=""gene"" id=""12843258-3-114-119"">ClC-5</span> protein could be identified by Western blot.",CTD_human
3,0,Biomarker,C0878681,Dent's disease,disease,Dent's disease,1184,CLCN5,CLCN5,CTD_human,15719255,"This is the first report to characterize mutations in the CLCN5 gene in Korean patients with Dent's disease, and expands the spectrum of CLCN5 mutations by reporting a novel mutation, E609X.",0.22026426949714,"This is the first report to characterize mutations in the <span class=""gene"" id=""15719255-8-58-63"">CLCN5</span> gene in Korean patients with <span class=""disease"" id=""15719255-8-93-107"">Dent's disease</span>, and expands the spectrum of <span class=""gene"" id=""15719255-8-137-142"">CLCN5</span> mutations by reporting a novel mutation, E609X.",CTD_human
3,0,Biomarker,C0878681,Dent's disease,disease,Dent disease,1184,CLCN5,CLCN5,CTD_human,20804101,"Dent disease is X-linked recessive proximal tubulopathy, due to mutations in the CLCN5 gene.",0.22026426949714,"<span class=""disease"" id=""20804101-1-0-12"">Dent disease</span> is X-linked recessive proximal tubulopathy, due to mutations in the <span class=""gene"" id=""20804101-1-81-86"">CLCN5</span> gene.",CTD_human
3,0,Biomarker,C0878681,Dent's disease,disease,Dent's disease,1184,CLCN5,CLC-5,CTD_human,10561751,"Thus, mutations that result in a loss of function of the voltage-gated chloride channel, CLC-5, are associated with Dent's disease, which is characterized by low-molecular weight proteinuria, hypercalciuria, nephrolithiasis, and renal failure.",0.22026426949714,"Thus, mutations that result in a loss of function of the voltage-gated chloride channel, <span class=""gene"" id=""10561751-2-89-94"">CLC-5</span>, are associated with <span class=""disease"" id=""10561751-2-116-130"">Dent's disease</span>, which is characterized by low-molecular weight proteinuria, hypercalciuria, nephrolithiasis, and renal failure.",CTD_human
2,2,Biomarker,C0038013,Ankylosing spondylitis,disease,ankylosing spondylitis,118429,ANTXR2,ANTXR2,CTD_human,21743469,"Here we report the identification of three variants in the RUNX3, LTBR-TNFRSF1A and IL12B regions convincingly associated with ankylosing spondylitis (P < 5 × 10(-8) in the combined discovery and replication datasets) and a further four loci at PTGER4, TBKBP1, ANTXR2 and CARD9 that show strong association across all our datasets (P < 5 × 10(-6) overall, with support in each of the three datasets studied).",0.202472541057918,"Here we report the identification of three variants in the RUNX3, LTBR-TNFRSF1A and IL12B regions convincingly associated with <span class=""disease"" id=""21743469-2-127-149"">ankylosing spondylitis</span> (P &lt; 5 &times; 10(-8) in the combined discovery and replication datasets) and a further four loci at PTGER4, TBKBP1, <span class=""gene"" id=""21743469-2-261-267"">ANTXR2</span> and CARD9 that show strong association across all our datasets (P &lt; 5 &times; 10(-6) overall, with support in each of the three datasets studied).",CTD_human
2,11,Biomarker,C2745948,"Hyalinosis, Systemic",disease,ISH,118429,ANTXR2,CMG2,CTD_human,12973667,"Finally, and possibly providing insight into the pathophysiology of these diseases, analysis of fibroblasts derived from patients with JHF or ISH suggests that CMG2 mutations abrogate normal cell interactions with the extracellular matrix.",0.604120901763197,"Finally, and possibly providing insight into the pathophysiology of these diseases, analysis of fibroblasts derived from patients with <span class=""disease"" id=""12973667-8-135-138"">JHF</span> or <span class=""disease"" id=""12973667-8-142-145"">ISH</span> suggests that <span class=""gene"" id=""12973667-8-160-164"">CMG2</span> mutations abrogate normal cell interactions with the extracellular matrix.",CTD_human;ORPHANET;UNIPROT
2,11,Biomarker,C2745948,"Hyalinosis, Systemic",disease,infantile systemic hyalinosis,118429,ANTXR2,capillary morphogenesis protein 2,CTD_human,14508707,Mutations in the gene encoding capillary morphogenesis protein 2 cause juvenile hyaline fibromatosis and infantile systemic hyalinosis.,0.604120901763197,"Mutations in the gene encoding <span class=""gene"" id=""14508707-0-31-64"">capillary morphogenesis protein 2</span> cause <span class=""disease"" id=""14508707-0-71-100"">juvenile hyaline fibromatosis</span> and <span class=""disease"" id=""14508707-0-105-134"">infantile systemic hyalinosis</span>.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0004775,Bartter Disease,disease,Bartter's syndrome,1188,CLCNKB,CLC-Kb,CTD_human,10561751,"Mutations of another voltage-gated chloride channel, CLC-Kb, are associated with a form of Bartter's syndrome, whereas other forms of Bartter's syndrome are caused by mutations in the bumetanide-sensitive sodium-potassium-chloride cotransporter (NKCC2) and the potassium channel, ROMK.",0.22163163906624897,"Mutations of another voltage-gated chloride channel, <span class=""gene"" id=""10561751-3-53-59"">CLC-Kb</span>, are associated with a form of <span class=""disease"" id=""10561751-3-91-109"">Bartter's syndrome</span>, whereas other forms of <span class=""disease"" id=""10561751-3-134-152"">Bartter's syndrome</span> are caused by mutations in the bumetanide-sensitive sodium-potassium-chloride cotransporter (NKCC2) and the potassium channel, ROMK.",CTD_human
3,5,Biomarker,C0002395,Alzheimer's Disease,disease,Alzheimer's disease,1191,CLU,CLU,CTD_human,19734903,Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease.,0.258134727743681,"Genome-wide association study identifies variants at <span class=""gene"" id=""19734903-0-53-56"">CLU</span> and CR1 associated with <span class=""disease"" id=""19734903-0-81-100"">Alzheimer's disease</span>.",CTD_human
3,5,Biomarker,C0002395,Alzheimer's Disease,disease,Alzheimer's disease,1191,CLU,CLU,CTD_human,19734902,Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease.,0.258134727743681,"Genome-wide association study identifies variants at <span class=""gene"" id=""19734902-0-53-56"">CLU</span> and PICALM associated with <span class=""disease"" id=""19734902-0-84-103"">Alzheimer's disease</span>.",CTD_human
1,0,Biomarker,C0024141,"Lupus Erythematosus, Systemic",disease,systemic lupus erythematosus,1191,CLU,clusterin,CTD_human,15304052,Transcriptional down-regulation of the platelet ADP receptor P2Y(12) and clusterin in patients with systemic lupus erythematosus.,0.204106546385879,"Transcriptional down-regulation of the platelet ADP receptor P2Y(12) and <span class=""gene"" id=""15304052-0-73-82"">clusterin</span> in patients with <span class=""disease"" id=""15304052-0-100-128"">systemic lupus erythematosus</span>.",CTD_human
1,0,Therapeutic,C0025202,melanoma,disease,melanoma,1191,CLU,Clusterin,CTD_human,15955107,Clusterin regulates drug-resistance in melanoma cells.,0.20300763924902696,"<span class=""gene"" id=""15955107-0-0-9"">Clusterin</span> regulates drug-resistance in <span class=""disease"" id=""15955107-0-39-47"">melanoma</span> cells.",CTD_human
2,0,Biomarker,C0029408,Degenerative polyarthritis,disease,OA,1191,CLU,CLU,CTD_human,17568789,"HOXD10, HOXD11, HOXD13, CCL8 and LIM homeobox 2 were highly and exclusively expressed in RA and CLU, sarcoglycan-gamma, GPR64, POU3F3, peroxisome proliferative activated receptor-gamma and tripartite motif-containing 2 were expressed only in OA.",0.20054945356842604,"HOXD10, HOXD11, HOXD13, CCL8 and LIM homeobox 2 were highly and exclusively expressed in RA and <span class=""gene"" id=""17568789-4-96-99"">CLU</span>, sarcoglycan-gamma, GPR64, POU3F3, peroxisome proliferative activated receptor-gamma and tripartite motif-containing 2 were expressed only in <span class=""disease"" id=""17568789-4-242-244"">OA</span>.",CTD_human
1,0,Biomarker,C0036572,Seizures,phenotype,seizure,1191,CLU,clusterin,CTD_human,23266720,"The results of the present study suggest that E-64d, an elective inhibitor of calpain and autophagy, is potentially useful in the treatment of developmental seizure-induced brain damage both by regulating abnormal zinc signal transduction and through the modulation of altered lipid metabolism via ApoE/clusterin pathway in hippocampus.",0.2,"The results of the present study suggest that E-64d, an elective inhibitor of calpain and autophagy, is potentially useful in the treatment of developmental <span class=""disease"" id=""23266720-11-157-164"">seizure</span>-induced brain damage both by regulating abnormal zinc signal transduction and through the modulation of altered lipid metabolism via ApoE/<span class=""gene"" id=""23266720-11-303-312"">clusterin</span> pathway in hippocampus.",CTD_human
1,0,Biomarker,C0005695,Bladder Neoplasm,disease,Bladder cancer,119391,GSTO2,GSTO2,CTD_human,22306368,Bladder cancer risk overall was associated with GSTO2 Asn142Asp (homozygous; OR=1.4; 95% CI: 1.0-1.9; P for trend=0.06) and GSTZ1 Glu32Lys (homozygous; OR=1.3; 95% CI: 0.9-1.8; P for trend=0.06).,0.202681755307501,"<span class=""disease"" id=""22306368-7-0-14"">Bladder cancer</span> risk overall was associated with <span class=""gene"" id=""22306368-7-48-53"">GSTO2</span> Asn142Asp (homozygous; OR=1.4; 95% CI: 1.0-1.9; P for trend=0.06) and GSTZ1 Glu32Lys (homozygous; OR=1.3; 95% CI: 0.9-1.8; P for trend=0.06).",CTD_human
10,3,Biomarker,C0030567,Parkinson Disease,disease,PD,120892,LRRK2,LRRK2,CTD_human,19915576,"By comparing results of a GWAS performed on individuals of European ancestry, we identified PARK16, SNCA and LRRK2 as shared risk loci for PD and BST1 and MAPT as loci showing population differences.",0.44,"By comparing results of a GWAS performed on individuals of European ancestry, we identified PARK16, SNCA and <span class=""gene"" id=""19915576-4-109-114"">LRRK2</span> as shared risk loci for <span class=""disease"" id=""19915576-4-139-141"">PD</span> and BST1 and MAPT as loci showing population differences.",CTD_human
10,3,Biomarker,C0030567,Parkinson Disease,disease,PD,120892,LRRK2,LRRK2,CTD_human,25631236,"One major advance in this field has been the discovery of several genes associated to familial PD, including alpha synuclein, parkin, LRRK2, etc., thereby providing important insight toward basic research approaches.",0.44,"One major advance in this field has been the discovery of several genes associated to familial <span class=""disease"" id=""25631236-2-95-97"">PD</span>, including alpha synuclein, parkin, <span class=""gene"" id=""25631236-2-134-139"">LRRK2</span>, etc., thereby providing important insight toward basic research approaches.",CTD_human
10,3,Biomarker,C0030567,Parkinson Disease,disease,PD,120892,LRRK2,LRRK2,CTD_human,19915575,"We replicated the effect of a new locus detected in the Japanese cohort (PARK16, rs823128, OR = 0.66, P = 7.29 x 10(-8)) and provide supporting evidence that common variation around LRRK2 modulates risk for PD (rs1491923, OR = 1.14, P = 1.55 x 10(-5)).",0.44,"We replicated the effect of a new locus detected in the Japanese cohort (PARK16, rs823128, OR = 0.66, P = 7.29 x 10(-8)) and provide supporting evidence that common variation around <span class=""gene"" id=""19915575-5-182-187"">LRRK2</span> modulates risk for <span class=""disease"" id=""19915575-5-207-209"">PD</span> (rs1491923, OR = 1.14, P = 1.55 x 10(-5)).",CTD_human
10,3,Biomarker,C0030567,Parkinson Disease,disease,PD,120892,LRRK2,LRRK2,CTD_human,23472874,The LRRK2 mutation G2019S is the most common genetic cause of Parkinson's disease (PD).,0.44,"The <span class=""gene"" id=""23472874-1-4-9"">LRRK2</span> mutation G2019S is the most common genetic cause of <span class=""disease"" id=""23472874-1-62-81"">Parkinson's disease</span> (<span class=""disease"" id=""23472874-1-83-85"">PD</span>).",CTD_human
10,3,Biomarker,C0030567,Parkinson Disease,disease,PD,120892,LRRK2,LRRK2,CTD_human,23017109,"We report that adult neurogenesis is highly susceptible to multiple ""risk factors"" for PD, including ?-synuclein accumulation, LRRK2 G2019 mutation and exposure to environmental toxins.",0.44,"We report that adult neurogenesis is highly susceptible to multiple ""risk factors"" for <span class=""disease"" id=""23017109-11-87-89"">PD</span>, including &alpha;-synuclein accumulation, <span class=""gene"" id=""23017109-11-127-132"">LRRK2</span> G2019 mutation and exposure to environmental toxins.",CTD_human
10,3,Biomarker,C0030567,Parkinson Disease,disease,Parkinson's disease,120892,LRRK2,leucine-rich repeat kinase 2,CTD_human,17388990,A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson's disease in Russia.,0.44,"A common <span class=""gene"" id=""17388990-0-9-37"">leucine-rich repeat kinase 2</span> gene mutation in familial and sporadic <span class=""disease"" id=""17388990-0-77-96"">Parkinson's disease</span> in Russia.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,121278,TPH2,TPH2,CTD_human,15768392,Possible association between autism and variants in the brain-expressed tryptophan hydroxylase gene (TPH2).,0.21554107827657998,"Possible association between <span class=""disease"" id=""15768392-0-29-35"">autism</span> and variants in the brain-expressed tryptophan hydroxylase gene (<span class=""gene"" id=""15768392-0-101-105"">TPH2</span>).",CTD_human
6,0,Biomarker,C0011581,Depressive disorder,disease,depression,121278,TPH2,TPH2,CTD_human,17950541,"The results of the present study suggest that TPH2 gene expression in the midbrain part of the DRN is implicated in depression and stress response, as well as in the antidepressant fluoxetine action.",0.406593442821114,"The results of the present study suggest that <span class=""gene"" id=""17950541-7-46-50"">TPH2</span> gene expression in the midbrain part of the DRN is implicated in <span class=""disease"" id=""17950541-7-116-126"">depression</span> and stress response, as well as in the antidepressant fluoxetine action.",CTD_human;PSYGENET
1,2,Biomarker,C0003873,Rheumatoid Arthritis,disease,rheumatoid arthritis,122618,PLD4,PLD4,CTD_human,22446963,"Our study identified nine loci newly associated with rheumatoid arthritis at a threshold of P < 5.0 × 10(-8), including B3GNT2, ANXA3, CSF2, CD83, NFKBIE, ARID5B, PDE2A-ARAP1, PLD4 and PTPN2.",0.2,"Our study identified nine loci newly associated with <span class=""disease"" id=""22446963-3-53-73"">rheumatoid arthritis</span> at a threshold of P &lt; 5.0 &times; 10(-8), including B3GNT2, ANXA3, CSF2, CD83, NFKBIE, ARID5B, PDE2A-ARAP1, <span class=""gene"" id=""22446963-3-176-180"">PLD4</span> and PTPN2.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,hepatocellular carcinoma,122953,JDP2,JDP2,CTD_human,20214788,"The AP-1 repressor protein, JDP2, potentiates hepatocellular carcinoma in mice.",0.2,"The AP-1 repressor protein, <span class=""gene"" id=""20214788-0-28-32"">JDP2</span>, potentiates <span class=""disease"" id=""20214788-0-46-70"">hepatocellular carcinoma</span> in mice.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,hepatocellular carcinoma,1230,CCR1,CCR1,CTD_human,16284949,"Essential contribution of a chemokine, CCL3, and its receptor, CCR1, to hepatocellular carcinoma progression.",0.20656473206648,"Essential contribution of a chemokine, CCL3, and its receptor, <span class=""gene"" id=""16284949-0-63-67"">CCR1</span>, to <span class=""disease"" id=""16284949-0-72-96"">hepatocellular carcinoma</span> progression.",CTD_human
1,0,Biomarker,C0034069,Pulmonary Fibrosis,disease,lung fibrosis,1232,CCR3,CCR3,CTD_human,16314464,"Together, these data suggest that CCL11 and CCR3 are important in the pulmonary recruitment of granulocytes and play significant pathogenic roles in blm-induced lung fibrosis.",0.200274726784213,"Together, these data suggest that CCL11 and <span class=""gene"" id=""16314464-10-44-48"">CCR3</span> are important in the pulmonary recruitment of granulocytes and play significant pathogenic roles in blm-induced <span class=""disease"" id=""16314464-10-161-174"">lung fibrosis</span>.",CTD_human
2,0,Biomarker,C0008370,Cholestasis,disease,cholestasis,123264,SLC51B,OSTbeta,CTD_human,16423920,Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-OSTbeta in cholestasis in humans and rodents.,0.20300763924902696,"Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-<span class=""gene"" id=""16423920-0-82-89"">OSTbeta</span> in <span class=""disease"" id=""16423920-0-93-104"">cholestasis</span> in humans and rodents.",CTD_human
1,0,Biomarker,C0027697,Nephritis,disease,nephritis,1234,CCR5,CCR5,CTD_human,26055553,"C-C chemokine receptor 5 (CCR5) regulates leukocyte chemotaxis and activation, and its deficiency exacerbates development of nephritis.",0.2,"C-C chemokine receptor 5 (<span class=""gene"" id=""26055553-1-26-30"">CCR5</span>) regulates leukocyte chemotaxis and activation, and its deficiency exacerbates development of <span class=""disease"" id=""26055553-1-125-134"">nephritis</span>.",CTD_human
3,4,Biomarker,C0003873,Rheumatoid Arthritis,disease,rheumatoid arthritis,1235,CCR6,CCR6,CTD_human,20453841,A regulatory variant in CCR6 is associated with rheumatoid arthritis susceptibility.,0.20816193561444604,"A regulatory variant in <span class=""gene"" id=""20453841-0-24-28"">CCR6</span> is associated with <span class=""disease"" id=""20453841-0-48-68"">rheumatoid arthritis</span> susceptibility.",CTD_human
1,0,Biomarker,C0038220,Status Epilepticus,disease,status epilepticus,1236,CCR7,CCR7,CTD_human,17181556,"CCR7, CCR8, CCR9 and CCR10 in the mouse hippocampal CA1 area and the dentate gyrus during and after pilocarpine-induced status epilepticus.",0.2,"<span class=""gene"" id=""17181556-0-0-4"">CCR7</span>, CCR8, CCR9 and CCR10 in the mouse hippocampal CA1 area and the dentate gyrus during and after pilocarpine-induced <span class=""disease"" id=""17181556-0-120-138"">status epilepticus</span>.",CTD_human
1,0,Biomarker,C0038220,Status Epilepticus,disease,status epilepticus,1237,CCR8,CCR8,CTD_human,17181556,"CCR7, CCR8, CCR9 and CCR10 in the mouse hippocampal CA1 area and the dentate gyrus during and after pilocarpine-induced status epilepticus.",0.2,"CCR7, <span class=""gene"" id=""17181556-0-6-10"">CCR8</span>, CCR9 and CCR10 in the mouse hippocampal CA1 area and the dentate gyrus during and after pilocarpine-induced <span class=""disease"" id=""17181556-0-120-138"">status epilepticus</span>.",CTD_human
1,0,Biomarker,C0002170,Alopecia,disease,alopecia,1244,ABCC2,ABCC2,CTD_human,18381794,The intronic single-nucleotide polymorphism (SNP) ABCC2 IVS 23+56 T --> C was associated with alopecia in Caucasians (p = 0.035).,0.200274726784213,"The intronic single-nucleotide polymorphism (SNP) <span class=""gene"" id=""18381794-8-50-55"">ABCC2</span> IVS 23+56 T --&gt; C was associated with <span class=""disease"" id=""18381794-8-94-102"">alopecia</span> in Caucasians (p = 0.035).",CTD_human
1,0,Biomarker,C0003873,Rheumatoid Arthritis,disease,RA,1244,ABCC2,ABCC2,CTD_human,23897011,"Concurrent with evidence of an immune-activation gene signature in MTX-naive RA patients, significant up-regulation of the folate-metabolizing enzymes ?-glutamyl hydrolase and dihydrofolate reductase, as well as the MTX/folate efflux transporters ABCC2 and ABCC5, was observed in the MTX-naive RA group compared to healthy controls.",0.20240702852328799,"Concurrent with evidence of an immune-activation gene signature in MTX-naive <span class=""disease"" id=""23897011-6-77-79"">RA</span> patients, significant up-regulation of the folate-metabolizing enzymes &gamma;-glutamyl hydrolase and dihydrofolate reductase, as well as the MTX/folate efflux transporters <span class=""gene"" id=""23897011-6-247-252"">ABCC2</span> and ABCC5, was observed in the MTX-naive <span class=""disease"" id=""23897011-6-294-296"">RA</span> group compared to healthy controls.",CTD_human
3,0,Biomarker,C0008370,Cholestasis,disease,cholestasis,1244,ABCC2,Mrp2,CTD_human,22521610,ANIT-induced biliary injury is a commonly used model of experimental cholestasis and has been shown to be dependent upon Mrp2-mediated efflux of an ANIT glutathione conjugate that selectively injures biliary epithelial cells.,0.28219781427370505,"ANIT-induced biliary injury is a commonly used model of experimental <span class=""disease"" id=""22521610-6-69-80"">cholestasis</span> and has been shown to be dependent upon <span class=""gene"" id=""22521610-6-121-125"">Mrp2</span>-mediated efflux of an ANIT glutathione conjugate that selectively injures biliary epithelial cells.",CTD_human
3,0,Biomarker,C0008370,Cholestasis,disease,cholestasis,1244,ABCC2,Mrp2,CTD_human,17681005,"Conclusion: The disturbed colocalization of Mrp2 and radixin may contribute to the endocytic retrieval of Mrp2 in cholestasis due to the failure to anchor Mrp2 in the canalicular membrane, in which the phosphorylated radixin may play a major role.",0.28219781427370505,"Conclusion: The disturbed colocalization of <span class=""gene"" id=""17681005-9-44-48"">Mrp2</span> and radixin may contribute to the endocytic retrieval of <span class=""gene"" id=""17681005-9-106-110"">Mrp2</span> in <span class=""disease"" id=""17681005-9-114-125"">cholestasis</span> due to the failure to anchor <span class=""gene"" id=""17681005-9-155-159"">Mrp2</span> in the canalicular membrane, in which the phosphorylated radixin may play a major role.",CTD_human
3,0,Biomarker,C0008370,Cholestasis,disease,cholestasis,1244,ABCC2,Mrp2,CTD_human,10869290,Mrp2 is essential for estradiol-17beta(beta-D-glucuronide)-induced cholestasis in rats.,0.28219781427370505,"<span class=""gene"" id=""10869290-0-0-4"">Mrp2</span> is essential for estradiol-17beta(beta-D-glucuronide)-induced <span class=""disease"" id=""10869290-0-67-78"">cholestasis</span> in rats.",CTD_human
1,0,Biomarker,C0020433,Hyperbilirubinemia,disease,hyperbilirubinemia,1244,ABCC2,Mrp2,CTD_human,16611851,"To obtain insight in the pharmacological and physiological functions of Mrp2, we generated Mrp2 knockout mice, which were viable and fertile but suffered from mild hyperbilirubinemia due to impaired excretion of bilirubin monoglucuronides into bile.",0.201648360705279,"To obtain insight in the pharmacological and physiological functions of <span class=""gene"" id=""16611851-2-72-76"">Mrp2</span>, we generated <span class=""gene"" id=""16611851-2-91-95"">Mrp2</span> knockout mice, which were viable and fertile but suffered from mild <span class=""disease"" id=""16611851-2-164-182"">hyperbilirubinemia</span> due to impaired excretion of bilirubin monoglucuronides into bile.",CTD_human
5,15,Biomarker,C0022350,"Jaundice, Chronic Idiopathic",disease,Dubin-Johnson syndrome,1244,ABCC2,ABCC2,CTD_human,16952291,Identification of a novel 974C-->G nonsense mutation of the MRP2/ABCC2 gene in a patient with Dubin-Johnson syndrome and analysis of the effects of rifampicin and ursodeoxycholic acid on serum bilirubin and bile acids.,0.701631639066249,"Identification of a novel 974C--&gt;G nonsense mutation of the <span class=""gene"" id=""16952291-0-60-64"">MRP2</span>/<span class=""gene"" id=""16952291-0-65-70"">ABCC2</span> gene in a patient with <span class=""disease"" id=""16952291-0-94-116"">Dubin-Johnson syndrome</span> and analysis of the effects of rifampicin and ursodeoxycholic acid on serum bilirubin and bile acids.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0023892,Biliary cirrhosis,disease,biliary cirrhosis,1244,ABCC2,multidrug resistance associated protein 2,CTD_human,15542527,Significant downregulation of the transport proteins multidrug resistance associated protein 2 and breast cancer resistance protein was observed in biliary cirrhosis.,0.2,"Significant downregulation of the transport proteins <span class=""gene"" id=""15542527-6-53-94"">multidrug resistance associated protein 2</span> and breast cancer resistance protein was observed in <span class=""disease"" id=""15542527-6-148-165"">biliary cirrhosis</span>.",CTD_human
1,0,Biomarker,C0036572,Seizures,phenotype,seizures,1244,ABCC2,MRP2,CTD_human,16504477,Expression of the multidrug transporter MRP2 in the blood-brain barrier after pilocarpine-induced seizures in rats.,0.20054945356842604,"Expression of the multidrug transporter <span class=""gene"" id=""16504477-0-40-44"">MRP2</span> in the blood-brain barrier after pilocarpine-induced <span class=""disease"" id=""16504477-0-98-106"">seizures</span> in rats.",CTD_human
1,0,Biomarker,C0038220,Status Epilepticus,disease,status epilepticus,1244,ABCC2,MRP2,CTD_human,16504477,"However, after a pilocarpine-induced convulsive status epilepticus, clear MRP2 staining became visible in brain capillary endothelial cells and, less frequently, perivascular astroglia and neurons in various brain regions.",0.2,"However, after a pilocarpine-induced convulsive <span class=""disease"" id=""16504477-9-48-66"">status epilepticus</span>, clear <span class=""gene"" id=""16504477-9-74-78"">MRP2</span> staining became visible in brain capillary endothelial cells and, less frequently, perivascular astroglia and neurons in various brain regions.",CTD_human
1,0,Biomarker,C0279626,Squamous cell carcinoma of esophagus,disease,ESCC,1244,ABCC2,MRP2,CTD_human,21206495,"Our data suggested that MRP2 is one of molecules, which regulate the sensitivity to chemotherapy including CDDP in advanced ESCC patients.",0.20054945356842604,"Our data suggested that <span class=""gene"" id=""21206495-10-24-28"">MRP2</span> is one of molecules, which regulate the sensitivity to chemotherapy including CDDP in advanced <span class=""disease"" id=""21206495-10-124-128"">ESCC</span> patients.",CTD_human
1,0,Biomarker,C1168401,Squamous cell carcinoma of the head and neck,disease,HNSCC,1244,ABCC2,ABCC2,CTD_human,25275603,"Cluster analysis however revealed that simultaneous high expression of SLC31A1, ABCC2, and ABCG2 indicates poor survival of HNSCC patients.",0.200274726784213,"Cluster analysis however revealed that simultaneous high expression of SLC31A1, <span class=""gene"" id=""25275603-8-80-85"">ABCC2</span>, and ABCG2 indicates poor survival of <span class=""disease"" id=""25275603-8-124-129"">HNSCC</span> patients.",CTD_human
1,0,Biomarker,C3714756,Intellectual Disability,group,intellectual disability,124512,METTL23,METTL23,CTD_human,24626631,Disruption of the methyltransferase-like 23 gene METTL23 causes mild autosomal recessive intellectual disability.,0.200274726784213,"Disruption of the <span class=""gene"" id=""24626631-0-18-43"">methyltransferase-like 23</span> gene <span class=""gene"" id=""24626631-0-49-56"">METTL23</span> causes mild autosomal recessive <span class=""disease"" id=""24626631-0-89-112"">intellectual disability</span>.",CTD_human
8,1,Biomarker,C0001973,"Alcoholic Intoxication, Chronic",disease,alcoholism,125,ADH1B,ADH1B,CTD_human,21168396,In this study the functional effects of the two SNPs (rs1159918 and rs1229982) in the proximal promoter region of ADH1B that were associated with alcoholism were explored.,0.509395765910802,"In this study the functional effects of the two SNPs (rs1159918 and rs1229982) in the proximal promoter region of <span class=""gene"" id=""21168396-4-114-119"">ADH1B</span> that were associated with <span class=""disease"" id=""21168396-4-146-156"">alcoholism</span> were explored.",CTD_human;PSYGENET
8,1,Biomarker,C0001973,"Alcoholic Intoxication, Chronic",disease,alcoholism,125,ADH1B,ADH1B,CTD_human,17590986,"To date, the only genes that have been consistently replicated across racial and ethnic groups to influence alcoholism vulnerability are polymorphisms in the alcohol-metabolizing enzymes, i.e. cytosolic alcohol dehydrogenase 1B (ADH1B) and mitochondrial aldehyde dehydrogenase 2 (ALDH2).",0.509395765910802,"To date, the only genes that have been consistently replicated across racial and ethnic groups to influence <span class=""disease"" id=""17590986-1-108-118"">alcoholism</span> vulnerability are polymorphisms in the alcohol-metabolizing enzymes, i.e. cytosolic <span class=""gene"" id=""17590986-1-203-227"">alcohol dehydrogenase 1B</span> (<span class=""gene"" id=""17590986-1-229-234"">ADH1B</span>) and mitochondrial aldehyde dehydrogenase 2 (ALDH2).",CTD_human;PSYGENET
8,1,Biomarker,C0001973,"Alcoholic Intoxication, Chronic",disease,alcohol dependence,125,ADH1B,ADH1B,CTD_human,16404797,The hypothesized mechanism underlying the associations of the ADH1B and ALDH2 polymorphisms with alcohol dependence is that the isoenzymes encoded by these alleles lead to an accumulation of acetaldehyde during alcohol metabolism.,0.509395765910802,"The hypothesized mechanism underlying the associations of the <span class=""gene"" id=""16404797-5-62-67"">ADH1B</span> and ALDH2 polymorphisms with <span class=""disease"" id=""16404797-5-97-115"">alcohol dependence</span> is that the isoenzymes encoded by these alleles lead to an accumulation of acetaldehyde during alcohol metabolism.",CTD_human;PSYGENET
1,0,Biomarker,C0007785,Cerebral Infarction,disease,cerebral infarction,125,ADH1B,ADH2,CTD_human,15534263,Multiple regression analyses confirmed that the risk of lacunae and cerebral infarction was increased by the ADH2*1 allele.,0.20541466777231498,"Multiple regression analyses confirmed that the risk of lacunae and <span class=""disease"" id=""15534263-4-68-87"">cerebral infarction</span> was increased by the <span class=""gene"" id=""15534263-4-109-113"">ADH2</span>*1 allele.",CTD_human
1,0,Biomarker,C0279626,Squamous cell carcinoma of esophagus,disease,ESCC,125,ADH1B,ADH1B,CTD_human,22960999,"We confirmed the known association of the ALDH2 locus on 12q24 to ESCC, and a joint analysis showed that drinkers with both of the ADH1B and ALDH2 risk alleles had a fourfold increased risk for ESCC compared to drinkers without these risk alleles.",0.20467035533162303,"We confirmed the known association of the ALDH2 locus on 12q24 to <span class=""disease"" id=""22960999-4-66-70"">ESCC</span>, and a joint analysis showed that drinkers with both of the <span class=""gene"" id=""22960999-4-131-136"">ADH1B</span> and ALDH2 risk alleles had a fourfold increased risk for <span class=""disease"" id=""22960999-4-194-198"">ESCC</span> compared to drinkers without these risk alleles.",CTD_human
2,1,Biomarker,C0033860,Psoriasis,disease,psoriasis,125893,ZNF816,ZNF816A,CTD_human,20953187,"ERAP1 and ZNF816A were associated with type 1 (early onset) psoriasis in the Chinese Han population (test for heterogeneity P = 6.5 × 10?³ and P = 1.5 × 10?³, respectively).",0.203231208875927,"ERAP1 and <span class=""gene"" id=""20953187-4-10-17"">ZNF816A</span> were associated with type 1 (early onset) <span class=""disease"" id=""20953187-4-60-69"">psoriasis</span> in the Chinese Han population (test for heterogeneity P = 6.5 &times; 10?³ and P = 1.5 &times; 10?³, respectively).",CTD_human
2,1,Biomarker,C0033860,Psoriasis,disease,psoriasis,125893,ZNF816,ZNF816A,CTD_human,24212883,"We discovered two independent missense SNVs in IL23R and GJB2 of low frequency and five common missense SNVs in LCE3D, ERAP1, CARD14 and ZNF816A associated with psoriasis at genome-wide significance.",0.203231208875927,"We discovered two independent missense SNVs in IL23R and GJB2 of low frequency and five common missense SNVs in LCE3D, ERAP1, CARD14 and <span class=""gene"" id=""24212883-2-137-144"">ZNF816A</span> associated with <span class=""disease"" id=""24212883-2-161-170"">psoriasis</span> at genome-wide significance.",CTD_human
6,0,Biomarker,C0001973,"Alcoholic Intoxication, Chronic",disease,alcohol dependence,126,ADH1C,ADH1C,CTD_human,16404797,"Studies of the ADHIBand ADH1C haplotypes, however, have shown that ADH1C*I is in linkage disequilibrium with ADHiB*2, and the ADH1C*i allele does not appear to have significant unique associations with alcohol dependence.",0.47796744152142207,"Studies of the ADHIBand <span class=""gene"" id=""16404797-4-24-29"">ADH1C</span> haplotypes, however, have shown that <span class=""gene"" id=""16404797-4-67-72"">ADH1C</span>*I is in linkage disequilibrium with ADHiB*2, and the <span class=""gene"" id=""16404797-4-126-131"">ADH1C</span>*i allele does not appear to have significant unique associations with <span class=""disease"" id=""16404797-4-202-220"">alcohol dependence</span>.",CTD_human;PSYGENET
1,0,Biomarker,C0025202,melanoma,disease,melanoma,126129,CPT1C,CPT1C,CTD_human,16778180,"CGIs in putative promoter regions of 34 genes (ABHD9, BARHL1, CLIC5, CNNM1, COL2A1, CPT1C, DDIT4L, DERL3, DHRS3, DPYS, EFEMP2, FAM62C, FAM78A, FLJ33790, GBX2, GPR10, GPRASP1, HOXA9, HOXD11, HOXD12, HOXD13, p14ARF, PAX6, PRDX2, PTPRG, RASD1, RAX, REC8L1, SLC27A3, TGFB2, TLX2, TMEM22, TMEM30B, and UNC5C) were found to be methylated in at least 1 of 13 melanoma cell lines but not in two cultured normal melanocytes.",0.2,"CGIs in putative promoter regions of 34 genes (ABHD9, BARHL1, CLIC5, CNNM1, COL2A1, <span class=""gene"" id=""16778180-3-84-89"">CPT1C</span>, DDIT4L, DERL3, DHRS3, DPYS, EFEMP2, FAM62C, FAM78A, FLJ33790, GBX2, GPR10, GPRASP1, HOXA9, HOXD11, HOXD12, HOXD13, p14ARF, PAX6, PRDX2, PTPRG, RASD1, RAX, REC8L1, SLC27A3, TGFB2, TLX2, TMEM22, TMEM30B, and UNC5C) were found to be methylated in at least 1 of 13 <span class=""disease"" id=""16778180-3-352-360"">melanoma</span> cell lines but not in two cultured normal melanocytes.",CTD_human
1,0,Biomarker,C0031117,Peripheral Neuropathy,group,peripheral neuropathy,126129,CPT1C,CPT1C,CTD_human,20864405,"Significant genes in myeloma plasma cells from patients that were associated with early-onset bortezomib-induced peripheral neuropathy were the enzyme coding genes RHOBTB2 (upregulated by 1·59 times; p=4·5×10(-5)), involved in drug-induced apoptosis, CPT1C (1·44 times; p=2·9×10(-7)), involved in mitochondrial dysfunction, and SOX8 (1·68 times; p=4·28×10(-13)), involved in development of peripheral nervous system.",0.200274726784213,"Significant genes in myeloma plasma cells from patients that were associated with early-onset bortezomib-induced <span class=""disease"" id=""20864405-9-113-134"">peripheral neuropathy</span> were the enzyme coding genes RHOBTB2 (upregulated by 1·59 times; p=4·5&times;10(-5)), involved in drug-induced apoptosis, <span class=""gene"" id=""20864405-9-251-256"">CPT1C</span> (1·44 times; p=2·9&times;10(-7)), involved in mitochondrial dysfunction, and SOX8 (1·68 times; p=4·28&times;10(-13)), involved in development of peripheral nervous system.",CTD_human
1,0,Biomarker,C0740394,Hyperuricemia,disease,hyperuricemia,126133,ALDH16A1,ALDH16A1,CTD_human,23348497,These results lead to the intriguing possibility that association between ALDH16A1 and HPRT1 may be required for optimal HPRT activity with disruption of this interaction possibly contributing to the hyperuricemia seen in ALDH16A1*2 carriers.,0.200274726784213,"These results lead to the intriguing possibility that association between <span class=""gene"" id=""23348497-10-74-82"">ALDH16A1</span> and HPRT1 may be required for optimal HPRT activity with disruption of this interaction possibly contributing to the <span class=""disease"" id=""23348497-10-200-213"">hyperuricemia</span> seen in <span class=""gene"" id=""23348497-10-222-230"">ALDH16A1</span>*2 carriers.",CTD_human
2,0,Biomarker,C0003469,Anxiety Disorders,group,anxiety disorders,1268,CNR1,CB(1,CTD_human,15081793,"They suggest that alterations in the functional activity of the CB(1) receptor may be related to the emergence of anxiety disorders, and may affect treatment with anxiolytics.",0.202197814273705,"They suggest that alterations in the functional activity of the <span class=""gene"" id=""15081793-9-64-68"">CB(1</span>) receptor may be related to the emergence of <span class=""disease"" id=""15081793-9-114-131"">anxiety disorders</span>, and may affect treatment with anxiolytics.",CTD_human
1,0,Therapeutic,C0014556,"Epilepsy, Temporal Lobe",disease,TLE,1268,CNR1,CB1R,CTD_human,20498848,These findings indicate that activation of CB1R present on nerve terminals can suppress recurrent excitation in the dentate gyrus of mice with TLE.,0.2,"These findings indicate that activation of <span class=""gene"" id=""20498848-10-43-47"">CB1R</span> present on nerve terminals can suppress recurrent excitation in the dentate gyrus of mice with <span class=""disease"" id=""20498848-10-143-146"">TLE</span>.",CTD_human
2,0,Biomarker,C0023890,Liver Cirrhosis,disease,liver cirrhosis,1268,CNR1,CB1,CTD_human,11433348,Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis.,0.202732912464814,"Endocannabinoids acting at vascular <span class=""gene"" id=""11433348-0-36-39"">CB1</span> receptors mediate the vasodilated state in advanced <span class=""disease"" id=""11433348-0-92-107"">liver cirrhosis</span>.",CTD_human
1,0,Biomarker,C0026838,Muscle Spasticity,phenotype,spastic,1268,CNR1,CB1,CTD_human,17220914,Gene knockout technology provides an important tool in target validation and indicates that the CB1 receptor is the main cannabinoid target for an anti-spastic effect.,0.2,"Gene knockout technology provides an important tool in target validation and indicates that the <span class=""gene"" id=""17220914-10-96-99"">CB1</span> receptor is the main cannabinoid target for an anti-<span class=""disease"" id=""17220914-10-152-159"">spastic</span> effect.",CTD_human
1,0,Biomarker,C0028754,Obesity,disease,obese,1268,CNR1,CB1,CTD_human,18722357,"In obese Zucker rats, a significant decrease in CB1 receptor levels, measured by western blot, was observed in brain cortex after fluoxetine treatment.",0.23478462981719103,"In <span class=""disease"" id=""18722357-6-3-8"">obese</span> Zucker rats, a significant decrease in <span class=""gene"" id=""18722357-6-48-51"">CB1</span> receptor levels, measured by western blot, was observed in brain cortex after fluoxetine treatment.",CTD_human
1,0,Therapeutic,C0030193,Pain,phenotype,pain,1268,CNR1,CB(1,CTD_human,19193902,The effects of cannabinoid receptor agonists and antagonists on pain-related responses to CRD were assessed in rats and in wild-type and CB(1) receptor knock-out mice.,0.204055389228567,"The effects of cannabinoid receptor agonists and antagonists on <span class=""disease"" id=""19193902-3-64-68"">pain</span>-related responses to CRD were assessed in rats and in wild-type and <span class=""gene"" id=""19193902-3-137-141"">CB(1</span>) receptor knock-out mice.",CTD_human
1,0,Biomarker,C0035412,Rhabdomyosarcoma,disease,rhabdomyosarcoma,1268,CNR1,Cannabinoid receptor 1,CTD_human,19509271,Cannabinoid receptor 1 is a potential drug target for treatment of translocation-positive rhabdomyosarcoma.,0.200274726784213,"<span class=""gene"" id=""19509271-0-0-22"">Cannabinoid receptor 1</span> is a potential drug target for treatment of translocation-positive <span class=""disease"" id=""19509271-0-90-106"">rhabdomyosarcoma</span>.",CTD_human
1,0,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,1268,CNR1,CNR1,CTD_human,21513772,"Recently, an (AAT)n triplet repeat polymorphism within the cannabinoid receptor gene CNR1 has been found to be associated with both schizophrenia and substance dependence, and to modulate the P300 potential.",0.32510131357339,"Recently, an (AAT)n triplet repeat polymorphism within the cannabinoid receptor gene <span class=""gene"" id=""21513772-2-85-89"">CNR1</span> has been found to be associated with both <span class=""disease"" id=""21513772-2-132-145"">schizophrenia</span> and substance dependence, and to modulate the P300 potential.",CTD_human
1,0,Biomarker,C0036572,Seizures,phenotype,seizure,1268,CNR1,CB1,CTD_human,12954810,"By demonstrating a role for the endogenous cannabinoid system in regulating seizure activity, these studies define a role for the endogenous cannabinoid system in modulating neuroexcitation and suggest that plasticity of the CB1 receptor occurs with epilepsy.",0.2,"By demonstrating a role for the endogenous cannabinoid system in regulating <span class=""disease"" id=""12954810-9-76-83"">seizure</span> activity, these studies define a role for the endogenous cannabinoid system in modulating neuroexcitation and suggest that plasticity of the <span class=""gene"" id=""12954810-9-225-228"">CB1</span> receptor occurs with epilepsy.",CTD_human
1,0,Biomarker,C0038220,Status Epilepticus,disease,status epilepticus,1268,CNR1,CB(1,CTD_human,19368833,Temporal characterization of changes in hippocampal cannabinoid CB(1) receptor expression following pilocarpine-induced status epilepticus.,0.2,"Temporal characterization of changes in hippocampal cannabinoid <span class=""gene"" id=""19368833-0-64-68"">CB(1</span>) receptor expression following pilocarpine-induced <span class=""disease"" id=""19368833-0-120-138"">status epilepticus</span>.",CTD_human
1,0,Biomarker,C1263846,Attention deficit hyperactivity disorder,disease,hyperactivity disorder,1268,CNR1,CB1,CTD_human,22034972,Loss of striatal cannabinoid CB1 receptor function in attention-deficit?/?hyperactivity disorder mice with point-mutation of the dopamine transporter.,0.202681755307501,"Loss of striatal cannabinoid <span class=""gene"" id=""22034972-0-29-32"">CB1</span> receptor function in attention-deficit?/?<span class=""disease"" id=""22034972-0-74-96"">hyperactivity disorder</span> mice with point-mutation of the dopamine transporter.",CTD_human
1,0,Therapeutic,C0004153,Atherosclerosis,disease,atherosclerosis,1269,CNR2,CB2,CTD_human,15815632,"Thus, THC or cannabinoids with activity at the CB2 receptor may be valuable targets for treating atherosclerosis.",0.201098907136852,"Thus, THC or cannabinoids with activity at the <span class=""gene"" id=""15815632-11-47-50"">CB2</span> receptor may be valuable targets for treating <span class=""disease"" id=""15815632-11-97-112"">atherosclerosis</span>.",CTD_human
5,0,Biomarker,C0011581,Depressive disorder,disease,depression,1269,CNR2,CB2-R,CTD_human,18286196,Our data demonstrate the functional expression of CB2-Rs in brain that may provide novel targets for the effects of cannabinoids in depression and substance abuse disorders beyond neuro-immunocannabinoid activity.,0.4010989071368521,"Our data demonstrate the functional expression of <span class=""gene"" id=""18286196-10-50-55"">CB2-R</span>s in brain that may provide novel targets for the effects of cannabinoids in <span class=""disease"" id=""18286196-10-132-142"">depression</span> and substance abuse disorders beyond neuro-immunocannabinoid activity.",CTD_human;PSYGENET
1,0,Biomarker,C0023890,Liver Cirrhosis,disease,cirrhosis,1269,CNR2,CB2,CTD_human,15765409,"In liver biopsy specimens from patients with active cirrhosis of various etiologies, CB2 receptors were expressed in nonparenchymal cells located within and at the edge of fibrous septa in smooth muscle alpha-actin-positive cells.",0.200274726784213,"In liver biopsy specimens from patients with active <span class=""disease"" id=""15765409-7-52-61"">cirrhosis</span> of various etiologies, <span class=""gene"" id=""15765409-7-85-88"">CB2</span> receptors were expressed in nonparenchymal cells located within and at the edge of fibrous septa in smooth muscle alpha-actin-positive cells.",CTD_human
1,0,Biomarker,C0030297,Pancreatic Neoplasm,disease,pancreatic tumor,1269,CNR2,CB(2,CTD_human,16818650,"In conclusion, results presented here show that cannabinoids lead to apoptosis of pancreatic tumor cells via a CB(2) receptor and de novo synthesized ceramide-dependent up-regulation of p8 and the endoplasmic reticulum stress-related genes ATF-4 and TRB3.",0.2,"In conclusion, results presented here show that cannabinoids lead to apoptosis of <span class=""disease"" id=""16818650-10-82-98"">pancreatic tumor</span> cells via a <span class=""gene"" id=""16818650-10-111-115"">CB(2</span>) receptor and de novo synthesized ceramide-dependent up-regulation of p8 and the endoplasmic reticulum stress-related genes ATF-4 and TRB3.",CTD_human
1,0,Biomarker,C0030305,Pancreatitis,disease,pancreatitis,1269,CNR2,CB2,CTD_human,17484889,"Antagonists at CB1- and CB2-receptors were effective in reversing HU210-induced antinociception, whereas a combination of CB1- and CB2-antagonists was required to block the anti-inflammatory effects of HU210 in pancreatitis.",0.200274726784213,"Antagonists at CB1- and <span class=""gene"" id=""17484889-10-24-27"">CB2</span>-receptors were effective in reversing HU210-induced antinociception, whereas a combination of CB1- and CB2-antagonists was required to block the anti-inflammatory effects of HU210 in <span class=""disease"" id=""17484889-10-211-223"">pancreatitis</span>.",CTD_human
1,0,Biomarker,C0036421,Systemic Scleroderma,disease,SSc,1278,COL1A2,COL1A2,CTD_human,24706986,"A novel small-molecule inhibitor of MRTF/SRF-regulated transcription (CCG-203971) inhibits expression of connective tissue growth factor (CTGF), ?-smooth muscle actin (?-SMA), and collagen 1 (COL1A2) in both SSc fibroblasts and in lysophosphatidic acid (LPA)-and transforming growth factor ? (TGF?)-stimulated fibroblasts.",0.21008502310393803,"A novel small-molecule inhibitor of MRTF/SRF-regulated transcription (CCG-203971) inhibits expression of connective tissue growth factor (CTGF), &alpha;-smooth muscle actin (&alpha;-SMA), and collagen 1 (<span class=""gene"" id=""24706986-5-192-198"">COL1A2</span>) in both <span class=""disease"" id=""24706986-5-208-211"">SSc</span> fibroblasts and in lysophosphatidic acid (LPA)-and transforming growth factor &beta; (TGF&beta;)-stimulated fibroblasts.",CTD_human
1,4,Biomarker,C1857034,"Ehlers-Danlos syndrome, cardiac valvular form",disease,cardiac valvular form of Ehlers-Danlos syndrome,1278,COL1A2,COL1A2,CTD_human,15077201,Rare autosomal recessive cardiac valvular form of Ehlers-Danlos syndrome results from mutations in the COL1A2 gene that activate the nonsense-mediated RNA decay pathway.,0.4,"Rare autosomal recessive <span class=""disease"" id=""15077201-0-25-72"">cardiac valvular form of Ehlers-Danlos syndrome</span> results from mutations in the <span class=""gene"" id=""15077201-0-103-109"">COL1A2</span> gene that activate the nonsense-mediated RNA decay pathway.",CTD_human;ORPHANET
1,0,Biomarker,C0008479,Chondrosarcoma,disease,chondrosarcoma,1280,COL2A1,COL2A1,CTD_human,23770606,Frequent mutation of the major cartilage collagen gene COL2A1 in chondrosarcoma.,0.20082418035263896,"Frequent mutation of the major <span class=""gene"" id=""23770606-0-31-49"">cartilage collagen</span> gene <span class=""gene"" id=""23770606-0-55-61"">COL2A1</span> in <span class=""disease"" id=""23770606-0-65-79"">chondrosarcoma</span>.",CTD_human
1,0,Biomarker,C0025202,melanoma,disease,melanoma,1280,COL2A1,COL2A1,CTD_human,16778180,"CGIs in putative promoter regions of 34 genes (ABHD9, BARHL1, CLIC5, CNNM1, COL2A1, CPT1C, DDIT4L, DERL3, DHRS3, DPYS, EFEMP2, FAM62C, FAM78A, FLJ33790, GBX2, GPR10, GPRASP1, HOXA9, HOXD11, HOXD12, HOXD13, p14ARF, PAX6, PRDX2, PTPRG, RASD1, RAX, REC8L1, SLC27A3, TGFB2, TLX2, TMEM22, TMEM30B, and UNC5C) were found to be methylated in at least 1 of 13 melanoma cell lines but not in two cultured normal melanocytes.",0.2,"CGIs in putative promoter regions of 34 genes (ABHD9, BARHL1, CLIC5, CNNM1, <span class=""gene"" id=""16778180-3-76-82"">COL2A1</span>, CPT1C, DDIT4L, DERL3, DHRS3, DPYS, EFEMP2, FAM62C, FAM78A, FLJ33790, GBX2, GPR10, GPRASP1, HOXA9, HOXD11, HOXD12, HOXD13, p14ARF, PAX6, PRDX2, PTPRG, RASD1, RAX, REC8L1, SLC27A3, TGFB2, TLX2, TMEM22, TMEM30B, and UNC5C) were found to be methylated in at least 1 of 13 <span class=""disease"" id=""16778180-3-352-360"">melanoma</span> cell lines but not in two cultured normal melanocytes.",CTD_human
1,0,Biomarker,C0027092,Myopia,disease,myopia,1280,COL2A1,COL2A1,CTD_human,17653045,"SNPs were also analyzed in genes where their expression pattern or their association with syndromes conveys myopia as part of the phenotype (FGF2, BDNF, COL2A1, COL18A1, and PAX6).",0.405363510615002,"SNPs were also analyzed in genes where their expression pattern or their association with syndromes conveys <span class=""disease"" id=""17653045-8-108-114"">myopia</span> as part of the phenotype (FGF2, BDNF, <span class=""gene"" id=""17653045-8-153-159"">COL2A1</span>, COL18A1, and PAX6).",CTD_human;HPO
1,0,Biomarker,C0035305,Retinal Detachment,disease,retinal detachment,1280,COL2A1,COL2A1,CTD_human,8317498,Mutation in type II procollagen (COL2A1) that substitutes aspartate for glycine alpha 1-67 and that causes cataracts and retinal detachment: evidence for molecular heterogeneity in the Wagner syndrome and the Stickler syndrome (arthro-ophthalmopathy),0.40651357490916706,"Mutation in type II procollagen (<span class=""gene"" id=""8317498-0-33-39"">COL2A1</span>) that substitutes aspartate for glycine alpha 1-67 and that causes cataracts and <span class=""disease"" id=""8317498-0-121-139"">retinal detachment</span>: evidence for molecular heterogeneity in the Wagner syndrome and the Stickler syndrome (arthro-ophthalmopathy)",CTD_human;HPO
1,0,Biomarker,C0086543,Cataract,disease,cataracts,1280,COL2A1,COL2A1,CTD_human,8317498,Mutation in type II procollagen (COL2A1) that substitutes aspartate for glycine alpha 1-67 and that causes cataracts and retinal detachment: evidence for molecular heterogeneity in the Wagner syndrome and the Stickler syndrome (arthro-ophthalmopathy),0.40027472678421294,"Mutation in type II procollagen (<span class=""gene"" id=""8317498-0-33-39"">COL2A1</span>) that substitutes aspartate for glycine alpha 1-67 and that causes <span class=""disease"" id=""8317498-0-107-116"">cataracts</span> and retinal detachment: evidence for molecular heterogeneity in the Wagner syndrome and the Stickler syndrome (arthro-ophthalmopathy)",CTD_human;HPO
1,0,Biomarker,C1840452,Hyaloideoretinal degeneration of Wagner,disease,Wagner's disease,1280,COL2A1,COL2A1,CTD_human,11812423,Tissue-specific alternative splicing of COL2A1 mRNAs thus provides an elegant biochemical mechanism for a clinical phenotype of Wagner's disease in this kindred.,0.201648360705279,"Tissue-specific alternative splicing of <span class=""gene"" id=""11812423-14-40-46"">COL2A1</span> mRNAs thus provides an elegant biochemical mechanism for a clinical phenotype of <span class=""disease"" id=""11812423-14-128-144"">Wagner's disease</span> in this kindred.",CTD_human
1,0,Biomarker,C1855310,Megaepiphyseal dwarfism,disease,OSMED,1280,COL2A1,COL2A1,CTD_human,16189708,We have identified a novel COL2A1 mutation at a splice-acceptor site within intron 10 (c.709-2A>G) in an OSMED patient.,0.200274726784213,"We have identified a novel <span class=""gene"" id=""16189708-3-27-33"">COL2A1</span> mutation at a splice-acceptor site within intron 10 (c.709-2A&gt;G) in an <span class=""disease"" id=""16189708-3-105-110"">OSMED</span> patient.",CTD_human
1,0,Biomarker,C0020456,Hyperglycemia,disease,hyperglycaemia,1281,COL3A1,Col3A1,CTD_human,20836762,"In the present study, we have investigated the hyperinsulinaemia/hyperglycaemia-induced epigenetic changes and alteration of Fbn1 (fibrillin 1) and Col3A1 (collagen type III ?1) gene expression.",0.200274726784213,"In the present study, we have investigated the hyperinsulinaemia/<span class=""disease"" id=""20836762-2-65-79"">hyperglycaemia</span>-induced epigenetic changes and alteration of Fbn1 (fibrillin 1) and <span class=""gene"" id=""20836762-2-148-154"">Col3A1</span> (collagen type III &alpha;1) gene expression.",CTD_human
1,0,Biomarker,C0020459,Hyperinsulinism,disease,hyperinsulinaemia,1281,COL3A1,Col3A1,CTD_human,20836762,"In the present study, we have investigated the hyperinsulinaemia/hyperglycaemia-induced epigenetic changes and alteration of Fbn1 (fibrillin 1) and Col3A1 (collagen type III ?1) gene expression.",0.200274726784213,"In the present study, we have investigated the <span class=""disease"" id=""20836762-2-47-64"">hyperinsulinaemia</span>/hyperglycaemia-induced epigenetic changes and alteration of Fbn1 (fibrillin 1) and <span class=""gene"" id=""20836762-2-148-154"">Col3A1</span> (collagen type III &alpha;1) gene expression.",CTD_human
3,19,Biomarker,C0268335,Ehlers-Danlos syndrome type 1,disease,Ehlers-Danlos syndrome type I,1289,COL5A1,COL5A1,CTD_human,8752669,The gene encoding collagen alpha1(V)(COL5A1) is linked to mixed Ehlers-Danlos syndrome type I/II.,0.40082418035263895,"The gene encoding collagen alpha1(V)(<span class=""gene"" id=""8752669-0-37-43"">COL5A1</span>) is linked to mixed <span class=""disease"" id=""8752669-0-64-93"">Ehlers-Danlos syndrome type I</span>/II.",CTD_human;ORPHANET
1,0,Biomarker,C0026850,Muscular Dystrophy,disease,MD,1291,COL6A1,Col6a1,CTD_human,20716577,"Pargyline, an MAO inhibitor, reduced ROS accumulation along with a beneficial effect on the dystrophic phenotype of Col6a1(-/-) mice, a model of Bethlem myopathy and Ullrich congenital MD, and mdx mice, a model of Duchenne MD.",0.21476346946092104,"Pargyline, an MAO inhibitor, reduced ROS accumulation along with a beneficial effect on the dystrophic phenotype of <span class=""gene"" id=""20716577-4-116-122"">Col6a1</span>(-/-) mice, a model of Bethlem myopathy and Ullrich congenital <span class=""disease"" id=""20716577-4-185-187"">MD</span>, and mdx mice, a model of Duchenne <span class=""disease"" id=""20716577-4-223-225"">MD</span>.",CTD_human
1,0,Biomarker,C0000768,Congenital Abnormality,group,birth defects,1295,COL8A1,COL8A1,CTD_human,19035365,"Taken together, the data identify a new protein essential for notochord morphogenesis, extend our understanding of gene-nutrient interactions in early development, and suggest that human mutations in COL8A1 may cause structural birth defects.",0.2,"Taken together, the data identify a new protein essential for notochord morphogenesis, extend our understanding of gene-nutrient interactions in early development, and suggest that human mutations in <span class=""gene"" id=""19035365-6-200-206"">COL8A1</span> may cause structural <span class=""disease"" id=""19035365-6-228-241"">birth defects</span>.",CTD_human
1,2,Biomarker,C0796113,"Nephroblastomatosis, fetal ascites, macrosomia and Wilms tumor",disease,Perlman syndrome,129563,DIS3L2,DIS3L2,CTD_human,22306653,Germline mutations in DIS3L2 cause the Perlman syndrome of overgrowth and Wilms tumor susceptibility.,0.6013736339210661,"Germline mutations in <span class=""gene"" id=""22306653-0-22-28"">DIS3L2</span> cause the <span class=""disease"" id=""22306653-0-39-55"">Perlman syndrome</span> of overgrowth and Wilms tumor susceptibility.",CTD_human;ORPHANET;UNIPROT
1,3,Biomarker,C0265235,Marshall syndrome,disease,Marshall syndrome,1301,COL11A1,COL11A1,CTD_human,9529347,Marshall syndrome associated with a splicing defect at the COL11A1 locus.,0.48109890713685205,"<span class=""disease"" id=""9529347-0-0-17"">Marshall syndrome</span> associated with a splicing defect at the <span class=""gene"" id=""9529347-0-59-66"">COL11A1</span> locus.",CTD_human;ORPHANET
2,3,Biomarker,C1855310,Megaepiphyseal dwarfism,disease,OSMED,1302,COL11A2,COL11A2,CTD_human,16637051,Oto-spondylo-megaepiphyseal dysplasia (OSMED): clinical and radiological findings in sibs homozygous for premature stop codon mutation in the COL11A2 gene.,0.6827472678421309,"<span class=""disease"" id=""16637051-0-0-37"">Oto-spondylo-megaepiphyseal dysplasia</span> (<span class=""disease"" id=""16637051-0-39-44"">OSMED</span>): clinical and radiological findings in sibs homozygous for premature stop codon mutation in the <span class=""gene"" id=""16637051-0-142-149"">COL11A2</span> gene.",CTD_human;ORPHANET;UNIPROT
9,14,Biomarker,C0410538,Pseudoachondroplasia,disease,Pseudoachondroplasia,1311,COMP,cartilage oligomeric matrix protein,CTD_human,7670472,Pseudoachondroplasia and multiple epiphyseal dysplasia due to mutations in the cartilage oligomeric matrix protein gene.,0.7026712980204279,"<span class=""disease"" id=""7670472-0-0-20"">Pseudoachondroplasia</span> and multiple epiphyseal dysplasia due to mutations in the <span class=""gene"" id=""7670472-0-79-114"">cartilage oligomeric matrix protein</span> gene.",CTD_human;ORPHANET;UNIPROT
9,14,Biomarker,C0410538,Pseudoachondroplasia,disease,pseudoachondroplasia,1311,COMP,COMP,CTD_human,7670471,Mutations in exon 17B of cartilage oligomeric matrix protein (COMP) cause pseudoachondroplasia.,0.7026712980204279,"Mutations in exon 17B of <span class=""gene"" id=""7670471-0-25-60"">cartilage oligomeric matrix protein</span> (<span class=""gene"" id=""7670471-0-62-66"">COMP</span>) cause <span class=""disease"" id=""7670471-0-74-94"">pseudoachondroplasia</span>.",CTD_human;ORPHANET;UNIPROT
9,14,Biomarker,C0410538,Pseudoachondroplasia,disease,PSACH,1311,COMP,COMP,CTD_human,9887340,"About one-third of PSACH cases result from heterozygosity for deletion of one codon within a very short triplet repeat, (GAC)5, which encodes five consecutive aspartic acid residues within the calmodulin-like region of the COMP protein.",0.7026712980204279,"About one-third of <span class=""disease"" id=""9887340-3-19-24"">PSACH</span> cases result from heterozygosity for deletion of one codon within a very short triplet repeat, (GAC)5, which encodes five consecutive aspartic acid residues within the calmodulin-like region of the <span class=""gene"" id=""9887340-3-223-227"">COMP</span> protein.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0001973,"Alcoholic Intoxication, Chronic",disease,alcoholism,1312,COMT,COMT,CTD_human,10395222,Association between the functional variant of the catechol-O-methyltransferase (COMT) gene and type 1 alcoholism.,0.23580366904209601,"Association between the functional variant of the <span class=""gene"" id=""10395222-0-50-78"">catechol-O-methyltransferase</span> (<span class=""gene"" id=""10395222-0-80-84"">COMT</span>) gene and type 1 <span class=""disease"" id=""10395222-0-102-112"">alcoholism</span>.",CTD_human
1,0,Biomarker,C0004936,Mental disorders,group,psychiatric disorders,1312,COMT,COMT,CTD_human,16780746,This study supported that there is heterogeneity in COMT gene in suicide attempters and there is interaction between COMT Val/Val and suicide impulsion and psychiatric disorders.,0.212846646323386,"This study supported that there is heterogeneity in <span class=""gene"" id=""16780746-11-52-56"">COMT</span> gene in suicide attempters and there is interaction between <span class=""gene"" id=""16780746-11-117-121"">COMT</span> Val/Val and suicide impulsion and <span class=""disease"" id=""16780746-11-156-177"">psychiatric disorders</span>.",CTD_human
6,0,Biomarker,C0005586,Bipolar Disorder,disease,bipolar disorder,1312,COMT,Catechol o-methyltransferase,CTD_human,11772685,"Catechol o-methyltransferase, serotonin transporter, and tryptophan hydroxylase gene polymorphisms in bipolar disorder patients with and without comorbid panic disorder.",0.462030381148353,"<span class=""gene"" id=""11772685-0-0-28"">Catechol o-methyltransferase</span>, serotonin transporter, and tryptophan hydroxylase gene polymorphisms in <span class=""disease"" id=""11772685-0-102-118"">bipolar disorder</span> patients with and without comorbid panic disorder.",CTD_human;PSYGENET
1,0,Biomarker,C0012236,DiGeorge Syndrome,disease,velo-cardio-facial syndrome,1312,COMT,catechol-O-methyltransferase,CTD_human,8886163,Association of codon 108/158 catechol-O-methyltransferase gene polymorphism with the psychiatric manifestations of velo-cardio-facial syndrome.,0.43606404044899205,"Association of codon 108/158 <span class=""gene"" id=""8886163-0-29-57"">catechol-O-methyltransferase</span> gene polymorphism with the psychiatric manifestations of <span class=""disease"" id=""8886163-0-115-142"">velo-cardio-facial syndrome</span>.",CTD_human;ORPHANET
1,0,Biomarker,C0031511,Pheochromocytoma,disease,PHEO,1312,COMT,COMT,CTD_human,22569243,"At both the protein and mRNA levels, MAOA and COMT are detected less often in PHEO compared with adrenal medulla, conversely to tyrosine hydroxylase, L-amino acid decarboxylase, and dopamine ?-hydroxylase, much more expressed in tumor tissue.",0.200274726784213,"At both the protein and mRNA levels, MAOA and <span class=""gene"" id=""22569243-9-46-50"">COMT</span> are detected less often in <span class=""disease"" id=""22569243-9-78-82"">PHEO</span> compared with adrenal medulla, conversely to tyrosine hydroxylase, L-amino acid decarboxylase, and dopamine &beta;-hydroxylase, much more expressed in tumor tissue.",CTD_human
4,1,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,1312,COMT,COMT,CTD_human,17123785,"COMT val108/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia.",0.43142896389540597,"<span class=""gene"" id=""17123785-0-0-4"">COMT</span> val108/158met genotype, cognitive function, and cognitive improvement with clozapine in <span class=""disease"" id=""17123785-0-93-106"">schizophrenia</span>.",CTD_human
1,0,Biomarker,C0039494,Temporomandibular Joint Disorders,group,TMD,1312,COMT,COMT,CTD_human,25218601,"Results show that the COMT rs4680 (val(158)met) polymorphism is most strongly associated with outcome measures, such that individuals with the minor A allele (met) exhibit reduced COMT activity, increased TMD risk, and increased musculoskeletal pain.",0.207561324888707,"Results show that the <span class=""gene"" id=""25218601-3-22-26"">COMT</span> rs4680 (val(158)met) polymorphism is most strongly associated with outcome measures, such that individuals with the minor A allele (met) exhibit reduced <span class=""gene"" id=""25218601-3-180-184"">COMT</span> activity, increased <span class=""disease"" id=""25218601-3-205-208"">TMD</span> risk, and increased musculoskeletal pain.",CTD_human
1,0,Biomarker,C1263846,Attention deficit hyperactivity disorder,disease,ADHD,1312,COMT,COMT,CTD_human,10490706,Haplotype relative risk study of catechol-O-methyltransferase (COMT) and attention deficit hyperactivity disorder (ADHD): association of the high-enzyme activity Val allele with ADHD impulsive-hyperactive phenotype.,0.457337579414052,"Haplotype relative risk study of <span class=""gene"" id=""10490706-0-33-61"">catechol-O-methyltransferase</span> (<span class=""gene"" id=""10490706-0-63-67"">COMT</span>) and <span class=""disease"" id=""10490706-0-73-113"">attention deficit hyperactivity disorder</span> (<span class=""disease"" id=""10490706-0-115-119"">ADHD</span>): association of the high-enzyme activity Val allele with <span class=""disease"" id=""10490706-0-178-182"">ADHD</span> impulsive-hyperactive phenotype.",CTD_human;HPO
1,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,1312,COMT,COMT,CTD_human,15341023,"In this molecular epidemiological study, we used logistic regression to compare the genotype frequencies of estrogen-metabolizing genes that are involved in estrogen biogenesis (CYP17), hydroxylation (CYP1A1) and inactivation of the reactive metabolites (catechol-O-methyltransferase, COMT) in HCC patients and control subjects, and determined their relationship with the risk of female HCC.",0.20054945356842604,"In this molecular epidemiological study, we used logistic regression to compare the genotype frequencies of estrogen-metabolizing genes that are involved in estrogen biogenesis (CYP17), hydroxylation (CYP1A1) and inactivation of the reactive metabolites (<span class=""gene"" id=""15341023-2-255-283"">catechol-O-methyltransferase</span>, <span class=""gene"" id=""15341023-2-285-289"">COMT</span>) in <span class=""disease"" id=""15341023-2-294-297"">HCC</span> patients and control subjects, and determined their relationship with the risk of female <span class=""disease"" id=""15341023-2-387-390"">HCC</span>.",CTD_human
1,0,Biomarker,C0003864,Arthritis,disease,arthritis,1314,COPA,COPA,CTD_human,25894502,COPA mutations impair ER-Golgi transport and cause hereditary autoimmune-mediated lung disease and arthritis.,0.200274726784213,"<span class=""gene"" id=""25894502-0-0-4"">COPA</span> mutations impair ER-Golgi transport and cause hereditary autoimmune-mediated lung disease and <span class=""disease"" id=""25894502-0-99-108"">arthritis</span>.",CTD_human
1,2,Biomarker,C0268514,Urocanase deficiency,disease,urocanic aciduria,131669,UROC1,UROC1,CTD_human,19304569,Mutations in the urocanase gene UROC1 are associated with urocanic aciduria.,0.600274726784213,"Mutations in the <span class=""gene"" id=""19304569-0-17-26"">urocanase</span> gene <span class=""gene"" id=""19304569-0-32-37"">UROC1</span> are associated with <span class=""disease"" id=""19304569-0-58-75"">urocanic aciduria</span>.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C3714756,Intellectual Disability,group,mental retardation,131669,UROC1,UROC1,CTD_human,19304569,"This report describes the first putative mutations, p.L70P and p.R450C, in the coding region of the UROC1 gene in a girl with urocanic aciduria presenting with mental retardation and intermittent ataxia.",0.200274726784213,"This report describes the first putative mutations, p.L70P and p.R450C, in the coding region of the <span class=""gene"" id=""19304569-2-100-105"">UROC1</span> gene in a girl with urocanic aciduria presenting with <span class=""disease"" id=""19304569-2-160-178"">mental retardation</span> and intermittent ataxia.",CTD_human
1,0,Biomarker,C1458155,Mammary Neoplasms,group,breast tumors,131965,METTL6,METTL6,CTD_human,25151356,"The genes identified include eight that are essential for cell proliferation (FGD5, METTL6, CPT1A, DTX3, MRPS23, EIF2S2, EIF6 and SLC2A10) and are uniquely amplified in patients with highly proliferative luminal breast tumors, a clinical subset of patients for which few therapeutic options are effective.",0.2,"The genes identified include eight that are essential for cell proliferation (FGD5, <span class=""gene"" id=""25151356-4-84-90"">METTL6</span>, CPT1A, DTX3, MRPS23, EIF2S2, EIF6 and SLC2A10) and are uniquely amplified in patients with highly proliferative luminal <span class=""disease"" id=""25151356-4-212-225"">breast tumors</span>, a clinical subset of patients for which few therapeutic options are effective.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,133,ADM,adrenomedullin,CTD_human,12579522,Pathophysiological role of nitric oxide and adrenomedullin in autism.,0.2,"Pathophysiological role of nitric oxide and <span class=""gene"" id=""12579522-0-44-58"">adrenomedullin</span> in <span class=""disease"" id=""12579522-0-62-68"">autism</span>.",CTD_human
2,0,Biomarker,C0017658,Glomerulonephritis,disease,glomerulonephritis,133,ADM,adrenomedullin,CTD_human,15063164,Mycophenolate mofetil prevents autoimmune glomerulonephritis and alterations of intrarenal adrenomedullin in rats.,0.200274726784213,"Mycophenolate mofetil prevents autoimmune <span class=""disease"" id=""15063164-0-42-60"">glomerulonephritis</span> and alterations of intrarenal <span class=""gene"" id=""15063164-0-91-105"">adrenomedullin</span> in rats.",CTD_human
2,0,Biomarker,C0017658,Glomerulonephritis,disease,glomerulonephritis,133,ADM,adrenomedullin,CTD_human,15680492,A novel immunosuppressant FTY720 ameliorates proteinuria and alterations of intrarenal adrenomedullin in rats with autoimmune glomerulonephritis.,0.200274726784213,"A novel immunosuppressant FTY720 ameliorates proteinuria and alterations of intrarenal <span class=""gene"" id=""15680492-0-87-101"">adrenomedullin</span> in rats with autoimmune <span class=""disease"" id=""15680492-0-126-144"">glomerulonephritis</span>.",CTD_human
1,0,Biomarker,C0020429,Hyperalgesia,phenotype,hyperalgesia,133,ADM,AM,CTD_human,17043245,"By activating specific receptors (likely AM2) and the PI3K/Akt/GSK3beta signaling pathway, AM could play a significant role in long-lasting heat hypersensitivity and inflammatory heat hyperalgesia.",0.2,"By activating specific receptors (likely AM2) and the PI3K/Akt/GSK3beta signaling pathway, <span class=""gene"" id=""17043245-9-91-93"">AM</span> could play a significant role in long-lasting heat hypersensitivity and inflammatory heat <span class=""disease"" id=""17043245-9-184-196"">hyperalgesia</span>.",CTD_human
1,0,Biomarker,C0030193,Pain,phenotype,pain,133,ADM,adrenomedullin,CTD_human,17043245,A role for adrenomedullin as a pain-related peptide in the rat.,0.2,"A role for <span class=""gene"" id=""17043245-0-11-25"">adrenomedullin</span> as a <span class=""disease"" id=""17043245-0-31-35"">pain</span>-related peptide in the rat.",CTD_human
1,0,Biomarker,C0243026,Sepsis,disease,sepsis,133,ADM,adrenomedullin,CTD_human,14766677,Role of cyclooxygenase in ventricular effects of adrenomedullin: is adrenomedullin a double-edged sword in sepsis?,0.292580010564534,"Role of cyclooxygenase in ventricular effects of <span class=""gene"" id=""14766677-0-49-63"">adrenomedullin</span>: is <span class=""gene"" id=""14766677-0-68-82"">adrenomedullin</span> a double-edged sword in <span class=""disease"" id=""14766677-0-107-113"">sepsis</span>?",CTD_human
1,0,Biomarker,C0038525,Subarachnoid Hemorrhage,disease,SAH,134,ADORA1,AR-A1,CTD_human,18950269,"Interestingly, E2 appears to effectively prevent cerebral vasospasm subsequent to SAH as well as attenuate secondary injury by reducing both apoptosis and a compensatory increase in AR-A1 expression in the dentate gyrus.",0.2,"Interestingly, E2 appears to effectively prevent cerebral vasospasm subsequent to <span class=""disease"" id=""18950269-14-82-85"">SAH</span> as well as attenuate secondary injury by reducing both apoptosis and a compensatory increase in <span class=""gene"" id=""18950269-14-182-187"">AR-A1</span> expression in the dentate gyrus.",CTD_human
4,0,Biomarker,C0003469,Anxiety Disorders,group,anxiety,135,ADORA2A,ADORA2A,CTD_human,18305461,Association between ADORA2A and DRD2 polymorphisms and caffeine-induced anxiety.,0.205154296365419,"Association between <span class=""gene"" id=""18305461-0-20-27"">ADORA2A</span> and DRD2 polymorphisms and caffeine-induced <span class=""disease"" id=""18305461-0-72-79"">anxiety</span>.",CTD_human
4,0,Biomarker,C0003469,Anxiety Disorders,group,anxiety,135,ADORA2A,adenosine A2A receptor,CTD_human,16118787,Interindividual variation in anxiety response to amphetamine: possible role for adenosine A2A receptor gene variants.,0.205154296365419,"Interindividual variation in <span class=""disease"" id=""16118787-0-29-36"">anxiety</span> response to amphetamine: possible role for <span class=""gene"" id=""16118787-0-80-102"">adenosine A2A receptor</span> gene variants.",CTD_human
1,0,Biomarker,C0036572,Seizures,phenotype,seizures,135,ADORA2A,Adenosine A2A receptor,CTD_human,19488739,Adenosine A2A receptor deficient mice are partially resistant to limbic seizures.,0.200274726784213,"<span class=""gene"" id=""19488739-0-0-22"">Adenosine A2A receptor</span> deficient mice are partially resistant to limbic <span class=""disease"" id=""19488739-0-72-80"">seizures</span>.",CTD_human
3,0,Biomarker,C0038587,Substance Withdrawal Syndrome,disease,withdrawal syndrome,135,ADORA2A,adenosine A2A receptor,CTD_human,16470403,Absence of quasi-morphine withdrawal syndrome in adenosine A2A receptor knockout mice.,0.2,"Absence of quasi-morphine <span class=""disease"" id=""16470403-0-26-45"">withdrawal syndrome</span> in <span class=""gene"" id=""16470403-0-49-71"">adenosine A2A receptor</span> knockout mice.",CTD_human
1,0,Biomarker,C0003873,Rheumatoid Arthritis,disease,rheumatoid arthritis,1356,CP,ceruloplasmin,CTD_human,26001728,Thrombin inhibits the anti-myeloperoxidase and ferroxidase functions of ceruloplasmin: relevance in rheumatoid arthritis.,0.20300763924902696,"Thrombin inhibits the anti-myeloperoxidase and <span class=""gene"" id=""26001728-0-47-58"">ferroxidase</span> functions of <span class=""gene"" id=""26001728-0-72-85"">ceruloplasmin</span>: relevance in <span class=""disease"" id=""26001728-0-100-120"">rheumatoid arthritis</span>.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,1356,CP,ceruloplasmin,CTD_human,15363659,Oxidative stress in autism: increased lipid peroxidation and reduced serum levels of ceruloplasmin and transferrin--the antioxidant proteins.,0.200274726784213,"Oxidative stress in <span class=""disease"" id=""15363659-0-20-26"">autism</span>: increased lipid peroxidation and reduced serum levels of <span class=""gene"" id=""15363659-0-85-98"">ceruloplasmin</span> and transferrin--the antioxidant proteins.",CTD_human
1,0,Biomarker,C0018995,Hemochromatosis,disease,hemochromatosis,1356,CP,ceruloplasmin,CTD_human,17258727,Genetic study of variation in normal mouse iron homeostasis reveals ceruloplasmin as an HFE-hemochromatosis modifier gene.,0.20328236603324,"Genetic study of variation in normal mouse iron homeostasis reveals <span class=""gene"" id=""17258727-0-68-81"">ceruloplasmin</span> as an HFE-<span class=""disease"" id=""17258727-0-92-107"">hemochromatosis</span> modifier gene.",CTD_human
3,0,Biomarker,C0019202,Hepatolenticular Degeneration,disease,Wilson disease,1356,CP,ceruloplasmin,CTD_human,22243965,"Low copper and ceruloplasmin in serum are the diagnostic hallmarks for Menkes disease, Wilson disease, and aceruloplasminemia.",0.211263798152737,"Low copper and <span class=""gene"" id=""22243965-1-15-28"">ceruloplasmin</span> in serum are the diagnostic hallmarks for Menkes disease, <span class=""disease"" id=""22243965-1-87-101"">Wilson disease</span>, and aceruloplasminemia.",CTD_human
3,0,Biomarker,C0019202,Hepatolenticular Degeneration,disease,Wilson's disease,1356,CP,ceruloplasmin,CTD_human,7849148,"The diminution of ceruloplasmin, which until a few years ago was mistakenly thought to be the pathogenetic cause of Wilson's disease, is an epiphenomenon of the underlying metabolic defect characterized by defective copper biliary excretion.",0.211263798152737,"The diminution of <span class=""gene"" id=""7849148-3-18-31"">ceruloplasmin</span>, which until a few years ago was mistakenly thought to be the pathogenetic cause of <span class=""disease"" id=""7849148-3-116-132"">Wilson's disease</span>, is an epiphenomenon of the underlying metabolic defect characterized by defective copper biliary excretion.",CTD_human
1,0,Biomarker,C0022716,Menkes Kinky Hair Syndrome,disease,Menkes disease,1356,CP,ceruloplasmin,CTD_human,22243965,"Low copper and ceruloplasmin in serum are the diagnostic hallmarks for Menkes disease, Wilson disease, and aceruloplasminemia.",0.20082418035263896,"Low copper and <span class=""gene"" id=""22243965-1-15-28"">ceruloplasmin</span> in serum are the diagnostic hallmarks for <span class=""disease"" id=""22243965-1-71-85"">Menkes disease</span>, Wilson disease, and aceruloplasminemia.",CTD_human
2,0,Biomarker,C0030567,Parkinson Disease,disease,Parkinson's disease,1356,CP,ceruloplasmin,CTD_human,19159062,Lower serum ceruloplasmin levels correlate with younger age of onset in Parkinson's disease.,0.21521060871472197,"Lower serum <span class=""gene"" id=""19159062-0-12-25"">ceruloplasmin</span> levels correlate with younger age of onset in <span class=""disease"" id=""19159062-0-72-91"">Parkinson's disease</span>.",CTD_human
2,0,Biomarker,C0030567,Parkinson Disease,disease,PD,1356,CP,CP,CTD_human,25758665,The results of this study suggest that common genetic variants of CP are associated with PD and further investigation is needed to explore their functions in PD.,0.21521060871472197,"The results of this study suggest that common genetic variants of <span class=""gene"" id=""25758665-10-66-68"">CP</span> are associated with <span class=""disease"" id=""25758665-10-89-91"">PD</span> and further investigation is needed to explore their functions in <span class=""disease"" id=""25758665-10-158-160"">PD</span>.",CTD_human
1,0,Biomarker,C0033860,Psoriasis,disease,psoriasis,1356,CP,ceruloplasmin,CTD_human,12559600,"The mean levels of atherogenic lipids (total cholesterol [TC], triacylglycerol [TG] and LDL cholesterol [LDL-C]), acute-phase reactants (CRP, ESR, PMNLs, ceruloplasmin and fibrinogen) and lipid peroxidation products, AuAb-oxLDL levels in patients with psoriasis were found to be significantly higher than those of healthy subjects.",0.2,"The mean levels of atherogenic lipids (total cholesterol [TC], triacylglycerol [TG] and LDL cholesterol [LDL-C]), acute-phase reactants (CRP, ESR, PMNLs, <span class=""gene"" id=""12559600-6-154-167"">ceruloplasmin</span> and fibrinogen) and lipid peroxidation products, AuAb-oxLDL levels in patients with <span class=""disease"" id=""12559600-6-252-261"">psoriasis</span> were found to be significantly higher than those of healthy subjects.",CTD_human
1,0,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,1356,CP,ferroxidase,CTD_human,16842975,"Plasma copper, iron, ceruloplasmin and ferroxidase activity in schizophrenia.",0.2,"Plasma copper, iron, <span class=""gene"" id=""16842975-0-21-34"">ceruloplasmin</span> and <span class=""gene"" id=""16842975-0-39-50"">ferroxidase</span> activity in <span class=""disease"" id=""16842975-0-63-76"">schizophrenia</span>.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,hepatocellular carcinoma,1356,CP,ceruloplasmin,CTD_human,19229483,Relevance of non-ceruloplasmin copper to oxidative stress in patients with hepatocellular carcinoma.,0.200274726784213,"Relevance of non-<span class=""gene"" id=""19229483-0-17-30"">ceruloplasmin</span> copper to oxidative stress in patients with <span class=""disease"" id=""19229483-0-75-99"">hepatocellular carcinoma</span>.",CTD_human
1,0,Biomarker,C0149521,"Pancreatitis, Chronic",disease,chronic pancreatitis,1357,CPA1,CPA1,CTD_human,23955596,Variants in CPA1 are strongly associated with early onset chronic pancreatitis.,0.20054945356842604,"Variants in <span class=""gene"" id=""23955596-0-12-16"">CPA1</span> are strongly associated with early onset <span class=""disease"" id=""23955596-0-58-78"">chronic pancreatitis</span>.",CTD_human
1,0,Biomarker,C0002453,Amenorrhea,phenotype,amenorrhea,1361,CPB2,TAFI,CTD_human,16167916,A significant correlation was found between baseline TAFI antigen concentrations and the duration of amenorrhea (P < 0.05; r = 0.33).,0.2,"A significant correlation was found between baseline <span class=""gene"" id=""16167916-9-53-57"">TAFI</span> antigen concentrations and the duration of <span class=""disease"" id=""16167916-9-101-111"">amenorrhea</span> (P &lt; 0.05; r = 0.33).",CTD_human
1,0,Biomarker,C0028754,Obesity,disease,obesity,1361,CPB2,TAFI,CTD_human,16959692,Decrements in the thrombin activatable fibrinolysis inhibitor (TAFI) levels in association with orlistat treatment in obesity.,0.2,"Decrements in the <span class=""gene"" id=""16959692-0-18-61"">thrombin activatable fibrinolysis inhibitor</span> (<span class=""gene"" id=""16959692-0-63-67"">TAFI</span>) levels in association with orlistat treatment in <span class=""disease"" id=""16959692-0-118-125"">obesity</span>.",CTD_human
1,0,Biomarker,C0032460,Polycystic Ovary Syndrome,disease,PCOS,1364,CLDN4,claudin-4,CTD_human,21411543,"Progesterone-regulated genes, including mitogen-inducible gene 6 (MIG6), leukemia inhibitory factor (LIF), GRB2-associated binding protein 1 (GAB1), S100P, and claudin-4 were significantly lower in PCOS endometrium; whereas cell proliferation genes, such as Anillin and cyclin B1, were up-regulated.",0.200274726784213,"Progesterone-regulated genes, including mitogen-inducible gene 6 (MIG6), leukemia inhibitory factor (LIF), GRB2-associated binding protein 1 (GAB1), S100P, and <span class=""gene"" id=""21411543-11-160-169"">claudin-4</span> were significantly lower in <span class=""disease"" id=""21411543-11-198-202"">PCOS</span> endometrium; whereas cell proliferation genes, such as Anillin and cyclin B1, were up-regulated.",CTD_human
1,0,Biomarker,C1458155,Mammary Neoplasms,group,breast tumours,1364,CLDN4,claudin-4,CTD_human,19142967,This relationship between increased claudin-4 expression and adverse outcome was validated at the mRNA level in a DNA microarray dataset of 295 breast tumours.,0.20054945356842604,"This relationship between increased <span class=""gene"" id=""19142967-9-36-45"">claudin-4</span> expression and adverse outcome was validated at the mRNA level in a DNA microarray dataset of 295 <span class=""disease"" id=""19142967-9-144-158"">breast tumours</span>.",CTD_human
1,0,Biomarker,C0677886,Epithelial ovarian cancer,disease,epithelial ovarian carcinoma,1366,CLDN7,claudin-7,CTD_human,21134740,High claudin-7 expression is associated with a poor response to platinum-based chemotherapy in epithelial ovarian carcinoma.,0.201098907136852,"High <span class=""gene"" id=""21134740-0-5-14"">claudin-7</span> expression is associated with a poor response to platinum-based chemotherapy in <span class=""disease"" id=""21134740-0-95-123"">epithelial ovarian carcinoma</span>.",CTD_human
10,9,Biomarker,C0162531,Hereditary Coproporphyria,disease,hereditary coproporphyria,1371,CPOX,coproporphyrinogen oxidase,CTD_human,11831056,The hereditary coproporphyria is caused by a new mutation in the coproporphyrinogen oxidase gene in the case of a dual porphyria with co-existence of porphyria cutanea tarda and hereditary coproporphyria.,0.68767799458065,"The <span class=""disease"" id=""11831056-15-4-29"">hereditary coproporphyria</span> is caused by a new mutation in the <span class=""gene"" id=""11831056-15-65-91"">coproporphyrinogen oxidase</span> gene in the case of a dual porphyria with co-existence of porphyria cutanea tarda and <span class=""disease"" id=""11831056-15-178-203"">hereditary coproporphyria</span>.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0162566,Porphyria Cutanea Tarda,disease,porphyria cutanea tarda,1371,CPOX,coproporphyrinogen oxidase,CTD_human,11831056,The hereditary coproporphyria is caused by a new mutation in the coproporphyrinogen oxidase gene in the case of a dual porphyria with co-existence of porphyria cutanea tarda and hereditary coproporphyria.,0.2,"The hereditary coproporphyria is caused by a new mutation in the <span class=""gene"" id=""11831056-15-65-91"">coproporphyrinogen oxidase</span> gene in the case of a dual porphyria with co-existence of <span class=""disease"" id=""11831056-15-150-173"">porphyria cutanea tarda</span> and hereditary coproporphyria.",CTD_human
1,0,Biomarker,C0017638,Glioma,disease,glioma,137196,CCDC26,CCDC26,CTD_human,19578367,"We identified five risk loci for glioma at 5p15.33 (rs2736100, TERT; P = 1.50 x 10(-17)), 8q24.21 (rs4295627, CCDC26; P = 2.34 x 10(-18)), 9p21.3 (rs4977756, CDKN2A-CDKN2B; P = 7.24 x 10(-15)), 20q13.33 (rs6010620, RTEL1; P = 2.52 x 10(-12)) and 11q23.3 (rs498872, PHLDB1; P = 1.07 x 10(-8)).",0.207561324888707,"We identified five risk loci for <span class=""disease"" id=""19578367-2-33-39"">glioma</span> at 5p15.33 (rs2736100, TERT; P = 1.50 x 10(-17)), 8q24.21 (rs4295627, <span class=""gene"" id=""19578367-2-110-116"">CCDC26</span>; P = 2.34 x 10(-18)), 9p21.3 (rs4977756, CDKN2A-CDKN2B; P = 7.24 x 10(-15)), 20q13.33 (rs6010620, RTEL1; P = 2.52 x 10(-12)) and 11q23.3 (rs498872, PHLDB1; P = 1.07 x 10(-8)).",CTD_human
1,0,Biomarker,C0022661,"Kidney Failure, Chronic",disease,CRF,1374,CPT1A,CPT1A,CTD_human,19878707,"CRF resulted in hypertension, proteinuria, renal tissue lipid accumulation, up-regulation of scavenger receptor A1 (SR-A1), acyl-CoA cholesterol acyltransferase-1 (ACAT1), carbohydrate-responsive element binding protein (ChREBP), fatty acid synthase (FAS), acyl-CoA carboxylase (ACC), liver X receptor (LXR), ATP binding cassette (ABC) A-1, ABCG-1, and SR-B1 and down-regulation of sterol responsive element binding protein-1 (SREBP-1), SREBP-2, HMG-CoA reductase, PPAR-alpha, fatty acid binding protein (L-FABP), and CPT1A.",0.200274726784213,"<span class=""disease"" id=""19878707-5-0-3"">CRF</span> resulted in hypertension, proteinuria, renal tissue lipid accumulation, up-regulation of scavenger receptor A1 (SR-A1), acyl-CoA cholesterol acyltransferase-1 (ACAT1), carbohydrate-responsive element binding protein (ChREBP), fatty acid synthase (FAS), acyl-CoA carboxylase (ACC), liver X receptor (LXR), ATP binding cassette (ABC) A-1, ABCG-1, and SR-B1 and down-regulation of sterol responsive element binding protein-1 (SREBP-1), SREBP-2, HMG-CoA reductase, PPAR-alpha, fatty acid binding protein (L-FABP), and <span class=""gene"" id=""19878707-5-518-523"">CPT1A</span>.",CTD_human
1,0,Biomarker,C1458155,Mammary Neoplasms,group,breast tumors,1374,CPT1A,CPT1A,CTD_human,25151356,"The genes identified include eight that are essential for cell proliferation (FGD5, METTL6, CPT1A, DTX3, MRPS23, EIF2S2, EIF6 and SLC2A10) and are uniquely amplified in patients with highly proliferative luminal breast tumors, a clinical subset of patients for which few therapeutic options are effective.",0.2,"The genes identified include eight that are essential for cell proliferation (FGD5, METTL6, <span class=""gene"" id=""25151356-4-92-97"">CPT1A</span>, DTX3, MRPS23, EIF2S2, EIF6 and SLC2A10) and are uniquely amplified in patients with highly proliferative luminal <span class=""disease"" id=""25151356-4-212-225"">breast tumors</span>, a clinical subset of patients for which few therapeutic options are effective.",CTD_human
1,0,Biomarker,C0027404,Narcolepsy,disease,narcolepsy,1375,CPT1B,CPT1B,CTD_human,18820697,Variant between CPT1B and CHKB associated with susceptibility to narcolepsy.,0.201373633921065,"Variant between <span class=""gene"" id=""18820697-0-16-21"">CPT1B</span> and CHKB associated with susceptibility to <span class=""disease"" id=""18820697-0-65-75"">narcolepsy</span>.",CTD_human
1,0,Biomarker,C0007134,Renal Cell Carcinoma,disease,renal cell carcinoma,1381,CRABP1,Cellular retinoic acid binding protein I,CTD_human,16254461,Cellular retinoic acid binding protein I: expression and functional influence in renal cell carcinoma.,0.20300763924902696,"<span class=""gene"" id=""16254461-0-0-40"">Cellular retinoic acid binding protein I</span>: expression and functional influence in <span class=""disease"" id=""16254461-0-81-101"">renal cell carcinoma</span>.",CTD_human
1,0,Biomarker,C0279626,Squamous cell carcinoma of esophagus,disease,esophageal squamous-cell carcinoma,1381,CRABP1,CRABP1,CTD_human,17438526,"Frequent methylation-associated silencing of a candidate tumor-suppressor, CRABP1, in esophageal squamous-cell carcinoma.",0.200274726784213,"Frequent methylation-associated silencing of a candidate tumor-suppressor, <span class=""gene"" id=""17438526-0-75-81"">CRABP1</span>, in <span class=""disease"" id=""17438526-0-86-120"">esophageal squamous-cell carcinoma</span>.",CTD_human
1,0,Biomarker,C0152013,Adenocarcinoma of lung (disorder),disease,ADC,1387,CREBBP,CREBBP,CTD_human,27158780,"New significantly mutated genes included PPP3CA, DOT1L, and FTSJD1 in lung ADC, RASA1 in lung SqCC, and KLF5, EP300, and CREBBP in both tumor types.",0.2,"New significantly mutated genes included PPP3CA, DOT1L, and FTSJD1 in lung <span class=""disease"" id=""27158780-3-75-78"">ADC</span>, RASA1 in lung SqCC, and KLF5, EP300, and <span class=""gene"" id=""27158780-3-121-127"">CREBBP</span> in both tumor types.",CTD_human
1,0,Biomarker,C0027051,Myocardial Infarction,disease,myocardial infarction,1390,CREM,inducible cAMP early repressor,CTD_human,19027736,Interventional effect of valsartan on expression of inducible cAMP early repressor and phosphodiesterase 3A in rats after myocardial infarction.,0.2,"Interventional effect of valsartan on expression of <span class=""gene"" id=""19027736-0-52-82"">inducible cAMP early repressor</span> and phosphodiesterase 3A in rats after <span class=""disease"" id=""19027736-0-122-143"">myocardial infarction</span>.",CTD_human
2,1,Biomarker,C0848558,Hypospadias,disease,hypospadias,139189,DGKK,DGKK,CTD_human,21113153,Common variants in DGKK are strongly associated with risk of hypospadias.,0.20082418035263896,"Common variants in <span class=""gene"" id=""21113153-0-19-23"">DGKK</span> are strongly associated with risk of <span class=""disease"" id=""21113153-0-61-72"">hypospadias</span>.",CTD_human
1,0,Biomarker,C0002170,Alopecia,disease,alopecia,1392,CRH,CRF,CTD_human,21359208,CRF receptor antagonist astressin-B reverses and prevents alopecia in CRF over-expressing mice.,0.200274726784213,"<span class=""gene"" id=""21359208-0-0-3"">CRF</span> receptor antagonist astressin-B reverses and prevents <span class=""disease"" id=""21359208-0-58-66"">alopecia</span> in <span class=""gene"" id=""21359208-0-70-73"">CRF</span> over-expressing mice.",CTD_human
1,0,Therapeutic,C0002395,Alzheimer's Disease,disease,Alzheimer's disease,1392,CRH,corticotropin releasing factor,CTD_human,7477348,Displacement of corticotropin releasing factor from its binding protein as a possible treatment for Alzheimer's disease.,0.20054945356842604,"Displacement of <span class=""gene"" id=""7477348-0-16-46"">corticotropin releasing factor</span> from its binding protein as a possible treatment for <span class=""disease"" id=""7477348-0-100-119"">Alzheimer's disease</span>.",CTD_human
1,0,Biomarker,C0003123,Anorexia,disease,anorexia,1392,CRH,Corticotropin-releasing factor,CTD_human,16420149,Corticotropin-releasing factor-1 receptors in the basolateral amygdala mediate stress-induced anorexia.,0.20082418035263896,"<span class=""gene"" id=""16420149-0-0-30"">Corticotropin-releasing factor</span>-1 receptors in the basolateral amygdala mediate stress-induced <span class=""disease"" id=""16420149-0-94-102"">anorexia</span>.",CTD_human
11,0,Biomarker,C0003469,Anxiety Disorders,group,anxiety,1392,CRH,CRF,CTD_human,12438692,"CRF elicited a wide range of behaviors, which fell into three broad categories: anxiety-like, depressive-like, and externally oriented.",0.206868169605328,"<span class=""gene"" id=""12438692-5-0-3"">CRF</span> elicited a wide range of behaviors, which fell into three broad categories: <span class=""disease"" id=""12438692-5-80-87"">anxiety</span>-like, depressive-like, and externally oriented.",CTD_human
11,0,Biomarker,C0003469,Anxiety Disorders,group,anxiety,1392,CRH,CRF,CTD_human,11875628,"These results suggest that the onset of r/hCRF and rUcn actions related to behavioral responses to anxiety is likely to depend on brain peptide-specific mechanisms including binding properties to CRF-receptors, differential distribution to specific functional brain sites and the distribution and effectiveness of binding-protein interactions.",0.206868169605328,"These results suggest that the onset of r/h<span class=""gene"" id=""11875628-11-43-46"">CRF</span> and rUcn actions related to behavioral responses to <span class=""disease"" id=""11875628-11-99-106"">anxiety</span> is likely to depend on brain peptide-specific mechanisms including binding properties to <span class=""gene"" id=""11875628-11-196-199"">CRF</span>-receptors, differential distribution to specific functional brain sites and the distribution and effectiveness of binding-protein interactions.",CTD_human
11,0,Biomarker,C0003469,Anxiety Disorders,group,anxiety,1392,CRH,corticotropin-releasing hormone,CTD_human,21268831,[Selective influence of dehydroepiandrosterone-sulphate on anxiety induced by corticotropin-releasing hormone injection].,0.206868169605328,"[Selective influence of dehydroepiandrosterone-sulphate on <span class=""disease"" id=""21268831-0-59-66"">anxiety</span> induced by <span class=""gene"" id=""21268831-0-78-109"">corticotropin-releasing hormone</span> injection].",CTD_human
11,0,Biomarker,C0003469,Anxiety Disorders,group,anxiety,1392,CRH,corticotropin-releasing factor,CTD_human,14575894,Hippocampal serotonergic system is involved in anxiety-like behavior induced by corticotropin-releasing factor.,0.206868169605328,"Hippocampal serotonergic system is involved in <span class=""disease"" id=""14575894-0-47-54"">anxiety</span>-like behavior induced by <span class=""gene"" id=""14575894-0-80-110"">corticotropin-releasing factor</span>.",CTD_human
11,0,Biomarker,C0003469,Anxiety Disorders,group,anxiety,1392,CRH,corticotropin-releasing hormone,CTD_human,11440811,Neuropeptide Y Y1 receptor-mediated anxiolysis in the dorsocaudal lateral septum: functional antagonism of corticotropin-releasing hormone-induced anxiety.,0.206868169605328,"Neuropeptide Y Y1 receptor-mediated anxiolysis in the dorsocaudal lateral septum: functional antagonism of <span class=""gene"" id=""11440811-0-107-138"">corticotropin-releasing hormone</span>-induced <span class=""disease"" id=""11440811-0-147-154"">anxiety</span>.",CTD_human
11,0,Biomarker,C0003469,Anxiety Disorders,group,anxiety,1392,CRH,corticotropin-releasing hormone,CTD_human,7816204,The neurosteroid tetrahydroprogesterone counteracts corticotropin-releasing hormone-induced anxiety and alters the release and gene expression of corticotropin-releasing hormone in the rat hypothalamus.,0.206868169605328,"The neurosteroid tetrahydroprogesterone counteracts <span class=""gene"" id=""7816204-0-52-83"">corticotropin-releasing hormone</span>-induced <span class=""disease"" id=""7816204-0-92-99"">anxiety</span> and alters the release and gene expression of <span class=""gene"" id=""7816204-0-146-177"">corticotropin-releasing hormone</span> in the rat hypothalamus.",CTD_human
11,0,Biomarker,C0003469,Anxiety Disorders,group,anxiety,1392,CRH,corticotropin-releasing hormone,CTD_human,8736133,"This paper reports the effects on grooming, related behaviors and levels of anxiety induced by the hypophysiotropic peptides corticotropin-releasing hormone (CRH, 1 microgram, 0.2 nmol, icv), thyrotropin-releasing hormone (TRH, 100 micrograms, 275 nmol, icv) and luteinizing hormone-releasing hormone (LHRH, 1.5 micrograms, 1.3 nmol, icv) administered into the lateral ventricle of the brain (icv) of adult male rats of a Holtzman-derived colony (N = 15, each group).",0.206868169605328,"This paper reports the effects on grooming, related behaviors and levels of <span class=""disease"" id=""8736133-1-76-83"">anxiety</span> induced by the hypophysiotropic peptides <span class=""gene"" id=""8736133-1-125-156"">corticotropin-releasing hormone</span> (CRH, 1 microgram, 0.2 nmol, icv), thyrotropin-releasing hormone (TRH, 100 micrograms, 275 nmol, icv) and luteinizing hormone-releasing hormone (LHRH, 1.5 micrograms, 1.3 nmol, icv) administered into the lateral ventricle of the brain (icv) of adult male rats of a Holtzman-derived colony (N = 15, each group).",CTD_human
1,0,Biomarker,C0008031,Chest Pain,phenotype,Chest pain,1392,CRH,corticotropin-releasing hormone,CTD_human,2563132,Chest pain after intravenous corticotropin-releasing hormone.,0.2,"<span class=""disease"" id=""2563132-0-0-10"">Chest pain</span> after intravenous <span class=""gene"" id=""2563132-0-29-60"">corticotropin-releasing hormone</span>.",CTD_human
1,0,Biomarker,C0010481,Cushing Syndrome,disease,Cushing's syndrome,1392,CRH,CRF,CTD_human,21359208,"We investigated whether the blockade of CRF receptors influences the development of hair loss in CRF over-expressing (OE)-mice that display phenotypes of Cushing's syndrome and chronic stress, including alopecia.",0.201098907136852,"We investigated whether the blockade of <span class=""gene"" id=""21359208-2-40-43"">CRF</span> receptors influences the development of hair loss in <span class=""gene"" id=""21359208-2-97-100"">CRF</span> over-expressing (OE)-mice that display phenotypes of <span class=""disease"" id=""21359208-2-154-172"">Cushing's syndrome</span> and chronic stress, including alopecia.",CTD_human
7,0,Biomarker,C0011581,Depressive disorder,disease,depression,1392,CRH,CRF,CTD_human,18698320,"Increased synthesis of CRF in CeA amplified CRF and arginine vasopressin peptide concentration in the paraventricular nucleus of the hypothalamus, and decreased glucocorticoid negative feedback, both markers associated with the pathophysiology of depression.",0.40824180352639294,"Increased synthesis of <span class=""gene"" id=""18698320-4-23-26"">CRF</span> in CeA amplified <span class=""gene"" id=""18698320-4-44-47"">CRF</span> and arginine vasopressin peptide concentration in the paraventricular nucleus of the hypothalamus, and decreased glucocorticoid negative feedback, both markers associated with the pathophysiology of <span class=""disease"" id=""18698320-4-247-257"">depression</span>.",CTD_human;PSYGENET
7,0,Biomarker,C0011581,Depressive disorder,disease,depression,1392,CRH,CRF,CTD_human,12438692,Patients suffering from depression have abnormal activity in stress responsive brain regions and elevated cerebrospinal fluid CRF.,0.40824180352639294,"Patients suffering from <span class=""disease"" id=""12438692-2-24-34"">depression</span> have abnormal activity in stress responsive brain regions and elevated cerebrospinal fluid <span class=""gene"" id=""12438692-2-126-129"">CRF</span>.",CTD_human;PSYGENET
1,0,Therapeutic,C0030193,Pain,phenotype,pain,1392,CRH,CRF,CTD_human,16495007,Our results establish that central CRF is a key modulator of pain behavior and indicates that CRF effects on nociception are largely independent of its mood modulating effect as well as its control of the HPA axis.,0.20054945356842604,"Our results establish that central <span class=""gene"" id=""16495007-9-35-38"">CRF</span> is a key modulator of <span class=""disease"" id=""16495007-9-61-65"">pain</span> behavior and indicates that <span class=""gene"" id=""16495007-9-94-97"">CRF</span> effects on nociception are largely independent of its mood modulating effect as well as its control of the HPA axis.",CTD_human
6,0,Biomarker,C0036572,Seizures,phenotype,seizures,1392,CRH,corticotropin-releasing factor,CTD_human,1700951,Some endorphin derivatives and hydrocortisone prevent EEG limbic seizures induced by corticotropin-releasing factor in rabbits.,0.200274726784213,"Some endorphin derivatives and hydrocortisone prevent EEG limbic <span class=""disease"" id=""1700951-0-65-73"">seizures</span> induced by <span class=""gene"" id=""1700951-0-85-115"">corticotropin-releasing factor</span> in rabbits.",CTD_human
6,0,Biomarker,C0036572,Seizures,phenotype,seizures,1392,CRH,corticotropin-releasing hormone,CTD_human,11074187,Increased expression of gamma-aminobutyric acid transporter-1 in the forebrain of infant rats with corticotropin-releasing hormone-induced seizures but not in those with hyperthermia-induced seizures.,0.200274726784213,"Increased expression of gamma-aminobutyric acid transporter-1 in the forebrain of infant rats with <span class=""gene"" id=""11074187-0-99-130"">corticotropin-releasing hormone</span>-induced <span class=""disease"" id=""11074187-0-139-147"">seizures</span> but not in those with hyperthermia-induced <span class=""disease"" id=""11074187-0-191-199"">seizures</span>.",CTD_human
6,0,Biomarker,C0036572,Seizures,phenotype,seizures,1392,CRH,Corticotropin-releasing hormone,CTD_human,1596084,Corticotropin-releasing hormone-induced seizures in infant rats originate in the amygdala.,0.200274726784213,"<span class=""gene"" id=""1596084-0-0-31"">Corticotropin-releasing hormone</span>-induced <span class=""disease"" id=""1596084-0-40-48"">seizures</span> in infant rats originate in the amygdala.",CTD_human
6,0,Biomarker,C0036572,Seizures,phenotype,seizures,1392,CRH,corticotropin-releasing factor,CTD_human,8923670,C-Fos expression as a molecular marker in corticotropin-releasing factor-induced seizures.,0.200274726784213,"C-Fos expression as a molecular marker in <span class=""gene"" id=""8923670-0-42-72"">corticotropin-releasing factor</span>-induced <span class=""disease"" id=""8923670-0-81-89"">seizures</span>.",CTD_human
6,0,Biomarker,C0036572,Seizures,phenotype,seizures,1392,CRH,CRH,CTD_human,1914160,"CRH-induced seizures occurred prior to any changes in serum corticosterone, and were eliminated by the administration of a CRH antagonist, as well as of phenytoin.",0.200274726784213,"<span class=""gene"" id=""1914160-4-0-3"">CRH</span>-induced <span class=""disease"" id=""1914160-4-12-20"">seizures</span> occurred prior to any changes in serum corticosterone, and were eliminated by the administration of a <span class=""gene"" id=""1914160-4-123-126"">CRH</span> antagonist, as well as of phenytoin.",CTD_human
6,0,Biomarker,C0036572,Seizures,phenotype,seizures,1392,CRH,CRH,CTD_human,7821275,CRH-induced seizure duration (88.2 +/- 9 vs. 74.7 +/- 9.4 min) and severity of seizures was also unchanged by ACTH treatment.,0.200274726784213,"<span class=""gene"" id=""7821275-10-0-3"">CRH</span>-induced <span class=""disease"" id=""7821275-10-12-19"">seizure</span> duration (88.2 +/- 9 vs. 74.7 +/- 9.4 min) and severity of <span class=""disease"" id=""7821275-10-79-87"">seizures</span> was also unchanged by ACTH treatment.",CTD_human
1,0,Biomarker,C0037769,West Syndrome,disease,IS,1392,CRH,CRH,CTD_human,11341487,"The CSF levels of CRH in patients with IS were lower, although, this trend was not significant.",0.200274726784213,"The CSF levels of <span class=""gene"" id=""11341487-4-18-21"">CRH</span> in patients with <span class=""disease"" id=""11341487-4-39-41"">IS</span> were lower, although, this trend was not significant.",CTD_human
1,0,Biomarker,C0038220,Status Epilepticus,disease,SE,1392,CRH,CRH,CTD_human,7756609,The results of the present study show that corticotropin releasing hormone (CRH)-induced SE causes limbic neuronal death and reorganization in infant rats.,0.2,"The results of the present study show that <span class=""gene"" id=""7756609-4-43-74"">corticotropin releasing hormone</span> (<span class=""gene"" id=""7756609-4-76-79"">CRH</span>)-induced <span class=""disease"" id=""7756609-4-89-91"">SE</span> causes limbic neuronal death and reorganization in infant rats.",CTD_human
1,0,Biomarker,C0038273,Stereotypic Movement Disorder,phenotype,stereotyped behavior,1392,CRH,CRH,CTD_human,1914160,Corticotropin-releasing hormone (CRH) administered into the cerebral ventricles of rats during the first postnatal week caused a specific and stereotyped behavior sequence: rhythmic chewing and licking (jaw myoclonus) were followed by 'limbic'-type seizures.,0.2,"<span class=""gene"" id=""1914160-1-0-31"">Corticotropin-releasing hormone</span> (<span class=""gene"" id=""1914160-1-33-36"">CRH</span>) administered into the cerebral ventricles of rats during the first postnatal week caused a specific and <span class=""disease"" id=""1914160-1-142-162"">stereotyped behavior</span> sequence: rhythmic chewing and licking (jaw myoclonus) were followed by 'limbic'-type seizures.",CTD_human
2,0,Biomarker,C0038587,Substance Withdrawal Syndrome,disease,withdrawal syndrome,1392,CRH,CRH,CTD_human,12968131,"Furthermore, cannabinoid antagonist administration precipitates a characteristic withdrawal syndrome in tolerant subjects, accompanied by neuronal activation and enhanced release of corticotropin-releasing hormone (CRH) in the central amygdala.",0.2,"Furthermore, cannabinoid antagonist administration precipitates a characteristic <span class=""disease"" id=""12968131-3-81-100"">withdrawal syndrome</span> in tolerant subjects, accompanied by neuronal activation and enhanced release of <span class=""gene"" id=""12968131-3-182-213"">corticotropin-releasing hormone</span> (<span class=""gene"" id=""12968131-3-215-218"">CRH</span>) in the central amygdala.",CTD_human
2,0,Biomarker,C0003469,Anxiety Disorders,group,anxiety,1394,CRHR1,Crhr1,CTD_human,22231481,"In MECP2-TG1 animals, reducing the levels of Crh or its receptor, Crhr1, suppressed anxiety-like behavior; in contrast, reducing Oprm1 expression improved abnormal social behavior.",0.203296721410557,"In MECP2-TG1 animals, reducing the levels of Crh or its receptor, <span class=""gene"" id=""22231481-5-66-71"">Crhr1</span>, suppressed <span class=""disease"" id=""22231481-5-84-91"">anxiety</span>-like behavior; in contrast, reducing Oprm1 expression improved abnormal social behavior.",CTD_human
2,0,Biomarker,C0003469,Anxiety Disorders,group,anxiety,1394,CRHR1,CRF1,CTD_human,9299637,The present studies examined the potential functional significance of the CRF2 receptor in relation to the CRF1 receptor using two animal models of anxiety and endocrine reactivity to a stressor.,0.203296721410557,"The present studies examined the potential functional significance of the CRF2 receptor in relation to the <span class=""gene"" id=""9299637-3-107-111"">CRF1</span> receptor using two animal models of <span class=""disease"" id=""9299637-3-148-155"">anxiety</span> and endocrine reactivity to a stressor.",CTD_human
5,0,Biomarker,C1269683,Major Depressive Disorder,disease,MDD,1394,CRHR1,CRHR1,CTD_human,23529111,These results suggest that the CRHR1 gene could modify the susceptibility to developing recurrent MDD following negative life events in adulthood.,0.40783605167292,"These results suggest that the <span class=""gene"" id=""23529111-6-31-36"">CRHR1</span> gene could modify the susceptibility to developing recurrent <span class=""disease"" id=""23529111-6-98-101"">MDD</span> following negative life events in adulthood.",CTD_human;PSYGENET
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,139411,PTCHD1,PTCHD1,CTD_human,21091464,Deletion in Xp22.11: PTCHD1 is a candidate gene for X-linked intellectual disability with or without autism.,0.202956482091714,"Deletion in Xp22.11: <span class=""gene"" id=""21091464-0-21-27"">PTCHD1</span> is a candidate gene for X-linked intellectual disability with or without <span class=""disease"" id=""21091464-0-101-107"">autism</span>.",CTD_human
2,0,Biomarker,C1510586,Autism Spectrum Disorders,disease,Autism spectrum disorder,139411,PTCHD1,PTCHD1,CTD_human,20844286,Disruption at the PTCHD1 Locus on Xp22.11 in Autism spectrum disorder and intellectual disability.,0.201923087489492,"Disruption at the <span class=""gene"" id=""20844286-0-18-24"">PTCHD1</span> Locus on Xp22.11 in <span class=""disease"" id=""20844286-0-45-69"">Autism spectrum disorder</span> and intellectual disability.",CTD_human
2,0,Biomarker,C1510586,Autism Spectrum Disorders,disease,ASD,139411,PTCHD1,PTCHD1,CTD_human,18252227,"Notwithstanding complexities, our results further implicate the SHANK3-NLGN4-NRXN1 postsynaptic density genes and also identify novel loci at DPP6-DPP10-PCDH9 (synapse complex), ANKRD11, DPYD, PTCHD1, 15q24, among others, for a role in ASD susceptibility.",0.201923087489492,"Notwithstanding complexities, our results further implicate the SHANK3-NLGN4-NRXN1 postsynaptic density genes and also identify novel loci at DPP6-DPP10-PCDH9 (synapse complex), ANKRD11, DPYD, <span class=""gene"" id=""18252227-8-193-199"">PTCHD1</span>, 15q24, among others, for a role in <span class=""disease"" id=""18252227-8-236-239"">ASD</span> susceptibility.",CTD_human
1,0,Biomarker,C3714756,Intellectual Disability,group,intellectual disability,139411,PTCHD1,PTCHD1,CTD_human,20844286,Disruption at the PTCHD1 Locus on Xp22.11 in Autism spectrum disorder and intellectual disability.,0.201373633921065,"Disruption at the <span class=""gene"" id=""20844286-0-18-24"">PTCHD1</span> Locus on Xp22.11 in Autism spectrum disorder and <span class=""disease"" id=""20844286-0-74-97"">intellectual disability</span>.",CTD_human
1,0,Biomarker,C0003123,Anorexia,disease,anorectic,1395,CRHR2,CRF(2,CTD_human,17627984,"Because central CRF(2) stimulation retains full anorectic efficacy at higher doses in the DIO model, manipulating this neuropeptidergic system might yield new therapeutic approaches for diet-induced obesity.",0.20082418035263896,"Because central <span class=""gene"" id=""17627984-10-16-21"">CRF(2</span>) stimulation retains full <span class=""disease"" id=""17627984-10-48-57"">anorectic</span> efficacy at higher doses in the DIO model, manipulating this neuropeptidergic system might yield new therapeutic approaches for diet-induced obesity.",CTD_human
1,0,Biomarker,C0003469,Anxiety Disorders,group,anxiety,1395,CRHR2,corticotropin-releasing hormone receptor-2,CTD_human,10742108,Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress.,0.201098907136852,"Mice deficient for <span class=""gene"" id=""10742108-0-19-61"">corticotropin-releasing hormone receptor-2</span> display <span class=""disease"" id=""10742108-0-70-77"">anxiety</span>-like behaviour and are hypersensitive to stress.",CTD_human
1,0,Therapeutic,C0024115,Lung diseases,group,lung diseases,1395,CRHR2,CRF(2,CTD_human,16855006,"Therefore, CRF(2) agonists appear to have both bronchorelaxant and anti-inflammatory activities and might represent an interesting therapeutic approach to the treatment of inflammatory lung diseases.",0.2,"Therefore, <span class=""gene"" id=""16855006-10-11-16"">CRF(2</span>) agonists appear to have both bronchorelaxant and anti-inflammatory activities and might represent an interesting therapeutic approach to the treatment of inflammatory <span class=""disease"" id=""16855006-10-185-198"">lung diseases</span>.",CTD_human
1,0,Biomarker,C0012236,DiGeorge Syndrome,disease,DGS,1399,CRKL,CRKL,CTD_human,16399080,"Here, we report that compound heterozygosity of mouse homologs of two 22q11 genes, CRKL and TBX1, results in a striking increase in the penetrance and expressivity of a DGS-like phenotype compared to heterozygosity at either locus.",0.280274726784213,"Here, we report that compound heterozygosity of mouse homologs of two 22q11 genes, <span class=""gene"" id=""16399080-2-83-87"">CRKL</span> and TBX1, results in a striking increase in the penetrance and expressivity of a <span class=""disease"" id=""16399080-2-169-172"">DGS</span>-like phenotype compared to heterozygosity at either locus.",CTD_human
1,0,Biomarker,C0004153,Atherosclerosis,disease,atherosclerosis,1401,CRP,CRP,CTD_human,16931792,"C-reactive protein (CRP) has been suggested to participate in the development of atherosclerosis, in part, by promoting endothelial dysfunction and impairing endothelial progenitor cell (EPC) survival and differentiation.",0.27682774550056105,"<span class=""gene"" id=""16931792-1-0-18"">C-reactive protein</span> (<span class=""gene"" id=""16931792-1-20-23"">CRP</span>) has been suggested to participate in the development of <span class=""disease"" id=""16931792-1-81-96"">atherosclerosis</span>, in part, by promoting endothelial dysfunction and impairing endothelial progenitor cell (EPC) survival and differentiation.",CTD_human
2,0,Biomarker,C0007222,Cardiovascular Diseases,group,cardiovascular disease,1401,CRP,CRP,CTD_human,16332659,"Isoflavones have beneficial effects on CRP concentrations, but not on other inflammatory biomarkers of cardiovascular disease risk in postmenopausal women, and may improve VCAM-1 in an ERbeta gene polymorphic subgroup.",0.310131841461728,"Isoflavones have beneficial effects on <span class=""gene"" id=""16332659-11-39-42"">CRP</span> concentrations, but not on other inflammatory biomarkers of <span class=""disease"" id=""16332659-11-103-125"">cardiovascular disease</span> risk in postmenopausal women, and may improve VCAM-1 in an ERbeta gene polymorphic subgroup.",CTD_human
1,0,Biomarker,C0011884,Diabetic Retinopathy,disease,diabetic retinopathy,1401,CRP,C-reactive protein,CTD_human,20012460,"Antioxidant potential, paraoxonase 1, ceruloplasmin activity and C-reactive protein concentration in diabetic retinopathy.",0.20054945356842604,"Antioxidant potential, paraoxonase 1, ceruloplasmin activity and <span class=""gene"" id=""20012460-0-65-83"">C-reactive protein</span> concentration in <span class=""disease"" id=""20012460-0-101-121"">diabetic retinopathy</span>.",CTD_human
1,0,Biomarker,C0018799,Heart Diseases,group,cardiac disease,1401,CRP,CRP,CTD_human,17388968,Elevation of C-reactive protein (CRP) levels in blood was recognized as one of the cardiac disease risk factors.,0.20701187132028098,"Elevation of <span class=""gene"" id=""17388968-1-13-31"">C-reactive protein</span> (<span class=""gene"" id=""17388968-1-33-36"">CRP</span>) levels in blood was recognized as one of the <span class=""disease"" id=""17388968-1-83-98"">cardiac disease</span> risk factors.",CTD_human
1,0,Biomarker,C0020503,"Hyperparathyroidism, Secondary",disease,SHP,1401,CRP,CRP,CTD_human,21350317,"All patients with SHP had low serum 1,25-dihydroxyvitamin D(3) levels and elevated serum levels of intact parathyroid hormone (iPTH), CRP and IL-6.",0.2,"All patients with <span class=""disease"" id=""21350317-7-18-21"">SHP</span> had low serum 1,25-dihydroxyvitamin D(3) levels and elevated serum levels of intact parathyroid hormone (iPTH), <span class=""gene"" id=""21350317-7-134-137"">CRP</span> and IL-6.",CTD_human
4,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,1401,CRP,C-reactive protein,CTD_human,19770776,Our study indicated that elevated plasma levels of high-sensitivity C-reactive protein and angiotensin II were positively and renin activity inversely associated with the risk of hypertension.,0.22536114435329002,"Our study indicated that elevated plasma levels of high-sensitivity <span class=""gene"" id=""19770776-6-68-86"">C-reactive protein</span> and angiotensin II were positively and renin activity inversely associated with the risk of <span class=""disease"" id=""19770776-6-179-191"">hypertension</span>.",CTD_human
4,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,1401,CRP,C-reactive protein,CTD_human,16680063,Effect of doxazosin on C-reactive protein plasma levels and on nitric oxide in patients with hypertension.,0.22536114435329002,"Effect of doxazosin on <span class=""gene"" id=""16680063-0-23-41"">C-reactive protein</span> plasma levels and on nitric oxide in patients with <span class=""disease"" id=""16680063-0-93-105"">hypertension</span>.",CTD_human
1,0,Biomarker,C0022661,"Kidney Failure, Chronic",disease,ESRD,1401,CRP,C-reactive protein,CTD_human,19539174,"Serum concentrations of C-reactive protein, adiponectin, resistin, interleukin-6, tumor necrosis factor-alpha, and monocyte chemoattractant protein-1 were significantly higher in the ESRD versus control group.",0.208371149864029,"Serum concentrations of <span class=""gene"" id=""19539174-7-24-42"">C-reactive protein</span>, adiponectin, resistin, interleukin-6, tumor necrosis factor-alpha, and monocyte chemoattractant protein-1 were significantly higher in the <span class=""disease"" id=""19539174-7-183-187"">ESRD</span> versus control group.",CTD_human
1,0,Biomarker,C0023290,"Leishmaniasis, Visceral",disease,kala-azar,1401,CRP,C-reactive protein,CTD_human,10467834,Prognostic value of serum C-reactive protein in kala-azar.,0.2,"Prognostic value of serum <span class=""gene"" id=""10467834-0-26-44"">C-reactive protein</span> in <span class=""disease"" id=""10467834-0-48-57"">kala-azar</span>.",CTD_human
1,0,Biomarker,C0024141,"Lupus Erythematosus, Systemic",disease,SLE,1401,CRP,CRP,CTD_human,17718048,"Compared with healthy controls, in SLE patients levels of anti-N-Hcy-albumin antibodies are significantly higher and are largely determined by tHcy, CRP and the disease duration.",0.226827322831996,"Compared with healthy controls, in <span class=""disease"" id=""17718048-11-35-38"">SLE</span> patients levels of anti-N-Hcy-albumin antibodies are significantly higher and are largely determined by tHcy, <span class=""gene"" id=""17718048-11-149-152"">CRP</span> and the disease duration.",CTD_human
1,0,Biomarker,C0024530,Malaria,disease,malaria,1401,CRP,C-reactive protein,CTD_human,8730300,C-reactive protein and haptoglobin in the evaluation of a community-based malaria control programme.,0.201648360705279,"<span class=""gene"" id=""8730300-0-0-18"">C-reactive protein</span> and haptoglobin in the evaluation of a community-based <span class=""disease"" id=""8730300-0-74-81"">malaria</span> control programme.",CTD_human
1,0,Biomarker,C0027059,Myocarditis,disease,myocarditis,1401,CRP,CRP,CTD_human,20361910,"Eosinophil counts should not be relied on for diagnosis of clozapine-related myocarditis, but elevated CRP may be an early indicator of developing myocarditis.",0.200274726784213,"Eosinophil counts should not be relied on for diagnosis of clozapine-related <span class=""disease"" id=""20361910-12-77-88"">myocarditis</span>, but elevated <span class=""gene"" id=""20361910-12-103-106"">CRP</span> may be an early indicator of developing <span class=""disease"" id=""20361910-12-147-158"">myocarditis</span>.",CTD_human
1,0,Biomarker,C0028754,Obesity,disease,obesity,1401,CRP,CRP,CTD_human,24042701,"We investigated the effect of endurance exercise on markers of oxidative damage (4-hydroxy-2-nonenal (4-HNE), protein carbonyls (PCs)) and antioxidant enzymes (superoxide dismutase (SOD), catalase) in skeletal muscle; urinary markers of oxidative stress (8-hydroxy-2-deoxyguanosine (8-OHdG), 8-isoprostane); and plasma cytokines (C-reactive protein (CRP), interleukin-6 (IL-6), leptin, adiponectin).Methods:Age- and fitness-matched sedentary obese and lean men (n=9 per group) underwent 3 months of moderate-intensity endurance cycling training with a vastus lateralis biopsy, 24-h urine sample and venous blood samples taken before and after the intervention.Results:Obese subjects had increased levels of oxidative damage: 4-HNE (+37%; P?0.03) and PC (+63%; P?0.02); evidence of increased adaptive response to oxidative stress because of elevated levels of copper/zinc SOD (Cu/ZnSOD) protein content (+84%; P?0.01); increased markers of inflammation: CRP (+737%; P?0.0001) and IL-6 (+85%; P?0.03), and these correlated with increased markers of obesity; and increased leptin (+262%; P?0.0001) with lower adiponectin (-27%; P?0.01) levels vs lean controls.",0.229826871055662,"We investigated the effect of endurance exercise on markers of oxidative damage (4-hydroxy-2-nonenal (4-HNE), protein carbonyls (PCs)) and antioxidant enzymes (superoxide dismutase (SOD), catalase) in skeletal muscle; urinary markers of oxidative stress (8-hydroxy-2-deoxyguanosine (8-OHdG), 8-isoprostane); and plasma cytokines (<span class=""gene"" id=""24042701-4-330-348"">C-reactive protein</span> (<span class=""gene"" id=""24042701-4-350-353"">CRP</span>), interleukin-6 (IL-6), leptin, adiponectin).Methods:Age- and fitness-matched sedentary <span class=""disease"" id=""24042701-4-442-447"">obese</span> and lean men (n=9 per group) underwent 3 months of moderate-intensity endurance cycling training with a vastus lateralis biopsy, 24-h urine sample and venous blood samples taken before and after the intervention.Results:<span class=""disease"" id=""24042701-4-668-673"">Obese</span> subjects had increased levels of oxidative damage: 4-HNE (+37%; P?0.03) and PC (+63%; P?0.02); evidence of increased adaptive response to oxidative stress because of elevated levels of copper/zinc SOD (Cu/ZnSOD) protein content (+84%; P?0.01); increased markers of inflammation: <span class=""gene"" id=""24042701-4-953-956"">CRP</span> (+737%; P?0.0001) and IL-6 (+85%; P?0.03), and these correlated with increased markers of <span class=""disease"" id=""24042701-4-1047-1054"">obesity</span>; and increased leptin (+262%; P?0.0001) with lower adiponectin (-27%; P?0.01) levels vs lean controls.",CTD_human
1,0,Biomarker,C0031099,Periodontitis,disease,periodontitis,1401,CRP,CRP,CTD_human,20011938,The increase of the CRP levels after PT in patients with CVD risk factors appeared associated with IL-1 gene polymorphisms and extensive periodontitis.,0.202197814273705,"The increase of the <span class=""gene"" id=""20011938-11-20-23"">CRP</span> levels after PT in patients with CVD risk factors appeared associated with IL-1 gene polymorphisms and extensive <span class=""disease"" id=""20011938-11-137-150"">periodontitis</span>.",CTD_human
1,0,Biomarker,C0033860,Psoriasis,disease,psoriasis,1401,CRP,CRP,CTD_human,12559600,"The mean levels of atherogenic lipids (total cholesterol [TC], triacylglycerol [TG] and LDL cholesterol [LDL-C]), acute-phase reactants (CRP, ESR, PMNLs, ceruloplasmin and fibrinogen) and lipid peroxidation products, AuAb-oxLDL levels in patients with psoriasis were found to be significantly higher than those of healthy subjects.",0.201373633921065,"The mean levels of atherogenic lipids (total cholesterol [TC], triacylglycerol [TG] and LDL cholesterol [LDL-C]), acute-phase reactants (<span class=""gene"" id=""12559600-6-137-140"">CRP</span>, ESR, PMNLs, ceruloplasmin and fibrinogen) and lipid peroxidation products, AuAb-oxLDL levels in patients with <span class=""disease"" id=""12559600-6-252-261"">psoriasis</span> were found to be significantly higher than those of healthy subjects.",CTD_human
1,0,Biomarker,C0151744,Myocardial Ischemia,disease,ischemic heart disease,1401,CRP,C-reactive protein,CTD_human,11840375,Persistent elevation of C-reactive protein and ischemic heart disease in patients with continuous ambulatory peritoneal dialysis.,0.21024308019620802,"Persistent elevation of <span class=""gene"" id=""11840375-0-24-42"">C-reactive protein</span> and <span class=""disease"" id=""11840375-0-47-69"">ischemic heart disease</span> in patients with continuous ambulatory peritoneal dialysis.",CTD_human
2,0,Biomarker,C0948089,Acute Coronary Syndrome,disease,acute coronary syndromes,1401,CRP,CRP,CTD_human,15966572,The strong correlations between cardiac markers and both CRP and GPx suggest that these parameters are promising prognostic factors in acute coronary syndromes.,0.217408422988427,"The strong correlations between cardiac markers and both <span class=""gene"" id=""15966572-16-57-60"">CRP</span> and GPx suggest that these parameters are promising prognostic factors in <span class=""disease"" id=""15966572-16-135-159"">acute coronary syndromes</span>.",CTD_human
1,0,Biomarker,C1956346,Coronary Artery Disease,disease,CAD,1401,CRP,C-reactive protein,CTD_human,24868163,"There was no correlation between Cd, Pb, or Hg and severity of CAD although severity correlated positively with atherosclerosis parameters (uric acid, creatinine, triglycerides, blood urea nitrogen, C-reactive protein) and negatively with high density lipoprotein cholesterol.",0.25949919042408104,"There was no correlation between Cd, Pb, or Hg and severity of <span class=""disease"" id=""24868163-6-63-66"">CAD</span> although severity correlated positively with atherosclerosis parameters (uric acid, creatinine, triglycerides, blood urea nitrogen, <span class=""gene"" id=""24868163-6-199-217"">C-reactive protein</span>) and negatively with high density lipoprotein cholesterol.",CTD_human
1,0,Biomarker,C0013336,Dwarfism,disease,dwarfism,1404,HAPLN1,Crtl1,CTD_human,9988279,"Most Crtl1(tm1Nid/tm1Nid) mice died shortly after birth due to respiratory failure, but some survived and developed progressive dwarfism and lordosis of the cervical spine.",0.2,"Most <span class=""gene"" id=""9988279-6-5-10"">Crtl1</span>(tm1Nid/tm1Nid) mice died shortly after birth due to respiratory failure, but some survived and developed progressive <span class=""disease"" id=""9988279-6-128-136"">dwarfism</span> and lordosis of the cervical spine.",CTD_human
2,1,Biomarker,C0339527,Leber Congenital Amaurosis,disease,Leber congenital amaurosis,1406,CRX,CRX,CTD_human,9931337,Leber congenital amaurosis caused by a homozygous mutation (R90W) in the homeodomain of the retinal transcription factor CRX: direct evidence for the involvement of CRX in the development of photoreceptor function.,0.40439562854741,"<span class=""disease"" id=""9931337-0-0-26"">Leber congenital amaurosis</span> caused by a homozygous mutation (R90W) in the homeodomain of the retinal transcription factor <span class=""gene"" id=""9931337-0-121-124"">CRX</span>: direct evidence for the involvement of <span class=""gene"" id=""9931337-0-165-168"">CRX</span> in the development of photoreceptor function.",CTD_human;ORPHANET
2,1,Biomarker,C0339527,Leber Congenital Amaurosis,disease,Leber congenital amaurosis,1406,CRX,CRX,CTD_human,9537410,De novo mutations in the CRX homeobox gene associated with Leber congenital amaurosis.,0.40439562854741,"De novo mutations in the <span class=""gene"" id=""9537410-0-25-28"">CRX</span> homeobox gene associated with <span class=""disease"" id=""9537410-0-59-85"">Leber congenital amaurosis</span>.",CTD_human;ORPHANET
1,0,Biomarker,C0023473,"Myeloid Leukemia, Chronic",disease,CML,1408,CRY2,hCRY2,CTD_human,16999817,"The expression levels of hPER1, hPER2, hPER3, hCRY1, hCRY2 and hBMAL1 were significantly impaired in both chronic phase and blastic crisis of CML cases compared with those in healthy individuals (P < 0.001).",0.200274726784213,"The expression levels of hPER1, hPER2, hPER3, hCRY1, <span class=""gene"" id=""16999817-3-53-58"">hCRY2</span> and hBMAL1 were significantly impaired in both chronic phase and blastic crisis of <span class=""disease"" id=""16999817-3-142-145"">CML</span> cases compared with those in healthy individuals (P &lt; 0.001).",CTD_human
1,0,Biomarker,C0086543,Cataract,disease,cataract,1414,CRYBB1,CRYBB1,CTD_human,12360425,"Sequencing failed to detect any nucleotide changes in CRYBA4; however, a G-->T transversion in exon 6 of CRYBB1 was found to cosegregate with cataract in the family.",0.40874819096286696,"Sequencing failed to detect any nucleotide changes in CRYBA4; however, a G--&gt;T transversion in exon 6 of <span class=""gene"" id=""12360425-4-105-111"">CRYBB1</span> was found to cosegregate with <span class=""disease"" id=""12360425-4-142-150"">cataract</span> in the family.",CTD_human;HPO
1,0,Biomarker,C0344523,"Cataract, congenital, cerulean type 1",disease,cerulean cataract,1415,CRYBB2,CRYBB2,CTD_human,9158139,Autosomal dominant cerulean cataract is associated with a chain termination mutation in the human beta-crystallin gene CRYBB2.,0.600549453568426,"Autosomal dominant <span class=""disease"" id=""9158139-0-19-36"">cerulean cataract</span> is associated with a chain termination mutation in the human beta-crystallin gene <span class=""gene"" id=""9158139-0-119-125"">CRYBB2</span>.",CTD_human;HPO;ORPHANET
1,0,Biomarker,C0002871,Anemia,disease,anemia,142,PARP1,PARP-1,CTD_human,20561897,"Here, we show that hPARP-1 mice exhibit impaired survival rates accompanied by reduced hair growth and premature development of several inflammation and age-associated pathologies, such as adiposity, kyphosis, nephropathy, dermatitis, pneumonitis, cardiomyopathy, hepatitis, and anemia.",0.200274726784213,"Here, we show that h<span class=""gene"" id=""20561897-6-20-26"">PARP-1</span> mice exhibit impaired survival rates accompanied by reduced hair growth and premature development of several inflammation and age-associated pathologies, such as adiposity, kyphosis, nephropathy, dermatitis, pneumonitis, cardiomyopathy, hepatitis, and <span class=""disease"" id=""20561897-6-279-285"">anemia</span>.",CTD_human
1,0,Biomarker,C0011603,Dermatitis,disease,dermatitis,142,PARP1,PARP-1,CTD_human,20561897,"Here, we show that hPARP-1 mice exhibit impaired survival rates accompanied by reduced hair growth and premature development of several inflammation and age-associated pathologies, such as adiposity, kyphosis, nephropathy, dermatitis, pneumonitis, cardiomyopathy, hepatitis, and anemia.",0.200274726784213,"Here, we show that h<span class=""gene"" id=""20561897-6-20-26"">PARP-1</span> mice exhibit impaired survival rates accompanied by reduced hair growth and premature development of several inflammation and age-associated pathologies, such as adiposity, kyphosis, nephropathy, <span class=""disease"" id=""20561897-6-223-233"">dermatitis</span>, pneumonitis, cardiomyopathy, hepatitis, and anemia.",CTD_human
1,0,Biomarker,C0019158,Hepatitis,disease,hepatitis,142,PARP1,PARP-1,CTD_human,20561897,"Here, we show that hPARP-1 mice exhibit impaired survival rates accompanied by reduced hair growth and premature development of several inflammation and age-associated pathologies, such as adiposity, kyphosis, nephropathy, dermatitis, pneumonitis, cardiomyopathy, hepatitis, and anemia.",0.200274726784213,"Here, we show that h<span class=""gene"" id=""20561897-6-20-26"">PARP-1</span> mice exhibit impaired survival rates accompanied by reduced hair growth and premature development of several inflammation and age-associated pathologies, such as adiposity, kyphosis, nephropathy, dermatitis, pneumonitis, cardiomyopathy, <span class=""disease"" id=""20561897-6-264-273"">hepatitis</span>, and anemia.",CTD_human
2,0,Biomarker,C0022658,Kidney Diseases,group,nephropathy,142,PARP1,PARP,CTD_human,21884784,"Thus, PARP activation plays an important role in cisplatin-induced kidney injury, and its pharmacological inhibition may represent a promising approach to preventing the cisplatin-induced nephropathy.",0.2,"Thus, <span class=""gene"" id=""21884784-7-6-10"">PARP</span> activation plays an important role in cisplatin-induced kidney injury, and its pharmacological inhibition may represent a promising approach to preventing the cisplatin-induced <span class=""disease"" id=""21884784-7-188-199"">nephropathy</span>.",CTD_human
2,0,Biomarker,C0022658,Kidney Diseases,group,nephropathy,142,PARP1,PARP-1,CTD_human,20561897,"Here, we show that hPARP-1 mice exhibit impaired survival rates accompanied by reduced hair growth and premature development of several inflammation and age-associated pathologies, such as adiposity, kyphosis, nephropathy, dermatitis, pneumonitis, cardiomyopathy, hepatitis, and anemia.",0.2,"Here, we show that h<span class=""gene"" id=""20561897-6-20-26"">PARP-1</span> mice exhibit impaired survival rates accompanied by reduced hair growth and premature development of several inflammation and age-associated pathologies, such as adiposity, kyphosis, <span class=""disease"" id=""20561897-6-210-221"">nephropathy</span>, dermatitis, pneumonitis, cardiomyopathy, hepatitis, and anemia.",CTD_human
1,0,Biomarker,C0022821,Kyphosis deformity of spine,phenotype,kyphosis,142,PARP1,PARP-1,CTD_human,20561897,"Here, we show that hPARP-1 mice exhibit impaired survival rates accompanied by reduced hair growth and premature development of several inflammation and age-associated pathologies, such as adiposity, kyphosis, nephropathy, dermatitis, pneumonitis, cardiomyopathy, hepatitis, and anemia.",0.200274726784213,"Here, we show that h<span class=""gene"" id=""20561897-6-20-26"">PARP-1</span> mice exhibit impaired survival rates accompanied by reduced hair growth and premature development of several inflammation and age-associated pathologies, such as adiposity, <span class=""disease"" id=""20561897-6-200-208"">kyphosis</span>, nephropathy, dermatitis, pneumonitis, cardiomyopathy, hepatitis, and anemia.",CTD_human
1,0,Biomarker,C0026764,Multiple Myeloma,disease,multiple myeloma,142,PARP1,PARP,CTD_human,21917757,"Bortezomib-induced ""BRCAness"" sensitizes multiple myeloma cells to PARP inhibitors.",0.20082418035263896,"Bortezomib-induced ""BRCAness"" sensitizes <span class=""disease"" id=""21917757-0-41-57"">multiple myeloma</span> cells to <span class=""gene"" id=""21917757-0-67-71"">PARP</span> inhibitors.",CTD_human
1,0,Biomarker,C0242422,Parkinsonian Disorders,group,Parkinsonism,142,PARP1,PARP-1,CTD_human,17640816,"PARP-1 mediates acute neuronal cell death induced by a variety of insults including cerebral ischemia, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism, and CNS trauma.",0.2,"<span class=""gene"" id=""17640816-3-0-6"">PARP-1</span> mediates acute neuronal cell death induced by a variety of insults including cerebral ischemia, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced <span class=""disease"" id=""17640816-3-156-168"">Parkinsonism</span>, and CNS trauma.",CTD_human
1,0,Biomarker,C0345967,Malignant mesothelioma,disease,MM,142,PARP1,PARP,CTD_human,21543585,High expression of PARP1 associated with low PARP activity was also found in MM biopsies.,0.20054945356842604,"High expression of <span class=""gene"" id=""21543585-9-19-24"">PARP1</span> associated with low <span class=""gene"" id=""21543585-9-45-49"">PARP</span> activity was also found in <span class=""disease"" id=""21543585-9-77-79"">MM</span> biopsies.",CTD_human
1,0,Biomarker,C0878544,Cardiomyopathies,group,cardiomyopathy,142,PARP1,PARP-1,CTD_human,20561897,"Here, we show that hPARP-1 mice exhibit impaired survival rates accompanied by reduced hair growth and premature development of several inflammation and age-associated pathologies, such as adiposity, kyphosis, nephropathy, dermatitis, pneumonitis, cardiomyopathy, hepatitis, and anemia.",0.2,"Here, we show that h<span class=""gene"" id=""20561897-6-20-26"">PARP-1</span> mice exhibit impaired survival rates accompanied by reduced hair growth and premature development of several inflammation and age-associated pathologies, such as adiposity, kyphosis, nephropathy, dermatitis, pneumonitis, <span class=""disease"" id=""20561897-6-248-262"">cardiomyopathy</span>, hepatitis, and anemia.",CTD_human
2,0,Biomarker,C0086543,Cataract,disease,cataract,1420,CRYGC,Crygc,CTD_human,11773036,A 6-bp deletion in the Crygc gene leading to a nuclear and radial cataract in the mouse.,0.40766363920333204,"A 6-bp deletion in the <span class=""gene"" id=""11773036-0-23-28"">Crygc</span> gene leading to a nuclear and radial <span class=""disease"" id=""11773036-0-66-74"">cataract</span> in the mouse.",CTD_human;HPO
1,0,Biomarker,C0001418,Adenocarcinoma,group,adenocarcinomas,143187,VTI1A,VTI1A,CTD_human,21892161,Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion.,0.2,"Genomic sequencing of colorectal <span class=""disease"" id=""21892161-0-33-48"">adenocarcinomas</span> identifies a recurrent <span class=""gene"" id=""21892161-0-72-77"">VTI1A</span>-TCF7L2 fusion.",CTD_human
1,0,Therapeutic,C0023473,"Myeloid Leukemia, Chronic",disease,CML,1432,MAPK14,p38,CTD_human,16818652,"In other studies, we show that the small-molecule p38 inhibitors SD-282 and SCIO-469 potentiate As(2)O(3)-mediated suppression of myeloid leukemic progenitor growth from CML patients, indicating a critical regulatory role for p38 in the induction of antileukemic responses.",0.201923087489492,"In other studies, we show that the small-molecule <span class=""gene"" id=""16818652-7-50-53"">p38</span> inhibitors SD-282 and SCIO-469 potentiate As(2)O(3)-mediated suppression of myeloid leukemic progenitor growth from <span class=""disease"" id=""16818652-7-170-173"">CML</span> patients, indicating a critical regulatory role for <span class=""gene"" id=""16818652-7-226-229"">p38</span> in the induction of antileukemic responses.",CTD_human
1,0,Biomarker,C0029401,Osteitis Deformans,disease,Paget's disease of bone,1435,CSF1,CSF1,CTD_human,20436471,"Genome-wide association study identifies variants at CSF1, OPTN and TNFRSF11A as genetic risk factors for Paget's disease of bone.",0.20350593566014002,"Genome-wide association study identifies variants at <span class=""gene"" id=""20436471-0-53-57"">CSF1</span>, OPTN and TNFRSF11A as genetic risk factors for <span class=""disease"" id=""20436471-0-106-129"">Paget's disease of bone</span>.",CTD_human
1,0,Biomarker,C0028960,Oligospermia,disease,oligozoospermia,143689,PIWIL4,HIWI2,CTD_human,20940137,"The haplotype analysis showed that a common haplotype of HIWI2 was associated with a significant reduction in the risk of oligozoospermia (OR = 0.73, 95% CI, 0.56-0.97).",0.202681755307501,"The haplotype analysis showed that a common haplotype of <span class=""gene"" id=""20940137-8-57-62"">HIWI2</span> was associated with a significant reduction in the risk of <span class=""disease"" id=""20940137-8-122-137"">oligozoospermia</span> (OR = 0.73, 95% CI, 0.56-0.97).",CTD_human
2,0,Biomarker,C0001824,Agranulocytosis,disease,granulocytopenia,1437,CSF2,GM-CSF,CTD_human,8120554,"Although the granulocyte nadirs were significantly lower at each 5-FU dose level with the concurrent GM-CSF schedule (eg, 490 mg/m2/d: median, 879/microL v3,286/microL; two-tailed P [P2] < .001), dose-limiting granulocytopenia complicated < or = 16% of cycles with 5-FU < or = 560 mg/m2/d (99 cycles); > or = grade 3 mucositis occurred in < or = 20% of cycles.",0.20054945356842604,"Although the granulocyte nadirs were significantly lower at each 5-FU dose level with the concurrent <span class=""gene"" id=""8120554-10-101-107"">GM-CSF</span> schedule (eg, 490 mg/m2/d: median, 879/microL v3,286/microL; two-tailed P [P2] &lt; .001), dose-limiting <span class=""disease"" id=""8120554-10-210-226"">granulocytopenia</span> complicated &lt; or = 16% of cycles with 5-FU &lt; or = 560 mg/m2/d (99 cycles); &gt; or = grade 3 mucositis occurred in &lt; or = 20% of cycles.",CTD_human
1,0,Therapeutic,C0002622,Amnesia,disease,amnesia,1437,CSF2,GM-CSF,CTD_human,8877002,Peripherally administered GM-CSF interferes with scopolamine-induced amnesia in mice: involvement of interleukin-1.,0.200274726784213,"Peripherally administered <span class=""gene"" id=""8877002-0-26-32"">GM-CSF</span> interferes with scopolamine-induced <span class=""disease"" id=""8877002-0-69-76"">amnesia</span> in mice: involvement of interleukin-1.",CTD_human
1,0,Biomarker,C0003873,Rheumatoid Arthritis,disease,rheumatoid arthritis,1437,CSF2,CSF2,CTD_human,22446963,"Our study identified nine loci newly associated with rheumatoid arthritis at a threshold of P < 5.0 × 10(-8), including B3GNT2, ANXA3, CSF2, CD83, NFKBIE, ARID5B, PDE2A-ARAP1, PLD4 and PTPN2.",0.20769234995796698,"Our study identified nine loci newly associated with <span class=""disease"" id=""22446963-3-53-73"">rheumatoid arthritis</span> at a threshold of P &lt; 5.0 &times; 10(-8), including B3GNT2, ANXA3, <span class=""gene"" id=""22446963-3-135-139"">CSF2</span>, CD83, NFKBIE, ARID5B, PDE2A-ARAP1, PLD4 and PTPN2.",CTD_human
1,0,Biomarker,C0023290,"Leishmaniasis, Visceral",disease,VL,1437,CSF2,GM-CSF,CTD_human,17404324,Patients with acute VL as well as VL patients receiving sodium stibogluconate treatment displayed significantly increased levels of PEG precipitate-induced GM-CSF.,0.200274726784213,"Patients with acute <span class=""disease"" id=""17404324-8-20-22"">VL</span> as well as VL patients receiving sodium stibogluconate treatment displayed significantly increased levels of PEG precipitate-induced <span class=""gene"" id=""17404324-8-156-162"">GM-CSF</span>.",CTD_human
1,0,Biomarker,C0023467,"Leukemia, Myelocytic, Acute",disease,AML,1437,CSF2,Csf2,CTD_human,21441929,"We identified such mutations using a Sleeping Beauty transposon, which caused rapid-onset AML in 80% of mice with Npm1c, associated with mutually exclusive integrations in Csf2, Flt3 or Rasgrp1 in 55 of 70 leukemias.",0.225535235554501,"We identified such mutations using a Sleeping Beauty transposon, which caused rapid-onset <span class=""disease"" id=""21441929-5-90-93"">AML</span> in 80% of mice with Npm1c, associated with mutually exclusive integrations in <span class=""gene"" id=""21441929-5-172-176"">Csf2</span>, Flt3 or Rasgrp1 in 55 of 70 leukemias.",CTD_human
1,0,Therapeutic,C0023903,Liver neoplasms,group,liver tumors,1437,CSF2,GM-CSF,CTD_human,17326190,Combined GM-CSF and IL-12 gene therapy synergistically suppresses the growth of orthotopic liver tumors.,0.201923087489492,"Combined <span class=""gene"" id=""17326190-0-9-15"">GM-CSF</span> and IL-12 gene therapy synergistically suppresses the growth of orthotopic <span class=""disease"" id=""17326190-0-91-103"">liver tumors</span>.",CTD_human
3,0,Therapeutic,C0024305,"Lymphoma, Non-Hodgkin",disease,non-Hodgkin's lymphoma,1437,CSF2,granulocyte macrophage colony stimulating factor,CTD_human,7680712,Phase I trial of m-BACOD and granulocyte macrophage colony stimulating factor in HIV-associated non-Hodgkin's lymphoma.,0.202732912464814,"Phase I trial of m-BACOD and <span class=""gene"" id=""7680712-0-29-77"">granulocyte macrophage colony stimulating factor</span> in HIV-associated <span class=""disease"" id=""7680712-0-96-118"">non-Hodgkin's lymphoma</span>.",CTD_human
1,0,Therapeutic,C0025202,melanoma,disease,melanoma,1437,CSF2,GM-CSF,CTD_human,11061616,"GM-CSF with biochemotherapy (cisplatin, DTIC, tamoxifen, IL-2 and interferon-alpha): a phase I trial in melanoma.",0.209615437447459,"<span class=""gene"" id=""11061616-0-0-6"">GM-CSF</span> with biochemotherapy (cisplatin, DTIC, tamoxifen, IL-2 and interferon-alpha): a phase I trial in <span class=""disease"" id=""11061616-0-104-112"">melanoma</span>.",CTD_human
3,0,Therapeutic,C0026764,Multiple Myeloma,disease,multiple myeloma,1437,CSF2,CSF,CTD_human,7540856,Comparative study of peripheral blood progenitor cell collection in patients with multiple myeloma after single-dose cyclophosphamide combined with rhGM-CSF or rhG-CSF.,0.20274726784213098,"Comparative study of peripheral blood progenitor cell collection in patients with <span class=""disease"" id=""7540856-0-82-98"">multiple myeloma</span> after single-dose cyclophosphamide combined with rhGM-<span class=""gene"" id=""7540856-0-153-156"">CSF</span> or rhG-<span class=""gene"" id=""7540856-0-164-167"">CSF</span>.",CTD_human
3,0,Therapeutic,C0026764,Multiple Myeloma,disease,multiple myeloma,1437,CSF2,granulocyte-macrophage colony-stimulating factor,CTD_human,8555506,Differential mobilization of myeloma cells and normal hematopoietic stem cells in multiple myeloma after treatment with cyclophosphamide and granulocyte-macrophage colony-stimulating factor.,0.20274726784213098,"Differential mobilization of <span class=""disease"" id=""8555506-0-29-36"">myeloma</span> cells and normal hematopoietic stem cells in <span class=""disease"" id=""8555506-0-82-98"">multiple myeloma</span> after treatment with cyclophosphamide and <span class=""gene"" id=""8555506-0-141-189"">granulocyte-macrophage colony-stimulating factor</span>.",CTD_human
1,0,Therapeutic,C0027794,Neural Tube Defects,group,NTD,1437,CSF2,GM-CSF,CTD_human,17075842,"The incidence of NTDs was 18% in fetuses exposed to VA alone, compared to 3.7% and 2.9% in fetuses exposed to IFN-gamma+VA, or GM-CSF+VA respectively.",0.2,"The incidence of <span class=""disease"" id=""17075842-8-17-20"">NTD</span>s was 18% in fetuses exposed to VA alone, compared to 3.7% and 2.9% in fetuses exposed to IFN-gamma+VA, or <span class=""gene"" id=""17075842-8-127-133"">GM-CSF</span>+VA respectively.",CTD_human
2,0,Therapeutic,C0027947,Neutropenia,disease,neutropenia,1437,CSF2,GM-CSF,CTD_human,7875148,"GM-CSF given subcutaneously at a dose of 5 micrograms/kg daily for ten days was well tolerated, reversed neutropenia rapidly and reduced the number of secondary infections in patients with leishmaniasis.",0.20274726784213098,"<span class=""gene"" id=""7875148-9-0-6"">GM-CSF</span> given subcutaneously at a dose of 5 micrograms/kg daily for ten days was well tolerated, reversed <span class=""disease"" id=""7875148-9-105-116"">neutropenia</span> rapidly and reduced the number of secondary infections in patients with leishmaniasis.",CTD_human
1,0,Biomarker,C0034069,Pulmonary Fibrosis,disease,pulmonary fibrosis,1437,CSF2,granulocyte-macrophage colony stimulating factor,CTD_human,17894541,Increased granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) levels in BAL fluid from patients with sulfur mustard gas-induced pulmonary fibrosis.,0.200274726784213,"Increased granulocyte-colony stimulating factor (G-CSF) and <span class=""gene"" id=""17894541-0-60-108"">granulocyte-macrophage colony stimulating factor</span> (GM-CSF) levels in BAL fluid from patients with sulfur mustard gas-induced <span class=""disease"" id=""17894541-0-184-202"">pulmonary fibrosis</span>.",CTD_human
2,0,Therapeutic,C0085090,"Lymphoma, AIDS-Related",disease,HIV-associated lymphoma,1437,CSF2,GMCSF,CTD_human,7680712,"We conclude that it is feasible to treat patients with HIV-associated lymphoma using standard dose m-BACOD plus GMCSF, but further study is needed to determine whether full-dose regimens improve survival when compared with reduced dose regimens in these individuals.",0.2,"We conclude that it is feasible to treat patients with <span class=""disease"" id=""7680712-5-55-78"">HIV-associated lymphoma</span> using standard dose m-BACOD plus <span class=""gene"" id=""7680712-5-112-117"">GMCSF</span>, but further study is needed to determine whether full-dose regimens improve survival when compared with reduced dose regimens in these individuals.",CTD_human
1,0,Therapeutic,C0242596,"Neoplasm, Residual",phenotype,minimal residual disease,1437,CSF2,GM-CSF,CTD_human,14654953,Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: Cytokine and gene therapy with IL-2 and GM-CSF.,0.200274726784213,"Treatment of <span class=""disease"" id=""14654953-0-13-37"">minimal residual disease</span> after surgery or chemotherapy in mice carrying HPV16-associated tumours: Cytokine and gene therapy with IL-2 and <span class=""gene"" id=""14654953-0-151-157"">GM-CSF</span>.",CTD_human
1,0,Biomarker,C0349639,Juvenile Myelomonocytic Leukemia,disease,Juvenile myelomonocytic leukemia,1437,CSF2,granulocyte macrophage-colony stimulating factor,CTD_human,22315502,Juvenile myelomonocytic leukemia is a lethal disease of children characterized by hypersensitivity of hematopoietic progenitors to granulocyte macrophage-colony stimulating factor.,0.20714289638954103,"<span class=""disease"" id=""22315502-1-0-32"">Juvenile myelomonocytic leukemia</span> is a lethal disease of children characterized by hypersensitivity of hematopoietic progenitors to <span class=""gene"" id=""22315502-1-131-179"">granulocyte macrophage-colony stimulating factor</span>.",CTD_human
1,0,Therapeutic,C1261473,Sarcoma,disease,sarcoma,1437,CSF2,GM-CSF,CTD_human,11605069,"The effectiveness of combined chemoimmunotherapy with ifosfamide derivative CBM-4A and granulocyte-macrophage colony-stimulating factor (GM-CSF) was investigated in two experimental tumor models, 3MC-induced MHC class I+ sarcoma Mc12 and HPV16 E6/E7 oncogene-induced MHC class I- carcinoma MK16, transplanted in syngeneic mice.",0.201098907136852,"The effectiveness of combined chemoimmunotherapy with ifosfamide derivative CBM-4A and <span class=""gene"" id=""11605069-1-87-135"">granulocyte-macrophage colony-stimulating factor</span> (<span class=""gene"" id=""11605069-1-137-143"">GM-CSF</span>) was investigated in two experimental tumor models, 3MC-induced MHC class I+ <span class=""disease"" id=""11605069-1-221-228"">sarcoma</span> Mc12 and HPV16 E6/E7 oncogene-induced MHC class I- carcinoma MK16, transplanted in syngeneic mice.",CTD_human
6,0,Biomarker,C0002874,Aplastic Anemia,disease,aplastic anemia,1440,CSF3,granulocyte colony-stimulating factor,CTD_human,9777751,Methimazole-induced aplastic anemia in third exposure: successful treatment with recombinant human granulocyte colony-stimulating factor.,0.201923087489492,"Methimazole-induced <span class=""disease"" id=""9777751-0-20-35"">aplastic anemia</span> in third exposure: successful treatment with recombinant human <span class=""gene"" id=""9777751-0-99-136"">granulocyte colony-stimulating factor</span>.",CTD_human
6,0,Therapeutic,C0002874,Aplastic Anemia,disease,aplastic anemia,1440,CSF3,G-CSF,CTD_human,10629575,Ticlopidine-induced aplastic anemia and quick recovery with G-CSF: case report and literature review.,0.201923087489492,"Ticlopidine-induced <span class=""disease"" id=""10629575-0-20-35"">aplastic anemia</span> and quick recovery with <span class=""gene"" id=""10629575-0-60-65"">G-CSF</span>: case report and literature review.",CTD_human
6,0,Biomarker,C0002874,Aplastic Anemia,disease,aplastic anemia,1440,CSF3,G-CSF,CTD_human,10629575,Ticlopidine-induced aplastic anemia and quick recovery with G-CSF: case report and literature review.,0.201923087489492,"Ticlopidine-induced <span class=""disease"" id=""10629575-0-20-35"">aplastic anemia</span> and quick recovery with <span class=""gene"" id=""10629575-0-60-65"">G-CSF</span>: case report and literature review.",CTD_human
6,0,Therapeutic,C0002874,Aplastic Anemia,disease,aplastic anemia,1440,CSF3,granulocyte colony-stimulating factor,CTD_human,9777751,Methimazole-induced aplastic anemia in third exposure: successful treatment with recombinant human granulocyte colony-stimulating factor.,0.201923087489492,"Methimazole-induced <span class=""disease"" id=""9777751-0-20-35"">aplastic anemia</span> in third exposure: successful treatment with recombinant human <span class=""gene"" id=""9777751-0-99-136"">granulocyte colony-stimulating factor</span>.",CTD_human
1,0,Biomarker,C0020433,Hyperbilirubinemia,disease,hyperbilirubinemia,1440,CSF3,G-CSF,CTD_human,8602625,"By contrast, two patients who received G-CSF with 30 mg/kg of VP-16 developed hyperbilirubinemia and veno-occlusive disease, which terminated this phase I study.",0.2,"By contrast, two patients who received <span class=""gene"" id=""8602625-6-39-44"">G-CSF</span> with 30 mg/kg of VP-16 developed <span class=""disease"" id=""8602625-6-78-96"">hyperbilirubinemia</span> and veno-occlusive disease, which terminated this phase I study.",CTD_human
1,0,Therapeutic,C0023467,"Leukemia, Myelocytic, Acute",disease,acute myeloid leukemia,1440,CSF3,G-CSF,CTD_human,7528855,Fludarabine + Ara-C + G-CSF: cytotoxic effect and induction of apoptosis on fresh acute myeloid leukemia cells.,0.219780328463343,"Fludarabine + Ara-C + <span class=""gene"" id=""7528855-0-22-27"">G-CSF</span>: cytotoxic effect and induction of apoptosis on fresh <span class=""disease"" id=""7528855-0-82-104"">acute myeloid leukemia</span> cells.",CTD_human
4,0,Therapeutic,C0023530,Leukopenia,disease,leukopenia,1440,CSF3,G-CSF,CTD_human,16120623,"Accidentally, we observed a complete response (CR) in a patient undergoing chemotherapy with bleomycin, vincristine or Oncovin, CCNU or lomustine, dacarbazine (BOLD) regimen for metastatic melanoma including brain metastases, who was also treated with G-CSF to manage a concomitant leukopenia.",0.212912158858016,"Accidentally, we observed a complete response (CR) in a patient undergoing chemotherapy with bleomycin, vincristine or Oncovin, CCNU or lomustine, dacarbazine (BOLD) regimen for metastatic melanoma including brain metastases, who was also treated with <span class=""gene"" id=""16120623-2-252-257"">G-CSF</span> to manage a concomitant <span class=""disease"" id=""16120623-2-282-292"">leukopenia</span>.",CTD_human
4,0,Biomarker,C0023530,Leukopenia,disease,leukopenia,1440,CSF3,G-CSF,CTD_human,16120623,"Accidentally, we observed a complete response (CR) in a patient undergoing chemotherapy with bleomycin, vincristine or Oncovin, CCNU or lomustine, dacarbazine (BOLD) regimen for metastatic melanoma including brain metastases, who was also treated with G-CSF to manage a concomitant leukopenia.",0.212912158858016,"Accidentally, we observed a complete response (CR) in a patient undergoing chemotherapy with bleomycin, vincristine or Oncovin, CCNU or lomustine, dacarbazine (BOLD) regimen for metastatic melanoma including brain metastases, who was also treated with <span class=""gene"" id=""16120623-2-252-257"">G-CSF</span> to manage a concomitant <span class=""disease"" id=""16120623-2-282-292"">leukopenia</span>.",CTD_human
2,0,Therapeutic,C0025202,melanoma,disease,melanoma,1440,CSF3,G-CSF,CTD_human,16120623,"We believe that the brilliant CR, the long duration of the disease-free intervals and the long survival in at least three of eight patients should encourage further research on BOLD with G-CSF for the treatment of advanced melanoma.",0.201373633921065,"We believe that the brilliant CR, the long duration of the disease-free intervals and the long survival in at least three of eight patients should encourage further research on BOLD with <span class=""gene"" id=""16120623-10-187-192"">G-CSF</span> for the treatment of advanced <span class=""disease"" id=""16120623-10-223-231"">melanoma</span>.",CTD_human
2,0,Therapeutic,C0026764,Multiple Myeloma,disease,multiple myeloma,1440,CSF3,G-CSF,CTD_human,7534716,G-CSF is a major component of colony-stimulating activity (CSA) in the plasma of patients with multiple myeloma after treatment with high-dose melphalan (HDM).,0.201373633921065,"<span class=""gene"" id=""7534716-0-0-5"">G-CSF</span> is a major component of colony-stimulating activity (CSA) in the plasma of patients with <span class=""disease"" id=""7534716-0-95-111"">multiple myeloma</span> after treatment with high-dose melphalan (HDM).",CTD_human
12,0,Therapeutic,C0027947,Neutropenia,disease,neutropenia,1440,CSF3,G-CSF,CTD_human,7529132,"Intricate dose-response surfaces of the effects of the different treatments on colony-forming units-erythroid, reticulocytes, hematocrit, colony-forming units-granulocyte/macrophage, and absolute neutrophil count were obtained, which revealed that: (a) simultaneous EPO administration was able to maintain reticulocyte production and to protect mice from VP-16 induced anemia; (b) simultaneous G-CSF administration was able to maintain granulocyte production and to protect mice from VP-16 induced neutropenia; (c) VP-16 dose escalation was feasible when EPO or G-CSF were simultaneously administered; and (d) no increased myelotoxicity on erythroid or granuloid progenitors was observed when EPO or G-CSF was simultaneously administered with VP-16.",0.215370344538616,"Intricate dose-response surfaces of the effects of the different treatments on colony-forming units-erythroid, reticulocytes, hematocrit, colony-forming units-granulocyte/macrophage, and absolute neutrophil count were obtained, which revealed that: (a) simultaneous EPO administration was able to maintain reticulocyte production and to protect mice from VP-16 induced anemia; (b) simultaneous <span class=""gene"" id=""7529132-4-394-399"">G-CSF</span> administration was able to maintain granulocyte production and to protect mice from VP-16 induced <span class=""disease"" id=""7529132-4-498-509"">neutropenia</span>; (c) VP-16 dose escalation was feasible when EPO or <span class=""gene"" id=""7529132-4-562-567"">G-CSF</span> were simultaneously administered; and (d) no increased myelotoxicity on erythroid or granuloid progenitors was observed when EPO or <span class=""gene"" id=""7529132-4-700-705"">G-CSF</span> was simultaneously administered with VP-16.",CTD_human
12,0,Therapeutic,C0027947,Neutropenia,disease,neutropenia,1440,CSF3,granulocyte colony-stimulating factor,CTD_human,16761898,Sulfur mustard-induced neutropenia: treatment with granulocyte colony-stimulating factor.,0.215370344538616,"Sulfur mustard-induced <span class=""disease"" id=""16761898-0-23-34"">neutropenia</span>: treatment with <span class=""gene"" id=""16761898-0-51-88"">granulocyte colony-stimulating factor</span>.",CTD_human
12,0,Biomarker,C0027947,Neutropenia,disease,neutropenia,1440,CSF3,G-CSF,CTD_human,12884814,"Neutropenia was a dose limiting factor with half of the cases (7/14) presenting with severe neutropenia (grade 3-4), but a response was observed in all of them on administration of G-CSF.",0.215370344538616,"<span class=""disease"" id=""12884814-10-0-11"">Neutropenia</span> was a dose limiting factor with half of the cases (7/14) presenting with severe <span class=""disease"" id=""12884814-10-92-103"">neutropenia</span> (grade 3-4), but a response was observed in all of them on administration of <span class=""gene"" id=""12884814-10-181-186"">G-CSF</span>.",CTD_human
12,0,Biomarker,C0027947,Neutropenia,disease,neutropenia,1440,CSF3,granulocyte colony-stimulating factor,CTD_human,16761898,Sulfur mustard-induced neutropenia: treatment with granulocyte colony-stimulating factor.,0.215370344538616,"Sulfur mustard-induced <span class=""disease"" id=""16761898-0-23-34"">neutropenia</span>: treatment with <span class=""gene"" id=""16761898-0-51-88"">granulocyte colony-stimulating factor</span>.",CTD_human
12,0,Biomarker,C0027947,Neutropenia,disease,neutropenia,1440,CSF3,G-CSF,CTD_human,9774950,All patients received granulocyte colony-stimulating factor (G-CSF) beginning on the day after paclitaxel and lasting until recovery from neutropenia.,0.215370344538616,"All patients received <span class=""gene"" id=""9774950-4-22-59"">granulocyte colony-stimulating factor</span> (<span class=""gene"" id=""9774950-4-61-66"">G-CSF</span>) beginning on the day after paclitaxel and lasting until recovery from <span class=""disease"" id=""9774950-4-138-149"">neutropenia</span>.",CTD_human
12,0,Therapeutic,C0027947,Neutropenia,disease,neutropenia,1440,CSF3,G-CSF,CTD_human,9774950,All patients received granulocyte colony-stimulating factor (G-CSF) beginning on the day after paclitaxel and lasting until recovery from neutropenia.,0.215370344538616,"All patients received <span class=""gene"" id=""9774950-4-22-59"">granulocyte colony-stimulating factor</span> (<span class=""gene"" id=""9774950-4-61-66"">G-CSF</span>) beginning on the day after paclitaxel and lasting until recovery from <span class=""disease"" id=""9774950-4-138-149"">neutropenia</span>.",CTD_human
12,0,Therapeutic,C0027947,Neutropenia,disease,neutropenia,1440,CSF3,G-CSF,CTD_human,12884814,"Neutropenia was a dose limiting factor with half of the cases (7/14) presenting with severe neutropenia (grade 3-4), but a response was observed in all of them on administration of G-CSF.",0.215370344538616,"<span class=""disease"" id=""12884814-10-0-11"">Neutropenia</span> was a dose limiting factor with half of the cases (7/14) presenting with severe <span class=""disease"" id=""12884814-10-92-103"">neutropenia</span> (grade 3-4), but a response was observed in all of them on administration of <span class=""gene"" id=""12884814-10-181-186"">G-CSF</span>.",CTD_human
12,0,Biomarker,C0027947,Neutropenia,disease,neutropenia,1440,CSF3,G-CSF,CTD_human,7529132,"Intricate dose-response surfaces of the effects of the different treatments on colony-forming units-erythroid, reticulocytes, hematocrit, colony-forming units-granulocyte/macrophage, and absolute neutrophil count were obtained, which revealed that: (a) simultaneous EPO administration was able to maintain reticulocyte production and to protect mice from VP-16 induced anemia; (b) simultaneous G-CSF administration was able to maintain granulocyte production and to protect mice from VP-16 induced neutropenia; (c) VP-16 dose escalation was feasible when EPO or G-CSF were simultaneously administered; and (d) no increased myelotoxicity on erythroid or granuloid progenitors was observed when EPO or G-CSF was simultaneously administered with VP-16.",0.215370344538616,"Intricate dose-response surfaces of the effects of the different treatments on colony-forming units-erythroid, reticulocytes, hematocrit, colony-forming units-granulocyte/macrophage, and absolute neutrophil count were obtained, which revealed that: (a) simultaneous EPO administration was able to maintain reticulocyte production and to protect mice from VP-16 induced anemia; (b) simultaneous <span class=""gene"" id=""7529132-4-394-399"">G-CSF</span> administration was able to maintain granulocyte production and to protect mice from VP-16 induced <span class=""disease"" id=""7529132-4-498-509"">neutropenia</span>; (c) VP-16 dose escalation was feasible when EPO or <span class=""gene"" id=""7529132-4-562-567"">G-CSF</span> were simultaneously administered; and (d) no increased myelotoxicity on erythroid or granuloid progenitors was observed when EPO or <span class=""gene"" id=""7529132-4-700-705"">G-CSF</span> was simultaneously administered with VP-16.",CTD_human
12,0,Therapeutic,C0027947,Neutropenia,disease,neutropenia,1440,CSF3,G-CSF,CTD_human,7688884,Initial data from primates revealed that G-CSF could ameliorate neutropenia following nitrogen mustard exposure.,0.215370344538616,"Initial data from primates revealed that <span class=""gene"" id=""7688884-3-41-46"">G-CSF</span> could ameliorate <span class=""disease"" id=""7688884-3-64-75"">neutropenia</span> following nitrogen mustard exposure.",CTD_human
12,0,Biomarker,C0027947,Neutropenia,disease,neutropenia,1440,CSF3,G-CSF,CTD_human,7688884,Initial data from primates revealed that G-CSF could ameliorate neutropenia following nitrogen mustard exposure.,0.215370344538616,"Initial data from primates revealed that <span class=""gene"" id=""7688884-3-41-46"">G-CSF</span> could ameliorate <span class=""disease"" id=""7688884-3-64-75"">neutropenia</span> following nitrogen mustard exposure.",CTD_human
2,0,Therapeutic,C0030312,Pancytopenia,disease,pancytopenia,1440,CSF3,granulocyte colony-stimulating factor,CTD_human,17505274,"In those patients who survive the initial phase of poisoning, filgrastim (granulocyte colony-stimulating factor) offers an effective method of treating pancytopenia and preventing overwhelming septicemia.",0.200274726784213,"In those patients who survive the initial phase of poisoning, <span class=""gene"" id=""17505274-7-62-72"">filgrastim</span> (<span class=""gene"" id=""17505274-7-74-111"">granulocyte colony-stimulating factor</span>) offers an effective method of treating <span class=""disease"" id=""17505274-7-152-164"">pancytopenia</span> and preventing overwhelming septicemia.",CTD_human
1,0,Biomarker,C0034069,Pulmonary Fibrosis,disease,pulmonary fibrosis,1440,CSF3,G-CSF,CTD_human,17894541,Increased granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) levels in BAL fluid from patients with sulfur mustard gas-induced pulmonary fibrosis.,0.2,"Increased <span class=""gene"" id=""17894541-0-10-47"">granulocyte-colony stimulating factor</span> (<span class=""gene"" id=""17894541-0-49-54"">G-CSF</span>) and granulocyte-macrophage colony stimulating factor (GM-CSF) levels in BAL fluid from patients with sulfur mustard gas-induced <span class=""disease"" id=""17894541-0-184-202"">pulmonary fibrosis</span>.",CTD_human
1,0,Biomarker,C0162557,"Liver Failure, Acute",disease,acute liver failure,1440,CSF3,Granulocyte colony-stimulating factor,CTD_human,21550386,Granulocyte colony-stimulating factor treatment ameliorates liver injury and improves survival in rats with D-galactosamine-induced acute liver failure.,0.2,"<span class=""gene"" id=""21550386-0-0-37"">Granulocyte colony-stimulating factor</span> treatment ameliorates liver injury and improves survival in rats with D-galactosamine-induced <span class=""disease"" id=""21550386-0-132-151"">acute liver failure</span>.",CTD_human
1,0,Therapeutic,C0243026,Sepsis,disease,septicemia,1440,CSF3,granulocyte colony-stimulating factor,CTD_human,17505274,"In those patients who survive the initial phase of poisoning, filgrastim (granulocyte colony-stimulating factor) offers an effective method of treating pancytopenia and preventing overwhelming septicemia.",0.20821309277175895,"In those patients who survive the initial phase of poisoning, <span class=""gene"" id=""17505274-7-62-72"">filgrastim</span> (<span class=""gene"" id=""17505274-7-74-111"">granulocyte colony-stimulating factor</span>) offers an effective method of treating pancytopenia and preventing overwhelming <span class=""disease"" id=""17505274-7-193-203"">septicemia</span>.",CTD_human
1,0,Biomarker,C0175693,Russell-Silver syndrome,disease,Silver-Russell syndrome,1442,CSH1,CSH1,CTD_human,14642004,"Characterization of genomic variants in CSH1 and GH2, two candidate genes for Silver-Russell syndrome in 17q24-q25.",0.20082418035263896,"Characterization of genomic variants in <span class=""gene"" id=""14642004-0-40-44"">CSH1</span> and GH2, two candidate genes for <span class=""disease"" id=""14642004-0-78-101"">Silver-Russell syndrome</span> in 17q24-q25.",CTD_human
1,0,Biomarker,C0024141,"Lupus Erythematosus, Systemic",disease,systemic lupus erythematosus,1445,CSK,CSK,CTD_human,23042117,CSK regulatory polymorphism is associated with systemic lupus erythematosus and influences B-cell signaling and activation.,0.20054945356842604,"<span class=""gene"" id=""23042117-0-0-3"">CSK</span> regulatory polymorphism is associated with <span class=""disease"" id=""23042117-0-47-75"">systemic lupus erythematosus</span> and influences B-cell signaling and activation.",CTD_human
1,6,Biomarker,C0796012,Krause-Kivlin syndrome,disease,Peters Plus syndrome,145173,B3GLCT,B3GALTL,CTD_human,16909395,"Peters Plus syndrome is caused by mutations in B3GALTL, a putative glycosyltransferase.",0.402472541057918,"<span class=""disease"" id=""16909395-0-0-20"">Peters Plus syndrome</span> is caused by mutations in <span class=""gene"" id=""16909395-0-47-54"">B3GALTL</span>, a putative glycosyltransferase.",CTD_human;ORPHANET
1,0,Biomarker,C0026850,Muscular Dystrophy,disease,muscular dystrophy,145270,PRIMA1,PRiMA,CTD_human,22906800,The AChE membrane-binding tail PRiMA is down-regulated in muscle and nerve of mice with muscular dystrophy by merosin deficiency.,0.200274726784213,"The AChE membrane-binding tail <span class=""gene"" id=""22906800-0-31-36"">PRiMA</span> is down-regulated in muscle and nerve of mice with <span class=""disease"" id=""22906800-0-88-106"">muscular dystrophy</span> by merosin deficiency.",CTD_human
1,0,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,type 2 diabetes,145741,C2CD4A,C2CD4A,CTD_human,20818381,A genome-wide association study in the Japanese population identifies susceptibility loci for type 2 diabetes at UBE2E2 and C2CD4A-C2CD4B.,0.20082418035263896,"A genome-wide association study in the Japanese population identifies susceptibility loci for <span class=""disease"" id=""20818381-0-94-109"">type 2 diabetes</span> at UBE2E2 and <span class=""gene"" id=""20818381-0-124-130"">C2CD4A</span>-C2CD4B.",CTD_human
1,0,Biomarker,C0087012,"Ataxia, Spinocerebellar",disease,spinocerebellar ataxia,146057,TTBK2,TTBK2,CTD_human,18037885,"Mutations in TTBK2, encoding a kinase implicated in tau phosphorylation, segregate with spinocerebellar ataxia type 11.",0.20350593566014002,"Mutations in <span class=""gene"" id=""18037885-0-13-18"">TTBK2</span>, encoding a kinase implicated in tau phosphorylation, segregate with <span class=""disease"" id=""18037885-0-88-110"">spinocerebellar ataxia</span> type 11.",CTD_human
1,0,Biomarker,C0018621,Hay fever,disease,seasonal allergic rhinitis,1469,CST1,Cystatin SN,CTD_human,23950865,Cystatin SN upregulation in patients with seasonal allergic rhinitis.,0.200274726784213,"<span class=""gene"" id=""23950865-0-0-11"">Cystatin SN</span> upregulation in patients with <span class=""disease"" id=""23950865-0-42-68"">seasonal allergic rhinitis</span>.",CTD_human
1,0,Biomarker,C0036572,Seizures,phenotype,seizure,147,ADRA1B,alpha 1b-adrenergic receptor,CTD_human,19125850,"The role of alpha 1b-adrenergic receptor (alpha 1b-AR) in relation with neuronal degeneration, drug addiction, and seizure susceptibility has recently emerged.",0.2,"The role of <span class=""gene"" id=""19125850-1-12-40"">alpha 1b-adrenergic receptor</span> (alpha 1b-AR) in relation with neuronal degeneration, drug addiction, and <span class=""disease"" id=""19125850-1-115-122"">seizure</span> susceptibility has recently emerged.",CTD_human
2,0,Biomarker,C0002395,Alzheimer's Disease,disease,Alzheimer's disease,1471,CST3,Cystatin C,CTD_human,18026100,Cystatin C inhibits amyloid-beta deposition in Alzheimer's disease mouse models.,0.26617831493456,"<span class=""gene"" id=""18026100-0-0-10"">Cystatin C</span> inhibits amyloid-beta deposition in <span class=""disease"" id=""18026100-0-47-66"">Alzheimer's disease</span> mouse models.",CTD_human
2,0,Therapeutic,C0002395,Alzheimer's Disease,disease,Alzheimer disease,1471,CST3,CST3,CTD_human,17192785,"In addition to identifying the epsilon4 allele of APOE and related effects, we pinpointed over a dozen potential Alzheimer disease susceptibility genes (ACE, CHRNB2, CST3, ESR1, GAPDHS, IDE, MTHFR, NCSTN, PRNP, PSEN1, TF, TFAM and TNF) with statistically significant allelic summary odds ratios (ranging from 1.11-1.38 for risk alleles and 0.92-0.67 for protective alleles).",0.26617831493456,"In addition to identifying the epsilon4 allele of APOE and related effects, we pinpointed over a dozen potential <span class=""disease"" id=""17192785-5-113-130"">Alzheimer disease</span> susceptibility genes (ACE, CHRNB2, <span class=""gene"" id=""17192785-5-166-170"">CST3</span>, ESR1, GAPDHS, IDE, MTHFR, NCSTN, PRNP, PSEN1, TF, TFAM and TNF) with statistically significant allelic summary odds ratios (ranging from 1.11-1.38 for risk alleles and 0.92-0.67 for protective alleles).",CTD_human
2,0,Therapeutic,C0002395,Alzheimer's Disease,disease,Alzheimer's disease,1471,CST3,Cystatin C,CTD_human,18026100,Cystatin C inhibits amyloid-beta deposition in Alzheimer's disease mouse models.,0.26617831493456,"<span class=""gene"" id=""18026100-0-0-10"">Cystatin C</span> inhibits amyloid-beta deposition in <span class=""disease"" id=""18026100-0-47-66"">Alzheimer's disease</span> mouse models.",CTD_human
2,0,Biomarker,C0002395,Alzheimer's Disease,disease,Alzheimer disease,1471,CST3,CST3,CTD_human,17192785,"In addition to identifying the epsilon4 allele of APOE and related effects, we pinpointed over a dozen potential Alzheimer disease susceptibility genes (ACE, CHRNB2, CST3, ESR1, GAPDHS, IDE, MTHFR, NCSTN, PRNP, PSEN1, TF, TFAM and TNF) with statistically significant allelic summary odds ratios (ranging from 1.11-1.38 for risk alleles and 0.92-0.67 for protective alleles).",0.26617831493456,"In addition to identifying the epsilon4 allele of APOE and related effects, we pinpointed over a dozen potential <span class=""disease"" id=""17192785-5-113-130"">Alzheimer disease</span> susceptibility genes (ACE, CHRNB2, <span class=""gene"" id=""17192785-5-166-170"">CST3</span>, ESR1, GAPDHS, IDE, MTHFR, NCSTN, PRNP, PSEN1, TF, TFAM and TNF) with statistically significant allelic summary odds ratios (ranging from 1.11-1.38 for risk alleles and 0.92-0.67 for protective alleles).",CTD_human
1,0,Biomarker,C0007222,Cardiovascular Diseases,group,cardiovascular diseases,1471,CST3,Cystatin C,CTD_human,21356263,Cystatin C has been accepted to be a significant prognostic factor for cardiovascular diseases.,0.204055389228567,"<span class=""gene"" id=""21356263-2-0-10"">Cystatin C</span> has been accepted to be a significant prognostic factor for <span class=""disease"" id=""21356263-2-71-94"">cardiovascular diseases</span>.",CTD_human
1,0,Biomarker,C0025286,Meningioma,disease,meningioma,1471,CST3,cystatin C,CTD_human,19747051,"In the clinical samples of meningioma, the levels of cathepsins B and L, stefin B, and cystatin C were highest in the tumors of higher histological grades, whereas stefin A and progesterone receptor were the only markers that were significantly increased and decreased, respectively, in WHO Grade III lesions.",0.20328236603324,"In the clinical samples of <span class=""disease"" id=""19747051-10-27-37"">meningioma</span>, the levels of cathepsins B and L, stefin B, and <span class=""gene"" id=""19747051-10-87-97"">cystatin C</span> were highest in the tumors of higher histological grades, whereas stefin A and progesterone receptor were the only markers that were significantly increased and decreased, respectively, in WHO Grade III lesions.",CTD_human
1,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,NSCLC,1474,CST6,cystatin E/M,CTD_human,17043644,"Of the more than 200 genes upregulated by these treatments, three of these, neuronatin, metallothionein 3 and cystatin E/M, were frequently hypermethylated and transcriptionally downregulated in NSCLC cell lines and tumors.",0.2,"Of the more than 200 genes upregulated by these treatments, three of these, neuronatin, metallothionein 3 and <span class=""gene"" id=""17043644-5-110-122"">cystatin E/M</span>, were frequently hypermethylated and transcriptionally downregulated in <span class=""disease"" id=""17043644-5-195-200"">NSCLC</span> cell lines and tumors.",CTD_human
1,0,Biomarker,C0033578,Prostatic Neoplasms,group,prostate tumor,1474,CST6,CST6,CTD_human,19503093,"Here, we show that CST6 is robustly expressed in normal human prostate epithelium, whereas its expression is downregulated in metastatic prostate cell lines and prostate tumor tissues.",0.200274726784213,"Here, we show that <span class=""gene"" id=""19503093-4-19-23"">CST6</span> is robustly expressed in normal human prostate epithelium, whereas its expression is downregulated in metastatic prostate cell lines and <span class=""disease"" id=""19503093-4-161-175"">prostate tumor</span> tissues.",CTD_human
1,1,Biomarker,C1854310,Hypotrichosis simplex,disease,hereditary hypotrichosis simplex,147495,APCDD1,APCDD1,CTD_human,20393562,APCDD1 is a novel Wnt inhibitor mutated in hereditary hypotrichosis simplex.,0.600549453568426,"<span class=""gene"" id=""20393562-0-0-6"">APCDD1</span> is a novel Wnt inhibitor mutated in <span class=""disease"" id=""20393562-0-43-75"">hereditary hypotrichosis simplex</span>.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C2931822,Nasopharyngeal carcinoma,disease,nasopharyngeal carcinoma,1475,CSTA,cystatin A,CTD_human,20461718,Identification of candidate nasopharyngeal carcinoma serum biomarkers by cancer cell secretome and tissue transcriptome analysis: potential usage of cystatin A for predicting nodal stage and poor prognosis.,0.200274726784213,"Identification of candidate <span class=""disease"" id=""20461718-0-28-52"">nasopharyngeal carcinoma</span> serum biomarkers by cancer cell secretome and tissue transcriptome analysis: potential usage of <span class=""gene"" id=""20461718-0-149-159"">cystatin A</span> for predicting nodal stage and poor prognosis.",CTD_human
1,0,Biomarker,C0025286,Meningioma,disease,meningioma,1476,CSTB,stefin B,CTD_human,19747051,"Of note, the known tumor invasiveness marker cathepsin B, measured in whole-tumor homogenates, was not prognostic, in contrast to its endogenous inhibitor stefin B, which was highly significant and the only independent prognostic factor to predict meningioma relapse in multivariate analysis and reported herein for the first time.",0.20328236603324,"Of note, the known tumor invasiveness marker cathepsin B, measured in whole-tumor homogenates, was not prognostic, in contrast to its endogenous inhibitor <span class=""gene"" id=""19747051-15-155-163"">stefin B</span>, which was highly significant and the only independent prognostic factor to predict <span class=""disease"" id=""19747051-15-248-258"">meningioma</span> relapse in multivariate analysis and reported herein for the first time.",CTD_human
1,0,Biomarker,C0279626,Squamous cell carcinoma of esophagus,disease,ESCC,1476,CSTB,CSTB,CTD_human,21517111,"Among these identified proteins, 33 proteins including keratin 17 (KRT17), biliverdin reductase B (BLVRB), proteasome activator subunit 1 (PSME1), manganese superoxide dismutase (MnSOD), high-mobility group box-1(HMGB1), heat shock protein 70 (HSP70), peroxiredoxin (PRDX1), keratin 13 (KRT13), and so on were overexpressed, and 14 proteins including cystatin B (CSTB), tropomyosin 2 (TPM2), annexin 1 (ANX1), transgelin (TAGLN), keratin 19 (KRT19), stratifin (SFN), and so on were down-expressed in ESCC.",0.2,"Among these identified proteins, 33 proteins including keratin 17 (KRT17), biliverdin reductase B (BLVRB), proteasome activator subunit 1 (PSME1), manganese superoxide dismutase (MnSOD), high-mobility group box-1(HMGB1), heat shock protein 70 (HSP70), peroxiredoxin (PRDX1), keratin 13 (KRT13), and so on were overexpressed, and 14 proteins including <span class=""gene"" id=""21517111-5-351-361"">cystatin B</span> (<span class=""gene"" id=""21517111-5-363-367"">CSTB</span>), tropomyosin 2 (TPM2), annexin 1 (ANX1), transgelin (TAGLN), keratin 19 (KRT19), stratifin (SFN), and so on were down-expressed in <span class=""disease"" id=""21517111-5-500-504"">ESCC</span>.",CTD_human
3,13,Biomarker,C0751785,Unverricht-Lundborg Syndrome,disease,EPM1,1476,CSTB,stefin B,CTD_human,25288807,"Stefin B (cystatin B) is an endogenous cysteine cathepsin inhibitor, and the loss-of-function mutations in the stefin B gene were reported in patients with Unverricht-Lundborg disease (EPM1).",0.6923627052895899,"<span class=""gene"" id=""25288807-1-0-8"">Stefin B</span> (cystatin B) is an endogenous cysteine cathepsin inhibitor, and the loss-of-function mutations in the <span class=""gene"" id=""25288807-1-111-119"">stefin B</span> gene were reported in patients with <span class=""disease"" id=""25288807-1-156-183"">Unverricht-Lundborg disease</span> (<span class=""disease"" id=""25288807-1-185-189"">EPM1</span>).",CTD_human;ORPHANET;UNIPROT
3,13,Biomarker,C0751785,Unverricht-Lundborg Syndrome,disease,Unverricht-Lundborg disease,1476,CSTB,cystatin B,CTD_human,11814737,Unverricht-Lundborg disease with cystatin B gene abnormalities.,0.6923627052895899,"<span class=""disease"" id=""11814737-0-0-27"">Unverricht-Lundborg disease</span> with <span class=""gene"" id=""11814737-0-33-43"">cystatin B</span> gene abnormalities.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0032273,Pneumoconiosis,disease,pneumoconiosis,148022,TICAM1,TICAM1,CTD_human,25445010,"By applying ICSNPathway analysis to the pneumoconiosis GWAS data, we identified candidate SNPs, genes such as TICAM1 and HIST3H3, and pathways involved in the positive regulation of TNF production that may contribute to pneumoconiosis susceptibility.",0.200274726784213,"By applying ICSNPathway analysis to the <span class=""disease"" id=""25445010-11-40-54"">pneumoconiosis</span> GWAS data, we identified candidate SNPs, genes such as <span class=""gene"" id=""25445010-11-110-116"">TICAM1</span> and HIST3H3, and pathways involved in the positive regulation of TNF production that may contribute to <span class=""disease"" id=""25445010-11-220-234"">pneumoconiosis</span> susceptibility.",CTD_human
1,0,Biomarker,C0035235,Respiratory Syncytial Virus Infections,group,respiratory syncytial virus infection,148022,TICAM1,TRIF,CTD_human,24478430,"Resveratrol inhibits the TRIF-dependent pathway by upregulating sterile alpha and armadillo motif protein, contributing to anti-inflammatory effects after respiratory syncytial virus infection.",0.20054945356842604,"Resveratrol inhibits the <span class=""gene"" id=""24478430-0-25-29"">TRIF</span>-dependent pathway by upregulating sterile alpha and armadillo motif protein, contributing to anti-inflammatory effects after <span class=""disease"" id=""24478430-0-155-192"">respiratory syncytial virus infection</span>.",CTD_human
1,0,Biomarker,C0004238,Atrial Fibrillation,disease,atrial fibrillation,1482,NKX2-5,NKX2-5,CTD_human,20062060,"Five of the loci, SCN5A, SCN10A, NKX2-5, CAV1-CAV2, and SOX5, were also associated with atrial fibrillation (N = 5,741 cases, P < 0.0056).",0.40137363392106606,"Five of the loci, SCN5A, SCN10A, <span class=""gene"" id=""20062060-6-33-39"">NKX2-5</span>, CAV1-CAV2, and SOX5, were also associated with <span class=""disease"" id=""20062060-6-88-107"">atrial fibrillation</span> (N = 5,741 cases, P &lt; 0.0056).",CTD_human;HPO
1,0,Biomarker,C0027126,Myotonic Dystrophy,disease,myotonic muscular dystrophy,1482,NKX2-5,NKX2-5,CTD_human,18084293,RNA toxicity in myotonic muscular dystrophy induces NKX2-5 expression.,0.200274726784213,"RNA toxicity in <span class=""disease"" id=""18084293-0-16-43"">myotonic muscular dystrophy</span> induces <span class=""gene"" id=""18084293-0-52-58"">NKX2-5</span> expression.",CTD_human
1,0,Biomarker,C0028754,Obesity,disease,obesity,1489,CTF1,CT-1,CTD_human,21803294,We conclude that CT-1 is a master regulator of fat and glucose metabolism with potential applications for treatment of obesity and insulin resistance.,0.200274726784213,"We conclude that <span class=""gene"" id=""21803294-8-17-21"">CT-1</span> is a master regulator of fat and glucose metabolism with potential applications for treatment of <span class=""disease"" id=""21803294-8-119-126"">obesity</span> and insulin resistance.",CTD_human
1,0,Biomarker,C0018801,Heart failure,disease,heart failure,1490,CTGF,connective tissue growth factor,CTD_human,17229371,[Expression of connective tissue growth factor in cardiomyocyte of young rats with heart failure and benazepril intervention].,0.201923087489492,"[Expression of <span class=""gene"" id=""17229371-0-15-46"">connective tissue growth factor</span> in cardiomyocyte of young rats with <span class=""disease"" id=""17229371-0-83-96"">heart failure</span> and benazepril intervention].",CTD_human
3,0,Biomarker,C0034069,Pulmonary Fibrosis,disease,pulmonary fibrosis,1490,CTGF,connective tissue growth factor,CTD_human,26817844,"Last, the in vivo silencing efficacy of SAMiRNAs was evaluated by targeting amphiregulin and connective tissue growth factor in bleomycin or TGF-? transgenic animal models of pulmonary fibrosis.",0.40274726784213105,"Last, the in vivo silencing efficacy of SAMiRNAs was evaluated by targeting amphiregulin and <span class=""gene"" id=""26817844-6-93-124"">connective tissue growth factor</span> in bleomycin or TGF-&beta; transgenic animal models of <span class=""disease"" id=""26817844-6-175-193"">pulmonary fibrosis</span>.",CTD_human;HPO
1,0,Biomarker,C0036421,Systemic Scleroderma,disease,SSc,1490,CTGF,CTGF,CTD_human,24706986,"A novel small-molecule inhibitor of MRTF/SRF-regulated transcription (CCG-203971) inhibits expression of connective tissue growth factor (CTGF), ?-smooth muscle actin (?-SMA), and collagen 1 (COL1A2) in both SSc fibroblasts and in lysophosphatidic acid (LPA)-and transforming growth factor ? (TGF?)-stimulated fibroblasts.",0.22307537114227696,"A novel small-molecule inhibitor of MRTF/SRF-regulated transcription (CCG-203971) inhibits expression of <span class=""gene"" id=""24706986-5-105-136"">connective tissue growth factor</span> (<span class=""gene"" id=""24706986-5-138-142"">CTGF</span>), &alpha;-smooth muscle actin (&alpha;-SMA), and collagen 1 (COL1A2) in both <span class=""disease"" id=""24706986-5-208-211"">SSc</span> fibroblasts and in lysophosphatidic acid (LPA)-and transforming growth factor &beta; (TGF&beta;)-stimulated fibroblasts.",CTD_human
2,0,Biomarker,C0235833,Congenital diaphragmatic hernia,disease,CDH,1490,CTGF,CTGF,CTD_human,20939759,"CTGF is suggested to enhance alveologenesis and microvascular development at late stages of lung development, and a decreased expression could lead to the impaired alveologenesis and abnormal microvascular pulmonary bed observed in CDH lungs.",0.2,"<span class=""gene"" id=""20939759-15-0-4"">CTGF</span> is suggested to enhance alveologenesis and microvascular development at late stages of lung development, and a decreased expression could lead to the impaired alveologenesis and abnormal microvascular pulmonary bed observed in <span class=""disease"" id=""20939759-15-232-235"">CDH</span> lungs.",CTD_human
2,0,Biomarker,C0235833,Congenital diaphragmatic hernia,disease,CDH,1490,CTGF,connective tissue growth factor,CTD_human,21258935,Prenatal administration of retinoic acid upregulates connective tissue growth factor in the nitrofen CDH model.,0.2,"Prenatal administration of retinoic acid upregulates <span class=""gene"" id=""21258935-0-53-84"">connective tissue growth factor</span> in the nitrofen <span class=""disease"" id=""21258935-0-101-104"">CDH</span> model.",CTD_human
1,0,Biomarker,C0524909,"Hepatitis B, Chronic",disease,chronic hepatitis B,1490,CTGF,CTGF,CTD_human,17657819,"Furthermore, an interferon gamma treatment of patients with chronic hepatitis B virus infection induced Smad7 expression in hepatocytes, leading to decreased CTGF expression and fibrogenesis.",0.20082418035263896,"Furthermore, an interferon gamma treatment of patients with <span class=""disease"" id=""17657819-11-60-79"">chronic hepatitis B</span> virus infection induced Smad7 expression in hepatocytes, leading to decreased <span class=""gene"" id=""17657819-11-158-162"">CTGF</span> expression and fibrogenesis.",CTD_human
3,5,Biomarker,C0009324,Ulcerative Colitis,disease,ulcerative colitis,149233,IL23R,IL23R,CTD_human,18438406,"We also show that several risk loci are common to ulcerative colitis and Crohn's disease (IL23R, IL12B, HLA, NKX2-3 and MST1), whereas autophagy genes ATG16L1 and IRGM, along with NOD2 (also known as CARD15), are specific for Crohn's disease.",0.278604854027156,"We also show that several risk loci are common to <span class=""disease"" id=""18438406-2-50-68"">ulcerative colitis</span> and Crohn's disease (<span class=""gene"" id=""18438406-2-90-95"">IL23R</span>, IL12B, HLA, NKX2-3 and MST1), whereas autophagy genes ATG16L1 and IRGM, along with NOD2 (also known as CARD15), are specific for Crohn's disease.",CTD_human
2,15,Biomarker,C0010346,Crohn Disease,disease,Crohn's disease,149233,IL23R,IL23R,CTD_human,18438406,"We also show that several risk loci are common to ulcerative colitis and Crohn's disease (IL23R, IL12B, HLA, NKX2-3 and MST1), whereas autophagy genes ATG16L1 and IRGM, along with NOD2 (also known as CARD15), are specific for Crohn's disease.",0.336985261965835,"We also show that several risk loci are common to ulcerative colitis and <span class=""disease"" id=""18438406-2-73-88"">Crohn's disease</span> (<span class=""gene"" id=""18438406-2-90-95"">IL23R</span>, IL12B, HLA, NKX2-3 and MST1), whereas autophagy genes ATG16L1 and IRGM, along with NOD2 (also known as CARD15), are specific for <span class=""disease"" id=""18438406-2-226-241"">Crohn's disease</span>.",CTD_human
3,1,Biomarker,C0021390,Inflammatory Bowel Diseases,group,inflammatory bowel disease,149233,IL23R,IL23R,CTD_human,23291587,"Three risk loci shared with ankylosing spondylitis and psoriasis (the MHC class I region, ERAP1 and IL23R and the MHC class I-ERAP1 interaction), as well as two loci shared with inflammatory bowel disease (IL23R and IL10) implicate shared pathogenic pathways in the spondyloarthritides and Beh?et's disease.",0.27698061845617894,"Three risk loci shared with ankylosing spondylitis and psoriasis (the MHC class I region, ERAP1 and <span class=""gene"" id=""23291587-8-100-105"">IL23R</span> and the MHC class I-ERAP1 interaction), as well as two loci shared with <span class=""disease"" id=""23291587-8-178-204"">inflammatory bowel disease</span> (<span class=""gene"" id=""23291587-8-206-211"">IL23R</span> and IL10) implicate shared pathogenic pathways in the spondyloarthritides and Beh&Ccedil;et's disease.",CTD_human
1,0,Biomarker,C0023343,Leprosy,disease,leprosy,149233,IL23R,IL23R,CTD_human,22019778,Identification of two new loci at IL23R and RAB32 that influence susceptibility to leprosy.,0.20082418035263896,"Identification of two new loci at <span class=""gene"" id=""22019778-0-34-39"">IL23R</span> and RAB32 that influence susceptibility to <span class=""disease"" id=""22019778-0-83-90"">leprosy</span>.",CTD_human
3,5,Biomarker,C0033860,Psoriasis,disease,psoriasis,149233,IL23R,IL23R,CTD_human,24212883,"We discovered two independent missense SNVs in IL23R and GJB2 of low frequency and five common missense SNVs in LCE3D, ERAP1, CARD14 and ZNF816A associated with psoriasis at genome-wide significance.",0.27033143285742,"We discovered two independent missense SNVs in <span class=""gene"" id=""24212883-2-47-52"">IL23R</span> and GJB2 of low frequency and five common missense SNVs in LCE3D, ERAP1, CARD14 and ZNF816A associated with <span class=""disease"" id=""24212883-2-161-170"">psoriasis</span> at genome-wide significance.",CTD_human
2,2,Biomarker,C0038013,Ankylosing spondylitis,disease,ankylosing spondylitis,149233,IL23R,IL23R,CTD_human,17952073,"Comparing these data against a common control dataset derived from 1,500 randomly selected healthy British individuals, we report initial association and independent replication in a North American sample of two new loci related to ankylosing spondylitis, ARTS1 and IL23R, and confirmation of the previously reported association of AITD with TSHR and FCRL3.",0.237242815497792,"Comparing these data against a common control dataset derived from 1,500 randomly selected healthy British individuals, we report initial association and independent replication in a North American sample of two new loci related to <span class=""disease"" id=""17952073-2-232-254"">ankylosing spondylitis</span>, ARTS1 and <span class=""gene"" id=""17952073-2-266-271"">IL23R</span>, and confirmation of the previously reported association of AITD with TSHR and FCRL3.",CTD_human
3,0,Biomarker,C0018213,Graves Disease,disease,Graves' disease,1493,CTLA4,CTLA4,CTD_human,23104008,"In 3 of the 14 regions, TCF7L2 (T2D), CTLA4 (Graves' disease) and CDKN2A-CDKN2B (T2D), much of the posterior probability rested on a single SNP, and, in 4 other regions (CDKN2A-CDKN2B (CAD) and CDKAL1, FTO and HHEX (T2D)), the 95% sets were small, thereby excluding most SNPs as potentially causal.",0.30907797299463696,"In 3 of the 14 regions, TCF7L2 (T2D), <span class=""gene"" id=""23104008-3-38-43"">CTLA4</span> (<span class=""disease"" id=""23104008-3-45-60"">Graves' disease</span>) and CDKN2A-CDKN2B (T2D), much of the posterior probability rested on a single SNP, and, in 4 other regions (CDKN2A-CDKN2B (CAD) and CDKAL1, FTO and HHEX (T2D)), the 95% sets were small, thereby excluding most SNPs as potentially causal.",CTD_human
3,0,Biomarker,C0018213,Graves Disease,disease,Graves' disease,1493,CTLA4,CTLA-4,CTD_human,19731979,CTLA-4 genotypes in exon 1 (A/G(49)) and CT60 were analyzed in 415 Japanese patients with Graves' disease and 65 patients with AATD.,0.30907797299463696,"<span class=""gene"" id=""19731979-5-0-6"">CTLA-4</span> genotypes in exon 1 (A/G(49)) and CT60 were analyzed in 415 Japanese patients with <span class=""disease"" id=""19731979-5-90-105"">Graves' disease</span> and 65 patients with AATD.",CTD_human
1,0,Therapeutic,C0025202,melanoma,disease,melanoma,1493,CTLA4,CTLA-4,CTD_human,21802280,"In 2011 immunomodulation with ipilimumab, a monoclonal antibody targeting the ligand CTLA-4, has been approved for patients with advanced melanoma in first- and second-line treatment by the Food and Drug Administration (FDA) and in second-line treatment by the European Medicines Agency (EMA).",0.21735726583111398,"In 2011 immunomodulation with ipilimumab, a monoclonal antibody targeting the ligand <span class=""gene"" id=""21802280-4-85-91"">CTLA-4</span>, has been approved for patients with advanced <span class=""disease"" id=""21802280-4-138-146"">melanoma</span> in first- and second-line treatment by the Food and Drug Administration (FDA) and in second-line treatment by the European Medicines Agency (EMA).",CTD_human
1,0,Biomarker,C0031117,Peripheral Neuropathy,group,PN,1493,CTLA4,CTLA4,CTD_human,21228734,"Genes associated with immune function (CTLA4, CTSS), reflexive coupling within Schwann cells (GJE1), drug binding (PSMB1), and neuron function (TCF4, DYNC1I1) associated with bortezomib-induced PN in this study.",0.200274726784213,"Genes associated with immune function (<span class=""gene"" id=""21228734-10-39-44"">CTLA4</span>, CTSS), reflexive coupling within Schwann cells (GJE1), drug binding (PSMB1), and neuron function (TCF4, DYNC1I1) associated with bortezomib-induced <span class=""disease"" id=""21228734-10-194-196"">PN</span> in this study.",CTD_human
1,1,Biomarker,C0004096,Asthma,disease,asthma,149628,PYHIN1,PYHIN1,CTD_human,21804549,"In addition, we identified a new asthma susceptibility locus at PYHIN1, with the association being specific to individuals of African descent (P = 3.9 × 10(-9)).",0.20082418035263896,"In addition, we identified a new <span class=""disease"" id=""21804549-4-33-39"">asthma</span> susceptibility locus at <span class=""gene"" id=""21804549-4-64-70"">PYHIN1</span>, with the association being specific to individuals of African descent (P = 3.9 &times; 10(-9)).",CTD_human
10,37,Biomarker,C2931187,Nephropathic cystinosis,disease,nephropathic cystinosis,1497,CTNS,CTNS,CTD_human,15879904,"The Swallowing Severity Score varied directly with the severity of muscle disease, but was not correlated with the presence or absence of the 57-kb CTNS deletion that commonly occurs in nephropathic cystinosis patients.",0.70109654087514,"The Swallowing Severity Score varied directly with the severity of muscle disease, but was not correlated with the presence or absence of the 57-kb <span class=""gene"" id=""15879904-9-148-152"">CTNS</span> deletion that commonly occurs in <span class=""disease"" id=""15879904-9-186-209"">nephropathic cystinosis</span> patients.",CTD_human;ORPHANET;UNIPROT
3,0,Biomarker,C0001418,Adenocarcinoma,group,adenocarcinomas,1499,CTNNB1,beta-catenin,CTD_human,15459021,"Colonic adenocarcinomas rapidly induced by the combined treatment with 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and dextran sodium sulfate in male ICR mice possess beta-catenin gene mutations and increases immunoreactivity for beta-catenin, cyclooxygenase-2 and inducible nitric oxide synthase.",0.215862376597774,"Colonic <span class=""disease"" id=""15459021-0-8-23"">adenocarcinomas</span> rapidly induced by the combined treatment with 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and dextran sodium sulfate in male ICR mice possess <span class=""gene"" id=""15459021-0-171-183"">beta-catenin</span> gene mutations and increases immunoreactivity for beta-catenin, cyclooxygenase-2 and inducible nitric oxide synthase.",CTD_human
3,0,Biomarker,C0001418,Adenocarcinoma,group,adenocarcinomas,1499,CTNNB1,beta-catenin,CTD_human,10965019,"More frequent beta-catenin gene mutations in adenomas than in aberrant crypt foci or adenocarcinomas in the large intestines of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-treated rats.",0.215862376597774,"More frequent <span class=""gene"" id=""10965019-0-14-26"">beta-catenin</span> gene mutations in adenomas than in aberrant crypt foci or <span class=""disease"" id=""10965019-0-85-100"">adenocarcinomas</span> in the large intestines of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-treated rats.",CTD_human
2,0,Biomarker,C0001430,Adenoma,group,adenomas,1499,CTNNB1,beta-catenin,CTD_human,10965019,"More frequent beta-catenin gene mutations in adenomas than in aberrant crypt foci or adenocarcinomas in the large intestines of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-treated rats.",0.21670091232773003,"More frequent <span class=""gene"" id=""10965019-0-14-26"">beta-catenin</span> gene mutations in <span class=""disease"" id=""10965019-0-45-53"">adenomas</span> than in aberrant crypt foci or adenocarcinomas in the large intestines of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-treated rats.",CTD_human
9,0,Biomarker,C0009375,Colonic Neoplasms,group,colon tumors,1499,CTNNB1,ctnnb1,CTD_human,9515794,High frequency of beta-catenin (ctnnb1) mutations in the colon tumors induced by two heterocyclic amines in the F344 rat.,0.23171039781823002,"High frequency of beta-catenin (<span class=""gene"" id=""9515794-0-32-38"">ctnnb1</span>) mutations in the <span class=""disease"" id=""9515794-0-57-69"">colon tumors</span> induced by two heterocyclic amines in the F344 rat.",CTD_human
1,0,Biomarker,C0010276,Craniopharyngioma,disease,craniopharyngiomas,1499,CTNNB1,CTNNB1,CTD_human,24413733,Targeted genotyping revealed BRAF p.Val600Glu in 95% of papillary craniopharyngiomas (36 of 39 tumors) and mutation of CTNNB1 in 96% of adamantinomatous craniopharyngiomas (51 of 53 tumors).,0.401648360705279,"Targeted genotyping revealed BRAF p.Val600Glu in 95% of papillary craniopharyngiomas (36 of 39 tumors) and mutation of <span class=""gene"" id=""24413733-4-119-125"">CTNNB1</span> in 96% of adamantinomatous <span class=""disease"" id=""24413733-4-153-171"">craniopharyngiomas</span> (51 of 53 tumors).",CTD_human;ORPHANET
1,0,Biomarker,C0018923,Hemangiosarcoma,disease,hemangiosarcomas,1499,CTNNB1,beta-catenin,CTD_human,13678655,"Chemical-specific alterations in ras, p53, and beta-catenin genes in hemangiosarcomas from B6C3F1 mice exposed to o-nitrotoluene or riddelliine for 2 years.",0.2,"Chemical-specific alterations in ras, p53, and <span class=""gene"" id=""13678655-0-47-59"">beta-catenin</span> genes in <span class=""disease"" id=""13678655-0-69-85"">hemangiosarcomas</span> from B6C3F1 mice exposed to o-nitrotoluene or riddelliine for 2 years.",CTD_human
2,0,Biomarker,C0023903,Liver neoplasms,group,liver tumor,1499,CTNNB1,Ctnnb1,CTD_human,21047994,"The prevalence of tumors in Ctnnb1 KO mice was ?7-fold higher than in wild-type mice, suggesting an enhancing effect of the gene KO on liver tumor development.",0.20924648737398102,"The prevalence of tumors in <span class=""gene"" id=""21047994-7-28-34"">Ctnnb1</span> KO mice was &sim;7-fold higher than in wild-type mice, suggesting an enhancing effect of the gene KO on <span class=""disease"" id=""21047994-7-135-146"">liver tumor</span> development.",CTD_human
1,0,Biomarker,C0024121,Lung Neoplasms,group,lung tumors,1499,CTNNB1,beta-catenin,CTD_human,18372914,"Beta-catenin accumulation is often found in lung tumors, but only a few patients have mutations in beta-catenin gene.",0.205740551713841,"Beta-catenin accumulation is often found in <span class=""disease"" id=""18372914-1-44-55"">lung tumors</span>, but only a few patients have mutations in <span class=""gene"" id=""18372914-1-99-111"">beta-catenin</span> gene.",CTD_human
1,0,Biomarker,C0027708,Nephroblastoma,disease,nephroblastoma,1499,CTNNB1,CTNNB1,CTD_human,21237236,GS expression was not observed in CTNNB1-mutated nephroblastoma.,0.208711389182872,"GS expression was not observed in <span class=""gene"" id=""21237236-9-34-40"">CTNNB1</span>-mutated <span class=""disease"" id=""21237236-9-49-63"">nephroblastoma</span>.",CTD_human
1,0,Biomarker,C0033578,Prostatic Neoplasms,group,Prostate tumors,1499,CTNNB1,beta-catenin,CTD_human,17363566,Prostate tumors induced by the deletion of Apc have elevated levels of beta-catenin protein and are highly proliferative.,0.22213802650272302,"<span class=""disease"" id=""17363566-3-0-15"">Prostate tumors</span> induced by the deletion of Apc have elevated levels of <span class=""gene"" id=""17363566-3-71-83"">beta-catenin</span> protein and are highly proliferative.",CTD_human
1,3,Biomarker,C0206624,Hepatoblastoma,disease,hepatoblastoma,1499,CTNNB1,CTNNB1,CTD_human,21237236,"In CTNNB1-mutated hepatoblastoma, expression of GS was only detected in tumour areas with epithelial, not with mesenchymal differentiation.",0.20822744814907604,"In <span class=""gene"" id=""21237236-7-3-9"">CTNNB1</span>-mutated <span class=""disease"" id=""21237236-7-18-32"">hepatoblastoma</span>, expression of GS was only detected in tumour areas with epithelial, not with mesenchymal differentiation.",CTD_human
3,2,Biomarker,C2239176,Liver carcinoma,disease,hepatomas,1499,CTNNB1,Ctnnb1,CTD_human,20118494,"Here, we show that the Wnt/beta-catenin pathway is also involved in the transcriptional regulation of GSTs: GSTm2, GSTm3, and GSTm6 are overexpressed in mouse hepatomas with activating Ctnnb1 (encoding beta-catenin) mutations and in transgenic hepatocytes expressing activated beta-catenin.",0.44733302273838105,"Here, we show that the Wnt/beta-catenin pathway is also involved in the transcriptional regulation of GSTs: GSTm2, GSTm3, and GSTm6 are overexpressed in mouse <span class=""disease"" id=""20118494-3-159-168"">hepatomas</span> with activating <span class=""gene"" id=""20118494-3-185-191"">Ctnnb1</span> (encoding beta-catenin) mutations and in transgenic hepatocytes expressing activated beta-catenin.",CTD_human;HPO
2,0,Biomarker,C0019189,"Hepatitis, Chronic",disease,chronic hepatitis,150684,COMMD1,COMMD1,CTD_human,25053573,COMMD1-deficient dogs progressively develop copper-induced chronic hepatitis.,0.20054945356842604,"<span class=""gene"" id=""25053573-1-0-6"">COMMD1</span>-deficient dogs progressively develop copper-induced <span class=""disease"" id=""25053573-1-59-76"">chronic hepatitis</span>.",CTD_human
2,0,Biomarker,C0019189,"Hepatitis, Chronic",disease,chronic hepatitis,150684,COMMD1,COMMD1,CTD_human,22879914,COMMD1-deficient dogs accumulate copper in hepatocytes and provide a good model for chronic hepatitis and fibrosis.,0.20054945356842604,"<span class=""gene"" id=""22879914-0-0-6"">COMMD1</span>-deficient dogs accumulate copper in hepatocytes and provide a good model for <span class=""disease"" id=""22879914-0-84-101"">chronic hepatitis</span> and fibrosis.",CTD_human
1,0,Biomarker,C0026848,Myopathy,group,myopathy,1508,CTSB,cathepsin B,CTD_human,7099197,In this report we examine the activities of the lysosomal endoproteinase cathepsin B and its endogenous inhibitor(s) in the red and white skeletal muscles of guinea pigs with nutritional muscular myopathy induced by vitamin E deficiency.,0.2,"In this report we examine the activities of the lysosomal endoproteinase <span class=""gene"" id=""7099197-2-73-84"">cathepsin B</span> and its endogenous inhibitor(s) in the red and white skeletal muscles of guinea pigs with nutritional muscular <span class=""disease"" id=""7099197-2-196-204"">myopathy</span> induced by vitamin E deficiency.",CTD_human
1,0,Biomarker,C0003873,Rheumatoid Arthritis,disease,RA,1509,CTSD,cathepsin D,CTD_human,12833524,The lower abundance of cathepsin D protein in RA compared to OA tissue was also reproduced in other patient samples.,0.200274726784213,"The lower abundance of <span class=""gene"" id=""12833524-7-23-34"">cathepsin D</span> protein in <span class=""disease"" id=""12833524-7-46-48"">RA</span> compared to OA tissue was also reproduced in other patient samples.",CTD_human
1,0,Biomarker,C0003873,Rheumatoid Arthritis,disease,rheumatoid arthritis,151056,PLB1,PLB1,CTD_human,24520335,Integration of sequence data from a Consanguineous family with genetic data from an outbred population identifies PLB1 as a candidate rheumatoid arthritis risk gene.,0.201098907136852,"Integration of sequence data from a Consanguineous family with genetic data from an outbred population identifies <span class=""gene"" id=""24520335-0-114-118"">PLB1</span> as a candidate <span class=""disease"" id=""24520335-0-134-154"">rheumatoid arthritis</span> risk gene.",CTD_human
1,0,Biomarker,C0017636,Glioblastoma,disease,glioblastoma,1513,CTSK,cathepsin K,CTD_human,25356585,Expression analysis of all protease genes reveals cathepsin K to be overexpressed in glioblastoma.,0.2,"Expression analysis of all protease genes reveals <span class=""gene"" id=""25356585-0-50-61"">cathepsin K</span> to be overexpressed in <span class=""disease"" id=""25356585-0-85-97"">glioblastoma</span>.",CTD_human
5,23,Biomarker,C0238402,Pycnodysostosis,disease,Pyknodysostosis,1513,CTSK,cathepsin K,CTD_human,15163881,Pyknodysostosis is a rare autosomal recessive osteosclerosing skeletal disorder caused by mutations in the CTSK gene situated at 1q21 that codes for cathepsin K - a lysosomal cysteine protease.,0.689065983879032,"<span class=""disease"" id=""15163881-1-0-15"">Pyknodysostosis</span> is a rare autosomal recessive osteosclerosing skeletal disorder caused by mutations in the <span class=""gene"" id=""15163881-1-107-111"">CTSK</span> gene situated at 1q21 that codes for <span class=""gene"" id=""15163881-1-149-160"">cathepsin K</span> - a lysosomal cysteine protease.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0009806,Constipation,phenotype,constipation,151306,GPBAR1,TGR5,CTD_human,23041323,"The receptor TGR5 mediates the effects of BAs on colonic motility, and deficiency of TGR5 causes constipation in mice.",0.2,"The receptor <span class=""gene"" id=""23041323-12-13-17"">TGR5</span> mediates the effects of BAs on colonic motility, and deficiency of <span class=""gene"" id=""23041323-12-85-89"">TGR5</span> causes <span class=""disease"" id=""23041323-12-97-109"">constipation</span> in mice.",CTD_human
1,0,Biomarker,C0010346,Crohn Disease,disease,CD,151306,GPBAR1,TGR5,CTD_human,23566200,"Among LPMCs, isolated CD14(+) intestinal M?s from patients with CD expressed TGR5.",0.2,"Among LPMCs, isolated CD14(+) intestinal M?s from patients with <span class=""disease"" id=""23566200-10-64-66"">CD</span> expressed <span class=""gene"" id=""23566200-10-77-81"">TGR5</span>.",CTD_human
1,0,Biomarker,C0025286,Meningioma,disease,meningioma,1514,CTSL,cathepsin L,CTD_human,19747051,"As to the second aim, the possible association of cathepsin B along with selected molecular markers, cathepsin L, and endogenous cysteine protease inhibitors (stefins A and B and cystatin C) with meningioma malignancy was determined using enzyme-linked immunosorbent assays in tumor homogenates.",0.20300763924902696,"As to the second aim, the possible association of cathepsin B along with selected molecular markers, <span class=""gene"" id=""19747051-5-101-112"">cathepsin L</span>, and endogenous cysteine protease inhibitors (stefins A and B and cystatin C) with <span class=""disease"" id=""19747051-5-196-206"">meningioma</span> malignancy was determined using enzyme-linked immunosorbent assays in tumor homogenates.",CTD_human
1,0,Biomarker,C0011615,"Dermatitis, Atopic",disease,atopic dermatitis,151887,CCDC80,CCDC80,CTD_human,23042114,"On the basis of data from a genome-wide association study (GWAS) and a validation study comprising a total of 3,328 subjects with atopic dermatitis and 14,992 controls in the Japanese population, we report here 8 new susceptibility loci: IL1RL1-IL18R1-IL18RAP (P(combined) = 8.36 × 10(-18)), the major histocompatibility complex (MHC) region (P = 8.38 × 10(-20)), OR10A3-NLRP10 (P = 1.54 × 10(-22)), GLB1 (P = 2.77 × 10(-16)), CCDC80 (P = 1.56 × 10(-19)), CARD11 (P = 7.83 × 10(-9)), ZNF365 (P = 5.85 × 10(-20)) and CYP24A1-PFDN4 (P = 1.65 × 10(-8)).",0.2,"On the basis of data from a genome-wide association study (GWAS) and a validation study comprising a total of 3,328 subjects with <span class=""disease"" id=""23042114-2-130-147"">atopic dermatitis</span> and 14,992 controls in the Japanese population, we report here 8 new susceptibility loci: IL1RL1-IL18R1-IL18RAP (P(combined) = 8.36 &times; 10(-18)), the major histocompatibility complex (MHC) region (P = 8.38 &times; 10(-20)), OR10A3-NLRP10 (P = 1.54 &times; 10(-22)), GLB1 (P = 2.77 &times; 10(-16)), <span class=""gene"" id=""23042114-2-427-433"">CCDC80</span> (P = 1.56 &times; 10(-19)), CARD11 (P = 7.83 &times; 10(-9)), ZNF365 (P = 5.85 &times; 10(-20)) and CYP24A1-PFDN4 (P = 1.65 &times; 10(-8)).",CTD_human
1,0,Biomarker,C1458155,Mammary Neoplasms,group,breast tumors,152273,FGD5,FGD5,CTD_human,25151356,"The genes identified include eight that are essential for cell proliferation (FGD5, METTL6, CPT1A, DTX3, MRPS23, EIF2S2, EIF6 and SLC2A10) and are uniquely amplified in patients with highly proliferative luminal breast tumors, a clinical subset of patients for which few therapeutic options are effective.",0.2,"The genes identified include eight that are essential for cell proliferation (<span class=""gene"" id=""25151356-4-78-82"">FGD5</span>, METTL6, CPT1A, DTX3, MRPS23, EIF2S2, EIF6 and SLC2A10) and are uniquely amplified in patients with highly proliferative luminal <span class=""disease"" id=""25151356-4-212-225"">breast tumors</span>, a clinical subset of patients for which few therapeutic options are effective.",CTD_human
1,0,Biomarker,C0596263,Carcinogenesis,phenotype,tumorigenesis,1523,CUX1,CUX1,CTD_human,24316979,Inactivating CUX1 mutations promote tumorigenesis.,0.201098907136852,"Inactivating <span class=""gene"" id=""24316979-0-13-17"">CUX1</span> mutations promote <span class=""disease"" id=""24316979-0-36-49"">tumorigenesis</span>.",CTD_human
5,0,Biomarker,C0018801,Heart failure,disease,heart failure,153,ADRB1,Beta 1-adrenergic receptor,CTD_human,14502278,Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure.,0.249985468774928,"<span class=""gene"" id=""14502278-0-0-26"">Beta 1-adrenergic receptor</span> polymorphisms confer differential function and predisposition to <span class=""disease"" id=""14502278-0-92-105"">heart failure</span>.",CTD_human
5,0,Biomarker,C0018801,Heart failure,disease,heart failure,153,ADRB1,ADRB1,CTD_human,21516734,"During long-term carvedilol therapy, CHF patients with the Arg/Arg genotype of the ADRB1 gene were observed to have a more pronounced decrease in the functional class of heart failure, a significant increase in left ventricular ejection, and a decrease in left ventricular end-systolic and end-diastolic sizes as compared with patients with the Gly/Arg genotype.",0.249985468774928,"During long-term carvedilol therapy, CHF patients with the Arg/Arg genotype of the <span class=""gene"" id=""21516734-6-83-88"">ADRB1</span> gene were observed to have a more pronounced decrease in the functional class of <span class=""disease"" id=""21516734-6-170-183"">heart failure</span>, a significant increase in left ventricular ejection, and a decrease in left ventricular end-systolic and end-diastolic sizes as compared with patients with the Gly/Arg genotype.",CTD_human
2,0,Biomarker,C0020538,Hypertensive disease,group,high blood pressure,153,ADRB1,beta(1)-adrenergic receptor,CTD_human,10673262,Antisense inhibition of beta(1)-adrenergic receptor mRNA in a single dose produces a profound and prolonged reduction in high blood pressure in spontaneously hypertensive rats.,0.35211831114099895,"Antisense inhibition of <span class=""gene"" id=""10673262-0-24-51"">beta(1)-adrenergic receptor</span> mRNA in a single dose produces a profound and prolonged reduction in <span class=""disease"" id=""10673262-0-121-140"">high blood pressure</span> in spontaneously hypertensive rats.",CTD_human
1,0,Biomarker,C0028754,Obesity,disease,obesity,153,ADRB1,ADRB1,CTD_human,12032746,Association between obesity and a polymorphism in the beta(1)-adrenoceptor gene (Gly389Arg ADRB1) in Caucasian women.,0.231356883337374,"Association between <span class=""disease"" id=""12032746-0-20-27"">obesity</span> and a polymorphism in the <span class=""gene"" id=""12032746-0-54-74"">beta(1)-adrenoceptor</span> gene (Gly389Arg <span class=""gene"" id=""12032746-0-91-96"">ADRB1</span>) in Caucasian women.",CTD_human
1,0,Biomarker,C0033578,Prostatic Neoplasms,group,prostate tumor,153090,DAB2IP,DAB2IP,CTD_human,18073375,Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP.,0.208473464178654,"Two genome-wide association studies of aggressive prostate cancer implicate putative <span class=""disease"" id=""18073375-0-85-99"">prostate tumor</span> suppressor gene <span class=""gene"" id=""18073375-0-116-122"">DAB2IP</span>.",CTD_human
1,1,Biomarker,C0162871,"Aortic Aneurysm, Abdominal",disease,abdominal aortic aneurysm,153090,DAB2IP,DAB2IP,CTD_human,20622881,Genome-wide association study identifies a sequence variant within the DAB2IP gene conferring susceptibility to abdominal aortic aneurysm.,0.201098907136852,"Genome-wide association study identifies a sequence variant within the <span class=""gene"" id=""20622881-0-71-77"">DAB2IP</span> gene conferring susceptibility to <span class=""disease"" id=""20622881-0-112-137"">abdominal aortic aneurysm</span>.",CTD_human
2,2,Biomarker,C0018203,Chronic granulomatous disease,group,chronic granulomatous disease,1536,CYBB,CYBB,CTD_human,11122248,Point mutations in the promoter region of the CYBB gene leading to mild chronic granulomatous disease.,0.45144583347621703,"Point mutations in the promoter region of the <span class=""gene"" id=""11122248-0-46-50"">CYBB</span> gene leading to mild <span class=""disease"" id=""11122248-0-72-101"">chronic granulomatous disease</span>.",CTD_human;ORPHANET
2,2,Biomarker,C0018203,Chronic granulomatous disease,group,CGD,1536,CYBB,gp91-phox,CTD_human,11498749,"He had had repeated serious infections from early childhood and was diagnosed as CGD, gp91-phox deficiency.",0.45144583347621703,"He had had repeated serious infections from early childhood and was diagnosed as <span class=""disease"" id=""11498749-3-81-84"">CGD</span>, <span class=""gene"" id=""11498749-3-86-95"">gp91-phox</span> deficiency.",CTD_human;ORPHANET
1,0,Biomarker,C0751955,Brain Infarction,disease,brain infarction,1536,CYBB,gp91(phox,CTD_human,19417757,"At 24 h of reperfusion, the gp91(phox)-/- and apocynin-treated mice showed 50% less brain infarction and 70% less cleaved spectrin compared with WT mice.",0.2,"At 24 h of reperfusion, the <span class=""gene"" id=""19417757-6-28-37"">gp91(phox</span>)-/- and apocynin-treated mice showed 50% less <span class=""disease"" id=""19417757-6-84-100"">brain infarction</span> and 70% less cleaved spectrin compared with WT mice.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,154,ADRB2,ADRB2,CTD_human,17199132,"In conclusion, the Glu27 allele of the ADRB2 gene may confer increased risk of autism and shows increased strength with exposure to pregnancy related stress.",0.207821696295603,"In conclusion, the Glu27 allele of the <span class=""gene"" id=""17199132-10-39-44"">ADRB2</span> gene may confer increased risk of <span class=""disease"" id=""17199132-10-79-85"">autism</span> and shows increased strength with exposure to pregnancy related stress.",CTD_human
1,0,Biomarker,C0023860,Listeriosis,disease,listeriosis,1540,CYLD,CYLD,CTD_human,23825949,CYLD enhances severe listeriosis by impairing IL-6/STAT3-dependent fibrin production.,0.2,"<span class=""gene"" id=""23825949-0-0-4"">CYLD</span> enhances severe <span class=""disease"" id=""23825949-0-21-32"">listeriosis</span> by impairing IL-6/STAT3-dependent fibrin production.",CTD_human
1,0,Biomarker,C1305968,Eccrine dermal cylindroma,disease,FC,1540,CYLD,CYLD,CTD_human,18234730,"25 families including 13 BSS, 3 FC, and 9 MFT families were examined and evaluated for mutations in the CYLD gene.",0.20521980890004898,"25 families including 13 BSS, 3 <span class=""disease"" id=""18234730-6-32-34"">FC</span>, and 9 MFT families were examined and evaluated for mutations in the <span class=""gene"" id=""18234730-6-104-108"">CYLD</span> gene.",CTD_human
1,0,Biomarker,C0018552,Hamartoma,disease,Hamartomas,1543,CYP1A1,cytochrome P450 1A1,CTD_human,21998131,"Hamartomas created a new compartment that concentrated TCDD up to 10-fold compared with serum and strongly expressed the TCDD-metabolizing enzyme cytochrome P450 1A1, thus representing a potentially significant source of enzymatic activity, which may add to the xenobiotic metabolism potential of the classical organs such as the liver.",0.200274726784213,"<span class=""disease"" id=""21998131-6-0-10"">Hamartomas</span> created a new compartment that concentrated TCDD up to 10-fold compared with serum and strongly expressed the TCDD-metabolizing enzyme <span class=""gene"" id=""21998131-6-146-165"">cytochrome P450 1A1</span>, thus representing a potentially significant source of enzymatic activity, which may add to the xenobiotic metabolism potential of the classical organs such as the liver.",CTD_human
2,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,1543,CYP1A1,CYP1A1,CTD_human,20634294,"These results demonstrate that CYP1A1 is required for TCDD-induced cardiovascular superoxide anion production, endothelial dysfunction, and hypertension.",0.204604842796993,"These results demonstrate that <span class=""gene"" id=""20634294-12-31-37"">CYP1A1</span> is required for TCDD-induced cardiovascular superoxide anion production, endothelial dysfunction, and <span class=""disease"" id=""20634294-12-140-152"">hypertension</span>.",CTD_human
1,0,Biomarker,C0039239,Sinus Tachycardia,disease,sinus tachycardia,1543,CYP1A1,CYP1A1,CTD_human,26988683,"CYP1A1 mRNA expression level was significantly higher in residents with sinus tachycardia or bradycardia than in residents with normal heart rate (1.47×10(-3)(0.87×10(-3), 2.77×10(-3)) vs.1.24×10(-3)(0.64×10(-3), 2.31×10(-3)), P<0.05).",0.2,"<span class=""gene"" id=""26988683-8-0-6"">CYP1A1</span> mRNA expression level was significantly higher in residents with <span class=""disease"" id=""26988683-8-72-89"">sinus tachycardia</span> or bradycardia than in residents with normal heart rate (1.47&times;10(-3)(0.87&times;10(-3), 2.77&times;10(-3)) vs.1.24&times;10(-3)(0.64&times;10(-3), 2.31&times;10(-3)), P&lt;0.05).",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,1543,CYP1A1,CYP1A1,CTD_human,15341023,"We found that the risk of HCC was elevated in women harboring either heterozygous or homozygous variants of the CYP1A1 gene and the respective OR (and 95% confidence interval) were 6.61 (1.35, 32.43) and 12.00 (1.73, 83.46).",0.214704221278248,"We found that the risk of <span class=""disease"" id=""15341023-4-26-29"">HCC</span> was elevated in women harboring either heterozygous or homozygous variants of the <span class=""gene"" id=""15341023-4-112-118"">CYP1A1</span> gene and the respective OR (and 95% confidence interval) were 6.61 (1.35, 32.43) and 12.00 (1.73, 83.46).",CTD_human
1,0,Biomarker,C0007137,Squamous cell carcinoma,disease,SCC,1544,CYP1A2,CYP1A2,CTD_human,22072123,"Our data also revealed that smokers or tobacco chewers carrying variant alleles of either CYP1A2*1D or CYP1A2*1F were at increased risk to SCC of lung, further demonstrating that CYP1A2 genotypes interact with environmental risk factors in enhancing the risk to squamous cell lung carcinoma.",0.20082418035263896,"Our data also revealed that smokers or tobacco chewers carrying variant alleles of either <span class=""gene"" id=""22072123-7-90-96"">CYP1A2</span>*1D or <span class=""gene"" id=""22072123-7-103-109"">CYP1A2</span>*1F were at increased risk to <span class=""disease"" id=""22072123-7-139-142"">SCC</span> of lung, further demonstrating that <span class=""gene"" id=""22072123-7-179-185"">CYP1A2</span> genotypes interact with environmental risk factors in enhancing the risk to squamous cell lung carcinoma.",CTD_human
1,0,Biomarker,C0024117,Chronic Obstructive Airway Disease,disease,chronic obstructive pulmonary disease,1544,CYP1A2,CYP1A2,CTD_human,20797314,The effect of CYP1A2 gene polymorphisms on Theophylline metabolism and chronic obstructive pulmonary disease in Turkish patients.,0.212910480126392,"The effect of <span class=""gene"" id=""20797314-0-14-20"">CYP1A2</span> gene polymorphisms on Theophylline metabolism and <span class=""disease"" id=""20797314-0-71-108"">chronic obstructive pulmonary disease</span> in Turkish patients.",CTD_human
1,0,Biomarker,C0025637,Methemoglobinemia,disease,methemoglobinemia,1544,CYP1A2,Cyp1a2,CTD_human,12030840,Decrease in 4-aminobiphenyl-induced methemoglobinemia in Cyp1a2(-/-) knockout mice.,0.2,"Decrease in 4-aminobiphenyl-induced <span class=""disease"" id=""12030840-0-36-53"">methemoglobinemia</span> in <span class=""gene"" id=""12030840-0-57-63"">Cyp1a2</span>(-/-) knockout mice.",CTD_human
1,0,Biomarker,C0027794,Neural Tube Defects,group,NTD,1544,CYP1A2,CYP1A2,CTD_human,20641098,The association identified between maternal CYP1A2*1F fast oxidation status and NTDs should be examined further in the context of the other substrates of CYP1A2.,0.200274726784213,"The association identified between maternal <span class=""gene"" id=""20641098-10-44-50"">CYP1A2</span>*1F fast oxidation status and <span class=""disease"" id=""20641098-10-80-83"">NTD</span>s should be examined further in the context of the other substrates of <span class=""gene"" id=""20641098-10-154-160"">CYP1A2</span>.",CTD_human
1,0,Biomarker,C0162566,Porphyria Cutanea Tarda,disease,porphyria cutanea tarda,1544,CYP1A2,CYP1A2,CTD_human,11153915,Association between CYP1A2 polymorphism and susceptibility to porphyria cutanea tarda.,0.20919533021666797,"Association between <span class=""gene"" id=""11153915-0-20-26"">CYP1A2</span> polymorphism and susceptibility to <span class=""disease"" id=""11153915-0-62-85"">porphyria cutanea tarda</span>.",CTD_human
1,0,Biomarker,C0007137,Squamous cell carcinoma,disease,squamous cell carcinoma,1545,CYP1B1,CYP1B1,CTD_human,22114726,Expression profiling of CYP1B1 in oral squamous cell carcinoma: counterintuitive downregulation in tumors.,0.21340877653750603,"Expression profiling of <span class=""gene"" id=""22114726-0-24-30"">CYP1B1</span> in oral <span class=""disease"" id=""22114726-0-39-62"">squamous cell carcinoma</span>: counterintuitive downregulation in tumors.",CTD_human
1,0,Biomarker,C0025202,melanoma,disease,melanoma,1545,CYP1B1,CYP1B1,CTD_human,17145863,"Three of the genes, QPCT, CYP1B1, and LXN, are densely methylated in >95% of uncultured melanoma tumor samples.",0.2,"Three of the genes, QPCT, <span class=""gene"" id=""17145863-5-26-32"">CYP1B1</span>, and LXN, are densely methylated in &gt;95% of uncultured <span class=""disease"" id=""17145863-5-88-96"">melanoma</span> tumor samples.",CTD_human
1,0,Biomarker,C0009404,Colorectal Neoplasms,group,colorectal tumors,1548,CYP2A6,CYP2A6,CTD_human,17683511,Overexpression of CYP2A6 in human colorectal tumors.,0.205740551713841,"Overexpression of <span class=""gene"" id=""17683511-0-18-24"">CYP2A6</span> in human <span class=""disease"" id=""17683511-0-34-51"">colorectal tumors</span>.",CTD_human
1,0,Biomarker,C0019163,Hepatitis B,disease,hepatitis B,1548,CYP2A6,CYP2A6,CTD_human,8864187,"In sections of liver infected with hepatitis B virus (HBV) or hepatitis C virus (HCV), the expression of CYP2A6 was markedly increased in hepatocytes immediately adjacent to areas of fibrosis and inflammation.",0.2,"In sections of liver infected with <span class=""disease"" id=""8864187-4-35-46"">hepatitis B</span> virus (HBV) or hepatitis C virus (HCV), the expression of <span class=""gene"" id=""8864187-4-105-111"">CYP2A6</span> was markedly increased in hepatocytes immediately adjacent to areas of fibrosis and inflammation.",CTD_human
1,0,Biomarker,C0019196,Hepatitis C,disease,hepatitis C,1548,CYP2A6,CYP2A6,CTD_human,8864187,"In sections of liver infected with hepatitis B virus (HBV) or hepatitis C virus (HCV), the expression of CYP2A6 was markedly increased in hepatocytes immediately adjacent to areas of fibrosis and inflammation.",0.200274726784213,"In sections of liver infected with hepatitis B virus (HBV) or <span class=""disease"" id=""8864187-4-62-73"">hepatitis C</span> virus (HCV), the expression of <span class=""gene"" id=""8864187-4-105-111"">CYP2A6</span> was markedly increased in hepatocytes immediately adjacent to areas of fibrosis and inflammation.",CTD_human
1,0,Biomarker,C0034067,Pulmonary Emphysema,disease,pulmonary emphysema,1548,CYP2A6,CYP2A6,CTD_human,12832682,Association of CYP2A6 deletion polymorphism with smoking habit and development of pulmonary emphysema.,0.200274726784213,"Association of <span class=""gene"" id=""12832682-0-15-21"">CYP2A6</span> deletion polymorphism with smoking habit and development of <span class=""disease"" id=""12832682-0-82-101"">pulmonary emphysema</span>.",CTD_human
1,0,Biomarker,C0279626,Squamous cell carcinoma of esophagus,disease,esophageal squamous-cell carcinoma,1548,CYP2A6,CYP2A6,CTD_human,11241319,The allele frequency of the CYP2A6*4 deletion was 8.6% among controls compared with 8.4% among cases with esophageal squamous-cell carcinoma (p = 0.29) or 13.2% among cases with lung cancer (p < 0.01).,0.20054945356842604,"The allele frequency of the <span class=""gene"" id=""11241319-5-28-34"">CYP2A6</span>*4 deletion was 8.6% among controls compared with 8.4% among cases with <span class=""disease"" id=""11241319-5-106-140"">esophageal squamous-cell carcinoma</span> (p = 0.29) or 13.2% among cases with lung cancer (p &lt; 0.01).",CTD_human
2,0,Biomarker,C0018801,Heart failure,disease,Heart Failure,155,ADRB3,beta(3)-adrenoceptor,CTD_human,17440824,The level of beta(3)-adrenoceptor expression in the study groups was significantly higher than the Sham group (P < 0.01). beta(3)-adrenoceptor expression in the Carvedilol group was lower than the Heart Failure Control and Metoprolol groups (P < 0.01).,0.202681755307501,"The level of <span class=""gene"" id=""17440824-7-13-33"">beta(3)-adrenoceptor</span> expression in the study groups was significantly higher than the Sham group (P &lt; 0.01). <span class=""gene"" id=""17440824-7-122-142"">beta(3)-adrenoceptor</span> expression in the Carvedilol group was lower than the <span class=""disease"" id=""17440824-7-197-210"">Heart Failure</span> Control and Metoprolol groups (P &lt; 0.01).",CTD_human
2,0,Biomarker,C0018801,Heart failure,disease,HF,155,ADRB3,beta(3)-AR,CTD_human,15009959,"If the levels of beta(3)-AR were too high, they might contribute to the loss of cardiac function and be the foundation of the functional degradation of HF.",0.202681755307501,"If the levels of <span class=""gene"" id=""15009959-15-17-27"">beta(3)-AR</span> were too high, they might contribute to the loss of cardiac function and be the foundation of the functional degradation of <span class=""disease"" id=""15009959-15-152-154"">HF</span>.",CTD_human
1,0,Biomarker,C0152013,Adenocarcinoma of lung (disorder),disease,of lung adenocarcinoma,1553,CYP2A13,CYP2A13,CTD_human,18669584,"Characterization of CYP2A13*2, a variant cytochrome P450 allele previously found to be associated with decreased incidences of lung adenocarcinoma in smokers.",0.20082418035263896,"Characterization of <span class=""gene"" id=""18669584-0-20-27"">CYP2A13</span>*2, a variant cytochrome P450 allele previously found to be associated with decreased incidences <span class=""disease"" id=""18669584-0-124-146"">of lung adenocarcinoma</span> in smokers.",CTD_human
1,0,Biomarker,C0022661,"Kidney Failure, Chronic",disease,ESRD,1555,CYP2B6,CYP2B6,CTD_human,15248218,"In a survival analysis, patients homozygous for CYP2B6*5 (n = 3) or CYP2C19*2 (n = 4) had a higher probability of reaching ESRD (P = 0.0005) and of doubling the creatinine level (P = 0.0005) as well as a trend toward a lower probability of achieving a complete renal response (P = 0.051).",0.203231208875927,"In a survival analysis, patients homozygous for <span class=""gene"" id=""15248218-9-48-54"">CYP2B6</span>*5 (n = 3) or CYP2C19*2 (n = 4) had a higher probability of reaching <span class=""disease"" id=""15248218-9-123-127"">ESRD</span> (P = 0.0005) and of doubling the creatinine level (P = 0.0005) as well as a trend toward a lower probability of achieving a complete renal response (P = 0.051).",CTD_human
1,0,Biomarker,C0022661,"Kidney Failure, Chronic",disease,ESRD,1557,CYP2C19,CYP2C19,CTD_human,15248218,"In a survival analysis, patients homozygous for CYP2B6*5 (n = 3) or CYP2C19*2 (n = 4) had a higher probability of reaching ESRD (P = 0.0005) and of doubling the creatinine level (P = 0.0005) as well as a trend toward a lower probability of achieving a complete renal response (P = 0.051).",0.200274726784213,"In a survival analysis, patients homozygous for CYP2B6*5 (n = 3) or <span class=""gene"" id=""15248218-9-68-75"">CYP2C19</span>*2 (n = 4) had a higher probability of reaching <span class=""disease"" id=""15248218-9-123-127"">ESRD</span> (P = 0.0005) and of doubling the creatinine level (P = 0.0005) as well as a trend toward a lower probability of achieving a complete renal response (P = 0.051).",CTD_human
1,0,Biomarker,C0085215,"Ovarian Failure, Premature",disease,premature ovarian failure,1557,CYP2C19,CYP2C19,CTD_human,15248218,"Patients who were either heterozygous or homozygous for CYP2C19*2 had a significantly lower risk of developing premature ovarian failure (relative risk 0.10; 95% confidence interval 0.02-0.52), after adjustment for age and total number of cyclophosphamide pulses received.",0.202681755307501,"Patients who were either heterozygous or homozygous for <span class=""gene"" id=""15248218-8-56-63"">CYP2C19</span>*2 had a significantly lower risk of developing <span class=""disease"" id=""15248218-8-111-136"">premature ovarian failure</span> (relative risk 0.10; 95% confidence interval 0.02-0.52), after adjustment for age and total number of cyclophosphamide pulses received.",CTD_human
1,0,Biomarker,C0022658,Kidney Diseases,group,kidney disease,1558,CYP2C8,CYP2C8,CTD_human,18769365,The risk of kidney disease post-transplantation was positively associated with CYP2C8*3 genotype.,0.200274726784213,"The risk of <span class=""disease"" id=""18769365-6-12-26"">kidney disease</span> post-transplantation was positively associated with <span class=""gene"" id=""18769365-6-79-85"">CYP2C8</span>*3 genotype.",CTD_human
1,0,Biomarker,C0006118,Brain Neoplasms,group,brain tumors,1559,CYP2C9,CYP2C9,CTD_human,16475710,"The present study investigated CYP2C9 in regard to its allelic variants in 23 tumor samples (10 breast tumors, 1 breast tumor cell line, 5 brain tumors, 7 glioma cell lines) with restriction fragment length polymorphism polymerase chain reaction (RFLP-PCR).",0.200274726784213,"The present study investigated <span class=""gene"" id=""16475710-2-31-37"">CYP2C9</span> in regard to its allelic variants in 23 tumor samples (10 breast tumors, 1 breast tumor cell line, 5 <span class=""disease"" id=""16475710-2-139-151"">brain tumors</span>, 7 glioma cell lines) with restriction fragment length polymorphism polymerase chain reaction (RFLP-PCR).",CTD_human
1,0,Biomarker,C0003873,Rheumatoid Arthritis,disease,RA,156,GRK2,GRK-2,CTD_human,10094932,"Since proinflammatory cytokines are abundantly expressed in RA, it may provide an explanation for the decrease in GRK-2 expression and activity in patients.",0.200274726784213,"Since proinflammatory cytokines are abundantly expressed in <span class=""disease"" id=""10094932-7-60-62"">RA</span>, it may provide an explanation for the decrease in <span class=""gene"" id=""10094932-7-114-119"">GRK-2</span> expression and activity in patients.",CTD_human
1,0,Biomarker,C0007222,Cardiovascular Diseases,group,cardiovascular disease,156,GRK2,GRK2,CTD_human,26032411,The two most widely expressed GRKs (GRK2 and GRK5) play a role in cardiovascular disease and thus represent important targets for the development of novel therapeutic drugs.,0.2,"The two most widely expressed GRKs (<span class=""gene"" id=""26032411-2-36-40"">GRK2</span> and GRK5) play a role in <span class=""disease"" id=""26032411-2-66-88"">cardiovascular disease</span> and thus represent important targets for the development of novel therapeutic drugs.",CTD_human
1,0,Biomarker,C0018801,Heart failure,disease,heart failure,156,GRK2,GRK2,CTD_human,26670611,"Conversely, the dual-specific GRK2 and ERK cascade inhibitor, RKIP (Raf kinase inhibitor protein), triggered dysfunctional cardiomyocyte energetics and the expression of heart failure-promoting Pparg-regulated genes.",0.208176290991763,"Conversely, the dual-specific <span class=""gene"" id=""26670611-8-30-34"">GRK2</span> and ERK cascade inhibitor, RKIP (Raf kinase inhibitor protein), triggered dysfunctional cardiomyocyte energetics and the expression of <span class=""disease"" id=""26670611-8-170-183"">heart failure</span>-promoting Pparg-regulated genes.",CTD_human
1,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,156,GRK2,GRK2,CTD_human,11901213,"Moreover, they suggest that GRK2 plays an important role in vascular control and may represent a novel therapeutic target for hypertension.",0.20082418035263896,"Moreover, they suggest that <span class=""gene"" id=""11901213-9-28-32"">GRK2</span> plays an important role in vascular control and may represent a novel therapeutic target for <span class=""disease"" id=""11901213-9-126-138"">hypertension</span>.",CTD_human
1,0,Therapeutic,C0878544,Cardiomyopathies,group,cardiomyopathy,156,GRK2,GRK2,CTD_human,17008600,"In the adult heart, cardiac GRK2 is a major factor regulating inotropic and lusitropic tachyphylaxis to beta-adrenergic agonist, which likely contributes to its protective effects in catecholamine cardiomyopathy.",0.2,"In the adult heart, cardiac <span class=""gene"" id=""17008600-10-28-32"">GRK2</span> is a major factor regulating inotropic and lusitropic tachyphylaxis to beta-adrenergic agonist, which likely contributes to its protective effects in catecholamine <span class=""disease"" id=""17008600-10-197-211"">cardiomyopathy</span>.",CTD_human
2,0,Biomarker,C0030567,Parkinson Disease,disease,Parkinson's disease,1565,CYP2D6,CYP2D6,CTD_human,15174030,Further evidence that interactions between CYP2D6 and pesticide exposure increase risk for Parkinson's disease.,0.254721336641181,"Further evidence that interactions between <span class=""gene"" id=""15174030-0-43-49"">CYP2D6</span> and pesticide exposure increase risk for <span class=""disease"" id=""15174030-0-91-110"">Parkinson's disease</span>.",CTD_human
2,0,Biomarker,C0030567,Parkinson Disease,disease,Parkinson's disease,1565,CYP2D6,CYP2D6,CTD_human,14991823,"CYP2D6 polymorphism, pesticide exposure, and Parkinson's disease.",0.254721336641181,"<span class=""gene"" id=""14991823-0-0-6"">CYP2D6</span> polymorphism, pesticide exposure, and <span class=""disease"" id=""14991823-0-45-64"">Parkinson's disease</span>.",CTD_human
1,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,NSCLC,1571,CYP2E1,CYP2E1,CTD_human,16142352,A tandem repeat polymorphism in the 5'-flanking region of the CYP2E1 gene was investigated in non-small cell lung carcinoma (NSCLC) patients to clarify the relationship between CYP2E1 gene polymorphism and lung cancer susceptibility.,0.201923087489492,"A tandem repeat polymorphism in the 5'-flanking region of the <span class=""gene"" id=""16142352-2-62-68"">CYP2E1</span> gene was investigated in <span class=""disease"" id=""16142352-2-94-123"">non-small cell lung carcinoma</span> (<span class=""disease"" id=""16142352-2-125-130"">NSCLC</span>) patients to clarify the relationship between <span class=""gene"" id=""16142352-2-177-183"">CYP2E1</span> gene polymorphism and lung cancer susceptibility.",CTD_human
1,0,Biomarker,C0023891,"Liver Cirrhosis, Alcoholic",disease,alcoholic liver cirrhosis,1571,CYP2E1,cytochrome P450 2E1,CTD_human,20843640,Induction of blood lymphocyte cytochrome P450 2E1 in early stage alcoholic liver cirrhosis.,0.22391222814060896,"Induction of blood lymphocyte <span class=""gene"" id=""20843640-0-30-49"">cytochrome P450 2E1</span> in early stage <span class=""disease"" id=""20843640-0-65-90"">alcoholic liver cirrhosis</span>.",CTD_human
1,0,Biomarker,C0028754,Obesity,disease,Obese,1571,CYP2E1,Cyp2e1,CTD_human,23954404,"Obese mouse ovaries had decreased Irs1, Foxo3a, Cyp2e1, MiR-103, and MiR-21 but increased Kitlg, Akt1, and miR-184 levels relative to lean littermates.",0.205154296365419,"<span class=""disease"" id=""23954404-4-0-5"">Obese</span> mouse ovaries had decreased Irs1, Foxo3a, <span class=""gene"" id=""23954404-4-48-54"">Cyp2e1</span>, MiR-103, and MiR-21 but increased Kitlg, Akt1, and miR-184 levels relative to lean littermates.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,1571,CYP2E1,CYP2E1,CTD_human,15162526,"CYP2E1 expression descended along with the initiation and progression of HCC, which is noteworthy further investigations in its significance in the development of HCC.",0.22634338179819896,"<span class=""gene"" id=""15162526-11-0-6"">CYP2E1</span> expression descended along with the initiation and progression of <span class=""disease"" id=""15162526-11-73-76"">HCC</span>, which is noteworthy further investigations in its significance in the development of <span class=""disease"" id=""15162526-11-163-166"">HCC</span>.",CTD_human
4,28,Biomarker,C0392475,Roberts-SC phocomelia syndrome,disease,Roberts syndrome,157570,ESCO2,ESCO2,CTD_human,18186147,Prenatal diagnosis of Roberts syndrome and detection of an ESCO2 frameshift mutation in a Pakistani family.,0.6046703553316229,"Prenatal diagnosis of <span class=""disease"" id=""18186147-0-22-38"">Roberts syndrome</span> and detection of an <span class=""gene"" id=""18186147-0-59-64"">ESCO2</span> frameshift mutation in a Pakistani family.",CTD_human;ORPHANET;UNIPROT
4,28,Biomarker,C0392475,Roberts-SC phocomelia syndrome,disease,Roberts syndrome,157570,ESCO2,ESCO2,CTD_human,16380922,Inactivating mutations in ESCO2 cause SC phocomelia and Roberts syndrome: no phenotype-genotype correlation.,0.6046703553316229,"Inactivating mutations in <span class=""gene"" id=""16380922-0-26-31"">ESCO2</span> cause SC phocomelia and <span class=""disease"" id=""16380922-0-56-72"">Roberts syndrome</span>: no phenotype-genotype correlation.",CTD_human;ORPHANET;UNIPROT
6,184,Biomarker,C0265223,Cohen syndrome,disease,Cohen syndrome,157680,VPS13B,COH1,CTD_human,15154116,Allelic heterogeneity in the COH1 gene explains clinical variability in Cohen syndrome.,0.6065934428211139,"Allelic heterogeneity in the <span class=""gene"" id=""15154116-0-29-33"">COH1</span> gene explains clinical variability in <span class=""disease"" id=""15154116-0-72-86"">Cohen syndrome</span>.",CTD_human;ORPHANET;UNIPROT
6,184,Biomarker,C0265223,Cohen syndrome,disease,Cohen syndrome,157680,VPS13B,COH1,CTD_human,12730828,"Cohen syndrome is caused by mutations in a novel gene, COH1, encoding a transmembrane protein with a presumed role in vesicle-mediated sorting and intracellular protein transport.",0.6065934428211139,"<span class=""disease"" id=""12730828-0-0-14"">Cohen syndrome</span> is caused by mutations in a novel gene, <span class=""gene"" id=""12730828-0-55-59"">COH1</span>, encoding a transmembrane protein with a presumed role in vesicle-mediated sorting and intracellular protein transport.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,158,ADSL,ASL,CTD_human,15471876,"An Australian patient with autism was found to be heterozygous for two mutations in the gene encoding adenylosuccinate lyase (ASL), resulting in the protein mutations E80D and D87E.",0.4010989071368521,"An Australian patient with <span class=""disease"" id=""15471876-1-27-33"">autism</span> was found to be heterozygous for two mutations in the gene encoding <span class=""gene"" id=""15471876-1-102-124"">adenylosuccinate lyase</span> (<span class=""gene"" id=""15471876-1-126-129"">ASL</span>), resulting in the protein mutations E80D and D87E.",CTD_human;HPO
8,20,Biomarker,C0268126,Adenylosuccinate lyase deficiency (disorder),disease,ADSL deficiency,158,ADSL,ADSL,CTD_human,10888601,"Human adenylosuccinate lyase (ADSL), cloning and characterization of full-length cDNA and its isoform, gene structure and molecular basis for ADSL deficiency in six patients.",0.6019230874894921,"Human <span class=""gene"" id=""10888601-0-6-28"">adenylosuccinate lyase</span> (<span class=""gene"" id=""10888601-0-30-34"">ADSL</span>), cloning and characterization of full-length cDNA and its isoform, gene structure and molecular basis for <span class=""disease"" id=""10888601-0-142-157"">ADSL deficiency</span> in six patients.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0005695,Bladder Neoplasm,disease,bladder cancer,1580,CYP4B1,CYP4B1,CTD_human,18713828,Possible relationship between the risk of Japanese bladder cancer cases and the CYP4B1 genotype.,0.20328236603324,"Possible relationship between the risk of Japanese <span class=""disease"" id=""18713828-0-51-65"">bladder cancer</span> cases and the <span class=""gene"" id=""18713828-0-80-86"">CYP4B1</span> genotype.",CTD_human
2,0,Biomarker,C0008370,Cholestasis,disease,cholestasis,1581,CYP7A1,Cyp 7,CTD_human,9797378,Cyp 7-/- mice lack a functional cholesterol 7alpha-hydroxylase enzyme and develop cholestasis before up-regulation of 27-hydroxycholesterol 7alpha-hydroxylase activity.,0.40082418035263895,"<span class=""gene"" id=""9797378-1-0-5"">Cyp 7</span>-/- mice lack a functional cholesterol 7alpha-hydroxylase enzyme and develop <span class=""disease"" id=""9797378-1-82-93"">cholestasis</span> before up-regulation of 27-hydroxycholesterol 7alpha-hydroxylase activity.",CTD_human;HPO
1,0,Therapeutic,C0020443,Hypercholesterolemia,disease,hypercholesterolemia,1581,CYP7A1,cholesterol 7 alpha-hydroxylase,CTD_human,8245718,Bile acid excretion and cholesterol 7 alpha-hydroxylase expression in hypercholesterolemia-resistant rabbits.,0.40777053913829,"Bile acid excretion and <span class=""gene"" id=""8245718-0-24-55"">cholesterol 7 alpha-hydroxylase</span> expression in <span class=""disease"" id=""8245718-0-70-90"">hypercholesterolemia</span>-resistant rabbits.",CTD_human;HPO
1,0,Biomarker,C0001623,Adrenal gland hypofunction,phenotype,adrenal insufficiency,1583,CYP11A1,p450scc,CTD_human,11502818,"Heterozygous mutation in the cholesterol side chain cleavage enzyme (p450scc) gene in a patient with 46,XY sex reversal and adrenal insufficiency.",0.401923087489492,"Heterozygous mutation in the cholesterol side chain cleavage enzyme (<span class=""gene"" id=""11502818-0-69-76"">p450scc</span>) gene in a patient with 46,XY sex reversal and <span class=""disease"" id=""11502818-0-124-145"">adrenal insufficiency</span>.",CTD_human;HPO
1,0,Therapeutic,C0036572,Seizures,phenotype,seizures,1583,CYP11A1,P450scc,CTD_human,19125849,"Conversely, inhibition of neurosteroid synthesis accelerated the onset of spontaneous seizures, but only in animals exhibiting significant increases in P450scc.",0.2,"Conversely, inhibition of neurosteroid synthesis accelerated the onset of spontaneous <span class=""disease"" id=""19125849-11-86-94"">seizures</span>, but only in animals exhibiting significant increases in <span class=""gene"" id=""19125849-11-152-159"">P450scc</span>.",CTD_human
1,0,Biomarker,C0235833,Congenital diaphragmatic hernia,disease,congenital diaphragmatic hernia,158326,FREM1,FREM1,CTD_human,23221805,Deficiency of FRAS1-related extracellular matrix 1 (FREM1) causes congenital diaphragmatic hernia in humans and mice.,0.36027472678421296,"Deficiency of <span class=""gene"" id=""23221805-0-14-50"">FRAS1-related extracellular matrix 1</span> (<span class=""gene"" id=""23221805-0-52-57"">FREM1</span>) causes <span class=""disease"" id=""23221805-0-66-97"">congenital diaphragmatic hernia</span> in humans and mice.",CTD_human
1,0,Biomarker,C1609433,Congenital absence of kidneys syndrome,disease,renal agenesis,158326,FREM1,Frem1,CTD_human,23221805,"Frem1(eyes2) mice have eye defects, renal agenesis and develop retrosternal diaphragmatic hernias which are covered by a membranous sac.",0.200274726784213,"<span class=""gene"" id=""23221805-7-0-5"">Frem1</span>(eyes2) mice have eye defects, <span class=""disease"" id=""23221805-7-36-50"">renal agenesis</span> and develop retrosternal diaphragmatic hernias which are covered by a membranous sac.",CTD_human
2,2,Biomarker,C1855425,Marles Greenberg Persaud syndrome,disease,MOTA,158326,FREM1,FREM1,CTD_human,23221805,"Recessive mutations in the FRAS1-related extracellular matrix 1 (FREM1) gene have been shown to cause bifid nose with or without anorectal and renal anomalies (BNAR) syndrome and Manitoba oculotrichoanal (MOTA) syndrome, but have not been previously implicated in the development of CDH.",0.6813736339210661,"Recessive mutations in the <span class=""gene"" id=""23221805-2-27-63"">FRAS1-related extracellular matrix 1</span> (<span class=""gene"" id=""23221805-2-65-70"">FREM1</span>) gene have been shown to cause bifid nose with or without anorectal and renal anomalies (BNAR) syndrome and Manitoba oculotrichoanal (<span class=""disease"" id=""23221805-2-205-209"">MOTA</span>) syndrome, but have not been previously implicated in the development of CDH.",CTD_human;ORPHANET;UNIPROT
2,2,Biomarker,C2750433,Bifid Nose With Or Without Anorectal And Renal Anomalies,disease,BNAR,158326,FREM1,FREM1,CTD_human,23221805,"Recessive mutations in the FRAS1-related extracellular matrix 1 (FREM1) gene have been shown to cause bifid nose with or without anorectal and renal anomalies (BNAR) syndrome and Manitoba oculotrichoanal (MOTA) syndrome, but have not been previously implicated in the development of CDH.",0.6008241803526391,"Recessive mutations in the <span class=""gene"" id=""23221805-2-27-63"">FRAS1-related extracellular matrix 1</span> (<span class=""gene"" id=""23221805-2-65-70"">FREM1</span>) gene have been shown to cause <span class=""disease"" id=""23221805-2-102-158"">bifid nose with or without anorectal and renal anomalies</span> (<span class=""disease"" id=""23221805-2-160-164"">BNAR</span>) syndrome and Manitoba oculotrichoanal (MOTA) syndrome, but have not been previously implicated in the development of CDH.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0020595,Hypoaldosteronism,disease,hypoaldosteronism,1585,CYP11B2,aldosterone synthase,CTD_human,11238478,"We conclude that aldosterone synthase deficiency represents an unusual cause of hyperreninemic hypoaldosteronism presenting in adult life, but it should be suspected if the past medical history is positive for failure to thrive in childhood or if the patient manifests no other recognized causes of hyperreninemic hypoaldosteronism.",0.40274726784213105,"We conclude that <span class=""gene"" id=""11238478-8-17-37"">aldosterone synthase</span> deficiency represents an unusual cause of hyperreninemic <span class=""disease"" id=""11238478-8-95-112"">hypoaldosteronism</span> presenting in adult life, but it should be suspected if the past medical history is positive for failure to thrive in childhood or if the patient manifests no other recognized causes of hyperreninemic <span class=""disease"" id=""11238478-8-314-331"">hypoaldosteronism</span>.",CTD_human;HPO
1,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,1586,CYP17A1,CYP17,CTD_human,15341023,"In this molecular epidemiological study, we used logistic regression to compare the genotype frequencies of estrogen-metabolizing genes that are involved in estrogen biogenesis (CYP17), hydroxylation (CYP1A1) and inactivation of the reactive metabolites (catechol-O-methyltransferase, COMT) in HCC patients and control subjects, and determined their relationship with the risk of female HCC.",0.201098907136852,"In this molecular epidemiological study, we used logistic regression to compare the genotype frequencies of estrogen-metabolizing genes that are involved in estrogen biogenesis (<span class=""gene"" id=""15341023-2-178-183"">CYP17</span>), hydroxylation (CYP1A1) and inactivation of the reactive metabolites (catechol-O-methyltransferase, COMT) in <span class=""disease"" id=""15341023-2-294-297"">HCC</span> patients and control subjects, and determined their relationship with the risk of female <span class=""disease"" id=""15341023-2-387-390"">HCC</span>.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autistic,1588,CYP19A1,aromatase,CTD_human,21359227,"We further show that aromatase protein is significantly reduced in the frontal cortex of autistic subjects relative to sex- and age-matched controls, and is strongly correlated with RORA protein levels in the brain.",0.202681755307501,"We further show that <span class=""gene"" id=""21359227-4-21-30"">aromatase</span> protein is significantly reduced in the frontal cortex of <span class=""disease"" id=""21359227-4-89-97"">autistic</span> subjects relative to sex- and age-matched controls, and is strongly correlated with RORA protein levels in the brain.",CTD_human
2,0,Biomarker,C0014175,Endometriosis,disease,endometriosis,1588,CYP19A1,CYP19A1,CTD_human,21958689,"In summary, we report increased endometriosis risk with CYP19A1 gene-based tests; replication of the association between endometriosis and this gene or gene region is necessary in a larger study population.",0.32214024586134304,"In summary, we report increased <span class=""disease"" id=""21958689-9-32-45"">endometriosis</span> risk with <span class=""gene"" id=""21958689-9-56-63"">CYP19A1</span> gene-based tests; replication of the association between <span class=""disease"" id=""21958689-9-121-134"">endometriosis</span> and this gene or gene region is necessary in a larger study population.",CTD_human
1,0,Biomarker,C0029456,Osteoporosis,disease,osteoporosis,1588,CYP19A1,CYP19,CTD_human,20723554,"Dysfunction of the enzyme aromatase (CYP19) is associated with endocrine pathologies such as osteoporosis, impaired fertility and development of hormone-dependent cancers.",0.41007066772662,"Dysfunction of the enzyme aromatase (<span class=""gene"" id=""20723554-1-37-42"">CYP19</span>) is associated with endocrine pathologies such as <span class=""disease"" id=""20723554-1-93-105"">osteoporosis</span>, impaired fertility and development of hormone-dependent cancers.",CTD_human;HPO
4,0,Biomarker,C0032460,Polycystic Ovary Syndrome,disease,polycystic ovaries,1588,CYP19A1,CYP19,CTD_human,8265607,"We identified two mutations in the CYP19 gene responsible for aromatase deficiency in an 18-year-old 46,XX female with ambiguous external genitalia at birth, primary amenorrhea and sexual infantilism, and polycystic ovaries.",0.309117681663341,"We identified two mutations in the <span class=""gene"" id=""8265607-1-35-40"">CYP19</span> gene responsible for aromatase deficiency in an 18-year-old 46,XX female with ambiguous external genitalia at birth, primary amenorrhea and sexual infantilism, and <span class=""disease"" id=""8265607-1-205-223"">polycystic ovaries</span>.",CTD_human
1,0,Biomarker,C0242341,Sexual Infantilism,disease,sexual infantilism,1588,CYP19A1,CYP19,CTD_human,8265607,"We identified two mutations in the CYP19 gene responsible for aromatase deficiency in an 18-year-old 46,XX female with ambiguous external genitalia at birth, primary amenorrhea and sexual infantilism, and polycystic ovaries.",0.2,"We identified two mutations in the <span class=""gene"" id=""8265607-1-35-40"">CYP19</span> gene responsible for aromatase deficiency in an 18-year-old 46,XX female with ambiguous external genitalia at birth, primary amenorrhea and <span class=""disease"" id=""8265607-1-181-199"">sexual infantilism</span>, and polycystic ovaries.",CTD_human
6,10,Biomarker,C1960539,Aromatase deficiency,disease,aromatase deficiency,1588,CYP19A1,CYP19,CTD_human,8265607,"We identified two mutations in the CYP19 gene responsible for aromatase deficiency in an 18-year-old 46,XX female with ambiguous external genitalia at birth, primary amenorrhea and sexual infantilism, and polycystic ovaries.",0.602472541057918,"We identified two mutations in the <span class=""gene"" id=""8265607-1-35-40"">CYP19</span> gene responsible for <span class=""disease"" id=""8265607-1-62-82"">aromatase deficiency</span> in an 18-year-old 46,XX female with ambiguous external genitalia at birth, primary amenorrhea and sexual infantilism, and polycystic ovaries.",CTD_human;ORPHANET;UNIPROT
2,0,Biomarker,C0001627,Congenital adrenal hyperplasia,disease,congenital adrenal hyperplasia,1589,CYP21A2,CYP21A2,CTD_human,18445671,Functional and structural consequences of a novel point mutation in the CYP21A2 gene causing congenital adrenal hyperplasia: potential relevance of helix C for P450 oxidoreductase-21-hydroxylase interaction.,0.367754661797702,"Functional and structural consequences of a novel point mutation in the <span class=""gene"" id=""18445671-0-72-79"">CYP21A2</span> gene causing <span class=""disease"" id=""18445671-0-93-123"">congenital adrenal hyperplasia</span>: potential relevance of helix C for P450 oxidoreductase-21-hydroxylase interaction.",CTD_human
1,0,Biomarker,C0020437,Hypercalcemia,disease,Hypercalcemia,1591,CYP24A1,CYP24A1,CTD_human,22337913,"Hypercalcemia, hypercalciuria, and elevated calcitriol concentrations with autosomal dominant transmission due to CYP24A1 mutations: effects of ketoconazole therapy.",0.20762683742333699,"<span class=""disease"" id=""22337913-0-0-13"">Hypercalcemia</span>, hypercalciuria, and elevated calcitriol concentrations with autosomal dominant transmission due to <span class=""gene"" id=""22337913-0-114-121"">CYP24A1</span> mutations: effects of ketoconazole therapy.",CTD_human
1,0,Biomarker,C0020438,Hypercalciuria,phenotype,hypercalciuria,1591,CYP24A1,CYP24A1,CTD_human,22337913,"Hypercalcemia, hypercalciuria, and elevated calcitriol concentrations with autosomal dominant transmission due to CYP24A1 mutations: effects of ketoconazole therapy.",0.40268175530750105,"Hypercalcemia, <span class=""disease"" id=""22337913-0-15-29"">hypercalciuria</span>, and elevated calcitriol concentrations with autosomal dominant transmission due to <span class=""gene"" id=""22337913-0-114-121"">CYP24A1</span> mutations: effects of ketoconazole therapy.",CTD_human;HPO
1,0,Biomarker,C0392525,Nephrolithiasis,disease,nephrolithiasis,1591,CYP24A1,Cyp24A1,CTD_human,22337913,"Mutations of the CYP24A1 gene, which encodes the 1,25-dihydroxyvitamin D-24-hydroxylase cytochrome P450, Cyp24A1, are predicted to result in elevated 1,25-dihydroxyvitamin D concentrations, hypercalcemia, hypercalciuria, nephrolithiasis, and bone disease.",0.201648360705279,"Mutations of the <span class=""gene"" id=""22337913-1-17-24"">CYP24A1</span> gene, which encodes the 1,25-dihydroxyvitamin D-24-hydroxylase cytochrome P450, <span class=""gene"" id=""22337913-1-105-112"">Cyp24A1</span>, are predicted to result in elevated 1,25-dihydroxyvitamin D concentrations, hypercalcemia, hypercalciuria, <span class=""disease"" id=""22337913-1-221-236"">nephrolithiasis</span>, and bone disease.",CTD_human
1,0,Biomarker,C0001418,Adenocarcinoma,group,adenocarcinoma,1592,CYP26A1,CYP26A1,CTD_human,18059332,A novel role for the retinoic acid-catabolizing enzyme CYP26A1 in Barrett's associated adenocarcinoma.,0.200274726784213,"A novel role for the retinoic acid-catabolizing enzyme <span class=""gene"" id=""18059332-0-55-62"">CYP26A1</span> in Barrett's associated <span class=""disease"" id=""18059332-0-87-101"">adenocarcinoma</span>.",CTD_human
1,0,Biomarker,C0009375,Colonic Neoplasms,group,colon tumor,1592,CYP26A1,CYP26A1,CTD_human,16885356,Up-regulation of CYP26A1 in adenomatous polyposis coli-deficient vertebrates via a WNT-dependent mechanism: implications for intestinal cell differentiation and colon tumor development.,0.200274726784213,"Up-regulation of <span class=""gene"" id=""16885356-0-17-24"">CYP26A1</span> in adenomatous polyposis coli-deficient vertebrates via a WNT-dependent mechanism: implications for intestinal cell differentiation and <span class=""disease"" id=""16885356-0-161-172"">colon tumor</span> development.",CTD_human
1,0,Biomarker,C0032580,Adenomatous Polyposis Coli,disease,adenomatous polyposis coli,1592,CYP26A1,CYP26A1,CTD_human,16885356,Up-regulation of CYP26A1 in adenomatous polyposis coli-deficient vertebrates via a WNT-dependent mechanism: implications for intestinal cell differentiation and colon tumor development.,0.200274726784213,"Up-regulation of <span class=""gene"" id=""16885356-0-17-24"">CYP26A1</span> in <span class=""disease"" id=""16885356-0-28-54"">adenomatous polyposis coli</span>-deficient vertebrates via a WNT-dependent mechanism: implications for intestinal cell differentiation and colon tumor development.",CTD_human
3,1,Biomarker,C0009324,Ulcerative Colitis,disease,ulcerative colitis,159296,NKX2-3,NKX2-3,CTD_human,18438406,"We also show that several risk loci are common to ulcerative colitis and Crohn's disease (IL23R, IL12B, HLA, NKX2-3 and MST1), whereas autophagy genes ATG16L1 and IRGM, along with NOD2 (also known as CARD15), are specific for Crohn's disease.",0.21565774796852302,"We also show that several risk loci are common to <span class=""disease"" id=""18438406-2-50-68"">ulcerative colitis</span> and Crohn's disease (IL23R, IL12B, HLA, <span class=""gene"" id=""18438406-2-109-115"">NKX2-3</span> and MST1), whereas autophagy genes ATG16L1 and IRGM, along with NOD2 (also known as CARD15), are specific for Crohn's disease.",CTD_human
3,1,Biomarker,C0009324,Ulcerative Colitis,disease,ulcerative colitis,159296,NKX2-3,NKX2-3,CTD_human,18438405,"Among these loci, we identified variants in 3p21.31, NKX2-3 and CCNY as susceptibility factors for both diseases, whereas variants in PTPN2, HERC2 and STAT3 were associated only with ulcerative colitis in our sample collection.",0.21565774796852302,"Among these loci, we identified variants in 3p21.31, <span class=""gene"" id=""18438405-2-53-59"">NKX2-3</span> and CCNY as susceptibility factors for both diseases, whereas variants in PTPN2, HERC2 and STAT3 were associated only with <span class=""disease"" id=""18438405-2-183-201"">ulcerative colitis</span> in our sample collection.",CTD_human
3,2,Biomarker,C0010346,Crohn Disease,disease,Crohn's disease,159296,NKX2-3,NKX2-3,CTD_human,18438406,"We also show that several risk loci are common to ulcerative colitis and Crohn's disease (IL23R, IL12B, HLA, NKX2-3 and MST1), whereas autophagy genes ATG16L1 and IRGM, along with NOD2 (also known as CARD15), are specific for Crohn's disease.",0.233331127984178,"We also show that several risk loci are common to ulcerative colitis and <span class=""disease"" id=""18438406-2-73-88"">Crohn's disease</span> (IL23R, IL12B, HLA, <span class=""gene"" id=""18438406-2-109-115"">NKX2-3</span> and MST1), whereas autophagy genes ATG16L1 and IRGM, along with NOD2 (also known as CARD15), are specific for <span class=""disease"" id=""18438406-2-226-241"">Crohn's disease</span>.",CTD_human
2,0,Biomarker,C0004153,Atherosclerosis,disease,atherosclerosis,1593,CYP27A1,sterol 27-hydroxylase,CTD_human,11166758,"Genetic heterogeneity resulting in differences in sterol 27-hydroxylase activity between individuals may affect their ability to deal with accumulated cholesterol in the arterial intima, and hence their relative degree of predisposition to atherosclerosis.",0.20383181960166602,"Genetic heterogeneity resulting in differences in <span class=""gene"" id=""11166758-12-50-71"">sterol 27-hydroxylase</span> activity between individuals may affect their ability to deal with accumulated cholesterol in the arterial intima, and hence their relative degree of predisposition to <span class=""disease"" id=""11166758-12-240-255"">atherosclerosis</span>.",CTD_human
2,0,Biomarker,C0004153,Atherosclerosis,disease,atherosclerosis,1593,CYP27A1,CYP27A1,CTD_human,19801147,"Patients with inherited ""cerebrotendinous xanthomatosis"" lack sterol 27-hydroxylase (CYP27A1) and develop severe premature atherosclerosis despite normal serum cholesterol concentrations.",0.20383181960166602,"Patients with inherited ""cerebrotendinous xanthomatosis"" lack <span class=""gene"" id=""19801147-3-62-83"">sterol 27-hydroxylase</span> (<span class=""gene"" id=""19801147-3-85-92"">CYP27A1</span>) and develop severe premature <span class=""disease"" id=""19801147-3-123-138"">atherosclerosis</span> despite normal serum cholesterol concentrations.",CTD_human
1,0,Biomarker,C0008370,Cholestasis,disease,cholestasis,1593,CYP27A1,sterol 27-hydroxylase,CTD_human,15795599,Mutation in the sterol 27-hydroxylase gene associated with fatal cholestasis in infancy.,0.200274726784213,"Mutation in the <span class=""gene"" id=""15795599-0-16-37"">sterol 27-hydroxylase</span> gene associated with fatal <span class=""disease"" id=""15795599-0-65-76"">cholestasis</span> in infancy.",CTD_human
9,52,Biomarker,C0238052,"Xanthomatosis, Cerebrotendinous",disease,cerebrotendinous xanthomatosis,1593,CYP27A1,sterol 27-hydroxylase,CTD_human,17444890,Unique patient with cerebrotendinous xanthomatosis. Evidence for presence of a defect in a gene that is not identical to sterol 27-hydroxylase.,0.6389107157170401,"Unique patient with <span class=""disease"" id=""17444890-0-20-50"">cerebrotendinous xanthomatosis</span>. Evidence for presence of a defect in a gene that is not identical to <span class=""gene"" id=""17444890-0-121-142"">sterol 27-hydroxylase</span>.",CTD_human;ORPHANET;UNIPROT
9,52,Biomarker,C0238052,"Xanthomatosis, Cerebrotendinous",disease,cerebrotendinous xanthomatosis,1593,CYP27A1,CYP27A1,CTD_human,12117727,"Normolipidemic patients with the rare disease cerebrotendinous xanthomatosis, lacking the enzyme sterol 27-hydroxylase (CYP27A1), develop prominent xanthomas in tendons and brain containing both cholestanol and cholesterol, with a cholestanol:cholesterol ratio higher than that in the circulation.",0.6389107157170401,"Normolipidemic patients with the rare disease <span class=""disease"" id=""12117727-3-46-76"">cerebrotendinous xanthomatosis</span>, lacking the enzyme <span class=""gene"" id=""12117727-3-97-118"">sterol 27-hydroxylase</span> (<span class=""gene"" id=""12117727-3-120-127"">CYP27A1</span>), develop prominent xanthomas in tendons and brain containing both cholestanol and cholesterol, with a cholestanol:cholesterol ratio higher than that in the circulation.",CTD_human;ORPHANET;UNIPROT
9,52,Biomarker,C0238052,"Xanthomatosis, Cerebrotendinous",disease,CTX,1593,CYP27A1,sterol 27-hydroxylase,CTD_human,15795599,Fetal and neonatal deaths among siblings of patients with CTX have been reported previously and the present case supports the contention that reduced activity of the sterol 27-hydroxylase may predispose to the development of neonatal cholestasis.,0.6389107157170401,"Fetal and neonatal deaths among siblings of patients with <span class=""disease"" id=""15795599-9-58-61"">CTX</span> have been reported previously and the present case supports the contention that reduced activity of the <span class=""gene"" id=""15795599-9-166-187"">sterol 27-hydroxylase</span> may predispose to the development of neonatal cholestasis.",CTD_human;ORPHANET;UNIPROT
9,52,Biomarker,C0238052,"Xanthomatosis, Cerebrotendinous",disease,cerebrotendinous xanthomatosis,1593,CYP27A1,CYP27A1,CTD_human,19801147,"Patients with inherited ""cerebrotendinous xanthomatosis"" lack sterol 27-hydroxylase (CYP27A1) and develop severe premature atherosclerosis despite normal serum cholesterol concentrations.",0.6389107157170401,"Patients with inherited ""<span class=""disease"" id=""19801147-3-25-55"">cerebrotendinous xanthomatosis</span>"" lack <span class=""gene"" id=""19801147-3-62-83"">sterol 27-hydroxylase</span> (<span class=""gene"" id=""19801147-3-85-92"">CYP27A1</span>) and develop severe premature atherosclerosis despite normal serum cholesterol concentrations.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,1600,DAB1,Dab 1,CTD_human,15820235,"Reductions in Reelin protein and mRNA and Dab 1 mRNA and elevations in Reln receptor VLDLR mRNA demonstrate impairments in the Reelin signaling system in autism, accounting for some of the brain structural and cognitive deficits observed in the disorder.",0.20082418035263896,"Reductions in Reelin protein and mRNA and <span class=""gene"" id=""15820235-8-42-47"">Dab 1</span> mRNA and elevations in Reln receptor VLDLR mRNA demonstrate impairments in the Reelin signaling system in <span class=""disease"" id=""15820235-8-154-160"">autism</span>, accounting for some of the brain structural and cognitive deficits observed in the disorder.",CTD_human
1,0,Biomarker,C0740394,Hyperuricemia,disease,hyperuricemia,160728,SLC5A8,Smct1,CTD_human,20589576,"Thus, the induction of Smct1 by testosterone is a candidate mechanism underlying hyperuricemia in males.",0.2,"Thus, the induction of <span class=""gene"" id=""20589576-5-23-28"">Smct1</span> by testosterone is a candidate mechanism underlying <span class=""disease"" id=""20589576-5-81-94"">hyperuricemia</span> in males.",CTD_human
1,0,Biomarker,C0011881,Diabetic Nephropathy,disease,diabetic nephropathy,160851,DGKH,DGK eta,CTD_human,20665664,"Hepatic expression profiling shows involvement of PKC epsilon, DGK eta, Tnfaip, and Rho kinase in type 2 diabetic nephropathy rats.",0.2,"Hepatic expression profiling shows involvement of PKC epsilon, <span class=""gene"" id=""20665664-0-63-70"">DGK eta</span>, Tnfaip, and Rho kinase in type 2 <span class=""disease"" id=""20665664-0-105-125"">diabetic nephropathy</span> rats.",CTD_human
1,0,Biomarker,C0007138,"Carcinoma, Transitional Cell",disease,transitional cell carcinoma,1612,DAPK1,DAPK-1,CTD_human,17133271,To examine the significance of the methylation level of the p53 target and tumour suppressor genes apoptotic protease activating factor-1 (APAF-1) and death-associated protein kinase-1 (DAPK-1) in 80 microdissected tumour samples from transitional cell carcinoma (TCC) of the bladder and 80 tumour samples from clear-cell renal cell carcinoma (RCC) as well as from non-tumourous bladder and kidney tissue.,0.201373633921065,"To examine the significance of the methylation level of the p53 target and tumour suppressor genes apoptotic protease activating factor-1 (APAF-1) and <span class=""gene"" id=""17133271-1-151-184"">death-associated protein kinase-1</span> (<span class=""gene"" id=""17133271-1-186-192"">DAPK-1</span>) in 80 microdissected tumour samples from <span class=""disease"" id=""17133271-1-235-262"">transitional cell carcinoma</span> (TCC) of the bladder and 80 tumour samples from clear-cell renal cell carcinoma (RCC) as well as from non-tumourous bladder and kidney tissue.",CTD_human
1,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastases,1612,DAPK1,DAPK1,CTD_human,17319784,"Loss of DAPK1 expression is associated with a selective advantage for tumor cells to resist apoptotic stimuli, allowing them to separate from the original tumor; from this point of view, DAPK1 could be considered a tumor metastases inhibitor gene.",0.201373633921065,"Loss of <span class=""gene"" id=""17319784-2-8-13"">DAPK1</span> expression is associated with a selective advantage for tumor cells to resist apoptotic stimuli, allowing them to separate from the original tumor; from this point of view, <span class=""gene"" id=""17319784-2-187-192"">DAPK1</span> could be considered a tumor <span class=""disease"" id=""17319784-2-221-231"">metastases</span> inhibitor gene.",CTD_human
1,0,Biomarker,C0025202,melanoma,disease,melanoma,161291,TMEM30B,TMEM30B,CTD_human,16778180,"CGIs in putative promoter regions of 34 genes (ABHD9, BARHL1, CLIC5, CNNM1, COL2A1, CPT1C, DDIT4L, DERL3, DHRS3, DPYS, EFEMP2, FAM62C, FAM78A, FLJ33790, GBX2, GPR10, GPRASP1, HOXA9, HOXD11, HOXD12, HOXD13, p14ARF, PAX6, PRDX2, PTPRG, RASD1, RAX, REC8L1, SLC27A3, TGFB2, TLX2, TMEM22, TMEM30B, and UNC5C) were found to be methylated in at least 1 of 13 melanoma cell lines but not in two cultured normal melanocytes.",0.2,"CGIs in putative promoter regions of 34 genes (ABHD9, BARHL1, CLIC5, CNNM1, COL2A1, CPT1C, DDIT4L, DERL3, DHRS3, DPYS, EFEMP2, FAM62C, FAM78A, FLJ33790, GBX2, GPR10, GPRASP1, HOXA9, HOXD11, HOXD12, HOXD13, p14ARF, PAX6, PRDX2, PTPRG, RASD1, RAX, REC8L1, SLC27A3, TGFB2, TLX2, TMEM22, <span class=""gene"" id=""16778180-3-284-291"">TMEM30B</span>, and UNC5C) were found to be methylated in at least 1 of 13 <span class=""disease"" id=""16778180-3-352-360"">melanoma</span> cell lines but not in two cultured normal melanocytes.",CTD_human
1,0,Biomarker,C0021364,Male infertility,phenotype,male infertility,161582,DYX1C1,Dyx1c1,CTD_human,23872636,"Unexpectedly, we found that deleting exons 2-4 of Dyx1c1 in mice caused a phenotype resembling primary ciliary dyskinesia (PCD), a disorder characterized by chronic airway disease, laterality defects and male infertility.",0.200274726784213,"Unexpectedly, we found that deleting exons 2-4 of <span class=""gene"" id=""23872636-2-50-56"">Dyx1c1</span> in mice caused a phenotype resembling primary ciliary dyskinesia (PCD), a disorder characterized by chronic airway disease, laterality defects and <span class=""disease"" id=""23872636-2-204-220"">male infertility</span>.",CTD_human
1,0,Biomarker,C0022521,Kartagener Syndrome,disease,PCD,161582,DYX1C1,DYX1C1,CTD_human,23872636,"In humans, we identified recessive loss-of-function DYX1C1 mutations in 12 individuals with PCD.",0.400549453568426,"In humans, we identified recessive loss-of-function <span class=""gene"" id=""23872636-5-52-58"">DYX1C1</span> mutations in 12 individuals with <span class=""disease"" id=""23872636-5-92-95"">PCD</span>.",CTD_human;ORPHANET
1,0,Biomarker,C0206754,Neuroendocrine Tumors,group,neuroendocrine tumors,1616,DAXX,DAXX,CTD_human,21252315,"DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors.",0.20054945356842604,"<span class=""gene"" id=""21252315-0-0-4"">DAXX</span>/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic <span class=""disease"" id=""21252315-0-77-98"">neuroendocrine tumors</span>.",CTD_human
1,0,Biomarker,C0027831,Neurofibromatosis 1,disease,neurofibromatosis 1,161742,SPRED1,SPRED1,CTD_human,17704776,Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype.,0.21139314449037303,"Germline loss-of-function mutations in <span class=""gene"" id=""17704776-0-39-45"">SPRED1</span> cause a <span class=""disease"" id=""17704776-0-54-73"">neurofibromatosis 1</span>-like phenotype.",CTD_human
1,0,Biomarker,C0031511,Pheochromocytoma,disease,PHEO,1621,DBH,dopamine ?-hydroxylase,CTD_human,22569243,"At both the protein and mRNA levels, MAOA and COMT are detected less often in PHEO compared with adrenal medulla, conversely to tyrosine hydroxylase, L-amino acid decarboxylase, and dopamine ?-hydroxylase, much more expressed in tumor tissue.",0.20082418035263896,"At both the protein and mRNA levels, MAOA and COMT are detected less often in <span class=""disease"" id=""22569243-9-78-82"">PHEO</span> compared with adrenal medulla, conversely to tyrosine hydroxylase, L-amino acid decarboxylase, and <span class=""gene"" id=""22569243-9-182-204"">dopamine &beta;-hydroxylase</span>, much more expressed in tumor tissue.",CTD_human
3,0,Biomarker,C1456784,Paranoia,disease,paranoia,1621,DBH,dopamine beta-hydroxylase,CTD_human,10673769,"A haplotype at the DBH locus, associated with low plasma dopamine beta-hydroxylase activity, also associates with cocaine-induced paranoia.",0.203780662444353,"A haplotype at the <span class=""gene"" id=""10673769-0-19-22"">DBH</span> locus, associated with low plasma <span class=""gene"" id=""10673769-0-57-82"">dopamine beta-hydroxylase</span> activity, also associates with cocaine-induced <span class=""disease"" id=""10673769-0-130-138"">paranoia</span>.",CTD_human
3,0,Biomarker,C1456784,Paranoia,disease,paranoia,1621,DBH,Dopamine beta-hydroxylase,CTD_human,17157269,Dopamine beta-hydroxylase gene (DbetaH) -1021C-->T influences self-reported paranoia during cocaine self-administration.,0.203780662444353,"<span class=""gene"" id=""17157269-0-0-25"">Dopamine beta-hydroxylase</span> gene (DbetaH) -1021C--&gt;T influences self-reported <span class=""disease"" id=""17157269-0-76-84"">paranoia</span> during cocaine self-administration.",CTD_human
3,0,Biomarker,C1456784,Paranoia,disease,paranoia,1621,DBH,DBH,CTD_human,12555232,"Recently, two polymorphisms (DBH5'-Ins/del and DBH 444 g/a) of the Dopamine Beta Hydroxylase (DBH) gene were isolated, and one haplotype (Del-a) was found to be associated with low DBH activity and cocaine-induced paranoia.",0.203780662444353,"Recently, two polymorphisms (DBH5'-Ins/del and <span class=""gene"" id=""12555232-1-47-50"">DBH</span> 444 g/a) of the <span class=""gene"" id=""12555232-1-67-92"">Dopamine Beta Hydroxylase</span> (<span class=""gene"" id=""12555232-1-94-97"">DBH</span>) gene were isolated, and one haplotype (Del-a) was found to be associated with low <span class=""gene"" id=""12555232-1-181-184"">DBH</span> activity and cocaine-induced <span class=""disease"" id=""12555232-1-214-222"">paranoia</span>.",CTD_human
3,0,Biomarker,C0220994,Hyperammonemia,phenotype,hyperammonemia,162417,NAGS,N-acetylglutamate synthase,CTD_human,12594532,Null mutations in the N-acetylglutamate synthase gene associated with acute neonatal disease and hyperammonemia.,0.202197814273705,"Null mutations in the <span class=""gene"" id=""12594532-0-22-48"">N-acetylglutamate synthase</span> gene associated with acute neonatal disease and <span class=""disease"" id=""12594532-0-97-111"">hyperammonemia</span>.",CTD_human
3,0,Biomarker,C0220994,Hyperammonemia,phenotype,hyperammonaemia,162417,NAGS,NAGS,CTD_human,17703373,"A patient with recurrent episodes of hyperammonaemia (highest ammonia level recorded 229 micromol/L, normal 9-33) leading to altered levels of consciousness was diagnosed with partial N-acetylglutamate synthase (NAGS) deficiency (9% residual activity) at age 5 years and was treated with ammonia-conjugating agents (Ucephan 250 mg/kg per day and later sodium phenylbutyrate 200-250 mg/kg per day) for 15 years.",0.202197814273705,"A patient with recurrent episodes of <span class=""disease"" id=""17703373-1-37-52"">hyperammonaemia</span> (highest ammonia level recorded 229 micromol/L, normal 9-33) leading to altered levels of consciousness was diagnosed with partial <span class=""gene"" id=""17703373-1-184-210"">N-acetylglutamate synthase</span> (<span class=""gene"" id=""17703373-1-212-216"">NAGS</span>) deficiency (9% residual activity) at age 5 years and was treated with ammonia-conjugating agents (Ucephan 250 mg/kg per day and later sodium phenylbutyrate 200-250 mg/kg per day) for 15 years.",CTD_human
3,10,Biomarker,C0268543,"Hyperammonemia, type III",disease,NAGS deficiency,162417,NAGS,NAGS,CTD_human,12594532,The finding of deleterious mutations in the NAGS gene confirms the genetic origin of NAGS deficiency.,0.681098907136852,"The finding of deleterious mutations in the <span class=""gene"" id=""12594532-8-44-48"">NAGS</span> gene confirms the genetic origin of <span class=""disease"" id=""12594532-8-85-100"">NAGS deficiency</span>.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0238288,"Muscular Dystrophy, Facioscapulohumeral",disease,facioscapulohumeral muscular dystrophy,1634,DCN,decorin,CTD_human,12868502,"Expression of elastin, decorin, lumican and the extracellular matrix remodeling factor TIMP3 were reduced in facioscapulohumeral muscular dystrophy myoblasts.",0.2,"Expression of elastin, <span class=""gene"" id=""12868502-11-23-30"">decorin</span>, lumican and the extracellular matrix remodeling factor TIMP3 were reduced in <span class=""disease"" id=""12868502-11-109-147"">facioscapulohumeral muscular dystrophy</span> myoblasts.",CTD_human
4,0,Biomarker,C0002395,Alzheimer's Disease,disease,Alzheimer disease,1636,ACE,Angiotensin-converting enzyme,CTD_human,10643899,Angiotensin-converting enzyme genotype is associated with Alzheimer disease in the Japanese population.,0.319445813908148,"<span class=""gene"" id=""10643899-0-0-29"">Angiotensin-converting enzyme</span> genotype is associated with <span class=""disease"" id=""10643899-0-58-75"">Alzheimer disease</span> in the Japanese population.",CTD_human
4,0,Biomarker,C0002395,Alzheimer's Disease,disease,Alzheimer disease,1636,ACE,ACE,CTD_human,9916793,"Variation in DCP1, encoding ACE, is associated with susceptibility to Alzheimer disease.",0.319445813908148,"Variation in <span class=""gene"" id=""9916793-0-13-17"">DCP1</span>, encoding <span class=""gene"" id=""9916793-0-28-31"">ACE</span>, is associated with susceptibility to <span class=""disease"" id=""9916793-0-70-87"">Alzheimer disease</span>.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,Autism,1636,ACE,Angiotensin-Converting Enzyme,CTD_human,27082637,Genetic Variants of Angiotensin-Converting Enzyme Are Linked to Autism: A Case-Control Study.,0.200274726784213,"Genetic Variants of <span class=""gene"" id=""27082637-0-20-49"">Angiotensin-Converting Enzyme</span> Are Linked to <span class=""disease"" id=""27082637-0-64-70"">Autism</span>: A Case-Control Study.",CTD_human
3,0,Biomarker,C0007222,Cardiovascular Diseases,group,cardiovascular disease,1636,ACE,ACE,CTD_human,11498459,The ACE gene is a candidate gene for cardiovascular disease.,0.34095012120296503,"The <span class=""gene"" id=""11498459-1-4-7"">ACE</span> gene is a candidate gene for <span class=""disease"" id=""11498459-1-37-59"">cardiovascular disease</span>.",CTD_human
1,0,Biomarker,C0010068,Coronary heart disease,disease,coronary heart disease,1636,ACE,angiotensin-converting enzyme,CTD_human,8170965,Insertion/deletion polymorphism of the angiotensin-converting enzyme gene is strongly associated with coronary heart disease in non-insulin-dependent diabetes mellitus.,0.330810099702106,"Insertion/deletion polymorphism of the <span class=""gene"" id=""8170965-0-39-68"">angiotensin-converting enzyme</span> gene is strongly associated with <span class=""disease"" id=""8170965-0-102-124"">coronary heart disease</span> in non-insulin-dependent diabetes mellitus.",CTD_human
2,0,Biomarker,C0010200,Coughing,phenotype,cough,1636,ACE,ACE I,CTD_human,12848919,It was suggested that kidney function status and some specific characteristics surrogated by age and sex had modified the effect of ACE I/D variant on cough.,0.215946830130053,"It was suggested that kidney function status and some specific characteristics surrogated by age and sex had modified the effect of <span class=""gene"" id=""12848919-11-132-137"">ACE I</span>/D variant on <span class=""disease"" id=""12848919-11-151-156"">cough</span>.",CTD_human
2,0,Biomarker,C0010200,Coughing,phenotype,cough,1636,ACE,angiotensin-converting enzyme,CTD_human,15498266,[A prospective study on the cough mechanism induced by angiotensin-converting enzyme inhibitors in patients with hypertension].,0.215946830130053,"[A prospective study on the <span class=""disease"" id=""15498266-0-28-33"">cough</span> mechanism induced by <span class=""gene"" id=""15498266-0-55-84"">angiotensin-converting enzyme</span> inhibitors in patients with hypertension].",CTD_human
4,0,Biomarker,C0011881,Diabetic Nephropathy,disease,diabetic nephropathy,1636,ACE,ACE,CTD_human,10099885,The DD genotype of the ACE gene polymorphism is associated with progression of diabetic nephropathy to end stage renal failure in IDDM.,0.41657693905823295,"The DD genotype of the <span class=""gene"" id=""10099885-0-23-26"">ACE</span> gene polymorphism is associated with progression of <span class=""disease"" id=""10099885-0-79-99"">diabetic nephropathy</span> to end stage renal failure in IDDM.",CTD_human
4,0,Biomarker,C0011881,Diabetic Nephropathy,disease,diabetic nephropathy,1636,ACE,angiotensin I--converting enzyme,CTD_human,7909524,Genetic predisposition to diabetic nephropathy. Evidence for a role of the angiotensin I--converting enzyme gene.,0.41657693905823295,"Genetic predisposition to <span class=""disease"" id=""7909524-0-26-46"">diabetic nephropathy</span>. Evidence for a role of the <span class=""gene"" id=""7909524-0-75-107"">angiotensin I--converting enzyme</span> gene.",CTD_human
2,0,Biomarker,C0017661,IGA Glomerulonephritis,disease,IgA nephropathy,1636,ACE,angiotensin converting enzyme,CTD_human,7593601,Role of the deletion of polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy.,0.2584732883309,"Role of the deletion of polymorphism of the <span class=""gene"" id=""7593601-0-44-73"">angiotensin converting enzyme</span> gene in the progression and therapeutic responsiveness of <span class=""disease"" id=""7593601-0-132-147"">IgA nephropathy</span>.",CTD_human
2,0,Biomarker,C0017661,IGA Glomerulonephritis,disease,IgA nephropathy,1636,ACE,ACE,CTD_human,9259580,Our results suggest that polymorphisms at the AGT and ACE gene loci are important markers for predicting progression to chronic renal failure in Caucasian patients with IgA nephropathy.,0.2584732883309,"Our results suggest that polymorphisms at the AGT and <span class=""gene"" id=""9259580-12-54-57"">ACE</span> gene loci are important markers for predicting progression to chronic renal failure in Caucasian patients with <span class=""disease"" id=""9259580-12-169-184"">IgA nephropathy</span>.",CTD_human
1,0,Biomarker,C0017924,Glycogen Storage Disease Type V,disease,McArdle's disease,1636,ACE,ACE,CTD_human,12666117,We show that ACE insertion/deletion polymorphism may play a significant role as phenotype modulator in McArdle's disease.,0.213785817636344,"We show that <span class=""gene"" id=""12666117-11-13-16"">ACE</span> insertion/deletion polymorphism may play a significant role as phenotype modulator in <span class=""disease"" id=""12666117-11-103-120"">McArdle's disease</span>.",CTD_human
2,0,Biomarker,C0022661,"Kidney Failure, Chronic",disease,chronic renal failure,1636,ACE,ACE,CTD_human,7593601,"The results indicate that deletion polymorphism in the ACE gene, particularly the homozygote DD, is a risk factor for progression to chronic renal failure in IgA nephropathy.",0.305520880177184,"The results indicate that deletion polymorphism in the <span class=""gene"" id=""7593601-9-55-58"">ACE</span> gene, particularly the homozygote DD, is a risk factor for progression to <span class=""disease"" id=""7593601-9-133-154"">chronic renal failure</span> in IgA nephropathy.",CTD_human
2,0,Biomarker,C0022661,"Kidney Failure, Chronic",disease,end stage renal failure,1636,ACE,ACE,CTD_human,10099885,The DD genotype of the ACE gene polymorphism is associated with progression of diabetic nephropathy to end stage renal failure in IDDM.,0.305520880177184,"The DD genotype of the <span class=""gene"" id=""10099885-0-23-26"">ACE</span> gene polymorphism is associated with progression of diabetic nephropathy to <span class=""disease"" id=""10099885-0-103-126"">end stage renal failure</span> in IDDM.",CTD_human
1,0,Biomarker,C0025303,Meningococcal Infections,group,meningococcal disease,1636,ACE,angiotensin-converting enzyme,CTD_human,11956052,Severity of meningococcal disease in children and the angiotensin-converting enzyme insertion/deletion polymorphism.,0.202956482091714,"Severity of <span class=""disease"" id=""11956052-0-12-33"">meningococcal disease</span> in children and the <span class=""gene"" id=""11956052-0-54-83"">angiotensin-converting enzyme</span> insertion/deletion polymorphism.",CTD_human
2,0,Biomarker,C0027051,Myocardial Infarction,disease,myocardial infarction,1636,ACE,angiotensin-converting enzyme,CTD_human,1328889,Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction.,0.42696155846140993,"Deletion polymorphism in the gene for <span class=""gene"" id=""1328889-0-38-67"">angiotensin-converting enzyme</span> is a potent risk factor for <span class=""disease"" id=""1328889-0-96-117"">myocardial infarction</span>.",CTD_human
2,0,Biomarker,C0027051,Myocardial Infarction,disease,myocardial infarction,1636,ACE,angiotensin I-converting enzyme,CTD_human,8131300,Insertion/deletion (I/D) polymorphism at the locus for angiotensin I-converting enzyme and parental history of myocardial infarction.,0.42696155846140993,"Insertion/deletion (I/D) polymorphism at the locus for <span class=""gene"" id=""8131300-0-55-86"">angiotensin I-converting enzyme</span> and parental history of <span class=""disease"" id=""8131300-0-111-132"">myocardial infarction</span>.",CTD_human
1,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastases,1636,ACE,ACE,CTD_human,18059164,"ACE and AT2R were significantly upregulated in tumors and metastases, and expressed in the lymph node metastases of 26 (58%) and 40 (89%) gastric cancer patients, respectively.",0.20082418035263896,"<span class=""gene"" id=""18059164-5-0-3"">ACE</span> and AT2R were significantly upregulated in tumors and <span class=""disease"" id=""18059164-5-58-68"">metastases</span>, and expressed in the lymph node metastases of 26 (58%) and 40 (89%) gastric cancer patients, respectively.",CTD_human
1,0,Biomarker,C0149721,Left Ventricular Hypertrophy,disease,left ventricular hypertrophy,1636,ACE,angiotensin converting enzyme,CTD_human,8349331,"Systolic blood pressure, plasma renin activity, and cardiac angiotensin converting enzyme activity of L-NAME rats with left ventricular hypertrophy were significantly higher than those of the subgroup without.(ABSTRACT TRUNCATED AT 250 WORDS)",0.39674161219796894,"Systolic blood pressure, plasma renin activity, and cardiac <span class=""gene"" id=""8349331-6-60-89"">angiotensin converting enzyme</span> activity of L-NAME rats with <span class=""disease"" id=""8349331-6-119-147"">left ventricular hypertrophy</span> were significantly higher than those of the subgroup without.(ABSTRACT TRUNCATED AT 250 WORDS)",CTD_human
2,7,Biomarker,C0266313,Allanson Pantzar McLeod syndrome,disease,RTD,1636,ACE,ACE,CTD_human,20454656,"Patient with RTD in Lisbon, Portugal, maintained by peritoneal dialysis since birth, was found to have a homozygous substitution of Arg for Glu at position 1069 in the C-terminal domain of ACE (Q1069R) resulting in absence of plasma ACE activity; both parents and a brother who are heterozygous carriers of this mutation had exactly half-normal plasma ACE activity compared to healthy individuals.",0.6010989071368521,"Patient with <span class=""disease"" id=""20454656-3-13-16"">RTD</span> in Lisbon, Portugal, maintained by peritoneal dialysis since birth, was found to have a homozygous substitution of Arg for Glu at position 1069 in the C-terminal domain of <span class=""gene"" id=""20454656-3-189-192"">ACE</span> (<span class=""gene"" id=""20454656-3-194-200"">Q1069R</span>) resulting in absence of plasma <span class=""gene"" id=""20454656-3-233-236"">ACE</span> activity; both parents and a brother who are heterozygous carriers of this mutation had exactly half-normal plasma <span class=""gene"" id=""20454656-3-352-355"">ACE</span> activity compared to healthy individuals.",CTD_human;HPO;ORPHANET
2,7,Biomarker,C0266313,Allanson Pantzar McLeod syndrome,disease,renal tubular dysgenesis,1636,ACE,angiotensin converting enzyme,CTD_human,16116425,"We studied 11 individuals with renal tubular dysgenesis, belonging to nine families, and found that they had homozygous or compound heterozygous mutations in the genes encoding renin, angiotensinogen, angiotensin converting enzyme or angiotensin II receptor type 1.",0.6010989071368521,"We studied 11 individuals with <span class=""disease"" id=""16116425-3-31-55"">renal tubular dysgenesis</span>, belonging to nine families, and found that they had homozygous or compound heterozygous mutations in the genes encoding renin, angiotensinogen, <span class=""gene"" id=""16116425-3-201-230"">angiotensin converting enzyme</span> or angiotensin II receptor type 1.",CTD_human;HPO;ORPHANET
1,0,Biomarker,C1956346,Coronary Artery Disease,disease,coronary artery disease,1636,ACE,ACE,CTD_human,14989558,Interactive effects of the ACE DD polymorphism with the NOS III homozygous G849T (Glu298-->Asp) variant in determining endothelial function in coronary artery disease.,0.36143594576080107,"Interactive effects of the <span class=""gene"" id=""14989558-0-27-30"">ACE</span> DD polymorphism with the NOS III homozygous G849T (Glu298--&gt;Asp) variant in determining endothelial function in <span class=""disease"" id=""14989558-0-143-166"">coronary artery disease</span>.",CTD_human
2,0,Therapeutic,C0030567,Parkinson Disease,disease,idiopathic Parkinson's disease,1644,DDC,dopa decarboxylase,CTD_human,2969953,"Thirteen patients with idiopathic Parkinson's disease and ""on-off"" fluctuations on oral levodopa plus dopa decarboxylase inhibitor (DDI) were treated with continuous (24 hour) subcutaneous lisuride infusions together with a reduced dose of levodopa (plus DDI).",0.20357144819477,"Thirteen patients with <span class=""disease"" id=""2969953-1-23-53"">idiopathic Parkinson's disease</span> and ""on-off"" fluctuations on oral levodopa plus <span class=""gene"" id=""2969953-1-102-120"">dopa decarboxylase</span> inhibitor (DDI) were treated with continuous (24 hour) subcutaneous lisuride infusions together with a reduced dose of levodopa (plus DDI).",CTD_human
1,0,Biomarker,C0032460,Polycystic Ovary Syndrome,disease,PCOS,1645,AKR1C1,AKR1C1,CTD_human,22381227,"Compared with the controls, PCOS patients showed significantly higher levels of 3?-hydroxysteroid dehydrogenase1-2 (3?-HSD1-2), aldo-keto reductase 1C 1-3 (AKR1C1-3) and leptin, but lower level of P450 aromatase and 5?-reductase 1.",0.20054945356842604,"Compared with the controls, <span class=""disease"" id=""22381227-4-28-32"">PCOS</span> patients showed significantly higher levels of 3&beta;-hydroxysteroid dehydrogenase1-2 (3&beta;-HSD1-2), aldo-keto reductase 1C 1-3 (<span class=""gene"" id=""22381227-4-156-162"">AKR1C1</span>-3) and leptin, but lower level of P450 aromatase and 5&alpha;-reductase 1.",CTD_human
2,0,Biomarker,C0162316,Iron deficiency anemia,disease,iron deficiency anemia refractory,164656,TMPRSS6,TMPRSS6,CTD_human,18408718,"Here, we show that iron deficiency anemia refractory to oral iron therapy can be caused by germline mutations in TMPRSS6, which encodes a type II transmembrane serine protease produced by the liver that regulates the expression of the systemic iron regulatory hormone hepcidin.",0.203021994626344,"Here, we show that <span class=""disease"" id=""18408718-2-19-52"">iron deficiency anemia refractory</span> to oral iron therapy can be caused by germline mutations in <span class=""gene"" id=""18408718-2-113-120"">TMPRSS6</span>, which encodes a type II transmembrane serine protease produced by the liver that regulates the expression of the systemic iron regulatory hormone hepcidin.",CTD_human
1,0,Biomarker,C0028754,Obesity,disease,obese,1649,DDIT3,C/EBP-homologous protein,CTD_human,26655953,"In human renal biopsies, staining of 4-hydroxynonenal (4-HNE), glucose-regulated protein 78 (Grp78), and C/EBP-homologous protein, markers of endoplasmic reticulum stress, was more prominent in the proximal tubules of 15 obese patients compared with 16 non-obese patients.",0.20054945356842604,"In human renal biopsies, staining of 4-hydroxynonenal (4-HNE), glucose-regulated protein 78 (Grp78), and <span class=""gene"" id=""26655953-5-105-129"">C/EBP-homologous protein</span>, markers of endoplasmic reticulum stress, was more prominent in the proximal tubules of 15 <span class=""disease"" id=""26655953-5-221-226"">obese</span> patients compared with 16 non-<span class=""disease"" id=""26655953-5-257-262"">obese</span> patients.",CTD_human
1,0,Therapeutic,C0028840,Ocular Hypertension,disease,ocular hypertension,1649,DDIT3,CHOP,CTD_human,24691439,"Dexamethasone induced the transcriptional factor CHOP, a marker for chronic ER stress, in the anterior segment tissues, and Chop deletion reduced ER stress in these tissues and prevented dexamethasone-induced ocular hypertension.",0.200274726784213,"Dexamethasone induced the transcriptional factor <span class=""gene"" id=""24691439-8-49-53"">CHOP</span>, a marker for chronic ER stress, in the anterior segment tissues, and Chop deletion reduced ER stress in these tissues and prevented dexamethasone-induced <span class=""disease"" id=""24691439-8-209-228"">ocular hypertension</span>.",CTD_human
3,0,Biomarker,C0206634,"Liposarcoma, Myxoid",disease,myxoid liposarcoma,1649,DDIT3,CHOP,CTD_human,8510758,Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma.,0.61593415348436,"Fusion of <span class=""gene"" id=""8510758-0-10-14"">CHOP</span> to a novel RNA-binding protein in human <span class=""disease"" id=""8510758-0-55-73"">myxoid liposarcoma</span>.",CTD_human;HPO;ORPHANET
3,0,Biomarker,C0206634,"Liposarcoma, Myxoid",disease,myxoid liposarcomas,1649,DDIT3,CHOP,CTD_human,1283316,Rearrangement of the transcription factor gene CHOP in myxoid liposarcomas with t(12;16)(q13;p11).,0.61593415348436,"Rearrangement of the transcription factor gene <span class=""gene"" id=""1283316-0-47-51"">CHOP</span> in <span class=""disease"" id=""1283316-0-55-74"">myxoid liposarcomas</span> with t(12;16)(q13;p11).",CTD_human;HPO;ORPHANET
3,0,Biomarker,C0206634,"Liposarcoma, Myxoid",disease,myxoid liposarcoma,1649,DDIT3,CHOP,CTD_human,7503811,"We show that the translocation t(12;16)(q13:p11) in malignant myxoid liposarcoma can be a fusion of the CHOP dominant negative transcription factor gene with a novel gene, FUS, which can result in fusion of the FUS glycine-rich protein with the whole CHOP coding region.",0.61593415348436,"We show that the translocation t(12;16)(q13:p11) in malignant <span class=""disease"" id=""7503811-2-62-80"">myxoid liposarcoma</span> can be a fusion of the <span class=""gene"" id=""7503811-2-104-108"">CHOP</span> dominant negative transcription factor gene with a novel gene, FUS, which can result in fusion of the FUS glycine-rich protein with the whole <span class=""gene"" id=""7503811-2-251-255"">CHOP</span> coding region.",CTD_human;HPO;ORPHANET
1,0,Biomarker,C0079772,T-Cell Lymphoma,disease,T-cell lymphoma,1654,DDX3X,DDX3X,CTD_human,26192917,Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma.,0.200274726784213,"Exome sequencing identifies somatic mutations of <span class=""gene"" id=""26192917-0-49-54"">DDX3X</span> in natural killer/<span class=""disease"" id=""26192917-0-73-88"">T-cell lymphoma</span>.",CTD_human
1,0,Biomarker,C0023467,"Leukemia, Myelocytic, Acute",disease,AML,1665,DHX15,DHX15,CTD_human,27798625,"Outside of signaling alterations, RUNX1-RUNX1T1 and CBFB-MYH11 AMLs demonstrated remarkably different spectra of cooperating mutations, as RUNX1-RUNX1T1 cases harbored recurrent mutations in DHX15 and ZBTB7A, as well as an enrichment of mutations in epigenetic regulators, including ASXL2 and the cohesin complex.",0.2,"Outside of signaling alterations, RUNX1-RUNX1T1 and CBFB-MYH11 <span class=""disease"" id=""27798625-4-63-66"">AML</span>s demonstrated remarkably different spectra of cooperating mutations, as RUNX1-RUNX1T1 cases harbored recurrent mutations in <span class=""gene"" id=""27798625-4-191-196"">DHX15</span> and ZBTB7A, as well as an enrichment of mutations in epigenetic regulators, including ASXL2 and the cohesin complex.",CTD_human
2,0,Biomarker,C1269683,Major Depressive Disorder,disease,MDD,166752,FREM3,FREM3,CTD_human,26441752,"The A allele of the FRAS1-related extracellular matrix protein 3 (FREM3) rs7676614 single nucleotide polymorphism (SNP) was linked to major depressive disorder (MDD) in an early genome-wide association study (GWAS), and to symptoms of psychomotor retardation in a follow-up investigation.",0.40027472678421294,"The A allele of the <span class=""gene"" id=""26441752-1-20-64"">FRAS1-related extracellular matrix protein 3</span> (<span class=""gene"" id=""26441752-1-66-71"">FREM3</span>) rs7676614 single nucleotide polymorphism (SNP) was linked to <span class=""disease"" id=""26441752-1-134-159"">major depressive disorder</span> (<span class=""disease"" id=""26441752-1-161-164"">MDD</span>) in an early genome-wide association study (GWAS), and to symptoms of psychomotor retardation in a follow-up investigation.",CTD_human;PSYGENET
1,0,Biomarker,C0021390,Inflammatory Bowel Diseases,group,IBD,1670,DEFA5,DEFA5,CTD_human,18394979,"The SNPs genotyped in our study were surrogates for common variants, and observed associations between these and IBD status are likely due to linkage disequilibrium with a functional common DEFA5 variant.",0.20541466777231498,"The SNPs genotyped in our study were surrogates for common variants, and observed associations between these and <span class=""disease"" id=""18394979-12-113-116"">IBD</span> status are likely due to linkage disequilibrium with a functional common <span class=""gene"" id=""18394979-12-190-195"">DEFA5</span> variant.",CTD_human
1,0,Biomarker,C0004238,Atrial Fibrillation,disease,AF,1674,DES,desmin,CTD_human,20137276,"The expression of mRNA level of desmin and beta-tubulin were up-regulated in AF group than sham-operated group, (LA:1.0 +/- 0.3 vs 0.6 +/- 0.3, 0.9 +/- 0.4 vs 0.6 +/- 0.3; RA: 1.0 +/- 0.6 vs 0.6 +/- 0.2, 1.1 +/- 0.3 vs 0.7 +/- 0.4, P < 0.01) and they were down-regulated in benazepril group than AF group (LA:0.8 +/- 0.4 vs 1.0 +/- 0.3, 0.7 +/- 0.3 vs 0.9 +/- 0.4; RA:0.7 +/- 0.3 vs 1.0 +/- 0.6, 0.7 +/- 0.3 vs 1.1 +/- 0.3, P < 0.01).",0.2,"The expression of mRNA level of <span class=""gene"" id=""20137276-9-32-38"">desmin</span> and beta-tubulin were up-regulated in <span class=""disease"" id=""20137276-9-77-79"">AF</span> group than sham-operated group, (LA:1.0 +/- 0.3 vs 0.6 +/- 0.3, 0.9 +/- 0.4 vs 0.6 +/- 0.3; RA: 1.0 +/- 0.6 vs 0.6 +/- 0.2, 1.1 +/- 0.3 vs 0.7 +/- 0.4, P &lt; 0.01) and they were down-regulated in benazepril group than <span class=""disease"" id=""20137276-9-296-298"">AF</span> group (LA:0.8 +/- 0.4 vs 1.0 +/- 0.3, 0.7 +/- 0.3 vs 0.9 +/- 0.4; RA:0.7 +/- 0.3 vs 1.0 +/- 0.6, 0.7 +/- 0.3 vs 1.1 +/- 0.3, P &lt; 0.01).",CTD_human
1,0,Biomarker,C0027720,Nephrosis,disease,nephrosis,1674,DES,desmin,CTD_human,16418842,"To gain insight into the role of IF proteins in podocytes, we investigated the expression of nestin, vimentin, and desmin in puromycin aminonucleoside (PAN) nephrosis.",0.2,"To gain insight into the role of IF proteins in podocytes, we investigated the expression of nestin, vimentin, and <span class=""gene"" id=""16418842-2-115-121"">desmin</span> in puromycin aminonucleoside (PAN) <span class=""disease"" id=""16418842-2-157-166"">nephrosis</span>.",CTD_human
1,0,Biomarker,C0598608,Hyperhomocysteinemia,disease,Hyperhomocysteinemia,1674,DES,desmin,CTD_human,20116427,Hyperhomocysteinemia-induced decrease in nephrin expression and increase in desmin expression in gp91(+/+) mice were not observed in gp91(-/-) mice.,0.2,"<span class=""disease"" id=""20116427-4-0-20"">Hyperhomocysteinemia</span>-induced decrease in nephrin expression and increase in <span class=""gene"" id=""20116427-4-76-82"">desmin</span> expression in gp91(+/+) mice were not observed in gp91(-/-) mice.",CTD_human
1,0,Biomarker,C0025303,Meningococcal Infections,group,meningococcal infections,1675,CFD,complement factor D,CTD_human,16527897,Deficient alternative complement pathway activation due to factor D deficiency by 2 novel mutations in the complement factor D gene in a family with meningococcal infections.,0.200274726784213,"Deficient alternative complement pathway activation due to factor D deficiency by 2 novel mutations in the <span class=""gene"" id=""16527897-0-107-126"">complement factor D</span> gene in a family with <span class=""disease"" id=""16527897-0-149-173"">meningococcal infections</span>.",CTD_human
2,9,Biomarker,C0796074,MOHR-TRANEBJAERG SYNDROME,disease,deafness-dystonia syndrome,1678,TIMM8A,TIMM8a,CTD_human,11803487,Neuronal cell death in the visual cortex is a prominent feature of the X-linked recessive mitochondrial deafness-dystonia syndrome caused by mutations in the TIMM8a gene.,0.605494535684262,"Neuronal cell death in the visual cortex is a prominent feature of the X-linked recessive mitochondrial <span class=""disease"" id=""11803487-0-104-130"">deafness-dystonia syndrome</span> caused by mutations in the <span class=""gene"" id=""11803487-0-158-164"">TIMM8a</span> gene.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C1839564,Jensen syndrome,disease,Jensen syndrome,1678,TIMM8A,TIMM8a,CTD_human,11803487,"We identified a stop mutation (E24X) in the TIMM8a gene segregating with the disease in the original Danish family with the Jensen syndrome, which confirms that the two disorders are allelic conditions.",0.200274726784213,"We identified a stop mutation (E24X) in the <span class=""gene"" id=""11803487-3-44-50"">TIMM8a</span> gene segregating with the disease in the original Danish family with the <span class=""disease"" id=""11803487-3-124-139"">Jensen syndrome</span>, which confirms that the two disorders are allelic conditions.",CTD_human
6,2,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,type 2 diabetes,169026,SLC30A8,SLC30A8,CTD_human,24584071,Loss-of-function mutations in SLC30A8 protect against type 2 diabetes.,0.301703415952835,"Loss-of-function mutations in <span class=""gene"" id=""24584071-0-30-37"">SLC30A8</span> protect against <span class=""disease"" id=""24584071-0-54-69"">type 2 diabetes</span>.",CTD_human
6,2,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,type 2 diabetes,169026,SLC30A8,ZnT8,CTD_human,19542200,Insulin storage and glucose homeostasis in mice null for the granule zinc transporter ZnT8 and studies of the type 2 diabetes-associated variants.,0.301703415952835,"Insulin storage and glucose homeostasis in mice null for the granule zinc transporter <span class=""gene"" id=""19542200-0-86-90"">ZnT8</span> and studies of the <span class=""disease"" id=""19542200-0-110-125"">type 2 diabetes</span>-associated variants.",CTD_human
6,2,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,T2DM,169026,SLC30A8,ZnT-8,CTD_human,21461562,"In this study, we aimed to explore the expression of ZnT-8 in the development of T2DM.",0.301703415952835,"In this study, we aimed to explore the expression of <span class=""gene"" id=""21461562-3-53-58"">ZnT-8</span> in the development of <span class=""disease"" id=""21461562-3-81-85"">T2DM</span>.",CTD_human
6,2,Therapeutic,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,type 2 diabetes,169026,SLC30A8,SLC30A8,CTD_human,19479076,"A polymorphism in the SLC30A8 gene is associated with susceptibility to type 2 diabetes, although the molecular mechanism through which this phenotype is manifest is incompletely understood.",0.301703415952835,"A polymorphism in the <span class=""gene"" id=""19479076-2-22-29"">SLC30A8</span> gene is associated with susceptibility to <span class=""disease"" id=""19479076-2-72-87"">type 2 diabetes</span>, although the molecular mechanism through which this phenotype is manifest is incompletely understood.",CTD_human
6,2,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,type 2 diabetes,169026,SLC30A8,SLC30A8,CTD_human,19479076,"A polymorphism in the SLC30A8 gene is associated with susceptibility to type 2 diabetes, although the molecular mechanism through which this phenotype is manifest is incompletely understood.",0.301703415952835,"A polymorphism in the <span class=""gene"" id=""19479076-2-22-29"">SLC30A8</span> gene is associated with susceptibility to <span class=""disease"" id=""19479076-2-72-87"">type 2 diabetes</span>, although the molecular mechanism through which this phenotype is manifest is incompletely understood.",CTD_human
6,2,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,type 2 diabetes,169026,SLC30A8,SLC30A8,CTD_human,20424817,Polymorphisms of ZnT8 (also known as SLC30A8) gene in man are associated with increased risk of type 2 diabetes.,0.301703415952835,"Polymorphisms of <span class=""gene"" id=""20424817-3-17-21"">ZnT8</span> (also known as <span class=""gene"" id=""20424817-3-37-44"">SLC30A8</span>) gene in man are associated with increased risk of <span class=""disease"" id=""20424817-3-96-111"">type 2 diabetes</span>.",CTD_human
6,2,Therapeutic,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,type 2 diabetes,169026,SLC30A8,ZnT8,CTD_human,19542200,Insulin storage and glucose homeostasis in mice null for the granule zinc transporter ZnT8 and studies of the type 2 diabetes-associated variants.,0.301703415952835,"Insulin storage and glucose homeostasis in mice null for the granule zinc transporter <span class=""gene"" id=""19542200-0-86-90"">ZnT8</span> and studies of the <span class=""disease"" id=""19542200-0-110-125"">type 2 diabetes</span>-associated variants.",CTD_human
6,2,Therapeutic,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,T2DM,169026,SLC30A8,ZnT-8,CTD_human,21461562,"In this study, we aimed to explore the expression of ZnT-8 in the development of T2DM.",0.301703415952835,"In this study, we aimed to explore the expression of <span class=""gene"" id=""21461562-3-53-58"">ZnT-8</span> in the development of <span class=""disease"" id=""21461562-3-81-85"">T2DM</span>.",CTD_human
6,2,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,type 2 diabetes,169026,SLC30A8,SLC30A8,CTD_human,21779873,We hypothesised that the risk allele at the type 2 diabetes-associated missense polymorphism rs13266634 (R325W) in SLC30A8 would predict proinsulin levels in individuals at risk of type 2 diabetes and may modulate response to preventive interventions.,0.301703415952835,"We hypothesised that the risk allele at the <span class=""disease"" id=""21779873-4-44-59"">type 2 diabetes</span>-associated missense polymorphism rs13266634 (R325W) in <span class=""gene"" id=""21779873-4-115-122"">SLC30A8</span> would predict proinsulin levels in individuals at risk of <span class=""disease"" id=""21779873-4-181-196"">type 2 diabetes</span> and may modulate response to preventive interventions.",CTD_human
6,2,Therapeutic,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,type 2 diabetes,169026,SLC30A8,SLC30A8,CTD_human,24584071,Loss-of-function mutations in SLC30A8 protect against type 2 diabetes.,0.301703415952835,"Loss-of-function mutations in <span class=""gene"" id=""24584071-0-30-37"">SLC30A8</span> protect against <span class=""disease"" id=""24584071-0-54-69"">type 2 diabetes</span>.",CTD_human
6,2,Therapeutic,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,type 2 diabetes,169026,SLC30A8,SLC30A8,CTD_human,20424817,Polymorphisms of ZnT8 (also known as SLC30A8) gene in man are associated with increased risk of type 2 diabetes.,0.301703415952835,"Polymorphisms of <span class=""gene"" id=""20424817-3-17-21"">ZnT8</span> (also known as <span class=""gene"" id=""20424817-3-37-44"">SLC30A8</span>) gene in man are associated with increased risk of <span class=""disease"" id=""20424817-3-96-111"">type 2 diabetes</span>.",CTD_human
6,2,Therapeutic,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,type 2 diabetes,169026,SLC30A8,SLC30A8,CTD_human,21779873,We hypothesised that the risk allele at the type 2 diabetes-associated missense polymorphism rs13266634 (R325W) in SLC30A8 would predict proinsulin levels in individuals at risk of type 2 diabetes and may modulate response to preventive interventions.,0.301703415952835,"We hypothesised that the risk allele at the <span class=""disease"" id=""21779873-4-44-59"">type 2 diabetes</span>-associated missense polymorphism rs13266634 (R325W) in <span class=""gene"" id=""21779873-4-115-122"">SLC30A8</span> would predict proinsulin levels in individuals at risk of <span class=""disease"" id=""21779873-4-181-196"">type 2 diabetes</span> and may modulate response to preventive interventions.",CTD_human
1,3,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,T2D,169792,GLIS3,GLIS3,CTD_human,22158537,"The combined analysis identified eight new T2D loci reaching genome-wide significance, which mapped in or near GLIS3, PEPD, FITM2-R3HDML-HNF4A, KCNK16, MAEA, GCC1-PAX4, PSMD6 and ZFAND3.",0.201923087489492,"The combined analysis identified eight new <span class=""disease"" id=""22158537-3-43-46"">T2D</span> loci reaching genome-wide significance, which mapped in or near <span class=""gene"" id=""22158537-3-111-116"">GLIS3</span>, PEPD, FITM2-R3HDML-HNF4A, KCNK16, MAEA, GCC1-PAX4, PSMD6 and ZFAND3.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,170572,HTR3C,HTR3C,CTD_human,19035560,Allelic variants in HTR3C show association with autism.,0.202681755307501,"Allelic variants in <span class=""gene"" id=""19035560-0-20-25"">HTR3C</span> show association with <span class=""disease"" id=""19035560-0-48-54"">autism</span>.",CTD_human
1,1,Biomarker,C0036421,Systemic Scleroderma,disease,systemic sclerosis,170679,PSORS1C1,PSORS1C1,CTD_human,21750679,"Genome-wide scan identifies TNIP1, PSORS1C1, and RHOB as novel risk loci for systemic sclerosis.",0.20054945356842604,"Genome-wide scan identifies TNIP1, <span class=""gene"" id=""21750679-0-35-43"">PSORS1C1</span>, and RHOB as novel risk loci for <span class=""disease"" id=""21750679-0-77-95"">systemic sclerosis</span>.",CTD_human
1,5,Biomarker,C0796232,Bohring syndrome,disease,Bohring-Opitz syndrome,171023,ASXL1,ASXL1,CTD_human,21706002,De novo nonsense mutations in ASXL1 cause Bohring-Opitz syndrome.,0.401923087489492,"De novo nonsense mutations in <span class=""gene"" id=""21706002-0-30-35"">ASXL1</span> cause <span class=""disease"" id=""21706002-0-42-64"">Bohring-Opitz syndrome</span>.",CTD_human;ORPHANET
1,0,Biomarker,C0677886,Epithelial ovarian cancer,disease,EOC,171024,SYNPO2,SYNPO2,CTD_human,25581431,"Variants at 1p36 (nearest gene, WNT4), 4q26 (SYNPO2), 9q34.2 (ABO) and 17q11.2 (ATAD5) were associated with EOC risk, and at 1p34.3 (RSPO1) and 6p22.1 (GPX6) variants were specifically associated with the serous EOC subtype, all with P < 5 × 10(-8).",0.200274726784213,"Variants at 1p36 (nearest gene, WNT4), 4q26 (<span class=""gene"" id=""25581431-5-45-51"">SYNPO2</span>), 9q34.2 (ABO) and 17q11.2 (ATAD5) were associated with <span class=""disease"" id=""25581431-5-108-111"">EOC</span> risk, and at 1p34.3 (RSPO1) and 6p22.1 (GPX6) variants were specifically associated with the serous <span class=""disease"" id=""25581431-5-212-215"">EOC</span> subtype, all with P &lt; 5 &times; 10(-8).",CTD_human
16,61,Biomarker,C0175694,Smith-Lemli-Opitz Syndrome,disease,SLOS,1717,DHCR7,DHCR7,CTD_human,16814115,"Smith-Lemli-Opitz syndrome (SLOS) is a severe developmental disorder caused by mutations in the DHCR7 gene coding for 7-dehydrocholesterol (7-DHC) reductase, the enzyme involved in the last step of cholesterol biosynthesis.",0.73474087615515,"<span class=""disease"" id=""16814115-1-0-26"">Smith-Lemli-Opitz syndrome</span> (<span class=""disease"" id=""16814115-1-28-32"">SLOS</span>) is a severe developmental disorder caused by mutations in the <span class=""gene"" id=""16814115-1-96-101"">DHCR7</span> gene coding for 7-dehydrocholesterol (7-DHC) reductase, the enzyme involved in the last step of cholesterol biosynthesis.",CTD_human;ORPHANET;UNIPROT
16,61,Biomarker,C0175694,Smith-Lemli-Opitz Syndrome,disease,SLOS,1717,DHCR7,Dhcr7,CTD_human,14659996,"Using a targeting strategy designed to virtually eliminate Dhcr7 activity, we have created a SLOS mouse model that exhibits commissural deficiencies, hippocampal abnormalities, and hypermorphic development of serotonin (5-HT) neurons.",0.73474087615515,"Using a targeting strategy designed to virtually eliminate <span class=""gene"" id=""14659996-2-59-64"">Dhcr7</span> activity, we have created a <span class=""disease"" id=""14659996-2-93-97"">SLOS</span> mouse model that exhibits commissural deficiencies, hippocampal abnormalities, and hypermorphic development of serotonin (5-HT) neurons.",CTD_human;ORPHANET;UNIPROT
16,61,Biomarker,C0175694,Smith-Lemli-Opitz Syndrome,disease,SLOS,1717,DHCR7,7-dehydrocholesterol reductase,CTD_human,12906934,Smith-Lemli-Opitz syndrome (SLOS) is attributable to mutations in the gene coding for 7-dehydrocholesterol reductase.,0.73474087615515,"<span class=""disease"" id=""12906934-1-0-26"">Smith-Lemli-Opitz syndrome</span> (<span class=""disease"" id=""12906934-1-28-32"">SLOS</span>) is attributable to mutations in the gene coding for <span class=""gene"" id=""12906934-1-86-116"">7-dehydrocholesterol reductase</span>.",CTD_human;ORPHANET;UNIPROT
16,61,Biomarker,C0175694,Smith-Lemli-Opitz Syndrome,disease,SLOS,1717,DHCR7,DHCR7,CTD_human,16446309,"To circumvent this problem, we produced a hypomorphic SLOS mouse model by introducing a mutation corresponding to DHCR7(T93M).",0.73474087615515,"To circumvent this problem, we produced a hypomorphic <span class=""disease"" id=""16446309-6-54-58"">SLOS</span> mouse model by introducing a mutation corresponding to <span class=""gene"" id=""16446309-6-114-119"">DHCR7</span>(T93M).",CTD_human;ORPHANET;UNIPROT
16,61,Biomarker,C0175694,Smith-Lemli-Opitz Syndrome,disease,Smith-Lemli-Opitz syndrome,1717,DHCR7,DHCR7,CTD_human,19365639,A patient with Smith-Lemli-Opitz syndrome: novel mutation of the DHCR7 gene and effects of therapy with simvastatin and cholesterol supplement.,0.73474087615515,"A patient with <span class=""disease"" id=""19365639-0-15-41"">Smith-Lemli-Opitz syndrome</span>: novel mutation of the <span class=""gene"" id=""19365639-0-65-70"">DHCR7</span> gene and effects of therapy with simvastatin and cholesterol supplement.",CTD_human;ORPHANET;UNIPROT
16,61,Biomarker,C0175694,Smith-Lemli-Opitz Syndrome,disease,SLOS,1717,DHCR7,DHCR7,CTD_human,17994283,"SLOS is caused by the mutations in the gene for 3beta-hydroxysterol Delta(7) reductase (DHCR7; EC 1.3.1.21), which maps to chromosome 11q12-13.",0.73474087615515,"<span class=""disease"" id=""17994283-2-0-4"">SLOS</span> is caused by the mutations in the gene for 3beta-hydroxysterol Delta(7) reductase (<span class=""gene"" id=""17994283-2-88-93"">DHCR7</span>; EC 1.3.1.21), which maps to chromosome 11q12-13.",CTD_human;ORPHANET;UNIPROT
16,61,Biomarker,C0175694,Smith-Lemli-Opitz Syndrome,disease,SLO syndrome,1717,DHCR7,7DHCR,CTD_human,12818773,Better understanding of the 7DHCR gene regulation factors and of the compensatory mechanism of foeto-maternal cholesterol transfer are necessary to explain the wide clinical spectrum of the SLO syndrome.,0.73474087615515,"Better understanding of the <span class=""gene"" id=""12818773-10-28-33"">7DHCR</span> gene regulation factors and of the compensatory mechanism of foeto-maternal cholesterol transfer are necessary to explain the wide clinical spectrum of the <span class=""disease"" id=""12818773-10-190-202"">SLO syndrome</span>.",CTD_human;ORPHANET;UNIPROT
16,61,Biomarker,C0175694,Smith-Lemli-Opitz Syndrome,disease,SLOS,1717,DHCR7,DHCR7,CTD_human,27097157,"Increased levels of 7-DHC are associated with Smith-Lemli-Opitz syndrome (SLOS), a human condition that results from a mutation in the gene that encodes DHCR7.",0.73474087615515,"Increased levels of 7-DHC are associated with <span class=""disease"" id=""27097157-6-46-72"">Smith-Lemli-Opitz syndrome</span> (<span class=""disease"" id=""27097157-6-74-78"">SLOS</span>), a human condition that results from a mutation in the gene that encodes <span class=""gene"" id=""27097157-6-153-158"">DHCR7</span>.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0002395,Alzheimer's Disease,disease,AD,1718,DHCR24,DHCR24,CTD_human,23042211,"It has become of particular interest in the pathogenesis of Alzheimer's disease (AD) because of the report that the activity of the gene coding for the enzyme DHCR24, which metabolizes desmosterol to cholesterol, is selectively reduced in the affected areas of the brain.",0.21396799986291604,"It has become of particular interest in the pathogenesis of <span class=""disease"" id=""23042211-2-60-79"">Alzheimer's disease</span> (<span class=""disease"" id=""23042211-2-81-83"">AD</span>) because of the report that the activity of the gene coding for the enzyme <span class=""gene"" id=""23042211-2-159-165"">DHCR24</span>, which metabolizes desmosterol to cholesterol, is selectively reduced in the affected areas of the brain.",CTD_human
2,0,Biomarker,C0002888,"Anemia, Megaloblastic",disease,megaloblastic anemia,1719,DHFR,DHFR,CTD_human,21310276,"We describe three individuals from two families with a recessive inborn error of metabolism, characterized by megaloblastic anemia and/or pancytopenia, severe cerebral folate deficiency, and cerebral tetrahydrobiopterin deficiency due to a germline missense mutation in DHFR, resulting in profound enzyme deficiency.",0.40027472678421294,"We describe three individuals from two families with a recessive inborn error of metabolism, characterized by <span class=""disease"" id=""21310276-2-110-130"">megaloblastic anemia</span> and/or pancytopenia, severe cerebral folate deficiency, and cerebral tetrahydrobiopterin deficiency due to a germline missense mutation in <span class=""gene"" id=""21310276-2-270-274"">DHFR</span>, resulting in profound enzyme deficiency.",CTD_human;HPO
2,0,Biomarker,C0002888,"Anemia, Megaloblastic",disease,megaloblastic anemia,1719,DHFR,DHFR,CTD_human,21310277,Dihydrofolate reductase deficiency due to a homozygous DHFR mutation causes megaloblastic anemia and cerebral folate deficiency leading to severe neurologic disease.,0.40027472678421294,"Dihydrofolate reductase deficiency due to a homozygous <span class=""gene"" id=""21310277-0-55-59"">DHFR</span> mutation causes <span class=""disease"" id=""21310277-0-76-96"">megaloblastic anemia</span> and cerebral folate deficiency leading to severe neurologic disease.",CTD_human;HPO
1,0,Biomarker,C0003873,Rheumatoid Arthritis,disease,RA,1719,DHFR,dihydrofolate reductase,CTD_human,23897011,"Concurrent with evidence of an immune-activation gene signature in MTX-naive RA patients, significant up-regulation of the folate-metabolizing enzymes ?-glutamyl hydrolase and dihydrofolate reductase, as well as the MTX/folate efflux transporters ABCC2 and ABCC5, was observed in the MTX-naive RA group compared to healthy controls.",0.201098907136852,"Concurrent with evidence of an immune-activation gene signature in MTX-naive <span class=""disease"" id=""23897011-6-77-79"">RA</span> patients, significant up-regulation of the folate-metabolizing enzymes &gamma;-glutamyl hydrolase and <span class=""gene"" id=""23897011-6-176-199"">dihydrofolate reductase</span>, as well as the MTX/folate efflux transporters ABCC2 and ABCC5, was observed in the MTX-naive <span class=""disease"" id=""23897011-6-294-296"">RA</span> group compared to healthy controls.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,1719,DHFR,DHFR,CTD_human,17597297,Preliminary evidence for involvement of the folate gene polymorphism 19bp deletion-DHFR in occurrence of autism.,0.20300763924902696,"Preliminary evidence for involvement of the folate gene polymorphism 19bp deletion-<span class=""gene"" id=""17597297-0-83-87"">DHFR</span> in occurrence of <span class=""disease"" id=""17597297-0-105-111"">autism</span>.",CTD_human
2,0,Biomarker,C0025521,Inborn Errors of Metabolism,group,inborn error of metabolism,1719,DHFR,DHFR,CTD_human,21310276,"We describe three individuals from two families with a recessive inborn error of metabolism, characterized by megaloblastic anemia and/or pancytopenia, severe cerebral folate deficiency, and cerebral tetrahydrobiopterin deficiency due to a germline missense mutation in DHFR, resulting in profound enzyme deficiency.",0.2,"We describe three individuals from two families with a recessive <span class=""disease"" id=""21310276-2-65-91"">inborn error of metabolism</span>, characterized by megaloblastic anemia and/or pancytopenia, severe cerebral folate deficiency, and cerebral tetrahydrobiopterin deficiency due to a germline missense mutation in <span class=""gene"" id=""21310276-2-270-274"">DHFR</span>, resulting in profound enzyme deficiency.",CTD_human
1,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastases,1719,DHFR,DHFR,CTD_human,19159907,"DHFR and RFC1 expression was lower in initial osteosarcoma biopsy specimens than in metastases (P = .024 and P = .041, respectively).",0.281098907136852,"<span class=""gene"" id=""19159907-5-0-4"">DHFR</span> and RFC1 expression was lower in initial osteosarcoma biopsy specimens than in <span class=""disease"" id=""19159907-5-84-94"">metastases</span> (P = .024 and P = .041, respectively).",CTD_human
2,0,Biomarker,C0027765,nervous system disorder,group,neurological disease,1719,DHFR,DHFR,CTD_human,21310277,"In conclusion, the homozygous DHFR mutation p.Asp153Val causes DHFR deficiency and leads to a complex hematological and neurological disease that can be successfully treated with folinic acid.",0.200274726784213,"In conclusion, the homozygous <span class=""gene"" id=""21310277-10-30-34"">DHFR</span> mutation p.Asp153Val causes DHFR deficiency and leads to a complex hematological and <span class=""disease"" id=""21310277-10-120-140"">neurological disease</span> that can be successfully treated with folinic acid.",CTD_human
1,0,Biomarker,C0029463,Osteosarcoma,disease,osteosarcoma,1719,DHFR,DHFR,CTD_human,19159907,Altered expression of DHFR and RFC1 is a feasible mechanism by which osteosarcoma cells become resistant to methotrexate.,0.207114185634906,"Altered expression of <span class=""gene"" id=""19159907-9-22-26"">DHFR</span> and RFC1 is a feasible mechanism by which <span class=""disease"" id=""19159907-9-69-81"">osteosarcoma</span> cells become resistant to methotrexate.",CTD_human
1,0,Biomarker,C0030312,Pancytopenia,disease,pancytopenia,1719,DHFR,DHFR,CTD_human,21310276,"We describe three individuals from two families with a recessive inborn error of metabolism, characterized by megaloblastic anemia and/or pancytopenia, severe cerebral folate deficiency, and cerebral tetrahydrobiopterin deficiency due to a germline missense mutation in DHFR, resulting in profound enzyme deficiency.",0.4,"We describe three individuals from two families with a recessive inborn error of metabolism, characterized by megaloblastic anemia and/or <span class=""disease"" id=""21310276-2-138-150"">pancytopenia</span>, severe cerebral folate deficiency, and cerebral tetrahydrobiopterin deficiency due to a germline missense mutation in <span class=""gene"" id=""21310276-2-270-274"">DHFR</span>, resulting in profound enzyme deficiency.",CTD_human;HPO
1,0,Biomarker,C0004096,Asthma,disease,asthma,1728,NQO1,NQO1,CTD_human,20049212,Genetic polymorphisms in the NQO1 gene are related to asthma susceptibility among persons exposed to local traffic-related air pollution.,0.21663998541343302,"Genetic polymorphisms in the <span class=""gene"" id=""20049212-9-29-33"">NQO1</span> gene are related to <span class=""disease"" id=""20049212-9-54-60"">asthma</span> susceptibility among persons exposed to local traffic-related air pollution.",CTD_human
2,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,non-small cell lung cancer,1728,NQO1,NQO1,CTD_human,21479364,The NQO1*2/*2 polymorphism is associated with poor overall survival in patients following resection of stages II and IIIa non-small cell lung cancer.,0.20467035533162303,"The <span class=""gene"" id=""21479364-0-4-8"">NQO1</span>*2/*2 polymorphism is associated with poor overall survival in patients following resection of stages II and IIIa <span class=""disease"" id=""21479364-0-122-148"">non-small cell lung cancer</span>.",CTD_human
2,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,NSCLC,1728,NQO1,NQO1,CTD_human,9865924,"These data suggest that RH1 may be an effective NQO1-directed antitumor agent for the therapy of tumors with elevated NQO1 activity, such as NSCLC.",0.20467035533162303,"These data suggest that RH1 may be an effective <span class=""gene"" id=""9865924-10-48-52"">NQO1</span>-directed antitumor agent for the therapy of tumors with elevated <span class=""gene"" id=""9865924-10-118-122"">NQO1</span> activity, such as <span class=""disease"" id=""9865924-10-141-146"">NSCLC</span>.",CTD_human
1,0,Biomarker,C0019061,Hemolytic-Uremic Syndrome,disease,hemolytic uremic syndrome,1728,NQO1,DT-diaphorase,CTD_human,12588957,"These results suggest that a high expression of DT-diaphorase in podocytes could play a major role in the pathogenesis of renal toxicity and mitomycin C-induced hemolytic uremic syndrome, in which injury to the glomerular filtration mechanism is the primary damage, leading to a cascade of deleterious events including microangiopathic hemolytic anemia and thrombocytopenia.",0.2,"These results suggest that a high expression of <span class=""gene"" id=""12588957-6-48-61"">DT-diaphorase</span> in podocytes could play a major role in the pathogenesis of renal toxicity and mitomycin C-induced <span class=""disease"" id=""12588957-6-161-186"">hemolytic uremic syndrome</span>, in which injury to the glomerular filtration mechanism is the primary damage, leading to a cascade of deleterious events including microangiopathic hemolytic anemia and thrombocytopenia.",CTD_human
1,0,Therapeutic,C0020456,Hyperglycemia,disease,hyperglycemia,1728,NQO1,NQO1,CTD_human,23458895,"NQO1 knockout (KO) mice showed hyperglycemia, body weight loss, impaired glucose clearance rate and a lower plasma insulin level after MLDS treatment.",0.2,"<span class=""gene"" id=""23458895-3-0-4"">NQO1</span> knockout (KO) mice showed <span class=""disease"" id=""23458895-3-31-44"">hyperglycemia</span>, body weight loss, impaired glucose clearance rate and a lower plasma insulin level after MLDS treatment.",CTD_human
1,0,Biomarker,C0023470,Myeloid Leukemia,disease,myeloid leukemia,1728,NQO1,NQO1,CTD_human,11882782,"In cancer patients, the NQO1*2 allele appears to be associated with increased risk of chemotherapy-related myeloid leukemia.",0.20777053913829002,"In cancer patients, the <span class=""gene"" id=""11882782-9-24-28"">NQO1</span>*2 allele appears to be associated with increased risk of chemotherapy-related <span class=""disease"" id=""11882782-9-107-123"">myeloid leukemia</span>.",CTD_human
1,0,Biomarker,C0026764,Multiple Myeloma,disease,MM,1728,NQO1,NQO1,CTD_human,16949155,"Individuals who carried polymorphisms for GSTT1 null and/or high activity microsomal epoxide hydrolase (mEH 113YY+139HR or 113YY+139RR or 113YH+139RR) and/or low activity NAD(P)H:quinone oxidoreductase 1 (NQO1 187PS/SS) were 1.65, 2.49 and 13 times more likely to have MM (P(trend)=0.001).",0.206238848124954,"Individuals who carried polymorphisms for GSTT1 null and/or high activity microsomal epoxide hydrolase (mEH 113YY+139HR or 113YY+139RR or 113YH+139RR) and/or low activity NAD(P)H:quinone oxidoreductase 1 (<span class=""gene"" id=""16949155-3-205-209"">NQO1</span> 187PS/SS) were 1.65, 2.49 and 13 times more likely to have <span class=""disease"" id=""16949155-3-269-271"">MM</span> (P(trend)=0.001).",CTD_human
1,0,Biomarker,C0030567,Parkinson Disease,disease,Parkinson's disease,1728,NQO1,NQO1,CTD_human,17188257,Pesticide exposure on southwestern Taiwanese with MnSOD and NQO1 polymorphisms is associated with increased risk of Parkinson's disease.,0.220406292480469,"Pesticide exposure on southwestern Taiwanese with MnSOD and <span class=""gene"" id=""17188257-0-60-64"">NQO1</span> polymorphisms is associated with increased risk of <span class=""disease"" id=""17188257-0-116-135"">Parkinson's disease</span>.",CTD_human
1,0,Biomarker,C1458155,Mammary Neoplasms,group,breast tumors,1728,NQO1,NQO1,CTD_human,18511948,"We propose a model of defective anthracycline response in NQO1-deficient breast tumors, along with increased genomic instability promoted by elevated reactive oxygen species (ROS), and suggest that the NQO1 genotype is a prognostic and predictive marker for breast cancer.",0.215261765872035,"We propose a model of defective anthracycline response in <span class=""gene"" id=""18511948-5-58-62"">NQO1</span>-deficient <span class=""disease"" id=""18511948-5-73-86"">breast tumors</span>, along with increased genomic instability promoted by elevated reactive oxygen species (ROS), and suggest that the <span class=""gene"" id=""18511948-5-202-206"">NQO1</span> genotype is a prognostic and predictive marker for breast cancer.",CTD_human
1,0,Biomarker,C1961102,Precursor Cell Lymphoblastic Leukemia Lymphoma,disease,acute lymphoblastic leukemia,1728,NQO1,NQO1,CTD_human,17332311,Excess transmission of the NAD(P)H:quinone oxidoreductase 1 (NQO1) C609T polymorphism in families of children with acute lymphoblastic leukemia.,0.237530218927698,"Excess transmission of the NAD(P)H:quinone oxidoreductase 1 (<span class=""gene"" id=""17332311-0-61-65"">NQO1</span>) C609T polymorphism in families of children with <span class=""disease"" id=""17332311-0-115-143"">acute lymphoblastic leukemia</span>.",CTD_human
1,0,Biomarker,C0025500,Mesothelioma,disease,mesothelioma,1734,DIO2,type 2 iodothyronine deiodinase,CTD_human,11425850,The human type 2 iodothyronine deiodinase is a selenoprotein highly expressed in a mesothelioma cell line.,0.2,"The human <span class=""gene"" id=""11425850-0-10-41"">type 2 iodothyronine deiodinase</span> is a selenoprotein highly expressed in a <span class=""disease"" id=""11425850-0-83-95"">mesothelioma</span> cell line.",CTD_human
2,0,Biomarker,C0265965,Dyskeratosis Congenita,disease,DC,1736,DKC1,DKC1,CTD_human,17785587,"X-linked DC is due to mutations in DKC1, while heterozygous mutations in TERC (telomerase RNA component) and TERT (telomerase reverse transcriptase) have been found in autosomal dominant DC.",0.42190636585046204,"X-linked <span class=""disease"" id=""17785587-2-9-11"">DC</span> is due to mutations in <span class=""gene"" id=""17785587-2-35-39"">DKC1</span>, while heterozygous mutations in TERC (telomerase RNA component) and TERT (telomerase reverse transcriptase) have been found in autosomal dominant <span class=""disease"" id=""17785587-2-187-189"">DC</span>.",CTD_human;ORPHANET
2,0,Biomarker,C0265965,Dyskeratosis Congenita,disease,DC,1736,DKC1,dkc1,CTD_human,22299032,Our data therefore support a model that deficiency in dkc1 and nola1 in the H/ACA RNP complex likely contributes to the hematopoietic phenotype through p53 activation associated with rRNA processing defects rather than telomerase deficiency during the initial stage of DC pathogenesis.,0.42190636585046204,"Our data therefore support a model that deficiency in <span class=""gene"" id=""22299032-6-54-58"">dkc1</span> and nola1 in the H/ACA RNP complex likely contributes to the hematopoietic phenotype through p53 activation associated with rRNA processing defects rather than telomerase deficiency during the initial stage of <span class=""disease"" id=""22299032-6-269-271"">DC</span> pathogenesis.",CTD_human;ORPHANET
3,0,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,1739,DLG1,SAP97,CTD_human,18665322,An association analysis of synapse-associated protein 97 (SAP97) gene in schizophrenia.,0.206462417751855,"An association analysis of <span class=""gene"" id=""18665322-0-27-56"">synapse-associated protein 97</span> (<span class=""gene"" id=""18665322-0-58-63"">SAP97</span>) gene in <span class=""disease"" id=""18665322-0-73-86"">schizophrenia</span>.",CTD_human
3,0,Biomarker,C0036341,Schizophrenia,disease,SZ,1739,DLG1,DLG1,CTD_human,20691406,"Moreover, this 3q29 deletion region contains two linkage peaks from prior SZ family studies, and the minimal deletion interval implicates 20 annotated genes, including PAK2 and DLG1, both paralogous to X-linked ID genes and now strong candidates for SZ susceptibility.",0.206462417751855,"Moreover, this 3q29 deletion region contains two linkage peaks from prior <span class=""disease"" id=""20691406-8-74-76"">SZ</span> family studies, and the minimal deletion interval implicates 20 annotated genes, including PAK2 and <span class=""gene"" id=""20691406-8-177-181"">DLG1</span>, both paralogous to X-linked ID genes and now strong candidates for <span class=""disease"" id=""20691406-8-250-252"">SZ</span> susceptibility.",CTD_human
3,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,174,AFP,alpha-fetoprotein,CTD_human,9029167,"Molecular biological analyses of the induced lesions revealed point mutations in the p53 gene in 60.9% of HCCs, and elevated expression of mRNAs for p53, c-myc, c-fos, TGF-alpha, TGF-beta1, alpha-fetoprotein, GST-P, and GGT, and decreased mRNA expression of EGF and EGFR in HCCs when compared to controls.",0.32099368697220604,"Molecular biological analyses of the induced lesions revealed point mutations in the p53 gene in 60.9% of <span class=""disease"" id=""9029167-4-106-109"">HCC</span>s, and elevated expression of mRNAs for p53, c-myc, c-fos, TGF-alpha, TGF-beta1, <span class=""gene"" id=""9029167-4-190-207"">alpha-fetoprotein</span>, GST-P, and GGT, and decreased mRNA expression of EGF and EGFR in <span class=""disease"" id=""9029167-4-274-277"">HCC</span>s when compared to controls.",CTD_human
1,0,Biomarker,C1136249,"Mental Retardation, X-Linked",disease,X-linked mental retardation,1741,DLG3,DLG3,CTD_human,15185169,Mutations in the DLG3 gene cause nonsyndromic X-linked mental retardation.,0.20412090176319603,"Mutations in the <span class=""gene"" id=""15185169-0-17-21"">DLG3</span> gene cause nonsyndromic <span class=""disease"" id=""15185169-0-46-73"">X-linked mental retardation</span>.",CTD_human
1,0,Biomarker,C0175702,Williams Syndrome,disease,Williams' syndrome,1742,DLG4,DLG4,CTD_human,20952458,Association of mouse Dlg4 (PSD-95) gene deletion and human DLG4 gene variation with phenotypes relevant to autism spectrum disorders and Williams' syndrome.,0.280274726784213,"Association of mouse <span class=""gene"" id=""20952458-0-21-25"">Dlg4</span> (<span class=""gene"" id=""20952458-0-27-33"">PSD-95</span>) gene deletion and human <span class=""gene"" id=""20952458-0-59-63"">DLG4</span> gene variation with phenotypes relevant to autism spectrum disorders and <span class=""disease"" id=""20952458-0-137-155"">Williams' syndrome</span>.",CTD_human
1,0,Biomarker,C1510586,Autism Spectrum Disorders,disease,autism spectrum disorders,1742,DLG4,DLG4,CTD_human,20952458,Association of mouse Dlg4 (PSD-95) gene deletion and human DLG4 gene variation with phenotypes relevant to autism spectrum disorders and Williams' syndrome.,0.20054945356842604,"Association of mouse <span class=""gene"" id=""20952458-0-21-25"">Dlg4</span> (<span class=""gene"" id=""20952458-0-27-33"">PSD-95</span>) gene deletion and human <span class=""gene"" id=""20952458-0-59-63"">DLG4</span> gene variation with phenotypes relevant to <span class=""disease"" id=""20952458-0-107-132"">autism spectrum disorders</span> and Williams' syndrome.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,1745,DLX1,DLX1,CTD_human,18728693,We investigated 6 Tag SNPs within the DLX1/2 genes in two cohorts of multiplex (MPX) and one of simplex (SPX) families for association with autism.,0.20541466777231498,"We investigated 6 Tag SNPs within the <span class=""gene"" id=""18728693-4-38-42"">DLX1</span>/2 genes in two cohorts of multiplex (MPX) and one of simplex (SPX) families for association with <span class=""disease"" id=""18728693-4-140-146"">autism</span>.",CTD_human
1,0,Biomarker,C1510586,Autism Spectrum Disorders,disease,ASD,1745,DLX1,DLX1,CTD_human,21302352,A rare haplotype in the DLX1 promoter was associated with ASD (P-value?=?0.001).,0.200274726784213,"A rare haplotype in the <span class=""gene"" id=""21302352-4-24-28"">DLX1</span> promoter was associated with <span class=""disease"" id=""21302352-4-58-61"">ASD</span> (P-value?=?0.001).",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,1746,DLX2,DLX2,CTD_human,18728693,"The DLX1 and DLX2 genes lie head-to-head in 2q32, a region associated with autism susceptibility.",0.20568939455652804,"The DLX1 and <span class=""gene"" id=""18728693-3-13-17"">DLX2</span> genes lie head-to-head in 2q32, a region associated with <span class=""disease"" id=""18728693-3-75-81"">autism</span> susceptibility.",CTD_human
16,285,Biomarker,C0013264,"Muscular Dystrophy, Duchenne",disease,Duchenne muscular dystrophy,1756,DMD,dystrophin,CTD_human,12966700,"Aim of the study was to investigate whether the administration of gentamicin could restore dystrophin expression in striated muscles of patients with Duchenne muscular dystrophy caused by premature stop codon, as reported in mdx mice.",0.851089561087121,"Aim of the study was to investigate whether the administration of gentamicin could restore <span class=""gene"" id=""12966700-1-91-101"">dystrophin</span> expression in striated muscles of patients with <span class=""disease"" id=""12966700-1-150-177"">Duchenne muscular dystrophy</span> caused by premature stop codon, as reported in mdx mice.",CTD_human;ORPHANET;UNIPROT
16,285,Biomarker,C0013264,"Muscular Dystrophy, Duchenne",disease,DMD,1756,DMD,dystrophin,CTD_human,21273767,"In a 24-year-old male with DMD due to the point mutation c.4213C>T (p.Gln1405X) in exon 30 of the dystrophin gene, cardiologic examination at the age of 23 years revealed asymptomatic severely reduced systolic dysfunction with a fractional shortening of 14% in the absence of dilated cardiomyopathy.",0.851089561087121,"In a 24-year-old male with <span class=""disease"" id=""21273767-2-27-30"">DMD</span> due to the point mutation c.4213C&gt;T (p.Gln1405X) in exon 30 of the <span class=""gene"" id=""21273767-2-98-108"">dystrophin</span> gene, cardiologic examination at the age of 23 years revealed asymptomatic severely reduced systolic dysfunction with a fractional shortening of 14% in the absence of dilated cardiomyopathy.",CTD_human;ORPHANET;UNIPROT
16,285,Biomarker,C0013264,"Muscular Dystrophy, Duchenne",disease,DMD,1756,DMD,dystrophin,CTD_human,16122626,"In this study, we introduce an easy system to identify patients for this therapy and report for the first time, that dystrophin expression was detected in myotubes of DMD patients using gentamicin.",0.851089561087121,"In this study, we introduce an easy system to identify patients for this therapy and report for the first time, that <span class=""gene"" id=""16122626-7-117-127"">dystrophin</span> expression was detected in myotubes of <span class=""disease"" id=""16122626-7-167-170"">DMD</span> patients using gentamicin.",CTD_human;ORPHANET;UNIPROT
16,285,Biomarker,C0013264,"Muscular Dystrophy, Duchenne",disease,Duchenne muscular dystrophy,1756,DMD,dystrophin,CTD_human,10939566,"As a result of their ability to induce translational readthrough of stop codons, the aminoglycoside antibiotics are currently being tested for efficacy in the treatment of Duchenne muscular dystrophy patients carrying a nonsense mutation in the dystrophin gene.",0.851089561087121,"As a result of their ability to induce translational readthrough of stop codons, the aminoglycoside antibiotics are currently being tested for efficacy in the treatment of <span class=""disease"" id=""10939566-1-172-199"">Duchenne muscular dystrophy</span> patients carrying a nonsense mutation in the <span class=""gene"" id=""10939566-1-245-255"">dystrophin</span> gene.",CTD_human;ORPHANET;UNIPROT
16,285,Biomarker,C0013264,"Muscular Dystrophy, Duchenne",disease,DMD,1756,DMD,dystrophin,CTD_human,14751810,"In mice lacking dystrophin (mdx mice), a model for DMD, these mutations can be suppressed by aminoglycosides such as gentamicin.",0.851089561087121,"In mice lacking <span class=""gene"" id=""14751810-2-16-26"">dystrophin</span> (mdx mice), a model for <span class=""disease"" id=""14751810-2-51-54"">DMD</span>, these mutations can be suppressed by aminoglycosides such as gentamicin.",CTD_human;ORPHANET;UNIPROT
16,285,Biomarker,C0013264,"Muscular Dystrophy, Duchenne",disease,DMD,1756,DMD,dystrophin,CTD_human,24349043,"Duchenne Muscular Dystrophy (DMD) is a recessive X-linked genetic disease, caused by mutations in the gene encoding dystrophin.",0.851089561087121,"<span class=""disease"" id=""24349043-1-0-27"">Duchenne Muscular Dystrophy</span> (<span class=""disease"" id=""24349043-1-29-32"">DMD</span>) is a recessive X-linked genetic disease, caused by mutations in the gene encoding <span class=""gene"" id=""24349043-1-116-126"">dystrophin</span>.",CTD_human;ORPHANET;UNIPROT
4,0,Therapeutic,C0026850,Muscular Dystrophy,disease,muscular dystrophies,1756,DMD,dystrophin,CTD_human,10797403,Mutations in the dystrophin gene that lead to the expression of truncated forms of the dystrophin protein cause muscular dystrophies of varying severities both in humans and in mice.,0.49494520993952706,"Mutations in the <span class=""gene"" id=""10797403-1-17-27"">dystrophin</span> gene that lead to the expression of truncated forms of the <span class=""gene"" id=""10797403-1-87-97"">dystrophin</span> protein cause <span class=""disease"" id=""10797403-1-112-132"">muscular dystrophies</span> of varying severities both in humans and in mice.",CTD_human;HPO
4,0,Biomarker,C0026850,Muscular Dystrophy,disease,muscular dystrophies,1756,DMD,dystrophin,CTD_human,10797403,Mutations in the dystrophin gene that lead to the expression of truncated forms of the dystrophin protein cause muscular dystrophies of varying severities both in humans and in mice.,0.49494520993952706,"Mutations in the <span class=""gene"" id=""10797403-1-17-27"">dystrophin</span> gene that lead to the expression of truncated forms of the <span class=""gene"" id=""10797403-1-87-97"">dystrophin</span> protein cause <span class=""disease"" id=""10797403-1-112-132"">muscular dystrophies</span> of varying severities both in humans and in mice.",CTD_human;HPO
4,0,Therapeutic,C0026850,Muscular Dystrophy,disease,muscular dystrophies,1756,DMD,dystrophin,CTD_human,22906800,"Since Duchenne muscular dystrophy was attributed to mutations in the dystrophin gene, more than 30 genes have been found to be causally related with muscular dystrophies, about half of them encoding proteins of the dystrophin-glycoprotein complex (DGC).",0.49494520993952706,"Since Duchenne muscular dystrophy was attributed to mutations in the <span class=""gene"" id=""22906800-1-69-79"">dystrophin</span> gene, more than 30 genes have been found to be causally related with <span class=""disease"" id=""22906800-1-149-169"">muscular dystrophies</span>, about half of them encoding proteins of the <span class=""gene"" id=""22906800-1-215-225"">dystrophin</span>-glycoprotein complex (DGC).",CTD_human;HPO
4,0,Biomarker,C0026850,Muscular Dystrophy,disease,muscular dystrophies,1756,DMD,dystrophin,CTD_human,22906800,"Since Duchenne muscular dystrophy was attributed to mutations in the dystrophin gene, more than 30 genes have been found to be causally related with muscular dystrophies, about half of them encoding proteins of the dystrophin-glycoprotein complex (DGC).",0.49494520993952706,"Since Duchenne muscular dystrophy was attributed to mutations in the <span class=""gene"" id=""22906800-1-69-79"">dystrophin</span> gene, more than 30 genes have been found to be causally related with <span class=""disease"" id=""22906800-1-149-169"">muscular dystrophies</span>, about half of them encoding proteins of the <span class=""gene"" id=""22906800-1-215-225"">dystrophin</span>-glycoprotein complex (DGC).",CTD_human;HPO
1,0,Biomarker,C0038220,Status Epilepticus,disease,SE,1756,DMD,dystrophin,CTD_human,20886625,These findings suggest that SE may induce impairments of astroglial AQP4 functions via disruption of the dystrophin/?-syntrophin complex that worsen vasogenic edema.,0.28,"These findings suggest that <span class=""disease"" id=""20886625-8-28-30"">SE</span> may induce impairments of astroglial AQP4 functions via disruption of the <span class=""gene"" id=""20886625-8-105-115"">dystrophin</span>/&alpha;-syntrophin complex that worsen vasogenic edema.",CTD_human
1,0,Biomarker,C0238198,Gastrointestinal Stromal Tumors,group,GIST,1756,DMD,dystrophin,CTD_human,24793134,"Dystrophin inhibits myogenic sarcoma cell migration, invasion, anchorage independence and invadopodia formation, and dystrophin inactivation was found in 96%, 100% and 62% of metastatic GIST, embryonal RMS and LMS samples, respectively.",0.200274726784213,"<span class=""gene"" id=""24793134-4-0-10"">Dystrophin</span> inhibits myogenic sarcoma cell migration, invasion, anchorage independence and invadopodia formation, and <span class=""gene"" id=""24793134-4-117-127"">dystrophin</span> inactivation was found in 96%, 100% and 62% of metastatic <span class=""disease"" id=""24793134-4-186-190"">GIST</span>, embryonal RMS and LMS samples, respectively.",CTD_human
1,0,Biomarker,C0027126,Myotonic Dystrophy,disease,myotonic dystrophy,1760,DMPK,DMPK,CTD_human,24039817,"To address this, we utilized transgenic mice over-expressing the DMPK 3' UTR as part of an inducible RNA transcript to model early-onset myotonic dystrophy.",0.32902415576942606,"To address this, we utilized transgenic mice over-expressing the <span class=""gene"" id=""24039817-5-65-69"">DMPK</span> 3' UTR as part of an inducible RNA transcript to model early-onset <span class=""disease"" id=""24039817-5-137-155"">myotonic dystrophy</span>.",CTD_human
1,0,Biomarker,C0003873,Rheumatoid Arthritis,disease,rheumatoid arthritis,177,AGER,receptor for advanced glycation end products,CTD_human,16385501,Increased expression of receptor for advanced glycation end products by synovial tissue macrophages in rheumatoid arthritis.,0.209572371315507,"Increased expression of <span class=""gene"" id=""16385501-0-24-68"">receptor for advanced glycation end products</span> by synovial tissue macrophages in <span class=""disease"" id=""16385501-0-103-123"">rheumatoid arthritis</span>.",CTD_human
2,0,Biomarker,C0004153,Atherosclerosis,disease,atherosclerosis,177,AGER,RAGE,CTD_human,19939336,"Interestingly, the accelerated atherosclerosis could be prevented by RAS inhibition, or markedly reduced by RAGE blockade, probably through anti-inflammatory and antioxidative effects.",0.29823260334106605,"Interestingly, the accelerated <span class=""disease"" id=""19939336-17-31-46"">atherosclerosis</span> could be prevented by RAS inhibition, or markedly reduced by <span class=""gene"" id=""19939336-17-108-112"">RAGE</span> blockade, probably through anti-inflammatory and antioxidative effects.",CTD_human
1,0,Biomarker,C0027796,Neuralgia,phenotype,neuropathic pain,177,AGER,Receptor for Advanced Glycation End-products,CTD_human,25014009,Identification of a functional interaction of HMGB1 with Receptor for Advanced Glycation End-products in a model of neuropathic pain.,0.2,"Identification of a functional interaction of HMGB1 with <span class=""gene"" id=""25014009-0-57-101"">Receptor for Advanced Glycation End-products</span> in a model of <span class=""disease"" id=""25014009-0-116-132"">neuropathic pain</span>.",CTD_human
1,0,Biomarker,C0024141,"Lupus Erythematosus, Systemic",disease,systemic lupus erythematosus,1776,DNASE1L3,DNASE1L3,CTD_human,22019780,Loss-of-function variant in DNASE1L3 causes a familial form of systemic lupus erythematosus.,0.40082418035263895,"Loss-of-function variant in <span class=""gene"" id=""22019780-0-28-36"">DNASE1L3</span> causes a familial form of <span class=""disease"" id=""22019780-0-63-91"">systemic lupus erythematosus</span>.",CTD_human;HPO
1,0,Biomarker,C0025958,Microcephaly,disease,microcephaly,1778,DYNC1H1,DYNC1H1,CTD_human,23603762,"Mutations in TUBG1, DYNC1H1, KIF5C and KIF2A cause malformations of cortical development and microcephaly.",0.2,"Mutations in TUBG1, <span class=""gene"" id=""23603762-0-20-27"">DYNC1H1</span>, KIF5C and KIF2A cause malformations of cortical development and <span class=""disease"" id=""23603762-0-93-105"">microcephaly</span>.",CTD_human
1,0,Biomarker,C1955869,Malformations of Cortical Development,disease,malformations of cortical development,1778,DYNC1H1,DYNC1H1,CTD_human,23603762,"Mutations in TUBG1, DYNC1H1, KIF5C and KIF2A cause malformations of cortical development and microcephaly.",0.20054945356842604,"Mutations in TUBG1, <span class=""gene"" id=""23603762-0-20-27"">DYNC1H1</span>, KIF5C and KIF2A cause <span class=""disease"" id=""23603762-0-51-88"">malformations of cortical development</span> and microcephaly.",CTD_human
4,70,Biomarker,C0017922,Glycogen Storage Disease Type III,disease,GSD-III,178,AGL,4529insA,CTD_human,8990006,The 4529insA mutation appeared to be homozygous in this patient and was not found in 20 unrelated controls or 18 other GSD-III patients (14 GSD-IIIa and 4 GSD-IIIb).,0.7015948372862529,"The <span class=""gene"" id=""8990006-5-4-12"">4529insA</span> mutation appeared to be homozygous in this patient and was not found in 20 unrelated controls or 18 other <span class=""disease"" id=""8990006-5-119-126"">GSD-III</span> patients (14 GSD-IIIa and 4 GSD-IIIb).",CTD_human;ORPHANET;UNIPROT
4,70,Biomarker,C0017922,Glycogen Storage Disease Type III,disease,glycogen storage disease type III,178,AGL,glycogen debranching enzyme,CTD_human,8755644,Mutations in exon 3 of the glycogen debranching enzyme gene are associated with glycogen storage disease type III that is differentially expressed in liver and muscle.,0.7015948372862529,"Mutations in exon 3 of the <span class=""gene"" id=""8755644-0-27-54"">glycogen debranching enzyme</span> gene are associated with <span class=""disease"" id=""8755644-0-80-113"">glycogen storage disease type III</span> that is differentially expressed in liver and muscle.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0031117,Peripheral Neuropathy,group,PN,1780,DYNC1I1,DYNC1I1,CTD_human,21228734,"Genes associated with immune function (CTLA4, CTSS), reflexive coupling within Schwann cells (GJE1), drug binding (PSMB1), and neuron function (TCF4, DYNC1I1) associated with bortezomib-induced PN in this study.",0.200274726784213,"Genes associated with immune function (CTLA4, CTSS), reflexive coupling within Schwann cells (GJE1), drug binding (PSMB1), and neuron function (TCF4, <span class=""gene"" id=""21228734-10-150-157"">DYNC1I1</span>) associated with bortezomib-induced <span class=""disease"" id=""21228734-10-194-196"">PN</span> in this study.",CTD_human
1,0,Biomarker,C0003469,Anxiety Disorders,group,anxiety,1786,DNMT1,DNA methyltransferase 1,CTD_human,23791455,Persistent overexpression of DNA methyltransferase 1 attenuating GABAergic inhibition in basolateral amygdala accounts for anxiety in rat offspring exposed perinatally to low-dose bisphenol A.,0.2,"Persistent overexpression of <span class=""gene"" id=""23791455-0-29-52"">DNA methyltransferase 1</span> attenuating GABAergic inhibition in basolateral amygdala accounts for <span class=""disease"" id=""23791455-0-123-130"">anxiety</span> in rat offspring exposed perinatally to low-dose bisphenol A.",CTD_human
1,0,Biomarker,C0004096,Asthma,disease,asthma,1786,DNMT1,DNMT1,CTD_human,23423710,We proposed for the first time that DNMT1 played a key role in PDGF-induced RASM cell phenotypic switching and Aza-CdR is promising in intervening ASM remodeling in asthma.,0.2,"We proposed for the first time that <span class=""gene"" id=""23423710-11-36-41"">DNMT1</span> played a key role in PDGF-induced RASM cell phenotypic switching and Aza-CdR is promising in intervening ASM remodeling in <span class=""disease"" id=""23423710-11-165-171"">asthma</span>.",CTD_human
1,0,Biomarker,C0009375,Colonic Neoplasms,group,colon tumors,1786,DNMT1,DNMT1,CTD_human,19723570,"Further, 5-azacytidine potentiated cisplatin induced antitumor activity by involving decreased expression of pAKT, DNMT1 and an increased expression of p38 in colon tumors.",0.2,"Further, 5-azacytidine potentiated cisplatin induced antitumor activity by involving decreased expression of pAKT, <span class=""gene"" id=""19723570-8-115-120"">DNMT1</span> and an increased expression of p38 in <span class=""disease"" id=""19723570-8-159-171"">colon tumors</span>.",CTD_human
1,0,Biomarker,C0027889,Hereditary Sensory and Autonomic Neuropathies,group,hereditary sensory and autonomic neuropathy,1786,DNMT1,DNMT1,CTD_human,21532572,Here we show that mutations in DNMT1 cause both central and peripheral neurodegeneration in one form of hereditary sensory and autonomic neuropathy with dementia and hearing loss.,0.201373633921065,"Here we show that mutations in <span class=""gene"" id=""21532572-3-31-36"">DNMT1</span> cause both central and peripheral neurodegeneration in one form of <span class=""disease"" id=""21532572-3-104-147"">hereditary sensory and autonomic neuropathy</span> with dementia and hearing loss.",CTD_human
1,0,Biomarker,C0497327,Dementia,disease,dementia,1786,DNMT1,DNMT1,CTD_human,21532572,Mutations in DNMT1 cause hereditary sensory neuropathy with dementia and hearing loss.,0.40137363392106606,"Mutations in <span class=""gene"" id=""21532572-0-13-18"">DNMT1</span> cause hereditary sensory neuropathy with <span class=""disease"" id=""21532572-0-60-68"">dementia</span> and hearing loss.",CTD_human;HPO
1,0,Biomarker,C0020981,Angioimmunoblastic Lymphadenopathy,disease,AITL,1788,DNMT3A,DNMT3A,CTD_human,24413737,"Although frequent mutations in TET2, IDH2 and DNMT3A, which are common to various hematologic malignancies, have been identified in AITL, the molecular pathogenesis specific to this lymphoma subtype is unknown.",0.20082418035263896,"Although frequent mutations in TET2, IDH2 and <span class=""gene"" id=""24413737-2-46-52"">DNMT3A</span>, which are common to various hematologic malignancies, have been identified in <span class=""disease"" id=""24413737-2-132-136"">AITL</span>, the molecular pathogenesis specific to this lymphoma subtype is unknown.",CTD_human
1,0,Biomarker,C0023465,Acute monocytic leukemia,disease,acute monocytic leukemia,1788,DNMT3A,DNMT3A,CTD_human,21399634,Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia.,0.200274726784213,"Exome sequencing identifies somatic mutations of DNA methyltransferase gene <span class=""gene"" id=""21399634-0-76-82"">DNMT3A</span> in <span class=""disease"" id=""21399634-0-86-110"">acute monocytic leukemia</span>.",CTD_human
1,0,Biomarker,C0036920,Sezary Syndrome,disease,Sézary syndrome,1788,DNMT3A,DNMT3A,CTD_human,26551667,"These analyses identified a distinctive pattern of somatic copy number alterations in Sézary syndrome, including highly prevalent chromosomal deletions involving the TP53, RB1, PTEN, DNMT3A and CDKN1B tumor suppressors.",0.2,"These analyses identified a distinctive pattern of somatic copy number alterations in <span class=""disease"" id=""26551667-3-86-101"">S&eacute;zary syndrome</span>, including highly prevalent chromosomal deletions involving the TP53, RB1, PTEN, <span class=""gene"" id=""26551667-3-183-189"">DNMT3A</span> and CDKN1B tumor suppressors.",CTD_human
2,0,Biomarker,C0079774,Peripheral T-Cell Lymphoma,disease,PTCL,1788,DNMT3A,DNMT3A,CTD_human,24413734,"These analyses identified highly recurrent epigenetic factor mutations in TET2, DNMT3A and IDH2 as well as a new highly prevalent RHOA mutation encoding a p.Gly17Val alteration present in 22 of 35 (67%) angioimmunoblastic T cell lymphoma (AITL) samples and in 8 of 44 (18%) PTCL, not otherwise specified (PTCL-NOS) samples.",0.2,"These analyses identified highly recurrent epigenetic factor mutations in TET2, <span class=""gene"" id=""24413734-3-80-86"">DNMT3A</span> and IDH2 as well as a new highly prevalent RHOA mutation encoding a p.Gly17Val alteration present in 22 of 35 (67%) angioimmunoblastic T cell lymphoma (AITL) samples and in 8 of 44 (18%) <span class=""disease"" id=""24413734-3-274-278"">PTCL</span>, not otherwise specified (<span class=""disease"" id=""24413734-3-305-309"">PTCL</span>-NOS) samples.",CTD_human
1,0,Biomarker,C3714756,Intellectual Disability,group,intellectual disability,1788,DNMT3A,DNMT3A,CTD_human,24614070,Mutations in the DNA methyltransferase gene DNMT3A cause an overgrowth syndrome with intellectual disability.,0.200274726784213,"Mutations in the DNA methyltransferase gene <span class=""gene"" id=""24614070-0-44-50"">DNMT3A</span> cause an overgrowth syndrome with <span class=""disease"" id=""24614070-0-85-108"">intellectual disability</span>.",CTD_human
1,0,Biomarker,C0024121,Lung Neoplasms,group,lung tumor,1796,DOK1,Dok1,CTD_human,20139980,"Here we identify the downstream of tyrosine kinase (Dok) family members Dok1, Dok2 and Dok3 as lung tumor suppressors.",0.2,"Here we identify the downstream of tyrosine kinase (Dok) family members <span class=""gene"" id=""20139980-2-72-76"">Dok1</span>, Dok2 and Dok3 as <span class=""disease"" id=""20139980-2-95-105"">lung tumor</span> suppressors.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,18,ABAT,ABAT,CTD_human,15830322,Candidate-gene screening and association analysis at the autism-susceptibility locus on chromosome 16p: evidence of association at GRIN2A and ABAT.,0.202681755307501,"Candidate-gene screening and association analysis at the <span class=""disease"" id=""15830322-0-57-63"">autism</span>-susceptibility locus on chromosome 16p: evidence of association at GRIN2A and <span class=""gene"" id=""15830322-0-142-146"">ABAT</span>.",CTD_human
1,0,Biomarker,C0017168,Gastroesophageal reflux disease,disease,gastro esophageal reflux disease,18,ABAT,ABAT,CTD_human,21552517,4-aminobutyrate aminotransferase (ABAT): genetic and pharmacological evidence for an involvement in gastro esophageal reflux disease.,0.200274726784213,"<span class=""gene"" id=""21552517-0-0-32"">4-aminobutyrate aminotransferase</span> (<span class=""gene"" id=""21552517-0-34-38"">ABAT</span>): genetic and pharmacological evidence for an involvement in <span class=""disease"" id=""21552517-0-100-132"">gastro esophageal reflux disease</span>.",CTD_human
1,4,Biomarker,C0342708,Gamma aminobutyric acid transaminase deficiency,disease,GABA-transaminase) deficiency,18,ABAT,4-Aminobutyrate aminotransferase,CTD_human,10407778,4-Aminobutyrate aminotransferase (GABA-transaminase) deficiency.,0.6,"<span class=""gene"" id=""10407778-0-0-32"">4-Aminobutyrate aminotransferase</span> (<span class=""disease"" id=""10407778-0-34-63"">GABA-transaminase) deficiency</span>.",CTD_human;ORPHANET;UNIPROT
1,1,Biomarker,C0002736,Amyotrophic Lateral Sclerosis,disease,amyotrophic lateral sclerosis,1804,DPP6,DPP6,CTD_human,18084291,Genetic variation in DPP6 is associated with susceptibility to amyotrophic lateral sclerosis.,0.21187708552416898,"Genetic variation in <span class=""gene"" id=""18084291-0-21-25"">DPP6</span> is associated with susceptibility to <span class=""disease"" id=""18084291-0-63-92"">amyotrophic lateral sclerosis</span>.",CTD_human
2,0,Biomarker,C1510586,Autism Spectrum Disorders,disease,ASD,1804,DPP6,DPP6,CTD_human,18252227,"Notwithstanding complexities, our results further implicate the SHANK3-NLGN4-NRXN1 postsynaptic density genes and also identify novel loci at DPP6-DPP10-PCDH9 (synapse complex), ANKRD11, DPYD, PTCHD1, 15q24, among others, for a role in ASD susceptibility.",0.201373633921065,"Notwithstanding complexities, our results further implicate the SHANK3-NLGN4-NRXN1 postsynaptic density genes and also identify novel loci at <span class=""gene"" id=""18252227-8-142-146"">DPP6</span>-DPP10-PCDH9 (synapse complex), ANKRD11, DPYD, PTCHD1, 15q24, among others, for a role in <span class=""disease"" id=""18252227-8-236-239"">ASD</span> susceptibility.",CTD_human
2,0,Biomarker,C1510586,Autism Spectrum Disorders,disease,ASD,1804,DPP6,DPP6,CTD_human,20844286,"Two of the ASD individuals with missense changes also carried a de novo deletion at another ASD susceptibility locus (DPYD and DPP6), suggesting complex genetic contributions.",0.201373633921065,"Two of the <span class=""disease"" id=""20844286-6-11-14"">ASD</span> individuals with missense changes also carried a de novo deletion at another <span class=""disease"" id=""20844286-6-92-95"">ASD</span> susceptibility locus (DPYD and <span class=""gene"" id=""20844286-6-127-131"">DPP6</span>), suggesting complex genetic contributions.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autistic,1806,DPYD,DPYD,CTD_human,21114665,"Our study suggests that hemizygous deletions involving the DPYD locus present with variable phenotypes which can include speech delay and autistic features, and may also be influenced by additional mutations in other genes, issues which need to be considered in genetic counseling.",0.40027472678421294,"Our study suggests that hemizygous deletions involving the <span class=""gene"" id=""21114665-9-59-63"">DPYD</span> locus present with variable phenotypes which can include speech delay and <span class=""disease"" id=""21114665-9-138-146"">autistic</span> features, and may also be influenced by additional mutations in other genes, issues which need to be considered in genetic counseling.",CTD_human;HPO
1,0,Biomarker,C0031117,Peripheral Neuropathy,group,peripheral neuropathy,1806,DPYD,DPYD,CTD_human,20864405,"Late-onset vincristine-induced peripheral neuropathy was associated with the presence of SNPs in genes involved in absorption, distribution, metabolism, and excretion-eg, rs1413239 in DPYD (3·29, 1·47-7·37, 5·40×10(-3)) and rs3887412 in ABCC1 (3·36, 1·47-7·67, p=5·70×10(-3)).",0.200274726784213,"Late-onset vincristine-induced <span class=""disease"" id=""20864405-14-31-52"">peripheral neuropathy</span> was associated with the presence of SNPs in genes involved in absorption, distribution, metabolism, and excretion-eg, rs1413239 in <span class=""gene"" id=""20864405-14-184-188"">DPYD</span> (3·29, 1·47-7·37, 5·40&times;10(-3)) and rs3887412 in ABCC1 (3·36, 1·47-7·67, p=5·70&times;10(-3)).",CTD_human
2,0,Biomarker,C1510586,Autism Spectrum Disorders,disease,ASD,1806,DPYD,DPYD,CTD_human,18252227,"Notwithstanding complexities, our results further implicate the SHANK3-NLGN4-NRXN1 postsynaptic density genes and also identify novel loci at DPP6-DPP10-PCDH9 (synapse complex), ANKRD11, DPYD, PTCHD1, 15q24, among others, for a role in ASD susceptibility.",0.4010989071368521,"Notwithstanding complexities, our results further implicate the SHANK3-NLGN4-NRXN1 postsynaptic density genes and also identify novel loci at DPP6-DPP10-PCDH9 (synapse complex), ANKRD11, <span class=""gene"" id=""18252227-8-187-191"">DPYD</span>, PTCHD1, 15q24, among others, for a role in <span class=""disease"" id=""18252227-8-236-239"">ASD</span> susceptibility.",CTD_human;HPO
2,0,Biomarker,C1510586,Autism Spectrum Disorders,disease,ASD,1806,DPYD,DPYD,CTD_human,20844286,"Two of the ASD individuals with missense changes also carried a de novo deletion at another ASD susceptibility locus (DPYD and DPP6), suggesting complex genetic contributions.",0.4010989071368521,"Two of the <span class=""disease"" id=""20844286-6-11-14"">ASD</span> individuals with missense changes also carried a de novo deletion at another <span class=""disease"" id=""20844286-6-92-95"">ASD</span> susceptibility locus (<span class=""gene"" id=""20844286-6-118-122"">DPYD</span> and DPP6), suggesting complex genetic contributions.",CTD_human;HPO
1,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,1806,DPYD,DPD,CTD_human,18019677,The DPD mRNA level was lower and the TS mRNA level was higher in HCC than in adjacent liver.,0.201648360705279,"The <span class=""gene"" id=""18019677-12-4-7"">DPD</span> mRNA level was lower and the TS mRNA level was higher in <span class=""disease"" id=""18019677-12-65-68"">HCC</span> than in adjacent liver.",CTD_human
1,0,Biomarker,C0036349,Paranoid Schizophrenia,disease,paranoid-type schizophrenia,1808,DPYSL2,DRP-2,CTD_human,17105906,"The polymorphism *2236T>C in the 3' untranslated region of the DRP-2 gene, which has been shown to be a negative genetic risk factor for paranoid-type schizophrenia, was analyzed in 198 patients with METH psychosis and 221 corresponding healthy controls in a Japanese population.",0.20054945356842604,"The polymorphism *2236T&gt;C in the 3' untranslated region of the <span class=""gene"" id=""17105906-8-63-68"">DRP-2</span> gene, which has been shown to be a negative genetic risk factor for <span class=""disease"" id=""17105906-8-137-164"">paranoid-type schizophrenia</span>, was analyzed in 198 patients with METH psychosis and 221 corresponding healthy controls in a Japanese population.",CTD_human
6,0,Biomarker,C0005586,Bipolar Disorder,disease,bipolar disorder,1812,DRD1,Dopamine D1 receptor,CTD_human,19153942,Dopamine D1 receptor gene polymorphism is associated with prophylactic lithium response in bipolar disorder.,0.415657747968523,"<span class=""gene"" id=""19153942-0-0-20"">Dopamine D1 receptor</span> gene polymorphism is associated with prophylactic lithium response in <span class=""disease"" id=""19153942-0-91-107"">bipolar disorder</span>.",CTD_human;PSYGENET
1,0,Therapeutic,C0030567,Parkinson Disease,disease,Parkinson's disease,1812,DRD1,dopamine D1 receptor,CTD_human,8558425,"ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease.",0.282956482091714,"ABT-431: the diacetyl prodrug of A-86929, a potent and selective <span class=""gene"" id=""8558425-0-65-85"">dopamine D1 receptor</span> agonist: in vitro characterization and effects in animal models of <span class=""disease"" id=""8558425-0-153-172"">Parkinson's disease</span>.",CTD_human
2,0,Biomarker,C0003469,Anxiety Disorders,group,anxiety,1813,DRD2,DRD2,CTD_human,18305461,Association between ADORA2A and DRD2 polymorphisms and caffeine-induced anxiety.,0.20625320350227103,"Association between ADORA2A and <span class=""gene"" id=""18305461-0-32-36"">DRD2</span> polymorphisms and caffeine-induced <span class=""disease"" id=""18305461-0-72-79"">anxiety</span>.",CTD_human
4,0,Biomarker,C0007370,Catalepsy,disease,catalepsy,1813,DRD2,dopamine D2 receptor,CTD_human,7845605,"In the catalepsy test, felbamate antagonized dopamine D2 receptor- but not D1 receptor-induced akinesia.",0.2,"In the <span class=""disease"" id=""7845605-2-7-16"">catalepsy</span> test, felbamate antagonized <span class=""gene"" id=""7845605-2-45-65"">dopamine D2 receptor</span>- but not D1 receptor-induced akinesia.",CTD_human
2,0,Biomarker,C0020514,Hyperprolactinemia,disease,Hyperprolactinaemia,1813,DRD2,D(2) dopamine receptor,CTD_human,15286066,Hyperprolactinaemia induced by D(2) dopamine receptor antagonist antipsychotic medication can result in significant health problems.,0.20914417305935604,"<span class=""disease"" id=""15286066-1-0-19"">Hyperprolactinaemia</span> induced by <span class=""gene"" id=""15286066-1-31-53"">D(2) dopamine receptor</span> antagonist antipsychotic medication can result in significant health problems.",CTD_human
2,0,Biomarker,C0020514,Hyperprolactinemia,disease,hyperprolactinemia,1813,DRD2,dopamine D2 receptor,CTD_human,19339912,Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents.,0.20914417305935604,"Variants of the <span class=""gene"" id=""19339912-0-16-36"">dopamine D2 receptor</span> gene and risperidone-induced <span class=""disease"" id=""19339912-0-66-84"">hyperprolactinemia</span> in children and adolescents.",CTD_human
1,0,Biomarker,C0023015,Language Disorders,group,LI,1813,DRD2,DRD2,CTD_human,23691092,Our results show that smoking during pregnancy increases the risk for LI and poor performance on language tasks and that ANKK1/DRD2 contributes to language performance.,0.200274726784213,"Our results show that smoking during pregnancy increases the risk for <span class=""disease"" id=""23691092-8-70-72"">LI</span> and poor performance on language tasks and that ANKK1/<span class=""gene"" id=""23691092-8-127-131"">DRD2</span> contributes to language performance.",CTD_human
1,0,Biomarker,C0030193,Pain,phenotype,pain,1813,DRD2,dopamine D2 receptor,CTD_human,15996639,Influence of the dopamine D2 receptor knockout on pain-related behavior in the mouse.,0.202956482091714,"Influence of the <span class=""gene"" id=""15996639-0-17-37"">dopamine D2 receptor</span> knockout on <span class=""disease"" id=""15996639-0-50-54"">pain</span>-related behavior in the mouse.",CTD_human
4,0,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,1813,DRD2,dopamine D2 receptor,CTD_human,11245917,"Because dopamine D2 receptors are the primary targets for antipsychotic drugs, including clozapine and quetiapine, and because some studies have found D2 receptors to be elevated in schizophrenia, we examined the mRNA of three forms of the D2 receptor, particularly the new form of the dopamine D2 receptor, D2(Longer), in post-mortem brains from patients who died with schizophrenia.",0.37504308657560104,"Because dopamine D2 receptors are the primary targets for antipsychotic drugs, including clozapine and quetiapine, and because some studies have found D2 receptors to be elevated in <span class=""disease"" id=""11245917-1-182-195"">schizophrenia</span>, we examined the mRNA of three forms of the D2 receptor, particularly the new form of the <span class=""gene"" id=""11245917-1-286-306"">dopamine D2 receptor</span>, D2(Longer), in post-mortem brains from patients who died with <span class=""disease"" id=""11245917-1-370-383"">schizophrenia</span>.",CTD_human
4,0,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,1813,DRD2,dopamine D(2) receptor,CTD_human,10831489,Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone.,0.37504308657560104,"Subjective experience and striatal <span class=""gene"" id=""10831489-0-35-57"">dopamine D(2) receptor</span> occupancy in patients with <span class=""disease"" id=""10831489-0-85-98"">schizophrenia</span> stabilized by olanzapine or risperidone.",CTD_human
4,0,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,1813,DRD2,DRD2,CTD_human,21187413,"DRD2/AKT1 interaction on D2 c-AMP independent signaling, attentional processing, and response to olanzapine treatment in schizophrenia.",0.37504308657560104,"<span class=""gene"" id=""21187413-0-0-4"">DRD2</span>/AKT1 interaction on D2 c-AMP independent signaling, attentional processing, and response to olanzapine treatment in <span class=""disease"" id=""21187413-0-121-134"">schizophrenia</span>.",CTD_human
1,0,Biomarker,C1263846,Attention deficit hyperactivity disorder,disease,ADHD,1813,DRD2,DRD2,CTD_human,17671965,"Polymorphisms TaqI A of the DRD2, BalI of the DRD3, exon III repeat of the DRD4, and 3' UTR VNTR of the DAT: association with childhood ADHD in male African-Caribbean cocaine dependents?",0.235752511884784,"Polymorphisms TaqI A of the <span class=""gene"" id=""17671965-0-28-32"">DRD2</span>, BalI of the DRD3, exon III repeat of the DRD4, and 3' UTR VNTR of the DAT: association with childhood <span class=""disease"" id=""17671965-0-136-140"">ADHD</span> in male African-Caribbean cocaine dependents?",CTD_human
1,0,Biomarker,C0003477,Separation Anxiety Disorder,disease,separation anxiety disorder,1815,DRD4,DRD4,CTD_human,20731709,"Association of DRD4 polymorphism with severity of oppositional defiant disorder, separation anxiety disorder and repetitive behaviors in children with autism spectrum disorder.",0.2,"Association of <span class=""gene"" id=""20731709-0-15-19"">DRD4</span> polymorphism with severity of oppositional defiant disorder, <span class=""disease"" id=""20731709-0-81-108"">separation anxiety disorder</span> and repetitive behaviors in children with autism spectrum disorder.",CTD_human
3,0,Biomarker,C1263846,Attention deficit hyperactivity disorder,disease,ADHD,1815,DRD4,DRD4,CTD_human,14699430,Transmission disequilibrium testing of dopamine-related candidate gene polymorphisms in ADHD: confirmation of association of ADHD with DRD4 and DRD5.,0.40804847648265796,"Transmission disequilibrium testing of dopamine-related candidate gene polymorphisms in <span class=""disease"" id=""14699430-0-88-92"">ADHD</span>: confirmation of association of <span class=""disease"" id=""14699430-0-125-129"">ADHD</span> with <span class=""gene"" id=""14699430-0-135-139"">DRD4</span> and DRD5.",CTD_human
3,0,Biomarker,C1263846,Attention deficit hyperactivity disorder,disease,attention deficit/hyperactivity disorder,1815,DRD4,dopamine D4 receptor,CTD_human,14699433,The dopamine D4 receptor is essential for hyperactivity and impaired behavioral inhibition in a mouse model of attention deficit/hyperactivity disorder.,0.40804847648265796,"The <span class=""gene"" id=""14699433-0-4-24"">dopamine D4 receptor</span> is essential for hyperactivity and impaired behavioral inhibition in a mouse model of <span class=""disease"" id=""14699433-0-111-151"">attention deficit/hyperactivity disorder</span>.",CTD_human
3,0,Biomarker,C1263846,Attention deficit hyperactivity disorder,disease,ADHD,1815,DRD4,DRD4,CTD_human,17671965,"Polymorphisms TaqI A of the DRD2, BalI of the DRD3, exon III repeat of the DRD4, and 3' UTR VNTR of the DAT: association with childhood ADHD in male African-Caribbean cocaine dependents?",0.40804847648265796,"Polymorphisms TaqI A of the DRD2, BalI of the DRD3, exon III repeat of the <span class=""gene"" id=""17671965-0-75-79"">DRD4</span>, and 3' UTR VNTR of the DAT: association with childhood <span class=""disease"" id=""17671965-0-136-140"">ADHD</span> in male African-Caribbean cocaine dependents?",CTD_human
1,0,Biomarker,C0005747,Blepharospasm,disease,blepharospasm,1816,DRD5,DRD5,CTD_human,11781417,A polymorphism in the dopamine receptor DRD5 is associated with blepharospasm.,0.202681755307501,"A polymorphism in the dopamine receptor <span class=""gene"" id=""11781417-0-40-44"">DRD5</span> is associated with <span class=""disease"" id=""11781417-0-64-77"">blepharospasm</span>.",CTD_human
2,0,Biomarker,C1263846,Attention deficit hyperactivity disorder,disease,attention-deficit/hyperactivity disorder,1816,DRD5,DRD5,CTD_human,14732906,Joint analysis of the DRD5 marker concludes association with attention-deficit/hyperactivity disorder confined to the predominantly inattentive and combined subtypes.,0.22420131030214,"Joint analysis of the <span class=""gene"" id=""14732906-0-22-26"">DRD5</span> marker concludes association with <span class=""disease"" id=""14732906-0-61-101"">attention-deficit/hyperactivity disorder</span> confined to the predominantly inattentive and combined subtypes.",CTD_human
2,0,Biomarker,C1263846,Attention deficit hyperactivity disorder,disease,ADHD,1816,DRD5,DRD5,CTD_human,14699430,Transmission disequilibrium testing of dopamine-related candidate gene polymorphisms in ADHD: confirmation of association of ADHD with DRD4 and DRD5.,0.22420131030214,"Transmission disequilibrium testing of dopamine-related candidate gene polymorphisms in <span class=""disease"" id=""14699430-0-88-92"">ADHD</span>: confirmation of association of <span class=""disease"" id=""14699430-0-125-129"">ADHD</span> with DRD4 and <span class=""gene"" id=""14699430-0-144-148"">DRD5</span>.",CTD_human
1,0,Biomarker,C0018798,Congenital Heart Defects,group,congenital heart defects,182,JAG1,JAG1,CTD_human,12022040,"Our findings revealed a unique phenotype with highly penetrant deafness, posterior embryotoxon, and congenital heart defects but with variable expressivity in a large kindred, which demonstrates that mutation in JAG1 can cause hearing loss.",0.203557092817453,"Our findings revealed a unique phenotype with highly penetrant deafness, posterior embryotoxon, and <span class=""disease"" id=""12022040-9-100-124"">congenital heart defects</span> but with variable expressivity in a large kindred, which demonstrates that mutation in <span class=""gene"" id=""12022040-9-212-216"">JAG1</span> can cause hearing loss.",CTD_human
2,1,Biomarker,C0039685,Tetralogy of Fallot,disease,Tetralogy of Fallot,182,JAG1,jagged1,CTD_human,11152664,Familial Tetralogy of Fallot caused by mutation in the jagged1 gene.,0.6099683534119951,"Familial <span class=""disease"" id=""11152664-0-9-28"">Tetralogy of Fallot</span> caused by mutation in the <span class=""gene"" id=""11152664-0-55-62"">jagged1</span> gene.",CTD_human;HPO;ORPHANET;UNIPROT
3,1,Biomarker,C0085280,Alagille Syndrome,disease,Alagille syndrome,182,JAG1,Jagged1,CTD_human,9207787,Mutations in the human Jagged1 gene are responsible for Alagille syndrome.,0.241006215676119,"Mutations in the human <span class=""gene"" id=""9207787-0-23-30"">Jagged1</span> gene are responsible for <span class=""disease"" id=""9207787-0-56-73"">Alagille syndrome</span>.",CTD_human
3,1,Biomarker,C0085280,Alagille Syndrome,disease,Alagille syndrome,182,JAG1,Jagged1,CTD_human,9207788,"Alagille syndrome is caused by mutations in human Jagged1, which encodes a ligand for Notch1.",0.241006215676119,"<span class=""disease"" id=""9207788-0-0-17"">Alagille syndrome</span> is caused by mutations in human <span class=""gene"" id=""9207788-0-50-57"">Jagged1</span>, which encodes a ligand for Notch1.",CTD_human
1,0,Biomarker,C0013080,Down Syndrome,disease,Down syndrome,1827,RCAN1,DSCR1,CTD_human,15906378,Restoration of DSCR1 to disomy in the trisomy 16 mouse model of Down syndrome does not correct cardiac or craniofacial development anomalies.,0.22766127294161997,"Restoration of <span class=""gene"" id=""15906378-0-15-20"">DSCR1</span> to disomy in the trisomy 16 mouse model of <span class=""disease"" id=""15906378-0-64-77"">Down syndrome</span> does not correct cardiac or craniofacial development anomalies.",CTD_human
1,0,Biomarker,C0020179,Huntington Disease,disease,Huntington disease,1827,RCAN1,RCAN1,CTD_human,19270310,Regulator of calcineurin (RCAN1-1L) is deficient in Huntington disease and protective against mutant huntingtin toxicity in vitro.,0.200274726784213,"Regulator of calcineurin (<span class=""gene"" id=""19270310-0-26-31"">RCAN1</span>-1L) is deficient in <span class=""disease"" id=""19270310-0-52-70"">Huntington disease</span> and protective against mutant huntingtin toxicity in vitro.",CTD_human
1,0,Biomarker,C0011603,Dermatitis,disease,dermatitis,1828,DSG1,Desmoglein 1,CTD_human,23974871,"Desmoglein 1 deficiency results in severe dermatitis, multiple allergies and metabolic wasting.",0.20054945356842604,"<span class=""gene"" id=""23974871-0-0-12"">Desmoglein 1</span> deficiency results in severe <span class=""disease"" id=""23974871-0-42-52"">dermatitis</span>, multiple allergies and metabolic wasting.",CTD_human
1,0,Biomarker,C0002871,Anemia,disease,anemia,183,AGT,angiotensin II,CTD_human,3524928,It is concluded from the present study that the reduction of angiotensin II by captopril might contribute to the worsening of anemia seen in chronic hemodialysis patients.,0.2,"It is concluded from the present study that the reduction of <span class=""gene"" id=""3524928-10-61-75"">angiotensin II</span> by captopril might contribute to the worsening of <span class=""disease"" id=""3524928-10-126-132"">anemia</span> seen in chronic hemodialysis patients.",CTD_human
2,0,Biomarker,C0004153,Atherosclerosis,disease,atherosclerosis,183,AGT,angiotensin II,CTD_human,21925196,Polychlorinated biphenyl 77 augments angiotensin II-induced atherosclerosis and abdominal aortic aneurysms in male apolipoprotein E deficient mice.,0.32184765829478396,"Polychlorinated biphenyl 77 augments <span class=""gene"" id=""21925196-0-37-51"">angiotensin II</span>-induced <span class=""disease"" id=""21925196-0-60-75"">atherosclerosis</span> and abdominal aortic aneurysms in male apolipoprotein E deficient mice.",CTD_human
1,0,Biomarker,C0007192,"Cardiomyopathy, Alcoholic",disease,alcoholic cardiomyopathy,183,AGT,angiotensin II,CTD_human,22497828,"Alcohol-induced nitrative stress and apoptosis, which are mediated by angiotensin II interaction with AT1 and subsequent activation of a PKC-?1-dependent NOX pathway, are a causal factor in the development of alcoholic cardiomyopathy.",0.2,"Alcohol-induced nitrative stress and apoptosis, which are mediated by <span class=""gene"" id=""22497828-13-70-84"">angiotensin II</span> interaction with AT1 and subsequent activation of a PKC-&beta;1-dependent NOX pathway, are a causal factor in the development of <span class=""disease"" id=""22497828-13-209-233"">alcoholic cardiomyopathy</span>.",CTD_human
1,0,Biomarker,C0011884,Diabetic Retinopathy,disease,diabetic retinopathy,183,AGT,angiotensin II,CTD_human,15387897,There is increasing interest in a pathogenetic role for angiotensin II in ischaemic retinopathies such as diabetic retinopathy and retinopathy of prematurity.,0.288371149864029,"There is increasing interest in a pathogenetic role for <span class=""gene"" id=""15387897-3-56-70"">angiotensin II</span> in ischaemic retinopathies such as <span class=""disease"" id=""15387897-3-106-126"">diabetic retinopathy</span> and retinopathy of prematurity.",CTD_human
1,0,Biomarker,C0017658,Glomerulonephritis,disease,glomerulonephritis,183,AGT,angiotensin II,CTD_human,11459117,"In patients with glomerulonephritis, the serum levels of AM are elevated as well as hypertensive agents norepinephrine (NE) and angiotensin II (AII).",0.203780662444353,"In patients with <span class=""disease"" id=""11459117-2-17-35"">glomerulonephritis</span>, the serum levels of AM are elevated as well as hypertensive agents norepinephrine (NE) and <span class=""gene"" id=""11459117-2-128-142"">angiotensin II</span> (AII).",CTD_human
1,0,Biomarker,C0017661,IGA Glomerulonephritis,disease,IgA nephropathy,183,AGT,AGT,CTD_human,9259580,Our results suggest that polymorphisms at the AGT and ACE gene loci are important markers for predicting progression to chronic renal failure in Caucasian patients with IgA nephropathy.,0.24072004040329698,"Our results suggest that polymorphisms at the <span class=""gene"" id=""9259580-12-46-49"">AGT</span> and ACE gene loci are important markers for predicting progression to chronic renal failure in Caucasian patients with <span class=""disease"" id=""9259580-12-169-184"">IgA nephropathy</span>.",CTD_human
3,0,Biomarker,C0018801,Heart failure,disease,heart failure,183,AGT,Angiotensin II,CTD_human,12025466,"Angiotensin II and norepinephrine induce programmed cell death (apoptosis) in myocardial cells, thereby contributing to the progression of left ventricular function to heart failure.",0.297595190835332,"<span class=""gene"" id=""12025466-3-0-14"">Angiotensin II</span> and norepinephrine induce programmed cell death (apoptosis) in myocardial cells, thereby contributing to the progression of left ventricular function to <span class=""disease"" id=""12025466-3-168-181"">heart failure</span>.",CTD_human
1,0,Biomarker,C0020452,Hyperemia,disease,hyperemia,183,AGT,angiotensin II,CTD_human,15815331,The unanticipated interaction of angiotensin II and isoflurane producing a sustained cerebral hyperemia suggests that previous studies that used angiotensin II to support MABP during isoflurane may have reported the effects of angiotensin II in addition to or rather than the effects of isoflurane.,0.2,"The unanticipated interaction of <span class=""gene"" id=""15815331-10-33-47"">angiotensin II</span> and isoflurane producing a sustained cerebral <span class=""disease"" id=""15815331-10-94-103"">hyperemia</span> suggests that previous studies that used <span class=""gene"" id=""15815331-10-145-159"">angiotensin II</span> to support MABP during isoflurane may have reported the effects of <span class=""gene"" id=""15815331-10-227-241"">angiotensin II</span> in addition to or rather than the effects of isoflurane.",CTD_human
69,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensin II,CTD_human,1432030,Effect of intracarotid infusion of etoposide with angiotensin II-induced hypertension on the blood-brain barrier and the brain tissue.,0.52,"Effect of intracarotid infusion of etoposide with <span class=""gene"" id=""1432030-0-50-64"">angiotensin II</span>-induced <span class=""disease"" id=""1432030-0-73-85"">hypertension</span> on the blood-brain barrier and the brain tissue.",CTD_human
69,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensin II,CTD_human,21420289,"On the other hand, artemetin did not change angiotensin II-induced hypertension.",0.52,"On the other hand, artemetin did not change <span class=""gene"" id=""21420289-8-44-58"">angiotensin II</span>-induced <span class=""disease"" id=""21420289-8-67-79"">hypertension</span>.",CTD_human
69,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,183,AGT,Angiotensin II,CTD_human,12084390,The aim of this study was to investigate the effects of Angiotensin II (ANG II) receptor antagonist losartan on the blood-brain barrier (BBB) permeability in L-NAME-induced hypertension and/or in ANG II-induced acute hypertension in normotensive and hypertensive rats.,0.52,"The aim of this study was to investigate the effects of <span class=""gene"" id=""12084390-2-56-70"">Angiotensin II</span> (ANG II) receptor antagonist losartan on the blood-brain barrier (BBB) permeability in L-NAME-induced <span class=""disease"" id=""12084390-2-173-185"">hypertension</span> and/or in ANG II-induced acute <span class=""disease"" id=""12084390-2-217-229"">hypertension</span> in normotensive and hypertensive rats.",CTD_human
69,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensin II,CTD_human,15851630,"Cyclooxygenase-2 inhibitors attenuate angiotensin II-induced oxidative stress, hypertension, and cardiac hypertrophy in rats.",0.52,"Cyclooxygenase-2 inhibitors attenuate <span class=""gene"" id=""15851630-0-38-52"">angiotensin II</span>-induced oxidative stress, <span class=""disease"" id=""15851630-0-79-91"">hypertension</span>, and cardiac hypertrophy in rats.",CTD_human
69,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensin II,CTD_human,1849535,The antihypertensive effect of calcitonin gene-related peptide in rats with norepinephrine- and angiotensin II-induced hypertension.,0.52,"The antihypertensive effect of calcitonin gene-related peptide in rats with norepinephrine- and <span class=""gene"" id=""1849535-0-96-110"">angiotensin II</span>-induced <span class=""disease"" id=""1849535-0-119-131"">hypertension</span>.",CTD_human
69,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensin II,CTD_human,15699457,Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension.,0.52,"Soluble epoxide hydrolase is a main effector of <span class=""gene"" id=""15699457-0-48-62"">angiotensin II</span>-induced <span class=""disease"" id=""15699457-0-71-83"">hypertension</span>.",CTD_human
69,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensinogen,CTD_human,1394429,Molecular basis of human hypertension: role of angiotensinogen.,0.52,"Molecular basis of human <span class=""disease"" id=""1394429-0-25-37"">hypertension</span>: role of <span class=""gene"" id=""1394429-0-47-62"">angiotensinogen</span>.",CTD_human
69,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensin II,CTD_human,3158602,The effects of the calcium entry blocker nitrendipine on blood pressure (BP) and renal hemodynamics were studied in rats with angiotensin II (ANG II)-induced hypertension.,0.52,"The effects of the calcium entry blocker nitrendipine on blood pressure (BP) and renal hemodynamics were studied in rats with <span class=""gene"" id=""3158602-1-126-140"">angiotensin II</span> (ANG II)-induced <span class=""disease"" id=""3158602-1-158-170"">hypertension</span>.",CTD_human
69,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensin II,CTD_human,10526905,Delayed recovery of hypertension after single dose losartan in angiotensin II-infused conscious rats.,0.52,"Delayed recovery of <span class=""disease"" id=""10526905-0-20-32"">hypertension</span> after single dose losartan in <span class=""gene"" id=""10526905-0-63-77"">angiotensin II</span>-infused conscious rats.",CTD_human
69,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,183,AGT,dTGR,CTD_human,20429690,"Untreated dTGR developed severe hypertension as well as cardiac hypertrophy, and showed pronounced cardiovascular mortality compared with normotensive SD rats.",0.52,"Untreated <span class=""gene"" id=""20429690-6-10-14"">dTGR</span> developed severe <span class=""disease"" id=""20429690-6-32-44"">hypertension</span> as well as cardiac hypertrophy, and showed pronounced cardiovascular mortality compared with normotensive SD rats.",CTD_human
69,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensin II,CTD_human,26564064,Role of the Na+/H+ exchanger 3 in angiotensin II-induced hypertension in NHE3-deficient mice with transgenic rescue of NHE3 in small intestines.,0.52,"Role of the Na+/H+ exchanger 3 in <span class=""gene"" id=""26564064-0-34-48"">angiotensin II</span>-induced <span class=""disease"" id=""26564064-0-57-69"">hypertension</span> in NHE3-deficient mice with transgenic rescue of NHE3 in small intestines.",CTD_human
69,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,183,AGT,AngII,CTD_human,24965170,"Finally, daily chronic administration of RSVl alleviated hypertension in the experimental model of AngII-induced hypertensive mice, and these effects were accompanied by the activation of AMPK, significantly decreased RhoA activity and phosphorylation levels of MYPT1 and MLC in AngII-treated murine aortic VSMCs.",0.52,"Finally, daily chronic administration of RSVl alleviated <span class=""disease"" id=""24965170-8-57-69"">hypertension</span> in the experimental model of <span class=""gene"" id=""24965170-8-99-104"">AngII</span>-induced hypertensive mice, and these effects were accompanied by the activation of AMPK, significantly decreased RhoA activity and phosphorylation levels of MYPT1 and MLC in AngII-treated murine aortic VSMCs.",CTD_human
69,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,183,AGT,AngII,CTD_human,18847324,"Thus, blocking the synthesis of AngII may be an effective treatment of osteoporosis and hypertension, especially for those afflicted with both conditions.",0.52,"Thus, blocking the synthesis of <span class=""gene"" id=""18847324-8-32-37"">AngII</span> may be an effective treatment of osteoporosis and <span class=""disease"" id=""18847324-8-88-100"">hypertension</span>, especially for those afflicted with both conditions.",CTD_human
69,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensin II,CTD_human,9024144,Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension.,0.52,"Role of superoxide in <span class=""gene"" id=""9024144-0-22-36"">angiotensin II</span>-induced but not catecholamine-induced <span class=""disease"" id=""9024144-0-75-87"">hypertension</span>.",CTD_human
69,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensin II,CTD_human,8109997,"Under angiotensin II (A II)-induced hypertension, the pressure of all arteriolar vessels increased roughly in proportion to the increase in mean arterial blood pressure.",0.52,"Under <span class=""gene"" id=""8109997-4-6-20"">angiotensin II</span> (A II)-induced <span class=""disease"" id=""8109997-4-36-48"">hypertension</span>, the pressure of all arteriolar vessels increased roughly in proportion to the increase in mean arterial blood pressure.",CTD_human
69,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensin II,CTD_human,21420289,"On the other hand, artemetin did not change angiotensin II-induced hypertension.",0.52,"On the other hand, artemetin did not change <span class=""gene"" id=""21420289-8-44-58"">angiotensin II</span>-induced <span class=""disease"" id=""21420289-8-67-79"">hypertension</span>.",CTD_human
69,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensin II,CTD_human,25259750,"The hypertension caused by angiotensin II in CD4(-/-) and MHCII(-/-) mice was similar to that observed in wild-type mice, whereas CD8(-/-) mice and OT1xRAG-1(-/-) mice, which have only 1 T-cell receptor, exhibited a blunted hypertensive response to angiotensin II.",0.52,"The <span class=""disease"" id=""25259750-5-4-16"">hypertension</span> caused by <span class=""gene"" id=""25259750-5-27-41"">angiotensin II</span> in CD4(-/-) and MHCII(-/-) mice was similar to that observed in wild-type mice, whereas CD8(-/-) mice and OT1xRAG-1(-/-) mice, which have only 1 T-cell receptor, exhibited a blunted hypertensive response to <span class=""gene"" id=""25259750-5-249-263"">angiotensin II</span>.",CTD_human
69,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensinogen,CTD_human,1394429,Molecular basis of human hypertension: role of angiotensinogen.,0.52,"Molecular basis of human <span class=""disease"" id=""1394429-0-25-37"">hypertension</span>: role of <span class=""gene"" id=""1394429-0-47-62"">angiotensinogen</span>.",CTD_human
69,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensinogen,CTD_human,21393355,"The hypertensive double-transgenic (dTG) rat strain, expressing human renin and angiotensinogen, develops severe hypertension and organ damage and 50% of individuals die by 7 weeks of age.",0.52,"The hypertensive double-transgenic (dTG) rat strain, expressing human renin and <span class=""gene"" id=""21393355-1-80-95"">angiotensinogen</span>, develops severe <span class=""disease"" id=""21393355-1-113-125"">hypertension</span> and organ damage and 50% of individuals die by 7 weeks of age.",CTD_human
69,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensin II,CTD_human,8109997,"Under angiotensin II (A II)-induced hypertension, the pressure of all arteriolar vessels increased roughly in proportion to the increase in mean arterial blood pressure.",0.52,"Under <span class=""gene"" id=""8109997-4-6-20"">angiotensin II</span> (A II)-induced <span class=""disease"" id=""8109997-4-36-48"">hypertension</span>, the pressure of all arteriolar vessels increased roughly in proportion to the increase in mean arterial blood pressure.",CTD_human
69,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensin II,CTD_human,16618834,Increased angiotensin II (Ang II) sensitivity predisposes to hypertension and plaque instability.,0.52,"Increased <span class=""gene"" id=""16618834-1-10-24"">angiotensin II</span> (Ang II) sensitivity predisposes to <span class=""disease"" id=""16618834-1-61-73"">hypertension</span> and plaque instability.",CTD_human
69,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensin II,CTD_human,24342267,Chronic infusion of enalaprilat into hypothalamic paraventricular nucleus attenuates angiotensin II-induced hypertension and cardiac hypertrophy by restoring neurotransmitters and cytokines.,0.52,"Chronic infusion of enalaprilat into hypothalamic paraventricular nucleus attenuates <span class=""gene"" id=""24342267-0-85-99"">angiotensin II</span>-induced <span class=""disease"" id=""24342267-0-108-120"">hypertension</span> and cardiac hypertrophy by restoring neurotransmitters and cytokines.",CTD_human
69,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensin II,CTD_human,16788141,Urea transporter UT-A1 and aquaporin-2 proteins decrease in response to angiotensin II or norepinephrine-induced acute hypertension.,0.52,"Urea transporter UT-A1 and aquaporin-2 proteins decrease in response to <span class=""gene"" id=""16788141-0-72-86"">angiotensin II</span> or norepinephrine-induced acute <span class=""disease"" id=""16788141-0-119-131"">hypertension</span>.",CTD_human
69,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensin II,CTD_human,1860718,"Furthermore, acute hypertension induced by angiotensin II or phenylephrine did not affect the plasma irET-1 concentration in rats.",0.52,"Furthermore, acute <span class=""disease"" id=""1860718-9-19-31"">hypertension</span> induced by <span class=""gene"" id=""1860718-9-43-57"">angiotensin II</span> or phenylephrine did not affect the plasma irET-1 concentration in rats.",CTD_human
69,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensin II,CTD_human,22753205,Role of copper transport protein antioxidant 1 in angiotensin II-induced hypertension: a key regulator of extracellular superoxide dismutase.,0.52,"Role of copper transport protein antioxidant 1 in <span class=""gene"" id=""22753205-0-50-64"">angiotensin II</span>-induced <span class=""disease"" id=""22753205-0-73-85"">hypertension</span>: a key regulator of extracellular superoxide dismutase.",CTD_human
69,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,183,AGT,dTGR,CTD_human,20429690,"Untreated dTGR developed severe hypertension as well as cardiac hypertrophy, and showed pronounced cardiovascular mortality compared with normotensive SD rats.",0.52,"Untreated <span class=""gene"" id=""20429690-6-10-14"">dTGR</span> developed severe <span class=""disease"" id=""20429690-6-32-44"">hypertension</span> as well as cardiac hypertrophy, and showed pronounced cardiovascular mortality compared with normotensive SD rats.",CTD_human
69,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensin II,CTD_human,19770776,Our study indicated that elevated plasma levels of high-sensitivity C-reactive protein and angiotensin II were positively and renin activity inversely associated with the risk of hypertension.,0.52,"Our study indicated that elevated plasma levels of high-sensitivity C-reactive protein and <span class=""gene"" id=""19770776-6-91-105"">angiotensin II</span> were positively and renin activity inversely associated with the risk of <span class=""disease"" id=""19770776-6-179-191"">hypertension</span>.",CTD_human
69,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensin II,CTD_human,22214961,"Airway resistance, inflammation and oxidative stress following exposure to diesel exhaust particle in angiotensin II-induced hypertension in mice.",0.52,"Airway resistance, inflammation and oxidative stress following exposure to diesel exhaust particle in <span class=""gene"" id=""22214961-0-102-116"">angiotensin II</span>-induced <span class=""disease"" id=""22214961-0-125-137"">hypertension</span> in mice.",CTD_human
69,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensin II,CTD_human,1849535,The antihypertensive effect of calcitonin gene-related peptide in rats with norepinephrine- and angiotensin II-induced hypertension.,0.52,"The antihypertensive effect of calcitonin gene-related peptide in rats with norepinephrine- and <span class=""gene"" id=""1849535-0-96-110"">angiotensin II</span>-induced <span class=""disease"" id=""1849535-0-119-131"">hypertension</span>.",CTD_human
69,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensin II,CTD_human,15699457,Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension.,0.52,"Soluble epoxide hydrolase is a main effector of <span class=""gene"" id=""15699457-0-48-62"">angiotensin II</span>-induced <span class=""disease"" id=""15699457-0-71-83"">hypertension</span>.",CTD_human
69,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensin II,CTD_human,3158602,The effects of the calcium entry blocker nitrendipine on blood pressure (BP) and renal hemodynamics were studied in rats with angiotensin II (ANG II)-induced hypertension.,0.52,"The effects of the calcium entry blocker nitrendipine on blood pressure (BP) and renal hemodynamics were studied in rats with <span class=""gene"" id=""3158602-1-126-140"">angiotensin II</span> (ANG II)-induced <span class=""disease"" id=""3158602-1-158-170"">hypertension</span>.",CTD_human
69,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensin II,CTD_human,16788141,Urea transporter UT-A1 and aquaporin-2 proteins decrease in response to angiotensin II or norepinephrine-induced acute hypertension.,0.52,"Urea transporter UT-A1 and aquaporin-2 proteins decrease in response to <span class=""gene"" id=""16788141-0-72-86"">angiotensin II</span> or norepinephrine-induced acute <span class=""disease"" id=""16788141-0-119-131"">hypertension</span>.",CTD_human
69,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensin II,CTD_human,1432030,Effect of intracarotid infusion of etoposide with angiotensin II-induced hypertension on the blood-brain barrier and the brain tissue.,0.52,"Effect of intracarotid infusion of etoposide with <span class=""gene"" id=""1432030-0-50-64"">angiotensin II</span>-induced <span class=""disease"" id=""1432030-0-73-85"">hypertension</span> on the blood-brain barrier and the brain tissue.",CTD_human
69,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensin II,CTD_human,26564064,Role of the Na+/H+ exchanger 3 in angiotensin II-induced hypertension in NHE3-deficient mice with transgenic rescue of NHE3 in small intestines.,0.52,"Role of the Na+/H+ exchanger 3 in <span class=""gene"" id=""26564064-0-34-48"">angiotensin II</span>-induced <span class=""disease"" id=""26564064-0-57-69"">hypertension</span> in NHE3-deficient mice with transgenic rescue of NHE3 in small intestines.",CTD_human
69,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensin II,CTD_human,15243307,"SSR149744C, which has no or low affinity for alpha 1 and beta 1 adrenergic and angiotensin II AT1 receptors, reduced isoproterenol-induced tachycardia and phenylephrine- or angiotensin II-induced hypertension in anaesthetized dogs.",0.52,"SSR149744C, which has no or low affinity for alpha 1 and beta 1 adrenergic and <span class=""gene"" id=""15243307-5-79-93"">angiotensin II</span> AT1 receptors, reduced isoproterenol-induced tachycardia and phenylephrine- or <span class=""gene"" id=""15243307-5-173-187"">angiotensin II</span>-induced <span class=""disease"" id=""15243307-5-196-208"">hypertension</span> in anaesthetized dogs.",CTD_human
69,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensin II,CTD_human,22753205,Role of copper transport protein antioxidant 1 in angiotensin II-induced hypertension: a key regulator of extracellular superoxide dismutase.,0.52,"Role of copper transport protein antioxidant 1 in <span class=""gene"" id=""22753205-0-50-64"">angiotensin II</span>-induced <span class=""disease"" id=""22753205-0-73-85"">hypertension</span>: a key regulator of extracellular superoxide dismutase.",CTD_human
69,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensin II,CTD_human,24935938,Sex-specific T-cell regulation of angiotensin II-dependent hypertension.,0.52,"Sex-specific T-cell regulation of <span class=""gene"" id=""24935938-0-34-48"">angiotensin II</span>-dependent <span class=""disease"" id=""24935938-0-59-71"">hypertension</span>.",CTD_human
69,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensin II,CTD_human,1860718,"Furthermore, acute hypertension induced by angiotensin II or phenylephrine did not affect the plasma irET-1 concentration in rats.",0.52,"Furthermore, acute <span class=""disease"" id=""1860718-9-19-31"">hypertension</span> induced by <span class=""gene"" id=""1860718-9-43-57"">angiotensin II</span> or phenylephrine did not affect the plasma irET-1 concentration in rats.",CTD_human
69,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensin II,CTD_human,16618834,Increased angiotensin II (Ang II) sensitivity predisposes to hypertension and plaque instability.,0.52,"Increased <span class=""gene"" id=""16618834-1-10-24"">angiotensin II</span> (Ang II) sensitivity predisposes to <span class=""disease"" id=""16618834-1-61-73"">hypertension</span> and plaque instability.",CTD_human
69,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensin II,CTD_human,17272743,Role of the multidrug resistance protein-1 in hypertension and vascular dysfunction caused by angiotensin II.,0.52,"Role of the multidrug resistance protein-1 in <span class=""disease"" id=""17272743-0-46-58"">hypertension</span> and vascular dysfunction caused by <span class=""gene"" id=""17272743-0-94-108"">angiotensin II</span>.",CTD_human
69,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,183,AGT,Angiotensin II,CTD_human,12600921,Angiotensin II-induced hypertension is associated with NAD(P)H oxidase-dependent superoxide production in the vessel wall.,0.52,"<span class=""gene"" id=""12600921-1-0-14"">Angiotensin II</span>-induced <span class=""disease"" id=""12600921-1-23-35"">hypertension</span> is associated with NAD(P)H oxidase-dependent superoxide production in the vessel wall.",CTD_human
69,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensin II,CTD_human,10400907,Modulation of extracellular superoxide dismutase expression by angiotensin II and hypertension.,0.52,"Modulation of extracellular superoxide dismutase expression by <span class=""gene"" id=""10400907-0-63-77"">angiotensin II</span> and <span class=""disease"" id=""10400907-0-82-94"">hypertension</span>.",CTD_human
69,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensin II,CTD_human,18768397,Role of Menkes ATPase in angiotensin II-induced hypertension: a key modulator for extracellular superoxide dismutase function.,0.52,"Role of Menkes ATPase in <span class=""gene"" id=""18768397-0-25-39"">angiotensin II</span>-induced <span class=""disease"" id=""18768397-0-48-60"">hypertension</span>: a key modulator for extracellular superoxide dismutase function.",CTD_human
69,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensin II,CTD_human,7323490,Most of these effects of angiotensin II were opposite to the effects of hypertension caused by phenylephrine and aortic balloon inflation.,0.52,"Most of these effects of <span class=""gene"" id=""7323490-5-25-39"">angiotensin II</span> were opposite to the effects of <span class=""disease"" id=""7323490-5-72-84"">hypertension</span> caused by phenylephrine and aortic balloon inflation.",CTD_human
69,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,183,AGT,AngII,CTD_human,24965170,"Finally, daily chronic administration of RSVl alleviated hypertension in the experimental model of AngII-induced hypertensive mice, and these effects were accompanied by the activation of AMPK, significantly decreased RhoA activity and phosphorylation levels of MYPT1 and MLC in AngII-treated murine aortic VSMCs.",0.52,"Finally, daily chronic administration of RSVl alleviated <span class=""disease"" id=""24965170-8-57-69"">hypertension</span> in the experimental model of <span class=""gene"" id=""24965170-8-99-104"">AngII</span>-induced hypertensive mice, and these effects were accompanied by the activation of AMPK, significantly decreased RhoA activity and phosphorylation levels of MYPT1 and MLC in AngII-treated murine aortic VSMCs.",CTD_human
69,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensin II,CTD_human,19770776,Our study indicated that elevated plasma levels of high-sensitivity C-reactive protein and angiotensin II were positively and renin activity inversely associated with the risk of hypertension.,0.52,"Our study indicated that elevated plasma levels of high-sensitivity C-reactive protein and <span class=""gene"" id=""19770776-6-91-105"">angiotensin II</span> were positively and renin activity inversely associated with the risk of <span class=""disease"" id=""19770776-6-179-191"">hypertension</span>.",CTD_human
69,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,183,AGT,Angiotensin II,CTD_human,12084390,The aim of this study was to investigate the effects of Angiotensin II (ANG II) receptor antagonist losartan on the blood-brain barrier (BBB) permeability in L-NAME-induced hypertension and/or in ANG II-induced acute hypertension in normotensive and hypertensive rats.,0.52,"The aim of this study was to investigate the effects of <span class=""gene"" id=""12084390-2-56-70"">Angiotensin II</span> (ANG II) receptor antagonist losartan on the blood-brain barrier (BBB) permeability in L-NAME-induced <span class=""disease"" id=""12084390-2-173-185"">hypertension</span> and/or in ANG II-induced acute <span class=""disease"" id=""12084390-2-217-229"">hypertension</span> in normotensive and hypertensive rats.",CTD_human
69,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensin II,CTD_human,10526905,Delayed recovery of hypertension after single dose losartan in angiotensin II-infused conscious rats.,0.52,"Delayed recovery of <span class=""disease"" id=""10526905-0-20-32"">hypertension</span> after single dose losartan in <span class=""gene"" id=""10526905-0-63-77"">angiotensin II</span>-infused conscious rats.",CTD_human
69,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensin II,CTD_human,9024144,Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension.,0.52,"Role of superoxide in <span class=""gene"" id=""9024144-0-22-36"">angiotensin II</span>-induced but not catecholamine-induced <span class=""disease"" id=""9024144-0-75-87"">hypertension</span>.",CTD_human
69,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensin II,CTD_human,15851630,"Cyclooxygenase-2 inhibitors attenuate angiotensin II-induced oxidative stress, hypertension, and cardiac hypertrophy in rats.",0.52,"Cyclooxygenase-2 inhibitors attenuate <span class=""gene"" id=""15851630-0-38-52"">angiotensin II</span>-induced oxidative stress, <span class=""disease"" id=""15851630-0-79-91"">hypertension</span>, and cardiac hypertrophy in rats.",CTD_human
69,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensin II,CTD_human,20231528,Sex chromosome effects unmasked in angiotensin II-induced hypertension.,0.52,"Sex chromosome effects unmasked in <span class=""gene"" id=""20231528-0-35-49"">angiotensin II</span>-induced <span class=""disease"" id=""20231528-0-58-70"">hypertension</span>.",CTD_human
69,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,183,AGT,Angiotensin II,CTD_human,16868307,"Angiotensin II, interstitial inflammation, and the pathogenesis of salt-sensitive hypertension.",0.52,"<span class=""gene"" id=""16868307-0-0-14"">Angiotensin II</span>, interstitial inflammation, and the pathogenesis of salt-sensitive <span class=""disease"" id=""16868307-0-82-94"">hypertension</span>.",CTD_human
69,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensinogen,CTD_human,21393355,"The hypertensive double-transgenic (dTG) rat strain, expressing human renin and angiotensinogen, develops severe hypertension and organ damage and 50% of individuals die by 7 weeks of age.",0.52,"The hypertensive double-transgenic (dTG) rat strain, expressing human renin and <span class=""gene"" id=""21393355-1-80-95"">angiotensinogen</span>, develops severe <span class=""disease"" id=""21393355-1-113-125"">hypertension</span> and organ damage and 50% of individuals die by 7 weeks of age.",CTD_human
69,0,Biomarker,C0020538,Hypertensive disease,group,high blood pressure,183,AGT,angiotensin II,CTD_human,8505092,"Thus, endogenous angiotensin II acting within the kidney appears to play an important role in the maintenance of high blood pressure in spontaneously hypertensive rats.",0.52,"Thus, endogenous <span class=""gene"" id=""8505092-6-17-31"">angiotensin II</span> acting within the kidney appears to play an important role in the maintenance of <span class=""disease"" id=""8505092-6-113-132"">high blood pressure</span> in spontaneously hypertensive rats.",CTD_human
69,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensin II,CTD_human,25259750,"The hypertension caused by angiotensin II in CD4(-/-) and MHCII(-/-) mice was similar to that observed in wild-type mice, whereas CD8(-/-) mice and OT1xRAG-1(-/-) mice, which have only 1 T-cell receptor, exhibited a blunted hypertensive response to angiotensin II.",0.52,"The <span class=""disease"" id=""25259750-5-4-16"">hypertension</span> caused by <span class=""gene"" id=""25259750-5-27-41"">angiotensin II</span> in CD4(-/-) and MHCII(-/-) mice was similar to that observed in wild-type mice, whereas CD8(-/-) mice and OT1xRAG-1(-/-) mice, which have only 1 T-cell receptor, exhibited a blunted hypertensive response to <span class=""gene"" id=""25259750-5-249-263"">angiotensin II</span>.",CTD_human
69,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensin II,CTD_human,24342267,Chronic infusion of enalaprilat into hypothalamic paraventricular nucleus attenuates angiotensin II-induced hypertension and cardiac hypertrophy by restoring neurotransmitters and cytokines.,0.52,"Chronic infusion of enalaprilat into hypothalamic paraventricular nucleus attenuates <span class=""gene"" id=""24342267-0-85-99"">angiotensin II</span>-induced <span class=""disease"" id=""24342267-0-108-120"">hypertension</span> and cardiac hypertrophy by restoring neurotransmitters and cytokines.",CTD_human
69,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensinogen,CTD_human,17537837,"Renal renin and angiotensinogen mRNA expression were significantly decreased at birth (80 and 60%, respectively); plasma and renal RAS did not differ in conjunction with hypertension (mean increase of 14 mmHg) in young IUGR offspring; however, hypertension (mean increase of 22 mmHg) in adult IUGR offspring was associated with marked increases in renal angiotensin-converting enzyme (ACE) activity (122%) and renal renin and angiotensinogen mRNA (7-fold and 7.4-fold, respectively), but no change in renal ANG II or angiotensin type 1 receptor.",0.52,"Renal renin and <span class=""gene"" id=""17537837-5-16-31"">angiotensinogen</span> mRNA expression were significantly decreased at birth (80 and 60%, respectively); plasma and renal RAS did not differ in conjunction with <span class=""disease"" id=""17537837-5-170-182"">hypertension</span> (mean increase of 14 mmHg) in young IUGR offspring; however, <span class=""disease"" id=""17537837-5-244-256"">hypertension</span> (mean increase of 22 mmHg) in adult IUGR offspring was associated with marked increases in renal angiotensin-converting enzyme (ACE) activity (122%) and renal renin and <span class=""gene"" id=""17537837-5-426-441"">angiotensinogen</span> mRNA (7-fold and 7.4-fold, respectively), but no change in renal ANG II or angiotensin type 1 receptor.",CTD_human
69,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensin II,CTD_human,20231528,Sex chromosome effects unmasked in angiotensin II-induced hypertension.,0.52,"Sex chromosome effects unmasked in <span class=""gene"" id=""20231528-0-35-49"">angiotensin II</span>-induced <span class=""disease"" id=""20231528-0-58-70"">hypertension</span>.",CTD_human
69,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensin-II,CTD_human,20937366,We examined the interaction of cigarette mainstream smoke (MS) and angiotensin-II (Ang II)-induced hypertension in the atherosclerotic process using hyperlipidemic apolipoprotein E-knockout (ApoE(-/-)) mice.,0.52,"We examined the interaction of cigarette mainstream smoke (MS) and <span class=""gene"" id=""20937366-2-67-81"">angiotensin-II</span> (Ang II)-induced <span class=""disease"" id=""20937366-2-99-111"">hypertension</span> in the atherosclerotic process using hyperlipidemic apolipoprotein E-knockout (ApoE(-/-)) mice.",CTD_human
69,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensin II,CTD_human,17989111,Purinergic receptors contribute to early mesangial cell transformation and renal vessel hypertrophy during angiotensin II-induced hypertension.,0.52,"Purinergic receptors contribute to early mesangial cell transformation and renal vessel hypertrophy during <span class=""gene"" id=""17989111-0-107-121"">angiotensin II</span>-induced <span class=""disease"" id=""17989111-0-130-142"">hypertension</span>.",CTD_human
69,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensin II,CTD_human,17272743,Role of the multidrug resistance protein-1 in hypertension and vascular dysfunction caused by angiotensin II.,0.52,"Role of the multidrug resistance protein-1 in <span class=""disease"" id=""17272743-0-46-58"">hypertension</span> and vascular dysfunction caused by <span class=""gene"" id=""17272743-0-94-108"">angiotensin II</span>.",CTD_human
69,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensin II,CTD_human,10400907,Modulation of extracellular superoxide dismutase expression by angiotensin II and hypertension.,0.52,"Modulation of extracellular superoxide dismutase expression by <span class=""gene"" id=""10400907-0-63-77"">angiotensin II</span> and <span class=""disease"" id=""10400907-0-82-94"">hypertension</span>.",CTD_human
69,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,183,AGT,Angiotensin II,CTD_human,16868307,"Angiotensin II, interstitial inflammation, and the pathogenesis of salt-sensitive hypertension.",0.52,"<span class=""gene"" id=""16868307-0-0-14"">Angiotensin II</span>, interstitial inflammation, and the pathogenesis of salt-sensitive <span class=""disease"" id=""16868307-0-82-94"">hypertension</span>.",CTD_human
69,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensin II,CTD_human,8021468,"Inducing acute hypertension (coronary pressure 200 mmHg) pharmacologically with angiotensin II also augmented constriction to serotonin, whereas phenylephrine-induced hypertension did not.",0.52,"Inducing acute <span class=""disease"" id=""8021468-11-15-27"">hypertension</span> (coronary pressure 200 mmHg) pharmacologically with <span class=""gene"" id=""8021468-11-80-94"">angiotensin II</span> also augmented constriction to serotonin, whereas phenylephrine-induced <span class=""disease"" id=""8021468-11-167-179"">hypertension</span> did not.",CTD_human
69,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensin II,CTD_human,18768397,Role of Menkes ATPase in angiotensin II-induced hypertension: a key modulator for extracellular superoxide dismutase function.,0.52,"Role of Menkes ATPase in <span class=""gene"" id=""18768397-0-25-39"">angiotensin II</span>-induced <span class=""disease"" id=""18768397-0-48-60"">hypertension</span>: a key modulator for extracellular superoxide dismutase function.",CTD_human
69,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensinogen,CTD_human,17537837,"Renal renin and angiotensinogen mRNA expression were significantly decreased at birth (80 and 60%, respectively); plasma and renal RAS did not differ in conjunction with hypertension (mean increase of 14 mmHg) in young IUGR offspring; however, hypertension (mean increase of 22 mmHg) in adult IUGR offspring was associated with marked increases in renal angiotensin-converting enzyme (ACE) activity (122%) and renal renin and angiotensinogen mRNA (7-fold and 7.4-fold, respectively), but no change in renal ANG II or angiotensin type 1 receptor.",0.52,"Renal renin and <span class=""gene"" id=""17537837-5-16-31"">angiotensinogen</span> mRNA expression were significantly decreased at birth (80 and 60%, respectively); plasma and renal RAS did not differ in conjunction with <span class=""disease"" id=""17537837-5-170-182"">hypertension</span> (mean increase of 14 mmHg) in young IUGR offspring; however, <span class=""disease"" id=""17537837-5-244-256"">hypertension</span> (mean increase of 22 mmHg) in adult IUGR offspring was associated with marked increases in renal angiotensin-converting enzyme (ACE) activity (122%) and renal renin and <span class=""gene"" id=""17537837-5-426-441"">angiotensinogen</span> mRNA (7-fold and 7.4-fold, respectively), but no change in renal ANG II or angiotensin type 1 receptor.",CTD_human
69,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensin II,CTD_human,7323490,Most of these effects of angiotensin II were opposite to the effects of hypertension caused by phenylephrine and aortic balloon inflation.,0.52,"Most of these effects of <span class=""gene"" id=""7323490-5-25-39"">angiotensin II</span> were opposite to the effects of <span class=""disease"" id=""7323490-5-72-84"">hypertension</span> caused by phenylephrine and aortic balloon inflation.",CTD_human
69,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensin II,CTD_human,15243307,"SSR149744C, which has no or low affinity for alpha 1 and beta 1 adrenergic and angiotensin II AT1 receptors, reduced isoproterenol-induced tachycardia and phenylephrine- or angiotensin II-induced hypertension in anaesthetized dogs.",0.52,"SSR149744C, which has no or low affinity for alpha 1 and beta 1 adrenergic and <span class=""gene"" id=""15243307-5-79-93"">angiotensin II</span> AT1 receptors, reduced isoproterenol-induced tachycardia and phenylephrine- or <span class=""gene"" id=""15243307-5-173-187"">angiotensin II</span>-induced <span class=""disease"" id=""15243307-5-196-208"">hypertension</span> in anaesthetized dogs.",CTD_human
69,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensin II,CTD_human,24935938,Sex-specific T-cell regulation of angiotensin II-dependent hypertension.,0.52,"Sex-specific T-cell regulation of <span class=""gene"" id=""24935938-0-34-48"">angiotensin II</span>-dependent <span class=""disease"" id=""24935938-0-59-71"">hypertension</span>.",CTD_human
69,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensin II,CTD_human,18420994,Administration of resveratrol suppressed AT1R expression in the mouse aorta and blunted angiotensin II-induced hypertension.,0.52,"Administration of resveratrol suppressed AT1R expression in the mouse aorta and blunted <span class=""gene"" id=""18420994-9-88-102"">angiotensin II</span>-induced <span class=""disease"" id=""18420994-9-111-123"">hypertension</span>.",CTD_human
69,0,Therapeutic,C0020538,Hypertensive disease,group,high blood pressure,183,AGT,angiotensin II,CTD_human,8505092,"Thus, endogenous angiotensin II acting within the kidney appears to play an important role in the maintenance of high blood pressure in spontaneously hypertensive rats.",0.52,"Thus, endogenous <span class=""gene"" id=""8505092-6-17-31"">angiotensin II</span> acting within the kidney appears to play an important role in the maintenance of <span class=""disease"" id=""8505092-6-113-132"">high blood pressure</span> in spontaneously hypertensive rats.",CTD_human
69,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensin II,CTD_human,8021468,"Inducing acute hypertension (coronary pressure 200 mmHg) pharmacologically with angiotensin II also augmented constriction to serotonin, whereas phenylephrine-induced hypertension did not.",0.52,"Inducing acute <span class=""disease"" id=""8021468-11-15-27"">hypertension</span> (coronary pressure 200 mmHg) pharmacologically with <span class=""gene"" id=""8021468-11-80-94"">angiotensin II</span> also augmented constriction to serotonin, whereas phenylephrine-induced <span class=""disease"" id=""8021468-11-167-179"">hypertension</span> did not.",CTD_human
69,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,183,AGT,AngII,CTD_human,18847324,"Thus, blocking the synthesis of AngII may be an effective treatment of osteoporosis and hypertension, especially for those afflicted with both conditions.",0.52,"Thus, blocking the synthesis of <span class=""gene"" id=""18847324-8-32-37"">AngII</span> may be an effective treatment of osteoporosis and <span class=""disease"" id=""18847324-8-88-100"">hypertension</span>, especially for those afflicted with both conditions.",CTD_human
69,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensin-II,CTD_human,20937366,We examined the interaction of cigarette mainstream smoke (MS) and angiotensin-II (Ang II)-induced hypertension in the atherosclerotic process using hyperlipidemic apolipoprotein E-knockout (ApoE(-/-)) mice.,0.52,"We examined the interaction of cigarette mainstream smoke (MS) and <span class=""gene"" id=""20937366-2-67-81"">angiotensin-II</span> (Ang II)-induced <span class=""disease"" id=""20937366-2-99-111"">hypertension</span> in the atherosclerotic process using hyperlipidemic apolipoprotein E-knockout (ApoE(-/-)) mice.",CTD_human
69,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensin II,CTD_human,22214961,"Airway resistance, inflammation and oxidative stress following exposure to diesel exhaust particle in angiotensin II-induced hypertension in mice.",0.52,"Airway resistance, inflammation and oxidative stress following exposure to diesel exhaust particle in <span class=""gene"" id=""22214961-0-102-116"">angiotensin II</span>-induced <span class=""disease"" id=""22214961-0-125-137"">hypertension</span> in mice.",CTD_human
69,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,183,AGT,Angiotensin II,CTD_human,12600921,Angiotensin II-induced hypertension is associated with NAD(P)H oxidase-dependent superoxide production in the vessel wall.,0.52,"<span class=""gene"" id=""12600921-1-0-14"">Angiotensin II</span>-induced <span class=""disease"" id=""12600921-1-23-35"">hypertension</span> is associated with NAD(P)H oxidase-dependent superoxide production in the vessel wall.",CTD_human
69,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensin II,CTD_human,18420994,Administration of resveratrol suppressed AT1R expression in the mouse aorta and blunted angiotensin II-induced hypertension.,0.52,"Administration of resveratrol suppressed AT1R expression in the mouse aorta and blunted <span class=""gene"" id=""18420994-9-88-102"">angiotensin II</span>-induced <span class=""disease"" id=""18420994-9-111-123"">hypertension</span>.",CTD_human
69,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,183,AGT,angiotensin II,CTD_human,17989111,Purinergic receptors contribute to early mesangial cell transformation and renal vessel hypertrophy during angiotensin II-induced hypertension.,0.52,"Purinergic receptors contribute to early mesangial cell transformation and renal vessel hypertrophy during <span class=""gene"" id=""17989111-0-107-121"">angiotensin II</span>-induced <span class=""disease"" id=""17989111-0-130-142"">hypertension</span>.",CTD_human
4,0,Biomarker,C0022658,Kidney Diseases,group,nephropathy,183,AGT,AngII,CTD_human,15213268,"Plasma renin activity and plasma AngII were not different between rats with nephropathy and controls (2.08 +/- 0.7 versus 2.03 +/- 0.5 ng/ml/h and 94.3 +/- 18 versus 78.9 +/- 16 fmol/ml, respectively).",0.23512486913603398,"Plasma renin activity and plasma <span class=""gene"" id=""15213268-6-33-38"">AngII</span> were not different between rats with <span class=""disease"" id=""15213268-6-76-87"">nephropathy</span> and controls (2.08 +/- 0.7 versus 2.03 +/- 0.5 ng/ml/h and 94.3 +/- 18 versus 78.9 +/- 16 fmol/ml, respectively).",CTD_human
1,0,Biomarker,C0035344,Retinopathy of Prematurity,disease,retinopathy of prematurity,183,AGT,angiotensin II,CTD_human,15387897,There is increasing interest in a pathogenetic role for angiotensin II in ischaemic retinopathies such as diabetic retinopathy and retinopathy of prematurity.,0.2,"There is increasing interest in a pathogenetic role for <span class=""gene"" id=""15387897-3-56-70"">angiotensin II</span> in ischaemic retinopathies such as diabetic retinopathy and <span class=""disease"" id=""15387897-3-131-157"">retinopathy of prematurity</span>.",CTD_human
6,0,Biomarker,C0149721,Left Ventricular Hypertrophy,disease,LV hypertrophy,183,AGT,angiotensin II,CTD_human,24688123,"In contrast to TAC, antagonizing the function of CTGF had no effect on LV dysfunction or LV hypertrophy in mice subjected to 4-week angiotensin II infusion.",0.254301229410391,"In contrast to TAC, antagonizing the function of CTGF had no effect on LV dysfunction or <span class=""disease"" id=""24688123-7-89-103"">LV hypertrophy</span> in mice subjected to 4-week <span class=""gene"" id=""24688123-7-132-146"">angiotensin II</span> infusion.",CTD_human
6,0,Therapeutic,C0149721,Left Ventricular Hypertrophy,disease,LV hypertrophy,183,AGT,angiotensin II,CTD_human,24688123,"In contrast to TAC, antagonizing the function of CTGF had no effect on LV dysfunction or LV hypertrophy in mice subjected to 4-week angiotensin II infusion.",0.254301229410391,"In contrast to TAC, antagonizing the function of CTGF had no effect on LV dysfunction or <span class=""disease"" id=""24688123-7-89-103"">LV hypertrophy</span> in mice subjected to 4-week <span class=""gene"" id=""24688123-7-132-146"">angiotensin II</span> infusion.",CTD_human
4,0,Biomarker,C0162871,"Aortic Aneurysm, Abdominal",disease,abdominal aortic aneurysms,183,AGT,angiotensin II,CTD_human,25301841,Angiotensin-converting enzyme 2 decreases formation and severity of angiotensin II-induced abdominal aortic aneurysms.,0.212571919539173,"Angiotensin-converting enzyme 2 decreases formation and severity of <span class=""gene"" id=""25301841-0-68-82"">angiotensin II</span>-induced <span class=""disease"" id=""25301841-0-91-117"">abdominal aortic aneurysms</span>.",CTD_human
4,0,Biomarker,C0162871,"Aortic Aneurysm, Abdominal",disease,AAA,183,AGT,AngII,CTD_human,22539767,Neonatal testosterone administration increased abdominal aortic AT1aR mRNA abundance and promoted a striking increase in AngII-induced AAAs in adult females exhibiting low serum testosterone concentrations.,0.212571919539173,"Neonatal testosterone administration increased abdominal aortic AT1aR mRNA abundance and promoted a striking increase in <span class=""gene"" id=""22539767-7-121-126"">AngII</span>-induced <span class=""disease"" id=""22539767-7-135-138"">AAA</span>s in adult females exhibiting low serum testosterone concentrations.",CTD_human
4,0,Biomarker,C0162871,"Aortic Aneurysm, Abdominal",disease,abdominal aortic aneurysm,183,AGT,angiotensin II,CTD_human,16514081,Selective cyclooxygenase-2 inhibition with celecoxib decreases angiotensin II-induced abdominal aortic aneurysm formation in mice.,0.212571919539173,"Selective cyclooxygenase-2 inhibition with celecoxib decreases <span class=""gene"" id=""16514081-0-63-77"">angiotensin II</span>-induced <span class=""disease"" id=""16514081-0-86-111"">abdominal aortic aneurysm</span> formation in mice.",CTD_human
2,4,Biomarker,C0266313,Allanson Pantzar McLeod syndrome,disease,renal tubular dysgenesis,183,AGT,angiotensinogen,CTD_human,16116425,"We studied 11 individuals with renal tubular dysgenesis, belonging to nine families, and found that they had homozygous or compound heterozygous mutations in the genes encoding renin, angiotensinogen, angiotensin converting enzyme or angiotensin II receptor type 1.",0.600274726784213,"We studied 11 individuals with <span class=""disease"" id=""16116425-3-31-55"">renal tubular dysgenesis</span>, belonging to nine families, and found that they had homozygous or compound heterozygous mutations in the genes encoding renin, <span class=""gene"" id=""16116425-3-184-199"">angiotensinogen</span>, angiotensin converting enzyme or angiotensin II receptor type 1.",CTD_human;HPO;ORPHANET;UNIPROT
2,4,Biomarker,C0266313,Allanson Pantzar McLeod syndrome,disease,renal tubular dysgenesis,183,AGT,angiotensinogen,CTD_human,17036344,A case surviving for over a year of renal tubular dysgenesis with compound heterozygous angiotensinogen gene mutations.,0.600274726784213,"A case surviving for over a year of <span class=""disease"" id=""17036344-0-36-60"">renal tubular dysgenesis</span> with compound heterozygous <span class=""gene"" id=""17036344-0-88-103"">angiotensinogen</span> gene mutations.",CTD_human;HPO;ORPHANET;UNIPROT
1,0,Therapeutic,C0520459,Necrotizing Enterocolitis,disease,necrotizing enterocolitis,1839,HBEGF,Heparin-binding epidermal growth factor,CTD_human,16567187,Heparin-binding epidermal growth factor-like growth factor reduces intestinal apoptosis in neonatal rats with necrotizing enterocolitis.,0.20054945356842604,"<span class=""gene"" id=""16567187-0-0-39"">Heparin-binding epidermal growth factor</span>-like growth factor reduces intestinal apoptosis in neonatal rats with <span class=""disease"" id=""16567187-0-110-135"">necrotizing enterocolitis</span>.",CTD_human
1,0,Biomarker,C0017636,Glioblastoma,disease,glioblastomas,1848,DUSP6,DUSP6,CTD_human,21499306,Dual-specificity phosphatase DUSP6 has tumor-promoting properties in human glioblastomas.,0.200274726784213,"Dual-specificity phosphatase <span class=""gene"" id=""21499306-0-29-34"">DUSP6</span> has tumor-promoting properties in human <span class=""disease"" id=""21499306-0-75-88"">glioblastomas</span>.",CTD_human
1,0,Biomarker,C0011884,Diabetic Retinopathy,disease,diabetic retinopathy,185,AGTR1,angiotensin II type 1 receptor,CTD_human,16601577,Role of the angiotensin II type 1 receptor in the pathogenesis of diabetic retinopathy: effects of blood pressure control and beyond.,0.20541466777231498,"Role of the <span class=""gene"" id=""16601577-0-12-42"">angiotensin II type 1 receptor</span> in the pathogenesis of <span class=""disease"" id=""16601577-0-66-86"">diabetic retinopathy</span>: effects of blood pressure control and beyond.",CTD_human
2,0,Biomarker,C0013274,Patent ductus arteriosus,disease,ductus arteriosus,185,AGTR1,Angiotensin II type 1 receptor,CTD_human,12904590,Angiotensin II type 1 receptor A1166C polymorphism and prophylactic indomethacin treatment induced ductus arteriosus closure in very low birth weight neonates.,0.203780662444353,"<span class=""gene"" id=""12904590-0-0-30"">Angiotensin II type 1 receptor</span> A1166C polymorphism and prophylactic indomethacin treatment induced <span class=""disease"" id=""12904590-0-99-116"">ductus arteriosus</span> closure in very low birth weight neonates.",CTD_human
2,0,Biomarker,C0013274,Patent ductus arteriosus,disease,patent ductus arteriosus,185,AGTR1,angiotensin II type I receptor,CTD_human,19336370,An angiotensin II type I receptor polymorphism previously reported to be associated with patent ductus arteriosus after prophylactic indomethacin administration was not associated with the presence of a patent ductus arteriosus in our population.,0.203780662444353,"An <span class=""gene"" id=""19336370-11-3-33"">angiotensin II type I receptor</span> polymorphism previously reported to be associated with <span class=""disease"" id=""19336370-11-89-113"">patent ductus arteriosus</span> after prophylactic indomethacin administration was not associated with the presence of a <span class=""disease"" id=""19336370-11-203-227"">patent ductus arteriosus</span> in our population.",CTD_human
3,0,Biomarker,C0018801,Heart failure,disease,heart failure,185,AGTR1,angiotensin II type 1 receptor,CTD_human,17208988,"Blockade of angiotensin II type 1 receptor (AT1) signaling attenuates heart failure following myocardial infarction (MI), perhaps through reduction of fibrosis in the noninfarcted myocardium.",0.2981159336491239,"Blockade of <span class=""gene"" id=""17208988-1-12-42"">angiotensin II type 1 receptor</span> (AT1) signaling attenuates <span class=""disease"" id=""17208988-1-70-83"">heart failure</span> following myocardial infarction (MI), perhaps through reduction of fibrosis in the noninfarcted myocardium.",CTD_human
4,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,185,AGTR1,AT1-R,CTD_human,27292124,"In this study, we determined whether AT1-R antagonist telmisartan within the hypothalamic paraventricular nucleus (PVN) attenuates hypertension and hypothalamic inflammation via both the TLR4/MyD88/NF-?B signaling pathway and peroxisome proliferator-activated receptor-? (PPAR-?) in the PVN in hypertensive rats.",0.44296946344754207,"In this study, we determined whether <span class=""gene"" id=""27292124-2-37-42"">AT1-R</span> antagonist telmisartan within the hypothalamic paraventricular nucleus (PVN) attenuates <span class=""disease"" id=""27292124-2-131-143"">hypertension</span> and hypothalamic inflammation via both the TLR4/MyD88/NF-&kappa;B signaling pathway and peroxisome proliferator-activated receptor-&gamma; (PPAR-&gamma;) in the PVN in hypertensive rats.",CTD_human
4,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,185,AGTR1,AT1R,CTD_human,23603059,"Taken together, our results indicate that arsenic indeed upregulates the AT1R expression, thus highlighting a role of arsenic-induced aberrant AT1R signaling in the pathogenesis of hypertension.",0.44296946344754207,"Taken together, our results indicate that arsenic indeed upregulates the <span class=""gene"" id=""23603059-7-73-77"">AT1R</span> expression, thus highlighting a role of arsenic-induced aberrant AT1R signaling in the pathogenesis of <span class=""disease"" id=""23603059-7-181-193"">hypertension</span>.",CTD_human
1,0,Biomarker,C0162871,"Aortic Aneurysm, Abdominal",disease,AAA,185,AGTR1,AT1aR,CTD_human,22539767,These data reveal an unrecognized role of transient sex hormone exposures during neonatal development as long-lasting mediators of regional aortic AT1aR expression and sexual dimorphism of AAAs.,0.21400938726324398,"These data reveal an unrecognized role of transient sex hormone exposures during neonatal development as long-lasting mediators of regional aortic <span class=""gene"" id=""22539767-13-147-152"">AT1aR</span> expression and sexual dimorphism of <span class=""disease"" id=""22539767-13-189-192"">AAA</span>s.",CTD_human
1,5,Biomarker,C0266313,Allanson Pantzar McLeod syndrome,disease,renal tubular dysgenesis,185,AGTR1,angiotensin II receptor type 1,CTD_human,16116425,"We studied 11 individuals with renal tubular dysgenesis, belonging to nine families, and found that they had homozygous or compound heterozygous mutations in the genes encoding renin, angiotensinogen, angiotensin converting enzyme or angiotensin II receptor type 1.",0.6,"We studied 11 individuals with <span class=""disease"" id=""16116425-3-31-55"">renal tubular dysgenesis</span>, belonging to nine families, and found that they had homozygous or compound heterozygous mutations in the genes encoding renin, angiotensinogen, angiotensin converting enzyme or <span class=""gene"" id=""16116425-3-234-264"">angiotensin II receptor type 1</span>.",CTD_human;HPO;ORPHANET;UNIPROT
1,0,Biomarker,C0020538,Hypertensive disease,group,High blood pressure,186,AGTR2,angiotensin II type 2 receptor,CTD_human,15710752,High blood pressure reduction reverses angiotensin II type 2 receptor-mediated vasoconstriction into vasodilation in spontaneously hypertensive rats.,0.333239124053534,"<span class=""disease"" id=""15710752-0-0-19"">High blood pressure</span> reduction reverses <span class=""gene"" id=""15710752-0-39-69"">angiotensin II type 2 receptor</span>-mediated vasoconstriction into vasodilation in spontaneously hypertensive rats.",CTD_human
1,0,Biomarker,C0149721,Left Ventricular Hypertrophy,disease,left ventricular hypertrophy,186,AGTR2,angiotensin II type 2 receptor,CTD_human,20467270,Role of the angiotensin II type 2 receptor gene (+1675G/A) polymorphism on left ventricular hypertrophy and geometry in treated hypertensive patients.,0.21892575862444602,"Role of the <span class=""gene"" id=""20467270-0-12-42"">angiotensin II type 2 receptor</span> gene (+1675G/A) polymorphism on <span class=""disease"" id=""20467270-0-75-103"">left ventricular hypertrophy</span> and geometry in treated hypertensive patients.",CTD_human
2,0,Biomarker,C0853897,Diabetic Cardiomyopathies,disease,diabetic cardiomyopathy,186,AGTR2,AT2,CTD_human,16025228,A high expression of AT2 may accelerate the apoptosis of cardiomyocytes in diabetic rats and play a role in precipitating diabetic cardiomyopathy; taurine may protect diabetic rats from developing cardiomyopathy also by downregulating AT2 receptors.,0.2,"A high expression of AT2 may accelerate the apoptosis of cardiomyocytes in diabetic rats and play a role in precipitating <span class=""disease"" id=""16025228-19-122-145"">diabetic cardiomyopathy</span>; taurine may protect diabetic rats from developing cardiomyopathy also by downregulating <span class=""gene"" id=""16025228-19-235-238"">AT2</span> receptors.",CTD_human
2,0,Biomarker,C0853897,Diabetic Cardiomyopathies,disease,diabetic cardiomyopathy,186,AGTR2,AT2,CTD_human,15587404,Our results suggested that high expression of AT2 might accelerate the apoptosis of cardiomyocytes in diabetic rats and play an important role in precipitating diabetic cardiomyopathy and astragalus protects diabetic rats from developing cardiomyopathy by downregulating AT2.,0.2,"Our results suggested that high expression of <span class=""gene"" id=""15587404-12-46-49"">AT2</span> might accelerate the apoptosis of cardiomyocytes in diabetic rats and play an important role in precipitating <span class=""disease"" id=""15587404-12-160-183"">diabetic cardiomyopathy</span> and astragalus protects diabetic rats from developing cardiomyopathy by downregulating <span class=""gene"" id=""15587404-12-271-274"">AT2</span>.",CTD_human
1,0,Biomarker,C1136249,"Mental Retardation, X-Linked",disease,X-linked mental retardation,186,AGTR2,AGTR2,CTD_human,12089445,AGTR2 mutations in X-linked mental retardation.,0.205740551713841,"<span class=""gene"" id=""12089445-0-0-5"">AGTR2</span> mutations in <span class=""disease"" id=""12089445-0-19-46"">X-linked mental retardation</span>.",CTD_human
3,0,Biomarker,C0013421,Dystonia,phenotype,dystonia,1861,TOR1A,DYT1,CTD_human,21078339,"In the present study, we further characterized transgenic DYT1 mice, which were initially described to exhibit ""dystonia-like"" postures.",0.292856122274185,"In the present study, we further characterized transgenic <span class=""gene"" id=""21078339-4-58-62"">DYT1</span> mice, which were initially described to exhibit ""<span class=""disease"" id=""21078339-4-112-120"">dystonia</span>-like"" postures.",CTD_human
3,0,Biomarker,C0013421,Dystonia,phenotype,dystonia,1861,TOR1A,DYT1,CTD_human,20227500,Dopamine D2 receptor dysfunction is rescued by adenosine A2A receptor antagonism in a model of DYT1 dystonia.,0.292856122274185,"Dopamine D2 receptor dysfunction is rescued by adenosine A2A receptor antagonism in a model of <span class=""gene"" id=""20227500-0-95-99"">DYT1</span> <span class=""disease"" id=""20227500-0-100-108"">dystonia</span>.",CTD_human
2,0,Biomarker,C0025202,melanoma,disease,melanoma,1869,E2F1,E2F-1,CTD_human,16827129,Alteration of gene expression in melanoma cells following combined treatment with E2F-1 and doxorubicin.,0.213143819510277,"Alteration of gene expression in <span class=""disease"" id=""16827129-0-33-41"">melanoma</span> cells following combined treatment with <span class=""gene"" id=""16827129-0-82-87"">E2F-1</span> and doxorubicin.",CTD_human
2,0,Therapeutic,C0025202,melanoma,disease,melanoma,1869,E2F1,E2F-1,CTD_human,16827129,Alteration of gene expression in melanoma cells following combined treatment with E2F-1 and doxorubicin.,0.213143819510277,"Alteration of gene expression in <span class=""disease"" id=""16827129-0-33-41"">melanoma</span> cells following combined treatment with <span class=""gene"" id=""16827129-0-82-87"">E2F-1</span> and doxorubicin.",CTD_human
2,0,Therapeutic,C0025202,melanoma,disease,melanoma,1869,E2F1,E2F1,CTD_human,15574415,Eugenol causes melanoma growth suppression through inhibition of E2F1 transcriptional activity.,0.213143819510277,"Eugenol causes <span class=""disease"" id=""15574415-0-15-23"">melanoma</span> growth suppression through inhibition of <span class=""gene"" id=""15574415-0-65-69"">E2F1</span> transcriptional activity.",CTD_human
2,0,Biomarker,C0025202,melanoma,disease,melanoma,1869,E2F1,E2F1,CTD_human,15574415,Eugenol causes melanoma growth suppression through inhibition of E2F1 transcriptional activity.,0.213143819510277,"Eugenol causes <span class=""disease"" id=""15574415-0-15-23"">melanoma</span> growth suppression through inhibition of <span class=""gene"" id=""15574415-0-65-69"">E2F1</span> transcriptional activity.",CTD_human
2,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,1869,E2F1,E2f1,CTD_human,15565109,"Gene expression patterns in HCCs from Myc, E2f1 and Myc E2f1 transgenic mice were most similar to those of the better survival group of human HCCs, whereas the expression patterns in HCCs from Myc Tgfa transgenic mice and in diethylnitrosamine-induced mouse HCCs were most similar to those of the poorer survival group of human HCCs.",0.20741762317375398,"Gene expression patterns in <span class=""disease"" id=""15565109-5-28-31"">HCC</span>s from Myc, <span class=""gene"" id=""15565109-5-43-47"">E2f1</span> and Myc <span class=""gene"" id=""15565109-5-56-60"">E2f1</span> transgenic mice were most similar to those of the better survival group of human <span class=""disease"" id=""15565109-5-142-145"">HCC</span>s, whereas the expression patterns in <span class=""disease"" id=""15565109-5-183-186"">HCC</span>s from Myc Tgfa transgenic mice and in diethylnitrosamine-induced mouse <span class=""disease"" id=""15565109-5-258-261"">HCC</span>s were most similar to those of the poorer survival group of human <span class=""disease"" id=""15565109-5-328-331"">HCC</span>s.",CTD_human
2,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,1869,E2F1,E2F1,CTD_human,12029619,"In nodules and/or HCCs of Wistar and BN rats, low or no increases in c-myc, Cyclins D1, E, and A, and E2F1 expression, and Cyclin-CDKs complex formation were associated with p16(INK4A) overexpression and pRb hypophosphorylation.",0.20741762317375398,"In nodules and/or <span class=""disease"" id=""12029619-6-18-21"">HCC</span>s of Wistar and BN rats, low or no increases in c-myc, Cyclins D1, E, and A, and <span class=""gene"" id=""12029619-6-102-106"">E2F1</span> expression, and Cyclin-CDKs complex formation were associated with p16(INK4A) overexpression and pRb hypophosphorylation.",CTD_human
2,0,Biomarker,C0018798,Congenital Heart Defects,group,cardiac abnormalities,1889,ECE1,ECE-1,CTD_human,9449665,ECE-1-/- term embryos exhibited craniofacial and cardiac abnormalities virtually identical to the defects seen in ET-1 and endothelin A receptor (ETA)-deficient embryos.,0.200274726784213,"<span class=""gene"" id=""9449665-5-0-5"">ECE-1</span>-/- term embryos exhibited craniofacial and <span class=""disease"" id=""9449665-5-49-70"">cardiac abnormalities</span> virtually identical to the defects seen in ET-1 and endothelin A receptor (ETA)-deficient embryos.",CTD_human
1,0,Biomarker,C0279626,Squamous cell carcinoma of esophagus,disease,esophageal squamous cell carcinoma,1890,TYMP,thymidine phosphorylase,CTD_human,11641616,The expression of thymidine phosphorylase suppresses spontaneous apoptosis of cancer cells in esophageal squamous cell carcinoma.,0.200274726784213,"The expression of <span class=""gene"" id=""11641616-0-18-41"">thymidine phosphorylase</span> suppresses spontaneous apoptosis of cancer cells in <span class=""disease"" id=""11641616-0-94-128"">esophageal squamous cell carcinoma</span>.",CTD_human
1,0,Biomarker,C0009324,Ulcerative Colitis,disease,ulcerative colitis,1893,ECM1,ECM1,CTD_human,18438406,Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn's disease.,0.207337755261807,"Genetic determinants of <span class=""disease"" id=""18438406-0-24-42"">ulcerative colitis</span> include the <span class=""gene"" id=""18438406-0-55-59"">ECM1</span> locus and five loci implicated in Crohn's disease.",CTD_human
1,0,Biomarker,C0004153,Atherosclerosis,disease,atherosclerosis,19,ABCA1,ABCA1,CTD_human,22022523,ABCA1 protects against atherosclerosis by facilitating cholesterol efflux from macrophage foam cells in the arterial wall to extracellular apolipoprotein (apo) A-I.,0.26675707777394,"<span class=""gene"" id=""22022523-1-0-5"">ABCA1</span> protects against <span class=""disease"" id=""22022523-1-23-38"">atherosclerosis</span> by facilitating cholesterol efflux from macrophage foam cells in the arterial wall to extracellular apolipoprotein (apo) A-I.",CTD_human
1,0,Biomarker,C0020443,Hypercholesterolemia,disease,high-cholesterol,19,ABCA1,ABCA1,CTD_human,22022523,"LDL receptor knockout (KO) mice were transplanted with bone marrow from ABCA1/apoE double KO (dKO) mice, their respective single KO's, and wild-type (WT) controls and were challenged with a high-fat/high-cholesterol diet for 9 weeks.",0.210778178387317,"LDL receptor knockout (KO) mice were transplanted with bone marrow from <span class=""gene"" id=""22022523-4-72-77"">ABCA1</span>/apoE double KO (dKO) mice, their respective single KO's, and wild-type (WT) controls and were challenged with a high-fat/<span class=""disease"" id=""22022523-4-199-215"">high-cholesterol</span> diet for 9 weeks.",CTD_human
19,20,Biomarker,C0039292,Tangier Disease,disease,Tangier disease,19,ABCA1,ABC1,CTD_human,10431236,Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency.,0.7191629960985741,"Mutations in <span class=""gene"" id=""10431236-0-13-17"">ABC1</span> in <span class=""disease"" id=""10431236-0-21-36"">Tangier disease</span> and familial high-density lipoprotein deficiency.",CTD_human;ORPHANET;UNIPROT
19,20,Biomarker,C0039292,Tangier Disease,disease,Tangier disease,19,ABCA1,ABCA1,CTD_human,11476965,Novel mutations in ABCA1 gene in Japanese patients with Tangier disease and familial high density lipoprotein deficiency with coronary heart disease.,0.7191629960985741,"Novel mutations in <span class=""gene"" id=""11476965-0-19-24"">ABCA1</span> gene in Japanese patients with <span class=""disease"" id=""11476965-0-56-71"">Tangier disease</span> and familial high density lipoprotein deficiency with coronary heart disease.",CTD_human;ORPHANET;UNIPROT
2,0,Biomarker,C2931838,Familial HDL deficiency,disease,familial high-density lipoprotein deficiency,19,ABCA1,ABC1,CTD_human,10431236,Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency.,0.20521980890004898,"Mutations in <span class=""gene"" id=""10431236-0-13-17"">ABC1</span> in Tangier disease and <span class=""disease"" id=""10431236-0-41-85"">familial high-density lipoprotein deficiency</span>.",CTD_human
2,0,Biomarker,C2931838,Familial HDL deficiency,disease,familial high density lipoprotein deficiency,19,ABCA1,ABCA1,CTD_human,11476965,Novel mutations in ABCA1 gene in Japanese patients with Tangier disease and familial high density lipoprotein deficiency with coronary heart disease.,0.20521980890004898,"Novel mutations in <span class=""gene"" id=""11476965-0-19-24"">ABCA1</span> gene in Japanese patients with Tangier disease and <span class=""disease"" id=""11476965-0-76-120"">familial high density lipoprotein deficiency</span> with coronary heart disease.",CTD_human
1,0,Biomarker,C0004096,Asthma,disease,asthmatic,1906,EDN1,ET-1,CTD_human,16981460,"MZC is the effective part of MZ and the anti-asthmatic mechanisms ware related to its significant reduction in contents of ET-1, NO, EOS and the damage of lung tissue possibly.",0.22238053712727301,"MZC is the effective part of MZ and the anti-<span class=""disease"" id=""16981460-8-45-54"">asthmatic</span> mechanisms ware related to its significant reduction in contents of <span class=""gene"" id=""16981460-8-123-127"">ET-1</span>, NO, EOS and the damage of lung tissue possibly.",CTD_human
7,0,Biomarker,C0018801,Heart failure,disease,heart failure,1906,EDN1,endothelin-1,CTD_human,11136700,"The combination of ACE inhibitor and ARB, independently of the hypotensive effect, improved LV phenotypic change and increased LV endothelin-1 production and collagen accumulation, diastolic dysfunction, and survival in a rat heart failure model more effectively than either agent alone, thereby providing solid experimental evidence that the combination of these 2 agents is more beneficial than monotherapy for treatment of heart failure.",0.29806477649181107,"The combination of ACE inhibitor and ARB, independently of the hypotensive effect, improved LV phenotypic change and increased LV <span class=""gene"" id=""11136700-7-130-142"">endothelin-1</span> production and collagen accumulation, diastolic dysfunction, and survival in a rat <span class=""disease"" id=""11136700-7-226-239"">heart failure</span> model more effectively than either agent alone, thereby providing solid experimental evidence that the combination of these 2 agents is more beneficial than monotherapy for treatment of <span class=""disease"" id=""11136700-7-426-439"">heart failure</span>.",CTD_human
7,0,Biomarker,C0018801,Heart failure,disease,heart failure,1906,EDN1,endothelin-1,CTD_human,16762801,"The prognostic value of big endothelin-1 in more than 2,300 patients with heart failure enrolled in the Valsartan Heart Failure Trial (Val-HeFT).",0.29806477649181107,"The prognostic value of big <span class=""gene"" id=""16762801-0-28-40"">endothelin-1</span> in more than 2,300 patients with <span class=""disease"" id=""16762801-0-74-87"">heart failure</span> enrolled in the Valsartan Heart Failure Trial (Val-HeFT).",CTD_human
7,0,Biomarker,C0018801,Heart failure,disease,heart failure,1906,EDN1,endothelin-1,CTD_human,7967349,"Elevated levels of the vasocontrictor peptide endothelin-1 have been demonstrated in various pathological conditions that are characterized by sodium retention and/or renal vasoconstriction, such as heart failure, hepatorenal syndrome, renal failure and during administration of cyclosporin and radiocontrast.",0.29806477649181107,"Elevated levels of the vasocontrictor peptide <span class=""gene"" id=""7967349-1-46-58"">endothelin-1</span> have been demonstrated in various pathological conditions that are characterized by sodium retention and/or renal vasoconstriction, such as <span class=""disease"" id=""7967349-1-199-212"">heart failure</span>, hepatorenal syndrome, renal failure and during administration of cyclosporin and radiocontrast.",CTD_human
1,0,Biomarker,C0019212,Hepatorenal Syndrome,disease,hepatorenal syndrome,1906,EDN1,endothelin-1,CTD_human,7967349,"Elevated levels of the vasocontrictor peptide endothelin-1 have been demonstrated in various pathological conditions that are characterized by sodium retention and/or renal vasoconstriction, such as heart failure, hepatorenal syndrome, renal failure and during administration of cyclosporin and radiocontrast.",0.2,"Elevated levels of the vasocontrictor peptide <span class=""gene"" id=""7967349-1-46-58"">endothelin-1</span> have been demonstrated in various pathological conditions that are characterized by sodium retention and/or renal vasoconstriction, such as heart failure, <span class=""disease"" id=""7967349-1-214-234"">hepatorenal syndrome</span>, renal failure and during administration of cyclosporin and radiocontrast.",CTD_human
1,0,Biomarker,C0020429,Hyperalgesia,phenotype,hyperalgesia,1906,EDN1,ET-1,CTD_human,19429182,"The potentiation of capsaicin-induced nociception by ET-1 was abolished by prior i.pl. injection of BQ-123 (ET(A) receptor antagonist, 10 nmol), but unaffected by BQ-788 (ET(B) receptors antagonist, 10 nmol), whereas the enhancement of capsaicin-induced hyperalgesia by ET-1 was attenuated by both antagonists.",0.200274726784213,"The potentiation of capsaicin-induced nociception by <span class=""gene"" id=""19429182-5-53-57"">ET-1</span> was abolished by prior i.pl. injection of BQ-123 (ET(A) receptor antagonist, 10 nmol), but unaffected by BQ-788 (ET(B) receptors antagonist, 10 nmol), whereas the enhancement of capsaicin-induced <span class=""disease"" id=""19429182-5-254-266"">hyperalgesia</span> by <span class=""gene"" id=""19429182-5-270-274"">ET-1</span> was attenuated by both antagonists.",CTD_human
1,0,Biomarker,C0020443,Hypercholesterolemia,disease,Hypercholesterolemia,1906,EDN1,endothelin-1,CTD_human,15486036,Hypercholesterolemia upregulated ventricular preproendothelin-1 mRNA as assessed by real-time quantitative RT-PCR and elevated production of cardiac endothelin-1 concentration.,0.2,"<span class=""disease"" id=""15486036-8-0-20"">Hypercholesterolemia</span> upregulated ventricular <span class=""gene"" id=""15486036-8-45-63"">preproendothelin-1</span> mRNA as assessed by real-time quantitative RT-PCR and elevated production of cardiac <span class=""gene"" id=""15486036-8-149-161"">endothelin-1</span> concentration.",CTD_human
14,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,1906,EDN1,Endothelin-1,CTD_human,7721406,"Endothelin-1 infusion into humans to obtain pathophysiological plasma levels causes mild hypertension, strong renal vasoconstriction, and sodium retention.",0.33956302422708695,"<span class=""gene"" id=""7721406-1-0-12"">Endothelin-1</span> infusion into humans to obtain pathophysiological plasma levels causes mild <span class=""disease"" id=""7721406-1-89-101"">hypertension</span>, strong renal vasoconstriction, and sodium retention.",CTD_human
14,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,1906,EDN1,endothelin-1,CTD_human,15314687,Collecting duct-specific knockout of endothelin-1 causes hypertension and sodium retention.,0.33956302422708695,"Collecting duct-specific knockout of <span class=""gene"" id=""15314687-0-37-49"">endothelin-1</span> causes <span class=""disease"" id=""15314687-0-57-69"">hypertension</span> and sodium retention.",CTD_human
14,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,1906,EDN1,endothelin-1,CTD_human,12425201,"The objective of the investigation was to assess whether circulating adhesion molecules, von Willebrand factor (vWf) and endothelin-1 are elevated in patients with mild uncomplicated essential hypertension without further risk factors of atherosclerosis and whether they could serve as indicators of endothelial dysfunction in this form of hypertension.",0.33956302422708695,"The objective of the investigation was to assess whether circulating adhesion molecules, von Willebrand factor (vWf) and <span class=""gene"" id=""12425201-1-121-133"">endothelin-1</span> are elevated in patients with mild uncomplicated essential hypertension without further risk factors of atherosclerosis and whether they could serve as indicators of endothelial dysfunction in this form of <span class=""disease"" id=""12425201-1-340-352"">hypertension</span>.",CTD_human
14,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,1906,EDN1,endothelin-1,CTD_human,15188945,Studies suggest that endothelin-1 contributes to the pathogenesis of hypertension.,0.33956302422708695,"Studies suggest that <span class=""gene"" id=""15188945-1-21-33"">endothelin-1</span> contributes to the pathogenesis of <span class=""disease"" id=""15188945-1-69-81"">hypertension</span>.",CTD_human
14,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,1906,EDN1,endothelin-1,CTD_human,11847185,"No study has yet determined the impact of this polymorphism on vascular reactivity, although a functional role for endothelin-1 in the pathophysiology of hypertension has been clarified.",0.33956302422708695,"No study has yet determined the impact of this polymorphism on vascular reactivity, although a functional role for <span class=""gene"" id=""11847185-2-115-127"">endothelin-1</span> in the pathophysiology of <span class=""disease"" id=""11847185-2-154-166"">hypertension</span> has been clarified.",CTD_human
14,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,1906,EDN1,endothelin-1,CTD_human,17130675,Our results indicated that endothelin-1 plays a key role in the FK506-induced change in vascular reactivity to noradrenaline in renal vascular beds and drug-induced hypertension in the rats.,0.33956302422708695,"Our results indicated that <span class=""gene"" id=""17130675-10-27-39"">endothelin-1</span> plays a key role in the FK506-induced change in vascular reactivity to noradrenaline in renal vascular beds and drug-induced <span class=""disease"" id=""17130675-10-165-177"">hypertension</span> in the rats.",CTD_human
14,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,1906,EDN1,Endothelin-1,CTD_human,12600921,Endothelin-1 increases vascular superoxide via endothelin(A)-NADPH oxidase pathway in low-renin hypertension.,0.33956302422708695,"<span class=""gene"" id=""12600921-0-0-12"">Endothelin-1</span> increases vascular superoxide via endothelin(A)-NADPH oxidase pathway in low-renin <span class=""disease"" id=""12600921-0-96-108"">hypertension</span>.",CTD_human
14,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,1906,EDN1,endothelin-1,CTD_human,12149661,"The levels of adhesion molecules (intercellular cell adhesion molecule-1 [ICAM-1], E-selectin, P-selectin), von Willebrand factor (vWf) and endothelin-1 were measured in patients with hypertension without any other risk factors of atherosclerosis before and after treatment with quinapril (n = 22) and in normotensive controls (n = 22).",0.33956302422708695,"The levels of adhesion molecules (intercellular cell adhesion molecule-1 [ICAM-1], E-selectin, P-selectin), von Willebrand factor (vWf) and <span class=""gene"" id=""12149661-3-140-152"">endothelin-1</span> were measured in patients with <span class=""disease"" id=""12149661-3-184-196"">hypertension</span> without any other risk factors of atherosclerosis before and after treatment with quinapril (n = 22) and in normotensive controls (n = 22).",CTD_human
3,0,Biomarker,C0022658,Kidney Diseases,group,Renal disease,1906,EDN1,ET-1,CTD_human,8604712,Renal disease progression in the rat is associated with a time-dependent upregulation of renal endothelin-1 (ET-1) gene expression and synthesis.,0.20433011601278,"<span class=""disease"" id=""8604712-1-0-13"">Renal disease</span> progression in the rat is associated with a time-dependent upregulation of renal <span class=""gene"" id=""8604712-1-95-107"">endothelin-1</span> (<span class=""gene"" id=""8604712-1-109-113"">ET-1</span>) gene expression and synthesis.",CTD_human
2,0,Biomarker,C0030193,Pain,phenotype,pain,1906,EDN1,ET-1,CTD_human,20042899,Our results suggested that TRPA1 is involved in ET-1-induced spontaneous pain-like behavior in mice.,0.201373633921065,"Our results suggested that TRPA1 is involved in <span class=""gene"" id=""20042899-9-48-52"">ET-1</span>-induced spontaneous <span class=""disease"" id=""20042899-9-73-77"">pain</span>-like behavior in mice.",CTD_human
1,0,Biomarker,C0034069,Pulmonary Fibrosis,disease,pulmonary fibrosis,1906,EDN1,ET-1,CTD_human,17235729,We also observed significant decreases in pulmonary fibrosis in Group PZ compared with Group P. These findings suggest that GTE inhibits paraquat-induced pulmonary fibrosis by suppression of oxidative stress and ET-1 expression.,0.207114185634906,"We also observed significant decreases in <span class=""disease"" id=""17235729-9-42-60"">pulmonary fibrosis</span> in Group PZ compared with Group P. These findings suggest that GTE inhibits paraquat-induced <span class=""disease"" id=""17235729-9-154-172"">pulmonary fibrosis</span> by suppression of oxidative stress and <span class=""gene"" id=""17235729-9-212-216"">ET-1</span> expression.",CTD_human
1,0,Biomarker,C0038525,Subarachnoid Hemorrhage,disease,SAH,1906,EDN1,ET1,CTD_human,8587695,"In the cerebrospinal fluid, SAH increased endothelin-1 (ET1) and big ET1 by 6 and 3.8 times, respectively; in the basilar artery, SAH increased ET1 concentration, big ET1 concentration, and ET-converting enzyme activity by 1.3, 2, and 2.7 times, respectively.",0.204381273170092,"In the cerebrospinal fluid, <span class=""disease"" id=""8587695-8-28-31"">SAH</span> increased <span class=""gene"" id=""8587695-8-42-54"">endothelin-1</span> (<span class=""gene"" id=""8587695-8-56-59"">ET1</span>) and big <span class=""gene"" id=""8587695-8-69-72"">ET1</span> by 6 and 3.8 times, respectively; in the basilar artery, <span class=""disease"" id=""8587695-8-130-133"">SAH</span> increased <span class=""gene"" id=""8587695-8-144-147"">ET1</span> concentration, big <span class=""gene"" id=""8587695-8-167-170"">ET1</span> concentration, and ET-converting enzyme activity by 1.3, 2, and 2.7 times, respectively.",CTD_human
2,0,Biomarker,C0149721,Left Ventricular Hypertrophy,disease,left ventricular hypertrophy,1906,EDN1,preproendothelin-1,CTD_human,10601118,Carvedilol at a lower dose (7.5 mg x kg(-1) x d(-1)) and lacidipine 1 mg x kg(-1) x d(-1) had only moderate and nonsignificant effects on carotid pressure but largely prevented left ventricular hypertrophy (P<0.01) and preproendothelin-1 overexpression (P<0.05).,0.293459933694818,"Carvedilol at a lower dose (7.5 mg x kg(-1) x d(-1)) and lacidipine 1 mg x kg(-1) x d(-1) had only moderate and nonsignificant effects on carotid pressure but largely prevented <span class=""disease"" id=""10601118-6-177-205"">left ventricular hypertrophy</span> (P&lt;0.01) and <span class=""gene"" id=""10601118-6-219-237"">preproendothelin-1</span> overexpression (P&lt;0.05).",CTD_human
3,0,Biomarker,C0151744,Myocardial Ischemia,disease,myocardial ischemia,1906,EDN1,endothelin-1,CTD_human,16306806,Flow-independent myocardial ischemia induced by endothelin-1: an NADH fluorescence analysis.,0.20054945356842604,"Flow-independent <span class=""disease"" id=""16306806-0-17-36"">myocardial ischemia</span> induced by <span class=""gene"" id=""16306806-0-48-60"">endothelin-1</span>: an NADH fluorescence analysis.",CTD_human
4,0,Biomarker,C0376634,Craniofacial Abnormalities,group,craniofacial abnormalities,1906,EDN1,Edn1,CTD_human,9671575,"Mice harboring a null mutation of the endothelin-1 gene (Edn1), which is expressed in the epithelial layer of the branchial arches and encodes for the endothelin-1 (ET-1) signaling peptide, have a phenotype similar to CATCH-22 syndrome with aortic arch defects and craniofacial abnormalities.",0.2,"Mice harboring a null mutation of the <span class=""gene"" id=""9671575-3-38-50"">endothelin-1</span> gene (<span class=""gene"" id=""9671575-3-57-61"">Edn1</span>), which is expressed in the epithelial layer of the branchial arches and encodes for the endothelin-1 (ET-1) signaling peptide, have a phenotype similar to CATCH-22 syndrome with aortic arch defects and <span class=""disease"" id=""9671575-3-265-291"">craniofacial abnormalities</span>.",CTD_human
4,0,Biomarker,C0376634,Craniofacial Abnormalities,group,craniofacial abnormalities,1906,EDN1,endothelin-1,CTD_human,8152482,Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1.,0.2,"Elevated blood pressure and <span class=""disease"" id=""8152482-0-28-54"">craniofacial abnormalities</span> in mice deficient in <span class=""gene"" id=""8152482-0-76-88"">endothelin-1</span>.",CTD_human
1,0,Biomarker,C0878544,Cardiomyopathies,group,cardiomyopathy,1906,EDN1,endothelin-1,CTD_human,11589785,Increased plasma endothelin-1 and cardiac nitric oxide during doxorubicin-induced cardiomyopathy.,0.200274726784213,"Increased plasma <span class=""gene"" id=""11589785-0-17-29"">endothelin-1</span> and cardiac nitric oxide during doxorubicin-induced <span class=""disease"" id=""11589785-0-82-96"">cardiomyopathy</span>.",CTD_human
4,0,Biomarker,C0019569,Hirschsprung Disease,disease,Hirschsprung disease,1908,EDN3,Endothelin-3,CTD_human,9359047,Endothelin-3 gene mutations in isolated and syndromic Hirschsprung disease.,0.614950237307826,"<span class=""gene"" id=""9359047-0-0-12"">Endothelin-3</span> gene mutations in isolated and syndromic <span class=""disease"" id=""9359047-0-54-74"">Hirschsprung disease</span>.",CTD_human;HPO;ORPHANET
4,0,Biomarker,C0019569,Hirschsprung Disease,disease,HSCR,1908,EDN3,EDN3,CTD_human,8630502,"EDN3 thus becomes the third known gene (after RET and EDNRB) predisposing to HSCR, supporting the view that the endothelin-signaling pathways play a major role in the development of neural crests.",0.614950237307826,"<span class=""gene"" id=""8630502-6-0-4"">EDN3</span> thus becomes the third known gene (after RET and EDNRB) predisposing to <span class=""disease"" id=""8630502-6-77-81"">HSCR</span>, supporting the view that the endothelin-signaling pathways play a major role in the development of neural crests.",CTD_human;HPO;ORPHANET
4,0,Biomarker,C0019569,Hirschsprung Disease,disease,HSCR,1908,EDN3,EDN3,CTD_human,8630503,"Here, we describe a mutation of the human gene for endothelin 3 (EDN3), homozygously present in a patient with a combined Waardenburg syndrome type 2 (WS2) and HSCR phenotype (Shah-Waardenburg syndrome).",0.614950237307826,"Here, we describe a mutation of the human gene for <span class=""gene"" id=""8630503-5-51-63"">endothelin 3</span> (<span class=""gene"" id=""8630503-5-65-69"">EDN3</span>), homozygously present in a patient with a combined Waardenburg syndrome type 2 (WS2) and <span class=""disease"" id=""8630503-5-160-164"">HSCR</span> phenotype (Shah-Waardenburg syndrome).",CTD_human;HPO;ORPHANET
1,0,Biomarker,C1275808,Congenital central hypoventilation,disease,congenital central hypoventilation syndrome,1908,EDN3,Endothelin-3,CTD_human,8696331,Endothelin-3 frameshift mutation in congenital central hypoventilation syndrome.,0.4,"<span class=""gene"" id=""8696331-0-0-12"">Endothelin-3</span> frameshift mutation in <span class=""disease"" id=""8696331-0-36-79"">congenital central hypoventilation syndrome</span>.",CTD_human;ORPHANET
3,0,Biomarker,C1848519,"WAARDENBURG SYNDROME, TYPE 4A",disease,Shah-Waardenburg syndrome,1908,EDN3,endothelin-3,CTD_human,8630502,Mutation of the endothelin-3 gene in the Waardenburg-Hirschsprung disease (Shah-Waardenburg syndrome).,0.401648360705279,"Mutation of the <span class=""gene"" id=""8630502-0-16-28"">endothelin-3</span> gene in the <span class=""disease"" id=""8630502-0-41-73"">Waardenburg-Hirschsprung disease</span> (<span class=""disease"" id=""8630502-0-75-100"">Shah-Waardenburg syndrome</span>).",CTD_human;ORPHANET
3,0,Biomarker,C1848519,"WAARDENBURG SYNDROME, TYPE 4A",disease,Waardenburg syndrome type IV,1908,EDN3,endothelin 3,CTD_human,17516928,A mouse model of Waardenburg syndrome type IV resulting from an ENU-induced mutation in endothelin 3.,0.401648360705279,"A mouse model of <span class=""disease"" id=""17516928-0-17-45"">Waardenburg syndrome type IV</span> resulting from an ENU-induced mutation in <span class=""gene"" id=""17516928-0-88-100"">endothelin 3</span>.",CTD_human;ORPHANET
3,0,Biomarker,C1848519,"WAARDENBURG SYNDROME, TYPE 4A",disease,Shah-Waardenburg syndrome,1908,EDN3,endothelin-3,CTD_human,8630503,A homozygous mutation in the endothelin-3 gene associated with a combined Waardenburg type 2 and Hirschsprung phenotype (Shah-Waardenburg syndrome).,0.401648360705279,"A homozygous mutation in the <span class=""gene"" id=""8630503-0-29-41"">endothelin-3</span> gene associated with a combined Waardenburg type 2 and Hirschsprung phenotype (<span class=""disease"" id=""8630503-0-121-146"">Shah-Waardenburg syndrome</span>).",CTD_human;ORPHANET
1,0,Biomarker,C0242350,Erectile dysfunction,disease,ED,1909,EDNRA,ET(A,CTD_human,18823320,ET(A) receptor blockade may represent an alternative therapeutic approach for ED associated with salt-sensitive hypertension and in pathological conditions where increased levels of ET-1 are present.,0.2,"<span class=""gene"" id=""18823320-16-0-4"">ET(A</span>) receptor blockade may represent an alternative therapeutic approach for <span class=""disease"" id=""18823320-16-78-80"">ED</span> associated with salt-sensitive hypertension and in pathological conditions where increased levels of ET-1 are present.",CTD_human
1,0,Biomarker,C0520679,"Sleep Apnea, Obstructive",disease,obstructive sleep apnea syndrome,1909,EDNRA,endothelin-receptor-subtype-a,CTD_human,20083432,Genetic polymorphisms in endothelin-receptor-subtype-a-gene as susceptibility factor for obstructive sleep apnea syndrome.,0.205363510615002,"Genetic polymorphisms in <span class=""gene"" id=""20083432-0-25-54"">endothelin-receptor-subtype-a</span>-gene as susceptibility factor for <span class=""disease"" id=""20083432-0-89-121"">obstructive sleep apnea syndrome</span>.",CTD_human
1,0,Biomarker,C0019202,Hepatolenticular Degeneration,disease,WD,191,AHCY,S-adenosylhomocysteine hydrolase,CTD_human,23519153,"Of note, reciprocal expression of Asmt and Bhmt is an important clue that altered S-adenosylhomocysteine metabolism underlies brain injury in WD, which is directly correlated to the decreased expression of S-adenosylhomocysteine hydrolase in hepatic tissue in LEC rats.",0.200274726784213,"Of note, reciprocal expression of Asmt and Bhmt is an important clue that altered S-adenosylhomocysteine metabolism underlies brain injury in <span class=""disease"" id=""23519153-8-142-144"">WD</span>, which is directly correlated to the decreased expression of <span class=""gene"" id=""23519153-8-206-238"">S-adenosylhomocysteine hydrolase</span> in hepatic tissue in LEC rats.",CTD_human
1,0,Biomarker,C0027720,Nephrosis,disease,nephrosis,1910,EDNRB,ETB,CTD_human,7756592,These data indicate that glomerular ET-1 and ETB receptor expression in PAN nephrosis in increased at the mRNA level and that methylprednisolone treatment results in an attenuated increase.,0.2,"These data indicate that glomerular ET-1 and <span class=""gene"" id=""7756592-9-45-48"">ETB</span> receptor expression in PAN <span class=""disease"" id=""7756592-9-76-85"">nephrosis</span> in increased at the mRNA level and that methylprednisolone treatment results in an attenuated increase.",CTD_human
1,0,Therapeutic,C1458155,Mammary Neoplasms,group,breast tumor,1910,EDNRB,Endothelin B receptor,CTD_human,16244791,"Endothelin B receptor agonist, IRL 1620, enhances the anti-tumor efficacy of paclitaxel in breast tumor rats.",0.202732912464814,"<span class=""gene"" id=""16244791-0-0-21"">Endothelin B receptor</span> agonist, IRL 1620, enhances the anti-tumor efficacy of paclitaxel in <span class=""disease"" id=""16244791-0-91-103"">breast tumor</span> rats.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,192683,SCAMP5,SCAMP5,CTD_human,20071347,"SCAMP5, NBEA and AMISYN: three candidate genes for autism involved in secretion of large dense-core vesicles.",0.2,"<span class=""gene"" id=""20071347-0-0-6"">SCAMP5</span>, NBEA and AMISYN: three candidate genes for <span class=""disease"" id=""20071347-0-51-57"">autism</span> involved in secretion of large dense-core vesicles.",CTD_human
1,0,Biomarker,C0028754,Obesity,disease,obesity,1947,EFNB1,EFNB1,CTD_human,24098442,"In obesity, reduction of adipose EFNB1 may accelerate the vicious cycle involved in adipose tissue inflammation.",0.2,"In <span class=""disease"" id=""24098442-9-3-10"">obesity</span>, reduction of adipose <span class=""gene"" id=""24098442-9-33-38"">EFNB1</span> may accelerate the vicious cycle involved in adipose tissue inflammation.",CTD_human
3,10,Biomarker,C0220767,Craniofrontonasal dysplasia,disease,craniofrontonasal syndrome,1947,EFNB1,EFNB1,CTD_human,15166289,"Mutations of ephrin-B1 (EFNB1), a marker of tissue boundary formation, cause craniofrontonasal syndrome.",0.6854945356842621,"Mutations of <span class=""gene"" id=""15166289-0-13-22"">ephrin-B1</span> (<span class=""gene"" id=""15166289-0-24-29"">EFNB1</span>), a marker of tissue boundary formation, cause <span class=""disease"" id=""15166289-0-77-103"">craniofrontonasal syndrome</span>.",CTD_human;ORPHANET;UNIPROT
3,10,Biomarker,C0220767,Craniofrontonasal dysplasia,disease,craniofrontonasal syndrome,1947,EFNB1,ephrin-B1,CTD_human,15124102,Mutations of the ephrin-B1 gene cause craniofrontonasal syndrome.,0.6854945356842621,"Mutations of the <span class=""gene"" id=""15124102-0-17-26"">ephrin-B1</span> gene cause <span class=""disease"" id=""15124102-0-38-64"">craniofrontonasal syndrome</span>.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,1950,EGF,EGF,CTD_human,17626784,"SNP analyses of growth factor genes EGF, TGFbeta-1, and HGF reveal haplotypic association of EGF with autism.",0.200274726784213,"SNP analyses of growth factor genes <span class=""gene"" id=""17626784-0-36-39"">EGF</span>, TGFbeta-1, and HGF reveal haplotypic association of <span class=""gene"" id=""17626784-0-93-96"">EGF</span> with <span class=""disease"" id=""17626784-0-102-108"">autism</span>.",CTD_human
1,0,Biomarker,C0008925,Cleft Palate,disease,cleft palate,1950,EGF,EGF,CTD_human,11399798,"In conclusion, this study demonstrated that expression of EGF influences the induction of cleft palate by TCDD.",0.2,"In conclusion, this study demonstrated that expression of <span class=""gene"" id=""11399798-11-58-61"">EGF</span> influences the induction of <span class=""disease"" id=""11399798-11-90-102"">cleft palate</span> by TCDD.",CTD_human
2,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastasis,1950,EGF,EGF,CTD_human,21942447,"Triple-negative breast cancers, often expressing epidermal growth factor (EGF) receptor (EGFR), are associated with metastasis and poor survival.",0.2230770498739,"Triple-negative breast cancers, often expressing <span class=""gene"" id=""21942447-4-49-72"">epidermal growth factor</span> (<span class=""gene"" id=""21942447-4-74-77"">EGF</span>) receptor (EGFR), are associated with <span class=""disease"" id=""21942447-4-116-126"">metastasis</span> and poor survival.",CTD_human
1,0,Biomarker,C0034069,Pulmonary Fibrosis,disease,PF,1950,EGF,EGF,CTD_human,17266442,"TGF-beta, EGF, and IGF-1 levels were also significantly increased in patients with PF compared with controls.",0.2,"TGF-beta, <span class=""gene"" id=""17266442-6-10-13"">EGF</span>, and IGF-1 levels were also significantly increased in patients with <span class=""disease"" id=""17266442-6-83-85"">PF</span> compared with controls.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,1950,EGF,EGF,CTD_human,9029167,"Molecular biological analyses of the induced lesions revealed point mutations in the p53 gene in 60.9% of HCCs, and elevated expression of mRNAs for p53, c-myc, c-fos, TGF-alpha, TGF-beta1, alpha-fetoprotein, GST-P, and GGT, and decreased mRNA expression of EGF and EGFR in HCCs when compared to controls.",0.22648876224477602,"Molecular biological analyses of the induced lesions revealed point mutations in the p53 gene in 60.9% of <span class=""disease"" id=""9029167-4-106-109"">HCC</span>s, and elevated expression of mRNAs for p53, c-myc, c-fos, TGF-alpha, TGF-beta1, alpha-fetoprotein, GST-P, and GGT, and decreased mRNA expression of <span class=""gene"" id=""9029167-4-258-261"">EGF</span> and EGFR in <span class=""disease"" id=""9029167-4-274-277"">HCC</span>s when compared to controls.",CTD_human
4,0,Biomarker,C0001418,Adenocarcinoma,group,adenocarcinomas,1956,EGFR,epidermal growth factor receptor,CTD_human,20934974,Co-activation of epidermal growth factor receptor and c-MET defines a distinct subset of lung adenocarcinomas.,0.44,"Co-activation of <span class=""gene"" id=""20934974-0-17-49"">epidermal growth factor receptor</span> and c-MET defines a distinct subset of lung <span class=""disease"" id=""20934974-0-94-109"">adenocarcinomas</span>.",CTD_human
16,16,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,nsclc,1956,EGFR,EGFR,CTD_human,22787409,"However, the benefits of these agents are not uniform across the spectrum of nsclc, and optimizing their utility requires some degree of subgrouping of nsclc by the presence or absence of certain biomarkers.The biomarkers of current or imminent value are EGFR and KRAS mutational status, ALK rearrangements, and MET immunohistochemistry.",0.34596742195335306,"However, the benefits of these agents are not uniform across the spectrum of <span class=""disease"" id=""22787409-3-77-82"">nsclc</span>, and optimizing their utility requires some degree of subgrouping of <span class=""disease"" id=""22787409-3-152-157"">nsclc</span> by the presence or absence of certain biomarkers.The biomarkers of current or imminent value are <span class=""gene"" id=""22787409-3-255-259"">EGFR</span> and KRAS mutational status, ALK rearrangements, and MET immunohistochemistry.",CTD_human
16,16,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,NSCLC,1956,EGFR,EGFR,CTD_human,22617245,"We selected NSCLC cell lines--A549 (KRAS G12S), NCI-H3255 (EGFR L858R), NCI-H3122 (EML4-ALK E13;A20), and HCC78 (SLC34A2-ROS1)-to evaluate the antiproliferative effects of submicromolar concentrations of the multitargeted TKIs imatinib, sorafenib, erlotinib, and crizotinib.",0.34596742195335306,"We selected <span class=""disease"" id=""22617245-3-12-17"">NSCLC</span> cell lines--A549 (KRAS G12S), NCI-H3255 (<span class=""gene"" id=""22617245-3-59-63"">EGFR</span> L858R), NCI-H3122 (EML4-ALK E13;A20), and HCC78 (SLC34A2-ROS1)-to evaluate the antiproliferative effects of submicromolar concentrations of the multitargeted TKIs imatinib, sorafenib, erlotinib, and crizotinib.",CTD_human
16,16,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,non-small cell lung cancer,1956,EGFR,EGFR,CTD_human,21777763,The arrival of tyrosine kinase inhibitors (TKI) in first line of treatment for advanced non-small cell lung cancer with EGFR mutations has changed the strategy of treatment of theses patients.,0.34596742195335306,"The arrival of tyrosine kinase inhibitors (TKI) in first line of treatment for advanced <span class=""disease"" id=""21777763-1-88-114"">non-small cell lung cancer</span> with <span class=""gene"" id=""21777763-1-120-124"">EGFR</span> mutations has changed the strategy of treatment of theses patients.",CTD_human
16,16,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,NSCLC,1956,EGFR,EGFR,CTD_human,21440325,"In presence of EGFR mutation negative or unknown status, patients with advanced squamous NSCLC, with good performance status (PS) and without major co-morbidities, chemotherapy with third-generation regimens containing cisplatin is the recommended treatment.",0.34596742195335306,"In presence of <span class=""gene"" id=""21440325-9-15-19"">EGFR</span> mutation negative or unknown status, patients with advanced squamous <span class=""disease"" id=""21440325-9-89-94"">NSCLC</span>, with good performance status (PS) and without major co-morbidities, chemotherapy with third-generation regimens containing cisplatin is the recommended treatment.",CTD_human
16,16,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,NSCLC,1956,EGFR,EGFR,CTD_human,21791641,"These mechanisms can occur independently, or in the same cancer, suggesting that the combination of both ALK and EGFR inhibitors may represent an effective therapy for these subsets of NSCLC patients.",0.34596742195335306,"These mechanisms can occur independently, or in the same cancer, suggesting that the combination of both ALK and <span class=""gene"" id=""21791641-10-113-117"">EGFR</span> inhibitors may represent an effective therapy for these subsets of <span class=""disease"" id=""21791641-10-185-190"">NSCLC</span> patients.",CTD_human
16,16,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,NSCLC,1956,EGFR,EGFR,CTD_human,23435014,"TP53, EGFR and KRAS mutations were found in NSCLC with no link with asbestos exposure.NF2 was only altered in MPM.",0.34596742195335306,"TP53, <span class=""gene"" id=""23435014-6-6-10"">EGFR</span> and KRAS mutations were found in <span class=""disease"" id=""23435014-6-44-49"">NSCLC</span> with no link with asbestos exposure.NF2 was only altered in MPM.",CTD_human
16,16,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,NSCLC,1956,EGFR,EGFR,CTD_human,21782507,"Findings from the phase 3 FLEX study showed that the addition of cetuximab to cisplatin and vinorelbine significantly improved overall survival, compared with cisplatin and vinorelbine alone, in the first-line treatment of EGFR-expressing, advanced non-small-cell lung cancer (NSCLC).",0.34596742195335306,"Findings from the phase 3 FLEX study showed that the addition of cetuximab to cisplatin and vinorelbine significantly improved overall survival, compared with cisplatin and vinorelbine alone, in the first-line treatment of <span class=""gene"" id=""21782507-1-223-227"">EGFR</span>-expressing, advanced <span class=""disease"" id=""21782507-1-249-275"">non-small-cell lung cancer</span> (<span class=""disease"" id=""21782507-1-277-282"">NSCLC</span>).",CTD_human
16,16,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,NSCLC,1956,EGFR,EGFR,CTD_human,22751098,"Human non-small cell lung cancers (NSCLCs) with activating mutations in EGFR frequently respond to treatment with EGFR-targeted tyrosine kinase inhibitors (TKIs), such as erlotinib, but responses are not durable, as tumors acquire resistance.",0.34596742195335306,"Human non-small cell lung cancers (<span class=""disease"" id=""22751098-1-35-40"">NSCLC</span>s) with activating mutations in <span class=""gene"" id=""22751098-1-72-76"">EGFR</span> frequently respond to treatment with <span class=""gene"" id=""22751098-1-114-118"">EGFR</span>-targeted tyrosine kinase inhibitors (TKIs), such as erlotinib, but responses are not durable, as tumors acquire resistance.",CTD_human
16,16,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,non-small cell lung cancer,1956,EGFR,EGFR,CTD_human,21904575,"Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities.",0.34596742195335306,"Genotype-driven therapies for <span class=""disease"" id=""21904575-0-30-56"">non-small cell lung cancer</span>: focus on <span class=""gene"" id=""21904575-0-67-71"">EGFR</span>, KRAS and ALK gene abnormalities.",CTD_human
16,16,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,NSCLC,1956,EGFR,EGFR,CTD_human,22286583,"At the moment, established personalized treatment approaches include treatment of patients with NSCLC and activating epidermal growth factor receptor (EGFR) mutations with the EGFR-directed tyrosine kinase inhibitors gefitinib or erlotinib, and treatment of NSCLC patients with genetic aberrations in the anaplastic lymphoma kinase (ALK) oncogene with the mesenchymal-epithelial transition factor (MET)/ALK inhibitor crizotinib.",0.34596742195335306,"At the moment, established personalized treatment approaches include treatment of patients with <span class=""disease"" id=""22286583-4-96-101"">NSCLC</span> and activating <span class=""gene"" id=""22286583-4-117-149"">epidermal growth factor receptor</span> (<span class=""gene"" id=""22286583-4-151-155"">EGFR</span>) mutations with the <span class=""gene"" id=""22286583-4-176-180"">EGFR</span>-directed tyrosine kinase inhibitors gefitinib or erlotinib, and treatment of <span class=""disease"" id=""22286583-4-258-263"">NSCLC</span> patients with genetic aberrations in the anaplastic lymphoma kinase (ALK) oncogene with the mesenchymal-epithelial transition factor (MET)/ALK inhibitor crizotinib.",CTD_human
16,16,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,nsclc,1956,EGFR,EGFR,CTD_human,22787412,"As more health authorities approve targeted compounds in a variety of treatment lines, use of this approach is expected only to increase.Gefitinib, an oral tyrosine kinase inhibitor (tki), is approved by Health Canada in the first-line setting of advanced non-small-cell lung carcinoma (nsclc) for tumours that harbour the EGFR gene mutation.",0.34596742195335306,"As more health authorities approve targeted compounds in a variety of treatment lines, use of this approach is expected only to increase.Gefitinib, an oral tyrosine kinase inhibitor (tki), is approved by Health Canada in the first-line setting of advanced <span class=""disease"" id=""22787412-2-256-285"">non-small-cell lung carcinoma</span> (<span class=""disease"" id=""22787412-2-287-292"">nsclc</span>) for tumours that harbour the <span class=""gene"" id=""22787412-2-323-327"">EGFR</span> gene mutation.",CTD_human
16,16,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,NSCLC,1956,EGFR,EGFR,CTD_human,21478906,"The epidermal growth factor receptor (EGFR) represents the main target for non-small cell lung cancer (NSCLC) therapy, as its overexpression or constitutive activation contributes to malignancy and correlates with poor prognosis.",0.34596742195335306,"The <span class=""gene"" id=""21478906-2-4-36"">epidermal growth factor receptor</span> (<span class=""gene"" id=""21478906-2-38-42"">EGFR</span>) represents the main target for <span class=""disease"" id=""21478906-2-75-101"">non-small cell lung cancer</span> (<span class=""disease"" id=""21478906-2-103-108"">NSCLC</span>) therapy, as its overexpression or constitutive activation contributes to malignancy and correlates with poor prognosis.",CTD_human
16,16,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,non-small cell lung cancer,1956,EGFR,EGFR,CTD_human,21336183,"In an ALK-enriched population, patients with metastatic non-small cell lung cancer were screened by ALK fluorescence in situ hybridization and for epidermal growth factor receptor (EGFR) and KRAS mutations.",0.34596742195335306,"In an ALK-enriched population, patients with metastatic <span class=""disease"" id=""21336183-2-56-82"">non-small cell lung cancer</span> were screened by ALK fluorescence in situ hybridization and for <span class=""gene"" id=""21336183-2-147-179"">epidermal growth factor receptor</span> (<span class=""gene"" id=""21336183-2-181-185"">EGFR</span>) and KRAS mutations.",CTD_human
16,16,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,NSCLC,1956,EGFR,EGFR,CTD_human,22948846,"We have established a panel of patient-derived xenografts (PDXs) from treatment naïve Asian NSCLC patients, including those containing ""classic"" EGFR activating mutations.",0.34596742195335306,"We have established a panel of patient-derived xenografts (PDXs) from treatment naïve Asian <span class=""disease"" id=""22948846-3-92-97"">NSCLC</span> patients, including those containing ""classic"" <span class=""gene"" id=""22948846-3-145-149"">EGFR</span> activating mutations.",CTD_human
3,0,Biomarker,C0007137,Squamous cell carcinoma,disease,squamous cell carcinoma,1956,EGFR,EGFR,CTD_human,22042947,EGFR-amplified tumors showed the highest fraction of squamous cell carcinoma (17%; n = 4 of 23).,0.36473878565891,"<span class=""gene"" id=""22042947-7-0-4"">EGFR</span>-amplified tumors showed the highest fraction of <span class=""disease"" id=""22042947-7-53-76"">squamous cell carcinoma</span> (17%; n = 4 of 23).",CTD_human
3,0,Biomarker,C0007137,Squamous cell carcinoma,disease,SCC,1956,EGFR,EGFR,CTD_human,22948846,"Some of these EGFR-mutated PDXs do not respond to erlotinib: LU1868 containing L858R/T790M mutations, and LU0858 having L858R mutation as well as c-MET gene amplification, both squamous cell carcinoma (SCC).",0.36473878565891,"Some of these <span class=""gene"" id=""22948846-4-14-18"">EGFR</span>-mutated PDXs do not respond to erlotinib: LU1868 containing L858R/T790M mutations, and LU0858 having L858R mutation as well as c-MET gene amplification, both <span class=""disease"" id=""22948846-4-177-200"">squamous cell carcinoma</span> (<span class=""disease"" id=""22948846-4-202-205"">SCC</span>).",CTD_human
3,0,Biomarker,C0014859,Esophageal Neoplasms,group,esophageal cancer,1956,EGFR,epidermal growth factor receptor,CTD_human,21298351,Polymorphism in epidermal growth factor receptor intron 1 predicts prognosis of patients with esophageal cancer after chemoradiation and surgery.,0.22201326578542002,"Polymorphism in <span class=""gene"" id=""21298351-0-16-48"">epidermal growth factor receptor</span> intron 1 predicts prognosis of patients with <span class=""disease"" id=""21298351-0-94-111"">esophageal cancer</span> after chemoradiation and surgery.",CTD_human
3,0,Biomarker,C0017636,Glioblastoma,disease,GBM,1956,EGFR,EGFR,CTD_human,19204207,These observations make EGFR-inhibiting drugs a logical approach for trials in recurrent GBM.,0.336087625994986,"These observations make <span class=""gene"" id=""19204207-3-24-28"">EGFR</span>-inhibiting drugs a logical approach for trials in recurrent <span class=""disease"" id=""19204207-3-89-92"">GBM</span>.",CTD_human
3,0,Biomarker,C0017636,Glioblastoma,disease,glioblastoma,1956,EGFR,EGFR,CTD_human,23917401,"We also report recurrent translocations that fuse the coding sequence of EGFR to several partners, with EGFR-SEPT14 being the most frequent functional gene fusion in human glioblastoma.",0.336087625994986,"We also report recurrent translocations that fuse the coding sequence of <span class=""gene"" id=""23917401-6-73-77"">EGFR</span> to several partners, with <span class=""gene"" id=""23917401-6-104-108"">EGFR</span>-SEPT14 being the most frequent functional gene fusion in human <span class=""disease"" id=""23917401-6-172-184"">glioblastoma</span>.",CTD_human
3,0,Biomarker,C0017636,Glioblastoma,disease,Glioblastoma,1956,EGFR,EGFR,CTD_human,26455392,EGFR Mutation Promotes Glioblastoma through Epigenome and Transcription Factor Network Remodeling.,0.336087625994986,"<span class=""gene"" id=""26455392-0-0-4"">EGFR</span> Mutation Promotes <span class=""disease"" id=""26455392-0-23-35"">Glioblastoma</span> through Epigenome and Transcription Factor Network Remodeling.",CTD_human
3,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastasis,1956,EGFR,EGFR,CTD_human,17575224,"A marked decrease on EGFR phosphorylation (P < 0.01) and c-Myc activation (P = 0.02) was observed in patients with R497K polymorphism, which is associated with decreased invasion (P = 0.01), lower nodal involvement (P = 0.02), reduced subsequent metastasis (P < 0.01), and longer disease-free (P < 0.01) as well as overall (P < 0.01) survival in stage II/III colorectal carcinoma patients who had received curative surgery.",0.31663135479976395,"A marked decrease on <span class=""gene"" id=""17575224-5-21-25"">EGFR</span> phosphorylation (P &lt; 0.01) and c-Myc activation (P = 0.02) was observed in patients with R497K polymorphism, which is associated with decreased invasion (P = 0.01), lower nodal involvement (P = 0.02), reduced subsequent <span class=""disease"" id=""17575224-5-246-256"">metastasis</span> (P &lt; 0.01), and longer disease-free (P &lt; 0.01) as well as overall (P &lt; 0.01) survival in stage II/III colorectal carcinoma patients who had received curative surgery.",CTD_human
3,0,Biomarker,C0033578,Prostatic Neoplasms,group,prostate tumors,1956,EGFR,EGFR,CTD_human,17136230,"Antisense oligonucleotides (oligos) against transforming growth factor-alpha (TGF-alpha; MR(1)) and its binding site, the epidermal growth factor receptor (EGFR; MR(2)), have proven efficacious against PC-3 and LNCaP prostate tumors when evaluated in both in vitro and in vivo models.",0.223526015801106,"Antisense oligonucleotides (oligos) against transforming growth factor-alpha (TGF-alpha; MR(1)) and its binding site, the <span class=""gene"" id=""17136230-1-122-154"">epidermal growth factor receptor</span> (<span class=""gene"" id=""17136230-1-156-160"">EGFR</span>; MR(2)), have proven efficacious against PC-3 and LNCaP <span class=""disease"" id=""17136230-1-217-232"">prostate tumors</span> when evaluated in both in vitro and in vivo models.",CTD_human
3,0,Therapeutic,C0033578,Prostatic Neoplasms,group,prostate tumors,1956,EGFR,EGFR,CTD_human,17136230,"Antisense oligonucleotides (oligos) against transforming growth factor-alpha (TGF-alpha; MR(1)) and its binding site, the epidermal growth factor receptor (EGFR; MR(2)), have proven efficacious against PC-3 and LNCaP prostate tumors when evaluated in both in vitro and in vivo models.",0.223526015801106,"Antisense oligonucleotides (oligos) against transforming growth factor-alpha (TGF-alpha; MR(1)) and its binding site, the <span class=""gene"" id=""17136230-1-122-154"">epidermal growth factor receptor</span> (<span class=""gene"" id=""17136230-1-156-160"">EGFR</span>; MR(2)), have proven efficacious against PC-3 and LNCaP <span class=""disease"" id=""17136230-1-217-232"">prostate tumors</span> when evaluated in both in vitro and in vivo models.",CTD_human
1,0,Biomarker,C0085548,Autosomal Recessive Polycystic Kidney Disease,disease,ARPKD,1956,EGFR,EGFR,CTD_human,9486961,"These results suggest that changes in the expression of the EGFR contribute to the formation of cysts in the collecting ducts, and that drugs that target the tyrosine kinase activity of the EGFR may potentially be therapeutic in ARPKD.",0.20054945356842604,"These results suggest that changes in the expression of the <span class=""gene"" id=""9486961-4-60-64"">EGFR</span> contribute to the formation of cysts in the collecting ducts, and that drugs that target the tyrosine kinase activity of the <span class=""gene"" id=""9486961-4-190-194"">EGFR</span> may potentially be therapeutic in <span class=""disease"" id=""9486961-4-229-234"">ARPKD</span>.",CTD_human
1,0,Biomarker,C0149925,Small cell carcinoma of lung,disease,Small-cell carcinoma,1956,EGFR,epidermal growth factor receptor,CTD_human,20837450,Small-cell carcinoma with an epidermal growth factor receptor mutation in a never-smoker with gefitinib-responsive adenocarcinoma of the lung.,0.21836362841032603,"<span class=""disease"" id=""20837450-0-0-20"">Small-cell carcinoma</span> with an <span class=""gene"" id=""20837450-0-29-61"">epidermal growth factor receptor</span> mutation in a never-smoker with gefitinib-responsive adenocarcinoma of the lung.",CTD_human
2,0,Biomarker,C0152013,Adenocarcinoma of lung (disorder),disease,adenocarcinoma of the lung,1956,EGFR,EGFR,CTD_human,22135231,"We examined epidermal growth factor receptor (EGFR), Kirsten rate sarcoma viral oncogene homolog (KRAS), v-Raf murine sarcoma viral oncogene homolog B1 (BRAF), human epidermal growth factor receptor 2 (HER2), PIK3CA, v-akt murine thymoma vial oncogene homolog 1 (AKT1), v-ras neuroblastoma viral oncogene homolog (NRAS), dual specificity mitogen-activated protein kinase kinase 1 (MEK1), and anaplastic lymphoma kinase (ALK) in patients with adenocarcinoma of the lung to identify driver mutations.",0.28,"We examined <span class=""gene"" id=""22135231-4-12-44"">epidermal growth factor receptor</span> (<span class=""gene"" id=""22135231-4-46-50"">EGFR</span>), Kirsten rate sarcoma viral oncogene homolog (KRAS), v-Raf murine sarcoma viral oncogene homolog B1 (BRAF), human epidermal growth factor receptor 2 (HER2), PIK3CA, v-akt murine thymoma vial oncogene homolog 1 (AKT1), v-ras neuroblastoma viral oncogene homolog (NRAS), dual specificity mitogen-activated protein kinase kinase 1 (MEK1), and anaplastic lymphoma kinase (ALK) in patients with <span class=""disease"" id=""22135231-4-442-468"">adenocarcinoma of the lung</span> to identify driver mutations.",CTD_human
1,0,Biomarker,C0206686,Adrenocortical carcinoma,disease,adrenocortical carcinoma,1956,EGFR,epidermal growth factor receptor,CTD_human,23585556,Mutational analyses of epidermal growth factor receptor and downstream pathways in adrenocortical carcinoma.,0.201098907136852,"Mutational analyses of <span class=""gene"" id=""23585556-0-23-55"">epidermal growth factor receptor</span> and downstream pathways in <span class=""disease"" id=""23585556-0-83-107"">adrenocortical carcinoma</span>.",CTD_human
1,0,Therapeutic,C0206698,Cholangiocarcinoma,disease,cholangiocarcinoma,1956,EGFR,epidermal growth factor receptor,CTD_human,17341899,Effects of the anti-epidermal growth factor receptor antibody cetuximab on cholangiocarcinoma of the liver.,0.21281793556875103,"Effects of the anti-<span class=""gene"" id=""17341899-0-20-52"">epidermal growth factor receptor</span> antibody cetuximab on <span class=""disease"" id=""17341899-0-75-93"">cholangiocarcinoma</span> of the liver.",CTD_human
1,0,Biomarker,C0263454,Chloracne,disease,chloracne,1956,EGFR,EGFR,CTD_human,21237254,"Abnormal expression of MAPK, EGFR, CK17 and TGk in the skin lesions of chloracne patients exposed to dioxins.",0.200274726784213,"Abnormal expression of MAPK, <span class=""gene"" id=""21237254-0-29-33"">EGFR</span>, CK17 and TGk in the skin lesions of <span class=""disease"" id=""21237254-0-71-80"">chloracne</span> patients exposed to dioxins.",CTD_human
1,0,Biomarker,C0279626,Squamous cell carcinoma of esophagus,disease,esophageal squamous cell carcinoma,1956,EGFR,epidermal growth factor receptor,CTD_human,21947696,"Prognosis of esophageal squamous cell carcinoma in patients positive for human epidermal growth factor receptor family can be improved by initial chemotherapy with docetaxel, fluorouracil, and cisplatin.",0.210439617800098,"Prognosis of <span class=""disease"" id=""21947696-0-13-47"">esophageal squamous cell carcinoma</span> in patients positive for human <span class=""gene"" id=""21947696-0-79-111"">epidermal growth factor receptor</span> family can be improved by initial chemotherapy with docetaxel, fluorouracil, and cisplatin.",CTD_human
6,0,Biomarker,C1458155,Mammary Neoplasms,group,breast tumors,1956,EGFR,EGFR,CTD_human,19075277,"mRNA levels of 10 BCAR genes (AKT1, AKT2, BCAR1, BCAR3, EGFR, ERBB2, GRB7, SRC, TLE3, and TRERF1) were measured in estrogen receptor-positive breast tumors using quantitative reverse-transcriptase polymerase chain reaction.",0.29531918738130397,"mRNA levels of 10 BCAR genes (AKT1, AKT2, BCAR1, BCAR3, <span class=""gene"" id=""19075277-3-56-60"">EGFR</span>, ERBB2, GRB7, SRC, TLE3, and TRERF1) were measured in estrogen receptor-positive <span class=""disease"" id=""19075277-3-142-155"">breast tumors</span> using quantitative reverse-transcriptase polymerase chain reaction.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,1956,EGFR,EGFR,CTD_human,9029167,"Molecular biological analyses of the induced lesions revealed point mutations in the p53 gene in 60.9% of HCCs, and elevated expression of mRNAs for p53, c-myc, c-fos, TGF-alpha, TGF-beta1, alpha-fetoprotein, GST-P, and GGT, and decreased mRNA expression of EGF and EGFR in HCCs when compared to controls.",0.228202635484685,"Molecular biological analyses of the induced lesions revealed point mutations in the p53 gene in 60.9% of <span class=""disease"" id=""9029167-4-106-109"">HCC</span>s, and elevated expression of mRNAs for p53, c-myc, c-fos, TGF-alpha, TGF-beta1, alpha-fetoprotein, GST-P, and GGT, and decreased mRNA expression of EGF and <span class=""gene"" id=""9029167-4-266-270"">EGFR</span> in <span class=""disease"" id=""9029167-4-274-277"">HCC</span>s when compared to controls.",CTD_human
1,0,Biomarker,C0020295,Hydronephrosis,disease,hydronephrosis,1958,EGR1,Egr-1,CTD_human,25015655,"Although these mouse strains possess AhR alleles tightly bound to TCDD, their difference in incidence and severity of hydronephrosis can be explained, in part, by differences in the expression of mPGES-1 and Egr-1.",0.2,"Although these mouse strains possess AhR alleles tightly bound to TCDD, their difference in incidence and severity of <span class=""disease"" id=""25015655-9-118-132"">hydronephrosis</span> can be explained, in part, by differences in the expression of mPGES-1 and <span class=""gene"" id=""25015655-9-208-213"">Egr-1</span>.",CTD_human
1,0,Biomarker,C0025500,Mesothelioma,disease,MM,1958,EGR1,egr-1,CTD_human,15878867,An analog of coenzyme Q targeted to mitochondria and superoxide dismutase overrode inhibition of MM cell proliferation by alpha-TOS as well as alpha-TOS-induced inhibition of egr-1-dependent transactivation.,0.200274726784213,"An analog of coenzyme Q targeted to mitochondria and superoxide dismutase overrode inhibition of <span class=""disease"" id=""15878867-7-97-99"">MM</span> cell proliferation by alpha-TOS as well as alpha-TOS-induced inhibition of <span class=""gene"" id=""15878867-7-175-180"">egr-1</span>-dependent transactivation.",CTD_human
1,0,Biomarker,C0033578,Prostatic Neoplasms,group,prostate tumors,1958,EGR1,EGR1,CTD_human,16552752,"In many prostate tumors, the activity of the transcription factor EGR1 (early growth response gene 1) is elevated due to overexpression of EGR1 and/or downregulation of the co-repressor, NAB2.",0.21039655166814603,"In many <span class=""disease"" id=""16552752-3-8-23"">prostate tumors</span>, the activity of the transcription factor <span class=""gene"" id=""16552752-3-66-70"">EGR1</span> (early growth response gene 1) is elevated due to overexpression of <span class=""gene"" id=""16552752-3-139-143"">EGR1</span> and/or downregulation of the co-repressor, NAB2.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,1959,EGR2,EGR2,CTD_human,19000991,Reciprocal co-regulation of EGR2 and MECP2 is disrupted in Rett syndrome and autism.,0.20300763924902696,"Reciprocal co-regulation of <span class=""gene"" id=""19000991-0-28-32"">EGR2</span> and MECP2 is disrupted in Rett syndrome and <span class=""disease"" id=""19000991-0-77-83"">autism</span>.",CTD_human
1,0,Biomarker,C0035372,Rett Syndrome,disease,Rett syndrome,1959,EGR2,EGR2,CTD_human,19000991,Reciprocal co-regulation of EGR2 and MECP2 is disrupted in Rett syndrome and autism.,0.20300763924902696,"Reciprocal co-regulation of <span class=""gene"" id=""19000991-0-28-32"">EGR2</span> and MECP2 is disrupted in <span class=""disease"" id=""19000991-0-59-72"">Rett syndrome</span> and autism.",CTD_human
1,1,Biomarker,C0553580,Ewings sarcoma,disease,Ewing sarcoma,1959,EGR2,EGR2,CTD_human,26214589,Chimeric EWSR1-FLI1 regulates the Ewing sarcoma susceptibility gene EGR2 via a GGAA microsatellite.,0.20054945356842604,"Chimeric EWSR1-FLI1 regulates the <span class=""disease"" id=""26214589-0-34-47"">Ewing sarcoma</span> susceptibility gene <span class=""gene"" id=""26214589-0-68-72"">EGR2</span> via a GGAA microsatellite.",CTD_human
1,0,Biomarker,C0003873,Rheumatoid Arthritis,disease,rheumatoid arthritis,196,AHR,aryl hydrocarbon receptor,CTD_human,18617548,A role for the aryl hydrocarbon receptor and the dioxin TCDD in rheumatoid arthritis.,0.201373633921065,"A role for the <span class=""gene"" id=""18617548-0-15-40"">aryl hydrocarbon receptor</span> and the dioxin TCDD in <span class=""disease"" id=""18617548-0-64-84"">rheumatoid arthritis</span>.",CTD_human
1,0,Biomarker,C0004153,Atherosclerosis,disease,atherosclerosis,196,AHR,aryl hydrocarbon receptor,CTD_human,22228805,"Inherent and benzo[a]pyrene-induced differential aryl hydrocarbon receptor signaling greatly affects life span, atherosclerosis, cardiac gene expression, and body and heart growth in mice.",0.20082418035263896,"Inherent and benzo[a]pyrene-induced differential <span class=""gene"" id=""22228805-0-49-74"">aryl hydrocarbon receptor</span> signaling greatly affects life span, <span class=""disease"" id=""22228805-0-112-127"">atherosclerosis</span>, cardiac gene expression, and body and heart growth in mice.",CTD_human
1,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,196,AHR,Ahr,CTD_human,21115475,"We also report that Ahr- and Vav3-deficient mice display hypertension, tachypnea, and sympathoexcitation.",0.200274726784213,"We also report that <span class=""gene"" id=""21115475-6-20-23"">Ahr</span>- and Vav3-deficient mice display <span class=""disease"" id=""21115475-6-57-69"">hypertension</span>, tachypnea, and sympathoexcitation.",CTD_human
1,0,Biomarker,C0021364,Male infertility,phenotype,male infertility,196,AHR,aryl hydrocarbon receptor,CTD_human,21613234,Assessment of an association between an aryl hydrocarbon receptor gene (AHR) polymorphism and risk of male infertility.,0.20082418035263896,"Assessment of an association between an <span class=""gene"" id=""21613234-0-40-65"">aryl hydrocarbon receptor</span> gene (AHR) polymorphism and risk of <span class=""disease"" id=""21613234-0-102-118"">male infertility</span>.",CTD_human
1,0,Biomarker,C0023903,Liver neoplasms,group,liver tumor,196,AHR,AHR,CTD_human,19996281,"To test this hypothesis and determine whether the mouse Ahr gene acts as a tumor suppressor gene in vivo, we have examined the role of Ahr ablation in liver tumorigenesis induced by the genotoxic chemical diethylnitrosamine (DEN), a hepatic carcinogen that is not an AHR ligand.In mice given a single i.p. injection of DEN, AHR antagonized liver tumor formation and growth by regulating cell proliferation, inflammatory cytokine expression, and DNA damage, parameters which were significantly elevated in the livers of control and, more so, of DEN-exposed Ahr-/- mice.",0.206593442821114,"To test this hypothesis and determine whether the mouse <span class=""gene"" id=""19996281-4-56-59"">Ahr</span> gene acts as a tumor suppressor gene in vivo, we have examined the role of Ahr ablation in liver tumorigenesis induced by the genotoxic chemical diethylnitrosamine (DEN), a hepatic carcinogen that is not an <span class=""gene"" id=""19996281-4-267-270"">AHR</span> ligand.In mice given a single i.p. injection of DEN, <span class=""gene"" id=""19996281-4-324-327"">AHR</span> antagonized <span class=""disease"" id=""19996281-4-340-351"">liver tumor</span> formation and growth by regulating cell proliferation, inflammatory cytokine expression, and DNA damage, parameters which were significantly elevated in the livers of control and, more so, of DEN-exposed Ahr-/- mice.",CTD_human
1,0,Biomarker,C0025517,Metabolic Diseases,group,metabolic disorders,196,AHR,AHR,CTD_human,25768209,"Further, dietary TCDF inhibited the farnesoid X receptor (FXR) signaling pathway, triggered significant inflammation and host metabolic disorders as a result of activation of bacterial fermentation, and altered hepatic lipogenesis, gluconeogenesis, and glycogenolysis in an AHR-dependent manner.",0.2,"Further, dietary TCDF inhibited the farnesoid X receptor (FXR) signaling pathway, triggered significant inflammation and host <span class=""disease"" id=""25768209-9-126-145"">metabolic disorders</span> as a result of activation of bacterial fermentation, and altered hepatic lipogenesis, gluconeogenesis, and glycogenolysis in an <span class=""gene"" id=""25768209-9-274-277"">AHR</span>-dependent manner.",CTD_human
1,0,Therapeutic,C0027627,Neoplasm Metastasis,phenotype,metastasis,196,AHR,aryl hydrocarbon receptor,CTD_human,21948867,Activation of the aryl hydrocarbon receptor by TCDD inhibits mammary tumor metastasis in a syngeneic mouse model of breast cancer.,0.201373633921065,"Activation of the <span class=""gene"" id=""21948867-0-18-43"">aryl hydrocarbon receptor</span> by TCDD inhibits mammary tumor <span class=""disease"" id=""21948867-0-75-85"">metastasis</span> in a syngeneic mouse model of breast cancer.",CTD_human
1,0,Biomarker,C0028754,Obesity,disease,obesity,196,AHR,AHR,CTD_human,27020609,"Inhibition of the aryl hydrocarbon receptor prevents Western diet-induced obesity. Model for AHR activation by kynurenine via oxidized-LDL, TLR2/4, TGF?, and IDO1.",0.200274726784213,"Inhibition of the <span class=""gene"" id=""27020609-0-18-43"">aryl hydrocarbon receptor</span> prevents Western diet-induced <span class=""disease"" id=""27020609-0-74-81"">obesity</span>. Model for <span class=""gene"" id=""27020609-0-93-96"">AHR</span> activation by kynurenine via oxidized-LDL, TLR2/4, TGF&beta;, and IDO1.",CTD_human
1,0,Biomarker,C0032285,Pneumonia,disease,lung inflammation,196,AHR,AhR,CTD_human,23337360,These findings suggest that decreased activation of the pulmonary AhR in newborn AhRd mice augments hyperoxia-induced alveolar simplification and lung inflammation in these mice.,0.200274726784213,"These findings suggest that decreased activation of the pulmonary <span class=""gene"" id=""23337360-10-66-69"">AhR</span> in newborn AhRd mice augments hyperoxia-induced alveolar simplification and <span class=""disease"" id=""23337360-10-146-163"">lung inflammation</span> in these mice.",CTD_human
1,0,Biomarker,C0038356,Stomach Neoplasms,group,stomach tumors,196,AHR,aryl hydrocarbon receptor,CTD_human,12107286,A constitutively active dioxin/aryl hydrocarbon receptor induces stomach tumors.,0.202732912464814,"A constitutively active dioxin/<span class=""gene"" id=""12107286-0-31-56"">aryl hydrocarbon receptor</span> induces <span class=""disease"" id=""12107286-0-65-79"">stomach tumors</span>.",CTD_human
1,0,Biomarker,C0242339,Dyslipidemias,group,dyslipidemia,196,AHR,AhR,CTD_human,21890736,"2,3,7,8-tetrachlorodibenzo-?-dioxin (TCDD) induces hepatic dyslipidemia mediated by the aryl hydrocarbon receptor (AhR).",0.2,"2,3,7,8-tetrachlorodibenzo-?-dioxin (TCDD) induces hepatic <span class=""disease"" id=""21890736-1-59-71"">dyslipidemia</span> mediated by the <span class=""gene"" id=""21890736-1-88-113"">aryl hydrocarbon receptor</span> (<span class=""gene"" id=""21890736-1-115-118"">AhR</span>).",CTD_human
1,0,Biomarker,C0559470,Allergy to peanuts,phenotype,peanut allergy,196,AHR,aryl hydrocarbon receptor,CTD_human,21804081,Activation of the aryl hydrocarbon receptor suppresses sensitization in a mouse peanut allergy model.,0.2,"Activation of the <span class=""gene"" id=""21804081-0-18-43"">aryl hydrocarbon receptor</span> suppresses sensitization in a mouse <span class=""disease"" id=""21804081-0-80-94"">peanut allergy</span> model.",CTD_human
1,0,Biomarker,C0220633,Uveal melanoma,disease,uveal melanoma,1964,EIF1AX,EIF1AX,CTD_human,23793026,Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3.,0.201373633921065,"Exome sequencing identifies recurrent somatic mutations in <span class=""gene"" id=""23793026-0-59-65"">EIF1AX</span> and SF3B1 in <span class=""disease"" id=""23793026-0-79-93"">uveal melanoma</span> with disomy 3.",CTD_human
1,0,Biomarker,C1458155,Mammary Neoplasms,group,breast tumors,196403,DTX3,DTX3,CTD_human,25151356,"The genes identified include eight that are essential for cell proliferation (FGD5, METTL6, CPT1A, DTX3, MRPS23, EIF2S2, EIF6 and SLC2A10) and are uniquely amplified in patients with highly proliferative luminal breast tumors, a clinical subset of patients for which few therapeutic options are effective.",0.2,"The genes identified include eight that are essential for cell proliferation (FGD5, METTL6, CPT1A, <span class=""gene"" id=""25151356-4-99-103"">DTX3</span>, MRPS23, EIF2S2, EIF6 and SLC2A10) and are uniquely amplified in patients with highly proliferative luminal <span class=""disease"" id=""25151356-4-212-225"">breast tumors</span>, a clinical subset of patients for which few therapeutic options are effective.",CTD_human
1,1,Biomarker,C0028754,Obesity,disease,obese,196475,RMST,RMST,CTD_human,23563609,"Evaluation of 29 SNPs (P < 1 × 10(-5)) in an additional 971 severely obese children and 1,990 controls identified 4 new loci associated with severe obesity (LEPR, PRKCH, PACS1 and RMST).",0.2,"Evaluation of 29 SNPs (P &lt; 1 &times; 10(-5)) in an additional 971 severely <span class=""disease"" id=""23563609-3-69-74"">obese</span> children and 1,990 controls identified 4 new loci associated with severe obesity (LEPR, PRKCH, PACS1 and <span class=""gene"" id=""23563609-3-180-184"">RMST</span>).",CTD_human
2,0,Biomarker,C2239176,Liver carcinoma,disease,hepatocellular carcinoma,196528,ARID2,ARID2,CTD_human,21822264,Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma.,0.201648360705279,"Inactivating mutations of the chromatin remodeling gene <span class=""gene"" id=""21822264-0-56-61"">ARID2</span> in <span class=""disease"" id=""21822264-0-65-89"">hepatocellular carcinoma</span>.",CTD_human
1,0,Biomarker,C0038454,Cerebrovascular accident,group,cerebral stroke,196743,PAOX,Polyamine oxidase,CTD_human,16269634,Polyamine oxidase and acrolein as novel biochemical markers for diagnosis of cerebral stroke.,0.2,"<span class=""gene"" id=""16269634-0-0-17"">Polyamine oxidase</span> and acrolein as novel biochemical markers for diagnosis of <span class=""disease"" id=""16269634-0-77-92"">cerebral stroke</span>.",CTD_human
1,0,Biomarker,C0022665,Kidney Neoplasm,disease,kidney tumor,1978,EIF4EBP1,4EBP1,CTD_human,21813464,"The data indicate that Raf-1/MEK/ERK participates in crosstalk with 4EBP1, which represents a novel pathway interaction leading to increased protein synthesis, cell growth, and kidney tumor formation.",0.200274726784213,"The data indicate that Raf-1/MEK/ERK participates in crosstalk with <span class=""gene"" id=""21813464-10-68-73"">4EBP1</span>, which represents a novel pathway interaction leading to increased protein synthesis, cell growth, and <span class=""disease"" id=""21813464-10-177-189"">kidney tumor</span> formation.",CTD_human
1,0,Biomarker,C0023467,"Leukemia, Myelocytic, Acute",disease,AML,1978,EIF4EBP1,4E-BP1,CTD_human,19458359,We identified the Pim-2 serine/threonine kinase as mainly responsible for 4E-BP1 phosphorylation on the S(65) residue and subsequent translation control in AML.,0.201923087489492,"We identified the Pim-2 serine/threonine kinase as mainly responsible for <span class=""gene"" id=""19458359-7-74-80"">4E-BP1</span> phosphorylation on the S(65) residue and subsequent translation control in <span class=""disease"" id=""19458359-7-156-159"">AML</span>.",CTD_human
1,0,Biomarker,C0334634,"Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse",disease,MCL,1978,EIF4EBP1,eIF4E binding protein 1,CTD_human,17148679,"Total eIF4E binding protein 1 and eukaryotic initiation factor 4E were expressed in 13 of 14 (93%) and 16 of 29 (55%) MCL tumors, respectively.",0.20082418035263896,"Total <span class=""gene"" id=""17148679-9-6-29"">eIF4E binding protein 1</span> and eukaryotic initiation factor 4E were expressed in 13 of 14 (93%) and 16 of 29 (55%) <span class=""disease"" id=""17148679-9-118-121"">MCL</span> tumors, respectively.",CTD_human
3,0,Biomarker,C0002395,Alzheimer's Disease,disease,Alzheimer disease,2,A2M,Alpha-2 macroglobulin,CTD_human,9697696,Alpha-2 macroglobulin is genetically associated with Alzheimer disease.,0.263324147157471,"<span class=""gene"" id=""9697696-0-0-21"">Alpha-2 macroglobulin</span> is genetically associated with <span class=""disease"" id=""9697696-0-53-70"">Alzheimer disease</span>.",CTD_human
3,0,Biomarker,C0002395,Alzheimer's Disease,disease,AD,2,A2M,A2M,CTD_human,15023809,The MPO and A2M polymorphisms are associated with sporadic AD in southern Italy.,0.263324147157471,"The MPO and <span class=""gene"" id=""15023809-11-12-15"">A2M</span> polymorphisms are associated with sporadic <span class=""disease"" id=""15023809-11-59-61"">AD</span> in southern Italy.",CTD_human
1,0,Biomarker,C0024115,Lung diseases,group,pulmonary disease,2,A2M,A2M,CTD_human,2475424,The patient is heterozygous for an alteration in the A2M gene; this may be responsible for his serum A2M deficiency and may be relevant to the early onset of pulmonary disease in his case.,0.20082418035263896,"The patient is heterozygous for an alteration in the <span class=""gene"" id=""2475424-8-53-56"">A2M</span> gene; this may be responsible for his serum <span class=""gene"" id=""2475424-8-101-104"">A2M</span> deficiency and may be relevant to the early onset of <span class=""disease"" id=""2475424-8-158-175"">pulmonary disease</span> in his case.",CTD_human
2,0,Biomarker,C0024121,Lung Neoplasms,group,lung tumor,2,A2M,alpha-2-macroglobulin,CTD_human,19180532,"Notably, expression of alpha-2-macroglobulin, transthyretin, alpha-1-antitrypsin, and properdin was in common in different lung tumor models, but regulation of orosomucoid-8, apolipoprotein-A1, apolipoprotein-C3, apolipoprotein-E, glutathione peroxidase-3, plasma retinol-binding protein, and serum amyloid P component was unique when the serum proteomes of c-myc and c-raf tumor bearing mice were compared.",0.2,"Notably, expression of <span class=""gene"" id=""19180532-8-23-44"">alpha-2-macroglobulin</span>, transthyretin, alpha-1-antitrypsin, and properdin was in common in different <span class=""disease"" id=""19180532-8-123-133"">lung tumor</span> models, but regulation of orosomucoid-8, apolipoprotein-A1, apolipoprotein-C3, apolipoprotein-E, glutathione peroxidase-3, plasma retinol-binding protein, and serum amyloid P component was unique when the serum proteomes of c-myc and c-raf tumor bearing mice were compared.",CTD_human
2,0,Biomarker,C0024121,Lung Neoplasms,group,lung tumor,2,A2M,alpha-2-macroglobulin,CTD_human,17902193,"Notably, we demonstrate significant regulation of alpha-1-antitrypsin, alpha-2-macroglobulin, hemoglobin subunit alpha, vitamin D-binding protein, major urinary proteins, and transthyretin (up to eight-fold) in serum of lung tumor bearing mice.",0.2,"Notably, we demonstrate significant regulation of alpha-1-antitrypsin, <span class=""gene"" id=""17902193-7-71-92"">alpha-2-macroglobulin</span>, hemoglobin subunit alpha, vitamin D-binding protein, major urinary proteins, and transthyretin (up to eight-fold) in serum of <span class=""disease"" id=""17902193-7-220-230"">lung tumor</span> bearing mice.",CTD_human
1,0,Biomarker,C0027726,Nephrotic Syndrome,group,NS,2,A2M,alpha 2-M,CTD_human,11304663,"We studied plasma antithrombin III (AT-III), alpha 1-PI, alpha 2-antiplasmin (alpha 2-A), alpha 2-macroglobulin (alpha 2-M) activity, and some blood coagulation and fibrinolysis tests in children with frequently relapsing prednisone-responsive NS.",0.200274726784213,"We studied plasma antithrombin III (AT-III), alpha 1-PI, alpha 2-antiplasmin (alpha 2-A), <span class=""gene"" id=""11304663-4-90-111"">alpha 2-macroglobulin</span> (<span class=""gene"" id=""11304663-4-113-122"">alpha 2-M</span>) activity, and some blood coagulation and fibrinolysis tests in children with frequently relapsing prednisone-responsive <span class=""disease"" id=""11304663-4-244-246"">NS</span>.",CTD_human
1,0,Biomarker,C0206669,Hepatocellular Adenoma,disease,HCA,2,A2M,alpha(2)M,CTD_human,15509519,"Distinctive immunohistochemical staining for alpha(2)M could be consistently demonstrated in GST-P-negative HAF, HCA, and HCC induced not only by peroxisome proliferators but also N-nitrosodiethylamine alone.",0.2,"Distinctive immunohistochemical staining for <span class=""gene"" id=""15509519-7-45-54"">alpha(2)M</span> could be consistently demonstrated in GST-P-negative HAF, <span class=""disease"" id=""15509519-7-113-116"">HCA</span>, and HCC induced not only by peroxisome proliferators but also N-nitrosodiethylamine alone.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,2,A2M,alpha(2)M,CTD_human,15509519,"Distinctive immunohistochemical staining for alpha(2)M could be consistently demonstrated in GST-P-negative HAF, HCA, and HCC induced not only by peroxisome proliferators but also N-nitrosodiethylamine alone.",0.20082418035263896,"Distinctive immunohistochemical staining for <span class=""gene"" id=""15509519-7-45-54"">alpha(2)M</span> could be consistently demonstrated in GST-P-negative HAF, HCA, and <span class=""disease"" id=""15509519-7-122-125"">HCC</span> induced not only by peroxisome proliferators but also N-nitrosodiethylamine alone.",CTD_human
2,25,Biomarker,C0003499,Supravalvular aortic stenosis,disease,SVAS,2006,ELN,ELN,CTD_human,20007321,"WBS is thought to be caused by haploinsufficiency of certain dosage-sensitive genes within the deleted region, and the feature of supravalvular aortic stenosis (SVAS) has been attributed to reduced elastin caused by deletion of ELN.",0.619700460551396,"WBS is thought to be caused by haploinsufficiency of certain dosage-sensitive genes within the deleted region, and the feature of <span class=""disease"" id=""20007321-3-130-159"">supravalvular aortic stenosis</span> (<span class=""disease"" id=""20007321-3-161-165"">SVAS</span>) has been attributed to reduced <span class=""gene"" id=""20007321-3-198-205"">elastin</span> caused by deletion of <span class=""gene"" id=""20007321-3-228-231"">ELN</span>.",CTD_human;HPO;ORPHANET
2,25,Biomarker,C0003499,Supravalvular aortic stenosis,disease,supravalvular aortic stenosis,2006,ELN,elastin,CTD_human,8096434,The elastin gene is disrupted by a translocation associated with supravalvular aortic stenosis.,0.619700460551396,"The <span class=""gene"" id=""8096434-0-4-11"">elastin</span> gene is disrupted by a translocation associated with <span class=""disease"" id=""8096434-0-65-94"">supravalvular aortic stenosis</span>.",CTD_human;HPO;ORPHANET
1,0,Biomarker,C0019284,Diaphragmatic Hernia,phenotype,diaphragmatic hernia,2006,ELN,tropoelastin,CTD_human,10359170,Increased tropoelastin and procollagen expression in the lung of nitrofen-induced diaphragmatic hernia in rats.,0.200274726784213,"Increased <span class=""gene"" id=""10359170-0-10-22"">tropoelastin</span> and procollagen expression in the lung of nitrofen-induced <span class=""disease"" id=""10359170-0-82-102"">diaphragmatic hernia</span> in rats.",CTD_human
1,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,2006,ELN,elastin,CTD_human,17039479,"The aims of this study were: 1) to determine serum cobalt concentrations in children with hypertension; and 2) to study the correlation between serum cobalt and some biological markers of the extracellular matrix of the vascular wall, i.e., anti-elastin and anti-collagen type IV antibodies.",0.205703749933845,"The aims of this study were: 1) to determine serum cobalt concentrations in children with <span class=""disease"" id=""17039479-3-90-102"">hypertension</span>; and 2) to study the correlation between serum cobalt and some biological markers of the extracellular matrix of the vascular wall, i.e., anti-<span class=""gene"" id=""17039479-3-246-253"">elastin</span> and anti-collagen type IV antibodies.",CTD_human
1,0,Biomarker,C0024117,Chronic Obstructive Airway Disease,disease,COPD,2006,ELN,elastin,CTD_human,25106431,This reveals that the SPC-TNF? model is a suitable model to study processes underlying matrix remodeling and in particular elastin breakdown as seen in COPD.,0.20575490709115804,"This reveals that the SPC-TNF&alpha; model is a suitable model to study processes underlying matrix remodeling and in particular <span class=""gene"" id=""25106431-11-123-130"">elastin</span> breakdown as seen in <span class=""disease"" id=""25106431-11-152-156"">COPD</span>.",CTD_human
2,0,Biomarker,C0034069,Pulmonary Fibrosis,disease,pulmonary fibrosis,2006,ELN,Elastin,CTD_human,10761639,Elastin gene expression is upregulated during pulmonary fibrosis.,0.20054945356842604,"<span class=""gene"" id=""10761639-0-0-7"">Elastin</span> gene expression is upregulated during <span class=""disease"" id=""10761639-0-46-64"">pulmonary fibrosis</span>.",CTD_human
1,0,Biomarker,C0238288,"Muscular Dystrophy, Facioscapulohumeral",disease,facioscapulohumeral muscular dystrophy,2006,ELN,elastin,CTD_human,12868502,"Expression of elastin, decorin, lumican and the extracellular matrix remodeling factor TIMP3 were reduced in facioscapulohumeral muscular dystrophy myoblasts.",0.2,"Expression of <span class=""gene"" id=""12868502-11-14-21"">elastin</span>, decorin, lumican and the extracellular matrix remodeling factor TIMP3 were reduced in <span class=""disease"" id=""12868502-11-109-147"">facioscapulohumeral muscular dystrophy</span> myoblasts.",CTD_human
1,0,Biomarker,C0020678,Hypotrichosis,disease,hypotrichosis,200879,LIPH,LIPH,CTD_human,23066499,Sequence analysis of the LIPH gene revealed a novel nonsense mutation (p.Arg260X) associated with hypotrichosis without woolly hair in one family.,0.21177018558921198,"Sequence analysis of the <span class=""gene"" id=""23066499-4-25-29"">LIPH</span> gene revealed a novel nonsense mutation (p.Arg260X) associated with <span class=""disease"" id=""23066499-4-98-111"">hypotrichosis</span> without woolly hair in one family.",CTD_human
5,56,Biomarker,C0346010,Multiple fibrofolliculomas,disease,BHD,201163,FLCN,FLCN,CTD_human,24726356,"Spontaneous pneumothoraces due to lung cyst rupture afflict patients with the rare disease Birt-Hogg-Dubé (BHD) syndrome, which is caused by mutations of the tumor suppressor gene folliculin (FLCN).",0.6951099731317211,"Spontaneous pneumothoraces due to lung cyst rupture afflict patients with the rare disease Birt-Hogg-Dub&eacute; (<span class=""disease"" id=""24726356-1-107-110"">BHD</span>) syndrome, which is caused by mutations of the tumor suppressor gene <span class=""gene"" id=""24726356-1-180-190"">folliculin</span> (<span class=""gene"" id=""24726356-1-192-196"">FLCN</span>).",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0346255,"Oncocytoma, renal",disease,renal oncocytoma,201163,FLCN,folliculin,CTD_human,12204536,"Discovery of disease-causing mutations in BHD, a novel kidney cancer gene associated with renal oncocytoma or chromophobe renal cancer, will contribute to understanding the role of folliculin in pathways common to skin, lung, and kidney development.",0.20054945356842604,"Discovery of disease-causing mutations in BHD, a novel kidney cancer gene associated with <span class=""disease"" id=""12204536-6-90-106"">renal oncocytoma</span> or chromophobe renal cancer, will contribute to understanding the role of <span class=""gene"" id=""12204536-6-181-191"">folliculin</span> in pathways common to skin, lung, and kidney development.",CTD_human
1,0,Biomarker,C0007137,Squamous cell carcinoma,disease,squamous cell carcinoma,2017,CTTN,Cortactin,CTD_human,27148699,Cortactin is a prognostic marker for oral squamous cell carcinoma and its overexpression is involved in oral carcinogenesis.,0.21122073202078498,"<span class=""gene"" id=""27148699-0-0-9"">Cortactin</span> is a prognostic marker for oral <span class=""disease"" id=""27148699-0-42-65"">squamous cell carcinoma</span> and its overexpression is involved in oral carcinogenesis.",CTD_human
1,0,Biomarker,C0023531,Leukoplakia,disease,leukoplakia,2017,CTTN,cortactin,CTD_human,27148699,The immunostaining results show over- to moderate expression of cortactin in 85% (104/122) of oral squamous cell carcinoma (OSCC) tissues and in all 15 leukoplakia tissues examined.,0.200274726784213,"The immunostaining results show over- to moderate expression of <span class=""gene"" id=""27148699-3-64-73"">cortactin</span> in 85% (104/122) of oral squamous cell carcinoma (OSCC) tissues and in all 15 <span class=""disease"" id=""27148699-3-152-163"">leukoplakia</span> tissues examined.",CTD_human
4,0,Biomarker,C0004352,Autistic Disorder,disease,autism,2020,EN2,engrailed homeobox 2,CTD_human,20523082,Intronic single nucleotide polymorphisms of engrailed homeobox 2 modulate the disease vulnerability of autism in a han chinese population.,0.302329379969961,"Intronic single nucleotide polymorphisms of <span class=""gene"" id=""20523082-0-44-64"">engrailed homeobox 2</span> modulate the disease vulnerability of <span class=""disease"" id=""20523082-0-103-109"">autism</span> in a han chinese population.",CTD_human
12,16,Biomarker,C0039445,Hereditary hemorrhagic telangiectasia,disease,hereditary haemorrhagic telangiectasia,2022,ENG,Endoglin,CTD_human,15115879,Endoglin germline mutation in a patient with hereditary haemorrhagic telangiectasia and dexfenfluramine associated pulmonary arterial hypertension.,0.7384784724675519,"<span class=""gene"" id=""15115879-0-0-8"">Endoglin</span> germline mutation in a patient with <span class=""disease"" id=""15115879-0-45-83"">hereditary haemorrhagic telangiectasia</span> and dexfenfluramine associated pulmonary arterial hypertension.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0003873,Rheumatoid Arthritis,disease,rheumatoid arthritis,2023,ENO1,alpha-enolase,CTD_human,19898480,"Specific interaction between genotype, smoking and autoimmunity to citrullinated alpha-enolase in the etiology of rheumatoid arthritis.",0.206029633875371,"Specific interaction between genotype, smoking and autoimmunity to citrullinated <span class=""gene"" id=""19898480-0-81-94"">alpha-enolase</span> in the etiology of <span class=""disease"" id=""19898480-0-114-134"">rheumatoid arthritis</span>.",CTD_human
1,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,NSCLC,2023,ENO1,ENO1,CTD_human,17094902,Multiple secreted proteins of A549 cells were identified in this study and the overexpression of ENO1 and PEBP in NSCLC was revealed for the first time.,0.2,"Multiple secreted proteins of A549 cells were identified in this study and the overexpression of <span class=""gene"" id=""17094902-12-97-101"">ENO1</span> and PEBP in <span class=""disease"" id=""17094902-12-114-119"">NSCLC</span> was revealed for the first time.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,2023,ENO1,?-enolase,CTD_human,21472284,"These identified proteins, which include stratifin (14-3-3), transgelin 2, heat-shock protein (HSP)70, HSP27, manganese superoxide dismutase, prohibitin, DJ1, ?-enolase, peroxiredoxin 6, aldo-keto reductase family member B10, phosphoglycerate kinase 1, ?-1-antitrypsin and nm23-H1, may play a role in the development of HCC.",0.20328236603324,"These identified proteins, which include stratifin (14-3-3), transgelin 2, heat-shock protein (HSP)70, HSP27, manganese superoxide dismutase, prohibitin, DJ1, <span class=""gene"" id=""21472284-9-159-168"">&alpha;-enolase</span>, peroxiredoxin 6, aldo-keto reductase family member B10, phosphoglycerate kinase 1, &alpha;-1-antitrypsin and nm23-H1, may play a role in the development of <span class=""disease"" id=""21472284-9-320-323"">HCC</span>.",CTD_human
1,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,NSCLC,2026,ENO2,NSE,CTD_human,21595568,"Expression of NSE was present in 22.4%, ChrA in 15.5% and Syn in 14.8% of patients with NSCLC.",0.202197814273705,"Expression of <span class=""gene"" id=""21595568-4-14-17"">NSE</span> was present in 22.4%, ChrA in 15.5% and Syn in 14.8% of patients with <span class=""disease"" id=""21595568-4-88-93"">NSCLC</span>.",CTD_human
1,0,Biomarker,C0586323,Alcohol Withdrawal Seizures,disease,alcohol withdrawal seizures,2030,SLC29A1,SLC29A1,CTD_human,21283641,Functional role of the polymorphic 647 T/C variant of ENT1 (SLC29A1) and its association with alcohol withdrawal seizures.,0.200274726784213,"Functional role of the polymorphic 647 T/C variant of <span class=""gene"" id=""21283641-0-54-58"">ENT1</span> (<span class=""gene"" id=""21283641-0-60-67"">SLC29A1</span>) and its association with <span class=""disease"" id=""21283641-0-94-121"">alcohol withdrawal seizures</span>.",CTD_human
1,0,Biomarker,C0037221,Situs Inversus,disease,situs inversus,203286,ANKS6,ANKS6,CTD_human,23793029,"We also identify six families with ANKS6 mutations affected by nephronophthisis, including severe cardiovascular abnormalities, liver fibrosis and situs inversus.",0.2,"We also identify six families with <span class=""gene"" id=""23793029-5-35-40"">ANKS6</span> mutations affected by nephronophthisis, including severe cardiovascular abnormalities, liver fibrosis and <span class=""disease"" id=""23793029-5-147-161"">situs inversus</span>.",CTD_human
1,0,Biomarker,C0243050,Cardiovascular Abnormalities,group,cardiovascular abnormalities,203286,ANKS6,ANKS6,CTD_human,23793029,"We also identify six families with ANKS6 mutations affected by nephronophthisis, including severe cardiovascular abnormalities, liver fibrosis and situs inversus.",0.2,"We also identify six families with <span class=""gene"" id=""23793029-5-35-40"">ANKS6</span> mutations affected by nephronophthisis, including severe <span class=""disease"" id=""23793029-5-98-126"">cardiovascular abnormalities</span>, liver fibrosis and situs inversus.",CTD_human
1,0,Biomarker,C0025202,melanoma,disease,melanoma,2033,EP300,p300 HAT,CTD_human,23698071,"Selective inhibition of p300 HAT blocks cell cycle progression, induces cellular senescence, and inhibits the DNA damage response in melanoma cells.",0.200274726784213,"Selective inhibition of <span class=""gene"" id=""23698071-0-24-32"">p300 HAT</span> blocks cell cycle progression, induces cellular senescence, and inhibits the DNA damage response in <span class=""disease"" id=""23698071-0-133-141"">melanoma</span> cells.",CTD_human
1,0,Biomarker,C0028754,Obesity,disease,obesity,2033,EP300,EP300,CTD_human,26441656,Systems pharmacology of adiposity reveals inhibition of EP300 as a common therapeutic mechanism of caloric restriction and resveratrol for obesity.,0.2,"Systems pharmacology of adiposity reveals inhibition of <span class=""gene"" id=""26441656-0-56-61"">EP300</span> as a common therapeutic mechanism of caloric restriction and resveratrol for <span class=""disease"" id=""26441656-0-139-146"">obesity</span>.",CTD_human
1,0,Biomarker,C0152013,Adenocarcinoma of lung (disorder),disease,ADC,2033,EP300,EP300,CTD_human,27158780,"New significantly mutated genes included PPP3CA, DOT1L, and FTSJD1 in lung ADC, RASA1 in lung SqCC, and KLF5, EP300, and CREBBP in both tumor types.",0.2,"New significantly mutated genes included PPP3CA, DOT1L, and FTSJD1 in lung <span class=""disease"" id=""27158780-3-75-78"">ADC</span>, RASA1 in lung SqCC, and KLF5, <span class=""gene"" id=""27158780-3-110-115"">EP300</span>, and CREBBP in both tumor types.",CTD_human
1,2,Biomarker,C0007134,Renal Cell Carcinoma,disease,RCC,2034,EPAS1,hypoxia-inducible-factor-2 alpha,CTD_human,21131975,"Two correlated variants (r² = 0.99 in controls), rs11894252 (P = 1.8 × 10??) and rs7579899 (P = 2.3 × 10??), map to EPAS1 on 2p21, which encodes hypoxia-inducible-factor-2 alpha, a transcription factor previously implicated in RCC.",0.291784540966529,"Two correlated variants (r² = 0.99 in controls), rs11894252 (P = 1.8 &times; 10??) and rs7579899 (P = 2.3 &times; 10??), map to <span class=""gene"" id=""21131975-3-116-121"">EPAS1</span> on 2p21, which encodes <span class=""gene"" id=""21131975-3-145-177"">hypoxia-inducible-factor-2 alpha</span>, a transcription factor previously implicated in <span class=""disease"" id=""21131975-3-227-230"">RCC</span>.",CTD_human
2,0,Biomarker,C0002395,Alzheimer's Disease,disease,Alzheimer's disease,2041,EPHA1,EPHA1,CTD_human,21460840,"Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease.",0.202472541057918,"Common variants at ABCA7, MS4A6A/MS4A4E, <span class=""gene"" id=""21460840-0-41-46"">EPHA1</span>, CD33 and CD2AP are associated with <span class=""disease"" id=""21460840-0-83-102"">Alzheimer's disease</span>.",CTD_human
1,0,Biomarker,C0024117,Chronic Obstructive Airway Disease,disease,COPD,2052,EPHX1,mEPHX,CTD_human,9288046,The proportion of individuals with innate slow mEPHX activity (homozygotes) was significantly higher in both the COPD group and the emphysema group than in the control group (COPD 13 [19%] vs control 13 [6%]; emphysema 21 [22%] vs 13 [6%]).,0.252047672359041,"The proportion of individuals with innate slow <span class=""gene"" id=""9288046-5-47-52"">mEPHX</span> activity (homozygotes) was significantly higher in both the <span class=""disease"" id=""9288046-5-113-117"">COPD</span> group and the emphysema group than in the control group (COPD 13 [19%] vs control 13 [6%]; emphysema 21 [22%] vs 13 [6%]).",CTD_human
1,0,Biomarker,C0026764,Multiple Myeloma,disease,MM,2052,EPHX1,microsomal epoxide hydrolase,CTD_human,16949155,"Individuals who carried polymorphisms for GSTT1 null and/or high activity microsomal epoxide hydrolase (mEH 113YY+139HR or 113YY+139RR or 113YH+139RR) and/or low activity NAD(P)H:quinone oxidoreductase 1 (NQO1 187PS/SS) were 1.65, 2.49 and 13 times more likely to have MM (P(trend)=0.001).",0.205638237399215,"Individuals who carried polymorphisms for GSTT1 null and/or high activity <span class=""gene"" id=""16949155-3-74-102"">microsomal epoxide hydrolase</span> (mEH 113YY+139HR or 113YY+139RR or 113YH+139RR) and/or low activity NAD(P)H:quinone oxidoreductase 1 (NQO1 187PS/SS) were 1.65, 2.49 and 13 times more likely to have <span class=""disease"" id=""16949155-3-269-271"">MM</span> (P(trend)=0.001).",CTD_human
1,0,Biomarker,C0034067,Pulmonary Emphysema,disease,emphysema,2052,EPHX1,microsomal epoxide hydrolase,CTD_human,9288046,Association between polymorphism in gene for microsomal epoxide hydrolase and susceptibility to emphysema.,0.202197814273705,"Association between polymorphism in gene for <span class=""gene"" id=""9288046-0-45-73"">microsomal epoxide hydrolase</span> and susceptibility to <span class=""disease"" id=""9288046-0-96-105"">emphysema</span>.",CTD_human
1,0,Biomarker,C0345967,Malignant mesothelioma,disease,MM,2052,EPHX1,EPHX1,CTD_human,16697254,"The NAT2 fast acetylator and EPHX1 low-activity genotypes were positively associated with MM in the Italian study, while they were negatively associated with this malignancy in the Finnish one.",0.202681755307501,"The NAT2 fast acetylator and <span class=""gene"" id=""16697254-8-29-34"">EPHX1</span> low-activity genotypes were positively associated with <span class=""disease"" id=""16697254-8-90-92"">MM</span> in the Italian study, while they were negatively associated with this malignancy in the Finnish one.",CTD_human
1,0,Biomarker,C0018801,Heart failure,disease,heart failure,2053,EPHX2,Ephx2,CTD_human,18443590,"We further demonstrated differential regulation of EPHX2 in human heart failure, suggesting a cross-species role for Ephx2 in this complex disease.",0.20054945356842604,"We further demonstrated differential regulation of <span class=""gene"" id=""18443590-7-51-56"">EPHX2</span> in human <span class=""disease"" id=""18443590-7-66-79"">heart failure</span>, suggesting a cross-species role for <span class=""gene"" id=""18443590-7-117-122"">Ephx2</span> in this complex disease.",CTD_human
1,0,Biomarker,C0021364,Male infertility,phenotype,male infertility,2054,STX2,Epim,CTD_human,18277055,We therefore concluded that the male infertility of the repro34/repro34 mouse is caused by the interruption of spermatogenesis during transition from the spermatocyte to spermatid and that the nonsense mutation of the Stx2/Epim gene is responsible for the interruption of spermatogenesis.,0.2,"We therefore concluded that the <span class=""disease"" id=""18277055-11-32-48"">male infertility</span> of the repro34/repro34 mouse is caused by the interruption of spermatogenesis during transition from the spermatocyte to spermatid and that the nonsense mutation of the <span class=""gene"" id=""18277055-11-218-222"">Stx2</span>/<span class=""gene"" id=""18277055-11-223-227"">Epim</span> gene is responsible for the interruption of spermatogenesis.",CTD_human
1,0,Biomarker,C1510586,Autism Spectrum Disorders,disease,ASD,205428,C3orf58,DIA1,CTD_human,21283809,"Nematodes lack a DIA1 homologue, indicating Caenorhabditis elegans is not suitable for studying all aspects of ASD etiology, while zebrafish encode two DIA1 paralogues.",0.200274726784213,"Nematodes lack a <span class=""gene"" id=""21283809-6-17-21"">DIA1</span> homologue, indicating Caenorhabditis elegans is not suitable for studying all aspects of <span class=""disease"" id=""21283809-6-111-114"">ASD</span> etiology, while zebrafish encode two <span class=""gene"" id=""21283809-6-152-156"">DIA1</span> paralogues.",CTD_human
64,0,Therapeutic,C0002871,Anemia,disease,anemia,2056,EPO,rHuEPO-beta,CTD_human,12820454,Our data suggest that rHuEPO-beta correctable CAB-induced anemia occurs in 14.3% of prostate cancer patients after 6 months of therapy.,0.240919935470435,"Our data suggest that <span class=""gene"" id=""12820454-14-22-33"">rHuEPO-beta</span> correctable CAB-induced <span class=""disease"" id=""12820454-14-58-64"">anemia</span> occurs in 14.3% of prostate cancer patients after 6 months of therapy.",CTD_human
64,0,Therapeutic,C0002871,Anemia,disease,anemia,2056,EPO,erythropoietin,CTD_human,15232364,"Using the normal human response to anemia as the population line, for our population there was a significant difference in the slope of hematocrit (x) versus log10 erythropoietin (y) (-8.7 vs. -3.098 respectively, P < 0.001) and y-intercept (4.609 vs. 2.753 respectively, P < 0.001).",0.240919935470435,"Using the normal human response to <span class=""disease"" id=""15232364-6-35-41"">anemia</span> as the population line, for our population there was a significant difference in the slope of hematocrit (x) versus log10 <span class=""gene"" id=""15232364-6-164-178"">erythropoietin</span> (y) (-8.7 vs. -3.098 respectively, P &lt; 0.001) and y-intercept (4.609 vs. 2.753 respectively, P &lt; 0.001).",CTD_human
64,0,Biomarker,C0002871,Anemia,disease,anaemia,2056,EPO,erythropoietin,CTD_human,12897097,Average daily ribavirin dose was 200-800 mg. Ribavirin-induced anaemia was managed in five of seven patients with low-dose iron and erythropoietin between 4000 and 20 000 IU/week.,0.240919935470435,"Average daily ribavirin dose was 200-800 mg. Ribavirin-induced <span class=""disease"" id=""12897097-15-63-70"">anaemia</span> was managed in five of seven patients with low-dose iron and <span class=""gene"" id=""12897097-15-132-146"">erythropoietin</span> between 4000 and 20 000 IU/week.",CTD_human
64,0,Therapeutic,C0002871,Anemia,disease,anemia,2056,EPO,erythropoietin,CTD_human,18265628,High dose of erythropoietin in management of interferon/ribavirin induced anemia.,0.240919935470435,"High dose of <span class=""gene"" id=""18265628-0-13-27"">erythropoietin</span> in management of interferon/ribavirin induced <span class=""disease"" id=""18265628-0-74-80"">anemia</span>.",CTD_human
64,0,Therapeutic,C0002871,Anemia,disease,anemia,2056,EPO,EPO,CTD_human,7602351,r-Hu-EPO at a dose of either 150 or 300 IU/kg three times weekly delays the onset of anemia and reduces RBC transfusion requirements in patients who undergo intensive chemotherapy for SCLC.,0.240919935470435,"r-Hu-<span class=""gene"" id=""7602351-12-5-8"">EPO</span> at a dose of either 150 or 300 IU/kg three times weekly delays the onset of <span class=""disease"" id=""7602351-12-85-91"">anemia</span> and reduces RBC transfusion requirements in patients who undergo intensive chemotherapy for SCLC.",CTD_human
64,0,Therapeutic,C0002871,Anemia,disease,anemia,2056,EPO,Erythropoietin,CTD_human,9118049,Erythropoietin reduces anemia and transfusions after chemotherapy with paclitaxel and carboplatin.,0.240919935470435,"<span class=""gene"" id=""9118049-0-0-14"">Erythropoietin</span> reduces <span class=""disease"" id=""9118049-0-23-29"">anemia</span> and transfusions after chemotherapy with paclitaxel and carboplatin.",CTD_human
64,0,Therapeutic,C0002871,Anemia,disease,anaemia,2056,EPO,epoetin,CTD_human,9743294,"These data suggest that the correction of chemotherapy-induced anaemia by rhEPO (epoetin beta) treatment increases tumour radiosensitivity, presumably as a result of an improved oxygen supply to tumour tissue.",0.240919935470435,"These data suggest that the correction of chemotherapy-induced <span class=""disease"" id=""9743294-8-63-70"">anaemia</span> by rhEPO (<span class=""gene"" id=""9743294-8-81-88"">epoetin</span> beta) treatment increases tumour radiosensitivity, presumably as a result of an improved oxygen supply to tumour tissue.",CTD_human
64,0,Therapeutic,C0002871,Anemia,disease,anemia,2056,EPO,erythropoietin,CTD_human,15660393,"The main side effect was anemia, which was controlled with erythropoietin.",0.240919935470435,"The main side effect was <span class=""disease"" id=""15660393-9-25-31"">anemia</span>, which was controlled with <span class=""gene"" id=""15660393-9-59-73"">erythropoietin</span>.",CTD_human
64,0,Biomarker,C0002871,Anemia,disease,anemia,2056,EPO,erythropoietin,CTD_human,17397412,Administering erythropoietin can improve anemia caused by peginterferon and ribavirin therapy and is more effective than dose reduction at improving QOL during treatment.,0.240919935470435,"Administering <span class=""gene"" id=""17397412-4-14-28"">erythropoietin</span> can improve <span class=""disease"" id=""17397412-4-41-47"">anemia</span> caused by peginterferon and ribavirin therapy and is more effective than dose reduction at improving QOL during treatment.",CTD_human
64,0,Biomarker,C0002871,Anemia,disease,anemia,2056,EPO,Erythropoietin,CTD_human,15160343,Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase.,0.240919935470435,"<span class=""gene"" id=""15160343-0-0-14"">Erythropoietin</span> is effective in improving the <span class=""disease"" id=""15160343-0-45-51"">anemia</span> induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase.",CTD_human
64,0,Therapeutic,C0002871,Anemia,disease,anemia,2056,EPO,Erythropoietin,CTD_human,15160343,Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase.,0.240919935470435,"<span class=""gene"" id=""15160343-0-0-14"">Erythropoietin</span> is effective in improving the <span class=""disease"" id=""15160343-0-45-51"">anemia</span> induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase.",CTD_human
64,0,Biomarker,C0002871,Anemia,disease,anemia,2056,EPO,EPO,CTD_human,22174104,"Irrespective of the antioxidant mechanism, this property of EPO, shown in this model of Al exposure, let us suggest potential benefits by EPO treatment of patients with anemia associated to altered redox environment.",0.240919935470435,"Irrespective of the antioxidant mechanism, this property of <span class=""gene"" id=""22174104-11-60-63"">EPO</span>, shown in this model of Al exposure, let us suggest potential benefits by EPO treatment of patients with <span class=""disease"" id=""22174104-11-169-175"">anemia</span> associated to altered redox environment.",CTD_human
64,0,Biomarker,C0002871,Anemia,disease,anemia,2056,EPO,erythropoietin,CTD_human,7631396,"The key findings were that 1) 81 percent of centers used identical red cell transfusion criteria for HIV-infected and noninfected patients; 2) 52 percent used recombinant human erythropoietin as initial treatment for zidovudine-induced anemia, while 46 percent used recombinant human erythropoietin for anemia not associated with zidovudine; 3) 35 percent of centers used white cell-reduced blood components in lieu of cytomegalovirus (CMV)-seronegative components when administering transfusion(s) to CMV-seronegative patients; 4) 27 percent gamma-radiated cellular components, but no case of graft-versus-host disease had been observed; 5) > 85 percent of centers used monoclonal factor VIII for pediatric and adult hemophiliacs infected with HIV; 6) approximately one-third of centers routinely white cell-reduced cellular components; and 7) the most common reasons for white cell reduction included reduction of febrile reactions and CMV risk, reduction of platelet alloimmunization, and delay of immunomodulatory consequences of transfusion.",0.240919935470435,"The key findings were that 1) 81 percent of centers used identical red cell transfusion criteria for HIV-infected and noninfected patients; 2) 52 percent used recombinant human <span class=""gene"" id=""7631396-6-177-191"">erythropoietin</span> as initial treatment for zidovudine-induced <span class=""disease"" id=""7631396-6-236-242"">anemia</span>, while 46 percent used recombinant human <span class=""gene"" id=""7631396-6-284-298"">erythropoietin</span> for <span class=""disease"" id=""7631396-6-303-309"">anemia</span> not associated with zidovudine; 3) 35 percent of centers used white cell-reduced blood components in lieu of cytomegalovirus (CMV)-seronegative components when administering transfusion(s) to CMV-seronegative patients; 4) 27 percent gamma-radiated cellular components, but no case of graft-versus-host disease had been observed; 5) &gt; 85 percent of centers used monoclonal factor VIII for pediatric and adult hemophiliacs infected with HIV; 6) approximately one-third of centers routinely white cell-reduced cellular components; and 7) the most common reasons for white cell reduction included reduction of febrile reactions and CMV risk, reduction of platelet alloimmunization, and delay of immunomodulatory consequences of transfusion.",CTD_human
64,0,Biomarker,C0002871,Anemia,disease,anemia,2056,EPO,erythropoietin,CTD_human,14568602,[Use of erythropoietin in the treatment of anemia induced by ribavirin/interferon in patients with hepatitis C].,0.240919935470435,"[Use of <span class=""gene"" id=""14568602-0-8-22"">erythropoietin</span> in the treatment of <span class=""disease"" id=""14568602-0-43-49"">anemia</span> induced by ribavirin/interferon in patients with hepatitis C].",CTD_human
64,0,Therapeutic,C0002871,Anemia,disease,anemia,2056,EPO,erythropoietin,CTD_human,8250662,Clinical studies have shown recombinant human erythropoietin (r-HuEPO) to be effective in correcting the anemia of zidovudine-treated patients infected with human immunodeficiency virus with baseline serum erythropoietin levels of 500 U/L or less.,0.240919935470435,"Clinical studies have shown recombinant human erythropoietin (r-HuEPO) to be effective in correcting the <span class=""disease"" id=""8250662-2-105-111"">anemia</span> of zidovudine-treated patients infected with human immunodeficiency virus with baseline serum <span class=""gene"" id=""8250662-2-206-220"">erythropoietin</span> levels of 500 U/L or less.",CTD_human
64,0,Therapeutic,C0002871,Anemia,disease,anemia,2056,EPO,erythropoietin,CTD_human,17168855,The only proven effective prevention of RBV-induced anemia is the concomitant administration of erythropoietin.,0.240919935470435,"The only proven effective prevention of RBV-induced <span class=""disease"" id=""17168855-9-52-58"">anemia</span> is the concomitant administration of <span class=""gene"" id=""17168855-9-96-110"">erythropoietin</span>.",CTD_human
64,0,Therapeutic,C0002871,Anemia,disease,anemia,2056,EPO,erythropoietin,CTD_human,18611800,Recombinant human erythropoietin for treatment of anemia in persons with AIDS not receiving zidovudine.,0.240919935470435,"Recombinant human <span class=""gene"" id=""18611800-0-18-32"">erythropoietin</span> for treatment of <span class=""disease"" id=""18611800-0-50-56"">anemia</span> in persons with AIDS not receiving zidovudine.",CTD_human
64,0,Biomarker,C0002871,Anemia,disease,anemia,2056,EPO,EPO,CTD_human,7602351,r-Hu-EPO at a dose of either 150 or 300 IU/kg three times weekly delays the onset of anemia and reduces RBC transfusion requirements in patients who undergo intensive chemotherapy for SCLC.,0.240919935470435,"r-Hu-<span class=""gene"" id=""7602351-12-5-8"">EPO</span> at a dose of either 150 or 300 IU/kg three times weekly delays the onset of <span class=""disease"" id=""7602351-12-85-91"">anemia</span> and reduces RBC transfusion requirements in patients who undergo intensive chemotherapy for SCLC.",CTD_human
64,0,Biomarker,C0002871,Anemia,disease,anemia,2056,EPO,erythropoietin,CTD_human,17168855,The only proven effective prevention of RBV-induced anemia is the concomitant administration of erythropoietin.,0.240919935470435,"The only proven effective prevention of RBV-induced <span class=""disease"" id=""17168855-9-52-58"">anemia</span> is the concomitant administration of <span class=""gene"" id=""17168855-9-96-110"">erythropoietin</span>.",CTD_human
64,0,Therapeutic,C0002871,Anemia,disease,anemia,2056,EPO,erythropoietin,CTD_human,1516988,"We compared blood pressure after three different methods of partial correction of anemia in hemodialysis patients with similar baseline hematocrits (erythropoietin n = 12, intravenous iron alone n = 10, androgens n = 9).",0.240919935470435,"We compared blood pressure after three different methods of partial correction of <span class=""disease"" id=""1516988-2-82-88"">anemia</span> in hemodialysis patients with similar baseline hematocrits (<span class=""gene"" id=""1516988-2-149-163"">erythropoietin</span> n = 12, intravenous iron alone n = 10, androgens n = 9).",CTD_human
64,0,Biomarker,C0002871,Anemia,disease,anemia,2056,EPO,erythropoietin,CTD_human,8250662,Clinical studies have shown recombinant human erythropoietin (r-HuEPO) to be effective in correcting the anemia of zidovudine-treated patients infected with human immunodeficiency virus with baseline serum erythropoietin levels of 500 U/L or less.,0.240919935470435,"Clinical studies have shown recombinant human erythropoietin (r-HuEPO) to be effective in correcting the <span class=""disease"" id=""8250662-2-105-111"">anemia</span> of zidovudine-treated patients infected with human immunodeficiency virus with baseline serum <span class=""gene"" id=""8250662-2-206-220"">erythropoietin</span> levels of 500 U/L or less.",CTD_human
64,0,Biomarker,C0002871,Anemia,disease,anaemia,2056,EPO,epoetin,CTD_human,9743294,"These data suggest that the correction of chemotherapy-induced anaemia by rhEPO (epoetin beta) treatment increases tumour radiosensitivity, presumably as a result of an improved oxygen supply to tumour tissue.",0.240919935470435,"These data suggest that the correction of chemotherapy-induced <span class=""disease"" id=""9743294-8-63-70"">anaemia</span> by rhEPO (<span class=""gene"" id=""9743294-8-81-88"">epoetin</span> beta) treatment increases tumour radiosensitivity, presumably as a result of an improved oxygen supply to tumour tissue.",CTD_human
64,0,Biomarker,C0002871,Anemia,disease,anemia,2056,EPO,erythropoietin,CTD_human,17409018,"However, antiviral treatment was limited by anemia, resulting in premature withdrawal from therapy and requiring substitution with recombinant erythropoietin in most patients.",0.240919935470435,"However, antiviral treatment was limited by <span class=""disease"" id=""17409018-6-44-50"">anemia</span>, resulting in premature withdrawal from therapy and requiring substitution with recombinant <span class=""gene"" id=""17409018-6-143-157"">erythropoietin</span> in most patients.",CTD_human
64,0,Biomarker,C0002871,Anemia,disease,anemia,2056,EPO,Erythropoietin,CTD_human,8418619,"Erythropoietin for the treatment of anemia has become part of the standard treatment regimen of dialysis patients, but experience with its use in pregnancy is limited.",0.240919935470435,"<span class=""gene"" id=""8418619-2-0-14"">Erythropoietin</span> for the treatment of <span class=""disease"" id=""8418619-2-36-42"">anemia</span> has become part of the standard treatment regimen of dialysis patients, but experience with its use in pregnancy is limited.",CTD_human
64,0,Biomarker,C0002871,Anemia,disease,anemia,2056,EPO,Erythropoietin,CTD_human,9118049,Erythropoietin reduces anemia and transfusions after chemotherapy with paclitaxel and carboplatin.,0.240919935470435,"<span class=""gene"" id=""9118049-0-0-14"">Erythropoietin</span> reduces <span class=""disease"" id=""9118049-0-23-29"">anemia</span> and transfusions after chemotherapy with paclitaxel and carboplatin.",CTD_human
64,0,Biomarker,C0002871,Anemia,disease,anemia,2056,EPO,erythropoietin,CTD_human,15660393,"The main side effect was anemia, which was controlled with erythropoietin.",0.240919935470435,"The main side effect was <span class=""disease"" id=""15660393-9-25-31"">anemia</span>, which was controlled with <span class=""gene"" id=""15660393-9-59-73"">erythropoietin</span>.",CTD_human
64,0,Therapeutic,C0002871,Anemia,disease,anemia,2056,EPO,erythropoietin,CTD_human,10506726,Erythropoietin reduces anemia and transfusions: A randomized trial with or without erythropoietin during chemotherapy.,0.240919935470435,"<span class=""gene"" id=""10506726-0-0-14"">Erythropoietin</span> reduces <span class=""disease"" id=""10506726-0-23-29"">anemia</span> and transfusions: A randomized trial with or without <span class=""gene"" id=""10506726-0-83-97"">erythropoietin</span> during chemotherapy.",CTD_human
64,0,Therapeutic,C0002871,Anemia,disease,anemia,2056,EPO,Erythropoietin,CTD_human,8418619,"Erythropoietin for the treatment of anemia has become part of the standard treatment regimen of dialysis patients, but experience with its use in pregnancy is limited.",0.240919935470435,"<span class=""gene"" id=""8418619-2-0-14"">Erythropoietin</span> for the treatment of <span class=""disease"" id=""8418619-2-36-42"">anemia</span> has become part of the standard treatment regimen of dialysis patients, but experience with its use in pregnancy is limited.",CTD_human
64,0,Therapeutic,C0002871,Anemia,disease,anemia,2056,EPO,erythropoietin,CTD_human,14568602,[Use of erythropoietin in the treatment of anemia induced by ribavirin/interferon in patients with hepatitis C].,0.240919935470435,"[Use of <span class=""gene"" id=""14568602-0-8-22"">erythropoietin</span> in the treatment of <span class=""disease"" id=""14568602-0-43-49"">anemia</span> induced by ribavirin/interferon in patients with hepatitis C].",CTD_human
64,0,Biomarker,C0002871,Anemia,disease,anemia,2056,EPO,rHuEPO-beta,CTD_human,12820454,Our data suggest that rHuEPO-beta correctable CAB-induced anemia occurs in 14.3% of prostate cancer patients after 6 months of therapy.,0.240919935470435,"Our data suggest that <span class=""gene"" id=""12820454-14-22-33"">rHuEPO-beta</span> correctable CAB-induced <span class=""disease"" id=""12820454-14-58-64"">anemia</span> occurs in 14.3% of prostate cancer patients after 6 months of therapy.",CTD_human
64,0,Biomarker,C0002871,Anemia,disease,anemia,2056,EPO,EPO,CTD_human,7529132,"Intricate dose-response surfaces of the effects of the different treatments on colony-forming units-erythroid, reticulocytes, hematocrit, colony-forming units-granulocyte/macrophage, and absolute neutrophil count were obtained, which revealed that: (a) simultaneous EPO administration was able to maintain reticulocyte production and to protect mice from VP-16 induced anemia; (b) simultaneous G-CSF administration was able to maintain granulocyte production and to protect mice from VP-16 induced neutropenia; (c) VP-16 dose escalation was feasible when EPO or G-CSF were simultaneously administered; and (d) no increased myelotoxicity on erythroid or granuloid progenitors was observed when EPO or G-CSF was simultaneously administered with VP-16.",0.240919935470435,"Intricate dose-response surfaces of the effects of the different treatments on colony-forming units-erythroid, reticulocytes, hematocrit, colony-forming units-granulocyte/macrophage, and absolute neutrophil count were obtained, which revealed that: (a) simultaneous <span class=""gene"" id=""7529132-4-266-269"">EPO</span> administration was able to maintain reticulocyte production and to protect mice from VP-16 induced <span class=""disease"" id=""7529132-4-369-375"">anemia</span>; (b) simultaneous G-CSF administration was able to maintain granulocyte production and to protect mice from VP-16 induced neutropenia; (c) VP-16 dose escalation was feasible when <span class=""gene"" id=""7529132-4-555-558"">EPO</span> or G-CSF were simultaneously administered; and (d) no increased myelotoxicity on erythroid or granuloid progenitors was observed when <span class=""gene"" id=""7529132-4-693-696"">EPO</span> or G-CSF was simultaneously administered with VP-16.",CTD_human
64,0,Biomarker,C0002871,Anemia,disease,anaemia,2056,EPO,erythropoietin,CTD_human,9616293,Management of chemotherapy-related anaemia with low-dose recombinant human erythropoietin in patients with small cell lung cancer.,0.240919935470435,"Management of chemotherapy-related <span class=""disease"" id=""9616293-0-35-42"">anaemia</span> with low-dose recombinant human <span class=""gene"" id=""9616293-0-75-89"">erythropoietin</span> in patients with small cell lung cancer.",CTD_human
64,0,Biomarker,C0002871,Anemia,disease,anemia,2056,EPO,Epo,CTD_human,8260696,"Administration of a lower Epo dose (1 U Epo) resulted in only a modest retardation of AZT-induced anemia, although, when combined with heme, there was a great improvement in recovery of erythropoiesis.",0.240919935470435,"Administration of a lower <span class=""gene"" id=""8260696-4-26-29"">Epo</span> dose (1 U <span class=""gene"" id=""8260696-4-40-43"">Epo</span>) resulted in only a modest retardation of AZT-induced <span class=""disease"" id=""8260696-4-98-104"">anemia</span>, although, when combined with heme, there was a great improvement in recovery of erythropoiesis.",CTD_human
64,0,Therapeutic,C0002871,Anemia,disease,anaemia,2056,EPO,rHuEpo,CTD_human,23077460,"Human recombinant erythropoietin (rHuEpo) that is used for the treatment of the chemotherapy-induced anaemia in cancer patients was shown to cause detrimental effects on the course of disease due to increased adverse events inflicting patient's survival, potentially related to rHuEpo-induced cancer progression.",0.240919935470435,"Human recombinant <span class=""gene"" id=""23077460-1-18-32"">erythropoietin</span> (<span class=""gene"" id=""23077460-1-34-40"">rHuEpo</span>) that is used for the treatment of the chemotherapy-induced <span class=""disease"" id=""23077460-1-101-108"">anaemia</span> in cancer patients was shown to cause detrimental effects on the course of disease due to increased adverse events inflicting patient's survival, potentially related to <span class=""gene"" id=""23077460-1-278-284"">rHuEpo</span>-induced cancer progression.",CTD_human
64,0,Biomarker,C0002871,Anemia,disease,anemia,2056,EPO,Erythropoietin,CTD_human,11245434,Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumors.,0.240919935470435,"<span class=""gene"" id=""11245434-0-0-14"">Erythropoietin</span> restores the <span class=""disease"" id=""11245434-0-28-34"">anemia</span>-induced reduction in cyclophosphamide cytotoxicity in rat tumors.",CTD_human
64,0,Biomarker,C0002871,Anemia,disease,anemia,2056,EPO,erythropoietin,CTD_human,8504984,The use of recombinant human erythropoietin to prevent carboplatin-induced anemia.,0.240919935470435,"The use of recombinant human <span class=""gene"" id=""8504984-0-29-43"">erythropoietin</span> to prevent carboplatin-induced <span class=""disease"" id=""8504984-0-75-81"">anemia</span>.",CTD_human
64,0,Biomarker,C0002871,Anemia,disease,anaemia,2056,EPO,erythropoietin,CTD_human,1574960,Recombinant human erythropoietin in patients with ovarian carcinoma and anaemia secondary to cisplatin and carboplatin chemotherapy: preliminary results.,0.240919935470435,"Recombinant human <span class=""gene"" id=""1574960-0-18-32"">erythropoietin</span> in patients with ovarian carcinoma and <span class=""disease"" id=""1574960-0-72-79"">anaemia</span> secondary to cisplatin and carboplatin chemotherapy: preliminary results.",CTD_human
64,0,Biomarker,C0002871,Anemia,disease,anemia,2056,EPO,Epo,CTD_human,21860424,Erythropoietin (Epo) is widely used clinically to treat anemia associated with various clinical conditions including cancer.,0.240919935470435,"<span class=""gene"" id=""21860424-1-0-14"">Erythropoietin</span> (<span class=""gene"" id=""21860424-1-16-19"">Epo</span>) is widely used clinically to treat <span class=""disease"" id=""21860424-1-56-62"">anemia</span> associated with various clinical conditions including cancer.",CTD_human
64,0,Biomarker,C0002871,Anemia,disease,anaemia,2056,EPO,erythropoietin,CTD_human,16637862,Ribavirin-induced anaemia was treated with high doses of erythropoietin and low doses of iron.Blood-transfusions were not needed.,0.240919935470435,"Ribavirin-induced <span class=""disease"" id=""16637862-8-18-25"">anaemia</span> was treated with high doses of <span class=""gene"" id=""16637862-8-57-71"">erythropoietin</span> and low doses of iron.Blood-transfusions were not needed.",CTD_human
64,0,Therapeutic,C0002871,Anemia,disease,anemia,2056,EPO,EPO,CTD_human,22174104,"Irrespective of the antioxidant mechanism, this property of EPO, shown in this model of Al exposure, let us suggest potential benefits by EPO treatment of patients with anemia associated to altered redox environment.",0.240919935470435,"Irrespective of the antioxidant mechanism, this property of <span class=""gene"" id=""22174104-11-60-63"">EPO</span>, shown in this model of Al exposure, let us suggest potential benefits by EPO treatment of patients with <span class=""disease"" id=""22174104-11-169-175"">anemia</span> associated to altered redox environment.",CTD_human
64,0,Biomarker,C0002871,Anemia,disease,anemia,2056,EPO,Epoetin,CTD_human,19212639,Optimized pro-active management of anemia by Epoetin alpha in pre-operative chemotherapy for primary breast cancer.,0.240919935470435,"Optimized pro-active management of <span class=""disease"" id=""19212639-0-35-41"">anemia</span> by <span class=""gene"" id=""19212639-0-45-52"">Epoetin</span> alpha in pre-operative chemotherapy for primary breast cancer.",CTD_human
64,0,Therapeutic,C0002871,Anemia,disease,anemia,2056,EPO,erythropoietin,CTD_human,11569724,A preliminary study of erythropoietin for anemia associated with ribavirin and interferon-alpha.,0.240919935470435,"A preliminary study of <span class=""gene"" id=""11569724-0-23-37"">erythropoietin</span> for <span class=""disease"" id=""11569724-0-42-48"">anemia</span> associated with ribavirin and interferon-alpha.",CTD_human
64,0,Biomarker,C0002871,Anemia,disease,anaemia,2056,EPO,rHuEpo,CTD_human,23077460,"Human recombinant erythropoietin (rHuEpo) that is used for the treatment of the chemotherapy-induced anaemia in cancer patients was shown to cause detrimental effects on the course of disease due to increased adverse events inflicting patient's survival, potentially related to rHuEpo-induced cancer progression.",0.240919935470435,"Human recombinant <span class=""gene"" id=""23077460-1-18-32"">erythropoietin</span> (<span class=""gene"" id=""23077460-1-34-40"">rHuEpo</span>) that is used for the treatment of the chemotherapy-induced <span class=""disease"" id=""23077460-1-101-108"">anaemia</span> in cancer patients was shown to cause detrimental effects on the course of disease due to increased adverse events inflicting patient's survival, potentially related to <span class=""gene"" id=""23077460-1-278-284"">rHuEpo</span>-induced cancer progression.",CTD_human
64,0,Biomarker,C0002871,Anemia,disease,anemia,2056,EPO,erythropoietin,CTD_human,18611800,Recombinant human erythropoietin for treatment of anemia in persons with AIDS not receiving zidovudine.,0.240919935470435,"Recombinant human <span class=""gene"" id=""18611800-0-18-32"">erythropoietin</span> for treatment of <span class=""disease"" id=""18611800-0-50-56"">anemia</span> in persons with AIDS not receiving zidovudine.",CTD_human
64,0,Therapeutic,C0002871,Anemia,disease,anemia,2056,EPO,Epo,CTD_human,21860424,Erythropoietin (Epo) is widely used clinically to treat anemia associated with various clinical conditions including cancer.,0.240919935470435,"<span class=""gene"" id=""21860424-1-0-14"">Erythropoietin</span> (<span class=""gene"" id=""21860424-1-16-19"">Epo</span>) is widely used clinically to treat <span class=""disease"" id=""21860424-1-56-62"">anemia</span> associated with various clinical conditions including cancer.",CTD_human
64,0,Therapeutic,C0002871,Anemia,disease,anemia,2056,EPO,erythropoietin,CTD_human,18403296,"The aim of this retrospective data-analysis was to determine the rate of transfusions and the maintenance of chemotherapeutic dose intensity in 9 small cell lung cancer patients receiving beta-erythropoietin, due to anemia observed after the first cycle of chemotherapy.",0.240919935470435,"The aim of this retrospective data-analysis was to determine the rate of transfusions and the maintenance of chemotherapeutic dose intensity in 9 small cell lung cancer patients receiving beta-<span class=""gene"" id=""18403296-3-193-207"">erythropoietin</span>, due to <span class=""disease"" id=""18403296-3-216-222"">anemia</span> observed after the first cycle of chemotherapy.",CTD_human
64,0,Therapeutic,C0002871,Anemia,disease,anaemia,2056,EPO,erythropoietin,CTD_human,12713065,Normal erythropoietin response in chronic hepatitis C patients with ribavirin-induced anaemia.,0.240919935470435,"Normal <span class=""gene"" id=""12713065-0-7-21"">erythropoietin</span> response in chronic hepatitis C patients with ribavirin-induced <span class=""disease"" id=""12713065-0-86-93"">anaemia</span>.",CTD_human
64,0,Therapeutic,C0002871,Anemia,disease,anaemia,2056,EPO,erythropoietin,CTD_human,9616293,Management of chemotherapy-related anaemia with low-dose recombinant human erythropoietin in patients with small cell lung cancer.,0.240919935470435,"Management of chemotherapy-related <span class=""disease"" id=""9616293-0-35-42"">anaemia</span> with low-dose recombinant human <span class=""gene"" id=""9616293-0-75-89"">erythropoietin</span> in patients with small cell lung cancer.",CTD_human
64,0,Therapeutic,C0002871,Anemia,disease,anemia,2056,EPO,erythropoietin,CTD_human,8202718,"Very preliminary analysis of an ongoing phase III trial studying two erythropoietin doses given continuously subcutaneously versus a retrospective analysis of a ""control group"" (drawn from historical data on the occurrence of anemia in cisplatin- and/or carboplatin-treated patients) has shown beneficial effects of erythropoietin during treatment with these platinating agents.",0.240919935470435,"Very preliminary analysis of an ongoing phase III trial studying two <span class=""gene"" id=""8202718-5-69-83"">erythropoietin</span> doses given continuously subcutaneously versus a retrospective analysis of a ""control group"" (drawn from historical data on the occurrence of <span class=""disease"" id=""8202718-5-226-232"">anemia</span> in cisplatin- and/or carboplatin-treated patients) has shown beneficial effects of <span class=""gene"" id=""8202718-5-316-330"">erythropoietin</span> during treatment with these platinating agents.",CTD_human
64,0,Biomarker,C0002871,Anemia,disease,anemia,2056,EPO,erythropoietin,CTD_human,18265628,High dose of erythropoietin in management of interferon/ribavirin induced anemia.,0.240919935470435,"High dose of <span class=""gene"" id=""18265628-0-13-27"">erythropoietin</span> in management of interferon/ribavirin induced <span class=""disease"" id=""18265628-0-74-80"">anemia</span>.",CTD_human
64,0,Biomarker,C0002871,Anemia,disease,anemia,2056,EPO,erythropoietin,CTD_human,11569724,A preliminary study of erythropoietin for anemia associated with ribavirin and interferon-alpha.,0.240919935470435,"A preliminary study of <span class=""gene"" id=""11569724-0-23-37"">erythropoietin</span> for <span class=""disease"" id=""11569724-0-42-48"">anemia</span> associated with ribavirin and interferon-alpha.",CTD_human
64,0,Therapeutic,C0002871,Anemia,disease,anaemia,2056,EPO,epoetin,CTD_human,16970600,"We retrospectively analysed the incidence of anaemia, RBV dose reduction and epoetin-alpha (EPO) use among coinfected patients treated with PEG-IFN and weight-based RBV (800-1400 mg/day) who enrolled in two clinical trials and had haemoglobin (Hb) levels assessed at baseline and after 4 and/or 12 weeks of HCV treatment.",0.240919935470435,"We retrospectively analysed the incidence of <span class=""disease"" id=""16970600-3-45-52"">anaemia</span>, RBV dose reduction and <span class=""gene"" id=""16970600-3-77-84"">epoetin</span>-alpha (EPO) use among coinfected patients treated with PEG-IFN and weight-based RBV (800-1400 mg/day) who enrolled in two clinical trials and had haemoglobin (Hb) levels assessed at baseline and after 4 and/or 12 weeks of HCV treatment.",CTD_human
64,0,Biomarker,C0002871,Anemia,disease,anemias,2056,EPO,EPO,CTD_human,16949463,"Serum EPO levels in patients with chronic kidney disease are usually within the normal range and thus fail to show an appropriate increase with decreasing hemoglobin levels, as found in nonrenal anemias.",0.240919935470435,"Serum <span class=""gene"" id=""16949463-3-6-9"">EPO</span> levels in patients with chronic kidney disease are usually within the normal range and thus fail to show an appropriate increase with decreasing hemoglobin levels, as found in nonrenal <span class=""disease"" id=""16949463-3-195-202"">anemias</span>.",CTD_human
64,0,Biomarker,C0002871,Anemia,disease,anemia,2056,EPO,erythropoietin,CTD_human,15232364,"Using the normal human response to anemia as the population line, for our population there was a significant difference in the slope of hematocrit (x) versus log10 erythropoietin (y) (-8.7 vs. -3.098 respectively, P < 0.001) and y-intercept (4.609 vs. 2.753 respectively, P < 0.001).",0.240919935470435,"Using the normal human response to <span class=""disease"" id=""15232364-6-35-41"">anemia</span> as the population line, for our population there was a significant difference in the slope of hematocrit (x) versus log10 <span class=""gene"" id=""15232364-6-164-178"">erythropoietin</span> (y) (-8.7 vs. -3.098 respectively, P &lt; 0.001) and y-intercept (4.609 vs. 2.753 respectively, P &lt; 0.001).",CTD_human
64,0,Biomarker,C0002871,Anemia,disease,anemia,2056,EPO,erythropoietin,CTD_human,10506726,Erythropoietin reduces anemia and transfusions: A randomized trial with or without erythropoietin during chemotherapy.,0.240919935470435,"<span class=""gene"" id=""10506726-0-0-14"">Erythropoietin</span> reduces <span class=""disease"" id=""10506726-0-23-29"">anemia</span> and transfusions: A randomized trial with or without <span class=""gene"" id=""10506726-0-83-97"">erythropoietin</span> during chemotherapy.",CTD_human
64,0,Biomarker,C0002871,Anemia,disease,anemia,2056,EPO,Epo,CTD_human,16511603,"Present studies reveal that, unlike steady-state erythropoiesis, erythropoiesis during anemia depends sharply on an Epo receptor-phosphotyrosine-343-Stat5 signaling axis.",0.240919935470435,"Present studies reveal that, unlike steady-state erythropoiesis, erythropoiesis during <span class=""disease"" id=""16511603-2-87-93"">anemia</span> depends sharply on an <span class=""gene"" id=""16511603-2-116-119"">Epo</span> receptor-phosphotyrosine-343-Stat5 signaling axis.",CTD_human
64,0,Therapeutic,C0002871,Anemia,disease,anemia,2056,EPO,Epo,CTD_human,8260696,"Administration of a lower Epo dose (1 U Epo) resulted in only a modest retardation of AZT-induced anemia, although, when combined with heme, there was a great improvement in recovery of erythropoiesis.",0.240919935470435,"Administration of a lower <span class=""gene"" id=""8260696-4-26-29"">Epo</span> dose (1 U <span class=""gene"" id=""8260696-4-40-43"">Epo</span>) resulted in only a modest retardation of AZT-induced <span class=""disease"" id=""8260696-4-98-104"">anemia</span>, although, when combined with heme, there was a great improvement in recovery of erythropoiesis.",CTD_human
64,0,Therapeutic,C0002871,Anemia,disease,anemia,2056,EPO,EPO,CTD_human,7529132,"Intricate dose-response surfaces of the effects of the different treatments on colony-forming units-erythroid, reticulocytes, hematocrit, colony-forming units-granulocyte/macrophage, and absolute neutrophil count were obtained, which revealed that: (a) simultaneous EPO administration was able to maintain reticulocyte production and to protect mice from VP-16 induced anemia; (b) simultaneous G-CSF administration was able to maintain granulocyte production and to protect mice from VP-16 induced neutropenia; (c) VP-16 dose escalation was feasible when EPO or G-CSF were simultaneously administered; and (d) no increased myelotoxicity on erythroid or granuloid progenitors was observed when EPO or G-CSF was simultaneously administered with VP-16.",0.240919935470435,"Intricate dose-response surfaces of the effects of the different treatments on colony-forming units-erythroid, reticulocytes, hematocrit, colony-forming units-granulocyte/macrophage, and absolute neutrophil count were obtained, which revealed that: (a) simultaneous <span class=""gene"" id=""7529132-4-266-269"">EPO</span> administration was able to maintain reticulocyte production and to protect mice from VP-16 induced <span class=""disease"" id=""7529132-4-369-375"">anemia</span>; (b) simultaneous G-CSF administration was able to maintain granulocyte production and to protect mice from VP-16 induced neutropenia; (c) VP-16 dose escalation was feasible when <span class=""gene"" id=""7529132-4-555-558"">EPO</span> or G-CSF were simultaneously administered; and (d) no increased myelotoxicity on erythroid or granuloid progenitors was observed when <span class=""gene"" id=""7529132-4-693-696"">EPO</span> or G-CSF was simultaneously administered with VP-16.",CTD_human
64,0,Therapeutic,C0002871,Anemia,disease,anemia,2056,EPO,erythropoietin,CTD_human,17559739,The cost of treating ribavirin-induced anemia in hepatitis C: the impact of using recombinant human erythropoietin.,0.240919935470435,"The cost of treating ribavirin-induced <span class=""disease"" id=""17559739-0-39-45"">anemia</span> in hepatitis C: the impact of using recombinant human <span class=""gene"" id=""17559739-0-100-114"">erythropoietin</span>.",CTD_human
64,0,Biomarker,C0002871,Anemia,disease,anaemia,2056,EPO,epoetin,CTD_human,16970600,"We retrospectively analysed the incidence of anaemia, RBV dose reduction and epoetin-alpha (EPO) use among coinfected patients treated with PEG-IFN and weight-based RBV (800-1400 mg/day) who enrolled in two clinical trials and had haemoglobin (Hb) levels assessed at baseline and after 4 and/or 12 weeks of HCV treatment.",0.240919935470435,"We retrospectively analysed the incidence of <span class=""disease"" id=""16970600-3-45-52"">anaemia</span>, RBV dose reduction and <span class=""gene"" id=""16970600-3-77-84"">epoetin</span>-alpha (EPO) use among coinfected patients treated with PEG-IFN and weight-based RBV (800-1400 mg/day) who enrolled in two clinical trials and had haemoglobin (Hb) levels assessed at baseline and after 4 and/or 12 weeks of HCV treatment.",CTD_human
64,0,Biomarker,C0002871,Anemia,disease,anemia,2056,EPO,erythropoietin,CTD_human,9617462,Effectiveness of weekly subcutaneous recombinant human erythropoietin administration for chemotherapy-induced anemia.,0.240919935470435,"Effectiveness of weekly subcutaneous recombinant human <span class=""gene"" id=""9617462-0-55-69"">erythropoietin</span> administration for chemotherapy-induced <span class=""disease"" id=""9617462-0-110-116"">anemia</span>.",CTD_human
64,0,Therapeutic,C0002871,Anemia,disease,anaemia,2056,EPO,EPO,CTD_human,1982298,These findings indicate that the anaemia induced by gentamicin is due not only to a deficiency of EPO but also to an enhancement of fragility of erythrocytes in an azotaemic environment.,0.240919935470435,"These findings indicate that the <span class=""disease"" id=""1982298-6-33-40"">anaemia</span> induced by gentamicin is due not only to a deficiency of <span class=""gene"" id=""1982298-6-98-101"">EPO</span> but also to an enhancement of fragility of erythrocytes in an azotaemic environment.",CTD_human
64,0,Therapeutic,C0002871,Anemia,disease,anemia,2056,EPO,erythropoietin,CTD_human,11981781,Treatment of ribavirin/interferon-induced anemia with erythropoietin in patients with hepatitis C.,0.240919935470435,"Treatment of ribavirin/interferon-induced <span class=""disease"" id=""11981781-0-42-48"">anemia</span> with <span class=""gene"" id=""11981781-0-54-68"">erythropoietin</span> in patients with hepatitis C.",CTD_human
64,0,Therapeutic,C0002871,Anemia,disease,anemia,2056,EPO,Erythropoietin,CTD_human,11245434,Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumors.,0.240919935470435,"<span class=""gene"" id=""11245434-0-0-14"">Erythropoietin</span> restores the <span class=""disease"" id=""11245434-0-28-34"">anemia</span>-induced reduction in cyclophosphamide cytotoxicity in rat tumors.",CTD_human
64,0,Biomarker,C0002871,Anemia,disease,anemia,2056,EPO,erythropoietin,CTD_human,18403296,"The aim of this retrospective data-analysis was to determine the rate of transfusions and the maintenance of chemotherapeutic dose intensity in 9 small cell lung cancer patients receiving beta-erythropoietin, due to anemia observed after the first cycle of chemotherapy.",0.240919935470435,"The aim of this retrospective data-analysis was to determine the rate of transfusions and the maintenance of chemotherapeutic dose intensity in 9 small cell lung cancer patients receiving beta-<span class=""gene"" id=""18403296-3-193-207"">erythropoietin</span>, due to <span class=""disease"" id=""18403296-3-216-222"">anemia</span> observed after the first cycle of chemotherapy.",CTD_human
64,0,Therapeutic,C0002871,Anemia,disease,anemia,2056,EPO,erythropoietin,CTD_human,10713657,"In this study, we demonstrated that anemia in cancer patients was caused by blunted erythropoietin response, rather than its quantitative deficiency.",0.240919935470435,"In this study, we demonstrated that <span class=""disease"" id=""10713657-11-36-42"">anemia</span> in cancer patients was caused by blunted <span class=""gene"" id=""10713657-11-84-98"">erythropoietin</span> response, rather than its quantitative deficiency.",CTD_human
64,0,Biomarker,C0002871,Anemia,disease,anemia,2056,EPO,erythropoietin,CTD_human,11828949,Double-blind randomized control trial of the effect of recombinant human erythropoietin on chemotherapy-induced anemia in patients with non-small cell lung cancer.,0.240919935470435,"Double-blind randomized control trial of the effect of recombinant human <span class=""gene"" id=""11828949-0-73-87"">erythropoietin</span> on chemotherapy-induced <span class=""disease"" id=""11828949-0-112-118"">anemia</span> in patients with non-small cell lung cancer.",CTD_human
64,0,Therapeutic,C0002871,Anemia,disease,anemia,2056,EPO,erythropoietin,CTD_human,11828949,Double-blind randomized control trial of the effect of recombinant human erythropoietin on chemotherapy-induced anemia in patients with non-small cell lung cancer.,0.240919935470435,"Double-blind randomized control trial of the effect of recombinant human <span class=""gene"" id=""11828949-0-73-87"">erythropoietin</span> on chemotherapy-induced <span class=""disease"" id=""11828949-0-112-118"">anemia</span> in patients with non-small cell lung cancer.",CTD_human
64,0,Therapeutic,C0002871,Anemia,disease,anemia,2056,EPO,EPO,CTD_human,19015056,One third to half of patients with hypothyroidism have anemia due to some decrease in normal red blood cell mass and erythropoietin (EPO) resistance.,0.240919935470435,"One third to half of patients with hypothyroidism have <span class=""disease"" id=""19015056-2-55-61"">anemia</span> due to some decrease in normal red blood cell mass and <span class=""gene"" id=""19015056-2-117-131"">erythropoietin</span> (<span class=""gene"" id=""19015056-2-133-136"">EPO</span>) resistance.",CTD_human
64,0,Therapeutic,C0002871,Anemia,disease,anaemia,2056,EPO,erythropoietin,CTD_human,12897097,Average daily ribavirin dose was 200-800 mg. Ribavirin-induced anaemia was managed in five of seven patients with low-dose iron and erythropoietin between 4000 and 20 000 IU/week.,0.240919935470435,"Average daily ribavirin dose was 200-800 mg. Ribavirin-induced <span class=""disease"" id=""12897097-15-63-70"">anaemia</span> was managed in five of seven patients with low-dose iron and <span class=""gene"" id=""12897097-15-132-146"">erythropoietin</span> between 4000 and 20 000 IU/week.",CTD_human
64,0,Therapeutic,C0002871,Anemia,disease,anemia,2056,EPO,erythropoietin,CTD_human,17409018,"However, antiviral treatment was limited by anemia, resulting in premature withdrawal from therapy and requiring substitution with recombinant erythropoietin in most patients.",0.240919935470435,"However, antiviral treatment was limited by <span class=""disease"" id=""17409018-6-44-50"">anemia</span>, resulting in premature withdrawal from therapy and requiring substitution with recombinant <span class=""gene"" id=""17409018-6-143-157"">erythropoietin</span> in most patients.",CTD_human
64,0,Therapeutic,C0002871,Anemia,disease,anaemia,2056,EPO,Epo,CTD_human,2206997,These results suggest that rHu Epo might be useful for the therapy of anaemia associated with anticancer chemotherapy.,0.240919935470435,"These results suggest that rHu <span class=""gene"" id=""2206997-6-31-34"">Epo</span> might be useful for the therapy of <span class=""disease"" id=""2206997-6-70-77"">anaemia</span> associated with anticancer chemotherapy.",CTD_human
64,0,Therapeutic,C0002871,Anemia,disease,anaemia,2056,EPO,erythropoietin,CTD_human,16637862,Ribavirin-induced anaemia was treated with high doses of erythropoietin and low doses of iron.Blood-transfusions were not needed.,0.240919935470435,"Ribavirin-induced <span class=""disease"" id=""16637862-8-18-25"">anaemia</span> was treated with high doses of <span class=""gene"" id=""16637862-8-57-71"">erythropoietin</span> and low doses of iron.Blood-transfusions were not needed.",CTD_human
64,0,Therapeutic,C0002871,Anemia,disease,anaemia,2056,EPO,erythropoietin,CTD_human,1574960,Recombinant human erythropoietin in patients with ovarian carcinoma and anaemia secondary to cisplatin and carboplatin chemotherapy: preliminary results.,0.240919935470435,"Recombinant human <span class=""gene"" id=""1574960-0-18-32"">erythropoietin</span> in patients with ovarian carcinoma and <span class=""disease"" id=""1574960-0-72-79"">anaemia</span> secondary to cisplatin and carboplatin chemotherapy: preliminary results.",CTD_human
64,0,Biomarker,C0002871,Anemia,disease,anemia,2056,EPO,EPO,CTD_human,19015056,One third to half of patients with hypothyroidism have anemia due to some decrease in normal red blood cell mass and erythropoietin (EPO) resistance.,0.240919935470435,"One third to half of patients with hypothyroidism have <span class=""disease"" id=""19015056-2-55-61"">anemia</span> due to some decrease in normal red blood cell mass and <span class=""gene"" id=""19015056-2-117-131"">erythropoietin</span> (<span class=""gene"" id=""19015056-2-133-136"">EPO</span>) resistance.",CTD_human
64,0,Biomarker,C0002871,Anemia,disease,anaemia,2056,EPO,EPO,CTD_human,1982298,These findings indicate that the anaemia induced by gentamicin is due not only to a deficiency of EPO but also to an enhancement of fragility of erythrocytes in an azotaemic environment.,0.240919935470435,"These findings indicate that the <span class=""disease"" id=""1982298-6-33-40"">anaemia</span> induced by gentamicin is due not only to a deficiency of <span class=""gene"" id=""1982298-6-98-101"">EPO</span> but also to an enhancement of fragility of erythrocytes in an azotaemic environment.",CTD_human
64,0,Therapeutic,C0002871,Anemia,disease,anemia,2056,EPO,erythropoietin,CTD_human,7631396,"The key findings were that 1) 81 percent of centers used identical red cell transfusion criteria for HIV-infected and noninfected patients; 2) 52 percent used recombinant human erythropoietin as initial treatment for zidovudine-induced anemia, while 46 percent used recombinant human erythropoietin for anemia not associated with zidovudine; 3) 35 percent of centers used white cell-reduced blood components in lieu of cytomegalovirus (CMV)-seronegative components when administering transfusion(s) to CMV-seronegative patients; 4) 27 percent gamma-radiated cellular components, but no case of graft-versus-host disease had been observed; 5) > 85 percent of centers used monoclonal factor VIII for pediatric and adult hemophiliacs infected with HIV; 6) approximately one-third of centers routinely white cell-reduced cellular components; and 7) the most common reasons for white cell reduction included reduction of febrile reactions and CMV risk, reduction of platelet alloimmunization, and delay of immunomodulatory consequences of transfusion.",0.240919935470435,"The key findings were that 1) 81 percent of centers used identical red cell transfusion criteria for HIV-infected and noninfected patients; 2) 52 percent used recombinant human <span class=""gene"" id=""7631396-6-177-191"">erythropoietin</span> as initial treatment for zidovudine-induced <span class=""disease"" id=""7631396-6-236-242"">anemia</span>, while 46 percent used recombinant human <span class=""gene"" id=""7631396-6-284-298"">erythropoietin</span> for <span class=""disease"" id=""7631396-6-303-309"">anemia</span> not associated with zidovudine; 3) 35 percent of centers used white cell-reduced blood components in lieu of cytomegalovirus (CMV)-seronegative components when administering transfusion(s) to CMV-seronegative patients; 4) 27 percent gamma-radiated cellular components, but no case of graft-versus-host disease had been observed; 5) &gt; 85 percent of centers used monoclonal factor VIII for pediatric and adult hemophiliacs infected with HIV; 6) approximately one-third of centers routinely white cell-reduced cellular components; and 7) the most common reasons for white cell reduction included reduction of febrile reactions and CMV risk, reduction of platelet alloimmunization, and delay of immunomodulatory consequences of transfusion.",CTD_human
64,0,Therapeutic,C0002871,Anemia,disease,anemia,2056,EPO,erythropoietin,CTD_human,8504984,The use of recombinant human erythropoietin to prevent carboplatin-induced anemia.,0.240919935470435,"The use of recombinant human <span class=""gene"" id=""8504984-0-29-43"">erythropoietin</span> to prevent carboplatin-induced <span class=""disease"" id=""8504984-0-75-81"">anemia</span>.",CTD_human
64,0,Therapeutic,C0002871,Anemia,disease,anemia,2056,EPO,Epoetin,CTD_human,19212639,Optimized pro-active management of anemia by Epoetin alpha in pre-operative chemotherapy for primary breast cancer.,0.240919935470435,"Optimized pro-active management of <span class=""disease"" id=""19212639-0-35-41"">anemia</span> by <span class=""gene"" id=""19212639-0-45-52"">Epoetin</span> alpha in pre-operative chemotherapy for primary breast cancer.",CTD_human
64,0,Biomarker,C0002871,Anemia,disease,anemia,2056,EPO,erythropoietin,CTD_human,1516988,"We compared blood pressure after three different methods of partial correction of anemia in hemodialysis patients with similar baseline hematocrits (erythropoietin n = 12, intravenous iron alone n = 10, androgens n = 9).",0.240919935470435,"We compared blood pressure after three different methods of partial correction of <span class=""disease"" id=""1516988-2-82-88"">anemia</span> in hemodialysis patients with similar baseline hematocrits (<span class=""gene"" id=""1516988-2-149-163"">erythropoietin</span> n = 12, intravenous iron alone n = 10, androgens n = 9).",CTD_human
64,0,Therapeutic,C0002871,Anemia,disease,anemia,2056,EPO,erythropoietin,CTD_human,9617462,Effectiveness of weekly subcutaneous recombinant human erythropoietin administration for chemotherapy-induced anemia.,0.240919935470435,"Effectiveness of weekly subcutaneous recombinant human <span class=""gene"" id=""9617462-0-55-69"">erythropoietin</span> administration for chemotherapy-induced <span class=""disease"" id=""9617462-0-110-116"">anemia</span>.",CTD_human
64,0,Biomarker,C0002871,Anemia,disease,anemia,2056,EPO,erythropoietin,CTD_human,11981781,Treatment of ribavirin/interferon-induced anemia with erythropoietin in patients with hepatitis C.,0.240919935470435,"Treatment of ribavirin/interferon-induced <span class=""disease"" id=""11981781-0-42-48"">anemia</span> with <span class=""gene"" id=""11981781-0-54-68"">erythropoietin</span> in patients with hepatitis C.",CTD_human
64,0,Biomarker,C0002871,Anemia,disease,anemia,2056,EPO,erythropoietin,CTD_human,8202718,"Very preliminary analysis of an ongoing phase III trial studying two erythropoietin doses given continuously subcutaneously versus a retrospective analysis of a ""control group"" (drawn from historical data on the occurrence of anemia in cisplatin- and/or carboplatin-treated patients) has shown beneficial effects of erythropoietin during treatment with these platinating agents.",0.240919935470435,"Very preliminary analysis of an ongoing phase III trial studying two <span class=""gene"" id=""8202718-5-69-83"">erythropoietin</span> doses given continuously subcutaneously versus a retrospective analysis of a ""control group"" (drawn from historical data on the occurrence of <span class=""disease"" id=""8202718-5-226-232"">anemia</span> in cisplatin- and/or carboplatin-treated patients) has shown beneficial effects of <span class=""gene"" id=""8202718-5-316-330"">erythropoietin</span> during treatment with these platinating agents.",CTD_human
64,0,Biomarker,C0002871,Anemia,disease,anemia,2056,EPO,erythropoietin,CTD_human,17559739,The cost of treating ribavirin-induced anemia in hepatitis C: the impact of using recombinant human erythropoietin.,0.240919935470435,"The cost of treating ribavirin-induced <span class=""disease"" id=""17559739-0-39-45"">anemia</span> in hepatitis C: the impact of using recombinant human <span class=""gene"" id=""17559739-0-100-114"">erythropoietin</span>.",CTD_human
64,0,Biomarker,C0002871,Anemia,disease,anaemia,2056,EPO,Epo,CTD_human,2206997,These results suggest that rHu Epo might be useful for the therapy of anaemia associated with anticancer chemotherapy.,0.240919935470435,"These results suggest that rHu <span class=""gene"" id=""2206997-6-31-34"">Epo</span> might be useful for the therapy of <span class=""disease"" id=""2206997-6-70-77"">anaemia</span> associated with anticancer chemotherapy.",CTD_human
64,0,Biomarker,C0002871,Anemia,disease,anemia,2056,EPO,erythropoietin,CTD_human,16798232,Treatment with erythropoietin is effective and well tolerated in patients with esophagogastric adenocarcinoma who experience anemia during neoadjuvant chemotherapy.,0.240919935470435,"Treatment with <span class=""gene"" id=""16798232-12-15-29"">erythropoietin</span> is effective and well tolerated in patients with esophagogastric adenocarcinoma who experience <span class=""disease"" id=""16798232-12-125-131"">anemia</span> during neoadjuvant chemotherapy.",CTD_human
64,0,Therapeutic,C0002871,Anemia,disease,anemia,2056,EPO,Epo,CTD_human,16511603,"Present studies reveal that, unlike steady-state erythropoiesis, erythropoiesis during anemia depends sharply on an Epo receptor-phosphotyrosine-343-Stat5 signaling axis.",0.240919935470435,"Present studies reveal that, unlike steady-state erythropoiesis, erythropoiesis during <span class=""disease"" id=""16511603-2-87-93"">anemia</span> depends sharply on an <span class=""gene"" id=""16511603-2-116-119"">Epo</span> receptor-phosphotyrosine-343-Stat5 signaling axis.",CTD_human
64,0,Therapeutic,C0002871,Anemia,disease,anemia,2056,EPO,erythropoietin,CTD_human,16798232,Treatment with erythropoietin is effective and well tolerated in patients with esophagogastric adenocarcinoma who experience anemia during neoadjuvant chemotherapy.,0.240919935470435,"Treatment with <span class=""gene"" id=""16798232-12-15-29"">erythropoietin</span> is effective and well tolerated in patients with esophagogastric adenocarcinoma who experience <span class=""disease"" id=""16798232-12-125-131"">anemia</span> during neoadjuvant chemotherapy.",CTD_human
64,0,Biomarker,C0002871,Anemia,disease,anaemia,2056,EPO,erythropoietin,CTD_human,12713065,Normal erythropoietin response in chronic hepatitis C patients with ribavirin-induced anaemia.,0.240919935470435,"Normal <span class=""gene"" id=""12713065-0-7-21"">erythropoietin</span> response in chronic hepatitis C patients with ribavirin-induced <span class=""disease"" id=""12713065-0-86-93"">anaemia</span>.",CTD_human
64,0,Therapeutic,C0002871,Anemia,disease,anemia,2056,EPO,erythropoietin,CTD_human,17397412,Administering erythropoietin can improve anemia caused by peginterferon and ribavirin therapy and is more effective than dose reduction at improving QOL during treatment.,0.240919935470435,"Administering <span class=""gene"" id=""17397412-4-14-28"">erythropoietin</span> can improve <span class=""disease"" id=""17397412-4-41-47"">anemia</span> caused by peginterferon and ribavirin therapy and is more effective than dose reduction at improving QOL during treatment.",CTD_human
64,0,Biomarker,C0002871,Anemia,disease,anemia,2056,EPO,erythropoietin,CTD_human,10713657,"In this study, we demonstrated that anemia in cancer patients was caused by blunted erythropoietin response, rather than its quantitative deficiency.",0.240919935470435,"In this study, we demonstrated that <span class=""disease"" id=""10713657-11-36-42"">anemia</span> in cancer patients was caused by blunted <span class=""gene"" id=""10713657-11-84-98"">erythropoietin</span> response, rather than its quantitative deficiency.",CTD_human
64,0,Therapeutic,C0002871,Anemia,disease,anemias,2056,EPO,EPO,CTD_human,16949463,"Serum EPO levels in patients with chronic kidney disease are usually within the normal range and thus fail to show an appropriate increase with decreasing hemoglobin levels, as found in nonrenal anemias.",0.240919935470435,"Serum <span class=""gene"" id=""16949463-3-6-9"">EPO</span> levels in patients with chronic kidney disease are usually within the normal range and thus fail to show an appropriate increase with decreasing hemoglobin levels, as found in nonrenal <span class=""disease"" id=""16949463-3-195-202"">anemias</span>.",CTD_human
1,0,Therapeutic,C0007682,CNS disorder,group,CNS disorders,2056,EPO,erythropoietin,CTD_human,15816862,Astroglial cytoprotection by erythropoietin pre-conditioning: implications for ischemic and degenerative CNS disorders.,0.200274726784213,"Astroglial cytoprotection by <span class=""gene"" id=""15816862-0-29-43"">erythropoietin</span> pre-conditioning: implications for ischemic and degenerative <span class=""disease"" id=""15816862-0-105-118"">CNS disorders</span>.",CTD_human
1,0,Biomarker,C0018818,Ventricular Septal Defects,group,ventricular septal defect,2056,EPO,erythropoietin,CTD_human,19337937,We report the case of a 50-year-old body-builder Caucasian man with a long-standing abuse of nandrolone and erythropoietin that developed a ventricular septal defect following acute myocardial infarction.,0.2,"We report the case of a 50-year-old body-builder Caucasian man with a long-standing abuse of nandrolone and <span class=""gene"" id=""19337937-2-108-122"">erythropoietin</span> that developed a <span class=""disease"" id=""19337937-2-140-165"">ventricular septal defect</span> following acute myocardial infarction.",CTD_human
1,0,Therapeutic,C0019061,Hemolytic-Uremic Syndrome,disease,hemolytic-uremic syndrome,2056,EPO,Erythropoietin,CTD_human,12053072,Erythropoietin is beneficial in mitomycin-induced hemolytic-uremic syndrome.,0.2,"<span class=""gene"" id=""12053072-0-0-14"">Erythropoietin</span> is beneficial in mitomycin-induced <span class=""disease"" id=""12053072-0-50-75"">hemolytic-uremic syndrome</span>.",CTD_human
2,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,2056,EPO,erythropoietin,CTD_human,1516988,"It is not known whether recombinant human erythropoietin has a direct, clinically apparent pressor effect in hemodialysis patients or whether hypertension developing or aggravated in these patients merely reflects increased hematocrit.",0.202472541057918,"It is not known whether recombinant human <span class=""gene"" id=""1516988-1-42-56"">erythropoietin</span> has a direct, clinically apparent pressor effect in hemodialysis patients or whether <span class=""disease"" id=""1516988-1-142-154"">hypertension</span> developing or aggravated in these patients merely reflects increased hematocrit.",CTD_human
2,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,2056,EPO,erythropoietin,CTD_human,10694834,Role of erythropoietin in cortisol-induced hypertension.,0.202472541057918,"Role of <span class=""gene"" id=""10694834-0-8-22"">erythropoietin</span> in cortisol-induced <span class=""disease"" id=""10694834-0-43-55"">hypertension</span>.",CTD_human
1,0,Therapeutic,C0022658,Kidney Diseases,group,nephropathy,2056,EPO,EPO,CTD_human,20606417,rhEPO is involved in the pathophysiology of DXR nephropathy. rhEPO mitigated elevated plasma phosphate concentrations in an experimental model of chronic kidney disease via the expression of Klotho.,0.201923087489492,"rh<span class=""gene"" id=""20606417-12-2-5"">EPO</span> is involved in the pathophysiology of DXR <span class=""disease"" id=""20606417-12-48-59"">nephropathy</span>. rhEPO mitigated elevated plasma phosphate concentrations in an experimental model of chronic kidney disease via the expression of Klotho.",CTD_human
1,0,Biomarker,C0025202,melanoma,disease,melanoma,2056,EPO,erythropoietin,CTD_human,15743794,Functional erythropoietin autocrine loop in melanoma.,0.203557092817453,"Functional <span class=""gene"" id=""15743794-0-11-25"">erythropoietin</span> autocrine loop in <span class=""disease"" id=""15743794-0-44-52"">melanoma</span>.",CTD_human
1,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastasis,2056,EPO,epo,CTD_human,16699298,"Erythropoietin (Epo) and the epo-receptor (EpoR) have been implicated in tumor growth, invasion and metastasis.",0.20328236603324,"<span class=""gene"" id=""16699298-1-0-14"">Erythropoietin</span> (<span class=""gene"" id=""16699298-1-16-19"">Epo</span>) and the <span class=""gene"" id=""16699298-1-29-32"">epo</span>-receptor (EpoR) have been implicated in tumor growth, invasion and <span class=""disease"" id=""16699298-1-100-110"">metastasis</span>.",CTD_human
2,0,Therapeutic,C0038220,Status Epilepticus,disease,status epilepticus,2056,EPO,erythropoietin,CTD_human,17166730,Neuroprotective effects of erythropoietin in the rat hippocampus after pilocarpine-induced status epilepticus.,0.2,"Neuroprotective effects of <span class=""gene"" id=""17166730-0-27-41"">erythropoietin</span> in the rat hippocampus after pilocarpine-induced <span class=""disease"" id=""17166730-0-91-109"">status epilepticus</span>.",CTD_human
2,0,Therapeutic,C0038220,Status Epilepticus,disease,status epilepticus,2056,EPO,Erythropoietin,CTD_human,16679645,Erythropoietin preconditioning on hippocampus neuronal apoptosis following status epilepticus induced by Li-pilocarpine in rats through anti-caspase-3 expression.,0.2,"<span class=""gene"" id=""16679645-0-0-14"">Erythropoietin</span> preconditioning on hippocampus neuronal apoptosis following <span class=""disease"" id=""16679645-0-75-93"">status epilepticus</span> induced by Li-pilocarpine in rats through anti-caspase-3 expression.",CTD_human
1,0,Therapeutic,C0038358,Gastric ulcer,disease,gastric ulcer,2056,EPO,erythropoietin,CTD_human,20723003,These results support the view that erythropoietin counteracts the effects of indometacin in inducing gastric ulcer and could be used as a an antiulcer compound.,0.2,"These results support the view that <span class=""gene"" id=""20723003-9-36-50"">erythropoietin</span> counteracts the effects of indometacin in inducing <span class=""disease"" id=""20723003-9-102-115"">gastric ulcer</span> and could be used as a an antiulcer compound.",CTD_human
1,0,Therapeutic,C0040034,Thrombocytopenia,phenotype,thrombocytopenia,2056,EPO,Epo,CTD_human,8260696,Treatment with Epo (10 U for 5 times/week) stimulated hematopoietic recovery in the AZT-treated animals and reduced the severe anemia and thrombocytopenia by 3 weeks.,0.200274726784213,"Treatment with <span class=""gene"" id=""8260696-3-15-18"">Epo</span> (10 U for 5 times/week) stimulated hematopoietic recovery in the AZT-treated animals and reduced the severe anemia and <span class=""disease"" id=""8260696-3-138-154"">thrombocytopenia</span> by 3 weeks.",CTD_human
4,0,Therapeutic,C0878544,Cardiomyopathies,group,cardiomyopathy,2056,EPO,erythropoietin,CTD_human,16449733,Preventive effect of erythropoietin on cardiac dysfunction in doxorubicin-induced cardiomyopathy.,0.2,"Preventive effect of <span class=""gene"" id=""16449733-0-21-35"">erythropoietin</span> on cardiac dysfunction in doxorubicin-induced <span class=""disease"" id=""16449733-0-82-96"">cardiomyopathy</span>.",CTD_human
4,0,Therapeutic,C0878544,Cardiomyopathies,group,cardiomyopathy,2056,EPO,Erythropoietin,CTD_human,17928571,Erythropoietin protects against doxorubicin-induced cardiomyopathy via a phosphatidylinositol 3-kinase-dependent pathway.,0.2,"<span class=""gene"" id=""17928571-0-0-14"">Erythropoietin</span> protects against doxorubicin-induced <span class=""disease"" id=""17928571-0-52-66"">cardiomyopathy</span> via a phosphatidylinositol 3-kinase-dependent pathway.",CTD_human
4,0,Therapeutic,C0878544,Cardiomyopathies,group,cardiomyopathy,2056,EPO,Erythropoietin,CTD_human,16731534,Erythropoietin improves myocardial performance in doxorubicin-induced cardiomyopathy.,0.2,"<span class=""gene"" id=""16731534-0-0-14"">Erythropoietin</span> improves myocardial performance in doxorubicin-induced <span class=""disease"" id=""16731534-0-70-84"">cardiomyopathy</span>.",CTD_human
4,0,Therapeutic,C0878544,Cardiomyopathies,group,cardiomyopathy,2056,EPO,erythropoietin,CTD_human,17924179,Preventive cardioprotection of erythropoietin against doxorubicin-induced cardiomyopathy.,0.2,"Preventive cardioprotection of <span class=""gene"" id=""17924179-0-31-45"">erythropoietin</span> against doxorubicin-induced <span class=""disease"" id=""17924179-0-74-88"">cardiomyopathy</span>.",CTD_human
2,0,Therapeutic,C3463824,MYELODYSPLASTIC SYNDROME,group,myelodysplastic syndrome,2056,EPO,erythropoietin,CTD_human,16076383,Long-term erythropoietin therapy improves response in myelodysplastic syndrome.,0.20900047134440197,"Long-term <span class=""gene"" id=""16076383-0-10-24"">erythropoietin</span> therapy improves response in <span class=""disease"" id=""16076383-0-54-78"">myelodysplastic syndrome</span>.",CTD_human
1,0,Biomarker,C0025202,melanoma,disease,melanoma,2057,EPOR,Erythropoietin receptor,CTD_human,21860424,Erythropoietin receptor contributes to melanoma cell survival in vivo.,0.201098907136852,"<span class=""gene"" id=""21860424-0-0-23"">Erythropoietin receptor</span> contributes to <span class=""disease"" id=""21860424-0-39-47"">melanoma</span> cell survival in vivo.",CTD_human
2,0,Biomarker,C0001418,Adenocarcinoma,group,Adenocarcinomas,2064,ERBB2,HER2,CTD_human,21673877,HER2 Testing in Gastric/Gastroesophageal Junction Adenocarcinomas: Unique Features of a Familiar Test.,0.301983033067515,"<span class=""gene"" id=""21673877-0-0-4"">HER2</span> Testing in Gastric/Gastroesophageal Junction <span class=""disease"" id=""21673877-0-50-65"">Adenocarcinomas</span>: Unique Features of a Familiar Test.",CTD_human
1,0,Biomarker,C0007134,Renal Cell Carcinoma,disease,renal cell carcinoma,2064,ERBB2,HER-2/neu,CTD_human,10897039,HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes.,0.20412090176319603,"<span class=""gene"" id=""10897039-0-0-9"">HER-2/neu</span> is expressed in human <span class=""disease"" id=""10897039-0-32-52"">renal cell carcinoma</span> at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes.",CTD_human
1,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastatic cancer,2064,ERBB2,HER2,CTD_human,16984552,"Also, the serum HER2 level was significantly higher in bone metastatic cancer patients (14.3 +/- 6.3 ng/mL) than in non-metastatic patients (T2: 11.9 +/- 2.3 ng/mL, P = 0.003; T3: 12.2 +/- 2.8 ng/mL, P = 0.011).",0.33127356894841,"Also, the serum <span class=""gene"" id=""16984552-7-16-20"">HER2</span> level was significantly higher in bone <span class=""disease"" id=""16984552-7-60-77"">metastatic cancer</span> patients (14.3 +/- 6.3 ng/mL) than in non-metastatic patients (T2: 11.9 +/- 2.3 ng/mL, P = 0.003; T3: 12.2 +/- 2.8 ng/mL, P = 0.011).",CTD_human
40,0,Therapeutic,C1458155,Mammary Neoplasms,group,breast tumors,2064,ERBB2,HER-2,CTD_human,12655533,"HER-2 status did not correlate with pathologic or clinical response (assessed by physical examination or imaging), although a nonsignificant trend was noted toward better response in patients with breast tumors that overexpressed HER-2.",0.36962811409315205,"<span class=""gene"" id=""12655533-9-0-5"">HER-2</span> status did not correlate with pathologic or clinical response (assessed by physical examination or imaging), although a nonsignificant trend was noted toward better response in patients with <span class=""disease"" id=""12655533-9-197-210"">breast tumors</span> that overexpressed <span class=""gene"" id=""12655533-9-230-235"">HER-2</span>.",CTD_human
40,0,Biomarker,C1458155,Mammary Neoplasms,group,breast tumors,2064,ERBB2,HER-2,CTD_human,12655533,"HER-2 status did not correlate with pathologic or clinical response (assessed by physical examination or imaging), although a nonsignificant trend was noted toward better response in patients with breast tumors that overexpressed HER-2.",0.36962811409315205,"<span class=""gene"" id=""12655533-9-0-5"">HER-2</span> status did not correlate with pathologic or clinical response (assessed by physical examination or imaging), although a nonsignificant trend was noted toward better response in patients with <span class=""disease"" id=""12655533-9-197-210"">breast tumors</span> that overexpressed <span class=""gene"" id=""12655533-9-230-235"">HER-2</span>.",CTD_human
40,0,Therapeutic,C1458155,Mammary Neoplasms,group,breast tumors,2064,ERBB2,ERBB2,CTD_human,19075277,"mRNA levels of 10 BCAR genes (AKT1, AKT2, BCAR1, BCAR3, EGFR, ERBB2, GRB7, SRC, TLE3, and TRERF1) were measured in estrogen receptor-positive breast tumors using quantitative reverse-transcriptase polymerase chain reaction.",0.36962811409315205,"mRNA levels of 10 BCAR genes (AKT1, AKT2, BCAR1, BCAR3, EGFR, <span class=""gene"" id=""19075277-3-62-67"">ERBB2</span>, GRB7, SRC, TLE3, and TRERF1) were measured in estrogen receptor-positive <span class=""disease"" id=""19075277-3-142-155"">breast tumors</span> using quantitative reverse-transcriptase polymerase chain reaction.",CTD_human
40,0,Biomarker,C1458155,Mammary Neoplasms,group,breast tumors,2064,ERBB2,ERBB2,CTD_human,19075277,"mRNA levels of 10 BCAR genes (AKT1, AKT2, BCAR1, BCAR3, EGFR, ERBB2, GRB7, SRC, TLE3, and TRERF1) were measured in estrogen receptor-positive breast tumors using quantitative reverse-transcriptase polymerase chain reaction.",0.36962811409315205,"mRNA levels of 10 BCAR genes (AKT1, AKT2, BCAR1, BCAR3, EGFR, <span class=""gene"" id=""19075277-3-62-67"">ERBB2</span>, GRB7, SRC, TLE3, and TRERF1) were measured in estrogen receptor-positive <span class=""disease"" id=""19075277-3-142-155"">breast tumors</span> using quantitative reverse-transcriptase polymerase chain reaction.",CTD_human
1,0,Biomarker,C0025202,melanoma,disease,melanoma,2066,ERBB4,ERBB4,CTD_human,19718025,Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.,0.205703749933845,"Analysis of the tyrosine kinome in <span class=""disease"" id=""19718025-0-35-43"">melanoma</span> reveals recurrent mutations in <span class=""gene"" id=""19718025-0-75-80"">ERBB4</span>.",CTD_human
2,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,nonsmall cell lung cancer,2067,ERCC1,ERCC1,CTD_human,23912706,Pemetrexed downregulates ERCC1 expression and enhances cytotoxicity effected by resveratrol in human nonsmall cell lung cancer cells.,0.23949514439205702,"Pemetrexed downregulates <span class=""gene"" id=""23912706-0-25-30"">ERCC1</span> expression and enhances cytotoxicity effected by resveratrol in human <span class=""disease"" id=""23912706-0-101-126"">nonsmall cell lung cancer</span> cells.",CTD_human
2,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,non-small cell lung cancer,2067,ERCC1,ERCC1,CTD_human,21553054,Expression of ERCC1 and its clinicopathological correlations in non-small cell lung cancer.,0.23949514439205702,"Expression of <span class=""gene"" id=""21553054-0-14-19"">ERCC1</span> and its clinicopathological correlations in <span class=""disease"" id=""21553054-0-64-90"">non-small cell lung cancer</span>.",CTD_human
1,0,Biomarker,C0025202,melanoma,disease,melanoma,2067,ERCC1,Ercc1,CTD_human,21722328,Identification of DNA repair gene Ercc1 as a novel target in melanoma.,0.20591296418342803,"Identification of DNA repair gene <span class=""gene"" id=""21722328-0-34-39"">Ercc1</span> as a novel target in <span class=""disease"" id=""21722328-0-61-69"">melanoma</span>.",CTD_human
1,0,Biomarker,C0031117,Peripheral Neuropathy,group,peripheral neuropathy,2067,ERCC1,ERCC1,CTD_human,20979931,Associations between oxaliplatin-induced peripheral neuropathy and polymorphisms of the ERCC1 and GSTP1 genes.,0.202681755307501,"Associations between oxaliplatin-induced <span class=""disease"" id=""20979931-0-41-62"">peripheral neuropathy</span> and polymorphisms of the <span class=""gene"" id=""20979931-0-88-93"">ERCC1</span> and GSTP1 genes.",CTD_human
1,0,Biomarker,C2931822,Nasopharyngeal carcinoma,disease,nasopharyngeal carcinoma,2067,ERCC1,ERCC1,CTD_human,20605357,Can the analysis of ERCC1 expression contribute to individualized therapy in nasopharyngeal carcinoma?,0.201923087489492,"Can the analysis of <span class=""gene"" id=""20605357-0-20-25"">ERCC1</span> expression contribute to individualized therapy in <span class=""disease"" id=""20605357-0-77-101"">nasopharyngeal carcinoma</span>?",CTD_human
1,0,Biomarker,C0162568,Erythropoietic Protoporphyria,disease,EPP,2069,EREG,epiregulin,CTD_human,19267999,"We observed that the expression of amphiregulin, betacellulin and epiregulin was significantly increased in young EPP mice when compared to aged-matched controls in all genetic backgrounds.",0.2,"We observed that the expression of amphiregulin, betacellulin and <span class=""gene"" id=""19267999-6-66-76"">epiregulin</span> was significantly increased in young <span class=""disease"" id=""19267999-6-114-117"">EPP</span> mice when compared to aged-matched controls in all genetic backgrounds.",CTD_human
1,0,Biomarker,C0024809,Marijuana Abuse,disease,cannabis,207,AKT1,AKT1,CTD_human,21041608,"Genetic variation in AKT1 may mediate both short-term as well as longer-term effects on psychosis expression associated with use of cannabis, possibly through a mechanism of cannabinoid-regulated AKT1/GSK-3 signaling downstream of the dopamine D(2) receptor.",0.204055389228567,"Genetic variation in <span class=""gene"" id=""21041608-11-21-25"">AKT1</span> may mediate both short-term as well as longer-term effects on psychosis expression associated with use of <span class=""disease"" id=""21041608-11-132-140"">cannabis</span>, possibly through a mechanism of cannabinoid-regulated <span class=""gene"" id=""21041608-11-196-200"">AKT1</span>/GSK-3 signaling downstream of the dopamine D(2) receptor.",CTD_human
1,0,Biomarker,C0025286,Meningioma,disease,meningiomas,207,AKT1,AKT1,CTD_human,23334667,Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations.,0.401648360705279,"Genomic sequencing of <span class=""disease"" id=""23334667-0-22-33"">meningiomas</span> identifies oncogenic SMO and <span class=""gene"" id=""23334667-0-63-67"">AKT1</span> mutations.",CTD_human;HPO
1,0,Biomarker,C0028754,Obesity,disease,Obese,207,AKT1,Akt1,CTD_human,23954404,"Obese mouse ovaries had decreased Irs1, Foxo3a, Cyp2e1, MiR-103, and MiR-21 but increased Kitlg, Akt1, and miR-184 levels relative to lean littermates.",0.201923087489492,"<span class=""disease"" id=""23954404-4-0-5"">Obese</span> mouse ovaries had decreased Irs1, Foxo3a, Cyp2e1, MiR-103, and MiR-21 but increased Kitlg, <span class=""gene"" id=""23954404-4-97-101"">Akt1</span>, and miR-184 levels relative to lean littermates.",CTD_human
1,0,Biomarker,C0030193,Pain,phenotype,pain,207,AKT1,protein kinase B,CTD_human,17084039,Activation of protein kinase B/Akt in the periphery contributes to pain behavior induced by capsaicin in rats.,0.2,"Activation of <span class=""gene"" id=""17084039-0-14-30"">protein kinase B</span>/Akt in the periphery contributes to <span class=""disease"" id=""17084039-0-67-71"">pain</span> behavior induced by capsaicin in rats.",CTD_human
4,0,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,207,AKT1,AKT1,CTD_human,14745448,Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia.,0.334585725951589,"Convergent evidence for impaired <span class=""gene"" id=""14745448-0-33-37"">AKT1</span>-GSK3beta signaling in <span class=""disease"" id=""14745448-0-60-73"">schizophrenia</span>.",CTD_human
4,0,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,207,AKT1,AKT1,CTD_human,21187413,"DRD2/AKT1 interaction on D2 c-AMP independent signaling, attentional processing, and response to olanzapine treatment in schizophrenia.",0.334585725951589,"DRD2/<span class=""gene"" id=""21187413-0-5-9"">AKT1</span> interaction on D2 c-AMP independent signaling, attentional processing, and response to olanzapine treatment in <span class=""disease"" id=""21187413-0-121-134"">schizophrenia</span>.",CTD_human
4,0,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,207,AKT1,AKT1,CTD_human,17915974,Association of AKT1 gene polymorphisms with risk of schizophrenia and with response to antipsychotics in the Chinese population.,0.334585725951589,"Association of <span class=""gene"" id=""17915974-0-15-19"">AKT1</span> gene polymorphisms with risk of <span class=""disease"" id=""17915974-0-52-65"">schizophrenia</span> and with response to antipsychotics in the Chinese population.",CTD_human
4,0,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,207,AKT1,AKT1,CTD_human,15982448,"For schizophrenia, positive associations of SNPs and AKT1 haplotypes were reported in US and Japanese samples.",0.334585725951589,"For <span class=""disease"" id=""15982448-3-4-17"">schizophrenia</span>, positive associations of SNPs and <span class=""gene"" id=""15982448-3-53-57"">AKT1</span> haplotypes were reported in US and Japanese samples.",CTD_human
1,0,Biomarker,C0037286,Skin Neoplasms,group,skin tumor,207,AKT1,AKT,CTD_human,21351258,We show that skin tumor progression parallels enhanced AKT activation and increased resistance to cisplatin-induced apoptosis.,0.20054945356842604,"We show that <span class=""disease"" id=""21351258-5-13-23"">skin tumor</span> progression parallels enhanced <span class=""gene"" id=""21351258-5-55-58"">AKT</span> activation and increased resistance to cisplatin-induced apoptosis.",CTD_human
1,0,Biomarker,C0005695,Bladder Neoplasm,disease,bladder cancer,2072,ERCC4,XPF,CTD_human,20062074,Our results suggest that the XPF promoter -357A>C polymorphism may regulate the expression of XPF and thereby contribute to susceptibility to and prognosis of bladder cancer.,0.20054945356842604,"Our results suggest that the <span class=""gene"" id=""20062074-9-29-32"">XPF</span> promoter -357A&gt;C polymorphism may regulate the expression of XPF and thereby contribute to susceptibility to and prognosis of <span class=""disease"" id=""20062074-9-159-173"">bladder cancer</span>.",CTD_human
1,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,Metastases,2072,ERCC4,XPF,CTD_human,20372803,Metastases of squamous cell carcinoma of the head and neck show increased levels of nucleotide excision repair protein XPF in vivo that correlate with increased chemoresistance ex vivo.,0.2,"<span class=""disease"" id=""20372803-0-0-10"">Metastases</span> of squamous cell carcinoma of the head and neck show increased levels of nucleotide excision repair protein <span class=""gene"" id=""20372803-0-119-122"">XPF</span> in vivo that correlate with increased chemoresistance ex vivo.",CTD_human
6,1,Biomarker,C0009207,Cockayne Syndrome,disease,CS,2074,ERCC6,CSB,CTD_human,25440059,Cockayne syndrome (CS) is an accelerated aging disorder characterized by progressive neurodegeneration caused by mutations in genes encoding the DNA repair proteins CS group A or B (CSA or CSB).,0.24486048168046304,"<span class=""disease"" id=""25440059-1-0-17"">Cockayne syndrome</span> (<span class=""disease"" id=""25440059-1-19-21"">CS</span>) is an accelerated aging disorder characterized by progressive neurodegeneration caused by mutations in genes encoding the DNA repair proteins <span class=""disease"" id=""25440059-1-165-167"">CS</span> group A or B (CSA or <span class=""gene"" id=""25440059-1-189-192"">CSB</span>).",CTD_human
6,1,Biomarker,C0009207,Cockayne Syndrome,disease,CS,2074,ERCC6,ERCC6,CTD_human,22466612,"UV(S)S comprises three groups, UV(S)S/CS-A, UV(S)S/CS-B and UV(S)S-A, caused by mutations in ERCC8, ERCC6 and an unidentified gene, respectively.",0.24486048168046304,"UV(S)S comprises three groups, UV(S)S/<span class=""disease"" id=""22466612-3-38-40"">CS</span>-A, UV(S)S/<span class=""disease"" id=""22466612-3-51-53"">CS</span>-B and UV(S)S-A, caused by mutations in ERCC8, <span class=""gene"" id=""22466612-3-100-105"">ERCC6</span> and an unidentified gene, respectively.",CTD_human
6,1,Biomarker,C0009207,Cockayne Syndrome,disease,CS,2074,ERCC6,CSB,CTD_human,10739753,The abnormalities in CS are associated with mutations in the CSA or CSB genes.,0.24486048168046304,"The abnormalities in <span class=""disease"" id=""10739753-4-21-23"">CS</span> are associated with mutations in the CSA or <span class=""gene"" id=""10739753-4-68-71"">CSB</span> genes.",CTD_human
6,1,Biomarker,C0009207,Cockayne Syndrome,disease,Cockayne syndrome,2074,ERCC6,ERCC6,CTD_human,9443879,Molecular analysis of mutations in the CSB (ERCC6) gene in patients with Cockayne syndrome.,0.24486048168046304,"Molecular analysis of mutations in the <span class=""gene"" id=""9443879-0-39-42"">CSB</span> (<span class=""gene"" id=""9443879-0-44-49"">ERCC6</span>) gene in patients with <span class=""disease"" id=""9443879-0-73-90"">Cockayne syndrome</span>.",CTD_human
6,1,Biomarker,C0009207,Cockayne Syndrome,disease,Cockayne syndrome,2074,ERCC6,CSB,CTD_human,10767341,Identical mutations in the CSB gene associated with either Cockayne syndrome or the DeSanctis-cacchione variant of xeroderma pigmentosum.,0.24486048168046304,"Identical mutations in the <span class=""gene"" id=""10767341-0-27-30"">CSB</span> gene associated with either <span class=""disease"" id=""10767341-0-59-76"">Cockayne syndrome</span> or the DeSanctis-cacchione variant of xeroderma pigmentosum.",CTD_human
1,0,Biomarker,C0242383,Age related macular degeneration,disease,age-related macular degeneration,2074,ERCC6,ERCC6,CTD_human,16754848,Synergic effect of polymorphisms in ERCC6 5' flanking region and complement factor H on age-related macular degeneration predisposition.,0.208371149864029,"Synergic effect of polymorphisms in <span class=""gene"" id=""16754848-0-36-41"">ERCC6</span> 5' flanking region and complement factor H on <span class=""disease"" id=""16754848-0-88-120"">age-related macular degeneration</span> predisposition.",CTD_human
1,0,Biomarker,C1961102,Precursor Cell Lymphoblastic Leukemia Lymphoma,disease,acute lymphoblastic leukemia,2078,ERG,ERG,CTD_human,27776115,Deregulation of DUX4 and ERG in acute lymphoblastic leukemia.,0.204381273170092,"Deregulation of DUX4 and <span class=""gene"" id=""27776115-0-25-28"">ERG</span> in <span class=""disease"" id=""27776115-0-32-60"">acute lymphoblastic leukemia</span>.",CTD_human
1,0,Biomarker,C0271694,Familial partial lipodystrophy,disease,familial partial lipodystrophy,208,AKT2,AKT2,CTD_human,19793595,"Sequencing of candidate genes LMNA, PPARG, AKT2, caveolin-1, as well as the PPARG4 promoter gene, which are known to be associated with familial partial lipodystrophy, revealed no genetic abnormalities, suggesting that this case may involve a novel gene.",0.2,"Sequencing of candidate genes LMNA, PPARG, <span class=""gene"" id=""19793595-4-43-47"">AKT2</span>, caveolin-1, as well as the PPARG4 promoter gene, which are known to be associated with <span class=""disease"" id=""19793595-4-136-166"">familial partial lipodystrophy</span>, revealed no genetic abnormalities, suggesting that this case may involve a novel gene.",CTD_human
1,0,Biomarker,C1458155,Mammary Neoplasms,group,breast tumors,208,AKT2,AKT2,CTD_human,19075277,"mRNA levels of 10 BCAR genes (AKT1, AKT2, BCAR1, BCAR3, EGFR, ERBB2, GRB7, SRC, TLE3, and TRERF1) were measured in estrogen receptor-positive breast tumors using quantitative reverse-transcriptase polymerase chain reaction.",0.20546582492962803,"mRNA levels of 10 BCAR genes (AKT1, <span class=""gene"" id=""19075277-3-36-40"">AKT2</span>, BCAR1, BCAR3, EGFR, ERBB2, GRB7, SRC, TLE3, and TRERF1) were measured in estrogen receptor-positive <span class=""disease"" id=""19075277-3-142-155"">breast tumors</span> using quantitative reverse-transcriptase polymerase chain reaction.",CTD_human
3,0,Biomarker,C0004364,Autoimmune Diseases,group,autoimmune condition,2091,FBL,fibrillarin,CTD_human,19077085,"Treatment with gold in the form of aurothiomaleate, silver or mercury (Hg) in genetically susceptible mouse strains (H-2(s)) induces a systemic autoimmune condition characterized by anti-nuclear antibodies targeting the 34-kDa nucleolar protein fibrillarin, as well as lymphoproliferation and systemic immune-complex (IC) deposits.",0.200274726784213,"Treatment with gold in the form of aurothiomaleate, silver or mercury (Hg) in genetically susceptible mouse strains (H-2(s)) induces a systemic <span class=""disease"" id=""19077085-1-144-164"">autoimmune condition</span> characterized by anti-nuclear antibodies targeting the 34-kDa nucleolar protein <span class=""gene"" id=""19077085-1-245-256"">fibrillarin</span>, as well as lymphoproliferation and systemic immune-complex (IC) deposits.",CTD_human
2,0,Biomarker,C0001418,Adenocarcinoma,group,adenocarcinoma,2099,ESR1,ESR1,CTD_human,15639718,"Comparison of methylation in adenocarcinoma cell lines and tumors versus non-tumor lung tissue showed methylation of ESR1, PGR1 and RASSF1 to be significantly elevated in adenocarcinoma, with RASSF1 being most significant (P=0.0002).",0.215066906999769,"Comparison of methylation in <span class=""disease"" id=""15639718-8-29-43"">adenocarcinoma</span> cell lines and tumors versus non-tumor lung tissue showed methylation of <span class=""gene"" id=""15639718-8-117-121"">ESR1</span>, PGR1 and RASSF1 to be significantly elevated in <span class=""disease"" id=""15639718-8-171-185"">adenocarcinoma</span>, with RASSF1 being most significant (P=0.0002).",CTD_human
2,0,Biomarker,C0001418,Adenocarcinoma,group,adenocarcinomas,2099,ESR1,ESR1,CTD_human,20458558,"ESR1 gene multiple copies were confirmed in 13/60 (21.6%) breast adenocarcinomas, but high amplification only in 8/13 (62.8%).",0.215066906999769,"<span class=""gene"" id=""20458558-9-0-4"">ESR1</span> gene multiple copies were confirmed in 13/60 (21.6%) breast <span class=""disease"" id=""20458558-9-65-80"">adenocarcinomas</span>, but high amplification only in 8/13 (62.8%).",CTD_human
1,0,Biomarker,C0002395,Alzheimer's Disease,disease,Alzheimer disease,2099,ESR1,ESR1,CTD_human,17192785,"In addition to identifying the epsilon4 allele of APOE and related effects, we pinpointed over a dozen potential Alzheimer disease susceptibility genes (ACE, CHRNB2, CST3, ESR1, GAPDHS, IDE, MTHFR, NCSTN, PRNP, PSEN1, TF, TFAM and TNF) with statistically significant allelic summary odds ratios (ranging from 1.11-1.38 for risk alleles and 0.92-0.67 for protective alleles).",0.259450940155477,"In addition to identifying the epsilon4 allele of APOE and related effects, we pinpointed over a dozen potential <span class=""disease"" id=""17192785-5-113-130"">Alzheimer disease</span> susceptibility genes (ACE, CHRNB2, CST3, <span class=""gene"" id=""17192785-5-172-176"">ESR1</span>, GAPDHS, IDE, MTHFR, NCSTN, PRNP, PSEN1, TF, TFAM and TNF) with statistically significant allelic summary odds ratios (ranging from 1.11-1.38 for risk alleles and 0.92-0.67 for protective alleles).",CTD_human
1,0,Biomarker,C0004153,Atherosclerosis,disease,atherosclerosis,2099,ESR1,estrogen receptor 1,CTD_human,11894143,Coronary artery wall atherosclerosis in relation to the estrogen receptor 1 gene polymorphism: an autopsy study.,0.214558840831671,"Coronary artery wall <span class=""disease"" id=""11894143-0-21-36"">atherosclerosis</span> in relation to the <span class=""gene"" id=""11894143-0-56-75"">estrogen receptor 1</span> gene polymorphism: an autopsy study.",CTD_human
1,0,Biomarker,C0023267,Fibroid Tumor,disease,leiomyomas,2099,ESR1,ER-alpha,CTD_human,18701604,Further analysis of the DNA methylation status by bisulfite restriction mapping among 11 paired samples of myometrium and leiomyoma indicated that CpG sites in the distal region of ER-alpha promoter are hypomethylated in leiomyomas of nine patients.,0.243462722625096,"Further analysis of the DNA methylation status by bisulfite restriction mapping among 11 paired samples of myometrium and <span class=""disease"" id=""18701604-7-122-131"">leiomyoma</span> indicated that CpG sites in the distal region of <span class=""gene"" id=""18701604-7-181-189"">ER-alpha</span> promoter are hypomethylated in <span class=""disease"" id=""18701604-7-221-231"">leiomyomas</span> of nine patients.",CTD_human
2,0,Biomarker,C0024121,Lung Neoplasms,group,lung tumors,2099,ESR1,estrogen receptor,CTD_human,11872642,Aberrant CpG island methylation of the p16(INK4a) and estrogen receptor genes in rat lung tumors induced by particulate carcinogens.,0.204106546385879,"Aberrant CpG island methylation of the p16(INK4a) and <span class=""gene"" id=""11872642-0-54-71"">estrogen receptor</span> genes in rat <span class=""disease"" id=""11872642-0-85-96"">lung tumors</span> induced by particulate carcinogens.",CTD_human
1,0,Biomarker,C0027051,Myocardial Infarction,disease,MI,2099,ESR1,ESR1,CTD_human,14600184,Whether ESR1 c.454-397T>C is causally related to MI risk or in linkage disequilibrium with 1 or more causal variants remains to be determined.,0.225285862061675,"Whether <span class=""gene"" id=""14600184-11-8-12"">ESR1</span> c.454-397T&gt;C is causally related to <span class=""disease"" id=""14600184-11-49-51"">MI</span> risk or in linkage disequilibrium with 1 or more causal variants remains to be determined.",CTD_human
1,0,Biomarker,C0149931,Migraine Disorders,group,migraine,2099,ESR1,estrogen receptor 1,CTD_human,15133719,The estrogen receptor 1 G594A polymorphism is associated with migraine susceptibility in two independent case/control groups.,0.22884295487912804,"The <span class=""gene"" id=""15133719-0-4-23"">estrogen receptor 1</span> G594A polymorphism is associated with <span class=""disease"" id=""15133719-0-62-70"">migraine</span> susceptibility in two independent case/control groups.",CTD_human
11,0,Biomarker,C1458155,Mammary Neoplasms,group,breast tumors,2099,ESR1,ESR1,CTD_human,24185512,We conducted a comprehensive genetic analysis of two independent cohorts of metastatic ER-positive breast tumors and identified mutations in ESR1 affecting the ligand-binding domain (LBD) in 14 of 80 cases.,0.379256228186304,"We conducted a comprehensive genetic analysis of two independent cohorts of metastatic <span class=""gene"" id=""24185512-3-87-89"">ER</span>-positive <span class=""disease"" id=""24185512-3-99-112"">breast tumors</span> and identified mutations in <span class=""gene"" id=""24185512-3-141-145"">ESR1</span> affecting the ligand-binding domain (LBD) in 14 of 80 cases.",CTD_human
1,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,210,ALAD,ALAD,CTD_human,20123609,"The main objective is to determine the role of the aminolevulinic acid dehydratase (ALAD) gene, which encodes the main carrier protein of lead in blood, in the association between lead exposure and blood pressure (BP) and hypertension in the U.S. population.",0.202956482091714,"The main objective is to determine the role of the aminolevulinic acid dehydratase (<span class=""gene"" id=""20123609-3-84-88"">ALAD</span>) gene, which encodes the main carrier protein of lead in blood, in the association between lead exposure and blood pressure (BP) and <span class=""disease"" id=""20123609-3-222-234"">hypertension</span> in the U.S. population.",CTD_human
1,0,Biomarker,C0025286,Meningioma,disease,meningioma,210,ALAD,ALAD,CTD_human,16140629,"ALAD genotype was determined for 94% of these samples (355 glioma, 151 meningioma, 67 acoustic neuroma, and 505 controls).",0.2,"<span class=""gene"" id=""16140629-5-0-4"">ALAD</span> genotype was determined for 94% of these samples (355 glioma, 151 <span class=""disease"" id=""16140629-5-71-81"">meningioma</span>, 67 acoustic neuroma, and 505 controls).",CTD_human
1,0,Biomarker,C0014175,Endometriosis,disease,endometriosis,2100,ESR2,estrogen receptor 2,CTD_human,17625110,Promoter methylation regulates estrogen receptor 2 in human endometrium and endometriosis.,0.22938782282722198,"Promoter methylation regulates <span class=""gene"" id=""17625110-0-31-50"">estrogen receptor 2</span> in human endometrium and <span class=""disease"" id=""17625110-0-76-89"">endometriosis</span>.",CTD_human
1,0,Therapeutic,C0025149,Medulloblastoma,disease,MB,2100,ESR2,ER?,CTD_human,21351254,"We next investigated the molecular mechanisms by which estrogen might influence tumor progression and show that ER?, but not ER?, is involved in modulation of MB development by estrogens.",0.201098907136852,"We next investigated the molecular mechanisms by which estrogen might influence tumor progression and show that <span class=""gene"" id=""21351254-8-112-115"">ER&beta;</span>, but not ER&alpha;, is involved in modulation of <span class=""disease"" id=""21351254-8-159-161"">MB</span> development by estrogens.",CTD_human
6,0,Therapeutic,C0033578,Prostatic Neoplasms,group,prostate tumours,2100,ESR2,ESR2,CTD_human,26443449,The mRNA levels of PPFIBP2 and ESR2 are differentially expressed in prostate tumours and paired normal tissues.,0.22897748535341603,"The mRNA levels of PPFIBP2 and <span class=""gene"" id=""26443449-5-31-35"">ESR2</span> are differentially expressed in <span class=""disease"" id=""26443449-5-68-84"">prostate tumours</span> and paired normal tissues.",CTD_human
6,0,Biomarker,C0033578,Prostatic Neoplasms,group,prostate tumours,2100,ESR2,ESR2,CTD_human,26443449,The mRNA levels of PPFIBP2 and ESR2 are differentially expressed in prostate tumours and paired normal tissues.,0.22897748535341603,"The mRNA levels of PPFIBP2 and <span class=""gene"" id=""26443449-5-31-35"">ESR2</span> are differentially expressed in <span class=""disease"" id=""26443449-5-68-84"">prostate tumours</span> and paired normal tissues.",CTD_human
1,0,Biomarker,C0029463,Osteosarcoma,disease,osteosarcoma,2101,ESRRA,Estrogen-related receptor alpha,CTD_human,24967384,Estrogen-related receptor alpha confers methotrexate resistance via attenuation of reactive oxygen species production and P53 mediated apoptosis in osteosarcoma cells.,0.2,"<span class=""gene"" id=""24967384-0-0-31"">Estrogen-related receptor alpha</span> confers methotrexate resistance via attenuation of reactive oxygen species production and P53 mediated apoptosis in <span class=""disease"" id=""24967384-0-148-160"">osteosarcoma</span> cells.",CTD_human
2,0,Biomarker,C0033578,Prostatic Neoplasms,group,prostate tumours,2115,ETV1,ETV1,CTD_human,17671502,"We identified previously unknown 5' fusion partners in prostate tumours with ETV1 outlier expression, including untranslated regions from a prostate-specific androgen-induced gene (SLC45A3) and an endogenous retroviral element (HERV-K_22q11.23), a prostate-specific androgen-repressed gene (C15orf21), and a strongly expressed housekeeping gene (HNRPA2B1).",0.215312923029347,"We identified previously unknown 5' fusion partners in <span class=""disease"" id=""17671502-4-55-71"">prostate tumours</span> with <span class=""gene"" id=""17671502-4-77-81"">ETV1</span> outlier expression, including untranslated regions from a prostate-specific androgen-induced gene (SLC45A3) and an endogenous retroviral element (HERV-K_22q11.23), a prostate-specific androgen-repressed gene (C15orf21), and a strongly expressed housekeeping gene (HNRPA2B1).",CTD_human
1,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastasis,2118,ETV4,ETV4,CTD_human,27869830,"Inactivation of CIC relieves repression of its effector ETV4, driving ETV4-mediated upregulation of MMP24, which is necessary and sufficient for metastasis.",0.21096036061389004,"Inactivation of CIC relieves repression of its effector <span class=""gene"" id=""27869830-3-56-60"">ETV4</span>, driving <span class=""gene"" id=""27869830-3-70-74"">ETV4</span>-mediated upregulation of MMP24, which is necessary and sufficient for <span class=""disease"" id=""27869830-3-145-155"">metastasis</span>.",CTD_human
10,18,Biomarker,C0221018,Hereditary sideroblastic anemia,disease,X-linked sideroblastic anaemia,212,ALAS2,ALAS2,CTD_human,18637800,"The most frequent form is X-linked sideroblastic anaemia, caused by mutations of delta-aminolevulinic acid synthase 2 (ALAS2), the enzyme that catalyses the first and regulatory step of haem synthesis in erythroid precursors and is post-transcriptionally controlled by the iron regulatory proteins.",0.609890164231672,"The most frequent form is <span class=""disease"" id=""18637800-2-26-56"">X-linked sideroblastic anaemia</span>, caused by mutations of delta-aminolevulinic acid synthase 2 (<span class=""gene"" id=""18637800-2-119-124"">ALAS2</span>), the enzyme that catalyses the first and regulatory step of haem synthesis in erythroid precursors and is post-transcriptionally controlled by the iron regulatory proteins.",CTD_human;ORPHANET;UNIPROT
2,2,Biomarker,C0040034,Thrombocytopenia,phenotype,thrombocytopenia,2120,ETV6,ETV6,CTD_human,25581430,Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy.,0.40082418035263895,"Germline <span class=""gene"" id=""25581430-0-9-13"">ETV6</span> mutations in familial <span class=""disease"" id=""25581430-0-36-52"">thrombocytopenia</span> and hematologic malignancy.",CTD_human;HPO
2,2,Biomarker,C0040034,Thrombocytopenia,phenotype,thrombocytopenia,2120,ETV6,ETV6,CTD_human,25807284,"Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia.",0.40082418035263895,"Germline mutations in <span class=""gene"" id=""25807284-0-22-26"">ETV6</span> are associated with <span class=""disease"" id=""25807284-0-47-63"">thrombocytopenia</span>, red cell macrocytosis and predisposition to lymphoblastic leukemia.",CTD_human;HPO
1,3,Biomarker,C0376545,Hematologic Neoplasms,group,hematologic malignancy,2120,ETV6,ETV6,CTD_human,25581430,Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy.,0.20741762317375398,"Germline <span class=""gene"" id=""25581430-0-9-13"">ETV6</span> mutations in familial thrombocytopenia and <span class=""disease"" id=""25581430-0-57-79"">hematologic malignancy</span>.",CTD_human
1,0,Biomarker,C0006111,Brain Diseases,group,encephalopathy,213,ALB,Albumin,CTD_human,15923801,"Albumin was significantly lower among those patients who experienced encephalopathy, whereas age, creatinine, and ifosfamide dose were not significantly different between the 2 groups.",0.200274726784213,"<span class=""gene"" id=""15923801-16-0-7"">Albumin</span> was significantly lower among those patients who experienced <span class=""disease"" id=""15923801-16-69-83"">encephalopathy</span>, whereas age, creatinine, and ifosfamide dose were not significantly different between the 2 groups.",CTD_human
8,0,Biomarker,C0017658,Glomerulonephritis,disease,glomerulonephritis,213,ALB,serum albumin,CTD_human,18462998,Deletion of IL-18 receptor ameliorates renal injury in bovine serum albumin-induced glomerulonephritis.,0.20082418035263896,"Deletion of IL-18 receptor ameliorates renal injury in bovine <span class=""gene"" id=""18462998-0-62-75"">serum albumin</span>-induced <span class=""disease"" id=""18462998-0-84-102"">glomerulonephritis</span>.",CTD_human
8,0,Biomarker,C0017658,Glomerulonephritis,disease,glomerulonephritis,213,ALB,serum albumin,CTD_human,6769622,"The binding of polymorphonuclear leucocytes (PMN) to the glomeruli of rats in which glomerulonephritis had been induced by bovine serum albumin, suggested a biological activity of the immune complexes localized in the glomeruli.",0.20082418035263896,"The binding of polymorphonuclear leucocytes (PMN) to the glomeruli of rats in which <span class=""disease"" id=""6769622-1-84-102"">glomerulonephritis</span> had been induced by bovine <span class=""gene"" id=""6769622-1-130-143"">serum albumin</span>, suggested a biological activity of the immune complexes localized in the glomeruli.",CTD_human
8,0,Biomarker,C0017658,Glomerulonephritis,disease,glomerulonephritis,213,ALB,Serum Albumin,CTD_human,17161813,The effect of APS on glomerulonephritis rats induced by cationic Bovine Serum Albumin(C-BSA) was evaluated by flow cytometry using Nuclear Transcription Factor-kappaB (NF-kappaB) as marker.,0.20082418035263896,"The effect of APS on <span class=""disease"" id=""17161813-3-21-39"">glomerulonephritis</span> rats induced by cationic Bovine <span class=""gene"" id=""17161813-3-72-85"">Serum Albumin</span>(C-BSA) was evaluated by flow cytometry using Nuclear Transcription Factor-kappaB (NF-kappaB) as marker.",CTD_human
6,0,Biomarker,C0017665,Membranous glomerulonephritis,disease,membranous nephropathy,213,ALB,serum albumin,CTD_human,15385633,Mouse model of membranous nephropathy induced by cationic bovine serum albumin: antigen dose-response relations and strain differences.,0.201648360705279,"Mouse model of <span class=""disease"" id=""15385633-0-15-37"">membranous nephropathy</span> induced by cationic bovine <span class=""gene"" id=""15385633-0-65-78"">serum albumin</span>: antigen dose-response relations and strain differences.",CTD_human
6,0,Biomarker,C0017665,Membranous glomerulonephritis,disease,membranous glomerulonephritis,213,ALB,serum albumin,CTD_human,1342223,These data show that rats with membranous glomerulonephritis induced by cationic bovine serum albumin presented an increased macromolecule uptake by the glomerular mesangium.,0.201648360705279,"These data show that rats with <span class=""disease"" id=""1342223-9-31-60"">membranous glomerulonephritis</span> induced by cationic bovine <span class=""gene"" id=""1342223-9-88-101"">serum albumin</span> presented an increased macromolecule uptake by the glomerular mesangium.",CTD_human
6,0,Biomarker,C0017665,Membranous glomerulonephritis,disease,Membranous nephropathy,213,ALB,serum albumin,CTD_human,11938814,Membranous nephropathy model was induced by cationized bovine serum albumin intravenous administration in rats for 7 weeks and developed to CRF.,0.201648360705279,"<span class=""disease"" id=""11938814-2-0-22"">Membranous nephropathy</span> model was induced by cationized bovine <span class=""gene"" id=""11938814-2-62-75"">serum albumin</span> intravenous administration in rats for 7 weeks and developed to CRF.",CTD_human
6,0,Biomarker,C0017665,Membranous glomerulonephritis,disease,membranous glomerulonephritis,213,ALB,serum albumin,CTD_human,9794552,Effects of FK506 on experimental membranous glomerulonephritis induced by cationized bovine serum albumin in rats.,0.201648360705279,"Effects of FK506 on experimental <span class=""disease"" id=""9794552-0-33-62"">membranous glomerulonephritis</span> induced by cationized bovine <span class=""gene"" id=""9794552-0-92-105"">serum albumin</span> in rats.",CTD_human
6,0,Biomarker,C0017665,Membranous glomerulonephritis,disease,membranous nephropathy,213,ALB,serum albumin,CTD_human,17622271,Kinetics of adaptive immunity to cationic bovine serum albumin-induced membranous nephropathy.,0.201648360705279,"Kinetics of adaptive immunity to cationic bovine <span class=""gene"" id=""17622271-0-49-62"">serum albumin</span>-induced <span class=""disease"" id=""17622271-0-71-93"">membranous nephropathy</span>.",CTD_human
6,0,Biomarker,C0017665,Membranous glomerulonephritis,disease,membranous nephropathy,213,ALB,serum albumin,CTD_human,12776520,"The rabbit membranous nephropathy model was induced by cationic bovine serum albumin, and the immunity of mice together with urine volume and haemorheological property of rats were also estimated.",0.201648360705279,"The rabbit <span class=""disease"" id=""12776520-2-11-33"">membranous nephropathy</span> model was induced by cationic bovine <span class=""gene"" id=""12776520-2-71-84"">serum albumin</span>, and the immunity of mice together with urine volume and haemorheological property of rats were also estimated.",CTD_human
1,0,Biomarker,C0019693,HIV Infections,group,HIV infection,213,ALB,serum albumin,CTD_human,16903978,"We conclude that, in developing countries where many patients may not be able to afford to pay for CD4 cell counts and viral load tests, which are the traditional markers for HIV disease, serum albumin would be a very useful surrogate test for predicting severity of HIV infection and for clinical monitoring of response to antiretroviral therapy.",0.2,"We conclude that, in developing countries where many patients may not be able to afford to pay for CD4 cell counts and viral load tests, which are the traditional markers for <span class=""disease"" id=""16903978-9-175-186"">HIV disease</span>, <span class=""gene"" id=""16903978-9-188-201"">serum albumin</span> would be a very useful surrogate test for predicting severity of <span class=""disease"" id=""16903978-9-267-280"">HIV infection</span> and for clinical monitoring of response to antiretroviral therapy.",CTD_human
8,0,Biomarker,C0022658,Kidney Diseases,group,nephropathy,213,ALB,serum albumin,CTD_human,350256,Bovine serum albumin chronic serum sickness nephropathy in rats.,0.21535598916129897,"Bovine <span class=""gene"" id=""350256-0-7-20"">serum albumin</span> chronic serum sickness <span class=""disease"" id=""350256-0-44-55"">nephropathy</span> in rats.",CTD_human
1,0,Biomarker,C0022661,"Kidney Failure, Chronic",disease,CRF,213,ALB,serum albumin,CTD_human,11938814,Membranous nephropathy model was induced by cationized bovine serum albumin intravenous administration in rats for 7 weeks and developed to CRF.,0.20357144819477,"Membranous nephropathy model was induced by cationized bovine <span class=""gene"" id=""11938814-2-62-75"">serum albumin</span> intravenous administration in rats for 7 weeks and developed to <span class=""disease"" id=""11938814-2-140-143"">CRF</span>.",CTD_human
2,0,Biomarker,C0023890,Liver Cirrhosis,disease,liver cirrhosis,213,ALB,albumin,CTD_human,21851314,This study aimed to assess IMA and IMAR as a liver function test and to investigate whether albumin infusion changes IMAR in patients with liver cirrhosis.,0.20412090176319603,"This study aimed to assess IMA and IMAR as a liver function test and to investigate whether <span class=""gene"" id=""21851314-3-92-99"">albumin</span> infusion changes IMAR in patients with <span class=""disease"" id=""21851314-3-139-154"">liver cirrhosis</span>.",CTD_human
3,0,Biomarker,C0025290,Aseptic Meningitis,disease,Aseptic meningitis,213,ALB,serum albumin,CTD_human,5109917,Aseptic meningitis following intrathecal radioiodinated serum albumin.,0.2,"<span class=""disease"" id=""5109917-0-0-18"">Aseptic meningitis</span> following intrathecal radioiodinated <span class=""gene"" id=""5109917-0-56-69"">serum albumin</span>.",CTD_human
3,0,Biomarker,C0025290,Aseptic Meningitis,disease,Aseptic meningitis,213,ALB,serum albumin,CTD_human,5536438,Aseptic meningitis following the intrathecal injection of radioiodinated serum albumin.,0.2,"<span class=""disease"" id=""5536438-0-0-18"">Aseptic meningitis</span> following the intrathecal injection of radioiodinated <span class=""gene"" id=""5536438-0-73-86"">serum albumin</span>.",CTD_human
6,0,Biomarker,C0027697,Nephritis,disease,nephritis,213,ALB,serum albumin,CTD_human,2945356,"The distribution of heparan sulfate proteoglycan (HS-PG) was examined electron microscopically by the high iron diamine (HID) method in puromycin aminonucleoside (PAN) nephrosis, accelerated Masugi nephritis (NTN), and serum sickness nephritis induced by bovine serum albumin (BSA nephritis) in the rat.",0.2,"The distribution of heparan sulfate proteoglycan (HS-PG) was examined electron microscopically by the high iron diamine (HID) method in puromycin aminonucleoside (PAN) nephrosis, accelerated Masugi nephritis (NTN), and serum sickness <span class=""disease"" id=""2945356-1-234-243"">nephritis</span> induced by bovine <span class=""gene"" id=""2945356-1-262-275"">serum albumin</span> (BSA <span class=""disease"" id=""2945356-1-281-290"">nephritis</span>) in the rat.",CTD_human
6,0,Biomarker,C0027697,Nephritis,disease,nephritis,213,ALB,serum albumin,CTD_human,4065304,Sections of rat kidney with bovine serum albumin nephritis were incubated either with a single component of complement or with several components in sequence and then reacted with granulocytes.,0.2,"Sections of rat kidney with bovine <span class=""gene"" id=""4065304-1-35-48"">serum albumin</span> <span class=""disease"" id=""4065304-1-49-58"">nephritis</span> were incubated either with a single component of complement or with several components in sequence and then reacted with granulocytes.",CTD_human
6,0,Biomarker,C0027697,Nephritis,disease,nephritis,213,ALB,serum albumin,CTD_human,3656695,[Suppressive effect of mizoribine on progression of bovine serum albumin nephritis in mice].,0.2,"[Suppressive effect of mizoribine on progression of bovine <span class=""gene"" id=""3656695-0-59-72"">serum albumin</span> <span class=""disease"" id=""3656695-0-73-82"">nephritis</span> in mice].",CTD_human
1,0,Biomarker,C0027720,Nephrosis,disease,nephrosis,213,ALB,albumin,CTD_human,3301049,"Following stimulation of albumin synthesis by the induction of nephrosis, albumin mRNA was detected in the cytoplasm of the hepatocytes.",0.200274726784213,"Following stimulation of <span class=""gene"" id=""3301049-8-25-32"">albumin</span> synthesis by the induction of <span class=""disease"" id=""3301049-8-63-72"">nephrosis</span>, <span class=""gene"" id=""3301049-8-74-81"">albumin</span> mRNA was detected in the cytoplasm of the hepatocytes.",CTD_human
2,0,Biomarker,C0027726,Nephrotic Syndrome,group,NS,213,ALB,albumin,CTD_human,17178036,Nephrotic syndrome (NS) is characterized by marked urinary excretion of albumin and other intermediated-size plasma proteins such as transferrin.,0.201098907136852,"<span class=""disease"" id=""17178036-1-0-18"">Nephrotic syndrome</span> (<span class=""disease"" id=""17178036-1-20-22"">NS</span>) is characterized by marked urinary excretion of <span class=""gene"" id=""17178036-1-72-79"">albumin</span> and other intermediated-size plasma proteins such as transferrin.",CTD_human
1,0,Biomarker,C0030305,Pancreatitis,disease,pancreatitis,213,ALB,albumin,CTD_human,17169977,"To determine whether the comparable human albumin fragment could be detected in sera from pancreatitis patients, we analyzed sera from normal individuals and from patients with diabetes, vasculitis, pancreatic cancer, and pancreatitis.",0.2,"To determine whether the comparable human <span class=""gene"" id=""17169977-9-42-49"">albumin</span> fragment could be detected in sera from <span class=""disease"" id=""17169977-9-90-102"">pancreatitis</span> patients, we analyzed sera from normal individuals and from patients with diabetes, vasculitis, pancreatic cancer, and <span class=""disease"" id=""17169977-9-222-234"">pancreatitis</span>.",CTD_human
2,0,Biomarker,C0036830,Serum Sickness,disease,serum sickness,213,ALB,serum albumin,CTD_human,350256,Bovine serum albumin chronic serum sickness nephropathy in rats.,0.2,"Bovine <span class=""gene"" id=""350256-0-7-20"">serum albumin</span> chronic <span class=""disease"" id=""350256-0-29-43"">serum sickness</span> nephropathy in rats.",CTD_human
1,0,Therapeutic,C0038325,Stevens-Johnson Syndrome,disease,Stevens-Johnson syndrome,213,ALB,albumin,CTD_human,12239465,"Her hepatic failure and symptoms of Stevens-Johnson syndrome were successfully treated with intravenous prednisolone and infusion of fresh-frozen plasma or albumin, as the occasion demanded.",0.2,"Her hepatic failure and symptoms of <span class=""disease"" id=""12239465-2-36-60"">Stevens-Johnson syndrome</span> were successfully treated with intravenous prednisolone and infusion of fresh-frozen plasma or <span class=""gene"" id=""12239465-2-156-163"">albumin</span>, as the occasion demanded.",CTD_human
4,0,Biomarker,C0038454,Cerebrovascular accident,group,Stroke,213,ALB,ALB,CTD_human,16809570,"After adjusting for the tPA effect, the probability of good outcome (defined as modified Rankin Scale 0 to 1 or NIH Stroke Scale 0 to 1 at 3 months) at the highest three ALB doses was 81% greater than in the lower dose-tiers (relative risk [RR], 1.81; 95% confidence interval [CI], 1.11 to 2.94) and was 95% greater than in the comparable NINDS rt-PA Stroke Study cohort (RR, 1.95; 95% CI, 1.47 to 2.57).",0.20054945356842604,"After adjusting for the tPA effect, the probability of good outcome (defined as modified Rankin Scale 0 to 1 or NIH <span class=""disease"" id=""16809570-9-116-122"">Stroke</span> Scale 0 to 1 at 3 months) at the highest three <span class=""gene"" id=""16809570-9-170-173"">ALB</span> doses was 81% greater than in the lower dose-tiers (relative risk [RR], 1.81; 95% confidence interval [CI], 1.11 to 2.94) and was 95% greater than in the comparable NINDS rt-PA <span class=""disease"" id=""16809570-9-351-357"">Stroke</span> Study cohort (RR, 1.95; 95% CI, 1.47 to 2.57).",CTD_human
4,0,Therapeutic,C0038454,Cerebrovascular accident,group,Stroke,213,ALB,ALB,CTD_human,16809570,"After adjusting for the tPA effect, the probability of good outcome (defined as modified Rankin Scale 0 to 1 or NIH Stroke Scale 0 to 1 at 3 months) at the highest three ALB doses was 81% greater than in the lower dose-tiers (relative risk [RR], 1.81; 95% confidence interval [CI], 1.11 to 2.94) and was 95% greater than in the comparable NINDS rt-PA Stroke Study cohort (RR, 1.95; 95% CI, 1.47 to 2.57).",0.20054945356842604,"After adjusting for the tPA effect, the probability of good outcome (defined as modified Rankin Scale 0 to 1 or NIH <span class=""disease"" id=""16809570-9-116-122"">Stroke</span> Scale 0 to 1 at 3 months) at the highest three <span class=""gene"" id=""16809570-9-170-173"">ALB</span> doses was 81% greater than in the lower dose-tiers (relative risk [RR], 1.81; 95% confidence interval [CI], 1.11 to 2.94) and was 95% greater than in the comparable NINDS rt-PA <span class=""disease"" id=""16809570-9-351-357"">Stroke</span> Study cohort (RR, 1.95; 95% CI, 1.47 to 2.57).",CTD_human
4,0,Biomarker,C0038454,Cerebrovascular accident,group,stroke,213,ALB,serum albumin,CTD_human,14514741,"After adjustment for age and other patient characteristics, three markers of malnutrition were associated with the risk of stroke-serum albumin (per 1 g/dl decrease, hazard ratio [HR] = 1.43), height-adjusted body weight (per 25% decrease, HR = 1.09), and a subjective assessment of undernourishment (HR = 1.27)-as was higher mean BP (per 10 mmHg, HR = 1.11).",0.20054945356842604,"After adjustment for age and other patient characteristics, three markers of malnutrition were associated with the risk of <span class=""disease"" id=""14514741-8-123-129"">stroke</span>-<span class=""gene"" id=""14514741-8-130-143"">serum albumin</span> (per 1 g/dl decrease, hazard ratio [HR] = 1.43), height-adjusted body weight (per 25% decrease, HR = 1.09), and a subjective assessment of undernourishment (HR = 1.27)-as was higher mean BP (per 10 mmHg, HR = 1.11).",CTD_human
4,0,Therapeutic,C0038454,Cerebrovascular accident,group,stroke,213,ALB,serum albumin,CTD_human,14514741,"After adjustment for age and other patient characteristics, three markers of malnutrition were associated with the risk of stroke-serum albumin (per 1 g/dl decrease, hazard ratio [HR] = 1.43), height-adjusted body weight (per 25% decrease, HR = 1.09), and a subjective assessment of undernourishment (HR = 1.27)-as was higher mean BP (per 10 mmHg, HR = 1.11).",0.20054945356842604,"After adjustment for age and other patient characteristics, three markers of malnutrition were associated with the risk of <span class=""disease"" id=""14514741-8-123-129"">stroke</span>-<span class=""gene"" id=""14514741-8-130-143"">serum albumin</span> (per 1 g/dl decrease, hazard ratio [HR] = 1.43), height-adjusted body weight (per 25% decrease, HR = 1.09), and a subjective assessment of undernourishment (HR = 1.27)-as was higher mean BP (per 10 mmHg, HR = 1.11).",CTD_human
1,0,Biomarker,C0042109,Urticaria,disease,Urticaria,213,ALB,serum albumin,CTD_human,8458210,Urticaria and angioedema during insemination with fluid containing bovine serum albumin.,0.2,"<span class=""disease"" id=""8458210-0-0-9"">Urticaria</span> and angioedema during insemination with fluid containing bovine <span class=""gene"" id=""8458210-0-74-87"">serum albumin</span>.",CTD_human
2,0,Biomarker,C0162557,"Liver Failure, Acute",disease,acute liver failure,213,ALB,albumin,CTD_human,16750869,Lactate was increased and albumin was decreased in patients with acute liver failure compared to healthy controls resulting in normal net metabolic acid-base state.,0.20054945356842604,"Lactate was increased and <span class=""gene"" id=""16750869-6-26-33"">albumin</span> was decreased in patients with <span class=""disease"" id=""16750869-6-65-84"">acute liver failure</span> compared to healthy controls resulting in normal net metabolic acid-base state.",CTD_human
2,0,Therapeutic,C0162557,"Liver Failure, Acute",disease,acute liver failure,213,ALB,albumin,CTD_human,16750869,Lactate was increased and albumin was decreased in patients with acute liver failure compared to healthy controls resulting in normal net metabolic acid-base state.,0.20054945356842604,"Lactate was increased and <span class=""gene"" id=""16750869-6-26-33"">albumin</span> was decreased in patients with <span class=""disease"" id=""16750869-6-65-84"">acute liver failure</span> compared to healthy controls resulting in normal net metabolic acid-base state.",CTD_human
2,0,Therapeutic,C0162557,"Liver Failure, Acute",disease,acute liver failure,213,ALB,albumin,CTD_human,18609519,Acetaminophen-induced acute liver failure treated with single-pass albumin dialysis: report of a case.,0.20054945356842604,"Acetaminophen-induced <span class=""disease"" id=""18609519-0-22-41"">acute liver failure</span> treated with single-pass <span class=""gene"" id=""18609519-0-67-74"">albumin</span> dialysis: report of a case.",CTD_human
2,0,Biomarker,C0162557,"Liver Failure, Acute",disease,acute liver failure,213,ALB,albumin,CTD_human,18609519,Acetaminophen-induced acute liver failure treated with single-pass albumin dialysis: report of a case.,0.20054945356842604,"Acetaminophen-induced <span class=""disease"" id=""18609519-0-22-41"">acute liver failure</span> treated with single-pass <span class=""gene"" id=""18609519-0-67-74"">albumin</span> dialysis: report of a case.",CTD_human
4,2,Biomarker,C0342185,"Hyperthyroxinemia, Familial Dysalbuminemic",disease,familial dysalbuminemic hyperthyroxinemia,213,ALB,albumin,CTD_human,8048949,An identical missense mutation in the albumin gene results in familial dysalbuminemic hyperthyroxinemia in 8 unrelated families.,0.40879125709481895,"An identical missense mutation in the <span class=""gene"" id=""8048949-0-38-45"">albumin</span> gene results in <span class=""disease"" id=""8048949-0-62-103"">familial dysalbuminemic hyperthyroxinemia</span> in 8 unrelated families.",CTD_human;UNIPROT
4,2,Biomarker,C0342185,"Hyperthyroxinemia, Familial Dysalbuminemic",disease,familial dysalbuminaemic hyperthyroxinaemia,213,ALB,serum albumin,CTD_human,8064810,A point mutation in the human serum albumin gene results in familial dysalbuminaemic hyperthyroxinaemia.,0.40879125709481895,"A point mutation in the human <span class=""gene"" id=""8064810-0-30-43"">serum albumin</span> gene results in <span class=""disease"" id=""8064810-0-60-103"">familial dysalbuminaemic hyperthyroxinaemia</span>.",CTD_human;UNIPROT
4,2,Biomarker,C0342185,"Hyperthyroxinemia, Familial Dysalbuminemic",disease,familial dysalbuminemic hyperthyroxinemia,213,ALB,albumin,CTD_human,9329347,A novel missense mutation in codon 218 of the albumin gene in a distinct phenotype of familial dysalbuminemic hyperthyroxinemia in a Japanese kindred.,0.40879125709481895,"A novel missense mutation in codon 218 of the <span class=""gene"" id=""9329347-0-46-53"">albumin</span> gene in a distinct phenotype of <span class=""disease"" id=""9329347-0-86-127"">familial dysalbuminemic hyperthyroxinemia</span> in a Japanese kindred.",CTD_human;UNIPROT
1,0,Biomarker,C0206663,"Neuroectodermal Tumor, Primitive",disease,Primitive neuroectodermal tumor,2130,EWSR1,EWS-FLI1,CTD_human,12162413,Primitive neuroectodermal tumor of the transverse colonic mesentery defined by the presence of EWS-FLI1 chimeric mRNA in a Japanese woman.,0.20851653031060602,"<span class=""disease"" id=""12162413-0-0-31"">Primitive neuroectodermal tumor</span> of the transverse colonic mesentery defined by the presence of <span class=""gene"" id=""12162413-0-95-103"">EWS-FLI1</span> chimeric mRNA in a Japanese woman.",CTD_human
3,0,Biomarker,C0553580,Ewings sarcoma,disease,Ewing sarcoma,2130,EWSR1,EWSR1,CTD_human,26214589,Chimeric EWSR1-FLI1 regulates the Ewing sarcoma susceptibility gene EGR2 via a GGAA microsatellite.,0.68,"Chimeric <span class=""gene"" id=""26214589-0-9-14"">EWSR1</span>-FLI1 regulates the <span class=""disease"" id=""26214589-0-34-47"">Ewing sarcoma</span> susceptibility gene EGR2 via a GGAA microsatellite.",CTD_human;HPO;ORPHANET
3,0,Biomarker,C0553580,Ewings sarcoma,disease,Ewing sarcoma,2130,EWSR1,EWS/Fli1,CTD_human,27006472,Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1.,0.68,"Targeting the epigenetic readers in <span class=""disease"" id=""27006472-0-36-49"">Ewing sarcoma</span> inhibits the oncogenic transcription factor <span class=""gene"" id=""27006472-0-94-102"">EWS/Fli1</span>.",CTD_human;HPO;ORPHANET
3,0,Biomarker,C0553580,Ewings sarcoma,disease,ES,2130,EWSR1,EWS,CTD_human,16646077,"Ewing sarcoma (ES), a highly malignant pediatric tumor, is consistently associated with translocations that fuse the EWS gene with a member of the ETS family gene, most commonly FLI-1.",0.68,"<span class=""disease"" id=""16646077-1-0-13"">Ewing sarcoma</span> (<span class=""disease"" id=""16646077-1-15-17"">ES</span>), a highly malignant pediatric tumor, is consistently associated with translocations that fuse the <span class=""gene"" id=""16646077-1-117-120"">EWS</span> gene with a member of the ETS family gene, most commonly FLI-1.",CTD_human;HPO;ORPHANET
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,2131,EXT1,EXT1,CTD_human,12032595,Association of autism in two patients with hereditary multiple exostoses caused by novel deletion mutations of EXT1.,0.28300763924902694,"Association of <span class=""disease"" id=""12032595-0-15-21"">autism</span> in two patients with hereditary multiple exostoses caused by novel deletion mutations of <span class=""gene"" id=""12032595-0-111-115"">EXT1</span>.",CTD_human
8,5,Biomarker,C0015306,Hereditary Multiple Exostoses,disease,MO,2131,EXT1,Ext1,CTD_human,20080592,"Mice heterozygous for Ext1 or Ext2, modeling the human genotypes that cause MO, occasionally develop solitary osteochondroma-like structures on ribs [Lin et al.",0.7383588958869008,"Mice heterozygous for <span class=""gene"" id=""20080592-3-22-26"">Ext1</span> or Ext2, modeling the human genotypes that cause <span class=""disease"" id=""20080592-3-76-78"">MO</span>, occasionally develop solitary osteochondroma-like structures on ribs [Lin et al.",CTD_human;HPO;ORPHANET;UNIPROT
8,5,Biomarker,C0015306,Hereditary Multiple Exostoses,disease,multiple osteochondromas,2131,EXT1,EXT1,CTD_human,23439489,Mutations in the EXT1 and EXT2 genes in Spanish patients with multiple osteochondromas.,0.7383588958869008,"Mutations in the <span class=""gene"" id=""23439489-0-17-21"">EXT1</span> and EXT2 genes in Spanish patients with <span class=""disease"" id=""23439489-0-62-86"">multiple osteochondromas</span>.",CTD_human;HPO;ORPHANET;UNIPROT
1,0,Biomarker,C0015306,Hereditary Multiple Exostoses,disease,multiple osteochondromas,2132,EXT2,EXT2,CTD_human,23439489,Mutations in the EXT1 and EXT2 genes in Spanish patients with multiple osteochondromas.,0.641541313867228,"Mutations in the EXT1 and <span class=""gene"" id=""23439489-0-26-30"">EXT2</span> genes in Spanish patients with <span class=""disease"" id=""23439489-0-62-86"">multiple osteochondromas</span>.",CTD_human;HPO;ORPHANET
1,0,Biomarker,C0018777,Conductive hearing loss,disease,conductive hearing loss,2138,EYA1,Eya1,CTD_human,10471511,"Eya1 heterozygotes show renal abnormalities and a conductive hearing loss similar to BOR syndrome, whereas Eya1 homozygotes lack ears and kidneys due to defective inductive tissue interactions and apoptotic regression of the organ primordia.",0.40027472678421294,"<span class=""gene"" id=""10471511-3-0-4"">Eya1</span> heterozygotes show renal abnormalities and a <span class=""disease"" id=""10471511-3-50-73"">conductive hearing loss</span> similar to BOR syndrome, whereas <span class=""gene"" id=""10471511-3-107-111"">Eya1</span> homozygotes lack ears and kidneys due to defective inductive tissue interactions and apoptotic regression of the organ primordia.",CTD_human;HPO
7,19,Biomarker,C0265234,Branchio-Oto-Renal Syndrome,disease,BOR syndrome,2138,EYA1,Eya 1,CTD_human,12834866,"Interestingly, these Six1 defects are very similar to phenotypes caused by mutations of Eya 1, which are responsible for the BOR syndrome in humans.",0.7054778140452321,"Interestingly, these Six1 defects are very similar to phenotypes caused by mutations of <span class=""gene"" id=""12834866-7-88-93"">Eya 1</span>, which are responsible for the <span class=""disease"" id=""12834866-7-125-137"">BOR syndrome</span> in humans.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0376634,Craniofacial Abnormalities,group,craniofacial abnormalities,2138,EYA1,EYA1,CTD_human,10471511,"Haploinsufficiency for human EYA1, a homologue of the Drosophila melanogaster gene eyes absent (eya), results in the dominantly inherited disorders branchio-oto-renal (BOR) syndrome and branchio-oto (BO) syndrome, which are characterized by craniofacial abnormalities and hearing loss with (BOR) or without (BO) kidney defects.",0.200274726784213,"Haploinsufficiency for human <span class=""gene"" id=""10471511-1-29-33"">EYA1</span>, a homologue of the Drosophila melanogaster gene eyes absent (eya), results in the dominantly inherited disorders branchio-oto-renal (BOR) syndrome and branchio-oto (BO) syndrome, which are characterized by <span class=""disease"" id=""10471511-1-241-267"">craniofacial abnormalities</span> and hearing loss with (BOR) or without (BO) kidney defects.",CTD_human
1,0,Biomarker,C0431406,Asymmetric crying face association,disease,cardiofacial syndrome,2138,EYA1,EYA1,CTD_human,15493068,EYA1 mutation in a newborn female presenting with cardiofacial syndrome.,0.200274726784213,"<span class=""gene"" id=""15493068-0-0-4"">EYA1</span> mutation in a newborn female presenting with <span class=""disease"" id=""15493068-0-50-71"">cardiofacial syndrome</span>.",CTD_human
1,0,Biomarker,C0001815,Primary Myelofibrosis,disease,myelofibrosis,2146,EZH2,EZH2,CTD_human,20601953,"Screening of a total of 614 individuals with myeloid disorders revealed 49 monoallelic or biallelic EZH2 mutations in 42 individuals; the mutations were found most commonly in those with myelodysplastic/myeloproliferative neoplasms (27 out of 219 individuals, or 12%) and in those with myelofibrosis (4 out of 30 individuals, or 13%).",0.200274726784213,"Screening of a total of 614 individuals with myeloid disorders revealed 49 monoallelic or biallelic <span class=""gene"" id=""20601953-3-100-104"">EZH2</span> mutations in 42 individuals; the mutations were found most commonly in those with myelodysplastic/myeloproliferative neoplasms (27 out of 219 individuals, or 12%) and in those with <span class=""disease"" id=""20601953-3-286-299"">myelofibrosis</span> (4 out of 30 individuals, or 13%).",CTD_human
1,0,Biomarker,C0010278,Craniosynostosis,disease,craniosynostosis,2146,EZH2,Ezh2,CTD_human,26424790,"Conditional genetic loss of Ezh2 in uncommitted mesenchymal cells (Prrx1-Cre) results in multiple defects in skeletal patterning and bone formation, including shortened forelimbs, craniosynostosis, and clinodactyly.",0.2,"Conditional genetic loss of <span class=""gene"" id=""26424790-8-28-32"">Ezh2</span> in uncommitted mesenchymal cells (Prrx1-Cre) results in multiple defects in skeletal patterning and bone formation, including shortened forelimbs, <span class=""disease"" id=""26424790-8-180-196"">craniosynostosis</span>, and clinodactyly.",CTD_human
1,0,Biomarker,C3463824,MYELODYSPLASTIC SYNDROME,group,myelodysplastic syndromes,2146,EZH2,EZH2,CTD_human,20601954,Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes.,0.203846174978983,"Somatic mutations of the histone methyltransferase gene <span class=""gene"" id=""20601954-0-56-60"">EZH2</span> in <span class=""disease"" id=""20601954-0-64-89"">myelodysplastic syndromes</span>.",CTD_human
11,10,Biomarker,C0020640,Inherited Factor II deficiency,disease,hypoprothrombinemia,2147,F2,prothrombin,CTD_human,3567158,"The prothrombin sample used was from a heterozygote but contained exclusively a defective prothrombin molecule, since the patient was heterozygous for both dysprothrombinemia and hypoprothrombinemia.",0.6141772141125,"The <span class=""gene"" id=""3567158-2-4-15"">prothrombin</span> sample used was from a heterozygote but contained exclusively a defective <span class=""gene"" id=""3567158-2-90-101"">prothrombin</span> molecule, since the patient was heterozygous for both dysprothrombinemia and <span class=""disease"" id=""3567158-2-179-198"">hypoprothrombinemia</span>.",CTD_human;ORPHANET;UNIPROT
11,10,Biomarker,C0020640,Inherited Factor II deficiency,disease,hypoprothrombinemia,2147,F2,prothrombin,CTD_human,7740448,"A patient with a severe bleeding tendency and hypoprothrombinemia (Factor II activity 2%, Factor II antigen 5%) was screened for the presence of alterations in his prothrombin gene.",0.6141772141125,"A patient with a severe bleeding tendency and <span class=""disease"" id=""7740448-1-46-65"">hypoprothrombinemia</span> (Factor II activity 2%, Factor II antigen 5%) was screened for the presence of alterations in his <span class=""gene"" id=""7740448-1-164-175"">prothrombin</span> gene.",CTD_human;ORPHANET;UNIPROT
3,0,Biomarker,C0027051,Myocardial Infarction,disease,myocardial infarction,2147,F2,prothrombin,CTD_human,9531249,Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A.,0.263822443568585,"Interaction of coagulation defects and cardiovascular risk factors: increased risk of <span class=""disease"" id=""9531249-0-86-107"">myocardial infarction</span> associated with factor V Leiden or <span class=""gene"" id=""9531249-0-143-154"">prothrombin</span> 20210A.",CTD_human
3,0,Biomarker,C0027051,Myocardial Infarction,disease,myocardial infarction,2147,F2,prothrombin,CTD_human,9292507,A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women.,0.263822443568585,"A common <span class=""gene"" id=""9292507-0-9-20"">prothrombin</span> variant (20210 G to A) increases the risk of <span class=""disease"" id=""9292507-0-66-87"">myocardial infarction</span> in young women.",CTD_human
3,0,Biomarker,C0027051,Myocardial Infarction,disease,MI,2147,F2,prothrombin,CTD_human,10027711,Our findings suggest that the 20210 G-->A mutation in the prothrombin gene is a genetic risk factor for MI.,0.263822443568585,"Our findings suggest that the 20210 G--&gt;A mutation in the <span class=""gene"" id=""10027711-8-58-69"">prothrombin</span> gene is a genetic risk factor for <span class=""disease"" id=""10027711-8-104-106"">MI</span>.",CTD_human
1,0,Biomarker,C0085605,Liver Failure,disease,hepatic failure,2147,F2,prothrombin,CTD_human,18618250,"Patients (n = 47) with reactivated hepatitis due to lamivudine-resistant HBV were classified into two groups, with and without potential for progression to hepatic failure, according to the criteria using the data of serum bilirubin level and prothrombin activity after the reactivated hepatitis.",0.20054945356842604,"Patients (n = 47) with reactivated hepatitis due to lamivudine-resistant HBV were classified into two groups, with and without potential for progression to <span class=""disease"" id=""18618250-2-156-171"">hepatic failure</span>, according to the criteria using the data of serum bilirubin level and <span class=""gene"" id=""18618250-2-243-254"">prothrombin</span> activity after the reactivated hepatitis.",CTD_human
3,0,Biomarker,C0015695,Fatty Liver,disease,hepatic steatosis,2149,F2R,Protease-activated receptor 1,CTD_human,21907177,Protease-activated receptor 1 and hematopoietic cell tissue factor are required for hepatic steatosis in mice fed a Western diet.,0.2,"<span class=""gene"" id=""21907177-0-0-29"">Protease-activated receptor 1</span> and hematopoietic cell tissue factor are required for <span class=""disease"" id=""21907177-0-84-101"">hepatic steatosis</span> in mice fed a Western diet.",CTD_human
1,0,Biomarker,C0019158,Hepatitis,disease,liver inflammation,2149,F2R,PAR-1,CTD_human,21907177,These studies indicate that PAR-1 and hematopoietic cell TF are required for liver inflammation and steatosis in mice fed a Western diet.,0.2,"These studies indicate that <span class=""gene"" id=""21907177-10-28-33"">PAR-1</span> and hematopoietic cell TF are required for <span class=""disease"" id=""21907177-10-77-95"">liver inflammation</span> and steatosis in mice fed a Western diet.",CTD_human
23,53,Biomarker,C0162309,Adrenoleukodystrophy,disease,X-ALD,215,ABCD1,ABCD1,CTD_human,22057157,X-linked adrenoleukodystrophy (X-ALD) is characterized by ABCD1 deficiency.,0.7400503227241311,"<span class=""disease"" id=""22057157-1-0-29"">X-linked adrenoleukodystrophy</span> (<span class=""disease"" id=""22057157-1-31-36"">X-ALD</span>) is characterized by <span class=""gene"" id=""22057157-1-58-63"">ABCD1</span> deficiency.",CTD_human;ORPHANET;UNIPROT
3,0,Biomarker,C0012739,Disseminated Intravascular Coagulation,disease,DIC,2152,F3,TF,CTD_human,7740478,We measured plasma levels of tissue factor (TF) and tissue factor pathway inhibitor (TFPI) in patients with thrombotic thrombocytopenic purpura (TTP) and disseminated intravascular coagulation (DIC) to examine the relationship between TFPI and vascular endothelial cell injury.,0.28412090176319704,"We measured plasma levels of <span class=""gene"" id=""7740478-1-29-42"">tissue factor</span> (<span class=""gene"" id=""7740478-1-44-46"">TF</span>) and tissue factor pathway inhibitor (TFPI) in patients with thrombotic thrombocytopenic purpura (TTP) and <span class=""disease"" id=""7740478-1-154-192"">disseminated intravascular coagulation</span> (<span class=""disease"" id=""7740478-1-194-197"">DIC</span>) to examine the relationship between TFPI and vascular endothelial cell injury.",CTD_human
3,0,Biomarker,C0012739,Disseminated Intravascular Coagulation,disease,consumptive coagulopathy,2152,F3,tissue factor,CTD_human,20642682,Recipient tissue factor expression is associated with consumptive coagulopathy in pig-to-primate kidney xenotransplantation.,0.28412090176319704,"Recipient <span class=""gene"" id=""20642682-0-10-23"">tissue factor</span> expression is associated with <span class=""disease"" id=""20642682-0-54-78"">consumptive coagulopathy</span> in pig-to-primate kidney xenotransplantation.",CTD_human
3,0,Biomarker,C0012739,Disseminated Intravascular Coagulation,disease,DIC,2152,F3,thromboplastin,CTD_human,9134660,We therefore further compared the antithrombotic (Benefit: dose required for 50% inhibition of fibrinogen decrease: ED50) and hemorrhagic (Risk: minimum dose required for significant prolongation of bleeding time) effects of MR-33 and LMW-heparin in the thromboplastin-induced DIC model.,0.28412090176319704,"We therefore further compared the antithrombotic (Benefit: dose required for 50% inhibition of fibrinogen decrease: ED50) and hemorrhagic (Risk: minimum dose required for significant prolongation of bleeding time) effects of MR-33 and LMW-heparin in the <span class=""gene"" id=""9134660-7-254-268"">thromboplastin</span>-induced <span class=""disease"" id=""9134660-7-277-280"">DIC</span> model.",CTD_human
1,0,Biomarker,C0023487,Acute Promyelocytic Leukemia,disease,APL,2152,F3,TF,CTD_human,16206674,Abnormal high expression of TF in APL cell was downregulated in patients treated with ATRA or As2O3.,0.20357144819477,"Abnormal high expression of <span class=""gene"" id=""16206674-7-28-30"">TF</span> in <span class=""disease"" id=""16206674-7-34-37"">APL</span> cell was downregulated in patients treated with ATRA or As2O3.",CTD_human
1,0,Biomarker,C0027726,Nephrotic Syndrome,group,nephrotic syndrome,2152,F3,tissue factor,CTD_human,17513194,Simvastatin inhibits tissue factor and plasminogen activator inhibitor-1 secretion by peripheral blood mononuclear cells in patients with primary nephrotic syndrome.,0.202732912464814,"Simvastatin inhibits <span class=""gene"" id=""17513194-0-21-34"">tissue factor</span> and plasminogen activator inhibitor-1 secretion by peripheral blood mononuclear cells in patients with primary <span class=""disease"" id=""17513194-0-146-164"">nephrotic syndrome</span>.",CTD_human
1,0,Biomarker,C0034155,"Purpura, Thrombotic Thrombocytopenic",disease,TTP,2152,F3,TF,CTD_human,7740478,"One month after treatment, TTP patients showed a significant decrease in plasma TM levels, and a significant increase in plasma TFPI levels, but plasma levels of TF antigen were not significantly increased.",0.2,"One month after treatment, <span class=""disease"" id=""7740478-5-27-30"">TTP</span> patients showed a significant decrease in plasma TM levels, and a significant increase in plasma TFPI levels, but plasma levels of <span class=""gene"" id=""7740478-5-162-164"">TF</span> antigen were not significantly increased.",CTD_human
1,0,Biomarker,C0151744,Myocardial Ischemia,disease,Myocardial ischemia,2152,F3,tissue factor,CTD_human,16286589,Myocardial ischemia induces interleukin-6 and tissue factor production in patients with coronary artery disease: a dobutamine stress echocardiography study.,0.202681755307501,"<span class=""disease"" id=""16286589-0-0-19"">Myocardial ischemia</span> induces interleukin-6 and <span class=""gene"" id=""16286589-0-46-59"">tissue factor</span> production in patients with coronary artery disease: a dobutamine stress echocardiography study.",CTD_human
1,0,Biomarker,C0027051,Myocardial Infarction,disease,myocardial infarction,2153,F5,factor V Leiden,CTD_human,9531249,Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A.,0.278422671800583,"Interaction of coagulation defects and cardiovascular risk factors: increased risk of <span class=""disease"" id=""9531249-0-86-107"">myocardial infarction</span> associated with <span class=""gene"" id=""9531249-0-124-139"">factor V Leiden</span> or prothrombin 20210A.",CTD_human
2,0,Biomarker,C0028754,Obesity,disease,obesity,2166,FAAH,FAAH,CTD_human,19103437,A common single nucleotide polymorphism (C385A) in the human FAAH gene has been associated with increased risk for addiction and obesity.,0.22399209605255702,"A common single nucleotide polymorphism (C385A) in the human <span class=""gene"" id=""19103437-2-61-65"">FAAH</span> gene has been associated with increased risk for addiction and <span class=""disease"" id=""19103437-2-129-136"">obesity</span>.",CTD_human
1,0,Therapeutic,C0036572,Seizures,phenotype,seizures,2166,FAAH,FAAH,CTD_human,25933444,"The FAAH inhibitor, URB597, reduced cocaine-induced seizures and epileptiform electroencephalographic activity.",0.2,"The <span class=""gene"" id=""25933444-7-4-8"">FAAH</span> inhibitor, URB597, reduced cocaine-induced <span class=""disease"" id=""25933444-7-52-60"">seizures</span> and epileptiform electroencephalographic activity.",CTD_human
1,0,Biomarker,C0022661,"Kidney Failure, Chronic",disease,CRF,2168,FABP1,L-FABP,CTD_human,19878707,"CRF resulted in hypertension, proteinuria, renal tissue lipid accumulation, up-regulation of scavenger receptor A1 (SR-A1), acyl-CoA cholesterol acyltransferase-1 (ACAT1), carbohydrate-responsive element binding protein (ChREBP), fatty acid synthase (FAS), acyl-CoA carboxylase (ACC), liver X receptor (LXR), ATP binding cassette (ABC) A-1, ABCG-1, and SR-B1 and down-regulation of sterol responsive element binding protein-1 (SREBP-1), SREBP-2, HMG-CoA reductase, PPAR-alpha, fatty acid binding protein (L-FABP), and CPT1A.",0.2,"<span class=""disease"" id=""19878707-5-0-3"">CRF</span> resulted in hypertension, proteinuria, renal tissue lipid accumulation, up-regulation of scavenger receptor A1 (SR-A1), acyl-CoA cholesterol acyltransferase-1 (ACAT1), carbohydrate-responsive element binding protein (ChREBP), fatty acid synthase (FAS), acyl-CoA carboxylase (ACC), liver X receptor (LXR), ATP binding cassette (ABC) A-1, ABCG-1, and SR-B1 and down-regulation of sterol responsive element binding protein-1 (SREBP-1), SREBP-2, HMG-CoA reductase, PPAR-alpha, fatty acid binding protein (<span class=""gene"" id=""19878707-5-505-511"">L-FABP</span>), and CPT1A.",CTD_human
7,1,Biomarker,C0001973,"Alcoholic Intoxication, Chronic",disease,alcoholism,217,ALDH2,ALDH2,CTD_human,17590986,"Direct correlations of blood ethanol and acetaldehyde concentrations, cardiovascular haemodynamic responses, and the subjective perceptions after challenge with low (0.2g/kg) to moderate (0.5g/kg) alcohol in individuals with different ALDH2 genotypes support the notion that full protection against alcoholism byALDH2*2/*2 may derive from either abstinence or deliberate moderation in alcohol consumption due to strong discomfort from physiological and psychological responses caused by persistently elevated blood acetaldehyde after ingestion of a small amount of alcohol, and that the partial protection by ALDH2*1/*2 can be ascribed to significantly lower acetaldehyde build-up in blood and the according adverse reactions.",0.51543975516349,"Direct correlations of blood ethanol and acetaldehyde concentrations, cardiovascular haemodynamic responses, and the subjective perceptions after challenge with low (0.2g/kg) to moderate (0.5g/kg) alcohol in individuals with different <span class=""gene"" id=""17590986-6-235-240"">ALDH2</span> genotypes support the notion that full protection against <span class=""disease"" id=""17590986-6-299-309"">alcoholism</span> byALDH2*2/*2 may derive from either abstinence or deliberate moderation in alcohol consumption due to strong discomfort from physiological and psychological responses caused by persistently elevated blood acetaldehyde after ingestion of a small amount of alcohol, and that the partial protection by <span class=""gene"" id=""17590986-6-609-614"">ALDH2</span>*1/*2 can be ascribed to significantly lower acetaldehyde build-up in blood and the according adverse reactions.",CTD_human;PSYGENET
7,1,Biomarker,C0001973,"Alcoholic Intoxication, Chronic",disease,alcohol dependence,217,ALDH2,ALDH2,CTD_human,16404797,"Data are consistent with the hypothesis that elevations in acetaldehyde, increased sensitivity to alcohol, and lower levels of drinking reflect the mechanism by which the ALDH2*2 allele reduces risk for alcohol dependence.",0.51543975516349,"Data are consistent with the hypothesis that elevations in acetaldehyde, increased sensitivity to alcohol, and lower levels of drinking reflect the mechanism by which the <span class=""gene"" id=""16404797-8-171-176"">ALDH2</span>*2 allele reduces risk for <span class=""disease"" id=""16404797-8-203-221"">alcohol dependence</span>.",CTD_human;PSYGENET
2,0,Biomarker,C0004096,Asthma,disease,bronchial asthma,217,ALDH2,ALDH-2,CTD_human,11506308,"Since bronchial asthma patients who are homozygous for mutant ALDH-2 genes are susceptible to acute severe alcohol-induced asthma attacks, strict clinical attention is thought a necessity.",0.206462417751855,"Since <span class=""disease"" id=""11506308-5-6-22"">bronchial asthma</span> patients who are homozygous for mutant <span class=""gene"" id=""11506308-5-62-68"">ALDH-2</span> genes are susceptible to acute severe alcohol-induced asthma attacks, strict clinical attention is thought a necessity.",CTD_human
2,0,Biomarker,C0004096,Asthma,disease,asthma,217,ALDH2,acetaldehyde dehydrogenase-2,CTD_human,9600491,Correlation between alcohol-induced asthma and acetaldehyde dehydrogenase-2 genotype.,0.206462417751855,"Correlation between alcohol-induced <span class=""disease"" id=""9600491-0-36-42"">asthma</span> and <span class=""gene"" id=""9600491-0-47-75"">acetaldehyde dehydrogenase-2</span> genotype.",CTD_human
1,0,Biomarker,C0014859,Esophageal Neoplasms,group,esophageal cancer,217,ALDH2,ALDH2,CTD_human,8850269,"These results suggest that to help lower their risk for esophageal cancer, persons with the ALDH2*2 allele should be encouraged to reduce their consumption of alcoholic beverages.",0.293647635892623,"These results suggest that to help lower their risk for <span class=""disease"" id=""8850269-7-56-73"">esophageal cancer</span>, persons with the <span class=""gene"" id=""8850269-7-92-97"">ALDH2</span>*2 allele should be encouraged to reduce their consumption of alcoholic beverages.",CTD_human
1,0,Biomarker,C0016382,Flushing,phenotype,flushing,217,ALDH2,ALDH2,CTD_human,8903321,The mutation in the mitochondrial aldehyde dehydrogenase (ALDH2) gene responsible for alcohol-induced flushing increases turnover of the enzyme tetramers in a dominant fashion.,0.23911474582997103,"The mutation in the mitochondrial aldehyde dehydrogenase (<span class=""gene"" id=""8903321-0-58-63"">ALDH2</span>) gene responsible for alcohol-induced <span class=""disease"" id=""8903321-0-102-110"">flushing</span> increases turnover of the enzyme tetramers in a dominant fashion.",CTD_human
2,0,Biomarker,C0279626,Squamous cell carcinoma of esophagus,disease,ESCC,217,ALDH2,ALDH2,CTD_human,16639733,"The findings indicated that individuals with low dietary selenium intake and ALDH2 Lys/Lys and XRCC1 399Gln/Gln or Gln/Arg genotypes were associated with an increased ESCC risk, especially in the presence of exposure to tobacco and alcohol carcinogens.",0.20604398925268802,"The findings indicated that individuals with low dietary selenium intake and <span class=""gene"" id=""16639733-10-77-82"">ALDH2</span> Lys/Lys and XRCC1 399Gln/Gln or Gln/Arg genotypes were associated with an increased <span class=""disease"" id=""16639733-10-167-171"">ESCC</span> risk, especially in the presence of exposure to tobacco and alcohol carcinogens.",CTD_human
2,0,Biomarker,C0279626,Squamous cell carcinoma of esophagus,disease,ESCC,217,ALDH2,ALDH2,CTD_human,22960999,"We confirmed the known association of the ALDH2 locus on 12q24 to ESCC, and a joint analysis showed that drinkers with both of the ADH1B and ALDH2 risk alleles had a fourfold increased risk for ESCC compared to drinkers without these risk alleles.",0.20604398925268802,"We confirmed the known association of the <span class=""gene"" id=""22960999-4-42-47"">ALDH2</span> locus on 12q24 to <span class=""disease"" id=""22960999-4-66-70"">ESCC</span>, and a joint analysis showed that drinkers with both of the ADH1B and <span class=""gene"" id=""22960999-4-141-146"">ALDH2</span> risk alleles had a fourfold increased risk for <span class=""disease"" id=""22960999-4-194-198"">ESCC</span> compared to drinkers without these risk alleles.",CTD_human
1,1,Biomarker,C0015625,Fanconi Anemia,disease,FA,2177,FANCD2,Fancd2,CTD_human,14667412,"Thus, Fancd2 is essential during embryogenesis to prevent inappropriate apoptosis in neural cells and other tissues undergoing high levels of proliferative expansion, implicating this mechanism in the congenital abnormalities observed in human infants with FA.",0.45073832281552,"Thus, <span class=""gene"" id=""14667412-5-6-12"">Fancd2</span> is essential during embryogenesis to prevent inappropriate apoptosis in neural cells and other tissues undergoing high levels of proliferative expansion, implicating this mechanism in the congenital abnormalities observed in human infants with <span class=""disease"" id=""14667412-5-257-259"">FA</span>.",CTD_human;ORPHANET
1,0,Biomarker,C0011581,Depressive disorder,disease,depression,2182,ACSL4,long-chain fatty acid-CoA ligase 4,CTD_human,15108178,Association of a long-chain fatty acid-CoA ligase 4 gene polymorphism with depression and with enhanced niacin-induced dermal erythema.,0.200274726784213,"Association of a <span class=""gene"" id=""15108178-0-17-51"">long-chain fatty acid-CoA ligase 4</span> gene polymorphism with <span class=""disease"" id=""15108178-0-75-85"">depression</span> and with enhanced niacin-induced dermal erythema.",CTD_human
1,0,Biomarker,C0041834,Erythema,phenotype,erythema,2182,ACSL4,long-chain fatty acid-CoA ligase 4,CTD_human,15108178,Association of a long-chain fatty acid-CoA ligase 4 gene polymorphism with depression and with enhanced niacin-induced dermal erythema.,0.200274726784213,"Association of a <span class=""gene"" id=""15108178-0-17-51"">long-chain fatty acid-CoA ligase 4</span> gene polymorphism with depression and with enhanced niacin-induced dermal <span class=""disease"" id=""15108178-0-126-134"">erythema</span>.",CTD_human
1,0,Biomarker,C0025202,melanoma,disease,melanomas,2185,PTK2B,PTK2B,CTD_human,19718025,We found ERBB4 mutations in 19% of individuals with melanoma and found mutations in two other kinases (FLT1 and PTK2B) in 10% of individuals with melanomas.,0.204055389228567,"We found ERBB4 mutations in 19% of individuals with <span class=""disease"" id=""19718025-4-52-60"">melanoma</span> and found mutations in two other kinases (FLT1 and <span class=""gene"" id=""19718025-4-112-117"">PTK2B</span>) in 10% of individuals with <span class=""disease"" id=""19718025-4-146-155"">melanomas</span>.",CTD_human
1,0,Biomarker,C0038220,Status Epilepticus,disease,SE,2185,PTK2B,Pyk2,CTD_human,16600505,"The onset of SE was accompanied by activation of Src-family tyrosine kinases and Pyk2 in the post-synaptic density, consistent with a role for these enzymes in SE-induced tyrosine phosphorylation.",0.2,"The onset of <span class=""disease"" id=""16600505-6-13-15"">SE</span> was accompanied by activation of Src-family tyrosine kinases and <span class=""gene"" id=""16600505-6-81-85"">Pyk2</span> in the post-synaptic density, consistent with a role for these enzymes in <span class=""disease"" id=""16600505-6-160-162"">SE</span>-induced tyrosine phosphorylation.",CTD_human
2,2,Biomarker,C0015625,Fanconi Anemia,disease,Fanconi anaemia,2189,FANCG,XRCC9,CTD_human,11093276,"Spectrum of mutations in the Fanconi anaemia group G gene, FANCG/XRCC9.",0.413158174887594,"Spectrum of mutations in the <span class=""disease"" id=""11093276-0-29-44"">Fanconi anaemia</span> group G gene, <span class=""gene"" id=""11093276-0-59-64"">FANCG</span>/<span class=""gene"" id=""11093276-0-65-70"">XRCC9</span>.",CTD_human;ORPHANET
2,2,Biomarker,C0015625,Fanconi Anemia,disease,Fanconi anemia,2189,FANCG,FANCG,CTD_human,10807541,Novel mutations of the FANCG gene causing alternative splicing in Japanese Fanconi anemia.,0.413158174887594,"Novel mutations of the <span class=""gene"" id=""10807541-0-23-28"">FANCG</span> gene causing alternative splicing in Japanese <span class=""disease"" id=""10807541-0-75-89"">Fanconi anemia</span>.",CTD_human;ORPHANET
1,0,Biomarker,C0018801,Heart failure,disease,heart failure,2194,FASN,FASN,CTD_human,26670611,"The development of disturbed substrate utilization of FASN transgenic cardiomyocytes and signs of heart failure were retarded by the transgenic expression of GRKInh, a peptide inhibitor of GRK2.",0.2,"The development of disturbed substrate utilization of <span class=""gene"" id=""26670611-6-54-58"">FASN</span> transgenic cardiomyocytes and signs of <span class=""disease"" id=""26670611-6-98-111"">heart failure</span> were retarded by the transgenic expression of GRKInh, a peptide inhibitor of GRK2.",CTD_human
1,0,Biomarker,C0022661,"Kidney Failure, Chronic",disease,CRF,2194,FASN,FAS,CTD_human,19878707,"CRF resulted in hypertension, proteinuria, renal tissue lipid accumulation, up-regulation of scavenger receptor A1 (SR-A1), acyl-CoA cholesterol acyltransferase-1 (ACAT1), carbohydrate-responsive element binding protein (ChREBP), fatty acid synthase (FAS), acyl-CoA carboxylase (ACC), liver X receptor (LXR), ATP binding cassette (ABC) A-1, ABCG-1, and SR-B1 and down-regulation of sterol responsive element binding protein-1 (SREBP-1), SREBP-2, HMG-CoA reductase, PPAR-alpha, fatty acid binding protein (L-FABP), and CPT1A.",0.2,"<span class=""disease"" id=""19878707-5-0-3"">CRF</span> resulted in hypertension, proteinuria, renal tissue lipid accumulation, up-regulation of scavenger receptor A1 (SR-A1), acyl-CoA cholesterol acyltransferase-1 (ACAT1), carbohydrate-responsive element binding protein (ChREBP), <span class=""gene"" id=""19878707-5-230-249"">fatty acid synthase</span> (<span class=""gene"" id=""19878707-5-251-254"">FAS</span>), acyl-CoA carboxylase (ACC), liver X receptor (LXR), ATP binding cassette (ABC) A-1, ABCG-1, and SR-B1 and down-regulation of sterol responsive element binding protein-1 (SREBP-1), SREBP-2, HMG-CoA reductase, PPAR-alpha, fatty acid binding protein (L-FABP), and CPT1A.",CTD_human
1,0,Therapeutic,C0023827,liposarcoma,disease,LS,2194,FASN,FASN,CTD_human,20372807,"The FASN inhibitors cerulenin and orlistat reduced the growth of two LS cell lines (LiSa2, SW872), as did inhibition of ACC with soraphen A. CDDO-Me, a synthetic triterpenoid, suppressed expression of Spot 14 and FASN genes and likewise inhibited LS cell growth.",0.20054945356842604,"The <span class=""gene"" id=""20372807-4-4-8"">FASN</span> inhibitors cerulenin and orlistat reduced the growth of two <span class=""disease"" id=""20372807-4-69-71"">LS</span> cell lines (LiSa2, SW872), as did inhibition of ACC with soraphen A. CDDO-Me, a synthetic triterpenoid, suppressed expression of Spot 14 and <span class=""gene"" id=""20372807-4-213-217"">FASN</span> genes and likewise inhibited <span class=""disease"" id=""20372807-4-247-249"">LS</span> cell growth.",CTD_human
3,0,Biomarker,C0025202,melanoma,disease,melanoma,2194,FASN,fatty acid synthase,CTD_human,21213365,Visualizing inhibition of fatty acid synthase through mass spectrometric analysis of mitochondria from melanoma cells.,0.20054945356842604,"Visualizing inhibition of <span class=""gene"" id=""21213365-0-26-45"">fatty acid synthase</span> through mass spectrometric analysis of mitochondria from <span class=""disease"" id=""21213365-0-103-111"">melanoma</span> cells.",CTD_human
3,0,Biomarker,C0025202,melanoma,disease,melanoma,2194,FASN,Fatty acid synthase,CTD_human,18770866,Fatty acid synthase inhibition with Orlistat promotes apoptosis and reduces cell growth and lymph node metastasis in a mouse melanoma model.,0.20054945356842604,"<span class=""gene"" id=""18770866-0-0-19"">Fatty acid synthase</span> inhibition with Orlistat promotes apoptosis and reduces cell growth and lymph node metastasis in a mouse <span class=""disease"" id=""18770866-0-125-133"">melanoma</span> model.",CTD_human
3,0,Biomarker,C0025202,melanoma,disease,melanoma,2194,FASN,fatty acid synthase,CTD_human,20805790,Inhibition of fatty acid synthase in melanoma cells activates the intrinsic pathway of apoptosis.,0.20054945356842604,"Inhibition of <span class=""gene"" id=""20805790-0-14-33"">fatty acid synthase</span> in <span class=""disease"" id=""20805790-0-37-45"">melanoma</span> cells activates the intrinsic pathway of apoptosis.",CTD_human
1,0,Biomarker,C0948089,Acute Coronary Syndrome,disease,acute coronary syndrome,2194,FASN,fatty acid synthase,CTD_human,23305094,Effects of soluble epoxide hydrolase inhibitor on the expression of fatty acid synthase in peripheral blood mononuclear cell in patients with acute coronary syndrome.,0.200274726784213,"Effects of soluble epoxide hydrolase inhibitor on the expression of <span class=""gene"" id=""23305094-0-68-87"">fatty acid synthase</span> in peripheral blood mononuclear cell in patients with <span class=""disease"" id=""23305094-0-142-165"">acute coronary syndrome</span>.",CTD_human
3,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,2194,FASN,fatty acid synthase,CTD_human,21147110,"Suppression of the genes adenosine triphosphate citrate lyase, acetyl-CoA carboxylase, fatty acid synthase, stearoyl-CoA desaturase 1, or sterol regulatory element-binding protein 1, which are involved in lipogenesis, reduced proliferation, and survival of HCC cell lines and AKT-dependent cell proliferation.",0.20412090176319603,"Suppression of the genes adenosine triphosphate citrate lyase, acetyl-CoA carboxylase, <span class=""gene"" id=""21147110-9-87-106"">fatty acid synthase</span>, stearoyl-CoA desaturase 1, or sterol regulatory element-binding protein 1, which are involved in lipogenesis, reduced proliferation, and survival of <span class=""disease"" id=""21147110-9-257-260"">HCC</span> cell lines and AKT-dependent cell proliferation.",CTD_human
1,0,Biomarker,C0017636,Glioblastoma,disease,glioblastoma,2195,FAT1,FAT1,CTD_human,23354438,"Here, we report recurrent somatic mutations of the Drosophila melanogaster tumor suppressor-related gene FAT1 in glioblastoma (20.5%), colorectal cancer (7.7%), and head and neck cancer (6.7%).",0.200274726784213,"Here, we report recurrent somatic mutations of the Drosophila melanogaster tumor suppressor-related gene <span class=""gene"" id=""23354438-3-105-109"">FAT1</span> in <span class=""disease"" id=""23354438-3-113-125"">glioblastoma</span> (20.5%), colorectal cancer (7.7%), and head and neck cancer (6.7%).",CTD_human
1,1,Biomarker,C0009324,Ulcerative Colitis,disease,ulcerative colitis,219771,CCNY,CCNY,CTD_human,18438405,"Among these loci, we identified variants in 3p21.31, NKX2-3 and CCNY as susceptibility factors for both diseases, whereas variants in PTPN2, HERC2 and STAT3 were associated only with ulcerative colitis in our sample collection.",0.21022872481889102,"Among these loci, we identified variants in 3p21.31, NKX2-3 and <span class=""gene"" id=""18438405-2-64-68"">CCNY</span> as susceptibility factors for both diseases, whereas variants in PTPN2, HERC2 and STAT3 were associated only with <span class=""disease"" id=""18438405-2-183-201"">ulcerative colitis</span> in our sample collection.",CTD_human
1,0,Biomarker,C0020456,Hyperglycemia,disease,hyperglycaemia,2200,FBN1,fibrillin 1,CTD_human,20836762,"In the present study, we have investigated the hyperinsulinaemia/hyperglycaemia-induced epigenetic changes and alteration of Fbn1 (fibrillin 1) and Col3A1 (collagen type III ?1) gene expression.",0.200274726784213,"In the present study, we have investigated the hyperinsulinaemia/<span class=""disease"" id=""20836762-2-65-79"">hyperglycaemia</span>-induced epigenetic changes and alteration of <span class=""gene"" id=""20836762-2-125-129"">Fbn1</span> (<span class=""gene"" id=""20836762-2-131-142"">fibrillin 1</span>) and Col3A1 (collagen type III &alpha;1) gene expression.",CTD_human
1,0,Biomarker,C0020459,Hyperinsulinism,disease,hyperinsulinaemia,2200,FBN1,fibrillin 1,CTD_human,20836762,"In the present study, we have investigated the hyperinsulinaemia/hyperglycaemia-induced epigenetic changes and alteration of Fbn1 (fibrillin 1) and Col3A1 (collagen type III ?1) gene expression.",0.200274726784213,"In the present study, we have investigated the <span class=""disease"" id=""20836762-2-47-64"">hyperinsulinaemia</span>/hyperglycaemia-induced epigenetic changes and alteration of <span class=""gene"" id=""20836762-2-125-129"">Fbn1</span> (<span class=""gene"" id=""20836762-2-131-142"">fibrillin 1</span>) and Col3A1 (collagen type III &alpha;1) gene expression.",CTD_human
48,353,Biomarker,C0024796,Marfan Syndrome,disease,Marfan syndrome,2200,FBN1,FBN1,CTD_human,17657824,The importance of mutation detection in Marfan syndrome and Marfan-related disorders: report of 193 FBN1 mutations.,0.8435425915757309,"The importance of mutation detection in <span class=""disease"" id=""17657824-0-40-55"">Marfan syndrome</span> and Marfan-related disorders: report of 193 <span class=""gene"" id=""17657824-0-100-104"">FBN1</span> mutations.",CTD_human;ORPHANET;UNIPROT
48,353,Biomarker,C0024796,Marfan Syndrome,disease,MFS,2200,FBN1,fibrillin-1,CTD_human,18178469,"The study employed a well-characterized animal model of MFS, namely fibrillin-1 under-expressing mice (mgR/mgR mice) that die spontaneously from rupture of the thoracic aorta between 2 to 4 months of age.",0.8435425915757309,"The study employed a well-characterized animal model of <span class=""disease"" id=""18178469-6-56-59"">MFS</span>, namely <span class=""gene"" id=""18178469-6-68-79"">fibrillin-1</span> under-expressing mice (mgR/mgR mice) that die spontaneously from rupture of the thoracic aorta between 2 to 4 months of age.",CTD_human;ORPHANET;UNIPROT
48,353,Biomarker,C0024796,Marfan Syndrome,disease,Marfan syndrome,2200,FBN1,FBN1,CTD_human,19430350,Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations.,0.8435425915757309,"Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in <span class=""disease"" id=""19430350-0-155-170"">Marfan syndrome</span> with <span class=""gene"" id=""19430350-0-176-180"">FBN1</span> gene mutations.",CTD_human;ORPHANET;UNIPROT
48,353,Biomarker,C0024796,Marfan Syndrome,disease,Marfan syndrome,2200,FBN1,FBN1,CTD_human,15235604,"Marfan syndrome is an extracellular matrix disorder with cardinal manifestations in the eye, skeleton and cardiovascular systems associated with defects in the gene encoding fibrillin (FBN1) at 15q21.1 (ref.1).",0.8435425915757309,"<span class=""disease"" id=""15235604-1-0-15"">Marfan syndrome</span> is an extracellular matrix disorder with cardinal manifestations in the eye, skeleton and cardiovascular systems associated with defects in the gene encoding fibrillin (<span class=""gene"" id=""15235604-1-185-189"">FBN1</span>) at 15q21.1 (ref.1).",CTD_human;ORPHANET;UNIPROT
48,353,Biomarker,C0024796,Marfan Syndrome,disease,MFS,2200,FBN1,Fbn1,CTD_human,22772368,Mice that harbor both a mutant Marfan syndrome (MFS) allele (Fbn1(C1039G/+)) and Tgfb2 haploinsufficiency show increased TGF-? signaling and phenotypic worsening in association with normalization of TGF-?2 expression and high expression of TGF-?1.,0.8435425915757309,"Mice that harbor both a mutant <span class=""disease"" id=""22772368-4-31-46"">Marfan syndrome</span> (<span class=""disease"" id=""22772368-4-48-51"">MFS</span>) allele (<span class=""gene"" id=""22772368-4-61-65"">Fbn1</span>(C1039G/+)) and Tgfb2 haploinsufficiency show increased TGF-&beta; signaling and phenotypic worsening in association with normalization of TGF-&beta;2 expression and high expression of TGF-&beta;1.",CTD_human;ORPHANET;UNIPROT
48,353,Biomarker,C0024796,Marfan Syndrome,disease,Marfan syndrome,2200,FBN1,FBN1,CTD_human,21909107,"This study shows that common genetic variants at 15q21.1 that probably act via FBN1 are associated with STAAD, suggesting a common pathogenesis of aortic disease in Marfan syndrome and STAAD.",0.8435425915757309,"This study shows that common genetic variants at 15q21.1 that probably act via <span class=""gene"" id=""21909107-6-79-83"">FBN1</span> are associated with STAAD, suggesting a common pathogenesis of aortic disease in <span class=""disease"" id=""21909107-6-165-180"">Marfan syndrome</span> and STAAD.",CTD_human;ORPHANET;UNIPROT
48,353,Biomarker,C0024796,Marfan Syndrome,disease,Marfan syndrome,2200,FBN1,fibrillin-1,CTD_human,18212506,"Occurrence of disease complications in the abdominal aorta in Marfan syndrome, a connective tissue disorder caused by mutations in the gene encoding fibrillin-1, is relatively rare.",0.8435425915757309,"Occurrence of disease complications in the abdominal aorta in <span class=""disease"" id=""18212506-1-62-77"">Marfan syndrome</span>, a connective tissue disorder caused by mutations in the gene encoding <span class=""gene"" id=""18212506-1-149-160"">fibrillin-1</span>, is relatively rare.",CTD_human;ORPHANET;UNIPROT
1,1,Biomarker,C0162872,"Aortic Aneurysm, Thoracic",disease,thoracic aortic aneurysms,2200,FBN1,FBN1,CTD_human,21909107,Genome-wide association study identifies a susceptibility locus for thoracic aortic aneurysms and aortic dissections spanning FBN1 at 15q21.1.,0.205429023149632,"Genome-wide association study identifies a susceptibility locus for <span class=""disease"" id=""21909107-0-68-93"">thoracic aortic aneurysms</span> and aortic dissections spanning <span class=""gene"" id=""21909107-0-126-130"">FBN1</span> at 15q21.1.",CTD_human
1,0,Biomarker,C0009375,Colonic Neoplasms,group,colon tumor,2203,FBP1,FBP1,CTD_human,22039417,"Here, we investigated the expression and DNA methylation of FBP1 in primary HCC and colon tumor.",0.200274726784213,"Here, we investigated the expression and DNA methylation of <span class=""gene"" id=""22039417-4-60-64"">FBP1</span> in primary HCC and <span class=""disease"" id=""22039417-4-84-95"">colon tumor</span>.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,hepatocellular carcinoma,2203,FBP1,FBP1,CTD_human,22039417,Promoter hypermethylation mediated downregulation of FBP1 in human hepatocellular carcinoma and colon cancer.,0.201373633921065,"Promoter hypermethylation mediated downregulation of <span class=""gene"" id=""22039417-0-53-57"">FBP1</span> in human <span class=""disease"" id=""22039417-0-67-91"">hepatocellular carcinoma</span> and colon cancer.",CTD_human
1,0,Biomarker,C0014038,Encephalitis,disease,encephalitis,2208,FCER2,CD23,CTD_human,11500085,Role of CD23 in astrocytes inflammatory reaction during HIV-1 related encephalitis.,0.200274726784213,"Role of <span class=""gene"" id=""11500085-0-8-12"">CD23</span> in astrocytes inflammatory reaction during HIV-1 related <span class=""disease"" id=""11500085-0-70-82"">encephalitis</span>.",CTD_human
1,0,Biomarker,C0036341,Schizophrenia,disease,SZ,220988,HNRNPA3,HNRPA3,CTD_human,16223876,"Implementing this systematic approach, we: (i) discovered 177 putative SZ risk genes in brain, 28 of which map to linked chromosomal loci; (ii) delineated six biological processes and 12 molecular functions that may be particularly disrupted in the illness; (iii) identified 123 putative SZ biomarkers in blood, 6 of which (BTG1, GSK3A, HLA-DRB1, HNRPA3, SELENBP1, and SFRS1) had corresponding differential expression in brain; (iv) verified the differential expression of the strongest candidate SZ biomarker (SELENBP1) in blood; and (v) demonstrated neuronal and glial expression of SELENBP1 protein in brain.",0.200274726784213,"Implementing this systematic approach, we: (i) discovered 177 putative <span class=""disease"" id=""16223876-4-71-73"">SZ</span> risk genes in brain, 28 of which map to linked chromosomal loci; (ii) delineated six biological processes and 12 molecular functions that may be particularly disrupted in the illness; (iii) identified 123 putative SZ biomarkers in blood, 6 of which (BTG1, GSK3A, HLA-DRB1, <span class=""gene"" id=""16223876-4-347-353"">HNRPA3</span>, SELENBP1, and SFRS1) had corresponding differential expression in brain; (iv) verified the differential expression of the strongest candidate SZ biomarker (SELENBP1) in blood; and (v) demonstrated neuronal and glial expression of SELENBP1 protein in brain.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,221035,REEP3,REEP3,CTD_human,17290275,Identification and characterization of the TRIP8 and REEP3 genes on chromosome 10q21.3 as novel candidate genes for autism.,0.20300763924902696,"Identification and characterization of the TRIP8 and <span class=""gene"" id=""17290275-0-53-58"">REEP3</span> genes on chromosome 10q21.3 as novel candidate genes for <span class=""disease"" id=""17290275-0-116-122"">autism</span>.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,221037,JMJD1C,TRIP8,CTD_human,17290275,Identification and characterization of the TRIP8 and REEP3 genes on chromosome 10q21.3 as novel candidate genes for autism.,0.20300763924902696,"Identification and characterization of the <span class=""gene"" id=""17290275-0-43-48"">TRIP8</span> and REEP3 genes on chromosome 10q21.3 as novel candidate genes for <span class=""disease"" id=""17290275-0-116-122"">autism</span>.",CTD_human
2,1,Biomarker,C0009324,Ulcerative Colitis,disease,ulcerative colitis,2212,FCGR2A,FCGR2A,CTD_human,20228799,"After testing an independent cohort of 2,009 cases of ulcerative colitis and 1,580 controls, we identified 13 loci that were significantly associated with ulcerative colitis (P < 5 x 10(-8)), including the immunoglobulin receptor gene FCGR2A, 5p15, 2p16 and ORMDL3 (orosomucoid1-like 3).",0.201648360705279,"After testing an independent cohort of 2,009 cases of <span class=""disease"" id=""20228799-5-54-72"">ulcerative colitis</span> and 1,580 controls, we identified 13 loci that were significantly associated with <span class=""disease"" id=""20228799-5-155-173"">ulcerative colitis</span> (P &lt; 5 x 10(-8)), including the immunoglobulin receptor gene <span class=""gene"" id=""20228799-5-235-241"">FCGR2A</span>, 5p15, 2p16 and ORMDL3 (orosomucoid1-like 3).",CTD_human
1,2,Biomarker,C0024141,"Lupus Erythematosus, Systemic",disease,SLE,2212,FCGR2A,FCGR2A,CTD_human,18204446,"We also found evidence for association (P < 1 x 10(-5)) at FCGR2A, PTPN22 and STAT4, regions previously associated with SLE and other autoimmune diseases, as well as at > or =9 other loci (P < 2 x 10(-7)).",0.28088085748118397,"We also found evidence for association (P &lt; 1 x 10(-5)) at <span class=""gene"" id=""18204446-4-59-65"">FCGR2A</span>, PTPN22 and STAT4, regions previously associated with <span class=""disease"" id=""18204446-4-120-123"">SLE</span> and other autoimmune diseases, as well as at &gt; or =9 other loci (P &lt; 2 x 10(-7)).",CTD_human
2,1,Biomarker,C0026691,Mucocutaneous Lymph Node Syndrome,disease,Kawasaki disease,2212,FCGR2A,FCGR2A,CTD_human,22081228,Genome-wide association study identifies FCGR2A as a susceptibility locus for Kawasaki disease.,0.205429023149632,"Genome-wide association study identifies <span class=""gene"" id=""22081228-0-41-47"">FCGR2A</span> as a susceptibility locus for <span class=""disease"" id=""22081228-0-78-94"">Kawasaki disease</span>.",CTD_human
2,1,Biomarker,C0026691,Mucocutaneous Lymph Node Syndrome,disease,Kawasaki disease,2212,FCGR2A,FCGR2A,CTD_human,22446962,"We also replicated the association of a functional SNP of FCGR2A (rs1801274, P = 1.6 × 10(-6)) identified in a recently reported GWAS of Kawasaki disease.",0.205429023149632,"We also replicated the association of a functional SNP of <span class=""gene"" id=""22446962-4-58-64"">FCGR2A</span> (rs1801274, P = 1.6 &times; 10(-6)) identified in a recently reported GWAS of <span class=""disease"" id=""22446962-4-137-153"">Kawasaki disease</span>.",CTD_human
2,2,Biomarker,C0027051,Myocardial Infarction,disease,Myocardial Infarction,221692,PHACTR1,PHACTR1,CTD_human,26098115,The Early-Onset Myocardial Infarction Associated PHACTR1 Gene Regulates Skeletal and Cardiac Alpha-Actin Gene Expression.,0.20433011601278,"The Early-Onset <span class=""disease"" id=""26098115-0-16-37"">Myocardial Infarction</span> Associated <span class=""gene"" id=""26098115-0-49-56"">PHACTR1</span> Gene Regulates Skeletal and Cardiac Alpha-Actin Gene Expression.",CTD_human
3,1,Biomarker,C1956346,Coronary Artery Disease,disease,coronary artery disease,221692,PHACTR1,PHACTR1,CTD_human,26098115,The phosphatase and actin regulator 1 (PHACTR1) locus is a very commonly identified hit in genome-wide association studies investigating coronary artery disease and myocardial infarction (MI).,0.204055389228567,"The <span class=""gene"" id=""26098115-1-4-37"">phosphatase and actin regulator 1</span> (<span class=""gene"" id=""26098115-1-39-46"">PHACTR1</span>) locus is a very commonly identified hit in genome-wide association studies investigating <span class=""disease"" id=""26098115-1-137-160"">coronary artery disease</span> and myocardial infarction (MI).",CTD_human
1,4,Biomarker,C0024141,"Lupus Erythematosus, Systemic",disease,systemic lupus erythematosus,221895,JAZF1,JAZF1,CTD_human,19838195,"A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus.",0.203231208875927,"A large-scale replication study identifies TNIP1, PRDM1, <span class=""gene"" id=""19838195-0-57-62"">JAZF1</span>, UHRF1BP1 and IL10 as risk loci for <span class=""disease"" id=""19838195-0-99-127"">systemic lupus erythematosus</span>.",CTD_human
1,0,Biomarker,C0033578,Prostatic Neoplasms,group,prostate tumors,222546,RFX6,RFX6,CTD_human,24390282,"Finally, we observe a significant association between the risk-associated T allele at rs339331 and increased RFX6 mRNA levels in human prostate tumors.",0.200274726784213,"Finally, we observe a significant association between the risk-associated T allele at rs339331 and increased <span class=""gene"" id=""24390282-7-109-113"">RFX6</span> mRNA levels in human <span class=""disease"" id=""24390282-7-135-150"">prostate tumors</span>.",CTD_human
1,1,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,222698,NKAPL,NKAPL,CTD_human,22037552,"We identified two susceptibility loci for schizophrenia at 6p21-p22.1 (rs1233710 in an intron of ZKSCAN4, P(combined) = 4.76 × 10(-11), odds ratio (OR) = 0.79; rs1635 in an exon of NKAPL, P(combined) = 6.91 × 10(-12), OR = 0.78; rs2142731 in an intron of PGBD1, P(combined) = 5.14 × 10(-10), OR = 0.79) and 11p11.2 (rs11038167 near the 5' UTR of TSPAN18, P(combined) = 1.09 × 10(-11), OR = 1.29; rs11038172, P(combined) = 7.21 × 10(-10), OR = 1.25; rs835784, P(combined) = 2.73 × 10(-11), OR = 1.27).",0.20082418035263896,"We identified two susceptibility loci for <span class=""disease"" id=""22037552-2-42-55"">schizophrenia</span> at 6p21-p22.1 (rs1233710 in an intron of ZKSCAN4, P(combined) = 4.76 &times; 10(-11), odds ratio (OR) = 0.79; rs1635 in an exon of <span class=""gene"" id=""22037552-2-181-186"">NKAPL</span>, P(combined) = 6.91 &times; 10(-12), OR = 0.78; rs2142731 in an intron of PGBD1, P(combined) = 5.14 &times; 10(-10), OR = 0.79) and 11p11.2 (rs11038167 near the 5' UTR of TSPAN18, P(combined) = 1.09 &times; 10(-11), OR = 1.29; rs11038172, P(combined) = 7.21 &times; 10(-10), OR = 1.25; rs835784, P(combined) = 2.73 &times; 10(-11), OR = 1.27).",CTD_human
17,19,Biomarker,C0162568,Erythropoietic Protoporphyria,disease,EPP,2235,FECH,FECH,CTD_human,15284838,Erythropoietic protoporphyria (EPP) is an inherited defect of the ferrochelatase (FECH) gene characterized by the accumulation of toxic protoporphyrin in the liver and bone marrow resulting in severe skin photosensitivity.,0.7309188263104691,"<span class=""disease"" id=""15284838-1-0-29"">Erythropoietic protoporphyria</span> (<span class=""disease"" id=""15284838-1-31-34"">EPP</span>) is an inherited defect of the <span class=""gene"" id=""15284838-1-66-80"">ferrochelatase</span> (<span class=""gene"" id=""15284838-1-82-86"">FECH</span>) gene characterized by the accumulation of toxic protoporphyrin in the liver and bone marrow resulting in severe skin photosensitivity.",CTD_human;ORPHANET;UNIPROT
17,19,Biomarker,C0162568,Erythropoietic Protoporphyria,disease,EPP,2235,FECH,FECH,CTD_human,12950064,"Erythropoietic protoporphyria (EPP) is an inherited disease characterised by a ferrochelatase (FECH) deficiency, the latest enzyme of the heme biosynthetic pathway, leading to the accumulation of toxic protoporphyrin in the liver, bone marrow and spleen.",0.7309188263104691,"<span class=""disease"" id=""12950064-1-0-29"">Erythropoietic protoporphyria</span> (<span class=""disease"" id=""12950064-1-31-34"">EPP</span>) is an inherited disease characterised by a <span class=""gene"" id=""12950064-1-79-93"">ferrochelatase</span> (<span class=""gene"" id=""12950064-1-95-99"">FECH</span>) deficiency, the latest enzyme of the heme biosynthetic pathway, leading to the accumulation of toxic protoporphyrin in the liver, bone marrow and spleen.",CTD_human;ORPHANET;UNIPROT
17,19,Therapeutic,C0162568,Erythropoietic Protoporphyria,disease,erythropoietic protoporphyria,2235,FECH,ferrochelatase,CTD_human,10464147,Reduced activity of ferrochelatase in erythropoietic protoporphyria (EPP) results in protoporphyrin (PP) accumulation in erythrocytes and liver.,0.7309188263104691,"Reduced activity of <span class=""gene"" id=""10464147-1-20-34"">ferrochelatase</span> in <span class=""disease"" id=""10464147-1-38-67"">erythropoietic protoporphyria</span> (EPP) results in protoporphyrin (PP) accumulation in erythrocytes and liver.",CTD_human;ORPHANET;UNIPROT
17,19,Therapeutic,C0162568,Erythropoietic Protoporphyria,disease,EPP,2235,FECH,FECH,CTD_human,15284838,Erythropoietic protoporphyria (EPP) is an inherited defect of the ferrochelatase (FECH) gene characterized by the accumulation of toxic protoporphyrin in the liver and bone marrow resulting in severe skin photosensitivity.,0.7309188263104691,"<span class=""disease"" id=""15284838-1-0-29"">Erythropoietic protoporphyria</span> (<span class=""disease"" id=""15284838-1-31-34"">EPP</span>) is an inherited defect of the <span class=""gene"" id=""15284838-1-66-80"">ferrochelatase</span> (<span class=""gene"" id=""15284838-1-82-86"">FECH</span>) gene characterized by the accumulation of toxic protoporphyrin in the liver and bone marrow resulting in severe skin photosensitivity.",CTD_human;ORPHANET;UNIPROT
17,19,Therapeutic,C0162568,Erythropoietic Protoporphyria,disease,erythropoietic protoporphyria,2235,FECH,ferrochelatase,CTD_human,15793285,BALB/c Fech(m1Pas) mice have a mutated ferrochelatase gene resulting in protoporphyria that models the hepatic injury occurring sporadically in human erythropoietic protoporphyria.,0.7309188263104691,"BALB/c Fech(m1Pas) mice have a mutated <span class=""gene"" id=""15793285-1-39-53"">ferrochelatase</span> gene resulting in <span class=""disease"" id=""15793285-1-72-86"">protoporphyria</span> that models the hepatic injury occurring sporadically in human <span class=""disease"" id=""15793285-1-150-179"">erythropoietic protoporphyria</span>.",CTD_human;ORPHANET;UNIPROT
17,19,Therapeutic,C0162568,Erythropoietic Protoporphyria,disease,EPP,2235,FECH,Ferrochelatase,CTD_human,17600043,Ferrochelatase-deficient (fch/fch) mice are an animal model for human EPP.,0.7309188263104691,"<span class=""gene"" id=""17600043-2-0-14"">Ferrochelatase</span>-deficient (fch/fch) mice are an animal model for human <span class=""disease"" id=""17600043-2-70-73"">EPP</span>.",CTD_human;ORPHANET;UNIPROT
17,19,Biomarker,C0162568,Erythropoietic Protoporphyria,disease,erythropoietic protoporphyria,2235,FECH,ferrochelatase,CTD_human,15793285,BALB/c Fech(m1Pas) mice have a mutated ferrochelatase gene resulting in protoporphyria that models the hepatic injury occurring sporadically in human erythropoietic protoporphyria.,0.7309188263104691,"BALB/c Fech(m1Pas) mice have a mutated <span class=""gene"" id=""15793285-1-39-53"">ferrochelatase</span> gene resulting in <span class=""disease"" id=""15793285-1-72-86"">protoporphyria</span> that models the hepatic injury occurring sporadically in human <span class=""disease"" id=""15793285-1-150-179"">erythropoietic protoporphyria</span>.",CTD_human;ORPHANET;UNIPROT
17,19,Therapeutic,C0162568,Erythropoietic Protoporphyria,disease,EPP,2235,FECH,FECH,CTD_human,12950064,"Erythropoietic protoporphyria (EPP) is an inherited disease characterised by a ferrochelatase (FECH) deficiency, the latest enzyme of the heme biosynthetic pathway, leading to the accumulation of toxic protoporphyrin in the liver, bone marrow and spleen.",0.7309188263104691,"<span class=""disease"" id=""12950064-1-0-29"">Erythropoietic protoporphyria</span> (<span class=""disease"" id=""12950064-1-31-34"">EPP</span>) is an inherited disease characterised by a <span class=""gene"" id=""12950064-1-79-93"">ferrochelatase</span> (<span class=""gene"" id=""12950064-1-95-99"">FECH</span>) deficiency, the latest enzyme of the heme biosynthetic pathway, leading to the accumulation of toxic protoporphyrin in the liver, bone marrow and spleen.",CTD_human;ORPHANET;UNIPROT
17,19,Biomarker,C0162568,Erythropoietic Protoporphyria,disease,erythropoietic protoporphyria,2235,FECH,ferrochelatase,CTD_human,10464147,Reduced activity of ferrochelatase in erythropoietic protoporphyria (EPP) results in protoporphyrin (PP) accumulation in erythrocytes and liver.,0.7309188263104691,"Reduced activity of <span class=""gene"" id=""10464147-1-20-34"">ferrochelatase</span> in <span class=""disease"" id=""10464147-1-38-67"">erythropoietic protoporphyria</span> (EPP) results in protoporphyrin (PP) accumulation in erythrocytes and liver.",CTD_human;ORPHANET;UNIPROT
17,19,Biomarker,C0162568,Erythropoietic Protoporphyria,disease,EPP,2235,FECH,Ferrochelatase,CTD_human,17600043,Ferrochelatase-deficient (fch/fch) mice are an animal model for human EPP.,0.7309188263104691,"<span class=""gene"" id=""17600043-2-0-14"">Ferrochelatase</span>-deficient (fch/fch) mice are an animal model for human <span class=""disease"" id=""17600043-2-70-73"">EPP</span>.",CTD_human;ORPHANET;UNIPROT
6,49,Biomarker,C0037231,Sjogren-Larsson Syndrome,disease,Sj?gren-Larsson syndrome,224,ALDH3A2,FALDH,CTD_human,16837225,Bezafibrate induces FALDH in human fibroblasts; implications for Sj?gren-Larsson syndrome.,0.637116974565184,"Bezafibrate induces <span class=""gene"" id=""16837225-0-20-25"">FALDH</span> in human fibroblasts; implications for <span class=""disease"" id=""16837225-0-65-89"">Sj&ouml;gren-Larsson syndrome</span>.",CTD_human;ORPHANET;UNIPROT
6,14,Biomarker,C0175701,Aarskog syndrome,disease,Aarskog-Scott syndrome,2245,FGD1,FGD1,CTD_human,14560308,Phenotypic and molecular characterisation of the Aarskog-Scott syndrome: a survey of the clinical variability in light of FGD1 mutation analysis in 46 patients.,0.6079670767421801,"Phenotypic and molecular characterisation of the <span class=""disease"" id=""14560308-0-49-71"">Aarskog-Scott syndrome</span>: a survey of the clinical variability in light of <span class=""gene"" id=""14560308-0-122-126"">FGD1</span> mutation analysis in 46 patients.",CTD_human;ORPHANET;UNIPROT
6,14,Biomarker,C0175701,Aarskog syndrome,disease,Aarskog syndrome,2245,FGD1,FGD1,CTD_human,11093277,Two novel mutations confirm FGD1 is responsible for the Aarskog syndrome.,0.6079670767421801,"Two novel mutations confirm <span class=""gene"" id=""11093277-0-28-32"">FGD1</span> is responsible for the <span class=""disease"" id=""11093277-0-56-72"">Aarskog syndrome</span>.",CTD_human;ORPHANET;UNIPROT
6,14,Biomarker,C0175701,Aarskog syndrome,disease,Aarskog-Scott syndrome,2245,FGD1,FGD1,CTD_human,10930571,A mutation in the pleckstrin homology (PH) domain of the FGD1 gene in an Italian family with faciogenital dysplasia (Aarskog-Scott syndrome).,0.6079670767421801,"A mutation in the pleckstrin homology (PH) domain of the <span class=""gene"" id=""10930571-0-57-61"">FGD1</span> gene in an Italian family with <span class=""disease"" id=""10930571-0-93-115"">faciogenital dysplasia</span> (<span class=""disease"" id=""10930571-0-117-139"">Aarskog-Scott syndrome</span>).",CTD_human;ORPHANET;UNIPROT
6,14,Biomarker,C0175701,Aarskog syndrome,disease,FGDY,2245,FGD1,FGD1,CTD_human,7954831,These results provide compelling evidence that FGD1 is responsible for FGDY and suggest that FGD1 is a Rho/RacGEF involved in mammalian development.,0.6079670767421801,"These results provide compelling evidence that <span class=""gene"" id=""7954831-6-47-51"">FGD1</span> is responsible for <span class=""disease"" id=""7954831-6-71-75"">FGDY</span> and suggest that <span class=""gene"" id=""7954831-6-93-97"">FGD1</span> is a Rho/RacGEF involved in mammalian development.",CTD_human;ORPHANET;UNIPROT
6,14,Biomarker,C0175701,Aarskog syndrome,disease,Aarskog-Scott syndrome,2245,FGD1,FGD1,CTD_human,17152066,Unusually severe expression of craniofacial features in Aarskog-Scott syndrome due to a novel truncating mutation of the FGD1 gene.,0.6079670767421801,"Unusually severe expression of craniofacial features in <span class=""disease"" id=""17152066-0-56-78"">Aarskog-Scott syndrome</span> due to a novel truncating mutation of the <span class=""gene"" id=""17152066-0-121-125"">FGD1</span> gene.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C1136249,"Mental Retardation, X-Linked",disease,X-linked mental retardation,2245,FGD1,FGD1,CTD_human,11940089,Non-syndromic X-linked mental retardation associated with a missense mutation (P312L) in the FGD1 gene.,0.20300763924902696,"Non-syndromic <span class=""disease"" id=""11940089-0-14-41"">X-linked mental retardation</span> associated with a missense mutation (P312L) in the <span class=""gene"" id=""11940089-0-93-97"">FGD1</span> gene.",CTD_human
1,0,Biomarker,C1263846,Attention deficit hyperactivity disorder,disease,ADHD,2245,FGD1,FGD1,CTD_human,15809997,Attention-deficit/hyperactivity disorder (ADHD) and variable clinical expression of Aarskog-Scott syndrome due to a novel FGD1 gene mutation (R408Q).,0.400549453568426,"<span class=""disease"" id=""15809997-0-0-40"">Attention-deficit/hyperactivity disorder</span> (<span class=""disease"" id=""15809997-0-42-46"">ADHD</span>) and variable clinical expression of Aarskog-Scott syndrome due to a novel <span class=""gene"" id=""15809997-0-122-126"">FGD1</span> gene mutation (R408Q).",CTD_human;HPO
1,0,Biomarker,C0023418,leukemia,disease,leukemia,2246,FGF1,FGF1,CTD_human,17219402,"Zebrafish fgf1 is syntenic to human FGF1, which maps to a critically deleted region in human del(5q) syndrome posing an increased risk of leukemia to patients.",0.200274726784213,"Zebrafish <span class=""gene"" id=""17219402-7-10-14"">fgf1</span> is syntenic to human <span class=""gene"" id=""17219402-7-36-40"">FGF1</span>, which maps to a critically deleted region in human del(5q) syndrome posing an increased risk of <span class=""disease"" id=""17219402-7-138-146"">leukemia</span> to patients.",CTD_human
1,0,Biomarker,C0025500,Mesothelioma,disease,MM,2246,FGF1,FGF-1,CTD_human,15878867,"Treatment of MM cells with egr-1 short interfering RNA suppressed proliferation, which was overridden by exogenously added recombinant FGF-1 and, in particular, FGF-2.",0.20054945356842604,"Treatment of <span class=""disease"" id=""15878867-6-13-15"">MM</span> cells with egr-1 short interfering RNA suppressed proliferation, which was overridden by exogenously added recombinant <span class=""gene"" id=""15878867-6-135-140"">FGF-1</span> and, in particular, FGF-2.",CTD_human
1,0,Biomarker,C0011581,Depressive disorder,disease,depression,2247,FGF2,FGF-2,CTD_human,16861106,"We found raised measures of FGFR1 mRNA+ in major depression and, less so, in schizophrenia, along with reduced FGF-2 mRNA density in depression.",0.200274726784213,"We found raised measures of FGFR1 mRNA+ in major depression and, less so, in schizophrenia, along with reduced <span class=""gene"" id=""16861106-10-111-116"">FGF-2</span> mRNA density in <span class=""disease"" id=""16861106-10-133-143"">depression</span>.",CTD_human
1,0,Biomarker,C0014549,Tonic-Clonic Epilepsy,disease,tonic-clonic convulsions,2247,FGF2,FGF-2,CTD_human,16023256,"At 4 h following pilocarpine-induced seizures, expression of NGF, BDNF, HB-EGF, and FGF-2 increased only in the mice manifesting tonic-clonic convulsions and not in mice without seizures.",0.2,"At 4 h following pilocarpine-induced seizures, expression of NGF, BDNF, HB-EGF, and <span class=""gene"" id=""16023256-5-84-89"">FGF-2</span> increased only in the mice manifesting <span class=""disease"" id=""16023256-5-129-153"">tonic-clonic convulsions</span> and not in mice without seizures.",CTD_human
1,0,Biomarker,C0022658,Kidney Diseases,group,nephropathy,2247,FGF2,FGF2,CTD_human,8995747,Changes in glomerular epithelial cells induced by FGF2 and FGF2 neutralizing antibody in puromycin aminonucleoside nephropathy.,0.201098907136852,"Changes in glomerular epithelial cells induced by <span class=""gene"" id=""8995747-0-50-54"">FGF2</span> and <span class=""gene"" id=""8995747-0-59-63"">FGF2</span> neutralizing antibody in puromycin aminonucleoside <span class=""disease"" id=""8995747-0-115-126"">nephropathy</span>.",CTD_human
1,0,Biomarker,C0025500,Mesothelioma,disease,MM,2247,FGF2,FGF-2,CTD_human,15878867,"Treatment of MM cells with egr-1 short interfering RNA suppressed proliferation, which was overridden by exogenously added recombinant FGF-1 and, in particular, FGF-2.",0.203557092817453,"Treatment of <span class=""disease"" id=""15878867-6-13-15"">MM</span> cells with egr-1 short interfering RNA suppressed proliferation, which was overridden by exogenously added recombinant FGF-1 and, in particular, <span class=""gene"" id=""15878867-6-161-166"">FGF-2</span>.",CTD_human
1,0,Therapeutic,C0036572,Seizures,phenotype,seizures,2247,FGF2,FGF-2,CTD_human,21269288,Localized overexpression of FGF-2 and BDNF in hippocampus reduces mossy fiber sprouting and spontaneous seizures up to 4 weeks after pilocarpine-induced status epilepticus.,0.200274726784213,"Localized overexpression of <span class=""gene"" id=""21269288-0-28-33"">FGF-2</span> and BDNF in hippocampus reduces mossy fiber sprouting and spontaneous <span class=""disease"" id=""21269288-0-104-112"">seizures</span> up to 4 weeks after pilocarpine-induced status epilepticus.",CTD_human
1,0,Biomarker,C0085109,Corneal Neovascularization,disease,corneal neovascularization,2247,FGF2,bFGF,CTD_human,9301478,Experiments examining thalidomide's enantiomers reveal-that the S(-)-enantiomer has the strongest antiangiogenic activity in VEGF-induced and bFGF-induced corneal neovascularization.,0.20300763924902696,"Experiments examining thalidomide's enantiomers reveal-that the S(-)-enantiomer has the strongest antiangiogenic activity in VEGF-induced and <span class=""gene"" id=""9301478-4-142-146"">bFGF</span>-induced <span class=""disease"" id=""9301478-4-155-181"">corneal neovascularization</span>.",CTD_human
1,0,Biomarker,C0034069,Pulmonary Fibrosis,disease,pulmonary fibrosis,2252,FGF7,Keratinocyte growth factor,CTD_human,15677771,Keratinocyte growth factor expression by fibroblasts in pulmonary fibrosis: poor response to interleukin-1beta.,0.200274726784213,"<span class=""gene"" id=""15677771-0-0-26"">Keratinocyte growth factor</span> expression by fibroblasts in <span class=""disease"" id=""15677771-0-56-74"">pulmonary fibrosis</span>: poor response to interleukin-1beta.",CTD_human
1,0,Biomarker,C2936346,22q11 Deletion Syndrome,disease,22q11 deletion syndrome,2253,FGF8,Fgf8,CTD_human,12223415,An Fgf8 mouse mutant phenocopies human 22q11 deletion syndrome.,0.200274726784213,"An <span class=""gene"" id=""12223415-0-3-7"">Fgf8</span> mouse mutant phenocopies human <span class=""disease"" id=""12223415-0-39-62"">22q11 deletion syndrome</span>.",CTD_human
1,0,Biomarker,C0001418,Adenocarcinoma,group,adenocarcinomas,2254,FGF9,FGF-9,CTD_human,20464547,FGF-9 staining intensity was positively correlated with status of disease and degree of lymph node metastasis in these lung adenocarcinomas.,0.200274726784213,"<span class=""gene"" id=""20464547-9-0-5"">FGF-9</span> staining intensity was positively correlated with status of disease and degree of lymph node metastasis in these lung <span class=""disease"" id=""20464547-9-124-139"">adenocarcinomas</span>.",CTD_human
1,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,NSCLC,2254,FGF9,FGF-9,CTD_human,19358281,We further compared AhR and FGF-9 expression in 146 non-small cell lung cancer (NSCLC) cases by immunohistochemistry.,0.201373633921065,"We further compared AhR and <span class=""gene"" id=""19358281-11-28-33"">FGF-9</span> expression in 146 <span class=""disease"" id=""19358281-11-52-78"">non-small cell lung cancer</span> (<span class=""disease"" id=""19358281-11-80-85"">NSCLC</span>) cases by immunohistochemistry.",CTD_human
1,0,Biomarker,C0009241,Cognition Disorders,group,cognitive impairments,2259,FGF14,SCA27,CTD_human,26089778,"Genetically inherited mutations in the fibroblast growth factor 14 (FGF14) gene lead to spinocerebellar ataxia type 27 (SCA27), an autosomal dominant disorder characterized by heterogeneous motor and cognitive impairments.",0.200274726784213,"Genetically inherited mutations in the <span class=""gene"" id=""26089778-1-39-66"">fibroblast growth factor 14</span> (<span class=""gene"" id=""26089778-1-68-73"">FGF14</span>) gene lead to spinocerebellar ataxia type 27 (<span class=""gene"" id=""26089778-1-120-125"">SCA27</span>), an autosomal dominant disorder characterized by heterogeneous motor and <span class=""disease"" id=""26089778-1-200-221"">cognitive impairments</span>.",CTD_human
2,2,Biomarker,C1836383,SPINOCEREBELLAR ATAXIA 27,disease,SCA27,2259,FGF14,FGF14,CTD_human,26089778,These results provide evidence of a critical role of FGF14 in maintaining presynaptic function at PF-Purkinje neuron synapses highlighting critical target mechanisms to recapitulate the complexity of the SCA27 disease.,0.6802747267842131,"These results provide evidence of a critical role of <span class=""gene"" id=""26089778-9-53-58"">FGF14</span> in maintaining presynaptic function at PF-Purkinje neuron synapses highlighting critical target mechanisms to recapitulate the complexity of the <span class=""disease"" id=""26089778-9-204-209"">SCA27</span> disease.",CTD_human;ORPHANET;UNIPROT
5,0,Biomarker,C0011581,Depressive disorder,disease,depression,2260,FGFR1,FGFR1,CTD_human,16861106,"We found raised measures of FGFR1 mRNA+ in major depression and, less so, in schizophrenia, along with reduced FGF-2 mRNA density in depression.",0.6,"We found raised measures of <span class=""gene"" id=""16861106-10-28-33"">FGFR1</span> mRNA+ in major depression and, less so, in schizophrenia, along with reduced FGF-2 mRNA density in <span class=""disease"" id=""16861106-10-133-143"">depression</span>.",CTD_human;HPO;PSYGENET
2,0,Biomarker,C0027022,Myeloproliferative disease,group,myeloproliferative neoplasm,2260,FGFR1,FGFR1,CTD_human,22875613,"The 8p11 myeloproliferative syndrome is a rare, aggressive myeloproliferative neoplasm characterized by constitutively active FGFR1 fusion proteins that arise from specific chromosomal translocations and which drive aberrant proliferation.",0.212073623128059,"The 8p11 myeloproliferative syndrome is a rare, aggressive <span class=""disease"" id=""22875613-1-59-86"">myeloproliferative neoplasm</span> characterized by constitutively active <span class=""gene"" id=""22875613-1-126-131"">FGFR1</span> fusion proteins that arise from specific chromosomal translocations and which drive aberrant proliferation.",CTD_human
1,0,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,2260,FGFR1,FGFR1,CTD_human,16861106,"Hippocampal FGF-2 and FGFR1 mRNA expression in major depression, schizophrenia and bipolar disorder.",0.202681755307501,"Hippocampal FGF-2 and <span class=""gene"" id=""16861106-0-22-27"">FGFR1</span> mRNA expression in major depression, <span class=""disease"" id=""16861106-0-65-78"">schizophrenia</span> and bipolar disorder.",CTD_human
4,0,Biomarker,C0005695,Bladder Neoplasm,disease,bladder cancer,2261,FGFR3,FGFR3,CTD_human,21936542,"On the basis of its in vitro profile, compound 1h (NVP-BGJ398) was selected for in vivo evaluation and showed significant antitumor activity in RT112 bladder cancer xenografts models overexpressing wild-type FGFR3.",0.252659731573388,"On the basis of its in vitro profile, compound 1h (NVP-BGJ398) was selected for in vivo evaluation and showed significant antitumor activity in RT112 <span class=""disease"" id=""21936542-2-150-164"">bladder cancer</span> xenografts models overexpressing wild-type <span class=""gene"" id=""21936542-2-208-213"">FGFR3</span>.",CTD_human
4,0,Biomarker,C0005695,Bladder Neoplasm,disease,bladder cancer,2261,FGFR3,FGFR3,CTD_human,19855393,Massively parallel sequencing of sperm DNA showed that levels of the FGFR3 mutation increase with paternal age and that the mutation spectrum at the Lys650 codon is similar to that observed in bladder cancer.,0.252659731573388,"Massively parallel sequencing of sperm DNA showed that levels of the <span class=""gene"" id=""19855393-4-69-74"">FGFR3</span> mutation increase with paternal age and that the mutation spectrum at the Lys650 codon is similar to that observed in <span class=""disease"" id=""19855393-4-193-207"">bladder cancer</span>.",CTD_human
1,0,Biomarker,C0036631,Seminoma,disease,seminomas,2261,FGFR3,FGFR3,CTD_human,19855393,Most spermatocytic seminomas show increased immunoreactivity for FGFR3 and/or HRAS.,0.200274726784213,"Most spermatocytic <span class=""disease"" id=""19855393-5-19-28"">seminomas</span> show increased immunoreactivity for <span class=""gene"" id=""19855393-5-65-70"">FGFR3</span> and/or HRAS.",CTD_human
1,0,Biomarker,C0039743,Thanatophoric Dysplasia,disease,thanatophoric dysplasia,2261,FGFR3,FGFR3,CTD_human,19855393,"Screening of 30 spermatocytic seminomas for oncogenic mutations in 17 genes identified 2 mutations in FGFR3 (both 1948A>G, encoding K650E, which causes thanatophoric dysplasia in the germline) and 5 mutations in HRAS.",0.231679860390191,"Screening of 30 spermatocytic seminomas for oncogenic mutations in 17 genes identified 2 mutations in <span class=""gene"" id=""19855393-3-102-107"">FGFR3</span> (both 1948A&gt;G, encoding K650E, which causes <span class=""disease"" id=""19855393-3-152-175"">thanatophoric dysplasia</span> in the germline) and 5 mutations in HRAS.",CTD_human
3,1,Biomarker,C2677099,CROUZON SYNDROME WITH ACANTHOSIS NIGRICANS (disorder),disease,Crouzon syndrome with Acanthosis Nigricans,2261,FGFR3,FGFR3,CTD_human,23437153,The A391E mutation in fibroblast growth factor receptor 3 (FGFR3) is the genetic cause for Crouzon syndrome with Acanthosis Nigricans.,0.6019230874894921,"The A391E mutation in <span class=""gene"" id=""23437153-1-22-57"">fibroblast growth factor receptor 3</span> (<span class=""gene"" id=""23437153-1-59-64"">FGFR3</span>) is the genetic cause for <span class=""disease"" id=""23437153-1-91-133"">Crouzon syndrome with Acanthosis Nigricans</span>.",CTD_human;ORPHANET;UNIPROT
1,1,Therapeutic,C0027726,Nephrotic Syndrome,group,nephrotic syndrome,2262,GPC5,GPC5,CTD_human,21441931,Common variation in GPC5 is associated with acquired nephrotic syndrome.,0.20054945356842604,"Common variation in <span class=""gene"" id=""21441931-0-20-24"">GPC5</span> is associated with acquired <span class=""disease"" id=""21441931-0-53-71"">nephrotic syndrome</span>.",CTD_human
3,0,Biomarker,C0010278,Craniosynostosis,disease,craniosynostosis,2263,FGFR2,FGFR2,CTD_human,8957519,FGFR2 mutation in clinically nonclassifiable autosomal dominant craniosynostosis with pronounced phenotypic variation.,0.44045676210769297,"<span class=""gene"" id=""8957519-0-0-5"">FGFR2</span> mutation in clinically nonclassifiable autosomal dominant <span class=""disease"" id=""8957519-0-64-80"">craniosynostosis</span> with pronounced phenotypic variation.",CTD_human;HPO
2,17,Biomarker,C1708350,Hereditary Leiomyomatosis and Renal Cell Cancer,disease,Reed's syndrome,2271,FH,fumarate hydratase,CTD_human,16403393,Genetic sequencing demonstrated a novel mutation in the fumarate hydratase gene that confirmed the diagnosis of Reed's syndrome.,0.6178572409738521,"Genetic sequencing demonstrated a novel mutation in the <span class=""gene"" id=""16403393-3-56-74"">fumarate hydratase</span> gene that confirmed the diagnosis of <span class=""disease"" id=""16403393-3-112-127"">Reed's syndrome</span>.",CTD_human;HPO;ORPHANET;UNIPROT
1,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,NSCLC,2272,FHIT,FHIT,CTD_human,11788890,"We examined aberrant expression of the Fhit protein and allele loss at the FHIT gene in a series of lung cancer cases, mainly of non-small cell carcinoma (NSCLC) histology.",0.208241803526393,"We examined aberrant expression of the <span class=""gene"" id=""11788890-2-39-43"">Fhit</span> protein and allele loss at the <span class=""gene"" id=""11788890-2-75-79"">FHIT</span> gene in a series of lung cancer cases, mainly of non-small cell carcinoma (<span class=""disease"" id=""11788890-2-155-160"">NSCLC</span>) histology.",CTD_human
1,1,Biomarker,C0004096,Asthma,disease,asthmatics,22806,IKZF3,IKAROS family zinc finger 3 (Aiolo,CTD_human,25256354,"In the Swedish Search study, we found significant differences in DNA methylation between asthmatics and controls in five CpG sites; after adjusting for lymphocyte and neutrophil cell counts, three remained significant: one in IKZF3 [IKAROS family zinc finger 3 (Aiolos); cg16293631] and two in the CpG island (CGI) of ORMDL3 (cg02305874 and cg16638648).",0.201098907136852,"In the Swedish Search study, we found significant differences in DNA methylation between <span class=""disease"" id=""25256354-5-89-99"">asthmatics</span> and controls in five CpG sites; after adjusting for lymphocyte and neutrophil cell counts, three remained significant: one in <span class=""gene"" id=""25256354-5-226-231"">IKZF3</span> [<span class=""gene"" id=""25256354-5-233-267"">IKAROS family zinc finger 3 (Aiolo</span>s); cg16293631] and two in the CpG island (CGI) of ORMDL3 (cg02305874 and cg16638648).",CTD_human
1,0,Biomarker,C0345967,Malignant mesothelioma,disease,MM,22820,COPG1,COPG1,CTD_human,26463840,BAP1 and COPG1 mutations were seen exclusively in MM.,0.200274726784213,"BAP1 and <span class=""gene"" id=""26463840-10-9-14"">COPG1</span> mutations were seen exclusively in <span class=""disease"" id=""26463840-10-50-52"">MM</span>.",CTD_human
1,0,Biomarker,C0005586,Bipolar Disorder,disease,bipolar disorder,22854,NTNG1,netrin-G1,CTD_human,17507910,Decreased mRNA expression of netrin-G1 and netrin-G2 in the temporal lobe in schizophrenia and bipolar disorder.,0.20054945356842604,"Decreased mRNA expression of <span class=""gene"" id=""17507910-0-29-38"">netrin-G1</span> and netrin-G2 in the temporal lobe in schizophrenia and <span class=""disease"" id=""17507910-0-95-111"">bipolar disorder</span>.",CTD_human
1,0,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,22854,NTNG1,netrin-G1,CTD_human,17507910,Decreased mRNA expression of netrin-G1 and netrin-G2 in the temporal lobe in schizophrenia and bipolar disorder.,0.21220296946569503,"Decreased mRNA expression of <span class=""gene"" id=""17507910-0-29-38"">netrin-G1</span> and netrin-G2 in the temporal lobe in <span class=""disease"" id=""17507910-0-77-90"">schizophrenia</span> and bipolar disorder.",CTD_human
1,2,Biomarker,C0011615,"Dermatitis, Atopic",disease,atopic dermatitis,22891,ZNF365,ZNF365,CTD_human,23042114,"On the basis of data from a genome-wide association study (GWAS) and a validation study comprising a total of 3,328 subjects with atopic dermatitis and 14,992 controls in the Japanese population, we report here 8 new susceptibility loci: IL1RL1-IL18R1-IL18RAP (P(combined) = 8.36 × 10(-18)), the major histocompatibility complex (MHC) region (P = 8.38 × 10(-20)), OR10A3-NLRP10 (P = 1.54 × 10(-22)), GLB1 (P = 2.77 × 10(-16)), CCDC80 (P = 1.56 × 10(-19)), CARD11 (P = 7.83 × 10(-9)), ZNF365 (P = 5.85 × 10(-20)) and CYP24A1-PFDN4 (P = 1.65 × 10(-8)).",0.2,"On the basis of data from a genome-wide association study (GWAS) and a validation study comprising a total of 3,328 subjects with <span class=""disease"" id=""23042114-2-130-147"">atopic dermatitis</span> and 14,992 controls in the Japanese population, we report here 8 new susceptibility loci: IL1RL1-IL18R1-IL18RAP (P(combined) = 8.36 &times; 10(-18)), the major histocompatibility complex (MHC) region (P = 8.38 &times; 10(-20)), OR10A3-NLRP10 (P = 1.54 &times; 10(-22)), GLB1 (P = 2.77 &times; 10(-16)), CCDC80 (P = 1.56 &times; 10(-19)), CARD11 (P = 7.83 &times; 10(-9)), <span class=""gene"" id=""23042114-2-484-490"">ZNF365</span> (P = 5.85 &times; 10(-20)) and CYP24A1-PFDN4 (P = 1.65 &times; 10(-8)).",CTD_human
1,0,Biomarker,C0025958,Microcephaly,disease,microcephaly,2290,FOXG1,forkhead box G1B,CTD_human,18627055,"FOXG1B (forkhead box G1B) is a very intriguing candidate gene since it is known to promote neuronal progenitor proliferation and to suppress premature neurogenesis and its disruption is reported in a patient with postnatal microcephaly, corpus callosum agenesis, seizures, and severe mental retardation.",0.202472541057918,"<span class=""gene"" id=""18627055-4-0-6"">FOXG1B</span> (<span class=""gene"" id=""18627055-4-8-24"">forkhead box G1B</span>) is a very intriguing candidate gene since it is known to promote neuronal progenitor proliferation and to suppress premature neurogenesis and its disruption is reported in a patient with postnatal <span class=""disease"" id=""18627055-4-223-235"">microcephaly</span>, corpus callosum agenesis, seizures, and severe mental retardation.",CTD_human
1,0,Biomarker,C0036572,Seizures,phenotype,seizures,2290,FOXG1,forkhead box G1B,CTD_human,18627055,"FOXG1B (forkhead box G1B) is a very intriguing candidate gene since it is known to promote neuronal progenitor proliferation and to suppress premature neurogenesis and its disruption is reported in a patient with postnatal microcephaly, corpus callosum agenesis, seizures, and severe mental retardation.",0.40082418035263895,"<span class=""gene"" id=""18627055-4-0-6"">FOXG1B</span> (<span class=""gene"" id=""18627055-4-8-24"">forkhead box G1B</span>) is a very intriguing candidate gene since it is known to promote neuronal progenitor proliferation and to suppress premature neurogenesis and its disruption is reported in a patient with postnatal microcephaly, corpus callosum agenesis, <span class=""disease"" id=""18627055-4-263-271"">seizures</span>, and severe mental retardation.",CTD_human;HPO
1,0,Biomarker,C0024899,Mastocytosis,disease,mastocytosis,2294,FOXF1,Foxf1,CTD_human,18421012,Pulmonary mastocytosis and enhanced lung inflammation in mice heterozygous null for the Foxf1 gene.,0.2,"Pulmonary <span class=""disease"" id=""18421012-0-10-22"">mastocytosis</span> and enhanced lung inflammation in mice heterozygous null for the <span class=""gene"" id=""18421012-0-88-93"">Foxf1</span> gene.",CTD_human
1,0,Biomarker,C3714756,Intellectual Disability,group,mental retardation,22941,SHANK2,SHANK2,CTD_human,20473310,Mutations in the SHANK2 synaptic scaffolding gene in autism spectrum disorder and mental retardation.,0.202197814273705,"Mutations in the <span class=""gene"" id=""20473310-0-17-23"">SHANK2</span> synaptic scaffolding gene in autism spectrum disorder and <span class=""disease"" id=""20473310-0-82-100"">mental retardation</span>.",CTD_human
1,0,Biomarker,C0014544,Epilepsy,disease,epilepsy,22953,P2RX2,P2X2,CTD_human,12941474,"Here we show that, in the seizure-sensitive (SS) gerbil hippocampus, a recognized genetic epilepsy model, the expressions of both P2X2 and P2X4 receptors are markedly decreased as compared with that in the seizure-resistant (SR) gerbil.",0.2,"Here we show that, in the seizure-sensitive (SS) gerbil hippocampus, a recognized genetic <span class=""disease"" id=""12941474-4-90-98"">epilepsy</span> model, the expressions of both <span class=""gene"" id=""12941474-4-130-134"">P2X2</span> and P2X4 receptors are markedly decreased as compared with that in the seizure-resistant (SR) gerbil.",CTD_human
1,0,Biomarker,C0010964,Dandy-Walker Syndrome,disease,Dandy-Walker malformation,2296,FOXC1,FOXC1,CTD_human,19668217,FOXC1 is required for normal cerebellar development and is a major contributor to chromosome 6p25.3 Dandy-Walker malformation.,0.20054945356842604,"<span class=""gene"" id=""19668217-0-0-5"">FOXC1</span> is required for normal cerebellar development and is a major contributor to chromosome 6p25.3 <span class=""disease"" id=""19668217-0-100-125"">Dandy-Walker malformation</span>.",CTD_human
1,0,Biomarker,C0039685,Tetralogy of Fallot,disease,TOF,2296,FOXC1,FOXC1,CTD_human,25093829,"We sequenced the coding, 5'UTR, and 3'UTR regions of twelve transcription factor genes implicated in cardiac outflow tract development (NKX2.5, GATA4, ISL1, TBX20, MEF2C, BOP/SMYD1, HAND2, FOXC1, FOXC2, FOXH, FOXA2 and TBX1) in 93 non-syndromic, non-Mendelian TOF cases.",0.2,"We sequenced the coding, 5'UTR, and 3'UTR regions of twelve transcription factor genes implicated in cardiac outflow tract development (NKX2.5, GATA4, ISL1, TBX20, MEF2C, BOP/SMYD1, HAND2, <span class=""gene"" id=""25093829-3-189-194"">FOXC1</span>, FOXC2, FOXH, FOXA2 and TBX1) in 93 non-syndromic, non-Mendelian <span class=""disease"" id=""25093829-3-260-263"">TOF</span> cases.",CTD_human
1,0,Biomarker,C0339573,"Glaucoma, Primary Open Angle",disease,primary open-angle glaucoma,2296,FOXC1,FOXC1,CTD_human,26752265,"Genome-wide association analysis identifies TXNRD2, ATXN2 and FOXC1 as susceptibility loci for primary open-angle glaucoma.",0.20054945356842604,"Genome-wide association analysis identifies TXNRD2, ATXN2 and <span class=""gene"" id=""26752265-0-62-67"">FOXC1</span> as susceptibility loci for <span class=""disease"" id=""26752265-0-95-122"">primary open-angle glaucoma</span>.",CTD_human
1,0,Biomarker,C0265202,Seckel syndrome,disease,Seckel syndrome,22995,CEP152,CEP152,CTD_human,21131973,CEP152 is a genome maintenance protein disrupted in Seckel syndrome.,0.40027472678421294,"<span class=""gene"" id=""21131973-0-0-6"">CEP152</span> is a genome maintenance protein disrupted in <span class=""disease"" id=""21131973-0-52-67"">Seckel syndrome</span>.",CTD_human;ORPHANET
1,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,NSCLC,23028,KDM1A,LSD1,CTD_human,22493729,Our results showed that over-expression of LSD1 protein were associated with shorter overall survival of NSCLC patients.,0.200274726784213,"Our results showed that over-expression of <span class=""gene"" id=""22493729-9-43-47"">LSD1</span> protein were associated with shorter overall survival of <span class=""disease"" id=""22493729-9-105-110"">NSCLC</span> patients.",CTD_human
1,0,Biomarker,C0039685,Tetralogy of Fallot,disease,TOF,2303,FOXC2,FOXC2,CTD_human,25093829,"We sequenced the coding, 5'UTR, and 3'UTR regions of twelve transcription factor genes implicated in cardiac outflow tract development (NKX2.5, GATA4, ISL1, TBX20, MEF2C, BOP/SMYD1, HAND2, FOXC1, FOXC2, FOXH, FOXA2 and TBX1) in 93 non-syndromic, non-Mendelian TOF cases.",0.4,"We sequenced the coding, 5'UTR, and 3'UTR regions of twelve transcription factor genes implicated in cardiac outflow tract development (NKX2.5, GATA4, ISL1, TBX20, MEF2C, BOP/SMYD1, HAND2, FOXC1, <span class=""gene"" id=""25093829-3-196-201"">FOXC2</span>, FOXH, FOXA2 and TBX1) in 93 non-syndromic, non-Mendelian <span class=""disease"" id=""25093829-3-260-263"">TOF</span> cases.",CTD_human;HPO
2,3,Biomarker,C0265345,Lymphedema distichiasis syndrome,disease,hereditary lymphedema-distichiasis syndrome,2303,FOXC2,MFH-1,CTD_human,11078474,"Mutations in FOXC2 (MFH-1), a forkhead family transcription factor, are responsible for the hereditary lymphedema-distichiasis syndrome.",0.6841209017631971,"Mutations in <span class=""gene"" id=""11078474-0-13-18"">FOXC2</span> (<span class=""gene"" id=""11078474-0-20-25"">MFH-1</span>), a forkhead family transcription factor, are responsible for the <span class=""disease"" id=""11078474-0-92-135"">hereditary lymphedema-distichiasis syndrome</span>.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0023418,leukemia,disease,leukemia,2305,FOXM1,FoxM1,CTD_human,19436953,"Here, we report on the synthesis of TMPP and DMPP and demonstrate that these agents hinder proliferation of leukemia cells by FoxM1 suppression, which leads to G2/M cell cycle block and subsequent caspase-3-dependent apoptosis in acute leukemia cells.",0.20082418035263896,"Here, we report on the synthesis of TMPP and DMPP and demonstrate that these agents hinder proliferation of <span class=""disease"" id=""19436953-7-108-116"">leukemia</span> cells by <span class=""gene"" id=""19436953-7-126-131"">FoxM1</span> suppression, which leads to G2/M cell cycle block and subsequent caspase-3-dependent apoptosis in acute leukemia cells.",CTD_human
2,0,Biomarker,C0024121,Lung Neoplasms,group,lung tumor,2305,FOXM1,Foxm1,CTD_human,16489016,We show that Mx-Cre Foxm1-/- mice exhibit diminished proliferation of lung tumor cells causing a significant reduction in number and size of lung adenomas.,0.201373633921065,"We show that Mx-Cre <span class=""gene"" id=""16489016-5-20-25"">Foxm1</span>-/- mice exhibit diminished proliferation of <span class=""disease"" id=""16489016-5-70-80"">lung tumor</span> cells causing a significant reduction in number and size of lung adenomas.",CTD_human
2,0,Biomarker,C2239176,Liver carcinoma,disease,hepatocellular carcinoma,2305,FOXM1,FoxM1,CTD_human,17173139,A cell-penetrating ARF peptide inhibitor of FoxM1 in mouse hepatocellular carcinoma treatment.,0.28659344282111404,"A cell-penetrating ARF peptide inhibitor of <span class=""gene"" id=""17173139-0-44-49"">FoxM1</span> in mouse <span class=""disease"" id=""17173139-0-59-83"">hepatocellular carcinoma</span> treatment.",CTD_human
2,0,Biomarker,C2239176,Liver carcinoma,disease,hepatocellular carcinomas,2305,FOXM1,Foxm1b,CTD_human,15082532,Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor.,0.28659344282111404,"<span class=""gene"" id=""15082532-0-0-6"">Foxm1b</span> transcription factor is essential for development of <span class=""disease"" id=""15082532-0-60-85"">hepatocellular carcinomas</span> and is negatively regulated by the p19ARF tumor suppressor.",CTD_human
1,0,Biomarker,C0022578,Keratoconus,disease,keratoconus,2308,FOXO1,FOXO1,CTD_human,23291589,"We further showed that 2 CCT-associated loci, FOXO1 and FNDC3B, conferred relatively large risks for keratoconus in 2 cohorts with 874 cases and 6,085 controls (rs2721051 near FOXO1 had odds ratio (OR) = 1.62, 95% confidence interval (CI) = 1.4-1.88, P = 2.7 × 10(-10), and rs4894535 in FNDC3B had OR = 1.47, 95% CI = 1.29-1.68, P = 4.9 × 10(-9)).",0.201098907136852,"We further showed that 2 CCT-associated loci, <span class=""gene"" id=""23291589-3-46-51"">FOXO1</span> and FNDC3B, conferred relatively large risks for <span class=""disease"" id=""23291589-3-101-112"">keratoconus</span> in 2 cohorts with 874 cases and 6,085 controls (rs2721051 near <span class=""gene"" id=""23291589-3-176-181"">FOXO1</span> had odds ratio (OR) = 1.62, 95% confidence interval (CI) = 1.4-1.88, P = 2.7 &times; 10(-10), and rs4894535 in FNDC3B had OR = 1.47, 95% CI = 1.29-1.68, P = 4.9 &times; 10(-9)).",CTD_human
1,0,Biomarker,C0024117,Chronic Obstructive Airway Disease,disease,COPD,2309,FOXO3,FoxO3A,CTD_human,23099361,Aberrantly activated EGFR contributes to enhanced IL-8 expression in COPD airways epithelial cells via regulation of nuclear FoxO3A.,0.20054945356842604,"Aberrantly activated EGFR contributes to enhanced IL-8 expression in <span class=""disease"" id=""23099361-0-69-73"">COPD</span> airways epithelial cells via regulation of nuclear <span class=""gene"" id=""23099361-0-125-131"">FoxO3A</span>.",CTD_human
1,0,Biomarker,C0028754,Obesity,disease,Obese,2309,FOXO3,Foxo3a,CTD_human,23954404,"Obese mouse ovaries had decreased Irs1, Foxo3a, Cyp2e1, MiR-103, and MiR-21 but increased Kitlg, Akt1, and miR-184 levels relative to lean littermates.",0.28,"<span class=""disease"" id=""23954404-4-0-5"">Obese</span> mouse ovaries had decreased Irs1, <span class=""gene"" id=""23954404-4-40-46"">Foxo3a</span>, Cyp2e1, MiR-103, and MiR-21 but increased Kitlg, Akt1, and miR-184 levels relative to lean littermates.",CTD_human
1,0,Biomarker,C0152013,Adenocarcinoma of lung (disorder),disease,LAC,2309,FOXO3,FOXO3a,CTD_human,19380174,This suggests that FOXO3a is a potential suppressor of carcinogenic damage in LAC.,0.201098907136852,"This suggests that <span class=""gene"" id=""19380174-11-19-25"">FOXO3a</span> is a potential suppressor of carcinogenic damage in <span class=""disease"" id=""19380174-11-78-81"">LAC</span>.",CTD_human
1,1,Biomarker,C0026769,Multiple Sclerosis,disease,multiple sclerosis,23095,KIF1B,KIF1B,CTD_human,18997785,Genetic variation in the KIF1B locus influences susceptibility to multiple sclerosis.,0.201373633921065,"Genetic variation in the <span class=""gene"" id=""18997785-0-25-30"">KIF1B</span> locus influences susceptibility to <span class=""disease"" id=""18997785-0-66-84"">multiple sclerosis</span>.",CTD_human
1,0,Biomarker,C0035235,Respiratory Syncytial Virus Infections,group,RSV infection,23098,SARM1,SARM,CTD_human,24478430,Resveratrol increased SARM expression and decreased TRIF expression after RSV infection.,0.200274726784213,"Resveratrol increased <span class=""gene"" id=""24478430-11-22-26"">SARM</span> expression and decreased TRIF expression after <span class=""disease"" id=""24478430-11-74-87"">RSV infection</span>.",CTD_human
1,0,Biomarker,C0014175,Endometriosis,disease,endometriosis,231,AKR1B1,AKR1B1,CTD_human,25446850,These cell models characterized in this study will enable further investigations into the role of PGF2? in the pathophysiology of endometriosis and the involvement of AKR1B1 and AKR1C3.,0.200274726784213,"These cell models characterized in this study will enable further investigations into the role of PGF2&alpha; in the pathophysiology of <span class=""disease"" id=""25446850-12-130-143"">endometriosis</span> and the involvement of <span class=""gene"" id=""25446850-12-167-173"">AKR1B1</span> and AKR1C3.",CTD_human
3,0,Biomarker,C0086543,Cataract,disease,cataract,231,AKR1B1,Aldose reductase,CTD_human,25541468,Aldose reductase expression as a risk factor for cataract.,0.281648360705279,"<span class=""gene"" id=""25541468-0-0-16"">Aldose reductase</span> expression as a risk factor for <span class=""disease"" id=""25541468-0-49-57"">cataract</span>.",CTD_human
3,0,Biomarker,C0086543,Cataract,disease,cataracts,231,AKR1B1,AKR1B1,CTD_human,21376710,"Rats have high levels of AKR1B1 in lenses and readily develop diabetic cataracts, whereas mice have very low levels of AKR1B1 in their lenses and are not susceptible to hyperglycemic cataracts.",0.281648360705279,"Rats have high levels of <span class=""gene"" id=""21376710-2-25-31"">AKR1B1</span> in lenses and readily develop diabetic <span class=""disease"" id=""21376710-2-71-80"">cataracts</span>, whereas mice have very low levels of <span class=""gene"" id=""21376710-2-119-125"">AKR1B1</span> in their lenses and are not susceptible to hyperglycemic <span class=""disease"" id=""21376710-2-183-192"">cataracts</span>.",CTD_human
4,0,Biomarker,C0011615,"Dermatitis, Atopic",disease,atopic dermatitis,2312,FLG,FLG,CTD_human,24061166,Mutations in the filaggrin (FLG) gene are strongly associated with common dermatological disorders such as atopic dermatitis.,0.351938112356185,"Mutations in the <span class=""gene"" id=""24061166-1-17-26"">filaggrin</span> (<span class=""gene"" id=""24061166-1-28-31"">FLG</span>) gene are strongly associated with common dermatological disorders such as <span class=""disease"" id=""24061166-1-107-124"">atopic dermatitis</span>.",CTD_human
4,0,Biomarker,C0011615,"Dermatitis, Atopic",disease,AD,2312,FLG,FLG,CTD_human,23348739,"Topical application of coal tar is one of the oldest therapies for atopic dermatitis (AD), a T helper 2 (Th2) lymphocyte-mediated skin disease associated with loss-of-function mutations in the skin barrier gene, filaggrin (FLG).",0.351938112356185,"Topical application of coal tar is one of the oldest therapies for <span class=""disease"" id=""23348739-1-67-84"">atopic dermatitis</span> (<span class=""disease"" id=""23348739-1-86-88"">AD</span>), a T helper 2 (Th2) lymphocyte-mediated skin disease associated with loss-of-function mutations in the skin barrier gene, <span class=""gene"" id=""23348739-1-212-221"">filaggrin</span> (<span class=""gene"" id=""23348739-1-223-226"">FLG</span>).",CTD_human
4,0,Biomarker,C0011615,"Dermatitis, Atopic",disease,atopic dermatitis,2312,FLG,FLG,CTD_human,23042114,"We also replicated the associations of the FLG, C11orf30, TMEM232-SLC25A46, TNFRSF6B-ZGPAT, OVOL1, ACTL9 and KIF3A-IL13 loci that were previously reported in GWAS of European and Chinese individuals and a meta-analysis of GWAS for atopic dermatitis.",0.351938112356185,"We also replicated the associations of the <span class=""gene"" id=""23042114-3-43-46"">FLG</span>, C11orf30, TMEM232-SLC25A46, TNFRSF6B-ZGPAT, OVOL1, ACTL9 and KIF3A-IL13 loci that were previously reported in GWAS of European and Chinese individuals and a meta-analysis of GWAS for <span class=""disease"" id=""23042114-3-231-248"">atopic dermatitis</span>.",CTD_human
1,0,Biomarker,C0013595,Eczema,disease,atopic dermatitis,2312,FLG,filaggrin,CTD_human,17417636,"We found three additional rare null mutations in this case series, suggesting that the genetic architecture of filaggrin-related atopic dermatitis consists of both prevalent and rare risk alleles.",0.492577890084944,"We found three additional rare null mutations in this case series, suggesting that the genetic architecture of <span class=""gene"" id=""17417636-6-111-120"">filaggrin</span>-related <span class=""disease"" id=""17417636-6-129-146"">atopic dermatitis</span> consists of both prevalent and rare risk alleles.",CTD_human;HPO
2,4,Biomarker,C0079584,Ichthyosis Vulgaris,disease,ichthyosis vulgaris,2312,FLG,filaggrin,CTD_human,17417636,Comprehensive analysis of the gene encoding filaggrin uncovers prevalent and rare mutations in ichthyosis vulgaris and atopic eczema.,0.23403573175616604,"Comprehensive analysis of the gene encoding <span class=""gene"" id=""17417636-0-44-53"">filaggrin</span> uncovers prevalent and rare mutations in <span class=""disease"" id=""17417636-0-95-114"">ichthyosis vulgaris</span> and atopic eczema.",CTD_human
3,0,Biomarker,C0553580,Ewings sarcoma,disease,Ewing sarcoma,2313,FLI1,FLI1,CTD_human,26214589,Chimeric EWSR1-FLI1 regulates the Ewing sarcoma susceptibility gene EGR2 via a GGAA microsatellite.,0.421912630202418,"Chimeric EWSR1-<span class=""gene"" id=""26214589-0-15-19"">FLI1</span> regulates the <span class=""disease"" id=""26214589-0-34-47"">Ewing sarcoma</span> susceptibility gene EGR2 via a GGAA microsatellite.",CTD_human;ORPHANET
3,0,Biomarker,C0553580,Ewings sarcoma,disease,ES,2313,FLI1,FLI-1,CTD_human,16646077,"Ewing sarcoma (ES), a highly malignant pediatric tumor, is consistently associated with translocations that fuse the EWS gene with a member of the ETS family gene, most commonly FLI-1.",0.421912630202418,"<span class=""disease"" id=""16646077-1-0-13"">Ewing sarcoma</span> (<span class=""disease"" id=""16646077-1-15-17"">ES</span>), a highly malignant pediatric tumor, is consistently associated with translocations that fuse the EWS gene with a member of the ETS family gene, most commonly <span class=""gene"" id=""16646077-1-178-183"">FLI-1</span>.",CTD_human;ORPHANET
1,0,Biomarker,C0025202,melanoma,disease,melanoma,2315,MLANA,MART-1,CTD_human,26640592,"Expression of MAAs such as MART-1 and gp100 is modulated by the MAPK signaling pathway, which is often deregulated in melanoma.",0.25670244415626103,"Expression of MAAs such as <span class=""gene"" id=""26640592-2-27-33"">MART-1</span> and gp100 is modulated by the MAPK signaling pathway, which is often deregulated in <span class=""disease"" id=""26640592-2-118-126"">melanoma</span>.",CTD_human
1,0,Biomarker,C0345967,Malignant mesothelioma,disease,malignant mesothelioma,2315,MLANA,melan-A,CTD_human,22784439,"Immunohistochemical analysis for epithelial membrane antigen, calretinin, vimentin, ?-catenin, melan-A, glucose transporter-1, cytokeratin CAM5.2, Wilms tumor antigen-1, D2-40, CD146, progesterone receptor, estrogen receptor, and cytokeratin 5/6 was indicative of malignant mesothelioma.",0.2,"Immunohistochemical analysis for epithelial membrane antigen, calretinin, vimentin, &beta;-catenin, <span class=""gene"" id=""22784439-5-95-102"">melan-A</span>, glucose transporter-1, cytokeratin CAM5.2, Wilms tumor antigen-1, D2-40, CD146, progesterone receptor, estrogen receptor, and cytokeratin 5/6 was indicative of <span class=""disease"" id=""22784439-5-264-286"">malignant mesothelioma</span>.",CTD_human
1,0,Biomarker,C0010701,Phyllodes Tumor,disease,phyllodes tumor,2316,FLNA,FLNA,CTD_human,26437033,"Second, phyllodes tumors exhibited mutations in FLNA, SETD2 and KMT2D, suggesting a role in driving phyllodes tumor development.",0.2,"Second, <span class=""disease"" id=""26437033-5-8-24"">phyllodes tumors</span> exhibited mutations in <span class=""gene"" id=""26437033-5-48-52"">FLNA</span>, SETD2 and KMT2D, suggesting a role in driving <span class=""disease"" id=""26437033-5-100-115"">phyllodes tumor</span> development.",CTD_human
1,0,Biomarker,C0014544,Epilepsy,disease,epilepsy,2316,FLNA,FLN1,CTD_human,11914408,"Missense mutations and distal truncations consistent with partial loss of FLN1 function cause familial BPNH with the classical clinical phenotype including epilepsy and mild mental retardation, if any.",0.4010989071368521,"Missense mutations and distal truncations consistent with partial loss of <span class=""gene"" id=""11914408-9-74-78"">FLN1</span> function cause familial BPNH with the classical clinical phenotype including <span class=""disease"" id=""11914408-9-156-164"">epilepsy</span> and mild mental retardation, if any.",CTD_human;HPO
1,0,Biomarker,C0220769,FG syndrome,disease,FG syndrome,2316,FLNA,Filamin A,CTD_human,17632775,Filamin A mutation is one cause of FG syndrome.,0.200274726784213,"<span class=""gene"" id=""17632775-0-0-9"">Filamin A</span> mutation is one cause of <span class=""disease"" id=""17632775-0-35-46"">FG syndrome</span>.",CTD_human
4,14,Biomarker,C0265251,Oto-Palato-digital syndrome type 1,disease,OPD1,2316,FLNA,FLNA,CTD_human,15940695,We present the phenotypic and molecular data of a sporadic female patient clinically diagnosed with an OPD1 syndrome who carried a novel FLNA point mutation resulting in an Asp203Tyr substitution in the actin-binding domain of the protein.,0.6805494535684261,"We present the phenotypic and molecular data of a sporadic female patient clinically diagnosed with an <span class=""disease"" id=""15940695-4-103-107"">OPD1</span> syndrome who carried a novel <span class=""gene"" id=""15940695-4-137-141"">FLNA</span> point mutation resulting in an Asp203Tyr substitution in the actin-binding domain of the protein.",CTD_human;ORPHANET;UNIPROT
4,3,Biomarker,C0265293,Frontometaphyseal dysplasia,disease,frontometaphyseal dysplasia,2316,FLNA,OPD2,CTD_human,12612583,"We identified localized mutations in FLNA that conserve the reading frame and lead to a broad range of congenital malformations, affecting craniofacial structures, skeleton, brain, viscera and urogenital tract, in four X-linked human disorders: otopalatodigital syndrome types 1 (OPD1; OMIM 311300) and 2 (OPD2; OMIM 304120), frontometaphyseal dysplasia (FMD; OMIM 305620) and Melnick-Needles syndrome (MNS; OMIM 309350).",0.602747267842131,"We identified localized mutations in <span class=""gene"" id=""12612583-3-37-41"">FLNA</span> that conserve the reading frame and lead to a broad range of congenital malformations, affecting craniofacial structures, skeleton, brain, viscera and urogenital tract, in four X-linked human disorders: otopalatodigital syndrome types 1 (<span class=""gene"" id=""12612583-3-280-284"">OPD1</span>; OMIM 311300) and 2 (<span class=""gene"" id=""12612583-3-306-310"">OPD2</span>; OMIM 304120), <span class=""disease"" id=""12612583-3-326-353"">frontometaphyseal dysplasia</span> (FMD; OMIM 305620) and Melnick-Needles syndrome (MNS; OMIM 309350).",CTD_human;ORPHANET;UNIPROT
4,3,Biomarker,C0265293,Frontometaphyseal dysplasia,disease,FMD,2316,FLNA,OPD1,CTD_human,16596676,"Our data may indicate that in females, genotype-phenotype correlation between certain FLNA mutations and OPD1 and FMD, respectively, is less strict than previously assumed.",0.602747267842131,"Our data may indicate that in females, genotype-phenotype correlation between certain <span class=""gene"" id=""16596676-9-86-90"">FLNA</span> mutations and <span class=""gene"" id=""16596676-9-105-109"">OPD1</span> and <span class=""disease"" id=""16596676-9-114-117"">FMD</span>, respectively, is less strict than previously assumed.",CTD_human;ORPHANET;UNIPROT
4,5,Biomarker,C1844696,"OTOPALATODIGITAL SYNDROME, TYPE II",disease,otopalatodigital syndrome type 2,2316,FLNA,FLNA,CTD_human,15378534,"Mutations in FLNA have been shown to cause a broad range of congenital malformations, including otopalatodigital syndrome type 2 in which a missense mutation occurring in exon 5 of FLNA results in omphalocele as part of the phenotype.",0.6827472678421309,"Mutations in <span class=""gene"" id=""15378534-13-13-17"">FLNA</span> have been shown to cause a broad range of congenital malformations, including <span class=""disease"" id=""15378534-13-96-128"">otopalatodigital syndrome type 2</span> in which a missense mutation occurring in exon 5 of <span class=""gene"" id=""15378534-13-181-185"">FLNA</span> results in omphalocele as part of the phenotype.",CTD_human;ORPHANET;UNIPROT
4,5,Biomarker,C1844696,"OTOPALATODIGITAL SYNDROME, TYPE II",disease,otopalatodigital syndrome,2316,FLNA,OPD2,CTD_human,12612583,"We identified localized mutations in FLNA that conserve the reading frame and lead to a broad range of congenital malformations, affecting craniofacial structures, skeleton, brain, viscera and urogenital tract, in four X-linked human disorders: otopalatodigital syndrome types 1 (OPD1; OMIM 311300) and 2 (OPD2; OMIM 304120), frontometaphyseal dysplasia (FMD; OMIM 305620) and Melnick-Needles syndrome (MNS; OMIM 309350).",0.6827472678421309,"We identified localized mutations in <span class=""gene"" id=""12612583-3-37-41"">FLNA</span> that conserve the reading frame and lead to a broad range of congenital malformations, affecting craniofacial structures, skeleton, brain, viscera and urogenital tract, in four X-linked human disorders: <span class=""disease"" id=""12612583-3-245-270"">otopalatodigital syndrome</span> types 1 (<span class=""gene"" id=""12612583-3-280-284"">OPD1</span>; OMIM 311300) and 2 (<span class=""gene"" id=""12612583-3-306-310"">OPD2</span>; OMIM 304120), frontometaphyseal dysplasia (FMD; OMIM 305620) and Melnick-Needles syndrome (MNS; OMIM 309350).",CTD_human;ORPHANET;UNIPROT
2,0,Biomarker,C1868720,Periventricular Nodular Heterotopia,disease,periventricular heterotopia,2316,FLNA,FLN1,CTD_human,11914408,Familial periventricular heterotopia: missense and distal truncating mutations of the FLN1 gene.,0.490714344584311,"Familial <span class=""disease"" id=""11914408-0-9-36"">periventricular heterotopia</span>: missense and distal truncating mutations of the <span class=""gene"" id=""11914408-0-86-90"">FLN1</span> gene.",CTD_human;ORPHANET
2,0,Biomarker,C1868720,Periventricular Nodular Heterotopia,disease,periventricular heterotopia,2316,FLNA,filamin 1,CTD_human,9883725,Mutations in filamin 1 prevent migration of cerebral cortical neurons in human periventricular heterotopia.,0.490714344584311,"Mutations in <span class=""gene"" id=""9883725-0-13-22"">filamin 1</span> prevent migration of cerebral cortical neurons in human <span class=""disease"" id=""9883725-0-79-106"">periventricular heterotopia</span>.",CTD_human;ORPHANET
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,23178,PASK,PASK,CTD_human,19365831,"FARP2, HDLBP and PASK are downregulated in a patient with autism and 2q37.3 deletion syndrome.",0.200274726784213,"FARP2, HDLBP and <span class=""gene"" id=""19365831-0-17-21"">PASK</span> are downregulated in a patient with <span class=""disease"" id=""19365831-0-58-64"">autism</span> and 2q37.3 deletion syndrome.",CTD_human
1,0,Biomarker,C0017638,Glioma,disease,glioma,23187,PHLDB1,PHLDB1,CTD_human,19578367,"We identified five risk loci for glioma at 5p15.33 (rs2736100, TERT; P = 1.50 x 10(-17)), 8q24.21 (rs4295627, CCDC26; P = 2.34 x 10(-18)), 9p21.3 (rs4977756, CDKN2A-CDKN2B; P = 7.24 x 10(-15)), 20q13.33 (rs6010620, RTEL1; P = 2.52 x 10(-12)) and 11q23.3 (rs498872, PHLDB1; P = 1.07 x 10(-8)).",0.20838550524134603,"We identified five risk loci for <span class=""disease"" id=""19578367-2-33-39"">glioma</span> at 5p15.33 (rs2736100, TERT; P = 1.50 x 10(-17)), 8q24.21 (rs4295627, CCDC26; P = 2.34 x 10(-18)), 9p21.3 (rs4977756, CDKN2A-CDKN2B; P = 7.24 x 10(-15)), 20q13.33 (rs6010620, RTEL1; P = 2.52 x 10(-12)) and 11q23.3 (rs498872, <span class=""gene"" id=""19578367-2-265-271"">PHLDB1</span>; P = 1.07 x 10(-8)).",CTD_human
4,30,Biomarker,C1858854,MEGALENCEPHALIC LEUKOENCEPHALOPATHY WITH SUBCORTICAL CYSTS,disease,megalencephalic leukoencephalopathy with subcortical cysts,23209,MLC1,MLC1,CTD_human,11254442,"Mutations of MLC1 (KIAA0027), encoding a putative membrane protein, cause megalencephalic leukoencephalopathy with subcortical cysts.",0.608791257094819,"Mutations of <span class=""gene"" id=""11254442-0-13-17"">MLC1</span> (<span class=""disease"" id=""11254442-0-19-27"">KIAA0027</span>), encoding a putative membrane protein, cause <span class=""disease"" id=""11254442-0-74-132"">megalencephalic leukoencephalopathy with subcortical cysts</span>.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0025202,melanoma,disease,melanomas,2321,FLT1,FLT1,CTD_human,19718025,We found ERBB4 mutations in 19% of individuals with melanoma and found mutations in two other kinases (FLT1 and PTK2B) in 10% of individuals with melanomas.,0.21089484807925998,"We found ERBB4 mutations in 19% of individuals with <span class=""disease"" id=""19718025-4-52-60"">melanoma</span> and found mutations in two other kinases (<span class=""gene"" id=""19718025-4-103-107"">FLT1</span> and PTK2B) in 10% of individuals with <span class=""disease"" id=""19718025-4-146-155"">melanomas</span>.",CTD_human
1,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastasis,2321,FLT1,VEGFR-1,CTD_human,21975929,Chemotherapy enhances metastasis formation via VEGFR-1-expressing endothelial cells.,0.20932635528592802,"Chemotherapy enhances <span class=""disease"" id=""21975929-0-22-32"">metastasis</span> formation via <span class=""gene"" id=""21975929-0-47-54"">VEGFR-1</span>-expressing endothelial cells.",CTD_human
1,0,Biomarker,C0919267,ovarian neoplasm,disease,ovarian tumors,23213,SULF1,HSulf-1,CTD_human,17310998,"Collectively, these data indicate that HSulf-1 is epigenetically silenced in ovarian cancer and that epigenetic therapy targeting HSulf-1 might sensitize ovarian tumors to conventional first-line therapies.",0.200274726784213,"Collectively, these data indicate that <span class=""gene"" id=""17310998-8-39-46"">HSulf-1</span> is epigenetically silenced in ovarian cancer and that epigenetic therapy targeting <span class=""gene"" id=""17310998-8-130-137"">HSulf-1</span> might sensitize <span class=""disease"" id=""17310998-8-154-168"">ovarian tumors</span> to conventional first-line therapies.",CTD_human
3,0,Biomarker,C0028754,Obesity,disease,obesity,23216,TBC1D1,Tbc1d1,CTD_human,18931681,Tbc1d1 mutation in lean mouse strain confers leanness and protects from diet-induced obesity.,0.204055389228567,"<span class=""gene"" id=""18931681-0-0-6"">Tbc1d1</span> mutation in lean mouse strain confers leanness and protects from diet-induced <span class=""disease"" id=""18931681-0-85-92"">obesity</span>.",CTD_human
3,0,Biomarker,C0028754,Obesity,disease,obesity,23216,TBC1D1,TBC1D1,CTD_human,16893906,TBC1D1 is a candidate for a severe obesity gene and evidence for a gene/gene interaction in obesity predisposition.,0.204055389228567,"<span class=""gene"" id=""16893906-0-0-6"">TBC1D1</span> is a candidate for a severe obesity gene and evidence for a gene/gene interaction in <span class=""disease"" id=""16893906-0-92-99"">obesity</span> predisposition.",CTD_human
3,0,Biomarker,C0028754,Obesity,disease,obesity,23216,TBC1D1,TBC1D1,CTD_human,18325908,"Analysis of 16 microsatellite markers on chromosome 4 restricted to the 42 pedigrees carrying the TBC1D1 R125W variant allele also revealed a suggestive evidence of linkage with obesity (maximum likelihood binomial LOD of 2.73, P = 0.0002) on chromosome 4p14, where resides TBC1D1.",0.204055389228567,"Analysis of 16 microsatellite markers on chromosome 4 restricted to the 42 pedigrees carrying the <span class=""gene"" id=""18325908-4-98-104"">TBC1D1</span> R125W variant allele also revealed a suggestive evidence of linkage with <span class=""disease"" id=""18325908-4-178-185"">obesity</span> (maximum likelihood binomial LOD of 2.73, P = 0.0002) on chromosome 4p14, where resides <span class=""gene"" id=""18325908-4-274-280"">TBC1D1</span>.",CTD_human
3,9,Biomarker,C0272302,Gray Platelet Syndrome,disease,gray platelet syndrome,23218,NBEAL2,NBEAL2,CTD_human,21765411,Exome sequencing identifies NBEAL2 as the causative gene for gray platelet syndrome.,0.6821978142737049,"Exome sequencing identifies <span class=""gene"" id=""21765411-0-28-34"">NBEAL2</span> as the causative gene for <span class=""disease"" id=""21765411-0-61-83"">gray platelet syndrome</span>.",CTD_human;ORPHANET;UNIPROT
3,9,Biomarker,C0272302,Gray Platelet Syndrome,disease,gray platelet syndrome,23218,NBEAL2,NBEAL2,CTD_human,21765412,NBEAL2 is mutated in gray platelet syndrome and is required for biogenesis of platelet ?-granules.,0.6821978142737049,"<span class=""gene"" id=""21765412-0-0-6"">NBEAL2</span> is mutated in <span class=""disease"" id=""21765412-0-21-43"">gray platelet syndrome</span> and is required for biogenesis of platelet &alpha;-granules.",CTD_human;ORPHANET;UNIPROT
3,9,Biomarker,C0272302,Gray Platelet Syndrome,disease,gray platelet syndrome,23218,NBEAL2,NBEAL2,CTD_human,21765413,"Mutations in NBEAL2, encoding a BEACH protein, cause gray platelet syndrome.",0.6821978142737049,"Mutations in <span class=""gene"" id=""21765413-0-13-19"">NBEAL2</span>, encoding a BEACH protein, cause <span class=""disease"" id=""21765413-0-53-75"">gray platelet syndrome</span>.",CTD_human;ORPHANET;UNIPROT
11,4,Biomarker,C0023467,"Leukemia, Myelocytic, Acute",disease,acute myeloid leukemia,2322,FLT3,FLT3,CTD_human,21482694,Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies.,0.52,"Potent activity of ponatinib (AP24534) in models of <span class=""gene"" id=""21482694-0-52-56"">FLT3</span>-driven <span class=""disease"" id=""21482694-0-64-86"">acute myeloid leukemia</span> and other hematologic malignancies.",CTD_human
11,4,Biomarker,C0023467,"Leukemia, Myelocytic, Acute",disease,acute myeloid leukemia,2322,FLT3,FLT3,CTD_human,21928377,Combined effects of FLT3 and NF-?B selective inhibitors on acute myeloid leukemia in vivo.,0.52,"Combined effects of <span class=""gene"" id=""21928377-0-20-24"">FLT3</span> and NF-&kappa;B selective inhibitors on <span class=""disease"" id=""21928377-0-59-81"">acute myeloid leukemia</span> in vivo.",CTD_human
11,4,Biomarker,C0023467,"Leukemia, Myelocytic, Acute",disease,AML,2322,FLT3,Flt3,CTD_human,17050201,Flt3 internal tandem duplication (Flt3-ITD) is a prevalent mutation in acute myeloid leukemia (AML).,0.52,"<span class=""gene"" id=""17050201-1-0-4"">Flt3</span> internal tandem duplication (<span class=""gene"" id=""17050201-1-34-38"">Flt3</span>-ITD) is a prevalent mutation in <span class=""disease"" id=""17050201-1-71-93"">acute myeloid leukemia</span> (<span class=""disease"" id=""17050201-1-95-98"">AML</span>).",CTD_human
11,4,Biomarker,C0023467,"Leukemia, Myelocytic, Acute",disease,acute myeloid leukemia,2322,FLT3,FLT3,CTD_human,24526162,"Preclinical evaluation of AMG 925, a FLT3/CDK4 dual kinase inhibitor for treating acute myeloid leukemia.",0.52,"Preclinical evaluation of AMG 925, a <span class=""gene"" id=""24526162-0-37-41"">FLT3</span>/CDK4 dual kinase inhibitor for treating <span class=""disease"" id=""24526162-0-82-104"">acute myeloid leukemia</span>.",CTD_human
11,4,Biomarker,C0023467,"Leukemia, Myelocytic, Acute",disease,AML,2322,FLT3,FLT3,CTD_human,22409268,The targeted therapy of FLT3-ITD-positive AML with ponatinib might be associated with a lower frequency of secondary resistance caused by acquired FLT3-TKD mutations.,0.52,"The targeted therapy of <span class=""gene"" id=""22409268-8-24-28"">FLT3</span>-ITD-positive <span class=""disease"" id=""22409268-8-42-45"">AML</span> with ponatinib might be associated with a lower frequency of secondary resistance caused by acquired <span class=""gene"" id=""22409268-8-147-151"">FLT3</span>-TKD mutations.",CTD_human
11,4,Biomarker,C0023467,"Leukemia, Myelocytic, Acute",disease,AML,2322,FLT3,FLT3,CTD_human,25053825,BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD.,0.52,"BET protein antagonist JQ1 is synergistically lethal with <span class=""gene"" id=""25053825-0-58-62"">FLT3</span> tyrosine kinase inhibitor (TKI) and overcomes resistance to <span class=""gene"" id=""25053825-0-123-127"">FLT3</span>-TKI in <span class=""disease"" id=""25053825-0-135-138"">AML</span> cells expressing FLT-ITD.",CTD_human
11,4,Biomarker,C0023467,"Leukemia, Myelocytic, Acute",disease,AML,2322,FLT3,Flt3,CTD_human,21441929,"We identified such mutations using a Sleeping Beauty transposon, which caused rapid-onset AML in 80% of mice with Npm1c, associated with mutually exclusive integrations in Csf2, Flt3 or Rasgrp1 in 55 of 70 leukemias.",0.52,"We identified such mutations using a Sleeping Beauty transposon, which caused rapid-onset <span class=""disease"" id=""21441929-5-90-93"">AML</span> in 80% of mice with Npm1c, associated with mutually exclusive integrations in Csf2, <span class=""gene"" id=""21441929-5-178-182"">Flt3</span> or Rasgrp1 in 55 of 70 leukemias.",CTD_human
11,4,Biomarker,C0023467,"Leukemia, Myelocytic, Acute",disease,acute myeloid leukemia,2322,FLT3,FLT3,CTD_human,23906301,Overexpression of Bcl2 protein predicts chemoresistance in acute myeloid leukemia: its correlation with FLT3.,0.52,"Overexpression of Bcl2 protein predicts chemoresistance in <span class=""disease"" id=""23906301-0-59-81"">acute myeloid leukemia</span>: its correlation with <span class=""gene"" id=""23906301-0-104-108"">FLT3</span>.",CTD_human
3,0,Biomarker,C0023487,Acute Promyelocytic Leukemia,disease,acute promyelocytic leukemia,2322,FLT3,FLT3,CTD_human,17454189,Impact of FLT3 internal tandem duplications on Indian acute promyelocytic leukemia patients: prognostic implications.,0.228555551449221,"Impact of <span class=""gene"" id=""17454189-0-10-14"">FLT3</span> internal tandem duplications on Indian <span class=""disease"" id=""17454189-0-54-82"">acute promyelocytic leukemia</span> patients: prognostic implications.",CTD_human
3,0,Biomarker,C0023487,Acute Promyelocytic Leukemia,disease,C9710,2322,FLT3,FLT3,CTD_human,24160850,Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype.,0.228555551449221,"Arsenic trioxide in front-line therapy of <span class=""disease"" id=""24160850-0-42-70"">acute promyelocytic leukemia</span> (<span class=""disease"" id=""24160850-0-72-77"">C9710</span>): prognostic significance of <span class=""gene"" id=""24160850-0-107-111"">FLT3</span> mutations and complex karyotype.",CTD_human
1,0,Biomarker,C0031117,Peripheral Neuropathy,group,peripheral neuropathy,23221,RHOBTB2,RHOBTB2,CTD_human,20864405,"Significant genes in myeloma plasma cells from patients that were associated with early-onset bortezomib-induced peripheral neuropathy were the enzyme coding genes RHOBTB2 (upregulated by 1·59 times; p=4·5×10(-5)), involved in drug-induced apoptosis, CPT1C (1·44 times; p=2·9×10(-7)), involved in mitochondrial dysfunction, and SOX8 (1·68 times; p=4·28×10(-13)), involved in development of peripheral nervous system.",0.200274726784213,"Significant genes in myeloma plasma cells from patients that were associated with early-onset bortezomib-induced <span class=""disease"" id=""20864405-9-113-134"">peripheral neuropathy</span> were the enzyme coding genes <span class=""gene"" id=""20864405-9-164-171"">RHOBTB2</span> (upregulated by 1·59 times; p=4·5&times;10(-5)), involved in drug-induced apoptosis, CPT1C (1·44 times; p=2·9&times;10(-7)), involved in mitochondrial dysfunction, and SOX8 (1·68 times; p=4·28&times;10(-13)), involved in development of peripheral nervous system.",CTD_human
1,0,Biomarker,C0002395,Alzheimer's Disease,disease,AD,23237,ARC,Arc,CTD_human,18503570,"Finally, we showed that Arc levels are decreased in the cortex of AD brains.",0.20054945356842604,"Finally, we showed that <span class=""gene"" id=""18503570-9-24-27"">Arc</span> levels are decreased in the cortex of <span class=""disease"" id=""18503570-9-66-68"">AD</span> brains.",CTD_human
1,0,Biomarker,C0001403,Addison Disease,disease,primary adrenal insufficiency,23274,CLEC16A,CLEC16A,CTD_human,18593762,Polymorphisms in CLEC16A and CIITA at 16p13 are associated with primary adrenal insufficiency.,0.20350593566014002,"Polymorphisms in <span class=""gene"" id=""18593762-0-17-24"">CLEC16A</span> and CIITA at 16p13 are associated with <span class=""disease"" id=""18593762-0-64-93"">primary adrenal insufficiency</span>.",CTD_human
2,2,Biomarker,C0011854,"Diabetes Mellitus, Insulin-Dependent",disease,type 1 diabetes,23274,CLEC16A,CLEC16A,CTD_human,18946483,Variation within the CLEC16A gene shows consistent disease association with both multiple sclerosis and type 1 diabetes in Sardinia.,0.231422395872004,"Variation within the <span class=""gene"" id=""18946483-0-21-28"">CLEC16A</span> gene shows consistent disease association with both multiple sclerosis and <span class=""disease"" id=""18946483-0-104-119"">type 1 diabetes</span> in Sardinia.",CTD_human
2,2,Biomarker,C0011854,"Diabetes Mellitus, Insulin-Dependent",disease,T1D,23274,CLEC16A,KIAA0350,CTD_human,17632545,These results indicate that KIAA0350 might be involved in the pathogenesis of T1D and demonstrate the utility of the genome-wide association approach in the identification of previously unsuspected genetic determinants of complex traits.,0.231422395872004,"These results indicate that <span class=""gene"" id=""17632545-8-28-36"">KIAA0350</span> might be involved in the pathogenesis of <span class=""disease"" id=""17632545-8-78-81"">T1D</span> and demonstrate the utility of the genome-wide association approach in the identification of previously unsuspected genetic determinants of complex traits.",CTD_human
1,3,Biomarker,C0024141,"Lupus Erythematosus, Systemic",disease,SLE,23274,CLEC16A,CLEC16A,CTD_human,19838195,"A candidate screen of alleles previously associated with other autoimmune diseases suggested five loci (P < 1 x 10(-3)) that may contribute to SLE: IFIH1, CFB, CLEC16A, IL12B and SH2B3.",0.202681755307501,"A candidate screen of alleles previously associated with other autoimmune diseases suggested five loci (P &lt; 1 x 10(-3)) that may contribute to <span class=""disease"" id=""19838195-5-143-146"">SLE</span>: IFIH1, CFB, <span class=""gene"" id=""19838195-5-160-167"">CLEC16A</span>, IL12B and SH2B3.",CTD_human
2,3,Biomarker,C0026769,Multiple Sclerosis,disease,multiple sclerosis,23274,CLEC16A,CLEC16A,CTD_human,18946483,Variation within the CLEC16A gene shows consistent disease association with both multiple sclerosis and type 1 diabetes in Sardinia.,0.243075911769273,"Variation within the <span class=""gene"" id=""18946483-0-21-28"">CLEC16A</span> gene shows consistent disease association with both <span class=""disease"" id=""18946483-0-81-99"">multiple sclerosis</span> and type 1 diabetes in Sardinia.",CTD_human
2,3,Biomarker,C0026769,Multiple Sclerosis,disease,MS,23274,CLEC16A,CLEC16A,CTD_human,19525955,"We also replicated several known MS associations (HLA-DR15, P = 7.0 x 10(-184); CD58, P = 9.6 x 10(-8); EVI5-RPL5, P = 2.5 x 10(-6); IL2RA, P = 7.4 x 10(-6); CLEC16A, P = 1.1 x 10(-4); IL7R, P = 1.3 x 10(-3); TYK2, P = 3.5 x 10(-3)) and observed a statistical interaction between SNPs in EVI5-RPL5 and HLA-DR15 (P = 0.001).",0.243075911769273,"We also replicated several known <span class=""disease"" id=""19525955-5-33-35"">MS</span> associations (HLA-DR15, P = 7.0 x 10(-184); CD58, P = 9.6 x 10(-8); EVI5-RPL5, P = 2.5 x 10(-6); IL2RA, P = 7.4 x 10(-6); <span class=""gene"" id=""19525955-5-158-165"">CLEC16A</span>, P = 1.1 x 10(-4); IL7R, P = 1.3 x 10(-3); TYK2, P = 3.5 x 10(-3)) and observed a statistical interaction between SNPs in EVI5-RPL5 and HLA-DR15 (P = 0.001).",CTD_human
1,0,Therapeutic,C0032580,Adenomatous Polyposis Coli,disease,familial adenomatous polyposis,2328,FMO3,FMO3,CTD_human,17559352,"Two commonly occurring polymorphisms of FMO3, E158K and E308G, have been associated with a reduction in polyp burden in patients with familial adenomatous polyposis who were treated with sulindac sulfide, an FMO3 substrate.",0.20082418035263896,"Two commonly occurring polymorphisms of <span class=""gene"" id=""17559352-6-40-44"">FMO3</span>, E158K and E308G, have been associated with a reduction in polyp burden in patients with <span class=""disease"" id=""17559352-6-134-164"">familial adenomatous polyposis</span> who were treated with sulindac sulfide, an <span class=""gene"" id=""17559352-6-208-212"">FMO3</span> substrate.",CTD_human
6,11,Biomarker,C0342739,Trimethylaminuria,disease,TMAU,2328,FMO3,FMO3,CTD_human,12214664,A number of FMO3 mutant alleles have been described and associated with a disease termed trimethylaminuria (TMAU).,0.606868169605328,"A number of <span class=""gene"" id=""12214664-3-12-16"">FMO3</span> mutant alleles have been described and associated with a disease termed <span class=""disease"" id=""12214664-3-89-106"">trimethylaminuria</span> (<span class=""disease"" id=""12214664-3-108-112"">TMAU</span>).",CTD_human;HPO;ORPHANET;UNIPROT
6,11,Biomarker,C0342739,Trimethylaminuria,disease,trimethylaminuria,2328,FMO3,FMO3,CTD_human,16601883,Diagnosis and management of trimethylaminuria (FMO3 deficiency) in children.,0.606868169605328,"Diagnosis and management of <span class=""disease"" id=""16601883-0-28-45"">trimethylaminuria</span> (<span class=""gene"" id=""16601883-0-47-51"">FMO3</span> deficiency) in children.",CTD_human;HPO;ORPHANET;UNIPROT
1,0,Biomarker,C1263846,Attention deficit hyperactivity disorder,disease,attention deficit hyperactivity disorder,23284,ADGRL3,LPHN3,CTD_human,22405201,"Mutations in LPHN3 are strongly associated with attention deficit hyperactivity disorder, suggesting a role for latrophilins in human cognitive function.",0.206527930286485,"Mutations in <span class=""gene"" id=""22405201-2-13-18"">LPHN3</span> are strongly associated with <span class=""disease"" id=""22405201-2-48-88"">attention deficit hyperactivity disorder</span>, suggesting a role for latrophilins in human cognitive function.",CTD_human
2,0,Biomarker,C0008925,Cleft Palate,disease,cleft palate,23314,SATB2,Satb2,CTD_human,16960803,"We find that, similar to the way in which SATB2 is perceived to act in humans, craniofacial defects due to haploinsufficiency of Satb2, including cleft palate (in approximately 25% of cases), phenocopy those seen with 2q32-q33 deletions and translocations in humans.",0.40137363392106606,"We find that, similar to the way in which <span class=""gene"" id=""16960803-2-42-47"">SATB2</span> is perceived to act in humans, craniofacial defects due to haploinsufficiency of <span class=""gene"" id=""16960803-2-129-134"">Satb2</span>, including <span class=""disease"" id=""16960803-2-146-158"">cleft palate</span> (in approximately 25% of cases), phenocopy those seen with 2q32-q33 deletions and translocations in humans.",CTD_human;HPO
5,0,Biomarker,C0004352,Autistic Disorder,disease,autism,2332,FMR1,FMR1,CTD_human,20425835,"FMR1 gene expansion, large deletion of Xp, and skewed X-inactivation in a girl with mental retardation and autism.",0.4979865873114879,"<span class=""gene"" id=""20425835-0-0-4"">FMR1</span> gene expansion, large deletion of Xp, and skewed X-inactivation in a girl with mental retardation and <span class=""disease"" id=""20425835-0-107-113"">autism</span>.",CTD_human;HPO
5,0,Biomarker,C0004352,Autistic Disorder,disease,autism,2332,FMR1,FMR1,CTD_human,14755444,Association and transmission analysis of the FMR1 IVS10 + 14C-T variant in autism.,0.4979865873114879,"Association and transmission analysis of the <span class=""gene"" id=""14755444-0-45-49"">FMR1</span> IVS10 + 14C-T variant in <span class=""disease"" id=""14755444-0-75-81"">autism</span>.",CTD_human;HPO
5,0,Biomarker,C0004352,Autistic Disorder,disease,infantile autism,2332,FMR1,FMR1,CTD_human,9806479,CGG repeat interruptions in the FMR1 gene in patients with infantile autism.,0.4979865873114879,"CGG repeat interruptions in the <span class=""gene"" id=""9806479-0-32-36"">FMR1</span> gene in patients with <span class=""disease"" id=""9806479-0-59-75"">infantile autism</span>.",CTD_human;HPO
5,0,Biomarker,C0004352,Autistic Disorder,disease,autistic,2332,FMR1,FMR1,CTD_human,15000256,Single-strand conformation polymorphism analysis of the FMR1 gene in autistic and mentally retarded children in Japan.,0.4979865873114879,"Single-strand conformation polymorphism analysis of the <span class=""gene"" id=""15000256-0-56-60"">FMR1</span> gene in <span class=""disease"" id=""15000256-0-69-77"">autistic</span> and mentally retarded children in Japan.",CTD_human;HPO
9,2,Biomarker,C0016667,Fragile X Syndrome,disease,FXS,2332,FMR1,Fmr1,CTD_human,20300527,Mice with deletion of the fragile X mental retardation 1 (Fmr1) gene are used to model autism because loss of Fmr1 gene function causes Fragile X Syndrome (FXS) and many people with FXS exhibit autistic-like behaviors.,0.948716369565796,"Mice with deletion of the <span class=""gene"" id=""20300527-2-26-56"">fragile X mental retardation 1</span> (<span class=""gene"" id=""20300527-2-58-62"">Fmr1</span>) gene are used to model autism because loss of <span class=""gene"" id=""20300527-2-110-114"">Fmr1</span> gene function causes <span class=""disease"" id=""20300527-2-136-154"">Fragile X Syndrome</span> (<span class=""disease"" id=""20300527-2-156-159"">FXS</span>) and many people with <span class=""disease"" id=""20300527-2-182-185"">FXS</span> exhibit autistic-like behaviors.",CTD_human;ORPHANET;UNIPROT
9,2,Biomarker,C0016667,Fragile X Syndrome,disease,fragile X syndrome,2332,FMR1,FMR1,CTD_human,16510718,"Fragile X mental retardation protein (FMRP), the lack of which causes fragile X syndrome, is an RNA-binding protein encoded by the FMR1 gene.",0.948716369565796,"Fragile X mental retardation protein (<span class=""gene"" id=""16510718-1-38-42"">FMRP</span>), the lack of which causes <span class=""disease"" id=""16510718-1-70-88"">fragile X syndrome</span>, is an RNA-binding protein encoded by the <span class=""gene"" id=""16510718-1-131-135"">FMR1</span> gene.",CTD_human;ORPHANET;UNIPROT
9,2,Biomarker,C0016667,Fragile X Syndrome,disease,FXS,2332,FMR1,FMR1,CTD_human,22043169,"Herein, we discuss the molecular mechanisms leading to FXS and the Prader-Willi phenotype with an emphasis on mouse FMR1 knockout studies that have shown the reversal of weight increase through mGluR antagonists.",0.948716369565796,"Herein, we discuss the molecular mechanisms leading to <span class=""disease"" id=""22043169-8-55-58"">FXS</span> and the Prader-Willi phenotype with an emphasis on mouse <span class=""gene"" id=""22043169-8-116-120"">FMR1</span> knockout studies that have shown the reversal of weight increase through mGluR antagonists.",CTD_human;ORPHANET;UNIPROT
9,2,Biomarker,C0016667,Fragile X Syndrome,disease,FXS,2332,FMR1,Fmr1,CTD_human,18835858,"Subjects with FXS and fragile X mental retardation gene knock out (Fmr1 KO) mice, an animal model for FXS, have been shown to exhibit defects in dendritic spine maturation that may underlie cognitive and behavioural abnormalities in FXS.",0.948716369565796,"Subjects with <span class=""disease"" id=""18835858-2-14-17"">FXS</span> and fragile X mental retardation gene knock out (<span class=""gene"" id=""18835858-2-67-71"">Fmr1</span> KO) mice, an animal model for <span class=""disease"" id=""18835858-2-102-105"">FXS</span>, have been shown to exhibit defects in dendritic spine maturation that may underlie cognitive and behavioural abnormalities in <span class=""disease"" id=""18835858-2-233-236"">FXS</span>.",CTD_human;ORPHANET;UNIPROT
9,2,Biomarker,C0016667,Fragile X Syndrome,disease,fragile X syndrome,2332,FMR1,Fmr1,CTD_human,17065172,"Contribution of mGluR and Fmr1 functional pathways to neurite morphogenesis, craniofacial development and fragile X syndrome.",0.948716369565796,"Contribution of mGluR and <span class=""gene"" id=""17065172-0-26-30"">Fmr1</span> functional pathways to neurite morphogenesis, craniofacial development and <span class=""disease"" id=""17065172-0-106-124"">fragile X syndrome</span>.",CTD_human;ORPHANET;UNIPROT
2,3,Biomarker,C3714756,Intellectual Disability,group,mental retardation,2332,FMR1,FMR1,CTD_human,20425835,"FMR1 gene expansion, large deletion of Xp, and skewed X-inactivation in a girl with mental retardation and autism.",0.256232858499782,"<span class=""gene"" id=""20425835-0-0-4"">FMR1</span> gene expansion, large deletion of Xp, and skewed X-inactivation in a girl with <span class=""disease"" id=""20425835-0-84-102"">mental retardation</span> and autism.",CTD_human
2,3,Biomarker,C3714756,Intellectual Disability,group,mental retardation,2332,FMR1,FMR1,CTD_human,15000256,"Although uncommon, point mutations in the FMR1 gene may be a cause of autism and mental retardation in Japanese patients.",0.256232858499782,"Although uncommon, point mutations in the <span class=""gene"" id=""15000256-8-42-46"">FMR1</span> gene may be a cause of autism and <span class=""disease"" id=""15000256-8-81-99"">mental retardation</span> in Japanese patients.",CTD_human
1,0,Biomarker,C0029408,Degenerative polyarthritis,disease,OA,23321,TRIM2,tripartite motif-containing 2,CTD_human,17568789,"HOXD10, HOXD11, HOXD13, CCL8 and LIM homeobox 2 were highly and exclusively expressed in RA and CLU, sarcoglycan-gamma, GPR64, POU3F3, peroxisome proliferative activated receptor-gamma and tripartite motif-containing 2 were expressed only in OA.",0.200274726784213,"HOXD10, HOXD11, HOXD13, CCL8 and LIM homeobox 2 were highly and exclusively expressed in RA and CLU, sarcoglycan-gamma, GPR64, POU3F3, peroxisome proliferative activated receptor-gamma and <span class=""gene"" id=""17568789-4-189-218"">tripartite motif-containing 2</span> were expressed only in <span class=""disease"" id=""17568789-4-242-244"">OA</span>.",CTD_human
2,0,Biomarker,C0022658,Kidney Diseases,group,renal disorder,23322,RPGRIP1L,RPGRIP1L,CTD_human,17558409,"In addition, we show that RPGRIP1L colocalizes at the basal body and centrosomes with the protein products of both NPHP6 and NPHP4, known genes associated with MKS, CORS and nephronophthisis (a related renal disorder and ciliopathy).",0.40027472678421294,"In addition, we show that <span class=""gene"" id=""17558409-3-26-34"">RPGRIP1L</span> colocalizes at the basal body and centrosomes with the protein products of both NPHP6 and NPHP4, known genes associated with MKS, CORS and nephronophthisis (a related <span class=""disease"" id=""17558409-3-202-216"">renal disorder</span> and ciliopathy).",CTD_human;HPO
1,0,Biomarker,C0008925,Cleft Palate,disease,cleft palate,23327,NEDD4L,NEDD4L,CTD_human,27694961,"Here we show that missense mutations in NEDD4L mapping to the HECT domain of the encoded E3 ubiquitin ligase lead to PNH associated with toe syndactyly, cleft palate and neurodevelopmental delay.",0.2,"Here we show that missense mutations in <span class=""gene"" id=""27694961-2-40-46"">NEDD4L</span> mapping to the HECT domain of the encoded E3 ubiquitin ligase lead to PNH associated with toe syndactyly, <span class=""disease"" id=""27694961-2-153-165"">cleft palate</span> and neurodevelopmental delay.",CTD_human
2,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,23327,NEDD4L,NEDD4-2,CTD_human,23348737,Renal tubular NEDD4-2 deficiency causes NCC-mediated salt-dependent hypertension.,0.22703653708157898,"Renal tubular <span class=""gene"" id=""23348737-0-14-21"">NEDD4-2</span> deficiency causes NCC-mediated salt-dependent <span class=""disease"" id=""23348737-0-68-80"">hypertension</span>.",CTD_human
2,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,23327,NEDD4L,Nedd4-2,CTD_human,18524855,Salt-sensitive hypertension and cardiac hypertrophy in mice deficient in the ubiquitin ligase Nedd4-2.,0.22703653708157898,"Salt-sensitive <span class=""disease"" id=""18524855-0-15-27"">hypertension</span> and cardiac hypertrophy in mice deficient in the ubiquitin ligase <span class=""gene"" id=""18524855-0-94-101"">Nedd4-2</span>.",CTD_human
1,0,Biomarker,C1868720,Periventricular Nodular Heterotopia,disease,periventricular nodular heterotopia,23327,NEDD4L,NEDD4L,CTD_human,27694961,Mutations in the HECT domain of NEDD4L lead to AKT-mTOR pathway deregulation and cause periventricular nodular heterotopia.,0.4,"Mutations in the HECT domain of <span class=""gene"" id=""27694961-0-32-38"">NEDD4L</span> lead to AKT-mTOR pathway deregulation and cause <span class=""disease"" id=""27694961-0-87-122"">periventricular nodular heterotopia</span>.",CTD_human;ORPHANET
1,0,Biomarker,C0011849,Diabetes Mellitus,group,Diabetes,2335,FN1,fibronectin,CTD_human,20551625,"Diabetes was associated with increasing renal fibronectin and type IV collagen protein expression, with the combination regimen resulting in the highest decrease in extracellular matrix accumulation.",0.20467035533162303,"<span class=""disease"" id=""20551625-7-0-8"">Diabetes</span> was associated with increasing renal <span class=""gene"" id=""20551625-7-46-57"">fibronectin</span> and type IV collagen protein expression, with the combination regimen resulting in the highest decrease in extracellular matrix accumulation.",CTD_human
1,0,Biomarker,C0017636,Glioblastoma,disease,glioblastomas,2335,FN1,fibronectin,CTD_human,17099729,"Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy.",0.202197814273705,"Transglutaminase 2 inhibitor, KCC009, disrupts <span class=""gene"" id=""17099729-0-47-58"">fibronectin</span> assembly in the extracellular matrix and sensitizes orthotopic <span class=""disease"" id=""17099729-0-122-135"">glioblastomas</span> to chemotherapy.",CTD_human
1,0,Biomarker,C0149721,Left Ventricular Hypertrophy,disease,LVH,2335,FN1,fibronectin,CTD_human,11181017,"Carvedilol reduced collagen I, III and fibronectin by 40/60/35% (0.1 microM; P<0.001) irrespective of LVH.",0.2,"Carvedilol reduced collagen I, III and <span class=""gene"" id=""11181017-13-39-50"">fibronectin</span> by 40/60/35% (0.1 microM; P&lt;0.001) irrespective of <span class=""disease"" id=""11181017-13-102-105"">LVH</span>.",CTD_human
1,0,Biomarker,C0002395,Alzheimer's Disease,disease,Alzheimer disease,23385,NCSTN,NCSTN,CTD_human,17192785,"In addition to identifying the epsilon4 allele of APOE and related effects, we pinpointed over a dozen potential Alzheimer disease susceptibility genes (ACE, CHRNB2, CST3, ESR1, GAPDHS, IDE, MTHFR, NCSTN, PRNP, PSEN1, TF, TFAM and TNF) with statistically significant allelic summary odds ratios (ranging from 1.11-1.38 for risk alleles and 0.92-0.67 for protective alleles).",0.22638476919852696,"In addition to identifying the epsilon4 allele of APOE and related effects, we pinpointed over a dozen potential <span class=""disease"" id=""17192785-5-113-130"">Alzheimer disease</span> susceptibility genes (ACE, CHRNB2, CST3, ESR1, GAPDHS, IDE, MTHFR, <span class=""gene"" id=""17192785-5-198-203"">NCSTN</span>, PRNP, PSEN1, TF, TFAM and TNF) with statistically significant allelic summary odds ratios (ranging from 1.11-1.38 for risk alleles and 0.92-0.67 for protective alleles).",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,23394,ADNP,ADNP,CTD_human,24531329,A SWI/SNF-related autism syndrome caused by de novo mutations in ADNP.,0.201373633921065,"A SWI/SNF-related <span class=""disease"" id=""24531329-0-18-24"">autism</span> syndrome caused by de novo mutations in <span class=""gene"" id=""24531329-0-65-69"">ADNP</span>.",CTD_human
2,0,Biomarker,C0027877,Neuronal Ceroid-Lipofuscinoses,disease,neuronal ceroid lipofuscinosis,23400,ATP13A2,ATP13A2,CTD_human,22022275,A one base pair deletion in the canine ATP13A2 gene causes exon skipping and late-onset neuronal ceroid lipofuscinosis in the Tibetan terrier.,0.201098907136852,"A one base pair deletion in the canine <span class=""gene"" id=""22022275-0-39-46"">ATP13A2</span> gene causes exon skipping and late-onset <span class=""disease"" id=""22022275-0-88-118"">neuronal ceroid lipofuscinosis</span> in the Tibetan terrier.",CTD_human
8,10,Biomarker,C1847640,KUFOR-RAKEB SYNDROME,disease,PARK9,23400,ATP13A2,ATP13A2,CTD_human,22022275,ATP13A2 mutations have been described in familial Parkinson syndrome (PARK9).,0.6879670767421799,"<span class=""gene"" id=""22022275-11-0-7"">ATP13A2</span> mutations have been described in familial Parkinson syndrome (<span class=""disease"" id=""22022275-11-70-75"">PARK9</span>).",CTD_human;ORPHANET;UNIPROT
8,10,Biomarker,C1847640,KUFOR-RAKEB SYNDROME,disease,KRS,23400,ATP13A2,ATP13A2,CTD_human,22768177,KRS mutations produce truncated forms of ATP13A2 with impaired protein stability resulting in a loss-of-function.,0.6879670767421799,"<span class=""disease"" id=""22768177-2-0-3"">KRS</span> mutations produce truncated forms of <span class=""gene"" id=""22768177-2-41-48"">ATP13A2</span> with impaired protein stability resulting in a loss-of-function.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0014175,Endometriosis,disease,endometriosis,23405,DICER1,DICER1,CTD_human,21063030,"Upregulation of microRNA 21 (MIR21) and DICER1 transcripts suggests roles for microRNAs (miRNAs) in the pathogenesis of severe versus mild endometriosis, potentially through regulation of gene silencing and epigenetic mechanisms.",0.200274726784213,"Upregulation of microRNA 21 (MIR21) and <span class=""gene"" id=""21063030-9-40-46"">DICER1</span> transcripts suggests roles for microRNAs (miRNAs) in the pathogenesis of severe versus mild <span class=""disease"" id=""21063030-9-139-152"">endometriosis</span>, potentially through regulation of gene silencing and epigenetic mechanisms.",CTD_human
1,0,Biomarker,C0007137,Squamous cell carcinoma,disease,OSCC,23410,SIRT3,SIRT3,CTD_human,21472714,"To further assess the in vivo role of SIRT3 in OSCC carcinogenesis, a floor-of-mouth oral cancer murine model was used to study the effect of SIRT3 down-regulation on OSCC tumor growth in immunodeficient mice.",0.200274726784213,"To further assess the in vivo role of <span class=""gene"" id=""21472714-8-38-43"">SIRT3</span> in OSCC carcinogenesis, a floor-of-mouth oral cancer murine model was used to study the effect of <span class=""gene"" id=""21472714-8-142-147"">SIRT3</span> down-regulation on <span class=""disease"" id=""21472714-8-167-171"">OSCC</span> tumor growth in immunodeficient mice.",CTD_human
1,0,Biomarker,C0028754,Obesity,disease,obesity,23410,SIRT3,SIRT3,CTD_human,23956348,"Skeletal muscle MnSOD, mitochondrial complex II, and SIRT3 enzyme activities are decreased in maternal obesity during human pregnancy and gestational diabetes mellitus.",0.28054945356842603,"Skeletal muscle MnSOD, mitochondrial complex II, and <span class=""gene"" id=""23956348-0-53-58"">SIRT3</span> enzyme activities are decreased in maternal <span class=""disease"" id=""23956348-0-103-110"">obesity</span> during human pregnancy and gestational diabetes mellitus.",CTD_human
1,0,Biomarker,C0004153,Atherosclerosis,disease,atherosclerosis,23411,SIRT1,SIRT1,CTD_human,20068143,Insulin resistance and subclinical atherosclerosis are associated with SIRT1 downregulation in monocytes.,0.286579087443797,"Insulin resistance and subclinical <span class=""disease"" id=""20068143-15-35-50"">atherosclerosis</span> are associated with <span class=""gene"" id=""20068143-15-71-76"">SIRT1</span> downregulation in monocytes.",CTD_human
1,0,Biomarker,C0006118,Brain Neoplasms,group,brain tumours,23411,SIRT1,Sirt-1,CTD_human,22523472,Tissue scan microarray analysis of grade I-IV brain tumours cDNA revealed increased gene expression of Sirt-1 from grade I-III but surprisingly not in grade IV brain tumours.,0.2,"Tissue scan microarray analysis of grade I-IV <span class=""disease"" id=""22523472-6-46-59"">brain tumours</span> cDNA revealed increased gene expression of <span class=""gene"" id=""22523472-6-103-109"">Sirt-1</span> from grade I-III but surprisingly not in grade IV <span class=""disease"" id=""22523472-6-160-173"">brain tumours</span>.",CTD_human
3,0,Biomarker,C0009319,Colitis,disease,colon inflammation,23411,SIRT1,SIRT-1,CTD_human,24548422,Involvement of TACE in colon inflammation: a novel mechanism of regulation via SIRT-1 activation.,0.20054945356842604,"Involvement of TACE in <span class=""disease"" id=""24548422-0-23-41"">colon inflammation</span>: a novel mechanism of regulation via <span class=""gene"" id=""24548422-0-79-85"">SIRT-1</span> activation.",CTD_human
3,0,Biomarker,C0009319,Colitis,disease,colitis,23411,SIRT1,SIRT1,CTD_human,19940103,"Furthermore, our results indicate that resveratrol may protect against colitis through up-regulation of SIRT1 in immune cells in the colon.",0.20054945356842604,"Furthermore, our results indicate that resveratrol may protect against <span class=""disease"" id=""19940103-11-71-78"">colitis</span> through up-regulation of <span class=""gene"" id=""19940103-11-104-109"">SIRT1</span> in immune cells in the colon.",CTD_human
3,0,Biomarker,C0009319,Colitis,disease,colitis,23411,SIRT1,SIRT1,CTD_human,24782617,"Collagen?I?and IGF-1 expression was increased, and SIRT1 expression was decreased (0.67 ± 0.04 vs 1.05 ± 0.07, P < 0.001) in TNBS-induced colitis compared with the control group.",0.20054945356842604,"Collagen?I?and IGF-1 expression was increased, and <span class=""gene"" id=""24782617-9-51-56"">SIRT1</span> expression was decreased (0.67 &plusmn; 0.04 vs 1.05 &plusmn; 0.07, P &lt; 0.001) in TNBS-induced <span class=""disease"" id=""24782617-9-138-145"">colitis</span> compared with the control group.",CTD_human
1,0,Therapeutic,C0011303,Demyelinating Diseases,group,demyelinating disease,23411,SIRT1,SIRT1,CTD_human,23547115,These results suggest that SIRT1 reduces neuronal loss in this chronic demyelinating disease model and that this is associated with a reduction in inflammation.,0.2,"These results suggest that <span class=""gene"" id=""23547115-9-27-32"">SIRT1</span> reduces neuronal loss in this chronic <span class=""disease"" id=""23547115-9-71-92"">demyelinating disease</span> model and that this is associated with a reduction in inflammation.",CTD_human
1,0,Biomarker,C0011849,Diabetes Mellitus,group,diabetes,23411,SIRT1,Sirt1,CTD_human,24894401,"Thus, in diabetes, increase in oxidative stress inhibits Sirt1 and p65 is hyperacetylated, increasing the binding of p65 at MMP-9 promoter.",0.20604398925268802,"Thus, in <span class=""disease"" id=""24894401-12-9-17"">diabetes</span>, increase in oxidative stress inhibits <span class=""gene"" id=""24894401-12-57-62"">Sirt1</span> and p65 is hyperacetylated, increasing the binding of p65 at MMP-9 promoter.",CTD_human
1,0,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,type 2 diabetes,23411,SIRT1,SIRT1,CTD_human,23834033,The miR-34a/NAMPT axis presents a potential target for treating obesity- and aging-related diseases involving SIRT1 dysfunction like steatosis and type 2 diabetes.,0.292440894469913,"The miR-34a/NAMPT axis presents a potential target for treating obesity- and aging-related diseases involving <span class=""gene"" id=""23834033-13-110-115"">SIRT1</span> dysfunction like steatosis and <span class=""disease"" id=""23834033-13-147-162"">type 2 diabetes</span>.",CTD_human
1,0,Biomarker,C0011884,Diabetic Retinopathy,disease,diabetic retinopathy,23411,SIRT1,Sirt1,CTD_human,24894401,"Sirt1, a negative regulator of matrix metalloproteinase-9 in diabetic retinopathy.",0.20054945356842604,"<span class=""gene"" id=""24894401-0-0-5"">Sirt1</span>, a negative regulator of matrix metalloproteinase-9 in <span class=""disease"" id=""24894401-0-61-81"">diabetic retinopathy</span>.",CTD_human
5,0,Biomarker,C0015695,Fatty Liver,disease,hepatic steatosis,23411,SIRT1,SIRT1,CTD_human,21321189,"These studies indicate that SIRT1 serves as a negative regulator of UPR signaling in T2DM and that SIRT1 attenuates hepatic steatosis, ameliorates insulin resistance, and restores glucose homeostasis, largely through the inhibition of mTORC1 and ER stress.",0.201923087489492,"These studies indicate that <span class=""gene"" id=""21321189-8-28-33"">SIRT1</span> serves as a negative regulator of UPR signaling in T2DM and that <span class=""gene"" id=""21321189-8-99-104"">SIRT1</span> attenuates <span class=""disease"" id=""21321189-8-116-133"">hepatic steatosis</span>, ameliorates insulin resistance, and restores glucose homeostasis, largely through the inhibition of mTORC1 and ER stress.",CTD_human
5,0,Therapeutic,C0015695,Fatty Liver,disease,hepatic steatosis,23411,SIRT1,SIRT1,CTD_human,21321189,"These studies indicate that SIRT1 serves as a negative regulator of UPR signaling in T2DM and that SIRT1 attenuates hepatic steatosis, ameliorates insulin resistance, and restores glucose homeostasis, largely through the inhibition of mTORC1 and ER stress.",0.201923087489492,"These studies indicate that <span class=""gene"" id=""21321189-8-28-33"">SIRT1</span> serves as a negative regulator of UPR signaling in T2DM and that <span class=""gene"" id=""21321189-8-99-104"">SIRT1</span> attenuates <span class=""disease"" id=""21321189-8-116-133"">hepatic steatosis</span>, ameliorates insulin resistance, and restores glucose homeostasis, largely through the inhibition of mTORC1 and ER stress.",CTD_human
5,0,Therapeutic,C0015695,Fatty Liver,disease,hepatic steatosis,23411,SIRT1,SIRT1,CTD_human,24184811,Hepatic SIRT1 attenuates hepatic steatosis and controls energy balance in mice by inducing fibroblast growth factor 21.,0.201923087489492,"Hepatic <span class=""gene"" id=""24184811-0-8-13"">SIRT1</span> attenuates <span class=""disease"" id=""24184811-0-25-42"">hepatic steatosis</span> and controls energy balance in mice by inducing fibroblast growth factor 21.",CTD_human
5,0,Biomarker,C0015695,Fatty Liver,disease,hepatic steatosis,23411,SIRT1,SIRT1,CTD_human,24184811,Hepatic SIRT1 attenuates hepatic steatosis and controls energy balance in mice by inducing fibroblast growth factor 21.,0.201923087489492,"Hepatic <span class=""gene"" id=""24184811-0-8-13"">SIRT1</span> attenuates <span class=""disease"" id=""24184811-0-25-42"">hepatic steatosis</span> and controls energy balance in mice by inducing fibroblast growth factor 21.",CTD_human
1,0,Therapeutic,C0018801,Heart failure,disease,heart failure,23411,SIRT1,SIRT1,CTD_human,24535859,"Resveratrol, an activator of SIRT1, upregulates AMPK and improves cardiac function in heart failure.",0.201098907136852,"Resveratrol, an activator of <span class=""gene"" id=""24535859-0-29-34"">SIRT1</span>, upregulates AMPK and improves cardiac function in <span class=""disease"" id=""24535859-0-86-99"">heart failure</span>.",CTD_human
1,0,Therapeutic,C0028754,Obesity,disease,obesity,23411,SIRT1,SIRT1,CTD_human,24184811,Strategies to activate SIRT1 or FGF21 could be used to treat fatty liver disease and obesity.,0.29573761588047,"Strategies to activate <span class=""gene"" id=""24184811-18-23-28"">SIRT1</span> or FGF21 could be used to treat fatty liver disease and <span class=""disease"" id=""24184811-18-85-92"">obesity</span>.",CTD_human
1,0,Therapeutic,C0032285,Pneumonia,disease,lung inflammation,23411,SIRT1,SIRT1,CTD_human,24633890,"Overall, these findings reveal a novel function of SIRT1, which is to reduce CS-induced oxidative stress, and this may contribute to its protective effects against lung inflammation and subsequent development of COPD.",0.20054945356842604,"Overall, these findings reveal a novel function of <span class=""gene"" id=""24633890-10-51-56"">SIRT1</span>, which is to reduce CS-induced oxidative stress, and this may contribute to its protective effects against <span class=""disease"" id=""24633890-10-164-181"">lung inflammation</span> and subsequent development of COPD.",CTD_human
1,0,Therapeutic,C0036421,Systemic Scleroderma,disease,Systemic Sclerosis,23411,SIRT1,Sirtuin 1,CTD_human,25707573,The Histone Deacetylase Sirtuin 1 Is Reduced in Systemic Sclerosis and Abrogates Fibrotic Responses by Targeting Transforming Growth Factor ? Signaling.,0.200274726784213,"The Histone Deacetylase <span class=""gene"" id=""25707573-0-24-33"">Sirtuin 1</span> Is Reduced in <span class=""disease"" id=""25707573-0-48-66"">Systemic Sclerosis</span> and Abrogates Fibrotic Responses by Targeting Transforming Growth Factor &beta; Signaling.",CTD_human
1,0,Biomarker,C0524620,Metabolic Syndrome X,disease,metabolic syndrome,23411,SIRT1,sirtuin 1,CTD_human,20068143,Downregulation of the longevity-associated protein sirtuin 1 in insulin resistance and metabolic syndrome: potential biochemical mechanisms.,0.284604842796993,"Downregulation of the longevity-associated protein <span class=""gene"" id=""20068143-0-51-60"">sirtuin 1</span> in insulin resistance and <span class=""disease"" id=""20068143-0-87-105"">metabolic syndrome</span>: potential biochemical mechanisms.",CTD_human
2,0,Therapeutic,C0524851,Neurodegenerative Disorders,group,neurodegenerative disorders,23411,SIRT1,SIRT1,CTD_human,17581637,"Thus, SIRT1 constitutes a unique molecular link between aging and human neurodegenerative disorders and provides a promising avenue for therapeutic intervention.",0.20685381422801,"Thus, <span class=""gene"" id=""17581637-7-6-11"">SIRT1</span> constitutes a unique molecular link between aging and human <span class=""disease"" id=""17581637-7-72-99"">neurodegenerative disorders</span> and provides a promising avenue for therapeutic intervention.",CTD_human
3,2,Biomarker,C0035334,Retinitis Pigmentosa,disease,retinitis pigmentosa,23418,CRB1,CRB1,CTD_human,11389483,Leber congenital amaurosis and retinitis pigmentosa with Coats-like exudative vasculopathy are associated with mutations in the crumbs homologue 1 (CRB1) gene.,0.610634476672364,"Leber congenital amaurosis and <span class=""disease"" id=""11389483-0-31-51"">retinitis pigmentosa</span> with Coats-like exudative vasculopathy are associated with mutations in the crumbs homologue 1 (<span class=""gene"" id=""11389483-0-148-152"">CRB1</span>) gene.",CTD_human;HPO;ORPHANET
3,2,Biomarker,C0035334,Retinitis Pigmentosa,disease,RP,23418,CRB1,CRB1,CTD_human,10508521,"In ten unrelated RP patients with preserved para-arteriolar RPE, we identified a homozygous AluY insertion disrupting the ORF, five homozygous missense mutations and four compound heterozygous mutations in CRB1.",0.610634476672364,"In ten unrelated <span class=""disease"" id=""10508521-7-17-19"">RP</span> patients with preserved para-arteriolar RPE, we identified a homozygous AluY insertion disrupting the ORF, five homozygous missense mutations and four compound heterozygous mutations in <span class=""gene"" id=""10508521-7-206-210"">CRB1</span>.",CTD_human;HPO;ORPHANET
3,2,Biomarker,C0035334,Retinitis Pigmentosa,disease,retinitis pigmentosa,23418,CRB1,CRB1,CTD_human,16272259,"Identification of mutations in the AIPL1, CRB1, GUCY2D, RPE65, and RPGRIP1 genes in patients with juvenile retinitis pigmentosa.",0.610634476672364,"Identification of mutations in the AIPL1, <span class=""gene"" id=""16272259-0-42-46"">CRB1</span>, GUCY2D, RPE65, and RPGRIP1 genes in patients with juvenile <span class=""disease"" id=""16272259-0-107-127"">retinitis pigmentosa</span>.",CTD_human;HPO;ORPHANET
1,1,Biomarker,C0339527,Leber Congenital Amaurosis,disease,Leber congenital amaurosis,23418,CRB1,CRB1,CTD_human,11389483,Leber congenital amaurosis and retinitis pigmentosa with Coats-like exudative vasculopathy are associated with mutations in the crumbs homologue 1 (CRB1) gene.,0.41009937848125505,"<span class=""disease"" id=""11389483-0-0-26"">Leber congenital amaurosis</span> and retinitis pigmentosa with Coats-like exudative vasculopathy are associated with mutations in the crumbs homologue 1 (<span class=""gene"" id=""11389483-0-148-152"">CRB1</span>) gene.",CTD_human;ORPHANET
1,0,Biomarker,C0017601,Glaucoma,disease,glaucoma,23424,TDRD7,TDRD7,CTD_human,21436445,Mutations in the RNA granule component TDRD7 cause cataract and glaucoma.,0.200274726784213,"Mutations in the RNA granule component <span class=""gene"" id=""21436445-0-39-44"">TDRD7</span> cause cataract and <span class=""disease"" id=""21436445-0-64-72"">glaucoma</span>.",CTD_human
1,0,Biomarker,C0086543,Cataract,disease,cataract,23424,TDRD7,TDRD7,CTD_human,21436445,Mutations in the RNA granule component TDRD7 cause cataract and glaucoma.,0.400549453568426,"Mutations in the RNA granule component <span class=""gene"" id=""21436445-0-39-44"">TDRD7</span> cause <span class=""disease"" id=""21436445-0-51-59"">cataract</span> and glaucoma.",CTD_human;HPO
6,0,Biomarker,C0002736,Amyotrophic Lateral Sclerosis,disease,ALS,23435,TARDBP,TDP-43,CTD_human,22879928,"Although the role of TDP-43 in motor neuron degeneration is not yet known, TDP-43 has been shown to accumulate in RNA stress granules (SGs) in cell models and in spinal cord tissue from ALS patients.",0.74024991515851,"Although the role of <span class=""gene"" id=""22879928-3-21-27"">TDP-43</span> in motor neuron degeneration is not yet known, <span class=""gene"" id=""22879928-3-75-81"">TDP-43</span> has been shown to accumulate in RNA stress granules (SGs) in cell models and in spinal cord tissue from <span class=""disease"" id=""22879928-3-186-189"">ALS</span> patients.",CTD_human;HPO;ORPHANET
6,0,Biomarker,C0002736,Amyotrophic Lateral Sclerosis,disease,ALS,23435,TARDBP,TDP-43,CTD_human,24019256,"The hits from this assay will be useful for elucidating regulation of TDP-43, stress granule response, and possible ALS therapeutics.",0.74024991515851,"The hits from this assay will be useful for elucidating regulation of <span class=""gene"" id=""24019256-8-70-76"">TDP-43</span>, stress granule response, and possible <span class=""disease"" id=""24019256-8-116-119"">ALS</span> therapeutics.",CTD_human;HPO;ORPHANET
6,0,Biomarker,C0002736,Amyotrophic Lateral Sclerosis,disease,ALS,23435,TARDBP,TDP-43,CTD_human,23104007,Inhibition of RNA lariat debranching enzyme suppresses TDP-43 toxicity in ALS disease models.,0.74024991515851,"Inhibition of RNA lariat debranching enzyme suppresses <span class=""gene"" id=""23104007-0-55-61"">TDP-43</span> toxicity in <span class=""disease"" id=""23104007-0-74-77"">ALS</span> disease models.",CTD_human;HPO;ORPHANET
6,0,Biomarker,C0002736,Amyotrophic Lateral Sclerosis,disease,ALS,23435,TARDBP,TDP-43,CTD_human,24252504,TAR DNA-binding protein 43 (TDP-43) is a protein that is involved in the pathology of Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Lobar Degeneration (FTLD).,0.74024991515851,"<span class=""gene"" id=""24252504-1-0-26"">TAR DNA-binding protein 43</span> (<span class=""gene"" id=""24252504-1-28-34"">TDP-43</span>) is a protein that is involved in the pathology of <span class=""disease"" id=""24252504-1-86-115"">Amyotrophic Lateral Sclerosis</span> (<span class=""disease"" id=""24252504-1-117-120"">ALS</span>) and Frontotemporal Lobar Degeneration (FTLD).",CTD_human;HPO;ORPHANET
6,0,Biomarker,C0002736,Amyotrophic Lateral Sclerosis,disease,amyotrophic lateral sclerosis,23435,TARDBP,TARDBP,CTD_human,18372902,TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis.,0.74024991515851,"<span class=""gene"" id=""18372902-0-0-6"">TARDBP</span> mutations in individuals with sporadic and familial <span class=""disease"" id=""18372902-0-59-88"">amyotrophic lateral sclerosis</span>.",CTD_human;HPO;ORPHANET
2,0,Biomarker,C0751072,Frontotemporal Lobar Degeneration,disease,FTLD,23435,TARDBP,TDP-43,CTD_human,24019256,TDP-43 is an RNA binding protein found to accumulate in the cytoplasm of brain and spinal cord from patients affected with amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD).,0.2592754728554,"<span class=""gene"" id=""24019256-1-0-6"">TDP-43</span> is an RNA binding protein found to accumulate in the cytoplasm of brain and spinal cord from patients affected with amyotrophic lateral sclerosis (ALS) and <span class=""disease"" id=""24019256-1-163-196"">frontotemporal lobar degeneration</span> (<span class=""disease"" id=""24019256-1-198-202"">FTLD</span>).",CTD_human
2,0,Biomarker,C0751072,Frontotemporal Lobar Degeneration,disease,FTLD,23435,TARDBP,TDP-43,CTD_human,24252504,TAR DNA-binding protein 43 (TDP-43) is a protein that is involved in the pathology of Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Lobar Degeneration (FTLD).,0.2592754728554,"<span class=""gene"" id=""24252504-1-0-26"">TAR DNA-binding protein 43</span> (<span class=""gene"" id=""24252504-1-28-34"">TDP-43</span>) is a protein that is involved in the pathology of Amyotrophic Lateral Sclerosis (ALS) and <span class=""disease"" id=""24252504-1-126-159"">Frontotemporal Lobar Degeneration</span> (<span class=""disease"" id=""24252504-1-161-165"">FTLD</span>).",CTD_human
1,0,Biomarker,C0267963,Exocrine pancreatic insufficiency,disease,pancreatic insufficiency,23436,CELA3B,E1,CTD_human,14687815,Diagnosis of pancreatic insufficiency was established for a fecal E1 <200 microg/g.,0.20082418035263896,"Diagnosis of <span class=""disease"" id=""14687815-8-13-37"">pancreatic insufficiency</span> was established for a fecal <span class=""gene"" id=""14687815-8-66-68"">E1</span> &lt;200 microg/g.",CTD_human
1,0,Biomarker,C0023434,Chronic Lymphocytic Leukemia,disease,chronic lymphocytic leukemia,23451,SF3B1,SF3B1,CTD_human,22158541,Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia.,0.20851653031060602,"Exome sequencing identifies recurrent mutations of the splicing factor <span class=""gene"" id=""22158541-0-71-76"">SF3B1</span> gene in <span class=""disease"" id=""22158541-0-85-113"">chronic lymphocytic leukemia</span>.",CTD_human
2,0,Biomarker,C0220633,Uveal melanoma,disease,uveal melanoma,23451,SF3B1,SF3B1,CTD_human,23793026,Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3.,0.40302199462634397,"Exome sequencing identifies recurrent somatic mutations in EIF1AX and <span class=""gene"" id=""23793026-0-70-75"">SF3B1</span> in <span class=""disease"" id=""23793026-0-79-93"">uveal melanoma</span> with disomy 3.",CTD_human;ORPHANET
2,0,Biomarker,C0220633,Uveal melanoma,disease,uveal melanoma,23451,SF3B1,SF3B1,CTD_human,23313955,Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma.,0.40302199462634397,"Recurrent mutations at codon 625 of the splicing factor <span class=""gene"" id=""23313955-0-56-61"">SF3B1</span> in <span class=""disease"" id=""23313955-0-65-79"">uveal melanoma</span>.",CTD_human;ORPHANET
1,0,Biomarker,C1510586,Autism Spectrum Disorders,disease,ASD,23462,HEY1,HEY1,CTD_human,20868653,"Our analysis identified several novel dysregulated genes and miRNAs in ASD compared with controls, including HEY1, SOX9, miR-486 and miR-181b.",0.2,"Our analysis identified several novel dysregulated genes and miRNAs in <span class=""disease"" id=""20868653-6-71-74"">ASD</span> compared with controls, including <span class=""gene"" id=""20868653-6-109-113"">HEY1</span>, SOX9, miR-486 and miR-181b.",CTD_human
1,0,Biomarker,C0002170,Alopecia,disease,alopecia,23476,BRD4,Brd4,CTD_human,25242322,"Brd4-depleted mice display reversible epidermal hyperplasia, alopecia, and decreased cellular diversity and stem cell depletion in the small intestine.",0.2,"<span class=""gene"" id=""25242322-4-0-4"">Brd4</span>-depleted mice display reversible epidermal hyperplasia, <span class=""disease"" id=""25242322-4-61-69"">alopecia</span>, and decreased cellular diversity and stem cell depletion in the small intestine.",CTD_human
1,0,Biomarker,C0085413,"Polycystic Kidney, Autosomal Dominant",disease,ADPKD,23476,BRD4,Brd4,CTD_human,25877301,"Therapeutic targeting of BET bromodomain protein, Brd4, delays cyst growth in ADPKD.",0.200274726784213,"Therapeutic targeting of BET bromodomain protein, <span class=""gene"" id=""25877301-0-50-54"">Brd4</span>, delays cyst growth in <span class=""disease"" id=""25877301-0-78-83"">ADPKD</span>.",CTD_human
1,0,Biomarker,C0000768,Congenital Abnormality,group,abnormal development,2348,FOLR1,Folr1,CTD_human,20235221,Suppression of Folr1 expression in the nascent cardiac NC by site-directed short-interfering RNA (siRNA) altered cardiac NC cell mitosis and subsequent migration patterns leading to abnormal development of the pharyngeal arch arteries (PAA) and outflow tract. qPCR analysis demonstrated that the siRNA treatment significantly reduced Folr1 24 hr after treatment.,0.200274726784213,"Suppression of <span class=""gene"" id=""20235221-3-15-20"">Folr1</span> expression in the nascent cardiac NC by site-directed short-interfering RNA (siRNA) altered cardiac NC cell mitosis and subsequent migration patterns leading to <span class=""disease"" id=""20235221-3-182-202"">abnormal development</span> of the pharyngeal arch arteries (PAA) and outflow tract. qPCR analysis demonstrated that the siRNA treatment significantly reduced <span class=""gene"" id=""20235221-3-334-339"">Folr1</span> 24 hr after treatment.",CTD_human
1,0,Biomarker,C0014544,Epilepsy,disease,epilepsy,2348,FOLR1,FOLR1,CTD_human,19732866,"Three patients carrying FOLR1 mutations developed progressive movement disturbance, psychomotor decline, and epilepsy and showed severely reduced folate concentrations in the cerebrospinal fluid (CSF).",0.4,"Three patients carrying <span class=""gene"" id=""19732866-4-24-29"">FOLR1</span> mutations developed progressive movement disturbance, psychomotor decline, and <span class=""disease"" id=""19732866-4-109-117"">epilepsy</span> and showed severely reduced folate concentrations in the cerebrospinal fluid (CSF).",CTD_human;HPO
1,0,Biomarker,C0029463,Osteosarcoma,disease,osteosarcoma,2348,FOLR1,folate receptor alpha,CTD_human,17473184,The folate receptor alpha is frequently overexpressed in osteosarcoma samples and plays a role in the uptake of the physiologic substrate 5-methyltetrahydrofolate.,0.200274726784213,"The <span class=""gene"" id=""17473184-0-4-25"">folate receptor alpha</span> is frequently overexpressed in <span class=""disease"" id=""17473184-0-57-69"">osteosarcoma</span> samples and plays a role in the uptake of the physiologic substrate 5-methyltetrahydrofolate.",CTD_human
1,0,Biomarker,C1142166,Brugada Syndrome (disorder),disease,Brugada syndrome,23493,HEY2,HEY2,CTD_human,23872634,"Common variants at SCN5A-SCN10A and HEY2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death.",0.20082418035263896,"Common variants at SCN5A-SCN10A and <span class=""gene"" id=""23872634-0-36-40"">HEY2</span> are associated with <span class=""disease"" id=""23872634-0-61-77"">Brugada syndrome</span>, a rare disease with high risk of sudden cardiac death.",CTD_human
1,0,Biomarker,C0017638,Glioma,disease,gliomas,23512,SUZ12,SUZ12,CTD_human,25119042,"Here we provide genomic, cellular, and mouse modelling data demonstrating that the polycomb group gene SUZ12 functions as tumour suppressor in PNS tumours, high-grade gliomas and melanomas by cooperating with mutations in NF1.",0.2,"Here we provide genomic, cellular, and mouse modelling data demonstrating that the polycomb group gene <span class=""gene"" id=""25119042-3-103-108"">SUZ12</span> functions as tumour suppressor in PNS tumours, high-grade <span class=""disease"" id=""25119042-3-167-174"">gliomas</span> and melanomas by cooperating with mutations in NF1.",CTD_human
1,0,Biomarker,C0025202,melanoma,disease,melanomas,23512,SUZ12,SUZ12,CTD_human,25119042,"Here we provide genomic, cellular, and mouse modelling data demonstrating that the polycomb group gene SUZ12 functions as tumour suppressor in PNS tumours, high-grade gliomas and melanomas by cooperating with mutations in NF1.",0.200274726784213,"Here we provide genomic, cellular, and mouse modelling data demonstrating that the polycomb group gene <span class=""gene"" id=""25119042-3-103-108"">SUZ12</span> functions as tumour suppressor in PNS tumours, high-grade gliomas and <span class=""disease"" id=""25119042-3-179-188"">melanomas</span> by cooperating with mutations in NF1.",CTD_human
2,0,Biomarker,C0206727,Nerve Sheath Tumors,group,neurofibromas,23512,SUZ12,SUZ12,CTD_human,25305755,"Sixteen MPNSTs but none of the neurofibromas tested were found to have somatic mutations in SUZ12, implicating it as having a central role in malignant transformation.",0.200274726784213,"Sixteen MPNSTs but none of the <span class=""disease"" id=""25305755-3-31-44"">neurofibromas</span> tested were found to have somatic mutations in <span class=""gene"" id=""25305755-3-92-97"">SUZ12</span>, implicating it as having a central role in malignant transformation.",CTD_human
4,0,Biomarker,C0036572,Seizures,phenotype,seizures,2353,FOS,Fos,CTD_human,9630518,"In order to follow the spatial and temporal evolution of neuronal damage, cellular activation and stress responses subsequent to lithium-pilocarpine seizures of various durations in the adult rat, we analyzed the expression of Fos protein and local cerebral glucose utilization as markers of cellular activation, HSP72 immunoreactivity and acid fuchsin staining as indicators of cellular stress and injury, and Cresyl violet staining for the assessment of neuronal damage.",0.2,"In order to follow the spatial and temporal evolution of neuronal damage, cellular activation and stress responses subsequent to lithium-pilocarpine <span class=""disease"" id=""9630518-1-149-157"">seizures</span> of various durations in the adult rat, we analyzed the expression of <span class=""gene"" id=""9630518-1-227-230"">Fos</span> protein and local cerebral glucose utilization as markers of cellular activation, HSP72 immunoreactivity and acid fuchsin staining as indicators of cellular stress and injury, and Cresyl violet staining for the assessment of neuronal damage.",CTD_human
4,0,Biomarker,C0036572,Seizures,phenotype,seizures,2353,FOS,C-Fos,CTD_human,8923670,C-Fos expression as a molecular marker in corticotropin-releasing factor-induced seizures.,0.2,"<span class=""gene"" id=""8923670-0-0-5"">C-Fos</span> expression as a molecular marker in corticotropin-releasing factor-induced <span class=""disease"" id=""8923670-0-81-89"">seizures</span>.",CTD_human
3,0,Biomarker,C0038587,Substance Withdrawal Syndrome,disease,withdrawal syndrome,2353,FOS,c-Fos,CTD_human,15196794,The present study revealed a significant increase in c-Fos protein expression in the cortex and thalamus of mice showing naloxone-precipitated withdrawal syndrome.,0.2,"The present study revealed a significant increase in <span class=""gene"" id=""15196794-4-53-58"">c-Fos</span> protein expression in the cortex and thalamus of mice showing naloxone-precipitated <span class=""disease"" id=""15196794-4-143-162"">withdrawal syndrome</span>.",CTD_human
1,0,Biomarker,C0023473,"Myeloid Leukemia, Chronic",disease,CML,23532,PRAME,PRAME,CTD_human,17157168,"Several LAAs are expressed in CML and therefore are candidate structures for specific immunotherapies: bcr-abl (100%), G250 (24%), hTERT (53%), MPP11 (91%), NEWREN60 (94%), PRAME (62%), Proteinase3 (71%), RHAMM/CD168 (83%), and WT1 (53%), but not BAGE, MAGE-A1, SSX2, or NY-ESO-1.",0.202472541057918,"Several LAAs are expressed in <span class=""disease"" id=""17157168-3-30-33"">CML</span> and therefore are candidate structures for specific immunotherapies: bcr-abl (100%), G250 (24%), hTERT (53%), MPP11 (91%), NEWREN60 (94%), <span class=""gene"" id=""17157168-3-173-178"">PRAME</span> (62%), Proteinase3 (71%), RHAMM/CD168 (83%), and WT1 (53%), but not BAGE, MAGE-A1, SSX2, or NY-ESO-1.",CTD_human
1,0,Biomarker,C0025202,melanoma,disease,melanoma,23532,PRAME,PRAME,CTD_human,16179254,"Conversely, knockdown of PRAME expression by RNA interference in RA-resistant human melanoma restores RAR signaling and reinstates sensitivity to the antiproliferative effects of RA in vitro and in vivo.",0.20274726784213098,"Conversely, knockdown of <span class=""gene"" id=""16179254-6-25-30"">PRAME</span> expression by RNA interference in RA-resistant human <span class=""disease"" id=""16179254-6-84-92"">melanoma</span> restores RAR signaling and reinstates sensitivity to the antiproliferative effects of RA in vitro and in vivo.",CTD_human
1,1,Biomarker,C0406587,Wrinkly skin syndrome,disease,wrinkly skin syndrome,23545,ATP6V0A2,ATP6V0A2,CTD_human,18157129,"We identified loss-of-function mutations in ATP6V0A2, encoding the a2 subunit of the V-type H+ ATPase, in several families with autosomal recessive cutis laxa type II or wrinkly skin syndrome.",0.40082418035263895,"We identified loss-of-function mutations in <span class=""gene"" id=""18157129-1-44-52"">ATP6V0A2</span>, encoding the a2 subunit of the V-type H+ ATPase, in several families with autosomal recessive cutis laxa type II or <span class=""disease"" id=""18157129-1-170-191"">wrinkly skin syndrome</span>.",CTD_human;ORPHANET
1,0,Biomarker,C0024305,"Lymphoma, Non-Hodgkin",disease,NHL,2356,FPGS,FPGS,CTD_human,17119116,"We observed a decreased risk of NHL over-all with BHMTEx8+453A>T and increased risk with CBS Ex13+41C>T, FPGS Ex15-263T>C, and SHMT1 Ex12+138C>T and Ex12+236C>T.",0.20481405704657604,"We observed a decreased risk of <span class=""disease"" id=""17119116-5-32-35"">NHL</span> over-all with BHMTEx8+453A&gt;T and increased risk with CBS Ex13+41C&gt;T, <span class=""gene"" id=""17119116-5-105-109"">FPGS</span> Ex15-263T&gt;C, and SHMT1 Ex12+138C&gt;T and Ex12+236C&gt;T.",CTD_human
1,0,Biomarker,C1961102,Precursor Cell Lymphoblastic Leukemia Lymphoma,disease,acute lymphoblastic leukemia,2356,FPGS,folylpolyglutamate synthase,CTD_human,25013492,Effect of folylpolyglutamate synthase A22G polymorphism on the risk and survival of patients with acute lymphoblastic leukemia.,0.20054945356842604,"Effect of <span class=""gene"" id=""25013492-0-10-37"">folylpolyglutamate synthase</span> A22G polymorphism on the risk and survival of patients with <span class=""disease"" id=""25013492-0-98-126"">acute lymphoblastic leukemia</span>.",CTD_human
1,2,Biomarker,C0022650,Kidney Calculi,disease,kidney stones,23562,CLDN14,CLDN14,CTD_human,19561606,Sequence variants in the CLDN14 gene associate with kidney stones and bone mineral density.,0.201098907136852,"Sequence variants in the <span class=""gene"" id=""19561606-0-25-31"">CLDN14</span> gene associate with <span class=""disease"" id=""19561606-0-52-65"">kidney stones</span> and bone mineral density.",CTD_human
1,0,Biomarker,C0010346,Crohn Disease,disease,Crohn's disease,2358,FPR2,FPR2,CTD_human,21659618,"Finally, we found that FPR2 gene expression was increased approximately sixfold in the colon of patients with Crohn's disease, a finding reproduced in vitro by the treatment of THP-1 cells with interferon-? or lipopolysaccharide.",0.200274726784213,"Finally, we found that <span class=""gene"" id=""21659618-6-23-27"">FPR2</span> gene expression was increased approximately sixfold in the colon of patients with <span class=""disease"" id=""21659618-6-110-125"">Crohn's disease</span>, a finding reproduced in vitro by the treatment of THP-1 cells with interferon-&gamma; or lipopolysaccharide.",CTD_human
1,0,Therapeutic,C0019100,Severe Dengue,disease,dengue haemorrhagic fever,23601,CLEC5A,CLEC5A,CTD_human,18496526,"Our observation that blockade of CLEC5A-mediated signalling attenuates the production of proinflammatory cytokines by macrophages infected with DV (either alone or complexed with an enhancing antibody) offers a promising strategy for alleviating tissue damage and increasing the survival of patients suffering from dengue haemorrhagic fever and dengue shock syndrome, and possibly even other virus-induced inflammatory diseases.",0.20054945356842604,"Our observation that blockade of <span class=""gene"" id=""18496526-7-33-39"">CLEC5A</span>-mediated signalling attenuates the production of proinflammatory cytokines by macrophages infected with DV (either alone or complexed with an enhancing antibody) offers a promising strategy for alleviating tissue damage and increasing the survival of patients suffering from <span class=""disease"" id=""18496526-7-315-340"">dengue haemorrhagic fever</span> and dengue shock syndrome, and possibly even other virus-induced inflammatory diseases.",CTD_human
2,2,Biomarker,C0002395,Alzheimer's Disease,disease,Alzheimer's disease,23607,CD2AP,CD2AP,CTD_human,21460840,"Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease.",0.202472541057918,"Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and <span class=""gene"" id=""21460840-0-57-62"">CD2AP</span> are associated with <span class=""disease"" id=""21460840-0-83-102"">Alzheimer's disease</span>.",CTD_human
1,0,Biomarker,C0002395,Alzheimer's Disease,disease,AD,23621,BACE1,BACE1,CTD_human,16407166,Our data strongly support a major role of PPARgamma in the modulation of amyloid-beta generation by inflammation and suggest that the protective mechanism of NSAIDs in AD involves activation of PPARgamma and decreased BACE1 gene transcription.,0.36425316589349,"Our data strongly support a major role of PPARgamma in the modulation of amyloid-beta generation by inflammation and suggest that the protective mechanism of NSAIDs in <span class=""disease"" id=""16407166-11-168-170"">AD</span> involves activation of PPARgamma and decreased <span class=""gene"" id=""16407166-11-218-223"">BACE1</span> gene transcription.",CTD_human
1,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastasis,23643,LY96,MD-2,CTD_human,22180778,"Accordingly, simultaneous examination of the expression of TLR4, MD-2 and CXCR7 in cancer tissues of colorectal carcinoma may provide valuable prognostic diagnosis of carcinoma growth and metastasis.",0.200274726784213,"Accordingly, simultaneous examination of the expression of TLR4, <span class=""gene"" id=""22180778-9-65-69"">MD-2</span> and CXCR7 in cancer tissues of colorectal carcinoma may provide valuable prognostic diagnosis of carcinoma growth and <span class=""disease"" id=""22180778-9-188-198"">metastasis</span>.",CTD_human
1,0,Biomarker,C0011581,Depressive disorder,disease,depression,23705,CADM1,Cadm1,CTD_human,22113448,"Furthermore, a candidate genetic locus that associates with baseline depressive-like behavior contains a gene that encodes for cellular proliferation/adhesion molecule (Cadm1), supporting a genetic basis for the role of neuro/gliogenesis in depression.",0.2,"Furthermore, a candidate genetic locus that associates with baseline depressive-like behavior contains a gene that encodes for cellular proliferation/adhesion molecule (<span class=""gene"" id=""22113448-8-169-174"">Cadm1</span>), supporting a genetic basis for the role of neuro/gliogenesis in <span class=""disease"" id=""22113448-8-241-251"">depression</span>.",CTD_human
1,0,Biomarker,C0035334,Retinitis Pigmentosa,disease,retinitis pigmentosa,23746,AIPL1,AIPL1,CTD_human,16272259,"Identification of mutations in the AIPL1, CRB1, GUCY2D, RPE65, and RPGRIP1 genes in patients with juvenile retinitis pigmentosa.",0.604381273170092,"Identification of mutations in the <span class=""gene"" id=""16272259-0-35-40"">AIPL1</span>, CRB1, GUCY2D, RPE65, and RPGRIP1 genes in patients with juvenile <span class=""disease"" id=""16272259-0-107-127"">retinitis pigmentosa</span>.",CTD_human;HPO;ORPHANET
28,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,non-small cell lung cancer,238,ALK,ALK,CTD_human,23020724,Treatment of ALK-positive non-small cell lung cancer.,0.28,"Treatment of <span class=""gene"" id=""23020724-0-13-16"">ALK</span>-positive <span class=""disease"" id=""23020724-0-26-52"">non-small cell lung cancer</span>.",CTD_human
28,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,nonsmall cell lung cancer,238,ALK,ALK,CTD_human,22282074,"Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer.",0.28,"Correlations between the percentage of tumor cells showing an <span class=""gene"" id=""22282074-0-62-88"">anaplastic lymphoma kinase</span> (<span class=""gene"" id=""22282074-0-90-93"">ALK</span>) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive <span class=""disease"" id=""22282074-0-225-250"">nonsmall cell lung cancer</span>.",CTD_human
28,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,NSCLC,238,ALK,ALK,CTD_human,21757253,The ALK inhibitor presented in this study is effective in EML4-ALK NSCLC cases.,0.28,"The <span class=""gene"" id=""21757253-17-4-7"">ALK</span> inhibitor presented in this study is effective in EML4-<span class=""gene"" id=""21757253-17-63-66"">ALK</span> <span class=""disease"" id=""21757253-17-67-72"">NSCLC</span> cases.",CTD_human
28,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,NSCLC,238,ALK,ALK,CTD_human,22277784,These results highlight the unique features of TKI resistance in ALK-positive NSCLCs and provide the rationale for pursuing combinatorial therapeutics that are tailored to the precise resistance mechanisms identified in patients who relapse on crizotinib treatment.,0.28,"These results highlight the unique features of TKI resistance in <span class=""gene"" id=""22277784-8-65-68"">ALK</span>-positive <span class=""disease"" id=""22277784-8-78-83"">NSCLC</span>s and provide the rationale for pursuing combinatorial therapeutics that are tailored to the precise resistance mechanisms identified in patients who relapse on crizotinib treatment.",CTD_human
28,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,non-small cell lung cancer,238,ALK,ALK,CTD_human,21904575,"Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities.",0.28,"Genotype-driven therapies for <span class=""disease"" id=""21904575-0-30-56"">non-small cell lung cancer</span>: focus on EGFR, KRAS and <span class=""gene"" id=""21904575-0-82-85"">ALK</span> gene abnormalities.",CTD_human
28,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,non-small-cell lung cancer,238,ALK,ALK,CTD_human,21823889,Ongoing studies will define the true utility of this drug in ALK-rearranged non-small-cell lung cancer patients and in patients with other tumors that also have ALK activation.,0.28,"Ongoing studies will define the true utility of this drug in <span class=""gene"" id=""21823889-8-61-64"">ALK</span>-rearranged <span class=""disease"" id=""21823889-8-76-102"">non-small-cell lung cancer</span> patients and in patients with other tumors that also have <span class=""gene"" id=""21823889-8-161-164"">ALK</span> activation.",CTD_human
28,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,non-small cell lung cancer,238,ALK,Anaplastic lymphoma kinase,CTD_human,21336183,Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed.,0.28,"<span class=""gene"" id=""21336183-0-0-26"">Anaplastic lymphoma kinase</span> gene rearrangements in <span class=""disease"" id=""21336183-0-50-76"">non-small cell lung cancer</span> are associated with prolonged progression-free survival on pemetrexed.",CTD_human
28,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,NSCLC,238,ALK,ALK,CTD_human,22617245,"We selected NSCLC cell lines--A549 (KRAS G12S), NCI-H3255 (EGFR L858R), NCI-H3122 (EML4-ALK E13;A20), and HCC78 (SLC34A2-ROS1)-to evaluate the antiproliferative effects of submicromolar concentrations of the multitargeted TKIs imatinib, sorafenib, erlotinib, and crizotinib.",0.28,"We selected <span class=""disease"" id=""22617245-3-12-17"">NSCLC</span> cell lines--A549 (KRAS G12S), NCI-H3255 (EGFR L858R), NCI-H3122 (EML4-<span class=""gene"" id=""22617245-3-88-91"">ALK</span> E13;A20), and HCC78 (SLC34A2-ROS1)-to evaluate the antiproliferative effects of submicromolar concentrations of the multitargeted TKIs imatinib, sorafenib, erlotinib, and crizotinib.",CTD_human
28,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,non-small cell lung cancer,238,ALK,ALK,CTD_human,22887466,"Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer.",0.28,"Pemetrexed-based chemotherapy in patients with advanced, <span class=""gene"" id=""22887466-0-57-60"">ALK</span>-positive <span class=""disease"" id=""22887466-0-70-96"">non-small cell lung cancer</span>.",CTD_human
28,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,non-small cell lung cancer,238,ALK,ALK,CTD_human,21102269,"Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer.",0.28,"Rapid and dramatic radiographic and clinical response to an <span class=""gene"" id=""21102269-0-60-63"">ALK</span> inhibitor (crizotinib, PF02341066) in an <span class=""gene"" id=""21102269-0-105-108"">ALK</span> translocation-positive patient with <span class=""disease"" id=""21102269-0-145-171"">non-small cell lung cancer</span>.",CTD_human
28,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,NSCLC,238,ALK,ALK,CTD_human,23686600,Crizotinib appears to be efficacious and well tolerated in patients with NSCLC and may have future potential applications in treating lymphomas and other cancers driven by ALK or c-MET gene mutations.,0.28,"Crizotinib appears to be efficacious and well tolerated in patients with <span class=""disease"" id=""23686600-9-73-78"">NSCLC</span> and may have future potential applications in treating lymphomas and other cancers driven by <span class=""gene"" id=""23686600-9-172-175"">ALK</span> or c-MET gene mutations.",CTD_human
28,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,non-small-cell lung cancer,238,ALK,ALK,CTD_human,22508824,Remarkable tumor response to crizotinib in a 14-year-old girl with ALK-positive non-small-cell lung cancer.,0.28,"Remarkable tumor response to crizotinib in a 14-year-old girl with <span class=""gene"" id=""22508824-0-67-70"">ALK</span>-positive <span class=""disease"" id=""22508824-0-80-106"">non-small-cell lung cancer</span>.",CTD_human
28,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,NSCLC,238,ALK,ALK,CTD_human,21791641,"These mechanisms can occur independently, or in the same cancer, suggesting that the combination of both ALK and EGFR inhibitors may represent an effective therapy for these subsets of NSCLC patients.",0.28,"These mechanisms can occur independently, or in the same cancer, suggesting that the combination of both <span class=""gene"" id=""21791641-10-105-108"">ALK</span> and EGFR inhibitors may represent an effective therapy for these subsets of <span class=""disease"" id=""21791641-10-185-190"">NSCLC</span> patients.",CTD_human
28,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,non-small cell lung cancer,238,ALK,anaplastic lymphoma kinase,CTD_human,22568572,Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-targeted therapy for advanced non-small cell lung cancer: molecular and clinical aspects.,0.28,"Echinoderm microtubule-associated protein-like 4-<span class=""gene"" id=""22568572-0-49-75"">anaplastic lymphoma kinase</span>-targeted therapy for advanced <span class=""disease"" id=""22568572-0-106-132"">non-small cell lung cancer</span>: molecular and clinical aspects.",CTD_human
28,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,NSCLC,238,ALK,ALK,CTD_human,22215748,ROS1 rearrangement defines a molecular subset of NSCLC with distinct clinical characteristics that are similar to those observed in patients with ALK-rearranged NSCLC.,0.28,"ROS1 rearrangement defines a molecular subset of <span class=""disease"" id=""22215748-12-49-54"">NSCLC</span> with distinct clinical characteristics that are similar to those observed in patients with <span class=""gene"" id=""22215748-12-146-149"">ALK</span>-rearranged <span class=""disease"" id=""22215748-12-161-166"">NSCLC</span>.",CTD_human
28,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,NSCLC,238,ALK,ALK,CTD_human,22286583,"At the moment, established personalized treatment approaches include treatment of patients with NSCLC and activating epidermal growth factor receptor (EGFR) mutations with the EGFR-directed tyrosine kinase inhibitors gefitinib or erlotinib, and treatment of NSCLC patients with genetic aberrations in the anaplastic lymphoma kinase (ALK) oncogene with the mesenchymal-epithelial transition factor (MET)/ALK inhibitor crizotinib.",0.28,"At the moment, established personalized treatment approaches include treatment of patients with <span class=""disease"" id=""22286583-4-96-101"">NSCLC</span> and activating epidermal growth factor receptor (EGFR) mutations with the EGFR-directed tyrosine kinase inhibitors gefitinib or erlotinib, and treatment of <span class=""disease"" id=""22286583-4-258-263"">NSCLC</span> patients with genetic aberrations in the <span class=""gene"" id=""22286583-4-305-331"">anaplastic lymphoma kinase</span> (<span class=""gene"" id=""22286583-4-333-336"">ALK</span>) oncogene with the mesenchymal-epithelial transition factor (MET)/<span class=""gene"" id=""22286583-4-403-406"">ALK</span> inhibitor crizotinib.",CTD_human
28,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,non-small-cell lung cancer,238,ALK,ALK,CTD_human,21933749,Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.,0.28,"Effect of crizotinib on overall survival in patients with advanced <span class=""disease"" id=""21933749-0-67-93"">non-small-cell lung cancer</span> harbouring <span class=""gene"" id=""21933749-0-105-108"">ALK</span> gene rearrangement: a retrospective analysis.",CTD_human
28,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,non-small cell lung cancer,238,ALK,ALK,CTD_human,22986231,Isolated central nervous system progression on Crizotinib: an Achilles heel of non-small cell lung cancer with EML4-ALK translocation?,0.28,"Isolated central nervous system progression on Crizotinib: an Achilles heel of <span class=""disease"" id=""22986231-0-79-105"">non-small cell lung cancer</span> with EML4-<span class=""gene"" id=""22986231-0-116-119"">ALK</span> translocation?",CTD_human
28,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,nsclc,238,ALK,ALK,CTD_human,22787409,"However, the benefits of these agents are not uniform across the spectrum of nsclc, and optimizing their utility requires some degree of subgrouping of nsclc by the presence or absence of certain biomarkers.The biomarkers of current or imminent value are EGFR and KRAS mutational status, ALK rearrangements, and MET immunohistochemistry.",0.28,"However, the benefits of these agents are not uniform across the spectrum of <span class=""disease"" id=""22787409-3-77-82"">nsclc</span>, and optimizing their utility requires some degree of subgrouping of <span class=""disease"" id=""22787409-3-152-157"">nsclc</span> by the presence or absence of certain biomarkers.The biomarkers of current or imminent value are EGFR and KRAS mutational status, <span class=""gene"" id=""22787409-3-288-291"">ALK</span> rearrangements, and MET immunohistochemistry.",CTD_human
28,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,non-small-cell lung cancer,238,ALK,Anaplastic lymphoma kinase,CTD_human,20979469,Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.,0.28,"<span class=""gene"" id=""20979469-0-0-26"">Anaplastic lymphoma kinase</span> inhibition in <span class=""disease"" id=""20979469-0-41-67"">non-small-cell lung cancer</span>.",CTD_human
28,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,non-small-cell lung cancer,238,ALK,ALK,CTD_human,17625570,Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.,0.28,"Identification of the transforming EML4-<span class=""gene"" id=""17625570-0-40-43"">ALK</span> fusion gene in <span class=""disease"" id=""17625570-0-59-85"">non-small-cell lung cancer</span>.",CTD_human
28,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,non-small-cell lung cancer,238,ALK,ALK,CTD_human,22954507,Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.,0.28,"Activity and safety of crizotinib in patients with <span class=""gene"" id=""22954507-0-51-54"">ALK</span>-positive <span class=""disease"" id=""22954507-0-64-90"">non-small-cell lung cancer</span>: updated results from a phase 1 study.",CTD_human
28,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,non-small cell lung cancer,238,ALK,ALK,CTD_human,22968692,"Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma.",0.28,"Targeting <span class=""gene"" id=""22968692-0-10-13"">ALK</span>: a promising strategy for the treatment of <span class=""disease"" id=""22968692-0-57-83"">non-small cell lung cancer</span>, non-Hodgkin's lymphoma, and neuroblastoma.",CTD_human
28,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,non-small cell lung cancer,238,ALK,anaplastic lymphoma kinase,CTD_human,21767331,Favorable response to crizotinib in three patients with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion-type oncogene-positive non-small cell lung cancer.,0.28,"Favorable response to crizotinib in three patients with echinoderm microtubule-associated protein-like 4-<span class=""gene"" id=""21767331-0-105-131"">anaplastic lymphoma kinase</span> fusion-type oncogene-positive <span class=""disease"" id=""21767331-0-162-188"">non-small cell lung cancer</span>.",CTD_human
28,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,non-small cell lung cancer,238,ALK,ALK,CTD_human,21587085,Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression.,0.28,"Detection of <span class=""gene"" id=""21587085-0-13-16"">ALK</span> gene rearrangement in <span class=""disease"" id=""21587085-0-39-65"">non-small cell lung cancer</span>: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of <span class=""gene"" id=""21587085-0-176-179"">ALK</span> protein expression.",CTD_human
28,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,NSCLC,238,ALK,ALK,CTD_human,22920921,"Crizotinib, an oral ALK inhibitor, has proved to provide dramatic clinical benefit in patients with NSCLC harboring ALK rearrangements.",0.28,"Crizotinib, an oral <span class=""gene"" id=""22920921-3-20-23"">ALK</span> inhibitor, has proved to provide dramatic clinical benefit in patients with <span class=""disease"" id=""22920921-3-100-105"">NSCLC</span> harboring <span class=""gene"" id=""22920921-3-116-119"">ALK</span> rearrangements.",CTD_human
12,0,Biomarker,C0027819,Neuroblastoma,disease,neuroblastoma,238,ALK,ALK,CTD_human,20576349,All-trans retinoic acid downregulates ALK in neuroblastoma cell lines and induces apoptosis in neuroblastoma cell lines with activated ALK.,0.44328389786177097,"All-trans retinoic acid downregulates <span class=""gene"" id=""20576349-0-38-41"">ALK</span> in <span class=""disease"" id=""20576349-0-45-58"">neuroblastoma</span> cell lines and induces apoptosis in <span class=""disease"" id=""20576349-0-95-108"">neuroblastoma</span> cell lines with activated <span class=""gene"" id=""20576349-0-135-138"">ALK</span>.",CTD_human;ORPHANET
12,0,Biomarker,C0027819,Neuroblastoma,disease,neuroblastoma,238,ALK,ALK,CTD_human,22789543,The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma.,0.44328389786177097,"The <span class=""gene"" id=""22789543-0-4-7"">ALK</span>(F1174L) mutation potentiates the oncogenic activity of MYCN in <span class=""disease"" id=""22789543-0-71-84"">neuroblastoma</span>.",CTD_human;ORPHANET
12,0,Biomarker,C0027819,Neuroblastoma,disease,neuroblastoma,238,ALK,ALK,CTD_human,22920921,"Chromosomal translocations and single point mutations involving the Anaplastic Lymphoma Kinase (ALK) gene have been described in several human tumors, including anaplastic large cell lymphoma (ALCL), non-small cell lung cancer (NCSLC), inflammatory myofibroblastic tumor (IMT) and neuroblastoma.",0.44328389786177097,"Chromosomal translocations and single point mutations involving the <span class=""gene"" id=""22920921-1-68-94"">Anaplastic Lymphoma Kinase</span> (<span class=""gene"" id=""22920921-1-96-99"">ALK</span>) gene have been described in several human tumors, including anaplastic large cell lymphoma (ALCL), non-small cell lung cancer (NCSLC), inflammatory myofibroblastic tumor (IMT) and <span class=""disease"" id=""22920921-1-281-294"">neuroblastoma</span>.",CTD_human;ORPHANET
12,0,Biomarker,C0027819,Neuroblastoma,disease,neuroblastoma,238,ALK,anaplastic lymphoma kinase,CTD_human,22072639,Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma.,0.44328389786177097,"Differential inhibitor sensitivity of <span class=""gene"" id=""22072639-0-38-64"">anaplastic lymphoma kinase</span> variants found in <span class=""disease"" id=""22072639-0-83-96"">neuroblastoma</span>.",CTD_human;ORPHANET
12,0,Biomarker,C0027819,Neuroblastoma,disease,neuroblastoma,238,ALK,ALK,CTD_human,22588779,"Crizotinib is a dual-specific inhibitor of ALK/Met and inhibits proliferation of neuroblastoma cells harboring R1275Q-mutated ALK or amplified wild-type ALK, but not cells harboring F1174L.",0.44328389786177097,"Crizotinib is a dual-specific inhibitor of <span class=""gene"" id=""22588779-10-43-46"">ALK</span>/Met and inhibits proliferation of <span class=""disease"" id=""22588779-10-81-94"">neuroblastoma</span> cells harboring R1275Q-mutated <span class=""gene"" id=""22588779-10-126-129"">ALK</span> or amplified wild-type <span class=""gene"" id=""22588779-10-153-156"">ALK</span>, but not cells harboring F1174L.",CTD_human;ORPHANET
12,0,Biomarker,C0027819,Neuroblastoma,disease,neuroblastoma,238,ALK,anaplastic lymphoma kinase,CTD_human,23104988,Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma.,0.44328389786177097,"Cell culture and Drosophila model systems define three classes of <span class=""gene"" id=""23104988-0-66-92"">anaplastic lymphoma kinase</span> mutations in <span class=""disease"" id=""23104988-0-106-119"">neuroblastoma</span>.",CTD_human;ORPHANET
12,0,Biomarker,C0027819,Neuroblastoma,disease,neuroblastoma,238,ALK,ALK,CTD_human,22968692,"Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma.",0.44328389786177097,"Targeting <span class=""gene"" id=""22968692-0-10-13"">ALK</span>: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and <span class=""disease"" id=""22968692-0-113-126"">neuroblastoma</span>.",CTD_human;ORPHANET
12,0,Biomarker,C0027819,Neuroblastoma,disease,neuroblastoma,238,ALK,anaplastic lymphoma kinase,CTD_human,22932897,The R1275Q neuroblastoma mutant and certain ATP-competitive inhibitors stabilize alternative activation loop conformations of anaplastic lymphoma kinase.,0.44328389786177097,"The R1275Q <span class=""disease"" id=""22932897-0-11-24"">neuroblastoma</span> mutant and certain ATP-competitive inhibitors stabilize alternative activation loop conformations of <span class=""gene"" id=""22932897-0-126-152"">anaplastic lymphoma kinase</span>.",CTD_human;ORPHANET
12,0,Biomarker,C0027819,Neuroblastoma,disease,neuroblastoma,238,ALK,ALK,CTD_human,22286764,Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells.,0.44328389786177097,"Anaplastic Lymphoma Kinase (<span class=""gene"" id=""22286764-0-28-31"">ALK</span>) regulates initiation of transcription of MYCN in <span class=""disease"" id=""22286764-0-82-95"">neuroblastoma</span> cells.",CTD_human;ORPHANET
8,0,Biomarker,C0152013,Adenocarcinoma of lung (disorder),disease,of lung adenocarcinoma,238,ALK,ALK,CTD_human,22980554,"EML4-ALK fusion gene, is found in 3 to 5 % of lung adenocarcinoma and can be targeted by tyrosine-kinase inhibitor (TKI) with impressive therapeutic results.",0.226648498068671,"EML4-<span class=""gene"" id=""22980554-1-5-8"">ALK</span> fusion gene, is found in 3 to 5 % <span class=""disease"" id=""22980554-1-43-65"">of lung adenocarcinoma</span> and can be targeted by tyrosine-kinase inhibitor (TKI) with impressive therapeutic results.",CTD_human
8,0,Biomarker,C0152013,Adenocarcinoma of lung (disorder),disease,Adenocarcinoma of the lung,238,ALK,anaplastic lymphoma kinase,CTD_human,22999080,Adenocarcinoma of the lung with miliary brain and pulmonary metastases with echinoderm microtubule-associated protein like 4-anaplastic lymphoma kinase translocation treated with crizotinib: a case report.,0.226648498068671,"<span class=""disease"" id=""22999080-0-0-26"">Adenocarcinoma of the lung</span> with miliary brain and pulmonary metastases with echinoderm microtubule-associated protein like 4-<span class=""gene"" id=""22999080-0-125-151"">anaplastic lymphoma kinase</span> translocation treated with crizotinib: a case report.",CTD_human
8,0,Biomarker,C0152013,Adenocarcinoma of lung (disorder),disease,adenocarcinoma of the lung,238,ALK,ALK,CTD_human,22135231,"We examined epidermal growth factor receptor (EGFR), Kirsten rate sarcoma viral oncogene homolog (KRAS), v-Raf murine sarcoma viral oncogene homolog B1 (BRAF), human epidermal growth factor receptor 2 (HER2), PIK3CA, v-akt murine thymoma vial oncogene homolog 1 (AKT1), v-ras neuroblastoma viral oncogene homolog (NRAS), dual specificity mitogen-activated protein kinase kinase 1 (MEK1), and anaplastic lymphoma kinase (ALK) in patients with adenocarcinoma of the lung to identify driver mutations.",0.226648498068671,"We examined epidermal growth factor receptor (EGFR), Kirsten rate sarcoma viral oncogene homolog (KRAS), v-Raf murine sarcoma viral oncogene homolog B1 (BRAF), human epidermal growth factor receptor 2 (HER2), PIK3CA, v-akt murine thymoma vial oncogene homolog 1 (AKT1), v-ras neuroblastoma viral oncogene homolog (NRAS), dual specificity mitogen-activated protein kinase kinase 1 (MEK1), and <span class=""gene"" id=""22135231-4-392-418"">anaplastic lymphoma kinase</span> (<span class=""gene"" id=""22135231-4-420-423"">ALK</span>) in patients with <span class=""disease"" id=""22135231-4-442-468"">adenocarcinoma of the lung</span> to identify driver mutations.",CTD_human
6,0,Biomarker,C0206180,Ki-1+ Anaplastic Large Cell Lymphoma,disease,anaplastic large cell lymphomas,238,ALK,ALK,CTD_human,19503098,Reactive oxygen species and lipoxygenases regulate the oncogenicity of NPM-ALK-positive anaplastic large cell lymphomas.,0.304596212183324,"Reactive oxygen species and lipoxygenases regulate the oncogenicity of NPM-<span class=""gene"" id=""19503098-0-75-78"">ALK</span>-positive <span class=""disease"" id=""19503098-0-88-119"">anaplastic large cell lymphomas</span>.",CTD_human
6,0,Biomarker,C0206180,Ki-1+ Anaplastic Large Cell Lymphoma,disease,ALCL,238,ALK,ALK,CTD_human,22920921,"Chromosomal translocations and single point mutations involving the Anaplastic Lymphoma Kinase (ALK) gene have been described in several human tumors, including anaplastic large cell lymphoma (ALCL), non-small cell lung cancer (NCSLC), inflammatory myofibroblastic tumor (IMT) and neuroblastoma.",0.304596212183324,"Chromosomal translocations and single point mutations involving the <span class=""gene"" id=""22920921-1-68-94"">Anaplastic Lymphoma Kinase</span> (<span class=""gene"" id=""22920921-1-96-99"">ALK</span>) gene have been described in several human tumors, including <span class=""disease"" id=""22920921-1-161-191"">anaplastic large cell lymphoma</span> (<span class=""disease"" id=""22920921-1-193-197"">ALCL</span>), non-small cell lung cancer (NCSLC), inflammatory myofibroblastic tumor (IMT) and neuroblastoma.",CTD_human
6,0,Biomarker,C0206180,Ki-1+ Anaplastic Large Cell Lymphoma,disease,ALCL,238,ALK,ALK,CTD_human,16151469,"LY293111 inhibited proliferation of both ALK(+) and ALK(-) ALCL cell in a dose-dependent fashion and induced complete G(1)-S cell cycle arrest, which was accompanied by upregulation of p27 and downregulation of cyclin E. Pretreatment with LY293111 for 4 h resulted in profound inhibition of serum-induced phosphorylation of extracellular-regulated kinases-1 and 2 and Akt and a concomitant increase in the phosphorylation of the stress-activated kinase c-jun N-terminal kinases (JNK).",0.304596212183324,"LY293111 inhibited proliferation of both <span class=""gene"" id=""16151469-4-41-44"">ALK</span>(+) and <span class=""gene"" id=""16151469-4-52-55"">ALK</span>(-) <span class=""disease"" id=""16151469-4-59-63"">ALCL</span> cell in a dose-dependent fashion and induced complete G(1)-S cell cycle arrest, which was accompanied by upregulation of p27 and downregulation of cyclin E. Pretreatment with LY293111 for 4 h resulted in profound inhibition of serum-induced phosphorylation of extracellular-regulated kinases-1 and 2 and Akt and a concomitant increase in the phosphorylation of the stress-activated kinase c-jun N-terminal kinases (JNK).",CTD_human
1,0,Biomarker,C0278601,Inflammatory Breast Carcinoma,disease,inflammatory breast cancers,238,ALK,ALK,CTD_human,22215853,ALK gene amplified in most inflammatory breast cancers.,0.20054945356842604,"<span class=""gene"" id=""22215853-0-0-3"">ALK</span> gene amplified in most <span class=""disease"" id=""22215853-0-27-54"">inflammatory breast cancers</span>.",CTD_human
8,7,Biomarker,C0016719,Friedreich Ataxia,disease,Friedreich's ataxia,2395,FXN,frataxin,CTD_human,16911956,"Humans with a frataxin deficiency have the cardio- and neurodegenerative disorder Friedreich's ataxia, commonly resulting from a GAA trinucleotide repeat expansion in the frataxin gene.",0.5053785633876691,"Humans with a <span class=""gene"" id=""16911956-2-14-22"">frataxin</span> deficiency have the cardio- and neurodegenerative disorder <span class=""disease"" id=""16911956-2-82-101"">Friedreich's ataxia</span>, commonly resulting from a GAA trinucleotide repeat expansion in the <span class=""gene"" id=""16911956-2-171-179"">frataxin</span> gene.",CTD_human;ORPHANET
8,7,Biomarker,C0016719,Friedreich Ataxia,disease,Friedreich ataxia,2395,FXN,frataxin,CTD_human,22016819,Mesenchymal stem cells restore frataxin expression and increase hydrogen peroxide scavenging enzymes in Friedreich ataxia fibroblasts.,0.5053785633876691,"Mesenchymal stem cells restore <span class=""gene"" id=""22016819-0-31-39"">frataxin</span> expression and increase hydrogen peroxide scavenging enzymes in <span class=""disease"" id=""22016819-0-104-121"">Friedreich ataxia</span> fibroblasts.",CTD_human;ORPHANET
8,7,Biomarker,C0016719,Friedreich Ataxia,disease,Friedreich's ataxia,2395,FXN,frataxin,CTD_human,20098685,Two new pimelic diphenylamide HDAC inhibitors induce sustained frataxin upregulation in cells from Friedreich's ataxia patients and in a mouse model.,0.5053785633876691,"Two new pimelic diphenylamide HDAC inhibitors induce sustained <span class=""gene"" id=""20098685-0-63-71"">frataxin</span> upregulation in cells from <span class=""disease"" id=""20098685-0-99-118"">Friedreich's ataxia</span> patients and in a mouse model.",CTD_human;ORPHANET
8,7,Biomarker,C0016719,Friedreich Ataxia,disease,Friedreich ataxia,2395,FXN,FXN,CTD_human,23418481,Pharmacological screening using an FXN-EGFP cellular genomic reporter assay for the therapy of Friedreich ataxia.,0.5053785633876691,"Pharmacological screening using an <span class=""gene"" id=""23418481-0-35-38"">FXN</span>-EGFP cellular genomic reporter assay for the therapy of <span class=""disease"" id=""23418481-0-95-112"">Friedreich ataxia</span>.",CTD_human;ORPHANET
8,7,Biomarker,C0016719,Friedreich Ataxia,disease,Friedreich Ataxia,2395,FXN,frataxin,CTD_human,12923074,"Friedreich Ataxia (FRDA), the most common inherited ataxia, arises from defective expression of the mitochondrial protein frataxin, which leads to increased mitochondrial oxidative damage.",0.5053785633876691,"<span class=""disease"" id=""12923074-1-0-17"">Friedreich Ataxia</span> (FRDA), the most common inherited ataxia, arises from defective expression of the mitochondrial protein <span class=""gene"" id=""12923074-1-122-130"">frataxin</span>, which leads to increased mitochondrial oxidative damage.",CTD_human;ORPHANET
8,7,Biomarker,C0016719,Friedreich Ataxia,disease,FA,2395,FXN,Friedreich ataxia,CTD_human,16120311,Friedreich ataxia (FA) is an inherited recessive disorder characterized by progressive neurological disability and heart abnormalities.,0.5053785633876691,"<span class=""gene"" id=""16120311-1-0-17"">Friedreich ataxia</span> (<span class=""disease"" id=""16120311-1-19-21"">FA</span>) is an inherited recessive disorder characterized by progressive neurological disability and heart abnormalities.",CTD_human;ORPHANET
1,0,Biomarker,C0008924,Cleft Lip,disease,cleft lip,24,ABCA4,ABCA4,CTD_human,20436469,A genome-wide association study of cleft lip with and without cleft palate identifies risk variants near MAFB and ABCA4.,0.202681755307501,"A genome-wide association study of <span class=""disease"" id=""20436469-0-35-44"">cleft lip</span> with and without cleft palate identifies risk variants near MAFB and <span class=""gene"" id=""20436469-0-114-119"">ABCA4</span>.",CTD_human
1,0,Biomarker,C0004153,Atherosclerosis,disease,atherosclerosis,240,ALOX5,5-LO,CTD_human,16698924,"In contrast to human plaques, levels of 5-LO mRNA are not significantly increased in plaque tissues from two atherosclerosis-prone mouse strains, and mouse plaques exhibit segregated cellular expression of LTA4H and 5-LO as well as strong increases of CysLT1 and CysLT2 mRNA.",0.21971313719709,"In contrast to human plaques, levels of <span class=""gene"" id=""16698924-7-40-44"">5-LO</span> mRNA are not significantly increased in plaque tissues from two <span class=""disease"" id=""16698924-7-109-124"">atherosclerosis</span>-prone mouse strains, and mouse plaques exhibit segregated cellular expression of LTA4H and <span class=""gene"" id=""16698924-7-216-220"">5-LO</span> as well as strong increases of CysLT1 and CysLT2 mRNA.",CTD_human
1,0,Biomarker,C0009319,Colitis,disease,colitis,240,ALOX5,5-Lipoxygenase,CTD_human,15821759,5-Lipoxygenase modulates colitis through the regulation of adhesion molecule expression and neutrophil migration.,0.2,"<span class=""gene"" id=""15821759-0-0-14"">5-Lipoxygenase</span> modulates <span class=""disease"" id=""15821759-0-25-32"">colitis</span> through the regulation of adhesion molecule expression and neutrophil migration.",CTD_human
1,0,Biomarker,C0009376,Colonic Polyps,phenotype,colon polyps,240,ALOX5,5-LOX,CTD_human,18927292,Overexpression of 5-lipoxygenase in colon polyps and cancer and the effect of 5-LOX inhibitors in vitro and in a murine model.,0.202681755307501,"Overexpression of <span class=""gene"" id=""18927292-0-18-32"">5-lipoxygenase</span> in <span class=""disease"" id=""18927292-0-36-48"">colon polyps</span> and cancer and the effect of <span class=""gene"" id=""18927292-0-78-83"">5-LOX</span> inhibitors in vitro and in a murine model.",CTD_human
1,0,Biomarker,C0020429,Hyperalgesia,phenotype,hyperalgesia,240,ALOX5,5-lipoxygenase,CTD_human,12582831,"Injection of 5- and 12-lipoxygenase produced hyperalgesia that was not antagonized by inhibitors of PKA, PKCepsilon or MAPK.These findings suggest that: (1). lipoxygenase products of arachidonic acid function as second messengers in the peripheral hyperalgesia induced by agents that act directly on primary afferent nociceptors (epinephrine and prostaglandin E(2)), (2). products of the 5-lipoxygenase and 12-lipoxygenase pathway are involved in this function, and (3). these lipoxygenase products contribute to hyperalgesia at or downstream of protein kinase A and PKCepsilon.",0.2,"Injection of 5- and 12-lipoxygenase produced <span class=""disease"" id=""12582831-5-45-57"">hyperalgesia</span> that was not antagonized by inhibitors of PKA, PKCepsilon or MAPK.These findings suggest that: (1). lipoxygenase products of arachidonic acid function as second messengers in the peripheral <span class=""disease"" id=""12582831-5-248-260"">hyperalgesia</span> induced by agents that act directly on primary afferent nociceptors (epinephrine and prostaglandin E(2)), (2). products of the <span class=""gene"" id=""12582831-5-388-402"">5-lipoxygenase</span> and 12-lipoxygenase pathway are involved in this function, and (3). these lipoxygenase products contribute to <span class=""disease"" id=""12582831-5-513-525"">hyperalgesia</span> at or downstream of protein kinase A and PKCepsilon.",CTD_human
2,0,Therapeutic,C0023473,"Myeloid Leukemia, Chronic",disease,chronic myeloid leukemia,240,ALOX5,Alox5,CTD_human,19823023,The Alox5 gene is a novel therapeutic target in cancer stem cells of chronic myeloid leukemia.,0.201373633921065,"The <span class=""gene"" id=""19823023-0-4-9"">Alox5</span> gene is a novel therapeutic target in cancer stem cells of <span class=""disease"" id=""19823023-0-69-93"">chronic myeloid leukemia</span>.",CTD_human
2,0,Therapeutic,C0023473,"Myeloid Leukemia, Chronic",disease,chronic myeloid leukemia,240,ALOX5,Alox5,CTD_human,19503090,Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia.,0.201373633921065,"Loss of the <span class=""gene"" id=""19503090-0-12-17"">Alox5</span> gene impairs leukemia stem cells and prevents <span class=""disease"" id=""19503090-0-64-88"">chronic myeloid leukemia</span>.",CTD_human
1,0,Biomarker,C0271650,Impaired glucose tolerance,phenotype,Glucose intolerance,2444,FRK,FRK,CTD_human,17179392,Glucose intolerance and reduced islet blood flow in transgenic mice expressing the FRK tyrosine kinase under the control of the rat insulin promoter.,0.2,"<span class=""disease"" id=""17179392-0-0-19"">Glucose intolerance</span> and reduced islet blood flow in transgenic mice expressing the <span class=""gene"" id=""17179392-0-83-86"">FRK</span> tyrosine kinase under the control of the rat insulin promoter.",CTD_human
1,0,Therapeutic,C0004153,Atherosclerosis,disease,atherosclerosis,246,ALOX15,12/15-Lipoxygenase,CTD_human,16303615,12/15-Lipoxygenase gene disruption and vitamin E administration diminish atherosclerosis and oxidative stress in apolipoprotein E deficient mice through a final common pathway.,0.224904235342504,"<span class=""gene"" id=""16303615-0-0-18"">12/15-Lipoxygenase</span> gene disruption and vitamin E administration diminish <span class=""disease"" id=""16303615-0-73-88"">atherosclerosis</span> and oxidative stress in apolipoprotein E deficient mice through a final common pathway.",CTD_human
1,0,Biomarker,C0014859,Esophageal Neoplasms,group,esophageal cancer,246,ALOX15,15-LOX-1,CTD_human,11406566,These findings demonstrate that 15-LOX-1 is down-regulated in human esophageal carcinomas and that NSAIDs induce apoptosis in esophageal cancer cells via up-regulation of 15-LOX-1.,0.200274726784213,"These findings demonstrate that <span class=""gene"" id=""11406566-5-32-40"">15-LOX-1</span> is down-regulated in human esophageal carcinomas and that NSAIDs induce apoptosis in <span class=""disease"" id=""11406566-5-126-143"">esophageal cancer</span> cells via up-regulation of <span class=""gene"" id=""11406566-5-171-179"">15-LOX-1</span>.",CTD_human
1,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,246,ALOX15,12/15-lipoxygenase,CTD_human,22467300,Mice lacking macrophage 12/15-lipoxygenase are resistant to experimental hypertension.,0.200274726784213,"Mice lacking macrophage <span class=""gene"" id=""22467300-0-24-42"">12/15-lipoxygenase</span> are resistant to experimental <span class=""disease"" id=""22467300-0-73-85"">hypertension</span>.",CTD_human
2,0,Therapeutic,C0033578,Prostatic Neoplasms,group,prostate tumor,246778,IL27,interleukin-27,CTD_human,21801027,Sonoporation delivery of interleukin-27 gene therapy efficiently reduces prostate tumor cell growth in vivo.,0.20082418035263896,"Sonoporation delivery of <span class=""gene"" id=""21801027-0-25-39"">interleukin-27</span> gene therapy efficiently reduces <span class=""disease"" id=""21801027-0-73-87"">prostate tumor</span> cell growth in vivo.",CTD_human
2,0,Therapeutic,C0033578,Prostatic Neoplasms,group,prostate tumor,246778,IL27,Interleukin-27,CTD_human,24028178,Interleukin-27 gene delivery for modifying malignant interactions between prostate tumor and bone.,0.20082418035263896,"<span class=""gene"" id=""24028178-0-0-14"">Interleukin-27</span> gene delivery for modifying malignant interactions between <span class=""disease"" id=""24028178-0-74-88"">prostate tumor</span> and bone.",CTD_human
1,0,Biomarker,C0025500,Mesothelioma,disease,mesothelioma,2475,MTOR,mTOR,CTD_human,21358348,The mTOR inhibitor temsirolimus is active against mesothelioma in vitro and in vivo and synergizes with chemotherapy.,0.20300763924902696,"The <span class=""gene"" id=""21358348-11-4-8"">mTOR</span> inhibitor temsirolimus is active against <span class=""disease"" id=""21358348-11-50-62"">mesothelioma</span> in vitro and in vivo and synergizes with chemotherapy.",CTD_human
1,0,Biomarker,C0149721,Left Ventricular Hypertrophy,disease,left ventricular hypertrophy,2475,MTOR,mTOR,CTD_human,19289642,Master regulators of protein synthesis such as mammalian target of rapamycin (mTOR) and p70S6 kinase contribute to left ventricular hypertrophy.,0.2,"Master regulators of protein synthesis such as <span class=""gene"" id=""19289642-1-47-76"">mammalian target of rapamycin</span> (<span class=""gene"" id=""19289642-1-78-82"">mTOR</span>) and p70S6 kinase contribute to <span class=""disease"" id=""19289642-1-115-143"">left ventricular hypertrophy</span>.",CTD_human
1,0,Biomarker,C0334634,"Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse",disease,MCL,2475,MTOR,mTOR,CTD_human,17148679,"We also assessed mTOR signaling in MCL tumors using immunohistochemical methods and a tissue microarray: 10 of 30 (33%) expressed Ser473p-AKT, 13 of 21 (62%) Ser2448p-mTOR, 22 of 22 (100%) p-p70S6K, and 5 of 20 (25%) p-ribosomal protein S6.",0.205205453522732,"We also assessed mTOR signaling in <span class=""disease"" id=""17148679-8-35-38"">MCL</span> tumors using immunohistochemical methods and a tissue microarray: 10 of 30 (33%) expressed Ser473p-AKT, 13 of 21 (62%) Ser2448p-<span class=""gene"" id=""17148679-8-167-171"">mTOR</span>, 22 of 22 (100%) p-p70S6K, and 5 of 20 (25%) p-ribosomal protein S6.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,2475,MTOR,mammalian target of rapamycin,CTD_human,21147110,"In HCC cell lines, the AKT-mammalian target of rapamycin complex 1-ribosomal protein S6 pathway promoted lipogenesis via transcriptional and post-transcriptional mechanisms that included inhibition of fatty acid synthase ubiquitination by the USP2a de-ubiquitinase and disruption of the SREBP1 and SREBP2 degradation complexes.",0.212333994534955,"In <span class=""disease"" id=""21147110-8-3-6"">HCC</span> cell lines, the AKT-<span class=""gene"" id=""21147110-8-27-56"">mammalian target of rapamycin</span> complex 1-ribosomal protein S6 pathway promoted lipogenesis via transcriptional and post-transcriptional mechanisms that included inhibition of fatty acid synthase ubiquitination by the USP2a de-ubiquitinase and disruption of the SREBP1 and SREBP2 degradation complexes.",CTD_human
1,1,Biomarker,C0032460,Polycystic Ovary Syndrome,disease,PCOS,2492,FSHR,FSHR,CTD_human,22885925,"In addition to confirming the three loci we previously reported, we identify eight new PCOS association signals at P < 5 × 10(-8): 9q22.32, 11q22.1, 12q13.2, 12q14.3, 16q12.1, 19p13.3, 20q13.2 and a second independent signal at 2p16.3 (the FSHR gene).",0.224043253209869,"In addition to confirming the three loci we previously reported, we identify eight new <span class=""disease"" id=""22885925-3-87-91"">PCOS</span> association signals at P &lt; 5 &times; 10(-8): 9q22.32, 11q22.1, 12q13.2, 12q14.3, 16q12.1, 19p13.3, 20q13.2 and a second independent signal at 2p16.3 (the <span class=""gene"" id=""22885925-3-240-244"">FSHR</span> gene).",CTD_human
1,0,Biomarker,C0003128,Anovulation,phenotype,anovulation,2494,NR5A2,Lrh1,CTD_human,18628394,"Using somatic targeted mutagenesis, we show that mice lacking Lrh1 in granulosa cells are sterile, due to anovulation.",0.2,"Using somatic targeted mutagenesis, we show that mice lacking <span class=""gene"" id=""18628394-4-62-66"">Lrh1</span> in granulosa cells are sterile, due to <span class=""disease"" id=""18628394-4-106-117"">anovulation</span>.",CTD_human
3,0,Biomarker,C0023473,"Myeloid Leukemia, Chronic",disease,CML,25,ABL1,ABL,CTD_human,18673174,"However, 95% of CML patients have the ABL gene from chromosome 9 fused with the breakpoint cluster (BCR) gene from chromosome 22, resulting in a short chromosome known as the Philadelphia chromosome.",0.531599452889936,"However, 95% of <span class=""disease"" id=""18673174-3-16-19"">CML</span> patients have the <span class=""gene"" id=""18673174-3-38-41"">ABL</span> gene from chromosome 9 fused with the breakpoint cluster (BCR) gene from chromosome 22, resulting in a short chromosome known as the Philadelphia chromosome.",CTD_human;ORPHANET
3,0,Biomarker,C0023473,"Myeloid Leukemia, Chronic",disease,chronic myeloid leukemia,25,ABL1,BCR-ABL,CTD_human,21908430,"We present cell-based and biochemical evidence establishing that BCR-ABL(35INS) is kinase-inactive and does not contribute to TKI resistance, and we find that detection of BCR-ABL(35INS) does not consistently track with or explain resistance in clinical samples from chronic myeloid leukemia patients.",0.531599452889936,"We present cell-based and biochemical evidence establishing that <span class=""gene"" id=""21908430-5-65-72"">BCR-ABL</span>(35INS) is kinase-inactive and does not contribute to TKI resistance, and we find that detection of <span class=""gene"" id=""21908430-5-172-179"">BCR-ABL</span>(35INS) does not consistently track with or explain resistance in clinical samples from <span class=""disease"" id=""21908430-5-267-291"">chronic myeloid leukemia</span> patients.",CTD_human;ORPHANET
1,0,Biomarker,C0596263,Carcinogenesis,phenotype,tumorigenesis,25,ABL1,ABL1,CTD_human,23968727,Hyper-methylated miR-203 dysregulates ABL1 and contributes to the nickel-induced tumorigenesis.,0.202197814273705,"Hyper-methylated miR-203 dysregulates <span class=""gene"" id=""23968727-0-38-42"">ABL1</span> and contributes to the nickel-induced <span class=""disease"" id=""23968727-0-81-94"">tumorigenesis</span>.",CTD_human
1,0,Biomarker,C0001623,Adrenal gland hypofunction,phenotype,adrenal failure,2516,NR5A1,steroidogenic factor-1,CTD_human,10369247,A mutation in the gene encoding steroidogenic factor-1 causes XY sex reversal and adrenal failure in humans.,0.208176290991763,"A mutation in the gene encoding <span class=""gene"" id=""10369247-0-32-54"">steroidogenic factor-1</span> causes XY sex reversal and <span class=""disease"" id=""10369247-0-82-97"">adrenal failure</span> in humans.",CTD_human
1,0,Biomarker,C0014175,Endometriosis,disease,endometriosis,2516,NR5A1,steroidogenic factor-1,CTD_human,17519303,Transcriptional activation of steroidogenic factor-1 by hypomethylation of the 5' CpG island in endometriosis.,0.204930726738519,"Transcriptional activation of <span class=""gene"" id=""17519303-0-30-52"">steroidogenic factor-1</span> by hypomethylation of the 5' CpG island in <span class=""disease"" id=""17519303-0-96-109"">endometriosis</span>.",CTD_human
1,0,Biomarker,C0021364,Male infertility,phenotype,male infertility,2516,NR5A1,steroidogenic factor 1,CTD_human,20887963,Human male infertility associated with mutations in NR5A1 encoding steroidogenic factor 1.,0.402956482091714,"Human <span class=""disease"" id=""20887963-0-6-22"">male infertility</span> associated with mutations in <span class=""gene"" id=""20887963-0-52-57"">NR5A1</span> encoding <span class=""gene"" id=""20887963-0-67-89"">steroidogenic factor 1</span>.",CTD_human;HPO
1,0,Biomarker,C0085215,"Ovarian Failure, Premature",disease,primary ovarian insufficiency,2516,NR5A1,NR5A1,CTD_human,19246354,"NR5A1 mutations are associated with 46,XX primary ovarian insufficiency and 46,XY disorders of sex development.",0.20439562854741,"<span class=""gene"" id=""19246354-11-0-5"">NR5A1</span> mutations are associated with 46,XX <span class=""disease"" id=""19246354-11-42-71"">primary ovarian insufficiency</span> and 46,XY disorders of sex development.",CTD_human
1,0,Biomarker,C0919267,ovarian neoplasm,disease,ovarian tumors,2516,NR5A1,steroidogenic factor?1,CTD_human,23291911,Genetic and epigenetic alterations of steroidogenic factor?1 in ovarian tumors.,0.20054945356842604,"Genetic and epigenetic alterations of <span class=""gene"" id=""23291911-0-38-60"">steroidogenic factor?1</span> in <span class=""disease"" id=""23291911-0-64-78"">ovarian tumors</span>.",CTD_human
1,0,Biomarker,C0004763,Barrett Esophagus,disease,BE,2520,GAST,gastrin,CTD_human,15387324,"(1) COX-2, PPARgamma, HGF, gastrin, and its receptor are significantly upregulated in BE, suggesting a possible role for these factors in Barrett's carcinogenesis; (2) the increased NFkappaB activity is probably linked to increased IL-8 and COX-2 expression; and (3) PPARgamma ligands might be useful as a new therapeutic option in the prevention and treatment of Barrett's carcinoma.",0.20082418035263896,"(1) COX-2, PPARgamma, HGF, <span class=""gene"" id=""15387324-9-27-34"">gastrin</span>, and its receptor are significantly upregulated in <span class=""disease"" id=""15387324-9-86-88"">BE</span>, suggesting a possible role for these factors in Barrett's carcinogenesis; (2) the increased NFkappaB activity is probably linked to increased IL-8 and COX-2 expression; and (3) PPARgamma ligands might be useful as a new therapeutic option in the prevention and treatment of Barrett's carcinoma.",CTD_human
1,0,Biomarker,C0030920,Peptic Ulcer,disease,peptic ulcer disease,2520,GAST,Gastrin,CTD_human,10700044,Gastrin is also implicated in the genesis of peptic ulcer disease both in conjunction with H. pylori infections and with gastrin-producing tumors.,0.201648360705279,"<span class=""gene"" id=""10700044-3-0-7"">Gastrin</span> is also implicated in the genesis of <span class=""disease"" id=""10700044-3-45-65"">peptic ulcer disease</span> both in conjunction with H. pylori infections and with gastrin-producing tumors.",CTD_human
2,0,Biomarker,C0206634,"Liposarcoma, Myxoid",disease,myxoid liposarcoma,2521,FUS,FUS,CTD_human,7503811,"We show that the translocation t(12;16)(q13:p11) in malignant myxoid liposarcoma can be a fusion of the CHOP dominant negative transcription factor gene with a novel gene, FUS, which can result in fusion of the FUS glycine-rich protein with the whole CHOP coding region.",0.413447257049125,"We show that the translocation t(12;16)(q13:p11) in malignant <span class=""disease"" id=""7503811-2-62-80"">myxoid liposarcoma</span> can be a fusion of the CHOP dominant negative transcription factor gene with a novel gene, <span class=""gene"" id=""7503811-2-172-175"">FUS</span>, which can result in fusion of the <span class=""gene"" id=""7503811-2-211-214"">FUS</span> glycine-rich protein with the whole CHOP coding region.",CTD_human;ORPHANET
1,0,Biomarker,C0079774,Peripheral T-Cell Lymphoma,disease,peripheral T cell lymphomas,2534,FYN,FYN,CTD_human,24413734,"Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas.",0.200274726784213,"Recurrent mutations in epigenetic regulators, RHOA and <span class=""gene"" id=""24413734-0-55-58"">FYN</span> kinase in <span class=""disease"" id=""24413734-0-69-96"">peripheral T cell lymphomas</span>.",CTD_human
3,0,Biomarker,C0002878,"Anemia, Hemolytic",disease,hemolytic anemia,2539,G6PD,G6PD,CTD_human,4794122,[Acute kidney failure and hemolytic anemia caused by erythrocytic G6PD dificit revealed by chloroquine administration].,0.221869564070466,"[Acute kidney failure and <span class=""disease"" id=""4794122-0-26-42"">hemolytic anemia</span> caused by erythrocytic <span class=""gene"" id=""4794122-0-66-70"">G6PD</span> dificit revealed by chloroquine administration].",CTD_human
3,0,Biomarker,C0002878,"Anemia, Hemolytic",disease,haemolytic anaemia,2539,G6PD,glucose-6-phosphate dehydrogenase,CTD_human,2502894,Aspirin-induced acute haemolytic anaemia in glucose-6-phosphate dehydrogenase-deficient children with systemic arthritis.,0.221869564070466,"Aspirin-induced acute <span class=""disease"" id=""2502894-0-22-40"">haemolytic anaemia</span> in <span class=""gene"" id=""2502894-0-44-77"">glucose-6-phosphate dehydrogenase</span>-deficient children with systemic arthritis.",CTD_human
2,0,Biomarker,C0015702,Favism,disease,favism,2539,G6PD,G6PD,CTD_human,12028056,We analysed the G6PD gene in 74 unrelated G6PD-deficient men with a history of favism.,0.21058331951505102,"We analysed the <span class=""gene"" id=""12028056-2-16-20"">G6PD</span> gene in 74 unrelated <span class=""gene"" id=""12028056-2-42-46"">G6PD</span>-deficient men with a history of <span class=""disease"" id=""12028056-2-79-85"">favism</span>.",CTD_human
3,1,Biomarker,C2939465,Deficiency of glucose-6-phosphate dehydrogenase,disease,G-6-PD deficiency,2539,G6PD,G-6-PD,CTD_human,4728291,Variants of glucose-6-phosphate dehydrogenase (G-6-PD) associated with G-6-PD deficiency in Puerto Ricans.,0.32751337829154903,"Variants of <span class=""gene"" id=""4728291-0-12-45"">glucose-6-phosphate dehydrogenase</span> (<span class=""gene"" id=""4728291-0-47-53"">G-6-PD</span>) associated with <span class=""disease"" id=""4728291-0-71-88"">G-6-PD deficiency</span> in Puerto Ricans.",CTD_human
34,131,Therapeutic,C0017921,Glycogen storage disease type II,disease,GSD II,2548,GAA,GAA,CTD_human,18176891,"Glycogen storage disease type II (GSD II) is an autosomal recessive deficiency of acidalpha-1,4-glucosidase(GAA) caused by mutations in the GAA gene located on human chromosome 17 (17q 25.2-q 25.3).",0.551609615332135,"<span class=""disease"" id=""18176891-1-0-32"">Glycogen storage disease type II</span> (<span class=""disease"" id=""18176891-1-34-40"">GSD II</span>) is an autosomal recessive deficiency of acidalpha-1,4-glucosidase(GAA) caused by mutations in the <span class=""gene"" id=""18176891-1-140-143"">GAA</span> gene located on human chromosome 17 (17q 25.2-q 25.3).",CTD_human;UNIPROT
34,131,Biomarker,C0017921,Glycogen storage disease type II,disease,Pompe disease,2548,GAA,GAA,CTD_human,21963784,"To investigate the feasibility of NBS for Pompe disease in Japan, we obtained dried blood spots (DBSs) from 496 healthy Japanese controls, 29 Japanese patients with Pompe disease, and five obligate carriers, and assayed GAA activity under the following conditions: (1) total GAA measured at pH 3.8, (2) GAA measured at pH 3.8 in the presence of acarbose, and (3) neutral glucosidase activity (NAG) measured at pH 7.0 without acarbose.",0.551609615332135,"To investigate the feasibility of NBS for <span class=""disease"" id=""21963784-4-42-55"">Pompe disease</span> in Japan, we obtained dried blood spots (DBSs) from 496 healthy Japanese controls, 29 Japanese patients with <span class=""disease"" id=""21963784-4-165-178"">Pompe disease</span>, and five obligate carriers, and assayed <span class=""gene"" id=""21963784-4-220-223"">GAA</span> activity under the following conditions: (1) total <span class=""gene"" id=""21963784-4-275-278"">GAA</span> measured at pH 3.8, (2) <span class=""gene"" id=""21963784-4-303-306"">GAA</span> measured at pH 3.8 in the presence of acarbose, and (3) neutral glucosidase activity (NAG) measured at pH 7.0 without acarbose.",CTD_human;UNIPROT
34,131,Biomarker,C0017921,Glycogen storage disease type II,disease,GSD II,2548,GAA,GAA,CTD_human,18176891,"Glycogen storage disease type II (GSD II) is an autosomal recessive deficiency of acidalpha-1,4-glucosidase(GAA) caused by mutations in the GAA gene located on human chromosome 17 (17q 25.2-q 25.3).",0.551609615332135,"<span class=""disease"" id=""18176891-1-0-32"">Glycogen storage disease type II</span> (<span class=""disease"" id=""18176891-1-34-40"">GSD II</span>) is an autosomal recessive deficiency of acidalpha-1,4-glucosidase(GAA) caused by mutations in the <span class=""gene"" id=""18176891-1-140-143"">GAA</span> gene located on human chromosome 17 (17q 25.2-q 25.3).",CTD_human;UNIPROT
34,131,Therapeutic,C0017921,Glycogen storage disease type II,disease,GSD II,2548,GAA,GAA,CTD_human,21644219,"Mutation analysis should be a routine method in the prenatal diagnosis of GSD II in Asian population, where pseudodeficiency allele can cause low GAA activity in normal individuals which is relatively common in Asian.",0.551609615332135,"Mutation analysis should be a routine method in the prenatal diagnosis of <span class=""disease"" id=""21644219-8-74-80"">GSD II</span> in Asian population, where pseudodeficiency allele can cause low <span class=""gene"" id=""21644219-8-146-149"">GAA</span> activity in normal individuals which is relatively common in Asian.",CTD_human;UNIPROT
34,131,Therapeutic,C0017921,Glycogen storage disease type II,disease,Pompe disease,2548,GAA,GAA,CTD_human,21963784,"To investigate the feasibility of NBS for Pompe disease in Japan, we obtained dried blood spots (DBSs) from 496 healthy Japanese controls, 29 Japanese patients with Pompe disease, and five obligate carriers, and assayed GAA activity under the following conditions: (1) total GAA measured at pH 3.8, (2) GAA measured at pH 3.8 in the presence of acarbose, and (3) neutral glucosidase activity (NAG) measured at pH 7.0 without acarbose.",0.551609615332135,"To investigate the feasibility of NBS for <span class=""disease"" id=""21963784-4-42-55"">Pompe disease</span> in Japan, we obtained dried blood spots (DBSs) from 496 healthy Japanese controls, 29 Japanese patients with <span class=""disease"" id=""21963784-4-165-178"">Pompe disease</span>, and five obligate carriers, and assayed <span class=""gene"" id=""21963784-4-220-223"">GAA</span> activity under the following conditions: (1) total <span class=""gene"" id=""21963784-4-275-278"">GAA</span> measured at pH 3.8, (2) <span class=""gene"" id=""21963784-4-303-306"">GAA</span> measured at pH 3.8 in the presence of acarbose, and (3) neutral glucosidase activity (NAG) measured at pH 7.0 without acarbose.",CTD_human;UNIPROT
34,131,Biomarker,C0017921,Glycogen storage disease type II,disease,GSD II,2548,GAA,GAA,CTD_human,21644219,"Mutation analysis should be a routine method in the prenatal diagnosis of GSD II in Asian population, where pseudodeficiency allele can cause low GAA activity in normal individuals which is relatively common in Asian.",0.551609615332135,"Mutation analysis should be a routine method in the prenatal diagnosis of <span class=""disease"" id=""21644219-8-74-80"">GSD II</span> in Asian population, where pseudodeficiency allele can cause low <span class=""gene"" id=""21644219-8-146-149"">GAA</span> activity in normal individuals which is relatively common in Asian.",CTD_human;UNIPROT
1,0,Biomarker,C0032460,Polycystic Ovary Syndrome,disease,PCOS,2549,GAB1,GAB1,CTD_human,21411543,"Progesterone-regulated genes, including mitogen-inducible gene 6 (MIG6), leukemia inhibitory factor (LIF), GRB2-associated binding protein 1 (GAB1), S100P, and claudin-4 were significantly lower in PCOS endometrium; whereas cell proliferation genes, such as Anillin and cyclin B1, were up-regulated.",0.20054945356842604,"Progesterone-regulated genes, including mitogen-inducible gene 6 (MIG6), leukemia inhibitory factor (LIF), <span class=""gene"" id=""21411543-11-107-140"">GRB2-associated binding protein 1</span> (<span class=""gene"" id=""21411543-11-142-146"">GAB1</span>), S100P, and claudin-4 were significantly lower in <span class=""disease"" id=""21411543-11-198-202"">PCOS</span> endometrium; whereas cell proliferation genes, such as Anillin and cyclin B1, were up-regulated.",CTD_human
2,0,Biomarker,C0004352,Autistic Disorder,disease,autism,2550,GABBR1,GABA(B) receptor,CTD_human,19002745,"Decreases in GABA(B) receptor subunits may help explain the presence of seizures that are often comorbid with autism, as well as cognitive difficulties prevalent in autism.",0.200274726784213,"Decreases in <span class=""gene"" id=""19002745-7-13-29"">GABA(B) receptor</span> subunits may help explain the presence of seizures that are often comorbid with <span class=""disease"" id=""19002745-7-110-116"">autism</span>, as well as cognitive difficulties prevalent in <span class=""disease"" id=""19002745-7-165-171"">autism</span>.",CTD_human
1,0,Biomarker,C0023015,Language Disorders,group,LI,255239,ANKK1,ANKK1,CTD_human,23691092,Our results show that smoking during pregnancy increases the risk for LI and poor performance on language tasks and that ANKK1/DRD2 contributes to language performance.,0.200274726784213,"Our results show that smoking during pregnancy increases the risk for <span class=""disease"" id=""23691092-8-70-72"">LI</span> and poor performance on language tasks and that <span class=""gene"" id=""23691092-8-121-126"">ANKK1</span>/DRD2 contributes to language performance.",CTD_human
2,0,Biomarker,C0004352,Autistic Disorder,disease,autism,2557,GABRA4,GABRA4,CTD_human,16080114,"Through the convergence of all analyses, we conclude that GABRA4 is involved in the etiology of autism and potentially increases autism risk through interaction with GABRB1.",0.20804526592250303,"Through the convergence of all analyses, we conclude that <span class=""gene"" id=""16080114-16-58-64"">GABRA4</span> is involved in the etiology of <span class=""disease"" id=""16080114-16-96-102"">autism</span> and potentially increases <span class=""disease"" id=""16080114-16-129-135"">autism</span> risk through interaction with GABRB1.",CTD_human
2,0,Biomarker,C0004352,Autistic Disorder,disease,autism,2557,GABRA4,GABRA4,CTD_human,16770606,"These results confirmed our earlier findings, indicating GABRA4 and GABRB1 as genes contributing to autism susceptibility, extending the effect to multiple ethnic groups and suggesting seizures as a stratifying phenotype.",0.20804526592250303,"These results confirmed our earlier findings, indicating <span class=""gene"" id=""16770606-8-57-63"">GABRA4</span> and GABRB1 as genes contributing to <span class=""disease"" id=""16770606-8-100-106"">autism</span> susceptibility, extending the effect to multiple ethnic groups and suggesting seizures as a stratifying phenotype.",CTD_human
1,0,Biomarker,C3711376,Isodicentric Chromosome 15 Syndrome,disease,IDIC-15,2558,GABRA5,GABRA5,CTD_human,23663378,"Paradoxical worsening of seizure activity with pregabalin in an adult with isodicentric 15 (IDIC-15) syndrome involving duplications of the GABRB3, GABRA5 and GABRG3 genes.",0.2,"Paradoxical worsening of seizure activity with pregabalin in an adult with isodicentric 15 (<span class=""disease"" id=""23663378-0-92-99"">IDIC-15</span>) syndrome involving duplications of the GABRB3, <span class=""gene"" id=""23663378-0-148-154"">GABRA5</span> and GABRG3 genes.",CTD_human
2,0,Biomarker,C0004352,Autistic Disorder,disease,autism,2560,GABRB1,GABRB1,CTD_human,16770606,"These results confirmed our earlier findings, indicating GABRA4 and GABRB1 as genes contributing to autism susceptibility, extending the effect to multiple ethnic groups and suggesting seizures as a stratifying phenotype.",0.20082418035263896,"These results confirmed our earlier findings, indicating GABRA4 and <span class=""gene"" id=""16770606-8-68-74"">GABRB1</span> as genes contributing to <span class=""disease"" id=""16770606-8-100-106"">autism</span> susceptibility, extending the effect to multiple ethnic groups and suggesting seizures as a stratifying phenotype.",CTD_human
2,0,Biomarker,C0004352,Autistic Disorder,disease,autism,2560,GABRB1,GABRB1,CTD_human,16080114,"Through the convergence of all analyses, we conclude that GABRA4 is involved in the etiology of autism and potentially increases autism risk through interaction with GABRB1.",0.20082418035263896,"Through the convergence of all analyses, we conclude that GABRA4 is involved in the etiology of <span class=""disease"" id=""16080114-16-96-102"">autism</span> and potentially increases <span class=""disease"" id=""16080114-16-129-135"">autism</span> risk through interaction with <span class=""gene"" id=""16080114-16-166-172"">GABRB1</span>.",CTD_human
2,0,Biomarker,C0004352,Autistic Disorder,disease,autistic disorder,2562,GABRB3,GABRB3,CTD_human,9545402,The convergence of GABRB3 as a positional and functional candidate along with the linkage-disequilibrium data suggests the need for further investigation of the role of GABRB3 or adjacent genes in autistic disorder.,0.30287883353838696,"The convergence of <span class=""gene"" id=""9545402-8-19-25"">GABRB3</span> as a positional and functional candidate along with the linkage-disequilibrium data suggests the need for further investigation of the role of <span class=""gene"" id=""9545402-8-169-175"">GABRB3</span> or adjacent genes in <span class=""disease"" id=""9545402-8-197-214"">autistic disorder</span>.",CTD_human
2,0,Biomarker,C0004352,Autistic Disorder,disease,autism,2562,GABRB3,GABRB3,CTD_human,11920158,Association between a GABRB3 polymorphism and autism.,0.30287883353838696,"Association between a <span class=""gene"" id=""11920158-0-22-28"">GABRB3</span> polymorphism and <span class=""disease"" id=""11920158-0-46-52"">autism</span>.",CTD_human
1,0,Biomarker,C0014553,Absence Epilepsy,disease,childhood absence epilepsy,2562,GABRB3,GABRB3,CTD_human,18514161,Hyperglycosylation and reduced GABA currents of mutated GABRB3 polypeptide in remitting childhood absence epilepsy.,0.21330187660254799,"Hyperglycosylation and reduced GABA currents of mutated <span class=""gene"" id=""18514161-0-56-62"">GABRB3</span> polypeptide in remitting <span class=""disease"" id=""18514161-0-88-114"">childhood absence epilepsy</span>.",CTD_human
1,0,Biomarker,C0162635,Angelman Syndrome,disease,Angelman syndrome,2562,GABRB3,gabrb3,CTD_human,15878204,"Since most children with Angelman syndrome are autosomal heterozygotes of maternal origin, apparently through genomic imprinting, we used gabrb3-deficient heterozygote mice of defined parental origin to investigate whether this phenotype is also maternally imprinted in mouse.",0.20604398925268802,"Since most children with <span class=""disease"" id=""15878204-2-25-42"">Angelman syndrome</span> are autosomal heterozygotes of maternal origin, apparently through genomic imprinting, we used <span class=""gene"" id=""15878204-2-138-144"">gabrb3</span>-deficient heterozygote mice of defined parental origin to investigate whether this phenotype is also maternally imprinted in mouse.",CTD_human
1,0,Biomarker,C3711376,Isodicentric Chromosome 15 Syndrome,disease,IDIC-15,2562,GABRB3,GABRB3,CTD_human,23663378,"Paradoxical worsening of seizure activity with pregabalin in an adult with isodicentric 15 (IDIC-15) syndrome involving duplications of the GABRB3, GABRA5 and GABRG3 genes.",0.200274726784213,"Paradoxical worsening of seizure activity with pregabalin in an adult with isodicentric 15 (<span class=""disease"" id=""23663378-0-92-99"">IDIC-15</span>) syndrome involving duplications of the <span class=""gene"" id=""23663378-0-140-146"">GABRB3</span>, GABRA5 and GABRG3 genes.",CTD_human
2,1,Biomarker,C1836780,PANCREATIC AND CEREBELLAR AGENESIS,disease,pancreatic and cerebellar agenesis,256297,PTF1A,PTF1A,CTD_human,15543146,Mutations in PTF1A cause pancreatic and cerebellar agenesis.,0.40027472678421294,"Mutations in <span class=""gene"" id=""15543146-0-13-18"">PTF1A</span> cause <span class=""disease"" id=""15543146-0-25-59"">pancreatic and cerebellar agenesis</span>.",CTD_human;ORPHANET
1,0,Biomarker,C0009952,Febrile Convulsions,disease,febrile seizures,2566,GABRG2,GABRG2,CTD_human,25362483,"Recurrent mutations in three main genes (SCN1A, SCN1B and GABRG2) have been identified that cause febrile seizures with or without epilepsy.",0.422823090760742,"Recurrent mutations in three main genes (SCN1A, SCN1B and <span class=""gene"" id=""25362483-2-58-64"">GABRG2</span>) have been identified that cause <span class=""disease"" id=""25362483-2-98-114"">febrile seizures</span> with or without epilepsy.",CTD_human;HPO
1,0,Biomarker,C3711376,Isodicentric Chromosome 15 Syndrome,disease,IDIC-15,2567,GABRG3,GABRG3,CTD_human,23663378,"Paradoxical worsening of seizure activity with pregabalin in an adult with isodicentric 15 (IDIC-15) syndrome involving duplications of the GABRB3, GABRA5 and GABRG3 genes.",0.2,"Paradoxical worsening of seizure activity with pregabalin in an adult with isodicentric 15 (<span class=""disease"" id=""23663378-0-92-99"">IDIC-15</span>) syndrome involving duplications of the GABRB3, GABRA5 and <span class=""gene"" id=""23663378-0-159-165"">GABRG3</span> genes.",CTD_human
1,6,Biomarker,C1876203,Frontonasal dysplasia,disease,frontonasal dysplasia,257,ALX3,ALX3,CTD_human,19409524,"Frontorhiny, a distinctive presentation of frontonasal dysplasia caused by recessive mutations in the ALX3 homeobox gene.",0.6013736339210661,"<span class=""disease"" id=""19409524-0-0-11"">Frontorhiny</span>, a distinctive presentation of <span class=""disease"" id=""19409524-0-43-64"">frontonasal dysplasia</span> caused by recessive mutations in the <span class=""gene"" id=""19409524-0-102-106"">ALX3</span> homeobox gene.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,2571,GAD1,GAD67,CTD_human,17918742,Increased GAD67 mRNA expression in cerebellar interneurons in autism: implications for Purkinje cell dysfunction.,0.203780662444353,"Increased <span class=""gene"" id=""17918742-0-10-15"">GAD67</span> mRNA expression in cerebellar interneurons in <span class=""disease"" id=""17918742-0-62-68"">autism</span>: implications for Purkinje cell dysfunction.",CTD_human
1,0,Biomarker,C0020514,Hyperprolactinemia,disease,Hyperprolactinemia,2571,GAD1,GAD,CTD_human,7138674,Hyperprolactinemia induced by anterior pituitary homograft under the kidney capsule or systemic sulpiride injection significantly increases GAD activity.,0.2,"<span class=""disease"" id=""7138674-5-0-18"">Hyperprolactinemia</span> induced by anterior pituitary homograft under the kidney capsule or systemic sulpiride injection significantly increases <span class=""gene"" id=""7138674-5-140-143"">GAD</span> activity.",CTD_human
4,0,Biomarker,C0036341,Schizophrenia,disease,SZ,2571,GAD1,GAD(67,CTD_human,19110320,This remodeling might contribute to reelin- and GAD(67)-promoter demethylation and might reverse the GABAergic-gene-expression downregulation associated with SZ morbidity.,0.24622434584454397,"This remodeling might contribute to reelin- and <span class=""gene"" id=""19110320-6-48-54"">GAD(67</span>)-promoter demethylation and might reverse the GABAergic-gene-expression downregulation associated with <span class=""disease"" id=""19110320-6-158-160"">SZ</span> morbidity.",CTD_human
4,0,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,2571,GAD1,GAD1,CTD_human,17942719,"Alterations in schizophrenia included decreased GAD1 expression and H3K4-trimethylation, predominantly in females and in conjunction with a risk haplotype at the 5' end of GAD1.",0.24622434584454397,"Alterations in <span class=""disease"" id=""17942719-3-15-28"">schizophrenia</span> included decreased <span class=""gene"" id=""17942719-3-48-52"">GAD1</span> expression and H3K4-trimethylation, predominantly in females and in conjunction with a risk haplotype at the 5' end of <span class=""gene"" id=""17942719-3-172-176"">GAD1</span>.",CTD_human
4,0,Biomarker,C0036341,Schizophrenia,disease,Schizophrenia,2571,GAD1,GAD(67,CTD_human,18923069,"Schizophrenia subjects showed significant decreases in mRNA levels of GAD(67), GAD(65), GAT-1, mGluR2, and neuronal nitric oxide synthase.",0.24622434584454397,"<span class=""disease"" id=""18923069-7-0-13"">Schizophrenia</span> subjects showed significant decreases in mRNA levels of <span class=""gene"" id=""18923069-7-70-76"">GAD(67</span>), GAD(65), GAT-1, mGluR2, and neuronal nitric oxide synthase.",CTD_human
2,0,Biomarker,C0036341,Schizophrenia,disease,Schizophrenia,2572,GAD2,GAD(65,CTD_human,18923069,"Schizophrenia subjects showed significant decreases in mRNA levels of GAD(67), GAD(65), GAT-1, mGluR2, and neuronal nitric oxide synthase.",0.21433527120476997,"<span class=""disease"" id=""18923069-7-0-13"">Schizophrenia</span> subjects showed significant decreases in mRNA levels of GAD(67), <span class=""gene"" id=""18923069-7-79-85"">GAD(65</span>), GAT-1, mGluR2, and neuronal nitric oxide synthase.",CTD_human
2,0,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,2572,GAD2,GAD 65,CTD_human,15560956,"This study demonstrates for the first time significant deficits in GABAergic markers Reelin and GAD 65 and 67 proteins in bipolar subjects and global deficits in the latter proteins in schizophrenia and mood disorders, accounting for the reported alterations in CSF/plasma levels of glutamate and GABA in these disorders.",0.21433527120476997,"This study demonstrates for the first time significant deficits in GABAergic markers Reelin and <span class=""gene"" id=""15560956-10-96-102"">GAD 65</span> and 67 proteins in bipolar subjects and global deficits in the latter proteins in <span class=""disease"" id=""15560956-10-185-198"">schizophrenia</span> and mood disorders, accounting for the reported alterations in CSF/plasma levels of glutamate and GABA in these disorders.",CTD_human
2,0,Biomarker,C0036572,Seizures,phenotype,seizures,2572,GAD2,GAD65,CTD_human,8954991,Mice lacking the 65 kDa isoform of glutamic acid decarboxylase (GAD65) maintain normal levels of GAD67 and GABA in their brains but are susceptible to seizures.,0.200274726784213,"Mice lacking the 65 kDa isoform of glutamic acid decarboxylase (<span class=""gene"" id=""8954991-0-64-69"">GAD65</span>) maintain normal levels of GAD67 and GABA in their brains but are susceptible to <span class=""disease"" id=""8954991-0-151-159"">seizures</span>.",CTD_human
2,0,Biomarker,C0036572,Seizures,phenotype,seizure,2572,GAD2,GAD65,CTD_human,8985701,Labeling for GAD65 mRNA and associated protein is substantially increased in the remaining GABA neurons at 2-4 months after the initial seizure episode.,0.200274726784213,"Labeling for <span class=""gene"" id=""8985701-6-13-18"">GAD65</span> mRNA and associated protein is substantially increased in the remaining GABA neurons at 2-4 months after the initial <span class=""disease"" id=""8985701-6-136-143"">seizure</span> episode.",CTD_human
1,0,Biomarker,C0677886,Epithelial ovarian cancer,disease,EOC,257202,GPX6,GPX6,CTD_human,25581431,"Variants at 1p36 (nearest gene, WNT4), 4q26 (SYNPO2), 9q34.2 (ABO) and 17q11.2 (ATAD5) were associated with EOC risk, and at 1p34.3 (RSPO1) and 6p22.1 (GPX6) variants were specifically associated with the serous EOC subtype, all with P < 5 × 10(-8).",0.200274726784213,"Variants at 1p36 (nearest gene, WNT4), 4q26 (SYNPO2), 9q34.2 (ABO) and 17q11.2 (ATAD5) were associated with <span class=""disease"" id=""25581431-5-108-111"">EOC</span> risk, and at 1p34.3 (RSPO1) and 6p22.1 (<span class=""gene"" id=""25581431-5-152-156"">GPX6</span>) variants were specifically associated with the serous <span class=""disease"" id=""25581431-5-212-215"">EOC</span> subtype, all with P &lt; 5 &times; 10(-8).",CTD_human
1,0,Biomarker,C0553580,Ewings sarcoma,disease,ET,25792,CIZ1,CIZ1,CTD_human,17508423,"Here, we show that an alternatively spliced human CIZ1 variant, lacking exon 4 (Delta E4), is misexpressed as a consequence of intronic mutation in Ewing tumor (ET) cell lines.",0.200274726784213,"Here, we show that an alternatively spliced human <span class=""gene"" id=""17508423-2-50-54"">CIZ1</span> variant, lacking exon 4 (Delta E4), is misexpressed as a consequence of intronic mutation in <span class=""disease"" id=""17508423-2-148-159"">Ewing tumor</span> (<span class=""disease"" id=""17508423-2-161-163"">ET</span>) cell lines.",CTD_human
1,0,Biomarker,C1865819,"CERVICAL DYSTONIA, PRIMARY",disease,primary cervical dystonia,25792,CIZ1,CIZ1,CTD_human,22447717,Mutations in CIZ1 cause adult onset primary cervical dystonia.,0.200274726784213,"Mutations in <span class=""gene"" id=""22447717-0-13-17"">CIZ1</span> cause adult onset <span class=""disease"" id=""22447717-0-36-61"">primary cervical dystonia</span>.",CTD_human
1,0,Biomarker,C0025202,melanoma,disease,melanoma,25797,QPCT,QPCT,CTD_human,17145863,"Three of the genes, QPCT, CYP1B1, and LXN, are densely methylated in >95% of uncultured melanoma tumor samples.",0.200274726784213,"Three of the genes, <span class=""gene"" id=""17145863-5-20-24"">QPCT</span>, CYP1B1, and LXN, are densely methylated in &gt;95% of uncultured <span class=""disease"" id=""17145863-5-88-96"">melanoma</span> tumor samples.",CTD_human
1,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastasis,25800,SLC39A6,LIV-1,CTD_human,12839489,Combining the crucial role that zinc plays in cell growth and the proven role of metalloproteases in metastasis presents an exciting indication of how LIV-1 plays a role in breast cancer progression.,0.201648360705279,"Combining the crucial role that zinc plays in cell growth and the proven role of metalloproteases in <span class=""disease"" id=""12839489-11-101-111"">metastasis</span> presents an exciting indication of how <span class=""gene"" id=""12839489-11-151-156"">LIV-1</span> plays a role in breast cancer progression.",CTD_human
1,0,Therapeutic,C0279626,Squamous cell carcinoma of esophagus,disease,esophageal squamous-cell carcinoma,25800,SLC39A6,SLC39A6,CTD_human,23644492,Genome-wide association study identifies common variants in SLC39A6 associated with length of survival in esophageal squamous-cell carcinoma.,0.20082418035263896,"Genome-wide association study identifies common variants in <span class=""gene"" id=""23644492-0-60-67"">SLC39A6</span> associated with length of survival in <span class=""disease"" id=""23644492-0-106-140"">esophageal squamous-cell carcinoma</span>.",CTD_human
1,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastasis,25816,TNFAIP8,TNFAIP8,CTD_human,21969086,"We detected correlations between TNFAIP8 expression and TNM stage (P < 0.001), tumor depth (P = 0.002), lymph node metastasis (P = 0.013), distant metastasis (P = 0.001), lymphatic invasion (P < 0.001), and venous invasion (P < 0.001) among the clinicopathological characteristics of ESCC patients, and high TNFAIP8 expression was found in poor survival.",0.201373633921065,"We detected correlations between <span class=""gene"" id=""21969086-6-33-40"">TNFAIP8</span> expression and TNM stage (P &lt; 0.001), tumor depth (P = 0.002), lymph node metastasis (P = 0.013), distant <span class=""disease"" id=""21969086-6-147-157"">metastasis</span> (P = 0.001), lymphatic invasion (P &lt; 0.001), and venous invasion (P &lt; 0.001) among the clinicopathological characteristics of ESCC patients, and high <span class=""gene"" id=""21969086-6-308-315"">TNFAIP8</span> expression was found in poor survival.",CTD_human
1,0,Biomarker,C0279626,Squamous cell carcinoma of esophagus,disease,esophageal squamous cell carcinoma,25816,TNFAIP8,TNFAIP8,CTD_human,21969086,TNFAIP8 overexpression: clinical relevance to esophageal squamous cell carcinoma.,0.200274726784213,"<span class=""gene"" id=""21969086-0-0-7"">TNFAIP8</span> overexpression: clinical relevance to <span class=""disease"" id=""21969086-0-46-80"">esophageal squamous cell carcinoma</span>.",CTD_human
1,0,Biomarker,C0080178,Spina Bifida,disease,spina bifida,25828,TXN2,TXN2,CTD_human,19165900,Genetic polymorphisms in the thioredoxin 2 (TXN2) gene and risk for spina bifida.,0.202681755307501,"Genetic polymorphisms in the <span class=""gene"" id=""19165900-0-29-42"">thioredoxin 2</span> (<span class=""gene"" id=""19165900-0-44-48"">TXN2</span>) gene and risk for <span class=""disease"" id=""19165900-0-68-80"">spina bifida</span>.",CTD_human
9,233,Biomarker,C0270972,Cornelia De Lange Syndrome,disease,CdLS,25836,NIPBL,NIPBL,CTD_human,19763162,"Cornelia de Lange Syndrome (CdLS) is a multi-organ system birth defects disorder linked, in at least half of cases, to heterozygous mutations in the NIPBL gene.",0.714189203228104,"<span class=""disease"" id=""19763162-1-0-26"">Cornelia de Lange Syndrome</span> (<span class=""disease"" id=""19763162-1-28-32"">CdLS</span>) is a multi-organ system birth defects disorder linked, in at least half of cases, to heterozygous mutations in the <span class=""gene"" id=""19763162-1-149-154"">NIPBL</span> gene.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0086543,Cataract,disease,cataracts,2584,GALK1,galactokinase,CTD_human,7670469,Cloning of the galactokinase cDNA and identification of mutations in two families with cataracts.,0.40329672141055706,"Cloning of the <span class=""gene"" id=""7670469-0-15-28"">galactokinase</span> cDNA and identification of mutations in two families with <span class=""disease"" id=""7670469-0-87-96"">cataracts</span>.",CTD_human;HPO
1,1,Biomarker,C0023434,Chronic Lymphocytic Leukemia,disease,CLL,25865,PRKD2,PRKD2,CTD_human,18758461,"We identified six previously unreported CLL risk loci at 2q13 (rs17483466; P = 2.36 x 10(-10)), 2q37.1 (rs13397985, SP140; P = 5.40 x 10(-10)), 6p25.3 (rs872071, IRF4; P = 1.91 x 10(-20)), 11q24.1 (rs735665; P = 3.78 x 10(-12)), 15q23 (rs7176508; P = 4.54 x 10(-12)) and 19q13.32 (rs11083846, PRKD2; P = 3.96 x 10(-9)).",0.207495812354077,"We identified six previously unreported <span class=""disease"" id=""18758461-2-40-43"">CLL</span> risk loci at 2q13 (rs17483466; P = 2.36 x 10(-10)), 2q37.1 (rs13397985, SP140; P = 5.40 x 10(-10)), 6p25.3 (rs872071, IRF4; P = 1.91 x 10(-20)), 11q24.1 (rs735665; P = 3.78 x 10(-12)), 15q23 (rs7176508; P = 4.54 x 10(-12)) and 19q13.32 (rs11083846, <span class=""gene"" id=""18758461-2-293-298"">PRKD2</span>; P = 3.96 x 10(-9)).",CTD_human
1,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,non-small cell lung carcinoma,25878,MXRA5,MXRA5,CTD_human,22696596,Exome sequencing identifies MXRA5 as a novel cancer gene frequently mutated in non-small cell lung carcinoma from Chinese patients.,0.20054945356842604,"Exome sequencing identifies <span class=""gene"" id=""22696596-0-28-33"">MXRA5</span> as a novel cancer gene frequently mutated in <span class=""disease"" id=""22696596-0-79-108"">non-small cell lung carcinoma</span> from Chinese patients.",CTD_human
1,0,Biomarker,C0025202,melanoma,disease,melanoma,25913,POT1,POT1,CTD_human,24686849,These findings suggest that POT1 variants predispose to melanoma formation via a direct effect on telomeres.,0.401648360705279,"These findings suggest that <span class=""gene"" id=""24686849-5-28-32"">POT1</span> variants predispose to <span class=""disease"" id=""24686849-5-56-64"">melanoma</span> formation via a direct effect on telomeres.",CTD_human;HPO
1,0,Biomarker,C0024145,Chilblain lupus 1,disease,chilblain lupus,25939,SAMHD1,SAMHD1,CTD_human,27566796,Familial chilblain lupus is a monogenic form of cutaneous lupus erythematosus caused by loss-of-function mutations in the nucleases TREX1 or SAMHD1.,0.4,"Familial <span class=""disease"" id=""27566796-1-9-24"">chilblain lupus</span> is a monogenic form of cutaneous lupus erythematosus caused by loss-of-function mutations in the nucleases TREX1 or <span class=""gene"" id=""27566796-1-141-147"">SAMHD1</span>.",CTD_human;ORPHANET
1,0,Biomarker,C0796126,AICARDI-GOUTIERES SYNDROME 1,disease,Aicardi-Goutieres syndrome,25939,SAMHD1,SAMHD1,CTD_human,23364794,Nuclease activity of the human SAMHD1 protein implicated in the Aicardi-Goutieres syndrome and HIV-1 restriction.,0.208241803526393,"Nuclease activity of the human <span class=""gene"" id=""23364794-0-31-37"">SAMHD1</span> protein implicated in the <span class=""disease"" id=""23364794-0-64-90"">Aicardi-Goutieres syndrome</span> and HIV-1 restriction.",CTD_human
1,0,Biomarker,C0013336,Dwarfism,disease,short stature,25942,SIN3A,SIN3A,CTD_human,27399968,"Here we identified dominant mutations in the gene encoding the transcriptional repressor and MeCP2 interactor switch-insensitive 3 family member A (SIN3A; chromosome 15q24.2) in individuals who, in addition to mild intellectual disability and ASD, share striking features, including facial dysmorphisms, microcephaly and short stature.",0.2,"Here we identified dominant mutations in the gene encoding the transcriptional repressor and MeCP2 interactor switch-insensitive 3 family member A (<span class=""gene"" id=""27399968-2-148-153"">SIN3A</span>; chromosome 15q24.2) in individuals who, in addition to mild intellectual disability and ASD, share striking features, including facial dysmorphisms, microcephaly and <span class=""disease"" id=""27399968-2-321-334"">short stature</span>.",CTD_human
1,0,Biomarker,C0025958,Microcephaly,disease,microcephaly,25942,SIN3A,SIN3A,CTD_human,27399968,"Here we identified dominant mutations in the gene encoding the transcriptional repressor and MeCP2 interactor switch-insensitive 3 family member A (SIN3A; chromosome 15q24.2) in individuals who, in addition to mild intellectual disability and ASD, share striking features, including facial dysmorphisms, microcephaly and short stature.",0.2,"Here we identified dominant mutations in the gene encoding the transcriptional repressor and MeCP2 interactor switch-insensitive 3 family member A (<span class=""gene"" id=""27399968-2-148-153"">SIN3A</span>; chromosome 15q24.2) in individuals who, in addition to mild intellectual disability and ASD, share striking features, including facial dysmorphisms, <span class=""disease"" id=""27399968-2-304-316"">microcephaly</span> and short stature.",CTD_human
1,0,Biomarker,C1510586,Autism Spectrum Disorders,disease,ASD,25942,SIN3A,SIN3A,CTD_human,27399968,"Here we identified dominant mutations in the gene encoding the transcriptional repressor and MeCP2 interactor switch-insensitive 3 family member A (SIN3A; chromosome 15q24.2) in individuals who, in addition to mild intellectual disability and ASD, share striking features, including facial dysmorphisms, microcephaly and short stature.",0.2,"Here we identified dominant mutations in the gene encoding the transcriptional repressor and MeCP2 interactor switch-insensitive 3 family member A (<span class=""gene"" id=""27399968-2-148-153"">SIN3A</span>; chromosome 15q24.2) in individuals who, in addition to mild intellectual disability and <span class=""disease"" id=""27399968-2-243-246"">ASD</span>, share striking features, including facial dysmorphisms, microcephaly and short stature.",CTD_human
1,0,Biomarker,C3714756,Intellectual Disability,group,intellectual disability,25942,SIN3A,SIN3A,CTD_human,27399968,"Together, our data establish that haploinsufficiency of SIN3A is associated with mild syndromic intellectual disability and that SIN3A can be considered to be a key transcriptional regulator of cortical brain development.",0.4,"Together, our data establish that haploinsufficiency of <span class=""gene"" id=""27399968-6-56-61"">SIN3A</span> is associated with mild syndromic <span class=""disease"" id=""27399968-6-96-119"">intellectual disability</span> and that <span class=""gene"" id=""27399968-6-129-134"">SIN3A</span> can be considered to be a key transcriptional regulator of cortical brain development.",CTD_human;HPO
1,0,Biomarker,C0948089,Acute Coronary Syndrome,disease,ACS,2597,GAPDH,glyceraldehyde-3-phosphate dehydrogenase,CTD_human,21751358,"The expression levels of proteins involved in cellular cytoskeleton (F-actin capping, ?-tubulin, ?-tubulin isotypes 1 and 2, vinculin, vimentin and two Ras-related protein Rab-7b isotypes), glycolysis pathway (glyceraldehyde-3-phosphate dehydrogenase, lactate dehydrogenase and two pyruvate kinase isotypes) and cellular-related antioxidant system (manganese superoxide dismutase) and even the expression and activity of glutathione-S-transferase were significantly reduced in platelets from ACS patients compared to CAD patients.",0.2,"The expression levels of proteins involved in cellular cytoskeleton (F-actin capping, &beta;-tubulin, &alpha;-tubulin isotypes 1 and 2, vinculin, vimentin and two Ras-related protein Rab-7b isotypes), glycolysis pathway (<span class=""gene"" id=""21751358-4-210-250"">glyceraldehyde-3-phosphate dehydrogenase</span>, lactate dehydrogenase and two pyruvate kinase isotypes) and cellular-related antioxidant system (manganese superoxide dismutase) and even the expression and activity of glutathione-S-transferase were significantly reduced in platelets from <span class=""disease"" id=""21751358-4-492-495"">ACS</span> patients compared to CAD patients.",CTD_human
1,0,Biomarker,C0002736,Amyotrophic Lateral Sclerosis,disease,ALS,25978,CHMP2B,charged multivesicular body protein 2B,CTD_human,16807408,ALS phenotypes with mutations in CHMP2B (charged multivesicular body protein 2B).,0.604055389228567,"<span class=""disease"" id=""16807408-0-0-3"">ALS</span> phenotypes with mutations in <span class=""gene"" id=""16807408-0-33-39"">CHMP2B</span> (<span class=""gene"" id=""16807408-0-41-79"">charged multivesicular body protein 2B</span>).",CTD_human;HPO;ORPHANET
1,0,Biomarker,C0338451,Frontotemporal dementia,disease,frontotemporal dementia,25978,CHMP2B,CHMP2B,CTD_human,16041373,Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia.,0.4068681696053279,"Mutations in the endosomal ESCRTIII-complex subunit <span class=""gene"" id=""16041373-0-52-58"">CHMP2B</span> in <span class=""disease"" id=""16041373-0-62-85"">frontotemporal dementia</span>.",CTD_human;HPO
1,0,Biomarker,C0751072,Frontotemporal Lobar Degeneration,disease,frontotemporal lobar degeneration,25978,CHMP2B,CHMP2B,CTD_human,17956895,CHMP2B C-truncating mutations in frontotemporal lobar degeneration are associated with an aberrant endosomal phenotype in vitro.,0.205154296365419,"<span class=""gene"" id=""17956895-0-0-6"">CHMP2B</span> C-truncating mutations in <span class=""disease"" id=""17956895-0-33-66"">frontotemporal lobar degeneration</span> are associated with an aberrant endosomal phenotype in vitro.",CTD_human
1,0,Biomarker,C0029294,Orofaciodigital Syndromes,disease,oral-facial-digital syndrome,26005,C2CD3,C2CD3,CTD_human,24997988,The oral-facial-digital syndrome gene C2CD3 encodes a positive regulator of centriole elongation.,0.200274726784213,"The <span class=""disease"" id=""24997988-0-4-32"">oral-facial-digital syndrome</span> gene <span class=""gene"" id=""24997988-0-38-43"">C2CD3</span> encodes a positive regulator of centriole elongation.",CTD_human
1,2,Biomarker,C0005586,Bipolar Disorder,disease,bipolar disorder,26011,TENM4,ODZ4,CTD_human,21926972,Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4.,0.201373633921065,"Large-scale genome-wide association analysis of <span class=""disease"" id=""21926972-0-48-64"">bipolar disorder</span> identifies a new susceptibility locus near <span class=""gene"" id=""21926972-0-108-112"">ODZ4</span>.",CTD_human
1,0,Biomarker,C0027819,Neuroblastoma,disease,neuroblastoma,26038,CHD5,CHD5,CTD_human,26121086,"Recurrent alterations at relapse included mutations in the putative CHD5 neuroblastoma tumor suppressor, chromosome 9p losses, DOCK8 mutations, inactivating mutations in PTPN14 and a relapse-specific activity pattern for the PTPN14 target YAP.",0.20357144819477,"Recurrent alterations at relapse included mutations in the putative <span class=""gene"" id=""26121086-6-68-72"">CHD5</span> <span class=""disease"" id=""26121086-6-73-86"">neuroblastoma</span> tumor suppressor, chromosome 9p losses, DOCK8 mutations, inactivating mutations in PTPN14 and a relapse-specific activity pattern for the PTPN14 target YAP.",CTD_human
6,6,Biomarker,C0265227,Schinzel-Giedion syndrome,disease,SGS,26040,SETBP1,SETBP1,CTD_human,23832012,"Closely positioned somatic SETBP1 mutations encoding changes in Asp868, Ser869, Gly870, Ile871 and Asp880, which match germline mutations in Schinzel-Giedion syndrome (SGS), were detected in 17% of secondary acute myeloid leukemias (sAML) and 15% of chronic myelomonocytic leukemia (CMML) cases.",0.6013736339210661,"Closely positioned somatic <span class=""gene"" id=""23832012-2-27-33"">SETBP1</span> mutations encoding changes in Asp868, Ser869, Gly870, Ile871 and Asp880, which match germline mutations in <span class=""disease"" id=""23832012-2-141-166"">Schinzel-Giedion syndrome</span> (<span class=""disease"" id=""23832012-2-168-171"">SGS</span>), were detected in 17% of secondary acute myeloid leukemias (sAML) and 15% of chronic myelomonocytic leukemia (CMML) cases.",CTD_human;ORPHANET;UNIPROT
2,1,Biomarker,C0349639,Juvenile Myelomonocytic Leukemia,disease,juvenile myelomonocytic leukemia,26040,SETBP1,SETBP1,CTD_human,23832011,Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia.,0.400549453568426,"Exome sequencing identifies secondary mutations of <span class=""gene"" id=""23832011-0-51-57"">SETBP1</span> and JAK3 in <span class=""disease"" id=""23832011-0-70-102"">juvenile myelomonocytic leukemia</span>.",CTD_human;UNIPROT
1,0,Biomarker,C1292772,"Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative",disease,atypical chronic myeloid leukemia,26040,SETBP1,SETBP1,CTD_human,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,0.201648360705279,"Recurrent <span class=""gene"" id=""23222956-0-10-16"">SETBP1</span> mutations in <span class=""disease"" id=""23222956-0-30-63"">atypical chronic myeloid leukemia</span>.",CTD_human
2,0,Biomarker,C3714756,Intellectual Disability,group,intellectual disability,26040,SETBP1,SETBP1,CTD_human,25217958,"These genetic changes include haploinsufficiency of SETBP1 associated with intellectual disability and loss of expressive language and truncations of ZMYND11 in individuals with autism, aggression and complex neuropsychiatric features.",0.40027472678421294,"These genetic changes include haploinsufficiency of <span class=""gene"" id=""25217958-6-52-58"">SETBP1</span> associated with <span class=""disease"" id=""25217958-6-75-98"">intellectual disability</span> and loss of expressive language and truncations of ZMYND11 in individuals with autism, aggression and complex neuropsychiatric features.",CTD_human;HPO
4,0,Biomarker,C0004352,Autistic Disorder,disease,autism,26047,CNTNAP2,CNTNAP2,CTD_human,21310003,We propose that these CNTNAP2 variants increase susceptibility to SLI or autism when they occur together with other risk factors.,0.30464386393560805,"We propose that these <span class=""gene"" id=""21310003-7-22-29"">CNTNAP2</span> variants increase susceptibility to SLI or <span class=""disease"" id=""21310003-7-73-79"">autism</span> when they occur together with other risk factors.",CTD_human
4,0,Biomarker,C0004352,Autistic Disorder,disease,autism,26047,CNTNAP2,CNTNAP2,CTD_human,20157312,"At a gene level, CAM genes associated in all three samples (NRXN1 and CNTNAP2), which were previously implicated in specific language disorder, autism and schizophrenia.",0.30464386393560805,"At a gene level, CAM genes associated in all three samples (NRXN1 and <span class=""gene"" id=""20157312-8-70-77"">CNTNAP2</span>), which were previously implicated in specific language disorder, <span class=""disease"" id=""20157312-8-144-150"">autism</span> and schizophrenia.",CTD_human
4,0,Biomarker,C0004352,Autistic Disorder,disease,autism,26047,CNTNAP2,CNTNAP2,CTD_human,18179894,A common genetic variant in the neurexin superfamily member CNTNAP2 increases familial risk of autism.,0.30464386393560805,"A common genetic variant in the neurexin superfamily member <span class=""gene"" id=""18179894-0-60-67"">CNTNAP2</span> increases familial risk of <span class=""disease"" id=""18179894-0-95-101"">autism</span>.",CTD_human
2,0,Biomarker,C0014544,Epilepsy,disease,epilepsy,26047,CNTNAP2,CNTNAP2,CTD_human,21962519,"Absence of CNTNAP2 leads to epilepsy, neuronal migration abnormalities, and core autism-related deficits.",0.40919533021666793,"Absence of <span class=""gene"" id=""21962519-0-11-18"">CNTNAP2</span> leads to <span class=""disease"" id=""21962519-0-28-36"">epilepsy</span>, neuronal migration abnormalities, and core autism-related deficits.",CTD_human;HPO
1,0,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,26047,CNTNAP2,CNTNAP2,CTD_human,20157312,"At a gene level, CAM genes associated in all three samples (NRXN1 and CNTNAP2), which were previously implicated in specific language disorder, autism and schizophrenia.",0.20788720883023298,"At a gene level, CAM genes associated in all three samples (NRXN1 and <span class=""gene"" id=""20157312-8-70-77"">CNTNAP2</span>), which were previously implicated in specific language disorder, autism and <span class=""disease"" id=""20157312-8-155-168"">schizophrenia</span>.",CTD_human
1,0,Biomarker,C0038506,Stuttering,phenotype,stuttering,26047,CNTNAP2,CNTNAP2,CTD_human,21108403,Identification of a microdeletion at the 7q33-q35 disrupting the CNTNAP2 gene in a Brazilian stuttering case.,0.20054945356842604,"Identification of a microdeletion at the 7q33-q35 disrupting the <span class=""gene"" id=""21108403-0-65-72"">CNTNAP2</span> gene in a Brazilian <span class=""disease"" id=""21108403-0-93-103"">stuttering</span> case.",CTD_human
1,0,Biomarker,C0424295,Hyperactive behavior,phenotype,hyperactivity,26047,CNTNAP2,CNTNAP2,CTD_human,21962519,"Cntnap2(-/-) mice show deficits in the three core ASD behavioral domains, as well as hyperactivity and epileptic seizures, as have been reported in humans with CNTNAP2 mutations.",0.40082418035263895,"<span class=""gene"" id=""21962519-4-0-7"">Cntnap2</span>(-/-) mice show deficits in the three core ASD behavioral domains, as well as <span class=""disease"" id=""21962519-4-85-98"">hyperactivity</span> and epileptic seizures, as have been reported in humans with <span class=""gene"" id=""21962519-4-160-167"">CNTNAP2</span> mutations.",CTD_human;HPO
4,0,Biomarker,C1510586,Autism Spectrum Disorders,disease,autism spectrum disorder,26047,CNTNAP2,CNTNAP2,CTD_human,21082657,"Comparison of the clinical and cytogenetic findings of our patients with previously reported patients, supports that haploinsuffiency of CNTNAP2 can result in language delay and/or autism spectrum disorder.",0.20604398925268802,"Comparison of the clinical and cytogenetic findings of our patients with previously reported patients, supports that haploinsuffiency of <span class=""gene"" id=""21082657-5-137-144"">CNTNAP2</span> can result in language delay and/or <span class=""disease"" id=""21082657-5-181-205"">autism spectrum disorder</span>.",CTD_human
4,0,Biomarker,C1510586,Autism Spectrum Disorders,disease,ASD,26047,CNTNAP2,CNTNAP2,CTD_human,21962519,These data demonstrate a functional role for CNTNAP2 in brain development and provide a new tool for mechanistic and therapeutic research in ASD.,0.20604398925268802,"These data demonstrate a functional role for <span class=""gene"" id=""21962519-7-45-52"">CNTNAP2</span> in brain development and provide a new tool for mechanistic and therapeutic research in <span class=""disease"" id=""21962519-7-141-144"">ASD</span>.",CTD_human
1,0,Biomarker,C1970431,PITT-HOPKINS SYNDROME,disease,Pitt-Hopkins syndrome,26047,CNTNAP2,CNTNAP2,CTD_human,19896112,"We now identified homozygous and compound-heterozygous deletions and mutations via molecular karyotyping and mutational screening in CNTNAP2 and NRXN1 in four patients with severe mental retardation (MR) and variable features, such as autistic behavior, epilepsy, and breathing anomalies, phenotypically overlapping with Pitt-Hopkins syndrome.",0.201098907136852,"We now identified homozygous and compound-heterozygous deletions and mutations via molecular karyotyping and mutational screening in <span class=""gene"" id=""19896112-2-133-140"">CNTNAP2</span> and NRXN1 in four patients with severe mental retardation (MR) and variable features, such as autistic behavior, epilepsy, and breathing anomalies, phenotypically overlapping with <span class=""disease"" id=""19896112-2-321-342"">Pitt-Hopkins syndrome</span>.",CTD_human
1,0,Biomarker,C0028768,Obsessive-Compulsive Disorder,disease,OCD,26050,SLITRK5,Slitrk5,CTD_human,20418887,"Thus, our studies identify Slitrk5 as an essential molecule at corticostriatal synapses and provide a new mouse model of OCD-like behaviors.",0.280274726784213,"Thus, our studies identify <span class=""gene"" id=""20418887-7-27-34"">Slitrk5</span> as an essential molecule at corticostriatal synapses and provide a new mouse model of <span class=""disease"" id=""20418887-7-121-124"">OCD</span>-like behaviors.",CTD_human
1,8,Biomarker,C0796121,Primrose syndrome,disease,Primrose syndrome,26137,ZBTB20,ZBTB20,CTD_human,25017102,Mutations in ZBTB20 cause Primrose syndrome.,0.600274726784213,"Mutations in <span class=""gene"" id=""25017102-0-13-19"">ZBTB20</span> cause <span class=""disease"" id=""25017102-0-26-43"">Primrose syndrome</span>.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0079154,Congenital Nonbullous Ichthyosiform Erythroderma,disease,lamellar ichthyosis,26154,ABCA12,ABCA12,CTD_human,16675967,No de novo mutation in ABCA12 has yet been reported either in HI or lamellar ichthyosis.,0.409572371315507,"No de novo mutation in <span class=""gene"" id=""16675967-10-23-29"">ABCA12</span> has yet been reported either in HI or <span class=""disease"" id=""16675967-10-68-87"">lamellar ichthyosis</span>.",CTD_human;ORPHANET
1,0,Biomarker,C0079541,Holoprosencephaly,disease,holoprosencephaly,2619,GAS1,Gas1,CTD_human,17525797,Gas1 is a modifier for holoprosencephaly and genetically interacts with sonic hedgehog.,0.20082418035263896,"<span class=""gene"" id=""17525797-0-0-4"">Gas1</span> is a modifier for <span class=""disease"" id=""17525797-0-23-40"">holoprosencephaly</span> and genetically interacts with sonic hedgehog.",CTD_human
4,1,Biomarker,C0003873,Rheumatoid Arthritis,disease,RA,26191,PTPN22,PTPN22,CTD_human,19898480,"Gene-environment associations are important in rheumatoid arthritis (RA) susceptibility, with an association existing between smoking, HLA- DRB1 'shared epitope' alleles, PTPN22 and antibodies to cyclic citrullinated peptides (CCP).",0.567076009833421,"Gene-environment associations are important in <span class=""disease"" id=""19898480-1-47-67"">rheumatoid arthritis</span> (<span class=""disease"" id=""19898480-1-69-71"">RA</span>) susceptibility, with an association existing between smoking, HLA- DRB1 'shared epitope' alleles, <span class=""gene"" id=""19898480-1-171-177"">PTPN22</span> and antibodies to cyclic citrullinated peptides (CCP).",CTD_human;UNIPROT
4,1,Biomarker,C0003873,Rheumatoid Arthritis,disease,rheumatoid arthritis,26191,PTPN22,ptpn22,CTD_human,21190368,"A single-nucleotide polymorphism (SNP) in the ptpn22 gene correlates with the incidence of various autoimmune diseases, including type 1 diabetes, rheumatoid arthritis, and systemic lupus erythematosus.",0.567076009833421,"A single-nucleotide polymorphism (SNP) in the <span class=""gene"" id=""21190368-2-46-52"">ptpn22</span> gene correlates with the incidence of various autoimmune diseases, including type 1 diabetes, <span class=""disease"" id=""21190368-2-147-167"">rheumatoid arthritis</span>, and systemic lupus erythematosus.",CTD_human;UNIPROT
1,0,Biomarker,C0004364,Autoimmune Diseases,group,autoimmune diseases,26191,PTPN22,PTPN22,CTD_human,21341673,"The lymphoid tyrosine phosphatase LYP, encoded by the PTPN22 gene, is a critical regulator of signaling in T cells and recently emerged as a candidate target for therapy of autoimmune diseases.",0.5178672575516471,"The lymphoid tyrosine phosphatase <span class=""gene"" id=""21341673-1-34-37"">LYP</span>, encoded by the <span class=""gene"" id=""21341673-1-54-60"">PTPN22</span> gene, is a critical regulator of signaling in T cells and recently emerged as a candidate target for therapy of <span class=""disease"" id=""21341673-1-173-192"">autoimmune diseases</span>.",CTD_human;HPO
11,1,Biomarker,C0011854,"Diabetes Mellitus, Insulin-Dependent",disease,type 1 diabetes,26191,PTPN22,ptpn22,CTD_human,21190368,"A single-nucleotide polymorphism (SNP) in the ptpn22 gene correlates with the incidence of various autoimmune diseases, including type 1 diabetes, rheumatoid arthritis, and systemic lupus erythematosus.",0.59760885868256,"A single-nucleotide polymorphism (SNP) in the <span class=""gene"" id=""21190368-2-46-52"">ptpn22</span> gene correlates with the incidence of various autoimmune diseases, including <span class=""disease"" id=""21190368-2-130-145"">type 1 diabetes</span>, rheumatoid arthritis, and systemic lupus erythematosus.",CTD_human;UNIPROT
2,1,Biomarker,C0024141,"Lupus Erythematosus, Systemic",disease,systemic lupus erythematosus,26191,PTPN22,ptpn22,CTD_human,21190368,"A single-nucleotide polymorphism (SNP) in the ptpn22 gene correlates with the incidence of various autoimmune diseases, including type 1 diabetes, rheumatoid arthritis, and systemic lupus erythematosus.",0.43287131208468393,"A single-nucleotide polymorphism (SNP) in the <span class=""gene"" id=""21190368-2-46-52"">ptpn22</span> gene correlates with the incidence of various autoimmune diseases, including type 1 diabetes, rheumatoid arthritis, and <span class=""disease"" id=""21190368-2-173-201"">systemic lupus erythematosus</span>.",CTD_human;UNIPROT
2,1,Biomarker,C0024141,"Lupus Erythematosus, Systemic",disease,SLE,26191,PTPN22,PTPN22,CTD_human,18204446,"We also found evidence for association (P < 1 x 10(-5)) at FCGR2A, PTPN22 and STAT4, regions previously associated with SLE and other autoimmune diseases, as well as at > or =9 other loci (P < 2 x 10(-7)).",0.43287131208468393,"We also found evidence for association (P &lt; 1 x 10(-5)) at FCGR2A, <span class=""gene"" id=""18204446-4-67-73"">PTPN22</span> and STAT4, regions previously associated with <span class=""disease"" id=""18204446-4-120-123"">SLE</span> and other autoimmune diseases, as well as at &gt; or =9 other loci (P &lt; 2 x 10(-7)).",CTD_human;UNIPROT
1,0,Biomarker,C0011881,Diabetic Nephropathy,disease,diabetic nephropathy,2621,GAS6,Gas6,CTD_human,12644472,Inhibition of the Gas6/Axl pathway in diabetic patients might be beneficial to slow down the progression of diabetic nephropathy.,0.20054945356842604,"Inhibition of the <span class=""gene"" id=""12644472-12-18-22"">Gas6</span>/Axl pathway in diabetic patients might be beneficial to slow down the progression of <span class=""disease"" id=""12644472-12-108-128"">diabetic nephropathy</span>.",CTD_human
1,0,Biomarker,C0025202,melanoma,disease,melanoma,26227,PHGDH,PHGDH,CTD_human,21804546,An analysis of human cancers showed that PHGDH is recurrently amplified in a genomic region of focal copy number gain most commonly found in melanoma.,0.20082418035263896,"An analysis of human cancers showed that <span class=""gene"" id=""21804546-3-41-46"">PHGDH</span> is recurrently amplified in a genomic region of focal copy number gain most commonly found in <span class=""disease"" id=""21804546-3-141-149"">melanoma</span>.",CTD_human
1,0,Biomarker,C0040034,Thrombocytopenia,phenotype,thrombocytopenia,2623,GATA1,Gata-1,CTD_human,16966598,A mutation in the translation initiation codon of Gata-1 disrupts megakaryocyte maturation and causes thrombocytopenia.,0.41094600523657204,"A mutation in the translation initiation codon of <span class=""gene"" id=""16966598-0-50-56"">Gata-1</span> disrupts megakaryocyte maturation and causes <span class=""disease"" id=""16966598-0-102-118"">thrombocytopenia</span>.",CTD_human;HPO
2,0,Biomarker,C0023467,"Leukemia, Myelocytic, Acute",disease,acute myeloid leukemia,2624,GATA2,GATA2,CTD_human,21892162,Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia.,0.20521980890004898,"Heritable <span class=""gene"" id=""21892162-0-10-15"">GATA2</span> mutations associated with familial myelodysplastic syndrome and <span class=""disease"" id=""21892162-0-80-102"">acute myeloid leukemia</span>.",CTD_human
2,0,Biomarker,C0023467,"Leukemia, Myelocytic, Acute",disease,acute myeloid leukemia,2624,GATA2,GATA2,CTD_human,21892158,Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome).,0.20521980890004898,"Mutations in <span class=""gene"" id=""21892158-0-13-18"">GATA2</span> cause primary lymphedema associated with a predisposition to <span class=""disease"" id=""21892158-0-80-102"">acute myeloid leukemia</span> (Emberger syndrome).",CTD_human
2,1,Biomarker,C3463824,MYELODYSPLASTIC SYNDROME,group,myelodysplastic syndrome,2624,GATA2,GATA2,CTD_human,21892162,Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia.,0.6079527213648629,"Heritable <span class=""gene"" id=""21892162-0-10-15"">GATA2</span> mutations associated with familial <span class=""disease"" id=""21892162-0-51-75"">myelodysplastic syndrome</span> and acute myeloid leukemia.",CTD_human;HPO;UNIPROT
1,2,Biomarker,C0019829,Hodgkin Disease,disease,Hodgkin's lymphoma,2625,GATA3,GATA3,CTD_human,21037568,"A genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3).",0.203780662444353,"A genome-wide association study of <span class=""disease"" id=""21037568-0-35-53"">Hodgkin's lymphoma</span> identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (<span class=""gene"" id=""21037568-0-125-130"">GATA3</span>).",CTD_human
3,7,Biomarker,C1840333,Barakat syndrome,disease,HDR-syndrome,2625,GATA3,GATA-3,CTD_human,20006695,"Based on observations that mutations of GATA-3 are responsible for the HDR-syndrome (hypoparathyroidism, deafness, renal defects) and that GATA-transcription factors have an important role to play in inner ear development, we hypothesized that these transcription factors may be involved in regulatory changes of prestin transcription.",0.689065983879032,"Based on observations that mutations of <span class=""gene"" id=""20006695-1-40-46"">GATA-3</span> are responsible for the <span class=""disease"" id=""20006695-1-71-83"">HDR-syndrome</span> (hypoparathyroidism, deafness, renal defects) and that GATA-transcription factors have an important role to play in inner ear development, we hypothesized that these transcription factors may be involved in regulatory changes of prestin transcription.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0001973,"Alcoholic Intoxication, Chronic",disease,alcohol dependence,2626,GATA4,GATA4,CTD_human,20585342,"Involvement of the atrial natriuretic peptide transcription factor GATA4 in alcohol dependence, relapse risk and treatment response to acamprosate.",0.203231208875927,"Involvement of the atrial natriuretic peptide transcription factor <span class=""gene"" id=""20585342-0-67-72"">GATA4</span> in <span class=""disease"" id=""20585342-0-76-94"">alcohol dependence</span>, relapse risk and treatment response to acamprosate.",CTD_human
1,0,Biomarker,C0019284,Diaphragmatic Hernia,phenotype,diaphragmatic hernia,2626,GATA4,GATA4,CTD_human,18280291,Downregulation of GATA4 and GATA6 in the heart of rats with nitrofen-induced diaphragmatic hernia.,0.2,"Downregulation of <span class=""gene"" id=""18280291-0-18-23"">GATA4</span> and GATA6 in the heart of rats with nitrofen-induced <span class=""disease"" id=""18280291-0-77-97"">diaphragmatic hernia</span>.",CTD_human
1,0,Therapeutic,C0027051,Myocardial Infarction,disease,Myocardial infarction,2626,GATA4,GATA-4,CTD_human,20200331,"Myocardial infarction, caused by ligating the left anterior descending coronary artery, significantly decreased the DNA binding activity of GATA-4 at day 1, whereas at 2 weeks the GATA-4 DNA binding was significantly upregulated.",0.280274726784213,"<span class=""disease"" id=""20200331-4-0-21"">Myocardial infarction</span>, caused by ligating the left anterior descending coronary artery, significantly decreased the DNA binding activity of <span class=""gene"" id=""20200331-4-140-146"">GATA-4</span> at day 1, whereas at 2 weeks the <span class=""gene"" id=""20200331-4-180-186"">GATA-4</span> DNA binding was significantly upregulated.",CTD_human
1,0,Biomarker,C0235833,Congenital diaphragmatic hernia,disease,congenital diaphragmatic hernia,2626,GATA4,GATA4,CTD_human,23426975,Decreased expression of GATA4 in the diaphragm of nitrofen-induced congenital diaphragmatic hernia.,0.281648360705279,"Decreased expression of <span class=""gene"" id=""23426975-0-24-29"">GATA4</span> in the diaphragm of nitrofen-induced <span class=""disease"" id=""23426975-0-67-98"">congenital diaphragmatic hernia</span>.",CTD_human
1,0,Biomarker,C0019284,Diaphragmatic Hernia,phenotype,diaphragmatic hernia,2627,GATA6,GATA6,CTD_human,18280291,Downregulation of GATA4 and GATA6 in the heart of rats with nitrofen-induced diaphragmatic hernia.,0.2,"Downregulation of GATA4 and <span class=""gene"" id=""18280291-0-28-33"">GATA6</span> in the heart of rats with nitrofen-induced <span class=""disease"" id=""18280291-0-77-97"">diaphragmatic hernia</span>.",CTD_human
1,0,Biomarker,C0265965,Dyskeratosis Congenita,disease,dyskeratosis congenita,26277,TINF2,TINF2,CTD_human,18252230,"TINF2, a component of the shelterin telomere protection complex, is mutated in dyskeratosis congenita.",0.412543208784538,"<span class=""gene"" id=""18252230-0-0-5"">TINF2</span>, a component of the shelterin telomere protection complex, is mutated in <span class=""disease"" id=""18252230-0-79-101"">dyskeratosis congenita</span>.",CTD_human;ORPHANET
1,4,Biomarker,C1327916,REVESZ SYNDROME (disorder),disease,Revesz syndrome,26277,TINF2,TINF2,CTD_human,18252230,"We demonstrate that a fifth gene, TINF2, is mutated in classical DC and, for the first time, in Revesz syndrome.",0.600274726784213,"We demonstrate that a fifth gene, <span class=""gene"" id=""18252230-5-34-39"">TINF2</span>, is mutated in classical DC and, for the first time, in <span class=""disease"" id=""18252230-5-96-111"">Revesz syndrome</span>.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0018801,Heart failure,disease,heart failure,2628,GATM,glycine amidinotransferase,CTD_human,16820567,Myocardial expression of the arginine:glycine amidinotransferase gene is elevated in heart failure and normalized after recovery: potential implications for local creatine synthesis.,0.200274726784213,"Myocardial expression of the arginine:<span class=""gene"" id=""16820567-0-38-64"">glycine amidinotransferase</span> gene is elevated in <span class=""disease"" id=""16820567-0-85-98"">heart failure</span> and normalized after recovery: potential implications for local creatine synthesis.",CTD_human
5,19,Biomarker,C0017205,Gaucher Disease,disease,Gaucher disease,2629,GBA,acid beta-glucosidase,CTD_human,10757640,Gaucher disease: expression and characterization of mild and severe acid beta-glucosidase mutations in Portuguese type 1 patients.,0.32430096454886703,"<span class=""disease"" id=""10757640-0-0-15"">Gaucher disease</span>: expression and characterization of mild and severe <span class=""gene"" id=""10757640-0-68-89"">acid beta-glucosidase</span> mutations in Portuguese type 1 patients.",CTD_human
1,0,Biomarker,C0752347,Lewy Body Disease,disease,Lewy body disease,2629,GBA,GBA,CTD_human,22803570,Lewy body disease (LBD) development is enhanced by mutations in the GBA gene coding for glucocerebrosidase (GCase).,0.21380017301366103,"<span class=""disease"" id=""22803570-1-0-17"">Lewy body disease</span> (LBD) development is enhanced by mutations in the <span class=""gene"" id=""22803570-1-68-71"">GBA</span> gene coding for glucocerebrosidase (GCase).",CTD_human
1,0,Therapeutic,C0011854,"Diabetes Mellitus, Insulin-Dependent",disease,type 1 diabetes,26291,FGF21,FGF21,CTD_human,23499715,Protective effect of FGF21 on type 1 diabetes-induced testicular apoptotic cell death probably via both mitochondrial- and endoplasmic reticulum stress-dependent pathways in the mouse model.,0.2,"Protective effect of <span class=""gene"" id=""23499715-0-21-26"">FGF21</span> on <span class=""disease"" id=""23499715-0-30-45"">type 1 diabetes</span>-induced testicular apoptotic cell death probably via both mitochondrial- and endoplasmic reticulum stress-dependent pathways in the mouse model.",CTD_human
1,0,Therapeutic,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,type 2 diabetes,26291,FGF21,FGF21,CTD_human,26797127,"On the basis of our findings, we propose selective FAP inhibition as a potential therapeutic approach to increase endogenous FGF21 activity for the treatment of obesity, type 2 diabetes, non-alcoholic steatohepatitis, and related metabolic disorders.",0.206579087443797,"On the basis of our findings, we propose selective FAP inhibition as a potential therapeutic approach to increase endogenous <span class=""gene"" id=""26797127-6-125-130"">FGF21</span> activity for the treatment of obesity, <span class=""disease"" id=""26797127-6-170-185"">type 2 diabetes</span>, non-alcoholic steatohepatitis, and related metabolic disorders.",CTD_human
1,0,Therapeutic,C0015695,Fatty Liver,disease,hepatic steatosis,26291,FGF21,fibroblast growth factor 21,CTD_human,24184811,Hepatic SIRT1 attenuates hepatic steatosis and controls energy balance in mice by inducing fibroblast growth factor 21.,0.202197814273705,"Hepatic SIRT1 attenuates <span class=""disease"" id=""24184811-0-25-42"">hepatic steatosis</span> and controls energy balance in mice by inducing <span class=""gene"" id=""24184811-0-91-118"">fibroblast growth factor 21</span>.",CTD_human
2,0,Therapeutic,C0028754,Obesity,disease,obesity,26291,FGF21,FGF21,CTD_human,24184811,Strategies to activate SIRT1 or FGF21 could be used to treat fatty liver disease and obesity.,0.206593442821114,"Strategies to activate SIRT1 or <span class=""gene"" id=""24184811-18-32-37"">FGF21</span> could be used to treat fatty liver disease and <span class=""disease"" id=""24184811-18-85-92"">obesity</span>.",CTD_human
2,0,Therapeutic,C0028754,Obesity,disease,obesity,26291,FGF21,FGF21,CTD_human,26797127,"On the basis of our findings, we propose selective FAP inhibition as a potential therapeutic approach to increase endogenous FGF21 activity for the treatment of obesity, type 2 diabetes, non-alcoholic steatohepatitis, and related metabolic disorders.",0.206593442821114,"On the basis of our findings, we propose selective FAP inhibition as a potential therapeutic approach to increase endogenous <span class=""gene"" id=""26797127-6-125-130"">FGF21</span> activity for the treatment of <span class=""disease"" id=""26797127-6-161-168"">obesity</span>, type 2 diabetes, non-alcoholic steatohepatitis, and related metabolic disorders.",CTD_human
1,0,Biomarker,C0002395,Alzheimer's Disease,disease,Alzheimer disease,26330,GAPDHS,GAPDHS,CTD_human,17192785,"In addition to identifying the epsilon4 allele of APOE and related effects, we pinpointed over a dozen potential Alzheimer disease susceptibility genes (ACE, CHRNB2, CST3, ESR1, GAPDHS, IDE, MTHFR, NCSTN, PRNP, PSEN1, TF, TFAM and TNF) with statistically significant allelic summary odds ratios (ranging from 1.11-1.38 for risk alleles and 0.92-0.67 for protective alleles).",0.209628114093152,"In addition to identifying the epsilon4 allele of APOE and related effects, we pinpointed over a dozen potential <span class=""disease"" id=""17192785-5-113-130"">Alzheimer disease</span> susceptibility genes (ACE, CHRNB2, CST3, ESR1, <span class=""gene"" id=""17192785-5-178-184"">GAPDHS</span>, IDE, MTHFR, NCSTN, PRNP, PSEN1, TF, TFAM and TNF) with statistically significant allelic summary odds ratios (ranging from 1.11-1.38 for risk alleles and 0.92-0.67 for protective alleles).",CTD_human
1,0,Biomarker,C0003873,Rheumatoid Arthritis,disease,rheumatoid arthritis,2638,GC,Gc (vitamin D binding protein,CTD_human,3874814,Gc (vitamin D binding protein) subtypes in rheumatoid arthritis.,0.202956482091714,"<span class=""gene"" id=""3874814-0-0-29"">Gc (vitamin D binding protein</span>) subtypes in <span class=""disease"" id=""3874814-0-43-63"">rheumatoid arthritis</span>.",CTD_human
1,0,Biomarker,C0018213,Graves Disease,disease,Graves' disease,2638,GC,vitamin D-binding protein,CTD_human,12050214,A polymorphism within the vitamin D-binding protein gene is associated with Graves' disease but not with Hashimoto's thyroiditis.,0.202956482091714,"A polymorphism within the <span class=""gene"" id=""12050214-0-26-51"">vitamin D-binding protein</span> gene is associated with <span class=""disease"" id=""12050214-0-76-91"">Graves' disease</span> but not with Hashimoto's thyroiditis.",CTD_human
1,0,Biomarker,C0019151,Hepatic Encephalopathy,disease,HE,2638,GC,Gc-globulin,CTD_human,11510020,A total Gc-globulin level less than 120 mg/L on day 2 is a good predictor of later HE.,0.2,"A total <span class=""gene"" id=""11510020-12-8-19"">Gc-globulin</span> level less than 120 mg/L on day 2 is a good predictor of later <span class=""disease"" id=""11510020-12-83-85"">HE</span>.",CTD_human
1,0,Biomarker,C0024121,Lung Neoplasms,group,lung tumor,2638,GC,vitamin D-binding protein,CTD_human,17902193,"Notably, we demonstrate significant regulation of alpha-1-antitrypsin, alpha-2-macroglobulin, hemoglobin subunit alpha, vitamin D-binding protein, major urinary proteins, and transthyretin (up to eight-fold) in serum of lung tumor bearing mice.",0.2,"Notably, we demonstrate significant regulation of alpha-1-antitrypsin, alpha-2-macroglobulin, hemoglobin subunit alpha, <span class=""gene"" id=""17902193-7-120-145"">vitamin D-binding protein</span>, major urinary proteins, and transthyretin (up to eight-fold) in serum of <span class=""disease"" id=""17902193-7-220-230"">lung tumor</span> bearing mice.",CTD_human
2,0,Biomarker,C0162557,"Liver Failure, Acute",disease,fulminant hepatic failure,2638,GC,Gc globulin,CTD_human,17852808,"Furthermore, low levels of Gc globulin in patients with fulminant hepatic failure and multiple trauma have been found to correlate with the morbidity and mortality of patients.",0.20546582492962803,"Furthermore, low levels of <span class=""gene"" id=""17852808-3-27-38"">Gc globulin</span> in patients with <span class=""disease"" id=""17852808-3-56-81"">fulminant hepatic failure</span> and multiple trauma have been found to correlate with the morbidity and mortality of patients.",CTD_human
2,0,Biomarker,C0162557,"Liver Failure, Acute",disease,fulminant hepatic failure,2638,GC,Gc-globulin,CTD_human,8666322,Admission levels of serum Gc-globulin: predictive value in fulminant hepatic failure.,0.20546582492962803,"Admission levels of serum <span class=""gene"" id=""8666322-0-26-37"">Gc-globulin</span>: predictive value in <span class=""disease"" id=""8666322-0-59-84"">fulminant hepatic failure</span>.",CTD_human
1,0,Biomarker,C0007370,Catalepsy,disease,catalepsy,2641,GCG,glucagon,CTD_human,9798264,"Moreover, glucagon inhibited the locomotor and exploratory activity as well as the amphetamine-induced hyperactivity and enhanced haloperidol-induced catalepsy.",0.2,"Moreover, <span class=""gene"" id=""9798264-11-10-18"">glucagon</span> inhibited the locomotor and exploratory activity as well as the amphetamine-induced hyperactivity and enhanced haloperidol-induced <span class=""disease"" id=""9798264-11-150-159"">catalepsy</span>.",CTD_human
1,0,Therapeutic,C0009319,Colitis,disease,colitis,2641,GCG,GLP-2,CTD_human,22323126,"Unexpectedly, hGLP-2(3-33) also reduced the colitis damage score by 32.0 ± 8.4% (P < 0.05).",0.200274726784213,"Unexpectedly, h<span class=""gene"" id=""22323126-7-15-20"">GLP-2</span>(3-33) also reduced the <span class=""disease"" id=""22323126-7-44-51"">colitis</span> damage score by 32.0 &plusmn; 8.4% (P &lt; 0.05).",CTD_human
2,0,Therapeutic,C0020456,Hyperglycemia,disease,hyperglycemia,2641,GCG,glucagon,CTD_human,3019152,These results suggest that in uremic humans propranolol independently reduces the hepatic response to glucagon and the insulin secretory response to hyperglycemia and/or hyperglucagonemia.,0.20851653031060602,"These results suggest that in uremic humans propranolol independently reduces the hepatic response to <span class=""gene"" id=""3019152-11-102-110"">glucagon</span> and the insulin secretory response to <span class=""disease"" id=""3019152-11-149-162"">hyperglycemia</span> and/or hyperglucagonemia.",CTD_human
2,0,Biomarker,C0020456,Hyperglycemia,disease,hyperglycemia,2641,GCG,glucagon,CTD_human,3019152,These results suggest that in uremic humans propranolol independently reduces the hepatic response to glucagon and the insulin secretory response to hyperglycemia and/or hyperglucagonemia.,0.20851653031060602,"These results suggest that in uremic humans propranolol independently reduces the hepatic response to <span class=""gene"" id=""3019152-11-102-110"">glucagon</span> and the insulin secretory response to <span class=""disease"" id=""3019152-11-149-162"">hyperglycemia</span> and/or hyperglucagonemia.",CTD_human
1,0,Biomarker,C0020459,Hyperinsulinism,disease,hyperinsulinemia,2641,GCG,glucagon,CTD_human,3019152,"In contrast to uremic subjects, normal controls exhibited lesser degrees of hyperglycemia and hyperinsulinemia at all glucagon infusion rates.",0.201923087489492,"In contrast to uremic subjects, normal controls exhibited lesser degrees of hyperglycemia and <span class=""disease"" id=""3019152-9-94-110"">hyperinsulinemia</span> at all <span class=""gene"" id=""3019152-9-118-126"">glucagon</span> infusion rates.",CTD_human
1,0,Therapeutic,C0020473,Hyperlipidemia,disease,hyperlipemia,2641,GCG,glucagon,CTD_human,69995,"Corresponding to this observation, drugs known to diminish the triglyceride secretion of the liver, such as actinomycin D, cycloheximide; glucagon, orotic acid, CFT 1201, and CFT 1042 reduce the alpha-HCH-induced hyperlipemia.",0.2,"Corresponding to this observation, drugs known to diminish the triglyceride secretion of the liver, such as actinomycin D, cycloheximide; <span class=""gene"" id=""69995-6-138-146"">glucagon</span>, orotic acid, CFT 1201, and CFT 1042 reduce the alpha-HCH-induced <span class=""disease"" id=""69995-6-213-225"">hyperlipemia</span>.",CTD_human
1,0,Therapeutic,C0424295,Hyperactive behavior,phenotype,hyperactivity,2641,GCG,glucagon,CTD_human,9798264,"Moreover, glucagon inhibited the locomotor and exploratory activity as well as the amphetamine-induced hyperactivity and enhanced haloperidol-induced catalepsy.",0.2,"Moreover, <span class=""gene"" id=""9798264-11-10-18"">glucagon</span> inhibited the locomotor and exploratory activity as well as the amphetamine-induced <span class=""disease"" id=""9798264-11-103-116"">hyperactivity</span> and enhanced haloperidol-induced catalepsy.",CTD_human
1,0,Biomarker,C0013421,Dystonia,phenotype,dystonia,2643,GCH1,GCH1,CTD_human,15389992,"Amantadine suppressed severe levodopa-induced choreic dyskinesia, which developed at initiation of levodopa therapy, in two siblings manifesting dystonia with motor delay phenotype of GTP cyclohydrolase I deficiency caused by compound heterozygous GCH1 mutations.",0.44024128350615294,"Amantadine suppressed severe levodopa-induced choreic dyskinesia, which developed at initiation of levodopa therapy, in two siblings manifesting <span class=""disease"" id=""15389992-1-145-153"">dystonia</span> with motor delay phenotype of GTP cyclohydrolase I deficiency caused by compound heterozygous <span class=""gene"" id=""15389992-1-248-252"">GCH1</span> mutations.",CTD_human;HPO
1,0,Biomarker,C0026837,Muscle Rigidity,phenotype,rigid,2643,GCH1,GTP cyclohydrolase 1,CTD_human,17368676,We report on a GTP cyclohydrolase 1 mutation-confirmed heterozygous case presenting with an infantile hypokinetic rigid syndrome and delay in attainment of motor milestones starting from the first year of life.,0.4,"We report on a <span class=""gene"" id=""17368676-1-15-35"">GTP cyclohydrolase 1</span> mutation-confirmed heterozygous case presenting with an infantile hypokinetic <span class=""disease"" id=""17368676-1-114-119"">rigid</span> syndrome and delay in attainment of motor milestones starting from the first year of life.",CTD_human;HPO
1,0,Biomarker,C0030193,Pain,phenotype,pain,2643,GCH1,GCH1,CTD_human,19081190,Polymorphisms in the GTP cyclohydrolase gene (GCH1) are associated with ratings of capsaicin pain.,0.221585067529269,"Polymorphisms in the GTP cyclohydrolase gene (<span class=""gene"" id=""19081190-0-46-50"">GCH1</span>) are associated with ratings of capsaicin <span class=""disease"" id=""19081190-0-93-97"">pain</span>.",CTD_human
4,2,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,type 2 diabetes,2645,GCK,GCK,CTD_human,20081858,"We also demonstrated association of ADCY5, PROX1, GCK, GCKR and DGKB-TMEM195 with type 2 diabetes.",0.898965770964596,"We also demonstrated association of ADCY5, PROX1, <span class=""gene"" id=""20081858-5-50-53"">GCK</span>, GCKR and DGKB-TMEM195 with <span class=""disease"" id=""20081858-5-82-97"">type 2 diabetes</span>.",CTD_human;HPO;ORPHANET
4,2,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,type 2 diabetes,2645,GCK,glucokinase,CTD_human,15161764,"A new mouse model of type 2 diabetes, produced by N-ethyl-nitrosourea mutagenesis, is the result of a missense mutation in the glucokinase gene.",0.898965770964596,"A new mouse model of <span class=""disease"" id=""15161764-0-21-36"">type 2 diabetes</span>, produced by N-ethyl-nitrosourea mutagenesis, is the result of a missense mutation in the <span class=""gene"" id=""15161764-0-127-138"">glucokinase</span> gene.",CTD_human;HPO;ORPHANET
1,0,Biomarker,C3888018,Congenital Hyperinsulinism,disease,persistent hyperinsulinemic hypoglycemia,2645,GCK,glucokinase,CTD_human,15277402,Severe persistent hyperinsulinemic hypoglycemia due to a de novo glucokinase mutation.,0.21194259805879898,"Severe <span class=""disease"" id=""15277402-0-7-47"">persistent hyperinsulinemic hypoglycemia</span> due to a de novo <span class=""gene"" id=""15277402-0-65-76"">glucokinase</span> mutation.",CTD_human
1,1,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,type 2 diabetes,2646,GCKR,GCKR,CTD_human,20081858,"We also demonstrated association of ADCY5, PROX1, GCK, GCKR and DGKB-TMEM195 with type 2 diabetes.",0.23925844754492398,"We also demonstrated association of ADCY5, PROX1, GCK, <span class=""gene"" id=""20081858-5-55-59"">GCKR</span> and DGKB-TMEM195 with <span class=""disease"" id=""20081858-5-82-97"">type 2 diabetes</span>.",CTD_human
1,1,Biomarker,C0020557,Hypertriglyceridemia,phenotype,HTG,2646,GCKR,GCKR,CTD_human,20657596,"Through GWAS, we identified common variants in APOA5, GCKR, LPL and APOB associated with HTG.",0.20859471949093,"Through GWAS, we identified common variants in APOA5, <span class=""gene"" id=""20657596-5-54-58"">GCKR</span>, LPL and APOB associated with <span class=""disease"" id=""20657596-5-89-92"">HTG</span>.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,26470,SEZ6L2,SEZ6L2,CTD_human,19242545,We found a significant association between autism and a coding variant in the seizure-related gene SEZ6L2 (12/1106 autism vs. 3/1161 controls; p = 0.018).,0.202681755307501,"We found a significant association between <span class=""disease"" id=""19242545-8-43-49"">autism</span> and a coding variant in the seizure-related gene <span class=""gene"" id=""19242545-8-99-105"">SEZ6L2</span> (12/1106 <span class=""disease"" id=""19242545-8-115-121"">autism</span> vs. 3/1161 controls; p = 0.018).",CTD_human
1,0,Biomarker,C0025202,melanoma,disease,melanoma,26507,CNNM1,CNNM1,CTD_human,16778180,"CGIs in putative promoter regions of 34 genes (ABHD9, BARHL1, CLIC5, CNNM1, COL2A1, CPT1C, DDIT4L, DERL3, DHRS3, DPYS, EFEMP2, FAM62C, FAM78A, FLJ33790, GBX2, GPR10, GPRASP1, HOXA9, HOXD11, HOXD12, HOXD13, p14ARF, PAX6, PRDX2, PTPRG, RASD1, RAX, REC8L1, SLC27A3, TGFB2, TLX2, TMEM22, TMEM30B, and UNC5C) were found to be methylated in at least 1 of 13 melanoma cell lines but not in two cultured normal melanocytes.",0.2,"CGIs in putative promoter regions of 34 genes (ABHD9, BARHL1, CLIC5, <span class=""gene"" id=""16778180-3-69-74"">CNNM1</span>, COL2A1, CPT1C, DDIT4L, DERL3, DHRS3, DPYS, EFEMP2, FAM62C, FAM78A, FLJ33790, GBX2, GPR10, GPRASP1, HOXA9, HOXD11, HOXD12, HOXD13, p14ARF, PAX6, PRDX2, PTPRG, RASD1, RAX, REC8L1, SLC27A3, TGFB2, TLX2, TMEM22, TMEM30B, and UNC5C) were found to be methylated in at least 1 of 13 <span class=""disease"" id=""16778180-3-352-360"">melanoma</span> cell lines but not in two cultured normal melanocytes.",CTD_human
1,0,Biomarker,C0035412,Rhabdomyosarcoma,disease,RMS,26519,TIMM10,Tim10,CTD_human,16669873,"Prothymosin alpha (PTMA), and translocase of inner mitochondrial membrane 10 (Tim10), two genes not previously implicated in RMS, showed reduced expression during differentiation.",0.200274726784213,"Prothymosin alpha (PTMA), and <span class=""gene"" id=""16669873-7-30-76"">translocase of inner mitochondrial membrane 10</span> (<span class=""gene"" id=""16669873-7-78-83"">Tim10</span>), two genes not previously implicated in <span class=""disease"" id=""16669873-7-125-128"">RMS</span>, showed reduced expression during differentiation.",CTD_human
1,0,Biomarker,C0004114,Astrocytoma,disease,astrocytoma,26524,LATS2,LATS2,CTD_human,17049657,Promoter hypermethylation-mediated down-regulation of LATS1 and LATS2 in human astrocytoma.,0.200274726784213,"Promoter hypermethylation-mediated down-regulation of LATS1 and <span class=""gene"" id=""17049657-0-64-69"">LATS2</span> in human <span class=""disease"" id=""17049657-0-79-90"">astrocytoma</span>.",CTD_human
1,2,Biomarker,C0039685,Tetralogy of Fallot,disease,tetralogy of Fallot,2657,GDF1,GDF1,CTD_human,17924340,"Here, we show that heterozygous loss-of-function mutations in the human GDF1 gene contribute to cardiac defects ranging from tetralogy of Fallot to transposition of the great arteries and that decreased TGF- beta signaling provides a framework for understanding their pathogenesis.",0.600274726784213,"Here, we show that heterozygous loss-of-function mutations in the human <span class=""gene"" id=""17924340-4-72-76"">GDF1</span> gene contribute to cardiac defects ranging from <span class=""disease"" id=""17924340-4-125-144"">tetralogy of Fallot</span> to transposition of the great arteries and that decreased TGF- beta signaling provides a framework for understanding their pathogenesis.",CTD_human;HPO;ORPHANET;UNIPROT
1,0,Biomarker,C0040761,Transposition of Great Vessels,disease,transposition of the great arteries,2657,GDF1,GDF1,CTD_human,17924340,"Here, we show that heterozygous loss-of-function mutations in the human GDF1 gene contribute to cardiac defects ranging from tetralogy of Fallot to transposition of the great arteries and that decreased TGF- beta signaling provides a framework for understanding their pathogenesis.",0.200274726784213,"Here, we show that heterozygous loss-of-function mutations in the human <span class=""gene"" id=""17924340-4-72-76"">GDF1</span> gene contribute to cardiac defects ranging from tetralogy of Fallot to <span class=""disease"" id=""17924340-4-148-183"">transposition of the great arteries</span> and that decreased TGF- beta signaling provides a framework for understanding their pathogenesis.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,hepatocellular carcinoma,2658,GDF2,BMP9,CTD_human,23936038,BMP9 is a proliferative and survival factor for human hepatocellular carcinoma cells.,0.200274726784213,"<span class=""gene"" id=""23936038-0-0-4"">BMP9</span> is a proliferative and survival factor for human <span class=""disease"" id=""23936038-0-54-78"">hepatocellular carcinoma</span> cells.",CTD_human
1,0,Biomarker,C0023787,Lipodystrophy,disease,lipodystrophy,26580,BSCL2,Bscl2,CTD_human,25462787,Segregated responses of mammary gland development and vaginal opening to prepubertal genistein exposure in Bscl2(-/-) female mice with lipodystrophy.,0.41041090704546296,"Segregated responses of mammary gland development and vaginal opening to prepubertal genistein exposure in <span class=""gene"" id=""25462787-0-107-112"">Bscl2</span>(-/-) female mice with <span class=""disease"" id=""25462787-0-135-148"">lipodystrophy</span>.",CTD_human;HPO
1,0,Biomarker,C0018801,Heart failure,disease,heart failure,2660,MSTN,Myostatin,CTD_human,16968467,Myostatin expression in ventricular myocardium in a rat model of volume-overload heart failure.,0.200274726784213,"<span class=""gene"" id=""16968467-0-0-9"">Myostatin</span> expression in ventricular myocardium in a rat model of volume-overload <span class=""disease"" id=""16968467-0-81-94"">heart failure</span>.",CTD_human
1,0,Biomarker,C0032460,Polycystic Ovary Syndrome,disease,polycystic ovary syndrome,2661,GDF9,GDF9,CTD_human,22825968,Single-cell expression analysis of BMP15 and GDF9 in mature oocytes and BMPR2 in cumulus cells of women with polycystic ovary syndrome undergoing controlled ovarian hyperstimulation.,0.205154296365419,"Single-cell expression analysis of BMP15 and <span class=""gene"" id=""22825968-0-45-49"">GDF9</span> in mature oocytes and BMPR2 in cumulus cells of women with <span class=""disease"" id=""22825968-0-109-134"">polycystic ovary syndrome</span> undergoing controlled ovarian hyperstimulation.",CTD_human
1,0,Biomarker,C0025500,Mesothelioma,disease,mesotheliomas,2662,GDF10,BMP3b,CTD_human,18949431,The aberrant promoter methylation of BMP3b and BMP6 in malignant pleural mesotheliomas.,0.20300763924902696,"The aberrant promoter methylation of <span class=""gene"" id=""18949431-0-37-42"">BMP3b</span> and BMP6 in malignant pleural <span class=""disease"" id=""18949431-0-73-86"">mesotheliomas</span>.",CTD_human
1,0,Biomarker,C0017636,Glioblastoma,disease,glioblastoma,2668,GDNF,GDNF,CTD_human,19138852,"Pre-treatment of glioblastoma cell lines with GDNF but not the alternative ligand neurturin, promoted mitogenic behaviour and conferred chemoresistance to 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU).",0.201098907136852,"Pre-treatment of <span class=""disease"" id=""19138852-6-17-29"">glioblastoma</span> cell lines with <span class=""gene"" id=""19138852-6-46-50"">GDNF</span> but not the alternative ligand neurturin, promoted mitogenic behaviour and conferred chemoresistance to 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU).",CTD_human
1,0,Biomarker,C0017638,Glioma,disease,gliomas,2668,GDNF,GDNF,CTD_human,19138852,GDNF is overexpressed in glioblastoma cell lines and human gliomas.,0.202472541057918,"<span class=""gene"" id=""19138852-3-0-4"">GDNF</span> is overexpressed in glioblastoma cell lines and human <span class=""disease"" id=""19138852-3-59-66"">gliomas</span>.",CTD_human
2,0,Biomarker,C0019569,Hirschsprung Disease,disease,Hirschsprung disease,2668,GDNF,GDNF,CTD_human,8968758,"De novo mutation of GDNF, ligand for the RET/GDNFR-alpha receptor complex, in Hirschsprung disease.",0.620928714025885,"De novo mutation of <span class=""gene"" id=""8968758-0-20-24"">GDNF</span>, ligand for the RET/GDNFR-alpha receptor complex, in <span class=""disease"" id=""8968758-0-78-98"">Hirschsprung disease</span>.",CTD_human;HPO;ORPHANET
2,0,Biomarker,C0019569,Hirschsprung Disease,disease,Hirschsprung disease,2668,GDNF,GDNF,CTD_human,8896568,Germline mutations in glial cell line-derived neurotrophic factor (GDNF) and RET in a Hirschsprung disease patient.,0.620928714025885,"Germline mutations in <span class=""gene"" id=""8896568-0-22-65"">glial cell line-derived neurotrophic factor</span> (<span class=""gene"" id=""8896568-0-67-71"">GDNF</span>) and RET in a <span class=""disease"" id=""8896568-0-86-106"">Hirschsprung disease</span> patient.",CTD_human;HPO;ORPHANET
1,0,Therapeutic,C0020179,Huntington Disease,disease,Huntington's disease,2668,GDNF,GDNF,CTD_human,16943855,Neuroprotection by GDNF-secreting stem cells in a Huntington's disease model: optical neuroimage tracking of brain-grafted cells.,0.20328236603324,"Neuroprotection by <span class=""gene"" id=""16943855-0-19-23"">GDNF</span>-secreting stem cells in a <span class=""disease"" id=""16943855-0-50-70"">Huntington's disease</span> model: optical neuroimage tracking of brain-grafted cells.",CTD_human
2,0,Therapeutic,C0030567,Parkinson Disease,disease,Parkinson's disease,2668,GDNF,GDNF,CTD_human,11031079,"Thus, GDNF gene therapy may ameliorate the consequences of Parkinson's disease through rescuing compromised dopaminergic neurons.",0.22005505524755606,"Thus, <span class=""gene"" id=""11031079-11-6-10"">GDNF</span> gene therapy may ameliorate the consequences of <span class=""disease"" id=""11031079-11-59-78"">Parkinson's disease</span> through rescuing compromised dopaminergic neurons.",CTD_human
2,0,Therapeutic,C0030567,Parkinson Disease,disease,Parkinson's disease,2668,GDNF,GDNF,CTD_human,16324109,Ex vivo gene delivery of GDNF using primary astrocytes transduced with a lentiviral vector provides neuroprotection in a rat model of Parkinson's disease.,0.22005505524755606,"Ex vivo gene delivery of <span class=""gene"" id=""16324109-0-25-29"">GDNF</span> using primary astrocytes transduced with a lentiviral vector provides neuroprotection in a rat model of <span class=""disease"" id=""16324109-0-134-153"">Parkinson's disease</span>.",CTD_human
1,0,Biomarker,C0031511,Pheochromocytoma,disease,phaeochromocytoma,2668,GDNF,GDNF,CTD_human,9215674,"Genetic predisposition to phaeochromocytoma: analysis of candidate genes GDNF, RET and VHL.",0.201373633921065,"Genetic predisposition to <span class=""disease"" id=""9215674-0-26-43"">phaeochromocytoma</span>: analysis of candidate genes <span class=""gene"" id=""9215674-0-73-77"">GDNF</span>, RET and VHL.",CTD_human
2,0,Biomarker,C0038220,Status Epilepticus,disease,status epilepticus,2668,GDNF,GDNF,CTD_human,12914250,To observe the dynamic expression of GDNF and their receptors in the brain of rats after status epilepticus(SE).,0.2,"To observe the dynamic expression of <span class=""gene"" id=""12914250-1-37-41"">GDNF</span> and their receptors in the brain of rats after <span class=""disease"" id=""12914250-1-89-107"">status epilepticus</span>(SE).",CTD_human
2,0,Biomarker,C0038220,Status Epilepticus,disease,status epilepticus,2668,GDNF,GDNF,CTD_human,7854063,Glial cell-line derived neurotrophic factor (GDNF) mRNA upregulation in striatum and cortical areas after pilocarpine-induced status epilepticus in rats.,0.2,"<span class=""gene"" id=""7854063-0-0-43"">Glial cell-line derived neurotrophic factor</span> (<span class=""gene"" id=""7854063-0-45-49"">GDNF</span>) mRNA upregulation in striatum and cortical areas after pilocarpine-induced <span class=""disease"" id=""7854063-0-126-144"">status epilepticus</span> in rats.",CTD_human
2,0,Therapeutic,C0242422,Parkinsonian Disorders,group,parkinsonism,2668,GDNF,GDNF,CTD_human,9266731,"Thus, combined GDNF-Sinemet treatment could be of therapeutic value in treating parkinsonism, by producing a greater functional response and by mitigating adverse responses to Sinemet treatment.",0.28054945356842603,"Thus, combined <span class=""gene"" id=""9266731-11-15-19"">GDNF</span>-Sinemet treatment could be of therapeutic value in treating <span class=""disease"" id=""9266731-11-80-92"">parkinsonism</span>, by producing a greater functional response and by mitigating adverse responses to Sinemet treatment.",CTD_human
1,0,Biomarker,C0002395,Alzheimer's Disease,disease,AD,267,AMFR,AMFR,CTD_human,22313999,"Aging studies in the senescence-accelerated mouse strain (SAM) prone/8 (SAMP8), an animal model of Alzheimer's disease (AD), revealed significantly decreased mRNA and protein expression of AMF and AMFR in the hippocampus.",0.2,"Aging studies in the senescence-accelerated mouse strain (SAM) prone/8 (SAMP8), an animal model of <span class=""disease"" id=""22313999-4-99-118"">Alzheimer's disease</span> (<span class=""disease"" id=""22313999-4-120-122"">AD</span>), revealed significantly decreased mRNA and protein expression of AMF and <span class=""gene"" id=""22313999-4-197-201"">AMFR</span> in the hippocampus.",CTD_human
1,0,Biomarker,C0027873,Neuromyelitis Optica,disease,neuromyelitis optica,2670,GFAP,glial fibrillary acidic protein,CTD_human,18509235,A prominent elevation of glial fibrillary acidic protein in the cerebrospinal fluid during relapse in neuromyelitis optica.,0.201098907136852,"A prominent elevation of <span class=""gene"" id=""18509235-0-25-56"">glial fibrillary acidic protein</span> in the cerebrospinal fluid during relapse in <span class=""disease"" id=""18509235-0-102-122"">neuromyelitis optica</span>.",CTD_human
1,0,Biomarker,C0030567,Parkinson Disease,disease,PD,2670,GFAP,glial fibrillary acidic protein,CTD_human,19276553,"IGF-I and IGF-II resistance was present in DLB but not PD frontal cortex, and associated with reduced expression of Hu, nerve growth factor, and Trk neurotrophin receptors, and increased levels of glial fibrillary acidic protein, alpha-synuclein, dopamine-beta-hydroxylase, 4-hydroxy-2-nonenal (HNE), and ubiquitin immunoreactivity.",0.201648360705279,"IGF-I and IGF-II resistance was present in DLB but not <span class=""disease"" id=""19276553-4-55-57"">PD</span> frontal cortex, and associated with reduced expression of Hu, nerve growth factor, and Trk neurotrophin receptors, and increased levels of <span class=""gene"" id=""19276553-4-197-228"">glial fibrillary acidic protein</span>, alpha-synuclein, dopamine-beta-hydroxylase, 4-hydroxy-2-nonenal (HNE), and ubiquitin immunoreactivity.",CTD_human
1,0,Biomarker,C0752347,Lewy Body Disease,disease,DLB,2670,GFAP,glial fibrillary acidic protein,CTD_human,19276553,"IGF-I and IGF-II resistance was present in DLB but not PD frontal cortex, and associated with reduced expression of Hu, nerve growth factor, and Trk neurotrophin receptors, and increased levels of glial fibrillary acidic protein, alpha-synuclein, dopamine-beta-hydroxylase, 4-hydroxy-2-nonenal (HNE), and ubiquitin immunoreactivity.",0.200274726784213,"IGF-I and IGF-II resistance was present in <span class=""disease"" id=""19276553-4-43-46"">DLB</span> but not PD frontal cortex, and associated with reduced expression of Hu, nerve growth factor, and Trk neurotrophin receptors, and increased levels of <span class=""gene"" id=""19276553-4-197-228"">glial fibrillary acidic protein</span>, alpha-synuclein, dopamine-beta-hydroxylase, 4-hydroxy-2-nonenal (HNE), and ubiquitin immunoreactivity.",CTD_human
1,0,Therapeutic,C0162557,"Liver Failure, Acute",disease,acute hepatic failure,2671,GFER,ALR,CTD_human,15968720,"After the rats with acute hepatic failure were treated with recombinant pcDNA3-ALR plasmid, the survival rate (40%) significantly increased in treatment groups compared to control group (15%, P<0.01).",0.200274726784213,"After the rats with <span class=""disease"" id=""15968720-16-20-41"">acute hepatic failure</span> were treated with recombinant pcDNA3-<span class=""gene"" id=""15968720-16-79-82"">ALR</span> plasmid, the survival rate (40%) significantly increased in treatment groups compared to control group (15%, P&lt;0.01).",CTD_human
1,0,Biomarker,C0596263,Carcinogenesis,phenotype,tumorigenesis,26799,SNORD50A,SNORD50A,CTD_human,26595770,"In agreement with this hypothesis, CRISPR-mediated deletion of SNORD50A and SNORD50B in KRAS-mutant tumor cells enhanced tumorigenesis, and SNORD50A and SNORD50B deletion and oncogenic KRAS mutation co-occurred significantly in multiple human tumor types.",0.2,"In agreement with this hypothesis, CRISPR-mediated deletion of <span class=""gene"" id=""26595770-7-63-71"">SNORD50A</span> and SNORD50B in KRAS-mutant tumor cells enhanced <span class=""disease"" id=""26595770-7-121-134"">tumorigenesis</span>, and <span class=""gene"" id=""26595770-7-140-148"">SNORD50A</span> and SNORD50B deletion and oncogenic KRAS mutation co-occurred significantly in multiple human tumor types.",CTD_human
7,0,Biomarker,C0001206,Acromegaly,disease,acromegaly,2688,GH1,growth hormone,CTD_human,18388193,Epithelial sodium channel is a key mediator of growth hormone-induced sodium retention in acromegaly.,0.210714344584311,"Epithelial sodium channel is a key mediator of <span class=""gene"" id=""18388193-0-47-61"">growth hormone</span>-induced sodium retention in <span class=""disease"" id=""18388193-0-90-100"">acromegaly</span>.",CTD_human
7,0,Biomarker,C0001206,Acromegaly,disease,acromegaly,2688,GH1,growth hormone,CTD_human,7440347,"The history of frequent and excessive administration of a progestational agent suggested that the progestational drug induced the acromegaly.During the monitoring period. soft tissue changes diminished and there was normalization of several factors: plasma growth hormone concentration, response of plasma insulin and glucose to an oral glucose load, and response of plasma glucose hormone to the injection of insulin.",0.210714344584311,"The history of frequent and excessive administration of a progestational agent suggested that the progestational drug induced the <span class=""disease"" id=""7440347-2-130-140"">acromegaly</span>.During the monitoring period. soft tissue changes diminished and there was normalization of several factors: plasma <span class=""gene"" id=""7440347-2-257-271"">growth hormone</span> concentration, response of plasma insulin and glucose to an oral glucose load, and response of plasma glucose hormone to the injection of insulin.",CTD_human
1,0,Biomarker,C0028754,Obesity,disease,obese,2688,GH1,GH,CTD_human,8923850,Restoration of growth hormone (GH) response to GH-releasing hormone in elderly and obese subjects by acute pharmacological reduction of plasma free fatty acids.,0.211263798152737,"Restoration of <span class=""gene"" id=""8923850-0-15-29"">growth hormone</span> (<span class=""gene"" id=""8923850-0-31-33"">GH</span>) response to <span class=""gene"" id=""8923850-0-47-49"">GH</span>-releasing hormone in elderly and <span class=""disease"" id=""8923850-0-83-88"">obese</span> subjects by acute pharmacological reduction of plasma free fatty acids.",CTD_human
1,0,Biomarker,C0032019,Pituitary Neoplasms,group,pituitary tumor,2688,GH1,GH,CTD_human,19420816,"Endocrine examination revealed elevated plasma levels of growth hormone (GH) and insulin-like growth factor (IGF)-1, and an oral glucose tolerance test failed to suppress plasma GH levels, consistent with the diagnosis of GH-producing pituitary tumor.",0.21701870524389497,"Endocrine examination revealed elevated plasma levels of <span class=""gene"" id=""19420816-3-57-71"">growth hormone</span> (<span class=""gene"" id=""19420816-3-73-75"">GH</span>) and insulin-like growth factor (IGF)-1, and an oral glucose tolerance test failed to suppress plasma <span class=""gene"" id=""19420816-3-178-180"">GH</span> levels, consistent with the diagnosis of <span class=""gene"" id=""19420816-3-222-224"">GH</span>-producing <span class=""disease"" id=""19420816-3-235-250"">pituitary tumor</span>.",CTD_human
1,0,Biomarker,C0032461,Polycythemia,disease,Polycythemia,2688,GH1,growth hormone,CTD_human,15161484,"Polycythemia in a physician secondary to self-administered growth hormone, testosterone, and dehydroepiandrosterone to prevent aging.",0.2,"<span class=""disease"" id=""15161484-0-0-12"">Polycythemia</span> in a physician secondary to self-administered <span class=""gene"" id=""15161484-0-59-73"">growth hormone</span>, testosterone, and dehydroepiandrosterone to prevent aging.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,2690,GHR,GHBP,CTD_human,17547689,"Children with autism/ASD had significantly higher levels of many growth-related hormones: IGF-1, IGF-2, IGFBP-3 and GHBP.",0.2,"Children with <span class=""disease"" id=""17547689-12-14-20"">autism</span>/ASD had significantly higher levels of many growth-related hormones: IGF-1, IGF-2, IGFBP-3 and <span class=""gene"" id=""17547689-12-116-120"">GHBP</span>.",CTD_human
2,0,Biomarker,C0004352,Autistic Disorder,disease,autism,26960,NBEA,NBEA,CTD_human,20071347,"SCAMP5, NBEA and AMISYN: three candidate genes for autism involved in secretion of large dense-core vesicles.",0.281098907136852,"SCAMP5, <span class=""gene"" id=""20071347-0-8-12"">NBEA</span> and AMISYN: three candidate genes for <span class=""disease"" id=""20071347-0-51-57"">autism</span> involved in secretion of large dense-core vesicles.",CTD_human
2,0,Biomarker,C0004352,Autistic Disorder,disease,autism,26960,NBEA,neurobeachin,CTD_human,12746398,The neurobeachin gene is disrupted by a translocation in a patient with idiopathic autism.,0.281098907136852,"The <span class=""gene"" id=""12746398-0-4-16"">neurobeachin</span> gene is disrupted by a translocation in a patient with idiopathic <span class=""disease"" id=""12746398-0-83-89"">autism</span>.",CTD_human
1,0,Biomarker,C0001430,Adenoma,group,adenomas,2697,GJA1,Cx43,CTD_human,16926031,"Surprisingly, in lung adenomas Cx32 and Cx43 expressions were not detected, although the expression of connexins 26 and 46 was present.",0.2,"Surprisingly, in lung <span class=""disease"" id=""16926031-11-22-30"">adenomas</span> Cx32 and <span class=""gene"" id=""16926031-11-40-44"">Cx43</span> expressions were not detected, although the expression of connexins 26 and 46 was present.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,2697,GJA1,connexin 43,CTD_human,18435417,Expression of astrocytic markers aquaporin 4 and connexin 43 is altered in brains of subjects with autism.,0.202732912464814,"Expression of astrocytic markers aquaporin 4 and <span class=""gene"" id=""18435417-0-49-60"">connexin 43</span> is altered in brains of subjects with <span class=""disease"" id=""18435417-0-99-105"">autism</span>.",CTD_human
2,0,Biomarker,C0024121,Lung Neoplasms,group,lung tumors,2697,GJA1,Cx43,CTD_human,16926031,"These results may indicate a role of Cx32 and Cx43 in urethane-induced lung carcinogenesis, since their absence may contribute to the development of urethane induced lung tumors.",0.20300763924902696,"These results may indicate a role of Cx32 and <span class=""gene"" id=""16926031-13-46-50"">Cx43</span> in urethane-induced lung carcinogenesis, since their absence may contribute to the development of urethane induced <span class=""disease"" id=""16926031-13-166-177"">lung tumors</span>.",CTD_human
1,0,Biomarker,C0007138,"Carcinoma, Transitional Cell",disease,UC,26986,PABPC1,PABPC1,CTD_human,25783786,"The most significant joint region contained the gene PABPC1, which should be considered further for its role in UC progression.",0.2,"The most significant joint region contained the gene <span class=""gene"" id=""25783786-11-53-59"">PABPC1</span>, which should be considered further for its role in <span class=""disease"" id=""25783786-11-112-114"">UC</span> progression.",CTD_human
2,0,Biomarker,C0026848,Myopathy,group,myopathy,270,AMPD1,AMPD1,CTD_human,11102975,First missense mutations (R388W and R425H) of AMPD1 accompanied with myopathy found in a Japanese patient.,0.202681755307501,"First missense mutations (R388W and R425H) of <span class=""gene"" id=""11102975-0-46-51"">AMPD1</span> accompanied with <span class=""disease"" id=""11102975-0-69-77"">myopathy</span> found in a Japanese patient.",CTD_human
1,0,Biomarker,C0151786,Muscle Weakness,phenotype,muscle weakness,270,AMPD1,AMPD1,CTD_human,10996775,Myoadenylate deaminase deficiency with progressive muscle weakness and atrophy caused by new missense mutations in AMPD1 gene: case report in a Japanese patient.,0.400549453568426,"Myoadenylate deaminase deficiency with progressive <span class=""disease"" id=""10996775-0-51-66"">muscle weakness</span> and atrophy caused by new missense mutations in <span class=""gene"" id=""10996775-0-115-120"">AMPD1</span> gene: case report in a Japanese patient.",CTD_human;HPO
2,6,Biomarker,C0022521,Kartagener Syndrome,disease,PCD,27019,DNAI1,DNAI1,CTD_human,19675306,"Dnaic1 is the murine homolog of human DNAI1, which is mutated in approximately 10% of human PCD cases.",0.686802657070698,"Dnaic1 is the murine homolog of human <span class=""gene"" id=""19675306-3-38-43"">DNAI1</span>, which is mutated in approximately 10% of human <span class=""disease"" id=""19675306-3-92-95"">PCD</span> cases.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0020538,Hypertensive disease,group,high blood pressure,2702,GJA5,Cx40,CTD_human,19109587,The high blood pressure of the Cx40 knockout mice was significantly reduced when Cx45 was knocked into the locus but remained mildly elevated compared to wild-type mice.,0.285912964183428,"The <span class=""disease"" id=""19109587-6-4-23"">high blood pressure</span> of the <span class=""gene"" id=""19109587-6-31-35"">Cx40</span> knockout mice was significantly reduced when Cx45 was knocked into the locus but remained mildly elevated compared to wild-type mice.",CTD_human
1,0,Biomarker,C0086543,Cataract,disease,cataract,2703,GJA8,GJA8,CTD_human,9497259,"Sequence analysis of the entire protein-coding region of the GJA8 gene from the pedigree detected a C-->T transition in codon 88, which introduced a novel MnlI restriction-enzyme site that also cosegregated with the cataract.",0.422954115830002,"Sequence analysis of the entire protein-coding region of the <span class=""gene"" id=""9497259-7-61-65"">GJA8</span> gene from the pedigree detected a C--&gt;T transition in codon 88, which introduced a novel MnlI restriction-enzyme site that also cosegregated with the <span class=""disease"" id=""9497259-7-216-224"">cataract</span>.",CTD_human;HPO
1,0,Biomarker,C0014859,Esophageal Neoplasms,group,esophageal cancer,27030,MLH3,Mlh3,CTD_human,16981255,Mutation screening of mismatch repair gene Mlh3 in familial esophageal cancer.,0.200274726784213,"Mutation screening of mismatch repair gene <span class=""gene"" id=""16981255-0-43-47"">Mlh3</span> in familial <span class=""disease"" id=""16981255-0-60-77"">esophageal cancer</span>.",CTD_human
7,5,Biomarker,C0085106,Familial benign pemphigus,disease,HHD,27032,ATP2C1,SPCA1,CTD_human,20338123,"Darier disease (DD) and Hailey-Hailey disease (HHD) are rare autosomal dominantly inherited genodermatoses with mutations in the respective genes, ATP2A2 and ATP2C1, that encode the respective calcium adenosine triphosphatases SERCA2 and PMRI/SPCA1.",0.6530960208549,"Darier disease (DD) and <span class=""disease"" id=""20338123-1-24-45"">Hailey-Hailey disease</span> (<span class=""disease"" id=""20338123-1-47-50"">HHD</span>) are rare autosomal dominantly inherited genodermatoses with mutations in the respective genes, ATP2A2 and <span class=""gene"" id=""20338123-1-158-164"">ATP2C1</span>, that encode the respective calcium adenosine triphosphatases SERCA2 and PMRI/<span class=""gene"" id=""20338123-1-243-248"">SPCA1</span>.",CTD_human;ORPHANET;UNIPROT
7,5,Biomarker,C0085106,Familial benign pemphigus,disease,Hailey-Hailey disease,27032,ATP2C1,ATP2C1,CTD_human,16621454,ATP2C1 is a calcium/manganese-ATPase localized in the Golgi apparatus and known as responsible gene for Hailey-Hailey disease.,0.6530960208549,"<span class=""gene"" id=""16621454-1-0-6"">ATP2C1</span> is a calcium/manganese-ATPase localized in the Golgi apparatus and known as responsible gene for <span class=""disease"" id=""16621454-1-104-125"">Hailey-Hailey disease</span>.",CTD_human;ORPHANET;UNIPROT
7,5,Biomarker,C0085106,Familial benign pemphigus,disease,Hailey-Hailey disease,27032,ATP2C1,ATP2C1,CTD_human,11450592,"The gene responsible for Hailey-Hailey disease was recently identified as ATP2C1, and it encodes a Ca(2+)-transport ATPase with broad expression, including in skin and liver.",0.6530960208549,"The gene responsible for <span class=""disease"" id=""11450592-6-25-46"">Hailey-Hailey disease</span> was recently identified as <span class=""gene"" id=""11450592-6-74-80"">ATP2C1</span>, and it encodes a Ca(2+)-transport ATPase with broad expression, including in skin and liver.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0009375,Colonic Neoplasms,group,colon tumors,27035,NOX1,Nox1,CTD_human,20715105,"In the PhIP-induced colon tumors obtained after 1 year, Nox1, Nox4, NF?B-p50 and NF?B-p65 were all highly overexpressed compared with their levels in adjacent normal-looking colonic mucosa.",0.20300763924902696,"In the PhIP-induced <span class=""disease"" id=""20715105-3-20-32"">colon tumors</span> obtained after 1 year, <span class=""gene"" id=""20715105-3-56-60"">Nox1</span>, Nox4, NF&kappa;B-p50 and NF&kappa;B-p65 were all highly overexpressed compared with their levels in adjacent normal-looking colonic mucosa.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,27044,SND1,SND1,CTD_human,20442744,"Our results strengthen the case for a more detailed study of the role of RELN and GRIK2 in autism susceptibility, as well as identifying two new potential candidate genes, MKL2 and SND1.",0.202681755307501,"Our results strengthen the case for a more detailed study of the role of RELN and GRIK2 in <span class=""disease"" id=""20442744-10-91-97"">autism</span> susceptibility, as well as identifying two new potential candidate genes, MKL2 and <span class=""gene"" id=""20442744-10-181-185"">SND1</span>.",CTD_human
1,0,Biomarker,C0001430,Adenoma,group,adenomas,2705,GJB1,Cx32,CTD_human,16926031,"Surprisingly, in lung adenomas Cx32 and Cx43 expressions were not detected, although the expression of connexins 26 and 46 was present.",0.2,"Surprisingly, in lung <span class=""disease"" id=""16926031-11-22-30"">adenomas</span> <span class=""gene"" id=""16926031-11-31-35"">Cx32</span> and Cx43 expressions were not detected, although the expression of connexins 26 and 46 was present.",CTD_human
1,0,Biomarker,C0007134,Renal Cell Carcinoma,disease,renal carcinoma,2705,GJB1,connexin 32,CTD_human,18264126,5-Aza-2'-deoxycytidine suppresses human renal carcinoma cell growth in a xenograft model via up-regulation of the connexin 32 gene.,0.20575490709115804,"5-Aza-2'-deoxycytidine suppresses human <span class=""disease"" id=""18264126-0-40-55"">renal carcinoma</span> cell growth in a xenograft model via up-regulation of the <span class=""gene"" id=""18264126-0-114-125"">connexin 32</span> gene.",CTD_human
1,0,Biomarker,C0023903,Liver neoplasms,group,liver tumors,2705,GJB1,connexin 32,CTD_human,2559087,A rat liver gap junction (GJ) cDNA probe that detects mRNA encoding the 32 Kd GJ-protein (connexin 32) was employed to study GJ-protein gene expression in rat liver tumors induced by a single exposure to diethylnitrosamine (DEN) followed by exposure to 2-acetylaminofluorene (AAF)/CCl4/AAF or induced by systemic administration of N-ethyl-N-hydroxyethylnitrosamine (EHEN).,0.202197814273705,"A rat liver gap junction (GJ) cDNA probe that detects mRNA encoding the 32 Kd GJ-protein (<span class=""gene"" id=""2559087-1-90-101"">connexin 32</span>) was employed to study GJ-protein gene expression in rat <span class=""disease"" id=""2559087-1-159-171"">liver tumors</span> induced by a single exposure to diethylnitrosamine (DEN) followed by exposure to 2-acetylaminofluorene (AAF)/CCl4/AAF or induced by systemic administration of N-ethyl-N-hydroxyethylnitrosamine (EHEN).",CTD_human
2,0,Biomarker,C0024121,Lung Neoplasms,group,lung tumors,2705,GJB1,Cx32,CTD_human,16926031,"These results may indicate a role of Cx32 and Cx43 in urethane-induced lung carcinogenesis, since their absence may contribute to the development of urethane induced lung tumors.",0.202732912464814,"These results may indicate a role of <span class=""gene"" id=""16926031-13-37-41"">Cx32</span> and Cx43 in urethane-induced lung carcinogenesis, since their absence may contribute to the development of urethane induced <span class=""disease"" id=""16926031-13-166-177"">lung tumors</span>.",CTD_human
2,0,Biomarker,C0024121,Lung Neoplasms,group,lung tumor,2705,GJB1,Cx32,CTD_human,15492231,"Cx32-deficient nontumorous lung tissue exhibited an increased proliferative index (P < 0.001), and, after exposure to the carcinogen diethylnitrosamine, Cx32-deficient mice exhibited a highly statistically significant (P < 0.001) increase in bronchioloalveolar lung tumor incidence (28 of 45, 62%) and a 45% increase in average multiplicity compared with wild-type mice (7 of 29, 24%).",0.202732912464814,"<span class=""gene"" id=""15492231-3-0-4"">Cx32</span>-deficient nontumorous lung tissue exhibited an increased proliferative index (P &lt; 0.001), and, after exposure to the carcinogen diethylnitrosamine, <span class=""gene"" id=""15492231-3-153-157"">Cx32</span>-deficient mice exhibited a highly statistically significant (P &lt; 0.001) increase in bronchioloalveolar <span class=""disease"" id=""15492231-3-261-271"">lung tumor</span> incidence (28 of 45, 62%) and a 45% increase in average multiplicity compared with wild-type mice (7 of 29, 24%).",CTD_human
1,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastasis,2705,GJB1,Cx32,CTD_human,17978847,The second experiment focused on the effects of Cx32 disruption on metastasis by HCCs induced by administration of DEN and N-nitrosomorpholine.,0.20383181960166602,"The second experiment focused on the effects of <span class=""gene"" id=""17978847-6-48-52"">Cx32</span> disruption on <span class=""disease"" id=""17978847-6-67-77"">metastasis</span> by HCCs induced by administration of DEN and N-nitrosomorpholine.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,2705,GJB1,Cx32,CTD_human,17978847,The second experiment focused on the effects of Cx32 disruption on metastasis by HCCs induced by administration of DEN and N-nitrosomorpholine.,0.20876254634018498,"The second experiment focused on the effects of <span class=""gene"" id=""17978847-6-48-52"">Cx32</span> disruption on metastasis by <span class=""disease"" id=""17978847-6-81-84"">HCC</span>s induced by administration of DEN and N-nitrosomorpholine.",CTD_human
1,0,Biomarker,C0022568,Keratitis,disease,keratitis,2706,GJB2,GJB2,CTD_human,16172043,"Keratitis-Ichthyosis-Deafness syndrome is a rare congenital disorder of the ectoderm caused by mutations in the connexin-26 gene (GJB2) on chromosome 13q11-q12, giving rise to keratitis, erythrokeratoderma and neurosensory deafness.",0.40521980890004905,"Keratitis-Ichthyosis-Deafness syndrome is a rare congenital disorder of the ectoderm caused by mutations in the <span class=""gene"" id=""16172043-1-112-123"">connexin-26</span> gene (<span class=""gene"" id=""16172043-1-130-134"">GJB2</span>) on chromosome 13q11-q12, giving rise to <span class=""disease"" id=""16172043-1-176-185"">keratitis</span>, erythrokeratoderma and neurosensory deafness.",CTD_human;HPO
2,0,Biomarker,C0033860,Psoriasis,disease,psoriasis,2706,GJB2,GJB2,CTD_human,24212883,"We discovered two independent missense SNVs in IL23R and GJB2 of low frequency and five common missense SNVs in LCE3D, ERAP1, CARD14 and ZNF816A associated with psoriasis at genome-wide significance.",0.20350593566014002,"We discovered two independent missense SNVs in IL23R and <span class=""gene"" id=""24212883-2-57-61"">GJB2</span> of low frequency and five common missense SNVs in LCE3D, ERAP1, CARD14 and ZNF816A associated with <span class=""disease"" id=""24212883-2-161-170"">psoriasis</span> at genome-wide significance.",CTD_human
2,0,Biomarker,C0033860,Psoriasis,disease,psoriasis,2706,GJB2,GJB2,CTD_human,20953187,"We identified six new susceptibility loci associated with psoriasis in the Chinese study containing the candidate genes ERAP1, PTTG1, CSMD1, GJB2, SERPINB8 and ZNF816A (combined P < 5 × 10??) and replicated one locus, 5q33.1 (TNIP1-ANXA6), previously reported (combined P = 3.8 × 10?²¹) in the European studies.",0.20350593566014002,"We identified six new susceptibility loci associated with <span class=""disease"" id=""20953187-2-58-67"">psoriasis</span> in the Chinese study containing the candidate genes ERAP1, PTTG1, CSMD1, <span class=""gene"" id=""20953187-2-141-145"">GJB2</span>, SERPINB8 and ZNF816A (combined P &lt; 5 &times; 10??) and replicated one locus, 5q33.1 (TNIP1-ANXA6), previously reported (combined P = 3.8 &times; 10?²¹) in the European studies.",CTD_human
1,0,Biomarker,C0018784,Sensorineural Hearing Loss (disorder),disease,sensorineural hearing impairment,2707,GJB3,D66del,CTD_human,11309368,We report here a dominant mutation in the GJB3 gene (D66del) in a family affected with peripheral neuropathy and sensorineural hearing impairment.,0.40137363392106606,"We report here a dominant mutation in the <span class=""gene"" id=""11309368-2-42-46"">GJB3</span> gene (<span class=""gene"" id=""11309368-2-53-59"">D66del</span>) in a family affected with peripheral neuropathy and <span class=""disease"" id=""11309368-2-113-145"">sensorineural hearing impairment</span>.",CTD_human;HPO
1,0,Biomarker,C0031117,Peripheral Neuropathy,group,Peripheral neuropathy,2707,GJB3,GJB3,CTD_human,11309368,"Peripheral neuropathy is the third phenotypic alteration linked to GJB3 mutations, which enlarges the list of genes that cause this group of heterogeneous disorders.",0.201098907136852,"<span class=""disease"" id=""11309368-7-0-21"">Peripheral neuropathy</span> is the third phenotypic alteration linked to <span class=""gene"" id=""11309368-7-67-71"">GJB3</span> mutations, which enlarges the list of genes that cause this group of heterogeneous disorders.",CTD_human
3,7,Biomarker,C0265961,Erythrokeratodermia variabilis,disease,erythrokeratodermia variabilis,2707,GJB3,GJB3,CTD_human,9843209,Mutations in the human connexin gene GJB3 cause erythrokeratodermia variabilis.,0.684945082115836,"Mutations in the human connexin gene <span class=""gene"" id=""9843209-0-37-41"">GJB3</span> cause <span class=""disease"" id=""9843209-0-48-78"">erythrokeratodermia variabilis</span>.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0006413,Burkitt Lymphoma,disease,Burkitt lymphoma,27113,BBC3,PUMA,CTD_human,18573879,"Burkitt lymphoma cell lines phenocopy the primary tumors with respect to DNA methylation and diminished PUMA expression, which can be reactivated following inhibition of DNA methyltransferases.",0.20300763924902696,"<span class=""disease"" id=""18573879-5-0-16"">Burkitt lymphoma</span> cell lines phenocopy the primary tumors with respect to DNA methylation and diminished <span class=""gene"" id=""18573879-5-104-108"">PUMA</span> expression, which can be reactivated following inhibition of DNA methyltransferases.",CTD_human
1,0,Biomarker,C0018798,Congenital Heart Defects,group,heart defects,27125,AFF4,AFF4,CTD_human,25730767,"Using exome sequencing, we discovered missense mutations in AFF4, a core component of the SEC, in three unrelated probands with a new syndrome that phenotypically overlaps Cornelia de Lange syndrome (CdLS) that we have named CHOPS syndrome (C for cognitive impairment and coarse facies, H for heart defects, O for obesity, P for pulmonary involvement and S for short stature and skeletal dysplasia).",0.200274726784213,"Using exome sequencing, we discovered missense mutations in <span class=""gene"" id=""25730767-3-60-64"">AFF4</span>, a core component of the SEC, in three unrelated probands with a new syndrome that phenotypically overlaps Cornelia de Lange syndrome (CdLS) that we have named CHOPS syndrome (C for cognitive impairment and coarse facies, H for <span class=""disease"" id=""25730767-3-293-306"">heart defects</span>, O for obesity, P for pulmonary involvement and S for short stature and skeletal dysplasia).",CTD_human
1,0,Biomarker,C0028754,Obesity,disease,obesity,27125,AFF4,AFF4,CTD_human,25730767,"Using exome sequencing, we discovered missense mutations in AFF4, a core component of the SEC, in three unrelated probands with a new syndrome that phenotypically overlaps Cornelia de Lange syndrome (CdLS) that we have named CHOPS syndrome (C for cognitive impairment and coarse facies, H for heart defects, O for obesity, P for pulmonary involvement and S for short stature and skeletal dysplasia).",0.40027472678421294,"Using exome sequencing, we discovered missense mutations in <span class=""gene"" id=""25730767-3-60-64"">AFF4</span>, a core component of the SEC, in three unrelated probands with a new syndrome that phenotypically overlaps Cornelia de Lange syndrome (CdLS) that we have named CHOPS syndrome (C for cognitive impairment and coarse facies, H for heart defects, O for <span class=""disease"" id=""25730767-3-314-321"">obesity</span>, P for pulmonary involvement and S for short stature and skeletal dysplasia).",CTD_human;HPO
1,0,Biomarker,C0023470,Myeloid Leukemia,disease,myeloid leukaemia,27161,AGO2,AGO2,CTD_human,21535412,Knock-down of argonaute 2 (AGO2) induces apoptosis in myeloid leukaemia cells and inhibits siRNA-mediated silencing of transfected oncogenes in HEK-293 cells.,0.200274726784213,"Knock-down of argonaute 2 (<span class=""gene"" id=""21535412-0-27-31"">AGO2</span>) induces apoptosis in <span class=""disease"" id=""21535412-0-54-71"">myeloid leukaemia</span> cells and inhibits siRNA-mediated silencing of transfected oncogenes in HEK-293 cells.",CTD_human
32,168,Biomarker,C0002986,Fabry Disease,disease,Fabry disease,2717,GLA,Gla,CTD_human,18565198,Fabry disease results from an X-linked mutation in the lysosomal alpha-galactosidase A (Gla) gene.,0.799071836466372,"<span class=""disease"" id=""18565198-1-0-13"">Fabry disease</span> results from an X-linked mutation in the lysosomal <span class=""gene"" id=""18565198-1-65-86"">alpha-galactosidase A</span> (<span class=""gene"" id=""18565198-1-88-91"">Gla</span>) gene.",CTD_human;ORPHANET;UNIPROT
2,0,Biomarker,C0004352,Autistic Disorder,disease,autism,27185,DISC1,DISC1,CTD_human,17579608,Association of DISC1 with autism and Asperger syndrome.,0.204655999954305,"Association of <span class=""gene"" id=""17579608-0-15-20"">DISC1</span> with <span class=""disease"" id=""17579608-0-26-32"">autism</span> and Asperger syndrome.",CTD_human
2,0,Biomarker,C0004352,Autistic Disorder,disease,autism,27185,DISC1,DISC1,CTD_human,20002455,DISC1 duplication in two brothers with autism and mild mental retardation.,0.204655999954305,"<span class=""gene"" id=""20002455-0-0-5"">DISC1</span> duplication in two brothers with <span class=""disease"" id=""20002455-0-39-45"">autism</span> and mild mental retardation.",CTD_human
1,0,Biomarker,C0030193,Pain,phenotype,pain,27185,DISC1,DISC1,CTD_human,20561508,"At baseline, deletion of NRG1 and DISC1 each reduced thermal pain sensitivity, while deletion of COMT increased pain sensitivity.",0.2,"At baseline, deletion of NRG1 and <span class=""gene"" id=""20561508-4-34-39"">DISC1</span> each reduced thermal <span class=""disease"" id=""20561508-4-61-65"">pain</span> sensitivity, while deletion of COMT increased <span class=""disease"" id=""20561508-4-112-116"">pain</span> sensitivity.",CTD_human
2,0,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,27185,DISC1,DISC1,CTD_human,20531374,Association of Disrupted in Schizophrenia 1 (DISC1) missense variants with ultra-resistant schizophrenia.,0.46389102079896505,"Association of <span class=""gene"" id=""20531374-0-15-43"">Disrupted in Schizophrenia 1</span> (<span class=""gene"" id=""20531374-0-45-50"">DISC1</span>) missense variants with ultra-resistant <span class=""disease"" id=""20531374-0-91-104"">schizophrenia</span>.",CTD_human
2,0,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,27185,DISC1,DISC1,CTD_human,20561508,"Disruption of thermal nociceptive behaviour in mice mutant for the schizophrenia-associated genes NRG1, COMT and DISC1.",0.46389102079896505,"Disruption of thermal nociceptive behaviour in mice mutant for the <span class=""disease"" id=""20561508-0-67-80"">schizophrenia</span>-associated genes NRG1, COMT and <span class=""gene"" id=""20561508-0-113-118"">DISC1</span>.",CTD_human
1,0,Biomarker,C0236792,Asperger Syndrome,disease,Asperger syndrome,27185,DISC1,DISC1,CTD_human,17579608,Association of DISC1 with autism and Asperger syndrome.,0.20678830169338,"Association of <span class=""gene"" id=""17579608-0-15-20"">DISC1</span> with autism and <span class=""disease"" id=""17579608-0-37-54"">Asperger syndrome</span>.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,hepatocellular carcinoma,2719,GPC3,OCI-5,CTD_human,16698587,Gradual upregulation of OCI-5 expression during occurrence and progression of rat hepatocellular carcinoma.,0.238100890741717,"Gradual upregulation of <span class=""gene"" id=""16698587-0-24-29"">OCI-5</span> expression during occurrence and progression of rat <span class=""disease"" id=""16698587-0-82-106"">hepatocellular carcinoma</span>.",CTD_human
1,1,Biomarker,C0011615,"Dermatitis, Atopic",disease,atopic dermatitis,2720,GLB1,GLB1,CTD_human,23042114,"On the basis of data from a genome-wide association study (GWAS) and a validation study comprising a total of 3,328 subjects with atopic dermatitis and 14,992 controls in the Japanese population, we report here 8 new susceptibility loci: IL1RL1-IL18R1-IL18RAP (P(combined) = 8.36 × 10(-18)), the major histocompatibility complex (MHC) region (P = 8.38 × 10(-20)), OR10A3-NLRP10 (P = 1.54 × 10(-22)), GLB1 (P = 2.77 × 10(-16)), CCDC80 (P = 1.56 × 10(-19)), CARD11 (P = 7.83 × 10(-9)), ZNF365 (P = 5.85 × 10(-20)) and CYP24A1-PFDN4 (P = 1.65 × 10(-8)).",0.2,"On the basis of data from a genome-wide association study (GWAS) and a validation study comprising a total of 3,328 subjects with <span class=""disease"" id=""23042114-2-130-147"">atopic dermatitis</span> and 14,992 controls in the Japanese population, we report here 8 new susceptibility loci: IL1RL1-IL18R1-IL18RAP (P(combined) = 8.36 &times; 10(-18)), the major histocompatibility complex (MHC) region (P = 8.38 &times; 10(-20)), OR10A3-NLRP10 (P = 1.54 &times; 10(-22)), <span class=""gene"" id=""23042114-2-400-404"">GLB1</span> (P = 2.77 &times; 10(-16)), CCDC80 (P = 1.56 &times; 10(-19)), CARD11 (P = 7.83 &times; 10(-9)), ZNF365 (P = 5.85 &times; 10(-20)) and CYP24A1-PFDN4 (P = 1.65 &times; 10(-8)).",CTD_human
2,0,Biomarker,C0026707,Mucopolysaccharidosis IV,disease,keratan sulfaturia,2720,GLB1,beta-galactosidase,CTD_human,7586649,"Mild keratan sulfaturia was found, and beta-galactosidase was deficient in fibroblasts.",0.200274726784213,"Mild <span class=""disease"" id=""7586649-2-5-23"">keratan sulfaturia</span> was found, and <span class=""gene"" id=""7586649-2-39-57"">beta-galactosidase</span> was deficient in fibroblasts.",CTD_human
1,0,Biomarker,C0019189,"Hepatitis, Chronic",disease,chronic hepatitis,27232,GNMT,GNMT,CTD_human,19146867,"Previously, we reported that glycine N-methyltransferase (GNMT) knockout mice develop chronic hepatitis and hepatocellular carcinoma (HCC) spontaneously.",0.20054945356842604,"Previously, we reported that <span class=""gene"" id=""19146867-1-29-56"">glycine N-methyltransferase</span> (<span class=""gene"" id=""19146867-1-58-62"">GNMT</span>) knockout mice develop <span class=""disease"" id=""19146867-1-86-103"">chronic hepatitis</span> and hepatocellular carcinoma (HCC) spontaneously.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,27232,GNMT,GNMT,CTD_human,19146867,"Therefore, GNMT is a tumor suppressor for HCC and it exerts protective effects in hepatocytes via direct interaction with AFB(1), resulting in reduced AFB(1)-DNA adducts formation and cell death.",0.29013618026125,"Therefore, <span class=""gene"" id=""19146867-12-11-15"">GNMT</span> is a tumor suppressor for <span class=""disease"" id=""19146867-12-42-45"">HCC</span> and it exerts protective effects in hepatocytes via direct interaction with AFB(1), resulting in reduced AFB(1)-DNA adducts formation and cell death.",CTD_human
1,0,Biomarker,C0002736,Amyotrophic Lateral Sclerosis,disease,amyotrophic lateral sclerosis,27242,TNFRSF21,DR6,CTD_human,24113175,Death receptor 6 (DR6) antagonist antibody is neuroprotective in the mouse SOD1G93A model of amyotrophic lateral sclerosis.,0.200274726784213,"<span class=""gene"" id=""24113175-0-0-16"">Death receptor 6</span> (<span class=""gene"" id=""24113175-0-18-21"">DR6</span>) antagonist antibody is neuroprotective in the mouse SOD1G93A model of <span class=""disease"" id=""24113175-0-93-122"">amyotrophic lateral sclerosis</span>.",CTD_human
1,0,Biomarker,C0002878,"Anemia, Hemolytic",disease,hemolytic anemia,2729,GCLC,gamma-glutamylcysteine synthetase,CTD_human,10515893,A patient with hemolytic anemia and low red blood cell glutathione levels was found to have a deficiency of gamma-glutamylcysteine synthetase activity.,0.40082418035263895,"A patient with <span class=""disease"" id=""10515893-3-15-31"">hemolytic anemia</span> and low red blood cell glutathione levels was found to have a deficiency of <span class=""gene"" id=""10515893-3-108-141"">gamma-glutamylcysteine synthetase</span> activity.",CTD_human;HPO
1,0,Biomarker,C0027051,Myocardial Infarction,disease,myocardial infarction,2729,GCLC,glutamate-cysteine ligase catalytic subunit,CTD_human,12598062,Association of polymorphism in glutamate-cysteine ligase catalytic subunit gene with coronary vasomotor dysfunction and myocardial infarction.,0.202956482091714,"Association of polymorphism in <span class=""gene"" id=""12598062-0-31-74"">glutamate-cysteine ligase catalytic subunit</span> gene with coronary vasomotor dysfunction and <span class=""disease"" id=""12598062-0-120-141"">myocardial infarction</span>.",CTD_human
2,0,Biomarker,C0027051,Myocardial Infarction,disease,myocardial infarction,2730,GCLM,glutamate-cysteine ligase modifier subunit,CTD_human,12081989,Polymorphism in the 5'-flanking region of human glutamate-cysteine ligase modifier subunit gene is associated with myocardial infarction.,0.208096423079816,"Polymorphism in the 5'-flanking region of human <span class=""gene"" id=""12081989-0-48-90"">glutamate-cysteine ligase modifier subunit</span> gene is associated with <span class=""disease"" id=""12081989-0-115-136"">myocardial infarction</span>.",CTD_human
1,0,Biomarker,C1336708,Testicular Germ Cell Tumor,disease,TGCT,27306,HPGDS,HPGDS,CTD_human,23666239,"In the combined analysis, risk of TGCT was significantly associated with markers at four previously unreported loci: 4q22.2 in HPGDS (per-allele odds ratio (OR) = 1.19, 95% confidence interval (CI) = 1.12-1.26; P = 1.11 × 10(-8)), 7p22.3 in MAD1L1 (OR = 1.21, 95% CI = 1.14-1.29; P = 5.59 × 10(-9)), 16q22.3 in RFWD3 (OR = 1.26, 95% CI = 1.18-1.34; P = 5.15 × 10(-12)) and 17q22 (rs9905704: OR = 1.27, 95% CI = 1.18-1.33; P = 4.32 × 10(-13) and rs7221274: OR = 1.20, 95% CI = 1.12-1.28; P = 4.04 × 10(-9)), a locus that includes TEX14, RAD51C and PPM1E.",0.20054945356842604,"In the combined analysis, risk of <span class=""disease"" id=""23666239-4-34-38"">TGCT</span> was significantly associated with markers at four previously unreported loci: 4q22.2 in <span class=""gene"" id=""23666239-4-127-132"">HPGDS</span> (per-allele odds ratio (OR) = 1.19, 95% confidence interval (CI) = 1.12-1.26; P = 1.11 &times; 10(-8)), 7p22.3 in MAD1L1 (OR = 1.21, 95% CI = 1.14-1.29; P = 5.59 &times; 10(-9)), 16q22.3 in RFWD3 (OR = 1.26, 95% CI = 1.18-1.34; P = 5.15 &times; 10(-12)) and 17q22 (rs9905704: OR = 1.27, 95% CI = 1.18-1.33; P = 4.32 &times; 10(-13) and rs7221274: OR = 1.20, 95% CI = 1.12-1.28; P = 4.04 &times; 10(-9)), a locus that includes TEX14, RAD51C and PPM1E.",CTD_human
6,88,Biomarker,C0751748,Nonketotic Hyperglycinemia,disease,nonketotic hyperglycinemia,2731,GLDC,GLDC,CTD_human,16404748,Treatment from birth of nonketotic hyperglycinemia due to a novel GLDC mutation.,0.49474102305824297,"Treatment from birth of <span class=""disease"" id=""16404748-0-24-50"">nonketotic hyperglycinemia</span> due to a novel <span class=""gene"" id=""16404748-0-66-70"">GLDC</span> mutation.",CTD_human;UNIPROT
6,88,Biomarker,C0751748,Nonketotic Hyperglycinemia,disease,nonketotic hyperglycinemia,2731,GLDC,GLDC,CTD_human,16450403,"Comprehensive mutation analysis of GLDC, AMT, and GCSH in nonketotic hyperglycinemia.",0.49474102305824297,"Comprehensive mutation analysis of <span class=""gene"" id=""16450403-0-35-39"">GLDC</span>, AMT, and GCSH in <span class=""disease"" id=""16450403-0-58-84"">nonketotic hyperglycinemia</span>.",CTD_human;UNIPROT
6,88,Biomarker,C0751748,Nonketotic Hyperglycinemia,disease,non-ketotic hyperglycinaemia,2731,GLDC,GLDC,CTD_human,17361008,Genomic deletion within GLDC is a major cause of non-ketotic hyperglycinaemia.,0.49474102305824297,"Genomic deletion within <span class=""gene"" id=""17361008-0-24-28"">GLDC</span> is a major cause of <span class=""disease"" id=""17361008-0-49-77"">non-ketotic hyperglycinaemia</span>.",CTD_human;UNIPROT
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,27347,STK39,STK39,CTD_human,18348195,An analysis of candidate autism loci on chromosome 2q24-q33: evidence for association to the STK39 gene.,0.202681755307501,"An analysis of candidate <span class=""disease"" id=""18348195-0-25-31"">autism</span> loci on chromosome 2q24-q33: evidence for association to the <span class=""gene"" id=""18348195-0-93-98"">STK39</span> gene.",CTD_human
1,0,Biomarker,C0023487,Acute Promyelocytic Leukemia,disease,APL,2735,GLI1,Gli1,CTD_human,23867347,"In newly diagnosed APL patients, Gli2 expression was significantly positively correlated with Gli1 (R = 0.57, p < 0.001) and Smo (R = 0.56, p < 0.001) and the expression of Hh pathway components was significantly higher in the high WBC group (p < 0.05).",0.2,"In newly diagnosed <span class=""disease"" id=""23867347-6-19-22"">APL</span> patients, Gli2 expression was significantly positively correlated with <span class=""gene"" id=""23867347-6-94-98"">Gli1</span> (R = 0.57, p &lt; 0.001) and Smo (R = 0.56, p &lt; 0.001) and the expression of Hh pathway components was significantly higher in the high WBC group (p &lt; 0.05).",CTD_human
1,0,Biomarker,C0031117,Peripheral Neuropathy,group,peripheral neuropathy,2735,GLI1,GLI1,CTD_human,20864405,"By contrast, early-onset vincristine-induced peripheral neuropathy was characterised by upregulation of genes involved in cell cycle and proliferation, including AURKA (3·31 times; p=1·04×10(-2)) and MKI67 (3·66 times; p=1·82×10(-3)), and the presence of SNPs in genes involved in these processes-eg, GLI1 (rs2228224 [0·13, 0·02-0·97, p=1·18×10(-2)] and rs2242578 [0·14, 0·02-1·12, p=3·00×10(-2)]).",0.2,"By contrast, early-onset vincristine-induced <span class=""disease"" id=""20864405-13-45-66"">peripheral neuropathy</span> was characterised by upregulation of genes involved in cell cycle and proliferation, including AURKA (3·31 times; p=1·04&times;10(-2)) and MKI67 (3·66 times; p=1·82&times;10(-3)), and the presence of SNPs in genes involved in these processes-eg, <span class=""gene"" id=""20864405-13-301-305"">GLI1</span> (rs2228224 [0·13, 0·02-0·97, p=1·18&times;10(-2)] and rs2242578 [0·14, 0·02-1·12, p=3·00&times;10(-2)]).",CTD_human
1,0,Biomarker,C0079744,Diffuse Large B-Cell Lymphoma,disease,DLBCL,2735,GLI1,GLI1,CTD_human,21625222,"Furthermore, in DLBCL tumor samples, significantly high ABCG2 and GLI1 levels were found in DLBCL tumors with lymph node involvement in comparison with DLBCL tumor cells collected from pleural and/or peritoneal effusions.",0.201098907136852,"Furthermore, in <span class=""disease"" id=""21625222-6-16-21"">DLBCL</span> tumor samples, significantly high ABCG2 and <span class=""gene"" id=""21625222-6-66-70"">GLI1</span> levels were found in <span class=""disease"" id=""21625222-6-92-97"">DLBCL</span> tumors with lymph node involvement in comparison with <span class=""disease"" id=""21625222-6-152-157"">DLBCL</span> tumor cells collected from pleural and/or peritoneal effusions.",CTD_human
1,0,Biomarker,C0023487,Acute Promyelocytic Leukemia,disease,APL,2736,GLI2,Gli2,CTD_human,23867347,"In newly diagnosed APL patients, Gli2 expression was significantly positively correlated with Gli1 (R = 0.57, p < 0.001) and Smo (R = 0.56, p < 0.001) and the expression of Hh pathway components was significantly higher in the high WBC group (p < 0.05).",0.2,"In newly diagnosed <span class=""disease"" id=""23867347-6-19-22"">APL</span> patients, <span class=""gene"" id=""23867347-6-33-37"">Gli2</span> expression was significantly positively correlated with Gli1 (R = 0.57, p &lt; 0.001) and Smo (R = 0.56, p &lt; 0.001) and the expression of Hh pathway components was significantly higher in the high WBC group (p &lt; 0.05).",CTD_human
1,1,Biomarker,C0152427,Polydactyly,disease,polydactyly,2737,GLI3,Gli3,CTD_human,17688467,"The gene responsible for the polydactyly/arhinencephaly (Pdn/Pdn) mouse, which exhibits polysyndactyly and arhinencephaly and has a 13.2% risk of neural tube defects (NTD), has been identified as Gli3.",0.20625320350227103,"The gene responsible for the <span class=""disease"" id=""17688467-1-29-40"">polydactyly</span>/arhinencephaly (Pdn/Pdn) mouse, which exhibits polysyndactyly and arhinencephaly and has a 13.2% risk of neural tube defects (NTD), has been identified as <span class=""gene"" id=""17688467-1-196-200"">Gli3</span>.",CTD_human
1,0,Biomarker,C0162835,Hypopigmentation disorder,disease,hypopigmentation,2737,GLI3,Gli3,CTD_human,18397875,Complementation tests using a second allele of Gli3 (Gli3(Xt-J)) confirmed that a null mutation of Gli3 causes the increased hypopigmentation in Sox10(LacZ/+);Gli3(Mos1/)(+) double heterozygotes.,0.200274726784213,"Complementation tests using a second allele of <span class=""gene"" id=""18397875-6-47-51"">Gli3</span> (<span class=""gene"" id=""18397875-6-53-63"">Gli3(Xt-J)</span>) confirmed that a null mutation of <span class=""gene"" id=""18397875-6-99-103"">Gli3</span> causes the increased <span class=""disease"" id=""18397875-6-125-141"">hypopigmentation</span> in Sox10(LacZ/+);<span class=""gene"" id=""18397875-6-159-163"">Gli3</span>(Mos1/)(+) double heterozygotes.",CTD_human
2,30,Biomarker,C0265220,Pallister-Hall syndrome,disease,PHS,2737,GLI3,GLI3,CTD_human,15739154,"To test these hypotheses, we screened patients with PHS and GCPS for GLI3 mutations.",0.490359749888151,"To test these hypotheses, we screened patients with <span class=""disease"" id=""15739154-3-52-55"">PHS</span> and GCPS for <span class=""gene"" id=""15739154-3-69-73"">GLI3</span> mutations.",CTD_human;ORPHANET
8,9,Biomarker,C0265306,Greig cephalopolysyndactyly syndrome,disease,GCPS,2737,GLI3,GLI3,CTD_human,15739154,"To test these hypotheses, we screened patients with PHS and GCPS for GLI3 mutations.",0.6874176231737541,"To test these hypotheses, we screened patients with PHS and <span class=""disease"" id=""15739154-3-60-64"">GCPS</span> for <span class=""gene"" id=""15739154-3-69-73"">GLI3</span> mutations.",CTD_human;ORPHANET;UNIPROT
8,9,Biomarker,C0265306,Greig cephalopolysyndactyly syndrome,disease,GCPS,2737,GLI3,GLI3,CTD_human,14608643,"We conclude that patients with GCPS caused by large deletions that include GLI3 are likely to have cognitive deficits, and we hypothesize that this severe GCPS phenotype is caused by deletion of contiguous genes.",0.6874176231737541,"We conclude that patients with <span class=""disease"" id=""14608643-10-31-35"">GCPS</span> caused by large deletions that include <span class=""gene"" id=""14608643-10-75-79"">GLI3</span> are likely to have cognitive deficits, and we hypothesize that this severe <span class=""disease"" id=""14608643-10-155-159"">GCPS</span> phenotype is caused by deletion of contiguous genes.",CTD_human;ORPHANET;UNIPROT
8,9,Biomarker,C0265306,Greig cephalopolysyndactyly syndrome,disease,GCPS,2737,GLI3,GLI3,CTD_human,18154020,"A novel syndrome, combining features of CCM and GCPS, can be added to the group of entities that result from deleterious genetic variants involving GLI3, including GCPS, acrocallosal syndrome, Pallister-Hall syndrome, and contiguous gene syndrome.",0.6874176231737541,"A novel syndrome, combining features of CCM and <span class=""disease"" id=""18154020-8-48-52"">GCPS</span>, can be added to the group of entities that result from deleterious genetic variants involving <span class=""gene"" id=""18154020-8-148-152"">GLI3</span>, including <span class=""disease"" id=""18154020-8-164-168"">GCPS</span>, acrocallosal syndrome, Pallister-Hall syndrome, and contiguous gene syndrome.",CTD_human;ORPHANET;UNIPROT
8,9,Biomarker,C0265306,Greig cephalopolysyndactyly syndrome,disease,Greig cephalopolysyndactyly syndrome,2737,GLI3,GLI3,CTD_human,10441342,Point mutations throughout the GLI3 gene cause Greig cephalopolysyndactyly syndrome.,0.6874176231737541,"Point mutations throughout the <span class=""gene"" id=""10441342-0-31-35"">GLI3</span> gene cause <span class=""disease"" id=""10441342-0-47-83"">Greig cephalopolysyndactyly syndrome</span>.",CTD_human;ORPHANET;UNIPROT
8,9,Biomarker,C0265306,Greig cephalopolysyndactyly syndrome,disease,GCPS,2737,GLI3,GLI3,CTD_human,18241058,Greig cephalopolysyndactyly syndrome (GCPS) is a rare multiple congenital anomaly syndrome that is inherited in an autosomal dominant pattern and is caused by haploinsufficiency of the GLI3 gene.,0.6874176231737541,"<span class=""disease"" id=""18241058-1-0-36"">Greig cephalopolysyndactyly syndrome</span> (<span class=""disease"" id=""18241058-1-38-42"">GCPS</span>) is a rare multiple congenital anomaly syndrome that is inherited in an autosomal dominant pattern and is caused by haploinsufficiency of the <span class=""gene"" id=""18241058-1-185-189"">GLI3</span> gene.",CTD_human;ORPHANET;UNIPROT
8,9,Biomarker,C0265306,Greig cephalopolysyndactyly syndrome,disease,Greig syndrome,2737,GLI3,GLI3,CTD_human,9302279,Point mutations in human GLI3 cause Greig syndrome.,0.6874176231737541,"Point mutations in human <span class=""gene"" id=""9302279-0-25-29"">GLI3</span> cause <span class=""disease"" id=""9302279-0-36-50"">Greig syndrome</span>.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0003469,Anxiety Disorders,group,anxiety,2739,GLO1,GLO1,CTD_human,22113448,"Glyoxylase 1 (GLO1) and guanine nucleotide-binding protein 1 (GNB1) mostly account for baseline anxiety-like and depressive-like behavior, indicating a common biological link between depression and anxiety.",0.201373633921065,"Glyoxylase 1 (<span class=""gene"" id=""22113448-4-14-18"">GLO1</span>) and guanine nucleotide-binding protein 1 (GNB1) mostly account for baseline <span class=""disease"" id=""22113448-4-96-103"">anxiety</span>-like and depressive-like behavior, indicating a common biological link between depression and <span class=""disease"" id=""22113448-4-198-205"">anxiety</span>.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,2739,GLO1,glyoxalase I,CTD_human,15386471,Proteomic studies identified a single nucleotide polymorphism in glyoxalase I as autism susceptibility factor.,0.206462417751855,"Proteomic studies identified a single nucleotide polymorphism in <span class=""gene"" id=""15386471-0-65-77"">glyoxalase I</span> as <span class=""disease"" id=""15386471-0-81-87"">autism</span> susceptibility factor.",CTD_human
2,0,Biomarker,C0011581,Depressive disorder,disease,depression,2739,GLO1,GLO1,CTD_human,22113448,"Glyoxylase 1 (GLO1) and guanine nucleotide-binding protein 1 (GNB1) mostly account for baseline anxiety-like and depressive-like behavior, indicating a common biological link between depression and anxiety.",0.4,"Glyoxylase 1 (<span class=""gene"" id=""22113448-4-14-18"">GLO1</span>) and guanine nucleotide-binding protein 1 (GNB1) mostly account for baseline anxiety-like and depressive-like behavior, indicating a common biological link between <span class=""disease"" id=""22113448-4-183-193"">depression</span> and anxiety.",CTD_human;PSYGENET
1,0,Biomarker,C0025202,melanoma,disease,malignant melanoma,2739,GLO1,GLO1,CTD_human,20093988,GLO1 overexpression in human malignant melanoma.,0.200274726784213,"<span class=""gene"" id=""20093988-0-0-4"">GLO1</span> overexpression in human <span class=""disease"" id=""20093988-0-29-47"">malignant melanoma</span>.",CTD_human
6,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,non-small-cell lung cancer,27436,EML4,EML4,CTD_human,17625570,Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.,0.23626393551612898,"Identification of the transforming <span class=""gene"" id=""17625570-0-35-39"">EML4</span>-ALK fusion gene in <span class=""disease"" id=""17625570-0-59-85"">non-small-cell lung cancer</span>.",CTD_human
6,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,non-small cell lung cancer,27436,EML4,EML4,CTD_human,22986231,Isolated central nervous system progression on Crizotinib: an Achilles heel of non-small cell lung cancer with EML4-ALK translocation?,0.23626393551612898,"Isolated central nervous system progression on Crizotinib: an Achilles heel of <span class=""disease"" id=""22986231-0-79-105"">non-small cell lung cancer</span> with <span class=""gene"" id=""22986231-0-111-115"">EML4</span>-ALK translocation?",CTD_human
6,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,NSCLC,27436,EML4,EML4,CTD_human,21757253,The ALK inhibitor presented in this study is effective in EML4-ALK NSCLC cases.,0.23626393551612898,"The ALK inhibitor presented in this study is effective in <span class=""gene"" id=""21757253-17-58-62"">EML4</span>-ALK <span class=""disease"" id=""21757253-17-67-72"">NSCLC</span> cases.",CTD_human
6,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,non-small cell lung cancer,27436,EML4,Echinoderm microtubule-associated protein-like 4,CTD_human,22568572,Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-targeted therapy for advanced non-small cell lung cancer: molecular and clinical aspects.,0.23626393551612898,"<span class=""gene"" id=""22568572-0-0-48"">Echinoderm microtubule-associated protein-like 4</span>-anaplastic lymphoma kinase-targeted therapy for advanced <span class=""disease"" id=""22568572-0-106-132"">non-small cell lung cancer</span>: molecular and clinical aspects.",CTD_human
6,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,NSCLC,27436,EML4,EML4,CTD_human,22617245,"We selected NSCLC cell lines--A549 (KRAS G12S), NCI-H3255 (EGFR L858R), NCI-H3122 (EML4-ALK E13;A20), and HCC78 (SLC34A2-ROS1)-to evaluate the antiproliferative effects of submicromolar concentrations of the multitargeted TKIs imatinib, sorafenib, erlotinib, and crizotinib.",0.23626393551612898,"We selected <span class=""disease"" id=""22617245-3-12-17"">NSCLC</span> cell lines--A549 (KRAS G12S), NCI-H3255 (EGFR L858R), NCI-H3122 (<span class=""gene"" id=""22617245-3-83-87"">EML4</span>-ALK E13;A20), and HCC78 (SLC34A2-ROS1)-to evaluate the antiproliferative effects of submicromolar concentrations of the multitargeted TKIs imatinib, sorafenib, erlotinib, and crizotinib.",CTD_human
6,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,non-small cell lung cancer,27436,EML4,echinoderm microtubule-associated protein-like 4,CTD_human,21767331,Favorable response to crizotinib in three patients with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion-type oncogene-positive non-small cell lung cancer.,0.23626393551612898,"Favorable response to crizotinib in three patients with <span class=""gene"" id=""21767331-0-56-104"">echinoderm microtubule-associated protein-like 4</span>-anaplastic lymphoma kinase fusion-type oncogene-positive <span class=""disease"" id=""21767331-0-162-188"">non-small cell lung cancer</span>.",CTD_human
2,0,Biomarker,C0152013,Adenocarcinoma of lung (disorder),disease,Adenocarcinoma of the lung,27436,EML4,echinoderm microtubule-associated protein like 4,CTD_human,22999080,Adenocarcinoma of the lung with miliary brain and pulmonary metastases with echinoderm microtubule-associated protein like 4-anaplastic lymphoma kinase translocation treated with crizotinib: a case report.,0.205769262468475,"<span class=""disease"" id=""22999080-0-0-26"">Adenocarcinoma of the lung</span> with miliary brain and pulmonary metastases with <span class=""gene"" id=""22999080-0-76-124"">echinoderm microtubule-associated protein like 4</span>-anaplastic lymphoma kinase translocation treated with crizotinib: a case report.",CTD_human
2,0,Biomarker,C0152013,Adenocarcinoma of lung (disorder),disease,of lung adenocarcinoma,27436,EML4,EML4,CTD_human,22980554,"EML4-ALK fusion gene, is found in 3 to 5 % of lung adenocarcinoma and can be targeted by tyrosine-kinase inhibitor (TKI) with impressive therapeutic results.",0.205769262468475,"<span class=""gene"" id=""22980554-1-0-4"">EML4</span>-ALK fusion gene, is found in 3 to 5 % <span class=""disease"" id=""22980554-1-43-65"">of lung adenocarcinoma</span> and can be targeted by tyrosine-kinase inhibitor (TKI) with impressive therapeutic results.",CTD_human
1,0,Biomarker,C0027794,Neural Tube Defects,group,neural tube defect,27443,CECR2,Cecr2,CTD_human,15640247,"Mice homozygous for the Cecr2 genetrap-induced mutation show a high penetrance of the neural tube defect exencephaly, the human equivalent of anencephaly, in a strain-dependent fashion.",0.20082418035263896,"Mice homozygous for the <span class=""gene"" id=""15640247-6-24-29"">Cecr2</span> genetrap-induced mutation show a high penetrance of the <span class=""disease"" id=""15640247-6-86-104"">neural tube defect</span> exencephaly, the human equivalent of anencephaly, in a strain-dependent fashion.",CTD_human
7,26,Biomarker,C0751748,Nonketotic Hyperglycinemia,disease,nonketotic hyperglycinemia,275,AMT,AMT,CTD_human,16450403,"Comprehensive mutation analysis of GLDC, AMT, and GCSH in nonketotic hyperglycinemia.",0.40433011601278,"Comprehensive mutation analysis of GLDC, <span class=""gene"" id=""16450403-0-41-44"">AMT</span>, and GCSH in <span class=""disease"" id=""16450403-0-58-84"">nonketotic hyperglycinemia</span>.",CTD_human;UNIPROT
1,0,Biomarker,C0019151,Hepatic Encephalopathy,disease,portal-systemic encephalopathy,2752,GLUL,glutamine synthetase,CTD_human,10564534,"In portal-systemic encephalopathy resulting from chronic liver failure, astrocytes manifest altered expression of several key proteins and enzymes including monoamine oxidase B, glutamine synthetase, and the so-called peripheral-type benzodiazepine receptors.",0.2,"In <span class=""disease"" id=""10564534-5-3-33"">portal-systemic encephalopathy</span> resulting from chronic liver failure, astrocytes manifest altered expression of several key proteins and enzymes including monoamine oxidase B, <span class=""gene"" id=""10564534-5-178-198"">glutamine synthetase</span>, and the so-called peripheral-type benzodiazepine receptors.",CTD_human
1,2,Biomarker,C1864910,"Glutamine deficiency, congenital",disease,Congenital glutamine deficiency,2752,GLUL,glutamine synthetase,CTD_human,16267323,Congenital glutamine deficiency with glutamine synthetase mutations.,0.600549453568426,"<span class=""disease"" id=""16267323-0-0-31"">Congenital glutamine deficiency</span> with <span class=""gene"" id=""16267323-0-37-57"">glutamine synthetase</span> mutations.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0025202,melanoma,disease,melanoma,2767,GNA11,GNA11,CTD_human,23432625,"The mutations, such as those in NRAS, BRAF, GNAQ and GNA11, promote the growth of melanoma cells in most part through the mitogen-activated protein kinase (MAPK) pathway.",0.20735211063912398,"The mutations, such as those in NRAS, BRAF, GNAQ and <span class=""gene"" id=""23432625-2-53-58"">GNA11</span>, promote the growth of <span class=""disease"" id=""23432625-2-82-90"">melanoma</span> cells in most part through the mitogen-activated protein kinase (MAPK) pathway.",CTD_human
3,0,Biomarker,C0220633,Uveal melanoma,disease,uveal melanoma,2767,GNA11,GNA11,CTD_human,22733540,Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner.,0.40824180352639294,"Combination small molecule MEK and PI3K inhibition enhances <span class=""disease"" id=""22733540-0-60-74"">uveal melanoma</span> cell death in a mutant GNAQ- and <span class=""gene"" id=""22733540-0-108-113"">GNA11</span>-dependent manner.",CTD_human;ORPHANET
3,0,Biomarker,C0220633,Uveal melanoma,disease,UM,2767,GNA11,Gna11,CTD_human,26397223,"In addition, administration of JQ1 to mouse xenograft models of Gnaq-mutant UM resulted in significant inhibition of tumor growth.Collectively, our results define BRD4 targeting as a novel therapeutic intervention against UM with Gnaq/Gna11 mutations.",0.40824180352639294,"In addition, administration of JQ1 to mouse xenograft models of Gnaq-mutant <span class=""disease"" id=""26397223-9-76-78"">UM</span> resulted in significant inhibition of tumor growth.Collectively, our results define BRD4 targeting as a novel therapeutic intervention against <span class=""disease"" id=""26397223-9-222-224"">UM</span> with Gnaq/<span class=""gene"" id=""26397223-9-235-240"">Gna11</span> mutations.",CTD_human;ORPHANET
3,0,Biomarker,C0220633,Uveal melanoma,disease,uveal melanoma,2767,GNA11,GNA11,CTD_human,27089179,"We analyzed genomics data from 136 uveal melanoma samples and found a recurrent mutation in CYSLTR2 (cysteinyl leukotriene receptor 2) encoding a p.Leu129Gln substitution in 4 of 9 samples that lacked mutations in GNAQ, GNA11, and PLCB4 but in 0 of 127 samples that harbored mutations in these genes.",0.40824180352639294,"We analyzed genomics data from 136 <span class=""disease"" id=""27089179-3-35-49"">uveal melanoma</span> samples and found a recurrent mutation in CYSLTR2 (cysteinyl leukotriene receptor 2) encoding a p.Leu129Gln substitution in 4 of 9 samples that lacked mutations in GNAQ, <span class=""gene"" id=""27089179-3-220-225"">GNA11</span>, and PLCB4 but in 0 of 127 samples that harbored mutations in these genes.",CTD_human;ORPHANET
1,0,Biomarker,C0025202,melanoma,disease,melanoma,2776,GNAQ,GNAQ,CTD_human,23432625,"The mutations, such as those in NRAS, BRAF, GNAQ and GNA11, promote the growth of melanoma cells in most part through the mitogen-activated protein kinase (MAPK) pathway.",0.21758083545801502,"The mutations, such as those in NRAS, BRAF, <span class=""gene"" id=""23432625-2-44-48"">GNAQ</span> and GNA11, promote the growth of <span class=""disease"" id=""23432625-2-82-90"">melanoma</span> cells in most part through the mitogen-activated protein kinase (MAPK) pathway.",CTD_human
2,1,Biomarker,C0038505,Sturge-Weber Syndrome,disease,Sturge-Weber syndrome,2776,GNAQ,GNAQ,CTD_human,23656586,Sturge-Weber syndrome and port-wine stains caused by somatic mutation in GNAQ.,0.6013736339210661,"<span class=""disease"" id=""23656586-0-0-21"">Sturge-Weber syndrome</span> and port-wine stains caused by somatic mutation in <span class=""gene"" id=""23656586-0-73-77"">GNAQ</span>.",CTD_human;ORPHANET;UNIPROT
3,0,Biomarker,C0220633,Uveal melanoma,disease,uveal melanoma,2776,GNAQ,GNAQ,CTD_human,22733540,Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner.,0.41016489101588505,"Combination small molecule MEK and PI3K inhibition enhances <span class=""disease"" id=""22733540-0-60-74"">uveal melanoma</span> cell death in a mutant <span class=""gene"" id=""22733540-0-98-102"">GNAQ</span>- and GNA11-dependent manner.",CTD_human;ORPHANET
3,0,Biomarker,C0220633,Uveal melanoma,disease,uveal melanoma,2776,GNAQ,GNAQ,CTD_human,27089179,"We analyzed genomics data from 136 uveal melanoma samples and found a recurrent mutation in CYSLTR2 (cysteinyl leukotriene receptor 2) encoding a p.Leu129Gln substitution in 4 of 9 samples that lacked mutations in GNAQ, GNA11, and PLCB4 but in 0 of 127 samples that harbored mutations in these genes.",0.41016489101588505,"We analyzed genomics data from 136 <span class=""disease"" id=""27089179-3-35-49"">uveal melanoma</span> samples and found a recurrent mutation in CYSLTR2 (cysteinyl leukotriene receptor 2) encoding a p.Leu129Gln substitution in 4 of 9 samples that lacked mutations in <span class=""gene"" id=""27089179-3-214-218"">GNAQ</span>, GNA11, and PLCB4 but in 0 of 127 samples that harbored mutations in these genes.",CTD_human;ORPHANET
1,0,Biomarker,C0235752,Port-Wine Stain,disease,port-wine stains,2776,GNAQ,GNAQ,CTD_human,23656586,Sturge-Weber syndrome and port-wine stains caused by somatic mutation in GNAQ.,0.600549453568426,"Sturge-Weber syndrome and <span class=""disease"" id=""23656586-0-26-42"">port-wine stains</span> caused by somatic mutation in <span class=""gene"" id=""23656586-0-73-77"">GNAQ</span>.",CTD_human;HPO;ORPHANET
1,0,Biomarker,C0001206,Acromegaly,disease,acromegaly,2778,GNAS,GNAS1,CTD_human,11254676,Imprinting of the G(s)alpha gene GNAS1 in the pathogenesis of acromegaly.,0.4010989071368521,"Imprinting of the G(s)alpha gene <span class=""gene"" id=""11254676-0-33-38"">GNAS1</span> in the pathogenesis of <span class=""disease"" id=""11254676-0-62-72"">acromegaly</span>.",CTD_human;HPO
1,0,Biomarker,C0027819,Neuroblastoma,disease,neuroblastoma,2778,GNAS,NESP55,CTD_human,20862257,"The data confirms that chronic tumor hypoxia is a key microenvironmental factor for neuroblastoma cell differentiation, causing induction of chromaffin features and NESP55 provides a reliable marker for this neuronal to neuroendocrine transition.",0.20054945356842604,"The data confirms that chronic tumor hypoxia is a key microenvironmental factor for <span class=""disease"" id=""20862257-11-84-97"">neuroblastoma</span> cell differentiation, causing induction of chromaffin features and <span class=""gene"" id=""20862257-11-165-171"">NESP55</span> provides a reliable marker for this neuronal to neuroendocrine transition.",CTD_human
1,0,Biomarker,C0028754,Obesity,disease,obesity,2778,GNAS,GNAS,CTD_human,17062894,The CC genotype of the GNAS T393C polymorphism is associated with obesity and insulin resistance in women with polycystic ovary syndrome.,0.401923087489492,"The CC genotype of the <span class=""gene"" id=""17062894-0-23-27"">GNAS</span> T393C polymorphism is associated with <span class=""disease"" id=""17062894-0-66-73"">obesity</span> and insulin resistance in women with polycystic ovary syndrome.",CTD_human;HPO
4,0,Biomarker,C2931404,Albright's hereditary osteodystrophy,disease,albright hereditary osteodystrophy,2778,GNAS,GNAS,CTD_human,17299070,"A disruptive mutation in exon 3 of the GNAS gene with albright hereditary osteodystrophy, normocalcemic pseudohypoparathyroidism, and selective long transcript variant Gsalpha-L deficiency.",0.21916536236028697,"A disruptive mutation in exon 3 of the <span class=""gene"" id=""17299070-0-39-43"">GNAS</span> gene with <span class=""disease"" id=""17299070-0-54-88"">albright hereditary osteodystrophy</span>, normocalcemic pseudohypoparathyroidism, and selective long transcript variant Gsalpha-L deficiency.",CTD_human
1,0,Biomarker,C2932715,Pseudohypoparathyroidism Type 1B,disease,PHP-1b,2778,GNAS,GNAS,CTD_human,21836370,We designed two primer pairs specific for the methylated and unmethylated alleles and evaluated the methylation status of GNAS exon A/B in samples from PHP-1b patients and normal controls.,0.401923087489492,"We designed two primer pairs specific for the methylated and unmethylated alleles and evaluated the methylation status of <span class=""gene"" id=""21836370-3-122-126"">GNAS</span> exon A/B in samples from <span class=""disease"" id=""21836370-3-152-158"">PHP-1b</span> patients and normal controls.",CTD_human;ORPHANET
1,0,Biomarker,C0003469,Anxiety Disorders,group,anxiety,2782,GNB1,GNB1,CTD_human,22113448,"Glyoxylase 1 (GLO1) and guanine nucleotide-binding protein 1 (GNB1) mostly account for baseline anxiety-like and depressive-like behavior, indicating a common biological link between depression and anxiety.",0.2,"Glyoxylase 1 (GLO1) and guanine nucleotide-binding protein 1 (<span class=""gene"" id=""22113448-4-62-66"">GNB1</span>) mostly account for baseline <span class=""disease"" id=""22113448-4-96-103"">anxiety</span>-like and depressive-like behavior, indicating a common biological link between depression and <span class=""disease"" id=""22113448-4-198-205"">anxiety</span>.",CTD_human
1,0,Biomarker,C0011581,Depressive disorder,disease,depression,2782,GNB1,GNB1,CTD_human,22113448,"Glyoxylase 1 (GLO1) and guanine nucleotide-binding protein 1 (GNB1) mostly account for baseline anxiety-like and depressive-like behavior, indicating a common biological link between depression and anxiety.",0.2,"Glyoxylase 1 (GLO1) and guanine nucleotide-binding protein 1 (<span class=""gene"" id=""22113448-4-62-66"">GNB1</span>) mostly account for baseline anxiety-like and depressive-like behavior, indicating a common biological link between <span class=""disease"" id=""22113448-4-183-193"">depression</span> and anxiety.",CTD_human
1,0,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,type 2 diabetes mellitus,2784,GNB3,GNB3,CTD_human,12511541,Our findings suggest an effect of GNB3 gene polymorphism on important phenotypic variations in type 2 diabetes mellitus.,0.229001011971399,"Our findings suggest an effect of <span class=""gene"" id=""12511541-10-34-38"">GNB3</span> gene polymorphism on important phenotypic variations in <span class=""disease"" id=""12511541-10-95-119"">type 2 diabetes mellitus</span>.",CTD_human
1,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,2796,GNRH1,LHRH,CTD_human,6350720,"In addition, intraventricular administration of TRH, LHRH or LH caused tachycardia, hypertension and a reduction in the epinephrine-induced reflex bradycardia.",0.2,"In addition, intraventricular administration of TRH, <span class=""gene"" id=""6350720-5-53-57"">LHRH</span> or LH caused tachycardia, <span class=""disease"" id=""6350720-5-84-96"">hypertension</span> and a reduction in the epinephrine-induced reflex bradycardia.",CTD_human
1,0,Biomarker,C0342384,Idiopathic hypogonadotropic hypogonadism,disease,IHH,2796,GNRH1,GNRH1,CTD_human,19535795,"We identified a homozygous GNRH1 frameshift mutation, an insertion of an adenine at nucleotide position 18 (c.18-19insA), in the sequence encoding the N-terminal region of the signal peptide-containing protein precursor of gonadotropin-releasing hormone (prepro-GnRH) in a teenage brother and sister, who had normosmic IHH.",0.202197814273705,"We identified a homozygous <span class=""gene"" id=""19535795-2-27-32"">GNRH1</span> frameshift mutation, an insertion of an adenine at nucleotide position 18 (c.18-19insA), in the sequence encoding the N-terminal region of the signal peptide-containing protein precursor of gonadotropin-releasing hormone (prepro-GnRH) in a teenage brother and sister, who had normosmic <span class=""disease"" id=""19535795-2-319-322"">IHH</span>.",CTD_human
1,0,Biomarker,C0013295,Duodenal Ulcer,disease,duodenal ulcer,28,ABO,ABO,CTD_human,22387998,The T allele of rs2294008 encodes a translation initiation codon upstream of the reported site and changes protein localization from the cytoplasm to the cell surface. rs505922 at ABO was also associated with duodenal ulcer in a recessive model (OR = 1.32; P = 1.15 × 10(-10)).,0.201098907136852,"The T allele of rs2294008 encodes a translation initiation codon upstream of the reported site and changes protein localization from the cytoplasm to the cell surface. rs505922 at <span class=""gene"" id=""22387998-3-180-183"">ABO</span> was also associated with <span class=""disease"" id=""22387998-3-209-223"">duodenal ulcer</span> in a recessive model (OR = 1.32; P = 1.15 &times; 10(-10)).",CTD_human
1,0,Biomarker,C0007137,Squamous cell carcinoma,disease,SCC,2810,SFN,stratifin,CTD_human,15274141,"At least, SCC antigen, G protein, glutathione S-transferase, manganese superoxide dismutase, annexins, voltage-dependent anion channel, cyclophilin A, stratifin and galectin 7 are candidates for targeted proteins.",0.20656473206648,"At least, <span class=""disease"" id=""15274141-8-10-13"">SCC</span> antigen, G protein, glutathione S-transferase, manganese superoxide dismutase, annexins, voltage-dependent anion channel, cyclophilin A, <span class=""gene"" id=""15274141-8-151-160"">stratifin</span> and galectin 7 are candidates for targeted proteins.",CTD_human
1,0,Biomarker,C0022548,Keloid,disease,KS,2810,SFN,stratifin,CTD_human,20128793,"Significant increases in expression of asporin, stratifin, galectin-1 and MIF were observed by Western blot analysis in KS.",0.2,"Significant increases in expression of asporin, <span class=""gene"" id=""20128793-7-48-57"">stratifin</span>, galectin-1 and MIF were observed by Western blot analysis in <span class=""disease"" id=""20128793-7-120-122"">KS</span>.",CTD_human
1,0,Biomarker,C0279626,Squamous cell carcinoma of esophagus,disease,ESCC,2810,SFN,SFN,CTD_human,21517111,"Among these identified proteins, 33 proteins including keratin 17 (KRT17), biliverdin reductase B (BLVRB), proteasome activator subunit 1 (PSME1), manganese superoxide dismutase (MnSOD), high-mobility group box-1(HMGB1), heat shock protein 70 (HSP70), peroxiredoxin (PRDX1), keratin 13 (KRT13), and so on were overexpressed, and 14 proteins including cystatin B (CSTB), tropomyosin 2 (TPM2), annexin 1 (ANX1), transgelin (TAGLN), keratin 19 (KRT19), stratifin (SFN), and so on were down-expressed in ESCC.",0.20054945356842604,"Among these identified proteins, 33 proteins including keratin 17 (KRT17), biliverdin reductase B (BLVRB), proteasome activator subunit 1 (PSME1), manganese superoxide dismutase (MnSOD), high-mobility group box-1(HMGB1), heat shock protein 70 (HSP70), peroxiredoxin (PRDX1), keratin 13 (KRT13), and so on were overexpressed, and 14 proteins including cystatin B (CSTB), tropomyosin 2 (TPM2), annexin 1 (ANX1), transgelin (TAGLN), keratin 19 (KRT19), <span class=""gene"" id=""21517111-5-450-459"">stratifin</span> (<span class=""gene"" id=""21517111-5-461-464"">SFN</span>), and so on were down-expressed in <span class=""disease"" id=""21517111-5-500-504"">ESCC</span>.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,2810,SFN,stratifin,CTD_human,21472284,"These identified proteins, which include stratifin (14-3-3), transgelin 2, heat-shock protein (HSP)70, HSP27, manganese superoxide dismutase, prohibitin, DJ1, ?-enolase, peroxiredoxin 6, aldo-keto reductase family member B10, phosphoglycerate kinase 1, ?-1-antitrypsin and nm23-H1, may play a role in the development of HCC.",0.200274726784213,"These identified proteins, which include <span class=""gene"" id=""21472284-9-41-50"">stratifin</span> (14-3-3), transgelin 2, heat-shock protein (HSP)70, HSP27, manganese superoxide dismutase, prohibitin, DJ1, &alpha;-enolase, peroxiredoxin 6, aldo-keto reductase family member B10, phosphoglycerate kinase 1, &alpha;-1-antitrypsin and nm23-H1, may play a role in the development of <span class=""disease"" id=""21472284-9-320-323"">HCC</span>.",CTD_human
1,0,Biomarker,C0040034,Thrombocytopenia,phenotype,thrombocytopenia,2812,GP1BB,GPIBB,CTD_human,15213848,"We describe a syndrome of thrombocytopenia, bleeding episodes, congenital heart disease and facial dysmorphism in a newborn infant, and trace the cause to mutations on chromosome 22 that involve the gene for platelet glycoprotein Ib beta (GPIb beta, Human Genome Organisation gene symbol GPIBB), a critical component of the von Willebrand factor (vWF) receptor.",0.40481405704657597,"We describe a syndrome of <span class=""disease"" id=""15213848-1-26-42"">thrombocytopenia</span>, bleeding episodes, congenital heart disease and facial dysmorphism in a newborn infant, and trace the cause to mutations on chromosome 22 that involve the gene for platelet glycoprotein Ib beta (GPIb beta, Human Genome Organisation gene symbol <span class=""gene"" id=""15213848-1-288-293"">GPIBB</span>), a critical component of the von Willebrand factor (vWF) receptor.",CTD_human;HPO
1,0,Biomarker,C0002878,"Anemia, Hemolytic",disease,hemolytic anemia,2821,GPI,GPI,CTD_human,8822954,We report here two new cases of glucose phosphate isomerase (GPI) deficiency associated with hemolytic anemia and present the results of molecular analysis of the five Japanese GPI variants.,0.204655999954305,"We report here two new cases of <span class=""gene"" id=""8822954-1-32-59"">glucose phosphate isomerase</span> (<span class=""gene"" id=""8822954-1-61-64"">GPI</span>) deficiency associated with <span class=""disease"" id=""8822954-1-93-109"">hemolytic anemia</span> and present the results of molecular analysis of the five Japanese <span class=""gene"" id=""8822954-1-177-180"">GPI</span> variants.",CTD_human
1,0,Biomarker,C0038220,Status Epilepticus,disease,status epilepticus,2826,CCR10,CCR10,CTD_human,17181556,"CCR7, CCR8, CCR9 and CCR10 in the mouse hippocampal CA1 area and the dentate gyrus during and after pilocarpine-induced status epilepticus.",0.2,"CCR7, CCR8, CCR9 and <span class=""gene"" id=""17181556-0-21-26"">CCR10</span> in the mouse hippocampal CA1 area and the dentate gyrus during and after pilocarpine-induced <span class=""disease"" id=""17181556-0-120-138"">status epilepticus</span>.",CTD_human
1,0,Therapeutic,C1168401,Squamous cell carcinoma of the head and neck,disease,head and neck squamous cell carcinoma,282617,IFNL3,Interleukin-28B,CTD_human,21304406,Interleukin-28B acts synergistically with cisplatin to suppress the growth of head and neck squamous cell carcinoma.,0.2,"<span class=""gene"" id=""21304406-0-0-15"">Interleukin-28B</span> acts synergistically with cisplatin to suppress the growth of <span class=""disease"" id=""21304406-0-78-115"">head and neck squamous cell carcinoma</span>.",CTD_human
1,1,Biomarker,C0023343,Leprosy,disease,leprosy,283234,CCDC88B,CCDC88B,CTD_human,25642632,"Besides confirming all previously published loci, we discovered six new susceptibility loci, and further gene prioritization analysis of these loci implicated BATF3, CCDC88B and CIITA-SOCS1 as new susceptibility genes for leprosy.",0.200274726784213,"Besides confirming all previously published loci, we discovered six new susceptibility loci, and further gene prioritization analysis of these loci implicated BATF3, <span class=""gene"" id=""25642632-4-166-173"">CCDC88B</span> and CIITA-SOCS1 as new susceptibility genes for <span class=""disease"" id=""25642632-4-222-229"">leprosy</span>.",CTD_human
1,0,Biomarker,C0002171,Alopecia Areata,disease,alopecia areata,2833,CXCR3,Cxcr3,CTD_human,22358057,"Increased expression of Cxcr3 and its ligands, Cxcl9 and Cxcl10, during the development of alopecia areata in the mouse.",0.2,"Increased expression of <span class=""gene"" id=""22358057-0-24-29"">Cxcr3</span> and its ligands, Cxcl9 and Cxcl10, during the development of <span class=""disease"" id=""22358057-0-91-106"">alopecia areata</span> in the mouse.",CTD_human
1,0,Biomarker,C0004364,Autoimmune Diseases,group,autoimmune disease,2833,CXCR3,CXCR3,CTD_human,12517959,"The CXCR3 chemokine receptor, a member of the CXCR family, has been linked to a pathological role in autoimmune disease, inflammatory disease, allograft rejection, and ischemia.",0.201098907136852,"The <span class=""gene"" id=""12517959-1-4-9"">CXCR3</span> chemokine receptor, a member of the CXCR family, has been linked to a pathological role in <span class=""disease"" id=""12517959-1-101-119"">autoimmune disease</span>, inflammatory disease, allograft rejection, and ischemia.",CTD_human
1,0,Biomarker,C0017658,Glomerulonephritis,disease,glomerulonephritis,2833,CXCR3,CXCR3,CTD_human,12517959,"In the kidney, expression of the CXCR3 receptor and its ligands is up-regulated in states of glomerulonephritis and in allograft rejection, but little is known about the expression and functional role the CXCR3 receptor might play.",0.2,"In the kidney, expression of the <span class=""gene"" id=""12517959-2-33-38"">CXCR3</span> receptor and its ligands is up-regulated in states of <span class=""disease"" id=""12517959-2-93-111"">glomerulonephritis</span> and in allograft rejection, but little is known about the expression and functional role the <span class=""gene"" id=""12517959-2-205-210"">CXCR3</span> receptor might play.",CTD_human
1,0,Therapeutic,C0243026,Sepsis,disease,sepsis,284,ANGPT1,Angiopoietin-1,CTD_human,16005988,Angiopoietin-1 increases arteriolar vasoconstriction to phenylephrine during sepsis.,0.203557092817453,"<span class=""gene"" id=""16005988-0-0-14"">Angiopoietin-1</span> increases arteriolar vasoconstriction to phenylephrine during <span class=""disease"" id=""16005988-0-77-83"">sepsis</span>.",CTD_human
2,0,Biomarker,C3714756,Intellectual Disability,group,intellectual disability,284058,KANSL1,KANSL1,CTD_human,22544363,"We show that haploinsufficiency of KANSL1 is sufficient to cause the 17q21.31 microdeletion syndrome, a multisystem disorder characterized by intellectual disability, hypotonia and distinctive facial features.",0.20082418035263896,"We show that haploinsufficiency of <span class=""gene"" id=""22544363-1-35-41"">KANSL1</span> is sufficient to cause the 17q21.31 microdeletion syndrome, a multisystem disorder characterized by <span class=""disease"" id=""22544363-1-142-165"">intellectual disability</span>, hypotonia and distinctive facial features.",CTD_human
1,0,Biomarker,C0015695,Fatty Liver,disease,hepatic steatosis,284111,SLC13A5,mINDY,CTD_human,26303333,AhR-dependent induction of the mINDY gene might contribute to the development of hepatic steatosis.,0.200274726784213,"AhR-dependent induction of the <span class=""gene"" id=""26303333-11-31-36"">mINDY</span> gene might contribute to the development of <span class=""disease"" id=""26303333-11-81-98"">hepatic steatosis</span>.",CTD_human
1,0,Biomarker,C0011615,"Dermatitis, Atopic",disease,atopic dermatitis,284382,ACTL9,ACTL9,CTD_human,23042114,"We also replicated the associations of the FLG, C11orf30, TMEM232-SLC25A46, TNFRSF6B-ZGPAT, OVOL1, ACTL9 and KIF3A-IL13 loci that were previously reported in GWAS of European and Chinese individuals and a meta-analysis of GWAS for atopic dermatitis.",0.20054945356842604,"We also replicated the associations of the FLG, C11orf30, TMEM232-SLC25A46, TNFRSF6B-ZGPAT, OVOL1, <span class=""gene"" id=""23042114-3-99-104"">ACTL9</span> and KIF3A-IL13 loci that were previously reported in GWAS of European and Chinese individuals and a meta-analysis of GWAS for <span class=""disease"" id=""23042114-3-231-248"">atopic dermatitis</span>.",CTD_human
2,0,Biomarker,C0025958,Microcephaly,disease,microcephaly,284403,WDR62,WDR62,CTD_human,20890279,WDR62 is associated with the spindle pole and is mutated in human microcephaly.,0.201648360705279,"<span class=""gene"" id=""20890279-0-0-5"">WDR62</span> is associated with the spindle pole and is mutated in human <span class=""disease"" id=""20890279-0-66-78"">microcephaly</span>.",CTD_human
2,0,Biomarker,C0025958,Microcephaly,disease,microcephaly,284403,WDR62,WDR62,CTD_human,20890278,"Mutations in WDR62, encoding a centrosome-associated protein, cause microcephaly with simplified gyri and abnormal cortical architecture.",0.201648360705279,"Mutations in <span class=""gene"" id=""20890278-0-13-18"">WDR62</span>, encoding a centrosome-associated protein, cause <span class=""disease"" id=""20890278-0-68-80"">microcephaly</span> with simplified gyri and abnormal cortical architecture.",CTD_human
1,0,Biomarker,C0677886,Epithelial ovarian cancer,disease,EOC,284654,RSPO1,RSPO1,CTD_human,25581431,"Variants at 1p36 (nearest gene, WNT4), 4q26 (SYNPO2), 9q34.2 (ABO) and 17q11.2 (ATAD5) were associated with EOC risk, and at 1p34.3 (RSPO1) and 6p22.1 (GPX6) variants were specifically associated with the serous EOC subtype, all with P < 5 × 10(-8).",0.200274726784213,"Variants at 1p36 (nearest gene, WNT4), 4q26 (SYNPO2), 9q34.2 (ABO) and 17q11.2 (ATAD5) were associated with <span class=""disease"" id=""25581431-5-108-111"">EOC</span> risk, and at 1p34.3 (<span class=""gene"" id=""25581431-5-133-138"">RSPO1</span>) and 6p22.1 (GPX6) variants were specifically associated with the serous <span class=""disease"" id=""25581431-5-212-215"">EOC</span> subtype, all with P &lt; 5 &times; 10(-8).",CTD_human
3,21,Biomarker,C0268263,Multiple Sulfatase Deficiency Disease,disease,Multiple sulfatase deficiency,285362,SUMF1,SUMF1,CTD_human,17657823,Multiple sulfatase deficiency is due to hypomorphic mutations of the SUMF1 gene.,0.6835714481947701,"<span class=""disease"" id=""17657823-0-0-29"">Multiple sulfatase deficiency</span> is due to hypomorphic mutations of the <span class=""gene"" id=""17657823-0-69-74"">SUMF1</span> gene.",CTD_human;ORPHANET;UNIPROT
2,0,Biomarker,C0002452,Amelogenesis Imperfecta,disease,amelogenesis imperfecta,286077,FAM83H,FAM83H,CTD_human,19407157,Phenotypic variation in FAM83H-associated amelogenesis imperfecta.,0.205480180306945,"Phenotypic variation in <span class=""gene"" id=""19407157-0-24-30"">FAM83H</span>-associated <span class=""disease"" id=""19407157-0-42-65"">amelogenesis imperfecta</span>.",CTD_human
1,0,Biomarker,C0007222,Cardiovascular Diseases,group,cardiovascular disease,2869,GRK5,GRK5,CTD_human,26032411,The two most widely expressed GRKs (GRK2 and GRK5) play a role in cardiovascular disease and thus represent important targets for the development of novel therapeutic drugs.,0.200274726784213,"The two most widely expressed GRKs (GRK2 and <span class=""gene"" id=""26032411-2-45-49"">GRK5</span>) play a role in <span class=""disease"" id=""26032411-2-66-88"">cardiovascular disease</span> and thus represent important targets for the development of novel therapeutic drugs.",CTD_human
1,0,Biomarker,C0003873,Rheumatoid Arthritis,disease,RA,2870,GRK6,GRK-6,CTD_human,10094932,"Moreover, GRK-6 protein expression is reduced in RA patients whereas GRK-5 protein levels were unchanged.",0.200274726784213,"Moreover, <span class=""gene"" id=""10094932-5-10-15"">GRK-6</span> protein expression is reduced in <span class=""disease"" id=""10094932-5-49-51"">RA</span> patients whereas GRK-5 protein levels were unchanged.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,2876,GPX1,glutathione peroxidase 1,CTD_human,19195803,Genetic variant of glutathione peroxidase 1 in autism.,0.202681755307501,"Genetic variant of <span class=""gene"" id=""19195803-0-19-43"">glutathione peroxidase 1</span> in <span class=""disease"" id=""19195803-0-47-53"">autism</span>.",CTD_human
1,0,Biomarker,C0005695,Bladder Neoplasm,disease,bladder cancer,2876,GPX1,glutathione peroxidase 1,CTD_human,15247771,Increased risk of bladder cancer associated with a glutathione peroxidase 1 codon 198 variant.,0.205480180306945,"Increased risk of <span class=""disease"" id=""15247771-0-18-32"">bladder cancer</span> associated with a <span class=""gene"" id=""15247771-0-51-75"">glutathione peroxidase 1</span> codon 198 variant.",CTD_human
1,0,Biomarker,C0007137,Squamous cell carcinoma,disease,squamous cell carcinoma,2876,GPX1,GPx-1,CTD_human,15557674,"These data implicate GPx-1 in the development of squamous cell carcinoma the head and neck and suggest that allelic loss of this gene, or one tightly linked to it, is an early event in the development of this type of malignancy.",0.20596412134074102,"These data implicate <span class=""gene"" id=""15557674-10-21-26"">GPx-1</span> in the development of <span class=""disease"" id=""15557674-10-49-72"">squamous cell carcinoma</span> the head and neck and suggest that allelic loss of this gene, or one tightly linked to it, is an early event in the development of this type of malignancy.",CTD_human
1,0,Biomarker,C0007193,"Cardiomyopathy, Dilated",group,dilated cardiomyopathy,2876,GPX1,glutathione peroxidase-1,CTD_human,18940188,Interaction of glutathione peroxidase-1 and selenium in endemic dilated cardiomyopathy.,0.203231208875927,"Interaction of <span class=""gene"" id=""18940188-0-15-39"">glutathione peroxidase-1</span> and selenium in endemic <span class=""disease"" id=""18940188-0-64-86"">dilated cardiomyopathy</span>.",CTD_human
2,0,Biomarker,C0020459,Hyperinsulinism,disease,hyperinsulinaemia,2876,GPX1,glutathione peroxidase-1,CTD_human,18560803,Molecular mechanisms for hyperinsulinaemia induced by overproduction of selenium-dependent glutathione peroxidase-1 in mice.,0.200274726784213,"Molecular mechanisms for <span class=""disease"" id=""18560803-0-25-42"">hyperinsulinaemia</span> induced by overproduction of selenium-dependent <span class=""gene"" id=""18560803-0-91-115"">glutathione peroxidase-1</span> in mice.",CTD_human
1,0,Biomarker,C0020550,Hyperthyroidism,disease,hyperthyroid,2876,GPX1,GPx1,CTD_human,19914224,"Translated products of AOGs showed differential expression in the liver of hyperthyroid rats, where Cu/Zn SOD (SOD1), CAT and GR were decreased in contrast to Mn SOD (SOD2) and GPx1.",0.28,"Translated products of AOGs showed differential expression in the liver of <span class=""disease"" id=""19914224-6-75-87"">hyperthyroid</span> rats, where Cu/Zn SOD (SOD1), CAT and GR were decreased in contrast to Mn SOD (SOD2) and <span class=""gene"" id=""19914224-6-177-181"">GPx1</span>.",CTD_human
1,0,Biomarker,C0028754,Obesity,disease,obesity,2876,GPX1,cellular glutathione peroxidase,CTD_human,15184668,Development of insulin resistance and obesity in mice overexpressing cellular glutathione peroxidase.,0.20054945356842604,"Development of insulin resistance and <span class=""disease"" id=""15184668-0-38-45"">obesity</span> in mice overexpressing <span class=""gene"" id=""15184668-0-69-100"">cellular glutathione peroxidase</span>.",CTD_human
1,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastasis,2877,GPX2,glutathione peroxidase 2,CTD_human,23867582,Expression of glutathione peroxidase 2 is associated with not only early hepatocarcinogenesis but also late stage metastasis.,0.20054945356842604,"Expression of <span class=""gene"" id=""23867582-0-14-38"">glutathione peroxidase 2</span> is associated with not only early hepatocarcinogenesis but also late stage <span class=""disease"" id=""23867582-0-114-124"">metastasis</span>.",CTD_human
2,0,Biomarker,C0028754,Obesity,disease,obesity,2878,GPX3,Gpx3,CTD_human,19270708,"Perturbation of eight out of the nine genes, with Gas7, Me1 and Gpx3 being newly confirmed, resulted in significant changes in obesity-related traits.",0.20054945356842604,"Perturbation of eight out of the nine genes, with Gas7, Me1 and <span class=""gene"" id=""19270708-4-64-68"">Gpx3</span> being newly confirmed, resulted in significant changes in <span class=""disease"" id=""19270708-4-127-134"">obesity</span>-related traits.",CTD_human
1,0,Biomarker,C0010417,Cryptorchidism,disease,cryptorchidism,2879,GPX4,Phospholipid hydroperoxide glutathione peroxidase,CTD_human,26050606,Phospholipid hydroperoxide glutathione peroxidase is involved in the maintenance of male fertility under cryptorchidism in mice.,0.2,"<span class=""gene"" id=""26050606-0-0-49"">Phospholipid hydroperoxide glutathione peroxidase</span> is involved in the maintenance of male fertility under <span class=""disease"" id=""26050606-0-105-119"">cryptorchidism</span> in mice.",CTD_human
1,0,Biomarker,C0015695,Fatty Liver,disease,liver steatosis,2879,GPX4,GPx4,CTD_human,26042203,"Following HFHS diet, WT mice displayed moderate increases in 4-hydroxynonenal (HNE)-adducts and carbonyl stress, and a 1.5-fold increase in GPx4 enzyme in both liver and heart, while gpx4 haploinsufficient (GPx4(+/-)) mice had marked carbonyl stress in these organs accompanied by exacerbated glucose intolerance, dyslipidemia, and liver steatosis.",0.2,"Following HFHS diet, WT mice displayed moderate increases in 4-hydroxynonenal (HNE)-adducts and carbonyl stress, and a 1.5-fold increase in <span class=""gene"" id=""26042203-7-140-144"">GPx4</span> enzyme in both liver and heart, while <span class=""gene"" id=""26042203-7-183-187"">gpx4</span> haploinsufficient (<span class=""gene"" id=""26042203-7-207-211"">GPx4</span>(+/-)) mice had marked carbonyl stress in these organs accompanied by exacerbated glucose intolerance, dyslipidemia, and <span class=""disease"" id=""26042203-7-332-347"">liver steatosis</span>.",CTD_human
2,0,Biomarker,C0021364,Male infertility,phenotype,male infertility,2879,GPX4,glutathione peroxidase 4,CTD_human,19417079,Mitochondrial glutathione peroxidase 4 disruption causes male infertility.,0.200274726784213,"Mitochondrial <span class=""gene"" id=""19417079-0-14-38"">glutathione peroxidase 4</span> disruption causes <span class=""disease"" id=""19417079-0-57-73"">male infertility</span>.",CTD_human
1,0,Biomarker,C0271650,Impaired glucose tolerance,phenotype,glucose intolerance,2879,GPX4,GPx4,CTD_human,26042203,"Following HFHS diet, WT mice displayed moderate increases in 4-hydroxynonenal (HNE)-adducts and carbonyl stress, and a 1.5-fold increase in GPx4 enzyme in both liver and heart, while gpx4 haploinsufficient (GPx4(+/-)) mice had marked carbonyl stress in these organs accompanied by exacerbated glucose intolerance, dyslipidemia, and liver steatosis.",0.2,"Following HFHS diet, WT mice displayed moderate increases in 4-hydroxynonenal (HNE)-adducts and carbonyl stress, and a 1.5-fold increase in <span class=""gene"" id=""26042203-7-140-144"">GPx4</span> enzyme in both liver and heart, while <span class=""gene"" id=""26042203-7-183-187"">gpx4</span> haploinsufficient (<span class=""gene"" id=""26042203-7-207-211"">GPx4</span>(+/-)) mice had marked carbonyl stress in these organs accompanied by exacerbated <span class=""disease"" id=""26042203-7-293-312"">glucose intolerance</span>, dyslipidemia, and liver steatosis.",CTD_human
1,0,Biomarker,C1458155,Mammary Neoplasms,group,breast tumors,2879,GPX4,GPX4,CTD_human,17634480,"We found that the common allele is preferentially expressed in normal lymphocytes, normal breast, and breast tumors compared with the rare allele, but there were no differences in total levels of GPX4 mRNA across genotypes.",0.20328236603324,"We found that the common allele is preferentially expressed in normal lymphocytes, normal breast, and <span class=""disease"" id=""17634480-8-102-115"">breast tumors</span> compared with the rare allele, but there were no differences in total levels of <span class=""gene"" id=""17634480-8-196-200"">GPX4</span> mRNA across genotypes.",CTD_human
7,6,Biomarker,C0005586,Bipolar Disorder,disease,bipolar disorder,288,ANK3,ANK3,CTD_human,18711365,Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder.,0.41695319270926495,"Collaborative genome-wide association analysis supports a role for <span class=""gene"" id=""18711365-0-67-71"">ANK3</span> and CACNA1C in <span class=""disease"" id=""18711365-0-87-103"">bipolar disorder</span>.",CTD_human;PSYGENET
7,6,Biomarker,C0005586,Bipolar Disorder,disease,bipolar disorder,288,ANK3,ANK3,CTD_human,21926974,"In a joint analysis with a bipolar disorder sample (16,374 affected individuals and 14,044 controls), three loci reached genome-wide significance: CACNA1C (rs4765905, P = 7.0 × 10(-9)), ANK3 (rs10994359, P = 2.5 × 10(-8)) and the ITIH3-ITIH4 region (rs2239547, P = 7.8 × 10(-9)).",0.41695319270926495,"In a joint analysis with a <span class=""disease"" id=""21926974-5-27-43"">bipolar disorder</span> sample (16,374 affected individuals and 14,044 controls), three loci reached genome-wide significance: CACNA1C (rs4765905, P = 7.0 &times; 10(-9)), <span class=""gene"" id=""21926974-5-186-190"">ANK3</span> (rs10994359, P = 2.5 &times; 10(-8)) and the ITIH3-ITIH4 region (rs2239547, P = 7.8 &times; 10(-9)).",CTD_human;PSYGENET
1,0,Biomarker,C0033300,Progeria,disease,Hutchinson-Gilford progeria syndrome,288,ANK3,ANK3,CTD_human,27217151,"Of note, ANK3 was previously reported to be overexpressed in fibroblasts from patients with Hutchinson-Gilford progeria syndrome, a form of accelerated aging.",0.202732912464814,"Of note, <span class=""gene"" id=""27217151-19-9-13"">ANK3</span> was previously reported to be overexpressed in fibroblasts from patients with <span class=""disease"" id=""27217151-19-92-128"">Hutchinson-Gilford progeria syndrome</span>, a form of accelerated aging.",CTD_human
2,0,Therapeutic,C1458155,Mammary Neoplasms,group,breast tumors,2886,GRB7,GRB7,CTD_human,19075277,"mRNA levels of 10 BCAR genes (AKT1, AKT2, BCAR1, BCAR3, EGFR, ERBB2, GRB7, SRC, TLE3, and TRERF1) were measured in estrogen receptor-positive breast tumors using quantitative reverse-transcriptase polymerase chain reaction.",0.20328236603324,"mRNA levels of 10 BCAR genes (AKT1, AKT2, BCAR1, BCAR3, EGFR, ERBB2, <span class=""gene"" id=""19075277-3-69-73"">GRB7</span>, SRC, TLE3, and TRERF1) were measured in estrogen receptor-positive <span class=""disease"" id=""19075277-3-142-155"">breast tumors</span> using quantitative reverse-transcriptase polymerase chain reaction.",CTD_human
2,0,Biomarker,C1458155,Mammary Neoplasms,group,breast tumors,2886,GRB7,GRB7,CTD_human,19075277,"mRNA levels of 10 BCAR genes (AKT1, AKT2, BCAR1, BCAR3, EGFR, ERBB2, GRB7, SRC, TLE3, and TRERF1) were measured in estrogen receptor-positive breast tumors using quantitative reverse-transcriptase polymerase chain reaction.",0.20328236603324,"mRNA levels of 10 BCAR genes (AKT1, AKT2, BCAR1, BCAR3, EGFR, ERBB2, <span class=""gene"" id=""19075277-3-69-73"">GRB7</span>, SRC, TLE3, and TRERF1) were measured in estrogen receptor-positive <span class=""disease"" id=""19075277-3-142-155"">breast tumors</span> using quantitative reverse-transcriptase polymerase chain reaction.",CTD_human
1,0,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,T2D,2888,GRB14,GRB14,CTD_human,21874001,"In the combined analysis, we identified common genetic variants at six loci (GRB14, ST6GAL1, VPS26A, HMG20A, AP3S2 and HNF4A) newly associated with T2D (P = 4.1 × 10(-8) to P = 1.9 × 10(-11)).",0.20054945356842604,"In the combined analysis, we identified common genetic variants at six loci (<span class=""gene"" id=""21874001-4-77-82"">GRB14</span>, ST6GAL1, VPS26A, HMG20A, AP3S2 and HNF4A) newly associated with <span class=""disease"" id=""21874001-4-148-151"">T2D</span> (P = 4.1 &times; 10(-8) to P = 1.9 &times; 10(-11)).",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,2890,GRIA1,AMPA 1,CTD_human,11706102,"The mRNA levels of several genes were significantly increased in autism, including excitatory amino acid transporter 1 and glutamate receptor AMPA 1, two members of the glutamate system.",0.2,"The mRNA levels of several genes were significantly increased in <span class=""disease"" id=""11706102-7-65-71"">autism</span>, including excitatory amino acid transporter 1 and glutamate receptor <span class=""gene"" id=""11706102-7-142-148"">AMPA 1</span>, two members of the glutamate system.",CTD_human
2,0,Biomarker,C0424295,Hyperactive behavior,phenotype,hyperactivity,2890,GRIA1,GluR1,CTD_human,18171924,"Intrahippocampal infusion studies with the AMPA-specific inhibitor GYKI 52466 [4-(8-methyl-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepin-5-yl)-benzenamine hydrochloride], a GluR1-specific TAT-S845 peptide, showed that GluR1/2 was essential for the development of manic/hedonic-like behaviors such as amphetamine-induced hyperactivity.",0.2,"Intrahippocampal infusion studies with the AMPA-specific inhibitor GYKI 52466 [4-(8-methyl-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepin-5-yl)-benzenamine hydrochloride], a <span class=""gene"" id=""18171924-6-167-172"">GluR1</span>-specific TAT-S845 peptide, showed that <span class=""gene"" id=""18171924-6-212-217"">GluR1</span>/2 was essential for the development of manic/hedonic-like behaviors such as amphetamine-induced <span class=""disease"" id=""18171924-6-314-327"">hyperactivity</span>.",CTD_human
1,0,Biomarker,C0038220,Status Epilepticus,disease,SE,2891,GRIA2,GluR2,CTD_human,19222700,"However, GluR2 mRNAs bearing the long 3'-UTRs were shifted from untranslating mRNP complexes to ribosome-containing complexes after SE, pointing to a selective translational derepression of GluR2 mRNA mediated by the long 3'UTR.",0.200274726784213,"However, <span class=""gene"" id=""19222700-7-9-14"">GluR2</span> mRNAs bearing the long 3'-UTRs were shifted from untranslating mRNP complexes to ribosome-containing complexes after <span class=""disease"" id=""19222700-7-132-134"">SE</span>, pointing to a selective translational derepression of <span class=""gene"" id=""19222700-7-190-195"">GluR2</span> mRNA mediated by the long 3'UTR.",CTD_human
2,7,Biomarker,C0338451,Frontotemporal dementia,disease,frontotemporal dementia,2896,GRN,Progranulin,CTD_human,22028881,"Progranulin, a glycoprotein deficient in frontotemporal dementia, is a novel substrate of several protein disulfide isomerase family proteins.",0.444034474654419,"<span class=""gene"" id=""22028881-0-0-11"">Progranulin</span>, a glycoprotein deficient in <span class=""disease"" id=""22028881-0-41-64"">frontotemporal dementia</span>, is a novel substrate of several protein disulfide isomerase family proteins.",CTD_human;HPO
2,7,Biomarker,C0338451,Frontotemporal dementia,disease,frontotemporal dementia,2896,GRN,progranulin,CTD_human,21454553,Suberoylanilide hydroxamic acid (vorinostat) up-regulates progranulin transcription: rational therapeutic approach to frontotemporal dementia.,0.444034474654419,"Suberoylanilide hydroxamic acid (vorinostat) up-regulates <span class=""gene"" id=""21454553-0-58-69"">progranulin</span> transcription: rational therapeutic approach to <span class=""disease"" id=""21454553-0-118-141"">frontotemporal dementia</span>.",CTD_human;HPO
2,0,Biomarker,C0497327,Dementia,disease,dementia,2896,GRN,PGRN,CTD_human,17436289,It also demonstrates that half of the patients with a PGRN mutation in our series had no apparent family history of dementia.,0.27576396141208,"It also demonstrates that half of the patients with a <span class=""gene"" id=""17436289-10-54-58"">PGRN</span> mutation in our series had no apparent family history of <span class=""disease"" id=""17436289-10-116-124"">dementia</span>.",CTD_human
1,0,Biomarker,C0424295,Hyperactive behavior,phenotype,Hyperactivity,28964,GIT1,Git1,CTD_human,21499268,"Hyperactivity in Git1(-/-) mice is reversed by amphetamine and methylphenidate, psychostimulants commonly used to treat ADHD.",0.200274726784213,"<span class=""disease"" id=""21499268-5-0-13"">Hyperactivity</span> in <span class=""gene"" id=""21499268-5-17-21"">Git1</span>(-/-) mice is reversed by amphetamine and methylphenidate, psychostimulants commonly used to treat ADHD.",CTD_human
1,0,Biomarker,C1263846,Attention deficit hyperactivity disorder,disease,ADHD,28964,GIT1,Git1,CTD_human,21499268,"Hyperactivity in Git1(-/-) mice is reversed by amphetamine and methylphenidate, psychostimulants commonly used to treat ADHD.",0.28054945356842603,"Hyperactivity in <span class=""gene"" id=""21499268-5-17-21"">Git1</span>(-/-) mice is reversed by amphetamine and methylphenidate, psychostimulants commonly used to treat <span class=""disease"" id=""21499268-5-120-124"">ADHD</span>.",CTD_human
2,0,Biomarker,C0004352,Autistic Disorder,disease,autism,2898,GRIK2,GRIK2,CTD_human,20442744,"Our results strengthen the case for a more detailed study of the role of RELN and GRIK2 in autism susceptibility, as well as identifying two new potential candidate genes, MKL2 and SND1.",0.220299392545511,"Our results strengthen the case for a more detailed study of the role of RELN and <span class=""gene"" id=""20442744-10-82-87"">GRIK2</span> in <span class=""disease"" id=""20442744-10-91-97"">autism</span> susceptibility, as well as identifying two new potential candidate genes, MKL2 and SND1.",CTD_human
2,0,Biomarker,C0004352,Autistic Disorder,disease,autism,2898,GRIK2,glutamate receptor 6,CTD_human,11920157,Linkage and association of the glutamate receptor 6 gene with autism.,0.220299392545511,"Linkage and association of the <span class=""gene"" id=""11920157-0-31-51"">glutamate receptor 6</span> gene with <span class=""disease"" id=""11920157-0-62-68"">autism</span>.",CTD_human
3,0,Biomarker,C0005586,Bipolar Disorder,disease,bipolar disorder,2898,GRIK2,GRIK2,CTD_human,18332879,"The glutamate receptor 6 (GluR6 or GRIK2, one of the kainate receptors) gene resides in a genetic linkage region (6q21) associated with bipolar disorder (BPD), but its function in affective regulation is unknown.",0.400549453568426,"The <span class=""gene"" id=""18332879-1-4-24"">glutamate receptor 6</span> (<span class=""gene"" id=""18332879-1-26-31"">GluR6</span> or <span class=""gene"" id=""18332879-1-35-40"">GRIK2</span>, one of the kainate receptors) gene resides in a genetic linkage region (6q21) associated with <span class=""disease"" id=""18332879-1-136-152"">bipolar disorder</span> (BPD), but its function in affective regulation is unknown.",CTD_human;PSYGENET
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,2903,GRIN2A,GRIN2A,CTD_human,15830322,Candidate-gene screening and association analysis at the autism-susceptibility locus on chromosome 16p: evidence of association at GRIN2A and ABAT.,0.200274726784213,"Candidate-gene screening and association analysis at the <span class=""disease"" id=""15830322-0-57-63"">autism</span>-susceptibility locus on chromosome 16p: evidence of association at <span class=""gene"" id=""15830322-0-131-137"">GRIN2A</span> and ABAT.",CTD_human
2,0,Biomarker,C0014544,Epilepsy,disease,epilepsy,2903,GRIN2A,GRIN2A,CTD_human,23933818,GRIN2A mutations cause epilepsy-aphasia spectrum disorders.,0.40412090176319704,"<span class=""gene"" id=""23933818-0-0-6"">GRIN2A</span> mutations cause <span class=""disease"" id=""23933818-0-23-31"">epilepsy</span>-aphasia spectrum disorders.",CTD_human;HPO
2,0,Biomarker,C0014544,Epilepsy,disease,epilepsy,2903,GRIN2A,NR2A,CTD_human,20890276,"Either GRIN2B or GRIN2A, encoding the NMDA receptor subunits NR2B and NR2A, was found to be disrupted by chromosome translocation breakpoints in individuals with mental retardation and/or epilepsy.",0.40412090176319704,"Either GRIN2B or <span class=""gene"" id=""20890276-3-17-23"">GRIN2A</span>, encoding the NMDA receptor subunits NR2B and <span class=""gene"" id=""20890276-3-70-74"">NR2A</span>, was found to be disrupted by chromosome translocation breakpoints in individuals with mental retardation and/or <span class=""disease"" id=""20890276-3-188-196"">epilepsy</span>.",CTD_human;HPO
1,0,Biomarker,C0025202,melanoma,disease,melanoma,2903,GRIN2A,GRIN2A,CTD_human,21499247,Exome sequencing identifies GRIN2A as frequently mutated in melanoma.,0.20054945356842604,"Exome sequencing identifies <span class=""gene"" id=""21499247-0-28-34"">GRIN2A</span> as frequently mutated in <span class=""disease"" id=""21499247-0-60-68"">melanoma</span>.",CTD_human
1,0,Biomarker,C0037822,Speech Disorders,group,speech impairment,2903,GRIN2A,GluN2A,CTD_human,23933820,"Here we demonstrate that about 20% of cases of LKS, CSWSS and electroclinically atypical rolandic epilepsy often associated with speech impairment can have a genetic origin sustained by de novo or inherited mutations in the GRIN2A gene (encoding the N-methyl-D-aspartate (NMDA) glutamate receptor ?2 subunit, GluN2A).",0.200274726784213,"Here we demonstrate that about 20% of cases of <span class=""gene"" id=""23933820-4-47-50"">LKS</span>, CSWSS and electroclinically atypical rolandic epilepsy often associated with <span class=""disease"" id=""23933820-4-129-146"">speech impairment</span> can have a genetic origin sustained by de novo or inherited mutations in the <span class=""gene"" id=""23933820-4-224-230"">GRIN2A</span> gene (encoding the N-methyl-D-aspartate (NMDA) glutamate receptor &alpha;2 subunit, <span class=""gene"" id=""23933820-4-309-315"">GluN2A</span>).",CTD_human
1,0,Biomarker,C0282512,Landau-Kleffner Syndrome,disease,acquired epileptic aphasia,2903,GRIN2A,GRIN2A,CTD_human,23933820,GRIN2A mutations in acquired epileptic aphasia and related childhood focal epilepsies and encephalopathies with speech and language dysfunction.,0.400549453568426,"<span class=""gene"" id=""23933820-0-0-6"">GRIN2A</span> mutations in <span class=""disease"" id=""23933820-0-20-46"">acquired epileptic aphasia</span> and related childhood focal epilepsies and encephalopathies with speech and language dysfunction.",CTD_human;ORPHANET
1,1,Biomarker,C0014544,Epilepsy,disease,epileptic,2904,GRIN2B,NR2B,CTD_human,16407536,Tonic facilitation of glutamate release by presynaptic NR2B-containing NMDA receptors is increased in the entorhinal cortex of chronically epileptic rats.,0.40027472678421294,"Tonic facilitation of glutamate release by presynaptic <span class=""gene"" id=""16407536-0-55-59"">NR2B</span>-containing NMDA receptors is increased in the entorhinal cortex of chronically <span class=""disease"" id=""16407536-0-139-148"">epileptic</span> rats.",CTD_human;HPO
1,0,Biomarker,C0020429,Hyperalgesia,phenotype,hyperalgesia,2904,GRIN2B,NR2B,CTD_human,20042082,This study provides direct evidence that tyrosine phosphorylation of the NR2B at Tyr1472 in spinal dosal horn contributes to postoperative hyperalgesia induced by remifentanil and supports the potential therapeutic value of ketamine for improving postoperative hyperalgesia induced by remifentanil.,0.2,"This study provides direct evidence that tyrosine phosphorylation of the <span class=""gene"" id=""20042082-6-73-77"">NR2B</span> at Tyr1472 in spinal dosal horn contributes to postoperative <span class=""disease"" id=""20042082-6-139-151"">hyperalgesia</span> induced by remifentanil and supports the potential therapeutic value of ketamine for improving postoperative <span class=""disease"" id=""20042082-6-261-273"">hyperalgesia</span> induced by remifentanil.",CTD_human
1,1,Biomarker,C3714756,Intellectual Disability,group,mental retardation,2904,GRIN2B,GRIN2B,CTD_human,20890276,"Sequencing of GRIN2B in 468 individuals with mental retardation revealed four de novo mutations: a frameshift, a missense and two splice-site mutations.",0.40137363392106606,"Sequencing of <span class=""gene"" id=""20890276-4-14-20"">GRIN2B</span> in 468 individuals with <span class=""disease"" id=""20890276-4-45-63"">mental retardation</span> revealed four de novo mutations: a frameshift, a missense and two splice-site mutations.",CTD_human;HPO
1,0,Biomarker,C0030567,Parkinson Disease,disease,Parkinson's disease,29058,TMEM230,TMEM230,CTD_human,27270108,Identification of TMEM230 mutations in familial Parkinson's disease.,0.2,"Identification of <span class=""gene"" id=""27270108-0-18-25"">TMEM230</span> mutations in familial <span class=""disease"" id=""27270108-0-48-67"">Parkinson's disease</span>.",CTD_human
1,0,Biomarker,C0010701,Phyllodes Tumor,disease,phyllodes tumor,29072,SETD2,SETD2,CTD_human,26437033,"Second, phyllodes tumors exhibited mutations in FLNA, SETD2 and KMT2D, suggesting a role in driving phyllodes tumor development.",0.2,"Second, <span class=""disease"" id=""26437033-5-8-24"">phyllodes tumors</span> exhibited mutations in FLNA, <span class=""gene"" id=""26437033-5-54-59"">SETD2</span> and KMT2D, suggesting a role in driving <span class=""disease"" id=""26437033-5-100-115"">phyllodes tumor</span> development.",CTD_human
1,0,Biomarker,C0023418,leukemia,disease,leukemia,29072,SETD2,SETD2,CTD_human,24509477,Disruption of the SETD2-H3K36me3 pathway is a distinct epigenetic mechanism for leukemia development.,0.201373633921065,"Disruption of the <span class=""gene"" id=""24509477-7-18-23"">SETD2</span>-H3K36me3 pathway is a distinct epigenetic mechanism for <span class=""disease"" id=""24509477-7-80-88"">leukemia</span> development.",CTD_human
2,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,2908,NR3C1,glucocorticoid receptor,CTD_human,20659135,The glucocorticoid receptor is required for experimental adrenocorticotrophic hormone-induced hypertension in mice.,0.41510829440009706,"The <span class=""gene"" id=""20659135-0-4-27"">glucocorticoid receptor</span> is required for experimental adrenocorticotrophic hormone-induced <span class=""disease"" id=""20659135-0-94-106"">hypertension</span> in mice.",CTD_human;HPO
1,0,Biomarker,C0028840,Ocular Hypertension,disease,ocular hypertension,2908,NR3C1,glucocorticoid receptor,CTD_human,17563720,The variant N363S of glucocorticoid receptor in steroid-induced ocular hypertension in Hungarian patients treated with photorefractive keratectomy.,0.20328236603324,"The variant N363S of <span class=""gene"" id=""17563720-0-21-44"">glucocorticoid receptor</span> in steroid-induced <span class=""disease"" id=""17563720-0-64-83"">ocular hypertension</span> in Hungarian patients treated with photorefractive keratectomy.",CTD_human
2,0,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,2908,NR3C1,GR,CTD_human,21647420,"Moreover, significant reductions in Flk1 and GR protein levels were found in postmortem prefrontal cortex samples from schizophrenia subjects.",0.20816193561444604,"Moreover, significant reductions in Flk1 and <span class=""gene"" id=""21647420-10-45-47"">GR</span> protein levels were found in postmortem prefrontal cortex samples from <span class=""disease"" id=""21647420-10-119-132"">schizophrenia</span> subjects.",CTD_human
1,0,Biomarker,C0919267,ovarian neoplasm,disease,ovarian tumors,29086,BABAM1,MERIT40,CTD_human,20852633,"Expression analysis of candidate genes at this locus in ovarian tumors supported a role for the BRCA1-interacting gene C19orf62, also known as MERIT40, which contains rs8170, in EOC development.",0.200274726784213,"Expression analysis of candidate genes at this locus in <span class=""disease"" id=""20852633-5-56-70"">ovarian tumors</span> supported a role for the BRCA1-interacting gene <span class=""gene"" id=""20852633-5-119-127"">C19orf62</span>, also known as <span class=""gene"" id=""20852633-5-143-150"">MERIT40</span>, which contains rs8170, in EOC development.",CTD_human
1,0,Biomarker,C0152013,Adenocarcinoma of lung (disorder),disease,ADC,2909,ARHGAP35,ARHGAP35,CTD_human,27158780,"Lung ADCs lacking receptor tyrosine kinase-Ras-Raf pathway alterations had mutations in SOS1, VAV1, RASA1, and ARHGAP35.",0.200274726784213,"Lung <span class=""disease"" id=""27158780-5-5-8"">ADC</span>s lacking receptor tyrosine kinase-Ras-Raf pathway alterations had mutations in SOS1, VAV1, RASA1, and <span class=""gene"" id=""27158780-5-111-119"">ARHGAP35</span>.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,29091,STXBP6,AMISYN,CTD_human,20071347,"SCAMP5, NBEA and AMISYN: three candidate genes for autism involved in secretion of large dense-core vesicles.",0.200274726784213,"SCAMP5, NBEA and <span class=""gene"" id=""20071347-0-17-23"">AMISYN</span>: three candidate genes for <span class=""disease"" id=""20071347-0-51-57"">autism</span> involved in secretion of large dense-core vesicles.",CTD_human
1,0,Therapeutic,C0853897,Diabetic Cardiomyopathies,disease,diabetic cardiomyopathy,291,SLC25A4,ANT1,CTD_human,18945756,"Cardiomyocyte-restricted overexpression of ANT1 prevents the development of diabetic cardiomyopathy; therefore, accelerated ADP/ATP exchange could be a new promising target to treat diabetic cardiomyopathy.",0.2,"Cardiomyocyte-restricted overexpression of <span class=""gene"" id=""18945756-12-43-47"">ANT1</span> prevents the development of <span class=""disease"" id=""18945756-12-76-99"">diabetic cardiomyopathy</span>; therefore, accelerated ADP/ATP exchange could be a new promising target to treat <span class=""disease"" id=""18945756-12-182-205"">diabetic cardiomyopathy</span>.",CTD_human
1,0,Biomarker,C0021364,Male infertility,phenotype,male infertility,29102,DROSHA,DROSHA,CTD_human,22381205,"The results showed that variants of DICER1 and DROSHA may modify the risk of abnormal semen parameters, which could result in male infertility.",0.2,"The results showed that variants of DICER1 and <span class=""gene"" id=""22381205-9-47-53"">DROSHA</span> may modify the risk of abnormal semen parameters, which could result in <span class=""disease"" id=""22381205-9-126-142"">male infertility</span>.",CTD_human
1,0,Biomarker,C0001418,Adenocarcinoma,group,adenocarcinoma,29108,PYCARD,TMS1,CTD_human,16778195,"The incidence of ASC/TMS1 hypermethylation in sputum DNA fully mimics the tissue findings being present in only 2% (2 of 85) of high-risk, cancer-free smokers, 15% (3 of 18) of patients with stage I non-small-cell lung cancer (NSCLC), but 41% of patients with stage III NSCLC (18 of 44), including 56% (10 of 18) of those with adenocarcinoma.",0.201648360705279,"The incidence of <span class=""gene"" id=""16778195-7-17-20"">ASC</span>/<span class=""gene"" id=""16778195-7-21-25"">TMS1</span> hypermethylation in sputum DNA fully mimics the tissue findings being present in only 2% (2 of 85) of high-risk, cancer-free smokers, 15% (3 of 18) of patients with stage I non-small-cell lung cancer (NSCLC), but 41% of patients with stage III NSCLC (18 of 44), including 56% (10 of 18) of those with <span class=""disease"" id=""16778195-7-327-341"">adenocarcinoma</span>.",CTD_human
1,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,NSCLC,29108,PYCARD,TMS1,CTD_human,16778195,"The incidence of ASC/TMS1 hypermethylation in sputum DNA fully mimics the tissue findings being present in only 2% (2 of 85) of high-risk, cancer-free smokers, 15% (3 of 18) of patients with stage I non-small-cell lung cancer (NSCLC), but 41% of patients with stage III NSCLC (18 of 44), including 56% (10 of 18) of those with adenocarcinoma.",0.201373633921065,"The incidence of <span class=""gene"" id=""16778195-7-17-20"">ASC</span>/<span class=""gene"" id=""16778195-7-21-25"">TMS1</span> hypermethylation in sputum DNA fully mimics the tissue findings being present in only 2% (2 of 85) of high-risk, cancer-free smokers, 15% (3 of 18) of patients with stage I non-small-cell lung cancer (<span class=""disease"" id=""16778195-7-227-232"">NSCLC</span>), but 41% of patients with stage III NSCLC (18 of 44), including 56% (10 of 18) of those with adenocarcinoma.",CTD_human
1,0,Biomarker,C0007137,Squamous cell carcinoma,disease,squamous cell carcinomas,29108,PYCARD,TMS1,CTD_human,16778195,"Hypermethylation of ASC/TMS1 is also associated with invasive cancers (41 of 152 or 27.0% of all lung cancer types) with variation in incidence between histopathologic types including 32.1% (26 of 81) of adenocarcinomas, 13.2% (7 of 53) of squamous cell carcinomas, 38.5% (5 of 13) of large-cell carcinomas, and 60% (3 of 5) of small-cell lung cancers.",0.200274726784213,"Hypermethylation of <span class=""gene"" id=""16778195-5-20-23"">ASC</span>/<span class=""gene"" id=""16778195-5-24-28"">TMS1</span> is also associated with invasive cancers (41 of 152 or 27.0% of all lung cancer types) with variation in incidence between histopathologic types including 32.1% (26 of 81) of adenocarcinomas, 13.2% (7 of 53) of <span class=""disease"" id=""16778195-5-240-264"">squamous cell carcinomas</span>, 38.5% (5 of 13) of large-cell carcinomas, and 60% (3 of 5) of small-cell lung cancers.",CTD_human
1,0,Biomarker,C0206704,"Carcinoma, Large Cell",disease,large-cell carcinomas,29108,PYCARD,TMS1,CTD_human,16778195,"Hypermethylation of ASC/TMS1 is also associated with invasive cancers (41 of 152 or 27.0% of all lung cancer types) with variation in incidence between histopathologic types including 32.1% (26 of 81) of adenocarcinomas, 13.2% (7 of 53) of squamous cell carcinomas, 38.5% (5 of 13) of large-cell carcinomas, and 60% (3 of 5) of small-cell lung cancers.",0.200274726784213,"Hypermethylation of <span class=""gene"" id=""16778195-5-20-23"">ASC</span>/<span class=""gene"" id=""16778195-5-24-28"">TMS1</span> is also associated with invasive cancers (41 of 152 or 27.0% of all lung cancer types) with variation in incidence between histopathologic types including 32.1% (26 of 81) of adenocarcinomas, 13.2% (7 of 53) of squamous cell carcinomas, 38.5% (5 of 13) of <span class=""disease"" id=""16778195-5-285-306"">large-cell carcinomas</span>, and 60% (3 of 5) of small-cell lung cancers.",CTD_human
1,0,Biomarker,C0598608,Hyperhomocysteinemia,disease,hHcy,29108,PYCARD,ASC,CTD_human,22647887,"Pathologically, hHcys-associated albuminuria, foot process effacement of podocytes, loss of podocyte slit diaphragm molecules, and glomerulosclerosis at the late stage were significantly improved by local ASC gene silencing or by caspase 1 inhibition.",0.2,"Pathologically, <span class=""disease"" id=""22647887-7-16-20"">hHcy</span>s-associated albuminuria, foot process effacement of podocytes, loss of podocyte slit diaphragm molecules, and glomerulosclerosis at the late stage were significantly improved by local <span class=""gene"" id=""22647887-7-205-208"">ASC</span> gene silencing or by caspase 1 inhibition.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,hepatocellular carcinoma,29108,PYCARD,TMS1,CTD_human,17471463,Transcriptional silencing of the TMS1/ASC tumour suppressor gene by an epigenetic mechanism in hepatocellular carcinoma cells.,0.20054945356842604,"Transcriptional silencing of the <span class=""gene"" id=""17471463-0-33-37"">TMS1</span>/ASC tumour suppressor gene by an epigenetic mechanism in <span class=""disease"" id=""17471463-0-95-119"">hepatocellular carcinoma</span> cells.",CTD_human
1,0,Biomarker,C0014544,Epilepsy,disease,epileptic,2911,GRM1,metabotropic glutamate receptor 1,CTD_human,19853022,Abnormal expressions of glutamate transporters and metabotropic glutamate receptor 1 in the spontaneously epileptic rat hippocampus.,0.2,"Abnormal expressions of glutamate transporters and <span class=""gene"" id=""19853022-0-51-84"">metabotropic glutamate receptor 1</span> in the spontaneously <span class=""disease"" id=""19853022-0-106-115"">epileptic</span> rat hippocampus.",CTD_human
1,0,Biomarker,C0014556,"Epilepsy, Temporal Lobe",disease,TLE,2911,GRM1,mGluR1,CTD_human,15694259,"Here, we examine the transcription levels of mGluRs class I (mGluR1 and 5) and III (mGluR4 and 7) in experimental TLE and correlate differential mGluR subunit expression with mouse-strain-dependent susceptibility to TLE induced by pilocarpine.",0.28300763924902694,"Here, we examine the transcription levels of mGluRs class I (<span class=""gene"" id=""15694259-6-61-67"">mGluR1</span> and 5) and III (mGluR4 and 7) in experimental <span class=""disease"" id=""15694259-6-114-117"">TLE</span> and correlate differential mGluR subunit expression with mouse-strain-dependent susceptibility to <span class=""disease"" id=""15694259-6-216-219"">TLE</span> induced by pilocarpine.",CTD_human
2,0,Biomarker,C0038220,Status Epilepticus,disease,SE,2911,GRM1,mGluR1,CTD_human,17446080,Status epilepticus (SE) was induced in (a) mice overexpressing mGluR1-EGFP and (b) mice deficient for mGluR4 (mGluR4 KO) as well as littermate controls.,0.2,"<span class=""disease"" id=""17446080-5-0-18"">Status epilepticus</span> (<span class=""disease"" id=""17446080-5-20-22"">SE</span>) was induced in (a) mice overexpressing <span class=""gene"" id=""17446080-5-63-69"">mGluR1</span>-EGFP and (b) mice deficient for mGluR4 (mGluR4 KO) as well as littermate controls.",CTD_human
1,1,Biomarker,C0004096,Asthma,disease,asthma,29119,CTNNA3,CTNNA3,CTD_human,19187332,Alpha-T-catenin (CTNNA3) gene was identified as a risk variant for toluene diisocyanate-induced asthma by genome-wide association analysis.,0.201373633921065,"<span class=""gene"" id=""19187332-0-0-15"">Alpha-T-catenin</span> (<span class=""gene"" id=""19187332-0-17-23"">CTNNA3</span>) gene was identified as a risk variant for toluene diisocyanate-induced <span class=""disease"" id=""19187332-0-96-102"">asthma</span> by genome-wide association analysis.",CTD_human
1,0,Biomarker,C0014556,"Epilepsy, Temporal Lobe",disease,temporal lobe epilepsy,2912,GRM2,mGlu2,CTD_human,18804094,"These data indicate a long-lasting impairment of mGlu2/3 expression that may contribute to abnormal presynaptic plasticity, exaggerate glutamate release and hyperexcitability in temporal lobe epilepsy.",0.200274726784213,"These data indicate a long-lasting impairment of <span class=""gene"" id=""18804094-8-49-54"">mGlu2</span>/3 expression that may contribute to abnormal presynaptic plasticity, exaggerate glutamate release and hyperexcitability in <span class=""disease"" id=""18804094-8-178-200"">temporal lobe epilepsy</span>.",CTD_human
1,0,Biomarker,C0036341,Schizophrenia,disease,Schizophrenia,2912,GRM2,mGluR2,CTD_human,18923069,"Schizophrenia subjects showed significant decreases in mRNA levels of GAD(67), GAD(65), GAT-1, mGluR2, and neuronal nitric oxide synthase.",0.21111841770616,"<span class=""disease"" id=""18923069-7-0-13"">Schizophrenia</span> subjects showed significant decreases in mRNA levels of GAD(67), GAD(65), GAT-1, <span class=""gene"" id=""18923069-7-95-101"">mGluR2</span>, and neuronal nitric oxide synthase.",CTD_human
1,0,Biomarker,C1510586,Autism Spectrum Disorders,disease,ASD,29123,ANKRD11,ANKRD11,CTD_human,18252227,"Notwithstanding complexities, our results further implicate the SHANK3-NLGN4-NRXN1 postsynaptic density genes and also identify novel loci at DPP6-DPP10-PCDH9 (synapse complex), ANKRD11, DPYD, PTCHD1, 15q24, among others, for a role in ASD susceptibility.",0.20082418035263896,"Notwithstanding complexities, our results further implicate the SHANK3-NLGN4-NRXN1 postsynaptic density genes and also identify novel loci at DPP6-DPP10-PCDH9 (synapse complex), <span class=""gene"" id=""18252227-8-178-185"">ANKRD11</span>, DPYD, PTCHD1, 15q24, among others, for a role in <span class=""disease"" id=""18252227-8-236-239"">ASD</span> susceptibility.",CTD_human
2,0,Biomarker,C0025202,melanoma,disease,melanoma,2913,GRM3,GRM3,CTD_human,21946352,Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma.,0.200274726784213,"Exon capture analysis of G protein-coupled receptors identifies activating mutations in <span class=""gene"" id=""21946352-0-88-92"">GRM3</span> in <span class=""disease"" id=""21946352-0-96-104"">melanoma</span>.",CTD_human
1,1,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,2913,GRM3,GRM3,CTD_human,18256595,Expression of a GRM3 splice variant is increased in the dorsolateral prefrontal cortex of individuals carrying a schizophrenia risk SNP.,0.263370718694451,"Expression of a <span class=""gene"" id=""18256595-0-16-20"">GRM3</span> splice variant is increased in the dorsolateral prefrontal cortex of individuals carrying a <span class=""disease"" id=""18256595-0-113-126"">schizophrenia</span> risk SNP.",CTD_human
1,0,Biomarker,C0014556,"Epilepsy, Temporal Lobe",disease,TLE,2914,GRM4,mGluR4,CTD_human,15694259,"Here, we examine the transcription levels of mGluRs class I (mGluR1 and 5) and III (mGluR4 and 7) in experimental TLE and correlate differential mGluR subunit expression with mouse-strain-dependent susceptibility to TLE induced by pilocarpine.",0.2,"Here, we examine the transcription levels of mGluRs class I (mGluR1 and 5) and III (<span class=""gene"" id=""15694259-6-84-90"">mGluR4</span> and 7) in experimental <span class=""disease"" id=""15694259-6-114-117"">TLE</span> and correlate differential mGluR subunit expression with mouse-strain-dependent susceptibility to <span class=""disease"" id=""15694259-6-216-219"">TLE</span> induced by pilocarpine.",CTD_human
1,0,Biomarker,C0027796,Neuralgia,phenotype,neuropathic pain,2915,GRM5,mGluR5,CTD_human,19840219,Regulation of increased glutamatergic input to spinal dorsal horn neurons by mGluR5 in diabetic neuropathic pain.,0.2,"Regulation of increased glutamatergic input to spinal dorsal horn neurons by <span class=""gene"" id=""19840219-0-77-83"">mGluR5</span> in diabetic <span class=""disease"" id=""19840219-0-96-112"">neuropathic pain</span>.",CTD_human
2,0,Biomarker,C0038220,Status Epilepticus,disease,status epilepticus,2915,GRM5,mGluR5,CTD_human,18774262,mGluR5-PLCbeta4-PKCbeta2/PKCgamma pathways in hippocampal CA1 pyramidal neurons in pilocarpine model of status epilepticus in mGluR5+/+ mice.,0.2,"<span class=""gene"" id=""18774262-0-0-6"">mGluR5</span>-PLCbeta4-PKCbeta2/PKCgamma pathways in hippocampal CA1 pyramidal neurons in pilocarpine model of <span class=""disease"" id=""18774262-0-104-122"">status epilepticus</span> in <span class=""gene"" id=""18774262-0-126-132"">mGluR5</span>+/+ mice.",CTD_human
2,0,Biomarker,C0038220,Status Epilepticus,disease,status epilepticus,2915,GRM5,mGluR5,CTD_human,17634364,Loss of metabotropic glutamate receptor-dependent long-term depression via downregulation of mGluR5 after status epilepticus.,0.2,"Loss of metabotropic glutamate receptor-dependent long-term depression via downregulation of <span class=""gene"" id=""17634364-0-93-99"">mGluR5</span> after <span class=""disease"" id=""17634364-0-106-124"">status epilepticus</span>.",CTD_human
2,1,Biomarker,C1263846,Attention deficit hyperactivity disorder,disease,ADHD,2915,GRM5,GRM5,CTD_human,19546859,"A deletion within the glutamate receptor gene, GRM5, was found in an affected parent and all three affected offspring whose ADHD phenotypes closely resembled those of the GRM5 null mouse.",0.201373633921065,"A deletion within the glutamate receptor gene, <span class=""gene"" id=""19546859-6-47-51"">GRM5</span>, was found in an affected parent and all three affected offspring whose <span class=""disease"" id=""19546859-6-124-128"">ADHD</span> phenotypes closely resembled those of the <span class=""gene"" id=""19546859-6-171-175"">GRM5</span> null mouse.",CTD_human
1,0,Biomarker,C0003469,Anxiety Disorders,group,anxiety,2918,GRM8,mGluR8,CTD_human,17434465,These data provide a potential role for mGluR8 in anxiety and suggest that mGluR8 may not be a therapeutic target for schizophrenia.,0.200274726784213,"These data provide a potential role for <span class=""gene"" id=""17434465-8-40-46"">mGluR8</span> in <span class=""disease"" id=""17434465-8-50-57"">anxiety</span> and suggest that <span class=""gene"" id=""17434465-8-75-81"">mGluR8</span> may not be a therapeutic target for schizophrenia.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,2918,GRM8,metabotropic glutamate receptor 8,CTD_human,12676915,The metabotropic glutamate receptor 8 gene at 7q31: partial duplication and possible association with autism.,0.20541466777231498,"The <span class=""gene"" id=""12676915-0-4-37"">metabotropic glutamate receptor 8</span> gene at 7q31: partial duplication and possible association with <span class=""disease"" id=""12676915-0-102-108"">autism</span>.",CTD_human
1,0,Biomarker,C0014859,Esophageal Neoplasms,group,esophageal cancer,2920,CXCL2,CXCL2,CTD_human,21509778,"The analyses pointed out the potential importance of CXCL2, and monitoring CXCL2 with quantitative videomicroscopy indicated that its biologic activity was silenced in OE21 esophageal cancer cells.",0.200274726784213,"The analyses pointed out the potential importance of <span class=""gene"" id=""21509778-5-53-58"">CXCL2</span>, and monitoring <span class=""gene"" id=""21509778-5-75-80"">CXCL2</span> with quantitative videomicroscopy indicated that its biologic activity was silenced in OE21 <span class=""disease"" id=""21509778-5-173-190"">esophageal cancer</span> cells.",CTD_human
1,0,Biomarker,C0029408,Degenerative polyarthritis,disease,osteoarthritis,2920,CXCL2,CXCL2,CTD_human,15292528,"While these differences may represent differential behaviour of synovial fibroblasts in in vitro culture, these observations suggest that TFPI2, GRObeta (CXCL2), MnSOD and GCP-2 (CXCL6) may represent new targets for treatments specifically tailored to osteoarthritis.",0.20082418035263896,"While these differences may represent differential behaviour of synovial fibroblasts in in vitro culture, these observations suggest that TFPI2, GRObeta (<span class=""gene"" id=""15292528-12-154-159"">CXCL2</span>), MnSOD and GCP-2 (CXCL6) may represent new targets for treatments specifically tailored to <span class=""disease"" id=""15292528-12-252-266"">osteoarthritis</span>.",CTD_human
1,0,Therapeutic,C0002622,Amnesia,disease,memory loss,2922,GRP,gastrin-releasing peptide,CTD_human,11564462,Posttraining administration of gastrin-releasing peptide improves memory loss in scopolamine- and hypoxia-induced amnesic mice.,0.2,"Posttraining administration of <span class=""gene"" id=""11564462-0-31-56"">gastrin-releasing peptide</span> improves <span class=""disease"" id=""11564462-0-66-77"">memory loss</span> in scopolamine- and hypoxia-induced amnesic mice.",CTD_human
1,0,Biomarker,C0033578,Prostatic Neoplasms,group,prostate tumor,2925,GRPR,gastrin-releasing peptide receptor,CTD_human,17204703,Androgen-dependent expression of the gastrin-releasing peptide receptor in human prostate tumor xenografts.,0.203557092817453,"Androgen-dependent expression of the <span class=""gene"" id=""17204703-0-37-71"">gastrin-releasing peptide receptor</span> in human <span class=""disease"" id=""17204703-0-81-95"">prostate tumor</span> xenografts.",CTD_human
1,0,Biomarker,C0036341,Schizophrenia,disease,SZ,2931,GSK3A,GSK3A,CTD_human,16223876,"Implementing this systematic approach, we: (i) discovered 177 putative SZ risk genes in brain, 28 of which map to linked chromosomal loci; (ii) delineated six biological processes and 12 molecular functions that may be particularly disrupted in the illness; (iii) identified 123 putative SZ biomarkers in blood, 6 of which (BTG1, GSK3A, HLA-DRB1, HNRPA3, SELENBP1, and SFRS1) had corresponding differential expression in brain; (iv) verified the differential expression of the strongest candidate SZ biomarker (SELENBP1) in blood; and (v) demonstrated neuronal and glial expression of SELENBP1 protein in brain.",0.205363510615002,"Implementing this systematic approach, we: (i) discovered 177 putative <span class=""disease"" id=""16223876-4-71-73"">SZ</span> risk genes in brain, 28 of which map to linked chromosomal loci; (ii) delineated six biological processes and 12 molecular functions that may be particularly disrupted in the illness; (iii) identified 123 putative SZ biomarkers in blood, 6 of which (BTG1, <span class=""gene"" id=""16223876-4-330-335"">GSK3A</span>, HLA-DRB1, HNRPA3, SELENBP1, and SFRS1) had corresponding differential expression in brain; (iv) verified the differential expression of the strongest candidate SZ biomarker (SELENBP1) in blood; and (v) demonstrated neuronal and glial expression of SELENBP1 protein in brain.",CTD_human
2,0,Biomarker,C0002395,Alzheimer's Disease,disease,AD,2932,GSK3B,GSK3?,CTD_human,22944069,"In experiments with cultured HEK293T cells, we show here that GSK3? stabilizes synaptic acetylcholinesterase (AChE-S), a critical component of AD development.",0.31313168349158,"In experiments with cultured HEK293T cells, we show here that <span class=""gene"" id=""22944069-3-62-67"">GSK3&beta;</span> stabilizes synaptic acetylcholinesterase (AChE-S), a critical component of <span class=""disease"" id=""22944069-3-143-145"">AD</span> development.",CTD_human
1,0,Biomarker,C0002736,Amyotrophic Lateral Sclerosis,disease,ALS,2936,GSR,GR,CTD_human,16681429,"We determined activity of the following ADEs: copper-zinc superoxide dismutase (CuZn SOD), catalase (CAT), glutathione peroxidase (GSH-Px) and glutathione reductase (GR) in erythrocytes from sporadic ALS patients [SALS (-/+)], familial ALS patients with the Leu144Phe mutation in the SOD1 gene [FALS (+/+)], asymptomatic carriers with the Leu144Phe mutation in the SOD1 gene (+/-), and control subjects (-/-).",0.200274726784213,"We determined activity of the following ADEs: copper-zinc superoxide dismutase (CuZn SOD), catalase (CAT), glutathione peroxidase (GSH-Px) and <span class=""gene"" id=""16681429-5-143-164"">glutathione reductase</span> (<span class=""gene"" id=""16681429-5-166-168"">GR</span>) in erythrocytes from sporadic <span class=""disease"" id=""16681429-5-200-203"">ALS</span> patients [SALS (-/+)], familial <span class=""disease"" id=""16681429-5-236-239"">ALS</span> patients with the Leu144Phe mutation in the SOD1 gene [FALS (+/+)], asymptomatic carriers with the Leu144Phe mutation in the SOD1 gene (+/-), and control subjects (-/-).",CTD_human
1,0,Biomarker,C0002878,"Anemia, Hemolytic",disease,hemolytic anemia,2936,GSR,glutathione reductase,CTD_human,13931269,[A new enzymopenic hemolytic anemia with glutathione reductase deficiency].,0.2,"[A new enzymopenic <span class=""disease"" id=""13931269-0-19-35"">hemolytic anemia</span> with <span class=""gene"" id=""13931269-0-41-62"">glutathione reductase</span> deficiency].",CTD_human
1,0,Biomarker,C0020550,Hyperthyroidism,disease,hyperthyroid,2936,GSR,GR,CTD_human,19914224,"Translated products of AOGs showed differential expression in the liver of hyperthyroid rats, where Cu/Zn SOD (SOD1), CAT and GR were decreased in contrast to Mn SOD (SOD2) and GPx1.",0.2,"Translated products of AOGs showed differential expression in the liver of <span class=""disease"" id=""19914224-6-75-87"">hyperthyroid</span> rats, where Cu/Zn SOD (SOD1), CAT and <span class=""gene"" id=""19914224-6-126-128"">GR</span> were decreased in contrast to Mn SOD (SOD2) and GPx1.",CTD_human
1,0,Biomarker,C0020615,Hypoglycemia,disease,hypoglycemia,2936,GSR,glutathione disulfide reductase,CTD_human,20620209,Both STZ-induced diabetes and insulin-induced hypoglycemia promote a significant increase in TBARS levels and a decrease in glutathione disulfide reductase activity.,0.2,"Both STZ-induced diabetes and insulin-induced <span class=""disease"" id=""20620209-5-46-58"">hypoglycemia</span> promote a significant increase in TBARS levels and a decrease in <span class=""gene"" id=""20620209-5-124-155"">glutathione disulfide reductase</span> activity.",CTD_human
1,0,Biomarker,C0033626,Protein Deficiency,disease,Protein deficiency,2936,GSR,glutathione reductase,CTD_human,15865262,"Protein deficiency in normal rats resulted in a significant increase in hepatic activities of catalase, glutathione peroxidase, glutathione reductase, and glutathione-S-transferase and the levels of lipid peroxidation.",0.2,"<span class=""disease"" id=""15865262-5-0-18"">Protein deficiency</span> in normal rats resulted in a significant increase in hepatic activities of catalase, glutathione peroxidase, <span class=""gene"" id=""15865262-5-128-149"">glutathione reductase</span>, and glutathione-S-transferase and the levels of lipid peroxidation.",CTD_human
1,0,Biomarker,C1456865,Ureteral Calculi,disease,ureteral stone,2936,GSR,glutathione reductase,CTD_human,24360074,The ureteral stone group also had significantly lower erythrocyte glutathione peroxidase levels and glutathione reductase activity than the controls.,0.2,"The <span class=""disease"" id=""24360074-8-4-18"">ureteral stone</span> group also had significantly lower erythrocyte glutathione peroxidase levels and <span class=""gene"" id=""24360074-8-100-121"">glutathione reductase</span> activity than the controls.",CTD_human
1,0,Biomarker,C0400966,Non-alcoholic Fatty Liver Disease,disease,NAFLD,2938,GSTA1,GSTA1,CTD_human,23643483,"This is the first report to show that the combination of current-smoking and harboring high-risk GSTM1, GSTP1 and/or GSTA1 genotypes is interactively associated with the risk of NAFLD.",0.200274726784213,"This is the first report to show that the combination of current-smoking and harboring high-risk GSTM1, GSTP1 and/or <span class=""gene"" id=""23643483-8-117-122"">GSTA1</span> genotypes is interactively associated with the risk of <span class=""disease"" id=""23643483-8-178-183"">NAFLD</span>.",CTD_human
2,0,Biomarker,C0003850,Arteriosclerosis,disease,atherosclerosis,2941,GSTA4,Glutathione-S-transferase A4-4,CTD_human,15064094,Glutathione-S-transferase A4-4 modulates oxidative stress in endothelium: possible role in human atherosclerosis.,0.2,"<span class=""gene"" id=""15064094-0-0-30"">Glutathione-S-transferase A4-4</span> modulates oxidative stress in endothelium: possible role in human <span class=""disease"" id=""15064094-0-97-112"">atherosclerosis</span>.",CTD_human
2,0,Therapeutic,C0003850,Arteriosclerosis,disease,atherosclerosis,2941,GSTA4,Glutathione-S-transferase A4-4,CTD_human,15064094,Glutathione-S-transferase A4-4 modulates oxidative stress in endothelium: possible role in human atherosclerosis.,0.2,"<span class=""gene"" id=""15064094-0-0-30"">Glutathione-S-transferase A4-4</span> modulates oxidative stress in endothelium: possible role in human <span class=""disease"" id=""15064094-0-97-112"">atherosclerosis</span>.",CTD_human
2,0,Biomarker,C0004096,Asthma,disease,asthmatic,2944,GSTM1,GSTM1,CTD_human,16870661,GSTM1 and GSTP1 and respiratory health in asthmatic children exposed to ozone.,0.31420739984503004,"<span class=""gene"" id=""16870661-0-0-5"">GSTM1</span> and GSTP1 and respiratory health in <span class=""disease"" id=""16870661-0-42-51"">asthmatic</span> children exposed to ozone.",CTD_human
2,0,Biomarker,C0004096,Asthma,disease,asthma,2944,GSTM1,GSTM1,CTD_human,18988661,"Glutathione-S-transferase (GST) P1, GSTM1, exercise, ozone and asthma incidence in school children.",0.31420739984503004,"Glutathione-S-transferase (GST) P1, <span class=""gene"" id=""18988661-0-36-41"">GSTM1</span>, exercise, ozone and <span class=""disease"" id=""18988661-0-63-69"">asthma</span> incidence in school children.",CTD_human
1,0,Biomarker,C0004153,Atherosclerosis,disease,atherosclerosis,2944,GSTM1,Gstm1,CTD_human,19822795,"Genetic variants that cause a decremental change in expression of Gstm1 may permit an environment of exaggerated oxidative stress, leading to susceptibility to vascular remodeling and atherosclerosis.",0.22090458889158301,"Genetic variants that cause a decremental change in expression of <span class=""gene"" id=""19822795-11-66-71"">Gstm1</span> may permit an environment of exaggerated oxidative stress, leading to susceptibility to vascular remodeling and <span class=""disease"" id=""19822795-11-184-199"">atherosclerosis</span>.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,2944,GSTM1,GSTM1,CTD_human,16472391,Analysis of case-parent trios at a locus with a deletion allele: association of GSTM1 with autism.,0.20568939455652804,"Analysis of case-parent trios at a locus with a deletion allele: association of <span class=""gene"" id=""16472391-0-80-85"">GSTM1</span> with <span class=""disease"" id=""16472391-0-91-97"">autism</span>.",CTD_human
2,0,Biomarker,C0005695,Bladder Neoplasm,disease,bladder cancer,2944,GSTM1,GSTM1,CTD_human,18505952,"When the OR used to determine statistical power was lowered to 1.2, 2 of the 4 noteworthy associations remained so: GSTM1 null with bladder cancer and acute leukemia.",0.258297968972603,"When the OR used to determine statistical power was lowered to 1.2, 2 of the 4 noteworthy associations remained so: <span class=""gene"" id=""18505952-11-116-121"">GSTM1</span> null with <span class=""disease"" id=""18505952-11-132-146"">bladder cancer</span> and acute leukemia.",CTD_human
1,0,Biomarker,C0007134,Renal Cell Carcinoma,disease,RCC,2944,GSTM1,GSTM1,CTD_human,18566013,"In the largest RCC case-control study with genotype information conducted to date, we observed that risk associated with pesticide exposure was exclusive to individuals with active GSTM1/T1 genotypes.",0.213474289072135,"In the largest <span class=""disease"" id=""18566013-9-15-18"">RCC</span> case-control study with genotype information conducted to date, we observed that risk associated with pesticide exposure was exclusive to individuals with active <span class=""gene"" id=""18566013-9-181-186"">GSTM1</span>/T1 genotypes.",CTD_human
1,0,Biomarker,C0007137,Squamous cell carcinoma,disease,SCC,2944,GSTM1,GSTM1,CTD_human,22072123,"Moreover, a significant increase in the risk to SCC of lung in the cases carrying combination of variant genotype of CYP1A2 with either CYP1A1 or GSTM1 have shown that gene-gene interactions may play an important role in squamous cell lung cancer risk.",0.305477814045232,"Moreover, a significant increase in the risk to <span class=""disease"" id=""22072123-6-48-51"">SCC</span> of lung in the cases carrying combination of variant genotype of CYP1A2 with either CYP1A1 or <span class=""gene"" id=""22072123-6-146-151"">GSTM1</span> have shown that gene-gene interactions may play an important role in squamous cell lung cancer risk.",CTD_human
1,0,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,type 2 diabetes mellitus risk,2944,GSTM1,GSTM1,CTD_human,22652274,"The role of GSTM1, GSTT1, GSTP1, and OGG1 polymorphisms in type 2 diabetes mellitus risk: a case-control study in a Turkish population.",0.22420131030214,"The role of <span class=""gene"" id=""22652274-0-12-17"">GSTM1</span>, GSTT1, GSTP1, and OGG1 polymorphisms in <span class=""disease"" id=""22652274-0-59-88"">type 2 diabetes mellitus risk</span>: a case-control study in a Turkish population.",CTD_human
2,0,Biomarker,C0023418,leukemia,disease,leukemia,2944,GSTM1,glutathione S transferase M1,CTD_human,14694614,To study the relationship between glutathione S transferase M1(GST mu) gene deletion and leukemia in workers exposed to benzene.,0.24118962605977698,"To study the relationship between <span class=""gene"" id=""14694614-1-34-62"">glutathione S transferase M1</span>(GST mu) gene deletion and <span class=""disease"" id=""14694614-1-89-97"">leukemia</span> in workers exposed to benzene.",CTD_human
1,0,Biomarker,C0030567,Parkinson Disease,disease,PD,2944,GSTM1,GSTM1,CTD_human,17449559,GSTM1 null subjects heavily exposed to solvents appear to be at increased risk of PD.,0.244933486724135,"<span class=""gene"" id=""17449559-12-0-5"">GSTM1</span> null subjects heavily exposed to solvents appear to be at increased risk of <span class=""disease"" id=""17449559-12-82-84"">PD</span>.",CTD_human
1,0,Biomarker,C0345967,Malignant mesothelioma,disease,MM,2944,GSTM1,GSTM1,CTD_human,16697254,"Combination of NAT2 fast acetylator and GSTM1 null genotype posed a significantly increased risk of MM in the Italian, but not in the Finnish study.",0.20350593566014002,"Combination of NAT2 fast acetylator and <span class=""gene"" id=""16697254-10-40-45"">GSTM1</span> null genotype posed a significantly increased risk of <span class=""disease"" id=""16697254-10-100-102"">MM</span> in the Italian, but not in the Finnish study.",CTD_human
1,0,Biomarker,C0400966,Non-alcoholic Fatty Liver Disease,disease,NAFLD,2944,GSTM1,GSTM1,CTD_human,23643483,"This is the first report to show that the combination of current-smoking and harboring high-risk GSTM1, GSTP1 and/or GSTA1 genotypes is interactively associated with the risk of NAFLD.",0.20082418035263896,"This is the first report to show that the combination of current-smoking and harboring high-risk <span class=""gene"" id=""23643483-8-97-102"">GSTM1</span>, GSTP1 and/or GSTA1 genotypes is interactively associated with the risk of <span class=""disease"" id=""23643483-8-178-183"">NAFLD</span>.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,2944,GSTM1,GSTM1,CTD_human,7892276,"These results indicate that individuals with mutant genotypes at EPHX and GSTM1 may be at greater risk of developing AFB1 adducts, p53 mutations, and HCC when exposed to AFB1.",0.250479179565709,"These results indicate that individuals with mutant genotypes at EPHX and <span class=""gene"" id=""7892276-7-74-79"">GSTM1</span> may be at greater risk of developing AFB1 adducts, p53 mutations, and <span class=""disease"" id=""7892276-7-150-153"">HCC</span> when exposed to AFB1.",CTD_human
3,0,Biomarker,C0004096,Asthma,disease,asthmatic,2950,GSTP1,GSTP1,CTD_human,16870661,GSTM1 and GSTP1 and respiratory health in asthmatic children exposed to ozone.,0.30520308726101897,"GSTM1 and <span class=""gene"" id=""16870661-0-10-15"">GSTP1</span> and respiratory health in <span class=""disease"" id=""16870661-0-42-51"">asthmatic</span> children exposed to ozone.",CTD_human
3,0,Biomarker,C0004096,Asthma,disease,asthma,2950,GSTP1,GSTP1,CTD_human,11994713,These data suggest that homozygosity for the GSTP1*Val allele confers protection against TDI-induced asthma and airway hyperresponsiveness.,0.30520308726101897,"These data suggest that homozygosity for the <span class=""gene"" id=""11994713-8-45-50"">GSTP1</span>*Val allele confers protection against TDI-induced <span class=""disease"" id=""11994713-8-101-107"">asthma</span> and airway hyperresponsiveness.",CTD_human
3,0,Biomarker,C0004096,Asthma,disease,asthma,2950,GSTP1,GSTP1,CTD_human,18988661,GSTM1 null was independently associated with an increased risk of asthma and showed little variation with air pollution or GSTP1 genotype.,0.30520308726101897,"GSTM1 null was independently associated with an increased risk of <span class=""disease"" id=""18988661-8-66-72"">asthma</span> and showed little variation with air pollution or <span class=""gene"" id=""18988661-8-123-128"">GSTP1</span> genotype.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,AD,2950,GSTP1,GSTP1,CTD_human,17404132,Overtransmission of the GSTP1*A haplotype to case mothers suggests that action in the mother during pregnancy likely increases the likelihood of AD in her fetus.,0.20082418035263896,"Overtransmission of the <span class=""gene"" id=""17404132-11-24-29"">GSTP1</span>*A haplotype to case mothers suggests that action in the mother during pregnancy likely increases the likelihood of <span class=""disease"" id=""17404132-11-145-147"">AD</span> in her fetus.",CTD_human
3,0,Biomarker,C0005695,Bladder Neoplasm,disease,bladder cancer,2950,GSTP1,GSTP1,CTD_human,12500666,"GSTP1 AG or GG genotype has a higher frequency in the patients with benzidine related occupational bladder cancer, and further work is needed to confirm if GSTP1 AG or GG genotype plays a role in the development of occupational bladder cancer.",0.303596113956068,"<span class=""gene"" id=""12500666-11-0-5"">GSTP1</span> AG or GG genotype has a higher frequency in the patients with benzidine related occupational <span class=""disease"" id=""12500666-11-99-113"">bladder cancer</span>, and further work is needed to confirm if <span class=""gene"" id=""12500666-11-156-161"">GSTP1</span> AG or GG genotype plays a role in the development of occupational <span class=""disease"" id=""12500666-11-228-242"">bladder cancer</span>.",CTD_human
1,0,Biomarker,C0023473,"Myeloid Leukemia, Chronic",disease,chronic myeloid leukemia,2950,GSTP1,Ile105Val,CTD_human,20843134,Association of the GSTP1 gene (Ile105Val) polymorphism with chronic myeloid leukemia.,0.20350593566014002,"Association of the <span class=""gene"" id=""20843134-0-19-24"">GSTP1</span> gene (<span class=""gene"" id=""20843134-0-31-40"">Ile105Val</span>) polymorphism with <span class=""disease"" id=""20843134-0-60-84"">chronic myeloid leukemia</span>.",CTD_human
1,0,Biomarker,C0024121,Lung Neoplasms,group,lung tumors,2950,GSTP1,Gstp1,CTD_human,17909032,"To clearly establish a role for GSTP in lung tumorigenesis, we investigated whether deletion of the murine Gstp genes (Gstp1 and Gstp2) alters susceptibility to chemically induced lung tumors following exposure to BaP, 3-methylcholanthrene (3-MC), and urethane.",0.33713996159485804,"To clearly establish a role for GSTP in lung tumorigenesis, we investigated whether deletion of the murine <span class=""gene"" id=""17909032-5-107-111"">Gstp</span> genes (<span class=""gene"" id=""17909032-5-119-124"">Gstp1</span> and Gstp2) alters susceptibility to chemically induced <span class=""disease"" id=""17909032-5-180-191"">lung tumors</span> following exposure to BaP, 3-methylcholanthrene (3-MC), and urethane.",CTD_human
2,0,Biomarker,C0030567,Parkinson Disease,disease,PD,2950,GSTP1,GSTP1,CTD_human,17190945,"Using the GenePD Study sample of familial PD cases, we explored whether GSTP1 polymorphisms were associated with the age at onset of PD symptoms and whether that relation was modified by exposure to herbicides.",0.226268099506585,"Using the Gene<span class=""disease"" id=""17190945-2-14-16"">PD</span> Study sample of familial <span class=""disease"" id=""17190945-2-42-44"">PD</span> cases, we explored whether <span class=""gene"" id=""17190945-2-72-77"">GSTP1</span> polymorphisms were associated with the age at onset of PD symptoms and whether that relation was modified by exposure to herbicides.",CTD_human
1,0,Biomarker,C0031117,Peripheral Neuropathy,group,peripheral neuropathy,2950,GSTP1,GSTP1,CTD_human,20979931,Associations between oxaliplatin-induced peripheral neuropathy and polymorphisms of the ERCC1 and GSTP1 genes.,0.21045229444579103,"Associations between oxaliplatin-induced <span class=""disease"" id=""20979931-0-41-62"">peripheral neuropathy</span> and polymorphisms of the ERCC1 and <span class=""gene"" id=""20979931-0-98-103"">GSTP1</span> genes.",CTD_human
1,0,Biomarker,C0400966,Non-alcoholic Fatty Liver Disease,disease,NAFLD,2950,GSTP1,GSTP1,CTD_human,23643483,"This is the first report to show that the combination of current-smoking and harboring high-risk GSTM1, GSTP1 and/or GSTA1 genotypes is interactively associated with the risk of NAFLD.",0.20082418035263896,"This is the first report to show that the combination of current-smoking and harboring high-risk GSTM1, <span class=""gene"" id=""23643483-8-104-109"">GSTP1</span> and/or GSTA1 genotypes is interactively associated with the risk of <span class=""disease"" id=""23643483-8-178-183"">NAFLD</span>.",CTD_human
1,0,Biomarker,C0003949,Asbestosis,disease,asbestosis,2952,GSTT1,GSTT1,CTD_human,17563610,Glutathione S-transferases GSTM1 and GSTT1 polymorphisms and asbestosis.,0.202956482091714,"Glutathione S-transferases GSTM1 and <span class=""gene"" id=""17563610-0-37-42"">GSTT1</span> polymorphisms and <span class=""disease"" id=""17563610-0-61-71"">asbestosis</span>.",CTD_human
1,0,Biomarker,C0017636,Glioblastoma,disease,glioblastoma,2952,GSTT1,GSTT1,CTD_human,16874663,"Given the polymorphism of GSTT1 and its potential activity towards BCNU, the localization of GSTT1 in glioblastoma cells can be considered as a possible factor of non-homogeneous chemotherapy response among patients with different GSTT1 genotypes.",0.20328236603324,"Given the polymorphism of <span class=""gene"" id=""16874663-12-26-31"">GSTT1</span> and its potential activity towards BCNU, the localization of <span class=""gene"" id=""16874663-12-93-98"">GSTT1</span> in <span class=""disease"" id=""16874663-12-102-114"">glioblastoma</span> cells can be considered as a possible factor of non-homogeneous chemotherapy response among patients with different <span class=""gene"" id=""16874663-12-231-236"">GSTT1</span> genotypes.",CTD_human
1,0,Biomarker,C0026764,Multiple Myeloma,disease,MM,2952,GSTT1,GSTT1,CTD_human,16949155,"Individuals who carried polymorphisms for GSTT1 null and/or high activity microsomal epoxide hydrolase (mEH 113YY+139HR or 113YY+139RR or 113YH+139RR) and/or low activity NAD(P)H:quinone oxidoreductase 1 (NQO1 187PS/SS) were 1.65, 2.49 and 13 times more likely to have MM (P(trend)=0.001).",0.206187690967642,"Individuals who carried polymorphisms for <span class=""gene"" id=""16949155-3-42-47"">GSTT1</span> null and/or high activity microsomal epoxide hydrolase (mEH 113YY+139HR or 113YY+139RR or 113YH+139RR) and/or low activity NAD(P)H:quinone oxidoreductase 1 (NQO1 187PS/SS) were 1.65, 2.49 and 13 times more likely to have <span class=""disease"" id=""16949155-3-269-271"">MM</span> (P(trend)=0.001).",CTD_human
1,0,Biomarker,C0279626,Squamous cell carcinoma of esophagus,disease,ESCC,2952,GSTT1,GSTT1,CTD_human,17173682,"Our results demonstrated that dietary and environmental exposures, some demographic parameters and genetic polymorphism of GSTT1 may play important roles in the development of ESCC in Huaian area, China.",0.201373633921065,"Our results demonstrated that dietary and environmental exposures, some demographic parameters and genetic polymorphism of <span class=""gene"" id=""17173682-10-123-128"">GSTT1</span> may play important roles in the development of <span class=""disease"" id=""17173682-10-176-180"">ESCC</span> in Huaian area, China.",CTD_human
1,0,Biomarker,C0400966,Non-alcoholic Fatty Liver Disease,disease,NAFLD,2952,GSTT1,GSTT1,CTD_human,23643483,"The GSTM1 null, GSTT1 null, GSTP1 A/B or B/B and GSTA1 A/B or B/B genotypes were determined and deemed to be high-risk genotypes.The prevalence of NAFLD was 18.7%.",0.20054945356842604,"The GSTM1 null, <span class=""gene"" id=""23643483-6-16-21"">GSTT1</span> null, GSTP1 A/B or B/B and GSTA1 A/B or B/B genotypes were determined and deemed to be high-risk genotypes.The prevalence of <span class=""disease"" id=""23643483-6-147-152"">NAFLD</span> was 18.7%.",CTD_human
1,0,Biomarker,C0005695,Bladder Neoplasm,disease,Bladder cancer,2954,GSTZ1,GSTZ1,CTD_human,22306368,Bladder cancer risk overall was associated with GSTO2 Asn142Asp (homozygous; OR=1.4; 95% CI: 1.0-1.9; P for trend=0.06) and GSTZ1 Glu32Lys (homozygous; OR=1.3; 95% CI: 0.9-1.8; P for trend=0.06).,0.20054945356842604,"<span class=""disease"" id=""22306368-7-0-14"">Bladder cancer</span> risk overall was associated with GSTO2 Asn142Asp (homozygous; OR=1.4; 95% CI: 1.0-1.9; P for trend=0.06) and <span class=""gene"" id=""22306368-7-124-129"">GSTZ1</span> Glu32Lys (homozygous; OR=1.3; 95% CI: 0.9-1.8; P for trend=0.06).",CTD_human
2,0,Biomarker,C0175702,Williams Syndrome,disease,Williams Syndrome,2969,GTF2I,Gtf2i,CTD_human,21328569,"Haploinsufficiency of Gtf2i, a gene deleted in Williams Syndrome, leads to increases in social interactions.",0.488516530310606,"Haploinsufficiency of <span class=""gene"" id=""21328569-0-22-27"">Gtf2i</span>, a gene deleted in <span class=""disease"" id=""21328569-0-47-64"">Williams Syndrome</span>, leads to increases in social interactions.",CTD_human;ORPHANET
2,0,Biomarker,C0175702,Williams Syndrome,disease,WBS,2969,GTF2I,GTF2I,CTD_human,20007321,"Human genetic mapping data have implicated two related genes GTF2IRD1 and GTF2I in the cause of some the key features of WBS, including craniofacial dysmorphology, hypersociability, and visuospatial deficits.",0.488516530310606,"Human genetic mapping data have implicated two related genes GTF2IRD1 and <span class=""gene"" id=""20007321-4-74-79"">GTF2I</span> in the cause of some the key features of <span class=""disease"" id=""20007321-4-121-124"">WBS</span>, including craniofacial dysmorphology, hypersociability, and visuospatial deficits.",CTD_human;ORPHANET
1,0,Biomarker,C1510586,Autism Spectrum Disorders,disease,autism spectrum disorders,2969,GTF2I,GTF2i,CTD_human,22048961,Association of GTF2i in the Williams-Beuren syndrome critical region with autism spectrum disorders.,0.200274726784213,"Association of <span class=""gene"" id=""22048961-0-15-20"">GTF2i</span> in the Williams-Beuren syndrome critical region with <span class=""disease"" id=""22048961-0-74-99"">autism spectrum disorders</span>.",CTD_human
1,0,Biomarker,C0033860,Psoriasis,disease,psoriasis,29785,CYP2S1,CYP2S1,CTD_human,12711469,Cutaneous expression of cytochrome P450 CYP2S1: individuality in regulation by therapeutic agents for psoriasis and other skin diseases.,0.200274726784213,"Cutaneous expression of cytochrome P450 <span class=""gene"" id=""12711469-0-40-46"">CYP2S1</span>: individuality in regulation by therapeutic agents for <span class=""disease"" id=""12711469-0-102-111"">psoriasis</span> and other skin diseases.",CTD_human
1,0,Biomarker,C0035334,Retinitis Pigmentosa,disease,RP,2979,GUCA1B,GUCA1B,CTD_human,15452722,"We investigated mutations in the gene coding for guanylate-cyclase activating protein 2 (GCAP2), also known as GUCA1B gene, in Japanese patients with retinitis pigmentosa (RP) and tried to identify phenotypic characteristics associated with mutations in the gene.",0.6032312088759271,"We investigated mutations in the gene coding for guanylate-cyclase activating protein 2 (<span class=""gene"" id=""15452722-1-89-94"">GCAP2</span>), also known as <span class=""gene"" id=""15452722-1-111-117"">GUCA1B</span> gene, in Japanese patients with <span class=""disease"" id=""15452722-1-150-170"">retinitis pigmentosa</span> (<span class=""disease"" id=""15452722-1-172-174"">RP</span>) and tried to identify phenotypic characteristics associated with mutations in the gene.",CTD_human;HPO;ORPHANET
1,0,Biomarker,C0022661,"Kidney Failure, Chronic",disease,chronic renal failure,2981,GUCA2B,Uroguanylin,CTD_human,15780094,"Uroguanylin concentrations are increased in patients with chronic renal failure, nephrotic syndrome, or those on dialysis.",0.20300763924902696,"<span class=""gene"" id=""15780094-3-0-11"">Uroguanylin</span> concentrations are increased in patients with <span class=""disease"" id=""15780094-3-58-79"">chronic renal failure</span>, nephrotic syndrome, or those on dialysis.",CTD_human
1,0,Biomarker,C0027726,Nephrotic Syndrome,group,nephrotic syndrome,2981,GUCA2B,Uroguanylin,CTD_human,15780094,"Uroguanylin concentrations are increased in patients with chronic renal failure, nephrotic syndrome, or those on dialysis.",0.202732912464814,"<span class=""gene"" id=""15780094-3-0-11"">Uroguanylin</span> concentrations are increased in patients with chronic renal failure, <span class=""disease"" id=""15780094-3-81-99"">nephrotic syndrome</span>, or those on dialysis.",CTD_human
1,0,Biomarker,C0009404,Colorectal Neoplasms,group,colorectal tumors,2984,GUCY2C,guanylyl cyclase C,CTD_human,17155897,"This opportunity exploits the discovery that an intestinal receptor, guanylyl cyclase C, which mediates diarrhea induced by bacterial heat-stable enterotoxins (STs), is over-expressed by metastatic colorectal tumors only.",0.20656473206648,"This opportunity exploits the discovery that an intestinal receptor, <span class=""gene"" id=""17155897-5-69-87"">guanylyl cyclase C</span>, which mediates diarrhea induced by bacterial heat-stable enterotoxins (STs), is over-expressed by metastatic <span class=""disease"" id=""17155897-5-198-215"">colorectal tumors</span> only.",CTD_human
1,0,Biomarker,C0011991,Diarrhea,phenotype,diarrhea,2984,GUCY2C,GUCY2C,CTD_human,22436048,Familial diarrhea syndrome caused by an activating GUCY2C mutation.,0.40027472678421294,"Familial <span class=""disease"" id=""22436048-0-9-17"">diarrhea</span> syndrome caused by an activating <span class=""gene"" id=""22436048-0-51-57"">GUCY2C</span> mutation.",CTD_human;HPO
1,7,Biomarker,C1858695,Chudley-Mccullough syndrome,disease,Chudley-McCullough syndrome,29899,GPSM2,GPSM2,CTD_human,22578326,GPSM2 mutations cause the brain malformations and hearing loss in Chudley-McCullough syndrome.,0.48109890713685205,"<span class=""gene"" id=""22578326-0-0-5"">GPSM2</span> mutations cause the brain malformations and hearing loss in <span class=""disease"" id=""22578326-0-66-93"">Chudley-McCullough syndrome</span>.",CTD_human;ORPHANET
1,0,Biomarker,C0037286,Skin Neoplasms,group,skin tumors,2993,GYPA,GPA,CTD_human,17029826,"These data demonstrate that arsenic exposure is associated with mutations at the GPA locus, an effect exaggerated in patients bearing arsenic-induced skin tumors.",0.200274726784213,"These data demonstrate that arsenic exposure is associated with mutations at the <span class=""gene"" id=""17029826-10-81-84"">GPA</span> locus, an effect exaggerated in patients bearing arsenic-induced <span class=""disease"" id=""17029826-10-150-161"">skin tumors</span>.",CTD_human
1,0,Biomarker,C0035334,Retinitis Pigmentosa,disease,retinitis pigmentosa,3000,GUCY2D,GUCY2D,CTD_human,16272259,"Identification of mutations in the AIPL1, CRB1, GUCY2D, RPE65, and RPGRIP1 genes in patients with juvenile retinitis pigmentosa.",0.609875808854354,"Identification of mutations in the AIPL1, CRB1, <span class=""gene"" id=""16272259-0-48-54"">GUCY2D</span>, RPE65, and RPGRIP1 genes in patients with juvenile <span class=""disease"" id=""16272259-0-107-127"">retinitis pigmentosa</span>.",CTD_human;HPO;ORPHANET
1,0,Biomarker,C0004096,Asthma,disease,asthma,30009,TBX21,TBX21,CTD_human,15806396,"In order to examine whether polymorphisms in the candidate gene, TBX21, located on chromosome 17q21.32, are related to the risk of human asthma phenotypes, we have searched for genetic variations in the human TBX21 gene and identified 24 single nucleotide polymorphisms (SNPs), including five novel SNPs, by direct sequencing in Japanese subjects.",0.431352297717041,"In order to examine whether polymorphisms in the candidate gene, <span class=""gene"" id=""15806396-4-65-70"">TBX21</span>, located on chromosome 17q21.32, are related to the risk of human <span class=""disease"" id=""15806396-4-137-143"">asthma</span> phenotypes, we have searched for genetic variations in the human <span class=""gene"" id=""15806396-4-209-214"">TBX21</span> gene and identified 24 single nucleotide polymorphisms (SNPs), including five novel SNPs, by direct sequencing in Japanese subjects.",CTD_human;HPO
1,0,Biomarker,C1319853,"Asthma, Aspirin-Induced",disease,AIA,30009,TBX21,TBX21,CTD_human,16502481,"Several single nucleotide polymorphisms (SNPs) in the promoters of EP2, TBX21, COX-2, Fc epsilon RIbeta, and TBXA2R were associated with AIA, while an Fc epsilon RIalpha promoter polymorphism was associated with AIU.",0.40027472678421294,"Several single nucleotide polymorphisms (SNPs) in the promoters of EP2, <span class=""gene"" id=""16502481-6-72-77"">TBX21</span>, COX-2, Fc epsilon RIbeta, and TBXA2R were associated with <span class=""disease"" id=""16502481-6-137-140"">AIA</span>, while an Fc epsilon RIalpha promoter polymorphism was associated with AIU.",CTD_human;HPO
1,0,Biomarker,C0004352,Autistic Disorder,disease,autistic disorder,30061,SLC40A1,SLC11A3,CTD_human,15446388,"We performed family-based association studies of polymorphisms in metal-regulatory transcription factor 1(MTF1), a multispecific organic anion transporter (ABCC1), proton-coupled divalent metal ion transporters (SLC11A3 and SLC11A2), paraoxonase 1 (PON1), and glutathione S-transferase (GSTP1) genes in 196 autistic disorder families.",0.2,"We performed family-based association studies of polymorphisms in metal-regulatory transcription factor 1(MTF1), a multispecific organic anion transporter (ABCC1), proton-coupled divalent metal ion transporters (<span class=""gene"" id=""15446388-4-212-219"">SLC11A3</span> and SLC11A2), paraoxonase 1 (PON1), and glutathione S-transferase (GSTP1) genes in 196 <span class=""disease"" id=""15446388-4-307-324"">autistic disorder</span> families.",CTD_human
1,0,Biomarker,C0025202,melanoma,disease,melanoma,30062,RAX,RAX,CTD_human,16778180,"CGIs in putative promoter regions of 34 genes (ABHD9, BARHL1, CLIC5, CNNM1, COL2A1, CPT1C, DDIT4L, DERL3, DHRS3, DPYS, EFEMP2, FAM62C, FAM78A, FLJ33790, GBX2, GPR10, GPRASP1, HOXA9, HOXD11, HOXD12, HOXD13, p14ARF, PAX6, PRDX2, PTPRG, RASD1, RAX, REC8L1, SLC27A3, TGFB2, TLX2, TMEM22, TMEM30B, and UNC5C) were found to be methylated in at least 1 of 13 melanoma cell lines but not in two cultured normal melanocytes.",0.2,"CGIs in putative promoter regions of 34 genes (ABHD9, BARHL1, CLIC5, CNNM1, COL2A1, CPT1C, DDIT4L, DERL3, DHRS3, DPYS, EFEMP2, FAM62C, FAM78A, FLJ33790, GBX2, GPR10, GPRASP1, HOXA9, HOXD11, HOXD12, HOXD13, p14ARF, PAX6, PRDX2, PTPRG, RASD1, <span class=""gene"" id=""16778180-3-241-244"">RAX</span>, REC8L1, SLC27A3, TGFB2, TLX2, TMEM22, TMEM30B, and UNC5C) were found to be methylated in at least 1 of 13 <span class=""disease"" id=""16778180-3-352-360"">melanoma</span> cell lines but not in two cultured normal melanocytes.",CTD_human
1,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastasis,301,ANXA1,Annexin A1,CTD_human,20308542,Annexin A1 regulates TGF-beta signaling and promotes metastasis formation of basal-like breast cancer cells.,0.283021994626344,"<span class=""gene"" id=""20308542-0-0-10"">Annexin A1</span> regulates TGF-beta signaling and promotes <span class=""disease"" id=""20308542-0-53-63"">metastasis</span> formation of basal-like breast cancer cells.",CTD_human
1,0,Biomarker,C0152013,Adenocarcinoma of lung (disorder),disease,lung adenocarcinoma,301,ANXA1,annexin 1,CTD_human,19381893,"(4) To validate the results screened by proteome research, immunohistochemistry was used to validate several lung adenocarcinoma differentially expressed proteins including 14-3-3 sigma, annexin 1, and manganese superoxide dismutase.",0.20054945356842604,"(4) To validate the results screened by proteome research, immunohistochemistry was used to validate several <span class=""disease"" id=""19381893-8-109-128"">lung adenocarcinoma</span> differentially expressed proteins including 14-3-3 sigma, <span class=""gene"" id=""19381893-8-187-196"">annexin 1</span>, and manganese superoxide dismutase.",CTD_human
1,0,Biomarker,C0279626,Squamous cell carcinoma of esophagus,disease,ESCC,301,ANXA1,ANX1,CTD_human,21517111,"Among these identified proteins, 33 proteins including keratin 17 (KRT17), biliverdin reductase B (BLVRB), proteasome activator subunit 1 (PSME1), manganese superoxide dismutase (MnSOD), high-mobility group box-1(HMGB1), heat shock protein 70 (HSP70), peroxiredoxin (PRDX1), keratin 13 (KRT13), and so on were overexpressed, and 14 proteins including cystatin B (CSTB), tropomyosin 2 (TPM2), annexin 1 (ANX1), transgelin (TAGLN), keratin 19 (KRT19), stratifin (SFN), and so on were down-expressed in ESCC.",0.20082418035263896,"Among these identified proteins, 33 proteins including keratin 17 (KRT17), biliverdin reductase B (BLVRB), proteasome activator subunit 1 (PSME1), manganese superoxide dismutase (MnSOD), high-mobility group box-1(HMGB1), heat shock protein 70 (HSP70), peroxiredoxin (PRDX1), keratin 13 (KRT13), and so on were overexpressed, and 14 proteins including cystatin B (CSTB), tropomyosin 2 (TPM2), <span class=""gene"" id=""21517111-5-392-401"">annexin 1</span> (<span class=""gene"" id=""21517111-5-403-407"">ANX1</span>), transgelin (TAGLN), keratin 19 (KRT19), stratifin (SFN), and so on were down-expressed in <span class=""disease"" id=""21517111-5-500-504"">ESCC</span>.",CTD_human
2,0,Biomarker,C1458155,Mammary Neoplasms,group,breast tumor,3014,H2AFX,H2AX,CTD_human,21463514,"It was observed that H2AX gene expression was negatively correlated with miR-24-2 expression and not in accordance with the gene copy number status, both in cell lines and in sporadic breast tumor tissues.",0.202732912464814,"It was observed that <span class=""gene"" id=""21463514-10-21-25"">H2AX</span> gene expression was negatively correlated with miR-24-2 expression and not in accordance with the gene copy number status, both in cell lines and in sporadic <span class=""disease"" id=""21463514-10-184-196"">breast tumor</span> tissues.",CTD_human
1,0,Biomarker,C0345967,Malignant mesothelioma,disease,malignant mesothelioma,302,ANXA2,AnxA2,CTD_human,20682992,The antibody titer against AnxA2 may be a potentially useful new diagnostic surrogate marker for asbestos-related lung cancer and malignant mesothelioma.,0.2,"The antibody titer against <span class=""gene"" id=""20682992-6-27-32"">AnxA2</span> may be a potentially useful new diagnostic surrogate marker for asbestos-related lung cancer and <span class=""disease"" id=""20682992-6-130-152"">malignant mesothelioma</span>.",CTD_human
2,0,Biomarker,C0017636,Glioblastoma,disease,glioblastoma,3020,H3F3A,H3F3A,CTD_human,23817572,"Notably, we identified the same FGFR1 mutations in a subset of H3F3A-mutated pediatric glioblastoma with additional alterations in the NF1 gene.",0.20439562854741,"Notably, we identified the same FGFR1 mutations in a subset of <span class=""gene"" id=""23817572-7-63-68"">H3F3A</span>-mutated pediatric <span class=""disease"" id=""23817572-7-87-99"">glioblastoma</span> with additional alterations in the NF1 gene.",CTD_human
1,0,Biomarker,C0206638,Giant Cell Tumor of Bone,disease,giant cell tumor of bone,3020,H3F3A,H3F3A,CTD_human,24162739,Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone.,0.20054945356842604,"Distinct <span class=""gene"" id=""24162739-0-9-14"">H3F3A</span> and H3F3B driver mutations define chondroblastoma and <span class=""disease"" id=""24162739-0-69-93"">giant cell tumor of bone</span>.",CTD_human
1,0,Biomarker,C0008441,Chondroblastoma,disease,chondroblastoma,3021,H3F3B,H3F3B,CTD_human,24162739,Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone.,0.20054945356842604,"Distinct H3F3A and <span class=""gene"" id=""24162739-0-19-24"">H3F3B</span> driver mutations define <span class=""disease"" id=""24162739-0-49-64"">chondroblastoma</span> and giant cell tumor of bone.",CTD_human
1,0,Biomarker,C0015695,Fatty Liver,disease,hepatic steatosis,3032,HADHB,mitochondrial trifunctional protein beta-subunit,CTD_human,17116638,ENU mutagenesis identifies mice with cardiac fibrosis and hepatic steatosis caused by a mutation in the mitochondrial trifunctional protein beta-subunit.,0.2,"ENU mutagenesis identifies mice with cardiac fibrosis and <span class=""disease"" id=""17116638-0-58-75"">hepatic steatosis</span> caused by a mutation in the <span class=""gene"" id=""17116638-0-104-152"">mitochondrial trifunctional protein beta-subunit</span>.",CTD_human
1,0,Biomarker,C0005283,beta Thalassemia,disease,beta-thalassemia,3040,HBA2,HbA2,CTD_human,17292142,The study reports analysis with HbA0 (the major component of human Hb) and HbA2 (a variant that is associated with beta-thalassemia).,0.251004958574372,"The study reports analysis with HbA0 (the major component of human Hb) and <span class=""gene"" id=""17292142-2-75-79"">HbA2</span> (a variant that is associated with <span class=""disease"" id=""17292142-2-115-131"">beta-thalassemia</span>).",CTD_human
14,39,Biomarker,C0005283,beta Thalassemia,disease,beta-Thalassemia,3043,HBB,hemoglobin beta-chain,CTD_human,16755567,beta-Thalassemia is an inherited anemia in which synthesis of the hemoglobin beta-chain is decreased.,0.80372659943702,"<span class=""disease"" id=""16755567-1-0-16"">beta-Thalassemia</span> is an inherited anemia in which synthesis of the <span class=""gene"" id=""16755567-1-66-87"">hemoglobin beta-chain</span> is decreased.",CTD_human;ORPHANET;UNIPROT
14,39,Biomarker,C0005283,beta Thalassemia,disease,beta-thalassaemia,3043,HBB,beta-globin,CTD_human,6280057,Linkage of beta-thalassaemia mutations and beta-globin gene polymorphisms with DNA polymorphisms in human beta-globin gene cluster.,0.80372659943702,"Linkage of <span class=""disease"" id=""6280057-0-11-28"">beta-thalassaemia</span> mutations and <span class=""gene"" id=""6280057-0-43-54"">beta-globin</span> gene polymorphisms with DNA polymorphisms in human <span class=""gene"" id=""6280057-0-106-117"">beta-globin</span> gene cluster.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0023903,Liver neoplasms,group,liver tumors,3054,HCFC1,Hcf1,CTD_human,19255062,"BR males are also moderately susceptible, and the susceptibility of both sexes of BR mice to liver tumors induced with N,N-diethylnitrosamine relative to the resistant C57BL/6J (B6) strain is caused by two loci designated Hcf1 and Hcf2 (hepatocarcinogenesis in females) located on chromosomes 17 and 1, respectively.",0.200274726784213,"BR males are also moderately susceptible, and the susceptibility of both sexes of BR mice to <span class=""disease"" id=""19255062-3-93-105"">liver tumors</span> induced with N,N-diethylnitrosamine relative to the resistant C57BL/6J (B6) strain is caused by two loci designated <span class=""gene"" id=""19255062-3-222-226"">Hcf1</span> and Hcf2 (hepatocarcinogenesis in females) located on chromosomes 17 and 1, respectively.",CTD_human
1,1,Biomarker,C0003873,Rheumatoid Arthritis,disease,rheumatoid arthritis,306,ANXA3,ANXA3,CTD_human,22446963,"Our study identified nine loci newly associated with rheumatoid arthritis at a threshold of P < 5.0 × 10(-8), including B3GNT2, ANXA3, CSF2, CD83, NFKBIE, ARID5B, PDE2A-ARAP1, PLD4 and PTPN2.",0.2,"Our study identified nine loci newly associated with <span class=""disease"" id=""22446963-3-53-73"">rheumatoid arthritis</span> at a threshold of P &lt; 5.0 &times; 10(-8), including B3GNT2, <span class=""gene"" id=""22446963-3-128-133"">ANXA3</span>, CSF2, CD83, NFKBIE, ARID5B, PDE2A-ARAP1, PLD4 and PTPN2.",CTD_human
1,0,Biomarker,C0024141,"Lupus Erythematosus, Systemic",disease,systemic lupus erythematosus,306,ANXA3,ANXA3,CTD_human,22446963,"ANXA3 was also associated with susceptibility to systemic lupus erythematosus (P = 0.0040), and B3GNT2 and ARID5B were associated with Graves' disease (P = 3.5 × 10(-4) and 2.9 × 10(-4), respectively).",0.200274726784213,"<span class=""gene"" id=""22446963-4-0-5"">ANXA3</span> was also associated with susceptibility to <span class=""disease"" id=""22446963-4-49-77"">systemic lupus erythematosus</span> (P = 0.0040), and B3GNT2 and ARID5B were associated with Graves' disease (P = 3.5 &times; 10(-4) and 2.9 &times; 10(-4), respectively).",CTD_human
1,0,Therapeutic,C0030193,Pain,phenotype,pain,3060,HCRT,orexin,CTD_human,16202530,Furthermore we studied effects of histamine H1 and H2 receptor antagonists on orexin A-produced antinociception in C57BL/6 mice.The antinociceptive effects of i.c.v. orexin A were greater in histamine H1 receptor or H2 receptor knockout mice than in the wild-type mice in all four assays of pain.,0.200274726784213,"Furthermore we studied effects of histamine H1 and H2 receptor antagonists on <span class=""gene"" id=""16202530-6-78-84"">orexin</span> A-produced antinociception in C57BL/6 mice.The antinociceptive effects of i.c.v. <span class=""gene"" id=""16202530-6-166-172"">orexin</span> A were greater in histamine H1 receptor or H2 receptor knockout mice than in the wild-type mice in all four assays of <span class=""disease"" id=""16202530-6-291-295"">pain</span>.",CTD_human
1,0,Biomarker,C0027404,Narcolepsy,disease,narcolepsy,3062,HCRTR2,HCRTR-2,CTD_human,17521418,"By using microarray technology we have screened the expression of 29760 genes in the brains of Doberman dogs with a heritable form of narcolepsy (homozygous for the canarc-1 [HCRTR-2-2] mutation), and their unaffected heterozygous siblings.",0.202472541057918,"By using microarray technology we have screened the expression of 29760 genes in the brains of Doberman dogs with a heritable form of <span class=""disease"" id=""17521418-4-134-144"">narcolepsy</span> (homozygous for the canarc-1 [<span class=""gene"" id=""17521418-4-175-182"">HCRTR-2</span>-2] mutation), and their unaffected heterozygous siblings.",CTD_human
9,0,Biomarker,C0020179,Huntington Disease,disease,HD,3064,HTT,huntingtin,CTD_human,16137562,Huntington's disease (HD) is a neurodegenerative disorder caused by an elongated glutamine repeat in huntingtin.,0.762380931889865,"<span class=""disease"" id=""16137562-1-0-20"">Huntington's disease</span> (<span class=""disease"" id=""16137562-1-22-24"">HD</span>) is a neurodegenerative disorder caused by an elongated glutamine repeat in <span class=""gene"" id=""16137562-1-101-111"">huntingtin</span>.",CTD_human;ORPHANET
9,0,Biomarker,C0020179,Huntington Disease,disease,HD,3064,HTT,huntingtin,CTD_human,17018277,Huntington's disease (HD) is an inherited neurodegenerative disease caused by a glutamine repeat expansion in huntingtin protein.,0.762380931889865,"<span class=""disease"" id=""17018277-1-0-20"">Huntington's disease</span> (<span class=""disease"" id=""17018277-1-22-24"">HD</span>) is an inherited neurodegenerative disease caused by a glutamine repeat expansion in <span class=""gene"" id=""17018277-1-110-120"">huntingtin</span> protein.",CTD_human;ORPHANET
9,0,Biomarker,C0020179,Huntington Disease,disease,HD,3064,HTT,huntingtin,CTD_human,19094060,"As opposed to the effect of depleting wild-type huntingtin, specifically silencing the mutant species actually lowered caspase-3 activation and protected HD cells under stress conditions.",0.762380931889865,"As opposed to the effect of depleting wild-type <span class=""gene"" id=""19094060-10-48-58"">huntingtin</span>, specifically silencing the mutant species actually lowered caspase-3 activation and protected <span class=""disease"" id=""19094060-10-154-156"">HD</span> cells under stress conditions.",CTD_human;ORPHANET
9,0,Biomarker,C0020179,Huntington Disease,disease,HD,3064,HTT,Htt,CTD_human,18831068,"Furthermore, DNA damage and activated H2AX are present in HD transgenic mice before the formation of mutant Htt aggregates and HD pathogenesis.",0.762380931889865,"Furthermore, DNA damage and activated H2AX are present in <span class=""disease"" id=""18831068-9-58-60"">HD</span> transgenic mice before the formation of mutant <span class=""gene"" id=""18831068-9-108-111"">Htt</span> aggregates and <span class=""disease"" id=""18831068-9-127-129"">HD</span> pathogenesis.",CTD_human;ORPHANET
9,0,Biomarker,C0020179,Huntington Disease,disease,HD,3064,HTT,huntingtin,CTD_human,17925440,Huntington's disease (HD) is a progressive neurodegenerative disease caused by a glutamine expansion within huntingtin protein.,0.762380931889865,"<span class=""disease"" id=""17925440-1-0-20"">Huntington's disease</span> (<span class=""disease"" id=""17925440-1-22-24"">HD</span>) is a progressive neurodegenerative disease caused by a glutamine expansion within <span class=""gene"" id=""17925440-1-108-118"">huntingtin</span> protein.",CTD_human;ORPHANET
9,0,Biomarker,C0020179,Huntington Disease,disease,HD,3064,HTT,Huntingtin,CTD_human,15312898,"Pathogenesis in HD includes the cytoplasmic cleavage of Huntingtin and release of an amino-terminal fragment capable of nuclear localization, where expanded-Huntingtin (Exp-Htt) might lead to aberrant transcriptional regulation, neuronal dysfunction and degeneration.",0.762380931889865,"Pathogenesis in <span class=""disease"" id=""15312898-2-16-18"">HD</span> includes the cytoplasmic cleavage of <span class=""gene"" id=""15312898-2-56-66"">Huntingtin</span> and release of an amino-terminal fragment capable of nuclear localization, where expanded-Huntingtin (Exp-Htt) might lead to aberrant transcriptional regulation, neuronal dysfunction and degeneration.",CTD_human;ORPHANET
1,0,Biomarker,C0007137,Squamous cell carcinoma,disease,squamous cell carcinoma,3065,HDAC1,HDAC1,CTD_human,21527555,Physical association of HDAC1 and HDAC2 with p63 mediates transcriptional repression and tumor maintenance in squamous cell carcinoma.,0.20328236603324,"Physical association of <span class=""gene"" id=""21527555-0-24-29"">HDAC1</span> and HDAC2 with p63 mediates transcriptional repression and tumor maintenance in <span class=""disease"" id=""21527555-0-110-133"">squamous cell carcinoma</span>.",CTD_human
1,0,Biomarker,C0007137,Squamous cell carcinoma,disease,squamous cell carcinoma,3066,HDAC2,HDAC2,CTD_human,21527555,Physical association of HDAC1 and HDAC2 with p63 mediates transcriptional repression and tumor maintenance in squamous cell carcinoma.,0.20054945356842604,"Physical association of HDAC1 and <span class=""gene"" id=""21527555-0-34-39"">HDAC2</span> with p63 mediates transcriptional repression and tumor maintenance in <span class=""disease"" id=""21527555-0-110-133"">squamous cell carcinoma</span>.",CTD_human
1,0,Biomarker,C0023470,Myeloid Leukemia,disease,myeloid leukaemia,3066,HDAC2,histone deacetylase 2,CTD_human,21535412,"Further investigations revealed that knock-down of AGO2 by custom-made AGO2 siRNA in HEK-293 cells resulted in silencing of the expression of target genes vascular endothelial growth factor A and histone deacetylase 2, which are known to be involved in the development of myeloid leukaemia.",0.200274726784213,"Further investigations revealed that knock-down of AGO2 by custom-made AGO2 siRNA in HEK-293 cells resulted in silencing of the expression of target genes vascular endothelial growth factor A and <span class=""gene"" id=""21535412-5-196-217"">histone deacetylase 2</span>, which are known to be involved in the development of <span class=""disease"" id=""21535412-5-272-289"">myeloid leukaemia</span>.",CTD_human
2,0,Biomarker,C0024117,Chronic Obstructive Airway Disease,disease,COPD,3066,HDAC2,HDAC2,CTD_human,18421014,"Histone deacetylase-2 (HDAC2), a critical component of the corticosteroid anti-inflammatory action, is impaired in lungs of patients with COPD and correlates with disease severity.",0.28274726784213106,"<span class=""gene"" id=""18421014-2-0-21"">Histone deacetylase-2</span> (<span class=""gene"" id=""18421014-2-23-28"">HDAC2</span>), a critical component of the corticosteroid anti-inflammatory action, is impaired in lungs of patients with <span class=""disease"" id=""18421014-2-138-142"">COPD</span> and correlates with disease severity.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,3069,HDLBP,HDLBP,CTD_human,19365831,"FARP2, HDLBP and PASK are downregulated in a patient with autism and 2q37.3 deletion syndrome.",0.200274726784213,"FARP2, <span class=""gene"" id=""19365831-0-7-12"">HDLBP</span> and PASK are downregulated in a patient with <span class=""disease"" id=""19365831-0-58-64"">autism</span> and 2q37.3 deletion syndrome.",CTD_human
1,0,Biomarker,C0007134,Renal Cell Carcinoma,disease,RCC,307,ANXA4,annexin IV,CTD_human,15108329,"Overexpression of three proteins, alphabeta-crystallin, manganese superoxide dismutase (MnSOD), and annexin IV, most commonly observed in primary RCC cell cultures, were also observed by immunoblot analysis of proteins from the RCC tissues from which the primary cell cultures were derived.",0.20328236603324,"Overexpression of three proteins, alphabeta-crystallin, manganese superoxide dismutase (MnSOD), and <span class=""gene"" id=""15108329-7-100-110"">annexin IV</span>, most commonly observed in primary <span class=""disease"" id=""15108329-7-146-149"">RCC</span> cell cultures, were also observed by immunoblot analysis of proteins from the <span class=""disease"" id=""15108329-7-228-231"">RCC</span> tissues from which the primary cell cultures were derived.",CTD_human
22,75,Biomarker,C0039373,Tay-Sachs Disease,disease,Tay-Sachs disease,3073,HEXA,GM2 gangliosidosis,CTD_human,11392526,"The late-onset form of GM2 gangliosidosis (Tay-Sachs disease) is an autosomal-recessive disorder with progressive neurologic disease, mainly characterized by motor neuron and spinocerebellar dysfunction.",0.509105005017648,"The late-onset form of <span class=""gene"" id=""11392526-1-23-41"">GM2 gangliosidosis</span> (<span class=""disease"" id=""11392526-1-43-60"">Tay-Sachs disease</span>) is an autosomal-recessive disorder with progressive neurologic disease, mainly characterized by motor neuron and spinocerebellar dysfunction.",CTD_human;UNIPROT
1,0,Biomarker,C0017662,"Glomerulonephritis, Membranoproliferative",disease,membranoproliferative glomerulonephritis,3075,CFH,factor h,CTD_human,14978182,Heterozygous and homozygous factor h deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases.,0.212059267750742,"Heterozygous and homozygous <span class=""gene"" id=""14978182-0-28-36"">factor h</span> deficiencies associated with hemolytic uremic syndrome or <span class=""disease"" id=""14978182-0-95-135"">membranoproliferative glomerulonephritis</span>: report and genetic analysis of 16 cases.",CTD_human
1,0,Biomarker,C0025303,Meningococcal Infections,group,meningococcal disease,3075,CFH,CFH,CTD_human,20694013,Genome-wide association study identifies variants in the CFH region associated with host susceptibility to meningococcal disease.,0.204604842796993,"Genome-wide association study identifies variants in the <span class=""gene"" id=""20694013-0-57-60"">CFH</span> region associated with host susceptibility to <span class=""disease"" id=""20694013-0-107-128"">meningococcal disease</span>.",CTD_human
6,13,Biomarker,C0242383,Age related macular degeneration,disease,age-related macular degeneration,3075,CFH,complement factor H,CTD_human,16754848,Synergic effect of polymorphisms in ERCC6 5' flanking region and complement factor H on age-related macular degeneration predisposition.,0.44,"Synergic effect of polymorphisms in ERCC6 5' flanking region and <span class=""gene"" id=""16754848-0-65-84"">complement factor H</span> on <span class=""disease"" id=""16754848-0-88-120"">age-related macular degeneration</span> predisposition.",CTD_human
6,13,Biomarker,C0242383,Age related macular degeneration,disease,AMD,3075,CFH,CFH,CTD_human,21909106,"In addition to CFH (rs800292, P = 4.23 × 10(-15)) and ARMS2 (rs3750847, P = 8.67 × 10(-29)) loci, we identified two new susceptibility loci for exudative AMD: TNFRSF10A-LOC389641 on chromosome 8p21 (rs13278062, combined P = 1.03 × 10(-12), odds ratio = 0.73) and REST-C4orf14-POLR2B-IGFBP7 on chromosome 4q12 (rs1713985, combined P = 2.34 × 10(-8), odds ratio = 1.30).",0.44,"In addition to <span class=""gene"" id=""21909106-3-15-18"">CFH</span> (rs800292, P = 4.23 &times; 10(-15)) and ARMS2 (rs3750847, P = 8.67 &times; 10(-29)) loci, we identified two new susceptibility loci for exudative <span class=""disease"" id=""21909106-3-154-157"">AMD</span>: TNFRSF10A-LOC389641 on chromosome 8p21 (rs13278062, combined P = 1.03 &times; 10(-12), odds ratio = 0.73) and REST-C4orf14-POLR2B-IGFBP7 on chromosome 4q12 (rs1713985, combined P = 2.34 &times; 10(-8), odds ratio = 1.30).",CTD_human
6,13,Biomarker,C0242383,Age related macular degeneration,disease,age-related macular degeneration,3075,CFH,CFH,CTD_human,22019782,A rare penetrant mutation in CFH confers high risk of age-related macular degeneration.,0.44,"A rare penetrant mutation in <span class=""gene"" id=""22019782-0-29-32"">CFH</span> confers high risk of <span class=""disease"" id=""22019782-0-54-86"">age-related macular degeneration</span>.",CTD_human
6,13,Biomarker,C0242383,Age related macular degeneration,disease,age-related macular degeneration,3075,CFH,FH,CTD_human,17554167,"An allotypic variant of FH, 402His, has been associated with age-related macular degeneration, the leading cause of blindness in the elderly.",0.44,"An allotypic variant of <span class=""gene"" id=""17554167-2-24-26"">FH</span>, 402His, has been associated with <span class=""disease"" id=""17554167-2-61-93"">age-related macular degeneration</span>, the leading cause of blindness in the elderly.",CTD_human
6,13,Biomarker,C0242383,Age related macular degeneration,disease,AMD,3075,CFH,CFH,CTD_human,16518403,"Variants in the factor H gene (CFH, also known as HF1), which encodes a major inhibitor of the alternative complement pathway, are associated with the risk for developing AMD.",0.44,"Variants in the <span class=""gene"" id=""16518403-2-16-24"">factor H</span> gene (<span class=""gene"" id=""16518403-2-31-34"">CFH</span>, also known as HF1), which encodes a major inhibitor of the alternative complement pathway, are associated with the risk for developing <span class=""disease"" id=""16518403-2-171-174"">AMD</span>.",CTD_human
2,1,Biomarker,C2931788,Atypical Hemolytic Uremic Syndrome,disease,HUS,3075,CFH,FH,CTD_human,14978182,"Four children with homozygous or heterozygous FH deficiency and HUS underwent renal transplantation, which was successful in three but failed as a result of recurrence of HUS in one patient.",0.31530873009423,"Four children with homozygous or heterozygous <span class=""gene"" id=""14978182-5-46-48"">FH</span> deficiency and <span class=""disease"" id=""14978182-5-64-67"">HUS</span> underwent renal transplantation, which was successful in three but failed as a result of recurrence of <span class=""disease"" id=""14978182-5-171-174"">HUS</span> in one patient.",CTD_human
2,0,Biomarker,C0002395,Alzheimer's Disease,disease,AD,3077,HFE,HFE,CTD_human,15060098,We have examined the interaction between the C2 variant of the transferrin (TF) gene and the C282Y allele of the haemochromatosis (HFE) gene as risk factors for developing AD.,0.248490579541588,"We have examined the interaction between the C2 variant of the transferrin (TF) gene and the C282Y allele of the haemochromatosis (<span class=""gene"" id=""15060098-4-131-134"">HFE</span>) gene as risk factors for developing <span class=""disease"" id=""15060098-4-172-174"">AD</span>.",CTD_human
14,0,Biomarker,C0018995,Hemochromatosis,disease,hemochromatosis,3077,HFE,HFE,CTD_human,17258727,Genetic study of variation in normal mouse iron homeostasis reveals ceruloplasmin as an HFE-hemochromatosis modifier gene.,0.44,"Genetic study of variation in normal mouse iron homeostasis reveals ceruloplasmin as an <span class=""gene"" id=""17258727-0-88-91"">HFE</span>-<span class=""disease"" id=""17258727-0-92-107"">hemochromatosis</span> modifier gene.",CTD_human
14,0,Biomarker,C0018995,Hemochromatosis,disease,hemochromatosis,3077,HFE,HFE,CTD_human,23705020,"Both iron and manganese absorption are regulated by iron status, but the relationships between the transport pathways of these metals and how they are affected by HFE-associated hemochromatosis remain poorly understood.",0.44,"Both iron and manganese absorption are regulated by iron status, but the relationships between the transport pathways of these metals and how they are affected by <span class=""gene"" id=""23705020-2-163-166"">HFE</span>-associated <span class=""disease"" id=""23705020-2-178-193"">hemochromatosis</span> remain poorly understood.",CTD_human
14,0,Biomarker,C0018995,Hemochromatosis,disease,iron overload disease,3077,HFE,HFE,CTD_human,20843714,"Rare HFE variants have been shown to be associated with hereditary hemochromatosis (HH), an iron overload disease.",0.44,"Rare <span class=""gene"" id=""20843714-1-5-8"">HFE</span> variants have been shown to be associated with hereditary hemochromatosis (HH), an <span class=""disease"" id=""20843714-1-92-113"">iron overload disease</span>.",CTD_human
14,0,Biomarker,C0018995,Hemochromatosis,disease,hemochromatosis,3077,HFE,HFE,CTD_human,17255318,"Genetic iron overload, or hemochromatosis, can be caused by mutations in HFE, hemojuvelin, and hepcidin genes.",0.44,"Genetic iron overload, or <span class=""disease"" id=""17255318-1-26-41"">hemochromatosis</span>, can be caused by mutations in <span class=""gene"" id=""17255318-1-73-76"">HFE</span>, hemojuvelin, and hepcidin genes.",CTD_human
14,0,Biomarker,C0018995,Hemochromatosis,disease,hemochromatosis,3077,HFE,HFE,CTD_human,17376729,To shed a light on the molecular mechanism of HFE-related hemochromatosis we studied protein expression changes elicited by HFE-deficiency in the liver which is the organ critical for the regulation of iron metabolism.,0.44,"To shed a light on the molecular mechanism of <span class=""gene"" id=""17376729-5-46-49"">HFE</span>-related <span class=""disease"" id=""17376729-5-58-73"">hemochromatosis</span> we studied protein expression changes elicited by <span class=""gene"" id=""17376729-5-124-127"">HFE</span>-deficiency in the liver which is the organ critical for the regulation of iron metabolism.",CTD_human
1,0,Biomarker,C0030567,Parkinson Disease,disease,Parkinson's disease,3077,HFE,HFE,CTD_human,16824219,"Association of HFE common mutations with Parkinson's disease, Alzheimer's disease and mild cognitive impairment in a Portuguese cohort.",0.21964762466246,"Association of <span class=""gene"" id=""16824219-0-15-18"">HFE</span> common mutations with <span class=""disease"" id=""16824219-0-41-60"">Parkinson's disease</span>, Alzheimer's disease and mild cognitive impairment in a Portuguese cohort.",CTD_human
1,0,Biomarker,C3463824,MYELODYSPLASTIC SYNDROME,group,MDS,3077,HFE,HFE,CTD_human,17001480,We found significant differences in the frequencies of the HFE genetic variants between MDS and MM patients with strong correlation to their iron metabolism.,0.21155120158264398,"We found significant differences in the frequencies of the <span class=""gene"" id=""17001480-8-59-62"">HFE</span> genetic variants between <span class=""disease"" id=""17001480-8-88-91"">MDS</span> and MM patients with strong correlation to their iron metabolism.",CTD_human
1,0,Biomarker,C0019202,Hepatolenticular Degeneration,disease,WD,308,ANXA5,annexin A5,CTD_human,21751376,"Notably, the expression of malate dehydrogenase 1 was downregulated while the annexin A5 was overexpressed in an age-dependent manner, indicating that these proteins may be involved in the WD process.",0.28,"Notably, the expression of malate dehydrogenase 1 was downregulated while the <span class=""gene"" id=""21751376-5-78-88"">annexin A5</span> was overexpressed in an age-dependent manner, indicating that these proteins may be involved in the <span class=""disease"" id=""21751376-5-189-191"">WD</span> process.",CTD_human
1,0,Biomarker,C0031117,Peripheral Neuropathy,group,peripheral neuropathy,30812,SOX8,SOX8,CTD_human,20864405,"Significant genes in myeloma plasma cells from patients that were associated with early-onset bortezomib-induced peripheral neuropathy were the enzyme coding genes RHOBTB2 (upregulated by 1·59 times; p=4·5×10(-5)), involved in drug-induced apoptosis, CPT1C (1·44 times; p=2·9×10(-7)), involved in mitochondrial dysfunction, and SOX8 (1·68 times; p=4·28×10(-13)), involved in development of peripheral nervous system.",0.200274726784213,"Significant genes in myeloma plasma cells from patients that were associated with early-onset bortezomib-induced <span class=""disease"" id=""20864405-9-113-134"">peripheral neuropathy</span> were the enzyme coding genes RHOBTB2 (upregulated by 1·59 times; p=4·5&times;10(-5)), involved in drug-induced apoptosis, CPT1C (1·44 times; p=2·9&times;10(-7)), involved in mitochondrial dysfunction, and <span class=""gene"" id=""20864405-9-328-332"">SOX8</span> (1·68 times; p=4·28&times;10(-13)), involved in development of peripheral nervous system.",CTD_human
1,0,Biomarker,C0014008,Empty Sella Syndrome,disease,empty sella,30813,VSX1,RINX,CTD_human,15051220,"VSX1 (RINX) mutation with craniofacial anomalies, empty sella, corneal endothelial changes, and abnormal retinal and auditory bipolar cells.",0.2,"<span class=""gene"" id=""15051220-0-0-4"">VSX1</span> (<span class=""gene"" id=""15051220-0-6-10"">RINX</span>) mutation with craniofacial anomalies, <span class=""disease"" id=""15051220-0-50-61"">empty sella</span>, corneal endothelial changes, and abnormal retinal and auditory bipolar cells.",CTD_human
2,0,Biomarker,C0022578,Keratoconus,disease,keratoconus,30813,VSX1,VSX1,CTD_human,15623752,VSX1 mutational analysis in a series of Italian patients affected by keratoconus: detection of a novel mutation.,0.427875072811535,"<span class=""gene"" id=""15623752-0-0-4"">VSX1</span> mutational analysis in a series of Italian patients affected by <span class=""disease"" id=""15623752-0-69-80"">keratoconus</span>: detection of a novel mutation.",CTD_human;HPO
2,0,Biomarker,C0022578,Keratoconus,disease,keratoconus,30813,VSX1,VSX1,CTD_human,11978762,VSX1: a gene for posterior polymorphous dystrophy and keratoconus.,0.427875072811535,"<span class=""gene"" id=""11978762-0-0-4"">VSX1</span>: a gene for posterior polymorphous dystrophy and <span class=""disease"" id=""11978762-0-54-65"">keratoconus</span>.",CTD_human;HPO
1,0,Biomarker,C0376634,Craniofacial Abnormalities,group,craniofacial anomalies,30813,VSX1,RINX,CTD_human,15051220,"VSX1 (RINX) mutation with craniofacial anomalies, empty sella, corneal endothelial changes, and abnormal retinal and auditory bipolar cells.",0.200274726784213,"<span class=""gene"" id=""15051220-0-0-4"">VSX1</span> (<span class=""gene"" id=""15051220-0-6-10"">RINX</span>) mutation with <span class=""disease"" id=""15051220-0-26-48"">craniofacial anomalies</span>, empty sella, corneal endothelial changes, and abnormal retinal and auditory bipolar cells.",CTD_human
1,0,Biomarker,C0004114,Astrocytoma,disease,astrocytoma,3082,HGF,hepatocyte growth factor,CTD_human,11223164,Agonists of the retinoic acid- and retinoid X-receptors inhibit hepatocyte growth factor secretion and expression in U87 human astrocytoma cells.,0.201098907136852,"Agonists of the retinoic acid- and retinoid X-receptors inhibit <span class=""gene"" id=""11223164-0-64-88"">hepatocyte growth factor</span> secretion and expression in U87 human <span class=""disease"" id=""11223164-0-127-138"">astrocytoma</span> cells.",CTD_human
1,0,Biomarker,C0004763,Barrett Esophagus,disease,BE,3082,HGF,HGF,CTD_human,15387324,"(1) COX-2, PPARgamma, HGF, gastrin, and its receptor are significantly upregulated in BE, suggesting a possible role for these factors in Barrett's carcinogenesis; (2) the increased NFkappaB activity is probably linked to increased IL-8 and COX-2 expression; and (3) PPARgamma ligands might be useful as a new therapeutic option in the prevention and treatment of Barrett's carcinoma.",0.2,"(1) COX-2, PPARgamma, <span class=""gene"" id=""15387324-9-22-25"">HGF</span>, gastrin, and its receptor are significantly upregulated in <span class=""disease"" id=""15387324-9-86-88"">BE</span>, suggesting a possible role for these factors in Barrett's carcinogenesis; (2) the increased NFkappaB activity is probably linked to increased IL-8 and COX-2 expression; and (3) PPARgamma ligands might be useful as a new therapeutic option in the prevention and treatment of Barrett's carcinoma.",CTD_human
1,0,Therapeutic,C0011882,Diabetic Neuropathies,group,diabetic neuropathy,3082,HGF,HGF,CTD_human,26000320,"Double-blind, placebo-controlled study of HGF gene therapy in diabetic neuropathy.",0.200274726784213,"Double-blind, placebo-controlled study of <span class=""gene"" id=""26000320-0-42-45"">HGF</span> gene therapy in <span class=""disease"" id=""26000320-0-62-81"">diabetic neuropathy</span>.",CTD_human
1,0,Biomarker,C0023467,"Leukemia, Myelocytic, Acute",disease,AML,3082,HGF,HGF,CTD_human,22683780,"Our results show a widespread dependence of AML cells on autocrine activation of MET, as well as the key role of compensatory upregulation of HGF expression in maintaining leukemogenic signaling by this receptor.",0.20300763924902696,"Our results show a widespread dependence of <span class=""disease"" id=""22683780-8-44-47"">AML</span> cells on autocrine activation of MET, as well as the key role of compensatory upregulation of <span class=""gene"" id=""22683780-8-142-145"">HGF</span> expression in maintaining leukemogenic signaling by this receptor.",CTD_human
1,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastasis,3082,HGF,HGF,CTD_human,25971889,Hepatocyte growth factor (HGF)-mediated activation of c-Met signaling has been suggested as a therapeutic target for melanoma metastasis.,0.24087686933848299,"<span class=""gene"" id=""25971889-3-0-24"">Hepatocyte growth factor</span> (<span class=""gene"" id=""25971889-3-26-29"">HGF</span>)-mediated activation of c-Met signaling has been suggested as a therapeutic target for melanoma <span class=""disease"" id=""25971889-3-126-136"">metastasis</span>.",CTD_human
1,0,Biomarker,C0027819,Neuroblastoma,disease,neuroblastoma,3082,HGF,HGF,CTD_human,16051641,We conclude that TrkB expression in neuroblastoma cells results in an increase in their invasive capability via upregulated expression of HGF/c-Met and enhanced activity of proteolytic networks.,0.201098907136852,"We conclude that TrkB expression in <span class=""disease"" id=""16051641-12-36-49"">neuroblastoma</span> cells results in an increase in their invasive capability via upregulated expression of <span class=""gene"" id=""16051641-12-138-141"">HGF</span>/c-Met and enhanced activity of proteolytic networks.",CTD_human
1,0,Therapeutic,C0030305,Pancreatitis,disease,pancreatitis,3082,HGF,hepatocyte growth factor,CTD_human,14751415,Inhibition of cyclooxygenase-2 reduces the protective effect of hepatocyte growth factor in experimental pancreatitis.,0.2,"Inhibition of cyclooxygenase-2 reduces the protective effect of <span class=""gene"" id=""14751415-0-64-88"">hepatocyte growth factor</span> in experimental <span class=""disease"" id=""14751415-0-105-117"">pancreatitis</span>.",CTD_human
1,0,Therapeutic,C0030567,Parkinson Disease,disease,Parkinson's disease,3082,HGF,hepatocyte growth factor,CTD_human,16791285,Prevention of onset of Parkinson's disease by in vivo gene transfer of human hepatocyte growth factor in rodent model: a model of gene therapy for Parkinson's disease.,0.200274726784213,"Prevention of onset of <span class=""disease"" id=""16791285-0-23-42"">Parkinson's disease</span> by in vivo gene transfer of human <span class=""gene"" id=""16791285-0-77-101"">hepatocyte growth factor</span> in rodent model: a model of gene therapy for <span class=""disease"" id=""16791285-0-147-166"">Parkinson's disease</span>.",CTD_human
2,0,Therapeutic,C0878544,Cardiomyopathies,group,cardiomyopathy,3082,HGF,hepatocyte growth factor,CTD_human,18083897,Treatment with an adenoviral vector encoding hepatocyte growth factor mitigates established cardiac dysfunction in doxorubicin-induced cardiomyopathy.,0.20082418035263896,"Treatment with an adenoviral vector encoding <span class=""gene"" id=""18083897-0-45-69"">hepatocyte growth factor</span> mitigates established cardiac dysfunction in doxorubicin-induced <span class=""disease"" id=""18083897-0-135-149"">cardiomyopathy</span>.",CTD_human
2,0,Therapeutic,C0878544,Cardiomyopathies,group,cardiomyopathy,3082,HGF,Hepatocyte growth factor,CTD_human,16109756,Hepatocyte growth factor delivered by ultrasound-mediated destruction of microbubbles induces proliferation of cardiomyocytes and amelioration of left ventricular contractile function in Doxorubicin-induced cardiomyopathy.,0.20082418035263896,"<span class=""gene"" id=""16109756-0-0-24"">Hepatocyte growth factor</span> delivered by ultrasound-mediated destruction of microbubbles induces proliferation of cardiomyocytes and amelioration of left ventricular contractile function in Doxorubicin-induced <span class=""disease"" id=""16109756-0-207-221"">cardiomyopathy</span>.",CTD_human
1,0,Biomarker,C0011311,Dengue Fever,disease,dengue,30835,CD209,CD209,CTD_human,15838506,A variant in the CD209 promoter is associated with severity of dengue disease.,0.203296721410557,"A variant in the <span class=""gene"" id=""15838506-0-17-22"">CD209</span> promoter is associated with severity of <span class=""disease"" id=""15838506-0-63-69"">dengue</span> disease.",CTD_human
1,0,Therapeutic,C0018801,Heart failure,disease,heart failure,3084,NRG1,NRG1,CTD_human,19801490,Neuregulin-1 (NRG1) is a potential therapeutic agent for the treatment of doxorubicin (Dox)-induced heart failure.,0.201098907136852,"<span class=""gene"" id=""19801490-1-0-12"">Neuregulin-1</span> (<span class=""gene"" id=""19801490-1-14-18"">NRG1</span>) is a potential therapeutic agent for the treatment of doxorubicin (Dox)-induced <span class=""disease"" id=""19801490-1-100-113"">heart failure</span>.",CTD_human
1,2,Biomarker,C0019569,Hirschsprung Disease,disease,Hirschsprung disease,3084,NRG1,NRG1,CTD_human,22974608,Aberrant high expression of NRG1 gene in Hirschsprung disease.,0.20274726784213098,"Aberrant high expression of <span class=""gene"" id=""22974608-0-28-32"">NRG1</span> gene in <span class=""disease"" id=""22974608-0-41-61"">Hirschsprung disease</span>.",CTD_human
1,0,Biomarker,C0030193,Pain,phenotype,pain,3084,NRG1,NRG1,CTD_human,20561508,"At baseline, deletion of NRG1 and DISC1 each reduced thermal pain sensitivity, while deletion of COMT increased pain sensitivity.",0.200274726784213,"At baseline, deletion of <span class=""gene"" id=""20561508-4-25-29"">NRG1</span> and DISC1 each reduced thermal <span class=""disease"" id=""20561508-4-61-65"">pain</span> sensitivity, while deletion of COMT increased <span class=""disease"" id=""20561508-4-112-116"">pain</span> sensitivity.",CTD_human
7,0,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,3084,NRG1,neuregulin 1,CTD_human,17333138,It appears that variation in the schizophrenia-related neuregulin 1 gene alters the sensitivity to the behavioural effects of cannabinoids.,0.41384644970576795,"It appears that variation in the <span class=""disease"" id=""17333138-10-33-46"">schizophrenia</span>-related <span class=""gene"" id=""17333138-10-55-67"">neuregulin 1</span> gene alters the sensitivity to the behavioural effects of cannabinoids.",CTD_human
7,0,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,3084,NRG1,Neuregulin 1,CTD_human,12145742,Neuregulin 1 and susceptibility to schizophrenia.,0.41384644970576795,"<span class=""gene"" id=""12145742-0-0-12"">Neuregulin 1</span> and susceptibility to <span class=""disease"" id=""12145742-0-35-48"">schizophrenia</span>.",CTD_human
7,0,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,3084,NRG1,NRG1,CTD_human,17460065,"Furthermore, we showed that NRG1+/- mutant mice display behavioral abnormalities that are reversed by clozapine, an atypical antipsychotic drug used for the treatment of schizophrenia.",0.41384644970576795,"Furthermore, we showed that <span class=""gene"" id=""17460065-2-28-32"">NRG1</span>+/- mutant mice display behavioral abnormalities that are reversed by clozapine, an atypical antipsychotic drug used for the treatment of <span class=""disease"" id=""17460065-2-170-183"">schizophrenia</span>.",CTD_human
7,0,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,3084,NRG1,Nrg1,CTD_human,17905522,"Consistent with Nrg1 HET mice exhibiting a schizophrenia-related phenotype, these mice expressed greater drug-free levels of c-Fos in two regions thought to be involved in schizophrenia, the shell of the nucleus accumbens and the lateral septum.",0.41384644970576795,"Consistent with <span class=""gene"" id=""17905522-7-16-20"">Nrg1</span> HET mice exhibiting a <span class=""disease"" id=""17905522-7-43-56"">schizophrenia</span>-related phenotype, these mice expressed greater drug-free levels of c-Fos in two regions thought to be involved in <span class=""disease"" id=""17905522-7-172-185"">schizophrenia</span>, the shell of the nucleus accumbens and the lateral septum.",CTD_human
7,0,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,3084,NRG1,NRG1,CTD_human,20561508,"Disruption of thermal nociceptive behaviour in mice mutant for the schizophrenia-associated genes NRG1, COMT and DISC1.",0.41384644970576795,"Disruption of thermal nociceptive behaviour in mice mutant for the <span class=""disease"" id=""20561508-0-67-80"">schizophrenia</span>-associated genes <span class=""gene"" id=""20561508-0-98-102"">NRG1</span>, COMT and DISC1.",CTD_human
7,0,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,3084,NRG1,neuregulin 1,CTD_human,20701826,The schizophrenia susceptibility gene neuregulin 1 modulates tolerance to the effects of cannabinoids.,0.41384644970576795,"The <span class=""disease"" id=""20701826-0-4-17"">schizophrenia</span> susceptibility gene <span class=""gene"" id=""20701826-0-38-50"">neuregulin 1</span> modulates tolerance to the effects of cannabinoids.",CTD_human
1,0,Biomarker,C0023467,"Leukemia, Myelocytic, Acute",disease,AML,30845,EHD3,Ehd3,CTD_human,17330099,Ehd3 was methylated in 63% of AML patients examined.,0.200274726784213,"<span class=""gene"" id=""17330099-8-0-4"">Ehd3</span> was methylated in 63% of <span class=""disease"" id=""17330099-8-30-33"">AML</span> patients examined.",CTD_human
1,0,Biomarker,C0025149,Medulloblastoma,disease,medulloblastoma,3090,HIC1,Hic1,CTD_human,18347096,Cooperation between the Hic1 and Ptch1 tumor suppressors in medulloblastoma.,0.205205453522732,"Cooperation between the <span class=""gene"" id=""18347096-0-24-28"">Hic1</span> and Ptch1 tumor suppressors in <span class=""disease"" id=""18347096-0-60-75"">medulloblastoma</span>.",CTD_human
1,0,Biomarker,C0032584,polyps,phenotype,polyp,3090,HIC1,Hic1,CTD_human,21297660,Loss of a single Hic1 allele accelerates polyp formation in Apc(?716) mice.,0.200274726784213,"Loss of a single <span class=""gene"" id=""21297660-0-17-21"">Hic1</span> allele accelerates <span class=""disease"" id=""21297660-0-41-46"">polyp</span> formation in Apc(&Delta;716) mice.",CTD_human
1,0,Biomarker,C0007124,Noninfiltrating Intraductal Carcinoma,disease,DCIS,3091,HIF1A,HIF-1alpha,CTD_human,20526721,"HIF-1alpha was not expressed in benign breast tissue, whereas it was significantly expressed in DH, ADH, DCIS, and IDC (p < 0.001).",0.202956482091714,"<span class=""gene"" id=""20526721-8-0-10"">HIF-1alpha</span> was not expressed in benign breast tissue, whereas it was significantly expressed in DH, ADH, <span class=""disease"" id=""20526721-8-105-109"">DCIS</span>, and IDC (p &lt; 0.001).",CTD_human
1,0,Biomarker,C0018801,Heart failure,disease,heart failure,3091,HIF1A,HIF-1alpha,CTD_human,15732037,HIF-1alpha and VEGF mRNA and protein expression were upregulated in the rat model of volume-overload heart failure.,0.281923087489492,"<span class=""gene"" id=""15732037-13-0-10"">HIF-1alpha</span> and VEGF mRNA and protein expression were upregulated in the rat model of volume-overload <span class=""disease"" id=""15732037-13-101-114"">heart failure</span>.",CTD_human
1,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,3091,HIF1A,HIF-1?,CTD_human,22349312,Overexpression of HIF-1? transgene in the renal medulla attenuated salt sensitive hypertension in Dahl S rats.,0.206579087443797,"Overexpression of <span class=""gene"" id=""22349312-0-18-24"">HIF-1&alpha;</span> transgene in the renal medulla attenuated salt sensitive <span class=""disease"" id=""22349312-0-82-94"">hypertension</span> in Dahl S rats.",CTD_human
1,0,Biomarker,C0279626,Squamous cell carcinoma of esophagus,disease,esophageal squamous cell carcinoma,3091,HIF1A,HIF-1alpha,CTD_human,17201171,"HIF-1alpha mRNA expression is differentially upregulated in esophageal squamous cell carcinoma compared to adenocarcinomas, but does not predict tumor regression or prognosis.",0.202197814273705,"<span class=""gene"" id=""17201171-9-0-10"">HIF-1alpha</span> mRNA expression is differentially upregulated in <span class=""disease"" id=""17201171-9-60-94"">esophageal squamous cell carcinoma</span> compared to adenocarcinomas, but does not predict tumor regression or prognosis.",CTD_human
2,0,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,3094,HINT1,HINT1,CTD_human,20514075,"Because nicotine dependence (ND) is highly comorbid with schizophrenia and other substance abuse, we examined the association of HINT1 with ND.",0.203231208875927,"Because nicotine dependence (ND) is highly comorbid with <span class=""disease"" id=""20514075-2-57-70"">schizophrenia</span> and other substance abuse, we examined the association of <span class=""gene"" id=""20514075-2-129-134"">HINT1</span> with ND.",CTD_human
2,0,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,3094,HINT1,HINT1,CTD_human,17203012,"In view of the documented link between dopamine (DA) transmission and schizophrenia, the present study used behavioral and neurochemical approaches to examine the influence of constitutive PKCI/HINT1 deletion upon: (i) basal and amphetamine (AMPH)-evoked locomotor activity; (ii) DA dynamics in the dorsal striatum, and (iii) postsynaptic DA receptor function.",0.203231208875927,"In view of the documented link between dopamine (DA) transmission and <span class=""disease"" id=""17203012-4-70-83"">schizophrenia</span>, the present study used behavioral and neurochemical approaches to examine the influence of constitutive PKCI/<span class=""gene"" id=""17203012-4-194-199"">HINT1</span> deletion upon: (i) basal and amphetamine (AMPH)-evoked locomotor activity; (ii) DA dynamics in the dorsal striatum, and (iii) postsynaptic DA receptor function.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autistic,3105,HLA-A,HLA-A,CTD_human,16720216,"To better understand which HLA genetic loci may be associated with autism, we compared the class I HLA-A and -B alleles in autistic probands with case control subjects from Caucasian families.",0.20568939455652804,"To better understand which HLA genetic loci may be associated with <span class=""disease"" id=""16720216-2-67-73"">autism</span>, we compared the class I <span class=""gene"" id=""16720216-2-99-104"">HLA-A</span> and -B alleles in <span class=""disease"" id=""16720216-2-123-131"">autistic</span> probands with case control subjects from Caucasian families.",CTD_human
1,0,Biomarker,C0017638,Glioma,disease,glioma,3105,HLA-A,HLA-A,CTD_human,14511464,"By flow cytometry, a panel of 18 primary glioma cell explants exhibited high expression of class I HLA-A, B, C, but class II HLA-DR expression was absent.",0.203231208875927,"By flow cytometry, a panel of 18 primary <span class=""disease"" id=""14511464-1-41-47"">glioma</span> cell explants exhibited high expression of class I <span class=""gene"" id=""14511464-1-99-104"">HLA-A</span>, B, C, but class II HLA-DR expression was absent.",CTD_human
1,0,Biomarker,C0026764,Multiple Myeloma,disease,multiple myeloma,3105,HLA-A,HLA-A,CTD_human,17283154,"Both multiple myeloma cell lines and primary multiple myeloma cells expressed HLA-A at higher levels than normal myeloid cells, lymphocytes, or hematopoietic stem cells.",0.203557092817453,"Both <span class=""disease"" id=""17283154-5-5-21"">multiple myeloma</span> cell lines and primary <span class=""disease"" id=""17283154-5-45-61"">multiple myeloma</span> cells expressed <span class=""gene"" id=""17283154-5-78-83"">HLA-A</span> at higher levels than normal myeloid cells, lymphocytes, or hematopoietic stem cells.",CTD_human
2,0,Biomarker,C0004943,Behcet Syndrome,disease,Beh?et's disease,3106,HLA-B,HLA-B,CTD_human,23396137,"Our data suggest that the robust HLA-B*51 association in Beh?et's disease is explained by a variant located between the HLA-B and MICA genes (rs116799036: odds ratio (OR) = 3.88, P = 9.42 × 10(-50)).",0.5112614318910239,"Our data suggest that the robust <span class=""gene"" id=""23396137-5-33-38"">HLA-B</span>*51 association in <span class=""disease"" id=""23396137-5-57-73"">Beh&Ccedil;et's disease</span> is explained by a variant located between the <span class=""gene"" id=""23396137-5-120-125"">HLA-B</span> and MICA genes (rs116799036: odds ratio (OR) = 3.88, P = 9.42 &times; 10(-50)).",CTD_human;ORPHANET
2,0,Biomarker,C0004943,Behcet Syndrome,disease,Beh?et's disease,3106,HLA-B,HLA-B,CTD_human,20622878,"We confirmed the known association of Beh?et's disease with HLA-B*51 and identified a second, independent association within the MHC Class I region.",0.5112614318910239,"We confirmed the known association of <span class=""disease"" id=""20622878-3-38-54"">Beh&Ccedil;et's disease</span> with <span class=""gene"" id=""20622878-3-60-65"">HLA-B</span>*51 and identified a second, independent association within the MHC Class I region.",CTD_human;ORPHANET
2,0,Biomarker,C0011603,Dermatitis,disease,dermatitis,3106,HLA-B,HLA-B,CTD_human,18007983,HLA-B*1301 as a biomarker for genetic susceptibility to hypersensitivity dermatitis induced by trichloroethylene among workers in China.,0.20541466777231498,"<span class=""gene"" id=""18007983-0-0-5"">HLA-B</span>*1301 as a biomarker for genetic susceptibility to hypersensitivity <span class=""disease"" id=""18007983-0-73-83"">dermatitis</span> induced by trichloroethylene among workers in China.",CTD_human
1,0,Biomarker,C0019693,HIV Infections,group,HIV,3106,HLA-B,HLA-B,CTD_human,17496894,Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1.,0.29782853021921696,"Innate partnership of <span class=""gene"" id=""17496894-0-22-27"">HLA-B</span> and KIR3DL1 subtypes against <span class=""disease"" id=""17496894-0-57-60"">HIV</span>-1.",CTD_human
9,0,Biomarker,C0038325,Stevens-Johnson Syndrome,disease,Stevens-Johnson syndrome,3106,HLA-B,HLA-B,CTD_human,15057820,"Here we show that there is a strong association in Han Chinese between a genetic marker, the human leukocyte antigen HLA-B*1502, and Stevens-Johnson syndrome induced by carbamazepine, a drug commonly prescribed for the treatment of seizures.",0.457454249105995,"Here we show that there is a strong association in Han Chinese between a genetic marker, the human leukocyte antigen <span class=""gene"" id=""15057820-2-117-122"">HLA-B</span>*1502, and <span class=""disease"" id=""15057820-2-133-157"">Stevens-Johnson syndrome</span> induced by carbamazepine, a drug commonly prescribed for the treatment of seizures.",CTD_human;ORPHANET
9,0,Biomarker,C0038325,Stevens-Johnson Syndrome,disease,Stevens-Johnson syndrome,3106,HLA-B,HLA-B,CTD_human,20485159,The association of the HLA-B*1502 allele with CBZ-induced Stevens-Johnson syndrome in Asian population has also recently been observed.,0.457454249105995,"The association of the <span class=""gene"" id=""20485159-5-23-28"">HLA-B</span>*1502 allele with CBZ-induced <span class=""disease"" id=""20485159-5-58-82"">Stevens-Johnson syndrome</span> in Asian population has also recently been observed.",CTD_human;ORPHANET
9,0,Biomarker,C0038325,Stevens-Johnson Syndrome,disease,Stevens-Johnson syndrome,3106,HLA-B,HLA-B,CTD_human,25099164,"Furthermore, the variant allele HLA-B*15:02, encoding human leukocyte antigen, is associated with an increased risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in response to phenytoin treatment.",0.457454249105995,"Furthermore, the variant allele <span class=""gene"" id=""25099164-2-32-37"">HLA-B</span>*15:02, encoding human leukocyte antigen, is associated with an increased risk of <span class=""disease"" id=""25099164-2-119-143"">Stevens-Johnson syndrome</span> and toxic epidermal necrolysis in response to phenytoin treatment.",CTD_human;ORPHANET
9,0,Biomarker,C0038325,Stevens-Johnson Syndrome,disease,Stevens-Johnson syndrome,3106,HLA-B,HLA-B,CTD_human,19694795,It is reported recently that the human leukocyte antigen HLA-B*1502 is associated with Stevens-Johnson syndrome (SJS) induced by CBZ in Han Chinese.,0.457454249105995,"It is reported recently that the human leukocyte antigen <span class=""gene"" id=""19694795-2-57-62"">HLA-B</span>*1502 is associated with <span class=""disease"" id=""19694795-2-87-111"">Stevens-Johnson syndrome</span> (SJS) induced by CBZ in Han Chinese.",CTD_human;ORPHANET
9,0,Biomarker,C0038325,Stevens-Johnson Syndrome,disease,Stevens-Johnson syndrome,3106,HLA-B,HLA-B,CTD_human,19915237,Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians.,0.457454249105995,"Association of <span class=""gene"" id=""19915237-0-15-20"">HLA-B</span>*1502 allele and carbamazepine-induced <span class=""disease"" id=""19915237-0-59-83"">Stevens-Johnson syndrome</span> among Indians.",CTD_human;ORPHANET
9,0,Biomarker,C0038325,Stevens-Johnson Syndrome,disease,Stevens-Johnson syndrome,3106,HLA-B,HLA-B,CTD_human,18855540,"Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations.",0.457454249105995,"Carbamazepine, <span class=""gene"" id=""18855540-0-15-20"">HLA-B</span>*1502 and risk of <span class=""disease"" id=""18855540-0-38-62"">Stevens-Johnson syndrome</span> and toxic epidermal necrolysis: US FDA recommendations.",CTD_human;ORPHANET
1,1,Biomarker,C0003872,"Arthritis, Psoriatic",disease,PsA,3107,HLA-C,HLA-C,CTD_human,20953186,"We replicated PsA associations at HLA-C and IL12B and identified a new association at TRAF3IP2 (rs13190932, P = 8.56 × 10?¹?).",0.24976189914802802,"We replicated <span class=""disease"" id=""20953186-3-14-17"">PsA</span> associations at <span class=""gene"" id=""20953186-3-34-39"">HLA-C</span> and IL12B and identified a new association at TRAF3IP2 (rs13190932, P = 8.56 &times; 10?¹?).",CTD_human
2,0,Biomarker,C0033860,Psoriasis,disease,psoriasis,3107,HLA-C,HLA-C,CTD_human,20953190,A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1.,0.340860147699453,"A genome-wide association study identifies new <span class=""disease"" id=""20953190-0-47-56"">psoriasis</span> susceptibility loci and an interaction between <span class=""gene"" id=""20953190-0-104-109"">HLA-C</span> and ERAP1.",CTD_human
1,0,Biomarker,C0036202,Sarcoidosis,disease,sarcoidosis,311,ANXA11,ANXA11,CTD_human,19165924,Genome-wide association study identifies ANXA11 as a new susceptibility locus for sarcoidosis.,0.20673714453606798,"Genome-wide association study identifies <span class=""gene"" id=""19165924-0-41-47"">ANXA11</span> as a new susceptibility locus for <span class=""disease"" id=""19165924-0-82-93"">sarcoidosis</span>.",CTD_human
1,1,Biomarker,C0524909,"Hepatitis B, Chronic",disease,chronic hepatitis B,3113,HLA-DPA1,HLA-DPA1,CTD_human,19349983,"Through a two-stage genome-wide association study using 786 Japanese chronic hepatitis B cases and 2,201 controls, we identified a significant association of chronic hepatitis B with 11 SNPs in a region including HLA-DPA1 and HLA-DPB1.",0.20350593566014002,"Through a two-stage genome-wide association study using 786 Japanese <span class=""disease"" id=""19349983-2-69-88"">chronic hepatitis B</span> cases and 2,201 controls, we identified a significant association of <span class=""disease"" id=""19349983-2-158-177"">chronic hepatitis B</span> with 11 SNPs in a region including <span class=""gene"" id=""19349983-2-213-221"">HLA-DPA1</span> and HLA-DPB1.",CTD_human
2,1,Biomarker,C0004096,Asthma,disease,asthma,3115,HLA-DPB1,DPB1,CTD_human,16792590,The HLA haplotype DRB1*15-DPB1*05 can be a susceptibility gene marker for the development of TDI-induced asthma among the exposed workers in the Korean population.,0.225113449592087,"The HLA haplotype DRB1*15-<span class=""gene"" id=""16792590-10-26-30"">DPB1</span>*05 can be a susceptibility gene marker for the development of TDI-induced <span class=""disease"" id=""16792590-10-105-111"">asthma</span> among the exposed workers in the Korean population.",CTD_human
3,0,Biomarker,C0036202,Sarcoidosis,disease,sarcoidosis,3115,HLA-DPB1,HLA-DPB,CTD_human,8909942,HLA-DPB polymorphisms: Glu 69 association with sarcoidosis.,0.20701187132028098,"<span class=""gene"" id=""8909942-0-0-7"">HLA-DPB</span> polymorphisms: Glu 69 association with <span class=""disease"" id=""8909942-0-47-58"">sarcoidosis</span>.",CTD_human
3,0,Biomarker,C0036202,Sarcoidosis,disease,sarcoidosis,3115,HLA-DPB1,DPB1,CTD_human,14508706,"In addition to being susceptibility markers, HLA class II alleles may be markers for different phenotypes of sarcoidosis (DRB1*0401 for eye in blacks and whites, DRB3 for bone marrow in blacks, and DPB1*0101 for hypercalcemia in whites).",0.20701187132028098,"In addition to being susceptibility markers, HLA class II alleles may be markers for different phenotypes of <span class=""disease"" id=""14508706-11-109-120"">sarcoidosis</span> (DRB1*0401 for eye in blacks and whites, DRB3 for bone marrow in blacks, and <span class=""gene"" id=""14508706-11-198-202"">DPB1</span>*0101 for hypercalcemia in whites).",CTD_human
1,1,Biomarker,C0524909,"Hepatitis B, Chronic",disease,chronic hepatitis B,3115,HLA-DPB1,HLA-DP,CTD_human,19349983,A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians.,0.206802657070698,"A genome-wide association study identifies variants in the <span class=""gene"" id=""19349983-0-59-65"">HLA-DP</span> locus associated with <span class=""disease"" id=""19349983-0-88-107"">chronic hepatitis B</span> in Asians.",CTD_human
1,1,Biomarker,C1319853,"Asthma, Aspirin-Induced",disease,AIA,3115,HLA-DPB1,DPB1,CTD_human,16502481,"An HLA study suggested that DPB1*0301 is a strong genetic marker for AIA, and that HLA DRB1*1302 and DQB1*0609 are markers for AIU susceptibility.",0.20054945356842604,"An HLA study suggested that <span class=""gene"" id=""16502481-5-28-32"">DPB1</span>*0301 is a strong genetic marker for <span class=""disease"" id=""16502481-5-69-72"">AIA</span>, and that HLA DRB1*1302 and DQB1*0609 are markers for AIU susceptibility.",CTD_human
1,0,Biomarker,C0011603,Dermatitis,disease,dermatitis,3117,HLA-DQA1,HLA-DQA1,CTD_human,16836882,The genetic polymorphisms of HLA-DQA1 might be one of the factors influencing the individual susceptibility to TCE-induced severe generalized dermatitis.,0.20240702852328799,"The genetic polymorphisms of <span class=""gene"" id=""16836882-8-29-37"">HLA-DQA1</span> might be one of the factors influencing the individual susceptibility to TCE-induced severe generalized <span class=""disease"" id=""16836882-8-142-152"">dermatitis</span>.",CTD_human
1,0,Biomarker,C0014848,Esophageal Achalasia,disease,achalasia,3117,HLA-DQA1,HLA-DQA1,CTD_human,24997987,"In addition, two amino acid substitutions in the extracellular domain of HLA-DQ?1 at position 41 (lysine encoded by HLA-DQA1*01:03; P=5.60×10(-10)) and of HLA-DQ?1 at position 45 (glutamic acid encoded by HLA-DQB1*03:01 and HLA-DQB1*03:04; P=1.20×10(-9)) independently confer achalasia risk.",0.40027472678421294,"In addition, two amino acid substitutions in the extracellular domain of HLA-DQ&alpha;1 at position 41 (lysine encoded by <span class=""gene"" id=""24997987-5-116-124"">HLA-DQA1</span>*01:03; P=5.60&times;10(-10)) and of HLA-DQ&beta;1 at position 45 (glutamic acid encoded by HLA-DQB1*03:01 and HLA-DQB1*03:04; P=1.20&times;10(-9)) independently confer <span class=""disease"" id=""24997987-5-276-285"">achalasia</span> risk.",CTD_human;HPO
1,0,Biomarker,C0023290,"Leishmaniasis, Visceral",disease,visceral leishmaniasis,3117,HLA-DQA1,HLA-DQA1,CTD_human,23291585,Common variants in the HLA-DRB1-HLA-DQA1 HLA class II region are associated with susceptibility to visceral leishmaniasis.,0.200274726784213,"Common variants in the HLA-DRB1-<span class=""gene"" id=""23291585-0-32-40"">HLA-DQA1</span> HLA class II region are associated with susceptibility to <span class=""disease"" id=""23291585-0-99-121"">visceral leishmaniasis</span>.",CTD_human
1,0,Biomarker,C0030305,Pancreatitis,disease,pancreatitis,3117,HLA-DQA1,HLA-DQA1,CTD_human,25217962,HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants.,0.200274726784213,"<span class=""gene"" id=""25217962-0-0-8"">HLA-DQA1</span>-HLA-DRB1 variants confer susceptibility to <span class=""disease"" id=""25217962-0-52-64"">pancreatitis</span> induced by thiopurine immunosuppressants.",CTD_human
1,0,Biomarker,C0014848,Esophageal Achalasia,disease,achalasia,3119,HLA-DQB1,HLA-DQB1,CTD_human,24997987,"In addition, two amino acid substitutions in the extracellular domain of HLA-DQ?1 at position 41 (lysine encoded by HLA-DQA1*01:03; P=5.60×10(-10)) and of HLA-DQ?1 at position 45 (glutamic acid encoded by HLA-DQB1*03:01 and HLA-DQB1*03:04; P=1.20×10(-9)) independently confer achalasia risk.",0.40027472678421294,"In addition, two amino acid substitutions in the extracellular domain of HLA-DQ&alpha;1 at position 41 (lysine encoded by HLA-DQA1*01:03; P=5.60&times;10(-10)) and of HLA-DQ&beta;1 at position 45 (glutamic acid encoded by <span class=""gene"" id=""24997987-5-205-213"">HLA-DQB1</span>*03:01 and <span class=""gene"" id=""24997987-5-224-232"">HLA-DQB1</span>*03:04; P=1.20&times;10(-9)) independently confer <span class=""disease"" id=""24997987-5-276-285"">achalasia</span> risk.",CTD_human;HPO
1,2,Biomarker,C0026769,Multiple Sclerosis,disease,multiple sclerosis,3122,HLA-DRA,HLA-DRA,CTD_human,17660530,"Of these SNPs, two within the interleukin-2 receptor alpha gene (IL2RA) were strongly associated with multiple sclerosis (P=2.96x10(-8)), as were a nonsynonymous SNP in the interleukin-7 receptor alpha gene (IL7RA) (P=2.94x10(-7)) and multiple SNPs in the HLA-DRA locus (P=8.94x10(-81)).",0.21345993369481797,"Of these SNPs, two within the interleukin-2 receptor alpha gene (IL2RA) were strongly associated with <span class=""disease"" id=""17660530-9-102-120"">multiple sclerosis</span> (P=2.96x10(-8)), as were a nonsynonymous SNP in the interleukin-7 receptor alpha gene (IL7RA) (P=2.94x10(-7)) and multiple SNPs in the <span class=""gene"" id=""17660530-9-256-263"">HLA-DRA</span> locus (P=8.94x10(-81)).",CTD_human
3,0,Biomarker,C0003873,Rheumatoid Arthritis,disease,RA,3123,HLA-DRB1,HLA-DRB1,CTD_human,19898480,"In 1,497 individuals from three RA cohorts, antibodies to the immunodominant citrullinated alpha-enolase CEP-1 epitope were detected in 43-63% of the anti-CCP-positive individuals, and this subset was preferentially linked to HLA-DRB1*04.",0.44,"In 1,497 individuals from three <span class=""disease"" id=""19898480-3-32-34"">RA</span> cohorts, antibodies to the immunodominant citrullinated alpha-enolase CEP-1 epitope were detected in 43-63% of the anti-CCP-positive individuals, and this subset was preferentially linked to <span class=""gene"" id=""19898480-3-226-234"">HLA-DRB1</span>*04.",CTD_human
3,0,Biomarker,C0003873,Rheumatoid Arthritis,disease,rheumatoid arthritis,3123,HLA-DRB1,HLA-DRB1,CTD_human,22286218,The genetic association of the major histocompatibility complex (MHC) to rheumatoid arthritis risk has commonly been attributed to alleles in HLA-DRB1.,0.44,"The genetic association of the major histocompatibility complex (MHC) to <span class=""disease"" id=""22286218-1-73-93"">rheumatoid arthritis</span> risk has commonly been attributed to alleles in <span class=""gene"" id=""22286218-1-142-150"">HLA-DRB1</span>.",CTD_human
1,0,Biomarker,C0004096,Asthma,disease,asthma,3123,HLA-DRB1,DRB1,CTD_human,16792590,The HLA haplotype DRB1*15-DPB1*05 can be a susceptibility gene marker for the development of TDI-induced asthma among the exposed workers in the Korean population.,0.25560935079682606,"The HLA haplotype <span class=""gene"" id=""16792590-10-18-22"">DRB1</span>*15-DPB1*05 can be a susceptibility gene marker for the development of TDI-induced <span class=""disease"" id=""16792590-10-105-111"">asthma</span> among the exposed workers in the Korean population.",CTD_human
1,0,Biomarker,C0009324,Ulcerative Colitis,disease,ulcerative colitis,3123,HLA-DRB1,HLA-DRB1,CTD_human,25559196,High-density mapping of the MHC identifies a shared role for HLA-DRB1*01:03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis.,0.269149152403592,"High-density mapping of the MHC identifies a shared role for <span class=""gene"" id=""25559196-0-61-69"">HLA-DRB1</span>*01:03 in inflammatory bowel diseases and heterozygous advantage in <span class=""disease"" id=""25559196-0-137-155"">ulcerative colitis</span>.",CTD_human
1,0,Biomarker,C0010346,Crohn Disease,disease,Crohn's disease,3123,HLA-DRB1,HLA-DRB1,CTD_human,25559196,"To address this, we performed high-density SNP typing of the MHC in >32,000 individuals with IBD, implicating multiple HLA alleles, with a primary role for HLA-DRB1*01:03 in both Crohn's disease and ulcerative colitis.",0.22885731025644498,"To address this, we performed high-density SNP typing of the MHC in &gt;32,000 individuals with IBD, implicating multiple HLA alleles, with a primary role for <span class=""gene"" id=""25559196-4-156-164"">HLA-DRB1</span>*01:03 in both <span class=""disease"" id=""25559196-4-179-194"">Crohn's disease</span> and ulcerative colitis.",CTD_human
1,0,Biomarker,C0023290,"Leishmaniasis, Visceral",disease,visceral leishmaniasis,3123,HLA-DRB1,HLA-DRB1,CTD_human,23291585,Common variants in the HLA-DRB1-HLA-DQA1 HLA class II region are associated with susceptibility to visceral leishmaniasis.,0.200274726784213,"Common variants in the <span class=""gene"" id=""23291585-0-23-31"">HLA-DRB1</span>-HLA-DQA1 HLA class II region are associated with susceptibility to <span class=""disease"" id=""23291585-0-99-121"">visceral leishmaniasis</span>.",CTD_human
1,0,Biomarker,C0024305,"Lymphoma, Non-Hodgkin",disease,NHL,3123,HLA-DRB1,HLA-DRB1,CTD_human,22096508,"Finally, control participants with either HLA-DRB1*01:01 or AH 8.1 reported having a family history of NHL twice as likely as those who did not have either allele or haplotype, providing the first empirical evidence that HLA associations may explain some of the well-established relationship between family history and NHL risk.",0.21992235144667302,"Finally, control participants with either <span class=""gene"" id=""22096508-9-42-50"">HLA-DRB1</span>*01:01 or AH 8.1 reported having a family history of <span class=""disease"" id=""22096508-9-103-106"">NHL</span> twice as likely as those who did not have either allele or haplotype, providing the first empirical evidence that HLA associations may explain some of the well-established relationship between family history and <span class=""disease"" id=""22096508-9-319-322"">NHL</span> risk.",CTD_human
1,0,Biomarker,C0026769,Multiple Sclerosis,disease,Multiple Sclerosis,3123,HLA-DRB1,DRB1,CTD_human,25911099,"Role of a Novel Human Leukocyte Antigen-DQA1*01:02;DRB1*15:01 Mixed Isotype Heterodimer in the Pathogenesis of ""Humanized"" Multiple Sclerosis-like Disease.",0.411925336831461,"Role of a Novel Human Leukocyte Antigen-DQA1*01:02;<span class=""gene"" id=""25911099-0-51-55"">DRB1</span>*15:01 Mixed Isotype Heterodimer in the Pathogenesis of ""Humanized"" <span class=""disease"" id=""25911099-0-123-141"">Multiple Sclerosis</span>-like Disease.",CTD_human
1,0,Biomarker,C0027404,Narcolepsy,disease,narcolepsy,3123,HLA-DRB1,DRB1,CTD_human,20711174,"To further define the genetic basis of narcolepsy risk, we performed a genome-wide association study (GWAS) in 562 European individuals with narcolepsy (cases) and 702 ethnically matched controls, with independent replication in 370 cases and 495 controls, all heterozygous for DRB1*1501-DQB1*0602.",0.43748883152737,"To further define the genetic basis of <span class=""disease"" id=""20711174-3-39-49"">narcolepsy</span> risk, we performed a genome-wide association study (GWAS) in 562 European individuals with <span class=""disease"" id=""20711174-3-141-151"">narcolepsy</span> (cases) and 702 ethnically matched controls, with independent replication in 370 cases and 495 controls, all heterozygous for <span class=""gene"" id=""20711174-3-278-282"">DRB1</span>*1501-DQB1*0602.",CTD_human;ORPHANET
1,0,Biomarker,C0030305,Pancreatitis,disease,pancreatitis,3123,HLA-DRB1,HLA-DRB1,CTD_human,25217962,HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants.,0.207821696295603,"HLA-DQA1-<span class=""gene"" id=""25217962-0-9-17"">HLA-DRB1</span> variants confer susceptibility to <span class=""disease"" id=""25217962-0-52-64"">pancreatitis</span> induced by thiopurine immunosuppressants.",CTD_human
1,0,Biomarker,C0036202,Sarcoidosis,disease,sarcoidosis,3123,HLA-DRB1,HLA-DRB1,CTD_human,14508706,HLA-DRB1*1101: a significant risk factor for sarcoidosis in blacks and whites.,0.47269188984372795,"<span class=""gene"" id=""14508706-0-0-8"">HLA-DRB1</span>*1101: a significant risk factor for <span class=""disease"" id=""14508706-0-45-56"">sarcoidosis</span> in blacks and whites.",CTD_human;ORPHANET
1,0,Biomarker,C0036341,Schizophrenia,disease,SZ,3123,HLA-DRB1,HLA-DRB1,CTD_human,16223876,"Implementing this systematic approach, we: (i) discovered 177 putative SZ risk genes in brain, 28 of which map to linked chromosomal loci; (ii) delineated six biological processes and 12 molecular functions that may be particularly disrupted in the illness; (iii) identified 123 putative SZ biomarkers in blood, 6 of which (BTG1, GSK3A, HLA-DRB1, HNRPA3, SELENBP1, and SFRS1) had corresponding differential expression in brain; (iv) verified the differential expression of the strongest candidate SZ biomarker (SELENBP1) in blood; and (v) demonstrated neuronal and glial expression of SELENBP1 protein in brain.",0.21106726054884697,"Implementing this systematic approach, we: (i) discovered 177 putative <span class=""disease"" id=""16223876-4-71-73"">SZ</span> risk genes in brain, 28 of which map to linked chromosomal loci; (ii) delineated six biological processes and 12 molecular functions that may be particularly disrupted in the illness; (iii) identified 123 putative SZ biomarkers in blood, 6 of which (BTG1, GSK3A, <span class=""gene"" id=""16223876-4-337-345"">HLA-DRB1</span>, HNRPA3, SELENBP1, and SFRS1) had corresponding differential expression in brain; (iv) verified the differential expression of the strongest candidate SZ biomarker (SELENBP1) in blood; and (v) demonstrated neuronal and glial expression of SELENBP1 protein in brain.",CTD_human
1,0,Biomarker,C0041466,Typhoid Fever,disease,enteric fever,3123,HLA-DRB1,HLA-DRB1,CTD_human,25383971,Variation at HLA-DRB1 is associated with resistance to enteric fever.,0.20777053913829002,"Variation at <span class=""gene"" id=""25383971-0-13-21"">HLA-DRB1</span> is associated with resistance to <span class=""disease"" id=""25383971-0-55-68"">enteric fever</span>.",CTD_human
1,0,Biomarker,C0085179,Eosinophilia-Myalgia Syndrome,disease,EMS,3123,HLA-DRB1,DRB1,CTD_human,19790128,"Similar risk and protective factors were seen for developing EMS following ingestion of implicated LT, except that DRB1*03 was not a risk factor and DQA1*0201 was an additional protective factor.",0.202681755307501,"Similar risk and protective factors were seen for developing <span class=""disease"" id=""19790128-5-61-64"">EMS</span> following ingestion of implicated LT, except that <span class=""gene"" id=""19790128-5-115-119"">DRB1</span>*03 was not a risk factor and DQA1*0201 was an additional protective factor.",CTD_human
1,0,Biomarker,C1961102,Precursor Cell Lymphoblastic Leukemia Lymphoma,disease,acute lymphoblastic leukemia,3131,HLF,HLF,CTD_human,26214592,Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options.,0.20821309277175895,"Genomics and drug profiling of fatal TCF3-<span class=""gene"" id=""26214592-0-42-45"">HLF</span>-positive <span class=""disease"" id=""26214592-0-55-83"">acute lymphoblastic leukemia</span> identifies recurrent mutation patterns and therapeutic options.",CTD_human
31,31,Biomarker,C0162565,Acute intermittent porphyria,disease,Acute intermittent porphyria,3145,HMBS,uroporphyrinogen I synthase,CTD_human,6132132,Acute intermittent porphyria has hitherto been recognised as an autosomal dominant inborn error of haem metabolism characterised by a depressed activity of the enzyme uroporphyrinogen I synthase (URO.S).,0.7528395475382479,"<span class=""disease"" id=""6132132-1-0-28"">Acute intermittent porphyria</span> has hitherto been recognised as an autosomal dominant inborn error of haem metabolism characterised by a depressed activity of the enzyme <span class=""gene"" id=""6132132-1-167-194"">uroporphyrinogen I synthase</span> (URO.S).",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0020429,Hyperalgesia,phenotype,hyperalgesia,3146,HMGB1,HMGB1,CTD_human,27474498,"Tissue protein levels were determined by immunoblotting.Repeated i.p. administration of the anti-HMGB1-neutralizing antibody or recombinant human soluble thrombomodulin (rhsTM), known to inactivate HMGB1, prevented the development of hyperalgesia and/or allodynia induced by paclitaxel or vincristine in rats.A single i.p. or intraplantar (i.pl.) administration of the antibody or rhsTM reversed the chemotherapy-induced neuropathy.A single i.pl. administration of a TLR4 antagonist or low molecular weight heparin, known to inhibit RAGE, attenuated the hyperalgesia caused by i.pl.",0.28,"Tissue protein levels were determined by immunoblotting.Repeated i.p. administration of the anti-<span class=""gene"" id=""27474498-4-97-102"">HMGB1</span>-neutralizing antibody or recombinant human soluble thrombomodulin (rhsTM), known to inactivate <span class=""gene"" id=""27474498-4-198-203"">HMGB1</span>, prevented the development of <span class=""disease"" id=""27474498-4-234-246"">hyperalgesia</span> and/or allodynia induced by paclitaxel or vincristine in rats.A single i.p. or intraplantar (i.pl.) administration of the antibody or rhsTM reversed the chemotherapy-induced neuropathy.A single i.pl. administration of a TLR4 antagonist or low molecular weight heparin, known to inhibit RAGE, attenuated the <span class=""disease"" id=""27474498-4-554-566"">hyperalgesia</span> caused by i.pl.",CTD_human
1,0,Biomarker,C0027051,Myocardial Infarction,disease,infarction myocardial inflammation,3146,HMGB1,HMGB1,CTD_human,21113057,These findings indicate that peroxynitrite represents a key mediator of HMGB1 overexpression and release by cardiac cells and provide a novel mechanism linking myocardial oxidative/nitrosative stress with post-infarction myocardial inflammation.,0.28054945356842603,"These findings indicate that peroxynitrite represents a key mediator of <span class=""gene"" id=""21113057-9-72-77"">HMGB1</span> overexpression and release by cardiac cells and provide a novel mechanism linking myocardial oxidative/nitrosative stress with post-<span class=""disease"" id=""21113057-9-210-244"">infarction myocardial inflammation</span>.",CTD_human
1,0,Biomarker,C0027796,Neuralgia,phenotype,neuropathic pain,3146,HMGB1,HMGB1,CTD_human,25014009,Identification of a functional interaction of HMGB1 with Receptor for Advanced Glycation End-products in a model of neuropathic pain.,0.200274726784213,"Identification of a functional interaction of <span class=""gene"" id=""25014009-0-46-51"">HMGB1</span> with Receptor for Advanced Glycation End-products in a model of <span class=""disease"" id=""25014009-0-116-132"">neuropathic pain</span>.",CTD_human
1,0,Biomarker,C0034069,Pulmonary Fibrosis,disease,pulmonary fibrosis,3146,HMGB1,HMGB1,CTD_human,27616297,Mounting evidence indicates that high-mobility group box 1 (HMGB1) is involved in pulmonary fibrosis.,0.20300763924902696,"Mounting evidence indicates that <span class=""gene"" id=""27616297-2-33-58"">high-mobility group box 1</span> (<span class=""gene"" id=""27616297-2-60-65"">HMGB1</span>) is involved in <span class=""disease"" id=""27616297-2-82-100"">pulmonary fibrosis</span>.",CTD_human
2,0,Biomarker,C0243026,Sepsis,disease,sepsis,3146,HMGB1,HMGB1,CTD_human,19265175,"Quercetin delivery, a strategy to pharmacologically inhibit HMGB1 release that is effective at clinically achievable concentrations, now warrants further evaluation in sepsis and other systemic inflammatory disorders.",0.21441513911671697,"Quercetin delivery, a strategy to pharmacologically inhibit <span class=""gene"" id=""19265175-8-60-65"">HMGB1</span> release that is effective at clinically achievable concentrations, now warrants further evaluation in <span class=""disease"" id=""19265175-8-168-174"">sepsis</span> and other systemic inflammatory disorders.",CTD_human
2,0,Biomarker,C0243026,Sepsis,disease,sepsis,3146,HMGB1,HMGB1,CTD_human,23146691,"Collectively, this study shows EG can protect barrier integrity and inhibit HMGB1-mediated inflammatory responses, which suggests a potential use as a therapy for sepsis or septic shock.",0.21441513911671697,"Collectively, this study shows EG can protect barrier integrity and inhibit <span class=""gene"" id=""23146691-7-76-81"">HMGB1</span>-mediated inflammatory responses, which suggests a potential use as a therapy for <span class=""disease"" id=""23146691-7-163-169"">sepsis</span> or septic shock.",CTD_human
1,0,Biomarker,C0279626,Squamous cell carcinoma of esophagus,disease,ESCC,3146,HMGB1,HMGB1,CTD_human,21517111,The results showed that both HSP70 and HMGB1 can induce autoantibody response in ESCC sera and have higher expression in ESCC tissues.,0.200274726784213,"The results showed that both HSP70 and <span class=""gene"" id=""21517111-8-39-44"">HMGB1</span> can induce autoantibody response in <span class=""disease"" id=""21517111-8-81-85"">ESCC</span> sera and have higher expression in <span class=""disease"" id=""21517111-8-121-125"">ESCC</span> tissues.",CTD_human
1,0,Biomarker,C1850383,"Neuropathy, Painful",disease,painful neuropathy,3146,HMGB1,HMGB1,CTD_human,27474498,HMGB1 inactivation is considered useful to prevent and treat the chemotherapy-induced painful neuropathy.,0.2,"<span class=""gene"" id=""27474498-8-0-5"">HMGB1</span> inactivation is considered useful to prevent and treat the chemotherapy-induced <span class=""disease"" id=""27474498-8-86-104"">painful neuropathy</span>.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,hepatocellular carcinoma,3148,HMGB2,high-mobility group box 2,CTD_human,20851854,Overexpression of high-mobility group box 2 is associated with tumor aggressiveness and prognosis of hepatocellular carcinoma.,0.20054945356842604,"Overexpression of <span class=""gene"" id=""20851854-0-18-43"">high-mobility group box 2</span> is associated with tumor aggressiveness and prognosis of <span class=""disease"" id=""20851854-0-101-125"">hepatocellular carcinoma</span>.",CTD_human
1,0,Biomarker,C0026848,Myopathy,group,myopathy,3156,HMGCR,HMGCR,CTD_human,23953224,Identification of anti-HMGCR antibodies in statin-exposed patients with myopathy appears to be helpful both for differential diagnosis and for treatment strategy.,0.20054945356842604,"Identification of anti-<span class=""gene"" id=""23953224-12-23-28"">HMGCR</span> antibodies in statin-exposed patients with <span class=""disease"" id=""23953224-12-72-80"">myopathy</span> appears to be helpful both for differential diagnosis and for treatment strategy.",CTD_human
2,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,3156,HMGCR,3-hydroxy-3-methylglutaryl-coenzyme A reductase,CTD_human,9207284,"Protein and messenger RNA (mRNA) levels for both G6PD and malic enzyme increased in hyperplastic livers and HCC. mRNA levels for 3-hydroxy-3-methylglutaryl-coenzyme A reductase decreased in hyperplasia and increased in HCC, whereas low-density lipoprotein receptor mRNA increased in hyperplasia and decreased in HCC.",0.201373633921065,"Protein and messenger RNA (mRNA) levels for both G6PD and malic enzyme increased in hyperplastic livers and <span class=""disease"" id=""9207284-7-108-111"">HCC</span>. mRNA levels for <span class=""gene"" id=""9207284-7-129-176"">3-hydroxy-3-methylglutaryl-coenzyme A reductase</span> decreased in hyperplasia and increased in <span class=""disease"" id=""9207284-7-219-222"">HCC</span>, whereas low-density lipoprotein receptor mRNA increased in hyperplasia and decreased in <span class=""disease"" id=""9207284-7-312-315"">HCC</span>.",CTD_human
1,0,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,T2D,3159,HMGA1,HMGA1,CTD_human,23512162,"Association between rs146052672 variant and MetS occurred independently of T2D, indicating that HMGA1 gene defects play a pathogenetic role in MetS and other insulin-resistance-related conditions.",0.285154296365419,"Association between rs146052672 variant and MetS occurred independently of <span class=""disease"" id=""23512162-7-75-78"">T2D</span>, indicating that <span class=""gene"" id=""23512162-7-96-101"">HMGA1</span> gene defects play a pathogenetic role in MetS and other insulin-resistance-related conditions.",CTD_human
1,0,Biomarker,C0023269,leiomyosarcoma,disease,leiomyosarcomas,3159,HMGA1,HMGA1a,CTD_human,18645019,"Similarly, we found that HMGA1a and COX-2 are overexpressed in human leiomyosarcomas, a highly malignant uterine cancer.",0.200274726784213,"Similarly, we found that <span class=""gene"" id=""18645019-5-25-31"">HMGA1a</span> and COX-2 are overexpressed in human <span class=""disease"" id=""18645019-5-69-84"">leiomyosarcomas</span>, a highly malignant uterine cancer.",CTD_human
1,0,Biomarker,C0524620,Metabolic Syndrome X,disease,metabolic syndrome,3159,HMGA1,HMGA1,CTD_human,23512162,A polymorphism of HMGA1 is associated with increased risk of metabolic syndrome and related components.,0.200274726784213,"A polymorphism of <span class=""gene"" id=""23512162-0-18-23"">HMGA1</span> is associated with increased risk of <span class=""disease"" id=""23512162-0-61-79"">metabolic syndrome</span> and related components.",CTD_human
1,0,Biomarker,C0023473,"Myeloid Leukemia, Chronic",disease,CML,3161,HMMR,RHAMM,CTD_human,17157168,"Therefore, vaccination strategies inducing such RHAMM-R3-directed effector T cells might be a promising approach to enhance specific immune responses against CML cells.",0.203557092817453,"Therefore, vaccination strategies inducing such <span class=""gene"" id=""17157168-8-48-53"">RHAMM</span>-R3-directed effector T cells might be a promising approach to enhance specific immune responses against <span class=""disease"" id=""17157168-8-158-161"">CML</span> cells.",CTD_human
1,0,Biomarker,C0004096,Asthma,disease,asthma,3162,HMOX1,HMOX-1,CTD_human,18048809,Functional promoter variants in CAT and HMOX-1 showed ethnicity-specific associations with new-onset asthma.,0.208645876648242,"Functional promoter variants in CAT and <span class=""gene"" id=""18048809-10-40-46"">HMOX-1</span> showed ethnicity-specific associations with new-onset <span class=""disease"" id=""18048809-10-101-107"">asthma</span>.",CTD_human
2,0,Therapeutic,C0009319,Colitis,disease,colitis,3162,HMOX1,heme oxygenase 1,CTD_human,16365149,Carbon monoxide ameliorates chronic murine colitis through a heme oxygenase 1-dependent pathway.,0.28082418035263895,"Carbon monoxide ameliorates chronic murine <span class=""disease"" id=""16365149-0-43-50"">colitis</span> through a <span class=""gene"" id=""16365149-0-61-77"">heme oxygenase 1</span>-dependent pathway.",CTD_human
2,0,Therapeutic,C0009319,Colitis,disease,colitis,3162,HMOX1,heme oxygenase-1,CTD_human,21444764,An anti-inflammatory role for carbon monoxide and heme oxygenase-1 in chronic Th2-mediated murine colitis.,0.28082418035263895,"An anti-inflammatory role for carbon monoxide and <span class=""gene"" id=""21444764-0-50-66"">heme oxygenase-1</span> in chronic Th2-mediated murine <span class=""disease"" id=""21444764-0-98-105"">colitis</span>.",CTD_human
1,0,Biomarker,C0019212,Hepatorenal Syndrome,disease,hepatorenal syndrome,3162,HMOX1,HO-1,CTD_human,21253390,To investigate the role of heme oxygenase-1 (HO-1) in pathogenesis of experimental hepatorenal syndrome (HRS).,0.200274726784213,"To investigate the role of <span class=""gene"" id=""21253390-1-27-43"">heme oxygenase-1</span> (<span class=""gene"" id=""21253390-1-45-49"">HO-1</span>) in pathogenesis of experimental <span class=""disease"" id=""21253390-1-83-103"">hepatorenal syndrome</span> (HRS).",CTD_human
1,0,Biomarker,C0023290,"Leishmaniasis, Visceral",disease,VL,3162,HMOX1,HO-1,CTD_human,22461696,Manipulation of HO-1 pathways during VL could serve as an adjunctive therapeutic approach.,0.200274726784213,"Manipulation of <span class=""gene"" id=""22461696-12-16-20"">HO-1</span> pathways during <span class=""disease"" id=""22461696-12-37-39"">VL</span> could serve as an adjunctive therapeutic approach.",CTD_human
3,0,Biomarker,C0028754,Obesity,disease,obesity,3162,HMOX1,Heme oxygenase-1,CTD_human,19171794,Heme oxygenase-1 induction remodels adipose tissue and improves insulin sensitivity in obesity-induced diabetic rats.,0.203231208875927,"<span class=""gene"" id=""19171794-0-0-16"">Heme oxygenase-1</span> induction remodels adipose tissue and improves insulin sensitivity in <span class=""disease"" id=""19171794-0-87-94"">obesity</span>-induced diabetic rats.",CTD_human
1,0,Biomarker,C0030567,Parkinson Disease,disease,Parkinson's Disease,3162,HMOX1,Heme oxygenase-1,CTD_human,21318773,"Table 1 Biochemical Alterations in Substantia Nigra of Parkinson's Disease Indicating Oxidative Stress Elevated Decreased Iron (in microglia, astrocytes, oligodendrocytes, and melanized dopamine neurons and mitochondria) GSH (GSSG unchanged); GSH/GSSG ratio decreased Mitochondrial complex I Ferritin Calcium binding protein (calbindin 28) Mitochondrial monoamine oxidase B Transferrin and transferrin receptor Lipofuscin Vitamins E and C Ubiquitin Copper Cu/Zn-superoxide dismutase Cytotoxic cytokines (TNF-a, IL-1, IL-6) Inflammatory transcription factor NFKB Heme oxygenase-1 Ratio of oxidized to reduced glutathione (GSSG/GSH) Nitric oxide Neuromelanin.",0.210568964137734,"Table 1 Biochemical Alterations in Substantia Nigra of <span class=""disease"" id=""21318773-12-55-74"">Parkinson's Disease</span> Indicating Oxidative Stress Elevated Decreased Iron (in microglia, astrocytes, oligodendrocytes, and melanized dopamine neurons and mitochondria) GSH (GSSG unchanged); GSH/GSSG ratio decreased Mitochondrial complex I Ferritin Calcium binding protein (calbindin 28) Mitochondrial monoamine oxidase B Transferrin and transferrin receptor Lipofuscin Vitamins E and C Ubiquitin Copper Cu/Zn-superoxide dismutase Cytotoxic cytokines (TNF-a, IL-1, IL-6) Inflammatory transcription factor NFKB <span class=""gene"" id=""21318773-12-562-578"">Heme oxygenase-1</span> Ratio of oxidized to reduced glutathione (GSSG/GSH) Nitric oxide Neuromelanin.",CTD_human
1,0,Biomarker,C0032285,Pneumonia,disease,pneumonia,3162,HMOX1,HO-1,CTD_human,16582079,The large size of a (GT)n repeat in the HO-1 gene promoter may be associated with susceptibility to pneumonia in the older Japanese population.,0.203231208875927,"The large size of a (GT)n repeat in the <span class=""gene"" id=""16582079-10-40-44"">HO-1</span> gene promoter may be associated with susceptibility to <span class=""disease"" id=""16582079-10-100-109"">pneumonia</span> in the older Japanese population.",CTD_human
1,0,Biomarker,C0034067,Pulmonary Emphysema,disease,emphysema,3162,HMOX1,heme oxygenase-1,CTD_human,10631150,Microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with susceptibility to emphysema.,0.20082418035263896,"Microsatellite polymorphism in the <span class=""gene"" id=""10631150-0-35-51"">heme oxygenase-1</span> gene promoter is associated with susceptibility to <span class=""disease"" id=""10631150-0-103-112"">emphysema</span>.",CTD_human
1,0,Biomarker,C0034069,Pulmonary Fibrosis,disease,pulmonary fibrosis,3162,HMOX1,HO-1,CTD_human,15814490,"Oxidative stress is thought to be the pathogenesis of pulmonary fibrosis induced by asbestos, and heme oxygenase-1 (HO-1) protects lung tissue against oxidative stress.",0.200274726784213,"Oxidative stress is thought to be the pathogenesis of <span class=""disease"" id=""15814490-1-54-72"">pulmonary fibrosis</span> induced by asbestos, and <span class=""gene"" id=""15814490-1-98-114"">heme oxygenase-1</span> (<span class=""gene"" id=""15814490-1-116-120"">HO-1</span>) protects lung tissue against oxidative stress.",CTD_human
1,0,Biomarker,C0038220,Status Epilepticus,disease,SE,3162,HMOX1,Hsp32,CTD_human,20971094,"Interestingly, while Hsp32 and Hsp70 expression was transient, Hsp25 demonstrated a sustained induction pattern, which may reflect an additional role of Hsp25 in subsequent remodeling events in the days following SE.",0.2,"Interestingly, while <span class=""gene"" id=""20971094-5-21-26"">Hsp32</span> and Hsp70 expression was transient, Hsp25 demonstrated a sustained induction pattern, which may reflect an additional role of Hsp25 in subsequent remodeling events in the days following <span class=""disease"" id=""20971094-5-213-215"">SE</span>.",CTD_human
1,0,Therapeutic,C0152020,Gastroparesis,disease,delayed gastric emptying,3162,HMOX1,HO1,CTD_human,20378827,"Diabetic gastroparesis is associated with increased oxidative stress attributable to loss of upregulation of heme oxygenase-1 (HO1), with resultant damage to interstitial cells of Cajal and delayed gastric emptying.",0.2,"Diabetic gastroparesis is associated with increased oxidative stress attributable to loss of upregulation of <span class=""gene"" id=""20378827-1-109-125"">heme oxygenase-1</span> (<span class=""gene"" id=""20378827-1-127-130"">HO1</span>), with resultant damage to interstitial cells of Cajal and <span class=""disease"" id=""20378827-1-190-214"">delayed gastric emptying</span>.",CTD_human
3,0,Biomarker,C0524851,Neurodegenerative Disorders,group,neurodegenerative disorders,3162,HMOX1,HO-1,CTD_human,10942521,"Activation of this HO-1-MnSOD axis may play an important role in the pathogenesis of Alzheimer disease, Parkinson disease and other free radical-related neurodegenerative disorders.",0.201373633921065,"Activation of this <span class=""gene"" id=""10942521-6-19-23"">HO-1</span>-MnSOD axis may play an important role in the pathogenesis of Alzheimer disease, Parkinson disease and other free radical-related <span class=""disease"" id=""10942521-6-153-180"">neurodegenerative disorders</span>.",CTD_human
1,0,Biomarker,C1956346,Coronary Artery Disease,disease,coronary artery disease,3162,HMOX1,heme oxygenase-1,CTD_human,12136229,Microsatellite polymorphism in promoter of heme oxygenase-1 gene is associated with susceptibility to coronary artery disease in type 2 diabetic patients.,0.225504846068243,"Microsatellite polymorphism in promoter of <span class=""gene"" id=""12136229-0-43-59"">heme oxygenase-1</span> gene is associated with susceptibility to <span class=""disease"" id=""12136229-0-102-125"">coronary artery disease</span> in type 2 diabetic patients.",CTD_human
2,0,Biomarker,C0033578,Prostatic Neoplasms,group,prostate tumor,3169,FOXA1,FOXA1,CTD_human,26457646,"Introduction of FOXA1 and HOXB13 into an immortalized prostate cell line reprogrammed the AR cistrome to resemble that of a prostate tumor, functionally linking these specific factors to AR cistrome reprogramming.",0.20300763924902696,"Introduction of <span class=""gene"" id=""26457646-6-16-21"">FOXA1</span> and HOXB13 into an immortalized prostate cell line reprogrammed the AR cistrome to resemble that of a <span class=""disease"" id=""26457646-6-124-138"">prostate tumor</span>, functionally linking these specific factors to AR cistrome reprogramming.",CTD_human
1,0,Biomarker,C0007138,"Carcinoma, Transitional Cell",disease,transitional cell carcinoma,317,APAF1,APAF-1,CTD_human,17133271,To examine the significance of the methylation level of the p53 target and tumour suppressor genes apoptotic protease activating factor-1 (APAF-1) and death-associated protein kinase-1 (DAPK-1) in 80 microdissected tumour samples from transitional cell carcinoma (TCC) of the bladder and 80 tumour samples from clear-cell renal cell carcinoma (RCC) as well as from non-tumourous bladder and kidney tissue.,0.20054945356842604,"To examine the significance of the methylation level of the p53 target and tumour suppressor genes <span class=""gene"" id=""17133271-1-99-137"">apoptotic protease activating factor-1</span> (<span class=""gene"" id=""17133271-1-139-145"">APAF-1</span>) and death-associated protein kinase-1 (DAPK-1) in 80 microdissected tumour samples from <span class=""disease"" id=""17133271-1-235-262"">transitional cell carcinoma</span> (TCC) of the bladder and 80 tumour samples from clear-cell renal cell carcinoma (RCC) as well as from non-tumourous bladder and kidney tissue.",CTD_human
2,0,Biomarker,C0376634,Craniofacial Abnormalities,group,craniofacial abnormalities,317,APAF1,Apaf1,CTD_human,9753321,Apaf1-deficient mice exhibited reduced apoptosis in the brain and striking craniofacial abnormalities with hyperproliferation of neuronal cells.,0.2,"<span class=""gene"" id=""9753321-3-0-5"">Apaf1</span>-deficient mice exhibited reduced apoptosis in the brain and striking <span class=""disease"" id=""9753321-3-75-101"">craniofacial abnormalities</span> with hyperproliferation of neuronal cells.",CTD_human
1,0,Biomarker,C0009324,Ulcerative Colitis,disease,ulcerative colitis,3172,HNF4A,HNF4A,CTD_human,19915572,"Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region.",0.201648360705279,"Genome-wide association study of <span class=""disease"" id=""19915572-0-33-51"">ulcerative colitis</span> identifies three new susceptibility loci, including the <span class=""gene"" id=""19915572-0-108-113"">HNF4A</span> region.",CTD_human
4,2,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,T2D,3172,HNF4A,HNF4A,CTD_human,22158537,The evidence of an association with T2D for PEPD and HNF4A has been shown in previous studies.,0.7288439460806629,"The evidence of an association with <span class=""disease"" id=""22158537-5-36-39"">T2D</span> for PEPD and <span class=""gene"" id=""22158537-5-53-58"">HNF4A</span> has been shown in previous studies.",CTD_human;ORPHANET;UNIPROT
4,2,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,T2D,3172,HNF4A,HNF4A,CTD_human,21874001,"In the combined analysis, we identified common genetic variants at six loci (GRB14, ST6GAL1, VPS26A, HMG20A, AP3S2 and HNF4A) newly associated with T2D (P = 4.1 × 10(-8) to P = 1.9 × 10(-11)).",0.7288439460806629,"In the combined analysis, we identified common genetic variants at six loci (GRB14, ST6GAL1, VPS26A, HMG20A, AP3S2 and <span class=""gene"" id=""21874001-4-119-124"">HNF4A</span>) newly associated with <span class=""disease"" id=""21874001-4-148-151"">T2D</span> (P = 4.1 &times; 10(-8) to P = 1.9 &times; 10(-11)).",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0004096,Asthma,disease,asthma,3176,HNMT,HNMT,CTD_human,17651147,"The variant HNMT allele frequencies were slightly higher among patients with asthma [16.0%, 95% confidence interval (CI) 12.0-20.0] and among patients with rhinitis (13.2, 95% CI 10.3-16.1) as compared with healthy subjects (11.5 95% CI 8.9-14.1).",0.21127647479843104,"The variant <span class=""gene"" id=""17651147-5-12-16"">HNMT</span> allele frequencies were slightly higher among patients with <span class=""disease"" id=""17651147-5-77-83"">asthma</span> [16.0%, 95% confidence interval (CI) 12.0-20.0] and among patients with rhinitis (13.2, 95% CI 10.3-16.1) as compared with healthy subjects (11.5 95% CI 8.9-14.1).",CTD_human
1,0,Biomarker,C0035455,Rhinitis,disease,rhinitis,3176,HNMT,HNMT,CTD_human,17651147,"The variant HNMT allele frequencies were slightly higher among patients with asthma [16.0%, 95% confidence interval (CI) 12.0-20.0] and among patients with rhinitis (13.2, 95% CI 10.3-16.1) as compared with healthy subjects (11.5 95% CI 8.9-14.1).",0.200274726784213,"The variant <span class=""gene"" id=""17651147-5-12-16"">HNMT</span> allele frequencies were slightly higher among patients with asthma [16.0%, 95% confidence interval (CI) 12.0-20.0] and among patients with <span class=""disease"" id=""17651147-5-156-164"">rhinitis</span> (13.2, 95% CI 10.3-16.1) as compared with healthy subjects (11.5 95% CI 8.9-14.1).",CTD_human
1,0,Biomarker,C1961099,Precursor T-Cell Lymphoblastic Leukemia-Lymphoma,disease,T-ALL,3195,TLX1,TLX1,CTD_human,20972433,Here we show that transgenic expression of human TLX1 in mice induces T-ALL with frequent deletions and mutations in Bcl11b (encoding B cell leukemia/lymphoma-11B) and identify the presence of recurrent mutations and deletions in BCL11B in 16% of human T-ALLs.,0.21181325172116297,"Here we show that transgenic expression of human <span class=""gene"" id=""20972433-3-49-53"">TLX1</span> in mice induces <span class=""disease"" id=""20972433-3-70-75"">T-ALL</span> with frequent deletions and mutations in Bcl11b (encoding B cell leukemia/lymphoma-11B) and identify the presence of recurrent mutations and deletions in BCL11B in 16% of human <span class=""disease"" id=""20972433-3-253-258"">T-ALL</span>s.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,3198,HOXA1,HOXA1,CTD_human,11091361,"The results support a role for HOXA1 in susceptibility to autism, and add to the existing body of evidence implicating early brain stem injury in the etiology of ASDs.",0.21001951056930804,"The results support a role for <span class=""gene"" id=""11091361-11-31-36"">HOXA1</span> in susceptibility to <span class=""disease"" id=""11091361-11-58-64"">autism</span>, and add to the existing body of evidence implicating early brain stem injury in the etiology of ASDs.",CTD_human
1,0,Biomarker,C0005695,Bladder Neoplasm,disease,Bladder Cancer,3205,HOXA9,HOXA9,CTD_human,26332997,Methylation of HOXA9 and ISL1 Predicts Patient Outcome in High-Grade Non-Invasive Bladder Cancer.,0.2,"Methylation of <span class=""gene"" id=""26332997-0-15-20"">HOXA9</span> and ISL1 Predicts Patient Outcome in High-Grade Non-Invasive <span class=""disease"" id=""26332997-0-82-96"">Bladder Cancer</span>.",CTD_human
1,0,Biomarker,C0025202,melanoma,disease,melanoma,3205,HOXA9,HOXA9,CTD_human,16778180,"CGIs in putative promoter regions of 34 genes (ABHD9, BARHL1, CLIC5, CNNM1, COL2A1, CPT1C, DDIT4L, DERL3, DHRS3, DPYS, EFEMP2, FAM62C, FAM78A, FLJ33790, GBX2, GPR10, GPRASP1, HOXA9, HOXD11, HOXD12, HOXD13, p14ARF, PAX6, PRDX2, PTPRG, RASD1, RAX, REC8L1, SLC27A3, TGFB2, TLX2, TMEM22, TMEM30B, and UNC5C) were found to be methylated in at least 1 of 13 melanoma cell lines but not in two cultured normal melanocytes.",0.2,"CGIs in putative promoter regions of 34 genes (ABHD9, BARHL1, CLIC5, CNNM1, COL2A1, CPT1C, DDIT4L, DERL3, DHRS3, DPYS, EFEMP2, FAM62C, FAM78A, FLJ33790, GBX2, GPR10, GPRASP1, <span class=""gene"" id=""16778180-3-175-180"">HOXA9</span>, HOXD11, HOXD12, HOXD13, p14ARF, PAX6, PRDX2, PTPRG, RASD1, RAX, REC8L1, SLC27A3, TGFB2, TLX2, TMEM22, TMEM30B, and UNC5C) were found to be methylated in at least 1 of 13 <span class=""disease"" id=""16778180-3-352-360"">melanoma</span> cell lines but not in two cultured normal melanocytes.",CTD_human
1,0,Biomarker,C0001418,Adenocarcinoma,group,adenocarcinoma,3206,HOXA10,HOXA10,CTD_human,21670700,Expression of HOXA10 in endometrial hyperplasia and adenocarcinoma and regulation by sex hormones in vitro.,0.20082418035263896,"Expression of <span class=""gene"" id=""21670700-0-14-20"">HOXA10</span> in endometrial hyperplasia and <span class=""disease"" id=""21670700-0-52-66"">adenocarcinoma</span> and regulation by sex hormones in vitro.",CTD_human
5,3,Biomarker,C1841679,Hand foot uterus syndrome,disease,hand-foot-genital syndrome,3209,HOXA13,HOXA13,CTD_human,9020844,Mutation of HOXA13 in hand-foot-genital syndrome.,0.6835714481947701,"Mutation of <span class=""gene"" id=""9020844-0-12-18"">HOXA13</span> in <span class=""disease"" id=""9020844-0-22-48"">hand-foot-genital syndrome</span>.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0040953,Trichotillomania,disease,trichotillomania,3218,HOXB8,Hoxb8,CTD_human,11779477,"The aberrant behavior observed in Hoxb8 mutants is not unlike that of humans suffering from the OC-spectrum disorder, trichotillomania.",0.280274726784213,"The aberrant behavior observed in <span class=""gene"" id=""11779477-8-34-39"">Hoxb8</span> mutants is not unlike that of humans suffering from the OC-spectrum disorder, <span class=""disease"" id=""11779477-8-118-134"">trichotillomania</span>.",CTD_human
1,0,Biomarker,C0009404,Colorectal Neoplasms,group,colorectal tumors,3235,HOXD9,HOXD9,CTD_human,26075790,"We identified significant expression quantitative trait locus (eQTL) associations for HOXD9 at 2q31.1 in ovarian (P = 4.95 × 10(-4), false discovery rate (FDR) = 0.003) and colorectal (P = 0.01, FDR = 0.09) tumors and for PAX8 at 2q13 in colorectal tumors (P = 0.03, FDR = 0.09).",0.200274726784213,"We identified significant expression quantitative trait locus (eQTL) associations for <span class=""gene"" id=""26075790-3-86-91"">HOXD9</span> at 2q31.1 in ovarian (P = 4.95 &times; 10(-4), false discovery rate (FDR) = 0.003) and colorectal (P = 0.01, FDR = 0.09) tumors and for PAX8 at 2q13 in <span class=""disease"" id=""26075790-3-238-255"">colorectal tumors</span> (P = 0.03, FDR = 0.09).",CTD_human
1,0,Biomarker,C0003873,Rheumatoid Arthritis,disease,RA,3236,HOXD10,HOXD10,CTD_human,17568789,"HOXD10, HOXD11, HOXD13, CCL8 and LIM homeobox 2 were highly and exclusively expressed in RA and CLU, sarcoglycan-gamma, GPR64, POU3F3, peroxisome proliferative activated receptor-gamma and tripartite motif-containing 2 were expressed only in OA.",0.2,"<span class=""gene"" id=""17568789-4-0-6"">HOXD10</span>, HOXD11, HOXD13, CCL8 and LIM homeobox 2 were highly and exclusively expressed in <span class=""disease"" id=""17568789-4-89-91"">RA</span> and CLU, sarcoglycan-gamma, GPR64, POU3F3, peroxisome proliferative activated receptor-gamma and tripartite motif-containing 2 were expressed only in OA.",CTD_human
3,1,Biomarker,C0240912,Vertical Talus,disease,congenital vertical talus,3236,HOXD10,HOXD10,CTD_human,16450407,HOXD10 M319K mutation in a family with isolated congenital vertical talus.,0.6010989071368521,"<span class=""gene"" id=""16450407-0-0-6"">HOXD10</span> M319K mutation in a family with isolated <span class=""disease"" id=""16450407-0-48-73"">congenital vertical talus</span>.",CTD_human;HPO;UNIPROT
1,0,Biomarker,C0003873,Rheumatoid Arthritis,disease,RA,3237,HOXD11,HOXD11,CTD_human,17568789,"HOXD10, HOXD11, HOXD13, CCL8 and LIM homeobox 2 were highly and exclusively expressed in RA and CLU, sarcoglycan-gamma, GPR64, POU3F3, peroxisome proliferative activated receptor-gamma and tripartite motif-containing 2 were expressed only in OA.",0.2,"HOXD10, <span class=""gene"" id=""17568789-4-8-14"">HOXD11</span>, HOXD13, CCL8 and LIM homeobox 2 were highly and exclusively expressed in <span class=""disease"" id=""17568789-4-89-91"">RA</span> and CLU, sarcoglycan-gamma, GPR64, POU3F3, peroxisome proliferative activated receptor-gamma and tripartite motif-containing 2 were expressed only in OA.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,non-ASD,3237,HOXD11,HOXD11,CTD_human,19540081,"However, the G-112T heterozygote in the promoter region of HOXD11 was observed in only four patients with ASD and in none of the healthy controls or non-ASD subjects.",0.202681755307501,"However, the G-112T heterozygote in the promoter region of <span class=""gene"" id=""19540081-7-59-65"">HOXD11</span> was observed in only four patients with ASD and in none of the healthy controls or <span class=""disease"" id=""19540081-7-149-156"">non-ASD</span> subjects.",CTD_human
1,0,Biomarker,C0025202,melanoma,disease,melanoma,3238,HOXD12,HOXD12,CTD_human,16778180,"CGIs in putative promoter regions of 34 genes (ABHD9, BARHL1, CLIC5, CNNM1, COL2A1, CPT1C, DDIT4L, DERL3, DHRS3, DPYS, EFEMP2, FAM62C, FAM78A, FLJ33790, GBX2, GPR10, GPRASP1, HOXA9, HOXD11, HOXD12, HOXD13, p14ARF, PAX6, PRDX2, PTPRG, RASD1, RAX, REC8L1, SLC27A3, TGFB2, TLX2, TMEM22, TMEM30B, and UNC5C) were found to be methylated in at least 1 of 13 melanoma cell lines but not in two cultured normal melanocytes.",0.2,"CGIs in putative promoter regions of 34 genes (ABHD9, BARHL1, CLIC5, CNNM1, COL2A1, CPT1C, DDIT4L, DERL3, DHRS3, DPYS, EFEMP2, FAM62C, FAM78A, FLJ33790, GBX2, GPR10, GPRASP1, HOXA9, HOXD11, <span class=""gene"" id=""16778180-3-190-196"">HOXD12</span>, HOXD13, p14ARF, PAX6, PRDX2, PTPRG, RASD1, RAX, REC8L1, SLC27A3, TGFB2, TLX2, TMEM22, TMEM30B, and UNC5C) were found to be methylated in at least 1 of 13 <span class=""disease"" id=""16778180-3-352-360"">melanoma</span> cell lines but not in two cultured normal melanocytes.",CTD_human
1,0,Biomarker,C0003873,Rheumatoid Arthritis,disease,RA,3239,HOXD13,HOXD13,CTD_human,17568789,"HOXD10, HOXD11, HOXD13, CCL8 and LIM homeobox 2 were highly and exclusively expressed in RA and CLU, sarcoglycan-gamma, GPR64, POU3F3, peroxisome proliferative activated receptor-gamma and tripartite motif-containing 2 were expressed only in OA.",0.200274726784213,"HOXD10, HOXD11, <span class=""gene"" id=""17568789-4-16-22"">HOXD13</span>, CCL8 and LIM homeobox 2 were highly and exclusively expressed in <span class=""disease"" id=""17568789-4-89-91"">RA</span> and CLU, sarcoglycan-gamma, GPR64, POU3F3, peroxisome proliferative activated receptor-gamma and tripartite motif-containing 2 were expressed only in OA.",CTD_human
2,0,Biomarker,C0001418,Adenocarcinoma,group,adenocarcinoma,324,APC,APC,CTD_human,15639718,"Analysis of methylation levels in 10 MM and 8 adenocarcinoma cell lines showed that methylation of APC was significantly elevated in adenocarcinoma compared to MM cell lines (P=0.0003), while methylation of CDH1 was higher in MM (P<0.02).",0.22680029080898498,"Analysis of methylation levels in 10 MM and 8 <span class=""disease"" id=""15639718-5-46-60"">adenocarcinoma</span> cell lines showed that methylation of <span class=""gene"" id=""15639718-5-99-102"">APC</span> was significantly elevated in <span class=""disease"" id=""15639718-5-133-147"">adenocarcinoma</span> compared to MM cell lines (P=0.0003), while methylation of CDH1 was higher in MM (P&lt;0.02).",CTD_human
4,0,Biomarker,C0001430,Adenoma,group,adenomas,324,APC,adenomatous polyposis coli,CTD_human,10383901,"Min/+ mice are heterozygous for a nonsense mutation in the adenomatous polyposis coli gene and spontaneously develop multiple intestinal adenomas, primarily in the small intestine.",0.275880483162242,"Min/+ mice are heterozygous for a nonsense mutation in the <span class=""gene"" id=""10383901-2-59-85"">adenomatous polyposis coli</span> gene and spontaneously develop multiple intestinal <span class=""disease"" id=""10383901-2-137-145"">adenomas</span>, primarily in the small intestine.",CTD_human
1,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,NSCLC,324,APC,APC,CTD_human,18337602,"In a multivariate model, promoter methylation of the cyclin-dependent kinase inhibitor 2A gene p16, the H-cadherin gene CDH13, the Ras association domain family 1 gene RASSF1A, and the adenomatous polyposis coli gene APC in tumors and in histologically tumor-negative lymph nodes was associated with tumor recurrence, independently of NSCLC stage, age, sex, race, smoking history, and histologic characteristics of the tumor.",0.203296721410557,"In a multivariate model, promoter methylation of the cyclin-dependent kinase inhibitor 2A gene p16, the H-cadherin gene CDH13, the Ras association domain family 1 gene RASSF1A, and the <span class=""gene"" id=""18337602-5-185-211"">adenomatous polyposis coli</span> gene <span class=""gene"" id=""18337602-5-217-220"">APC</span> in tumors and in histologically tumor-negative lymph nodes was associated with tumor recurrence, independently of <span class=""disease"" id=""18337602-5-335-340"">NSCLC</span> stage, age, sex, race, smoking history, and histologic characteristics of the tumor.",CTD_human
7,0,Biomarker,C0009375,Colonic Neoplasms,group,colon tumors,324,APC,Apc,CTD_human,7846077,"Specific 5'-GGGA-3'-->5'-GGA-3' mutation of the Apc gene in rat colon tumors induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine.",0.31180920672782697,"Specific 5'-GGGA-3'--&gt;5'-GGA-3' mutation of the <span class=""gene"" id=""7846077-0-48-51"">Apc</span> gene in rat <span class=""disease"" id=""7846077-0-64-76"">colon tumors</span> induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine.",CTD_human
7,0,Biomarker,C0009375,Colonic Neoplasms,group,colon tumors,324,APC,APC,CTD_human,8608549,Only 2 of 13 IQ-induced colon tumors had mutations of the APC gene and these were base substitution mutations.,0.31180920672782697,"Only 2 of 13 IQ-induced <span class=""disease"" id=""8608549-8-24-36"">colon tumors</span> had mutations of the <span class=""gene"" id=""8608549-8-58-61"">APC</span> gene and these were base substitution mutations.",CTD_human
3,0,Biomarker,C0021846,Intestinal Polyps,phenotype,intestinal polyps,324,APC,Apc,CTD_human,14991580,"As with cyclooxygenase (COX)-2, genetic disruption of COX-1 gene or pharmacologic inhibition of its activity has been shown to decrease the number of intestinal polyps in Apc gene-deficient mice.",0.205154296365419,"As with cyclooxygenase (COX)-2, genetic disruption of COX-1 gene or pharmacologic inhibition of its activity has been shown to decrease the number of <span class=""disease"" id=""14991580-1-150-167"">intestinal polyps</span> in <span class=""gene"" id=""14991580-1-171-174"">Apc</span> gene-deficient mice.",CTD_human
3,0,Biomarker,C0021846,Intestinal Polyps,phenotype,intestinal polyps,324,APC,Apc,CTD_human,12189188,"When Apc gene knockout mice (APC1309 mice) were given 600 or 1200 p.p.m. mofezolac in their diet for 8 weeks, the numbers of intestinal polyps were also dose-dependently decreased, with reduction to 59% of that in the control diet group at the higher dose.",0.205154296365419,"When <span class=""gene"" id=""12189188-6-5-8"">Apc</span> gene knockout mice (APC1309 mice) were given 600 or 1200 p.p.m. mofezolac in their diet for 8 weeks, the numbers of <span class=""disease"" id=""12189188-6-125-142"">intestinal polyps</span> were also dose-dependently decreased, with reduction to 59% of that in the control diet group at the higher dose.",CTD_human
14,4,Biomarker,C0032580,Adenomatous Polyposis Coli,disease,familial adenomatous polyposis,324,APC,APC,CTD_human,18704758,Identification of somatic APC mutations in recurrent desmoid tumors in a patient with familial adenomatous polyposis to determine actual recurrence of the original tumor or de novo occurrence.,0.8977686845589119,"Identification of somatic <span class=""gene"" id=""18704758-0-26-29"">APC</span> mutations in recurrent desmoid tumors in a patient with <span class=""disease"" id=""18704758-0-86-116"">familial adenomatous polyposis</span> to determine actual recurrence of the original tumor or de novo occurrence.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0079218,"Fibromatosis, Aggressive",disease,desmoid tumors,324,APC,APC,CTD_human,11816139,"It has been shown in molecular genetic examinations, that different mutations of the APC gene are responsible for desmoid tumors in FAP.",0.623243197991532,"It has been shown in molecular genetic examinations, that different mutations of the <span class=""gene"" id=""11816139-3-85-88"">APC</span> gene are responsible for <span class=""disease"" id=""11816139-3-114-128"">desmoid tumors</span> in FAP.",CTD_human;HPO;ORPHANET
1,0,Biomarker,C0002871,Anemia,disease,anaemia,3240,HP,haptoglobin,CTD_human,16637741,Seasonal childhood anaemia in West Africa is associated with the haptoglobin 2-2 genotype.,0.20591296418342803,"Seasonal childhood <span class=""disease"" id=""16637741-0-19-26"">anaemia</span> in West Africa is associated with the <span class=""gene"" id=""16637741-0-65-76"">haptoglobin</span> 2-2 genotype.",CTD_human
1,0,Biomarker,C0007222,Cardiovascular Diseases,group,CVD,3240,HP,haptoglobin,CTD_human,19769483,The haptoglobin (Hp) 2-2 genotype is associated with increased risk of cardiovascular disease (CVD) in diabetes (DM).,0.21654744085579197,"The <span class=""gene"" id=""19769483-1-4-15"">haptoglobin</span> (Hp) 2-2 genotype is associated with increased risk of <span class=""disease"" id=""19769483-1-71-93"">cardiovascular disease</span> (<span class=""disease"" id=""19769483-1-95-98"">CVD</span>) in diabetes (DM).",CTD_human
1,0,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,type 2 diabetes,3240,HP,Haptoglobin,CTD_human,16506275,Haptoglobin was higher in both type 1 and type 2 diabetes (p < 0.001) and haemopexin was higher in type 2 diabetes (p < 0.001).,0.29299034803833895,"<span class=""gene"" id=""16506275-6-0-11"">Haptoglobin</span> was higher in both type 1 and <span class=""disease"" id=""16506275-6-42-57"">type 2 diabetes</span> (p &lt; 0.001) and haemopexin was higher in <span class=""disease"" id=""16506275-6-99-114"">type 2 diabetes</span> (p &lt; 0.001).",CTD_human
2,0,Biomarker,C0024530,Malaria,disease,malaria,3240,HP,haptoglobin,CTD_human,8730300,C-reactive protein and haptoglobin in the evaluation of a community-based malaria control programme.,0.20975913916241198,"C-reactive protein and <span class=""gene"" id=""8730300-0-23-34"">haptoglobin</span> in the evaluation of a community-based <span class=""disease"" id=""8730300-0-74-81"">malaria</span> control programme.",CTD_human
3,0,Biomarker,C0027051,Myocardial Infarction,disease,myocardial infarct,3240,HP,Haptoglobin,CTD_human,17207726,Haptoglobin genotype determines myocardial infarct size in diabetic mice.,0.21433527120476997,"<span class=""gene"" id=""17207726-0-0-11"">Haptoglobin</span> genotype determines <span class=""disease"" id=""17207726-0-32-50"">myocardial infarct</span> size in diabetic mice.",CTD_human
3,0,Biomarker,C0027051,Myocardial Infarction,disease,myocardial infarction,3240,HP,Hp,CTD_human,17068284,Two common alleles exist at the Hp locus and the Hp 2 allele has been associated with increased risk of myocardial infarction.,0.21433527120476997,"Two common alleles exist at the <span class=""gene"" id=""17068284-4-32-34"">Hp</span> locus and the Hp 2 allele has been associated with increased risk of <span class=""disease"" id=""17068284-4-104-125"">myocardial infarction</span>.",CTD_human
1,0,Biomarker,C0041296,Tuberculosis,disease,tuberculosis,3240,HP,haptoglobin,CTD_human,16597321,Iron and infection: effects of host iron status and the iron-regulatory genes haptoglobin and NRAMP1 (SLC11A1) on host-pathogen interactions in tuberculosis and HIV.,0.203557092817453,"Iron and infection: effects of host iron status and the iron-regulatory genes <span class=""gene"" id=""16597321-0-78-89"">haptoglobin</span> and NRAMP1 (SLC11A1) on host-pathogen interactions in <span class=""disease"" id=""16597321-0-144-156"">tuberculosis</span> and HIV.",CTD_human
1,0,Biomarker,C0740394,Hyperuricemia,disease,hyperuricemia,3251,HPRT1,HPRT,CTD_human,23348497,These results lead to the intriguing possibility that association between ALDH16A1 and HPRT1 may be required for optimal HPRT activity with disruption of this interaction possibly contributing to the hyperuricemia seen in ALDH16A1*2 carriers.,0.211509814182316,"These results lead to the intriguing possibility that association between ALDH16A1 and <span class=""gene"" id=""23348497-10-87-92"">HPRT1</span> may be required for optimal <span class=""gene"" id=""23348497-10-121-125"">HPRT</span> activity with disruption of this interaction possibly contributing to the <span class=""disease"" id=""23348497-10-200-213"">hyperuricemia</span> seen in ALDH16A1*2 carriers.",CTD_human
1,0,Biomarker,C0006840,Candidiasis,disease,candidiasis,326,AIRE,AIRE,CTD_human,12050215,"The only association between the phenotype and the AIRE genotype was the higher prevalence of candidiasis in the patients with the most common mutation, R257X, than in those with other mutations.",0.208436662398659,"The only association between the phenotype and the <span class=""gene"" id=""12050215-6-51-55"">AIRE</span> genotype was the higher prevalence of <span class=""disease"" id=""12050215-6-94-105"">candidiasis</span> in the patients with the most common mutation, R257X, than in those with other mutations.",CTD_human
1,0,Biomarker,C0004364,Autoimmune Diseases,group,autoimmunity,3263,HPX,hemopexin,CTD_human,18641331,"To this end, we chose a mouse model of mercury-induced autoimmunity and evaluated the susceptibility of hemopexin-null mice to mercury treatment compared with wild-type controls.",0.2,"To this end, we chose a mouse model of mercury-induced <span class=""disease"" id=""18641331-5-55-67"">autoimmunity</span> and evaluated the susceptibility of <span class=""gene"" id=""18641331-5-104-113"">hemopexin</span>-null mice to mercury treatment compared with wild-type controls.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,3265,HRAS,HRAS-1,CTD_human,8098541,Possible association of c-Harvey-Ras-1 (HRAS-1) marker with autism.,0.202956482091714,"Possible association of c-Harvey-Ras-1 (<span class=""gene"" id=""8098541-0-40-46"">HRAS-1</span>) marker with <span class=""disease"" id=""8098541-0-60-66"">autism</span>.",CTD_human
5,0,Biomarker,C0023903,Liver neoplasms,group,liver tumors,3265,HRAS,Ha-ras,CTD_human,17514646,Global gene expression in Ha-ras and B-raf mutated mouse liver tumors.,0.203296721410557,"Global gene expression in <span class=""gene"" id=""17514646-0-26-32"">Ha-ras</span> and B-raf mutated mouse <span class=""disease"" id=""17514646-0-57-69"">liver tumors</span>.",CTD_human
5,0,Biomarker,C0023903,Liver neoplasms,group,liver tumors,3265,HRAS,Hras-1,CTD_human,16410370,There was a significant difference in Kras2 mutation incidence for spontaneous versus induced mouse lung tumors and in Hras-1 mutation incidence and spectrum for spontaneous versus induced mouse liver tumors.,0.203296721410557,"There was a significant difference in Kras2 mutation incidence for spontaneous versus induced mouse lung tumors and in <span class=""gene"" id=""16410370-4-119-125"">Hras-1</span> mutation incidence and spectrum for spontaneous versus induced mouse <span class=""disease"" id=""16410370-4-195-207"">liver tumors</span>.",CTD_human
5,0,Biomarker,C0024121,Lung Neoplasms,group,lung tumors,3265,HRAS,Ha-ras,CTD_human,12765245,Previous studies showed that significant differences in mutation frequency of the human c-Ha-ras transgene between vinyl carbamate (VC)- and ethyl carbamate (urethane)-induced lung tumors were observed in rasH2 mice.,0.201098907136852,"Previous studies showed that significant differences in mutation frequency of the human c-<span class=""gene"" id=""12765245-1-90-96"">Ha-ras</span> transgene between vinyl carbamate (VC)- and ethyl carbamate (urethane)-induced <span class=""disease"" id=""12765245-1-176-187"">lung tumors</span> were observed in rasH2 mice.",CTD_human
5,0,Biomarker,C0024121,Lung Neoplasms,group,lung tumors,3265,HRAS,Ha-ras,CTD_human,10779650,Carcinogen dose-dependent variation in the transgene mutation spectrum in urethane-induced lung tumors in transgenic mice carrying the human prototype c-Ha-ras gene.,0.201098907136852,"Carcinogen dose-dependent variation in the transgene mutation spectrum in urethane-induced <span class=""disease"" id=""10779650-0-91-102"">lung tumors</span> in transgenic mice carrying the human prototype c-<span class=""gene"" id=""10779650-0-153-159"">Ha-ras</span> gene.",CTD_human
1,0,Biomarker,C0036631,Seminoma,disease,seminomas,3265,HRAS,HRAS,CTD_human,19855393,Most spermatocytic seminomas show increased immunoreactivity for FGFR3 and/or HRAS.,0.200274726784213,"Most spermatocytic <span class=""disease"" id=""19855393-5-19-28"">seminomas</span> show increased immunoreactivity for FGFR3 and/or <span class=""gene"" id=""19855393-5-78-82"">HRAS</span>.",CTD_human
7,0,Biomarker,C0037286,Skin Neoplasms,group,skin tumors,3265,HRAS,Ha-ras,CTD_human,9766437,"In skin tumors, AZT exposure did not increase the number of Ha-ras codon 61 mutations, and no Ki-ras mutations were observed.",0.201923087489492,"In <span class=""disease"" id=""9766437-11-3-14"">skin tumors</span>, AZT exposure did not increase the number of <span class=""gene"" id=""9766437-11-60-66"">Ha-ras</span> codon 61 mutations, and no Ki-ras mutations were observed.",CTD_human
7,0,Biomarker,C0037286,Skin Neoplasms,group,skin tumor,3265,HRAS,Ha-ras,CTD_human,8508502,"Characterization of skin tumor promotion by mirex: structure-activity relationships, sexual dimorphism and presence of Ha-ras mutation.",0.201923087489492,"Characterization of <span class=""disease"" id=""8508502-0-20-30"">skin tumor</span> promotion by mirex: structure-activity relationships, sexual dimorphism and presence of <span class=""gene"" id=""8508502-0-119-125"">Ha-ras</span> mutation.",CTD_human
3,0,Biomarker,C2239176,Liver carcinoma,disease,hepatocellular carcinomas,3265,HRAS,Ha-ras,CTD_human,9311599,"At week 16, rats that had received the mutated Ha-ras antisense oligonucleotides had significantly fewer and smaller preneoplastic lesions positive for glutathione-S-transferase, placental type, and had smaller hepatocellular carcinomas than rats that had received the sense oligonucleotide.",0.20412090176319603,"At week 16, rats that had received the mutated <span class=""gene"" id=""9311599-5-47-53"">Ha-ras</span> antisense oligonucleotides had significantly fewer and smaller preneoplastic lesions positive for glutathione-S-transferase, placental type, and had smaller <span class=""disease"" id=""9311599-5-211-236"">hepatocellular carcinomas</span> than rats that had received the sense oligonucleotide.",CTD_human
1,2,Biomarker,C3854181,Nevus sebaceous,disease,nevus sebaceous,3265,HRAS,HRAS,CTD_human,22683711,Postzygotic HRAS and KRAS mutations cause nevus sebaceous and Schimmelpenning syndrome.,0.600274726784213,"Postzygotic <span class=""gene"" id=""22683711-0-12-16"">HRAS</span> and KRAS mutations cause <span class=""disease"" id=""22683711-0-42-57"">nevus sebaceous</span> and Schimmelpenning syndrome.",CTD_human;HPO;ORPHANET;UNIPROT
1,0,Biomarker,C0033774,Pruritus,phenotype,pruritus,3269,HRH1,histamine H1 receptor,CTD_human,19652466,We have also investigated the effect of histamine H4 receptor antagonists on histamine H1 receptor antagonist-resistant pruritus using a mouse model.,0.2,"We have also investigated the effect of histamine H4 receptor antagonists on <span class=""gene"" id=""19652466-5-77-98"">histamine H1 receptor</span> antagonist-resistant <span class=""disease"" id=""19652466-5-120-128"">pruritus</span> using a mouse model.",CTD_human
1,0,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,3269,HRH1,histamine H1 receptor,CTD_human,1912125,Down-regulation of the histamine H1 receptor in the frontal cortex may be involved in the pathophysiology of schizophrenia.,0.20754696951139004,"Down-regulation of the <span class=""gene"" id=""1912125-7-23-44"">histamine H1 receptor</span> in the frontal cortex may be involved in the pathophysiology of <span class=""disease"" id=""1912125-7-109-122"">schizophrenia</span>.",CTD_human
1,0,Biomarker,C2607914,Allergic rhinitis (disorder),disease,allergic rhinitis,3269,HRH1,H1R,CTD_human,23333628,It has been reported that the histamine H1 receptor (H1R) gene is up-regulated in patients with allergic rhinitis and H1R expression level strongly correlates with the severity of allergy symptoms.,0.201373633921065,"It has been reported that the histamine H1 receptor (<span class=""gene"" id=""23333628-1-53-56"">H1R</span>) gene is up-regulated in patients with <span class=""disease"" id=""23333628-1-96-113"">allergic rhinitis</span> and H1R expression level strongly correlates with the severity of allergy symptoms.",CTD_human
1,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastasis,3274,HRH2,histamine H2 receptor,CTD_human,6224980,The relationship of histamine H2 receptor-bearing suppressor cells with the growth and metastasis of FANFT-induced bladder cancer.,0.2,"The relationship of <span class=""gene"" id=""6224980-0-20-41"">histamine H2 receptor</span>-bearing suppressor cells with the growth and <span class=""disease"" id=""6224980-0-87-97"">metastasis</span> of FANFT-induced bladder cancer.",CTD_human
1,0,Biomarker,C0025202,melanoma,disease,melanoma,328,APEX1,Ref-1,CTD_human,16373707,Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE/Ref-1) in human melanoma and identification of the therapeutic potential of resveratrol as an APE/Ref-1 inhibitor.,0.21433527120476997,"Alterations in the expression of the <span class=""gene"" id=""16373707-0-37-73"">apurinic/apyrimidinic endonuclease-1</span>/redox factor-1 (<span class=""gene"" id=""16373707-0-90-93"">APE</span>/Ref-1) in human <span class=""disease"" id=""16373707-0-110-118"">melanoma</span> and identification of the therapeutic potential of resveratrol as an <span class=""gene"" id=""16373707-0-188-191"">APE</span>/<span class=""gene"" id=""16373707-0-192-197"">Ref-1</span> inhibitor.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,hepatocellular carcinoma,328,APEX1,APE,CTD_human,25109342,The role of APE/Ref-1 signaling pathway in hepatocellular carcinoma progression.,0.20575490709115804,"The role of <span class=""gene"" id=""25109342-0-12-15"">APE</span>/Ref-1 signaling pathway in <span class=""disease"" id=""25109342-0-43-67"">hepatocellular carcinoma</span> progression.",CTD_human
1,0,Biomarker,C0001627,Congenital adrenal hyperplasia,disease,congenital adrenal hyperplasia,3284,HSD3B2,HSD3B2,CTD_human,18252794,3beta-Hydroxysteroid dehydrogenase (3beta-HSD) deficiency is a rare cause of congenital adrenal hyperplasia caused by inactivating mutations in the HSD3B2 gene.,0.40219781427370505,"3beta-Hydroxysteroid dehydrogenase (3beta-HSD) deficiency is a rare cause of <span class=""disease"" id=""18252794-1-77-107"">congenital adrenal hyperplasia</span> caused by inactivating mutations in the <span class=""gene"" id=""18252794-1-148-154"">HSD3B2</span> gene.",CTD_human;HPO
1,0,Biomarker,C0848558,Hypospadias,disease,hypospadias,3284,HSD3B2,HSD3B2,CTD_human,14764821,We conclude that subtle molecular abnormalities in the HSD3B2 gene may be observed in some patients with apparent idiopathic hypospadias but that this finding is uncommon.,0.20568939455652804,"We conclude that subtle molecular abnormalities in the <span class=""gene"" id=""14764821-11-55-61"">HSD3B2</span> gene may be observed in some patients with apparent idiopathic <span class=""disease"" id=""14764821-11-125-136"">hypospadias</span> but that this finding is uncommon.",CTD_human
4,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,3291,HSD11B2,11 beta HSD,CTD_human,7670488,The syndrome of apparent mineralocorticoid excess (AME) is an inherited form of human hypertension thought to result from a deficiency of 11 beta-hydroxysteroid dehydrogenase (11 beta HSD).,0.442052286924035,"The syndrome of apparent mineralocorticoid excess (AME) is an inherited form of human <span class=""disease"" id=""7670488-1-86-98"">hypertension</span> thought to result from a deficiency of 11 beta-hydroxysteroid dehydrogenase (<span class=""gene"" id=""7670488-1-176-187"">11 beta HSD</span>).",CTD_human;HPO
4,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,3291,HSD11B2,HSD11B2,CTD_human,9707624,"Recently, we have studied an unusual patient with mild low-renin hypertension and a homozygous mutation in the HSD11B2 gene.",0.442052286924035,"Recently, we have studied an unusual patient with mild low-renin <span class=""disease"" id=""9707624-5-65-77"">hypertension</span> and a homozygous mutation in the <span class=""gene"" id=""9707624-5-111-118"">HSD11B2</span> gene.",CTD_human;HPO
4,0,Biomarker,C0020538,Hypertensive disease,group,high blood pressure,3291,HSD11B2,11 beta-HSD2,CTD_human,9683905,"Finally, in the placenta 11 beta-HSD2 reduces fetal exposure to maternal glucocorticoids and a decreased activity of this isozyme may result in low birth weight and increased risk of high blood pressure at adult age.",0.442052286924035,"Finally, in the placenta <span class=""gene"" id=""9683905-13-25-37"">11 beta-HSD2</span> reduces fetal exposure to maternal glucocorticoids and a decreased activity of this isozyme may result in low birth weight and increased risk of <span class=""disease"" id=""9683905-13-183-202"">high blood pressure</span> at adult age.",CTD_human;HPO
1,0,Biomarker,C0023890,Liver Cirrhosis,disease,liver cirrhosis,3291,HSD11B2,HSD2,CTD_human,15199296,"Renal sodium retention in liver cirrhosis, nephrotic syndrome and hypoxia have been linked to 11beta-HSD2 reduced activity.",0.2,"Renal sodium retention in <span class=""disease"" id=""15199296-8-26-41"">liver cirrhosis</span>, nephrotic syndrome and hypoxia have been linked to 11beta-<span class=""gene"" id=""15199296-8-101-105"">HSD2</span> reduced activity.",CTD_human
1,0,Biomarker,C0027726,Nephrotic Syndrome,group,nephrotic syndrome,3291,HSD11B2,HSD2,CTD_human,15199296,"Renal sodium retention in liver cirrhosis, nephrotic syndrome and hypoxia have been linked to 11beta-HSD2 reduced activity.",0.2,"Renal sodium retention in liver cirrhosis, <span class=""disease"" id=""15199296-8-43-61"">nephrotic syndrome</span> and hypoxia have been linked to 11beta-<span class=""gene"" id=""15199296-8-101-105"">HSD2</span> reduced activity.",CTD_human
12,8,Biomarker,C3887949,Apparent mineralocorticoid excess,disease,apparent mineralocorticoid excess,3291,HSD11B2,HSD11B2,CTD_human,7608290,A mutation in the HSD11B2 gene in a family with apparent mineralocorticoid excess.,0.48961543744745895,"A mutation in the <span class=""gene"" id=""7608290-0-18-25"">HSD11B2</span> gene in a family with <span class=""disease"" id=""7608290-0-48-81"">apparent mineralocorticoid excess</span>.",CTD_human;UNIPROT
12,8,Biomarker,C3887949,Apparent mineralocorticoid excess,disease,AME,3291,HSD11B2,11 beta HSD,CTD_human,7670488,We have analysed the gene encoding the kidney isozyme of 11 beta HSD and found mutations on both alleles in nine of 11 AME patients (eight of nine kindreds).,0.48961543744745895,"We have analysed the gene encoding the kidney isozyme of <span class=""gene"" id=""7670488-3-57-68"">11 beta HSD</span> and found mutations on both alleles in nine of 11 <span class=""disease"" id=""7670488-3-119-122"">AME</span> patients (eight of nine kindreds).",CTD_human;UNIPROT
12,8,Biomarker,C3887949,Apparent mineralocorticoid excess,disease,AME,3291,HSD11B2,11 beta-HSD2,CTD_human,9683905,"In the apparent mineral corticoid excess (AME) syndrome type 1, absence of 11 beta-HSD2 activity is caused by mutations in the gene coding for 11 beta-HSD2.",0.48961543744745895,"In the apparent mineral corticoid excess (<span class=""disease"" id=""9683905-7-42-45"">AME</span>) syndrome type 1, absence of <span class=""gene"" id=""9683905-7-75-87"">11 beta-HSD2</span> activity is caused by mutations in the gene coding for <span class=""gene"" id=""9683905-7-143-155"">11 beta-HSD2</span>.",CTD_human;UNIPROT
12,8,Biomarker,C3887949,Apparent mineralocorticoid excess,disease,AME,3291,HSD11B2,HSD2,CTD_human,9707624,"Typical patients with AME have defective 11beta-HSD2 activity, as evidenced by an abnormal ratio of cortisol to cortisone metabolites and by an exceedingly diminished ability to convert [11-3H]cortisol to cortisone.",0.48961543744745895,"Typical patients with <span class=""disease"" id=""9707624-4-22-25"">AME</span> have defective 11beta-<span class=""gene"" id=""9707624-4-48-52"">HSD2</span> activity, as evidenced by an abnormal ratio of cortisol to cortisone metabolites and by an exceedingly diminished ability to convert [11-3H]cortisol to cortisone.",CTD_human;UNIPROT
1,0,Biomarker,C0014175,Endometriosis,disease,endometriosis,3292,HSD17B1,HSD17B1,CTD_human,18815356,"In 8-Br-cAMP-treated hESF from eutopic endometrium of women with endometriosis, the balance in estradiol (E2) and P4 biosynthetic and metabolizing enzymes is disturbed (decreased HSD3B1 and HSD17B2, and increased HSD17B1 and aromatase), with the equilibrium being shifted towards an E2-enriched milieu.",0.21302714981833498,"In 8-Br-cAMP-treated hESF from eutopic endometrium of women with <span class=""disease"" id=""18815356-5-65-78"">endometriosis</span>, the balance in estradiol (E2) and P4 biosynthetic and metabolizing enzymes is disturbed (decreased HSD3B1 and HSD17B2, and increased <span class=""gene"" id=""18815356-5-213-220"">HSD17B1</span> and aromatase), with the equilibrium being shifted towards an E2-enriched milieu.",CTD_human
2,0,Biomarker,C0014175,Endometriosis,disease,endometriosis,3294,HSD17B2,HSD17B2,CTD_human,18815356,"In 8-Br-cAMP-treated hESF from eutopic endometrium of women with endometriosis, the balance in estradiol (E2) and P4 biosynthetic and metabolizing enzymes is disturbed (decreased HSD3B1 and HSD17B2, and increased HSD17B1 and aromatase), with the equilibrium being shifted towards an E2-enriched milieu.",0.20629000528226699,"In 8-Br-cAMP-treated hESF from eutopic endometrium of women with <span class=""disease"" id=""18815356-5-65-78"">endometriosis</span>, the balance in estradiol (E2) and P4 biosynthetic and metabolizing enzymes is disturbed (decreased HSD3B1 and <span class=""gene"" id=""18815356-5-190-197"">HSD17B2</span>, and increased HSD17B1 and aromatase), with the equilibrium being shifted towards an E2-enriched milieu.",CTD_human
1,0,Biomarker,C0037769,West Syndrome,disease,infantile spasms,3295,HSD17B4,D-bifunctional protein,CTD_human,16919904,D-bifunctional protein deficiency associated with drug resistant infantile spasms.,0.200274726784213,"<span class=""gene"" id=""16919904-0-0-22"">D-bifunctional protein</span> deficiency associated with drug resistant <span class=""disease"" id=""16919904-0-65-81"">infantile spasms</span>.",CTD_human
1,0,Biomarker,C0043459,Zellweger Syndrome,disease,Zellweger syndrome,3295,HSD17B4,17beta-hydroxysteroid dehydrogenase 4,CTD_human,10343282,Unique multifunctional HSD17B4 gene product: 17beta-hydroxysteroid dehydrogenase 4 and D-3-hydroxyacyl-coenzyme A dehydrogenase/hydratase involved in Zellweger syndrome.,0.20082418035263896,"Unique multifunctional <span class=""gene"" id=""10343282-0-23-30"">HSD17B4</span> gene product: <span class=""gene"" id=""10343282-0-45-82"">17beta-hydroxysteroid dehydrogenase 4</span> and D-3-hydroxyacyl-coenzyme A dehydrogenase/hydratase involved in <span class=""disease"" id=""10343282-0-150-168"">Zellweger syndrome</span>.",CTD_human
2,0,Biomarker,C0282528,Peroxisomal Disorders,group,peroxisomal disorder,3295,HSD17B4,D-3-hydroxyacyl-CoA dehydratase,CTD_human,9345094,D-3-hydroxyacyl-CoA dehydratase/D-3-hydroxyacyl-CoA dehydrogenase bifunctional protein deficiency: a newly identified peroxisomal disorder.,0.20054945356842604,"<span class=""gene"" id=""9345094-0-0-31"">D-3-hydroxyacyl-CoA dehydratase</span>/D-3-hydroxyacyl-CoA dehydrogenase bifunctional protein deficiency: a newly identified <span class=""disease"" id=""9345094-0-118-138"">peroxisomal disorder</span>.",CTD_human
1,0,Biomarker,C0005695,Bladder Neoplasm,disease,bladder cancer,330,BIRC3,cIAP-2,CTD_human,12926068,cIAP-2 block apoptotic events in bladder cancer cells.,0.20300763924902696,"<span class=""gene"" id=""12926068-0-0-6"">cIAP-2</span> block apoptotic events in <span class=""disease"" id=""12926068-0-33-47"">bladder cancer</span> cells.",CTD_human
1,0,Biomarker,C0025202,melanoma,disease,melanoma,3303,HSPA1A,HSPA1,CTD_human,26984758,"The stress-inducible chaperone protein HSP70 (HSPA1) is implicated in melanoma development, and HSP70 inhibitors exert tumor-specific cytotoxic activity in cancer.",0.200274726784213,"The stress-inducible chaperone protein HSP70 (<span class=""gene"" id=""26984758-1-46-51"">HSPA1</span>) is implicated in <span class=""disease"" id=""26984758-1-70-78"">melanoma</span> development, and HSP70 inhibitors exert tumor-specific cytotoxic activity in cancer.",CTD_human
1,0,Therapeutic,C0030567,Parkinson Disease,disease,PD,3303,HSPA1A,HSPA1A,CTD_human,15585408,"Here we tested the potential of Hsp70 (approved gene symbol HSPA1A) for gene therapy in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of idiopathic PD.",0.202681755307501,"Here we tested the potential of Hsp70 (approved gene symbol <span class=""gene"" id=""15585408-6-60-66"">HSPA1A</span>) for gene therapy in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of idiopathic <span class=""disease"" id=""15585408-6-170-172"">PD</span>.",CTD_human
1,0,Biomarker,C0004153,Atherosclerosis,disease,atherosclerosis,3304,HSPA1B,Hsp70-2,CTD_human,16513158,"In this paper, we reviewed data regarding to the pivotal role played by the zinc-gene interaction in affecting some relevant cytokines (IL-6 and TNF-alpha) and heat shock proteins (Hsp70-2) in ageing, successful ageing (nonagenarians) and in some age-related diseases (atherosclerosis and infections).",0.200274726784213,"In this paper, we reviewed data regarding to the pivotal role played by the zinc-gene interaction in affecting some relevant cytokines (IL-6 and TNF-alpha) and heat shock proteins (<span class=""gene"" id=""16513158-1-181-188"">Hsp70-2</span>) in ageing, successful ageing (nonagenarians) and in some age-related diseases (<span class=""disease"" id=""16513158-1-269-284"">atherosclerosis</span> and infections).",CTD_human
1,0,Biomarker,C0028754,Obesity,disease,obese,3309,HSPA5,Grp78,CTD_human,26655953,"In human renal biopsies, staining of 4-hydroxynonenal (4-HNE), glucose-regulated protein 78 (Grp78), and C/EBP-homologous protein, markers of endoplasmic reticulum stress, was more prominent in the proximal tubules of 15 obese patients compared with 16 non-obese patients.",0.200274726784213,"In human renal biopsies, staining of 4-hydroxynonenal (4-HNE), glucose-regulated protein 78 (<span class=""gene"" id=""26655953-5-93-98"">Grp78</span>), and C/EBP-homologous protein, markers of endoplasmic reticulum stress, was more prominent in the proximal tubules of 15 <span class=""disease"" id=""26655953-5-221-226"">obese</span> patients compared with 16 non-<span class=""disease"" id=""26655953-5-257-262"">obese</span> patients.",CTD_human
1,0,Biomarker,C0014859,Esophageal Neoplasms,group,esophageal cancer,331,XIAP,XIAP,CTD_human,17611394,XIAP is highly expressed in esophageal cancer and its downregulation by RNAi sensitizes esophageal carcinoma cell lines to chemotherapeutics.,0.202732912464814,"<span class=""gene"" id=""17611394-0-0-4"">XIAP</span> is highly expressed in <span class=""disease"" id=""17611394-0-28-45"">esophageal cancer</span> and its downregulation by RNAi sensitizes esophageal carcinoma cell lines to chemotherapeutics.",CTD_human
1,0,Biomarker,C0030567,Parkinson Disease,disease,Parkinson disease,3313,HSPA9,GRP75,CTD_human,16565515,"Proteomic identification of a stress protein, mortalin/mthsp70/GRP75: relevance to Parkinson disease.",0.207337755261807,"Proteomic identification of a stress protein, <span class=""gene"" id=""16565515-0-46-54"">mortalin</span>/mthsp70/<span class=""gene"" id=""16565515-0-63-68"">GRP75</span>: relevance to <span class=""disease"" id=""16565515-0-83-100"">Parkinson disease</span>.",CTD_human
1,0,Therapeutic,C0018801,Heart failure,disease,HF,3315,HSPB1,Hsp27,CTD_human,17481944,"Transgenic mice (TG) with cardiac specific over-expression of Hsp27 and their wild type littermates (WT) were challenged with doxorubicin (25 mg/kg, IP) to induce HF.",0.2,"Transgenic mice (TG) with cardiac specific over-expression of <span class=""gene"" id=""17481944-4-62-67"">Hsp27</span> and their wild type littermates (WT) were challenged with doxorubicin (25 mg/kg, IP) to induce <span class=""disease"" id=""17481944-4-163-165"">HF</span>.",CTD_human
1,0,Biomarker,C0026764,Multiple Myeloma,disease,multiple myeloma,3315,HSPB1,Hsp27,CTD_human,12855565,Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance.,0.20300763924902696,"<span class=""gene"" id=""12855565-0-0-5"">Hsp27</span> inhibits release of mitochondrial protein Smac in <span class=""disease"" id=""12855565-0-56-72"">multiple myeloma</span> cells and confers dexamethasone resistance.",CTD_human
1,0,Biomarker,C0038220,Status Epilepticus,disease,SE,3315,HSPB1,Hsp25,CTD_human,20971094,"Interestingly, while Hsp32 and Hsp70 expression was transient, Hsp25 demonstrated a sustained induction pattern, which may reflect an additional role of Hsp25 in subsequent remodeling events in the days following SE.",0.2,"Interestingly, while Hsp32 and Hsp70 expression was transient, <span class=""gene"" id=""20971094-5-63-68"">Hsp25</span> demonstrated a sustained induction pattern, which may reflect an additional role of <span class=""gene"" id=""20971094-5-153-158"">Hsp25</span> in subsequent remodeling events in the days following <span class=""disease"" id=""20971094-5-213-215"">SE</span>.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,3315,HSPB1,HSP27,CTD_human,21472284,"These identified proteins, which include stratifin (14-3-3), transgelin 2, heat-shock protein (HSP)70, HSP27, manganese superoxide dismutase, prohibitin, DJ1, ?-enolase, peroxiredoxin 6, aldo-keto reductase family member B10, phosphoglycerate kinase 1, ?-1-antitrypsin and nm23-H1, may play a role in the development of HCC.",0.210671278452359,"These identified proteins, which include stratifin (14-3-3), transgelin 2, heat-shock protein (HSP)70, <span class=""gene"" id=""21472284-9-103-108"">HSP27</span>, manganese superoxide dismutase, prohibitin, DJ1, &alpha;-enolase, peroxiredoxin 6, aldo-keto reductase family member B10, phosphoglycerate kinase 1, &alpha;-1-antitrypsin and nm23-H1, may play a role in the development of <span class=""disease"" id=""21472284-9-320-323"">HCC</span>.",CTD_human
1,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,NSCLC,332,BIRC5,survivin,CTD_human,16382892,"Univariate analysis (log-rank test) showed that significant independent prognostic factors in NSCLC included: stage of the disease according to TNM classification (p = 0.006), response to chemotherapy (p = 0.005) and pattern of survivin gene expression (p = 0.00003).",0.20467035533162303,"Univariate analysis (log-rank test) showed that significant independent prognostic factors in <span class=""disease"" id=""16382892-10-94-99"">NSCLC</span> included: stage of the disease according to TNM classification (p = 0.006), response to chemotherapy (p = 0.005) and pattern of <span class=""gene"" id=""16382892-10-228-236"">survivin</span> gene expression (p = 0.00003).",CTD_human
1,0,Biomarker,C0206180,Ki-1+ Anaplastic Large Cell Lymphoma,disease,anaplastic large cell lymphoma,3320,HSP90AA1,HSP90,CTD_human,17157164,The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression.,0.200274726784213,"The <span class=""gene"" id=""17157164-0-4-9"">HSP90</span> inhibitor 17-AAG synergizes with doxorubicin and U0126 in <span class=""disease"" id=""17157164-0-68-98"">anaplastic large cell lymphoma</span> irrespective of ALK expression.",CTD_human
1,0,Therapeutic,C0878544,Cardiomyopathies,group,cardiomyopathy,3329,HSPD1,Hsp60,CTD_human,12967636,These data provide a novel link between Hsp10/Hsp60 and cardiac protection in doxorubicin cardiomyopathy.,0.2,"These data provide a novel link between Hsp10/<span class=""gene"" id=""12967636-15-46-51"">Hsp60</span> and cardiac protection in doxorubicin <span class=""disease"" id=""12967636-15-90-104"">cardiomyopathy</span>.",CTD_human
2,2,Biomarker,C1854467,"Spastic paraplegia 13, autosomal dominant",disease,SPG13,3329,HSPD1,Hsp60,CTD_human,18571143,"Our findings suggest that Hsp60 defects can cause neurodegenerative pathologies of varying severity, not previously suspected on the basis of the SPG13 phenotype.",0.6805494535684261,"Our findings suggest that <span class=""gene"" id=""18571143-10-26-31"">Hsp60</span> defects can cause neurodegenerative pathologies of varying severity, not previously suspected on the basis of the <span class=""disease"" id=""18571143-10-146-151"">SPG13</span> phenotype.",CTD_human;ORPHANET;UNIPROT
1,1,Biomarker,C2677109,"Leukodystrophy, Hypomyelinating, 4",disease,MitCHAP-60 disease,3329,HSPD1,Hsp60,CTD_human,18571143,"The disorder, which we have termed MitCHAP-60 disease, can be distinguished from spastic paraplegia 13 (SPG13), another Hsp60-associated autosomal-dominant neurodegenerative disorder, by its autosomal-recessive inheritance pattern, as well as by its early-onset, profound cerebral involvement and lethality.",0.6008241803526391,"The disorder, which we have termed <span class=""disease"" id=""18571143-9-35-53"">MitCHAP-60 disease</span>, can be distinguished from spastic paraplegia 13 (<span class=""gene"" id=""18571143-9-104-109"">SPG13</span>), another <span class=""gene"" id=""18571143-9-120-125"">Hsp60</span>-associated autosomal-dominant neurodegenerative disorder, by its autosomal-recessive inheritance pattern, as well as by its early-onset, profound cerebral involvement and lethality.",CTD_human;ORPHANET;UNIPROT
1,0,Therapeutic,C0878544,Cardiomyopathies,group,cardiomyopathy,3336,HSPE1,Hsp10,CTD_human,12967636,These data provide a novel link between Hsp10/Hsp60 and cardiac protection in doxorubicin cardiomyopathy.,0.2,"These data provide a novel link between <span class=""gene"" id=""12967636-15-40-45"">Hsp10</span>/Hsp60 and cardiac protection in doxorubicin <span class=""disease"" id=""12967636-15-90-104"">cardiomyopathy</span>.",CTD_human
2,0,Biomarker,C0029422,Osteochondrodysplasias,group,skeletal dysplasia,3339,HSPG2,Hspg2,CTD_human,10545953,"The remaining Hspg2-/- mice died just after birth with skeletal dysplasia characterized by micromelia with broad and bowed long bones, narrow thorax and craniofacial abnormalities.",0.40300763924902705,"The remaining <span class=""gene"" id=""10545953-5-14-19"">Hspg2</span>-/- mice died just after birth with <span class=""disease"" id=""10545953-5-55-73"">skeletal dysplasia</span> characterized by micromelia with broad and bowed long bones, narrow thorax and craniofacial abnormalities.",CTD_human;HPO
1,0,Biomarker,C0376634,Craniofacial Abnormalities,group,craniofacial abnormalities,3339,HSPG2,Hspg2,CTD_human,10545953,"The remaining Hspg2-/- mice died just after birth with skeletal dysplasia characterized by micromelia with broad and bowed long bones, narrow thorax and craniofacial abnormalities.",0.200274726784213,"The remaining <span class=""gene"" id=""10545953-5-14-19"">Hspg2</span>-/- mice died just after birth with skeletal dysplasia characterized by micromelia with broad and bowed long bones, narrow thorax and <span class=""disease"" id=""10545953-5-153-179"">craniofacial abnormalities</span>.",CTD_human
1,1,Biomarker,C1857100,Dyssegmental dysplasia,disease,"Dyssegmental dysplasia, Silverman-Handmaker type",3339,HSPG2,perlecan,CTD_human,11279527,"Dyssegmental dysplasia, Silverman-Handmaker type, is caused by functional null mutations of the perlecan gene.",0.48082418035263896,"<span class=""disease"" id=""11279527-0-0-48"">Dyssegmental dysplasia, Silverman-Handmaker type</span>, is caused by functional null mutations of the <span class=""gene"" id=""11279527-0-96-104"">perlecan</span> gene.",CTD_human;ORPHANET
1,0,Biomarker,C0004352,Autistic Disorder,disease,autistic,3346,HTN1,histatin 1,CTD_human,19367726,"Phosphorylation level of four specific salivary phospho-peptides, namely statherin, histatin 1 (both, p < 0.0001) and acidic proline-rich proteins (both entire and truncated isoforms) (p < 0.005) was found significantly lower in autistic patients, with hypo-phosphorylation of at least one peptide observed in 18 ASD subjects (66%).",0.2,"Phosphorylation level of four specific salivary phospho-peptides, namely statherin, <span class=""gene"" id=""19367726-2-84-94"">histatin 1</span> (both, p &lt; 0.0001) and acidic proline-rich proteins (both entire and truncated isoforms) (p &lt; 0.005) was found significantly lower in <span class=""disease"" id=""19367726-2-229-237"">autistic</span> patients, with hypo-phosphorylation of at least one peptide observed in 18 ASD subjects (66%).",CTD_human
1,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,335,APOA1,apolipoprotein A-I,CTD_human,18224302,Simvastatin reverses the hypertension of heterozygous mice lacking cystathionine beta-synthase and apolipoprotein A-I.,0.491602358739956,"Simvastatin reverses the <span class=""disease"" id=""18224302-0-25-37"">hypertension</span> of heterozygous mice lacking cystathionine beta-synthase and <span class=""gene"" id=""18224302-0-99-117"">apolipoprotein A-I</span>.",CTD_human;HPO
1,0,Biomarker,C0024121,Lung Neoplasms,group,lung tumor,335,APOA1,apolipoprotein-A1,CTD_human,19180532,"Notably, expression of alpha-2-macroglobulin, transthyretin, alpha-1-antitrypsin, and properdin was in common in different lung tumor models, but regulation of orosomucoid-8, apolipoprotein-A1, apolipoprotein-C3, apolipoprotein-E, glutathione peroxidase-3, plasma retinol-binding protein, and serum amyloid P component was unique when the serum proteomes of c-myc and c-raf tumor bearing mice were compared.",0.202732912464814,"Notably, expression of alpha-2-macroglobulin, transthyretin, alpha-1-antitrypsin, and properdin was in common in different <span class=""disease"" id=""19180532-8-123-133"">lung tumor</span> models, but regulation of orosomucoid-8, <span class=""gene"" id=""19180532-8-175-192"">apolipoprotein-A1</span>, apolipoprotein-C3, apolipoprotein-E, glutathione peroxidase-3, plasma retinol-binding protein, and serum amyloid P component was unique when the serum proteomes of c-myc and c-raf tumor bearing mice were compared.",CTD_human
1,0,Therapeutic,C0853897,Diabetic Cardiomyopathies,disease,diabetic cardiomyopathy,335,APOA1,apolipoprotein A-I,CTD_human,18332268,Human apolipoprotein A-I gene transfer reduces the development of experimental diabetic cardiomyopathy.,0.200274726784213,"Human <span class=""gene"" id=""18332268-0-6-24"">apolipoprotein A-I</span> gene transfer reduces the development of experimental <span class=""disease"" id=""18332268-0-79-102"">diabetic cardiomyopathy</span>.",CTD_human
1,0,Therapeutic,C0030193,Pain,phenotype,pain,3350,HTR1A,5-HT(1A,CTD_human,12595749,"These results help to establish large-magnitude 5-HT(1A) receptor activation as a new molecular mechanism of profound, central analgesia and suggest that F 13640 may be particularly effective against pain arising from severe tonic nociceptive stimulation.",0.202956482091714,"These results help to establish large-magnitude <span class=""gene"" id=""12595749-8-48-55"">5-HT(1A</span>) receptor activation as a new molecular mechanism of profound, central analgesia and suggest that F 13640 may be particularly effective against <span class=""disease"" id=""12595749-8-200-204"">pain</span> arising from severe tonic nociceptive stimulation.",CTD_human
3,0,Therapeutic,C0036572,Seizures,phenotype,seizures,3350,HTR1A,5-HT1A,CTD_human,2533336,"In conclusion, the present study suggests that the inhibition of pilocarpine-induced seizures may be mediated by stimulation of 5-HT1A and by blockade of 5-HT1B receptors, located probably on the cholinergic terminals.",0.2,"In conclusion, the present study suggests that the inhibition of pilocarpine-induced <span class=""disease"" id=""2533336-6-85-93"">seizures</span> may be mediated by stimulation of <span class=""gene"" id=""2533336-6-128-134"">5-HT1A</span> and by blockade of 5-HT1B receptors, located probably on the cholinergic terminals.",CTD_human
3,0,Therapeutic,C0036572,Seizures,phenotype,seizure,3350,HTR1A,5-HT(1A,CTD_human,12646302,"Taken together, these results suggest that 5-HT(1A) receptor activation is a critical step in the activation of seizure-induced cell proliferation and survival in the dentate gyrus, however, not for the onset of spontaneously recurrent seizures and MFS.",0.2,"Taken together, these results suggest that <span class=""gene"" id=""12646302-8-43-50"">5-HT(1A</span>) receptor activation is a critical step in the activation of <span class=""disease"" id=""12646302-8-112-119"">seizure</span>-induced cell proliferation and survival in the dentate gyrus, however, not for the onset of spontaneously recurrent seizures and MFS.",CTD_human
3,0,Biomarker,C0036572,Seizures,phenotype,seizure,3350,HTR1A,5-HT(1A,CTD_human,12646302,"Taken together, these results suggest that 5-HT(1A) receptor activation is a critical step in the activation of seizure-induced cell proliferation and survival in the dentate gyrus, however, not for the onset of spontaneously recurrent seizures and MFS.",0.2,"Taken together, these results suggest that <span class=""gene"" id=""12646302-8-43-50"">5-HT(1A</span>) receptor activation is a critical step in the activation of <span class=""disease"" id=""12646302-8-112-119"">seizure</span>-induced cell proliferation and survival in the dentate gyrus, however, not for the onset of spontaneously recurrent seizures and MFS.",CTD_human
3,0,Therapeutic,C0036572,Seizures,phenotype,seizure,3350,HTR1A,5-HT 1A,CTD_human,16313900,Stimulation of 5-HT 1A receptors increases the seizure threshold for picrotoxin in mice.,0.2,"Stimulation of <span class=""gene"" id=""16313900-0-15-22"">5-HT 1A</span> receptors increases the <span class=""disease"" id=""16313900-0-47-54"">seizure</span> threshold for picrotoxin in mice.",CTD_human
3,0,Biomarker,C0036572,Seizures,phenotype,seizures,3350,HTR1A,5-HT1A,CTD_human,2533336,"In conclusion, the present study suggests that the inhibition of pilocarpine-induced seizures may be mediated by stimulation of 5-HT1A and by blockade of 5-HT1B receptors, located probably on the cholinergic terminals.",0.2,"In conclusion, the present study suggests that the inhibition of pilocarpine-induced <span class=""disease"" id=""2533336-6-85-93"">seizures</span> may be mediated by stimulation of <span class=""gene"" id=""2533336-6-128-134"">5-HT1A</span> and by blockade of 5-HT1B receptors, located probably on the cholinergic terminals.",CTD_human
3,0,Biomarker,C0036572,Seizures,phenotype,seizure,3350,HTR1A,5-HT 1A,CTD_human,16313900,Stimulation of 5-HT 1A receptors increases the seizure threshold for picrotoxin in mice.,0.2,"Stimulation of <span class=""gene"" id=""16313900-0-15-22"">5-HT 1A</span> receptors increases the <span class=""disease"" id=""16313900-0-47-54"">seizure</span> threshold for picrotoxin in mice.",CTD_human
1,0,Biomarker,C0040822,Tremor,phenotype,tremor,3350,HTR1A,5-HT(1A,CTD_human,11070179,These findings suggest that nicotine-induced tail tremor is mediated by 5-HT(1A) receptors and that 5-HT(1A) receptor antagonists are effective in the treatment of tremor.,0.2,"These findings suggest that nicotine-induced tail <span class=""disease"" id=""11070179-5-50-56"">tremor</span> is mediated by <span class=""gene"" id=""11070179-5-72-79"">5-HT(1A</span>) receptors and that <span class=""gene"" id=""11070179-5-100-107"">5-HT(1A</span>) receptor antagonists are effective in the treatment of <span class=""disease"" id=""11070179-5-164-170"">tremor</span>.",CTD_human
1,0,Biomarker,C0036572,Seizures,phenotype,seizures,3351,HTR1B,5-HT1B,CTD_human,2533336,"In conclusion, the present study suggests that the inhibition of pilocarpine-induced seizures may be mediated by stimulation of 5-HT1A and by blockade of 5-HT1B receptors, located probably on the cholinergic terminals.",0.2,"In conclusion, the present study suggests that the inhibition of pilocarpine-induced <span class=""disease"" id=""2533336-6-85-93"">seizures</span> may be mediated by stimulation of 5-HT1A and by blockade of <span class=""gene"" id=""2533336-6-154-160"">5-HT1B</span> receptors, located probably on the cholinergic terminals.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,3356,HTR2A,HTR2A,CTD_human,17280648,The global chi(2) test for haplotype transmission revealed a significant association between HTR2A and autism.,0.22418695492482302,"The global chi(2) test for haplotype transmission revealed a significant association between <span class=""gene"" id=""17280648-10-93-98"">HTR2A</span> and <span class=""disease"" id=""17280648-10-103-109"">autism</span>.",CTD_human
1,0,Biomarker,C0024117,Chronic Obstructive Airway Disease,disease,COPD,3356,HTR2A,5-HTR(2A),CTD_human,22048642,Blockade of serotonin receptor 2A (5-HTR(2A)) with ketanserin has been found to improve lung function in COPD patients.,0.202681755307501,"Blockade of <span class=""gene"" id=""22048642-2-12-33"">serotonin receptor 2A</span> (<span class=""gene"" id=""22048642-2-35-44"">5-HTR(2A)</span>) with ketanserin has been found to improve lung function in <span class=""disease"" id=""22048642-2-105-109"">COPD</span> patients.",CTD_human
1,0,Biomarker,C0028754,Obesity,disease,obese,3356,HTR2A,5-HT2A,CTD_human,17097612,Increased hypothalamic 5-HT2A receptor gene expression and effects of pharmacologic 5-HT2A receptor inactivation in obese Ay mice.,0.21450768367435802,"Increased hypothalamic <span class=""gene"" id=""17097612-0-23-29"">5-HT2A</span> receptor gene expression and effects of pharmacologic <span class=""gene"" id=""17097612-0-84-90"">5-HT2A</span> receptor inactivation in <span class=""disease"" id=""17097612-0-116-121"">obese</span> Ay mice.",CTD_human
2,0,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,3356,HTR2A,5-HT2A,CTD_human,18513383,Excess of transmission of the G allele of the -1438A/G polymorphism of the 5-HT2A receptor gene in patients with schizophrenia responsive to antipsychotics.,0.42243673151814504,"Excess of transmission of the G allele of the -1438A/G polymorphism of the <span class=""gene"" id=""18513383-0-75-81"">5-HT2A</span> receptor gene in patients with <span class=""disease"" id=""18513383-0-113-126"">schizophrenia</span> responsive to antipsychotics.",CTD_human
1,0,Biomarker,C0149931,Migraine Disorders,group,migraine,3356,HTR2A,5 -HT2A,CTD_human,12482207,2002 Wolff Award. 5 -HT2A receptor activation and nitric oxide synthesis: a possible mechanism determining migraine attacks.,0.20831999270671597,"2002 Wolff Award. <span class=""gene"" id=""12482207-0-18-25"">5 -HT2A</span> receptor activation and nitric oxide synthesis: a possible mechanism determining <span class=""disease"" id=""12482207-0-107-115"">migraine</span> attacks.",CTD_human
2,0,Biomarker,C0424295,Hyperactive behavior,phenotype,hyperactivity,3356,HTR2A,5-HT(2A,CTD_human,19347958,"Pharmacological stimulation of 5-HT(2A) receptors enhances the conditioned hyperlocomotion, while activation of 5-HT(2C) receptors decreases both the response to acute nicotine and conditioned hyperactivity.",0.20054945356842604,"Pharmacological stimulation of <span class=""gene"" id=""19347958-11-31-38"">5-HT(2A</span>) receptors enhances the conditioned hyperlocomotion, while activation of 5-HT(2C) receptors decreases both the response to acute nicotine and conditioned <span class=""disease"" id=""19347958-11-193-206"">hyperactivity</span>.",CTD_human
1,0,Biomarker,C0018801,Heart failure,disease,heart failure,3357,HTR2B,5-HT(2B,CTD_human,19023134,"Accordingly, antagonists of 5-HT(2B) receptors might represent novel therapeutics for sympathetic overstimulation-dependent heart failure.",0.28,"Accordingly, antagonists of <span class=""gene"" id=""19023134-10-28-35"">5-HT(2B</span>) receptors might represent novel therapeutics for sympathetic overstimulation-dependent <span class=""disease"" id=""19023134-10-124-137"">heart failure</span>.",CTD_human
4,0,Biomarker,C0018824,Heart valve disease,group,cardiac valvulopathy,3357,HTR2B,5-HT(2B,CTD_human,11104741,Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications.,0.28,"Evidence for possible involvement of <span class=""gene"" id=""11104741-0-37-44"">5-HT(2B</span>) receptors in the <span class=""disease"" id=""11104741-0-63-83"">cardiac valvulopathy</span> associated with fenfluramine and other serotonergic medications.",CTD_human
4,0,Biomarker,C0018824,Heart valve disease,group,valvulopathy,3357,HTR2B,5-HT(2B,CTD_human,19505264,A more likely cause of fenfluramine-induced valvulopathy is activation of 5-HT(2B) receptors on heart valves by the metabolite norfenfluramine.,0.28,"A more likely cause of fenfluramine-induced <span class=""disease"" id=""19505264-7-44-56"">valvulopathy</span> is activation of <span class=""gene"" id=""19505264-7-74-81"">5-HT(2B</span>) receptors on heart valves by the metabolite norfenfluramine.",CTD_human
2,0,Biomarker,C0028754,Obesity,disease,obesity,3358,HTR2C,HTR2C,CTD_human,19142110,"The frequency of patients homozygous for the HTR2C haplotype A (-759C, -697G, and 23Cys) was significantly higher among clozapine-treated patients with obesity (BMI >/= 30 kg/m) compared with nonobese patients (P = 0.015; odds ratio, 28; 95% confidence interval, 2-380).",0.226333612041215,"The frequency of patients homozygous for the <span class=""gene"" id=""19142110-5-45-50"">HTR2C</span> haplotype A (-759C, -697G, and 23Cys) was significantly higher among clozapine-treated patients with <span class=""disease"" id=""19142110-5-152-159"">obesity</span> (BMI &gt;/= 30 kg/m) compared with nonobese patients (P = 0.015; odds ratio, 28; 95% confidence interval, 2-380).",CTD_human
2,0,Biomarker,C0028754,Obesity,disease,obesity,3358,HTR2C,HTR2C,CTD_human,17702092,Evidence was based on the observation that knock-out mice for the HTR2C receptor gene develop obesity and that many antipsychotics (AP) with potent HTR2C antagonism may induce weight gain in susceptible individuals.,0.226333612041215,"Evidence was based on the observation that knock-out mice for the <span class=""gene"" id=""17702092-2-66-71"">HTR2C</span> receptor gene develop <span class=""disease"" id=""17702092-2-94-101"">obesity</span> and that many antipsychotics (AP) with potent <span class=""gene"" id=""17702092-2-148-153"">HTR2C</span> antagonism may induce weight gain in susceptible individuals.",CTD_human
1,0,Therapeutic,C0424295,Hyperactive behavior,phenotype,hyperactivity,3358,HTR2C,5-HT(2C,CTD_human,19347958,"Pharmacological stimulation of 5-HT(2A) receptors enhances the conditioned hyperlocomotion, while activation of 5-HT(2C) receptors decreases both the response to acute nicotine and conditioned hyperactivity.",0.2,"Pharmacological stimulation of 5-HT(2A) receptors enhances the conditioned hyperlocomotion, while activation of <span class=""gene"" id=""19347958-11-112-119"">5-HT(2C</span>) receptors decreases both the response to acute nicotine and conditioned <span class=""disease"" id=""19347958-11-193-206"">hyperactivity</span>.",CTD_human
3,0,Biomarker,C0524620,Metabolic Syndrome X,disease,metabolic syndrome,3358,HTR2C,5-HT(2C,CTD_human,18515891,"Patients (n=134) were assessed for measures of obesity, other factors contributing to metabolic syndrome, and two genetic polymorphisms (5-HT(2C) receptor -759C/T and leptin -2548A/G).",0.20673714453606798,"Patients (n=134) were assessed for measures of obesity, other factors contributing to <span class=""disease"" id=""18515891-4-86-104"">metabolic syndrome</span>, and two genetic polymorphisms (<span class=""gene"" id=""18515891-4-137-144"">5-HT(2C</span>) receptor -759C/T and leptin -2548A/G).",CTD_human
3,0,Biomarker,C0524620,Metabolic Syndrome X,disease,metabolic syndrome,3358,HTR2C,HTR2C,CTD_human,17632216,The association between HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia.,0.20673714453606798,"The association between <span class=""gene"" id=""17632216-0-24-29"">HTR2C</span> gene polymorphisms and the <span class=""disease"" id=""17632216-0-57-75"">metabolic syndrome</span> in patients with schizophrenia.",CTD_human
3,0,Biomarker,C0524620,Metabolic Syndrome X,disease,metabolic syndrome,3358,HTR2C,HTR2C,CTD_human,19142101,HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: a replication study.,0.20673714453606798,"<span class=""gene"" id=""19142101-0-0-5"">HTR2C</span> gene polymorphisms and the <span class=""disease"" id=""19142101-0-33-51"">metabolic syndrome</span> in patients with schizophrenia: a replication study.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,3359,HTR3A,HTR3A,CTD_human,19184136,"These data suggest that variation within genes on the serotonin pathway, particularly HTR3A, may have modest effects on autism risk.",0.202681755307501,"These data suggest that variation within genes on the serotonin pathway, particularly <span class=""gene"" id=""19184136-8-86-91"">HTR3A</span>, may have modest effects on <span class=""disease"" id=""19184136-8-120-126"">autism</span> risk.",CTD_human
1,0,Biomarker,C0020445,"Hypercholesterolemia, Familial",disease,familial hypercholesterolemia,336,APOA2,apolipoprotein A-II,CTD_human,12522687,Interaction between the LDL-receptor gene bearing a novel mutation and a variant in the apolipoprotein A-II promoter: molecular study in a 1135-member familial hypercholesterolemia kindred.,0.200274726784213,"Interaction between the LDL-receptor gene bearing a novel mutation and a variant in the <span class=""gene"" id=""12522687-0-88-107"">apolipoprotein A-II</span> promoter: molecular study in a 1135-member <span class=""disease"" id=""12522687-0-151-180"">familial hypercholesterolemia</span> kindred.",CTD_human
1,0,Biomarker,C0003123,Anorexia,disease,anorexia,3360,HTR4,5-HT4,CTD_human,15146954,"Our recent data indicate that the pharmacological inactivation, using a systemic injection of the 5-HT4 receptor antagonist RS39604 (0.5 mg/kg), suppressed restraint stress-induced anorexia in wild-type female mice.",0.2,"Our recent data indicate that the pharmacological inactivation, using a systemic injection of the <span class=""gene"" id=""15146954-3-98-103"">5-HT4</span> receptor antagonist RS39604 (0.5 mg/kg), suppressed restraint stress-induced <span class=""disease"" id=""15146954-3-181-189"">anorexia</span> in wild-type female mice.",CTD_human
1,0,Therapeutic,C0004238,Atrial Fibrillation,disease,atrial fibrillation,3360,HTR4,5-HT4,CTD_human,7886817,"In this article, Alberto Kaumann suggests that 5-HT may be involved in the genesis of atrial fibrillation and associated thromboembolic stroke and that both the arrhythmia and stroke could be prevented by inhibiting 5-HT4 receptors.",0.20054945356842604,"In this article, Alberto Kaumann suggests that 5-HT may be involved in the genesis of <span class=""disease"" id=""7886817-5-86-105"">atrial fibrillation</span> and associated thromboembolic stroke and that both the arrhythmia and stroke could be prevented by inhibiting <span class=""gene"" id=""7886817-5-216-221"">5-HT4</span> receptors.",CTD_human
1,0,Therapeutic,C0038454,Cerebrovascular accident,group,stroke,3360,HTR4,5-HT4,CTD_human,7886817,"In this article, Alberto Kaumann suggests that 5-HT may be involved in the genesis of atrial fibrillation and associated thromboembolic stroke and that both the arrhythmia and stroke could be prevented by inhibiting 5-HT4 receptors.",0.2,"In this article, Alberto Kaumann suggests that 5-HT may be involved in the genesis of atrial fibrillation and associated thromboembolic <span class=""disease"" id=""7886817-5-136-142"">stroke</span> and that both the arrhythmia and <span class=""disease"" id=""7886817-5-176-182"">stroke</span> could be prevented by inhibiting <span class=""gene"" id=""7886817-5-216-221"">5-HT4</span> receptors.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,3361,HTR5A,HTR5A,CTD_human,17203304,"We report a significant main effect of the HTR5A gene in autism (P = 0.0088), and a significant three-locus model comprising a synergistic interaction between the ITGB3 and SLC6A4 genes with an additive effect of HTR5A (P < 0.0010).",0.202681755307501,"We report a significant main effect of the <span class=""gene"" id=""17203304-6-43-48"">HTR5A</span> gene in <span class=""disease"" id=""17203304-6-57-63"">autism</span> (P = 0.0088), and a significant three-locus model comprising a synergistic interaction between the ITGB3 and SLC6A4 genes with an additive effect of <span class=""gene"" id=""17203304-6-213-218"">HTR5A</span> (P &lt; 0.0010).",CTD_human
1,0,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,3362,HTR6,5-HT(6,CTD_human,12165372,An RT-PCR study of 5-HT(6) and 5-HT(7) receptor mRNAs in the hippocampal formation and prefrontal cortex in schizophrenia.,0.22019707823088602,"An RT-PCR study of <span class=""gene"" id=""12165372-0-19-25"">5-HT(6</span>) and 5-HT(7) receptor mRNAs in the hippocampal formation and prefrontal cortex in <span class=""disease"" id=""12165372-0-108-121"">schizophrenia</span>.",CTD_human
1,0,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,3363,HTR7,5-HT(7,CTD_human,12165372,An RT-PCR study of 5-HT(6) and 5-HT(7) receptor mRNAs in the hippocampal formation and prefrontal cortex in schizophrenia.,0.21368350332171898,"An RT-PCR study of 5-HT(6) and <span class=""gene"" id=""12165372-0-31-37"">5-HT(7</span>) receptor mRNAs in the hippocampal formation and prefrontal cortex in <span class=""disease"" id=""12165372-0-108-121"">schizophrenia</span>.",CTD_human
1,0,Therapeutic,C0004153,Atherosclerosis,disease,atherosclerosis,337,APOA4,apolipoprotein A-IV,CTD_human,15822908,"Among the identified proteins, apolipoprotein A-IV may protect lipid peroxidation and atherosclerosis induced by TCDD exposure and the expression level of phosphoglycerate mutase increases due to hyperthyroidism induced by TCDD exposure.",0.20761248204601998,"Among the identified proteins, <span class=""gene"" id=""15822908-7-31-50"">apolipoprotein A-IV</span> may protect lipid peroxidation and <span class=""disease"" id=""15822908-7-86-101"">atherosclerosis</span> induced by TCDD exposure and the expression level of phosphoglycerate mutase increases due to hyperthyroidism induced by TCDD exposure.",CTD_human
1,0,Biomarker,C0004096,Asthma,disease,asthma,3371,TNC,tenascin-C,CTD_human,16115819,Coding SNP in tenascin-C Fn-III-D domain associates with adult asthma.,0.21034539451083303,"Coding SNP in <span class=""gene"" id=""16115819-0-14-24"">tenascin-C</span> Fn-III-D domain associates with adult <span class=""disease"" id=""16115819-0-63-69"">asthma</span>.",CTD_human
2,0,Biomarker,C0007222,Cardiovascular Diseases,group,cardiovascular disease,338,APOB,apolipoprotein B,CTD_human,17002798,"This mixed dyslipidemia (or ""lipid quartet""): hypertriglyceridemia, low high-density lipoprotein cholesterol levels, a preponderance of small, dense low-density lipoprotein particles and an accumulation of cholesterol-rich remnant particles (e.g. high levels of apolipoprotein B)--emerged as the greatest ""competitor"" of low-density lipoprotein-cholesterol among lipid risk factors for cardiovascular disease.",0.23224657622464298,"This mixed dyslipidemia (or ""lipid quartet""): hypertriglyceridemia, low high-density lipoprotein cholesterol levels, a preponderance of small, dense low-density lipoprotein particles and an accumulation of cholesterol-rich remnant particles (e.g. high levels of <span class=""gene"" id=""17002798-4-262-278"">apolipoprotein B</span>)--emerged as the greatest ""competitor"" of low-density lipoprotein-cholesterol among lipid risk factors for <span class=""disease"" id=""17002798-4-386-408"">cardiovascular disease</span>.",CTD_human
1,0,Biomarker,C0010068,Coronary heart disease,disease,coronary heart disease,338,APOB,apolipoprotein B,CTD_human,17658632,"High levels of apolipoprotein B-containing lipoproteins, most prominently carried by low-density lipoprotein (LDL) particles, are an important risk factor for coronary heart disease.",0.259284792037846,"High levels of <span class=""gene"" id=""17658632-3-15-31"">apolipoprotein B</span>-containing lipoproteins, most prominently carried by low-density lipoprotein (LDL) particles, are an important risk factor for <span class=""disease"" id=""17658632-3-159-181"">coronary heart disease</span>.",CTD_human
1,5,Biomarker,C0020445,"Hypercholesterolemia, Familial",disease,familial hypercholesterolaemia,338,APOB,apoB-100,CTD_human,10952765,Numerous different molecular defects have been identified in the LDL receptor (LDLR) and few specific mutations in the apolipoprotein B (APOB) gene resulting in familial hypercholesterolaemia and familial defective apoB-100 respectively.,0.48481834886072295,"Numerous different molecular defects have been identified in the LDL receptor (LDLR) and few specific mutations in the <span class=""gene"" id=""10952765-2-119-135"">apolipoprotein B</span> (<span class=""gene"" id=""10952765-2-137-141"">APOB</span>) gene resulting in <span class=""disease"" id=""10952765-2-161-191"">familial hypercholesterolaemia</span> and familial defective <span class=""gene"" id=""10952765-2-215-223"">apoB-100</span> respectively.",CTD_human;HPO
1,0,Biomarker,C0020557,Hypertriglyceridemia,phenotype,HTG,338,APOB,APOB,CTD_human,20657596,"Through GWAS, we identified common variants in APOA5, GCKR, LPL and APOB associated with HTG.",0.289418899843569,"Through GWAS, we identified common variants in APOA5, GCKR, LPL and <span class=""gene"" id=""20657596-5-68-72"">APOB</span> associated with <span class=""disease"" id=""20657596-5-89-92"">HTG</span>.",CTD_human
1,0,Therapeutic,C0242339,Dyslipidemias,group,dyslipidemia,338,APOB,apolipoprotein B-48,CTD_human,18230960,"Atherogenic dyslipidemia is associated with increased levels of chylomicrons and their remnants containing 3 main components: apolipoprotein B-48, triglycerides and cholesterol ester of intestinal origin.",0.21577441766046598,"Atherogenic <span class=""disease"" id=""18230960-12-12-24"">dyslipidemia</span> is associated with increased levels of chylomicrons and their remnants containing 3 main components: <span class=""gene"" id=""18230960-12-126-145"">apolipoprotein B-48</span>, triglycerides and cholesterol ester of intestinal origin.",CTD_human
2,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastasis,3381,IBSP,BSP,CTD_human,22407340,"Bone sialoprotein (BSP) and osteopontin (OPN) are important factors in the metastasis of breast cancer, which were examined as targets for antineoplastic therapy by siRNA.",0.209861453477037,"<span class=""gene"" id=""22407340-1-0-17"">Bone sialoprotein</span> (<span class=""gene"" id=""22407340-1-19-22"">BSP</span>) and osteopontin (OPN) are important factors in the <span class=""disease"" id=""22407340-1-75-85"">metastasis</span> of breast cancer, which were examined as targets for antineoplastic therapy by siRNA.",CTD_human
2,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastasis,3381,IBSP,bone sialoprotein,CTD_human,24980816,Sustained conditional knockdown reveals intracellular bone sialoprotein as essential for breast cancer skeletal metastasis.,0.209861453477037,"Sustained conditional knockdown reveals intracellular <span class=""gene"" id=""24980816-0-54-71"">bone sialoprotein</span> as essential for breast cancer skeletal <span class=""disease"" id=""24980816-0-112-122"">metastasis</span>.",CTD_human
2,0,Biomarker,C0004096,Asthma,disease,asthma,3383,ICAM1,intercellular adhesion molecule-1,CTD_human,17014439,Role of intercellular adhesion molecule-1 in a murine model of toluene diisocyanate-induced asthma.,0.21821824796374897,"Role of <span class=""gene"" id=""17014439-0-8-41"">intercellular adhesion molecule-1</span> in a murine model of toluene diisocyanate-induced <span class=""disease"" id=""17014439-0-92-98"">asthma</span>.",CTD_human
2,0,Biomarker,C0004096,Asthma,disease,asthma,3383,ICAM1,ICAM1,CTD_human,25003170,"Both ICAM1 and ETS, and interactions between these two factors are likely to be involved in the development of asthma in childhood.",0.21821824796374897,"Both <span class=""gene"" id=""25003170-10-5-10"">ICAM1</span> and ETS, and interactions between these two factors are likely to be involved in the development of <span class=""disease"" id=""25003170-10-111-117"">asthma</span> in childhood.",CTD_human
1,0,Biomarker,C0006267,Bronchiectasis,disease,bronchiectasis,3383,ICAM1,ICAM-1,CTD_human,17931847,Upregulation of ICAM-1 expression in bronchial epithelial cells by airway secretions in bronchiectasis.,0.2,"Upregulation of <span class=""gene"" id=""17931847-0-16-22"">ICAM-1</span> expression in bronchial epithelial cells by airway secretions in <span class=""disease"" id=""17931847-0-88-102"">bronchiectasis</span>.",CTD_human
2,0,Biomarker,C0007222,Cardiovascular Diseases,group,CVD,3383,ICAM1,ICAM1,CTD_human,25575156,"Of the 170 SNPs tested, multiplicative interactions between well-water arsenic and two SNPs, rs281432 in ICAM1 (padj = 0.0002) and rs3176867 in VCAM1 (padj = 0.035), were significant for CVD after adjustment for multiple testing.",0.21593247475273603,"Of the 170 SNPs tested, multiplicative interactions between well-water arsenic and two SNPs, rs281432 in <span class=""gene"" id=""25575156-6-105-110"">ICAM1</span> (padj = 0.0002) and rs3176867 in VCAM1 (padj = 0.035), were significant for <span class=""disease"" id=""25575156-6-187-190"">CVD</span> after adjustment for multiple testing.",CTD_human
1,0,Biomarker,C0009324,Ulcerative Colitis,disease,UC,3383,ICAM1,ICAM-1,CTD_human,15553846,"The results showed that NF-kappaB DNA binding activity, mRNA and protein expression of ICAM-1 and VCAM-1 were increased significantly in patients with UC, compared with normal control (P<0.05).",0.21515945155740898,"The results showed that NF-kappaB DNA binding activity, mRNA and protein expression of <span class=""gene"" id=""15553846-9-87-93"">ICAM-1</span> and VCAM-1 were increased significantly in patients with <span class=""disease"" id=""15553846-9-151-153"">UC</span>, compared with normal control (P&lt;0.05).",CTD_human
2,0,Biomarker,C0009375,Colonic Neoplasms,group,colonic neoplasms,3383,ICAM1,ICAM-1,CTD_human,16497620,Colonic epithelial cell expression of ICAM-1 relates to loss of surface continuity: a comparative study of inflammatory bowel disease and colonic neoplasms.,0.20300763924902696,"Colonic epithelial cell expression of <span class=""gene"" id=""16497620-0-38-44"">ICAM-1</span> relates to loss of surface continuity: a comparative study of inflammatory bowel disease and <span class=""disease"" id=""16497620-0-138-155"">colonic neoplasms</span>.",CTD_human
1,0,Therapeutic,C0011884,Diabetic Retinopathy,disease,diabetic retinopathy,3383,ICAM1,intercellular adhesion molecule-1,CTD_human,10485912,Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition.,0.30029939254551097,"Prevention of leukostasis and vascular leakage in streptozotocin-induced <span class=""disease"" id=""10485912-0-73-93"">diabetic retinopathy</span> via <span class=""gene"" id=""10485912-0-98-131"">intercellular adhesion molecule-1</span> inhibition.",CTD_human
2,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,3383,ICAM1,ICAM-1,CTD_human,12149661,"The levels of adhesion molecules (intercellular cell adhesion molecule-1 [ICAM-1], E-selectin, P-selectin), von Willebrand factor (vWf) and endothelin-1 were measured in patients with hypertension without any other risk factors of atherosclerosis before and after treatment with quinapril (n = 22) and in normotensive controls (n = 22).",0.201373633921065,"The levels of adhesion molecules (intercellular cell adhesion molecule-1 [<span class=""gene"" id=""12149661-3-74-80"">ICAM-1</span>], E-selectin, P-selectin), von Willebrand factor (vWf) and endothelin-1 were measured in patients with <span class=""disease"" id=""12149661-3-184-196"">hypertension</span> without any other risk factors of atherosclerosis before and after treatment with quinapril (n = 22) and in normotensive controls (n = 22).",CTD_human
1,0,Biomarker,C0026769,Multiple Sclerosis,disease,MS,3383,ICAM1,ICAM-1,CTD_human,20175758,"Soluble forms of vascular cell adhesion molecule-1 (VCAM-1), intracellular adhesion molecule-1 (ICAM-1) and E-Selectin play a role in the regulation of blood-brain barrier damage and represent markers of the clinical course of multiple sclerosis (MS) and magnetic resonance imaging activity.",0.21548533549893498,"Soluble forms of vascular cell adhesion molecule-1 (VCAM-1), intracellular adhesion molecule-1 (<span class=""gene"" id=""20175758-1-96-102"">ICAM-1</span>) and E-Selectin play a role in the regulation of blood-brain barrier damage and represent markers of the clinical course of <span class=""disease"" id=""20175758-1-227-245"">multiple sclerosis</span> (<span class=""disease"" id=""20175758-1-247-249"">MS</span>) and magnetic resonance imaging activity.",CTD_human
1,0,Biomarker,C0027720,Nephrosis,disease,nephrosis,3383,ICAM1,CD54,CTD_human,12845231,"Increased expression of CD54, CD18, MHC class II molecules, and proliferating cell nuclear antigen in acute puromycin aminonucleoside nephrosis.",0.2,"Increased expression of <span class=""gene"" id=""12845231-0-24-28"">CD54</span>, CD18, MHC class II molecules, and proliferating cell nuclear antigen in acute puromycin aminonucleoside <span class=""disease"" id=""12845231-0-134-143"">nephrosis</span>.",CTD_human
1,0,Biomarker,C0028754,Obesity,disease,obesity,3383,ICAM1,intercellular adhesion molecule-1,CTD_human,11782876,Elevated soluble intercellular adhesion molecule-1 levels in obesity: relationship to insulin resistance and tumor necrosis factor-alpha system activity.,0.204055389228567,"Elevated soluble <span class=""gene"" id=""11782876-0-17-50"">intercellular adhesion molecule-1</span> levels in <span class=""disease"" id=""11782876-0-61-68"">obesity</span>: relationship to insulin resistance and tumor necrosis factor-alpha system activity.",CTD_human
1,0,Biomarker,C0282548,Leukostasis,disease,leukostasis,3383,ICAM1,intercellular adhesion molecule-1,CTD_human,10485912,Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition.,0.200274726784213,"Prevention of <span class=""disease"" id=""10485912-0-14-25"">leukostasis</span> and vascular leakage in streptozotocin-induced diabetic retinopathy via <span class=""gene"" id=""10485912-0-98-131"">intercellular adhesion molecule-1</span> inhibition.",CTD_human
1,0,Biomarker,C0948089,Acute Coronary Syndrome,disease,ACS,338382,RAB7B,Ras-related protein Rab-7b,CTD_human,21751358,"The expression levels of proteins involved in cellular cytoskeleton (F-actin capping, ?-tubulin, ?-tubulin isotypes 1 and 2, vinculin, vimentin and two Ras-related protein Rab-7b isotypes), glycolysis pathway (glyceraldehyde-3-phosphate dehydrogenase, lactate dehydrogenase and two pyruvate kinase isotypes) and cellular-related antioxidant system (manganese superoxide dismutase) and even the expression and activity of glutathione-S-transferase were significantly reduced in platelets from ACS patients compared to CAD patients.",0.2,"The expression levels of proteins involved in cellular cytoskeleton (F-actin capping, &beta;-tubulin, &alpha;-tubulin isotypes 1 and 2, vinculin, vimentin and two <span class=""gene"" id=""21751358-4-152-178"">Ras-related protein Rab-7b</span> isotypes), glycolysis pathway (glyceraldehyde-3-phosphate dehydrogenase, lactate dehydrogenase and two pyruvate kinase isotypes) and cellular-related antioxidant system (manganese superoxide dismutase) and even the expression and activity of glutathione-S-transferase were significantly reduced in platelets from <span class=""disease"" id=""21751358-4-492-495"">ACS</span> patients compared to CAD patients.",CTD_human
1,0,Biomarker,C0016382,Flushing,phenotype,flushing,338442,HCAR2,HM74A,CTD_human,16322797,GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing.,0.201373633921065,"<span class=""gene"" id=""16322797-0-0-7"">GPR109A</span> (<span class=""gene"" id=""16322797-0-9-15"">PUMA-G</span>/<span class=""gene"" id=""16322797-0-16-21"">HM74A</span>) mediates nicotinic acid-induced <span class=""disease"" id=""16322797-0-55-63"">flushing</span>.",CTD_human
1,0,Biomarker,C0033860,Psoriasis,disease,psoriasis,338442,HCAR2,nicotinic acid receptor,CTD_human,18722346,The psoriasis drug monomethylfumarate is a potent nicotinic acid receptor agonist.,0.2,"The <span class=""disease"" id=""18722346-0-4-13"">psoriasis</span> drug monomethylfumarate is a potent <span class=""gene"" id=""18722346-0-50-73"">nicotinic acid receptor</span> agonist.",CTD_human
1,0,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,338442,HCAR2,HM74A,CTD_human,18639743,The high-affinity niacin receptor HM74A is decreased in the anterior cingulate cortex of individuals with schizophrenia.,0.20300763924902696,"The high-affinity niacin receptor <span class=""gene"" id=""18639743-0-34-39"">HM74A</span> is decreased in the anterior cingulate cortex of individuals with <span class=""disease"" id=""18639743-0-106-119"">schizophrenia</span>.",CTD_human
1,0,Biomarker,C0026769,Multiple Sclerosis,disease,multiple sclerosis,3394,IRF8,IRF8,CTD_human,19525953,"Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci.",0.21182592836685699,"Meta-analysis of genome scans and replication identify CD6, <span class=""gene"" id=""19525953-0-60-64"">IRF8</span> and TNFRSF1A as new <span class=""disease"" id=""19525953-0-85-103"">multiple sclerosis</span> susceptibility loci.",CTD_human
2,0,Biomarker,C0006413,Burkitt Lymphoma,disease,Burkitt lymphoma,3399,ID3,ID3,CTD_human,23143595,"Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing.",0.20054945356842604,"Recurrent mutation of the <span class=""gene"" id=""23143595-0-26-29"">ID3</span> gene in <span class=""disease"" id=""23143595-0-38-54"">Burkitt lymphoma</span> identified by integrated genome, exome and transcriptome sequencing.",CTD_human
1,0,Biomarker,C0024145,Chilblain lupus 1,disease,chilblain lupus,340061,TMEM173,STING,CTD_human,27566796,Familial chilblain lupus due to a gain-of-function mutation in STING.,0.2,"Familial <span class=""disease"" id=""27566796-0-9-24"">chilblain lupus</span> due to a gain-of-function mutation in <span class=""gene"" id=""27566796-0-63-68"">STING</span>.",CTD_human
1,0,Biomarker,C0025202,melanoma,disease,malignant melanoma,340273,ABCB5,ABCB5,CTD_human,15899824,ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma.,0.213143819510277,"<span class=""gene"" id=""15899824-0-0-5"">ABCB5</span>-mediated doxorubicin transport and chemoresistance in human <span class=""disease"" id=""15899824-0-66-84"">malignant melanoma</span>.",CTD_human
1,0,Biomarker,C0002395,Alzheimer's Disease,disease,Alzheimer disease,3416,IDE,IDE,CTD_human,17192785,"In addition to identifying the epsilon4 allele of APOE and related effects, we pinpointed over a dozen potential Alzheimer disease susceptibility genes (ACE, CHRNB2, CST3, ESR1, GAPDHS, IDE, MTHFR, NCSTN, PRNP, PSEN1, TF, TFAM and TNF) with statistically significant allelic summary odds ratios (ranging from 1.11-1.38 for risk alleles and 0.92-0.67 for protective alleles).",0.256523168818397,"In addition to identifying the epsilon4 allele of APOE and related effects, we pinpointed over a dozen potential <span class=""disease"" id=""17192785-5-113-130"">Alzheimer disease</span> susceptibility genes (ACE, CHRNB2, CST3, ESR1, GAPDHS, <span class=""gene"" id=""17192785-5-186-189"">IDE</span>, MTHFR, NCSTN, PRNP, PSEN1, TF, TFAM and TNF) with statistically significant allelic summary odds ratios (ranging from 1.11-1.38 for risk alleles and 0.92-0.67 for protective alleles).",CTD_human
2,3,Biomarker,C0265233,Cryptophthalmos syndrome,disease,FS,341640,FREM2,FREM2,CTD_human,17163535,"While recent research has led to the identification of the genes FRAS1 and FREM2 as the cause of FS, the genetic basis of AMS continues to be enigmatic.",0.6838461749789829,"While recent research has led to the identification of the genes FRAS1 and <span class=""gene"" id=""17163535-2-75-80"">FREM2</span> as the cause of <span class=""disease"" id=""17163535-2-97-99"">FS</span>, the genetic basis of AMS continues to be enigmatic.",CTD_human;ORPHANET;UNIPROT
2,0,Biomarker,C0014084,Enchondromatosis,disease,Ollier disease,3417,IDH1,IDH1,CTD_human,22057236,Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2.,0.6019230874894921,"<span class=""disease"" id=""22057236-0-0-14"">Ollier disease</span> and Maffucci syndrome are caused by somatic mosaic mutations of <span class=""gene"" id=""22057236-0-79-83"">IDH1</span> and IDH2.",CTD_human;HPO;ORPHANET
2,0,Biomarker,C0014084,Enchondromatosis,disease,Ollier disease,3417,IDH1,IDH1,CTD_human,22057234,Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome.,0.6019230874894921,"Somatic mosaic <span class=""gene"" id=""22057234-0-15-19"">IDH1</span> and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in <span class=""disease"" id=""22057234-0-102-116"">Ollier disease</span> and Maffucci syndrome.",CTD_human;HPO;ORPHANET
4,0,Biomarker,C0017638,Glioma,disease,gliomas,3417,IDH1,IDH1,CTD_human,19901110,"IDH1 mutations are a novel positive prognostic factor in anaplastic gliomas, with a favorable impact stronger than that of 1p/19q codeletion or MGMT promoter methylation.",0.302315024592644,"<span class=""gene"" id=""19901110-14-0-4"">IDH1</span> mutations are a novel positive prognostic factor in anaplastic <span class=""disease"" id=""19901110-14-68-75"">gliomas</span>, with a favorable impact stronger than that of 1p/19q codeletion or MGMT promoter methylation.",CTD_human
4,0,Biomarker,C0017638,Glioma,disease,gliomas,3417,IDH1,IDH1,CTD_human,26618343,"To understand the molecular mechanisms underlying the malignant progression of low-grade gliomas with mutations in IDH1 (encoding isocitrate dehydrogenase 1), we studied paired tumor samples from 41 patients, comparing higher-grade, progressed samples to their lower-grade counterparts.",0.302315024592644,"To understand the molecular mechanisms underlying the malignant progression of low-grade <span class=""disease"" id=""26618343-2-89-96"">gliomas</span> with mutations in <span class=""gene"" id=""26618343-2-115-119"">IDH1</span> (encoding isocitrate dehydrogenase 1), we studied paired tumor samples from 41 patients, comparing higher-grade, progressed samples to their lower-grade counterparts.",CTD_human
1,0,Biomarker,C0018916,Hemangioma,disease,hemangiomas,3417,IDH1,IDH1,CTD_human,22057234,We report somatic heterozygous mutations in IDH1 (c.394C>T encoding an R132C substitution and c.395G>A encoding an R132H substitution) or IDH2 (c.516G>C encoding R172S) in 87% of enchondromas (benign cartilage tumors) and in 70% of spindle cell hemangiomas (benign vascular lesions).,0.201098907136852,"We report somatic heterozygous mutations in <span class=""gene"" id=""22057234-2-44-48"">IDH1</span> (c.394C&gt;T encoding an R132C substitution and c.395G&gt;A encoding an R132H substitution) or IDH2 (c.516G&gt;C encoding R172S) in 87% of enchondromas (benign cartilage tumors) and in 70% of spindle cell <span class=""disease"" id=""22057234-2-245-256"">hemangiomas</span> (benign vascular lesions).",CTD_human
1,0,Biomarker,C0023467,"Leukemia, Myelocytic, Acute",disease,acute myeloid leukemia,3417,IDH1,IDH1,CTD_human,25324972,Mutations in the isocitrate dehydrogenase 2 gene and IDH1 SNP 105C?>?T have a prognostic value in acute myeloid leukemia.,0.253675265393265,"Mutations in the isocitrate dehydrogenase 2 gene and <span class=""gene"" id=""25324972-0-53-57"">IDH1</span> SNP 105C?&gt;?T have a prognostic value in <span class=""disease"" id=""25324972-0-98-120"">acute myeloid leukemia</span>.",CTD_human
2,0,Biomarker,C0014084,Enchondromatosis,disease,Ollier disease,3418,IDH2,IDH2,CTD_human,22057236,Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2.,0.6013736339210661,"<span class=""disease"" id=""22057236-0-0-14"">Ollier disease</span> and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and <span class=""gene"" id=""22057236-0-88-92"">IDH2</span>.",CTD_human;HPO;ORPHANET
2,0,Biomarker,C0014084,Enchondromatosis,disease,Ollier disease,3418,IDH2,IDH2,CTD_human,22057234,Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome.,0.6013736339210661,"Somatic mosaic IDH1 and <span class=""gene"" id=""22057234-0-24-28"">IDH2</span> mutations are associated with enchondroma and spindle cell hemangioma in <span class=""disease"" id=""22057234-0-102-116"">Ollier disease</span> and Maffucci syndrome.",CTD_human;HPO;ORPHANET
1,0,Biomarker,C0018916,Hemangioma,disease,hemangiomas,3418,IDH2,IDH2,CTD_human,22057234,We report somatic heterozygous mutations in IDH1 (c.394C>T encoding an R132C substitution and c.395G>A encoding an R132H substitution) or IDH2 (c.516G>C encoding R172S) in 87% of enchondromas (benign cartilage tumors) and in 70% of spindle cell hemangiomas (benign vascular lesions).,0.20082418035263896,"We report somatic heterozygous mutations in IDH1 (c.394C&gt;T encoding an R132C substitution and c.395G&gt;A encoding an R132H substitution) or <span class=""gene"" id=""22057234-2-138-142"">IDH2</span> (c.516G&gt;C encoding R172S) in 87% of enchondromas (benign cartilage tumors) and in 70% of spindle cell <span class=""disease"" id=""22057234-2-245-256"">hemangiomas</span> (benign vascular lesions).",CTD_human
1,0,Biomarker,C0020981,Angioimmunoblastic Lymphadenopathy,disease,AITL,3418,IDH2,IDH2,CTD_human,24413737,"Although frequent mutations in TET2, IDH2 and DNMT3A, which are common to various hematologic malignancies, have been identified in AITL, the molecular pathogenesis specific to this lymphoma subtype is unknown.",0.202197814273705,"Although frequent mutations in TET2, <span class=""gene"" id=""24413737-2-37-41"">IDH2</span> and DNMT3A, which are common to various hematologic malignancies, have been identified in <span class=""disease"" id=""24413737-2-132-136"">AITL</span>, the molecular pathogenesis specific to this lymphoma subtype is unknown.",CTD_human
1,0,Biomarker,C0023467,"Leukemia, Myelocytic, Acute",disease,AML,3418,IDH2,IDH2,CTD_human,25324972,Our results indicate that AML-patients with IDH2 mutations or the IDH1 SNP 105C?>?T variant can represent a new subgroup for risk stratification and may indicate new treatment options.,0.24068491735492603,"Our results indicate that <span class=""disease"" id=""25324972-12-26-29"">AML</span>-patients with <span class=""gene"" id=""25324972-12-44-48"">IDH2</span> mutations or the IDH1 SNP 105C?&gt;?T variant can represent a new subgroup for risk stratification and may indicate new treatment options.",CTD_human
2,0,Biomarker,C0079774,Peripheral T-Cell Lymphoma,disease,PTCL,3418,IDH2,IDH2,CTD_human,24413734,"These analyses identified highly recurrent epigenetic factor mutations in TET2, DNMT3A and IDH2 as well as a new highly prevalent RHOA mutation encoding a p.Gly17Val alteration present in 22 of 35 (67%) angioimmunoblastic T cell lymphoma (AITL) samples and in 8 of 44 (18%) PTCL, not otherwise specified (PTCL-NOS) samples.",0.201098907136852,"These analyses identified highly recurrent epigenetic factor mutations in TET2, DNMT3A and <span class=""gene"" id=""24413734-3-91-95"">IDH2</span> as well as a new highly prevalent RHOA mutation encoding a p.Gly17Val alteration present in 22 of 35 (67%) angioimmunoblastic T cell lymphoma (AITL) samples and in 8 of 44 (18%) <span class=""disease"" id=""24413734-3-274-278"">PTCL</span>, not otherwise specified (<span class=""disease"" id=""24413734-3-305-309"">PTCL</span>-NOS) samples.",CTD_human
5,3,Therapeutic,C0023786,Mucopolysaccharidosis I,disease,mucopolysaccharidosis type I,3425,IDUA,IDUA,CTD_human,15194053,"To determine the potential for treatment of mucopolysaccharidosis type I using a gene delivery approach, a recombinant adeno-associated virus (AAV) vector, vTRCA1, transducing the human iduronidase (IDUA) gene was constructed and 1 x 10(10) particles were injected intravenously into 1-day-old Idua(-/-) mice.",0.23230918187056399,"To determine the potential for treatment of <span class=""disease"" id=""15194053-2-44-72"">mucopolysaccharidosis type I</span> using a gene delivery approach, a recombinant adeno-associated virus (AAV) vector, vTRCA1, transducing the human iduronidase (<span class=""gene"" id=""15194053-2-199-203"">IDUA</span>) gene was constructed and 1 x 10(10) particles were injected intravenously into 1-day-old Idua(-/-) mice.",CTD_human
5,3,Therapeutic,C0023786,Mucopolysaccharidosis I,disease,mucopolysaccharidosis type I,3425,IDUA,alpha-L-iduronidase,CTD_human,15081804,alpha-L-iduronidase premature stop codons and potential read-through in mucopolysaccharidosis type I patients.,0.23230918187056399,"<span class=""gene"" id=""15081804-0-0-19"">alpha-L-iduronidase</span> premature stop codons and potential read-through in <span class=""disease"" id=""15081804-0-72-100"">mucopolysaccharidosis type I</span> patients.",CTD_human
5,3,Biomarker,C0023786,Mucopolysaccharidosis I,disease,mucopolysaccharidosis type I,3425,IDUA,IDUA,CTD_human,15194053,"To determine the potential for treatment of mucopolysaccharidosis type I using a gene delivery approach, a recombinant adeno-associated virus (AAV) vector, vTRCA1, transducing the human iduronidase (IDUA) gene was constructed and 1 x 10(10) particles were injected intravenously into 1-day-old Idua(-/-) mice.",0.23230918187056399,"To determine the potential for treatment of <span class=""disease"" id=""15194053-2-44-72"">mucopolysaccharidosis type I</span> using a gene delivery approach, a recombinant adeno-associated virus (AAV) vector, vTRCA1, transducing the human iduronidase (<span class=""gene"" id=""15194053-2-199-203"">IDUA</span>) gene was constructed and 1 x 10(10) particles were injected intravenously into 1-day-old Idua(-/-) mice.",CTD_human
5,3,Biomarker,C0023786,Mucopolysaccharidosis I,disease,mucopolysaccharidosis type I,3425,IDUA,alpha-L-iduronidase,CTD_human,15081804,alpha-L-iduronidase premature stop codons and potential read-through in mucopolysaccharidosis type I patients.,0.23230918187056399,"<span class=""gene"" id=""15081804-0-0-19"">alpha-L-iduronidase</span> premature stop codons and potential read-through in <span class=""disease"" id=""15081804-0-72-100"">mucopolysaccharidosis type I</span> patients.",CTD_human
3,2,Biomarker,C0242383,Age related macular degeneration,disease,age-related macular degeneration,3426,CFI,CFI,CTD_human,24036952,"Rare variants in CFI, C3 and C9 are associated with high risk of advanced age-related macular degeneration.",0.216756655105375,"Rare variants in <span class=""gene"" id=""24036952-0-17-20"">CFI</span>, C3 and C9 are associated with high risk of advanced <span class=""disease"" id=""24036952-0-74-106"">age-related macular degeneration</span>.",CTD_human
3,2,Biomarker,C0242383,Age related macular degeneration,disease,age-related macular degeneration,3426,CFI,CFI,CTD_human,23685748,A functional variant in the CFI gene confers a high risk of age-related macular degeneration.,0.216756655105375,"A functional variant in the <span class=""gene"" id=""23685748-0-28-31"">CFI</span> gene confers a high risk of <span class=""disease"" id=""23685748-0-60-92"">age-related macular degeneration</span>.",CTD_human
1,0,Therapeutic,C0019163,Hepatitis B,disease,HBV,3439,IFNA1,interferon alpha 1b,CTD_human,15504288,"To explore a new strategy for effective and economical anti-virus therapy for HBV infection, we conducted a sequence administration of lamivudine and interferon alpha 1b to evaluate its effects on HBV replication and rebound as well as YMDD mutation induced by lamivudine.",0.213736339210655,"To explore a new strategy for effective and economical anti-virus therapy for <span class=""disease"" id=""15504288-1-78-81"">HBV</span> infection, we conducted a sequence administration of lamivudine and <span class=""gene"" id=""15504288-1-150-169"">interferon alpha 1b</span> to evaluate its effects on HBV replication and rebound as well as YMDD mutation induced by lamivudine.",CTD_human
1,0,Therapeutic,C0023890,Liver Cirrhosis,disease,liver cirrhosis,3439,IFNA1,IFN-alpha,CTD_human,18665156,These results suggest that IFN-alpha gene therapy is a promising strategy to treat HCC patients who have concomitant liver cirrhosis.,0.20927519812861603,"These results suggest that <span class=""gene"" id=""18665156-8-27-36"">IFN-alpha</span> gene therapy is a promising strategy to treat HCC patients who have concomitant <span class=""disease"" id=""18665156-8-117-132"">liver cirrhosis</span>.",CTD_human
3,0,Therapeutic,C2239176,Liver carcinoma,disease,HCC,3439,IFNA1,IFN-alpha,CTD_human,18665156,These results suggest that IFN-alpha gene therapy is a promising strategy to treat HCC patients who have concomitant liver cirrhosis.,0.20769234995796698,"These results suggest that <span class=""gene"" id=""18665156-8-27-36"">IFN-alpha</span> gene therapy is a promising strategy to treat <span class=""disease"" id=""18665156-8-83-86"">HCC</span> patients who have concomitant liver cirrhosis.",CTD_human
3,0,Therapeutic,C2239176,Liver carcinoma,disease,HCC,3439,IFNA1,IFN,CTD_human,17088986,"Measuring the expression levels of IFN receptors, and their ability to be up-regulated, may be a promising method for selecting HCC patients for this type of combination therapy.",0.20769234995796698,"Measuring the expression levels of <span class=""gene"" id=""17088986-7-35-38"">IFN</span> receptors, and their ability to be up-regulated, may be a promising method for selecting <span class=""disease"" id=""17088986-7-128-131"">HCC</span> patients for this type of combination therapy.",CTD_human
1,0,Therapeutic,C0007134,Renal Cell Carcinoma,disease,renal cell carcinoma,3440,IFNA2,interferon alpha-2B,CTD_human,8886046,"[Combination therapy with 5-fluorouracil (5-FU), cisplatin (CDDP) and interferon alpha-2B (IFN alpha-2B) for advanced renal cell carcinoma].",0.20054945356842604,"[Combination therapy with 5-fluorouracil (5-FU), cisplatin (CDDP) and <span class=""gene"" id=""8886046-0-70-89"">interferon alpha-2B</span> (IFN alpha-2B) for advanced <span class=""disease"" id=""8886046-0-118-138"">renal cell carcinoma</span>].",CTD_human
1,0,Therapeutic,C0024301,"Lymphoma, Follicular",disease,follicular lymphoma,3440,IFNA2,interferon alpha 2b,CTD_human,12855623,High molecular response rate and clinical correlation in patients with follicular lymphoma treated with cyclophosphamide-vincristine-prednisone plus interferon alpha 2b.,0.2,"High molecular response rate and clinical correlation in patients with <span class=""disease"" id=""12855623-0-71-90"">follicular lymphoma</span> treated with cyclophosphamide-vincristine-prednisone plus <span class=""gene"" id=""12855623-0-149-168"">interferon alpha 2b</span>.",CTD_human
18,0,Therapeutic,C0025202,melanoma,disease,MM,3440,IFNA2,IFNalpha,CTD_human,17973783,"Malignant melanoma (MM) patients undergoing phase II-randomized chemoimmunotherapy trials were treated with DTIC, IFNalpha (Hoffmann-La Roche) (group A, n = 31), and with DTIC, IFNalpha and 13-cis-RA (Isotretinoin, Hoffmann-La Roche, Basel, Switzerland) (group B, n = 29).",0.205429023149632,"<span class=""disease"" id=""17973783-2-0-18"">Malignant melanoma</span> (<span class=""disease"" id=""17973783-2-20-22"">MM</span>) patients undergoing phase II-randomized chemoimmunotherapy trials were treated with DTIC, <span class=""gene"" id=""17973783-2-114-122"">IFNalpha</span> (Hoffmann-La Roche) (group A, n = 31), and with DTIC, <span class=""gene"" id=""17973783-2-177-185"">IFNalpha</span> and 13-cis-RA (Isotretinoin, Hoffmann-La Roche, Basel, Switzerland) (group B, n = 29).",CTD_human
18,0,Therapeutic,C0025202,melanoma,disease,melanoma,3440,IFNA2,interferon {alpha}2a,CTD_human,18281266,Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis.,0.205429023149632,"Adjuvant low-dose <span class=""gene"" id=""18281266-0-18-38"">interferon {alpha}2a</span> with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in <span class=""disease"" id=""18281266-0-146-154"">melanoma</span> patients with regional lymph node metastasis.",CTD_human
1,0,Therapeutic,C0040028,"Thrombocythemia, Essential",disease,essential thrombocytosis,3440,IFNA2,interferon alpha-2a,CTD_human,12924084,Alternatives to hydroxyurea are imatinib for the treatment of CML and interferon alpha-2a or anagrelide for essential thrombocytosis.,0.201648360705279,"Alternatives to hydroxyurea are imatinib for the treatment of CML and <span class=""gene"" id=""12924084-7-70-89"">interferon alpha-2a</span> or anagrelide for <span class=""disease"" id=""12924084-7-108-132"">essential thrombocytosis</span>.",CTD_human
4,0,Biomarker,C0040034,Thrombocytopenia,phenotype,thrombocytopenia,3440,IFNA2,interferon-alpha-2b,CTD_human,15274073,"Twenty-six courses were delayed by a median of 7 days (range, 3-29 days), with interferon-alpha-2b administration frequently omitted because of thrombocytopenia, most often after Day 5.",0.2,"Twenty-six courses were delayed by a median of 7 days (range, 3-29 days), with <span class=""gene"" id=""15274073-7-79-98"">interferon-alpha-2b</span> administration frequently omitted because of <span class=""disease"" id=""15274073-7-144-160"">thrombocytopenia</span>, most often after Day 5.",CTD_human
4,0,Biomarker,C0042170,Uveomeningoencephalitic Syndrome,disease,Vogt-Koyanagi-Harada disease,3440,IFNA2,interferon alpha-2b,CTD_human,14633182,Vogt-Koyanagi-Harada disease associated with interferon alpha-2b/ribavirin combination therapy.,0.2,"<span class=""disease"" id=""14633182-0-0-28"">Vogt-Koyanagi-Harada disease</span> associated with <span class=""gene"" id=""14633182-0-45-64"">interferon alpha-2b</span>/ribavirin combination therapy.",CTD_human
4,0,Biomarker,C0042170,Uveomeningoencephalitic Syndrome,disease,Harada disease,3440,IFNA2,interferon-alpha 2a,CTD_human,20172621,Physicians should be aware of the association between interferon-alpha 2a and ribavirin use for hepatitis C infection and the development of Harada disease.,0.2,"Physicians should be aware of the association between <span class=""gene"" id=""20172621-4-54-73"">interferon-alpha 2a</span> and ribavirin use for hepatitis C infection and the development of <span class=""disease"" id=""20172621-4-141-155"">Harada disease</span>.",CTD_human
7,0,Therapeutic,C0524909,"Hepatitis B, Chronic",disease,chronic hepatitis B,3440,IFNA2,Interferon alpha-2b,CTD_human,16557544,Interferon alpha-2b with and without ribavirin in the treatment of hepatitis B e antigen-positive chronic hepatitis B: a randomized study.,0.20604398925268802,"<span class=""gene"" id=""16557544-0-0-19"">Interferon alpha-2b</span> with and without ribavirin in the treatment of hepatitis B e antigen-positive <span class=""disease"" id=""16557544-0-98-117"">chronic hepatitis B</span>: a randomized study.",CTD_human
7,0,Therapeutic,C0524909,"Hepatitis B, Chronic",disease,chronic hepatitis B,3440,IFNA2,interferon alpha 2a,CTD_human,16944240,Lamivudine and high-dose interferon alpha 2a combination treatment in naïve HBeAg-positive immunoactive chronic hepatitis B in children: an East Mediterranean center's experience.,0.20604398925268802,"Lamivudine and high-dose <span class=""gene"" id=""16944240-0-25-44"">interferon alpha 2a</span> combination treatment in naïve HBeAg-positive immunoactive <span class=""disease"" id=""16944240-0-104-123"">chronic hepatitis B</span> in children: an East Mediterranean center's experience.",CTD_human
7,0,Therapeutic,C0524909,"Hepatitis B, Chronic",disease,chronic hepatitis B,3440,IFNA2,interferon-alpha-2b,CTD_human,12802750,Comparison of 12-month courses of interferon-alpha-2b-lamivudine combination therapy and interferon-alpha-2b monotherapy among patients with untreated chronic hepatitis B.,0.20604398925268802,"Comparison of 12-month courses of <span class=""gene"" id=""12802750-0-34-53"">interferon-alpha-2b</span>-lamivudine combination therapy and <span class=""gene"" id=""12802750-0-89-108"">interferon-alpha-2b</span> monotherapy among patients with untreated <span class=""disease"" id=""12802750-0-151-170"">chronic hepatitis B</span>.",CTD_human
10,0,Therapeutic,C0524910,"Hepatitis C, Chronic",disease,chronic hepatitis C,3440,IFNA2,interferon-alpha 2b,CTD_human,9563925,"We conclude that combination therapy with ursodeoxycholic acid and interferon-alpha 2b was no more effective than interferon monotherapy in inducing a biochemical response in previously untreated patients with chronic hepatitis C. Ursodeoxycholic acid, however, may be useful in prolonging the biochemical response to interferon therapy.",0.23901120335826,"We conclude that combination therapy with ursodeoxycholic acid and <span class=""gene"" id=""9563925-10-67-86"">interferon-alpha 2b</span> was no more effective than interferon monotherapy in inducing a biochemical response in previously untreated patients with <span class=""disease"" id=""9563925-10-210-229"">chronic hepatitis C</span>. Ursodeoxycholic acid, however, may be useful in prolonging the biochemical response to interferon therapy.",CTD_human
10,0,Therapeutic,C0524910,"Hepatitis C, Chronic",disease,chronic hepatitis C,3440,IFNA2,Interferon-alpha-2B,CTD_human,9860407,"Interferon-alpha-2B and ribavirin in combination for chronic hepatitis C patients not responding to interferon-alpha alone: an Italian multicenter, randomized, controlled, clinical study.",0.23901120335826,"<span class=""gene"" id=""9860407-0-0-19"">Interferon-alpha-2B</span> and ribavirin in combination for <span class=""disease"" id=""9860407-0-53-72"">chronic hepatitis C</span> patients not responding to interferon-alpha alone: an Italian multicenter, randomized, controlled, clinical study.",CTD_human
10,0,Therapeutic,C0524910,"Hepatitis C, Chronic",disease,chronic hepatitis C,3440,IFNA2,interferon alpha 2b,CTD_human,15996025,Twenty-three patients with chronic hepatitis C were treated with interferon alpha 2b plus RBV with (NYT group) or without (control group) NYT by a randomized selection.,0.23901120335826,"Twenty-three patients with <span class=""disease"" id=""15996025-5-27-46"">chronic hepatitis C</span> were treated with <span class=""gene"" id=""15996025-5-65-84"">interferon alpha 2b</span> plus RBV with (NYT group) or without (control group) NYT by a randomized selection.",CTD_human
1,0,Biomarker,C0024121,Lung Neoplasms,group,lung tumor,345,APOC3,apolipoprotein-C3,CTD_human,19180532,"Notably, expression of alpha-2-macroglobulin, transthyretin, alpha-1-antitrypsin, and properdin was in common in different lung tumor models, but regulation of orosomucoid-8, apolipoprotein-A1, apolipoprotein-C3, apolipoprotein-E, glutathione peroxidase-3, plasma retinol-binding protein, and serum amyloid P component was unique when the serum proteomes of c-myc and c-raf tumor bearing mice were compared.",0.2,"Notably, expression of alpha-2-macroglobulin, transthyretin, alpha-1-antitrypsin, and properdin was in common in different <span class=""disease"" id=""19180532-8-123-133"">lung tumor</span> models, but regulation of orosomucoid-8, apolipoprotein-A1, <span class=""gene"" id=""19180532-8-194-211"">apolipoprotein-C3</span>, apolipoprotein-E, glutathione peroxidase-3, plasma retinol-binding protein, and serum amyloid P component was unique when the serum proteomes of c-myc and c-raf tumor bearing mice were compared.",CTD_human
1,0,Biomarker,C0042769,Virus Diseases,group,viral infection,3454,IFNAR1,IFNAR1,CTD_human,18722370,Cigarette smoking condensate (but not pure nicotine) stimulated specific serine phosphorylation-dependent ubiquitination and degradation of the IFNAR1 subunit of the Type I IFN receptor leading to attenuation of IFN signaling and decreased resistance to viral infection.,0.201648360705279,"Cigarette smoking condensate (but not pure nicotine) stimulated specific serine phosphorylation-dependent ubiquitination and degradation of the <span class=""gene"" id=""18722370-3-144-150"">IFNAR1</span> subunit of the Type I IFN receptor leading to attenuation of IFN signaling and decreased resistance to <span class=""disease"" id=""18722370-3-254-269"">viral infection</span>.",CTD_human
2,0,Therapeutic,C0025202,melanoma,disease,melanoma,3456,IFNB1,interferon-?,CTD_human,21846298,Anti-tumor effects of canine adipose tissue-derived mesenchymal stromal cell-based interferon-? gene therapy and cisplatin in a mouse melanoma model.,0.21994647658097502,"Anti-tumor effects of canine adipose tissue-derived mesenchymal stromal cell-based <span class=""gene"" id=""21846298-0-83-95"">interferon-&beta;</span> gene therapy and cisplatin in a mouse <span class=""disease"" id=""21846298-0-134-142"">melanoma</span> model.",CTD_human
3,0,Therapeutic,C0026769,Multiple Sclerosis,disease,multiple sclerosis,3456,IFNB1,interferon beta,CTD_human,10520943,Course of depression during the initiation of interferon beta-1a treatment for multiple sclerosis.,0.253506210386925,"Course of depression during the initiation of <span class=""gene"" id=""10520943-0-46-61"">interferon beta</span>-1a treatment for <span class=""disease"" id=""10520943-0-79-97"">multiple sclerosis</span>.",CTD_human
3,0,Therapeutic,C0026769,Multiple Sclerosis,disease,multiple sclerosis,3456,IFNB1,interferon beta,CTD_human,12432978,"Seizures and extrapyramidal symptoms in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with interferon beta-1a and clomipramine.",0.253506210386925,"Seizures and extrapyramidal symptoms in a patient with Tourette's syndrome, Asperger's syndrome, and <span class=""disease"" id=""12432978-0-101-119"">multiple sclerosis</span> treated with <span class=""gene"" id=""12432978-0-133-148"">interferon beta</span>-1a and clomipramine.",CTD_human
3,0,Therapeutic,C0026769,Multiple Sclerosis,disease,multiple sclerosis,3456,IFNB1,interferon beta,CTD_human,12424511,Described here is a case of development of aplastic anemia with interferon beta-1a in a patient with multiple sclerosis.,0.253506210386925,"Described here is a case of development of aplastic anemia with <span class=""gene"" id=""12424511-8-64-79"">interferon beta</span>-1a in a patient with <span class=""disease"" id=""12424511-8-101-119"">multiple sclerosis</span>.",CTD_human
1,0,Biomarker,C0036572,Seizures,phenotype,Seizures,3456,IFNB1,interferon beta,CTD_human,12432978,"Seizures and extrapyramidal symptoms in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with interferon beta-1a and clomipramine.",0.2,"<span class=""disease"" id=""12432978-0-0-8"">Seizures</span> and extrapyramidal symptoms in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with <span class=""gene"" id=""12432978-0-133-148"">interferon beta</span>-1a and clomipramine.",CTD_human
4,4,Biomarker,C0010346,Crohn Disease,disease,Crohn's disease,345611,IRGM,IRGM,CTD_human,18438406,"We also show that several risk loci are common to ulcerative colitis and Crohn's disease (IL23R, IL12B, HLA, NKX2-3 and MST1), whereas autophagy genes ATG16L1 and IRGM, along with NOD2 (also known as CARD15), are specific for Crohn's disease.",0.254534568794276,"We also show that several risk loci are common to ulcerative colitis and <span class=""disease"" id=""18438406-2-73-88"">Crohn's disease</span> (IL23R, IL12B, HLA, NKX2-3 and MST1), whereas autophagy genes ATG16L1 and <span class=""gene"" id=""18438406-2-163-167"">IRGM</span>, along with NOD2 (also known as CARD15), are specific for <span class=""disease"" id=""18438406-2-226-241"">Crohn's disease</span>.",CTD_human
4,4,Biomarker,C0010346,Crohn Disease,disease,Crohn's disease,345611,IRGM,IRGM,CTD_human,21278745,A synonymous variant in IRGM alters a binding site for miR-196 and causes deregulation of IRGM-dependent xenophagy in Crohn's disease.,0.254534568794276,"A synonymous variant in <span class=""gene"" id=""21278745-0-24-28"">IRGM</span> alters a binding site for miR-196 and causes deregulation of <span class=""gene"" id=""21278745-0-90-94"">IRGM</span>-dependent xenophagy in <span class=""disease"" id=""21278745-0-118-133"">Crohn's disease</span>.",CTD_human
4,4,Biomarker,C0010346,Crohn Disease,disease,Crohn's disease,345611,IRGM,IRGM,CTD_human,19165925,Deletion polymorphism upstream of IRGM associated with altered IRGM expression and Crohn's disease.,0.254534568794276,"Deletion polymorphism upstream of <span class=""gene"" id=""19165925-0-34-38"">IRGM</span> associated with altered <span class=""gene"" id=""19165925-0-63-67"">IRGM</span> expression and <span class=""disease"" id=""19165925-0-83-98"">Crohn's disease</span>.",CTD_human
4,4,Biomarker,C0010346,Crohn Disease,disease,Crohn's disease,345611,IRGM,IRGM,CTD_human,17554261,Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility.,0.254534568794276,"Sequence variants in the autophagy gene <span class=""gene"" id=""17554261-0-40-44"">IRGM</span> and multiple other replicating loci contribute to <span class=""disease"" id=""17554261-0-95-110"">Crohn's disease</span> susceptibility.",CTD_human
2,0,Biomarker,C0004364,Autoimmune Diseases,group,autoimmunity,3458,IFNG,IFN-gamma,CTD_human,9647229,"To further define their roles in systemic autoimmunity, IL-4 and IFN-gamma gene knockout mice were studied for susceptibility to the prototypic Th2-mediated mercury-induced autoimmunity.",0.215253674846674,"To further define their roles in systemic <span class=""disease"" id=""9647229-2-42-54"">autoimmunity</span>, IL-4 and <span class=""gene"" id=""9647229-2-65-74"">IFN-gamma</span> gene knockout mice were studied for susceptibility to the prototypic Th2-mediated mercury-induced <span class=""disease"" id=""9647229-2-173-185"">autoimmunity</span>.",CTD_human
1,0,Biomarker,C0017658,Glomerulonephritis,disease,glomerulonephritis,3458,IFNG,Interferon gamma,CTD_human,1825860,Interferon gamma-mediated renal MHC expression in mercuric chloride-induced glomerulonephritis.,0.200274726784213,"<span class=""gene"" id=""1825860-0-0-16"">Interferon gamma</span>-mediated renal MHC expression in mercuric chloride-induced <span class=""disease"" id=""1825860-0-76-94"">glomerulonephritis</span>.",CTD_human
1,0,Therapeutic,C0025500,Mesothelioma,disease,mesothelioma,3458,IFNG,IFN-gamma,CTD_human,12768194,"In order to evaluate the effect of local delivery of cytokines such as interferon gamma (IFN-gamma) by gene transfer, we characterized and used a murine model, AK7, which appeared very similar to human mesothelioma.",0.20054945356842604,"In order to evaluate the effect of local delivery of cytokines such as <span class=""gene"" id=""12768194-4-71-87"">interferon gamma</span> (<span class=""gene"" id=""12768194-4-89-98"">IFN-gamma</span>) by gene transfer, we characterized and used a murine model, AK7, which appeared very similar to human <span class=""disease"" id=""12768194-4-202-214"">mesothelioma</span>.",CTD_human
1,0,Therapeutic,C0027794,Neural Tube Defects,group,NTD,3458,IFNG,IFN-gamma,CTD_human,17075842,"The incidence of NTDs was 18% in fetuses exposed to VA alone, compared to 3.7% and 2.9% in fetuses exposed to IFN-gamma+VA, or GM-CSF+VA respectively.",0.2,"The incidence of <span class=""disease"" id=""17075842-8-17-20"">NTD</span>s was 18% in fetuses exposed to VA alone, compared to 3.7% and 2.9% in fetuses exposed to <span class=""gene"" id=""17075842-8-110-119"">IFN-gamma</span>+VA, or GM-CSF+VA respectively.",CTD_human
1,0,Therapeutic,C0041341,Tuberous Sclerosis,disease,tuberous sclerosis complex,3458,IFNG,interferon-gamma,CTD_human,16845661,Combination of a rapamycin analog (CCI-779) and interferon-gamma is more effective than single agents in treating a mouse model of tuberous sclerosis complex.,0.200274726784213,"Combination of a rapamycin analog (CCI-779) and <span class=""gene"" id=""16845661-0-48-64"">interferon-gamma</span> is more effective than single agents in treating a mouse model of <span class=""disease"" id=""16845661-0-131-157"">tuberous sclerosis complex</span>.",CTD_human
1,0,Biomarker,C0243026,Sepsis,disease,sepsis,3458,IFNG,IFN-gamma,CTD_human,9806674,"The proinflammatory cytokines, including tumor necrosis factor-alpha (TNF-alpha) and interferon-gamma (IFN-gamma), are increased in heart failure and sepsis, clinical conditions for which the IV anesthetic ketamine is useful.",0.21160235873995603,"The proinflammatory cytokines, including tumor necrosis factor-alpha (TNF-alpha) and <span class=""gene"" id=""9806674-1-85-101"">interferon-gamma</span> (<span class=""gene"" id=""9806674-1-103-112"">IFN-gamma</span>), are increased in heart failure and <span class=""disease"" id=""9806674-1-150-156"">sepsis</span>, clinical conditions for which the IV anesthetic ketamine is useful.",CTD_human
1,0,Biomarker,C0017636,Glioblastoma,disease,glioblastoma,346288,SEPT14,SEPT14,CTD_human,23917401,"We also report recurrent translocations that fuse the coding sequence of EGFR to several partners, with EGFR-SEPT14 being the most frequent functional gene fusion in human glioblastoma.",0.200274726784213,"We also report recurrent translocations that fuse the coding sequence of EGFR to several partners, with EGFR-<span class=""gene"" id=""23917401-6-109-115"">SEPT14</span> being the most frequent functional gene fusion in human <span class=""disease"" id=""23917401-6-172-184"">glioblastoma</span>.",CTD_human
1,0,Biomarker,C0017638,Glioma,disease,glioma,347,APOD,APOD,CTD_human,16865689,Treatment of glioma cell lines with 5-aza-2'-deoxycytidine and trichostatin A resulted in increased expression of AMOG and APOD transcripts.,0.200274726784213,"Treatment of <span class=""disease"" id=""16865689-5-13-19"">glioma</span> cell lines with 5-aza-2'-deoxycytidine and trichostatin A resulted in increased expression of AMOG and <span class=""gene"" id=""16865689-5-123-127"">APOD</span> transcripts.",CTD_human
1,0,Biomarker,C1510586,Autism Spectrum Disorders,disease,ASD,347731,LRRTM3,LRRTM3,CTD_human,20678249,"Overall, our findings implicate the neuronal leucine-rich genes LRRN3 and LRRTM3 in ASD susceptibility.",0.2,"Overall, our findings implicate the neuronal leucine-rich genes LRRN3 and <span class=""gene"" id=""20678249-8-74-80"">LRRTM3</span> in <span class=""disease"" id=""20678249-8-84-87"">ASD</span> susceptibility.",CTD_human
4,0,Biomarker,C0001206,Acromegaly,disease,acromegaly,3479,IGF1,IGF-I,CTD_human,18388193,"Our findings provide the first evidence that GH, in concert with IGF-I, stimulates ENaC-mediated sodium transport in the late distal nephron, accounting for the pathogenesis of sodium retention in acromegaly.",0.215304832003986,"Our findings provide the first evidence that GH, in concert with <span class=""gene"" id=""18388193-6-65-70"">IGF-I</span>, stimulates ENaC-mediated sodium transport in the late distal nephron, accounting for the pathogenesis of sodium retention in <span class=""disease"" id=""18388193-6-197-207"">acromegaly</span>.",CTD_human
4,0,Biomarker,C0001206,Acromegaly,disease,acromegaly,3479,IGF1,IGF-I,CTD_human,18381583,Excess GH and IGF-I in acromegaly are associated with reduced life expectancy due to cardiovascular complications.,0.215304832003986,"Excess GH and <span class=""gene"" id=""18381583-1-14-19"">IGF-I</span> in <span class=""disease"" id=""18381583-1-23-33"">acromegaly</span> are associated with reduced life expectancy due to cardiovascular complications.",CTD_human
1,0,Biomarker,C0002395,Alzheimer's Disease,disease,AD,3479,IGF1,IGF-I,CTD_human,15750215,"The strikingly reduced CNS expression of genes encoding insulin, IGF-I, and IGF-II, as well as the insulin and IGF-I receptors, suggests that AD may represent a neuro-endocrine disorder that resembles, yet is distinct from diabetes mellitus.",0.213642115921391,"The strikingly reduced CNS expression of genes encoding insulin, <span class=""gene"" id=""15750215-6-65-70"">IGF-I</span>, and IGF-II, as well as the insulin and <span class=""gene"" id=""15750215-6-111-116"">IGF-I</span> receptors, suggests that <span class=""disease"" id=""15750215-6-142-144"">AD</span> may represent a neuro-endocrine disorder that resembles, yet is distinct from diabetes mellitus.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,3479,IGF1,IGF-1,CTD_human,17547689,"Children with autism/ASD had significantly higher levels of many growth-related hormones: IGF-1, IGF-2, IGFBP-3 and GHBP.",0.20240702852328799,"Children with <span class=""disease"" id=""17547689-12-14-20"">autism</span>/ASD had significantly higher levels of many growth-related hormones: <span class=""gene"" id=""17547689-12-90-95"">IGF-1</span>, IGF-2, IGFBP-3 and GHBP.",CTD_human
1,0,Biomarker,C0005695,Bladder Neoplasm,disease,bladder cancer,3479,IGF1,IGF-1,CTD_human,19415693,These results present further evidence for the role of IGF-1 in bladder cancer progression.,0.20082418035263896,"These results present further evidence for the role of <span class=""gene"" id=""19415693-7-55-60"">IGF-1</span> in <span class=""disease"" id=""19415693-7-64-78"">bladder cancer</span> progression.",CTD_human
1,0,Biomarker,C0009319,Colitis,disease,colitis,3479,IGF1,IGF-1,CTD_human,24782617,"Collagen?I?and IGF-1 expression was increased, and SIRT1 expression was decreased (0.67 ± 0.04 vs 1.05 ± 0.07, P < 0.001) in TNBS-induced colitis compared with the control group.",0.2,"Collagen?I?and <span class=""gene"" id=""24782617-9-15-20"">IGF-1</span> expression was increased, and SIRT1 expression was decreased (0.67 &plusmn; 0.04 vs 1.05 &plusmn; 0.07, P &lt; 0.001) in TNBS-induced <span class=""disease"" id=""24782617-9-138-145"">colitis</span> compared with the control group.",CTD_human
1,0,Biomarker,C0010346,Crohn Disease,disease,Crohn's disease,3479,IGF1,IGF-I,CTD_human,19751734,Endogenous IGF-I and alphaVbeta3 integrin ligands regulate increased smooth muscle hyperplasia in stricturing Crohn's disease.,0.201373633921065,"Endogenous <span class=""gene"" id=""19751734-0-11-16"">IGF-I</span> and alphaVbeta3 integrin ligands regulate increased smooth muscle hyperplasia in stricturing <span class=""disease"" id=""19751734-0-110-125"">Crohn's disease</span>.",CTD_human
2,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,3479,IGF1,IGF-I,CTD_human,19502719,"Since administration of capsaicin and isoflavone increases serum levels of IGF-I by sensory neuron stimulation in subjects with alopecia, it is possible that administration of capsaicin and isoflavone reduces arterial blood pressure in patients with hypertension.",0.21351109085213102,"Since administration of capsaicin and isoflavone increases serum levels of <span class=""gene"" id=""19502719-2-75-80"">IGF-I</span> by sensory neuron stimulation in subjects with alopecia, it is possible that administration of capsaicin and isoflavone reduces arterial blood pressure in patients with <span class=""disease"" id=""19502719-2-250-262"">hypertension</span>.",CTD_human
2,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,3479,IGF1,IGF-I,CTD_human,19502719,"Since administration of capsaicin and isoflavone increases serum levels of IGF-I by sensory neuron stimulation in subjects with alopecia, it is possible that administration of capsaicin and isoflavone reduces arterial blood pressure in patients with hypertension.",0.21351109085213102,"Since administration of capsaicin and isoflavone increases serum levels of <span class=""gene"" id=""19502719-2-75-80"">IGF-I</span> by sensory neuron stimulation in subjects with alopecia, it is possible that administration of capsaicin and isoflavone reduces arterial blood pressure in patients with <span class=""disease"" id=""19502719-2-250-262"">hypertension</span>.",CTD_human
1,0,Therapeutic,C0022658,Kidney Diseases,group,nephropathy,3479,IGF1,insulin-like growth factor-I,CTD_human,8825380,The effect of recombinant human insulin-like growth factor-I on chronic puromycin aminonucleoside nephropathy in rats.,0.205740551713841,"The effect of recombinant human <span class=""gene"" id=""8825380-0-32-60"">insulin-like growth factor-I</span> on chronic puromycin aminonucleoside <span class=""disease"" id=""8825380-0-98-109"">nephropathy</span> in rats.",CTD_human
1,0,Therapeutic,C0022661,"Kidney Failure, Chronic",disease,end-stage chronic renal failure,3479,IGF1,Insulin-like growth factor I,CTD_human,10198369,Insulin-like growth factor I improves renal function in patients with end-stage chronic renal failure.,0.20054945356842604,"<span class=""gene"" id=""10198369-0-0-28"">Insulin-like growth factor I</span> improves renal function in patients with <span class=""disease"" id=""10198369-0-70-101"">end-stage chronic renal failure</span>.",CTD_human
2,0,Therapeutic,C0031117,Peripheral Neuropathy,group,peripheral neuropathy,3479,IGF1,IGF-I,CTD_human,9452187,"To assess whether insulin-like growth factor-I (IGF-I), a neurotrophic agent that supports the survival of motoneurons and enhances regeneration of motor and sensory neurons, could prevent the peripheral neuropathy produced by vincristine, mice were treated with both vincristine (1.7 mg/kg, i.p., 2 x /week) and/or IGF-I (0.3 or 1 mg/kg, s.c. daily) for 10 weeks.",0.2,"To assess whether <span class=""gene"" id=""9452187-2-18-46"">insulin-like growth factor-I</span> (<span class=""gene"" id=""9452187-2-48-53"">IGF-I</span>), a neurotrophic agent that supports the survival of motoneurons and enhances regeneration of motor and sensory neurons, could prevent the <span class=""disease"" id=""9452187-2-193-214"">peripheral neuropathy</span> produced by vincristine, mice were treated with both vincristine (1.7 mg/kg, i.p., 2 x /week) and/or <span class=""gene"" id=""9452187-2-316-321"">IGF-I</span> (0.3 or 1 mg/kg, s.c. daily) for 10 weeks.",CTD_human
1,0,Biomarker,C0034069,Pulmonary Fibrosis,disease,pulmonary fibrosis,3479,IGF1,insulin-like growth factor I,CTD_human,15286697,"Fatal pulmonary fibrosis associated with BCNU: the relative role of platelet-derived growth factor-B, insulin-like growth factor I, transforming growth factor-beta1 and cyclooxygenase-2.",0.204106546385879,"Fatal <span class=""disease"" id=""15286697-0-6-24"">pulmonary fibrosis</span> associated with BCNU: the relative role of platelet-derived growth factor-B, <span class=""gene"" id=""15286697-0-102-130"">insulin-like growth factor I</span>, transforming growth factor-beta1 and cyclooxygenase-2.",CTD_human
1,0,Therapeutic,C0853897,Diabetic Cardiomyopathies,disease,diabetic cardiomyopathy,3479,IGF1,IGF-1,CTD_human,11375343,IGF-1 overexpression inhibits the development of diabetic cardiomyopathy and angiotensin II-mediated oxidative stress.,0.2,"<span class=""gene"" id=""11375343-0-0-5"">IGF-1</span> overexpression inhibits the development of <span class=""disease"" id=""11375343-0-49-72"">diabetic cardiomyopathy</span> and angiotensin II-mediated oxidative stress.",CTD_human
4,2,Biomarker,C0002395,Alzheimer's Disease,disease,AD,348,APOE,APOE,CTD_human,20819998,"The APOE epsilon4 allele is an established risk factor for Alzheimer disease (AD), yet findings are mixed for how early its effects are manifest.",0.64,"The <span class=""gene"" id=""20819998-1-4-8"">APOE</span> epsilon4 allele is an established risk factor for <span class=""disease"" id=""20819998-1-59-76"">Alzheimer disease</span> (<span class=""disease"" id=""20819998-1-78-80"">AD</span>), yet findings are mixed for how early its effects are manifest.",CTD_human;HPO
4,2,Biomarker,C0002395,Alzheimer's Disease,disease,Alzheimer's disease,348,APOE,apolipoprotein E,CTD_human,24162737,"In addition to the APOE locus (encoding apolipoprotein E), 19 loci reached genome-wide significance (P < 5 × 10(-8)) in the combined stage 1 and stage 2 analysis, of which 11 are newly associated with Alzheimer's disease.",0.64,"In addition to the <span class=""gene"" id=""24162737-5-19-23"">APOE</span> locus (encoding <span class=""gene"" id=""24162737-5-40-56"">apolipoprotein E</span>), 19 loci reached genome-wide significance (P &lt; 5 &times; 10(-8)) in the combined stage 1 and stage 2 analysis, of which 11 are newly associated with <span class=""disease"" id=""24162737-5-201-220"">Alzheimer's disease</span>.",CTD_human;HPO
4,2,Biomarker,C0002395,Alzheimer's Disease,disease,Alzheimer's disease,348,APOE,apolipoprotein E,CTD_human,8346443,Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families.,0.64,"Gene dose of <span class=""gene"" id=""8346443-0-13-29"">apolipoprotein E</span> type 4 allele and the risk of <span class=""disease"" id=""8346443-0-60-79"">Alzheimer's disease</span> in late onset families.",CTD_human;HPO
1,0,Biomarker,C0002726,Amyloidosis,disease,amyloidosis,348,APOE,APOE,CTD_human,15993987,Induction of vascular amyloidosis-beta by oxidative stress depends on APOE genotype.,0.284814057046576,"Induction of vascular <span class=""disease"" id=""15993987-0-22-33"">amyloidosis</span>-beta by oxidative stress depends on <span class=""gene"" id=""15993987-0-70-74"">APOE</span> genotype.",CTD_human
2,0,Biomarker,C0003850,Arteriosclerosis,disease,atherosclerosis,348,APOE,apolipoprotein E,CTD_human,17118406,"To assess the effect of folic acid on the development of atherosclerosis, male apolipoprotein E-deficient mice fed a standard chow diet received either water (control group) or an aqueous solution of folic acid that provided a dose of 75 microg/kg/day, for ten weeks.",0.29203514261644004,"To assess the effect of folic acid on the development of <span class=""disease"" id=""17118406-2-57-72"">atherosclerosis</span>, male <span class=""gene"" id=""17118406-2-79-95"">apolipoprotein E</span>-deficient mice fed a standard chow diet received either water (control group) or an aqueous solution of folic acid that provided a dose of 75 microg/kg/day, for ten weeks.",CTD_human
2,0,Biomarker,C0003850,Arteriosclerosis,disease,atherosclerosis,348,APOE,apolipoprotein E,CTD_human,18287887,Molecular mechanisms of felodipine suppressing atherosclerosis in high-cholesterol-diet apolipoprotein E-knockout mice.,0.29203514261644004,"Molecular mechanisms of felodipine suppressing <span class=""disease"" id=""18287887-0-47-62"">atherosclerosis</span> in high-cholesterol-diet <span class=""gene"" id=""18287887-0-88-104"">apolipoprotein E</span>-knockout mice.",CTD_human
25,0,Biomarker,C0004153,Atherosclerosis,disease,atherosclerosis,348,APOE,apolipoprotein E,CTD_human,20093625,Specific dietary polyphenols attenuate atherosclerosis in apolipoprotein E-knockout mice by alleviating inflammation and endothelial dysfunction.,0.5873291246481379,"Specific dietary polyphenols attenuate <span class=""disease"" id=""20093625-0-39-54"">atherosclerosis</span> in <span class=""gene"" id=""20093625-0-58-74"">apolipoprotein E</span>-knockout mice by alleviating inflammation and endothelial dysfunction.",CTD_human;HPO
25,0,Biomarker,C0004153,Atherosclerosis,disease,atherosclerosis,348,APOE,apolipoprotein E,CTD_human,11231916,Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL.,0.5873291246481379,"Troglitazone inhibits <span class=""disease"" id=""11231916-0-22-37"">atherosclerosis</span> in <span class=""gene"" id=""11231916-0-41-57"">apolipoprotein E</span>-knockout mice: pleiotropic effects on CD36 expression and HDL.",CTD_human;HPO
25,0,Biomarker,C0004153,Atherosclerosis,disease,atherosclerosis,348,APOE,apolipoprotein E,CTD_human,24017971,Dietary quercetin attenuates oxidant-induced endothelial dysfunction and atherosclerosis in apolipoprotein E knockout mice fed a high-fat diet: a critical role for heme oxygenase-1.,0.5873291246481379,"Dietary quercetin attenuates oxidant-induced endothelial dysfunction and <span class=""disease"" id=""24017971-0-73-88"">atherosclerosis</span> in <span class=""gene"" id=""24017971-0-92-108"">apolipoprotein E</span> knockout mice fed a high-fat diet: a critical role for heme oxygenase-1.",CTD_human;HPO
25,0,Biomarker,C0004153,Atherosclerosis,disease,atherosclerosis,348,APOE,apolipoprotein E,CTD_human,11947894,Low density lipoprotein receptor deficient (LDLR-KO) and apolipoprotein E deficient (apo E-KO) mice both develop hyperlipidemia and atherosclerosis by different mechanisms.,0.5873291246481379,"Low density lipoprotein receptor deficient (LDLR-KO) and <span class=""gene"" id=""11947894-1-57-73"">apolipoprotein E</span> deficient (apo E-KO) mice both develop hyperlipidemia and <span class=""disease"" id=""11947894-1-132-147"">atherosclerosis</span> by different mechanisms.",CTD_human;HPO
25,0,Biomarker,C0004153,Atherosclerosis,disease,atherosclerosis,348,APOE,apolipoprotein E,CTD_human,17438151,"Using a mouse (apolipoprotein E [ApoE](-/-)) model of high-fat diet-induced atherosclerosis, we demonstrate an association between cell death and oxidative stress-associated DNA damage and PARP activation within atherosclerotic plaques.",0.5873291246481379,"Using a mouse (<span class=""gene"" id=""17438151-3-15-31"">apolipoprotein E</span> [ApoE](-/-)) model of high-fat diet-induced <span class=""disease"" id=""17438151-3-76-91"">atherosclerosis</span>, we demonstrate an association between cell death and oxidative stress-associated DNA damage and PARP activation within atherosclerotic plaques.",CTD_human;HPO
25,0,Biomarker,C0004153,Atherosclerosis,disease,atherosclerosis,348,APOE,ApoE,CTD_human,14594625,"The studies presented here were performed to evaluate the atherogenic potential of arsenic using a well-established and controlled animal model of human atherosclerosis, mice deficient in apolipoprotein E (ApoE), and in vitro systems including primary human vascular cells.",0.5873291246481379,"The studies presented here were performed to evaluate the atherogenic potential of arsenic using a well-established and controlled animal model of human <span class=""disease"" id=""14594625-2-153-168"">atherosclerosis</span>, mice deficient in <span class=""gene"" id=""14594625-2-188-204"">apolipoprotein E</span> (<span class=""gene"" id=""14594625-2-206-210"">ApoE</span>), and in vitro systems including primary human vascular cells.",CTD_human;HPO
25,0,Biomarker,C0004153,Atherosclerosis,disease,atherosclerosis,348,APOE,apoE,CTD_human,9649566,"Thus, comparisons between the 2/2 and 3/3 mice unequivocally demonstrate that a single amino acid difference (Arg158 Cys) in the apoE protein is sufficient to cause type III HLP and spontaneous atherosclerosis in mice.",0.5873291246481379,"Thus, comparisons between the 2/2 and 3/3 mice unequivocally demonstrate that a single amino acid difference (Arg158 Cys) in the <span class=""gene"" id=""9649566-6-129-133"">apoE</span> protein is sufficient to cause type III HLP and spontaneous <span class=""disease"" id=""9649566-6-194-209"">atherosclerosis</span> in mice.",CTD_human;HPO
25,0,Biomarker,C0004153,Atherosclerosis,disease,atherosclerosis,348,APOE,apolipoprotein E,CTD_human,25020133,Chronic ingestion of H1-antihistamines increase progression of atherosclerosis in apolipoprotein E-/- mice.,0.5873291246481379,"Chronic ingestion of H1-antihistamines increase progression of <span class=""disease"" id=""25020133-0-63-78"">atherosclerosis</span> in <span class=""gene"" id=""25020133-0-82-98"">apolipoprotein E</span>-/- mice.",CTD_human;HPO
25,0,Biomarker,C0004153,Atherosclerosis,disease,atherosclerosis,348,APOE,apolipoprotein E,CTD_human,9409251,"Reduced progression of atherosclerosis in apolipoprotein E-deficient mice following consumption of red wine, or its polyphenols quercetin or catechin, is associated with reduced susceptibility of LDL to oxidation and aggregation.",0.5873291246481379,"Reduced progression of <span class=""disease"" id=""9409251-0-23-38"">atherosclerosis</span> in <span class=""gene"" id=""9409251-0-42-58"">apolipoprotein E</span>-deficient mice following consumption of red wine, or its polyphenols quercetin or catechin, is associated with reduced susceptibility of LDL to oxidation and aggregation.",CTD_human;HPO
25,0,Biomarker,C0004153,Atherosclerosis,disease,atherosclerosis,348,APOE,apolipoprotein E,CTD_human,21908651,"Now, we tested the hypothesis that activation of TRPV1 channels attenuates atherosclerosis in apolipoprotein E knockout mice (ApoE(-/-)) but not ApoE(-/-)TRPV1(-/-) double knockout mice on a high-fat diet.",0.5873291246481379,"Now, we tested the hypothesis that activation of TRPV1 channels attenuates <span class=""disease"" id=""21908651-2-75-90"">atherosclerosis</span> in <span class=""gene"" id=""21908651-2-94-110"">apolipoprotein E</span> knockout mice (ApoE(-/-)) but not ApoE(-/-)TRPV1(-/-) double knockout mice on a high-fat diet.",CTD_human;HPO
25,0,Biomarker,C0004153,Atherosclerosis,disease,atherosclerosis,348,APOE,apoE,CTD_human,9169506,"Since mice with a targeted disruption of the apoE gene (apoE 0 mice) develop profound atherosclerosis, we examined the role of IFN-gamma in this process.",0.5873291246481379,"Since mice with a targeted disruption of the <span class=""gene"" id=""9169506-2-45-49"">apoE</span> gene (apoE 0 mice) develop profound <span class=""disease"" id=""9169506-2-86-101"">atherosclerosis</span>, we examined the role of IFN-gamma in this process.",CTD_human;HPO
25,0,Biomarker,C0004153,Atherosclerosis,disease,atherosclerosis,348,APOE,apolipoprotein E,CTD_human,16303615,12/15-Lipoxygenase gene disruption and vitamin E administration diminish atherosclerosis and oxidative stress in apolipoprotein E deficient mice through a final common pathway.,0.5873291246481379,"12/15-Lipoxygenase gene disruption and vitamin E administration diminish <span class=""disease"" id=""16303615-0-73-88"">atherosclerosis</span> and oxidative stress in <span class=""gene"" id=""16303615-0-113-129"">apolipoprotein E</span> deficient mice through a final common pathway.",CTD_human;HPO
25,0,Biomarker,C0004153,Atherosclerosis,disease,atherosclerosis,348,APOE,apolipoprotein(E,CTD_human,12871831,"In aortae from apolipoprotein(E)-deficient mice (apoE(0)) with hyperlipidemia and atherosclerosis, superoxide production is largely derived from NADPH oxidase.",0.5873291246481379,"In aortae from <span class=""gene"" id=""12871831-7-15-31"">apolipoprotein(E</span>)-deficient mice (apoE(0)) with hyperlipidemia and <span class=""disease"" id=""12871831-7-82-97"">atherosclerosis</span>, superoxide production is largely derived from NADPH oxidase.",CTD_human;HPO
25,0,Biomarker,C0004153,Atherosclerosis,disease,atherosclerosis,348,APOE,apolipoprotein E,CTD_human,19124646,"Using a high-fat diet-induced atherosclerosis apolipoprotein E(-/-) mouse model, we demonstrate that administration of the potent PARP inhibitor, thieno[2,3-c]isoquinolin-5-one (TIQ-A), when combined with a regular diet regimen during treatment, induced regression of established plaques.",0.5873291246481379,"Using a high-fat diet-induced <span class=""disease"" id=""19124646-4-30-45"">atherosclerosis</span> <span class=""gene"" id=""19124646-4-46-62"">apolipoprotein E</span>(-/-) mouse model, we demonstrate that administration of the potent PARP inhibitor, thieno[2,3-c]isoquinolin-5-one (TIQ-A), when combined with a regular diet regimen during treatment, induced regression of established plaques.",CTD_human;HPO
25,0,Biomarker,C0004153,Atherosclerosis,disease,atherosclerosis,348,APOE,apolipoprotein E,CTD_human,11095717,"Here we show that in atherosclerosis-susceptible apolipoprotein E knockout mice, vitamin E deficiency caused by disruption of the alpha-tocopherol transfer protein gene (Ttpa) increased the severity of atherosclerotic lesions in the proximal aorta.",0.5873291246481379,"Here we show that in <span class=""disease"" id=""11095717-2-21-36"">atherosclerosis</span>-susceptible <span class=""gene"" id=""11095717-2-49-65"">apolipoprotein E</span> knockout mice, vitamin E deficiency caused by disruption of the alpha-tocopherol transfer protein gene (Ttpa) increased the severity of atherosclerotic lesions in the proximal aorta.",CTD_human;HPO
1,0,Biomarker,C0007282,Carotid Stenosis,disease,carotid stenosis,348,APOE,apolipoprotein E,CTD_human,17243563,"Association of methylenetetrahydrofolate (MTHFR) and apolipoprotein E (apo E) genotypes with homocysteine, vitamin and lipid levels in carotid stenosis.",0.21072702123000397,"Association of methylenetetrahydrofolate (MTHFR) and <span class=""gene"" id=""17243563-0-53-69"">apolipoprotein E</span> (apo E) genotypes with homocysteine, vitamin and lipid levels in <span class=""disease"" id=""17243563-0-135-151"">carotid stenosis</span>.",CTD_human
1,0,Biomarker,C0010068,Coronary heart disease,disease,coronary heart disease,348,APOE,apolipoprotein E,CTD_human,10736278,Carriers of the epsilon4 allele of the apolipoprotein E gene are at a higher risk of coronary heart disease than individuals with other genotypes.,0.343925208457749,"Carriers of the epsilon4 allele of the <span class=""gene"" id=""10736278-1-39-55"">apolipoprotein E</span> gene are at a higher risk of <span class=""disease"" id=""10736278-1-85-107"">coronary heart disease</span> than individuals with other genotypes.",CTD_human
1,0,Biomarker,C0019202,Hepatolenticular Degeneration,disease,Wilson's disease,348,APOE,apolipoprotein E,CTD_human,10686180,The impact of apolipoprotein E genotypes on age at onset of symptoms and phenotypic expression in Wilson's disease.,0.203231208875927,"The impact of <span class=""gene"" id=""10686180-0-14-30"">apolipoprotein E</span> genotypes on age at onset of symptoms and phenotypic expression in <span class=""disease"" id=""10686180-0-98-114"">Wilson's disease</span>.",CTD_human
4,0,Biomarker,C0020473,Hyperlipidemia,disease,hyperlipidemia,348,APOE,apolipoprotein(E,CTD_human,12871831,"In aortae from apolipoprotein(E)-deficient mice (apoE(0)) with hyperlipidemia and atherosclerosis, superoxide production is largely derived from NADPH oxidase.",0.385766896206762,"In aortae from <span class=""gene"" id=""12871831-7-15-31"">apolipoprotein(E</span>)-deficient mice (apoE(0)) with <span class=""disease"" id=""12871831-7-63-77"">hyperlipidemia</span> and atherosclerosis, superoxide production is largely derived from NADPH oxidase.",CTD_human
4,0,Biomarker,C0020473,Hyperlipidemia,disease,hyperlipidemia,348,APOE,apolipoprotein E,CTD_human,11947894,Low density lipoprotein receptor deficient (LDLR-KO) and apolipoprotein E deficient (apo E-KO) mice both develop hyperlipidemia and atherosclerosis by different mechanisms.,0.385766896206762,"Low density lipoprotein receptor deficient (LDLR-KO) and <span class=""gene"" id=""11947894-1-57-73"">apolipoprotein E</span> deficient (apo E-KO) mice both develop <span class=""disease"" id=""11947894-1-113-127"">hyperlipidemia</span> and atherosclerosis by different mechanisms.",CTD_human
3,9,Biomarker,C0020479,Hyperlipoproteinemia Type III,disease,type III hyperlipidemia,348,APOE,APOE,CTD_human,16143024,The great majority of patients with type III hyperlipidemia (type III HLP) are homozygous for the epsilon2 allele of the APOE gene.,0.43229941211358003,"The great majority of patients with <span class=""disease"" id=""16143024-1-36-59"">type III hyperlipidemia</span> (type III HLP) are homozygous for the epsilon2 allele of the <span class=""gene"" id=""16143024-1-121-125"">APOE</span> gene.",CTD_human;ORPHANET
2,0,Biomarker,C0024121,Lung Neoplasms,group,lung tumor,348,APOE,apolipoprotein-E,CTD_human,19180532,"Notably, expression of alpha-2-macroglobulin, transthyretin, alpha-1-antitrypsin, and properdin was in common in different lung tumor models, but regulation of orosomucoid-8, apolipoprotein-A1, apolipoprotein-C3, apolipoprotein-E, glutathione peroxidase-3, plasma retinol-binding protein, and serum amyloid P component was unique when the serum proteomes of c-myc and c-raf tumor bearing mice were compared.",0.202732912464814,"Notably, expression of alpha-2-macroglobulin, transthyretin, alpha-1-antitrypsin, and properdin was in common in different <span class=""disease"" id=""19180532-8-123-133"">lung tumor</span> models, but regulation of orosomucoid-8, apolipoprotein-A1, apolipoprotein-C3, <span class=""gene"" id=""19180532-8-213-229"">apolipoprotein-E</span>, glutathione peroxidase-3, plasma retinol-binding protein, and serum amyloid P component was unique when the serum proteomes of c-myc and c-raf tumor bearing mice were compared.",CTD_human
1,0,Biomarker,C0026769,Multiple Sclerosis,disease,MS,348,APOE,APOE,CTD_human,15048896,"Accelerated evolution of brain atrophy and ""black holes"" in MS patients with APOE-epsilon 4.",0.316712901443335,"Accelerated evolution of brain atrophy and ""black holes"" in <span class=""disease"" id=""15048896-0-60-62"">MS</span> patients with <span class=""gene"" id=""15048896-0-77-81"">APOE</span>-epsilon 4.",CTD_human
1,1,Biomarker,C0027051,Myocardial Infarction,disease,myocardial infarction,348,APOE,APOE,CTD_human,10587578,Independent association of an APOE gene promoter polymorphism with increased risk of myocardial infarction and decreased APOE plasma concentrations-the ECTIM study.,0.302744901580418,"Independent association of an <span class=""gene"" id=""10587578-0-30-34"">APOE</span> gene promoter polymorphism with increased risk of <span class=""disease"" id=""10587578-0-85-106"">myocardial infarction</span> and decreased <span class=""gene"" id=""10587578-0-121-125"">APOE</span> plasma concentrations-the ECTIM study.",CTD_human
1,0,Biomarker,C0028754,Obesity,disease,obesity,348,APOE,APOE,CTD_human,20975297,"A dysregulation in CES1, APOE and other lipid metabolism-related genes is associated to cardiovascular risk factors linked to obesity.",0.47921005037322706,"A dysregulation in CES1, <span class=""gene"" id=""20975297-0-25-29"">APOE</span> and other lipid metabolism-related genes is associated to cardiovascular risk factors linked to <span class=""disease"" id=""20975297-0-126-133"">obesity</span>.",CTD_human;HPO
1,0,Biomarker,C0033860,Psoriasis,disease,psoriasis,348,APOE,Apolipoprotein E,CTD_human,16433808,Apolipoprotein E gene polymorphisms are associated with psoriasis but do not determine disease response to acitretin.,0.20886944627514298,"<span class=""gene"" id=""16433808-0-0-16"">Apolipoprotein E</span> gene polymorphisms are associated with <span class=""disease"" id=""16433808-0-56-65"">psoriasis</span> but do not determine disease response to acitretin.",CTD_human
1,0,Biomarker,C0085220,Cerebral Amyloid Angiopathy,disease,Cerebral amyloid angiopathy,348,APOE,APOE,CTD_human,11061249,Cerebral amyloid angiopathy (CAA) is a major cause of spontaneous lobar hemorrhage in the elderly and is associated with specific alleles of the APOE gene.,0.45110850104608297,"<span class=""disease"" id=""11061249-3-0-27"">Cerebral amyloid angiopathy</span> (CAA) is a major cause of spontaneous lobar hemorrhage in the elderly and is associated with specific alleles of the <span class=""gene"" id=""11061249-3-145-149"">APOE</span> gene.",CTD_human;HPO
1,1,Biomarker,C0242383,Age related macular degeneration,disease,AMD,348,APOE,APOE,CTD_human,16453339,Apolipoprotein (APOE) gene is associated with progression of age-related macular degeneration (AMD).,0.277194418326095,"Apolipoprotein (<span class=""gene"" id=""16453339-0-16-20"">APOE</span>) gene is associated with progression of <span class=""disease"" id=""16453339-0-61-93"">age-related macular degeneration</span> (<span class=""disease"" id=""16453339-0-95-98"">AMD</span>).",CTD_human
1,0,Biomarker,C0751967,"Multiple Sclerosis, Relapsing-Remitting",disease,relapsing-remitting multiple sclerosis,348,APOE,apolipoprotein E,CTD_human,15096402,Influence of apolipoprotein E epsilon4 genotype on brain tissue integrity in relapsing-remitting multiple sclerosis.,0.202956482091714,"Influence of <span class=""gene"" id=""15096402-0-13-29"">apolipoprotein E</span> epsilon4 genotype on brain tissue integrity in <span class=""disease"" id=""15096402-0-77-115"">relapsing-remitting multiple sclerosis</span>.",CTD_human
1,0,Biomarker,C0037286,Skin Neoplasms,group,skin tumor,3480,IGF1R,insulin-like growth factor-1 receptor,CTD_human,10365914,Enhancement of susceptibility to diverse skin tumor promoters by activation of the insulin-like growth factor-1 receptor in the epidermis of transgenic mice.,0.2,"Enhancement of susceptibility to diverse <span class=""disease"" id=""10365914-0-41-51"">skin tumor</span> promoters by activation of the <span class=""gene"" id=""10365914-0-83-120"">insulin-like growth factor-1 receptor</span> in the epidermis of transgenic mice.",CTD_human
1,0,Therapeutic,C0002871,Anemia,disease,anemia,3481,IGF2,insulin-like growth factor II,CTD_human,12090760,Azidothymidine (AZT)-induced anemia in mice can be reversed by the administration of IGF-IL-3 (fusion protein of insulin-like growth factor II (IGF II) and interleukin 3).,0.2,"Azidothymidine (AZT)-induced <span class=""disease"" id=""12090760-1-29-35"">anemia</span> in mice can be reversed by the administration of IGF-IL-3 (fusion protein of <span class=""gene"" id=""12090760-1-113-142"">insulin-like growth factor II</span> (IGF II) and interleukin 3).",CTD_human
1,0,Biomarker,C0004153,Atherosclerosis,disease,atherosclerosis,3481,IGF2,Insulin-like growth factor II,CTD_human,11726660,Insulin-like growth factor II plays a central role in atherosclerosis in a mouse model.,0.20568939455652804,"<span class=""gene"" id=""11726660-0-0-29"">Insulin-like growth factor II</span> plays a central role in <span class=""disease"" id=""11726660-0-54-69"">atherosclerosis</span> in a mouse model.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,3481,IGF2,IGF-2,CTD_human,17547689,"Children with autism/ASD had significantly higher levels of many growth-related hormones: IGF-1, IGF-2, IGFBP-3 and GHBP.",0.20240702852328799,"Children with <span class=""disease"" id=""17547689-12-14-20"">autism</span>/ASD had significantly higher levels of many growth-related hormones: IGF-1, <span class=""gene"" id=""17547689-12-97-102"">IGF-2</span>, IGFBP-3 and GHBP.",CTD_human
2,0,Biomarker,C0004903,Beckwith-Wiedemann Syndrome,disease,Beckwith-Wiedemann syndrome,3481,IGF2,Igf2,CTD_human,9349812,Transactivation of Igf2 in a mouse model of Beckwith-Wiedemann syndrome.,0.222736810555057,"Transactivation of <span class=""gene"" id=""9349812-0-19-23"">Igf2</span> in a mouse model of <span class=""disease"" id=""9349812-0-44-71"">Beckwith-Wiedemann syndrome</span>.",CTD_human
2,0,Biomarker,C0004903,Beckwith-Wiedemann Syndrome,disease,Beckwith-Wiedemann syndrome,3481,IGF2,insulin-like growth factor 2,CTD_human,8252039,Disruption of insulin-like growth factor 2 imprinting in Beckwith-Wiedemann syndrome.,0.222736810555057,"Disruption of <span class=""gene"" id=""8252039-0-14-42"">insulin-like growth factor 2</span> imprinting in <span class=""disease"" id=""8252039-0-57-84"">Beckwith-Wiedemann syndrome</span>.",CTD_human
1,0,Biomarker,C0020615,Hypoglycemia,disease,hypoglycemia,3481,IGF2,insulin-like growth factor II,CTD_human,3185662,Synthesis and secretion of insulin-like growth factor II by a leiomyosarcoma with associated hypoglycemia.,0.20494508211583604,"Synthesis and secretion of <span class=""gene"" id=""3185662-0-27-56"">insulin-like growth factor II</span> by a leiomyosarcoma with associated <span class=""disease"" id=""3185662-0-93-105"">hypoglycemia</span>.",CTD_human
1,0,Biomarker,C0027708,Nephroblastoma,disease,Wilms tumour,3481,IGF2,IGF2,CTD_human,8252039,"Constitutional loss of IGF2 imprinting in a subgroup of our BWS patients, and recent reports of loss of imprinting in sporadic Wilms tumour, further strengthens the view that IGF2 overexpression plays an important role in somatic overgrowth and the development of embryonal tumours.",0.41950560167913,"Constitutional loss of <span class=""gene"" id=""8252039-4-23-27"">IGF2</span> imprinting in a subgroup of our BWS patients, and recent reports of loss of imprinting in sporadic <span class=""disease"" id=""8252039-4-127-139"">Wilms tumour</span>, further strengthens the view that <span class=""gene"" id=""8252039-4-175-179"">IGF2</span> overexpression plays an important role in somatic overgrowth and the development of embryonal tumours.",CTD_human;HPO
1,0,Biomarker,C0030567,Parkinson Disease,disease,PD,3481,IGF2,IGF-II,CTD_human,19276553,"The results suggest that: 1) IGF-I, IGF-II, and neurotrophin signaling are more impaired in DLB than PD, corresponding with DLB's more pronounced neurodegeneration, oxidative stress, and alpha-synuclein accumulation; 2) MnCl2 exposure causes PD/DLB associated abnormalities in central nervous system neurons, and therefore may contribute to their molecular pathogenesis; and 3) molecular abnormalities in PD/DLB overlap with but are distinguishable from Alzheimer's disease.",0.20568939455652804,"The results suggest that: 1) IGF-I, <span class=""gene"" id=""19276553-6-36-42"">IGF-II</span>, and neurotrophin signaling are more impaired in DLB than <span class=""disease"" id=""19276553-6-101-103"">PD</span>, corresponding with DLB's more pronounced neurodegeneration, oxidative stress, and alpha-synuclein accumulation; 2) MnCl2 exposure causes <span class=""disease"" id=""19276553-6-242-244"">PD</span>/DLB associated abnormalities in central nervous system neurons, and therefore may contribute to their molecular pathogenesis; and 3) molecular abnormalities in <span class=""disease"" id=""19276553-6-405-407"">PD</span>/DLB overlap with but are distinguishable from Alzheimer's disease.",CTD_human
1,0,Biomarker,C0035412,Rhabdomyosarcoma,disease,rhabdomyosarcomas,3481,IGF2,IGF-II,CTD_human,7981680,"Among different types of muscle tumors, relaxation of imprinting seems to arise prevalently in rhabdomyosarcomas, since we have detected only one case of partial reactivation of the maternal IGF-II allele out of 7 leiomyosarcomas tested.",0.206593442821114,"Among different types of muscle tumors, relaxation of imprinting seems to arise prevalently in <span class=""disease"" id=""7981680-6-95-112"">rhabdomyosarcomas</span>, since we have detected only one case of partial reactivation of the maternal <span class=""gene"" id=""7981680-6-191-197"">IGF-II</span> allele out of 7 leiomyosarcomas tested.",CTD_human
1,0,Biomarker,C0175693,Russell-Silver syndrome,disease,SRS,3481,IGF2,IGF2,CTD_human,19066168,Epigenetic mutations of the imprinted IGF2-H19 domain in Silver-Russell syndrome (SRS): results from a large cohort of patients with SRS and SRS-like phenotypes.,0.206868169605328,"Epigenetic mutations of the imprinted <span class=""gene"" id=""19066168-0-38-42"">IGF2</span>-H19 domain in <span class=""disease"" id=""19066168-0-57-80"">Silver-Russell syndrome</span> (<span class=""disease"" id=""19066168-0-82-85"">SRS</span>): results from a large cohort of patients with <span class=""disease"" id=""19066168-0-133-136"">SRS</span> and <span class=""disease"" id=""19066168-0-141-144"">SRS</span>-like phenotypes.",CTD_human
1,0,Biomarker,C0752347,Lewy Body Disease,disease,DLB,3481,IGF2,IGF-II,CTD_human,19276553,"The results suggest that: 1) IGF-I, IGF-II, and neurotrophin signaling are more impaired in DLB than PD, corresponding with DLB's more pronounced neurodegeneration, oxidative stress, and alpha-synuclein accumulation; 2) MnCl2 exposure causes PD/DLB associated abnormalities in central nervous system neurons, and therefore may contribute to their molecular pathogenesis; and 3) molecular abnormalities in PD/DLB overlap with but are distinguishable from Alzheimer's disease.",0.200274726784213,"The results suggest that: 1) IGF-I, <span class=""gene"" id=""19276553-6-36-42"">IGF-II</span>, and neurotrophin signaling are more impaired in <span class=""disease"" id=""19276553-6-92-95"">DLB</span> than PD, corresponding with <span class=""disease"" id=""19276553-6-124-127"">DLB</span>'s more pronounced neurodegeneration, oxidative stress, and alpha-synuclein accumulation; 2) MnCl2 exposure causes PD/<span class=""disease"" id=""19276553-6-245-248"">DLB</span> associated abnormalities in central nervous system neurons, and therefore may contribute to their molecular pathogenesis; and 3) molecular abnormalities in PD/<span class=""disease"" id=""19276553-6-408-411"">DLB</span> overlap with but are distinguishable from Alzheimer's disease.",CTD_human
2,0,Biomarker,C2239176,Liver carcinoma,disease,hepatocellular carcinoma,3481,IGF2,insulin-like-growth factor II,CTD_human,16092956,Characterization of insulin-like-growth factor II (IGF II) mRNA positive hepatic altered foci and IGF II expression in hepatocellular carcinoma during diethylnitrosamine-induced hepatocarcinogenesis in rats.,0.43391447644389103,"Characterization of <span class=""gene"" id=""16092956-0-20-49"">insulin-like-growth factor II</span> (IGF II) mRNA positive hepatic altered foci and IGF II expression in <span class=""disease"" id=""16092956-0-119-143"">hepatocellular carcinoma</span> during diethylnitrosamine-induced hepatocarcinogenesis in rats.",CTD_human;HPO
1,2,Biomarker,C2239176,Liver carcinoma,disease,hepatocellular carcinomas,3482,IGF2R,M6p/Igf2 receptor,CTD_human,15057872,Alterations of the M6p/Igf2 receptor gene in hepatocellular carcinomas induced by N-nitrosodiethylamine and a choline-deficient L-amino acid-defined diet in rats.,0.41116957486347294,"Alterations of the <span class=""gene"" id=""15057872-0-19-36"">M6p/Igf2 receptor</span> gene in <span class=""disease"" id=""15057872-0-45-70"">hepatocellular carcinomas</span> induced by N-nitrosodiethylamine and a choline-deficient L-amino acid-defined diet in rats.",CTD_human;HPO
1,0,Biomarker,C0028754,Obesity,disease,obesity,3485,IGFBP2,IGFBP2,CTD_human,22537059,Insulin-like growth factor binding protein-2 (IGFBP2) is a key regulator of IGF activity that has been associated with insulin resistance and obesity.,0.20054945356842604,"<span class=""gene"" id=""22537059-1-0-44"">Insulin-like growth factor binding protein-2</span> (<span class=""gene"" id=""22537059-1-46-52"">IGFBP2</span>) is a key regulator of IGF activity that has been associated with insulin resistance and <span class=""disease"" id=""22537059-1-142-149"">obesity</span>.",CTD_human
1,0,Biomarker,C0003873,Rheumatoid Arthritis,disease,RA,3486,IGFBP3,insulin-like growth factor binding protein 3,CTD_human,17379860,"Treatment with methotrexate resulted in the reversion of the RA-related expression profile of genes associated with growth and apoptosis including insulin-like growth factor binding protein 3, retinoic acid induced 3, and caveolin 2 as well as in the re-expression of the cell adhesion molecule integrin alpha6.",0.20054945356842604,"Treatment with methotrexate resulted in the reversion of the <span class=""disease"" id=""17379860-6-61-63"">RA</span>-related expression profile of genes associated with growth and apoptosis including <span class=""gene"" id=""17379860-6-147-191"">insulin-like growth factor binding protein 3</span>, retinoic acid induced 3, and caveolin 2 as well as in the re-expression of the cell adhesion molecule integrin alpha6.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,3486,IGFBP3,IGFBP-3,CTD_human,17547689,"Children with autism/ASD had significantly higher levels of many growth-related hormones: IGF-1, IGF-2, IGFBP-3 and GHBP.",0.2,"Children with <span class=""disease"" id=""17547689-12-14-20"">autism</span>/ASD had significantly higher levels of many growth-related hormones: IGF-1, IGF-2, <span class=""gene"" id=""17547689-12-104-111"">IGFBP-3</span> and GHBP.",CTD_human
1,0,Biomarker,C0005695,Bladder Neoplasm,disease,bladder cancer,3486,IGFBP3,IGFBP-3,CTD_human,21347663,The association between bladder cancer and a single nucleotide polymorphism (rs2854744) in the insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) gene.,0.201098907136852,"The association between <span class=""disease"" id=""21347663-0-24-38"">bladder cancer</span> and a single nucleotide polymorphism (rs2854744) in the insulin-like growth factor (<span class=""gene"" id=""21347663-0-123-145"">IGF)-binding protein-3</span> (<span class=""gene"" id=""21347663-0-147-154"">IGFBP-3</span>) gene.",CTD_human
1,0,Biomarker,C0004134,Ataxia,phenotype,coordination impairment,348980,HCN1,HCN1,CTD_human,19747469,In this study we showed that the motor coordination impairment observed in HCN1-/- mice is paralleled by a decline of GABA content in the cerebellum.,0.2,"In this study we showed that the motor <span class=""disease"" id=""19747469-4-39-62"">coordination impairment</span> observed in <span class=""gene"" id=""19747469-4-75-79"">HCN1</span>-/- mice is paralleled by a decline of GABA content in the cerebellum.",CTD_human
1,0,Biomarker,C0014544,Epilepsy,disease,epileptic,348980,HCN1,HCN1,CTD_human,12890777,"In contrast, in chronic epileptic HS hippocampus studied here, the profound loss of interneuronal and principal cell populations and consequent reduced inhibition, coupled with increased dendritic excitation of surviving GCs, might provoke a ""compensatory"" enhancement of HCN1 mRNA and protein expression.",0.202197814273705,"In contrast, in chronic <span class=""disease"" id=""12890777-13-24-33"">epileptic</span> HS hippocampus studied here, the profound loss of interneuronal and principal cell populations and consequent reduced inhibition, coupled with increased dendritic excitation of surviving GCs, might provoke a ""compensatory"" enhancement of <span class=""gene"" id=""12890777-13-272-276"">HCN1</span> mRNA and protein expression.",CTD_human
1,0,Biomarker,C0036572,Seizures,phenotype,seizure,348980,HCN1,HCN1,CTD_human,20384728,Increased seizure severity and seizure-related death in mice lacking HCN1 channels.,0.28054945356842603,"Increased <span class=""disease"" id=""20384728-0-10-17"">seizure</span> severity and <span class=""disease"" id=""20384728-0-31-38"">seizure</span>-related death in mice lacking <span class=""gene"" id=""20384728-0-69-73"">HCN1</span> channels.",CTD_human
1,0,Therapeutic,C0033578,Prostatic Neoplasms,group,prostate tumor,3490,IGFBP7,Mac25,CTD_human,12592389,Increased manganese superoxide dismutase (SOD-2) is part of the mechanism for prostate tumor suppression by Mac25/insulin-like growth factor binding-protein-related protein-1.,0.206015278498054,"Increased manganese superoxide dismutase (SOD-2) is part of the mechanism for <span class=""disease"" id=""12592389-0-78-92"">prostate tumor</span> suppression by <span class=""gene"" id=""12592389-0-108-113"">Mac25</span>/insulin-like growth factor binding-protein-related protein-1.",CTD_human
55,13,Biomarker,C0002395,Alzheimer's Disease,disease,AD,351,APP,APP,CTD_human,17239395,"Amyloid beta peptide (Abeta), generated by proteolytic cleavage of the amyloid precursor protein (APP), is central to AD pathogenesis.",0.885733541942472,"Amyloid beta peptide (Abeta), generated by proteolytic cleavage of the <span class=""gene"" id=""17239395-2-71-96"">amyloid precursor protein</span> (<span class=""gene"" id=""17239395-2-98-101"">APP</span>), is central to <span class=""disease"" id=""17239395-2-118-120"">AD</span> pathogenesis.",CTD_human;HPO;ORPHANET;UNIPROT
55,13,Biomarker,C0002395,Alzheimer's Disease,disease,Alzheimer's disease,351,APP,APP,CTD_human,12572668,"Two proteins related to neurodegenerative diseases have been described as copper binding proteins: the amyloid precursor protein (APP), a protein related to Alzheimer's disease, and the Prion protein (PrP), related to Creutzfeldt-Jakob disease.",0.885733541942472,"Two proteins related to neurodegenerative diseases have been described as copper binding proteins: the <span class=""gene"" id=""12572668-3-103-128"">amyloid precursor protein</span> (<span class=""gene"" id=""12572668-3-130-133"">APP</span>), a protein related to <span class=""disease"" id=""12572668-3-157-176"">Alzheimer's disease</span>, and the Prion protein (PrP), related to Creutzfeldt-Jakob disease.",CTD_human;HPO;ORPHANET;UNIPROT
55,13,Biomarker,C0002395,Alzheimer's Disease,disease,AD,351,APP,Abeta,CTD_human,12746438,"These results show that the muscarinic regulation of GABA transmission is impaired in the AD model, probably due to the Abeta-mediated interference of mAChR activation of PKC.",0.885733541942472,"These results show that the muscarinic regulation of GABA transmission is impaired in the <span class=""disease"" id=""12746438-10-90-92"">AD</span> model, probably due to the <span class=""gene"" id=""12746438-10-120-125"">Abeta</span>-mediated interference of mAChR activation of PKC.",CTD_human;HPO;ORPHANET;UNIPROT
55,13,Biomarker,C0002395,Alzheimer's Disease,disease,AD,351,APP,APP,CTD_human,15591071,APP is a large membrane-bound copper-binding protein that is essential in maintaining synaptic function and may play a role in synaptogenesis. beta-Amyloid has been shown to contribute to the oxidative stress that accompanies AD.,0.885733541942472,"<span class=""gene"" id=""15591071-2-0-3"">APP</span> is a large membrane-bound copper-binding protein that is essential in maintaining synaptic function and may play a role in synaptogenesis. beta-Amyloid has been shown to contribute to the oxidative stress that accompanies <span class=""disease"" id=""15591071-2-226-228"">AD</span>.",CTD_human;HPO;ORPHANET;UNIPROT
55,13,Biomarker,C0002395,Alzheimer's Disease,disease,AD,351,APP,APP,CTD_human,18583042,Here we first reported the differential effects of AD-related metal ions at subtoxic concentrations on the transcription levels of APP and BACE1 in PC12 cells.,0.885733541942472,"Here we first reported the differential effects of <span class=""disease"" id=""18583042-7-51-53"">AD</span>-related metal ions at subtoxic concentrations on the transcription levels of <span class=""gene"" id=""18583042-7-131-134"">APP</span> and BACE1 in PC12 cells.",CTD_human;HPO;ORPHANET;UNIPROT
55,13,Biomarker,C0002395,Alzheimer's Disease,disease,Alzheimer's Disease,351,APP,APP,CTD_human,25714973,Protective Effect of Notoginsenoside R1 on an APP/PS1 Mouse Model of Alzheimer's Disease by Up-Regulating Insulin Degrading Enzyme and Inhibiting A? Accumulation.,0.885733541942472,"Protective Effect of Notoginsenoside R1 on an <span class=""gene"" id=""25714973-0-46-49"">APP</span>/PS1 Mouse Model of <span class=""disease"" id=""25714973-0-69-88"">Alzheimer's Disease</span> by Up-Regulating Insulin Degrading Enzyme and Inhibiting A&beta; Accumulation.",CTD_human;HPO;ORPHANET;UNIPROT
55,13,Biomarker,C0002395,Alzheimer's Disease,disease,AD,351,APP,APP,CTD_human,20111991,"Amyloid beta peptide (Abeta), generated by proteolytic cleavage of the amyloid precursor protein (APP), plays a pivotal role in the pathogenesis of Alzheimer's disease (AD).",0.885733541942472,"Amyloid beta peptide (Abeta), generated by proteolytic cleavage of the <span class=""gene"" id=""20111991-1-71-96"">amyloid precursor protein</span> (<span class=""gene"" id=""20111991-1-98-101"">APP</span>), plays a pivotal role in the pathogenesis of <span class=""disease"" id=""20111991-1-148-167"">Alzheimer's disease</span> (<span class=""disease"" id=""20111991-1-169-171"">AD</span>).",CTD_human;HPO;ORPHANET;UNIPROT
55,13,Biomarker,C0002395,Alzheimer's Disease,disease,Alzheimer's disease,351,APP,APP,CTD_human,19818510,"APP expression, distribution and accumulation are altered by aluminum in a rodent model for Alzheimer's disease.",0.885733541942472,"<span class=""gene"" id=""19818510-0-0-3"">APP</span> expression, distribution and accumulation are altered by aluminum in a rodent model for <span class=""disease"" id=""19818510-0-92-111"">Alzheimer's disease</span>.",CTD_human;HPO;ORPHANET;UNIPROT
1,0,Biomarker,C0002622,Amnesia,disease,amnesia,351,APP,beta-amyloid peptide,CTD_human,12642396,"(2) To test whether dimemorfan has anti-amnesic effects similar to a sigma(1) receptor agonist, this study examined its effects on scopolamine- and beta-amyloid peptide-(25-35)-induced amnesia in mice.(3) Dimemorfan (10-40 mg kg(-1), i.p.) administered 30 min before the training trial, immediately after the training trial, or 30 min before the retention test significantly improved scopolamine (1 mg kg(-1), i.p.)- or beta-amyloid peptide-(25-35) (3 nmol mouse(-1), i.c.v.)-induced amnesia in a step-through passive avoidance test.Dimemorfan (5-40 mg kg(-1), i.p.) pretreatment also attenuated scopolamine (8 mg kg(-1), i.p.)-induced amnesia in a water-maze test.",0.202197814273705,"(2) To test whether dimemorfan has anti-amnesic effects similar to a sigma(1) receptor agonist, this study examined its effects on scopolamine- and <span class=""gene"" id=""12642396-2-148-168"">beta-amyloid peptide</span>-(25-35)-induced <span class=""disease"" id=""12642396-2-185-192"">amnesia</span> in mice.(3) Dimemorfan (10-40 mg kg(-1), i.p.) administered 30 min before the training trial, immediately after the training trial, or 30 min before the retention test significantly improved scopolamine (1 mg kg(-1), i.p.)- or <span class=""gene"" id=""12642396-2-420-440"">beta-amyloid peptide</span>-(25-35) (3 nmol mouse(-1), i.c.v.)-induced <span class=""disease"" id=""12642396-2-484-491"">amnesia</span> in a step-through passive avoidance test.Dimemorfan (5-40 mg kg(-1), i.p.) pretreatment also attenuated scopolamine (8 mg kg(-1), i.p.)-induced <span class=""disease"" id=""12642396-2-636-643"">amnesia</span> in a water-maze test.",CTD_human
1,0,Biomarker,C0002726,Amyloidosis,disease,A?,351,APP,APP,CTD_human,23541064,"Importantly, we found that Trien blocked the receptor for AGEs (RAGE), downregulated ?-site APP cleaving enzyme 1 (BACE1), inhibited amyloidogenic APP cleavage, and subsequently reduced A? levels.",0.288198737394441,"Importantly, we found that Trien blocked the receptor for AGEs (RAGE), downregulated &beta;-site APP cleaving enzyme 1 (BACE1), inhibited amyloidogenic <span class=""gene"" id=""23541064-5-147-150"">APP</span> cleavage, and subsequently reduced <span class=""disease"" id=""23541064-5-186-188"">A&beta;</span> levels.",CTD_human
1,0,Biomarker,C0003469,Anxiety Disorders,group,anxiety,351,APP,APP,CTD_human,19664757,"Fear responses might reflect an influence of anxiety, because the anxiolytic compounds valproate, diazepam, and buspirone reduced efficiently unconditioned and conditioned fear responses in APP transgenic mice.",0.203021994626344,"Fear responses might reflect an influence of <span class=""disease"" id=""19664757-8-45-52"">anxiety</span>, because the anxiolytic compounds valproate, diazepam, and buspirone reduced efficiently unconditioned and conditioned fear responses in <span class=""gene"" id=""19664757-8-190-193"">APP</span> transgenic mice.",CTD_human
1,0,Biomarker,C0338656,Impaired cognition,disease,cognitive impairments,351,APP,APP,CTD_human,25288670,"Exposure to As-, Cd-, and Pb-mixture induces A?, amyloidogenic APP processing and cognitive impairments via oxidative stress-dependent neuroinflammation in young rats.",0.221978142737048,"Exposure to As-, Cd-, and Pb-mixture induces A&beta;, amyloidogenic <span class=""gene"" id=""25288670-0-63-66"">APP</span> processing and <span class=""disease"" id=""25288670-0-82-103"">cognitive impairments</span> via oxidative stress-dependent neuroinflammation in young rats.",CTD_human
1,0,Biomarker,C0497327,Dementia,disease,dementia,351,APP,APP,CTD_human,22300406,"Genetic studies show that a simple duplication of the A? precursor (APP) gene, as occurs in Down syndrome (trisomy 21), with a 1.5-fold increase in expression, can cause dementia with the complete AD associated neuropathology.",0.442951749568289,"Genetic studies show that a simple duplication of the A&beta; precursor (<span class=""gene"" id=""22300406-4-68-71"">APP</span>) gene, as occurs in Down syndrome (trisomy 21), with a 1.5-fold increase in expression, can cause <span class=""disease"" id=""22300406-4-170-178"">dementia</span> with the complete AD associated neuropathology.",CTD_human;HPO
1,0,Biomarker,C2936349,"Plaque, Amyloid",disease,amyloid plaque,351,APP,APP,CTD_human,19818510,Up-regulated expression of amyloid precursor protein (APP) occurs early in the cascade of events that leads to amyloid plaque formation in the human brain.,0.252747542568915,"Up-regulated expression of <span class=""gene"" id=""19818510-1-27-52"">amyloid precursor protein</span> (<span class=""gene"" id=""19818510-1-54-57"">APP</span>) occurs early in the cascade of events that leads to <span class=""disease"" id=""19818510-1-111-125"">amyloid plaque</span> formation in the human brain.",CTD_human
1,3,Biomarker,C0022521,Kartagener Syndrome,disease,primary ciliary dyskinesia,352909,DNAAF3,DNAAF3,CTD_human,22387996,Mutations in axonemal dynein assembly factor DNAAF3 cause primary ciliary dyskinesia.,0.4010989071368521,"Mutations in axonemal dynein assembly factor <span class=""gene"" id=""22387996-0-45-51"">DNAAF3</span> cause <span class=""disease"" id=""22387996-0-58-84"">primary ciliary dyskinesia</span>.",CTD_human;ORPHANET
2,0,Biomarker,C0451641,Urolithiasis,disease,urolithiasis,353,APRT,APRT,CTD_human,3876264,"In the present investigations, we have shown that this characteristic is common in mutant enzymes from all the four separate Japanese urolithiasis families associated with partial APRT deficiencies so far tested.",0.20082418035263896,"In the present investigations, we have shown that this characteristic is common in mutant enzymes from all the four separate Japanese <span class=""disease"" id=""3876264-4-134-146"">urolithiasis</span> families associated with partial <span class=""gene"" id=""3876264-4-180-184"">APRT</span> deficiencies so far tested.",CTD_human
1,0,Biomarker,C0033860,Psoriasis,disease,psoriasis,353143,LCE3B,LCE3B,CTD_human,19169253,Deletion of the late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis.,0.221636224686581,"Deletion of the late cornified envelope <span class=""gene"" id=""19169253-0-40-45"">LCE3B</span> and LCE3C genes as a susceptibility factor for <span class=""disease"" id=""19169253-0-93-102"">psoriasis</span>.",CTD_human
1,0,Biomarker,C0033860,Psoriasis,disease,psoriasis,353144,LCE3C,LCE3C,CTD_human,19169253,Deletion of the late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis.,0.221636224686581,"Deletion of the late cornified envelope LCE3B and <span class=""gene"" id=""19169253-0-50-55"">LCE3C</span> genes as a susceptibility factor for <span class=""disease"" id=""19169253-0-93-102"">psoriasis</span>.",CTD_human
1,0,Biomarker,C1704436,Peripheral Arterial Diseases,group,PAD,353500,BMP8A,BMP8A,CTD_human,27082954,"Further investigation of BMP8A using the Genotype Tissue Expression Database revealed multiple variants with nominally significant (P < 0.05) interaction P-values in our EA cohort were significant BMP8A eQTLs in tissue types highlight relevant for PAD such as rs755249 (tibial nerve, eQTL P = 3.6x10-6) and rs1180341 (tibial artery, eQTL P = 5.3x10-6).",0.200274726784213,"Further investigation of <span class=""gene"" id=""27082954-9-25-30"">BMP8A</span> using the Genotype Tissue Expression Database revealed multiple variants with nominally significant (P &lt; 0.05) interaction P-values in our EA cohort were significant <span class=""gene"" id=""27082954-9-197-202"">BMP8A</span> eQTLs in tissue types highlight relevant for <span class=""disease"" id=""27082954-9-248-251"">PAD</span> such as rs755249 (tibial nerve, eQTL P = 3.6x10-6) and rs1180341 (tibial artery, eQTL P = 5.3x10-6).",CTD_human
10,0,Biomarker,C0033578,Prostatic Neoplasms,group,prostate tumor,354,KLK3,PSA,CTD_human,18500220,"The addition of a dual inhibitor of 5-a-reductase types 1 and 2 to antiandrogen therapy may further inhibit tumor growth, thus reducing the concentration of intracellular dihydrotestosterone, which is the primary androgen mediator of PSA gene expression in prostate tumor cell lines.",0.291747739186533,"The addition of a dual inhibitor of 5-a-reductase types 1 and 2 to antiandrogen therapy may further inhibit tumor growth, thus reducing the concentration of intracellular dihydrotestosterone, which is the primary androgen mediator of <span class=""gene"" id=""18500220-19-234-237"">PSA</span> gene expression in <span class=""disease"" id=""18500220-19-257-271"">prostate tumor</span> cell lines.",CTD_human
1,0,Biomarker,C1334615,Malignant Phyllodes Tumor of Prostate,disease,phyllodes tumor of the prostate,354,KLK3,PSA,CTD_human,22360509,"In this report, we describe a case of phyllodes tumor of the prostate with a high value of prostate-specific antigen (PSA).",0.2,"In this report, we describe a case of <span class=""disease"" id=""22360509-1-38-69"">phyllodes tumor of the prostate</span> with a high value of <span class=""gene"" id=""22360509-1-91-116"">prostate-specific antigen</span> (<span class=""gene"" id=""22360509-1-118-121"">PSA</span>).",CTD_human
1,0,Biomarker,C0020532,Hypersplenism,disease,hypersplenism,355,FAS,FAS,CTD_human,15877736,"Autoimmune lymphoproliferative syndrome (ALPS) is a disorder of apoptosis associated most often with heritable FAS mutations leading to lymphadenopathy, hypersplenism and chronic refractory autoimmune cytopenias.",0.2,"Autoimmune lymphoproliferative syndrome (ALPS) is a disorder of apoptosis associated most often with heritable <span class=""gene"" id=""15877736-1-111-114"">FAS</span> mutations leading to lymphadenopathy, <span class=""disease"" id=""15877736-1-153-166"">hypersplenism</span> and chronic refractory autoimmune cytopenias.",CTD_human
1,0,Biomarker,C0023467,"Leukemia, Myelocytic, Acute",disease,AML,355,FAS,Fas,CTD_human,7579353,Apoptotic cell death induced by cross-linking Fas receptor (FasR/CD95) has been investigated in human acute myelogenous leukemia (AML) cells.,0.20728659810449399,"Apoptotic cell death induced by cross-linking <span class=""gene"" id=""7579353-1-46-49"">Fas</span> receptor (FasR/CD95) has been investigated in human <span class=""disease"" id=""7579353-1-102-128"">acute myelogenous leukemia</span> (<span class=""disease"" id=""7579353-1-130-133"">AML</span>) cells.",CTD_human
1,0,Biomarker,C0024535,"Malaria, Falciparum",disease,falciparum malaria,355,FAS,FAS,CTD_human,21625619,"Here, a candidate-gene association study including variant discovery at the FAS gene locus was carried out in a case-control group comprising 1,195 pediatric cases of severe falciparum malaria and 769 unaffected controls from a region highly endemic for malaria in Ghana, West Africa.",0.2,"Here, a candidate-gene association study including variant discovery at the <span class=""gene"" id=""21625619-3-76-79"">FAS</span> gene locus was carried out in a case-control group comprising 1,195 pediatric cases of severe <span class=""disease"" id=""21625619-3-174-192"">falciparum malaria</span> and 769 unaffected controls from a region highly endemic for malaria in Ghana, West Africa.",CTD_human
1,0,Biomarker,C0026896,Myasthenia Gravis,disease,MG,355,FAS,Fas,CTD_human,15169653,"Abnormalities of apoptosis and Fas gene expression of MG patients' thymocytes, and Fas gene mutation may be related to the pathogenesis and progression of MG.",0.2,"Abnormalities of apoptosis and <span class=""gene"" id=""15169653-11-31-34"">Fas</span> gene expression of <span class=""disease"" id=""15169653-11-54-56"">MG</span> patients' thymocytes, and <span class=""gene"" id=""15169653-11-83-86"">Fas</span> gene mutation may be related to the pathogenesis and progression of <span class=""disease"" id=""15169653-11-155-157"">MG</span>.",CTD_human
3,0,Biomarker,C0878544,Cardiomyopathies,group,cardiomyopathy,355,FAS,APO-1,CTD_human,10716473,"Peripartum cardiomyopathy: analysis of clinical outcome, left ventricular function, plasma levels of cytokines and Fas/APO-1.",0.2,"Peripartum <span class=""disease"" id=""10716473-0-11-25"">cardiomyopathy</span>: analysis of clinical outcome, left ventricular function, plasma levels of cytokines and Fas/<span class=""gene"" id=""10716473-0-119-124"">APO-1</span>.",CTD_human
1,0,Therapeutic,C0002622,Amnesia,disease,amnesia,3552,IL1A,IL-1 alpha,CTD_human,8003924,Peripherally administered IL-1 alpha interferes with scopolamine-induced amnesia in mice.,0.2,"Peripherally administered <span class=""gene"" id=""8003924-0-26-36"">IL-1 alpha</span> interferes with scopolamine-induced <span class=""disease"" id=""8003924-0-73-80"">amnesia</span> in mice.",CTD_human
1,0,Biomarker,C0003165,Anthracosis,disease,coal workers' pneumoconiosis,3552,IL1A,IL1,CTD_human,20005085,Possible effect of gene polymorphisms on the release of TNF? and IL1 cytokines in coal workers' pneumoconiosis.,0.202681755307501,"Possible effect of gene polymorphisms on the release of TNF&alpha; and <span class=""gene"" id=""20005085-0-65-68"">IL1</span> cytokines in <span class=""disease"" id=""20005085-0-82-110"">coal workers' pneumoconiosis</span>.",CTD_human
1,0,Biomarker,C0020429,Hyperalgesia,phenotype,Hyperalgesia,3552,IL1A,IL-1,CTD_human,12727271,"Hyperalgesia induced by both PLA(2)s was blocked by the histamine and serotonin receptor antagonists promethazine and methysergide, respectively, by the bradykinin B(2) receptor antagonist HOE 140 and by antibodies to tumor necrosis factor alfa (TNFalpha) and interleukin 1 (IL-1).",0.2,"<span class=""disease"" id=""12727271-7-0-12"">Hyperalgesia</span> induced by both PLA(2)s was blocked by the histamine and serotonin receptor antagonists promethazine and methysergide, respectively, by the bradykinin B(2) receptor antagonist HOE 140 and by antibodies to tumor necrosis factor alfa (TNFalpha) and interleukin 1 (<span class=""gene"" id=""12727271-7-275-279"">IL-1</span>).",CTD_human
1,0,Biomarker,C0085655,Polymyositis,disease,polymyositis,3552,IL1A,interleukin-1 alpha,CTD_human,7979221,"To evaluate the possible role of cytokines in human immunodeficiency virus (HIV)-associated muscular disorders, we performed immunocytochemistry for interleukin-1 alpha, -1 beta, and -6 and tumor necrosis factor-alpha on frozen muscle biopsy specimens from HIV-infected patients with various myopathies (HIV polymyositis in 5, HIV-wasting syndrome in 5, zidovudine myopathy in 10) and from seronegative individuals (normal muscle in 2, mitochondrial cytopathies in 10).",0.20054945356842604,"To evaluate the possible role of cytokines in human immunodeficiency virus (HIV)-associated muscular disorders, we performed immunocytochemistry for <span class=""gene"" id=""7979221-1-149-168"">interleukin-1 alpha</span>, -1 beta, and -6 and tumor necrosis factor-alpha on frozen muscle biopsy specimens from HIV-infected patients with various myopathies (HIV <span class=""disease"" id=""7979221-1-308-320"">polymyositis</span> in 5, HIV-wasting syndrome in 5, zidovudine myopathy in 10) and from seronegative individuals (normal muscle in 2, mitochondrial cytopathies in 10).",CTD_human
1,0,Biomarker,C0343755,HIV Wasting Syndrome,disease,HIV-wasting syndrome,3552,IL1A,interleukin-1 alpha,CTD_human,7979221,"To evaluate the possible role of cytokines in human immunodeficiency virus (HIV)-associated muscular disorders, we performed immunocytochemistry for interleukin-1 alpha, -1 beta, and -6 and tumor necrosis factor-alpha on frozen muscle biopsy specimens from HIV-infected patients with various myopathies (HIV polymyositis in 5, HIV-wasting syndrome in 5, zidovudine myopathy in 10) and from seronegative individuals (normal muscle in 2, mitochondrial cytopathies in 10).",0.2,"To evaluate the possible role of cytokines in human immunodeficiency virus (HIV)-associated muscular disorders, we performed immunocytochemistry for <span class=""gene"" id=""7979221-1-149-168"">interleukin-1 alpha</span>, -1 beta, and -6 and tumor necrosis factor-alpha on frozen muscle biopsy specimens from HIV-infected patients with various myopathies (HIV polymyositis in 5, <span class=""disease"" id=""7979221-1-327-347"">HIV-wasting syndrome</span> in 5, zidovudine myopathy in 10) and from seronegative individuals (normal muscle in 2, mitochondrial cytopathies in 10).",CTD_human
1,0,Biomarker,C0345967,Malignant mesothelioma,disease,MM,3552,IL1A,IL-1 alpha,CTD_human,25162674,"A specific pattern of cytokines were found highly expressed in Asb-workers: IFN-alpha (p<0.05), EOTAXIN (p<0.01), RANTES (p<0.001), and in MM patients: IL-12(p40), IL-3, IL-1 alpha, MCP-3, beta-NGF, TNF-beta, RANTES (p<0.001).",0.200274726784213,"A specific pattern of cytokines were found highly expressed in Asb-workers: IFN-alpha (p&lt;0.05), EOTAXIN (p&lt;0.01), RANTES (p&lt;0.001), and in <span class=""disease"" id=""25162674-8-139-141"">MM</span> patients: IL-12(p40), IL-3, <span class=""gene"" id=""25162674-8-170-180"">IL-1 alpha</span>, MCP-3, beta-NGF, TNF-beta, RANTES (p&lt;0.001).",CTD_human
1,0,Biomarker,C0003123,Anorexia,disease,anorexia,3553,IL1B,interleukin-1?,CTD_human,25392278,Role of tumor necrosis factor-? and interleukin-1? in anorexia induction following oral exposure to the trichothecene deoxynivalenol (vomitoxin) in the mouse.,0.202681755307501,"Role of tumor necrosis factor-&alpha; and <span class=""gene"" id=""25392278-0-36-50"">interleukin-1&beta;</span> in <span class=""disease"" id=""25392278-0-54-62"">anorexia</span> induction following oral exposure to the trichothecene deoxynivalenol (vomitoxin) in the mouse.",CTD_human
1,0,Biomarker,C0004096,Asthma,disease,asthmatic,3553,IL1B,IL-1,CTD_human,9176529,Effect of inhaled glucocorticoids on IL-1 beta and IL-1 receptor antagonist (IL-1 ra) expression in asthmatic bronchial epithelium.,0.236143908360939,"Effect of inhaled glucocorticoids on <span class=""gene"" id=""9176529-0-37-46"">IL-1 beta</span> and <span class=""gene"" id=""9176529-0-51-55"">IL-1</span> receptor antagonist (IL-1 ra) expression in <span class=""disease"" id=""9176529-0-100-109"">asthmatic</span> bronchial epithelium.",CTD_human
2,0,Biomarker,C0009319,Colitis,disease,colitis,3553,IL1B,IL-1?,CTD_human,23810507,Elevation of serum IL-1? level due to colitis was also attenuated by both treatments.,0.281923087489492,"Elevation of serum <span class=""gene"" id=""23810507-12-19-24"">IL-1&beta;</span> level due to <span class=""disease"" id=""23810507-12-38-45"">colitis</span> was also attenuated by both treatments.",CTD_human
6,0,Biomarker,C0020429,Hyperalgesia,phenotype,Hyperalgesia,3553,IL1B,IL-1,CTD_human,12727271,"Hyperalgesia induced by both PLA(2)s was blocked by the histamine and serotonin receptor antagonists promethazine and methysergide, respectively, by the bradykinin B(2) receptor antagonist HOE 140 and by antibodies to tumor necrosis factor alfa (TNFalpha) and interleukin 1 (IL-1).",0.280274726784213,"<span class=""disease"" id=""12727271-7-0-12"">Hyperalgesia</span> induced by both PLA(2)s was blocked by the histamine and serotonin receptor antagonists promethazine and methysergide, respectively, by the bradykinin B(2) receptor antagonist HOE 140 and by antibodies to tumor necrosis factor alfa (TNFalpha) and interleukin 1 (<span class=""gene"" id=""12727271-7-275-279"">IL-1</span>).",CTD_human
6,0,Biomarker,C0020429,Hyperalgesia,phenotype,hyperalgesia,3553,IL1B,IL-1 beta,CTD_human,7582491,These data suggest that IL-10 limits the inflammatory hyperalgesia evoked by carrageenin and bradykinin by two mechanisms: inhibition of cytokine production and inhibition of IL-1 beta evoked PGE2 production.,0.280274726784213,"These data suggest that IL-10 limits the inflammatory <span class=""disease"" id=""7582491-7-54-66"">hyperalgesia</span> evoked by carrageenin and bradykinin by two mechanisms: inhibition of cytokine production and inhibition of <span class=""gene"" id=""7582491-7-175-184"">IL-1 beta</span> evoked PGE2 production.",CTD_human
6,0,Biomarker,C0020429,Hyperalgesia,phenotype,hyperalgesia,3553,IL1B,IL-1 beta,CTD_human,10401557,"The ODQ potentiated hyperalgesia induced by carrageenan, bradykinin, TNF alpha, IL-1 beta, IL-6 and IL-8.",0.280274726784213,"The ODQ potentiated <span class=""disease"" id=""10401557-10-20-32"">hyperalgesia</span> induced by carrageenan, bradykinin, TNF alpha, <span class=""gene"" id=""10401557-10-80-89"">IL-1 beta</span>, IL-6 and IL-8.",CTD_human
6,0,Biomarker,C0020429,Hyperalgesia,phenotype,hyperalgesia,3553,IL1B,IL-1,CTD_human,20937348,The present study suggests that an IL-1 receptor antagonist effectively attenuates or blocks long-lasting hyperalgesia and microglia activation produced by LPS exposure in the neonatal period of rats.,0.280274726784213,"The present study suggests that an <span class=""gene"" id=""20937348-9-35-39"">IL-1</span> receptor antagonist effectively attenuates or blocks long-lasting <span class=""disease"" id=""20937348-9-106-118"">hyperalgesia</span> and microglia activation produced by LPS exposure in the neonatal period of rats.",CTD_human
1,0,Biomarker,C0020452,Hyperemia,disease,hyperemia,3553,IL1B,IL-1 beta,CTD_human,8846404,The hyperemia evoked by intraplantar calcitonin gene related peptide (0.038-3.8 ng) was not altered by IL-1 beta (50 pg).,0.200274726784213,"The <span class=""disease"" id=""8846404-7-4-13"">hyperemia</span> evoked by intraplantar calcitonin gene related peptide (0.038-3.8 ng) was not altered by <span class=""gene"" id=""8846404-7-103-112"">IL-1 beta</span> (50 pg).",CTD_human
1,0,Biomarker,C0023380,Lethargy,phenotype,lethargy,3553,IL1B,IL-1?,CTD_human,22143887,Mice lacking the Tak1 gene in brain endothelial cells showed a blunted fever response and reduced lethargy upon intravenous injection of the endogenous pyrogen IL-1?.,0.2,"Mice lacking the Tak1 gene in brain endothelial cells showed a blunted fever response and reduced <span class=""disease"" id=""22143887-6-98-106"">lethargy</span> upon intravenous injection of the endogenous pyrogen <span class=""gene"" id=""22143887-6-160-165"">IL-1&beta;</span>.",CTD_human
1,0,Biomarker,C0024312,Lymphopenia,disease,lymphocytopenia,3553,IL1B,IL-1 beta,CTD_human,1884014,"Transient neutropenia, monocytopenia, and lymphocytopenia were observed followed by a 1.3- to 6.0-fold (mean, 3.46-fold) dose-dependent neutrophil leukocytosis (P less than .00001) on the days of IL-1 beta administration.",0.2,"Transient neutropenia, monocytopenia, and <span class=""disease"" id=""1884014-2-42-57"">lymphocytopenia</span> were observed followed by a 1.3- to 6.0-fold (mean, 3.46-fold) dose-dependent neutrophil leukocytosis (P less than .00001) on the days of <span class=""gene"" id=""1884014-2-196-205"">IL-1 beta</span> administration.",CTD_human
1,0,Biomarker,C0026848,Myopathy,group,myopathy,3553,IL1B,IL-1 beta,CTD_human,9184656,"Semi-quantitative PCR showed that production of IL-1 beta mRNA was higher in sarcoid myopathy than in AZT myopathy, and in AZT myopathy than in controls.",0.20300763924902696,"Semi-quantitative PCR showed that production of <span class=""gene"" id=""9184656-5-48-57"">IL-1 beta</span> mRNA was higher in sarcoid myopathy than in AZT <span class=""disease"" id=""9184656-5-106-114"">myopathy</span>, and in AZT <span class=""disease"" id=""9184656-5-127-135"">myopathy</span> than in controls.",CTD_human
1,0,Biomarker,C0027947,Neutropenia,disease,neutropenia,3553,IL1B,IL-1 beta,CTD_human,1884014,"Fewer days of neutropenia were noted after 5-FU plus IL-1 beta than after 5-FU alone; however, this difference did not reach statistical significance.",0.20240702852328799,"Fewer days of <span class=""disease"" id=""1884014-7-14-25"">neutropenia</span> were noted after 5-FU plus <span class=""gene"" id=""1884014-7-53-62"">IL-1 beta</span> than after 5-FU alone; however, this difference did not reach statistical significance.",CTD_human
1,0,Biomarker,C0029458,"Osteoporosis, Postmenopausal",disease,postmenopausal osteoporosis,3553,IL1B,IL-1 beta,CTD_human,9032749,"Increase in cytokine production (IL-1 beta, IL-6, TNF-alpha but not IFN-gamma, GM-CSF or LIF) by stimulated whole blood cells in postmenopausal osteoporosis.",0.205363510615002,"Increase in cytokine production (<span class=""gene"" id=""9032749-0-33-42"">IL-1 beta</span>, IL-6, TNF-alpha but not IFN-gamma, GM-CSF or LIF) by stimulated whole blood cells in <span class=""disease"" id=""9032749-0-129-156"">postmenopausal osteoporosis</span>.",CTD_human
1,0,Biomarker,C0033860,Psoriasis,disease,psoriasis,3553,IL1B,IL-1 beta,CTD_human,7744320,Increased mRNA expression of manganese superoxide dismutase in psoriasis skin lesions and in cultured human keratinocytes exposed to IL-1 beta and TNF-alpha.,0.20845101777597602,"Increased mRNA expression of manganese superoxide dismutase in <span class=""disease"" id=""7744320-0-63-72"">psoriasis</span> skin lesions and in cultured human keratinocytes exposed to <span class=""gene"" id=""7744320-0-133-142"">IL-1 beta</span> and TNF-alpha.",CTD_human
1,0,Biomarker,C0037116,Silicosis,disease,silicosis,3553,IL1B,IL-1?,CTD_human,23640035,"Interleukin-1 beta (IL-1?) plays an important role in silica-induced lung inflammation, but the mechanisms that underlie the influence of IL-1? on the progression of silicosis remain unclear.",0.210503451603104,"<span class=""gene"" id=""23640035-2-0-18"">Interleukin-1 beta</span> (<span class=""gene"" id=""23640035-2-20-25"">IL-1&beta;</span>) plays an important role in silica-induced lung inflammation, but the mechanisms that underlie the influence of <span class=""gene"" id=""23640035-2-138-143"">IL-1&beta;</span> on the progression of <span class=""disease"" id=""23640035-2-166-175"">silicosis</span> remain unclear.",CTD_human
1,0,Therapeutic,C0003123,Anorexia,disease,anorexia,3557,IL1RN,IL-1RA,CTD_human,25392278,"While, the type 1 IL-1 receptor (IL-1R1) antagonist IL-1RA dose-dependently attenuated both IL-1?- and DON-induced anorexia.",0.28,"While, the type 1 IL-1 receptor (IL-1R1) antagonist <span class=""gene"" id=""25392278-8-52-58"">IL-1RA</span> dose-dependently attenuated both IL-1&beta;- and DON-induced <span class=""disease"" id=""25392278-8-115-123"">anorexia</span>.",CTD_human
2,0,Therapeutic,C0003873,Rheumatoid Arthritis,disease,RA,3557,IL1RN,interleukin-1 receptor antagonist,CTD_human,7706905,"Human recombinant interleukin-1 receptor antagonist (rhIL-1ra), a 17.2 kd protein is currently in clinical trials for the treatment of rheumatoid arthritis (RA).",0.259348625840852,"Human recombinant <span class=""gene"" id=""7706905-1-18-51"">interleukin-1 receptor antagonist</span> (rhIL-1ra), a 17.2 kd protein is currently in clinical trials for the treatment of <span class=""disease"" id=""7706905-1-135-155"">rheumatoid arthritis</span> (<span class=""disease"" id=""7706905-1-157-159"">RA</span>).",CTD_human
2,0,Biomarker,C0003873,Rheumatoid Arthritis,disease,RA,3557,IL1RN,interleukin-1 receptor antagonist,CTD_human,7706905,"Human recombinant interleukin-1 receptor antagonist (rhIL-1ra), a 17.2 kd protein is currently in clinical trials for the treatment of rheumatoid arthritis (RA).",0.259348625840852,"Human recombinant <span class=""gene"" id=""7706905-1-18-51"">interleukin-1 receptor antagonist</span> (rhIL-1ra), a 17.2 kd protein is currently in clinical trials for the treatment of <span class=""disease"" id=""7706905-1-135-155"">rheumatoid arthritis</span> (<span class=""disease"" id=""7706905-1-157-159"">RA</span>).",CTD_human
1,0,Biomarker,C0004096,Asthma,disease,asthmatic,3557,IL1RN,IL-1 ra,CTD_human,9176529,Effect of inhaled glucocorticoids on IL-1 beta and IL-1 receptor antagonist (IL-1 ra) expression in asthmatic bronchial epithelium.,0.23491397615482698,"Effect of inhaled glucocorticoids on IL-1 beta and IL-1 receptor antagonist (<span class=""gene"" id=""9176529-0-77-84"">IL-1 ra</span>) expression in <span class=""disease"" id=""9176529-0-100-109"">asthmatic</span> bronchial epithelium.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,3557,IL1RN,IL-1RA,CTD_human,11803234,These results suggest that autism may be accompanied by an activation of the monocytic (increased IL-1RA) and Th-1-like (increased IFN-gamma) arm of the IRS.,0.2,"These results suggest that <span class=""disease"" id=""11803234-7-27-33"">autism</span> may be accompanied by an activation of the monocytic (increased <span class=""gene"" id=""11803234-7-98-104"">IL-1RA</span>) and Th-1-like (increased IFN-gamma) arm of the IRS.",CTD_human
4,0,Therapeutic,C0020429,Hyperalgesia,phenotype,hyperalgesia,3557,IL1RN,Interleukin-1 receptor antagonist,CTD_human,20937348,Interleukin-1 receptor antagonist ameliorates neonatal lipopolysaccharide-induced long-lasting hyperalgesia in the adult rats.,0.28,"<span class=""gene"" id=""20937348-0-0-33"">Interleukin-1 receptor antagonist</span> ameliorates neonatal lipopolysaccharide-induced long-lasting <span class=""disease"" id=""20937348-0-95-107"">hyperalgesia</span> in the adult rats.",CTD_human
4,0,Biomarker,C0020429,Hyperalgesia,phenotype,hyperalgesia,3557,IL1RN,IL-1ra,CTD_human,8864563,"Interleukin-1 receptor antagonist (IL-1ra 0.1 microgram) reduced the development of SP-induced hyperalgesia up to 4 h after administration, but did not reverse an established hyperalgesia.",0.28,"<span class=""gene"" id=""8864563-9-0-33"">Interleukin-1 receptor antagonist</span> (<span class=""gene"" id=""8864563-9-35-41"">IL-1ra</span> 0.1 microgram) reduced the development of SP-induced <span class=""disease"" id=""8864563-9-95-107"">hyperalgesia</span> up to 4 h after administration, but did not reverse an established <span class=""disease"" id=""8864563-9-175-187"">hyperalgesia</span>.",CTD_human
4,0,Biomarker,C0020429,Hyperalgesia,phenotype,hyperalgesia,3557,IL1RN,IL-1ra,CTD_human,15317861,"Similarly, intrathecal IL-1ra administered after the establishment of morphine tolerance reversed hyperalgesia and prevented the additional development of tolerance and allodynia.",0.28,"Similarly, intrathecal <span class=""gene"" id=""15317861-5-23-29"">IL-1ra</span> administered after the establishment of morphine tolerance reversed <span class=""disease"" id=""15317861-5-98-110"">hyperalgesia</span> and prevented the additional development of tolerance and allodynia.",CTD_human
4,0,Therapeutic,C0020429,Hyperalgesia,phenotype,hyperalgesia,3557,IL1RN,IL-1ra,CTD_human,15317861,"Similarly, intrathecal IL-1ra administered after the establishment of morphine tolerance reversed hyperalgesia and prevented the additional development of tolerance and allodynia.",0.28,"Similarly, intrathecal <span class=""gene"" id=""15317861-5-23-29"">IL-1ra</span> administered after the establishment of morphine tolerance reversed <span class=""disease"" id=""15317861-5-98-110"">hyperalgesia</span> and prevented the additional development of tolerance and allodynia.",CTD_human
4,0,Biomarker,C0020429,Hyperalgesia,phenotype,hyperalgesia,3557,IL1RN,Interleukin-1 receptor antagonist,CTD_human,20937348,Interleukin-1 receptor antagonist ameliorates neonatal lipopolysaccharide-induced long-lasting hyperalgesia in the adult rats.,0.28,"<span class=""gene"" id=""20937348-0-0-33"">Interleukin-1 receptor antagonist</span> ameliorates neonatal lipopolysaccharide-induced long-lasting <span class=""disease"" id=""20937348-0-95-107"">hyperalgesia</span> in the adult rats.",CTD_human
4,0,Therapeutic,C0020429,Hyperalgesia,phenotype,hyperalgesia,3557,IL1RN,IL-1ra,CTD_human,8864563,"Interleukin-1 receptor antagonist (IL-1ra 0.1 microgram) reduced the development of SP-induced hyperalgesia up to 4 h after administration, but did not reverse an established hyperalgesia.",0.28,"<span class=""gene"" id=""8864563-9-0-33"">Interleukin-1 receptor antagonist</span> (<span class=""gene"" id=""8864563-9-35-41"">IL-1ra</span> 0.1 microgram) reduced the development of SP-induced <span class=""disease"" id=""8864563-9-95-107"">hyperalgesia</span> up to 4 h after administration, but did not reverse an established <span class=""disease"" id=""8864563-9-175-187"">hyperalgesia</span>.",CTD_human
1,0,Biomarker,C0027121,Myositis,disease,myositis,3557,IL1RN,IL-1RN,CTD_human,10886238,"Because IL-1alpha and IL-1beta, and the anti-inflammatory competitive inhibitor, IL-1 receptor antagonist (IL-1Ra), have been implicated in the pathogenesis of myositis, we assessed the role of variable number tandem repeat (VNTR) polymorphisms of the IL-1Ra gene (IL-1RN) in the aetiology of JIIM: IL-1RN VNTR polymorphisms were performed on 250 JIIM patients and 471 race-matched controls and were correlated with clinical characteristics.",0.20054945356842604,"Because IL-1alpha and IL-1beta, and the anti-inflammatory competitive inhibitor, IL-1 receptor antagonist (<span class=""gene"" id=""10886238-2-107-113"">IL-1Ra</span>), have been implicated in the pathogenesis of <span class=""disease"" id=""10886238-2-160-168"">myositis</span>, we assessed the role of variable number tandem repeat (VNTR) polymorphisms of the <span class=""gene"" id=""10886238-2-252-258"">IL-1Ra</span> gene (<span class=""gene"" id=""10886238-2-265-271"">IL-1RN</span>) in the aetiology of JIIM: <span class=""gene"" id=""10886238-2-299-305"">IL-1RN</span> VNTR polymorphisms were performed on 250 JIIM patients and 471 race-matched controls and were correlated with clinical characteristics.",CTD_human
1,0,Therapeutic,C0038220,Status Epilepticus,disease,SE,3557,IL1RN,IL-1ra,CTD_human,19010416,Animals pre-treated with IL-1ra exhibited significant reduction of SE onset and of BBB damage.,0.2,"Animals pre-treated with <span class=""gene"" id=""19010416-9-25-31"">IL-1ra</span> exhibited significant reduction of <span class=""disease"" id=""19010416-9-67-69"">SE</span> onset and of BBB damage.",CTD_human
1,0,Therapeutic,C0162557,"Liver Failure, Acute",disease,ALF,3557,IL1RN,IL-1Ra,CTD_human,20644519,These results prompted us to investigate the roles of IL-1Ra in APAP-induced ALF mice.,0.20082418035263896,"These results prompted us to investigate the roles of <span class=""gene"" id=""20644519-5-54-60"">IL-1Ra</span> in APAP-induced <span class=""disease"" id=""20644519-5-77-80"">ALF</span> mice.",CTD_human
1,0,Therapeutic,C0524988,Schnitzler Syndrome,disease,Schnitzler's syndrome,3557,IL1RN,interleukin 1 receptor antagonist,CTD_human,16096327,"To assess treatment with thalidomide and an interleukin 1 receptor antagonist, anakinra, in Schnitzler's syndrome.",0.20054945356842604,"To assess treatment with thalidomide and an <span class=""gene"" id=""16096327-3-44-77"">interleukin 1 receptor antagonist</span>, anakinra, in <span class=""disease"" id=""16096327-3-92-113"">Schnitzler's syndrome</span>.",CTD_human
1,0,Biomarker,C0002622,Amnesia,disease,amnesia,3558,IL2,Interleukin-2,CTD_human,8241462,Interleukin-2 enhances scopolamine-induced amnesia and hyperactivity in the mouse.,0.2,"<span class=""gene"" id=""8241462-0-0-13"">Interleukin-2</span> enhances scopolamine-induced <span class=""disease"" id=""8241462-0-43-50"">amnesia</span> and hyperactivity in the mouse.",CTD_human
2,0,Biomarker,C0004352,Autistic Disorder,disease,autism,3558,IL2,IL-2,CTD_human,18929414,"Low natural killer cell cytotoxic activity in autism: the role of glutathione, IL-2 and IL-15.",0.2,"Low natural killer cell cytotoxic activity in <span class=""disease"" id=""18929414-0-46-52"">autism</span>: the role of glutathione, <span class=""gene"" id=""18929414-0-79-83"">IL-2</span> and IL-15.",CTD_human
2,0,Therapeutic,C0005695,Bladder Neoplasm,disease,bladder cancer,3558,IL2,interleukin 2,CTD_human,3495671,Reduction of bladder cancer growth in mice treated with intravesical Bacillus Calmette Guerin and systemic interleukin 2.,0.201648360705279,"Reduction of <span class=""disease"" id=""3495671-0-13-27"">bladder cancer</span> growth in mice treated with intravesical Bacillus Calmette Guerin and systemic <span class=""gene"" id=""3495671-0-107-120"">interleukin 2</span>.",CTD_human
2,0,Therapeutic,C0005695,Bladder Neoplasm,disease,bladder cancer,3558,IL2,interleukin 2,CTD_human,1949363,Combined therapy of interleukin 2 with cyclophosphamide or bacillus Calmette-Guérin against implanted bladder cancer cells in mice.,0.201648360705279,"Combined therapy of <span class=""gene"" id=""1949363-0-20-33"">interleukin 2</span> with cyclophosphamide or bacillus Calmette-Gu&eacute;rin against implanted <span class=""disease"" id=""1949363-0-102-116"">bladder cancer</span> cells in mice.",CTD_human
1,0,Therapeutic,C0017636,Glioblastoma,disease,glioblastoma,3558,IL2,Interleukin-2,CTD_human,7719933,Interleukin-2 gene therapy in a patient with glioblastoma.,0.201923087489492,"<span class=""gene"" id=""7719933-0-0-13"">Interleukin-2</span> gene therapy in a patient with <span class=""disease"" id=""7719933-0-45-57"">glioblastoma</span>.",CTD_human
2,0,Biomarker,C0017658,Glomerulonephritis,disease,GN,3558,IL2,IL-2,CTD_human,10910440,"Memory cells, and IL-2 receptors also were elevated in the GN group.",0.20054945356842604,"Memory cells, and <span class=""gene"" id=""10910440-6-18-22"">IL-2</span> receptors also were elevated in the <span class=""disease"" id=""10910440-6-59-61"">GN</span> group.",CTD_human
22,0,Therapeutic,C0025202,melanoma,disease,melanoma,3558,IL2,IL-2,CTD_human,18999936,Pulse IL-2 with famotidine has activity in melanoma.,0.23426098011469,"Pulse <span class=""gene"" id=""18999936-12-6-10"">IL-2</span> with famotidine has activity in <span class=""disease"" id=""18999936-12-43-51"">melanoma</span>.",CTD_human
22,0,Therapeutic,C0025202,melanoma,disease,Melanoma,3558,IL2,interleukin-2,CTD_human,17023156,"Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: a randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group.",0.23426098011469,"Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and <span class=""gene"" id=""17023156-0-71-84"">interleukin-2</span> versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: a randomised phase II study of the European Organization for Research and Treatment of Cancer <span class=""disease"" id=""17023156-0-281-289"">Melanoma</span> Group.",CTD_human
22,0,Therapeutic,C0025202,melanoma,disease,melanoma,3558,IL2,IL-2,CTD_human,20423231,Pulse IL-2 with famotidine and cyclophosphamide produced activity in previously treated patients with melanoma and may be given on an outpatient basis to selected individuals.,0.23426098011469,"Pulse <span class=""gene"" id=""20423231-18-6-10"">IL-2</span> with famotidine and cyclophosphamide produced activity in previously treated patients with <span class=""disease"" id=""20423231-18-102-110"">melanoma</span> and may be given on an outpatient basis to selected individuals.",CTD_human
22,0,Therapeutic,C0025202,melanoma,disease,melanoma,3558,IL2,interleukin-2,CTD_human,16432458,"Twenty-three patients with advanced inoperable melanoma were hospitalized for 5-6 days for the following treatment: cisplatin 20 mg/m daily for 4 days, vinblastine 1.6 mg/m daily for 4 days and oral temozolomide 250 mg/m daily for 5 days, with 18 x 10 IU/m intravenous interleukin-2 by continuous infusion for 4 days (the dose was cut daily by 50%) and 5 x 10 U/m interferon-alfa subcutaneously daily for 5 days, repeated at 28-day intervals for a maximum of nine courses.",0.23426098011469,"Twenty-three patients with advanced inoperable <span class=""disease"" id=""16432458-2-47-55"">melanoma</span> were hospitalized for 5-6 days for the following treatment: cisplatin 20 mg/m daily for 4 days, vinblastine 1.6 mg/m daily for 4 days and oral temozolomide 250 mg/m daily for 5 days, with 18 x 10 IU/m intravenous <span class=""gene"" id=""16432458-2-269-282"">interleukin-2</span> by continuous infusion for 4 days (the dose was cut daily by 50%) and 5 x 10 U/m interferon-alfa subcutaneously daily for 5 days, repeated at 28-day intervals for a maximum of nine courses.",CTD_human
22,0,Therapeutic,C0025202,melanoma,disease,melanoma,3558,IL2,interleukin-2,CTD_human,16131448,Biochemotherapy with low doses of subcutaneous interleukin-2 in patients with melanoma: results of a phase II trial.,0.23426098011469,"Biochemotherapy with low doses of subcutaneous <span class=""gene"" id=""16131448-0-47-60"">interleukin-2</span> in patients with <span class=""disease"" id=""16131448-0-78-86"">melanoma</span>: results of a phase II trial.",CTD_human
22,0,Therapeutic,C0025202,melanoma,disease,melanoma,3558,IL2,IL-2,CTD_human,18298334,Cyclophosphamide and IL-2 with famotidine has evidence of antitumor activity in previously treated kidney cancer and melanoma.,0.23426098011469,"Cyclophosphamide and <span class=""gene"" id=""18298334-12-21-25"">IL-2</span> with famotidine has evidence of antitumor activity in previously treated kidney cancer and <span class=""disease"" id=""18298334-12-117-125"">melanoma</span>.",CTD_human
22,0,Therapeutic,C0025202,melanoma,disease,melanoma,3558,IL2,interleukin-2,CTD_human,17105418,Activity of continuous infusion plus pulse interleukin-2 with famotidine in patients with metastatic kidney cancer or melanoma previously treated with interleukin-2.,0.23426098011469,"Activity of continuous infusion plus pulse <span class=""gene"" id=""17105418-0-43-56"">interleukin-2</span> with famotidine in patients with metastatic kidney cancer or <span class=""disease"" id=""17105418-0-118-126"">melanoma</span> previously treated with <span class=""gene"" id=""17105418-0-151-164"">interleukin-2</span>.",CTD_human
1,0,Therapeutic,C0030193,Pain,phenotype,pain,3558,IL2,IL-2,CTD_human,12421473,Therapeutic applications of IL-2 may also be expanded to relieve morphine-insensitive pain.,0.2,"Therapeutic applications of <span class=""gene"" id=""12421473-8-28-32"">IL-2</span> may also be expanded to relieve morphine-insensitive <span class=""disease"" id=""12421473-8-86-90"">pain</span>.",CTD_human
1,0,Therapeutic,C0242596,"Neoplasm, Residual",phenotype,minimal residual disease,3558,IL2,IL-2,CTD_human,14654953,Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: Cytokine and gene therapy with IL-2 and GM-CSF.,0.20054945356842604,"Treatment of <span class=""disease"" id=""14654953-0-13-37"">minimal residual disease</span> after surgery or chemotherapy in mice carrying HPV16-associated tumours: Cytokine and gene therapy with <span class=""gene"" id=""14654953-0-142-146"">IL-2</span> and GM-CSF.",CTD_human
1,0,Biomarker,C0424295,Hyperactive behavior,phenotype,hyperactivity,3558,IL2,Interleukin-2,CTD_human,8241462,Interleukin-2 enhances scopolamine-induced amnesia and hyperactivity in the mouse.,0.201098907136852,"<span class=""gene"" id=""8241462-0-0-13"">Interleukin-2</span> enhances scopolamine-induced amnesia and <span class=""disease"" id=""8241462-0-55-68"">hyperactivity</span> in the mouse.",CTD_human
1,0,Biomarker,C1269683,Major Depressive Disorder,disease,major depression,3558,IL2,IL-2,CTD_human,12635532,"A reduction in NK-cell activity and DHEA levels, and an increase in IL-2 levels appear to be associated with major depression.",0.200274726784213,"A reduction in NK-cell activity and DHEA levels, and an increase in <span class=""gene"" id=""12635532-7-68-72"">IL-2</span> levels appear to be associated with <span class=""disease"" id=""12635532-7-109-125"">major depression</span>.",CTD_human
3,2,Biomarker,C0003873,Rheumatoid Arthritis,disease,RA,3559,IL2RA,CD25,CTD_human,20476861,"We observed an increased expression of full-length FoxP3 mRNA in RA patients when compared to healthy controls, as well as an increase in CD25 mRNA expression, but no corresponding increase in CTLA-4 mRNA expression.",0.21539737656162697,"We observed an increased expression of full-length FoxP3 mRNA in <span class=""disease"" id=""20476861-4-65-67"">RA</span> patients when compared to healthy controls, as well as an increase in <span class=""gene"" id=""20476861-4-138-142"">CD25</span> mRNA expression, but no corresponding increase in CTLA-4 mRNA expression.",CTD_human
3,2,Biomarker,C0003873,Rheumatoid Arthritis,disease,rheumatoid arthritis,3559,IL2RA,IL2RA,CTD_human,20453842,We also refined associations at two established rheumatoid arthritis risk loci (IL2RA and CCL21) and confirmed the association at AFF3.,0.21539737656162697,"We also refined associations at two established <span class=""disease"" id=""20453842-4-48-68"">rheumatoid arthritis</span> risk loci (<span class=""gene"" id=""20453842-4-80-85"">IL2RA</span> and CCL21) and confirmed the association at AFF3.",CTD_human
3,3,Biomarker,C0011854,"Diabetes Mellitus, Insulin-Dependent",disease,type 1 diabetes,3559,IL2RA,IL2RA,CTD_human,19119414,IL2RA genetic heterogeneity in multiple sclerosis and type 1 diabetes susceptibility and soluble interleukin-2 receptor production.,0.250182006378818,"<span class=""gene"" id=""19119414-0-0-5"">IL2RA</span> genetic heterogeneity in multiple sclerosis and <span class=""disease"" id=""19119414-0-54-69"">type 1 diabetes</span> susceptibility and soluble interleukin-2 receptor production.",CTD_human
3,3,Biomarker,C0011854,"Diabetes Mellitus, Insulin-Dependent",disease,type 1 diabetes,3559,IL2RA,IL2RA,CTD_human,17676041,Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes.,0.250182006378818,"Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the <span class=""gene"" id=""17676041-0-99-104"">IL2RA</span> region in <span class=""disease"" id=""17676041-0-115-130"">type 1 diabetes</span>.",CTD_human
3,3,Biomarker,C0011854,"Diabetes Mellitus, Insulin-Dependent",disease,T1D,3559,IL2RA,IL2RA,CTD_human,19701192,"Here we use polychromatic flow cytometry to show that differences in surface expression of the human interleukin-2 (IL-2) receptor alpha (IL2RA, or CD25) protein are restricted to particular immune cell types and correlate with several haplotypes in the IL2RA region that have previously been associated with two autoimmune diseases, type 1 diabetes (T1D) and multiple sclerosis.",0.250182006378818,"Here we use polychromatic flow cytometry to show that differences in surface expression of the human interleukin-2 (IL-2) receptor alpha (<span class=""gene"" id=""19701192-4-138-143"">IL2RA</span>, or <span class=""gene"" id=""19701192-4-148-152"">CD25</span>) protein are restricted to particular immune cell types and correlate with several haplotypes in the <span class=""gene"" id=""19701192-4-254-259"">IL2RA</span> region that have previously been associated with two autoimmune diseases, <span class=""disease"" id=""19701192-4-334-349"">type 1 diabetes</span> (<span class=""disease"" id=""19701192-4-351-354"">T1D</span>) and multiple sclerosis.",CTD_human
4,4,Biomarker,C0026769,Multiple Sclerosis,disease,multiple sclerosis,3559,IL2RA,IL2RA,CTD_human,19119414,IL2RA genetic heterogeneity in multiple sclerosis and type 1 diabetes susceptibility and soluble interleukin-2 receptor production.,0.26608577037692005,"<span class=""gene"" id=""19119414-0-0-5"">IL2RA</span> genetic heterogeneity in <span class=""disease"" id=""19119414-0-31-49"">multiple sclerosis</span> and type 1 diabetes susceptibility and soluble interleukin-2 receptor production.",CTD_human
4,4,Biomarker,C0026769,Multiple Sclerosis,disease,multiple sclerosis,3559,IL2RA,IL2RA,CTD_human,17660530,Alleles of IL2RA and IL7RA and those in the HLA locus are identified as heritable risk factors for multiple sclerosis.,0.26608577037692005,"Alleles of <span class=""gene"" id=""17660530-10-11-16"">IL2RA</span> and IL7RA and those in the HLA locus are identified as heritable risk factors for <span class=""disease"" id=""17660530-10-99-117"">multiple sclerosis</span>.",CTD_human
4,4,Biomarker,C0026769,Multiple Sclerosis,disease,MS,3559,IL2RA,IL2RA,CTD_human,19525955,"We also replicated several known MS associations (HLA-DR15, P = 7.0 x 10(-184); CD58, P = 9.6 x 10(-8); EVI5-RPL5, P = 2.5 x 10(-6); IL2RA, P = 7.4 x 10(-6); CLEC16A, P = 1.1 x 10(-4); IL7R, P = 1.3 x 10(-3); TYK2, P = 3.5 x 10(-3)) and observed a statistical interaction between SNPs in EVI5-RPL5 and HLA-DR15 (P = 0.001).",0.26608577037692005,"We also replicated several known <span class=""disease"" id=""19525955-5-33-35"">MS</span> associations (HLA-DR15, P = 7.0 x 10(-184); CD58, P = 9.6 x 10(-8); EVI5-RPL5, P = 2.5 x 10(-6); <span class=""gene"" id=""19525955-5-133-138"">IL2RA</span>, P = 7.4 x 10(-6); CLEC16A, P = 1.1 x 10(-4); IL7R, P = 1.3 x 10(-3); TYK2, P = 3.5 x 10(-3)) and observed a statistical interaction between SNPs in EVI5-RPL5 and HLA-DR15 (P = 0.001).",CTD_human
1,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,non-small cell lung cancer,356,FASLG,FasL,CTD_human,21807637,A polymorphic -844T/C in FasL promoter predicts survival and relapse in non-small cell lung cancer.,0.201098907136852,"A polymorphic -844T/C in <span class=""gene"" id=""21807637-0-25-29"">FasL</span> promoter predicts survival and relapse in <span class=""disease"" id=""21807637-0-72-98"">non-small cell lung cancer</span>.",CTD_human
2,0,Therapeutic,C0002871,Anemia,disease,anemia,3562,IL3,interleukin 3,CTD_human,12090760,Antagonism between interleukin 3 and erythropoietin in mice with azidothymidine-induced anemia and in bone marrow endothelial cells.,0.20054945356842604,"Antagonism between <span class=""gene"" id=""12090760-0-19-32"">interleukin 3</span> and erythropoietin in mice with azidothymidine-induced <span class=""disease"" id=""12090760-0-88-94"">anemia</span> and in bone marrow endothelial cells.",CTD_human
1,0,Biomarker,C0345967,Malignant mesothelioma,disease,MM,3562,IL3,IL-3,CTD_human,25162674,"A specific pattern of cytokines were found highly expressed in Asb-workers: IFN-alpha (p<0.05), EOTAXIN (p<0.01), RANTES (p<0.001), and in MM patients: IL-12(p40), IL-3, IL-1 alpha, MCP-3, beta-NGF, TNF-beta, RANTES (p<0.001).",0.2,"A specific pattern of cytokines were found highly expressed in Asb-workers: IFN-alpha (p&lt;0.05), EOTAXIN (p&lt;0.01), RANTES (p&lt;0.001), and in <span class=""disease"" id=""25162674-8-139-141"">MM</span> patients: IL-12(p40), <span class=""gene"" id=""25162674-8-164-168"">IL-3</span>, IL-1 alpha, MCP-3, beta-NGF, TNF-beta, RANTES (p&lt;0.001).",CTD_human
1,0,Biomarker,C0004096,Asthma,disease,asthmatic,3565,IL4,interleukin-4,CTD_human,18357729,These results suggest that arsenic trioxide induces T cell apoptosis and decreases interleukin-4 release in T cells of asthmatic patients in vitro and that down-regulation of Bcl-2 expression may be an important mechanism.,0.440351394001266,"These results suggest that arsenic trioxide induces T cell apoptosis and decreases <span class=""gene"" id=""18357729-14-83-96"">interleukin-4</span> release in T cells of <span class=""disease"" id=""18357729-14-119-128"">asthmatic</span> patients in vitro and that down-regulation of Bcl-2 expression may be an important mechanism.",CTD_human
3,0,Biomarker,C0004364,Autoimmune Diseases,group,autoimmunity,3565,IL4,IL-4,CTD_human,8898950,"These data further support the key role of IL-4 in HgCl2-induced autoimmunity, and suggest that failure of up-regulation of IL-4, together with higher baseline IFN-gamma expression, accounts for resistance of LEW rats to HgCl2.",0.20900047134440197,"These data further support the key role of <span class=""gene"" id=""8898950-12-43-47"">IL-4</span> in HgCl2-induced <span class=""disease"" id=""8898950-12-65-77"">autoimmunity</span>, and suggest that failure of up-regulation of <span class=""gene"" id=""8898950-12-124-128"">IL-4</span>, together with higher baseline IFN-gamma expression, accounts for resistance of LEW rats to HgCl2.",CTD_human
3,0,Biomarker,C0004364,Autoimmune Diseases,group,autoimmunity,3565,IL4,Interleukin-4,CTD_human,7871386,Interleukin-4 gene expression in mercury-induced autoimmunity.,0.20900047134440197,"<span class=""gene"" id=""7871386-0-0-13"">Interleukin-4</span> gene expression in mercury-induced <span class=""disease"" id=""7871386-0-49-61"">autoimmunity</span>.",CTD_human
3,0,Biomarker,C0004364,Autoimmune Diseases,group,autoimmunity,3565,IL4,IL-4,CTD_human,19077085,"Therefore, the attenuated autoimmunity following loss of IL-4 and IL-6 is dose-dependent, as higher doses of Hg are able to override the attenuation observed using lower doses.",0.20900047134440197,"Therefore, the attenuated <span class=""disease"" id=""19077085-7-26-38"">autoimmunity</span> following loss of <span class=""gene"" id=""19077085-7-57-61"">IL-4</span> and IL-6 is dose-dependent, as higher doses of Hg are able to override the attenuation observed using lower doses.",CTD_human
1,0,Therapeutic,C0009319,Colitis,disease,colitis,3565,IL4,interleukin-4,CTD_human,24314293,Effects of interleukin-4 or interleukin-10 gene therapy on trinitrobenzenesulfonic acid-induced murine colitis.,0.201098907136852,"Effects of <span class=""gene"" id=""24314293-0-11-24"">interleukin-4</span> or interleukin-10 gene therapy on trinitrobenzenesulfonic acid-induced murine <span class=""disease"" id=""24314293-0-103-110"">colitis</span>.",CTD_human
3,0,Biomarker,C0011615,"Dermatitis, Atopic",disease,atopic dermatitis,3565,IL4,interleukin-4,CTD_human,11886533,Anti-mycotics suppress interleukin-4 and interleukin-5 production in anti-CD3 plus anti-CD28-stimulated T cells from patients with atopic dermatitis.,0.306503117622094,"Anti-mycotics suppress <span class=""gene"" id=""11886533-0-23-36"">interleukin-4</span> and interleukin-5 production in anti-CD3 plus anti-CD28-stimulated T cells from patients with <span class=""disease"" id=""11886533-0-131-148"">atopic dermatitis</span>.",CTD_human
3,0,Biomarker,C0011615,"Dermatitis, Atopic",disease,atopic dermatitis,3565,IL4,interleukin-4,CTD_human,12230500,Ketoconazole suppresses interleukin-4 plus anti-CD40-induced IgE class switching in surface IgE negative B cells from patients with atopic dermatitis.,0.306503117622094,"Ketoconazole suppresses <span class=""gene"" id=""12230500-0-24-37"">interleukin-4</span> plus anti-CD40-induced IgE class switching in surface IgE negative B cells from patients with <span class=""disease"" id=""12230500-0-132-149"">atopic dermatitis</span>.",CTD_human
1,0,Biomarker,C0024141,"Lupus Erythematosus, Systemic",disease,systemic lupus erythematosus,3565,IL4,interleukin-4,CTD_human,18158872,Hypomethylation of interleukin-4 and -6 promoters in T cells from systemic lupus erythematosus patients.,0.21976429435440198,"Hypomethylation of <span class=""gene"" id=""18158872-0-19-32"">interleukin-4</span> and -6 promoters in T cells from <span class=""disease"" id=""18158872-0-66-94"">systemic lupus erythematosus</span> patients.",CTD_human
2,0,Biomarker,C0034069,Pulmonary Fibrosis,disease,lung fibrosis,3565,IL4,IL-4,CTD_human,12574379,"Taken together, these data suggest dual effects of IL-4 in this model of lung fibrosis: 1) limiting early recruitment of T lymphocytes, and 2) stimulation of fibrosis chronically.",0.285638237399215,"Taken together, these data suggest dual effects of <span class=""gene"" id=""12574379-8-51-55"">IL-4</span> in this model of <span class=""disease"" id=""12574379-8-73-86"">lung fibrosis</span>: 1) limiting early recruitment of T lymphocytes, and 2) stimulation of fibrosis chronically.",CTD_human
2,0,Biomarker,C0034069,Pulmonary Fibrosis,disease,lung fibrosis,3565,IL4,IL-4,CTD_human,15322207,Regulation of found in inflammatory zone 1 expression in bleomycin-induced lung fibrosis: role of IL-4/IL-13 and mediation via STAT-6.,0.285638237399215,"Regulation of found in inflammatory zone 1 expression in bleomycin-induced <span class=""disease"" id=""15322207-0-75-88"">lung fibrosis</span>: role of <span class=""gene"" id=""15322207-0-98-102"">IL-4</span>/IL-13 and mediation via STAT-6.",CTD_human
1,0,Biomarker,C0035455,Rhinitis,disease,rhinitis,3565,IL4,IL-4,CTD_human,19672097,"Ovalbumin sensitization and challenge caused rhinitis pathology including inflammatory cell infiltration, IL-4, and protein leakage in the nasal lavage fluid (NLF) and presence of inflammatory cells in nasal epithelium.",0.201648360705279,"Ovalbumin sensitization and challenge caused <span class=""disease"" id=""19672097-7-45-53"">rhinitis</span> pathology including inflammatory cell infiltration, <span class=""gene"" id=""19672097-7-106-110"">IL-4</span>, and protein leakage in the nasal lavage fluid (NLF) and presence of inflammatory cells in nasal epithelium.",CTD_human
1,0,Biomarker,C0878544,Cardiomyopathies,group,cardiomyopathy,3565,IL4,interleukin-4,CTD_human,7578376,"Other important chemotherapy-related cardiac toxicities discussed include fluorouracil-induced angina and arrhythmias, interleukin-4 induced-cardiomyopathy, and cardiotoxicity associated with autologous bone marrow transplantation procedures.",0.2,"Other important chemotherapy-related cardiac toxicities discussed include fluorouracil-induced angina and arrhythmias, <span class=""gene"" id=""7578376-9-119-132"">interleukin-4</span> induced-<span class=""disease"" id=""7578376-9-141-155"">cardiomyopathy</span>, and cardiotoxicity associated with autologous bone marrow transplantation procedures.",CTD_human
2,0,Biomarker,C0004096,Asthma,disease,asthmatic,3567,IL5,IL-5,CTD_human,7540862,IL-5 production by CD4+ T cells of asthmatic patients is suppressed by glucocorticoids and the immunosuppressants FK506 and cyclosporin A.,0.326724320987281,"<span class=""gene"" id=""7540862-0-0-4"">IL-5</span> production by CD4+ T cells of <span class=""disease"" id=""7540862-0-35-44"">asthmatic</span> patients is suppressed by glucocorticoids and the immunosuppressants FK506 and cyclosporin A.",CTD_human
2,0,Biomarker,C0011615,"Dermatitis, Atopic",disease,atopic dermatitis,3567,IL5,interleukin-5,CTD_human,11886533,Anti-mycotics suppress interleukin-4 and interleukin-5 production in anti-CD3 plus anti-CD28-stimulated T cells from patients with atopic dermatitis.,0.206304360659584,"Anti-mycotics suppress interleukin-4 and <span class=""gene"" id=""11886533-0-41-54"">interleukin-5</span> production in anti-CD3 plus anti-CD28-stimulated T cells from patients with <span class=""disease"" id=""11886533-0-131-148"">atopic dermatitis</span>.",CTD_human
2,0,Biomarker,C0014457,Eosinophilia,disease,eosinophilia,3567,IL5,interleukin 5,CTD_human,1988543,Transgenic mice expressing a B cell growth and differentiation factor gene (interleukin 5) develop eosinophilia and autoantibody production.,0.30928718724421994,"Transgenic mice expressing a B cell growth and differentiation factor gene (<span class=""gene"" id=""1988543-0-76-89"">interleukin 5</span>) develop <span class=""disease"" id=""1988543-0-99-111"">eosinophilia</span> and autoantibody production.",CTD_human
2,0,Biomarker,C0014457,Eosinophilia,disease,eosinophilia,3567,IL5,interleukin-5,CTD_human,11006010,Regulation of cyclophosphamide-induced eosinophilia in contact sensitivity: functional roles of interleukin-5-producing CD4(+) lymphocytes.,0.30928718724421994,"Regulation of cyclophosphamide-induced <span class=""disease"" id=""11006010-0-39-51"">eosinophilia</span> in contact sensitivity: functional roles of <span class=""gene"" id=""11006010-0-96-109"">interleukin-5</span>-producing CD4(+) lymphocytes.",CTD_human
1,0,Biomarker,C0034069,Pulmonary Fibrosis,disease,pulmonary fibrosis,3567,IL5,IL-5,CTD_human,17620002,Relationship between eosinophilia and levels of chemokines (CCL5 and CCL11) and IL-5 in bronchoalveolar lavage fluid of patients with mustard gas-induced pulmonary fibrosis.,0.202732912464814,"Relationship between eosinophilia and levels of chemokines (CCL5 and CCL11) and <span class=""gene"" id=""17620002-0-80-84"">IL-5</span> in bronchoalveolar lavage fluid of patients with mustard gas-induced <span class=""disease"" id=""17620002-0-154-172"">pulmonary fibrosis</span>.",CTD_human
1,0,Therapeutic,C0002622,Amnesia,disease,amnesia,3569,IL6,Interleukin-6,CTD_human,9189931,"Interleukin-6 affects scopolamine-induced amnesia, but not brain amino acid levels in mice.",0.202681755307501,"<span class=""gene"" id=""9189931-0-0-13"">Interleukin-6</span> affects scopolamine-induced <span class=""disease"" id=""9189931-0-42-49"">amnesia</span>, but not brain amino acid levels in mice.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autistic,3569,IL6,IL-6,CTD_human,8964908,"Since autoimmune response involves immune activation, the plasma levels of interferon-alpha (IFN-alpha), interferon-gamma (IFN-gamma), interleukin-12 (IL-12), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and soluble intercellular adhesion molecule-1 (sICAM-1) were measured in autistic patients and age-matched normal controls.",0.20054945356842604,"Since autoimmune response involves immune activation, the plasma levels of interferon-alpha (IFN-alpha), interferon-gamma (IFN-gamma), interleukin-12 (IL-12), <span class=""gene"" id=""8964908-2-159-172"">interleukin-6</span> (<span class=""gene"" id=""8964908-2-174-178"">IL-6</span>), tumor necrosis factor-alpha (TNF-alpha), and soluble intercellular adhesion molecule-1 (sICAM-1) were measured in <span class=""disease"" id=""8964908-2-295-303"">autistic</span> patients and age-matched normal controls.",CTD_human
1,0,Biomarker,C0004364,Autoimmune Diseases,group,autoimmunity,3569,IL6,IL-6,CTD_human,19077085,"Therefore, the attenuated autoimmunity following loss of IL-4 and IL-6 is dose-dependent, as higher doses of Hg are able to override the attenuation observed using lower doses.",0.41936022123255295,"Therefore, the attenuated <span class=""disease"" id=""19077085-7-26-38"">autoimmunity</span> following loss of IL-4 and <span class=""gene"" id=""19077085-7-66-70"">IL-6</span> is dose-dependent, as higher doses of Hg are able to override the attenuation observed using lower doses.",CTD_human;HPO
1,0,Biomarker,C0006625,Cachexia,phenotype,cachexia,3569,IL6,IL-6,CTD_human,17878525,"At the protein level, TNF-alpha was found expressed only in CIX, whereas IL-1 and IL-6 were not cachexia specific.",0.217133696204214,"At the protein level, TNF-alpha was found expressed only in CIX, whereas IL-1 and <span class=""gene"" id=""17878525-8-82-86"">IL-6</span> were not <span class=""disease"" id=""17878525-8-96-104"">cachexia</span> specific.",CTD_human
1,0,Biomarker,C0007134,Renal Cell Carcinoma,disease,renal cell carcinoma,3569,IL6,interleukin 6,CTD_human,7834629,Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody.,0.21096036061389004,"Sensitization of human <span class=""disease"" id=""7834629-0-23-43"">renal cell carcinoma</span> cells to cis-diamminedichloroplatinum(II) by anti-<span class=""gene"" id=""7834629-0-94-107"">interleukin 6</span> monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody.",CTD_human
2,0,Biomarker,C0009319,Colitis,disease,colitis,3569,IL6,IL-6,CTD_human,22410118,"Furthermore, the level of IL-6, a pleiotropic cytokine which is implicated in the pathogenesis of IBD and colitis-associated cancer, was suppressed by DPhP in rat colon tissue and serum.",0.21015053563856698,"Furthermore, the level of <span class=""gene"" id=""22410118-8-26-30"">IL-6</span>, a pleiotropic cytokine which is implicated in the pathogenesis of IBD and <span class=""disease"" id=""22410118-8-106-113"">colitis</span>-associated cancer, was suppressed by DPhP in rat colon tissue and serum.",CTD_human
6,0,Biomarker,C0011581,Depressive disorder,disease,depression,3569,IL6,interleukin-6,CTD_human,18458677,"Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment.",0.484945082115836,"Functional polymorphisms in the <span class=""gene"" id=""18458677-0-32-45"">interleukin-6</span> and serotonin transporter genes, and <span class=""disease"" id=""18458677-0-83-93"">depression</span> and fatigue induced by interferon-alpha and ribavirin treatment.",CTD_human;PSYGENET
1,0,Biomarker,C0017531,Angiolymphoid hyperplasia,disease,Castleman's disease,3569,IL6,IL-6,CTD_human,15182131,Considering the involvement of IL-6 in Castleman's disease we treated the patient with thalidomide obtaining the remission of the nephrotic syndrome.,0.20575490709115804,"Considering the involvement of <span class=""gene"" id=""15182131-4-31-35"">IL-6</span> in <span class=""disease"" id=""15182131-4-39-58"">Castleman's disease</span> we treated the patient with thalidomide obtaining the remission of the nephrotic syndrome.",CTD_human
2,0,Biomarker,C0018801,Heart failure,disease,Heart failure,3569,IL6,IL-6,CTD_human,15135663,"Heart failure due to a variety of causes is accompanied by an upregulation of cytokines, such as tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta) and interleukin-6 (IL-6).",0.205429023149632,"<span class=""disease"" id=""15135663-1-0-13"">Heart failure</span> due to a variety of causes is accompanied by an upregulation of cytokines, such as tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta) and <span class=""gene"" id=""15135663-1-171-184"">interleukin-6</span> (<span class=""gene"" id=""15135663-1-186-190"">IL-6</span>).",CTD_human
1,0,Biomarker,C0019202,Hepatolenticular Degeneration,disease,WD,3569,IL6,IL6,CTD_human,25002079,"The serum IL6 {median (IQRs), 9.42(10.92) vs. 5.2(5.34) pg/ml; P=0.001}, IL8 {12.37(10.92) vs. 5.63(5.52) pg/ml; P<0.001}, IL10 {8.33(8.3) vs. 2.05(1.37) pg/ml; P=0.001} and TNF? {6.14(8.95) vs. 3.61(3.58) pg/ml; P<0.001} were also increased in WD patients compared to controls.",0.20054945356842604,"The serum <span class=""gene"" id=""25002079-6-10-13"">IL6</span> {median (IQRs), 9.42(10.92) vs. 5.2(5.34) pg/ml; P=0.001}, IL8 {12.37(10.92) vs. 5.63(5.52) pg/ml; P&lt;0.001}, IL10 {8.33(8.3) vs. 2.05(1.37) pg/ml; P=0.001} and TNF&alpha; {6.14(8.95) vs. 3.61(3.58) pg/ml; P&lt;0.001} were also increased in <span class=""disease"" id=""25002079-6-245-247"">WD</span> patients compared to controls.",CTD_human
3,0,Biomarker,C0020429,Hyperalgesia,phenotype,hyperalgesia,3569,IL6,IL-6,CTD_human,10401557,"The ODQ potentiated hyperalgesia induced by carrageenan, bradykinin, TNF alpha, IL-1 beta, IL-6 and IL-8.",0.28,"The ODQ potentiated <span class=""disease"" id=""10401557-10-20-32"">hyperalgesia</span> induced by carrageenan, bradykinin, TNF alpha, IL-1 beta, <span class=""gene"" id=""10401557-10-91-95"">IL-6</span> and IL-8.",CTD_human
1,0,Biomarker,C0020437,Hypercalcemia,disease,hypercalcaemia,3569,IL6,interleukin-6,CTD_human,10638776,The patient had hypercalcaemia associated with increased calcitriol serum levels; circulating interleukin-6 and tumour necrosis factor alpha levels were also elevated.,0.20082418035263896,"The patient had <span class=""disease"" id=""10638776-3-16-30"">hypercalcaemia</span> associated with increased calcitriol serum levels; circulating <span class=""gene"" id=""10638776-3-94-107"">interleukin-6</span> and tumour necrosis factor alpha levels were also elevated.",CTD_human
1,0,Biomarker,C0020500,Hyperoxaluria,disease,Hox,3569,IL6,IL-6,CTD_human,16284884,"These results suggest that Hox stimulates the NF-kappaB cascade and, therefore, induces the overexpression of inflammatory mediators like IL-6, MCP-1, and RANTES.",0.2,"These results suggest that <span class=""disease"" id=""16284884-11-27-30"">Hox</span> stimulates the NF-kappaB cascade and, therefore, induces the overexpression of inflammatory mediators like <span class=""gene"" id=""16284884-11-138-142"">IL-6</span>, MCP-1, and RANTES.",CTD_human
1,0,Biomarker,C0020503,"Hyperparathyroidism, Secondary",disease,SHP,3569,IL6,IL-6,CTD_human,21350317,"All patients with SHP had low serum 1,25-dihydroxyvitamin D(3) levels and elevated serum levels of intact parathyroid hormone (iPTH), CRP and IL-6.",0.2,"All patients with <span class=""disease"" id=""21350317-7-18-21"">SHP</span> had low serum 1,25-dihydroxyvitamin D(3) levels and elevated serum levels of intact parathyroid hormone (iPTH), CRP and <span class=""gene"" id=""21350317-7-142-146"">IL-6</span>.",CTD_human
2,0,Biomarker,C0022876,Premature Obstetric Labor,phenotype,preterm labor,3569,IL6,IL-6,CTD_human,20610570,IL-6 abundance in amniotic fluid and uterine tissues increases in late gestation or with infection-associated preterm labor.,0.21210065515107002,"<span class=""gene"" id=""20610570-1-0-4"">IL-6</span> abundance in amniotic fluid and uterine tissues increases in late gestation or with infection-associated <span class=""disease"" id=""20610570-1-110-123"">preterm labor</span>.",CTD_human
2,0,Biomarker,C0022876,Premature Obstetric Labor,phenotype,preterm labor,3569,IL6,IL-6,CTD_human,22122352,"Our preliminary results suggest that vaginal progesterone might prevent spontaneous preterm labor through a mechanism involving anti-inflammatory effects on UCFs, particularly suppression of IL-6 production.",0.21210065515107002,"Our preliminary results suggest that vaginal progesterone might prevent spontaneous <span class=""disease"" id=""22122352-9-84-97"">preterm labor</span> through a mechanism involving anti-inflammatory effects on UCFs, particularly suppression of <span class=""gene"" id=""22122352-9-191-195"">IL-6</span> production.",CTD_human
3,0,Biomarker,C0023290,"Leishmaniasis, Visceral",disease,visceral leishmaniasis,3569,IL6,Interleukin 6,CTD_human,7554475,Interleukin 6 during active visceral leishmaniasis and after treatment.,0.200274726784213,"<span class=""gene"" id=""7554475-0-0-13"">Interleukin 6</span> during active <span class=""disease"" id=""7554475-0-28-50"">visceral leishmaniasis</span> and after treatment.",CTD_human
1,0,Biomarker,C0025290,Aseptic Meningitis,disease,aseptic meningitis,3569,IL6,Interleukin 6,CTD_human,10888991,Interleukin 6 may be an important mediator of trimethoprim-induced systemic adverse reaction resembling aseptic meningitis.,0.2,"<span class=""gene"" id=""10888991-0-0-13"">Interleukin 6</span> may be an important mediator of trimethoprim-induced systemic adverse reaction resembling <span class=""disease"" id=""10888991-0-104-122"">aseptic meningitis</span>.",CTD_human
3,0,Biomarker,C0026764,Multiple Myeloma,disease,multiple myeloma,3569,IL6,Interleukin-6,CTD_human,19330649,Interleukin-6-independent expression of glucocorticoid receptor is upregulated by triptolide in multiple myeloma.,0.31170995607026397,"<span class=""gene"" id=""19330649-0-0-13"">Interleukin-6</span>-independent expression of glucocorticoid receptor is upregulated by triptolide in <span class=""disease"" id=""19330649-0-96-112"">multiple myeloma</span>.",CTD_human
3,0,Biomarker,C0026764,Multiple Myeloma,disease,multiple myeloma,3569,IL6,IL-6,CTD_human,8520508,An interleukin 1 receptor antagonist blocks the IL-1-induced IL-6 paracrine production through a prostaglandin E2-related mechanism in multiple myeloma.,0.31170995607026397,"An interleukin 1 receptor antagonist blocks the IL-1-induced <span class=""gene"" id=""8520508-0-61-65"">IL-6</span> paracrine production through a prostaglandin E2-related mechanism in <span class=""disease"" id=""8520508-0-135-151"">multiple myeloma</span>.",CTD_human
1,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastasis,3569,IL6,IL-6,CTD_human,21937440,The cytokines oncostatin M (OSM) and IL-6 promote breast cancer cell migration and metastasis.,0.22578125158407997,"The cytokines oncostatin M (OSM) and <span class=""gene"" id=""21937440-1-37-41"">IL-6</span> promote breast cancer cell migration and <span class=""disease"" id=""21937440-1-83-93"">metastasis</span>.",CTD_human
2,0,Biomarker,C0028754,Obesity,disease,obesity,3569,IL6,IL-6,CTD_human,20141834,Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression.,0.37637413606369896,"Dietary and genetic <span class=""disease"" id=""20141834-0-20-27"">obesity</span> promote liver inflammation and tumorigenesis by enhancing <span class=""gene"" id=""20141834-0-86-90"">IL-6</span> and TNF expression.",CTD_human
2,0,Biomarker,C0028754,Obesity,disease,obesity,3569,IL6,IL-6,CTD_human,24042701,"Training reduced 4-HNE (-10%; P?0.04), PC (-21%; P?0.05), 8-isoprostane (-26%; P?0.02) and leptin levels (-33%; P?0.01); had a tendency to decrease IL-6 levels (-21%; P=0.07) and IR (-17%; P=0.10); and increased manganese SOD (MnSOD) levels (+47%; P?0.01).Conclusion:Endurance exercise reduced skeletal muscle-specific and systemic oxidative damage while improving IR and cytokine profile associated with obesity, independent of weight loss.",0.37637413606369896,"Training reduced 4-HNE (-10%; P?0.04), PC (-21%; P?0.05), 8-isoprostane (-26%; P?0.02) and leptin levels (-33%; P?0.01); had a tendency to decrease <span class=""gene"" id=""24042701-5-148-152"">IL-6</span> levels (-21%; P=0.07) and IR (-17%; P=0.10); and increased manganese SOD (MnSOD) levels (+47%; P?0.01).Conclusion:Endurance exercise reduced skeletal muscle-specific and systemic oxidative damage while improving IR and cytokine profile associated with <span class=""disease"" id=""24042701-5-405-412"">obesity</span>, independent of weight loss.",CTD_human
1,0,Biomarker,C0029458,"Osteoporosis, Postmenopausal",disease,postmenopausal osteoporosis,3569,IL6,IL-6,CTD_human,9032749,"Increase in cytokine production (IL-1 beta, IL-6, TNF-alpha but not IFN-gamma, GM-CSF or LIF) by stimulated whole blood cells in postmenopausal osteoporosis.",0.220355135323156,"Increase in cytokine production (IL-1 beta, <span class=""gene"" id=""9032749-0-44-48"">IL-6</span>, TNF-alpha but not IFN-gamma, GM-CSF or LIF) by stimulated whole blood cells in <span class=""disease"" id=""9032749-0-129-156"">postmenopausal osteoporosis</span>.",CTD_human
1,0,Biomarker,C0030567,Parkinson Disease,disease,Parkinson's Disease,3569,IL6,IL-6,CTD_human,21318773,"Table 1 Biochemical Alterations in Substantia Nigra of Parkinson's Disease Indicating Oxidative Stress Elevated Decreased Iron (in microglia, astrocytes, oligodendrocytes, and melanized dopamine neurons and mitochondria) GSH (GSSG unchanged); GSH/GSSG ratio decreased Mitochondrial complex I Ferritin Calcium binding protein (calbindin 28) Mitochondrial monoamine oxidase B Transferrin and transferrin receptor Lipofuscin Vitamins E and C Ubiquitin Copper Cu/Zn-superoxide dismutase Cytotoxic cytokines (TNF-a, IL-1, IL-6) Inflammatory transcription factor NFKB Heme oxygenase-1 Ratio of oxidized to reduced glutathione (GSSG/GSH) Nitric oxide Neuromelanin.",0.21127647479843104,"Table 1 Biochemical Alterations in Substantia Nigra of <span class=""disease"" id=""21318773-12-55-74"">Parkinson's Disease</span> Indicating Oxidative Stress Elevated Decreased Iron (in microglia, astrocytes, oligodendrocytes, and melanized dopamine neurons and mitochondria) GSH (GSSG unchanged); GSH/GSSG ratio decreased Mitochondrial complex I Ferritin Calcium binding protein (calbindin 28) Mitochondrial monoamine oxidase B Transferrin and transferrin receptor Lipofuscin Vitamins E and C Ubiquitin Copper Cu/Zn-superoxide dismutase Cytotoxic cytokines (TNF-a, IL-1, <span class=""gene"" id=""21318773-12-517-521"">IL-6</span>) Inflammatory transcription factor NFKB Heme oxygenase-1 Ratio of oxidized to reduced glutathione (GSSG/GSH) Nitric oxide Neuromelanin.",CTD_human
1,0,Biomarker,C0033860,Psoriasis,disease,psoriasis,3569,IL6,IL-6,CTD_human,16844318,Possible association of psoriasis and reduced bone mineral density due to increased TNF-alpha and IL-6 concentrations.,0.21336738913717804,"Possible association of <span class=""disease"" id=""16844318-0-24-33"">psoriasis</span> and reduced bone mineral density due to increased TNF-alpha and <span class=""gene"" id=""16844318-0-98-102"">IL-6</span> concentrations.",CTD_human
2,0,Biomarker,C0034069,Pulmonary Fibrosis,disease,PF,3569,IL6,IL-6,CTD_human,17266442,"There were significant differences in cytokine (IL-8, IL-1beta, IL-6, TNF-alpha, IL-12) levels of BAL fluid between patients with PF and healthy controls.",0.20783605167292002,"There were significant differences in cytokine (IL-8, IL-1beta, <span class=""gene"" id=""17266442-5-64-68"">IL-6</span>, TNF-alpha, IL-12) levels of BAL fluid between patients with <span class=""disease"" id=""17266442-5-130-132"">PF</span> and healthy controls.",CTD_human
1,0,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,3569,IL6,IL-6,CTD_human,8067274,We conclude that: (a) schizophrenia in younger people is accompanied by increased IL-6 and sIL-2R secretion; and (b) subchronic treatment with clozapine increases sIL-2R levels.,0.20783605167292002,"We conclude that: (a) <span class=""disease"" id=""8067274-6-22-35"">schizophrenia</span> in younger people is accompanied by increased <span class=""gene"" id=""8067274-6-82-86"">IL-6</span> and sIL-2R secretion; and (b) subchronic treatment with clozapine increases sIL-2R levels.",CTD_human
1,0,Biomarker,C0036572,Seizures,phenotype,seizures,3569,IL6,IL-6,CTD_human,12836160,Profound increase in sensitivity to glutamatergic- but not cholinergic agonist-induced seizures in transgenic mice with astrocyte production of IL-6.,0.20082418035263896,"Profound increase in sensitivity to glutamatergic- but not cholinergic agonist-induced <span class=""disease"" id=""12836160-0-87-95"">seizures</span> in transgenic mice with astrocyte production of <span class=""gene"" id=""12836160-0-144-148"">IL-6</span>.",CTD_human
1,0,Biomarker,C0038454,Cerebrovascular accident,group,stroke,3569,IL6,IL-6,CTD_human,18319729,"These analyses showed that IL-6 was independently associated with stroke severity as the outcome (B=3.738, P=0.036), and aspirin resistance was independently associated with IL-6 (B=0.765, P=0.005) as the outcome.",0.250068842091904,"These analyses showed that <span class=""gene"" id=""18319729-8-27-31"">IL-6</span> was independently associated with <span class=""disease"" id=""18319729-8-66-72"">stroke</span> severity as the outcome (B=3.738, P=0.036), and aspirin resistance was independently associated with <span class=""gene"" id=""18319729-8-174-178"">IL-6</span> (B=0.765, P=0.005) as the outcome.",CTD_human
1,0,Biomarker,C0151744,Myocardial Ischemia,disease,Myocardial ischemia,3569,IL6,interleukin-6,CTD_human,16286589,Myocardial ischemia induces interleukin-6 and tissue factor production in patients with coronary artery disease: a dobutamine stress echocardiography study.,0.206187690967642,"<span class=""disease"" id=""16286589-0-0-19"">Myocardial ischemia</span> induces <span class=""gene"" id=""16286589-0-28-41"">interleukin-6</span> and tissue factor production in patients with coronary artery disease: a dobutamine stress echocardiography study.",CTD_human
1,0,Biomarker,C0206698,Cholangiocarcinoma,disease,cholangiocarcinoma,3569,IL6,IL-6,CTD_human,17621267,Interleukin-6 (IL-6) is overexpressed and contributes to tumor cell growth in cholangiocarcinoma.,0.20767799458065,"<span class=""gene"" id=""17621267-1-0-13"">Interleukin-6</span> (<span class=""gene"" id=""17621267-1-15-19"">IL-6</span>) is overexpressed and contributes to tumor cell growth in <span class=""disease"" id=""17621267-1-78-96"">cholangiocarcinoma</span>.",CTD_human
1,0,Biomarker,C0948089,Acute Coronary Syndrome,disease,ACS,3569,IL6,IL-6,CTD_human,23305094,"(2) The expression of FAS, IL-6 mRNA and protein in PBMCs from the ACS group were dose-dependently inhibited by sEHi (all P<0.05).",0.220848846113937,"(2) The expression of FAS, <span class=""gene"" id=""23305094-12-27-31"">IL-6</span> mRNA and protein in PBMCs from the <span class=""disease"" id=""23305094-12-67-70"">ACS</span> group were dose-dependently inhibited by sEHi (all P&lt;0.05).",CTD_human
3,0,Biomarker,C2239176,Liver carcinoma,disease,hepatocellular carcinoma,3569,IL6,IL-6,CTD_human,20818158,"IL-6, a risk factor for hepatocellular carcinoma: FLLL32 inhibits IL-6-induced STAT3 phosphorylation in human hepatocellular cancer cells.",0.24814102104029898,"<span class=""gene"" id=""20818158-0-0-4"">IL-6</span>, a risk factor for <span class=""disease"" id=""20818158-0-24-48"">hepatocellular carcinoma</span>: FLLL32 inhibits <span class=""gene"" id=""20818158-0-66-70"">IL-6</span>-induced STAT3 phosphorylation in human hepatocellular cancer cells.",CTD_human
3,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,3569,IL6,IL-6,CTD_human,17615358,"We propose that estrogen-mediated inhibition of IL-6 production by KCs reduces liver cancer risk in females, and these findings may be used to prevent HCC in males.",0.24814102104029898,"We propose that estrogen-mediated inhibition of <span class=""gene"" id=""17615358-7-48-52"">IL-6</span> production by KCs reduces liver cancer risk in females, and these findings may be used to prevent <span class=""disease"" id=""17615358-7-151-154"">HCC</span> in males.",CTD_human
2,1,Biomarker,C0003873,Rheumatoid Arthritis,disease,rheumatoid arthritis,3570,IL6R,interleukin-6 receptor,CTD_human,16729287,"Anti-interleukin-6 receptor antibody therapy favors adrenal androgen secretion in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled study.",0.20625320350227103,"Anti-<span class=""gene"" id=""16729287-0-5-27"">interleukin-6 receptor</span> antibody therapy favors adrenal androgen secretion in patients with <span class=""disease"" id=""16729287-0-96-116"">rheumatoid arthritis</span>: a randomized, double-blind, placebo-controlled study.",CTD_human
2,1,Therapeutic,C0003873,Rheumatoid Arthritis,disease,rheumatoid arthritis,3570,IL6R,interleukin-6 receptor,CTD_human,16729287,"Anti-interleukin-6 receptor antibody therapy favors adrenal androgen secretion in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled study.",0.20625320350227103,"Anti-<span class=""gene"" id=""16729287-0-5-27"">interleukin-6 receptor</span> antibody therapy favors adrenal androgen secretion in patients with <span class=""disease"" id=""16729287-0-96-116"">rheumatoid arthritis</span>: a randomized, double-blind, placebo-controlled study.",CTD_human
1,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,NSCLC,3570,IL6R,IL-6R,CTD_human,22552503,"Therefore, we suggest that IL-6R is both a viable target for the development of CSC-directed lung cancer therapeutics and a potential CSC marker in NSCLC.",0.200274726784213,"Therefore, we suggest that <span class=""gene"" id=""22552503-12-27-32"">IL-6R</span> is both a viable target for the development of CSC-directed lung cancer therapeutics and a potential CSC marker in <span class=""disease"" id=""22552503-12-148-153"">NSCLC</span>.",CTD_human
1,0,Biomarker,C0007134,Renal Cell Carcinoma,disease,renal cell carcinoma,3570,IL6R,interleukin 6 receptor,CTD_human,7834629,Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody.,0.2,"Sensitization of human <span class=""disease"" id=""7834629-0-23-43"">renal cell carcinoma</span> cells to cis-diamminedichloroplatinum(II) by anti-interleukin 6 monoclonal antibody or anti-<span class=""gene"" id=""7834629-0-136-158"">interleukin 6 receptor</span> monoclonal antibody.",CTD_human
1,0,Biomarker,C0024312,Lymphopenia,disease,lymphopenia,3574,IL7,IL-7,CTD_human,17151827,An IL-7 splicing-defect lymphopenia mouse model revealed by genome-wide mutagenesis.,0.204381273170092,"An <span class=""gene"" id=""17151827-0-3-7"">IL-7</span> splicing-defect <span class=""disease"" id=""17151827-0-24-35"">lymphopenia</span> mouse model revealed by genome-wide mutagenesis.",CTD_human
1,0,Biomarker,C0026769,Multiple Sclerosis,disease,multiple sclerosis,3574,IL7,IL7,CTD_human,17660816,"In addition, we report altered expression of the genes encoding IL7Ralpha and its ligand, IL7, in the cerebrospinal fluid compartment of individuals with multiple sclerosis.",0.20948441237819898,"In addition, we report altered expression of the genes encoding IL7Ralpha and its ligand, <span class=""gene"" id=""17660816-6-90-93"">IL7</span>, in the cerebrospinal fluid compartment of individuals with <span class=""disease"" id=""17660816-6-154-172"">multiple sclerosis</span>.",CTD_human
4,1,Biomarker,C0026769,Multiple Sclerosis,disease,multiple sclerosis,3575,IL7R,IL7RA,CTD_human,17660530,Alleles of IL2RA and IL7RA and those in the HLA locus are identified as heritable risk factors for multiple sclerosis.,0.270280275700107,"Alleles of IL2RA and <span class=""gene"" id=""17660530-10-21-26"">IL7RA</span> and those in the HLA locus are identified as heritable risk factors for <span class=""disease"" id=""17660530-10-99-117"">multiple sclerosis</span>.",CTD_human
4,1,Biomarker,C0026769,Multiple Sclerosis,disease,multiple sclerosis,3575,IL7R,IL7R,CTD_human,17660817,Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis.,0.270280275700107,"<span class=""gene"" id=""17660817-0-0-34"">Interleukin 7 receptor alpha chain</span> (<span class=""gene"" id=""17660817-0-36-40"">IL7R</span>) shows allelic and functional association with <span class=""disease"" id=""17660817-0-88-106"">multiple sclerosis</span>.",CTD_human
4,1,Biomarker,C0026769,Multiple Sclerosis,disease,MS,3575,IL7R,IL7R,CTD_human,19525955,"We also replicated several known MS associations (HLA-DR15, P = 7.0 x 10(-184); CD58, P = 9.6 x 10(-8); EVI5-RPL5, P = 2.5 x 10(-6); IL2RA, P = 7.4 x 10(-6); CLEC16A, P = 1.1 x 10(-4); IL7R, P = 1.3 x 10(-3); TYK2, P = 3.5 x 10(-3)) and observed a statistical interaction between SNPs in EVI5-RPL5 and HLA-DR15 (P = 0.001).",0.270280275700107,"We also replicated several known <span class=""disease"" id=""19525955-5-33-35"">MS</span> associations (HLA-DR15, P = 7.0 x 10(-184); CD58, P = 9.6 x 10(-8); EVI5-RPL5, P = 2.5 x 10(-6); IL2RA, P = 7.4 x 10(-6); CLEC16A, P = 1.1 x 10(-4); <span class=""gene"" id=""19525955-5-185-189"">IL7R</span>, P = 1.3 x 10(-3); TYK2, P = 3.5 x 10(-3)) and observed a statistical interaction between SNPs in EVI5-RPL5 and HLA-DR15 (P = 0.001).",CTD_human
4,1,Biomarker,C0026769,Multiple Sclerosis,disease,multiple sclerosis,3575,IL7R,IL7R,CTD_human,17660816,Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis.,0.270280275700107,"Variation in <span class=""gene"" id=""17660816-0-13-47"">interleukin 7 receptor alpha chain</span> (<span class=""gene"" id=""17660816-0-49-53"">IL7R</span>) influences risk of <span class=""disease"" id=""17660816-0-74-92"">multiple sclerosis</span>.",CTD_human
1,0,Biomarker,C1961099,Precursor T-Cell Lymphoblastic Leukemia-Lymphoma,disease,T-ALL,3575,IL7R,IL7R,CTD_human,21892159,"Overall, our findings indicate that IL7R mutational activation is involved in human T-cell leukemogenesis, paving the way for therapeutic targeting of IL-7R-mediated signaling in T-ALL.",0.201923087489492,"Overall, our findings indicate that <span class=""gene"" id=""21892159-7-36-40"">IL7R</span> mutational activation is involved in human T-cell leukemogenesis, paving the way for therapeutic targeting of IL-7R-mediated signaling in <span class=""disease"" id=""21892159-7-179-184"">T-ALL</span>.",CTD_human
1,0,Biomarker,C0002965,"Angina, Unstable",disease,unstable angina pectoris,3576,CXCL8,interleukin-8,CTD_human,10660968,Increased plasma levels of interleukin-8 in patients with unstable angina pectoris.,0.2,"Increased plasma levels of <span class=""gene"" id=""10660968-0-27-40"">interleukin-8</span> in patients with <span class=""disease"" id=""10660968-0-58-82"">unstable angina pectoris</span>.",CTD_human
1,0,Biomarker,C0004763,Barrett Esophagus,disease,BE,3576,CXCL8,IL-8,CTD_human,15387324,"(1) COX-2, PPARgamma, HGF, gastrin, and its receptor are significantly upregulated in BE, suggesting a possible role for these factors in Barrett's carcinogenesis; (2) the increased NFkappaB activity is probably linked to increased IL-8 and COX-2 expression; and (3) PPARgamma ligands might be useful as a new therapeutic option in the prevention and treatment of Barrett's carcinoma.",0.202956482091714,"(1) COX-2, PPARgamma, HGF, gastrin, and its receptor are significantly upregulated in <span class=""disease"" id=""15387324-9-86-88"">BE</span>, suggesting a possible role for these factors in Barrett's carcinogenesis; (2) the increased NFkappaB activity is probably linked to increased <span class=""gene"" id=""15387324-9-232-236"">IL-8</span> and COX-2 expression; and (3) PPARgamma ligands might be useful as a new therapeutic option in the prevention and treatment of Barrett's carcinoma.",CTD_human
1,0,Biomarker,C0004943,Behcet Syndrome,disease,BD,3576,CXCL8,IL-8,CTD_human,8712863,The concentration of IL-8 was also found to be significantly increased in sera of patients with BD (490 (SD 470) pg/ml) compared with normal controls (97.5 (56.3) pg/ml).,0.207663639203332,"The concentration of <span class=""gene"" id=""8712863-10-21-25"">IL-8</span> was also found to be significantly increased in sera of patients with <span class=""disease"" id=""8712863-10-96-98"">BD</span> (490 (SD 470) pg/ml) compared with normal controls (97.5 (56.3) pg/ml).",CTD_human
1,0,Biomarker,C0006625,Cachexia,phenotype,cachexia,3576,CXCL8,IL-8,CTD_human,17878525,The expression of the IL-8 gene was also elevated in cachexia inducing xenografts (CIX).,0.203557092817453,"The expression of the <span class=""gene"" id=""17878525-7-22-26"">IL-8</span> gene was also elevated in <span class=""disease"" id=""17878525-7-53-61"">cachexia</span> inducing xenografts (CIX).",CTD_human
1,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,non-small cell lung carcinoma,3576,CXCL8,IL-8,CTD_human,15956251,"In the present studies, mice bearing established xenografts (A431 epidermoid carcinoma, H125 non-small cell lung carcinoma, SF767 glioblastoma, and MDA-MB-468 mammary carcinoma) were treated with efficacious and subefficacious doses of CI-1033, and plasma levels and xenograft gene expression of VEGF and IL-8 were evaluated.",0.20521980890004898,"In the present studies, mice bearing established xenografts (A431 epidermoid carcinoma, H125 <span class=""disease"" id=""15956251-4-93-122"">non-small cell lung carcinoma</span>, SF767 glioblastoma, and MDA-MB-468 mammary carcinoma) were treated with efficacious and subefficacious doses of CI-1033, and plasma levels and xenograft gene expression of VEGF and <span class=""gene"" id=""15956251-4-305-309"">IL-8</span> were evaluated.",CTD_human
1,0,Biomarker,C0007137,Squamous cell carcinoma,disease,epidermoid carcinoma,3576,CXCL8,IL-8,CTD_human,15956251,"In the present studies, mice bearing established xenografts (A431 epidermoid carcinoma, H125 non-small cell lung carcinoma, SF767 glioblastoma, and MDA-MB-468 mammary carcinoma) were treated with efficacious and subefficacious doses of CI-1033, and plasma levels and xenograft gene expression of VEGF and IL-8 were evaluated.",0.22194775325079003,"In the present studies, mice bearing established xenografts (A431 <span class=""disease"" id=""15956251-4-66-86"">epidermoid carcinoma</span>, H125 non-small cell lung carcinoma, SF767 glioblastoma, and MDA-MB-468 mammary carcinoma) were treated with efficacious and subefficacious doses of CI-1033, and plasma levels and xenograft gene expression of VEGF and <span class=""gene"" id=""15956251-4-305-309"">IL-8</span> were evaluated.",CTD_human
2,0,Biomarker,C0009324,Ulcerative Colitis,disease,UC,3576,CXCL8,IL-8,CTD_human,12133438,"(1) The expression of IL-1beta mRNA and IL-8 mRNA was increased significantly in patients with UC, as compared with that in the control specimens (P < 0.05) and had a significant positive correlation with NF-kappaB DNA binding activity (r = 0.8363, P < 0.05; r = 0.6024, P < 0.05, respectively).",0.21063447667236398,"(1) The expression of IL-1beta mRNA and <span class=""gene"" id=""12133438-9-40-44"">IL-8</span> mRNA was increased significantly in patients with <span class=""disease"" id=""12133438-9-95-97"">UC</span>, as compared with that in the control specimens (P &lt; 0.05) and had a significant positive correlation with NF-kappaB DNA binding activity (r = 0.8363, P &lt; 0.05; r = 0.6024, P &lt; 0.05, respectively).",CTD_human
2,0,Biomarker,C0009324,Ulcerative Colitis,disease,ulcerative colitis,3576,CXCL8,IL-8,CTD_human,15955209,Increased activation of NF-kappaB and high levels of the expression of interleukin (IL)-1beta mRNA and IL-8 mRNA were detected in biopsy specimens from patients with ulcerative colitis.,0.21063447667236398,"Increased activation of NF-kappaB and high levels of the expression of interleukin (IL)-1beta mRNA and <span class=""gene"" id=""15955209-8-103-107"">IL-8</span> mRNA were detected in biopsy specimens from patients with <span class=""disease"" id=""15955209-8-166-184"">ulcerative colitis</span>.",CTD_human
1,0,Biomarker,C0013080,Down Syndrome,disease,Down syndrome,3576,CXCL8,IL-8,CTD_human,16289943,"We discuss interrelationships of VIP, NT-3 and IL-8 and their potential relevance to features of the neuropathology of autism or Down syndrome.",0.200274726784213,"We discuss interrelationships of VIP, NT-3 and <span class=""gene"" id=""16289943-12-47-51"">IL-8</span> and their potential relevance to features of the neuropathology of autism or <span class=""disease"" id=""16289943-12-129-142"">Down syndrome</span>.",CTD_human
1,0,Biomarker,C0014869,Peptic Esophagitis,disease,RE,3576,CXCL8,IL-8,CTD_human,18193101,"Treatment with a proton pump inhibitor, lansoprazole reduces the mucosal levels of IL-8 mRNA and protein in GERD, including RE and NERD.",0.20383181960166602,"Treatment with a proton pump inhibitor, lansoprazole reduces the mucosal levels of <span class=""gene"" id=""18193101-10-83-87"">IL-8</span> mRNA and protein in GERD, including <span class=""disease"" id=""18193101-10-124-126"">RE</span> and NERD.",CTD_human
2,0,Biomarker,C0017168,Gastroesophageal reflux disease,disease,GERD,3576,CXCL8,IL-8,CTD_human,18193101,"Treatment with a proton pump inhibitor, lansoprazole reduces the mucosal levels of IL-8 mRNA and protein in GERD, including RE and NERD.",0.204655999954305,"Treatment with a proton pump inhibitor, lansoprazole reduces the mucosal levels of <span class=""gene"" id=""18193101-10-83-87"">IL-8</span> mRNA and protein in <span class=""disease"" id=""18193101-10-108-112"">GERD</span>, including RE and NERD.",CTD_human
1,0,Biomarker,C0019202,Hepatolenticular Degeneration,disease,WD,3576,CXCL8,IL8,CTD_human,25002079,"The serum IL6 {median (IQRs), 9.42(10.92) vs. 5.2(5.34) pg/ml; P=0.001}, IL8 {12.37(10.92) vs. 5.63(5.52) pg/ml; P<0.001}, IL10 {8.33(8.3) vs. 2.05(1.37) pg/ml; P=0.001} and TNF? {6.14(8.95) vs. 3.61(3.58) pg/ml; P<0.001} were also increased in WD patients compared to controls.",0.2,"The serum IL6 {median (IQRs), 9.42(10.92) vs. 5.2(5.34) pg/ml; P=0.001}, <span class=""gene"" id=""25002079-6-73-76"">IL8</span> {12.37(10.92) vs. 5.63(5.52) pg/ml; P&lt;0.001}, IL10 {8.33(8.3) vs. 2.05(1.37) pg/ml; P=0.001} and TNF&alpha; {6.14(8.95) vs. 3.61(3.58) pg/ml; P&lt;0.001} were also increased in <span class=""disease"" id=""25002079-6-245-247"">WD</span> patients compared to controls.",CTD_human
2,0,Biomarker,C0020429,Hyperalgesia,phenotype,hyperalgesia,3576,CXCL8,IL-8,CTD_human,10401557,"The ODQ potentiated hyperalgesia induced by carrageenan, bradykinin, TNF alpha, IL-1 beta, IL-6 and IL-8.",0.2,"The ODQ potentiated <span class=""disease"" id=""10401557-10-20-32"">hyperalgesia</span> induced by carrageenan, bradykinin, TNF alpha, IL-1 beta, IL-6 and <span class=""gene"" id=""10401557-10-100-104"">IL-8</span>.",CTD_human
2,0,Biomarker,C0020429,Hyperalgesia,phenotype,hyperalgesia,3576,CXCL8,interleukin-8,CTD_human,7881729,"Post-treatment with S14080 dose-dependently antagonized the hyperalgesia induced by prostaglandin E2, bradykinin, dopamine and by the hyperalgesic cytokines reported to be released by carrageenin (tumour necrosis factor alpha, interleukin-1 and interleukin-8).3.",0.2,"Post-treatment with S14080 dose-dependently antagonized the <span class=""disease"" id=""7881729-3-60-72"">hyperalgesia</span> induced by prostaglandin E2, bradykinin, dopamine and by the hyperalgesic cytokines reported to be released by carrageenin (tumour necrosis factor alpha, interleukin-1 and <span class=""gene"" id=""7881729-3-245-258"">interleukin-8</span>).3.",CTD_human
1,0,Biomarker,C0023283,"Leishmaniasis, Cutaneous",disease,cutaneous leishmaniasis,3576,CXCL8,interleukin-8,CTD_human,20102417,"Evaluation of localized and systemic immune responses in cutaneous leishmaniasis caused by Leishmania tropica: interleukin-8, monocyte chemotactic protein-1 and nitric oxide are major regulatory factors.",0.2,"Evaluation of localized and systemic immune responses in <span class=""disease"" id=""20102417-0-57-80"">cutaneous leishmaniasis</span> caused by Leishmania tropica: <span class=""gene"" id=""20102417-0-111-124"">interleukin-8</span>, monocyte chemotactic protein-1 and nitric oxide are major regulatory factors.",CTD_human
2,0,Biomarker,C0024117,Chronic Obstructive Airway Disease,disease,COPD,3576,CXCL8,IL-8,CTD_human,15337792,"Theophylline induced a sixfold increase in HDAC activity in COPD AM lysates and significantly enhanced dexamethasone suppression of induced IL-8 release, an effect that was blocked by the HDAC inhibitor trichostatin A.",0.21895446937907997,"Theophylline induced a sixfold increase in HDAC activity in <span class=""disease"" id=""15337792-6-60-64"">COPD</span> AM lysates and significantly enhanced dexamethasone suppression of induced <span class=""gene"" id=""15337792-6-140-144"">IL-8</span> release, an effect that was blocked by the HDAC inhibitor trichostatin A.",CTD_human
2,0,Biomarker,C0024117,Chronic Obstructive Airway Disease,disease,COPD,3576,CXCL8,IL-8,CTD_human,23099361,Aberrantly activated EGFR contributes to enhanced IL-8 expression in COPD airways epithelial cells via regulation of nuclear FoxO3A.,0.21895446937907997,"Aberrantly activated EGFR contributes to enhanced <span class=""gene"" id=""23099361-0-50-54"">IL-8</span> expression in <span class=""disease"" id=""23099361-0-69-73"">COPD</span> airways epithelial cells via regulation of nuclear FoxO3A.",CTD_human
1,0,Biomarker,C0030805,Bullous pemphigoid,disease,bullous pemphigoid,3576,CXCL8,IL-8,CTD_human,11359455,"The IL-8 release from cultured human keratinocytes, mediated by antibodies to bullous pemphigoid autoantigen 180, is inhibited by dapsone.",0.2,"The <span class=""gene"" id=""11359455-0-4-8"">IL-8</span> release from cultured human keratinocytes, mediated by antibodies to <span class=""disease"" id=""11359455-0-78-96"">bullous pemphigoid</span> autoantigen 180, is inhibited by dapsone.",CTD_human
2,0,Biomarker,C0034069,Pulmonary Fibrosis,disease,PF,3576,CXCL8,IL-8,CTD_human,17894541,IL-8 and G-CSF levels in BAL fluid correlate only with the percentage and the absolute number of neutrophils of the BAL fluid in patients with PF (p = 0.02/p = 0.01; p = 0.01/p = 0.01; respectively).,0.200274726784213,"<span class=""gene"" id=""17894541-7-0-4"">IL-8</span> and G-CSF levels in BAL fluid correlate only with the percentage and the absolute number of neutrophils of the BAL fluid in patients with <span class=""disease"" id=""17894541-7-143-145"">PF</span> (p = 0.02/p = 0.01; p = 0.01/p = 0.01; respectively).",CTD_human
2,0,Biomarker,C0034069,Pulmonary Fibrosis,disease,PF,3576,CXCL8,IL-8,CTD_human,17266442,"A significant negative correlation was observed between the percentage of D(LCO) and IL-8 levels in BAL fluid in patients with PF (r = -0.47, p = 0.04).",0.200274726784213,"A significant negative correlation was observed between the percentage of D(LCO) and <span class=""gene"" id=""17266442-7-85-89"">IL-8</span> levels in BAL fluid in patients with <span class=""disease"" id=""17266442-7-127-129"">PF</span> (r = -0.47, p = 0.04).",CTD_human
1,0,Therapeutic,C2239176,Liver carcinoma,disease,hepatocellular carcinoma,3576,CXCL8,interleukin-8,CTD_human,12432545,"The copper chelator trientine has an antiangiogenic effect against hepatocellular carcinoma, possibly through inhibition of interleukin-8 production.",0.215030105219773,"The copper chelator trientine has an antiangiogenic effect against <span class=""disease"" id=""12432545-0-67-91"">hepatocellular carcinoma</span>, possibly through inhibition of <span class=""gene"" id=""12432545-0-124-137"">interleukin-8</span> production.",CTD_human
1,0,Biomarker,C0024894,Mastitis,disease,mastitis,3579,CXCR2,CXCR2,CTD_human,16041010,Recent research conducted within our laboratory has identified a genetic marker in the CXCR2 gene associated with mastitis susceptibility.,0.2,"Recent research conducted within our laboratory has identified a genetic marker in the <span class=""gene"" id=""16041010-2-87-92"">CXCR2</span> gene associated with <span class=""disease"" id=""16041010-2-114-122"">mastitis</span> susceptibility.",CTD_human
1,0,Biomarker,C0030193,Pain,phenotype,pain,358,AQP1,Aquaporin-1,CTD_human,20018876,Aquaporin-1 tunes pain perception by interaction with Na(v)1.8 Na+ channels in dorsal root ganglion neurons.,0.200274726784213,"<span class=""gene"" id=""20018876-0-0-11"">Aquaporin-1</span> tunes <span class=""disease"" id=""20018876-0-18-22"">pain</span> perception by interaction with Na(v)1.8 Na+ channels in dorsal root ganglion neurons.",CTD_human
1,0,Biomarker,C0085548,Autosomal Recessive Polycystic Kidney Disease,disease,autosomal recessive polycystic kidney disease,358,AQP1,AQP1,CTD_human,18988797,"Our data suggest that hepatic cystogenesis in autosomal recessive polycystic kidney disease may involve increased fluid accumulation because of overexpression and abnormal location of AQP1, CFTR, and AE2 in cystic cholangiocytes.",0.200274726784213,"Our data suggest that hepatic cystogenesis in <span class=""disease"" id=""18988797-8-46-91"">autosomal recessive polycystic kidney disease</span> may involve increased fluid accumulation because of overexpression and abnormal location of <span class=""gene"" id=""18988797-8-184-188"">AQP1</span>, CFTR, and AE2 in cystic cholangiocytes.",CTD_human
1,0,Biomarker,C0003615,Appendicitis,disease,appendicitis,3586,IL10,IL-10,CTD_human,16367942,The increased IFN-gamma may support the notion of gangrenous appendicitis as an uncontrolled Th1 mediated inflammatory response and increased IL-10 may speculatively indicate the involvement of cytotoxic cells in the progression to perforation.,0.2,"The increased IFN-gamma may support the notion of gangrenous <span class=""disease"" id=""16367942-10-61-73"">appendicitis</span> as an uncontrolled Th1 mediated inflammatory response and increased <span class=""gene"" id=""16367942-10-142-147"">IL-10</span> may speculatively indicate the involvement of cytotoxic cells in the progression to perforation.",CTD_human
2,2,Biomarker,C0004943,Behcet Syndrome,disease,Beh?et's disease,3586,IL10,IL10,CTD_human,20622878,"Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Beh?et's disease.",0.413539801606765,"Genome-wide association study identifies variants in the MHC class I, <span class=""gene"" id=""20622878-0-70-74"">IL10</span>, and IL23R-IL12RB2 regions associated with <span class=""disease"" id=""20622878-0-118-134"">Beh&Ccedil;et's disease</span>.",CTD_human;ORPHANET
2,2,Biomarker,C0004943,Behcet Syndrome,disease,Beh?et's disease,3586,IL10,IL10,CTD_human,20622879,Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Beh?et's disease susceptibility loci.,0.413539801606765,"Genome-wide association studies identify IL23R-IL12RB2 and <span class=""gene"" id=""20622879-0-59-63"">IL10</span> as <span class=""disease"" id=""20622879-0-67-83"">Beh&Ccedil;et's disease</span> susceptibility loci.",CTD_human;ORPHANET
1,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,non-small cell lung cancer,3586,IL10,IL10,CTD_human,20471133,"A combination of functional polymorphisms in the CASP8, MMP1, IL10 and SEPS1 genes affects risk of non-small cell lung cancer.",0.203846174978983,"A combination of functional polymorphisms in the CASP8, MMP1, <span class=""gene"" id=""20471133-0-62-66"">IL10</span> and SEPS1 genes affects risk of <span class=""disease"" id=""20471133-0-99-125"">non-small cell lung cancer</span>.",CTD_human
4,0,Therapeutic,C0009319,Colitis,disease,colitis,3586,IL10,IL-10,CTD_human,19238344,"Loss of iNOS, studied using iNOS(-/-) mice in both TNBS-induced and IL-10(-/-) colitis models, significantly attenuated the colitis-related WISP-1 increase.",0.30443632841764895,"Loss of iNOS, studied using iNOS(-/-) mice in both TNBS-induced and <span class=""gene"" id=""19238344-6-68-73"">IL-10</span>(-/-) <span class=""disease"" id=""19238344-6-79-86"">colitis</span> models, significantly attenuated the <span class=""disease"" id=""19238344-6-124-131"">colitis</span>-related WISP-1 increase.",CTD_human
4,0,Biomarker,C0009319,Colitis,disease,colitis,3586,IL10,interleukin-10,CTD_human,24314293,Effects of interleukin-4 or interleukin-10 gene therapy on trinitrobenzenesulfonic acid-induced murine colitis.,0.30443632841764895,"Effects of interleukin-4 or <span class=""gene"" id=""24314293-0-28-42"">interleukin-10</span> gene therapy on trinitrobenzenesulfonic acid-induced murine <span class=""disease"" id=""24314293-0-103-110"">colitis</span>.",CTD_human
4,0,Biomarker,C0009319,Colitis,disease,colitis,3586,IL10,IL-10,CTD_human,22119709,Cannabinoid receptor-2 (CB2) agonist ameliorates colitis in IL-10(-/-) mice by attenuating the activation of T cells and promoting their apoptosis.,0.30443632841764895,"Cannabinoid receptor-2 (CB2) agonist ameliorates <span class=""disease"" id=""22119709-0-49-56"">colitis</span> in <span class=""gene"" id=""22119709-0-60-65"">IL-10</span>(-/-) mice by attenuating the activation of T cells and promoting their apoptosis.",CTD_human
4,0,Biomarker,C0009319,Colitis,disease,colitis,3586,IL10,IL-10,CTD_human,21807089,We report that resveratrol effectively attenuated overall clinical scores as well as various pathological markers of colitis in IL-10(-/-) mice by down regulating Th1 responses.,0.30443632841764895,"We report that resveratrol effectively attenuated overall clinical scores as well as various pathological markers of <span class=""disease"" id=""21807089-4-117-124"">colitis</span> in <span class=""gene"" id=""21807089-4-128-133"">IL-10</span>(-/-) mice by down regulating Th1 responses.",CTD_human
4,0,Therapeutic,C0009319,Colitis,disease,colitis,3586,IL10,IL-10,CTD_human,21807089,We report that resveratrol effectively attenuated overall clinical scores as well as various pathological markers of colitis in IL-10(-/-) mice by down regulating Th1 responses.,0.30443632841764895,"We report that resveratrol effectively attenuated overall clinical scores as well as various pathological markers of <span class=""disease"" id=""21807089-4-117-124"">colitis</span> in <span class=""gene"" id=""21807089-4-128-133"">IL-10</span>(-/-) mice by down regulating Th1 responses.",CTD_human
4,0,Therapeutic,C0009319,Colitis,disease,colitis,3586,IL10,interleukin-10,CTD_human,24314293,Effects of interleukin-4 or interleukin-10 gene therapy on trinitrobenzenesulfonic acid-induced murine colitis.,0.30443632841764895,"Effects of interleukin-4 or <span class=""gene"" id=""24314293-0-28-42"">interleukin-10</span> gene therapy on trinitrobenzenesulfonic acid-induced murine <span class=""disease"" id=""24314293-0-103-110"">colitis</span>.",CTD_human
4,0,Therapeutic,C0009319,Colitis,disease,colitis,3586,IL10,IL-10,CTD_human,22119709,Cannabinoid receptor-2 (CB2) agonist ameliorates colitis in IL-10(-/-) mice by attenuating the activation of T cells and promoting their apoptosis.,0.30443632841764895,"Cannabinoid receptor-2 (CB2) agonist ameliorates <span class=""disease"" id=""22119709-0-49-56"">colitis</span> in <span class=""gene"" id=""22119709-0-60-65"">IL-10</span>(-/-) mice by attenuating the activation of T cells and promoting their apoptosis.",CTD_human
4,0,Biomarker,C0009319,Colitis,disease,colitis,3586,IL10,IL-10,CTD_human,19238344,"Loss of iNOS, studied using iNOS(-/-) mice in both TNBS-induced and IL-10(-/-) colitis models, significantly attenuated the colitis-related WISP-1 increase.",0.30443632841764895,"Loss of iNOS, studied using iNOS(-/-) mice in both TNBS-induced and <span class=""gene"" id=""19238344-6-68-73"">IL-10</span>(-/-) <span class=""disease"" id=""19238344-6-79-86"">colitis</span> models, significantly attenuated the <span class=""disease"" id=""19238344-6-124-131"">colitis</span>-related WISP-1 increase.",CTD_human
2,1,Biomarker,C0009324,Ulcerative Colitis,disease,ulcerative colitis,3586,IL10,IL10,CTD_human,18836448,"Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility.",0.25092631881951,"Sequence variants in <span class=""gene"" id=""18836448-0-21-25"">IL10</span>, ARPC2 and multiple other loci contribute to <span class=""disease"" id=""18836448-0-71-89"">ulcerative colitis</span> susceptibility.",CTD_human
1,0,Biomarker,C0019202,Hepatolenticular Degeneration,disease,WD,3586,IL10,IL10,CTD_human,25002079,"The serum IL6 {median (IQRs), 9.42(10.92) vs. 5.2(5.34) pg/ml; P=0.001}, IL8 {12.37(10.92) vs. 5.63(5.52) pg/ml; P<0.001}, IL10 {8.33(8.3) vs. 2.05(1.37) pg/ml; P=0.001} and TNF? {6.14(8.95) vs. 3.61(3.58) pg/ml; P<0.001} were also increased in WD patients compared to controls.",0.200274726784213,"The serum IL6 {median (IQRs), 9.42(10.92) vs. 5.2(5.34) pg/ml; P=0.001}, IL8 {12.37(10.92) vs. 5.63(5.52) pg/ml; P&lt;0.001}, <span class=""gene"" id=""25002079-6-123-127"">IL10</span> {8.33(8.3) vs. 2.05(1.37) pg/ml; P=0.001} and TNF&alpha; {6.14(8.95) vs. 3.61(3.58) pg/ml; P&lt;0.001} were also increased in <span class=""disease"" id=""25002079-6-245-247"">WD</span> patients compared to controls.",CTD_human
2,0,Therapeutic,C0020429,Hyperalgesia,phenotype,hyperalgesia,3586,IL10,interleukin-10,CTD_human,7582491,Cytokine-mediated inflammatory hyperalgesia limited by interleukin-10.,0.28,"Cytokine-mediated inflammatory <span class=""disease"" id=""7582491-0-31-43"">hyperalgesia</span> limited by <span class=""gene"" id=""7582491-0-55-69"">interleukin-10</span>.",CTD_human
2,0,Biomarker,C0020429,Hyperalgesia,phenotype,hyperalgesia,3586,IL10,interleukin-10,CTD_human,7582491,Cytokine-mediated inflammatory hyperalgesia limited by interleukin-10.,0.28,"Cytokine-mediated inflammatory <span class=""disease"" id=""7582491-0-31-43"">hyperalgesia</span> limited by <span class=""gene"" id=""7582491-0-55-69"">interleukin-10</span>.",CTD_human
1,1,Biomarker,C0021390,Inflammatory Bowel Diseases,group,inflammatory bowel disease,3586,IL10,IL10,CTD_human,23291587,"Three risk loci shared with ankylosing spondylitis and psoriasis (the MHC class I region, ERAP1 and IL23R and the MHC class I-ERAP1 interaction), as well as two loci shared with inflammatory bowel disease (IL23R and IL10) implicate shared pathogenic pathways in the spondyloarthritides and Beh?et's disease.",0.246909410102563,"Three risk loci shared with ankylosing spondylitis and psoriasis (the MHC class I region, ERAP1 and IL23R and the MHC class I-ERAP1 interaction), as well as two loci shared with <span class=""disease"" id=""23291587-8-178-204"">inflammatory bowel disease</span> (IL23R and <span class=""gene"" id=""23291587-8-216-220"">IL10</span>) implicate shared pathogenic pathways in the spondyloarthritides and Beh&Ccedil;et's disease.",CTD_human
2,0,Biomarker,C0023281,Leishmaniasis,disease,leishmaniasis,3586,IL10,IL-10,CTD_human,20404924,Quantification of parasite load in clinical samples of leishmaniasis patients: IL-10 level correlates with parasite load in visceral leishmaniasis.,0.20629000528226699,"Quantification of parasite load in clinical samples of <span class=""disease"" id=""20404924-0-55-68"">leishmaniasis</span> patients: <span class=""gene"" id=""20404924-0-79-84"">IL-10</span> level correlates with parasite load in visceral leishmaniasis.",CTD_human
3,0,Biomarker,C0023290,"Leishmaniasis, Visceral",disease,visceral leishmaniasis,3586,IL10,Interleukin 10,CTD_human,15716043,Interleukin 10 receptor blockade--pentavalent antimony treatment in experimental visceral leishmaniasis.,0.20575490709115804,"<span class=""gene"" id=""15716043-0-0-14"">Interleukin 10</span> receptor blockade--pentavalent antimony treatment in experimental <span class=""disease"" id=""15716043-0-81-103"">visceral leishmaniasis</span>.",CTD_human
1,0,Biomarker,C0024121,Lung Neoplasms,group,lung tumor,3586,IL10,IL-10,CTD_human,14587096,Tnfa and Il-10 deficiencies have contrasting effects on lung tumor susceptibility: gender-dependent modulation of IL-10 haploinsufficiency.,0.21717049798420898,"Tnfa and <span class=""gene"" id=""14587096-0-9-14"">Il-10</span> deficiencies have contrasting effects on <span class=""disease"" id=""14587096-0-56-66"">lung tumor</span> susceptibility: gender-dependent modulation of <span class=""gene"" id=""14587096-0-114-119"">IL-10</span> haploinsufficiency.",CTD_human
2,1,Biomarker,C0024141,"Lupus Erythematosus, Systemic",disease,systemic lupus erythematosus,3586,IL10,IL10,CTD_human,19838195,"A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus.",0.31989847313318104,"A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and <span class=""gene"" id=""19838195-0-77-81"">IL10</span> as risk loci for <span class=""disease"" id=""19838195-0-99-127"">systemic lupus erythematosus</span>.",CTD_human
1,0,Therapeutic,C0243026,Sepsis,disease,sepsis,3586,IL10,IL-10,CTD_human,11441115,Adenoviral delivery of human and viral IL-10 in murine sepsis.,0.34191371145641,"Adenoviral delivery of human and viral <span class=""gene"" id=""11441115-0-39-44"">IL-10</span> in murine <span class=""disease"" id=""11441115-0-55-61"">sepsis</span>.",CTD_human
4,5,Therapeutic,C0162283,Nephrogenic Diabetes Insipidus,disease,nephrogenic diabetes insipidus,359,AQP2,AQP2,CTD_human,16121255,"Using these animals, we have directly proven this hypothesis of improper AQP2 translocation as the molecular defect in nephrogenic diabetes insipidus in the intact organism.",0.639706185315044,"Using these animals, we have directly proven this hypothesis of improper <span class=""gene"" id=""16121255-7-73-77"">AQP2</span> translocation as the molecular defect in <span class=""disease"" id=""16121255-7-119-149"">nephrogenic diabetes insipidus</span> in the intact organism.",CTD_human;HPO;ORPHANET
4,5,Therapeutic,C0162283,Nephrogenic Diabetes Insipidus,disease,nephrogenic diabetes insipidus,359,AQP2,aquaporin-2,CTD_human,18854434,Hsp90 inhibitor partially corrects nephrogenic diabetes insipidus in a conditional knock-in mouse model of aquaporin-2 mutation.,0.639706185315044,"Hsp90 inhibitor partially corrects <span class=""disease"" id=""18854434-0-35-65"">nephrogenic diabetes insipidus</span> in a conditional knock-in mouse model of <span class=""gene"" id=""18854434-0-107-118"">aquaporin-2</span> mutation.",CTD_human;HPO;ORPHANET
4,5,Biomarker,C0162283,Nephrogenic Diabetes Insipidus,disease,nephrogenic diabetes insipidus,359,AQP2,aquaporin-2,CTD_human,18854434,Hsp90 inhibitor partially corrects nephrogenic diabetes insipidus in a conditional knock-in mouse model of aquaporin-2 mutation.,0.639706185315044,"Hsp90 inhibitor partially corrects <span class=""disease"" id=""18854434-0-35-65"">nephrogenic diabetes insipidus</span> in a conditional knock-in mouse model of <span class=""gene"" id=""18854434-0-107-118"">aquaporin-2</span> mutation.",CTD_human;HPO;ORPHANET
4,5,Therapeutic,C0162283,Nephrogenic Diabetes Insipidus,disease,nephrogenic diabetes insipidus,359,AQP2,aquaporin 2,CTD_human,18653713,Novel treatment for lithium-induced nephrogenic diabetes insipidus rat model using the Sendai-virus vector carrying aquaporin 2 gene.,0.639706185315044,"Novel treatment for lithium-induced <span class=""disease"" id=""18653713-0-36-66"">nephrogenic diabetes insipidus</span> rat model using the Sendai-virus vector carrying <span class=""gene"" id=""18653713-0-116-127"">aquaporin 2</span> gene.",CTD_human;HPO;ORPHANET
4,5,Biomarker,C0162283,Nephrogenic Diabetes Insipidus,disease,nephrogenic diabetes insipidus,359,AQP2,AQP2,CTD_human,16121255,"Using these animals, we have directly proven this hypothesis of improper AQP2 translocation as the molecular defect in nephrogenic diabetes insipidus in the intact organism.",0.639706185315044,"Using these animals, we have directly proven this hypothesis of improper <span class=""gene"" id=""16121255-7-73-77"">AQP2</span> translocation as the molecular defect in <span class=""disease"" id=""16121255-7-119-149"">nephrogenic diabetes insipidus</span> in the intact organism.",CTD_human;HPO;ORPHANET
4,5,Biomarker,C0162283,Nephrogenic Diabetes Insipidus,disease,nephrogenic diabetes insipidus,359,AQP2,aquaporin 2,CTD_human,18653713,Novel treatment for lithium-induced nephrogenic diabetes insipidus rat model using the Sendai-virus vector carrying aquaporin 2 gene.,0.639706185315044,"Novel treatment for lithium-induced <span class=""disease"" id=""18653713-0-36-66"">nephrogenic diabetes insipidus</span> rat model using the Sendai-virus vector carrying <span class=""gene"" id=""18653713-0-116-127"">aquaporin 2</span> gene.",CTD_human;HPO;ORPHANET
1,0,Biomarker,C0003872,"Arthritis, Psoriatic",disease,PsA,3593,IL12B,IL12B,CTD_human,20953186,"We replicated PsA associations at HLA-C and IL12B and identified a new association at TRAF3IP2 (rs13190932, P = 8.56 × 10?¹?).",0.213250719445235,"We replicated <span class=""disease"" id=""20953186-3-14-17"">PsA</span> associations at HLA-C and <span class=""gene"" id=""20953186-3-44-49"">IL12B</span> and identified a new association at TRAF3IP2 (rs13190932, P = 8.56 &times; 10?¹?).",CTD_human
3,0,Biomarker,C0009324,Ulcerative Colitis,disease,ulcerative colitis,3593,IL12B,IL12B,CTD_human,18438406,"We also show that several risk loci are common to ulcerative colitis and Crohn's disease (IL23R, IL12B, HLA, NKX2-3 and MST1), whereas autophagy genes ATG16L1 and IRGM, along with NOD2 (also known as CARD15), are specific for Crohn's disease.",0.21215181230838298,"We also show that several risk loci are common to <span class=""disease"" id=""18438406-2-50-68"">ulcerative colitis</span> and Crohn's disease (IL23R, <span class=""gene"" id=""18438406-2-97-102"">IL12B</span>, HLA, NKX2-3 and MST1), whereas autophagy genes ATG16L1 and IRGM, along with NOD2 (also known as CARD15), are specific for Crohn's disease.",CTD_human
1,0,Biomarker,C0010346,Crohn Disease,disease,Crohn's disease,3593,IL12B,IL12B,CTD_human,18438406,"We also show that several risk loci are common to ulcerative colitis and Crohn's disease (IL23R, IL12B, HLA, NKX2-3 and MST1), whereas autophagy genes ATG16L1 and IRGM, along with NOD2 (also known as CARD15), are specific for Crohn's disease.",0.21911252647135102,"We also show that several risk loci are common to ulcerative colitis and <span class=""disease"" id=""18438406-2-73-88"">Crohn's disease</span> (IL23R, <span class=""gene"" id=""18438406-2-97-102"">IL12B</span>, HLA, NKX2-3 and MST1), whereas autophagy genes ATG16L1 and IRGM, along with NOD2 (also known as CARD15), are specific for <span class=""disease"" id=""18438406-2-226-241"">Crohn's disease</span>.",CTD_human
2,0,Biomarker,C0024141,"Lupus Erythematosus, Systemic",disease,SLE,3593,IL12B,IL12B,CTD_human,19838195,"A candidate screen of alleles previously associated with other autoimmune diseases suggested five loci (P < 1 x 10(-3)) that may contribute to SLE: IFIH1, CFB, CLEC16A, IL12B and SH2B3.",0.20591296418342803,"A candidate screen of alleles previously associated with other autoimmune diseases suggested five loci (P &lt; 1 x 10(-3)) that may contribute to <span class=""disease"" id=""19838195-5-143-146"">SLE</span>: IFIH1, CFB, CLEC16A, <span class=""gene"" id=""19838195-5-169-174"">IL12B</span> and SH2B3.",CTD_human
1,0,Biomarker,C0038013,Ankylosing spondylitis,disease,ankylosing spondylitis,3593,IL12B,IL12B,CTD_human,21743469,"Here we report the identification of three variants in the RUNX3, LTBR-TNFRSF1A and IL12B regions convincingly associated with ankylosing spondylitis (P < 5 × 10(-8) in the combined discovery and replication datasets) and a further four loci at PTGER4, TBKBP1, ANTXR2 and CARD9 that show strong association across all our datasets (P < 5 × 10(-6) overall, with support in each of the three datasets studied).",0.201373633921065,"Here we report the identification of three variants in the RUNX3, LTBR-TNFRSF1A and <span class=""gene"" id=""21743469-2-84-89"">IL12B</span> regions convincingly associated with <span class=""disease"" id=""21743469-2-127-149"">ankylosing spondylitis</span> (P &lt; 5 &times; 10(-8) in the combined discovery and replication datasets) and a further four loci at PTGER4, TBKBP1, ANTXR2 and CARD9 that show strong association across all our datasets (P &lt; 5 &times; 10(-6) overall, with support in each of the three datasets studied).",CTD_human
1,0,Biomarker,C0007134,Renal Cell Carcinoma,disease,renal cell carcinoma,3596,IL13,IL-13,CTD_human,22317767,Polymorphisms in the IL-13 and IL-4R genes are associated with the development of renal cell carcinoma.,0.201373633921065,"Polymorphisms in the <span class=""gene"" id=""22317767-0-21-26"">IL-13</span> and IL-4R genes are associated with the development of <span class=""disease"" id=""22317767-0-82-102"">renal cell carcinoma</span>.",CTD_human
2,1,Biomarker,C0011615,"Dermatitis, Atopic",disease,AD,3596,IL13,IL-13,CTD_human,22355542,These studies indicate that IL-13 induces AD and atopic march via a TSLP dependent mechanism.,0.303675981868016,"These studies indicate that <span class=""gene"" id=""22355542-6-28-33"">IL-13</span> induces <span class=""disease"" id=""22355542-6-42-44"">AD</span> and atopic march via a TSLP dependent mechanism.",CTD_human
1,0,Biomarker,C0034069,Pulmonary Fibrosis,disease,lung fibrosis,3596,IL13,IL-13,CTD_human,15322207,Regulation of found in inflammatory zone 1 expression in bleomycin-induced lung fibrosis: role of IL-4/IL-13 and mediation via STAT-6.,0.20082418035263896,"Regulation of found in inflammatory zone 1 expression in bleomycin-induced <span class=""disease"" id=""15322207-0-75-88"">lung fibrosis</span>: role of IL-4/<span class=""gene"" id=""15322207-0-103-108"">IL-13</span> and mediation via STAT-6.",CTD_human
1,0,Biomarker,C0023487,Acute Promyelocytic Leukemia,disease,acute promyelocytic leukemia,359948,IRF2BP2,IRF2BP2,CTD_human,25583766,"Identification of a novel fusion gene, IRF2BP2-RARA, in acute promyelocytic leukemia.",0.20054945356842604,"Identification of a novel fusion gene, <span class=""gene"" id=""25583766-0-39-46"">IRF2BP2</span>-RARA, in <span class=""disease"" id=""25583766-0-56-84"">acute promyelocytic leukemia</span>.",CTD_human
1,0,Biomarker,C0007137,Squamous cell carcinoma,disease,squamous cell carcinoma,360,AQP3,aquaporin 3,CTD_human,21401805,Critical role of aquaporin 3 on growth of human esophageal and oral squamous cell carcinoma.,0.20054945356842604,"Critical role of <span class=""gene"" id=""21401805-0-17-28"">aquaporin 3</span> on growth of human esophageal and oral <span class=""disease"" id=""21401805-0-68-91"">squamous cell carcinoma</span>.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,3600,IL15,IL-15,CTD_human,18929414,"Low natural killer cell cytotoxic activity in autism: the role of glutathione, IL-2 and IL-15.",0.2,"Low natural killer cell cytotoxic activity in <span class=""disease"" id=""18929414-0-46-52"">autism</span>: the role of glutathione, IL-2 and <span class=""gene"" id=""18929414-0-88-93"">IL-15</span>.",CTD_human
1,0,Biomarker,C0007570,Celiac Disease,disease,celiac disease,3600,IL15,IL-15,CTD_human,23269601,"Tofacitinib, a janus kinase inhibitor demonstrates efficacy in an IL-15 transgenic mouse model that recapitulates pathologic manifestations of celiac disease.",0.20521980890004898,"Tofacitinib, a janus kinase inhibitor demonstrates efficacy in an <span class=""gene"" id=""23269601-0-66-71"">IL-15</span> transgenic mouse model that recapitulates pathologic manifestations of <span class=""disease"" id=""23269601-0-143-157"">celiac disease</span>.",CTD_human
1,0,Biomarker,C0003873,Rheumatoid Arthritis,disease,rheumatoid arthritis,3606,IL18,Interleukin-18,CTD_human,16368150,Interleukin-18 induces the production of vascular endothelial growth factor (VEGF) in rheumatoid arthritis synovial fibroblasts via AP-1-dependent pathways.,0.236963503093246,"<span class=""gene"" id=""16368150-0-0-14"">Interleukin-18</span> induces the production of vascular endothelial growth factor (VEGF) in <span class=""disease"" id=""16368150-0-86-106"">rheumatoid arthritis</span> synovial fibroblasts via AP-1-dependent pathways.",CTD_human
1,0,Therapeutic,C0017658,Glomerulonephritis,disease,glomerulonephritis,3606,IL18,IL-18,CTD_human,18462998,Deletion of IL-18 receptor ameliorates renal injury in bovine serum albumin-induced glomerulonephritis.,0.20054945356842604,"Deletion of <span class=""gene"" id=""18462998-0-12-17"">IL-18</span> receptor ameliorates renal injury in bovine serum albumin-induced <span class=""disease"" id=""18462998-0-84-102"">glomerulonephritis</span>.",CTD_human
1,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastasis,3606,IL18,interleukin-18,CTD_human,12748951,Identification of metastasis-associated proteins by proteomic analysis and functional exploration of interleukin-18 in metastasis.,0.206304360659584,"Identification of <span class=""disease"" id=""12748951-0-18-28"">metastasis</span>-associated proteins by proteomic analysis and functional exploration of <span class=""gene"" id=""12748951-0-101-115"">interleukin-18</span> in <span class=""disease"" id=""12748951-0-119-129"">metastasis</span>.",CTD_human
1,0,Biomarker,C0036202,Sarcoidosis,disease,sarcoidosis,3606,IL18,interleukin-18,CTD_human,16100009,Endotoxin up-regulates interleukin-18: potential role for gram-negative colonization in sarcoidosis.,0.22090000327125,"Endotoxin up-regulates <span class=""gene"" id=""16100009-0-23-37"">interleukin-18</span>: potential role for gram-negative colonization in <span class=""disease"" id=""16100009-0-88-99"">sarcoidosis</span>.",CTD_human
1,0,Biomarker,C0042109,Urticaria,disease,AIU,3606,IL18,IL-18,CTD_human,18204966,A role for IL-18 in the pathogenesis of AIU is also suggested.,0.200274726784213,"A role for <span class=""gene"" id=""18204966-8-11-16"">IL-18</span> in the pathogenesis of <span class=""disease"" id=""18204966-8-40-43"">AIU</span> is also suggested.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,361,AQP4,aquaporin 4,CTD_human,18435417,Expression of astrocytic markers aquaporin 4 and connexin 43 is altered in brains of subjects with autism.,0.202732912464814,"Expression of astrocytic markers <span class=""gene"" id=""18435417-0-33-44"">aquaporin 4</span> and connexin 43 is altered in brains of subjects with <span class=""disease"" id=""18435417-0-99-105"">autism</span>.",CTD_human
2,0,Biomarker,C0027873,Neuromyelitis Optica,disease,neuromyelitis optica,361,AQP4,AQP4,CTD_human,24070676,"Two channel proteins, inwardly rectifying potassium channel 4.1 (Kir4.1) and water channel aquaporin-4 (AQP4), were recently identified as targets of an autoantibody response in patients with multiple sclerosis and neuromyelitis optica, respectively.",0.23317016400319895,"Two channel proteins, inwardly rectifying potassium channel 4.1 (Kir4.1) and water channel <span class=""gene"" id=""24070676-1-91-102"">aquaporin-4</span> (<span class=""gene"" id=""24070676-1-104-108"">AQP4</span>), were recently identified as targets of an autoantibody response in patients with multiple sclerosis and <span class=""disease"" id=""24070676-1-215-235"">neuromyelitis optica</span>, respectively.",CTD_human
2,0,Biomarker,C0027873,Neuromyelitis Optica,disease,NMO,361,AQP4,AQP4,CTD_human,18509235,"Our recent neuropathological study revealed the extensive loss of AQP4 and glial fibrillary acidic protein (GFAP), an astrocyte-specific protein, in NMO lesions, but not in MS lesions, suggesting that severe astrocytic damage or dysfunction may be related to the pathogenesis of NMO.",0.23317016400319895,"Our recent neuropathological study revealed the extensive loss of <span class=""gene"" id=""18509235-2-66-70"">AQP4</span> and glial fibrillary acidic protein (GFAP), an astrocyte-specific protein, in <span class=""disease"" id=""18509235-2-149-152"">NMO</span> lesions, but not in MS lesions, suggesting that severe astrocytic damage or dysfunction may be related to the pathogenesis of <span class=""disease"" id=""18509235-2-279-282"">NMO</span>.",CTD_human
1,0,Biomarker,C0038220,Status Epilepticus,disease,SE,361,AQP4,AQP4,CTD_human,20886625,These findings suggest that SE may induce impairments of astroglial AQP4 functions via disruption of the dystrophin/?-syntrophin complex that worsen vasogenic edema.,0.2,"These findings suggest that <span class=""disease"" id=""20886625-8-28-30"">SE</span> may induce impairments of astroglial <span class=""gene"" id=""20886625-8-68-72"">AQP4</span> functions via disruption of the dystrophin/&alpha;-syntrophin complex that worsen vasogenic edema.",CTD_human
1,0,Therapeutic,C0014544,Epilepsy,disease,epilepsy,3611,ILK,ILK,CTD_human,20064661,"Together with ILK expression and Akt activation, these molecules could be involved in hippocampal neuroprotection in epilepsy.",0.2,"Together with <span class=""gene"" id=""20064661-14-14-17"">ILK</span> expression and Akt activation, these molecules could be involved in hippocampal neuroprotection in <span class=""disease"" id=""20064661-14-117-125"">epilepsy</span>.",CTD_human
1,0,Biomarker,C0036572,Seizures,phenotype,seizures,3612,IMPA1,IMPA1,CTD_human,17460611,"Behavioral analysis of the IMPA1-/- mice indicated an increased motor activity in both the open-field test and the forced-swim test as well as a strongly increased sensitivity to pilocarpine-induced seizures, the latter supporting the idea that IMPA1 represents a physiologically relevant target for lithium.",0.2,"Behavioral analysis of the <span class=""gene"" id=""17460611-6-27-32"">IMPA1</span>-/- mice indicated an increased motor activity in both the open-field test and the forced-swim test as well as a strongly increased sensitivity to pilocarpine-induced <span class=""disease"" id=""17460611-6-199-207"">seizures</span>, the latter supporting the idea that <span class=""gene"" id=""17460611-6-245-250"">IMPA1</span> represents a physiologically relevant target for lithium.",CTD_human
1,0,Biomarker,C0009952,Febrile Convulsions,disease,febrile seizures,3613,IMPA2,IMPA2,CTD_human,15557493,Linkage and association of febrile seizures to the IMPA2 gene on human chromosome 18.,0.203231208875927,"Linkage and association of <span class=""disease"" id=""15557493-0-27-43"">febrile seizures</span> to the <span class=""gene"" id=""15557493-0-51-56"">IMPA2</span> gene on human chromosome 18.",CTD_human
2,1,Biomarker,C0035334,Retinitis Pigmentosa,disease,retinitis pigmentosa,3614,IMPDH1,IMPDH1,CTD_human,11875050,"Since many of the genes known to cause retinitis pigmentosa are under CRX control in photoreceptors, IMPDH1 became a high-priority candidate for mutation screening.",0.623358188951851,"Since many of the genes known to cause <span class=""disease"" id=""11875050-6-39-59"">retinitis pigmentosa</span> are under CRX control in photoreceptors, <span class=""gene"" id=""11875050-6-101-107"">IMPDH1</span> became a high-priority candidate for mutation screening.",CTD_human;HPO;ORPHANET
1,0,Biomarker,C0339527,Leber Congenital Amaurosis,disease,leber congenital amaurosis,3614,IMPDH1,IMPDH1,CTD_human,16384941,Spectrum and frequency of mutations in IMPDH1 associated with autosomal dominant retinitis pigmentosa and leber congenital amaurosis.,0.40082418035263895,"Spectrum and frequency of mutations in <span class=""gene"" id=""16384941-0-39-45"">IMPDH1</span> associated with autosomal dominant retinitis pigmentosa and <span class=""disease"" id=""16384941-0-106-132"">leber congenital amaurosis</span>.",CTD_human;ORPHANET
1,0,Biomarker,C0028754,Obesity,disease,obesity,3620,IDO1,IDO1,CTD_human,27020609,"Inhibition of the aryl hydrocarbon receptor prevents Western diet-induced obesity. Model for AHR activation by kynurenine via oxidized-LDL, TLR2/4, TGF?, and IDO1.",0.2,"Inhibition of the aryl hydrocarbon receptor prevents Western diet-induced <span class=""disease"" id=""27020609-0-74-81"">obesity</span>. Model for AHR activation by kynurenine via oxidized-LDL, TLR2/4, TGF&beta;, and <span class=""gene"" id=""27020609-0-158-162"">IDO1</span>.",CTD_human
1,0,Biomarker,C0002171,Alopecia Areata,disease,alopecia areata,3627,CXCL10,Cxcl10,CTD_human,22358057,"Increased expression of Cxcr3 and its ligands, Cxcl9 and Cxcl10, during the development of alopecia areata in the mouse.",0.2,"Increased expression of Cxcr3 and its ligands, Cxcl9 and <span class=""gene"" id=""22358057-0-57-63"">Cxcl10</span>, during the development of <span class=""disease"" id=""22358057-0-91-106"">alopecia areata</span> in the mouse.",CTD_human
1,0,Biomarker,C0282488,Interstitial Cystitis,disease,IC,3627,CXCL10,CXCL10,CTD_human,18957084,"Serum levels of monokine-induced by interferon-gamma (IFN-gamma) (MIG/CXCL9), IFN-gamma-inducible protein-10 (IP-10/CXCL10), and IFN-gamma-inducible T cell alpha chemoattractant (I-TAC/CXCL11) were elevated in patients with IC.",0.2,"Serum levels of monokine-induced by interferon-gamma (IFN-gamma) (MIG/CXCL9), IFN-gamma-inducible protein-10 (<span class=""gene"" id=""18957084-2-110-115"">IP-10</span>/<span class=""gene"" id=""18957084-2-116-122"">CXCL10</span>), and IFN-gamma-inducible T cell alpha chemoattractant (I-TAC/CXCL11) were elevated in patients with <span class=""disease"" id=""18957084-2-224-226"">IC</span>.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,3628,INPP1,INPP1,CTD_human,14627686,"Association of INPP1, PIK3CG, and TSC2 gene variants with autistic disorder: implications for phosphatidylinositol signalling in autism.",0.2,"Association of <span class=""gene"" id=""14627686-0-15-20"">INPP1</span>, PIK3CG, and TSC2 gene variants with <span class=""disease"" id=""14627686-0-58-75"">autistic disorder</span>: implications for phosphatidylinositol signalling in <span class=""disease"" id=""14627686-0-129-135"">autism</span>.",CTD_human
8,0,Therapeutic,C0011849,Diabetes Mellitus,group,diabetes,3630,INS,INS,CTD_human,18162506,"Insulin mutation screening in 1,044 patients with diabetes: mutations in the INS gene are a common cause of neonatal diabetes but a rare cause of diabetes diagnosed in childhood or adulthood.",0.53745302094891,"Insulin mutation screening in 1,044 patients with <span class=""disease"" id=""18162506-0-50-58"">diabetes</span>: mutations in the <span class=""gene"" id=""18162506-0-77-80"">INS</span> gene are a common cause of neonatal diabetes but a rare cause of <span class=""disease"" id=""18162506-0-146-154"">diabetes</span> diagnosed in childhood or adulthood.",CTD_human;HPO
8,0,Biomarker,C0011849,Diabetes Mellitus,group,diabetes,3630,INS,INS,CTD_human,18162506,"Insulin mutation screening in 1,044 patients with diabetes: mutations in the INS gene are a common cause of neonatal diabetes but a rare cause of diabetes diagnosed in childhood or adulthood.",0.53745302094891,"Insulin mutation screening in 1,044 patients with <span class=""disease"" id=""18162506-0-50-58"">diabetes</span>: mutations in the <span class=""gene"" id=""18162506-0-77-80"">INS</span> gene are a common cause of neonatal diabetes but a rare cause of <span class=""disease"" id=""18162506-0-146-154"">diabetes</span> diagnosed in childhood or adulthood.",CTD_human;HPO
10,0,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,type 2 diabetes,3630,INS,proinsulin,CTD_human,21779873,We hypothesised that the risk allele at the type 2 diabetes-associated missense polymorphism rs13266634 (R325W) in SLC30A8 would predict proinsulin levels in individuals at risk of type 2 diabetes and may modulate response to preventive interventions.,0.6019614210980179,"We hypothesised that the risk allele at the <span class=""disease"" id=""21779873-4-44-59"">type 2 diabetes</span>-associated missense polymorphism rs13266634 (R325W) in SLC30A8 would predict <span class=""gene"" id=""21779873-4-137-147"">proinsulin</span> levels in individuals at risk of <span class=""disease"" id=""21779873-4-181-196"">type 2 diabetes</span> and may modulate response to preventive interventions.",CTD_human;ORPHANET
10,0,Therapeutic,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,type 2 diabetes,3630,INS,proinsulin,CTD_human,21779873,We hypothesised that the risk allele at the type 2 diabetes-associated missense polymorphism rs13266634 (R325W) in SLC30A8 would predict proinsulin levels in individuals at risk of type 2 diabetes and may modulate response to preventive interventions.,0.6019614210980179,"We hypothesised that the risk allele at the <span class=""disease"" id=""21779873-4-44-59"">type 2 diabetes</span>-associated missense polymorphism rs13266634 (R325W) in SLC30A8 would predict <span class=""gene"" id=""21779873-4-137-147"">proinsulin</span> levels in individuals at risk of <span class=""disease"" id=""21779873-4-181-196"">type 2 diabetes</span> and may modulate response to preventive interventions.",CTD_human;ORPHANET
1,0,Biomarker,C0271650,Impaired glucose tolerance,phenotype,impaired glucose tolerance,3630,INS,proinsulin,CTD_human,21779873,"Individuals with impaired glucose tolerance have increased proinsulin levels, despite normal glucose or C-peptide levels.",0.20575490709115804,"Individuals with <span class=""disease"" id=""21779873-1-17-43"">impaired glucose tolerance</span> have increased <span class=""gene"" id=""21779873-1-59-69"">proinsulin</span> levels, despite normal glucose or C-peptide levels.",CTD_human
2,0,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,type 2 diabetes,3636,INPPL1,SHIP2,CTD_human,12086927,"The gene INPPL1, encoding the lipid phosphatase SHIP2, is a candidate for type 2 diabetes in rat and man.",0.202197814273705,"The gene <span class=""gene"" id=""12086927-0-9-15"">INPPL1</span>, encoding the lipid phosphatase <span class=""gene"" id=""12086927-0-48-53"">SHIP2</span>, is a candidate for <span class=""disease"" id=""12086927-0-74-89"">type 2 diabetes</span> in rat and man.",CTD_human
2,0,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,Type 2 diabetes mellitus,3636,INPPL1,SHIP2,CTD_human,25635986,Single nucleotide polymorphisms on SHIP2 is associated with Type 2 diabetes mellitus in Chinese Han population.,0.202197814273705,"Single nucleotide polymorphisms on <span class=""gene"" id=""25635986-0-35-40"">SHIP2</span> is associated with <span class=""disease"" id=""25635986-0-60-84"">Type 2 diabetes mellitus</span> in Chinese Han population.",CTD_human
1,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,3636,INPPL1,INPPL1,CTD_human,15220217,"In a cohort of 905 French type 2 diabetic patients, we found evidence of association of INPPL1 SNPs with the presence of hypertension.",0.203231208875927,"In a cohort of 905 French type 2 diabetic patients, we found evidence of association of <span class=""gene"" id=""15220217-6-88-94"">INPPL1</span> SNPs with the presence of <span class=""disease"" id=""15220217-6-121-133"">hypertension</span>.",CTD_human
1,0,Biomarker,C0524620,Metabolic Syndrome X,disease,metabolic syndrome,3636,INPPL1,SHIP2,CTD_human,15220217,"Polymorphisms in type II SH2 domain-containing inositol 5-phosphatase (INPPL1, SHIP2) are associated with physiological abnormalities of the metabolic syndrome.",0.201373633921065,"Polymorphisms in type II SH2 domain-containing inositol 5-phosphatase (<span class=""gene"" id=""15220217-0-71-77"">INPPL1</span>, <span class=""gene"" id=""15220217-0-79-84"">SHIP2</span>) are associated with physiological abnormalities of the <span class=""disease"" id=""15220217-0-141-159"">metabolic syndrome</span>.",CTD_human
1,0,Biomarker,C0028754,Obesity,disease,obese,364,AQP7,aquaporin 7,CTD_human,16325777,Differential expression of aquaporin 7 in adipose tissue of lean and obese high fat consumers.,0.202472541057918,"Differential expression of <span class=""gene"" id=""16325777-0-27-38"">aquaporin 7</span> in adipose tissue of lean and <span class=""disease"" id=""16325777-0-69-74"">obese</span> high fat consumers.",CTD_human
5,5,Biomarker,C0010417,Cryptorchidism,disease,cryptorchidism,3640,INSL3,insl3,CTD_human,16102138,"A second Leydig cell product, insl3, is also significantly down regulated and is likely responsible for the cryptorchidism commonly seen in these phthalate-treated animals.",0.499727492574407,"A second Leydig cell product, <span class=""gene"" id=""16102138-5-30-35"">insl3</span>, is also significantly down regulated and is likely responsible for the <span class=""disease"" id=""16102138-5-108-122"">cryptorchidism</span> commonly seen in these phthalate-treated animals.",CTD_human;UNIPROT
5,5,Biomarker,C0010417,Cryptorchidism,disease,cryptorchidism,3640,INSL3,insl3,CTD_human,14687758,"Targeted inactivation of the insulin-like hormone 3 (insl3) gene in male mice results in altered gubernacular development, disrupted testis decent, and cryptorchidism.",0.499727492574407,"Targeted inactivation of the insulin-like hormone 3 (<span class=""gene"" id=""14687758-1-53-58"">insl3</span>) gene in male mice results in altered gubernacular development, disrupted testis decent, and <span class=""disease"" id=""14687758-1-152-166"">cryptorchidism</span>.",CTD_human;UNIPROT
1,0,Biomarker,C0011882,Diabetic Neuropathies,group,diabetic neuropathy,3643,INSR,insulin receptor,CTD_human,18331706,Early changes in insulin receptor signaling and pain sensation in streptozotocin-induced diabetic neuropathy in rats.,0.2,"Early changes in <span class=""gene"" id=""18331706-0-17-33"">insulin receptor</span> signaling and pain sensation in streptozotocin-induced <span class=""disease"" id=""18331706-0-89-108"">diabetic neuropathy</span> in rats.",CTD_human
2,0,Biomarker,C0020459,Hyperinsulinism,disease,hyperinsulinism,3643,INSR,INSR,CTD_human,18411068,"We report on a 13-year-old girl with Donohue syndrome like dysmorphism, hyperinsulinism and prolonged survival due to two novel INSR missense mutations within the insulin binding domain.",0.410425262422781,"We report on a 13-year-old girl with Donohue syndrome like dysmorphism, <span class=""disease"" id=""18411068-3-72-87"">hyperinsulinism</span> and prolonged survival due to two novel <span class=""gene"" id=""18411068-3-128-132"">INSR</span> missense mutations within the insulin binding domain.",CTD_human;HPO
14,15,Biomarker,C0265344,Donohue Syndrome,disease,Donohue syndrome,3643,INSR,INSR,CTD_human,18411068,"We report on a 13-year-old girl with Donohue syndrome like dysmorphism, hyperinsulinism and prolonged survival due to two novel INSR missense mutations within the insulin binding domain.",0.616418094518156,"We report on a 13-year-old girl with <span class=""disease"" id=""18411068-3-37-53"">Donohue syndrome</span> like dysmorphism, hyperinsulinism and prolonged survival due to two novel <span class=""gene"" id=""18411068-3-128-132"">INSR</span> missense mutations within the insulin binding domain.",CTD_human;ORPHANET;UNIPROT
2,0,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,T2D,3651,PDX1,PDX1,CTD_human,24464100,"In addition, two missense variants in PAM, encoding p.Asp563Gly (frequency of 4.98%) and p.Ser539Trp (frequency of 0.65%), confer moderately higher risk of T2D (OR = 1.23, P = 3.9 × 10(-10) and OR = 1.47, P = 1.7 × 10(-5), respectively), and a rare (0.20%) frameshift variant in PDX1, encoding p.Gly218Alafs*12, associates with high risk of T2D (OR = 2.27, P = 7.3 × 10(-7)).",0.634011606621864,"In addition, two missense variants in PAM, encoding p.Asp563Gly (frequency of 4.98%) and p.Ser539Trp (frequency of 0.65%), confer moderately higher risk of <span class=""disease"" id=""24464100-4-156-159"">T2D</span> (OR = 1.23, P = 3.9 &times; 10(-10) and OR = 1.47, P = 1.7 &times; 10(-5), respectively), and a rare (0.20%) frameshift variant in <span class=""gene"" id=""24464100-4-279-283"">PDX1</span>, encoding p.Gly218Alafs*12, associates with high risk of <span class=""disease"" id=""24464100-4-341-344"">T2D</span> (OR = 2.27, P = 7.3 &times; 10(-7)).",CTD_human;HPO;ORPHANET
1,0,Biomarker,C1956346,Coronary Artery Disease,disease,non-CAD,3654,IRAK1,IRAK1,CTD_human,20524934,"Levels of miR-146a/b, IRAK1 mRNA, TRAF6 mRNA and TLR4 mRNA/TLR4 protein were significantly higher in the CAD group than in the non-CAD group (all P<0.01).",0.20054945356842604,"Levels of miR-146a/b, <span class=""gene"" id=""20524934-7-22-27"">IRAK1</span> mRNA, TRAF6 mRNA and TLR4 mRNA/TLR4 protein were significantly higher in the CAD group than in the <span class=""disease"" id=""20524934-7-127-134"">non-CAD</span> group (all P&lt;0.01).",CTD_human
1,0,Therapeutic,C0023418,leukemia,disease,leukemia,366,AQP9,AQP9,CTD_human,15336539,Drug uptake and pharmacological modulation of drug sensitivity in leukemia by AQP9.,0.200274726784213,"Drug uptake and pharmacological modulation of drug sensitivity in <span class=""disease"" id=""15336539-0-66-74"">leukemia</span> by <span class=""gene"" id=""15336539-0-78-82"">AQP9</span>.",CTD_human
1,0,Biomarker,C0023487,Acute Promyelocytic Leukemia,disease,acute promyelocytic leukemia,366,AQP9,Aquaporin 9,CTD_human,23563754,"Aquaporin 9, a promising predictor for the cytocidal effects of arsenic trioxide in acute promyelocytic leukemia cell lines and primary blasts.",0.20082418035263896,"<span class=""gene"" id=""23563754-0-0-11"">Aquaporin 9</span>, a promising predictor for the cytocidal effects of arsenic trioxide in <span class=""disease"" id=""23563754-0-84-112"">acute promyelocytic leukemia</span> cell lines and primary blasts.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,3660,IRF2,IRF2,CTD_human,22561517,"We found new recurrent alterations in four genes (ARID1A, RPS6KA3, NFE2L2 and IRF2) not previously described in HCC.",0.20054945356842604,"We found new recurrent alterations in four genes (ARID1A, RPS6KA3, NFE2L2 and <span class=""gene"" id=""22561517-4-78-82"">IRF2</span>) not previously described in <span class=""disease"" id=""22561517-4-112-115"">HCC</span>.",CTD_human
1,2,Biomarker,C0023434,Chronic Lymphocytic Leukemia,disease,CLL,3662,IRF4,IRF4,CTD_human,18758461,"We identified six previously unreported CLL risk loci at 2q13 (rs17483466; P = 2.36 x 10(-10)), 2q37.1 (rs13397985, SP140; P = 5.40 x 10(-10)), 6p25.3 (rs872071, IRF4; P = 1.91 x 10(-20)), 11q24.1 (rs735665; P = 3.78 x 10(-12)), 15q23 (rs7176508; P = 4.54 x 10(-12)) and 19q13.32 (rs11083846, PRKD2; P = 3.96 x 10(-9)).",0.21182592836685699,"We identified six previously unreported <span class=""disease"" id=""18758461-2-40-43"">CLL</span> risk loci at 2q13 (rs17483466; P = 2.36 x 10(-10)), 2q37.1 (rs13397985, SP140; P = 5.40 x 10(-10)), 6p25.3 (rs872071, <span class=""gene"" id=""18758461-2-162-166"">IRF4</span>; P = 1.91 x 10(-20)), 11q24.1 (rs735665; P = 3.78 x 10(-12)), 15q23 (rs7176508; P = 4.54 x 10(-12)) and 19q13.32 (rs11083846, PRKD2; P = 3.96 x 10(-9)).",CTD_human
1,0,Biomarker,C0026764,Multiple Myeloma,disease,multiple myeloma,3662,IRF4,IRF4,CTD_human,18568025,IRF4 addiction in multiple myeloma.,0.21113277308347697,"<span class=""gene"" id=""18568025-0-0-4"">IRF4</span> addiction in <span class=""disease"" id=""18568025-0-18-34"">multiple myeloma</span>.",CTD_human
2,3,Biomarker,C0024141,"Lupus Erythematosus, Systemic",disease,SLE,3663,IRF5,IRF5,CTD_human,18204446,"Aside from the expected strong association between SLE and the HLA region on chromosome 6p21 and the previously confirmed non-HLA locus IRF5 on chromosome 7q32, we found evidence of association with replication (1.1 x 10(-7) < P(overall) < 1.6 x 10(-23); odds ratio = 0.82-1.62) in four regions: 16p11.2 (ITGAM), 11p15.5 (KIAA1542), 3p14.3 (PXK) and 1q25.1 (rs10798269).",0.30987437694354103,"Aside from the expected strong association between <span class=""disease"" id=""18204446-3-51-54"">SLE</span> and the HLA region on chromosome 6p21 and the previously confirmed non-HLA locus <span class=""gene"" id=""18204446-3-136-140"">IRF5</span> on chromosome 7q32, we found evidence of association with replication (1.1 x 10(-7) &lt; P(overall) &lt; 1.6 x 10(-23); odds ratio = 0.82-1.62) in four regions: 16p11.2 (ITGAM), 11p15.5 (KIAA1542), 3p14.3 (PXK) and 1q25.1 (rs10798269).",CTD_human
3,1,Biomarker,C0008924,Cleft Lip,disease,cleft lip,3664,IRF6,IRF6,CTD_human,20436469,"SNPs near two genes not previously associated with cleft lip with and without cleft palate (MAFB, most significant SNP rs13041247, with odds ratio (OR) per minor allele = 0.704, 95% CI 0.635-0.778, P = 1.44 x 10(-11); and ABCA4, most significant SNP rs560426, with OR = 1.432, 95% CI 1.292-1.587, P = 5.01 x 10(-12)) and two previously identified regions (at chromosome 8q24 and IRF6) attained genome-wide significance.",0.649249247359597,"SNPs near two genes not previously associated with <span class=""disease"" id=""20436469-2-51-60"">cleft lip</span> with and without cleft palate (MAFB, most significant SNP rs13041247, with odds ratio (OR) per minor allele = 0.704, 95% CI 0.635-0.778, P = 1.44 x 10(-11); and ABCA4, most significant SNP rs560426, with OR = 1.432, 95% CI 1.292-1.587, P = 5.01 x 10(-12)) and two previously identified regions (at chromosome 8q24 and <span class=""gene"" id=""20436469-2-379-383"">IRF6</span>) attained genome-wide significance.",CTD_human;HPO;ORPHANET
3,1,Biomarker,C0008924,Cleft Lip,disease,cleft lip,3664,IRF6,IRF6,CTD_human,18836445,Disruption of an AP-2alpha binding site in an IRF6 enhancer is associated with cleft lip.,0.649249247359597,"Disruption of an AP-2alpha binding site in an <span class=""gene"" id=""18836445-0-46-50"">IRF6</span> enhancer is associated with <span class=""disease"" id=""18836445-0-79-88"">cleft lip</span>.",CTD_human;HPO;ORPHANET
12,14,Biomarker,C0175697,Van der Woude syndrome,disease,Van der Woude syndrome,3664,IRF6,IRF6,CTD_human,16998136,Novel IRF6 mutations in Chinese patients with Van der Woude syndrome.,0.697242274870795,"Novel <span class=""gene"" id=""16998136-0-6-10"">IRF6</span> mutations in Chinese patients with <span class=""disease"" id=""16998136-0-46-68"">Van der Woude syndrome</span>.",CTD_human;ORPHANET;UNIPROT
12,14,Biomarker,C0175697,Van der Woude syndrome,disease,Van der Woude syndrome,3664,IRF6,IRF6,CTD_human,16211254,Identification of novel mutations of IRF6 gene in Chinese families with Van der Woude syndrome.,0.697242274870795,"Identification of novel mutations of <span class=""gene"" id=""16211254-0-37-41"">IRF6</span> gene in Chinese families with <span class=""disease"" id=""16211254-0-72-94"">Van der Woude syndrome</span>.",CTD_human;ORPHANET;UNIPROT
12,14,Biomarker,C0175697,Van der Woude syndrome,disease,Van der Woude syndrome,3664,IRF6,IRF6,CTD_human,18813858,Novel mutations in the IRF6 gene in Brazilian families with Van der Woude syndrome.,0.697242274870795,"Novel mutations in the <span class=""gene"" id=""18813858-0-23-27"">IRF6</span> gene in Brazilian families with <span class=""disease"" id=""18813858-0-60-82"">Van der Woude syndrome</span>.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0011849,Diabetes Mellitus,group,diabetes,3667,IRS1,IRS-1,CTD_human,10591678,"Besides the increased frequency of diabetes, carriers showed a more atherogenic lipid profile, suggesting a potential role of the IRS-1 gene in the pathogenesis of lipid abnormalities associated with CAD.",0.21009937848125498,"Besides the increased frequency of <span class=""disease"" id=""10591678-15-35-43"">diabetes</span>, carriers showed a more atherogenic lipid profile, suggesting a potential role of the <span class=""gene"" id=""10591678-15-130-135"">IRS-1</span> gene in the pathogenesis of lipid abnormalities associated with CAD.",CTD_human
7,1,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,noninsulin-dependent diabetes mellitus,3667,IRS1,insulin receptor substrate-1,CTD_human,8723689,Deletion of Gly723 in the insulin receptor substrate-1 of a patient with noninsulin-dependent diabetes mellitus.,0.669945219479228,"Deletion of Gly723 in the <span class=""gene"" id=""8723689-0-26-54"">insulin receptor substrate-1</span> of a patient with <span class=""disease"" id=""8723689-0-73-111"">noninsulin-dependent diabetes mellitus</span>.",CTD_human;UNIPROT
7,1,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,type 2 diabetes,3667,IRS1,insulin receptor substrate-1,CTD_human,12679424,A novel T608R missense mutation in insulin receptor substrate-1 identified in a subject with type 2 diabetes impairs metabolic insulin signaling.,0.669945219479228,"A novel T608R missense mutation in <span class=""gene"" id=""12679424-0-35-63"">insulin receptor substrate-1</span> identified in a subject with <span class=""disease"" id=""12679424-0-93-108"">type 2 diabetes</span> impairs metabolic insulin signaling.",CTD_human;UNIPROT
7,1,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,type 2 diabetes,3667,IRS1,IRS1,CTD_human,19734900,"Genetic variant near IRS1 is associated with type 2 diabetes, insulin resistance and hyperinsulinemia.",0.669945219479228,"Genetic variant near <span class=""gene"" id=""19734900-0-21-25"">IRS1</span> is associated with <span class=""disease"" id=""19734900-0-45-60"">type 2 diabetes</span>, insulin resistance and hyperinsulinemia.",CTD_human;UNIPROT
7,1,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,type 2 diabetes mellitus,3667,IRS1,IRS-1,CTD_human,15688983,"Of these, the gene encoding insulin receptor substrate-1 (IRS-1), the protein product of which has been previously reported to be decreased, missing, altered, or defective in persons with type 2 diabetes mellitus, was evaluated by real time quantitative PCR to corroborate the array data.",0.669945219479228,"Of these, the gene encoding <span class=""gene"" id=""15688983-5-28-56"">insulin receptor substrate-1</span> (<span class=""gene"" id=""15688983-5-58-63"">IRS-1</span>), the protein product of which has been previously reported to be decreased, missing, altered, or defective in persons with <span class=""disease"" id=""15688983-5-188-212"">type 2 diabetes mellitus</span>, was evaluated by real time quantitative PCR to corroborate the array data.",CTD_human;UNIPROT
7,1,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,non-insulin-dependent diabetes mellitus,3667,IRS1,insulin receptor substrate-1,CTD_human,8104271,Aminoacid polymorphisms of insulin receptor substrate-1 in non-insulin-dependent diabetes mellitus.,0.669945219479228,"Aminoacid polymorphisms of <span class=""gene"" id=""8104271-0-27-55"">insulin receptor substrate-1</span> in <span class=""disease"" id=""8104271-0-59-98"">non-insulin-dependent diabetes mellitus</span>.",CTD_human;UNIPROT
7,1,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,type 2 diabetes,3667,IRS1,IRS-1,CTD_human,10430617,"The most prevalent IRS-1 variant, a Gly-->Arg change at the codon 972, has been reported to be increased in prevalence among patients with type 2 diabetes.",0.669945219479228,"The most prevalent <span class=""gene"" id=""10430617-2-19-24"">IRS-1</span> variant, a Gly--&gt;Arg change at the codon 972, has been reported to be increased in prevalence among patients with <span class=""disease"" id=""10430617-2-139-154"">type 2 diabetes</span>.",CTD_human;UNIPROT
1,0,Biomarker,C0020459,Hyperinsulinism,disease,hyperinsulinemia,3667,IRS1,IRS1,CTD_human,19734900,"Genetic variant near IRS1 is associated with type 2 diabetes, insulin resistance and hyperinsulinemia.",0.201923087489492,"Genetic variant near <span class=""gene"" id=""19734900-0-21-25"">IRS1</span> is associated with type 2 diabetes, insulin resistance and <span class=""disease"" id=""19734900-0-85-101"">hyperinsulinemia</span>.",CTD_human
1,0,Biomarker,C0028754,Obesity,disease,Obese,3667,IRS1,Irs1,CTD_human,23954404,"Obese mouse ovaries had decreased Irs1, Foxo3a, Cyp2e1, MiR-103, and MiR-21 but increased Kitlg, Akt1, and miR-184 levels relative to lean littermates.",0.29951827832482397,"<span class=""disease"" id=""23954404-4-0-5"">Obese</span> mouse ovaries had decreased <span class=""gene"" id=""23954404-4-34-38"">Irs1</span>, Foxo3a, Cyp2e1, MiR-103, and MiR-21 but increased Kitlg, Akt1, and miR-184 levels relative to lean littermates.",CTD_human
1,0,Biomarker,C1956346,Coronary Artery Disease,disease,coronary artery disease,3667,IRS1,insulin receptor substrate-1,CTD_human,10591678,A common mutation of the insulin receptor substrate-1 gene is a risk factor for coronary artery disease.,0.20728659810449399,"A common mutation of the <span class=""gene"" id=""10591678-0-25-53"">insulin receptor substrate-1</span> gene is a risk factor for <span class=""disease"" id=""10591678-0-80-103"">coronary artery disease</span>.",CTD_human
2,0,Biomarker,C2239176,Liver carcinoma,disease,hepatocellular carcinoma,3667,IRS1,insulin receptor substrate-1,CTD_human,1311924,Cloning and increased expression of an insulin receptor substrate-1-like gene in human hepatocellular carcinoma.,0.20357144819477,"Cloning and increased expression of an <span class=""gene"" id=""1311924-0-39-67"">insulin receptor substrate-1</span>-like gene in human <span class=""disease"" id=""1311924-0-87-111"">hepatocellular carcinoma</span>.",CTD_human
1,0,Biomarker,C0004114,Astrocytoma,disease,astrocytic neoplasm,367,AR,AR,CTD_human,24680642,"In this study, the expression of AR, ERs, and SRCs, and the possible roles of them in astrocytic neoplasm were evaluated and compared to normal brain tissues by nickel-intensified immunohistochemistry with tissue microarrays.",0.2,"In this study, the expression of <span class=""gene"" id=""24680642-3-33-35"">AR</span>, ERs, and SRCs, and the possible roles of them in <span class=""disease"" id=""24680642-3-86-105"">astrocytic neoplasm</span> were evaluated and compared to normal brain tissues by nickel-intensified immunohistochemistry with tissue microarrays.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,367,AR,AR,CTD_human,19167832,"The results lend some support for an influence of the studied polymorphisms on the susceptibility for autism, but argue against the possibility that mutations in the AR gene are common in subjects with this condition.",0.20591296418342803,"The results lend some support for an influence of the studied polymorphisms on the susceptibility for <span class=""disease"" id=""19167832-9-102-108"">autism</span>, but argue against the possibility that mutations in the <span class=""gene"" id=""19167832-9-166-168"">AR</span> gene are common in subjects with this condition.",CTD_human
1,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,367,AR,androgen receptor,CTD_human,10523385,Gender differences in hypertension in spontaneously hypertensive rats: role of androgens and androgen receptor.,0.28268175530750106,"Gender differences in <span class=""disease"" id=""10523385-0-22-34"">hypertension</span> in spontaneously hypertensive rats: role of androgens and <span class=""gene"" id=""10523385-0-93-110"">androgen receptor</span>.",CTD_human
3,0,Biomarker,C0021364,Male infertility,phenotype,male infertility,367,AR,androgen receptor,CTD_human,18554162,"Thus in a very near future, for a comprehensive male infertility panel, it will be essential to include additional genetic tests, such as CFTR gene mutations, sperm mitochondrial DNA mutations, and androgen receptor gene mutations, besides the conventional chromosomal analyses, Y chromosome microdeletion detection, and sperm-FISH analyses.",0.26920030956090396,"Thus in a very near future, for a comprehensive <span class=""disease"" id=""18554162-11-48-64"">male infertility</span> panel, it will be essential to include additional genetic tests, such as CFTR gene mutations, sperm mitochondrial DNA mutations, and <span class=""gene"" id=""18554162-11-198-215"">androgen receptor</span> gene mutations, besides the conventional chromosomal analyses, Y chromosome microdeletion detection, and sperm-FISH analyses.",CTD_human
3,0,Biomarker,C0021364,Male infertility,phenotype,male infertility,367,AR,AR,CTD_human,12220434,"Y chromosome microdeletions contribute to male infertility in our azoospermic population, and the mean length of the AR-CAG is significantly longer in our infertile population than in fertile men.",0.26920030956090396,"Y chromosome microdeletions contribute to <span class=""disease"" id=""12220434-9-42-58"">male infertility</span> in our azoospermic population, and the mean length of the <span class=""gene"" id=""12220434-9-117-119"">AR</span>-CAG is significantly longer in our infertile population than in fertile men.",CTD_human
1,0,Biomarker,C0023418,leukemia,disease,leukemia,367,AR,Androgen receptor,CTD_human,19235587,Androgen receptor CpG island methylation status in human leukemia cancer cells.,0.20054945356842604,"<span class=""gene"" id=""19235587-0-0-17"">Androgen receptor</span> CpG island methylation status in human <span class=""disease"" id=""19235587-0-57-65"">leukemia</span> cancer cells.",CTD_human
1,0,Biomarker,C0282612,Prostatic Intraepithelial Neoplasias,disease,prostatic intraepithelial neoplasia,367,AR,androgen receptor,CTD_human,20601956,"Finally, unlike normal prostate epithelium, prostatic intraepithelial neoplasia cells showed strong coexpression of androgen receptor and TOP2B.",0.204655999954305,"Finally, unlike normal prostate epithelium, <span class=""disease"" id=""20601956-5-44-79"">prostatic intraepithelial neoplasia</span> cells showed strong coexpression of <span class=""gene"" id=""20601956-5-116-133"">androgen receptor</span> and TOP2B.",CTD_human
1,0,Therapeutic,C2239176,Liver carcinoma,disease,hepatocellular carcinoma,367,AR,Androgen receptor,CTD_human,18639551,Androgen receptor is a new potential therapeutic target for the treatment of hepatocellular carcinoma.,0.21714805158153103,"<span class=""gene"" id=""18639551-0-0-17"">Androgen receptor</span> is a new potential therapeutic target for the treatment of <span class=""disease"" id=""18639551-0-77-101"">hepatocellular carcinoma</span>.",CTD_human
1,0,Biomarker,C0005695,Bladder Neoplasm,disease,Bladder Cancer,3670,ISL1,ISL1,CTD_human,26332997,Methylation of HOXA9 and ISL1 Predicts Patient Outcome in High-Grade Non-Invasive Bladder Cancer.,0.200274726784213,"Methylation of HOXA9 and <span class=""gene"" id=""26332997-0-25-29"">ISL1</span> Predicts Patient Outcome in High-Grade Non-Invasive <span class=""disease"" id=""26332997-0-82-96"">Bladder Cancer</span>.",CTD_human
1,0,Biomarker,C0023434,Chronic Lymphocytic Leukemia,disease,CLL,3676,ITGA4,CD49d,CTD_human,21093051,CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL.,0.21909358547370103,"<span class=""gene"" id=""21093051-0-0-5"">CD49d</span> is an independent prognostic marker that is associated with CXCR4 expression in <span class=""disease"" id=""21093051-0-86-89"">CLL</span>.",CTD_human
21,87,Biomarker,C0033847,Pseudoxanthoma Elasticum,disease,Pseudoxanthoma elasticum,368,ABCC6,Abcc6,CTD_human,18049453,Pseudoxanthoma elasticum: oxidative stress and antioxidant diet in a mouse model (Abcc6-/-).,0.7779099309983829,"<span class=""disease"" id=""18049453-0-0-24"">Pseudoxanthoma elasticum</span>: oxidative stress and antioxidant diet in a mouse model (<span class=""gene"" id=""18049453-0-82-87"">Abcc6</span>-/-).",CTD_human;ORPHANET;UNIPROT
21,87,Biomarker,C0033847,Pseudoxanthoma Elasticum,disease,PXE,368,ABCC6,ABCC6,CTD_human,17045963,This constitutes the first direct proof of previously suggested involvement of nuclear hormone receptors in ABCC6 gene expression and the first identification of a transcription factor which may be relevant to regulation of ABCC6 level in tissues and in some PXE patients.,0.7779099309983829,"This constitutes the first direct proof of previously suggested involvement of nuclear hormone receptors in <span class=""gene"" id=""17045963-4-108-113"">ABCC6</span> gene expression and the first identification of a transcription factor which may be relevant to regulation of <span class=""gene"" id=""17045963-4-224-229"">ABCC6</span> level in tissues and in some <span class=""disease"" id=""17045963-4-259-262"">PXE</span> patients.",CTD_human;ORPHANET;UNIPROT
21,87,Biomarker,C0033847,Pseudoxanthoma Elasticum,disease,pseudoxanthoma elasticum,368,ABCC6,MRP6,CTD_human,11880368,Loss of ATP-dependent transport activity in pseudoxanthoma elasticum-associated mutants of human ABCC6 (MRP6).,0.7779099309983829,"Loss of ATP-dependent transport activity in <span class=""disease"" id=""11880368-0-44-68"">pseudoxanthoma elasticum</span>-associated mutants of human <span class=""gene"" id=""11880368-0-97-102"">ABCC6</span> (<span class=""gene"" id=""11880368-0-104-108"">MRP6</span>).",CTD_human;ORPHANET;UNIPROT
21,87,Biomarker,C0033847,Pseudoxanthoma Elasticum,disease,PXE,368,ABCC6,ABCC6,CTD_human,16571645,Pseudoxanthoma elasticum (PXE) is a heritable connective tissue disorder caused by mutations in the ABCC6 gene.,0.7779099309983829,"<span class=""disease"" id=""16571645-1-0-24"">Pseudoxanthoma elasticum</span> (<span class=""disease"" id=""16571645-1-26-29"">PXE</span>) is a heritable connective tissue disorder caused by mutations in the <span class=""gene"" id=""16571645-1-100-105"">ABCC6</span> gene.",CTD_human;ORPHANET;UNIPROT
21,87,Biomarker,C0033847,Pseudoxanthoma Elasticum,disease,PXE,368,ABCC6,MRP6,CTD_human,12069597,"In addition to providing large amounts of active protein for detailed biochemical studies, this system should also prove useful to identify potential rMrp6 substrates in [(125)I]-IAARh123 photolabeling competition studies, as well as to study the molecular basis of PXE mutations, which are most often found in the NBD2 of MRP6.",0.7779099309983829,"In addition to providing large amounts of active protein for detailed biochemical studies, this system should also prove useful to identify potential rMrp6 substrates in [(125)I]-IAARh123 photolabeling competition studies, as well as to study the molecular basis of <span class=""disease"" id=""12069597-12-266-269"">PXE</span> mutations, which are most often found in the NBD2 of <span class=""gene"" id=""12069597-12-323-327"">MRP6</span>.",CTD_human;ORPHANET;UNIPROT
21,87,Biomarker,C0033847,Pseudoxanthoma Elasticum,disease,pseudoxanthoma elasticum,368,ABCC6,Abcc6,CTD_human,23415960,Warfarin accelerates ectopic mineralization in Abcc6(-/-) mice: clinical relevance to pseudoxanthoma elasticum.,0.7779099309983829,"Warfarin accelerates ectopic mineralization in <span class=""gene"" id=""23415960-0-47-52"">Abcc6</span>(-/-) mice: clinical relevance to <span class=""disease"" id=""23415960-0-86-110"">pseudoxanthoma elasticum</span>.",CTD_human;ORPHANET;UNIPROT
21,87,Biomarker,C0033847,Pseudoxanthoma Elasticum,disease,Pseudoxanthoma elasticum,368,ABCC6,MRP6,CTD_human,14667841,Multidrug resistance protein-6 (MRP6) in human dermal fibroblasts. Comparison between cells from normal subjects and from Pseudoxanthoma elasticum patients.,0.7779099309983829,"Multidrug resistance protein-6 (<span class=""gene"" id=""14667841-0-32-36"">MRP6</span>) in human dermal fibroblasts. Comparison between cells from normal subjects and from <span class=""disease"" id=""14667841-0-122-146"">Pseudoxanthoma elasticum</span> patients.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0004943,Behcet Syndrome,disease,BD,3683,ITGAL,CD11a,CTD_human,8712863,The number of CD11a positive neutrophils was greater in the blood of patients with BD than in that of healthy controls (89.4% v 71%; p < 0.001).,0.20082418035263896,"The number of <span class=""gene"" id=""8712863-7-14-19"">CD11a</span> positive neutrophils was greater in the blood of patients with <span class=""disease"" id=""8712863-7-83-85"">BD</span> than in that of healthy controls (89.4% v 71%; p &lt; 0.001).",CTD_human
1,0,Biomarker,C0023487,Acute Promyelocytic Leukemia,disease,AML-M3,3683,ITGAL,CD11a,CTD_human,16764927,"We demonstrate the clinical usefulness of a panel of beta2 integrins (CD11a, CD11b and CD11c) in accurate prediction of AML-M3, and recommend inclusion of this immunophenotypic analysis to identify patients who require ATRA therapy.",0.20054945356842604,"We demonstrate the clinical usefulness of a panel of beta2 integrins (<span class=""gene"" id=""16764927-8-70-75"">CD11a</span>, CD11b and CD11c) in accurate prediction of <span class=""disease"" id=""16764927-8-120-126"">AML-M3</span>, and recommend inclusion of this immunophenotypic analysis to identify patients who require ATRA therapy.",CTD_human
1,0,Biomarker,C0020877,Ileitis,disease,ileitis,3684,ITGAM,alphaM-MAC-1,CTD_human,10647630,Effect of anti-CD11b (alphaM-MAC-1) and anti-CD54 (ICAM-1) monoclonal antibodies on indomethacin induced chronic ileitis in rats.,0.2,"Effect of anti-<span class=""gene"" id=""10647630-0-15-20"">CD11b</span> (<span class=""gene"" id=""10647630-0-22-34"">alphaM-MAC-1</span>) and anti-CD54 (ICAM-1) monoclonal antibodies on indomethacin induced chronic <span class=""disease"" id=""10647630-0-113-120"">ileitis</span> in rats.",CTD_human
1,0,Biomarker,C0023487,Acute Promyelocytic Leukemia,disease,AML-M3,3684,ITGAM,CD11b,CTD_human,16764927,"We demonstrate the clinical usefulness of a panel of beta2 integrins (CD11a, CD11b and CD11c) in accurate prediction of AML-M3, and recommend inclusion of this immunophenotypic analysis to identify patients who require ATRA therapy.",0.201923087489492,"We demonstrate the clinical usefulness of a panel of beta2 integrins (CD11a, <span class=""gene"" id=""16764927-8-77-82"">CD11b</span> and CD11c) in accurate prediction of <span class=""disease"" id=""16764927-8-120-126"">AML-M3</span>, and recommend inclusion of this immunophenotypic analysis to identify patients who require ATRA therapy.",CTD_human
2,7,Biomarker,C0024141,"Lupus Erythematosus, Systemic",disease,systemic lupus erythematosus,3684,ITGAM,ITGAM,CTD_human,18204448,A nonsynonymous functional variant in integrin-alpha(M) (encoded by ITGAM) is associated with systemic lupus erythematosus.,0.230505670961724,"A nonsynonymous functional variant in <span class=""gene"" id=""18204448-0-38-54"">integrin-alpha(M</span>) (encoded by <span class=""gene"" id=""18204448-0-68-73"">ITGAM</span>) is associated with <span class=""disease"" id=""18204448-0-94-122"">systemic lupus erythematosus</span>.",CTD_human
1,0,Biomarker,C0038454,Cerebrovascular accident,group,stroke,3685,ITGAV,vitronectin receptor,CTD_human,9445356,"Decreased platelet glycoprotein Ib, IIb, IIIa, and IIb/IIIa and vitronectin receptor expression were observed in the stroke patient.",0.2,"Decreased platelet glycoprotein Ib, IIb, IIIa, and IIb/IIIa and <span class=""gene"" id=""9445356-8-64-84"">vitronectin receptor</span> expression were observed in the <span class=""disease"" id=""9445356-8-117-123"">stroke</span> patient.",CTD_human
1,0,Biomarker,C0023487,Acute Promyelocytic Leukemia,disease,AML-M3,3687,ITGAX,CD11c,CTD_human,16764927,"We demonstrate the clinical usefulness of a panel of beta2 integrins (CD11a, CD11b and CD11c) in accurate prediction of AML-M3, and recommend inclusion of this immunophenotypic analysis to identify patients who require ATRA therapy.",0.20054945356842604,"We demonstrate the clinical usefulness of a panel of beta2 integrins (CD11a, CD11b and <span class=""gene"" id=""16764927-8-87-92"">CD11c</span>) in accurate prediction of <span class=""disease"" id=""16764927-8-120-126"">AML-M3</span>, and recommend inclusion of this immunophenotypic analysis to identify patients who require ATRA therapy.",CTD_human
1,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastasis,3688,ITGB1,integrin ?1,CTD_human,23562787,Shikonin attenuates lung cancer cell adhesion to extracellular matrix and metastasis by inhibiting integrin ?1 expression and the ERK1/2 signaling pathway.,0.212319639157638,"Shikonin attenuates lung cancer cell adhesion to extracellular matrix and <span class=""disease"" id=""23562787-0-74-84"">metastasis</span> by inhibiting <span class=""gene"" id=""23562787-0-99-110"">integrin &beta;1</span> expression and the ERK1/2 signaling pathway.",CTD_human
1,0,Biomarker,C0004943,Behcet Syndrome,disease,BD,3689,ITGB2,CD18,CTD_human,8712863,"Adhesion of neutrophils from patients with BD to HUVEC stimulated with tumour necrosis factor (TNF), interleukin-1 (IL-1), and lipopolysaccharide (LPS) and adhesion molecule (CD11a, CD11b, CD18 and L-selectin) expression on the patient's neutrophils and lymphocytes were determined, and the serum concentration of IL-8 was measured.",0.20054945356842604,"Adhesion of neutrophils from patients with <span class=""disease"" id=""8712863-4-43-45"">BD</span> to HUVEC stimulated with tumour necrosis factor (TNF), interleukin-1 (IL-1), and lipopolysaccharide (LPS) and adhesion molecule (CD11a, CD11b, <span class=""gene"" id=""8712863-4-189-193"">CD18</span> and L-selectin) expression on the patient's neutrophils and lymphocytes were determined, and the serum concentration of IL-8 was measured.",CTD_human
1,0,Biomarker,C0027720,Nephrosis,disease,nephrosis,3689,ITGB2,CD18,CTD_human,12845231,"Increased expression of CD54, CD18, MHC class II molecules, and proliferating cell nuclear antigen in acute puromycin aminonucleoside nephrosis.",0.2,"Increased expression of CD54, <span class=""gene"" id=""12845231-0-30-34"">CD18</span>, MHC class II molecules, and proliferating cell nuclear antigen in acute puromycin aminonucleoside <span class=""disease"" id=""12845231-0-134-143"">nephrosis</span>.",CTD_human
1,0,Biomarker,C0037299,Skin Ulcer,phenotype,skin ulceration,3689,ITGB2,CD18,CTD_human,9653089,Spontaneous skin ulceration and defective T cell function in CD18 null mice.,0.200274726784213,"Spontaneous <span class=""disease"" id=""9653089-0-12-27"">skin ulceration</span> and defective T cell function in <span class=""gene"" id=""9653089-0-61-65"">CD18</span> null mice.",CTD_human
3,0,Biomarker,C0004352,Autistic Disorder,disease,autism,3690,ITGB3,ITGB3,CTD_human,16724005,Variation in ITGB3 is associated with whole-blood serotonin level and autism susceptibility.,0.217017026512271,"Variation in <span class=""gene"" id=""16724005-0-13-18"">ITGB3</span> is associated with whole-blood serotonin level and <span class=""disease"" id=""16724005-0-70-76"">autism</span> susceptibility.",CTD_human
3,0,Biomarker,C0004352,Autistic Disorder,disease,autism,3690,ITGB3,ITGB3,CTD_human,17203304,Evidence for epistasis between SLC6A4 and ITGB3 in autism etiology and in the determination of platelet serotonin levels.,0.217017026512271,"Evidence for epistasis between SLC6A4 and <span class=""gene"" id=""17203304-0-42-47"">ITGB3</span> in <span class=""disease"" id=""17203304-0-51-57"">autism</span> etiology and in the determination of platelet serotonin levels.",CTD_human
3,0,Biomarker,C0004352,Autistic Disorder,disease,autism,3690,ITGB3,ITGB3,CTD_human,16721604,We also show preliminary evidence that genotypes at the ITGB3 and SLC6A4 loci may interact to affect autism susceptibility (P=0.033).,0.217017026512271,"We also show preliminary evidence that genotypes at the <span class=""gene"" id=""16721604-7-56-61"">ITGB3</span> and SLC6A4 loci may interact to affect <span class=""disease"" id=""16721604-7-101-107"">autism</span> susceptibility (P=0.033).",CTD_human
1,0,Biomarker,C1510586,Autism Spectrum Disorders,disease,ASD,3690,ITGB3,integrin ?3,CTD_human,21254450,"These preliminary studies reveal altered social and repetitive behavior in these mice, which suggests that the integrin ?3 subunit may be involved in brain systems relevant to ASD.",0.201098907136852,"These preliminary studies reveal altered social and repetitive behavior in these mice, which suggests that the <span class=""gene"" id=""21254450-10-111-122"">integrin &beta;3</span> subunit may be involved in brain systems relevant to <span class=""disease"" id=""21254450-10-176-179"">ASD</span>.",CTD_human
1,0,Biomarker,C0014527,Epidermolysis Bullosa,disease,epidermolysis bullosa,3691,ITGB4,integrin beta-4,CTD_human,18348258,"Deletion of the first pair of fibronectin type III repeats of the integrin beta-4 gene is associated with epidermolysis bullosa, pyloric atresia and aplasia cutis congenita in the original Carmi syndrome patients.",0.20629000528226699,"Deletion of the first pair of fibronectin type III repeats of the <span class=""gene"" id=""18348258-0-66-81"">integrin beta-4</span> gene is associated with <span class=""disease"" id=""18348258-0-106-127"">epidermolysis bullosa</span>, pyloric atresia and aplasia cutis congenita in the original Carmi syndrome patients.",CTD_human
2,0,Biomarker,C0266159,Pyloric Atresia,disease,pyloric atresia,3691,ITGB4,integrin beta-4,CTD_human,18348258,"Deletion of the first pair of fibronectin type III repeats of the integrin beta-4 gene is associated with epidermolysis bullosa, pyloric atresia and aplasia cutis congenita in the original Carmi syndrome patients.",0.201648360705279,"Deletion of the first pair of fibronectin type III repeats of the <span class=""gene"" id=""18348258-0-66-81"">integrin beta-4</span> gene is associated with epidermolysis bullosa, <span class=""disease"" id=""18348258-0-129-144"">pyloric atresia</span> and aplasia cutis congenita in the original Carmi syndrome patients.",CTD_human
9,12,Biomarker,C1856934,Epidermolysis bullosa with pyloric atresia,disease,junctional epidermolysis bullosa with pyloric atresia,3691,ITGB4,Integrin beta 4,CTD_human,7545057,Integrin beta 4 mutations associated with junctional epidermolysis bullosa with pyloric atresia.,0.6841209017631971,"<span class=""gene"" id=""7545057-0-0-15"">Integrin beta 4</span> mutations associated with <span class=""disease"" id=""7545057-0-42-95"">junctional epidermolysis bullosa with pyloric atresia</span>.",CTD_human;ORPHANET;UNIPROT
9,12,Biomarker,C1856934,Epidermolysis bullosa with pyloric atresia,disease,Carmi syndrome,3691,ITGB4,integrin beta-4,CTD_human,18348258,"Deletion of the first pair of fibronectin type III repeats of the integrin beta-4 gene is associated with epidermolysis bullosa, pyloric atresia and aplasia cutis congenita in the original Carmi syndrome patients.",0.6841209017631971,"Deletion of the first pair of fibronectin type III repeats of the <span class=""gene"" id=""18348258-0-66-81"">integrin beta-4</span> gene is associated with epidermolysis bullosa, pyloric atresia and aplasia cutis congenita in the original <span class=""disease"" id=""18348258-0-189-203"">Carmi syndrome</span> patients.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C1458155,Mammary Neoplasms,group,breast tumors,3692,EIF6,EIF6,CTD_human,25151356,"The genes identified include eight that are essential for cell proliferation (FGD5, METTL6, CPT1A, DTX3, MRPS23, EIF2S2, EIF6 and SLC2A10) and are uniquely amplified in patients with highly proliferative luminal breast tumors, a clinical subset of patients for which few therapeutic options are effective.",0.2,"The genes identified include eight that are essential for cell proliferation (FGD5, METTL6, CPT1A, DTX3, MRPS23, EIF2S2, <span class=""gene"" id=""25151356-4-121-125"">EIF6</span> and SLC2A10) and are uniquely amplified in patients with highly proliferative luminal <span class=""disease"" id=""25151356-4-212-225"">breast tumors</span>, a clinical subset of patients for which few therapeutic options are effective.",CTD_human
1,0,Biomarker,C0034067,Pulmonary Emphysema,disease,emphysema,3694,ITGB6,Itgb6,CTD_human,12634787,"Here we report that Itgb6-null mice develop age-related emphysema that is completely abrogated either by transgenic expression of versions of the beta6 integrin subunit that support TGF-beta activation, or by the loss of Mmp12.",0.20082418035263896,"Here we report that <span class=""gene"" id=""12634787-4-20-25"">Itgb6</span>-null mice develop age-related <span class=""disease"" id=""12634787-4-56-65"">emphysema</span> that is completely abrogated either by transgenic expression of versions of the beta6 integrin subunit that support TGF-beta activation, or by the loss of Mmp12.",CTD_human
1,0,Therapeutic,C0002878,"Anemia, Hemolytic",disease,hemolytic anemia,3704,ITPA,ITPA,CTD_human,20547162,Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction.,0.20838550524134603,"Variants in the <span class=""gene"" id=""20547162-0-16-20"">ITPA</span> gene protect against ribavirin-induced <span class=""disease"" id=""20547162-0-60-76"">hemolytic anemia</span> and decrease the need for ribavirin dose reduction.",CTD_human
9,1,Biomarker,C0001815,Primary Myelofibrosis,disease,primary myelofibrosis,3717,JAK2,JAK2,CTD_human,19287384,"Given that the identical somatic activating mutation in the JAK2 tyrosine kinase gene (JAK2(V617F)) is observed in most individuals with polycythemia vera, essential thrombocythemia and primary myelofibrosis, there likely are additional genetic events that contribute to the pathogenesis of these phenotypically distinct disorders.",0.381891422860773,"Given that the identical somatic activating mutation in the <span class=""gene"" id=""19287384-2-60-64"">JAK2</span> tyrosine kinase gene (<span class=""gene"" id=""19287384-2-87-91"">JAK2</span>(V617F)) is observed in most individuals with polycythemia vera, essential thrombocythemia and <span class=""disease"" id=""19287384-2-186-207"">primary myelofibrosis</span>, there likely are additional genetic events that contribute to the pathogenesis of these phenotypically distinct disorders.",CTD_human
9,1,Biomarker,C0001815,Primary Myelofibrosis,disease,idiopathic myelofibrosis,3717,JAK2,JAK2,CTD_human,15781101,"A single point mutation (Val617Phe) was identified in JAK2 in 71 (97%) of 73 patients with polycythaemia vera, 29 (57%) of 51 with essential thrombocythaemia, and eight (50%) of 16 with idiopathic myelofibrosis.",0.381891422860773,"A single point mutation (Val617Phe) was identified in <span class=""gene"" id=""15781101-7-54-58"">JAK2</span> in 71 (97%) of 73 patients with polycythaemia vera, 29 (57%) of 51 with essential thrombocythaemia, and eight (50%) of 16 with <span class=""disease"" id=""15781101-7-186-210"">idiopathic myelofibrosis</span>.",CTD_human
9,1,Biomarker,C0001815,Primary Myelofibrosis,disease,myelofibrosis,3717,JAK2,JAK2,CTD_human,19287382,"We report here that JAK2(V617F)-associated disease is strongly associated with a specific constitutional JAK2 haplotype, designated 46/1, in all three disease entities compared to healthy controls (polycythemia vera, n = 192, P = 2.9 x 10(-16); essential thrombocythemia, n = 78, P = 8.2 x 10(-9) and myelofibrosis, n = 41, P = 8.0 x 10(-5)).",0.381891422860773,"We report here that <span class=""gene"" id=""19287382-3-20-24"">JAK2</span>(V617F)-associated disease is strongly associated with a specific constitutional <span class=""gene"" id=""19287382-3-105-109"">JAK2</span> haplotype, designated 46/1, in all three disease entities compared to healthy controls (polycythemia vera, n = 192, P = 2.9 x 10(-16); essential thrombocythemia, n = 78, P = 8.2 x 10(-9) and <span class=""disease"" id=""19287382-3-301-314"">myelofibrosis</span>, n = 41, P = 8.0 x 10(-5)).",CTD_human
9,1,Biomarker,C0001815,Primary Myelofibrosis,disease,CIMF,3717,JAK2,Janus kinase 2,CTD_human,16951397,At the fore front of these advances is the discovery that 35%-55% of patients with CIMF harbor mutations in the Janus kinase 2 tyrosine kinase gene.,0.381891422860773,"At the fore front of these advances is the discovery that 35%-55% of patients with <span class=""disease"" id=""16951397-3-83-87"">CIMF</span> harbor mutations in the <span class=""gene"" id=""16951397-3-112-126"">Janus kinase 2</span> tyrosine kinase gene.",CTD_human
1,2,Biomarker,C0023467,"Leukemia, Myelocytic, Acute",disease,acute myelogenous leukemias,3717,JAK2,JAK2,CTD_human,16247455,The JAK2 V617F mutation in de novo acute myelogenous leukemias.,0.445269140422645,"The <span class=""gene"" id=""16247455-0-4-8"">JAK2</span> V617F mutation in de novo <span class=""disease"" id=""16247455-0-35-62"">acute myelogenous leukemias</span>.",CTD_human;UNIPROT
1,2,Biomarker,C0027022,Myeloproliferative disease,group,myeloproliferative disorders,3717,JAK2,Jak2,CTD_human,22087750,Developing Janus kinase 2 (Jak2) inhibitors has become a significant focus for small molecule drug discovery programs in recent years due to the identification of a Jak2 gain-of-function mutation in the majority of patients with myeloproliferative disorders (MPD).,0.64,"Developing <span class=""gene"" id=""22087750-1-11-25"">Janus kinase 2</span> (<span class=""gene"" id=""22087750-1-27-31"">Jak2</span>) inhibitors has become a significant focus for small molecule drug discovery programs in recent years due to the identification of a <span class=""gene"" id=""22087750-1-165-169"">Jak2</span> gain-of-function mutation in the majority of patients with <span class=""disease"" id=""22087750-1-229-257"">myeloproliferative disorders</span> (MPD).",CTD_human;HPO
14,1,Biomarker,C0032463,Polycythemia Vera,disease,polycythaemia vera,3717,JAK2,JAK2,CTD_human,15781101,"A single point mutation (Val617Phe) was identified in JAK2 in 71 (97%) of 73 patients with polycythaemia vera, 29 (57%) of 51 with essential thrombocythaemia, and eight (50%) of 16 with idiopathic myelofibrosis.",0.907396798652064,"A single point mutation (Val617Phe) was identified in <span class=""gene"" id=""15781101-7-54-58"">JAK2</span> in 71 (97%) of 73 patients with <span class=""disease"" id=""15781101-7-91-109"">polycythaemia vera</span>, 29 (57%) of 51 with essential thrombocythaemia, and eight (50%) of 16 with idiopathic myelofibrosis.",CTD_human;ORPHANET;UNIPROT
14,1,Biomarker,C0032463,Polycythemia Vera,disease,polycythemia vera,3717,JAK2,JAK2,CTD_human,19287382,"We report here that JAK2(V617F)-associated disease is strongly associated with a specific constitutional JAK2 haplotype, designated 46/1, in all three disease entities compared to healthy controls (polycythemia vera, n = 192, P = 2.9 x 10(-16); essential thrombocythemia, n = 78, P = 8.2 x 10(-9) and myelofibrosis, n = 41, P = 8.0 x 10(-5)).",0.907396798652064,"We report here that <span class=""gene"" id=""19287382-3-20-24"">JAK2</span>(V617F)-associated disease is strongly associated with a specific constitutional <span class=""gene"" id=""19287382-3-105-109"">JAK2</span> haplotype, designated 46/1, in all three disease entities compared to healthy controls (<span class=""disease"" id=""19287382-3-198-215"">polycythemia vera</span>, n = 192, P = 2.9 x 10(-16); essential thrombocythemia, n = 78, P = 8.2 x 10(-9) and myelofibrosis, n = 41, P = 8.0 x 10(-5)).",CTD_human;ORPHANET;UNIPROT
14,1,Biomarker,C0032463,Polycythemia Vera,disease,polycythemia vera,3717,JAK2,JAK2,CTD_human,19287384,"Given that the identical somatic activating mutation in the JAK2 tyrosine kinase gene (JAK2(V617F)) is observed in most individuals with polycythemia vera, essential thrombocythemia and primary myelofibrosis, there likely are additional genetic events that contribute to the pathogenesis of these phenotypically distinct disorders.",0.907396798652064,"Given that the identical somatic activating mutation in the <span class=""gene"" id=""19287384-2-60-64"">JAK2</span> tyrosine kinase gene (<span class=""gene"" id=""19287384-2-87-91"">JAK2</span>(V617F)) is observed in most individuals with <span class=""disease"" id=""19287384-2-137-154"">polycythemia vera</span>, essential thrombocythemia and primary myelofibrosis, there likely are additional genetic events that contribute to the pathogenesis of these phenotypically distinct disorders.",CTD_human;ORPHANET;UNIPROT
14,1,Biomarker,C0032463,Polycythemia Vera,disease,polycythaemia vera,3717,JAK2,JAK2,CTD_human,15793561,A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.,0.907396798652064,"A unique clonal <span class=""gene"" id=""15793561-0-16-20"">JAK2</span> mutation leading to constitutive signalling causes <span class=""disease"" id=""15793561-0-72-90"">polycythaemia vera</span>.",CTD_human;ORPHANET;UNIPROT
14,1,Biomarker,C0032463,Polycythemia Vera,disease,PV,3717,JAK2,JAK2,CTD_human,18717827,"Although JAK2(V617F) transcript levels did not decrease upon exposure to dasatinib, the drug might suppress PV progenitors through inhibition of a yet undefined molecular target.",0.907396798652064,"Although <span class=""gene"" id=""18717827-14-9-13"">JAK2</span>(V617F) transcript levels did not decrease upon exposure to dasatinib, the drug might suppress <span class=""disease"" id=""18717827-14-108-110"">PV</span> progenitors through inhibition of a yet undefined molecular target.",CTD_human;ORPHANET;UNIPROT
14,1,Biomarker,C0032463,Polycythemia Vera,disease,PV,3717,JAK2,JAK2-V617F,CTD_human,16484586,"The recently discovered single somatic activating point mutation in the JAK2 gene (JAK2-V617F) is found in the great majority of patients with PV, but also in many patients with phenotypically classified ET and other MPDs.",0.907396798652064,"The recently discovered single somatic activating point mutation in the <span class=""gene"" id=""16484586-3-72-76"">JAK2</span> gene (<span class=""gene"" id=""16484586-3-83-93"">JAK2-V617F</span>) is found in the great majority of patients with <span class=""disease"" id=""16484586-3-143-145"">PV</span>, but also in many patients with phenotypically classified ET and other MPDs.",CTD_human;ORPHANET;UNIPROT
8,0,Biomarker,C0040028,"Thrombocythemia, Essential",disease,essential thrombocythemia,3717,JAK2,JAK2,CTD_human,20434300,He was diagnosed with essential thrombocythemia after he tested positive for the JAK2 V617F mutation.,0.632640290938448,"He was diagnosed with <span class=""disease"" id=""20434300-5-22-47"">essential thrombocythemia</span> after he tested positive for the <span class=""gene"" id=""20434300-5-81-85"">JAK2</span> V617F mutation.",CTD_human;ORPHANET
8,0,Biomarker,C0040028,"Thrombocythemia, Essential",disease,ET,3717,JAK2,JAK2,CTD_human,19636672,A somatic point mutation that causes a constitutive activation of the JAK2 gene is found in one in two ET patients.,0.632640290938448,"A somatic point mutation that causes a constitutive activation of the <span class=""gene"" id=""19636672-2-70-74"">JAK2</span> gene is found in one in two <span class=""disease"" id=""19636672-2-103-105"">ET</span> patients.",CTD_human;ORPHANET
8,0,Biomarker,C0040028,"Thrombocythemia, Essential",disease,ET,3717,JAK2,JAK2-V617F,CTD_human,16484586,"The recently discovered single somatic activating point mutation in the JAK2 gene (JAK2-V617F) is found in the great majority of patients with PV, but also in many patients with phenotypically classified ET and other MPDs.",0.632640290938448,"The recently discovered single somatic activating point mutation in the <span class=""gene"" id=""16484586-3-72-76"">JAK2</span> gene (<span class=""gene"" id=""16484586-3-83-93"">JAK2-V617F</span>) is found in the great majority of patients with PV, but also in many patients with phenotypically classified <span class=""disease"" id=""16484586-3-204-206"">ET</span> and other MPDs.",CTD_human;ORPHANET
8,0,Biomarker,C0040028,"Thrombocythemia, Essential",disease,essential thrombocythaemia,3717,JAK2,JAK2,CTD_human,15781101,"A single point mutation (Val617Phe) was identified in JAK2 in 71 (97%) of 73 patients with polycythaemia vera, 29 (57%) of 51 with essential thrombocythaemia, and eight (50%) of 16 with idiopathic myelofibrosis.",0.632640290938448,"A single point mutation (Val617Phe) was identified in <span class=""gene"" id=""15781101-7-54-58"">JAK2</span> in 71 (97%) of 73 patients with polycythaemia vera, 29 (57%) of 51 with <span class=""disease"" id=""15781101-7-131-157"">essential thrombocythaemia</span>, and eight (50%) of 16 with idiopathic myelofibrosis.",CTD_human;ORPHANET
2,1,Biomarker,C0856761,Budd-Chiari Syndrome,disease,BCS,3717,JAK2,JAK2,CTD_human,19293426,ECs of the other BCS patient with PV and 2 patients with hepatoportal sclerosis without PV contained exclusively wild-type JAK2.,0.616207201536949,"ECs of the other <span class=""disease"" id=""19293426-6-17-20"">BCS</span> patient with PV and 2 patients with hepatoportal sclerosis without PV contained exclusively wild-type <span class=""gene"" id=""19293426-6-123-127"">JAK2</span>.",CTD_human;HPO;ORPHANET
2,1,Biomarker,C0856761,Budd-Chiari Syndrome,disease,Budd-Chiari syndrome,3717,JAK2,JAK2,CTD_human,16762626,Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome.,0.616207201536949,"Prevalence of the activating <span class=""gene"" id=""16762626-0-29-33"">JAK2</span> tyrosine kinase mutation V617F in the <span class=""disease"" id=""16762626-0-72-92"">Budd-Chiari syndrome</span>.",CTD_human;HPO;ORPHANET
1,0,Biomarker,C0349639,Juvenile Myelomonocytic Leukemia,disease,juvenile myelomonocytic leukemia,3718,JAK3,JAK3,CTD_human,23832011,Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia.,0.200274726784213,"Exome sequencing identifies secondary mutations of SETBP1 and <span class=""gene"" id=""23832011-0-62-66"">JAK3</span> in <span class=""disease"" id=""23832011-0-70-102"">juvenile myelomonocytic leukemia</span>.",CTD_human
1,0,Biomarker,C1510586,Autism Spectrum Disorders,disease,ASD,3720,JARID2,JARID2,CTD_human,21308764,The analysis using the posterior probability of membership to an LC detected an association in the JARID2 gene as significant as that for ASD (P = 3 × 10(-5)) but with a larger effect size (odds ratio = 2.17 vs. 1.55).,0.200274726784213,"The analysis using the posterior probability of membership to an LC detected an association in the <span class=""gene"" id=""21308764-8-99-105"">JARID2</span> gene as significant as that for <span class=""disease"" id=""21308764-8-138-141"">ASD</span> (P = 3 &times; 10(-5)) but with a larger effect size (odds ratio = 2.17 vs. 1.55).",CTD_human
1,0,Biomarker,C0024121,Lung Neoplasms,group,lung tumor,3725,JUN,AP-1,CTD_human,20716630,"Our results support the concept that AP-1 is a key regulator of mouse lung tumorigenesis, and identify AP-1-dependent transcription as a potential target to prevent lung tumor progression.",0.202732912464814,"Our results support the concept that <span class=""gene"" id=""20716630-10-37-41"">AP-1</span> is a key regulator of mouse lung tumorigenesis, and identify <span class=""gene"" id=""20716630-10-103-107"">AP-1</span>-dependent transcription as a potential target to prevent <span class=""disease"" id=""20716630-10-165-175"">lung tumor</span> progression.",CTD_human
1,0,Biomarker,C0017658,Glomerulonephritis,disease,glomerulonephritis,3727,JUND,AP-1,CTD_human,18443593,"Here we show by combined congenic, linkage and microarray studies that the activator protein-1 (AP-1) transcription factor JunD is a major determinant of macrophage activity and is associated with glomerulonephritis susceptibility.",0.20300763924902696,"Here we show by combined congenic, linkage and microarray studies that the <span class=""gene"" id=""18443593-3-75-94"">activator protein-1</span> (<span class=""gene"" id=""18443593-3-96-100"">AP-1</span>) transcription factor JunD is a major determinant of macrophage activity and is associated with <span class=""disease"" id=""18443593-3-197-215"">glomerulonephritis</span> susceptibility.",CTD_human
1,0,Therapeutic,C0027627,Neoplasm Metastasis,phenotype,tumor metastasis,3732,CD82,CD82,CTD_human,20075392,CD82 is recognized as a wide-spectrum tumor metastasis suppressor that inhibits cancer cell motility and invasiveness.,0.249089962110241,"<span class=""gene"" id=""20075392-1-0-4"">CD82</span> is recognized as a wide-spectrum <span class=""disease"" id=""20075392-1-38-54"">tumor metastasis</span> suppressor that inhibits cancer cell motility and invasiveness.",CTD_human
1,0,Biomarker,C0004096,Asthma,disease,bronchial asthma,374,AREG,amphiregulin,CTD_human,15696081,"Therefore, amphiregulin may be a new target molecule for treatment of overproduction of sputum in bronchial asthma.",0.204655999954305,"Therefore, <span class=""gene"" id=""15696081-13-11-23"">amphiregulin</span> may be a new target molecule for treatment of overproduction of sputum in <span class=""disease"" id=""15696081-13-98-114"">bronchial asthma</span>.",CTD_human
2,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,NSCLC,374,AREG,amphiregulin,CTD_human,16230376,Our data suggest that the status of amphiregulin and TGF-alpha in serum can be an important predictor of the resistance to gefitinib among patients with advanced NSCLC.,0.201373633921065,"Our data suggest that the status of <span class=""gene"" id=""16230376-9-36-48"">amphiregulin</span> and TGF-alpha in serum can be an important predictor of the resistance to gefitinib among patients with advanced <span class=""disease"" id=""16230376-9-162-167"">NSCLC</span>.",CTD_human
2,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,NSCLC,374,AREG,amphiregulin,CTD_human,15496427,"Moreover, we proved that the anti-apoptotic activity of amphiregulin, a protein that was significantly over-expressed in non-responders but undetectable in responders, leads to resistance of NSCLC cells to gefitinib in vitro.",0.201373633921065,"Moreover, we proved that the anti-apoptotic activity of <span class=""gene"" id=""15496427-8-56-68"">amphiregulin</span>, a protein that was significantly over-expressed in non-responders but undetectable in responders, leads to resistance of <span class=""disease"" id=""15496427-8-191-196"">NSCLC</span> cells to gefitinib in vitro.",CTD_human
1,0,Biomarker,C0034069,Pulmonary Fibrosis,disease,pulmonary fibrosis,374,AREG,amphiregulin,CTD_human,26817844,"Last, the in vivo silencing efficacy of SAMiRNAs was evaluated by targeting amphiregulin and connective tissue growth factor in bleomycin or TGF-? transgenic animal models of pulmonary fibrosis.",0.20054945356842604,"Last, the in vivo silencing efficacy of SAMiRNAs was evaluated by targeting <span class=""gene"" id=""26817844-6-76-88"">amphiregulin</span> and connective tissue growth factor in bleomycin or TGF-&beta; transgenic animal models of <span class=""disease"" id=""26817844-6-175-193"">pulmonary fibrosis</span>.",CTD_human
1,0,Biomarker,C0162568,Erythropoietic Protoporphyria,disease,EPP,374,AREG,amphiregulin,CTD_human,19267999,"We observed that the expression of amphiregulin, betacellulin and epiregulin was significantly increased in young EPP mice when compared to aged-matched controls in all genetic backgrounds.",0.2,"We observed that the expression of <span class=""gene"" id=""19267999-6-35-47"">amphiregulin</span>, betacellulin and epiregulin was significantly increased in young <span class=""disease"" id=""19267999-6-114-117"">EPP</span> mice when compared to aged-matched controls in all genetic backgrounds.",CTD_human
1,0,Biomarker,C0004238,Atrial Fibrillation,disease,AF,3741,KCNA5,KCNA5,CTD_human,19698954,"Recent studies, however, have shown that loss-of-function mutations in KCNA5, the gene that encodes K(V)1.5, the alpha subunit of the I(Kur) channel, is associated with the development of AF and that inhibition of I(Kur) can promote the induction of AF in experimental models.",0.21160235873995603,"Recent studies, however, have shown that loss-of-function mutations in <span class=""gene"" id=""19698954-4-71-76"">KCNA5</span>, the gene that encodes K(V)1.5, the alpha subunit of the I(Kur) channel, is associated with the development of <span class=""disease"" id=""19698954-4-188-190"">AF</span> and that inhibition of I(Kur) can promote the induction of <span class=""disease"" id=""19698954-4-250-252"">AF</span> in experimental models.",CTD_human
1,0,Biomarker,C0008350,Cholelithiasis,disease,Cholelithiasis,374569,ASPG,asparaginase,CTD_human,12902918,Cholelithiasis and choledocholithiasis after sequential cytarabine and asparaginase.,0.2,"<span class=""disease"" id=""12902918-0-0-14"">Cholelithiasis</span> and choledocholithiasis after sequential cytarabine and <span class=""gene"" id=""12902918-0-71-83"">asparaginase</span>.",CTD_human
1,0,Biomarker,C0701818,Choledocholithiasis,disease,choledocholithiasis,374569,ASPG,asparaginase,CTD_human,12902918,Cholelithiasis and choledocholithiasis after sequential cytarabine and asparaginase.,0.2,"Cholelithiasis and <span class=""disease"" id=""12902918-0-19-38"">choledocholithiasis</span> after sequential cytarabine and <span class=""gene"" id=""12902918-0-71-83"">asparaginase</span>.",CTD_human
1,0,Biomarker,C0751778,"Myoclonic Epilepsies, Progressive",disease,progressive myoclonus epilepsy,3746,KCNC1,KCNC1,CTD_human,25401298,A recurrent de novo mutation in KCNC1 causes progressive myoclonus epilepsy.,0.200274726784213,"A recurrent de novo mutation in <span class=""gene"" id=""25401298-0-32-37"">KCNC1</span> causes <span class=""disease"" id=""25401298-0-45-75"">progressive myoclonus epilepsy</span>.",CTD_human
1,0,Biomarker,C0008925,Cleft Palate,disease,cleft palate,374654,KIF7,KIF7,CTD_human,21552264,"Here we report mutations in KIF7 in individuals with hydrolethalus and acrocallosal syndromes, two multiple malformation disorders with overlapping features that include polydactyly, brain abnormalities and cleft palate.",0.200274726784213,"Here we report mutations in <span class=""gene"" id=""21552264-2-28-32"">KIF7</span> in individuals with hydrolethalus and acrocallosal syndromes, two multiple malformation disorders with overlapping features that include polydactyly, brain abnormalities and <span class=""disease"" id=""21552264-2-207-219"">cleft palate</span>.",CTD_human
1,11,Biomarker,C0796147,Acrocallosal Syndrome,disease,acrocallosal syndromes,374654,KIF7,KIF7,CTD_human,21552264,KIF7 mutations cause fetal hydrolethalus and acrocallosal syndromes.,0.681923087489492,"<span class=""gene"" id=""21552264-0-0-4"">KIF7</span> mutations cause fetal hydrolethalus and <span class=""disease"" id=""21552264-0-45-67"">acrocallosal syndromes</span>.",CTD_human;ORPHANET;UNIPROT
1,1,Biomarker,C0022387,Jervell-Lange Nielsen Syndrome,disease,jervell and Lange-Nielsen syndrome,3753,KCNE1,KCNE1,CTD_human,9354783,KCNE1 mutations cause jervell and Lange-Nielsen syndrome.,0.409586726692824,"<span class=""gene"" id=""9354783-0-0-5"">KCNE1</span> mutations cause <span class=""disease"" id=""9354783-0-22-56"">jervell and Lange-Nielsen syndrome</span>.",CTD_human;ORPHANET
3,4,Biomarker,C0023976,Long QT Syndrome,disease,LQT,3753,KCNE1,KCNE1,CTD_human,9354802,"Here, we define KCNE1 missense mutations in affected members of two LQT families.",0.24173098860284198,"Here, we define <span class=""gene"" id=""9354802-5-16-21"">KCNE1</span> missense mutations in affected members of two <span class=""disease"" id=""9354802-5-68-71"">LQT</span> families.",CTD_human
1,0,Biomarker,C0014544,Epilepsy,disease,epilepsy,3756,KCNH1,KCNH1,CTD_human,25420144,Mutations in the voltage-gated potassium channel gene KCNH1 cause Temple-Baraitser syndrome and epilepsy.,0.400549453568426,"Mutations in the voltage-gated potassium channel gene <span class=""gene"" id=""25420144-0-54-59"">KCNH1</span> cause Temple-Baraitser syndrome and <span class=""disease"" id=""25420144-0-96-104"">epilepsy</span>.",CTD_human;HPO
1,0,Biomarker,C0029463,Osteosarcoma,disease,osteosarcoma,3756,KCNH1,hEAG1,CTD_human,22248279,Our data provide evidence that hEAG1 is overexpressed in human osteosarcoma and the hEAG1 polyclonal antibody offers a good tool for further characterization of the oncogenic function of hEAG1 in osteosarcoma.,0.201648360705279,"Our data provide evidence that <span class=""gene"" id=""22248279-8-31-36"">hEAG1</span> is overexpressed in human <span class=""disease"" id=""22248279-8-63-75"">osteosarcoma</span> and the <span class=""gene"" id=""22248279-8-84-89"">hEAG1</span> polyclonal antibody offers a good tool for further characterization of the oncogenic function of <span class=""gene"" id=""22248279-8-187-192"">hEAG1</span> in <span class=""disease"" id=""22248279-8-196-208"">osteosarcoma</span>.",CTD_human
1,6,Biomarker,C0796013,Zimmerman Laband syndrome,disease,Zimmermann-Laband syndrome,3756,KCNH1,KCNH1,CTD_human,25915598,Mutations in KCNH1 and ATP6V1B2 cause Zimmermann-Laband syndrome.,0.6008241803526391,"Mutations in <span class=""gene"" id=""25915598-0-13-18"">KCNH1</span> and ATP6V1B2 cause <span class=""disease"" id=""25915598-0-38-64"">Zimmermann-Laband syndrome</span>.",CTD_human;ORPHANET;UNIPROT
2,4,Biomarker,C2678486,Temple-Baraitser Syndrome,disease,Temple-Baraitser syndrome,3756,KCNH1,KCNH1,CTD_human,25420144,Mutations in the voltage-gated potassium channel gene KCNH1 cause Temple-Baraitser syndrome and epilepsy.,0.6008241803526391,"Mutations in the voltage-gated potassium channel gene <span class=""gene"" id=""25420144-0-54-59"">KCNH1</span> cause <span class=""disease"" id=""25420144-0-66-91"">Temple-Baraitser syndrome</span> and epilepsy.",CTD_human;ORPHANET;UNIPROT
18,30,Biomarker,C0023976,Long QT Syndrome,disease,long QT syndrome,3757,KCNH2,HERG,CTD_human,7889573,A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome.,0.34884157981895,"A molecular basis for cardiac arrhythmia: <span class=""gene"" id=""7889573-0-42-46"">HERG</span> mutations cause <span class=""disease"" id=""7889573-0-63-79"">long QT syndrome</span>.",CTD_human
18,30,Biomarker,C0023976,Long QT Syndrome,disease,long QT syndrome,3757,KCNH2,HERG,CTD_human,15043509,Probucol aggravates long QT syndrome associated with a novel missense mutation M124T in the N-terminus of HERG.,0.34884157981895,"Probucol aggravates <span class=""disease"" id=""15043509-0-20-36"">long QT syndrome</span> associated with a novel missense mutation M124T in the N-terminus of <span class=""gene"" id=""15043509-0-106-110"">HERG</span>.",CTD_human
18,30,Biomarker,C0023976,Long QT Syndrome,disease,long QT syndrome,3757,KCNH2,HERG,CTD_human,19057127,"In this paper, we will report a case of drug-induced long QT syndrome associated with an H(1)-receptor antagonist, hydroxyzine, in which a mutation was identified in the HERG gene.",0.34884157981895,"In this paper, we will report a case of drug-induced <span class=""disease"" id=""19057127-2-53-69"">long QT syndrome</span> associated with an H(1)-receptor antagonist, hydroxyzine, in which a mutation was identified in the <span class=""gene"" id=""19057127-2-170-174"">HERG</span> gene.",CTD_human
18,30,Biomarker,C0023976,Long QT Syndrome,disease,LQTS,3757,KCNH2,LQT2,CTD_human,23103450,"Arsenic trioxide (As(2)O(3)), which is used to treat acute promyelocytic leukemia, can cause LQTS type 2 (LQT2) by reducing the hERG current through the diversion of hERG trafficking to the cytoplasmic membrane.",0.34884157981895,"Arsenic trioxide (As(2)O(3)), which is used to treat acute promyelocytic leukemia, can cause <span class=""disease"" id=""23103450-4-93-97"">LQTS</span> type 2 (<span class=""gene"" id=""23103450-4-106-110"">LQT2</span>) by reducing the hERG current through the diversion of hERG trafficking to the cytoplasmic membrane.",CTD_human
18,30,Biomarker,C0023976,Long QT Syndrome,disease,long QT syndrome,3757,KCNH2,LQT2,CTD_human,11741928,"Mutations in the human ether-a-gogo-related gene (HERG) K(+) channel gene cause chromosome 7-linked long QT syndrome type 2 (LQT2), which is characterized by a prolonged QT interval in the electrocardiogram and an increased susceptibility to life-threatening cardiac arrhythmias.",0.34884157981895,"Mutations in the human ether-a-gogo-related gene (HERG) K(+) channel gene cause chromosome 7-linked <span class=""disease"" id=""11741928-1-100-116"">long QT syndrome</span> type 2 (<span class=""gene"" id=""11741928-1-125-129"">LQT2</span>), which is characterized by a prolonged QT interval in the electrocardiogram and an increased susceptibility to life-threatening cardiac arrhythmias.",CTD_human
3,0,Biomarker,C0004775,Bartter Disease,disease,Bartter syndrome,3758,KCNJ1,ROMK,CTD_human,12911542,Classification and rescue of ROMK mutations underlying hyperprostaglandin E syndrome/antenatal Bartter syndrome.,0.21288344810338103,"Classification and rescue of <span class=""gene"" id=""12911542-0-29-33"">ROMK</span> mutations underlying hyperprostaglandin E syndrome/antenatal <span class=""disease"" id=""12911542-0-95-111"">Bartter syndrome</span>.",CTD_human
3,0,Biomarker,C0004775,Bartter Disease,disease,Bartter's syndrome,3758,KCNJ1,ROMK,CTD_human,10561751,"Mutations of another voltage-gated chloride channel, CLC-Kb, are associated with a form of Bartter's syndrome, whereas other forms of Bartter's syndrome are caused by mutations in the bumetanide-sensitive sodium-potassium-chloride cotransporter (NKCC2) and the potassium channel, ROMK.",0.21288344810338103,"Mutations of another voltage-gated chloride channel, CLC-Kb, are associated with a form of <span class=""disease"" id=""10561751-3-91-109"">Bartter's syndrome</span>, whereas other forms of <span class=""disease"" id=""10561751-3-134-152"">Bartter's syndrome</span> are caused by mutations in the bumetanide-sensitive sodium-potassium-chloride cotransporter (NKCC2) and the potassium channel, <span class=""gene"" id=""10561751-3-280-284"">ROMK</span>.",CTD_human
7,17,Biomarker,C1563715,Andersen Syndrome,disease,Andersen syndrome,3759,KCNJ2,KCNJ2,CTD_human,17399643,Electrophysiologic characteristics of an Andersen syndrome patient with KCNJ2 mutation.,0.6312327211363901,"Electrophysiologic characteristics of an <span class=""disease"" id=""17399643-0-41-58"">Andersen syndrome</span> patient with <span class=""gene"" id=""17399643-0-72-77"">KCNJ2</span> mutation.",CTD_human;ORPHANET;UNIPROT
7,17,Biomarker,C1563715,Andersen Syndrome,disease,Andersen-Tawil syndrome,3759,KCNJ2,KCNJ2,CTD_human,19931173,Novel de novo mutation in the KCNJ2 gene in a patient with Andersen-Tawil syndrome.,0.6312327211363901,"Novel de novo mutation in the <span class=""gene"" id=""19931173-0-30-35"">KCNJ2</span> gene in a patient with <span class=""disease"" id=""19931173-0-59-82"">Andersen-Tawil syndrome</span>.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0042510,Ventricular Fibrillation,disease,Ventricular fibrillation,3764,KCNJ8,KCNJ8,CTD_human,19120683,Ventricular fibrillation with prominent early repolarization associated with a rare variant of KCNJ8/KATP channel.,0.20054945356842604,"<span class=""disease"" id=""19120683-0-0-24"">Ventricular fibrillation</span> with prominent early repolarization associated with a rare variant of <span class=""gene"" id=""19120683-0-95-100"">KCNJ8</span>/KATP channel.",CTD_human
2,2,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,type 2 diabetes,3767,KCNJ11,KCNJ11,CTD_human,22209866,"The common ATP-sensitive potassium (KATP) channel variants E23K and S1369A, found in the KCNJ11 and ABCC8 genes, respectively, form a haplotype that is associated with an increased risk for type 2 diabetes.",0.502252869521261,"The common ATP-sensitive potassium (KATP) channel variants E23K and S1369A, found in the <span class=""gene"" id=""22209866-1-89-95"">KCNJ11</span> and ABCC8 genes, respectively, form a haplotype that is associated with an increased risk for <span class=""disease"" id=""22209866-1-190-205"">type 2 diabetes</span>.",CTD_human;ORPHANET
6,0,Biomarker,C0011581,Depressive disorder,disease,depression,3776,KCNK2,TREK1,CTD_human,21871532,"Similar to mice treated with selective serotonin reuptake inhibitors (SSRIs), TREK1 knockout mice are resistant to depression-like behavior and have elevated serotonin levels leading to speculation that TREK1 inhibition may contribute to the therapeutic effects of SSRIs.",0.401648360705279,"Similar to mice treated with selective serotonin reuptake inhibitors (SSRIs), <span class=""gene"" id=""21871532-2-78-83"">TREK1</span> knockout mice are resistant to <span class=""disease"" id=""21871532-2-115-125"">depression</span>-like behavior and have elevated serotonin levels leading to speculation that <span class=""gene"" id=""21871532-2-203-208"">TREK1</span> inhibition may contribute to the therapeutic effects of SSRIs.",CTD_human;PSYGENET
1,0,Biomarker,C0038220,Status Epilepticus,disease,status epilepticus,3778,KCNMA1,Kcnma1,CTD_human,18695509,"By using comparative real-time PCR, Taqman gene expression assays, and the delta-delta comparative threshold method we detected a significant reduction in Kcnma1 expression in microdissected dentate gyrus at different intervals after status epilepticus (24 h, 10 days, 1 month, and more than 2 months).",0.2,"By using comparative real-time PCR, Taqman gene expression assays, and the delta-delta comparative threshold method we detected a significant reduction in <span class=""gene"" id=""18695509-3-155-161"">Kcnma1</span> expression in microdissected dentate gyrus at different intervals after <span class=""disease"" id=""18695509-3-234-252"">status epilepticus</span> (24 h, 10 days, 1 month, and more than 2 months).",CTD_human
1,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,3779,KCNMB1,KCNMB1,CTD_human,17700361,KCNMB1 is involved in calcium sensitivity and hypertension.,0.298273990741394,"<span class=""gene"" id=""17700361-2-0-6"">KCNMB1</span> is involved in calcium sensitivity and <span class=""disease"" id=""17700361-2-46-58"">hypertension</span>.",CTD_human
1,2,Biomarker,C0004238,Atrial Fibrillation,disease,AF,3782,KCNN3,KCNN3,CTD_human,20173747,"We identified an association on chromosome 1q21 to lone AF (rs13376333, adjusted odds ratio = 1.56; P = 6.3 x 10(-12)), and we replicated this association in two independent cohorts with lone AF (overall combined odds ratio = 1.52, 95% CI 1.40-1.64; P = 1.83 x 10(-21)). rs13376333 is intronic to KCNN3, which encodes a potassium channel protein involved in atrial repolarization.",0.203846174978983,"We identified an association on chromosome 1q21 to lone <span class=""disease"" id=""20173747-7-56-58"">AF</span> (rs13376333, adjusted odds ratio = 1.56; P = 6.3 x 10(-12)), and we replicated this association in two independent cohorts with lone <span class=""disease"" id=""20173747-7-192-194"">AF</span> (overall combined odds ratio = 1.52, 95% CI 1.40-1.64; P = 1.83 x 10(-21)). rs13376333 is intronic to <span class=""gene"" id=""20173747-7-297-302"">KCNN3</span>, which encodes a potassium channel protein involved in atrial repolarization.",CTD_human
1,0,Biomarker,C0001418,Adenocarcinoma,group,adenocarcinomas,3784,KCNQ1,Kcnq1,CTD_human,23975432,"Results demonstrated that Kcnq1 is a tumor suppressor gene as Kcnq1 mutant mice developed significantly more intestinal tumors, especially in the proximal small intestine and colon, and some of these tumors progressed to become aggressive adenocarcinomas.",0.200274726784213,"Results demonstrated that <span class=""gene"" id=""23975432-3-26-31"">Kcnq1</span> is a tumor suppressor gene as <span class=""gene"" id=""23975432-3-62-67"">Kcnq1</span> mutant mice developed significantly more intestinal tumors, especially in the proximal small intestine and colon, and some of these tumors progressed to become aggressive <span class=""disease"" id=""23975432-3-239-254"">adenocarcinomas</span>.",CTD_human
3,11,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,type 2 diabetes mellitus,3784,KCNQ1,KCNQ1,CTD_human,18711367,Variants in KCNQ1 are associated with susceptibility to type 2 diabetes mellitus.,0.297563909026569,"Variants in <span class=""gene"" id=""18711367-0-12-17"">KCNQ1</span> are associated with susceptibility to <span class=""disease"" id=""18711367-0-56-80"">type 2 diabetes mellitus</span>.",CTD_human
3,11,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,type 2 diabetes,3784,KCNQ1,KCNQ1,CTD_human,18711366,SNPs in KCNQ1 are associated with susceptibility to type 2 diabetes in East Asian and European populations.,0.297563909026569,"SNPs in <span class=""gene"" id=""18711366-0-8-13"">KCNQ1</span> are associated with susceptibility to <span class=""disease"" id=""18711366-0-52-67"">type 2 diabetes</span> in East Asian and European populations.",CTD_human
1,0,Biomarker,C0021841,Intestinal Neoplasms,group,intestinal tumors,3784,KCNQ1,Kcnq1,CTD_human,23975432,"Results demonstrated that Kcnq1 is a tumor suppressor gene as Kcnq1 mutant mice developed significantly more intestinal tumors, especially in the proximal small intestine and colon, and some of these tumors progressed to become aggressive adenocarcinomas.",0.200274726784213,"Results demonstrated that <span class=""gene"" id=""23975432-3-26-31"">Kcnq1</span> is a tumor suppressor gene as <span class=""gene"" id=""23975432-3-62-67"">Kcnq1</span> mutant mice developed significantly more <span class=""disease"" id=""23975432-3-109-126"">intestinal tumors</span>, especially in the proximal small intestine and colon, and some of these tumors progressed to become aggressive adenocarcinomas.",CTD_human
7,43,Biomarker,C0023976,Long QT Syndrome,disease,long QT syndrome,3784,KCNQ1,LQT1,CTD_human,15028050,Additional gene variants reduce effectiveness of beta-blockers in the LQT1 form of long QT syndrome.,0.380059945578023,"Additional gene variants reduce effectiveness of beta-blockers in the <span class=""gene"" id=""15028050-0-70-74"">LQT1</span> form of <span class=""disease"" id=""15028050-0-83-99"">long QT syndrome</span>.",CTD_human
36,138,Biomarker,C0035828,Romano-Ward Syndrome,disease,LQT1,3784,KCNQ1,Kcnq1,CTD_human,15004216,"To determine whether the neonatal mouse can serve as a useful model for studying the molecular pharmacological basis of Long QT Syndrome Type 1 (LQT1), which has been linked to mutations in the human KCNQ1 gene, we measured QT intervals from electrocardiogram (ECG) recordings of wild-type (WT) and Kcnq1 knockout (KO) neonates before and after injection with the beta-adrenergic receptor agonist, isoproterenol (0.17 mg/kg, i.p.).",0.698377983787643,"To determine whether the neonatal mouse can serve as a useful model for studying the molecular pharmacological basis of <span class=""disease"" id=""15004216-1-120-143"">Long QT Syndrome Type 1</span> (<span class=""disease"" id=""15004216-1-145-149"">LQT1</span>), which has been linked to mutations in the human <span class=""gene"" id=""15004216-1-200-205"">KCNQ1</span> gene, we measured QT intervals from electrocardiogram (ECG) recordings of wild-type (WT) and <span class=""gene"" id=""15004216-1-299-304"">Kcnq1</span> knockout (KO) neonates before and after injection with the beta-adrenergic receptor agonist, isoproterenol (0.17 mg/kg, i.p.).",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0014544,Epilepsy,disease,epilepsy,3785,KCNQ2,Kcnq2,CTD_human,16464983,Severe epilepsy resulting from genetic interaction between Scn2a and Kcnq2.,0.41996083195829204,"Severe <span class=""disease"" id=""16464983-0-7-15"">epilepsy</span> resulting from genetic interaction between Scn2a and <span class=""gene"" id=""16464983-0-69-74"">Kcnq2</span>.",CTD_human;HPO
1,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastasis,378938,MALAT1,MALAT1,CTD_human,24244343,Resveratrol inhibits invasion and metastasis of colorectal cancer cells via MALAT1 mediated Wnt/?-catenin signal pathway.,0.22170341595283502,"Resveratrol inhibits invasion and <span class=""disease"" id=""24244343-0-34-44"">metastasis</span> of colorectal cancer cells via <span class=""gene"" id=""24244343-0-76-82"">MALAT1</span> mediated Wnt/&beta;-catenin signal pathway.",CTD_human
1,0,Biomarker,C0279626,Squamous cell carcinoma of esophagus,disease,esophageal squamous cell carcinoma,378938,MALAT1,MALAT1,CTD_human,25538231,"Silencing of long noncoding RNA MALAT1 by miR-101 and miR-217 inhibits proliferation, migration, and invasion of esophageal squamous cell carcinoma cells.",0.201098907136852,"Silencing of long noncoding RNA <span class=""gene"" id=""25538231-0-32-38"">MALAT1</span> by miR-101 and miR-217 inhibits proliferation, migration, and invasion of <span class=""disease"" id=""25538231-0-113-147"">esophageal squamous cell carcinoma</span> cells.",CTD_human
1,0,Biomarker,C0011881,Diabetic Nephropathy,disease,DN,3791,KDR,Flk-1,CTD_human,18630688,"VEGF and Flk-1 play an important role in the pathogenesis of DN, of which over-expression may lead to the damage of kidney.",0.200274726784213,"VEGF and <span class=""gene"" id=""18630688-5-9-14"">Flk-1</span> play an important role in the pathogenesis of <span class=""disease"" id=""18630688-5-61-63"">DN</span>, of which over-expression may lead to the damage of kidney.",CTD_human
1,0,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,3791,KDR,Flk1,CTD_human,21647420,"Moreover, significant reductions in Flk1 and GR protein levels were found in postmortem prefrontal cortex samples from schizophrenia subjects.",0.2,"Moreover, significant reductions in <span class=""gene"" id=""21647420-10-36-40"">Flk1</span> and GR protein levels were found in postmortem prefrontal cortex samples from <span class=""disease"" id=""21647420-10-119-132"">schizophrenia</span> subjects.",CTD_human
3,2,Biomarker,C0268160,Deficiency of fructokinase,disease,fructosuria,3795,KHK,ketohexokinase (fructokinase,CTD_human,7833921,Molecular basis of essential fructosuria: molecular cloning and mutational analysis of human ketohexokinase (fructokinase).,0.600549453568426,"Molecular basis of essential <span class=""disease"" id=""7833921-0-29-40"">fructosuria</span>: molecular cloning and mutational analysis of human <span class=""gene"" id=""7833921-0-93-121"">ketohexokinase (fructokinase</span>).",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0025958,Microcephaly,disease,microcephaly,3796,KIF2A,KIF2A,CTD_human,23603762,"Mutations in TUBG1, DYNC1H1, KIF5C and KIF2A cause malformations of cortical development and microcephaly.",0.2,"Mutations in TUBG1, DYNC1H1, KIF5C and <span class=""gene"" id=""23603762-0-39-44"">KIF2A</span> cause malformations of cortical development and <span class=""disease"" id=""23603762-0-93-105"">microcephaly</span>.",CTD_human
1,0,Biomarker,C1955869,Malformations of Cortical Development,disease,malformations of cortical development,3796,KIF2A,KIF2A,CTD_human,23603762,"Mutations in TUBG1, DYNC1H1, KIF5C and KIF2A cause malformations of cortical development and microcephaly.",0.2,"Mutations in TUBG1, DYNC1H1, KIF5C and <span class=""gene"" id=""23603762-0-39-44"">KIF2A</span> cause <span class=""disease"" id=""23603762-0-51-88"">malformations of cortical development</span> and microcephaly.",CTD_human
1,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,NSCLC,3799,KIF5B,KIF5B,CTD_human,21757253,"Out of 404 cases, there were 14 of EML4-ALK non-small cell carcinoma (NSCLC) and one KIF5B-ALK NSCLC case (8 men, 7 women; mean age, 61.9 years, range 48-82).",0.201923087489492,"Out of 404 cases, there were 14 of EML4-ALK non-small cell carcinoma (<span class=""disease"" id=""21757253-6-70-75"">NSCLC</span>) and one <span class=""gene"" id=""21757253-6-85-90"">KIF5B</span>-ALK <span class=""disease"" id=""21757253-6-95-100"">NSCLC</span> case (8 men, 7 women; mean age, 61.9 years, range 48-82).",CTD_human
1,0,Biomarker,C0011849,Diabetes Mellitus,group,Diabetes,3799,KIF5B,KIF5B,CTD_human,23776493,Diabetes alters KIF1A and KIF5B motor proteins in the hippocampus.,0.2,"<span class=""disease"" id=""23776493-0-0-8"">Diabetes</span> alters KIF1A and <span class=""gene"" id=""23776493-0-26-31"">KIF5B</span> motor proteins in the hippocampus.",CTD_human
1,0,Biomarker,C0036572,Seizures,phenotype,EXP1,38,ACAT1,ACAT1,CTD_human,23266720,"Among the total twelve genes, six genes were strongly up- (MT-3, ACAT1, clusterin and ApoE) or down- (ZnT-1 and PRG-3) regulated by developmental seizures (EXP1) compared with that in the CONT1.",0.2,"Among the total twelve genes, six genes were strongly up- (MT-3, <span class=""gene"" id=""23266720-8-65-70"">ACAT1</span>, clusterin and ApoE) or down- (ZnT-1 and PRG-3) regulated by developmental <span class=""disease"" id=""23266720-8-146-154"">seizures</span> (<span class=""disease"" id=""23266720-8-156-160"">EXP1</span>) compared with that in the CONT1.",CTD_human
1,0,Biomarker,C0025958,Microcephaly,disease,microcephaly,3800,KIF5C,KIF5C,CTD_human,23603762,"Mutations in TUBG1, DYNC1H1, KIF5C and KIF2A cause malformations of cortical development and microcephaly.",0.2,"Mutations in TUBG1, DYNC1H1, <span class=""gene"" id=""23603762-0-29-34"">KIF5C</span> and KIF2A cause malformations of cortical development and <span class=""disease"" id=""23603762-0-93-105"">microcephaly</span>.",CTD_human
1,0,Biomarker,C1955869,Malformations of Cortical Development,disease,malformations of cortical development,3800,KIF5C,KIF5C,CTD_human,23603762,"Mutations in TUBG1, DYNC1H1, KIF5C and KIF2A cause malformations of cortical development and microcephaly.",0.2,"Mutations in TUBG1, DYNC1H1, <span class=""gene"" id=""23603762-0-29-34"">KIF5C</span> and KIF2A cause <span class=""disease"" id=""23603762-0-51-88"">malformations of cortical development</span> and microcephaly.",CTD_human
1,0,Biomarker,C0019693,HIV Infections,group,HIV,3811,KIR3DL1,KIR3DL1,CTD_human,17496894,Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1.,0.22124482821042601,"Innate partnership of HLA-B and <span class=""gene"" id=""17496894-0-32-39"">KIR3DL1</span> subtypes against <span class=""disease"" id=""17496894-0-57-60"">HIV</span>-1.",CTD_human
1,0,Therapeutic,C1168401,Squamous cell carcinoma of the head and neck,disease,head and neck squamous cell carcinoma,3814,KISS1,KiSS1,CTD_human,21383688,KiSS1 mediates platinum sensitivity and metastasis suppression in head and neck squamous cell carcinoma.,0.200274726784213,"<span class=""gene"" id=""21383688-0-0-5"">KiSS1</span> mediates platinum sensitivity and metastasis suppression in <span class=""disease"" id=""21383688-0-66-103"">head and neck squamous cell carcinoma</span>.",CTD_human
1,0,Biomarker,C0149925,Small cell carcinoma of lung,disease,SCLC,3815,KIT,c-kit,CTD_human,15499612,"The level of c-kit mRNA expression was variable in SCLC tumors (positive for 2 of 4 xenografts), and c-kit protein was not detected by immunohistochemistry.",0.21069998920699398,"The level of c-kit mRNA expression was variable in <span class=""disease"" id=""15499612-4-51-55"">SCLC</span> tumors (positive for 2 of 4 xenografts), and <span class=""gene"" id=""15499612-4-101-106"">c-kit</span> protein was not detected by immunohistochemistry.",CTD_human
4,5,Biomarker,C0238198,Gastrointestinal Stromal Tumors,group,gastrointestinal stromal tumor,3815,KIT,c-KIT,CTD_human,16740725,Flavopiridol targets c-KIT transcription and induces apoptosis in gastrointestinal stromal tumor cells.,0.880919484895896,"Flavopiridol targets <span class=""gene"" id=""16740725-0-21-26"">c-KIT</span> transcription and induces apoptosis in <span class=""disease"" id=""16740725-0-66-96"">gastrointestinal stromal tumor</span> cells.",CTD_human;HPO;ORPHANET;UNIPROT
4,5,Biomarker,C0238198,Gastrointestinal Stromal Tumors,group,GIST,3815,KIT,KIT,CTD_human,20028860,We show that bortezomib rapidly triggers apoptosis in GIST cells through a combination of mechanisms involving H2AX upregulation and loss of KIT protein expression.,0.880919484895896,"We show that bortezomib rapidly triggers apoptosis in <span class=""disease"" id=""20028860-6-54-58"">GIST</span> cells through a combination of mechanisms involving H2AX upregulation and loss of <span class=""gene"" id=""20028860-6-141-144"">KIT</span> protein expression.",CTD_human;HPO;ORPHANET;UNIPROT
1,0,Therapeutic,C0011881,Diabetic Nephropathy,disease,diabetic nephropathy,3816,KLK1,tissue kallikrein,CTD_human,19516248,"Here, we determined the role of the kallikrein-kinin system in the pathogenesis of streptozotocin-induced diabetic nephropathy in wild-type and tissue kallikrein-knockout mice.",0.200274726784213,"Here, we determined the role of the kallikrein-kinin system in the pathogenesis of streptozotocin-induced <span class=""disease"" id=""19516248-2-106-126"">diabetic nephropathy</span> in wild-type and <span class=""gene"" id=""19516248-2-144-161"">tissue kallikrein</span>-knockout mice.",CTD_human
1,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,3816,KLK1,tissue kallikrein,CTD_human,14568997,Gene therapy with human tissue kallikrein reduces hypertension and hyperinsulinemia in fructose-induced hypertensive rats.,0.226487083513153,"Gene therapy with human <span class=""gene"" id=""14568997-0-24-41"">tissue kallikrein</span> reduces <span class=""disease"" id=""14568997-0-50-62"">hypertension</span> and hyperinsulinemia in fructose-induced hypertensive rats.",CTD_human
1,0,Therapeutic,C0027051,Myocardial Infarction,disease,MI,3816,KLK1,tissue kallikrein,CTD_human,12411458,"Rats were subjected to coronary artery ligation to induce MI, and adenovirus carrying the human tissue kallikrein or luciferase gene was injected into the tail vein at 1 week after surgery.",0.201373633921065,"Rats were subjected to coronary artery ligation to induce <span class=""disease"" id=""12411458-2-58-60"">MI</span>, and adenovirus carrying the human <span class=""gene"" id=""12411458-2-96-113"">tissue kallikrein</span> or luciferase gene was injected into the tail vein at 1 week after surgery.",CTD_human
1,0,Therapeutic,C0853897,Diabetic Cardiomyopathies,disease,diabetic cardiomyopathy,3816,KLK1,hKLK1,CTD_human,16129698,These diabetic cardiomyopathy-associated alterations were significantly attenuated (P<0.05) in diabetic transgenic rats expressing the human kallikrein 1 (hKLK1) gene with STZ-induced diabetes.,0.20054945356842604,"These <span class=""disease"" id=""16129698-5-6-29"">diabetic cardiomyopathy</span>-associated alterations were significantly attenuated (P&lt;0.05) in diabetic transgenic rats expressing the human kallikrein 1 (<span class=""gene"" id=""16129698-5-155-160"">hKLK1</span>) gene with STZ-induced diabetes.",CTD_human
1,0,Biomarker,C0010200,Coughing,phenotype,cough,3827,KNG1,BK,CTD_human,22693178,TRPV1 and TRPA1 blockers partially inhibited the tussive response to PGE2 and BK with a complete inhibition obtained in the presence of both antagonists together in a guinea pig conscious cough model.,0.201648360705279,"TRPV1 and TRPA1 blockers partially inhibited the tussive response to PGE2 and <span class=""gene"" id=""22693178-9-78-80"">BK</span> with a complete inhibition obtained in the presence of both antagonists together in a guinea pig conscious <span class=""disease"" id=""22693178-9-188-193"">cough</span> model.",CTD_human
1,0,Biomarker,C0019243,"Angioedemas, Hereditary",disease,C1 esterase inhibitor deficiency,3827,KNG1,Bradykinin,CTD_human,9734886,"Bradykinin is believed to be the main mediator of symptoms in hereditary (HA) and acquired (AA) angio-oedema due to C1 esterase inhibitor deficiency, as well as in angio-oedema that complicates treatment with inhibitors of angiotensin-converting enzyme (ACE).",0.210439617800098,"<span class=""gene"" id=""9734886-1-0-10"">Bradykinin</span> is believed to be the main mediator of symptoms in hereditary (HA) and acquired (AA) angio-oedema due to <span class=""disease"" id=""9734886-1-116-148"">C1 esterase inhibitor deficiency</span>, as well as in angio-oedema that complicates treatment with inhibitors of angiotensin-converting enzyme (ACE).",CTD_human
17,0,Biomarker,C0020429,Hyperalgesia,phenotype,hyperalgesia,3827,KNG1,bradykinin,CTD_human,7582491,These data suggest that IL-10 limits the inflammatory hyperalgesia evoked by carrageenin and bradykinin by two mechanisms: inhibition of cytokine production and inhibition of IL-1 beta evoked PGE2 production.,0.28082418035263895,"These data suggest that IL-10 limits the inflammatory <span class=""disease"" id=""7582491-7-54-66"">hyperalgesia</span> evoked by carrageenin and <span class=""gene"" id=""7582491-7-93-103"">bradykinin</span> by two mechanisms: inhibition of cytokine production and inhibition of IL-1 beta evoked PGE2 production.",CTD_human
17,0,Biomarker,C0020429,Hyperalgesia,phenotype,hyperalgesia,3827,KNG1,bradykinin,CTD_human,3061568,Characterization of the arachidonic acid metabolites mediating bradykinin and noradrenaline hyperalgesia.,0.28082418035263895,"Characterization of the arachidonic acid metabolites mediating <span class=""gene"" id=""3061568-0-63-73"">bradykinin</span> and noradrenaline <span class=""disease"" id=""3061568-0-92-104"">hyperalgesia</span>.",CTD_human
17,0,Biomarker,C0020429,Hyperalgesia,phenotype,hyperalgesia,3827,KNG1,bradykinin,CTD_human,16259764,"In addition, the ME of B. microstachya (3--300 mg kg(-1), i.p., 30 min earlier) inhibited, in a graded manner, the hyperalgesia induced by bradykinin (3.2 microg/paw), substance P (13.5 microg/paw), carrageenan (300 microg/paw), capsaicin (100 microg/paw) and adrenaline (100 ng/paw) in the rat paw, with mean ID50 values of 20.5, 17.9, 101.8, 54.2 and 99.7 mg kg(-1), respectively.",0.28082418035263895,"In addition, the ME of B. microstachya (3--300 mg kg(-1), i.p., 30 min earlier) inhibited, in a graded manner, the <span class=""disease"" id=""16259764-5-115-127"">hyperalgesia</span> induced by <span class=""gene"" id=""16259764-5-139-149"">bradykinin</span> (3.2 microg/paw), substance P (13.5 microg/paw), carrageenan (300 microg/paw), capsaicin (100 microg/paw) and adrenaline (100 ng/paw) in the rat paw, with mean ID50 values of 20.5, 17.9, 101.8, 54.2 and 99.7 mg kg(-1), respectively.",CTD_human
17,0,Biomarker,C0020429,Hyperalgesia,phenotype,hyperalgesia,3827,KNG1,bradykinin,CTD_human,16793879,"In wild-type mice, activation of PKRs by the PKR agonist Bv8 caused hyperalgesia and sensitized to the actions of capsaicin. pkr1-null mice exhibited impaired responses to Bv8 but showed normal hyperalgesic responses to bradykinin and PGE2 (prostaglandin E2).",0.28082418035263895,"In wild-type mice, activation of PKRs by the PKR agonist Bv8 caused <span class=""disease"" id=""16793879-5-68-80"">hyperalgesia</span> and sensitized to the actions of capsaicin. pkr1-null mice exhibited impaired responses to Bv8 but showed normal hyperalgesic responses to <span class=""gene"" id=""16793879-5-220-230"">bradykinin</span> and PGE2 (prostaglandin E2).",CTD_human
17,0,Biomarker,C0020429,Hyperalgesia,phenotype,hyperalgesia,3827,KNG1,bradykinin,CTD_human,10543429,"Given orally NPC 18884, but not HOE 140, caused graded inhibition of BK-induced nociception (mean ID50 value of 50 nmol/kg).In rats, NPC 18884 given i.p. prevented BK and carrageenan-induced hyperalgesia (mean ID50 values of 6 nmol/kg and 13 nmol/kg), without affecting the hyperalgesia induced by des-Arg9-bradykinin (DABK) or by prostaglandin E2 (PGE2).NPC 18884 given i.p. inhibited the mouse paw oedema induced by tyrosine8-bradykinin or by carrageenan, but had no effect on DABK-induced oedema in mice pre-treated with Escherichia coli endotoxin, or that induced by PGE2.",0.28082418035263895,"Given orally NPC 18884, but not HOE 140, caused graded inhibition of <span class=""gene"" id=""10543429-5-69-71"">BK</span>-induced nociception (mean ID50 value of 50 nmol/kg).In rats, NPC 18884 given i.p. prevented <span class=""gene"" id=""10543429-5-164-166"">BK</span> and carrageenan-induced <span class=""disease"" id=""10543429-5-191-203"">hyperalgesia</span> (mean ID50 values of 6 nmol/kg and 13 nmol/kg), without affecting the <span class=""disease"" id=""10543429-5-274-286"">hyperalgesia</span> induced by des-Arg9-bradykinin (DABK) or by prostaglandin E2 (PGE2).NPC 18884 given i.p. inhibited the mouse paw oedema induced by tyrosine8-<span class=""gene"" id=""10543429-5-428-438"">bradykinin</span> or by carrageenan, but had no effect on DABK-induced oedema in mice pre-treated with Escherichia coli endotoxin, or that induced by PGE2.",CTD_human
17,0,Biomarker,C0020429,Hyperalgesia,phenotype,hyperalgesia,3827,KNG1,bradykinin,CTD_human,10401557,"The ODQ potentiated hyperalgesia induced by carrageenan, bradykinin, TNF alpha, IL-1 beta, IL-6 and IL-8.",0.28082418035263895,"The ODQ potentiated <span class=""disease"" id=""10401557-10-20-32"">hyperalgesia</span> induced by carrageenan, <span class=""gene"" id=""10401557-10-57-67"">bradykinin</span>, TNF alpha, IL-1 beta, IL-6 and IL-8.",CTD_human
17,0,Biomarker,C0020429,Hyperalgesia,phenotype,hyperalgesia,3827,KNG1,bradykinin,CTD_human,7881729,"Post-treatment with S14080 dose-dependently antagonized the hyperalgesia induced by prostaglandin E2, bradykinin, dopamine and by the hyperalgesic cytokines reported to be released by carrageenin (tumour necrosis factor alpha, interleukin-1 and interleukin-8).3.",0.28082418035263895,"Post-treatment with S14080 dose-dependently antagonized the <span class=""disease"" id=""7881729-3-60-72"">hyperalgesia</span> induced by prostaglandin E2, <span class=""gene"" id=""7881729-3-102-112"">bradykinin</span>, dopamine and by the hyperalgesic cytokines reported to be released by carrageenin (tumour necrosis factor alpha, interleukin-1 and interleukin-8).3.",CTD_human
17,0,Biomarker,C0020429,Hyperalgesia,phenotype,hyperalgesia,3827,KNG1,bradykinin,CTD_human,9714424,"The HE (3 to 100 mg kg(-1), p.o., 1 h) inhibited in a graded manner, the hyperalgesia induced by bradykinin (3 nmol/paw) or substance P (10 nmol/paw) in rat paw, with mean ED50 values of 54.5 and 53.7 mg kg(-1), respectively.",0.28082418035263895,"The HE (3 to 100 mg kg(-1), p.o., 1 h) inhibited in a graded manner, the <span class=""disease"" id=""9714424-5-73-85"">hyperalgesia</span> induced by <span class=""gene"" id=""9714424-5-97-107"">bradykinin</span> (3 nmol/paw) or substance P (10 nmol/paw) in rat paw, with mean ED50 values of 54.5 and 53.7 mg kg(-1), respectively.",CTD_human
17,0,Biomarker,C0020429,Hyperalgesia,phenotype,hyperalgesia,3827,KNG1,bradykinin,CTD_human,10499367,"GAEE significantly inhibited the hyperalgesia induced by bradykinin or substance P in rat paw, but did not affect the hyperalgesia caused by carrageenan or prostaglandin E2.",0.28082418035263895,"GAEE significantly inhibited the <span class=""disease"" id=""10499367-2-33-45"">hyperalgesia</span> induced by <span class=""gene"" id=""10499367-2-57-67"">bradykinin</span> or substance P in rat paw, but did not affect the <span class=""disease"" id=""10499367-2-118-130"">hyperalgesia</span> caused by carrageenan or prostaglandin E2.",CTD_human
17,0,Biomarker,C0020429,Hyperalgesia,phenotype,Hyperalgesia,3827,KNG1,bradykinin,CTD_human,9720808,"Hyperalgesia induced by prostaglandin E2 remained unaffected by FR173657.5.Blood pressure reflexes following i.p. instillation of bradykinin in anaesthetized rats were inhibited by FR173657 s.c. with an ID50 of 1.1 micromol kg(-1), while the peptidic B2 antagonist icatibant (Hoe-140; D-Arg0-[Hyp3, Thi5, D-Tic7, Oic8]-bradykinin) caused inhibition at significantly lower doses (ID50 8.5 nmol kg(-1) P < 0.001).Responses to hydrochloric acid i.p. remained unaffected by FR173657.6.",0.28082418035263895,"<span class=""disease"" id=""9720808-7-0-12"">Hyperalgesia</span> induced by prostaglandin E2 remained unaffected by FR173657.5.Blood pressure reflexes following i.p. instillation of <span class=""gene"" id=""9720808-7-130-140"">bradykinin</span> in anaesthetized rats were inhibited by FR173657 s.c. with an ID50 of 1.1 micromol kg(-1), while the peptidic B2 antagonist icatibant (Hoe-140; D-Arg0-[Hyp3, Thi5, D-Tic7, Oic8]-<span class=""gene"" id=""9720808-7-319-329"">bradykinin</span>) caused inhibition at significantly lower doses (ID50 8.5 nmol kg(-1) P &lt; 0.001).Responses to hydrochloric acid i.p. remained unaffected by FR173657.6.",CTD_human
17,0,Biomarker,C0020429,Hyperalgesia,phenotype,hyperalgesia,3827,KNG1,bradykinin,CTD_human,2128375,Characterization of distinct phospholipases mediating bradykinin and noradrenaline hyperalgesia.,0.28082418035263895,"Characterization of distinct phospholipases mediating <span class=""gene"" id=""2128375-0-54-64"">bradykinin</span> and noradrenaline <span class=""disease"" id=""2128375-0-83-95"">hyperalgesia</span>.",CTD_human
17,0,Biomarker,C0020429,Hyperalgesia,phenotype,hyperalgesia,3827,KNG1,BK,CTD_human,2010815,"Pertussis toxin prevented the inhibition of BK-induced hyperalgesia by U50,488H, DPDPE, or DAMGO.",0.28082418035263895,"Pertussis toxin prevented the inhibition of <span class=""gene"" id=""2010815-5-44-46"">BK</span>-induced <span class=""disease"" id=""2010815-5-55-67"">hyperalgesia</span> by U50,488H, DPDPE, or DAMGO.",CTD_human
1,0,Biomarker,C0020452,Hyperemia,disease,hyperemia,3827,KNG1,bradykinin,CTD_human,11837250,Role of bradykinin in acid-induced mesenteric hyperemia and duodenal villous damage.,0.2,"Role of <span class=""gene"" id=""11837250-0-8-18"">bradykinin</span> in acid-induced mesenteric <span class=""disease"" id=""11837250-0-46-55"">hyperemia</span> and duodenal villous damage.",CTD_human
1,0,Biomarker,C0020453,Hyperesthesia,phenotype,hyperaesthesia,3827,KNG1,bradykinin,CTD_human,8190269,The B-2 receptor antagonist HOE 140 (0.1 mg/kg) prevented bradykinin- but not prostaglandin E2-induced thermal hyperaesthesia.,0.2,"The B-2 receptor antagonist HOE 140 (0.1 mg/kg) prevented <span class=""gene"" id=""8190269-3-58-68"">bradykinin</span>- but not prostaglandin E2-induced thermal <span class=""disease"" id=""8190269-3-111-125"">hyperaesthesia</span>.",CTD_human
6,0,Biomarker,C0030193,Pain,phenotype,pain,3827,KNG1,bradykinin,CTD_human,16076651,"However, hepatic GSH, which is involved in the detoxification of chemical compounds, significantly decreased after i.p. morphine injection at 02:00 but not at 14:00 h. Overall, the results suggest that the analgesic effect of morphine is greater after dosing during the resting than during the activity phase of mice that have been induced with bradykinin-mediated pain.",0.202472541057918,"However, hepatic GSH, which is involved in the detoxification of chemical compounds, significantly decreased after i.p. morphine injection at 02:00 but not at 14:00 h. Overall, the results suggest that the analgesic effect of morphine is greater after dosing during the resting than during the activity phase of mice that have been induced with <span class=""gene"" id=""16076651-4-345-355"">bradykinin</span>-mediated <span class=""disease"" id=""16076651-4-365-369"">pain</span>.",CTD_human
6,0,Biomarker,C0030193,Pain,phenotype,pain,3827,KNG1,bradykinin,CTD_human,3951883,Morphine reduced pain produced by capsaicin (presumed to selectively excite unmyelinated peripheral afferents) but did not diminish pain elicited by bradykinin (presumed to excite A delta and C nociceptors).,0.202472541057918,"Morphine reduced <span class=""disease"" id=""3951883-7-17-21"">pain</span> produced by capsaicin (presumed to selectively excite unmyelinated peripheral afferents) but did not diminish <span class=""disease"" id=""3951883-7-132-136"">pain</span> elicited by <span class=""gene"" id=""3951883-7-149-159"">bradykinin</span> (presumed to excite A delta and C nociceptors).",CTD_human
6,0,Biomarker,C0030193,Pain,phenotype,pain,3827,KNG1,bradykinin,CTD_human,20018876,"Behavioral studies showed greatly reduced thermal inflammatory pain perception in AQP1(-/-) mice evoked by bradykinin, prostaglandin E(2), and capsaicin as well as reduced cold pain perception.",0.202472541057918,"Behavioral studies showed greatly reduced thermal inflammatory pain perception in AQP1(-/-) mice evoked by <span class=""gene"" id=""20018876-3-107-117"">bradykinin</span>, prostaglandin E(2), and capsaicin as well as reduced cold <span class=""disease"" id=""20018876-3-177-181"">pain</span> perception.",CTD_human
6,0,Biomarker,C0030193,Pain,phenotype,pain,3827,KNG1,BK,CTD_human,1281941,"We also verified that L-NAME (50 mg/kg i.c.) reduced the BK-, but not the CAP- and/or RCM-induced pain responses which suggests that an L-arginine-derived NO or related compound is involved in BK activation of perivascular nociceptors.Indeed, we found that i.c. injection of 20 mg of S-nitrosocysteine, a putative EDRF, caused BK-like responses.",0.202472541057918,"We also verified that L-NAME (50 mg/kg i.c.) reduced the <span class=""gene"" id=""1281941-5-57-59"">BK</span>-, but not the CAP- and/or RCM-induced <span class=""disease"" id=""1281941-5-98-102"">pain</span> responses which suggests that an L-arginine-derived NO or related compound is involved in <span class=""gene"" id=""1281941-5-193-195"">BK</span> activation of perivascular nociceptors.Indeed, we found that i.c. injection of 20 mg of S-nitrosocysteine, a putative EDRF, caused <span class=""gene"" id=""1281941-5-327-329"">BK</span>-like responses.",CTD_human
2,0,Biomarker,C0004096,Asthma,disease,asthma,383,ARG1,ARG1,CTD_human,19281908,The association between ARG1 variation and asthma might depend on atopy and ambient ozone levels.,0.210294237353521,"The association between <span class=""gene"" id=""19281908-11-24-28"">ARG1</span> variation and <span class=""disease"" id=""19281908-11-43-49"">asthma</span> might depend on atopy and ambient ozone levels.",CTD_human
1,0,Biomarker,C0004096,Asthma,disease,asthma,384,ARG2,ARG2,CTD_human,19281908,"Compared with the most common haplotype within each locus, 1 ARG1 haplotype was associated with reduced risk (odds ratio [OR] per haplotype copy, 0.55; 95% CI, 0.36-0.84), and 1 ARG2 haplotype was associated with increased risk (OR per haplotype copy, 1.35; 95% CI, 1.04-1.76) of asthma.",0.20728659810449399,"Compared with the most common haplotype within each locus, 1 ARG1 haplotype was associated with reduced risk (odds ratio [OR] per haplotype copy, 0.55; 95% CI, 0.36-0.84), and 1 <span class=""gene"" id=""19281908-7-178-182"">ARG2</span> haplotype was associated with increased risk (OR per haplotype copy, 1.35; 95% CI, 1.04-1.76) of <span class=""disease"" id=""19281908-7-280-286"">asthma</span>.",CTD_human
1,0,Biomarker,C0887833,"Carcinoma, Pancreatic Ductal",disease,pancreatic ductal carcinoma,384,ARG2,ARG2,CTD_human,23424623,Here we studied the expression of ARG2 in pancreatic ductal carcinoma (PDC) tissue clinicopathologically by examining over 200 cases of PDC.,0.200274726784213,"Here we studied the expression of <span class=""gene"" id=""23424623-5-34-38"">ARG2</span> in <span class=""disease"" id=""23424623-5-42-69"">pancreatic ductal carcinoma</span> (PDC) tissue clinicopathologically by examining over 200 cases of PDC.",CTD_human
3,0,Biomarker,C0001418,Adenocarcinoma,group,adenocarcinomas,3845,KRAS,KRAS,CTD_human,20101149,The Kras mutational spectra of chemically induced lung tumors in different inbred mice mimics the spectra of KRAS mutations in adenocarcinomas in smokers versus nonsmokers.,0.4047461312648579,"The Kras mutational spectra of chemically induced lung tumors in different inbred mice mimics the spectra of <span class=""gene"" id=""20101149-0-109-113"">KRAS</span> mutations in <span class=""disease"" id=""20101149-0-127-142"">adenocarcinomas</span> in smokers versus nonsmokers.",CTD_human
6,10,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,non-small cell lung cancer,3845,KRAS,KRAS,CTD_human,24688052,KRAS mutation status is associated with enhanced dependency on folate metabolism pathways in non-small cell lung cancer cells.,0.303792209811992,"<span class=""gene"" id=""24688052-0-0-4"">KRAS</span> mutation status is associated with enhanced dependency on folate metabolism pathways in <span class=""disease"" id=""24688052-0-93-119"">non-small cell lung cancer</span> cells.",CTD_human
6,10,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,NSCLC,3845,KRAS,KRAS,CTD_human,22617245,"We selected NSCLC cell lines--A549 (KRAS G12S), NCI-H3255 (EGFR L858R), NCI-H3122 (EML4-ALK E13;A20), and HCC78 (SLC34A2-ROS1)-to evaluate the antiproliferative effects of submicromolar concentrations of the multitargeted TKIs imatinib, sorafenib, erlotinib, and crizotinib.",0.303792209811992,"We selected <span class=""disease"" id=""22617245-3-12-17"">NSCLC</span> cell lines--A549 (<span class=""gene"" id=""22617245-3-36-40"">KRAS</span> G12S), NCI-H3255 (EGFR L858R), NCI-H3122 (EML4-ALK E13;A20), and HCC78 (SLC34A2-ROS1)-to evaluate the antiproliferative effects of submicromolar concentrations of the multitargeted TKIs imatinib, sorafenib, erlotinib, and crizotinib.",CTD_human
6,10,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,nsclc,3845,KRAS,KRAS,CTD_human,22787409,"However, the benefits of these agents are not uniform across the spectrum of nsclc, and optimizing their utility requires some degree of subgrouping of nsclc by the presence or absence of certain biomarkers.The biomarkers of current or imminent value are EGFR and KRAS mutational status, ALK rearrangements, and MET immunohistochemistry.",0.303792209811992,"However, the benefits of these agents are not uniform across the spectrum of <span class=""disease"" id=""22787409-3-77-82"">nsclc</span>, and optimizing their utility requires some degree of subgrouping of <span class=""disease"" id=""22787409-3-152-157"">nsclc</span> by the presence or absence of certain biomarkers.The biomarkers of current or imminent value are EGFR and <span class=""gene"" id=""22787409-3-264-268"">KRAS</span> mutational status, ALK rearrangements, and MET immunohistochemistry.",CTD_human
6,10,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,non-small cell lung cancer,3845,KRAS,KRAS,CTD_human,21336183,"In an ALK-enriched population, patients with metastatic non-small cell lung cancer were screened by ALK fluorescence in situ hybridization and for epidermal growth factor receptor (EGFR) and KRAS mutations.",0.303792209811992,"In an ALK-enriched population, patients with metastatic <span class=""disease"" id=""21336183-2-56-82"">non-small cell lung cancer</span> were screened by ALK fluorescence in situ hybridization and for epidermal growth factor receptor (EGFR) and <span class=""gene"" id=""21336183-2-191-195"">KRAS</span> mutations.",CTD_human
6,10,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,NSCLC,3845,KRAS,KRAS,CTD_human,23435014,"TP53, EGFR and KRAS mutations were found in NSCLC with no link with asbestos exposure.NF2 was only altered in MPM.",0.303792209811992,"TP53, EGFR and <span class=""gene"" id=""23435014-6-15-19"">KRAS</span> mutations were found in <span class=""disease"" id=""23435014-6-44-49"">NSCLC</span> with no link with asbestos exposure.NF2 was only altered in MPM.",CTD_human
31,0,Biomarker,C0024121,Lung Neoplasms,group,lung tumor,3845,KRAS,Kras2,CTD_human,16823377,"We propose that the Pas1 modifier effect is due to Kras2, and that a sensitive balance between the expression levels of wild-type and mutant alleles determines lung tumor susceptibility.",0.30456034475422805,"We propose that the Pas1 modifier effect is due to <span class=""gene"" id=""16823377-6-51-56"">Kras2</span>, and that a sensitive balance between the expression levels of wild-type and mutant alleles determines <span class=""disease"" id=""16823377-6-160-170"">lung tumor</span> susceptibility.",CTD_human
31,0,Biomarker,C0024121,Lung Neoplasms,group,lung tumor,3845,KRAS,Ki-ras,CTD_human,10545420,"BHT, a lung tumor promoter in adult mice, had no statistically significant effects on either tumor incidence, tumor multiplicity or the mutational spectrum produced in the Ki-ras gene by in utero MC treatment.",0.30456034475422805,"BHT, a <span class=""disease"" id=""10545420-12-7-17"">lung tumor</span> promoter in adult mice, had no statistically significant effects on either tumor incidence, tumor multiplicity or the mutational spectrum produced in the <span class=""gene"" id=""10545420-12-172-178"">Ki-ras</span> gene by in utero MC treatment.",CTD_human
31,0,Biomarker,C0024121,Lung Neoplasms,group,lung tumors,3845,KRAS,KRAS2,CTD_human,16410370,"The incidence of KRAS2 mutations in human compared to mouse lung tumors differed significantly, as did the incidence of Hras and p53 gene mutations in human compared to mouse liver tumors.",0.30456034475422805,"The incidence of <span class=""gene"" id=""16410370-8-17-22"">KRAS2</span> mutations in human compared to mouse <span class=""disease"" id=""16410370-8-60-71"">lung tumors</span> differed significantly, as did the incidence of Hras and p53 gene mutations in human compared to mouse liver tumors.",CTD_human
31,0,Biomarker,C0024121,Lung Neoplasms,group,lung tumors,3845,KRAS,KRAS,CTD_human,20101149,The Kras mutational spectra of chemically induced lung tumors in different inbred mice mimics the spectra of KRAS mutations in adenocarcinomas in smokers versus nonsmokers.,0.30456034475422805,"The Kras mutational spectra of chemically induced <span class=""disease"" id=""20101149-0-50-61"">lung tumors</span> in different inbred mice mimics the spectra of <span class=""gene"" id=""20101149-0-109-113"">KRAS</span> mutations in adenocarcinomas in smokers versus nonsmokers.",CTD_human
4,8,Biomarker,C0028326,Noonan Syndrome,disease,Noonan syndrome,3845,KRAS,KRAS,CTD_human,17603483,"Increased RAS signaling owing to PTPN11, SOS1 and KRAS mutations causes approximately 60% of Noonan syndrome cases, and PTPN11 mutations cause 90% of LEOPARD syndrome cases.",0.426343381798199,"Increased RAS signaling owing to PTPN11, SOS1 and <span class=""gene"" id=""17603483-2-50-54"">KRAS</span> mutations causes approximately 60% of <span class=""disease"" id=""17603483-2-93-108"">Noonan syndrome</span> cases, and PTPN11 mutations cause 90% of LEOPARD syndrome cases.",CTD_human;ORPHANET
4,8,Biomarker,C0028326,Noonan Syndrome,disease,Noonan syndrome,3845,KRAS,KRAS,CTD_human,17603482,"Mutations of PTPN11, KRAS and SOS1 in the RAS-MAPK pathway cause approximately 60% of cases of Noonan syndrome.",0.426343381798199,"Mutations of PTPN11, <span class=""gene"" id=""17603482-2-21-25"">KRAS</span> and SOS1 in the RAS-MAPK pathway cause approximately 60% of cases of <span class=""disease"" id=""17603482-2-95-110"">Noonan syndrome</span>.",CTD_human;ORPHANET
4,8,Biomarker,C0028326,Noonan Syndrome,disease,Noonan syndrome,3845,KRAS,KRAS,CTD_human,17468812,We report on a novel KRAS gene mutation in a patient presenting the clinical features typical of Costello syndrome and the additional findings seen in Noonan syndrome.,0.426343381798199,"We report on a novel <span class=""gene"" id=""17468812-4-21-25"">KRAS</span> gene mutation in a patient presenting the clinical features typical of Costello syndrome and the additional findings seen in <span class=""disease"" id=""17468812-4-151-166"">Noonan syndrome</span>.",CTD_human;ORPHANET
5,0,Biomarker,C0152013,Adenocarcinoma of lung (disorder),disease,LAC,3845,KRAS,KRAS,CTD_human,26463840,KRAS mutations in LAC were not associated with asbestos exposure.,0.232901701570942,"<span class=""gene"" id=""26463840-15-0-4"">KRAS</span> mutations in <span class=""disease"" id=""26463840-15-18-21"">LAC</span> were not associated with asbestos exposure.",CTD_human
2,0,Biomarker,C0587248,Costello syndrome (disorder),disease,Costello syndrome,3845,KRAS,KRAS,CTD_human,17468812,Further evidence of genetic heterogeneity in Costello syndrome: involvement of the KRAS gene.,0.202197814273705,"Further evidence of genetic heterogeneity in <span class=""disease"" id=""17468812-0-45-62"">Costello syndrome</span>: involvement of the <span class=""gene"" id=""17468812-0-83-87"">KRAS</span> gene.",CTD_human
1,0,Biomarker,C0596263,Carcinogenesis,phenotype,tumorigenesis,3845,KRAS,KRAS,CTD_human,26595770,"In agreement with this hypothesis, CRISPR-mediated deletion of SNORD50A and SNORD50B in KRAS-mutant tumor cells enhanced tumorigenesis, and SNORD50A and SNORD50B deletion and oncogenic KRAS mutation co-occurred significantly in multiple human tumor types.",0.23543975516349,"In agreement with this hypothesis, CRISPR-mediated deletion of SNORD50A and SNORD50B in <span class=""gene"" id=""26595770-7-88-92"">KRAS</span>-mutant tumor cells enhanced <span class=""disease"" id=""26595770-7-121-134"">tumorigenesis</span>, and SNORD50A and SNORD50B deletion and oncogenic <span class=""gene"" id=""26595770-7-185-189"">KRAS</span> mutation co-occurred significantly in multiple human tumor types.",CTD_human
2,0,Biomarker,C2239176,Liver carcinoma,disease,hepatocellular carcinomas,3845,KRAS,k- ras -2,CTD_human,11286481,Frequent k- ras -2 mutations and p16(INK4A)methylation in hepatocellular carcinomas in workers exposed to vinyl chloride.,0.28412090176319704,"Frequent <span class=""gene"" id=""11286481-0-9-18"">k- ras -2</span> mutations and p16(INK4A)methylation in <span class=""disease"" id=""11286481-0-58-83"">hepatocellular carcinomas</span> in workers exposed to vinyl chloride.",CTD_human
2,0,Biomarker,C2239176,Liver carcinoma,disease,hepatocellular carcinomas,3845,KRAS,K-ras-2,CTD_human,11563603,High prevalence of K-ras-2 mutations in hepatocellular carcinomas in workers exposed to vinyl chloride.,0.28412090176319704,"High prevalence of <span class=""gene"" id=""11563603-0-19-26"">K-ras-2</span> mutations in <span class=""disease"" id=""11563603-0-40-65"">hepatocellular carcinomas</span> in workers exposed to vinyl chloride.",CTD_human
1,0,Biomarker,C3854181,Nevus sebaceous,disease,nevus sebaceous,3845,KRAS,KRAS,CTD_human,22683711,Postzygotic HRAS and KRAS mutations cause nevus sebaceous and Schimmelpenning syndrome.,0.600549453568426,"Postzygotic HRAS and <span class=""gene"" id=""22683711-0-21-25"">KRAS</span> mutations cause <span class=""disease"" id=""22683711-0-42-57"">nevus sebaceous</span> and Schimmelpenning syndrome.",CTD_human;HPO;ORPHANET
2,0,Biomarker,C0007134,Renal Cell Carcinoma,disease,RCC,3855,KRT7,CK7,CTD_human,16927643,Our study provides further evidence that CK7 and parvalbumin immunostains may be useful in differentiating oncocytoma from chromophobe RCC in problematic cases.,0.21039655166814603,"Our study provides further evidence that <span class=""gene"" id=""16927643-11-41-44"">CK7</span> and parvalbumin immunostains may be useful in differentiating oncocytoma from chromophobe <span class=""disease"" id=""16927643-11-135-138"">RCC</span> in problematic cases.",CTD_human
1,0,Biomarker,C1510502,Oxyphilic Adenoma,disease,oncocytoma,3855,KRT7,CK7,CTD_human,16927643,Negative or patchy staining (< 50% cells) for CK7 and/or parvalbumin strongly favors the diagnosis of oncocytoma.,0.20054945356842604,"Negative or patchy staining (&lt; 50% cells) for <span class=""gene"" id=""16927643-12-46-49"">CK7</span> and/or parvalbumin strongly favors the diagnosis of <span class=""disease"" id=""16927643-12-102-112"">oncocytoma</span>.",CTD_human
1,0,Biomarker,C0162557,"Liver Failure, Acute",disease,ALF,3856,KRT8,KRT8,CTD_human,20538000,KRT8 and KRT18 are important susceptibility genes for ALF development.,0.202956482091714,"<span class=""gene"" id=""20538000-11-0-4"">KRT8</span> and KRT18 are important susceptibility genes for <span class=""disease"" id=""20538000-11-54-57"">ALF</span> development.",CTD_human
1,0,Biomarker,C0279626,Squamous cell carcinoma of esophagus,disease,ESCC,3860,KRT13,KRT13,CTD_human,21517111,"Among these identified proteins, 33 proteins including keratin 17 (KRT17), biliverdin reductase B (BLVRB), proteasome activator subunit 1 (PSME1), manganese superoxide dismutase (MnSOD), high-mobility group box-1(HMGB1), heat shock protein 70 (HSP70), peroxiredoxin (PRDX1), keratin 13 (KRT13), and so on were overexpressed, and 14 proteins including cystatin B (CSTB), tropomyosin 2 (TPM2), annexin 1 (ANX1), transgelin (TAGLN), keratin 19 (KRT19), stratifin (SFN), and so on were down-expressed in ESCC.",0.200274726784213,"Among these identified proteins, 33 proteins including keratin 17 (KRT17), biliverdin reductase B (BLVRB), proteasome activator subunit 1 (PSME1), manganese superoxide dismutase (MnSOD), high-mobility group box-1(HMGB1), heat shock protein 70 (HSP70), peroxiredoxin (PRDX1), <span class=""gene"" id=""21517111-5-275-285"">keratin 13</span> (<span class=""gene"" id=""21517111-5-287-292"">KRT13</span>), and so on were overexpressed, and 14 proteins including cystatin B (CSTB), tropomyosin 2 (TPM2), annexin 1 (ANX1), transgelin (TAGLN), keratin 19 (KRT19), stratifin (SFN), and so on were down-expressed in <span class=""disease"" id=""21517111-5-500-504"">ESCC</span>.",CTD_human
1,0,Biomarker,C0343111,Naegeli syndrome,disease,Naegeli-Franceschetti-Jadassohn syndrome,3861,KRT14,KRT14,CTD_human,16960809,Naegeli-Franceschetti-Jadassohn syndrome and dermatopathia pigmentosa reticularis: two allelic ectodermal dysplasias caused by dominant mutations in KRT14.,0.400549453568426,"<span class=""disease"" id=""16960809-0-0-40"">Naegeli-Franceschetti-Jadassohn syndrome</span> and dermatopathia pigmentosa reticularis: two allelic ectodermal dysplasias caused by dominant mutations in <span class=""gene"" id=""16960809-0-149-154"">KRT14</span>.",CTD_human;ORPHANET
2,0,Biomarker,C0020981,Angioimmunoblastic Lymphadenopathy,disease,angioimmunoblastic T cell lymphoma,387,RHOA,RHOA,CTD_human,24584070,A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma.,0.202197814273705,"A recurrent inactivating mutation in <span class=""gene"" id=""24584070-0-37-41"">RHOA</span> GTPase in <span class=""disease"" id=""24584070-0-52-86"">angioimmunoblastic T cell lymphoma</span>.",CTD_human
2,0,Biomarker,C0020981,Angioimmunoblastic Lymphadenopathy,disease,angioimmunoblastic T cell lymphoma,387,RHOA,RHOA,CTD_human,24413737,Somatic RHOA mutation in angioimmunoblastic T cell lymphoma.,0.202197814273705,"Somatic <span class=""gene"" id=""24413737-0-8-12"">RHOA</span> mutation in <span class=""disease"" id=""24413737-0-25-59"">angioimmunoblastic T cell lymphoma</span>.",CTD_human
1,0,Biomarker,C0079772,T-Cell Lymphoma,disease,T cell lymphoma,387,RHOA,RHOA,CTD_human,24584070,Further examination of the RHOA mutation encoding p.Gly17Val in 239 lymphoma samples showed that the mutation was specific to T cell lymphoma and was absent from B cell lymphoma.,0.20082418035263896,"Further examination of the <span class=""gene"" id=""24584070-3-27-31"">RHOA</span> mutation encoding p.Gly17Val in 239 lymphoma samples showed that the mutation was specific to <span class=""disease"" id=""24584070-3-126-141"">T cell lymphoma</span> and was absent from B cell lymphoma.",CTD_human
2,0,Biomarker,C0079774,Peripheral T-Cell Lymphoma,disease,peripheral T cell lymphomas,387,RHOA,RHOA,CTD_human,24413734,"Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas.",0.201098907136852,"Recurrent mutations in epigenetic regulators, <span class=""gene"" id=""24413734-0-46-50"">RHOA</span> and FYN kinase in <span class=""disease"" id=""24413734-0-69-96"">peripheral T cell lymphomas</span>.",CTD_human
1,1,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,387032,ZKSCAN4,ZKSCAN4,CTD_human,22037552,"We identified two susceptibility loci for schizophrenia at 6p21-p22.1 (rs1233710 in an intron of ZKSCAN4, P(combined) = 4.76 × 10(-11), odds ratio (OR) = 0.79; rs1635 in an exon of NKAPL, P(combined) = 6.91 × 10(-12), OR = 0.78; rs2142731 in an intron of PGBD1, P(combined) = 5.14 × 10(-10), OR = 0.79) and 11p11.2 (rs11038167 near the 5' UTR of TSPAN18, P(combined) = 1.09 × 10(-11), OR = 1.29; rs11038172, P(combined) = 7.21 × 10(-10), OR = 1.25; rs835784, P(combined) = 2.73 × 10(-11), OR = 1.27).",0.20054945356842604,"We identified two susceptibility loci for <span class=""disease"" id=""22037552-2-42-55"">schizophrenia</span> at 6p21-p22.1 (rs1233710 in an intron of <span class=""gene"" id=""22037552-2-97-104"">ZKSCAN4</span>, P(combined) = 4.76 &times; 10(-11), odds ratio (OR) = 0.79; rs1635 in an exon of NKAPL, P(combined) = 6.91 &times; 10(-12), OR = 0.78; rs2142731 in an intron of PGBD1, P(combined) = 5.14 &times; 10(-10), OR = 0.79) and 11p11.2 (rs11038167 near the 5' UTR of TSPAN18, P(combined) = 1.09 &times; 10(-11), OR = 1.29; rs11038172, P(combined) = 7.21 &times; 10(-10), OR = 1.25; rs835784, P(combined) = 2.73 &times; 10(-11), OR = 1.27).",CTD_human
3,0,Biomarker,C0004096,Asthma,disease,asthma,387129,NPSR1,NPSR1,CTD_human,16926187,The neuropeptide S (NPS)-NPS receptor 1 (NPSR1) pathway has recently been implicated in the pathogenesis of asthma.,0.259967097348936,"The neuropeptide S (NPS)-NPS receptor 1 (<span class=""gene"" id=""16926187-1-41-46"">NPSR1</span>) pathway has recently been implicated in the pathogenesis of <span class=""disease"" id=""16926187-1-108-114"">asthma</span>.",CTD_human
3,0,Biomarker,C0004096,Asthma,disease,asthma,387129,NPSR1,GPRA,CTD_human,15764725,"Using matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) technology, 1,872 German children aged 9 to 11 years (including 624 children with asthma and/or bronchial hyperresponsiveness) were genotyped for seven polymorphisms in the GPRA gene.",0.259967097348936,"Using matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) technology, 1,872 German children aged 9 to 11 years (including 624 children with <span class=""disease"" id=""15764725-4-159-165"">asthma</span> and/or bronchial hyperresponsiveness) were genotyped for seven polymorphisms in the <span class=""gene"" id=""15764725-4-250-254"">GPRA</span> gene.",CTD_human
3,0,Biomarker,C0004096,Asthma,disease,asthma,387129,NPSR1,G protein-coupled receptor 154,CTD_human,15710598,Haplotypes of G protein-coupled receptor 154 are associated with childhood allergy and asthma.,0.259967097348936,"Haplotypes of <span class=""gene"" id=""15710598-0-14-44"">G protein-coupled receptor 154</span> are associated with childhood allergy and <span class=""disease"" id=""15710598-0-87-93"">asthma</span>.",CTD_human
1,0,Biomarker,C0279626,Squamous cell carcinoma of esophagus,disease,ESCC,3872,KRT17,KRT17,CTD_human,21517111,"Among these identified proteins, 33 proteins including keratin 17 (KRT17), biliverdin reductase B (BLVRB), proteasome activator subunit 1 (PSME1), manganese superoxide dismutase (MnSOD), high-mobility group box-1(HMGB1), heat shock protein 70 (HSP70), peroxiredoxin (PRDX1), keratin 13 (KRT13), and so on were overexpressed, and 14 proteins including cystatin B (CSTB), tropomyosin 2 (TPM2), annexin 1 (ANX1), transgelin (TAGLN), keratin 19 (KRT19), stratifin (SFN), and so on were down-expressed in ESCC.",0.2,"Among these identified proteins, 33 proteins including <span class=""gene"" id=""21517111-5-55-65"">keratin 17</span> (<span class=""gene"" id=""21517111-5-67-72"">KRT17</span>), biliverdin reductase B (BLVRB), proteasome activator subunit 1 (PSME1), manganese superoxide dismutase (MnSOD), high-mobility group box-1(HMGB1), heat shock protein 70 (HSP70), peroxiredoxin (PRDX1), keratin 13 (KRT13), and so on were overexpressed, and 14 proteins including cystatin B (CSTB), tropomyosin 2 (TPM2), annexin 1 (ANX1), transgelin (TAGLN), keratin 19 (KRT19), stratifin (SFN), and so on were down-expressed in <span class=""disease"" id=""21517111-5-500-504"">ESCC</span>.",CTD_human
1,0,Biomarker,C0162557,"Liver Failure, Acute",disease,ALF,3875,KRT18,KRT18,CTD_human,20538000,KRT8 and KRT18 are important susceptibility genes for ALF development.,0.202681755307501,"KRT8 and <span class=""gene"" id=""20538000-11-9-14"">KRT18</span> are important susceptibility genes for <span class=""disease"" id=""20538000-11-54-57"">ALF</span> development.",CTD_human
1,0,Biomarker,C0021364,Male infertility,phenotype,male infertility,387712,ENO4,eno4,CTD_human,23446454,Disruption of a spermatogenic cell-specific mouse enolase 4 (eno4) gene causes sperm structural defects and male infertility.,0.2,"Disruption of a spermatogenic cell-specific mouse <span class=""gene"" id=""23446454-0-50-59"">enolase 4</span> (<span class=""gene"" id=""23446454-0-61-65"">eno4</span>) gene causes sperm structural defects and <span class=""disease"" id=""23446454-0-108-124"">male infertility</span>.",CTD_human
3,3,Biomarker,C0242383,Age related macular degeneration,disease,age-related macular degeneration,387715,ARMS2,ARMS2,CTD_human,17884985,"A variant of mitochondrial protein LOC387715/ARMS2, not HTRA1, is strongly associated with age-related macular degeneration.",0.36853577601839,"A variant of mitochondrial protein <span class=""gene"" id=""17884985-0-35-44"">LOC387715</span>/<span class=""gene"" id=""17884985-0-45-50"">ARMS2</span>, not HTRA1, is strongly associated with <span class=""disease"" id=""17884985-0-91-123"">age-related macular degeneration</span>.",CTD_human
3,3,Biomarker,C0242383,Age related macular degeneration,disease,AMD,387715,ARMS2,ARMS2,CTD_human,21909106,"In addition to CFH (rs800292, P = 4.23 × 10(-15)) and ARMS2 (rs3750847, P = 8.67 × 10(-29)) loci, we identified two new susceptibility loci for exudative AMD: TNFRSF10A-LOC389641 on chromosome 8p21 (rs13278062, combined P = 1.03 × 10(-12), odds ratio = 0.73) and REST-C4orf14-POLR2B-IGFBP7 on chromosome 4q12 (rs1713985, combined P = 2.34 × 10(-8), odds ratio = 1.30).",0.36853577601839,"In addition to CFH (rs800292, P = 4.23 &times; 10(-15)) and <span class=""gene"" id=""21909106-3-54-59"">ARMS2</span> (rs3750847, P = 8.67 &times; 10(-29)) loci, we identified two new susceptibility loci for exudative <span class=""disease"" id=""21909106-3-154-157"">AMD</span>: TNFRSF10A-LOC389641 on chromosome 8p21 (rs13278062, combined P = 1.03 &times; 10(-12), odds ratio = 0.73) and REST-C4orf14-POLR2B-IGFBP7 on chromosome 4q12 (rs1713985, combined P = 2.34 &times; 10(-8), odds ratio = 1.30).",CTD_human
3,3,Biomarker,C0242383,Age related macular degeneration,disease,Age-related macular degeneration,387715,ARMS2,LOC387715,CTD_human,18511946,Age-related macular degeneration is associated with an unstable ARMS2 (LOC387715) mRNA.,0.36853577601839,"<span class=""disease"" id=""18511946-0-0-32"">Age-related macular degeneration</span> is associated with an unstable <span class=""gene"" id=""18511946-0-64-69"">ARMS2</span> (<span class=""gene"" id=""18511946-0-71-80"">LOC387715</span>) mRNA.",CTD_human
1,0,Biomarker,C0036421,Systemic Scleroderma,disease,systemic sclerosis,388,RHOB,RHOB,CTD_human,21750679,"Genome-wide scan identifies TNIP1, PSORS1C1, and RHOB as novel risk loci for systemic sclerosis.",0.20082418035263896,"Genome-wide scan identifies TNIP1, PSORS1C1, and <span class=""gene"" id=""21750679-0-49-53"">RHOB</span> as novel risk loci for <span class=""disease"" id=""21750679-0-77-95"">systemic sclerosis</span>.",CTD_human
1,0,Biomarker,C0004096,Asthma,disease,asthma,3880,KRT19,cytokeratin 19,CTD_human,15478392,Increased levels of IgG to cytokeratin 19 in sera of patients with toluene diisocyanate-induced asthma.,0.200274726784213,"Increased levels of IgG to <span class=""gene"" id=""15478392-0-27-41"">cytokeratin 19</span> in sera of patients with toluene diisocyanate-induced <span class=""disease"" id=""15478392-0-96-102"">asthma</span>.",CTD_human
1,0,Biomarker,C0279626,Squamous cell carcinoma of esophagus,disease,ESCC,3880,KRT19,KRT19,CTD_human,21517111,"Among these identified proteins, 33 proteins including keratin 17 (KRT17), biliverdin reductase B (BLVRB), proteasome activator subunit 1 (PSME1), manganese superoxide dismutase (MnSOD), high-mobility group box-1(HMGB1), heat shock protein 70 (HSP70), peroxiredoxin (PRDX1), keratin 13 (KRT13), and so on were overexpressed, and 14 proteins including cystatin B (CSTB), tropomyosin 2 (TPM2), annexin 1 (ANX1), transgelin (TAGLN), keratin 19 (KRT19), stratifin (SFN), and so on were down-expressed in ESCC.",0.200274726784213,"Among these identified proteins, 33 proteins including keratin 17 (KRT17), biliverdin reductase B (BLVRB), proteasome activator subunit 1 (PSME1), manganese superoxide dismutase (MnSOD), high-mobility group box-1(HMGB1), heat shock protein 70 (HSP70), peroxiredoxin (PRDX1), keratin 13 (KRT13), and so on were overexpressed, and 14 proteins including cystatin B (CSTB), tropomyosin 2 (TPM2), annexin 1 (ANX1), transgelin (TAGLN), <span class=""gene"" id=""21517111-5-430-440"">keratin 19</span> (<span class=""gene"" id=""21517111-5-442-447"">KRT19</span>), stratifin (SFN), and so on were down-expressed in <span class=""disease"" id=""21517111-5-500-504"">ESCC</span>.",CTD_human
1,0,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,type 2 diabetes,388125,C2CD4B,C2CD4B,CTD_human,20818381,A genome-wide association study in the Japanese population identifies susceptibility loci for type 2 diabetes at UBE2E2 and C2CD4A-C2CD4B.,0.205363510615002,"A genome-wide association study in the Japanese population identifies susceptibility loci for <span class=""disease"" id=""20818381-0-94-109"">type 2 diabetes</span> at UBE2E2 and C2CD4A-<span class=""gene"" id=""20818381-0-131-137"">C2CD4B</span>.",CTD_human
2,1,Biomarker,C0027819,Neuroblastoma,disease,neuroblastoma,389421,LIN28B,LIN28B,CTD_human,22941191,Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastoma.,0.40219781427370505,"Common variation at 6q16 within HACE1 and <span class=""gene"" id=""22941191-0-42-48"">LIN28B</span> influences susceptibility to <span class=""disease"" id=""22941191-0-78-91"">neuroblastoma</span>.",CTD_human;ORPHANET
2,1,Biomarker,C0027819,Neuroblastoma,disease,neuroblastoma,389421,LIN28B,LIN28B,CTD_human,23042116,LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression.,0.40219781427370505,"<span class=""gene"" id=""23042116-0-0-6"">LIN28B</span> induces <span class=""disease"" id=""23042116-0-15-28"">neuroblastoma</span> and enhances MYCN levels via let-7 suppression.",CTD_human;ORPHANET
1,0,Biomarker,C0007134,Renal Cell Carcinoma,disease,RCC,3897,L1CAM,L1-CAM,CTD_human,21097529,"To determine the clinical usefulness of L1-CAM as a therapeutic or prognostic marker molecule in renal cancer patients, we analyzed its expression on a cohort of 282 renal cell carcinoma (RCC) patients.",0.200274726784213,"To determine the clinical usefulness of <span class=""gene"" id=""21097529-2-40-46"">L1-CAM</span> as a therapeutic or prognostic marker molecule in renal cancer patients, we analyzed its expression on a cohort of 282 <span class=""disease"" id=""21097529-2-166-186"">renal cell carcinoma</span> (<span class=""disease"" id=""21097529-2-188-191"">RCC</span>) patients.",CTD_human
17,15,Biomarker,C0265216,X-linked hydrocephalus syndrome,disease,X-linked hydrocephalus,3897,L1CAM,L1CAM,CTD_human,7920660,"Since it has been shown that X-linked hydrocephalus can be caused by mutations in L1CAM, a neuronal cell adhesion molecule, we performed an L1CAM mutation analysis in eight unrelated patients with MASA syndrome.",0.612087978505376,"Since it has been shown that <span class=""disease"" id=""7920660-2-29-51"">X-linked hydrocephalus</span> can be caused by mutations in <span class=""gene"" id=""7920660-2-82-87"">L1CAM</span>, a neuronal cell adhesion molecule, we performed an <span class=""gene"" id=""7920660-2-140-145"">L1CAM</span> mutation analysis in eight unrelated patients with MASA syndrome.",CTD_human;ORPHANET;UNIPROT
17,15,Biomarker,C0265216,X-linked hydrocephalus syndrome,disease,X-linked hydrocephalus,3897,L1CAM,L1CAM,CTD_human,7920659,"We have previously shown that X-linked hydrocephalus is caused by mutations in the gene for neural cell adhesion molecule L1 (L1CAM), an axonal glycoprotein involved in neuronal migration and differentiation.",0.612087978505376,"We have previously shown that <span class=""disease"" id=""7920659-2-30-52"">X-linked hydrocephalus</span> is caused by mutations in the gene for <span class=""gene"" id=""7920659-2-92-124"">neural cell adhesion molecule L1</span> (<span class=""gene"" id=""7920659-2-126-131"">L1CAM</span>), an axonal glycoprotein involved in neuronal migration and differentiation.",CTD_human;ORPHANET;UNIPROT
12,9,Biomarker,C0795953,MASA SYNDROME (disorder),disease,SPG1,3897,L1CAM,HSAS,CTD_human,7920659,"Here we report mutations of the L1 gene in MASA syndrome and SPG1, in addition to HSAS families.",0.6854945356842621,"Here we report mutations of the L1 gene in <span class=""disease"" id=""7920659-3-43-56"">MASA syndrome</span> and <span class=""disease"" id=""7920659-3-61-65"">SPG1</span>, in addition to <span class=""gene"" id=""7920659-3-82-86"">HSAS</span> families.",CTD_human;ORPHANET;UNIPROT
12,9,Biomarker,C0795953,MASA SYNDROME (disorder),disease,MASA syndrome,3897,L1CAM,L1CAM,CTD_human,7920660,MASA syndrome is due to mutations in the neural cell adhesion gene L1CAM.,0.6854945356842621,"<span class=""disease"" id=""7920660-0-0-13"">MASA syndrome</span> is due to mutations in the neural cell adhesion gene <span class=""gene"" id=""7920660-0-67-72"">L1CAM</span>.",CTD_human;ORPHANET;UNIPROT
2,0,Biomarker,C0003873,Rheumatoid Arthritis,disease,rheumatoid arthritis,3899,AFF3,AFF3,CTD_human,20453842,We also refined associations at two established rheumatoid arthritis risk loci (IL2RA and CCL21) and confirmed the association at AFF3.,0.20673714453606798,"We also refined associations at two established <span class=""disease"" id=""20453842-4-48-68"">rheumatoid arthritis</span> risk loci (IL2RA and CCL21) and confirmed the association at <span class=""gene"" id=""20453842-4-130-134"">AFF3</span>.",CTD_human
2,0,Biomarker,C0026850,Muscular Dystrophy,disease,muscular dystrophy,3908,LAMA2,merosin,CTD_human,22906800,The AChE membrane-binding tail PRiMA is down-regulated in muscle and nerve of mice with muscular dystrophy by merosin deficiency.,0.430640201436012,"The AChE membrane-binding tail PRiMA is down-regulated in muscle and nerve of mice with <span class=""disease"" id=""22906800-0-88-106"">muscular dystrophy</span> by <span class=""gene"" id=""22906800-0-110-117"">merosin</span> deficiency.",CTD_human;HPO
1,0,Biomarker,C0079301,Junctional Epidermolysis Bullosa,disease,junctional epidermolysis bullosa,3909,LAMA3,LAMA3,CTD_human,12915477,"This region includes the laminin alpha3 gene (LAMA3), in which loss-of-expression mutations cause the lethal skin blistering disorder Herlitz junctional epidermolysis bullosa.",0.209586726692824,"This region includes the laminin alpha3 gene (<span class=""gene"" id=""12915477-4-46-51"">LAMA3</span>), in which loss-of-expression mutations cause the lethal skin blistering disorder Herlitz <span class=""disease"" id=""12915477-4-142-174"">junctional epidermolysis bullosa</span>.",CTD_human
1,0,Therapeutic,C0041364,Tumor Lysis Syndrome,disease,tumor lysis syndrome,391051,UOX,urate oxidase,CTD_human,16313266,Rasburicase is a recombinant urate oxidase that is produced by a genetically modified Saccharomyces cerevisiae and has been approved for prophylaxis and treatment of tumor lysis syndrome in 2001.,0.200274726784213,"Rasburicase is a recombinant <span class=""gene"" id=""16313266-1-29-42"">urate oxidase</span> that is produced by a genetically modified Saccharomyces cerevisiae and has been approved for prophylaxis and treatment of <span class=""disease"" id=""16313266-1-166-186"">tumor lysis syndrome</span> in 2001.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,3912,LAMB1,LAMB1,CTD_human,15523497,"Analysis of genetic variants provided evidence for association with autism for one of the new missense changes identified in LAMB1; this effect was stronger in a subgroup of affected male sibling pair families, implying a possible specific sex-related effect for this variant.",0.20082418035263896,"Analysis of genetic variants provided evidence for association with <span class=""disease"" id=""15523497-3-68-74"">autism</span> for one of the new missense changes identified in <span class=""gene"" id=""15523497-3-125-130"">LAMB1</span>; this effect was stronger in a subgroup of affected male sibling pair families, implying a possible specific sex-related effect for this variant.",CTD_human
1,2,Biomarker,C0022738,Klippel-Feil Syndrome,disease,Klippel-Feil syndrome,392255,GDF6,GDF6,CTD_human,18425797,Mutations in GDF6 are associated with vertebral segmentation defects in Klippel-Feil syndrome.,0.40355709281745294,"Mutations in <span class=""gene"" id=""18425797-0-13-17"">GDF6</span> are associated with vertebral segmentation defects in <span class=""disease"" id=""18425797-0-72-93"">Klippel-Feil syndrome</span>.",CTD_human;ORPHANET
1,0,Biomarker,C0033578,Prostatic Neoplasms,group,prostate tumor,3925,STMN1,Stathmin,CTD_human,17455228,Stathmin levels increase early during normal mouse prostate development and again during prostate tumor development and progression.,0.20054945356842604,"<span class=""gene"" id=""17455228-6-0-8"">Stathmin</span> levels increase early during normal mouse prostate development and again during <span class=""disease"" id=""17455228-6-89-103"">prostate tumor</span> development and progression.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,3927,LASP1,LASP1,CTD_human,17376794,"Nominally significant single SNP and/or haplotype-based association results were detected in 15 genes, of which, MYO1D, ACCN1 and LASP1 stand out as genes with autism risk alleles requiring further study, with potential GRRs in the range of 1.34-2.29.",0.202681755307501,"Nominally significant single SNP and/or haplotype-based association results were detected in 15 genes, of which, MYO1D, ACCN1 and <span class=""gene"" id=""17376794-9-130-135"">LASP1</span> stand out as genes with <span class=""disease"" id=""17376794-9-160-166"">autism</span> risk alleles requiring further study, with potential GRRs in the range of 1.34-2.29.",CTD_human
1,0,Biomarker,C0028754,Obesity,disease,obesity,3929,LBP,LBP,CTD_human,23349936,Determinants of serum concentrations of lipopolysaccharide-binding protein (LBP) in the adult population: the role of obesity.,0.28082418035263895,"Determinants of serum concentrations of <span class=""gene"" id=""23349936-0-40-74"">lipopolysaccharide-binding protein</span> (<span class=""gene"" id=""23349936-0-76-79"">LBP</span>) in the adult population: the role of <span class=""disease"" id=""23349936-0-118-125"">obesity</span>.",CTD_human
1,0,Biomarker,C0243026,Sepsis,disease,sepsis,3929,LBP,lipopolysaccharide binding protein,CTD_human,22167001,A functional variant of lipopolysaccharide binding protein predisposes to sepsis and organ dysfunction in patients with major trauma.,0.20886944627514298,"A functional variant of <span class=""gene"" id=""22167001-0-24-58"">lipopolysaccharide binding protein</span> predisposes to <span class=""disease"" id=""22167001-0-74-80"">sepsis</span> and organ dysfunction in patients with major trauma.",CTD_human
1,0,Biomarker,C0524620,Metabolic Syndrome X,disease,metabolic syndrome,3929,LBP,LBP,CTD_human,23349936,"Overweight, obesity, and having metabolic syndrome (particularly, low HDL cholesterol levels) were associated with higher LBP concentrations.",0.20054945356842604,"Overweight, obesity, and having <span class=""disease"" id=""23349936-12-32-50"">metabolic syndrome</span> (particularly, low HDL cholesterol levels) were associated with higher <span class=""gene"" id=""23349936-12-122-125"">LBP</span> concentrations.",CTD_human
1,0,Biomarker,C0005283,beta Thalassemia,disease,beta-thalassemia,3934,LCN2,NGAL,CTD_human,16755567,"We found decreased expression of hepcidin and TfR2 and increased expression of TfR1 and NGAL in the beta-thalassemia mouse models, compared with the control mice.",0.20300763924902696,"We found decreased expression of hepcidin and TfR2 and increased expression of TfR1 and <span class=""gene"" id=""16755567-7-88-92"">NGAL</span> in the <span class=""disease"" id=""16755567-7-100-116"">beta-thalassemia</span> mouse models, compared with the control mice.",CTD_human
1,0,Biomarker,C0007124,Noninfiltrating Intraductal Carcinoma,disease,ductal carcinoma in situ,3945,LDHB,LDH-B,CTD_human,23437403,"Absent immuno-expression of LDH-B protein (<10% cells stained), was seen in 23/26 (88%) breast cancer cases, and in 4/8 cases of adjacent ductal carcinoma in situ lesions.",0.200274726784213,"Absent immuno-expression of <span class=""gene"" id=""23437403-9-28-33"">LDH-B</span> protein (&lt;10% cells stained), was seen in 23/26 (88%) breast cancer cases, and in 4/8 cases of adjacent <span class=""disease"" id=""23437403-9-138-162"">ductal carcinoma in situ</span> lesions.",CTD_human
2,0,Biomarker,C0021364,Male infertility,phenotype,male infertility,3948,LDHC,lactate dehydrogenase C,CTD_human,21565994,"We demonstrated previously that disruption of the germ cell-specific lactate dehydrogenase C gene (Ldhc) led to male infertility due to defects in sperm function, including a rapid decline in sperm ATP levels, a decrease in progressive motility, and a failure to develop hyperactivated motility.",0.2,"We demonstrated previously that disruption of the germ cell-specific <span class=""gene"" id=""21565994-1-69-92"">lactate dehydrogenase C</span> gene (Ldhc) led to <span class=""disease"" id=""21565994-1-112-128"">male infertility</span> due to defects in sperm function, including a rapid decline in sperm ATP levels, a decrease in progressive motility, and a failure to develop hyperactivated motility.",CTD_human
4,1,Therapeutic,C0004153,Atherosclerosis,disease,atherosclerosis,3949,LDLR,LDLR,CTD_human,11947894,Male LDLR-KO mice fed a high cholesterol (HC; 1%) diet developed atherosclerosis at 8 months of age with hypercholesterolemia.,0.26187568151933,"Male <span class=""gene"" id=""11947894-3-5-9"">LDLR</span>-KO mice fed a high cholesterol (HC; 1%) diet developed <span class=""disease"" id=""11947894-3-65-80"">atherosclerosis</span> at 8 months of age with hypercholesterolemia.",CTD_human
4,1,Biomarker,C0004153,Atherosclerosis,disease,atherosclerosis,3949,LDLR,LDL receptor,CTD_human,18450471,"We have recently demonstrated that liver mitochondria isolated from the atherosclerosis-prone hypercholesterolemic LDL receptor knockout (LDLr(-/-)) mice have lower content of NADP(H)-linked substrates than the controls and, as consequence, higher sensitivity to oxidative stress and mitochondrial membrane permeability transition (MPT).",0.26187568151933,"We have recently demonstrated that liver mitochondria isolated from the <span class=""disease"" id=""18450471-2-72-87"">atherosclerosis</span>-prone hypercholesterolemic <span class=""gene"" id=""18450471-2-115-127"">LDL receptor</span> knockout (LDLr(-/-)) mice have lower content of NADP(H)-linked substrates than the controls and, as consequence, higher sensitivity to oxidative stress and mitochondrial membrane permeability transition (MPT).",CTD_human
4,1,Biomarker,C0004153,Atherosclerosis,disease,atherosclerosis,3949,LDLR,LDLR,CTD_human,11947894,Male LDLR-KO mice fed a high cholesterol (HC; 1%) diet developed atherosclerosis at 8 months of age with hypercholesterolemia.,0.26187568151933,"Male <span class=""gene"" id=""11947894-3-5-9"">LDLR</span>-KO mice fed a high cholesterol (HC; 1%) diet developed <span class=""disease"" id=""11947894-3-65-80"">atherosclerosis</span> at 8 months of age with hypercholesterolemia.",CTD_human
4,1,Biomarker,C0004153,Atherosclerosis,disease,atherosclerosis,3949,LDLR,LDLR,CTD_human,22153697,"The hepatocyte low density lipoprotein receptor (LDLR) plays a pivotal role in lipoprotein metabolism by lowering plasma LDL-cholesterol, a risk factor for atherosclerosis.",0.26187568151933,"The hepatocyte <span class=""gene"" id=""22153697-1-15-47"">low density lipoprotein receptor</span> (<span class=""gene"" id=""22153697-1-49-53"">LDLR</span>) plays a pivotal role in lipoprotein metabolism by lowering plasma LDL-cholesterol, a risk factor for <span class=""disease"" id=""22153697-1-156-171"">atherosclerosis</span>.",CTD_human
4,1,Therapeutic,C0004153,Atherosclerosis,disease,atherosclerosis,3949,LDLR,LDL receptor,CTD_human,18450471,"We have recently demonstrated that liver mitochondria isolated from the atherosclerosis-prone hypercholesterolemic LDL receptor knockout (LDLr(-/-)) mice have lower content of NADP(H)-linked substrates than the controls and, as consequence, higher sensitivity to oxidative stress and mitochondrial membrane permeability transition (MPT).",0.26187568151933,"We have recently demonstrated that liver mitochondria isolated from the <span class=""disease"" id=""18450471-2-72-87"">atherosclerosis</span>-prone hypercholesterolemic <span class=""gene"" id=""18450471-2-115-127"">LDL receptor</span> knockout (LDLr(-/-)) mice have lower content of NADP(H)-linked substrates than the controls and, as consequence, higher sensitivity to oxidative stress and mitochondrial membrane permeability transition (MPT).",CTD_human
4,1,Therapeutic,C0004153,Atherosclerosis,disease,atherosclerosis,3949,LDLR,LDLR,CTD_human,22153697,"The hepatocyte low density lipoprotein receptor (LDLR) plays a pivotal role in lipoprotein metabolism by lowering plasma LDL-cholesterol, a risk factor for atherosclerosis.",0.26187568151933,"The hepatocyte <span class=""gene"" id=""22153697-1-15-47"">low density lipoprotein receptor</span> (<span class=""gene"" id=""22153697-1-49-53"">LDLR</span>) plays a pivotal role in lipoprotein metabolism by lowering plasma LDL-cholesterol, a risk factor for <span class=""disease"" id=""22153697-1-156-171"">atherosclerosis</span>.",CTD_human
1,0,Biomarker,C0010068,Coronary heart disease,disease,coronary heart disease,3949,LDLR,LDL) receptor,CTD_human,9430375,"Patients with homozygous familial hypercholesterolaemia (HFH) have abnormalities in both low-density lipoprotein (LDL) receptor alleles, resulting in severe hypercholesterolaemia and premature coronary heart disease.",0.24883249759205397,"Patients with homozygous familial hypercholesterolaemia (HFH) have abnormalities in both low-density lipoprotein (<span class=""gene"" id=""9430375-1-114-127"">LDL) receptor</span> alleles, resulting in severe hypercholesterolaemia and premature <span class=""disease"" id=""9430375-1-193-215"">coronary heart disease</span>.",CTD_human
6,1072,Biomarker,C0020445,"Hypercholesterolemia, Familial",disease,familial hypercholesterolemia,3949,LDLR,LDLR,CTD_human,12673584,To investigate low density lipoprotein receptor (LDLR) function and gene mutation in Chinese patients with familial hypercholesterolemia(FH).,0.6228569866907161,"To investigate <span class=""gene"" id=""12673584-1-15-47"">low density lipoprotein receptor</span> (<span class=""gene"" id=""12673584-1-49-53"">LDLR</span>) function and gene mutation in Chinese patients with <span class=""disease"" id=""12673584-1-107-136"">familial hypercholesterolemia</span>(FH).",CTD_human;HPO
6,1072,Biomarker,C0020445,"Hypercholesterolemia, Familial",disease,familial hypercholesterolaemia,3949,LDLR,LDLR,CTD_human,10952765,Numerous different molecular defects have been identified in the LDL receptor (LDLR) and few specific mutations in the apolipoprotein B (APOB) gene resulting in familial hypercholesterolaemia and familial defective apoB-100 respectively.,0.6228569866907161,"Numerous different molecular defects have been identified in the <span class=""gene"" id=""10952765-2-65-77"">LDL receptor</span> (<span class=""gene"" id=""10952765-2-79-83"">LDLR</span>) and few specific mutations in the apolipoprotein B (APOB) gene resulting in <span class=""disease"" id=""10952765-2-161-191"">familial hypercholesterolaemia</span> and familial defective apoB-100 respectively.",CTD_human;HPO
6,1072,Biomarker,C0020445,"Hypercholesterolemia, Familial",disease,familial hypercholesterolemia,3949,LDLR,LDL) receptor,CTD_human,11600564,"Genetic diagnosis of familial hypercholesterolemia in a South European outbreed population: influence of low-density lipoprotein (LDL) receptor gene mutations on treatment response to simvastatin in total, LDL, and high-density lipoprotein cholesterol.",0.6228569866907161,"Genetic diagnosis of <span class=""disease"" id=""11600564-0-21-50"">familial hypercholesterolemia</span> in a South European outbreed population: influence of low-density lipoprotein (<span class=""gene"" id=""11600564-0-130-143"">LDL) receptor</span> gene mutations on treatment response to simvastatin in total, LDL, and high-density lipoprotein cholesterol.",CTD_human;HPO
6,1072,Biomarker,C0020445,"Hypercholesterolemia, Familial",disease,familial hypercholesterolemia,3949,LDLR,LDL-receptor,CTD_human,12009418,"A ""de novo"" mutation of the LDL-receptor gene as the cause of familial hypercholesterolemia.",0.6228569866907161,"A ""de novo"" mutation of the <span class=""gene"" id=""12009418-0-28-40"">LDL-receptor</span> gene as the cause of <span class=""disease"" id=""12009418-0-62-91"">familial hypercholesterolemia</span>.",CTD_human;HPO
6,1072,Biomarker,C0020445,"Hypercholesterolemia, Familial",disease,familial hypercholesterolemia,3949,LDLR,LDL-receptor,CTD_human,12522687,Interaction between the LDL-receptor gene bearing a novel mutation and a variant in the apolipoprotein A-II promoter: molecular study in a 1135-member familial hypercholesterolemia kindred.,0.6228569866907161,"Interaction between the <span class=""gene"" id=""12522687-0-24-36"">LDL-receptor</span> gene bearing a novel mutation and a variant in the apolipoprotein A-II promoter: molecular study in a 1135-member <span class=""disease"" id=""12522687-0-151-180"">familial hypercholesterolemia</span> kindred.",CTD_human;HPO
2,0,Biomarker,C0020473,Hyperlipidemia,disease,hyperlipidemia,3949,LDLR,LDLR,CTD_human,11947894,Low density lipoprotein receptor deficient (LDLR-KO) and apolipoprotein E deficient (apo E-KO) mice both develop hyperlipidemia and atherosclerosis by different mechanisms.,0.410583319515051,"<span class=""gene"" id=""11947894-1-0-32"">Low density lipoprotein receptor</span> deficient (<span class=""gene"" id=""11947894-1-44-48"">LDLR</span>-KO) and apolipoprotein E deficient (apo E-KO) mice both develop <span class=""disease"" id=""11947894-1-113-127"">hyperlipidemia</span> and atherosclerosis by different mechanisms.",CTD_human;HPO
3,0,Biomarker,C0400966,Non-alcoholic Fatty Liver Disease,disease,nonalcoholic fatty liver disease,3949,LDLR,low density lipoprotein receptor,CTD_human,23127599,Alleviative effects of resveratrol on nonalcoholic fatty liver disease are associated with up regulation of hepatic low density lipoprotein receptor and scavenger receptor class B type I gene expressions in rats.,0.201373633921065,"Alleviative effects of resveratrol on <span class=""disease"" id=""23127599-0-38-70"">nonalcoholic fatty liver disease</span> are associated with up regulation of hepatic <span class=""gene"" id=""23127599-0-116-148"">low density lipoprotein receptor</span> and scavenger receptor class B type I gene expressions in rats.",CTD_human
1,0,Therapeutic,C0002395,Alzheimer's Disease,disease,AD,3952,LEP,leptin,CTD_human,20157255,We propose that leptin administration may prevent the progression of sporadic forms of AD that are related to increased cholesterol and oxidized cholesterol metabolite levels.,0.281923087489492,"We propose that <span class=""gene"" id=""20157255-11-16-22"">leptin</span> administration may prevent the progression of sporadic forms of <span class=""disease"" id=""20157255-11-87-89"">AD</span> that are related to increased cholesterol and oxidized cholesterol metabolite levels.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,3952,LEP,leptin,CTD_human,17347881,Brief report: plasma leptin levels are elevated in autism: association with early onset phenotype?,0.2,"Brief report: plasma <span class=""gene"" id=""17347881-0-21-27"">leptin</span> levels are elevated in <span class=""disease"" id=""17347881-0-51-57"">autism</span>: association with early onset phenotype?",CTD_human
1,0,Biomarker,C0010346,Crohn Disease,disease,Crohn's disease,3952,LEP,leptin,CTD_human,21829567,"Mesenteric adipose tissue from rodent colitis and Crohn's disease is metabolically active and shows inflammation-driven regulation of PPAR?, FXR and leptin.",0.201373633921065,"Mesenteric adipose tissue from rodent colitis and <span class=""disease"" id=""21829567-11-50-65"">Crohn's disease</span> is metabolically active and shows inflammation-driven regulation of PPAR&gamma;, FXR and <span class=""gene"" id=""21829567-11-149-155"">leptin</span>.",CTD_human
1,0,Therapeutic,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,type 2 diabetes mellitus,3952,LEP,leptin,CTD_human,15070752,"We document here that leptin replacement therapy in leptin-deficient adults with established morbid obesity results in profound weight loss, increased physical activity, changes in endocrine function and metabolism, including resolution of type 2 diabetes mellitus and hypogonadism, and beneficial effects on ingestive and noningestive behavior.",0.324762752986171,"We document here that <span class=""gene"" id=""15070752-8-22-28"">leptin</span> replacement therapy in <span class=""gene"" id=""15070752-8-52-58"">leptin</span>-deficient adults with established morbid obesity results in profound weight loss, increased physical activity, changes in endocrine function and metabolism, including resolution of <span class=""disease"" id=""15070752-8-240-264"">type 2 diabetes mellitus</span> and hypogonadism, and beneficial effects on ingestive and noningestive behavior.",CTD_human
4,0,Biomarker,C0015695,Fatty Liver,disease,hepatic steatosis,3952,LEP,leptin,CTD_human,12661780,Serum leptin levels are associated with tamoxifen-induced hepatic steatosis.,0.211444301647686,"Serum <span class=""gene"" id=""12661780-0-6-12"">leptin</span> levels are associated with tamoxifen-induced <span class=""disease"" id=""12661780-0-58-75"">hepatic steatosis</span>.",CTD_human
1,0,Biomarker,C0019337,Heroin Dependence,disease,heroin addiction,3952,LEP,leptin,CTD_human,15717844,"In conclusion, circulating concentrations of leptin, adiponectin and resistin are markedly altered in patients with chronic heroin addiction.",0.2,"In conclusion, circulating concentrations of <span class=""gene"" id=""15717844-6-45-51"">leptin</span>, adiponectin and resistin are markedly altered in patients with chronic <span class=""disease"" id=""15717844-6-124-140"">heroin addiction</span>.",CTD_human
4,0,Biomarker,C0020538,Hypertensive disease,group,Hypertension,3952,LEP,Leptin,CTD_human,27226618,Central Leptin and Tumor Necrosis Factor-? (TNF?) in Diurnal Control of Blood Pressure and Hypertension.,0.241437320820979,"Central <span class=""gene"" id=""27226618-0-8-14"">Leptin</span> and Tumor Necrosis Factor-&alpha; (TNF&alpha;) in Diurnal Control of Blood Pressure and <span class=""disease"" id=""27226618-0-91-103"">Hypertension</span>.",CTD_human
4,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,3952,LEP,Leptin,CTD_human,12050272,Leptin gene polymorphism is associated with hypertension independent of obesity.,0.241437320820979,"<span class=""gene"" id=""12050272-0-0-6"">Leptin</span> gene polymorphism is associated with <span class=""disease"" id=""12050272-0-44-56"">hypertension</span> independent of obesity.",CTD_human
4,0,Biomarker,C0020538,Hypertensive disease,group,high blood pressure,3952,LEP,leptin,CTD_human,16827954,Serum leptin levels correlation with high blood pressure in adult females.,0.241437320820979,"Serum <span class=""gene"" id=""16827954-0-6-12"">leptin</span> levels correlation with <span class=""disease"" id=""16827954-0-37-56"">high blood pressure</span> in adult females.",CTD_human
2,0,Therapeutic,C0020619,Hypogonadism,disease,hypogonadism,3952,LEP,leptin,CTD_human,15070752,"Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults.",0.48109890713685205,"Phenotypic effects of <span class=""gene"" id=""15070752-0-22-28"">leptin</span> replacement on morbid obesity, diabetes mellitus, <span class=""disease"" id=""15070752-0-79-91"">hypogonadism</span>, and behavior in <span class=""gene"" id=""15070752-0-109-115"">leptin</span>-deficient adults.",CTD_human;HPO
2,0,Biomarker,C0020619,Hypogonadism,disease,hypogonadism,3952,LEP,leptin,CTD_human,9500540,A leptin missense mutation associated with hypogonadism and morbid obesity.,0.48109890713685205,"A <span class=""gene"" id=""9500540-0-2-8"">leptin</span> missense mutation associated with <span class=""disease"" id=""9500540-0-43-55"">hypogonadism</span> and morbid obesity.",CTD_human;HPO
2,0,Therapeutic,C0020619,Hypogonadism,disease,hypogonadism,3952,LEP,leptin,CTD_human,9500540,A leptin missense mutation associated with hypogonadism and morbid obesity.,0.48109890713685205,"A <span class=""gene"" id=""9500540-0-2-8"">leptin</span> missense mutation associated with <span class=""disease"" id=""9500540-0-43-55"">hypogonadism</span> and morbid obesity.",CTD_human;HPO
2,0,Biomarker,C0020619,Hypogonadism,disease,hypogonadism,3952,LEP,leptin,CTD_human,15070752,"Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults.",0.48109890713685205,"Phenotypic effects of <span class=""gene"" id=""15070752-0-22-28"">leptin</span> replacement on morbid obesity, diabetes mellitus, <span class=""disease"" id=""15070752-0-79-91"">hypogonadism</span>, and behavior in <span class=""gene"" id=""15070752-0-109-115"">leptin</span>-deficient adults.",CTD_human;HPO
13,0,Biomarker,C0028754,Obesity,disease,Obesity,3952,LEP,Leptin,CTD_human,26186301,Severe Early-Onset Obesity Due to Bioinactive Leptin Caused by a p.N103K Mutation in the Leptin Gene.,0.72,"Severe Early-Onset <span class=""disease"" id=""26186301-0-19-26"">Obesity</span> Due to Bioinactive <span class=""gene"" id=""26186301-0-46-52"">Leptin</span> Caused by a p.N103K Mutation in the <span class=""gene"" id=""26186301-0-89-95"">Leptin</span> Gene.",CTD_human;HPO
13,0,Biomarker,C0028754,Obesity,disease,obesity,3952,LEP,leptin,CTD_human,9202122,"The extreme obesity of the obese (ob/ob) mouse is attributable to mutations in the gene encoding leptin, an adipocyte-specific secreted protein which has profound effects on appetite and energy expenditure.",0.72,"The extreme <span class=""disease"" id=""9202122-1-12-19"">obesity</span> of the obese (ob/ob) mouse is attributable to mutations in the gene encoding <span class=""gene"" id=""9202122-1-97-103"">leptin</span>, an adipocyte-specific secreted protein which has profound effects on appetite and energy expenditure.",CTD_human;HPO
13,0,Biomarker,C0028754,Obesity,disease,obese,3952,LEP,leptin,CTD_human,20122948,"Compared with the wild-type non-obese mice, the leptin-deficient obese mice also exhibited greater activation of NF-kappaB/p65 and fewer apoptotic cells in the UVB-irradiated skin.",0.72,"Compared with the wild-type non-<span class=""disease"" id=""20122948-8-32-37"">obese</span> mice, the <span class=""gene"" id=""20122948-8-48-54"">leptin</span>-deficient <span class=""disease"" id=""20122948-8-65-70"">obese</span> mice also exhibited greater activation of NF-kappaB/p65 and fewer apoptotic cells in the UVB-irradiated skin.",CTD_human;HPO
13,0,Biomarker,C0028754,Obesity,disease,obese,3952,LEP,leptin,CTD_human,9502777,"Troglitazone also caused a dramatic decrease in the expression levels of leptin, which were increased by 4-10-fold in the white adipose tissues of obese rats.",0.72,"Troglitazone also caused a dramatic decrease in the expression levels of <span class=""gene"" id=""9502777-9-73-79"">leptin</span>, which were increased by 4-10-fold in the white adipose tissues of <span class=""disease"" id=""9502777-9-147-152"">obese</span> rats.",CTD_human;HPO
13,0,Therapeutic,C0028754,Obesity,disease,obesity,3952,LEP,leptin,CTD_human,18515891,"Patients (n=134) were assessed for measures of obesity, other factors contributing to metabolic syndrome, and two genetic polymorphisms (5-HT(2C) receptor -759C/T and leptin -2548A/G).",0.72,"Patients (n=134) were assessed for measures of <span class=""disease"" id=""18515891-4-47-54"">obesity</span>, other factors contributing to metabolic syndrome, and two genetic polymorphisms (5-HT(2C) receptor -759C/T and <span class=""gene"" id=""18515891-4-167-173"">leptin</span> -2548A/G).",CTD_human;HPO
13,0,Biomarker,C0028754,Obesity,disease,obesity,3952,LEP,leptin,CTD_human,18515891,"Patients (n=134) were assessed for measures of obesity, other factors contributing to metabolic syndrome, and two genetic polymorphisms (5-HT(2C) receptor -759C/T and leptin -2548A/G).",0.72,"Patients (n=134) were assessed for measures of <span class=""disease"" id=""18515891-4-47-54"">obesity</span>, other factors contributing to metabolic syndrome, and two genetic polymorphisms (5-HT(2C) receptor -759C/T and <span class=""gene"" id=""18515891-4-167-173"">leptin</span> -2548A/G).",CTD_human;HPO
13,0,Therapeutic,C0028754,Obesity,disease,obesity,3952,LEP,leptin,CTD_human,24042701,"Training reduced 4-HNE (-10%; P?0.04), PC (-21%; P?0.05), 8-isoprostane (-26%; P?0.02) and leptin levels (-33%; P?0.01); had a tendency to decrease IL-6 levels (-21%; P=0.07) and IR (-17%; P=0.10); and increased manganese SOD (MnSOD) levels (+47%; P?0.01).Conclusion:Endurance exercise reduced skeletal muscle-specific and systemic oxidative damage while improving IR and cytokine profile associated with obesity, independent of weight loss.",0.72,"Training reduced 4-HNE (-10%; P?0.04), PC (-21%; P?0.05), 8-isoprostane (-26%; P?0.02) and <span class=""gene"" id=""24042701-5-91-97"">leptin</span> levels (-33%; P?0.01); had a tendency to decrease IL-6 levels (-21%; P=0.07) and IR (-17%; P=0.10); and increased manganese SOD (MnSOD) levels (+47%; P?0.01).Conclusion:Endurance exercise reduced skeletal muscle-specific and systemic oxidative damage while improving IR and cytokine profile associated with <span class=""disease"" id=""24042701-5-405-412"">obesity</span>, independent of weight loss.",CTD_human;HPO
13,0,Therapeutic,C0028754,Obesity,disease,obesity,3952,LEP,leptin,CTD_human,9202122,"The extreme obesity of the obese (ob/ob) mouse is attributable to mutations in the gene encoding leptin, an adipocyte-specific secreted protein which has profound effects on appetite and energy expenditure.",0.72,"The extreme <span class=""disease"" id=""9202122-1-12-19"">obesity</span> of the obese (ob/ob) mouse is attributable to mutations in the gene encoding <span class=""gene"" id=""9202122-1-97-103"">leptin</span>, an adipocyte-specific secreted protein which has profound effects on appetite and energy expenditure.",CTD_human;HPO
13,0,Biomarker,C0028754,Obesity,disease,obesity,3952,LEP,leptin,CTD_human,24042701,"Training reduced 4-HNE (-10%; P?0.04), PC (-21%; P?0.05), 8-isoprostane (-26%; P?0.02) and leptin levels (-33%; P?0.01); had a tendency to decrease IL-6 levels (-21%; P=0.07) and IR (-17%; P=0.10); and increased manganese SOD (MnSOD) levels (+47%; P?0.01).Conclusion:Endurance exercise reduced skeletal muscle-specific and systemic oxidative damage while improving IR and cytokine profile associated with obesity, independent of weight loss.",0.72,"Training reduced 4-HNE (-10%; P?0.04), PC (-21%; P?0.05), 8-isoprostane (-26%; P?0.02) and <span class=""gene"" id=""24042701-5-91-97"">leptin</span> levels (-33%; P?0.01); had a tendency to decrease IL-6 levels (-21%; P=0.07) and IR (-17%; P=0.10); and increased manganese SOD (MnSOD) levels (+47%; P?0.01).Conclusion:Endurance exercise reduced skeletal muscle-specific and systemic oxidative damage while improving IR and cytokine profile associated with <span class=""disease"" id=""24042701-5-405-412"">obesity</span>, independent of weight loss.",CTD_human;HPO
13,0,Biomarker,C0028754,Obesity,disease,obesity,3952,LEP,leptin,CTD_human,25551525,Biologically inactive leptin and early-onset extreme obesity.,0.72,"Biologically inactive <span class=""gene"" id=""25551525-0-22-28"">leptin</span> and early-onset extreme <span class=""disease"" id=""25551525-0-53-60"">obesity</span>.",CTD_human;HPO
13,0,Biomarker,C0028754,Obesity,disease,Obese,3952,LEP,leptin,CTD_human,23839791,"Obese leptin deficient (ob/ob) mice are a model of adiposity that displays increased levels of fat, glucose, and liver lipids.",0.72,"<span class=""disease"" id=""23839791-1-0-5"">Obese</span> <span class=""gene"" id=""23839791-1-6-12"">leptin</span> deficient (ob/ob) mice are a model of adiposity that displays increased levels of fat, glucose, and liver lipids.",CTD_human;HPO
13,0,Therapeutic,C0028754,Obesity,disease,Obese,3952,LEP,leptin,CTD_human,23839791,"Obese leptin deficient (ob/ob) mice are a model of adiposity that displays increased levels of fat, glucose, and liver lipids.",0.72,"<span class=""disease"" id=""23839791-1-0-5"">Obese</span> <span class=""gene"" id=""23839791-1-6-12"">leptin</span> deficient (ob/ob) mice are a model of adiposity that displays increased levels of fat, glucose, and liver lipids.",CTD_human;HPO
13,0,Therapeutic,C0028754,Obesity,disease,obese,3952,LEP,leptin,CTD_human,20122948,"Compared with the wild-type non-obese mice, the leptin-deficient obese mice also exhibited greater activation of NF-kappaB/p65 and fewer apoptotic cells in the UVB-irradiated skin.",0.72,"Compared with the wild-type non-<span class=""disease"" id=""20122948-8-32-37"">obese</span> mice, the <span class=""gene"" id=""20122948-8-48-54"">leptin</span>-deficient <span class=""disease"" id=""20122948-8-65-70"">obese</span> mice also exhibited greater activation of NF-kappaB/p65 and fewer apoptotic cells in the UVB-irradiated skin.",CTD_human;HPO
13,0,Therapeutic,C0028754,Obesity,disease,obese,3952,LEP,leptin,CTD_human,9502777,"Troglitazone also caused a dramatic decrease in the expression levels of leptin, which were increased by 4-10-fold in the white adipose tissues of obese rats.",0.72,"Troglitazone also caused a dramatic decrease in the expression levels of <span class=""gene"" id=""9502777-9-73-79"">leptin</span>, which were increased by 4-10-fold in the white adipose tissues of <span class=""disease"" id=""9502777-9-147-152"">obese</span> rats.",CTD_human;HPO
13,0,Therapeutic,C0028754,Obesity,disease,Obesity,3952,LEP,Leptin,CTD_human,26186301,Severe Early-Onset Obesity Due to Bioinactive Leptin Caused by a p.N103K Mutation in the Leptin Gene.,0.72,"Severe Early-Onset <span class=""disease"" id=""26186301-0-19-26"">Obesity</span> Due to Bioinactive <span class=""gene"" id=""26186301-0-46-52"">Leptin</span> Caused by a p.N103K Mutation in the <span class=""gene"" id=""26186301-0-89-95"">Leptin</span> Gene.",CTD_human;HPO
13,0,Therapeutic,C0028754,Obesity,disease,obesity,3952,LEP,leptin,CTD_human,25551525,Biologically inactive leptin and early-onset extreme obesity.,0.72,"Biologically inactive <span class=""gene"" id=""25551525-0-22-28"">leptin</span> and early-onset extreme <span class=""disease"" id=""25551525-0-53-60"">obesity</span>.",CTD_human;HPO
2,0,Therapeutic,C0028756,"Obesity, Morbid",disease,morbid obesity,3952,LEP,leptin,CTD_human,15070752,"Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults.",0.21064883204968102,"Phenotypic effects of <span class=""gene"" id=""15070752-0-22-28"">leptin</span> replacement on <span class=""disease"" id=""15070752-0-44-58"">morbid obesity</span>, diabetes mellitus, hypogonadism, and behavior in <span class=""gene"" id=""15070752-0-109-115"">leptin</span>-deficient adults.",CTD_human
2,0,Therapeutic,C0028756,"Obesity, Morbid",disease,morbid obesity,3952,LEP,leptin,CTD_human,9500540,A leptin missense mutation associated with hypogonadism and morbid obesity.,0.21064883204968102,"A <span class=""gene"" id=""9500540-0-2-8"">leptin</span> missense mutation associated with hypogonadism and <span class=""disease"" id=""9500540-0-60-74"">morbid obesity</span>.",CTD_human
2,0,Biomarker,C0028756,"Obesity, Morbid",disease,morbid obesity,3952,LEP,leptin,CTD_human,15070752,"Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults.",0.21064883204968102,"Phenotypic effects of <span class=""gene"" id=""15070752-0-22-28"">leptin</span> replacement on <span class=""disease"" id=""15070752-0-44-58"">morbid obesity</span>, diabetes mellitus, hypogonadism, and behavior in <span class=""gene"" id=""15070752-0-109-115"">leptin</span>-deficient adults.",CTD_human
2,0,Biomarker,C0028756,"Obesity, Morbid",disease,morbid obesity,3952,LEP,leptin,CTD_human,9500540,A leptin missense mutation associated with hypogonadism and morbid obesity.,0.21064883204968102,"A <span class=""gene"" id=""9500540-0-2-8"">leptin</span> missense mutation associated with hypogonadism and <span class=""disease"" id=""9500540-0-60-74"">morbid obesity</span>.",CTD_human
1,0,Biomarker,C0032460,Polycystic Ovary Syndrome,disease,PCOS,3952,LEP,leptin,CTD_human,22381227,These data suggested that sex steroid converting enzymes expression was different in SAT of PCOS patients that might contribute to abnormal testosterone and leptin level of PCOS patients.,0.21800903371416602,"These data suggested that sex steroid converting enzymes expression was different in SAT of <span class=""disease"" id=""22381227-8-92-96"">PCOS</span> patients that might contribute to abnormal testosterone and <span class=""gene"" id=""22381227-8-157-163"">leptin</span> level of <span class=""disease"" id=""22381227-8-173-177"">PCOS</span> patients.",CTD_human
1,0,Therapeutic,C0036572,Seizures,phenotype,seizures,3952,LEP,leptin,CTD_human,17993459,"Leptin receptor-deficient mice (db/db mice) are more vulnerable to seizure-induced hippocampal damage, and intraventricular administration of leptin protects neurons against seizures.",0.20054945356842604,"Leptin receptor-deficient mice (db/db mice) are more vulnerable to <span class=""disease"" id=""17993459-7-67-74"">seizure</span>-induced hippocampal damage, and intraventricular administration of <span class=""gene"" id=""17993459-7-142-148"">leptin</span> protects neurons against <span class=""disease"" id=""17993459-7-174-182"">seizures</span>.",CTD_human
6,0,Therapeutic,C0038358,Gastric ulcer,disease,gastric ulcer,3952,LEP,leptin,CTD_human,18181030,"This study investigated the involvement of neutrophil infiltration, disturbances in nitric oxide (NO) generation and oxidative stress in indomethacin-induced gastric ulcer, and the possible gastroprotective potentials of leptin, known for its angiogenic effect.",0.2,"This study investigated the involvement of neutrophil infiltration, disturbances in nitric oxide (NO) generation and oxidative stress in indomethacin-induced <span class=""disease"" id=""18181030-1-158-171"">gastric ulcer</span>, and the possible gastroprotective potentials of <span class=""gene"" id=""18181030-1-221-227"">leptin</span>, known for its angiogenic effect.",CTD_human
6,0,Therapeutic,C0038358,Gastric ulcer,disease,gastric ulcerations,3952,LEP,leptin,CTD_human,11787760,"Leptin, a product of ob gene controlling food intake, has recently been detected in the stomach and shown to be released by CCK and implicated in gastroprotection against various noxious agents but it is unknown whether centrally applied leptin influences ischemia-reperfusion (I/R)-induced gastric erosions that progress into deeper gastric ulcerations.",0.2,"<span class=""gene"" id=""11787760-1-0-6"">Leptin</span>, a product of <span class=""gene"" id=""11787760-1-21-23"">ob</span> gene controlling food intake, has recently been detected in the stomach and shown to be released by CCK and implicated in gastroprotection against various noxious agents but it is unknown whether centrally applied <span class=""gene"" id=""11787760-1-238-244"">leptin</span> influences ischemia-reperfusion (I/R)-induced gastric erosions that progress into deeper <span class=""disease"" id=""11787760-1-334-353"">gastric ulcerations</span>.",CTD_human
6,0,Therapeutic,C0038358,Gastric ulcer,disease,gastric ulcer,3952,LEP,leptin,CTD_human,16015682,Mechanisms of action of leptin in preventing gastric ulcer.,0.2,"Mechanisms of action of <span class=""gene"" id=""16015682-0-24-30"">leptin</span> in preventing <span class=""disease"" id=""16015682-0-45-58"">gastric ulcer</span>.",CTD_human
2,0,Biomarker,C0524620,Metabolic Syndrome X,disease,metabolic syndrome,3952,LEP,leptin,CTD_human,18515891,"However, both leptin genotype and smoking were significantly associated with metabolic syndrome.",0.29909984982565696,"However, both <span class=""gene"" id=""18515891-6-14-20"">leptin</span> genotype and smoking were significantly associated with <span class=""disease"" id=""18515891-6-77-95"">metabolic syndrome</span>.",CTD_human
2,0,Biomarker,C0524620,Metabolic Syndrome X,disease,metabolic syndrome,3952,LEP,leptin,CTD_human,16793964,"Serum adiponectin and leptin levels in relation to the metabolic syndrome, androgenic profile and somatotropic axis in healthy non-diabetic elderly men.",0.29909984982565696,"Serum adiponectin and <span class=""gene"" id=""16793964-0-22-28"">leptin</span> levels in relation to the <span class=""disease"" id=""16793964-0-55-73"">metabolic syndrome</span>, androgenic profile and somatotropic axis in healthy non-diabetic elderly men.",CTD_human
8,2,Biomarker,C0028754,Obesity,disease,obesity,3953,LEPR,leptin-receptor,CTD_human,17229951,"A single family has been described in which obesity results from a mutation in the leptin-receptor gene (LEPR), but the prevalence of such mutations in severe, early-onset obesity has not been systematically examined.",0.6880771872372919,"A single family has been described in which <span class=""disease"" id=""17229951-1-44-51"">obesity</span> results from a mutation in the <span class=""gene"" id=""17229951-1-83-98"">leptin-receptor</span> gene (LEPR), but the prevalence of such mutations in severe, early-onset <span class=""disease"" id=""17229951-1-172-179"">obesity</span> has not been systematically examined.",CTD_human;HPO
8,2,Biomarker,C0028754,Obesity,disease,obese,3953,LEPR,LEPR,CTD_human,23563609,"Evaluation of 29 SNPs (P < 1 × 10(-5)) in an additional 971 severely obese children and 1,990 controls identified 4 new loci associated with severe obesity (LEPR, PRKCH, PACS1 and RMST).",0.6880771872372919,"Evaluation of 29 SNPs (P &lt; 1 &times; 10(-5)) in an additional 971 severely <span class=""disease"" id=""23563609-3-69-74"">obese</span> children and 1,990 controls identified 4 new loci associated with severe obesity (<span class=""gene"" id=""23563609-3-157-161"">LEPR</span>, PRKCH, PACS1 and RMST).",CTD_human;HPO
1,0,Biomarker,C0028756,"Obesity, Morbid",disease,morbid obesity,3953,LEPR,leptin receptor,CTD_human,9537324,"In rodents, homozygous mutations in genes encoding leptin or the leptin receptor cause early-onset morbid obesity, hyperphagia and reduced energy expenditure.",0.20866023202555897,"In rodents, homozygous mutations in genes encoding leptin or the <span class=""gene"" id=""9537324-3-65-80"">leptin receptor</span> cause early-onset <span class=""disease"" id=""9537324-3-99-113"">morbid obesity</span>, hyperphagia and reduced energy expenditure.",CTD_human
1,0,Biomarker,C0032002,Pituitary Diseases,group,pituitary,3953,LEPR,leptin receptor,CTD_human,9537324,A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction.,0.202472541057918,"A mutation in the human <span class=""gene"" id=""9537324-0-24-39"">leptin receptor</span> gene causes obesity and <span class=""disease"" id=""9537324-0-64-73"">pituitary</span> dysfunction.",CTD_human
1,0,Biomarker,C0036572,Seizures,phenotype,seizures,3954,LETM1,LETM1,CTD_human,14706454,LETM1 is deleted in almost all patients with the full phenotype and has recently been suggested as an excellent candidate gene for the seizures in WHS patients.,0.40329672141055706,"<span class=""gene"" id=""14706454-2-0-5"">LETM1</span> is deleted in almost all patients with the full phenotype and has recently been suggested as an excellent candidate gene for the <span class=""disease"" id=""14706454-2-135-143"">seizures</span> in WHS patients.",CTD_human;HPO
1,0,Biomarker,C1956097,Wolf-Hirschhorn Syndrome,disease,Wolf-Hirschhorn syndrome,3954,LETM1,LETM1,CTD_human,14706454,"LETM1, a gene deleted in Wolf-Hirschhorn syndrome, encodes an evolutionarily conserved mitochondrial protein.",0.40384617497898295,"<span class=""gene"" id=""14706454-0-0-5"">LETM1</span>, a gene deleted in <span class=""disease"" id=""14706454-0-25-49"">Wolf-Hirschhorn syndrome</span>, encodes an evolutionarily conserved mitochondrial protein.",CTD_human;ORPHANET
1,0,Therapeutic,C2239176,Liver carcinoma,disease,HCC,3954,LETM1,LETM1,CTD_human,23392203,"Successful self-cleavage of 2A-peptide induced synergistic antitumor effect in the liver of H-ras12V, the HCC model mice, by simultaneous activation of LETM1 (Leucine zipper/EF hand-containing transmembrane-1) and CTMP (carboxyl-terminal modulator protein).",0.2,"Successful self-cleavage of 2A-peptide induced synergistic antitumor effect in the liver of H-ras12V, the <span class=""disease"" id=""23392203-3-106-109"">HCC</span> model mice, by simultaneous activation of <span class=""gene"" id=""23392203-3-152-157"">LETM1</span> (Leucine zipper/EF hand-containing transmembrane-1) and CTMP (carboxyl-terminal modulator protein).",CTD_human
1,0,Biomarker,C3714756,Intellectual Disability,group,mental retardation,3954,LETM1,LETM1,CTD_human,14706454,"The leucine zipper-, EF-hand-containing transmembrane protein 1 (LETM1) has recently been cloned in an attempt to identify genes deleted in Wolf-Hirschhorn syndrome (WHS), a microdeletion syndrome characterized by severe growth and mental retardation, hypotonia, seizures, and typical facial dysmorphic features.",0.200274726784213,"The <span class=""gene"" id=""14706454-1-4-63"">leucine zipper-, EF-hand-containing transmembrane protein 1</span> (<span class=""gene"" id=""14706454-1-65-70"">LETM1</span>) has recently been cloned in an attempt to identify genes deleted in Wolf-Hirschhorn syndrome (WHS), a microdeletion syndrome characterized by severe growth and <span class=""disease"" id=""14706454-1-232-250"">mental retardation</span>, hypotonia, seizures, and typical facial dysmorphic features.",CTD_human
1,0,Biomarker,C0022548,Keloid,disease,KS,3956,LGALS1,galectin-1,CTD_human,20128793,"Significant increases in expression of asporin, stratifin, galectin-1 and MIF were observed by Western blot analysis in KS.",0.2,"Significant increases in expression of asporin, stratifin, <span class=""gene"" id=""20128793-7-59-69"">galectin-1</span> and MIF were observed by Western blot analysis in <span class=""disease"" id=""20128793-7-120-122"">KS</span>.",CTD_human
1,0,Biomarker,C0027051,Myocardial Infarction,disease,myocardial infarction,3957,LGALS2,LGALS2,CTD_human,15129282,Functional variation in LGALS2 confers risk of myocardial infarction and regulates lymphotoxin-alpha secretion in vitro.,0.21620720153694897,"Functional variation in <span class=""gene"" id=""15129282-0-24-30"">LGALS2</span> confers risk of <span class=""disease"" id=""15129282-0-47-68"">myocardial infarction</span> and regulates lymphotoxin-alpha secretion in vitro.",CTD_human
1,0,Biomarker,C0014859,Esophageal Neoplasms,group,esophageal cancer,3958,LGALS3,galectin-3,CTD_human,17634542,"The present study evaluated the prognostic significance of apoptosis-related proteins, p53, Bcl-2, Bax, and galectin-3 in patients with locally advanced esophageal cancer treated with definitive chemoradiotherapy.",0.20082418035263896,"The present study evaluated the prognostic significance of apoptosis-related proteins, p53, Bcl-2, Bax, and <span class=""gene"" id=""17634542-1-108-118"">galectin-3</span> in patients with locally advanced <span class=""disease"" id=""17634542-1-153-170"">esophageal cancer</span> treated with definitive chemoradiotherapy.",CTD_human
1,0,Biomarker,C0025202,melanoma,disease,melanoma,3958,LGALS3,galectin-3,CTD_human,23994248,De novo galectin-3 expression influences the response of melanoma cells to isatin-Schiff base copper (II) complex-induced oxidative stimulus.,0.20793836598754503,"De novo <span class=""gene"" id=""23994248-0-8-18"">galectin-3</span> expression influences the response of <span class=""disease"" id=""23994248-0-57-65"">melanoma</span> cells to isatin-Schiff base copper (II) complex-induced oxidative stimulus.",CTD_human
1,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastasis,3958,LGALS3,galectin-3,CTD_human,25882088,It is therefore suggested that the blockade of galectin-3 mediated lung metastasis appears to be a result of an inhibition of mixed functions induced during metastasis.,0.219202164140283,"It is therefore suggested that the blockade of <span class=""gene"" id=""25882088-8-47-57"">galectin-3</span> mediated lung metastasis appears to be a result of an inhibition of mixed functions induced during <span class=""disease"" id=""25882088-8-157-167"">metastasis</span>.",CTD_human
1,0,Biomarker,C0007137,Squamous cell carcinoma,disease,SCC,3963,LGALS7,galectin 7,CTD_human,15274141,"At least, SCC antigen, G protein, glutathione S-transferase, manganese superoxide dismutase, annexins, voltage-dependent anion channel, cyclophilin A, stratifin and galectin 7 are candidates for targeted proteins.",0.20054945356842604,"At least, <span class=""disease"" id=""15274141-8-10-13"">SCC</span> antigen, G protein, glutathione S-transferase, manganese superoxide dismutase, annexins, voltage-dependent anion channel, cyclophilin A, stratifin and <span class=""gene"" id=""15274141-8-165-175"">galectin 7</span> are candidates for targeted proteins.",CTD_human
4,0,Biomarker,C0020619,Hypogonadism,disease,Hypogonadism,3972,LHB,luteinizing hormone beta-subunit,CTD_human,15602022,Hypogonadism in a patient with a mutation in the luteinizing hormone beta-subunit gene.,0.203231208875927,"<span class=""disease"" id=""15602022-0-0-12"">Hypogonadism</span> in a patient with a mutation in the <span class=""gene"" id=""15602022-0-49-81"">luteinizing hormone beta-subunit</span> gene.",CTD_human
4,0,Therapeutic,C0020619,Hypogonadism,disease,Hypogonadism,3972,LHB,luteinizing hormone beta-subunit,CTD_human,15602022,Hypogonadism in a patient with a mutation in the luteinizing hormone beta-subunit gene.,0.203231208875927,"<span class=""disease"" id=""15602022-0-0-12"">Hypogonadism</span> in a patient with a mutation in the <span class=""gene"" id=""15602022-0-49-81"">luteinizing hormone beta-subunit</span> gene.",CTD_human
15,12,Biomarker,C0342549,Familial Testotoxicosis,disease,peripheral precocious puberty,3973,LHCGR,LHCGR,CTD_human,26831561,We report here two patients who presented with peripheral precocious puberty and an activating mutation in the LHCGR gene: one with a family history and previously determined mutation and the other without family history and with a novel mutation (c.830G>T).,0.608176290991763,"We report here two patients who presented with <span class=""disease"" id=""26831561-5-47-76"">peripheral precocious puberty</span> and an activating mutation in the <span class=""gene"" id=""26831561-5-111-116"">LHCGR</span> gene: one with a family history and previously determined mutation and the other without family history and with a novel mutation (c.830G&gt;T).",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0032460,Polycystic Ovary Syndrome,disease,PCOS,3976,LIF,LIF,CTD_human,21411543,"Progesterone-regulated genes, including mitogen-inducible gene 6 (MIG6), leukemia inhibitory factor (LIF), GRB2-associated binding protein 1 (GAB1), S100P, and claudin-4 were significantly lower in PCOS endometrium; whereas cell proliferation genes, such as Anillin and cyclin B1, were up-regulated.",0.20054945356842604,"Progesterone-regulated genes, including mitogen-inducible gene 6 (MIG6), <span class=""gene"" id=""21411543-11-73-99"">leukemia inhibitory factor</span> (<span class=""gene"" id=""21411543-11-101-104"">LIF</span>), GRB2-associated binding protein 1 (GAB1), S100P, and claudin-4 were significantly lower in <span class=""disease"" id=""21411543-11-198-202"">PCOS</span> endometrium; whereas cell proliferation genes, such as Anillin and cyclin B1, were up-regulated.",CTD_human
2,4,Biomarker,C0796176,STUVE-WIEDEMANN SYNDROME,disease,SWS,3977,LIFR,leukemia inhibitory factor receptor,CTD_human,19603067,The Stüve-Wiedemann Syndrome (SWS) is a frequently lethal chondrodysplasia caused by null mutations in the leukemia inhibitory factor receptor gene (LIFR) responsible for an impaired activation of the JAK-STAT pathway after LIF stimulation.,0.6019230874894921,"The <span class=""disease"" id=""19603067-1-4-28"">Stüve-Wiedemann Syndrome</span> (<span class=""disease"" id=""19603067-1-30-33"">SWS</span>) is a frequently lethal chondrodysplasia caused by null mutations in the <span class=""gene"" id=""19603067-1-107-142"">leukemia inhibitory factor receptor</span> gene (LIFR) responsible for an impaired activation of the JAK-STAT pathway after LIF stimulation.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0086543,Cataract,disease,cataract,3982,LIM2,LIM2,CTD_human,11917274,"To our knowledge, this constitutes the first report, in humans, of cataract formation associated with a mutation in LIM2.",0.20328236603324,"To our knowledge, this constitutes the first report, in humans, of <span class=""disease"" id=""11917274-4-67-75"">cataract</span> formation associated with a mutation in <span class=""gene"" id=""11917274-4-116-120"">LIM2</span>.",CTD_human
1,0,Biomarker,C0008384,Cholesterol Ester Storage Disease,disease,cholesteryl ester storage disease,3988,LIPA,lysosomal acid lipase,CTD_human,24295952,A practical fluorometric assay method to measure lysosomal acid lipase activity in dried blood spots for the screening of cholesteryl ester storage disease and Wolman disease.,0.40900047134440204,"A practical fluorometric assay method to measure <span class=""gene"" id=""24295952-0-49-70"">lysosomal acid lipase</span> activity in dried blood spots for the screening of <span class=""disease"" id=""24295952-0-122-155"">cholesteryl ester storage disease</span> and Wolman disease.",CTD_human;ORPHANET
1,0,Therapeutic,C0220756,"Niemann-Pick Disease, Type C",disease,Niemann-Pick type C disease,3988,LIPA,lysosomal acid lipase,CTD_human,20557099,Thiadiazole carbamates: potent inhibitors of lysosomal acid lipase and potential Niemann-Pick type C disease therapeutics.,0.2,"Thiadiazole carbamates: potent inhibitors of <span class=""gene"" id=""20557099-0-45-66"">lysosomal acid lipase</span> and potential <span class=""disease"" id=""20557099-0-81-108"">Niemann-Pick type C disease</span> therapeutics.",CTD_human
2,0,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,NIDDM,3990,LIPC,hepatic lipase,CTD_human,15656877,The G-250A substitution in the promoter region of the hepatic lipase gene is associated with the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial.,0.23589621359973698,"The G-250A substitution in the promoter region of the <span class=""gene"" id=""15656877-0-54-68"">hepatic lipase</span> gene is associated with the conversion from impaired glucose tolerance to <span class=""disease"" id=""15656877-0-143-158"">type 2 diabetes</span>: the STOP-<span class=""disease"" id=""15656877-0-169-174"">NIDDM</span> trial.",CTD_human
2,0,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,type 2 diabetes mellitus,3990,LIPC,hepatic lipase,CTD_human,15126514,The G-250A promoter polymorphism of the hepatic lipase gene predicts the conversion from impaired glucose tolerance to type 2 diabetes mellitus: the Finnish Diabetes Prevention Study.,0.23589621359973698,"The G-250A promoter polymorphism of the <span class=""gene"" id=""15126514-0-40-54"">hepatic lipase</span> gene predicts the conversion from impaired glucose tolerance to <span class=""disease"" id=""15126514-0-119-143"">type 2 diabetes mellitus</span>: the Finnish Diabetes Prevention Study.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,40,ASIC2,ACCN1,CTD_human,17376794,"Nominally significant single SNP and/or haplotype-based association results were detected in 15 genes, of which, MYO1D, ACCN1 and LASP1 stand out as genes with autism risk alleles requiring further study, with potential GRRs in the range of 1.34-2.29.",0.202681755307501,"Nominally significant single SNP and/or haplotype-based association results were detected in 15 genes, of which, MYO1D, <span class=""gene"" id=""17376794-9-120-125"">ACCN1</span> and LASP1 stand out as genes with <span class=""disease"" id=""17376794-9-160-166"">autism</span> risk alleles requiring further study, with potential GRRs in the range of 1.34-2.29.",CTD_human
3,50,Biomarker,C0007193,"Cardiomyopathy, Dilated",group,dilated cardiomyopathy,4000,LMNA,lamin A/C,CTD_human,21689390,Late gadolinium enhanced cardiovascular magnetic resonance of lamin A/C gene mutation related dilated cardiomyopathy.,0.457850829718802,"Late gadolinium enhanced cardiovascular magnetic resonance of <span class=""gene"" id=""21689390-0-62-71"">lamin A/C</span> gene mutation related <span class=""disease"" id=""21689390-0-94-116"">dilated cardiomyopathy</span>.",CTD_human;HPO
3,50,Biomarker,C0007193,"Cardiomyopathy, Dilated",group,dilated cardiomyopathy,4000,LMNA,lamin A/C,CTD_human,20019332,Effects of mechanical stress and carvedilol in lamin A/C-deficient dilated cardiomyopathy.,0.457850829718802,"Effects of mechanical stress and carvedilol in <span class=""gene"" id=""20019332-0-47-56"">lamin A/C</span>-deficient <span class=""disease"" id=""20019332-0-67-89"">dilated cardiomyopathy</span>.",CTD_human;HPO
14,20,Biomarker,C0033300,Progeria,disease,progeria,4000,LMNA,LMNA,CTD_human,17469202,Here we present two patients with extraordinarily severe forms of progeria caused by unusual mutations in LMNA.,0.752630333288665,"Here we present two patients with extraordinarily severe forms of <span class=""disease"" id=""17469202-5-66-74"">progeria</span> caused by unusual mutations in <span class=""gene"" id=""17469202-5-106-110"">LMNA</span>.",CTD_human;ORPHANET;UNIPROT
14,20,Biomarker,C0033300,Progeria,disease,Hutchinson-Gilford syndrome,4000,LMNA,lamin,CTD_human,15726408,"The diagnosis of Hutchinson-Gilford syndrome was confirmed by analysis of the lamin A gene, revealing a heterozygous c.1824C > T (G608G) mutation.",0.752630333288665,"The diagnosis of <span class=""disease"" id=""15726408-7-17-44"">Hutchinson-Gilford syndrome</span> was confirmed by analysis of the <span class=""gene"" id=""15726408-7-78-83"">lamin</span> A gene, revealing a heterozygous c.1824C &gt; T (G608G) mutation.",CTD_human;ORPHANET;UNIPROT
4,0,Biomarker,C0271694,Familial partial lipodystrophy,disease,familial partial lipodystrophy,4000,LMNA,LMNA,CTD_human,19793595,"Sequencing of candidate genes LMNA, PPARG, AKT2, caveolin-1, as well as the PPARG4 promoter gene, which are known to be associated with familial partial lipodystrophy, revealed no genetic abnormalities, suggesting that this case may involve a novel gene.",0.23859918715283104,"Sequencing of candidate genes <span class=""gene"" id=""19793595-4-30-34"">LMNA</span>, PPARG, AKT2, caveolin-1, as well as the PPARG4 promoter gene, which are known to be associated with <span class=""disease"" id=""19793595-4-136-166"">familial partial lipodystrophy</span>, revealed no genetic abnormalities, suggesting that this case may involve a novel gene.",CTD_human
4,0,Biomarker,C0271694,Familial partial lipodystrophy,disease,familial partial lipodystrophy,4000,LMNA,LMNA,CTD_human,14510863,Response to treatment with rosiglitazone in familial partial lipodystrophy due to a mutation in the LMNA gene.,0.23859918715283104,"Response to treatment with rosiglitazone in <span class=""disease"" id=""14510863-0-44-74"">familial partial lipodystrophy</span> due to a mutation in the <span class=""gene"" id=""14510863-0-100-104"">LMNA</span> gene.",CTD_human
4,0,Biomarker,C0271694,Familial partial lipodystrophy,disease,FPLD,4000,LMNA,LMNA,CTD_human,16241930,"Dunnigan-type familial partial lipodystrophy (FPLD) is caused by mutations in LMNA, the gene that encodes nuclear lamins A and C. FPLD is characterized by peripheral fat loss, excess central adiposity, insulin resistance, and hyperlipidaemia, which are difficult to treat.",0.23859918715283104,"Dunnigan-type <span class=""disease"" id=""16241930-1-14-44"">familial partial lipodystrophy</span> (<span class=""disease"" id=""16241930-1-46-50"">FPLD</span>) is caused by mutations in <span class=""gene"" id=""16241930-1-78-82"">LMNA</span>, the gene that encodes nuclear lamins A and C. <span class=""disease"" id=""16241930-1-130-134"">FPLD</span> is characterized by peripheral fat loss, excess central adiposity, insulin resistance, and hyperlipidaemia, which are difficult to treat.",CTD_human
4,0,Biomarker,C0271694,Familial partial lipodystrophy,disease,FPL,4000,LMNA,lamin A/C,CTD_human,12844477,"Recently, missense mutations of LMNA encoding lamin A/C have been described in FPL providing evidence for a pivotal role of lamin A/C in the regulation of adipocytes.",0.23859918715283104,"Recently, missense mutations of <span class=""gene"" id=""12844477-2-32-36"">LMNA</span> encoding <span class=""gene"" id=""12844477-2-46-55"">lamin A/C</span> have been described in <span class=""disease"" id=""12844477-2-79-82"">FPL</span> providing evidence for a pivotal role of <span class=""gene"" id=""12844477-2-124-133"">lamin A/C</span> in the regulation of adipocytes.",CTD_human
5,12,Biomarker,C0432291,Mandibuloacral dysostosis,disease,mandibuloacral dysplasia,4000,LMNA,LMNA,CTD_human,17848409,Compound heterozygosity for mutations in LMNA in a patient with a myopathic and lipodystrophic mandibuloacral dysplasia type A phenotype.,0.6046703553316229,"Compound heterozygosity for mutations in <span class=""gene"" id=""17848409-0-41-45"">LMNA</span> in a patient with a myopathic and lipodystrophic <span class=""disease"" id=""17848409-0-95-119"">mandibuloacral dysplasia</span> type A phenotype.",CTD_human;ORPHANET;UNIPROT
5,12,Biomarker,C0432291,Mandibuloacral dysostosis,disease,MAD,4000,LMNA,LMNA,CTD_human,12788894,"Besides LMNA gene, other as yet unmapped loci could be linked to MAD.",0.6046703553316229,"Besides <span class=""gene"" id=""12788894-10-8-12"">LMNA</span> gene, other as yet unmapped loci could be linked to <span class=""disease"" id=""12788894-10-65-68"">MAD</span>.",CTD_human;ORPHANET;UNIPROT
1,3,Biomarker,C0686353,"Muscular Dystrophies, Limb-Girdle",group,limb-girdle muscular dystrophy,4000,LMNA,LMNA,CTD_human,12032588,Identification of lamin A/C ( LMNA) gene mutations in Korean patients with autosomal dominant Emery-Dreifuss muscular dystrophy and limb-girdle muscular dystrophy 1B.,0.41424272664712897,"Identification of <span class=""gene"" id=""12032588-0-18-27"">lamin A/C</span> ( <span class=""gene"" id=""12032588-0-30-34"">LMNA</span>) gene mutations in Korean patients with autosomal dominant Emery-Dreifuss muscular dystrophy and <span class=""disease"" id=""12032588-0-132-162"">limb-girdle muscular dystrophy</span> 1B.",CTD_human;HPO
1,0,Biomarker,C0023492,"Leukemia, T-Cell",disease,T-cell leukemia,4005,LMO2,Rhom-2,CTD_human,2034676,"Therefore, chromosome bands 11p15 (rhombotin) and 11p13 (Rhom-2) are consistent sites of chromosome translocation in T-cell leukemia, with the 11p15 target more rarely involved.",0.203021994626344,"Therefore, chromosome bands 11p15 (rhombotin) and 11p13 (<span class=""gene"" id=""2034676-10-57-63"">Rhom-2</span>) are consistent sites of chromosome translocation in <span class=""disease"" id=""2034676-10-117-132"">T-cell leukemia</span>, with the 11p15 target more rarely involved.",CTD_human
2,0,Biomarker,C1458155,Mammary Neoplasms,group,breast tumours,400500,BCAR4,BCAR4,CTD_human,20859285,Our cell model suggests that BCAR4-positive breast tumours are driven by ERBB2/ERBB3 signalling.,0.20328236603324,"Our cell model suggests that <span class=""gene"" id=""20859285-11-29-34"">BCAR4</span>-positive <span class=""disease"" id=""20859285-11-44-58"">breast tumours</span> are driven by ERBB2/ERBB3 signalling.",CTD_human
2,0,Biomarker,C1458155,Mammary Neoplasms,group,breast tumors,400500,BCAR4,BCAR4,CTD_human,21506106,BCAR4 is expressed in 27% of primary breast tumors.,0.20328236603324,"<span class=""gene"" id=""21506106-4-0-5"">BCAR4</span> is expressed in 27% of primary <span class=""disease"" id=""21506106-4-37-50"">breast tumors</span>.",CTD_human
1,1,Biomarker,C0009324,Ulcerative Colitis,disease,ulcerative colitis,400935,IL17REL,IL17REL,CTD_human,20228798,Genome-wide association study for ulcerative colitis identifies risk loci at 7q22 and 22q13 (IL17REL).,0.200274726784213,"Genome-wide association study for <span class=""disease"" id=""20228798-0-34-52"">ulcerative colitis</span> identifies risk loci at 7q22 and 22q13 (<span class=""gene"" id=""20228798-0-93-100"">IL17REL</span>).",CTD_human
6,10,Biomarker,C0027341,Nail-Patella Syndrome,disease,nail-patella syndrome,4010,LMX1B,LMX1B,CTD_human,19147669,The clinical diagnosis of nail-patella syndrome was confirmed by demonstrating a splice mutation in the intron 5 (750 + 1 G>A) of the LMX1B gene.,0.712852371087034,"The clinical diagnosis of <span class=""disease"" id=""19147669-4-26-47"">nail-patella syndrome</span> was confirmed by demonstrating a splice mutation in the intron 5 (750 + 1 G&gt;A) of the <span class=""gene"" id=""19147669-4-134-139"">LMX1B</span> gene.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0019202,Hepatolenticular Degeneration,disease,Wilson's disease,4015,LOX,lysyl oxidase,CTD_human,16023247,Abnormal deposition of collagen around hepatocytes in Wilson's disease is associated with hepatocyte specific expression of lysyl oxidase and lysyl oxidase like protein-2.,0.20328236603324,"Abnormal deposition of collagen around hepatocytes in <span class=""disease"" id=""16023247-0-54-70"">Wilson's disease</span> is associated with hepatocyte specific expression of <span class=""gene"" id=""16023247-0-124-137"">lysyl oxidase</span> and lysyl oxidase like protein-2.",CTD_human
1,0,Biomarker,C0029463,Osteosarcoma,disease,osteosarcoma,4015,LOX,LOX,CTD_human,23886186,Interactive effect of bisphenol A (BPA) exposure with -22G/C polymorphism in LOX gene on the risk of osteosarcoma.,0.201098907136852,"Interactive effect of bisphenol A (BPA) exposure with -22G/C polymorphism in <span class=""gene"" id=""23886186-0-77-80"">LOX</span> gene on the risk of <span class=""disease"" id=""23886186-0-101-113"">osteosarcoma</span>.",CTD_human
1,0,Biomarker,C0005695,Bladder Neoplasm,disease,bladder cancer,4016,LOXL1,LOXL1,CTD_human,17456585,LOXL1 and LOXL4 are epigenetically silenced and can inhibit ras/extracellular signal-regulated kinase signaling pathway in human bladder cancer.,0.200274726784213,"<span class=""gene"" id=""17456585-0-0-5"">LOXL1</span> and LOXL4 are epigenetically silenced and can inhibit ras/extracellular signal-regulated kinase signaling pathway in human <span class=""disease"" id=""17456585-0-129-143"">bladder cancer</span>.",CTD_human
1,3,Biomarker,C0206368,Exfoliation Syndrome,disease,XFS,4016,LOXL1,LOXL1,CTD_human,25706626,Our findings represent the first genetic locus outside of LOXL1 surpassing genome-wide significance for XFS and provide insight into the biology and pathogenesis of the disease.,0.297554737785903,"Our findings represent the first genetic locus outside of <span class=""gene"" id=""25706626-5-58-63"">LOXL1</span> surpassing genome-wide significance for <span class=""disease"" id=""25706626-5-104-107"">XFS</span> and provide insight into the biology and pathogenesis of the disease.",CTD_human
1,0,Biomarker,C0019202,Hepatolenticular Degeneration,disease,Wilson's disease,4017,LOXL2,lysyl oxidase like protein-2,CTD_human,16023247,Abnormal deposition of collagen around hepatocytes in Wilson's disease is associated with hepatocyte specific expression of lysyl oxidase and lysyl oxidase like protein-2.,0.20300763924902696,"Abnormal deposition of collagen around hepatocytes in <span class=""disease"" id=""16023247-0-54-70"">Wilson's disease</span> is associated with hepatocyte specific expression of lysyl oxidase and <span class=""gene"" id=""16023247-0-142-170"">lysyl oxidase like protein-2</span>.",CTD_human
1,0,Biomarker,C0279626,Squamous cell carcinoma of esophagus,disease,esophageal squamous cell carcinoma,4017,LOXL2,LOXL2,CTD_human,24716982,Protein-protein interaction network analyses for elucidating the roles of LOXL2-delta72 in esophageal squamous cell carcinoma.,0.201098907136852,"Protein-protein interaction network analyses for elucidating the roles of <span class=""gene"" id=""24716982-0-74-79"">LOXL2</span>-delta72 in <span class=""disease"" id=""24716982-0-91-125"">esophageal squamous cell carcinoma</span>.",CTD_human
2,0,Biomarker,C1458155,Mammary Neoplasms,group,breast tumor,4017,LOXL2,LOXL2,CTD_human,19330836,Results support the role of LOXL2 in selectively promoting a metastatic phenotype in breast tumor cells.,0.200274726784213,"Results support the role of <span class=""gene"" id=""19330836-7-28-33"">LOXL2</span> in selectively promoting a metastatic phenotype in <span class=""disease"" id=""19330836-7-85-97"">breast tumor</span> cells.",CTD_human
3,0,Biomarker,C0004153,Atherosclerosis,disease,atherosclerosis,4018,LPA,apolipoprotein(a,CTD_human,9770530,Fibrinogen deficiency reduces vascular accumulation of apolipoprotein(a) and development of atherosclerosis in apolipoprotein(a) transgenic mice.,0.228491717646215,"Fibrinogen deficiency reduces vascular accumulation of <span class=""gene"" id=""9770530-0-55-71"">apolipoprotein(a</span>) and development of <span class=""disease"" id=""9770530-0-92-107"">atherosclerosis</span> in <span class=""gene"" id=""9770530-0-111-127"">apolipoprotein(a</span>) transgenic mice.",CTD_human
3,0,Biomarker,C0004153,Atherosclerosis,disease,atherosclerosis,4018,LPA,lipoprotein Lp(a,CTD_human,1465128,"Elevated plasma levels of the lipoprotein Lp(a) are associated with increased risk for atherosclerosis and its manifestations, myocardial infarction, stroke and restenosis (for reviews, see refs 1-3).",0.228491717646215,"Elevated plasma levels of the <span class=""gene"" id=""1465128-1-30-46"">lipoprotein Lp(a</span>) are associated with increased risk for <span class=""disease"" id=""1465128-1-87-102"">atherosclerosis</span> and its manifestations, myocardial infarction, stroke and restenosis (for reviews, see refs 1-3).",CTD_human
1,0,Biomarker,C0007222,Cardiovascular Diseases,group,cardiovascular disease,4018,LPA,lipoprotein(a,CTD_human,18775538,"Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy.",0.22863541936116896,"Polymorphism in the <span class=""gene"" id=""18775538-0-20-36"">apolipoprotein(a</span>) gene, plasma <span class=""gene"" id=""18775538-0-51-64"">lipoprotein(a</span>), <span class=""disease"" id=""18775538-0-67-89"">cardiovascular disease</span>, and low-dose aspirin therapy.",CTD_human
1,4,Biomarker,C0010068,Coronary heart disease,disease,coronary heart disease,4018,LPA,apolipoprotein(a,CTD_human,10484779,"High plasma concentrations of lipoprotein(a) [Lp(a)], a covalent low-density lipoprotein-apolipoprotein(a) [apo(a)] complex, are associated with coronary heart disease and stroke.",0.252051029822288,"High plasma concentrations of <span class=""gene"" id=""10484779-1-30-43"">lipoprotein(a</span>) [Lp(a)], a covalent low-density lipoprotein-<span class=""gene"" id=""10484779-1-89-105"">apolipoprotein(a</span>) [apo(a)] complex, are associated with <span class=""disease"" id=""10484779-1-145-167"">coronary heart disease</span> and stroke.",CTD_human
1,1,Biomarker,C0038454,Cerebrovascular accident,group,stroke,4018,LPA,apolipoprotein(a,CTD_human,10484779,"High plasma concentrations of lipoprotein(a) [Lp(a)], a covalent low-density lipoprotein-apolipoprotein(a) [apo(a)] complex, are associated with coronary heart disease and stroke.",0.221580481908936,"High plasma concentrations of <span class=""gene"" id=""10484779-1-30-43"">lipoprotein(a</span>) [Lp(a)], a covalent low-density lipoprotein-<span class=""gene"" id=""10484779-1-89-105"">apolipoprotein(a</span>) [apo(a)] complex, are associated with coronary heart disease and <span class=""disease"" id=""10484779-1-172-178"">stroke</span>.",CTD_human
2,1,Biomarker,C1956346,Coronary Artery Disease,disease,coronary artery disease,4018,LPA,LPA,CTD_human,20435227,A variant in LPA was consistent with a family history of coronary artery disease.,0.25276831023997004,"A variant in <span class=""gene"" id=""20435227-12-13-16"">LPA</span> was consistent with a family history of <span class=""disease"" id=""20435227-12-57-80"">coronary artery disease</span>.",CTD_human
1,0,Therapeutic,C0019196,Hepatitis C,disease,HCV,4023,LPL,Lipoprotein lipase,CTD_human,17517063,Lipoprotein lipase mediates hepatitis C virus (HCV) cell entry and inhibits HCV infection.,0.2,"<span class=""gene"" id=""17517063-0-0-18"">Lipoprotein lipase</span> mediates <span class=""disease"" id=""17517063-0-28-39"">hepatitis C</span> virus (HCV) cell entry and inhibits <span class=""disease"" id=""17517063-0-76-79"">HCV</span> infection.",CTD_human
2,0,Therapeutic,C0020557,Hypertriglyceridemia,phenotype,hypertriglyceridemia,4023,LPL,lipoprotein lipase,CTD_human,8147947,Effects of treatment with bezafibrate on lipoprotein lipase activity and mass in patients with hypertriglyceridemia.,0.3064913753273,"Effects of treatment with bezafibrate on <span class=""gene"" id=""8147947-0-41-59"">lipoprotein lipase</span> activity and mass in patients with <span class=""disease"" id=""8147947-0-95-115"">hypertriglyceridemia</span>.",CTD_human
2,0,Therapeutic,C0020557,Hypertriglyceridemia,phenotype,HTG,4023,LPL,LPL,CTD_human,20657596,"Through GWAS, we identified common variants in APOA5, GCKR, LPL and APOB associated with HTG.",0.3064913753273,"Through GWAS, we identified common variants in APOA5, GCKR, <span class=""gene"" id=""20657596-5-60-63"">LPL</span> and APOB associated with <span class=""disease"" id=""20657596-5-89-92"">HTG</span>.",CTD_human
2,0,Biomarker,C0020557,Hypertriglyceridemia,phenotype,hypertriglyceridemia,4023,LPL,lipoprotein lipase,CTD_human,8147947,Effects of treatment with bezafibrate on lipoprotein lipase activity and mass in patients with hypertriglyceridemia.,0.3064913753273,"Effects of treatment with bezafibrate on <span class=""gene"" id=""8147947-0-41-59"">lipoprotein lipase</span> activity and mass in patients with <span class=""disease"" id=""8147947-0-95-115"">hypertriglyceridemia</span>.",CTD_human
2,0,Biomarker,C0020557,Hypertriglyceridemia,phenotype,HTG,4023,LPL,LPL,CTD_human,20657596,"Through GWAS, we identified common variants in APOA5, GCKR, LPL and APOB associated with HTG.",0.3064913753273,"Through GWAS, we identified common variants in APOA5, GCKR, <span class=""gene"" id=""20657596-5-60-63"">LPL</span> and APOB associated with <span class=""disease"" id=""20657596-5-89-92"">HTG</span>.",CTD_human
1,0,Biomarker,C0030305,Pancreatitis,disease,pancreatitis,4023,LPL,lipoprotein lipase,CTD_human,18936103,Enhanced susceptibility to pancreatitis in severe hypertriglyceridaemic lipoprotein lipase-deficient mice and agonist-like function of pancreatic lipase in pancreatic cells.,0.410634476672364,"Enhanced susceptibility to <span class=""disease"" id=""18936103-0-27-39"">pancreatitis</span> in severe hypertriglyceridaemic <span class=""gene"" id=""18936103-0-72-90"">lipoprotein lipase</span>-deficient mice and agonist-like function of pancreatic lipase in pancreatic cells.",CTD_human;HPO
1,1,Biomarker,C0149931,Migraine Disorders,group,migraine,4035,LRP1,LRP1,CTD_human,21666692,"TRPM8 has been the focus of neuropathic pain models, whereas LRP1 modulates neuronal glutamate signaling, plausibly linking both genes to migraine pathophysiology.",0.201648360705279,"TRPM8 has been the focus of neuropathic pain models, whereas <span class=""gene"" id=""21666692-7-61-65"">LRP1</span> modulates neuronal glutamate signaling, plausibly linking both genes to <span class=""disease"" id=""21666692-7-138-146"">migraine</span> pathophysiology.",CTD_human
1,0,Biomarker,C0042870,Vitamin D Deficiency,disease,vitamin D deficiency,4036,LRP2,Megalin,CTD_human,10052453,Megalin-/- mice are unable to retrieve the steroid from the glomerular filtrate and develop vitamin D deficiency and bone disease.,0.200274726784213,"<span class=""gene"" id=""10052453-5-0-7"">Megalin</span>-/- mice are unable to retrieve the steroid from the glomerular filtrate and develop <span class=""disease"" id=""10052453-5-92-112"">vitamin D deficiency</span> and bone disease.",CTD_human
8,23,Biomarker,C0432252,Osteoporosis with pseudoglioma,disease,OPPG,4041,LRP5,LRP5,CTD_human,18825883,Three years follow-up of pamidronate therapy in two brothers with osteoporosis-pseudoglioma syndrome (OPPG) carrying an LRP5 mutation.,0.686043989252688,"Three years follow-up of pamidronate therapy in two brothers with <span class=""disease"" id=""18825883-0-66-100"">osteoporosis-pseudoglioma syndrome</span> (<span class=""disease"" id=""18825883-0-102-106"">OPPG</span>) carrying an <span class=""gene"" id=""18825883-0-120-124"">LRP5</span> mutation.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0004153,Atherosclerosis,disease,atherosclerosis,4048,LTA4H,LTA4H,CTD_human,16698924,The abundant expression of LTA4H and correlation with plaque instability identify LTA4H as a potential target for pharmacological intervention in treatment of human atherosclerosis.,0.202956482091714,"The abundant expression of <span class=""gene"" id=""16698924-9-27-32"">LTA4H</span> and correlation with plaque instability identify <span class=""gene"" id=""16698924-9-82-87"">LTA4H</span> as a potential target for pharmacological intervention in treatment of human <span class=""disease"" id=""16698924-9-165-180"">atherosclerosis</span>.",CTD_human
1,0,Biomarker,C0023343,Leprosy,disease,leprosy,4049,LTA,lymphotoxin-alpha,CTD_human,17353895,Stepwise replication identifies a low-producing lymphotoxin-alpha allele as a major risk factor for early-onset leprosy.,0.202681755307501,"Stepwise replication identifies a low-producing <span class=""gene"" id=""17353895-0-48-65"">lymphotoxin-alpha</span> allele as a major risk factor for early-onset <span class=""disease"" id=""17353895-0-112-119"">leprosy</span>.",CTD_human
2,2,Biomarker,C0027051,Myocardial Infarction,disease,myocardial infarction,4049,LTA,lymphotoxin-alpha,CTD_human,15129282,Functional variation in LGALS2 confers risk of myocardial infarction and regulates lymphotoxin-alpha secretion in vitro.,0.258495734733578,"Functional variation in LGALS2 confers risk of <span class=""disease"" id=""15129282-0-47-68"">myocardial infarction</span> and regulates <span class=""gene"" id=""15129282-0-83-100"">lymphotoxin-alpha</span> secretion in vitro.",CTD_human
2,2,Biomarker,C0027051,Myocardial Infarction,disease,myocardial infarction,4049,LTA,lymphotoxin-alpha,CTD_human,12426569,Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction.,0.258495734733578,"Functional SNPs in the <span class=""gene"" id=""12426569-0-23-40"">lymphotoxin-alpha</span> gene that are associated with susceptibility to <span class=""disease"" id=""12426569-0-89-110"">myocardial infarction</span>.",CTD_human
1,0,Biomarker,C0243026,Sepsis,disease,sepsis,4049,LTA,tumor necrosis factor ?,CTD_human,22977509,Association of tumor necrosis factor ? genetic polymorphism and sepsis susceptibility.,0.228675128029873,"Association of <span class=""gene"" id=""22977509-0-15-38"">tumor necrosis factor &beta;</span> genetic polymorphism and <span class=""disease"" id=""22977509-0-64-70"">sepsis</span> susceptibility.",CTD_human
1,0,Biomarker,C0345967,Malignant mesothelioma,disease,MM,4049,LTA,TNF-beta,CTD_human,25162674,"A specific pattern of cytokines were found highly expressed in Asb-workers: IFN-alpha (p<0.05), EOTAXIN (p<0.01), RANTES (p<0.001), and in MM patients: IL-12(p40), IL-3, IL-1 alpha, MCP-3, beta-NGF, TNF-beta, RANTES (p<0.001).",0.2,"A specific pattern of cytokines were found highly expressed in Asb-workers: IFN-alpha (p&lt;0.05), EOTAXIN (p&lt;0.01), RANTES (p&lt;0.001), and in <span class=""disease"" id=""25162674-8-139-141"">MM</span> patients: IL-12(p40), IL-3, IL-1 alpha, MCP-3, beta-NGF, <span class=""gene"" id=""25162674-8-199-207"">TNF-beta</span>, RANTES (p&lt;0.001).",CTD_human
1,0,Biomarker,C1956346,Coronary Artery Disease,disease,coronary artery disease,4049,LTA,lymphotoxin-alpha,CTD_human,15266304,A trio family study showing association of the lymphotoxin-alpha N26 (804A) allele with coronary artery disease.,0.225611746003201,"A trio family study showing association of the <span class=""gene"" id=""15266304-0-47-64"">lymphotoxin-alpha</span> N26 (804A) allele with <span class=""disease"" id=""15266304-0-88-111"">coronary artery disease</span>.",CTD_human
1,0,Biomarker,C0025202,melanoma,disease,melanoma,405,ARNT,ARNT,CTD_human,21983785,"The associated variants at the 1q21.3 locus span a region with ten genes, and plausible candidate genes for melanoma susceptibility include ARNT and SETDB1.",0.201648360705279,"The associated variants at the 1q21.3 locus span a region with ten genes, and plausible candidate genes for <span class=""disease"" id=""21983785-6-108-116"">melanoma</span> susceptibility include <span class=""gene"" id=""21983785-6-140-144"">ARNT</span> and SETDB1.",CTD_human
1,0,Biomarker,C0002452,Amelogenesis Imperfecta,disease,amelogenesis imperfecta,4054,LTBP3,LTBP3,CTD_human,25669657,Mutations in the latent TGF-beta binding protein 3 (LTBP3) gene cause brachyolmia with amelogenesis imperfecta.,0.40027472678421294,"Mutations in the <span class=""gene"" id=""25669657-0-17-50"">latent TGF-beta binding protein 3</span> (<span class=""gene"" id=""25669657-0-52-57"">LTBP3</span>) gene cause brachyolmia with <span class=""disease"" id=""25669657-0-87-110"">amelogenesis imperfecta</span>.",CTD_human;HPO
1,0,Biomarker,C0432228,Brachyolmia,disease,brachyolmia,4054,LTBP3,LTBP3,CTD_human,25669657,Mutations in the latent TGF-beta binding protein 3 (LTBP3) gene cause brachyolmia with amelogenesis imperfecta.,0.200274726784213,"Mutations in the <span class=""gene"" id=""25669657-0-17-50"">latent TGF-beta binding protein 3</span> (<span class=""gene"" id=""25669657-0-52-57"">LTBP3</span>) gene cause <span class=""disease"" id=""25669657-0-70-81"">brachyolmia</span> with amelogenesis imperfecta.",CTD_human
1,0,Biomarker,C0024530,Malaria,disease,malaria,4055,LTBR,lymphotoxin beta receptor,CTD_human,15788153,Testosterone responsiveness of spleen and liver in female lymphotoxin beta receptor-deficient mice resistant to blood-stage malaria.,0.2,"Testosterone responsiveness of spleen and liver in female <span class=""gene"" id=""15788153-0-58-83"">lymphotoxin beta receptor</span>-deficient mice resistant to blood-stage <span class=""disease"" id=""15788153-0-124-131"">malaria</span>.",CTD_human
4,0,Biomarker,C1319853,"Asthma, Aspirin-Induced",disease,aspirin-induced asthma,4056,LTC4S,Leukotriene C4 synthase,CTD_human,9393345,Leukotriene C4 synthase promoter polymorphism and risk of aspirin-induced asthma.,0.206462417751855,"<span class=""gene"" id=""9393345-0-0-23"">Leukotriene C4 synthase</span> promoter polymorphism and risk of <span class=""disease"" id=""9393345-0-58-80"">aspirin-induced asthma</span>.",CTD_human
1,0,Biomarker,C0238288,"Muscular Dystrophy, Facioscapulohumeral",disease,facioscapulohumeral muscular dystrophy,4060,LUM,lumican,CTD_human,12868502,"Expression of elastin, decorin, lumican and the extracellular matrix remodeling factor TIMP3 were reduced in facioscapulohumeral muscular dystrophy myoblasts.",0.200274726784213,"Expression of elastin, decorin, <span class=""gene"" id=""12868502-11-32-39"">lumican</span> and the extracellular matrix remodeling factor TIMP3 were reduced in <span class=""disease"" id=""12868502-11-109-147"">facioscapulohumeral muscular dystrophy</span> myoblasts.",CTD_human
1,0,Biomarker,C0023467,"Leukemia, Myelocytic, Acute",disease,acute myeloblastic leukemia,4066,LYL1,LYL1,CTD_human,16094422,Oncogenic potential of the transcription factor LYL1 in acute myeloblastic leukemia.,0.200274726784213,"Oncogenic potential of the transcription factor <span class=""gene"" id=""16094422-0-48-52"">LYL1</span> in <span class=""disease"" id=""16094422-0-56-83"">acute myeloblastic leukemia</span>.",CTD_human
1,0,Biomarker,C3463824,MYELODYSPLASTIC SYNDROME,group,myelodysplastic syndrome,4066,LYL1,LYL1,CTD_human,16094422,"Using real-time quantitative RT-PCR assay, we found that the expression of LYL1 was at higher levels in the majority cases of acute myeloblastic leukemia (AML) or myelodysplastic syndrome when compared to normal bone marrow.",0.200274726784213,"Using real-time quantitative RT-PCR assay, we found that the expression of <span class=""gene"" id=""16094422-2-75-79"">LYL1</span> was at higher levels in the majority cases of acute myeloblastic leukemia (AML) or <span class=""disease"" id=""16094422-2-163-187"">myelodysplastic syndrome</span> when compared to normal bone marrow.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autistic,406900,MIR106B,miR-106b,CTD_human,20374639,"Interestingly, the up-regulation of miR-23a and down-regulation of miR-106b in this study reflected miRNA changes previously reported in post-mortem autistic cerebellum by Abu-Elneel et al. in 2008.",0.2,"Interestingly, the up-regulation of miR-23a and down-regulation of <span class=""gene"" id=""20374639-9-67-75"">miR-106b</span> in this study reflected miRNA changes previously reported in post-mortem <span class=""disease"" id=""20374639-9-149-157"">autistic</span> cerebellum by Abu-Elneel et al. in 2008.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,hepatocellular carcinomas,406906,MIR122,miR-122,CTD_human,16924677,Downregulation of miR-122 in the rodent and human hepatocellular carcinomas.,0.231825240836768,"Downregulation of <span class=""gene"" id=""16924677-0-18-25"">miR-122</span> in the rodent and human <span class=""disease"" id=""16924677-0-50-75"">hepatocellular carcinomas</span>.",CTD_human
1,0,Therapeutic,C0007131,Non-Small Cell Lung Carcinoma,disease,NSCLC,406913,MIR126,hsa-miR-126,CTD_human,20097187,"The first aim of this study was to confirm a role for three miRNAs (let-7a, hsa-miR-126, and hsa-miR-145) in the inhibition of proliferation in non-small cell lung cancer (NSCLC) cells.",0.203296721410557,"The first aim of this study was to confirm a role for three miRNAs (let-7a, <span class=""gene"" id=""20097187-5-76-87"">hsa-miR-126</span>, and hsa-miR-145) in the inhibition of proliferation in <span class=""disease"" id=""20097187-5-144-170"">non-small cell lung cancer</span> (<span class=""disease"" id=""20097187-5-172-177"">NSCLC</span>) cells.",CTD_human
1,0,Biomarker,C0345967,Malignant mesothelioma,disease,malignant mesothelioma,406913,MIR126,MiR-126,CTD_human,21483773,"Association of MiR-126 with soluble mesothelin-related peptides, a marker for malignant mesothelioma.",0.201373633921065,"Association of <span class=""gene"" id=""21483773-0-15-22"">MiR-126</span> with soluble mesothelin-related peptides, a marker for <span class=""disease"" id=""21483773-0-78-100"">malignant mesothelioma</span>.",CTD_human
1,1,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,406928,MIR137,MIR137,CTD_human,21926974,"Four other schizophrenia loci achieving genome-wide significance contain predicted targets of MIR137, suggesting MIR137-mediated dysregulation as a previously unknown etiologic mechanism in schizophrenia.",0.209615437447459,"Four other <span class=""disease"" id=""21926974-4-11-24"">schizophrenia</span> loci achieving genome-wide significance contain predicted targets of <span class=""gene"" id=""21926974-4-94-100"">MIR137</span>, suggesting <span class=""gene"" id=""21926974-4-113-119"">MIR137</span>-mediated dysregulation as a previously unknown etiologic mechanism in <span class=""disease"" id=""21926974-4-190-203"">schizophrenia</span>.",CTD_human
1,0,Therapeutic,C0007131,Non-Small Cell Lung Carcinoma,disease,NSCLC,406937,MIR145,hsa-miR-145,CTD_human,20097187,"The first aim of this study was to confirm a role for three miRNAs (let-7a, hsa-miR-126, and hsa-miR-145) in the inhibition of proliferation in non-small cell lung cancer (NSCLC) cells.",0.20357144819477,"The first aim of this study was to confirm a role for three miRNAs (let-7a, hsa-miR-126, and <span class=""gene"" id=""20097187-5-93-104"">hsa-miR-145</span>) in the inhibition of proliferation in <span class=""disease"" id=""20097187-5-144-170"">non-small cell lung cancer</span> (<span class=""disease"" id=""20097187-5-172-177"">NSCLC</span>) cells.",CTD_human
1,0,Biomarker,C0011881,Diabetic Nephropathy,disease,diabetic nephropathy,406937,MIR145,miR-145,CTD_human,24223694,"Similarly, in an animal model of early experimental diabetic nephropathy, urinary exosomal miR-145 levels were increased and this was paralleled by miR-145 overexpression within the glomeruli.",0.2,"Similarly, in an animal model of early experimental <span class=""disease"" id=""24223694-5-52-72"">diabetic nephropathy</span>, urinary exosomal <span class=""gene"" id=""24223694-5-91-98"">miR-145</span> levels were increased and this was paralleled by <span class=""gene"" id=""24223694-5-148-155"">miR-145</span> overexpression within the glomeruli.",CTD_human
1,0,Biomarker,C0014859,Esophageal Neoplasms,group,esophageal cancer,406937,MIR145,miR-145,CTD_human,21248297,"Using 98 formalin-fixed, paraffin-embedded samples obtained from patients with esophageal cancer who had received preoperative chemotherapy followed by surgery, we measured expression levels of several miRNAs that are considered to be involved in the regulation of stem cell function (e.g., let-7a, let-7g, miR-21, miR-134, miR-145, miR-155, miR-200c, miR-203, and miR-296) by real-time reverse transcriptase PCR.",0.201098907136852,"Using 98 formalin-fixed, paraffin-embedded samples obtained from patients with <span class=""disease"" id=""21248297-2-79-96"">esophageal cancer</span> who had received preoperative chemotherapy followed by surgery, we measured expression levels of several miRNAs that are considered to be involved in the regulation of stem cell function (e.g., let-7a, let-7g, miR-21, miR-134, <span class=""gene"" id=""21248297-2-324-331"">miR-145</span>, miR-155, miR-200c, miR-203, and miR-296) by real-time reverse transcriptase PCR.",CTD_human
1,0,Biomarker,C1956346,Coronary Artery Disease,disease,coronary artery disease,406938,MIR146A,miR-146a,CTD_human,20524934,Expression of miR-146a/b is associated with the Toll-like receptor 4 signal in coronary artery disease: effect of renin-angiotensin system blockade and statins on miRNA-146a/b and Toll-like receptor 4 levels.,0.201098907136852,"Expression of <span class=""gene"" id=""20524934-0-14-22"">miR-146a</span>/b is associated with the Toll-like receptor 4 signal in <span class=""disease"" id=""20524934-0-79-102"">coronary artery disease</span>: effect of renin-angiotensin system blockade and statins on miRNA-146a/b and Toll-like receptor 4 levels.",CTD_human
1,0,Biomarker,C0028754,Obesity,disease,Obese,406960,MIR184,miR-184,CTD_human,23954404,"Obese mouse ovaries had decreased Irs1, Foxo3a, Cyp2e1, MiR-103, and MiR-21 but increased Kitlg, Akt1, and miR-184 levels relative to lean littermates.",0.2,"<span class=""disease"" id=""23954404-4-0-5"">Obese</span> mouse ovaries had decreased Irs1, Foxo3a, Cyp2e1, MiR-103, and MiR-21 but increased Kitlg, Akt1, and <span class=""gene"" id=""23954404-4-107-114"">miR-184</span> levels relative to lean littermates.",CTD_human
1,0,Biomarker,C0019569,Hirschsprung Disease,disease,Hirschsprung's disease,406971,MIR195,MiR-195,CTD_human,25007945,MiR-195 affects cell migration and cell proliferation by down-regulating DIEXF in Hirschsprung's disease.,0.200274726784213,"<span class=""gene"" id=""25007945-0-0-7"">MiR-195</span> affects cell migration and cell proliferation by down-regulating DIEXF in <span class=""disease"" id=""25007945-0-82-104"">Hirschsprung's disease</span>.",CTD_human
1,0,Biomarker,C0014859,Esophageal Neoplasms,group,esophageal cancer,406985,MIR200C,miR-200c,CTD_human,21248297,"Using 98 formalin-fixed, paraffin-embedded samples obtained from patients with esophageal cancer who had received preoperative chemotherapy followed by surgery, we measured expression levels of several miRNAs that are considered to be involved in the regulation of stem cell function (e.g., let-7a, let-7g, miR-21, miR-134, miR-145, miR-155, miR-200c, miR-203, and miR-296) by real-time reverse transcriptase PCR.",0.200274726784213,"Using 98 formalin-fixed, paraffin-embedded samples obtained from patients with <span class=""disease"" id=""21248297-2-79-96"">esophageal cancer</span> who had received preoperative chemotherapy followed by surgery, we measured expression levels of several miRNAs that are considered to be involved in the regulation of stem cell function (e.g., let-7a, let-7g, miR-21, miR-134, miR-145, miR-155, <span class=""gene"" id=""21248297-2-342-350"">miR-200c</span>, miR-203, and miR-296) by real-time reverse transcriptase PCR.",CTD_human
1,0,Therapeutic,C0596263,Carcinogenesis,phenotype,tumorigenesis,406986,MIR203A,miR-203,CTD_human,23968727,Hyper-methylated miR-203 dysregulates ABL1 and contributes to the nickel-induced tumorigenesis.,0.201373633921065,"Hyper-methylated <span class=""gene"" id=""23968727-0-17-24"">miR-203</span> dysregulates ABL1 and contributes to the nickel-induced <span class=""disease"" id=""23968727-0-81-94"">tumorigenesis</span>.",CTD_human
1,0,Biomarker,C0007137,Squamous cell carcinoma,disease,squamous cell carcinoma,406988,MIR205,miR-205,CTD_human,21563230,"In addition, over-expression of the well known squamous cell carcinoma-associated miR-205 was linked to down-regulation of the DOK4 gene.",0.20467035533162303,"In addition, over-expression of the well known <span class=""disease"" id=""21563230-9-47-70"">squamous cell carcinoma</span>-associated <span class=""gene"" id=""21563230-9-82-89"">miR-205</span> was linked to down-regulation of the DOK4 gene.",CTD_human
1,0,Biomarker,C0007138,"Carcinoma, Transitional Cell",disease,urothelial carcinoma,406988,MIR205,miR-205,CTD_human,25586904,Our study suggests that exposure to arsenic rapidly induces a multifaceted dedifferentiation program and miR-205 has potential to be used as a marker of arsenic exposure as well as a maker of early urothelial carcinoma detection.,0.20054945356842604,"Our study suggests that exposure to arsenic rapidly induces a multifaceted dedifferentiation program and <span class=""gene"" id=""25586904-12-105-112"">miR-205</span> has potential to be used as a marker of arsenic exposure as well as a maker of early <span class=""disease"" id=""25586904-12-198-218"">urothelial carcinoma</span> detection.",CTD_human
1,0,Biomarker,C0019569,Hirschsprung Disease,disease,Hirschsprung disease,406989,MIR206,miR-206,CTD_human,25792468,Down-regulation of miR-206 is associated with Hirschsprung disease and suppresses cell migration and proliferation in cell models.,0.200274726784213,"Down-regulation of <span class=""gene"" id=""25792468-0-19-26"">miR-206</span> is associated with <span class=""disease"" id=""25792468-0-46-66"">Hirschsprung disease</span> and suppresses cell migration and proliferation in cell models.",CTD_human
1,0,Biomarker,C0014175,Endometriosis,disease,endometriosis,406991,MIR21,MIR21,CTD_human,21063030,"Upregulation of microRNA 21 (MIR21) and DICER1 transcripts suggests roles for microRNAs (miRNAs) in the pathogenesis of severe versus mild endometriosis, potentially through regulation of gene silencing and epigenetic mechanisms.",0.20054945356842604,"Upregulation of <span class=""gene"" id=""21063030-9-16-27"">microRNA 21</span> (<span class=""gene"" id=""21063030-9-29-34"">MIR21</span>) and DICER1 transcripts suggests roles for microRNAs (miRNAs) in the pathogenesis of severe versus mild <span class=""disease"" id=""21063030-9-139-152"">endometriosis</span>, potentially through regulation of gene silencing and epigenetic mechanisms.",CTD_human
1,0,Biomarker,C0014859,Esophageal Neoplasms,group,esophageal cancer,406991,MIR21,miR-21,CTD_human,21248297,"Using 98 formalin-fixed, paraffin-embedded samples obtained from patients with esophageal cancer who had received preoperative chemotherapy followed by surgery, we measured expression levels of several miRNAs that are considered to be involved in the regulation of stem cell function (e.g., let-7a, let-7g, miR-21, miR-134, miR-145, miR-155, miR-200c, miR-203, and miR-296) by real-time reverse transcriptase PCR.",0.203846174978983,"Using 98 formalin-fixed, paraffin-embedded samples obtained from patients with <span class=""disease"" id=""21248297-2-79-96"">esophageal cancer</span> who had received preoperative chemotherapy followed by surgery, we measured expression levels of several miRNAs that are considered to be involved in the regulation of stem cell function (e.g., let-7a, let-7g, <span class=""gene"" id=""21248297-2-307-313"">miR-21</span>, miR-134, miR-145, miR-155, miR-200c, miR-203, and miR-296) by real-time reverse transcriptase PCR.",CTD_human
1,0,Biomarker,C0028754,Obesity,disease,Obese,406991,MIR21,MiR-21,CTD_human,23954404,"Obese mouse ovaries had decreased Irs1, Foxo3a, Cyp2e1, MiR-103, and MiR-21 but increased Kitlg, Akt1, and miR-184 levels relative to lean littermates.",0.20082418035263896,"<span class=""disease"" id=""23954404-4-0-5"">Obese</span> mouse ovaries had decreased Irs1, Foxo3a, Cyp2e1, MiR-103, and <span class=""gene"" id=""23954404-4-69-75"">MiR-21</span> but increased Kitlg, Akt1, and miR-184 levels relative to lean littermates.",CTD_human
1,0,Biomarker,C0033578,Prostatic Neoplasms,group,prostate-tumor,406991,MIR21,miR-21,CTD_human,23272133,"Using microarray studies, we show that resveratrol reduced the expression of various prostate-tumor associated microRNAs (miRs) including miR-21 in androgen-receptor negative and highly aggressive human prostate cancer cells, PC-3M-MM2.",0.20054945356842604,"Using microarray studies, we show that resveratrol reduced the expression of various <span class=""disease"" id=""23272133-5-85-99"">prostate-tumor</span> associated microRNAs (miRs) including <span class=""gene"" id=""23272133-5-138-144"">miR-21</span> in androgen-receptor negative and highly aggressive human prostate cancer cells, PC-3M-MM2.",CTD_human
1,0,Biomarker,C0279626,Squamous cell carcinoma of esophagus,disease,esophageal squamous cell carcinoma,406999,MIR217,miR-217,CTD_human,25538231,"Silencing of long noncoding RNA MALAT1 by miR-101 and miR-217 inhibits proliferation, migration, and invasion of esophageal squamous cell carcinoma cells.",0.200274726784213,"Silencing of long noncoding RNA MALAT1 by miR-101 and <span class=""gene"" id=""25538231-0-54-61"">miR-217</span> inhibits proliferation, migration, and invasion of <span class=""disease"" id=""25538231-0-113-147"">esophageal squamous cell carcinoma</span> cells.",CTD_human
1,0,Biomarker,C0019569,Hirschsprung Disease,disease,Hirschsprung's disease,407000,MIR218-1,miR-218-1,CTD_human,25786906,SLIT2/ROBO1-miR-218-1-RET/PLAG1: a new disease pathway involved in Hirschsprung's disease.,0.200274726784213,"SLIT2/ROBO1-<span class=""gene"" id=""25786906-0-12-21"">miR-218-1</span>-RET/PLAG1: a new disease pathway involved in <span class=""disease"" id=""25786906-0-67-89"">Hirschsprung's disease</span>.",CTD_human
1,0,Biomarker,C0079773,"Lymphoma, T-Cell, Cutaneous",disease,cutaneous T-Cell lymphoma,407004,MIR22,miR-22,CTD_human,26244872,"Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma.",0.200274726784213,"Jak3, STAT3, and STAT5 inhibit expression of <span class=""gene"" id=""26244872-0-45-51"">miR-22</span>, a novel tumor suppressor microRNA, in <span class=""disease"" id=""26244872-0-91-116"">cutaneous T-Cell lymphoma</span>.",CTD_human
1,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastatic disease,407007,MIR222,hsa-miR-222,CTD_human,19487542,"Our results indicate that hsa-miR-222 plays an important role in OTSCC invasion, and may serve as a novel therapeutic target for OTSCC patients at risk of metastatic disease.",0.201098907136852,"Our results indicate that <span class=""gene"" id=""19487542-10-26-37"">hsa-miR-222</span> plays an important role in OTSCC invasion, and may serve as a novel therapeutic target for OTSCC patients at risk of <span class=""disease"" id=""19487542-10-155-173"">metastatic disease</span>.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autistic,407010,MIR23A,miR-23a,CTD_human,20374639,"Interestingly, the up-regulation of miR-23a and down-regulation of miR-106b in this study reflected miRNA changes previously reported in post-mortem autistic cerebellum by Abu-Elneel et al. in 2008.",0.2,"Interestingly, the up-regulation of <span class=""gene"" id=""20374639-9-36-43"">miR-23a</span> and down-regulation of miR-106b in this study reflected miRNA changes previously reported in post-mortem <span class=""disease"" id=""20374639-9-149-157"">autistic</span> cerebellum by Abu-Elneel et al. in 2008.",CTD_human
1,0,Biomarker,C1458155,Mammary Neoplasms,group,breast tumor,407013,MIR24-2,miR-24-2,CTD_human,21463514,"It was observed that H2AX gene expression was negatively correlated with miR-24-2 expression and not in accordance with the gene copy number status, both in cell lines and in sporadic breast tumor tissues.",0.200274726784213,"It was observed that H2AX gene expression was negatively correlated with <span class=""gene"" id=""21463514-10-73-81"">miR-24-2</span> expression and not in accordance with the gene copy number status, both in cell lines and in sporadic <span class=""disease"" id=""21463514-10-184-196"">breast tumor</span> tissues.",CTD_human
1,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,NSCLC,407031,MIR30C1,miR-30c-1,CTD_human,20889907,"However, in the validation set, only miR-30c-1 rs928508 was consistently an NSCLC survival predictor and the protective role of rs928508 AG/GG genotypes was more pronounced among early-stage (stage I/II) patients and patients treated with surgery.",0.201098907136852,"However, in the validation set, only <span class=""gene"" id=""20889907-5-37-46"">miR-30c-1</span> rs928508 was consistently an <span class=""disease"" id=""20889907-5-76-81"">NSCLC</span> survival predictor and the protective role of rs928508 AG/GG genotypes was more pronounced among early-stage (stage I/II) patients and patients treated with surgery.",CTD_human
1,0,Biomarker,C0028754,Obesity,disease,obesity,407040,MIR34A,microRNA-34a,CTD_human,23834033,Elevated microRNA-34a in obesity reduces NAD+ levels and SIRT1 activity by directly targeting NAMPT.,0.20054945356842604,"Elevated <span class=""gene"" id=""23834033-0-9-21"">microRNA-34a</span> in <span class=""disease"" id=""23834033-0-25-32"">obesity</span> reduces NAD+ levels and SIRT1 activity by directly targeting NAMPT.",CTD_human
1,0,Biomarker,C0271650,Impaired glucose tolerance,phenotype,glucose intolerance,407040,MIR34A,miR-34a,CTD_human,23834033,"Conversely, antagonism of miR-34a in diet-induced obese mice restored NAMPT/NAD(+) levels and alleviated steatosis, inflammation, and glucose intolerance.",0.2,"Conversely, antagonism of <span class=""gene"" id=""23834033-10-26-33"">miR-34a</span> in diet-induced obese mice restored NAMPT/NAD(+) levels and alleviated steatosis, inflammation, and <span class=""disease"" id=""23834033-10-134-153"">glucose intolerance</span>.",CTD_human
2,0,Biomarker,C0024121,Lung Neoplasms,group,lung tumors,407041,MIR34B,miR-34b,CTD_human,21339737,"A microRNA, miR-34b, that suppresses the expression of ?4 through specific binding to the 3'-untranslated region of ?4 is downregulated in transformed or human lung tumors.",0.200274726784213,"A microRNA, <span class=""gene"" id=""21339737-7-12-19"">miR-34b</span>, that suppresses the expression of &alpha;4 through specific binding to the 3'-untranslated region of &alpha;4 is downregulated in transformed or human <span class=""disease"" id=""21339737-7-160-171"">lung tumors</span>.",CTD_human
1,0,Biomarker,C0025958,Microcephaly,disease,microcephaly,407975,MIR17HG,miR-17?92,CTD_human,21892160,"Here we report the identification of germline hemizygous deletions of MIR17HG, encoding the miR-17?92 polycistronic miRNA cluster, in individuals with microcephaly, short stature and digital abnormalities.",0.200274726784213,"Here we report the identification of germline hemizygous deletions of <span class=""gene"" id=""21892160-4-70-77"">MIR17HG</span>, encoding the <span class=""gene"" id=""21892160-4-92-101"">miR-17&sim;92</span> polycistronic miRNA cluster, in individuals with <span class=""disease"" id=""21892160-4-151-163"">microcephaly</span>, short stature and digital abnormalities.",CTD_human
1,0,Biomarker,C0279626,Squamous cell carcinoma of esophagus,disease,ESCC,4085,MAD2L1,hsMAD2,CTD_human,18691855,"The mitotic checkpoint genes, hsMAD2 and BubR1, were co-ordinately overexpressed in ESCC.",0.200274726784213,"The mitotic checkpoint genes, <span class=""gene"" id=""18691855-13-30-36"">hsMAD2</span> and BubR1, were co-ordinately overexpressed in <span class=""disease"" id=""18691855-13-84-88"">ESCC</span>.",CTD_human
2,0,Biomarker,C0376634,Craniofacial Abnormalities,group,craniofacial abnormalities,4087,SMAD2,Smad2,CTD_human,9655392,"Mice trans-heterozygous for both Smad2 and nodal mutations display a range of phenotypes, including gastrulation defects, complex craniofacial abnormalities such as cyclopia, and defects in left-right patterning, indicating that Smad2 may mediate nodal signalling in these developmental processes.",0.2,"Mice trans-heterozygous for both <span class=""gene"" id=""9655392-7-33-38"">Smad2</span> and nodal mutations display a range of phenotypes, including gastrulation defects, complex <span class=""disease"" id=""9655392-7-130-156"">craniofacial abnormalities</span> such as cyclopia, and defects in left-right patterning, indicating that <span class=""gene"" id=""9655392-7-229-234"">Smad2</span> may mediate nodal signalling in these developmental processes.",CTD_human
1,0,Biomarker,C0003486,Aortic Aneurysm,disease,aortic aneurysms,4088,SMAD3,SMAD3,CTD_human,21217753,Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis.,0.40082418035263895,"Mutations in <span class=""gene"" id=""21217753-0-13-18"">SMAD3</span> cause a syndromic form of <span class=""disease"" id=""21217753-0-45-61"">aortic aneurysms</span> and dissections with early-onset osteoarthritis.",CTD_human;HPO
1,0,Biomarker,C0023267,Fibroid Tumor,disease,leiomyomas,4088,SMAD3,Smad3,CTD_human,22228119,"Taken together, these results suggest that downregulation of activin A and Smad3, both members of the TGF-? pathway, may offer a mechanistic explanation for the inhibitory effect of a high-dose of genistein on UtLM cells, and might be potential therapeutic targets for treatment of clinical cases of uterine leiomyomas.",0.20054945356842604,"Taken together, these results suggest that downregulation of activin A and <span class=""gene"" id=""22228119-6-75-80"">Smad3</span>, both members of the TGF-&beta; pathway, may offer a mechanistic explanation for the inhibitory effect of a high-dose of genistein on UtLM cells, and might be potential therapeutic targets for treatment of clinical cases of uterine <span class=""disease"" id=""22228119-6-308-318"">leiomyomas</span>.",CTD_human
2,0,Biomarker,C0029408,Degenerative polyarthritis,disease,osteoarthritis,4088,SMAD3,SMAD3,CTD_human,21217753,Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis.,0.20795272136486298,"Mutations in <span class=""gene"" id=""21217753-0-13-18"">SMAD3</span> cause a syndromic form of aortic aneurysms and dissections with early-onset <span class=""disease"" id=""21217753-0-95-109"">osteoarthritis</span>.",CTD_human
1,3,Biomarker,C2697932,Loeys-Dietz Syndrome,disease,LDS,4088,SMAD3,SMAD3,CTD_human,22772368,"Loeys-Dietz syndrome (LDS) associates with a tissue signature for high transforming growth factor (TGF)-? signaling but is often caused by heterozygous mutations in genes encoding positive effectors of TGF-? signaling, including either subunit of the TGF-? receptor or SMAD3, thereby engendering controversy regarding the mechanism of disease.",0.201098907136852,"<span class=""disease"" id=""22772368-1-0-20"">Loeys-Dietz syndrome</span> (<span class=""disease"" id=""22772368-1-22-25"">LDS</span>) associates with a tissue signature for high transforming growth factor (TGF)-&beta; signaling but is often caused by heterozygous mutations in genes encoding positive effectors of TGF-&beta; signaling, including either subunit of the TGF-&beta; receptor or <span class=""gene"" id=""22772368-1-269-274"">SMAD3</span>, thereby engendering controversy regarding the mechanism of disease.",CTD_human
2,4,Biomarker,C0796081,Growth mental deficiency syndrome of Myhre,disease,Myhre syndrome,4089,SMAD4,SMAD4,CTD_human,22158539,Mutations at a single codon in Mad homology 2 domain of SMAD4 cause Myhre syndrome.,0.602197814273705,"Mutations at a single codon in Mad homology 2 domain of <span class=""gene"" id=""22158539-0-56-61"">SMAD4</span> cause <span class=""disease"" id=""22158539-0-68-82"">Myhre syndrome</span>.",CTD_human;ORPHANET;UNIPROT
1,0,Therapeutic,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,type 2 diabetes,4090,SMAD5,Smad5,CTD_human,20079400,These finding reveals Smad5 as a potential target for the therapeutic of type 2 diabetes.,0.2,"These finding reveals <span class=""gene"" id=""20079400-9-22-27"">Smad5</span> as a potential target for the therapeutic of <span class=""disease"" id=""20079400-9-73-88"">type 2 diabetes</span>.",CTD_human
1,0,Therapeutic,C0034069,Pulmonary Fibrosis,disease,pulmonary fibrosis,4092,SMAD7,Smad 7,CTD_human,23590892,Docosahexaenoic acid (DHA) ameliorates paraquat-induced pulmonary fibrosis in rats possibly through up-regulation of Smad 7 and SnoN.,0.2,"Docosahexaenoic acid (DHA) ameliorates paraquat-induced <span class=""disease"" id=""23590892-0-56-74"">pulmonary fibrosis</span> in rats possibly through up-regulation of <span class=""gene"" id=""23590892-0-117-123"">Smad 7</span> and SnoN.",CTD_human
11,19,Biomarker,C0026709,Mucopolysaccharidosis VI,disease,Maroteaux-Lamy syndrome,411,ARSB,ARSB,CTD_human,17458871,"Mucopolysaccharidosis type VI (MPS VI; Maroteaux-Lamy syndrome) is a lysosomal storage disorder caused by mutations in the N-acetylgalactosamine-4-sulfatase (arylsulfatase B, ARSB) gene.",0.49865271057185606,"<span class=""disease"" id=""17458871-1-0-37"">Mucopolysaccharidosis type VI (MPS VI</span>; <span class=""disease"" id=""17458871-1-39-62"">Maroteaux-Lamy syndrome</span>) is a lysosomal storage disorder caused by mutations in the <span class=""gene"" id=""17458871-1-123-156"">N-acetylgalactosamine-4-sulfatase</span> (<span class=""gene"" id=""17458871-1-158-173"">arylsulfatase B</span>, <span class=""gene"" id=""17458871-1-175-179"">ARSB</span>) gene.",CTD_human;UNIPROT
1,0,Biomarker,C0007137,Squamous cell carcinoma,disease,squamous cell carcinomas,4118,MAL,T-lymphocyte maturation-associated protein,CTD_human,19445022,T-lymphocyte maturation-associated protein gene as a candidate metastasis suppressor for head and neck squamous cell carcinomas.,0.20328236603324,"<span class=""gene"" id=""19445022-0-0-42"">T-lymphocyte maturation-associated protein</span> gene as a candidate metastasis suppressor for head and neck <span class=""disease"" id=""19445022-0-103-127"">squamous cell carcinomas</span>.",CTD_human
1,0,Therapeutic,C0015695,Fatty Liver,disease,hepatic steatosis,412,STS,STS,CTD_human,24497646,"In defining the functional relevance of STS induction in metabolic disease, we showed that overexpression of STS in the liver of transgenic mice alleviated HFD and ob/ob models of obesity and type 2 diabetes, including reduced body weight, improved insulin sensitivity, and decreased hepatic steatosis and inflammation.",0.2,"In defining the functional relevance of <span class=""gene"" id=""24497646-3-40-43"">STS</span> induction in metabolic disease, we showed that overexpression of <span class=""gene"" id=""24497646-3-109-112"">STS</span> in the liver of transgenic mice alleviated HFD and ob/ob models of obesity and type 2 diabetes, including reduced body weight, improved insulin sensitivity, and decreased <span class=""disease"" id=""24497646-3-284-301"">hepatic steatosis</span> and inflammation.",CTD_human
1,0,Therapeutic,C0028754,Obesity,disease,obesity,412,STS,steroid sulfatase,CTD_human,24497646,Hepatic overexpression of steroid sulfatase ameliorates mouse models of obesity and type 2 diabetes through sex-specific mechanisms.,0.20082418035263896,"Hepatic overexpression of <span class=""gene"" id=""24497646-0-26-43"">steroid sulfatase</span> ameliorates mouse models of <span class=""disease"" id=""24497646-0-72-79"">obesity</span> and type 2 diabetes through sex-specific mechanisms.",CTD_human
5,5,Biomarker,C0079588,"Ichthyosis, X-Linked",disease,X-linked ichthyosis,412,STS,steroid sulfatase,CTD_human,10679952,PCR diagnosis of X-linked ichthyosis: identification of a novel mutation (E560P) of the steroid sulfatase gene.,0.622462083770844,"PCR diagnosis of <span class=""disease"" id=""10679952-0-17-36"">X-linked ichthyosis</span>: identification of a novel mutation (E560P) of the <span class=""gene"" id=""10679952-0-88-105"">steroid sulfatase</span> gene.",CTD_human;ORPHANET;UNIPROT
5,5,Biomarker,C0079588,"Ichthyosis, X-Linked",disease,XLI,412,STS,STS,CTD_human,14641695,"It is known that an undetectable maternal serum, unconjugated estriol, associated with placental steroid sulfatase (STS) deficiency, may be the cause of cause of XLI.",0.622462083770844,"It is known that an undetectable maternal serum, unconjugated estriol, associated with placental <span class=""gene"" id=""14641695-3-97-114"">steroid sulfatase</span> (<span class=""gene"" id=""14641695-3-116-119"">STS</span>) deficiency, may be the cause of cause of <span class=""disease"" id=""14641695-3-162-165"">XLI</span>.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C1263846,Attention deficit hyperactivity disorder,disease,ADHD,412,STS,STS,CTD_human,18413370,ADHD diagnoses were present in those with both deletions and presumed point mutations of STS.,0.40350593566014,"<span class=""disease"" id=""18413370-10-0-4"">ADHD</span> diagnoses were present in those with both deletions and presumed point mutations of <span class=""gene"" id=""18413370-10-89-92"">STS</span>.",CTD_human;HPO
3,0,Biomarker,C0004352,Autistic Disorder,disease,autism,4128,MAOA,monoamine oxidase A,CTD_human,18361446,Cortical enlargement in autism is associated with a functional VNTR in the monoamine oxidase A gene.,0.414782410458571,"Cortical enlargement in <span class=""disease"" id=""18361446-0-24-30"">autism</span> is associated with a functional VNTR in the <span class=""gene"" id=""18361446-0-75-94"">monoamine oxidase A</span> gene.",CTD_human;HPO
3,0,Biomarker,C0004352,Autistic Disorder,disease,autism,4128,MAOA,monoamine oxidase A,CTD_human,12919132,Association of autism severity with a monoamine oxidase A functional polymorphism.,0.414782410458571,"Association of <span class=""disease"" id=""12919132-0-15-21"">autism</span> severity with a <span class=""gene"" id=""12919132-0-38-57"">monoamine oxidase A</span> functional polymorphism.",CTD_human;HPO
3,0,Biomarker,C0004352,Autistic Disorder,disease,Autism,4128,MAOA,MAOA,CTD_human,20573161,Autism severity is associated with child and maternal MAOA genotypes.,0.414782410458571,"<span class=""disease"" id=""20573161-0-0-6"">Autism</span> severity is associated with child and maternal <span class=""gene"" id=""20573161-0-54-58"">MAOA</span> genotypes.",CTD_human;HPO
3,0,Biomarker,C0019151,Hepatic Encephalopathy,disease,hepatic encephalopathy,4128,MAOA,monoamine oxidase A,CTD_human,9048767,Increased density of catalytic sites and expression of brain monoamine oxidase A in humans with hepatic encephalopathy.,0.200274726784213,"Increased density of catalytic sites and expression of brain <span class=""gene"" id=""9048767-0-61-80"">monoamine oxidase A</span> in humans with <span class=""disease"" id=""9048767-0-96-118"">hepatic encephalopathy</span>.",CTD_human
1,0,Biomarker,C0020179,Huntington Disease,disease,Huntington's disease,4128,MAOA,MAO-A,CTD_human,21075085,Up-regulation of the isoenzymes MAO-A and MAO-B in the human basal ganglia and pons in Huntington's disease revealed by quantitative enzyme radioautography.,0.20054945356842604,"Up-regulation of the isoenzymes <span class=""gene"" id=""21075085-0-32-37"">MAO-A</span> and MAO-B in the human basal ganglia and pons in <span class=""disease"" id=""21075085-0-87-107"">Huntington's disease</span> revealed by quantitative enzyme radioautography.",CTD_human
1,0,Biomarker,C0026848,Myopathy,group,myopathy,4128,MAOA,MAO-A,CTD_human,15946989,"We suggest that MAO-A-mediated oxidative stress can lead to cell damage, representing a novel pathogenetic mechanism for glucocorticoid-induced myopathy and a potential target for therapeutic intervention.",0.200274726784213,"We suggest that <span class=""gene"" id=""15946989-9-16-21"">MAO-A</span>-mediated oxidative stress can lead to cell damage, representing a novel pathogenetic mechanism for glucocorticoid-induced <span class=""disease"" id=""15946989-9-144-152"">myopathy</span> and a potential target for therapeutic intervention.",CTD_human
1,0,Biomarker,C0031511,Pheochromocytoma,disease,pheochromocytoma,4128,MAOA,Monoamine oxidase A,CTD_human,22569243,Monoamine oxidase A down-regulation contributes to high metanephrine concentration in pheochromocytoma.,0.200274726784213,"<span class=""gene"" id=""22569243-0-0-19"">Monoamine oxidase A</span> down-regulation contributes to high metanephrine concentration in <span class=""disease"" id=""22569243-0-86-102"">pheochromocytoma</span>.",CTD_human
2,0,Biomarker,C0002395,Alzheimer's Disease,disease,Alzheimer's diseases,4129,MAOB,monoamine oxidase B,CTD_human,7816197,"Lazabemide, a selective reversible monoamine oxidase B inhibitor, is currently under clinical evaluation for the treatment of Parkinson's and Alzheimer's diseases.",0.206513574909167,"Lazabemide, a selective reversible <span class=""gene"" id=""7816197-10-35-54"">monoamine oxidase B</span> inhibitor, is currently under clinical evaluation for the treatment of Parkinson's and <span class=""disease"" id=""7816197-10-142-162"">Alzheimer's diseases</span>.",CTD_human
2,0,Biomarker,C0002395,Alzheimer's Disease,disease,Alzheimer's disease,4129,MAOB,MAO-B,CTD_human,21075085,"Abnormally high levels of monoamine oxidase (MAO) activity, which are potentially linked to cytotoxic free radical formation, are known to occur during aging and in neurodegenerative disorders (MAO-B is markedly increased in plaque-associated astrocytes in Alzheimer's disease).",0.206513574909167,"Abnormally high levels of monoamine oxidase (MAO) activity, which are potentially linked to cytotoxic free radical formation, are known to occur during aging and in neurodegenerative disorders (<span class=""gene"" id=""21075085-2-194-199"">MAO-B</span> is markedly increased in plaque-associated astrocytes in <span class=""disease"" id=""21075085-2-257-276"">Alzheimer's disease</span>).",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autistic,4129,MAOB,MAOB,CTD_human,19221690,"We have measured the activity of two platelet 5HT-associated proteins: 5HT transporter (5HTT) and monoamine oxidase B (MAOB), and indirectly studied the activity of 5HT(2A) receptor (5HT(2A)r) in 15 hyperserotonemic (HS) and 17 normoserotonemic (NS) autistic subjects, and 15 healthy controls (C).",0.202681755307501,"We have measured the activity of two platelet 5HT-associated proteins: 5HT transporter (5HTT) and <span class=""gene"" id=""19221690-3-98-117"">monoamine oxidase B</span> (<span class=""gene"" id=""19221690-3-119-123"">MAOB</span>), and indirectly studied the activity of 5HT(2A) receptor (5HT(2A)r) in 15 hyperserotonemic (HS) and 17 normoserotonemic (NS) <span class=""disease"" id=""19221690-3-250-258"">autistic</span> subjects, and 15 healthy controls (C).",CTD_human
1,0,Biomarker,C0019151,Hepatic Encephalopathy,disease,portal-systemic encephalopathy,4129,MAOB,monoamine oxidase B,CTD_human,10564534,"In portal-systemic encephalopathy resulting from chronic liver failure, astrocytes manifest altered expression of several key proteins and enzymes including monoamine oxidase B, glutamine synthetase, and the so-called peripheral-type benzodiazepine receptors.",0.200274726784213,"In <span class=""disease"" id=""10564534-5-3-33"">portal-systemic encephalopathy</span> resulting from chronic liver failure, astrocytes manifest altered expression of several key proteins and enzymes including <span class=""gene"" id=""10564534-5-157-176"">monoamine oxidase B</span>, glutamine synthetase, and the so-called peripheral-type benzodiazepine receptors.",CTD_human
1,0,Biomarker,C0020179,Huntington Disease,disease,Huntington's disease,4129,MAOB,MAO-B,CTD_human,21075085,Up-regulation of the isoenzymes MAO-A and MAO-B in the human basal ganglia and pons in Huntington's disease revealed by quantitative enzyme radioautography.,0.2,"Up-regulation of the isoenzymes MAO-A and <span class=""gene"" id=""21075085-0-42-47"">MAO-B</span> in the human basal ganglia and pons in <span class=""disease"" id=""21075085-0-87-107"">Huntington's disease</span> revealed by quantitative enzyme radioautography.",CTD_human
1,0,Biomarker,C0030567,Parkinson Disease,disease,Parkinson's Disease,4129,MAOB,monoamine oxidase B,CTD_human,21318773,"Table 1 Biochemical Alterations in Substantia Nigra of Parkinson's Disease Indicating Oxidative Stress Elevated Decreased Iron (in microglia, astrocytes, oligodendrocytes, and melanized dopamine neurons and mitochondria) GSH (GSSG unchanged); GSH/GSSG ratio decreased Mitochondrial complex I Ferritin Calcium binding protein (calbindin 28) Mitochondrial monoamine oxidase B Transferrin and transferrin receptor Lipofuscin Vitamins E and C Ubiquitin Copper Cu/Zn-superoxide dismutase Cytotoxic cytokines (TNF-a, IL-1, IL-6) Inflammatory transcription factor NFKB Heme oxygenase-1 Ratio of oxidized to reduced glutathione (GSSG/GSH) Nitric oxide Neuromelanin.",0.27805540045872995,"Table 1 Biochemical Alterations in Substantia Nigra of <span class=""disease"" id=""21318773-12-55-74"">Parkinson's Disease</span> Indicating Oxidative Stress Elevated Decreased Iron (in microglia, astrocytes, oligodendrocytes, and melanized dopamine neurons and mitochondria) GSH (GSSG unchanged); GSH/GSSG ratio decreased Mitochondrial complex I Ferritin Calcium binding protein (calbindin 28) Mitochondrial <span class=""gene"" id=""21318773-12-354-373"">monoamine oxidase B</span> Transferrin and transferrin receptor Lipofuscin Vitamins E and C Ubiquitin Copper Cu/Zn-superoxide dismutase Cytotoxic cytokines (TNF-a, IL-1, IL-6) Inflammatory transcription factor NFKB Heme oxygenase-1 Ratio of oxidized to reduced glutathione (GSSG/GSH) Nitric oxide Neuromelanin.",CTD_human
1,0,Biomarker,C0036341,Schizophrenia,disease,SCZ,4129,MAOB,monoamine oxidase B,CTD_human,20479760,"Hum Mol Genet 2008) and the monoamine degradation enzyme monoamine oxidase B were found in ASD and SCZ, respectively.",0.21134198733306098,"Hum Mol Genet 2008) and the monoamine degradation enzyme <span class=""gene"" id=""20479760-7-57-76"">monoamine oxidase B</span> were found in ASD and <span class=""disease"" id=""20479760-7-99-102"">SCZ</span>, respectively.",CTD_human
7,0,Biomarker,C0002395,Alzheimer's Disease,disease,AD,4137,MAPT,tau,CTD_human,20157255,Accumulation of amyloid-beta (Abeta) peptide and deposition of hyperphosphorylated tau protein are two major pathological hallmarks of Alzheimer's disease (AD).,0.412954627512336,"Accumulation of amyloid-beta (Abeta) peptide and deposition of hyperphosphorylated <span class=""gene"" id=""20157255-1-83-86"">tau</span> protein are two major pathological hallmarks of <span class=""disease"" id=""20157255-1-135-154"">Alzheimer's disease</span> (<span class=""disease"" id=""20157255-1-156-158"">AD</span>).",CTD_human
7,0,Biomarker,C0002395,Alzheimer's Disease,disease,Alzheimer's disease,4137,MAPT,tau,CTD_human,12852432,Amyloid beta peptides and phosphorylated tau protein have been implicated in the selective regional neuronal loss and protein accumulations characteristic of Alzheimer's disease.,0.412954627512336,"Amyloid beta peptides and phosphorylated <span class=""gene"" id=""12852432-2-41-44"">tau</span> protein have been implicated in the selective regional neuronal loss and protein accumulations characteristic of <span class=""disease"" id=""12852432-2-158-177"">Alzheimer's disease</span>.",CTD_human
4,6,Biomarker,C0038868,Progressive supranuclear palsy,disease,PSP,4137,MAPT,MAPT,CTD_human,21685912,"We confirmed two independent variants in MAPT affecting risk for PSP, one of which influences MAPT brain expression.",0.6796594668749711,"We confirmed two independent variants in <span class=""gene"" id=""21685912-6-41-45"">MAPT</span> affecting risk for <span class=""disease"" id=""21685912-6-65-68"">PSP</span>, one of which influences <span class=""gene"" id=""21685912-6-94-98"">MAPT</span> brain expression.",CTD_human;ORPHANET;UNIPROT
4,6,Biomarker,C0038868,Progressive supranuclear palsy,disease,progressive supranuclear palsy,4137,MAPT,MAPT,CTD_human,12325083,"MAPT, the gene encoding tau, was screened for mutations in 96 progressive supranuclear palsy subjects.",0.6796594668749711,"<span class=""gene"" id=""12325083-1-0-4"">MAPT</span>, the gene encoding tau, was screened for mutations in 96 <span class=""disease"" id=""12325083-1-62-92"">progressive supranuclear palsy</span> subjects.",CTD_human;ORPHANET;UNIPROT
4,6,Biomarker,C0038868,Progressive supranuclear palsy,disease,PSP,4137,MAPT,MAPT,CTD_human,19458322,"Occasionally, mutations in MAPT are found in patients with a clinical phenotype similar to PSP.",0.6796594668749711,"Occasionally, mutations in <span class=""gene"" id=""19458322-3-27-31"">MAPT</span> are found in patients with a clinical phenotype similar to <span class=""disease"" id=""19458322-3-91-94"">PSP</span>.",CTD_human;ORPHANET;UNIPROT
6,4,Biomarker,C0236642,Pick Disease of the Brain,disease,Pick's disease,4137,MAPT,tau,CTD_human,11117542,Pick's disease is associated with mutations in the tau gene.,0.46124971750220395,"<span class=""disease"" id=""11117542-0-0-14"">Pick's disease</span> is associated with mutations in the <span class=""gene"" id=""11117542-0-51-54"">tau</span> gene.",CTD_human;UNIPROT
6,4,Biomarker,C0236642,Pick Disease of the Brain,disease,Pick's disease,4137,MAPT,FTDP-17,CTD_human,9641683,"Thirteen families have been described with an autosomal dominantly inherited dementia named frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), historically termed Pick's disease.",0.46124971750220395,"Thirteen families have been described with an autosomal dominantly inherited dementia named <span class=""disease"" id=""9641683-1-92-115"">frontotemporal dementia</span> and parkinsonism linked to chromosome 17 (<span class=""gene"" id=""9641683-1-158-165"">FTDP-17</span>), historically termed <span class=""disease"" id=""9641683-1-188-202"">Pick's disease</span>.",CTD_human;UNIPROT
6,4,Biomarker,C0236642,Pick Disease of the Brain,disease,Pick's disease,4137,MAPT,Tau,CTD_human,11601501,Pick's disease associated with the novel Tau gene mutation K369I.,0.46124971750220395,"<span class=""disease"" id=""11601501-0-0-14"">Pick's disease</span> associated with the novel <span class=""gene"" id=""11601501-0-41-44"">Tau</span> gene mutation K369I.",CTD_human;UNIPROT
2,0,Biomarker,C0242422,Parkinsonian Disorders,group,parkinsonism,4137,MAPT,tau,CTD_human,10802785,Two brothers with frontotemporal dementia and parkinsonism with an N279K mutation of the tau gene.,0.44760774952259397,"Two brothers with frontotemporal dementia and <span class=""disease"" id=""10802785-0-46-58"">parkinsonism</span> with an N279K mutation of the <span class=""gene"" id=""10802785-0-89-92"">tau</span> gene.",CTD_human;HPO
24,14,Biomarker,C0338451,Frontotemporal dementia,disease,frontotemporal dementia,4137,MAPT,tau,CTD_human,11117542,"Recently, mutations within the tau gene have been associated with some familial forms of frontotemporal dementia.",0.7016632567095921,"Recently, mutations within the <span class=""gene"" id=""11117542-1-31-34"">tau</span> gene have been associated with some familial forms of <span class=""disease"" id=""11117542-1-89-112"">frontotemporal dementia</span>.",CTD_human;HPO;UNIPROT
24,14,Biomarker,C0338451,Frontotemporal dementia,disease,frontotemporal dementia,4137,MAPT,tau,CTD_human,10802785,Two brothers with frontotemporal dementia and parkinsonism with an N279K mutation of the tau gene.,0.7016632567095921,"Two brothers with <span class=""disease"" id=""10802785-0-18-41"">frontotemporal dementia</span> and parkinsonism with an N279K mutation of the <span class=""gene"" id=""10802785-0-89-92"">tau</span> gene.",CTD_human;HPO;UNIPROT
24,14,Biomarker,C0338451,Frontotemporal dementia,disease,FTD,4137,MAPT,MAPT,CTD_human,16495328,Mutations in microtubule associated protein tau (MAPT) are detected in approximately 30% of familial FTD kindreds.,0.7016632567095921,"Mutations in <span class=""gene"" id=""16495328-6-13-47"">microtubule associated protein tau</span> (<span class=""gene"" id=""16495328-6-49-53"">MAPT</span>) are detected in approximately 30% of familial <span class=""disease"" id=""16495328-6-101-104"">FTD</span> kindreds.",CTD_human;HPO;UNIPROT
24,14,Biomarker,C0338451,Frontotemporal dementia,disease,FTDP-17,4137,MAPT,tau,CTD_human,9789048,"For these reasons, we investigated the possibility that PPND and other FTDP-17 syndromes might be caused by mutations in the tau gene.",0.7016632567095921,"For these reasons, we investigated the possibility that PPND and other <span class=""disease"" id=""9789048-5-71-78"">FTDP-17</span> syndromes might be caused by mutations in the <span class=""gene"" id=""9789048-5-125-128"">tau</span> gene.",CTD_human;HPO;UNIPROT
24,14,Biomarker,C0338451,Frontotemporal dementia,disease,frontotemporal dementia,4137,MAPT,tau,CTD_human,11912108,Inherited frontotemporal dementia in nine British families associated with intronic mutations in the tau gene.,0.7016632567095921,"Inherited <span class=""disease"" id=""11912108-0-10-33"">frontotemporal dementia</span> in nine British families associated with intronic mutations in the <span class=""gene"" id=""11912108-0-101-104"">tau</span> gene.",CTD_human;HPO;UNIPROT
24,14,Biomarker,C0338451,Frontotemporal dementia,disease,frontotemporal dementia,4137,MAPT,FTDP-17,CTD_human,9641683,"Thirteen families have been described with an autosomal dominantly inherited dementia named frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), historically termed Pick's disease.",0.7016632567095921,"Thirteen families have been described with an autosomal dominantly inherited dementia named <span class=""disease"" id=""9641683-1-92-115"">frontotemporal dementia</span> and parkinsonism linked to chromosome 17 (<span class=""gene"" id=""9641683-1-158-165"">FTDP-17</span>), historically termed Pick's disease.",CTD_human;HPO;UNIPROT
2,0,Biomarker,C0524851,Neurodegenerative Disorders,group,neurodegenerative disorders,4137,MAPT,tau,CTD_human,9789048,Pathogenic implications of mutations in the tau gene in pallido-ponto-nigral degeneration and related neurodegenerative disorders linked to chromosome 17.,0.27934503142205397,"Pathogenic implications of mutations in the <span class=""gene"" id=""9789048-0-44-47"">tau</span> gene in pallido-ponto-nigral degeneration and related <span class=""disease"" id=""9789048-0-102-129"">neurodegenerative disorders</span> linked to chromosome 17.",CTD_human
4,0,Biomarker,C0949664,Tauopathies,group,tauopathy,4137,MAPT,Tau,CTD_human,10604746,Tau gene mutation G389R causes a tauopathy with abundant pick body-like inclusions and axonal deposits.,0.292242834902753,"<span class=""gene"" id=""10604746-0-0-3"">Tau</span> gene mutation G389R causes a <span class=""disease"" id=""10604746-0-33-42"">tauopathy</span> with abundant pick body-like inclusions and axonal deposits.",CTD_human
4,0,Biomarker,C0949664,Tauopathies,group,tauopathies,4137,MAPT,tau,CTD_human,24556215,These actions are of particular interest for the treatment of neurodegenerative diseases with tau protein aggregates known as tauopathies.,0.292242834902753,"These actions are of particular interest for the treatment of neurodegenerative diseases with <span class=""gene"" id=""24556215-3-94-97"">tau</span> protein aggregates known as <span class=""disease"" id=""24556215-3-126-137"">tauopathies</span>.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,4139,MARK1,MARK1,CTD_human,18492799,Convergent evidence identifying MAP/microtubule affinity-regulating kinase 1 (MARK1) as a susceptibility gene for autism.,0.20568939455652804,"Convergent evidence identifying <span class=""gene"" id=""18492799-0-32-76"">MAP/microtubule affinity-regulating kinase 1</span> (<span class=""gene"" id=""18492799-0-78-83"">MARK1</span>) as a susceptibility gene for <span class=""disease"" id=""18492799-0-114-120"">autism</span>.",CTD_human
1,0,Biomarker,C0031511,Pheochromocytoma,disease,pheochromocytoma,4149,MAX,MAX,CTD_human,21685915,Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma.,0.203021994626344,"Exome sequencing identifies <span class=""gene"" id=""21685915-0-28-31"">MAX</span> mutations as a cause of hereditary <span class=""disease"" id=""21685915-0-67-83"">pheochromocytoma</span>.",CTD_human
4,11,Biomarker,C1844853,Brachytelephalangic Chondrodysplasia Punctata,disease,brachytelephalangic chondrodysplasia punctata,415,ARSE,arylsulfatase E,CTD_human,18348268,Clinical and molecular analysis of arylsulfatase E in patients with brachytelephalangic chondrodysplasia punctata.,0.6010989071368521,"Clinical and molecular analysis of <span class=""gene"" id=""18348268-0-35-50"">arylsulfatase E</span> in patients with <span class=""disease"" id=""18348268-0-68-113"">brachytelephalangic chondrodysplasia punctata</span>.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0019693,HIV Infections,group,HIV infection,4153,MBL2,mannose-binding lectin,CTD_human,16960176,Synergy between mannose-binding lectin gene polymorphisms and supplementation with vitamin A influences susceptibility to HIV infection in infants born to HIV-positive mothers.,0.24596688132635697,"Synergy between <span class=""gene"" id=""16960176-0-16-38"">mannose-binding lectin</span> gene polymorphisms and supplementation with vitamin A influences susceptibility to <span class=""disease"" id=""16960176-0-122-135"">HIV infection</span> in infants born to HIV-positive mothers.",CTD_human
1,0,Biomarker,C0020429,Hyperalgesia,phenotype,hyperalgesia,4157,MC1R,melanocortin-1 receptor,CTD_human,19996949,Sex-specific mediation of opioid-induced hyperalgesia by the melanocortin-1 receptor.,0.200274726784213,"Sex-specific mediation of opioid-induced <span class=""disease"" id=""19996949-0-41-53"">hyperalgesia</span> by the <span class=""gene"" id=""19996949-0-61-84"">melanocortin-1 receptor</span>.",CTD_human
3,0,Biomarker,C0025202,melanoma,disease,MM,4157,MC1R,MC1R,CTD_human,21559390,"Furthermore, individuals carrying two or more mutations in MC1R, a well-known low penetrance melanoma-predisposing gene, had a decreased MM risk if concurrently bearing the SLC45A2 protective variant.",0.568492709886438,"Furthermore, individuals carrying two or more mutations in <span class=""gene"" id=""21559390-12-59-63"">MC1R</span>, a well-known low penetrance <span class=""disease"" id=""21559390-12-93-101"">melanoma</span>-predisposing gene, had a decreased <span class=""disease"" id=""21559390-12-137-139"">MM</span> risk if concurrently bearing the SLC45A2 protective variant.",CTD_human;HPO
3,0,Biomarker,C0025202,melanoma,disease,melanoma,4157,MC1R,MC1R,CTD_human,21983785,"In this discovery phase, we confirm several previously characterized melanoma-associated loci at MC1R, ASIP and MTAP-CDKN2A.",0.568492709886438,"In this discovery phase, we confirm several previously characterized <span class=""disease"" id=""21983785-2-69-77"">melanoma</span>-associated loci at <span class=""gene"" id=""21983785-2-97-101"">MC1R</span>, ASIP and MTAP-CDKN2A.",CTD_human;HPO
3,0,Biomarker,C0025202,melanoma,disease,melanoma,4157,MC1R,MC1R,CTD_human,19578364,"MC1R and TYR are associated with pigmentation, freckling and cutaneous sun sensitivity, well-recognized melanoma risk factors.",0.568492709886438,"<span class=""gene"" id=""19578364-4-0-4"">MC1R</span> and TYR are associated with pigmentation, freckling and cutaneous sun sensitivity, well-recognized <span class=""disease"" id=""19578364-4-104-112"">melanoma</span> risk factors.",CTD_human;HPO
13,28,Biomarker,C0028754,Obesity,disease,obesity,4160,MC4R,MC4R,CTD_human,23251400,"Thus, studies that combine clinical screening of obese patients and investigation of the functional defects of the obesity-linked MC4R variants can identify specific ways to correct these defects and are the first steps towards personalized medicine.",0.9130773246006851,"Thus, studies that combine clinical screening of <span class=""disease"" id=""23251400-10-49-54"">obese</span> patients and investigation of the functional defects of the <span class=""disease"" id=""23251400-10-115-122"">obesity</span>-linked <span class=""gene"" id=""23251400-10-130-134"">MC4R</span> variants can identify specific ways to correct these defects and are the first steps towards personalized medicine.",CTD_human;HPO;ORPHANET;UNIPROT
13,28,Biomarker,C0028754,Obesity,disease,obesity,4160,MC4R,melanocortin-4 receptor,CTD_human,17143585,Point mutations in the melanocortin-4 receptor cause variable obesity in mice.,0.9130773246006851,"Point mutations in the <span class=""gene"" id=""17143585-0-23-46"">melanocortin-4 receptor</span> cause variable <span class=""disease"" id=""17143585-0-62-69"">obesity</span> in mice.",CTD_human;HPO;ORPHANET;UNIPROT
13,28,Biomarker,C0028754,Obesity,disease,obesity,4160,MC4R,MC4R,CTD_human,18454148,"Common variants near MC4R are associated with fat mass, weight and risk of obesity.",0.9130773246006851,"Common variants near <span class=""gene"" id=""18454148-0-21-25"">MC4R</span> are associated with fat mass, weight and risk of <span class=""disease"" id=""18454148-0-75-82"">obesity</span>.",CTD_human;HPO;ORPHANET;UNIPROT
13,28,Biomarker,C0028754,Obesity,disease,obesity,4160,MC4R,MC4R,CTD_human,19151714,"In addition to FTO and MC4R, we detected significant association of obesity with three new risk loci in NPC1 (endosomal/lysosomal Niemann-Pick C1 gene, P = 2.9 x 10(-7)), near MAF (encoding the transcription factor c-MAF, P = 3.8 x 10(-13)) and near PTER (phosphotriesterase-related gene, P = 2.1 x 10(-7)).",0.9130773246006851,"In addition to FTO and <span class=""gene"" id=""19151714-3-23-27"">MC4R</span>, we detected significant association of <span class=""disease"" id=""19151714-3-68-75"">obesity</span> with three new risk loci in NPC1 (endosomal/lysosomal Niemann-Pick C1 gene, P = 2.9 x 10(-7)), near MAF (encoding the transcription factor c-MAF, P = 3.8 x 10(-13)) and near PTER (phosphotriesterase-related gene, P = 2.1 x 10(-7)).",CTD_human;HPO;ORPHANET;UNIPROT
13,28,Biomarker,C0028754,Obesity,disease,obesity,4160,MC4R,MC4R,CTD_human,19079260,"This includes previously identified variants close to or in the FTO, MC4R, BDNF and SH2B1 genes, in addition to variants at seven loci not previously connected with obesity.",0.9130773246006851,"This includes previously identified variants close to or in the FTO, <span class=""gene"" id=""19079260-5-69-73"">MC4R</span>, BDNF and SH2B1 genes, in addition to variants at seven loci not previously connected with <span class=""disease"" id=""19079260-5-165-172"">obesity</span>.",CTD_human;HPO;ORPHANET;UNIPROT
1,0,Therapeutic,C0026769,Multiple Sclerosis,disease,MS,4162,MCAM,CD146,CTD_human,23595028,"Moreover, treating both active and passive MS models with the anti-CD146 antibody AA98 significantly decreased the infiltrated lymphocytes in the CNS and decreased neuroinflammation.",0.2,"Moreover, treating both active and passive <span class=""disease"" id=""23595028-3-43-45"">MS</span> models with the anti-<span class=""gene"" id=""23595028-3-67-72"">CD146</span> antibody AA98 significantly decreased the infiltrated lymphocytes in the CNS and decreased neuroinflammation.",CTD_human
2,0,Biomarker,C0345967,Malignant mesothelioma,disease,malignant mesothelioma,4162,MCAM,CD146,CTD_human,22784439,"Immunohistochemical analysis for epithelial membrane antigen, calretinin, vimentin, ?-catenin, melan-A, glucose transporter-1, cytokeratin CAM5.2, Wilms tumor antigen-1, D2-40, CD146, progesterone receptor, estrogen receptor, and cytokeratin 5/6 was indicative of malignant mesothelioma.",0.28,"Immunohistochemical analysis for epithelial membrane antigen, calretinin, vimentin, &beta;-catenin, melan-A, glucose transporter-1, cytokeratin CAM5.2, Wilms tumor antigen-1, D2-40, <span class=""gene"" id=""22784439-5-177-182"">CD146</span>, progesterone receptor, estrogen receptor, and cytokeratin 5/6 was indicative of <span class=""disease"" id=""22784439-5-264-286"">malignant mesothelioma</span>.",CTD_human
2,0,Biomarker,C0345967,Malignant mesothelioma,disease,MM,4162,MCAM,CD146,CTD_human,23621518,These results suggest that CD146 and IMP3 are useful diagnostic and prognostic markers of MM.,0.28,"These results suggest that <span class=""gene"" id=""23621518-10-27-32"">CD146</span> and IMP3 are useful diagnostic and prognostic markers of <span class=""disease"" id=""23621518-10-90-92"">MM</span>.",CTD_human
1,0,Biomarker,C0026764,Multiple Myeloma,disease,multiple myeloma,4170,MCL1,Mcl-1,CTD_human,12429644,The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1.,0.221660349820883,"The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in <span class=""disease"" id=""12429644-0-72-88"">multiple myeloma</span> cells through transcriptional repression and down-regulation of <span class=""gene"" id=""12429644-0-153-158"">Mcl-1</span>.",CTD_human
1,0,Biomarker,C0079773,"Lymphoma, T-Cell, Cutaneous",disease,CTCL,4170,MCL1,Mcl-1,CTD_human,12754746,Overexpression of Mcl-1 and synthesis of non-functional Bax may be responsible for the resistance of CTCL cells to the anti-cancer drugs chlorambucil and sulindac.,0.20054945356842604,"Overexpression of <span class=""gene"" id=""12754746-8-18-23"">Mcl-1</span> and synthesis of non-functional Bax may be responsible for the resistance of <span class=""disease"" id=""12754746-8-101-105"">CTCL</span> cells to the anti-cancer drugs chlorambucil and sulindac.",CTD_human
1,0,Biomarker,C1261473,Sarcoma,disease,sarcoma,4170,MCL1,mcl-1,CTD_human,15217956,Mcl-1 is a novel therapeutic target for human sarcoma: synergistic inhibition of human sarcoma xenotransplants by a combination of mcl-1 antisense oligonucleotides with low-dose cyclophosphamide.,0.200274726784213,"<span class=""gene"" id=""15217956-0-0-5"">Mcl-1</span> is a novel therapeutic target for human <span class=""disease"" id=""15217956-0-46-53"">sarcoma</span>: synergistic inhibition of human <span class=""disease"" id=""15217956-0-87-94"">sarcoma</span> xenotransplants by a combination of <span class=""gene"" id=""15217956-0-131-136"">mcl-1</span> antisense oligonucleotides with low-dose cyclophosphamide.",CTD_human
1,0,Biomarker,C0025007,Measles,disease,measles,4179,CD46,CD46 molecule,CTD_human,8402913,The human CD46 molecule is a receptor for measles virus (Edmonston strain).,0.21208797850537603,"The human <span class=""gene"" id=""8402913-0-10-23"">CD46 molecule</span> is a receptor for <span class=""disease"" id=""8402913-0-42-49"">measles</span> virus (Edmonston strain).",CTD_human
1,0,Biomarker,C0003469,Anxiety Disorders,group,anxiety,4192,MDK,midkine,CTD_human,19217924,We previously demonstrated that midkine-deficient (Mdk(-/-)) mice exhibited a delayed hippocampal development with impaired working memory and increased anxiety only at the age of 4 weeks.,0.2,"We previously demonstrated that <span class=""gene"" id=""19217924-2-32-39"">midkine</span>-deficient (Mdk(-/-)) mice exhibited a delayed hippocampal development with impaired working memory and increased <span class=""disease"" id=""19217924-2-153-160"">anxiety</span> only at the age of 4 weeks.",CTD_human
1,0,Biomarker,C0011881,Diabetic Nephropathy,disease,diabetic nephropathy,4192,MDK,Midkine,CTD_human,17607302,Midkine is involved in tubulointerstitial inflammation associated with diabetic nephropathy.,0.202732912464814,"<span class=""gene"" id=""17607302-0-0-7"">Midkine</span> is involved in tubulointerstitial inflammation associated with <span class=""disease"" id=""17607302-0-71-91"">diabetic nephropathy</span>.",CTD_human
1,0,Biomarker,C0017638,Glioma,disease,glioma,4192,MDK,midkine,CTD_human,21233844,Stimulation of the midkine/ALK axis renders glioma cells resistant to cannabinoid antitumoral action.,0.20383181960166602,"Stimulation of the <span class=""gene"" id=""21233844-0-19-26"">midkine</span>/ALK axis renders <span class=""disease"" id=""21233844-0-44-50"">glioma</span> cells resistant to cannabinoid antitumoral action.",CTD_human
2,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,non-small cell lung cancer,4193,MDM2,MDM2,CTD_human,21268124,MDM2 SNP309 contributes to non-small cell lung cancer survival in Chinese.,0.20851653031060602,"<span class=""gene"" id=""21268124-0-0-4"">MDM2</span> SNP309 contributes to <span class=""disease"" id=""21268124-0-27-53"">non-small cell lung cancer</span> survival in Chinese.",CTD_human
1,0,Biomarker,C0021364,Male infertility,phenotype,male infertility,4193,MDM2,MDM2,CTD_human,22773013,Genetic variants in TP53 and MDM2 associated with male infertility in Chinese population.,0.200274726784213,"Genetic variants in TP53 and <span class=""gene"" id=""22773013-0-29-33"">MDM2</span> associated with <span class=""disease"" id=""22773013-0-50-66"">male infertility</span> in Chinese population.",CTD_human
1,0,Biomarker,C0025202,melanoma,disease,melanoma,4193,MDM2,Mdm2,CTD_human,17210701,Treatment of melanoma cells with DW1/2 was instead found to decrease levels of Mdm2 and Mdm4.,0.212990348038339,"Treatment of <span class=""disease"" id=""17210701-8-13-21"">melanoma</span> cells with DW1/2 was instead found to decrease levels of <span class=""gene"" id=""17210701-8-79-83"">Mdm2</span> and Mdm4.",CTD_human
1,0,Biomarker,C0003469,Anxiety Disorders,group,anxiety,4204,MECP2,MECP2,CTD_human,22231481,These data indicate that increased MeCP2 levels affect molecular pathways underlying anxiety and social behavior and provide new insight into potential therapies for MECP2-related disorders.,0.20082418035263896,"These data indicate that increased <span class=""gene"" id=""22231481-6-35-40"">MeCP2</span> levels affect molecular pathways underlying <span class=""disease"" id=""22231481-6-85-92"">anxiety</span> and social behavior and provide new insight into potential therapies for <span class=""gene"" id=""22231481-6-166-171"">MECP2</span>-related disorders.",CTD_human
3,0,Biomarker,C0004352,Autistic Disorder,disease,autistic,4204,MECP2,MECP2,CTD_human,19921286,"We evaluated 226 autistic individuals for alterations in the four genes most homologous to MECP2: MBD1, MBD2, MBD3, and MBD4.",0.43781639420052,"We evaluated 226 <span class=""disease"" id=""19921286-3-17-25"">autistic</span> individuals for alterations in the four genes most homologous to <span class=""gene"" id=""19921286-3-91-96"">MECP2</span>: MBD1, MBD2, MBD3, and MBD4.",CTD_human;HPO
3,0,Biomarker,C0004352,Autistic Disorder,disease,autism,4204,MECP2,MECP2,CTD_human,15211631,"MECP2 structural and 3'-UTR variants in schizophrenia, autism and other psychiatric diseases: a possible association with autism.",0.43781639420052,"<span class=""gene"" id=""15211631-0-0-5"">MECP2</span> structural and 3'-UTR variants in schizophrenia, <span class=""disease"" id=""15211631-0-55-61"">autism</span> and other psychiatric diseases: a possible association with <span class=""disease"" id=""15211631-0-122-128"">autism</span>.",CTD_human;HPO
1,0,Biomarker,C0027066,Myoclonus,phenotype,myoclonic jerks,4204,MECP2,MECP2,CTD_human,19559301,"Here we report on a male infant with neonatal encephalopathy, myoclonic jerks, and irregular breathing patterns caused by a novel frameshift mutation in the MECP2 gene.",0.4,"Here we report on a male infant with neonatal encephalopathy, <span class=""disease"" id=""19559301-2-62-77"">myoclonic jerks</span>, and irregular breathing patterns caused by a novel frameshift mutation in the <span class=""gene"" id=""19559301-2-157-162"">MECP2</span> gene.",CTD_human;HPO
1,0,Biomarker,C0034069,Pulmonary Fibrosis,disease,pulmonary fibrosis,4204,MECP2,MeCP2,CTD_human,21435439,Essential role of MeCP2 in the regulation of myofibroblast differentiation during pulmonary fibrosis.,0.200274726784213,"Essential role of <span class=""gene"" id=""21435439-0-18-23"">MeCP2</span> in the regulation of myofibroblast differentiation during <span class=""disease"" id=""21435439-0-82-100"">pulmonary fibrosis</span>.",CTD_human
35,277,Biomarker,C0035372,Rett Syndrome,disease,RTT,4204,MECP2,MECP2,CTD_human,26214522,"Therefore, the elevated PTP1B that accompanies disruption of MECP2 function in RTT represents a barrier to BDNF signaling.",0.92,"Therefore, the elevated PTP1B that accompanies disruption of <span class=""gene"" id=""26214522-7-61-66"">MECP2</span> function in <span class=""disease"" id=""26214522-7-79-82"">RTT</span> represents a barrier to BDNF signaling.",CTD_human;ORPHANET;UNIPROT
35,277,Biomarker,C0035372,Rett Syndrome,disease,Rett syndrome,4204,MECP2,MECP2,CTD_human,19921286,"Misregulation of the methyl-CpG-binding protein 2 (MECP2) gene has been found to cause a myriad of neurological disorders including autism, mental retardation, seizures, learning disabilities, and Rett syndrome.",0.92,"Misregulation of the <span class=""gene"" id=""19921286-1-21-49"">methyl-CpG-binding protein 2</span> (<span class=""gene"" id=""19921286-1-51-56"">MECP2</span>) gene has been found to cause a myriad of neurological disorders including autism, mental retardation, seizures, learning disabilities, and <span class=""disease"" id=""19921286-1-197-210"">Rett syndrome</span>.",CTD_human;ORPHANET;UNIPROT
35,277,Biomarker,C0035372,Rett Syndrome,disease,RTT,4204,MECP2,MECP2,CTD_human,20098342,"The MECP2 gene mutations cause Rett syndrome (RTT) (OMIM: 312750), an X-linked dominant disorder primarily affecting girls.",0.92,"The <span class=""gene"" id=""20098342-1-4-9"">MECP2</span> gene mutations cause <span class=""disease"" id=""20098342-1-31-44"">Rett syndrome</span> (<span class=""disease"" id=""20098342-1-46-49"">RTT</span>) (OMIM: 312750), an X-linked dominant disorder primarily affecting girls.",CTD_human;ORPHANET;UNIPROT
35,277,Biomarker,C0035372,Rett Syndrome,disease,Rett syndrome,4204,MECP2,MeCP2,CTD_human,22532851,Alterations of gene expression and glutamate clearance in astrocytes derived from an MeCP2-null mouse model of Rett syndrome.,0.92,"Alterations of gene expression and glutamate clearance in astrocytes derived from an <span class=""gene"" id=""22532851-0-85-90"">MeCP2</span>-null mouse model of <span class=""disease"" id=""22532851-0-111-124"">Rett syndrome</span>.",CTD_human;ORPHANET;UNIPROT
35,277,Biomarker,C0035372,Rett Syndrome,disease,RTT,4204,MECP2,MECP2,CTD_human,19190538,Rett Syndrome (RTT) is caused in more than 60% of cases by nonsense mutations in the MECP2 gene.,0.92,"<span class=""disease"" id=""19190538-1-0-13"">Rett Syndrome</span> (<span class=""disease"" id=""19190538-1-15-18"">RTT</span>) is caused in more than 60% of cases by nonsense mutations in the <span class=""gene"" id=""19190538-1-85-90"">MECP2</span> gene.",CTD_human;ORPHANET;UNIPROT
35,277,Biomarker,C0035372,Rett Syndrome,disease,RTT,4204,MECP2,MeCP2,CTD_human,21966470,"These include the identification of many MeCP2 target genes, better understanding of the neurobiological consequences of the loss- or mis-function of MeCP2, and drug testing in RTT mice and clinical trials in human RTT patients.",0.92,"These include the identification of many <span class=""gene"" id=""21966470-3-41-46"">MeCP2</span> target genes, better understanding of the neurobiological consequences of the loss- or mis-function of <span class=""gene"" id=""21966470-3-150-155"">MeCP2</span>, and drug testing in <span class=""disease"" id=""21966470-3-177-180"">RTT</span> mice and clinical trials in human <span class=""disease"" id=""21966470-3-215-218"">RTT</span> patients.",CTD_human;ORPHANET;UNIPROT
35,277,Biomarker,C0035372,Rett Syndrome,disease,Rett syndrome,4204,MECP2,methyl-CpG-binding protein 2,CTD_human,21316312,Autonomic dysfunction with mutations in the gene that encodes methyl-CpG-binding protein 2: insights into Rett syndrome.,0.92,"Autonomic dysfunction with mutations in the gene that encodes <span class=""gene"" id=""21316312-0-62-90"">methyl-CpG-binding protein 2</span>: insights into <span class=""disease"" id=""21316312-0-106-119"">Rett syndrome</span>.",CTD_human;ORPHANET;UNIPROT
35,277,Biomarker,C0035372,Rett Syndrome,disease,Rett syndrome,4204,MECP2,MECP2,CTD_human,22343140,Rett syndrome is an X-linked ASD caused by mutations in the epigenetic factor methyl-CpG binding protein 2 (MECP2).,0.92,"<span class=""disease"" id=""22343140-4-0-13"">Rett syndrome</span> is an X-linked ASD caused by mutations in the epigenetic factor <span class=""gene"" id=""22343140-4-78-106"">methyl-CpG binding protein 2</span> (<span class=""gene"" id=""22343140-4-108-113"">MECP2</span>).",CTD_human;ORPHANET;UNIPROT
35,277,Biomarker,C0035372,Rett Syndrome,disease,Rett syndrome,4204,MECP2,Mecp2,CTD_human,23892605,A suppressor screen in Mecp2 mutant mice implicates cholesterol metabolism in Rett syndrome.,0.92,"A suppressor screen in <span class=""gene"" id=""23892605-0-23-28"">Mecp2</span> mutant mice implicates cholesterol metabolism in <span class=""disease"" id=""23892605-0-78-91"">Rett syndrome</span>.",CTD_human;ORPHANET;UNIPROT
35,277,Biomarker,C0035372,Rett Syndrome,disease,Rett syndrome,4204,MECP2,MeCP2,CTD_human,16670375,"Mutations within the MeCP2 gene have been found to cause Rett syndrome, a disorder of arrested neuronal development.",0.92,"Mutations within the <span class=""gene"" id=""16670375-2-21-26"">MeCP2</span> gene have been found to cause <span class=""disease"" id=""16670375-2-57-70"">Rett syndrome</span>, a disorder of arrested neuronal development.",CTD_human;ORPHANET;UNIPROT
35,277,Biomarker,C0035372,Rett Syndrome,disease,Rett syndrome,4204,MECP2,MECP2,CTD_human,19000991,Reciprocal co-regulation of EGR2 and MECP2 is disrupted in Rett syndrome and autism.,0.92,"Reciprocal co-regulation of EGR2 and <span class=""gene"" id=""19000991-0-37-42"">MECP2</span> is disrupted in <span class=""disease"" id=""19000991-0-59-72"">Rett syndrome</span> and autism.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0036572,Seizures,phenotype,seizures,4204,MECP2,MECP2,CTD_human,19921286,"Misregulation of the methyl-CpG-binding protein 2 (MECP2) gene has been found to cause a myriad of neurological disorders including autism, mental retardation, seizures, learning disabilities, and Rett syndrome.",0.491942598058799,"Misregulation of the <span class=""gene"" id=""19921286-1-21-49"">methyl-CpG-binding protein 2</span> (<span class=""gene"" id=""19921286-1-51-56"">MECP2</span>) gene has been found to cause a myriad of neurological disorders including autism, mental retardation, <span class=""disease"" id=""19921286-1-160-168"">seizures</span>, learning disabilities, and Rett syndrome.",CTD_human;HPO
1,0,Biomarker,C2239176,Liver carcinoma,disease,hepatocellular carcinoma,4204,MECP2,MeCP2,CTD_human,26189965,Melittin induces PTCH1 expression by down-regulating MeCP2 in human hepatocellular carcinoma SMMC-7721 cells.,0.281098907136852,"Melittin induces PTCH1 expression by down-regulating <span class=""gene"" id=""26189965-0-53-58"">MeCP2</span> in human <span class=""disease"" id=""26189965-0-68-92"">hepatocellular carcinoma</span> SMMC-7721 cells.",CTD_human
2,3,Biomarker,C3714756,Intellectual Disability,group,mental retardation,4204,MECP2,MECP2,CTD_human,19921286,"Misregulation of the methyl-CpG-binding protein 2 (MECP2) gene has been found to cause a myriad of neurological disorders including autism, mental retardation, seizures, learning disabilities, and Rett syndrome.",0.43426907114005103,"Misregulation of the <span class=""gene"" id=""19921286-1-21-49"">methyl-CpG-binding protein 2</span> (<span class=""gene"" id=""19921286-1-51-56"">MECP2</span>) gene has been found to cause a myriad of neurological disorders including autism, <span class=""disease"" id=""19921286-1-140-158"">mental retardation</span>, seizures, learning disabilities, and Rett syndrome.",CTD_human;HPO
2,3,Biomarker,C3714756,Intellectual Disability,group,MR,4204,MECP2,MECP2,CTD_human,20098342,MECP2 gene mutations may be considered a rare cause of MR in males although great phenotypic variation hinders genotype-phenotype correlation.,0.43426907114005103,"<span class=""gene"" id=""20098342-12-0-5"">MECP2</span> gene mutations may be considered a rare cause of <span class=""disease"" id=""20098342-12-55-57"">MR</span> in males although great phenotypic variation hinders genotype-phenotype correlation.",CTD_human;HPO
1,0,Biomarker,C0004352,Autistic Disorder,disease,Autistic,4208,MEF2C,MEF2C,CTD_human,19131610,Autistic phenotype from MEF2C knockout cells.,0.2,"<span class=""disease"" id=""19131610-0-0-8"">Autistic</span> phenotype from <span class=""gene"" id=""19131610-0-24-29"">MEF2C</span> knockout cells.",CTD_human
1,0,Biomarker,C0014544,Epilepsy,disease,epilepsy,4208,MEF2C,MEF2C,CTD_human,20412115,"Here we present two additional patients with severe MR, autism spectrum disorder and epilepsy, carrying a very small deletion encompassing the MEF2C gene.",0.40082418035263895,"Here we present two additional patients with severe MR, autism spectrum disorder and <span class=""disease"" id=""20412115-5-85-93"">epilepsy</span>, carrying a very small deletion encompassing the <span class=""gene"" id=""20412115-5-143-148"">MEF2C</span> gene.",CTD_human;HPO
1,0,Biomarker,C0038220,Status Epilepticus,disease,status epilepticus,4208,MEF2C,MEF2C,CTD_human,18949272,Myocyte-specific enhancer binding factor 2C (MEF2C) expression in the dentate gyrus during development and after pilocarpine-induced status epilepticus: a preliminary report.,0.2,"Myocyte-specific enhancer binding factor 2C (<span class=""gene"" id=""18949272-0-45-50"">MEF2C</span>) expression in the dentate gyrus during development and after pilocarpine-induced <span class=""disease"" id=""18949272-0-133-151"">status epilepticus</span>: a preliminary report.",CTD_human
1,0,Biomarker,C1510586,Autism Spectrum Disorders,disease,autism spectrum disorder,4208,MEF2C,MEF2C,CTD_human,20412115,"Here we present two additional patients with severe MR, autism spectrum disorder and epilepsy, carrying a very small deletion encompassing the MEF2C gene.",0.4,"Here we present two additional patients with severe MR, <span class=""disease"" id=""20412115-5-56-80"">autism spectrum disorder</span> and epilepsy, carrying a very small deletion encompassing the <span class=""gene"" id=""20412115-5-143-148"">MEF2C</span> gene.",CTD_human;HPO
1,0,Biomarker,C0003872,"Arthritis, Psoriatic",disease,psoriatic arthritis,4210,MEFV,MEFV,CTD_human,17408446,This case has been presented to remind that cases with psoriatic arthritis may also carry mutations in the MEFV gene.,0.202681755307501,"This case has been presented to remind that cases with <span class=""disease"" id=""17408446-10-55-74"">psoriatic arthritis</span> may also carry mutations in the <span class=""gene"" id=""17408446-10-107-111"">MEFV</span> gene.",CTD_human
22,50,Biomarker,C0031069,Familial Mediterranean Fever,disease,familial Mediterranean fever,4210,MEFV,pyrin,CTD_human,15805719,A Japanese patient with familial Mediterranean fever associated with compound heterozygosity for pyrin variant E148Q/M694I.,0.872794949577765,"A Japanese patient with <span class=""disease"" id=""15805719-0-24-52"">familial Mediterranean fever</span> associated with compound heterozygosity for <span class=""gene"" id=""15805719-0-97-102"">pyrin</span> variant E148Q/M694I.",CTD_human;ORPHANET;UNIPROT
1,1,Biomarker,C0035258,Restless Legs Syndrome,disease,RLS,4211,MEIS1,MEIS1,CTD_human,17637780,"MEIS1 has been implicated in limb development, raising the possibility that RLS has components of a developmental disorder.",0.21265010871949602,"<span class=""gene"" id=""17637780-5-0-5"">MEIS1</span> has been implicated in limb development, raising the possibility that <span class=""disease"" id=""17637780-5-76-79"">RLS</span> has components of a developmental disorder.",CTD_human
1,0,Biomarker,C1458155,Mammary Neoplasms,group,breast tumour,4211,MEIS1,Meis 1,CTD_human,19776672,"TMEM25, REPS2 and Meis 1 expression was investigated by qRT-PCR, in triplicate, in 103 breast tumour biopsies procured in 1993-1994.",0.2,"TMEM25, REPS2 and <span class=""gene"" id=""19776672-4-18-24"">Meis 1</span> expression was investigated by qRT-PCR, in triplicate, in 103 <span class=""disease"" id=""19776672-4-87-100"">breast tumour</span> biopsies procured in 1993-1994.",CTD_human
1,0,Biomarker,C0025202,melanoma,disease,melanoma,4217,MAP3K5,MAP3K5,CTD_human,22197930,"The position of the mutations and the loss of heterozygosity of MAP3K5 and MAP3K9 in 85% and 67% of melanoma samples, respectively, together suggest that the mutations are likely to be inactivating.",0.20082418035263896,"The position of the mutations and the loss of heterozygosity of <span class=""gene"" id=""22197930-4-64-70"">MAP3K5</span> and MAP3K9 in 85% and 67% of <span class=""disease"" id=""22197930-4-100-108"">melanoma</span> samples, respectively, together suggest that the mutations are likely to be inactivating.",CTD_human
1,0,Biomarker,C0030567,Parkinson Disease,disease,Parkinson's disease,4217,MAP3K5,ASK1,CTD_human,21815648,Levodopa activates apoptosis signaling kinase 1 (ASK1) and promotes apoptosis in a neuronal model: implications for the treatment of Parkinson's disease.,0.20383181960166602,"Levodopa activates apoptosis signaling kinase 1 (<span class=""gene"" id=""21815648-0-49-53"">ASK1</span>) and promotes apoptosis in a neuronal model: implications for the treatment of <span class=""disease"" id=""21815648-0-133-152"">Parkinson's disease</span>.",CTD_human
1,0,Biomarker,C0017150,Gastrinoma,disease,gastrinomas,4221,MEN1,menin,CTD_human,17961653,"Somatic mutations of menin are present in about 20% of sporadic neoplasms, particularly gastrinomas and insulinomas.30-75% of patients with MEN1 have EPTs.",0.213143819510277,"Somatic mutations of <span class=""gene"" id=""17961653-4-21-26"">menin</span> are present in about 20% of sporadic neoplasms, particularly <span class=""disease"" id=""17961653-4-88-99"">gastrinomas</span> and insulinomas.30-75% of patients with MEN1 have EPTs.",CTD_human
38,55,Biomarker,C0025267,Multiple Endocrine Neoplasia Type 1,disease,MEN1,4221,MEN1,Men1,CTD_human,19847644,Menin is a tumor suppressor encoded by Men1 that is mutated in the human-inherited tumor syndrome multiple endocrine neoplasia type 1 (MEN1); it also serves as a critical link in the recruitment of nuclear receptor-mediated transcription.,0.8281227686114259,"<span class=""gene"" id=""19847644-2-0-5"">Menin</span> is a tumor suppressor encoded by <span class=""gene"" id=""19847644-2-39-43"">Men1</span> that is mutated in the human-inherited tumor syndrome <span class=""disease"" id=""19847644-2-98-133"">multiple endocrine neoplasia type 1</span> (<span class=""disease"" id=""19847644-2-135-139"">MEN1</span>); it also serves as a critical link in the recruitment of nuclear receptor-mediated transcription.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0206754,Neuroendocrine Tumors,group,neuroendocrine tumors,4221,MEN1,MEN1,CTD_human,21252315,"DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors.",0.215839930195095,"DAXX/ATRX, <span class=""gene"" id=""21252315-0-11-15"">MEN1</span>, and mTOR pathway genes are frequently altered in pancreatic <span class=""disease"" id=""21252315-0-77-98"">neuroendocrine tumors</span>.",CTD_human
2,0,Biomarker,C0001418,Adenocarcinoma,group,adenocarcinomas,4233,MET,c-MET,CTD_human,20934974,Co-activation of epidermal growth factor receptor and c-MET defines a distinct subset of lung adenocarcinomas.,0.230929283597542,"Co-activation of epidermal growth factor receptor and <span class=""gene"" id=""20934974-0-54-59"">c-MET</span> defines a distinct subset of lung <span class=""disease"" id=""20934974-0-94-109"">adenocarcinomas</span>.",CTD_human
2,0,Biomarker,C0001418,Adenocarcinoma,group,adenocarcinoma,4233,MET,MET,CTD_human,22042947,MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.,0.230929283597542,"<span class=""gene"" id=""22042947-0-0-3"">MET</span> amplification identifies a small and aggressive subgroup of esophagogastric <span class=""disease"" id=""22042947-0-80-94"">adenocarcinoma</span> with evidence of responsiveness to crizotinib.",CTD_human
2,0,Biomarker,C0004352,Autistic Disorder,disease,autism,4233,MET,MET,CTD_human,17053076,A genetic variant that disrupts MET transcription is associated with autism.,0.218614230060237,"A genetic variant that disrupts <span class=""gene"" id=""17053076-0-32-35"">MET</span> transcription is associated with <span class=""disease"" id=""17053076-0-69-75"">autism</span>.",CTD_human
2,0,Biomarker,C0004352,Autistic Disorder,disease,autism,4233,MET,MET,CTD_human,21328570,The autism risk genes MET and PLAUR differentially impact cortical development.,0.218614230060237,"The <span class=""disease"" id=""21328570-0-4-10"">autism</span> risk genes <span class=""gene"" id=""21328570-0-22-25"">MET</span> and PLAUR differentially impact cortical development.",CTD_human
4,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,NSCLC,4233,MET,MET,CTD_human,21815704,Receptor kinase inhibitors target NSCLC: two antibodies and a small-molecule MET inhibitor.,0.22747267842131,"Receptor kinase inhibitors target <span class=""disease"" id=""21815704-0-34-39"">NSCLC</span>: two antibodies and a small-molecule <span class=""gene"" id=""21815704-0-77-80"">MET</span> inhibitor.",CTD_human
4,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,nsclc,4233,MET,MET,CTD_human,22787409,"However, the benefits of these agents are not uniform across the spectrum of nsclc, and optimizing their utility requires some degree of subgrouping of nsclc by the presence or absence of certain biomarkers.The biomarkers of current or imminent value are EGFR and KRAS mutational status, ALK rearrangements, and MET immunohistochemistry.",0.22747267842131,"However, the benefits of these agents are not uniform across the spectrum of <span class=""disease"" id=""22787409-3-77-82"">nsclc</span>, and optimizing their utility requires some degree of subgrouping of <span class=""disease"" id=""22787409-3-152-157"">nsclc</span> by the presence or absence of certain biomarkers.The biomarkers of current or imminent value are EGFR and KRAS mutational status, ALK rearrangements, and <span class=""gene"" id=""22787409-3-312-315"">MET</span> immunohistochemistry.",CTD_human
1,0,Biomarker,C0007137,Squamous cell carcinoma,disease,SCC,4233,MET,c-MET,CTD_human,22948846,"Some of these EGFR-mutated PDXs do not respond to erlotinib: LU1868 containing L858R/T790M mutations, and LU0858 having L858R mutation as well as c-MET gene amplification, both squamous cell carcinoma (SCC).",0.209861453477037,"Some of these EGFR-mutated PDXs do not respond to erlotinib: LU1868 containing L858R/T790M mutations, and LU0858 having L858R mutation as well as <span class=""gene"" id=""22948846-4-146-151"">c-MET</span> gene amplification, both <span class=""disease"" id=""22948846-4-177-200"">squamous cell carcinoma</span> (<span class=""disease"" id=""22948846-4-202-205"">SCC</span>).",CTD_human
1,0,Biomarker,C0017636,Glioblastoma,disease,glioblastoma,4233,MET,MET,CTD_human,22162573,Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor.,0.21042526242278098,"Rapid radiographic and clinical improvement after treatment of a <span class=""gene"" id=""22162573-0-65-68"">MET</span>-amplified recurrent <span class=""disease"" id=""22162573-0-89-101"">glioblastoma</span> with a mesenchymal-epithelial transition inhibitor.",CTD_human
1,0,Biomarker,C0023467,"Leukemia, Myelocytic, Acute",disease,acute myeloid leukemia,4233,MET,MET,CTD_human,22683780,Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia.,0.20082418035263896,"Autocrine activation of the <span class=""gene"" id=""22683780-0-28-31"">MET</span> receptor tyrosine kinase in <span class=""disease"" id=""22683780-0-60-82"">acute myeloid leukemia</span>.",CTD_human
2,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,tumor metastasis,4233,MET,MET,CTD_human,20080979,"The MET proto-oncogene is primarily linked to tumor metastasis, but MET is also involved in neurodevelopment and influences risk for autism.",0.23292414797362,"The <span class=""gene"" id=""20080979-4-4-22"">MET proto-oncogene</span> is primarily linked to <span class=""disease"" id=""20080979-4-46-62"">tumor metastasis</span>, but <span class=""gene"" id=""20080979-4-68-71"">MET</span> is also involved in neurodevelopment and influences risk for autism.",CTD_human
1,0,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,4233,MET,MET proto-oncogene,CTD_human,20080979,Association of genetic variation in the MET proto-oncogene with schizophrenia and general cognitive ability.,0.202956482091714,"Association of genetic variation in the <span class=""gene"" id=""20080979-0-40-58"">MET proto-oncogene</span> with <span class=""disease"" id=""20080979-0-64-77"">schizophrenia</span> and general cognitive ability.",CTD_human
1,0,Biomarker,C1458155,Mammary Neoplasms,group,mammary tumor,4240,MFGE8,MFG-E8,CTD_human,21127199,"We first identified MFG-E8 downregulation in invasive lesions in transgenic mammary tumor models, which were confirmed in LCM-isolated human invasive ductal carcinomas compared with patient-matched normal tissues.",0.20082418035263896,"We first identified <span class=""gene"" id=""21127199-3-20-26"">MFG-E8</span> downregulation in invasive lesions in transgenic <span class=""disease"" id=""21127199-3-76-89"">mammary tumor</span> models, which were confirmed in LCM-isolated human invasive ductal carcinomas compared with patient-matched normal tissues.",CTD_human
1,0,Biomarker,C0027430,Nasal Polyps,disease,nasal polyps,4254,KITLG,SCF,CTD_human,15813808,"For the whole group of patients, the number of polypectomies correlated with expression of SCF mRNA (r = 0.62; P < 0.005), SCF protein in the NPECs supernatants (r = 0.39; P < 0.05) and with density of mast cells in epithelial layer (r = 0.37; P < 0.05) and stromal layer (r = 0.5; P < 0.01) of nasal polyps.",0.20054945356842604,"For the whole group of patients, the number of polypectomies correlated with expression of SCF mRNA (r = 0.62; P &lt; 0.005), <span class=""gene"" id=""15813808-6-123-126"">SCF</span> protein in the NPECs supernatants (r = 0.39; P &lt; 0.05) and with density of mast cells in epithelial layer (r = 0.37; P &lt; 0.05) and stromal layer (r = 0.5; P &lt; 0.01) of <span class=""disease"" id=""15813808-6-295-307"">nasal polyps</span>.",CTD_human
2,0,Biomarker,C0017636,Glioblastoma,disease,glioblastoma,4255,MGMT,MGMT,CTD_human,20131314,"MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma.",0.295886059984109,"<span class=""gene"" id=""20131314-0-0-4"">MGMT</span> activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and <span class=""disease"" id=""20131314-0-149-161"">glioblastoma</span>.",CTD_human
3,0,Biomarker,C0017638,Glioma,disease,gliomas,4255,MGMT,MGMT,CTD_human,19901110,"IDH1 mutations are a novel positive prognostic factor in anaplastic gliomas, with a favorable impact stronger than that of 1p/19q codeletion or MGMT promoter methylation.",0.262094665525898,"IDH1 mutations are a novel positive prognostic factor in anaplastic <span class=""disease"" id=""19901110-14-68-75"">gliomas</span>, with a favorable impact stronger than that of 1p/19q codeletion or <span class=""gene"" id=""19901110-14-144-148"">MGMT</span> promoter methylation.",CTD_human
3,0,Biomarker,C0017638,Glioma,disease,gliomas,4255,MGMT,O6-methylguanine-DNA methyltransferase,CTD_human,16033832,Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas.,0.262094665525898,"Prognostic significance of <span class=""gene"" id=""16033832-0-27-65"">O6-methylguanine-DNA methyltransferase</span> determined by promoter hypermethylation and immunohistochemical expression in anaplastic <span class=""disease"" id=""16033832-0-155-162"">gliomas</span>.",CTD_human
1,0,Biomarker,C0279626,Squamous cell carcinoma of esophagus,disease,esophageal squamous cell carcinoma,4255,MGMT,MGMT,CTD_human,25520135,Promoter methylation of MGMT gene in serum of patients with esophageal squamous cell carcinoma in North East India.,0.203021994626344,"Promoter methylation of <span class=""gene"" id=""25520135-0-24-28"">MGMT</span> gene in serum of patients with <span class=""disease"" id=""25520135-0-60-94"">esophageal squamous cell carcinoma</span> in North East India.",CTD_human
1,0,Biomarker,C0042345,Varicosity,disease,varicose veins,4256,MGP,matrix gla protein,CTD_human,17643059,Identification of differentially expressed genes in human varicose veins: involvement of matrix gla protein in extracellular matrix remodeling.,0.20300763924902696,"Identification of differentially expressed genes in human <span class=""disease"" id=""17643059-0-58-72"">varicose veins</span>: involvement of <span class=""gene"" id=""17643059-0-89-107"">matrix gla protein</span> in extracellular matrix remodeling.",CTD_human
1,0,Biomarker,C0001403,Addison Disease,disease,primary adrenal insufficiency,4261,CIITA,CIITA,CTD_human,18593762,Polymorphisms in CLEC16A and CIITA at 16p13 are associated with primary adrenal insufficiency.,0.20508878383078896,"Polymorphisms in CLEC16A and <span class=""gene"" id=""18593762-0-29-34"">CIITA</span> at 16p13 are associated with <span class=""disease"" id=""18593762-0-64-93"">primary adrenal insufficiency</span>.",CTD_human
1,0,Biomarker,C0206637,"Chondrosarcoma, Mesenchymal",disease,MC,4267,CD99,CD99,CTD_human,12817616,"The results showed that malignant mesenchymal chondroblasts exhibit stronger expressions of CD99, IL-1alpha, cPKC-alpha, p-PKC-alpha/betaII, PDGFR-alpha, p-JNK, Ki-67, and bcl-2 antigens than their more mature-appearing chondrocytic counterparts in MC.",0.2,"The results showed that malignant mesenchymal chondroblasts exhibit stronger expressions of <span class=""gene"" id=""12817616-4-92-96"">CD99</span>, IL-1alpha, cPKC-alpha, p-PKC-alpha/betaII, PDGFR-alpha, p-JNK, Ki-67, and bcl-2 antigens than their more mature-appearing chondrocytic counterparts in <span class=""disease"" id=""12817616-4-249-251"">MC</span>.",CTD_human
1,0,Biomarker,C0003873,Rheumatoid Arthritis,disease,rheumatoid arthritis,4282,MIF,Macrophage migration inhibitory factor,CTD_human,16872482,Macrophage migration inhibitory factor: a mediator of matrix metalloproteinase-2 production in rheumatoid arthritis.,0.22708769423889202,"<span class=""gene"" id=""16872482-0-0-38"">Macrophage migration inhibitory factor</span>: a mediator of matrix metalloproteinase-2 production in <span class=""disease"" id=""16872482-0-95-115"">rheumatoid arthritis</span>.",CTD_human
1,0,Therapeutic,C0009319,Colitis,disease,colitis,4282,MIF,macrophage migration inhibitory factor,CTD_human,12105854,Amelioration of dextran sulfate sodium-induced colitis by anti-macrophage migration inhibitory factor antibody in mice.,0.200274726784213,"Amelioration of dextran sulfate sodium-induced <span class=""disease"" id=""12105854-0-47-54"">colitis</span> by anti-<span class=""gene"" id=""12105854-0-63-101"">macrophage migration inhibitory factor</span> antibody in mice.",CTD_human
1,0,Biomarker,C0002171,Alopecia Areata,disease,alopecia areata,4283,CXCL9,Cxcl9,CTD_human,22358057,"Increased expression of Cxcr3 and its ligands, Cxcl9 and Cxcl10, during the development of alopecia areata in the mouse.",0.2,"Increased expression of Cxcr3 and its ligands, <span class=""gene"" id=""22358057-0-47-52"">Cxcl9</span> and Cxcl10, during the development of <span class=""disease"" id=""22358057-0-91-106"">alopecia areata</span> in the mouse.",CTD_human
1,0,Biomarker,C0282488,Interstitial Cystitis,disease,IC,4283,CXCL9,IFN-gamma,CTD_human,18957084,"Serum levels of monokine-induced by interferon-gamma (IFN-gamma) (MIG/CXCL9), IFN-gamma-inducible protein-10 (IP-10/CXCL10), and IFN-gamma-inducible T cell alpha chemoattractant (I-TAC/CXCL11) were elevated in patients with IC.",0.2,"Serum levels of <span class=""gene"" id=""18957084-2-16-52"">monokine-induced by interferon-gamma</span> (<span class=""gene"" id=""18957084-2-54-63"">IFN-gamma</span>) (<span class=""gene"" id=""18957084-2-66-69"">MIG</span>/<span class=""gene"" id=""18957084-2-70-75"">CXCL9</span>), <span class=""gene"" id=""18957084-2-78-87"">IFN-gamma</span>-inducible protein-10 (IP-10/CXCL10), and <span class=""gene"" id=""18957084-2-129-138"">IFN-gamma</span>-inducible T cell alpha chemoattractant (I-TAC/CXCL11) were elevated in patients with <span class=""disease"" id=""18957084-2-224-226"">IC</span>.",CTD_human
1,0,Biomarker,C0086543,Cataract,disease,cataracts,4284,MIP,MIP,CTD_human,10802646,Missense mutations in MIP underlie autosomal dominant 'polymorphic' and lamellar cataracts linked to 12q.,0.40357144819477,"Missense mutations in <span class=""gene"" id=""10802646-0-22-25"">MIP</span> underlie autosomal dominant 'polymorphic' and lamellar <span class=""disease"" id=""10802646-0-81-90"">cataracts</span> linked to 12q.",CTD_human;HPO
1,0,Biomarker,C0007134,Renal Cell Carcinoma,disease,renal carcinoma,4286,MITF,MITF,CTD_human,22012259,A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma.,0.202197814273705,"A SUMOylation-defective <span class=""gene"" id=""22012259-0-24-28"">MITF</span> germline mutation predisposes to melanoma and <span class=""disease"" id=""22012259-0-75-90"">renal carcinoma</span>.",CTD_human
1,0,Biomarker,C0031117,Peripheral Neuropathy,group,peripheral neuropathy,4288,MKI67,MKI67,CTD_human,20864405,"By contrast, early-onset vincristine-induced peripheral neuropathy was characterised by upregulation of genes involved in cell cycle and proliferation, including AURKA (3·31 times; p=1·04×10(-2)) and MKI67 (3·66 times; p=1·82×10(-3)), and the presence of SNPs in genes involved in these processes-eg, GLI1 (rs2228224 [0·13, 0·02-0·97, p=1·18×10(-2)] and rs2242578 [0·14, 0·02-1·12, p=3·00×10(-2)]).",0.200274726784213,"By contrast, early-onset vincristine-induced <span class=""disease"" id=""20864405-13-45-66"">peripheral neuropathy</span> was characterised by upregulation of genes involved in cell cycle and proliferation, including AURKA (3·31 times; p=1·04&times;10(-2)) and <span class=""gene"" id=""20864405-13-200-205"">MKI67</span> (3·66 times; p=1·82&times;10(-3)), and the presence of SNPs in genes involved in these processes-eg, GLI1 (rs2228224 [0·13, 0·02-0·97, p=1·18&times;10(-2)] and rs2242578 [0·14, 0·02-1·12, p=3·00&times;10(-2)]).",CTD_human
1,0,Biomarker,C0149925,Small cell carcinoma of lung,disease,Small Cell Lung Cancer,429,ASCL1,ASCL1,CTD_human,26253517,Sensitivity of Small Cell Lung Cancer to BET Inhibition Is Mediated by Regulation of ASCL1 Gene Expression.,0.20467035533162303,"Sensitivity of <span class=""disease"" id=""26253517-0-15-37"">Small Cell Lung Cancer</span> to BET Inhibition Is Mediated by Regulation of <span class=""gene"" id=""26253517-0-85-90"">ASCL1</span> Gene Expression.",CTD_human
1,0,Biomarker,C0024299,Lymphoma,group,lymphoma,4292,MLH1,Mlh1,CTD_human,15700306,"However, the Mlh1-deficient mice treated with DES tended to become moribund at an early age and had very early onset of lymphoma.",0.40438127317009204,"However, the <span class=""gene"" id=""15700306-7-13-17"">Mlh1</span>-deficient mice treated with DES tended to become moribund at an early age and had very early onset of <span class=""disease"" id=""15700306-7-120-128"">lymphoma</span>.",CTD_human;HPO
1,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastasis,4292,MLH1,hMLH1,CTD_human,17717427,Advanced CRC patients whose tumours have deficient MMR demonstrate a shorter time to metastasis than those with normal hMLH1/hMSH2 expression.,0.206304360659584,"Advanced CRC patients whose tumours have deficient MMR demonstrate a shorter time to <span class=""disease"" id=""17717427-6-85-95"">metastasis</span> than those with normal <span class=""gene"" id=""17717427-6-119-124"">hMLH1</span>/hMSH2 expression.",CTD_human
1,0,Biomarker,C0025202,melanoma,disease,melanoma,4293,MAP3K9,MAP3K9,CTD_human,22197930,"Attenuation of MAP3K9 function in melanoma cells using siRNA led to increased cell viability after temozolomide treatment, suggesting that decreased MAP3K pathway activity can lead to chemoresistance in melanoma.",0.20054945356842604,"Attenuation of <span class=""gene"" id=""22197930-7-15-21"">MAP3K9</span> function in <span class=""disease"" id=""22197930-7-34-42"">melanoma</span> cells using siRNA led to increased cell viability after temozolomide treatment, suggesting that decreased MAP3K pathway activity can lead to chemoresistance in <span class=""disease"" id=""22197930-7-203-211"">melanoma</span>.",CTD_human
2,0,Biomarker,C0023418,leukemia,disease,leukaemia,4297,KMT2A,MLL,CTD_human,12937054,A single case is described of congenital leukaemia with 11q23/MLL rearrangement in a preterm female newborn.,0.320341919089155,"A single case is described of congenital <span class=""disease"" id=""12937054-1-41-50"">leukaemia</span> with 11q23/<span class=""gene"" id=""12937054-1-62-65"">MLL</span> rearrangement in a preterm female newborn.",CTD_human
2,0,Biomarker,C0023467,"Leukemia, Myelocytic, Acute",disease,acute myeloid leukemias,4297,KMT2A,MLL,CTD_human,26237430,The transcriptomic landscape and directed chemical interrogation of MLL-rearranged acute myeloid leukemias.,0.409970033182307,"The transcriptomic landscape and directed chemical interrogation of <span class=""gene"" id=""26237430-0-68-71"">MLL</span>-rearranged <span class=""disease"" id=""26237430-0-83-106"">acute myeloid leukemias</span>.",CTD_human
2,0,Biomarker,C1961102,Precursor Cell Lymphoblastic Leukemia Lymphoma,disease,Acute lymphoblastic leukemia,4297,KMT2A,MLL,CTD_human,24736461,Acute lymphoblastic leukemia in infants (< 1 year-of-age) is characterized by a high incidence of MLL rearrangements.,0.33013144773782505,"<span class=""disease"" id=""24736461-1-0-28"">Acute lymphoblastic leukemia</span> in infants (&lt; 1 year-of-age) is characterized by a high incidence of <span class=""gene"" id=""24736461-1-98-101"">MLL</span> rearrangements.",CTD_human
2,0,Biomarker,C0002395,Alzheimer's Disease,disease,AD,43,ACHE,AChE-S,CTD_human,22944069,"In experiments with cultured HEK293T cells, we show here that GSK3? stabilizes synaptic acetylcholinesterase (AChE-S), a critical component of AD development.",0.23021826753181698,"In experiments with cultured HEK293T cells, we show here that GSK3&beta; stabilizes synaptic <span class=""gene"" id=""22944069-3-88-108"">acetylcholinesterase</span> (<span class=""gene"" id=""22944069-3-110-116"">AChE-S</span>), a critical component of <span class=""disease"" id=""22944069-3-143-145"">AD</span> development.",CTD_human
2,0,Therapeutic,C0036572,Seizures,phenotype,seizures,43,ACHE,acetylcholinesterase,CTD_human,19941057,Pilocarpine-induced seizures produce alterations on choline acetyltransferase and acetylcholinesterase activities and deficit memory in rats.,0.2,"Pilocarpine-induced <span class=""disease"" id=""19941057-0-20-28"">seizures</span> produce alterations on choline acetyltransferase and <span class=""gene"" id=""19941057-0-82-102"">acetylcholinesterase</span> activities and deficit memory in rats.",CTD_human
2,0,Biomarker,C0036572,Seizures,phenotype,seizures,43,ACHE,acetylcholinesterase,CTD_human,19941057,Pilocarpine-induced seizures produce alterations on choline acetyltransferase and acetylcholinesterase activities and deficit memory in rats.,0.2,"Pilocarpine-induced <span class=""disease"" id=""19941057-0-20-28"">seizures</span> produce alterations on choline acetyltransferase and <span class=""gene"" id=""19941057-0-82-102"">acetylcholinesterase</span> activities and deficit memory in rats.",CTD_human
2,0,Biomarker,C0018801,Heart failure,disease,heart failure,4306,NR3C2,mineralocorticoid receptor,CTD_human,21321305,Antagonists of the mineralocorticoid receptor improve morbidity and mortality in patients with severe heart failure.,0.203296721410557,"Antagonists of the <span class=""gene"" id=""21321305-1-19-45"">mineralocorticoid receptor</span> improve morbidity and mortality in patients with severe <span class=""disease"" id=""21321305-1-102-115"">heart failure</span>.",CTD_human
2,0,Biomarker,C0027051,Myocardial Infarction,disease,myocardial infarction,4306,NR3C2,mineralocorticoid receptor,CTD_human,16413583,Regulation of cardiac and renal mineralocorticoid receptor expression by captopril following myocardial infarction in rats.,0.201648360705279,"Regulation of cardiac and renal <span class=""gene"" id=""16413583-0-32-58"">mineralocorticoid receptor</span> expression by captopril following <span class=""disease"" id=""16413583-0-93-114"">myocardial infarction</span> in rats.",CTD_human
2,0,Biomarker,C0027051,Myocardial Infarction,disease,MI,4306,NR3C2,MR,CTD_human,17587755,"Real time reverse transcription-polymerase chain reaction (RT-PCR) analysis showed that the expression of mineralocorticoid receptor (MR) mRNA and that of 11beta-hydroxysteroid dehydrogenase 2 (11beta-HSD2) mRNA, which is known to confer aldosterone selectivity on MR, were upregulated in the untreated MI group, and that spironolactone significantly suppressed the expression of these genes.",0.201648360705279,"Real time reverse transcription-polymerase chain reaction (RT-PCR) analysis showed that the expression of <span class=""gene"" id=""17587755-9-106-132"">mineralocorticoid receptor</span> (<span class=""gene"" id=""17587755-9-134-136"">MR</span>) mRNA and that of 11beta-hydroxysteroid dehydrogenase 2 (11beta-HSD2) mRNA, which is known to confer aldosterone selectivity on <span class=""gene"" id=""17587755-9-265-267"">MR</span>, were upregulated in the untreated <span class=""disease"" id=""17587755-9-303-305"">MI</span> group, and that spironolactone significantly suppressed the expression of these genes.",CTD_human
1,0,Biomarker,C0002940,Aneurysm,disease,aneurysms,4312,MMP1,MMP-1,CTD_human,21742783,"In this study, we demonstrate that matrix metalloproteinase-1 (MMP-1), a collagenase expressed in atherosclerosis and aneurysms but not in the normal vessel wall, is induced in the aortic endothelium of rabbits exposed to cigarette smoke.",0.20054945356842604,"In this study, we demonstrate that <span class=""gene"" id=""21742783-2-35-61"">matrix metalloproteinase-1</span> (<span class=""gene"" id=""21742783-2-63-68"">MMP-1</span>), a collagenase expressed in atherosclerosis and <span class=""disease"" id=""21742783-2-118-127"">aneurysms</span> but not in the normal vessel wall, is induced in the aortic endothelium of rabbits exposed to cigarette smoke.",CTD_human
1,0,Biomarker,C0004153,Atherosclerosis,disease,atherosclerosis,4312,MMP1,MMP-1,CTD_human,21742783,"In this study, we demonstrate that matrix metalloproteinase-1 (MMP-1), a collagenase expressed in atherosclerosis and aneurysms but not in the normal vessel wall, is induced in the aortic endothelium of rabbits exposed to cigarette smoke.",0.21247769624990803,"In this study, we demonstrate that <span class=""gene"" id=""21742783-2-35-61"">matrix metalloproteinase-1</span> (<span class=""gene"" id=""21742783-2-63-68"">MMP-1</span>), a collagenase expressed in <span class=""disease"" id=""21742783-2-98-113"">atherosclerosis</span> and aneurysms but not in the normal vessel wall, is induced in the aortic endothelium of rabbits exposed to cigarette smoke.",CTD_human
1,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,non-small cell lung cancer,4312,MMP1,MMP1,CTD_human,20471133,"A combination of functional polymorphisms in the CASP8, MMP1, IL10 and SEPS1 genes affects risk of non-small cell lung cancer.",0.203231208875927,"A combination of functional polymorphisms in the CASP8, <span class=""gene"" id=""20471133-0-56-60"">MMP1</span>, IL10 and SEPS1 genes affects risk of <span class=""disease"" id=""20471133-0-99-125"">non-small cell lung cancer</span>.",CTD_human
1,0,Therapeutic,C0028840,Ocular Hypertension,disease,ocular hypertension,4312,MMP1,MMP1,CTD_human,20089869,Treatment of sheep steroid-induced ocular hypertension with a glucocorticoid-inducible MMP1 gene therapy virus.,0.2,"Treatment of sheep steroid-induced <span class=""disease"" id=""20089869-0-35-54"">ocular hypertension</span> with a glucocorticoid-inducible <span class=""gene"" id=""20089869-0-87-91"">MMP1</span> gene therapy virus.",CTD_human
1,0,Biomarker,C0003873,Rheumatoid Arthritis,disease,rheumatoid arthritis,4313,MMP2,matrix metalloproteinase-2,CTD_human,16872482,Macrophage migration inhibitory factor: a mediator of matrix metalloproteinase-2 production in rheumatoid arthritis.,0.21249205162722604,"Macrophage migration inhibitory factor: a mediator of <span class=""gene"" id=""16872482-0-54-80"">matrix metalloproteinase-2</span> production in <span class=""disease"" id=""16872482-0-95-115"">rheumatoid arthritis</span>.",CTD_human
1,0,Biomarker,C0011882,Diabetic Neuropathies,group,diabetic neuropathy,4313,MMP2,MMP-2,CTD_human,20213226,The results of the present study suggest that MMP-2 and MMP-9 inhibition in the presence of COX inhibitor prevents the development of experimental diabetic neuropathy in rats and can be a potential approach for the treatment.,0.2,"The results of the present study suggest that <span class=""gene"" id=""20213226-5-46-51"">MMP-2</span> and MMP-9 inhibition in the presence of COX inhibitor prevents the development of experimental <span class=""disease"" id=""20213226-5-147-166"">diabetic neuropathy</span> in rats and can be a potential approach for the treatment.",CTD_human
1,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,4313,MMP2,matrix metalloproteinase-2,CTD_human,18836702,Evidence of early involvement of matrix metalloproteinase-2 in lead-induced hypertension.,0.21247769624990803,"Evidence of early involvement of <span class=""gene"" id=""18836702-0-33-59"">matrix metalloproteinase-2</span> in lead-induced <span class=""disease"" id=""18836702-0-76-88"">hypertension</span>.",CTD_human
1,0,Biomarker,C0024796,Marfan Syndrome,disease,MFS,4313,MMP2,MMP-2,CTD_human,18178469,"This study demonstrates that doxycycline significantly delays aneurysm rupture in MFS-like mice by inhibiting expression of tissue MMP-2 and MMP-9 and thus, degradation of the elastic matrix.",0.200274726784213,"This study demonstrates that doxycycline significantly delays aneurysm rupture in <span class=""disease"" id=""18178469-15-82-85"">MFS</span>-like mice by inhibiting expression of tissue <span class=""gene"" id=""18178469-15-131-136"">MMP-2</span> and MMP-9 and thus, degradation of the elastic matrix.",CTD_human
5,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastasis,4313,MMP2,MMP-2,CTD_human,18398872,Matrix metalloproteinase-2 (MMP-2) is a key enzyme in the degradation of extracellular matrices and its expression has been dysregulated in breast cancer invasion and metastasis.,0.377587404520105,"<span class=""gene"" id=""18398872-5-0-26"">Matrix metalloproteinase-2</span> (<span class=""gene"" id=""18398872-5-28-33"">MMP-2</span>) is a key enzyme in the degradation of extracellular matrices and its expression has been dysregulated in breast cancer invasion and <span class=""disease"" id=""18398872-5-167-177"">metastasis</span>.",CTD_human
5,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,tumor metastasis,4313,MMP2,MMP2,CTD_human,22321834,It is widely recognized that activation of MMP2 and MYC is tightly associated with tumor metastasis and tumor progression.,0.377587404520105,"It is widely recognized that activation of <span class=""gene"" id=""22321834-6-43-47"">MMP2</span> and MYC is tightly associated with <span class=""disease"" id=""22321834-6-83-99"">tumor metastasis</span> and tumor progression.",CTD_human
5,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastasis,4313,MMP2,MMP-2,CTD_human,21209944,"Treatment of mice with resveratrol and TRAIL alone inhibited angiogenesis (as demonstrated by reduced number of blood vessels, and VEGF and VEGFR2 positive cells) and markers of metastasis (MMP-2 and MMP-9).",0.377587404520105,"Treatment of mice with resveratrol and TRAIL alone inhibited angiogenesis (as demonstrated by reduced number of blood vessels, and VEGF and VEGFR2 positive cells) and markers of <span class=""disease"" id=""21209944-7-178-188"">metastasis</span> (<span class=""gene"" id=""21209944-7-190-195"">MMP-2</span> and MMP-9).",CTD_human
1,0,Biomarker,C0029463,Osteosarcoma,disease,osteosarcomas,4313,MMP2,matrix metalloproteinase-2,CTD_human,25605016,Upregulation of miR-328 and inhibition of CREB-DNA-binding activity are critical for resveratrol-mediated suppression of matrix metalloproteinase-2 and subsequent metastatic ability in human osteosarcomas.,0.20932635528592802,"Upregulation of miR-328 and inhibition of CREB-DNA-binding activity are critical for resveratrol-mediated suppression of <span class=""gene"" id=""25605016-0-121-147"">matrix metalloproteinase-2</span> and subsequent metastatic ability in human <span class=""disease"" id=""25605016-0-191-204"">osteosarcomas</span>.",CTD_human
1,0,Biomarker,C0034069,Pulmonary Fibrosis,disease,pulmonary fibrosis,4313,MMP2,MMP-2,CTD_human,21468558,"In this study, we examined the sequential expression of MMP-2, MMP-9 and TIMP-1 in a rat model of pulmonary fibrosis induced by PQ.",0.20328236603324,"In this study, we examined the sequential expression of <span class=""gene"" id=""21468558-3-56-61"">MMP-2</span>, MMP-9 and TIMP-1 in a rat model of <span class=""disease"" id=""21468558-3-98-116"">pulmonary fibrosis</span> induced by PQ.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,hepatocellular carcinoma,4313,MMP2,MMP-2,CTD_human,20084675,Our results reveal that BA exerts its anti-metastatic effect against DEN-induced hepatocellular carcinoma by inhibiting the activities and expressions of MMP-2 and MMP-9.,0.22160919266357101,"Our results reveal that BA exerts its anti-metastatic effect against DEN-induced <span class=""disease"" id=""20084675-9-81-105"">hepatocellular carcinoma</span> by inhibiting the activities and expressions of <span class=""gene"" id=""20084675-9-154-159"">MMP-2</span> and MMP-9.",CTD_human
1,0,Biomarker,C2931822,Nasopharyngeal carcinoma,disease,NPC,4313,MMP2,matrix metalloproteinase 2,CTD_human,20461718,"The results showed that serum levels of all the four proteins were indeed higher in NPC patients versus healthy controls and that the use of a three-marker panel (cystatin A, manganese superoxide dismutase and matrix metalloproteinase 2) can contribute to a better NPC detection than each marker alone.",0.20439562854741,"The results showed that serum levels of all the four proteins were indeed higher in <span class=""disease"" id=""20461718-4-84-87"">NPC</span> patients versus healthy controls and that the use of a three-marker panel (cystatin A, manganese superoxide dismutase and <span class=""gene"" id=""20461718-4-210-236"">matrix metalloproteinase 2</span>) can contribute to a better <span class=""disease"" id=""20461718-4-265-268"">NPC</span> detection than each marker alone.",CTD_human
1,0,Biomarker,C0004114,Astrocytoma,disease,astroglioma,4314,MMP3,MMP-3,CTD_human,20188714,"In the present study, we found that glycitein, a bacterial metabolite of the isoflavone glycitin, inhibits the expression of MMP-3 and MMP-9 at promoter, mRNA, and protein levels in PMA-stimulated U87MG human astroglioma cells.",0.203231208875927,"In the present study, we found that glycitein, a bacterial metabolite of the isoflavone glycitin, inhibits the expression of <span class=""gene"" id=""20188714-3-125-130"">MMP-3</span> and MMP-9 at promoter, mRNA, and protein levels in PMA-stimulated U87MG human <span class=""disease"" id=""20188714-3-209-220"">astroglioma</span> cells.",CTD_human
1,0,Biomarker,C1956346,Coronary Artery Disease,disease,coronary heart disease,4314,MMP3,stromelysin-1,CTD_human,8662692,"Thus, the common 5A/6A polymorphism of the human stromelysin-1 promoter appears to play an important role in regulating stromelysin-1 gene expression and may be involved in the progression of coronary heart disease.",0.22512780496940402,"Thus, the common 5A/6A polymorphism of the human <span class=""gene"" id=""8662692-8-49-62"">stromelysin-1</span> promoter appears to play an important role in regulating <span class=""gene"" id=""8662692-8-120-133"">stromelysin-1</span> gene expression and may be involved in the progression of <span class=""disease"" id=""8662692-8-192-214"">coronary heart disease</span>.",CTD_human
1,0,Therapeutic,C0025202,melanoma,disease,melanoma,4317,MMP8,MMP8,CTD_human,19330028,Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma.,0.206513574909167,"Analysis of the matrix metalloproteinase family reveals that <span class=""gene"" id=""19330028-0-61-65"">MMP8</span> is often mutated in <span class=""disease"" id=""19330028-0-86-94"">melanoma</span>.",CTD_human
1,0,Biomarker,C0003486,Aortic Aneurysm,disease,aortic aneurysms,4318,MMP9,MMP-9,CTD_human,10231640,PGE2 and MMP-9 are elevated in aortic aneurysms.,0.206839458850693,"PGE2 and <span class=""gene"" id=""10231640-2-9-14"">MMP-9</span> are elevated in <span class=""disease"" id=""10231640-2-31-47"">aortic aneurysms</span>.",CTD_human
2,0,Biomarker,C0004096,Asthma,disease,asthma,4318,MMP9,MMP-9,CTD_human,15131573,Previous studies have reported that MMP-9 might play a role in chronic airway inflammation and remodeling in asthma.,0.22687847998930802,"Previous studies have reported that <span class=""gene"" id=""15131573-4-36-41"">MMP-9</span> might play a role in chronic airway inflammation and remodeling in <span class=""disease"" id=""15131573-4-109-115"">asthma</span>.",CTD_human
2,0,Biomarker,C0004096,Asthma,disease,asthma,4318,MMP9,MMP-9,CTD_human,11742282,"Murine TDI-induced asthma includes findings of (1) increased inflammatory cells, including neutrophils, lymphocytes, and eosinophils; (2) histologic changes, including infiltration of inflammatory cells around bronchioles, thickened airway epithelium, and accumulation of mucus and debris in the bronchioles; (3) increased MMP-9 activity in inflammatory cells in the airway lumen; and (4) airway hyperresponsiveness.",0.22687847998930802,"Murine TDI-induced <span class=""disease"" id=""11742282-7-19-25"">asthma</span> includes findings of (1) increased inflammatory cells, including neutrophils, lymphocytes, and eosinophils; (2) histologic changes, including infiltration of inflammatory cells around bronchioles, thickened airway epithelium, and accumulation of mucus and debris in the bronchioles; (3) increased <span class=""gene"" id=""11742282-7-323-328"">MMP-9</span> activity in inflammatory cells in the airway lumen; and (4) airway hyperresponsiveness.",CTD_human
1,0,Biomarker,C0004114,Astrocytoma,disease,astroglioma,4318,MMP9,MMP-9,CTD_human,20188714,"In the present study, we found that glycitein, a bacterial metabolite of the isoflavone glycitin, inhibits the expression of MMP-3 and MMP-9 at promoter, mRNA, and protein levels in PMA-stimulated U87MG human astroglioma cells.",0.205205453522732,"In the present study, we found that glycitein, a bacterial metabolite of the isoflavone glycitin, inhibits the expression of MMP-3 and <span class=""gene"" id=""20188714-3-135-140"">MMP-9</span> at promoter, mRNA, and protein levels in PMA-stimulated U87MG human <span class=""disease"" id=""20188714-3-209-220"">astroglioma</span> cells.",CTD_human
1,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,non-small cell lung cancer,4318,MMP9,Matrix metalloproteinase-9,CTD_human,21789004,Matrix metalloproteinase-9 decreased after chemotherapy in patients with non-small cell lung cancer.,0.212846646323386,"<span class=""gene"" id=""21789004-0-0-26"">Matrix metalloproteinase-9</span> decreased after chemotherapy in patients with <span class=""disease"" id=""21789004-0-73-99"">non-small cell lung cancer</span>.",CTD_human
1,0,Biomarker,C0011882,Diabetic Neuropathies,group,diabetic neuropathy,4318,MMP9,MMP-9,CTD_human,20213226,The results of the present study suggest that MMP-2 and MMP-9 inhibition in the presence of COX inhibitor prevents the development of experimental diabetic neuropathy in rats and can be a potential approach for the treatment.,0.2,"The results of the present study suggest that MMP-2 and <span class=""gene"" id=""20213226-5-56-61"">MMP-9</span> inhibition in the presence of COX inhibitor prevents the development of experimental <span class=""disease"" id=""20213226-5-147-166"">diabetic neuropathy</span> in rats and can be a potential approach for the treatment.",CTD_human
1,0,Biomarker,C0017636,Glioblastoma,disease,U87MG,4318,MMP9,MMP-9,CTD_human,16598420,Our results also show that treatment of U87MG cells with the two isoflavones induced decreases in the enzymatic activity of MMP-9 and the protein levels of MT1-MMP and uPAR.,0.218623999817222,"Our results also show that treatment of <span class=""disease"" id=""16598420-9-40-45"">U87MG</span> cells with the two isoflavones induced decreases in the enzymatic activity of <span class=""gene"" id=""16598420-9-124-129"">MMP-9</span> and the protein levels of MT1-MMP and uPAR.",CTD_human
1,0,Biomarker,C0024117,Chronic Obstructive Airway Disease,disease,COPD,4318,MMP9,MMP-9,CTD_human,19299917,"However, it remained uncertain how cigarette smoke induced MMP-9 and how simvastatin inhibited cigarette smoke-induced MMP-9 expression in alveolar macrophages (AMs), a major source of MMP-9 in the lungs of COPD patients.",0.24946823136616503,"However, it remained uncertain how cigarette smoke induced <span class=""gene"" id=""19299917-3-59-64"">MMP-9</span> and how simvastatin inhibited cigarette smoke-induced <span class=""gene"" id=""19299917-3-119-124"">MMP-9</span> expression in alveolar macrophages (AMs), a major source of <span class=""gene"" id=""19299917-3-185-190"">MMP-9</span> in the lungs of <span class=""disease"" id=""19299917-3-207-211"">COPD</span> patients.",CTD_human
1,0,Biomarker,C0024796,Marfan Syndrome,disease,MFS,4318,MMP9,MMP-9,CTD_human,18178469,"This study demonstrates that doxycycline significantly delays aneurysm rupture in MFS-like mice by inhibiting expression of tissue MMP-2 and MMP-9 and thus, degradation of the elastic matrix.",0.2,"This study demonstrates that doxycycline significantly delays aneurysm rupture in <span class=""disease"" id=""18178469-15-82-85"">MFS</span>-like mice by inhibiting expression of tissue MMP-2 and <span class=""gene"" id=""18178469-15-141-146"">MMP-9</span> and thus, degradation of the elastic matrix.",CTD_human
1,0,Biomarker,C0026552,Morphine Dependence,disease,morphine dependence,4318,MMP9,MMP-9,CTD_human,20519536,"Thus, we hypothesize that spinal MMP-9 may contribute to the development of morphine dependence primarily through neuronal activation and interaction with NR1 and NR2B receptors via integrin-beta1 and NO pathways.",0.2,"Thus, we hypothesize that spinal <span class=""gene"" id=""20519536-9-33-38"">MMP-9</span> may contribute to the development of <span class=""disease"" id=""20519536-9-76-95"">morphine dependence</span> primarily through neuronal activation and interaction with NR1 and NR2B receptors via integrin-beta1 and NO pathways.",CTD_human
2,0,Biomarker,C0027051,Myocardial Infarction,disease,MI,4318,MMP9,MMP-9,CTD_human,24358288,MMP-9 protein levels were increased in the non-infarct region of WT-MI vs WT-sham.,0.307311263865792,"<span class=""gene"" id=""24358288-12-0-5"">MMP-9</span> protein levels were increased in the non-infarct region of WT-<span class=""disease"" id=""24358288-12-68-70"">MI</span> vs WT-sham.",CTD_human
5,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastasis,4318,MMP9,MMP-9,CTD_human,15659795,"In contrast, the metastasis-derived COH tumor expressed very high levels of active MMP-9.",0.40694010429895505,"In contrast, the <span class=""disease"" id=""15659795-9-17-27"">metastasis</span>-derived COH tumor expressed very high levels of active <span class=""gene"" id=""15659795-9-83-88"">MMP-9</span>.",CTD_human
5,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastasis,4318,MMP9,MMP-9,CTD_human,21209944,"Treatment of mice with resveratrol and TRAIL alone inhibited angiogenesis (as demonstrated by reduced number of blood vessels, and VEGF and VEGFR2 positive cells) and markers of metastasis (MMP-2 and MMP-9).",0.40694010429895505,"Treatment of mice with resveratrol and TRAIL alone inhibited angiogenesis (as demonstrated by reduced number of blood vessels, and VEGF and VEGFR2 positive cells) and markers of <span class=""disease"" id=""21209944-7-178-188"">metastasis</span> (MMP-2 and <span class=""gene"" id=""21209944-7-200-205"">MMP-9</span>).",CTD_human
1,0,Biomarker,C0034069,Pulmonary Fibrosis,disease,pulmonary fibrosis,4318,MMP9,MMP-9,CTD_human,21468558,"In this study, we examined the sequential expression of MMP-2, MMP-9 and TIMP-1 in a rat model of pulmonary fibrosis induced by PQ.",0.20082418035263896,"In this study, we examined the sequential expression of MMP-2, <span class=""gene"" id=""21468558-3-63-68"">MMP-9</span> and TIMP-1 in a rat model of <span class=""disease"" id=""21468558-3-98-116"">pulmonary fibrosis</span> induced by PQ.",CTD_human
1,0,Biomarker,C0038358,Gastric ulcer,disease,gastric ulceration,4318,MMP9,MMP-9,CTD_human,17603938,These findings furnish a novel MMP-9-mediated pathway and its inhibition via proinflammatory cytokines by famotidine in ethanol-induced gastric ulceration.,0.202956482091714,"These findings furnish a novel <span class=""gene"" id=""17603938-11-31-36"">MMP-9</span>-mediated pathway and its inhibition via proinflammatory cytokines by famotidine in ethanol-induced <span class=""disease"" id=""17603938-11-136-154"">gastric ulceration</span>.",CTD_human
1,0,Biomarker,C0162871,"Aortic Aneurysm, Abdominal",disease,abdominal aortic aneurysm,4318,MMP9,MMP-9,CTD_human,17196988,Experimental abdominal aortic aneurysm formation is associated with early increases in MnSOD expression and an increase in MMP-9 activity.,0.23657210661709,"Experimental <span class=""disease"" id=""17196988-17-13-38"">abdominal aortic aneurysm</span> formation is associated with early increases in MnSOD expression and an increase in <span class=""gene"" id=""17196988-17-123-128"">MMP-9</span> activity.",CTD_human
1,0,Biomarker,C0162872,"Aortic Aneurysm, Thoracic",disease,thoracic aortic aneurysms,4318,MMP9,matrix metalloproteinase 9,CTD_human,16159824,Effects of deletion of the matrix metalloproteinase 9 gene on development of murine thoracic aortic aneurysms.,0.20054945356842604,"Effects of deletion of the <span class=""gene"" id=""16159824-0-27-53"">matrix metalloproteinase 9</span> gene on development of murine <span class=""disease"" id=""16159824-0-84-109"">thoracic aortic aneurysms</span>.",CTD_human
1,0,Biomarker,C0243026,Sepsis,disease,sepsis,4318,MMP9,MMP-9,CTD_human,16003065,"We have been interested in investigating the role of posttreatment with CMT-3 on hepatic MMP-9, TGF-beta1, and caspase-3 activity following sepsis.",0.28328236603324,"We have been interested in investigating the role of posttreatment with CMT-3 on hepatic <span class=""gene"" id=""16003065-4-89-94"">MMP-9</span>, TGF-beta1, and caspase-3 activity following <span class=""disease"" id=""16003065-4-140-146"">sepsis</span>.",CTD_human
1,0,Biomarker,C0340288,Stable angina,disease,SAP,4318,MMP9,MMP-9,CTD_human,20981132,"(1) Expressions of TLR4, levels of TNF-? and MMP-9 were increased and the rate was rising from the control group, to SAP group and then to ACS group.",0.201098907136852,"(1) Expressions of TLR4, levels of TNF-&alpha; and <span class=""gene"" id=""20981132-6-45-50"">MMP-9</span> were increased and the rate was rising from the control group, to <span class=""disease"" id=""20981132-6-117-120"">SAP</span> group and then to ACS group.",CTD_human
1,0,Biomarker,C0432291,Mandibuloacral dysostosis,disease,MADA,4318,MMP9,MMP-9,CTD_human,18554282,"These data suggest a possible involvement of MMP-9 in MADA disease, underlying the potential use in diagnosis and therapy.",0.200274726784213,"These data suggest a possible involvement of <span class=""gene"" id=""18554282-9-45-50"">MMP-9</span> in <span class=""disease"" id=""18554282-9-54-58"">MADA</span> disease, underlying the potential use in diagnosis and therapy.",CTD_human
1,0,Biomarker,C0948089,Acute Coronary Syndrome,disease,acute coronary syndromes,4318,MMP9,matrix metalloproteinase-9,CTD_human,20981132,"Expression of toll-like receptor 4, tumor necrosis factor- alpha, matrix metalloproteinase-9 and effects of benazepril in patients with acute coronary syndromes.",0.21433527120476997,"Expression of toll-like receptor 4, tumor necrosis factor- alpha, <span class=""gene"" id=""20981132-0-66-92"">matrix metalloproteinase-9</span> and effects of benazepril in patients with <span class=""disease"" id=""20981132-0-136-160"">acute coronary syndromes</span>.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,hepatocellular carcinoma,4318,MMP9,MMP-9,CTD_human,20084675,Our results reveal that BA exerts its anti-metastatic effect against DEN-induced hepatocellular carcinoma by inhibiting the activities and expressions of MMP-2 and MMP-9.,0.242625865626763,"Our results reveal that BA exerts its anti-metastatic effect against DEN-induced <span class=""disease"" id=""20084675-9-81-105"">hepatocellular carcinoma</span> by inhibiting the activities and expressions of MMP-2 and <span class=""gene"" id=""20084675-9-164-169"">MMP-9</span>.",CTD_human
1,0,Biomarker,C0004096,Asthma,disease,asthma,4319,MMP10,MMP10,CTD_human,16926187,"Because remodeling of airway epithelium is a feature of chronic asthma, the up-regulation of MMP10 and TIMP3 by NPS-NPSR1 signaling may be of relevance in the pathogenesis of asthma.",0.200274726784213,"Because remodeling of airway epithelium is a feature of chronic asthma, the up-regulation of <span class=""gene"" id=""16926187-8-93-98"">MMP10</span> and TIMP3 by NPS-NPSR1 signaling may be of relevance in the pathogenesis of <span class=""disease"" id=""16926187-8-175-181"">asthma</span>.",CTD_human
1,0,Biomarker,C0024121,Lung Neoplasms,group,lung tumor,4319,MMP10,Mmp10,CTD_human,22022614,"We conclude that Mmp10 plays an important role in lung tumor initiation via maintenance of a highly tumorigenic, cancer-initiating, stem-like cell population, and that Mmp10 expression is associated with stem-like, highly metastatic genotypes in human lung cancers.",0.20328236603324,"We conclude that <span class=""gene"" id=""22022614-11-17-22"">Mmp10</span> plays an important role in <span class=""disease"" id=""22022614-11-50-60"">lung tumor</span> initiation via maintenance of a highly tumorigenic, cancer-initiating, stem-like cell population, and that <span class=""gene"" id=""22022614-11-168-173"">Mmp10</span> expression is associated with stem-like, highly metastatic genotypes in human lung cancers.",CTD_human
1,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,tumor metastasis,4319,MMP10,MMP10,CTD_human,22022614,Gene set enhancement analysis (GSEA) demonstrates that elevated MMP10 expression correlates with both cancer stem cell and tumor metastasis genomic signatures in human lung cancer.,0.201373633921065,"Gene set enhancement analysis (GSEA) demonstrates that elevated <span class=""gene"" id=""22022614-9-64-69"">MMP10</span> expression correlates with both cancer stem cell and <span class=""disease"" id=""22022614-9-123-139"">tumor metastasis</span> genomic signatures in human lung cancer.",CTD_human
1,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,non-small cell lung cancer,4320,MMP11,stromelysin 3,CTD_human,10741738,Overexpression level of stromelysin 3 is related to the lymph node involvement in non-small cell lung cancer.,0.20054945356842604,"Overexpression level of <span class=""gene"" id=""10741738-0-24-37"">stromelysin 3</span> is related to the lymph node involvement in <span class=""disease"" id=""10741738-0-82-108"">non-small cell lung cancer</span>.",CTD_human
2,0,Biomarker,C0034067,Pulmonary Emphysema,disease,emphysema,4321,MMP12,Mmp12,CTD_human,12634787,Loss of integrin alpha(v)beta6-mediated TGF-beta activation causes Mmp12-dependent emphysema.,0.203296721410557,"Loss of integrin alpha(v)beta6-mediated TGF-beta activation causes <span class=""gene"" id=""12634787-0-67-72"">Mmp12</span>-dependent <span class=""disease"" id=""12634787-0-83-92"">emphysema</span>.",CTD_human
1,0,Biomarker,C0376634,Craniofacial Abnormalities,group,craniofacial abnormalities,4322,MMP13,MMP-13,CTD_human,17728286,"Acute exposure to dexamethasone and hydrocortisone resulted in abnormal zebra fish development including craniofacial abnormalities, altered somitogenesis, blood pooling and pericardial and yolk sac edema as well as increased MMP-13 mRNA and activity at 72 hpf.",0.2,"Acute exposure to dexamethasone and hydrocortisone resulted in abnormal zebra fish development including <span class=""disease"" id=""17728286-9-105-131"">craniofacial abnormalities</span>, altered somitogenesis, blood pooling and pericardial and yolk sac edema as well as increased <span class=""gene"" id=""17728286-9-226-232"">MMP-13</span> mRNA and activity at 72 hpf.",CTD_human
1,0,Biomarker,C0024117,Chronic Obstructive Airway Disease,disease,COPD,4323,MMP14,MMP14,CTD_human,19661247,"Taken together, these findings implicate acrolein-induced MMP14 expression and activity in mucin production in COPD.",0.20541466777231498,"Taken together, these findings implicate acrolein-induced <span class=""gene"" id=""19661247-14-58-63"">MMP14</span> expression and activity in mucin production in <span class=""disease"" id=""19661247-14-111-115"">COPD</span>.",CTD_human
1,0,Biomarker,C0162871,"Aortic Aneurysm, Abdominal",disease,AAA,4323,MMP14,MT1-MMP,CTD_human,19010778,"These studies demonstrate that destruction of the elastin fiber network during AAA formation is dependent on macrophage-derived MT1-MMP, which unexpectedly serves as a direct-acting regulator of macrophage proteolytic activity.",0.20054945356842604,"These studies demonstrate that destruction of the elastin fiber network during <span class=""disease"" id=""19010778-7-79-82"">AAA</span> formation is dependent on macrophage-derived <span class=""gene"" id=""19010778-7-128-135"">MT1-MMP</span>, which unexpectedly serves as a direct-acting regulator of macrophage proteolytic activity.",CTD_human
1,1,Biomarker,C0038868,Progressive supranuclear palsy,disease,PSP,4336,MOBP,MOBP,CTD_human,21685912,"We found significant previously unidentified signals (P < 5 × 10(-8)) associated with PSP risk at STX6, EIF2AK3 and MOBP.",0.200274726784213,"We found significant previously unidentified signals (P &lt; 5 &times; 10(-8)) associated with <span class=""disease"" id=""21685912-5-86-89"">PSP</span> risk at STX6, EIF2AK3 and <span class=""gene"" id=""21685912-5-116-120"">MOBP</span>.",CTD_human
3,0,Biomarker,C0025202,melanoma,disease,melanoma,434,ASIP,agouti signaling protein,CTD_human,18641652,"Gray horses carrying a loss-of-function mutation in ASIP (agouti signaling protein) had a higher incidence of melanoma, implying that increased melanocortin-1 receptor signaling promotes melanoma development in Gray horses.",0.22205465318574802,"Gray horses carrying a loss-of-function mutation in <span class=""gene"" id=""18641652-4-52-56"">ASIP</span> (<span class=""gene"" id=""18641652-4-58-82"">agouti signaling protein</span>) had a higher incidence of <span class=""disease"" id=""18641652-4-110-118"">melanoma</span>, implying that increased melanocortin-1 receptor signaling promotes <span class=""disease"" id=""18641652-4-187-195"">melanoma</span> development in Gray horses.",CTD_human
3,0,Biomarker,C0025202,melanoma,disease,melanoma,434,ASIP,ASIP,CTD_human,21983785,"In this discovery phase, we confirm several previously characterized melanoma-associated loci at MC1R, ASIP and MTAP-CDKN2A.",0.22205465318574802,"In this discovery phase, we confirm several previously characterized <span class=""disease"" id=""21983785-2-69-77"">melanoma</span>-associated loci at MC1R, <span class=""gene"" id=""21983785-2-103-107"">ASIP</span> and MTAP-CDKN2A.",CTD_human
3,0,Biomarker,C0025202,melanoma,disease,cutaneous melanoma,434,ASIP,ASIP,CTD_human,18488027,ASIP and TYR pigmentation variants associate with cutaneous melanoma and basal cell carcinoma.,0.22205465318574802,"<span class=""gene"" id=""18488027-0-0-4"">ASIP</span> and TYR pigmentation variants associate with <span class=""disease"" id=""18488027-0-50-68"">cutaneous melanoma</span> and basal cell carcinoma.",CTD_human
2,0,Biomarker,C0836924,Thrombocytosis,disease,thrombocytosis,4352,MPL,thrombopoietin receptor,CTD_human,16484586,"In contrast to the acquired MPDs, mutations of the erythropoietin receptor and thrombopoietin receptor have been identified in familial forms of nonclonal erythrocytosis and thrombocytosis, respectively.",0.41855848728259204,"In contrast to the acquired MPDs, mutations of the erythropoietin receptor and <span class=""gene"" id=""16484586-4-79-102"">thrombopoietin receptor</span> have been identified in familial forms of nonclonal erythrocytosis and <span class=""disease"" id=""16484586-4-174-188"">thrombocytosis</span>, respectively.",CTD_human;HPO
1,0,Biomarker,C0002395,Alzheimer's Disease,disease,Alzheimer disease,4353,MPO,MPO,CTD_human,15023809,Increased risk for Alzheimer disease with the interaction of MPO and A2M polymorphisms.,0.21992235144667302,"Increased risk for <span class=""disease"" id=""15023809-0-19-36"">Alzheimer disease</span> with the interaction of <span class=""gene"" id=""15023809-0-61-64"">MPO</span> and A2M polymorphisms.",CTD_human
2,0,Biomarker,C0003873,Rheumatoid Arthritis,disease,rheumatoid arthritis,4353,MPO,myeloperoxidase,CTD_human,26001728,Thrombin inhibits the anti-myeloperoxidase and ferroxidase functions of ceruloplasmin: relevance in rheumatoid arthritis.,0.20082418035263896,"Thrombin inhibits the anti-<span class=""gene"" id=""26001728-0-27-42"">myeloperoxidase</span> and ferroxidase functions of ceruloplasmin: relevance in <span class=""disease"" id=""26001728-0-100-120"">rheumatoid arthritis</span>.",CTD_human
1,0,Biomarker,C0005695,Bladder Neoplasm,disease,bladder cancer,4353,MPO,MPO,CTD_human,14729580,"Genetic polymorphisms of MPO, COMT, MnSOD, NQO1, interactions with environmental exposures and bladder cancer risk.",0.202956482091714,"Genetic polymorphisms of <span class=""gene"" id=""14729580-0-25-28"">MPO</span>, COMT, MnSOD, NQO1, interactions with environmental exposures and <span class=""disease"" id=""14729580-0-95-109"">bladder cancer</span> risk.",CTD_human
1,0,Biomarker,C0007222,Cardiovascular Diseases,group,cardiovascular disease,4353,MPO,MPO,CTD_human,19326902,"Elevated plasma MPO levels are a strong independent risk factor, and predictor of outcomes, for cardiovascular disease.",0.20487956958120604,"Elevated plasma <span class=""gene"" id=""19326902-3-16-19"">MPO</span> levels are a strong independent risk factor, and predictor of outcomes, for <span class=""disease"" id=""19326902-3-96-118"">cardiovascular disease</span>.",CTD_human
1,0,Biomarker,C0009319,Colitis,disease,colitis,4353,MPO,MPO,CTD_human,23810507,"Both nicotine and huperzine A reduced the extent of colonic lesions, increased colonic MDA level, high MPO activity and NF-?B expression in the colitis group.",0.203021994626344,"Both nicotine and huperzine A reduced the extent of colonic lesions, increased colonic MDA level, high <span class=""gene"" id=""23810507-11-103-106"">MPO</span> activity and NF-&kappa;B expression in the <span class=""disease"" id=""23810507-11-144-151"">colitis</span> group.",CTD_human
2,0,Biomarker,C0023891,"Liver Cirrhosis, Alcoholic",disease,alcoholic cirrhosis,4353,MPO,Myeloperoxidase,CTD_human,19731237,Myeloperoxidase and superoxide dismutase 2 polymorphisms comodulate the risk of hepatocellular carcinoma and death in alcoholic cirrhosis.,0.202681755307501,"<span class=""gene"" id=""19731237-0-0-15"">Myeloperoxidase</span> and superoxide dismutase 2 polymorphisms comodulate the risk of hepatocellular carcinoma and death in <span class=""disease"" id=""19731237-0-118-137"">alcoholic cirrhosis</span>.",CTD_human
1,0,Biomarker,C0030305,Pancreatitis,disease,pancreatitis,4353,MPO,MPO,CTD_human,16440434,"The serum amylase, pancreatic MPO and the score of pathologic damage increased after the induction of pancreatitis, early (3, 6 h) SAP samples were characterized by decreased pancreatic SOD and increased pancreatic MDA.",0.2,"The serum amylase, pancreatic <span class=""gene"" id=""16440434-8-30-33"">MPO</span> and the score of pathologic damage increased after the induction of <span class=""disease"" id=""16440434-8-102-114"">pancreatitis</span>, early (3, 6 h) SAP samples were characterized by decreased pancreatic SOD and increased pancreatic MDA.",CTD_human
1,0,Biomarker,C0032927,Precancerous Conditions,phenotype,premalignant,4353,MPO,MPO,CTD_human,14580687,"Our findings, although based on small numbers, suggest that the oxidative stress genes MPO and CAT may influence the risk of arsenic-induced premalignant hyperkeratotic skin lesions.",0.202681755307501,"Our findings, although based on small numbers, suggest that the oxidative stress genes <span class=""gene"" id=""14580687-6-87-90"">MPO</span> and CAT may influence the risk of arsenic-induced <span class=""disease"" id=""14580687-6-141-153"">premalignant</span> hyperkeratotic skin lesions.",CTD_human
1,0,Biomarker,C0042109,Urticaria,disease,AIU,4353,MPO,MPO,CTD_human,18204966,"Within the AIU groups, significant correlations were noted between the levels of MPO and IL-8, and IL-8 and IL-18.",0.2,"Within the <span class=""disease"" id=""18204966-6-11-14"">AIU</span> groups, significant correlations were noted between the levels of <span class=""gene"" id=""18204966-6-81-84"">MPO</span> and IL-8, and IL-8 and IL-18.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,hepatocellular carcinoma,4353,MPO,Myeloperoxidase,CTD_human,19731237,Myeloperoxidase and superoxide dismutase 2 polymorphisms comodulate the risk of hepatocellular carcinoma and death in alcoholic cirrhosis.,0.20350593566014002,"<span class=""gene"" id=""19731237-0-0-15"">Myeloperoxidase</span> and superoxide dismutase 2 polymorphisms comodulate the risk of <span class=""disease"" id=""19731237-0-80-104"">hepatocellular carcinoma</span> and death in alcoholic cirrhosis.",CTD_human
1,0,Biomarker,C0017668,Focal glomerulosclerosis,disease,FSGS,4358,MPV17,Mpv17,CTD_human,18818194,"The coat of the Mpv17(-/-) mice turned gray early in adulthood, and 18-month or older mice developed focal segmental glomerulosclerosis (FSGS) with massive proteinuria.",0.20054945356842604,"The coat of the <span class=""gene"" id=""18818194-9-16-21"">Mpv17</span>(-/-) mice turned gray early in adulthood, and 18-month or older mice developed <span class=""disease"" id=""18818194-9-101-135"">focal segmental glomerulosclerosis</span> (<span class=""disease"" id=""18818194-9-137-141"">FSGS</span>) with massive proteinuria.",CTD_human
1,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,4363,ABCC1,MRP1,CTD_human,17272743,MRP1 plays a crucial role in the genesis of multiple vascular abnormalities that accompany hypertension and its presence is essential for the hypertensive response to angiotensin II.,0.2,"<span class=""gene"" id=""17272743-11-0-4"">MRP1</span> plays a crucial role in the genesis of multiple vascular abnormalities that accompany <span class=""disease"" id=""17272743-11-91-103"">hypertension</span> and its presence is essential for the hypertensive response to angiotensin II.",CTD_human
1,0,Biomarker,C0031117,Peripheral Neuropathy,group,peripheral neuropathy,4363,ABCC1,ABCC1,CTD_human,20864405,"Late-onset vincristine-induced peripheral neuropathy was associated with the presence of SNPs in genes involved in absorption, distribution, metabolism, and excretion-eg, rs1413239 in DPYD (3·29, 1·47-7·37, 5·40×10(-3)) and rs3887412 in ABCC1 (3·36, 1·47-7·67, p=5·70×10(-3)).",0.200274726784213,"Late-onset vincristine-induced <span class=""disease"" id=""20864405-14-31-52"">peripheral neuropathy</span> was associated with the presence of SNPs in genes involved in absorption, distribution, metabolism, and excretion-eg, rs1413239 in DPYD (3·29, 1·47-7·37, 5·40&times;10(-3)) and rs3887412 in <span class=""gene"" id=""20864405-14-237-242"">ABCC1</span> (3·36, 1·47-7·67, p=5·70&times;10(-3)).",CTD_human
1,0,Biomarker,C0034091,Pulmonary Veno-Occlusive Disease (disorder),disease,pulmonary veno-occlusive disease,440275,EIF2AK4,EIF2AK4,CTD_human,24292273,"EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension.",0.4010989071368521,"<span class=""gene"" id=""24292273-0-0-7"">EIF2AK4</span> mutations cause <span class=""disease"" id=""24292273-0-24-56"">pulmonary veno-occlusive disease</span>, a recessive form of pulmonary hypertension.",CTD_human;ORPHANET
1,0,Biomarker,C0028960,Oligospermia,disease,oligozoospermia,440822,PIWIL3,HIWI3,CTD_human,20940137,"The variant-containing genotypes of HIWI2 rs508485 exhibited a significantly increased risk, with an odds ratios (OR) of 1.49 [95% confidence interval (CI), 1.02-2.18], and individuals with HIWI3 non-synonymous rs11703684 variant genotypes exhibited a significantly reduced oligozoospermia risk (OR = 0.70; 95% CI, 0.49-1.00).",0.202681755307501,"The variant-containing genotypes of HIWI2 rs508485 exhibited a significantly increased risk, with an odds ratios (OR) of 1.49 [95% confidence interval (CI), 1.02-2.18], and individuals with <span class=""gene"" id=""20940137-7-190-195"">HIWI3</span> non-synonymous rs11703684 variant genotypes exhibited a significantly reduced <span class=""disease"" id=""20940137-7-274-289"">oligozoospermia</span> risk (OR = 0.70; 95% CI, 0.49-1.00).",CTD_human
1,2,Biomarker,C0341106,Eosinophilic esophagitis,disease,EoE,440854,CAPN14,CAPN14,CTD_human,25017104,"We propose a model to explain the tissue-specific nature of EoE that involves the interplay of allergic sensitization with an EoE-specific, IL-13-inducible esophageal response involving CAPN14.",0.20054945356842604,"We propose a model to explain the tissue-specific nature of <span class=""disease"" id=""25017104-6-60-63"">EoE</span> that involves the interplay of allergic sensitization with an <span class=""disease"" id=""25017104-6-126-129"">EoE</span>-specific, IL-13-inducible esophageal response involving <span class=""gene"" id=""25017104-6-186-192"">CAPN14</span>.",CTD_human
1,0,Therapeutic,C0029463,Osteosarcoma,disease,osteosarcoma,442894,MIR302B,miR-302b,CTD_human,23845851,Epirubicin-mediated expression of miR-302b is involved in osteosarcoma apoptosis and cell cycle regulation.,0.2,"Epirubicin-mediated expression of <span class=""gene"" id=""23845851-0-34-42"">miR-302b</span> is involved in <span class=""disease"" id=""23845851-0-58-70"">osteosarcoma</span> apoptosis and cell cycle regulation.",CTD_human
1,0,Biomarker,C0029463,Osteosarcoma,disease,osteosarcomas,442901,MIR328,miR-328,CTD_human,25605016,Upregulation of miR-328 and inhibition of CREB-DNA-binding activity are critical for resveratrol-mediated suppression of matrix metalloproteinase-2 and subsequent metastatic ability in human osteosarcomas.,0.200274726784213,"Upregulation of <span class=""gene"" id=""25605016-0-16-23"">miR-328</span> and inhibition of CREB-DNA-binding activity are critical for resveratrol-mediated suppression of matrix metalloproteinase-2 and subsequent metastatic ability in human <span class=""disease"" id=""25605016-0-191-204"">osteosarcomas</span>.",CTD_human
1,0,Biomarker,C0025202,melanoma,disease,melanoma,442908,MIR340,MicroRNA-340,CTD_human,25043973,MicroRNA-340 as a modulator of RAS-RAF-MAPK signaling in melanoma.,0.20054945356842604,"<span class=""gene"" id=""25043973-0-0-12"">MicroRNA-340</span> as a modulator of RAS-RAF-MAPK signaling in <span class=""disease"" id=""25043973-0-57-65"">melanoma</span>.",CTD_human
10,35,Biomarker,C0206307,Canavan Disease,disease,Canavan disease,443,ASPA,aspartoacylase,CTD_human,17194761,"Structure of aspartoacylase, the brain enzyme impaired in Canavan disease.",0.500785012310931,"Structure of <span class=""gene"" id=""17194761-0-13-27"">aspartoacylase</span>, the brain enzyme impaired in <span class=""disease"" id=""17194761-0-58-73"">Canavan disease</span>.",CTD_human;UNIPROT
10,35,Biomarker,C0206307,Canavan Disease,disease,Canavan disease,443,ASPA,aspartoacylase,CTD_human,17027983,"Identification of the zinc binding ligands and the catalytic residue in human aspartoacylase, an enzyme involved in Canavan disease.",0.500785012310931,"Identification of the zinc binding ligands and the catalytic residue in human <span class=""gene"" id=""17027983-0-78-92"">aspartoacylase</span>, an enzyme involved in <span class=""disease"" id=""17027983-0-116-131"">Canavan disease</span>.",CTD_human;UNIPROT
2,1,Biomarker,C0009324,Ulcerative Colitis,disease,ulcerative colitis,4485,MST1,MST1,CTD_human,18438406,"We also show that several risk loci are common to ulcerative colitis and Crohn's disease (IL23R, IL12B, HLA, NKX2-3 and MST1), whereas autophagy genes ATG16L1 and IRGM, along with NOD2 (also known as CARD15), are specific for Crohn's disease.",0.20974478378509498,"We also show that several risk loci are common to <span class=""disease"" id=""18438406-2-50-68"">ulcerative colitis</span> and Crohn's disease (IL23R, IL12B, HLA, NKX2-3 and <span class=""gene"" id=""18438406-2-120-124"">MST1</span>), whereas autophagy genes ATG16L1 and IRGM, along with NOD2 (also known as CARD15), are specific for Crohn's disease.",CTD_human
1,1,Biomarker,C0010346,Crohn Disease,disease,Crohn's disease,4485,MST1,MST1,CTD_human,18438406,"We also show that several risk loci are common to ulcerative colitis and Crohn's disease (IL23R, IL12B, HLA, NKX2-3 and MST1), whereas autophagy genes ATG16L1 and IRGM, along with NOD2 (also known as CARD15), are specific for Crohn's disease.",0.209968353411995,"We also show that several risk loci are common to ulcerative colitis and <span class=""disease"" id=""18438406-2-73-88"">Crohn's disease</span> (IL23R, IL12B, HLA, NKX2-3 and <span class=""gene"" id=""18438406-2-120-124"">MST1</span>), whereas autophagy genes ATG16L1 and IRGM, along with NOD2 (also known as CARD15), are specific for <span class=""disease"" id=""18438406-2-226-241"">Crohn's disease</span>.",CTD_human
3,0,Biomarker,C0008925,Cleft Palate,disease,cleft palate,4487,MSX1,Msx1,CTD_human,12163415,Rescue of cleft palate in Msx1-deficient mice by transgenic Bmp4 reveals a network of BMP and Shh signaling in the regulation of mammalian palatogenesis.,0.431524710186629,"Rescue of <span class=""disease"" id=""12163415-0-10-22"">cleft palate</span> in <span class=""gene"" id=""12163415-0-26-30"">Msx1</span>-deficient mice by transgenic Bmp4 reveals a network of BMP and Shh signaling in the regulation of mammalian palatogenesis.",CTD_human;HPO
3,0,Biomarker,C0008925,Cleft Palate,disease,cleft palate,4487,MSX1,Msx1,CTD_human,12701100,Transgenic rescue of the cleft palate of Msx1(-/-) mice overcame the neonatal lethality and allowed Msx1(-/-) mice to grow into adulthood but retain the phenotype of the absence of the malleal processus brevis.,0.431524710186629,"Transgenic rescue of the <span class=""disease"" id=""12701100-7-25-37"">cleft palate</span> of <span class=""gene"" id=""12701100-7-41-45"">Msx1</span>(-/-) mice overcame the neonatal lethality and allowed <span class=""gene"" id=""12701100-7-100-104"">Msx1</span>(-/-) mice to grow into adulthood but retain the phenotype of the absence of the malleal processus brevis.",CTD_human;HPO
4,0,Biomarker,C0376634,Craniofacial Abnormalities,group,craniofacial abnormalities,4487,MSX1,Msx1,CTD_human,14654219,"The Msx1 gene controls many aspects of craniofacial development, as evidenced by craniofacial abnormalities seen in Msx1(-/-) mice, including the arrest of tooth development and the absence of the alveolar bone.",0.200274726784213,"The <span class=""gene"" id=""14654219-4-4-8"">Msx1</span> gene controls many aspects of craniofacial development, as evidenced by <span class=""disease"" id=""14654219-4-81-107"">craniofacial abnormalities</span> seen in <span class=""gene"" id=""14654219-4-116-120"">Msx1</span>(-/-) mice, including the arrest of tooth development and the absence of the alveolar bone.",CTD_human
4,0,Biomarker,C0376634,Craniofacial Abnormalities,group,craniofacial abnormalities,4487,MSX1,Msx1,CTD_human,12163415,"We have used Msx1-deficient mice as a model system that exhibits severe craniofacial abnormalities, including cleft secondary palate and lack of teeth, to study the genetic regulation of mammalian palatogenesis.",0.200274726784213,"We have used <span class=""gene"" id=""12163415-3-13-17"">Msx1</span>-deficient mice as a model system that exhibits severe <span class=""disease"" id=""12163415-3-72-98"">craniofacial abnormalities</span>, including cleft secondary palate and lack of teeth, to study the genetic regulation of mammalian palatogenesis.",CTD_human
1,0,Biomarker,C1956097,Wolf-Hirschhorn Syndrome,disease,Wolf-Hirschhorn syndrome,4487,MSX1,MSX1,CTD_human,14630905,MSX1 gene is deleted in Wolf-Hirschhorn syndrome patients with oligodontia.,0.20082418035263896,"<span class=""gene"" id=""14630905-0-0-4"">MSX1</span> gene is deleted in <span class=""disease"" id=""14630905-0-24-48"">Wolf-Hirschhorn syndrome</span> patients with oligodontia.",CTD_human
1,0,Biomarker,C0011849,Diabetes Mellitus,group,Diabetes,4502,MT2A,MT2A,CTD_human,27122239,Metallothionein MT2A A-5G Polymorphism as a Risk Factor for Chronic Kidney Disease and Diabetes: Cross-Sectional and Cohort Studies.,0.20054945356842604,"Metallothionein <span class=""gene"" id=""27122239-0-16-20"">MT2A</span> A-5G Polymorphism as a Risk Factor for Chronic Kidney Disease and <span class=""disease"" id=""27122239-0-87-95"">Diabetes</span>: Cross-Sectional and Cohort Studies.",CTD_human
1,0,Biomarker,C0005695,Bladder Neoplasm,disease,bladder cancer,4504,MT3,MT-3,CTD_human,16854967,The results provide strong evidence that MT-3 could be a biomarker for the development of high-grade bladder cancer and that the expression of the MT-3 gene is not involved in the in vitro malignant transformation of UROtsa cells by Cd(+2) and As(+3).,0.200274726784213,"The results provide strong evidence that MT-3 could be a biomarker for the development of high-grade <span class=""disease"" id=""16854967-9-101-115"">bladder cancer</span> and that the expression of the <span class=""gene"" id=""16854967-9-147-151"">MT-3</span> gene is not involved in the in vitro malignant transformation of UROtsa cells by Cd(+2) and As(+3).",CTD_human
1,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,NSCLC,4504,MT3,metallothionein 3,CTD_human,17043644,"Of the more than 200 genes upregulated by these treatments, three of these, neuronatin, metallothionein 3 and cystatin E/M, were frequently hypermethylated and transcriptionally downregulated in NSCLC cell lines and tumors.",0.200274726784213,"Of the more than 200 genes upregulated by these treatments, three of these, neuronatin, <span class=""gene"" id=""17043644-5-88-105"">metallothionein 3</span> and cystatin E/M, were frequently hypermethylated and transcriptionally downregulated in <span class=""disease"" id=""17043644-5-195-200"">NSCLC</span> cell lines and tumors.",CTD_human
1,0,Biomarker,C0027819,Neuroblastoma,disease,neuroblastoma,4513,COX2,COX-2,CTD_human,15492235,Treatment of established neuroblastoma xenografts in nude rats with the dual COX-1/COX-2 inhibitor diclofenac or the COX-2-specific inhibitor celecoxib significantly inhibited tumor growth in vivo (P < 0.001).,0.201098907136852,"Treatment of established <span class=""disease"" id=""15492235-6-25-38"">neuroblastoma</span> xenografts in nude rats with the dual COX-1/<span class=""gene"" id=""15492235-6-83-88"">COX-2</span> inhibitor diclofenac or the <span class=""gene"" id=""15492235-6-117-122"">COX-2</span>-specific inhibitor celecoxib significantly inhibited tumor growth in vivo (P &lt; 0.001).",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autistic disorder,4520,MTF1,MTF1,CTD_human,15446388,"We performed family-based association studies of polymorphisms in metal-regulatory transcription factor 1(MTF1), a multispecific organic anion transporter (ABCC1), proton-coupled divalent metal ion transporters (SLC11A3 and SLC11A2), paraoxonase 1 (PON1), and glutathione S-transferase (GSTP1) genes in 196 autistic disorder families.",0.2,"We performed family-based association studies of polymorphisms in <span class=""gene"" id=""15446388-4-66-105"">metal-regulatory transcription factor 1</span>(<span class=""gene"" id=""15446388-4-106-110"">MTF1</span>), a multispecific organic anion transporter (ABCC1), proton-coupled divalent metal ion transporters (SLC11A3 and SLC11A2), paraoxonase 1 (PON1), and glutathione S-transferase (GSTP1) genes in 196 <span class=""disease"" id=""15446388-4-307-324"">autistic disorder</span> families.",CTD_human
2,0,Biomarker,C0027794,Neural Tube Defects,group,NTD,4522,MTHFD1,MTHFD1,CTD_human,12384833,We conclude that genetic variation in the MTHFD1 gene is associated with an increase in the genetically determined risk that a woman will bear a child with NTD and that the gene may be associated with decreased embryo survival.,0.218614230060237,"We conclude that genetic variation in the <span class=""gene"" id=""12384833-8-42-48"">MTHFD1</span> gene is associated with an increase in the genetically determined risk that a woman will bear a child with <span class=""disease"" id=""12384833-8-156-159"">NTD</span> and that the gene may be associated with decreased embryo survival.",CTD_human
2,0,Biomarker,C0027794,Neural Tube Defects,group,NTD,4522,MTHFD1,MTHFD1,CTD_human,16552426,We have established that the MTHFD1 1958G>A polymorphism has a significant role in influencing a mother's risk of having an NTD-affected pregnancy in the Irish population.,0.218614230060237,"We have established that the <span class=""gene"" id=""16552426-8-29-35"">MTHFD1</span> 1958G&gt;A polymorphism has a significant role in influencing a mother's risk of having an <span class=""disease"" id=""16552426-8-124-127"">NTD</span>-affected pregnancy in the Irish population.",CTD_human
1,0,Biomarker,C0002170,Alopecia,disease,alopecia,4524,MTHFR,MTHFR,CTD_human,18381794,"Of these, only the MTHFR 677 C --> T SNP was associated with alopecia, and only in African Americans (p = 0.032).",0.20054945356842604,"Of these, only the <span class=""gene"" id=""18381794-11-19-24"">MTHFR</span> 677 C --&gt; T SNP was associated with <span class=""disease"" id=""18381794-11-61-69"">alopecia</span>, and only in African Americans (p = 0.032).",CTD_human
1,0,Biomarker,C0002395,Alzheimer's Disease,disease,Alzheimer disease,4524,MTHFR,MTHFR,CTD_human,17192785,"In addition to identifying the epsilon4 allele of APOE and related effects, we pinpointed over a dozen potential Alzheimer disease susceptibility genes (ACE, CHRNB2, CST3, ESR1, GAPDHS, IDE, MTHFR, NCSTN, PRNP, PSEN1, TF, TFAM and TNF) with statistically significant allelic summary odds ratios (ranging from 1.11-1.38 for risk alleles and 0.92-0.67 for protective alleles).",0.277063393256835,"In addition to identifying the epsilon4 allele of APOE and related effects, we pinpointed over a dozen potential <span class=""disease"" id=""17192785-5-113-130"">Alzheimer disease</span> susceptibility genes (ACE, CHRNB2, CST3, ESR1, GAPDHS, IDE, <span class=""gene"" id=""17192785-5-191-196"">MTHFR</span>, NCSTN, PRNP, PSEN1, TF, TFAM and TNF) with statistically significant allelic summary odds ratios (ranging from 1.11-1.38 for risk alleles and 0.92-0.67 for protective alleles).",CTD_human
2,0,Biomarker,C0002871,Anemia,disease,anemia,4524,MTHFR,MTHFR,CTD_human,19391036,"Subjects with MTHFR polymorphism for A1298C (AC, CC) had significantly higher MTX levels at 48 h (p = 0.02), and had more grade III/IV anemia (p = 0.02), thrombocytopenia (p = 0.0001), elevated AST levels (p = 0.04) and frequent febrile neutropenic episodes (p = 0.004).",0.205638237399215,"Subjects with <span class=""gene"" id=""19391036-6-14-19"">MTHFR</span> polymorphism for A1298C (AC, CC) had significantly higher MTX levels at 48 h (p = 0.02), and had more grade III/IV <span class=""disease"" id=""19391036-6-135-141"">anemia</span> (p = 0.02), thrombocytopenia (p = 0.0001), elevated AST levels (p = 0.04) and frequent febrile neutropenic episodes (p = 0.004).",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,AD,4524,MTHFR,MTHFR,CTD_human,19267885,"The current study investigated the metabolites in the methionine cycle, the transsulphuration pathway, folate, vitamin B(12) and the C677T polymorphism of the MTHFR gene in three groups of children diagnosed with AD (n= 15), AS (n= 5) and PDD-NOS (n= 19) and their age- and sex-matched controls (n= 25).",0.21100174801421803,"The current study investigated the metabolites in the methionine cycle, the transsulphuration pathway, folate, vitamin B(12) and the C677T polymorphism of the <span class=""gene"" id=""19267885-2-159-164"">MTHFR</span> gene in three groups of children diagnosed with <span class=""disease"" id=""19267885-2-213-215"">AD</span> (n= 15), AS (n= 5) and PDD-NOS (n= 19) and their age- and sex-matched controls (n= 25).",CTD_human
6,0,Biomarker,C0005586,Bipolar Disorder,disease,bipolar disorder,4524,MTHFR,MTHFR,CTD_human,17074966,"The authors performed a meta-analysis of studies examining the association between polymorphisms in the 5,10-methylenetetrahydrofolate reductase (MTHFR) gene, including MTHFR C677T and A1298C, and common psychiatric disorders, including unipolar depression, anxiety disorders, bipolar disorder, and schizophrenia.",0.420797688956625,"The authors performed a meta-analysis of studies examining the association between polymorphisms in the 5,10-methylenetetrahydrofolate reductase (<span class=""gene"" id=""17074966-1-146-151"">MTHFR</span>) gene, including MTHFR C677T and A1298C, and common psychiatric disorders, including unipolar depression, anxiety disorders, <span class=""disease"" id=""17074966-1-277-293"">bipolar disorder</span>, and schizophrenia.",CTD_human;PSYGENET
1,0,Biomarker,C0005695,Bladder Neoplasm,disease,bladder cancer,4524,MTHFR,MTHFR,CTD_human,22747749,Variation in As3MT and MTHFR is associated with bladder cancer among those exposed to relatively low concentrations of inorganic arsenic.,0.21653308547847502,"Variation in As3MT and <span class=""gene"" id=""22747749-10-23-28"">MTHFR</span> is associated with <span class=""disease"" id=""22747749-10-48-62"">bladder cancer</span> among those exposed to relatively low concentrations of inorganic arsenic.",CTD_human
2,0,Biomarker,C0007222,Cardiovascular Diseases,group,cardiovascular disease,4524,MTHFR,MTHFR,CTD_human,25050994,Correlations of MTHFR 677C>T polymorphism with cardiovascular disease in patients with end-stage renal disease: a meta-analysis.,0.32521507637662395,"Correlations of <span class=""gene"" id=""25050994-0-16-21"">MTHFR</span> 677C&gt;T polymorphism with <span class=""disease"" id=""25050994-0-47-69"">cardiovascular disease</span> in patients with end-stage renal disease: a meta-analysis.",CTD_human
2,0,Biomarker,C0007222,Cardiovascular Diseases,group,cardiovascular disease,4524,MTHFR,methylenetetrahydrofolate reductase,CTD_human,16958597,"The methylenetetrahydrofolate reductase C677T gene mutation is associated with hyperhomocysteinemia, cardiovascular disease and plasma B-type natriuretic peptide levels in Korea.",0.32521507637662395,"The <span class=""gene"" id=""16958597-0-4-39"">methylenetetrahydrofolate reductase</span> C677T gene mutation is associated with hyperhomocysteinemia, <span class=""disease"" id=""16958597-0-101-123"">cardiovascular disease</span> and plasma B-type natriuretic peptide levels in Korea.",CTD_human
1,0,Biomarker,C0009081,Congenital clubfoot,disease,clubfoot,4524,MTHFR,methylenetetrahydrofolate reductase,CTD_human,16936070,"The C677T polymorphism in the methylenetetrahydrofolate reductase gene (MTHFR), maternal use of folic acid supplements, and risk of isolated clubfoot: A case-parent-triad analysis.",0.202681755307501,"The C677T polymorphism in the <span class=""gene"" id=""16936070-0-30-65"">methylenetetrahydrofolate reductase</span> gene (MTHFR), maternal use of folic acid supplements, and risk of isolated <span class=""disease"" id=""16936070-0-141-149"">clubfoot</span>: A case-parent-triad analysis.",CTD_human
1,0,Biomarker,C0010068,Coronary heart disease,disease,CHD,4524,MTHFR,MTHFR,CTD_human,16792904,These results suggested that maternal MTHFR 677TT genotype was one of the risks to the occurrence of CHD in offspring but parents' CBS gene 833 T-->C mutation did not get involved in CHD.,0.32197577647533504,"These results suggested that maternal <span class=""gene"" id=""16792904-5-38-43"">MTHFR</span> 677TT genotype was one of the risks to the occurrence of <span class=""disease"" id=""16792904-5-101-104"">CHD</span> in offspring but parents' CBS gene 833 T--&gt;C mutation did not get involved in <span class=""disease"" id=""16792904-5-183-186"">CHD</span>.",CTD_human
4,0,Biomarker,C0013080,Down Syndrome,disease,Down syndrome,4524,MTHFR,MTHFR,CTD_human,16845273,The 677-1298 T-C haplotype at the MTHFR locus was also a risk factor for Down syndrome (P = 0.0022).,0.320241283506153,"The 677-1298 T-C haplotype at the <span class=""gene"" id=""16845273-7-34-39"">MTHFR</span> locus was also a risk factor for <span class=""disease"" id=""16845273-7-73-86"">Down syndrome</span> (P = 0.0022).",CTD_human
4,0,Biomarker,C0013080,Down Syndrome,disease,trisomy 21,4524,MTHFR,Methylenetetrahydrofolate reductase,CTD_human,16353284,Methylenetetrahydrofolate reductase gene polymorphisms and their association with trisomy 21.,0.320241283506153,"<span class=""gene"" id=""16353284-0-0-35"">Methylenetetrahydrofolate reductase</span> gene polymorphisms and their association with <span class=""disease"" id=""16353284-0-82-92"">trisomy 21</span>.",CTD_human
1,0,Biomarker,C0018133,Graft-vs-Host Disease,disease,graft-versus-host disease,4524,MTHFR,methylenetetrahydrofolate reductase,CTD_human,16518429,Donor methylenetetrahydrofolate reductase genotype is associated with graft-versus-host disease in hematopoietic stem cell transplant patients treated with methotrexate.,0.22308804778797,"Donor <span class=""gene"" id=""16518429-0-6-41"">methylenetetrahydrofolate reductase</span> genotype is associated with <span class=""disease"" id=""16518429-0-70-95"">graft-versus-host disease</span> in hematopoietic stem cell transplant patients treated with methotrexate.",CTD_human
1,0,Biomarker,C0018798,Congenital Heart Defects,group,congenital heart defects,4524,MTHFR,MTHFR,CTD_human,16524890,Maternal MTHFR 677C>T is a risk factor for congenital heart defects: effect modification by periconceptional folate supplementation.,0.247773299123906,"Maternal <span class=""gene"" id=""16524890-0-9-14"">MTHFR</span> 677C&gt;T is a risk factor for <span class=""disease"" id=""16524890-0-43-67"">congenital heart defects</span>: effect modification by periconceptional folate supplementation.",CTD_human
1,0,Biomarker,C0021364,Male infertility,phenotype,male infertility,4524,MTHFR,MTHFR,CTD_human,16861746,"By analysis of a large number of subjects and a more specific patient selection, we showed the first genetic evidence that MTHFR C677T, MS A2756G and MTRR A66G genotypes were independently associated with male infertility.",0.23132985131436298,"By analysis of a large number of subjects and a more specific patient selection, we showed the first genetic evidence that <span class=""gene"" id=""16861746-8-123-128"">MTHFR</span> C677T, MS A2756G and MTRR A66G genotypes were independently associated with <span class=""disease"" id=""16861746-8-205-221"">male infertility</span>.",CTD_human
1,0,Biomarker,C0023530,Leukopenia,disease,leukopenia,4524,MTHFR,MTHFR,CTD_human,19648163,"MTHFR 677C>T also increased the risk of leukopenia and gastrointestinal toxicity, whilst thymidylate synthase 28 bp repeat polymorphism increased the risk of anemia (odds ratio 8.48, 95% confidence interval 2.00-36.09).",0.204055389228567,"<span class=""gene"" id=""19648163-7-0-5"">MTHFR</span> 677C&gt;T also increased the risk of <span class=""disease"" id=""19648163-7-40-50"">leukopenia</span> and gastrointestinal toxicity, whilst thymidylate synthase 28 bp repeat polymorphism increased the risk of anemia (odds ratio 8.48, 95% confidence interval 2.00-36.09).",CTD_human
1,0,Biomarker,C0023895,Liver diseases,group,liver disease,4524,MTHFR,MTHFR,CTD_human,16877991,Our data suggest that folate intake and the MTHFR polymorphism represent a part of the link between antioxidant status and liver disease in obese adolescent girls.,0.209902840877365,"Our data suggest that folate intake and the <span class=""gene"" id=""16877991-12-44-49"">MTHFR</span> polymorphism represent a part of the link between antioxidant status and <span class=""disease"" id=""16877991-12-123-136"">liver disease</span> in obese adolescent girls.",CTD_human
1,0,Biomarker,C0024301,"Lymphoma, Follicular",disease,FL,4524,MTHFR,MTHFR,CTD_human,16410450,We report that the risk of FL was doubled by the association of one mutant allele at both MTHFR polymorphisms.,0.20591296418342803,"We report that the risk of <span class=""disease"" id=""16410450-5-27-29"">FL</span> was doubled by the association of one mutant allele at both <span class=""gene"" id=""16410450-5-90-95"">MTHFR</span> polymorphisms.",CTD_human
1,0,Biomarker,C0024305,"Lymphoma, Non-Hodgkin",disease,NHL,4524,MTHFR,MTHFR,CTD_human,17488658,"Our data suggest that MTHFR gene variants play a critical role in NHL outcome, possibly by interfering with the action of methotrexate with significant effects on toxicity and survival.",0.21856307290292498,"Our data suggest that <span class=""gene"" id=""17488658-15-22-27"">MTHFR</span> gene variants play a critical role in <span class=""disease"" id=""17488658-15-66-69"">NHL</span> outcome, possibly by interfering with the action of methotrexate with significant effects on toxicity and survival.",CTD_human
1,0,Biomarker,C0027794,Neural Tube Defects,group,neural tube defects,4524,MTHFR,MTHFR,CTD_human,23056169,Association of the maternal MTHFR C677T polymorphism with susceptibility to neural tube defects in offsprings: evidence from 25 case-control studies.,0.32851179778718104,"Association of the maternal <span class=""gene"" id=""23056169-0-28-33"">MTHFR</span> C677T polymorphism with susceptibility to <span class=""disease"" id=""23056169-0-76-95"">neural tube defects</span> in offsprings: evidence from 25 case-control studies.",CTD_human
3,0,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,4524,MTHFR,methylenetetrahydrofolate reductase,CTD_human,16641680,We measured the serum level of homocysteine/folate and methylenetetrahydrofolate reductase C677T/A1298C gene polymorphism in 235 patients with schizophrenia.,0.300258939496083,"We measured the serum level of homocysteine/folate and <span class=""gene"" id=""16641680-3-55-90"">methylenetetrahydrofolate reductase</span> C677T/A1298C gene polymorphism in 235 patients with <span class=""disease"" id=""16641680-3-143-156"">schizophrenia</span>.",CTD_human
3,0,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,4524,MTHFR,MTHFR,CTD_human,17074966,"The authors performed a meta-analysis of studies examining the association between polymorphisms in the 5,10-methylenetetrahydrofolate reductase (MTHFR) gene, including MTHFR C677T and A1298C, and common psychiatric disorders, including unipolar depression, anxiety disorders, bipolar disorder, and schizophrenia.",0.300258939496083,"The authors performed a meta-analysis of studies examining the association between polymorphisms in the 5,10-methylenetetrahydrofolate reductase (<span class=""gene"" id=""17074966-1-146-151"">MTHFR</span>) gene, including MTHFR C677T and A1298C, and common psychiatric disorders, including unipolar depression, anxiety disorders, bipolar disorder, and <span class=""disease"" id=""17074966-1-299-312"">schizophrenia</span>.",CTD_human
1,0,Biomarker,C0037928,Spinal Cord Diseases,group,myelopathy,4524,MTHFR,methylenetetrahydrofolate reductase,CTD_human,16361298,"Reversible nitrous oxide myelopathy and a polymorphism in the gene encoding 5,10-methylenetetrahydrofolate reductase.",0.200274726784213,"Reversible nitrous oxide <span class=""disease"" id=""16361298-0-25-35"">myelopathy</span> and a polymorphism in the gene encoding 5,10-<span class=""gene"" id=""16361298-0-81-116"">methylenetetrahydrofolate reductase</span>.",CTD_human
1,0,Biomarker,C0040034,Thrombocytopenia,phenotype,thrombocytopenia,4524,MTHFR,MTHFR,CTD_human,19391036,"Subjects with MTHFR polymorphism for A1298C (AC, CC) had significantly higher MTX levels at 48 h (p = 0.02), and had more grade III/IV anemia (p = 0.02), thrombocytopenia (p = 0.0001), elevated AST levels (p = 0.04) and frequent febrile neutropenic episodes (p = 0.004).",0.207495812354077,"Subjects with <span class=""gene"" id=""19391036-6-14-19"">MTHFR</span> polymorphism for A1298C (AC, CC) had significantly higher MTX levels at 48 h (p = 0.02), and had more grade III/IV anemia (p = 0.02), <span class=""disease"" id=""19391036-6-154-170"">thrombocytopenia</span> (p = 0.0001), elevated AST levels (p = 0.04) and frequent febrile neutropenic episodes (p = 0.004).",CTD_human
1,0,Biomarker,C0040156,Thyrotoxicosis,disease,thyrotoxicosis,4524,MTHFR,MTHFR,CTD_human,18941937,Cerebral sinus venous thrombosis in a subject with thyrotoxicosis and MTHFR gene polymorphism.,0.200274726784213,"Cerebral sinus venous thrombosis in a subject with <span class=""disease"" id=""18941937-0-51-65"">thyrotoxicosis</span> and <span class=""gene"" id=""18941937-0-70-75"">MTHFR</span> gene polymorphism.",CTD_human
1,0,Biomarker,C0042373,Vascular Diseases,group,vascular diseases,4524,MTHFR,MTHFR,CTD_human,19646848,MTHFR 677C/T polymorphism is associated with the risk of vascular diseases due to hyperhomocysteinemia.,0.23573983523908998,"<span class=""gene"" id=""19646848-8-0-5"">MTHFR</span> 677C/T polymorphism is associated with the risk of <span class=""disease"" id=""19646848-8-57-74"">vascular diseases</span> due to hyperhomocysteinemia.",CTD_human
1,0,Biomarker,C0206064,Microvascular Angina,disease,cardiac syndrome X,4524,MTHFR,MTHFR,CTD_human,17491230,Endothelial cell dysfunction in women with cardiac syndrome X and MTHFR C677T mutation.,0.202681755307501,"Endothelial cell dysfunction in women with <span class=""disease"" id=""17491230-0-43-61"">cardiac syndrome X</span> and <span class=""gene"" id=""17491230-0-66-71"">MTHFR</span> C677T mutation.",CTD_human
1,0,Biomarker,C0206708,Cervical Intraepithelial Neoplasia,disease,cervical intraepithelial neoplasia,4524,MTHFR,MTHFR,CTD_human,17303386,Protective association of MTHFR polymorphism on cervical intraepithelial neoplasia is modified by riboflavin status.,0.217031381889588,"Protective association of <span class=""gene"" id=""17303386-0-26-31"">MTHFR</span> polymorphism on <span class=""disease"" id=""17303386-0-48-82"">cervical intraepithelial neoplasia</span> is modified by riboflavin status.",CTD_human
11,0,Biomarker,C0598608,Hyperhomocysteinemia,disease,hyperhomocysteinemia,4524,MTHFR,Mthfr,CTD_human,19204075,"In humans, severe hyperhomocysteinemia due to genetic alterations in cystathionine beta-synthase (Cbs) or methylenetetrahydrofolate reductase (Mthfr) results in neurological abnormalities and premature death from vascular complications.",0.421414491598346,"In humans, severe <span class=""disease"" id=""19204075-2-18-38"">hyperhomocysteinemia</span> due to genetic alterations in cystathionine beta-synthase (Cbs) or <span class=""gene"" id=""19204075-2-106-141"">methylenetetrahydrofolate reductase</span> (<span class=""gene"" id=""19204075-2-143-148"">Mthfr</span>) results in neurological abnormalities and premature death from vascular complications.",CTD_human
11,0,Therapeutic,C0598608,Hyperhomocysteinemia,disease,hyperhomocysteinemia,4524,MTHFR,methylenetetrahydrofolate reductase,CTD_human,10459572,A common mutation in the methylenetetrahydrofolate reductase gene is a determinant of hyperhomocysteinemia in epileptic patients receiving anticonvulsants.,0.421414491598346,"A common mutation in the <span class=""gene"" id=""10459572-0-25-60"">methylenetetrahydrofolate reductase</span> gene is a determinant of <span class=""disease"" id=""10459572-0-86-106"">hyperhomocysteinemia</span> in epileptic patients receiving anticonvulsants.",CTD_human
11,0,Biomarker,C0598608,Hyperhomocysteinemia,disease,hyperhomocysteinemia,4524,MTHFR,methylenetetrahydrofolate reductase,CTD_human,15226090,"C677T polymorphism in methylenetetrahydrofolate reductase gene (MTHFR) is a major determinant of hyperhomocysteinemia, which results in endothelial dysfunction.",0.421414491598346,"C677T polymorphism in <span class=""gene"" id=""15226090-2-22-57"">methylenetetrahydrofolate reductase</span> gene (MTHFR) is a major determinant of <span class=""disease"" id=""15226090-2-97-117"">hyperhomocysteinemia</span>, which results in endothelial dysfunction.",CTD_human
11,0,Biomarker,C0598608,Hyperhomocysteinemia,disease,hyperhomocysteinemia,4524,MTHFR,methylenetetrahydrofolate reductase,CTD_human,18234410,Evaluation of the relationship between C677T variants of methylenetetrahydrofolate reductase gene and hyperhomocysteinemia in children receiving antiepileptic drug therapy.,0.421414491598346,"Evaluation of the relationship between C677T variants of <span class=""gene"" id=""18234410-0-57-92"">methylenetetrahydrofolate reductase</span> gene and <span class=""disease"" id=""18234410-0-102-122"">hyperhomocysteinemia</span> in children receiving antiepileptic drug therapy.",CTD_human
11,0,Biomarker,C0598608,Hyperhomocysteinemia,disease,hyperhomocysteinemia,4524,MTHFR,methylenetetrahydrofolate reductase,CTD_human,10459572,A common mutation in the methylenetetrahydrofolate reductase gene is a determinant of hyperhomocysteinemia in epileptic patients receiving anticonvulsants.,0.421414491598346,"A common mutation in the <span class=""gene"" id=""10459572-0-25-60"">methylenetetrahydrofolate reductase</span> gene is a determinant of <span class=""disease"" id=""10459572-0-86-106"">hyperhomocysteinemia</span> in epileptic patients receiving anticonvulsants.",CTD_human
11,0,Therapeutic,C0598608,Hyperhomocysteinemia,disease,hyperhomocysteinemia,4524,MTHFR,MTHFR,CTD_human,16411416,"Splenic thrombosis in three patients with moderate hyperhomocysteinemia, low folate and the C677T variant of the methylenetetrahydrofolate reductase (MTHFR) gene.",0.421414491598346,"Splenic thrombosis in three patients with moderate <span class=""disease"" id=""16411416-0-51-71"">hyperhomocysteinemia</span>, low folate and the C677T variant of the <span class=""gene"" id=""16411416-0-113-148"">methylenetetrahydrofolate reductase</span> (<span class=""gene"" id=""16411416-0-150-155"">MTHFR</span>) gene.",CTD_human
11,0,Therapeutic,C0598608,Hyperhomocysteinemia,disease,hyperhomocysteinemia,4524,MTHFR,methylenetetrahydrofolate reductase,CTD_human,18234410,Evaluation of the relationship between C677T variants of methylenetetrahydrofolate reductase gene and hyperhomocysteinemia in children receiving antiepileptic drug therapy.,0.421414491598346,"Evaluation of the relationship between C677T variants of <span class=""gene"" id=""18234410-0-57-92"">methylenetetrahydrofolate reductase</span> gene and <span class=""disease"" id=""18234410-0-102-122"">hyperhomocysteinemia</span> in children receiving antiepileptic drug therapy.",CTD_human
11,0,Biomarker,C0598608,Hyperhomocysteinemia,disease,hyperhomocysteinemia,4524,MTHFR,MTHFR,CTD_human,16411416,"Splenic thrombosis in three patients with moderate hyperhomocysteinemia, low folate and the C677T variant of the methylenetetrahydrofolate reductase (MTHFR) gene.",0.421414491598346,"Splenic thrombosis in three patients with moderate <span class=""disease"" id=""16411416-0-51-71"">hyperhomocysteinemia</span>, low folate and the C677T variant of the <span class=""gene"" id=""16411416-0-113-148"">methylenetetrahydrofolate reductase</span> (<span class=""gene"" id=""16411416-0-150-155"">MTHFR</span>) gene.",CTD_human
11,0,Therapeutic,C0598608,Hyperhomocysteinemia,disease,hyperhomocysteinemia,4524,MTHFR,methylenetetrahydrofolate reductase,CTD_human,15226090,"C677T polymorphism in methylenetetrahydrofolate reductase gene (MTHFR) is a major determinant of hyperhomocysteinemia, which results in endothelial dysfunction.",0.421414491598346,"C677T polymorphism in <span class=""gene"" id=""15226090-2-22-57"">methylenetetrahydrofolate reductase</span> gene (MTHFR) is a major determinant of <span class=""disease"" id=""15226090-2-97-117"">hyperhomocysteinemia</span>, which results in endothelial dysfunction.",CTD_human
11,0,Therapeutic,C0598608,Hyperhomocysteinemia,disease,hyperhomocysteinemia,4524,MTHFR,MTHFR,CTD_human,19646848,MTHFR 677C/T polymorphism is associated with the risk of vascular diseases due to hyperhomocysteinemia.,0.421414491598346,"<span class=""gene"" id=""19646848-8-0-5"">MTHFR</span> 677C/T polymorphism is associated with the risk of vascular diseases due to <span class=""disease"" id=""19646848-8-82-102"">hyperhomocysteinemia</span>.",CTD_human
11,0,Biomarker,C0598608,Hyperhomocysteinemia,disease,hyperhomocysteinemia,4524,MTHFR,MTHFR,CTD_human,18551038,"After MTX treatment, MTHFR-Tg mice exhibited the same decreases in hematological parameters as Mthfr-deficient mice, and significantly decreased thymidine synthesis (higher 2'-deoxyuridine 5'-triphosphate/2'-deoxythymidine 5'-triphosphate ratios) compared with wild-type mice, but they were protected from MTX-induced hyperhomocysteinemia.",0.421414491598346,"After MTX treatment, <span class=""gene"" id=""18551038-10-21-26"">MTHFR</span>-Tg mice exhibited the same decreases in hematological parameters as Mthfr-deficient mice, and significantly decreased thymidine synthesis (higher 2'-deoxyuridine 5'-triphosphate/2'-deoxythymidine 5'-triphosphate ratios) compared with wild-type mice, but they were protected from MTX-induced <span class=""disease"" id=""18551038-10-318-338"">hyperhomocysteinemia</span>.",CTD_human
11,0,Biomarker,C0598608,Hyperhomocysteinemia,disease,hyperhomocysteinemia,4524,MTHFR,MTHFR,CTD_human,19646848,MTHFR 677C/T polymorphism is associated with the risk of vascular diseases due to hyperhomocysteinemia.,0.421414491598346,"<span class=""gene"" id=""19646848-8-0-5"">MTHFR</span> 677C/T polymorphism is associated with the risk of vascular diseases due to <span class=""disease"" id=""19646848-8-82-102"">hyperhomocysteinemia</span>.",CTD_human
11,0,Therapeutic,C0598608,Hyperhomocysteinemia,disease,hyperhomocysteinemia,4524,MTHFR,MTHFR,CTD_human,18551038,"After MTX treatment, MTHFR-Tg mice exhibited the same decreases in hematological parameters as Mthfr-deficient mice, and significantly decreased thymidine synthesis (higher 2'-deoxyuridine 5'-triphosphate/2'-deoxythymidine 5'-triphosphate ratios) compared with wild-type mice, but they were protected from MTX-induced hyperhomocysteinemia.",0.421414491598346,"After MTX treatment, <span class=""gene"" id=""18551038-10-21-26"">MTHFR</span>-Tg mice exhibited the same decreases in hematological parameters as Mthfr-deficient mice, and significantly decreased thymidine synthesis (higher 2'-deoxyuridine 5'-triphosphate/2'-deoxythymidine 5'-triphosphate ratios) compared with wild-type mice, but they were protected from MTX-induced <span class=""disease"" id=""18551038-10-318-338"">hyperhomocysteinemia</span>.",CTD_human
11,0,Therapeutic,C0598608,Hyperhomocysteinemia,disease,hyperhomocysteinemia,4524,MTHFR,Mthfr,CTD_human,19204075,"In humans, severe hyperhomocysteinemia due to genetic alterations in cystathionine beta-synthase (Cbs) or methylenetetrahydrofolate reductase (Mthfr) results in neurological abnormalities and premature death from vascular complications.",0.421414491598346,"In humans, severe <span class=""disease"" id=""19204075-2-18-38"">hyperhomocysteinemia</span> due to genetic alterations in cystathionine beta-synthase (Cbs) or <span class=""gene"" id=""19204075-2-106-141"">methylenetetrahydrofolate reductase</span> (<span class=""gene"" id=""19204075-2-143-148"">Mthfr</span>) results in neurological abnormalities and premature death from vascular complications.",CTD_human
6,11,Biomarker,C0917796,"Optic Atrophy, Hereditary, Leber",disease,Leber's hereditary optic neuropathy,4535,ND1,ND1,CTD_human,15505787,The ND1 gene of complex I is a mutational hot spot for Leber's hereditary optic neuropathy.,0.6121661676857,"The <span class=""gene"" id=""15505787-0-4-7"">ND1</span> gene of complex I is a mutational hot spot for <span class=""disease"" id=""15505787-0-55-90"">Leber's hereditary optic neuropathy</span>.",CTD_human;HPO;ORPHANET;UNIPROT
1,0,Biomarker,C1510586,Autism Spectrum Disorders,disease,ASD,4543,MTNR1A,MTNR1A,CTD_human,20657642,The prevalence of these deleterious mutations in cases and controls indicates that they do not represent major risk factor for ASD (MTNR1A case 3.6% vs controls 4.4%; MTNR1B case 4.7% vs 3% controls).,0.20054945356842604,"The prevalence of these deleterious mutations in cases and controls indicates that they do not represent major risk factor for <span class=""disease"" id=""20657642-10-127-130"">ASD</span> (<span class=""gene"" id=""20657642-10-132-138"">MTNR1A</span> case 3.6% vs controls 4.4%; MTNR1B case 4.7% vs 3% controls).",CTD_human
5,1,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,type 2 diabetes,4544,MTNR1B,MTNR1B,CTD_human,19060908,Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion.,0.25328219018548603,"Common variant in <span class=""gene"" id=""19060908-0-18-24"">MTNR1B</span> associated with increased risk of <span class=""disease"" id=""19060908-0-59-74"">type 2 diabetes</span> and impaired early insulin secretion.",CTD_human
5,1,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,type 2 diabetes,4544,MTNR1B,MTNR1B,CTD_human,19060909,A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk.,0.25328219018548603,"A variant near <span class=""gene"" id=""19060909-0-15-21"">MTNR1B</span> is associated with increased fasting plasma glucose levels and <span class=""disease"" id=""19060909-0-85-100"">type 2 diabetes</span> risk.",CTD_human
5,1,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,type 2 diabetes,4544,MTNR1B,melatonin receptor 1B,CTD_human,22286214,Rare MTNR1B variants impairing melatonin receptor 1B function contribute to type 2 diabetes.,0.25328219018548603,"Rare <span class=""gene"" id=""22286214-0-5-11"">MTNR1B</span> variants impairing <span class=""gene"" id=""22286214-0-31-52"">melatonin receptor 1B</span> function contribute to <span class=""disease"" id=""22286214-0-76-91"">type 2 diabetes</span>.",CTD_human
5,1,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,T2D,4544,MTNR1B,MTNR1B,CTD_human,26551672,"We observed allele-specific differences in NEUROD1 binding in islet-derived cells, consistent with evidence that the T2D risk allele increases islet MTNR1B expression.",0.25328219018548603,"We observed allele-specific differences in NEUROD1 binding in islet-derived cells, consistent with evidence that the <span class=""disease"" id=""26551672-6-117-120"">T2D</span> risk allele increases islet <span class=""gene"" id=""26551672-6-149-155"">MTNR1B</span> expression.",CTD_human
1,0,Biomarker,C0032460,Polycystic Ovary Syndrome,disease,polycystic ovary syndrome,4544,MTNR1B,MTNR1B,CTD_human,20207350,"Common genetic variation in MTNR1B is associated with serum testosterone, glucose tolerance, and insulin secretion in polycystic ovary syndrome patients.",0.202956482091714,"Common genetic variation in <span class=""gene"" id=""20207350-0-28-34"">MTNR1B</span> is associated with serum testosterone, glucose tolerance, and insulin secretion in <span class=""disease"" id=""20207350-0-118-143"">polycystic ovary syndrome</span> patients.",CTD_human
1,0,Biomarker,C1510586,Autism Spectrum Disorders,disease,ASD,4544,MTNR1B,MTNR1B,CTD_human,20657642,The prevalence of these deleterious mutations in cases and controls indicates that they do not represent major risk factor for ASD (MTNR1A case 3.6% vs controls 4.4%; MTNR1B case 4.7% vs 3% controls).,0.200274726784213,"The prevalence of these deleterious mutations in cases and controls indicates that they do not represent major risk factor for <span class=""disease"" id=""20657642-10-127-130"">ASD</span> (MTNR1A case 3.6% vs controls 4.4%; <span class=""gene"" id=""20657642-10-167-173"">MTNR1B</span> case 4.7% vs 3% controls).",CTD_human
1,0,Biomarker,C0021364,Male infertility,phenotype,male infertility,4548,MTR,MS,CTD_human,16861746,"By analysis of a large number of subjects and a more specific patient selection, we showed the first genetic evidence that MTHFR C677T, MS A2756G and MTRR A66G genotypes were independently associated with male infertility.",0.203780662444353,"By analysis of a large number of subjects and a more specific patient selection, we showed the first genetic evidence that MTHFR C677T, <span class=""gene"" id=""16861746-8-136-138"">MS</span> A2756G and MTRR A66G genotypes were independently associated with <span class=""disease"" id=""16861746-8-205-221"">male infertility</span>.",CTD_human
1,0,Biomarker,C0024299,Lymphoma,group,malignant lymphoma,4548,MTR,MS,CTD_human,16799656,For the MS 2756 AG genotype polymorphism there was also a higher susceptibility to developing malignant lymphoma (OR=2.6; 95% CI 1.1- 6.4).,0.215266351492367,"For the <span class=""gene"" id=""16799656-9-8-10"">MS</span> 2756 AG genotype polymorphism there was also a higher susceptibility to developing <span class=""disease"" id=""16799656-9-94-112"">malignant lymphoma</span> (OR=2.6; 95% CI 1.1- 6.4).",CTD_human
1,0,Biomarker,C0024301,"Lymphoma, Follicular",disease,FL,4548,MTR,MTR,CTD_human,16410450,"The MTR 2756AA genotype conferred a greater multivariate-adjusted relative risk of FL, and the risk was multiplied by almost 5 in the TYMS2R(-)/MTR 2756AA combination.",0.202956482091714,"The <span class=""gene"" id=""16410450-7-4-7"">MTR</span> 2756AA genotype conferred a greater multivariate-adjusted relative risk of <span class=""disease"" id=""16410450-7-83-85"">FL</span>, and the risk was multiplied by almost 5 in the TYMS2R(-)/<span class=""gene"" id=""16410450-7-144-147"">MTR</span> 2756AA combination.",CTD_human
2,0,Biomarker,C0019880,Homocystinuria,disease,homocystinuria,4552,MTRR,methionine synthase reductase,CTD_human,12555939,CblE type of homocystinuria due to methionine synthase reductase deficiency: clinical and molecular studies and prenatal diagnosis in two families.,0.401648360705279,"CblE type of <span class=""disease"" id=""12555939-0-13-27"">homocystinuria</span> due to <span class=""gene"" id=""12555939-0-35-64"">methionine synthase reductase</span> deficiency: clinical and molecular studies and prenatal diagnosis in two families.",CTD_human;HPO
2,0,Biomarker,C0019880,Homocystinuria,disease,homocystinuria,4552,MTRR,methionine synthase reductase,CTD_human,15714522,cblE type of homocystinuria due to methionine synthase reductase deficiency: functional correction by minigene expression.,0.401648360705279,"cblE type of <span class=""disease"" id=""15714522-0-13-27"">homocystinuria</span> due to <span class=""gene"" id=""15714522-0-35-64"">methionine synthase reductase</span> deficiency: functional correction by minigene expression.",CTD_human;HPO
1,0,Biomarker,C0162671,MELAS Syndrome,disease,MELAS syndrome,4574,TRNS1,MTTS1,CTD_human,17894844,MELAS syndrome in a patient with a point mutation in MTTS1.,0.40027472678421294,"<span class=""disease"" id=""17894844-0-0-14"">MELAS syndrome</span> in a patient with a point mutation in <span class=""gene"" id=""17894844-0-53-58"">MTTS1</span>.",CTD_human;ORPHANET
1,0,Biomarker,C0025500,Mesothelioma,disease,mesothelioma,4582,MUC1,MUC1,CTD_human,18454162,"Thus, as in other cancers, alterations in MUC1 biology occur in mesothelioma and these results suggest that specific MUC1 characteristics may be useful for mesothelioma diagnosis and should also be investigated as a potential therapeutic target.",0.203557092817453,"Thus, as in other cancers, alterations in <span class=""gene"" id=""18454162-11-42-46"">MUC1</span> biology occur in <span class=""disease"" id=""18454162-11-64-76"">mesothelioma</span> and these results suggest that specific <span class=""gene"" id=""18454162-11-117-121"">MUC1</span> characteristics may be useful for <span class=""disease"" id=""18454162-11-156-168"">mesothelioma</span> diagnosis and should also be investigated as a potential therapeutic target.",CTD_human
1,0,Biomarker,C0026764,Multiple Myeloma,disease,multiple myeloma,4582,MUC1,Muc-1,CTD_human,9949172,Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone.,0.206029633875371,"<span class=""gene"" id=""9949172-0-0-5"">Muc-1</span> core protein is expressed on <span class=""disease"" id=""9949172-0-35-51"">multiple myeloma</span> cells and is induced by dexamethasone.",CTD_human
1,0,Biomarker,C1868139,Medullary cystic kidney disease 1,disease,MCKD1,4582,MUC1,mucin 1,CTD_human,23396133,"Ultimately, only by cloning, capillary sequencing and de novo assembly did we find that each of six families with MCKD1 harbors an equivalent but apparently independently arising mutation in sequence markedly under-represented in massively parallel sequencing data: the insertion of a single cytosine in one copy (but a different copy in each family) of the repeat unit comprising the extremely long (?1.5-5 kb), GC-rich (>80%) coding variable-number tandem repeat (VNTR) sequence in the MUC1 gene encoding mucin 1.",0.20274726784213098,"Ultimately, only by cloning, capillary sequencing and de novo assembly did we find that each of six families with <span class=""disease"" id=""23396133-3-114-119"">MCKD1</span> harbors an equivalent but apparently independently arising mutation in sequence markedly under-represented in massively parallel sequencing data: the insertion of a single cytosine in one copy (but a different copy in each family) of the repeat unit comprising the extremely long (&sim;1.5-5 kb), GC-rich (&gt;80%) coding variable-number tandem repeat (VNTR) sequence in the <span class=""gene"" id=""23396133-3-488-492"">MUC1</span> gene encoding <span class=""gene"" id=""23396133-3-507-514"">mucin 1</span>.",CTD_human
4,13,Biomarker,C0524582,Mulibrey Nanism,disease,MUL,4591,TRIM37,TRIM37,CTD_human,14757854,"In this work, we analysed the clinical characteristics of 85 Finnish patients with MUL, most of whom were homozygous for the Finn major mutation of TRIM37.",0.694503098054025,"In this work, we analysed the clinical characteristics of 85 Finnish patients with <span class=""disease"" id=""14757854-2-83-86"">MUL</span>, most of whom were homozygous for the Finn major mutation of <span class=""gene"" id=""14757854-2-148-154"">TRIM37</span>.",CTD_human;ORPHANET;UNIPROT
3,0,Biomarker,C0342731,Deficiency of mevalonate kinase,disease,HIDS,4598,MVK,MVK,CTD_human,10369261,"Subsequent analysis of cells from four unrelated HIDS patients revealed reduced activities of mevalonate kinase (MK; encoded by the gene MVK), a key enzyme of isoprenoid biosynthesis.",0.413121373107599,"Subsequent analysis of cells from four unrelated <span class=""disease"" id=""10369261-4-49-53"">HIDS</span> patients revealed reduced activities of <span class=""gene"" id=""10369261-4-94-111"">mevalonate kinase</span> (MK; encoded by the gene <span class=""gene"" id=""10369261-4-137-140"">MVK</span>), a key enzyme of isoprenoid biosynthesis.",CTD_human;ORPHANET
2,0,Biomarker,C0010606,Adenoid Cystic Carcinoma,disease,adenoid cystic carcinoma,4602,MYB,MYB,CTD_human,26829750,An oncogenic MYB feedback loop drives alternate cell fates in adenoid cystic carcinoma.,0.209065983879032,"An oncogenic <span class=""gene"" id=""26829750-0-13-16"">MYB</span> feedback loop drives alternate cell fates in <span class=""disease"" id=""26829750-0-62-86"">adenoid cystic carcinoma</span>.",CTD_human
2,0,Biomarker,C0017638,Glioma,disease,gliomas,4602,MYB,MYB,CTD_human,26829751,We identified MYB-QKI fusions as a specific and single candidate driver event in angiocentric gliomas.,0.20082418035263896,"We identified <span class=""gene"" id=""26829751-3-14-17"">MYB</span>-QKI fusions as a specific and single candidate driver event in angiocentric <span class=""disease"" id=""26829751-3-94-101"">gliomas</span>.",CTD_human
1,0,Biomarker,C1961099,Precursor T-Cell Lymphoblastic Leukemia-Lymphoma,disease,T cell acute lymphoblastic leukemia,4602,MYB,MYB,CTD_human,17435759,Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia.,0.201923087489492,"Duplication of the <span class=""gene"" id=""17435759-0-19-22"">MYB</span> oncogene in <span class=""disease"" id=""17435759-0-35-70"">T cell acute lymphoblastic leukemia</span>.",CTD_human
3,52,Biomarker,C0007194,Hypertrophic Cardiomyopathy,disease,HCM,4607,MYBPC3,MYBPC3,CTD_human,23816408,This observation underscores the significance of insertions into the coding sequence of the MYBPC3 gene for the development and pathogenesis of HCM.,0.49636328609141,"This observation underscores the significance of insertions into the coding sequence of the <span class=""gene"" id=""23816408-5-92-98"">MYBPC3</span> gene for the development and pathogenesis of <span class=""disease"" id=""23816408-5-144-147"">HCM</span>.",CTD_human;HPO
3,52,Biomarker,C0007194,Hypertrophic Cardiomyopathy,disease,HCM,4607,MYBPC3,Mybpc3,CTD_human,25566086,"Here we tested whether proteasome inhibition could also reverse the disease phenotype in a genetically-modified mouse model of hypertrophic cardiomyopathy (HCM), which carries a mutation in Mybpc3, encoding the myofilament protein cardiac myosin-binding protein C. At 7 weeks of age, homozygous mutant mice (KI) have 39% higher left ventricular mass-to-body-weight ratio and 29% lower fractional area shortening (FAS) than wild-type (WT) mice.",0.49636328609141,"Here we tested whether proteasome inhibition could also reverse the disease phenotype in a genetically-modified mouse model of <span class=""disease"" id=""25566086-3-127-154"">hypertrophic cardiomyopathy</span> (<span class=""disease"" id=""25566086-3-156-159"">HCM</span>), which carries a mutation in <span class=""gene"" id=""25566086-3-190-196"">Mybpc3</span>, encoding the myofilament protein cardiac myosin-binding protein C. At 7 weeks of age, homozygous mutant mice (KI) have 39% higher left ventricular mass-to-body-weight ratio and 29% lower fractional area shortening (FAS) than wild-type (WT) mice.",CTD_human;HPO
3,52,Biomarker,C0007194,Hypertrophic Cardiomyopathy,disease,HCM,4607,MYBPC3,MYBPC3,CTD_human,22076249,"Hypertrophic cardiomyopathy (HCM) is characterized by asymmetric septal hypertrophy and is often caused by mutations in MYBPC3 gene encoding cardiac myosin-binding protein C. In contrast to humans, who are already affected at the heterozygous state, mouse models develop the phenotype mainly at the homozygous state.",0.49636328609141,"<span class=""disease"" id=""22076249-1-0-27"">Hypertrophic cardiomyopathy</span> (<span class=""disease"" id=""22076249-1-29-32"">HCM</span>) is characterized by asymmetric septal hypertrophy and is often caused by mutations in <span class=""gene"" id=""22076249-1-120-126"">MYBPC3</span> gene encoding cardiac myosin-binding protein C. In contrast to humans, who are already affected at the heterozygous state, mouse models develop the phenotype mainly at the homozygous state.",CTD_human;HPO
1,26,Biomarker,C0878544,Cardiomyopathies,group,cardiomyopathies,4607,MYBPC3,MYBPC3,CTD_human,19151713,A common MYBPC3 (cardiac myosin binding protein C) variant associated with cardiomyopathies in South Asia.,0.231198826245103,"A common <span class=""gene"" id=""19151713-0-9-15"">MYBPC3</span> (cardiac myosin binding protein C) variant associated with <span class=""disease"" id=""19151713-0-75-91"">cardiomyopathies</span> in South Asia.",CTD_human
1,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,NSCLC,4609,MYC,MYC,CTD_human,24688052,"Moreover, pathway analysis and knockdown studies suggest a role for MYC transcriptional activity in the expression of these pathways in KRAS-mutant NSCLC cells.",0.205769262468475,"Moreover, pathway analysis and knockdown studies suggest a role for <span class=""gene"" id=""24688052-5-68-71"">MYC</span> transcriptional activity in the expression of these pathways in KRAS-mutant <span class=""disease"" id=""24688052-5-148-153"">NSCLC</span> cells.",CTD_human
1,0,Biomarker,C0023467,"Leukemia, Myelocytic, Acute",disease,acute myeloid leukemia,4609,MYC,MYC,CTD_human,25956709,Direct and indirect targeting of MYC to treat acute myeloid leukemia.,0.21755380343500397,"Direct and indirect targeting of <span class=""gene"" id=""25956709-0-33-36"">MYC</span> to treat <span class=""disease"" id=""25956709-0-46-68"">acute myeloid leukemia</span>.",CTD_human
2,0,Biomarker,C0023903,Liver neoplasms,group,liver tumors,4609,MYC,c-myc,CTD_human,11532874,"Hence, chloroform prevented the hypomethylation and increased mRNA expression of the c-myc gene and the promotion of liver tumors by DCA, while enhancing DCA-promotion of kidney tumors.",0.209586726692824,"Hence, chloroform prevented the hypomethylation and increased mRNA expression of the <span class=""gene"" id=""11532874-12-85-90"">c-myc</span> gene and the promotion of <span class=""disease"" id=""11532874-12-117-129"">liver tumors</span> by DCA, while enhancing DCA-promotion of kidney tumors.",CTD_human
1,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,tumor metastasis,4609,MYC,MYC,CTD_human,22321834,It is widely recognized that activation of MMP2 and MYC is tightly associated with tumor metastasis and tumor progression.,0.218601553414544,"It is widely recognized that activation of MMP2 and <span class=""gene"" id=""22321834-6-52-55"">MYC</span> is tightly associated with <span class=""disease"" id=""22321834-6-83-99"">tumor metastasis</span> and tumor progression.",CTD_human
1,0,Biomarker,C0152013,Adenocarcinoma of lung (disorder),disease,MYC-LASE,4609,MYC,MYC,CTD_human,26656844,"CRISPR/Cas9-mediated repression or deletion of a constituent enhancer within the MYC-LASE region led to significant reductions in the expression of MYC and its target genes and to the impairment of anchorage-independent and clonogenic growth, consistent with an oncogenic function.",0.203021994626344,"CRISPR/Cas9-mediated repression or deletion of a constituent enhancer within the <span class=""disease"" id=""26656844-5-81-89"">MYC-LASE</span> region led to significant reductions in the expression of <span class=""gene"" id=""26656844-5-148-151"">MYC</span> and its target genes and to the impairment of anchorage-independent and clonogenic growth, consistent with an oncogenic function.",CTD_human
1,0,Therapeutic,C0149925,Small cell carcinoma of lung,disease,SCLC,4610,MYCL,MYCL1,CTD_human,22941189,Silencing of MYCL1 in SCLC cell lines that had the RLF-MYCL1 fusion decreased cell proliferation.,0.20467035533162303,"Silencing of <span class=""gene"" id=""22941189-9-13-18"">MYCL1</span> in <span class=""disease"" id=""22941189-9-22-26"">SCLC</span> cell lines that had the RLF-<span class=""gene"" id=""22941189-9-55-60"">MYCL1</span> fusion decreased cell proliferation.",CTD_human
12,0,Biomarker,C0027819,Neuroblastoma,disease,NB,4613,MYCN,MYCN,CTD_human,16989911,"Expression of the high-affinity nerve growth factor (NGF) TrkA receptor in NB is correlated with good prognosis, while MYCN amplification is associated with advanced stages of disease.",0.49366456232406897,"Expression of the high-affinity nerve growth factor (NGF) TrkA receptor in <span class=""disease"" id=""16989911-4-75-77"">NB</span> is correlated with good prognosis, while <span class=""gene"" id=""16989911-4-119-123"">MYCN</span> amplification is associated with advanced stages of disease.",CTD_human;ORPHANET
12,0,Biomarker,C0027819,Neuroblastoma,disease,neuroblastoma,4613,MYCN,MYCN,CTD_human,17283129,"Interestingly, we found that miRNA expression levels substantially change in a MYCN-amplified cell line following exposure to retinoic acid, a compound which is well known for causing reductions in MYCN expression and for inducing neuroblastoma cell lines to undergo neuronal differentiation.",0.49366456232406897,"Interestingly, we found that miRNA expression levels substantially change in a <span class=""gene"" id=""17283129-4-79-83"">MYCN</span>-amplified cell line following exposure to retinoic acid, a compound which is well known for causing reductions in <span class=""gene"" id=""17283129-4-198-202"">MYCN</span> expression and for inducing <span class=""disease"" id=""17283129-4-231-244"">neuroblastoma</span> cell lines to undergo neuronal differentiation.",CTD_human;ORPHANET
12,0,Biomarker,C0027819,Neuroblastoma,disease,neuroblastoma,4613,MYCN,N-Myc,CTD_human,26733615,Our findings have identified a novel strategy to reduce the N-Myc oncoprotein expression and a novel therapeutic approach for the treatment of aggressive neuroblastoma.Clin Cancer Res; 22(10); 2534-44.2016 AACR.,0.49366456232406897,"Our findings have identified a novel strategy to reduce the <span class=""gene"" id=""26733615-11-60-65"">N-Myc</span> oncoprotein expression and a novel therapeutic approach for the treatment of aggressive <span class=""disease"" id=""26733615-11-154-167"">neuroblastoma</span>.Clin Cancer Res; 22(10); 2534-44.2016 AACR.",CTD_human;ORPHANET
12,0,Biomarker,C0027819,Neuroblastoma,disease,neuroblastoma,4613,MYCN,MYCN,CTD_human,23042116,LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression.,0.49366456232406897,"LIN28B induces <span class=""disease"" id=""23042116-0-15-28"">neuroblastoma</span> and enhances <span class=""gene"" id=""23042116-0-42-46"">MYCN</span> levels via let-7 suppression.",CTD_human;ORPHANET
12,0,Biomarker,C0027819,Neuroblastoma,disease,neuroblastoma,4613,MYCN,MYCN,CTD_human,22789543,The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma.,0.49366456232406897,"The ALK(F1174L) mutation potentiates the oncogenic activity of <span class=""gene"" id=""22789543-0-63-67"">MYCN</span> in <span class=""disease"" id=""22789543-0-71-84"">neuroblastoma</span>.",CTD_human;ORPHANET
12,0,Biomarker,C0027819,Neuroblastoma,disease,neuroblastoma,4613,MYCN,MYCN,CTD_human,22286764,Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells.,0.49366456232406897,"Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of <span class=""gene"" id=""22286764-0-74-78"">MYCN</span> in <span class=""disease"" id=""22286764-0-82-95"">neuroblastoma</span> cells.",CTD_human;ORPHANET
12,0,Biomarker,C0027819,Neuroblastoma,disease,neuroblastoma,4613,MYCN,MYCN,CTD_human,25174395,A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies.,0.49366456232406897,"A Cre-conditional <span class=""gene"" id=""25174395-0-18-22"">MYCN</span>-driven <span class=""disease"" id=""25174395-0-30-43"">neuroblastoma</span> mouse model as an improved tool for preclinical studies.",CTD_human;ORPHANET
3,7,Biomarker,C0796068,Oculodigitoesophagoduodenal syndrome,disease,Feingold syndrome,4613,MYCN,MYCN,CTD_human,19852433,"Clinical presentation of the family was suggestive of Feingold syndrome, and genetic testing of the MYCN gene confirmed the diagnosis.",0.6013736339210661,"Clinical presentation of the family was suggestive of <span class=""disease"" id=""19852433-9-54-71"">Feingold syndrome</span>, and genetic testing of the <span class=""gene"" id=""19852433-9-100-104"">MYCN</span> gene confirmed the diagnosis.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0014457,Eosinophilia,disease,eosinophilia,4615,MYD88,MyD88,CTD_human,26882889,These results indicate that ASD exacerbates lung eosinophilia in a MyD88-dependent pathway.,0.2,"These results indicate that ASD exacerbates lung <span class=""disease"" id=""26882889-8-49-61"">eosinophilia</span> in a <span class=""gene"" id=""26882889-8-67-72"">MyD88</span>-dependent pathway.",CTD_human
1,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,4615,MYD88,MyD88,CTD_human,27292124,TLR4/MyD88/NF-?B signaling and PPAR-? within the paraventricular nucleus are involved in the effects of telmisartan in hypertension.,0.2,"TLR4/<span class=""gene"" id=""27292124-0-5-10"">MyD88</span>/NF-&kappa;B signaling and PPAR-&gamma; within the paraventricular nucleus are involved in the effects of telmisartan in <span class=""disease"" id=""27292124-0-119-131"">hypertension</span>.",CTD_human
3,0,Biomarker,C0012739,Disseminated Intravascular Coagulation,disease,Disseminated intravascular coagulation,462,SERPINC1,antithrombin III,CTD_human,6233579,[Disseminated intravascular coagulation induced by heparin. Treatment with a combination of low-molecular weight heparin and concentrated antithrombin III].,0.20082418035263896,"[<span class=""disease"" id=""6233579-0-1-39"">Disseminated intravascular coagulation</span> induced by heparin. Treatment with a combination of low-molecular weight heparin and concentrated <span class=""gene"" id=""6233579-0-138-154"">antithrombin III</span>].",CTD_human
3,0,Therapeutic,C0012739,Disseminated Intravascular Coagulation,disease,Disseminated intravascular coagulation,462,SERPINC1,antithrombin III,CTD_human,6233579,[Disseminated intravascular coagulation induced by heparin. Treatment with a combination of low-molecular weight heparin and concentrated antithrombin III].,0.20082418035263896,"[<span class=""disease"" id=""6233579-0-1-39"">Disseminated intravascular coagulation</span> induced by heparin. Treatment with a combination of low-molecular weight heparin and concentrated <span class=""gene"" id=""6233579-0-138-154"">antithrombin III</span>].",CTD_human
3,0,Biomarker,C0012739,Disseminated Intravascular Coagulation,disease,DIC,462,SERPINC1,antithrombin III,CTD_human,9637888,"He was then given heparin and antithrombin III, and his DIC symptoms improved soon thereafter.",0.20082418035263896,"He was then given heparin and <span class=""gene"" id=""9637888-3-30-46"">antithrombin III</span>, and his <span class=""disease"" id=""9637888-3-56-59"">DIC</span> symptoms improved soon thereafter.",CTD_human
3,0,Therapeutic,C0012739,Disseminated Intravascular Coagulation,disease,DIC,462,SERPINC1,antithrombin III,CTD_human,9637888,"He was then given heparin and antithrombin III, and his DIC symptoms improved soon thereafter.",0.20082418035263896,"He was then given heparin and <span class=""gene"" id=""9637888-3-30-46"">antithrombin III</span>, and his <span class=""disease"" id=""9637888-3-56-59"">DIC</span> symptoms improved soon thereafter.",CTD_human
1,0,Biomarker,C0027726,Nephrotic Syndrome,group,NS,462,SERPINC1,AT-III,CTD_human,11304663,"We studied plasma antithrombin III (AT-III), alpha 1-PI, alpha 2-antiplasmin (alpha 2-A), alpha 2-macroglobulin (alpha 2-M) activity, and some blood coagulation and fibrinolysis tests in children with frequently relapsing prednisone-responsive NS.",0.28,"We studied plasma <span class=""gene"" id=""11304663-4-18-34"">antithrombin III</span> (<span class=""gene"" id=""11304663-4-36-42"">AT-III</span>), alpha 1-PI, alpha 2-antiplasmin (alpha 2-A), alpha 2-macroglobulin (alpha 2-M) activity, and some blood coagulation and fibrinolysis tests in children with frequently relapsing prednisone-responsive <span class=""disease"" id=""11304663-4-244-246"">NS</span>.",CTD_human
1,0,Therapeutic,C0948089,Acute Coronary Syndrome,disease,acute coronary syndromes,462,SERPINC1,antithrombin III,CTD_human,7923645,"Although intravenous heparin is routinely used in the treatment of patients with acute coronary syndromes, this anticoagulant requires antithrombin III as a cofactor, has no affinity to clot-bound thrombin, and is bound or inactivated by several plasma proteins and platelet factor 4.",0.2,"Although intravenous heparin is routinely used in the treatment of patients with <span class=""disease"" id=""7923645-1-81-105"">acute coronary syndromes</span>, this anticoagulant requires <span class=""gene"" id=""7923645-1-135-151"">antithrombin III</span> as a cofactor, has no affinity to clot-bound thrombin, and is bound or inactivated by several plasma proteins and platelet factor 4.",CTD_human
1,0,Biomarker,C0018817,Atrial Septal Defects,group,atrial septal defect,4624,MYH6,myosin heavy chain 6,CTD_human,15735645,Mutation in myosin heavy chain 6 causes atrial septal defect.,0.206238848124954,"Mutation in <span class=""gene"" id=""15735645-0-12-32"">myosin heavy chain 6</span> causes <span class=""disease"" id=""15735645-0-40-60"">atrial septal defect</span>.",CTD_human
1,0,Biomarker,C0037052,Sick Sinus Syndrome,disease,sick sinus syndrome,4624,MYH6,MYH6,CTD_human,21378987,A rare variant in MYH6 is associated with high risk of sick sinus syndrome.,0.40082418035263895,"A rare variant in <span class=""gene"" id=""21378987-0-18-22"">MYH6</span> is associated with high risk of <span class=""disease"" id=""21378987-0-55-74"">sick sinus syndrome</span>.",CTD_human;ORPHANET
1,0,Biomarker,C0017668,Focal glomerulosclerosis,disease,focal segmental glomerulosclerosis,4627,MYH9,MYH9,CTD_human,18794856,MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis.,0.213041505195652,"<span class=""gene"" id=""18794856-0-0-4"">MYH9</span> is a major-effect risk gene for <span class=""disease"" id=""18794856-0-37-71"">focal segmental glomerulosclerosis</span>.",CTD_human
2,0,Biomarker,C0022661,"Kidney Failure, Chronic",disease,end-stage renal disease,4627,MYH9,MYH9,CTD_human,18794854,MYH9 is associated with nondiabetic end-stage renal disease in African Americans.,0.21381452839097798,"<span class=""gene"" id=""18794854-0-0-4"">MYH9</span> is associated with nondiabetic <span class=""disease"" id=""18794854-0-36-59"">end-stage renal disease</span> in African Americans.",CTD_human
2,7,Biomarker,C1854520,SEBASTIAN SYNDROME,disease,Fechtner Syndrome,4627,MYH9,MYH9,CTD_human,10973259,"Mutations in MYH9 result in the May-Hegglin anomaly, and Fechtner and Sebastian syndromes. The May-Heggllin/Fechtner Syndrome Consortium.",0.694011065994868,"Mutations in <span class=""gene"" id=""10973259-0-13-17"">MYH9</span> result in the <span class=""disease"" id=""10973259-0-32-51"">May-Hegglin anomaly</span>, and Fechtner and Sebastian syndromes. The May-Heggllin/<span class=""disease"" id=""10973259-0-108-125"">Fechtner Syndrome</span> Consortium.",CTD_human;ORPHANET;UNIPROT
2,7,Biomarker,C1854520,SEBASTIAN SYNDROME,disease,APSM,4627,MYH9,MYH9,CTD_human,11590545,"Altogether, our data suggest that MHA, SBS, FTNS, EPS, and APSM comprise a phenotypic spectrum of disorders, all caused by MYH9 mutations.",0.694011065994868,"Altogether, our data suggest that <span class=""disease"" id=""11590545-12-34-37"">MHA</span>, SBS, FTNS, EPS, and <span class=""disease"" id=""11590545-12-59-63"">APSM</span> comprise a phenotypic spectrum of disorders, all caused by <span class=""gene"" id=""11590545-12-123-127"">MYH9</span> mutations.",CTD_human;ORPHANET;UNIPROT
2,0,Biomarker,C0023467,"Leukemia, Myelocytic, Acute",disease,AML,4629,MYH11,MYH11,CTD_human,27798625,"Outside of signaling alterations, RUNX1-RUNX1T1 and CBFB-MYH11 AMLs demonstrated remarkably different spectra of cooperating mutations, as RUNX1-RUNX1T1 cases harbored recurrent mutations in DHX15 and ZBTB7A, as well as an enrichment of mutations in epigenetic regulators, including ASXL2 and the cohesin complex.",0.225000137363392,"Outside of signaling alterations, RUNX1-RUNX1T1 and CBFB-<span class=""gene"" id=""27798625-4-57-62"">MYH11</span> <span class=""disease"" id=""27798625-4-63-66"">AML</span>s demonstrated remarkably different spectra of cooperating mutations, as RUNX1-RUNX1T1 cases harbored recurrent mutations in DHX15 and ZBTB7A, as well as an enrichment of mutations in epigenetic regulators, including ASXL2 and the cohesin complex.",CTD_human
1,0,Biomarker,C0023479,Acute myelomonocytic leukemia,disease,FAB M4,4629,MYH11,MYH11,CTD_human,10958941,"A unique structural abnormality of chromosome 16 resulting in a CBF beta-MYH11 fusion transcript in a patient with acute myeloid leukemia, FAB M4.",0.404655999954306,"A unique structural abnormality of chromosome 16 resulting in a CBF beta-<span class=""gene"" id=""10958941-0-73-78"">MYH11</span> fusion transcript in a patient with acute myeloid leukemia, <span class=""disease"" id=""10958941-0-139-145"">FAB M4</span>.",CTD_human;ORPHANET
3,2,Biomarker,C0004238,Atrial Fibrillation,disease,atrial fibrillation,463,ZFHX3,ZFHX3,CTD_human,19597492,Variants in ZFHX3 are associated with atrial fibrillation in individuals of European ancestry.,0.20412090176319603,"Variants in <span class=""gene"" id=""19597492-0-12-17"">ZFHX3</span> are associated with <span class=""disease"" id=""19597492-0-38-57"">atrial fibrillation</span> in individuals of European ancestry.",CTD_human
3,2,Biomarker,C0004238,Atrial Fibrillation,disease,atrial fibrillation,463,ZFHX3,ZFHX3,CTD_human,19597491,A sequence variant in ZFHX3 on 16q22 associates with atrial fibrillation and ischemic stroke.,0.20412090176319603,"A sequence variant in <span class=""gene"" id=""19597491-0-22-27"">ZFHX3</span> on 16q22 associates with <span class=""disease"" id=""19597491-0-53-72"">atrial fibrillation</span> and ischemic stroke.",CTD_human
2,0,Biomarker,C0033578,Prostatic Neoplasms,group,prostate tumor,463,ZFHX3,ATBF1,CTD_human,16637072,ATBF1 has been recently identified as a candidate prostate tumor suppressor gene.,0.208473464178654,"<span class=""gene"" id=""16637072-1-0-5"">ATBF1</span> has been recently identified as a candidate <span class=""disease"" id=""16637072-1-50-64"">prostate tumor</span> suppressor gene.",CTD_human
1,0,Biomarker,C0017601,Glaucoma,disease,glaucoma,4638,MYLK,MYLK,CTD_human,20375339,MYLK may be a new target for intervention in glaucoma to alter reactive astrocyte migration in the ONH.,0.200274726784213,"<span class=""gene"" id=""20375339-11-0-4"">MYLK</span> may be a new target for intervention in <span class=""disease"" id=""20375339-11-45-53"">glaucoma</span> to alter reactive astrocyte migration in the ONH.",CTD_human
1,0,Biomarker,C0017638,Glioma,disease,glioma,4638,MYLK,myosin light chain kinase,CTD_human,10232591,"We have investigated the role of myosin II in glioma motility and invasiveness by examining the effects of two inhibitors of myosin light chain kinase, ML7 and KT5926.",0.2,"We have investigated the role of myosin II in <span class=""disease"" id=""10232591-5-46-52"">glioma</span> motility and invasiveness by examining the effects of two inhibitors of <span class=""gene"" id=""10232591-5-125-150"">myosin light chain kinase</span>, ML7 and KT5926.",CTD_human
1,0,Biomarker,C0020443,Hypercholesterolemia,disease,hypercholesterolemia,4638,MYLK,MLCK,CTD_human,21052790,These results indicate for the first time that hypercholesterolemia may be associated with MLCK expression and activity through which endothelial permeability is increased.,0.2,"These results indicate for the first time that <span class=""disease"" id=""21052790-9-47-67"">hypercholesterolemia</span> may be associated with <span class=""gene"" id=""21052790-9-91-95"">MLCK</span> expression and activity through which endothelial permeability is increased.",CTD_human
2,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastatic cancer,4638,MYLK,MLCK,CTD_human,12970723,Dependence of metastatic cancer cell invasion on MLCK-catalyzed phosphorylation of myosin regulatory light chain.,0.20054945356842604,"Dependence of <span class=""disease"" id=""12970723-0-14-31"">metastatic cancer</span> cell invasion on <span class=""gene"" id=""12970723-0-49-53"">MLCK</span>-catalyzed phosphorylation of myosin regulatory light chain.",CTD_human
2,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,tumor metastasis,4638,MYLK,MLCK,CTD_human,18710790,Myosin light-chain kinase (MLCK) plays a crucial role in the cell migration and tumor metastasis.,0.20054945356842604,"<span class=""gene"" id=""18710790-1-0-25"">Myosin light-chain kinase</span> (<span class=""gene"" id=""18710790-1-27-31"">MLCK</span>) plays a crucial role in the cell migration and <span class=""disease"" id=""18710790-1-80-96"">tumor metastasis</span>.",CTD_human
1,0,Biomarker,C0032285,Pneumonia,disease,lung inflammation,4638,MYLK,MLCK,CTD_human,15863634,LPS-induced lung inflammation is linked to increased epithelial permeability: role of MLCK.,0.20240702852328799,"LPS-induced <span class=""disease"" id=""15863634-0-12-29"">lung inflammation</span> is linked to increased epithelial permeability: role of <span class=""gene"" id=""15863634-0-86-90"">MLCK</span>.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,4642,MYO1D,MYO1D,CTD_human,17376794,"Nominally significant single SNP and/or haplotype-based association results were detected in 15 genes, of which, MYO1D, ACCN1 and LASP1 stand out as genes with autism risk alleles requiring further study, with potential GRRs in the range of 1.34-2.29.",0.202681755307501,"Nominally significant single SNP and/or haplotype-based association results were detected in 15 genes, of which, <span class=""gene"" id=""17376794-9-113-118"">MYO1D</span>, ACCN1 and LASP1 stand out as genes with <span class=""disease"" id=""17376794-9-160-166"">autism</span> risk alleles requiring further study, with potential GRRs in the range of 1.34-2.29.",CTD_human
1,0,Biomarker,C0031117,Peripheral Neuropathy,group,peripheral neuropathy,4644,MYO5A,MYO5A,CTD_human,20864405,"In late-onset bortezomib-induced peripheral neuropathy, the significant genes were SOD2 (upregulated by 1·18 times; p=9·6×10(-3)) and MYO5A (1·93 times; p=3·2×10(-2)), involved in development and function of the nervous system.",0.200274726784213,"In late-onset bortezomib-induced <span class=""disease"" id=""20864405-11-33-54"">peripheral neuropathy</span>, the significant genes were SOD2 (upregulated by 1·18 times; p=9·6&times;10(-3)) and <span class=""gene"" id=""20864405-11-134-139"">MYO5A</span> (1·93 times; p=3·2&times;10(-2)), involved in development and function of the nervous system.",CTD_human
1,0,Biomarker,C0206656,"Rhabdomyosarcoma, Embryonal",disease,embryonal rhabdomyosarcoma,4654,MYOD1,MYOD1,CTD_human,24793135,A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations.,0.201373633921065,"A recurrent neomorphic mutation in <span class=""gene"" id=""24793135-0-35-40"">MYOD1</span> defines a clinically aggressive subset of <span class=""disease"" id=""24793135-0-83-109"">embryonal rhabdomyosarcoma</span> associated with PI3K-AKT pathway mutations.",CTD_human
1,0,Biomarker,C0235833,Congenital diaphragmatic hernia,disease,CDH,4654,MYOD1,MyoD,CTD_human,21258934,This is the first study showing that MyoD expression is selectively decreased in the diaphragm muscle in the nitrofen model of CDH.,0.2,"This is the first study showing that <span class=""gene"" id=""21258934-13-37-41"">MyoD</span> expression is selectively decreased in the diaphragm muscle in the nitrofen model of <span class=""disease"" id=""21258934-13-127-130"">CDH</span>.",CTD_human
2,0,Biomarker,C1266119,Solitary fibrous tumor,disease,solitary fibrous tumor,4665,NAB2,NAB2,CTD_human,23313952,Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing.,0.205769262468475,"Identification of recurrent <span class=""gene"" id=""23313952-0-28-32"">NAB2</span>-STAT6 gene fusions in <span class=""disease"" id=""23313952-0-55-77"">solitary fibrous tumor</span> by integrative sequencing.",CTD_human
2,0,Biomarker,C1266119,Solitary fibrous tumor,disease,solitary fibrous tumors,4665,NAB2,NAB2,CTD_human,23313954,Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors.,0.205769262468475,"Whole-exome sequencing identifies a recurrent <span class=""gene"" id=""23313954-0-46-50"">NAB2</span>-STAT6 fusion in <span class=""disease"" id=""23313954-0-67-90"">solitary fibrous tumors</span>.",CTD_human
3,3,Biomarker,C1836544,"Schindler Disease, Type I",disease,Schindler disease,4668,NAGA,alpha-N-acetylgalactosaminidase,CTD_human,2243144,Schindler disease: the molecular lesion in the alpha-N-acetylgalactosaminidase gene that causes an infantile neuroaxonal dystrophy.,0.6016483607052789,"<span class=""disease"" id=""2243144-0-0-17"">Schindler disease</span>: the molecular lesion in the <span class=""gene"" id=""2243144-0-47-78"">alpha-N-acetylgalactosaminidase</span> gene that causes an infantile neuroaxonal dystrophy.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0033578,Prostatic Neoplasms,group,prostate tumors,467,ATF3,ATF3,CTD_human,16516039,They indicate that ATF3 is an androgen regulated gene that is highly expressed in prostate tumors and stimulating cell proliferation.,0.20300763924902696,"They indicate that <span class=""gene"" id=""16516039-11-19-23"">ATF3</span> is an androgen regulated gene that is highly expressed in <span class=""disease"" id=""16516039-11-82-97"">prostate tumors</span> and stimulating cell proliferation.",CTD_human
1,0,Biomarker,C0848558,Hypospadias,disease,hypospadias,467,ATF3,activating transcription factor 3,CTD_human,18001166,"Estradiol upregulates activating transcription factor 3, a candidate gene in the etiology of hypospadias.",0.20947005700088103,"Estradiol upregulates <span class=""gene"" id=""18001166-0-22-55"">activating transcription factor 3</span>, a candidate gene in the etiology of <span class=""disease"" id=""18001166-0-93-104"">hypospadias</span>.",CTD_human
1,0,Biomarker,C0038362,Stomatitis,disease,oral mucositis,4683,NBN,NBN,CTD_human,24594932,Direct correlation of heterozygous and mutant alleles with acute reactions as well as haplotype correlation revealed NBN variants to be of predictive significance in analysing oral mucositis prior to radiotherapy.,0.200274726784213,"Direct correlation of heterozygous and mutant alleles with acute reactions as well as haplotype correlation revealed <span class=""gene"" id=""24594932-6-117-120"">NBN</span> variants to be of predictive significance in analysing <span class=""disease"" id=""24594932-6-176-190"">oral mucositis</span> prior to radiotherapy.",CTD_human
3,47,Biomarker,C0398791,Nijmegen Breakage Syndrome,disease,NBS,4683,NBN,NBS1,CTD_human,17395558,"We describe a patient with a NBS clinical phenotype, chromosomal sensitivity to X-rays but without mutations in the whole NBS1 or in the Cernunnos gene.",0.537330086905011,"We describe a patient with a <span class=""disease"" id=""17395558-6-29-32"">NBS</span> clinical phenotype, chromosomal sensitivity to X-rays but without mutations in the whole <span class=""gene"" id=""17395558-6-122-126"">NBS1</span> or in the Cernunnos gene.",CTD_human;ORPHANET
18,236,Biomarker,C0004135,Ataxia Telangiectasia,disease,AT,472,ATM,ATM,CTD_human,11507245,"In contrast, in AT cells in which ATM is absent or mutated activation of P53 and its target genes is abrogated, allowing cells to replicate with damage in the presence of As, with cell death ensuing by a pathway different from P53.",0.829100420436003,"In contrast, in <span class=""disease"" id=""11507245-10-16-18"">AT</span> cells in which <span class=""gene"" id=""11507245-10-34-37"">ATM</span> is absent or mutated activation of P53 and its target genes is abrogated, allowing cells to replicate with damage in the presence of As, with cell death ensuing by a pathway different from P53.",CTD_human;ORPHANET;UNIPROT
18,236,Biomarker,C0004135,Ataxia Telangiectasia,disease,ataxia telangiectasia,472,ATM,ATM,CTD_human,11507241,"While in controls both subpathways may be mediated by ATM kinase, in ataxia telangiectasia cells caffeine-sensitive ATR kinase and the caffeine-insensitive DNA-PK kinases might be responsible for DNA repair and the G(2) delay subpathways, respectively.",0.829100420436003,"While in controls both subpathways may be mediated by <span class=""gene"" id=""11507241-7-54-57"">ATM</span> kinase, in <span class=""disease"" id=""11507241-7-69-90"">ataxia telangiectasia</span> cells caffeine-sensitive ATR kinase and the caffeine-insensitive DNA-PK kinases might be responsible for DNA repair and the G(2) delay subpathways, respectively.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0023434,Chronic Lymphocytic Leukemia,disease,chronic lymphocytic leukemia,472,ATM,ATM,CTD_human,17968022,Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion.,0.437397965701353,"Mutation status of the residual <span class=""gene"" id=""17968022-0-32-35"">ATM</span> allele is an important determinant of the cellular response to chemotherapy and survival in patients with <span class=""disease"" id=""17968022-0-142-170"">chronic lymphocytic leukemia</span> containing an 11q deletion.",CTD_human;ORPHANET
1,0,Biomarker,C0027051,Myocardial Infarction,disease,myocardial infarction,472,ATM,ataxia telangiectasia mutated,CTD_human,24358288,Deficiency of ataxia telangiectasia mutated kinase modulates cardiac remodeling following myocardial infarction: involvement in fibrosis and apoptosis.,0.201923087489492,"Deficiency of <span class=""gene"" id=""24358288-0-14-43"">ataxia telangiectasia mutated</span> kinase modulates cardiac remodeling following <span class=""disease"" id=""24358288-0-90-111"">myocardial infarction</span>: involvement in fibrosis and apoptosis.",CTD_human
1,0,Biomarker,C0079774,Peripheral T-Cell Lymphoma,disease,PTCL,472,ATM,ATM,CTD_human,24413734,"In addition, we describe new and recurrent, albeit less frequent, genetic defects including mutations in FYN, ATM, B2M and CD58 implicating SRC signaling, impaired DNA damage response and escape from immune surveillance mechanisms in the pathogenesis of PTCL.",0.20082418035263896,"In addition, we describe new and recurrent, albeit less frequent, genetic defects including mutations in FYN, <span class=""gene"" id=""24413734-5-110-113"">ATM</span>, B2M and CD58 implicating SRC signaling, impaired DNA damage response and escape from immune surveillance mechanisms in the pathogenesis of <span class=""disease"" id=""24413734-5-254-258"">PTCL</span>.",CTD_human
1,0,Biomarker,C0086543,Cataract,disease,cataracts,472,ATM,ATM,CTD_human,16799786,The relative biological effectiveness of densely ionizing heavy-ion radiation for inducing ocular cataracts in wild type versus mice heterozygous for the ATM gene.,0.2,"The relative biological effectiveness of densely ionizing heavy-ion radiation for inducing ocular <span class=""disease"" id=""16799786-0-98-107"">cataracts</span> in wild type versus mice heterozygous for the <span class=""gene"" id=""16799786-0-154-157"">ATM</span> gene.",CTD_human
1,0,Biomarker,C0878544,Cardiomyopathies,group,cardiomyopathy,4720,NDUFS2,NDUFS2,CTD_human,14729820,"While mutations in the NDUFS3 gene thus result in Leigh syndrome, a dissimilar clinical phenotype is observed in mutations in the NDUFV2 and NDUFS2 genes, resulting in encephalomyopathy and cardiomyopathy.",0.20054945356842604,"While mutations in the NDUFS3 gene thus result in Leigh syndrome, a dissimilar clinical phenotype is observed in mutations in the NDUFV2 and <span class=""gene"" id=""14729820-6-141-147"">NDUFS2</span> genes, resulting in encephalomyopathy and <span class=""disease"" id=""14729820-6-190-204"">cardiomyopathy</span>.",CTD_human
1,0,Biomarker,C0023264,Leigh Disease,disease,Leigh syndrome,4722,NDUFS3,NDUFS3,CTD_human,14729820,Mutant NDUFS3 subunit of mitochondrial complex I causes Leigh syndrome.,0.400549453568426,"Mutant <span class=""gene"" id=""14729820-0-7-13"">NDUFS3</span> subunit of mitochondrial complex I causes <span class=""disease"" id=""14729820-0-56-70"">Leigh syndrome</span>.",CTD_human;ORPHANET
5,0,Biomarker,C0005586,Bipolar Disorder,disease,bipolar disorder,4729,NDUFV2,NDUFV2,CTD_human,19135101,Expression of mitochondrial complex I subunit gene NDUFV2 in the lymphoblastoid cells derived from patients with bipolar disorder and schizophrenia.,0.420574119329724,"Expression of mitochondrial complex I subunit gene <span class=""gene"" id=""19135101-0-51-57"">NDUFV2</span> in the lymphoblastoid cells derived from patients with <span class=""disease"" id=""19135101-0-113-129"">bipolar disorder</span> and schizophrenia.",CTD_human;PSYGENET
1,0,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,4729,NDUFV2,NDUFV2,CTD_human,19135101,Expression of mitochondrial complex I subunit gene NDUFV2 in the lymphoblastoid cells derived from patients with bipolar disorder and schizophrenia.,0.20952121415819394,"Expression of mitochondrial complex I subunit gene <span class=""gene"" id=""19135101-0-51-57"">NDUFV2</span> in the lymphoblastoid cells derived from patients with bipolar disorder and <span class=""disease"" id=""19135101-0-134-147"">schizophrenia</span>.",CTD_human
1,0,Biomarker,C0878544,Cardiomyopathies,group,cardiomyopathy,4729,NDUFV2,NDUFV2,CTD_human,14729820,"While mutations in the NDUFS3 gene thus result in Leigh syndrome, a dissimilar clinical phenotype is observed in mutations in the NDUFV2 and NDUFS2 genes, resulting in encephalomyopathy and cardiomyopathy.",0.200274726784213,"While mutations in the NDUFS3 gene thus result in Leigh syndrome, a dissimilar clinical phenotype is observed in mutations in the <span class=""gene"" id=""14729820-6-130-136"">NDUFV2</span> and NDUFS2 genes, resulting in encephalomyopathy and <span class=""disease"" id=""14729820-6-190-204"">cardiomyopathy</span>.",CTD_human
1,0,Biomarker,C0025149,Medulloblastoma,disease,medulloblastoma,474,ATOH1,Atoh1,CTD_human,18347096,"Given that Atoh1 is also a putative target of Hh signaling, we conclude that the Hic1 and Ptch1 tumor suppressors cooperate to silence Atoh1 expression during a critical phase in GCP differentiation in which malignant transformation may lead to medulloblastoma.",0.202197814273705,"Given that <span class=""gene"" id=""18347096-9-11-16"">Atoh1</span> is also a putative target of Hh signaling, we conclude that the Hic1 and Ptch1 tumor suppressors cooperate to silence <span class=""gene"" id=""18347096-9-135-140"">Atoh1</span> expression during a critical phase in GCP differentiation in which malignant transformation may lead to <span class=""disease"" id=""18347096-9-245-260"">medulloblastoma</span>.",CTD_human
1,0,Biomarker,C0010278,Craniosynostosis,disease,craniosynostosis,4745,NELL1,Nell-1,CTD_human,14672347,"Overexpression of Nell-1, a craniosynostosis-associated gene, induces apoptosis in osteoblasts during craniofacial development.",0.20383181960166602,"Overexpression of <span class=""gene"" id=""14672347-0-18-24"">Nell-1</span>, a <span class=""disease"" id=""14672347-0-28-44"">craniosynostosis</span>-associated gene, induces apoptosis in osteoblasts during craniofacial development.",CTD_human
1,0,Biomarker,C0279628,Adenocarcinoma Of Esophagus,disease,esophageal adenocarcinoma,4745,NELL1,NELL1,CTD_human,17452981,"The nel-like1 (NELL1) gene maps to chromosome 11p15, which frequently undergoes loss of heterozygosity in esophageal adenocarcinoma (EAC).",0.200274726784213,"The nel-like1 (<span class=""gene"" id=""17452981-1-15-20"">NELL1</span>) gene maps to chromosome 11p15, which frequently undergoes loss of heterozygosity in <span class=""disease"" id=""17452981-1-106-131"">esophageal adenocarcinoma</span> (EAC).",CTD_human
1,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,475,ATOX1,Atox1,CTD_human,22753205,"In summary, Atox1 functions to prevent Ang II-induced endothelial dysfunction and hypercontraction in resistant vessels, as well as hypertension, in vivo by reducing extracellular superoxide levels via increasing vascular SOD3 expression and activity.",0.2,"In summary, <span class=""gene"" id=""22753205-10-12-17"">Atox1</span> functions to prevent Ang II-induced endothelial dysfunction and hypercontraction in resistant vessels, as well as <span class=""disease"" id=""22753205-10-132-144"">hypertension</span>, in vivo by reducing extracellular superoxide levels via increasing vascular SOD3 expression and activity.",CTD_human
2,0,Biomarker,C0002736,Amyotrophic Lateral Sclerosis,disease,amyotrophic lateral sclerosis,4750,NEK1,NEK1,CTD_human,26945885,NEK1 mutations in familial amyotrophic lateral sclerosis.,0.2,"<span class=""gene"" id=""26945885-0-0-4"">NEK1</span> mutations in familial <span class=""disease"" id=""26945885-0-27-56"">amyotrophic lateral sclerosis</span>.",CTD_human
2,0,Biomarker,C0002736,Amyotrophic Lateral Sclerosis,disease,amyotrophic lateral sclerosis,4750,NEK1,NEK1,CTD_human,27455347,NEK1 variants confer susceptibility to amyotrophic lateral sclerosis.,0.2,"<span class=""gene"" id=""27455347-0-0-4"">NEK1</span> variants confer susceptibility to <span class=""disease"" id=""27455347-0-39-68"">amyotrophic lateral sclerosis</span>.",CTD_human
2,0,Biomarker,C0036996,Short Rib-Polydactyly Syndrome,disease,short-rib polydactyly syndrome,4750,NEK1,NEK1,CTD_human,21211617,NEK1 mutations cause short-rib polydactyly syndrome type majewski.,0.200274726784213,"<span class=""gene"" id=""21211617-0-0-4"">NEK1</span> mutations cause <span class=""disease"" id=""21211617-0-21-51"">short-rib polydactyly syndrome</span> type majewski.",CTD_human
2,0,Biomarker,C0001430,Adenoma,group,adenomas,476,ATP1A1,ATP1A1,CTD_human,23416519,Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension.,0.20082418035263896,"Somatic mutations in <span class=""gene"" id=""23416519-0-21-27"">ATP1A1</span> and ATP2B3 lead to aldosterone-producing <span class=""disease"" id=""23416519-0-69-77"">adenomas</span> and secondary hypertension.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,4763,NF1,neurofibromatosis-1,CTD_human,15389774,Association between the neurofibromatosis-1 (NF1) locus and autism in the Japanese population.,0.204055389228567,"Association between the <span class=""gene"" id=""15389774-0-24-43"">neurofibromatosis-1</span> (NF1) locus and <span class=""disease"" id=""15389774-0-60-66"">autism</span> in the Japanese population.",CTD_human
1,0,Biomarker,C0031511,Pheochromocytoma,disease,pheochromocytomas,4763,NF1,neurofibromatosis,CTD_human,11151443,"Transplantable tumors and cell lines have been developed from pheochromocytomas arising in mice with a heterozygous knockout mutation of the neurofibromatosis gene, Nf1.",0.208711389182872,"Transplantable tumors and cell lines have been developed from <span class=""disease"" id=""11151443-1-62-79"">pheochromocytomas</span> arising in mice with a heterozygous knockout mutation of the <span class=""gene"" id=""11151443-1-141-158"">neurofibromatosis</span> gene, Nf1.",CTD_human
1,0,Biomarker,C3714756,Intellectual Disability,group,mental retardation,4763,NF1,NF1,CTD_human,21236316,A functional tetranucleotide (AAAT) polymorphism in an Alu element in the NF1 gene is associated with mental retardation.,0.40082418035263895,"A functional tetranucleotide (AAAT) polymorphism in an Alu element in the <span class=""gene"" id=""21236316-0-74-77"">NF1</span> gene is associated with <span class=""disease"" id=""21236316-0-102-120"">mental retardation</span>.",CTD_human;HPO
6,0,Biomarker,C0025500,Mesothelioma,disease,mesothelioma,4771,NF2,NF2,CTD_human,12136076,"Immunohistochemical analysis of the mesothelioma confirmed loss of expression of the NF2 protein, and comparative genomic hybridization revealed losses of chromosomes 14, 15, and 22, and gain of 7.",0.207114185634906,"Immunohistochemical analysis of the <span class=""disease"" id=""12136076-3-36-48"">mesothelioma</span> confirmed loss of expression of the <span class=""gene"" id=""12136076-3-85-88"">NF2</span> protein, and comparative genomic hybridization revealed losses of chromosomes 14, 15, and 22, and gain of 7.",CTD_human
6,0,Biomarker,C0025500,Mesothelioma,disease,mesothelioma,4771,NF2,Nf2,CTD_human,12802287,"In order to assess whether NF2 hemizygosity may enhance susceptibility to asbestos fibres, we investigated the Nf2 status in mesothelioma developed in mice presenting a heterozygous mutation of the Nf2 gene (Nf2(KO3/+)), after intraperitoneal inoculation of crocidolite fibres.",0.207114185634906,"In order to assess whether NF2 hemizygosity may enhance susceptibility to asbestos fibres, we investigated the Nf2 status in <span class=""disease"" id=""12802287-2-125-137"">mesothelioma</span> developed in mice presenting a heterozygous mutation of the <span class=""gene"" id=""12802287-2-198-201"">Nf2</span> gene (Nf2(KO3/+)), after intraperitoneal inoculation of crocidolite fibres.",CTD_human
1,0,Biomarker,C0013421,Dystonia,phenotype,dystonia,478,ATP1A3,DYT12,CTD_human,15260953,"Rapid-onset dystonia-parkinsonism (RDP, DYT12) is a distinctive autosomal-dominant movement disorder with variable expressivity and reduced penetrance characterized by abrupt onset of dystonia, usually accompanied by signs of parkinsonism.",0.40657908744379706,"Rapid-onset dystonia-parkinsonism (RDP, <span class=""gene"" id=""15260953-1-40-45"">DYT12</span>) is a distinctive autosomal-dominant movement disorder with variable expressivity and reduced penetrance characterized by abrupt onset of <span class=""disease"" id=""15260953-1-184-192"">dystonia</span>, usually accompanied by signs of parkinsonism.",CTD_human;HPO
1,0,Biomarker,C0242422,Parkinsonian Disorders,group,parkinsonism,478,ATP1A3,DYT12,CTD_human,15260953,"Rapid-onset dystonia-parkinsonism (RDP, DYT12) is a distinctive autosomal-dominant movement disorder with variable expressivity and reduced penetrance characterized by abrupt onset of dystonia, usually accompanied by signs of parkinsonism.",0.404655999954306,"Rapid-onset dystonia-parkinsonism (RDP, <span class=""gene"" id=""15260953-1-40-45"">DYT12</span>) is a distinctive autosomal-dominant movement disorder with variable expressivity and reduced penetrance characterized by abrupt onset of dystonia, usually accompanied by signs of <span class=""disease"" id=""15260953-1-226-238"">parkinsonism</span>.",CTD_human;HPO
2,0,Biomarker,C0338488,Alternating hemiplegia of childhood,disease,alternating hemiplegia of childhood,478,ATP1A3,ATP1A3,CTD_human,22842232,De novo mutations in ATP1A3 cause alternating hemiplegia of childhood.,0.407417623173754,"De novo mutations in <span class=""gene"" id=""22842232-0-21-27"">ATP1A3</span> cause <span class=""disease"" id=""22842232-0-34-69"">alternating hemiplegia of childhood</span>.",CTD_human;ORPHANET
2,0,Biomarker,C0338488,Alternating hemiplegia of childhood,disease,Alternating Hemiplegia of Childhood,478,ATP1A3,ATP1A3,CTD_human,24631656,"De novo mutations in ATP1A3, the gene encoding the ?3-subunit of Na(+),K(+)-ATPase, are associated with the neurodevelopmental disorder Alternating Hemiplegia of Childhood (AHC).",0.407417623173754,"De novo mutations in <span class=""gene"" id=""24631656-1-21-27"">ATP1A3</span>, the gene encoding the &alpha;3-subunit of Na(+),K(+)-ATPase, are associated with the neurodevelopmental disorder <span class=""disease"" id=""24631656-1-136-171"">Alternating Hemiplegia of Childhood</span> (AHC).",CTD_human;ORPHANET
3,18,Biomarker,C1868681,DYSTONIA 12,disease,rapid-onset dystonia parkinsonism,478,ATP1A3,ATP1A3,CTD_human,15260953,Mutations in the Na+/K+ -ATPase alpha3 gene ATP1A3 are associated with rapid-onset dystonia parkinsonism.,0.608791257094819,"Mutations in the Na+/K+ -ATPase alpha3 gene <span class=""gene"" id=""15260953-0-44-50"">ATP1A3</span> are associated with <span class=""disease"" id=""15260953-0-71-104"">rapid-onset dystonia parkinsonism</span>.",CTD_human;ORPHANET;UNIPROT
2,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,non-small cell lung cancer,4780,NFE2L2,NRF2,CTD_human,26482881,NRF2 regulates serine biosynthesis in non-small cell lung cancer.,0.20714289638954103,"<span class=""gene"" id=""26482881-0-0-4"">NRF2</span> regulates serine biosynthesis in <span class=""disease"" id=""26482881-0-38-64"">non-small cell lung cancer</span>.",CTD_human
2,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,non-small-cell lung carcinoma,4780,NFE2L2,NRF2,CTD_human,22684020,Regulatory role of KEAP1 and NRF2 in PPAR? expression and chemoresistance in human non-small-cell lung carcinoma cells.,0.20714289638954103,"Regulatory role of KEAP1 and <span class=""gene"" id=""22684020-0-29-33"">NRF2</span> in PPAR&gamma; expression and chemoresistance in human <span class=""disease"" id=""22684020-0-83-112"">non-small-cell lung carcinoma</span> cells.",CTD_human
1,0,Therapeutic,C0011881,Diabetic Nephropathy,disease,diabetic nephropathy,4780,NFE2L2,Nrf2,CTD_human,20103708,The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy.,0.281923087489492,"The protective role of <span class=""gene"" id=""20103708-0-23-27"">Nrf2</span> in streptozotocin-induced <span class=""disease"" id=""20103708-0-54-74"">diabetic nephropathy</span>.",CTD_human
1,0,Biomarker,C0020456,Hyperglycemia,disease,hyperglycemia,4780,NFE2L2,Nuclear factor erythroid 2-related factor 2,CTD_human,20086057,Nuclear factor erythroid 2-related factor 2 deletion impairs glucose tolerance and exacerbates hyperglycemia in type 1 diabetic mice.,0.20082418035263896,"<span class=""gene"" id=""20086057-0-0-43"">Nuclear factor erythroid 2-related factor 2</span> deletion impairs glucose tolerance and exacerbates <span class=""disease"" id=""20086057-0-95-108"">hyperglycemia</span> in type 1 diabetic mice.",CTD_human
2,0,Biomarker,C0033578,Prostatic Neoplasms,group,prostate tumors,4780,NFE2L2,Nrf2,CTD_human,23441843,We previously demonstrated that the progression of prostate tumors in TRAMP mice is associated with methylation silencing of the Nrf2 promoter and a reduced level of transcription of Nrf2 and Nrf2 target genes.,0.2,"We previously demonstrated that the progression of <span class=""disease"" id=""23441843-2-51-66"">prostate tumors</span> in TRAMP mice is associated with methylation silencing of the <span class=""gene"" id=""23441843-2-129-133"">Nrf2</span> promoter and a reduced level of transcription of <span class=""gene"" id=""23441843-2-183-187"">Nrf2</span> and <span class=""gene"" id=""23441843-2-192-196"">Nrf2</span> target genes.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,4780,NFE2L2,NFE2L2,CTD_human,22561517,"We found new recurrent alterations in four genes (ARID1A, RPS6KA3, NFE2L2 and IRF2) not previously described in HCC.",0.20467035533162303,"We found new recurrent alterations in four genes (ARID1A, RPS6KA3, <span class=""gene"" id=""22561517-4-67-73"">NFE2L2</span> and IRF2) not previously described in <span class=""disease"" id=""22561517-4-112-115"">HCC</span>.",CTD_human
1,0,Biomarker,C0019829,Hodgkin Disease,disease,HL,4792,NFKBIA,NFKBIA,CTD_human,19223558,Nominally significant associations with HL risk were detected for SNPs in NFKBIA and CYP2C9.,0.20701187132028098,"Nominally significant associations with <span class=""disease"" id=""19223558-8-40-42"">HL</span> risk were detected for SNPs in <span class=""gene"" id=""19223558-8-74-80"">NFKBIA</span> and CYP2C9.",CTD_human
1,2,Biomarker,C0003873,Rheumatoid Arthritis,disease,rheumatoid arthritis,4794,NFKBIE,NFKBIE,CTD_human,22446963,"Our study identified nine loci newly associated with rheumatoid arthritis at a threshold of P < 5.0 × 10(-8), including B3GNT2, ANXA3, CSF2, CD83, NFKBIE, ARID5B, PDE2A-ARAP1, PLD4 and PTPN2.",0.202681755307501,"Our study identified nine loci newly associated with <span class=""disease"" id=""22446963-3-53-73"">rheumatoid arthritis</span> at a threshold of P &lt; 5.0 &times; 10(-8), including B3GNT2, ANXA3, CSF2, CD83, <span class=""gene"" id=""22446963-3-147-153"">NFKBIE</span>, ARID5B, PDE2A-ARAP1, PLD4 and PTPN2.",CTD_human
2,0,Therapeutic,C0002622,Amnesia,disease,amnesia,4803,NGF,NGF,CTD_human,19694610,"As shown by the passive avoidance reflex (PAR) test, the intravenous administration of the nanoparticle-bound NGF successfully reversed scopolamine-induced amnesia and improved recognition and memory.",0.200274726784213,"As shown by the passive avoidance reflex (PAR) test, the intravenous administration of the nanoparticle-bound <span class=""gene"" id=""19694610-8-110-113"">NGF</span> successfully reversed scopolamine-induced <span class=""disease"" id=""19694610-8-156-163"">amnesia</span> and improved recognition and memory.",CTD_human
2,0,Therapeutic,C0002622,Amnesia,disease,amnesia,4803,NGF,NGF,CTD_human,16405025,"In the form of an aqueous solution, NGF did not inhibit the scopolamine-induced amnesia.",0.200274726784213,"In the form of an aqueous solution, <span class=""gene"" id=""16405025-5-36-39"">NGF</span> did not inhibit the scopolamine-induced <span class=""disease"" id=""16405025-5-80-87"">amnesia</span>.",CTD_human
1,0,Therapeutic,C0010043,Corneal Ulcer,disease,corneal ulcers,4803,NGF,nerve growth factor,CTD_human,24244623,"Considering that nerve growth factor exerts beneficial effects in the treatment of major central and peripheral neurodegenerative diseases, skin and corneal ulcers, we asked whether nerve growth factor could also exert a role in Cyclosporine A-induced graft nephrotoxicity.",0.2,"Considering that <span class=""gene"" id=""24244623-3-17-36"">nerve growth factor</span> exerts beneficial effects in the treatment of major central and peripheral neurodegenerative diseases, skin and <span class=""disease"" id=""24244623-3-149-163"">corneal ulcers</span>, we asked whether <span class=""gene"" id=""24244623-3-182-201"">nerve growth factor</span> could also exert a role in Cyclosporine A-induced graft nephrotoxicity.",CTD_human
1,0,Biomarker,C0010692,Cystitis,disease,inflammation of bladder,4803,NGF,NGF,CTD_human,16889433,Overexpression of NGF is known to mediate inflammation of bladder in this model.,0.28054945356842603,"Overexpression of <span class=""gene"" id=""16889433-6-18-21"">NGF</span> is known to mediate <span class=""disease"" id=""16889433-6-42-65"">inflammation of bladder</span> in this model.",CTD_human
1,0,Biomarker,C0014549,Tonic-Clonic Epilepsy,disease,tonic-clonic convulsions,4803,NGF,NGF,CTD_human,16023256,"At 4 h following pilocarpine-induced seizures, expression of NGF, BDNF, HB-EGF, and FGF-2 increased only in the mice manifesting tonic-clonic convulsions and not in mice without seizures.",0.2,"At 4 h following pilocarpine-induced seizures, expression of <span class=""gene"" id=""16023256-5-61-64"">NGF</span>, BDNF, HB-EGF, and FGF-2 increased only in the mice manifesting <span class=""disease"" id=""16023256-5-129-153"">tonic-clonic convulsions</span> and not in mice without seizures.",CTD_human
1,0,Biomarker,C0020429,Hyperalgesia,phenotype,hyperalgesia,4803,NGF,NGF,CTD_human,20457222,"After injection of NGF, GDNF or PsiepsilonRACK, at a time at which hyperalgesia induced by PGE(2) is markedly prolonged (hyperalgesic priming) in control rats, in IB4-saporin-pretreated rats PGE(2) failed to produce this prolonged hyperalgesia.",0.28054945356842603,"After injection of <span class=""gene"" id=""20457222-6-19-22"">NGF</span>, GDNF or PsiepsilonRACK, at a time at which <span class=""disease"" id=""20457222-6-67-79"">hyperalgesia</span> induced by PGE(2) is markedly prolonged (hyperalgesic priming) in control rats, in IB4-saporin-pretreated rats PGE(2) failed to produce this prolonged <span class=""disease"" id=""20457222-6-231-243"">hyperalgesia</span>.",CTD_human
1,0,Biomarker,C0022661,"Kidney Failure, Chronic",disease,end-stage renal disease,4803,NGF,Nerve growth factor,CTD_human,24244623,"Nerve growth factor serum concentrations increase during many inflammatory and autoimmune diseases, glomerulonephritis, chronic kidney disease, end-stage renal disease and, particularly, in renal transplant.",0.200274726784213,"<span class=""gene"" id=""24244623-2-0-19"">Nerve growth factor</span> serum concentrations increase during many inflammatory and autoimmune diseases, glomerulonephritis, chronic kidney disease, <span class=""disease"" id=""24244623-2-144-167"">end-stage renal disease</span> and, particularly, in renal transplant.",CTD_human
1,0,Biomarker,C0030567,Parkinson Disease,disease,PD,4803,NGF,nerve growth factor,CTD_human,19276553,"IGF-I and IGF-II resistance was present in DLB but not PD frontal cortex, and associated with reduced expression of Hu, nerve growth factor, and Trk neurotrophin receptors, and increased levels of glial fibrillary acidic protein, alpha-synuclein, dopamine-beta-hydroxylase, 4-hydroxy-2-nonenal (HNE), and ubiquitin immunoreactivity.",0.20082418035263896,"IGF-I and IGF-II resistance was present in DLB but not <span class=""disease"" id=""19276553-4-55-57"">PD</span> frontal cortex, and associated with reduced expression of Hu, <span class=""gene"" id=""19276553-4-120-139"">nerve growth factor</span>, and Trk neurotrophin receptors, and increased levels of glial fibrillary acidic protein, alpha-synuclein, dopamine-beta-hydroxylase, 4-hydroxy-2-nonenal (HNE), and ubiquitin immunoreactivity.",CTD_human
1,0,Biomarker,C0036572,Seizures,phenotype,seizures,4803,NGF,NGF,CTD_human,18815271,"Overall, these studies demonstrate the requirement for NRIF to signal p75(NTR)-mediated apoptosis of hippocampal neurons and that blocking pro-NGF can inhibit neuronal loss after seizures.",0.20082418035263896,"Overall, these studies demonstrate the requirement for NRIF to signal p75(NTR)-mediated apoptosis of hippocampal neurons and that blocking pro-<span class=""gene"" id=""18815271-9-143-146"">NGF</span> can inhibit neuronal loss after <span class=""disease"" id=""18815271-9-179-187"">seizures</span>.",CTD_human
2,0,Biomarker,C0038220,Status Epilepticus,disease,status epilepticus,4803,NGF,NGF,CTD_human,8821376,"Cellular hybridization for BDNF, trkB, and NGF mRNAs and BDNF-immunoreactivity in rat forebrain after pilocarpine-induced status epilepticus.",0.2,"Cellular hybridization for BDNF, trkB, and <span class=""gene"" id=""8821376-0-43-46"">NGF</span> mRNAs and BDNF-immunoreactivity in rat forebrain after pilocarpine-induced <span class=""disease"" id=""8821376-0-122-140"">status epilepticus</span>.",CTD_human
2,0,Biomarker,C0038220,Status Epilepticus,disease,SE,4803,NGF,NGF,CTD_human,8635431,We studied the effects of status epilepticus (SE) induced by lithium chloride/pilocarpine treatment on gene expression of neurotrophins of the nerve growth factor (NGF) family and of their high-affinity receptors of the tyrosine protein kinase (trk) family in the forebrain.,0.2,"We studied the effects of <span class=""disease"" id=""8635431-1-26-44"">status epilepticus</span> (<span class=""disease"" id=""8635431-1-46-48"">SE</span>) induced by lithium chloride/pilocarpine treatment on gene expression of neurotrophins of the <span class=""gene"" id=""8635431-1-143-162"">nerve growth factor</span> (<span class=""gene"" id=""8635431-1-164-167"">NGF</span>) family and of their high-affinity receptors of the tyrosine protein kinase (trk) family in the forebrain.",CTD_human
1,0,Therapeutic,C0242422,Parkinsonian Disorders,group,Parkinsonian syndrome,4803,NGF,NGF,CTD_human,19694610,"The present study investigates brain delivery of NGF adsorbed on poly(butyl cyanoacrylate) (PBCA) nanoparticles coated with polysorbate 80 and the pharmacological efficacy of this delivery system in the model of acute scopolamine-induced amnesia in rats as well as in the model of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinsonian syndrome.",0.2,"The present study investigates brain delivery of <span class=""gene"" id=""19694610-7-49-52"">NGF</span> adsorbed on poly(butyl cyanoacrylate) (PBCA) nanoparticles coated with polysorbate 80 and the pharmacological efficacy of this delivery system in the model of acute scopolamine-induced amnesia in rats as well as in the model of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced <span class=""disease"" id=""19694610-7-341-362"">Parkinsonian syndrome</span>.",CTD_human
1,0,Biomarker,C0345967,Malignant mesothelioma,disease,MM,4803,NGF,NGF,CTD_human,25162674,"A specific pattern of cytokines were found highly expressed in Asb-workers: IFN-alpha (p<0.05), EOTAXIN (p<0.01), RANTES (p<0.001), and in MM patients: IL-12(p40), IL-3, IL-1 alpha, MCP-3, beta-NGF, TNF-beta, RANTES (p<0.001).",0.200274726784213,"A specific pattern of cytokines were found highly expressed in Asb-workers: IFN-alpha (p&lt;0.05), EOTAXIN (p&lt;0.01), RANTES (p&lt;0.001), and in <span class=""disease"" id=""25162674-8-139-141"">MM</span> patients: IL-12(p40), IL-3, IL-1 alpha, MCP-3, beta-<span class=""gene"" id=""25162674-8-194-197"">NGF</span>, TNF-beta, RANTES (p&lt;0.001).",CTD_human
1,0,Biomarker,C0424295,Hyperactive behavior,phenotype,hyperactivity,4803,NGF,NGF,CTD_human,1661212,"More striking, NGF pups showed a marked hyperactivity after scopolamine, an effect which normally appears only around weaning time.",0.20082418035263896,"More striking, <span class=""gene"" id=""1661212-4-15-18"">NGF</span> pups showed a marked <span class=""disease"" id=""1661212-4-40-53"">hyperactivity</span> after scopolamine, an effect which normally appears only around weaning time.",CTD_human
1,0,Therapeutic,C0524851,Neurodegenerative Disorders,group,neurodegenerative diseases,4803,NGF,nerve growth factor,CTD_human,24244623,"Considering that nerve growth factor exerts beneficial effects in the treatment of major central and peripheral neurodegenerative diseases, skin and corneal ulcers, we asked whether nerve growth factor could also exert a role in Cyclosporine A-induced graft nephrotoxicity.",0.201648360705279,"Considering that <span class=""gene"" id=""24244623-3-17-36"">nerve growth factor</span> exerts beneficial effects in the treatment of major central and peripheral <span class=""disease"" id=""24244623-3-112-138"">neurodegenerative diseases</span>, skin and corneal ulcers, we asked whether <span class=""gene"" id=""24244623-3-182-201"">nerve growth factor</span> could also exert a role in Cyclosporine A-induced graft nephrotoxicity.",CTD_human
1,0,Biomarker,C0752347,Lewy Body Disease,disease,DLB,4803,NGF,nerve growth factor,CTD_human,19276553,"IGF-I and IGF-II resistance was present in DLB but not PD frontal cortex, and associated with reduced expression of Hu, nerve growth factor, and Trk neurotrophin receptors, and increased levels of glial fibrillary acidic protein, alpha-synuclein, dopamine-beta-hydroxylase, 4-hydroxy-2-nonenal (HNE), and ubiquitin immunoreactivity.",0.200274726784213,"IGF-I and IGF-II resistance was present in <span class=""disease"" id=""19276553-4-43-46"">DLB</span> but not PD frontal cortex, and associated with reduced expression of Hu, <span class=""gene"" id=""19276553-4-120-139"">nerve growth factor</span>, and Trk neurotrophin receptors, and increased levels of glial fibrillary acidic protein, alpha-synuclein, dopamine-beta-hydroxylase, 4-hydroxy-2-nonenal (HNE), and ubiquitin immunoreactivity.",CTD_human
1,0,Biomarker,C0878773,Overactive Bladder,disease,overactive bladder,4803,NGF,Nerve growth factor,CTD_human,16600756,Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder.,0.28,"<span class=""gene"" id=""16600756-0-0-19"">Nerve growth factor</span> and prostaglandins in the urine of female patients with <span class=""disease"" id=""16600756-0-76-94"">overactive bladder</span>.",CTD_human
2,0,Biomarker,C0033578,Prostatic Neoplasms,group,prostate tumor,4804,NGFR,p75NTR,CTD_human,17409433,The aryl propionic acid R-flurbiprofen selectively induces p75NTR-dependent decreased survival of prostate tumor cells.,0.20082418035263896,"The aryl propionic acid R-flurbiprofen selectively induces <span class=""gene"" id=""17409433-0-59-65"">p75NTR</span>-dependent decreased survival of <span class=""disease"" id=""17409433-0-98-112"">prostate tumor</span> cells.",CTD_human
2,0,Therapeutic,C0033578,Prostatic Neoplasms,group,prostate tumor,4804,NGFR,p75NTR,CTD_human,17409433,The aryl propionic acid R-flurbiprofen selectively induces p75NTR-dependent decreased survival of prostate tumor cells.,0.20082418035263896,"The aryl propionic acid R-flurbiprofen selectively induces <span class=""gene"" id=""17409433-0-59-65"">p75NTR</span>-dependent decreased survival of <span class=""disease"" id=""17409433-0-98-112"">prostate tumor</span> cells.",CTD_human
1,0,Biomarker,C0036572,Seizures,phenotype,Seizure,4804,NGFR,p75NTR,CTD_human,10436046,"Seizure-induced increases in p75NTR protein and mRNA were detected in hippocampus, piriform cortex, and entorhinal cortex.",0.28,"<span class=""disease"" id=""10436046-6-0-7"">Seizure</span>-induced increases in <span class=""gene"" id=""10436046-6-29-35"">p75NTR</span> protein and mRNA were detected in hippocampus, piriform cortex, and entorhinal cortex.",CTD_human
1,0,Biomarker,C0017638,Glioma,disease,glioma,482,ATP1B2,AMOG,CTD_human,16865689,"Taken together, we identified interesting novel candidate genes that likely contribute to glioma progression and provide first evidence for a role of epigenetic silencing of AMOG in malignant glioma cells.",0.203557092817453,"Taken together, we identified interesting novel candidate genes that likely contribute to <span class=""disease"" id=""16865689-7-90-96"">glioma</span> progression and provide first evidence for a role of epigenetic silencing of <span class=""gene"" id=""16865689-7-174-178"">AMOG</span> in malignant glioma cells.",CTD_human
1,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,NSCLC,4826,NNAT,neuronatin,CTD_human,17043644,"Of the more than 200 genes upregulated by these treatments, three of these, neuronatin, metallothionein 3 and cystatin E/M, were frequently hypermethylated and transcriptionally downregulated in NSCLC cell lines and tumors.",0.200274726784213,"Of the more than 200 genes upregulated by these treatments, three of these, <span class=""gene"" id=""17043644-5-76-86"">neuronatin</span>, metallothionein 3 and cystatin E/M, were frequently hypermethylated and transcriptionally downregulated in <span class=""disease"" id=""17043644-5-195-200"">NSCLC</span> cell lines and tumors.",CTD_human
1,0,Biomarker,C0027819,Neuroblastoma,disease,neuroblastoma,4826,NNAT,neuronatin,CTD_human,17762496,High expressions of neuronatin isoforms in favorable neuroblastoma.,0.20054945356842604,"High expressions of <span class=""gene"" id=""17762496-0-20-30"">neuronatin</span> isoforms in favorable <span class=""disease"" id=""17762496-0-53-66"">neuroblastoma</span>.",CTD_human
1,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastasis,4830,NME1,NM23-M1,CTD_human,15928304,The lack of NM23-M1 expression promotes metastasis in the SV40 animal model of liver carcinogenesis.,0.30068117603303496,"The lack of <span class=""gene"" id=""15928304-13-12-19"">NM23-M1</span> expression promotes <span class=""disease"" id=""15928304-13-40-50"">metastasis</span> in the SV40 animal model of liver carcinogenesis.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,4830,NME1,nm23-H1,CTD_human,21472284,"These identified proteins, which include stratifin (14-3-3), transgelin 2, heat-shock protein (HSP)70, HSP27, manganese superoxide dismutase, prohibitin, DJ1, ?-enolase, peroxiredoxin 6, aldo-keto reductase family member B10, phosphoglycerate kinase 1, ?-1-antitrypsin and nm23-H1, may play a role in the development of HCC.",0.20494508211583604,"These identified proteins, which include stratifin (14-3-3), transgelin 2, heat-shock protein (HSP)70, HSP27, manganese superoxide dismutase, prohibitin, DJ1, &alpha;-enolase, peroxiredoxin 6, aldo-keto reductase family member B10, phosphoglycerate kinase 1, &alpha;-1-antitrypsin and <span class=""gene"" id=""21472284-9-273-280"">nm23-H1</span>, may play a role in the development of <span class=""disease"" id=""21472284-9-320-323"">HCC</span>.",CTD_human
1,0,Biomarker,C0001824,Agranulocytosis,disease,agranulocytosis,4835,NQO2,NQO2,CTD_human,14617031,NQO2 gene is associated with clozapine-induced agranulocytosis.,0.202681755307501,"<span class=""gene"" id=""14617031-0-0-4"">NQO2</span> gene is associated with clozapine-induced <span class=""disease"" id=""14617031-0-47-62"">agranulocytosis</span>.",CTD_human
1,0,Biomarker,C0079541,Holoprosencephaly,disease,HPE,4838,NODAL,NODAL,CTD_human,23264560,NODAL and SHH dose-dependent double inhibition promotes an HPE-like phenotype in chick embryos.,0.20300763924902696,"<span class=""gene"" id=""23264560-0-0-5"">NODAL</span> and SHH dose-dependent double inhibition promotes an <span class=""disease"" id=""23264560-0-59-62"">HPE</span>-like phenotype in chick embryos.",CTD_human
1,0,Biomarker,C0007760,Cerebellar Diseases,group,cerebellar dysfunction,4842,NOS1,nNOS,CTD_human,25511929,"Thus, homozygous mutation of the nNOS gene increases vulnerability to alcohol-induced cerebellar dysfunction and neuronal loss. nNOS is the first gene identified whose mutation worsens alcohol-induced cerebellar behavioral deficits.",0.2,"Thus, homozygous mutation of the <span class=""gene"" id=""25511929-13-33-37"">nNOS</span> gene increases vulnerability to alcohol-induced <span class=""disease"" id=""25511929-13-86-108"">cerebellar dysfunction</span> and neuronal loss. nNOS is the first gene identified whose mutation worsens alcohol-induced cerebellar behavioral deficits.",CTD_human
1,0,Biomarker,C0030567,Parkinson Disease,disease,PD,4842,NOS1,NOS1,CTD_human,26383258,Our data provide evidence for NOS1 modifying PD risk in OP exposed populations.,0.21182592836685699,"Our data provide evidence for <span class=""gene"" id=""26383258-11-30-34"">NOS1</span> modifying <span class=""disease"" id=""26383258-11-45-47"">PD</span> risk in OP exposed populations.",CTD_human
1,0,Biomarker,C0004096,Asthma,disease,airway hyperreactivity,4843,NOS2,NOS2,CTD_human,19800904,"We found that administration of nor-NOHA significantly decreased airway hyperreactivity and eosinophilic airway inflammation in ovalbumin-exposed C57BL/6 mice, but these parameters were unchanged in ovalbumin-exposed NOS2-/- mice.",0.23076604236862,"We found that administration of nor-NOHA significantly decreased <span class=""disease"" id=""19800904-5-65-87"">airway hyperreactivity</span> and eosinophilic airway inflammation in ovalbumin-exposed C57BL/6 mice, but these parameters were unchanged in ovalbumin-exposed <span class=""gene"" id=""19800904-5-217-221"">NOS2</span>-/- mice.",CTD_human
2,0,Biomarker,C0008370,Cholestasis,disease,cholestasis,4843,NOS2,NOS2,CTD_human,12612912,"Our findings show that proinflammatory cytokines stimulate the biliary epithelium to generate NO, via NOS2 induction, and that NO causes ductular cholestasis by a RNOS-mediated inhibition of AC and of cAMP-dependent HCO(3)(-) and Cl(-) secretory mechanisms.",0.2,"Our findings show that proinflammatory cytokines stimulate the biliary epithelium to generate NO, via <span class=""gene"" id=""12612912-5-102-106"">NOS2</span> induction, and that NO causes ductular <span class=""disease"" id=""12612912-5-146-157"">cholestasis</span> by a RNOS-mediated inhibition of AC and of cAMP-dependent HCO(3)(-) and Cl(-) secretory mechanisms.",CTD_human
2,0,Biomarker,C0009319,Colitis,disease,colitis,4843,NOS2,iNOS,CTD_human,17449036,"Neutrophils were the main source of iNOS in DSS-induced colitis. iNOS-/- chimeric lines had decreased colonic macrophage inflammatory protein 1beta and tumor necrosis factor alpha expression and increased levels of the protective growth factor, keratinocyte growth factor.",0.20082418035263896,"Neutrophils were the main source of <span class=""gene"" id=""17449036-10-36-40"">iNOS</span> in DSS-induced <span class=""disease"" id=""17449036-10-56-63"">colitis</span>. <span class=""gene"" id=""17449036-10-65-69"">iNOS</span>-/- chimeric lines had decreased colonic macrophage inflammatory protein 1beta and tumor necrosis factor alpha expression and increased levels of the protective growth factor, keratinocyte growth factor.",CTD_human
2,0,Biomarker,C0013295,Duodenal Ulcer,disease,duodenal ulcers,4843,NOS2,NOS,CTD_human,12481160,"We investigated the effects of COX and NOS inhibitors on the healing of duodenal ulcers, in comparison with gastric ulcers, in rats.",0.2,"We investigated the effects of COX and <span class=""gene"" id=""12481160-2-39-42"">NOS</span> inhibitors on the healing of <span class=""disease"" id=""12481160-2-72-87"">duodenal ulcers</span>, in comparison with gastric ulcers, in rats.",CTD_human
1,0,Biomarker,C0018801,Heart failure,disease,HF,4843,NOS2,NOS,CTD_human,19168511,NOS inhibition by L-NAME increased basal frequency and attenuated the positive chronotropic effect of beta-adrenergic stimulation in the HF group (P<0.05).,0.203780662444353,"<span class=""gene"" id=""19168511-9-0-3"">NOS</span> inhibition by L-NAME increased basal frequency and attenuated the positive chronotropic effect of beta-adrenergic stimulation in the <span class=""disease"" id=""19168511-9-137-139"">HF</span> group (P&lt;0.05).",CTD_human
2,0,Biomarker,C0020429,Hyperalgesia,phenotype,hyperalgesia,4843,NOS2,inducible NO synthase,CTD_human,19300402,"In streptozotocin-induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway.",0.2,"In streptozotocin-induced <span class=""disease"" id=""19300402-8-26-38"">hyperalgesia</span>, <span class=""gene"" id=""19300402-8-40-61"">inducible NO synthase</span> participates in pronociceptive activity of bradykinin, whereas in vincristine-induced <span class=""disease"" id=""19300402-8-148-160"">hyperalgesia</span> bradykinin seemed to activate neuronal NO synthase pathway.",CTD_human
1,0,Biomarker,C0021831,Intestinal Diseases,group,enteropathy,4843,NOS2,iNOS,CTD_human,11713966,Our data suggest that NO derived from iNOS may be a key factor in the pathogenesis of acute INDO-induced enteropathy in rats.,0.200274726784213,"Our data suggest that NO derived from <span class=""gene"" id=""11713966-9-38-42"">iNOS</span> may be a key factor in the pathogenesis of acute INDO-induced <span class=""disease"" id=""11713966-9-105-116"">enteropathy</span> in rats.",CTD_human
2,0,Biomarker,C0024121,Lung Neoplasms,group,lung tumors,4843,NOS2,iNOS,CTD_human,12460898,"Genetic disruption of iNOS decreased urethane-induced lung tumor multiplicity by 80% (P < 0.0001). iNOS protein was expressed in lung tumors growing in wild-type mice and bronchiolar Clara cells isolated from normal mouse lungs, but was undetectable in whole lung extracts by immunoblotting.",0.2,"Genetic disruption of iNOS decreased urethane-induced <span class=""disease"" id=""12460898-4-54-64"">lung tumor</span> multiplicity by 80% (P &lt; 0.0001). <span class=""gene"" id=""12460898-4-99-103"">iNOS</span> protein was expressed in <span class=""disease"" id=""12460898-4-129-140"">lung tumors</span> growing in wild-type mice and bronchiolar Clara cells isolated from normal mouse lungs, but was undetectable in whole lung extracts by immunoblotting.",CTD_human
2,0,Biomarker,C0027051,Myocardial Infarction,disease,Myocardial infarction,4843,NOS2,iNOS,CTD_human,10090345,"Myocardial infarction was induced by ligation of the left anterior descending coronary artery (LAD), and tissue was collected at selected times thereafter from both ligated and sham-operated rats. iNOS mRNA was induced in the infarcted region of the left ventricle for 7 days; iNOS protein was also detected in the infarcted area.",0.20082418035263896,"<span class=""disease"" id=""10090345-4-0-21"">Myocardial infarction</span> was induced by ligation of the left anterior descending coronary artery (LAD), and tissue was collected at selected times thereafter from both ligated and sham-operated rats. iNOS mRNA was induced in the infarcted region of the left ventricle for 7 days; <span class=""gene"" id=""10090345-4-277-281"">iNOS</span> protein was also detected in the infarcted area.",CTD_human
3,0,Biomarker,C0038358,Gastric ulcer,disease,gastric ulcers,4843,NOS2,NOS,CTD_human,12481160,"We investigated the effects of COX and NOS inhibitors on the healing of duodenal ulcers, in comparison with gastric ulcers, in rats.",0.202732912464814,"We investigated the effects of COX and <span class=""gene"" id=""12481160-2-39-42"">NOS</span> inhibitors on the healing of duodenal ulcers, in comparison with <span class=""disease"" id=""12481160-2-108-122"">gastric ulcers</span>, in rats.",CTD_human
1,0,Biomarker,C0038525,Subarachnoid Hemorrhage,disease,SAH,4843,NOS2,iNOS,CTD_human,17053178,"Treatment of the SAH rat with E(2) did not affect the nuclear translocation of p65 subunit of nuclear factor kappaB, but caused an increase of the association of p65/ER, and reversed the SAH-induced increase of the p65 binding on iNOS promoter.",0.200274726784213,"Treatment of the <span class=""disease"" id=""17053178-8-17-20"">SAH</span> rat with E(2) did not affect the nuclear translocation of p65 subunit of nuclear factor kappaB, but caused an increase of the association of p65/ER, and reversed the <span class=""disease"" id=""17053178-8-187-190"">SAH</span>-induced increase of the p65 binding on <span class=""gene"" id=""17053178-8-230-234"">iNOS</span> promoter.",CTD_human
2,0,Biomarker,C0002395,Alzheimer's Disease,disease,Alzheimer's disease,4846,NOS3,NOS3,CTD_human,10514107,Association between Alzheimer's disease and the NOS3 gene.,0.236287610075892,"Association between <span class=""disease"" id=""10514107-0-20-39"">Alzheimer's disease</span> and the <span class=""gene"" id=""10514107-0-48-52"">NOS3</span> gene.",CTD_human
2,0,Biomarker,C0002395,Alzheimer's Disease,disease,Alzheimer disease,4846,NOS3,endothelial nitric oxide synthase,CTD_human,16813604,Genetic association between endothelial nitric oxide synthase and Alzheimer disease.,0.236287610075892,"Genetic association between <span class=""gene"" id=""16813604-0-28-61"">endothelial nitric oxide synthase</span> and <span class=""disease"" id=""16813604-0-66-83"">Alzheimer disease</span>.",CTD_human
1,0,Therapeutic,C0003850,Arteriosclerosis,disease,atherosclerosis,4846,NOS3,eNOS,CTD_human,14736551,"In conclusion, in vivo gene transfer of eNOS, but not iNOS or eNOS plus iNOS, regressed atherosclerosis.",0.21510997313172103,"In conclusion, in vivo gene transfer of <span class=""gene"" id=""14736551-9-40-44"">eNOS</span>, but not iNOS or <span class=""gene"" id=""14736551-9-62-66"">eNOS</span> plus iNOS, regressed <span class=""disease"" id=""14736551-9-88-103"">atherosclerosis</span>.",CTD_human
1,0,Therapeutic,C0004238,Atrial Fibrillation,disease,atrial fibrillation,4846,NOS3,eNOS,CTD_human,11761419,"In addition, 2 digoxin-treated eNOS-deficient mice and 1 wild-type mouse had inducible nonsustained atrial fibrillation.",0.21340877653750603,"In addition, 2 digoxin-treated <span class=""gene"" id=""11761419-9-31-35"">eNOS</span>-deficient mice and 1 wild-type mouse had inducible nonsustained <span class=""disease"" id=""11761419-9-100-119"">atrial fibrillation</span>.",CTD_human
2,0,Biomarker,C0010073,Coronary Artery Vasospasm,disease,coronary spasm,4846,NOS3,endothelial nitric oxide synthase,CTD_human,9737779,A missense Glu298Asp variant in the endothelial nitric oxide synthase gene is associated with coronary spasm in the Japanese.,0.21895446937907997,"A missense Glu298Asp variant in the <span class=""gene"" id=""9737779-0-36-69"">endothelial nitric oxide synthase</span> gene is associated with <span class=""disease"" id=""9737779-0-94-108"">coronary spasm</span> in the Japanese.",CTD_human
2,0,Biomarker,C0010073,Coronary Artery Vasospasm,disease,coronary spasm,4846,NOS3,endothelial nitric oxide synthase,CTD_human,10359729,T-786-->C mutation in the 5'-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm.,0.21895446937907997,"T-786--&gt;C mutation in the 5'-flanking region of the <span class=""gene"" id=""10359729-0-52-85"">endothelial nitric oxide synthase</span> gene is associated with <span class=""disease"" id=""10359729-0-110-124"">coronary spasm</span>.",CTD_human
2,0,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,type 2 diabetes,4846,NOS3,Endothelial nitric oxide synthase,CTD_human,12716763,Endothelial nitric oxide synthase polymorphisms are associated with type 2 diabetes and the insulin resistance syndrome.,0.28304186997489394,"<span class=""gene"" id=""12716763-0-0-33"">Endothelial nitric oxide synthase</span> polymorphisms are associated with <span class=""disease"" id=""12716763-0-68-83"">type 2 diabetes</span> and the insulin resistance syndrome.",CTD_human
1,0,Biomarker,C0020456,Hyperglycemia,disease,Hyperglycemia,4846,NOS3,endothelial nitric oxide synthase,CTD_human,11696579,Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site.,0.20706302847759303,"<span class=""disease"" id=""11696579-0-0-13"">Hyperglycemia</span> inhibits <span class=""gene"" id=""11696579-0-23-56"">endothelial nitric oxide synthase</span> activity by posttranslational modification at the Akt site.",CTD_human
1,0,Therapeutic,C0020459,Hyperinsulinism,disease,hyperinsulinemia,4846,NOS3,endothelial nitric-oxide synthase,CTD_human,19008412,Increased endothelial nitric-oxide synthase expression reduces hypertension and hyperinsulinemia in fructose-treated rats.,0.202956482091714,"Increased <span class=""gene"" id=""19008412-0-10-43"">endothelial nitric-oxide synthase</span> expression reduces hypertension and <span class=""disease"" id=""19008412-0-80-96"">hyperinsulinemia</span> in fructose-treated rats.",CTD_human
1,0,Biomarker,C0020473,Hyperlipidemia,disease,hyperlipidemia,4846,NOS3,endothelial nitric oxide synthase,CTD_human,11457755,"Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase.",0.20054945356842604,"Insulin resistance, <span class=""disease"" id=""11457755-0-20-34"">hyperlipidemia</span>, and hypertension in mice lacking <span class=""gene"" id=""11457755-0-69-102"">endothelial nitric oxide synthase</span>.",CTD_human
5,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,4846,NOS3,endothelial nitric-oxide synthase,CTD_human,19008412,Increased endothelial nitric-oxide synthase expression reduces hypertension and hyperinsulinemia in fructose-treated rats.,0.353425802886669,"Increased <span class=""gene"" id=""19008412-0-10-43"">endothelial nitric-oxide synthase</span> expression reduces <span class=""disease"" id=""19008412-0-63-75"">hypertension</span> and hyperinsulinemia in fructose-treated rats.",CTD_human
5,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,4846,NOS3,endothelial nitric-oxide synthase,CTD_human,19008412,Increased endothelial nitric-oxide synthase expression reduces hypertension and hyperinsulinemia in fructose-treated rats.,0.353425802886669,"Increased <span class=""gene"" id=""19008412-0-10-43"">endothelial nitric-oxide synthase</span> expression reduces <span class=""disease"" id=""19008412-0-63-75"">hypertension</span> and hyperinsulinemia in fructose-treated rats.",CTD_human
5,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,4846,NOS3,endothelial nitric oxide synthase,CTD_human,11457755,"Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase.",0.353425802886669,"Insulin resistance, hyperlipidemia, and <span class=""disease"" id=""11457755-0-40-52"">hypertension</span> in mice lacking <span class=""gene"" id=""11457755-0-69-102"">endothelial nitric oxide synthase</span>.",CTD_human
5,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,4846,NOS3,NOS3,CTD_human,19407804,"Genetic and pharmacogenetic associations between NOS3 polymorphisms, blood pressure, and cardiovascular events in hypertension.",0.353425802886669,"Genetic and pharmacogenetic associations between <span class=""gene"" id=""19407804-0-49-53"">NOS3</span> polymorphisms, blood pressure, and cardiovascular events in <span class=""disease"" id=""19407804-0-114-126"">hypertension</span>.",CTD_human
5,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,4846,NOS3,endothelial nitric oxide synthase,CTD_human,11457755,"Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase.",0.353425802886669,"Insulin resistance, hyperlipidemia, and <span class=""disease"" id=""11457755-0-40-52"">hypertension</span> in mice lacking <span class=""gene"" id=""11457755-0-69-102"">endothelial nitric oxide synthase</span>.",CTD_human
5,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,4846,NOS3,NOS3,CTD_human,19407804,"Genetic and pharmacogenetic associations between NOS3 polymorphisms, blood pressure, and cardiovascular events in hypertension.",0.353425802886669,"Genetic and pharmacogenetic associations between <span class=""gene"" id=""19407804-0-49-53"">NOS3</span> polymorphisms, blood pressure, and cardiovascular events in <span class=""disease"" id=""19407804-0-114-126"">hypertension</span>.",CTD_human
1,0,Therapeutic,C0020541,"Hypertension, Portal",disease,portal hypertension,4846,NOS3,eNOS,CTD_human,18070013,These data indicate that intrahepatic eNOS plays an important role in the pathogenesis of portal hypertension and gene transfer of eNOS is a potential and novel therapy for portal hypertension.,0.28300763924902694,"These data indicate that intrahepatic <span class=""gene"" id=""18070013-8-38-42"">eNOS</span> plays an important role in the pathogenesis of <span class=""disease"" id=""18070013-8-90-109"">portal hypertension</span> and gene transfer of <span class=""gene"" id=""18070013-8-131-135"">eNOS</span> is a potential and novel therapy for <span class=""disease"" id=""18070013-8-173-192"">portal hypertension</span>.",CTD_human
1,0,Therapeutic,C0020545,"Hypertension, Renovascular",disease,renovascular hypertension,4846,NOS3,eNOS,CTD_human,18641695,"The data indicate that eNOS overexpression was able to prevent the development of 2K1C renovascular hypertension in mice, without affecting other characteristic cardiovascular dysfunctions.",0.200274726784213,"The data indicate that <span class=""gene"" id=""18641695-9-23-27"">eNOS</span> overexpression was able to prevent the development of 2K1C <span class=""disease"" id=""18641695-9-87-112"">renovascular hypertension</span> in mice, without affecting other characteristic cardiovascular dysfunctions.",CTD_human
1,0,Biomarker,C0021364,Male infertility,phenotype,male infertility,4846,NOS3,NOS3,CTD_human,25517965,"Of five NOS gene polymorphisms investigated in the present study, we found NOS3 rs1799983 might cause oxidative sperm DNA damage, thereby contributing to male infertility.",0.206462417751855,"Of five NOS gene polymorphisms investigated in the present study, we found <span class=""gene"" id=""25517965-11-75-79"">NOS3</span> rs1799983 might cause oxidative sperm DNA damage, thereby contributing to <span class=""disease"" id=""25517965-11-154-170"">male infertility</span>.",CTD_human
1,0,Biomarker,C0024117,Chronic Obstructive Airway Disease,disease,COPD,4846,NOS3,eNOS,CTD_human,21843929,Reduced levels of endothelial NOS (eNOS) and elevated levels of inducible NOS (iNOS) in the skeletal muscle of COPD patients have been recently reported.,0.219149328251346,"Reduced levels of <span class=""gene"" id=""21843929-3-18-33"">endothelial NOS</span> (<span class=""gene"" id=""21843929-3-35-39"">eNOS</span>) and elevated levels of inducible NOS (iNOS) in the skeletal muscle of <span class=""disease"" id=""21843929-3-111-115"">COPD</span> patients have been recently reported.",CTD_human
2,0,Biomarker,C0027051,Myocardial Infarction,disease,myocardial infarction,4846,NOS3,eNOS,CTD_human,16337503,Genetic polymorphisms G894T on the eNOS gene is associated with endothelial function and vWF levels in premature myocardial infarction survivors.,0.36822838249997497,"Genetic polymorphisms G894T on the <span class=""gene"" id=""16337503-0-35-39"">eNOS</span> gene is associated with endothelial function and vWF levels in premature <span class=""disease"" id=""16337503-0-113-134"">myocardial infarction</span> survivors.",CTD_human
2,0,Biomarker,C0027051,Myocardial Infarction,disease,MI,4846,NOS3,eNOS,CTD_human,10510054,Homozygosity for a common NOS 3 polymorphism (894 G-->T) which encodes a Glu298-->Asp amino acid substitution in eNOS is a risk factor for angiographic CAD and recent MI in this population.,0.36822838249997497,"Homozygosity for a common <span class=""gene"" id=""10510054-9-26-31"">NOS 3</span> polymorphism (894 G--&gt;T) which encodes a Glu298--&gt;Asp amino acid substitution in <span class=""gene"" id=""10510054-9-113-117"">eNOS</span> is a risk factor for angiographic CAD and recent <span class=""disease"" id=""10510054-9-167-169"">MI</span> in this population.",CTD_human
1,0,Therapeutic,C0034063,Pulmonary Edema,phenotype,pulmonary edema,4846,NOS3,eNOS,CTD_human,16844920,"In conclusion, low-dose simvastatin therapy significantly improves survival and cardiac function and reduces both cardiac hypertrophy and pulmonary edema via an eNOS-dependent mechanism in a murine model of CHF.",0.20541466777231498,"In conclusion, low-dose simvastatin therapy significantly improves survival and cardiac function and reduces both cardiac hypertrophy and <span class=""disease"" id=""16844920-9-138-153"">pulmonary edema</span> via an <span class=""gene"" id=""16844920-9-161-165"">eNOS</span>-dependent mechanism in a murine model of CHF.",CTD_human
1,0,Therapeutic,C0042514,"Tachycardia, Ventricular",disease,ventricular tachycardia,4846,NOS3,eNOS,CTD_human,11761419,"After digoxin pretreatment, 7 of 17 eNOS-deficient mice had inducible ventricular tachycardia and 2 others had frequent ventricular premature beats, compared with only 3 of 11 wild-type mice with inducible ventricular tachycardia.",0.2,"After digoxin pretreatment, 7 of 17 <span class=""gene"" id=""11761419-8-36-40"">eNOS</span>-deficient mice had inducible <span class=""disease"" id=""11761419-8-70-93"">ventricular tachycardia</span> and 2 others had frequent ventricular premature beats, compared with only 3 of 11 wild-type mice with inducible <span class=""disease"" id=""11761419-8-206-229"">ventricular tachycardia</span>.",CTD_human
2,0,Therapeutic,C0242350,Erectile dysfunction,disease,erectile dysfunction,4846,NOS3,endothelial nitric oxide synthase,CTD_human,17071732,Mesenchymal stem cells alone or ex vivo gene modified with endothelial nitric oxide synthase reverse age-associated erectile dysfunction.,0.22688306560964103,"Mesenchymal stem cells alone or ex vivo gene modified with <span class=""gene"" id=""17071732-0-59-92"">endothelial nitric oxide synthase</span> reverse age-associated <span class=""disease"" id=""17071732-0-116-136"">erectile dysfunction</span>.",CTD_human
2,0,Biomarker,C0242350,Erectile dysfunction,disease,erectile dysfunction,4846,NOS3,endothelial nitric oxide synthase,CTD_human,17071732,Mesenchymal stem cells alone or ex vivo gene modified with endothelial nitric oxide synthase reverse age-associated erectile dysfunction.,0.22688306560964103,"Mesenchymal stem cells alone or ex vivo gene modified with <span class=""gene"" id=""17071732-0-59-92"">endothelial nitric oxide synthase</span> reverse age-associated <span class=""disease"" id=""17071732-0-116-136"">erectile dysfunction</span>.",CTD_human
1,0,Biomarker,C0243026,Sepsis,disease,sepsis,4846,NOS3,eNOS,CTD_human,20035746,"Despite a marked decrease in the arterial endothelial nitric oxide synthase (eNOS) mRNA and phosphorylated-eNOS (p-eNOS) protein expressions in sepsis, endothelium-dependent relaxation to acetylcholine (ACh) mediated by NO, acetylcholine-stimulated NO release and tissue cGMP levels were moderately inhibited.",0.20591296418342803,"Despite a marked decrease in the arterial <span class=""gene"" id=""20035746-6-42-75"">endothelial nitric oxide synthase</span> (<span class=""gene"" id=""20035746-6-77-81"">eNOS</span>) mRNA and phosphorylated-eNOS (p-eNOS) protein expressions in <span class=""disease"" id=""20035746-6-144-150"">sepsis</span>, endothelium-dependent relaxation to acetylcholine (ACh) mediated by NO, acetylcholine-stimulated NO release and tissue cGMP levels were moderately inhibited.",CTD_human
3,0,Biomarker,C0524620,Metabolic Syndrome X,disease,metabolic syndrome,4846,NOS3,NOS3,CTD_human,15269839,Association of NOS3 gene with metabolic syndrome in hypertensive patients.,0.22392658351792702,"Association of <span class=""gene"" id=""15269839-0-15-19"">NOS3</span> gene with <span class=""disease"" id=""15269839-0-30-48"">metabolic syndrome</span> in hypertensive patients.",CTD_human
3,0,Biomarker,C0524620,Metabolic Syndrome X,disease,metabolic syndrome,4846,NOS3,endothelial nitric oxide synthase,CTD_human,20876122,Dietary inorganic nitrate reverses features of metabolic syndrome in endothelial nitric oxide synthase-deficient mice.,0.22392658351792702,"Dietary inorganic nitrate reverses features of <span class=""disease"" id=""20876122-0-47-65"">metabolic syndrome</span> in <span class=""gene"" id=""20876122-0-69-102"">endothelial nitric oxide synthase</span>-deficient mice.",CTD_human
3,0,Biomarker,C0524620,Metabolic Syndrome X,disease,metabolic syndrome,4846,NOS3,eNOS,CTD_human,12947532,"We wondered, whether eNOS deficiency in mice is associated with a phenotype mimicking the human metabolic syndrome.",0.22392658351792702,"We wondered, whether <span class=""gene"" id=""12947532-3-21-25"">eNOS</span> deficiency in mice is associated with a phenotype mimicking the human <span class=""disease"" id=""12947532-3-96-114"">metabolic syndrome</span>.",CTD_human
4,1,Biomarker,C1956346,Coronary Artery Disease,disease,coronary artery disease,4846,NOS3,endothelial nitric oxide synthase,CTD_human,10510054,A common variant of the endothelial nitric oxide synthase (Glu298-->Asp) is a major risk factor for coronary artery disease in the UK.,0.32130081780888103,"A common variant of the <span class=""gene"" id=""10510054-0-24-57"">endothelial nitric oxide synthase</span> (Glu298--&gt;Asp) is a major risk factor for <span class=""disease"" id=""10510054-0-100-123"">coronary artery disease</span> in the UK.",CTD_human
4,1,Biomarker,C1956346,Coronary Artery Disease,disease,CAD,4846,NOS3,nos-3,CTD_human,19696404,This FSS-induced rise in SOD-2 expression in CC-genotype ECs effectively stabilizes their antiatherosclerotic phenotype and may explain not only the comparatively slow onset of CAD in homozygous carriers of the C-allele of the nos-3 gene but also define a general strategy for preventing endothelial dysfunction at the outset of atherosclerosis.,0.32130081780888103,"This FSS-induced rise in SOD-2 expression in CC-genotype ECs effectively stabilizes their antiatherosclerotic phenotype and may explain not only the comparatively slow onset of <span class=""disease"" id=""19696404-6-177-180"">CAD</span> in homozygous carriers of the C-allele of the <span class=""gene"" id=""19696404-6-227-232"">nos-3</span> gene but also define a general strategy for preventing endothelial dysfunction at the outset of atherosclerosis.",CTD_human
4,1,Biomarker,C1956346,Coronary Artery Disease,disease,coronary artery disease,4846,NOS3,NOS III,CTD_human,14989558,Interactive effects of the ACE DD polymorphism with the NOS III homozygous G849T (Glu298-->Asp) variant in determining endothelial function in coronary artery disease.,0.32130081780888103,"Interactive effects of the ACE DD polymorphism with the <span class=""gene"" id=""14989558-0-56-63"">NOS III</span> homozygous G849T (Glu298--&gt;Asp) variant in determining endothelial function in <span class=""disease"" id=""14989558-0-143-166"">coronary artery disease</span>.",CTD_human
1,0,Biomarker,C1961099,Precursor T-Cell Lymphoblastic Leukemia-Lymphoma,disease,T-cell acute lymphoblastic leukemia,4849,CNOT3,CNOT3,CTD_human,23263491,Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia.,0.200274726784213,"Exome sequencing identifies mutation in <span class=""gene"" id=""23263491-0-40-45"">CNOT3</span> and ribosomal genes RPL5 and RPL10 in <span class=""disease"" id=""23263491-0-84-119"">T-cell acute lymphoblastic leukemia</span>.",CTD_human
1,0,Biomarker,C0000768,Congenital Abnormality,group,birth defects,4851,NOTCH1,Notch1,CTD_human,17849441,Dll3 and Notch1 genetic interactions model axial segmental and craniofacial malformations of human birth defects.,0.202197814273705,"Dll3 and <span class=""gene"" id=""17849441-0-9-15"">Notch1</span> genetic interactions model axial segmental and craniofacial <span class=""disease"" id=""17849441-0-76-89"">malformations</span> of human <span class=""disease"" id=""17849441-0-99-112"">birth defects</span>.",CTD_human
1,0,Biomarker,C0017636,Glioblastoma,disease,GBM,4851,NOTCH1,Notch1,CTD_human,21127729,"Knockdown of individual Notch receptors revealed that Notch1 and Notch2 receptors differentially contributed to GBM cell growth, with Notch2 having a predominant role.",0.203021994626344,"Knockdown of individual Notch receptors revealed that <span class=""gene"" id=""21127729-5-54-60"">Notch1</span> and Notch2 receptors differentially contributed to <span class=""disease"" id=""21127729-5-112-115"">GBM</span> cell growth, with Notch2 having a predominant role.",CTD_human
1,0,Biomarker,C0024299,Lymphoma,group,lymphoma,4851,NOTCH1,Notch1,CTD_human,18798262,Notch1 is a frequent mutational target in chemically induced lymphoma in mouse.,0.212869092726064,"<span class=""gene"" id=""18798262-0-0-6"">Notch1</span> is a frequent mutational target in chemically induced <span class=""disease"" id=""18798262-0-61-69"">lymphoma</span> in mouse.",CTD_human
4,0,Biomarker,C1961099,Precursor T-Cell Lymphoblastic Leukemia-Lymphoma,disease,T-ALL,4851,NOTCH1,Notch1,CTD_human,24394663,"We and others have shown that Notch1 directly regulates c-Myc, a known regulator of quiescence in stem and progenitor populations, leading us to examine whether c-Myc inhibition results in efficient targeting of T-ALL-initiating cells.",0.254314356630623,"We and others have shown that <span class=""gene"" id=""24394663-3-30-36"">Notch1</span> directly regulates c-Myc, a known regulator of quiescence in stem and progenitor populations, leading us to examine whether c-Myc inhibition results in efficient targeting of <span class=""disease"" id=""24394663-3-212-217"">T-ALL</span>-initiating cells.",CTD_human
4,0,Biomarker,C1961099,Precursor T-Cell Lymphoblastic Leukemia-Lymphoma,disease,T-ALL,4851,NOTCH1,NOTCH1,CTD_human,19246562,This work supports the idea of targeting NOTCH1 in T-ALL and suggests that inhibition of the mTOR and NOTCH1 pathways may have added efficacy.,0.254314356630623,"This work supports the idea of targeting <span class=""gene"" id=""19246562-10-41-47"">NOTCH1</span> in <span class=""disease"" id=""19246562-10-51-56"">T-ALL</span> and suggests that inhibition of the mTOR and <span class=""gene"" id=""19246562-10-102-108"">NOTCH1</span> pathways may have added efficacy.",CTD_human
4,0,Biomarker,C1961099,Precursor T-Cell Lymphoblastic Leukemia-Lymphoma,disease,T-ALL,4851,NOTCH1,NOTCH1,CTD_human,19318552,NOTCH signaling is deregulated in the majority of T-cell acute lymphoblastic leukemias (T-ALL) as a result of activating mutations in NOTCH1.,0.254314356630623,"NOTCH signaling is deregulated in the majority of <span class=""disease"" id=""19318552-1-50-86"">T-cell acute lymphoblastic leukemias</span> (<span class=""disease"" id=""19318552-1-88-93"">T-ALL</span>) as a result of activating mutations in <span class=""gene"" id=""19318552-1-134-140"">NOTCH1</span>.",CTD_human
4,0,Biomarker,C1961099,Precursor T-Cell Lymphoblastic Leukemia-Lymphoma,disease,T-ALL,4851,NOTCH1,NOTCH1,CTD_human,21498710,"The effects of the combination of GSI-XXI plus the Hedgehog inhibitor, cyclopamine (Cy), or the Wnt inhibitor, quercetin (Qu), on the in vitro cell growth, colony formation and Notch1 protein expression of three T-cell acute lymphoblastic leukemia (T-ALL) cell lines with NOTCH1 mutations and three acute myeloid leukemia cell lines were examined.",0.254314356630623,"The effects of the combination of GSI-XXI plus the Hedgehog inhibitor, cyclopamine (Cy), or the Wnt inhibitor, quercetin (Qu), on the in vitro cell growth, colony formation and <span class=""gene"" id=""21498710-4-177-183"">Notch1</span> protein expression of three <span class=""disease"" id=""21498710-4-212-247"">T-cell acute lymphoblastic leukemia</span> (<span class=""disease"" id=""21498710-4-249-254"">T-ALL</span>) cell lines with <span class=""gene"" id=""21498710-4-272-278"">NOTCH1</span> mutations and three acute myeloid leukemia cell lines were examined.",CTD_human
6,0,Biomarker,C0001973,"Alcoholic Intoxication, Chronic",disease,alcoholism,4852,NPY,NPY,CTD_human,17572454,Rat models of alcoholism also show altered NPY.,0.416705497948063,"Rat models of <span class=""disease"" id=""17572454-5-14-24"">alcoholism</span> also show altered <span class=""gene"" id=""17572454-5-43-46"">NPY</span>.",CTD_human;PSYGENET
1,0,Biomarker,C0002395,Alzheimer's Disease,disease,Alzheimer's disease,4852,NPY,Neuropeptide Y,CTD_human,11709213,"Neuropeptide Y, peptide YY and aluminum in Alzheimer's disease: is there an etiological relationship?",0.281373633921066,"<span class=""gene"" id=""11709213-0-0-14"">Neuropeptide Y</span>, peptide YY and aluminum in <span class=""disease"" id=""11709213-0-43-62"">Alzheimer's disease</span>: is there an etiological relationship?",CTD_human
3,0,Biomarker,C0003123,Anorexia,disease,anorectic,4852,NPY,NPY,CTD_human,16101753,"To determine if PKCalpha was involved in the anorectic response of AMPH, the infusions of antisense oligonucleotide into the brain were performed 1 h before daily AMPH treatment in freely moving rats, and the results showed that PKCalpha knock down could block the anorectic response and restore NPY mRNA levels in AMPH-treated rats.",0.281923087489492,"To determine if PKCalpha was involved in the <span class=""disease"" id=""16101753-7-45-54"">anorectic</span> response of AMPH, the infusions of antisense oligonucleotide into the brain were performed 1 h before daily AMPH treatment in freely moving rats, and the results showed that PKCalpha knock down could block the <span class=""disease"" id=""16101753-7-265-274"">anorectic</span> response and restore <span class=""gene"" id=""16101753-7-296-299"">NPY</span> mRNA levels in AMPH-treated rats.",CTD_human
3,0,Biomarker,C0003123,Anorexia,disease,anorectic,4852,NPY,NPY,CTD_human,16084549,"To determine if c-fos or c-jun was involved in the anorectic response of AMPH, infusions of antisense oligonucleotide into the brain were performed at 1 h before daily AMPH treatment in freely moving rats, and the results showed that c-fos or c-jun knockdown could block this anorectic response and restore NPY mRNA level.",0.281923087489492,"To determine if c-fos or c-jun was involved in the <span class=""disease"" id=""16084549-5-51-60"">anorectic</span> response of AMPH, infusions of antisense oligonucleotide into the brain were performed at 1 h before daily AMPH treatment in freely moving rats, and the results showed that c-fos or c-jun knockdown could block this <span class=""disease"" id=""16084549-5-276-285"">anorectic</span> response and restore <span class=""gene"" id=""16084549-5-307-310"">NPY</span> mRNA level.",CTD_human
3,0,Biomarker,C0003123,Anorexia,disease,anorexia,4852,NPY,NPY,CTD_human,25825358,"Results showed that, in AMPH-treated rats, (1) food intake and NPY expression decreased, while CART, GST, and GP expression increased; (2) NPY knockdown in the brain enhanced the decrease in NPY and the increases in CART, GST, and GP expression; and (3) central inhibition of reactive oxygen species production decreased GST and GP and modulated AMPH anorexia and the expression levels of NPY and CART.",0.281923087489492,"Results showed that, in AMPH-treated rats, (1) food intake and <span class=""gene"" id=""25825358-6-63-66"">NPY</span> expression decreased, while CART, GST, and GP expression increased; (2) <span class=""gene"" id=""25825358-6-139-142"">NPY</span> knockdown in the brain enhanced the decrease in <span class=""gene"" id=""25825358-6-191-194"">NPY</span> and the increases in CART, GST, and GP expression; and (3) central inhibition of reactive oxygen species production decreased GST and GP and modulated AMPH <span class=""disease"" id=""25825358-6-351-359"">anorexia</span> and the expression levels of <span class=""gene"" id=""25825358-6-389-392"">NPY</span> and CART.",CTD_human
1,0,Therapeutic,C0003469,Anxiety Disorders,group,anxiety,4852,NPY,Neuropeptide Y,CTD_human,11440811,Neuropeptide Y Y1 receptor-mediated anxiolysis in the dorsocaudal lateral septum: functional antagonism of corticotropin-releasing hormone-induced anxiety.,0.20769234995796698,"<span class=""gene"" id=""11440811-0-0-14"">Neuropeptide Y</span> Y1 receptor-mediated anxiolysis in the dorsocaudal lateral septum: functional antagonism of corticotropin-releasing hormone-induced <span class=""disease"" id=""11440811-0-147-154"">anxiety</span>.",CTD_human
1,0,Biomarker,C0004096,Asthma,disease,asthma,4852,NPY,NPY,CTD_human,9731035,"By comparison with those in normal subjects, the numbers of VIP-immunoreactive nerves were not significantly decreased in patients with asthma and chronic bronchitis, but NPY-immunoreactive nerves were significantly decreased in the smooth muscle of these latter two groups of patients (p < 0.005).",0.20054945356842604,"By comparison with those in normal subjects, the numbers of VIP-immunoreactive nerves were not significantly decreased in patients with <span class=""disease"" id=""9731035-6-136-142"">asthma</span> and chronic bronchitis, but <span class=""gene"" id=""9731035-6-171-174"">NPY</span>-immunoreactive nerves were significantly decreased in the smooth muscle of these latter two groups of patients (p &lt; 0.005).",CTD_human
1,0,Biomarker,C0007785,Cerebral Infarction,disease,cerebral ischemia,4852,NPY,NPY,CTD_human,11821007,These results indicate that peripheral or central administration of NPY impairs reperfusion following experimental MCAO and worsens the outcome of focal cerebral ischemia.,0.28,"These results indicate that peripheral or central administration of <span class=""gene"" id=""11821007-11-68-71"">NPY</span> impairs reperfusion following experimental MCAO and worsens the outcome of focal <span class=""disease"" id=""11821007-11-153-170"">cerebral ischemia</span>.",CTD_human
1,0,Biomarker,C0008677,"Bronchitis, Chronic",disease,chronic bronchitis,4852,NPY,NPY,CTD_human,9731035,"By comparison with those in normal subjects, the numbers of VIP-immunoreactive nerves were not significantly decreased in patients with asthma and chronic bronchitis, but NPY-immunoreactive nerves were significantly decreased in the smooth muscle of these latter two groups of patients (p < 0.005).",0.2,"By comparison with those in normal subjects, the numbers of VIP-immunoreactive nerves were not significantly decreased in patients with asthma and <span class=""disease"" id=""9731035-6-147-165"">chronic bronchitis</span>, but <span class=""gene"" id=""9731035-6-171-174"">NPY</span>-immunoreactive nerves were significantly decreased in the smooth muscle of these latter two groups of patients (p &lt; 0.005).",CTD_human
7,0,Biomarker,C0011581,Depressive disorder,disease,depression,4852,NPY,neuropeptide Y,CTD_human,9729278,Alterations in neuropeptide Y and Y1 receptor mRNA expression in brains from an animal model of depression: region specific adaptation after fluoxetine treatment.,0.48357144819477,"Alterations in <span class=""gene"" id=""9729278-0-15-29"">neuropeptide Y</span> and Y1 receptor mRNA expression in brains from an animal model of <span class=""disease"" id=""9729278-0-96-106"">depression</span>: region specific adaptation after fluoxetine treatment.",CTD_human;PSYGENET
7,0,Biomarker,C0011581,Depressive disorder,disease,depression,4852,NPY,NPY,CTD_human,17572454,The data support our hypothesis that the NPY system dysregulation constitutes one of the biological underpinnings of depression and that one common mechanism of action of antidepressive treatment modalities may be effects on NPY and its receptors.,0.48357144819477,"The data support our hypothesis that the <span class=""gene"" id=""17572454-9-41-44"">NPY</span> system dysregulation constitutes one of the biological underpinnings of <span class=""disease"" id=""17572454-9-117-127"">depression</span> and that one common mechanism of action of antidepressive treatment modalities may be effects on <span class=""gene"" id=""17572454-9-225-228"">NPY</span> and its receptors.",CTD_human;PSYGENET
7,0,Therapeutic,C0011581,Depressive disorder,disease,depression,4852,NPY,NPY,CTD_human,17572454,The data support our hypothesis that the NPY system dysregulation constitutes one of the biological underpinnings of depression and that one common mechanism of action of antidepressive treatment modalities may be effects on NPY and its receptors.,0.48357144819477,"The data support our hypothesis that the <span class=""gene"" id=""17572454-9-41-44"">NPY</span> system dysregulation constitutes one of the biological underpinnings of <span class=""disease"" id=""17572454-9-117-127"">depression</span> and that one common mechanism of action of antidepressive treatment modalities may be effects on <span class=""gene"" id=""17572454-9-225-228"">NPY</span> and its receptors.",CTD_human;PSYGENET
7,0,Therapeutic,C0011581,Depressive disorder,disease,depression,4852,NPY,neuropeptide Y,CTD_human,9729278,Alterations in neuropeptide Y and Y1 receptor mRNA expression in brains from an animal model of depression: region specific adaptation after fluoxetine treatment.,0.48357144819477,"Alterations in <span class=""gene"" id=""9729278-0-15-29"">neuropeptide Y</span> and Y1 receptor mRNA expression in brains from an animal model of <span class=""disease"" id=""9729278-0-96-106"">depression</span>: region specific adaptation after fluoxetine treatment.",CTD_human;PSYGENET
2,0,Therapeutic,C0014544,Epilepsy,disease,epileptic,4852,NPY,NPY,CTD_human,8868293,"NPY in a dose of 2 mg (470 pmol), but not 1 mg, inhibited some excitatory effects of picrotoxin, but did not change the epileptic symptoms.",0.201373633921065,"<span class=""gene"" id=""8868293-6-0-3"">NPY</span> in a dose of 2 mg (470 pmol), but not 1 mg, inhibited some excitatory effects of picrotoxin, but did not change the <span class=""disease"" id=""8868293-6-120-129"">epileptic</span> symptoms.",CTD_human
2,0,Therapeutic,C0014544,Epilepsy,disease,epileptic,4852,NPY,neuropeptide Y,CTD_human,20064661,Results suggest that neuropeptide Y (as anticonvulsant) might act in protective mechanisms occurred during epileptic phenomena.,0.201373633921065,"Results suggest that <span class=""gene"" id=""20064661-13-21-35"">neuropeptide Y</span> (as anticonvulsant) might act in protective mechanisms occurred during <span class=""disease"" id=""20064661-13-107-116"">epileptic</span> phenomena.",CTD_human
1,0,Therapeutic,C0014556,"Epilepsy, Temporal Lobe",disease,temporal lobe epilepsy,4852,NPY,NPY,CTD_human,15716408,"In the pilocarpine model of temporal lobe epilepsy, mossy fibers coexpress the inhibitory transmitter neuropeptide Y (NPY) with glutamate.",0.20082418035263896,"In the pilocarpine model of <span class=""disease"" id=""15716408-1-28-50"">temporal lobe epilepsy</span>, mossy fibers coexpress the inhibitory transmitter <span class=""gene"" id=""15716408-1-102-116"">neuropeptide Y</span> (<span class=""gene"" id=""15716408-1-118-121"">NPY</span>) with glutamate.",CTD_human
1,0,Therapeutic,C0026837,Muscle Rigidity,phenotype,muscular rigidity,4852,NPY,neuropeptide Y,CTD_human,10675796,Inhibition by neuropeptide Y of fentanyl-induced muscular rigidity at the locus coeruleus in rats.,0.2,"Inhibition by <span class=""gene"" id=""10675796-0-14-28"">neuropeptide Y</span> of fentanyl-induced <span class=""disease"" id=""10675796-0-49-66"">muscular rigidity</span> at the locus coeruleus in rats.",CTD_human
3,0,Biomarker,C0036572,Seizures,phenotype,seizure,4852,NPY,neuropeptide Y,CTD_human,16194568,Differential effects of vigabatrin and zonisamide on the neuropeptide Y system in the hippocampus of seizure prone gerbil.,0.28274726784213106,"Differential effects of vigabatrin and zonisamide on the <span class=""gene"" id=""16194568-0-57-71"">neuropeptide Y</span> system in the hippocampus of <span class=""disease"" id=""16194568-0-101-108"">seizure</span> prone gerbil.",CTD_human
3,0,Therapeutic,C0036572,Seizures,phenotype,seizure,4852,NPY,neuropeptide Y,CTD_human,16194568,Differential effects of vigabatrin and zonisamide on the neuropeptide Y system in the hippocampus of seizure prone gerbil.,0.28274726784213106,"Differential effects of vigabatrin and zonisamide on the <span class=""gene"" id=""16194568-0-57-71"">neuropeptide Y</span> system in the hippocampus of <span class=""disease"" id=""16194568-0-101-108"">seizure</span> prone gerbil.",CTD_human
3,0,Therapeutic,C0036572,Seizures,phenotype,seizure,4852,NPY,neuropeptide-Y,CTD_human,15451008,Seizure susceptibility of neuropeptide-Y null mutant mice in amygdala kindling and chemical-induced seizure models.,0.28274726784213106,"<span class=""disease"" id=""15451008-0-0-7"">Seizure</span> susceptibility of <span class=""gene"" id=""15451008-0-26-40"">neuropeptide-Y</span> null mutant mice in amygdala kindling and chemical-induced <span class=""disease"" id=""15451008-0-100-107"">seizure</span> models.",CTD_human
3,0,Therapeutic,C0036572,Seizures,phenotype,seizures,4852,NPY,NPY,CTD_human,18005069,Intracerebroventricular (10 nmol/3 microL) and intrahippocampal (20-50 microm) NPY administration increased hippocampal dopamine and attenuated pilocarpine-induced seizures.,0.28274726784213106,"Intracerebroventricular (10 nmol/3 microL) and intrahippocampal (20-50 microm) <span class=""gene"" id=""18005069-8-79-82"">NPY</span> administration increased hippocampal dopamine and attenuated pilocarpine-induced <span class=""disease"" id=""18005069-8-164-172"">seizures</span>.",CTD_human
3,0,Biomarker,C0036572,Seizures,phenotype,seizure,4852,NPY,neuropeptide-Y,CTD_human,15451008,Seizure susceptibility of neuropeptide-Y null mutant mice in amygdala kindling and chemical-induced seizure models.,0.28274726784213106,"<span class=""disease"" id=""15451008-0-0-7"">Seizure</span> susceptibility of <span class=""gene"" id=""15451008-0-26-40"">neuropeptide-Y</span> null mutant mice in amygdala kindling and chemical-induced <span class=""disease"" id=""15451008-0-100-107"">seizure</span> models.",CTD_human
3,0,Biomarker,C0036572,Seizures,phenotype,seizures,4852,NPY,NPY,CTD_human,18005069,Intracerebroventricular (10 nmol/3 microL) and intrahippocampal (20-50 microm) NPY administration increased hippocampal dopamine and attenuated pilocarpine-induced seizures.,0.28274726784213106,"Intracerebroventricular (10 nmol/3 microL) and intrahippocampal (20-50 microm) <span class=""gene"" id=""18005069-8-79-82"">NPY</span> administration increased hippocampal dopamine and attenuated pilocarpine-induced <span class=""disease"" id=""18005069-8-164-172"">seizures</span>.",CTD_human
1,0,Biomarker,C0424295,Hyperactive behavior,phenotype,hyperactivity,4852,NPY,NPY,CTD_human,19063928,Results revealed that NPY injections augmented cocaine-induced hyperactivity and moderately increased cocaine self-administration.,0.20054945356842604,"Results revealed that <span class=""gene"" id=""19063928-11-22-25"">NPY</span> injections augmented cocaine-induced <span class=""disease"" id=""19063928-11-63-76"">hyperactivity</span> and moderately increased cocaine self-administration.",CTD_human
1,0,Biomarker,C0017636,Glioblastoma,disease,GBM,4853,NOTCH2,Notch2,CTD_human,21127729,"Knockdown of individual Notch receptors revealed that Notch1 and Notch2 receptors differentially contributed to GBM cell growth, with Notch2 having a predominant role.",0.201648360705279,"Knockdown of individual Notch receptors revealed that Notch1 and <span class=""gene"" id=""21127729-5-65-71"">Notch2</span> receptors differentially contributed to <span class=""disease"" id=""21127729-5-112-115"">GBM</span> cell growth, with <span class=""gene"" id=""21127729-5-134-140"">Notch2</span> having a predominant role.",CTD_human
2,5,Biomarker,C0917715,Hajdu-Cheney Syndrome,disease,Hajdu-Cheney syndrome,4853,NOTCH2,NOTCH2,CTD_human,21378985,"Mutations in NOTCH2 cause Hajdu-Cheney syndrome, a disorder of severe and progressive bone loss.",0.48357144819477,"Mutations in <span class=""gene"" id=""21378985-0-13-19"">NOTCH2</span> cause <span class=""disease"" id=""21378985-0-26-47"">Hajdu-Cheney syndrome</span>, a disorder of severe and progressive bone loss.",CTD_human;ORPHANET
1,0,Biomarker,C0004352,Autistic Disorder,disease,autistic disorder,4862,NPAS2,Npas2,CTD_human,17264841,Association of Per1 and Npas2 with autistic disorder: support for the clock genes/social timing hypothesis.,0.202681755307501,"Association of Per1 and <span class=""gene"" id=""17264841-0-24-29"">Npas2</span> with <span class=""disease"" id=""17264841-0-35-52"">autistic disorder</span>: support for the clock genes/social timing hypothesis.",CTD_human
1,0,Therapeutic,C0004153,Atherosclerosis,disease,atherosclerosis,4864,NPC1,Npc1,CTD_human,18483620,High-fat diet-fed chimeric Npc1-/- mice reconstituted with Ldlr-/-Npc1-/- macrophages exhibited accelerated atherosclerosis despite lower serum cholesterol compared with mice reconstituted with wild-type macrophages.,0.2,"High-fat diet-fed chimeric <span class=""gene"" id=""18483620-4-27-31"">Npc1</span>-/- mice reconstituted with Ldlr-/-<span class=""gene"" id=""18483620-4-66-70"">Npc1</span>-/- macrophages exhibited accelerated <span class=""disease"" id=""18483620-4-108-123"">atherosclerosis</span> despite lower serum cholesterol compared with mice reconstituted with wild-type macrophages.",CTD_human
1,1,Biomarker,C0028754,Obesity,disease,obesity,4864,NPC1,NPC1,CTD_human,19151714,"In addition to FTO and MC4R, we detected significant association of obesity with three new risk loci in NPC1 (endosomal/lysosomal Niemann-Pick C1 gene, P = 2.9 x 10(-7)), near MAF (encoding the transcription factor c-MAF, P = 3.8 x 10(-13)) and near PTER (phosphotriesterase-related gene, P = 2.1 x 10(-7)).",0.20914417305935604,"In addition to FTO and MC4R, we detected significant association of <span class=""disease"" id=""19151714-3-68-75"">obesity</span> with three new risk loci in <span class=""gene"" id=""19151714-3-104-108"">NPC1</span> (endosomal/lysosomal Niemann-Pick C1 gene, P = 2.9 x 10(-7)), near MAF (encoding the transcription factor c-MAF, P = 3.8 x 10(-13)) and near PTER (phosphotriesterase-related gene, P = 2.1 x 10(-7)).",CTD_human
2,2,Biomarker,C0220756,"Niemann-Pick Disease, Type C",disease,NPC,4864,NPC1,Npc1,CTD_human,22216111,"Here, we assessed hepatic tissue integrity, biochemical and oxidative stress parameters of wild-type control (Npc1(+/+); WT) and homozygous-mutant (Npc1(-/-); NPC) mice.",0.225078326543716,"Here, we assessed hepatic tissue integrity, biochemical and oxidative stress parameters of wild-type control (<span class=""gene"" id=""22216111-5-110-114"">Npc1</span>(+/+); WT) and homozygous-mutant (<span class=""gene"" id=""22216111-5-148-152"">Npc1</span>(-/-); <span class=""disease"" id=""22216111-5-159-162"">NPC</span>) mice.",CTD_human
2,0,Biomarker,C3501848,"Nephrosis, congenital",disease,congenital nephrotic syndrome,4868,NPHS1,NPHS1,CTD_human,11012881,The recently identified gene NPHS1 with its mutations causing congenital nephrotic syndrome of the Finnish type (CNF) is highly promising in providing new understanding of pathophysiology of proteinuria.,0.41669282130236895,"The recently identified gene <span class=""gene"" id=""11012881-1-29-34"">NPHS1</span> with its mutations causing <span class=""disease"" id=""11012881-1-62-91"">congenital nephrotic syndrome</span> of the Finnish type (CNF) is highly promising in providing new understanding of pathophysiology of proteinuria.",CTD_human;HPO
3,1,Biomarker,C0023467,"Leukemia, Myelocytic, Acute",disease,AML,4869,NPM1,nucleophosmin,CTD_human,21441929,"Acute myeloid leukemia (AML) is a molecularly diverse malignancy with a poor prognosis whose largest subgroup is characterized by somatic mutations in NPM1, which encodes nucleophosmin.",0.40927613351820297,"<span class=""disease"" id=""21441929-1-0-22"">Acute myeloid leukemia</span> (<span class=""disease"" id=""21441929-1-24-27"">AML</span>) is a molecularly diverse malignancy with a poor prognosis whose largest subgroup is characterized by somatic mutations in <span class=""gene"" id=""21441929-1-151-155"">NPM1</span>, which encodes <span class=""gene"" id=""21441929-1-171-184"">nucleophosmin</span>.",CTD_human
3,1,Biomarker,C0023467,"Leukemia, Myelocytic, Acute",disease,AML,4869,NPM1,NPM1,CTD_human,23877794,"Mutations in exon 12 of the nucleophosmin (NPM1) gene (NPMc+ (NPM1 COOH terminal mutations)) define a distinct subset of acute myelogenous leukemias (AMLs), in which the NPMc+ protein localizes aberrantly to the leukemic cell cytoplasm.",0.40927613351820297,"Mutations in exon 12 of the <span class=""gene"" id=""23877794-1-28-41"">nucleophosmin</span> (<span class=""gene"" id=""23877794-1-43-47"">NPM1</span>) gene (NPMc+ (<span class=""gene"" id=""23877794-1-62-66"">NPM1</span> COOH terminal mutations)) define a distinct subset of <span class=""disease"" id=""23877794-1-121-148"">acute myelogenous leukemias</span> (<span class=""disease"" id=""23877794-1-150-153"">AML</span>s), in which the NPMc+ protein localizes aberrantly to the leukemic cell cytoplasm.",CTD_human
2,0,Biomarker,C0023487,Acute Promyelocytic Leukemia,disease,APL,4869,NPM1,NPM,CTD_human,14508522,"Induction of apoptosis was seen also in the PML-RARalpha-expressing APL cell line NB4, and in several other atRA-sensitive leukemia cell lines, demonstrating that this effect is limited neither to the monocyte lineage nor to the rare NPM-RARalpha fusion variant.",0.40576926246847494,"Induction of apoptosis was seen also in the PML-RARalpha-expressing <span class=""disease"" id=""14508522-7-68-71"">APL</span> cell line NB4, and in several other atRA-sensitive leukemia cell lines, demonstrating that this effect is limited neither to the monocyte lineage nor to the rare <span class=""gene"" id=""14508522-7-234-237"">NPM</span>-RARalpha fusion variant.",CTD_human;ORPHANET
7,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,4878,NPPA,NPPA,CTD_human,19219041,Common genetic variants at the NPPA-NPPB locus found to be associated with circulating natriuretic peptide concentrations contribute to interindividual variation in blood pressure and hypertension.,0.323229383241211,"Common genetic variants at the <span class=""gene"" id=""19219041-4-31-35"">NPPA</span>-NPPB locus found to be associated with circulating natriuretic peptide concentrations contribute to interindividual variation in blood pressure and <span class=""disease"" id=""19219041-4-184-196"">hypertension</span>.",CTD_human
7,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,4878,NPPA,NPPA,CTD_human,19219041,Common genetic variants at the NPPA-NPPB locus found to be associated with circulating natriuretic peptide concentrations contribute to interindividual variation in blood pressure and hypertension.,0.323229383241211,"Common genetic variants at the <span class=""gene"" id=""19219041-4-31-35"">NPPA</span>-NPPB locus found to be associated with circulating natriuretic peptide concentrations contribute to interindividual variation in blood pressure and <span class=""disease"" id=""19219041-4-184-196"">hypertension</span>.",CTD_human
3,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,4879,NPPB,NPPB,CTD_human,19219041,Common genetic variants at the NPPA-NPPB locus found to be associated with circulating natriuretic peptide concentrations contribute to interindividual variation in blood pressure and hypertension.,0.22095116042856303,"Common genetic variants at the NPPA-<span class=""gene"" id=""19219041-4-36-40"">NPPB</span> locus found to be associated with circulating natriuretic peptide concentrations contribute to interindividual variation in blood pressure and <span class=""disease"" id=""19219041-4-184-196"">hypertension</span>.",CTD_human
3,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,4879,NPPB,NPPB,CTD_human,19219041,Common genetic variants at the NPPA-NPPB locus found to be associated with circulating natriuretic peptide concentrations contribute to interindividual variation in blood pressure and hypertension.,0.22095116042856303,"Common genetic variants at the NPPA-<span class=""gene"" id=""19219041-4-36-40"">NPPB</span> locus found to be associated with circulating natriuretic peptide concentrations contribute to interindividual variation in blood pressure and <span class=""disease"" id=""19219041-4-184-196"">hypertension</span>.",CTD_human
1,0,Biomarker,C1956346,Coronary Artery Disease,disease,CAD,4879,NPPB,BNP,CTD_human,18022110,"One hundred and two patients with stable, documented CAD (EF, 62% +/- 8%) underwent an exercise-rest thallium-201 gated-MPI and serial Nt-pro-BNP assays.",0.21120637664346803,"One hundred and two patients with stable, documented <span class=""disease"" id=""18022110-3-53-56"">CAD</span> (EF, 62% +/- 8%) underwent an exercise-rest thallium-201 gated-MPI and serial Nt-pro-<span class=""gene"" id=""18022110-3-142-145"">BNP</span> assays.",CTD_human
4,7,Biomarker,C0022595,Keratosis Follicularis,disease,Darier's disease,488,ATP2A2,SERCA2,CTD_human,16733453,"Darier's disease is caused by mutations of the ATP2A2 gene, which codes for the SERCA2 endoplasmic reticulum calcium pump.",0.723761574543611,"<span class=""disease"" id=""16733453-8-0-16"">Darier's disease</span> is caused by mutations of the <span class=""gene"" id=""16733453-8-47-53"">ATP2A2</span> gene, which codes for the <span class=""gene"" id=""16733453-8-80-86"">SERCA2</span> endoplasmic reticulum calcium pump.",CTD_human;ORPHANET;UNIPROT
4,7,Biomarker,C0022595,Keratosis Follicularis,disease,DD,488,ATP2A2,SERCA2,CTD_human,20338123,"Darier disease (DD) and Hailey-Hailey disease (HHD) are rare autosomal dominantly inherited genodermatoses with mutations in the respective genes, ATP2A2 and ATP2C1, that encode the respective calcium adenosine triphosphatases SERCA2 and PMRI/SPCA1.",0.723761574543611,"<span class=""disease"" id=""20338123-1-0-14"">Darier disease</span> (<span class=""disease"" id=""20338123-1-16-18"">DD</span>) and Hailey-Hailey disease (HHD) are rare autosomal dominantly inherited genodermatoses with mutations in the respective genes, <span class=""gene"" id=""20338123-1-147-153"">ATP2A2</span> and ATP2C1, that encode the respective calcium adenosine triphosphatases <span class=""gene"" id=""20338123-1-227-233"">SERCA2</span> and PMRI/SPCA1.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,4881,NPR1,natriuretic peptide receptor-A,CTD_human,20881240,"Mice carrying a targeted disruption of the Npr1 gene coding for guanylyl cyclase-A/natriuretic peptide receptor-A exhibit changes that are similar to those that occur in untreated human hypertension, including elevated blood pressure, cardiac hypertrophy, and congestive heart failure.",0.219698781819772,"Mice carrying a targeted disruption of the <span class=""gene"" id=""20881240-2-43-47"">Npr1</span> gene coding for guanylyl cyclase-A/<span class=""gene"" id=""20881240-2-83-113"">natriuretic peptide receptor-A</span> exhibit changes that are similar to those that occur in untreated human <span class=""disease"" id=""20881240-2-186-198"">hypertension</span>, including elevated blood pressure, cardiac hypertrophy, and congestive heart failure.",CTD_human
1,0,Biomarker,C0028754,Obesity,disease,obese,4886,NPY1R,NPY1R,CTD_human,20975297,"Several genes and transcripts involved in lipolysis were down-regulated, such as AKAP1, PRKAR2B, Gi and CIDEA, whereas NPY1R and CES1 were up-regulated, when comparing obese to lean subjects.",0.364814057046576,"Several genes and transcripts involved in lipolysis were down-regulated, such as AKAP1, PRKAR2B, Gi and CIDEA, whereas <span class=""gene"" id=""20975297-3-119-124"">NPY1R</span> and CES1 were up-regulated, when comparing <span class=""disease"" id=""20975297-3-168-173"">obese</span> to lean subjects.",CTD_human
2,0,Biomarker,C0001973,"Alcoholic Intoxication, Chronic",disease,alcohol dependence,4887,NPY2R,NPY2R,CTD_human,18828811,"SNPs in NPY2R provided significant evidence of association with alcohol dependence, alcohol withdrawal symptoms, comorbid alcohol and cocaine dependence, and cocaine dependence (all p < 0.03).",0.402956482091714,"SNPs in <span class=""gene"" id=""18828811-7-8-13"">NPY2R</span> provided significant evidence of association with <span class=""disease"" id=""18828811-7-64-82"">alcohol dependence</span>, alcohol withdrawal symptoms, comorbid alcohol and cocaine dependence, and cocaine dependence (all p &lt; 0.03).",CTD_human;PSYGENET
1,0,Biomarker,C0028754,Obesity,disease,obesity,4889,NPY5R,Y5 receptor,CTD_human,10849579,Novel polymorphisms in the neuropeptide-Y Y5 receptor associated with obesity in Pima Indians.,0.285912964183428,"Novel polymorphisms in the neuropeptide-Y <span class=""gene"" id=""10849579-0-42-53"">Y5 receptor</span> associated with <span class=""disease"" id=""10849579-0-70-77"">obesity</span> in Pima Indians.",CTD_human
5,0,Biomarker,C0025202,melanoma,disease,melanoma,4893,NRAS,NRAS,CTD_human,26214590,"Our analysis established NF1, encoding a negative regulator of RAS, as the third most frequently mutated gene in melanoma, after BRAF and NRAS.",0.528158588016459,"Our analysis established NF1, encoding a negative regulator of RAS, as the third most frequently mutated gene in <span class=""disease"" id=""26214590-2-113-121"">melanoma</span>, after BRAF and <span class=""gene"" id=""26214590-2-138-142"">NRAS</span>.",CTD_human;HPO
5,0,Biomarker,C0025202,melanoma,disease,melanoma,4893,NRAS,NRAS,CTD_human,22842228,"This activating mutation, the third most frequent in our cohort of sun-exposed melanoma after those of BRAF and NRAS, changes Pro29 to serine (RAC1(P29S)) in the highly conserved switch I domain.",0.528158588016459,"This activating mutation, the third most frequent in our cohort of sun-exposed <span class=""disease"" id=""22842228-5-79-87"">melanoma</span> after those of BRAF and <span class=""gene"" id=""22842228-5-112-116"">NRAS</span>, changes Pro29 to serine (RAC1(P29S)) in the highly conserved switch I domain.",CTD_human;HPO
5,0,Biomarker,C0025202,melanoma,disease,melanoma,4893,NRAS,NRAS,CTD_human,23432625,"The mutations, such as those in NRAS, BRAF, GNAQ and GNA11, promote the growth of melanoma cells in most part through the mitogen-activated protein kinase (MAPK) pathway.",0.528158588016459,"The mutations, such as those in <span class=""gene"" id=""23432625-2-32-36"">NRAS</span>, BRAF, GNAQ and GNA11, promote the growth of <span class=""disease"" id=""23432625-2-82-90"">melanoma</span> cells in most part through the mitogen-activated protein kinase (MAPK) pathway.",CTD_human;HPO
5,0,Biomarker,C0025202,melanoma,disease,melanomas,4893,NRAS,NRAS,CTD_human,22535842,"Besides frequent mutations in growth- and survival-promoting genes like BRAF and NRAS, melanomas additionally harbor complex non-random genomic alterations.",0.528158588016459,"Besides frequent mutations in growth- and survival-promoting genes like BRAF and <span class=""gene"" id=""22535842-2-81-85"">NRAS</span>, <span class=""disease"" id=""22535842-2-87-96"">melanomas</span> additionally harbor complex non-random genomic alterations.",CTD_human;HPO
1,2,Biomarker,C0028326,Noonan Syndrome,disease,Noonan syndrome,4893,NRAS,NRAS,CTD_human,19966803,A restricted spectrum of NRAS mutations causes Noonan syndrome.,0.401923087489492,"A restricted spectrum of <span class=""gene"" id=""19966803-0-25-29"">NRAS</span> mutations causes <span class=""disease"" id=""19966803-0-47-62"">Noonan syndrome</span>.",CTD_human;ORPHANET
1,0,Biomarker,C0206729,Neurofibrosarcoma,disease,neurofibrosarcoma,4893,NRAS,N-Ras,CTD_human,16239399,Affinity purification showed N-Ras to be the predominant activated isoform of Ras in two independent neurofibrosarcoma cell lines from NF1 patients (lines ST88-14 and NF90-8).,0.200274726784213,"Affinity purification showed <span class=""gene"" id=""16239399-3-29-34"">N-Ras</span> to be the predominant activated isoform of Ras in two independent <span class=""disease"" id=""16239399-3-101-118"">neurofibrosarcoma</span> cell lines from NF1 patients (lines ST88-14 and NF90-8).",CTD_human
2,2,Biomarker,C0349639,Juvenile Myelomonocytic Leukemia,disease,juvenile myelomonocytic leukaemia,4893,NRAS,NRAS,CTD_human,19775298,Germ-line mutation of the NRAS gene may be responsible for the development of juvenile myelomonocytic leukaemia.,0.610634476672364,"Germ-line mutation of the <span class=""gene"" id=""19775298-0-26-30"">NRAS</span> gene may be responsible for the development of <span class=""disease"" id=""19775298-0-78-111"">juvenile myelomonocytic leukaemia</span>.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C1328840,Autoimmune Lymphoproliferative Syndrome,disease,autoimmune lymphoproliferative syndrome,4893,NRAS,NRAS,CTD_human,17517660,NRAS mutation causes a human autoimmune lymphoproliferative syndrome.,0.20054945356842604,"<span class=""gene"" id=""17517660-0-0-4"">NRAS</span> mutation causes a human <span class=""disease"" id=""17517660-0-29-68"">autoimmune lymphoproliferative syndrome</span>.",CTD_human
2,0,Biomarker,C0004352,Autistic Disorder,disease,autism,4897,NRCAM,NRCAM,CTD_human,18664314,Association of the neuronal cell adhesion molecule (NRCAM) gene variants with autism.,0.28618769096764196,"Association of the <span class=""gene"" id=""18664314-0-19-50"">neuronal cell adhesion molecule</span> (<span class=""gene"" id=""18664314-0-52-57"">NRCAM</span>) gene variants with <span class=""disease"" id=""18664314-0-78-84"">autism</span>.",CTD_human
2,0,Biomarker,C0004352,Autistic Disorder,disease,autism,4897,NRCAM,NrCAM,CTD_human,17106428,Association analysis of the NrCAM gene in autism and in subsets of families with severe obsessive-compulsive or self-stimulatory behaviors.,0.28618769096764196,"Association analysis of the <span class=""gene"" id=""17106428-0-28-33"">NrCAM</span> gene in <span class=""disease"" id=""17106428-0-42-48"">autism</span> and in subsets of families with severe obsessive-compulsive or self-stimulatory behaviors.",CTD_human
1,1,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,4900,NRGN,neurogranin,CTD_human,17140601,Association of the gene encoding neurogranin with schizophrenia in males.,0.20981029631972398,"Association of the gene encoding <span class=""gene"" id=""17140601-0-33-44"">neurogranin</span> with <span class=""disease"" id=""17140601-0-50-63"">schizophrenia</span> in males.",CTD_human
2,1,Biomarker,C0035334,Retinitis Pigmentosa,disease,retinitis pigmentosa,4901,NRL,NRL,CTD_human,12796249,Phenotype of retinitis pigmentosa associated with the Ser50Thr mutation in the NRL gene.,0.6091953302166679,"Phenotype of <span class=""disease"" id=""12796249-0-13-33"">retinitis pigmentosa</span> associated with the Ser50Thr mutation in the <span class=""gene"" id=""12796249-0-79-82"">NRL</span> gene.",CTD_human;HPO;ORPHANET
1,0,Biomarker,C1458155,Mammary Neoplasms,group,breast tumors,4904,YBX1,YB-1,CTD_human,15703814,We found that breast tumors which were both estrogen receptor-negative and lymph node positive were associated with high YB-1 expression (P=0.017).,0.203557092817453,"We found that <span class=""disease"" id=""15703814-7-14-27"">breast tumors</span> which were both estrogen receptor-negative and lymph node positive were associated with high <span class=""gene"" id=""15703814-7-121-125"">YB-1</span> expression (P=0.017).",CTD_human
2,0,Biomarker,C0004352,Autistic Disorder,disease,autism,4909,NTF4,neurotrophin 4,CTD_human,11357950,"In archived neonatal blood of children with autistic spectrum disorders (n = 69), mental retardation without autism (n = 60), or cerebral palsy (CP, n = 63) and of control children (n = 54), we used recycling immunoaffinity chromatography to measure the neuropeptides substance P (SP), vasoactive intestinal peptide (VIP), pituitary adenylate cyclase-activating polypeptide (PACAP), calcitonin gene-related peptide (CGRP), and the neurotrophins nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin 3 (NT3), and neurotrophin 4/5 (NT4/5).",0.20240702852328799,"In archived neonatal blood of children with <span class=""disease"" id=""11357950-2-44-52"">autistic</span> spectrum disorders (n = 69), mental retardation without <span class=""disease"" id=""11357950-2-109-115"">autism</span> (n = 60), or cerebral palsy (CP, n = 63) and of control children (n = 54), we used recycling immunoaffinity chromatography to measure the neuropeptides substance P (SP), vasoactive intestinal peptide (VIP), pituitary adenylate cyclase-activating polypeptide (PACAP), calcitonin gene-related peptide (CGRP), and the neurotrophins nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin 3 (NT3), and <span class=""gene"" id=""11357950-2-540-554"">neurotrophin 4</span>/5 (NT4/5).",CTD_human
2,0,Biomarker,C0004352,Autistic Disorder,disease,autism,4909,NTF4,NT-4/5,CTD_human,16289943,Concentrations of NT-4/5 and CGRP were correlated in infants with autism but not in Down syndrome or controls.,0.20240702852328799,"Concentrations of <span class=""gene"" id=""16289943-10-18-24"">NT-4/5</span> and CGRP were correlated in infants with <span class=""disease"" id=""16289943-10-66-72"">autism</span> but not in Down syndrome or controls.",CTD_human
1,0,Biomarker,C3714756,Intellectual Disability,group,mental retardation,4909,NTF4,neurotrophin 4,CTD_human,11357950,"In archived neonatal blood of children with autistic spectrum disorders (n = 69), mental retardation without autism (n = 60), or cerebral palsy (CP, n = 63) and of control children (n = 54), we used recycling immunoaffinity chromatography to measure the neuropeptides substance P (SP), vasoactive intestinal peptide (VIP), pituitary adenylate cyclase-activating polypeptide (PACAP), calcitonin gene-related peptide (CGRP), and the neurotrophins nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin 3 (NT3), and neurotrophin 4/5 (NT4/5).",0.2,"In archived neonatal blood of children with autistic spectrum disorders (n = 69), <span class=""disease"" id=""11357950-2-82-100"">mental retardation</span> without autism (n = 60), or cerebral palsy (CP, n = 63) and of control children (n = 54), we used recycling immunoaffinity chromatography to measure the neuropeptides substance P (SP), vasoactive intestinal peptide (VIP), pituitary adenylate cyclase-activating polypeptide (PACAP), calcitonin gene-related peptide (CGRP), and the neurotrophins nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin 3 (NT3), and <span class=""gene"" id=""11357950-2-540-554"">neurotrophin 4</span>/5 (NT4/5).",CTD_human
1,0,Biomarker,C0032580,Adenomatous Polyposis Coli,disease,adenomatous polyposis,4913,NTHL1,NTHL1,CTD_human,25938944,A germline homozygous mutation in the base-excision repair gene NTHL1 causes adenomatous polyposis and colorectal cancer.,0.202681755307501,"A germline homozygous mutation in the base-excision repair gene <span class=""gene"" id=""25938944-0-64-69"">NTHL1</span> causes <span class=""disease"" id=""25938944-0-77-98"">adenomatous polyposis</span> and colorectal cancer.",CTD_human
1,0,Biomarker,C0027819,Neuroblastoma,disease,NB,4914,NTRK1,TrkA,CTD_human,16989911,"Expression of the high-affinity nerve growth factor (NGF) TrkA receptor in NB is correlated with good prognosis, while MYCN amplification is associated with advanced stages of disease.",0.21695319270926502,"Expression of the high-affinity nerve growth factor (NGF) <span class=""gene"" id=""16989911-4-58-62"">TrkA</span> receptor in <span class=""disease"" id=""16989911-4-75-77"">NB</span> is correlated with good prognosis, while MYCN amplification is associated with advanced stages of disease.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,4915,NTRK2,NTRK2,CTD_human,20662941,Increased BDNF levels and NTRK2 gene association suggest a disruption of BDNF/TrkB signaling in autism.,0.202681755307501,"Increased BDNF levels and <span class=""gene"" id=""20662941-0-26-31"">NTRK2</span> gene association suggest a disruption of BDNF/TrkB signaling in <span class=""disease"" id=""20662941-0-96-102"">autism</span>.",CTD_human
3,0,Biomarker,C0005586,Bipolar Disorder,disease,bipolar illness,4915,NTRK2,NTRK2,CTD_human,19018715,"This paper describes a relationship between response to lithium prophylaxis and polymorphisms of two functionally connected genes: BDNF and NTRK2, in bipolar illness.",0.405638237399215,"This paper describes a relationship between response to lithium prophylaxis and polymorphisms of two functionally connected genes: BDNF and <span class=""gene"" id=""19018715-2-140-145"">NTRK2</span>, in <span class=""disease"" id=""19018715-2-150-165"">bipolar illness</span>.",CTD_human;PSYGENET
1,0,Biomarker,C0028754,Obesity,disease,obesity,4915,NTRK2,NTRK2,CTD_human,15494731,"Mutation of NTRK2, which encodes TrkB, seems to result in a unique human syndrome of hyperphagic obesity.",0.40082418035263895,"Mutation of <span class=""gene"" id=""15494731-3-12-17"">NTRK2</span>, which encodes TrkB, seems to result in a unique human syndrome of hyperphagic <span class=""disease"" id=""15494731-3-97-104"">obesity</span>.",CTD_human;HPO
1,0,Biomarker,C0001430,Adenoma,group,adenomas,492,ATP2B3,ATP2B3,CTD_human,23416519,Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension.,0.201098907136852,"Somatic mutations in ATP1A1 and <span class=""gene"" id=""23416519-0-32-38"">ATP2B3</span> lead to aldosterone-producing <span class=""disease"" id=""23416519-0-69-77"">adenomas</span> and secondary hypertension.",CTD_human
4,8,Biomarker,C1849334,"Robinow syndrome, autosomal recessive",disease,Autosomal recessive Robinow syndrome,4920,ROR2,ROR2,CTD_human,15952209,"Autosomal recessive Robinow syndrome is caused by mutations in ROR2 and is characterized by short stature, mesomelic limb shortening, brachydactyly, vertebral abnormalities, and a characteristic ""fetal face"" dysmorphology.",0.6824725410579179,"<span class=""disease"" id=""15952209-1-0-36"">Autosomal recessive Robinow syndrome</span> is caused by mutations in <span class=""gene"" id=""15952209-1-63-67"">ROR2</span> and is characterized by short stature, mesomelic limb shortening, brachydactyly, vertebral abnormalities, and a characteristic ""fetal face"" dysmorphology.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0152013,Adenocarcinoma of lung (disorder),disease,of lung adenocarcinoma,4921,DDR2,DDR2,CTD_human,26206333,"DDR2(L63V);TP53(L/L) tumors displayed robust expression of DDR2 and immunohistochemical markers of lung adenocarcinoma comparable with previously generated models, though also displayed concomitant expression of the squamous cell markers p63 and SOX2.",0.200274726784213,"<span class=""gene"" id=""26206333-6-0-4"">DDR2</span>(L63V);TP53(L/L) tumors displayed robust expression of <span class=""gene"" id=""26206333-6-59-63"">DDR2</span> and immunohistochemical markers <span class=""disease"" id=""26206333-6-96-118"">of lung adenocarcinoma</span> comparable with previously generated models, though also displayed concomitant expression of the squamous cell markers p63 and SOX2.",CTD_human
1,0,Therapeutic,C0007370,Catalepsy,disease,catalepsy,4922,NTS,neurotensin,CTD_human,20882060,Effects of pallidal neurotensin on haloperidol-induced parkinsonian catalepsy: behavioral and electrophysiological studies.,0.2,"Effects of pallidal <span class=""gene"" id=""20882060-0-20-31"">neurotensin</span> on haloperidol-induced parkinsonian <span class=""disease"" id=""20882060-0-68-77"">catalepsy</span>: behavioral and electrophysiological studies.",CTD_human
1,0,Therapeutic,C0026837,Muscle Rigidity,phenotype,muscular rigidity,4922,NTS,neurotensin,CTD_human,8036282,Antagonization of fentanyl-induced muscular rigidity by neurotensin at the locus coeruleus of the rat.,0.2,"Antagonization of fentanyl-induced <span class=""disease"" id=""8036282-0-35-52"">muscular rigidity</span> by <span class=""gene"" id=""8036282-0-56-67"">neurotensin</span> at the locus coeruleus of the rat.",CTD_human
2,0,Therapeutic,C0424295,Hyperactive behavior,phenotype,hyperactivity,4922,NTS,neurotensin,CTD_human,3748325,Centrally administered neurotensin suppresses locomotor hyperactivity induced by d-amphetamine but not by scopolamine or caffeine.,0.2,"Centrally administered <span class=""gene"" id=""3748325-0-23-34"">neurotensin</span> suppresses locomotor <span class=""disease"" id=""3748325-0-56-69"">hyperactivity</span> induced by d-amphetamine but not by scopolamine or caffeine.",CTD_human
2,0,Therapeutic,C0424295,Hyperactive behavior,phenotype,hyperactivity,4922,NTS,NT,CTD_human,6682440,"These actions of NT are distinct from those of the dopamine receptor antagonist haloperidol, which blocked the locomotor hyperactivity induced by all five stimulant drugs in rats.",0.2,"These actions of <span class=""gene"" id=""6682440-5-17-19"">NT</span> are distinct from those of the dopamine receptor antagonist haloperidol, which blocked the locomotor <span class=""disease"" id=""6682440-5-121-134"">hyperactivity</span> induced by all five stimulant drugs in rats.",CTD_human
1,0,Biomarker,C0042769,Virus Diseases,group,viral infection,4938,OAS1,OAS1,CTD_human,15732009,This genetic polymorphism makes OAS1 an excellent candidate for a human gene that influences host susceptibility to viral infection.,0.200274726784213,"This genetic polymorphism makes <span class=""gene"" id=""15732009-12-32-36"">OAS1</span> an excellent candidate for a human gene that influences host susceptibility to <span class=""disease"" id=""15732009-12-116-131"">viral infection</span>.",CTD_human
9,40,Biomarker,C0028860,Oculocerebrorenal Syndrome,disease,Lowe syndrome,4952,OCRL,OCRL inositol polyphosphate 5-phosphatase,CTD_human,9430698,"Cell lines from kidney proximal tubules of a patient with Lowe syndrome lack OCRL inositol polyphosphate 5-phosphatase and accumulate phosphatidylinositol 4,5-bisphosphate.",0.627704339073571,"Cell lines from kidney proximal tubules of a patient with <span class=""disease"" id=""9430698-0-58-71"">Lowe syndrome</span> lack <span class=""gene"" id=""9430698-0-77-118"">OCRL inositol polyphosphate 5-phosphatase</span> and accumulate phosphatidylinositol 4,5-bisphosphate.",CTD_human;ORPHANET;UNIPROT
2,0,Biomarker,C0037286,Skin Neoplasms,group,skin tumor,4953,ODC1,ODC,CTD_human,2591024,The induction of epidermal ornithine decarboxylase (ODC) activity by benzoyl peroxide (BPO) was characterized to evaluate the usefulness of this effect as a short-term marker of BPO-induced mouse skin tumor promotion.,0.200274726784213,"The induction of epidermal <span class=""gene"" id=""2591024-1-27-50"">ornithine decarboxylase</span> (<span class=""gene"" id=""2591024-1-52-55"">ODC</span>) activity by benzoyl peroxide (BPO) was characterized to evaluate the usefulness of this effect as a short-term marker of BPO-induced mouse <span class=""disease"" id=""2591024-1-196-206"">skin tumor</span> promotion.",CTD_human
2,0,Biomarker,C0037286,Skin Neoplasms,group,skin tumor,4953,ODC1,ornithine decarboxylase,CTD_human,7653998,"Ability of m-chloroperoxybenzoic acid to induce the ornithine decarboxylase marker of skin tumor promotion and inhibition of this response by gallotannins, oligomeric proanthocyanidins, and their monomeric units in mouse epidermis in vivo.",0.200274726784213,"Ability of m-chloroperoxybenzoic acid to induce the <span class=""gene"" id=""7653998-0-52-75"">ornithine decarboxylase</span> marker of <span class=""disease"" id=""7653998-0-86-96"">skin tumor</span> promotion and inhibition of this response by gallotannins, oligomeric proanthocyanidins, and their monomeric units in mouse epidermis in vivo.",CTD_human
1,0,Biomarker,C0001418,Adenocarcinoma,group,adenocarcinomas,4968,OGG1,Ogg1,CTD_human,19336973,"The presently utilized Ogg1 gene-deficient mice model may be useful to draw mechanism-based strategies to control human lung adenocarcinomas, especially in women.",0.21586696221810603,"The presently utilized <span class=""gene"" id=""19336973-8-23-27"">Ogg1</span> gene-deficient mice model may be useful to draw mechanism-based strategies to control human lung <span class=""disease"" id=""19336973-8-125-140"">adenocarcinomas</span>, especially in women.",CTD_human
1,0,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,type 2 diabetes mellitus risk,4968,OGG1,OGG1,CTD_human,22652274,"The role of GSTM1, GSTT1, GSTP1, and OGG1 polymorphisms in type 2 diabetes mellitus risk: a case-control study in a Turkish population.",0.20941889984356898,"The role of GSTM1, GSTT1, GSTP1, and <span class=""gene"" id=""22652274-0-37-41"">OGG1</span> polymorphisms in <span class=""disease"" id=""22652274-0-59-88"">type 2 diabetes mellitus risk</span>: a case-control study in a Turkish population.",CTD_human
1,0,Biomarker,C0020179,Huntington Disease,disease,Huntington's disease,4968,OGG1,hOGG1,CTD_human,19857538,The hOGG1 Ser326Cys polymorphism and Huntington's disease.,0.204055389228567,"The <span class=""gene"" id=""19857538-0-4-9"">hOGG1</span> Ser326Cys polymorphism and <span class=""disease"" id=""19857538-0-37-57"">Huntington's disease</span>.",CTD_human
1,0,Biomarker,C0021364,Male infertility,phenotype,male infertility,4968,OGG1,OGG1,CTD_human,23376476,OGG1 Ser326Cys polymorphism interacts with cigarette smoking to increase oxidative DNA damage in human sperm and the risk of male infertility.,0.200274726784213,"<span class=""gene"" id=""23376476-0-0-4"">OGG1</span> Ser326Cys polymorphism interacts with cigarette smoking to increase oxidative DNA damage in human sperm and the risk of <span class=""disease"" id=""23376476-0-125-141"">male infertility</span>.",CTD_human
2,0,Therapeutic,C0024121,Lung Neoplasms,group,lung tumors,4968,OGG1,Ogg1,CTD_human,17441966,"Electron microscopic examination revealed the growth of microvilli, with increased numbers of mitochondria only in lungs and lung tumors of DMA(V)-exposed Ogg1(-/-) mice.",0.21749638192573498,"Electron microscopic examination revealed the growth of microvilli, with increased numbers of mitochondria only in lungs and <span class=""disease"" id=""17441966-8-125-136"">lung tumors</span> of DMA(V)-exposed <span class=""gene"" id=""17441966-8-155-159"">Ogg1</span>(-/-) mice.",CTD_human
2,0,Biomarker,C0024121,Lung Neoplasms,group,lung tumors,4968,OGG1,Ogg1,CTD_human,17441966,"Electron microscopic examination revealed the growth of microvilli, with increased numbers of mitochondria only in lungs and lung tumors of DMA(V)-exposed Ogg1(-/-) mice.",0.21749638192573498,"Electron microscopic examination revealed the growth of microvilli, with increased numbers of mitochondria only in lungs and <span class=""disease"" id=""17441966-8-125-136"">lung tumors</span> of DMA(V)-exposed <span class=""gene"" id=""17441966-8-155-159"">Ogg1</span>(-/-) mice.",CTD_human
2,2,Biomarker,C0027051,Myocardial Infarction,disease,myocardial infarction,4973,OLR1,OLR1,CTD_human,12646194,Oxidized LDL receptor gene (OLR1) is associated with the risk of myocardial infarction.,0.20974478378509498,"Oxidized LDL receptor gene (<span class=""gene"" id=""12646194-0-28-32"">OLR1</span>) is associated with the risk of <span class=""disease"" id=""12646194-0-65-86"">myocardial infarction</span>.",CTD_human
21,52,Biomarker,C0338508,"Optic Atrophy, Autosomal Dominant",disease,ADOA,4976,OPA1,OPA1,CTD_human,19900585,"We study the effect of EMB on mitochondrial metabolism in fibroblasts from controls and from a man carrying an OPA1 mutation, in whom the drug induced the development of autosomal dominant optic atrophy (ADOA).",0.7675231490872221,"We study the effect of EMB on mitochondrial metabolism in fibroblasts from controls and from a man carrying an <span class=""gene"" id=""19900585-2-111-115"">OPA1</span> mutation, in whom the drug induced the development of <span class=""disease"" id=""19900585-2-170-202"">autosomal dominant optic atrophy</span> (<span class=""disease"" id=""19900585-2-204-208"">ADOA</span>).",CTD_human;ORPHANET;UNIPROT
21,52,Biomarker,C0338508,"Optic Atrophy, Autosomal Dominant",disease,ADOA,4976,OPA1,Opa1,CTD_human,23409176,"The B6; C3-Opa1(Q285STOP) mouse model of ADOA displays optic nerve abnormalities, RGC dendropathy and functional visual disruption.",0.7675231490872221,"The B6; C3-<span class=""gene"" id=""23409176-6-11-15"">Opa1</span>(Q285STOP) mouse model of <span class=""disease"" id=""23409176-6-41-45"">ADOA</span> displays optic nerve abnormalities, RGC dendropathy and functional visual disruption.",CTD_human;ORPHANET;UNIPROT
1,0,Therapeutic,C0020429,Hyperalgesia,phenotype,hyperalgesia,4982,TNFRSF11B,osteoprotegerin,CTD_human,16769263,"CFA-induced hyperalgesia was significantly suppressed by the bisphosphonates, zoledronic acid (ZOL) and alendronate and osteoprotegerin. c-src-deficient mice in which osteoclasts are inherently dysfunctional exhibited reduced CFA-induced hyperalgesia.",0.2,"CFA-induced <span class=""disease"" id=""16769263-6-12-24"">hyperalgesia</span> was significantly suppressed by the bisphosphonates, zoledronic acid (ZOL) and alendronate and <span class=""gene"" id=""16769263-6-120-135"">osteoprotegerin</span>. c-src-deficient mice in which osteoclasts are inherently dysfunctional exhibited reduced CFA-induced <span class=""disease"" id=""16769263-6-238-250"">hyperalgesia</span>.",CTD_human
1,0,Therapeutic,C0020437,Hypercalcemia,disease,hypercalcemia,4982,TNFRSF11B,OPG,CTD_human,15845617,"In both models, hypercalcemia gradually returned despite clear evidence of ongoing suppression of bone resorption by OPG.",0.20082418035263896,"In both models, <span class=""disease"" id=""15845617-8-16-29"">hypercalcemia</span> gradually returned despite clear evidence of ongoing suppression of bone resorption by <span class=""gene"" id=""15845617-8-117-120"">OPG</span>.",CTD_human
1,0,Biomarker,C1136249,"Mental Retardation, X-Linked",disease,X-linked mental retardation,4983,OPHN1,OPHN1,CTD_human,17941886,"Previously, the OPHN1 gene has been shown to be responsible for recessive X-linked mental retardation.",0.20575490709115804,"Previously, the <span class=""gene"" id=""17941886-8-16-21"">OPHN1</span> gene has been shown to be responsible for recessive <span class=""disease"" id=""17941886-8-74-101"">X-linked mental retardation</span>.",CTD_human
1,0,Biomarker,C0030193,Pain,phenotype,pain,4986,OPRK1,KOR,CTD_human,9463367,The analysis of responses to various nociceptive stimuli suggests that the KOR gene product is implicated in the perception of visceral chemical pain.,0.20433011601278,"The analysis of responses to various nociceptive stimuli suggests that the <span class=""gene"" id=""9463367-4-75-78"">KOR</span> gene product is implicated in the perception of visceral chemical <span class=""disease"" id=""9463367-4-145-149"">pain</span>.",CTD_human
1,0,Biomarker,C0013384,Dyskinetic syndrome,disease,dyskinesia,4988,OPRM1,mu opioid receptor,CTD_human,16435402,"Carrying the G-allele of the A118G single nucleotide coding region polymorphism of the mu opioid receptor, as well as a history of never smoking, were independently associated with increased risk of earlier onset of dyskinesia (P=0.05 and 0.02, respectively).",0.200274726784213,"Carrying the G-allele of the A118G single nucleotide coding region polymorphism of the <span class=""gene"" id=""16435402-5-87-105"">mu opioid receptor</span>, as well as a history of never smoking, were independently associated with increased risk of earlier onset of <span class=""disease"" id=""16435402-5-216-226"">dyskinesia</span> (P=0.05 and 0.02, respectively).",CTD_human
1,0,Biomarker,C0019151,Hepatic Encephalopathy,disease,HE,4988,OPRM1,mu-opioid receptor,CTD_human,11991257,"The mean density of mu-opioid receptor sites (Bmax) in rats with stage II, III, and IV HE was 15, 29, and 33% higher, respectively, than the corresponding control value (p<0.01).",0.2,"The mean density of <span class=""gene"" id=""11991257-6-20-38"">mu-opioid receptor</span> sites (Bmax) in rats with stage II, III, and IV <span class=""disease"" id=""11991257-6-87-89"">HE</span> was 15, 29, and 33% higher, respectively, than the corresponding control value (p&lt;0.01).",CTD_human
2,0,Biomarker,C1868684,"EAR, PATELLA, SHORT STATURE SYNDROME",disease,Meier-Gorlin syndrome,5000,ORC4,ORC4,CTD_human,21358631,Mutations in origin recognition complex gene ORC4 cause Meier-Gorlin syndrome.,0.40027472678421294,"Mutations in origin recognition complex gene <span class=""gene"" id=""21358631-0-45-49"">ORC4</span> cause <span class=""disease"" id=""21358631-0-56-77"">Meier-Gorlin syndrome</span>.",CTD_human;ORPHANET
1,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastasis,5008,OSM,OSM,CTD_human,21937440,The cytokines oncostatin M (OSM) and IL-6 promote breast cancer cell migration and metastasis.,0.20082418035263896,"The cytokines <span class=""gene"" id=""21937440-1-14-26"">oncostatin M</span> (<span class=""gene"" id=""21937440-1-28-31"">OSM</span>) and IL-6 promote breast cancer cell migration and <span class=""disease"" id=""21937440-1-83-93"">metastasis</span>.",CTD_human
29,117,Therapeutic,C0268542,Ornithine carbamoyltransferase deficiency,disease,OTC deficiency,5009,OTC,OTC,CTD_human,19669271,"Analysis of the OTC gene showed a Pro-225-Thr (P225T) change in exon 7, a mutation that has been previously implicated in OTC deficiency.",0.699425733767183,"Analysis of the <span class=""gene"" id=""19669271-9-16-19"">OTC</span> gene showed a Pro-225-Thr (P225T) change in exon 7, a mutation that has been previously implicated in <span class=""disease"" id=""19669271-9-122-136"">OTC deficiency</span>.",CTD_human;ORPHANET;UNIPROT
29,117,Biomarker,C0268542,Ornithine carbamoyltransferase deficiency,disease,OTC deficiency,5009,OTC,OTC,CTD_human,19669271,"Analysis of the OTC gene showed a Pro-225-Thr (P225T) change in exon 7, a mutation that has been previously implicated in OTC deficiency.",0.699425733767183,"Analysis of the <span class=""gene"" id=""19669271-9-16-19"">OTC</span> gene showed a Pro-225-Thr (P225T) change in exon 7, a mutation that has been previously implicated in <span class=""disease"" id=""19669271-9-122-136"">OTC deficiency</span>.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0009363,Congenital ocular coloboma (disorder),disease,coloboma,501,ALDH7A1,aldh7a1,CTD_human,25004007,"We show that morpholino knockdown of aldh7a1 in zebrafish causes uveal coloboma and misregulation of nlz1, another known contributor to the coloboma phenotype, as well as skeletal abnormalities.",0.2,"We show that morpholino knockdown of <span class=""gene"" id=""25004007-4-37-44"">aldh7a1</span> in zebrafish causes uveal <span class=""disease"" id=""25004007-4-71-79"">coloboma</span> and misregulation of nlz1, another known contributor to the <span class=""disease"" id=""25004007-4-140-148"">coloboma</span> phenotype, as well as skeletal abnormalities.",CTD_human
1,0,Biomarker,C0026769,Multiple Sclerosis,disease,MS,5010,CLDN11,hOSP,CTD_human,25911099,"Here, we analyzed the impact of the different HLA-DR15 haplotype alleles on disease susceptibility in a new ""humanized"" model of MS induced in HLA-transgenic (Tg) mice by human oligodendrocyte-specific protein (OSP)/claudin-11 (hOSP), one of the bona fide potential primary target antigens in MS. We show that the hOSP-associated MS-like disease is dominated by the DRB1*15:01 allele not only as the DRA1*01:01;DRB1*15:01 isotypic heterodimer but also, unexpectedly, as a functional DQA1*01:02;DRB1*15:01 mixed isotype heterodimer.",0.20054945356842604,"Here, we analyzed the impact of the different HLA-DR15 haplotype alleles on disease susceptibility in a new ""humanized"" model of <span class=""disease"" id=""25911099-3-129-131"">MS</span> induced in HLA-transgenic (Tg) mice by human <span class=""gene"" id=""25911099-3-177-209"">oligodendrocyte-specific protein</span> (<span class=""gene"" id=""25911099-3-211-214"">OSP</span>)/<span class=""gene"" id=""25911099-3-216-226"">claudin-11</span> (<span class=""gene"" id=""25911099-3-228-232"">hOSP</span>), one of the bona fide potential primary target antigens in <span class=""disease"" id=""25911099-3-293-295"">MS</span>. We show that the <span class=""gene"" id=""25911099-3-314-318"">hOSP</span>-associated <span class=""disease"" id=""25911099-3-330-332"">MS</span>-like disease is dominated by the DRB1*15:01 allele not only as the DRA1*01:01;DRB1*15:01 isotypic heterodimer but also, unexpectedly, as a functional DQA1*01:02;DRB1*15:01 mixed isotype heterodimer.",CTD_human
1,1,Biomarker,C0011615,"Dermatitis, Atopic",disease,atopic dermatitis,5017,OVOL1,OVOL1,CTD_human,23042114,"We also replicated the associations of the FLG, C11orf30, TMEM232-SLC25A46, TNFRSF6B-ZGPAT, OVOL1, ACTL9 and KIF3A-IL13 loci that were previously reported in GWAS of European and Chinese individuals and a meta-analysis of GWAS for atopic dermatitis.",0.200274726784213,"We also replicated the associations of the FLG, C11orf30, TMEM232-SLC25A46, TNFRSF6B-ZGPAT, <span class=""gene"" id=""23042114-3-92-97"">OVOL1</span>, ACTL9 and KIF3A-IL13 loci that were previously reported in GWAS of European and Chinese individuals and a meta-analysis of GWAS for <span class=""disease"" id=""23042114-3-231-248"">atopic dermatitis</span>.",CTD_human
1,0,Biomarker,C0206711,Pilomatrixoma,disease,Pilomatricoma,5017,OVOL1,OVOL1,CTD_human,26873447,Activation of the OVOL1-OVOL2 Axis in the Hair Bulb and in Pilomatricoma.,0.200274726784213,"Activation of the <span class=""gene"" id=""26873447-0-18-23"">OVOL1</span>-OVOL2 Axis in the Hair Bulb and in <span class=""disease"" id=""26873447-0-59-72"">Pilomatricoma</span>.",CTD_human
1,0,Therapeutic,C0003469,Anxiety Disorders,group,anxiety,5020,OXT,Oxytocin,CTD_human,19228979,Oxytocin infusion facilitated serotonin release within the median raphe nucleus and reduced anxiety-related behavior.,0.202197814273705,"<span class=""gene"" id=""19228979-5-0-8"">Oxytocin</span> infusion facilitated serotonin release within the median raphe nucleus and reduced <span class=""disease"" id=""19228979-5-92-99"">anxiety</span>-related behavior.",CTD_human
2,0,Biomarker,C0004352,Autistic Disorder,disease,autism,5020,OXT,oxytocin,CTD_human,15288368,Could oxytocin administration during labor contribute to autism and related behavioral disorders?--A look at the literature.,0.217096894424218,"Could <span class=""gene"" id=""15288368-0-6-14"">oxytocin</span> administration during labor contribute to <span class=""disease"" id=""15288368-0-57-63"">autism</span> and related behavioral disorders?--A look at the literature.",CTD_human
2,0,Therapeutic,C0004352,Autistic Disorder,disease,autism,5020,OXT,oxytocin,CTD_human,15288368,Could oxytocin administration during labor contribute to autism and related behavioral disorders?--A look at the literature.,0.217096894424218,"Could <span class=""gene"" id=""15288368-0-6-14"">oxytocin</span> administration during labor contribute to <span class=""disease"" id=""15288368-0-57-63"">autism</span> and related behavioral disorders?--A look at the literature.",CTD_human
2,0,Biomarker,C0014549,Tonic-Clonic Epilepsy,disease,grand mal,5020,OXT,oxytocin,CTD_human,6407273,Prostaglandin-oxytocin induction of mid-trimester abortion complicated by grand mal-like seizures.,0.2,"Prostaglandin-<span class=""gene"" id=""6407273-0-14-22"">oxytocin</span> induction of mid-trimester abortion complicated by <span class=""disease"" id=""6407273-0-74-83"">grand mal</span>-like seizures.",CTD_human
1,0,Biomarker,C0015930,Fetal Distress,disease,fetal distress,5020,OXT,oxytocin,CTD_human,2862618,Use of tocolytic drugs to reverse oxytocin-induced uterine hypertonus and fetal distress.,0.2,"Use of tocolytic drugs to reverse <span class=""gene"" id=""2862618-0-34-42"">oxytocin</span>-induced uterine hypertonus and <span class=""disease"" id=""2862618-0-74-88"">fetal distress</span>.",CTD_human
2,0,Therapeutic,C0030193,Pain,phenotype,Pain,5020,OXT,oxytocin,CTD_human,17420069,"Pain stimulation induced oxytocin concentration decrease in the hypothalamic supraoptic nucleus, and increase in the locus coeruleus, raphe magnus nucleus, caudate nucleus and spinal cord, but no change in the hypothalamic paraventricular nucleus and plasma.",0.200274726784213,"<span class=""disease"" id=""17420069-4-0-4"">Pain</span> stimulation induced <span class=""gene"" id=""17420069-4-25-33"">oxytocin</span> concentration decrease in the hypothalamic supraoptic nucleus, and increase in the locus coeruleus, raphe magnus nucleus, caudate nucleus and spinal cord, but no change in the hypothalamic paraventricular nucleus and plasma.",CTD_human
2,0,Therapeutic,C0030193,Pain,phenotype,Pain,5020,OXT,oxytocin,CTD_human,6094376,"Pain threshold changes in rats following central injection of beta-endorphin, met-enkephalin, vasopressin or oxytocin antisera.",0.200274726784213,"<span class=""disease"" id=""6094376-0-0-4"">Pain</span> threshold changes in rats following central injection of beta-endorphin, met-enkephalin, vasopressin or <span class=""gene"" id=""6094376-0-109-117"">oxytocin</span> antisera.",CTD_human
1,0,Biomarker,C0032617,Polyuria,phenotype,polyuria,5020,OXT,Oxytocin,CTD_human,20649851,Oxytocin polyuria and polydipsia is blocked by NaCl administration in food-deprived male rats.,0.2,"<span class=""gene"" id=""20649851-0-0-8"">Oxytocin</span> <span class=""disease"" id=""20649851-0-9-17"">polyuria</span> and polydipsia is blocked by NaCl administration in food-deprived male rats.",CTD_human
1,0,Biomarker,C0033575,Prostatic Diseases,group,prostate disease,5020,OXT,OT,CTD_human,17492653,This study investigated whether the altered concentrations of OT present in prostate disease affect the proliferation of malignant and non-malignant human prostate cells.,0.2,"This study investigated whether the altered concentrations of <span class=""gene"" id=""17492653-3-62-64"">OT</span> present in <span class=""disease"" id=""17492653-3-76-92"">prostate disease</span> affect the proliferation of malignant and non-malignant human prostate cells.",CTD_human
6,0,Biomarker,C0036572,Seizures,phenotype,convulsions,5020,OXT,oxytocin,CTD_human,3923190,"In association with excessive self-administration of an oxytocin nasal spray, she developed severe water intoxication, with hyponatremic encephalopathy and convulsions.",0.2,"In association with excessive self-administration of an <span class=""gene"" id=""3923190-5-56-64"">oxytocin</span> nasal spray, she developed severe water intoxication, with hyponatremic encephalopathy and <span class=""disease"" id=""3923190-5-156-167"">convulsions</span>.",CTD_human
6,0,Biomarker,C0036572,Seizures,phenotype,convulsion,5020,OXT,oxytocin,CTD_human,644406,A generalized epileptiform convulsion after intra-amniotic prostaglandin with intravenous oxytocin infusion: a case report.,0.2,"A generalized epileptiform <span class=""disease"" id=""644406-0-27-37"">convulsion</span> after intra-amniotic prostaglandin with intravenous <span class=""gene"" id=""644406-0-90-98"">oxytocin</span> infusion: a case report.",CTD_human
6,0,Biomarker,C0036572,Seizures,phenotype,seizures,5020,OXT,Oxytocin,CTD_human,19397503,"Oxytocin infusion: acute hyponatraemia, seizures and coma.",0.2,"<span class=""gene"" id=""19397503-0-0-8"">Oxytocin</span> infusion: acute hyponatraemia, <span class=""disease"" id=""19397503-0-40-48"">seizures</span> and coma.",CTD_human
4,0,Biomarker,C0037763,Spasm,phenotype,spasms,5020,OXT,oxytocin,CTD_human,2444298,4 Intracellular microelectrode recording from myometrial strips showed that BRL 34915 (10 microM) inhibited action potentials and phasic spasms in the presence of oxytocin (0.2 nM) and produced a hyperpolarization of 5 mV.,0.2,"4 Intracellular microelectrode recording from myometrial strips showed that BRL 34915 (10 microM) inhibited action potentials and phasic <span class=""disease"" id=""2444298-6-137-143"">spasms</span> in the presence of <span class=""gene"" id=""2444298-6-163-171"">oxytocin</span> (0.2 nM) and produced a hyperpolarization of 5 mV.",CTD_human
4,0,Biomarker,C0037763,Spasm,phenotype,spasms,5020,OXT,oxytocin,CTD_human,8680739,"Relaxin was much less potent against the spasm dependent upon intracellular Ca2+ (that induced by oxytocin (20 nM) + nifedipine (500 nM)) than against the spasms dependent upon extracellular Ca2+, those induced by oxytocin (0.2 nM) and Bay K 8644 (1 microM).",0.2,"Relaxin was much less potent against the spasm dependent upon intracellular Ca2+ (that induced by <span class=""gene"" id=""8680739-15-98-106"">oxytocin</span> (20 nM) + nifedipine (500 nM)) than against the <span class=""disease"" id=""8680739-15-155-161"">spasms</span> dependent upon extracellular Ca2+, those induced by <span class=""gene"" id=""8680739-15-214-222"">oxytocin</span> (0.2 nM) and Bay K 8644 (1 microM).",CTD_human
8,0,Biomarker,C0043049,Water Intoxication,disease,Water intoxication,5020,OXT,oxytocin,CTD_human,3923190,Water intoxication and hyponatremic encephalopathy from the use of an oxytocin nasal spray. A case report.,0.2,"<span class=""disease"" id=""3923190-0-0-18"">Water intoxication</span> and hyponatremic encephalopathy from the use of an <span class=""gene"" id=""3923190-0-70-78"">oxytocin</span> nasal spray. A case report.",CTD_human
8,0,Biomarker,C0043049,Water Intoxication,disease,Water intoxication,5020,OXT,oxytocin,CTD_human,4988877,Water intoxication and grand mal seizure due to oxytocin.,0.2,"<span class=""disease"" id=""4988877-0-0-18"">Water intoxication</span> and grand mal seizure due to <span class=""gene"" id=""4988877-0-48-56"">oxytocin</span>.",CTD_human
8,0,Biomarker,C0043049,Water Intoxication,disease,Water intoxication,5020,OXT,oxytocin,CTD_human,803783,Water intoxication associated with oxytocin administration during saline-induced abortion.,0.2,"<span class=""disease"" id=""803783-0-0-18"">Water intoxication</span> associated with <span class=""gene"" id=""803783-0-35-43"">oxytocin</span> administration during saline-induced abortion.",CTD_human
8,0,Biomarker,C0043049,Water Intoxication,disease,water intoxication,5020,OXT,Oxytocin,CTD_human,5067144,"Oxytocin, ""salting out,"" and water intoxication.",0.2,"<span class=""gene"" id=""5067144-0-0-8"">Oxytocin</span>, ""salting out,"" and <span class=""disease"" id=""5067144-0-29-47"">water intoxication</span>.",CTD_human
8,0,Biomarker,C0043049,Water Intoxication,disease,Water intoxication,5020,OXT,oxytocin,CTD_human,5528113,Water intoxication secondary to oxytocin.,0.2,"<span class=""disease"" id=""5528113-0-0-18"">Water intoxication</span> secondary to <span class=""gene"" id=""5528113-0-32-40"">oxytocin</span>.",CTD_human
1,0,Therapeutic,C0424295,Hyperactive behavior,phenotype,hyperactivity,5020,OXT,oxytocin,CTD_human,18092152,Inhibition by oxytocin of methamphetamine-induced hyperactivity related to dopamine turnover in the mesolimbic region in mice.,0.200274726784213,"Inhibition by <span class=""gene"" id=""18092152-0-14-22"">oxytocin</span> of methamphetamine-induced <span class=""disease"" id=""18092152-0-50-63"">hyperactivity</span> related to dopamine turnover in the mesolimbic region in mice.",CTD_human
6,0,Biomarker,C0004352,Autistic Disorder,disease,autism,5021,OXTR,oxytocin receptor,CTD_human,15992526,Positive association of the oxytocin receptor gene (OXTR) with autism in the Chinese Han population.,0.226333612041215,"Positive association of the <span class=""gene"" id=""15992526-0-28-45"">oxytocin receptor</span> gene (OXTR) with <span class=""disease"" id=""15992526-0-63-69"">autism</span> in the Chinese Han population.",CTD_human
6,0,Biomarker,C0004352,Autistic Disorder,disease,autism,5021,OXTR,OXTR,CTD_human,17893705,Association between the oxytocin receptor (OXTR) gene and autism: relationship to Vineland Adaptive Behavior Scales and cognition.,0.226333612041215,"Association between the <span class=""gene"" id=""17893705-0-24-41"">oxytocin receptor</span> (<span class=""gene"" id=""17893705-0-43-47"">OXTR</span>) gene and <span class=""disease"" id=""17893705-0-58-64"">autism</span>: relationship to Vineland Adaptive Behavior Scales and cognition.",CTD_human
6,0,Biomarker,C0004352,Autistic Disorder,disease,autism,5021,OXTR,oxytocin receptor,CTD_human,17383819,Association of the oxytocin receptor gene (OXTR) in Caucasian children and adolescents with autism.,0.226333612041215,"Association of the <span class=""gene"" id=""17383819-0-19-36"">oxytocin receptor</span> gene (OXTR) in Caucasian children and adolescents with <span class=""disease"" id=""17383819-0-92-98"">autism</span>.",CTD_human
1,0,Biomarker,C1510586,Autism Spectrum Disorders,disease,ASD,5021,OXTR,OXTR,CTD_human,20832055,"Furthermore, amygdala volume measured with magnetic resonance imaging could be a useful intermediate phenotype to uncover the complex link between OXTR and social dysfunction in ASD.",0.203296721410557,"Furthermore, amygdala volume measured with magnetic resonance imaging could be a useful intermediate phenotype to uncover the complex link between <span class=""gene"" id=""20832055-10-147-151"">OXTR</span> and social dysfunction in <span class=""disease"" id=""20832055-10-178-181"">ASD</span>.",CTD_human
1,0,Biomarker,C0014544,Epilepsy,disease,epilepsy,5025,P2RX4,P2X4,CTD_human,12941474,"Here we show that, in the seizure-sensitive (SS) gerbil hippocampus, a recognized genetic epilepsy model, the expressions of both P2X2 and P2X4 receptors are markedly decreased as compared with that in the seizure-resistant (SR) gerbil.",0.2,"Here we show that, in the seizure-sensitive (SS) gerbil hippocampus, a recognized genetic <span class=""disease"" id=""12941474-4-90-98"">epilepsy</span> model, the expressions of both P2X2 and <span class=""gene"" id=""12941474-4-139-143"">P2X4</span> receptors are markedly decreased as compared with that in the seizure-resistant (SR) gerbil.",CTD_human
1,0,Biomarker,C0014556,"Epilepsy, Temporal Lobe",disease,temporal-lobe epilepsy,5025,P2RX4,P2X4,CTD_human,19084381,Alteration of purinergic P2X4 and P2X7 receptor expression in rats with temporal-lobe epilepsy induced by pilocarpine.,0.2,"Alteration of purinergic <span class=""gene"" id=""19084381-0-25-29"">P2X4</span> and P2X7 receptor expression in rats with <span class=""disease"" id=""19084381-0-72-94"">temporal-lobe epilepsy</span> induced by pilocarpine.",CTD_human
2,0,Biomarker,C0014556,"Epilepsy, Temporal Lobe",disease,temporal-lobe epilepsy,5027,P2RX7,P2X7 receptor,CTD_human,19084381,Alteration of purinergic P2X4 and P2X7 receptor expression in rats with temporal-lobe epilepsy induced by pilocarpine.,0.2,"Alteration of purinergic P2X4 and <span class=""gene"" id=""19084381-0-34-47"">P2X7 receptor</span> expression in rats with <span class=""disease"" id=""19084381-0-72-94"">temporal-lobe epilepsy</span> induced by pilocarpine.",CTD_human
1,0,Biomarker,C0027404,Narcolepsy,disease,narcolepsy,5032,P2RY11,P2RY11,CTD_human,21170044,Common variants in P2RY11 are associated with narcolepsy.,0.403780662444354,"Common variants in <span class=""gene"" id=""21170044-0-19-25"">P2RY11</span> are associated with <span class=""disease"" id=""21170044-0-46-56"">narcolepsy</span>.",CTD_human;ORPHANET
1,0,Biomarker,C0018801,Heart failure,disease,heart failure,5037,PEBP1,Raf kinase inhibitor protein,CTD_human,26670611,"Conversely, the dual-specific GRK2 and ERK cascade inhibitor, RKIP (Raf kinase inhibitor protein), triggered dysfunctional cardiomyocyte energetics and the expression of heart failure-promoting Pparg-regulated genes.",0.200274726784213,"Conversely, the dual-specific GRK2 and ERK cascade inhibitor, <span class=""gene"" id=""26670611-8-62-66"">RKIP</span> (<span class=""gene"" id=""26670611-8-68-96"">Raf kinase inhibitor protein</span>), triggered dysfunctional cardiomyocyte energetics and the expression of <span class=""disease"" id=""26670611-8-170-183"">heart failure</span>-promoting Pparg-regulated genes.",CTD_human
3,10,Biomarker,C0877024,Schimke immunoosseous dysplasia,disease,Schimke immuno-osseous dysplasia,50485,SMARCAL1,SMARCAL1,CTD_human,16237566,R561C missense mutation in the SMARCAL1 gene associated with mild Schimke immuno-osseous dysplasia.,0.6885165303106059,"R561C missense mutation in the <span class=""gene"" id=""16237566-0-31-39"">SMARCAL1</span> gene associated with mild <span class=""disease"" id=""16237566-0-66-98"">Schimke immuno-osseous dysplasia</span>.",CTD_human;ORPHANET;UNIPROT
2,0,Biomarker,C0010308,Congenital Hypothyroidism,disease,congenital goiter,50506,DUOX2,dual oxidase 2,CTD_human,16322276,"Three mutations (p.Q36H, p.G418fsX482, and g.IVS19-2A>C) in the dual oxidase 2 gene responsible for congenital goiter and iodide organification defect.",0.41453180880866,"Three mutations (p.Q36H, p.G418fsX482, and g.IVS19-2A&gt;C) in the <span class=""gene"" id=""16322276-0-64-78"">dual oxidase 2</span> gene responsible for <span class=""disease"" id=""16322276-0-100-117"">congenital goiter</span> and iodide organification defect.",CTD_human;HPO
2,0,Biomarker,C0010308,Congenital Hypothyroidism,disease,CH,50506,DUOX2,DUOX2,CTD_human,16134168,Only one study reported mutations in DUOX2 gene in congenital hypothyroidism (CH) associated with total iodide organification defect (TIOD) in homozygosity or with partial iodide organification defect (PIOD) in heterozygous patients.,0.41453180880866,"Only one study reported mutations in <span class=""gene"" id=""16134168-2-37-42"">DUOX2</span> gene in <span class=""disease"" id=""16134168-2-51-76"">congenital hypothyroidism</span> (<span class=""disease"" id=""16134168-2-78-80"">CH</span>) associated with total iodide organification defect (TIOD) in homozygosity or with partial iodide organification defect (PIOD) in heterozygous patients.",CTD_human;HPO
1,0,Biomarker,C0009375,Colonic Neoplasms,group,colon tumors,50507,NOX4,Nox4,CTD_human,20715105,"In the PhIP-induced colon tumors obtained after 1 year, Nox1, Nox4, NF?B-p50 and NF?B-p65 were all highly overexpressed compared with their levels in adjacent normal-looking colonic mucosa.",0.2,"In the PhIP-induced <span class=""disease"" id=""20715105-3-20-32"">colon tumors</span> obtained after 1 year, Nox1, <span class=""gene"" id=""20715105-3-62-66"">Nox4</span>, NF&kappa;B-p50 and NF&kappa;B-p65 were all highly overexpressed compared with their levels in adjacent normal-looking colonic mucosa.",CTD_human
1,0,Biomarker,C0004509,Azoospermia,disease,Azoospermia,50511,SYCP3,SYCP3,CTD_human,14643120,Azoospermia in patients heterozygous for a mutation in SYCP3.,0.403780662444354,"<span class=""disease"" id=""14643120-0-0-11"">Azoospermia</span> in patients heterozygous for a mutation in <span class=""gene"" id=""14643120-0-55-60"">SYCP3</span>.",CTD_human;HPO
1,0,Biomarker,C0022548,Keloid,disease,keloid,5052,PRDX1,peroxiredoxin I,CTD_human,20128793,"Various classes of proteins were found either to be present or to be upregulated in keloid tissue: (i) inflammatory/differentiated keratinocyte markers: S100 proteins, peroxiredoxin I; (ii) wound healing proteins: gelsolin-like capping protein; (iii) fibrogenetic proteins: mast cell ?-tryptase, macrophage migration inhibitory factor (MIF); (iv) antifibrotic proteins: asporin; (v) tumour suppressor proteins: stratifin, galectin-1, maspin; and (vi) antiangiogenic proteins: pigment epithelium-derived factor.",0.2,"Various classes of proteins were found either to be present or to be upregulated in <span class=""disease"" id=""20128793-6-84-90"">keloid</span> tissue: (i) inflammatory/differentiated keratinocyte markers: S100 proteins, <span class=""gene"" id=""20128793-6-168-183"">peroxiredoxin I</span>; (ii) wound healing proteins: gelsolin-like capping protein; (iii) fibrogenetic proteins: mast cell &beta;-tryptase, macrophage migration inhibitory factor (MIF); (iv) antifibrotic proteins: asporin; (v) tumour suppressor proteins: stratifin, galectin-1, maspin; and (vi) antiangiogenic proteins: pigment epithelium-derived factor.",CTD_human
1,0,Therapeutic,C0036323,Schistosomiasis,disease,schistosomiasis,5052,PRDX1,Prx-1,CTD_human,19041905,These findings suggest that Prx-1 may become a novel target of drugs and vaccines for schistosomiasis.,0.2,"These findings suggest that <span class=""gene"" id=""19041905-10-28-33"">Prx-1</span> may become a novel target of drugs and vaccines for <span class=""disease"" id=""19041905-10-86-101"">schistosomiasis</span>.",CTD_human
1,0,Biomarker,C0279626,Squamous cell carcinoma of esophagus,disease,ESCC,5052,PRDX1,PRDX1,CTD_human,21517111,"Among these identified proteins, 33 proteins including keratin 17 (KRT17), biliverdin reductase B (BLVRB), proteasome activator subunit 1 (PSME1), manganese superoxide dismutase (MnSOD), high-mobility group box-1(HMGB1), heat shock protein 70 (HSP70), peroxiredoxin (PRDX1), keratin 13 (KRT13), and so on were overexpressed, and 14 proteins including cystatin B (CSTB), tropomyosin 2 (TPM2), annexin 1 (ANX1), transgelin (TAGLN), keratin 19 (KRT19), stratifin (SFN), and so on were down-expressed in ESCC.",0.20054945356842604,"Among these identified proteins, 33 proteins including keratin 17 (KRT17), biliverdin reductase B (BLVRB), proteasome activator subunit 1 (PSME1), manganese superoxide dismutase (MnSOD), high-mobility group box-1(HMGB1), heat shock protein 70 (HSP70), peroxiredoxin (<span class=""gene"" id=""21517111-5-267-272"">PRDX1</span>), keratin 13 (KRT13), and so on were overexpressed, and 14 proteins including cystatin B (CSTB), tropomyosin 2 (TPM2), annexin 1 (ANX1), transgelin (TAGLN), keratin 19 (KRT19), stratifin (SFN), and so on were down-expressed in <span class=""disease"" id=""21517111-5-500-504"">ESCC</span>.",CTD_human
1,0,Biomarker,C0004943,Behcet Syndrome,disease,Beh?et's disease,5054,SERPINE1,PAI-1,CTD_human,12074830,"It was concluded that the observed increase of lipid, lipoproteins, lipid hydroperoxide, susceptibility of LDL to oxidation, autoantibodies against ox-LDL levels and decrease of antioxidant enzyme activities and total antioxidant status and increased secretion of endothelial derivated peptides including sICAM and PAI-1, and their interactions may indicate that there is a tendency to atherothrombotic events in patients with Beh?et's disease.",0.20508878383078896,"It was concluded that the observed increase of lipid, lipoproteins, lipid hydroperoxide, susceptibility of LDL to oxidation, autoantibodies against ox-LDL levels and decrease of antioxidant enzyme activities and total antioxidant status and increased secretion of endothelial derivated peptides including sICAM and <span class=""gene"" id=""12074830-13-315-320"">PAI-1</span>, and their interactions may indicate that there is a tendency to atherothrombotic events in patients with <span class=""disease"" id=""12074830-13-427-443"">Beh&Ccedil;et's disease</span>.",CTD_human
1,0,Biomarker,C0027726,Nephrotic Syndrome,group,nephrotic syndrome,5054,SERPINE1,plasminogen activator inhibitor-1,CTD_human,17513194,Simvastatin inhibits tissue factor and plasminogen activator inhibitor-1 secretion by peripheral blood mononuclear cells in patients with primary nephrotic syndrome.,0.20054945356842604,"Simvastatin inhibits tissue factor and <span class=""gene"" id=""17513194-0-39-72"">plasminogen activator inhibitor-1</span> secretion by peripheral blood mononuclear cells in patients with primary <span class=""disease"" id=""17513194-0-146-164"">nephrotic syndrome</span>.",CTD_human
1,0,Biomarker,C0028754,Obesity,disease,obesity,5054,SERPINE1,PAI-1,CTD_human,23819014,"Together, resveratrol can act as NF ? B inhibitor in adipocytes and thus the subsequently reduced PAI-1 expression in inflamed adipose tissue might provide a new insight towards novel treatment options of obesity.",0.24729103682173398,"Together, resveratrol can act as NF &kappa; B inhibitor in adipocytes and thus the subsequently reduced <span class=""gene"" id=""23819014-8-98-103"">PAI-1</span> expression in inflamed adipose tissue might provide a new insight towards novel treatment options of <span class=""disease"" id=""23819014-8-205-212"">obesity</span>.",CTD_human
1,0,Biomarker,C0007134,Renal Cell Carcinoma,disease,renal cell carcinoma,5058,PAK1,p21-activated kinase 1,CTD_human,17621631,Modulation of p21-activated kinase 1 alters the behavior of renal cell carcinoma.,0.20054945356842604,"Modulation of <span class=""gene"" id=""17621631-0-14-36"">p21-activated kinase 1</span> alters the behavior of <span class=""disease"" id=""17621631-0-60-80"">renal cell carcinoma</span>.",CTD_human
1,0,Therapeutic,C0024141,"Lupus Erythematosus, Systemic",disease,systemic lupus erythematosus,50615,IL21R,IL-21R,CTD_human,17911475,Treatment of BXSB-Yaa mice with IL-21R-Fc fusion protein minimally attenuates systemic lupus erythematosus.,0.203780662444353,"Treatment of BXSB-Yaa mice with <span class=""gene"" id=""17911475-0-32-38"">IL-21R</span>-Fc fusion protein minimally attenuates <span class=""disease"" id=""17911475-0-78-106"">systemic lupus erythematosus</span>.",CTD_human
1,1,Biomarker,C0036341,Schizophrenia,disease,SZ,5062,PAK2,PAK2,CTD_human,20691406,"Moreover, this 3q29 deletion region contains two linkage peaks from prior SZ family studies, and the minimal deletion interval implicates 20 annotated genes, including PAK2 and DLG1, both paralogous to X-linked ID genes and now strong candidates for SZ susceptibility.",0.202956482091714,"Moreover, this 3q29 deletion region contains two linkage peaks from prior <span class=""disease"" id=""20691406-8-74-76"">SZ</span> family studies, and the minimal deletion interval implicates 20 annotated genes, including <span class=""gene"" id=""20691406-8-168-172"">PAK2</span> and DLG1, both paralogous to X-linked ID genes and now strong candidates for <span class=""disease"" id=""20691406-8-250-252"">SZ</span> susceptibility.",CTD_human
1,0,Biomarker,C0003469,Anxiety Disorders,group,anxiety,5066,PAM,PAM,CTD_human,19815072,"Using mice heterozygous for peptidylglycine alpha-amidating monooxygenase (PAM), a cuproenzyme essential for the synthesis of many neuropeptides, we identified alterations in anxiety-like behavior, thermoregulation and seizure sensitivity.",0.2,"Using mice heterozygous for <span class=""gene"" id=""19815072-4-28-73"">peptidylglycine alpha-amidating monooxygenase</span> (<span class=""gene"" id=""19815072-4-75-78"">PAM</span>), a cuproenzyme essential for the synthesis of many neuropeptides, we identified alterations in <span class=""disease"" id=""19815072-4-175-182"">anxiety</span>-like behavior, thermoregulation and seizure sensitivity.",CTD_human
1,0,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,T2D,5066,PAM,PAM,CTD_human,24464100,"In addition, two missense variants in PAM, encoding p.Asp563Gly (frequency of 4.98%) and p.Ser539Trp (frequency of 0.65%), confer moderately higher risk of T2D (OR = 1.23, P = 3.9 × 10(-10) and OR = 1.47, P = 1.7 × 10(-5), respectively), and a rare (0.20%) frameshift variant in PDX1, encoding p.Gly218Alafs*12, associates with high risk of T2D (OR = 2.27, P = 7.3 × 10(-7)).",0.200274726784213,"In addition, two missense variants in <span class=""gene"" id=""24464100-4-38-41"">PAM</span>, encoding p.Asp563Gly (frequency of 4.98%) and p.Ser539Trp (frequency of 0.65%), confer moderately higher risk of <span class=""disease"" id=""24464100-4-156-159"">T2D</span> (OR = 1.23, P = 3.9 &times; 10(-10) and OR = 1.47, P = 1.7 &times; 10(-5), respectively), and a rare (0.20%) frameshift variant in PDX1, encoding p.Gly218Alafs*12, associates with high risk of <span class=""disease"" id=""24464100-4-341-344"">T2D</span> (OR = 2.27, P = 7.3 &times; 10(-7)).",CTD_human
1,0,Biomarker,C0036572,Seizures,phenotype,seizure,5066,PAM,PAM,CTD_human,19815072,"Using mice heterozygous for peptidylglycine alpha-amidating monooxygenase (PAM), a cuproenzyme essential for the synthesis of many neuropeptides, we identified alterations in anxiety-like behavior, thermoregulation and seizure sensitivity.",0.2,"Using mice heterozygous for <span class=""gene"" id=""19815072-4-28-73"">peptidylglycine alpha-amidating monooxygenase</span> (<span class=""gene"" id=""19815072-4-75-78"">PAM</span>), a cuproenzyme essential for the synthesis of many neuropeptides, we identified alterations in anxiety-like behavior, thermoregulation and <span class=""disease"" id=""19815072-4-219-226"">seizure</span> sensitivity.",CTD_human
1,0,Biomarker,C0002965,"Angina, Unstable",disease,unstable angina,5069,PAPPA,PAPP-A,CTD_human,11586954,PAPP-A is a new candidate marker of unstable angina and acute myocardial infarction.,0.200274726784213,"<span class=""gene"" id=""11586954-10-0-6"">PAPP-A</span> is a new candidate marker of <span class=""disease"" id=""11586954-10-36-51"">unstable angina</span> and acute myocardial infarction.",CTD_human
1,0,Biomarker,C0948089,Acute Coronary Syndrome,disease,acute coronary syndromes,5069,PAPPA,Pregnancy-associated plasma protein A,CTD_human,11586954,Pregnancy-associated plasma protein A as a marker of acute coronary syndromes.,0.20902291774708104,"<span class=""gene"" id=""11586954-0-0-37"">Pregnancy-associated plasma protein A</span> as a marker of <span class=""disease"" id=""11586954-0-53-77"">acute coronary syndromes</span>.",CTD_human
1,0,Biomarker,C0017636,Glioblastoma,disease,glioblastoma,5071,PARK2,PARK2,CTD_human,19946270,Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies.,0.20082418035263896,"Somatic mutations of the Parkinson's disease-associated gene <span class=""gene"" id=""19946270-0-61-66"">PARK2</span> in <span class=""disease"" id=""19946270-0-70-82"">glioblastoma</span> and other human malignancies.",CTD_human
12,0,Biomarker,C0030567,Parkinson Disease,disease,PD,5071,PARK2,Park-2,CTD_human,15882845,"In the present study, we examined the status of cannabinoid CB(1) receptors in the basal ganglia of female and male Park-2 knockout mice, a genetic model of PD that progresses with no neuronal death and that may be considered representative of early and presymptomatic parkinsonian deficits.",0.41384644970576795,"In the present study, we examined the status of cannabinoid CB(1) receptors in the basal ganglia of female and male <span class=""gene"" id=""15882845-2-116-122"">Park-2</span> knockout mice, a genetic model of <span class=""disease"" id=""15882845-2-157-159"">PD</span> that progresses with no neuronal death and that may be considered representative of early and presymptomatic parkinsonian deficits.",CTD_human
12,0,Biomarker,C0030567,Parkinson Disease,disease,Parkinson's disease,5071,PARK2,parkin,CTD_human,22841634,Mutations in the parkin gene are linked to development of juvenile onset of Parkinson's disease and recent studies have reported that parkin can protect against increased oxidative stress and mitochondrial dysfunction caused by a variety of oxidative and toxic insults.,0.41384644970576795,"Mutations in the <span class=""gene"" id=""22841634-1-17-23"">parkin</span> gene are linked to development of juvenile onset of <span class=""disease"" id=""22841634-1-76-95"">Parkinson's disease</span> and recent studies have reported that parkin can protect against increased oxidative stress and mitochondrial dysfunction caused by a variety of oxidative and toxic insults.",CTD_human
12,0,Biomarker,C0030567,Parkinson Disease,disease,Parkinson's disease,5071,PARK2,Park-2,CTD_human,16573651,PK-KO mice were more susceptible than WT to ROT and the combined effects of Park-2 suppression and ROT reproduced the cellular events observed in Parkinson's disease.,0.41384644970576795,"PK-KO mice were more susceptible than WT to ROT and the combined effects of <span class=""gene"" id=""16573651-16-76-82"">Park-2</span> suppression and ROT reproduced the cellular events observed in <span class=""disease"" id=""16573651-16-146-165"">Parkinson's disease</span>.",CTD_human
12,0,Biomarker,C0030567,Parkinson Disease,disease,Parkinson's disease,5071,PARK2,PARK2,CTD_human,19946270,Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies.,0.41384644970576795,"Somatic mutations of the <span class=""disease"" id=""19946270-0-25-44"">Parkinson's disease</span>-associated gene <span class=""gene"" id=""19946270-0-61-66"">PARK2</span> in glioblastoma and other human malignancies.",CTD_human
12,0,Biomarker,C0030567,Parkinson Disease,disease,PD,5071,PARK2,Park2,CTD_human,24582596,Here we have tested in vitro the effect of resveratrol treatment on primary fibroblast cultures from two patients with early-onset PD linked to different Park2 mutations.,0.41384644970576795,"Here we have tested in vitro the effect of resveratrol treatment on primary fibroblast cultures from two patients with early-onset <span class=""disease"" id=""24582596-5-131-133"">PD</span> linked to different <span class=""gene"" id=""24582596-5-154-159"">Park2</span> mutations.",CTD_human
7,0,Biomarker,C0242422,Parkinsonian Disorders,group,parkinsonism,5071,PARK2,PARK2,CTD_human,12764051,"Mutations in the parkin gene, PARK2, are a common cause of parkinsonism in familial as well as isolated cases with an age of onset <40 years and should be considered in the diagnostic work up of young-onset parkinsonism.",0.451699940531156,"Mutations in the <span class=""gene"" id=""12764051-1-17-23"">parkin</span> gene, <span class=""gene"" id=""12764051-1-30-35"">PARK2</span>, are a common cause of <span class=""disease"" id=""12764051-1-59-71"">parkinsonism</span> in familial as well as isolated cases with an age of onset &lt;40 years and should be considered in the diagnostic work up of young-onset <span class=""disease"" id=""12764051-1-207-219"">parkinsonism</span>.",CTD_human;HPO
7,0,Biomarker,C0242422,Parkinsonian Disorders,group,parkinsonism,5071,PARK2,parkin,CTD_human,10072423,Mutations in the parkin gene are therefore not invariably associated with early onset parkinsonism.,0.451699940531156,"Mutations in the <span class=""gene"" id=""10072423-12-17-23"">parkin</span> gene are therefore not invariably associated with early onset <span class=""disease"" id=""10072423-12-86-98"">parkinsonism</span>.",CTD_human;HPO
7,0,Therapeutic,C0242422,Parkinsonian Disorders,group,parkinsonism,5071,PARK2,PARK2,CTD_human,10894217,"A gene for autosomal recessive parkinsonism, PARK2 (parkin), has recently been identified on chromosome 6q and shown to be mutated in Japanese and European families, mostly with early-onset parkinsonism.",0.451699940531156,"A gene for autosomal recessive parkinsonism, <span class=""gene"" id=""10894217-1-45-50"">PARK2</span> (parkin), has recently been identified on chromosome 6q and shown to be mutated in Japanese and European families, mostly with early-onset <span class=""disease"" id=""10894217-1-190-202"">parkinsonism</span>.",CTD_human;HPO
7,0,Therapeutic,C0242422,Parkinsonian Disorders,group,parkinsonism,5071,PARK2,PARK2,CTD_human,12764051,"Mutations in the parkin gene, PARK2, are a common cause of parkinsonism in familial as well as isolated cases with an age of onset <40 years and should be considered in the diagnostic work up of young-onset parkinsonism.",0.451699940531156,"Mutations in the <span class=""gene"" id=""12764051-1-17-23"">parkin</span> gene, <span class=""gene"" id=""12764051-1-30-35"">PARK2</span>, are a common cause of <span class=""disease"" id=""12764051-1-59-71"">parkinsonism</span> in familial as well as isolated cases with an age of onset &lt;40 years and should be considered in the diagnostic work up of young-onset <span class=""disease"" id=""12764051-1-207-219"">parkinsonism</span>.",CTD_human;HPO
7,0,Therapeutic,C0242422,Parkinsonian Disorders,group,parkinsonism,5071,PARK2,parkin,CTD_human,10072423,Mutations in the parkin gene are therefore not invariably associated with early onset parkinsonism.,0.451699940531156,"Mutations in the <span class=""gene"" id=""10072423-12-17-23"">parkin</span> gene are therefore not invariably associated with early onset <span class=""disease"" id=""10072423-12-86-98"">parkinsonism</span>.",CTD_human;HPO
7,0,Biomarker,C0242422,Parkinsonian Disorders,group,parkinsonism,5071,PARK2,PARK2,CTD_human,10894217,"A gene for autosomal recessive parkinsonism, PARK2 (parkin), has recently been identified on chromosome 6q and shown to be mutated in Japanese and European families, mostly with early-onset parkinsonism.",0.451699940531156,"A gene for autosomal recessive parkinsonism, <span class=""gene"" id=""10894217-1-45-50"">PARK2</span> (parkin), has recently been identified on chromosome 6q and shown to be mutated in Japanese and European families, mostly with early-onset <span class=""disease"" id=""10894217-1-190-202"">parkinsonism</span>.",CTD_human;HPO
1,0,Biomarker,C0001418,Adenocarcinoma,group,adenocarcinomas,5074,PAWR,Par4,CTD_human,15877079,"Most (80%) Par4-null females presented endometrial hyperplasia by 9 months of age, and a significant proportion (36%) developed endometrial adenocarcinomas after 1 year of age.",0.2,"Most (80%) <span class=""gene"" id=""15877079-4-11-15"">Par4</span>-null females presented endometrial hyperplasia by 9 months of age, and a significant proportion (36%) developed endometrial <span class=""disease"" id=""15877079-4-140-155"">adenocarcinomas</span> after 1 year of age.",CTD_human
1,0,Biomarker,C0014175,Endometriosis,disease,endometriosis,5076,PAX2,Paired-box gene 2,CTD_human,22473392,Paired-box gene 2 is down-regulated in endometriosis and correlates with low epidermal growth factor receptor expression.,0.200274726784213,"<span class=""gene"" id=""22473392-0-0-17"">Paired-box gene 2</span> is down-regulated in <span class=""disease"" id=""22473392-0-39-52"">endometriosis</span> and correlates with low epidermal growth factor receptor expression.",CTD_human
1,0,Biomarker,C0022661,"Kidney Failure, Chronic",disease,end-stage renal failure,5076,PAX2,PAX2,CTD_human,16631587,"Persistent expression of Pax2 did not interfere with the initial differentiation of podocytes, but mice ectopically expressing PAX2 developed end-stage renal failure soon after birth.",0.200274726784213,"Persistent expression of <span class=""gene"" id=""16631587-4-25-29"">Pax2</span> did not interfere with the initial differentiation of podocytes, but mice ectopically expressing <span class=""gene"" id=""16631587-4-127-131"">PAX2</span> developed <span class=""disease"" id=""16631587-4-142-165"">end-stage renal failure</span> soon after birth.",CTD_human
3,0,Biomarker,C0027794,Neural Tube Defects,group,neural tube defects,5077,PAX3,Pax3,CTD_human,12854658,"This study examines interactions of a mutation in Pax3, embryonic sex, advanced maternal age, and arsenite exposure in the splotch (Sp) mouse model, with the aim of describing gene-environment interactions for neural tube defects and embryonic lethality.",0.206579087443797,"This study examines interactions of a mutation in <span class=""gene"" id=""12854658-1-50-54"">Pax3</span>, embryonic sex, advanced maternal age, and arsenite exposure in the splotch (Sp) mouse model, with the aim of describing gene-environment interactions for <span class=""disease"" id=""12854658-1-210-229"">neural tube defects</span> and embryonic lethality.",CTD_human
3,0,Biomarker,C0027794,Neural Tube Defects,group,neural tube defects,5077,PAX3,Pax-3,CTD_human,12739027,"In addition, induction of oxidative stress with antimycin A inhibited Pax-3 expression and increased neural tube defects.",0.206579087443797,"In addition, induction of oxidative stress with antimycin A inhibited <span class=""gene"" id=""12739027-8-70-75"">Pax-3</span> expression and increased <span class=""disease"" id=""12739027-8-101-120"">neural tube defects</span>.",CTD_human
3,0,Therapeutic,C0027794,Neural Tube Defects,group,neural tube defects,5077,PAX3,Pax3,CTD_human,12854658,"This study examines interactions of a mutation in Pax3, embryonic sex, advanced maternal age, and arsenite exposure in the splotch (Sp) mouse model, with the aim of describing gene-environment interactions for neural tube defects and embryonic lethality.",0.206579087443797,"This study examines interactions of a mutation in <span class=""gene"" id=""12854658-1-50-54"">Pax3</span>, embryonic sex, advanced maternal age, and arsenite exposure in the splotch (Sp) mouse model, with the aim of describing gene-environment interactions for <span class=""disease"" id=""12854658-1-210-229"">neural tube defects</span> and embryonic lethality.",CTD_human
3,0,Therapeutic,C0027794,Neural Tube Defects,group,neural tube defects,5077,PAX3,Pax-3,CTD_human,12739027,"In addition, induction of oxidative stress with antimycin A inhibited Pax-3 expression and increased neural tube defects.",0.206579087443797,"In addition, induction of oxidative stress with antimycin A inhibited <span class=""gene"" id=""12739027-8-70-75"">Pax-3</span> expression and increased <span class=""disease"" id=""12739027-8-101-120"">neural tube defects</span>.",CTD_human
4,0,Biomarker,C0080178,Spina Bifida,disease,spina bifida,5077,PAX3,PAX3,CTD_human,17149730,Screening for novel PAX3 polymorphisms and risks of spina bifida.,0.201923087489492,"Screening for novel <span class=""gene"" id=""17149730-0-20-24"">PAX3</span> polymorphisms and risks of <span class=""disease"" id=""17149730-0-52-64"">spina bifida</span>.",CTD_human
1,0,Biomarker,C0376634,Craniofacial Abnormalities,group,craniofacial anomalies,5077,PAX3,PAX3,CTD_human,14556253,"We have provided a 20-year follow-up of a syndrome characterized by craniofacial anomalies, hearing loss and hand deformities and which is caused by a PAX3 missense mutation.",0.2,"We have provided a 20-year follow-up of a syndrome characterized by <span class=""disease"" id=""14556253-7-68-90"">craniofacial anomalies</span>, hearing loss and hand deformities and which is caused by a <span class=""gene"" id=""14556253-7-151-155"">PAX3</span> missense mutation.",CTD_human
1,0,Biomarker,C1261473,Sarcoma,disease,sarcoma,5077,PAX3,PAX3,CTD_human,24859338,Recurrent PAX3-MAML3 fusion in biphenotypic sinonasal sarcoma.,0.202197814273705,"Recurrent <span class=""gene"" id=""24859338-0-10-14"">PAX3</span>-MAML3 fusion in biphenotypic sinonasal <span class=""disease"" id=""24859338-0-54-61"">sarcoma</span>.",CTD_human
2,1,Biomarker,C1852510,Craniofacial deafness hand syndrome,disease,CDHS,5077,PAX3,PAX3,CTD_human,18553554,"In addition, mutations in PAX3 have been found in WS type 3 that is distinguished by musculoskeletal abnormalities, and in a family with a rare subtype of WS, craniofacial-deafness-hand syndrome (CDHS), characterized by dysmorphic facial features, hand abnormalities, and absent or hypoplastic nasal and wrist bones.",0.600274726784213,"In addition, mutations in <span class=""gene"" id=""18553554-6-26-30"">PAX3</span> have been found in WS type 3 that is distinguished by musculoskeletal abnormalities, and in a family with a rare subtype of WS, <span class=""disease"" id=""18553554-6-159-194"">craniofacial-deafness-hand syndrome</span> (<span class=""disease"" id=""18553554-6-196-200"">CDHS</span>), characterized by dysmorphic facial features, hand abnormalities, and absent or hypoplastic nasal and wrist bones.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0025202,melanoma,disease,melanoma,5078,PAX4,PAX4,CTD_human,18949370,PAX4 has the potential to function as a tumor suppressor in human melanoma.,0.20300763924902696,"<span class=""gene"" id=""18949370-0-0-4"">PAX4</span> has the potential to function as a tumor suppressor in human <span class=""disease"" id=""18949370-0-66-74"">melanoma</span>.",CTD_human
16,8,Biomarker,C0003076,Aniridia,disease,aniridia,5080,PAX6,Pax6,CTD_human,18322702,"Pax6 3' deletion results in aniridia, autism and mental retardation.",0.7294221104037242,"<span class=""gene"" id=""18322702-0-0-4"">Pax6</span> 3' deletion results in <span class=""disease"" id=""18322702-0-28-36"">aniridia</span>, autism and mental retardation.",CTD_human;HPO;ORPHANET;UNIPROT
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,5080,PAX6,Pax6,CTD_human,18322702,"Pax6 3' deletion results in aniridia, autism and mental retardation.",0.283231208875927,"<span class=""gene"" id=""18322702-0-0-4"">Pax6</span> 3' deletion results in aniridia, <span class=""disease"" id=""18322702-0-38-44"">autism</span> and mental retardation.",CTD_human
1,0,Biomarker,C0025202,melanoma,disease,melanoma,5080,PAX6,PAX6,CTD_human,16778180,"CGIs in putative promoter regions of 34 genes (ABHD9, BARHL1, CLIC5, CNNM1, COL2A1, CPT1C, DDIT4L, DERL3, DHRS3, DPYS, EFEMP2, FAM62C, FAM78A, FLJ33790, GBX2, GPR10, GPRASP1, HOXA9, HOXD11, HOXD12, HOXD13, p14ARF, PAX6, PRDX2, PTPRG, RASD1, RAX, REC8L1, SLC27A3, TGFB2, TLX2, TMEM22, TMEM30B, and UNC5C) were found to be methylated in at least 1 of 13 melanoma cell lines but not in two cultured normal melanocytes.",0.2,"CGIs in putative promoter regions of 34 genes (ABHD9, BARHL1, CLIC5, CNNM1, COL2A1, CPT1C, DDIT4L, DERL3, DHRS3, DPYS, EFEMP2, FAM62C, FAM78A, FLJ33790, GBX2, GPR10, GPRASP1, HOXA9, HOXD11, HOXD12, HOXD13, p14ARF, <span class=""gene"" id=""16778180-3-214-218"">PAX6</span>, PRDX2, PTPRG, RASD1, RAX, REC8L1, SLC27A3, TGFB2, TLX2, TMEM22, TMEM30B, and UNC5C) were found to be methylated in at least 1 of 13 <span class=""disease"" id=""16778180-3-352-360"">melanoma</span> cell lines but not in two cultured normal melanocytes.",CTD_human
1,0,Biomarker,C3714756,Intellectual Disability,group,mental retardation,5080,PAX6,Pax6,CTD_human,18322702,"Pax6 3' deletion results in aniridia, autism and mental retardation.",0.40714289638954104,"<span class=""gene"" id=""18322702-0-0-4"">Pax6</span> 3' deletion results in aniridia, autism and <span class=""disease"" id=""18322702-0-49-67"">mental retardation</span>.",CTD_human;HPO
2,0,Biomarker,C0001973,"Alcoholic Intoxication, Chronic",disease,alcohol dependence,50833,TAS2R16,TAS2R16,CTD_human,17250611,"In contrast to the previously reported significant association between TAS2R16 and alcohol dependence, we found no evidence that TAS2R38 haplotypes influence alcohol dependence in the COGA dataset.",0.200274726784213,"In contrast to the previously reported significant association between <span class=""gene"" id=""17250611-11-71-78"">TAS2R16</span> and <span class=""disease"" id=""17250611-11-83-101"">alcohol dependence</span>, we found no evidence that TAS2R38 haplotypes influence <span class=""disease"" id=""17250611-11-158-176"">alcohol dependence</span> in the COGA dataset.",CTD_human
1,0,Biomarker,C0003873,Rheumatoid Arthritis,disease,rheumatoid arthritis,50943,FOXP3,FoxP3,CTD_human,20476861,Expression of full-length and splice forms of FoxP3 in rheumatoid arthritis.,0.205494535684262,"Expression of full-length and splice forms of <span class=""gene"" id=""20476861-0-46-51"">FoxP3</span> in <span class=""disease"" id=""20476861-0-55-75"">rheumatoid arthritis</span>.",CTD_human
2,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,51,ACOX1,AOX,CTD_human,12771043,"The overall commonality of expression between AOX-/- and ciprofibrate-induced liver tumors but not with DENA-induced tumors strongly implicates the activation of PPARalpha and PPARalpha-regulated genes in liver, including those participating in lipid catabolism, as key factors in the development of HCC in AOX-/- and in ciprofibrate-treated mice.",0.20082418035263896,"The overall commonality of expression between <span class=""gene"" id=""12771043-5-46-49"">AOX</span>-/- and ciprofibrate-induced liver tumors but not with DENA-induced tumors strongly implicates the activation of PPARalpha and PPARalpha-regulated genes in liver, including those participating in lipid catabolism, as key factors in the development of <span class=""disease"" id=""12771043-5-300-303"">HCC</span> in <span class=""gene"" id=""12771043-5-307-310"">AOX</span>-/- and in ciprofibrate-treated mice.",CTD_human
2,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,51,ACOX1,Acox1,CTD_human,15565109,Gene expression patterns in HCCs from Acox1(-/-) mice and in ciprofibrate-induced HCCs were least similar to those observed in human HCCs.,0.20082418035263896,"Gene expression patterns in <span class=""disease"" id=""15565109-6-28-31"">HCC</span>s from <span class=""gene"" id=""15565109-6-38-43"">Acox1</span>(-/-) mice and in ciprofibrate-induced <span class=""disease"" id=""15565109-6-82-85"">HCC</span>s were least similar to those observed in human <span class=""disease"" id=""15565109-6-133-136"">HCC</span>s.",CTD_human
1,0,Biomarker,C1510586,Autism Spectrum Disorders,disease,ASD,5101,PCDH9,PCDH9,CTD_human,18252227,"Notwithstanding complexities, our results further implicate the SHANK3-NLGN4-NRXN1 postsynaptic density genes and also identify novel loci at DPP6-DPP10-PCDH9 (synapse complex), ANKRD11, DPYD, PTCHD1, 15q24, among others, for a role in ASD susceptibility.",0.200274726784213,"Notwithstanding complexities, our results further implicate the SHANK3-NLGN4-NRXN1 postsynaptic density genes and also identify novel loci at DPP6-DPP10-<span class=""gene"" id=""18252227-8-153-158"">PCDH9</span> (synapse complex), ANKRD11, DPYD, PTCHD1, 15q24, among others, for a role in <span class=""disease"" id=""18252227-8-236-239"">ASD</span> susceptibility.",CTD_human
1,0,Biomarker,C1843504,Pontocerebellar Hypoplasia Type 1,disease,pontocerebellar hypoplasia type 1,51010,EXOSC3,exosome component 3,CTD_human,22544365,"By exome sequencing, we discovered recessive mutations in EXOSC3 (encoding exosome component 3) in four siblings with infantile spinal motor neuron disease, cerebellar atrophy, progressive microcephaly and profound global developmental delay, consistent with pontocerebellar hypoplasia type 1 (PCH1; MIM 607596).",0.401923087489492,"By exome sequencing, we discovered recessive mutations in <span class=""gene"" id=""22544365-2-58-64"">EXOSC3</span> (encoding <span class=""gene"" id=""22544365-2-75-94"">exosome component 3</span>) in four siblings with infantile spinal motor neuron disease, cerebellar atrophy, progressive microcephaly and profound global developmental delay, consistent with <span class=""disease"" id=""22544365-2-259-292"">pontocerebellar hypoplasia type 1</span> (PCH1; MIM 607596).",CTD_human;ORPHANET
1,0,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,5108,PCM1,pericentriolar material 1,CTD_human,19048012,A threonine to isoleucine missense mutation in the pericentriolar material 1 gene is strongly associated with schizophrenia.,0.21460999798898303,"A threonine to isoleucine missense mutation in the <span class=""gene"" id=""19048012-0-51-76"">pericentriolar material 1</span> gene is strongly associated with <span class=""disease"" id=""19048012-0-110-123"">schizophrenia</span>.",CTD_human
1,0,Biomarker,C0242387,Mandibulofacial Dysostosis,disease,TCS,51082,POLR1D,POLR1D,CTD_human,21131976,"Subsequently, we detected 20 additional heterozygous mutations of POLR1D in 252 individuals with TCS.",0.401648360705279,"Subsequently, we detected 20 additional heterozygous mutations of <span class=""gene"" id=""21131976-2-66-72"">POLR1D</span> in 252 individuals with <span class=""disease"" id=""21131976-2-97-100"">TCS</span>.",CTD_human;ORPHANET
1,0,Biomarker,C0022661,"Kidney Failure, Chronic",disease,CRF,51085,MLXIPL,ChREBP,CTD_human,19878707,"CRF resulted in hypertension, proteinuria, renal tissue lipid accumulation, up-regulation of scavenger receptor A1 (SR-A1), acyl-CoA cholesterol acyltransferase-1 (ACAT1), carbohydrate-responsive element binding protein (ChREBP), fatty acid synthase (FAS), acyl-CoA carboxylase (ACC), liver X receptor (LXR), ATP binding cassette (ABC) A-1, ABCG-1, and SR-B1 and down-regulation of sterol responsive element binding protein-1 (SREBP-1), SREBP-2, HMG-CoA reductase, PPAR-alpha, fatty acid binding protein (L-FABP), and CPT1A.",0.2,"<span class=""disease"" id=""19878707-5-0-3"">CRF</span> resulted in hypertension, proteinuria, renal tissue lipid accumulation, up-regulation of scavenger receptor A1 (SR-A1), acyl-CoA cholesterol acyltransferase-1 (ACAT1), <span class=""gene"" id=""19878707-5-172-219"">carbohydrate-responsive element binding protein</span> (<span class=""gene"" id=""19878707-5-221-227"">ChREBP</span>), fatty acid synthase (FAS), acyl-CoA carboxylase (ACC), liver X receptor (LXR), ATP binding cassette (ABC) A-1, ABCG-1, and SR-B1 and down-regulation of sterol responsive element binding protein-1 (SREBP-1), SREBP-2, HMG-CoA reductase, PPAR-alpha, fatty acid binding protein (L-FABP), and CPT1A.",CTD_human
1,0,Biomarker,C0022661,"Kidney Failure, Chronic",disease,ESRD,51094,ADIPOR1,Adiponectin receptor-1,CTD_human,19539174,Adiponectin receptor-1 and monocyte chemoattractant protein-1 mRNA expressions were significantly higher in visceral but not in subcutaneous adipose tissue of the ESRD group.,0.28082418035263895,"<span class=""gene"" id=""19539174-9-0-22"">Adiponectin receptor-1</span> and monocyte chemoattractant protein-1 mRNA expressions were significantly higher in visceral but not in subcutaneous adipose tissue of the <span class=""disease"" id=""19539174-9-163-167"">ESRD</span> group.",CTD_human
1,0,Biomarker,C0080178,Spina Bifida,disease,spina bifida,5110,PCMT1,PCMT1,CTD_human,16256389,A known functional polymorphism (Ile120Val) of the human PCMT1 gene and risk of spina bifida.,0.20568939455652804,"A known functional polymorphism (Ile120Val) of the human <span class=""gene"" id=""16256389-0-57-62"">PCMT1</span> gene and risk of <span class=""disease"" id=""16256389-0-80-92"">spina bifida</span>.",CTD_human
1,0,Biomarker,C0024121,Lung Neoplasms,group,lung tumors,5111,PCNA,PCNA,CTD_human,11884234,"Levels of K-ras p21, raf-1, mitogen-activated protein kinases Erk 1 and 2, the phosphorylated-activated forms of Erk 1 and 2 (Erk 1P and 2P), and proliferating cell nuclear antigen (PCNA) were measured by immunoblotting in mouse lung tumors (5 to 9 mm in size) caused by N-nitrosodimethylamine (NDMA) and in control lungs.",0.20383181960166602,"Levels of K-ras p21, raf-1, mitogen-activated protein kinases Erk 1 and 2, the phosphorylated-activated forms of Erk 1 and 2 (Erk 1P and 2P), and <span class=""gene"" id=""11884234-2-146-180"">proliferating cell nuclear antigen</span> (<span class=""gene"" id=""11884234-2-182-186"">PCNA</span>) were measured by immunoblotting in mouse <span class=""disease"" id=""11884234-2-229-240"">lung tumors</span> (5 to 9 mm in size) caused by N-nitrosodimethylamine (NDMA) and in control lungs.",CTD_human
1,0,Biomarker,C0206624,Hepatoblastoma,disease,hepatoblastomas,5111,PCNA,proliferating cell nuclear antigen,CTD_human,11560253,Greater expression of transforming growth factor alpha and proliferating cell nuclear antigen staining in mouse hepatoblastomas than hepatocellular carcinomas induced by a diethylnitrosamine-sodium phenobarbital regimen.,0.20082418035263896,"Greater expression of transforming growth factor alpha and <span class=""gene"" id=""11560253-0-59-93"">proliferating cell nuclear antigen</span> staining in mouse <span class=""disease"" id=""11560253-0-112-127"">hepatoblastomas</span> than hepatocellular carcinomas induced by a diethylnitrosamine-sodium phenobarbital regimen.",CTD_human
1,0,Therapeutic,C0027627,Neoplasm Metastasis,phenotype,metastasis,51129,ANGPTL4,Angiopoietin-like 4,CTD_human,17130448,Angiopoietin-like 4 prevents metastasis through inhibition of vascular permeability and tumor cell motility and invasiveness.,0.20274726784213098,"<span class=""gene"" id=""17130448-0-0-19"">Angiopoietin-like 4</span> prevents <span class=""disease"" id=""17130448-0-29-39"">metastasis</span> through inhibition of vascular permeability and tumor cell motility and invasiveness.",CTD_human
1,1,Biomarker,C0007137,Squamous cell carcinoma,disease,squamous cell carcinoma,51151,SLC45A2,SLC45A2,CTD_human,19578363,"A melanoma- and pigmentation-associated variant in the SLC45A2 gene, L374F, is associated with risk of both BCC and squamous cell carcinoma.",0.203231208875927,"A melanoma- and pigmentation-associated variant in the <span class=""gene"" id=""19578363-6-55-62"">SLC45A2</span> gene, L374F, is associated with risk of both BCC and <span class=""disease"" id=""19578363-6-116-139"">squamous cell carcinoma</span>.",CTD_human
2,1,Biomarker,C0025202,melanoma,disease,malignant melanoma,51151,SLC45A2,SLC45A2,CTD_human,18563784,SLC45A2: a novel malignant melanoma-associated gene.,0.21839066043333702,"<span class=""gene"" id=""18563784-0-0-7"">SLC45A2</span>: a novel <span class=""disease"" id=""18563784-0-17-35"">malignant melanoma</span>-associated gene.",CTD_human
2,1,Biomarker,C0025202,melanoma,disease,melanoma,51151,SLC45A2,SLC45A2,CTD_human,21559390,A customized pigmentation SNP array identifies a novel SNP associated with melanoma predisposition in the SLC45A2 gene.,0.21839066043333702,"A customized pigmentation SNP array identifies a novel SNP associated with <span class=""disease"" id=""21559390-0-75-83"">melanoma</span> predisposition in the <span class=""gene"" id=""21559390-0-106-113"">SLC45A2</span> gene.",CTD_human
1,0,Biomarker,C0398623,Thrombophilia,disease,thrombophilia,51156,SERPINA10,protein Z-dependent protease inhibitor,CTD_human,15461625,Mutations within the protein Z-dependent protease inhibitor gene are associated with venous thromboembolic disease: a new form of thrombophilia.,0.200274726784213,"Mutations within the <span class=""gene"" id=""15461625-0-21-59"">protein Z-dependent protease inhibitor</span> gene are associated with venous thromboembolic disease: a new form of <span class=""disease"" id=""15461625-0-130-143"">thrombophilia</span>.",CTD_human
1,0,Biomarker,C0265202,Seckel syndrome,disease,Seckel syndrome,5116,PCNT,pericentrin,CTD_human,18157127,Mutations in pericentrin cause Seckel syndrome with defective ATR-dependent DNA damage signaling.,0.40137363392106606,"Mutations in <span class=""gene"" id=""18157127-0-13-24"">pericentrin</span> cause <span class=""disease"" id=""18157127-0-31-46"">Seckel syndrome</span> with defective ATR-dependent DNA damage signaling.",CTD_human;ORPHANET
1,0,Therapeutic,C0002736,Amyotrophic Lateral Sclerosis,disease,ALS,51163,DBR1,RNA lariat debranching enzyme,CTD_human,23104007,Inhibition of RNA lariat debranching enzyme suppresses TDP-43 toxicity in ALS disease models.,0.200274726784213,"Inhibition of <span class=""gene"" id=""23104007-0-14-43"">RNA lariat debranching enzyme</span> suppresses TDP-43 toxicity in <span class=""disease"" id=""23104007-0-74-77"">ALS</span> disease models.",CTD_human
1,0,Biomarker,C0010674,Cystic Fibrosis,disease,cystic fibrosis,51164,DCTN4,DCTN4,CTD_human,22772370,Exome sequencing of extreme phenotypes identifies DCTN4 as a modifier of chronic Pseudomonas aeruginosa infection in cystic fibrosis.,0.400549453568426,"Exome sequencing of extreme phenotypes identifies <span class=""gene"" id=""22772370-0-50-55"">DCTN4</span> as a modifier of chronic Pseudomonas aeruginosa infection in <span class=""disease"" id=""22772370-0-117-132"">cystic fibrosis</span>.",CTD_human;ORPHANET
2,1,Biomarker,C0279626,Squamous cell carcinoma of esophagus,disease,esophageal squamous cell carcinoma,51196,PLCE1,PLCE1,CTD_human,20729852,A shared susceptibility locus in PLCE1 at 10q23 for gastric adenocarcinoma and esophageal squamous cell carcinoma.,0.205494535684262,"A shared susceptibility locus in <span class=""gene"" id=""20729852-0-33-38"">PLCE1</span> at 10q23 for gastric adenocarcinoma and <span class=""disease"" id=""20729852-0-79-113"">esophageal squamous cell carcinoma</span>.",CTD_human
2,1,Biomarker,C0279626,Squamous cell carcinoma of esophagus,disease,esophageal squamous cell carcinoma,51196,PLCE1,PLCE1,CTD_human,20729853,Genome-wide association study of esophageal squamous cell carcinoma in Chinese subjects identifies susceptibility loci at PLCE1 and C20orf54.,0.205494535684262,"Genome-wide association study of <span class=""disease"" id=""20729853-0-33-67"">esophageal squamous cell carcinoma</span> in Chinese subjects identifies susceptibility loci at <span class=""gene"" id=""20729853-0-122-127"">PLCE1</span> and C20orf54.",CTD_human
1,0,Biomarker,C0023264,Leigh Disease,disease,Leigh syndrome,51204,TACO1,TACO1,CTD_human,19503089,"Mutation in TACO1, encoding a translational activator of COX I, results in cytochrome c oxidase deficiency and late-onset Leigh syndrome.",0.40027472678421294,"Mutation in <span class=""gene"" id=""19503089-0-12-17"">TACO1</span>, encoding a translational activator of COX I, results in cytochrome c oxidase deficiency and late-onset <span class=""disease"" id=""19503089-0-122-136"">Leigh syndrome</span>.",CTD_human;ORPHANET
1,0,Biomarker,C0268237,Cytochrome-c Oxidase Deficiency,disease,cytochrome c oxidase deficiency,51204,TACO1,TACO1,CTD_human,19503089,"Mutation in TACO1, encoding a translational activator of COX I, results in cytochrome c oxidase deficiency and late-onset Leigh syndrome.",0.2,"Mutation in <span class=""gene"" id=""19503089-0-12-17"">TACO1</span>, encoding a translational activator of COX I, results in <span class=""disease"" id=""19503089-0-75-106"">cytochrome c oxidase deficiency</span> and late-onset Leigh syndrome.",CTD_human
1,0,Biomarker,C0028754,Obesity,disease,obesity,5122,PCSK1,PCSK1,CTD_human,18604207,Common nonsynonymous variants in PCSK1 confer risk of obesity.,0.507288817463114,"Common nonsynonymous variants in <span class=""gene"" id=""18604207-0-33-38"">PCSK1</span> confer risk of <span class=""disease"" id=""18604207-0-54-61"">obesity</span>.",CTD_human;HPO
1,0,Biomarker,C1531773,Currarino triad,disease,Currarino syndrome,5125,PCSK5,Pcsk5,CTD_human,18519639,VACTERL/caudal regression/Currarino syndrome-like malformations in mice with mutation in the proprotein convertase Pcsk5.,0.200274726784213,"VACTERL/caudal regression/<span class=""disease"" id=""18519639-0-26-44"">Currarino syndrome</span>-like malformations in mice with mutation in the proprotein convertase <span class=""gene"" id=""18519639-0-115-120"">Pcsk5</span>.",CTD_human
1,0,Biomarker,C0080178,Spina Bifida,disease,spina bifida,5130,PCYT1A,PCYT1A,CTD_human,17184542,"CHKA and PCYT1A gene polymorphisms, choline intake and spina bifida risk in a California population.",0.200274726784213,"CHKA and <span class=""gene"" id=""17184542-0-9-15"">PCYT1A</span> gene polymorphisms, choline intake and <span class=""disease"" id=""17184542-0-55-67"">spina bifida</span> risk in a California population.",CTD_human
1,0,Biomarker,C0014553,Absence Epilepsy,disease,absence epilepsy,51305,KCNK9,KCNK9,CTD_human,15781965,A TASK3 channel (KCNK9) mutation in a genetic model of absence epilepsy.,0.20054945356842604,"A <span class=""gene"" id=""15781965-0-2-7"">TASK3</span> channel (<span class=""gene"" id=""15781965-0-17-22"">KCNK9</span>) mutation in a genetic model of <span class=""disease"" id=""15781965-0-55-71"">absence epilepsy</span>.",CTD_human
1,0,Biomarker,C0027051,Myocardial Infarction,disease,MI,51330,TNFRSF12A,Fn14,CTD_human,20082609,"Likewise, a rapid and sustained elevation of Fn14 mRNA and protein levels in the left ventricle was observed after experimental MI.",0.2,"Likewise, a rapid and sustained elevation of <span class=""gene"" id=""20082609-7-45-49"">Fn14</span> mRNA and protein levels in the left ventricle was observed after experimental <span class=""disease"" id=""20082609-7-128-130"">MI</span>.",CTD_human
1,0,Biomarker,C0023467,"Leukemia, Myelocytic, Acute",disease,AML,51341,ZBTB7A,ZBTB7A,CTD_human,27798625,"Outside of signaling alterations, RUNX1-RUNX1T1 and CBFB-MYH11 AMLs demonstrated remarkably different spectra of cooperating mutations, as RUNX1-RUNX1T1 cases harbored recurrent mutations in DHX15 and ZBTB7A, as well as an enrichment of mutations in epigenetic regulators, including ASXL2 and the cohesin complex.",0.2,"Outside of signaling alterations, RUNX1-RUNX1T1 and CBFB-MYH11 <span class=""disease"" id=""27798625-4-63-66"">AML</span>s demonstrated remarkably different spectra of cooperating mutations, as RUNX1-RUNX1T1 cases harbored recurrent mutations in DHX15 and <span class=""gene"" id=""27798625-4-201-207"">ZBTB7A</span>, as well as an enrichment of mutations in epigenetic regulators, including ASXL2 and the cohesin complex.",CTD_human
1,0,Biomarker,C0027051,Myocardial Infarction,disease,myocardial infarction,5139,PDE3A,phosphodiesterase 3A,CTD_human,19027736,Interventional effect of valsartan on expression of inducible cAMP early repressor and phosphodiesterase 3A in rats after myocardial infarction.,0.2,"Interventional effect of valsartan on expression of inducible cAMP early repressor and <span class=""gene"" id=""19027736-0-87-107"">phosphodiesterase 3A</span> in rats after <span class=""disease"" id=""19027736-0-122-143"">myocardial infarction</span>.",CTD_human
1,5,Biomarker,C1862170,Brachydactyly with hypertension,disease,hypertension with brachydactyly,5139,PDE3A,PDE3A,CTD_human,25961942,PDE3A mutations cause autosomal dominant hypertension with brachydactyly.,0.600549453568426,"<span class=""gene"" id=""25961942-0-0-5"">PDE3A</span> mutations cause autosomal dominant <span class=""disease"" id=""25961942-0-41-72"">hypertension with brachydactyly</span>.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,5141,PDE4A,PDE4A,CTD_human,18090323,Our results demonstrate altered expressions of the PDE4A and PDE4B proteins in the brains of subjects with autism and might provide new therapeutic avenues for the treatment of this debilitating disorder.,0.200274726784213,"Our results demonstrate altered expressions of the <span class=""gene"" id=""18090323-6-51-56"">PDE4A</span> and PDE4B proteins in the brains of subjects with <span class=""disease"" id=""18090323-6-107-113"">autism</span> and might provide new therapeutic avenues for the treatment of this debilitating disorder.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,5142,PDE4B,PDE4B,CTD_human,18090323,Our results demonstrate altered expressions of the PDE4A and PDE4B proteins in the brains of subjects with autism and might provide new therapeutic avenues for the treatment of this debilitating disorder.,0.200274726784213,"Our results demonstrate altered expressions of the PDE4A and <span class=""gene"" id=""18090323-6-61-66"">PDE4B</span> proteins in the brains of subjects with <span class=""disease"" id=""18090323-6-107-113"">autism</span> and might provide new therapeutic avenues for the treatment of this debilitating disorder.",CTD_human
4,0,Biomarker,C0005586,Bipolar Disorder,disease,bipolar disorder,5142,PDE4B,PDE4B,CTD_human,18394866,"Thus, the present observations suggest that dysregulation of intracellular signaling mediated by PDE4B is a significant factor in the cause and expression, respectively, of schizophrenia and bipolar disorder and that targeting PDE4B-regulated signaling pathways may yield new therapies to treat the totality of these disorders.",0.403231208875927,"Thus, the present observations suggest that dysregulation of intracellular signaling mediated by <span class=""gene"" id=""18394866-6-97-102"">PDE4B</span> is a significant factor in the cause and expression, respectively, of schizophrenia and <span class=""disease"" id=""18394866-6-191-207"">bipolar disorder</span> and that targeting <span class=""gene"" id=""18394866-6-227-232"">PDE4B</span>-regulated signaling pathways may yield new therapies to treat the totality of these disorders.",CTD_human;PSYGENET
2,1,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,5142,PDE4B,PDE4B,CTD_human,16293762,DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling.,0.22545368891093,"DISC1 and <span class=""gene"" id=""16293762-0-10-15"">PDE4B</span> are interacting genetic factors in <span class=""disease"" id=""16293762-0-51-64"">schizophrenia</span> that regulate cAMP signaling.",CTD_human
2,1,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,5142,PDE4B,PDE4B,CTD_human,18394866,PDE4B polymorphisms and decreased PDE4B expression are associated with schizophrenia.,0.22545368891093,"<span class=""gene"" id=""18394866-0-0-5"">PDE4B</span> polymorphisms and decreased <span class=""gene"" id=""18394866-0-34-39"">PDE4B</span> expression are associated with <span class=""disease"" id=""18394866-0-71-84"">schizophrenia</span>.",CTD_human
1,0,Biomarker,C0017636,Glioblastoma,disease,Glioblastoma,51426,POLK,DNA Polymerase Kappa,CTD_human,26651356,Kynurenine Signaling Increases DNA Polymerase Kappa Expression and Promotes Genomic Instability in Glioblastoma Cells.,0.200274726784213,"Kynurenine Signaling Increases <span class=""gene"" id=""26651356-0-31-51"">DNA Polymerase Kappa</span> Expression and Promotes Genomic Instability in <span class=""disease"" id=""26651356-0-99-111"">Glioblastoma</span> Cells.",CTD_human
2,1,Biomarker,C0004096,Asthma,disease,asthmatic,5144,PDE4D,PDE4D,CTD_human,21611147,?2-Agonist induced cAMP is decreased in asthmatic airway smooth muscle due to increased PDE4D.,0.204604842796993,"&beta;2-Agonist induced cAMP is decreased in <span class=""disease"" id=""21611147-0-40-49"">asthmatic</span> airway smooth muscle due to increased <span class=""gene"" id=""21611147-0-88-93"">PDE4D</span>.",CTD_human
2,1,Biomarker,C0004096,Asthma,disease,asthma,5144,PDE4D,PDE4D,CTD_human,19426955,Genome-wide association analysis identifies PDE4D as an asthma-susceptibility gene.,0.204604842796993,"Genome-wide association analysis identifies <span class=""gene"" id=""19426955-0-44-49"">PDE4D</span> as an <span class=""disease"" id=""19426955-0-56-62"">asthma</span>-susceptibility gene.",CTD_human
1,0,Biomarker,C0025500,Mesothelioma,disease,mesothelioma,5154,PDGFA,PDGF-A,CTD_human,11415934,"Our data indicate, surprisingly, that for mesothelioma cells in vitro, high-level activation of a PDGF-A-PDGF receptor loop is antiproliferative whereas abrogation of PDGF-A expression stimulates growth.",0.200274726784213,"Our data indicate, surprisingly, that for <span class=""disease"" id=""11415934-6-42-54"">mesothelioma</span> cells in vitro, high-level activation of a <span class=""gene"" id=""11415934-6-98-104"">PDGF-A</span>-PDGF receptor loop is antiproliferative whereas abrogation of <span class=""gene"" id=""11415934-6-167-173"">PDGF-A</span> expression stimulates growth.",CTD_human
1,0,Biomarker,C0040028,"Thrombocythemia, Essential",disease,essential thrombocythemia,5154,PDGFA,PDGF-A,CTD_human,15682418,"PDGF-A, PDGF-B, TGFbeta, and bFGF mRNA levels in patients with essential thrombocythemia treated with anagrelide.",0.2,"<span class=""gene"" id=""15682418-0-0-6"">PDGF-A</span>, PDGF-B, TGFbeta, and bFGF mRNA levels in patients with <span class=""disease"" id=""15682418-0-63-88"">essential thrombocythemia</span> treated with anagrelide.",CTD_human
1,0,Biomarker,C0015695,Fatty Liver,disease,fatty liver,51547,SIRT7,SIRT7,CTD_human,24210820,SIRT7 represses Myc activity to suppress ER stress and prevent fatty liver disease.,0.200274726784213,"<span class=""gene"" id=""24210820-0-0-5"">SIRT7</span> represses Myc activity to suppress ER stress and prevent <span class=""disease"" id=""24210820-0-63-74"">fatty liver</span> disease.",CTD_human
1,0,Biomarker,C0080178,Spina Bifida,disease,spina bifida,5156,PDGFRA,PDGFRalpha,CTD_human,11023856,"The YAC transgene was expressed in neural crest cells, rescued the profound craniofacial abnormalities and spina bifida observed in PDGFRalpha knockout mice and prolonged survival until birth.",0.206513574909167,"The YAC transgene was expressed in neural crest cells, rescued the profound craniofacial abnormalities and <span class=""disease"" id=""11023856-4-107-119"">spina bifida</span> observed in <span class=""gene"" id=""11023856-4-132-142"">PDGFRalpha</span> knockout mice and prolonged survival until birth.",CTD_human
1,0,Biomarker,C0206637,"Chondrosarcoma, Mesenchymal",disease,MC,5156,PDGFRA,PDGFR-alpha,CTD_human,12817616,"The results showed that malignant mesenchymal chondroblasts exhibit stronger expressions of CD99, IL-1alpha, cPKC-alpha, p-PKC-alpha/betaII, PDGFR-alpha, p-JNK, Ki-67, and bcl-2 antigens than their more mature-appearing chondrocytic counterparts in MC.",0.2,"The results showed that malignant mesenchymal chondroblasts exhibit stronger expressions of CD99, IL-1alpha, cPKC-alpha, p-PKC-alpha/betaII, <span class=""gene"" id=""12817616-4-141-152"">PDGFR-alpha</span>, p-JNK, Ki-67, and bcl-2 antigens than their more mature-appearing chondrocytic counterparts in <span class=""disease"" id=""12817616-4-249-251"">MC</span>.",CTD_human
2,7,Biomarker,C0238198,Gastrointestinal Stromal Tumors,group,GIST,5156,PDGFRA,PDGFRA,CTD_human,20028860,Gastrointestinal stromal tumors (GIST) are caused by activating mutations in the KIT or PDGFRA receptor tyrosine kinase genes.,0.738620495450882,"<span class=""disease"" id=""20028860-1-0-31"">Gastrointestinal stromal tumors</span> (<span class=""disease"" id=""20028860-1-33-37"">GIST</span>) are caused by activating mutations in the KIT or <span class=""gene"" id=""20028860-1-88-94"">PDGFRA</span> receptor tyrosine kinase genes.",CTD_human;HPO;ORPHANET;UNIPROT
1,0,Biomarker,C0376634,Craniofacial Abnormalities,group,craniofacial abnormalities,5156,PDGFRA,PDGFRalpha,CTD_human,11023856,"The YAC transgene was expressed in neural crest cells, rescued the profound craniofacial abnormalities and spina bifida observed in PDGFRalpha knockout mice and prolonged survival until birth.",0.200274726784213,"The YAC transgene was expressed in neural crest cells, rescued the profound <span class=""disease"" id=""11023856-4-76-102"">craniofacial abnormalities</span> and spina bifida observed in <span class=""gene"" id=""11023856-4-132-142"">PDGFRalpha</span> knockout mice and prolonged survival until birth.",CTD_human
2,0,Biomarker,C0033860,Psoriasis,disease,psoriasis,51561,IL23A,IL-23,CTD_human,19169254,Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways.,0.218052099846117,"Genome-wide scan reveals association of <span class=""disease"" id=""19169254-0-40-49"">psoriasis</span> with <span class=""gene"" id=""19169254-0-55-60"">IL-23</span> and NF-kappaB pathways.",CTD_human
1,0,Biomarker,C0878544,Cardiomyopathies,group,cardiomyopathy,5164,PDK2,Pdk2,CTD_human,21037199,"A novel coexpression and integrated pathway network analysis indicated Prkaa2, Pdk2, Rhoj, and Sgcb are likely to play a central role in the pathophysiology of murine progressive cardiomyopathy in C3H/HeJ mice.",0.2,"A novel coexpression and integrated pathway network analysis indicated Prkaa2, <span class=""gene"" id=""21037199-7-79-83"">Pdk2</span>, Rhoj, and Sgcb are likely to play a central role in the pathophysiology of murine progressive <span class=""disease"" id=""21037199-7-179-193"">cardiomyopathy</span> in C3H/HeJ mice.",CTD_human
1,0,Biomarker,C1458155,Mammary Neoplasms,group,breast tumors,51649,MRPS23,MRPS23,CTD_human,25151356,"The genes identified include eight that are essential for cell proliferation (FGD5, METTL6, CPT1A, DTX3, MRPS23, EIF2S2, EIF6 and SLC2A10) and are uniquely amplified in patients with highly proliferative luminal breast tumors, a clinical subset of patients for which few therapeutic options are effective.",0.2,"The genes identified include eight that are essential for cell proliferation (FGD5, METTL6, CPT1A, DTX3, <span class=""gene"" id=""25151356-4-105-111"">MRPS23</span>, EIF2S2, EIF6 and SLC2A10) and are uniquely amplified in patients with highly proliferative luminal <span class=""disease"" id=""25151356-4-212-225"">breast tumors</span>, a clinical subset of patients for which few therapeutic options are effective.",CTD_human
3,0,Biomarker,C0018784,Sensorineural Hearing Loss (disorder),disease,sensorineural deafness,5172,SLC26A4,pendrin,CTD_human,15279074,Mutations in the SLC26A4 (pendrin) gene in patients with sensorineural deafness and enlarged vestibular aqueduct.,0.441167179657098,"Mutations in the <span class=""gene"" id=""15279074-0-17-24"">SLC26A4</span> (<span class=""gene"" id=""15279074-0-26-33"">pendrin</span>) gene in patients with <span class=""disease"" id=""15279074-0-57-79"">sensorineural deafness</span> and enlarged vestibular aqueduct.",CTD_human;HPO
22,114,Biomarker,C0271829,Pendred's syndrome,disease,Pendred syndrome,5172,SLC26A4,SLC26A4,CTD_human,17697873,Analysis of the SLC26A4 gene in patients with Pendred syndrome in Taiwan.,0.721287206812288,"Analysis of the <span class=""gene"" id=""17697873-0-16-23"">SLC26A4</span> gene in patients with <span class=""disease"" id=""17697873-0-46-62"">Pendred syndrome</span> in Taiwan.",CTD_human;ORPHANET;UNIPROT
22,114,Biomarker,C0271829,Pendred's syndrome,disease,PDS,5172,SLC26A4,pendrin,CTD_human,10644529,"The gene causing Pendred syndrome (PDS) encodes a protein designated pendrin, which is expressed in the thyroid, kidney, and fetal cochlea.",0.721287206812288,"The gene causing <span class=""disease"" id=""10644529-2-17-33"">Pendred syndrome</span> (<span class=""disease"" id=""10644529-2-35-38"">PDS</span>) encodes a protein designated <span class=""gene"" id=""10644529-2-69-76"">pendrin</span>, which is expressed in the thyroid, kidney, and fetal cochlea.",CTD_human;ORPHANET;UNIPROT
1,0,Therapeutic,C0002622,Amnesia,disease,amnesia,5173,PDYN,dynorphin,CTD_human,7768285,The effects of intracerebroventricular administration of dynorphin A-(1-13) on scopolamine-induced amnesia were investigated in mice by using a step-down type passive avoidance task.,0.2,"The effects of intracerebroventricular administration of <span class=""gene"" id=""7768285-1-57-66"">dynorphin</span> A-(1-13) on scopolamine-induced <span class=""disease"" id=""7768285-1-99-106"">amnesia</span> were investigated in mice by using a step-down type passive avoidance task.",CTD_human
1,0,Biomarker,C0008370,Cholestasis,disease,cholestasis,5173,PDYN,dynorphin,CTD_human,16919318,Serum levels of dynorphin A and nitric oxide were decreased in rats with cholestasis compared to control animals.,0.2,"Serum levels of <span class=""gene"" id=""16919318-6-16-25"">dynorphin</span> A and nitric oxide were decreased in rats with <span class=""disease"" id=""16919318-6-73-84"">cholestasis</span> compared to control animals.",CTD_human
1,0,Biomarker,C0013384,Dyskinetic syndrome,disease,dyskinesia,5173,PDYN,dynorphin,CTD_human,21984936,Imaging mass spectrometry reveals elevated nigral levels of dynorphin neuropeptides in L-DOPA-induced dyskinesia in rat model of Parkinson's disease.,0.20328236603324,"Imaging mass spectrometry reveals elevated nigral levels of <span class=""gene"" id=""21984936-0-60-69"">dynorphin</span> neuropeptides in L-DOPA-induced <span class=""disease"" id=""21984936-0-102-112"">dyskinesia</span> in rat model of Parkinson's disease.",CTD_human
2,0,Biomarker,C0030193,Pain,phenotype,pain,5173,PDYN,dynorphin,CTD_human,17670969,"They also blocked pathological pain induced by sustained administration of morphine or spinal injection of dynorphin A, an endogenous mediator of chronic pain.",0.20082418035263896,"They also blocked pathological <span class=""disease"" id=""17670969-3-31-35"">pain</span> induced by sustained administration of morphine or spinal injection of <span class=""gene"" id=""17670969-3-107-116"">dynorphin</span> A, an endogenous mediator of chronic pain.",CTD_human
2,0,Biomarker,C0030193,Pain,phenotype,pain,5173,PDYN,dynorphin,CTD_human,20068450,CONCLUSIONs: These findings indicate that spinally released dynorphin A (1-17) by noxious stimuli leads to the direct activation of ascending pain transmission.,0.20082418035263896,"CONCLUSIONs: These findings indicate that spinally released <span class=""gene"" id=""20068450-10-60-69"">dynorphin</span> A (1-17) by noxious stimuli leads to the direct activation of ascending <span class=""disease"" id=""20068450-10-142-146"">pain</span> transmission.",CTD_human
1,0,Therapeutic,C0036572,Seizures,phenotype,seizures,5173,PDYN,dynorphin,CTD_human,1675896,The injection of dynorphin-A-1-13 (kappa-opiate agonist) into substantia nigra reticulata induced the locomotor depression which was like one in postictal period and resulted in the decrease of picrotoxin-induced seizures severity.,0.20054945356842604,"The injection of <span class=""gene"" id=""1675896-4-17-26"">dynorphin</span>-A-1-13 (kappa-opiate agonist) into substantia nigra reticulata induced the locomotor depression which was like one in postictal period and resulted in the decrease of picrotoxin-induced <span class=""disease"" id=""1675896-4-213-221"">seizures</span> severity.",CTD_human
1,1,Biomarker,C0003873,Rheumatoid Arthritis,disease,rheumatoid arthritis,51744,CD244,CD244,CTD_human,18794858,Functional SNPs in CD244 increase the risk of rheumatoid arthritis in a Japanese population.,0.208920603432455,"Functional SNPs in <span class=""gene"" id=""18794858-0-19-24"">CD244</span> increase the risk of <span class=""disease"" id=""18794858-0-46-66"">rheumatoid arthritis</span> in a Japanese population.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autistic,5175,PECAM1,PECAM-1,CTD_human,17509538,There was a negative correlation between serum levels of PECAM-1 and head circumference at birth in the autistic subjects.,0.202732912464814,"There was a negative correlation between serum levels of <span class=""gene"" id=""17509538-7-57-64"">PECAM-1</span> and head circumference at birth in the <span class=""disease"" id=""17509538-7-104-112"">autistic</span> subjects.",CTD_human
2,0,Biomarker,C0017638,Glioma,disease,glioma,51750,RTEL1,RTEL1,CTD_human,19578367,"We identified five risk loci for glioma at 5p15.33 (rs2736100, TERT; P = 1.50 x 10(-17)), 8q24.21 (rs4295627, CCDC26; P = 2.34 x 10(-18)), 9p21.3 (rs4977756, CDKN2A-CDKN2B; P = 7.24 x 10(-15)), 20q13.33 (rs6010620, RTEL1; P = 2.52 x 10(-12)) and 11q23.3 (rs498872, PHLDB1; P = 1.07 x 10(-8)).",0.218353858653341,"We identified five risk loci for <span class=""disease"" id=""19578367-2-33-39"">glioma</span> at 5p15.33 (rs2736100, TERT; P = 1.50 x 10(-17)), 8q24.21 (rs4295627, CCDC26; P = 2.34 x 10(-18)), 9p21.3 (rs4977756, CDKN2A-CDKN2B; P = 7.24 x 10(-15)), 20q13.33 (rs6010620, <span class=""gene"" id=""19578367-2-215-220"">RTEL1</span>; P = 2.52 x 10(-12)) and 11q23.3 (rs498872, PHLDB1; P = 1.07 x 10(-8)).",CTD_human
2,0,Biomarker,C0017638,Glioma,disease,glioma,51750,RTEL1,RTEL1,CTD_human,19578366,Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility.,0.218353858653341,"Variants in the CDKN2B and <span class=""gene"" id=""19578366-0-27-32"">RTEL1</span> regions are associated with high-grade <span class=""disease"" id=""19578366-0-72-78"">glioma</span> susceptibility.",CTD_human
1,1,Biomarker,C0004943,Behcet Syndrome,disease,Beh?et's disease,51752,ERAP1,ERAP1,CTD_human,23291587,Genome-wide association analysis identifies new susceptibility loci for Beh?et's disease and epistasis between HLA-B*51 and ERAP1.,0.40302199462634397,"Genome-wide association analysis identifies new susceptibility loci for <span class=""disease"" id=""23291587-0-72-88"">Beh&Ccedil;et's disease</span> and epistasis between HLA-B*51 and <span class=""gene"" id=""23291587-0-124-129"">ERAP1</span>.",CTD_human;ORPHANET
4,3,Biomarker,C0033860,Psoriasis,disease,psoriasis,51752,ERAP1,ERAP1,CTD_human,24212883,"We discovered two independent missense SNVs in IL23R and GJB2 of low frequency and five common missense SNVs in LCE3D, ERAP1, CARD14 and ZNF816A associated with psoriasis at genome-wide significance.",0.20357144819477,"We discovered two independent missense SNVs in IL23R and GJB2 of low frequency and five common missense SNVs in LCE3D, <span class=""gene"" id=""24212883-2-119-124"">ERAP1</span>, CARD14 and ZNF816A associated with <span class=""disease"" id=""24212883-2-161-170"">psoriasis</span> at genome-wide significance.",CTD_human
4,3,Biomarker,C0033860,Psoriasis,disease,psoriasis,51752,ERAP1,ERAP1,CTD_human,20953187,"ERAP1 and ZNF816A were associated with type 1 (early onset) psoriasis in the Chinese Han population (test for heterogeneity P = 6.5 × 10?³ and P = 1.5 × 10?³, respectively).",0.20357144819477,"<span class=""gene"" id=""20953187-4-0-5"">ERAP1</span> and ZNF816A were associated with type 1 (early onset) <span class=""disease"" id=""20953187-4-60-69"">psoriasis</span> in the Chinese Han population (test for heterogeneity P = 6.5 &times; 10?³ and P = 1.5 &times; 10?³, respectively).",CTD_human
4,3,Biomarker,C0033860,Psoriasis,disease,psoriasis,51752,ERAP1,ERAP1,CTD_human,23291587,"Three risk loci shared with ankylosing spondylitis and psoriasis (the MHC class I region, ERAP1 and IL23R and the MHC class I-ERAP1 interaction), as well as two loci shared with inflammatory bowel disease (IL23R and IL10) implicate shared pathogenic pathways in the spondyloarthritides and Beh?et's disease.",0.20357144819477,"Three risk loci shared with ankylosing spondylitis and <span class=""disease"" id=""23291587-8-55-64"">psoriasis</span> (the MHC class I region, <span class=""gene"" id=""23291587-8-90-95"">ERAP1</span> and IL23R and the MHC class I-<span class=""gene"" id=""23291587-8-126-131"">ERAP1</span> interaction), as well as two loci shared with inflammatory bowel disease (IL23R and IL10) implicate shared pathogenic pathways in the spondyloarthritides and Beh&Ccedil;et's disease.",CTD_human
4,3,Biomarker,C0033860,Psoriasis,disease,psoriasis,51752,ERAP1,ERAP1,CTD_human,20953190,A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1.,0.20357144819477,"A genome-wide association study identifies new <span class=""disease"" id=""20953190-0-47-56"">psoriasis</span> susceptibility loci and an interaction between HLA-C and <span class=""gene"" id=""20953190-0-114-119"">ERAP1</span>.",CTD_human
4,3,Biomarker,C0038013,Ankylosing spondylitis,disease,ankylosing spondylitis,51752,ERAP1,ERAP1,CTD_human,23291587,"Three risk loci shared with ankylosing spondylitis and psoriasis (the MHC class I region, ERAP1 and IL23R and the MHC class I-ERAP1 interaction), as well as two loci shared with inflammatory bowel disease (IL23R and IL10) implicate shared pathogenic pathways in the spondyloarthritides and Beh?et's disease.",0.23448287100996698,"Three risk loci shared with <span class=""disease"" id=""23291587-8-28-50"">ankylosing spondylitis</span> and psoriasis (the MHC class I region, <span class=""gene"" id=""23291587-8-90-95"">ERAP1</span> and IL23R and the MHC class I-<span class=""gene"" id=""23291587-8-126-131"">ERAP1</span> interaction), as well as two loci shared with inflammatory bowel disease (IL23R and IL10) implicate shared pathogenic pathways in the spondyloarthritides and Beh&Ccedil;et's disease.",CTD_human
4,3,Biomarker,C0038013,Ankylosing spondylitis,disease,ankylosing spondylitis,51752,ERAP1,ARTS1,CTD_human,17952073,"Comparing these data against a common control dataset derived from 1,500 randomly selected healthy British individuals, we report initial association and independent replication in a North American sample of two new loci related to ankylosing spondylitis, ARTS1 and IL23R, and confirmation of the previously reported association of AITD with TSHR and FCRL3.",0.23448287100996698,"Comparing these data against a common control dataset derived from 1,500 randomly selected healthy British individuals, we report initial association and independent replication in a North American sample of two new loci related to <span class=""disease"" id=""17952073-2-232-254"">ankylosing spondylitis</span>, <span class=""gene"" id=""17952073-2-256-261"">ARTS1</span> and IL23R, and confirmation of the previously reported association of AITD with TSHR and FCRL3.",CTD_human
4,3,Biomarker,C0038013,Ankylosing spondylitis,disease,ankylosing spondylitis,51752,ERAP1,ERAP1,CTD_human,21743469,Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility.,0.23448287100996698,"Interaction between <span class=""gene"" id=""21743469-0-20-25"">ERAP1</span> and HLA-B27 in <span class=""disease"" id=""21743469-0-41-63"">ankylosing spondylitis</span> implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility.",CTD_human
1,0,Biomarker,C0022548,Keloid,disease,keloid,5176,SERPINF1,pigment epithelium-derived factor,CTD_human,20128793,"Various classes of proteins were found either to be present or to be upregulated in keloid tissue: (i) inflammatory/differentiated keratinocyte markers: S100 proteins, peroxiredoxin I; (ii) wound healing proteins: gelsolin-like capping protein; (iii) fibrogenetic proteins: mast cell ?-tryptase, macrophage migration inhibitory factor (MIF); (iv) antifibrotic proteins: asporin; (v) tumour suppressor proteins: stratifin, galectin-1, maspin; and (vi) antiangiogenic proteins: pigment epithelium-derived factor.",0.2,"Various classes of proteins were found either to be present or to be upregulated in <span class=""disease"" id=""20128793-6-84-90"">keloid</span> tissue: (i) inflammatory/differentiated keratinocyte markers: S100 proteins, peroxiredoxin I; (ii) wound healing proteins: gelsolin-like capping protein; (iii) fibrogenetic proteins: mast cell &beta;-tryptase, macrophage migration inhibitory factor (MIF); (iv) antifibrotic proteins: asporin; (v) tumour suppressor proteins: stratifin, galectin-1, maspin; and (vi) antiangiogenic proteins: <span class=""gene"" id=""20128793-6-476-509"">pigment epithelium-derived factor</span>.",CTD_human
1,1,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,T2D,5184,PEPD,PEPD,CTD_human,22158537,The evidence of an association with T2D for PEPD and HNF4A has been shown in previous studies.,0.202956482091714,"The evidence of an association with <span class=""disease"" id=""22158537-5-36-39"">T2D</span> for <span class=""gene"" id=""22158537-5-44-48"">PEPD</span> and HNF4A has been shown in previous studies.",CTD_human
5,12,Biomarker,C0268532,Deficiency of prolidase,disease,prolidase deficiency,5184,PEPD,PEPD,CTD_human,16470701,A nonsense mutation of PEPD in four Amish children with prolidase deficiency.,0.6016483607052789,"A nonsense mutation of <span class=""gene"" id=""16470701-0-23-27"">PEPD</span> in four Amish children with <span class=""disease"" id=""16470701-0-56-76"">prolidase deficiency</span>.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0004352,Autistic Disorder,disease,autistic disorder,5187,PER1,Per1,CTD_human,17264841,Association of Per1 and Npas2 with autistic disorder: support for the clock genes/social timing hypothesis.,0.202681755307501,"Association of <span class=""gene"" id=""17264841-0-15-19"">Per1</span> and Npas2 with <span class=""disease"" id=""17264841-0-35-52"">autistic disorder</span>: support for the clock genes/social timing hypothesis.",CTD_human
1,0,Biomarker,C0023473,"Myeloid Leukemia, Chronic",disease,CML,5187,PER1,hPER1,CTD_human,16999817,"The expression levels of hPER1, hPER2, hPER3, hCRY1, hCRY2 and hBMAL1 were significantly impaired in both chronic phase and blastic crisis of CML cases compared with those in healthy individuals (P < 0.001).",0.2,"The expression levels of <span class=""gene"" id=""16999817-3-25-30"">hPER1</span>, hPER2, hPER3, hCRY1, hCRY2 and hBMAL1 were significantly impaired in both chronic phase and blastic crisis of <span class=""disease"" id=""16999817-3-142-145"">CML</span> cases compared with those in healthy individuals (P &lt; 0.001).",CTD_human
7,63,Biomarker,C0043459,Zellweger Syndrome,disease,Zellweger syndrome,5189,PEX1,PEX1,CTD_human,10447258,Identification of a common PEX1 mutation in Zellweger syndrome.,0.688213092771759,"Identification of a common <span class=""gene"" id=""10447258-0-27-31"">PEX1</span> mutation in <span class=""disease"" id=""10447258-0-44-62"">Zellweger syndrome</span>.",CTD_human;ORPHANET;UNIPROT
7,63,Biomarker,C0043459,Zellweger Syndrome,disease,Zellweger syndrome,5189,PEX1,PEX1,CTD_human,9539740,Human PEX1 cloned by functional complementation on a CHO cell mutant is responsible for peroxisome-deficient Zellweger syndrome of complementation group I.,0.688213092771759,"Human <span class=""gene"" id=""9539740-0-6-10"">PEX1</span> cloned by functional complementation on a CHO cell mutant is responsible for peroxisome-deficient <span class=""disease"" id=""9539740-0-109-127"">Zellweger syndrome</span> of complementation group I.",CTD_human;ORPHANET;UNIPROT
3,1,Biomarker,C1832200,Peroxisome biogenesis disorders,group,peroxisome biogenesis disorders,5189,PEX1,PEX1,CTD_human,9398847,Mutations in PEX1 are the most common cause of peroxisome biogenesis disorders.,0.20357144819477,"Mutations in <span class=""gene"" id=""9398847-0-13-17"">PEX1</span> are the most common cause of <span class=""disease"" id=""9398847-0-47-78"">peroxisome biogenesis disorders</span>.",CTD_human
3,1,Biomarker,C1832200,Peroxisome biogenesis disorders,group,peroxisome biogenesis disorders,5189,PEX1,PEX1,CTD_human,9398848,Human PEX1 is mutated in complementation group 1 of the peroxisome biogenesis disorders.,0.20357144819477,"Human <span class=""gene"" id=""9398848-0-6-10"">PEX1</span> is mutated in complementation group 1 of the <span class=""disease"" id=""9398848-0-56-87"">peroxisome biogenesis disorders</span>.",CTD_human
2,0,Biomarker,C0043459,Zellweger Syndrome,disease,ZS,5190,PEX6,PAF-2,CTD_human,8940266,"Direct sequencing of the PAF-2 gene revealed a homozygous 1-bp insertion at nucleotide 511 (511 insT) in one patient with group C Zellweger syndrome (ZS), which introduces a premature termination codon in the PAF-2 gene, and, in the second patient, revealed a splice-site mutation in intron 3 (IVS3+1G-->A), which skipped exon 3, an event that leads to peroxisome deficiency.",0.40137363392106606,"Direct sequencing of the <span class=""gene"" id=""8940266-5-25-30"">PAF-2</span> gene revealed a homozygous 1-bp insertion at nucleotide 511 (511 insT) in one patient with group C <span class=""disease"" id=""8940266-5-130-148"">Zellweger syndrome</span> (<span class=""disease"" id=""8940266-5-150-152"">ZS</span>), which introduces a premature termination codon in the <span class=""gene"" id=""8940266-5-209-214"">PAF-2</span> gene, and, in the second patient, revealed a splice-site mutation in intron 3 (IVS3+1G--&gt;A), which skipped exon 3, an event that leads to peroxisome deficiency.",CTD_human;ORPHANET
2,0,Biomarker,C0043459,Zellweger Syndrome,disease,Zellweger syndrome,5190,PEX6,PEX6,CTD_human,10408779,Most of the mutations led to premature termination or large deletions of the PEX6 protein and resulted in the most severe peroxisome biogenesis disorder phenotype of Zellweger syndrome.,0.40137363392106606,"Most of the mutations led to premature termination or large deletions of the <span class=""gene"" id=""10408779-8-77-81"">PEX6</span> protein and resulted in the most severe peroxisome biogenesis disorder phenotype of <span class=""disease"" id=""10408779-8-166-184"">Zellweger syndrome</span>.",CTD_human;ORPHANET
2,0,Biomarker,C1832200,Peroxisome biogenesis disorders,group,peroxisome biogenesis disorders,5190,PEX6,peroxisome assembly factor-2,CTD_human,10408779,Genomic structure and identification of 11 novel mutations of the PEX6 (peroxisome assembly factor-2) gene in patients with peroxisome biogenesis disorders.,0.201648360705279,"Genomic structure and identification of 11 novel mutations of the <span class=""gene"" id=""10408779-0-66-70"">PEX6</span> (<span class=""gene"" id=""10408779-0-72-100"">peroxisome assembly factor-2</span>) gene in patients with <span class=""disease"" id=""10408779-0-124-155"">peroxisome biogenesis disorders</span>.",CTD_human
2,0,Biomarker,C1832200,Peroxisome biogenesis disorders,group,PBD,5190,PEX6,PAF-2,CTD_human,8940266,These results confirm that human PAF-2 cDNA restores peroxisome of group C cells and that defects in the PAF-2 produce peroxisome deficiency of group C PBD.,0.201648360705279,"These results confirm that human <span class=""gene"" id=""8940266-7-33-38"">PAF-2</span> cDNA restores peroxisome of group C cells and that defects in the <span class=""gene"" id=""8940266-7-105-110"">PAF-2</span> produce peroxisome deficiency of group C <span class=""disease"" id=""8940266-7-152-155"">PBD</span>.",CTD_human
1,2,Biomarker,C0034960,Refsum Disease,disease,Refsum disease,5191,PEX7,PEX7,CTD_human,12522768,Identification of PEX7 as the second gene involved in Refsum disease.,0.409572371315507,"Identification of <span class=""gene"" id=""12522768-0-18-22"">PEX7</span> as the second gene involved in <span class=""disease"" id=""12522768-0-54-68"">Refsum disease</span>.",CTD_human;ORPHANET
3,30,Biomarker,C1859133,"RHIZOMELIC CHONDRODYSPLASIA PUNCTATA, TYPE 1",disease,rhizomelic chondrodysplasia punctata type 1,5191,PEX7,PEX7,CTD_human,11781871,Mutational spectrum in the PEX7 gene and functional analysis of mutant alleles in 78 patients with rhizomelic chondrodysplasia punctata type 1.,0.681923087489492,"Mutational spectrum in the <span class=""gene"" id=""11781871-0-27-31"">PEX7</span> gene and functional analysis of mutant alleles in 78 patients with <span class=""disease"" id=""11781871-0-99-142"">rhizomelic chondrodysplasia punctata type 1</span>.",CTD_human;ORPHANET;UNIPROT
3,30,Biomarker,C1859133,"RHIZOMELIC CHONDRODYSPLASIA PUNCTATA, TYPE 1",disease,rhizomelic chondrodysplasia punctata type 1,5191,PEX7,PEX7,CTD_human,12522768,"Mutations in PEX7 normally cause rhizomelic chondrodysplasia punctata type 1, a severe peroxisomal disorder.",0.681923087489492,"Mutations in <span class=""gene"" id=""12522768-5-13-17"">PEX7</span> normally cause <span class=""disease"" id=""12522768-5-33-76"">rhizomelic chondrodysplasia punctata type 1</span>, a severe peroxisomal disorder.",CTD_human;ORPHANET;UNIPROT
4,1,Biomarker,C0043459,Zellweger Syndrome,disease,Zellweger syndrome,5192,PEX10,PEX10,CTD_human,9683594,"A Zellweger syndrome patient, PBD100, was homozygous for a splice donor-site mutation that results in exon skipping and loss of 407 bp from the PEX10 open reading frame.",0.40027472678421294,"A <span class=""disease"" id=""9683594-5-2-20"">Zellweger syndrome</span> patient, PBD100, was homozygous for a splice donor-site mutation that results in exon skipping and loss of 407 bp from the <span class=""gene"" id=""9683594-5-144-149"">PEX10</span> open reading frame.",CTD_human;ORPHANET
4,1,Biomarker,C0043459,Zellweger Syndrome,disease,ZS,5192,PEX10,PEX10,CTD_human,10862081,"All four PEX10-deficient Zellweger Syndrome (ZS) patients were found to have nonsense, frameshift, or splice site mutations that remove large portions of the PEX10 coding region.",0.40027472678421294,"All four <span class=""gene"" id=""10862081-4-9-14"">PEX10</span>-deficient <span class=""disease"" id=""10862081-4-25-43"">Zellweger Syndrome</span> (<span class=""disease"" id=""10862081-4-45-47"">ZS</span>) patients were found to have nonsense, frameshift, or splice site mutations that remove large portions of the <span class=""gene"" id=""10862081-4-158-163"">PEX10</span> coding region.",CTD_human;ORPHANET
3,0,Biomarker,C1832200,Peroxisome biogenesis disorders,group,PBD,5192,PEX10,PEX10,CTD_human,10862081,Mutations in PEX10 have been identified in patients from complementation group 7 (CG7) of the PBDs and we report here an analysis of the genotypes and phenotypes of PEX10-deficient patients.,0.201373633921065,"Mutations in <span class=""gene"" id=""10862081-3-13-18"">PEX10</span> have been identified in patients from complementation group 7 (CG7) of the <span class=""disease"" id=""10862081-3-94-97"">PBD</span>s and we report here an analysis of the genotypes and phenotypes of <span class=""gene"" id=""10862081-3-165-170"">PEX10</span>-deficient patients.",CTD_human
3,0,Biomarker,C1832200,Peroxisome biogenesis disorders,group,peroxisome-biogenesis disorders,5192,PEX10,PEX10,CTD_human,9683594,"Identification of PEX10, the gene defective in complementation group 7 of the peroxisome-biogenesis disorders.",0.201373633921065,"Identification of <span class=""gene"" id=""9683594-0-18-23"">PEX10</span>, the gene defective in complementation group 7 of the <span class=""disease"" id=""9683594-0-78-109"">peroxisome-biogenesis disorders</span>.",CTD_human
3,0,Biomarker,C1832200,Peroxisome biogenesis disorders,group,PBD,5192,PEX10,PEX10,CTD_human,9700193,These results demonstrate that mutation in PEX10 is the genetic cause of complementation group B PBD.,0.201373633921065,"These results demonstrate that mutation in <span class=""gene"" id=""9700193-9-43-48"">PEX10</span> is the genetic cause of complementation group B <span class=""disease"" id=""9700193-9-97-100"">PBD</span>.",CTD_human
1,0,Biomarker,C1832200,Peroxisome biogenesis disorders,group,peroxisome biogenesis disorders,5193,PEX12,PEX12,CTD_human,9090384,"Isolation of the human PEX12 gene, mutated in group 3 of the peroxisome biogenesis disorders.",0.20082418035263896,"Isolation of the human <span class=""gene"" id=""9090384-0-23-28"">PEX12</span> gene, mutated in group 3 of the <span class=""disease"" id=""9090384-0-61-92"">peroxisome biogenesis disorders</span>.",CTD_human
2,0,Biomarker,C0043459,Zellweger Syndrome,disease,Zellweger syndrome,5194,PEX13,PEX13,CTD_human,19449432,Zellweger syndrome caused by PEX13 deficiency: report of two novel mutations.,0.400549453568426,"<span class=""disease"" id=""19449432-0-0-18"">Zellweger syndrome</span> caused by <span class=""gene"" id=""19449432-0-29-34"">PEX13</span> deficiency: report of two novel mutations.",CTD_human;ORPHANET
2,0,Biomarker,C0043459,Zellweger Syndrome,disease,H-02,5194,PEX13,PEX13,CTD_human,10332040,"We now have evidence that the complete human cDNA encoding Pex13p, an SH3 protein of a docking factor for the peroxisome targeting signal 1 receptor (Pex5p), rescues peroxisomal matrix protein import and its assembly in fibroblasts from PBD patients of complementation group H. In addition, we detected mutations on the human PEX13 cDNA in two patients of group H. A severe phenotype of a ZS patient (H-02) was homozygous for a nonsense mutation, W234ter, which results in the loss of not only the SH3 domain but also the putative transmembrane domain of Pex13p.",0.400549453568426,"We now have evidence that the complete human cDNA encoding Pex13p, an SH3 protein of a docking factor for the peroxisome targeting signal 1 receptor (Pex5p), rescues peroxisomal matrix protein import and its assembly in fibroblasts from PBD patients of complementation group H. In addition, we detected mutations on the human <span class=""gene"" id=""10332040-3-326-331"">PEX13</span> cDNA in two patients of group H. A severe phenotype of a <span class=""disease"" id=""10332040-3-389-391"">ZS</span> patient (<span class=""disease"" id=""10332040-3-401-405"">H-02</span>) was homozygous for a nonsense mutation, W234ter, which results in the loss of not only the SH3 domain but also the putative transmembrane domain of Pex13p.",CTD_human;ORPHANET
3,0,Biomarker,C1832200,Peroxisome biogenesis disorders,group,peroxisome-biogenesis disorders,5194,PEX13,PEX13,CTD_human,10441568,PEX13 is mutated in complementation group 13 of the peroxisome-biogenesis disorders.,0.20082418035263896,"<span class=""gene"" id=""10441568-0-0-5"">PEX13</span> is mutated in complementation group 13 of the <span class=""disease"" id=""10441568-0-52-83"">peroxisome-biogenesis disorders</span>.",CTD_human
3,0,Biomarker,C1832200,Peroxisome biogenesis disorders,group,peroxisome biogenesis disorders,5194,PEX13,PEX13,CTD_human,10332040,Nonsense and temperature-sensitive mutations in PEX13 are the cause of complementation group H of peroxisome biogenesis disorders.,0.20082418035263896,"Nonsense and temperature-sensitive mutations in <span class=""gene"" id=""10332040-0-48-53"">PEX13</span> are the cause of complementation group H of <span class=""disease"" id=""10332040-0-98-129"">peroxisome biogenesis disorders</span>.",CTD_human
2,0,Biomarker,C0043459,Zellweger Syndrome,disease,Zellweger syndrome,5195,PEX14,PEX14,CTD_human,18285423,Identification of a novel PEX14 mutation in Zellweger syndrome.,0.40355709281745294,"Identification of a novel <span class=""gene"" id=""18285423-0-26-31"">PEX14</span> mutation in <span class=""disease"" id=""18285423-0-44-62"">Zellweger syndrome</span>.",CTD_human;ORPHANET
2,0,Biomarker,C0043459,Zellweger Syndrome,disease,Zellweger syndrome,5195,PEX14,PEX14,CTD_human,15146459,"Indeed, human PEX14 rescues the import of a PTS1-dependent as well as a PTS2-dependent protein into the peroxisomes in fibroblasts from a patient with Zellweger syndrome belonging to the new complementation group.",0.40355709281745294,"Indeed, human <span class=""gene"" id=""15146459-6-14-19"">PEX14</span> rescues the import of a PTS1-dependent as well as a PTS2-dependent protein into the peroxisomes in fibroblasts from a patient with <span class=""disease"" id=""15146459-6-151-169"">Zellweger syndrome</span> belonging to the new complementation group.",CTD_human;ORPHANET
3,0,Biomarker,C1832200,Peroxisome biogenesis disorders,group,peroxisome biogenesis disorders,5195,PEX14,PEX14,CTD_human,15146459,Identification of a new complementation group of the peroxisome biogenesis disorders and PEX14 as the mutated gene.,0.20082418035263896,"Identification of a new complementation group of the <span class=""disease"" id=""15146459-0-53-84"">peroxisome biogenesis disorders</span> and <span class=""gene"" id=""15146459-0-89-94"">PEX14</span> as the mutated gene.",CTD_human
7,0,Biomarker,C0040034,Thrombocytopenia,phenotype,thrombocytopenia,5196,PF4,PF4,CTD_human,8282825,These findings indicate that antibodies associated with HITP react with PF4 complexed with heparin in solution or with glycosaminoglycan molecules on the surface of endothelial cells and provide the basis for a new hypothesis to explain the development of thrombocytopenia with thrombosis or disseminated intravascular coagulation in patients sensitive to heparin.,0.204930726738519,"These findings indicate that antibodies associated with HITP react with <span class=""gene"" id=""8282825-8-72-75"">PF4</span> complexed with heparin in solution or with glycosaminoglycan molecules on the surface of endothelial cells and provide the basis for a new hypothesis to explain the development of <span class=""disease"" id=""8282825-8-256-272"">thrombocytopenia</span> with thrombosis or disseminated intravascular coagulation in patients sensitive to heparin.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,5218,CDK14,CDK14,CTD_human,22922871,"The results suggest that seven of these genes, including VCAM1 and CDK14, may confer growth and infiltration capacity to HCC cells.",0.201098907136852,"The results suggest that seven of these genes, including VCAM1 and <span class=""gene"" id=""22922871-7-67-72"">CDK14</span>, may confer growth and infiltration capacity to <span class=""disease"" id=""22922871-7-121-124"">HCC</span> cells.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,5230,PGK1,phosphoglycerate kinase 1,CTD_human,21472284,"These identified proteins, which include stratifin (14-3-3), transgelin 2, heat-shock protein (HSP)70, HSP27, manganese superoxide dismutase, prohibitin, DJ1, ?-enolase, peroxiredoxin 6, aldo-keto reductase family member B10, phosphoglycerate kinase 1, ?-1-antitrypsin and nm23-H1, may play a role in the development of HCC.",0.20082418035263896,"These identified proteins, which include stratifin (14-3-3), transgelin 2, heat-shock protein (HSP)70, HSP27, manganese superoxide dismutase, prohibitin, DJ1, &alpha;-enolase, peroxiredoxin 6, aldo-keto reductase family member B10, <span class=""gene"" id=""21472284-9-226-251"">phosphoglycerate kinase 1</span>, &alpha;-1-antitrypsin and nm23-H1, may play a role in the development of <span class=""disease"" id=""21472284-9-320-323"">HCC</span>.",CTD_human
3,0,Biomarker,C0025286,Meningioma,disease,meningioma,5241,PGR,progesterone receptor,CTD_human,19747051,"In the clinical samples of meningioma, the levels of cathepsins B and L, stefin B, and cystatin C were highest in the tumors of higher histological grades, whereas stefin A and progesterone receptor were the only markers that were significantly increased and decreased, respectively, in WHO Grade III lesions.",0.206579087443797,"In the clinical samples of <span class=""disease"" id=""19747051-10-27-37"">meningioma</span>, the levels of cathepsins B and L, stefin B, and cystatin C were highest in the tumors of higher histological grades, whereas stefin A and <span class=""gene"" id=""19747051-10-177-198"">progesterone receptor</span> were the only markers that were significantly increased and decreased, respectively, in WHO Grade III lesions.",CTD_human
2,0,Biomarker,C0003873,Rheumatoid Arthritis,disease,rheumatoid arthritis,5243,ABCB1,P-glycoprotein,CTD_human,20080907,"Tacrolimus, a calcineurin inhibitor, overcomes treatment unresponsiveness mediated by P-glycoprotein on lymphocytes in refractory rheumatoid arthritis.",0.215881317595423,"Tacrolimus, a calcineurin inhibitor, overcomes treatment unresponsiveness mediated by <span class=""gene"" id=""20080907-0-86-100"">P-glycoprotein</span> on lymphocytes in refractory <span class=""disease"" id=""20080907-0-130-150"">rheumatoid arthritis</span>.",CTD_human
1,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,non-small-cell lung cancer,5243,ABCB1,MDR1,CTD_human,20627363,Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine.,0.21181325172116297,"Single nucleotide polymorphisms in <span class=""gene"" id=""20627363-0-35-39"">MDR1</span> gen correlates with outcome in advanced <span class=""disease"" id=""20627363-0-80-106"">non-small-cell lung cancer</span> patients treated with cisplatin plus vinorelbine.",CTD_human
2,0,Biomarker,C0014544,Epilepsy,disease,epilepsy,5243,ABCB1,P-gp,CTD_human,19570321,Organic anion transporting polypeptide 2 and P-gp did not change at the mRNA or protein level with epilepsy in the liver or kidney.,0.278628979161458,"Organic anion transporting polypeptide 2 and <span class=""gene"" id=""19570321-14-45-49"">P-gp</span> did not change at the mRNA or protein level with <span class=""disease"" id=""19570321-14-99-107"">epilepsy</span> in the liver or kidney.",CTD_human
2,0,Biomarker,C0014544,Epilepsy,disease,epileptic,5243,ABCB1,P-glycoprotein,CTD_human,8001500,"In epileptic brain specimens with high MDR1 mRNA levels, expression of P-glycoprotein in astrocytes also was identified.",0.278628979161458,"In <span class=""disease"" id=""8001500-7-3-12"">epileptic</span> brain specimens with high <span class=""gene"" id=""8001500-7-39-43"">MDR1</span> mRNA levels, expression of <span class=""gene"" id=""8001500-7-71-85"">P-glycoprotein</span> in astrocytes also was identified.",CTD_human
1,0,Biomarker,C0014836,Escherichia coli Infections,group,E. coli infection,5243,ABCB1,P-glycoprotein,CTD_human,24498193,E. coli infection modulates the pharmacokinetics of oral enrofloxacin by targeting P-glycoprotein in small intestine and CYP450 3A in liver and kidney of broilers.,0.2,"<span class=""disease"" id=""24498193-0-0-17"">E. coli infection</span> modulates the pharmacokinetics of oral enrofloxacin by targeting <span class=""gene"" id=""24498193-0-83-97"">P-glycoprotein</span> in small intestine and CYP450 3A in liver and kidney of broilers.",CTD_human
1,0,Biomarker,C0014859,Esophageal Neoplasms,group,esophageal cancer,5243,ABCB1,ABCB1,CTD_human,21332314,Impact of ABCB1 C3435T polymorphism on lymph node regression in multimodality treatment of locally advanced esophageal cancer.,0.201648360705279,"Impact of <span class=""gene"" id=""21332314-0-10-15"">ABCB1</span> C3435T polymorphism on lymph node regression in multimodality treatment of locally advanced <span class=""disease"" id=""21332314-0-108-125"">esophageal cancer</span>.",CTD_human
1,0,Biomarker,C0018798,Congenital Heart Defects,group,congenital heart defects,5243,ABCB1,ABCB1,CTD_human,23874772,Increased risk for congenital heart defects in children carrying the ABCB1 Gene C3435T polymorphism and maternal periconceptional toxicants exposure.,0.20054945356842604,"Increased risk for <span class=""disease"" id=""23874772-0-19-43"">congenital heart defects</span> in children carrying the <span class=""gene"" id=""23874772-0-69-74"">ABCB1</span> Gene C3435T polymorphism and maternal periconceptional toxicants exposure.",CTD_human
2,0,Biomarker,C0027947,Neutropenia,disease,neutropenia,5243,ABCB1,ABCB1,CTD_human,16950614,Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia.,0.21051780698042102,"Association of <span class=""gene"" id=""16950614-0-15-20"">ABCB1</span> genotypes with paclitaxel-mediated peripheral neuropathy and <span class=""disease"" id=""16950614-0-82-93"">neutropenia</span>.",CTD_human
2,0,Biomarker,C0027947,Neutropenia,disease,neutropenia,5243,ABCB1,ABCB1,CTD_human,25007187,"In addition, a statistically significant association was found among neutropenia (absolute neutrophil count<500) and variant allele carriers of ABCB1 rs1045642 (OR=5.174; 95% CI: 1.674; 15.989) and ABCB1 rs1128503 (OR=3.364; 95% CI: 1.257; 9.004), respectively.",0.21051780698042102,"In addition, a statistically significant association was found among <span class=""disease"" id=""25007187-8-69-80"">neutropenia</span> (absolute neutrophil count&lt;500) and variant allele carriers of <span class=""gene"" id=""25007187-8-144-149"">ABCB1</span> rs1045642 (OR=5.174; 95% CI: 1.674; 15.989) and <span class=""gene"" id=""25007187-8-198-203"">ABCB1</span> rs1128503 (OR=3.364; 95% CI: 1.257; 9.004), respectively.",CTD_human
1,0,Biomarker,C0030567,Parkinson Disease,disease,Parkinson disease,5243,ABCB1,ABCB1,CTD_human,20558393,Interaction between ABCB1 and professional exposure to organochlorine insecticides in Parkinson disease.,0.23453234943565598,"Interaction between <span class=""gene"" id=""20558393-0-20-25"">ABCB1</span> and professional exposure to organochlorine insecticides in <span class=""disease"" id=""20558393-0-86-103"">Parkinson disease</span>.",CTD_human
1,0,Biomarker,C0031117,Peripheral Neuropathy,group,peripheral neuropathy,5243,ABCB1,ABCB1,CTD_human,16950614,Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia.,0.20082418035263896,"Association of <span class=""gene"" id=""16950614-0-15-20"">ABCB1</span> genotypes with paclitaxel-mediated <span class=""disease"" id=""16950614-0-56-77"">peripheral neuropathy</span> and neutropenia.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,hepatocellular carcinoma,5243,ABCB1,MDR1,CTD_human,17510421,No effect was shown on parental drug-sensitive or on MDR-positive hepatocellular carcinoma cells after transfection with MDR1 small interfering RNA.,0.310726333699915,"No effect was shown on parental drug-sensitive or on MDR-positive <span class=""disease"" id=""17510421-7-66-90"">hepatocellular carcinoma</span> cells after transfection with <span class=""gene"" id=""17510421-7-121-125"">MDR1</span> small interfering RNA.",CTD_human
1,0,Biomarker,C0008313,"Cholangitis, Sclerosing",disease,sclerosing cholangitis,5244,ABCB4,Abcb4,CTD_human,16472600,24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice.,0.202956482091714,"24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of <span class=""disease"" id=""16472600-0-83-105"">sclerosing cholangitis</span> in <span class=""gene"" id=""16472600-0-109-113"">Mdr2</span> (<span class=""gene"" id=""16472600-0-115-120"">Abcb4</span>) knockout mice.",CTD_human
2,0,Biomarker,C0023890,Liver Cirrhosis,disease,cirrhosis,5244,ABCB4,Abcb4,CTD_human,18221819,"Integrin beta6 mRNA increased with fibrosis stage in hepatitis C and was upregulated between 25- and 100-fold in TAA- and BDL-induced cirrhosis, in Mdr2(Abcb4)(-/-) mice and in human end-stage liver disease. alphavbeta6 protein was absent in normal livers and expressed de novo on (activated) bile duct epithelia and transitional hepatocytes.",0.40137363392106606,"Integrin beta6 mRNA increased with fibrosis stage in hepatitis C and was upregulated between 25- and 100-fold in TAA- and BDL-induced <span class=""disease"" id=""18221819-5-134-143"">cirrhosis</span>, in <span class=""gene"" id=""18221819-5-148-152"">Mdr2</span>(<span class=""gene"" id=""18221819-5-153-158"">Abcb4</span>)(-/-) mice and in human end-stage liver disease. alphavbeta6 protein was absent in normal livers and expressed de novo on (activated) bile duct epithelia and transitional hepatocytes.",CTD_human;HPO
1,0,Biomarker,C0400966,Non-alcoholic Fatty Liver Disease,disease,NAFLD,5244,ABCB4,MDR3,CTD_human,20040336,"However, in patients with PBC or NAFLD, diseases that represent cholesterol overload, MDR3 was already expressed at a high level to compensate for bile acids overproduction, and its expression was hardly affected by BF.",0.200274726784213,"However, in patients with PBC or <span class=""disease"" id=""20040336-10-33-38"">NAFLD</span>, diseases that represent cholesterol overload, <span class=""gene"" id=""20040336-10-86-90"">MDR3</span> was already expressed at a high level to compensate for bile acids overproduction, and its expression was hardly affected by BF.",CTD_human
1,0,Biomarker,C0745744,End Stage Liver Disease,disease,chronic liver failure,5244,ABCB4,Mdr2,CTD_human,22022477,Hepatocyte IKK2 protects Mdr2-/- mice from chronic liver failure.,0.200274726784213,"Hepatocyte IKK2 protects <span class=""gene"" id=""22022477-0-25-29"">Mdr2</span>-/- mice from <span class=""disease"" id=""22022477-0-43-64"">chronic liver failure</span>.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,5244,ABCB4,Mdr2,CTD_human,22022477,"To address the role of IKK2-mediated NF-?B activation in hepatocytes in the pathogenesis of liver disease and HCC in Mdr2(-/-) mice, we generated Mdr2-deficient animals lacking IKK2 specifically in hepatocytes using the Cre-loxP system.",0.281923087489492,"To address the role of IKK2-mediated NF-&kappa;B activation in hepatocytes in the pathogenesis of liver disease and <span class=""disease"" id=""22022477-4-110-113"">HCC</span> in <span class=""gene"" id=""22022477-4-117-121"">Mdr2</span>(-/-) mice, we generated <span class=""gene"" id=""22022477-4-146-150"">Mdr2</span>-deficient animals lacking IKK2 specifically in hepatocytes using the Cre-loxP system.",CTD_human
1,0,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,5245,PHB,prohibitin,CTD_human,18504422,A comparison of the synaptic proteome in human chronic schizophrenia and rat ketamine psychosis suggest that prohibitin is involved in the synaptic pathology of schizophrenia.,0.202732912464814,"A comparison of the synaptic proteome in human chronic schizophrenia and rat ketamine psychosis suggest that <span class=""gene"" id=""18504422-0-109-119"">prohibitin</span> is involved in the synaptic pathology of <span class=""disease"" id=""18504422-0-161-174"">schizophrenia</span>.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,5245,PHB,prohibitin,CTD_human,21472284,"These identified proteins, which include stratifin (14-3-3), transgelin 2, heat-shock protein (HSP)70, HSP27, manganese superoxide dismutase, prohibitin, DJ1, ?-enolase, peroxiredoxin 6, aldo-keto reductase family member B10, phosphoglycerate kinase 1, ?-1-antitrypsin and nm23-H1, may play a role in the development of HCC.",0.201098907136852,"These identified proteins, which include stratifin (14-3-3), transgelin 2, heat-shock protein (HSP)70, HSP27, manganese superoxide dismutase, <span class=""gene"" id=""21472284-9-142-152"">prohibitin</span>, DJ1, &alpha;-enolase, peroxiredoxin 6, aldo-keto reductase family member B10, phosphoglycerate kinase 1, &alpha;-1-antitrypsin and nm23-H1, may play a role in the development of <span class=""disease"" id=""21472284-9-320-323"">HCC</span>.",CTD_human
2,0,Biomarker,C3536983,Familial Hypophosphatemic Rickets,disease,hypophosphatemic rickets,5251,PHEX,PHEX,CTD_human,18775977,"In hypophosphatemic rickets, there are both inherited and acquired forms, where X-linked dominant hypophosphatemic rickets (XLH) is the most prevalent genetic form and caused by mutations in the phosphate-regulating endopeptidase (PHEX) gene.",0.221660349820883,"In <span class=""disease"" id=""18775977-1-3-27"">hypophosphatemic rickets</span>, there are both inherited and acquired forms, where X-linked dominant hypophosphatemic rickets (XLH) is the most prevalent genetic form and caused by mutations in the phosphate-regulating endopeptidase (<span class=""gene"" id=""18775977-1-231-235"">PHEX</span>) gene.",CTD_human
1,1,Biomarker,C0796013,Zimmerman Laband syndrome,disease,Zimmermann-Laband syndrome,526,ATP6V1B2,ATP6V1B2,CTD_human,25915598,Mutations in KCNH1 and ATP6V1B2 cause Zimmermann-Laband syndrome.,0.40027472678421294,"Mutations in KCNH1 and <span class=""gene"" id=""25915598-0-23-31"">ATP6V1B2</span> cause <span class=""disease"" id=""25915598-0-38-64"">Zimmermann-Laband syndrome</span>.",CTD_human;ORPHANET
4,8,Biomarker,C0034960,Refsum Disease,disease,RD,5264,PHYH,PHYH,CTD_human,12522768,"Linkage analysis of a few patients diagnosed with RD, but without mutations in PHYH, suggested a second locus on chromosome 6q22-24.",0.689861453477037,"Linkage analysis of a few patients diagnosed with <span class=""disease"" id=""12522768-3-50-52"">RD</span>, but without mutations in <span class=""gene"" id=""12522768-3-79-83"">PHYH</span>, suggested a second locus on chromosome 6q22-24.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0003469,Anxiety Disorders,group,anxiety disorder,5265,SERPINA1,AAT,CTD_human,17659342,"Proportion of reactive airway disease, obstructive pulmonary disease, and pre-existing anxiety disorder or bipolar disorder were significantly increased in persons carrying AAT non-M polymorphisms compared to normal MM genotype (respectively, 10, 20, 21, and 33% compared to 8, 12, 11, and 9%; contingency table, pulmonary: chi2 37, p=0.0001; affective disorder: chi2=171, p=0.0001).",0.20054945356842604,"Proportion of reactive airway disease, obstructive pulmonary disease, and pre-existing <span class=""disease"" id=""17659342-8-87-103"">anxiety disorder</span> or bipolar disorder were significantly increased in persons carrying <span class=""gene"" id=""17659342-8-173-176"">AAT</span> non-M polymorphisms compared to normal MM genotype (respectively, 10, 20, 21, and 33% compared to 8, 12, 11, and 9%; contingency table, pulmonary: chi2 37, p=0.0001; affective disorder: chi2=171, p=0.0001).",CTD_human
1,0,Biomarker,C0003949,Asbestosis,disease,asbestosis,5265,SERPINA1,alpha 1 antitrypsin,CTD_human,12368052,Pi*S and Pi*Z alpha 1 antitrypsin polymorphism and the risk for asbestosis in occupational exposure to asbestos.,0.20541466777231498,"Pi*S and Pi*Z <span class=""gene"" id=""12368052-0-14-33"">alpha 1 antitrypsin</span> polymorphism and the risk for <span class=""disease"" id=""12368052-0-64-74"">asbestosis</span> in occupational exposure to asbestos.",CTD_human
2,0,Biomarker,C0005586,Bipolar Disorder,disease,bipolar disorder,5265,SERPINA1,AAT,CTD_human,17659342,"Proportion of reactive airway disease, obstructive pulmonary disease, and pre-existing anxiety disorder or bipolar disorder were significantly increased in persons carrying AAT non-M polymorphisms compared to normal MM genotype (respectively, 10, 20, 21, and 33% compared to 8, 12, 11, and 9%; contingency table, pulmonary: chi2 37, p=0.0001; affective disorder: chi2=171, p=0.0001).",0.40082418035263895,"Proportion of reactive airway disease, obstructive pulmonary disease, and pre-existing anxiety disorder or <span class=""disease"" id=""17659342-8-107-123"">bipolar disorder</span> were significantly increased in persons carrying <span class=""gene"" id=""17659342-8-173-176"">AAT</span> non-M polymorphisms compared to normal MM genotype (respectively, 10, 20, 21, and 33% compared to 8, 12, 11, and 9%; contingency table, pulmonary: chi2 37, p=0.0001; affective disorder: chi2=171, p=0.0001).",CTD_human;PSYGENET
1,0,Biomarker,C0006267,Bronchiectasis,disease,bronchiectasis,5265,SERPINA1,alpha 1-antitrypsin,CTD_human,7785020,This report describes histologically proven bronchiectasis in a 21 year old man with massive haemoptysis and homozygous deficiency of alpha 1-antitrypsin.,0.21100174801421803,"This report describes histologically proven <span class=""disease"" id=""7785020-2-44-58"">bronchiectasis</span> in a 21 year old man with massive haemoptysis and homozygous deficiency of <span class=""gene"" id=""7785020-2-134-153"">alpha 1-antitrypsin</span>.",CTD_human
3,0,Biomarker,C0023890,Liver Cirrhosis,disease,liver cirrhosis,5265,SERPINA1,AAT,CTD_human,25579632,AAT deficiency is a genetic disease that manifests with emphysema and liver cirrhosis due to the accumulation of a misfolded AAT mutant in hepatocytes.,0.216822167640005,"AAT deficiency is a genetic disease that manifests with emphysema and <span class=""disease"" id=""25579632-2-70-85"">liver cirrhosis</span> due to the accumulation of a misfolded <span class=""gene"" id=""25579632-2-125-128"">AAT</span> mutant in hepatocytes.",CTD_human
1,0,Biomarker,C0024115,Lung diseases,group,lung disease,5265,SERPINA1,AAT,CTD_human,17659342,"This new proposed phenotype for AAT transcends classic pattern of strictly liver and lung disease, and should be considered for proper evaluation and management of patients presenting with classic AAT-related disorders, affective disorders, persons with ICE, white matter disease or multisystem disorders of memory.",0.22324319799153197,"This new proposed phenotype for <span class=""gene"" id=""17659342-21-32-35"">AAT</span> transcends classic pattern of strictly liver and <span class=""disease"" id=""17659342-21-85-97"">lung disease</span>, and should be considered for proper evaluation and management of patients presenting with classic <span class=""gene"" id=""17659342-21-197-200"">AAT</span>-related disorders, affective disorders, persons with ICE, white matter disease or multisystem disorders of memory.",CTD_human
2,0,Biomarker,C0024117,Chronic Obstructive Airway Disease,disease,COPD,5265,SERPINA1,AAT,CTD_human,25579632,"Lung AAT amount is inversely correlated with chronic obstructive pulmonary disease (COPD), a serious and often deadly condition, with increasing frequency in the aging population.",0.46260854547141406,"Lung <span class=""gene"" id=""25579632-3-5-8"">AAT</span> amount is inversely correlated with <span class=""disease"" id=""25579632-3-45-82"">chronic obstructive pulmonary disease</span> (<span class=""disease"" id=""25579632-3-84-88"">COPD</span>), a serious and often deadly condition, with increasing frequency in the aging population.",CTD_human;HPO
2,0,Biomarker,C0024117,Chronic Obstructive Airway Disease,disease,chronic obstructive pulmonary disease,5265,SERPINA1,SERPINA1,CTD_human,16278826,Cryptic haplotypes of SERPINA1 confer susceptibility to chronic obstructive pulmonary disease.,0.46260854547141406,"Cryptic haplotypes of <span class=""gene"" id=""16278826-0-22-30"">SERPINA1</span> confer susceptibility to <span class=""disease"" id=""16278826-0-56-93"">chronic obstructive pulmonary disease</span>.",CTD_human;HPO
1,0,Biomarker,C0024121,Lung Neoplasms,group,lung tumor,5265,SERPINA1,alpha-1-antitrypsin,CTD_human,17902193,"Notably, we demonstrate significant regulation of alpha-1-antitrypsin, alpha-2-macroglobulin, hemoglobin subunit alpha, vitamin D-binding protein, major urinary proteins, and transthyretin (up to eight-fold) in serum of lung tumor bearing mice.",0.20541466777231498,"Notably, we demonstrate significant regulation of <span class=""gene"" id=""17902193-7-50-69"">alpha-1-antitrypsin</span>, alpha-2-macroglobulin, hemoglobin subunit alpha, vitamin D-binding protein, major urinary proteins, and transthyretin (up to eight-fold) in serum of <span class=""disease"" id=""17902193-7-220-230"">lung tumor</span> bearing mice.",CTD_human
2,0,Biomarker,C0030328,"Panniculitis, Nodular Nonsuppurative",disease,Weber Christian disease,5265,SERPINA1,alpha 1 antitrypsin,CTD_human,6982619,Alpha 1 antitrypsin phenotypes and serum levels are presented for a family in which two brothers have Weber Christian disease and alpha 1 antitrypsin (PI) Z phenotypes.,0.20054945356842604,"Alpha 1 antitrypsin phenotypes and serum levels are presented for a family in which two brothers have <span class=""disease"" id=""6982619-1-102-125"">Weber Christian disease</span> and <span class=""gene"" id=""6982619-1-130-149"">alpha 1 antitrypsin</span> (PI) Z phenotypes.",CTD_human
1,0,Biomarker,C0034067,Pulmonary Emphysema,disease,emphysema,5265,SERPINA1,alpha 1-antitrypsin,CTD_human,3485249,Alpha 1-antitrypsin deficiency and emphysema caused by homozygous inheritance of non-expressing alpha 1-antitrypsin genes.,0.437832428309461,"Alpha 1-antitrypsin deficiency and <span class=""disease"" id=""3485249-0-35-44"">emphysema</span> caused by homozygous inheritance of non-expressing <span class=""gene"" id=""3485249-0-96-115"">alpha 1-antitrypsin</span> genes.",CTD_human;HPO
2,25,Biomarker,C0221757,alpha 1-Antitrypsin Deficiency,disease,Alpha 1-antitrypsin deficiency,5265,SERPINA1,alpha 1-antitrypsin,CTD_human,3485249,Alpha 1-antitrypsin deficiency and emphysema caused by homozygous inheritance of non-expressing alpha 1-antitrypsin genes.,0.482141179173555,"<span class=""disease"" id=""3485249-0-0-30"">Alpha 1-antitrypsin deficiency</span> and emphysema caused by homozygous inheritance of non-expressing <span class=""gene"" id=""3485249-0-96-115"">alpha 1-antitrypsin</span> genes.",CTD_human;ORPHANET
2,0,Biomarker,C2239176,Liver carcinoma,disease,hepatocellular carcinoma,5265,SERPINA1,Alpha 1-antitrypsin,CTD_human,6258829,Alpha 1-antitrypsin in patients with hepatocellular carcinoma and chronic active hepatitis.,0.417763017684587,"<span class=""gene"" id=""6258829-0-0-19"">Alpha 1-antitrypsin</span> in patients with <span class=""disease"" id=""6258829-0-37-61"">hepatocellular carcinoma</span> and chronic active hepatitis.",CTD_human;HPO
2,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,5265,SERPINA1,?-1-antitrypsin,CTD_human,21472284,"These identified proteins, which include stratifin (14-3-3), transgelin 2, heat-shock protein (HSP)70, HSP27, manganese superoxide dismutase, prohibitin, DJ1, ?-enolase, peroxiredoxin 6, aldo-keto reductase family member B10, phosphoglycerate kinase 1, ?-1-antitrypsin and nm23-H1, may play a role in the development of HCC.",0.417763017684587,"These identified proteins, which include stratifin (14-3-3), transgelin 2, heat-shock protein (HSP)70, HSP27, manganese superoxide dismutase, prohibitin, DJ1, &alpha;-enolase, peroxiredoxin 6, aldo-keto reductase family member B10, phosphoglycerate kinase 1, <span class=""gene"" id=""21472284-9-253-268"">&alpha;-1-antitrypsin</span> and nm23-H1, may play a role in the development of <span class=""disease"" id=""21472284-9-320-323"">HCC</span>.",CTD_human;HPO
1,0,Therapeutic,C2239176,Liver carcinoma,disease,hepatocellular carcinoma,5267,SERPINA4,kallistatin,CTD_human,19709125,Combining kallistatin gene therapy and meloxicam to treat hepatocellular carcinoma in mice.,0.2,"Combining <span class=""gene"" id=""19709125-0-10-21"">kallistatin</span> gene therapy and meloxicam to treat <span class=""disease"" id=""19709125-0-58-82"">hepatocellular carcinoma</span> in mice.",CTD_human
1,0,Biomarker,C1458155,Mammary Neoplasms,group,breast tumor,5268,SERPINB5,MASPIN,CTD_human,16799634,"Finally, small interfering RNA (siRNA)-mediated knockdown of G9A and DNMT1 led to increased MASPIN expression in MDA-MB-231 cells, to levels that were supra-additive, verifying the importance of these enzymes in maintaining multiple layers of epigenetic repression in breast tumor cells.",0.222687480071149,"Finally, small interfering RNA (siRNA)-mediated knockdown of G9A and DNMT1 led to increased <span class=""gene"" id=""16799634-6-92-98"">MASPIN</span> expression in MDA-MB-231 cells, to levels that were supra-additive, verifying the importance of these enzymes in maintaining multiple layers of epigenetic repression in <span class=""disease"" id=""16799634-6-268-280"">breast tumor</span> cells.",CTD_human
1,0,Biomarker,C0033860,Psoriasis,disease,psoriasis,5271,SERPINB8,SERPINB8,CTD_human,20953187,"We identified six new susceptibility loci associated with psoriasis in the Chinese study containing the candidate genes ERAP1, PTTG1, CSMD1, GJB2, SERPINB8 and ZNF816A (combined P < 5 × 10??) and replicated one locus, 5q33.1 (TNIP1-ANXA6), previously reported (combined P = 3.8 × 10?²¹) in the European studies.",0.20240702852328799,"We identified six new susceptibility loci associated with <span class=""disease"" id=""20953187-2-58-67"">psoriasis</span> in the Chinese study containing the candidate genes ERAP1, PTTG1, CSMD1, GJB2, <span class=""gene"" id=""20953187-2-147-155"">SERPINB8</span> and ZNF816A (combined P &lt; 5 &times; 10??) and replicated one locus, 5q33.1 (TNIP1-ANXA6), previously reported (combined P = 3.8 &times; 10?²¹) in the European studies.",CTD_human
1,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,tumour metastasis,5287,PIK3C2B,PIK3C2B,CTD_human,21986133,"Based on the tumour samples, expression of PIK3C2B was associated with tumour metastasis and in vitro assay suggested that it mediated cell migration.",0.201098907136852,"Based on the tumour samples, expression of <span class=""gene"" id=""21986133-8-43-50"">PIK3C2B</span> was associated with <span class=""disease"" id=""21986133-8-71-88"">tumour metastasis</span> and in vitro assay suggested that it mediated cell migration.",CTD_human
1,0,Biomarker,C0001418,Adenocarcinoma,group,adenocarcinomas,5290,PIK3CA,PIK3CA,CTD_human,22484628,"Frequently mutated genes in the adenocarcinomas included TP53 (11/15 tumors), PIK3CA (3/15) and ARID1A (3/15).",0.22235350510426302,"Frequently mutated genes in the <span class=""disease"" id=""22484628-3-32-47"">adenocarcinomas</span> included TP53 (11/15 tumors), <span class=""gene"" id=""22484628-3-78-84"">PIK3CA</span> (3/15) and ARID1A (3/15).",CTD_human
1,0,Biomarker,C0079744,Diffuse Large B-Cell Lymphoma,disease,DLBCL,5290,PIK3CA,PI3K,CTD_human,21173233,These results demonstrate a critical function of PI3K-PDK1 signaling upstream of MALT1 protease and NF-?B in distinct ABC DLBCL cells and provide a rationale for the pharmacologic use of PI3K inhibitors in DLBCL therapy.,0.20412090176319603,"These results demonstrate a critical function of <span class=""gene"" id=""21173233-6-49-53"">PI3K</span>-PDK1 signaling upstream of MALT1 protease and NF-&kappa;B in distinct ABC DLBCL cells and provide a rationale for the pharmacologic use of <span class=""gene"" id=""21173233-6-187-191"">PI3K</span> inhibitors in <span class=""disease"" id=""21173233-6-206-211"">DLBCL</span> therapy.",CTD_human
1,0,Biomarker,C0152013,Adenocarcinoma of lung (disorder),disease,lung adenocarcinoma,5290,PIK3CA,PIK3CA,CTD_human,22135231,Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.,0.203296721410557,"Coexistence of <span class=""gene"" id=""22135231-0-15-21"">PIK3CA</span> and other oncogene mutations in <span class=""disease"" id=""22135231-0-54-73"">lung adenocarcinoma</span>-rationale for comprehensive mutation profiling.",CTD_human
1,0,Biomarker,C1168401,Squamous cell carcinoma of the head and neck,disease,HNSCC,5290,PIK3CA,PI3K,CTD_human,23873848,"Although consistent inhibition of the PI3K pathway was not evident in HNSCC, we identified a combination of PI3K/TP53 events necessary, but not sufficient, for rigosertib sensitivity.",0.210989071368524,"Although consistent inhibition of the <span class=""gene"" id=""23873848-10-38-42"">PI3K</span> pathway was not evident in <span class=""disease"" id=""23873848-10-70-75"">HNSCC</span>, we identified a combination of <span class=""gene"" id=""23873848-10-108-112"">PI3K</span>/TP53 events necessary, but not sufficient, for rigosertib sensitivity.",CTD_human
8,0,Biomarker,C1458155,Mammary Neoplasms,group,breast tumors,5290,PIK3CA,Pik3ca,CTD_human,22370636,We found that activation of the latent Pik3ca(H1047R) allele resulted in breast tumors with multiple histological types.,0.254185158234768,"We found that activation of the latent <span class=""gene"" id=""22370636-3-39-45"">Pik3ca</span>(H1047R) allele resulted in <span class=""disease"" id=""22370636-3-73-86"">breast tumors</span> with multiple histological types.",CTD_human
1,0,Biomarker,C0079744,Diffuse Large B-Cell Lymphoma,disease,DLBCL,5291,PIK3CB,PI3K,CTD_human,21173233,These results demonstrate a critical function of PI3K-PDK1 signaling upstream of MALT1 protease and NF-?B in distinct ABC DLBCL cells and provide a rationale for the pharmacologic use of PI3K inhibitors in DLBCL therapy.,0.20412090176319603,"These results demonstrate a critical function of <span class=""gene"" id=""21173233-6-49-53"">PI3K</span>-PDK1 signaling upstream of MALT1 protease and NF-&kappa;B in distinct ABC DLBCL cells and provide a rationale for the pharmacologic use of <span class=""gene"" id=""21173233-6-187-191"">PI3K</span> inhibitors in <span class=""disease"" id=""21173233-6-206-211"">DLBCL</span> therapy.",CTD_human
1,0,Biomarker,C0017636,Glioblastoma,disease,glioblastoma,5292,PIM1,oncogene pim-1,CTD_human,23724780,U1 adaptors for the therapeutic knockdown of the oncogene pim-1 kinase in glioblastoma.,0.200274726784213,"U1 adaptors for the therapeutic knockdown of the <span class=""gene"" id=""23724780-0-49-63"">oncogene pim-1</span> kinase in <span class=""disease"" id=""23724780-0-74-86"">glioblastoma</span>.",CTD_human
1,0,Biomarker,C0034186,Pyelonephritis,disease,pyelonephritis,5292,PIM1,Pim1,CTD_human,23565217,"Furthermore, Pim1 overexpression, in combination with the hormone treatment, increased inflammation surrounding target tissues leading to pyelonephritis in transgenic animals.",0.200274726784213,"Furthermore, <span class=""gene"" id=""23565217-9-13-17"">Pim1</span> overexpression, in combination with the hormone treatment, increased inflammation surrounding target tissues leading to <span class=""disease"" id=""23565217-9-138-152"">pyelonephritis</span> in transgenic animals.",CTD_human
1,0,Biomarker,C0235833,Congenital diaphragmatic hernia,disease,congenital diaphragmatic hernia,5292,PIM1,PIM-1,CTD_human,25812446,Increased expression of activated pSTAT3 and PIM-1 in the pulmonary vasculature of experimental congenital diaphragmatic hernia.,0.2,"Increased expression of activated pSTAT3 and <span class=""gene"" id=""25812446-0-45-50"">PIM-1</span> in the pulmonary vasculature of experimental <span class=""disease"" id=""25812446-0-96-127"">congenital diaphragmatic hernia</span>.",CTD_human
1,0,Biomarker,C0079744,Diffuse Large B-Cell Lymphoma,disease,DLBCL,5293,PIK3CD,PI3K,CTD_human,21173233,These results demonstrate a critical function of PI3K-PDK1 signaling upstream of MALT1 protease and NF-?B in distinct ABC DLBCL cells and provide a rationale for the pharmacologic use of PI3K inhibitors in DLBCL therapy.,0.20439562854741,"These results demonstrate a critical function of <span class=""gene"" id=""21173233-6-49-53"">PI3K</span>-PDK1 signaling upstream of MALT1 protease and NF-&kappa;B in distinct ABC DLBCL cells and provide a rationale for the pharmacologic use of <span class=""gene"" id=""21173233-6-187-191"">PI3K</span> inhibitors in <span class=""disease"" id=""21173233-6-206-211"">DLBCL</span> therapy.",CTD_human
1,0,Biomarker,C0334634,"Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse",disease,MCL,5293,PIK3CD,PI3K,CTD_human,23676220,"PIK3IP1, a negative PI3K regulator, appears to mediate pG1 sensitization to PI3K inhibition; it is markedly reduced in MCL tumor cells compared with normal peripheral B cells, profoundly induced in pG1 and required for pG1 sensitization to GS-1101.",0.203021994626344,"PIK3IP1, a negative <span class=""gene"" id=""23676220-8-20-24"">PI3K</span> regulator, appears to mediate pG1 sensitization to <span class=""gene"" id=""23676220-8-76-80"">PI3K</span> inhibition; it is markedly reduced in <span class=""disease"" id=""23676220-8-119-122"">MCL</span> tumor cells compared with normal peripheral B cells, profoundly induced in pG1 and required for pG1 sensitization to GS-1101.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,5294,PIK3CG,PIK3CG,CTD_human,14627686,"Association of INPP1, PIK3CG, and TSC2 gene variants with autistic disorder: implications for phosphatidylinositol signalling in autism.",0.20054945356842604,"Association of INPP1, <span class=""gene"" id=""14627686-0-22-28"">PIK3CG</span>, and TSC2 gene variants with <span class=""disease"" id=""14627686-0-58-75"">autistic disorder</span>: implications for phosphatidylinositol signalling in <span class=""disease"" id=""14627686-0-129-135"">autism</span>.",CTD_human
1,0,Biomarker,C0018801,Heart failure,disease,heart failure,5294,PIK3CG,PI3Kgamma,CTD_human,12963636,"Thus, PI3Kgamma may represent a novel therapeutic target for the treatment of decreased cardiac function in heart failure.",0.201098907136852,"Thus, <span class=""gene"" id=""12963636-8-6-15"">PI3Kgamma</span> may represent a novel therapeutic target for the treatment of decreased cardiac function in <span class=""disease"" id=""12963636-8-108-121"">heart failure</span>.",CTD_human
1,0,Biomarker,C0025149,Medulloblastoma,disease,medulloblastoma,5294,PIK3CG,PI3K,CTD_human,21652733,A sensitized RNA interference screen identifies a novel role for the PI3K p110? isoform in medulloblastoma cell proliferation and chemoresistance.,0.202472541057918,"A sensitized RNA interference screen identifies a novel role for the <span class=""gene"" id=""21652733-0-69-73"">PI3K</span> p110&gamma; isoform in <span class=""disease"" id=""21652733-0-91-106"">medulloblastoma</span> cell proliferation and chemoresistance.",CTD_human
1,0,Biomarker,C0079744,Diffuse Large B-Cell Lymphoma,disease,DLBCL,5294,PIK3CG,PI3K,CTD_human,21173233,These results demonstrate a critical function of PI3K-PDK1 signaling upstream of MALT1 protease and NF-?B in distinct ABC DLBCL cells and provide a rationale for the pharmacologic use of PI3K inhibitors in DLBCL therapy.,0.20412090176319603,"These results demonstrate a critical function of <span class=""gene"" id=""21173233-6-49-53"">PI3K</span>-PDK1 signaling upstream of MALT1 protease and NF-&kappa;B in distinct ABC DLBCL cells and provide a rationale for the pharmacologic use of <span class=""gene"" id=""21173233-6-187-191"">PI3K</span> inhibitors in <span class=""disease"" id=""21173233-6-206-211"">DLBCL</span> therapy.",CTD_human
1,0,Biomarker,C0006413,Burkitt Lymphoma,disease,Burkitt lymphomas,5295,PIK3R1,PIK3R1,CTD_human,23143597,"We identified 70 genes that were recurrently mutated in Burkitt lymphomas, including ID3, GNA13, RET, PIK3R1 and the SWI/SNF genes ARID1A and SMARCA4.",0.2,"We identified 70 genes that were recurrently mutated in <span class=""disease"" id=""23143597-4-56-73"">Burkitt lymphomas</span>, including ID3, GNA13, RET, <span class=""gene"" id=""23143597-4-102-108"">PIK3R1</span> and the SWI/SNF genes ARID1A and SMARCA4.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,5307,PITX1,PITX1,CTD_human,18053270,Association of autism with polymorphisms in the paired-like homeodomain transcription factor 1 (PITX1) on chromosome 5q31: a candidate gene analysis.,0.20240702852328799,"Association of <span class=""disease"" id=""18053270-0-15-21"">autism</span> with polymorphisms in the <span class=""gene"" id=""18053270-0-48-94"">paired-like homeodomain transcription factor 1</span> (<span class=""gene"" id=""18053270-0-96-101"">PITX1</span>) on chromosome 5q31: a candidate gene analysis.",CTD_human
1,0,Biomarker,C1336708,Testicular Germ Cell Tumor,disease,TGCT,5307,PITX1,PITX1,CTD_human,23666240,"Furthermore, PITX1, at 5q31.1, regulates TERT expression and is the third TGCT-associated locus implicated in telomerase regulation.",0.200274726784213,"Furthermore, <span class=""gene"" id=""23666240-7-13-18"">PITX1</span>, at 5q31.1, regulates TERT expression and is the third <span class=""disease"" id=""23666240-7-74-78"">TGCT</span>-associated locus implicated in telomerase regulation.",CTD_human
10,6,Biomarker,C3714873,"Axenfeld-Rieger Syndrome, Type 1",disease,Rieger Syndrome type 1,5308,PITX2,Pitx2,CTD_human,14623826,"Pitx2, a paired-related homeobox gene that encodes multiple isoforms, is the gene mutated in the haploinsufficient Rieger Syndrome type 1 that includes dental, ocular and abdominal wall anomalies as cardinal features.",0.48027472678421296,"<span class=""gene"" id=""14623826-1-0-5"">Pitx2</span>, a paired-related homeobox gene that encodes multiple isoforms, is the gene mutated in the haploinsufficient <span class=""disease"" id=""14623826-1-115-137"">Rieger Syndrome type 1</span> that includes dental, ocular and abdominal wall anomalies as cardinal features.",CTD_human;UNIPROT
1,0,Biomarker,C0026010,Microphthalmos,disease,microphthalmia,5309,PITX3,PITX3,CTD_human,16565358,Also studied were two siblings who were homozygous for the PITX3 mutation who had microphthalmia and significant neurologic impairment.,0.4010989071368521,"Also studied were two siblings who were homozygous for the <span class=""gene"" id=""16565358-3-59-64"">PITX3</span> mutation who had <span class=""disease"" id=""16565358-3-82-96"">microphthalmia</span> and significant neurologic impairment.",CTD_human;HPO
2,0,Biomarker,C0086543,Cataract,disease,cataracts,5309,PITX3,PITX3,CTD_human,9620774,A novel homeobox gene PITX3 is mutated in families with autosomal-dominant cataracts and ASMD.,0.404655999954306,"A novel homeobox gene <span class=""gene"" id=""9620774-0-22-27"">PITX3</span> is mutated in families with autosomal-dominant <span class=""disease"" id=""9620774-0-75-84"">cataracts</span> and ASMD.",CTD_human;HPO
2,0,Biomarker,C0086543,Cataract,disease,cataracts,5309,PITX3,PITX3,CTD_human,16565358,Heterozygous and homozygous mutations in PITX3 in a large Lebanese family with posterior polar cataracts and neurodevelopmental abnormalities.,0.404655999954306,"Heterozygous and homozygous mutations in <span class=""gene"" id=""16565358-0-41-46"">PITX3</span> in a large Lebanese family with posterior polar <span class=""disease"" id=""16565358-0-95-104"">cataracts</span> and neurodevelopmental abnormalities.",CTD_human;HPO
2,0,Biomarker,C1862839,Anterior segment mesenchymal dysgenesis,disease,ASMD,5309,PITX3,PITX3,CTD_human,9620774,A novel homeobox gene PITX3 is mutated in families with autosomal-dominant cataracts and ASMD.,0.4813736339210661,"A novel homeobox gene <span class=""gene"" id=""9620774-0-22-27"">PITX3</span> is mutated in families with autosomal-dominant cataracts and <span class=""disease"" id=""9620774-0-89-93"">ASMD</span>.",CTD_human;ORPHANET
2,0,Biomarker,C1862839,Anterior segment mesenchymal dysgenesis,disease,ASMD,5309,PITX3,PITX3,CTD_human,18989383,A recurrent 17 bp duplication (c.657ins17bp) of a segment of the paired-like homeodomain transcription factor 3 (PITX3) gene on human chromosome 10 has been reported in seven families with autosomal dominant posterior polar cataracts with or without anterior segment mesenchymal dysgenesis (ASMD).,0.4813736339210661,"A recurrent 17 bp duplication (c.657ins17bp) of a segment of the <span class=""gene"" id=""18989383-1-65-111"">paired-like homeodomain transcription factor 3</span> (<span class=""gene"" id=""18989383-1-113-118"">PITX3</span>) gene on human chromosome 10 has been reported in seven families with autosomal dominant posterior polar cataracts with or without <span class=""disease"" id=""18989383-1-250-289"">anterior segment mesenchymal dysgenesis</span> (<span class=""disease"" id=""18989383-1-291-295"">ASMD</span>).",CTD_human;ORPHANET
2,1,Biomarker,C1864567,"CATARACT, POSTERIOR POLAR, 4 (disorder)",disease,CPP4,5309,PITX3,PITX3,CTD_human,15286169,Recurrent 17 bp duplication in PITX3 is primarily associated with posterior polar cataract (CPP4).,0.4,"Recurrent 17 bp duplication in <span class=""gene"" id=""15286169-0-31-36"">PITX3</span> is primarily associated with posterior polar cataract (<span class=""disease"" id=""15286169-0-92-96"">CPP4</span>).",CTD_human;UNIPROT
5,15,Biomarker,C0085413,"Polycystic Kidney, Autosomal Dominant",disease,ADPKD,5310,PKD1,PKD1,CTD_human,7581371,A novel nonsense mutation in the PKD1 gene (C3817T) is associated with autosomal dominant polycystic kidney disease (ADPKD) in a large three-generation Italian family.,0.307003240706612,"A novel nonsense mutation in the <span class=""gene"" id=""7581371-0-33-37"">PKD1</span> gene (C3817T) is associated with <span class=""disease"" id=""7581371-0-71-115"">autosomal dominant polycystic kidney disease</span> (<span class=""disease"" id=""7581371-0-117-122"">ADPKD</span>) in a large three-generation Italian family.",CTD_human
5,15,Biomarker,C0085413,"Polycystic Kidney, Autosomal Dominant",disease,ADPKD,5310,PKD1,PKD1,CTD_human,8004675,We identified a chromosome translocation associated with ADPKD that disrupts a gene (PBP) encoding a 14 kb transcript in the PKD1 candidate region.,0.307003240706612,"We identified a chromosome translocation associated with <span class=""disease"" id=""8004675-2-57-62"">ADPKD</span> that disrupts a gene (PBP) encoding a 14 kb transcript in the <span class=""gene"" id=""8004675-2-125-129"">PKD1</span> candidate region.",CTD_human
4,0,Biomarker,C0085413,"Polycystic Kidney, Autosomal Dominant",disease,ADPKD,5311,PKD2,polycystin-2,CTD_human,15001556,Deficiency of polycystin-2 reduces Ca2+ channel activity and cell proliferation in ADPKD lymphoblastoid cells.,0.26577469238725,"Deficiency of <span class=""gene"" id=""15001556-0-14-26"">polycystin-2</span> reduces Ca2+ channel activity and cell proliferation in <span class=""disease"" id=""15001556-0-83-88"">ADPKD</span> lymphoblastoid cells.",CTD_human
4,0,Biomarker,C0085413,"Polycystic Kidney, Autosomal Dominant",disease,autosomal-dominant polycystic kidney disease,5311,PKD2,polycystin-2,CTD_human,12089381,"In the (cy/+) rat, a model for autosomal-dominant polycystic kidney disease in which cysts originate predominantly from the proximal tubule, polycystin-2 immunoreactivity was lost in some distal tubules.",0.26577469238725,"In the (cy/+) rat, a model for <span class=""disease"" id=""12089381-8-31-75"">autosomal-dominant polycystic kidney disease</span> in which cysts originate predominantly from the proximal tubule, <span class=""gene"" id=""12089381-8-141-153"">polycystin-2</span> immunoreactivity was lost in some distal tubules.",CTD_human
4,0,Biomarker,C0085413,"Polycystic Kidney, Autosomal Dominant",disease,autosomal dominant polycystic kidney disease,5311,PKD2,TRPP2,CTD_human,24719335,Transient receptor potential channel TRPP2 is a nonselective cation channel that is mutated in autosomal dominant polycystic kidney disease.,0.26577469238725,"Transient receptor potential channel <span class=""gene"" id=""24719335-2-37-42"">TRPP2</span> is a nonselective cation channel that is mutated in <span class=""disease"" id=""24719335-2-95-139"">autosomal dominant polycystic kidney disease</span>.",CTD_human
11,173,Biomarker,C0085548,Autosomal Recessive Polycystic Kidney Disease,disease,ARPKD,5314,PKHD1,PKHD1,CTD_human,16133180,Analysis of missense variants in the PKHD1-gene in patients with autosomal recessive polycystic kidney disease (ARPKD).,0.7148041693311601,"Analysis of missense variants in the <span class=""gene"" id=""16133180-0-37-42"">PKHD1</span>-gene in patients with <span class=""disease"" id=""16133180-0-65-110"">autosomal recessive polycystic kidney disease</span> (<span class=""disease"" id=""16133180-0-112-117"">ARPKD</span>).",CTD_human;ORPHANET;UNIPROT
11,173,Biomarker,C0085548,Autosomal Recessive Polycystic Kidney Disease,disease,ARPKD,5314,PKHD1,FPC,CTD_human,19524688,"These observations should provide an important platform for determining FPC function and the pathogenesis of ARPKD, with the targeting of mTOR signaling being exploitable as a novel therapy.",0.7148041693311601,"These observations should provide an important platform for determining <span class=""gene"" id=""19524688-7-72-75"">FPC</span> function and the pathogenesis of <span class=""disease"" id=""19524688-7-109-114"">ARPKD</span>, with the targeting of mTOR signaling being exploitable as a novel therapy.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0004153,Atherosclerosis,disease,atherosclerosis,5320,PLA2G2A,sPLA2,CTD_human,19237014,Simvastatin may reduce the process of atherosclerosis by decreasing the expression level of sPLA2 IIa in myocardium and aorta.,0.206579087443797,"Simvastatin may reduce the process of <span class=""disease"" id=""19237014-13-38-53"">atherosclerosis</span> by decreasing the expression level of <span class=""gene"" id=""19237014-13-92-97"">sPLA2</span> IIa in myocardium and aorta.",CTD_human
1,0,Biomarker,C0014175,Endometriosis,disease,endometriosis,5320,PLA2G2A,PLA2G2A,CTD_human,25446850,"Higher expression of PLA2G2A, PTGS2, AKR1B1, AKR1C3 and ABCC4 was seen in 22-B endometriosis cells compared to HIESC control cells.",0.2,"Higher expression of <span class=""gene"" id=""25446850-11-21-28"">PLA2G2A</span>, PTGS2, AKR1B1, AKR1C3 and ABCC4 was seen in 22-B <span class=""disease"" id=""25446850-11-79-92"">endometriosis</span> cells compared to HIESC control cells.",CTD_human
1,0,Biomarker,C0002736,Amyotrophic Lateral Sclerosis,disease,ALS,5321,PLA2G4A,cPLA2,CTD_human,15816863,These results suggest that cPLA2 plays an important role in supplying arachidonic acid to the COX-2 driven inflammatory pathway in ALS associated with SOD1 mutations.,0.200274726784213,"These results suggest that <span class=""gene"" id=""15816863-9-27-32"">cPLA2</span> plays an important role in supplying arachidonic acid to the COX-2 driven inflammatory pathway in <span class=""disease"" id=""15816863-9-131-134"">ALS</span> associated with SOD1 mutations.",CTD_human
1,0,Biomarker,C0011603,Dermatitis,disease,dermatitis,5321,PLA2G4A,cPLA(2)alpha,CTD_human,18287786,"Furthermore, increased expression of cPLA(2)alpha, assessed by anti-phospho-cPLA2alpha antibody, was observed in the skin lesions of mite-antigen-induced dermatitis.",0.2,"Furthermore, increased expression of <span class=""gene"" id=""18287786-6-37-49"">cPLA(2)alpha</span>, assessed by anti-phospho-cPLA2alpha antibody, was observed in the skin lesions of mite-antigen-induced <span class=""disease"" id=""18287786-6-154-164"">dermatitis</span>.",CTD_human
1,0,Biomarker,C0035222,"Respiratory Distress Syndrome, Adult",disease,ARDS,5321,PLA2G4A,cPLA2,CTD_human,10881173,"Using a murine model of acute lung injury induced by septic syndrome or acid aspiration, we investigated the role of cytosolic phospholipase A2 (cPLA2) in ARDS.",0.2,"Using a murine model of acute lung injury induced by septic syndrome or acid aspiration, we investigated the role of <span class=""gene"" id=""10881173-3-117-143"">cytosolic phospholipase A2</span> (<span class=""gene"" id=""10881173-3-145-150"">cPLA2</span>) in <span class=""disease"" id=""10881173-3-155-159"">ARDS</span>.",CTD_human
1,0,Biomarker,C1260965,Lipoblastoma,disease,lipoblastoma,5324,PLAG1,PLAG1,CTD_human,16308870,"One such entity is lipoblastoma, which is a benign lipomatous tumour that often exhibits rearrangements of chromosome bands 8q11-13, and the gene PLAG1 has been implicated as the target of these chromosomal changes.",0.20494508211583604,"One such entity is <span class=""disease"" id=""16308870-2-19-31"">lipoblastoma</span>, which is a benign lipomatous tumour that often exhibits rearrangements of chromosome bands 8q11-13, and the gene <span class=""gene"" id=""16308870-2-146-151"">PLAG1</span> has been implicated as the target of these chromosomal changes.",CTD_human
35,0,Therapeutic,C0027051,Myocardial Infarction,disease,myocardial infarction,5327,PLAT,alteplase,CTD_human,12074692,"The longer antigen and activity half-lives, slower clearance and less complicated administration of lanoteplase compared with alteplase suggest that it may offer advantages for use as a single intravenous bolus to achieve reperfusion after myocardial infarction.",0.21302714981833498,"The longer antigen and activity half-lives, slower clearance and less complicated administration of lanoteplase compared with <span class=""gene"" id=""12074692-11-126-135"">alteplase</span> suggest that it may offer advantages for use as a single intravenous bolus to achieve reperfusion after <span class=""disease"" id=""12074692-11-240-261"">myocardial infarction</span>.",CTD_human
35,0,Therapeutic,C0027051,Myocardial Infarction,disease,myocardial infarction,5327,PLAT,alteplase,CTD_human,19341228,"The patients with myocardial infarction after administration of alteplase had statistically significantly higher coronary flow (TIMI-3), 72.5% as compared to the patients who received streptokinase, 39.2%.",0.21302714981833498,"The patients with <span class=""disease"" id=""19341228-6-18-39"">myocardial infarction</span> after administration of <span class=""gene"" id=""19341228-6-64-73"">alteplase</span> had statistically significantly higher coronary flow (TIMI-3), 72.5% as compared to the patients who received streptokinase, 39.2%.",CTD_human
9,0,Therapeutic,C0034065,Pulmonary Embolism,disease,Pulmonary Embolism,5327,PLAT,Alteplase,CTD_human,9199818,Fibrinogenolysis and thrombin generation after reduced dose bolus or conventional rt-PA for pulmonary embolism. The Coagulation Project Investigators of the Bolus Alteplase Pulmonary Embolism Group.,0.200274726784213,"Fibrinogenolysis and thrombin generation after reduced dose bolus or conventional rt-PA for <span class=""disease"" id=""9199818-0-92-110"">pulmonary embolism</span>. The Coagulation Project Investigators of the Bolus <span class=""gene"" id=""9199818-0-163-172"">Alteplase</span> <span class=""disease"" id=""9199818-0-173-191"">Pulmonary Embolism</span> Group.",CTD_human
9,0,Biomarker,C0034065,Pulmonary Embolism,disease,Pulmonary Embolism,5327,PLAT,Alteplase,CTD_human,8082347,Reduced dose bolus alteplase vs conventional alteplase infusion for pulmonary embolism thrombolysis. An international multicenter randomized trial. The Bolus Alteplase Pulmonary Embolism Group.,0.200274726784213,"Reduced dose bolus <span class=""gene"" id=""8082347-0-19-28"">alteplase</span> vs conventional <span class=""gene"" id=""8082347-0-45-54"">alteplase</span> infusion for <span class=""disease"" id=""8082347-0-68-86"">pulmonary embolism</span> thrombolysis. An international multicenter randomized trial. The Bolus <span class=""gene"" id=""8082347-0-158-167"">Alteplase</span> <span class=""disease"" id=""8082347-0-168-186"">Pulmonary Embolism</span> Group.",CTD_human
9,0,Biomarker,C0034065,Pulmonary Embolism,disease,Pulmonary Embolism,5327,PLAT,Alteplase,CTD_human,9199818,Fibrinogenolysis and thrombin generation after reduced dose bolus or conventional rt-PA for pulmonary embolism. The Coagulation Project Investigators of the Bolus Alteplase Pulmonary Embolism Group.,0.200274726784213,"Fibrinogenolysis and thrombin generation after reduced dose bolus or conventional rt-PA for <span class=""disease"" id=""9199818-0-92-110"">pulmonary embolism</span>. The Coagulation Project Investigators of the Bolus <span class=""gene"" id=""9199818-0-163-172"">Alteplase</span> <span class=""disease"" id=""9199818-0-173-191"">Pulmonary Embolism</span> Group.",CTD_human
9,0,Therapeutic,C0034065,Pulmonary Embolism,disease,Pulmonary Embolism,5327,PLAT,Alteplase,CTD_human,8082347,Reduced dose bolus alteplase vs conventional alteplase infusion for pulmonary embolism thrombolysis. An international multicenter randomized trial. The Bolus Alteplase Pulmonary Embolism Group.,0.200274726784213,"Reduced dose bolus <span class=""gene"" id=""8082347-0-19-28"">alteplase</span> vs conventional <span class=""gene"" id=""8082347-0-45-54"">alteplase</span> infusion for <span class=""disease"" id=""8082347-0-68-86"">pulmonary embolism</span> thrombolysis. An international multicenter randomized trial. The Bolus <span class=""gene"" id=""8082347-0-158-167"">Alteplase</span> <span class=""disease"" id=""8082347-0-168-186"">Pulmonary Embolism</span> Group.",CTD_human
59,0,Biomarker,C0038454,Cerebrovascular accident,group,stroke,5327,PLAT,alteplase,CTD_human,8598594,The higher rate of stroke in women after treatment with alteplase (2.0% vs 1.9% with streptokinase and intravenous heparin) was offset by a greater relative reduction in mortality (10.3% vs 11.1%).,0.221398299682364,"The higher rate of <span class=""disease"" id=""8598594-13-19-25"">stroke</span> in women after treatment with <span class=""gene"" id=""8598594-13-56-65"">alteplase</span> (2.0% vs 1.9% with streptokinase and intravenous heparin) was offset by a greater relative reduction in mortality (10.3% vs 11.1%).",CTD_human
59,0,Biomarker,C0038454,Cerebrovascular accident,group,Stroke,5327,PLAT,TPA,CTD_human,9056608,We then projected the effectiveness of tissue plasminogen activator (TPA) on disability as estimated with the aid of the odds ratio from the National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Trial onto our unselected sample to evaluate clinical efficiency of treatment as a function of arrival time and of hypothetical effects of educational efforts to reduce it.,0.221398299682364,"We then projected the effectiveness of tissue plasminogen activator (<span class=""gene"" id=""9056608-6-69-72"">TPA</span>) on disability as estimated with the aid of the odds ratio from the National Institute of Neurological Disorders and Stroke (NINDS) rt-PA <span class=""disease"" id=""9056608-6-211-217"">Stroke</span> Trial onto our unselected sample to evaluate clinical efficiency of treatment as a function of arrival time and of hypothetical effects of educational efforts to reduce it.",CTD_human
59,0,Therapeutic,C0038454,Cerebrovascular accident,group,stroke,5327,PLAT,alteplase,CTD_human,10171637,"An overview of the patency and stroke rates following thrombolysis with streptokinase, alteplase, and anistreplase used to treat an acute myocardial infarction.",0.221398299682364,"An overview of the patency and <span class=""disease"" id=""10171637-0-31-37"">stroke</span> rates following thrombolysis with streptokinase, <span class=""gene"" id=""10171637-0-87-96"">alteplase</span>, and anistreplase used to treat an acute myocardial infarction.",CTD_human
59,0,Biomarker,C0038454,Cerebrovascular accident,group,stroke,5327,PLAT,alteplase,CTD_human,10171637,"An overview of the patency and stroke rates following thrombolysis with streptokinase, alteplase, and anistreplase used to treat an acute myocardial infarction.",0.221398299682364,"An overview of the patency and <span class=""disease"" id=""10171637-0-31-37"">stroke</span> rates following thrombolysis with streptokinase, <span class=""gene"" id=""10171637-0-87-96"">alteplase</span>, and anistreplase used to treat an acute myocardial infarction.",CTD_human
59,0,Therapeutic,C0038454,Cerebrovascular accident,group,Stroke,5327,PLAT,TPA,CTD_human,9056608,We then projected the effectiveness of tissue plasminogen activator (TPA) on disability as estimated with the aid of the odds ratio from the National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Trial onto our unselected sample to evaluate clinical efficiency of treatment as a function of arrival time and of hypothetical effects of educational efforts to reduce it.,0.221398299682364,"We then projected the effectiveness of tissue plasminogen activator (<span class=""gene"" id=""9056608-6-69-72"">TPA</span>) on disability as estimated with the aid of the odds ratio from the National Institute of Neurological Disorders and Stroke (NINDS) rt-PA <span class=""disease"" id=""9056608-6-211-217"">Stroke</span> Trial onto our unselected sample to evaluate clinical efficiency of treatment as a function of arrival time and of hypothetical effects of educational efforts to reduce it.",CTD_human
59,0,Therapeutic,C0038454,Cerebrovascular accident,group,stroke,5327,PLAT,alteplase,CTD_human,8598594,The higher rate of stroke in women after treatment with alteplase (2.0% vs 1.9% with streptokinase and intravenous heparin) was offset by a greater relative reduction in mortality (10.3% vs 11.1%).,0.221398299682364,"The higher rate of <span class=""disease"" id=""8598594-13-19-25"">stroke</span> in women after treatment with <span class=""gene"" id=""8598594-13-56-65"">alteplase</span> (2.0% vs 1.9% with streptokinase and intravenous heparin) was offset by a greater relative reduction in mortality (10.3% vs 11.1%).",CTD_human
59,0,Biomarker,C0038454,Cerebrovascular accident,group,stroke,5327,PLAT,alteplase,CTD_human,16184341,Medline search identified one further study about the occurrence of alteplase-associated angioedema in stroke patients stratified to the use of ACEi.,0.221398299682364,"Medline search identified one further study about the occurrence of <span class=""gene"" id=""16184341-15-68-77"">alteplase</span>-associated angioedema in <span class=""disease"" id=""16184341-15-103-109"">stroke</span> patients stratified to the use of ACEi.",CTD_human
59,0,Therapeutic,C0038454,Cerebrovascular accident,group,stroke,5327,PLAT,alteplase,CTD_human,16184341,Medline search identified one further study about the occurrence of alteplase-associated angioedema in stroke patients stratified to the use of ACEi.,0.221398299682364,"Medline search identified one further study about the occurrence of <span class=""gene"" id=""16184341-15-68-77"">alteplase</span>-associated angioedema in <span class=""disease"" id=""16184341-15-103-109"">stroke</span> patients stratified to the use of ACEi.",CTD_human
14,0,Biomarker,C0151699,Intracranial Hemorrhages,group,intracranial haemorrhage,5327,PLAT,alteplase,CTD_human,7902905,"By multivariate analysis, four factors were identified as independent predictors of intracranial haemorrhage; age over 65 years (odds ratio 2.2 [95% Cl 1.4-3.5]), body weight below 70 kg (2.1 [1.3-3.2]), hypertension on hospital admission (2.0 [1.2-3.2]), and administration of alteplase (1.6 [1.0-2.5]).",0.20054945356842604,"By multivariate analysis, four factors were identified as independent predictors of <span class=""disease"" id=""7902905-6-84-108"">intracranial haemorrhage</span>; age over 65 years (odds ratio 2.2 [95% Cl 1.4-3.5]), body weight below 70 kg (2.1 [1.3-3.2]), hypertension on hospital admission (2.0 [1.2-3.2]), and administration of <span class=""gene"" id=""7902905-6-278-287"">alteplase</span> (1.6 [1.0-2.5]).",CTD_human
14,0,Biomarker,C0151699,Intracranial Hemorrhages,group,ICH,5327,PLAT,TPA,CTD_human,11320361,Nonrandomized comparisons with accelerated TPA suggest that lower doses of intravenous heparin are associated with lower rates of ICH.,0.20054945356842604,"Nonrandomized comparisons with accelerated <span class=""gene"" id=""11320361-7-43-46"">TPA</span> suggest that lower doses of intravenous heparin are associated with lower rates of <span class=""disease"" id=""11320361-7-130-133"">ICH</span>.",CTD_human
14,0,Biomarker,C0151699,Intracranial Hemorrhages,group,intracranial hemorrhages,5327,PLAT,alteplase,CTD_human,17687131,We also tested the hypothesis that NXY-059 would reduce alteplase-related intracranial hemorrhages.,0.20054945356842604,"We also tested the hypothesis that NXY-059 would reduce <span class=""gene"" id=""17687131-6-56-65"">alteplase</span>-related <span class=""disease"" id=""17687131-6-74-98"">intracranial hemorrhages</span>.",CTD_human
1,0,Biomarker,C0007138,"Carcinoma, Transitional Cell",disease,transitional cell carcinoma,5328,PLAU,uPA,CTD_human,14644129,"We compared expression levels of mRNA and protease activity of uPA and plasmin formation in primary cultures of the noninvasive transitional cell carcinoma, UCT-1, and in the highly invasive type, UCT-2.",0.20300763924902696,"We compared expression levels of mRNA and protease activity of <span class=""gene"" id=""14644129-2-63-66"">uPA</span> and plasmin formation in primary cultures of the noninvasive <span class=""disease"" id=""14644129-2-128-155"">transitional cell carcinoma</span>, UCT-1, and in the highly invasive type, UCT-2.",CTD_human
1,0,Biomarker,C0030297,Pancreatic Neoplasm,disease,pancreatic tumor,5328,PLAU,uPA,CTD_human,10467400,"These results show that uPA is one of the downstream target genes induced by constitutively activated RelA in human pancreatic tumor cells, and suggests that constitutive RelA activity may play a critical role in tumor invasion and metastasis.",0.20629000528226699,"These results show that <span class=""gene"" id=""10467400-7-24-27"">uPA</span> is one of the downstream target genes induced by constitutively activated RelA in human <span class=""disease"" id=""10467400-7-116-132"">pancreatic tumor</span> cells, and suggests that constitutive RelA activity may play a critical role in tumor invasion and metastasis.",CTD_human
1,0,Therapeutic,C1800706,Idiopathic Pulmonary Fibrosis,disease,IPF,5328,PLAU,uPA,CTD_human,18491991,The pathogenesis of IPF is complex and the urokinase-type plasminogen activator (uPA)/plasminogen system participates in the repair process.,0.20300763924902696,"The pathogenesis of <span class=""disease"" id=""18491991-2-20-23"">IPF</span> is complex and the <span class=""gene"" id=""18491991-2-43-79"">urokinase-type plasminogen activator</span> (<span class=""gene"" id=""18491991-2-81-84"">uPA</span>)/plasminogen system participates in the repair process.",CTD_human
1,0,Biomarker,C0220633,Uveal melanoma,disease,uveal melanoma,5332,PLCB4,PLCB4,CTD_human,27089179,"We analyzed genomics data from 136 uveal melanoma samples and found a recurrent mutation in CYSLTR2 (cysteinyl leukotriene receptor 2) encoding a p.Leu129Gln substitution in 4 of 9 samples that lacked mutations in GNAQ, GNA11, and PLCB4 but in 0 of 127 samples that harbored mutations in these genes.",0.200274726784213,"We analyzed genomics data from 136 <span class=""disease"" id=""27089179-3-35-49"">uveal melanoma</span> samples and found a recurrent mutation in CYSLTR2 (cysteinyl leukotriene receptor 2) encoding a p.Leu129Gln substitution in 4 of 9 samples that lacked mutations in GNAQ, GNA11, and <span class=""gene"" id=""27089179-3-231-236"">PLCB4</span> but in 0 of 127 samples that harbored mutations in these genes.",CTD_human
1,0,Biomarker,C0027051,Myocardial Infarction,disease,myocardial infarction,53345,TM6SF2,TM6SF2,CTD_human,24633158,Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk.,0.200274726784213,"Systematic evaluation of coding variation identifies a candidate causal variant in <span class=""gene"" id=""24633158-0-83-89"">TM6SF2</span> influencing total cholesterol and <span class=""disease"" id=""24633158-0-124-145"">myocardial infarction</span> risk.",CTD_human
1,0,Biomarker,C0400966,Non-alcoholic Fatty Liver Disease,disease,nonalcoholic fatty liver disease,53345,TM6SF2,TM6SF2,CTD_human,24531328,Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease.,0.205494535684262,"Exome-wide association study identifies a <span class=""gene"" id=""24531328-0-42-48"">TM6SF2</span> variant that confers susceptibility to <span class=""disease"" id=""24531328-0-88-120"">nonalcoholic fatty liver disease</span>.",CTD_human
1,0,Biomarker,C0018923,Hemangiosarcoma,disease,angiosarcoma,5335,PLCG1,PLCG1,CTD_human,24633157,Recurrent PTPRB and PLCG1 mutations in angiosarcoma.,0.201098907136852,"Recurrent PTPRB and <span class=""gene"" id=""24633157-0-20-25"">PLCG1</span> mutations in <span class=""disease"" id=""24633157-0-39-51"">angiosarcoma</span>.",CTD_human
1,0,Biomarker,C0028754,Obesity,disease,obesity,5346,PLIN1,Perilipin,CTD_human,15001633,Perilipin expression in human adipose tissue is elevated with obesity.,0.228596938849549,"<span class=""gene"" id=""15001633-0-0-9"">Perilipin</span> expression in human adipose tissue is elevated with <span class=""disease"" id=""15001633-0-62-69"">obesity</span>.",CTD_human
1,0,Biomarker,C0017638,Glioma,disease,glioma,5347,PLK1,PLK1,CTD_human,22000864,"Thus, the status of PLK1 mRNA expression might be an independent prognostic factor for glioma patients and targeting PLK1 could be a novel strategy for chemo- or radiosensitization of human malignant gliomas.",0.20082418035263896,"Thus, the status of <span class=""gene"" id=""22000864-14-20-24"">PLK1</span> mRNA expression might be an independent prognostic factor for <span class=""disease"" id=""22000864-14-87-93"">glioma</span> patients and targeting <span class=""gene"" id=""22000864-14-117-121"">PLK1</span> could be a novel strategy for chemo- or radiosensitization of human malignant gliomas.",CTD_human
2,0,Biomarker,C0027051,Myocardial Infarction,disease,MI,5350,PLN,PLB,CTD_human,16026515,"The expression of SERCA mRNA and protein were downregulated (P < 0.01), but the expression of PLB mRNA and protein were upregulated (P < 0.01) in MI rats compared with sham-operated rats.",0.280274726784213,"The expression of SERCA mRNA and protein were downregulated (P &lt; 0.01), but the expression of <span class=""gene"" id=""16026515-7-94-97"">PLB</span> mRNA and protein were upregulated (P &lt; 0.01) in <span class=""disease"" id=""16026515-7-146-148"">MI</span> rats compared with sham-operated rats.",CTD_human
2,0,Biomarker,C0027051,Myocardial Infarction,disease,MI,5350,PLN,phospholamban,CTD_human,16162791,"The messenger RNA and protein expression of SERCA were down-regulated (p < 0.01), but the expression of phospholamban messenger RNA and protein were up-regulated (p < 0.01) in MI rats compared to sham-operated rats.",0.280274726784213,"The messenger RNA and protein expression of SERCA were down-regulated (p &lt; 0.01), but the expression of <span class=""gene"" id=""16162791-6-104-117"">phospholamban</span> messenger RNA and protein were up-regulated (p &lt; 0.01) in <span class=""disease"" id=""16162791-6-176-178"">MI</span> rats compared to sham-operated rats.",CTD_human
1,0,Biomarker,C2936777,Nevo syndrome (disorder),disease,Nevo syndrome,5351,PLOD1,PLOD1,CTD_human,15666309,"Because some of these patients present clinical features similar to those of the kyphoscoliotic type of Ehlers-Danlos syndrome (EDS VIA), an inherited connective tissue disorder characterized by a deficiency of lysyl hydroxylase due to mutations in PLOD1, we studied seven patients with Nevo syndrome, three of whom have previously been reported, and four of whom are new.",0.2,"Because some of these patients present clinical features similar to those of the kyphoscoliotic type of Ehlers-Danlos syndrome (EDS VIA), an inherited connective tissue disorder characterized by a deficiency of lysyl hydroxylase due to mutations in <span class=""gene"" id=""15666309-4-249-254"">PLOD1</span>, we studied seven patients with <span class=""disease"" id=""15666309-4-287-300"">Nevo syndrome</span>, three of whom have previously been reported, and four of whom are new.",CTD_human
31,16,Biomarker,C0205711,Pelizaeus-Merzbacher Disease,disease,PMD,5354,PLP1,PLP1,CTD_human,18571143,The prototype of primary HMLs is the X-linked Pelizaeus-Merzbacher disease (PMD) caused by mutations in PLP1.,0.740599776292557,"The prototype of primary HMLs is the X-linked <span class=""disease"" id=""18571143-2-46-74"">Pelizaeus-Merzbacher disease</span> (<span class=""disease"" id=""18571143-2-76-79"">PMD</span>) caused by mutations in <span class=""gene"" id=""18571143-2-104-108"">PLP1</span>.",CTD_human;HPO;UNIPROT
1,0,Biomarker,C0020557,Hypertriglyceridemia,phenotype,HTG,5360,PLTP,PLTP,CTD_human,12754275,We propose that elevated PLTP activity in HTG is related to insulin resistance and not to increased PLTP mass.,0.202732912464814,"We propose that elevated <span class=""gene"" id=""12754275-10-25-29"">PLTP</span> activity in <span class=""disease"" id=""12754275-10-42-45"">HTG</span> is related to insulin resistance and not to increased <span class=""gene"" id=""12754275-10-100-104"">PLTP</span> mass.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autistic,53615,MBD3,MBD3,CTD_human,19921286,"We evaluated 226 autistic individuals for alterations in the four genes most homologous to MECP2: MBD1, MBD2, MBD3, and MBD4.",0.2,"We evaluated 226 <span class=""disease"" id=""19921286-3-17-25"">autistic</span> individuals for alterations in the four genes most homologous to MECP2: MBD1, MBD2, <span class=""gene"" id=""19921286-3-110-114"">MBD3</span>, and MBD4.",CTD_human
1,0,Biomarker,C0017636,Glioblastoma,disease,GBM,5371,PML,PML,CTD_human,23440206,"We analyzed GBM cell lines, patient-derived tumor cell cultures, and clinical samples from patients in phase 1 clinical trials, and find that the promyelocytic leukemia (PML) gene mediates resistance to mTOR-targeted therapies.",0.200274726784213,"We analyzed <span class=""disease"" id=""23440206-2-12-15"">GBM</span> cell lines, patient-derived tumor cell cultures, and clinical samples from patients in phase 1 clinical trials, and find that the <span class=""gene"" id=""23440206-2-146-168"">promyelocytic leukemia</span> (<span class=""gene"" id=""23440206-2-170-173"">PML</span>) gene mediates resistance to mTOR-targeted therapies.",CTD_human
20,0,Biomarker,C0023487,Acute Promyelocytic Leukemia,disease,APL,5371,PML,PML,CTD_human,16835227,"Thus, by fusing PML with RARalpha, the APL cells appear to have achieved functional suppression of Chk2 compromising the Chk2-p53 apoptotic pathway.",0.507329124648138,"Thus, by fusing <span class=""gene"" id=""16835227-8-16-19"">PML</span> with RARalpha, the <span class=""disease"" id=""16835227-8-39-42"">APL</span> cells appear to have achieved functional suppression of Chk2 compromising the Chk2-p53 apoptotic pathway.",CTD_human;ORPHANET
20,0,Biomarker,C0023487,Acute Promyelocytic Leukemia,disease,APL,5371,PML,PML,CTD_human,16935935,"These findings reveal a novel ATRA signaling on APL cell differentiation, in which ATRA coordinates G1 arrest and transition into differentiation by inducing MAT1 degradation and PML/RARalpha hypophosphorylation through disrupting PML/RARalpha binding and phosphorylation by CAK.",0.507329124648138,"These findings reveal a novel ATRA signaling on <span class=""disease"" id=""16935935-9-48-51"">APL</span> cell differentiation, in which ATRA coordinates G1 arrest and transition into differentiation by inducing MAT1 degradation and <span class=""gene"" id=""16935935-9-179-182"">PML</span>/RARalpha hypophosphorylation through disrupting <span class=""gene"" id=""16935935-9-231-234"">PML</span>/RARalpha binding and phosphorylation by CAK.",CTD_human;ORPHANET
20,0,Biomarker,C0023487,Acute Promyelocytic Leukemia,disease,APL,5371,PML,PML,CTD_human,16891316,"Based on this, we propose that a pathway composed of ATR, PML, Chk2, and p53 plays a role in ATO-mediated apoptosis, a notion that is consistent with the observation that Chk2 is genetically intact and mutations in the p53 gene are extremely rare in APL.",0.507329124648138,"Based on this, we propose that a pathway composed of ATR, <span class=""gene"" id=""16891316-9-58-61"">PML</span>, Chk2, and p53 plays a role in ATO-mediated apoptosis, a notion that is consistent with the observation that Chk2 is genetically intact and mutations in the p53 gene are extremely rare in <span class=""disease"" id=""16891316-9-250-253"">APL</span>.",CTD_human;ORPHANET
20,0,Biomarker,C0023487,Acute Promyelocytic Leukemia,disease,acute promyelocytic leukemia,5371,PML,PML,CTD_human,14706140,[Improved RT-PCR for detection of PML/RARalpha fusion gene in rapid diagnosis of acute promyelocytic leukemia].,0.507329124648138,"[Improved RT-PCR for detection of <span class=""gene"" id=""14706140-0-34-37"">PML</span>/RARalpha fusion gene in rapid diagnosis of <span class=""disease"" id=""14706140-0-81-109"">acute promyelocytic leukemia</span>].",CTD_human;ORPHANET
20,0,Biomarker,C0023487,Acute Promyelocytic Leukemia,disease,acute promyelocytic leukemia,5371,PML,PML,CTD_human,19029980,Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation.,0.507329124648138,"Eradication of <span class=""disease"" id=""19029980-0-15-43"">acute promyelocytic leukemia</span>-initiating cells through <span class=""gene"" id=""19029980-0-69-72"">PML</span>-RARA degradation.",CTD_human;ORPHANET
20,0,Biomarker,C0023487,Acute Promyelocytic Leukemia,disease,acute promyelocytic leukemia,5371,PML,PML,CTD_human,22213200,"Expression of PML-RAR? fusion proteins disrupted PML-NB structure and reduced HRR by up to 10-fold, raising the possibility that defective HRR and resulting genomic instability may figure in the pathogenesis, progression and relapse of acute promyelocytic leukemia.",0.507329124648138,"Expression of <span class=""gene"" id=""22213200-10-14-17"">PML</span>-RAR&alpha; fusion proteins disrupted <span class=""gene"" id=""22213200-10-49-52"">PML</span>-NB structure and reduced HRR by up to 10-fold, raising the possibility that defective HRR and resulting genomic instability may figure in the pathogenesis, progression and relapse of <span class=""disease"" id=""22213200-10-236-264"">acute promyelocytic leukemia</span>.",CTD_human;ORPHANET
20,0,Biomarker,C0023487,Acute Promyelocytic Leukemia,disease,APL,5371,PML,PML,CTD_human,23734343,The tumor suppressor promyelocytic leukemia (PML) protein is fused to the retinoic acid receptor alpha in patients suffering from acute promyelocytic leukemia (APL).,0.507329124648138,"The tumor suppressor <span class=""gene"" id=""23734343-1-21-43"">promyelocytic leukemia</span> (<span class=""gene"" id=""23734343-1-45-48"">PML</span>) protein is fused to the retinoic acid receptor alpha in patients suffering from <span class=""disease"" id=""23734343-1-130-158"">acute promyelocytic leukemia</span> (<span class=""disease"" id=""23734343-1-160-163"">APL</span>).",CTD_human;ORPHANET
20,0,Biomarker,C0023487,Acute Promyelocytic Leukemia,disease,acute promyelocytic leukaemia,5371,PML,PML,CTD_human,26728337,Mutations affecting both the rearranged and the unrearranged PML alleles in refractory acute promyelocytic leukaemia.,0.507329124648138,"Mutations affecting both the rearranged and the unrearranged <span class=""gene"" id=""26728337-0-61-64"">PML</span> alleles in refractory <span class=""disease"" id=""26728337-0-87-116"">acute promyelocytic leukaemia</span>.",CTD_human;ORPHANET
9,55,Biomarker,C0349653,Congenital disorder of glycosylation type 1A,disease,congenital disorder of glycosylation type Ia,5373,PMM2,PMM2,CTD_human,21539312,"In congenital disorder of glycosylation type Ia, PMM2 activity is compromised; thus, PMI inhibition is a potential strategy for the development of therapeutics.",0.689065983879032,"In <span class=""disease"" id=""21539312-2-3-47"">congenital disorder of glycosylation type Ia</span>, <span class=""gene"" id=""21539312-2-49-53"">PMM2</span> activity is compromised; thus, PMI inhibition is a potential strategy for the development of therapeutics.",CTD_human;ORPHANET;UNIPROT
2,0,Biomarker,C0031117,Peripheral Neuropathy,group,peripheral neuropathies,5376,PMP22,PMP22,CTD_human,20739560,Misexpression and cytosolic retention of peripheral myelin protein 22 (PMP22) within Schwann cells (SCs) is associated with a genetically heterogeneous group of demyelinating peripheral neuropathies.,0.209615437447459,"Misexpression and cytosolic retention of <span class=""gene"" id=""20739560-1-41-69"">peripheral myelin protein 22</span> (<span class=""gene"" id=""20739560-1-71-76"">PMP22</span>) within Schwann cells (SCs) is associated with a genetically heterogeneous group of demyelinating <span class=""disease"" id=""20739560-1-175-198"">peripheral neuropathies</span>.",CTD_human
35,84,Biomarker,C0022716,Menkes Kinky Hair Syndrome,disease,MD,538,ATP7A,ATP7A,CTD_human,22664332,Menkes disease (MD) is a genetic neurodegenerative disorder characterized by copper deficiency due to a defect in ATP7A.,0.72793363346412,"<span class=""disease"" id=""22664332-1-0-14"">Menkes disease</span> (<span class=""disease"" id=""22664332-1-16-18"">MD</span>) is a genetic neurodegenerative disorder characterized by copper deficiency due to a defect in <span class=""gene"" id=""22664332-1-114-119"">ATP7A</span>.",CTD_human;ORPHANET;UNIPROT
35,84,Biomarker,C0022716,Menkes Kinky Hair Syndrome,disease,Menkes disease,538,ATP7A,ATP7A,CTD_human,17483305,Phenotypic diversity of Menkes disease in mottled mice is associated with defects in localisation and trafficking of the ATP7A protein.,0.72793363346412,"Phenotypic diversity of <span class=""disease"" id=""17483305-0-24-38"">Menkes disease</span> in mottled mice is associated with defects in localisation and trafficking of the <span class=""gene"" id=""17483305-0-121-126"">ATP7A</span> protein.",CTD_human;ORPHANET;UNIPROT
35,84,Biomarker,C0022716,Menkes Kinky Hair Syndrome,disease,MNK,538,ATP7A,ATP7A,CTD_human,14579150,"The genes for two copper-transporting ATPases, ATP7A and ATP7B, are defective in the heritable disorders of copper imbalance, Menkes disease (MNK) and Wilson disease (WND), respectively.",0.72793363346412,"The genes for two copper-transporting ATPases, <span class=""gene"" id=""14579150-1-47-52"">ATP7A</span> and ATP7B, are defective in the heritable disorders of copper imbalance, <span class=""disease"" id=""14579150-1-126-140"">Menkes disease</span> (<span class=""disease"" id=""14579150-1-142-145"">MNK</span>) and Wilson disease (WND), respectively.",CTD_human;ORPHANET;UNIPROT
35,84,Biomarker,C0022716,Menkes Kinky Hair Syndrome,disease,Menkes disease,538,ATP7A,ATP7A,CTD_human,18779302,"One, ATP7A, is the protein nonfunctional in Menkes disease.",0.72793363346412,"One, <span class=""gene"" id=""18779302-9-5-10"">ATP7A</span>, is the protein nonfunctional in <span class=""disease"" id=""18779302-9-44-58"">Menkes disease</span>.",CTD_human;ORPHANET;UNIPROT
35,84,Biomarker,C0022716,Menkes Kinky Hair Syndrome,disease,Menkes disease,538,ATP7A,ATP7A,CTD_human,12228238,"The Menkes protein (MNK; ATP7A) is a copper-transporting P-type ATPase that is defective in the copper deficiency disorder, Menkes disease.",0.72793363346412,"The Menkes protein (MNK; <span class=""gene"" id=""12228238-1-25-30"">ATP7A</span>) is a copper-transporting P-type ATPase that is defective in the copper deficiency disorder, <span class=""disease"" id=""12228238-1-124-138"">Menkes disease</span>.",CTD_human;ORPHANET;UNIPROT
35,84,Biomarker,C0022716,Menkes Kinky Hair Syndrome,disease,Menkes disease,538,ATP7A,ATP7A,CTD_human,25247420,"Here, we analyzed changes in the systemic iron metabolism using an animal model of Menkes disease: copper-deficient mosaic mutant mice with dysfunction of the ATP7A copper transporter.",0.72793363346412,"Here, we analyzed changes in the systemic iron metabolism using an animal model of <span class=""disease"" id=""25247420-4-83-97"">Menkes disease</span>: copper-deficient mosaic mutant mice with dysfunction of the <span class=""gene"" id=""25247420-4-159-164"">ATP7A</span> copper transporter.",CTD_human;ORPHANET;UNIPROT
35,84,Biomarker,C0022716,Menkes Kinky Hair Syndrome,disease,Menkes disease,538,ATP7A,ATP7A,CTD_human,26199316,"Mutations in ATP7A result in Menkes disease, a disorder of copper metabolism.",0.72793363346412,"Mutations in <span class=""gene"" id=""26199316-4-13-18"">ATP7A</span> result in <span class=""disease"" id=""26199316-4-29-43"">Menkes disease</span>, a disorder of copper metabolism.",CTD_human;ORPHANET;UNIPROT
35,84,Biomarker,C0022716,Menkes Kinky Hair Syndrome,disease,Menkes disease,538,ATP7A,Atp7a,CTD_human,22815746,"Prenatal treatment of mosaic mice (Atp7a mo-ms) mouse model for Menkes disease, with copper combined by dimethyldithiocarbamate (DMDTC).",0.72793363346412,"Prenatal treatment of mosaic mice (<span class=""gene"" id=""22815746-0-35-40"">Atp7a</span> mo-ms) mouse model for <span class=""disease"" id=""22815746-0-64-78"">Menkes disease</span>, with copper combined by dimethyldithiocarbamate (DMDTC).",CTD_human;ORPHANET;UNIPROT
35,84,Biomarker,C0022716,Menkes Kinky Hair Syndrome,disease,MD,538,ATP7A,ATP7A,CTD_human,22728746,Menkes disease (MD) is a disorder of copper transport caused by ATP7A mutations.,0.72793363346412,"<span class=""disease"" id=""22728746-1-0-14"">Menkes disease</span> (<span class=""disease"" id=""22728746-1-16-18"">MD</span>) is a disorder of copper transport caused by <span class=""gene"" id=""22728746-1-64-69"">ATP7A</span> mutations.",CTD_human;ORPHANET;UNIPROT
35,84,Biomarker,C0022716,Menkes Kinky Hair Syndrome,disease,MD,538,ATP7A,ATP7A,CTD_human,15923132,Menkes disease (MD) is an X-linked recessive neurodegenerative disorder caused by mutations in a copper-transporting p-type ATPase (ATP7A) that normally delivers copper to the central nervous system.,0.72793363346412,"<span class=""disease"" id=""15923132-1-0-14"">Menkes disease</span> (<span class=""disease"" id=""15923132-1-16-18"">MD</span>) is an X-linked recessive neurodegenerative disorder caused by mutations in a copper-transporting p-type ATPase (<span class=""gene"" id=""15923132-1-132-137"">ATP7A</span>) that normally delivers copper to the central nervous system.",CTD_human;ORPHANET;UNIPROT
35,84,Biomarker,C0022716,Menkes Kinky Hair Syndrome,disease,Menkes disease,538,ATP7A,ATP7A,CTD_human,22455587,"These examples illustrate how impaired regulation of copper transport pathways can cause organ damage and provide important insights into the impact of defects in specific molecular processes, including those catalyzed by the copper-transporting ATPases, ATP7A (mutated in Menkes disease), ATP7B (Wilson's disease), and the copper chaperones such as those for cytochrome c oxidase, SCO1 and SCO2.",0.72793363346412,"These examples illustrate how impaired regulation of copper transport pathways can cause organ damage and provide important insights into the impact of defects in specific molecular processes, including those catalyzed by the copper-transporting ATPases, <span class=""gene"" id=""22455587-6-255-260"">ATP7A</span> (mutated in <span class=""disease"" id=""22455587-6-273-287"">Menkes disease</span>), ATP7B (Wilson's disease), and the copper chaperones such as those for cytochrome c oxidase, SCO1 and SCO2.",CTD_human;ORPHANET;UNIPROT
35,84,Biomarker,C0022716,Menkes Kinky Hair Syndrome,disease,Menkes disease,538,ATP7A,ATP7A,CTD_human,23064757,"The essential requirement for copper in early development is dramatically illustrated by Menkes disease, a fatal neurodegenerative disorder of early childhood caused by loss-of-function mutations in the gene encoding the copper transporting ATPase ATP7A.",0.72793363346412,"The essential requirement for copper in early development is dramatically illustrated by <span class=""disease"" id=""23064757-1-89-103"">Menkes disease</span>, a fatal neurodegenerative disorder of early childhood caused by loss-of-function mutations in the gene encoding the copper transporting ATPase <span class=""gene"" id=""23064757-1-248-253"">ATP7A</span>.",CTD_human;ORPHANET;UNIPROT
35,84,Biomarker,C0022716,Menkes Kinky Hair Syndrome,disease,Menkes disease,538,ATP7A,ATP7A,CTD_human,17009961,"Mutations in the MNK (ATP7A) gene result in Menkes disease, a fatal neurodegenerative copper deficiency disorder.",0.72793363346412,"Mutations in the <span class=""gene"" id=""17009961-2-17-20"">MNK</span> (<span class=""gene"" id=""17009961-2-22-27"">ATP7A</span>) gene result in <span class=""disease"" id=""17009961-2-44-58"">Menkes disease</span>, a fatal neurodegenerative copper deficiency disorder.",CTD_human;ORPHANET;UNIPROT
35,84,Biomarker,C0022716,Menkes Kinky Hair Syndrome,disease,Menkes disease,538,ATP7A,ATP7A,CTD_human,22695177,In utero copper treatment for Menkes disease associated with a severe ATP7A mutation.,0.72793363346412,"In utero copper treatment for <span class=""disease"" id=""22695177-0-30-44"">Menkes disease</span> associated with a severe <span class=""gene"" id=""22695177-0-70-75"">ATP7A</span> mutation.",CTD_human;ORPHANET;UNIPROT
35,84,Biomarker,C0022716,Menkes Kinky Hair Syndrome,disease,Menkes disease,538,ATP7A,MNK,CTD_human,11092760,Menkes disease is an X-linked recessive copper deficiency disorder caused by mutations in the ATP7A (MNK) gene.,0.72793363346412,"<span class=""disease"" id=""11092760-1-0-14"">Menkes disease</span> is an X-linked recessive copper deficiency disorder caused by mutations in the <span class=""gene"" id=""11092760-1-94-99"">ATP7A</span> (<span class=""gene"" id=""11092760-1-101-104"">MNK</span>) gene.",CTD_human;ORPHANET;UNIPROT
35,84,Biomarker,C0022716,Menkes Kinky Hair Syndrome,disease,Menkes disease,538,ATP7A,ATP7A,CTD_human,24627433,"Menkes disease (MD), an X-linked recessive disorder of copper metabolism caused by mutations in the copper-transporting ATP7A gene, results in growth failure and severe neurodegeneration in early childhood.",0.72793363346412,"<span class=""disease"" id=""24627433-1-0-14"">Menkes disease</span> (MD), an X-linked recessive disorder of copper metabolism caused by mutations in the copper-transporting <span class=""gene"" id=""24627433-1-120-125"">ATP7A</span> gene, results in growth failure and severe neurodegeneration in early childhood.",CTD_human;ORPHANET;UNIPROT
35,84,Biomarker,C0022716,Menkes Kinky Hair Syndrome,disease,Menkes disease,538,ATP7A,ATP7A,CTD_human,21667063,The copper-transporting capacity of ATP7A mutants associated with Menkes disease is ameliorated by COMMD1 as a result of improved protein expression.,0.72793363346412,"The copper-transporting capacity of <span class=""gene"" id=""21667063-0-36-41"">ATP7A</span> mutants associated with <span class=""disease"" id=""21667063-0-66-80"">Menkes disease</span> is ameliorated by COMMD1 as a result of improved protein expression.",CTD_human;ORPHANET;UNIPROT
35,84,Biomarker,C0022716,Menkes Kinky Hair Syndrome,disease,Menkes disease,538,ATP7A,Atp7a,CTD_human,20831904,Alterations in the expression of the Atp7a gene in the early postnatal development of the mosaic mutant mice (Atp7a mo-ms) - An animal model for Menkes disease.,0.72793363346412,"Alterations in the expression of the <span class=""gene"" id=""20831904-0-37-42"">Atp7a</span> gene in the early postnatal development of the mosaic mutant mice (<span class=""gene"" id=""20831904-0-110-115"">Atp7a</span> mo-ms) - An animal model for <span class=""disease"" id=""20831904-0-145-159"">Menkes disease</span>.",CTD_human;ORPHANET;UNIPROT
35,84,Biomarker,C0022716,Menkes Kinky Hair Syndrome,disease,Menkes disease,538,ATP7A,MNK,CTD_human,12221109,"In this study, a Menkes disease mutation, G1019D, located in the large cytoplasmic loop of MNK, was characterized in transfected cultured cells.",0.72793363346412,"In this study, a <span class=""disease"" id=""12221109-5-17-31"">Menkes disease</span> mutation, G1019D, located in the large cytoplasmic loop of <span class=""gene"" id=""12221109-5-91-94"">MNK</span>, was characterized in transfected cultured cells.",CTD_human;ORPHANET;UNIPROT
35,84,Biomarker,C0022716,Menkes Kinky Hair Syndrome,disease,Menkes disease,538,ATP7A,Atp7a,CTD_human,17003121,"Menkes disease, a fatal neurodegenerative disorder resulting in seizures, hypotonia, and failure to thrive, is due to inherited loss-of-function mutations in the gene encoding a copper-transporting ATPase (Atp7a) on the X chromosome.",0.72793363346412,"<span class=""disease"" id=""17003121-1-0-14"">Menkes disease</span>, a fatal neurodegenerative disorder resulting in seizures, hypotonia, and failure to thrive, is due to inherited loss-of-function mutations in the gene encoding a copper-transporting ATPase (<span class=""gene"" id=""17003121-1-206-211"">Atp7a</span>) on the X chromosome.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0235833,Congenital diaphragmatic hernia,disease,congenital diaphragmatic hernia,53834,FGFRL1,FGFRL1,CTD_human,20938900,Downregulation of FGFRL1 contributes to the development of the diaphragmatic defect in the nitrofen model of congenital diaphragmatic hernia.,0.200274726784213,"Downregulation of <span class=""gene"" id=""20938900-0-18-24"">FGFRL1</span> contributes to the development of the diaphragmatic defect in the nitrofen model of <span class=""disease"" id=""20938900-0-109-140"">congenital diaphragmatic hernia</span>.",CTD_human
1,0,Biomarker,C0035412,Rhabdomyosarcoma,disease,rhabdomyosarcoma,5395,PMS2,PMS2,CTD_human,19293170,"In family 2, immunohistochemistry analysis showed isolated loss of PMS2 expression in all tumours in the affected patients, including rhabdomyosarcoma itself and the surrounding normal tissue.",0.40027472678421294,"In family 2, immunohistochemistry analysis showed isolated loss of <span class=""gene"" id=""19293170-7-67-71"">PMS2</span> expression in all tumours in the affected patients, including <span class=""disease"" id=""19293170-7-134-150"">rhabdomyosarcoma</span> itself and the surrounding normal tissue.",CTD_human;HPO
4,12,Biomarker,C0265325,Turcot syndrome (disorder),disease,Turcot's syndrome,5395,PMS2,PMS2,CTD_human,10763829,Evidence for a recessive inheritance of Turcot's syndrome caused by compound heterozygous mutations within the PMS2 gene.,0.603846174978984,"Evidence for a recessive inheritance of <span class=""disease"" id=""10763829-0-40-57"">Turcot's syndrome</span> caused by compound heterozygous mutations within the <span class=""gene"" id=""10763829-0-111-115"">PMS2</span> gene.",CTD_human;ORPHANET;UNIPROT
4,12,Biomarker,C0265325,Turcot syndrome (disorder),disease,childhood cancer syndrome,5395,PMS2,PMS2,CTD_human,15077197,Novel PMS2 pseudogenes can conceal recessive mutations causing a distinctive childhood cancer syndrome.,0.603846174978984,"Novel <span class=""gene"" id=""15077197-0-6-10"">PMS2</span> pseudogenes can conceal recessive mutations causing a distinctive <span class=""disease"" id=""15077197-0-77-102"">childhood cancer syndrome</span>.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C3494422,Retrognathia,disease,retrognathia,5396,PRRX1,PRRX1,CTD_human,23444262,We studied the PRRX1 gene in a non-consanguineous Indonesian female infant who was diagnosed prenatally with severe retrognathia (bilateral Pruzansky type III).,0.200274726784213,"We studied the <span class=""gene"" id=""23444262-2-15-20"">PRRX1</span> gene in a non-consanguineous Indonesian female infant who was diagnosed prenatally with severe <span class=""disease"" id=""23444262-2-116-128"">retrognathia</span> (bilateral Pruzansky type III).",CTD_human
1,0,Biomarker,C0009404,Colorectal Neoplasms,group,colorectal tumors,540,ATP7B,ATP7B,CTD_human,19296535,"In conclusion, ATP7B mRNA and protein expression in colorectal tumors is associated with clinical outcome to oxaliplatin/5FU.",0.200274726784213,"In conclusion, <span class=""gene"" id=""19296535-7-15-20"">ATP7B</span> mRNA and protein expression in <span class=""disease"" id=""19296535-7-52-69"">colorectal tumors</span> is associated with clinical outcome to oxaliplatin/5FU.",CTD_human
96,174,Biomarker,C0019202,Hepatolenticular Degeneration,disease,Wilson disease,540,ATP7B,ATP7B,CTD_human,11472373,Haemolytic onset of Wilson disease in a patient with homozygous truncation of ATP7B at Arg1319.,0.8857694202755161,"Haemolytic onset of <span class=""disease"" id=""11472373-0-20-34"">Wilson disease</span> in a patient with homozygous truncation of <span class=""gene"" id=""11472373-0-78-83"">ATP7B</span> at Arg1319.",CTD_human;ORPHANET;UNIPROT
96,174,Biomarker,C0019202,Hepatolenticular Degeneration,disease,Wilson's disease,540,ATP7B,Atp7b,CTD_human,22565294,A systems approach implicates nuclear receptor targeting in the Atp7b(-/-) mouse model of Wilson's disease.,0.8857694202755161,"A systems approach implicates nuclear receptor targeting in the <span class=""gene"" id=""22565294-0-64-69"">Atp7b</span>(-/-) mouse model of <span class=""disease"" id=""22565294-0-90-106"">Wilson's disease</span>.",CTD_human;ORPHANET;UNIPROT
96,174,Biomarker,C0019202,Hepatolenticular Degeneration,disease,WD,540,ATP7B,ATP7B,CTD_human,16607473,"Wilson's disease (WD) is characterized by impaired hepatic copper secretion and subsequent copper accumulation in many organs predominantly liver and brain, secondary to loss of function mutations in the copper transport protein ATP7B.",0.8857694202755161,"<span class=""disease"" id=""16607473-1-0-16"">Wilson's disease</span> (<span class=""disease"" id=""16607473-1-18-20"">WD</span>) is characterized by impaired hepatic copper secretion and subsequent copper accumulation in many organs predominantly liver and brain, secondary to loss of function mutations in the copper transport protein <span class=""gene"" id=""16607473-1-229-234"">ATP7B</span>.",CTD_human;ORPHANET;UNIPROT
96,174,Biomarker,C0019202,Hepatolenticular Degeneration,disease,WD,540,ATP7B,ATP7B,CTD_human,11405812,"After cloning of ATP7B, the spectrum of mutations and their clinical consequences have been investigated in patients with WD in different ethnic populations.",0.8857694202755161,"After cloning of <span class=""gene"" id=""11405812-2-17-22"">ATP7B</span>, the spectrum of mutations and their clinical consequences have been investigated in patients with <span class=""disease"" id=""11405812-2-122-124"">WD</span> in different ethnic populations.",CTD_human;ORPHANET;UNIPROT
96,174,Biomarker,C0019202,Hepatolenticular Degeneration,disease,Wilson's disease,540,ATP7B,ATP7B,CTD_human,10982773,"Mutations in the ATP7B gene, encoding a copper-transporting P-type adenosine triphosphatase, lead to excessive hepatic copper accumulation because of impaired biliary copper excretion in Wilson's disease.",0.8857694202755161,"Mutations in the <span class=""gene"" id=""10982773-1-17-22"">ATP7B</span> gene, encoding a copper-transporting P-type adenosine triphosphatase, lead to excessive hepatic copper accumulation because of impaired biliary copper excretion in <span class=""disease"" id=""10982773-1-187-203"">Wilson's disease</span>.",CTD_human;ORPHANET;UNIPROT
96,174,Biomarker,C0019202,Hepatolenticular Degeneration,disease,WD,540,ATP7B,ATP7B,CTD_human,22677543,"In 78 selected patients of the cohort with two mutations in ATP7B, we have examined genotype-phenotype correlation between the detected changes in Atox1 and COMMD1 genes, and the presentation of the WD patients.",0.8857694202755161,"In 78 selected patients of the cohort with two mutations in <span class=""gene"" id=""22677543-9-60-65"">ATP7B</span>, we have examined genotype-phenotype correlation between the detected changes in Atox1 and COMMD1 genes, and the presentation of the <span class=""disease"" id=""22677543-9-199-201"">WD</span> patients.",CTD_human;ORPHANET;UNIPROT
96,174,Biomarker,C0019202,Hepatolenticular Degeneration,disease,Wilson disease,540,ATP7B,ATP7B,CTD_human,17182432,Genetic analysis identified a compound heterozygosity of ATP7B responsible for the primary copper toxicosis of Wilson disease without mutations in HFE.,0.8857694202755161,"Genetic analysis identified a compound heterozygosity of <span class=""gene"" id=""17182432-2-57-62"">ATP7B</span> responsible for the primary copper toxicosis of <span class=""disease"" id=""17182432-2-111-125"">Wilson disease</span> without mutations in HFE.",CTD_human;ORPHANET;UNIPROT
96,174,Biomarker,C0019202,Hepatolenticular Degeneration,disease,Wilson disease,540,ATP7B,ATP7B,CTD_human,22130675,"Clusterin and COMMD1 facilitated the degradation of ATP7B containing the same Wilson disease-causing C-terminal mutations via different degradation pathways, clusterin via the lysosomal pathway and COMMD1 via the proteasomal pathway.",0.8857694202755161,"Clusterin and COMMD1 facilitated the degradation of <span class=""gene"" id=""22130675-7-52-57"">ATP7B</span> containing the same <span class=""disease"" id=""22130675-7-78-92"">Wilson disease</span>-causing C-terminal mutations via different degradation pathways, clusterin via the lysosomal pathway and COMMD1 via the proteasomal pathway.",CTD_human;ORPHANET;UNIPROT
96,174,Biomarker,C0019202,Hepatolenticular Degeneration,disease,Wilson's disease,540,ATP7B,ATP7B,CTD_human,12820478,ATP7B mutation is well-known as a cause of Wilson's disease.,0.8857694202755161,"<span class=""gene"" id=""12820478-5-0-5"">ATP7B</span> mutation is well-known as a cause of <span class=""disease"" id=""12820478-5-43-59"">Wilson's disease</span>.",CTD_human;ORPHANET;UNIPROT
96,174,Biomarker,C0019202,Hepatolenticular Degeneration,disease,WD,540,ATP7B,Atp7b,CTD_human,21364284,"The present study focuses on the structural mitochondrial alterations that precede clinical symptoms in the livers of rats lacking Atp7b, an animal model for WD.",0.8857694202755161,"The present study focuses on the structural mitochondrial alterations that precede clinical symptoms in the livers of rats lacking <span class=""gene"" id=""21364284-2-131-136"">Atp7b</span>, an animal model for <span class=""disease"" id=""21364284-2-158-160"">WD</span>.",CTD_human;ORPHANET;UNIPROT
96,174,Biomarker,C0019202,Hepatolenticular Degeneration,disease,Wilson disease,540,ATP7B,ATP7B,CTD_human,22981378,"The Drosophila ATP7 copper transporter has sequence homology to the human copper transporters ATP7A and ATP7B, which are defective in Menkes and Wilson disease, respectively.",0.8857694202755161,"The Drosophila ATP7 copper transporter has sequence homology to the human copper transporters ATP7A and <span class=""gene"" id=""22981378-1-104-109"">ATP7B</span>, which are defective in Menkes and <span class=""disease"" id=""22981378-1-145-159"">Wilson disease</span>, respectively.",CTD_human;ORPHANET;UNIPROT
96,174,Biomarker,C0019202,Hepatolenticular Degeneration,disease,Wilson disease,540,ATP7B,ATP7B,CTD_human,18371106,Genotyping microarray as a novel approach for the detection of ATP7B gene mutations in patients with Wilson disease.,0.8857694202755161,"Genotyping microarray as a novel approach for the detection of <span class=""gene"" id=""18371106-0-63-68"">ATP7B</span> gene mutations in patients with <span class=""disease"" id=""18371106-0-101-115"">Wilson disease</span>.",CTD_human;ORPHANET;UNIPROT
96,174,Biomarker,C0019202,Hepatolenticular Degeneration,disease,Wilson's disease,540,ATP7B,ATP7B,CTD_human,10790207,Mutational analysis of ATP7B and genotype-phenotype correlation in Japanese with Wilson's disease.,0.8857694202755161,"Mutational analysis of <span class=""gene"" id=""10790207-0-23-28"">ATP7B</span> and genotype-phenotype correlation in Japanese with <span class=""disease"" id=""10790207-0-81-97"">Wilson's disease</span>.",CTD_human;ORPHANET;UNIPROT
96,174,Biomarker,C0019202,Hepatolenticular Degeneration,disease,WND,540,ATP7B,ATP7B,CTD_human,23963605,"In Wilson's disease (WND), biallelic ATP7B gene mutation is responsible for pathological copper accumulation in the liver, brain and other organs.",0.8857694202755161,"In <span class=""disease"" id=""23963605-1-3-19"">Wilson's disease</span> (<span class=""disease"" id=""23963605-1-21-24"">WND</span>), biallelic <span class=""gene"" id=""23963605-1-37-42"">ATP7B</span> gene mutation is responsible for pathological copper accumulation in the liver, brain and other organs.",CTD_human;ORPHANET;UNIPROT
96,174,Biomarker,C0019202,Hepatolenticular Degeneration,disease,Wd,540,ATP7B,ATP7B,CTD_human,19888908,"Wilson's disease (Wd) is a genetic disorder resulting in Cu2+ accumulation, and is caused by mutations in the ATP7B gene, the copper transporter.",0.8857694202755161,"<span class=""disease"" id=""19888908-1-0-16"">Wilson's disease</span> (<span class=""disease"" id=""19888908-1-18-20"">Wd</span>) is a genetic disorder resulting in Cu2+ accumulation, and is caused by mutations in the <span class=""gene"" id=""19888908-1-110-115"">ATP7B</span> gene, the copper transporter.",CTD_human;ORPHANET;UNIPROT
96,174,Biomarker,C0019202,Hepatolenticular Degeneration,disease,WD,540,ATP7B,ATP7B,CTD_human,24892424,"Cu chelators and zinc salts are the two most important drugs used in the treatment of WD patients; however, the molecular mechanisms of the drugs with regard to ATP7B expression have not been determined.",0.8857694202755161,"Cu chelators and zinc salts are the two most important drugs used in the treatment of <span class=""disease"" id=""24892424-2-86-88"">WD</span> patients; however, the molecular mechanisms of the drugs with regard to <span class=""gene"" id=""24892424-2-161-166"">ATP7B</span> expression have not been determined.",CTD_human;ORPHANET;UNIPROT
96,174,Biomarker,C0019202,Hepatolenticular Degeneration,disease,WD,540,ATP7B,ATP7B,CTD_human,25134866,"OSIP108 increased not only viability of Cu-treated CHO cells transgenically expressing ATP7B and the common WD-causing mutant ATP7B(H1069Q), but also viability of Cu-treated human glioblastoma U87 cells.",0.8857694202755161,"OSIP108 increased not only viability of Cu-treated CHO cells transgenically expressing <span class=""gene"" id=""25134866-4-87-92"">ATP7B</span> and the common <span class=""disease"" id=""25134866-4-108-110"">WD</span>-causing mutant <span class=""gene"" id=""25134866-4-126-131"">ATP7B</span>(H1069Q), but also viability of Cu-treated human glioblastoma U87 cells.",CTD_human;ORPHANET;UNIPROT
96,174,Biomarker,C0019202,Hepatolenticular Degeneration,disease,Wilson disease,540,ATP7B,ATP7B,CTD_human,18779302,Mutations in ATP7B lead to Wilson disease.,0.8857694202755161,"Mutations in <span class=""gene"" id=""18779302-12-13-18"">ATP7B</span> lead to <span class=""disease"" id=""18779302-12-27-41"">Wilson disease</span>.",CTD_human;ORPHANET;UNIPROT
96,174,Biomarker,C0019202,Hepatolenticular Degeneration,disease,Wilson disease,540,ATP7B,Atp7b,CTD_human,14574444,"The Long-Evans cinnamon (LEC) rat, an authentic model for Wilson disease, is characterized by a mutation in the Atp7b gene leading to a defective copper excretion and, as a consequence, to an accumulation of the metal in the liver and copper-associated hepatotoxicity.",0.8857694202755161,"The Long-Evans cinnamon (LEC) rat, an authentic model for <span class=""disease"" id=""14574444-1-58-72"">Wilson disease</span>, is characterized by a mutation in the <span class=""gene"" id=""14574444-1-112-117"">Atp7b</span> gene leading to a defective copper excretion and, as a consequence, to an accumulation of the metal in the liver and copper-associated hepatotoxicity.",CTD_human;ORPHANET;UNIPROT
96,174,Biomarker,C0019202,Hepatolenticular Degeneration,disease,WD,540,ATP7B,ATP7B,CTD_human,17634212,"Wilson disease (WD) is an autosomal recessive disorder caused by defects in the ATPase, Cu(2+) transporting, beta-polypeptide gene (ATP7B) resulting in accumulation of copper in liver and brain.",0.8857694202755161,"<span class=""disease"" id=""17634212-1-0-14"">Wilson disease</span> (<span class=""disease"" id=""17634212-1-16-18"">WD</span>) is an autosomal recessive disorder caused by defects in the <span class=""gene"" id=""17634212-1-80-125"">ATPase, Cu(2+) transporting, beta-polypeptide</span> gene (<span class=""gene"" id=""17634212-1-132-137"">ATP7B</span>) resulting in accumulation of copper in liver and brain.",CTD_human;ORPHANET;UNIPROT
96,174,Biomarker,C0019202,Hepatolenticular Degeneration,disease,WD,540,ATP7B,ATP7B,CTD_human,22802922,"In Wilson's disease (WD), this function is disrupted due to inactivation of the copper transporter ATP7B resulting in hepatic copper overload.",0.8857694202755161,"In <span class=""disease"" id=""22802922-2-3-19"">Wilson's disease</span> (<span class=""disease"" id=""22802922-2-21-23"">WD</span>), this function is disrupted due to inactivation of the copper transporter <span class=""gene"" id=""22802922-2-99-104"">ATP7B</span> resulting in hepatic copper overload.",CTD_human;ORPHANET;UNIPROT
96,174,Biomarker,C0019202,Hepatolenticular Degeneration,disease,Wilson disease,540,ATP7B,ATP7B,CTD_human,21242307,"A Wilson disease patient mutation (G85V) led to enhanced ATP7B turnover, which was further exacerbated when cells overexpressed clusterin.",0.8857694202755161,"A <span class=""disease"" id=""21242307-7-2-16"">Wilson disease</span> patient mutation (G85V) led to enhanced <span class=""gene"" id=""21242307-7-57-62"">ATP7B</span> turnover, which was further exacerbated when cells overexpressed clusterin.",CTD_human;ORPHANET;UNIPROT
96,174,Biomarker,C0019202,Hepatolenticular Degeneration,disease,Wilson's disease,540,ATP7B,ATP7B,CTD_human,22455587,"These examples illustrate how impaired regulation of copper transport pathways can cause organ damage and provide important insights into the impact of defects in specific molecular processes, including those catalyzed by the copper-transporting ATPases, ATP7A (mutated in Menkes disease), ATP7B (Wilson's disease), and the copper chaperones such as those for cytochrome c oxidase, SCO1 and SCO2.",0.8857694202755161,"These examples illustrate how impaired regulation of copper transport pathways can cause organ damage and provide important insights into the impact of defects in specific molecular processes, including those catalyzed by the copper-transporting ATPases, ATP7A (mutated in Menkes disease), <span class=""gene"" id=""22455587-6-290-295"">ATP7B</span> (<span class=""disease"" id=""22455587-6-297-313"">Wilson's disease</span>), and the copper chaperones such as those for cytochrome c oxidase, SCO1 and SCO2.",CTD_human;ORPHANET;UNIPROT
96,174,Biomarker,C0019202,Hepatolenticular Degeneration,disease,WD,540,ATP7B,ATP7B,CTD_human,21406592,Wilson disease (WD) is a monogenic disorder caused by mutations in the copper-transporting P-type ATPase ATP7B.,0.8857694202755161,"<span class=""disease"" id=""21406592-2-0-14"">Wilson disease</span> (<span class=""disease"" id=""21406592-2-16-18"">WD</span>) is a monogenic disorder caused by mutations in the copper-transporting P-type ATPase <span class=""gene"" id=""21406592-2-105-110"">ATP7B</span>.",CTD_human;ORPHANET;UNIPROT
96,174,Biomarker,C0019202,Hepatolenticular Degeneration,disease,Wilson disease,540,ATP7B,ATP7B,CTD_human,23235335,Mutational analysis of ATP7B in north Chinese patients with Wilson disease.,0.8857694202755161,"Mutational analysis of <span class=""gene"" id=""23235335-0-23-28"">ATP7B</span> in north Chinese patients with <span class=""disease"" id=""23235335-0-60-74"">Wilson disease</span>.",CTD_human;ORPHANET;UNIPROT
96,174,Biomarker,C0019202,Hepatolenticular Degeneration,disease,Wilson disease,540,ATP7B,ATP7B,CTD_human,12544487,Identification of novel mutations and the three most common mutations in the human ATP7B gene of Korean patients with Wilson disease.,0.8857694202755161,"Identification of novel mutations and the three most common mutations in the human <span class=""gene"" id=""12544487-0-83-88"">ATP7B</span> gene of Korean patients with <span class=""disease"" id=""12544487-0-118-132"">Wilson disease</span>.",CTD_human;ORPHANET;UNIPROT
96,174,Biomarker,C0019202,Hepatolenticular Degeneration,disease,Wilson disease,540,ATP7B,ATP7B,CTD_human,25003971,"ATP7B is one of two copper-transporting ATPases in humans, its vital role being manifested in Wilson disease due to a mutation in the gene that encodes this pump.",0.8857694202755161,"<span class=""gene"" id=""25003971-2-0-5"">ATP7B</span> is one of two copper-transporting ATPases in humans, its vital role being manifested in <span class=""disease"" id=""25003971-2-94-108"">Wilson disease</span> due to a mutation in the gene that encodes this pump.",CTD_human;ORPHANET;UNIPROT
96,174,Biomarker,C0019202,Hepatolenticular Degeneration,disease,Wilson disease,540,ATP7B,ATP7B,CTD_human,12228238,"A similar effect on trafficking was observed with a phosphatase mutation in the closely related copper ATPase, ATP7B, affected in Wilson disease.",0.8857694202755161,"A similar effect on trafficking was observed with a phosphatase mutation in the closely related copper ATPase, <span class=""gene"" id=""12228238-8-111-116"">ATP7B</span>, affected in <span class=""disease"" id=""12228238-8-130-144"">Wilson disease</span>.",CTD_human;ORPHANET;UNIPROT
96,174,Biomarker,C0019202,Hepatolenticular Degeneration,disease,WD,540,ATP7B,ATP7B,CTD_human,16133174,Thus a total of nine mutations including five novel changes were identified in the ATP7B of WD patients.,0.8857694202755161,"Thus a total of nine mutations including five novel changes were identified in the <span class=""gene"" id=""16133174-7-83-88"">ATP7B</span> of <span class=""disease"" id=""16133174-7-92-94"">WD</span> patients.",CTD_human;ORPHANET;UNIPROT
96,174,Biomarker,C0019202,Hepatolenticular Degeneration,disease,Wilson disease,540,ATP7B,ATP7B,CTD_human,14998371,The Wilson protein (ATP7B) is a copper-transporting CPx-type ATPase defective in the copper toxicity disorder Wilson disease.,0.8857694202755161,"The Wilson protein (<span class=""gene"" id=""14998371-1-20-25"">ATP7B</span>) is a copper-transporting CPx-type ATPase defective in the copper toxicity disorder <span class=""disease"" id=""14998371-1-110-124"">Wilson disease</span>.",CTD_human;ORPHANET;UNIPROT
96,174,Biomarker,C0019202,Hepatolenticular Degeneration,disease,Wilson's disease,540,ATP7B,ATP7B,CTD_human,17919502,Distinct Wilson's disease mutations in ATP7B are associated with enhanced binding to COMMD1 and reduced stability of ATP7B.,0.8857694202755161,"Distinct <span class=""disease"" id=""17919502-0-9-25"">Wilson's disease</span> mutations in <span class=""gene"" id=""17919502-0-39-44"">ATP7B</span> are associated with enhanced binding to COMMD1 and reduced stability of <span class=""gene"" id=""17919502-0-117-122"">ATP7B</span>.",CTD_human;ORPHANET;UNIPROT
96,174,Biomarker,C0019202,Hepatolenticular Degeneration,disease,Wilson disease,540,ATP7B,ATP7B,CTD_human,23333878,Mutation analysis of ATP7B gene in Turkish Wilson disease patients: identification of five novel mutations.,0.8857694202755161,"Mutation analysis of <span class=""gene"" id=""23333878-0-21-26"">ATP7B</span> gene in Turkish <span class=""disease"" id=""23333878-0-43-57"">Wilson disease</span> patients: identification of five novel mutations.",CTD_human;ORPHANET;UNIPROT
96,174,Biomarker,C0019202,Hepatolenticular Degeneration,disease,WND,540,ATP7B,ATP7B,CTD_human,14579150,"The genes for two copper-transporting ATPases, ATP7A and ATP7B, are defective in the heritable disorders of copper imbalance, Menkes disease (MNK) and Wilson disease (WND), respectively.",0.8857694202755161,"The genes for two copper-transporting ATPases, ATP7A and <span class=""gene"" id=""14579150-1-57-62"">ATP7B</span>, are defective in the heritable disorders of copper imbalance, Menkes disease (MNK) and <span class=""disease"" id=""14579150-1-151-165"">Wilson disease</span> (<span class=""disease"" id=""14579150-1-167-170"">WND</span>), respectively.",CTD_human;ORPHANET;UNIPROT
96,174,Biomarker,C0019202,Hepatolenticular Degeneration,disease,Wilson's disease,540,ATP7B,ATPase Cu(2+) transporting beta polypeptide,CTD_human,23843956,Novel ATPase Cu(2+) transporting beta polypeptide mutations in Chinese families with Wilson's disease.,0.8857694202755161,"Novel <span class=""gene"" id=""23843956-0-6-49"">ATPase Cu(2+) transporting beta polypeptide</span> mutations in Chinese families with <span class=""disease"" id=""23843956-0-85-101"">Wilson's disease</span>.",CTD_human;ORPHANET;UNIPROT
96,174,Biomarker,C0019202,Hepatolenticular Degeneration,disease,Wilson's disease,540,ATP7B,ATP7B,CTD_human,23789284,Mutational analysis of ATP7B gene and the genotype-phenotype correlation in patients with Wilson's disease in Serbia.,0.8857694202755161,"Mutational analysis of <span class=""gene"" id=""23789284-0-23-28"">ATP7B</span> gene and the genotype-phenotype correlation in patients with <span class=""disease"" id=""23789284-0-90-106"">Wilson's disease</span> in Serbia.",CTD_human;ORPHANET;UNIPROT
96,174,Biomarker,C0019202,Hepatolenticular Degeneration,disease,WD,540,ATP7B,Atp7b,CTD_human,21146535,Previous studies on the mouse model for WD (Atp7b(-)(/-)) revealed copper accumulation in hepatic nuclei and specific changes in mRNA profile prior to the onset of pathology.,0.8857694202755161,"Previous studies on the mouse model for <span class=""disease"" id=""21146535-3-40-42"">WD</span> (<span class=""gene"" id=""21146535-3-44-49"">Atp7b</span>(-)(/-)) revealed copper accumulation in hepatic nuclei and specific changes in mRNA profile prior to the onset of pathology.",CTD_human;ORPHANET;UNIPROT
96,174,Biomarker,C0019202,Hepatolenticular Degeneration,disease,WD,540,ATP7B,ATP7B,CTD_human,24094725,"By utilizing the age at onset, neurological involvement score and ATP7B mutation background, we generated a genotype-phenotype matrix that could be effectively used to depict the phenotypic spectra of WD affected individuals and serve as a platform to identify prospective ""outliers"" to be investigated for their remarkable phenotypic divergence.",0.8857694202755161,"By utilizing the age at onset, neurological involvement score and <span class=""gene"" id=""24094725-9-66-71"">ATP7B</span> mutation background, we generated a genotype-phenotype matrix that could be effectively used to depict the phenotypic spectra of <span class=""disease"" id=""24094725-9-201-203"">WD</span> affected individuals and serve as a platform to identify prospective ""outliers"" to be investigated for their remarkable phenotypic divergence.",CTD_human;ORPHANET;UNIPROT
96,174,Biomarker,C0019202,Hepatolenticular Degeneration,disease,WD,540,ATP7B,ATP7B,CTD_human,16932613,Wilson's disease (WD) is an inborn error of copper metabolism caused by a mutation to the copper-transporting gene ATP7B.,0.8857694202755161,"<span class=""disease"" id=""16932613-1-0-16"">Wilson's disease</span> (<span class=""disease"" id=""16932613-1-18-20"">WD</span>) is an inborn error of copper metabolism caused by a mutation to the copper-transporting gene <span class=""gene"" id=""16932613-1-115-120"">ATP7B</span>.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0022665,Kidney Neoplasm,disease,kidney tumors,540,ATP7B,Atp7b,CTD_human,11509115,"In an N-diethylnitrosamine (DEN)-induced long-term carcinogenicity study, 1) LEC rats were similarly or rather less susceptible to hepatocellular tumors than WKAH.C-Atp7b and WKAH rats, indicating that the progression of the preneoplastic foci to liver cancer in LEC rats was worse than that in WKAH.C-Atp7b and WKAH rats, 2) the incidences of kidney tumors in LEC and WKAH.C-Atp7b rats were higher than that in WKAH rats and high copper concentrations in the kidneys were observed in LEC and WKAH.C-Atp7b rats, 3) LEC rats were resistant to lung carcinogenesis.",0.2,"In an N-diethylnitrosamine (DEN)-induced long-term carcinogenicity study, 1) LEC rats were similarly or rather less susceptible to hepatocellular tumors than WKAH.C-<span class=""gene"" id=""11509115-5-165-170"">Atp7b</span> and WKAH rats, indicating that the progression of the preneoplastic foci to liver cancer in LEC rats was worse than that in WKAH.C-<span class=""gene"" id=""11509115-5-302-307"">Atp7b</span> and WKAH rats, 2) the incidences of <span class=""disease"" id=""11509115-5-344-357"">kidney tumors</span> in LEC and WKAH.C-<span class=""gene"" id=""11509115-5-376-381"">Atp7b</span> rats were higher than that in WKAH rats and high copper concentrations in the kidneys were observed in LEC and WKAH.C-<span class=""gene"" id=""11509115-5-500-505"">Atp7b</span> rats, 3) LEC rats were resistant to lung carcinogenesis.",CTD_human
1,0,Biomarker,C0023890,Liver Cirrhosis,disease,cirrhosis,540,ATP7B,ATP7B,CTD_human,25134866,"Wilson disease (WD) is caused by accumulation of excess copper (Cu) due to a mutation in the gene encoding the liver Cu transporter ATP7B, and is characterized by acute liver failure or cirrhosis and neuronal cell death.",0.40027472678421294,"Wilson disease (WD) is caused by accumulation of excess copper (Cu) due to a mutation in the gene encoding the liver Cu transporter <span class=""gene"" id=""25134866-1-132-137"">ATP7B</span>, and is characterized by acute liver failure or <span class=""disease"" id=""25134866-1-186-195"">cirrhosis</span> and neuronal cell death.",CTD_human;HPO
1,0,Biomarker,C0023903,Liver neoplasms,group,liver tumors,540,ATP7B,Atp7b,CTD_human,11509115,"Incidences of spontaneous liver tumors in LEC, WKAH.C-Atp7b and WKAH rats correlated with hepatic copper and iron concentrations.",0.201373633921065,"Incidences of spontaneous <span class=""disease"" id=""11509115-3-26-38"">liver tumors</span> in LEC, WKAH.C-<span class=""gene"" id=""11509115-3-54-59"">Atp7b</span> and WKAH rats correlated with hepatic copper and iron concentrations.",CTD_human
1,0,Biomarker,C0162557,"Liver Failure, Acute",disease,acute liver failure,540,ATP7B,ATP7B,CTD_human,25134866,"Wilson disease (WD) is caused by accumulation of excess copper (Cu) due to a mutation in the gene encoding the liver Cu transporter ATP7B, and is characterized by acute liver failure or cirrhosis and neuronal cell death.",0.403231208875927,"Wilson disease (WD) is caused by accumulation of excess copper (Cu) due to a mutation in the gene encoding the liver Cu transporter <span class=""gene"" id=""25134866-1-132-137"">ATP7B</span>, and is characterized by <span class=""disease"" id=""25134866-1-163-182"">acute liver failure</span> or cirrhosis and neuronal cell death.",CTD_human;HPO
2,0,Biomarker,C0010346,Crohn Disease,disease,Crohn's disease,54106,TLR9,TLR9,CTD_human,17914947,"TLR2, TLR4 and TLR9 polymorphisms and Crohn's disease in a New Zealand Caucasian cohort.",0.21072702123000397,"TLR2, TLR4 and <span class=""gene"" id=""17914947-0-15-19"">TLR9</span> polymorphisms and <span class=""disease"" id=""17914947-0-38-53"">Crohn's disease</span> in a New Zealand Caucasian cohort.",CTD_human
2,0,Biomarker,C0010346,Crohn Disease,disease,Crohn's disease,54106,TLR9,toll-like receptor-9,CTD_human,15236225,Crohn's disease is associated with a toll-like receptor-9 polymorphism.,0.21072702123000397,"<span class=""disease"" id=""15236225-0-0-15"">Crohn's disease</span> is associated with a <span class=""gene"" id=""15236225-0-37-57"">toll-like receptor-9</span> polymorphism.",CTD_human
1,0,Biomarker,C0524851,Neurodegenerative Disorders,group,neurodegenerative disease,5413,SEPT5,septin 5,CTD_human,22430071,"After validation by Western blot and quantitative real-time PCR, the expressions of three proteins related to neurodegenerative disease, septin 5, ?-internexin, and ?-synuclein, were identified to be altered by MCLR exposure.",0.2,"After validation by Western blot and quantitative real-time PCR, the expressions of three proteins related to <span class=""disease"" id=""22430071-4-110-135"">neurodegenerative disease</span>, <span class=""gene"" id=""22430071-4-137-145"">septin 5</span>, &alpha;-internexin, and &alpha;-synuclein, were identified to be altered by MCLR exposure.",CTD_human
1,0,Biomarker,C0032460,Polycystic Ovary Syndrome,disease,PCOS,54206,ERRFI1,MIG6,CTD_human,21411543,"Progesterone-regulated genes, including mitogen-inducible gene 6 (MIG6), leukemia inhibitory factor (LIF), GRB2-associated binding protein 1 (GAB1), S100P, and claudin-4 were significantly lower in PCOS endometrium; whereas cell proliferation genes, such as Anillin and cyclin B1, were up-regulated.",0.200274726784213,"Progesterone-regulated genes, including mitogen-inducible gene 6 (<span class=""gene"" id=""21411543-11-66-70"">MIG6</span>), leukemia inhibitory factor (LIF), GRB2-associated binding protein 1 (GAB1), S100P, and claudin-4 were significantly lower in <span class=""disease"" id=""21411543-11-198-202"">PCOS</span> endometrium; whereas cell proliferation genes, such as Anillin and cyclin B1, were up-regulated.",CTD_human
1,1,Biomarker,C0002395,Alzheimer's Disease,disease,Alzheimer's disease,54209,TREM2,trem2,CTD_human,24663666,Evidence of trem2 variant associated with triple risk of Alzheimer's disease.,0.220864880222878,"Evidence of <span class=""gene"" id=""24663666-0-12-17"">trem2</span> variant associated with triple risk of <span class=""disease"" id=""24663666-0-57-76"">Alzheimer's disease</span>.",CTD_human
1,0,Biomarker,C0497327,Dementia,disease,dementia,54209,TREM2,TREM2,CTD_human,18546367,Mutations in TREM2 lead to pure early-onset dementia without bone cysts.,0.202197814273705,"Mutations in <span class=""gene"" id=""18546367-0-13-18"">TREM2</span> lead to pure early-onset <span class=""disease"" id=""18546367-0-44-52"">dementia</span> without bone cysts.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,54221,SNTG2,SNTG2,CTD_human,17292328,"Interestingly, the binding was influenced by autism-related mutations, implying that the impaired interaction between NLs and SNTG2 contributes to the etiology of autism.",0.200274726784213,"Interestingly, the binding was influenced by <span class=""disease"" id=""17292328-3-45-51"">autism</span>-related mutations, implying that the impaired interaction between NLs and <span class=""gene"" id=""17292328-3-126-131"">SNTG2</span> contributes to the etiology of <span class=""disease"" id=""17292328-3-163-169"">autism</span>.",CTD_human
1,0,Biomarker,C0023787,Lipodystrophy,disease,lipodystrophy,5424,POLD1,POLD1,CTD_human,23770608,An in-frame deletion at the polymerase active site of POLD1 causes a multisystem disorder with lipodystrophy.,0.400549453568426,"An in-frame deletion at the polymerase active site of <span class=""gene"" id=""23770608-0-54-59"">POLD1</span> causes a multisystem disorder with <span class=""disease"" id=""23770608-0-95-108"">lipodystrophy</span>.",CTD_human;HPO
3,0,Biomarker,C0007795,Diffuse Cerebral Sclerosis of Schilder,disease,Alpers syndrome,5428,POLG,POLG1,CTD_human,17923349,Alpers syndrome is a fatal neurogenetic disorder caused by the mutations in POLG1 gene encoding the mitochondrial DNA polymerase gamma (polgamma).,0.219932121203657,"<span class=""disease"" id=""17923349-1-0-15"">Alpers syndrome</span> is a fatal neurogenetic disorder caused by the mutations in <span class=""gene"" id=""17923349-1-76-81"">POLG1</span> gene encoding the mitochondrial DNA polymerase gamma (polgamma).",CTD_human
2,0,Biomarker,C0036572,Seizures,phenotype,seizures,5428,POLG,POLG,CTD_human,20138553,"Our data support an emerging proposal that POLG gene testing should be considered in any child or adolescent who presents or develops intractable seizures with or without status epilepticus or epilepsia partialis continua, particularly when there is a history of psychomotor regression.",0.40651357490916706,"Our data support an emerging proposal that <span class=""gene"" id=""20138553-13-43-47"">POLG</span> gene testing should be considered in any child or adolescent who presents or develops intractable <span class=""disease"" id=""20138553-13-146-154"">seizures</span> with or without status epilepticus or epilepsia partialis continua, particularly when there is a history of psychomotor regression.",CTD_human;HPO
1,0,Biomarker,C0013336,Dwarfism,disease,dwarfism,54361,WNT4,Wnt4,CTD_human,17505543,Conditional expression of Wnt4 during chondrogenesis leads to dwarfism in mice.,0.2,"Conditional expression of <span class=""gene"" id=""17505543-0-26-30"">Wnt4</span> during chondrogenesis leads to <span class=""disease"" id=""17505543-0-62-70"">dwarfism</span> in mice.",CTD_human
1,0,Biomarker,C0022658,Kidney Diseases,group,nephropathy,54361,WNT4,Wnt4,CTD_human,11832423,"Wnt4 expression is induced throughout the collecting ducts in four murine models of renal injury that produce tubulointerstitial fibrosis: folic acid-induced nephropathy, unilateral ureteral obstruction, renal needle puncture, and genetic polycystic kidney disease.",0.2,"<span class=""gene"" id=""11832423-2-0-4"">Wnt4</span> expression is induced throughout the collecting ducts in four murine models of renal injury that produce tubulointerstitial fibrosis: folic acid-induced <span class=""disease"" id=""11832423-2-158-169"">nephropathy</span>, unilateral ureteral obstruction, renal needle puncture, and genetic polycystic kidney disease.",CTD_human
1,0,Biomarker,C0677886,Epithelial ovarian cancer,disease,EOC,54361,WNT4,WNT4,CTD_human,25581431,"Variants at 1p36 (nearest gene, WNT4), 4q26 (SYNPO2), 9q34.2 (ABO) and 17q11.2 (ATAD5) were associated with EOC risk, and at 1p34.3 (RSPO1) and 6p22.1 (GPX6) variants were specifically associated with the serous EOC subtype, all with P < 5 × 10(-8).",0.200274726784213,"Variants at 1p36 (nearest gene, <span class=""gene"" id=""25581431-5-32-36"">WNT4</span>), 4q26 (SYNPO2), 9q34.2 (ABO) and 17q11.2 (ATAD5) were associated with <span class=""disease"" id=""25581431-5-108-111"">EOC</span> risk, and at 1p34.3 (RSPO1) and 6p22.1 (GPX6) variants were specifically associated with the serous <span class=""disease"" id=""25581431-5-212-215"">EOC</span> subtype, all with P &lt; 5 &times; 10(-8).",CTD_human
2,0,Biomarker,C0004352,Autistic Disorder,disease,autism,54413,NLGN3,NLGN3,CTD_human,12669065,Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism.,0.218782056909492,"Mutations of the X-linked genes encoding neuroligins <span class=""gene"" id=""12669065-0-53-58"">NLGN3</span> and NLGN4 are associated with <span class=""disease"" id=""12669065-0-89-95"">autism</span>.",CTD_human
1,0,Biomarker,C0002622,Amnesia,disease,amnesia,5443,POMC,ACTH,CTD_human,2841920,Naloxone had no effect of its own and did not influence the reversal of ACTH-induced amnesia caused by pretest ACTH in the afternoon.,0.2,"Naloxone had no effect of its own and did not influence the reversal of <span class=""gene"" id=""2841920-6-72-76"">ACTH</span>-induced <span class=""disease"" id=""2841920-6-85-92"">amnesia</span> caused by pretest <span class=""gene"" id=""2841920-6-111-115"">ACTH</span> in the afternoon.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autistic,5443,POMC,pro-opiomelanocortin,CTD_human,8570775,"These results suggest a possible linkage between abnormal plasma chemistries, especially those related to the pro-opiomelanocortin system, and autistic symptoms.",0.201098907136852,"These results suggest a possible linkage between abnormal plasma chemistries, especially those related to the <span class=""gene"" id=""8570775-8-110-130"">pro-opiomelanocortin</span> system, and <span class=""disease"" id=""8570775-8-143-151"">autistic</span> symptoms.",CTD_human
1,0,Biomarker,C0007134,Renal Cell Carcinoma,disease,Grawitz tumor,5443,POMC,ACTH,CTD_human,2844640,We authors believe that this is the first documented case of ACTH-producing Grawitz tumor in the literature.,0.200274726784213,"We authors believe that this is the first documented case of <span class=""gene"" id=""2844640-9-61-65"">ACTH</span>-producing <span class=""disease"" id=""2844640-9-76-89"">Grawitz tumor</span> in the literature.",CTD_human
5,0,Biomarker,C0007194,Hypertrophic Cardiomyopathy,disease,Hypertrophic cardiomyopathy,5443,POMC,ACTH,CTD_human,2831920,[Hypertrophic cardiomyopathy induced by ACTH].,0.2,"[<span class=""disease"" id=""2831920-0-1-28"">Hypertrophic cardiomyopathy</span> induced by <span class=""gene"" id=""2831920-0-40-44"">ACTH</span>].",CTD_human
2,0,Biomarker,C0007370,Catalepsy,disease,Catalepsy,5443,POMC,Met-enkephalin,CTD_human,2999739,"Catalepsy, hypermotility, increase of striatal acetylcholine release induced by morphine and Met-enkephalin as affected by prolonged hydrocortisone and ACTH treatment.",0.2,"<span class=""disease"" id=""2999739-0-0-9"">Catalepsy</span>, hypermotility, increase of striatal acetylcholine release induced by morphine and <span class=""gene"" id=""2999739-0-93-107"">Met-enkephalin</span> as affected by prolonged hydrocortisone and ACTH treatment.",CTD_human
2,0,Biomarker,C0007370,Catalepsy,disease,catalepsy,5443,POMC,beta-endorphin,CTD_human,6329457,Evidence that spinal endorphin mediates intraventricular beta-endorphin-induced tail flick inhibition and catalepsy.,0.2,"Evidence that spinal endorphin mediates intraventricular <span class=""gene"" id=""6329457-0-57-71"">beta-endorphin</span>-induced tail flick inhibition and <span class=""disease"" id=""6329457-0-106-115"">catalepsy</span>.",CTD_human
2,0,Therapeutic,C0007370,Catalepsy,disease,catalepsy,5443,POMC,beta-endorphin,CTD_human,6329457,Evidence that spinal endorphin mediates intraventricular beta-endorphin-induced tail flick inhibition and catalepsy.,0.2,"Evidence that spinal endorphin mediates intraventricular <span class=""gene"" id=""6329457-0-57-71"">beta-endorphin</span>-induced tail flick inhibition and <span class=""disease"" id=""6329457-0-106-115"">catalepsy</span>.",CTD_human
2,0,Therapeutic,C0007370,Catalepsy,disease,Catalepsy,5443,POMC,Met-enkephalin,CTD_human,2999739,"Catalepsy, hypermotility, increase of striatal acetylcholine release induced by morphine and Met-enkephalin as affected by prolonged hydrocortisone and ACTH treatment.",0.2,"<span class=""disease"" id=""2999739-0-0-9"">Catalepsy</span>, hypermotility, increase of striatal acetylcholine release induced by morphine and <span class=""gene"" id=""2999739-0-93-107"">Met-enkephalin</span> as affected by prolonged hydrocortisone and ACTH treatment.",CTD_human
1,0,Therapeutic,C0007789,Cerebral Palsy,disease,cerebral palsy,5443,POMC,Adrenocorticotropic hormone,CTD_human,8980841,Adrenocorticotropic hormone and vigabatrin treatment of children with infantile spasms underlying cerebral palsy.,0.200274726784213,"<span class=""gene"" id=""8980841-0-0-27"">Adrenocorticotropic hormone</span> and vigabatrin treatment of children with infantile spasms underlying <span class=""disease"" id=""8980841-0-98-112"">cerebral palsy</span>.",CTD_human
1,0,Therapeutic,C0009806,Constipation,phenotype,constipating,5443,POMC,ACTH,CTD_human,3421781,ACTH-(1-24) antagonizes the cholestatic and constipating effects of morphine.,0.2,"<span class=""gene"" id=""3421781-0-0-4"">ACTH</span>-(1-24) antagonizes the cholestatic and <span class=""disease"" id=""3421781-0-44-56"">constipating</span> effects of morphine.",CTD_human
6,0,Biomarker,C0011581,Depressive disorder,disease,depression,5443,POMC,Adrenocorticotropic hormone,CTD_human,18201294,Adrenocorticotropic hormone and cortisol plasma levels directly correlate with childhood neglect and depression measures in addicted patients.,0.40082418035263895,"<span class=""gene"" id=""18201294-0-0-27"">Adrenocorticotropic hormone</span> and cortisol plasma levels directly correlate with childhood neglect and <span class=""disease"" id=""18201294-0-101-111"">depression</span> measures in addicted patients.",CTD_human;PSYGENET
1,0,Therapeutic,C0011848,Diabetes Insipidus,disease,diabetes insipidus,5443,POMC,beta-Endorphin,CTD_human,6258694,"1 beta-Endorphin (2 micrograms injected into the lateral ventricles) produced a significant decrease in the urine outflow and in the excretion of Na+ and K+ in Brattleboro rats, animals suffering from severe diabetes insipidus.",0.2,"1 <span class=""gene"" id=""6258694-1-2-16"">beta-Endorphin</span> (2 micrograms injected into the lateral ventricles) produced a significant decrease in the urine outflow and in the excretion of Na+ and K+ in Brattleboro rats, animals suffering from severe <span class=""disease"" id=""6258694-1-208-226"">diabetes insipidus</span>.",CTD_human
1,0,Therapeutic,C0014544,Epilepsy,disease,epilepsy,5443,POMC,ACTH,CTD_human,20708863,ACTH therapy successfully controlled epilepsy and electroencephalograms were normalized.,0.20054945356842604,"<span class=""gene"" id=""20708863-3-0-4"">ACTH</span> therapy successfully controlled <span class=""disease"" id=""20708863-3-37-45"">epilepsy</span> and electroencephalograms were normalized.",CTD_human
1,0,Biomarker,C0015695,Fatty Liver,disease,fatty liver,5443,POMC,ACTH,CTD_human,167377,Inhibitory effect of prolactin on the development of fatty liver induced by ACTH in thrat.,0.2,"Inhibitory effect of prolactin on the development of <span class=""disease"" id=""167377-0-53-64"">fatty liver</span> induced by <span class=""gene"" id=""167377-0-76-80"">ACTH</span> in thrat.",CTD_human
2,0,Biomarker,C0020438,Hypercalciuria,phenotype,hypercalciuria,5443,POMC,ACTH,CTD_human,1324751,Thiazide therapy for ACTH-induced hypercalciuria and nephrolithiasis.,0.2,"Thiazide therapy for <span class=""gene"" id=""1324751-0-21-25"">ACTH</span>-induced <span class=""disease"" id=""1324751-0-34-48"">hypercalciuria</span> and nephrolithiasis.",CTD_human
2,0,Biomarker,C0020488,Hypernatremia,phenotype,hypernatremia,5443,POMC,ACTH,CTD_human,6279499,"In dogs with aldosterone hypertension, however, ACTH did not produce kaliuresis, hypernatremia, or hypokalemia; moreover, ACTH did not exacerbate aldosterone hypertension.",0.200274726784213,"In dogs with aldosterone hypertension, however, <span class=""gene"" id=""6279499-8-48-52"">ACTH</span> did not produce kaliuresis, <span class=""disease"" id=""6279499-8-81-94"">hypernatremia</span>, or hypokalemia; moreover, <span class=""gene"" id=""6279499-8-122-126"">ACTH</span> did not exacerbate aldosterone hypertension.",CTD_human
68,0,Biomarker,C0020538,Hypertensive disease,group,increased blood pressure,5443,POMC,beta-endorphin,CTD_human,2455169,"Besides via sympathetic inhibition, clonidine also may reduce the increased blood pressure further by normalizing central beta-endorphin release.",0.203846174978983,"Besides via sympathetic inhibition, clonidine also may reduce the <span class=""disease"" id=""2455169-6-66-90"">increased blood pressure</span> further by normalizing central <span class=""gene"" id=""2455169-6-122-136"">beta-endorphin</span> release.",CTD_human
68,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,5443,POMC,adrenocorticotropic hormone,CTD_human,15132301,Role of tetrahydrobiopterin in adrenocorticotropic hormone-induced hypertension in the rat.,0.203846174978983,"Role of tetrahydrobiopterin in <span class=""gene"" id=""15132301-0-31-58"">adrenocorticotropic hormone</span>-induced <span class=""disease"" id=""15132301-0-67-79"">hypertension</span> in the rat.",CTD_human
68,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,5443,POMC,ACTH,CTD_human,6100240,Failure of neomycin to modify ACTH induced hypertension in sheep.,0.203846174978983,"Failure of neomycin to modify <span class=""gene"" id=""6100240-0-30-34"">ACTH</span> induced <span class=""disease"" id=""6100240-0-43-55"">hypertension</span> in sheep.",CTD_human
68,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,5443,POMC,adrenocorticotropic hormone,CTD_human,16620303,Atorvastatin prevented and partially reversed adrenocorticotropic hormone-induced hypertension in the rat.,0.203846174978983,"Atorvastatin prevented and partially reversed <span class=""gene"" id=""16620303-0-46-73"">adrenocorticotropic hormone</span>-induced <span class=""disease"" id=""16620303-0-82-94"">hypertension</span> in the rat.",CTD_human
68,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,5443,POMC,ACTH,CTD_human,1321309,The role of this increased pressor responsiveness in ACTH/steroid-induced hypertension remains to be determined.,0.203846174978983,"The role of this increased pressor responsiveness in <span class=""gene"" id=""1321309-8-53-57"">ACTH</span>/steroid-induced <span class=""disease"" id=""1321309-8-74-86"">hypertension</span> remains to be determined.",CTD_human
68,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,5443,POMC,ACTH,CTD_human,2992854,Potentiation of ACTH hypertension in man with salt loading.,0.203846174978983,"Potentiation of <span class=""gene"" id=""2992854-0-16-20"">ACTH</span> <span class=""disease"" id=""2992854-0-21-33"">hypertension</span> in man with salt loading.",CTD_human
68,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,5443,POMC,ACTH,CTD_human,1321309,The role of this increased pressor responsiveness in ACTH/steroid-induced hypertension remains to be determined.,0.203846174978983,"The role of this increased pressor responsiveness in <span class=""gene"" id=""1321309-8-53-57"">ACTH</span>/steroid-induced <span class=""disease"" id=""1321309-8-74-86"">hypertension</span> remains to be determined.",CTD_human
68,0,Therapeutic,C0020538,Hypertensive disease,group,systemic hypertension,5443,POMC,adrenocorticotropic hormone,CTD_human,8279378,Cardiac size and function during adrenocorticotropic hormone-induced systolic systemic hypertension in infants.,0.203846174978983,"Cardiac size and function during <span class=""gene"" id=""8279378-0-33-60"">adrenocorticotropic hormone</span>-induced systolic <span class=""disease"" id=""8279378-0-78-99"">systemic hypertension</span> in infants.",CTD_human
68,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,5443,POMC,ACTH,CTD_human,2822310,Effect of sodium depletion on pressor responsiveness in ACTH-induced hypertension in man.,0.203846174978983,"Effect of sodium depletion on pressor responsiveness in <span class=""gene"" id=""2822310-0-56-60"">ACTH</span>-induced <span class=""disease"" id=""2822310-0-69-81"">hypertension</span> in man.",CTD_human
68,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,5443,POMC,ACTH,CTD_human,6100240,Failure of neomycin to modify ACTH induced hypertension in sheep.,0.203846174978983,"Failure of neomycin to modify <span class=""gene"" id=""6100240-0-30-34"">ACTH</span> induced <span class=""disease"" id=""6100240-0-43-55"">hypertension</span> in sheep.",CTD_human
68,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,5443,POMC,ACTH,CTD_human,16243970,This result indicates that the cardiac glycoside binding site of the alpha1 isoform can also mediate ACTH-induced hypertension.,0.203846174978983,"This result indicates that the cardiac glycoside binding site of the alpha1 isoform can also mediate <span class=""gene"" id=""16243970-9-101-105"">ACTH</span>-induced <span class=""disease"" id=""16243970-9-114-126"">hypertension</span>.",CTD_human
68,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,5443,POMC,ACTH,CTD_human,323586,"Study of a 3-year-old child who presented with short stature, hypertension, hypokalemic alkalosis, suppressed renin and ACTH, and decreased excretion of all known steroids suggested excessive secretion of a pressor hormone.",0.203846174978983,"Study of a 3-year-old child who presented with short stature, <span class=""disease"" id=""323586-10-62-74"">hypertension</span>, hypokalemic alkalosis, suppressed renin and <span class=""gene"" id=""323586-10-120-124"">ACTH</span>, and decreased excretion of all known steroids suggested excessive secretion of a pressor hormone.",CTD_human
68,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,5443,POMC,ACTH,CTD_human,3015460,Changes in pressor responsiveness do not explain ACTH hypertension.,0.203846174978983,"Changes in pressor responsiveness do not explain <span class=""gene"" id=""3015460-6-49-53"">ACTH</span> <span class=""disease"" id=""3015460-6-54-66"">hypertension</span>.",CTD_human
68,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,5443,POMC,adrenocorticotropic hormone,CTD_human,15132301,Role of tetrahydrobiopterin in adrenocorticotropic hormone-induced hypertension in the rat.,0.203846174978983,"Role of tetrahydrobiopterin in <span class=""gene"" id=""15132301-0-31-58"">adrenocorticotropic hormone</span>-induced <span class=""disease"" id=""15132301-0-67-79"">hypertension</span> in the rat.",CTD_human
68,0,Therapeutic,C0020538,Hypertensive disease,group,Hypertension,5443,POMC,ACTH,CTD_human,3001556,[Hypertension induced by adrenocorticotropin (ACTH)].,0.203846174978983,"[<span class=""disease"" id=""3001556-0-1-13"">Hypertension</span> induced by <span class=""gene"" id=""3001556-0-25-44"">adrenocorticotropin</span> (<span class=""gene"" id=""3001556-0-46-50"">ACTH</span>)].",CTD_human
68,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,5443,POMC,ACTH,CTD_human,16546835,N-acetylcysteine antagonizes the development but does not reverse ACTH-induced hypertension in the rat.,0.203846174978983,"N-acetylcysteine antagonizes the development but does not reverse <span class=""gene"" id=""16546835-0-66-70"">ACTH</span>-induced <span class=""disease"" id=""16546835-0-79-91"">hypertension</span> in the rat.",CTD_human
68,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,5443,POMC,ACTH,CTD_human,16243970,This result indicates that the cardiac glycoside binding site of the alpha1 isoform can also mediate ACTH-induced hypertension.,0.203846174978983,"This result indicates that the cardiac glycoside binding site of the alpha1 isoform can also mediate <span class=""gene"" id=""16243970-9-101-105"">ACTH</span>-induced <span class=""disease"" id=""16243970-9-114-126"">hypertension</span>.",CTD_human
68,0,Therapeutic,C0020538,Hypertensive disease,group,increased blood pressure,5443,POMC,beta-endorphin,CTD_human,2455169,"Besides via sympathetic inhibition, clonidine also may reduce the increased blood pressure further by normalizing central beta-endorphin release.",0.203846174978983,"Besides via sympathetic inhibition, clonidine also may reduce the <span class=""disease"" id=""2455169-6-66-90"">increased blood pressure</span> further by normalizing central <span class=""gene"" id=""2455169-6-122-136"">beta-endorphin</span> release.",CTD_human
68,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,5443,POMC,ACTH,CTD_human,2822310,Effect of sodium depletion on pressor responsiveness in ACTH-induced hypertension in man.,0.203846174978983,"Effect of sodium depletion on pressor responsiveness in <span class=""gene"" id=""2822310-0-56-60"">ACTH</span>-induced <span class=""disease"" id=""2822310-0-69-81"">hypertension</span> in man.",CTD_human
68,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,5443,POMC,ACTH,CTD_human,2992854,Potentiation of ACTH hypertension in man with salt loading.,0.203846174978983,"Potentiation of <span class=""gene"" id=""2992854-0-16-20"">ACTH</span> <span class=""disease"" id=""2992854-0-21-33"">hypertension</span> in man with salt loading.",CTD_human
68,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,5443,POMC,ACTH,CTD_human,3015460,Changes in pressor responsiveness do not explain ACTH hypertension.,0.203846174978983,"Changes in pressor responsiveness do not explain <span class=""gene"" id=""3015460-6-49-53"">ACTH</span> <span class=""disease"" id=""3015460-6-54-66"">hypertension</span>.",CTD_human
68,0,Biomarker,C0020538,Hypertensive disease,group,systemic hypertension,5443,POMC,adrenocorticotropic hormone,CTD_human,8279378,Cardiac size and function during adrenocorticotropic hormone-induced systolic systemic hypertension in infants.,0.203846174978983,"Cardiac size and function during <span class=""gene"" id=""8279378-0-33-60"">adrenocorticotropic hormone</span>-induced systolic <span class=""disease"" id=""8279378-0-78-99"">systemic hypertension</span> in infants.",CTD_human
68,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,5443,POMC,ACTH,CTD_human,2849322,Control of sodium excretion in NE-ACTH hypertension: role of pressure natriuresis.,0.203846174978983,"Control of sodium excretion in NE-<span class=""gene"" id=""2849322-0-34-38"">ACTH</span> <span class=""disease"" id=""2849322-0-39-51"">hypertension</span>: role of pressure natriuresis.",CTD_human
68,0,Biomarker,C0020538,Hypertensive disease,group,Hypertension,5443,POMC,ACTH,CTD_human,3001556,[Hypertension induced by adrenocorticotropin (ACTH)].,0.203846174978983,"[<span class=""disease"" id=""3001556-0-1-13"">Hypertension</span> induced by <span class=""gene"" id=""3001556-0-25-44"">adrenocorticotropin</span> (<span class=""gene"" id=""3001556-0-46-50"">ACTH</span>)].",CTD_human
68,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,5443,POMC,adrenocorticotropic hormone,CTD_human,16053986,Apocynin but not allopurinol prevents and reverses adrenocorticotropic hormone-induced hypertension in the rat.,0.203846174978983,"Apocynin but not allopurinol prevents and reverses <span class=""gene"" id=""16053986-0-51-78"">adrenocorticotropic hormone</span>-induced <span class=""disease"" id=""16053986-0-87-99"">hypertension</span> in the rat.",CTD_human
68,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,5443,POMC,adrenocorticotropic hormone,CTD_human,17954371,Aspirin prevents and partially reverses adrenocorticotropic hormone-induced hypertension in the rat.,0.203846174978983,"Aspirin prevents and partially reverses <span class=""gene"" id=""17954371-0-40-67"">adrenocorticotropic hormone</span>-induced <span class=""disease"" id=""17954371-0-76-88"">hypertension</span> in the rat.",CTD_human
68,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,5443,POMC,ACTH,CTD_human,6135010,Vasodilator prostanoids and ACTH-dependent hypertension.,0.203846174978983,"Vasodilator prostanoids and <span class=""gene"" id=""6135010-0-28-32"">ACTH</span>-dependent <span class=""disease"" id=""6135010-0-43-55"">hypertension</span>.",CTD_human
68,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,5443,POMC,ACTH,CTD_human,6097376,"Acute glucocorticoid (corticosterone) hypertension in the rate is significantly attenuated by neomycin administration (Honour 1981), as is ACTH-induced hypertension is the same species (Honour & Kent 1981) presumably by altering gut bacterial steroid metabolism.",0.203846174978983,"Acute glucocorticoid (corticosterone) <span class=""disease"" id=""6097376-1-38-50"">hypertension</span> in the rate is significantly attenuated by neomycin administration (Honour 1981), as is <span class=""gene"" id=""6097376-1-139-143"">ACTH</span>-induced <span class=""disease"" id=""6097376-1-152-164"">hypertension</span> is the same species (Honour & Kent 1981) presumably by altering gut bacterial steroid metabolism.",CTD_human
68,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,5443,POMC,ACTH,CTD_human,6135010,Vasodilator prostanoids and ACTH-dependent hypertension.,0.203846174978983,"Vasodilator prostanoids and <span class=""gene"" id=""6135010-0-28-32"">ACTH</span>-dependent <span class=""disease"" id=""6135010-0-43-55"">hypertension</span>.",CTD_human
68,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,5443,POMC,ACTH,CTD_human,2849322,Control of sodium excretion in NE-ACTH hypertension: role of pressure natriuresis.,0.203846174978983,"Control of sodium excretion in NE-<span class=""gene"" id=""2849322-0-34-38"">ACTH</span> <span class=""disease"" id=""2849322-0-39-51"">hypertension</span>: role of pressure natriuresis.",CTD_human
68,0,Therapeutic,C0020538,Hypertensive disease,group,arterial hypertension,5443,POMC,ACTH,CTD_human,6088243,"Based on the various biological effects of ACTH different explanations are proposed: oedema or deposition of glycogen in the myocardial tissue, hyperinsulinism, arterial hypertension and increased inotropic stimulus.",0.203846174978983,"Based on the various biological effects of <span class=""gene"" id=""6088243-8-43-47"">ACTH</span> different explanations are proposed: oedema or deposition of glycogen in the myocardial tissue, hyperinsulinism, <span class=""disease"" id=""6088243-8-161-182"">arterial hypertension</span> and increased inotropic stimulus.",CTD_human
68,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,5443,POMC,ACTH,CTD_human,323586,"Study of a 3-year-old child who presented with short stature, hypertension, hypokalemic alkalosis, suppressed renin and ACTH, and decreased excretion of all known steroids suggested excessive secretion of a pressor hormone.",0.203846174978983,"Study of a 3-year-old child who presented with short stature, <span class=""disease"" id=""323586-10-62-74"">hypertension</span>, hypokalemic alkalosis, suppressed renin and <span class=""gene"" id=""323586-10-120-124"">ACTH</span>, and decreased excretion of all known steroids suggested excessive secretion of a pressor hormone.",CTD_human
68,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,5443,POMC,adrenocorticotropic hormone,CTD_human,16053986,Apocynin but not allopurinol prevents and reverses adrenocorticotropic hormone-induced hypertension in the rat.,0.203846174978983,"Apocynin but not allopurinol prevents and reverses <span class=""gene"" id=""16053986-0-51-78"">adrenocorticotropic hormone</span>-induced <span class=""disease"" id=""16053986-0-87-99"">hypertension</span> in the rat.",CTD_human
68,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,5443,POMC,adrenocorticotropic hormone,CTD_human,17954371,Aspirin prevents and partially reverses adrenocorticotropic hormone-induced hypertension in the rat.,0.203846174978983,"Aspirin prevents and partially reverses <span class=""gene"" id=""17954371-0-40-67"">adrenocorticotropic hormone</span>-induced <span class=""disease"" id=""17954371-0-76-88"">hypertension</span> in the rat.",CTD_human
68,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,5443,POMC,adrenocorticotropic hormone,CTD_human,16620303,Atorvastatin prevented and partially reversed adrenocorticotropic hormone-induced hypertension in the rat.,0.203846174978983,"Atorvastatin prevented and partially reversed <span class=""gene"" id=""16620303-0-46-73"">adrenocorticotropic hormone</span>-induced <span class=""disease"" id=""16620303-0-82-94"">hypertension</span> in the rat.",CTD_human
68,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,5443,POMC,ACTH,CTD_human,17324744,"Given that BH(4) failed to prevent ACTH or Dex hypertension, folic acid is unlikely to be acting through increased BH(4) production.",0.203846174978983,"Given that BH(4) failed to prevent <span class=""gene"" id=""17324744-13-35-39"">ACTH</span> or Dex <span class=""disease"" id=""17324744-13-47-59"">hypertension</span>, folic acid is unlikely to be acting through increased BH(4) production.",CTD_human
68,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,5443,POMC,ACTH,CTD_human,15110907,These data suggest that EPO is not causal in ACTH-induced hypertension.,0.203846174978983,"These data suggest that EPO is not causal in <span class=""gene"" id=""15110907-13-45-49"">ACTH</span>-induced <span class=""disease"" id=""15110907-13-58-70"">hypertension</span>.",CTD_human
68,0,Biomarker,C0020538,Hypertensive disease,group,arterial hypertension,5443,POMC,ACTH,CTD_human,6088243,"Based on the various biological effects of ACTH different explanations are proposed: oedema or deposition of glycogen in the myocardial tissue, hyperinsulinism, arterial hypertension and increased inotropic stimulus.",0.203846174978983,"Based on the various biological effects of <span class=""gene"" id=""6088243-8-43-47"">ACTH</span> different explanations are proposed: oedema or deposition of glycogen in the myocardial tissue, hyperinsulinism, <span class=""disease"" id=""6088243-8-161-182"">arterial hypertension</span> and increased inotropic stimulus.",CTD_human
68,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,5443,POMC,ACTH,CTD_human,2821097,Children who develop hypertension during ACTH therapy should be considered at risk for hypertrophic cardiomyopathy and should undergo routine echocardiographic evaluation.,0.203846174978983,"Children who develop <span class=""disease"" id=""2821097-5-21-33"">hypertension</span> during <span class=""gene"" id=""2821097-5-41-45"">ACTH</span> therapy should be considered at risk for hypertrophic cardiomyopathy and should undergo routine echocardiographic evaluation.",CTD_human
68,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,5443,POMC,ACTH,CTD_human,187612,Evidence for an unidentified ACTH-induced steroid hormone causing hypertension.,0.203846174978983,"Evidence for an unidentified <span class=""gene"" id=""187612-0-29-33"">ACTH</span>-induced steroid hormone causing <span class=""disease"" id=""187612-0-66-78"">hypertension</span>.",CTD_human
68,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,5443,POMC,ACTH,CTD_human,6097376,"Acute glucocorticoid (corticosterone) hypertension in the rate is significantly attenuated by neomycin administration (Honour 1981), as is ACTH-induced hypertension is the same species (Honour & Kent 1981) presumably by altering gut bacterial steroid metabolism.",0.203846174978983,"Acute glucocorticoid (corticosterone) <span class=""disease"" id=""6097376-1-38-50"">hypertension</span> in the rate is significantly attenuated by neomycin administration (Honour 1981), as is <span class=""gene"" id=""6097376-1-139-143"">ACTH</span>-induced <span class=""disease"" id=""6097376-1-152-164"">hypertension</span> is the same species (Honour & Kent 1981) presumably by altering gut bacterial steroid metabolism.",CTD_human
68,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,5443,POMC,ACTH,CTD_human,18487447,ACTH-induced hypertension is dependent on the ouabain-binding site of the alpha2-Na+-K+-ATPase subunit.,0.203846174978983,"<span class=""gene"" id=""18487447-0-0-4"">ACTH</span>-induced <span class=""disease"" id=""18487447-0-13-25"">hypertension</span> is dependent on the ouabain-binding site of the alpha2-Na+-K+-ATPase subunit.",CTD_human
68,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,5443,POMC,ACTH,CTD_human,187612,Evidence for an unidentified ACTH-induced steroid hormone causing hypertension.,0.203846174978983,"Evidence for an unidentified <span class=""gene"" id=""187612-0-29-33"">ACTH</span>-induced steroid hormone causing <span class=""disease"" id=""187612-0-66-78"">hypertension</span>.",CTD_human
68,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,5443,POMC,ACTH,CTD_human,2821097,Children who develop hypertension during ACTH therapy should be considered at risk for hypertrophic cardiomyopathy and should undergo routine echocardiographic evaluation.,0.203846174978983,"Children who develop <span class=""disease"" id=""2821097-5-21-33"">hypertension</span> during <span class=""gene"" id=""2821097-5-41-45"">ACTH</span> therapy should be considered at risk for hypertrophic cardiomyopathy and should undergo routine echocardiographic evaluation.",CTD_human
68,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,5443,POMC,ACTH,CTD_human,17324744,"Given that BH(4) failed to prevent ACTH or Dex hypertension, folic acid is unlikely to be acting through increased BH(4) production.",0.203846174978983,"Given that BH(4) failed to prevent <span class=""gene"" id=""17324744-13-35-39"">ACTH</span> or Dex <span class=""disease"" id=""17324744-13-47-59"">hypertension</span>, folic acid is unlikely to be acting through increased BH(4) production.",CTD_human
68,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,5443,POMC,ACTH,CTD_human,16546835,N-acetylcysteine antagonizes the development but does not reverse ACTH-induced hypertension in the rat.,0.203846174978983,"N-acetylcysteine antagonizes the development but does not reverse <span class=""gene"" id=""16546835-0-66-70"">ACTH</span>-induced <span class=""disease"" id=""16546835-0-79-91"">hypertension</span> in the rat.",CTD_human
68,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,5443,POMC,ACTH,CTD_human,15110907,These data suggest that EPO is not causal in ACTH-induced hypertension.,0.203846174978983,"These data suggest that EPO is not causal in <span class=""gene"" id=""15110907-13-45-49"">ACTH</span>-induced <span class=""disease"" id=""15110907-13-58-70"">hypertension</span>.",CTD_human
68,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,5443,POMC,ACTH,CTD_human,18487447,ACTH-induced hypertension is dependent on the ouabain-binding site of the alpha2-Na+-K+-ATPase subunit.,0.203846174978983,"<span class=""gene"" id=""18487447-0-0-4"">ACTH</span>-induced <span class=""disease"" id=""18487447-0-13-25"">hypertension</span> is dependent on the ouabain-binding site of the alpha2-Na+-K+-ATPase subunit.",CTD_human
1,0,Biomarker,C0022650,Kidney Calculi,disease,nephrolithiasis,5443,POMC,ACTH,CTD_human,1324751,Thiazide therapy for ACTH-induced hypercalciuria and nephrolithiasis.,0.2,"Thiazide therapy for <span class=""gene"" id=""1324751-0-21-25"">ACTH</span>-induced hypercalciuria and <span class=""disease"" id=""1324751-0-53-68"">nephrolithiasis</span>.",CTD_human
1,0,Therapeutic,C0025202,melanoma,disease,melanoma,5443,POMC,Proopiomelanocortin,CTD_human,24412703,Proopiomelanocortin gene delivery induces apoptosis in melanoma through NADPH oxidase 4-mediated ROS generation.,0.21578877303778302,"<span class=""gene"" id=""24412703-0-0-19"">Proopiomelanocortin</span> gene delivery induces apoptosis in <span class=""disease"" id=""24412703-0-55-63"">melanoma</span> through NADPH oxidase 4-mediated ROS generation.",CTD_human
2,0,Therapeutic,C0026769,Multiple Sclerosis,disease,multiple sclerosis,5443,POMC,ACTH,CTD_human,2843795,Hypomanic reactions to ACTH and prednisone treatment for multiple sclerosis.,0.20054945356842604,"Hypomanic reactions to <span class=""gene"" id=""2843795-0-23-27"">ACTH</span> and prednisone treatment for <span class=""disease"" id=""2843795-0-57-75"">multiple sclerosis</span>.",CTD_human
1,0,Biomarker,C0027497,Nausea,phenotype,nausea,5443,POMC,adrenocorticotropic hormone,CTD_human,11141589,Intractable nausea attributable to isolated deficiency of adrenocorticotropic hormone: prompt resolution after administration of glucocorticoid.,0.2,"Intractable <span class=""disease"" id=""11141589-0-12-18"">nausea</span> attributable to isolated deficiency of <span class=""gene"" id=""11141589-0-58-85"">adrenocorticotropic hormone</span>: prompt resolution after administration of glucocorticoid.",CTD_human
2,0,Biomarker,C0028754,Obesity,disease,obesity,5443,POMC,POMC,CTD_human,16289378,"Decrease in brain POMC mRNA expression and onset of obesity in guinea pigs exposed to 2-chloroethyl ethyl sulfide, a mustard analogue.",0.5281152171743729,"Decrease in brain <span class=""gene"" id=""16289378-0-18-22"">POMC</span> mRNA expression and onset of <span class=""disease"" id=""16289378-0-52-59"">obesity</span> in guinea pigs exposed to 2-chloroethyl ethyl sulfide, a mustard analogue.",CTD_human;HPO
1,0,Biomarker,C0028961,Oliguria,phenotype,oliguria,5443,POMC,ACTH,CTD_human,6254450,Four children developed oliguria and hyperkalaemia during and after withdrawal of ACTH.,0.2,"Four children developed <span class=""disease"" id=""6254450-6-24-32"">oliguria</span> and hyperkalaemia during and after withdrawal of <span class=""gene"" id=""6254450-6-82-86"">ACTH</span>.",CTD_human
3,0,Biomarker,C0030193,Pain,phenotype,pain,5443,POMC,ACTH,CTD_human,4345333,"Cortisol, growth hormone response, and pain following tetracosactrin depot and ACTH gel.",0.20274726784213098,"Cortisol, growth hormone response, and <span class=""disease"" id=""4345333-0-39-43"">pain</span> following tetracosactrin depot and <span class=""gene"" id=""4345333-0-79-83"">ACTH</span> gel.",CTD_human
3,0,Therapeutic,C0030193,Pain,phenotype,pain,5443,POMC,ACTH,CTD_human,4345333,"Cortisol, growth hormone response, and pain following tetracosactrin depot and ACTH gel.",0.20274726784213098,"Cortisol, growth hormone response, and <span class=""disease"" id=""4345333-0-39-43"">pain</span> following tetracosactrin depot and <span class=""gene"" id=""4345333-0-79-83"">ACTH</span> gel.",CTD_human
3,0,Therapeutic,C0030193,Pain,phenotype,Pain,5443,POMC,met-enkephalin,CTD_human,6094376,"Pain threshold changes in rats following central injection of beta-endorphin, met-enkephalin, vasopressin or oxytocin antisera.",0.20274726784213098,"<span class=""disease"" id=""6094376-0-0-4"">Pain</span> threshold changes in rats following central injection of <span class=""gene"" id=""6094376-0-62-76"">beta-endorphin</span>, <span class=""gene"" id=""6094376-0-78-92"">met-enkephalin</span>, vasopressin or oxytocin antisera.",CTD_human
3,0,Biomarker,C0030193,Pain,phenotype,pain,5443,POMC,beta-endorphin,CTD_human,20084599,The endogenous opioid beta-endorphin is a known indicator of stress and pain.,0.20274726784213098,"The endogenous opioid <span class=""gene"" id=""20084599-1-22-36"">beta-endorphin</span> is a known indicator of stress and <span class=""disease"" id=""20084599-1-72-76"">pain</span>.",CTD_human
3,0,Therapeutic,C0030193,Pain,phenotype,pain,5443,POMC,beta-endorphin,CTD_human,20084599,The endogenous opioid beta-endorphin is a known indicator of stress and pain.,0.20274726784213098,"The endogenous opioid <span class=""gene"" id=""20084599-1-22-36"">beta-endorphin</span> is a known indicator of stress and <span class=""disease"" id=""20084599-1-72-76"">pain</span>.",CTD_human
3,0,Biomarker,C0030193,Pain,phenotype,Pain,5443,POMC,met-enkephalin,CTD_human,6094376,"Pain threshold changes in rats following central injection of beta-endorphin, met-enkephalin, vasopressin or oxytocin antisera.",0.20274726784213098,"<span class=""disease"" id=""6094376-0-0-4"">Pain</span> threshold changes in rats following central injection of <span class=""gene"" id=""6094376-0-62-76"">beta-endorphin</span>, <span class=""gene"" id=""6094376-0-78-92"">met-enkephalin</span>, vasopressin or oxytocin antisera.",CTD_human
1,0,Biomarker,C0035258,Restless Legs Syndrome,disease,restless legs syndrome,5443,POMC,adrenocorticotropic hormone,CTD_human,18464280,Alpha-melanocyte stimulating hormone and adrenocorticotropic hormone: an alternative approach when thinking about restless legs syndrome?,0.2,"<span class=""gene"" id=""18464280-0-0-36"">Alpha-melanocyte stimulating hormone</span> and <span class=""gene"" id=""18464280-0-41-68"">adrenocorticotropic hormone</span>: an alternative approach when thinking about <span class=""disease"" id=""18464280-0-114-136"">restless legs syndrome</span>?",CTD_human
6,0,Biomarker,C0036572,Seizures,phenotype,seizures,5443,POMC,ACTH,CTD_human,2554740,ACTH-induced seizures in an infant with West syndrome.,0.202472541057918,"<span class=""gene"" id=""2554740-0-0-4"">ACTH</span>-induced <span class=""disease"" id=""2554740-0-13-21"">seizures</span> in an infant with West syndrome.",CTD_human
6,0,Therapeutic,C0036572,Seizures,phenotype,seizures,5443,POMC,ACTH,CTD_human,2554740,ACTH-induced seizures in an infant with West syndrome.,0.202472541057918,"<span class=""gene"" id=""2554740-0-0-4"">ACTH</span>-induced <span class=""disease"" id=""2554740-0-13-21"">seizures</span> in an infant with West syndrome.",CTD_human
6,0,Biomarker,C0036572,Seizures,phenotype,seizures,5443,POMC,adrenocorticotropic hormone,CTD_human,1656808,The seizures occurred following the suppression of infantile spasms with adrenocorticotropic hormone therapy and disappeared following the cessation of clonazepam administration.,0.202472541057918,"The <span class=""disease"" id=""1656808-2-4-12"">seizures</span> occurred following the suppression of infantile spasms with <span class=""gene"" id=""1656808-2-73-100"">adrenocorticotropic hormone</span> therapy and disappeared following the cessation of clonazepam administration.",CTD_human
6,0,Therapeutic,C0036572,Seizures,phenotype,seizures,5443,POMC,beta-endorphin,CTD_human,7127082,Lower doses of systemic morphine (50 mg/kg) were necessary to block i.c.v. morphine seizures than the dose (100 mg/kg) necessary to block seizures induced by i.c.v.Leu-enkephalin and beta-endorphin.,0.202472541057918,"Lower doses of systemic morphine (50 mg/kg) were necessary to block i.c.v. morphine <span class=""disease"" id=""7127082-6-84-92"">seizures</span> than the dose (100 mg/kg) necessary to block <span class=""disease"" id=""7127082-6-138-146"">seizures</span> induced by i.c.v.Leu-enkephalin and <span class=""gene"" id=""7127082-6-183-197"">beta-endorphin</span>.",CTD_human
6,0,Therapeutic,C0036572,Seizures,phenotype,seizures,5443,POMC,adrenocorticotropic hormone,CTD_human,1656808,The seizures occurred following the suppression of infantile spasms with adrenocorticotropic hormone therapy and disappeared following the cessation of clonazepam administration.,0.202472541057918,"The <span class=""disease"" id=""1656808-2-4-12"">seizures</span> occurred following the suppression of infantile spasms with <span class=""gene"" id=""1656808-2-73-100"">adrenocorticotropic hormone</span> therapy and disappeared following the cessation of clonazepam administration.",CTD_human
6,0,Biomarker,C0036572,Seizures,phenotype,seizures,5443,POMC,beta-endorphin,CTD_human,7127082,Lower doses of systemic morphine (50 mg/kg) were necessary to block i.c.v. morphine seizures than the dose (100 mg/kg) necessary to block seizures induced by i.c.v.Leu-enkephalin and beta-endorphin.,0.202472541057918,"Lower doses of systemic morphine (50 mg/kg) were necessary to block i.c.v. morphine <span class=""disease"" id=""7127082-6-84-92"">seizures</span> than the dose (100 mg/kg) necessary to block <span class=""disease"" id=""7127082-6-138-146"">seizures</span> induced by i.c.v.Leu-enkephalin and <span class=""gene"" id=""7127082-6-183-197"">beta-endorphin</span>.",CTD_human
6,0,Biomarker,C0036572,Seizures,phenotype,seizures,5443,POMC,ACTH,CTD_human,2169275,"The features of these are 1) late onset of seizures, 2) good response to ACTH therapy, 3) no significant abnormalities of brain except for agenesis of corpus callosum.",0.202472541057918,"The features of these are 1) late onset of <span class=""disease"" id=""2169275-9-43-51"">seizures</span>, 2) good response to <span class=""gene"" id=""2169275-9-73-77"">ACTH</span> therapy, 3) no significant abnormalities of brain except for agenesis of corpus callosum.",CTD_human
6,0,Therapeutic,C0036572,Seizures,phenotype,seizures,5443,POMC,ACTH,CTD_human,2169275,"The features of these are 1) late onset of seizures, 2) good response to ACTH therapy, 3) no significant abnormalities of brain except for agenesis of corpus callosum.",0.202472541057918,"The features of these are 1) late onset of <span class=""disease"" id=""2169275-9-43-51"">seizures</span>, 2) good response to <span class=""gene"" id=""2169275-9-73-77"">ACTH</span> therapy, 3) no significant abnormalities of brain except for agenesis of corpus callosum.",CTD_human
20,0,Biomarker,C0037769,West Syndrome,disease,infantile spasms,5443,POMC,adrenocorticotropic hormone,CTD_human,1656808,The seizures occurred following the suppression of infantile spasms with adrenocorticotropic hormone therapy and disappeared following the cessation of clonazepam administration.,0.203021994626344,"The seizures occurred following the suppression of <span class=""disease"" id=""1656808-2-51-67"">infantile spasms</span> with <span class=""gene"" id=""1656808-2-73-100"">adrenocorticotropic hormone</span> therapy and disappeared following the cessation of clonazepam administration.",CTD_human
20,0,Therapeutic,C0037769,West Syndrome,disease,infantile spasms,5443,POMC,ACTH,CTD_human,6143199,Renal and pancreatic calcification during treatment of infantile spasms with ACTH.,0.203021994626344,"Renal and pancreatic calcification during treatment of <span class=""disease"" id=""6143199-0-55-71"">infantile spasms</span> with <span class=""gene"" id=""6143199-0-77-81"">ACTH</span>.",CTD_human
20,0,Biomarker,C0037769,West Syndrome,disease,infantile spasms,5443,POMC,ACTH,CTD_human,11341487,Decreased cerebrospinal fluid levels of beta-endorphin and ACTH in children with infantile spasms.,0.203021994626344,"Decreased cerebrospinal fluid levels of <span class=""gene"" id=""11341487-0-40-54"">beta-endorphin</span> and <span class=""gene"" id=""11341487-0-59-63"">ACTH</span> in children with <span class=""disease"" id=""11341487-0-81-97"">infantile spasms</span>.",CTD_human
20,0,Therapeutic,C0037769,West Syndrome,disease,infantile spasms,5443,POMC,ACTH,CTD_human,1327015,[Treatment of infantile spasms with long-term low dose ACTH].,0.203021994626344,"[Treatment of <span class=""disease"" id=""1327015-0-14-30"">infantile spasms</span> with long-term low dose <span class=""gene"" id=""1327015-0-55-59"">ACTH</span>].",CTD_human
20,0,Therapeutic,C0037769,West Syndrome,disease,West syndrome,5443,POMC,ACTH,CTD_human,2554740,ACTH-induced seizures in an infant with West syndrome.,0.203021994626344,"<span class=""gene"" id=""2554740-0-0-4"">ACTH</span>-induced seizures in an infant with <span class=""disease"" id=""2554740-0-40-53"">West syndrome</span>.",CTD_human
20,0,Biomarker,C0037769,West Syndrome,disease,infantile spasm,5443,POMC,ACTH,CTD_human,6107850,[Lethal side effects from ACTH-therapy in infantile spasm (author's transl)].,0.203021994626344,"[Lethal side effects from <span class=""gene"" id=""6107850-0-26-30"">ACTH</span>-therapy in <span class=""disease"" id=""6107850-0-42-57"">infantile spasm</span> (author's transl)].",CTD_human
20,0,Biomarker,C0037769,West Syndrome,disease,west syndrome,5443,POMC,ACTH,CTD_human,19039989,[Case of west syndrome associated with transient marked sinus dysfunction during ACTH therapy].,0.203021994626344,"[Case of <span class=""disease"" id=""19039989-0-9-22"">west syndrome</span> associated with transient marked sinus dysfunction during <span class=""gene"" id=""19039989-0-81-85"">ACTH</span> therapy].",CTD_human
20,0,Therapeutic,C0037769,West Syndrome,disease,infantile spasms,5443,POMC,ACTH,CTD_human,2983143,A fatal incident during combined anticonvulsive therapy with ACTH and Dexamethason prompted us to reevaluate our treatment results in 19 children suffering from infantile spasms.,0.203021994626344,"A fatal incident during combined anticonvulsive therapy with <span class=""gene"" id=""2983143-1-61-65"">ACTH</span> and Dexamethason prompted us to reevaluate our treatment results in 19 children suffering from <span class=""disease"" id=""2983143-1-161-177"">infantile spasms</span>.",CTD_human
20,0,Biomarker,C0037769,West Syndrome,disease,infantile spasms,5443,POMC,ACTH,CTD_human,1327015,[Treatment of infantile spasms with long-term low dose ACTH].,0.203021994626344,"[Treatment of <span class=""disease"" id=""1327015-0-14-30"">infantile spasms</span> with long-term low dose <span class=""gene"" id=""1327015-0-55-59"">ACTH</span>].",CTD_human
20,0,Therapeutic,C0037769,West Syndrome,disease,west syndrome,5443,POMC,ACTH,CTD_human,19039989,[Case of west syndrome associated with transient marked sinus dysfunction during ACTH therapy].,0.203021994626344,"[Case of <span class=""disease"" id=""19039989-0-9-22"">west syndrome</span> associated with transient marked sinus dysfunction during <span class=""gene"" id=""19039989-0-81-85"">ACTH</span> therapy].",CTD_human
20,0,Biomarker,C0037769,West Syndrome,disease,infantile spasms,5443,POMC,ACTH,CTD_human,6143199,Renal and pancreatic calcification during treatment of infantile spasms with ACTH.,0.203021994626344,"Renal and pancreatic calcification during treatment of <span class=""disease"" id=""6143199-0-55-71"">infantile spasms</span> with <span class=""gene"" id=""6143199-0-77-81"">ACTH</span>.",CTD_human
20,0,Biomarker,C0037769,West Syndrome,disease,infantile spasms,5443,POMC,ACTH,CTD_human,2983143,A fatal incident during combined anticonvulsive therapy with ACTH and Dexamethason prompted us to reevaluate our treatment results in 19 children suffering from infantile spasms.,0.203021994626344,"A fatal incident during combined anticonvulsive therapy with <span class=""gene"" id=""2983143-1-61-65"">ACTH</span> and Dexamethason prompted us to reevaluate our treatment results in 19 children suffering from <span class=""disease"" id=""2983143-1-161-177"">infantile spasms</span>.",CTD_human
20,0,Therapeutic,C0037769,West Syndrome,disease,infantile spasms,5443,POMC,ACTH,CTD_human,6254450,ACTH therapy in infantile spasms: side effects.,0.203021994626344,"<span class=""gene"" id=""6254450-0-0-4"">ACTH</span> therapy in <span class=""disease"" id=""6254450-0-16-32"">infantile spasms</span>: side effects.",CTD_human
20,0,Biomarker,C0037769,West Syndrome,disease,infantile spasms,5443,POMC,ACTH,CTD_human,1324751,A one-year-old boy presented with hypercalciuria and nephrolithiasis following a course of ACTH therapy for infantile spasms.,0.203021994626344,"A one-year-old boy presented with hypercalciuria and nephrolithiasis following a course of <span class=""gene"" id=""1324751-1-91-95"">ACTH</span> therapy for <span class=""disease"" id=""1324751-1-108-124"">infantile spasms</span>.",CTD_human
20,0,Biomarker,C0037769,West Syndrome,disease,infantile spasms,5443,POMC,Adrenocorticotropic hormone,CTD_human,8980841,Adrenocorticotropic hormone and vigabatrin treatment of children with infantile spasms underlying cerebral palsy.,0.203021994626344,"<span class=""gene"" id=""8980841-0-0-27"">Adrenocorticotropic hormone</span> and vigabatrin treatment of children with <span class=""disease"" id=""8980841-0-70-86"">infantile spasms</span> underlying cerebral palsy.",CTD_human
20,0,Therapeutic,C0037769,West Syndrome,disease,infantile spasms,5443,POMC,ACTH,CTD_human,11341487,Decreased cerebrospinal fluid levels of beta-endorphin and ACTH in children with infantile spasms.,0.203021994626344,"Decreased cerebrospinal fluid levels of <span class=""gene"" id=""11341487-0-40-54"">beta-endorphin</span> and <span class=""gene"" id=""11341487-0-59-63"">ACTH</span> in children with <span class=""disease"" id=""11341487-0-81-97"">infantile spasms</span>.",CTD_human
20,0,Therapeutic,C0037769,West Syndrome,disease,infantile spasms,5443,POMC,ACTH,CTD_human,1324751,A one-year-old boy presented with hypercalciuria and nephrolithiasis following a course of ACTH therapy for infantile spasms.,0.203021994626344,"A one-year-old boy presented with hypercalciuria and nephrolithiasis following a course of <span class=""gene"" id=""1324751-1-91-95"">ACTH</span> therapy for <span class=""disease"" id=""1324751-1-108-124"">infantile spasms</span>.",CTD_human
20,0,Therapeutic,C0037769,West Syndrome,disease,infantile spasm,5443,POMC,ACTH,CTD_human,6107850,[Lethal side effects from ACTH-therapy in infantile spasm (author's transl)].,0.203021994626344,"[Lethal side effects from <span class=""gene"" id=""6107850-0-26-30"">ACTH</span>-therapy in <span class=""disease"" id=""6107850-0-42-57"">infantile spasm</span> (author's transl)].",CTD_human
20,0,Biomarker,C0037769,West Syndrome,disease,infantile spasms,5443,POMC,ACTH,CTD_human,6259007,"In spite of conflicting views as to the long-term effects of ACTH, prompt treatment seems to be mandatory, at least in cryptogenic cases of infantile spasms.",0.203021994626344,"In spite of conflicting views as to the long-term effects of <span class=""gene"" id=""6259007-11-61-65"">ACTH</span>, prompt treatment seems to be mandatory, at least in cryptogenic cases of <span class=""disease"" id=""6259007-11-140-156"">infantile spasms</span>.",CTD_human
20,0,Biomarker,C0037769,West Syndrome,disease,infantile spasms,5443,POMC,ACTH,CTD_human,6254450,ACTH therapy in infantile spasms: side effects.,0.203021994626344,"<span class=""gene"" id=""6254450-0-0-4"">ACTH</span> therapy in <span class=""disease"" id=""6254450-0-16-32"">infantile spasms</span>: side effects.",CTD_human
20,0,Therapeutic,C0037769,West Syndrome,disease,infantile spasms,5443,POMC,ACTH,CTD_human,20078871,Clinical profile and treatment of infantile spasms using vigabatrin and ACTH--a developing country perspective.,0.203021994626344,"Clinical profile and treatment of <span class=""disease"" id=""20078871-0-34-50"">infantile spasms</span> using vigabatrin and <span class=""gene"" id=""20078871-0-72-76"">ACTH</span>--a developing country perspective.",CTD_human
20,0,Biomarker,C0037769,West Syndrome,disease,infantile spasms,5443,POMC,ACTH,CTD_human,20078871,Clinical profile and treatment of infantile spasms using vigabatrin and ACTH--a developing country perspective.,0.203021994626344,"Clinical profile and treatment of <span class=""disease"" id=""20078871-0-34-50"">infantile spasms</span> using vigabatrin and <span class=""gene"" id=""20078871-0-72-76"">ACTH</span>--a developing country perspective.",CTD_human
20,0,Therapeutic,C0037769,West Syndrome,disease,infantile spasms,5443,POMC,adrenocorticotropic hormone,CTD_human,1656808,The seizures occurred following the suppression of infantile spasms with adrenocorticotropic hormone therapy and disappeared following the cessation of clonazepam administration.,0.203021994626344,"The seizures occurred following the suppression of <span class=""disease"" id=""1656808-2-51-67"">infantile spasms</span> with <span class=""gene"" id=""1656808-2-73-100"">adrenocorticotropic hormone</span> therapy and disappeared following the cessation of clonazepam administration.",CTD_human
20,0,Therapeutic,C0037769,West Syndrome,disease,infantile spasms,5443,POMC,ACTH,CTD_human,6259007,"In spite of conflicting views as to the long-term effects of ACTH, prompt treatment seems to be mandatory, at least in cryptogenic cases of infantile spasms.",0.203021994626344,"In spite of conflicting views as to the long-term effects of <span class=""gene"" id=""6259007-11-61-65"">ACTH</span>, prompt treatment seems to be mandatory, at least in cryptogenic cases of <span class=""disease"" id=""6259007-11-140-156"">infantile spasms</span>.",CTD_human
20,0,Biomarker,C0037769,West Syndrome,disease,West syndrome,5443,POMC,ACTH,CTD_human,2554740,ACTH-induced seizures in an infant with West syndrome.,0.203021994626344,"<span class=""gene"" id=""2554740-0-0-4"">ACTH</span>-induced seizures in an infant with <span class=""disease"" id=""2554740-0-40-53"">West syndrome</span>.",CTD_human
20,0,Therapeutic,C0037769,West Syndrome,disease,infantile spasms,5443,POMC,Adrenocorticotropic hormone,CTD_human,8980841,Adrenocorticotropic hormone and vigabatrin treatment of children with infantile spasms underlying cerebral palsy.,0.203021994626344,"<span class=""gene"" id=""8980841-0-0-27"">Adrenocorticotropic hormone</span> and vigabatrin treatment of children with <span class=""disease"" id=""8980841-0-70-86"">infantile spasms</span> underlying cerebral palsy.",CTD_human
1,0,Therapeutic,C0162557,"Liver Failure, Acute",disease,acute liver failure,5443,POMC,alpha-melanocyte-stimulating hormone,CTD_human,15313186,Single injection of naked plasmid encoding alpha-melanocyte-stimulating hormone protects against thioacetamide-induced acute liver failure in mice.,0.2,"Single injection of naked plasmid encoding <span class=""gene"" id=""15313186-0-43-79"">alpha-melanocyte-stimulating hormone</span> protects against thioacetamide-induced <span class=""disease"" id=""15313186-0-119-138"">acute liver failure</span> in mice.",CTD_human
1,0,Biomarker,C0221406,Pituitary-dependent Cushing's disease,disease,Cushing disease,5443,POMC,ACTH,CTD_human,16809932,"Cushing disease, which is caused by the excessive production of ACTH, is a rare and complex endocrine disorder that still represents a major challenge for the physician in terms of accurate diagnosis and efficient treatment.",0.21782853021921697,"<span class=""disease"" id=""16809932-1-0-15"">Cushing disease</span>, which is caused by the excessive production of <span class=""gene"" id=""16809932-1-64-68"">ACTH</span>, is a rare and complex endocrine disorder that still represents a major challenge for the physician in terms of accurate diagnosis and efficient treatment.",CTD_human
1,0,Therapeutic,C0553730,Calcium pyrophosphate deposition disease,disease,pseudogout,5443,POMC,ACTH,CTD_human,8035395,"ACTH is a safe and effective treatment for acute gout and pseudogout, especially in patients with multiple medical problems.",0.2,"<span class=""gene"" id=""8035395-9-0-4"">ACTH</span> is a safe and effective treatment for acute gout and <span class=""disease"" id=""8035395-9-58-68"">pseudogout</span>, especially in patients with multiple medical problems.",CTD_human
1,0,Therapeutic,C0574960,Sacroiliitis,disease,sacroiliitis,5443,POMC,ACTH,CTD_human,19533139,"We report a case of acute sacroiliitis with severe disability after only 3 weeks of isotretinoin therapy with graduate reduction of pain, limitation and muscle incompetence after discontinuation of the drug and ACTH-depo injection and Ethodolac therapy.",0.2,"We report a case of acute <span class=""disease"" id=""19533139-1-26-38"">sacroiliitis</span> with severe disability after only 3 weeks of isotretinoin therapy with graduate reduction of pain, limitation and muscle incompetence after discontinuation of the drug and <span class=""gene"" id=""19533139-1-211-215"">ACTH</span>-depo injection and Ethodolac therapy.",CTD_human
1,0,Biomarker,C0265965,Dyskeratosis Congenita,disease,DC,54433,GAR1,nola1,CTD_human,22299032,Our data therefore support a model that deficiency in dkc1 and nola1 in the H/ACA RNP complex likely contributes to the hematopoietic phenotype through p53 activation associated with rRNA processing defects rather than telomerase deficiency during the initial stage of DC pathogenesis.,0.20054945356842604,"Our data therefore support a model that deficiency in dkc1 and <span class=""gene"" id=""22299032-6-63-68"">nola1</span> in the H/ACA RNP complex likely contributes to the hematopoietic phenotype through p53 activation associated with rRNA processing defects rather than telomerase deficiency during the initial stage of <span class=""disease"" id=""22299032-6-269-271"">DC</span> pathogenesis.",CTD_human
1,0,Biomarker,C0003873,Rheumatoid Arthritis,disease,rheumatoid arthritis,5444,PON1,paraoxonase 1,CTD_human,16055108,Assessment of paraoxonase 1 activity and malondialdehyde levels in patients with rheumatoid arthritis.,0.20919533021666797,"Assessment of <span class=""gene"" id=""16055108-0-14-27"">paraoxonase 1</span> activity and malondialdehyde levels in patients with <span class=""disease"" id=""16055108-0-81-101"">rheumatoid arthritis</span>.",CTD_human
6,0,Biomarker,C0004153,Atherosclerosis,disease,atherosclerosis,5444,PON1,PON1,CTD_human,16229851,"The abnormal serum PON1 distribution in diabetic patients, could be responsible for the accelerated atherosclerosis development in these patients.",0.286433413191035,"The abnormal serum <span class=""gene"" id=""16229851-9-19-23"">PON1</span> distribution in diabetic patients, could be responsible for the accelerated <span class=""disease"" id=""16229851-9-100-115"">atherosclerosis</span> development in these patients.",CTD_human
6,0,Biomarker,C0004153,Atherosclerosis,disease,atherosclerosis,5444,PON1,PON1,CTD_human,26241956,The results of the present study suggested that the PON1 R and M alleles may play a role in the pathogenesis of cardiac ischemia in our North African population and that a decrease in PON1 activity may be a valuable marker for monitoring the development of the atherosclerosis process and the associated cardiovascular complications.,0.286433413191035,"The results of the present study suggested that the <span class=""gene"" id=""26241956-10-52-56"">PON1</span> R and M alleles may play a role in the pathogenesis of cardiac ischemia in our North African population and that a decrease in <span class=""gene"" id=""26241956-10-184-188"">PON1</span> activity may be a valuable marker for monitoring the development of the <span class=""disease"" id=""26241956-10-261-276"">atherosclerosis</span> process and the associated cardiovascular complications.",CTD_human
6,0,Therapeutic,C0004153,Atherosclerosis,disease,atherosclerosis,5444,PON1,PON1,CTD_human,26241956,The results of the present study suggested that the PON1 R and M alleles may play a role in the pathogenesis of cardiac ischemia in our North African population and that a decrease in PON1 activity may be a valuable marker for monitoring the development of the atherosclerosis process and the associated cardiovascular complications.,0.286433413191035,"The results of the present study suggested that the <span class=""gene"" id=""26241956-10-52-56"">PON1</span> R and M alleles may play a role in the pathogenesis of cardiac ischemia in our North African population and that a decrease in <span class=""gene"" id=""26241956-10-184-188"">PON1</span> activity may be a valuable marker for monitoring the development of the <span class=""disease"" id=""26241956-10-261-276"">atherosclerosis</span> process and the associated cardiovascular complications.",CTD_human
6,0,Therapeutic,C0004153,Atherosclerosis,disease,atherosclerosis,5444,PON1,PON1,CTD_human,19371607,"No significant association was found between atherosclerosis and four polymorphisms of the PON gene cluster (PON1 -108C/T, PON1 Q192R, PON2 A148G, PON2 C311S).",0.286433413191035,"No significant association was found between <span class=""disease"" id=""19371607-7-45-60"">atherosclerosis</span> and four polymorphisms of the <span class=""gene"" id=""19371607-7-91-94"">PON</span> gene cluster (<span class=""gene"" id=""19371607-7-109-113"">PON1</span> -108C/T, <span class=""gene"" id=""19371607-7-123-127"">PON1</span> Q192R, PON2 A148G, PON2 C311S).",CTD_human
6,0,Therapeutic,C0004153,Atherosclerosis,disease,atherosclerosis,5444,PON1,PON1,CTD_human,21629682,"Human serum paraoxonase-1 (PON1) prevents oxidation of low density lipoprotein cholesterol (LDL-C) and hydrolyzes the oxidized form, therefore preventing the development of atherosclerosis.",0.286433413191035,"Human serum <span class=""gene"" id=""21629682-1-12-25"">paraoxonase-1</span> (<span class=""gene"" id=""21629682-1-27-31"">PON1</span>) prevents oxidation of low density lipoprotein cholesterol (LDL-C) and hydrolyzes the oxidized form, therefore preventing the development of <span class=""disease"" id=""21629682-1-173-188"">atherosclerosis</span>.",CTD_human
6,0,Therapeutic,C0004153,Atherosclerosis,disease,atherosclerosis,5444,PON1,PON1,CTD_human,16331452,PON1 also plays a key role in prevention of atherosclerosis.,0.286433413191035,"<span class=""gene"" id=""16331452-4-0-4"">PON1</span> also plays a key role in prevention of <span class=""disease"" id=""16331452-4-44-59"">atherosclerosis</span>.",CTD_human
6,0,Therapeutic,C0004153,Atherosclerosis,disease,atherosclerosis,5444,PON1,PON1,CTD_human,16229851,"The abnormal serum PON1 distribution in diabetic patients, could be responsible for the accelerated atherosclerosis development in these patients.",0.286433413191035,"The abnormal serum <span class=""gene"" id=""16229851-9-19-23"">PON1</span> distribution in diabetic patients, could be responsible for the accelerated <span class=""disease"" id=""16229851-9-100-115"">atherosclerosis</span> development in these patients.",CTD_human
6,0,Biomarker,C0004153,Atherosclerosis,disease,atherosclerosis,5444,PON1,PON1,CTD_human,16331452,PON1 also plays a key role in prevention of atherosclerosis.,0.286433413191035,"<span class=""gene"" id=""16331452-4-0-4"">PON1</span> also plays a key role in prevention of <span class=""disease"" id=""16331452-4-44-59"">atherosclerosis</span>.",CTD_human
6,0,Biomarker,C0004153,Atherosclerosis,disease,atherosclerosis,5444,PON1,PON1,CTD_human,21629682,"Human serum paraoxonase-1 (PON1) prevents oxidation of low density lipoprotein cholesterol (LDL-C) and hydrolyzes the oxidized form, therefore preventing the development of atherosclerosis.",0.286433413191035,"Human serum <span class=""gene"" id=""21629682-1-12-25"">paraoxonase-1</span> (<span class=""gene"" id=""21629682-1-27-31"">PON1</span>) prevents oxidation of low density lipoprotein cholesterol (LDL-C) and hydrolyzes the oxidized form, therefore preventing the development of <span class=""disease"" id=""21629682-1-173-188"">atherosclerosis</span>.",CTD_human
6,0,Biomarker,C0004153,Atherosclerosis,disease,atherosclerosis,5444,PON1,PON1,CTD_human,19371607,"No significant association was found between atherosclerosis and four polymorphisms of the PON gene cluster (PON1 -108C/T, PON1 Q192R, PON2 A148G, PON2 C311S).",0.286433413191035,"No significant association was found between <span class=""disease"" id=""19371607-7-45-60"">atherosclerosis</span> and four polymorphisms of the <span class=""gene"" id=""19371607-7-91-94"">PON</span> gene cluster (<span class=""gene"" id=""19371607-7-109-113"">PON1</span> -108C/T, <span class=""gene"" id=""19371607-7-123-127"">PON1</span> Q192R, PON2 A148G, PON2 C311S).",CTD_human
3,0,Biomarker,C0004352,Autistic Disorder,disease,autism,5444,PON1,paraoxonase 1,CTD_human,16297937,High levels of homocysteine and low serum paraoxonase 1 arylesterase activity in children with autism.,0.20054945356842604,"High levels of homocysteine and low serum <span class=""gene"" id=""16297937-0-42-55"">paraoxonase 1</span> arylesterase activity in children with <span class=""disease"" id=""16297937-0-95-101"">autism</span>.",CTD_human
3,0,Biomarker,C0004352,Autistic Disorder,disease,autism,5444,PON1,paraoxonase-1,CTD_human,22490277,"Gene variants of paraoxonase-1 are associated with autism in North America, but not in Italy, indicating regional specificity in gene-environment interactions.",0.20054945356842604,"Gene variants of <span class=""gene"" id=""22490277-5-17-30"">paraoxonase-1</span> are associated with <span class=""disease"" id=""22490277-5-51-57"">autism</span> in North America, but not in Italy, indicating regional specificity in gene-environment interactions.",CTD_human
3,0,Biomarker,C0004352,Autistic Disorder,disease,autism,5444,PON1,PON1,CTD_human,16027737,"As predicted, Caucasian-American and not Italian families display a significant association between autism and PON1 variants less active in vitro on the OP diazinon (R192), according to case-control contrasts (Q192R: chi2=6.33, 1 df, P<0.025), transmission/disequilibrium tests (Q192R: TDT chi2=5.26, 1 df, P<0.025), family-based association tests (Q192R and L55M: FBAT Z=2.291 and 2.435 respectively, P<0.025), and haplotype-based association tests (L55/R192: HBAT Z=2.430, P<0.025).",0.20054945356842604,"As predicted, Caucasian-American and not Italian families display a significant association between <span class=""disease"" id=""16027737-6-100-106"">autism</span> and <span class=""gene"" id=""16027737-6-111-115"">PON1</span> variants less active in vitro on the OP diazinon (R192), according to case-control contrasts (Q192R: chi2=6.33, 1 df, P&lt;0.025), transmission/disequilibrium tests (Q192R: TDT chi2=5.26, 1 df, P&lt;0.025), family-based association tests (Q192R and L55M: FBAT Z=2.291 and 2.435 respectively, P&lt;0.025), and haplotype-based association tests (L55/R192: HBAT Z=2.430, P&lt;0.025).",CTD_human
2,0,Biomarker,C0010068,Coronary heart disease,disease,coronary heart disease,5444,PON1,PON1,CTD_human,16353344,The discovery that PON1 can also metabolize oxidized phospholipids has spurred research on its possible role in coronary heart disease and atherosclerosis.,0.275696622204046,"The discovery that <span class=""gene"" id=""16353344-2-19-23"">PON1</span> can also metabolize oxidized phospholipids has spurred research on its possible role in <span class=""disease"" id=""16353344-2-112-134"">coronary heart disease</span> and atherosclerosis.",CTD_human
1,0,Biomarker,C0010073,Coronary Artery Vasospasm,disease,coronary spasm,5444,PON1,PON1,CTD_human,11810302,"Thus, there is a significant association between the PON1-192R allele and coronary spasm; the PON1-192R allele may play an important role in the genesis of coronary spasm, probably by attenuating the suppression of oxidative stress.",0.202956482091714,"Thus, there is a significant association between the <span class=""gene"" id=""11810302-10-53-57"">PON1</span>-192R allele and <span class=""disease"" id=""11810302-10-74-88"">coronary spasm</span>; the <span class=""gene"" id=""11810302-10-94-98"">PON1</span>-192R allele may play an important role in the genesis of <span class=""disease"" id=""11810302-10-156-170"">coronary spasm</span>, probably by attenuating the suppression of oxidative stress.",CTD_human
1,0,Biomarker,C0011581,Depressive disorder,disease,depressive disorders,5444,PON1,PON1,CTD_human,19272368,Decreased PON1 and ghrelin levels as well as fluctuations in lipid profiles may be involved in the etiology of depressive disorders.,0.4010989071368521,"Decreased <span class=""gene"" id=""19272368-8-10-14"">PON1</span> and ghrelin levels as well as fluctuations in lipid profiles may be involved in the etiology of <span class=""disease"" id=""19272368-8-111-131"">depressive disorders</span>.",CTD_human;HPO
2,0,Biomarker,C0011849,Diabetes Mellitus,group,diabetes,5444,PON1,PON1,CTD_human,16229851,"Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoprotein-deficient serum: relevance to diabetes.",0.21962059263944897,"<span class=""gene"" id=""16229851-0-0-13"">Paraoxonase 1</span> (<span class=""gene"" id=""16229851-0-15-19"">PON1</span>) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoprotein-deficient serum: relevance to <span class=""disease"" id=""16229851-0-168-176"">diabetes</span>.",CTD_human
2,0,Biomarker,C0011849,Diabetes Mellitus,group,diabetes,5444,PON1,PON1,CTD_human,19022366,"The PON1 Q/R polymorphism was found to have significant association with hypertension (p=0.046) and chronic constipation (p=0.028) whereas, the L/M polymorphism, with diabetes (p=0.036), arteritis (trend p=0.022) and hemorrhoids (trend p=0.027).",0.21962059263944897,"The <span class=""gene"" id=""19022366-7-4-8"">PON1</span> Q/R polymorphism was found to have significant association with hypertension (p=0.046) and chronic constipation (p=0.028) whereas, the L/M polymorphism, with <span class=""disease"" id=""19022366-7-167-175"">diabetes</span> (p=0.036), arteritis (trend p=0.022) and hemorrhoids (trend p=0.027).",CTD_human
2,0,Biomarker,C0011884,Diabetic Retinopathy,disease,diabetic retinopathy,5444,PON1,paraoxonase 1,CTD_human,20012460,"Antioxidant potential, paraoxonase 1, ceruloplasmin activity and C-reactive protein concentration in diabetic retinopathy.",0.210177567661578,"Antioxidant potential, <span class=""gene"" id=""20012460-0-23-36"">paraoxonase 1</span>, ceruloplasmin activity and C-reactive protein concentration in <span class=""disease"" id=""20012460-0-101-121"">diabetic retinopathy</span>.",CTD_human
2,0,Biomarker,C0011884,Diabetic Retinopathy,disease,diabetic retinopathy,5444,PON1,PON1,CTD_human,9661650,A variant of paraoxonase (PON1) gene is associated with diabetic retinopathy in IDDM.,0.210177567661578,"A variant of paraoxonase (<span class=""gene"" id=""9661650-0-26-30"">PON1</span>) gene is associated with <span class=""disease"" id=""9661650-0-56-76"">diabetic retinopathy</span> in IDDM.",CTD_human
1,0,Biomarker,C0015695,Fatty Liver,disease,liver steatosis,5444,PON1,PON1,CTD_human,26945512,"We evaluated the effects of metformin in the liver of PON1-deficient mice which, untreated, present a mild degree of liver steatosis.",0.2,"We evaluated the effects of metformin in the liver of <span class=""gene"" id=""26945512-6-54-58"">PON1</span>-deficient mice which, untreated, present a mild degree of <span class=""disease"" id=""26945512-6-117-132"">liver steatosis</span>.",CTD_human
1,0,Biomarker,C0017662,"Glomerulonephritis, Membranoproliferative",disease,MPGN,5444,PON1,PON1,CTD_human,16175651,"In conclusion, we suggest that the PON1 activities are affected by PON1 genetic variability in Turkish patients with MPGN.",0.20300763924902696,"In conclusion, we suggest that the <span class=""gene"" id=""16175651-12-35-39"">PON1</span> activities are affected by <span class=""gene"" id=""16175651-12-67-71"">PON1</span> genetic variability in Turkish patients with <span class=""disease"" id=""16175651-12-117-121"">MPGN</span>.",CTD_human
1,0,Biomarker,C0019112,Hemorrhoids,disease,hemorrhoids,5444,PON1,PON1,CTD_human,19022366,"The PON1 Q/R polymorphism was found to have significant association with hypertension (p=0.046) and chronic constipation (p=0.028) whereas, the L/M polymorphism, with diabetes (p=0.036), arteritis (trend p=0.022) and hemorrhoids (trend p=0.027).",0.200274726784213,"The <span class=""gene"" id=""19022366-7-4-8"">PON1</span> Q/R polymorphism was found to have significant association with hypertension (p=0.046) and chronic constipation (p=0.028) whereas, the L/M polymorphism, with diabetes (p=0.036), arteritis (trend p=0.022) and <span class=""disease"" id=""19022366-7-217-228"">hemorrhoids</span> (trend p=0.027).",CTD_human
2,0,Biomarker,C0020445,"Hypercholesterolemia, Familial",disease,familial hypercholesterolaemia,5444,PON1,paraoxonase-1,CTD_human,16238680,The effect of statin therapy on plasma high-density lipoprotein cholesterol levels is modified by paraoxonase-1 in patients with familial hypercholesterolaemia.,0.204381273170092,"The effect of statin therapy on plasma high-density lipoprotein cholesterol levels is modified by <span class=""gene"" id=""16238680-0-98-111"">paraoxonase-1</span> in patients with <span class=""disease"" id=""16238680-0-129-159"">familial hypercholesterolaemia</span>.",CTD_human
2,0,Biomarker,C0021364,Male infertility,phenotype,male infertility,5444,PON1,PON1,CTD_human,21561808,Association between male infertility and genetic variability at the PON1/2 and GSTM1/T1 gene loci.,0.201098907136852,"Association between <span class=""disease"" id=""21561808-0-20-36"">male infertility</span> and genetic variability at the <span class=""gene"" id=""21561808-0-68-72"">PON1</span>/2 and GSTM1/T1 gene loci.",CTD_human
2,0,Biomarker,C0021364,Male infertility,phenotype,male infertility,5444,PON1,PON1,CTD_human,22206979,The results indicated that the PON1 Arg192Glu (rs662) and SOD2 Val16Ala (rs4880) variant genotypes were associated with a significantly higher risk of male infertility.,0.201098907136852,"The results indicated that the <span class=""gene"" id=""22206979-5-31-35"">PON1</span> Arg192Glu (rs662) and SOD2 Val16Ala (rs4880) variant genotypes were associated with a significantly higher risk of <span class=""disease"" id=""22206979-5-151-167"">male infertility</span>.",CTD_human
1,0,Biomarker,C0080178,Spina Bifida,disease,spina bifida,5444,PON1,Paraoxonase 1,CTD_human,21031563,Paraoxonase 1 polymorphisms and haplotypes and the risk for having offspring affected with spina bifida in Southeast Mexico.,0.200274726784213,"<span class=""gene"" id=""21031563-0-0-13"">Paraoxonase 1</span> polymorphisms and haplotypes and the risk for having offspring affected with <span class=""disease"" id=""21031563-0-91-103"">spina bifida</span> in Southeast Mexico.",CTD_human
1,0,Biomarker,C0524620,Metabolic Syndrome X,disease,metabolic syndrome,5444,PON1,paraoxonase-1,CTD_human,21573798,Association between paraoxonase-1 gene polymorphisms and risk of metabolic syndrome.,0.20728659810449399,"Association between <span class=""gene"" id=""21573798-0-20-33"">paraoxonase-1</span> gene polymorphisms and risk of <span class=""disease"" id=""21573798-0-65-83"">metabolic syndrome</span>.",CTD_human
2,0,Biomarker,C0598608,Hyperhomocysteinemia,disease,hyperhomocysteinemia,5444,PON1,paraoxonase-1,CTD_human,17292331,"However, chronic administration of catechin but not quercetin significantly reduced plasma homocysteine levels, attenuated the reduction of the hepatic CBS activity, and restored the decreased paraoxonase-1 gene expression and activity induced by chronic hyperhomocysteinemia.",0.20350593566014002,"However, chronic administration of catechin but not quercetin significantly reduced plasma homocysteine levels, attenuated the reduction of the hepatic CBS activity, and restored the decreased <span class=""gene"" id=""17292331-4-193-206"">paraoxonase-1</span> gene expression and activity induced by chronic <span class=""disease"" id=""17292331-4-255-275"">hyperhomocysteinemia</span>.",CTD_human
1,0,Biomarker,C0948089,Acute Coronary Syndrome,disease,Acute Coronary Syndrome,5444,PON1,PON1,CTD_human,26241956,Association between Paraoxonase 1 (PON1) Polymorphisms and the Risk of Acute Coronary Syndrome in a North African Population.,0.20886944627514298,"Association between <span class=""gene"" id=""26241956-0-20-33"">Paraoxonase 1</span> (<span class=""gene"" id=""26241956-0-35-39"">PON1</span>) Polymorphisms and the Risk of <span class=""disease"" id=""26241956-0-71-94"">Acute Coronary Syndrome</span> in a North African Population.",CTD_human
3,0,Therapeutic,C1956346,Coronary Artery Disease,disease,CAD,5444,PON1,PON1,CTD_human,21629682,"As studies are lacking in North-West Indian Punjabi's, a distinct ethnic group with high incidence of CAD, we determined PON1 activity, genotypes and haplotypes in this population and correlated them with the risk of CAD.",0.29807715933131895,"As studies are lacking in North-West Indian Punjabi's, a distinct ethnic group with high incidence of <span class=""disease"" id=""21629682-3-102-105"">CAD</span>, we determined <span class=""gene"" id=""21629682-3-121-125"">PON1</span> activity, genotypes and haplotypes in this population and correlated them with the risk of <span class=""disease"" id=""21629682-3-217-220"">CAD</span>.",CTD_human
3,0,Biomarker,C1956346,Coronary Artery Disease,disease,CAD,5444,PON1,PON1,CTD_human,21629682,"As studies are lacking in North-West Indian Punjabi's, a distinct ethnic group with high incidence of CAD, we determined PON1 activity, genotypes and haplotypes in this population and correlated them with the risk of CAD.",0.29807715933131895,"As studies are lacking in North-West Indian Punjabi's, a distinct ethnic group with high incidence of <span class=""disease"" id=""21629682-3-102-105"">CAD</span>, we determined <span class=""gene"" id=""21629682-3-121-125"">PON1</span> activity, genotypes and haplotypes in this population and correlated them with the risk of <span class=""disease"" id=""21629682-3-217-220"">CAD</span>.",CTD_human
1,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,non-small-cell lung cancer,54458,PRR13,TXR1,CTD_human,21157449,"Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer.",0.200274726784213,"Correlation of BRCA1, <span class=""gene"" id=""21157449-0-22-26"">TXR1</span> and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic <span class=""disease"" id=""21157449-0-155-181"">non-small-cell lung cancer</span>.",CTD_human
1,0,Biomarker,C0002453,Amenorrhea,phenotype,amenorrhea,5447,POR,POR,CTD_human,14758361,"We identified mutations in POR, encoding P450 oxidoreductase, the obligate electron donor for these enzymes, in a woman with amenorrhea and three children with ABS, even though knock-out of POR is embryonically lethal in mice.",0.200274726784213,"We identified mutations in <span class=""gene"" id=""14758361-2-27-30"">POR</span>, encoding P450 oxidoreductase, the obligate electron donor for these enzymes, in a woman with <span class=""disease"" id=""14758361-2-125-135"">amenorrhea</span> and three children with ABS, even though knock-out of <span class=""gene"" id=""14758361-2-190-193"">POR</span> is embryonically lethal in mice.",CTD_human
1,0,Biomarker,C0013338,Pituitary dwarfism,disease,Pituitary dwarfism,5449,POU1F1,Pit-1,CTD_human,9392392,Pituitary dwarfism in the R271W Pit-1 gene mutation.,0.201098907136852,"<span class=""disease"" id=""9392392-0-0-18"">Pituitary dwarfism</span> in the R271W <span class=""gene"" id=""9392392-0-32-37"">Pit-1</span> gene mutation.",CTD_human
1,0,Biomarker,C0038454,Cerebrovascular accident,group,stroke,54498,SMOX,SMO,CTD_human,16269634,"The results indicate that increased levels of AcPAO, SMO, and acrolein are good markers of stroke.",0.2,"The results indicate that increased levels of AcPAO, <span class=""gene"" id=""16269634-11-53-56"">SMO</span>, and acrolein are good markers of <span class=""disease"" id=""16269634-11-91-97"">stroke</span>.",CTD_human
1,1,Biomarker,C0017612,"Glaucoma, Open-Angle",disease,open angle glaucoma,54499,TMCO1,TMCO1,CTD_human,21532571,Genome-wide association study identifies susceptibility loci for open angle glaucoma at TMCO1 and CDKN2B-AS1.,0.200274726784213,"Genome-wide association study identifies susceptibility loci for <span class=""disease"" id=""21532571-0-65-84"">open angle glaucoma</span> at <span class=""gene"" id=""21532571-0-88-93"">TMCO1</span> and CDKN2B-AS1.",CTD_human
1,0,Biomarker,C3714756,Intellectual Disability,group,mental retardation,54499,TMCO1,TMCO1,CTD_human,20018682,"Homozygous frameshift mutation in TMCO1 causes a syndrome with craniofacial dysmorphism, skeletal anomalies, and mental retardation.",0.400549453568426,"Homozygous frameshift mutation in <span class=""gene"" id=""20018682-0-34-39"">TMCO1</span> causes a syndrome with craniofacial dysmorphism, skeletal anomalies, and <span class=""disease"" id=""20018682-0-113-131"">mental retardation</span>.",CTD_human;HPO
1,0,Biomarker,C0002170,Alopecia,disease,alopecia,54503,ZDHHC13,Zdhhc13,CTD_human,20548961,"Mice with alopecia, osteoporosis, and systemic amyloidosis due to mutation in Zdhhc13, a gene coding for palmitoyl acyltransferase.",0.200274726784213,"Mice with <span class=""disease"" id=""20548961-0-10-18"">alopecia</span>, osteoporosis, and systemic amyloidosis due to mutation in <span class=""gene"" id=""20548961-0-78-85"">Zdhhc13</span>, a gene coding for palmitoyl acyltransferase.",CTD_human
1,0,Biomarker,C0029456,Osteoporosis,disease,osteoporosis,54503,ZDHHC13,Zdhhc13,CTD_human,20548961,"Mice with alopecia, osteoporosis, and systemic amyloidosis due to mutation in Zdhhc13, a gene coding for palmitoyl acyltransferase.",0.2,"Mice with alopecia, <span class=""disease"" id=""20548961-0-20-32"">osteoporosis</span>, and systemic amyloidosis due to mutation in <span class=""gene"" id=""20548961-0-78-85"">Zdhhc13</span>, a gene coding for palmitoyl acyltransferase.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autistic,54538,ROBO4,ROBO4,CTD_human,18270976,"We further compared the mRNA expressions of ROBO1, ROBO2, ROBO3, and ROBO4 in the lymphocytes of 19 drug-naïve autistic patients and 20 age- and sex-matched controls.",0.202681755307501,"We further compared the mRNA expressions of ROBO1, ROBO2, ROBO3, and <span class=""gene"" id=""18270976-10-69-74"">ROBO4</span> in the lymphocytes of 19 drug-naïve <span class=""disease"" id=""18270976-10-111-119"">autistic</span> patients and 20 age- and sex-matched controls.",CTD_human
1,0,Therapeutic,C0023418,leukemia,disease,leukemia,54541,DDIT4,RTP801,CTD_human,17379067,"Taken together, our data suggest that RTP801 is an important RA-regulated gene involved in myeloid differentiation, which could represent a therapeutic target in leukemia.",0.200274726784213,"Taken together, our data suggest that <span class=""gene"" id=""17379067-10-38-44"">RTP801</span> is an important RA-regulated gene involved in myeloid differentiation, which could represent a therapeutic target in <span class=""disease"" id=""17379067-10-162-170"">leukemia</span>.",CTD_human
1,0,Therapeutic,C0030567,Parkinson Disease,disease,Parkinson's disease,54541,DDIT4,RTP801,CTD_human,17005863,RTP801 is elevated in Parkinson brain substantia nigral neurons and mediates death in cellular models of Parkinson's disease by a mechanism involving mammalian target of rapamycin inactivation.,0.201098907136852,"<span class=""gene"" id=""17005863-0-0-6"">RTP801</span> is elevated in Parkinson brain substantia nigral neurons and mediates death in cellular models of <span class=""disease"" id=""17005863-0-105-124"">Parkinson's disease</span> by a mechanism involving mammalian target of rapamycin inactivation.",CTD_human
1,0,Biomarker,C0029408,Degenerative polyarthritis,disease,OA,5455,POU3F3,POU3F3,CTD_human,17568789,"HOXD10, HOXD11, HOXD13, CCL8 and LIM homeobox 2 were highly and exclusively expressed in RA and CLU, sarcoglycan-gamma, GPR64, POU3F3, peroxisome proliferative activated receptor-gamma and tripartite motif-containing 2 were expressed only in OA.",0.2,"HOXD10, HOXD11, HOXD13, CCL8 and LIM homeobox 2 were highly and exclusively expressed in RA and CLU, sarcoglycan-gamma, GPR64, <span class=""gene"" id=""17568789-4-127-133"">POU3F3</span>, peroxisome proliferative activated receptor-gamma and tripartite motif-containing 2 were expressed only in <span class=""disease"" id=""17568789-4-242-244"">OA</span>.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,54551,MAGEL2,MAGEL2,CTD_human,24076603,Truncating mutations of MAGEL2 cause Prader-Willi phenotypes and autism.,0.20054945356842604,"Truncating mutations of <span class=""gene"" id=""24076603-0-24-30"">MAGEL2</span> cause Prader-Willi phenotypes and <span class=""disease"" id=""24076603-0-65-71"">autism</span>.",CTD_human
1,0,Biomarker,C0032897,Prader-Willi Syndrome,disease,PWS,54551,MAGEL2,MAGEL2,CTD_human,24076603,These findings suggest that MAGEL2 is a new gene causing complex ASD and that MAGEL2 loss of function can contribute to several aspects of the PWS phenotype.,0.283021994626344,"These findings suggest that <span class=""gene"" id=""24076603-6-28-34"">MAGEL2</span> is a new gene causing complex ASD and that <span class=""gene"" id=""24076603-6-78-84"">MAGEL2</span> loss of function can contribute to several aspects of the <span class=""disease"" id=""24076603-6-143-146"">PWS</span> phenotype.",CTD_human
1,0,Biomarker,C0206708,Cervical Intraepithelial Neoplasia,disease,CIN,5457,POU4F1,Brn-3a,CTD_human,20190800,"Therefore, this study defines the specific interplay between the cellular transactivator Brn-3a, the environmental smoking-related substance nicotine and specific HPV variants in cervical carcinogenesis, and thus helps to explain why some women are susceptible to rapid CIN progression and cancer and others are not.",0.200274726784213,"Therefore, this study defines the specific interplay between the cellular transactivator <span class=""gene"" id=""20190800-7-89-95"">Brn-3a</span>, the environmental smoking-related substance nicotine and specific HPV variants in cervical carcinogenesis, and thus helps to explain why some women are susceptible to rapid <span class=""disease"" id=""20190800-7-270-273"">CIN</span> progression and cancer and others are not.",CTD_human
1,0,Biomarker,C0010417,Cryptorchidism,disease,cryptorchidism,546,ATRX,ATRX,CTD_human,19291773,"Detailed comparison of the clinical characteristics and the function of the genes located in the commonly duplicated regions of these patients led us to the hypothesis that an increased dosage of ATRX and perhaps of other genes is involved in the pathogenetic mechanism of this XLMR phenotype, including mental retardation, short stature, and genital abnormalities comprising cryptorchidism and/or a small penis.",0.40027472678421294,"Detailed comparison of the clinical characteristics and the function of the genes located in the commonly duplicated regions of these patients led us to the hypothesis that an increased dosage of <span class=""gene"" id=""19291773-4-196-200"">ATRX</span> and perhaps of other genes is involved in the pathogenetic mechanism of this XLMR phenotype, including mental retardation, short stature, and genital abnormalities comprising <span class=""disease"" id=""19291773-4-376-390"">cryptorchidism</span> and/or a small penis.",CTD_human;HPO
1,0,Biomarker,C0206754,Neuroendocrine Tumors,group,neuroendocrine tumors,546,ATRX,ATRX,CTD_human,21252315,"DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors.",0.201373633921065,"DAXX/<span class=""gene"" id=""21252315-0-5-9"">ATRX</span>, MEN1, and mTOR pathway genes are frequently altered in pancreatic <span class=""disease"" id=""21252315-0-77-98"">neuroendocrine tumors</span>.",CTD_human
1,0,Biomarker,C1136249,"Mental Retardation, X-Linked",disease,XLMR,546,ATRX,ATRX,CTD_human,19291773,"Detailed comparison of the clinical characteristics and the function of the genes located in the commonly duplicated regions of these patients led us to the hypothesis that an increased dosage of ATRX and perhaps of other genes is involved in the pathogenetic mechanism of this XLMR phenotype, including mental retardation, short stature, and genital abnormalities comprising cryptorchidism and/or a small penis.",0.20412090176319603,"Detailed comparison of the clinical characteristics and the function of the genes located in the commonly duplicated regions of these patients led us to the hypothesis that an increased dosage of <span class=""gene"" id=""19291773-4-196-200"">ATRX</span> and perhaps of other genes is involved in the pathogenetic mechanism of this <span class=""disease"" id=""19291773-4-278-282"">XLMR</span> phenotype, including mental retardation, short stature, and genital abnormalities comprising cryptorchidism and/or a small penis.",CTD_human
1,0,Biomarker,C3463824,MYELODYSPLASTIC SYNDROME,group,myelodysplastic syndromes,546,ATRX,ATRX,CTD_human,19157545,Assessment of ATRX expression in patients with myelodysplastic syndromes treated with decitabine.,0.407114185634906,"Assessment of <span class=""gene"" id=""19157545-0-14-18"">ATRX</span> expression in patients with <span class=""disease"" id=""19157545-0-47-72"">myelodysplastic syndromes</span> treated with decitabine.",CTD_human;HPO
1,0,Biomarker,C0018798,Congenital Heart Defects,group,heart malformations,5460,POU5F1,POU5F1,CTD_human,26507003,These findings indicate for the first time that low-frequency functional variant in POU5F1 may contribute to the risk of congenital heart malformations.,0.200274726784213,"These findings indicate for the first time that low-frequency functional variant in <span class=""gene"" id=""26507003-8-84-90"">POU5F1</span> may contribute to the risk of congenital <span class=""disease"" id=""26507003-8-132-151"">heart malformations</span>.",CTD_human
1,0,Biomarker,C2931618,Gestational trophoblastic disease,disease,gestational trophoblastic disease,5460,POU5F1,Oct4,CTD_human,18440631,Oct4 is epigenetically regulated by methylation in normal placenta and gestational trophoblastic disease.,0.200274726784213,"<span class=""gene"" id=""18440631-0-0-4"">Oct4</span> is epigenetically regulated by methylation in normal placenta and <span class=""disease"" id=""18440631-0-71-104"">gestational trophoblastic disease</span>.",CTD_human
1,0,Biomarker,C0011615,"Dermatitis, Atopic",disease,atopic dermatitis,5465,PPARA,Peroxisome proliferator-activated receptor alpha,CTD_human,18249437,Peroxisome proliferator-activated receptor alpha regulates skin inflammation and humoral response in atopic dermatitis.,0.20383181960166602,"<span class=""gene"" id=""18249437-0-0-48"">Peroxisome proliferator-activated receptor alpha</span> regulates skin inflammation and humoral response in <span class=""disease"" id=""18249437-0-101-118"">atopic dermatitis</span>.",CTD_human
1,0,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,NIDDM,5465,PPARA,peroxisome proliferator-activated receptor-alpha,CTD_human,17317762,Single nucleotide polymorphisms of the peroxisome proliferator-activated receptor-alpha gene (PPARA) influence the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial.,0.23620942089556896,"Single nucleotide polymorphisms of the <span class=""gene"" id=""17317762-0-39-87"">peroxisome proliferator-activated receptor-alpha</span> gene (PPARA) influence the conversion from impaired glucose tolerance to <span class=""disease"" id=""17317762-0-161-176"">type 2 diabetes</span>: the STOP-<span class=""disease"" id=""17317762-0-187-192"">NIDDM</span> trial.",CTD_human
1,0,Therapeutic,C0020473,Hyperlipidemia,disease,lipidemia,5465,PPARA,PPAR?,CTD_human,21640707,Activation of peroxisome proliferator-activated receptor-? (PPAR?) suppresses postprandial lipidemia through fatty acid oxidation in enterocytes.,0.204604842796993,"Activation of <span class=""gene"" id=""21640707-0-14-58"">peroxisome proliferator-activated receptor-&alpha;</span> (<span class=""gene"" id=""21640707-0-60-65"">PPAR&alpha;</span>) suppresses postprandial <span class=""disease"" id=""21640707-0-91-100"">lipidemia</span> through fatty acid oxidation in enterocytes.",CTD_human
2,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,5465,PPARA,peroxisome proliferator-activated receptor-alpha,CTD_human,19834340,Effect of peroxisome proliferator-activated receptor-alpha siRNA on hypertension and renal injury in the rat following nitric oxide withdrawal and high salt diet.,0.21318520691060502,"Effect of <span class=""gene"" id=""19834340-0-10-58"">peroxisome proliferator-activated receptor-alpha</span> siRNA on <span class=""disease"" id=""19834340-0-68-80"">hypertension</span> and renal injury in the rat following nitric oxide withdrawal and high salt diet.",CTD_human
2,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,5465,PPARA,peroxisome proliferator-activated receptor-alpha,CTD_human,19834340,Effect of peroxisome proliferator-activated receptor-alpha siRNA on hypertension and renal injury in the rat following nitric oxide withdrawal and high salt diet.,0.21318520691060502,"Effect of <span class=""gene"" id=""19834340-0-10-58"">peroxisome proliferator-activated receptor-alpha</span> siRNA on <span class=""disease"" id=""19834340-0-68-80"">hypertension</span> and renal injury in the rat following nitric oxide withdrawal and high salt diet.",CTD_human
2,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,5465,PPARA,PPARalpha,CTD_human,16054168,"Thus, apart from inhibition of ET-1 production, PPARalpha activation exerts protective actions in hypertension via a mechanism that involves NO production and/or inhibition of NAD(P)H oxidase activity.",0.21318520691060502,"Thus, apart from inhibition of ET-1 production, <span class=""gene"" id=""16054168-11-48-57"">PPARalpha</span> activation exerts protective actions in <span class=""disease"" id=""16054168-11-98-110"">hypertension</span> via a mechanism that involves NO production and/or inhibition of NAD(P)H oxidase activity.",CTD_human
2,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,5465,PPARA,PPARalpha,CTD_human,16054168,"Thus, apart from inhibition of ET-1 production, PPARalpha activation exerts protective actions in hypertension via a mechanism that involves NO production and/or inhibition of NAD(P)H oxidase activity.",0.21318520691060502,"Thus, apart from inhibition of ET-1 production, <span class=""gene"" id=""16054168-11-48-57"">PPARalpha</span> activation exerts protective actions in <span class=""disease"" id=""16054168-11-98-110"">hypertension</span> via a mechanism that involves NO production and/or inhibition of NAD(P)H oxidase activity.",CTD_human
1,0,Biomarker,C0020615,Hypoglycemia,disease,hypoglycemia,5465,PPARA,PPARalpha,CTD_human,16777972,Here we compared PPARalpha knockout mice with wild type and confirmed that the former developed hypoglycemia during fasting.,0.2,"Here we compared <span class=""gene"" id=""16777972-2-17-26"">PPARalpha</span> knockout mice with wild type and confirmed that the former developed <span class=""disease"" id=""16777972-2-96-108"">hypoglycemia</span> during fasting.",CTD_human
1,0,Biomarker,C0026848,Myopathy,group,myopathy,5465,PPARA,PPARalpha,CTD_human,19683050,This study was designed to investigate the effects of bezafibrate as a PPARalpha agonist on human embryo rhabdomyosarcoma (RD) cells and possible mechanisms responsible for bezafibrate-mediated myopathy.,0.200274726784213,"This study was designed to investigate the effects of bezafibrate as a <span class=""gene"" id=""19683050-3-71-80"">PPARalpha</span> agonist on human embryo rhabdomyosarcoma (RD) cells and possible mechanisms responsible for bezafibrate-mediated <span class=""disease"" id=""19683050-3-194-202"">myopathy</span>.",CTD_human
1,0,Biomarker,C0400966,Non-alcoholic Fatty Liver Disease,disease,NAFLD,5465,PPARA,PPAR?,CTD_human,23603006,Amelioration by chicory seed extract of diabetes- and oleic acid-induced non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) via modulation of PPAR? and SREBP-1.,0.20494508211583604,"Amelioration by chicory seed extract of diabetes- and oleic acid-induced <span class=""disease"" id=""23603006-0-73-106"">non-alcoholic fatty liver disease</span> (<span class=""disease"" id=""23603006-0-108-113"">NAFLD</span>)/non-alcoholic steatohepatitis (NASH) via modulation of <span class=""gene"" id=""23603006-0-170-175"">PPAR&alpha;</span> and SREBP-1.",CTD_human
8,10,Biomarker,C0017551,Gilbert Disease (disorder),disease,Gilbert's syndrome,54658,UGT1A1,UGT1A1,CTD_human,10421657,"Of the 4 patients with the lowest UGT1A1 levels, 3 were homozygotes for the UGT1A1 promoter variant sequence associated with Gilbert's syndrome, and the fourth was a heterozygote.",0.47320622036378207,"Of the 4 patients with the lowest <span class=""gene"" id=""10421657-6-34-40"">UGT1A1</span> levels, 3 were homozygotes for the <span class=""gene"" id=""10421657-6-76-82"">UGT1A1</span> promoter variant sequence associated with <span class=""disease"" id=""10421657-6-125-143"">Gilbert's syndrome</span>, and the fourth was a heterozygote.",CTD_human;UNIPROT
8,10,Biomarker,C0017551,Gilbert Disease (disorder),disease,GS,54658,UGT1A1,UGT1A1,CTD_human,15180166,Patients with GS might be more susceptible to unexpected side effects while taking acetaminophen and other drugs which are substrates of UGT1A1.,0.47320622036378207,"Patients with <span class=""disease"" id=""15180166-4-14-16"">GS</span> might be more susceptible to unexpected side effects while taking acetaminophen and other drugs which are substrates of <span class=""gene"" id=""15180166-4-137-143"">UGT1A1</span>.",CTD_human;UNIPROT
1,0,Biomarker,C0019829,Hodgkin Disease,disease,Hodgkin lymphomas,54658,UGT1A1,UGT1A1,CTD_human,18768784,Pharmacogenetic study in Hodgkin lymphomas reveals the impact of UGT1A1 polymorphisms on patient prognosis.,0.203231208875927,"Pharmacogenetic study in <span class=""disease"" id=""18768784-0-25-42"">Hodgkin lymphomas</span> reveals the impact of <span class=""gene"" id=""18768784-0-65-71"">UGT1A1</span> polymorphisms on patient prognosis.",CTD_human
5,7,Biomarker,C0020433,Hyperbilirubinemia,disease,hyperbilirubinemia,54658,UGT1A1,UGT1A1,CTD_human,23950218,Human infants physiologically develop hyperbilirubinemia as the result of inadequate expression of UGT1A1 in the liver.,0.304641891397799,"Human infants physiologically develop <span class=""disease"" id=""23950218-2-38-56"">hyperbilirubinemia</span> as the result of inadequate expression of <span class=""gene"" id=""23950218-2-99-105"">UGT1A1</span> in the liver.",CTD_human
5,7,Biomarker,C0020433,Hyperbilirubinemia,disease,hyperbilirubinemia,54658,UGT1A1,UGT1A1,CTD_human,27060662,Cadmium and arsenic override NF-?B developmental regulation of the intestinal UGT1A1 gene and control of hyperbilirubinemia.,0.304641891397799,"Cadmium and arsenic override NF-&kappa;B developmental regulation of the intestinal <span class=""gene"" id=""27060662-0-78-84"">UGT1A1</span> gene and control of <span class=""disease"" id=""27060662-0-105-123"">hyperbilirubinemia</span>.",CTD_human
5,7,Biomarker,C0020433,Hyperbilirubinemia,disease,hyperbilirubinemia,54658,UGT1A1,UGT1,CTD_human,21983082,Reduced expression of UGT1A1 in intestines of humanized UGT1 mice via inactivation of NF-?B leads to hyperbilirubinemia.,0.304641891397799,"Reduced expression of <span class=""gene"" id=""21983082-0-22-28"">UGT1A1</span> in intestines of humanized <span class=""gene"" id=""21983082-0-56-60"">UGT1</span> mice via inactivation of NF-&kappa;B leads to <span class=""disease"" id=""21983082-0-101-119"">hyperbilirubinemia</span>.",CTD_human
5,7,Biomarker,C0020433,Hyperbilirubinemia,disease,hyperbilirubinemia,54658,UGT1A1,UGT1,CTD_human,20194756,Developmental hyperbilirubinemia and CNS toxicity in mice humanized with the UDP glucuronosyltransferase 1 (UGT1) locus.,0.304641891397799,"Developmental <span class=""disease"" id=""20194756-0-14-32"">hyperbilirubinemia</span> and CNS toxicity in mice humanized with the UDP glucuronosyltransferase 1 (<span class=""gene"" id=""20194756-0-108-112"">UGT1</span>) locus.",CTD_human
1,0,Biomarker,C0027947,Neutropenia,disease,neutropenia,54658,UGT1A1,UGT1A1,CTD_human,17549067,Risk for Grade III-IV neutropenia was significantly associated with UGT1A1*28 7/7 genotype.,0.23065105140830103,"Risk for Grade III-IV <span class=""disease"" id=""17549067-5-22-33"">neutropenia</span> was significantly associated with <span class=""gene"" id=""17549067-5-68-74"">UGT1A1</span>*28 7/7 genotype.",CTD_human
2,0,Therapeutic,C0028754,Obesity,disease,obesity,5467,PPARD,peroxisome proliferator-activated receptor-delta,CTD_human,20176998,Telmisartan prevents weight gain and obesity through activation of peroxisome proliferator-activated receptor-delta-dependent pathways.,0.21484792299320102,"Telmisartan prevents weight gain and <span class=""disease"" id=""20176998-0-37-44"">obesity</span> through activation of <span class=""gene"" id=""20176998-0-67-115"">peroxisome proliferator-activated receptor-delta</span>-dependent pathways.",CTD_human
1,0,Biomarker,C1510586,Autism Spectrum Disorders,disease,ASD,54674,LRRN3,LRRN3,CTD_human,20678249,"Overall, our findings implicate the neuronal leucine-rich genes LRRN3 and LRRTM3 in ASD susceptibility.",0.2,"Overall, our findings implicate the neuronal leucine-rich genes <span class=""gene"" id=""20678249-8-64-69"">LRRN3</span> and LRRTM3 in <span class=""disease"" id=""20678249-8-84-87"">ASD</span> susceptibility.",CTD_human
1,0,Biomarker,C0001418,Adenocarcinoma,group,adenocarcinomas,5468,PPARG,PPARgamma,CTD_human,11034103,Immunohistochemical study of resected human pancreata using a polyclonal PPARgamma antibody revealed that PPARgamma protein expression in the nuclei of carcinoma cells was observed in 9 of 10 pancreatic adenocarcinomas.,0.218115933649124,"Immunohistochemical study of resected human pancreata using a polyclonal <span class=""gene"" id=""11034103-2-73-82"">PPARgamma</span> antibody revealed that <span class=""gene"" id=""11034103-2-106-115"">PPARgamma</span> protein expression in the nuclei of carcinoma cells was observed in 9 of 10 pancreatic <span class=""disease"" id=""11034103-2-203-218"">adenocarcinomas</span>.",CTD_human
2,0,Biomarker,C0002395,Alzheimer's Disease,disease,AD,5468,PPARG,PPARgamma,CTD_human,16407166,Our data strongly support a major role of PPARgamma in the modulation of amyloid-beta generation by inflammation and suggest that the protective mechanism of NSAIDs in AD involves activation of PPARgamma and decreased BACE1 gene transcription.,0.225193317504034,"Our data strongly support a major role of <span class=""gene"" id=""16407166-11-42-51"">PPARgamma</span> in the modulation of amyloid-beta generation by inflammation and suggest that the protective mechanism of NSAIDs in <span class=""disease"" id=""16407166-11-168-170"">AD</span> involves activation of <span class=""gene"" id=""16407166-11-194-203"">PPARgamma</span> and decreased BACE1 gene transcription.",CTD_human
2,0,Biomarker,C0002395,Alzheimer's Disease,disease,Alzheimer's disease,5468,PPARG,PPARgamma,CTD_human,15993441,"These findings demonstrate that PPARgamma agonists attenuate the effects of Abeta on LTP, and support the potential use of these agents to alleviate the symptoms of Alzheimer's disease.",0.225193317504034,"These findings demonstrate that <span class=""gene"" id=""15993441-9-32-41"">PPARgamma</span> agonists attenuate the effects of Abeta on LTP, and support the potential use of these agents to alleviate the symptoms of <span class=""disease"" id=""15993441-9-165-184"">Alzheimer's disease</span>.",CTD_human
1,0,Biomarker,C0004763,Barrett Esophagus,disease,Barrett's esophagus,5468,PPARG,PPARgamma,CTD_human,15387324,"Activation of NFkappaB represents the central event in the neoplastic progression associated with Barrett's esophagus: a possible link to the inflammation and overexpression of COX-2, PPARgamma and growth factors.",0.200274726784213,"Activation of NFkappaB represents the central event in the neoplastic progression associated with <span class=""disease"" id=""15387324-0-98-117"">Barrett's esophagus</span>: a possible link to the inflammation and overexpression of COX-2, <span class=""gene"" id=""15387324-0-184-193"">PPARgamma</span> and growth factors.",CTD_human
1,0,Biomarker,C0010346,Crohn Disease,disease,Crohn's disease,5468,PPARG,PPAR?,CTD_human,21829567,"Mesenteric adipose tissue from rodent colitis and Crohn's disease is metabolically active and shows inflammation-driven regulation of PPAR?, FXR and leptin.",0.207561324888707,"Mesenteric adipose tissue from rodent colitis and <span class=""disease"" id=""21829567-11-50-65"">Crohn's disease</span> is metabolically active and shows inflammation-driven regulation of <span class=""gene"" id=""21829567-11-134-139"">PPAR&gamma;</span>, FXR and leptin.",CTD_human
5,1,Therapeutic,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,type 2 diabetes,5468,PPARG,PPARG,CTD_human,16249460,Our results suggest that PPARG variation may underlie response to TZD therapy in women at risk for type 2 diabetes.,0.35735811012955604,"Our results suggest that <span class=""gene"" id=""16249460-12-25-30"">PPARG</span> variation may underlie response to TZD therapy in women at risk for <span class=""disease"" id=""16249460-12-99-114"">type 2 diabetes</span>.",CTD_human
5,1,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,type 2 diabetes,5468,PPARG,PPARG,CTD_human,16249460,Our results suggest that PPARG variation may underlie response to TZD therapy in women at risk for type 2 diabetes.,0.35735811012955604,"Our results suggest that <span class=""gene"" id=""16249460-12-25-30"">PPARG</span> variation may underlie response to TZD therapy in women at risk for <span class=""disease"" id=""16249460-12-99-114"">type 2 diabetes</span>.",CTD_human
3,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,5468,PPARG,PPAR-gamma,CTD_human,19666838,Our findings suggest that PPAR-gamma may be a key regulator of blood-brain barrier permeability and a potential therapeutic target during hypertension.,0.540972861411829,"Our findings suggest that <span class=""gene"" id=""19666838-8-26-36"">PPAR-gamma</span> may be a key regulator of blood-brain barrier permeability and a potential therapeutic target during <span class=""disease"" id=""19666838-8-138-150"">hypertension</span>.",CTD_human;HPO
3,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,5468,PPARG,peroxisome proliferator-activated receptor gamma,CTD_human,15199296,Three individuals with loss-of-function mutations of peroxisome proliferator-activated receptor gamma developed early hypertension.,0.540972861411829,"Three individuals with loss-of-function mutations of <span class=""gene"" id=""15199296-11-53-101"">peroxisome proliferator-activated receptor gamma</span> developed early <span class=""disease"" id=""15199296-11-118-130"">hypertension</span>.",CTD_human;HPO
3,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,5468,PPARG,PPAR-?,CTD_human,27292124,TLR4/MyD88/NF-?B signaling and PPAR-? within the paraventricular nucleus are involved in the effects of telmisartan in hypertension.,0.540972861411829,"TLR4/MyD88/NF-&kappa;B signaling and <span class=""gene"" id=""27292124-0-31-37"">PPAR-&gamma;</span> within the paraventricular nucleus are involved in the effects of telmisartan in <span class=""disease"" id=""27292124-0-119-131"">hypertension</span>.",CTD_human;HPO
3,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,5468,PPARG,peroxisome proliferator-activated receptor gamma,CTD_human,15199296,Three individuals with loss-of-function mutations of peroxisome proliferator-activated receptor gamma developed early hypertension.,0.540972861411829,"Three individuals with loss-of-function mutations of <span class=""gene"" id=""15199296-11-53-101"">peroxisome proliferator-activated receptor gamma</span> developed early <span class=""disease"" id=""15199296-11-118-130"">hypertension</span>.",CTD_human;HPO
3,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,5468,PPARG,PPAR-?,CTD_human,27292124,TLR4/MyD88/NF-?B signaling and PPAR-? within the paraventricular nucleus are involved in the effects of telmisartan in hypertension.,0.540972861411829,"TLR4/MyD88/NF-&kappa;B signaling and <span class=""gene"" id=""27292124-0-31-37"">PPAR-&gamma;</span> within the paraventricular nucleus are involved in the effects of telmisartan in <span class=""disease"" id=""27292124-0-119-131"">hypertension</span>.",CTD_human;HPO
3,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,5468,PPARG,PPAR-gamma,CTD_human,19666838,Our findings suggest that PPAR-gamma may be a key regulator of blood-brain barrier permeability and a potential therapeutic target during hypertension.,0.540972861411829,"Our findings suggest that <span class=""gene"" id=""19666838-8-26-36"">PPAR-gamma</span> may be a key regulator of blood-brain barrier permeability and a potential therapeutic target during <span class=""disease"" id=""19666838-8-138-150"">hypertension</span>.",CTD_human;HPO
1,0,Biomarker,C0025202,melanoma,disease,melanoma,5468,PPARG,PPARgamma,CTD_human,14512786,The effect of PPARgamma ligands on the proliferation and apoptosis of human melanoma cells.,0.20924648737398102,"The effect of <span class=""gene"" id=""14512786-0-14-23"">PPARgamma</span> ligands on the proliferation and apoptosis of human <span class=""disease"" id=""14512786-0-76-84"">melanoma</span> cells.",CTD_human
1,0,Biomarker,C0029408,Degenerative polyarthritis,disease,OA,5468,PPARG,peroxisome proliferative activated receptor-gamma,CTD_human,17568789,"HOXD10, HOXD11, HOXD13, CCL8 and LIM homeobox 2 were highly and exclusively expressed in RA and CLU, sarcoglycan-gamma, GPR64, POU3F3, peroxisome proliferative activated receptor-gamma and tripartite motif-containing 2 were expressed only in OA.",0.203021994626344,"HOXD10, HOXD11, HOXD13, CCL8 and LIM homeobox 2 were highly and exclusively expressed in RA and CLU, sarcoglycan-gamma, GPR64, POU3F3, <span class=""gene"" id=""17568789-4-135-184"">peroxisome proliferative activated receptor-gamma</span> and tripartite motif-containing 2 were expressed only in <span class=""disease"" id=""17568789-4-242-244"">OA</span>.",CTD_human
1,0,Therapeutic,C0033860,Psoriasis,disease,psoriasis,5468,PPARG,peroxisome proliferator-activated receptor-gamma,CTD_human,10815854,Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation.,0.20328236603324,"Troglitazone improves <span class=""disease"" id=""10815854-0-22-31"">psoriasis</span> and normalizes models of proliferative skin disease: ligands for <span class=""gene"" id=""10815854-0-97-145"">peroxisome proliferator-activated receptor-gamma</span> inhibit keratinocyte proliferation.",CTD_human
1,0,Biomarker,C0079772,T-Cell Lymphoma,disease,T-cell lymphoma,5468,PPARG,PPARgamma,CTD_human,17255338,"In this report, we show that PPARgamma is expressed in human primary T-cell lymphoma tissues and activation of PPARgamma with low doses of ligands protects lymphoma cells from serum starvation-induced apoptosis.",0.2,"In this report, we show that <span class=""gene"" id=""17255338-5-29-38"">PPARgamma</span> is expressed in human primary <span class=""disease"" id=""17255338-5-69-84"">T-cell lymphoma</span> tissues and activation of <span class=""gene"" id=""17255338-5-111-120"">PPARgamma</span> with low doses of ligands protects lymphoma cells from serum starvation-induced apoptosis.",CTD_human
1,0,Biomarker,C0085413,"Polycystic Kidney, Autosomal Dominant",disease,ADPKD,5468,PPARG,PPARgamma,CTD_human,20210794,These results suggest PPARgamma agonist might serve as a promising drug for the treatment of ADPKD.,0.200274726784213,"These results suggest <span class=""gene"" id=""20210794-10-22-31"">PPARgamma</span> agonist might serve as a promising drug for the treatment of <span class=""disease"" id=""20210794-10-93-98"">ADPKD</span>.",CTD_human
1,1,Biomarker,C0271694,Familial partial lipodystrophy,disease,familial partial lipodystrophy,5468,PPARG,PPARG,CTD_human,19793595,"Sequencing of candidate genes LMNA, PPARG, AKT2, caveolin-1, as well as the PPARG4 promoter gene, which are known to be associated with familial partial lipodystrophy, revealed no genetic abnormalities, suggesting that this case may involve a novel gene.",0.206029633875371,"Sequencing of candidate genes LMNA, <span class=""gene"" id=""19793595-4-36-41"">PPARG</span>, AKT2, caveolin-1, as well as the PPARG4 promoter gene, which are known to be associated with <span class=""disease"" id=""19793595-4-136-166"">familial partial lipodystrophy</span>, revealed no genetic abnormalities, suggesting that this case may involve a novel gene.",CTD_human
1,0,Therapeutic,C0282548,Leukostasis,disease,leukostasis,5468,PPARG,PPAR-gamma,CTD_human,12468449,"As a consequence of PPAR-gamma activation, pulmonary leukostasis was decreased and oxygenation and overall survival were improved.",0.20054945356842604,"As a consequence of <span class=""gene"" id=""12468449-7-20-30"">PPAR-gamma</span> activation, pulmonary <span class=""disease"" id=""12468449-7-53-64"">leukostasis</span> was decreased and oxygenation and overall survival were improved.",CTD_human
1,0,Therapeutic,C2239176,Liver carcinoma,disease,HCC,5468,PPARG,PPARgamma,CTD_human,16374840,"In conclusion, collectively, these results indicate that PPARgamma could be a regulator of cell survival and growth in HCC.",0.205494535684262,"In conclusion, collectively, these results indicate that <span class=""gene"" id=""16374840-13-57-66"">PPARgamma</span> could be a regulator of cell survival and growth in <span class=""disease"" id=""16374840-13-119-122"">HCC</span>.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,5469,MED1,MED1,CTD_human,20007298,These results indicate that PBP/MED1 is essential for the development of HCC in the mouse.,0.2,"These results indicate that PBP/<span class=""gene"" id=""20007298-13-32-36"">MED1</span> is essential for the development of <span class=""disease"" id=""20007298-13-73-76"">HCC</span> in the mouse.",CTD_human
1,0,Biomarker,C0011849,Diabetes Mellitus,group,Diabetes,547,KIF1A,KIF1A,CTD_human,23776493,Diabetes alters KIF1A and KIF5B motor proteins in the hippocampus.,0.2,"<span class=""disease"" id=""23776493-0-0-8"">Diabetes</span> alters <span class=""gene"" id=""23776493-0-16-21"">KIF1A</span> and KIF5B motor proteins in the hippocampus.",CTD_human
2,0,Biomarker,C0004352,Autistic Disorder,disease,autism,54715,RBFOX1,FOX1,CTD_human,17503474,Cytogenetic and molecular characterization of A2BP1/FOX1 as a candidate gene for autism.,0.202197814273705,"Cytogenetic and molecular characterization of A2BP1/<span class=""gene"" id=""17503474-0-52-56"">FOX1</span> as a candidate gene for <span class=""disease"" id=""17503474-0-81-87"">autism</span>.",CTD_human
1,0,Biomarker,C0036572,Seizures,phenotype,seizures,54715,RBFOX1,Rbfox1,CTD_human,21623373,"Thus, Rbfox1 directs a genetic program required in the prevention of neuronal hyperexcitation and seizures.",0.20054945356842604,"Thus, <span class=""gene"" id=""21623373-6-6-12"">Rbfox1</span> directs a genetic program required in the prevention of neuronal hyperexcitation and <span class=""disease"" id=""21623373-6-98-106"">seizures</span>.",CTD_human
1,0,Biomarker,C0268654,Iminoglycinuria,disease,iminoglycinuria,54716,SLC6A20,SLC6A20,CTD_human,21572414,"Variants at three of these loci have previously been linked with important clinical outcomes: SLC7A9 is a risk locus for chronic kidney disease, NAT2 for coronary artery disease and genotype-dependent response to drug toxicity, and SLC6A20 for iminoglycinuria.",0.4,"Variants at three of these loci have previously been linked with important clinical outcomes: SLC7A9 is a risk locus for chronic kidney disease, NAT2 for coronary artery disease and genotype-dependent response to drug toxicity, and <span class=""gene"" id=""21572414-5-232-239"">SLC6A20</span> for <span class=""disease"" id=""21572414-5-244-259"">iminoglycinuria</span>.",CTD_human;ORPHANET
2,0,Biomarker,C0020255,Hydrocephalus,disease,hydrocephalus,54768,HYDIN,HYDIN,CTD_human,19029900,"Notably, a paralog of the HYDIN gene located on 16q22.2 and implicated in autosomal recessive hydrocephalus was inserted into the 1q21.1 region during the evolution of Homo sapiens; we found this locus to be deleted or duplicated in the individuals we studied, making it a probable candidate for the head size abnormalities observed.",0.20082418035263896,"Notably, a paralog of the <span class=""gene"" id=""19029900-5-26-31"">HYDIN</span> gene located on 16q22.2 and implicated in autosomal recessive <span class=""disease"" id=""19029900-5-94-107"">hydrocephalus</span> was inserted into the 1q21.1 region during the evolution of Homo sapiens; we found this locus to be deleted or duplicated in the individuals we studied, making it a probable candidate for the head size abnormalities observed.",CTD_human
1,0,Biomarker,C0007137,Squamous cell carcinoma,disease,SCC,5478,PPIA,cyclophilin A,CTD_human,15274141,"At least, SCC antigen, G protein, glutathione S-transferase, manganese superoxide dismutase, annexins, voltage-dependent anion channel, cyclophilin A, stratifin and galectin 7 are candidates for targeted proteins.",0.2,"At least, <span class=""disease"" id=""15274141-8-10-13"">SCC</span> antigen, G protein, glutathione S-transferase, manganese superoxide dismutase, annexins, voltage-dependent anion channel, <span class=""gene"" id=""15274141-8-136-149"">cyclophilin A</span>, stratifin and galectin 7 are candidates for targeted proteins.",CTD_human
1,0,Biomarker,C0020981,Angioimmunoblastic Lymphadenopathy,disease,AITL,54790,TET2,TET2,CTD_human,24413737,Our findings suggest that impaired RHOA function in cooperation with preceding loss of TET2 function contributes to AITL-specific pathogenesis.,0.201373633921065,"Our findings suggest that impaired RHOA function in cooperation with preceding loss of <span class=""gene"" id=""24413737-8-87-91"">TET2</span> function contributes to <span class=""disease"" id=""24413737-8-116-120"">AITL</span>-specific pathogenesis.",CTD_human
2,0,Biomarker,C0079774,Peripheral T-Cell Lymphoma,disease,PTCL,54790,TET2,TET2,CTD_human,24413734,"These analyses identified highly recurrent epigenetic factor mutations in TET2, DNMT3A and IDH2 as well as a new highly prevalent RHOA mutation encoding a p.Gly17Val alteration present in 22 of 35 (67%) angioimmunoblastic T cell lymphoma (AITL) samples and in 8 of 44 (18%) PTCL, not otherwise specified (PTCL-NOS) samples.",0.20054945356842604,"These analyses identified highly recurrent epigenetic factor mutations in <span class=""gene"" id=""24413734-3-74-78"">TET2</span>, DNMT3A and IDH2 as well as a new highly prevalent RHOA mutation encoding a p.Gly17Val alteration present in 22 of 35 (67%) angioimmunoblastic T cell lymphoma (AITL) samples and in 8 of 44 (18%) <span class=""disease"" id=""24413734-3-274-278"">PTCL</span>, not otherwise specified (<span class=""disease"" id=""24413734-3-305-309"">PTCL</span>-NOS) samples.",CTD_human
1,0,Biomarker,C3463824,MYELODYSPLASTIC SYNDROME,group,myelodysplastic syndromes,54790,TET2,TET2,CTD_human,19483684,Acquired mutations in TET2 are common in myelodysplastic syndromes.,0.43566164605876706,"Acquired mutations in <span class=""gene"" id=""19483684-0-22-26"">TET2</span> are common in <span class=""disease"" id=""19483684-0-41-66"">myelodysplastic syndromes</span>.",CTD_human;HPO
1,0,Biomarker,C0376634,Craniofacial Abnormalities,group,craniofacial abnormalities,54796,BNC2,basonuclin 2,CTD_human,19706529,We also note the possibility that some human craniofacial abnormalities are due to a lack of basonuclin 2.,0.2,"We also note the possibility that some human <span class=""disease"" id=""19706529-11-45-71"">craniofacial abnormalities</span> are due to a lack of <span class=""gene"" id=""19706529-11-93-105"">basonuclin 2</span>.",CTD_human
1,0,Biomarker,C0036572,Seizures,phenotype,seizures,54805,CNNM2,CNNM2,CTD_human,23027747,"Interestingly, mutations in the CNNM2 gene cause familial dominant hypomagnesaemia (MIM:607803), a rare human disorder characterized by renal and intestinal magnesium (Mg(2+)) wasting, which may lead to symptoms of Mg(2+) depletion such as tetany, seizures and cardiac arrhythmias.",0.40027472678421294,"Interestingly, mutations in the <span class=""gene"" id=""23027747-5-32-37"">CNNM2</span> gene cause familial dominant hypomagnesaemia (MIM:607803), a rare human disorder characterized by renal and intestinal magnesium (Mg(2+)) wasting, which may lead to symptoms of Mg(2+) depletion such as tetany, <span class=""disease"" id=""23027747-5-248-256"">seizures</span> and cardiac arrhythmias.",CTD_human;HPO
1,0,Biomarker,C0039621,Tetany,disease,tetany,54805,CNNM2,CNNM2,CTD_human,23027747,"Interestingly, mutations in the CNNM2 gene cause familial dominant hypomagnesaemia (MIM:607803), a rare human disorder characterized by renal and intestinal magnesium (Mg(2+)) wasting, which may lead to symptoms of Mg(2+) depletion such as tetany, seizures and cardiac arrhythmias.",0.2,"Interestingly, mutations in the <span class=""gene"" id=""23027747-5-32-37"">CNNM2</span> gene cause familial dominant hypomagnesaemia (MIM:607803), a rare human disorder characterized by renal and intestinal magnesium (Mg(2+)) wasting, which may lead to symptoms of Mg(2+) depletion such as <span class=""disease"" id=""23027747-5-240-246"">tetany</span>, seizures and cardiac arrhythmias.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,54806,AHI1,AHI1,CTD_human,18782849,Association of common variants in the Joubert syndrome gene (AHI1) with autism.,0.20350593566014002,"Association of common variants in the Joubert syndrome gene (<span class=""gene"" id=""18782849-0-61-65"">AHI1</span>) with <span class=""disease"" id=""18782849-0-72-78"">autism</span>.",CTD_human
1,0,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,54806,AHI1,AHI1,CTD_human,20371615,Fine mapping of AHI1 as a schizophrenia susceptibility gene: from association to evolutionary evidence.,0.217841206864911,"Fine mapping of <span class=""gene"" id=""20371615-0-16-20"">AHI1</span> as a <span class=""disease"" id=""20371615-0-26-39"">schizophrenia</span> susceptibility gene: from association to evolutionary evidence.",CTD_human
1,0,Biomarker,C0021831,Intestinal Diseases,group,enteropathy,54809,SAMD9,MIRAGE,CTD_human,27182967,"Here we define a new form of syndromic adrenal hypoplasia, which we propose to term MIRAGE (myelodysplasia, infection, restriction of growth, adrenal hypoplasia, genital phenotypes, and enteropathy) syndrome.",0.2,"Here we define a new form of syndromic adrenal hypoplasia, which we propose to term <span class=""gene"" id=""27182967-2-84-90"">MIRAGE</span> (myelodysplasia, infection, restriction of growth, adrenal hypoplasia, genital phenotypes, and <span class=""disease"" id=""27182967-2-186-197"">enteropathy</span>) syndrome.",CTD_human
1,0,Biomarker,C3463824,MYELODYSPLASTIC SYNDROME,group,myelodysplasia,54809,SAMD9,MIRAGE,CTD_human,27182967,"Here we define a new form of syndromic adrenal hypoplasia, which we propose to term MIRAGE (myelodysplasia, infection, restriction of growth, adrenal hypoplasia, genital phenotypes, and enteropathy) syndrome.",0.2,"Here we define a new form of syndromic adrenal hypoplasia, which we propose to term <span class=""gene"" id=""27182967-2-84-90"">MIRAGE</span> (<span class=""disease"" id=""27182967-2-92-106"">myelodysplasia</span>, infection, restriction of growth, adrenal hypoplasia, genital phenotypes, and enteropathy) syndrome.",CTD_human
1,0,Biomarker,C0022548,Keloid,disease,KS,54829,ASPN,asporin,CTD_human,20128793,"Significant increases in expression of asporin, stratifin, galectin-1 and MIF were observed by Western blot analysis in KS.",0.2,"Significant increases in expression of <span class=""gene"" id=""20128793-7-39-46"">asporin</span>, stratifin, galectin-1 and MIF were observed by Western blot analysis in <span class=""disease"" id=""20128793-7-120-122"">KS</span>.",CTD_human
1,0,Biomarker,C0022665,Kidney Neoplasm,disease,renal tumors,54880,BCOR,BCL6 corepressor,CTD_human,26098867,We identified internal tandem duplications in the BCOR gene (BCL6 corepressor) affecting the C terminus in 100% (20/20) of CCSK tumors but in none (0/193) of the other pediatric renal tumors.,0.200274726784213,"We identified internal tandem duplications in the <span class=""gene"" id=""26098867-2-50-54"">BCOR</span> gene (<span class=""gene"" id=""26098867-2-61-77"">BCL6 corepressor</span>) affecting the C terminus in 100% (20/20) of CCSK tumors but in none (0/193) of the other pediatric <span class=""disease"" id=""26098867-2-178-190"">renal tumors</span>.",CTD_human
1,0,Biomarker,C0029463,Osteosarcoma,disease,bone sarcoma,54880,BCOR,BCOR,CTD_human,22387997,A new subtype of bone sarcoma defined by BCOR-CCNB3 gene fusion.,0.200274726784213,"A new subtype of <span class=""disease"" id=""22387997-0-17-29"">bone sarcoma</span> defined by <span class=""gene"" id=""22387997-0-41-45"">BCOR</span>-CCNB3 gene fusion.",CTD_human
2,8,Biomarker,C1846265,"Microphthalmia, syndromic 2",disease,OFCD syndrome,54880,BCOR,BCOR,CTD_human,17517692,"To study the function of BCOR, we used morpholino oligonucleotides (MOs) to knockdown expression of xtBcor in Xenopus tropicalis, thus creating an animal model for OFCD syndrome.",0.603021994626344,"To study the function of <span class=""gene"" id=""17517692-4-25-29"">BCOR</span>, we used morpholino oligonucleotides (MOs) to knockdown expression of xtBcor in Xenopus tropicalis, thus creating an animal model for <span class=""disease"" id=""17517692-4-164-177"">OFCD syndrome</span>.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0036572,Seizures,phenotype,EXP1,54886,PLPPR1,PRG-3,CTD_human,23266720,"Further, E-64d-pretreated seizure rats (EXP2) showed a significant downregulation of mRNA expression of PRG-1, PRG-3 and PRG-5, cathepsin B and ApoE, as well as up-regulated nSMase and ANX7 in hippocampus when compared with EXP1 rats.",0.2,"Further, E-64d-pretreated <span class=""disease"" id=""23266720-10-26-33"">seizure</span> rats (EXP2) showed a significant downregulation of mRNA expression of PRG-1, <span class=""gene"" id=""23266720-10-111-116"">PRG-3</span> and PRG-5, cathepsin B and ApoE, as well as up-regulated nSMase and ANX7 in hippocampus when compared with <span class=""disease"" id=""23266720-10-224-228"">EXP1</span> rats.",CTD_human
1,2,Biomarker,C0024141,"Lupus Erythematosus, Systemic",disease,systemic lupus erythematosus,54887,UHRF1BP1,UHRF1BP1,CTD_human,19838195,"A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus.",0.202956482091714,"A large-scale replication study identifies TNIP1, PRDM1, JAZF1, <span class=""gene"" id=""19838195-0-64-72"">UHRF1BP1</span> and IL10 as risk loci for <span class=""disease"" id=""19838195-0-99-127"">systemic lupus erythematosus</span>.",CTD_human
3,12,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,type 2 diabetes,54901,CDKAL1,CDKAL1,CTD_human,23202124,"Five of the loci are known to be associated with other phenotypes: ADCY5 and CDKAL1 with type 2 diabetes, ADRB1 with adult blood pressure and HMGA2 and LCORL with adult height.",0.38252759630547395,"Five of the loci are known to be associated with other phenotypes: ADCY5 and <span class=""gene"" id=""23202124-4-77-83"">CDKAL1</span> with <span class=""disease"" id=""23202124-4-89-104"">type 2 diabetes</span>, ADRB1 with adult blood pressure and HMGA2 and LCORL with adult height.",CTD_human
3,12,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,type 2 diabetes,54901,CDKAL1,CDKAL1,CTD_human,17460697,A variant in CDKAL1 influences insulin response and risk of type 2 diabetes.,0.38252759630547395,"A variant in <span class=""gene"" id=""17460697-0-13-19"">CDKAL1</span> influences insulin response and risk of <span class=""disease"" id=""17460697-0-60-75"">type 2 diabetes</span>.",CTD_human
1,0,Biomarker,C0752166,Bardet-Biedl Syndrome,disease,BBS,54903,MKS1,MKS1,CTD_human,18327255,"Five of six families with both MKS1 and BBS mutations manifested seizures, a feature that is not a typical component of either syndrome.",0.40383181960166603,"Five of six families with both <span class=""gene"" id=""18327255-4-31-35"">MKS1</span> and <span class=""disease"" id=""18327255-4-40-43"">BBS</span> mutations manifested seizures, a feature that is not a typical component of either syndrome.",CTD_human;ORPHANET
1,0,Biomarker,C0027877,Neuronal Ceroid-Lipofuscinoses,disease,neuronal ceroid lipofuscinosis,54982,CLN6,CLN6,CTD_human,23789114,Altered biometal homeostasis is associated with CLN6 mRNA loss in mouse neuronal ceroid lipofuscinosis.,0.2166353997931,"Altered biometal homeostasis is associated with <span class=""gene"" id=""23789114-0-48-52"">CLN6</span> mRNA loss in mouse <span class=""disease"" id=""23789114-0-72-102"">neuronal ceroid lipofuscinosis</span>.",CTD_human
1,4,Biomarker,C0026764,Multiple Myeloma,disease,multiple myeloma,54986,ULK4,ULK4,CTD_human,22120009,"We identified risk loci for multiple myeloma at 3p22.1 (rs1052501 in ULK4; odds ratio (OR) = 1.32; P = 7.47 × 10(-9)) and 7p15.3 (rs4487645, OR = 1.38; P = 3.33 × 10(-15)).",0.200274726784213,"We identified risk loci for <span class=""disease"" id=""22120009-2-28-44"">multiple myeloma</span> at 3p22.1 (rs1052501 in <span class=""gene"" id=""22120009-2-69-73"">ULK4</span>; odds ratio (OR) = 1.32; P = 7.47 &times; 10(-9)) and 7p15.3 (rs4487645, OR = 1.38; P = 3.33 &times; 10(-15)).",CTD_human
1,0,Biomarker,C0025202,melanoma,disease,melanomas,55014,STX17,STX17,CTD_human,18641652,Both STX17 and the neighboring NR4A3 gene are overexpressed in melanomas from Gray horses.,0.203231208875927,"Both <span class=""gene"" id=""18641652-3-5-10"">STX17</span> and the neighboring NR4A3 gene are overexpressed in <span class=""disease"" id=""18641652-3-63-72"">melanomas</span> from Gray horses.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,hepatocellular carcinomas,5502,PPP1R1A,Protein phosphatase inhibitor-1,CTD_human,15010824,Protein phosphatase inhibitor-1 mRNA expression correlates with neoplastic transformation of epithelial liver cells and progression of hepatocellular carcinomas.,0.2,"<span class=""gene"" id=""15010824-0-0-31"">Protein phosphatase inhibitor-1</span> mRNA expression correlates with neoplastic transformation of epithelial liver cells and progression of <span class=""disease"" id=""15010824-0-135-160"">hepatocellular carcinomas</span>.",CTD_human
1,3,Biomarker,C0024141,"Lupus Erythematosus, Systemic",disease,systemic lupus erythematosus,55024,BANK1,BANK1,CTD_human,18204447,Functional variants in the B-cell gene BANK1 are associated with systemic lupus erythematosus.,0.220471805015099,"Functional variants in the B-cell gene <span class=""gene"" id=""18204447-0-39-44"">BANK1</span> are associated with <span class=""disease"" id=""18204447-0-65-93"">systemic lupus erythematosus</span>.",CTD_human
1,0,Biomarker,C0022521,Kartagener Syndrome,disease,PCD,55036,CCDC40,CCDC40,CTD_human,21131974,"CCDC40 localizes to motile cilia and the apical cytoplasm and is required for axonemal recruitment of CCDC39, disruption of which underlies a similar variant of PCD.",0.40082418035263895,"<span class=""gene"" id=""21131974-6-0-6"">CCDC40</span> localizes to motile cilia and the apical cytoplasm and is required for axonemal recruitment of CCDC39, disruption of which underlies a similar variant of <span class=""disease"" id=""21131974-6-161-164"">PCD</span>.",CTD_human;ORPHANET
2,7,Biomarker,C0010346,Crohn Disease,disease,Crohn's disease,55054,ATG16L1,ATG16L1,CTD_human,18438406,"We also show that several risk loci are common to ulcerative colitis and Crohn's disease (IL23R, IL12B, HLA, NKX2-3 and MST1), whereas autophagy genes ATG16L1 and IRGM, along with NOD2 (also known as CARD15), are specific for Crohn's disease.",0.335090885230978,"We also show that several risk loci are common to ulcerative colitis and <span class=""disease"" id=""18438406-2-73-88"">Crohn's disease</span> (IL23R, IL12B, HLA, NKX2-3 and MST1), whereas autophagy genes <span class=""gene"" id=""18438406-2-151-158"">ATG16L1</span> and IRGM, along with NOD2 (also known as CARD15), are specific for <span class=""disease"" id=""18438406-2-226-241"">Crohn's disease</span>.",CTD_human
1,0,Therapeutic,C0002622,Amnesia,disease,amnesia,551,AVP,arginine-vasopressin,CTD_human,7562510,"In addition, coadministration of JTP-4819 and substance P, arginine-vasopressin or thyrotropin-releasing hormone (at doses at which each drug alone did not prolong the retention time) improved the retention time of rats with scopolamine-induced amnesia.",0.2,"In addition, coadministration of JTP-4819 and substance P, <span class=""gene"" id=""7562510-4-59-79"">arginine-vasopressin</span> or thyrotropin-releasing hormone (at doses at which each drug alone did not prolong the retention time) improved the retention time of rats with scopolamine-induced <span class=""disease"" id=""7562510-4-245-252"">amnesia</span>.",CTD_human
1,0,Therapeutic,C0011175,Dehydration,phenotype,dehydrated,551,AVP,arginine vasopressin,CTD_human,2554359,"Our results in the methadone group suggest (a) near-maximal stimulation of prolactin secretion, with a blunted prolactin response to insulin hypoglycemia, (b) mild suppression of cortisol levels, but an exaggerated cortisol response to stimulation, (c) a delayed and inhibited insulin response to food ingestion with resulting mild hyperglycemia, (d) low body weight, but elevated calorie ingestion, and (e) inability to concentrate urine when dehydrated, which was partially corrected by administration of arginine vasopressin.",0.201098907136852,"Our results in the methadone group suggest (a) near-maximal stimulation of prolactin secretion, with a blunted prolactin response to insulin hypoglycemia, (b) mild suppression of cortisol levels, but an exaggerated cortisol response to stimulation, (c) a delayed and inhibited insulin response to food ingestion with resulting mild hyperglycemia, (d) low body weight, but elevated calorie ingestion, and (e) inability to concentrate urine when <span class=""disease"" id=""2554359-4-444-454"">dehydrated</span>, which was partially corrected by administration of <span class=""gene"" id=""2554359-4-507-527"">arginine vasopressin</span>.",CTD_human
5,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,551,AVP,arginine vasopressin,CTD_human,3346065,Our previous finding that dexamethasone-induced hypertension in rats is associated with enhanced reactivity of mesenteric arteries to arginine vasopressin but not to angiotensin II (Ang II) or norepinephrine has led us to postulate that vasopressin contributes to the development or maintenance of glucocorticoid-induced hypertension.,0.20082418035263896,"Our previous finding that dexamethasone-induced <span class=""disease"" id=""3346065-1-48-60"">hypertension</span> in rats is associated with enhanced reactivity of mesenteric arteries to <span class=""gene"" id=""3346065-1-134-154"">arginine vasopressin</span> but not to angiotensin II (Ang II) or norepinephrine has led us to postulate that vasopressin contributes to the development or maintenance of glucocorticoid-induced <span class=""disease"" id=""3346065-1-321-333"">hypertension</span>.",CTD_human
1,0,Biomarker,C0037019,Shy-Drager Syndrome,disease,MSA,551,AVP,AVP,CTD_human,6850280,In conclusion: (1) the postural stimulation of AVP release is blunted in MSA; (2) this postural rise in AVP is not inhibited by a dopamine agonist or opioid antagonist in MSA suggesting loss of dopaminergic and opioid pathways involved in AVP release; (3) endogenous opioids do not contribute to orthostatic hypotension in MSA; (4) patients with MSA are supersensitive to the hypotensive effects of an acute L-DOPA infusion.,0.2,"In conclusion: (1) the postural stimulation of <span class=""gene"" id=""6850280-12-47-50"">AVP</span> release is blunted in <span class=""disease"" id=""6850280-12-73-76"">MSA</span>; (2) this postural rise in <span class=""gene"" id=""6850280-12-104-107"">AVP</span> is not inhibited by a dopamine agonist or opioid antagonist in <span class=""disease"" id=""6850280-12-171-174"">MSA</span> suggesting loss of dopaminergic and opioid pathways involved in <span class=""gene"" id=""6850280-12-239-242"">AVP</span> release; (3) endogenous opioids do not contribute to orthostatic hypotension in <span class=""disease"" id=""6850280-12-323-326"">MSA</span>; (4) patients with <span class=""disease"" id=""6850280-12-346-349"">MSA</span> are supersensitive to the hypotensive effects of an acute L-DOPA infusion.",CTD_human
2,2,Biomarker,C0015625,Fanconi Anemia,disease,Fanconi anemia,55120,FANCL,PHF9,CTD_human,12973351,Our data suggest that PHF9 has a crucial role in the Fanconi anemia pathway as the likely catalytic subunit required for monoubiquitination of FANCD2.,0.40602963387537105,"Our data suggest that <span class=""gene"" id=""12973351-8-22-26"">PHF9</span> has a crucial role in the <span class=""disease"" id=""12973351-8-53-67"">Fanconi anemia</span> pathway as the likely catalytic subunit required for monoubiquitination of FANCD2.",CTD_human;ORPHANET
2,2,Biomarker,C0015625,Fanconi Anemia,disease,Fanconi anemia,55120,FANCL,FANCL,CTD_human,19405097,Identification and characterization of mutations in FANCL gene: a second case of Fanconi anemia belonging to FA-L complementation group.,0.40602963387537105,"Identification and characterization of mutations in <span class=""gene"" id=""19405097-0-52-57"">FANCL</span> gene: a second case of <span class=""disease"" id=""19405097-0-81-95"">Fanconi anemia</span> belonging to FA-L complementation group.",CTD_human;ORPHANET
1,0,Biomarker,C1336708,Testicular Germ Cell Tumor,disease,TGCT,55159,RFWD3,RFWD3,CTD_human,23666239,"In the combined analysis, risk of TGCT was significantly associated with markers at four previously unreported loci: 4q22.2 in HPGDS (per-allele odds ratio (OR) = 1.19, 95% confidence interval (CI) = 1.12-1.26; P = 1.11 × 10(-8)), 7p22.3 in MAD1L1 (OR = 1.21, 95% CI = 1.14-1.29; P = 5.59 × 10(-9)), 16q22.3 in RFWD3 (OR = 1.26, 95% CI = 1.18-1.34; P = 5.15 × 10(-12)) and 17q22 (rs9905704: OR = 1.27, 95% CI = 1.18-1.33; P = 4.32 × 10(-13) and rs7221274: OR = 1.20, 95% CI = 1.12-1.28; P = 4.04 × 10(-9)), a locus that includes TEX14, RAD51C and PPM1E.",0.200274726784213,"In the combined analysis, risk of <span class=""disease"" id=""23666239-4-34-38"">TGCT</span> was significantly associated with markers at four previously unreported loci: 4q22.2 in HPGDS (per-allele odds ratio (OR) = 1.19, 95% confidence interval (CI) = 1.12-1.26; P = 1.11 &times; 10(-8)), 7p22.3 in MAD1L1 (OR = 1.21, 95% CI = 1.14-1.29; P = 5.59 &times; 10(-9)), 16q22.3 in <span class=""gene"" id=""23666239-4-311-316"">RFWD3</span> (OR = 1.26, 95% CI = 1.18-1.34; P = 5.15 &times; 10(-12)) and 17q22 (rs9905704: OR = 1.27, 95% CI = 1.18-1.33; P = 4.32 &times; 10(-13) and rs7221274: OR = 1.20, 95% CI = 1.12-1.28; P = 4.04 &times; 10(-9)), a locus that includes TEX14, RAD51C and PPM1E.",CTD_human
1,0,Biomarker,C0038220,Status Epilepticus,disease,SE,55163,PNPO,PNPO,CTD_human,19356691,Linear regression analysis identified a direct proportional relationship between PLK/PNPO immunoreactivity and normalized population spike amplitude ratio in the dentate gyrus and the CA1 region as excluded the data obtained from 4 weeks after SE.,0.2,"Linear regression analysis identified a direct proportional relationship between PLK/<span class=""gene"" id=""19356691-4-85-89"">PNPO</span> immunoreactivity and normalized population spike amplitude ratio in the dentate gyrus and the CA1 region as excluded the data obtained from 4 weeks after <span class=""disease"" id=""19356691-4-244-246"">SE</span>.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,552,AVPR1A,AVPR1a,CTD_human,16520824,Association between the arginine vasopressin 1a receptor (AVPR1a) gene and autism in a family-based study: mediation by socialization skills.,0.214884724773196,"Association between the arginine vasopressin 1a receptor (<span class=""gene"" id=""16520824-0-58-64"">AVPR1a</span>) gene and <span class=""disease"" id=""16520824-0-75-81"">autism</span> in a family-based study: mediation by socialization skills.",CTD_human
1,0,Biomarker,C1510586,Autism Spectrum Disorders,disease,autism spectrum disorders,552,AVPR1A,AVPR1A,CTD_human,20546835,Association study between single nucleotide polymorphisms in promoter region of AVPR1A and Korean autism spectrum disorders.,0.201098907136852,"Association study between single nucleotide polymorphisms in promoter region of <span class=""gene"" id=""20546835-0-80-86"">AVPR1A</span> and Korean <span class=""disease"" id=""20546835-0-98-123"">autism spectrum disorders</span>.",CTD_human
1,0,Biomarker,C0023467,"Leukemia, Myelocytic, Acute",disease,AML,55252,ASXL2,ASXL2,CTD_human,27798625,"Outside of signaling alterations, RUNX1-RUNX1T1 and CBFB-MYH11 AMLs demonstrated remarkably different spectra of cooperating mutations, as RUNX1-RUNX1T1 cases harbored recurrent mutations in DHX15 and ZBTB7A, as well as an enrichment of mutations in epigenetic regulators, including ASXL2 and the cohesin complex.",0.200274726784213,"Outside of signaling alterations, RUNX1-RUNX1T1 and CBFB-MYH11 <span class=""disease"" id=""27798625-4-63-66"">AML</span>s demonstrated remarkably different spectra of cooperating mutations, as RUNX1-RUNX1T1 cases harbored recurrent mutations in DHX15 and ZBTB7A, as well as an enrichment of mutations in epigenetic regulators, including <span class=""gene"" id=""27798625-4-283-288"">ASXL2</span> and the cohesin complex.",CTD_human
1,0,Biomarker,C0033578,Prostatic Neoplasms,group,prostate tumor,55256,ADI1,ADI1,CTD_human,17786183,"Immunohistochemistry of prostate tumor tissue microarrays showed that benign regions expressed more ADI1 than tumors, suggesting a suppressive role for ADI1 in prostate cancer.",0.20300763924902696,"Immunohistochemistry of <span class=""disease"" id=""17786183-6-24-38"">prostate tumor</span> tissue microarrays showed that benign regions expressed more <span class=""gene"" id=""17786183-6-100-104"">ADI1</span> than tumors, suggesting a suppressive role for <span class=""gene"" id=""17786183-6-152-156"">ADI1</span> in prostate cancer.",CTD_human
1,0,Biomarker,C0024121,Lung Neoplasms,group,lung tumors,55259,CASC1,Las1,CTD_human,15064703,"In (A/J x C57BL/6J)F1 mouse lung tumors, the Lmna-rs1 gene was completely downregulated, whereas allele-specific downregulation of the C57BL/6J-derived allele was observed at the Las1 gene, suggesting the potential role of these genes in tumor suppression.",0.20350593566014002,"In (A/J x C57BL/6J)F1 mouse <span class=""disease"" id=""15064703-5-28-39"">lung tumors</span>, the Lmna-rs1 gene was completely downregulated, whereas allele-specific downregulation of the C57BL/6J-derived allele was observed at the <span class=""gene"" id=""15064703-5-179-183"">Las1</span> gene, suggesting the potential role of these genes in tumor suppression.",CTD_human
1,0,Biomarker,C0017638,Glioma,disease,gliomas,55294,FBXW7,FBXW7,CTD_human,18931460,Promoter hypermethylation is not the major mechanism for inactivation of the FBXW7 beta-form in human gliomas.,0.20656473206648,"Promoter hypermethylation is not the major mechanism for inactivation of the <span class=""gene"" id=""18931460-0-77-82"">FBXW7</span> beta-form in human <span class=""disease"" id=""18931460-0-102-109"">gliomas</span>.",CTD_human
1,0,Biomarker,C1458155,Mammary Neoplasms,group,breast tumor,55294,FBXW7,FBXW7,CTD_human,17588203,"Copy number loss of FBXW7, however was associated with enhanced genomic instability in the Complex breast tumor subtype, but instability may not be due to FBXW7 haploinsufficiency, since transcript levels were not reduced in tumors with loss of the locus, whereas reduced expression was observed for other neighboring genes involved in maintenance of genome stability.",0.20300763924902696,"Copy number loss of <span class=""gene"" id=""17588203-5-20-25"">FBXW7</span>, however was associated with enhanced genomic instability in the Complex <span class=""disease"" id=""17588203-5-99-111"">breast tumor</span> subtype, but instability may not be due to <span class=""gene"" id=""17588203-5-155-160"">FBXW7</span> haploinsufficiency, since transcript levels were not reduced in tumors with loss of the locus, whereas reduced expression was observed for other neighboring genes involved in maintenance of genome stability.",CTD_human
1,0,Biomarker,C0152013,Adenocarcinoma of lung (disorder),disease,ADC,5530,PPP3CA,PPP3CA,CTD_human,27158780,"New significantly mutated genes included PPP3CA, DOT1L, and FTSJD1 in lung ADC, RASA1 in lung SqCC, and KLF5, EP300, and CREBBP in both tumor types.",0.2,"New significantly mutated genes included <span class=""gene"" id=""27158780-3-41-47"">PPP3CA</span>, DOT1L, and FTSJD1 in lung <span class=""disease"" id=""27158780-3-75-78"">ADC</span>, RASA1 in lung SqCC, and KLF5, EP300, and CREBBP in both tumor types.",CTD_human
2,0,Biomarker,C0011854,"Diabetes Mellitus, Insulin-Dependent",disease,insulin-dependent diabetes,55315,SLC29A3,SLC29A3,CTD_human,19336477,"In summary, inactivating mutations in SLC29A3 cause a syndromic form of insulin-dependent diabetes in humans and in Drosophila profoundly affect cell size/number through interactions with the insulin signaling pathway.",0.203780662444353,"In summary, inactivating mutations in <span class=""gene"" id=""19336477-8-38-45"">SLC29A3</span> cause a syndromic form of <span class=""disease"" id=""19336477-8-72-98"">insulin-dependent diabetes</span> in humans and in Drosophila profoundly affect cell size/number through interactions with the insulin signaling pathway.",CTD_human
1,0,Biomarker,C0019618,Histiocytosis,disease,histiocytosis,55315,SLC29A3,SLC29A3,CTD_human,22238637,"With the exception of insulin-dependent diabetes and mild finger and toe contractures in one sibling, the two patients with nasal granulomatous histiocytosis studied here displayed none of the many SLC29A3-associated phenotypes.",0.40137363392106606,"With the exception of insulin-dependent diabetes and mild finger and toe contractures in one sibling, the two patients with nasal granulomatous <span class=""disease"" id=""22238637-4-144-157"">histiocytosis</span> studied here displayed none of the many <span class=""gene"" id=""22238637-4-198-205"">SLC29A3</span>-associated phenotypes.",CTD_human;HPO
1,0,Biomarker,C0019625,Sinus histiocytosis,disease,RDD,55315,SLC29A3,SLC29A3,CTD_human,20140240,Mutation analysis of candidate genes within the target interval identified biallelic germline mutations in SLC29A3 in the FHC kindred and in two families reported to have familial RDD.,0.201648360705279,"Mutation analysis of candidate genes within the target interval identified biallelic germline mutations in <span class=""gene"" id=""20140240-5-107-114"">SLC29A3</span> in the FHC kindred and in two families reported to have familial <span class=""disease"" id=""20140240-5-180-183"">RDD</span>.",CTD_human
2,0,Biomarker,C0020555,Hypertrichosis,disease,hypertrichosis,55315,SLC29A3,SLC29A3,CTD_human,20140240,"Recently germline mutations in SLC29A3 were also described in two rare autosomal recessive disorders with overlapping phenotypes: (a) H syndrome (MIM 612391) that is characterised by cutaneous hyperpigmentation and hypertrichosis, hepatomegaly, heart anomalies, hearing loss, and hypogonadism; and (b) PHID (pigmented hypertrichosis with insulin-dependent diabetes mellitus) syndrome.",0.40082418035263895,"Recently germline mutations in <span class=""gene"" id=""20140240-8-31-38"">SLC29A3</span> were also described in two rare autosomal recessive disorders with overlapping phenotypes: (a) H syndrome (MIM 612391) that is characterised by cutaneous hyperpigmentation and <span class=""disease"" id=""20140240-8-215-229"">hypertrichosis</span>, hepatomegaly, heart anomalies, hearing loss, and hypogonadism; and (b) PHID (pigmented hypertrichosis with insulin-dependent diabetes mellitus) syndrome.",CTD_human;HPO
1,0,Biomarker,C0020619,Hypogonadism,disease,hypogonadism,55315,SLC29A3,SLC29A3,CTD_human,20140240,"Recently germline mutations in SLC29A3 were also described in two rare autosomal recessive disorders with overlapping phenotypes: (a) H syndrome (MIM 612391) that is characterised by cutaneous hyperpigmentation and hypertrichosis, hepatomegaly, heart anomalies, hearing loss, and hypogonadism; and (b) PHID (pigmented hypertrichosis with insulin-dependent diabetes mellitus) syndrome.",0.200274726784213,"Recently germline mutations in <span class=""gene"" id=""20140240-8-31-38"">SLC29A3</span> were also described in two rare autosomal recessive disorders with overlapping phenotypes: (a) H syndrome (MIM 612391) that is characterised by cutaneous hyperpigmentation and hypertrichosis, hepatomegaly, heart anomalies, hearing loss, and <span class=""disease"" id=""20140240-8-280-292"">hypogonadism</span>; and (b) PHID (pigmented hypertrichosis with insulin-dependent diabetes mellitus) syndrome.",CTD_human
7,15,Biomarker,C1864445,Histiocytosis with joint contractures and sensorineural deafness,disease,familial Rosai-Dorfman disease,55315,SLC29A3,ENT3,CTD_human,20140240,"Mutations in SLC29A3, encoding an equilibrative nucleoside transporter ENT3, cause a familial histiocytosis syndrome (Faisalabad histiocytosis) and familial Rosai-Dorfman disease.",0.60439562854741,"Mutations in <span class=""gene"" id=""20140240-0-13-20"">SLC29A3</span>, encoding an equilibrative nucleoside transporter <span class=""gene"" id=""20140240-0-71-75"">ENT3</span>, cause a familial histiocytosis syndrome (<span class=""disease"" id=""20140240-0-118-142"">Faisalabad histiocytosis</span>) and <span class=""disease"" id=""20140240-0-148-178"">familial Rosai-Dorfman disease</span>.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0033860,Psoriasis,disease,psoriasis,55350,VNN3,vanin-3,CTD_human,19322213,"Using submerged and organotypic keratinocyte cultures, we found that vanin-1 and vanin-3 are induced at the mRNA and protein level by psoriasis-associated proinflammatory cytokines (Th17/Th1) but not by Th2 cytokines.",0.20054945356842604,"Using submerged and organotypic keratinocyte cultures, we found that vanin-1 and <span class=""gene"" id=""19322213-6-81-88"">vanin-3</span> are induced at the mRNA and protein level by <span class=""disease"" id=""19322213-6-134-143"">psoriasis</span>-associated proinflammatory cytokines (Th17/Th1) but not by Th2 cytokines.",CTD_human
1,0,Biomarker,C0025202,melanoma,disease,melanomas,5537,PPP6C,PPP6C,CTD_human,22842228,"Among the newly identified cancer genes was PPP6C, encoding a serine/threonine phosphatase, which harbored mutations that clustered in the active site in 12% of sun-exposed melanomas, exclusively in tumors with mutations in BRAF or NRAS.",0.201098907136852,"Among the newly identified cancer genes was <span class=""gene"" id=""22842228-3-44-49"">PPP6C</span>, encoding a serine/threonine phosphatase, which harbored mutations that clustered in the active site in 12% of sun-exposed <span class=""disease"" id=""22842228-3-173-182"">melanomas</span>, exclusively in tumors with mutations in BRAF or NRAS.",CTD_human
1,0,Biomarker,C0028961,Oliguria,phenotype,oliguria,554,AVPR2,arginine vasopressin V2-receptor,CTD_human,7977526,These results suggest that (1) fetal oliguria secondary to indomethacin is mediated through the stimulation of the renal arginine vasopressin V2-receptor and (2) prostaglandin synthesis inhibition may play a role in renal tubular sodium handling.,0.2,"These results suggest that (1) fetal <span class=""disease"" id=""7977526-9-37-45"">oliguria</span> secondary to indomethacin is mediated through the stimulation of the renal <span class=""gene"" id=""7977526-9-121-153"">arginine vasopressin V2-receptor</span> and (2) prostaglandin synthesis inhibition may play a role in renal tubular sodium handling.",CTD_human
5,15,Biomarker,C0162283,Nephrogenic Diabetes Insipidus,disease,nephrogenic diabetes insipidus,554,AVPR2,AVPR2,CTD_human,12414899,"By screening patients with X-linked nephrogenic diabetes insipidus (NDI) for mutations within the V(2) vasopressin receptor (AVPR2) gene, we have identified six novel and two recurrent mutations.",0.6437615745436109,"By screening patients with X-linked <span class=""disease"" id=""12414899-1-36-66"">nephrogenic diabetes insipidus</span> (NDI) for mutations within the V(2) vasopressin receptor (<span class=""gene"" id=""12414899-1-125-130"">AVPR2</span>) gene, we have identified six novel and two recurrent mutations.",CTD_human;HPO;ORPHANET
5,15,Biomarker,C0162283,Nephrogenic Diabetes Insipidus,disease,nephrogenic diabetes insipidus,554,AVPR2,222delA,CTD_human,19703807,A novel mutation in the AVPR2 gene (222delA) associated with X-linked nephrogenic diabetes insipidus in a boy with growth failure.,0.6437615745436109,"A novel mutation in the <span class=""gene"" id=""19703807-0-24-29"">AVPR2</span> gene (<span class=""gene"" id=""19703807-0-36-43"">222delA</span>) associated with X-linked <span class=""disease"" id=""19703807-0-70-100"">nephrogenic diabetes insipidus</span> in a boy with growth failure.",CTD_human;HPO;ORPHANET
1,0,Biomarker,C0025202,melanoma,disease,melanoma,55504,TNFRSF19,TROY,CTD_human,17187358,"In summary, TROY is the first TNFRSF member that is a biomarker for melanoma.",0.20300763924902696,"In summary, <span class=""gene"" id=""17187358-11-12-16"">TROY</span> is the first TNFRSF member that is a biomarker for <span class=""disease"" id=""17187358-11-68-76"">melanoma</span>.",CTD_human
1,1,Biomarker,C0023343,Leprosy,disease,leprosy,55509,BATF3,BATF3,CTD_human,25642632,"Besides confirming all previously published loci, we discovered six new susceptibility loci, and further gene prioritization analysis of these loci implicated BATF3, CCDC88B and CIITA-SOCS1 as new susceptibility genes for leprosy.",0.200274726784213,"Besides confirming all previously published loci, we discovered six new susceptibility loci, and further gene prioritization analysis of these loci implicated <span class=""gene"" id=""25642632-4-159-164"">BATF3</span>, CCDC88B and CIITA-SOCS1 as new susceptibility genes for <span class=""disease"" id=""25642632-4-222-229"">leprosy</span>.",CTD_human
1,0,Biomarker,C0023418,leukemia,disease,leukemia,55512,SMPD3,NSMase2,CTD_human,18283525,"This alteration is supposed to change the cellular sphingolipid metabolites; however, positive correlations were observed between daunorubicin (DA)-IC50 and the SPHK1 message but not between DA-IC50 and NSMase2 messages, when 16 different leukemia cell lines were used to analyze the relationship between gene expressions and chemosensitivity against DA.",0.200274726784213,"This alteration is supposed to change the cellular sphingolipid metabolites; however, positive correlations were observed between daunorubicin (DA)-IC50 and the SPHK1 message but not between DA-IC50 and <span class=""gene"" id=""18283525-2-203-210"">NSMase2</span> messages, when 16 different <span class=""disease"" id=""18283525-2-239-247"">leukemia</span> cell lines were used to analyze the relationship between gene expressions and chemosensitivity against DA.",CTD_human
1,0,Biomarker,C3463824,MYELODYSPLASTIC SYNDROME,group,myelodysplastic syndromes,55512,SMPD3,NSMase2,CTD_human,18283525,We recently reported increased sphingosine kinase 1 (SPHK1) and decreased neutral sphingomyelinase 2 (NSMase2) gene expression in myelodysplastic syndromes and acute leukemia.,0.2,"We recently reported increased sphingosine kinase 1 (SPHK1) and decreased <span class=""gene"" id=""18283525-1-74-100"">neutral sphingomyelinase 2</span> (<span class=""gene"" id=""18283525-1-102-109"">NSMase2</span>) gene expression in <span class=""disease"" id=""18283525-1-130-155"">myelodysplastic syndromes</span> and acute leukemia.",CTD_human
1,0,Biomarker,C0013421,Dystonia,phenotype,Dystonia,55532,SLC30A10,SLC30A10,CTD_human,22926781,Dystonia with brain manganese accumulation resulting from SLC30A10 mutations: a new treatable disorder.,0.40082418035263895,"<span class=""disease"" id=""22926781-0-0-8"">Dystonia</span> with brain manganese accumulation resulting from <span class=""gene"" id=""22926781-0-58-66"">SLC30A10</span> mutations: a new treatable disorder.",CTD_human;HPO
3,9,Biomarker,C2750442,Hypermanganesemia with Dystonia Polycythemia and Cirrhosis,disease,"parkinsonism and dystonia with hypermanganesemia, polycythemia, and chronic liver disease",55532,SLC30A10,SLC30A10,CTD_human,22341971,"Mutations in SLC30A10 cause parkinsonism and dystonia with hypermanganesemia, polycythemia, and chronic liver disease.",0.600549453568426,"Mutations in <span class=""gene"" id=""22341971-0-13-21"">SLC30A10</span> cause <span class=""disease"" id=""22341971-0-28-117"">parkinsonism and dystonia with hypermanganesemia, polycythemia, and chronic liver disease</span>.",CTD_human;ORPHANET;UNIPROT
3,9,Biomarker,C2750442,Hypermanganesemia with Dystonia Polycythemia and Cirrhosis,disease,"hepatic cirrhosis, dystonia, polycythemia, and hypermanganesemia",55532,SLC30A10,SLC30A10,CTD_human,22926781,"Mutations in the SLC30A10 gene, encoding a manganese transporter, cause a syndrome of hepatic cirrhosis, dystonia, polycythemia, and hypermanganesemia.",0.600549453568426,"Mutations in the <span class=""gene"" id=""22926781-2-17-25"">SLC30A10</span> gene, encoding a manganese transporter, cause a syndrome of <span class=""disease"" id=""22926781-2-86-150"">hepatic cirrhosis, dystonia, polycythemia, and hypermanganesemia</span>.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C1261473,Sarcoma,disease,sarcoma,55534,MAML3,MAML3,CTD_human,24859338,Recurrent PAX3-MAML3 fusion in biphenotypic sinonasal sarcoma.,0.200274726784213,"Recurrent PAX3-<span class=""gene"" id=""24859338-0-15-20"">MAML3</span> fusion in biphenotypic sinonasal <span class=""disease"" id=""24859338-0-54-61"">sarcoma</span>.",CTD_human
1,0,Biomarker,C0878544,Cardiomyopathies,group,cardiomyopathy,5563,PRKAA2,Prkaa2,CTD_human,21037199,"A novel coexpression and integrated pathway network analysis indicated Prkaa2, Pdk2, Rhoj, and Sgcb are likely to play a central role in the pathophysiology of murine progressive cardiomyopathy in C3H/HeJ mice.",0.200274726784213,"A novel coexpression and integrated pathway network analysis indicated <span class=""gene"" id=""21037199-7-71-77"">Prkaa2</span>, Pdk2, Rhoj, and Sgcb are likely to play a central role in the pathophysiology of murine progressive <span class=""disease"" id=""21037199-7-179-193"">cardiomyopathy</span> in C3H/HeJ mice.",CTD_human
6,7,Biomarker,C0221036,Acrodermatitis enteropathica,disease,acrodermatitis enteropathica,55630,SLC39A4,SLC39A4,CTD_human,12068297,"Identification of SLC39A4, a gene involved in acrodermatitis enteropathica.",0.6843956285474101,"Identification of <span class=""gene"" id=""12068297-0-18-25"">SLC39A4</span>, a gene involved in <span class=""disease"" id=""12068297-0-46-74"">acrodermatitis enteropathica</span>.",CTD_human;ORPHANET;UNIPROT
6,7,Biomarker,C0221036,Acrodermatitis enteropathica,disease,Acrodermatitis enteropathica,55630,SLC39A4,ZIP4,CTD_human,14709598,"Acrodermatitis enteropathica mutations affect transport activity, localization and zinc-responsive trafficking of the mouse ZIP4 zinc transporter.",0.6843956285474101,"<span class=""disease"" id=""14709598-0-0-28"">Acrodermatitis enteropathica</span> mutations affect transport activity, localization and zinc-responsive trafficking of the mouse <span class=""gene"" id=""14709598-0-124-128"">ZIP4</span> zinc transporter.",CTD_human;ORPHANET;UNIPROT
6,7,Biomarker,C0221036,Acrodermatitis enteropathica,disease,acrodermatitis enteropathica,55630,SLC39A4,Zip4,CTD_human,17483098,"The human Zip4 gene (Slc39a4) is mutated in the rare recessive genetic disorder of zinc metabolism acrodermatitis enteropathica, but the physiological functions of Zip4 are not well understood.",0.6843956285474101,"The human <span class=""gene"" id=""17483098-1-10-14"">Zip4</span> gene (<span class=""gene"" id=""17483098-1-21-28"">Slc39a4</span>) is mutated in the rare recessive genetic disorder of zinc metabolism <span class=""disease"" id=""17483098-1-99-127"">acrodermatitis enteropathica</span>, but the physiological functions of <span class=""gene"" id=""17483098-1-164-168"">Zip4</span> are not well understood.",CTD_human;ORPHANET;UNIPROT
6,7,Biomarker,C0221036,Acrodermatitis enteropathica,disease,acrodermatitis enteropathica,55630,SLC39A4,ZIP4,CTD_human,15358787,"The ZIP5 gene encodes a protein closely related to ZIP4, a zinc transporter mutated in the human genetic disorder acrodermatitis enteropathica.",0.6843956285474101,"The ZIP5 gene encodes a protein closely related to <span class=""gene"" id=""15358787-1-51-55"">ZIP4</span>, a zinc transporter mutated in the human genetic disorder <span class=""disease"" id=""15358787-1-114-142"">acrodermatitis enteropathica</span>.",CTD_human;ORPHANET;UNIPROT
14,97,Biomarker,C0265354,CHARGE Syndrome,disease,CHARGE syndrome,55636,CHD7,CHD7,CTD_human,16615981,Phenotypic spectrum of CHARGE syndrome with CHD7 mutations.,0.709879706944598,"Phenotypic spectrum of <span class=""disease"" id=""16615981-0-23-38"">CHARGE syndrome</span> with <span class=""gene"" id=""16615981-0-44-48"">CHD7</span> mutations.",CTD_human;ORPHANET;UNIPROT
14,97,Biomarker,C0265354,CHARGE Syndrome,disease,CHARGE syndrome,55636,CHD7,Chd7,CTD_human,21532573,Regulation of disease-associated genes by a Sox2-Chd7 complex provides a plausible explanation for several malformations associated with SOX2 anophthalmia syndrome or CHARGE syndrome.,0.709879706944598,"Regulation of disease-associated genes by a Sox2-<span class=""gene"" id=""21532573-5-49-53"">Chd7</span> complex provides a plausible explanation for several malformations associated with SOX2 anophthalmia syndrome or <span class=""disease"" id=""21532573-5-167-182"">CHARGE syndrome</span>.",CTD_human;ORPHANET;UNIPROT
2,19,Biomarker,C0031511,Pheochromocytoma,disease,pheochromocytoma,55654,TMEM127,TMEM127,CTD_human,20154675,Germline mutations in TMEM127 confer susceptibility to pheochromocytoma.,0.408385505241346,"Germline mutations in <span class=""gene"" id=""20154675-0-22-29"">TMEM127</span> confer susceptibility to <span class=""disease"" id=""20154675-0-55-71"">pheochromocytoma</span>.",CTD_human;UNIPROT
2,1,Biomarker,C0043459,Zellweger Syndrome,disease,ZS,55670,PEX26,PEX26,CTD_human,12851857,"We studied the PEX26 genotype in fibroblasts of eight CG8 patients--four with the ZS phenotype, two with NALD, and two with IRD.",0.400549453568426,"We studied the <span class=""gene"" id=""12851857-4-15-20"">PEX26</span> genotype in fibroblasts of eight CG8 patients--four with the <span class=""disease"" id=""12851857-4-82-84"">ZS</span> phenotype, two with NALD, and two with IRD.",CTD_human;ORPHANET
1,0,Biomarker,C0162309,Adrenoleukodystrophy,disease,NALD,55670,PEX26,PEX26,CTD_human,12851857,"We studied the PEX26 genotype in fibroblasts of eight CG8 patients--four with the ZS phenotype, two with NALD, and two with IRD.",0.2,"We studied the <span class=""gene"" id=""12851857-4-15-20"">PEX26</span> genotype in fibroblasts of eight CG8 patients--four with the ZS phenotype, two with <span class=""disease"" id=""12851857-4-105-109"">NALD</span>, and two with IRD.",CTD_human
1,0,Biomarker,C0282527,Infantile Refsum Disease (disorder),disease,IRD,55670,PEX26,PEX26,CTD_human,12851857,"We studied the PEX26 genotype in fibroblasts of eight CG8 patients--four with the ZS phenotype, two with NALD, and two with IRD.",0.40027472678421294,"We studied the <span class=""gene"" id=""12851857-4-15-20"">PEX26</span> genotype in fibroblasts of eight CG8 patients--four with the ZS phenotype, two with NALD, and two with <span class=""disease"" id=""12851857-4-124-127"">IRD</span>.",CTD_human;ORPHANET
1,0,Biomarker,C1832200,Peroxisome biogenesis disorders,group,peroxisome-biogenesis disorders,55670,PEX26,PEX26,CTD_human,12851857,Mutations in novel peroxin gene PEX26 that cause peroxisome-biogenesis disorders of complementation group 8 provide a genotype-phenotype correlation.,0.201098907136852,"Mutations in novel peroxin gene <span class=""gene"" id=""12851857-0-32-37"">PEX26</span> that cause <span class=""disease"" id=""12851857-0-49-80"">peroxisome-biogenesis disorders</span> of complementation group 8 provide a genotype-phenotype correlation.",CTD_human
1,1,Biomarker,C0028754,Obesity,disease,obese,55690,PACS1,PACS1,CTD_human,23563609,"Evaluation of 29 SNPs (P < 1 × 10(-5)) in an additional 971 severely obese children and 1,990 controls identified 4 new loci associated with severe obesity (LEPR, PRKCH, PACS1 and RMST).",0.2,"Evaluation of 29 SNPs (P &lt; 1 &times; 10(-5)) in an additional 971 severely <span class=""disease"" id=""23563609-3-69-74"">obese</span> children and 1,990 controls identified 4 new loci associated with severe obesity (LEPR, PRKCH, <span class=""gene"" id=""23563609-3-170-175"">PACS1</span> and RMST).",CTD_human
1,0,Biomarker,C0023487,Acute Promyelocytic Leukemia,disease,acute promyelocytic leukemia,5573,PRKAR1A,PRKAR1A,CTD_human,17712046,The PRKAR1A gene is fused to RARA in a new variant acute promyelocytic leukemia.,0.400549453568426,"The <span class=""gene"" id=""17712046-0-4-11"">PRKAR1A</span> gene is fused to RARA in a new variant <span class=""disease"" id=""17712046-0-51-79"">acute promyelocytic leukemia</span>.",CTD_human;ORPHANET
1,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,NSCLC,55743,CHFR,CHFR,CTD_human,20705357,"A panel of seven human EGFR wild-type NSCLC cell lines was characterized for their sensitivity to sequential treatment with cisplatin and erlotinib, and the results were correlated with CHFR.",0.201373633921065,"A panel of seven human EGFR wild-type <span class=""disease"" id=""20705357-5-38-43"">NSCLC</span> cell lines was characterized for their sensitivity to sequential treatment with cisplatin and erlotinib, and the results were correlated with <span class=""gene"" id=""20705357-5-186-190"">CHFR</span>.",CTD_human
1,0,Biomarker,C0011881,Diabetic Nephropathy,disease,diabetic nephropathy,55748,CNDP2,CNDP2,CTD_human,21573905,"Two SNPs, rs2346061 in CNDP1 and rs7577 in CNDP2, were associated with an increased risk of diabetic nephropathy (rs2346061 p = 5.07 × 10(-4); rs7577 p = 0.021).",0.206238848124954,"Two SNPs, rs2346061 in CNDP1 and rs7577 in <span class=""gene"" id=""21573905-5-43-48"">CNDP2</span>, were associated with an increased risk of <span class=""disease"" id=""21573905-5-92-112"">diabetic nephropathy</span> (rs2346061 p = 5.07 &times; 10(-4); rs7577 p = 0.021).",CTD_human
1,4,Biomarker,C1859317,Cataract and cardiomyopathy,disease,Sengers syndrome,55750,AGK,acylglycerol kinase,CTD_human,23266196,Mitochondrial citrate synthase crystals: novel finding in Sengers syndrome caused by acylglycerol kinase (AGK) mutations.,0.40137363392106606,"Mitochondrial citrate synthase crystals: novel finding in <span class=""disease"" id=""23266196-0-58-74"">Sengers syndrome</span> caused by <span class=""gene"" id=""23266196-0-85-104"">acylglycerol kinase</span> (AGK) mutations.",CTD_human;ORPHANET
1,0,Biomarker,C0007193,"Cardiomyopathy, Dilated",group,dilated cardiomyopathy,55759,WDR12,WDR12,CTD_human,25915632,LV WDR12 protein levels were increased in patients with dilated cardiomyopathy and rats post-infarction.,0.200274726784213,"LV <span class=""gene"" id=""25915632-4-3-8"">WDR12</span> protein levels were increased in patients with <span class=""disease"" id=""25915632-4-56-78"">dilated cardiomyopathy</span> and rats post-infarction.",CTD_human
2,1,Biomarker,C0027051,Myocardial Infarction,disease,MI,55759,WDR12,WDR12,CTD_human,25915632,WDR12 triggers distinct deterioration of cardiac function in adult rat heart and the MI associated WDR12 variant is associated with diastolic dysfunction in human subjects.,0.202681755307501,"<span class=""gene"" id=""25915632-10-0-5"">WDR12</span> triggers distinct deterioration of cardiac function in adult rat heart and the <span class=""disease"" id=""25915632-10-85-87"">MI</span> associated <span class=""gene"" id=""25915632-10-99-104"">WDR12</span> variant is associated with diastolic dysfunction in human subjects.",CTD_human
1,0,Biomarker,C0028754,Obesity,disease,obese,5577,PRKAR2B,PRKAR2B,CTD_human,20975297,"Several genes and transcripts involved in lipolysis were down-regulated, such as AKAP1, PRKAR2B, Gi and CIDEA, whereas NPY1R and CES1 were up-regulated, when comparing obese to lean subjects.",0.200274726784213,"Several genes and transcripts involved in lipolysis were down-regulated, such as AKAP1, <span class=""gene"" id=""20975297-3-88-95"">PRKAR2B</span>, Gi and CIDEA, whereas NPY1R and CES1 were up-regulated, when comparing <span class=""disease"" id=""20975297-3-168-173"">obese</span> to lean subjects.",CTD_human
1,0,Biomarker,C0032617,Polyuria,phenotype,polyuria,5578,PRKCA,PKC?,CTD_human,25006961,"Our data show that ablation of PKC? preserves AQP2 and UT-A1 protein expression and localization in lithium-induced NDI, and prevents the development of the severe polyuria associated with lithium therapy.",0.2,"Our data show that ablation of <span class=""gene"" id=""25006961-12-31-35"">PKC&alpha;</span> preserves AQP2 and UT-A1 protein expression and localization in lithium-induced NDI, and prevents the development of the severe <span class=""disease"" id=""25006961-12-164-172"">polyuria</span> associated with lithium therapy.",CTD_human
1,0,Biomarker,C0152013,Adenocarcinoma of lung (disorder),disease,ADC,55783,CMTR2,FTSJD1,CTD_human,27158780,"New significantly mutated genes included PPP3CA, DOT1L, and FTSJD1 in lung ADC, RASA1 in lung SqCC, and KLF5, EP300, and CREBBP in both tumor types.",0.2,"New significantly mutated genes included PPP3CA, DOT1L, and <span class=""gene"" id=""27158780-3-60-66"">FTSJD1</span> in lung <span class=""disease"" id=""27158780-3-75-78"">ADC</span>, RASA1 in lung SqCC, and KLF5, EP300, and CREBBP in both tumor types.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,5579,PRKCB,PRKCB1,CTD_human,16027742,Haplotypes in the gene encoding protein kinase c-beta (PRKCB1) on chromosome 16 are associated with autism.,0.203231208875927,"Haplotypes in the gene encoding <span class=""gene"" id=""16027742-0-32-53"">protein kinase c-beta</span> (<span class=""gene"" id=""16027742-0-55-61"">PRKCB1</span>) on chromosome 16 are associated with <span class=""disease"" id=""16027742-0-100-106"">autism</span>.",CTD_human
1,0,Biomarker,C2931059,Marie Unna congenital hypotrichosis,disease,MUHH,55806,HR,HR,CTD_human,19122663,"Our results establish the link between MUHH and U2HR, show that fine-tuning of HR protein levels is important in control of hair growth, and identify a potential mechanism for preventing hair loss or promoting hair removal.",0.40027472678421294,"Our results establish the link between <span class=""disease"" id=""19122663-6-39-43"">MUHH</span> and U2HR, show that fine-tuning of <span class=""gene"" id=""19122663-6-79-81"">HR</span> protein levels is important in control of hair growth, and identify a potential mechanism for preventing hair loss or promoting hair removal.",CTD_human;ORPHANET
1,0,Biomarker,C1458155,Mammary Neoplasms,group,breast tumors,55809,TRERF1,TRERF1,CTD_human,19075277,"mRNA levels of 10 BCAR genes (AKT1, AKT2, BCAR1, BCAR3, EGFR, ERBB2, GRB7, SRC, TLE3, and TRERF1) were measured in estrogen receptor-positive breast tumors using quantitative reverse-transcriptase polymerase chain reaction.",0.20328236603324,"mRNA levels of 10 BCAR genes (AKT1, AKT2, BCAR1, BCAR3, EGFR, ERBB2, GRB7, SRC, TLE3, and <span class=""gene"" id=""19075277-3-90-96"">TRERF1</span>) were measured in estrogen receptor-positive <span class=""disease"" id=""19075277-3-142-155"">breast tumors</span> using quantitative reverse-transcriptase polymerase chain reaction.",CTD_human
3,0,Biomarker,C0020429,Hyperalgesia,phenotype,hyperalgesia,5581,PRKCE,PKCepsilon,CTD_human,12582831,"Injection of 5- and 12-lipoxygenase produced hyperalgesia that was not antagonized by inhibitors of PKA, PKCepsilon or MAPK.These findings suggest that: (1). lipoxygenase products of arachidonic acid function as second messengers in the peripheral hyperalgesia induced by agents that act directly on primary afferent nociceptors (epinephrine and prostaglandin E(2)), (2). products of the 5-lipoxygenase and 12-lipoxygenase pathway are involved in this function, and (3). these lipoxygenase products contribute to hyperalgesia at or downstream of protein kinase A and PKCepsilon.",0.202732912464814,"Injection of 5- and 12-lipoxygenase produced <span class=""disease"" id=""12582831-5-45-57"">hyperalgesia</span> that was not antagonized by inhibitors of PKA, <span class=""gene"" id=""12582831-5-105-115"">PKCepsilon</span> or MAPK.These findings suggest that: (1). lipoxygenase products of arachidonic acid function as second messengers in the peripheral <span class=""disease"" id=""12582831-5-248-260"">hyperalgesia</span> induced by agents that act directly on primary afferent nociceptors (epinephrine and prostaglandin E(2)), (2). products of the 5-lipoxygenase and 12-lipoxygenase pathway are involved in this function, and (3). these lipoxygenase products contribute to <span class=""disease"" id=""12582831-5-513-525"">hyperalgesia</span> at or downstream of protein kinase A and <span class=""gene"" id=""12582831-5-567-577"">PKCepsilon</span>.",CTD_human
3,0,Biomarker,C0020429,Hyperalgesia,phenotype,hyperalgesia,5581,PRKCE,PKCepsilon,CTD_human,20457222,"While PKCepsilon activation can induce acute hyperalgesia in the IB4(+) population, it fails to induce priming.",0.202732912464814,"While <span class=""gene"" id=""20457222-8-6-16"">PKCepsilon</span> activation can induce acute <span class=""disease"" id=""20457222-8-45-57"">hyperalgesia</span> in the IB4(+) population, it fails to induce priming.",CTD_human
1,0,Biomarker,C0035334,Retinitis Pigmentosa,disease,retinitis pigmentosa,55812,SPATA7,SPATA7,CTD_human,19268277,Mutations in SPATA7 cause Leber congenital amaurosis and juvenile retinitis pigmentosa.,0.40082418035263895,"Mutations in <span class=""gene"" id=""19268277-0-13-19"">SPATA7</span> cause Leber congenital amaurosis and juvenile <span class=""disease"" id=""19268277-0-66-86"">retinitis pigmentosa</span>.",CTD_human;ORPHANET
1,0,Biomarker,C0339527,Leber Congenital Amaurosis,disease,Leber congenital amaurosis,55812,SPATA7,SPATA7,CTD_human,19268277,Mutations in SPATA7 cause Leber congenital amaurosis and juvenile retinitis pigmentosa.,0.401648360705279,"Mutations in <span class=""gene"" id=""19268277-0-13-19"">SPATA7</span> cause <span class=""disease"" id=""19268277-0-26-52"">Leber congenital amaurosis</span> and juvenile retinitis pigmentosa.",CTD_human;ORPHANET
1,0,Biomarker,C0087012,"Ataxia, Spinocerebellar",disease,spinocerebellar ataxia,5582,PRKCG,SCA14,CTD_human,20398063,Mutant protein kinase C gamma that causes spinocerebellar ataxia type 14 (SCA14) is selectively degraded by autophagy.,0.21802338909148303,"Mutant <span class=""gene"" id=""20398063-0-7-29"">protein kinase C gamma</span> that causes <span class=""disease"" id=""20398063-0-42-64"">spinocerebellar ataxia</span> type 14 (<span class=""gene"" id=""20398063-0-74-79"">SCA14</span>) is selectively degraded by autophagy.",CTD_human
1,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,non-small cell lung cancer,55829,SELENOS,SEPS1,CTD_human,20471133,"A combination of functional polymorphisms in the CASP8, MMP1, IL10 and SEPS1 genes affects risk of non-small cell lung cancer.",0.200274726784213,"A combination of functional polymorphisms in the CASP8, MMP1, IL10 and <span class=""gene"" id=""20471133-0-71-76"">SEPS1</span> genes affects risk of <span class=""disease"" id=""20471133-0-99-125"">non-small cell lung cancer</span>.",CTD_human
1,1,Biomarker,C0028754,Obesity,disease,obese,5583,PRKCH,PRKCH,CTD_human,23563609,"Evaluation of 29 SNPs (P < 1 × 10(-5)) in an additional 971 severely obese children and 1,990 controls identified 4 new loci associated with severe obesity (LEPR, PRKCH, PACS1 and RMST).",0.2,"Evaluation of 29 SNPs (P &lt; 1 &times; 10(-5)) in an additional 971 severely <span class=""disease"" id=""23563609-3-69-74"">obese</span> children and 1,990 controls identified 4 new loci associated with severe obesity (LEPR, <span class=""gene"" id=""23563609-3-163-168"">PRKCH</span>, PACS1 and RMST).",CTD_human
1,0,Biomarker,C0001418,Adenocarcinoma,group,adenocarcinomas,5587,PRKD1,PRKD1,CTD_human,25240283,Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands.,0.20054945356842604,"Hotspot activating <span class=""gene"" id=""25240283-0-19-24"">PRKD1</span> somatic mutations in polymorphous low-grade <span class=""disease"" id=""25240283-0-69-84"">adenocarcinomas</span> of the salivary glands.",CTD_human
1,4,Biomarker,C0004096,Asthma,disease,asthma,55876,GSDMB,GSDMB,CTD_human,24241537,"Four of these, GSDMB, IL33, RAD50 and IL1RL1, were previously reported as asthma susceptibility loci, but the effect sizes for these loci in our cohort were considerably larger than in the previous genome-wide association studies of asthma.",0.21539737656162697,"Four of these, <span class=""gene"" id=""24241537-5-15-20"">GSDMB</span>, IL33, RAD50 and IL1RL1, were previously reported as <span class=""disease"" id=""24241537-5-74-80"">asthma</span> susceptibility loci, but the effect sizes for these loci in our cohort were considerably larger than in the previous genome-wide association studies of <span class=""disease"" id=""24241537-5-233-239"">asthma</span>.",CTD_human
2,3,Biomarker,C0158683,Polycystic liver disease,disease,polycystic liver disease,5589,PRKCSH,PRKCSH,CTD_human,21685914,Autosomal dominant polycystic liver disease results from mutations in PRKCSH or SEC63.,0.687077383854911,"Autosomal dominant <span class=""disease"" id=""21685914-1-19-43"">polycystic liver disease</span> results from mutations in <span class=""gene"" id=""21685914-1-70-76"">PRKCSH</span> or SEC63.",CTD_human;HPO;ORPHANET
1,0,Biomarker,C0023470,Myeloid Leukemia,disease,myeloid leukemias,55904,KMT2E,MLL5,CTD_human,18854576,"Human MLL5 is located on chromosome 7q22, which frequently is deleted in myeloid leukemias, suggesting a possible role in hemopoiesis.",0.20300763924902696,"Human <span class=""gene"" id=""18854576-2-6-10"">MLL5</span> is located on chromosome 7q22, which frequently is deleted in <span class=""disease"" id=""18854576-2-73-90"">myeloid leukemias</span>, suggesting a possible role in hemopoiesis.",CTD_human
2,0,Biomarker,C0020429,Hyperalgesia,phenotype,hyperalgesia,5594,MAPK1,ERK,CTD_human,12941468,"The upstream inhibitor of ERK phosphorylation, U0126 (100-400 microg/kg, i.v., 10 min pre-capsaicin), dose-dependently inhibited referred hyperalgesia 3-6 h after capsaicin.",0.2,"The upstream inhibitor of <span class=""gene"" id=""12941468-7-26-29"">ERK</span> phosphorylation, U0126 (100-400 microg/kg, i.v., 10 min pre-capsaicin), dose-dependently inhibited referred <span class=""disease"" id=""12941468-7-138-150"">hyperalgesia</span> 3-6 h after capsaicin.",CTD_human
1,0,Biomarker,C0022665,Kidney Neoplasm,disease,kidney tumor,5594,MAPK1,ERK,CTD_human,21813464,"The data indicate that Raf-1/MEK/ERK participates in crosstalk with 4EBP1, which represents a novel pathway interaction leading to increased protein synthesis, cell growth, and kidney tumor formation.",0.20054945356842604,"The data indicate that Raf-1/MEK/<span class=""gene"" id=""21813464-10-33-36"">ERK</span> participates in crosstalk with 4EBP1, which represents a novel pathway interaction leading to increased protein synthesis, cell growth, and <span class=""disease"" id=""21813464-10-177-189"">kidney tumor</span> formation.",CTD_human
1,0,Biomarker,C0243026,Sepsis,disease,sepsis,5594,MAPK1,p38,CTD_human,15489642,"These results indicate increased activity of TNF-alpha and MAPK following sepsis and demonstrate the beneficial effect of CMT-3 in preventing the increase in TNF-alpha, p38 MAPK, p42/44 MAPK, and the progression of septic shock.",0.200274726784213,"These results indicate increased activity of TNF-alpha and MAPK following <span class=""disease"" id=""15489642-10-74-80"">sepsis</span> and demonstrate the beneficial effect of CMT-3 in preventing the increase in TNF-alpha, <span class=""gene"" id=""15489642-10-169-172"">p38</span> MAPK, p42/44 MAPK, and the progression of septic shock.",CTD_human
2,0,Biomarker,C0020429,Hyperalgesia,phenotype,hyperalgesia,5595,MAPK3,ERK 1,CTD_human,12941468,Extracellular signaling-regulated kinase-1 and -2 (ERK 1/2) mediate referred hyperalgesia in a murine model of visceral pain.,0.2,"Extracellular signaling-regulated kinase-1 and -2 (<span class=""gene"" id=""12941468-0-51-56"">ERK 1</span>/2) mediate referred <span class=""disease"" id=""12941468-0-77-89"">hyperalgesia</span> in a murine model of visceral pain.",CTD_human
2,0,Biomarker,C0024121,Lung Neoplasms,group,lung tumors,5595,MAPK3,Erk 1,CTD_human,11884234,"Decrease in K-ras p21 and increase in Raf1 and activated Erk 1 and 2 in murine lung tumors initiated by N-nitrosodimethylamine and promoted by 2,3,7,8-tetrachlorodibenzo-p-dioxin.",0.20054945356842604,"Decrease in K-ras p21 and increase in Raf1 and activated <span class=""gene"" id=""11884234-0-57-62"">Erk 1</span> and 2 in murine <span class=""disease"" id=""11884234-0-79-90"">lung tumors</span> initiated by N-nitrosodimethylamine and promoted by 2,3,7,8-tetrachlorodibenzo-p-dioxin.",CTD_human
1,0,Biomarker,C0020429,Hyperalgesia,phenotype,hyperalgesia,5598,MAPK7,ERK5,CTD_human,17237256,"In contrast, there was no change in ERK5 phosphorylation in the spinal dorsal horn.The i.t. administration of ERK5 antisense oligodeoxynucleotide reversed heat hyperalgesia, but not mechanical allodynia, produced by capsaicin injection.",0.2,"In contrast, there was no change in <span class=""gene"" id=""17237256-7-36-40"">ERK5</span> phosphorylation in the spinal dorsal horn.The i.t. administration of <span class=""gene"" id=""17237256-7-110-114"">ERK5</span> antisense oligodeoxynucleotide reversed heat <span class=""disease"" id=""17237256-7-160-172"">hyperalgesia</span>, but not mechanical allodynia, produced by capsaicin injection.",CTD_human
1,0,Biomarker,C0011615,"Dermatitis, Atopic",disease,atopic dermatitis,5599,MAPK8,JNK1,CTD_human,24046278,The atopic dermatitis-like symptoms induced by MC903 were alleviated in JNK1 knockout mice.,0.2,"The <span class=""disease"" id=""24046278-0-4-21"">atopic dermatitis</span>-like symptoms induced by MC903 were alleviated in <span class=""gene"" id=""24046278-0-72-76"">JNK1</span> knockout mice.",CTD_human
1,0,Biomarker,C0013069,Double Outlet Right Ventricle,disease,double-outlet right ventricle,55997,CFC1,CFC1,CTD_human,11799476,CFC1 mutations in patients with transposition of the great arteries and double-outlet right ventricle.,0.20054945356842604,"<span class=""gene"" id=""11799476-0-0-4"">CFC1</span> mutations in patients with transposition of the great arteries and <span class=""disease"" id=""11799476-0-72-101"">double-outlet right ventricle</span>.",CTD_human
1,0,Biomarker,C0040761,Transposition of Great Vessels,disease,transposition of the great arteries,55997,CFC1,CFC1,CTD_human,11799476,CFC1 mutations in patients with transposition of the great arteries and double-outlet right ventricle.,0.200274726784213,"<span class=""gene"" id=""11799476-0-0-4"">CFC1</span> mutations in patients with <span class=""disease"" id=""11799476-0-32-67"">transposition of the great arteries</span> and double-outlet right ventricle.",CTD_human
1,0,Therapeutic,C0027627,Neoplasm Metastasis,phenotype,Metastasis,5601,MAPK9,c-Jun N-terminal Kinase 2,CTD_human,21779479,c-Jun N-terminal Kinase 2 Regulates Multiple Receptor Tyrosine Kinase Pathways in Mouse Mammary Tumor Growth and Metastasis.,0.2,"<span class=""gene"" id=""21779479-0-0-25"">c-Jun N-terminal Kinase 2</span> Regulates Multiple Receptor Tyrosine Kinase Pathways in Mouse Mammary Tumor Growth and <span class=""disease"" id=""21779479-0-113-123"">Metastasis</span>.",CTD_human
1,0,Biomarker,C0023443,Hairy Cell Leukemia,disease,hairy-cell leukemias,5604,MAP2K1,MAP2K1,CTD_human,24241536,High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias.,0.200274726784213,"High prevalence of <span class=""gene"" id=""24241536-0-19-25"">MAP2K1</span> mutations in variant and IGHV4-34-expressing <span class=""disease"" id=""24241536-0-71-91"">hairy-cell leukemias</span>.",CTD_human
1,0,Biomarker,C0025202,melanoma,disease,melanoma,5604,MAP2K1,MAP2K1,CTD_human,22197931,Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.,0.212608721319168,"Exome sequencing identifies recurrent somatic <span class=""gene"" id=""22197931-0-46-52"">MAP2K1</span> and MAP2K2 mutations in <span class=""disease"" id=""22197931-0-77-85"">melanoma</span>.",CTD_human
1,0,Biomarker,C0152013,Adenocarcinoma of lung (disorder),disease,adenocarcinoma of the lung,5604,MAP2K1,MEK1,CTD_human,22135231,"We examined epidermal growth factor receptor (EGFR), Kirsten rate sarcoma viral oncogene homolog (KRAS), v-Raf murine sarcoma viral oncogene homolog B1 (BRAF), human epidermal growth factor receptor 2 (HER2), PIK3CA, v-akt murine thymoma vial oncogene homolog 1 (AKT1), v-ras neuroblastoma viral oncogene homolog (NRAS), dual specificity mitogen-activated protein kinase kinase 1 (MEK1), and anaplastic lymphoma kinase (ALK) in patients with adenocarcinoma of the lung to identify driver mutations.",0.20082418035263896,"We examined epidermal growth factor receptor (EGFR), Kirsten rate sarcoma viral oncogene homolog (KRAS), v-Raf murine sarcoma viral oncogene homolog B1 (BRAF), human epidermal growth factor receptor 2 (HER2), PIK3CA, v-akt murine thymoma vial oncogene homolog 1 (AKT1), v-ras neuroblastoma viral oncogene homolog (NRAS), <span class=""gene"" id=""22135231-4-321-379"">dual specificity mitogen-activated protein kinase kinase 1</span> (<span class=""gene"" id=""22135231-4-381-385"">MEK1</span>), and anaplastic lymphoma kinase (ALK) in patients with <span class=""disease"" id=""22135231-4-442-468"">adenocarcinoma of the lung</span> to identify driver mutations.",CTD_human
1,0,Biomarker,C0025202,melanoma,disease,melanoma,5605,MAP2K2,MAP2K2,CTD_human,22197931,Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.,0.201648360705279,"Exome sequencing identifies recurrent somatic MAP2K1 and <span class=""gene"" id=""22197931-0-57-63"">MAP2K2</span> mutations in <span class=""disease"" id=""22197931-0-77-85"">melanoma</span>.",CTD_human
1,0,Biomarker,C0018801,Heart failure,disease,heart failure,5609,MAP2K7,MKK7,CTD_human,21284947,Deprivation of MKK7 in cardiomyocytes provokes heart failure in mice when exposed to pressure overload.,0.2,"Deprivation of <span class=""gene"" id=""21284947-0-15-19"">MKK7</span> in cardiomyocytes provokes <span class=""disease"" id=""21284947-0-47-60"">heart failure</span> in mice when exposed to pressure overload.",CTD_human
1,0,Biomarker,C0038220,Status Epilepticus,disease,status epilepticus,5610,EIF2AK2,PKR,CTD_human,16492139,Phosphorylation of the alpha subunit of translation initiation factor-2 by PKR mediates protein synthesis inhibition in the mouse brain during status epilepticus.,0.2,"Phosphorylation of the alpha subunit of translation initiation factor-2 by <span class=""gene"" id=""16492139-0-75-78"">PKR</span> mediates protein synthesis inhibition in the mouse brain during <span class=""disease"" id=""16492139-0-143-161"">status epilepticus</span>.",CTD_human
1,0,Biomarker,C0001418,Adenocarcinoma,group,adenocarcinomas,5617,PRL,prolactin,CTD_human,6280079,"Two continuous lines, BL-MaTU/A1 and BL-MaTU/s6, were established from C57Bl/10 mammary adenocarcinomas induced by DMBA-prolactin-estradiol treatment.",0.2,"Two continuous lines, BL-MaTU/A1 and BL-MaTU/s6, were established from C57Bl/10 mammary <span class=""disease"" id=""6280079-1-88-103"">adenocarcinomas</span> induced by DMBA-<span class=""gene"" id=""6280079-1-120-129"">prolactin</span>-estradiol treatment.",CTD_human
1,0,Biomarker,C0002453,Amenorrhea,phenotype,amenorrhoea,5617,PRL,PRL,CTD_human,6777091,In hyperprolactinaemic amenorrhoea pituitary hyper-responsiveness may not be due to PRL effects on ovarian steroidogenesis.,0.201098907136852,"In hyperprolactinaemic <span class=""disease"" id=""6777091-5-23-34"">amenorrhoea</span> pituitary hyper-responsiveness may not be due to <span class=""gene"" id=""6777091-5-84-87"">PRL</span> effects on ovarian steroidogenesis.",CTD_human
1,0,Biomarker,C0014175,Endometriosis,disease,endometriosis,5617,PRL,Prolactin,CTD_human,11925390,Prolactin and growth hormone secretion after thyrotrophin-releasing hormone infusion and dopaminergic (DA2) blockade in infertile patients with minimal/mild endometriosis.,0.201098907136852,"<span class=""gene"" id=""11925390-0-0-9"">Prolactin</span> and growth hormone secretion after thyrotrophin-releasing hormone infusion and dopaminergic (DA2) blockade in infertile patients with minimal/mild <span class=""disease"" id=""11925390-0-157-170"">endometriosis</span>.",CTD_human
2,0,Biomarker,C0018418,Gynecomastia,disease,gynecomastia,5617,PRL,Prolactin,CTD_human,9334596,"Prolactin should be determined only in cases of low sexual desire, gynecomastia and/or testosterone less than 4 ng./ml.",0.2,"<span class=""gene"" id=""9334596-20-0-9"">Prolactin</span> should be determined only in cases of low sexual desire, <span class=""disease"" id=""9334596-20-67-79"">gynecomastia</span> and/or testosterone less than 4 ng./ml.",CTD_human
4,0,Biomarker,C0020514,Hyperprolactinemia,disease,hyperprolactinemia,5617,PRL,PRL,CTD_human,17303669,"Antibodies developed by porcine or rat pituitary PRL reduced the bioactivity of rat serum PRL, and gonadal functions in these rats were normal despite hyperprolactinemia.",0.21179889634384602,"Antibodies developed by porcine or rat pituitary <span class=""gene"" id=""17303669-6-49-52"">PRL</span> reduced the bioactivity of rat serum <span class=""gene"" id=""17303669-6-90-93"">PRL</span>, and gonadal functions in these rats were normal despite <span class=""disease"" id=""17303669-6-151-169"">hyperprolactinemia</span>.",CTD_human
1,0,Biomarker,C0020619,Hypogonadism,disease,hypogonadism,5617,PRL,PRL,CTD_human,15829128,"Half of all men with prolactin (PRL)-producing macroadenomas present with hypogonadism, decreased libido and impotence, and therefore require testosterone replacement.",0.2,"Half of all men with <span class=""gene"" id=""15829128-1-21-30"">prolactin</span> (<span class=""gene"" id=""15829128-1-32-35"">PRL</span>)-producing macroadenomas present with <span class=""disease"" id=""15829128-1-74-86"">hypogonadism</span>, decreased libido and impotence, and therefore require testosterone replacement.",CTD_human
1,0,Biomarker,C0024141,"Lupus Erythematosus, Systemic",disease,systemic lupus erythematosus,5617,PRL,prolactin,CTD_human,14870917,Neuroendocrine dopaminergic regulation of prolactin release in systemic lupus erythematosus: a possible role of lymphocyte-derived prolactin.,0.22227363719231602,"Neuroendocrine dopaminergic regulation of <span class=""gene"" id=""14870917-0-42-51"">prolactin</span> release in <span class=""disease"" id=""14870917-0-63-91"">systemic lupus erythematosus</span>: a possible role of lymphocyte-derived <span class=""gene"" id=""14870917-0-131-140"">prolactin</span>.",CTD_human
3,0,Biomarker,C0032019,Pituitary Neoplasms,group,PT,5617,PRL,prolactin,CTD_human,6156259,"If animals were further treated with prolactin, the development of HT and MT was accelerated, whereas that of PT was suppressed.",0.21236270528958998,"If animals were further treated with <span class=""gene"" id=""6156259-3-37-46"">prolactin</span>, the development of HT and MT was accelerated, whereas that of <span class=""disease"" id=""6156259-3-110-112"">PT</span> was suppressed.",CTD_human
3,0,Therapeutic,C0032019,Pituitary Neoplasms,group,PT,5617,PRL,prolactin,CTD_human,6156259,"If animals were further treated with prolactin, the development of HT and MT was accelerated, whereas that of PT was suppressed.",0.21236270528958998,"If animals were further treated with <span class=""gene"" id=""6156259-3-37-46"">prolactin</span>, the development of HT and MT was accelerated, whereas that of <span class=""disease"" id=""6156259-3-110-112"">PT</span> was suppressed.",CTD_human
4,0,Biomarker,C0033375,Prolactinoma,disease,prolactinomas,5617,PRL,prolactin,CTD_human,3776530,Ultrastructural localization of prolactin in estrogen-induced prolactinoma of the rat pituitary. Experimental models for the human prolactinomas and the effects of bromocriptine.,0.213461612426442,"Ultrastructural localization of <span class=""gene"" id=""3776530-0-32-41"">prolactin</span> in estrogen-induced <span class=""disease"" id=""3776530-0-62-74"">prolactinoma</span> of the rat pituitary. Experimental models for the human <span class=""disease"" id=""3776530-0-131-144"">prolactinomas</span> and the effects of bromocriptine.",CTD_human
5,0,Biomarker,C0242350,Erectile dysfunction,disease,impotence,5617,PRL,prolactin,CTD_human,4001434,The patients who developed impotence were maintained on higher doses of sulpiride and exhibited higher prolactin levels in comparison to the potent patients.,0.200274726784213,"The patients who developed <span class=""disease"" id=""4001434-5-27-36"">impotence</span> were maintained on higher doses of sulpiride and exhibited higher <span class=""gene"" id=""4001434-5-103-112"">prolactin</span> levels in comparison to the potent patients.",CTD_human
5,0,Biomarker,C0242350,Erectile dysfunction,disease,impotence,5617,PRL,prolactin,CTD_human,8845563,A patient experiencing impotence was found to have increased prolactin and low testosterone concentrations.,0.200274726784213,"A patient experiencing <span class=""disease"" id=""8845563-2-23-32"">impotence</span> was found to have increased <span class=""gene"" id=""8845563-2-61-70"">prolactin</span> and low testosterone concentrations.",CTD_human
5,0,Biomarker,C0242350,Erectile dysfunction,disease,impotence,5617,PRL,PRL,CTD_human,15829128,"Half of all men with prolactin (PRL)-producing macroadenomas present with hypogonadism, decreased libido and impotence, and therefore require testosterone replacement.",0.200274726784213,"Half of all men with <span class=""gene"" id=""15829128-1-21-30"">prolactin</span> (<span class=""gene"" id=""15829128-1-32-35"">PRL</span>)-producing macroadenomas present with hypogonadism, decreased libido and <span class=""disease"" id=""15829128-1-109-118"">impotence</span>, and therefore require testosterone replacement.",CTD_human
1,0,Biomarker,C0349231,Phobic anxiety disorder,disease,Phobic disorder,5617,PRL,prolactin,CTD_human,2554359,Phobic disorder was associated with a lower prolactin response to both inhibitory and stimulatory challenges.,0.2,"<span class=""disease"" id=""2554359-5-0-15"">Phobic disorder</span> was associated with a lower <span class=""gene"" id=""2554359-5-44-53"">prolactin</span> response to both inhibitory and stimulatory challenges.",CTD_human
1,0,Biomarker,C0002395,Alzheimer's Disease,disease,Alzheimer disease,5621,PRNP,PRNP,CTD_human,17192785,"In addition to identifying the epsilon4 allele of APOE and related effects, we pinpointed over a dozen potential Alzheimer disease susceptibility genes (ACE, CHRNB2, CST3, ESR1, GAPDHS, IDE, MTHFR, NCSTN, PRNP, PSEN1, TF, TFAM and TNF) with statistically significant allelic summary odds ratios (ranging from 1.11-1.38 for risk alleles and 0.92-0.67 for protective alleles).",0.26807437040104104,"In addition to identifying the epsilon4 allele of APOE and related effects, we pinpointed over a dozen potential <span class=""disease"" id=""17192785-5-113-130"">Alzheimer disease</span> susceptibility genes (ACE, CHRNB2, CST3, ESR1, GAPDHS, IDE, MTHFR, NCSTN, <span class=""gene"" id=""17192785-5-205-209"">PRNP</span>, PSEN1, TF, TFAM and TNF) with statistically significant allelic summary odds ratios (ranging from 1.11-1.38 for risk alleles and 0.92-0.67 for protective alleles).",CTD_human
13,13,Biomarker,C0017495,Gerstmann-Straussler-Scheinker Disease,disease,Gerstmann-Str?ussler-Scheinker syndrome,5621,PRNP,prion protein,CTD_human,10203975,"[Gerstmann-Str?ussler-Scheinker syndrome with a Pro102Leu mutation in the prion protein gene and atypical MRI findings, hyperthermia, tachycardia, and hyperhidrosis].",0.7259800085465892,"[<span class=""disease"" id=""10203975-0-1-40"">Gerstmann-Str?ussler-Scheinker syndrome</span> with a Pro102Leu mutation in the <span class=""gene"" id=""10203975-0-74-87"">prion protein</span> gene and atypical MRI findings, hyperthermia, tachycardia, and hyperhidrosis].",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0019202,Hepatolenticular Degeneration,disease,Wilson disease,5621,PRNP,PrP,CTD_human,16831968,"This study shows for the first time, to our knowledge, that the human PrP polymorphism M129V influences the onset of symptoms in patients with the copper storage disorder Wilson disease.",0.208096423079816,"This study shows for the first time, to our knowledge, that the human <span class=""gene"" id=""16831968-8-70-73"">PrP</span> polymorphism M129V influences the onset of symptoms in patients with the copper storage disorder <span class=""disease"" id=""16831968-8-171-185"">Wilson disease</span>.",CTD_human
11,9,Biomarker,C0022336,Creutzfeldt-Jakob disease,disease,Creutzfeldt-Jakob disease,5621,PRNP,PrP,CTD_human,12572668,"Two proteins related to neurodegenerative diseases have been described as copper binding proteins: the amyloid precursor protein (APP), a protein related to Alzheimer's disease, and the Prion protein (PrP), related to Creutzfeldt-Jakob disease.",0.862766760370725,"Two proteins related to neurodegenerative diseases have been described as copper binding proteins: the amyloid precursor protein (APP), a protein related to Alzheimer's disease, and the <span class=""gene"" id=""12572668-3-186-199"">Prion protein</span> (<span class=""gene"" id=""12572668-3-201-204"">PrP</span>), related to <span class=""disease"" id=""12572668-3-218-243"">Creutzfeldt-Jakob disease</span>.",CTD_human;ORPHANET;UNIPROT
4,0,Biomarker,C0036457,Scrapie,disease,Scrapie,5621,PRNP,PrP,CTD_human,21533749,"The aim of this study is to investigate the profile of ovine PrP gene by amino acid polymorphism at codons 136, 141, 154, and 171 for determining the genetic predisposition to the Scrapie disease for the tribal sheep and rams, with different numbers and distribution in Bulgaria.",0.201373633921065,"The aim of this study is to investigate the profile of ovine <span class=""gene"" id=""21533749-1-61-64"">PrP</span> gene by amino acid polymorphism at codons 136, 141, 154, and 171 for determining the genetic predisposition to the <span class=""disease"" id=""21533749-1-180-187"">Scrapie</span> disease for the tribal sheep and rams, with different numbers and distribution in Bulgaria.",CTD_human
4,0,Biomarker,C0036457,Scrapie,disease,Scrapie,5621,PRNP,prion protein,CTD_human,18717736,Scrapie infection stimulated Gpc-1 autoprocessing and the generated HS degradation products colocalized with intracellular aggregates of the disease-related scrapie prion protein isoform (PrP(Sc)).,0.201373633921065,"<span class=""disease"" id=""18717736-6-0-7"">Scrapie</span> infection stimulated Gpc-1 autoprocessing and the generated HS degradation products colocalized with intracellular aggregates of the disease-related scrapie <span class=""gene"" id=""18717736-6-165-178"">prion protein</span> isoform (PrP(Sc)).",CTD_human
4,17,Biomarker,C0162534,Prion Diseases,group,prion diseases,5621,PRNP,PrP(C),CTD_human,11701772,"However, the interplay between PrPs (PrP(C), PrP(Sc) and possibly other abnormal species), copper, anti-oxidation activity and pathogenesis of prion diseases remain unclear.",0.32144541184634,"However, the interplay between PrPs (<span class=""gene"" id=""11701772-3-37-43"">PrP(C)</span>, PrP(Sc) and possibly other abnormal species), copper, anti-oxidation activity and pathogenesis of <span class=""disease"" id=""11701772-3-143-157"">prion diseases</span> remain unclear.",CTD_human
4,17,Biomarker,C0162534,Prion Diseases,group,transmissible spongiform encephalopathies,5621,PRNP,PrP-sen,CTD_human,11994310,Conversion of the normal membrane-bound prion protein (PrP-sen) to its pathological isoform (PrP-res) is a key event in the pathogenesis of transmissible spongiform encephalopathies.,0.32144541184634,"Conversion of the normal membrane-bound <span class=""gene"" id=""11994310-1-40-53"">prion protein</span> (<span class=""gene"" id=""11994310-1-55-62"">PrP-sen</span>) to its pathological isoform (PrP-res) is a key event in the pathogenesis of <span class=""disease"" id=""11994310-1-140-181"">transmissible spongiform encephalopathies</span>.",CTD_human
4,17,Biomarker,C0162534,Prion Diseases,group,Prion diseases,5621,PRNP,PrP,CTD_human,17257012,Prion diseases are caused by the misfolding and aggregation of the prion protein (PrP).,0.32144541184634,"<span class=""disease"" id=""17257012-1-0-14"">Prion diseases</span> are caused by the misfolding and aggregation of the <span class=""gene"" id=""17257012-1-67-80"">prion protein</span> (<span class=""gene"" id=""17257012-1-82-85"">PrP</span>).",CTD_human
1,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastasis,56261,GPCPD1,EDI3,CTD_human,25482527,"To confirm these results, we stably overexpressed EDI3 in MCF-7 cells which led to elevated integrin ?1 expression associated with enhanced cell attachment and spreading - two processes critical for metastasis.",0.200274726784213,"To confirm these results, we stably overexpressed <span class=""gene"" id=""25482527-8-50-54"">EDI3</span> in MCF-7 cells which led to elevated integrin &beta;1 expression associated with enhanced cell attachment and spreading - two processes critical for <span class=""disease"" id=""25482527-8-199-209"">metastasis</span>.",CTD_human
1,1,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,type 2 diabetes,5629,PROX1,PROX1,CTD_human,20081858,"We also demonstrated association of ADCY5, PROX1, GCK, GCKR and DGKB-TMEM195 with type 2 diabetes.",0.205638237399215,"We also demonstrated association of ADCY5, <span class=""gene"" id=""20081858-5-43-48"">PROX1</span>, GCK, GCKR and DGKB-TMEM195 with <span class=""disease"" id=""20081858-5-82-97"">type 2 diabetes</span>.",CTD_human
1,1,Biomarker,C0030305,Pancreatitis,disease,pancreatitis,5644,PRSS1,PRSS1,CTD_human,23143602,Common genetic variants in the CLDN2 and PRSS1-PRSS2 loci alter risk for alcohol-related and sporadic pancreatitis.,0.494168977222734,"Common genetic variants in the CLDN2 and <span class=""gene"" id=""23143602-0-41-46"">PRSS1</span>-PRSS2 loci alter risk for alcohol-related and sporadic <span class=""disease"" id=""23143602-0-102-114"">pancreatitis</span>.",CTD_human;HPO
1,0,Biomarker,C0149521,"Pancreatitis, Chronic",disease,chronic pancreatitis,5644,PRSS1,cationic trypsinogen,CTD_human,18206817,"Mutations in the PRSS1 gene, encoding cationic trypsinogen, play a causative role in chronic pancreatitis.",0.254181652829739,"Mutations in the <span class=""gene"" id=""18206817-6-17-22"">PRSS1</span> gene, encoding <span class=""gene"" id=""18206817-6-38-58"">cationic trypsinogen</span>, play a causative role in <span class=""disease"" id=""18206817-6-85-105"">chronic pancreatitis</span>.",CTD_human
9,16,Biomarker,C0238339,Hereditary pancreatitis,disease,Hereditary pancreatitis,5644,PRSS1,cationic trypsinogen,CTD_human,8841182,Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene.,0.628571585558163,"<span class=""disease"" id=""8841182-0-0-23"">Hereditary pancreatitis</span> is caused by a mutation in the <span class=""gene"" id=""8841182-0-55-75"">cationic trypsinogen</span> gene.",CTD_human;ORPHANET;UNIPROT
2,0,Biomarker,C0149521,"Pancreatitis, Chronic",disease,chronic pancreatitis,5645,PRSS2,PRSS2,CTD_human,16699518,A degradation-sensitive anionic trypsinogen (PRSS2) variant protects against chronic pancreatitis.,0.220574119329724,"A degradation-sensitive <span class=""gene"" id=""16699518-0-24-43"">anionic trypsinogen</span> (<span class=""gene"" id=""16699518-0-45-50"">PRSS2</span>) variant protects against <span class=""disease"" id=""16699518-0-77-97"">chronic pancreatitis</span>.",CTD_human
2,0,Biomarker,C0149521,"Pancreatitis, Chronic",disease,chronic pancreatitis,5645,PRSS2,PRSS2,CTD_human,18206817,"Other genes--such as the anionic trypsinogen (PRSS2), the serine protease inhibitor Kazal type 1 (SPINK1), and the cystic fibrosis transmembrane conductance regulator (CFTR)--have also been found to be associated with chronic pancreatitis (idiopathic and hereditary).",0.220574119329724,"Other genes--such as the <span class=""gene"" id=""18206817-8-25-44"">anionic trypsinogen</span> (<span class=""gene"" id=""18206817-8-46-51"">PRSS2</span>), the serine protease inhibitor Kazal type 1 (SPINK1), and the cystic fibrosis transmembrane conductance regulator (CFTR)--have also been found to be associated with <span class=""disease"" id=""18206817-8-218-238"">chronic pancreatitis</span> (idiopathic and hereditary).",CTD_human
1,0,Biomarker,C0005695,Bladder Neoplasm,disease,bladder cancer,5646,PRSS3,PRSS3,CTD_human,15987713,"We, therefore, examined, in a population-based study of human bladder cancer, the relationship between epigenetic silencing of three tumor suppressor genes, p16(INK4A), RASSF1A and PRSS3, and exposure to both tobacco and arsenic in bladder cancer.",0.203557092817453,"We, therefore, examined, in a population-based study of human <span class=""disease"" id=""15987713-5-62-76"">bladder cancer</span>, the relationship between epigenetic silencing of three tumor suppressor genes, p16(INK4A), RASSF1A and <span class=""gene"" id=""15987713-5-181-186"">PRSS3</span>, and exposure to both tobacco and arsenic in <span class=""disease"" id=""15987713-5-232-246"">bladder cancer</span>.",CTD_human
1,1,Biomarker,C0002395,Alzheimer's Disease,disease,Alzheimer's disease,5649,RELN,Reelin,CTD_human,20610758,Reduced Reelin expression accelerates amyloid-beta plaque formation and tau pathology in transgenic Alzheimer's disease mice.,0.20953556953551103,"Reduced <span class=""gene"" id=""20610758-0-8-14"">Reelin</span> expression accelerates amyloid-beta plaque formation and tau pathology in transgenic <span class=""disease"" id=""20610758-0-100-119"">Alzheimer's disease</span> mice.",CTD_human
3,0,Biomarker,C0004352,Autistic Disorder,disease,autistic,5649,RELN,Reelin,CTD_human,11814262,Dysregulation of Reelin and Bcl-2 proteins in autistic cerebellum.,0.232791444172737,"Dysregulation of <span class=""gene"" id=""11814262-0-17-23"">Reelin</span> and Bcl-2 proteins in <span class=""disease"" id=""11814262-0-46-54"">autistic</span> cerebellum.",CTD_human
3,0,Biomarker,C0004352,Autistic Disorder,disease,autistic disorder,5649,RELN,Reelin,CTD_human,11317216,Reelin gene alleles and haplotypes as a factor predisposing to autistic disorder.,0.232791444172737,"<span class=""gene"" id=""11317216-0-0-6"">Reelin</span> gene alleles and haplotypes as a factor predisposing to <span class=""disease"" id=""11317216-0-63-80"">autistic disorder</span>.",CTD_human
3,0,Biomarker,C0004352,Autistic Disorder,disease,autism,5649,RELN,RELN,CTD_human,20442744,"Our results strengthen the case for a more detailed study of the role of RELN and GRIK2 in autism susceptibility, as well as identifying two new potential candidate genes, MKL2 and SND1.",0.232791444172737,"Our results strengthen the case for a more detailed study of the role of <span class=""gene"" id=""20442744-10-73-77"">RELN</span> and GRIK2 in <span class=""disease"" id=""20442744-10-91-97"">autism</span> susceptibility, as well as identifying two new potential candidate genes, MKL2 and SND1.",CTD_human
8,0,Biomarker,C0005586,Bipolar Disorder,disease,bipolar disorder,5649,RELN,reelin,CTD_human,14708030,"In addition, reelin protein in the molecular layer of the dentate gyrus was decreased in schizophrenia, bipolar disorder, and depression at the trend level of statistical significance (P=0.065).",0.40433011601278,"In addition, <span class=""gene"" id=""14708030-5-13-19"">reelin</span> protein in the molecular layer of the dentate gyrus was decreased in schizophrenia, <span class=""disease"" id=""14708030-5-104-120"">bipolar disorder</span>, and depression at the trend level of statistical significance (P=0.065).",CTD_human;PSYGENET
8,0,Biomarker,C0005586,Bipolar Disorder,disease,bipolar disorder,5649,RELN,Reelin,CTD_human,15560956,"We employed SDS-PAGE and Western blotting to measure levels of GAD isomers 65 and 67 kDa and Reelin isoforms 410-, 330- and 180-kDa proteins as well as beta-actin in cerebellum of subjects with schizophrenia, bipolar disorder and major depression vs. controls (N = 15 per group).",0.40433011601278,"We employed SDS-PAGE and Western blotting to measure levels of GAD isomers 65 and 67 kDa and <span class=""gene"" id=""15560956-5-93-99"">Reelin</span> isoforms 410-, 330- and 180-kDa proteins as well as beta-actin in cerebellum of subjects with schizophrenia, <span class=""disease"" id=""15560956-5-209-225"">bipolar disorder</span> and major depression vs. controls (N = 15 per group).",CTD_human;PSYGENET
8,0,Biomarker,C0005586,Bipolar Disorder,disease,bipolar disorder,5649,RELN,Reelin,CTD_human,11126396,"Reduction in Reelin immunoreactivity in hippocampus of subjects with schizophrenia, bipolar disorder and major depression.",0.40433011601278,"Reduction in <span class=""gene"" id=""11126396-0-13-19"">Reelin</span> immunoreactivity in hippocampus of subjects with schizophrenia, <span class=""disease"" id=""11126396-0-84-100"">bipolar disorder</span> and major depression.",CTD_human;PSYGENET
4,0,Biomarker,C0011581,Depressive disorder,disease,depression,5649,RELN,reelin,CTD_human,14708030,"In addition, reelin protein in the molecular layer of the dentate gyrus was decreased in schizophrenia, bipolar disorder, and depression at the trend level of statistical significance (P=0.065).",0.4,"In addition, <span class=""gene"" id=""14708030-5-13-19"">reelin</span> protein in the molecular layer of the dentate gyrus was decreased in schizophrenia, bipolar disorder, and <span class=""disease"" id=""14708030-5-126-136"">depression</span> at the trend level of statistical significance (P=0.065).",CTD_human;PSYGENET
4,1,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,5649,RELN,reelin,CTD_human,14708030,"In addition, reelin protein in the molecular layer of the dentate gyrus was decreased in schizophrenia, bipolar disorder, and depression at the trend level of statistical significance (P=0.065).",0.328957258309358,"In addition, <span class=""gene"" id=""14708030-5-13-19"">reelin</span> protein in the molecular layer of the dentate gyrus was decreased in <span class=""disease"" id=""14708030-5-89-102"">schizophrenia</span>, bipolar disorder, and depression at the trend level of statistical significance (P=0.065).",CTD_human
4,1,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,5649,RELN,Reelin,CTD_human,11126396,"Reduction in Reelin immunoreactivity in hippocampus of subjects with schizophrenia, bipolar disorder and major depression.",0.328957258309358,"Reduction in <span class=""gene"" id=""11126396-0-13-19"">Reelin</span> immunoreactivity in hippocampus of subjects with <span class=""disease"" id=""11126396-0-69-82"">schizophrenia</span>, bipolar disorder and major depression.",CTD_human
4,1,Biomarker,C0036341,Schizophrenia,disease,SZ,5649,RELN,reelin,CTD_human,19110320,This remodeling might contribute to reelin- and GAD(67)-promoter demethylation and might reverse the GABAergic-gene-expression downregulation associated with SZ morbidity.,0.328957258309358,"This remodeling might contribute to <span class=""gene"" id=""19110320-6-36-42"">reelin</span>- and GAD(67)-promoter demethylation and might reverse the GABAergic-gene-expression downregulation associated with <span class=""disease"" id=""19110320-6-158-160"">SZ</span> morbidity.",CTD_human
4,1,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,5649,RELN,Reelin,CTD_human,15560956,GABAergic dysfunction in schizophrenia and mood disorders as reflected by decreased levels of glutamic acid decarboxylase 65 and 67 kDa and Reelin proteins in cerebellum.,0.328957258309358,"GABAergic dysfunction in <span class=""disease"" id=""15560956-0-25-38"">schizophrenia</span> and mood disorders as reflected by decreased levels of glutamic acid decarboxylase 65 and 67 kDa and <span class=""gene"" id=""15560956-0-140-146"">Reelin</span> proteins in cerebellum.",CTD_human
3,0,Biomarker,C1269683,Major Depressive Disorder,disease,major depression,5649,RELN,Reelin,CTD_human,11126396,"Reduction in Reelin immunoreactivity in hippocampus of subjects with schizophrenia, bipolar disorder and major depression.",0.4,"Reduction in <span class=""gene"" id=""11126396-0-13-19"">Reelin</span> immunoreactivity in hippocampus of subjects with schizophrenia, bipolar disorder and <span class=""disease"" id=""11126396-0-105-121"">major depression</span>.",CTD_human;PSYGENET
1,0,Biomarker,C0037274,Dermatologic disorders,group,skin diseases,56547,MMP26,MMP-26,CTD_human,16984259,Expression of MMP-26 was detected by immunohistochemistry in granulomatous skin diseases and actinic elastosis.,0.20054945356842604,"Expression of <span class=""gene"" id=""16984259-7-14-20"">MMP-26</span> was detected by immunohistochemistry in granulomatous <span class=""disease"" id=""16984259-7-75-88"">skin diseases</span> and actinic elastosis.",CTD_human
1,0,Biomarker,C0740394,Hyperuricemia,disease,hyperuricemia,56606,SLC2A9,SLC2A9,CTD_human,18989453,Mutations in the SLC2A9 gene cause hyperuricosuria and hyperuricemia in the dog.,0.20886944627514298,"Mutations in the <span class=""gene"" id=""18989453-0-17-23"">SLC2A9</span> gene cause hyperuricosuria and <span class=""disease"" id=""18989453-0-55-68"">hyperuricemia</span> in the dog.",CTD_human
3,20,Biomarker,C0431399,Familial aplasia of the vermis,disease,Joubert syndrome,56623,INPP5E,INPP5E,CTD_human,19668216,"INPP5E localized to cilia in major organs affected by Joubert syndrome, and mutations promoted premature destabilization of cilia in response to stimulation.",0.6016483607052789,"<span class=""gene"" id=""19668216-5-0-6"">INPP5E</span> localized to cilia in major organs affected by <span class=""disease"" id=""19668216-5-54-70"">Joubert syndrome</span>, and mutations promoted premature destabilization of cilia in response to stimulation.",CTD_human;ORPHANET;UNIPROT
12,0,Biomarker,C0002395,Alzheimer's Disease,disease,Alzheimer's disease,5663,PSEN1,presenilin-1,CTD_human,15622541,Pick bodies in a family with presenilin-1 Alzheimer's disease.,0.92,"Pick bodies in a family with <span class=""gene"" id=""15622541-0-29-41"">presenilin-1</span> <span class=""disease"" id=""15622541-0-42-61"">Alzheimer's disease</span>.",CTD_human;HPO;ORPHANET
12,0,Biomarker,C0002395,Alzheimer's Disease,disease,Alzheimer disease,5663,PSEN1,PSEN1,CTD_human,17192785,"In addition to identifying the epsilon4 allele of APOE and related effects, we pinpointed over a dozen potential Alzheimer disease susceptibility genes (ACE, CHRNB2, CST3, ESR1, GAPDHS, IDE, MTHFR, NCSTN, PRNP, PSEN1, TF, TFAM and TNF) with statistically significant allelic summary odds ratios (ranging from 1.11-1.38 for risk alleles and 0.92-0.67 for protective alleles).",0.92,"In addition to identifying the epsilon4 allele of APOE and related effects, we pinpointed over a dozen potential <span class=""disease"" id=""17192785-5-113-130"">Alzheimer disease</span> susceptibility genes (ACE, CHRNB2, CST3, ESR1, GAPDHS, IDE, MTHFR, NCSTN, PRNP, <span class=""gene"" id=""17192785-5-211-216"">PSEN1</span>, TF, TFAM and TNF) with statistically significant allelic summary odds ratios (ranging from 1.11-1.38 for risk alleles and 0.92-0.67 for protective alleles).",CTD_human;HPO;ORPHANET
1,0,Biomarker,C0002726,Amyloidosis,disease,A?,5663,PSEN1,presenilin-1,CTD_human,23541064,"In the present study, we evaluated the effects of a 3-month treatment course of trientine (Trien) on amyloidosis in 7-month-old ?-amyloid (A?) precursor protein and presenilin-1 (APP/PS1) double transgenic (Tg) AD model mice.",0.24807718723729302,"In the present study, we evaluated the effects of a 3-month treatment course of trientine (Trien) on <span class=""disease"" id=""23541064-3-101-112"">amyloidosis</span> in 7-month-old &beta;-<span class=""disease"" id=""23541064-3-130-137"">amyloid</span> (<span class=""disease"" id=""23541064-3-139-141"">A&beta;</span>) precursor protein and <span class=""gene"" id=""23541064-3-165-177"">presenilin-1</span> (APP/PS1) double transgenic (Tg) AD model mice.",CTD_human
2,1,Biomarker,C0236642,Pick Disease of the Brain,disease,Pick's disease,5663,PSEN1,PS-1,CTD_human,15622541,M146L mutant PS-1 may predispose to both Pick's disease and AD by affecting multiple intracellular pathways involving tau phosphorylation and amyloid metabolism.,0.20712854101222303,"M146L mutant <span class=""gene"" id=""15622541-4-13-17"">PS-1</span> may predispose to both <span class=""disease"" id=""15622541-4-41-55"">Pick's disease</span> and AD by affecting multiple intracellular pathways involving tau phosphorylation and amyloid metabolism.",CTD_human
2,1,Biomarker,C0236642,Pick Disease of the Brain,disease,Pick's disease,5663,PSEN1,presenilin 1,CTD_human,15122701,A novel presenilin 1 mutation associated with Pick's disease but not beta-amyloid plaques.,0.20712854101222303,"A novel <span class=""gene"" id=""15122701-0-8-20"">presenilin 1</span> mutation associated with <span class=""disease"" id=""15122701-0-46-60"">Pick's disease</span> but not beta-amyloid plaques.",CTD_human
1,1,Biomarker,C0338451,Frontotemporal dementia,disease,frontotemporal dementia,5663,PSEN1,PSEN1,CTD_human,11094121,The authors conclude that PSEN1 mutations can be associated with clinical features of frontotemporal dementia.,0.609484412378199,"The authors conclude that <span class=""gene"" id=""11094121-4-26-31"">PSEN1</span> mutations can be associated with clinical features of <span class=""disease"" id=""11094121-4-86-109"">frontotemporal dementia</span>.",CTD_human;HPO;UNIPROT
3,2,Biomarker,C0002395,Alzheimer's Disease,disease,Alzheimer disease,5664,PSEN2,PSEN2,CTD_human,12925374,To describe a novel mutation in the PSEN2 gene associated with early-onset autosomal dominant Alzheimer disease.,0.701621575503079,"To describe a novel mutation in the <span class=""gene"" id=""12925374-3-36-41"">PSEN2</span> gene associated with early-onset autosomal dominant <span class=""disease"" id=""12925374-3-94-111"">Alzheimer disease</span>.",CTD_human;HPO;ORPHANET
1,0,Therapeutic,C0004364,Autoimmune Diseases,group,autoimmunity,567,B2M,?2-microglobulin,CTD_human,21793797,?2-microglobulin is required for the full expression of xenobiotic-induced systemic autoimmunity.,0.200274726784213,"<span class=""gene"" id=""21793797-0-0-16"">&beta;2-microglobulin</span> is required for the full expression of xenobiotic-induced systemic <span class=""disease"" id=""21793797-0-84-96"">autoimmunity</span>.",CTD_human
1,0,Biomarker,C0079744,Diffuse Large B-Cell Lymphoma,disease,diffuse large cell lymphoma,567,B2M,beta 2 microglobulin,CTD_human,7688627,Value of serum beta 2 microglobulin as an indicator of early relapse in diffuse large cell lymphoma.,0.20054945356842604,"Value of serum <span class=""gene"" id=""7688627-0-15-35"">beta 2 microglobulin</span> as an indicator of early relapse in <span class=""disease"" id=""7688627-0-72-99"">diffuse large cell lymphoma</span>.",CTD_human
1,0,Biomarker,C0019337,Heroin Dependence,disease,heroin addiction,56729,RETN,resistin,CTD_human,15717844,"In conclusion, circulating concentrations of leptin, adiponectin and resistin are markedly altered in patients with chronic heroin addiction.",0.2,"In conclusion, circulating concentrations of leptin, adiponectin and <span class=""gene"" id=""15717844-6-69-77"">resistin</span> are markedly altered in patients with chronic <span class=""disease"" id=""15717844-6-124-140"">heroin addiction</span>.",CTD_human
1,0,Biomarker,C0022661,"Kidney Failure, Chronic",disease,ESRD,56729,RETN,resistin,CTD_human,19539174,"Serum concentrations of C-reactive protein, adiponectin, resistin, interleukin-6, tumor necrosis factor-alpha, and monocyte chemoattractant protein-1 were significantly higher in the ESRD versus control group.",0.20541466777231498,"Serum concentrations of C-reactive protein, adiponectin, <span class=""gene"" id=""19539174-7-57-65"">resistin</span>, interleukin-6, tumor necrosis factor-alpha, and monocyte chemoattractant protein-1 were significantly higher in the <span class=""disease"" id=""19539174-7-183-187"">ESRD</span> versus control group.",CTD_human
1,0,Biomarker,C0524620,Metabolic Syndrome X,disease,metabolic syndrome,56729,RETN,resistin,CTD_human,18328350,"Relationship between plasma resistin concentrations, inflammatory chemokines, and components of the metabolic syndrome in adults.",0.21079253376463397,"Relationship between plasma <span class=""gene"" id=""18328350-0-28-36"">resistin</span> concentrations, inflammatory chemokines, and components of the <span class=""disease"" id=""18328350-0-100-118"">metabolic syndrome</span> in adults.",CTD_human
1,1,Biomarker,C0027051,Myocardial Infarction,disease,myocardial infarction,5687,PSMA6,PSMA6,CTD_human,16845397,A functional SNP in PSMA6 confers risk of myocardial infarction in the Japanese population.,0.21779004970759802,"A functional SNP in <span class=""gene"" id=""16845397-0-20-25"">PSMA6</span> confers risk of <span class=""disease"" id=""16845397-0-42-63"">myocardial infarction</span> in the Japanese population.",CTD_human
1,0,Biomarker,C0031117,Peripheral Neuropathy,group,PN,5689,PSMB1,PSMB1,CTD_human,21228734,"Genes associated with immune function (CTLA4, CTSS), reflexive coupling within Schwann cells (GJE1), drug binding (PSMB1), and neuron function (TCF4, DYNC1I1) associated with bortezomib-induced PN in this study.",0.200274726784213,"Genes associated with immune function (CTLA4, CTSS), reflexive coupling within Schwann cells (GJE1), drug binding (<span class=""gene"" id=""21228734-10-115-120"">PSMB1</span>), and neuron function (TCF4, DYNC1I1) associated with bortezomib-induced <span class=""disease"" id=""21228734-10-194-196"">PN</span> in this study.",CTD_human
1,0,Biomarker,C0948089,Acute Coronary Syndrome,disease,ACS,5689,PSMB1,proteasome subunit ? type 1,CTD_human,21751358,"Moreover, reduction in the expression of proteins associated with cell survival such as proteasome subunit ? type 1 was also observed in ACS platelets compared with CAD platelets.",0.2,"Moreover, reduction in the expression of proteins associated with cell survival such as <span class=""gene"" id=""21751358-5-88-115"">proteasome subunit &beta; type 1</span> was also observed in <span class=""disease"" id=""21751358-5-137-140"">ACS</span> platelets compared with CAD platelets.",CTD_human
1,0,Biomarker,C0025202,melanoma,disease,melanoma,56925,LXN,LXN,CTD_human,17145863,"Three of the genes, QPCT, CYP1B1, and LXN, are densely methylated in >95% of uncultured melanoma tumor samples.",0.201098907136852,"Three of the genes, QPCT, CYP1B1, and <span class=""gene"" id=""17145863-5-38-41"">LXN</span>, are densely methylated in &gt;95% of uncultured <span class=""disease"" id=""17145863-5-88-96"">melanoma</span> tumor samples.",CTD_human
1,0,Biomarker,C0011615,"Dermatitis, Atopic",disease,atopic dermatitis,56946,EMSY,C11orf30,CTD_human,23042114,"We also replicated the associations of the FLG, C11orf30, TMEM232-SLC25A46, TNFRSF6B-ZGPAT, OVOL1, ACTL9 and KIF3A-IL13 loci that were previously reported in GWAS of European and Chinese individuals and a meta-analysis of GWAS for atopic dermatitis.",0.20054945356842604,"We also replicated the associations of the FLG, <span class=""gene"" id=""23042114-3-48-56"">C11orf30</span>, TMEM232-SLC25A46, TNFRSF6B-ZGPAT, OVOL1, ACTL9 and KIF3A-IL13 loci that were previously reported in GWAS of European and Chinese individuals and a meta-analysis of GWAS for <span class=""disease"" id=""23042114-3-231-248"">atopic dermatitis</span>.",CTD_human
1,0,Biomarker,C0007137,Squamous cell carcinoma,disease,squamous-cell carcinomas,56952,PRTFDC1,PRTFDC1,CTD_human,17599052,"PRTFDC1, a possible tumor-suppressor gene, is frequently silenced in oral squamous-cell carcinomas by aberrant promoter hypermethylation.",0.200274726784213,"<span class=""gene"" id=""17599052-0-0-7"">PRTFDC1</span>, a possible tumor-suppressor gene, is frequently silenced in oral <span class=""disease"" id=""17599052-0-74-98"">squamous-cell carcinomas</span> by aberrant promoter hypermethylation.",CTD_human
1,0,Biomarker,C0002395,Alzheimer's Disease,disease,Alzheimer's disease,5697,PYY,peptide YY,CTD_human,11709213,"Neuropeptide Y, peptide YY and aluminum in Alzheimer's disease: is there an etiological relationship?",0.2,"Neuropeptide Y, <span class=""gene"" id=""11709213-0-16-26"">peptide YY</span> and aluminum in <span class=""disease"" id=""11709213-0-43-62"">Alzheimer's disease</span>: is there an etiological relationship?",CTD_human
1,0,Biomarker,C0003123,Anorexia,disease,Anorexia,5697,PYY,peptide YY,CTD_human,22903826,Anorexia induction by the trichothecene deoxynivalenol (vomitoxin) is mediated by the release of the gut satiety hormone peptide YY.,0.20082418035263896,"<span class=""disease"" id=""22903826-0-0-8"">Anorexia</span> induction by the trichothecene deoxynivalenol (vomitoxin) is mediated by the release of the gut satiety hormone <span class=""gene"" id=""22903826-0-121-131"">peptide YY</span>.",CTD_human
1,0,Biomarker,C0027794,Neural Tube Defects,group,NTD,5697,PYY,PYY,CTD_human,17400914,"PYY Y1 receptor antagonist prevented the occurrence of NTD induced not only by PYY but also by vitamin A, a well-known teratogen in humans and animals.",0.2,"<span class=""gene"" id=""17400914-5-0-3"">PYY</span> Y1 receptor antagonist prevented the occurrence of <span class=""disease"" id=""17400914-5-55-58"">NTD</span> induced not only by <span class=""gene"" id=""17400914-5-79-82"">PYY</span> but also by vitamin A, a well-known teratogen in humans and animals.",CTD_human
1,0,Biomarker,C0028754,Obesity,disease,obesity,5697,PYY,PYY,CTD_human,16368708,A PYY Q62P variant linked to human obesity.,0.21484792299320102,"A <span class=""gene"" id=""16368708-0-2-5"">PYY</span> Q62P variant linked to human <span class=""disease"" id=""16368708-0-35-42"">obesity</span>.",CTD_human
1,0,Biomarker,C0035222,"Respiratory Distress Syndrome, Adult",disease,ARDS,56994,CHPT1,CPT,CTD_human,16292752,CEES induced ceramide accumulation may thus play an important role in the development of ARDS by modulating CPT enzyme.,0.2,"CEES induced ceramide accumulation may thus play an important role in the development of <span class=""disease"" id=""16292752-19-89-93"">ARDS</span> by modulating <span class=""gene"" id=""16292752-19-108-111"">CPT</span> enzyme.",CTD_human
2,0,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,T2DM,56999,ADAMTS9,ADAMTS9,CTD_human,23967108,"Additionally, genetic variants in ADAMTS9 may increase the risk of T2DM.",0.254328261433402,"Additionally, genetic variants in <span class=""gene"" id=""23967108-13-34-41"">ADAMTS9</span> may increase the risk of <span class=""disease"" id=""23967108-13-67-71"">T2DM</span>.",CTD_human
1,0,Biomarker,C0036572,Seizures,phenotype,seizure,57030,SLC17A7,VGLUT-1,CTD_human,18495095,"Ten-twelve weeks after hyperthermic seizure, animals (approximately 68%) showed electroencephalographic seizure activity with increased VGLUT-1 immunoreactivity in the dentate gyrus.",0.2,"Ten-twelve weeks after hyperthermic <span class=""disease"" id=""18495095-7-36-43"">seizure</span>, animals (approximately 68%) showed electroencephalographic <span class=""disease"" id=""18495095-7-104-111"">seizure</span> activity with increased <span class=""gene"" id=""18495095-7-136-143"">VGLUT-1</span> immunoreactivity in the dentate gyrus.",CTD_human
1,0,Biomarker,C0028738,Nystagmus,disease,nystagmus,57096,RPGRIP1,RPGRIP1,CTD_human,11283794,"Patients with RPGRIP1 mutations have a degeneration of both rod and cone photoreceptors, and, early in life, they experience a severe loss of central acuity, which leads to nystagmus.",0.200274726784213,"Patients with <span class=""gene"" id=""11283794-6-14-21"">RPGRIP1</span> mutations have a degeneration of both rod and cone photoreceptors, and, early in life, they experience a severe loss of central acuity, which leads to <span class=""disease"" id=""11283794-6-173-182"">nystagmus</span>.",CTD_human
1,0,Biomarker,C0035334,Retinitis Pigmentosa,disease,retinitis pigmentosa,57096,RPGRIP1,RPGRIP1,CTD_human,16272259,"Identification of mutations in the AIPL1, CRB1, GUCY2D, RPE65, and RPGRIP1 genes in patients with juvenile retinitis pigmentosa.",0.404930726738519,"Identification of mutations in the AIPL1, CRB1, GUCY2D, RPE65, and <span class=""gene"" id=""16272259-0-67-74"">RPGRIP1</span> genes in patients with juvenile <span class=""disease"" id=""16272259-0-107-127"">retinitis pigmentosa</span>.",CTD_human;ORPHANET
2,2,Biomarker,C0339527,Leber Congenital Amaurosis,disease,Leber congenital amaurosis,57096,RPGRIP1,RPGRIP1,CTD_human,11528500,Complete exon-intron structure of the RPGR-interacting protein (RPGRIP1) gene allows the identification of mutations underlying Leber congenital amaurosis.,0.40384617497898295,"Complete exon-intron structure of the RPGR-interacting protein (<span class=""gene"" id=""11528500-0-64-71"">RPGRIP1</span>) gene allows the identification of mutations underlying <span class=""disease"" id=""11528500-0-128-154"">Leber congenital amaurosis</span>.",CTD_human;ORPHANET
2,2,Biomarker,C0339527,Leber Congenital Amaurosis,disease,Leber congenital amaurosis,57096,RPGRIP1,RPGRIP1,CTD_human,11283794,Null RPGRIP1 alleles in patients with Leber congenital amaurosis.,0.40384617497898295,"Null <span class=""gene"" id=""11283794-0-5-12"">RPGRIP1</span> alleles in patients with <span class=""disease"" id=""11283794-0-38-64"">Leber congenital amaurosis</span>.",CTD_human;ORPHANET
1,0,Biomarker,C0220633,Uveal melanoma,disease,uveal melanoma,57105,CYSLTR2,CYSLTR2,CTD_human,27089179,Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma.,0.4,"Recurrent activating mutations of G-protein-coupled receptor <span class=""gene"" id=""27089179-0-61-68"">CYSLTR2</span> in <span class=""disease"" id=""27089179-0-72-86"">uveal melanoma</span>.",CTD_human;ORPHANET
2,0,Biomarker,C1319853,"Asthma, Aspirin-Induced",disease,AIA,57105,CYSLTR2,CYSLTR2,CTD_human,16502481,"Increased expression of CYSLTR1 with CYLSTR1 and CYSLTR2 polymorphisms are new findings in AIA, while the ALOX5 promoter polymorphism has been noted in AIU.",0.200274726784213,"Increased expression of CYSLTR1 with CYLSTR1 and <span class=""gene"" id=""16502481-4-49-56"">CYSLTR2</span> polymorphisms are new findings in <span class=""disease"" id=""16502481-4-91-94"">AIA</span>, while the ALOX5 promoter polymorphism has been noted in AIU.",CTD_human
2,0,Biomarker,C0033578,Prostatic Neoplasms,group,prostate tumors,572,BAD,BAD,CTD_human,19593445,"These results suggest that increased expression of BAD provides a proliferative advantage to prostate tumors, while BAD dephosphorylation increases sensitivity of prostate cancer cells to apoptosis.",0.20874819096286698,"These results suggest that increased expression of <span class=""gene"" id=""19593445-7-51-54"">BAD</span> provides a proliferative advantage to <span class=""disease"" id=""19593445-7-93-108"">prostate tumors</span>, while <span class=""gene"" id=""19593445-7-116-119"">BAD</span> dephosphorylation increases sensitivity of prostate cancer cells to apoptosis.",CTD_human
1,0,Biomarker,C0279626,Squamous cell carcinoma of esophagus,disease,ESCC,5720,PSME1,PSME1,CTD_human,21517111,"Among these identified proteins, 33 proteins including keratin 17 (KRT17), biliverdin reductase B (BLVRB), proteasome activator subunit 1 (PSME1), manganese superoxide dismutase (MnSOD), high-mobility group box-1(HMGB1), heat shock protein 70 (HSP70), peroxiredoxin (PRDX1), keratin 13 (KRT13), and so on were overexpressed, and 14 proteins including cystatin B (CSTB), tropomyosin 2 (TPM2), annexin 1 (ANX1), transgelin (TAGLN), keratin 19 (KRT19), stratifin (SFN), and so on were down-expressed in ESCC.",0.2,"Among these identified proteins, 33 proteins including keratin 17 (KRT17), biliverdin reductase B (BLVRB), <span class=""gene"" id=""21517111-5-107-137"">proteasome activator subunit 1</span> (<span class=""gene"" id=""21517111-5-139-144"">PSME1</span>), manganese superoxide dismutase (MnSOD), high-mobility group box-1(HMGB1), heat shock protein 70 (HSP70), peroxiredoxin (PRDX1), keratin 13 (KRT13), and so on were overexpressed, and 14 proteins including cystatin B (CSTB), tropomyosin 2 (TPM2), annexin 1 (ANX1), transgelin (TAGLN), keratin 19 (KRT19), stratifin (SFN), and so on were down-expressed in <span class=""disease"" id=""21517111-5-500-504"">ESCC</span>.",CTD_human
1,0,Biomarker,C0007758,Cerebellar Ataxia,phenotype,ataxia,57231,SNX14,SNX14,CTD_human,25848753,Our results characterize a unique ataxia syndrome due to biallelic SNX14 mutations leading to lysosome-autophagosome dysfunction.,0.20082418035263896,"Our results characterize a unique <span class=""disease"" id=""25848753-6-34-40"">ataxia</span> syndrome due to biallelic <span class=""gene"" id=""25848753-6-67-72"">SNX14</span> mutations leading to lysosome-autophagosome dysfunction.",CTD_human
1,0,Biomarker,C3714756,Intellectual Disability,group,intellectual disability,57231,SNX14,SNX14,CTD_human,25848753,"Here we describe a new clinically distinguishable recessive syndrome in 12 families with cerebellar atrophy together with ataxia, coarsened facial features and intellectual disability, due to truncating mutations in the sorting nexin gene SNX14, encoding a ubiquitously expressed modular PX domain-containing sorting factor.",0.20054945356842604,"Here we describe a new clinically distinguishable recessive syndrome in 12 families with cerebellar atrophy together with ataxia, coarsened facial features and <span class=""disease"" id=""25848753-2-160-183"">intellectual disability</span>, due to truncating mutations in the sorting nexin gene <span class=""gene"" id=""25848753-2-239-244"">SNX14</span>, encoding a ubiquitously expressed modular PX domain-containing sorting factor.",CTD_human
4,0,Biomarker,C0001973,"Alcoholic Intoxication, Chronic",disease,alcohol dependence,5726,TAS2R38,TAS2R38,CTD_human,17250611,"In contrast to the previously reported significant association between TAS2R16 and alcohol dependence, we found no evidence that TAS2R38 haplotypes influence alcohol dependence in the COGA dataset.",0.4010989071368521,"In contrast to the previously reported significant association between TAS2R16 and <span class=""disease"" id=""17250611-11-83-101"">alcohol dependence</span>, we found no evidence that <span class=""gene"" id=""17250611-11-129-136"">TAS2R38</span> haplotypes influence <span class=""disease"" id=""17250611-11-158-176"">alcohol dependence</span> in the COGA dataset.",CTD_human;PSYGENET
13,31,Biomarker,C0004779,Basal Cell Nevus Syndrome,disease,Gorlin syndrome,5727,PTCH1,PTCH1,CTD_human,19287498,PTCH1 +/- dermal fibroblasts isolated from healthy skin of Gorlin syndrome patients exhibit features of carcinoma associated fibroblasts.,0.73618979236783,"<span class=""gene"" id=""19287498-0-0-5"">PTCH1</span> +/- dermal fibroblasts isolated from healthy skin of <span class=""disease"" id=""19287498-0-59-74"">Gorlin syndrome</span> patients exhibit features of carcinoma associated fibroblasts.",CTD_human;ORPHANET;UNIPROT
13,31,Biomarker,C0004779,Basal Cell Nevus Syndrome,disease,Gorlin syndrome,5727,PTCH1,PTCH1,CTD_human,25559776,The first link of Hh signaling to cancer was established through discovery of genetic mutations of Hh receptor gene PTCH1 being responsible for Gorlin syndrome in 1996.,0.73618979236783,"The first link of Hh signaling to cancer was established through discovery of genetic mutations of Hh receptor gene <span class=""gene"" id=""25559776-3-116-121"">PTCH1</span> being responsible for <span class=""disease"" id=""25559776-3-144-159"">Gorlin syndrome</span> in 1996.",CTD_human;ORPHANET;UNIPROT
13,31,Biomarker,C0004779,Basal Cell Nevus Syndrome,disease,nevoid basal cell carcinoma syndrome,5727,PTCH1,PTCH1,CTD_human,25876211,"The Hh signaling pathway is involved in the pathogenesis of several tumors, including nevoid basal cell carcinoma syndrome that is associated with an alteration of the patched-1 (PTCH1) gene.",0.73618979236783,"The Hh signaling pathway is involved in the pathogenesis of several tumors, including <span class=""disease"" id=""25876211-4-86-122"">nevoid basal cell carcinoma syndrome</span> that is associated with an alteration of the <span class=""gene"" id=""25876211-4-168-177"">patched-1</span> (<span class=""gene"" id=""25876211-4-179-184"">PTCH1</span>) gene.",CTD_human;ORPHANET;UNIPROT
13,31,Biomarker,C0004779,Basal Cell Nevus Syndrome,disease,NBCCS,5727,PTCH1,PTCH1,CTD_human,18539553,"This variant was absent in the NBCCS patient that did not develop basal cell carcinomas, suggesting that this variant could have favored the development of skin cancers, in patients carrying the PTCH1 mutation.",0.73618979236783,"This variant was absent in the <span class=""disease"" id=""18539553-4-31-36"">NBCCS</span> patient that did not develop basal cell carcinomas, suggesting that this variant could have favored the development of skin cancers, in patients carrying the <span class=""gene"" id=""18539553-4-195-200"">PTCH1</span> mutation.",CTD_human;ORPHANET;UNIPROT
3,0,Biomarker,C0025149,Medulloblastoma,disease,medulloblastoma,5727,PTCH1,Ptch1,CTD_human,18347096,"When compared with Ptch1 heterozygous mutants, compound Ptch1/Hic1 heterozygotes display a fourfold increased incidence of medulloblastoma.",0.4945461641859771,"When compared with <span class=""gene"" id=""18347096-7-19-24"">Ptch1</span> heterozygous mutants, compound <span class=""gene"" id=""18347096-7-56-61"">Ptch1</span>/Hic1 heterozygotes display a fourfold increased incidence of <span class=""disease"" id=""18347096-7-123-138"">medulloblastoma</span>.",CTD_human;HPO
3,0,Biomarker,C0025149,Medulloblastoma,disease,medulloblastoma,5727,PTCH1,Ptc1,CTD_human,19213072,"To study the role of Ptc1 in cerebellar tumor development and to create a preclinical therapeutic platform, we have generated a conditional Ptc1 haploinsufficiency model of medulloblastoma by inactivating Ptc1 in Pax7-expressing cells of the cerebellum.",0.4945461641859771,"To study the role of <span class=""gene"" id=""19213072-3-21-25"">Ptc1</span> in cerebellar tumor development and to create a preclinical therapeutic platform, we have generated a conditional <span class=""gene"" id=""19213072-3-140-144"">Ptc1</span> haploinsufficiency model of <span class=""disease"" id=""19213072-3-173-188"">medulloblastoma</span> by inactivating <span class=""gene"" id=""19213072-3-205-209"">Ptc1</span> in Pax7-expressing cells of the cerebellum.",CTD_human;HPO
4,0,Biomarker,C0004352,Autistic Disorder,disease,autism,5728,PTEN,PTEN,CTD_human,11496368,PTEN mutation in a family with Cowden syndrome and autism.,0.5016873818438939,"<span class=""gene"" id=""11496368-0-0-4"">PTEN</span> mutation in a family with Cowden syndrome and <span class=""disease"" id=""11496368-0-51-57"">autism</span>.",CTD_human;HPO
1,0,Biomarker,C0017638,Glioma,disease,glioma,5728,PTEN,PTEN,CTD_human,12085208,"The reported patient, in addition to glioma, had suffered from benign meningioma in the past but did not show any clinical signs of Cowden disease or other hereditary diseases typically associated with PTEN germline mutations.",0.26698232613246503,"The reported patient, in addition to <span class=""disease"" id=""12085208-5-37-43"">glioma</span>, had suffered from benign meningioma in the past but did not show any clinical signs of Cowden disease or other hereditary diseases typically associated with <span class=""gene"" id=""12085208-5-202-206"">PTEN</span> germline mutations.",CTD_human
29,28,Biomarker,C0018553,"Hamartoma Syndrome, Multiple",disease,Cowden disease,5728,PTEN,PTEN,CTD_human,9140396,"Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome.",0.767443133233494,"Germline mutations of the <span class=""gene"" id=""9140396-0-26-30"">PTEN</span> gene in <span class=""disease"" id=""9140396-0-39-53"">Cowden disease</span>, an inherited breast and thyroid cancer syndrome.",CTD_human;ORPHANET;UNIPROT
29,28,Biomarker,C0018553,"Hamartoma Syndrome, Multiple",disease,Cowden syndrome,5728,PTEN,PTEN,CTD_human,19321504,"In adults, PTEN mutations cause Cowden syndrome where, in addition to the macrocephaly, there is a higher risk of tumour development.",0.767443133233494,"In adults, <span class=""gene"" id=""19321504-3-11-15"">PTEN</span> mutations cause <span class=""disease"" id=""19321504-3-32-47"">Cowden syndrome</span> where, in addition to the macrocephaly, there is a higher risk of tumour development.",CTD_human;ORPHANET;UNIPROT
29,28,Biomarker,C0018553,"Hamartoma Syndrome, Multiple",disease,Cowden disease,5728,PTEN,PTEN,CTD_human,9286463,Deletion of PTEN in a patient with Bannayan-Riley-Ruvalcaba syndrome suggests allelism with Cowden disease.,0.767443133233494,"Deletion of <span class=""gene"" id=""9286463-0-12-16"">PTEN</span> in a patient with Bannayan-Riley-Ruvalcaba syndrome suggests allelism with <span class=""disease"" id=""9286463-0-92-106"">Cowden disease</span>.",CTD_human;ORPHANET;UNIPROT
29,28,Biomarker,C0018553,"Hamartoma Syndrome, Multiple",disease,CS,5728,PTEN,PTEN,CTD_human,11748304,"While germline mutations at this chromosome 10q22-23 locus have been observed in patients with Cowden syndrome (CS) and Bannayan-Riley-Ruvalcaba syndrome (BRR), both of which phenotypes are associated with hamartomata and neoplasia, somatic mutation of PTEN has been established in a wide variety of sporadically occurring neoplasia.",0.767443133233494,"While germline mutations at this chromosome 10q22-23 locus have been observed in patients with <span class=""disease"" id=""11748304-2-95-110"">Cowden syndrome</span> (<span class=""disease"" id=""11748304-2-112-114"">CS</span>) and Bannayan-Riley-Ruvalcaba syndrome (BRR), both of which phenotypes are associated with hamartomata and neoplasia, somatic mutation of <span class=""gene"" id=""11748304-2-253-257"">PTEN</span> has been established in a wide variety of sporadically occurring neoplasia.",CTD_human;ORPHANET;UNIPROT
29,28,Biomarker,C0018553,"Hamartoma Syndrome, Multiple",disease,CS,5728,PTEN,PTEN,CTD_human,17427195,Polydactyly has previously been described in two patients with Lhermitte-Duclos disease and CS and is thus likely to be a rare sign of PTEN mutations.,0.767443133233494,"Polydactyly has previously been described in two patients with Lhermitte-Duclos disease and <span class=""disease"" id=""17427195-8-92-94"">CS</span> and is thus likely to be a rare sign of <span class=""gene"" id=""17427195-8-135-139"">PTEN</span> mutations.",CTD_human;ORPHANET;UNIPROT
29,28,Biomarker,C0018553,"Hamartoma Syndrome, Multiple",disease,Cowden disease,5728,PTEN,MMAC1,CTD_human,9259288,Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease.,0.767443133233494,"Germline mutations in the <span class=""gene"" id=""9259288-0-26-30"">PTEN</span>/<span class=""gene"" id=""9259288-0-31-36"">MMAC1</span> gene in patients with <span class=""disease"" id=""9259288-0-59-73"">Cowden disease</span>.",CTD_human;ORPHANET;UNIPROT
29,28,Biomarker,C0018553,"Hamartoma Syndrome, Multiple",disease,CD,5728,PTEN,PTEN,CTD_human,11685670,"This report provides clinical evidence that both BRR and CD are closely related and confirms the PTEN gene mutation in BRR and CD patients segregating in the same family, thus confirming the genetic linkage between the two genodermatoses.",0.767443133233494,"This report provides clinical evidence that both BRR and <span class=""disease"" id=""11685670-7-57-59"">CD</span> are closely related and confirms the <span class=""gene"" id=""11685670-7-97-101"">PTEN</span> gene mutation in BRR and <span class=""disease"" id=""11685670-7-127-129"">CD</span> patients segregating in the same family, thus confirming the genetic linkage between the two genodermatoses.",CTD_human;ORPHANET;UNIPROT
29,28,Biomarker,C0018553,"Hamartoma Syndrome, Multiple",disease,Cowden syndrome,5728,PTEN,PTEN,CTD_human,11496368,PTEN mutation in a family with Cowden syndrome and autism.,0.767443133233494,"<span class=""gene"" id=""11496368-0-0-4"">PTEN</span> mutation in a family with <span class=""disease"" id=""11496368-0-31-46"">Cowden syndrome</span> and autism.",CTD_human;ORPHANET;UNIPROT
29,28,Biomarker,C0018553,"Hamartoma Syndrome, Multiple",disease,Cowden syndrome,5728,PTEN,PTEN,CTD_human,10353779,Phenotypic findings of Cowden syndrome and Bannayan-Zonana syndrome in a family associated with a single germline mutation in PTEN.,0.767443133233494,"Phenotypic findings of <span class=""disease"" id=""10353779-0-23-38"">Cowden syndrome</span> and Bannayan-Zonana syndrome in a family associated with a single germline mutation in <span class=""gene"" id=""10353779-0-126-130"">PTEN</span>.",CTD_human;ORPHANET;UNIPROT
29,28,Biomarker,C0018553,"Hamartoma Syndrome, Multiple",disease,CS,5728,PTEN,PTEN,CTD_human,19968660,"Thus, analysis of PTEN expression abnormality, easily assessed by immunohistochemistry, may be of clinical value to screen those patients with CS.",0.767443133233494,"Thus, analysis of <span class=""gene"" id=""19968660-12-18-22"">PTEN</span> expression abnormality, easily assessed by immunohistochemistry, may be of clinical value to screen those patients with <span class=""disease"" id=""19968660-12-143-145"">CS</span>.",CTD_human;ORPHANET;UNIPROT
29,28,Biomarker,C0018553,"Hamartoma Syndrome, Multiple",disease,Cowden syndrome,5728,PTEN,PTEN,CTD_human,10400993,PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome.,0.767443133233494,"<span class=""gene"" id=""10400993-0-0-4"">PTEN</span> mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with <span class=""disease"" id=""10400993-0-125-140"">Cowden syndrome</span>.",CTD_human;ORPHANET;UNIPROT
29,28,Biomarker,C0018553,"Hamartoma Syndrome, Multiple",disease,CS,5728,PTEN,PTEN,CTD_human,14574156,We recommend offering BRRS cases with a mutation in PTEN the same surveillance protocol for (malignant) tumours as is currently recommended for CS.,0.767443133233494,"We recommend offering BRRS cases with a mutation in <span class=""gene"" id=""14574156-10-52-56"">PTEN</span> the same surveillance protocol for (malignant) tumours as is currently recommended for <span class=""disease"" id=""14574156-10-144-146"">CS</span>.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,5728,PTEN,PTEN,CTD_human,15646324,"The findings indicated that the expression of PTEN is reduced in hypertensive aorta, that the reduced PTEN experession can be reversed by captopril treatment, that AngII and the increased mechanical strain may participate in regulating expression of PTEN, and that PTEN may play a role in the arterial remodeling induced by hypertension.",0.2,"The findings indicated that the expression of <span class=""gene"" id=""15646324-9-46-50"">PTEN</span> is reduced in hypertensive aorta, that the reduced <span class=""gene"" id=""15646324-9-102-106"">PTEN</span> experession can be reversed by captopril treatment, that AngII and the increased mechanical strain may participate in regulating expression of <span class=""gene"" id=""15646324-9-250-254"">PTEN</span>, and that <span class=""gene"" id=""15646324-9-265-269"">PTEN</span> may play a role in the arterial remodeling induced by <span class=""disease"" id=""15646324-9-324-336"">hypertension</span>.",CTD_human
1,0,Biomarker,C0023801,Lipomatosis,disease,lipomatosis,5728,PTEN,PTEN,CTD_human,11748304,Investigation of other clinically distinct syndromes associated with lipomatosis and overgrowth has established germline and germline mosaic PTEN mutations in several patients with Proteus syndrome.,0.201098907136852,"Investigation of other clinically distinct syndromes associated with <span class=""disease"" id=""11748304-4-69-80"">lipomatosis</span> and overgrowth has established germline and germline mosaic <span class=""gene"" id=""11748304-4-141-145"">PTEN</span> mutations in several patients with Proteus syndrome.",CTD_human
3,3,Biomarker,C0025202,melanoma,disease,melanoma,5728,PTEN,PTEN,CTD_human,10978354,"These data support the notion that PTEN alterations occur in some metastatic melanomas, and that mutation of this gene plays a role in the progression of some forms of melanoma.",0.43510760687000793,"These data support the notion that <span class=""gene"" id=""10978354-8-35-39"">PTEN</span> alterations occur in some metastatic <span class=""disease"" id=""10978354-8-77-86"">melanomas</span>, and that mutation of this gene plays a role in the progression of some forms of <span class=""disease"" id=""10978354-8-168-176"">melanoma</span>.",CTD_human;HPO
3,3,Biomarker,C0025202,melanoma,disease,melanoma,5728,PTEN,PTEN,CTD_human,22535842,"Genes deregulated at the DNA and mRNA level included well-known cancer genes partly already linked to melanoma (RAS genes, PTEN, AURKA, MAPK inhibitors Sprouty/Spred), but also novel candidates like SIPA1 (a Rap1GAP).",0.43510760687000793,"Genes deregulated at the DNA and mRNA level included well-known cancer genes partly already linked to <span class=""disease"" id=""22535842-8-102-110"">melanoma</span> (RAS genes, <span class=""gene"" id=""22535842-8-123-127"">PTEN</span>, AURKA, MAPK inhibitors Sprouty/Spred), but also novel candidates like SIPA1 (a Rap1GAP).",CTD_human;HPO
1,0,Biomarker,C0036920,Sezary Syndrome,disease,Sézary syndrome,5728,PTEN,PTEN,CTD_human,26551667,"These analyses identified a distinctive pattern of somatic copy number alterations in Sézary syndrome, including highly prevalent chromosomal deletions involving the TP53, RB1, PTEN, DNMT3A and CDKN1B tumor suppressors.",0.200274726784213,"These analyses identified a distinctive pattern of somatic copy number alterations in <span class=""disease"" id=""26551667-3-86-101"">S&eacute;zary syndrome</span>, including highly prevalent chromosomal deletions involving the TP53, RB1, <span class=""gene"" id=""26551667-3-177-181"">PTEN</span>, DNMT3A and CDKN1B tumor suppressors.",CTD_human
3,0,Biomarker,C0085261,Proteus Syndrome,disease,Proteus syndrome,5728,PTEN,PTEN,CTD_human,12471211,Germline mutation of the tumour suppressor PTEN in Proteus syndrome.,0.405480180306945,"Germline mutation of the tumour suppressor <span class=""gene"" id=""12471211-0-43-47"">PTEN</span> in <span class=""disease"" id=""12471211-0-51-67"">Proteus syndrome</span>.",CTD_human;ORPHANET
3,0,Biomarker,C0085261,Proteus Syndrome,disease,Proteus syndrome,5728,PTEN,PTEN,CTD_human,11748304,Investigation of other clinically distinct syndromes associated with lipomatosis and overgrowth has established germline and germline mosaic PTEN mutations in several patients with Proteus syndrome.,0.405480180306945,"Investigation of other clinically distinct syndromes associated with lipomatosis and overgrowth has established germline and germline mosaic <span class=""gene"" id=""11748304-4-141-145"">PTEN</span> mutations in several patients with <span class=""disease"" id=""11748304-4-181-197"">Proteus syndrome</span>.",CTD_human;ORPHANET
3,0,Biomarker,C0085261,Proteus Syndrome,disease,Proteus syndrome,5728,PTEN,PTEN,CTD_human,17427195,"Mutations in the PTEN gene are associated with a broad spectrum of disorders, including Cowden syndrome (CS), Bannayan-Riley-Ruvalcaba syndrome, Proteus syndrome, and Lhermitte-Duclos disease.",0.405480180306945,"Mutations in the <span class=""gene"" id=""17427195-1-17-21"">PTEN</span> gene are associated with a broad spectrum of disorders, including Cowden syndrome (CS), Bannayan-Riley-Ruvalcaba syndrome, <span class=""disease"" id=""17427195-1-145-161"">Proteus syndrome</span>, and Lhermitte-Duclos disease.",CTD_human;ORPHANET
1,0,Biomarker,C0152427,Polydactyly,disease,Polydactyly,5728,PTEN,PTEN,CTD_human,17427195,Polydactyly has previously been described in two patients with Lhermitte-Duclos disease and CS and is thus likely to be a rare sign of PTEN mutations.,0.200274726784213,"<span class=""disease"" id=""17427195-8-0-11"">Polydactyly</span> has previously been described in two patients with Lhermitte-Duclos disease and CS and is thus likely to be a rare sign of <span class=""gene"" id=""17427195-8-135-139"">PTEN</span> mutations.",CTD_human
1,0,Therapeutic,C0014544,Epilepsy,disease,epilepsy,57282,SLC4A10,Slc4a10,CTD_human,18165320,"Hence, Slc4a10 is a promising pharmacological target for the therapy of epilepsy or elevated intracranial pressure.",0.20054945356842604,"Hence, <span class=""gene"" id=""18165320-8-7-14"">Slc4a10</span> is a promising pharmacological target for the therapy of <span class=""disease"" id=""18165320-8-72-80"">epilepsy</span> or elevated intracranial pressure.",CTD_human
1,0,Therapeutic,C0151740,Intracranial Hypertension,disease,elevated intracranial pressure,57282,SLC4A10,Slc4a10,CTD_human,18165320,"Hence, Slc4a10 is a promising pharmacological target for the therapy of epilepsy or elevated intracranial pressure.",0.2,"Hence, <span class=""gene"" id=""18165320-8-7-14"">Slc4a10</span> is a promising pharmacological target for the therapy of epilepsy or <span class=""disease"" id=""18165320-8-84-114"">elevated intracranial pressure</span>.",CTD_human
1,0,Biomarker,C3714756,Intellectual Disability,group,mental retardation,57282,SLC4A10,SLC4A10,CTD_human,18413482,Disruption of sodium bicarbonate transporter SLC4A10 in a patient with complex partial epilepsy and mental retardation.,0.200274726784213,"Disruption of sodium bicarbonate transporter <span class=""gene"" id=""18413482-0-45-52"">SLC4A10</span> in a patient with complex partial epilepsy and <span class=""disease"" id=""18413482-0-100-118"">mental retardation</span>.",CTD_human
1,0,Biomarker,C1134719,Invasive Ductal Breast Carcinoma,disease,invasive ductal carcinoma of the breast,573,BAG1,BAG-1,CTD_human,19066611,BAG-1 predicts patient outcome and tamoxifen responsiveness in ER-positive invasive ductal carcinoma of the breast.,0.200274726784213,"<span class=""gene"" id=""19066611-0-0-5"">BAG-1</span> predicts patient outcome and tamoxifen responsiveness in ER-positive <span class=""disease"" id=""19066611-0-75-114"">invasive ductal carcinoma of the breast</span>.",CTD_human
1,0,Biomarker,C0020429,Hyperalgesia,phenotype,hyperalgesia,5731,PTGER1,EP1,CTD_human,11375261,These results demonstrate that spinal EP1 receptors are involved in the PGE2-induced allodynia and that spinal EP3 receptors are involved in the hyperalgesia induced by low doses of PGE2.,0.2,"These results demonstrate that spinal <span class=""gene"" id=""11375261-10-38-41"">EP1</span> receptors are involved in the PGE2-induced allodynia and that spinal EP3 receptors are involved in the <span class=""disease"" id=""11375261-10-145-157"">hyperalgesia</span> induced by low doses of PGE2.",CTD_human
1,0,Biomarker,C0038325,Stevens-Johnson Syndrome,disease,Stevens-Johnson Syndrome,5733,PTGER3,PTGER3,CTD_human,21966456,"In our earlier genome-wide association study on Stevens-Johnson Syndrome (SJS) and its severe variant, toxic epidermal necrolysis (TEN), we found that in Japanese patients with these severe ocular surface complications there was an association with prostaglandin E receptor 3 (EP3) gene (PTGER3) polymorphisms.",0.200274726784213,"In our earlier genome-wide association study on <span class=""disease"" id=""21966456-1-48-72"">Stevens-Johnson Syndrome</span> (SJS) and its severe variant, toxic epidermal necrolysis (TEN), we found that in Japanese patients with these severe ocular surface complications there was an association with prostaglandin E receptor 3 (<span class=""gene"" id=""21966456-1-277-280"">EP3</span>) gene (<span class=""gene"" id=""21966456-1-288-294"">PTGER3</span>) polymorphisms.",CTD_human
1,0,Biomarker,C0014175,Endometriosis,disease,endometriosis,5734,PTGER4,EP4,CTD_human,19407222,"Results of the present study indicate that 1) PGE(2) promotes survival of human endometriotic cells through EP2 and EP4 receptors by activating ERK1/2, AKT, nuclear factor-kappaB, and beta-catenin signaling pathways; 2) selective inhibition of EP2 and EP4 suppresses these cell survival pathways and augments interactions between proapoptotic proteins (Bax and Bad) and antiapoptotic proteins (Bcl-2/Bcl-XL), facilitates the release of cytochrome c, and thus activates caspase-3/poly (ADP-ribose) polymerase-mediated intrinsic apoptotic pathways; and 3) these PGE(2) signaling components are more abundantly expressed in ectopic endometriosis tissues compared with eutopic endometrial tissues during the menstrual cycle in women.",0.20054945356842604,"Results of the present study indicate that 1) PGE(2) promotes survival of human endometriotic cells through EP2 and <span class=""gene"" id=""19407222-6-116-119"">EP4</span> receptors by activating ERK1/2, AKT, nuclear factor-kappaB, and beta-catenin signaling pathways; 2) selective inhibition of EP2 and EP4 suppresses these cell survival pathways and augments interactions between proapoptotic proteins (Bax and Bad) and antiapoptotic proteins (Bcl-2/Bcl-XL), facilitates the release of cytochrome c, and thus activates caspase-3/poly (ADP-ribose) polymerase-mediated intrinsic apoptotic pathways; and 3) these PGE(2) signaling components are more abundantly expressed in ectopic <span class=""disease"" id=""19407222-6-629-642"">endometriosis</span> tissues compared with eutopic endometrial tissues during the menstrual cycle in women.",CTD_human
1,0,Biomarker,C0038013,Ankylosing spondylitis,disease,ankylosing spondylitis,5734,PTGER4,PTGER4,CTD_human,21743469,"Here we report the identification of three variants in the RUNX3, LTBR-TNFRSF1A and IL12B regions convincingly associated with ankylosing spondylitis (P < 5 × 10(-8) in the combined discovery and replication datasets) and a further four loci at PTGER4, TBKBP1, ANTXR2 and CARD9 that show strong association across all our datasets (P < 5 × 10(-6) overall, with support in each of the three datasets studied).",0.20054945356842604,"Here we report the identification of three variants in the RUNX3, LTBR-TNFRSF1A and IL12B regions convincingly associated with <span class=""disease"" id=""21743469-2-127-149"">ankylosing spondylitis</span> (P &lt; 5 &times; 10(-8) in the combined discovery and replication datasets) and a further four loci at <span class=""gene"" id=""21743469-2-245-251"">PTGER4</span>, TBKBP1, ANTXR2 and CARD9 that show strong association across all our datasets (P &lt; 5 &times; 10(-6) overall, with support in each of the three datasets studied).",CTD_human
1,0,Biomarker,C0004364,Autoimmune Diseases,group,autoimmune disease,57379,AICDA,AID,CTD_human,21305519,Suppression of AID catalytic function to limit selection-based survival of GC B cells could become a novel therapy for the treatment of autoimmune disease.,0.201373633921065,"Suppression of <span class=""gene"" id=""21305519-12-15-18"">AID</span> catalytic function to limit selection-based survival of GC B cells could become a novel therapy for the treatment of <span class=""disease"" id=""21305519-12-136-154"">autoimmune disease</span>.",CTD_human
1,0,Biomarker,C0023448,Lymphoid leukemia,disease,lymphoid leukemia,57379,AICDA,AID,CTD_human,23589568,"Using a combination of human B lymphoid leukemia cells and mouse models, we now show that AID expression can be harnessed for antileukemic effect, after inhibition of the RAD51 homologous recombination (HR) factor with 4,4'-diisothiocyanatostilbene-2-2'-disulfonic acid (DIDS).",0.2,"Using a combination of human B <span class=""disease"" id=""23589568-4-31-48"">lymphoid leukemia</span> cells and mouse models, we now show that <span class=""gene"" id=""23589568-4-90-93"">AID</span> expression can be harnessed for antileukemic effect, after inhibition of the RAD51 homologous recombination (HR) factor with 4,4'-diisothiocyanatostilbene-2-2'-disulfonic acid (DIDS).",CTD_human
1,0,Biomarker,C0013274,Patent ductus arteriosus,disease,patency of the ductus arteriosus,5740,PTGIS,prostacyclin synthase,CTD_human,19336370,"Overall, our data support a role for genetic variations in transcription factor AP-2 beta, tumor necrosis factor receptor-associated factor 1, and prostacyclin synthase in the persistent patency of the ductus arteriosus seen in preterm infants.",0.200274726784213,"Overall, our data support a role for genetic variations in transcription factor AP-2 beta, tumor necrosis factor receptor-associated factor 1, and <span class=""gene"" id=""19336370-12-147-168"">prostacyclin synthase</span> in the persistent <span class=""disease"" id=""19336370-12-187-219"">patency of the ductus arteriosus</span> seen in preterm infants.",CTD_human
1,0,Therapeutic,C0024121,Lung Neoplasms,group,lung tumors,5740,PTGIS,prostacyclin synthase,CTD_human,11830527,We hypothesized that pulmonary overexpression of prostacyclin synthase may prevent the development of murine lung tumors.,0.20328236603324,"We hypothesized that pulmonary overexpression of <span class=""gene"" id=""11830527-4-49-70"">prostacyclin synthase</span> may prevent the development of murine <span class=""disease"" id=""11830527-4-109-120"">lung tumors</span>.",CTD_human
2,0,Biomarker,C0002871,Anemia,disease,Anemia,5741,PTH,PTH 1,CTD_human,19578808,Anemia was more pronounced with PTH 1-84 compared to PTH 1-34 and was reversed with each regimen discontinuation.,0.2,"<span class=""disease"" id=""19578808-4-0-6"">Anemia</span> was more pronounced with <span class=""gene"" id=""19578808-4-32-37"">PTH 1</span>-84 compared to <span class=""gene"" id=""19578808-4-53-58"">PTH 1</span>-34 and was reversed with each regimen discontinuation.",CTD_human
6,0,Biomarker,C0020437,Hypercalcemia,disease,hypercalcemia,5741,PTH,PTH,CTD_human,17164314,"Episodes were generally mild, and nearly all cases resolved spontaneously or with discontinuation of calcium and vitamin D. The algorithms used to address hypercalcemia and hypercalciuria in the PaTH trial proved effective in safely resolving clinical episodes of increased urinary or serum calcium and might therefore be helpful to clinicians caring for patients on PTH.",0.307747405205523,"Episodes were generally mild, and nearly all cases resolved spontaneously or with discontinuation of calcium and vitamin D. The algorithms used to address <span class=""disease"" id=""17164314-13-155-168"">hypercalcemia</span> and hypercalciuria in the PaTH trial proved effective in safely resolving clinical episodes of increased urinary or serum calcium and might therefore be helpful to clinicians caring for patients on <span class=""gene"" id=""17164314-13-367-370"">PTH</span>.",CTD_human
6,0,Biomarker,C0020437,Hypercalcemia,disease,hypercalcemia,5741,PTH,parathyroid hormone,CTD_human,4004906,Aspirin inhibition of 1 alpha-hydroxyvitamin D3 or parathyroid hormone induced hypercalcemia in vivo in rats. A mechanism independent of prostaglandin biosynthesis inhibition.,0.307747405205523,"Aspirin inhibition of 1 alpha-hydroxyvitamin D3 or <span class=""gene"" id=""4004906-0-51-70"">parathyroid hormone</span> induced <span class=""disease"" id=""4004906-0-79-92"">hypercalcemia</span> in vivo in rats. A mechanism independent of prostaglandin biosynthesis inhibition.",CTD_human
6,0,Biomarker,C0020437,Hypercalcemia,disease,hypercalcemia,5741,PTH,parathyroid hormone,CTD_human,12399635,Hyperphosphatemia modestly retards parathyroid hormone suppression during calcitriol-induced hypercalcemia in normal and azotemic rats.,0.307747405205523,"Hyperphosphatemia modestly retards <span class=""gene"" id=""12399635-0-35-54"">parathyroid hormone</span> suppression during calcitriol-induced <span class=""disease"" id=""12399635-0-93-106"">hypercalcemia</span> in normal and azotemic rats.",CTD_human
6,0,Biomarker,C0020437,Hypercalcemia,disease,hypercalcemia,5741,PTH,parathyroid hormone,CTD_human,7891547,Milk-alkali syndrome associated with calcium carbonate consumption. Report of 7 patients with parathyroid hormone levels and an estimate of prevalence among patients hospitalized with hypercalcemia.,0.307747405205523,"Milk-alkali syndrome associated with calcium carbonate consumption. Report of 7 patients with <span class=""gene"" id=""7891547-0-94-113"">parathyroid hormone</span> levels and an estimate of prevalence among patients hospitalized with <span class=""disease"" id=""7891547-0-184-197"">hypercalcemia</span>.",CTD_human
1,0,Biomarker,C0020438,Hypercalciuria,phenotype,hypercalciuria,5741,PTH,PTH,CTD_human,17164314,"Episodes were generally mild, and nearly all cases resolved spontaneously or with discontinuation of calcium and vitamin D. The algorithms used to address hypercalcemia and hypercalciuria in the PaTH trial proved effective in safely resolving clinical episodes of increased urinary or serum calcium and might therefore be helpful to clinicians caring for patients on PTH.",0.20494508211583604,"Episodes were generally mild, and nearly all cases resolved spontaneously or with discontinuation of calcium and vitamin D. The algorithms used to address hypercalcemia and <span class=""disease"" id=""17164314-13-173-187"">hypercalciuria</span> in the PaTH trial proved effective in safely resolving clinical episodes of increased urinary or serum calcium and might therefore be helpful to clinicians caring for patients on <span class=""gene"" id=""17164314-13-367-370"">PTH</span>.",CTD_human
1,0,Biomarker,C0020492,Hyperostosis,disease,Hyperostosis,5741,PTH,parathyroid hormone,CTD_human,25289773,"Hyperostosis occurred and was accompanied by substantial effects on calcium metabolism, including increased urinary calcium excretion and decreased levels of calcium regulating hormones (1,25-dihydroxyvitamin D and parathyroid hormone).",0.2,"<span class=""disease"" id=""25289773-7-0-12"">Hyperostosis</span> occurred and was accompanied by substantial effects on calcium metabolism, including increased urinary calcium excretion and decreased levels of calcium regulating hormones (1,25-dihydroxyvitamin D and <span class=""gene"" id=""25289773-7-215-234"">parathyroid hormone</span>).",CTD_human
2,0,Biomarker,C0020598,Hypocalcemia,phenotype,hypocalcemia,5741,PTH,Parathyroid hormone,CTD_human,11770836,Parathyroid hormone increases due to hypocalcemia even in the early phases of renal insufficiency.,0.41840669454227797,"<span class=""gene"" id=""11770836-1-0-19"">Parathyroid hormone</span> increases due to <span class=""disease"" id=""11770836-1-37-49"">hypocalcemia</span> even in the early phases of renal insufficiency.",CTD_human;HPO
5,0,Therapeutic,C0029456,Osteoporosis,disease,osteoporosis,5741,PTH,PTH,CTD_human,17317460,This study summarizes our own experience with the use of rhPTH(1-34) in the treatment of senile patients with severe osteoporosis.,0.291956953436117,"This study summarizes our own experience with the use of rh<span class=""gene"" id=""17317460-10-59-62"">PTH</span>(1-34) in the treatment of senile patients with severe <span class=""disease"" id=""17317460-10-117-129"">osteoporosis</span>.",CTD_human
5,0,Therapeutic,C0029456,Osteoporosis,disease,osteoporosis,5741,PTH,parathyroid hormone,CTD_human,19578808,Normochromic normocytic anemia in a postmenopausal woman with severe osteoporosis treated with intermittent parathyroid hormone.,0.291956953436117,"Normochromic normocytic anemia in a postmenopausal woman with severe <span class=""disease"" id=""19578808-0-69-81"">osteoporosis</span> treated with intermittent <span class=""gene"" id=""19578808-0-108-127"">parathyroid hormone</span>.",CTD_human
1,0,Biomarker,C0035579,Rickets,disease,rickets,5741,PTH,PTH,CTD_human,10375030,The reduction in the PTH/PTHrP receptor gene expression in rickets may be due to the high plasma levels of PTH.,0.201923087489492,"The reduction in the <span class=""gene"" id=""10375030-7-21-24"">PTH</span>/PTHrP receptor gene expression in <span class=""disease"" id=""10375030-7-59-66"">rickets</span> may be due to the high plasma levels of <span class=""gene"" id=""10375030-7-107-110"">PTH</span>.",CTD_human
1,0,Biomarker,C0085681,Hyperphosphatemia (disorder),disease,Hyperphosphatemia,5741,PTH,parathyroid hormone,CTD_human,12399635,Hyperphosphatemia modestly retards parathyroid hormone suppression during calcitriol-induced hypercalcemia in normal and azotemic rats.,0.489340710663245,"<span class=""disease"" id=""12399635-0-0-17"">Hyperphosphatemia</span> modestly retards <span class=""gene"" id=""12399635-0-35-54"">parathyroid hormone</span> suppression during calcitriol-induced hypercalcemia in normal and azotemic rats.",CTD_human;HPO
1,0,Biomarker,C0005695,Bladder Neoplasm,disease,bladder cancer,57412,AS3MT,As3MT,CTD_human,22747749,Variation in As3MT and MTHFR is associated with bladder cancer among those exposed to relatively low concentrations of inorganic arsenic.,0.200274726784213,"Variation in <span class=""gene"" id=""22747749-10-13-18"">As3MT</span> and MTHFR is associated with <span class=""disease"" id=""22747749-10-48-62"">bladder cancer</span> among those exposed to relatively low concentrations of inorganic arsenic.",CTD_human
1,1,Biomarker,C1263846,Attention deficit hyperactivity disorder,disease,attention-deficit hyperactivity disorder,57412,AS3MT,AS3MT,CTD_human,25461954,"Family-based association study of the arsenite methyltransferase gene (AS3MT, rs11191454) in Korean children with attention-deficit hyperactivity disorder.",0.200274726784213,"Family-based association study of the <span class=""gene"" id=""25461954-0-38-64"">arsenite methyltransferase</span> gene (<span class=""gene"" id=""25461954-0-71-76"">AS3MT</span>, rs11191454) in Korean children with <span class=""disease"" id=""25461954-0-114-154"">attention-deficit hyperactivity disorder</span>.",CTD_human
1,0,Biomarker,C0020429,Hyperalgesia,phenotype,hyperalgesia,5742,PTGS1,COX-1,CTD_human,17989504,"The results of the study suggest participation of COX-1, COX-2 and iNOS, but not nNOS, in transmission of pain stimuli in STZ-induced diabetic hyperalgesia.",0.2,"The results of the study suggest participation of <span class=""gene"" id=""17989504-5-50-55"">COX-1</span>, COX-2 and iNOS, but not nNOS, in transmission of pain stimuli in STZ-induced diabetic <span class=""disease"" id=""17989504-5-143-155"">hyperalgesia</span>.",CTD_human
2,0,Biomarker,C0021846,Intestinal Polyps,phenotype,intestinal polyps,5742,PTGS1,COX-1,CTD_human,12189188,"Recently, genetic disruption of COX-1, the other isoform, was shown to decrease the number of intestinal polyps and prostaglandin E(2) levels in intestinal mucosa, like the case with COX-2 gene disruption, in Min mice.",0.2,"Recently, genetic disruption of <span class=""gene"" id=""12189188-2-32-37"">COX-1</span>, the other isoform, was shown to decrease the number of <span class=""disease"" id=""12189188-2-94-111"">intestinal polyps</span> and prostaglandin E(2) levels in intestinal mucosa, like the case with COX-2 gene disruption, in Min mice.",CTD_human
2,0,Biomarker,C0001418,Adenocarcinoma,group,adenocarcinoma,5743,PTGS2,COX-2,CTD_human,16820089,"In human samples, peak COX-2 expression occurred in PanIN2 lesions and remained moderately elevated in PanIN3 and adenocarcinoma tissues.",0.29794046842642197,"In human samples, peak <span class=""gene"" id=""16820089-8-23-28"">COX-2</span> expression occurred in PanIN2 lesions and remained moderately elevated in PanIN3 and <span class=""disease"" id=""16820089-8-114-128"">adenocarcinoma</span> tissues.",CTD_human
2,0,Biomarker,C0002736,Amyotrophic Lateral Sclerosis,disease,amyotrophic lateral sclerosis,5743,PTGS2,cyclooxygenase-2,CTD_human,11220737,Increased expression of the pro-inflammatory enzyme cyclooxygenase-2 in amyotrophic lateral sclerosis.,0.203780662444353,"Increased expression of the pro-inflammatory enzyme <span class=""gene"" id=""11220737-0-52-68"">cyclooxygenase-2</span> in <span class=""disease"" id=""11220737-0-72-101"">amyotrophic lateral sclerosis</span>.",CTD_human
2,0,Biomarker,C0002736,Amyotrophic Lateral Sclerosis,disease,amyotrophic lateral sclerosis,5743,PTGS2,COX-2,CTD_human,15816863,Integrative role of cPLA with COX-2 and the effect of non-steriodal anti-inflammatory drugs in a transgenic mouse model of amyotrophic lateral sclerosis.,0.203780662444353,"Integrative role of cPLA with <span class=""gene"" id=""15816863-0-30-35"">COX-2</span> and the effect of non-steriodal anti-inflammatory drugs in a transgenic mouse model of <span class=""disease"" id=""15816863-0-123-152"">amyotrophic lateral sclerosis</span>.",CTD_human
3,0,Biomarker,C0004763,Barrett Esophagus,disease,Barrett's esophagus,5743,PTGS2,COX-2,CTD_human,15387324,"Activation of NFkappaB represents the central event in the neoplastic progression associated with Barrett's esophagus: a possible link to the inflammation and overexpression of COX-2, PPARgamma and growth factors.",0.21254320878453797,"Activation of NFkappaB represents the central event in the neoplastic progression associated with <span class=""disease"" id=""15387324-0-98-117"">Barrett's esophagus</span>: a possible link to the inflammation and overexpression of <span class=""gene"" id=""15387324-0-177-182"">COX-2</span>, PPARgamma and growth factors.",CTD_human
3,0,Biomarker,C0004763,Barrett Esophagus,disease,Barrett's esophagus,5743,PTGS2,COX-2,CTD_human,11059772,These observations suggest a potential role for selective COX-2 inhibitors in the prevention and treatment of esophageal adenocarcinoma for patients with Barrett's esophagus.,0.21254320878453797,"These observations suggest a potential role for selective <span class=""gene"" id=""11059772-11-58-63"">COX-2</span> inhibitors in the prevention and treatment of esophageal adenocarcinoma for patients with <span class=""disease"" id=""11059772-11-154-173"">Barrett's esophagus</span>.",CTD_human
6,0,Biomarker,C0005695,Bladder Neoplasm,disease,bladder cancer,5743,PTGS2,COX-2,CTD_human,17093206,Cyclooxygenase-2 (COX-2) causes hyperplasia in bladder cells and is considered a key biomarker in bladder cancer.,0.21068563382967603,"<span class=""gene"" id=""17093206-2-0-16"">Cyclooxygenase-2</span> (<span class=""gene"" id=""17093206-2-18-23"">COX-2</span>) causes hyperplasia in bladder cells and is considered a key biomarker in <span class=""disease"" id=""17093206-2-98-112"">bladder cancer</span>.",CTD_human
6,0,Biomarker,C0005695,Bladder Neoplasm,disease,bladder cancer,5743,PTGS2,cyclooxygenase-2,CTD_human,12442003,"Synergistic cytotoxicity and apoptosis of JTE-522, a selective cyclooxygenase-2 inhibitor, and 5-fluorouracil against bladder cancer.",0.21068563382967603,"Synergistic cytotoxicity and apoptosis of JTE-522, a selective <span class=""gene"" id=""12442003-0-63-79"">cyclooxygenase-2</span> inhibitor, and 5-fluorouracil against <span class=""disease"" id=""12442003-0-118-132"">bladder cancer</span>.",CTD_human
6,0,Biomarker,C0005695,Bladder Neoplasm,disease,bladder cancer,5743,PTGS2,COX-2,CTD_human,10582676,These results indicate that COX-2 may play a role in bladder cancer in humans and support further study of COX-2 inhibitors as potential antitumor agents in human bladder cancer.,0.21068563382967603,"These results indicate that <span class=""gene"" id=""10582676-5-28-33"">COX-2</span> may play a role in <span class=""disease"" id=""10582676-5-53-67"">bladder cancer</span> in humans and support further study of <span class=""gene"" id=""10582676-5-107-112"">COX-2</span> inhibitors as potential antitumor agents in human <span class=""disease"" id=""10582676-5-163-177"">bladder cancer</span>.",CTD_human
2,0,Biomarker,C0007137,Squamous cell carcinoma,disease,squamous cell carcinoma,5743,PTGS2,cyclooxygenase-2,CTD_human,18202791,Differential effects of selective cyclooxygenase-2 inhibitors in inhibiting proliferation and induction of apoptosis in oral squamous cell carcinoma.,0.307019128951148,"Differential effects of selective <span class=""gene"" id=""18202791-0-34-50"">cyclooxygenase-2</span> inhibitors in inhibiting proliferation and induction of apoptosis in oral <span class=""disease"" id=""18202791-0-125-148"">squamous cell carcinoma</span>.",CTD_human
4,0,Biomarker,C0007138,"Carcinoma, Transitional Cell",disease,transitional cell carcinoma,5743,PTGS2,Cyclooxygenase-2,CTD_human,10873095,Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder.,0.201373633921065,"<span class=""gene"" id=""10873095-0-0-16"">Cyclooxygenase-2</span> expression is up-regulated in <span class=""disease"" id=""10873095-0-47-74"">transitional cell carcinoma</span> and its preneoplastic lesions in the human urinary bladder.",CTD_human
4,0,Biomarker,C0007138,"Carcinoma, Transitional Cell",disease,transitional cell carcinoma,5743,PTGS2,COX-2,CTD_human,10582676,Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder.,0.201373633921065,"Expression of <span class=""gene"" id=""10582676-0-14-30"">cyclooxygenase-2</span> (<span class=""gene"" id=""10582676-0-32-37"">COX-2</span>) in human invasive <span class=""disease"" id=""10582676-0-57-84"">transitional cell carcinoma</span> (TCC) of the urinary bladder.",CTD_human
1,0,Biomarker,C0009241,Cognition Disorders,group,cognitive deficits,5743,PTGS2,COX-2,CTD_human,12410334,"We conclude that COX-2 is involved in the development of functional deficits following diffuse TBI, particularly cognitive deficits, and that these can be improved by administration of COX-2 inhibitors.",0.2,"We conclude that <span class=""gene"" id=""12410334-10-17-22"">COX-2</span> is involved in the development of functional deficits following diffuse TBI, particularly <span class=""disease"" id=""12410334-10-113-131"">cognitive deficits</span>, and that these can be improved by administration of <span class=""gene"" id=""12410334-10-185-190"">COX-2</span> inhibitors.",CTD_human
1,0,Biomarker,C0009319,Colitis,disease,colitis,5743,PTGS2,COX-2,CTD_human,11820457,TNBS-induced colitis was associated with enhanced COX-2 expression in the gut and increased circulating concentrations of PGE2 metabolite (PGEM).,0.282472541057918,"TNBS-induced <span class=""disease"" id=""11820457-3-13-20"">colitis</span> was associated with enhanced <span class=""gene"" id=""11820457-3-50-55"">COX-2</span> expression in the gut and increased circulating concentrations of PGE2 metabolite (PGEM).",CTD_human
3,0,Biomarker,C0009375,Colonic Neoplasms,group,colon tumors,5743,PTGS2,COX-2,CTD_human,17667525,Cyclooxygenase-2 (COX-2) is overexpressed in colon tumors.,0.24047294415841503,"<span class=""gene"" id=""17667525-1-0-16"">Cyclooxygenase-2</span> (<span class=""gene"" id=""17667525-1-18-23"">COX-2</span>) is overexpressed in <span class=""disease"" id=""17667525-1-45-57"">colon tumors</span>.",CTD_human
3,0,Biomarker,C0009375,Colonic Neoplasms,group,colon tumor,5743,PTGS2,cyclooxygenase-2,CTD_human,21081470,"Western blots revealed overexpression of ?-catenin, c-Myc, cyclin D1, inducible nitric oxide synthase and cyclooxygenase-2 in colon tumor samples.",0.24047294415841503,"Western blots revealed overexpression of &beta;-catenin, c-Myc, cyclin D1, inducible nitric oxide synthase and <span class=""gene"" id=""21081470-8-106-122"">cyclooxygenase-2</span> in <span class=""disease"" id=""21081470-8-126-137"">colon tumor</span> samples.",CTD_human
6,0,Biomarker,C0011581,Depressive disorder,disease,depression,5743,PTGS2,COX-2,CTD_human,19356723,"Furthermore, these data indicate that chronic celecoxib treatment reverse chronic unpredictable stress-induced depressive-like behavior might via reducing COX-2 enzyme in brain, and the selective COX-2 inhibitors could be developed as potential remedies for the management of depression.",0.401648360705279,"Furthermore, these data indicate that chronic celecoxib treatment reverse chronic unpredictable stress-induced depressive-like behavior might via reducing <span class=""gene"" id=""19356723-11-155-160"">COX-2</span> enzyme in brain, and the selective <span class=""gene"" id=""19356723-11-196-201"">COX-2</span> inhibitors could be developed as potential remedies for the management of <span class=""disease"" id=""19356723-11-276-286"">depression</span>.",CTD_human;PSYGENET
1,0,Biomarker,C0011849,Diabetes Mellitus,group,diabetes mellitus,5743,PTGS2,COX-2,CTD_human,15885672,The COX-2 up-regulation is temporally associated with the development of diabetes mellitus and vascular smooth muscle contractile hyperreactivity.,0.201648360705279,"The <span class=""gene"" id=""15885672-10-4-9"">COX-2</span> up-regulation is temporally associated with the development of <span class=""disease"" id=""15885672-10-73-90"">diabetes mellitus</span> and vascular smooth muscle contractile hyperreactivity.",CTD_human
1,0,Biomarker,C0013295,Duodenal Ulcer,disease,duodenal ulcers,5743,PTGS2,COX-2,CTD_human,12481160,"Healing of duodenal ulcers is not impaired by indomethacin or rofecoxib, the selective COX-2 inhibitor, in rats.",0.2,"Healing of <span class=""disease"" id=""12481160-0-11-26"">duodenal ulcers</span> is not impaired by indomethacin or rofecoxib, the selective <span class=""gene"" id=""12481160-0-87-92"">COX-2</span> inhibitor, in rats.",CTD_human
1,0,Biomarker,C0014175,Endometriosis,disease,endometriosis,5743,PTGS2,PTGS2,CTD_human,25446850,"Higher expression of PLA2G2A, PTGS2, AKR1B1, AKR1C3 and ABCC4 was seen in 22-B endometriosis cells compared to HIESC control cells.",0.31414613709615197,"Higher expression of PLA2G2A, <span class=""gene"" id=""25446850-11-30-35"">PTGS2</span>, AKR1B1, AKR1C3 and ABCC4 was seen in 22-B <span class=""disease"" id=""25446850-11-79-92"">endometriosis</span> cells compared to HIESC control cells.",CTD_human
3,0,Biomarker,C0014859,Esophageal Neoplasms,group,esophageal cancer,5743,PTGS2,cyclooxygenase-2,CTD_human,16322294,High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer.,0.30375417104833896,"High <span class=""gene"" id=""16322294-0-5-21"">cyclooxygenase-2</span> expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in <span class=""disease"" id=""16322294-0-145-162"">esophageal cancer</span>.",CTD_human
1,0,Biomarker,C0017168,Gastroesophageal reflux disease,disease,reflux,5743,PTGS2,COX-2,CTD_human,21451212,"Gastric acid and pepsin secretion and enhanced COX-2 expression were implicated in the pathogenesis of reflux esophagitis, but the effect of selective COX-2 inhibitors against lesions induced by the reflux of gastric acid content into esophagus has not been thoroughly studied.",0.201648360705279,"Gastric acid and pepsin secretion and enhanced <span class=""gene"" id=""21451212-4-47-52"">COX-2</span> expression were implicated in the pathogenesis of reflux esophagitis, but the effect of selective <span class=""gene"" id=""21451212-4-151-156"">COX-2</span> inhibitors against lesions induced by the <span class=""disease"" id=""21451212-4-199-205"">reflux</span> of gastric acid content into esophagus has not been thoroughly studied.",CTD_human
1,0,Biomarker,C0017638,Glioma,disease,gliomas,5743,PTGS2,COX-2,CTD_human,15561105,The induction of cyclooxygenase-2 (COX-2) expression is associated with more aggressive gliomas and poor survival.,0.21424272664712898,"The induction of <span class=""gene"" id=""15561105-1-17-33"">cyclooxygenase-2</span> (<span class=""gene"" id=""15561105-1-35-40"">COX-2</span>) expression is associated with more aggressive <span class=""disease"" id=""15561105-1-88-95"">gliomas</span> and poor survival.",CTD_human
2,0,Biomarker,C0020429,Hyperalgesia,phenotype,hyperalgesia,5743,PTGS2,COX-2,CTD_human,17112505,These results indicate that intrathecal administration of COX-2 inhibitors has an anti-hyperalgesic effect on streptozotocin-induced mechanical hyperalgesia and we concluded that spinal COX-2 is pivotal in streptozotocin-induced hyperalgesia.,0.200274726784213,"These results indicate that intrathecal administration of <span class=""gene"" id=""17112505-7-58-63"">COX-2</span> inhibitors has an anti-hyperalgesic effect on streptozotocin-induced mechanical hyperalgesia and we concluded that spinal <span class=""gene"" id=""17112505-7-186-191"">COX-2</span> is pivotal in streptozotocin-induced <span class=""disease"" id=""17112505-7-229-241"">hyperalgesia</span>.",CTD_human
2,0,Biomarker,C0020429,Hyperalgesia,phenotype,hyperalgesia,5743,PTGS2,COX-2,CTD_human,17989504,"The results of the study suggest participation of COX-1, COX-2 and iNOS, but not nNOS, in transmission of pain stimuli in STZ-induced diabetic hyperalgesia.",0.200274726784213,"The results of the study suggest participation of COX-1, <span class=""gene"" id=""17989504-5-57-62"">COX-2</span> and iNOS, but not nNOS, in transmission of pain stimuli in STZ-induced diabetic <span class=""disease"" id=""17989504-5-143-155"">hyperalgesia</span>.",CTD_human
1,0,Biomarker,C0020452,Hyperemia,disease,hyperemia,5743,PTGS2,COX-2,CTD_human,11820457,"In inflammatory bowel disease, increased production of prostaglandins by cyclooxygenase-2 (COX-2) contributes to bowel dysfunction, inflammatory edema, and hyperemia suggesting that inhibitors of COX-2 may have beneficial effect in gut inflammation.",0.2,"In inflammatory bowel disease, increased production of prostaglandins by <span class=""gene"" id=""11820457-1-73-89"">cyclooxygenase-2</span> (<span class=""gene"" id=""11820457-1-91-96"">COX-2</span>) contributes to bowel dysfunction, inflammatory edema, and <span class=""disease"" id=""11820457-1-156-165"">hyperemia</span> suggesting that inhibitors of <span class=""gene"" id=""11820457-1-196-201"">COX-2</span> may have beneficial effect in gut inflammation.",CTD_human
1,0,Biomarker,C0020456,Hyperglycemia,disease,hyperglycemia,5743,PTGS2,COX-2,CTD_human,14514642,"Our results suggest that hyperglycemia increases mitochondrial ROS production, resulting in NF-kappaB activation, COX-2 mRNA induction, COX-2 protein production, and PGE2 synthesis.",0.206015278498054,"Our results suggest that <span class=""disease"" id=""14514642-7-25-38"">hyperglycemia</span> increases mitochondrial ROS production, resulting in NF-kappaB activation, <span class=""gene"" id=""14514642-7-114-119"">COX-2</span> mRNA induction, <span class=""gene"" id=""14514642-7-136-141"">COX-2</span> protein production, and PGE2 synthesis.",CTD_human
4,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,5743,PTGS2,COX-2,CTD_human,15834289,"Our data also suggest a role for increased oxidative stress, which is at least in part dependent on enhanced COX-2 expression, in the mechanism(s) of enhanced aortic contractility in response to norepinephrine during DOCA-salt hypertension.",0.205154296365419,"Our data also suggest a role for increased oxidative stress, which is at least in part dependent on enhanced <span class=""gene"" id=""15834289-9-109-114"">COX-2</span> expression, in the mechanism(s) of enhanced aortic contractility in response to norepinephrine during DOCA-salt <span class=""disease"" id=""15834289-9-227-239"">hypertension</span>.",CTD_human
4,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,5743,PTGS2,cyclooxygenase-2,CTD_human,14757778,"Furthermore, an increase in the expression of cyclooxygenase-2 is implicated in the development of hypertension.",0.205154296365419,"Furthermore, an increase in the expression of <span class=""gene"" id=""14757778-12-46-62"">cyclooxygenase-2</span> is implicated in the development of <span class=""disease"" id=""14757778-12-99-111"">hypertension</span>.",CTD_human
4,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,5743,PTGS2,cyclooxygenase-2,CTD_human,14757778,"Furthermore, an increase in the expression of cyclooxygenase-2 is implicated in the development of hypertension.",0.205154296365419,"Furthermore, an increase in the expression of <span class=""gene"" id=""14757778-12-46-62"">cyclooxygenase-2</span> is implicated in the development of <span class=""disease"" id=""14757778-12-99-111"">hypertension</span>.",CTD_human
4,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,5743,PTGS2,COX-2,CTD_human,15834289,"Our data also suggest a role for increased oxidative stress, which is at least in part dependent on enhanced COX-2 expression, in the mechanism(s) of enhanced aortic contractility in response to norepinephrine during DOCA-salt hypertension.",0.205154296365419,"Our data also suggest a role for increased oxidative stress, which is at least in part dependent on enhanced <span class=""gene"" id=""15834289-9-109-114"">COX-2</span> expression, in the mechanism(s) of enhanced aortic contractility in response to norepinephrine during DOCA-salt <span class=""disease"" id=""15834289-9-227-239"">hypertension</span>.",CTD_human
1,0,Biomarker,C0021390,Inflammatory Bowel Diseases,group,inflammatory bowel disease,5743,PTGS2,COX-2,CTD_human,11820457,"In inflammatory bowel disease, increased production of prostaglandins by cyclooxygenase-2 (COX-2) contributes to bowel dysfunction, inflammatory edema, and hyperemia suggesting that inhibitors of COX-2 may have beneficial effect in gut inflammation.",0.205703749933845,"In <span class=""disease"" id=""11820457-1-3-29"">inflammatory bowel disease</span>, increased production of prostaglandins by <span class=""gene"" id=""11820457-1-73-89"">cyclooxygenase-2</span> (<span class=""gene"" id=""11820457-1-91-96"">COX-2</span>) contributes to bowel dysfunction, inflammatory edema, and hyperemia suggesting that inhibitors of <span class=""gene"" id=""11820457-1-196-201"">COX-2</span> may have beneficial effect in gut inflammation.",CTD_human
3,0,Biomarker,C0021846,Intestinal Polyps,phenotype,intestinal polyps,5743,PTGS2,cyclooxygenase-2,CTD_human,11507063,Suppression of intestinal polyps in Msh2-deficient and non-Msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor.,0.20082418035263896,"Suppression of <span class=""disease"" id=""11507063-0-15-32"">intestinal polyps</span> in Msh2-deficient and non-Msh2-deficient multiple intestinal neoplasia mice by a specific <span class=""gene"" id=""11507063-0-123-139"">cyclooxygenase-2</span> inhibitor and by a dual cyclooxygenase-1/2 inhibitor.",CTD_human
3,0,Biomarker,C0021846,Intestinal Polyps,phenotype,intestinal polyps,5743,PTGS2,COX-2,CTD_human,10753194,"While the exact mechanism(s) for this antitumor activity of p-XSC remains to be elucidated, it appears that modulation of beta-catenin expression and COX-2 activity is associated with inhibition of intestinal polyps.",0.20082418035263896,"While the exact mechanism(s) for this antitumor activity of p-XSC remains to be elucidated, it appears that modulation of beta-catenin expression and <span class=""gene"" id=""10753194-11-150-155"">COX-2</span> activity is associated with inhibition of <span class=""disease"" id=""10753194-11-198-215"">intestinal polyps</span>.",CTD_human
1,0,Biomarker,C0023269,leiomyosarcoma,disease,leiomyosarcomas,5743,PTGS2,COX-2,CTD_human,18645019,"Similarly, we found that HMGA1a and COX-2 are overexpressed in human leiomyosarcomas, a highly malignant uterine cancer.",0.200274726784213,"Similarly, we found that HMGA1a and <span class=""gene"" id=""18645019-5-36-41"">COX-2</span> are overexpressed in human <span class=""disease"" id=""18645019-5-69-84"">leiomyosarcomas</span>, a highly malignant uterine cancer.",CTD_human
1,0,Biomarker,C0023434,Chronic Lymphocytic Leukemia,disease,chronic lymphoid leukemia,5743,PTGS2,cyclooxygenase-2,CTD_human,16314473,Potential pathogenetic implications of cyclooxygenase-2 overexpression in B chronic lymphoid leukemia cells.,0.204106546385879,"Potential pathogenetic implications of <span class=""gene"" id=""16314473-0-39-55"">cyclooxygenase-2</span> overexpression in B <span class=""disease"" id=""16314473-0-76-101"">chronic lymphoid leukemia</span> cells.",CTD_human
1,0,Biomarker,C0023532,"Leukoplakia, Oral",disease,oral leukoplakia,5743,PTGS2,COX-2,CTD_human,18202791,"Although COX-2 is commonly overexpressed in a variety of premalignant and malignant conditions including oral leukoplakia and squamous cell carcinoma, relatively little research has compared the effects of various COX-2 inhibitors (celecoxib, NS-398, nimesulide and meloxicam).",0.203231208875927,"Although <span class=""gene"" id=""18202791-2-9-14"">COX-2</span> is commonly overexpressed in a variety of premalignant and malignant conditions including <span class=""disease"" id=""18202791-2-105-121"">oral leukoplakia</span> and squamous cell carcinoma, relatively little research has compared the effects of various <span class=""gene"" id=""18202791-2-214-219"">COX-2</span> inhibitors (celecoxib, NS-398, nimesulide and meloxicam).",CTD_human
1,0,Biomarker,C0024141,"Lupus Erythematosus, Systemic",disease,lupus,5743,PTGS2,cyclooxygenase-2,CTD_human,17761345,Apoptosis of murine lupus T cells induced by the selective cyclooxygenase-2 inhibitor celecoxib: molecular mechanisms and therapeutic potential.,0.20054945356842604,"Apoptosis of murine <span class=""disease"" id=""17761345-0-20-25"">lupus</span> T cells induced by the selective <span class=""gene"" id=""17761345-0-59-75"">cyclooxygenase-2</span> inhibitor celecoxib: molecular mechanisms and therapeutic potential.",CTD_human
3,0,Biomarker,C0025202,melanoma,disease,melanomas,5743,PTGS2,COX-2,CTD_human,18454317,"Pharmacological suppression of COX-2 and PI3K-AKT, or RNAi-mediated knockdown of COX-2, substantially increased levels of G2/M arrest of the cell cycle and decreased clonogenic survival of gamma-irradiated melanomas, predominantly via a necrotic mechanism.",0.22457376578064603,"Pharmacological suppression of <span class=""gene"" id=""18454317-5-31-36"">COX-2</span> and PI3K-AKT, or RNAi-mediated knockdown of <span class=""gene"" id=""18454317-5-81-86"">COX-2</span>, substantially increased levels of G2/M arrest of the cell cycle and decreased clonogenic survival of gamma-irradiated <span class=""disease"" id=""18454317-5-206-215"">melanomas</span>, predominantly via a necrotic mechanism.",CTD_human
3,0,Biomarker,C0025202,melanoma,disease,melanoma,5743,PTGS2,COX-2,CTD_human,17499752,"On the whole, the results of in vivo and in vitro studies suggest that COX-2 expressed in TAMs appears to act as an effective biomarker of melanoma progression, and melanoma cells themselves might stimulate COX-2 in macrophages.",0.22457376578064603,"On the whole, the results of in vivo and in vitro studies suggest that <span class=""gene"" id=""17499752-10-71-76"">COX-2</span> expressed in TAMs appears to act as an effective biomarker of <span class=""disease"" id=""17499752-10-139-147"">melanoma</span> progression, and <span class=""disease"" id=""17499752-10-165-173"">melanoma</span> cells themselves might stimulate <span class=""gene"" id=""17499752-10-207-212"">COX-2</span> in macrophages.",CTD_human
2,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastasized,5743,PTGS2,COX-2,CTD_human,16489006,"In a nude mouse model of bone metastasis, the MDA-MB-231 human breast cancer cells showed no COX-2 expression at orthotopic sites, whereas these cells, when metastasized to bone, intensely expressed COX-2, suggesting that the bone microenvironment induced COX-2 expression.",0.27006356894148204,"In a nude mouse model of bone metastasis, the MDA-MB-231 human breast cancer cells showed no <span class=""gene"" id=""16489006-5-93-98"">COX-2</span> expression at orthotopic sites, whereas these cells, when <span class=""disease"" id=""16489006-5-157-169"">metastasized</span> to bone, intensely expressed <span class=""gene"" id=""16489006-5-199-204"">COX-2</span>, suggesting that the bone microenvironment induced <span class=""gene"" id=""16489006-5-256-261"">COX-2</span> expression.",CTD_human
4,0,Biomarker,C0030297,Pancreatic Neoplasm,disease,pancreatic tumor,5743,PTGS2,COX-2,CTD_human,15705899,These findings imply that assessing the COX-2 profile of the pancreatic tumor is mandatory before initiating therapy with a selective COX-2 inhibitor.,0.21411170157787,"These findings imply that assessing the <span class=""gene"" id=""15705899-14-40-45"">COX-2</span> profile of the <span class=""disease"" id=""15705899-14-61-77"">pancreatic tumor</span> is mandatory before initiating therapy with a selective <span class=""gene"" id=""15705899-14-134-139"">COX-2</span> inhibitor.",CTD_human
4,0,Biomarker,C0030297,Pancreatic Neoplasm,disease,pancreatic tumors,5743,PTGS2,COX-2,CTD_human,16820089,COX-2 immunohistochemistry was performed in pancreata of hamsters subjected to the carcinogen N-nitrosobis-(2-oxopropyl)amine (BOP) and in human pancreatic tumors.,0.21411170157787,"<span class=""gene"" id=""16820089-3-0-5"">COX-2</span> immunohistochemistry was performed in pancreata of hamsters subjected to the carcinogen N-nitrosobis-(2-oxopropyl)amine (BOP) and in human <span class=""disease"" id=""16820089-3-145-162"">pancreatic tumors</span>.",CTD_human
4,0,Biomarker,C0030297,Pancreatic Neoplasm,disease,pancreatic tumor,5743,PTGS2,COX-2,CTD_human,10657949,"We also report that the COX inhibitors sulindac, indomethacin and NS-398 inhibit cell growth in both COX-2-positive (BxPC-3) and COX-2-negative (PaCa-2) pancreatic tumor cell lines.",0.21411170157787,"We also report that the COX inhibitors sulindac, indomethacin and NS-398 inhibit cell growth in both <span class=""gene"" id=""10657949-9-101-106"">COX-2</span>-positive (<span class=""gene"" id=""10657949-9-117-123"">BxPC-3</span>) and <span class=""gene"" id=""10657949-9-129-134"">COX-2</span>-negative (PaCa-2) <span class=""disease"" id=""10657949-9-153-169"">pancreatic tumor</span> cell lines.",CTD_human
1,0,Biomarker,C0030305,Pancreatitis,disease,pancreatitis,5743,PTGS2,COX-2,CTD_human,19820421,"Except for rs5275, the frequencies of COX-2 polymorphisms were both similar in patients with mild or severe pancreatitis, so were in pancreatitis patients and in controls.",0.200274726784213,"Except for rs5275, the frequencies of <span class=""gene"" id=""19820421-3-38-43"">COX-2</span> polymorphisms were both similar in patients with mild or severe <span class=""disease"" id=""19820421-3-108-120"">pancreatitis</span>, so were in <span class=""disease"" id=""19820421-3-133-145"">pancreatitis</span> patients and in controls.",CTD_human
2,0,Biomarker,C0030354,Papilloma,disease,papillomas,5743,PTGS2,COX-2,CTD_human,16144915,"We propose a positive feedback loop for COX-2 expression, with induction of COX-2 resulting in enhanced PGE2 synthesis and further expression of COX-2 that contributes to the growth of papillomas in vivo.",0.20328236603324,"We propose a positive feedback loop for <span class=""gene"" id=""16144915-10-40-45"">COX-2</span> expression, with induction of <span class=""gene"" id=""16144915-10-76-81"">COX-2</span> resulting in enhanced PGE2 synthesis and further expression of <span class=""gene"" id=""16144915-10-145-150"">COX-2</span> that contributes to the growth of <span class=""disease"" id=""16144915-10-185-195"">papillomas</span> in vivo.",CTD_human
2,0,Biomarker,C0030354,Papilloma,disease,papillomas,5743,PTGS2,COX-2,CTD_human,12151359,"As a molecular marker of oxidative stress, increased COX-2 expression was noted in 17 of 18 (94%) TCCs, 4 of 4 (100%) papillomas, and 39 of 47 (83%) PN hyperplasias.",0.20328236603324,"As a molecular marker of oxidative stress, increased <span class=""gene"" id=""12151359-18-53-58"">COX-2</span> expression was noted in 17 of 18 (94%) TCCs, 4 of 4 (100%) <span class=""disease"" id=""12151359-18-118-128"">papillomas</span>, and 39 of 47 (83%) PN hyperplasias.",CTD_human
1,0,Biomarker,C0036572,Seizures,phenotype,seizures,5743,PTGS2,COX-2,CTD_human,14518562,Inducible brain COX-2 facilitates the recurrence of hippocampal seizures in mouse rapid kindling.,0.200274726784213,"Inducible brain <span class=""gene"" id=""14518562-0-16-21"">COX-2</span> facilitates the recurrence of hippocampal <span class=""disease"" id=""14518562-0-64-72"">seizures</span> in mouse rapid kindling.",CTD_human
3,0,Biomarker,C0037286,Skin Neoplasms,group,skin tumor,5743,PTGS2,COX-2,CTD_human,19748995,Results from these studies support the hypothesis that combining ligand activation of PPARbeta/delta with inhibition of COX-2 activity can inhibit chemically induced skin tumor progression by modulating differentiation.,0.20678830169338,"Results from these studies support the hypothesis that combining ligand activation of PPARbeta/delta with inhibition of <span class=""gene"" id=""19748995-9-120-125"">COX-2</span> activity can inhibit chemically induced <span class=""disease"" id=""19748995-9-166-176"">skin tumor</span> progression by modulating differentiation.",CTD_human
1,0,Biomarker,C0038220,Status Epilepticus,disease,status epilepticus,5743,PTGS2,Cyclooxygenase-2,CTD_human,18988310,Cyclooxygenase-2 inhibitor inhibits hippocampal synaptic reorganization in pilocarpine-induced status epilepticus rats.,0.2,"<span class=""gene"" id=""18988310-0-0-16"">Cyclooxygenase-2</span> inhibitor inhibits hippocampal synaptic reorganization in pilocarpine-induced <span class=""disease"" id=""18988310-0-95-113"">status epilepticus</span> rats.",CTD_human
5,0,Biomarker,C0038358,Gastric ulcer,disease,gastric ulcers,5743,PTGS2,COX-2,CTD_human,11376495,Classic NSAID and selective cyclooxygenase (COX)-1 and COX-2 inhibitors in healing of chronic gastric ulcers.,0.207114185634906,"Classic NSAID and selective cyclooxygenase (COX)-1 and <span class=""gene"" id=""11376495-0-55-60"">COX-2</span> inhibitors in healing of chronic <span class=""disease"" id=""11376495-0-94-108"">gastric ulcers</span>.",CTD_human
1,0,Biomarker,C0079731,B-Cell Lymphomas,group,B cell lymphomas,5743,PTGS2,COX-2,CTD_human,14654083,"These findings suggest that increased COX-2 expression and activity, contributes to the pathogenesis of B cell lymphomas and point to a possible role for COX-2 inhibition in their treatment.",0.20350593566014002,"These findings suggest that increased <span class=""gene"" id=""14654083-13-38-43"">COX-2</span> expression and activity, contributes to the pathogenesis of <span class=""disease"" id=""14654083-13-104-120"">B cell lymphomas</span> and point to a possible role for <span class=""gene"" id=""14654083-13-154-159"">COX-2</span> inhibition in their treatment.",CTD_human
1,0,Biomarker,C0162871,"Aortic Aneurysm, Abdominal",disease,abdominal aortic aneurysm,5743,PTGS2,cyclooxygenase-2,CTD_human,16514081,Selective cyclooxygenase-2 inhibition with celecoxib decreases angiotensin II-induced abdominal aortic aneurysm formation in mice.,0.20054945356842604,"Selective <span class=""gene"" id=""16514081-0-10-26"">cyclooxygenase-2</span> inhibition with celecoxib decreases angiotensin II-induced <span class=""disease"" id=""16514081-0-86-111"">abdominal aortic aneurysm</span> formation in mice.",CTD_human
3,0,Biomarker,C0279626,Squamous cell carcinoma of esophagus,disease,esophageal squamous cell carcinoma,5743,PTGS2,COX-2,CTD_human,15756444,Predictive value of COX-2 for the effect of chemoradiotherapy on esophageal squamous cell carcinoma.,0.20851653031060602,"Predictive value of <span class=""gene"" id=""15756444-0-20-25"">COX-2</span> for the effect of chemoradiotherapy on <span class=""disease"" id=""15756444-0-65-99"">esophageal squamous cell carcinoma</span>.",CTD_human
3,0,Biomarker,C0279626,Squamous cell carcinoma of esophagus,disease,ESCC,5743,PTGS2,COX-2,CTD_human,18197933,COX-2 mRNA expression in esophageal squamous cell carcinoma (ESCC) and effect by NSAID.,0.20851653031060602,"<span class=""gene"" id=""18197933-0-0-5"">COX-2</span> mRNA expression in <span class=""disease"" id=""18197933-0-25-59"">esophageal squamous cell carcinoma</span> (<span class=""disease"" id=""18197933-0-61-65"">ESCC</span>) and effect by NSAID.",CTD_human
1,0,Biomarker,C0339143,Thyroid associated opthalmopathies,disease,Graves' ophthalmopathy,5743,PTGS2,COX-2,CTD_human,17614770,"COX-2 and SCD, markers of inflammation and adipogenesis, are related to disease activity in Graves' ophthalmopathy.",0.200274726784213,"<span class=""gene"" id=""17614770-0-0-5"">COX-2</span> and SCD, markers of inflammation and adipogenesis, are related to disease activity in <span class=""disease"" id=""17614770-0-92-114"">Graves' ophthalmopathy</span>.",CTD_human
1,0,Biomarker,C1134719,Invasive Ductal Breast Carcinoma,disease,ductal invasive breast carcinoma,5743,PTGS2,COX-2,CTD_human,21153458,Methylation status and overexpression of COX-2 in Tunisian patients with ductal invasive breast carcinoma.,0.201648360705279,"Methylation status and overexpression of <span class=""gene"" id=""21153458-0-41-46"">COX-2</span> in Tunisian patients with <span class=""disease"" id=""21153458-0-73-105"">ductal invasive breast carcinoma</span>.",CTD_human
2,0,Biomarker,C1319853,"Asthma, Aspirin-Induced",disease,AIA,5743,PTGS2,COX-2,CTD_human,16502481,"Several single nucleotide polymorphisms (SNPs) in the promoters of EP2, TBX21, COX-2, Fc epsilon RIbeta, and TBXA2R were associated with AIA, while an Fc epsilon RIalpha promoter polymorphism was associated with AIU.",0.200274726784213,"Several single nucleotide polymorphisms (SNPs) in the promoters of EP2, TBX21, <span class=""gene"" id=""16502481-6-79-84"">COX-2</span>, Fc epsilon RIbeta, and TBXA2R were associated with <span class=""disease"" id=""16502481-6-137-140"">AIA</span>, while an Fc epsilon RIalpha promoter polymorphism was associated with AIU.",CTD_human
5,0,Biomarker,C1458155,Mammary Neoplasms,group,breast tumors,5743,PTGS2,COX-2,CTD_human,16127422,"We speculate that high levels of COX-2 induce drug resistance in ERalpha-positive breast tumors, thus reducing the survival rate of patients with such tumors.",0.285769262468475,"We speculate that high levels of <span class=""gene"" id=""16127422-2-33-38"">COX-2</span> induce drug resistance in ERalpha-positive <span class=""disease"" id=""16127422-2-82-95"">breast tumors</span>, thus reducing the survival rate of patients with such tumors.",CTD_human
1,0,Biomarker,C1956346,Coronary Artery Disease,disease,coronary artery disease,5743,PTGS2,cyclooxygenase-2,CTD_human,14642682,Effect of cyclooxygenase-2 inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease.,0.212426539092596,"Effect of <span class=""gene"" id=""14642682-0-10-26"">cyclooxygenase-2</span> inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with <span class=""disease"" id=""14642682-0-122-145"">coronary artery disease</span>.",CTD_human
5,0,Biomarker,C2239176,Liver carcinoma,disease,hepatocellular carcinoma,5743,PTGS2,COX-2,CTD_human,17510421,"In several neoplastic diseases, including hepatocellular carcinoma, the expression of P-glycoprotein and cyclooxygenase-2 (COX-2) are often increased and involved in drug resistance and poor prognosis.",0.22791355332315502,"In several neoplastic diseases, including <span class=""disease"" id=""17510421-1-42-66"">hepatocellular carcinoma</span>, the expression of P-glycoprotein and <span class=""gene"" id=""17510421-1-105-121"">cyclooxygenase-2</span> (<span class=""gene"" id=""17510421-1-123-128"">COX-2</span>) are often increased and involved in drug resistance and poor prognosis.",CTD_human
5,0,Biomarker,C2239176,Liver carcinoma,disease,hepatocellular carcinoma,5743,PTGS2,cyclooxygenase-2,CTD_human,12024111,Rationale and feasibility of chemoprovention of hepatocellular carcinoma by cyclooxygenase-2 inhibitors.,0.22791355332315502,"Rationale and feasibility of chemoprovention of <span class=""disease"" id=""12024111-0-48-72"">hepatocellular carcinoma</span> by <span class=""gene"" id=""12024111-0-76-92"">cyclooxygenase-2</span> inhibitors.",CTD_human
5,0,Biomarker,C2239176,Liver carcinoma,disease,hepatoma,5743,PTGS2,COX-2,CTD_human,14563831,Dietary alpha-linolenic acid reduces COX-2 expression and induces apoptosis of hepatoma cells.,0.22791355332315502,"Dietary alpha-linolenic acid reduces <span class=""gene"" id=""14563831-0-37-42"">COX-2</span> expression and induces apoptosis of <span class=""disease"" id=""14563831-0-79-87"">hepatoma</span> cells.",CTD_human
5,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,5743,PTGS2,COX-2,CTD_human,16374840,Troglitazone-mediated PPARgamma activation also suppressed COX-2 expression and induced p27 in HCC cells.,0.22791355332315502,"Troglitazone-mediated PPARgamma activation also suppressed <span class=""gene"" id=""16374840-11-59-64"">COX-2</span> expression and induced p27 in <span class=""disease"" id=""16374840-11-95-98"">HCC</span> cells.",CTD_human
1,0,Therapeutic,C0007131,Non-Small Cell Lung Carcinoma,disease,nonsmall cell lung cancer,5744,PTHLH,Parathyroid hormone-related protein,CTD_human,17676588,Parathyroid hormone-related protein varies with sex and androgen status in nonsmall cell lung cancer.,0.20054945356842604,"<span class=""gene"" id=""17676588-0-0-35"">Parathyroid hormone-related protein</span> varies with sex and androgen status in <span class=""disease"" id=""17676588-0-75-100"">nonsmall cell lung cancer</span>.",CTD_human
1,0,Biomarker,C0020429,Hyperalgesia,phenotype,hyperalgesia,5744,PTHLH,parathyroid hormone-related protein,CTD_human,16769263,Repeated subcutaneous injections of parathyroid hormone-related protein into the hind-paw also induced hyperalgesia with increased osteoclastic bone resorption.,0.2,"Repeated subcutaneous injections of <span class=""gene"" id=""16769263-7-36-71"">parathyroid hormone-related protein</span> into the hind-paw also induced <span class=""disease"" id=""16769263-7-103-115"">hyperalgesia</span> with increased osteoclastic bone resorption.",CTD_human
4,0,Biomarker,C0020437,Hypercalcemia,disease,hypercalcaemia,5744,PTHLH,PTHrP,CTD_human,11054717,"The present findings are consistent with the view that PTHrP can be generated in myeloma cells in vivo, and could contribute to osteolysis and hypercalcaemia, as in patients with cancer.",0.22686580334361497,"The present findings are consistent with the view that <span class=""gene"" id=""11054717-7-55-60"">PTHrP</span> can be generated in myeloma cells in vivo, and could contribute to osteolysis and <span class=""disease"" id=""11054717-7-143-157"">hypercalcaemia</span>, as in patients with cancer.",CTD_human
4,0,Biomarker,C0020437,Hypercalcemia,disease,hypercalcaemia,5744,PTHLH,parathyroid hormone-related protein,CTD_human,12358896,Superior vena cava syndrome and hypercalcaemia in a patient with a primary mediastinal B-cell lymphoma secreting parathyroid hormone-related protein.,0.22686580334361497,"Superior vena cava syndrome and <span class=""disease"" id=""12358896-0-32-46"">hypercalcaemia</span> in a patient with a primary mediastinal B-cell lymphoma secreting <span class=""gene"" id=""12358896-0-113-148"">parathyroid hormone-related protein</span>.",CTD_human
1,0,Biomarker,C0026764,Multiple Myeloma,disease,multiple myeloma,5744,PTHLH,parathyroid hormone-related protein,CTD_human,11054717,Assessment of cellular expression of parathyroid hormone-related protein mRNA and protein in multiple myeloma.,0.201648360705279,"Assessment of cellular expression of <span class=""gene"" id=""11054717-0-37-72"">parathyroid hormone-related protein</span> mRNA and protein in <span class=""disease"" id=""11054717-0-93-109"">multiple myeloma</span>.",CTD_human
1,0,Biomarker,C0038833,Superior Vena Cava Syndrome,disease,Superior vena cava syndrome,5744,PTHLH,parathyroid hormone-related protein,CTD_human,12358896,Superior vena cava syndrome and hypercalcaemia in a patient with a primary mediastinal B-cell lymphoma secreting parathyroid hormone-related protein.,0.2,"<span class=""disease"" id=""12358896-0-0-27"">Superior vena cava syndrome</span> and hypercalcaemia in a patient with a primary mediastinal B-cell lymphoma secreting <span class=""gene"" id=""12358896-0-113-148"">parathyroid hormone-related protein</span>.",CTD_human
1,0,Biomarker,C0149521,"Pancreatitis, Chronic",disease,CP,5744,PTHLH,PTHrP,CTD_human,25035110,These findings establish PTHrP as a novel mediator of inflammation and fibrosis associated with CP.,0.20054945356842604,"These findings establish <span class=""gene"" id=""25035110-12-25-30"">PTHrP</span> as a novel mediator of inflammation and fibrosis associated with <span class=""disease"" id=""25035110-12-96-98"">CP</span>.",CTD_human
1,0,Biomarker,C0206754,Neuroendocrine Tumors,group,neuroendocrine tumour,5744,PTHLH,PTHrP,CTD_human,17625444,"To the best of our knowledge, this is the first report showing somatostatin receptor expression in a PTHrP-secreting pancreatic neuroendocrine tumour.",0.200274726784213,"To the best of our knowledge, this is the first report showing somatostatin receptor expression in a <span class=""gene"" id=""17625444-6-101-106"">PTHrP</span>-secreting pancreatic <span class=""disease"" id=""17625444-6-128-149"">neuroendocrine tumour</span>.",CTD_human
1,0,Biomarker,C0376670,"Pancreatitis, Alcoholic",disease,alcoholic pancreatitis,5744,PTHLH,PTHrP,CTD_human,22280800,Together these studies identify PTHrP as a potential mediator of the inflammatory and fibrogenic responses associated with alcoholic pancreatitis.,0.200274726784213,"Together these studies identify <span class=""gene"" id=""22280800-12-32-37"">PTHrP</span> as a potential mediator of the inflammatory and fibrogenic responses associated with <span class=""disease"" id=""22280800-12-123-145"">alcoholic pancreatitis</span>.",CTD_human
1,0,Therapeutic,C0027627,Neoplasm Metastasis,phenotype,metastasis,574466,MIR519C,miR-519c,CTD_human,20233879,"Consistent with the overexpression of miR-519c in cancer patients with better prognosis, mice injected with miR-519c-overexpressing cells exhibited dramatically reduced HIF-1alpha levels, followed by suppressed tumor angiogenesis, growth, and metastasis.",0.2,"Consistent with the overexpression of <span class=""gene"" id=""20233879-5-38-46"">miR-519c</span> in cancer patients with better prognosis, mice injected with <span class=""gene"" id=""20233879-5-108-116"">miR-519c</span>-overexpressing cells exhibited dramatically reduced HIF-1alpha levels, followed by suppressed tumor angiogenesis, growth, and <span class=""disease"" id=""20233879-5-243-253"">metastasis</span>.",CTD_human
1,0,Biomarker,C0038220,Status Epilepticus,disease,SE,57468,SLC12A5,KCC2,CTD_human,20600929,"Tyrosine phosphorylation of KCC2 is thus likely to play a key role in regulating the degradation of KCC2, a process that may be responsible for pathological losses of KCC2 function that are evident in SE and other forms of epilepsy.",0.200274726784213,"Tyrosine phosphorylation of <span class=""gene"" id=""20600929-9-28-32"">KCC2</span> is thus likely to play a key role in regulating the degradation of <span class=""gene"" id=""20600929-9-100-104"">KCC2</span>, a process that may be responsible for pathological losses of <span class=""gene"" id=""20600929-9-167-171"">KCC2</span> function that are evident in <span class=""disease"" id=""20600929-9-201-203"">SE</span> and other forms of epilepsy.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,hepatocellular carcinomas,5747,PTK2,PTK2,CTD_human,14578863,PTK2 and EIF3S3 genes may be amplification targets at 8q23-q24 and are associated with large hepatocellular carcinomas.,0.21307830697564697,"<span class=""gene"" id=""14578863-0-0-4"">PTK2</span> and EIF3S3 genes may be amplification targets at 8q23-q24 and are associated with large <span class=""disease"" id=""14578863-0-93-118"">hepatocellular carcinomas</span>.",CTD_human
1,0,Biomarker,C0027819,Neuroblastoma,disease,neuroblastoma,57492,ARID1B,ARID1B,CTD_human,23202128,Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma.,0.200274726784213,"Integrated genomic analyses identify ARID1A and <span class=""gene"" id=""23202128-0-48-54"">ARID1B</span> alterations in the childhood cancer <span class=""disease"" id=""23202128-0-91-104"">neuroblastoma</span>.",CTD_human
2,13,Biomarker,C0265338,Coffin-Siris syndrome,disease,Coffin-Siris syndrome,57492,ARID1B,ARID1B,CTD_human,22426309,Mutations in SWI/SNF chromatin remodeling complex gene ARID1B cause Coffin-Siris syndrome.,0.401648360705279,"Mutations in SWI/SNF chromatin remodeling complex gene <span class=""gene"" id=""22426309-0-55-61"">ARID1B</span> cause <span class=""disease"" id=""22426309-0-68-89"">Coffin-Siris syndrome</span>.",CTD_human;ORPHANET
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,57502,NLGN4X,NLGN4,CTD_human,12669065,Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism.,0.22950907813949697,"Mutations of the X-linked genes encoding neuroligins NLGN3 and <span class=""gene"" id=""12669065-0-63-68"">NLGN4</span> are associated with <span class=""disease"" id=""12669065-0-89-95"">autism</span>.",CTD_human
1,0,Biomarker,C1510586,Autism Spectrum Disorders,disease,ASD,57502,NLGN4X,NLGN4,CTD_human,18252227,"Notwithstanding complexities, our results further implicate the SHANK3-NLGN4-NRXN1 postsynaptic density genes and also identify novel loci at DPP6-DPP10-PCDH9 (synapse complex), ANKRD11, DPYD, PTCHD1, 15q24, among others, for a role in ASD susceptibility.",0.20412090176319603,"Notwithstanding complexities, our results further implicate the SHANK3-<span class=""gene"" id=""18252227-8-71-76"">NLGN4</span>-NRXN1 postsynaptic density genes and also identify novel loci at DPP6-DPP10-PCDH9 (synapse complex), ANKRD11, DPYD, PTCHD1, 15q24, among others, for a role in <span class=""disease"" id=""18252227-8-236-239"">ASD</span> susceptibility.",CTD_human
1,0,Biomarker,C0014544,Epilepsy,disease,epilepsy,57526,PCDH19,protocadherin 19,CTD_human,18469813,X-linked protocadherin 19 mutations cause female-limited epilepsy and cognitive impairment.,0.211524169559633,"X-linked <span class=""gene"" id=""18469813-0-9-25"">protocadherin 19</span> mutations cause female-limited <span class=""disease"" id=""18469813-0-57-65"">epilepsy</span> and cognitive impairment.",CTD_human
1,1,Biomarker,C0027819,Neuroblastoma,disease,neuroblastoma,57531,HACE1,HACE1,CTD_human,22941191,Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastoma.,0.40027472678421294,"Common variation at 6q16 within <span class=""gene"" id=""22941191-0-32-37"">HACE1</span> and LIN28B influences susceptibility to <span class=""disease"" id=""22941191-0-78-91"">neuroblastoma</span>.",CTD_human;ORPHANET
1,0,Biomarker,C0035412,Rhabdomyosarcoma,disease,RMS,5757,PTMA,PTMA,CTD_human,16669873,PTMA expression in RMS biopsy samples might prove to be an effective diagnostic marker for this disease.,0.200274726784213,"<span class=""gene"" id=""16669873-10-0-4"">PTMA</span> expression in <span class=""disease"" id=""16669873-10-19-22"">RMS</span> biopsy samples might prove to be an effective diagnostic marker for this disease.",CTD_human
1,0,Biomarker,C1510586,Autism Spectrum Disorders,disease,ASD,57616,TSHZ3,TSHZ3,CTD_human,27668656,"These findings highlight essential roles for Tshz3 in CPN development and function, whose alterations can account for ASD in the newly defined TSHZ3 deletion syndrome.",0.2,"These findings highlight essential roles for <span class=""gene"" id=""27668656-5-45-50"">Tshz3</span> in CPN development and function, whose alterations can account for <span class=""disease"" id=""27668656-5-118-121"">ASD</span> in the newly defined <span class=""gene"" id=""27668656-5-143-148"">TSHZ3</span> deletion syndrome.",CTD_human
1,0,Biomarker,C1510586,Autism Spectrum Disorders,disease,ASD,57628,DPP10,DPP10,CTD_human,18252227,"Notwithstanding complexities, our results further implicate the SHANK3-NLGN4-NRXN1 postsynaptic density genes and also identify novel loci at DPP6-DPP10-PCDH9 (synapse complex), ANKRD11, DPYD, PTCHD1, 15q24, among others, for a role in ASD susceptibility.",0.200274726784213,"Notwithstanding complexities, our results further implicate the SHANK3-NLGN4-NRXN1 postsynaptic density genes and also identify novel loci at DPP6-<span class=""gene"" id=""18252227-8-147-152"">DPP10</span>-PCDH9 (synapse complex), ANKRD11, DPYD, PTCHD1, 15q24, among others, for a role in <span class=""disease"" id=""18252227-8-236-239"">ASD</span> susceptibility.",CTD_human
1,2,Biomarker,C0024141,"Lupus Erythematosus, Systemic",disease,systemic lupus erythematosus,57661,PHRF1,KIAA1542,CTD_human,18204446,"Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci.",0.21400938726324398,"Genome-wide association scan in women with <span class=""disease"" id=""18204446-0-43-71"">systemic lupus erythematosus</span> identifies susceptibility variants in ITGAM, PXK, <span class=""gene"" id=""18204446-0-122-130"">KIAA1542</span> and other loci.",CTD_human
1,0,Biomarker,C0221355,Macrocephaly,disease,macrocephaly,57680,CHD8,chd8,CTD_human,24998929,"In addition to a high likelihood of an ASD diagnosis among patients bearing CHD8 mutations, characteristics enriched in this group included macrocephaly, distinct faces, and gastrointestinal complaints. chd8 disruption in zebrafish recapitulates features of the human phenotype, including increased head size as a result of expansion of the forebrain/midbrain and impairment of gastrointestinal motility due to a reduction in postmitotic enteric neurons.",0.201373633921065,"In addition to a high likelihood of an ASD diagnosis among patients bearing <span class=""gene"" id=""24998929-4-76-80"">CHD8</span> mutations, characteristics enriched in this group included <span class=""disease"" id=""24998929-4-140-152"">macrocephaly</span>, distinct faces, and gastrointestinal complaints. <span class=""gene"" id=""24998929-4-203-207"">chd8</span> disruption in zebrafish recapitulates features of the human phenotype, including increased head size as a result of expansion of the forebrain/midbrain and impairment of gastrointestinal motility due to a reduction in postmitotic enteric neurons.",CTD_human
1,0,Biomarker,C1510586,Autism Spectrum Disorders,disease,ASD,57680,CHD8,CHD8,CTD_human,24998929,Our findings indicate that CHD8 disruptions define a distinct ASD subtype and reveal unexpected comorbidities between brain development and enteric innervation.,0.203021994626344,"Our findings indicate that <span class=""gene"" id=""24998929-5-27-31"">CHD8</span> disruptions define a distinct <span class=""disease"" id=""24998929-5-62-65"">ASD</span> subtype and reveal unexpected comorbidities between brain development and enteric innervation.",CTD_human
1,0,Biomarker,C0015625,Fanconi Anemia,disease,Fanconi anemia,57697,FANCM,FANCM,CTD_human,16116422,Our data suggest an evolutionary link between Fanconi anemia-associated proteins and DNA repair; FANCM may act as an engine that translocates the Fanconi anemia core complex along DNA.,0.408502174933289,"Our data suggest an evolutionary link between <span class=""disease"" id=""16116422-9-46-60"">Fanconi anemia</span>-associated proteins and DNA repair; <span class=""gene"" id=""16116422-9-97-102"">FANCM</span> may act as an engine that translocates the <span class=""disease"" id=""16116422-9-146-160"">Fanconi anemia</span> core complex along DNA.",CTD_human;ORPHANET
1,0,Biomarker,C0019829,Hodgkin Disease,disease,Hodgkin lymphoma,5770,PTPN1,PTPN1,CTD_human,24531327,Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma.,0.200274726784213,"Recurrent somatic mutations of <span class=""gene"" id=""24531327-0-31-36"">PTPN1</span> in primary mediastinal B cell lymphoma and <span class=""disease"" id=""24531327-0-80-96"">Hodgkin lymphoma</span>.",CTD_human
1,0,Biomarker,C0028754,Obesity,disease,obesity,5770,PTPN1,PTP1B,CTD_human,10744717,"Recent studies have shown increased insulin sensitivity and resistance to obesity in PTP1B knockout mice, thus pointing to this enzyme as a potential drug target in diabetes.",0.21229719275495998,"Recent studies have shown increased insulin sensitivity and resistance to <span class=""disease"" id=""10744717-2-74-81"">obesity</span> in <span class=""gene"" id=""10744717-2-85-90"">PTP1B</span> knockout mice, thus pointing to this enzyme as a potential drug target in diabetes.",CTD_human
1,0,Biomarker,C0035372,Rett Syndrome,disease,Rett syndrome,5770,PTPN1,PTP1B,CTD_human,26214522,PTP1B inhibition suggests a therapeutic strategy for Rett syndrome.,0.2,"<span class=""gene"" id=""26214522-0-0-5"">PTP1B</span> inhibition suggests a therapeutic strategy for <span class=""disease"" id=""26214522-0-53-66"">Rett syndrome</span>.",CTD_human
1,0,Biomarker,C0079731,B-Cell Lymphomas,group,B cell lymphoma,5770,PTPN1,PTPN1,CTD_human,24531327,Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma.,0.20054945356842604,"Recurrent somatic mutations of <span class=""gene"" id=""24531327-0-31-36"">PTPN1</span> in primary mediastinal <span class=""disease"" id=""24531327-0-60-75"">B cell lymphoma</span> and Hodgkin lymphoma.",CTD_human
1,2,Biomarker,C0003873,Rheumatoid Arthritis,disease,rheumatoid arthritis,5771,PTPN2,PTPN2,CTD_human,22446963,"Our study identified nine loci newly associated with rheumatoid arthritis at a threshold of P < 5.0 × 10(-8), including B3GNT2, ANXA3, CSF2, CD83, NFKBIE, ARID5B, PDE2A-ARAP1, PLD4 and PTPN2.",0.206187690967642,"Our study identified nine loci newly associated with <span class=""disease"" id=""22446963-3-53-73"">rheumatoid arthritis</span> at a threshold of P &lt; 5.0 &times; 10(-8), including B3GNT2, ANXA3, CSF2, CD83, NFKBIE, ARID5B, PDE2A-ARAP1, PLD4 and <span class=""gene"" id=""22446963-3-185-190"">PTPN2</span>.",CTD_human
1,1,Biomarker,C0009324,Ulcerative Colitis,disease,ulcerative colitis,5771,PTPN2,PTPN2,CTD_human,18438405,"Among these loci, we identified variants in 3p21.31, NKX2-3 and CCNY as susceptibility factors for both diseases, whereas variants in PTPN2, HERC2 and STAT3 were associated only with ulcerative colitis in our sample collection.",0.20947005700088103,"Among these loci, we identified variants in 3p21.31, NKX2-3 and CCNY as susceptibility factors for both diseases, whereas variants in <span class=""gene"" id=""18438405-2-134-139"">PTPN2</span>, HERC2 and STAT3 were associated only with <span class=""disease"" id=""18438405-2-183-201"">ulcerative colitis</span> in our sample collection.",CTD_human
1,0,Biomarker,C1961099,Precursor T-Cell Lymphoblastic Leukemia-Lymphoma,disease,T-cell acute lymphoblastic leukemia,5771,PTPN2,PTPN2,CTD_human,20473312,Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia.,0.20082418035263896,"Deletion of the protein tyrosine phosphatase gene <span class=""gene"" id=""20473312-0-50-55"">PTPN2</span> in <span class=""disease"" id=""20473312-0-59-94"">T-cell acute lymphoblastic leukemia</span>.",CTD_human
1,7,Biomarker,C1855772,Absent corpus callosum cataract immunodeficiency,disease,Vici syndrome,57724,EPG5,EPG5,CTD_human,23222957,"Recessive mutations in EPG5 cause Vici syndrome, a multisystem disorder with defective autophagy.",0.6016483607052789,"Recessive mutations in <span class=""gene"" id=""23222957-0-23-27"">EPG5</span> cause <span class=""disease"" id=""23222957-0-34-47"">Vici syndrome</span>, a multisystem disorder with defective autophagy.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0524620,Metabolic Syndrome X,disease,metabolic syndrome,57761,TRIB3,TRB3,CTD_human,18497449,Overexpression of TRB3 gene in adipose tissue of rats with high fructose-induced metabolic syndrome.,0.202681755307501,"Overexpression of <span class=""gene"" id=""18497449-0-18-22"">TRB3</span> gene in adipose tissue of rats with high fructose-induced <span class=""disease"" id=""18497449-0-81-99"">metabolic syndrome</span>.",CTD_human
1,0,Biomarker,C0007137,Squamous cell carcinoma,disease,squamous cell carcinoma,5781,PTPN11,SHP2,CTD_human,26432044,"SHP2, PIAS3, and SOCS3 are STAT3 negative regulators; therefore, their statuses in cervical adenocarcinoma (HeLa) and squamous cell carcinoma (SiHa and C33A) cell lines without and with resveratrol treatment and their correlation with STAT3 activation in CC specimens were investigated.",0.200274726784213,"<span class=""gene"" id=""26432044-3-0-4"">SHP2</span>, PIAS3, and SOCS3 are STAT3 negative regulators; therefore, their statuses in cervical adenocarcinoma (HeLa) and <span class=""disease"" id=""26432044-3-118-141"">squamous cell carcinoma</span> (SiHa and C33A) cell lines without and with resveratrol treatment and their correlation with STAT3 activation in CC specimens were investigated.",CTD_human
2,0,Biomarker,C0014084,Enchondromatosis,disease,Ollier disease,5781,PTPN11,PTPN11,CTD_human,21533187,"Loss-of-function mutations in PTPN11 cause metachondromatosis, but not Ollier disease or Maffucci syndrome.",0.40027472678421294,"Loss-of-function mutations in <span class=""gene"" id=""21533187-0-30-36"">PTPN11</span> cause metachondromatosis, but not <span class=""disease"" id=""21533187-0-71-85"">Ollier disease</span> or Maffucci syndrome.",CTD_human;HPO
1,0,Biomarker,C0023418,leukemia,disease,leukemia,5781,PTPN11,Ptpn11,CTD_human,15273746,Our results clarify the relationship between Noonan syndrome and leukemia and show that a single Ptpn11 gain-of-function mutation evokes all major features of Noonan syndrome by acting on multiple developmental lineages in a gene dosage-dependent and pathway-selective manner.,0.21797223193417,"Our results clarify the relationship between Noonan syndrome and <span class=""disease"" id=""15273746-8-65-73"">leukemia</span> and show that a single <span class=""gene"" id=""15273746-8-97-103"">Ptpn11</span> gain-of-function mutation evokes all major features of Noonan syndrome by acting on multiple developmental lineages in a gene dosage-dependent and pathway-selective manner.",CTD_human
24,50,Biomarker,C0028326,Noonan Syndrome,disease,Noonan syndrome,5781,PTPN11,Ptpn11,CTD_human,15273746,Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation.,0.8180724268078942,"Mouse model of <span class=""disease"" id=""15273746-0-15-30"">Noonan syndrome</span> reveals cell type- and gene dosage-dependent effects of <span class=""gene"" id=""15273746-0-87-93"">Ptpn11</span> mutation.",CTD_human;ORPHANET;UNIPROT
24,50,Biomarker,C0028326,Noonan Syndrome,disease,Noonan syndrome,5781,PTPN11,PTPN11,CTD_human,17603483,"Here, we report that 18 of 231 individuals with Noonan syndrome without known mutations (corresponding to 3% of all affected individuals) and two of six individuals with LEOPARD syndrome without PTPN11 mutations have missense mutations in RAF1, which encodes a serine-threonine kinase that activates MEK1 and MEK2.",0.8180724268078942,"Here, we report that 18 of 231 individuals with <span class=""disease"" id=""17603483-3-48-63"">Noonan syndrome</span> without known mutations (corresponding to 3% of all affected individuals) and two of six individuals with LEOPARD syndrome without <span class=""gene"" id=""17603483-3-195-201"">PTPN11</span> mutations have missense mutations in RAF1, which encodes a serine-threonine kinase that activates MEK1 and MEK2.",CTD_human;ORPHANET;UNIPROT
24,50,Biomarker,C0028326,Noonan Syndrome,disease,Noonan syndrome,5781,PTPN11,PTPN11,CTD_human,17603482,"Mutations of PTPN11, KRAS and SOS1 in the RAS-MAPK pathway cause approximately 60% of cases of Noonan syndrome.",0.8180724268078942,"Mutations of <span class=""gene"" id=""17603482-2-13-19"">PTPN11</span>, KRAS and SOS1 in the RAS-MAPK pathway cause approximately 60% of cases of <span class=""disease"" id=""17603482-2-95-110"">Noonan syndrome</span>.",CTD_human;ORPHANET;UNIPROT
10,11,Biomarker,C0175704,LEOPARD Syndrome,disease,LEOPARD syndrome,5781,PTPN11,PTPN11,CTD_human,17603483,"Here, we report that 18 of 231 individuals with Noonan syndrome without known mutations (corresponding to 3% of all affected individuals) and two of six individuals with LEOPARD syndrome without PTPN11 mutations have missense mutations in RAF1, which encodes a serine-threonine kinase that activates MEK1 and MEK2.",0.72123787632838,"Here, we report that 18 of 231 individuals with Noonan syndrome without known mutations (corresponding to 3% of all affected individuals) and two of six individuals with <span class=""disease"" id=""17603483-3-170-186"">LEOPARD syndrome</span> without <span class=""gene"" id=""17603483-3-195-201"">PTPN11</span> mutations have missense mutations in RAF1, which encodes a serine-threonine kinase that activates MEK1 and MEK2.",CTD_human;ORPHANET;UNIPROT
4,8,Biomarker,C0349639,Juvenile Myelomonocytic Leukemia,disease,juvenile myelomonocytic leukemia,5781,PTPN11,Shp2,CTD_human,22315502,"Mutations in PTPN11, the gene encoding the protein tyrosine phosphatase Shp2, are common in juvenile myelomonocytic leukemia and induce hyperactivation of the phosphoinositide-3-kinase pathway.",0.7032431979915319,"Mutations in <span class=""gene"" id=""22315502-2-13-19"">PTPN11</span>, the gene encoding the protein tyrosine phosphatase <span class=""gene"" id=""22315502-2-72-76"">Shp2</span>, are common in <span class=""disease"" id=""22315502-2-92-124"">juvenile myelomonocytic leukemia</span> and induce hyperactivation of the phosphoinositide-3-kinase pathway.",CTD_human;HPO;ORPHANET;UNIPROT
3,0,Biomarker,C0002871,Anemia,disease,anemia,57817,HAMP,hepcidin,CTD_human,16627556,"Cytokine-mediated increases in hepcidin appear to be an important causative factor in anemia of inflammation, which is characterized by sequestration of iron in the macrophage system.",0.31234598365056,"Cytokine-mediated increases in <span class=""gene"" id=""16627556-5-31-39"">hepcidin</span> appear to be an important causative factor in <span class=""disease"" id=""16627556-5-86-92"">anemia</span> of inflammation, which is characterized by sequestration of iron in the macrophage system.",CTD_human
3,0,Biomarker,C0002871,Anemia,disease,anemia,57817,HAMP,hepcidin,CTD_human,24086573,"K7174 also ameliorated anemia induced by inflammatory cytokines in mice, which suggests a possible involvement of hepcidin regulation.",0.31234598365056,"K7174 also ameliorated <span class=""disease"" id=""24086573-4-23-29"">anemia</span> induced by inflammatory cytokines in mice, which suggests a possible involvement of <span class=""gene"" id=""24086573-4-114-122"">hepcidin</span> regulation.",CTD_human
1,0,Biomarker,C0005283,beta Thalassemia,disease,beta-thalassemia,57817,HAMP,hepcidin,CTD_human,16755567,"We found decreased expression of hepcidin and TfR2 and increased expression of TfR1 and NGAL in the beta-thalassemia mouse models, compared with the control mice.",0.20625320350227103,"We found decreased expression of <span class=""gene"" id=""16755567-7-33-41"">hepcidin</span> and TfR2 and increased expression of TfR1 and NGAL in the <span class=""disease"" id=""16755567-7-100-116"">beta-thalassemia</span> mouse models, compared with the control mice.",CTD_human
1,0,Biomarker,C0005411,Biliary Atresia,disease,biliary atresia,57817,HAMP,hepcidin,CTD_human,16627878,Liver hepcidin and stainable iron expression in biliary atresia.,0.20054945356842604,"Liver <span class=""gene"" id=""16627878-0-6-14"">hepcidin</span> and stainable iron expression in <span class=""disease"" id=""16627878-0-48-63"">biliary atresia</span>.",CTD_human
6,0,Biomarker,C0018995,Hemochromatosis,disease,hemochromatosis,57817,HAMP,hepcidin,CTD_human,17255318,"Genetic iron overload, or hemochromatosis, can be caused by mutations in HFE, hemojuvelin, and hepcidin genes.",0.24957222441241397,"Genetic iron overload, or <span class=""disease"" id=""17255318-1-26-41"">hemochromatosis</span>, can be caused by mutations in HFE, hemojuvelin, and <span class=""gene"" id=""17255318-1-95-103"">hepcidin</span> genes.",CTD_human
6,0,Biomarker,C0018995,Hemochromatosis,disease,hemochromatosis,57817,HAMP,hepcidin,CTD_human,16574947,Targeted disruption of the hepcidin 1 gene results in severe hemochromatosis.,0.24957222441241397,"Targeted disruption of the <span class=""gene"" id=""16574947-0-27-35"">hepcidin</span> 1 gene results in severe <span class=""disease"" id=""16574947-0-61-76"">hemochromatosis</span>.",CTD_human
1,0,Biomarker,C0022661,"Kidney Failure, Chronic",disease,chronic renal failure,57817,HAMP,Hepcidin,CTD_human,16929540,"Hepcidin, iron status, and renal function in chronic renal failure, kidney transplantation, and hemodialysis.",0.20383181960166602,"<span class=""gene"" id=""16929540-0-0-8"">Hepcidin</span>, iron status, and renal function in <span class=""disease"" id=""16929540-0-45-66"">chronic renal failure</span>, kidney transplantation, and hemodialysis.",CTD_human
2,0,Biomarker,C0282193,Iron Overload,disease,iron overload,57817,HAMP,hepcidin,CTD_human,20801540,"Iron accumulation in aceruloplasminemia is a result of defective cellular iron export, where hepcidin regulation is appropriate for the degree of iron overload.",0.332688442328023,"Iron accumulation in aceruloplasminemia is a result of defective cellular iron export, where <span class=""gene"" id=""20801540-11-93-101"">hepcidin</span> regulation is appropriate for the degree of <span class=""disease"" id=""20801540-11-146-159"">iron overload</span>.",CTD_human
2,0,Biomarker,C0282193,Iron Overload,disease,iron overload,57817,HAMP,hepcidin,CTD_human,22659129,"To further investigate the role of intracellular hepcidin under iron overload circumstances, we assessed the expression of hepcidin mRNA and FPN1 protein in vitro.",0.332688442328023,"To further investigate the role of intracellular <span class=""gene"" id=""22659129-5-49-57"">hepcidin</span> under <span class=""disease"" id=""22659129-5-64-77"">iron overload</span> circumstances, we assessed the expression of <span class=""gene"" id=""22659129-5-123-131"">hepcidin</span> mRNA and FPN1 protein in vitro.",CTD_human
1,0,Biomarker,C0027819,Neuroblastoma,disease,neuroblastoma,5784,PTPN14,PTPN14,CTD_human,26121086,"Recurrent alterations at relapse included mutations in the putative CHD5 neuroblastoma tumor suppressor, chromosome 9p losses, DOCK8 mutations, inactivating mutations in PTPN14 and a relapse-specific activity pattern for the PTPN14 target YAP.",0.2,"Recurrent alterations at relapse included mutations in the putative CHD5 <span class=""disease"" id=""26121086-6-73-86"">neuroblastoma</span> tumor suppressor, chromosome 9p losses, DOCK8 mutations, inactivating mutations in <span class=""gene"" id=""26121086-6-170-176"">PTPN14</span> and a relapse-specific activity pattern for the <span class=""gene"" id=""26121086-6-225-231"">PTPN14</span> target YAP.",CTD_human
1,0,Biomarker,C0018923,Hemangiosarcoma,disease,angiosarcoma,5787,PTPRB,PTPRB,CTD_human,24633157,Recurrent PTPRB and PLCG1 mutations in angiosarcoma.,0.20082418035263896,"Recurrent <span class=""gene"" id=""24633157-0-10-15"">PTPRB</span> and PLCG1 mutations in <span class=""disease"" id=""24633157-0-39-51"">angiosarcoma</span>.",CTD_human
1,2,Biomarker,C0035258,Restless Legs Syndrome,disease,RLS,5789,PTPRD,PTPRD,CTD_human,18660810,This work identifies PTPRD as the fourth genome-wide significant locus for RLS.,0.204381273170092,"This work identifies <span class=""gene"" id=""18660810-3-21-26"">PTPRD</span> as the fourth genome-wide significant locus for <span class=""disease"" id=""18660810-3-75-78"">RLS</span>.",CTD_human
1,0,Biomarker,C1263846,Attention deficit hyperactivity disorder,disease,ADHD,5789,PTPRD,PTPRD,CTD_human,19546859,"Four independent deletions were located within the protein tyrosine phosphatase gene, PTPRD, recently implicated as a candidate gene for restless legs syndrome, which frequently presents with ADHD.",0.200274726784213,"Four independent deletions were located within the protein tyrosine phosphatase gene, <span class=""gene"" id=""19546859-5-86-91"">PTPRD</span>, recently implicated as a candidate gene for restless legs syndrome, which frequently presents with <span class=""disease"" id=""19546859-5-192-196"">ADHD</span>.",CTD_human
1,0,Biomarker,C0038356,Stomach Neoplasms,group,gastric tumor,5793,PTPRG,PTPRG,CTD_human,17963294,"To screen out the differentially methylated DNA sequences between gastric primary tumor and metastatic lymph nodes, test the methylation difference of gene PTPRG between primary gastric tumor and metastatic lymph nodes, and test the regulatory function of 5-aza-2'-deoxycytidine which is an agent with suppression on methylation and the level of methylation in gastric cancer cell line.",0.20300763924902696,"To screen out the differentially methylated DNA sequences between gastric primary tumor and metastatic lymph nodes, test the methylation difference of gene <span class=""gene"" id=""17963294-1-156-161"">PTPRG</span> between primary <span class=""disease"" id=""17963294-1-178-191"">gastric tumor</span> and metastatic lymph nodes, and test the regulatory function of 5-aza-2'-deoxycytidine which is an agent with suppression on methylation and the level of methylation in gastric cancer cell line.",CTD_human
2,3,Biomarker,C0027819,Neuroblastoma,disease,neuroblastoma,580,BARD1,BARD1,CTD_human,19412175,Common variations in BARD1 influence susceptibility to high-risk neuroblastoma.,0.202197814273705,"Common variations in <span class=""gene"" id=""19412175-0-21-26"">BARD1</span> influence susceptibility to high-risk <span class=""disease"" id=""19412175-0-65-78"">neuroblastoma</span>.",CTD_human
1,0,Biomarker,C0034069,Pulmonary Fibrosis,disease,pulmonary fibrosis,5806,PTX3,PTX3,CTD_human,22210019,"Maximal plasma PTX3 level was significantly higher in the pulmonary fibrosis group, and plasma PTX3 was significantly increased throughout hemoperfusion therapy (p<0.01).",0.2,"Maximal plasma <span class=""gene"" id=""22210019-8-15-19"">PTX3</span> level was significantly higher in the <span class=""disease"" id=""22210019-8-58-76"">pulmonary fibrosis</span> group, and plasma <span class=""gene"" id=""22210019-8-95-99"">PTX3</span> was significantly increased throughout hemoperfusion therapy (p&lt;0.01).",CTD_human
1,0,Biomarker,C0079773,"Lymphoma, T-Cell, Cutaneous",disease,CTCL,581,BAX,Bax,CTD_human,12754746,"The Bcl-x, Mcl-1, Bad, and Bax proteins were also expressed in all CTCL skin lesions tested.",0.200274726784213,"The Bcl-x, Mcl-1, Bad, and <span class=""gene"" id=""12754746-6-27-30"">Bax</span> proteins were also expressed in all <span class=""disease"" id=""12754746-6-67-71"">CTCL</span> skin lesions tested.",CTD_human
1,0,Biomarker,C0005586,Bipolar Disorder,disease,bipolar disorder,5816,PVALB,parvalbumin,CTD_human,14708030,ANOVA with correction for multiple comparisons indicated that parvalbumin-containing cells in CA2 were reduced in schizophrenia and bipolar disorder.,0.20082418035263896,"ANOVA with correction for multiple comparisons indicated that <span class=""gene"" id=""14708030-4-62-73"">parvalbumin</span>-containing cells in CA2 were reduced in schizophrenia and <span class=""disease"" id=""14708030-4-132-148"">bipolar disorder</span>.",CTD_human
1,0,Biomarker,C0007134,Renal Cell Carcinoma,disease,RCC,5816,PVALB,parvalbumin,CTD_human,16927643,Our study provides further evidence that CK7 and parvalbumin immunostains may be useful in differentiating oncocytoma from chromophobe RCC in problematic cases.,0.201098907136852,"Our study provides further evidence that CK7 and <span class=""gene"" id=""16927643-11-49-60"">parvalbumin</span> immunostains may be useful in differentiating oncocytoma from chromophobe <span class=""disease"" id=""16927643-11-135-138"">RCC</span> in problematic cases.",CTD_human
1,0,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,5816,PVALB,parvalbumin,CTD_human,14708030,ANOVA with correction for multiple comparisons indicated that parvalbumin-containing cells in CA2 were reduced in schizophrenia and bipolar disorder.,0.21068563382967603,"ANOVA with correction for multiple comparisons indicated that <span class=""gene"" id=""14708030-4-62-73"">parvalbumin</span>-containing cells in CA2 were reduced in <span class=""disease"" id=""14708030-4-114-127"">schizophrenia</span> and bipolar disorder.",CTD_human
1,0,Biomarker,C1510502,Oxyphilic Adenoma,disease,oncocytoma,5816,PVALB,parvalbumin,CTD_human,16927643,Negative or patchy staining (< 50% cells) for CK7 and/or parvalbumin strongly favors the diagnosis of oncocytoma.,0.200274726784213,"Negative or patchy staining (&lt; 50% cells) for CK7 and/or <span class=""gene"" id=""16927643-12-57-68"">parvalbumin</span> strongly favors the diagnosis of <span class=""disease"" id=""16927643-12-102-112"">oncocytoma</span>.",CTD_human
1,0,Biomarker,C0043459,Zellweger Syndrome,disease,Zellweger syndrome,5824,PEX19,PEX19,CTD_human,10051604,"Human PEX19: cDNA cloning by functional complementation, mutation analysis in a patient with Zellweger syndrome, and potential role in peroxisomal membrane assembly.",0.4,"Human <span class=""gene"" id=""10051604-0-6-11"">PEX19</span>: cDNA cloning by functional complementation, mutation analysis in a patient with <span class=""disease"" id=""10051604-0-93-111"">Zellweger syndrome</span>, and potential role in peroxisomal membrane assembly.",CTD_human;ORPHANET
1,0,Biomarker,C0043459,Zellweger Syndrome,disease,ZS,5825,ABCD3,PMP70,CTD_human,1301993,Our results suggest that PMP70 plays an important role in peroxisome biogenesis and that mutations in PMP70 may be responsible for a subset of ZS patients.,0.20054945356842604,"Our results suggest that <span class=""gene"" id=""1301993-5-25-30"">PMP70</span> plays an important role in peroxisome biogenesis and that mutations in <span class=""gene"" id=""1301993-5-102-107"">PMP70</span> may be responsible for a subset of <span class=""disease"" id=""1301993-5-143-145"">ZS</span> patients.",CTD_human
1,0,Biomarker,C0282527,Infantile Refsum Disease (disorder),disease,IRD,5828,PEX2,PEX2,CTD_human,10528859,We identified a mutation in the PEX2 gene in an IRD patient with compound heterozygosity for a missense mutation and the known nonsense mutation detected in ZS patients.,0.40082418035263895,"We identified a mutation in the <span class=""gene"" id=""10528859-3-32-36"">PEX2</span> gene in an <span class=""disease"" id=""10528859-3-48-51"">IRD</span> patient with compound heterozygosity for a missense mutation and the known nonsense mutation detected in ZS patients.",CTD_human;ORPHANET
1,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,non-small cell lung cancer,5829,PXN,Paxillin,CTD_human,21159652,Paxillin predicts survival and relapse in non-small cell lung cancer by microRNA-218 targeting.,0.201098907136852,"<span class=""gene"" id=""21159652-0-0-8"">Paxillin</span> predicts survival and relapse in <span class=""disease"" id=""21159652-0-42-68"">non-small cell lung cancer</span> by microRNA-218 targeting.",CTD_human
1,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastasis,5829,PXN,paxillin,CTD_human,18492274,"Transfection produced a modest reduction on metastatic potential, indicating that: i) paxillin plays a role as inducer of melanoma metastasis; and ii) paxillin downregulation is not sufficient to explain the antimetastatic effect of 4-HC.",0.20467035533162303,"Transfection produced a modest reduction on metastatic potential, indicating that: i) <span class=""gene"" id=""18492274-13-86-94"">paxillin</span> plays a role as inducer of melanoma <span class=""disease"" id=""18492274-13-131-141"">metastasis</span>; and ii) <span class=""gene"" id=""18492274-13-151-159"">paxillin</span> downregulation is not sufficient to explain the antimetastatic effect of 4-HC.",CTD_human
2,21,Biomarker,C0017925,Glycogen Storage Disease Type VI,disease,GSD6,5836,PYGL,PYGL,CTD_human,9536091,This study is the first to demonstrate that a mutation in the PYGL gene can cause GSD6.,0.600274726784213,"This study is the first to demonstrate that a mutation in the <span class=""gene"" id=""9536091-9-62-66"">PYGL</span> gene can cause <span class=""disease"" id=""9536091-9-82-86"">GSD6</span>.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0014356,Enterocolitis,disease,enterocolitis,58484,NLRC4,NLRC4,CTD_human,25217960,Mutation of NLRC4 causes a syndrome of enterocolitis and autoinflammation.,0.200274726784213,"Mutation of <span class=""gene"" id=""25217960-0-12-17"">NLRC4</span> causes a syndrome of <span class=""disease"" id=""25217960-0-39-52"">enterocolitis</span> and autoinflammation.",CTD_human
1,0,Biomarker,C1096155,Macrophage Activation Syndrome,disease,macrophage activation syndrome,58484,NLRC4,NLRC4,CTD_human,25217959,An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome.,0.20054945356842604,"An activating <span class=""gene"" id=""25217959-0-14-19"">NLRC4</span> inflammasome mutation causes autoinflammation with recurrent <span class=""disease"" id=""25217959-0-81-111"">macrophage activation syndrome</span>.",CTD_human
1,0,Biomarker,C0206711,Pilomatrixoma,disease,Pilomatricoma,58495,OVOL2,OVOL2,CTD_human,26873447,Activation of the OVOL1-OVOL2 Axis in the Hair Bulb and in Pilomatricoma.,0.200274726784213,"Activation of the OVOL1-<span class=""gene"" id=""26873447-0-24-29"">OVOL2</span> Axis in the Hair Bulb and in <span class=""disease"" id=""26873447-0-59-72"">Pilomatricoma</span>.",CTD_human
1,0,Biomarker,C0023467,"Leukemia, Myelocytic, Acute",disease,acute myeloid leukemia,58508,KMT2C,MLL3,CTD_human,24794707,MLL3 is a haploinsufficient 7q tumor suppressor in acute myeloid leukemia.,0.201373633921065,"<span class=""gene"" id=""24794707-0-0-4"">MLL3</span> is a haploinsufficient 7q tumor suppressor in <span class=""disease"" id=""24794707-0-51-73"">acute myeloid leukemia</span>.",CTD_human
1,0,Biomarker,C0024776,Maple Syrup Urine Disease,disease,MSUD,587,BCAT2,BCAT-2,CTD_human,14755340,We conclude that BCAT-2 deficiency in the mouse can cause a disease that mimics human MSUD.,0.280274726784213,"We conclude that <span class=""gene"" id=""14755340-7-17-23"">BCAT-2</span> deficiency in the mouse can cause a disease that mimics human <span class=""disease"" id=""14755340-7-86-90"">MSUD</span>.",CTD_human
1,0,Biomarker,C0007193,"Cardiomyopathy, Dilated",group,dilated cardiomyopathy,5879,RAC1,Rac1,CTD_human,16155095,"A two-dimensional gel electrophoresis (2-DE)-based proteomic approach was used to study a transgenic mouse model of acerbated dilated cardiomyopathy in which the small monomeric GTPase, Rac1, was constitutively expressed exclusively in the myocardium.",0.2,"A two-dimensional gel electrophoresis (2-DE)-based proteomic approach was used to study a transgenic mouse model of acerbated <span class=""disease"" id=""16155095-1-126-148"">dilated cardiomyopathy</span> in which the small monomeric GTPase, <span class=""gene"" id=""16155095-1-186-190"">Rac1</span>, was constitutively expressed exclusively in the myocardium.",CTD_human
1,0,Biomarker,C0018801,Heart failure,disease,heart failure,5879,RAC1,Rac1,CTD_human,16155095,The majority of these mice displayed severe hypertrophy (heart-to-body weight ratios >2-fold greater in the Rac1 mice) and died from overt heart failure between days 14 and 17.,0.2,"The majority of these mice displayed severe hypertrophy (heart-to-body weight ratios &gt;2-fold greater in the <span class=""gene"" id=""16155095-3-108-112"">Rac1</span> mice) and died from overt <span class=""disease"" id=""16155095-3-139-152"">heart failure</span> between days 14 and 17.",CTD_human
1,0,Biomarker,C0025202,melanoma,disease,melanoma,5879,RAC1,RAC1,CTD_human,22842228,Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.,0.206579087443797,"Exome sequencing identifies recurrent somatic <span class=""gene"" id=""22842228-0-46-50"">RAC1</span> mutations in <span class=""disease"" id=""22842228-0-64-72"">melanoma</span>.",CTD_human
1,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastasis,5879,RAC1,Rac1,CTD_human,18506888,Melittin prevents liver cancer cell metastasis through inhibition of the Rac1-dependent pathway.,0.212073623128059,"Melittin prevents liver cancer cell <span class=""disease"" id=""18506888-0-36-46"">metastasis</span> through inhibition of the <span class=""gene"" id=""18506888-0-73-77"">Rac1</span>-dependent pathway.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,5879,RAC1,Rac1,CTD_human,18506888,"Melittin inhibits tumor cell metastasis by reducing cell motility and migration via the suppression of Rac1-dependent pathway, suggesting that melittin is a potential therapeutic agent for HCC.",0.204381273170092,"Melittin inhibits tumor cell metastasis by reducing cell motility and migration via the suppression of <span class=""gene"" id=""18506888-8-103-107"">Rac1</span>-dependent pathway, suggesting that melittin is a potential therapeutic agent for <span class=""disease"" id=""18506888-8-189-192"">HCC</span>.",CTD_human
1,0,Biomarker,C0349639,Juvenile Myelomonocytic Leukemia,disease,JMML,5880,RAC2,RAC2,CTD_human,26457648,"Multiple concomitant genetic hits targeting the RAS pathway were identified in 13 of 78 cases (17%), disproving the concept of mutually exclusive RAS pathway mutations and defining new pathways activated in JMML involving phosphoinositide 3-kinase (PI3K) and the mTORC2 complex through RAC2 mutation.",0.200274726784213,"Multiple concomitant genetic hits targeting the RAS pathway were identified in 13 of 78 cases (17%), disproving the concept of mutually exclusive RAS pathway mutations and defining new pathways activated in <span class=""disease"" id=""26457648-4-207-211"">JMML</span> involving phosphoinositide 3-kinase (PI3K) and the mTORC2 complex through <span class=""gene"" id=""26457648-4-286-290"">RAC2</span> mutation.",CTD_human
1,0,Biomarker,C0085183,"Neoplasms, Second Primary",phenotype,second malignancy,5883,RAD9A,RAD9A,CTD_human,21991345,"Collectively, our results support the idea that modulation of RAD9A and other cell cycle arrest and DNA repair proteins contribute to the risk of developing a second malignancy in childhood cancer patients.",0.200274726784213,"Collectively, our results support the idea that modulation of <span class=""gene"" id=""21991345-9-62-67"">RAD9A</span> and other cell cycle arrest and DNA repair proteins contribute to the risk of developing a <span class=""disease"" id=""21991345-9-159-176"">second malignancy</span> in childhood cancer patients.",CTD_human
1,0,Biomarker,C0015625,Fanconi Anemia,disease,Fanconi anemia,5889,RAD51C,RAD51C,CTD_human,20400963,Mutation of the RAD51C gene in a Fanconi anemia-like disorder.,0.40412090176319704,"Mutation of the <span class=""gene"" id=""20400963-0-16-22"">RAD51C</span> gene in a <span class=""disease"" id=""20400963-0-33-47"">Fanconi anemia</span>-like disorder.",CTD_human;ORPHANET
1,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,NSCLC,5894,RAF1,Raf-1,CTD_human,16862215,Proliferative signaling via nicotinic acetylcholine receptors (nAChRs) required the scaffolding protein beta-arrestin; ablation of beta-arrestin or disruption of the Rb-Raf-1 interaction blocked nicotine-induced proliferation of NSCLCs.,0.20274726784213098,"Proliferative signaling via nicotinic acetylcholine receptors (nAChRs) required the scaffolding protein beta-arrestin; ablation of beta-arrestin or disruption of the Rb-<span class=""gene"" id=""16862215-7-169-174"">Raf-1</span> interaction blocked nicotine-induced proliferation of <span class=""disease"" id=""16862215-7-229-234"">NSCLC</span>s.",CTD_human
1,0,Biomarker,C0007193,"Cardiomyopathy, Dilated",group,dilated cardiomyopathy,5894,RAF1,RAF1,CTD_human,24777450,RAF1 mutations in childhood-onset dilated cardiomyopathy.,0.40027472678421294,"<span class=""gene"" id=""24777450-0-0-4"">RAF1</span> mutations in childhood-onset <span class=""disease"" id=""24777450-0-34-56"">dilated cardiomyopathy</span>.",CTD_human;HPO
2,0,Biomarker,C0007194,Hypertrophic Cardiomyopathy,disease,hypertrophic cardiomyopathy,5894,RAF1,RAF1,CTD_human,17603483,Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy.,0.40575490709115797,"Gain-of-function <span class=""gene"" id=""17603483-0-17-21"">RAF1</span> mutations cause Noonan and LEOPARD syndromes with <span class=""disease"" id=""17603483-0-72-99"">hypertrophic cardiomyopathy</span>.",CTD_human;HPO
2,0,Biomarker,C0007194,Hypertrophic Cardiomyopathy,disease,HCM,5894,RAF1,RAF1,CTD_human,17603482,"We have identified five different mutations in RAF1 in ten individuals with Noonan syndrome; those with any of four mutations causing changes in the CR2 domain of RAF1 had hypertrophic cardiomyopathy (HCM), whereas affected individuals with mutations leading to changes in the CR3 domain did not.",0.40575490709115797,"We have identified five different mutations in <span class=""gene"" id=""17603482-4-47-51"">RAF1</span> in ten individuals with Noonan syndrome; those with any of four mutations causing changes in the CR2 domain of <span class=""gene"" id=""17603482-4-163-167"">RAF1</span> had <span class=""disease"" id=""17603482-4-172-199"">hypertrophic cardiomyopathy</span> (<span class=""disease"" id=""17603482-4-201-204"">HCM</span>), whereas affected individuals with mutations leading to changes in the CR3 domain did not.",CTD_human;HPO
1,0,Biomarker,C0022665,Kidney Neoplasm,disease,kidney tumor,5894,RAF1,Raf-1,CTD_human,21813464,"The data indicate that Raf-1/MEK/ERK participates in crosstalk with 4EBP1, which represents a novel pathway interaction leading to increased protein synthesis, cell growth, and kidney tumor formation.",0.2,"The data indicate that <span class=""gene"" id=""21813464-10-23-28"">Raf-1</span>/MEK/ERK participates in crosstalk with 4EBP1, which represents a novel pathway interaction leading to increased protein synthesis, cell growth, and <span class=""disease"" id=""21813464-10-177-189"">kidney tumor</span> formation.",CTD_human
1,0,Biomarker,C0024121,Lung Neoplasms,group,lung tumors,5894,RAF1,Raf1,CTD_human,11884234,"Decrease in K-ras p21 and increase in Raf1 and activated Erk 1 and 2 in murine lung tumors initiated by N-nitrosodimethylamine and promoted by 2,3,7,8-tetrachlorodibenzo-p-dioxin.",0.20054945356842604,"Decrease in K-ras p21 and increase in <span class=""gene"" id=""11884234-0-38-42"">Raf1</span> and activated Erk 1 and 2 in murine <span class=""disease"" id=""11884234-0-79-90"">lung tumors</span> initiated by N-nitrosodimethylamine and promoted by 2,3,7,8-tetrachlorodibenzo-p-dioxin.",CTD_human
2,16,Biomarker,C0028326,Noonan Syndrome,disease,Noonan syndrome,5894,RAF1,RAF1,CTD_human,17603483,"Of 19 subjects with a RAF1 mutation in two hotspots, 18 (or 95%) showed hypertrophic cardiomyopathy (HCM), compared with the 18% prevalence of HCM among individuals with Noonan syndrome in general.",0.42524447466134707,"Of 19 subjects with a <span class=""gene"" id=""17603483-5-22-26"">RAF1</span> mutation in two hotspots, 18 (or 95%) showed hypertrophic cardiomyopathy (HCM), compared with the 18% prevalence of HCM among individuals with <span class=""disease"" id=""17603483-5-170-185"">Noonan syndrome</span> in general.",CTD_human;ORPHANET
2,16,Biomarker,C0028326,Noonan Syndrome,disease,Noonan syndrome,5894,RAF1,RAF1,CTD_human,17603482,Germline gain-of-function mutations in RAF1 cause Noonan syndrome.,0.42524447466134707,"Germline gain-of-function mutations in <span class=""gene"" id=""17603482-0-39-43"">RAF1</span> cause <span class=""disease"" id=""17603482-0-50-65"">Noonan syndrome</span>.",CTD_human;ORPHANET
1,4,Biomarker,C0175704,LEOPARD Syndrome,disease,LEOPARD syndromes,5894,RAF1,RAF1,CTD_human,17603483,Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy.,0.408920603432455,"Gain-of-function <span class=""gene"" id=""17603483-0-17-21"">RAF1</span> mutations cause Noonan and <span class=""disease"" id=""17603483-0-49-66"">LEOPARD syndromes</span> with hypertrophic cardiomyopathy.",CTD_human;ORPHANET
1,0,Biomarker,C0162872,"Aortic Aneurysm, Thoracic",disease,thoracic aortic aneurysms,59,ACTA2,ACTA2,CTD_human,17994018,Mutations in smooth muscle alpha-actin (ACTA2) lead to thoracic aortic aneurysms and dissections.,0.40735211063912397,"Mutations in smooth muscle alpha-actin (<span class=""gene"" id=""17994018-0-40-45"">ACTA2</span>) lead to <span class=""disease"" id=""17994018-0-55-80"">thoracic aortic aneurysms</span> and dissections.",CTD_human;HPO
1,0,Biomarker,C0002395,Alzheimer's Disease,disease,Alzheimer's disease,590,BCHE,butyrylcholinesterase,CTD_human,23022600,Association analysis between K and -116A variants of butyrylcholinesterase and Alzheimer's disease in a Brazilian population.,0.29618278259646197,"Association analysis between K and -116A variants of <span class=""gene"" id=""23022600-0-53-74"">butyrylcholinesterase</span> and <span class=""disease"" id=""23022600-0-79-98"">Alzheimer's disease</span> in a Brazilian population.",CTD_human
1,0,Biomarker,C0015644,Muscular fasciculation,phenotype,fasciculations,590,BCHE,pseudocholinesterase,CTD_human,6465587,Violent fasciculations after small dose succinylcholine infusion as a first sign of atypical pseudocholinesterase.,0.2,"Violent <span class=""disease"" id=""6465587-0-8-22"">fasciculations</span> after small dose succinylcholine infusion as a first sign of atypical <span class=""gene"" id=""6465587-0-93-113"">pseudocholinesterase</span>.",CTD_human
1,0,Biomarker,C0017636,Glioblastoma,disease,glioblastoma,590,BCHE,BuChE,CTD_human,2317787,Our findings confirm previous genetic linkage mapping of the functional CHE gene to the 3q26-ter position and demonstrate that extended functional mRNA transcripts encoding a BuChE form with two modified amino acids are produced from this gene in glioblastoma and neuroblastoma cells.,0.200274726784213,"Our findings confirm previous genetic linkage mapping of the functional CHE gene to the 3q26-ter position and demonstrate that extended functional mRNA transcripts encoding a <span class=""gene"" id=""2317787-9-175-180"">BuChE</span> form with two modified amino acids are produced from this gene in <span class=""disease"" id=""2317787-9-247-259"">glioblastoma</span> and neuroblastoma cells.",CTD_human
1,0,Biomarker,C0020557,Hypertriglyceridemia,phenotype,hypertriglyceridemia,590,BCHE,BCHE,CTD_human,23000450,-116A and K BCHE gene variants associated with obesity and hypertriglyceridemia in adolescents from Southern Brazil.,0.20054945356842604,"-116A and K <span class=""gene"" id=""23000450-0-12-16"">BCHE</span> gene variants associated with obesity and <span class=""disease"" id=""23000450-0-59-79"">hypertriglyceridemia</span> in adolescents from Southern Brazil.",CTD_human
1,0,Biomarker,C0026769,Multiple Sclerosis,disease,multiple sclerosis,590,BCHE,Butyrylcholinesterase,CTD_human,20122907,Butyrylcholinesterase activity in multiple sclerosis neuropathology.,0.2,"<span class=""gene"" id=""20122907-0-0-21"">Butyrylcholinesterase</span> activity in <span class=""disease"" id=""20122907-0-34-52"">multiple sclerosis</span> neuropathology.",CTD_human
1,0,Biomarker,C0027819,Neuroblastoma,disease,neuroblastoma,590,BCHE,BuChE,CTD_human,2317787,Our findings confirm previous genetic linkage mapping of the functional CHE gene to the 3q26-ter position and demonstrate that extended functional mRNA transcripts encoding a BuChE form with two modified amino acids are produced from this gene in glioblastoma and neuroblastoma cells.,0.200274726784213,"Our findings confirm previous genetic linkage mapping of the functional CHE gene to the 3q26-ter position and demonstrate that extended functional mRNA transcripts encoding a <span class=""gene"" id=""2317787-9-175-180"">BuChE</span> form with two modified amino acids are produced from this gene in glioblastoma and <span class=""disease"" id=""2317787-9-264-277"">neuroblastoma</span> cells.",CTD_human
4,0,Therapeutic,C0028754,Obesity,disease,obesity,590,BCHE,BChE,CTD_human,27163854,"A long-acting cocaine hydrolase, known as CocH3-Fc(M3), engineered from human butyrylcholinesterase (BChE) was tested, in this study, for its potential anti-obesity effects.",0.20487956958120604,"A long-acting cocaine hydrolase, known as CocH3-Fc(M3), engineered from human <span class=""gene"" id=""27163854-1-78-99"">butyrylcholinesterase</span> (<span class=""gene"" id=""27163854-1-101-105"">BChE</span>) was tested, in this study, for its potential anti-<span class=""disease"" id=""27163854-1-157-164"">obesity</span> effects.",CTD_human
4,0,Therapeutic,C0028754,Obesity,disease,obese,590,BCHE,butyrylcholinesterase,CTD_human,18452903,The butyrylcholinesterase knockout mouse is obese on a high-fat diet.,0.20487956958120604,"The <span class=""gene"" id=""18452903-0-4-25"">butyrylcholinesterase</span> knockout mouse is <span class=""disease"" id=""18452903-0-44-49"">obese</span> on a high-fat diet.",CTD_human
4,0,Biomarker,C0028754,Obesity,disease,obesity,590,BCHE,BChE,CTD_human,27163854,"A long-acting cocaine hydrolase, known as CocH3-Fc(M3), engineered from human butyrylcholinesterase (BChE) was tested, in this study, for its potential anti-obesity effects.",0.20487956958120604,"A long-acting cocaine hydrolase, known as CocH3-Fc(M3), engineered from human <span class=""gene"" id=""27163854-1-78-99"">butyrylcholinesterase</span> (<span class=""gene"" id=""27163854-1-101-105"">BChE</span>) was tested, in this study, for its potential anti-<span class=""disease"" id=""27163854-1-157-164"">obesity</span> effects.",CTD_human
4,0,Therapeutic,C0028754,Obesity,disease,obesity,590,BCHE,BCHE,CTD_human,23000450,-116A and K BCHE gene variants associated with obesity and hypertriglyceridemia in adolescents from Southern Brazil.,0.20487956958120604,"-116A and K <span class=""gene"" id=""23000450-0-12-16"">BCHE</span> gene variants associated with <span class=""disease"" id=""23000450-0-47-54"">obesity</span> and hypertriglyceridemia in adolescents from Southern Brazil.",CTD_human
4,0,Biomarker,C0028754,Obesity,disease,obese,590,BCHE,butyrylcholinesterase,CTD_human,18452903,The butyrylcholinesterase knockout mouse is obese on a high-fat diet.,0.20487956958120604,"The <span class=""gene"" id=""18452903-0-4-25"">butyrylcholinesterase</span> knockout mouse is <span class=""disease"" id=""18452903-0-44-49"">obese</span> on a high-fat diet.",CTD_human
4,0,Biomarker,C0028754,Obesity,disease,obesity,590,BCHE,BCHE,CTD_human,23000450,-116A and K BCHE gene variants associated with obesity and hypertriglyceridemia in adolescents from Southern Brazil.,0.20487956958120604,"-116A and K <span class=""gene"" id=""23000450-0-12-16"">BCHE</span> gene variants associated with <span class=""disease"" id=""23000450-0-47-54"">obesity</span> and hypertriglyceridemia in adolescents from Southern Brazil.",CTD_human
3,0,Therapeutic,C0036572,Seizures,phenotype,convulsions,590,BCHE,BChE,CTD_human,20971807,"Pretreatment with the BChE mutant (i.e., 1 min before cocaine administration) dose-dependently protected mice against cocaine-induced convulsions and lethality.",0.20054945356842604,"Pretreatment with the <span class=""gene"" id=""20971807-6-22-26"">BChE</span> mutant (i.e., 1 min before cocaine administration) dose-dependently protected mice against cocaine-induced <span class=""disease"" id=""20971807-6-134-145"">convulsions</span> and lethality.",CTD_human
3,0,Therapeutic,C0036572,Seizures,phenotype,seizures,590,BCHE,cholinesterase,CTD_human,8667461,"At this dose, lethality was reduced to 30% (p < 0.001) and seizures were reduced to 40% (p < 0.001) by administration of 27.4 mg/kg of human plasma cholinesterase.",0.20054945356842604,"At this dose, lethality was reduced to 30% (p &lt; 0.001) and <span class=""disease"" id=""8667461-10-59-67"">seizures</span> were reduced to 40% (p &lt; 0.001) by administration of 27.4 mg/kg of human plasma <span class=""gene"" id=""8667461-10-148-162"">cholinesterase</span>.",CTD_human
1,0,Therapeutic,C0424295,Hyperactive behavior,phenotype,hyperactivity,590,BCHE,butyrylcholinesterase,CTD_human,12019200,Characterization of butyrylcholinesterase antagonism of cocaine-induced hyperactivity.,0.200274726784213,"Characterization of <span class=""gene"" id=""12019200-0-20-41"">butyrylcholinesterase</span> antagonism of cocaine-induced <span class=""disease"" id=""12019200-0-72-85"">hyperactivity</span>.",CTD_human
5,28,Biomarker,C1283400,Butyrylcholinesterase deficiency,disease,Butyrylcholinesterase deficiency,590,BCHE,BCHE,CTD_human,25054547,Butyrylcholinesterase deficiency is characterized by prolonged apnea after the use of muscle relaxants (suxamethonium or mivacurium) in patients who have mutations in the BCHE gene.,0.400549453568426,"<span class=""disease"" id=""25054547-1-0-32"">Butyrylcholinesterase deficiency</span> is characterized by prolonged apnea after the use of muscle relaxants (suxamethonium or mivacurium) in patients who have mutations in the <span class=""gene"" id=""25054547-1-171-175"">BCHE</span> gene.",CTD_human;ORPHANET
1,0,Biomarker,C0079744,Diffuse Large B-Cell Lymphoma,disease,DLBCL,5905,RANGAP1,RanGAP1,CTD_human,27150054,"We have reported that ON 01910.Na (rigosertib), a multikinase inhibitor, is selectively cytotoxic for DLBCL and induces more hyperphosphorylation and sumoylation of Ran GTPase-activating protein 1 (RanGAP1) in DLBCL cells than in non-neoplastic lymphoblastoid cell line.",0.200274726784213,"We have reported that ON 01910.Na (rigosertib), a multikinase inhibitor, is selectively cytotoxic for <span class=""disease"" id=""27150054-2-102-107"">DLBCL</span> and induces more hyperphosphorylation and sumoylation of <span class=""gene"" id=""27150054-2-165-196"">Ran GTPase-activating protein 1</span> (<span class=""gene"" id=""27150054-2-198-205"">RanGAP1</span>) in <span class=""disease"" id=""27150054-2-210-215"">DLBCL</span> cells than in non-neoplastic lymphoblastoid cell line.",CTD_human
1,0,Biomarker,C0007570,Celiac Disease,disease,celiac disease,59067,IL21,IL21,CTD_human,17558408,A genome-wide association study for celiac disease identifies risk variants in the region harboring IL2 and IL21.,0.21407489979787397,"A genome-wide association study for <span class=""disease"" id=""17558408-0-36-50"">celiac disease</span> identifies risk variants in the region harboring IL2 and <span class=""gene"" id=""17558408-0-108-112"">IL21</span>.",CTD_human
1,0,Biomarker,C0024141,"Lupus Erythematosus, Systemic",disease,SLE,59067,IL21,IL-21,CTD_human,17911475,This experiment provides preliminary evidence for a role of IL-21 in modulating the severity of SLE in BXSB-Yaa mice.,0.21113277308347697,"This experiment provides preliminary evidence for a role of <span class=""gene"" id=""17911475-10-60-65"">IL-21</span> in modulating the severity of <span class=""disease"" id=""17911475-10-96-99"">SLE</span> in BXSB-Yaa mice.",CTD_human
2,0,Biomarker,C0025202,melanoma,disease,melanoma,5909,RAP1GAP,Rap1GAP,CTD_human,22614916,"Rap1GAP is thought of as a putative tumor suppressor gene and plays an important role in human tumor progression including pancreatic cancer, thyroid cancer and melanoma.",0.204106546385879,"<span class=""gene"" id=""22614916-2-0-7"">Rap1GAP</span> is thought of as a putative tumor suppressor gene and plays an important role in human tumor progression including pancreatic cancer, thyroid cancer and <span class=""disease"" id=""22614916-2-161-169"">melanoma</span>.",CTD_human
2,0,Biomarker,C0025202,melanoma,disease,melanoma,5909,RAP1GAP,Rap1GAP,CTD_human,19147557,"Down-regulation of Rap1GAP via promoter hypermethylation promotes melanoma cell proliferation, survival, and migration.",0.204106546385879,"Down-regulation of <span class=""gene"" id=""19147557-0-19-26"">Rap1GAP</span> via promoter hypermethylation promotes <span class=""disease"" id=""19147557-0-66-74"">melanoma</span> cell proliferation, survival, and migration.",CTD_human
1,0,Biomarker,C0010701,Phyllodes Tumor,disease,phyllodes tumors,5914,RARA,RARA,CTD_human,26437033,"First, we frequently observed MED12 and RARA mutations in both fibroadenomas and phyllodes tumors, emphasizing the importance of these mutations in fibroepithelial tumorigenesis.",0.200274726784213,"First, we frequently observed MED12 and <span class=""gene"" id=""26437033-4-40-44"">RARA</span> mutations in both fibroadenomas and <span class=""disease"" id=""26437033-4-81-97"">phyllodes tumors</span>, emphasizing the importance of these mutations in fibroepithelial tumorigenesis.",CTD_human
22,0,Biomarker,C0023487,Acute Promyelocytic Leukemia,disease,acute promyelocytic leukemia,5914,RARA,retinoic acid receptor alpha,CTD_human,16239915,Aberrant promoter methylation of the retinoic acid receptor alpha gene in acute promyelocytic leukemia.,0.707329124648138,"Aberrant promoter methylation of the <span class=""gene"" id=""16239915-0-37-65"">retinoic acid receptor alpha</span> gene in <span class=""disease"" id=""16239915-0-74-102"">acute promyelocytic leukemia</span>.",CTD_human;HPO;ORPHANET
22,0,Biomarker,C0023487,Acute Promyelocytic Leukemia,disease,acute promyelocytic leukemia,5914,RARA,RAR?,CTD_human,22213200,"Expression of PML-RAR? fusion proteins disrupted PML-NB structure and reduced HRR by up to 10-fold, raising the possibility that defective HRR and resulting genomic instability may figure in the pathogenesis, progression and relapse of acute promyelocytic leukemia.",0.707329124648138,"Expression of PML-<span class=""gene"" id=""22213200-10-18-22"">RAR&alpha;</span> fusion proteins disrupted PML-NB structure and reduced HRR by up to 10-fold, raising the possibility that defective HRR and resulting genomic instability may figure in the pathogenesis, progression and relapse of <span class=""disease"" id=""22213200-10-236-264"">acute promyelocytic leukemia</span>.",CTD_human;HPO;ORPHANET
22,0,Biomarker,C0023487,Acute Promyelocytic Leukemia,disease,APL,5914,RARA,retinoic acid receptor alpha,CTD_human,16935935,"Acute promyelocytic leukemia (APL) cells express promyelocytic leukemia/retinoic acid receptor alpha (PML/RARalpha) fusion protein, which leads to the blocking of APL cell differentiation.",0.707329124648138,"<span class=""disease"" id=""16935935-1-0-28"">Acute promyelocytic leukemia</span> (<span class=""disease"" id=""16935935-1-30-33"">APL</span>) cells express <span class=""disease"" id=""16935935-1-49-71"">promyelocytic leukemia</span>/<span class=""gene"" id=""16935935-1-72-100"">retinoic acid receptor alpha</span> (PML/RARalpha) fusion protein, which leads to the blocking of <span class=""disease"" id=""16935935-1-163-166"">APL</span> cell differentiation.",CTD_human;HPO;ORPHANET
22,0,Biomarker,C0023487,Acute Promyelocytic Leukemia,disease,acute promyelocytic leukemia,5914,RARA,RARA,CTD_human,25583766,"Identification of a novel fusion gene, IRF2BP2-RARA, in acute promyelocytic leukemia.",0.707329124648138,"Identification of a novel fusion gene, IRF2BP2-<span class=""gene"" id=""25583766-0-47-51"">RARA</span>, in <span class=""disease"" id=""25583766-0-56-84"">acute promyelocytic leukemia</span>.",CTD_human;HPO;ORPHANET
22,0,Biomarker,C0023487,Acute Promyelocytic Leukemia,disease,promyelocytic leukemia,5914,RARA,PML-RARalpha,CTD_human,16788101,"In one such disease, acute promyelocytic leukemia (APL), a promyelocytic leukemia-retinoic acid receptor alpha (PML-RARalpha) fusion protein is expressed as a result of a t(15;17) chromosomal translocation.",0.707329124648138,"In one such disease, <span class=""disease"" id=""16788101-3-21-49"">acute promyelocytic leukemia</span> (<span class=""disease"" id=""16788101-3-51-54"">APL</span>), a <span class=""disease"" id=""16788101-3-59-81"">promyelocytic leukemia</span>-<span class=""gene"" id=""16788101-3-82-110"">retinoic acid receptor alpha</span> (<span class=""gene"" id=""16788101-3-112-124"">PML-RARalpha</span>) fusion protein is expressed as a result of a t(15;17) chromosomal translocation.",CTD_human;HPO;ORPHANET
22,0,Biomarker,C0023487,Acute Promyelocytic Leukemia,disease,APL,5914,RARA,RARA,CTD_human,26728337,"We identified one ATO-resistant t-APL patient, who presented a PML A216T mutation in both the rearranged and unrearranged PML alleles, and two mutations in the rearranged RARA gene.",0.707329124648138,"We identified one ATO-resistant t-<span class=""disease"" id=""26728337-4-34-37"">APL</span> patient, who presented a PML A216T mutation in both the rearranged and unrearranged PML alleles, and two mutations in the rearranged <span class=""gene"" id=""26728337-4-171-175"">RARA</span> gene.",CTD_human;HPO;ORPHANET
22,0,Biomarker,C0023487,Acute Promyelocytic Leukemia,disease,APL,5914,RARA,RARA,CTD_human,23208507,"Altogether, our findings of USP37-modulating PLZF/RARA stability and cell transformation suggest that USP37 is a potential therapeutic target for PLZF/RARA-associated APL.",0.707329124648138,"Altogether, our findings of USP37-modulating PLZF/<span class=""gene"" id=""23208507-11-50-54"">RARA</span> stability and cell transformation suggest that USP37 is a potential therapeutic target for PLZF/<span class=""gene"" id=""23208507-11-151-155"">RARA</span>-associated <span class=""disease"" id=""23208507-11-167-170"">APL</span>.",CTD_human;HPO;ORPHANET
22,0,Biomarker,C0023487,Acute Promyelocytic Leukemia,disease,acute promyelocytic leukemia,5914,RARA,RARA,CTD_human,19029980,Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation.,0.707329124648138,"Eradication of <span class=""disease"" id=""19029980-0-15-43"">acute promyelocytic leukemia</span>-initiating cells through PML-<span class=""gene"" id=""19029980-0-73-77"">RARA</span> degradation.",CTD_human;HPO;ORPHANET
22,0,Biomarker,C0023487,Acute Promyelocytic Leukemia,disease,acute promyelocytic leukemia,5914,RARA,RARA,CTD_human,17712046,The PRKAR1A gene is fused to RARA in a new variant acute promyelocytic leukemia.,0.707329124648138,"The PRKAR1A gene is fused to <span class=""gene"" id=""17712046-0-29-33"">RARA</span> in a new variant <span class=""disease"" id=""17712046-0-51-79"">acute promyelocytic leukemia</span>.",CTD_human;HPO;ORPHANET
1,0,Biomarker,C0206650,Fibroadenoma,disease,fibroadenomas,5914,RARA,RARA,CTD_human,26437033,"First, we frequently observed MED12 and RARA mutations in both fibroadenomas and phyllodes tumors, emphasizing the importance of these mutations in fibroepithelial tumorigenesis.",0.20054945356842604,"First, we frequently observed MED12 and <span class=""gene"" id=""26437033-4-40-44"">RARA</span> mutations in both <span class=""disease"" id=""26437033-4-63-76"">fibroadenomas</span> and phyllodes tumors, emphasizing the importance of these mutations in fibroepithelial tumorigenesis.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,5914,RARA,Rara,CTD_human,18026104,"We further show that deletion of a single retinoic acid receptor alpha (Rara) allele in a Trim24-null background suppresses HCC development and restores wild-type expression of retinoic acid-responsive genes in the liver, thus demonstrating that in this genetic background Rara expresses an oncogenic activity correlating with a dysregulation of the retinoic acid signaling pathway.",0.201373633921065,"We further show that deletion of a single <span class=""gene"" id=""18026104-5-42-70"">retinoic acid receptor alpha</span> (<span class=""gene"" id=""18026104-5-72-76"">Rara</span>) allele in a Trim24-null background suppresses <span class=""disease"" id=""18026104-5-124-127"">HCC</span> development and restores wild-type expression of retinoic acid-responsive genes in the liver, thus demonstrating that in this genetic background <span class=""gene"" id=""18026104-5-273-277"">Rara</span> expresses an oncogenic activity correlating with a dysregulation of the retinoic acid signaling pathway.",CTD_human
1,0,Biomarker,C0024121,Lung Neoplasms,group,lung tumors,5915,RARB,RAR-beta,CTD_human,14656941,These studies demonstrate that aberrant methylation of RAR-beta is an early and common alteration in murine lung tumors induced by several environmentally relevant exposures.,0.21148110342768103,"These studies demonstrate that aberrant methylation of <span class=""gene"" id=""14656941-10-55-63"">RAR-beta</span> is an early and common alteration in murine <span class=""disease"" id=""14656941-10-108-119"">lung tumors</span> induced by several environmentally relevant exposures.",CTD_human
1,0,Biomarker,C0152013,Adenocarcinoma of lung (disorder),disease,ADC,5921,RASA1,RASA1,CTD_human,27158780,"Lung ADCs lacking receptor tyrosine kinase-Ras-Raf pathway alterations had mutations in SOS1, VAV1, RASA1, and ARHGAP35.",0.200274726784213,"Lung <span class=""disease"" id=""27158780-5-5-8"">ADC</span>s lacking receptor tyrosine kinase-Ras-Raf pathway alterations had mutations in SOS1, VAV1, <span class=""gene"" id=""27158780-5-100-105"">RASA1</span>, and ARHGAP35.",CTD_human
2,0,Biomarker,C0025202,melanoma,disease,melanomas,5922,RASA2,RASA2,CTD_human,26214590,"Inactivating NF1 mutations were present in 46% of melanomas expressing wild-type BRAF and RAS, occurred in older patients and showed a distinct pattern of co-mutation with other RASopathy genes, particularly RASA2.",0.20054945356842604,"Inactivating NF1 mutations were present in 46% of <span class=""disease"" id=""26214590-3-50-59"">melanomas</span> expressing wild-type BRAF and RAS, occurred in older patients and showed a distinct pattern of co-mutation with other RASopathy genes, particularly <span class=""gene"" id=""26214590-3-208-213"">RASA2</span>.",CTD_human
2,0,Biomarker,C0025202,melanoma,disease,melanoma,5922,RASA2,RASA2,CTD_human,26502337,Recurrent inactivating RASA2 mutations in melanoma.,0.20054945356842604,"Recurrent inactivating <span class=""gene"" id=""26502337-0-23-28"">RASA2</span> mutations in <span class=""disease"" id=""26502337-0-42-50"">melanoma</span>.",CTD_human
1,0,Therapeutic,C0011881,Diabetic Nephropathy,disease,diabetic nephropathy,59272,ACE2,ACE) 2,CTD_human,20844835,Angiotensin-converting enzyme (ACE) 2 overexpression ameliorates glomerular injury in a rat model of diabetic nephropathy: a comparison with ACE inhibition.,0.21139314449037303,"Angiotensin-converting enzyme (<span class=""gene"" id=""20844835-0-31-37"">ACE) 2</span> overexpression ameliorates glomerular injury in a rat model of <span class=""disease"" id=""20844835-0-101-121"">diabetic nephropathy</span>: a comparison with ACE inhibition.",CTD_human
4,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,59272,ACE2,ACE2,CTD_human,17473847,We conclude that the ACE2 T allele confers a high risk for hypertension and reduced antihypertensive response to ACE inhibitors.,0.31848083872926497,"We conclude that the <span class=""gene"" id=""17473847-6-21-25"">ACE2</span> T allele confers a high risk for <span class=""disease"" id=""17473847-6-59-71"">hypertension</span> and reduced antihypertensive response to ACE inhibitors.",CTD_human
4,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,59272,ACE2,ACE2,CTD_human,17473847,We conclude that the ACE2 T allele confers a high risk for hypertension and reduced antihypertensive response to ACE inhibitors.,0.31848083872926497,"We conclude that the <span class=""gene"" id=""17473847-6-21-25"">ACE2</span> T allele confers a high risk for <span class=""disease"" id=""17473847-6-59-71"">hypertension</span> and reduced antihypertensive response to ACE inhibitors.",CTD_human
1,0,Therapeutic,C0162871,"Aortic Aneurysm, Abdominal",disease,abdominal aortic aneurysms,59272,ACE2,Angiotensin-converting enzyme 2,CTD_human,25301841,Angiotensin-converting enzyme 2 decreases formation and severity of angiotensin II-induced abdominal aortic aneurysms.,0.200274726784213,"<span class=""gene"" id=""25301841-0-0-31"">Angiotensin-converting enzyme 2</span> decreases formation and severity of angiotensin II-induced <span class=""disease"" id=""25301841-0-91-117"">abdominal aortic aneurysms</span>.",CTD_human
1,0,Biomarker,C0033774,Pruritus,phenotype,pruritus,59340,HRH4,histamine H4 receptor,CTD_human,19652466,Expression of histamine H4 receptor in human epidermal tissues and attenuation of experimental pruritus using H4 receptor antagonist.,0.2,"Expression of <span class=""gene"" id=""19652466-0-14-35"">histamine H4 receptor</span> in human epidermal tissues and attenuation of experimental <span class=""disease"" id=""19652466-0-95-103"">pruritus</span> using H4 receptor antagonist.",CTD_human
1,0,Biomarker,C0020625,Hyponatremia,phenotype,hyponatremia,59341,TRPV4,TRPV4,CTD_human,19666518,A loss-of-function nonsynonymous polymorphism in the osmoregulatory TRPV4 gene is associated with human hyponatremia.,0.202681755307501,"A loss-of-function nonsynonymous polymorphism in the osmoregulatory <span class=""gene"" id=""19666518-0-68-73"">TRPV4</span> gene is associated with human <span class=""disease"" id=""19666518-0-104-116"">hyponatremia</span>.",CTD_human
1,0,Biomarker,C0024117,Chronic Obstructive Airway Disease,disease,COPD,59341,TRPV4,TRPV4,CTD_human,21245013,"DEP evoked protracted Ca2+ influx via TRPV4, enhanced by the COPD-predisposing human genetic polymorphism TRPV4P19S.",0.203231208875927,"DEP evoked protracted Ca2+ influx via <span class=""gene"" id=""21245013-6-38-43"">TRPV4</span>, enhanced by the <span class=""disease"" id=""21245013-6-61-65"">COPD</span>-predisposing human genetic polymorphism TRPV4P19S.",CTD_human
1,0,Biomarker,C0029408,Degenerative polyarthritis,disease,osteoarthritis,59341,TRPV4,TRPV4,CTD_human,21964574,Our data raise the possibility that TRPV4 may also have a role in age- or injury-related osteoarthritis.,0.200274726784213,"Our data raise the possibility that <span class=""gene"" id=""21964574-7-36-41"">TRPV4</span> may also have a role in age- or injury-related <span class=""disease"" id=""21964574-7-89-103"">osteoarthritis</span>.",CTD_human
4,19,Biomarker,C0265281,Metatropic dwarfism,disease,metatropic dysplasia,59341,TRPV4,TRPV4,CTD_human,20425821,Dominant TRPV4 mutations in nonlethal and lethal metatropic dysplasia.,0.602747267842131,"Dominant <span class=""gene"" id=""20425821-0-9-14"">TRPV4</span> mutations in nonlethal and lethal <span class=""disease"" id=""20425821-0-49-69"">metatropic dysplasia</span>.",CTD_human;ORPHANET;UNIPROT
2,3,Biomarker,C0751335,Scapuloperoneal Form of Spinal Muscular Atrophy,disease,Scapuloperoneal spinal muscular atrophy,59341,TRPV4,TRPV4,CTD_human,20037587,Scapuloperoneal spinal muscular atrophy and CMT2C are allelic disorders caused by alterations in TRPV4.,0.6010989071368521,"<span class=""disease"" id=""20037587-0-0-39"">Scapuloperoneal spinal muscular atrophy</span> and CMT2C are allelic disorders caused by alterations in <span class=""gene"" id=""20037587-0-97-102"">TRPV4</span>.",CTD_human;ORPHANET;UNIPROT
2,0,Therapeutic,C0003469,Anxiety Disorders,group,anxiety,594857,NPS,NPS,CTD_human,19339610,"Our results suggest that NPS receptors may be an important target for drug abuse research and treatment and that CRF(1) mediates the cocaine-seeking and locomotor stimulant effects of NPS, but not its effects on anxiety-like behavior.",0.20412090176319603,"Our results suggest that <span class=""gene"" id=""19339610-7-25-28"">NPS</span> receptors may be an important target for drug abuse research and treatment and that CRF(1) mediates the cocaine-seeking and locomotor stimulant effects of <span class=""gene"" id=""19339610-7-184-187"">NPS</span>, but not its effects on <span class=""disease"" id=""19339610-7-212-219"">anxiety</span>-like behavior.",CTD_human
2,0,Biomarker,C0003469,Anxiety Disorders,group,anxiety,594857,NPS,NPS,CTD_human,19339610,"Our results suggest that NPS receptors may be an important target for drug abuse research and treatment and that CRF(1) mediates the cocaine-seeking and locomotor stimulant effects of NPS, but not its effects on anxiety-like behavior.",0.20412090176319603,"Our results suggest that <span class=""gene"" id=""19339610-7-25-28"">NPS</span> receptors may be an important target for drug abuse research and treatment and that CRF(1) mediates the cocaine-seeking and locomotor stimulant effects of <span class=""gene"" id=""19339610-7-184-187"">NPS</span>, but not its effects on <span class=""disease"" id=""19339610-7-212-219"">anxiety</span>-like behavior.",CTD_human
1,0,Biomarker,C0035334,Retinitis Pigmentosa,disease,RP,5949,RBP3,IRBP,CTD_human,23486466,Secretory defect and cytotoxicity: the potential disease mechanisms for the retinitis pigmentosa (RP)-associated interphotoreceptor retinoid-binding protein (IRBP).,0.604055389228567,"Secretory defect and cytotoxicity: the potential disease mechanisms for the <span class=""disease"" id=""23486466-0-76-96"">retinitis pigmentosa</span> (<span class=""disease"" id=""23486466-0-98-100"">RP</span>)-associated <span class=""gene"" id=""23486466-0-113-156"">interphotoreceptor retinoid-binding protein</span> (<span class=""gene"" id=""23486466-0-158-162"">IRBP</span>).",CTD_human;HPO;ORPHANET
4,0,Biomarker,C0009375,Colonic Neoplasms,group,colon tumor,595,CCND1,cyclin D1,CTD_human,21081470,"Western blots revealed overexpression of ?-catenin, c-Myc, cyclin D1, inducible nitric oxide synthase and cyclooxygenase-2 in colon tumor samples.",0.201648360705279,"Western blots revealed overexpression of &beta;-catenin, c-Myc, <span class=""gene"" id=""21081470-8-59-68"">cyclin D1</span>, inducible nitric oxide synthase and cyclooxygenase-2 in <span class=""disease"" id=""21081470-8-126-137"">colon tumor</span> samples.",CTD_human
1,0,Biomarker,C0014859,Esophageal Neoplasms,group,esophageal cancer,595,CCND1,cyclin D1,CTD_human,12235107,"Whereas L2D1(+) mice exhibit a histologic phenotype of oral-esophageal dysplasia, the combination of cyclin D1 expression and p53 deficiency results in invasive oral-esophageal cancer.",0.22715320677352105,"Whereas L2D1(+) mice exhibit a histologic phenotype of oral-esophageal dysplasia, the combination of <span class=""gene"" id=""12235107-5-101-110"">cyclin D1</span> expression and p53 deficiency results in invasive oral-<span class=""disease"" id=""12235107-5-166-183"">esophageal cancer</span>.",CTD_human
1,0,Biomarker,C0020502,Hyperparathyroidism,disease,hyperparathyroidism,595,CCND1,cyclin D1,CTD_human,21541686,"We previously reported the suppressive effect of cinacalcet on PTH secretion in vivo in a PHPT model mouse, in which parathyroid-targeted overexpression of the cyclin D1 oncogene caused chronic biochemical hyperparathyroidism and parathyroid cell hyperplasia.",0.20383181960166602,"We previously reported the suppressive effect of cinacalcet on PTH secretion in vivo in a PHPT model mouse, in which parathyroid-targeted overexpression of the <span class=""gene"" id=""21541686-2-160-169"">cyclin D1</span> oncogene caused chronic biochemical <span class=""disease"" id=""21541686-2-206-225"">hyperparathyroidism</span> and parathyroid cell hyperplasia.",CTD_human
1,0,Biomarker,C0022665,Kidney Neoplasm,disease,renal tumor,595,CCND1,cyclin D1,CTD_human,21693435,"Therefore, the loss of tuberin and engagement of the cAMP pathway may independently direct p27-cyclin D1 cytosolic stabilization during renal tumor formation.",0.20054945356842604,"Therefore, the loss of tuberin and engagement of the cAMP pathway may independently direct p27-<span class=""gene"" id=""21693435-11-95-104"">cyclin D1</span> cytosolic stabilization during <span class=""disease"" id=""21693435-11-136-147"">renal tumor</span> formation.",CTD_human
2,0,Biomarker,C0024121,Lung Neoplasms,group,lung tumors,595,CCND1,Cyclin D1,CTD_human,11307925,"Over-expression of Cyclin D1 in hyperplasias in rasH2 mice given triple doses was significantly increased, compared to that in the single-injection group, but no significant differences in Cyclin D1 between the single and triple injection groups were observed in hyperplasias in non-Tg mice or lung tumors in either rasH2 or non-Tg mice.",0.21717049798420898,"Over-expression of <span class=""gene"" id=""11307925-3-19-28"">Cyclin D1</span> in hyperplasias in rasH2 mice given triple doses was significantly increased, compared to that in the single-injection group, but no significant differences in <span class=""gene"" id=""11307925-3-189-198"">Cyclin D1</span> between the single and triple injection groups were observed in hyperplasias in non-Tg mice or <span class=""disease"" id=""11307925-3-294-305"">lung tumors</span> in either rasH2 or non-Tg mice.",CTD_human
1,2,Biomarker,C0026764,Multiple Myeloma,disease,multiple myeloma,595,CCND1,CCND1,CTD_human,23502783,The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma.,0.43919979787857005,"The <span class=""gene"" id=""23502783-0-4-9"">CCND1</span> c.870G&gt;A polymorphism is a risk factor for t(11;14)(q13;q32) <span class=""disease"" id=""23502783-0-71-87"">multiple myeloma</span>.",CTD_human;ORPHANET
1,0,Biomarker,C0030354,Papilloma,disease,papillomas,595,CCND1,Cyclin D1,CTD_human,12151359,"Cyclin D1 overexpression was observed in 26 of 47 (55%) PN hyperplasias, 3 of 4 (75%) papillomas, and 10 of 18 (56%) TCCs.",0.20082418035263896,"<span class=""gene"" id=""12151359-17-0-9"">Cyclin D1</span> overexpression was observed in 26 of 47 (55%) PN hyperplasias, 3 of 4 (75%) <span class=""disease"" id=""12151359-17-86-96"">papillomas</span>, and 10 of 18 (56%) TCCs.",CTD_human
5,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,595,CCND1,Cyclin D1,CTD_human,12029619,"Overexpression of c-myc, Cyclins D1, E, and A, and E2F1 genes, at messenger RNA (mRNA) and protein levels, rise in Cyclin D1-CDK4, Cyclin E-CDK2, and E2F1-DP1 complexes, and pRb hyperphosphorylation occurred in nodules and HCCs of F344 rats.",0.23060966400797303,"Overexpression of c-myc, Cyclins D1, E, and A, and E2F1 genes, at messenger RNA (mRNA) and protein levels, rise in <span class=""gene"" id=""12029619-4-115-124"">Cyclin D1</span>-CDK4, Cyclin E-CDK2, and E2F1-DP1 complexes, and pRb hyperphosphorylation occurred in nodules and <span class=""disease"" id=""12029619-4-223-226"">HCC</span>s of F344 rats.",CTD_human
1,0,Biomarker,C0032460,Polycystic Ovary Syndrome,disease,polycystic ovary syndrome,5950,RBP4,retinol-binding protein 4,CTD_human,17456573,"Raised serum, adipocyte, and adipose tissue retinol-binding protein 4 in overweight women with polycystic ovary syndrome: effects of gonadal and adrenal steroids.",0.205740551713841,"Raised serum, adipocyte, and adipose tissue <span class=""gene"" id=""17456573-0-44-69"">retinol-binding protein 4</span> in overweight women with <span class=""disease"" id=""17456573-0-95-120"">polycystic ovary syndrome</span>: effects of gonadal and adrenal steroids.",CTD_human
2,0,Biomarker,C0001430,Adenoma,group,adenomas,596,BCL2,Bcl-2,CTD_human,10223192,Results suggest that modulation of aberrant beta-catenin expression occurs during NSAID-induced regression of intestinal adenomas and that Bcl-2 may confer resistance to these effects.,0.20714289638954103,"Results suggest that modulation of aberrant beta-catenin expression occurs during NSAID-induced regression of intestinal <span class=""disease"" id=""10223192-9-121-129"">adenomas</span> and that <span class=""gene"" id=""10223192-9-139-144"">Bcl-2</span> may confer resistance to these effects.",CTD_human
2,0,Biomarker,C0001430,Adenoma,group,adenomas,596,BCL2,bcl-2,CTD_human,10426811,"Collectively, only 8% of preneoplastic foci, 3% of adenomas and 1.5% of carcinomas did not express either bcl-2 or bcl-X(L).",0.20714289638954103,"Collectively, only 8% of preneoplastic foci, 3% of <span class=""disease"" id=""10426811-10-51-59"">adenomas</span> and 1.5% of carcinomas did not express either <span class=""gene"" id=""10426811-10-106-111"">bcl-2</span> or bcl-X(L).",CTD_human
1,0,Biomarker,C0002395,Alzheimer's Disease,disease,AD,596,BCL2,Bcl-2,CTD_human,18077176,"The current investigation focused on detection of PtdSer on the outer leaflet of the bilayer in synaptosomes from brain of subjects with AD and amnestic mild cognitive impairment (MCI), as well as expression levels of apoptosis-related proteins Bcl-2, Bax, and caspase-3.",0.286253203502271,"The current investigation focused on detection of PtdSer on the outer leaflet of the bilayer in synaptosomes from brain of subjects with <span class=""disease"" id=""18077176-6-137-139"">AD</span> and amnestic mild cognitive impairment (MCI), as well as expression levels of apoptosis-related proteins <span class=""gene"" id=""18077176-6-245-250"">Bcl-2</span>, Bax, and caspase-3.",CTD_human
1,0,Biomarker,C0004096,Asthma,disease,asthmatic,596,BCL2,Bcl-2,CTD_human,18357729,In vitro arsenic trioxide induces apoptosis in T cells of asthmatic patients by a Bcl-2 related mechanism.,0.201373633921065,"In vitro arsenic trioxide induces apoptosis in T cells of <span class=""disease"" id=""18357729-0-58-67"">asthmatic</span> patients by a <span class=""gene"" id=""18357729-0-82-87"">Bcl-2</span> related mechanism.",CTD_human
2,0,Biomarker,C0004352,Autistic Disorder,disease,autistic,596,BCL2,Bcl-2,CTD_human,11814262,Dysregulation of Reelin and Bcl-2 proteins in autistic cerebellum.,0.20383181960166602,"Dysregulation of Reelin and <span class=""gene"" id=""11814262-0-28-33"">Bcl-2</span> proteins in <span class=""disease"" id=""11814262-0-46-54"">autistic</span> cerebellum.",CTD_human
2,0,Biomarker,C0004352,Autistic Disorder,disease,autistic,596,BCL2,BCL-2,CTD_human,20375269,Immunohistochemical analyses of tissue arrays containing slices of the cerebellum and frontal cortex of autistic and age- and sex-matched control subjects revealed decreased expression of RORA and BCL-2 proteins in the autistic brain.,0.20383181960166602,"Immunohistochemical analyses of tissue arrays containing slices of the cerebellum and frontal cortex of <span class=""disease"" id=""20375269-6-104-112"">autistic</span> and age- and sex-matched control subjects revealed decreased expression of RORA and <span class=""gene"" id=""20375269-6-197-202"">BCL-2</span> proteins in the <span class=""disease"" id=""20375269-6-219-227"">autistic</span> brain.",CTD_human
1,0,Biomarker,C0004509,Azoospermia,disease,azoospermia,596,BCL2,BCL2,CTD_human,20610805,BCL2 Ala43Thr is a functional variant associated with protection against azoospermia in a Han-Chinese population.,0.202681755307501,"<span class=""gene"" id=""20610805-0-0-4"">BCL2</span> Ala43Thr is a functional variant associated with protection against <span class=""disease"" id=""20610805-0-73-84"">azoospermia</span> in a Han-Chinese population.",CTD_human
3,0,Biomarker,C0009375,Colonic Neoplasms,group,colon tumors,596,BCL2,Bcl-2,CTD_human,17404573,"Bcl-2 overexpression in PhIP-induced colon tumors: cloning of the rat Bcl-2 promoter and characterization of a pathway involving beta-catenin, c-Myc and E2F1.",0.289572371315507,"<span class=""gene"" id=""17404573-0-0-5"">Bcl-2</span> overexpression in PhIP-induced <span class=""disease"" id=""17404573-0-37-49"">colon tumors</span>: cloning of the rat <span class=""gene"" id=""17404573-0-70-75"">Bcl-2</span> promoter and characterization of a pathway involving beta-catenin, c-Myc and E2F1.",CTD_human
1,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,596,BCL2,bcl-2,CTD_human,10075388,"Moreover, lisinopril and nifedipine appear to be capable of reducing bcl-2 concentrations, with potentially beneficial effects on vascular modifications in patients with hypertension.",0.280274726784213,"Moreover, lisinopril and nifedipine appear to be capable of reducing <span class=""gene"" id=""10075388-6-69-74"">bcl-2</span> concentrations, with potentially beneficial effects on vascular modifications in patients with <span class=""disease"" id=""10075388-6-170-182"">hypertension</span>.",CTD_human
1,0,Biomarker,C0021841,Intestinal Neoplasms,group,intestinal tumors,596,BCL2,Bcl-2,CTD_human,10223192,Relationship of beta-catenin and Bcl-2 expression to sulindac-induced regression of intestinal tumors in Min mice.,0.200274726784213,"Relationship of beta-catenin and <span class=""gene"" id=""10223192-0-33-38"">Bcl-2</span> expression to sulindac-induced regression of <span class=""disease"" id=""10223192-0-84-101"">intestinal tumors</span> in Min mice.",CTD_human
2,3,Biomarker,C0023434,Chronic Lymphocytic Leukemia,disease,CLL,596,BCL2,Bcl-2,CTD_human,21750559,Resistance to therapy in CLL depends on the expression and activity of anti-apoptotic proteins of the Bcl-2 family.,0.262188888815162,"Resistance to therapy in <span class=""disease"" id=""21750559-3-25-28"">CLL</span> depends on the expression and activity of anti-apoptotic proteins of the <span class=""gene"" id=""21750559-3-102-107"">Bcl-2</span> family.",CTD_human
1,0,Biomarker,C0023467,"Leukemia, Myelocytic, Acute",disease,acute myeloid leukemia,596,BCL2,Bcl2,CTD_human,23906301,Overexpression of Bcl2 protein predicts chemoresistance in acute myeloid leukemia: its correlation with FLT3.,0.231550514052555,"Overexpression of <span class=""gene"" id=""23906301-0-18-22"">Bcl2</span> protein predicts chemoresistance in <span class=""disease"" id=""23906301-0-59-81"">acute myeloid leukemia</span>: its correlation with FLT3.",CTD_human
2,0,Biomarker,C0024301,"Lymphoma, Follicular",disease,follicular lymphomas,596,BCL2,bcl-2,CTD_human,3287162,"Immunoreactive bcl-2 protein was observed in the neoplastic cells in almost all the follicular lymphomas, whereas no bcl-2 protein was detected in follicles affected by non-neoplastic processes or in normal lymphoid tissue.",0.503944444300272,"Immunoreactive <span class=""gene"" id=""3287162-3-15-20"">bcl-2</span> protein was observed in the neoplastic cells in almost all the <span class=""disease"" id=""3287162-3-84-104"">follicular lymphomas</span>, whereas no <span class=""gene"" id=""3287162-3-117-122"">bcl-2</span> protein was detected in follicles affected by non-neoplastic processes or in normal lymphoid tissue.",CTD_human;ORPHANET
2,0,Biomarker,C0024305,"Lymphoma, Non-Hodgkin",disease,NHL,596,BCL2,bcl-2,CTD_human,26239085,"Thus, bcl-2 overexpression might be considered a new independent prognostic parameter in NHL, aiding in the identification of patients at risk for treatment failure.",0.23269080858973498,"Thus, <span class=""gene"" id=""26239085-16-6-11"">bcl-2</span> overexpression might be considered a new independent prognostic parameter in <span class=""disease"" id=""26239085-16-89-92"">NHL</span>, aiding in the identification of patients at risk for treatment failure.",CTD_human
2,0,Biomarker,C0024305,"Lymphoma, Non-Hodgkin",disease,non-Hodgkin's lymphoma,596,BCL2,bcl-2,CTD_human,3287162,Expression in non-Hodgkin's lymphoma of the bcl-2 protein associated with the t(14;18) chromosomal translocation.,0.23269080858973498,"Expression in <span class=""disease"" id=""3287162-0-14-36"">non-Hodgkin's lymphoma</span> of the <span class=""gene"" id=""3287162-0-44-49"">bcl-2</span> protein associated with the t(14;18) chromosomal translocation.",CTD_human
1,0,Biomarker,C0026764,Multiple Myeloma,disease,myeloma,596,BCL2,Bcl-2,CTD_human,12429644,"MM cells express multiple Bcl-2 family members, including Bcl-2, Bcl-XL, and Mcl-1, which are thought to play a key role in the survival and drug resistance of myeloma.",0.21675833383699897,"MM cells express multiple <span class=""gene"" id=""12429644-2-26-31"">Bcl-2</span> family members, including <span class=""gene"" id=""12429644-2-58-63"">Bcl-2</span>, Bcl-XL, and Mcl-1, which are thought to play a key role in the survival and drug resistance of <span class=""disease"" id=""12429644-2-160-167"">myeloma</span>.",CTD_human
1,0,Biomarker,C0027051,Myocardial Infarction,disease,myocardial-infarction,596,BCL2,Bcl-2,CTD_human,19027736,"Following the improvement of cardiac function and ventricular remodeling, ICER and CREB mRNA in pre- and post- myocardial-infarction groups were down-regulated, and phosphodiesterase 3A and Bcl-2 mRNA were up-regulated (P<0.05).",0.200274726784213,"Following the improvement of cardiac function and ventricular remodeling, ICER and CREB mRNA in pre- and post- <span class=""disease"" id=""19027736-6-111-132"">myocardial-infarction</span> groups were down-regulated, and phosphodiesterase 3A and <span class=""gene"" id=""19027736-6-190-195"">Bcl-2</span> mRNA were up-regulated (P&lt;0.05).",CTD_human
1,0,Biomarker,C0032460,Polycystic Ovary Syndrome,disease,polycystic ovaries,596,BCL2,Bcl-2,CTD_human,21062263,Altered expression of Bcl-2 and Bax in follicles within dehydroepiandrosterone-induced polycystic ovaries in rats.,0.281098907136852,"Altered expression of <span class=""gene"" id=""21062263-0-22-27"">Bcl-2</span> and Bax in follicles within dehydroepiandrosterone-induced <span class=""disease"" id=""21062263-0-87-105"">polycystic ovaries</span> in rats.",CTD_human
1,0,Therapeutic,C0039101,synovial sarcoma,disease,synovial sarcoma,596,BCL2,Bcl-2,CTD_human,16450387,G3139 antisense oligonucleotide directed against antiapoptotic Bcl-2 enhances doxorubicin cytotoxicity in the FU-SY-1 synovial sarcoma cell line.,0.203846174978983,"G3139 antisense oligonucleotide directed against antiapoptotic <span class=""gene"" id=""16450387-0-63-68"">Bcl-2</span> enhances doxorubicin cytotoxicity in the FU-SY-1 <span class=""disease"" id=""16450387-0-118-134"">synovial sarcoma</span> cell line.",CTD_human
1,0,Biomarker,C0206637,"Chondrosarcoma, Mesenchymal",disease,mesenchymal chondrosarcoma,596,BCL2,bcl-2,CTD_human,12817616,"In conclusion, molecular profiling of mesenchymal chondrosarcoma using a proteomic approach characterized the mesenchymal chondroblasts as possessing pathways that incorporate PKC-alpha and PDGFR-alpha signaling and anti-apoptotic bcl-2 expression.",0.2,"In conclusion, molecular profiling of <span class=""disease"" id=""12817616-5-38-64"">mesenchymal chondrosarcoma</span> using a proteomic approach characterized the mesenchymal chondroblasts as possessing pathways that incorporate PKC-alpha and PDGFR-alpha signaling and anti-apoptotic <span class=""gene"" id=""12817616-5-231-236"">bcl-2</span> expression.",CTD_human
1,0,Biomarker,C0206681,"Adenocarcinoma, Clear Cell",disease,clear cell adenocarcinomas,596,BCL2,Bcl-2,CTD_human,9754764,Bcl-2 protein expression associated with resistance to apoptosis in clear cell adenocarcinomas of the vagina and cervix expressing wild-type p53.,0.200274726784213,"<span class=""gene"" id=""9754764-0-0-5"">Bcl-2</span> protein expression associated with resistance to apoptosis in <span class=""disease"" id=""9754764-0-68-94"">clear cell adenocarcinomas</span> of the vagina and cervix expressing wild-type p53.",CTD_human
1,0,Biomarker,C0242350,Erectile dysfunction,disease,erectile dysfunction,596,BCL2,Bcl-2,CTD_human,12394778,"We hypothesized that apoptosis is a downstream event in erectile dysfunction, and pro-apoptotic (Bak and Bax) and anti-apoptotic (Bcl-2 and Bcl-x) factors are involved in the etiology of aging erectile dysfunction.",0.28,"We hypothesized that apoptosis is a downstream event in <span class=""disease"" id=""12394778-3-56-76"">erectile dysfunction</span>, and pro-apoptotic (Bak and Bax) and anti-apoptotic (<span class=""gene"" id=""12394778-3-130-135"">Bcl-2</span> and Bcl-x) factors are involved in the etiology of aging <span class=""disease"" id=""12394778-3-193-213"">erectile dysfunction</span>.",CTD_human
1,0,Biomarker,C0345967,Malignant mesothelioma,disease,MM,596,BCL2,bcl-2,CTD_human,16850164,This speculation was partially confirmed by the detection of elevated bcl-2 expression levels in CD4 + peripheral blood T cells from patients with MM compared with those from patients with ASB or healthy donors.,0.200274726784213,"This speculation was partially confirmed by the detection of elevated <span class=""gene"" id=""16850164-5-70-75"">bcl-2</span> expression levels in CD4 + peripheral blood T cells from patients with <span class=""disease"" id=""16850164-5-147-149"">MM</span> compared with those from patients with ASB or healthy donors.",CTD_human
1,0,Biomarker,C0008370,Cholestasis,disease,cholestasis,5962,RDX,radixin,CTD_human,17681005,"Conclusion: The disturbed colocalization of Mrp2 and radixin may contribute to the endocytic retrieval of Mrp2 in cholestasis due to the failure to anchor Mrp2 in the canalicular membrane, in which the phosphorylated radixin may play a major role.",0.200274726784213,"Conclusion: The disturbed colocalization of Mrp2 and <span class=""gene"" id=""17681005-9-53-60"">radixin</span> may contribute to the endocytic retrieval of Mrp2 in <span class=""disease"" id=""17681005-9-114-125"">cholestasis</span> due to the failure to anchor Mrp2 in the canalicular membrane, in which the phosphorylated <span class=""gene"" id=""17681005-9-217-224"">radixin</span> may play a major role.",CTD_human
3,2,Biomarker,C0003873,Rheumatoid Arthritis,disease,rheumatoid arthritis,5966,REL,REL,CTD_human,19503088,"REL, encoding a member of the NF-kappaB family of transcription factors, is a newly defined risk locus for rheumatoid arthritis.",0.20886944627514298,"<span class=""gene"" id=""19503088-0-0-3"">REL</span>, encoding a member of the NF-kappaB family of transcription factors, is a newly defined risk locus for <span class=""disease"" id=""19503088-0-107-127"">rheumatoid arthritis</span>.",CTD_human
1,0,Biomarker,C0002871,Anemia,disease,anemia,5972,REN,renin,CTD_human,3524928,Participation of the renin-angiotensin system in the captopril-induced worsening of anemia in chronic hemodialysis patients.,0.40137363392106606,"Participation of the <span class=""gene"" id=""3524928-0-21-26"">renin</span>-angiotensin system in the captopril-induced worsening of <span class=""disease"" id=""3524928-0-84-90"">anemia</span> in chronic hemodialysis patients.",CTD_human;HPO
3,0,Biomarker,C0004775,Bartter Disease,disease,Bartter's syndrome,5972,REN,renin,CTD_human,3519017,Dynamic changes in plasma inactive renin levels in Bartter's syndrome after administration of captopril and angiotensin II.,0.20082418035263896,"Dynamic changes in plasma inactive <span class=""gene"" id=""3519017-0-35-40"">renin</span> levels in <span class=""disease"" id=""3519017-0-51-69"">Bartter's syndrome</span> after administration of captopril and angiotensin II.",CTD_human
3,0,Biomarker,C0018801,Heart failure,disease,heart failure,5972,REN,renin,CTD_human,1647690,Mechanisms of sodium retention in heart failure: relation to the renin-angiotensin-aldosterone system.,0.212846646323386,"Mechanisms of sodium retention in <span class=""disease"" id=""1647690-0-34-47"">heart failure</span>: relation to the <span class=""gene"" id=""1647690-0-65-70"">renin</span>-angiotensin-aldosterone system.",CTD_human
17,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,5972,REN,renin,CTD_human,998518,"In six additional patients with high renin levels induced by prior sodium depletion (10 mEq/day sodium diet), clonidine did not reduce blood pressure or renin, thus indicating that the suppressive action of this agent on renin pressor mechanisms occurs only in patients whose elevated renin levels are intrinsic to hypertension and unrelated to sodium depletion.",0.363794273440947,"In six additional patients with high <span class=""gene"" id=""998518-6-37-42"">renin</span> levels induced by prior sodium depletion (10 mEq/day sodium diet), clonidine did not reduce blood pressure or <span class=""gene"" id=""998518-6-153-158"">renin</span>, thus indicating that the suppressive action of this agent on <span class=""gene"" id=""998518-6-221-226"">renin</span> pressor mechanisms occurs only in patients whose elevated <span class=""gene"" id=""998518-6-285-290"">renin</span> levels are intrinsic to <span class=""disease"" id=""998518-6-315-327"">hypertension</span> and unrelated to sodium depletion.",CTD_human
17,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,5972,REN,renin,CTD_human,62162,Low renin hypertension. A distinct entity.,0.363794273440947,"Low <span class=""gene"" id=""62162-0-4-9"">renin</span> <span class=""disease"" id=""62162-0-10-22"">hypertension</span>. A distinct entity.",CTD_human
17,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,5972,REN,renin,CTD_human,21393355,"The hypertensive double-transgenic (dTG) rat strain, expressing human renin and angiotensinogen, develops severe hypertension and organ damage and 50% of individuals die by 7 weeks of age.",0.363794273440947,"The hypertensive double-transgenic (dTG) rat strain, expressing human <span class=""gene"" id=""21393355-1-70-75"">renin</span> and angiotensinogen, develops severe <span class=""disease"" id=""21393355-1-113-125"">hypertension</span> and organ damage and 50% of individuals die by 7 weeks of age.",CTD_human
17,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,5972,REN,renin,CTD_human,19770776,Our study indicated that elevated plasma levels of high-sensitivity C-reactive protein and angiotensin II were positively and renin activity inversely associated with the risk of hypertension.,0.363794273440947,"Our study indicated that elevated plasma levels of high-sensitivity C-reactive protein and angiotensin II were positively and <span class=""gene"" id=""19770776-6-126-131"">renin</span> activity inversely associated with the risk of <span class=""disease"" id=""19770776-6-179-191"">hypertension</span>.",CTD_human
17,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,5972,REN,renin,CTD_human,45830,"Estrogens and hypertension: effect of discontinuing estrogens on blood pressure, exchangeable sodium, and the renin-aldosterone system.",0.363794273440947,"Estrogens and <span class=""disease"" id=""45830-0-14-26"">hypertension</span>: effect of discontinuing estrogens on blood pressure, exchangeable sodium, and the <span class=""gene"" id=""45830-0-110-115"">renin</span>-aldosterone system.",CTD_human
17,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,5972,REN,renin,CTD_human,6381767,"Lateralization of renal vein renins and exaggerated hyperreninemia following captopril suggested renin-mediated hypertension in 1 case, which responded well to nephrectomy.",0.363794273440947,"Lateralization of renal vein renins and exaggerated hyperreninemia following captopril suggested <span class=""gene"" id=""6381767-2-97-102"">renin</span>-mediated <span class=""disease"" id=""6381767-2-112-124"">hypertension</span> in 1 case, which responded well to nephrectomy.",CTD_human
17,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,5972,REN,renin,CTD_human,18679781,"Controlling hypertension by angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB), mechanisms that inhibit later pathway steps in the renin-angiotensin system (RAS), have clinically afforded protection against cardiac and renal disease.",0.363794273440947,"Controlling <span class=""disease"" id=""18679781-1-12-24"">hypertension</span> by angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB), mechanisms that inhibit later pathway steps in the <span class=""gene"" id=""18679781-1-167-172"">renin</span>-angiotensin system (RAS), have clinically afforded protection against cardiac and renal disease.",CTD_human
17,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,5972,REN,renin,CTD_human,17537837,"Renal renin and angiotensinogen mRNA expression were significantly decreased at birth (80 and 60%, respectively); plasma and renal RAS did not differ in conjunction with hypertension (mean increase of 14 mmHg) in young IUGR offspring; however, hypertension (mean increase of 22 mmHg) in adult IUGR offspring was associated with marked increases in renal angiotensin-converting enzyme (ACE) activity (122%) and renal renin and angiotensinogen mRNA (7-fold and 7.4-fold, respectively), but no change in renal ANG II or angiotensin type 1 receptor.",0.363794273440947,"Renal <span class=""gene"" id=""17537837-5-6-11"">renin</span> and angiotensinogen mRNA expression were significantly decreased at birth (80 and 60%, respectively); plasma and renal RAS did not differ in conjunction with <span class=""disease"" id=""17537837-5-170-182"">hypertension</span> (mean increase of 14 mmHg) in young IUGR offspring; however, <span class=""disease"" id=""17537837-5-244-256"">hypertension</span> (mean increase of 22 mmHg) in adult IUGR offspring was associated with marked increases in renal angiotensin-converting enzyme (ACE) activity (122%) and renal <span class=""gene"" id=""17537837-5-416-421"">renin</span> and angiotensinogen mRNA (7-fold and 7.4-fold, respectively), but no change in renal ANG II or angiotensin type 1 receptor.",CTD_human
17,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,5972,REN,renin,CTD_human,12600921,Endothelin-1 increases vascular superoxide via endothelin(A)-NADPH oxidase pathway in low-renin hypertension.,0.363794273440947,"Endothelin-1 increases vascular superoxide via endothelin(A)-NADPH oxidase pathway in low-<span class=""gene"" id=""12600921-0-90-95"">renin</span> <span class=""disease"" id=""12600921-0-96-108"">hypertension</span>.",CTD_human
17,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,5972,REN,renin,CTD_human,18847324,Activation of renin-angiotensin system induces osteoporosis independently of hypertension.,0.363794273440947,"Activation of <span class=""gene"" id=""18847324-0-14-19"">renin</span>-angiotensin system induces osteoporosis independently of <span class=""disease"" id=""18847324-0-77-89"">hypertension</span>.",CTD_human
3,0,Biomarker,C0022658,Kidney Diseases,group,renal disease,5972,REN,renin,CTD_human,6156352,Plasma norepinephrine levels were higher (p less than 0.01) and plasma renin activity lower (p less than 0.02) in the group with progression of renal disease.,0.21641809451815602,"Plasma norepinephrine levels were higher (p less than 0.01) and plasma <span class=""gene"" id=""6156352-7-71-76"">renin</span> activity lower (p less than 0.02) in the group with progression of <span class=""disease"" id=""6156352-7-144-157"">renal disease</span>.",CTD_human
1,0,Biomarker,C0023890,Liver Cirrhosis,disease,cirrhosis,5972,REN,renin,CTD_human,15613622,"In patients with ascites and cirrhosis, inhibition of PDE5 did not promote natriuresis but led to increased plasma levels of the renin-angiotensin-aldosterone system.",0.20054945356842604,"In patients with ascites and <span class=""disease"" id=""15613622-13-29-38"">cirrhosis</span>, inhibition of PDE5 did not promote natriuresis but led to increased plasma levels of the <span class=""gene"" id=""15613622-13-129-134"">renin</span>-angiotensin-aldosterone system.",CTD_human
2,0,Biomarker,C0027720,Nephrosis,disease,nephrosis,5972,REN,Renin,CTD_human,6358456,Renin-sodium profile in experimental nephrosis induced by puromycin aminonucleoside.,0.2,"<span class=""gene"" id=""6358456-0-0-5"">Renin</span>-sodium profile in experimental <span class=""disease"" id=""6358456-0-37-46"">nephrosis</span> induced by puromycin aminonucleoside.",CTD_human
1,0,Biomarker,C0029456,Osteoporosis,disease,osteoporosis,5972,REN,renin,CTD_human,18847324,Activation of renin-angiotensin system induces osteoporosis independently of hypertension.,0.20054945356842604,"Activation of <span class=""gene"" id=""18847324-0-14-19"">renin</span>-angiotensin system induces <span class=""disease"" id=""18847324-0-47-59"">osteoporosis</span> independently of hypertension.",CTD_human
2,0,Biomarker,C0149721,Left Ventricular Hypertrophy,disease,left ventricular hypertrophy,5972,REN,renin,CTD_human,8349331,"Systolic blood pressure, plasma renin activity, and cardiac angiotensin converting enzyme activity of L-NAME rats with left ventricular hypertrophy were significantly higher than those of the subgroup without.(ABSTRACT TRUNCATED AT 250 WORDS)",0.28741762317375397,"Systolic blood pressure, plasma <span class=""gene"" id=""8349331-6-32-37"">renin</span> activity, and cardiac angiotensin converting enzyme activity of L-NAME rats with <span class=""disease"" id=""8349331-6-119-147"">left ventricular hypertrophy</span> were significantly higher than those of the subgroup without.(ABSTRACT TRUNCATED AT 250 WORDS)",CTD_human
1,5,Biomarker,C0266313,Allanson Pantzar McLeod syndrome,disease,renal tubular dysgenesis,5972,REN,renin,CTD_human,16116425,Mutations in genes in the renin-angiotensin system are associated with autosomal recessive renal tubular dysgenesis.,0.602197814273705,"Mutations in genes in the <span class=""gene"" id=""16116425-0-26-31"">renin</span>-angiotensin system are associated with autosomal recessive <span class=""disease"" id=""16116425-0-91-115"">renal tubular dysgenesis</span>.",CTD_human;HPO;ORPHANET;UNIPROT
1,0,Biomarker,C0027708,Nephroblastoma,disease,Wilms tumor,5978,REST,REST,CTD_human,26551668,Mutations in the transcriptional repressor REST predispose to Wilms tumor.,0.600274726784213,"Mutations in the transcriptional repressor <span class=""gene"" id=""26551668-0-43-47"">REST</span> predispose to <span class=""disease"" id=""26551668-0-62-73"">Wilms tumor</span>.",CTD_human;HPO;ORPHANET
1,0,Biomarker,C0006413,Burkitt Lymphoma,disease,Burkitt lymphomas,5979,RET,RET,CTD_human,23143597,"We identified 70 genes that were recurrently mutated in Burkitt lymphomas, including ID3, GNA13, RET, PIK3R1 and the SWI/SNF genes ARID1A and SMARCA4.",0.2,"We identified 70 genes that were recurrently mutated in <span class=""disease"" id=""23143597-4-56-73"">Burkitt lymphomas</span>, including ID3, GNA13, <span class=""gene"" id=""23143597-4-97-100"">RET</span>, PIK3R1 and the SWI/SNF genes ARID1A and SMARCA4.",CTD_human
2,4,Biomarker,C0019569,Hirschsprung Disease,disease,Hirschsprung's disease,5979,RET,RET proto-oncogene,CTD_human,8114938,Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease.,0.7933995583114649,"Point mutations affecting the tyrosine kinase domain of the <span class=""gene"" id=""8114938-0-60-78"">RET proto-oncogene</span> in <span class=""disease"" id=""8114938-0-82-104"">Hirschsprung's disease</span>.",CTD_human;HPO;ORPHANET
14,33,Biomarker,C0025268,Multiple Endocrine Neoplasia Type 2a,disease,multiple endocrine neoplasia type 2A,5979,RET,RET proto-oncogene,CTD_human,8099202,Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.,0.734458206287357,"Germ-line mutations of the <span class=""gene"" id=""8099202-0-27-45"">RET proto-oncogene</span> in <span class=""disease"" id=""8099202-0-49-85"">multiple endocrine neoplasia type 2A</span>.",CTD_human;ORPHANET;UNIPROT
14,33,Biomarker,C0025268,Multiple Endocrine Neoplasia Type 2a,disease,Multiple endocrine neoplasia type 2A (MEN 2A,5979,RET,RET proto-oncogene,CTD_human,12864791,Multiple endocrine neoplasia type 2A (MEN 2A) and familial medullary thyroid carcinoma (FMTC) are genetic diseases due to activating mutations of the RET proto-oncogene.,0.734458206287357,"<span class=""disease"" id=""12864791-1-0-44"">Multiple endocrine neoplasia type 2A (MEN 2A</span>) and familial medullary thyroid carcinoma (FMTC) are genetic diseases due to activating mutations of the <span class=""gene"" id=""12864791-1-150-168"">RET proto-oncogene</span>.",CTD_human;ORPHANET;UNIPROT
1,7,Biomarker,C0031511,Pheochromocytoma,disease,pheochromocytoma,5979,RET,RET,CTD_human,12000816,"Almost one fourth of patients with apparently sporadic pheochromocytoma may be carriers of mutations; routine analysis for mutations of RET, VHL, SDHD, and SDHB is indicated to identify pheochromocytoma-associated syndromes that would otherwise be missed.",0.7732279792363709,"Almost one fourth of patients with apparently sporadic <span class=""disease"" id=""12000816-11-55-71"">pheochromocytoma</span> may be carriers of mutations; routine analysis for mutations of <span class=""gene"" id=""12000816-11-136-139"">RET</span>, VHL, SDHD, and SDHB is indicated to identify <span class=""disease"" id=""12000816-11-186-202"">pheochromocytoma</span>-associated syndromes that would otherwise be missed.",CTD_human;HPO;UNIPROT
4,4,Biomarker,C1275808,Congenital central hypoventilation,disease,Congenital central hypoventilation syndrome,5979,RET,RET,CTD_human,12086152,Congenital central hypoventilation syndrome: a novel mutation of the RET gene in an isolated case.,0.6010989071368521,"<span class=""disease"" id=""12086152-0-0-43"">Congenital central hypoventilation syndrome</span>: a novel mutation of the <span class=""gene"" id=""12086152-0-69-72"">RET</span> gene in an isolated case.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C1609433,Congenital absence of kidneys syndrome,disease,bilateral renal agenesis,5979,RET,RET,CTD_human,18252215,Mutations in RET were found in 7 of 19 fetuses with bilateral renal agenesis (37%) and 2 of 10 fetuses (20%) with unilateral agenesis.,0.40137363392106606,"Mutations in <span class=""gene"" id=""18252215-4-13-16"">RET</span> were found in 7 of 19 fetuses with <span class=""disease"" id=""18252215-4-52-76"">bilateral renal agenesis</span> (37%) and 2 of 10 fetuses (20%) with unilateral agenesis.",CTD_human;ORPHANET
14,24,Biomarker,C1833921,Familial medullary thyroid carcinoma,disease,FMTC,5979,RET,RET,CTD_human,12864791,"Among 10 MEN 2A/FMTC families, the presence of CLA was found only in patients belonging to the three families with MEN 2A and RET mutation in codon 634.",0.648077187237293,"Among 10 MEN 2A/<span class=""disease"" id=""12864791-8-16-20"">FMTC</span> families, the presence of CLA was found only in patients belonging to the three families with MEN 2A and <span class=""gene"" id=""12864791-8-126-129"">RET</span> mutation in codon 634.",CTD_human;ORPHANET;UNIPROT
14,24,Biomarker,C1833921,Familial medullary thyroid carcinoma,disease,FMTC,5979,RET,RET,CTD_human,7915165,Germline RET mutations in MEN 2A and FMTC and their detection by simple DNA diagnostic tests.,0.648077187237293,"Germline <span class=""gene"" id=""7915165-0-9-12"">RET</span> mutations in MEN 2A and <span class=""disease"" id=""7915165-0-37-41"">FMTC</span> and their detection by simple DNA diagnostic tests.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0026764,Multiple Myeloma,disease,myeloma,598,BCL2L1,Bcl-XL,CTD_human,12429644,"MM cells express multiple Bcl-2 family members, including Bcl-2, Bcl-XL, and Mcl-1, which are thought to play a key role in the survival and drug resistance of myeloma.",0.204930726738519,"MM cells express multiple Bcl-2 family members, including Bcl-2, <span class=""gene"" id=""12429644-2-65-71"">Bcl-XL</span>, and Mcl-1, which are thought to play a key role in the survival and drug resistance of <span class=""disease"" id=""12429644-2-160-167"">myeloma</span>.",CTD_human
1,0,Biomarker,C0242350,Erectile dysfunction,disease,erectile dysfunction,598,BCL2L1,Bcl-x,CTD_human,12394778,"We hypothesized that apoptosis is a downstream event in erectile dysfunction, and pro-apoptotic (Bak and Bax) and anti-apoptotic (Bcl-2 and Bcl-x) factors are involved in the etiology of aging erectile dysfunction.",0.2,"We hypothesized that apoptosis is a downstream event in <span class=""disease"" id=""12394778-3-56-76"">erectile dysfunction</span>, and pro-apoptotic (Bak and Bax) and anti-apoptotic (Bcl-2 and <span class=""gene"" id=""12394778-3-140-145"">Bcl-x</span>) factors are involved in the etiology of aging <span class=""disease"" id=""12394778-3-193-213"">erectile dysfunction</span>.",CTD_human
2,0,Biomarker,C2239176,Liver carcinoma,disease,hepatocellular carcinomas,598,BCL2L1,bcl-xs,CTD_human,11509945,"To examine the effect of the bcl-xs gene on the sequence from hepatic precancerous lesions, foci and neoplastic nodules, to hepatocellular carcinomas, Sprague-Dawley rats were given water containing 175 mg/l N-nitrosomorpholine (NNM) for 8 weeks.",0.21367891770138603,"To examine the effect of the <span class=""gene"" id=""11509945-1-29-35"">bcl-xs</span> gene on the sequence from hepatic precancerous lesions, foci and neoplastic nodules, to <span class=""disease"" id=""11509945-1-124-149"">hepatocellular carcinomas</span>, Sprague-Dawley rats were given water containing 175 mg/l N-nitrosomorpholine (NNM) for 8 weeks.",CTD_human
2,0,Therapeutic,C2239176,Liver carcinoma,disease,hepatocellular carcinomas,598,BCL2L1,bcl-xs,CTD_human,11509945,"To examine the effect of the bcl-xs gene on the sequence from hepatic precancerous lesions, foci and neoplastic nodules, to hepatocellular carcinomas, Sprague-Dawley rats were given water containing 175 mg/l N-nitrosomorpholine (NNM) for 8 weeks.",0.21367891770138603,"To examine the effect of the <span class=""gene"" id=""11509945-1-29-35"">bcl-xs</span> gene on the sequence from hepatic precancerous lesions, foci and neoplastic nodules, to <span class=""disease"" id=""11509945-1-124-149"">hepatocellular carcinomas</span>, Sprague-Dawley rats were given water containing 175 mg/l N-nitrosomorpholine (NNM) for 8 weeks.",CTD_human
2,0,Biomarker,C0035334,Retinitis Pigmentosa,disease,retinitis pigmentosa,5995,RGR,RGR,CTD_human,10581022,"Mutations in RGR, encoding a light-sensitive opsin homologue, in patients with retinitis pigmentosa.",0.605363510615002,"Mutations in <span class=""gene"" id=""10581022-0-13-16"">RGR</span>, encoding a light-sensitive opsin homologue, in patients with <span class=""disease"" id=""10581022-0-79-99"">retinitis pigmentosa</span>.",CTD_human;HPO;ORPHANET
1,0,Biomarker,C0013421,Dystonia,phenotype,dystonia,60,ACTB,beta -actin,CTD_human,16685646,"A mutation of beta -actin that alters depolymerization dynamics is associated with autosomal dominant developmental malformations, deafness, and dystonia.",0.20300763924902696,"A mutation of <span class=""gene"" id=""16685646-0-14-25"">beta -actin</span> that alters depolymerization dynamics is associated with autosomal dominant developmental malformations, deafness, and <span class=""disease"" id=""16685646-0-145-153"">dystonia</span>.",CTD_human
7,6,Biomarker,C0035334,Retinitis Pigmentosa,disease,retinitis pigmentosa,6010,RHO,rhodopsin,CTD_human,2137202,A point mutation of the rhodopsin gene in one form of retinitis pigmentosa.,0.7083397790414959,"A point mutation of the <span class=""gene"" id=""2137202-0-24-33"">rhodopsin</span> gene in one form of <span class=""disease"" id=""2137202-0-54-74"">retinitis pigmentosa</span>.",CTD_human;HPO;ORPHANET
7,6,Biomarker,C0035334,Retinitis Pigmentosa,disease,RP,6010,RHO,rhodopsin,CTD_human,18273801,"In humans, RP is in most cases associated with missense mutations in the rhodopsin gene (RHO).",0.7083397790414959,"In humans, <span class=""disease"" id=""18273801-4-11-13"">RP</span> is in most cases associated with missense mutations in the <span class=""gene"" id=""18273801-4-73-82"">rhodopsin</span> gene (RHO).",CTD_human;HPO;ORPHANET
7,6,Biomarker,C0035334,Retinitis Pigmentosa,disease,RP,6010,RHO,rhodopsin,CTD_human,9020854,"Genetic linkage between an autosomal dominant RP locus and rhodopsin, the photoreactive pigment of the rod cells, led to the identification of mutations within the rhodopsin gene in both dominant and recessive forms of RP.",0.7083397790414959,"Genetic linkage between an autosomal dominant <span class=""disease"" id=""9020854-3-46-48"">RP</span> locus and <span class=""gene"" id=""9020854-3-59-68"">rhodopsin</span>, the photoreactive pigment of the rod cells, led to the identification of mutations within the <span class=""gene"" id=""9020854-3-164-173"">rhodopsin</span> gene in both dominant and recessive forms of <span class=""disease"" id=""9020854-3-219-221"">RP</span>.",CTD_human;HPO;ORPHANET
7,6,Biomarker,C0035334,Retinitis Pigmentosa,disease,RP,6010,RHO,rhodopsin,CTD_human,19206210,"Furthermore, chelation with EDTA stabilizes the structure of both wild-type rhodopsin and the most prevalent rhodopsin RP mutation, P(23)H. These interactions suggest that homeostatic regulation of trace metal concentrations in the rod outer segment of the retina may be important both physiologically and for an important cluster of RP mutations.",0.7083397790414959,"Furthermore, chelation with EDTA stabilizes the structure of both wild-type <span class=""gene"" id=""19206210-5-76-85"">rhodopsin</span> and the most prevalent <span class=""gene"" id=""19206210-5-109-118"">rhodopsin</span> <span class=""disease"" id=""19206210-5-119-121"">RP</span> mutation, P(23)H. These interactions suggest that homeostatic regulation of trace metal concentrations in the rod outer segment of the retina may be important both physiologically and for an important cluster of <span class=""disease"" id=""19206210-5-334-336"">RP</span> mutations.",CTD_human;HPO;ORPHANET
1,0,Biomarker,C0339535,"Night blindness, congenital stationary",disease,congenital stationary night blindness,6010,RHO,rhodopsin,CTD_human,8358437,Heterozygous missense mutation in the rhodopsin gene as a cause of congenital stationary night blindness.,0.60357144819477,"Heterozygous missense mutation in the <span class=""gene"" id=""8358437-0-38-47"">rhodopsin</span> gene as a cause of <span class=""disease"" id=""8358437-0-67-104"">congenital stationary night blindness</span>.",CTD_human;HPO;ORPHANET
3,0,Biomarker,C0004096,Asthma,disease,asthmatic,6037,RNASE3,ECP,CTD_human,8874658,This study was carried out to determine whether serum eosinophil cationic protein (ECP) represents a sensitive marker for disease activity in atopic asthmatic patients during the pollen season.,0.22473182287291601,"This study was carried out to determine whether serum <span class=""gene"" id=""8874658-1-54-81"">eosinophil cationic protein</span> (<span class=""gene"" id=""8874658-1-83-86"">ECP</span>) represents a sensitive marker for disease activity in atopic <span class=""disease"" id=""8874658-1-149-158"">asthmatic</span> patients during the pollen season.",CTD_human
3,0,Biomarker,C0004096,Asthma,disease,asthmatic,6037,RNASE3,ECP,CTD_human,12587966,Serum eosinophil cationic protein (ECP) concentration was used as a surrogate marker of asthmatic inflammation.,0.22473182287291601,"Serum <span class=""gene"" id=""12587966-5-6-33"">eosinophil cationic protein</span> (<span class=""gene"" id=""12587966-5-35-38"">ECP</span>) concentration was used as a surrogate marker of <span class=""disease"" id=""12587966-5-88-97"">asthmatic</span> inflammation.",CTD_human
3,0,Biomarker,C0004096,Asthma,disease,asthmatics,6037,RNASE3,eosinophil cationic protein,CTD_human,12153692,Long-term observations of the clinical course after step down of corticosteroid inhalation therapy in adult chronic asthmatics: correlation with serum levels of eosinophil cationic protein.,0.22473182287291601,"Long-term observations of the clinical course after step down of corticosteroid inhalation therapy in adult chronic <span class=""disease"" id=""12153692-0-116-126"">asthmatics</span>: correlation with serum levels of <span class=""gene"" id=""12153692-0-161-188"">eosinophil cationic protein</span>.",CTD_human
1,0,Biomarker,C0024305,"Lymphoma, Non-Hodgkin",disease,NHL,604,BCL6,BCL-6,CTD_human,25543051,BCL-6 is a multifunctional transcriptional repressor frequently mutated in NHLs and known to regulate critical events of B cell activation and differentiation.,0.223517924775745,"<span class=""gene"" id=""25543051-5-0-5"">BCL-6</span> is a multifunctional transcriptional repressor frequently mutated in <span class=""disease"" id=""25543051-5-75-78"">NHL</span>s and known to regulate critical events of B cell activation and differentiation.",CTD_human
1,5,Biomarker,C0403555,Ochoa syndrome,disease,urofacial syndrome,60495,HPSE2,HPSE2,CTD_human,20560209,Loss-of-function mutations in HPSE2 cause the autosomal recessive urofacial syndrome.,0.48219781427370506,"Loss-of-function mutations in <span class=""gene"" id=""20560209-0-30-35"">HPSE2</span> cause the autosomal recessive <span class=""disease"" id=""20560209-0-66-84"">urofacial syndrome</span>.",CTD_human;ORPHANET
1,0,Biomarker,C0152427,Polydactyly,disease,polydactyly,60529,ALX4,Alx4,CTD_human,9847249,"First, mutation of Cart1 exacerbates Alx4-dependent polydactyly in a manner that is dependent on gene dosage.",0.2,"First, mutation of Cart1 exacerbates <span class=""gene"" id=""9847249-8-37-41"">Alx4</span>-dependent <span class=""disease"" id=""9847249-8-52-63"">polydactyly</span> in a manner that is dependent on gene dosage.",CTD_human
1,1,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,T2D,60685,ZFAND3,ZFAND3,CTD_human,22158537,"The combined analysis identified eight new T2D loci reaching genome-wide significance, which mapped in or near GLIS3, PEPD, FITM2-R3HDML-HNF4A, KCNK16, MAEA, GCC1-PAX4, PSMD6 and ZFAND3.",0.2,"The combined analysis identified eight new <span class=""disease"" id=""22158537-3-43-46"">T2D</span> loci reaching genome-wide significance, which mapped in or near GLIS3, PEPD, FITM2-R3HDML-HNF4A, KCNK16, MAEA, GCC1-PAX4, PSMD6 and <span class=""gene"" id=""22158537-3-179-185"">ZFAND3</span>.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,6091,ROBO1,ROBO1,CTD_human,18270976,"Expressions of ROBO1 (P = 0.018) and ROBO2 (P = 0.023) were significantly reduced in the autistic group; the possibility of using the altered expressions of ROBO as peripheral markers for autism, may be explored.",0.200274726784213,"Expressions of <span class=""gene"" id=""18270976-11-15-20"">ROBO1</span> (P = 0.018) and ROBO2 (P = 0.023) were significantly reduced in the <span class=""disease"" id=""18270976-11-89-97"">autistic</span> group; the possibility of using the altered expressions of ROBO as peripheral markers for <span class=""disease"" id=""18270976-11-188-194"">autism</span>, may be explored.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,6092,ROBO2,ROBO2,CTD_human,18270976,"Expressions of ROBO1 (P = 0.018) and ROBO2 (P = 0.023) were significantly reduced in the autistic group; the possibility of using the altered expressions of ROBO as peripheral markers for autism, may be explored.",0.200274726784213,"Expressions of ROBO1 (P = 0.018) and <span class=""gene"" id=""18270976-11-37-42"">ROBO2</span> (P = 0.023) were significantly reduced in the <span class=""disease"" id=""18270976-11-89-97"">autistic</span> group; the possibility of using the altered expressions of ROBO as peripheral markers for <span class=""disease"" id=""18270976-11-188-194"">autism</span>, may be explored.",CTD_human
2,0,Biomarker,C0004352,Autistic Disorder,disease,autistic,6095,RORA,RORA,CTD_human,21359227,"We further show that aromatase protein is significantly reduced in the frontal cortex of autistic subjects relative to sex- and age-matched controls, and is strongly correlated with RORA protein levels in the brain.",0.200274726784213,"We further show that aromatase protein is significantly reduced in the frontal cortex of <span class=""disease"" id=""21359227-4-89-97"">autistic</span> subjects relative to sex- and age-matched controls, and is strongly correlated with <span class=""gene"" id=""21359227-4-182-186"">RORA</span> protein levels in the brain.",CTD_human
4,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,NSCLC,6098,ROS1,ROS1,CTD_human,22215748,Crizotinib shows in vitro activity and early evidence of clinical activity in ROS1-rearranged NSCLC.,0.217582514189638,"Crizotinib shows in vitro activity and early evidence of clinical activity in <span class=""gene"" id=""22215748-13-78-82"">ROS1</span>-rearranged <span class=""disease"" id=""22215748-13-94-99"">NSCLC</span>.",CTD_human
4,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,non-small cell lung cancer,6098,ROS1,ROS1,CTD_human,22919003,Identifying and targeting ROS1 gene fusions in non-small cell lung cancer.,0.217582514189638,"Identifying and targeting <span class=""gene"" id=""22919003-0-26-30"">ROS1</span> gene fusions in <span class=""disease"" id=""22919003-0-47-73"">non-small cell lung cancer</span>.",CTD_human
4,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,NSCLC,6098,ROS1,ROS1,CTD_human,22617245,Preclinical data supports the clinical development of crizotinib for ROS1-translocated NSCLC.,0.217582514189638,"Preclinical data supports the clinical development of crizotinib for <span class=""gene"" id=""22617245-9-69-73"">ROS1</span>-translocated <span class=""disease"" id=""22617245-9-87-92"">NSCLC</span>.",CTD_human
4,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,NSCLC,6098,ROS1,ROS1,CTD_human,22585869,ROS1 gene rearrangement is identified in NSCLC.,0.217582514189638,"<span class=""gene"" id=""22585869-0-0-4"">ROS1</span> gene rearrangement is identified in <span class=""disease"" id=""22585869-0-41-46"">NSCLC</span>.",CTD_human
1,0,Biomarker,C0017638,Glioma,disease,glioma,6098,ROS1,ROS,CTD_human,19276365,These results establish a strong link between c-ROS promoter demethylation and gain of c-ROS expression and function in glioma.,0.202197814273705,"These results establish a strong link between c-<span class=""gene"" id=""19276365-8-48-51"">ROS</span> promoter demethylation and gain of c-ROS expression and function in <span class=""disease"" id=""19276365-8-120-126"">glioma</span>.",CTD_human
3,6,Biomarker,C0035334,Retinitis Pigmentosa,disease,retinitis pigmentosa,6103,RPGR,RPGR,CTD_human,12920075,"RPGR mutation associated with retinitis pigmentosa, impaired hearing, and sinorespiratory infections.",0.6616395831885171,"<span class=""gene"" id=""12920075-0-0-4"">RPGR</span> mutation associated with <span class=""disease"" id=""12920075-0-30-50"">retinitis pigmentosa</span>, impaired hearing, and sinorespiratory infections.",CTD_human;HPO;ORPHANET
1,0,Biomarker,C0242383,Age related macular degeneration,disease,macular degeneration,6103,RPGR,RPGR,CTD_human,12160730,X-linked recessive atrophic macular degeneration from RPGR mutation.,0.20328236603324,"X-linked recessive atrophic <span class=""disease"" id=""12160730-0-28-48"">macular degeneration</span> from <span class=""gene"" id=""12160730-0-54-58"">RPGR</span> mutation.",CTD_human
3,2,Biomarker,C0035334,Retinitis Pigmentosa,disease,retinitis pigmentosa,6121,RPE65,RPE65,CTD_human,16272259,"Identification of mutations in the AIPL1, CRB1, GUCY2D, RPE65, and RPGRIP1 genes in patients with juvenile retinitis pigmentosa.",0.612803580191434,"Identification of mutations in the AIPL1, CRB1, GUCY2D, <span class=""gene"" id=""16272259-0-56-61"">RPE65</span>, and RPGRIP1 genes in patients with juvenile <span class=""disease"" id=""16272259-0-107-127"">retinitis pigmentosa</span>.",CTD_human;HPO;ORPHANET
3,0,Biomarker,C0339527,Leber Congenital Amaurosis,disease,Leber's congenital amaurosis,6121,RPE65,RPE65,CTD_human,9326927,Mutations in RPE65 cause Leber's congenital amaurosis.,0.41703306062121204,"Mutations in <span class=""gene"" id=""9326927-0-13-18"">RPE65</span> cause <span class=""disease"" id=""9326927-0-25-53"">Leber's congenital amaurosis</span>.",CTD_human;ORPHANET
3,0,Biomarker,C0339527,Leber Congenital Amaurosis,disease,leber congenital amaurosis,6121,RPE65,RPE65,CTD_human,9501220,Mutations in the RPE65 gene in patients with autosomal recessive retinitis pigmentosa or leber congenital amaurosis.,0.41703306062121204,"Mutations in the <span class=""gene"" id=""9501220-0-17-22"">RPE65</span> gene in patients with autosomal recessive retinitis pigmentosa or <span class=""disease"" id=""9501220-0-89-115"">leber congenital amaurosis</span>.",CTD_human;ORPHANET
3,0,Biomarker,C0339527,Leber Congenital Amaurosis,disease,Leber congenital amaurosis,6121,RPE65,RPE65,CTD_human,19339306,"Inactivating mutations in the retinoid isomerase (RPE65) or lecithin:retinol acyltransferase (LRAT) genes cause Leber congenital amaurosis (LCA), a severe visual impairment in humans.",0.41703306062121204,"Inactivating mutations in the retinoid isomerase (<span class=""gene"" id=""19339306-1-50-55"">RPE65</span>) or lecithin:retinol acyltransferase (LRAT) genes cause <span class=""disease"" id=""19339306-1-112-138"">Leber congenital amaurosis</span> (LCA), a severe visual impairment in humans.",CTD_human;ORPHANET
1,0,Biomarker,C0854723,Retinal Dystrophies,group,retinal dystrophy,6121,RPE65,RPE65,CTD_human,9326941,Mutations in RPE65 cause autosomal recessive childhood-onset severe retinal dystrophy.,0.205769262468475,"Mutations in <span class=""gene"" id=""9326941-0-13-18"">RPE65</span> cause autosomal recessive childhood-onset severe <span class=""disease"" id=""9326941-0-68-85"">retinal dystrophy</span>.",CTD_human
1,0,Biomarker,C1961099,Precursor T-Cell Lymphoblastic Leukemia-Lymphoma,disease,T-cell acute lymphoblastic leukemia,6125,RPL5,RPL5,CTD_human,23263491,Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia.,0.200274726784213,"Exome sequencing identifies mutation in CNOT3 and ribosomal genes <span class=""gene"" id=""23263491-0-66-70"">RPL5</span> and RPL10 in <span class=""disease"" id=""23263491-0-84-119"">T-cell acute lymphoblastic leukemia</span>.",CTD_human
1,0,Biomarker,C0005699,Blast Phase,disease,blast crisis,613,BCR,CML,CTD_human,21570118,We also observed satisfied therapy effects of As(2)O(3) and imatinib on patients with CML blast crisis.,0.226099044500245,"We also observed satisfied therapy effects of As(2)O(3) and imatinib on patients with <span class=""gene"" id=""21570118-5-86-89"">CML</span> <span class=""disease"" id=""21570118-5-90-102"">blast crisis</span>.",CTD_human
3,0,Biomarker,C0023473,"Myeloid Leukemia, Chronic",disease,chronic myeloid leukemia,613,BCR,BCR,CTD_human,21908430,The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia.,0.755869781131734,"The <span class=""gene"" id=""21908430-0-4-7"">BCR</span>-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in <span class=""disease"" id=""21908430-0-131-155"">chronic myeloid leukemia</span>.",CTD_human;HPO;ORPHANET
3,0,Biomarker,C0023473,"Myeloid Leukemia, Chronic",disease,CML,613,BCR,BCR,CTD_human,18673174,"However, 95% of CML patients have the ABL gene from chromosome 9 fused with the breakpoint cluster (BCR) gene from chromosome 22, resulting in a short chromosome known as the Philadelphia chromosome.",0.755869781131734,"However, 95% of <span class=""disease"" id=""18673174-3-16-19"">CML</span> patients have the ABL gene from chromosome 9 fused with the breakpoint cluster (<span class=""gene"" id=""18673174-3-100-103"">BCR</span>) gene from chromosome 22, resulting in a short chromosome known as the Philadelphia chromosome.",CTD_human;HPO;ORPHANET
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,6134,RPL10,RPL10,CTD_human,16940977,Mutations in the ribosomal protein gene RPL10 suggest a novel modulating disease mechanism for autism.,0.202956482091714,"Mutations in the ribosomal protein gene <span class=""gene"" id=""16940977-0-40-45"">RPL10</span> suggest a novel modulating disease mechanism for <span class=""disease"" id=""16940977-0-95-101"">autism</span>.",CTD_human
1,0,Biomarker,C1961099,Precursor T-Cell Lymphoblastic Leukemia-Lymphoma,disease,T-cell acute lymphoblastic leukemia,6134,RPL10,RPL10,CTD_human,23263491,Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia.,0.20054945356842604,"Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and <span class=""gene"" id=""23263491-0-75-80"">RPL10</span> in <span class=""disease"" id=""23263491-0-84-119"">T-cell acute lymphoblastic leukemia</span>.",CTD_human
1,0,Biomarker,C0007758,Cerebellar Ataxia,phenotype,ataxia,6157,RPL27A,Rpl27a,CTD_human,21674502,Rpl27a mutation in the sooty foot ataxia mouse phenocopies high p53 mouse models.,0.2,"<span class=""gene"" id=""21674502-0-0-6"">Rpl27a</span> mutation in the sooty foot <span class=""disease"" id=""21674502-0-34-40"">ataxia</span> mouse phenocopies high p53 mouse models.",CTD_human
1,0,Biomarker,C0030312,Pancytopenia,disease,pancytopenia,6157,RPL27A,Rpl27a,CTD_human,21674502,"We present a mutation in the ribosomal protein Rpl27a gene (sooty foot ataxia mice), isolated through a sensitized N-ethyl-N-nitrosourea (ENU) mutagenesis screen for p53 pathway defects, that shares striking phenotypic similarities with high p53 mouse models, including cerebellar ataxia, pancytopenia and epidermal hyperpigmentation.",0.2,"We present a mutation in the ribosomal protein <span class=""gene"" id=""21674502-2-47-53"">Rpl27a</span> gene (sooty foot ataxia mice), isolated through a sensitized N-ethyl-N-nitrosourea (ENU) mutagenesis screen for p53 pathway defects, that shares striking phenotypic similarities with high p53 mouse models, including cerebellar ataxia, <span class=""disease"" id=""21674502-2-289-301"">pancytopenia</span> and epidermal hyperpigmentation.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,6194,RPS6,ribosomal protein S6,CTD_human,21147110,"In HCC cell lines, the AKT-mammalian target of rapamycin complex 1-ribosomal protein S6 pathway promoted lipogenesis via transcriptional and post-transcriptional mechanisms that included inhibition of fatty acid synthase ubiquitination by the USP2a de-ubiquitinase and disruption of the SREBP1 and SREBP2 degradation complexes.",0.200274726784213,"In <span class=""disease"" id=""21147110-8-3-6"">HCC</span> cell lines, the AKT-mammalian target of rapamycin complex 1-<span class=""gene"" id=""21147110-8-67-87"">ribosomal protein S6</span> pathway promoted lipogenesis via transcriptional and post-transcriptional mechanisms that included inhibition of fatty acid synthase ubiquitination by the USP2a de-ubiquitinase and disruption of the SREBP1 and SREBP2 degradation complexes.",CTD_human
1,0,Biomarker,C1510586,Autism Spectrum Disorders,disease,ASD,619554,MIR486-1,miR-486,CTD_human,20868653,"Our analysis identified several novel dysregulated genes and miRNAs in ASD compared with controls, including HEY1, SOX9, miR-486 and miR-181b.",0.2,"Our analysis identified several novel dysregulated genes and miRNAs in <span class=""disease"" id=""20868653-6-71-74"">ASD</span> compared with controls, including HEY1, SOX9, <span class=""gene"" id=""20868653-6-121-128"">miR-486</span> and miR-181b.",CTD_human
6,11,Biomarker,C0265252,Coffin-Lowry syndrome,disease,Coffin-Lowry syndrome,6197,RPS6KA3,Rsk-2,CTD_human,8955270,Mutations in the kinase Rsk-2 associated with Coffin-Lowry syndrome.,0.7125264871455079,"Mutations in the kinase <span class=""gene"" id=""8955270-0-24-29"">Rsk-2</span> associated with <span class=""disease"" id=""8955270-0-46-67"">Coffin-Lowry syndrome</span>.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,6197,RPS6KA3,RPS6KA3,CTD_human,22561517,"We found new recurrent alterations in four genes (ARID1A, RPS6KA3, NFE2L2 and IRF2) not previously described in HCC.",0.200274726784213,"We found new recurrent alterations in four genes (ARID1A, <span class=""gene"" id=""22561517-4-58-65"">RPS6KA3</span>, NFE2L2 and IRF2) not previously described in <span class=""disease"" id=""22561517-4-112-115"">HCC</span>.",CTD_human
1,0,Biomarker,C0079744,Diffuse Large B-Cell Lymphoma,disease,DLBCL,6198,RPS6KB1,RPS6KB1,CTD_human,19223503,Simultaneously targeting the RPS6KB1 and CDC2 products phospho-p70S6K/p85S6K and cdc2/cdk1 is very effective in inhibiting DLBCL proliferation and overcoming drug resistance.,0.20054945356842604,"Simultaneously targeting the <span class=""gene"" id=""19223503-10-29-36"">RPS6KB1</span> and CDC2 products phospho-p70S6K/p85S6K and cdc2/cdk1 is very effective in inhibiting <span class=""disease"" id=""19223503-10-123-128"">DLBCL</span> proliferation and overcoming drug resistance.",CTD_human
1,0,Biomarker,C1458155,Mammary Neoplasms,group,breast tumors,6199,RPS6KB2,S6K2,CTD_human,20953835,S6K1/S6K2 gene copy number was determined by real-time PCR in 207 stage II breast tumors and S6K2 protein expression was investigated by immunohistochemistry in 792 node-negative breast cancers.,0.20054945356842604,"S6K1/<span class=""gene"" id=""20953835-5-5-9"">S6K2</span> gene copy number was determined by real-time PCR in 207 stage II <span class=""disease"" id=""20953835-5-75-88"">breast tumors</span> and <span class=""gene"" id=""20953835-5-93-97"">S6K2</span> protein expression was investigated by immunohistochemistry in 792 node-negative breast cancers.",CTD_human
1,0,Biomarker,C1260899,"Anemia, Diamond-Blackfan",disease,Diamond-Blackfan anemia,6218,RPS17,RPS17,CTD_human,17647292,Ribosomal protein S17 gene (RPS17) is mutated in Diamond-Blackfan anemia.,0.407337755261807,"<span class=""gene"" id=""17647292-0-0-21"">Ribosomal protein S17</span> gene (<span class=""gene"" id=""17647292-0-28-33"">RPS17</span>) is mutated in <span class=""disease"" id=""17647292-0-49-72"">Diamond-Blackfan anemia</span>.",CTD_human;ORPHANET
1,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,NSCLC,6236,RRAD,RRAD,CTD_human,17195088,"Loss of RRAD expression was found in 14 of 20 (70%) NSCLC cell lines, 11 of 11 (100%) SCLC cell lines, and 8 of 10 (80%) breast cancer cell lines; expression was not affected in normal bronchial and mammary epithelial cells.",0.20054945356842604,"Loss of <span class=""gene"" id=""17195088-4-8-12"">RRAD</span> expression was found in 14 of 20 (70%) <span class=""disease"" id=""17195088-4-52-57"">NSCLC</span> cell lines, 11 of 11 (100%) SCLC cell lines, and 8 of 10 (80%) breast cancer cell lines; expression was not affected in normal bronchial and mammary epithelial cells.",CTD_human
1,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,non-small cell lung cancer,6240,RRM1,RRM1,CTD_human,21496433,[Relations between RRM1 protein expression levels and effects of gemcitabine and cisplatin chemotherapy in advanced non-small cell lung cancer patients].,0.21614336773394296,"[Relations between <span class=""gene"" id=""21496433-0-19-23"">RRM1</span> protein expression levels and effects of gemcitabine and cisplatin chemotherapy in advanced <span class=""disease"" id=""21496433-0-116-142"">non-small cell lung cancer</span> patients].",CTD_human
1,0,Biomarker,C0206686,Adrenocortical carcinoma,disease,adrenocortical cancer,6240,RRM1,RRM1,CTD_human,22547773,Ribonucleotide reductase large subunit (RRM1) gene expression may predict efficacy of adjuvant mitotane in adrenocortical cancer.,0.20054945356842604,"<span class=""gene"" id=""22547773-0-0-38"">Ribonucleotide reductase large subunit</span> (<span class=""gene"" id=""22547773-0-40-44"">RRM1</span>) gene expression may predict efficacy of adjuvant mitotane in <span class=""disease"" id=""22547773-0-107-128"">adrenocortical cancer</span>.",CTD_human
49,94,Biomarker,C0024591,Malignant hyperpyrexia due to anesthesia,disease,MHS,6261,RYR1,RYR1,CTD_human,19191329,"The 13 remaining MHS patients presented no known variants, neither in RYR1 nor in the CACNA1S binding regions to RYR1.",0.7985988933466451,"The 13 remaining <span class=""disease"" id=""19191329-8-17-20"">MHS</span> patients presented no known variants, neither in <span class=""gene"" id=""19191329-8-70-74"">RYR1</span> nor in the CACNA1S binding regions to <span class=""gene"" id=""19191329-8-113-117"">RYR1</span>.",CTD_human;HPO;ORPHANET;UNIPROT
49,94,Biomarker,C0024591,Malignant hyperpyrexia due to anesthesia,disease,malignant hyperthermia,6261,RYR1,RYR1,CTD_human,14708096,"A new mutation in the skeletal ryanodine receptor gene (RYR1) is potentially causative of malignant hyperthermia, central core disease, and severe skeletal malformation.",0.7985988933466451,"A new mutation in the skeletal ryanodine receptor gene (<span class=""gene"" id=""14708096-0-56-60"">RYR1</span>) is potentially causative of <span class=""disease"" id=""14708096-0-90-112"">malignant hyperthermia</span>, central core disease, and severe skeletal malformation.",CTD_human;HPO;ORPHANET;UNIPROT
49,94,Biomarker,C0024591,Malignant hyperpyrexia due to anesthesia,disease,malignant hyperthermia,6261,RYR1,RyR1,CTD_human,11695996,Thus amino acids 2163-2458 form a regulatory domain (malignant hyperthermia regulatory domain 2) that regulates caffeine and 4-chloro-m-cresol sensitivity of RyR1.,0.7985988933466451,"Thus amino acids 2163-2458 form a regulatory domain (<span class=""disease"" id=""11695996-11-53-75"">malignant hyperthermia</span> regulatory domain 2) that regulates caffeine and 4-chloro-m-cresol sensitivity of <span class=""gene"" id=""11695996-11-158-162"">RyR1</span>.",CTD_human;HPO;ORPHANET;UNIPROT
49,94,Biomarker,C0024591,Malignant hyperpyrexia due to anesthesia,disease,MH,6261,RYR1,RYR1,CTD_human,14570802,Central core disease and malignant hyperthermia (MH) are both associated with mutations in the RYR1 gene.,0.7985988933466451,"Central core disease and <span class=""disease"" id=""14570802-1-25-47"">malignant hyperthermia</span> (<span class=""disease"" id=""14570802-1-49-51"">MH</span>) are both associated with mutations in the <span class=""gene"" id=""14570802-1-95-99"">RYR1</span> gene.",CTD_human;HPO;ORPHANET;UNIPROT
49,94,Biomarker,C0024591,Malignant hyperpyrexia due to anesthesia,disease,MH,6261,RYR1,RYR1,CTD_human,19191333,"Cells expressing RYR1 variants in the N-terminal and in the central region of the protein (p.Arg530His, p.Arg2163Pro, p.Asn2342Ser, p.Glu2371Gly and p.Arg2454His) displayed higher activity compared with controls; this could account for the MH-susceptible phenotype.",0.7985988933466451,"Cells expressing <span class=""gene"" id=""19191333-6-17-21"">RYR1</span> variants in the N-terminal and in the central region of the protein (p.Arg530His, p.Arg2163Pro, p.Asn2342Ser, p.Glu2371Gly and p.Arg2454His) displayed higher activity compared with controls; this could account for the <span class=""disease"" id=""19191333-6-240-242"">MH</span>-susceptible phenotype.",CTD_human;HPO;ORPHANET;UNIPROT
49,94,Biomarker,C0024591,Malignant hyperpyrexia due to anesthesia,disease,MH,6261,RYR1,RyR1,CTD_human,17707769,These findings demonstrate that RyR1-mediated calcium signaling modifies diverse DC responses and suggest the feasibility of using DC preparations for the diagnosis of MH.,0.7985988933466451,"These findings demonstrate that <span class=""gene"" id=""17707769-6-32-36"">RyR1</span>-mediated calcium signaling modifies diverse DC responses and suggest the feasibility of using DC preparations for the diagnosis of <span class=""disease"" id=""17707769-6-168-170"">MH</span>.",CTD_human;HPO;ORPHANET;UNIPROT
37,100,Biomarker,C0751951,Central Core Myopathy (disorder),disease,Central core disease,6261,RYR1,RYR1,CTD_human,14570802,Central core disease and malignant hyperthermia (MH) are both associated with mutations in the RYR1 gene.,0.7257133727877371,"<span class=""disease"" id=""14570802-1-0-20"">Central core disease</span> and malignant hyperthermia (MH) are both associated with mutations in the <span class=""gene"" id=""14570802-1-95-99"">RYR1</span> gene.",CTD_human;ORPHANET;UNIPROT
37,100,Biomarker,C0751951,Central Core Myopathy (disorder),disease,central core disease,6261,RYR1,RYR1,CTD_human,14708096,"A new mutation in the skeletal ryanodine receptor gene (RYR1) is potentially causative of malignant hyperthermia, central core disease, and severe skeletal malformation.",0.7257133727877371,"A new mutation in the skeletal ryanodine receptor gene (<span class=""gene"" id=""14708096-0-56-60"">RYR1</span>) is potentially causative of malignant hyperthermia, <span class=""disease"" id=""14708096-0-114-134"">central core disease</span>, and severe skeletal malformation.",CTD_human;ORPHANET;UNIPROT
12,36,Biomarker,C1631597,"VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 1 (disorder)",disease,CPVT,6262,RYR2,RyR2,CTD_human,20080988,Isolated murine ventricular myocytes harbouring a human RyR2 mutation (RyR2(R4496C+/-)) associated with CPVT were investigated in the absence and presence of 1 micromol/L JTV-519 (RyR2 stabilizer) followed by 100 micromol/L ouabain intervention to increase cytosolic [Na(+)] and SR Ca(2+) load.,0.706099044500245,"Isolated murine ventricular myocytes harbouring a human <span class=""gene"" id=""20080988-4-56-60"">RyR2</span> mutation (<span class=""gene"" id=""20080988-4-71-75"">RyR2</span>(R4496C+/-)) associated with <span class=""disease"" id=""20080988-4-104-108"">CPVT</span> were investigated in the absence and presence of 1 micromol/L JTV-519 (<span class=""gene"" id=""20080988-4-180-184"">RyR2</span> stabilizer) followed by 100 micromol/L ouabain intervention to increase cytosolic [Na(+)] and SR Ca(2+) load.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0002395,Alzheimer's Disease,disease,AD,627,BDNF,BDNF,CTD_human,17344400,"Thus, oligomeric Abeta(1-42) could compromise neuronal function, causing memory loss and cognitive dysfunction by downregulation of BDNF in AD.",0.38637929125569,"Thus, oligomeric Abeta(1-42) could compromise neuronal function, causing memory loss and cognitive dysfunction by downregulation of <span class=""gene"" id=""17344400-12-132-136"">BDNF</span> in <span class=""disease"" id=""17344400-12-140-142"">AD</span>.",CTD_human
2,0,Biomarker,C0004352,Autistic Disorder,disease,autism,627,BDNF,BDNF,CTD_human,20662941,Increased BDNF levels and NTRK2 gene association suggest a disruption of BDNF/TrkB signaling in autism.,0.21560659081120997,"Increased <span class=""gene"" id=""20662941-0-10-14"">BDNF</span> levels and NTRK2 gene association suggest a disruption of <span class=""gene"" id=""20662941-0-73-77"">BDNF</span>/TrkB signaling in <span class=""disease"" id=""20662941-0-96-102"">autism</span>.",CTD_human
2,0,Biomarker,C0004352,Autistic Disorder,disease,autism,627,BDNF,BDNF,CTD_human,17349978,Genetic analyses of the brain-derived neurotrophic factor (BDNF) gene in autism.,0.21560659081120997,"Genetic analyses of the <span class=""gene"" id=""17349978-0-24-57"">brain-derived neurotrophic factor</span> (<span class=""gene"" id=""17349978-0-59-63"">BDNF</span>) gene in <span class=""disease"" id=""17349978-0-73-79"">autism</span>.",CTD_human
7,0,Biomarker,C0005586,Bipolar Disorder,disease,bipolar illness,627,BDNF,BDNF,CTD_human,19018715,"This paper describes a relationship between response to lithium prophylaxis and polymorphisms of two functionally connected genes: BDNF and NTRK2, in bipolar illness.",0.516285637538083,"This paper describes a relationship between response to lithium prophylaxis and polymorphisms of two functionally connected genes: <span class=""gene"" id=""19018715-2-131-135"">BDNF</span> and NTRK2, in <span class=""disease"" id=""19018715-2-150-165"">bipolar illness</span>.",CTD_human;PSYGENET
1,0,Biomarker,C0014544,Epilepsy,disease,epilepsy,627,BDNF,BDNF,CTD_human,15282290,"Together, these results suggest that dendritic accumulation of BDNF mRNA and protein plays a critical role in the cellular changes leading to epilepsy.",0.2121661676857,"Together, these results suggest that dendritic accumulation of <span class=""gene"" id=""15282290-7-63-67"">BDNF</span> mRNA and protein plays a critical role in the cellular changes leading to <span class=""disease"" id=""15282290-7-142-150"">epilepsy</span>.",CTD_human
1,0,Biomarker,C0014549,Tonic-Clonic Epilepsy,disease,tonic-clonic convulsions,627,BDNF,BDNF,CTD_human,16023256,"At 4 h following pilocarpine-induced seizures, expression of NGF, BDNF, HB-EGF, and FGF-2 increased only in the mice manifesting tonic-clonic convulsions and not in mice without seizures.",0.2,"At 4 h following pilocarpine-induced seizures, expression of NGF, <span class=""gene"" id=""16023256-5-66-70"">BDNF</span>, HB-EGF, and FGF-2 increased only in the mice manifesting <span class=""disease"" id=""16023256-5-129-153"">tonic-clonic convulsions</span> and not in mice without seizures.",CTD_human
1,1,Biomarker,C0030567,Parkinson Disease,disease,Parkinson's disease,627,BDNF,neurotrophin,CTD_human,19276553,Brain insulin-like growth factor and neurotrophin resistance in Parkinson's disease and dementia with Lewy bodies: potential role of manganese neurotoxicity.,0.251405674232974,"Brain insulin-like growth factor and <span class=""gene"" id=""19276553-0-37-49"">neurotrophin</span> resistance in <span class=""disease"" id=""19276553-0-64-83"">Parkinson's disease</span> and dementia with Lewy bodies: potential role of manganese neurotoxicity.",CTD_human
4,0,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,627,BDNF,brain-derived neurotrophic factor,CTD_human,17442489,Serum levels of brain-derived neurotrophic factor in patients with schizophrenia and bipolar disorder.,0.382981452563146,"Serum levels of <span class=""gene"" id=""17442489-0-16-49"">brain-derived neurotrophic factor</span> in patients with <span class=""disease"" id=""17442489-0-67-80"">schizophrenia</span> and bipolar disorder.",CTD_human
4,0,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,627,BDNF,BDNF,CTD_human,18408624,BDNF gene is a genetic risk factor for schizophrenia and is related to the chlorpromazine-induced extrapyramidal syndrome in the Chinese population.,0.382981452563146,"<span class=""gene"" id=""18408624-0-0-4"">BDNF</span> gene is a genetic risk factor for <span class=""disease"" id=""18408624-0-39-52"">schizophrenia</span> and is related to the chlorpromazine-induced extrapyramidal syndrome in the Chinese population.",CTD_human
4,0,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,627,BDNF,BDNF,CTD_human,12951204,Our finding suggests that this BDNF-gene Val66Met polymorphism may be related to schizophrenia pathogenesis in patients responsive to clozapine treatment.,0.382981452563146,"Our finding suggests that this <span class=""gene"" id=""12951204-7-31-35"">BDNF</span>-gene Val66Met polymorphism may be related to <span class=""disease"" id=""12951204-7-81-94"">schizophrenia</span> pathogenesis in patients responsive to clozapine treatment.",CTD_human
3,0,Biomarker,C0036572,Seizures,phenotype,seizure,627,BDNF,BDNF,CTD_human,15781040,"PRI-2191 alone had no effect on gene expression, but it enhanced the seizure-evoked expression of HSP-70, had an opposite effect on BDNF mRNA level and did not affect prepro-TRH mRNA level.",0.20357144819477,"PRI-2191 alone had no effect on gene expression, but it enhanced the <span class=""disease"" id=""15781040-7-69-76"">seizure</span>-evoked expression of HSP-70, had an opposite effect on <span class=""gene"" id=""15781040-7-132-136"">BDNF</span> mRNA level and did not affect prepro-TRH mRNA level.",CTD_human
3,0,Biomarker,C0036572,Seizures,phenotype,seizures,627,BDNF,brain derived neurotrophic factor,CTD_human,9073163,Induction of brain derived neurotrophic factor mRNA by seizures in neonatal and juvenile rat brain.,0.20357144819477,"Induction of <span class=""gene"" id=""9073163-0-13-46"">brain derived neurotrophic factor</span> mRNA by <span class=""disease"" id=""9073163-0-55-63"">seizures</span> in neonatal and juvenile rat brain.",CTD_human
3,0,Therapeutic,C0036572,Seizures,phenotype,seizures,627,BDNF,BDNF,CTD_human,21269288,Localized overexpression of FGF-2 and BDNF in hippocampus reduces mossy fiber sprouting and spontaneous seizures up to 4 weeks after pilocarpine-induced status epilepticus.,0.20357144819477,"Localized overexpression of FGF-2 and <span class=""gene"" id=""21269288-0-38-42"">BDNF</span> in hippocampus reduces mossy fiber sprouting and spontaneous <span class=""disease"" id=""21269288-0-104-112"">seizures</span> up to 4 weeks after pilocarpine-induced status epilepticus.",CTD_human
3,0,Biomarker,C0036572,Seizures,phenotype,seizures,627,BDNF,BDNF,CTD_human,21269288,Localized overexpression of FGF-2 and BDNF in hippocampus reduces mossy fiber sprouting and spontaneous seizures up to 4 weeks after pilocarpine-induced status epilepticus.,0.20357144819477,"Localized overexpression of FGF-2 and <span class=""gene"" id=""21269288-0-38-42"">BDNF</span> in hippocampus reduces mossy fiber sprouting and spontaneous <span class=""disease"" id=""21269288-0-104-112"">seizures</span> up to 4 weeks after pilocarpine-induced status epilepticus.",CTD_human
3,0,Therapeutic,C0036572,Seizures,phenotype,seizure,627,BDNF,BDNF,CTD_human,15781040,"PRI-2191 alone had no effect on gene expression, but it enhanced the seizure-evoked expression of HSP-70, had an opposite effect on BDNF mRNA level and did not affect prepro-TRH mRNA level.",0.20357144819477,"PRI-2191 alone had no effect on gene expression, but it enhanced the <span class=""disease"" id=""15781040-7-69-76"">seizure</span>-evoked expression of HSP-70, had an opposite effect on <span class=""gene"" id=""15781040-7-132-136"">BDNF</span> mRNA level and did not affect prepro-TRH mRNA level.",CTD_human
3,0,Therapeutic,C0036572,Seizures,phenotype,seizures,627,BDNF,brain derived neurotrophic factor,CTD_human,9073163,Induction of brain derived neurotrophic factor mRNA by seizures in neonatal and juvenile rat brain.,0.20357144819477,"Induction of <span class=""gene"" id=""9073163-0-13-46"">brain derived neurotrophic factor</span> mRNA by <span class=""disease"" id=""9073163-0-55-63"">seizures</span> in neonatal and juvenile rat brain.",CTD_human
2,0,Biomarker,C0038220,Status Epilepticus,disease,SE,627,BDNF,neurotrophin,CTD_human,8635431,These results provide a complete description of changes in mRNA levels of neurotrophins and their receptors in the forebrain after SE and supply additional data supporting the view that neurotrophin gene expression is related to abnormal neuronal activity.,0.28082418035263895,"These results provide a complete description of changes in mRNA levels of neurotrophins and their receptors in the forebrain after <span class=""disease"" id=""8635431-9-131-133"">SE</span> and supply additional data supporting the view that <span class=""gene"" id=""8635431-9-186-198"">neurotrophin</span> gene expression is related to abnormal neuronal activity.",CTD_human
2,0,Biomarker,C0038220,Status Epilepticus,disease,status epilepticus,627,BDNF,BDNF,CTD_human,8821376,"Cellular hybridization for BDNF, trkB, and NGF mRNAs and BDNF-immunoreactivity in rat forebrain after pilocarpine-induced status epilepticus.",0.28082418035263895,"Cellular hybridization for <span class=""gene"" id=""8821376-0-27-31"">BDNF</span>, trkB, and NGF mRNAs and <span class=""gene"" id=""8821376-0-57-61"">BDNF</span>-immunoreactivity in rat forebrain after pilocarpine-induced <span class=""disease"" id=""8821376-0-122-140"">status epilepticus</span>.",CTD_human
1,0,Biomarker,C3714756,Intellectual Disability,group,mental retardation,627,BDNF,BDNF,CTD_human,11357950,"Neonatal concentrations of VIP, CGRP, BDNF, and NT4/5 were higher (ANOVA, all p values < 0.0001 by Scheffe test for pairwise differences) in children in the autistic spectrum and in those with mental retardation without autism than in control children.",0.40137363392106606,"Neonatal concentrations of VIP, CGRP, <span class=""gene"" id=""11357950-3-38-42"">BDNF</span>, and NT4/5 were higher (ANOVA, all p values &lt; 0.0001 by Scheffe test for pairwise differences) in children in the autistic spectrum and in those with <span class=""disease"" id=""11357950-3-193-211"">mental retardation</span> without autism than in control children.",CTD_human;HPO
1,0,Biomarker,C0007222,Cardiovascular Diseases,group,cardiovascular disease,6272,SORT1,SORT1,CTD_human,25805502,Genetic variation of SORT1 was strongly associated with cardiovascular disease risk in humans.,0.20082418035263896,"Genetic variation of <span class=""gene"" id=""25805502-3-21-26"">SORT1</span> was strongly associated with <span class=""disease"" id=""25805502-3-56-78"">cardiovascular disease</span> risk in humans.",CTD_human
1,0,Biomarker,C0025149,Medulloblastoma,disease,medulloblastomas,6275,S100A4,S100A4,CTD_human,17579622,"Assessment of these genes in the non-neoplastic cerebellum (from which medulloblastomas develop) revealed strong somatic methylation affecting S100A2 and S100A4, whereas S100A6 and S100A10 were unmethylated.",0.20328236603324,"Assessment of these genes in the non-neoplastic cerebellum (from which <span class=""disease"" id=""17579622-5-71-87"">medulloblastomas</span> develop) revealed strong somatic methylation affecting S100A2 and <span class=""gene"" id=""17579622-5-154-160"">S100A4</span>, whereas S100A6 and S100A10 were unmethylated.",CTD_human
2,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastasis,6275,S100A4,S100A4,CTD_human,21685359,Niclosamide inhibits S100A4-induced metastasis formation in a mouse model of colon cancer and has therapeutic potential.,0.245561580047423,"Niclosamide inhibits <span class=""gene"" id=""21685359-11-21-27"">S100A4</span>-induced <span class=""disease"" id=""21685359-11-36-46"">metastasis</span> formation in a mouse model of colon cancer and has therapeutic potential.",CTD_human
1,0,Biomarker,C0025149,Medulloblastoma,disease,medulloblastoma,6277,S100A6,S100A6,CTD_human,17579622,"Assessed against these normal tissue-specific methylation states, S100A6 and S100A10 demonstrated tumour-specific hypermethylation in medulloblastoma primary tumours (5 out of 40 and 4 out of 35, respectively, both 12%) and cell lines (both 7 out of 9, 78%), which was associated with their transcriptional silencing.",0.200274726784213,"Assessed against these normal tissue-specific methylation states, <span class=""gene"" id=""17579622-6-66-72"">S100A6</span> and S100A10 demonstrated tumour-specific hypermethylation in <span class=""disease"" id=""17579622-6-134-149"">medulloblastoma</span> primary tumours (5 out of 40 and 4 out of 35, respectively, both 12%) and cell lines (both 7 out of 9, 78%), which was associated with their transcriptional silencing.",CTD_human
1,0,Biomarker,C0033860,Psoriasis,disease,psoriasis,6278,S100A7,Psoriasin,CTD_human,18194266,"Psoriasin, an Escherichia coli-cidal antimicrobial protein, has been found to be overexpressed in psoriasis, a skin disease characterized by infiltration of neutrophils.",0.203846174978983,"<span class=""gene"" id=""18194266-2-0-9"">Psoriasin</span>, an Escherichia coli-cidal antimicrobial protein, has been found to be overexpressed in <span class=""disease"" id=""18194266-2-98-107"">psoriasis</span>, a skin disease characterized by infiltration of neutrophils.",CTD_human
3,0,Biomarker,C0011581,Depressive disorder,disease,depression,6281,S100A10,P11,CTD_human,21682946,Antidepressant treatment is associated with epigenetic alterations in the promoter of P11 in a genetic model of depression.,0.48219781427370506,"Antidepressant treatment is associated with epigenetic alterations in the promoter of <span class=""gene"" id=""21682946-0-86-89"">P11</span> in a genetic model of <span class=""disease"" id=""21682946-0-112-122"">depression</span>.",CTD_human;PSYGENET
1,0,Biomarker,C0025149,Medulloblastoma,disease,medulloblastoma,6281,S100A10,S100A10,CTD_human,17579622,"Assessed against these normal tissue-specific methylation states, S100A6 and S100A10 demonstrated tumour-specific hypermethylation in medulloblastoma primary tumours (5 out of 40 and 4 out of 35, respectively, both 12%) and cell lines (both 7 out of 9, 78%), which was associated with their transcriptional silencing.",0.200274726784213,"Assessed against these normal tissue-specific methylation states, S100A6 and <span class=""gene"" id=""17579622-6-77-84"">S100A10</span> demonstrated tumour-specific hypermethylation in <span class=""disease"" id=""17579622-6-134-149"">medulloblastoma</span> primary tumours (5 out of 40 and 4 out of 35, respectively, both 12%) and cell lines (both 7 out of 9, 78%), which was associated with their transcriptional silencing.",CTD_human
6,0,Biomarker,C0005586,Bipolar Disorder,disease,bipolar disorder,6285,S100B,S100B,CTD_human,15581912,Our findings reinforce the role of astroglial cells in the pathogenesis of bipolar disorder and S100B protein as a marker of bipolar mania.,0.40268175530750105,"Our findings reinforce the role of astroglial cells in the pathogenesis of <span class=""disease"" id=""15581912-5-75-91"">bipolar disorder</span> and <span class=""gene"" id=""15581912-5-96-101"">S100B</span> protein as a marker of bipolar mania.",CTD_human;PSYGENET
1,0,Biomarker,C0027051,Myocardial Infarction,disease,myocardial infarction,6285,S100B,S100beta,CTD_human,9788975,We now extend this work by showing that S100beta is induced in hearts of human subjects after myocardial infarction.,0.201373633921065,"We now extend this work by showing that <span class=""gene"" id=""9788975-2-40-48"">S100beta</span> is induced in hearts of human subjects after <span class=""disease"" id=""9788975-2-94-115"">myocardial infarction</span>.",CTD_human
1,0,Biomarker,C0032460,Polycystic Ovary Syndrome,disease,PCOS,6286,S100P,S100P,CTD_human,21411543,"Progesterone-regulated genes, including mitogen-inducible gene 6 (MIG6), leukemia inhibitory factor (LIF), GRB2-associated binding protein 1 (GAB1), S100P, and claudin-4 were significantly lower in PCOS endometrium; whereas cell proliferation genes, such as Anillin and cyclin B1, were up-regulated.",0.2,"Progesterone-regulated genes, including mitogen-inducible gene 6 (MIG6), leukemia inhibitory factor (LIF), GRB2-associated binding protein 1 (GAB1), <span class=""gene"" id=""21411543-11-149-154"">S100P</span>, and claudin-4 were significantly lower in <span class=""disease"" id=""21411543-11-198-202"">PCOS</span> endometrium; whereas cell proliferation genes, such as Anillin and cyclin B1, were up-regulated.",CTD_human
1,1,Biomarker,C0024141,"Lupus Erythematosus, Systemic",disease,SLE,629,CFB,CFB,CTD_human,19838195,"A candidate screen of alleles previously associated with other autoimmune diseases suggested five loci (P < 1 x 10(-3)) that may contribute to SLE: IFIH1, CFB, CLEC16A, IL12B and SH2B3.",0.209628114093152,"A candidate screen of alleles previously associated with other autoimmune diseases suggested five loci (P &lt; 1 x 10(-3)) that may contribute to <span class=""disease"" id=""19838195-5-143-146"">SLE</span>: IFIH1, <span class=""gene"" id=""19838195-5-155-158"">CFB</span>, CLEC16A, IL12B and SH2B3.",CTD_human
1,1,Biomarker,C2931788,Atypical Hemolytic Uremic Syndrome,disease,atypical hemolytic uremic syndrome,629,CFB,complement factor B,CTD_human,17182750,Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome.,0.201373633921065,"Gain-of-function mutations in <span class=""gene"" id=""17182750-0-30-49"">complement factor B</span> are associated with <span class=""disease"" id=""17182750-0-70-104"">atypical hemolytic uremic syndrome</span>.",CTD_human
1,0,Biomarker,C0035334,Retinitis Pigmentosa,disease,retinitis pigmentosa,6295,SAG,arrestin,CTD_human,9565049,We identified 3 unrelated patients with retinitis pigmentosa associated with a homozygous 1-base-pair deletion mutation in codon 309 of the arrestin gene designated as 1147delA.,0.604381273170092,"We identified 3 unrelated patients with <span class=""disease"" id=""9565049-7-40-60"">retinitis pigmentosa</span> associated with a homozygous 1-base-pair deletion mutation in codon 309 of the <span class=""gene"" id=""9565049-7-140-148"">arrestin</span> gene designated as 1147delA.",CTD_human;HPO;ORPHANET
1,0,Biomarker,C0042164,Uveitis,disease,uveitis,6295,SAG,retinal S-antigen,CTD_human,8407215,The experimental uveitis was induced in Lewis rats by retinal S-antigen.,0.2,"The experimental <span class=""disease"" id=""8407215-3-17-24"">uveitis</span> was induced in Lewis rats by <span class=""gene"" id=""8407215-3-54-71"">retinal S-antigen</span>.",CTD_human
2,5,Biomarker,C1306122,Oguchi disease,disease,Oguchi disease,6295,SAG,arrestin,CTD_human,7670478,A homozygous 1-base pair deletion in the arrestin gene is a frequent cause of Oguchi disease in Japanese.,0.603296721410557,"A homozygous 1-base pair deletion in the <span class=""gene"" id=""7670478-0-41-49"">arrestin</span> gene is a frequent cause of <span class=""disease"" id=""7670478-0-78-92"">Oguchi disease</span> in Japanese.",CTD_human;HPO;ORPHANET
1,0,Biomarker,C0000768,Congenital Abnormality,group,dysgenesis,6299,SALL1,Sall1,CTD_human,20127799,"Sall1 is expressed in the metanephric mesenchyme in the developing kidney, and mice deficient in Sall1 show kidney agenesis or dysgenesis.",0.201373633921065,"<span class=""gene"" id=""20127799-1-0-5"">Sall1</span> is expressed in the metanephric mesenchyme in the developing kidney, and mice deficient in <span class=""gene"" id=""20127799-1-97-102"">Sall1</span> show kidney agenesis or <span class=""disease"" id=""20127799-1-127-137"">dysgenesis</span>.",CTD_human
2,6,Biomarker,C0265246,Townes syndrome,disease,Townes-Brocks syndrome,6299,SALL1,SALL1,CTD_human,16088922,SALL1 mutation analysis in Townes-Brocks syndrome: twelve novel mutations and expansion of the phenotype.,0.48824180352639296,"<span class=""gene"" id=""16088922-0-0-5"">SALL1</span> mutation analysis in <span class=""disease"" id=""16088922-0-27-49"">Townes-Brocks syndrome</span>: twelve novel mutations and expansion of the phenotype.",CTD_human;ORPHANET
2,6,Biomarker,C0265246,Townes syndrome,disease,Townes-Brocks syndrome,6299,SALL1,SALL1,CTD_human,9425907,Mutations in the SALL1 putative transcription factor gene cause Townes-Brocks syndrome.,0.48824180352639296,"Mutations in the <span class=""gene"" id=""9425907-0-17-22"">SALL1</span> putative transcription factor gene cause <span class=""disease"" id=""9425907-0-64-86"">Townes-Brocks syndrome</span>.",CTD_human;ORPHANET
2,3,Biomarker,C1846421,Lathosterolosis,disease,Lathosterolosis,6309,SC5D,3beta-hydroxysteroid-delta5-desaturase,CTD_human,12189593,"Lathosterolosis, a novel multiple-malformation/mental retardation syndrome due to deficiency of 3beta-hydroxysteroid-delta5-desaturase.",0.6805494535684261,"<span class=""disease"" id=""12189593-0-0-15"">Lathosterolosis</span>, a novel multiple-malformation/mental retardation syndrome due to deficiency of <span class=""gene"" id=""12189593-0-96-134"">3beta-hydroxysteroid-delta5-desaturase</span>.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C3714756,Intellectual Disability,group,mental retardation,6309,SC5D,3beta-hydroxysteroid-delta5-desaturase,CTD_human,12189593,"Lathosterolosis, a novel multiple-malformation/mental retardation syndrome due to deficiency of 3beta-hydroxysteroid-delta5-desaturase.",0.200274726784213,"Lathosterolosis, a novel multiple-malformation/<span class=""disease"" id=""12189593-0-47-65"">mental retardation</span> syndrome due to deficiency of <span class=""gene"" id=""12189593-0-96-134"">3beta-hydroxysteroid-delta5-desaturase</span>.",CTD_human
1,0,Biomarker,C0339573,"Glaucoma, Primary Open Angle",disease,primary open-angle glaucoma,6311,ATXN2,ATXN2,CTD_human,26752265,"Genome-wide association analysis identifies TXNRD2, ATXN2 and FOXC1 as susceptibility loci for primary open-angle glaucoma.",0.200274726784213,"Genome-wide association analysis identifies TXNRD2, <span class=""gene"" id=""26752265-0-52-57"">ATXN2</span> and FOXC1 as susceptibility loci for <span class=""disease"" id=""26752265-0-95-122"">primary open-angle glaucoma</span>.",CTD_human
1,0,Biomarker,C0339143,Thyroid associated opthalmopathies,disease,Graves' ophthalmopathy,6319,SCD,SCD,CTD_human,17614770,"COX-2 and SCD, markers of inflammation and adipogenesis, are related to disease activity in Graves' ophthalmopathy.",0.200274726784213,"COX-2 and <span class=""gene"" id=""17614770-0-10-13"">SCD</span>, markers of inflammation and adipogenesis, are related to disease activity in <span class=""disease"" id=""17614770-0-92-114"">Graves' ophthalmopathy</span>.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,6319,SCD,stearoyl-CoA desaturase,CTD_human,21147110,"Suppression of the genes adenosine triphosphate citrate lyase, acetyl-CoA carboxylase, fatty acid synthase, stearoyl-CoA desaturase 1, or sterol regulatory element-binding protein 1, which are involved in lipogenesis, reduced proliferation, and survival of HCC cell lines and AKT-dependent cell proliferation.",0.20054945356842604,"Suppression of the genes adenosine triphosphate citrate lyase, acetyl-CoA carboxylase, fatty acid synthase, <span class=""gene"" id=""21147110-9-108-131"">stearoyl-CoA desaturase</span> 1, or sterol regulatory element-binding protein 1, which are involved in lipogenesis, reduced proliferation, and survival of <span class=""disease"" id=""21147110-9-257-260"">HCC</span> cell lines and AKT-dependent cell proliferation.",CTD_human
1,0,Biomarker,C0004096,Asthma,disease,asthma,632,BGLAP,osteocalcin,CTD_human,8429434,"Effects on bone formation were difficult to assess because asthma per se caused a significant reduction in osteocalcin, a sensitive marker of bone formation.",0.2,"Effects on bone formation were difficult to assess because <span class=""disease"" id=""8429434-11-59-65"">asthma</span> per se caused a significant reduction in <span class=""gene"" id=""8429434-11-107-118"">osteocalcin</span>, a sensitive marker of bone formation.",CTD_human
3,1,Biomarker,C0009952,Febrile Convulsions,disease,febrile seizures,6323,SCN1A,SCN1A,CTD_human,25362483,"Recurrent mutations in three main genes (SCN1A, SCN1B and GABRG2) have been identified that cause febrile seizures with or without epilepsy.",0.43679109062365795,"Recurrent mutations in three main genes (<span class=""gene"" id=""25362483-2-41-46"">SCN1A</span>, SCN1B and GABRG2) have been identified that cause <span class=""disease"" id=""25362483-2-98-114"">febrile seizures</span> with or without epilepsy.",CTD_human;HPO
3,1,Biomarker,C0009952,Febrile Convulsions,disease,febrile seizures,6323,SCN1A,SCN1A,CTD_human,25344690,"Furthermore, four loci were associated with febrile seizures in general, implicating the sodium channel genes SCN1A (rs6432860: P = 2.2 × 10(-16)) and SCN2A (rs3769955: P = 3.1 × 10(-10)), a TMEM16 family gene (ANO3; rs114444506: P = 3.7 × 10(-20)) and a region associated with magnesium levels (12q21.33; rs11105468: P = 3.4 × 10(-11)).",0.43679109062365795,"Furthermore, four loci were associated with <span class=""disease"" id=""25344690-4-44-60"">febrile seizures</span> in general, implicating the sodium channel genes <span class=""gene"" id=""25344690-4-110-115"">SCN1A</span> (rs6432860: P = 2.2 &times; 10(-16)) and SCN2A (rs3769955: P = 3.1 &times; 10(-10)), a TMEM16 family gene (ANO3; rs114444506: P = 3.7 &times; 10(-20)) and a region associated with magnesium levels (12q21.33; rs11105468: P = 3.4 &times; 10(-11)).",CTD_human;HPO
3,2,Biomarker,C0014544,Epilepsy,disease,epilepsy,6323,SCN1A,SCN1A,CTD_human,19694741,Differential role of sodium channels SCN1A and SCN2A gene polymorphisms with epilepsy and multiple drug resistance in the north Indian population.,0.487966782935994,"Differential role of sodium channels <span class=""gene"" id=""19694741-0-37-42"">SCN1A</span> and SCN2A gene polymorphisms with <span class=""disease"" id=""19694741-0-77-85"">epilepsy</span> and multiple drug resistance in the north Indian population.",CTD_human;HPO
1,0,Biomarker,C0009952,Febrile Convulsions,disease,febrile seizures,6324,SCN1B,SCN1B,CTD_human,25362483,"Recurrent mutations in three main genes (SCN1A, SCN1B and GABRG2) have been identified that cause febrile seizures with or without epilepsy.",0.40738891241911895,"Recurrent mutations in three main genes (SCN1A, <span class=""gene"" id=""25362483-2-48-53"">SCN1B</span> and GABRG2) have been identified that cause <span class=""disease"" id=""25362483-2-98-114"">febrile seizures</span> with or without epilepsy.",CTD_human;HPO
1,1,Biomarker,C0009952,Febrile Convulsions,disease,febrile seizures,6326,SCN2A,SCN2A,CTD_human,25344690,"Furthermore, four loci were associated with febrile seizures in general, implicating the sodium channel genes SCN1A (rs6432860: P = 2.2 × 10(-16)) and SCN2A (rs3769955: P = 3.1 × 10(-10)), a TMEM16 family gene (ANO3; rs114444506: P = 3.7 × 10(-20)) and a region associated with magnesium levels (12q21.33; rs11105468: P = 3.4 × 10(-11)).",0.406737144536068,"Furthermore, four loci were associated with <span class=""disease"" id=""25344690-4-44-60"">febrile seizures</span> in general, implicating the sodium channel genes SCN1A (rs6432860: P = 2.2 &times; 10(-16)) and <span class=""gene"" id=""25344690-4-151-156"">SCN2A</span> (rs3769955: P = 3.1 &times; 10(-10)), a TMEM16 family gene (ANO3; rs114444506: P = 3.7 &times; 10(-20)) and a region associated with magnesium levels (12q21.33; rs11105468: P = 3.4 &times; 10(-11)).",CTD_human;HPO
2,0,Biomarker,C0014544,Epilepsy,disease,epilepsy,6326,SCN2A,Scn2a,CTD_human,16464983,Severe epilepsy resulting from genetic interaction between Scn2a and Kcnq2.,0.423177685456902,"Severe <span class=""disease"" id=""16464983-0-7-15"">epilepsy</span> resulting from genetic interaction between <span class=""gene"" id=""16464983-0-59-64"">Scn2a</span> and Kcnq2.",CTD_human;HPO
1,0,Biomarker,C0238358,Hypokalemic periodic paralysis,disease,hypoPP,6329,SCN4A,SCN4A,CTD_human,11912116,"In addition, several mutations (Arg669His, Arg672His, Arg672Gly and Arg672Ser) in the voltage sensor of the skeletal muscle sodium channel alpha-subunit (SCN4A gene) have been found in families with hypoPP (type II).",0.41013618026125,"In addition, several mutations (Arg669His, Arg672His, Arg672Gly and Arg672Ser) in the voltage sensor of the <span class=""gene"" id=""11912116-4-108-152"">skeletal muscle sodium channel alpha-subunit</span> (<span class=""gene"" id=""11912116-4-154-159"">SCN4A</span> gene) have been found in families with <span class=""disease"" id=""11912116-4-199-205"">hypoPP</span> (type II).",CTD_human;ORPHANET
16,10,Biomarker,C2931826,Potassium aggravated myotonia,disease,Myotonia permanens,6329,SCN4A,SCN4A,CTD_human,16832098,Myotonia permanens is associated with a G1306E mutation in the SCN4A gene.,0.6016483607052789,"<span class=""disease"" id=""16832098-1-0-18"">Myotonia permanens</span> is associated with a G1306E mutation in the <span class=""gene"" id=""16832098-1-63-68"">SCN4A</span> gene.",CTD_human;ORPHANET;UNIPROT
1,3,Biomarker,C0004238,Atrial Fibrillation,disease,atrial fibrillation,6331,SCN5A,SCN5A,CTD_human,20062060,"Five of the loci, SCN5A, SCN10A, NKX2-5, CAV1-CAV2, and SOX5, were also associated with atrial fibrillation (N = 5,741 cases, P < 0.0056).",0.430384415649449,"Five of the loci, <span class=""gene"" id=""20062060-6-18-23"">SCN5A</span>, SCN10A, NKX2-5, CAV1-CAV2, and SOX5, were also associated with <span class=""disease"" id=""20062060-6-88-107"">atrial fibrillation</span> (N = 5,741 cases, P &lt; 0.0056).",CTD_human;HPO
8,13,Biomarker,C0023976,Long QT Syndrome,disease,long-QT syndrome,6331,SCN5A,SCN5A,CTD_human,12796143,"Mutations in SCN5A, the gene coding for the human cardiac Na+ channel alpha-subunit, are associated with variant 3 of the long-QT syndrome (LQT-3).",0.29564768440535305,"Mutations in <span class=""gene"" id=""12796143-1-13-18"">SCN5A</span>, the gene coding for the human cardiac Na+ channel alpha-subunit, are associated with variant 3 of the <span class=""disease"" id=""12796143-1-122-138"">long-QT syndrome</span> (LQT-3).",CTD_human
8,13,Biomarker,C0023976,Long QT Syndrome,disease,long QT syndrome,6331,SCN5A,SCN5A,CTD_human,10627139,"Identification of a new SCN5A mutation, D1840G, associated with the long QT syndrome. Mutations in brief no. 153. Online.",0.29564768440535305,"Identification of a new <span class=""gene"" id=""10627139-0-24-29"">SCN5A</span> mutation, D1840G, associated with the <span class=""disease"" id=""10627139-0-68-84"">long QT syndrome</span>. Mutations in brief no. 153. Online.",CTD_human
8,13,Biomarker,C0023976,Long QT Syndrome,disease,long-QT syndrome,6331,SCN5A,SCN5A,CTD_human,12208804,Drug-induced long-QT syndrome associated with a subclinical SCN5A mutation.,0.29564768440535305,"Drug-induced <span class=""disease"" id=""12208804-0-13-29"">long-QT syndrome</span> associated with a subclinical <span class=""gene"" id=""12208804-0-60-65"">SCN5A</span> mutation.",CTD_human
8,13,Biomarker,C0023976,Long QT Syndrome,disease,long-QT syndrome,6331,SCN5A,SCN5A,CTD_human,16301357,"Although L1825P generates late sodium current typical of SCN5A-linked long-QT syndrome (LQT3) in vitro, the patient reported had a normal QT interval before administration of the drug.",0.29564768440535305,"Although L1825P generates late sodium current typical of <span class=""gene"" id=""16301357-2-57-62"">SCN5A</span>-linked <span class=""disease"" id=""16301357-2-70-86"">long-QT syndrome</span> (LQT3) in vitro, the patient reported had a normal QT interval before administration of the drug.",CTD_human
2,0,Biomarker,C0040479,Torsades de Pointes,disease,torsade de pointes,6331,SCN5A,SCN5A,CTD_human,16301357,The cardiac sodium channel (SCN5A) mutation L1825P has been identified in a patient with drug-induced torsade de pointes precipitated by the IKr blocker cisapride.,0.40761248204602,"The cardiac sodium channel (<span class=""gene"" id=""16301357-1-28-33"">SCN5A</span>) mutation L1825P has been identified in a patient with drug-induced <span class=""disease"" id=""16301357-1-102-120"">torsade de pointes</span> precipitated by the IKr blocker cisapride.",CTD_human;HPO
51,124,Biomarker,C1142166,Brugada Syndrome (disorder),disease,Brugada syndrome,6331,SCN5A,SCN5A,CTD_human,16239976,A novel nonsense mutation in the SCN5A gene leads to Brugada syndrome and a silent gene mutation carrier state.,0.8435358854758079,"A novel nonsense mutation in the <span class=""gene"" id=""16239976-0-33-38"">SCN5A</span> gene leads to <span class=""disease"" id=""16239976-0-53-69"">Brugada syndrome</span> and a silent gene mutation carrier state.",CTD_human;ORPHANET;UNIPROT
51,124,Biomarker,C1142166,Brugada Syndrome (disorder),disease,Brugada syndrome,6331,SCN5A,SCN5A,CTD_human,16945804,Our findings indicate that bupivacaine may induce the electrocardiographic and arrhythmic manifestations of the Brugada syndrome in silent carriers of SCN5A mutations.,0.8435358854758079,"Our findings indicate that bupivacaine may induce the electrocardiographic and arrhythmic manifestations of the <span class=""disease"" id=""16945804-10-112-128"">Brugada syndrome</span> in silent carriers of <span class=""gene"" id=""16945804-10-151-156"">SCN5A</span> mutations.",CTD_human;ORPHANET;UNIPROT
51,124,Biomarker,C1142166,Brugada Syndrome (disorder),disease,Brugada syndrome,6331,SCN5A,SCN5A,CTD_human,10662748,"A mutation in the cardiac sodium channel gene (SCN5A) has been described in patients with the syndrome of right bundle branch block, ST-segment elevation in leads V1 to V3, and sudden death (Brugada syndrome).",0.8435358854758079,"A mutation in the cardiac sodium channel gene (<span class=""gene"" id=""10662748-1-47-52"">SCN5A</span>) has been described in patients with the syndrome of right bundle branch block, ST-segment elevation in leads V1 to V3, and sudden death (<span class=""disease"" id=""10662748-1-191-207"">Brugada syndrome</span>).",CTD_human;ORPHANET;UNIPROT
51,124,Biomarker,C1142166,Brugada Syndrome (disorder),disease,Brugada syndrome,6331,SCN5A,SCN5A,CTD_human,20174578,"Loss-of-function mutations in SCN5A, the gene encoding Na(v)1.5 Na+ channel, are associated with inherited cardiac conduction defects and Brugada syndrome, which both exhibit variable phenotypic penetrance of conduction defects.",0.8435358854758079,"Loss-of-function mutations in <span class=""gene"" id=""20174578-1-30-35"">SCN5A</span>, the gene encoding Na(v)1.5 Na+ channel, are associated with inherited cardiac conduction defects and <span class=""disease"" id=""20174578-1-138-154"">Brugada syndrome</span>, which both exhibit variable phenotypic penetrance of conduction defects.",CTD_human;ORPHANET;UNIPROT
51,124,Biomarker,C1142166,Brugada Syndrome (disorder),disease,Brugada syndrome,6331,SCN5A,SCN5A,CTD_human,15520322,Value of electrocardiographic parameters and ajmaline test in the diagnosis of Brugada syndrome caused by SCN5A mutations.,0.8435358854758079,"Value of electrocardiographic parameters and ajmaline test in the diagnosis of <span class=""disease"" id=""15520322-0-79-95"">Brugada syndrome</span> caused by <span class=""gene"" id=""15520322-0-106-111"">SCN5A</span> mutations.",CTD_human;ORPHANET;UNIPROT
51,124,Biomarker,C1142166,Brugada Syndrome (disorder),disease,Brugada syndrome,6331,SCN5A,SCN5A,CTD_human,18507554,"While a reduction in INa due to SCN5A mutation is implicated as the underlying mechanism in Brugada syndrome, hyponatremia, which can give rise to a reduced INa, has never been reported in literature as a cause or precipitating factor in this syndrome.",0.8435358854758079,"While a reduction in INa due to <span class=""gene"" id=""18507554-2-32-37"">SCN5A</span> mutation is implicated as the underlying mechanism in <span class=""disease"" id=""18507554-2-92-108"">Brugada syndrome</span>, hyponatremia, which can give rise to a reduced INa, has never been reported in literature as a cause or precipitating factor in this syndrome.",CTD_human;ORPHANET;UNIPROT
51,124,Biomarker,C1142166,Brugada Syndrome (disorder),disease,Brugada syndrome,6331,SCN5A,SCN5A,CTD_human,23872634,"Common variants at SCN5A-SCN10A and HEY2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death.",0.8435358854758079,"Common variants at <span class=""gene"" id=""23872634-0-19-24"">SCN5A</span>-SCN10A and HEY2 are associated with <span class=""disease"" id=""23872634-0-61-77"">Brugada syndrome</span>, a rare disease with high risk of sudden cardiac death.",CTD_human;ORPHANET;UNIPROT
51,124,Biomarker,C1142166,Brugada Syndrome (disorder),disease,BrS,6331,SCN5A,LQT3,CTD_human,17805561,We thus associate changes in the slopes of restitution curves with arrhythmogenicity in models of LQT3 and BrS.,0.8435358854758079,"We thus associate changes in the slopes of restitution curves with arrhythmogenicity in models of <span class=""gene"" id=""17805561-7-98-102"">LQT3</span> and <span class=""disease"" id=""17805561-7-107-110"">BrS</span>.",CTD_human;ORPHANET;UNIPROT
51,124,Biomarker,C1142166,Brugada Syndrome (disorder),disease,Brugada syndrome,6331,SCN5A,SCN5A,CTD_human,18599870,We characterized a novel double mutation of SCN5A (V232I in DI-S4+L1308F in DIII-S4) identified in a rare case of lidocaine (1 mg/kg)-induced Brugada syndrome.,0.8435358854758079,"We characterized a novel double mutation of <span class=""gene"" id=""18599870-4-44-49"">SCN5A</span> (V232I in DI-S4+L1308F in DIII-S4) identified in a rare case of lidocaine (1 mg/kg)-induced <span class=""disease"" id=""18599870-4-142-158"">Brugada syndrome</span>.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0007758,Cerebellar Ataxia,phenotype,ataxia,6334,SCN8A,SCN8A,CTD_human,16236810,"Heterozygosity for a protein truncation mutation of sodium channel SCN8A in a patient with cerebellar atrophy, ataxia, and mental retardation.",0.4010989071368521,"Heterozygosity for a protein truncation mutation of sodium channel <span class=""gene"" id=""16236810-0-67-72"">SCN8A</span> in a patient with cerebellar atrophy, <span class=""disease"" id=""16236810-0-111-117"">ataxia</span>, and mental retardation.",CTD_human;HPO
1,0,Biomarker,C0038220,Status Epilepticus,disease,status epilepticus,6334,SCN8A,SCN8A,CTD_human,19306853,Long-term increasing co-localization of SCN8A and ankyrin-G in rat hippocampal cornu ammonis 1 after pilocarpine induced status epilepticus.,0.2,"Long-term increasing co-localization of <span class=""gene"" id=""19306853-0-40-45"">SCN8A</span> and ankyrin-G in rat hippocampal cornu ammonis 1 after pilocarpine induced <span class=""disease"" id=""19306853-0-121-139"">status epilepticus</span>.",CTD_human
1,0,Biomarker,C3714756,Intellectual Disability,group,mental retardation,6334,SCN8A,SCN8A,CTD_human,16236810,"Heterozygosity for a protein truncation mutation of sodium channel SCN8A in a patient with cerebellar atrophy, ataxia, and mental retardation.",0.4010989071368521,"Heterozygosity for a protein truncation mutation of sodium channel <span class=""gene"" id=""16236810-0-67-72"">SCN8A</span> in a patient with cerebellar atrophy, ataxia, and <span class=""disease"" id=""16236810-0-123-141"">mental retardation</span>.",CTD_human;HPO
3,0,Biomarker,C0014804,Erythromelalgia,disease,erythromelalgia,6335,SCN9A,SCN9A,CTD_human,19549232,"Treatment with carbamazepine and gabapentin of a patient with primary erythermalgia (erythromelalgia) identified to have a mutation in the SCN9A gene, encoding a voltage-gated sodium channel.",0.419144742631014,"Treatment with carbamazepine and gabapentin of a patient with primary erythermalgia (<span class=""disease"" id=""19549232-0-85-100"">erythromelalgia</span>) identified to have a mutation in the <span class=""gene"" id=""19549232-0-139-144"">SCN9A</span> gene, encoding a voltage-gated sodium channel.",CTD_human;ORPHANET
1,0,Biomarker,C0004238,Atrial Fibrillation,disease,atrial fibrillation,6336,SCN10A,SCN10A,CTD_human,20062060,"Five of the loci, SCN5A, SCN10A, NKX2-5, CAV1-CAV2, and SOX5, were also associated with atrial fibrillation (N = 5,741 cases, P < 0.0056).",0.201648360705279,"Five of the loci, SCN5A, <span class=""gene"" id=""20062060-6-25-31"">SCN10A</span>, NKX2-5, CAV1-CAV2, and SOX5, were also associated with <span class=""disease"" id=""20062060-6-88-107"">atrial fibrillation</span> (N = 5,741 cases, P &lt; 0.0056).",CTD_human
1,1,Biomarker,C1142166,Brugada Syndrome (disorder),disease,Brugada syndrome,6336,SCN10A,SCN10A,CTD_human,23872634,"Common variants at SCN5A-SCN10A and HEY2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death.",0.401648360705279,"Common variants at SCN5A-<span class=""gene"" id=""23872634-0-25-31"">SCN10A</span> and HEY2 are associated with <span class=""disease"" id=""23872634-0-61-77"">Brugada syndrome</span>, a rare disease with high risk of sudden cardiac death.",CTD_human;ORPHANET
2,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,6337,SCNN1A,SCNN1A,CTD_human,11752024,A lower level of SCNN1A subunit expression among subjects with the AA genotype might lead to lower levels of sodium reabsorption in the kidney and might provide protection against the development of hypertension.,0.206187690967642,"A lower level of <span class=""gene"" id=""11752024-10-17-23"">SCNN1A</span> subunit expression among subjects with the AA genotype might lead to lower levels of sodium reabsorption in the kidney and might provide protection against the development of <span class=""disease"" id=""11752024-10-199-211"">hypertension</span>.",CTD_human
2,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,6337,SCNN1A,?ENaC,CTD_human,23348737,"Taken together, these results demonstrate that loss of NEDD4-2 in adult renal tubules causes a new form of mild, salt-sensitive hypertension without hyperkalemia that is characterized by upregulation of NCC, elevation of ?/?ENaC, but not ?ENaC, and a normal Na+/K+ balance maintained by downregulation of ENaC activity and upregulation of ROMK.",0.206187690967642,"Taken together, these results demonstrate that loss of NEDD4-2 in adult renal tubules causes a new form of mild, salt-sensitive <span class=""disease"" id=""23348737-8-128-140"">hypertension</span> without hyperkalemia that is characterized by upregulation of NCC, elevation of &beta;/&gamma;ENaC, but not <span class=""gene"" id=""23348737-8-238-243"">&alpha;ENaC</span>, and a normal Na+/K+ balance maintained by downregulation of ENaC activity and upregulation of ROMK.",CTD_human
2,0,Biomarker,C0010674,Cystic Fibrosis,disease,CF,6338,SCNN1B,SCNN1B,CTD_human,16463024,"The finding that TNFRSF1A, SCNN1B and SCNN1G are clinically relevant modulators of CF disease supports current concepts that the depletion of airway surface liquid and inadequate host inflammatory responses trigger pulmonary disease in CF.",0.29330187660254803,"The finding that TNFRSF1A, <span class=""gene"" id=""16463024-8-27-33"">SCNN1B</span> and SCNN1G are clinically relevant modulators of <span class=""disease"" id=""16463024-8-83-85"">CF</span> disease supports current concepts that the depletion of airway surface liquid and inadequate host inflammatory responses trigger pulmonary disease in <span class=""disease"" id=""16463024-8-236-238"">CF</span>.",CTD_human
3,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,6338,SCNN1B,SCNN1B,CTD_human,15174897,"The Thr594Met polymorphism of the ENaC beta-subunit gene SCNN1B occurs exclusively in Black individuals, with a frequency of 6-8% in those with hypertension.",0.42752047811537497,"The Thr594Met polymorphism of the ENaC beta-subunit gene <span class=""gene"" id=""15174897-6-57-63"">SCNN1B</span> occurs exclusively in Black individuals, with a frequency of 6-8% in those with <span class=""disease"" id=""15174897-6-144-156"">hypertension</span>.",CTD_human;HPO
3,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,6338,SCNN1B,SCNN1B,CTD_human,15198480,The roles of these missense mutations in the SCNN1B or SCNN1G gene identified in hypertensive patients are not clear in the pathogenesis of hypertension and the regulation of electrolytes.,0.42752047811537497,"The roles of these missense mutations in the <span class=""gene"" id=""15198480-8-45-51"">SCNN1B</span> or SCNN1G gene identified in hypertensive patients are not clear in the pathogenesis of <span class=""disease"" id=""15198480-8-140-152"">hypertension</span> and the regulation of electrolytes.",CTD_human;HPO
8,5,Biomarker,C0221043,Liddle Syndrome,disease,Liddle's syndrome,6338,SCNN1B,SCNN1B,CTD_human,18398334,The aim of the study was to search for mutations of SCNN1B and SCNN1G in an Italian family with apparently dominant autosomal transmission of a clinical phenotype consistent with Liddle's syndrome.,0.6830219946263439,"The aim of the study was to search for mutations of <span class=""gene"" id=""18398334-1-52-58"">SCNN1B</span> and SCNN1G in an Italian family with apparently dominant autosomal transmission of a clinical phenotype consistent with <span class=""disease"" id=""18398334-1-179-196"">Liddle's syndrome</span>.",CTD_human;ORPHANET;UNIPROT
8,5,Biomarker,C0221043,Liddle Syndrome,disease,Liddle's syndrome,6338,SCNN1B,SCNN1B,CTD_human,19344079,A novel mutation in the beta-subunit of the epithelial sodium channel gene (SCNN1B) in a Thai family with Liddle's syndrome.,0.6830219946263439,"A novel mutation in the beta-subunit of the epithelial sodium channel gene (<span class=""gene"" id=""19344079-0-76-82"">SCNN1B</span>) in a Thai family with <span class=""disease"" id=""19344079-0-106-123"">Liddle's syndrome</span>.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0010674,Cystic Fibrosis,disease,CF,6340,SCNN1G,SCNN1G,CTD_human,16463024,"The finding that TNFRSF1A, SCNN1B and SCNN1G are clinically relevant modulators of CF disease supports current concepts that the depletion of airway surface liquid and inadequate host inflammatory responses trigger pulmonary disease in CF.",0.211653515897269,"The finding that TNFRSF1A, SCNN1B and <span class=""gene"" id=""16463024-8-38-44"">SCNN1G</span> are clinically relevant modulators of <span class=""disease"" id=""16463024-8-83-85"">CF</span> disease supports current concepts that the depletion of airway surface liquid and inadequate host inflammatory responses trigger pulmonary disease in <span class=""disease"" id=""16463024-8-236-238"">CF</span>.",CTD_human
1,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,6340,SCNN1G,SCNN1G,CTD_human,15198480,The roles of these missense mutations in the SCNN1B or SCNN1G gene identified in hypertensive patients are not clear in the pathogenesis of hypertension and the regulation of electrolytes.,0.421779926401535,"The roles of these missense mutations in the SCNN1B or <span class=""gene"" id=""15198480-8-55-61"">SCNN1G</span> gene identified in hypertensive patients are not clear in the pathogenesis of <span class=""disease"" id=""15198480-8-140-152"">hypertension</span> and the regulation of electrolytes.",CTD_human;HPO
1,0,Biomarker,C0013421,Dystonia,phenotype,dystonia,6342,SCP2,SCPx,CTD_human,16685654,Mutations in the gene encoding peroxisomal sterol carrier protein X (SCPx) cause leukencephalopathy with dystonia and motor neuropathy.,0.200274726784213,"Mutations in the gene encoding peroxisomal <span class=""gene"" id=""16685654-0-43-67"">sterol carrier protein X</span> (<span class=""gene"" id=""16685654-0-69-73"">SCPx</span>) cause leukencephalopathy with <span class=""disease"" id=""16685654-0-105-113"">dystonia</span> and motor neuropathy.",CTD_human
4,0,Therapeutic,C0004352,Autistic Disorder,disease,autism,6343,SCT,secretin,CTD_human,15206007,Since autism is hypothesized to be a hypoglutamatergic disorder we investigated the in vivo effects of secretin on extracellular amino acids in the rat brain.,0.203557092817453,"Since <span class=""disease"" id=""15206007-2-6-12"">autism</span> is hypothesized to be a hypoglutamatergic disorder we investigated the in vivo effects of <span class=""gene"" id=""15206007-2-103-111"">secretin</span> on extracellular amino acids in the rat brain.",CTD_human
4,0,Therapeutic,C0004352,Autistic Disorder,disease,autism,6343,SCT,secretin,CTD_human,16168596,Administration of secretin for autism alters dopamine metabolism in the central nervous system.,0.203557092817453,"Administration of <span class=""gene"" id=""16168596-0-18-26"">secretin</span> for <span class=""disease"" id=""16168596-0-31-37"">autism</span> alters dopamine metabolism in the central nervous system.",CTD_human
4,0,Therapeutic,C0004352,Autistic Disorder,disease,autism,6343,SCT,secretin,CTD_human,15272612,[Efficacy of secretin for the treatment of autism].,0.203557092817453,"[Efficacy of <span class=""gene"" id=""15272612-0-13-21"">secretin</span> for the treatment of <span class=""disease"" id=""15272612-0-43-49"">autism</span>].",CTD_human
4,0,Therapeutic,C0004352,Autistic Disorder,disease,autistic,6343,SCT,secretin,CTD_human,12732234,"Recent observations that the deficits in social reciprocity skills seen in young (3-4-year-old) autistic children are improved after secretin infusions suggest an additional influence on neuronal activity.We show here that i.v. administration of secretin in rats induces Fos protein expression in the neurons of the central amygdala as well as the area postrema, bed nucleus of the stria terminalis, external lateral parabrachial nucleus and supraoptic nucleus.",0.203557092817453,"Recent observations that the deficits in social reciprocity skills seen in young (3-4-year-old) <span class=""disease"" id=""12732234-2-96-104"">autistic</span> children are improved after <span class=""gene"" id=""12732234-2-133-141"">secretin</span> infusions suggest an additional influence on neuronal activity.We show here that i.v. administration of <span class=""gene"" id=""12732234-2-246-254"">secretin</span> in rats induces Fos protein expression in the neurons of the central amygdala as well as the area postrema, bed nucleus of the stria terminalis, external lateral parabrachial nucleus and supraoptic nucleus.",CTD_human
1,0,Biomarker,C0017658,Glomerulonephritis,disease,glomerulonephritis,6346,CCL1,TCA3,CTD_human,10385480,"We previously reported that the gene expression of six CC chemokines-MCP-1, MCP-3, MIP-1alpha, MIP-1beta, RANTES, and TCA3-was enhanced in a rat model of crescentic glomerulonephritis, the most severe form of glomerulonephritis.",0.2,"We previously reported that the gene expression of six CC chemokines-MCP-1, MCP-3, MIP-1alpha, MIP-1beta, RANTES, and <span class=""gene"" id=""10385480-3-118-122"">TCA3</span>-was enhanced in a rat model of crescentic glomerulonephritis, the most severe form of <span class=""disease"" id=""10385480-3-209-227"">glomerulonephritis</span>.",CTD_human
1,0,Biomarker,C0004096,Asthma,disease,asthma,6347,CCL2,MCP-1,CTD_human,19373627,These findings suggest a possible role for MCP-1 in the pathogenesis of asthma and a potential role for its use in anti-asthma treatment in the future.,0.21478241045857102,"These findings suggest a possible role for <span class=""gene"" id=""19373627-10-43-48"">MCP-1</span> in the pathogenesis of <span class=""disease"" id=""19373627-10-72-78"">asthma</span> and a potential role for its use in anti-<span class=""disease"" id=""19373627-10-120-126"">asthma</span> treatment in the future.",CTD_human
1,0,Biomarker,C0007137,Squamous cell carcinoma,disease,squamous cell carcinoma,6347,CCL2,CCL2,CTD_human,25199511,Focal adhesion kinase knockdown in carcinoma-associated fibroblasts inhibits oral squamous cell carcinoma metastasis via downregulating MCP-1/CCL2 expression.,0.204655999954305,"Focal adhesion kinase knockdown in carcinoma-associated fibroblasts inhibits oral <span class=""disease"" id=""25199511-0-82-105"">squamous cell carcinoma</span> metastasis via downregulating <span class=""gene"" id=""25199511-0-136-141"">MCP-1</span>/<span class=""gene"" id=""25199511-0-142-146"">CCL2</span> expression.",CTD_human
1,0,Biomarker,C0011881,Diabetic Nephropathy,disease,diabetic nephropathy,6347,CCL2,MCP-1,CTD_human,16374426,"In conclusion, our study demonstrates that MCP-1-mediated macrophage accumulation and activation plays a critical role in the development of STZ-induced mouse diabetic nephropathy.",0.20685381422801,"In conclusion, our study demonstrates that <span class=""gene"" id=""16374426-9-43-48"">MCP-1</span>-mediated macrophage accumulation and activation plays a critical role in the development of STZ-induced mouse <span class=""disease"" id=""16374426-9-159-179"">diabetic nephropathy</span>.",CTD_human
1,0,Biomarker,C0017658,Glomerulonephritis,disease,glomerulonephritis,6347,CCL2,MCP-1,CTD_human,10385480,"We previously reported that the gene expression of six CC chemokines-MCP-1, MCP-3, MIP-1alpha, MIP-1beta, RANTES, and TCA3-was enhanced in a rat model of crescentic glomerulonephritis, the most severe form of glomerulonephritis.",0.201923087489492,"We previously reported that the gene expression of six CC chemokines-<span class=""gene"" id=""10385480-3-69-74"">MCP-1</span>, MCP-3, MIP-1alpha, MIP-1beta, RANTES, and TCA3-was enhanced in a rat model of crescentic glomerulonephritis, the most severe form of <span class=""disease"" id=""10385480-3-209-227"">glomerulonephritis</span>.",CTD_human
1,0,Biomarker,C0020500,Hyperoxaluria,disease,Hox,6347,CCL2,MCP-1,CTD_human,16284884,"These results suggest that Hox stimulates the NF-kappaB cascade and, therefore, induces the overexpression of inflammatory mediators like IL-6, MCP-1, and RANTES.",0.2,"These results suggest that <span class=""disease"" id=""16284884-11-27-30"">Hox</span> stimulates the NF-kappaB cascade and, therefore, induces the overexpression of inflammatory mediators like IL-6, <span class=""gene"" id=""16284884-11-144-149"">MCP-1</span>, and RANTES.",CTD_human
2,0,Biomarker,C0022661,"Kidney Failure, Chronic",disease,ESRD,6347,CCL2,monocyte chemoattractant protein-1,CTD_human,19539174,Adiponectin receptor-1 and monocyte chemoattractant protein-1 mRNA expressions were significantly higher in visceral but not in subcutaneous adipose tissue of the ESRD group.,0.28788720883023305,"Adiponectin receptor-1 and <span class=""gene"" id=""19539174-9-27-61"">monocyte chemoattractant protein-1</span> mRNA expressions were significantly higher in visceral but not in subcutaneous adipose tissue of the <span class=""disease"" id=""19539174-9-163-167"">ESRD</span> group.",CTD_human
1,0,Biomarker,C0022876,Premature Obstetric Labor,phenotype,preterm labor,6347,CCL2,CCL-2,CTD_human,18606702,Monocyte chemoattractant protein-1 (CCL-2) integrates mechanical and endocrine signals that mediate term and preterm labor.,0.20596412134074102,"<span class=""gene"" id=""18606702-0-0-34"">Monocyte chemoattractant protein-1</span> (<span class=""gene"" id=""18606702-0-36-41"">CCL-2</span>) integrates mechanical and endocrine signals that mediate term and <span class=""disease"" id=""18606702-0-109-122"">preterm labor</span>.",CTD_human
1,0,Biomarker,C0023283,"Leishmaniasis, Cutaneous",disease,cutaneous leishmaniasis,6347,CCL2,monocyte chemotactic protein-1,CTD_human,20102417,"Evaluation of localized and systemic immune responses in cutaneous leishmaniasis caused by Leishmania tropica: interleukin-8, monocyte chemotactic protein-1 and nitric oxide are major regulatory factors.",0.203231208875927,"Evaluation of localized and systemic immune responses in <span class=""disease"" id=""20102417-0-57-80"">cutaneous leishmaniasis</span> caused by Leishmania tropica: interleukin-8, <span class=""gene"" id=""20102417-0-126-156"">monocyte chemotactic protein-1</span> and nitric oxide are major regulatory factors.",CTD_human
1,0,Biomarker,C0026764,Multiple Myeloma,disease,MM,6347,CCL2,CCL2,CTD_human,16918137,CCL2 may be involved in MM pathobiology by tumor growth suppression.,0.202197814273705,"<span class=""gene"" id=""16918137-8-0-4"">CCL2</span> may be involved in <span class=""disease"" id=""16918137-8-24-26"">MM</span> pathobiology by tumor growth suppression.",CTD_human
1,0,Biomarker,C0032226,Pleural Diseases,group,pleural,6347,CCL2,MCP-1,CTD_human,10923243,These findings suggest that MCP-1 secretion by RPMC may have a role in the initiation and/or potentiation of asbestos-induced pleural injury.,0.200274726784213,"These findings suggest that <span class=""gene"" id=""10923243-8-28-33"">MCP-1</span> secretion by RPMC may have a role in the initiation and/or potentiation of asbestos-induced <span class=""disease"" id=""10923243-8-126-133"">pleural</span> injury.",CTD_human
3,0,Biomarker,C0034069,Pulmonary Fibrosis,disease,pulmonary fibrosis,6347,CCL2,MCP-1,CTD_human,17720292,"Elevated levels of MCP-1, MIP-alpha and MIP-1 beta in the bronchoalveolar lavage (BAL) fluid of patients with mustard gas-induced pulmonary fibrosis.",0.28328236603324,"Elevated levels of <span class=""gene"" id=""17720292-0-19-24"">MCP-1</span>, MIP-alpha and MIP-1 beta in the bronchoalveolar lavage (BAL) fluid of patients with mustard gas-induced <span class=""disease"" id=""17720292-0-130-148"">pulmonary fibrosis</span>.",CTD_human
1,0,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,6347,CCL2,CCL2,CTD_human,18486454,Patients with schizophrenia show raised serum levels of the pro-inflammatory chemokine CCL2: association with the metabolic syndrome in patients?,0.208920603432455,"Patients with <span class=""disease"" id=""18486454-0-14-27"">schizophrenia</span> show raised serum levels of the pro-inflammatory chemokine <span class=""gene"" id=""18486454-0-87-91"">CCL2</span>: association with the metabolic syndrome in patients?",CTD_human
1,0,Biomarker,C0037116,Silicosis,disease,silicosis,6347,CCL2,MCP-1,CTD_human,26163174,Role of human pulmonary fibroblast-derived MCP-1 in cell activation and migration in experimental silicosis.,0.200274726784213,"Role of human pulmonary fibroblast-derived <span class=""gene"" id=""26163174-0-43-48"">MCP-1</span> in cell activation and migration in experimental <span class=""disease"" id=""26163174-0-98-107"">silicosis</span>.",CTD_human
2,0,Biomarker,C0038220,Status Epilepticus,disease,status epilepticus,6347,CCL2,CCL2,CTD_human,20034406,Chemokine CCL2 and its receptor CCR2 are increased in the hippocampus following pilocarpine-induced status epilepticus.,0.2,"Chemokine <span class=""gene"" id=""20034406-0-10-14"">CCL2</span> and its receptor CCR2 are increased in the hippocampus following pilocarpine-induced <span class=""disease"" id=""20034406-0-100-118"">status epilepticus</span>.",CTD_human
2,0,Biomarker,C0041327,"Tuberculosis, Pulmonary",disease,pulmonary tuberculosis,6347,CCL2,MCP-1,CTD_human,18940815,"MCP-1 promoter variant -362C associated with protection from pulmonary tuberculosis in Ghana, West Africa.",0.21680781226268803,"<span class=""gene"" id=""18940815-0-0-5"">MCP-1</span> promoter variant -362C associated with protection from <span class=""disease"" id=""18940815-0-61-83"">pulmonary tuberculosis</span> in Ghana, West Africa.",CTD_human
2,0,Biomarker,C0041327,"Tuberculosis, Pulmonary",disease,pulmonary tuberculosis,6347,CCL2,monocyte chemoattractant protein-1,CTD_human,16352737,A functional promoter polymorphism in monocyte chemoattractant protein-1 is associated with increased susceptibility to pulmonary tuberculosis.,0.21680781226268803,"A functional promoter polymorphism in <span class=""gene"" id=""16352737-0-38-72"">monocyte chemoattractant protein-1</span> is associated with increased susceptibility to <span class=""disease"" id=""16352737-0-120-142"">pulmonary tuberculosis</span>.",CTD_human
1,0,Biomarker,C0080178,Spina Bifida,disease,spina bifida,6347,CCL2,monocyte chemoattractant protein 1,CTD_human,16596675,Maternal genotype for the monocyte chemoattractant protein 1 A(-2518)G promoter polymorphism is associated with the risk of spina bifida in offspring.,0.200274726784213,"Maternal genotype for the <span class=""gene"" id=""16596675-0-26-60"">monocyte chemoattractant protein 1</span> A(-2518)G promoter polymorphism is associated with the risk of <span class=""disease"" id=""16596675-0-124-136"">spina bifida</span> in offspring.",CTD_human
2,0,Biomarker,C0524620,Metabolic Syndrome X,disease,Metabolic Syndrome,6347,CCL2,CCL2,CTD_human,16188961,"This paradigm supports the notion that elevated CCL2 levels in visceral adipose tissue associated with Metabolic Syndrome is a chemotactic niche, whereby fibrocytes can home to and differentiate into adipocytes to perpetuate its tissue formation.",0.205154296365419,"This paradigm supports the notion that elevated <span class=""gene"" id=""16188961-8-48-52"">CCL2</span> levels in visceral adipose tissue associated with <span class=""disease"" id=""16188961-8-103-121"">Metabolic Syndrome</span> is a chemotactic niche, whereby fibrocytes can home to and differentiate into adipocytes to perpetuate its tissue formation.",CTD_human
2,0,Biomarker,C0524620,Metabolic Syndrome X,disease,metabolic syndrome,6347,CCL2,CCL2,CTD_human,18486454,Patients with schizophrenia show raised serum levels of the pro-inflammatory chemokine CCL2: association with the metabolic syndrome in patients?,0.205154296365419,"Patients with schizophrenia show raised serum levels of the pro-inflammatory chemokine <span class=""gene"" id=""18486454-0-87-91"">CCL2</span>: association with the <span class=""disease"" id=""18486454-0-114-132"">metabolic syndrome</span> in patients?",CTD_human
2,0,Biomarker,C1956346,Coronary Artery Disease,disease,CAD,6347,CCL2,MCP-1,CTD_human,11500196,Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD). Coincidence of elevated Lp(a) and MCP-1 -2518 G/G genotype in CAD patients.,0.301962108628107,"Involvement of polymorphisms in the chemokine system in the susceptibility for <span class=""disease"" id=""11500196-0-79-102"">coronary artery disease</span> (<span class=""disease"" id=""11500196-0-104-107"">CAD</span>). Coincidence of elevated Lp(a) and <span class=""gene"" id=""11500196-0-144-149"">MCP-1</span> -2518 G/G genotype in <span class=""disease"" id=""11500196-0-172-175"">CAD</span> patients.",CTD_human
2,0,Biomarker,C1956346,Coronary Artery Disease,disease,CAD,6347,CCL2,MCP-1,CTD_human,16934270,This study demonstrates for the first time that the MCP-1 gene -2578A>G polymorphism is associated with an excess risk of coronary atherosclerosis in an asymptomatic population and demonstrates an apparent interaction with CAD risk factor burden.,0.301962108628107,"This study demonstrates for the first time that the <span class=""gene"" id=""16934270-8-52-57"">MCP-1</span> gene -2578A&gt;G polymorphism is associated with an excess risk of coronary atherosclerosis in an asymptomatic population and demonstrates an apparent interaction with <span class=""disease"" id=""16934270-8-223-226"">CAD</span> risk factor burden.",CTD_human
2,0,Biomarker,C0034069,Pulmonary Fibrosis,disease,PF,6348,CCL3,MIP-1 alpha,CTD_human,17720292,"A significant negative correlation was observed between the percentage of Dlco and MCP-1 and MIP-1 alpha levels in BAL fluid in patients with PF (r=-0.65, p=0.003; r=-0.48, p=0.04; respectively).",0.2,"A significant negative correlation was observed between the percentage of Dlco and MCP-1 and <span class=""gene"" id=""17720292-7-93-104"">MIP-1 alpha</span> levels in BAL fluid in patients with <span class=""disease"" id=""17720292-7-142-144"">PF</span> (r=-0.65, p=0.003; r=-0.48, p=0.04; respectively).",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,hepatocellular carcinoma,6348,CCL3,CCL3,CTD_human,16284949,"Essential contribution of a chemokine, CCL3, and its receptor, CCR1, to hepatocellular carcinoma progression.",0.20300763924902696,"Essential contribution of a chemokine, <span class=""gene"" id=""16284949-0-39-43"">CCL3</span>, and its receptor, CCR1, to <span class=""disease"" id=""16284949-0-72-96"">hepatocellular carcinoma</span> progression.",CTD_human
1,0,Biomarker,C0027794,Neural Tube Defects,group,NTD,635,BHMT,BHMT,CTD_human,17035141,"In 304 Caucasian American NTD families with myelomeningocele or anencephaly, we examined 28 polymorphisms in 11 genes: folate receptor 1, folate receptor 2, solute carrier family 19 member 1, transcobalamin II, methylenetetrahydrofolate dehydrogenase 1, serine hydroxymethyl-transferase 1, 5,10-methylenetetrahydrofolate reductase (MTHFR), 5-methyltetrahydrofolate-homo-cysteine methyltransferase, 5-methyltetrahydrofolate-homocysteine methyltransferase reductase, betaine-homocysteine methyltransferase (BHMT), and cystathionine-beta-synthase.",0.202956482091714,"In 304 Caucasian American <span class=""disease"" id=""17035141-4-26-29"">NTD</span> families with myelomeningocele or anencephaly, we examined 28 polymorphisms in 11 genes: folate receptor 1, folate receptor 2, solute carrier family 19 member 1, transcobalamin II, methylenetetrahydrofolate dehydrogenase 1, serine hydroxymethyl-transferase 1, 5,10-methylenetetrahydrofolate reductase (MTHFR), 5-methyltetrahydrofolate-homo-cysteine methyltransferase, 5-methyltetrahydrofolate-homocysteine methyltransferase reductase, <span class=""gene"" id=""17035141-4-465-503"">betaine-homocysteine methyltransferase</span> (<span class=""gene"" id=""17035141-4-505-509"">BHMT</span>), and cystathionine-beta-synthase.",CTD_human
1,0,Biomarker,C0034069,Pulmonary Fibrosis,disease,pulmonary fibrosis,6351,CCL4,MIP-1 beta,CTD_human,17720292,"Elevated levels of MCP-1, MIP-alpha and MIP-1 beta in the bronchoalveolar lavage (BAL) fluid of patients with mustard gas-induced pulmonary fibrosis.",0.200274726784213,"Elevated levels of MCP-1, MIP-alpha and <span class=""gene"" id=""17720292-0-40-50"">MIP-1 beta</span> in the bronchoalveolar lavage (BAL) fluid of patients with mustard gas-induced <span class=""disease"" id=""17720292-0-130-148"">pulmonary fibrosis</span>.",CTD_human
1,0,Biomarker,C0004096,Asthma,disease,asthmatic,6352,CCL5,RANTES,CTD_human,8534483,"RANTES was also expressed in the bronchial epithelium in vivo, as indicated by positive immunocytochemical staining of bronchial biopsy tissues obtained from mild asthmatic patients before and after treatment with 500 micrograms of inhaled beclomethasone dipropionate (BDP) twice daily or matched placebo for 4 mo.",0.260367665065757,"<span class=""gene"" id=""8534483-6-0-6"">RANTES</span> was also expressed in the bronchial epithelium in vivo, as indicated by positive immunocytochemical staining of bronchial biopsy tissues obtained from mild <span class=""disease"" id=""8534483-6-163-172"">asthmatic</span> patients before and after treatment with 500 micrograms of inhaled beclomethasone dipropionate (BDP) twice daily or matched placebo for 4 mo.",CTD_human
1,0,Biomarker,C0017658,Glomerulonephritis,disease,glomerulonephritis,6352,CCL5,RANTES,CTD_human,10385480,"We previously reported that the gene expression of six CC chemokines-MCP-1, MCP-3, MIP-1alpha, MIP-1beta, RANTES, and TCA3-was enhanced in a rat model of crescentic glomerulonephritis, the most severe form of glomerulonephritis.",0.20054945356842604,"We previously reported that the gene expression of six CC chemokines-MCP-1, MCP-3, MIP-1alpha, MIP-1beta, <span class=""gene"" id=""10385480-3-106-112"">RANTES</span>, and TCA3-was enhanced in a rat model of crescentic glomerulonephritis, the most severe form of <span class=""disease"" id=""10385480-3-209-227"">glomerulonephritis</span>.",CTD_human
1,0,Biomarker,C0019187,"Hepatitis, Alcoholic",disease,alcoholic hepatitis,6352,CCL5,RANTES,CTD_human,12586603,"Thus, TNF-alpha-induced RANTES expression may have a critical role in cell-mediated liver injury associated with alcoholic hepatitis.",0.200274726784213,"Thus, TNF-alpha-induced <span class=""gene"" id=""12586603-4-24-30"">RANTES</span> expression may have a critical role in cell-mediated liver injury associated with <span class=""disease"" id=""12586603-4-113-132"">alcoholic hepatitis</span>.",CTD_human
1,0,Biomarker,C0020500,Hyperoxaluria,disease,Hox,6352,CCL5,RANTES,CTD_human,16284884,"These results suggest that Hox stimulates the NF-kappaB cascade and, therefore, induces the overexpression of inflammatory mediators like IL-6, MCP-1, and RANTES.",0.2,"These results suggest that <span class=""disease"" id=""16284884-11-27-30"">Hox</span> stimulates the NF-kappaB cascade and, therefore, induces the overexpression of inflammatory mediators like IL-6, MCP-1, and <span class=""gene"" id=""16284884-11-155-161"">RANTES</span>.",CTD_human
1,0,Biomarker,C0034069,Pulmonary Fibrosis,disease,pulmonary fibrosis,6352,CCL5,CCL5,CTD_human,17620002,Relationship between eosinophilia and levels of chemokines (CCL5 and CCL11) and IL-5 in bronchoalveolar lavage fluid of patients with mustard gas-induced pulmonary fibrosis.,0.20300763924902696,"Relationship between eosinophilia and levels of chemokines (<span class=""gene"" id=""17620002-0-60-64"">CCL5</span> and CCL11) and IL-5 in bronchoalveolar lavage fluid of patients with mustard gas-induced <span class=""disease"" id=""17620002-0-154-172"">pulmonary fibrosis</span>.",CTD_human
1,0,Biomarker,C0345967,Malignant mesothelioma,disease,malignant mesothelioma,6352,CCL5,RANTES,CTD_human,25162674,Increased levels of C-C chemokine RANTES in asbestos exposed workers and in malignant mesothelioma patients from an hyperendemic area.,0.200274726784213,"Increased levels of C-C chemokine <span class=""gene"" id=""25162674-0-34-40"">RANTES</span> in asbestos exposed workers and in <span class=""disease"" id=""25162674-0-76-98"">malignant mesothelioma</span> patients from an hyperendemic area.",CTD_human
1,0,Biomarker,C0017658,Glomerulonephritis,disease,glomerulonephritis,6354,CCL7,MCP-3,CTD_human,10385480,"We previously reported that the gene expression of six CC chemokines-MCP-1, MCP-3, MIP-1alpha, MIP-1beta, RANTES, and TCA3-was enhanced in a rat model of crescentic glomerulonephritis, the most severe form of glomerulonephritis.",0.28,"We previously reported that the gene expression of six CC chemokines-MCP-1, <span class=""gene"" id=""10385480-3-76-81"">MCP-3</span>, MIP-1alpha, MIP-1beta, RANTES, and TCA3-was enhanced in a rat model of crescentic glomerulonephritis, the most severe form of <span class=""disease"" id=""10385480-3-209-227"">glomerulonephritis</span>.",CTD_human
1,0,Biomarker,C0345967,Malignant mesothelioma,disease,MM,6354,CCL7,MCP-3,CTD_human,25162674,"A specific pattern of cytokines were found highly expressed in Asb-workers: IFN-alpha (p<0.05), EOTAXIN (p<0.01), RANTES (p<0.001), and in MM patients: IL-12(p40), IL-3, IL-1 alpha, MCP-3, beta-NGF, TNF-beta, RANTES (p<0.001).",0.2,"A specific pattern of cytokines were found highly expressed in Asb-workers: IFN-alpha (p&lt;0.05), EOTAXIN (p&lt;0.01), RANTES (p&lt;0.001), and in <span class=""disease"" id=""25162674-8-139-141"">MM</span> patients: IL-12(p40), IL-3, IL-1 alpha, <span class=""gene"" id=""25162674-8-182-187"">MCP-3</span>, beta-NGF, TNF-beta, RANTES (p&lt;0.001).",CTD_human
1,0,Biomarker,C0003873,Rheumatoid Arthritis,disease,RA,6355,CCL8,CCL8,CTD_human,17568789,"HOXD10, HOXD11, HOXD13, CCL8 and LIM homeobox 2 were highly and exclusively expressed in RA and CLU, sarcoglycan-gamma, GPR64, POU3F3, peroxisome proliferative activated receptor-gamma and tripartite motif-containing 2 were expressed only in OA.",0.200274726784213,"HOXD10, HOXD11, HOXD13, <span class=""gene"" id=""17568789-4-24-28"">CCL8</span> and LIM homeobox 2 were highly and exclusively expressed in <span class=""disease"" id=""17568789-4-89-91"">RA</span> and CLU, sarcoglycan-gamma, GPR64, POU3F3, peroxisome proliferative activated receptor-gamma and tripartite motif-containing 2 were expressed only in OA.",CTD_human
2,0,Biomarker,C0034069,Pulmonary Fibrosis,disease,pulmonary fibrosis,6356,CCL11,CCL11,CTD_human,17620002,Relationship between eosinophilia and levels of chemokines (CCL5 and CCL11) and IL-5 in bronchoalveolar lavage fluid of patients with mustard gas-induced pulmonary fibrosis.,0.20300763924902696,"Relationship between eosinophilia and levels of chemokines (CCL5 and <span class=""gene"" id=""17620002-0-69-74"">CCL11</span>) and IL-5 in bronchoalveolar lavage fluid of patients with mustard gas-induced <span class=""disease"" id=""17620002-0-154-172"">pulmonary fibrosis</span>.",CTD_human
2,0,Biomarker,C0034069,Pulmonary Fibrosis,disease,lung fibrosis,6356,CCL11,CCL11,CTD_human,16314464,"Together, these data suggest that CCL11 and CCR3 are important in the pulmonary recruitment of granulocytes and play significant pathogenic roles in blm-induced lung fibrosis.",0.20300763924902696,"Together, these data suggest that <span class=""gene"" id=""16314464-10-34-39"">CCL11</span> and CCR3 are important in the pulmonary recruitment of granulocytes and play significant pathogenic roles in blm-induced <span class=""disease"" id=""16314464-10-161-174"">lung fibrosis</span>.",CTD_human
1,0,Biomarker,C0009324,Ulcerative Colitis,disease,ulcerative colitis,6364,CCL20,CCL20,CTD_human,16306769,Increased expression of MIP-3alpha/CCL20 in peripheral blood mononuclear cells from patients with ulcerative colitis and its down-regulation by sulfasalazine and glucocorticoid treatment.,0.201098907136852,"Increased expression of MIP-3alpha/<span class=""gene"" id=""16306769-0-35-40"">CCL20</span> in peripheral blood mononuclear cells from patients with <span class=""disease"" id=""16306769-0-98-116"">ulcerative colitis</span> and its down-regulation by sulfasalazine and glucocorticoid treatment.",CTD_human
1,0,Therapeutic,C0011854,"Diabetes Mellitus, Insulin-Dependent",disease,type 1 diabetes,6364,CCL20,CCL20,CTD_human,21340626,"CCL20 peptides, which block CCR6 binding to CCL20, inhibited development of type 1 diabetes.",0.2,"<span class=""gene"" id=""21340626-11-0-5"">CCL20</span> peptides, which block CCR6 binding to <span class=""gene"" id=""21340626-11-44-49"">CCL20</span>, inhibited development of <span class=""disease"" id=""21340626-11-76-91"">type 1 diabetes</span>.",CTD_human
3,2,Biomarker,C0003873,Rheumatoid Arthritis,disease,rheumatoid arthritis,6366,CCL21,CCL21,CTD_human,20453842,We also refined associations at two established rheumatoid arthritis risk loci (IL2RA and CCL21) and confirmed the association at AFF3.,0.22905216912871104,"We also refined associations at two established <span class=""disease"" id=""20453842-4-48-68"">rheumatoid arthritis</span> risk loci (IL2RA and <span class=""gene"" id=""20453842-4-90-95"">CCL21</span>) and confirmed the association at AFF3.",CTD_human
2,0,Biomarker,C0011615,"Dermatitis, Atopic",disease,atopic dermatitis,6367,CCL22,CCL22,CTD_human,22125604,Variants of C-C motif chemokine 22 (CCL22) are associated with susceptibility to atopic dermatitis: case-control studies.,0.21230528378032104,"Variants of <span class=""gene"" id=""22125604-0-12-34"">C-C motif chemokine 22</span> (<span class=""gene"" id=""22125604-0-36-41"">CCL22</span>) are associated with susceptibility to <span class=""disease"" id=""22125604-0-81-98"">atopic dermatitis</span>: case-control studies.",CTD_human
1,0,Biomarker,C0029408,Degenerative polyarthritis,disease,osteoarthritis,6372,CXCL6,CXCL6,CTD_human,15292528,"While these differences may represent differential behaviour of synovial fibroblasts in in vitro culture, these observations suggest that TFPI2, GRObeta (CXCL2), MnSOD and GCP-2 (CXCL6) may represent new targets for treatments specifically tailored to osteoarthritis.",0.200274726784213,"While these differences may represent differential behaviour of synovial fibroblasts in in vitro culture, these observations suggest that TFPI2, GRObeta (CXCL2), MnSOD and <span class=""gene"" id=""15292528-12-172-177"">GCP-2</span> (<span class=""gene"" id=""15292528-12-179-184"">CXCL6</span>) may represent new targets for treatments specifically tailored to <span class=""disease"" id=""15292528-12-252-266"">osteoarthritis</span>.",CTD_human
1,0,Biomarker,C0282488,Interstitial Cystitis,disease,IC,6373,CXCL11,CXCL11,CTD_human,18957084,"Serum levels of monokine-induced by interferon-gamma (IFN-gamma) (MIG/CXCL9), IFN-gamma-inducible protein-10 (IP-10/CXCL10), and IFN-gamma-inducible T cell alpha chemoattractant (I-TAC/CXCL11) were elevated in patients with IC.",0.2,"Serum levels of monokine-induced by interferon-gamma (IFN-gamma) (MIG/CXCL9), IFN-gamma-inducible protein-10 (IP-10/CXCL10), and IFN-gamma-inducible T cell alpha chemoattractant (<span class=""gene"" id=""18957084-2-179-184"">I-TAC</span>/<span class=""gene"" id=""18957084-2-185-191"">CXCL11</span>) were elevated in patients with <span class=""disease"" id=""18957084-2-224-226"">IC</span>.",CTD_human
2,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastasis,6387,CXCL12,stromal cell-derived factor-1,CTD_human,21312072,The influence of intraoperative pleural perfusion with matrine-cisplatin or cisplatin on stromal cell-derived factor-1 in non-small cell lung cancer patients with subclinical pleural metastasis.,0.26660069941329395,"The influence of intraoperative pleural perfusion with matrine-cisplatin or cisplatin on <span class=""gene"" id=""21312072-0-89-118"">stromal cell-derived factor-1</span> in non-small cell lung cancer patients with subclinical pleural <span class=""disease"" id=""21312072-0-183-193"">metastasis</span>.",CTD_human
2,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastasis,6387,CXCL12,CXCL12,CTD_human,23743303,CXCR4 and its natural chemokine ligand C-X-C motif ligand 12 (CXCL12) play a critical role in metastasis.,0.26660069941329395,"CXCR4 and its natural chemokine ligand C-X-C motif ligand 12 (<span class=""gene"" id=""23743303-4-62-68"">CXCL12</span>) play a critical role in <span class=""disease"" id=""23743303-4-94-104"">metastasis</span>.",CTD_human
1,0,Biomarker,C1859722,Arthrogryposis renal dysfunction cholestasis syndrome,disease,"arthrogryposis, renal dysfunction and cholestasis",63894,VIPAS39,VIPAR,CTD_human,20190753,"Mutations in VIPAR cause an arthrogryposis, renal dysfunction and cholestasis syndrome phenotype with defects in epithelial polarization.",0.401648360705279,"Mutations in <span class=""gene"" id=""20190753-0-13-18"">VIPAR</span> cause an <span class=""disease"" id=""20190753-0-28-77"">arthrogryposis, renal dysfunction and cholestasis</span> syndrome phenotype with defects in epithelial polarization.",CTD_human;ORPHANET
3,0,Biomarker,C0003873,Rheumatoid Arthritis,disease,rheumatoid arthritis,639,PRDM1,PRDM1,CTD_human,19898481,"Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk.",0.205638237399215,"Genetic variants at CD28, <span class=""gene"" id=""19898481-0-26-31"">PRDM1</span> and CD2/CD58 are associated with <span class=""disease"" id=""19898481-0-65-85"">rheumatoid arthritis</span> risk.",CTD_human
1,0,Biomarker,C0024141,"Lupus Erythematosus, Systemic",disease,systemic lupus erythematosus,639,PRDM1,PRDM1,CTD_human,19838195,"A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus.",0.283780662444354,"A large-scale replication study identifies TNIP1, <span class=""gene"" id=""19838195-0-50-55"">PRDM1</span>, JAZF1, UHRF1BP1 and IL10 as risk loci for <span class=""disease"" id=""19838195-0-99-127"">systemic lupus erythematosus</span>.",CTD_human
1,0,Biomarker,C0030421,Paraganglioma,disease,PGL,6390,SDHB,SDHB,CTD_human,19927285,We report a 13-year-old African American boy with diffusely metastatic PGL and compound heterozygous mutation leading to a novel splice donor region DNA sequence variant in the SDHB gene.,0.5011887916265949,"We report a 13-year-old African American boy with diffusely metastatic <span class=""disease"" id=""19927285-4-71-74"">PGL</span> and compound heterozygous mutation leading to a novel splice donor region DNA sequence variant in the <span class=""gene"" id=""19927285-4-177-181"">SDHB</span> gene.",CTD_human;HPO
1,0,Biomarker,C0025202,melanoma,disease,melanoma,6392,SDHD,SDHD,CTD_human,25261935,SDHD promoter mutations are frequent in melanoma and are associated with reduced gene expression and poor prognosis.,0.20054945356842604,"<span class=""gene"" id=""25261935-7-0-4"">SDHD</span> promoter mutations are frequent in <span class=""disease"" id=""25261935-7-40-48"">melanoma</span> and are associated with reduced gene expression and poor prognosis.",CTD_human
1,1,Biomarker,C0149931,Migraine Disorders,group,migraine,63976,PRDM16,PRDM16,CTD_human,21666692,"In a population-based genome-wide analysis including 5,122 migraineurs and 18,108 non-migraineurs, rs2651899 (1p36.32, PRDM16), rs10166942 (2q37.1, TRPM8) and rs11172113 (12q13.3, LRP1) were among the top seven associations (P < 5 × 10(-6)) with migraine.",0.201648360705279,"In a population-based genome-wide analysis including 5,122 migraineurs and 18,108 non-migraineurs, rs2651899 (1p36.32, <span class=""gene"" id=""21666692-3-119-125"">PRDM16</span>), rs10166942 (2q37.1, TRPM8) and rs11172113 (12q13.3, LRP1) were among the top seven associations (P &lt; 5 &times; 10(-6)) with <span class=""disease"" id=""21666692-3-246-254"">migraine</span>.",CTD_human
1,0,Biomarker,C1961102,Precursor Cell Lymphoblastic Leukemia Lymphoma,disease,lymphoblastic lymphoma,63978,PRDM14,Prdm14,CTD_human,19043588,This study implicates Prdm14 as a proto-oncogene involved in lymphoblastic lymphoma formation.,0.2,"This study implicates <span class=""gene"" id=""19043588-9-22-28"">Prdm14</span> as a proto-oncogene involved in <span class=""disease"" id=""19043588-9-61-83"">lymphoblastic lymphoma</span> formation.",CTD_human
1,1,Biomarker,C0009952,Febrile Convulsions,disease,febrile seizures,63982,ANO3,ANO3,CTD_human,25344690,"Furthermore, four loci were associated with febrile seizures in general, implicating the sodium channel genes SCN1A (rs6432860: P = 2.2 × 10(-16)) and SCN2A (rs3769955: P = 3.1 × 10(-10)), a TMEM16 family gene (ANO3; rs114444506: P = 3.7 × 10(-20)) and a region associated with magnesium levels (12q21.33; rs11105468: P = 3.4 × 10(-11)).",0.200274726784213,"Furthermore, four loci were associated with <span class=""disease"" id=""25344690-4-44-60"">febrile seizures</span> in general, implicating the sodium channel genes SCN1A (rs6432860: P = 2.2 &times; 10(-16)) and SCN2A (rs3769955: P = 3.1 &times; 10(-10)), a TMEM16 family gene (<span class=""gene"" id=""25344690-4-211-215"">ANO3</span>; rs114444506: P = 3.7 &times; 10(-20)) and a region associated with magnesium levels (12q21.33; rs11105468: P = 3.4 &times; 10(-11)).",CTD_human
1,0,Biomarker,C0026691,Mucocutaneous Lymph Node Syndrome,disease,Kawasaki disease,640,BLK,B-lymphoid tyrosine kinase,CTD_human,22446961,"We report two new loci, one at BLK (encoding B-lymphoid tyrosine kinase) and one at CD40, that are associated with Kawasaki disease at genome-wide significance (P < 5 × 10(-8)).",0.201098907136852,"We report two new loci, one at <span class=""gene"" id=""22446961-2-31-34"">BLK</span> (encoding <span class=""gene"" id=""22446961-2-45-71"">B-lymphoid tyrosine kinase</span>) and one at CD40, that are associated with <span class=""disease"" id=""22446961-2-115-131"">Kawasaki disease</span> at genome-wide significance (P &lt; 5 &times; 10(-8)).",CTD_human
1,0,Biomarker,C0004238,Atrial Fibrillation,disease,atrial fibrillation,6401,SELE,E-selectin,CTD_human,17890461,"Soluble E-selectin, von Willebrand factor, soluble thrombomodulin, and total body nitrate/nitrite product as indices of endothelial damage/dysfunction in paroxysmal, persistent, and permanent atrial fibrillation.",0.202732912464814,"Soluble <span class=""gene"" id=""17890461-0-8-18"">E-selectin</span>, von Willebrand factor, soluble thrombomodulin, and total body nitrate/nitrite product as indices of endothelial damage/dysfunction in paroxysmal, persistent, and permanent <span class=""disease"" id=""17890461-0-192-211"">atrial fibrillation</span>.",CTD_human
1,0,Biomarker,C0026769,Multiple Sclerosis,disease,MS,6401,SELE,E-Selectin,CTD_human,20175758,"Soluble forms of vascular cell adhesion molecule-1 (VCAM-1), intracellular adhesion molecule-1 (ICAM-1) and E-Selectin play a role in the regulation of blood-brain barrier damage and represent markers of the clinical course of multiple sclerosis (MS) and magnetic resonance imaging activity.",0.205363510615002,"Soluble forms of vascular cell adhesion molecule-1 (VCAM-1), intracellular adhesion molecule-1 (ICAM-1) and <span class=""gene"" id=""20175758-1-108-118"">E-Selectin</span> play a role in the regulation of blood-brain barrier damage and represent markers of the clinical course of <span class=""disease"" id=""20175758-1-227-245"">multiple sclerosis</span> (<span class=""disease"" id=""20175758-1-247-249"">MS</span>) and magnetic resonance imaging activity.",CTD_human
1,0,Biomarker,C1961102,Precursor Cell Lymphoblastic Leukemia Lymphoma,disease,acute lymphoblastic leukemia,64109,CRLF2,CRLF2,CTD_human,19838194,Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia.,0.20467035533162303,"Rearrangement of <span class=""gene"" id=""19838194-0-17-22"">CRLF2</span> in B-progenitor- and Down syndrome-associated <span class=""disease"" id=""19838194-0-69-97"">acute lymphoblastic leukemia</span>.",CTD_human
1,0,Biomarker,C0024301,"Lymphoma, Follicular",disease,follicular lymphoma,64121,RRAGC,RRAGC,CTD_human,26691987,Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma.,0.200274726784213,"Recurrent mTORC1-activating <span class=""gene"" id=""26691987-0-28-33"">RRAGC</span> mutations in <span class=""disease"" id=""26691987-0-47-66"">follicular lymphoma</span>.",CTD_human
1,0,Biomarker,C0009324,Ulcerative Colitis,disease,ulcerative colitis,64127,NOD2,NOD2,CTD_human,20452301,"The present study was aimed at describing expression of innate immunity genes (NOD2, RIP2, ?-defensins HD5 and HD6) in inflamed colon and in ileum of children with ulcerative colitis.",0.315642705061117,"The present study was aimed at describing expression of innate immunity genes (<span class=""gene"" id=""20452301-2-79-83"">NOD2</span>, RIP2, &alpha;-defensins HD5 and HD6) in inflamed colon and in ileum of children with <span class=""disease"" id=""20452301-2-164-182"">ulcerative colitis</span>.",CTD_human
6,4,Biomarker,C0010346,Crohn Disease,disease,Crohn's disease,64127,NOD2,NOD2,CTD_human,11385576,Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease.,0.52,"Association of <span class=""gene"" id=""11385576-0-15-19"">NOD2</span> leucine-rich repeat variants with susceptibility to <span class=""disease"" id=""11385576-0-72-87"">Crohn's disease</span>.",CTD_human
6,4,Biomarker,C0010346,Crohn Disease,disease,Crohn's disease,64127,NOD2,NOD2,CTD_human,17568627,"The second models the NOD2 3020insC SNP, which is the most common and highest risk variant in Crohn's disease, and examines the ability of food components or extracts to restore the normal phenotype in the mutant cell line.",0.52,"The second models the <span class=""gene"" id=""17568627-6-22-26"">NOD2</span> 3020insC SNP, which is the most common and highest risk variant in <span class=""disease"" id=""17568627-6-94-109"">Crohn's disease</span>, and examines the ability of food components or extracts to restore the normal phenotype in the mutant cell line.",CTD_human
6,4,Biomarker,C0010346,Crohn Disease,disease,Crohn's disease,64127,NOD2,NOD2,CTD_human,11385577,A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease.,0.52,"A frameshift mutation in <span class=""gene"" id=""11385577-0-25-29"">NOD2</span> associated with susceptibility to <span class=""disease"" id=""11385577-0-64-79"">Crohn's disease</span>.",CTD_human
6,4,Biomarker,C0010346,Crohn Disease,disease,Crohn's disease,64127,NOD2,CARD15,CTD_human,18438406,"We also show that several risk loci are common to ulcerative colitis and Crohn's disease (IL23R, IL12B, HLA, NKX2-3 and MST1), whereas autophagy genes ATG16L1 and IRGM, along with NOD2 (also known as CARD15), are specific for Crohn's disease.",0.52,"We also show that several risk loci are common to ulcerative colitis and <span class=""disease"" id=""18438406-2-73-88"">Crohn's disease</span> (IL23R, IL12B, HLA, NKX2-3 and MST1), whereas autophagy genes ATG16L1 and IRGM, along with <span class=""gene"" id=""18438406-2-180-184"">NOD2</span> (also known as <span class=""gene"" id=""18438406-2-200-206"">CARD15</span>), are specific for <span class=""disease"" id=""18438406-2-226-241"">Crohn's disease</span>.",CTD_human
6,4,Biomarker,C0010346,Crohn Disease,disease,Crohn's disease,64127,NOD2,CARD15,CTD_human,18371140,NOD2/CARD15 gene variants are linked to failure of antibiotic treatment in perianal fistulating Crohn's disease.,0.52,"<span class=""gene"" id=""18371140-0-0-4"">NOD2</span>/<span class=""gene"" id=""18371140-0-5-11"">CARD15</span> gene variants are linked to failure of antibiotic treatment in perianal fistulating <span class=""disease"" id=""18371140-0-96-111"">Crohn's disease</span>.",CTD_human
1,1,Biomarker,C0033847,Pseudoxanthoma Elasticum,disease,PXE,64132,XYLT2,XYLT-II,CTD_human,16571645,Here we show for the first time that variations in the XYLT-II gene are genetic co-factors in the severity of PXE.,0.400549453568426,"Here we show for the first time that variations in the <span class=""gene"" id=""16571645-9-55-62"">XYLT-II</span> gene are genetic co-factors in the severity of <span class=""disease"" id=""16571645-9-110-113"">PXE</span>.",CTD_human;UNIPROT
1,0,Biomarker,C1136249,"Mental Retardation, X-Linked",disease,X-linked mental retardation,641339,ZNF674,ZNF674,CTD_human,16385466,ZNF674: a new kruppel-associated box-containing zinc-finger gene involved in nonsyndromic X-linked mental retardation.,0.20300763924902696,"<span class=""gene"" id=""16385466-0-0-6"">ZNF674</span>: a new kruppel-associated box-containing zinc-finger gene involved in nonsyndromic <span class=""disease"" id=""16385466-0-90-117"">X-linked mental retardation</span>.",CTD_human
1,0,Biomarker,C0018213,Graves Disease,disease,Graves' disease,64135,IFIH1,IFIH1,CTD_human,17535987,Genomic polymorphism at the interferon-induced helicase (IFIH1) locus contributes to Graves' disease susceptibility.,0.20350593566014002,"Genomic polymorphism at the interferon-induced helicase (<span class=""gene"" id=""17535987-0-57-62"">IFIH1</span>) locus contributes to <span class=""disease"" id=""17535987-0-85-100"">Graves' disease</span> susceptibility.",CTD_human
2,1,Biomarker,C0024141,"Lupus Erythematosus, Systemic",disease,SLE,64135,IFIH1,IFIH1,CTD_human,19838195,"A candidate screen of alleles previously associated with other autoimmune diseases suggested five loci (P < 1 x 10(-3)) that may contribute to SLE: IFIH1, CFB, CLEC16A, IL12B and SH2B3.",0.28838550524134604,"A candidate screen of alleles previously associated with other autoimmune diseases suggested five loci (P &lt; 1 x 10(-3)) that may contribute to <span class=""disease"" id=""19838195-5-143-146"">SLE</span>: <span class=""gene"" id=""19838195-5-148-153"">IFIH1</span>, CFB, CLEC16A, IL12B and SH2B3.",CTD_human
1,0,Biomarker,C0001430,Adenoma,group,adenoma,6414,SELENOP,SEPP1,CTD_human,18483336,"Consistent with the individual SNP results, we observed a significant overall association with adenoma risk for SEPP1 and TXNRD1 (global P = 0.02 and 0.008, respectively) but not for the four GPX genes.",0.20596412134074102,"Consistent with the individual SNP results, we observed a significant overall association with <span class=""disease"" id=""18483336-10-95-102"">adenoma</span> risk for <span class=""gene"" id=""18483336-10-112-117"">SEPP1</span> and TXNRD1 (global P = 0.02 and 0.008, respectively) but not for the four GPX genes.",CTD_human
1,0,Biomarker,C0033578,Prostatic Neoplasms,group,prostate tumors,6414,SELENOP,Selenoprotein-P,CTD_human,12235003,"Quantitative real-time reverse transcription-PCR for Selenoprotein-P demonstrated a similar down-regulation of the transcript of this gene in a subset of human prostate tumors, mouse tumors, and prostate carcinoma cell lines.",0.20054945356842604,"Quantitative real-time reverse transcription-PCR for <span class=""gene"" id=""12235003-8-53-68"">Selenoprotein-P</span> demonstrated a similar down-regulation of the transcript of this gene in a subset of human <span class=""disease"" id=""12235003-8-160-175"">prostate tumors</span>, mouse tumors, and prostate carcinoma cell lines.",CTD_human
1,2,Biomarker,C0038013,Ankylosing spondylitis,disease,ankylosing spondylitis,64170,CARD9,CARD9,CTD_human,21743469,"Here we report the identification of three variants in the RUNX3, LTBR-TNFRSF1A and IL12B regions convincingly associated with ankylosing spondylitis (P < 5 × 10(-8) in the combined discovery and replication datasets) and a further four loci at PTGER4, TBKBP1, ANTXR2 and CARD9 that show strong association across all our datasets (P < 5 × 10(-6) overall, with support in each of the three datasets studied).",0.201098907136852,"Here we report the identification of three variants in the RUNX3, LTBR-TNFRSF1A and IL12B regions convincingly associated with <span class=""disease"" id=""21743469-2-127-149"">ankylosing spondylitis</span> (P &lt; 5 &times; 10(-8) in the combined discovery and replication datasets) and a further four loci at PTGER4, TBKBP1, ANTXR2 and <span class=""gene"" id=""21743469-2-272-277"">CARD9</span> that show strong association across all our datasets (P &lt; 5 &times; 10(-6) overall, with support in each of the three datasets studied).",CTD_human
1,0,Biomarker,C0029434,Osteogenesis Imperfecta,disease,osteogenesis imperfecta,64175,P3H1,LEPRE1,CTD_human,18566967,CRTAP and LEPRE1 mutations in recessive osteogenesis imperfecta.,0.21096036061389004,"CRTAP and <span class=""gene"" id=""18566967-0-10-16"">LEPRE1</span> mutations in recessive <span class=""disease"" id=""18566967-0-40-63"">osteogenesis imperfecta</span>.",CTD_human
2,0,Biomarker,C0009404,Colorectal Neoplasms,group,colorectal tumor,6422,SFRP1,sFRP1,CTD_human,17923031,"Methylation of sFRP1, 2, 5 and WIF-1 genes might serve as biomarkers for the early detection of colorectal tumor.",0.205740551713841,"Methylation of <span class=""gene"" id=""17923031-16-15-20"">sFRP1</span>, 2, 5 and WIF-1 genes might serve as biomarkers for the early detection of <span class=""disease"" id=""17923031-16-96-112"">colorectal tumor</span>.",CTD_human
1,0,Biomarker,C0021390,Inflammatory Bowel Diseases,group,IBD,6422,SFRP1,SFRP1,CTD_human,18716850,"Moreover, methylation of APC1A, APC2, SFRP1, and SFRP2 appears to mark progression from IBD colitis to IBD-associated neoplasia, and these genes may serve as biomarkers for IBD-associated neoplasia.",0.200274726784213,"Moreover, methylation of APC1A, APC2, <span class=""gene"" id=""18716850-12-38-43"">SFRP1</span>, and SFRP2 appears to mark progression from <span class=""disease"" id=""18716850-12-88-91"">IBD</span> colitis to <span class=""disease"" id=""18716850-12-103-106"">IBD</span>-associated neoplasia, and these genes may serve as biomarkers for <span class=""disease"" id=""18716850-12-173-176"">IBD</span>-associated neoplasia.",CTD_human
1,0,Biomarker,C0023267,Fibroid Tumor,disease,leiomyomas,6422,SFRP1,sFRP1,CTD_human,15972578,"Compared with myometrial SMC, cells derived from leiomyomas had significantly higher levels of both Wnt5b and sFRP1 transcripts.",0.20054945356842604,"Compared with myometrial SMC, cells derived from <span class=""disease"" id=""15972578-7-49-59"">leiomyomas</span> had significantly higher levels of both Wnt5b and <span class=""gene"" id=""15972578-7-110-115"">sFRP1</span> transcripts.",CTD_human
1,0,Biomarker,C1458155,Mammary Neoplasms,group,breast tumours,6422,SFRP1,SFRP1,CTD_human,18283316,"In the present study, we found frequent methylation of SFRP family genes in breast cancer cell lines (SFRP1, 7 out of 11, 64%; SFRP2, 11 out of 11, 100%; SFRP5, 10 out of 11, 91%) and primary breast tumours (SFRP1, 31 out of 78, 40%; SFRP2, 60 out of 78, 77%; SFRP5, 55 out of 78, 71%).",0.212580010564534,"In the present study, we found frequent methylation of SFRP family genes in breast cancer cell lines (<span class=""gene"" id=""18283316-3-102-107"">SFRP1</span>, 7 out of 11, 64%; SFRP2, 11 out of 11, 100%; SFRP5, 10 out of 11, 91%) and primary <span class=""disease"" id=""18283316-3-192-206"">breast tumours</span> (<span class=""gene"" id=""18283316-3-208-213"">SFRP1</span>, 31 out of 78, 40%; SFRP2, 60 out of 78, 77%; SFRP5, 55 out of 78, 71%).",CTD_human
1,0,Biomarker,C0003119,Anophthalmos,disease,anophthalmia,64220,STRA6,STRA6,CTD_human,17273977,"Mutations in STRA6 cause a broad spectrum of malformations including anophthalmia, congenital heart defects, diaphragmatic hernia, alveolar capillary dysplasia, lung hypoplasia, and mental retardation.",0.21007066772661998,"Mutations in <span class=""gene"" id=""17273977-0-13-18"">STRA6</span> cause a broad spectrum of malformations including <span class=""disease"" id=""17273977-0-69-81"">anophthalmia</span>, congenital heart defects, diaphragmatic hernia, alveolar capillary dysplasia, lung hypoplasia, and mental retardation.",CTD_human
1,0,Biomarker,C0018798,Congenital Heart Defects,group,congenital heart defects,64220,STRA6,STRA6,CTD_human,17273977,"Mutations in STRA6 cause a broad spectrum of malformations including anophthalmia, congenital heart defects, diaphragmatic hernia, alveolar capillary dysplasia, lung hypoplasia, and mental retardation.",0.202732912464814,"Mutations in <span class=""gene"" id=""17273977-0-13-18"">STRA6</span> cause a broad spectrum of malformations including anophthalmia, <span class=""disease"" id=""17273977-0-83-107"">congenital heart defects</span>, diaphragmatic hernia, alveolar capillary dysplasia, lung hypoplasia, and mental retardation.",CTD_human
1,0,Biomarker,C0019284,Diaphragmatic Hernia,phenotype,diaphragmatic hernia,64220,STRA6,STRA6,CTD_human,17273977,"Mutations in STRA6 cause a broad spectrum of malformations including anophthalmia, congenital heart defects, diaphragmatic hernia, alveolar capillary dysplasia, lung hypoplasia, and mental retardation.",0.202732912464814,"Mutations in <span class=""gene"" id=""17273977-0-13-18"">STRA6</span> cause a broad spectrum of malformations including anophthalmia, congenital heart defects, <span class=""disease"" id=""17273977-0-109-129"">diaphragmatic hernia</span>, alveolar capillary dysplasia, lung hypoplasia, and mental retardation.",CTD_human
1,0,Biomarker,C0026010,Microphthalmos,disease,microphthalmia,64220,STRA6,Stra6,CTD_human,18316031,"These fatal consequences of Stra6 deficiency, including craniofacial and cardiac defects and microphthalmia, were largely alleviated by reducing embryonic Rbp4 levels by morpholino oligonucleotide or pharmacological treatments.",0.20350593566014002,"These fatal consequences of <span class=""gene"" id=""18316031-8-28-33"">Stra6</span> deficiency, including craniofacial and cardiac defects and <span class=""disease"" id=""18316031-8-93-107"">microphthalmia</span>, were largely alleviated by reducing embryonic Rbp4 levels by morpholino oligonucleotide or pharmacological treatments.",CTD_human
3,14,Biomarker,C1832661,ANOPHTHALMIA AND PULMONARY HYPOPLASIA,disease,Matthew-Wood syndrome,64220,STRA6,STRA6,CTD_human,17503335,Matthew-Wood syndrome is caused by truncating mutations in the retinol-binding protein receptor gene STRA6.,0.6016483607052789,"<span class=""disease"" id=""17503335-0-0-21"">Matthew-Wood syndrome</span> is caused by truncating mutations in the retinol-binding protein receptor gene <span class=""gene"" id=""17503335-0-101-106"">STRA6</span>.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C2677362,Alveolar capillary dysplasia,disease,alveolar capillary dysplasia,64220,STRA6,STRA6,CTD_human,17273977,"Mutations in STRA6 cause a broad spectrum of malformations including anophthalmia, congenital heart defects, diaphragmatic hernia, alveolar capillary dysplasia, lung hypoplasia, and mental retardation.",0.2,"Mutations in <span class=""gene"" id=""17273977-0-13-18"">STRA6</span> cause a broad spectrum of malformations including anophthalmia, congenital heart defects, diaphragmatic hernia, <span class=""disease"" id=""17273977-0-131-159"">alveolar capillary dysplasia</span>, lung hypoplasia, and mental retardation.",CTD_human
1,0,Biomarker,C3714756,Intellectual Disability,group,mental retardation,64220,STRA6,STRA6,CTD_human,17273977,"Mutations in STRA6 cause a broad spectrum of malformations including anophthalmia, congenital heart defects, diaphragmatic hernia, alveolar capillary dysplasia, lung hypoplasia, and mental retardation.",0.20300763924902696,"Mutations in <span class=""gene"" id=""17273977-0-13-18"">STRA6</span> cause a broad spectrum of malformations including anophthalmia, congenital heart defects, diaphragmatic hernia, alveolar capillary dysplasia, lung hypoplasia, and <span class=""disease"" id=""17273977-0-182-200"">mental retardation</span>.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autistic,64221,ROBO3,ROBO3,CTD_human,18270976,"We further compared the mRNA expressions of ROBO1, ROBO2, ROBO3, and ROBO4 in the lymphocytes of 19 drug-naïve autistic patients and 20 age- and sex-matched controls.",0.202681755307501,"We further compared the mRNA expressions of ROBO1, ROBO2, <span class=""gene"" id=""18270976-10-58-63"">ROBO3</span>, and ROBO4 in the lymphocytes of 19 drug-naïve <span class=""disease"" id=""18270976-10-111-119"">autistic</span> patients and 20 age- and sex-matched controls.",CTD_human
1,0,Biomarker,C0007134,Renal Cell Carcinoma,disease,RCC,6423,SFRP2,sFRP2,CTD_human,18404682,This is the first report indicating that aberrant DNA methylation and histone modifications work together to silence the sFRP2 gene in RCC cells.,0.20383181960166602,"This is the first report indicating that aberrant DNA methylation and histone modifications work together to silence the <span class=""gene"" id=""18404682-13-121-126"">sFRP2</span> gene in <span class=""disease"" id=""18404682-13-135-138"">RCC</span> cells.",CTD_human
1,0,Biomarker,C0021390,Inflammatory Bowel Diseases,group,IBD,6423,SFRP2,SFRP2,CTD_human,18716850,"Moreover, methylation of APC1A, APC2, SFRP1, and SFRP2 appears to mark progression from IBD colitis to IBD-associated neoplasia, and these genes may serve as biomarkers for IBD-associated neoplasia.",0.20054945356842604,"Moreover, methylation of APC1A, APC2, SFRP1, and <span class=""gene"" id=""18716850-12-49-54"">SFRP2</span> appears to mark progression from <span class=""disease"" id=""18716850-12-88-91"">IBD</span> colitis to <span class=""disease"" id=""18716850-12-103-106"">IBD</span>-associated neoplasia, and these genes may serve as biomarkers for <span class=""disease"" id=""18716850-12-173-176"">IBD</span>-associated neoplasia.",CTD_human
1,0,Biomarker,C1458155,Mammary Neoplasms,group,breast tumours,6423,SFRP2,SFRP2,CTD_human,18283316,"In the present study, we found frequent methylation of SFRP family genes in breast cancer cell lines (SFRP1, 7 out of 11, 64%; SFRP2, 11 out of 11, 100%; SFRP5, 10 out of 11, 91%) and primary breast tumours (SFRP1, 31 out of 78, 40%; SFRP2, 60 out of 78, 77%; SFRP5, 55 out of 78, 71%).",0.20054945356842604,"In the present study, we found frequent methylation of SFRP family genes in breast cancer cell lines (SFRP1, 7 out of 11, 64%; <span class=""gene"" id=""18283316-3-127-132"">SFRP2</span>, 11 out of 11, 100%; SFRP5, 10 out of 11, 91%) and primary <span class=""disease"" id=""18283316-3-192-206"">breast tumours</span> (SFRP1, 31 out of 78, 40%; <span class=""gene"" id=""18283316-3-234-239"">SFRP2</span>, 60 out of 78, 77%; SFRP5, 55 out of 78, 71%).",CTD_human
1,0,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,type 2 diabetes,6424,SFRP4,Secreted frizzled-related protein 4,CTD_human,23140642,Secreted frizzled-related protein 4 reduces insulin secretion and is overexpressed in type 2 diabetes.,0.20054945356842604,"<span class=""gene"" id=""23140642-0-0-35"">Secreted frizzled-related protein 4</span> reduces insulin secretion and is overexpressed in <span class=""disease"" id=""23140642-0-86-101"">type 2 diabetes</span>.",CTD_human
4,11,Biomarker,C0342907,Sitosterolemia,disease,sitosterolemia,64240,ABCG5,ABCG5,CTD_human,11138003,"We now report that a new member of the ABC transporter family, ABCG5, is mutant in nine unrelated sitosterolemia patients.",0.6854945356842621,"We now report that a new member of the ABC transporter family, <span class=""gene"" id=""11138003-9-63-68"">ABCG5</span>, is mutant in nine unrelated <span class=""disease"" id=""11138003-9-98-112"">sitosterolemia</span> patients.",CTD_human;ORPHANET;UNIPROT
4,11,Biomarker,C0342907,Sitosterolemia,disease,sitosterolemia,64240,ABCG5,ABCG5,CTD_human,11099417,"We identified seven different mutations in two adjacent, oppositely oriented genes that encode new members of the adenosine triphosphate (ATP)-binding cassette (ABC) transporter family (six mutations in ABCG8 and one in ABCG5) in nine patients with sitosterolemia.",0.6854945356842621,"We identified seven different mutations in two adjacent, oppositely oriented genes that encode new members of the adenosine triphosphate (ATP)-binding cassette (ABC) transporter family (six mutations in ABCG8 and one in <span class=""gene"" id=""11099417-3-220-225"">ABCG5</span>) in nine patients with <span class=""disease"" id=""11099417-3-249-263"">sitosterolemia</span>.",CTD_human;ORPHANET;UNIPROT
2,16,Biomarker,C0342907,Sitosterolemia,disease,sitosterolemia,64241,ABCG8,ABCG8,CTD_human,11099417,"We identified seven different mutations in two adjacent, oppositely oriented genes that encode new members of the adenosine triphosphate (ATP)-binding cassette (ABC) transporter family (six mutations in ABCG8 and one in ABCG5) in nine patients with sitosterolemia.",0.684945082115836,"We identified seven different mutations in two adjacent, oppositely oriented genes that encode new members of the adenosine triphosphate (ATP)-binding cassette (ABC) transporter family (six mutations in <span class=""gene"" id=""11099417-3-203-208"">ABCG8</span> and one in ABCG5) in nine patients with <span class=""disease"" id=""11099417-3-249-263"">sitosterolemia</span>.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C1458155,Mammary Neoplasms,group,breast tumours,6425,SFRP5,SFRP5,CTD_human,18283316,"In the present study, we found frequent methylation of SFRP family genes in breast cancer cell lines (SFRP1, 7 out of 11, 64%; SFRP2, 11 out of 11, 100%; SFRP5, 10 out of 11, 91%) and primary breast tumours (SFRP1, 31 out of 78, 40%; SFRP2, 60 out of 78, 77%; SFRP5, 55 out of 78, 71%).",0.20328236603324,"In the present study, we found frequent methylation of SFRP family genes in breast cancer cell lines (SFRP1, 7 out of 11, 64%; SFRP2, 11 out of 11, 100%; <span class=""gene"" id=""18283316-3-154-159"">SFRP5</span>, 10 out of 11, 91%) and primary <span class=""disease"" id=""18283316-3-192-206"">breast tumours</span> (SFRP1, 31 out of 78, 40%; SFRP2, 60 out of 78, 77%; <span class=""gene"" id=""18283316-3-260-265"">SFRP5</span>, 55 out of 78, 71%).",CTD_human
1,0,Biomarker,C0036341,Schizophrenia,disease,SZ,6426,SRSF1,SFRS1,CTD_human,16223876,"Implementing this systematic approach, we: (i) discovered 177 putative SZ risk genes in brain, 28 of which map to linked chromosomal loci; (ii) delineated six biological processes and 12 molecular functions that may be particularly disrupted in the illness; (iii) identified 123 putative SZ biomarkers in blood, 6 of which (BTG1, GSK3A, HLA-DRB1, HNRPA3, SELENBP1, and SFRS1) had corresponding differential expression in brain; (iv) verified the differential expression of the strongest candidate SZ biomarker (SELENBP1) in blood; and (v) demonstrated neuronal and glial expression of SELENBP1 protein in brain.",0.20054945356842604,"Implementing this systematic approach, we: (i) discovered 177 putative <span class=""disease"" id=""16223876-4-71-73"">SZ</span> risk genes in brain, 28 of which map to linked chromosomal loci; (ii) delineated six biological processes and 12 molecular functions that may be particularly disrupted in the illness; (iii) identified 123 putative SZ biomarkers in blood, 6 of which (BTG1, GSK3A, HLA-DRB1, HNRPA3, SELENBP1, and <span class=""gene"" id=""16223876-4-369-374"">SFRS1</span>) had corresponding differential expression in brain; (iv) verified the differential expression of the strongest candidate SZ biomarker (SELENBP1) in blood; and (v) demonstrated neuronal and glial expression of SELENBP1 protein in brain.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,64324,NSD1,NSD1,CTD_human,18001468,Our findings suggest that Sotos syndrome is a rare cause of autism spectrum disorders and that screening for NSD1 mutations and deletions in patients with autism and macrocephaly is not warranted in the absence of other features of Sotos syndrome.,0.202681755307501,"Our findings suggest that Sotos syndrome is a rare cause of autism spectrum disorders and that screening for <span class=""gene"" id=""18001468-9-109-113"">NSD1</span> mutations and deletions in patients with <span class=""disease"" id=""18001468-9-155-161"">autism</span> and macrocephaly is not warranted in the absence of other features of Sotos syndrome.",CTD_human
14,181,Biomarker,C0175695,Sotos' syndrome,disease,So,64324,NSD1,NSD1,CTD_human,15640245,Blast analysis of the Sos genomic region on 5q35 revealed two complex mosaic low-copy repeats (LCRs) that are centromeric and telomeric to NSD1.,0.6275508676016329,"Blast analysis of the <span class=""disease"" id=""15640245-4-22-24"">So</span>s genomic region on 5q35 revealed two complex mosaic low-copy repeats (LCRs) that are centromeric and telomeric to <span class=""gene"" id=""15640245-4-139-143"">NSD1</span>.",CTD_human;ORPHANET;UNIPROT
14,181,Biomarker,C0175695,Sotos' syndrome,disease,Sotos syndrome,64324,NSD1,NSD1,CTD_human,14571271,"Mutations in NSD1 are responsible for Sotos syndrome, but are not a frequent finding in other overgrowth phenotypes.",0.6275508676016329,"Mutations in <span class=""gene"" id=""14571271-0-13-17"">NSD1</span> are responsible for <span class=""disease"" id=""14571271-0-38-52"">Sotos syndrome</span>, but are not a frequent finding in other overgrowth phenotypes.",CTD_human;ORPHANET;UNIPROT
14,181,Biomarker,C0175695,Sotos' syndrome,disease,Sotos syndrome,64324,NSD1,NSD1,CTD_human,12807965,We conclude therefore that NSD1 mutations account for most cases of Sotos syndrome and a significant number of Weaver syndrome cases in our series.,0.6275508676016329,"We conclude therefore that <span class=""gene"" id=""12807965-8-27-31"">NSD1</span> mutations account for most cases of <span class=""disease"" id=""12807965-8-68-82"">Sotos syndrome</span> and a significant number of Weaver syndrome cases in our series.",CTD_human;ORPHANET;UNIPROT
14,181,Biomarker,C0175695,Sotos' syndrome,disease,SoS,64324,NSD1,NSD1,CTD_human,18505455,Haploinsufficiency of the NSD1 gene due to 5q35 microdeletions or intragenic mutations causes Sotos syndrome (SoS).,0.6275508676016329,"Haploinsufficiency of the <span class=""gene"" id=""18505455-1-26-30"">NSD1</span> gene due to 5q35 microdeletions or intragenic mutations causes <span class=""disease"" id=""18505455-1-94-108"">Sotos syndrome</span> (<span class=""disease"" id=""18505455-1-110-113"">SoS</span>).",CTD_human;ORPHANET;UNIPROT
14,181,Biomarker,C0175695,Sotos' syndrome,disease,Sotos syndrome,64324,NSD1,NSD1,CTD_human,15452385,"In our patients suspected of having Sotos syndrome, facial features and overgrowth were highly predictive of a NSD1 gene aberration, whereas developmental delay and advanced bone age were not.",0.6275508676016329,"In our patients suspected of having <span class=""disease"" id=""15452385-11-36-50"">Sotos syndrome</span>, facial features and overgrowth were highly predictive of a <span class=""gene"" id=""15452385-11-111-115"">NSD1</span> gene aberration, whereas developmental delay and advanced bone age were not.",CTD_human;ORPHANET;UNIPROT
14,181,Biomarker,C0175695,Sotos' syndrome,disease,sotos syndrome,64324,NSD1,NSD1,CTD_human,21972110,NSD1 PHD domains bind methylated H3K4 and H3K9 using interactions disrupted by point mutations in human sotos syndrome.,0.6275508676016329,"<span class=""gene"" id=""21972110-0-0-4"">NSD1</span> PHD domains bind methylated H3K4 and H3K9 using interactions disrupted by point mutations in human <span class=""disease"" id=""21972110-0-104-118"">sotos syndrome</span>.",CTD_human;ORPHANET;UNIPROT
14,181,Biomarker,C0175695,Sotos' syndrome,disease,Sotos syndrome,64324,NSD1,NSD1,CTD_human,20101679,"Most of the patients with Sotos syndrome have NSD1 gene deletions or mutations; however, the molecular basis of most of the Weaver syndrome patients is unknown.",0.6275508676016329,"Most of the patients with <span class=""disease"" id=""20101679-3-26-40"">Sotos syndrome</span> have <span class=""gene"" id=""20101679-3-46-50"">NSD1</span> gene deletions or mutations; however, the molecular basis of most of the Weaver syndrome patients is unknown.",CTD_human;ORPHANET;UNIPROT
14,181,Biomarker,C0175695,Sotos' syndrome,disease,SoS,64324,NSD1,NSD1,CTD_human,15580547,Haploinsufficiency of the NSD1 gene owing to either intragenic mutations or microdeletions is known to be the major cause of SoS.,0.6275508676016329,"Haploinsufficiency of the <span class=""gene"" id=""15580547-2-26-30"">NSD1</span> gene owing to either intragenic mutations or microdeletions is known to be the major cause of <span class=""disease"" id=""15580547-2-125-128"">SoS</span>.",CTD_human;ORPHANET;UNIPROT
14,181,Biomarker,C0175695,Sotos' syndrome,disease,Sotos syndrome,64324,NSD1,NSD1,CTD_human,16188863,Auxological data in patients clinically suspected of Sotos syndrome with NSD1 gene alterations.,0.6275508676016329,"Auxological data in patients clinically suspected of <span class=""disease"" id=""16188863-0-53-67"">Sotos syndrome</span> with <span class=""gene"" id=""16188863-0-73-77"">NSD1</span> gene alterations.",CTD_human;ORPHANET;UNIPROT
14,181,Biomarker,C0175695,Sotos' syndrome,disease,Sotos syndrome,64324,NSD1,NSD1,CTD_human,16232326,Spectrum of NSD1 gene mutations in southern Chinese patients with Sotos syndrome.,0.6275508676016329,"Spectrum of <span class=""gene"" id=""16232326-0-12-16"">NSD1</span> gene mutations in southern Chinese patients with <span class=""disease"" id=""16232326-0-66-80"">Sotos syndrome</span>.",CTD_human;ORPHANET;UNIPROT
14,181,Biomarker,C0175695,Sotos' syndrome,disease,Sotos syndrome,64324,NSD1,NSD1,CTD_human,17561922,Leukocyte cDNA analysis of NSD1 derived from confirmed Sotos syndrome patients.,0.6275508676016329,"Leukocyte cDNA analysis of <span class=""gene"" id=""17561922-0-27-31"">NSD1</span> derived from confirmed <span class=""disease"" id=""17561922-0-55-69"">Sotos syndrome</span> patients.",CTD_human;ORPHANET;UNIPROT
14,181,Biomarker,C0175695,Sotos' syndrome,disease,Sotos syndrome,64324,NSD1,NSD1,CTD_human,18001468,Our findings suggest that Sotos syndrome is a rare cause of autism spectrum disorders and that screening for NSD1 mutations and deletions in patients with autism and macrocephaly is not warranted in the absence of other features of Sotos syndrome.,0.6275508676016329,"Our findings suggest that <span class=""disease"" id=""18001468-9-26-40"">Sotos syndrome</span> is a rare cause of autism spectrum disorders and that screening for <span class=""gene"" id=""18001468-9-109-113"">NSD1</span> mutations and deletions in patients with autism and macrocephaly is not warranted in the absence of other features of <span class=""disease"" id=""18001468-9-232-246"">Sotos syndrome</span>.",CTD_human;ORPHANET;UNIPROT
14,181,Biomarker,C0175695,Sotos' syndrome,disease,SoS,64324,NSD1,NSD1,CTD_human,14517949,"We previously showed that haploinsufficiency of the NSD1 gene is the major cause of SoS, and submicroscopic deletions at 5q35, including NSD1, were found in about a half (20/42) of our patients examined.",0.6275508676016329,"We previously showed that haploinsufficiency of the <span class=""gene"" id=""14517949-2-52-56"">NSD1</span> gene is the major cause of <span class=""disease"" id=""14517949-2-84-87"">SoS</span>, and submicroscopic deletions at 5q35, including <span class=""gene"" id=""14517949-2-137-141"">NSD1</span>, were found in about a half (20/42) of our patients examined.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0265210,Weaver syndrome,disease,Weaver syndrome,64324,NSD1,NSD1,CTD_human,12807965,We conclude therefore that NSD1 mutations account for most cases of Sotos syndrome and a significant number of Weaver syndrome cases in our series.,0.40137363392106606,"We conclude therefore that <span class=""gene"" id=""12807965-8-27-31"">NSD1</span> mutations account for most cases of Sotos syndrome and a significant number of <span class=""disease"" id=""12807965-8-111-126"">Weaver syndrome</span> cases in our series.",CTD_human;ORPHANET
1,0,Biomarker,C3714756,Intellectual Disability,group,mental retardation,64324,NSD1,NSD1,CTD_human,12807965,"Interestingly, mental retardation was consistently more severe in patients with NSD1 deletions.",0.20328236603324,"Interestingly, <span class=""disease"" id=""12807965-9-15-33"">mental retardation</span> was consistently more severe in patients with <span class=""gene"" id=""12807965-9-80-84"">NSD1</span> deletions.",CTD_human
1,0,Biomarker,C0010073,Coronary Artery Vasospasm,disease,coronary artery spasm,64333,ARHGAP9,ARHGAP9,CTD_human,19911011,The Ala370Ser polymorphism in the ARHGAP9 gene is associated with coronary artery spasm.,0.200274726784213,"The Ala370Ser polymorphism in the <span class=""gene"" id=""19911011-9-34-41"">ARHGAP9</span> gene is associated with <span class=""disease"" id=""19911011-9-66-87"">coronary artery spasm</span>.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,hepatocellular carcinoma,64399,HHIP,hedgehog-interacting protein,CTD_human,18559595,Down-regulation of hedgehog-interacting protein through genetic and epigenetic alterations in human hepatocellular carcinoma.,0.20300763924902696,"Down-regulation of <span class=""gene"" id=""18559595-0-19-47"">hedgehog-interacting protein</span> through genetic and epigenetic alterations in human <span class=""disease"" id=""18559595-0-100-124"">hepatocellular carcinoma</span>.",CTD_human
1,0,Biomarker,C0008370,Cholestasis,disease,cholestasis,644,BLVRA,BVR,CTD_human,18706437,"When cholestasis was induced in pregnant rats, BVR alpha, SVCT1 and SVCT2 expression in maternal and fetal livers was stimulated, and this was further enhanced by UDCA treatment.",0.4,"When <span class=""disease"" id=""18706437-10-5-16"">cholestasis</span> was induced in pregnant rats, <span class=""gene"" id=""18706437-10-47-50"">BVR</span> alpha, SVCT1 and SVCT2 expression in maternal and fetal livers was stimulated, and this was further enhanced by UDCA treatment.",CTD_human;HPO
2,0,Biomarker,C0024121,Lung Neoplasms,group,lung tumors,6441,SFTPD,surfactant protein D,CTD_human,14522914,Serum levels of surfactant protein D are increased in mice with lung tumors.,0.20546582492962803,"Serum levels of <span class=""gene"" id=""14522914-0-16-36"">surfactant protein D</span> are increased in mice with <span class=""disease"" id=""14522914-0-64-75"">lung tumors</span>.",CTD_human
2,0,Biomarker,C0024121,Lung Neoplasms,group,lung tumors,6441,SFTPD,surfactant protein D,CTD_human,15136449,Serum levels of surfactant protein D are increased in mice with lung tumors.,0.20546582492962803,"Serum levels of <span class=""gene"" id=""15136449-0-16-36"">surfactant protein D</span> are increased in mice with <span class=""disease"" id=""15136449-0-64-75"">lung tumors</span>.",CTD_human
1,0,Biomarker,C0017668,Focal glomerulosclerosis,disease,focal segmental glomerulosclerosis,64423,INF2,INF2,CTD_human,20023659,Mutations in the formin gene INF2 cause focal segmental glomerulosclerosis.,0.20604398925268802,"Mutations in the formin gene <span class=""gene"" id=""20023659-0-29-33"">INF2</span> cause <span class=""disease"" id=""20023659-0-40-74"">focal segmental glomerulosclerosis</span>.",CTD_human
2,0,Biomarker,C0878544,Cardiomyopathies,group,cardiomyopathy,6444,SGCD,?-sarcoglycan,CTD_human,20675662,Intolerance to ?-blockade in a mouse model of ?-sarcoglycan-deficient muscular dystrophy cardiomyopathy.,0.202197814273705,"Intolerance to ?-blockade in a mouse model of <span class=""gene"" id=""20675662-0-46-59"">&delta;-sarcoglycan</span>-deficient muscular dystrophy <span class=""disease"" id=""20675662-0-89-103"">cardiomyopathy</span>.",CTD_human
2,6,Biomarker,C1832525,Limb-girdle muscular dystrophy type 2F,disease,Limb girdle muscular dystrophy type 2F,6444,SGCD,?-sarcoglycan,CTD_human,20675662,Metoprolol was given orally (2.5 mg/kg/day) over 8 weeks to mdx mice (model for Duchenne muscular dystrophy) and ?-sarcoglycan-deficient (Sgcd(null)) mice (model for Limb girdle muscular dystrophy type 2F).,0.681098907136852,"Metoprolol was given orally (2.5 mg/kg/day) over 8 weeks to mdx mice (model for Duchenne muscular dystrophy) and <span class=""gene"" id=""20675662-5-113-126"">&delta;-sarcoglycan</span>-deficient (Sgcd(null)) mice (model for <span class=""disease"" id=""20675662-5-166-204"">Limb girdle muscular dystrophy type 2F</span>).",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0029408,Degenerative polyarthritis,disease,OA,6445,SGCG,sarcoglycan-gamma,CTD_human,17568789,"HOXD10, HOXD11, HOXD13, CCL8 and LIM homeobox 2 were highly and exclusively expressed in RA and CLU, sarcoglycan-gamma, GPR64, POU3F3, peroxisome proliferative activated receptor-gamma and tripartite motif-containing 2 were expressed only in OA.",0.2,"HOXD10, HOXD11, HOXD13, CCL8 and LIM homeobox 2 were highly and exclusively expressed in RA and CLU, <span class=""gene"" id=""17568789-4-101-118"">sarcoglycan-gamma</span>, GPR64, POU3F3, peroxisome proliferative activated receptor-gamma and tripartite motif-containing 2 were expressed only in <span class=""disease"" id=""17568789-4-242-244"">OA</span>.",CTD_human
1,0,Biomarker,C0041948,Uremia,disease,uremia,6446,SGK1,sgk1,CTD_human,18768591,"During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs. 40 days in sgk1(+/+) mice).",0.2,"During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in <span class=""gene"" id=""18768591-8-101-105"">sgk1</span>(-/-) mice than in <span class=""gene"" id=""18768591-8-124-128"">sgk1</span>(+/+) mice leading to <span class=""disease"" id=""18768591-8-150-156"">uremia</span> and a reduced median survival in <span class=""gene"" id=""18768591-8-190-194"">sgk1</span>(-/-) mice (29 vs. 40 days in <span class=""gene"" id=""18768591-8-224-228"">sgk1</span>(+/+) mice).",CTD_human
1,0,Biomarker,C0025149,Medulloblastoma,disease,medulloblastomas,6447,SCG5,SGNE1,CTD_human,17334394,SGNE1/7B2 is epigenetically altered and transcriptionally downregulated in human medulloblastomas.,0.20300763924902696,"<span class=""gene"" id=""17334394-0-0-5"">SGNE1</span>/7B2 is epigenetically altered and transcriptionally downregulated in human <span class=""disease"" id=""17334394-0-81-97"">medulloblastomas</span>.",CTD_human
1,1,Biomarker,C0033860,Psoriasis,disease,psoriasis,64478,CSMD1,CSMD1,CTD_human,20953187,"We identified six new susceptibility loci associated with psoriasis in the Chinese study containing the candidate genes ERAP1, PTTG1, CSMD1, GJB2, SERPINB8 and ZNF816A (combined P < 5 × 10??) and replicated one locus, 5q33.1 (TNIP1-ANXA6), previously reported (combined P = 3.8 × 10?²¹) in the European studies.",0.202681755307501,"We identified six new susceptibility loci associated with <span class=""disease"" id=""20953187-2-58-67"">psoriasis</span> in the Chinese study containing the candidate genes ERAP1, PTTG1, <span class=""gene"" id=""20953187-2-134-139"">CSMD1</span>, GJB2, SERPINB8 and ZNF816A (combined P &lt; 5 &times; 10??) and replicated one locus, 5q33.1 (TNIP1-ANXA6), previously reported (combined P = 3.8 &times; 10?²¹) in the European studies.",CTD_human
1,0,Biomarker,C0279626,Squamous cell carcinoma of esophagus,disease,ESCC,645,BLVRB,BLVRB,CTD_human,21517111,"Among these identified proteins, 33 proteins including keratin 17 (KRT17), biliverdin reductase B (BLVRB), proteasome activator subunit 1 (PSME1), manganese superoxide dismutase (MnSOD), high-mobility group box-1(HMGB1), heat shock protein 70 (HSP70), peroxiredoxin (PRDX1), keratin 13 (KRT13), and so on were overexpressed, and 14 proteins including cystatin B (CSTB), tropomyosin 2 (TPM2), annexin 1 (ANX1), transgelin (TAGLN), keratin 19 (KRT19), stratifin (SFN), and so on were down-expressed in ESCC.",0.2,"Among these identified proteins, 33 proteins including keratin 17 (KRT17), <span class=""gene"" id=""21517111-5-75-97"">biliverdin reductase B</span> (<span class=""gene"" id=""21517111-5-99-104"">BLVRB</span>), proteasome activator subunit 1 (PSME1), manganese superoxide dismutase (MnSOD), high-mobility group box-1(HMGB1), heat shock protein 70 (HSP70), peroxiredoxin (PRDX1), keratin 13 (KRT13), and so on were overexpressed, and 14 proteins including cystatin B (CSTB), tropomyosin 2 (TPM2), annexin 1 (ANX1), transgelin (TAGLN), keratin 19 (KRT19), stratifin (SFN), and so on were down-expressed in <span class=""disease"" id=""21517111-5-500-504"">ESCC</span>.",CTD_human
1,0,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,type 2 diabetes,6462,SHBG,SHBG,CTD_human,21982312,"Polymorphisms in the SHBG gene are associated with risk of type 2 diabetes, but few studies have addressed SHBG as a predictor of CV events.",0.20948441237819898,"Polymorphisms in the <span class=""gene"" id=""21982312-4-21-25"">SHBG</span> gene are associated with risk of <span class=""disease"" id=""21982312-4-59-74"">type 2 diabetes</span>, but few studies have addressed <span class=""gene"" id=""21982312-4-107-111"">SHBG</span> as a predictor of CV events.",CTD_human
1,0,Biomarker,C0242350,Erectile dysfunction,disease,erectile dysfunction,6462,SHBG,sex hormone-binding globulin,CTD_human,17961146,Low sex hormone-binding globulin and testosterone levels in association with erectile dysfunction among human immunodeficiency virus-infected men receiving testosterone and oxandrolone.,0.2,"Low <span class=""gene"" id=""17961146-0-4-32"">sex hormone-binding globulin</span> and testosterone levels in association with <span class=""disease"" id=""17961146-0-77-97"">erectile dysfunction</span> among human immunodeficiency virus-infected men receiving testosterone and oxandrolone.",CTD_human
2,0,Biomarker,C0524620,Metabolic Syndrome X,disease,MetS,6462,SHBG,SHBG,CTD_human,16968811,Further studies are needed to support the notion that raising SHBG is a potential therapeutic target for prevention and treatment of MetS.,0.20357144819477,"Further studies are needed to support the notion that raising <span class=""gene"" id=""16968811-13-62-66"">SHBG</span> is a potential therapeutic target for prevention and treatment of <span class=""disease"" id=""16968811-13-133-137"">MetS</span>.",CTD_human
2,0,Biomarker,C0524620,Metabolic Syndrome X,disease,metabolic syndrome,6462,SHBG,SHBG,CTD_human,17992261,This provides a biological explanation for why SHBG is a sensitive biomarker of the metabolic syndrome and the metabolic disturbances associated with increased fructose consumption.,0.20357144819477,"This provides a biological explanation for why <span class=""gene"" id=""17992261-8-47-51"">SHBG</span> is a sensitive biomarker of the <span class=""disease"" id=""17992261-8-84-102"">metabolic syndrome</span> and the metabolic disturbances associated with increased fructose consumption.",CTD_human
3,0,Biomarker,C0079541,Holoprosencephaly,disease,holoprosencephaly,6469,SHH,sonic hedgehog,CTD_human,15107988,Wide phenotypic variability in families with holoprosencephaly and a sonic hedgehog mutation.,0.43310465146856897,"Wide phenotypic variability in families with <span class=""disease"" id=""15107988-0-45-62"">holoprosencephaly</span> and a <span class=""gene"" id=""15107988-0-69-83"">sonic hedgehog</span> mutation.",CTD_human;HPO
3,0,Biomarker,C0079541,Holoprosencephaly,disease,HPE,6469,SHH,SHH,CTD_human,23264560,NODAL and SHH dose-dependent double inhibition promotes an HPE-like phenotype in chick embryos.,0.43310465146856897,"NODAL and <span class=""gene"" id=""23264560-0-10-13"">SHH</span> dose-dependent double inhibition promotes an <span class=""disease"" id=""23264560-0-59-62"">HPE</span>-like phenotype in chick embryos.",CTD_human;HPO
3,0,Biomarker,C0079541,Holoprosencephaly,disease,holoprosencephaly,6469,SHH,sonic hedgehog,CTD_human,17525797,Gas1 is a modifier for holoprosencephaly and genetically interacts with sonic hedgehog.,0.43310465146856897,"Gas1 is a modifier for <span class=""disease"" id=""17525797-0-23-40"">holoprosencephaly</span> and genetically interacts with <span class=""gene"" id=""17525797-0-72-86"">sonic hedgehog</span>.",CTD_human;HPO
1,0,Biomarker,C0017605,Angle Closure Glaucoma,disease,angle-closure glaucoma,646960,PRSS56,PRSS56,CTD_human,21532570,Alteration of the serine protease PRSS56 causes angle-closure glaucoma in mice and posterior microphthalmia in humans and mice.,0.20082418035263896,"Alteration of the serine protease <span class=""gene"" id=""21532570-0-34-40"">PRSS56</span> causes <span class=""disease"" id=""21532570-0-48-70"">angle-closure glaucoma</span> in mice and posterior microphthalmia in humans and mice.",CTD_human
1,0,Biomarker,C0026010,Microphthalmos,disease,microphthalmia,646960,PRSS56,PRSS56,CTD_human,21532570,Alteration of the serine protease PRSS56 causes angle-closure glaucoma in mice and posterior microphthalmia in humans and mice.,0.40137363392106606,"Alteration of the serine protease <span class=""gene"" id=""21532570-0-34-40"">PRSS56</span> causes angle-closure glaucoma in mice and posterior <span class=""disease"" id=""21532570-0-93-107"">microphthalmia</span> in humans and mice.",CTD_human;ORPHANET
1,0,Biomarker,C0024305,"Lymphoma, Non-Hodgkin",disease,NHL,6470,SHMT1,SHMT1,CTD_human,17119116,"We observed a decreased risk of NHL over-all with BHMTEx8+453A>T and increased risk with CBS Ex13+41C>T, FPGS Ex15-263T>C, and SHMT1 Ex12+138C>T and Ex12+236C>T.",0.20831999270671597,"We observed a decreased risk of <span class=""disease"" id=""17119116-5-32-35"">NHL</span> over-all with BHMTEx8+453A&gt;T and increased risk with CBS Ex13+41C&gt;T, FPGS Ex15-263T&gt;C, and <span class=""gene"" id=""17119116-5-127-132"">SHMT1</span> Ex12+138C&gt;T and Ex12+236C&gt;T.",CTD_human
1,0,Biomarker,C0022578,Keratoconus,disease,keratoconus,64778,FNDC3B,FNDC3B,CTD_human,23291589,"We further showed that 2 CCT-associated loci, FOXO1 and FNDC3B, conferred relatively large risks for keratoconus in 2 cohorts with 874 cases and 6,085 controls (rs2721051 near FOXO1 had odds ratio (OR) = 1.62, 95% confidence interval (CI) = 1.4-1.88, P = 2.7 × 10(-10), and rs4894535 in FNDC3B had OR = 1.47, 95% CI = 1.29-1.68, P = 4.9 × 10(-9)).",0.201098907136852,"We further showed that 2 CCT-associated loci, FOXO1 and <span class=""gene"" id=""23291589-3-56-62"">FNDC3B</span>, conferred relatively large risks for <span class=""disease"" id=""23291589-3-101-112"">keratoconus</span> in 2 cohorts with 874 cases and 6,085 controls (rs2721051 near FOXO1 had odds ratio (OR) = 1.62, 95% confidence interval (CI) = 1.4-1.88, P = 2.7 &times; 10(-10), and rs4894535 in <span class=""gene"" id=""23291589-3-287-293"">FNDC3B</span> had OR = 1.47, 95% CI = 1.29-1.68, P = 4.9 &times; 10(-9)).",CTD_human
1,0,Biomarker,C0339573,"Glaucoma, Primary Open Angle",disease,primary open-angle glaucoma,64778,FNDC3B,FNDC3B,CTD_human,23291589,"FNDC3B was also associated with primary open-angle glaucoma (P = 5.6 × 10(-4); tested in 3 cohorts with 2,979 cases and 7,399 controls).",0.20054945356842604,"<span class=""gene"" id=""23291589-4-0-6"">FNDC3B</span> was also associated with <span class=""disease"" id=""23291589-4-32-59"">primary open-angle glaucoma</span> (P = 5.6 &times; 10(-4); tested in 3 cohorts with 2,979 cases and 7,399 controls).",CTD_human
1,0,Biomarker,C0020557,Hypertriglyceridemia,phenotype,hypertriglyceridemia,64788,LMF1,LMF1,CTD_human,17994020,Mutations in LMF1 cause combined lipase deficiency and severe hypertriglyceridemia.,0.202472541057918,"Mutations in <span class=""gene"" id=""17994020-0-13-17"">LMF1</span> cause combined lipase deficiency and severe <span class=""disease"" id=""17994020-0-62-82"">hypertriglyceridemia</span>.",CTD_human
1,0,Biomarker,C0017638,Glioma,disease,glioma,648,BMI1,Bmi-1,CTD_human,23383216,Bmi-1 promotes glioma angiogenesis by activating NF-?B signaling.,0.20822744814907604,"<span class=""gene"" id=""23383216-0-0-5"">Bmi-1</span> promotes <span class=""disease"" id=""23383216-0-15-21"">glioma</span> angiogenesis by activating NF-&kappa;B signaling.",CTD_human
1,0,Biomarker,C0029463,Osteosarcoma,disease,osteosarcoma,648,BMI1,BMI-1,CTD_human,21311599,Overexpression of BMI-1 promotes cell growth and resistance to cisplatin treatment in osteosarcoma.,0.20082418035263896,"Overexpression of <span class=""gene"" id=""21311599-0-18-23"">BMI-1</span> promotes cell growth and resistance to cisplatin treatment in <span class=""disease"" id=""21311599-0-86-98"">osteosarcoma</span>.",CTD_human
1,0,Biomarker,C3463824,MYELODYSPLASTIC SYNDROME,group,myelodysplastic syndromes,648,BMI1,BMI1,CTD_human,24571310,"In this study, we found that the patients of both myelodysplastic syndromes and chronic myeloid leukaemia with BMI1 overexpression had a higher risk in malignant myeloid progression.",0.201923087489492,"In this study, we found that the patients of both <span class=""disease"" id=""24571310-3-50-75"">myelodysplastic syndromes</span> and chronic myeloid leukaemia with <span class=""gene"" id=""24571310-3-111-115"">BMI1</span> overexpression had a higher risk in malignant myeloid progression.",CTD_human
1,1,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,T2D,6480,ST6GAL1,ST6GAL1,CTD_human,21874001,"In the combined analysis, we identified common genetic variants at six loci (GRB14, ST6GAL1, VPS26A, HMG20A, AP3S2 and HNF4A) newly associated with T2D (P = 4.1 × 10(-8) to P = 1.9 × 10(-11)).",0.2,"In the combined analysis, we identified common genetic variants at six loci (GRB14, <span class=""gene"" id=""21874001-4-84-91"">ST6GAL1</span>, VPS26A, HMG20A, AP3S2 and HNF4A) newly associated with <span class=""disease"" id=""21874001-4-148-151"">T2D</span> (P = 4.1 &times; 10(-8) to P = 1.9 &times; 10(-11)).",CTD_human
1,0,Biomarker,C0029124,Optic Atrophy,disease,optic atrophy,64802,NMNAT1,NMNAT1,CTD_human,22842229,Mutations in NMNAT1 cause Leber congenital amaurosis with early-onset severe macular and optic atrophy.,0.200274726784213,"Mutations in <span class=""gene"" id=""22842229-0-13-19"">NMNAT1</span> cause Leber congenital amaurosis with early-onset severe macular and <span class=""disease"" id=""22842229-0-89-102"">optic atrophy</span>.",CTD_human
4,0,Biomarker,C0339527,Leber Congenital Amaurosis,disease,Leber congenital amaurosis,64802,NMNAT1,NMNAT1,CTD_human,22842227,NMNAT1 mutations cause Leber congenital amaurosis.,0.40302199462634397,"<span class=""gene"" id=""22842227-0-0-6"">NMNAT1</span> mutations cause <span class=""disease"" id=""22842227-0-23-49"">Leber congenital amaurosis</span>.",CTD_human;ORPHANET
4,0,Biomarker,C0339527,Leber Congenital Amaurosis,disease,Leber congenital amaurosis,64802,NMNAT1,NMNAT1,CTD_human,22842231,Exome sequencing identifies NMNAT1 mutations as a cause of Leber congenital amaurosis.,0.40302199462634397,"Exome sequencing identifies <span class=""gene"" id=""22842231-0-28-34"">NMNAT1</span> mutations as a cause of <span class=""disease"" id=""22842231-0-59-85"">Leber congenital amaurosis</span>.",CTD_human;ORPHANET
4,0,Biomarker,C0339527,Leber Congenital Amaurosis,disease,Leber congenital amaurosis,64802,NMNAT1,NMNAT1,CTD_human,22842230,Mutations in NMNAT1 cause Leber congenital amaurosis and identify a new disease pathway for retinal degeneration.,0.40302199462634397,"Mutations in <span class=""gene"" id=""22842230-0-13-19"">NMNAT1</span> cause <span class=""disease"" id=""22842230-0-26-52"">Leber congenital amaurosis</span> and identify a new disease pathway for retinal degeneration.",CTD_human;ORPHANET
4,0,Biomarker,C0339527,Leber Congenital Amaurosis,disease,Leber congenital amaurosis,64802,NMNAT1,NMNAT1,CTD_human,22842229,Mutations in NMNAT1 cause Leber congenital amaurosis with early-onset severe macular and optic atrophy.,0.40302199462634397,"Mutations in <span class=""gene"" id=""22842229-0-13-19"">NMNAT1</span> cause <span class=""disease"" id=""22842229-0-26-52"">Leber congenital amaurosis</span> with early-onset severe macular and optic atrophy.",CTD_human;ORPHANET
1,0,Biomarker,C0027051,Myocardial Infarction,disease,myocardial infarction,64805,P2RY12,P2Y12,CTD_human,19334620,It is suggested that polymorphisms of the P2Y12 gene identified can be used for determination of the risk group for myocardial infarction in the young males.,0.210177567661578,"It is suggested that polymorphisms of the <span class=""gene"" id=""19334620-11-42-47"">P2Y12</span> gene identified can be used for determination of the risk group for <span class=""disease"" id=""19334620-11-116-137"">myocardial infarction</span> in the young males.",CTD_human
7,6,Biomarker,C0016395,Focal Dermal Hypoplasia,disease,focal dermal hypoplasia,64840,PORCN,PORCN,CTD_human,17546030,"Mutations in X-linked PORCN, a putative regulator of Wnt signaling, cause focal dermal hypoplasia.",0.695891087352408,"Mutations in X-linked <span class=""gene"" id=""17546030-0-22-27"">PORCN</span>, a putative regulator of Wnt signaling, cause <span class=""disease"" id=""17546030-0-74-97"">focal dermal hypoplasia</span>.",CTD_human;ORPHANET;UNIPROT
7,6,Biomarker,C0016395,Focal Dermal Hypoplasia,disease,focal dermal hypoplasia,64840,PORCN,PORCN,CTD_human,17546031,"Deficiency of PORCN, a regulator of Wnt signaling, is associated with focal dermal hypoplasia.",0.695891087352408,"Deficiency of <span class=""gene"" id=""17546031-0-14-19"">PORCN</span>, a regulator of Wnt signaling, is associated with <span class=""disease"" id=""17546031-0-70-93"">focal dermal hypoplasia</span>.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0025202,melanoma,disease,melanoma,6490,PMEL,gp100,CTD_human,26640592,"Expression of MAAs such as MART-1 and gp100 is modulated by the MAPK signaling pathway, which is often deregulated in melanoma.",0.238064088961722,"Expression of MAAs such as MART-1 and <span class=""gene"" id=""26640592-2-38-43"">gp100</span> is modulated by the MAPK signaling pathway, which is often deregulated in <span class=""disease"" id=""26640592-2-118-126"">melanoma</span>.",CTD_human
1,0,Biomarker,C0024299,Lymphoma,group,lymphomas,64919,BCL11B,Bcl11b,CTD_human,17941976,Bcl11b mutations identified in murine lymphomas increase the proliferation rate of hematopoietic progenitor cells.,0.201098907136852,"<span class=""gene"" id=""17941976-0-0-6"">Bcl11b</span> mutations identified in murine <span class=""disease"" id=""17941976-0-38-47"">lymphomas</span> increase the proliferation rate of hematopoietic progenitor cells.",CTD_human
1,0,Biomarker,C1961099,Precursor T-Cell Lymphoblastic Leukemia-Lymphoma,disease,T-ALL,64919,BCL11B,BCL11B,CTD_human,20972433,Here we show that transgenic expression of human TLX1 in mice induces T-ALL with frequent deletions and mutations in Bcl11b (encoding B cell leukemia/lymphoma-11B) and identify the presence of recurrent mutations and deletions in BCL11B in 16% of human T-ALLs.,0.203296721410557,"Here we show that transgenic expression of human TLX1 in mice induces <span class=""disease"" id=""20972433-3-70-75"">T-ALL</span> with frequent deletions and mutations in <span class=""gene"" id=""20972433-3-117-123"">Bcl11b</span> (encoding B cell leukemia/lymphoma-11B) and identify the presence of recurrent mutations and deletions in <span class=""gene"" id=""20972433-3-230-236"">BCL11B</span> in 16% of human <span class=""disease"" id=""20972433-3-253-258"">T-ALL</span>s.",CTD_human
1,0,Biomarker,C0376634,Craniofacial Abnormalities,group,Craniofacial abnormalities,6493,SIM2,Sim2,CTD_human,12203729,Craniofacial abnormalities resulting from targeted disruption of the murine Sim2 gene.,0.2,"<span class=""disease"" id=""12203729-0-0-26"">Craniofacial abnormalities</span> resulting from targeted disruption of the murine <span class=""gene"" id=""12203729-0-76-80"">Sim2</span> gene.",CTD_human
1,0,Biomarker,C0025202,melanoma,disease,melanoma,6494,SIPA1,SIPA1,CTD_human,22535842,"Accordingly, siRNA-mediated down-regulation of SIPA1 exerted significant effects on clonogenicity, adherence and migration in aggressive melanoma models.",0.200274726784213,"Accordingly, siRNA-mediated down-regulation of <span class=""gene"" id=""22535842-10-47-52"">SIPA1</span> exerted significant effects on clonogenicity, adherence and migration in aggressive <span class=""disease"" id=""22535842-10-137-145"">melanoma</span> models.",CTD_human
1,0,Biomarker,C0376634,Craniofacial Abnormalities,group,craniofacial abnormalities,6495,SIX1,Six 1,CTD_human,12834866,"Thymus, kidney and craniofacial abnormalities in Six 1 deficient mice.",0.2,"Thymus, kidney and <span class=""disease"" id=""12834866-0-19-45"">craniofacial abnormalities</span> in <span class=""gene"" id=""12834866-0-49-54"">Six 1</span> deficient mice.",CTD_human
1,0,Biomarker,C0079541,Holoprosencephaly,disease,holoprosencephaly,6496,SIX3,SIX3,CTD_human,10369266,Mutations in the homeodomain of the human SIX3 gene cause holoprosencephaly.,0.41719920873884403,"Mutations in the homeodomain of the human <span class=""gene"" id=""10369266-0-42-46"">SIX3</span> gene cause <span class=""disease"" id=""10369266-0-58-75"">holoprosencephaly</span>.",CTD_human;HPO
1,0,Biomarker,C0003486,Aortic Aneurysm,disease,aortic aneurysm,6497,SKI,SKI,CTD_human,23023332,Mutations in the TGF-? repressor SKI cause Shprintzen-Goldberg syndrome with aortic aneurysm.,0.200274726784213,"Mutations in the TGF-&beta; repressor <span class=""gene"" id=""23023332-0-33-36"">SKI</span> cause Shprintzen-Goldberg syndrome with <span class=""disease"" id=""23023332-0-77-92"">aortic aneurysm</span>.",CTD_human
4,11,Biomarker,C1321551,Shprintzen-Goldberg syndrome,disease,Shprintzen-Goldberg syndrome,6497,SKI,SKI,CTD_human,23023332,Mutations in the TGF-? repressor SKI cause Shprintzen-Goldberg syndrome with aortic aneurysm.,0.6010989071368521,"Mutations in the TGF-&beta; repressor <span class=""gene"" id=""23023332-0-33-36"">SKI</span> cause <span class=""disease"" id=""23023332-0-43-71"">Shprintzen-Goldberg syndrome</span> with aortic aneurysm.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C1704436,Peripheral Arterial Diseases,group,PAD,650,BMP2,BMP2,CTD_human,27082954,"Further investigation revealed several variants in BMP genes associated with PAD via an interaction with traffic exposure in both the EA and AA cohorts; this included interactions with non-synonymous variants in BMP2, which is regulated by air pollution exposure.",0.200274726784213,"Further investigation revealed several variants in BMP genes associated with <span class=""disease"" id=""27082954-7-77-80"">PAD</span> via an interaction with traffic exposure in both the EA and AA cohorts; this included interactions with non-synonymous variants in <span class=""gene"" id=""27082954-7-212-216"">BMP2</span>, which is regulated by air pollution exposure.",CTD_human
5,0,Biomarker,C0030567,Parkinson Disease,disease,PD,65018,PINK1,PINK1,CTD_human,17010972,"Many sporadic PD patients have a defect in mitochondria respiration, and some of the genes that cause PD are mitochondrial-related (e.g., PINK1, Parkin, DJ1).",0.397570682881075,"Many sporadic PD patients have a defect in mitochondria respiration, and some of the genes that cause <span class=""disease"" id=""17010972-3-102-104"">PD</span> are mitochondrial-related (e.g., <span class=""gene"" id=""17010972-3-138-143"">PINK1</span>, Parkin, DJ1).",CTD_human
5,0,Biomarker,C0030567,Parkinson Disease,disease,PD,65018,PINK1,PINK1,CTD_human,21366594,Mutation in the phosphatase and tensin homolog (PTEN)-induced putative kinase 1 (PINK1) gene causes an autosomal recessive form of PD.,0.397570682881075,"Mutation in the phosphatase and tensin homolog (<span class=""gene"" id=""21366594-2-48-79"">PTEN)-induced putative kinase 1</span> (<span class=""gene"" id=""21366594-2-81-86"">PINK1</span>) gene causes an autosomal recessive form of <span class=""disease"" id=""21366594-2-131-133"">PD</span>.",CTD_human
4,0,Biomarker,C0242422,Parkinsonian Disorders,group,parkinsonism,65018,PINK1,PINK1,CTD_human,15349871,Homozygous PINK1 C-terminus mutation causing early-onset parkinsonism.,0.257887631498798,"Homozygous <span class=""gene"" id=""15349871-0-11-16"">PINK1</span> C-terminus mutation causing early-onset <span class=""disease"" id=""15349871-0-57-69"">parkinsonism</span>.",CTD_human
4,0,Biomarker,C0242422,Parkinsonian Disorders,group,parkinsonism,65018,PINK1,PARK6,CTD_human,11254447,"Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36.",0.257887631498798,"Localization of a novel locus for autosomal recessive early-onset <span class=""disease"" id=""11254447-0-66-78"">parkinsonism</span>, <span class=""gene"" id=""11254447-0-80-85"">PARK6</span>, on human chromosome 1p35-p36.",CTD_human
17,19,Biomarker,C1853833,"Parkinson Disease 6, Autosomal Recessive Early-Onset",disease,PARK6,65018,PINK1,PINK1,CTD_human,21421046,PARK6 PINK1 mutants are defective in maintaining mitochondrial membrane potential and inhibiting ROS formation of substantia nigra dopaminergic neurons.,0.48027472678421296,"<span class=""disease"" id=""21421046-0-0-5"">PARK6</span> <span class=""gene"" id=""21421046-0-6-11"">PINK1</span> mutants are defective in maintaining mitochondrial membrane potential and inhibiting ROS formation of substantia nigra dopaminergic neurons.",CTD_human;UNIPROT
1,0,Biomarker,C0079744,Diffuse Large B-Cell Lymphoma,disease,DLBCL,6502,SKP2,SKP2,CTD_human,18850583,"Altogether, these results suggest that SKP2 and the ubiquitin-proteasome pathway may be a potential target for therapeutic intervention in DLBCL.",0.20054945356842604,"Altogether, these results suggest that <span class=""gene"" id=""18850583-9-39-43"">SKP2</span> and the ubiquitin-proteasome pathway may be a potential target for therapeutic intervention in <span class=""disease"" id=""18850583-9-139-144"">DLBCL</span>.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,hepatoma,6502,SKP2,Skp2,CTD_human,12717389,Troglitazone induces p27Kip1-associated cell-cycle arrest through down-regulating Skp2 in human hepatoma cells.,0.207403267796436,"Troglitazone induces p27Kip1-associated cell-cycle arrest through down-regulating <span class=""gene"" id=""12717389-0-82-86"">Skp2</span> in human <span class=""disease"" id=""12717389-0-96-104"">hepatoma</span> cells.",CTD_human
1,0,Biomarker,C0014544,Epilepsy,disease,epilepsy,6505,SLC1A1,EAAC1,CTD_human,12151515,"EAAC1 may participate in normal GABA neurosynthesis and limbic hyperexcitability, whereas epilepsy can result from a disruption of the interaction between EAAC1 and GABA metabolism.",0.20082418035263896,"<span class=""gene"" id=""12151515-8-0-5"">EAAC1</span> may participate in normal GABA neurosynthesis and limbic hyperexcitability, whereas <span class=""disease"" id=""12151515-8-90-98"">epilepsy</span> can result from a disruption of the interaction between <span class=""gene"" id=""12151515-8-155-160"">EAAC1</span> and GABA metabolism.",CTD_human
1,0,Biomarker,C0014556,"Epilepsy, Temporal Lobe",disease,TLE,6505,SLC1A1,EAAC1,CTD_human,11906504,Immunolabeling demonstrated that EAAT3/EAAC1 protein expression was enhanced in dentate granule cells from both rats and humans with TLE as well as in dysplastic neurons from human cortical dysplasia tissue.,0.200274726784213,"Immunolabeling demonstrated that <span class=""gene"" id=""11906504-7-33-38"">EAAT3</span>/<span class=""gene"" id=""11906504-7-39-44"">EAAC1</span> protein expression was enhanced in dentate granule cells from both rats and humans with <span class=""disease"" id=""11906504-7-133-136"">TLE</span> as well as in dysplastic neurons from human cortical dysplasia tissue.",CTD_human
1,0,Biomarker,C0036572,Seizures,phenotype,seizures,6505,SLC1A1,EAAT3,CTD_human,23262392,"Especially, dysfunction of excitatory amino acid transporter type 3 (EAAT3) can lead to seizures.",0.200274726784213,"Especially, dysfunction of excitatory amino acid transporter type 3 (<span class=""gene"" id=""23262392-3-69-74"">EAAT3</span>) can lead to <span class=""disease"" id=""23262392-3-88-96"">seizures</span>.",CTD_human
1,0,Biomarker,C0002736,Amyotrophic Lateral Sclerosis,disease,ALS,6506,SLC1A2,GLT-1,CTD_human,11723166,These findings indicate that the loss of GLT-1 protein in ALS mice selectively occurs in the areas affected by neurodegeneration and reactive astrocytosis and it is not associated with increases of glutamate levels in CSF.,0.212608721319168,"These findings indicate that the loss of <span class=""gene"" id=""11723166-8-41-46"">GLT-1</span> protein in <span class=""disease"" id=""11723166-8-58-61"">ALS</span> mice selectively occurs in the areas affected by neurodegeneration and reactive astrocytosis and it is not associated with increases of glutamate levels in CSF.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,6507,SLC1A3,excitatory amino acid transporter 1,CTD_human,11706102,"The mRNA levels of several genes were significantly increased in autism, including excitatory amino acid transporter 1 and glutamate receptor AMPA 1, two members of the glutamate system.",0.202681755307501,"The mRNA levels of several genes were significantly increased in <span class=""disease"" id=""11706102-7-65-71"">autism</span>, including <span class=""gene"" id=""11706102-7-83-118"">excitatory amino acid transporter 1</span> and glutamate receptor AMPA 1, two members of the glutamate system.",CTD_human
1,0,Biomarker,C1136249,"Mental Retardation, X-Linked",disease,X-linked mental retardation,65109,UPF3B,UPF3B,CTD_human,17704778,"By systematically sequencing 737 genes (annotated in the Vertebrate Genome Annotation database) on the human X chromosome in 250 families with X-linked mental retardation, we identified mutations in the UPF3 regulator of nonsense transcripts homolog B (yeast) (UPF3B) leading to protein truncations in three families: two with the Lujan-Fryns phenotype and one with the FG phenotype.",0.20054945356842604,"By systematically sequencing 737 genes (annotated in the Vertebrate Genome Annotation database) on the human X chromosome in 250 families with <span class=""disease"" id=""17704778-3-143-170"">X-linked mental retardation</span>, we identified mutations in the <span class=""gene"" id=""17704778-3-203-258"">UPF3 regulator of nonsense transcripts homolog B (yeast</span>) (<span class=""gene"" id=""17704778-3-261-266"">UPF3B</span>) leading to protein truncations in three families: two with the Lujan-Fryns phenotype and one with the FG phenotype.",CTD_human
1,0,Biomarker,C0007124,Noninfiltrating Intraductal Carcinoma,disease,DCIS,6513,SLC2A1,GLUT1,CTD_human,20526721,"GLUT1 and CAIX were expressed only in DCIS (56.8% and 25.0%) and IDC (44.1% and 30.5%), with higher expression in high grade DCIS than low/intermediate grade DCIS (79.2% vs. 30.0%, p = 0.001 and 37.5% vs. 10.0%, p = 0.036, respectively).",0.20054945356842604,"<span class=""gene"" id=""20526721-9-0-5"">GLUT1</span> and CAIX were expressed only in <span class=""disease"" id=""20526721-9-38-42"">DCIS</span> (56.8% and 25.0%) and IDC (44.1% and 30.5%), with higher expression in high grade <span class=""disease"" id=""20526721-9-125-129"">DCIS</span> than low/intermediate grade DCIS (79.2% vs. 30.0%, p = 0.001 and 37.5% vs. 10.0%, p = 0.036, respectively).",CTD_human
2,0,Biomarker,C0025958,Microcephaly,disease,microcephaly,6513,SLC2A1,SLC2A1,CTD_human,10980529,"Fifteen children presenting with infantile seizures, acquired microcephaly, and developmental delay were found to have novel heterozygous mutations in the GLUT1 (SLC2A1).",0.201923087489492,"Fifteen children presenting with infantile seizures, acquired <span class=""disease"" id=""10980529-1-62-74"">microcephaly</span>, and developmental delay were found to have novel heterozygous mutations in the <span class=""gene"" id=""10980529-1-155-160"">GLUT1</span> (<span class=""gene"" id=""10980529-1-162-168"">SLC2A1</span>).",CTD_human
3,0,Biomarker,C0036572,Seizures,phenotype,seizures,6513,SLC2A1,SLC2A1,CTD_human,10980529,"Fifteen children presenting with infantile seizures, acquired microcephaly, and developmental delay were found to have novel heterozygous mutations in the GLUT1 (SLC2A1).",0.40467035533162293,"Fifteen children presenting with infantile <span class=""disease"" id=""10980529-1-43-51"">seizures</span>, acquired microcephaly, and developmental delay were found to have novel heterozygous mutations in the <span class=""gene"" id=""10980529-1-155-160"">GLUT1</span> (<span class=""gene"" id=""10980529-1-162-168"">SLC2A1</span>).",CTD_human;HPO
14,24,Biomarker,C1847501,Glut1 Deficiency Syndrome,disease,Glut-1 deficiency syndrome,6513,SLC2A1,SLC2A1,CTD_human,10980529,Mutational analysis of GLUT1 (SLC2A1) in Glut-1 deficiency syndrome.,0.608516530310606,"Mutational analysis of <span class=""gene"" id=""10980529-0-23-28"">GLUT1</span> (<span class=""gene"" id=""10980529-0-30-36"">SLC2A1</span>) in <span class=""disease"" id=""10980529-0-41-67"">Glut-1 deficiency syndrome</span>.",CTD_human;ORPHANET;UNIPROT
14,24,Biomarker,C1847501,Glut1 Deficiency Syndrome,disease,GLUT1 deficiency syndrome,6513,SLC2A1,GLUT1,CTD_human,17489814,"The deletion of the GLUT1 gene was in line with the abnormal ratio of cerebrospinal fluid (CSF) glucose to blood glucose, indicative of GLUT1 deficiency syndrome (MIM #606777).",0.608516530310606,"The deletion of the <span class=""gene"" id=""17489814-3-20-25"">GLUT1</span> gene was in line with the abnormal ratio of cerebrospinal fluid (CSF) glucose to blood glucose, indicative of <span class=""disease"" id=""17489814-3-136-161"">GLUT1 deficiency syndrome</span> (MIM #606777).",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,6513,SLC2A1,GLUT 1,CTD_human,8364915,"Seven of 12 HCC contained many microvessels intensely stained for GLUT 1, a phenomenon never observed in normal liver.",0.205205453522732,"Seven of 12 <span class=""disease"" id=""8364915-13-12-15"">HCC</span> contained many microvessels intensely stained for <span class=""gene"" id=""8364915-13-66-72"">GLUT 1</span>, a phenomenon never observed in normal liver.",CTD_human
1,0,Biomarker,C0015695,Fatty Liver,disease,fatty liver,6514,SLC2A2,GLUT2,CTD_human,12048068,Enhanced GLUT2 gene expression in an oleic acid-induced in vitro fatty liver model.,0.2,"Enhanced <span class=""gene"" id=""12048068-0-9-14"">GLUT2</span> gene expression in an oleic acid-induced in vitro <span class=""disease"" id=""12048068-0-65-76"">fatty liver</span> model.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,6514,SLC2A2,GLUT 2,CTD_human,8364915,"In two cases of adenoid HCC, cells of ductular formations coexpressed GLUT 2 and GLUT 1.",0.20082418035263896,"In two cases of adenoid <span class=""disease"" id=""8364915-11-24-27"">HCC</span>, cells of ductular formations coexpressed <span class=""gene"" id=""8364915-11-70-76"">GLUT 2</span> and GLUT 1.",CTD_human
4,1,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,type 2 diabetes mellitus,6517,SLC2A4,GLUT4,CTD_human,11947963,Troglitazone improves GLUT4 expression in adipose tissue in an animal model of obese type 2 diabetes mellitus.,0.513267294181172,"Troglitazone improves <span class=""gene"" id=""11947963-0-22-27"">GLUT4</span> expression in adipose tissue in an animal model of obese <span class=""disease"" id=""11947963-0-85-109"">type 2 diabetes mellitus</span>.",CTD_human;UNIPROT
4,1,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,T2DM,6517,SLC2A4,GLUT4,CTD_human,22384078,All our results have thus highlighted the potential of Rut as both a valuable lead compound for anti-T2DM drug discovery and a promising chemical probe for GLUT4 associated pathways exploration.,0.513267294181172,"All our results have thus highlighted the potential of Rut as both a valuable lead compound for anti-<span class=""disease"" id=""22384078-7-101-105"">T2DM</span> drug discovery and a promising chemical probe for <span class=""gene"" id=""22384078-7-156-161"">GLUT4</span> associated pathways exploration.",CTD_human;UNIPROT
1,0,Therapeutic,C1458155,Mammary Neoplasms,group,breast tumors,6518,SLC2A5,Glut5,CTD_human,15449313,"The results imply an alternative way in treating breast tumor as the AS against Glut5, unlike tamoxifen, takes effect on breast tumor cells via suppressing the expression of Glut5 that they specifically possess, and regardless whether the breast tumors are estrogen dependent or not.",0.20054945356842604,"The results imply an alternative way in treating <span class=""disease"" id=""15449313-9-49-61"">breast tumor</span> as the AS against <span class=""gene"" id=""15449313-9-80-85"">Glut5</span>, unlike tamoxifen, takes effect on <span class=""disease"" id=""15449313-9-121-133"">breast tumor</span> cells via suppressing the expression of <span class=""gene"" id=""15449313-9-174-179"">Glut5</span> that they specifically possess, and regardless whether the <span class=""disease"" id=""15449313-9-239-252"">breast tumors</span> are estrogen dependent or not.",CTD_human
1,0,Biomarker,C0033375,Prolactinoma,disease,prolactinoma,652,BMP4,BMP-4,CTD_human,16809920,"Bone morphogenetic protein-4 (BMP-4), a member of the transforming growth factor-Beta(TGF-Beta) family, is overexpressed in different prolactinoma models and induces the development of these lineage adenomas.",0.20082418035263896,"<span class=""gene"" id=""16809920-1-0-28"">Bone morphogenetic protein-4</span> (<span class=""gene"" id=""16809920-1-30-35"">BMP-4</span>), a member of the transforming growth factor-Beta(TGF-Beta) family, is overexpressed in different <span class=""disease"" id=""16809920-1-134-146"">prolactinoma</span> models and induces the development of these lineage adenomas.",CTD_human
2,0,Therapeutic,C0033578,Prostatic Neoplasms,group,prostate tumor,6528,SLC5A5,NIS,CTD_human,14633711,"Iodide uptake in a panel of non-prostate tumor cell lines infected with Ad-ARR(2)PB/hNIS was no more than 2,500 cpm, demonstrating the tissue specificity of this construct.",0.20082418035263896,"Iodide uptake in a panel of non-<span class=""disease"" id=""14633711-9-32-46"">prostate tumor</span> cell lines infected with Ad-ARR(2)PB/h<span class=""gene"" id=""14633711-9-85-88"">NIS</span> was no more than 2,500 cpm, demonstrating the tissue specificity of this construct.",CTD_human
1,0,Biomarker,C0206698,Cholangiocarcinoma,disease,cholangiocarcinoma,6528,SLC5A5,Sodium iodide symporter,CTD_human,17408651,Sodium iodide symporter is expressed at the preneoplastic stages of liver carcinogenesis and in human cholangiocarcinoma.,0.20300763924902696,"<span class=""gene"" id=""17408651-0-0-23"">Sodium iodide symporter</span> is expressed at the preneoplastic stages of liver carcinogenesis and in human <span class=""disease"" id=""17408651-0-102-120"">cholangiocarcinoma</span>.",CTD_human
2,0,Therapeutic,C2239176,Liver carcinoma,disease,hepatocellular carcinoma,6528,SLC5A5,sodium iodide symporter,CTD_human,15347726,Establishment of a human hepatocellular carcinoma cell line highly expressing sodium iodide symporter for radionuclide gene therapy.,0.203846174978983,"Establishment of a human <span class=""disease"" id=""15347726-0-25-49"">hepatocellular carcinoma</span> cell line highly expressing <span class=""gene"" id=""15347726-0-78-101"">sodium iodide symporter</span> for radionuclide gene therapy.",CTD_human
2,0,Therapeutic,C2239176,Liver carcinoma,disease,hepatocarcinoma,6528,SLC5A5,NIS,CTD_human,15520214,"Injected in the portal vein in 5 healthy and 25 hepatocarcinoma-bearing rats and liver tumors in 9 hepatocarcinoma-bearing rats, Ad-CMV-rNIS drove expression of a functional NIS protein by hepatocytes and allowed marked (from 20 to 30% of the injected dose) and sustained (>11 days) iodine uptake.",0.203846174978983,"Injected in the portal vein in 5 healthy and 25 <span class=""disease"" id=""15520214-6-48-63"">hepatocarcinoma</span>-bearing rats and liver tumors in 9 <span class=""disease"" id=""15520214-6-99-114"">hepatocarcinoma</span>-bearing rats, Ad-CMV-rNIS drove expression of a functional <span class=""gene"" id=""15520214-6-174-177"">NIS</span> protein by hepatocytes and allowed marked (from 20 to 30% of the injected dose) and sustained (&gt;11 days) iodine uptake.",CTD_human
1,0,Biomarker,C0002736,Amyotrophic Lateral Sclerosis,disease,amyotrophic lateral sclerosis,6529,SLC6A1,GAT1,CTD_human,20132478,In vitro activation of GAT1 transporters expressed in spinal cord gliosomes stimulates glutamate release that is abnormally elevated in the SOD1/G93A(+) mouse model of amyotrophic lateral sclerosis.,0.200274726784213,"In vitro activation of <span class=""gene"" id=""20132478-0-23-27"">GAT1</span> transporters expressed in spinal cord gliosomes stimulates glutamate release that is abnormally elevated in the SOD1/G93A(+) mouse model of <span class=""disease"" id=""20132478-0-168-197"">amyotrophic lateral sclerosis</span>.",CTD_human
1,0,Biomarker,C0036341,Schizophrenia,disease,Schizophrenia,6529,SLC6A1,GAT-1,CTD_human,18923069,"Schizophrenia subjects showed significant decreases in mRNA levels of GAD(67), GAD(65), GAT-1, mGluR2, and neuronal nitric oxide synthase.",0.281098907136852,"<span class=""disease"" id=""18923069-7-0-13"">Schizophrenia</span> subjects showed significant decreases in mRNA levels of GAD(67), GAD(65), <span class=""gene"" id=""18923069-7-88-93"">GAT-1</span>, mGluR2, and neuronal nitric oxide synthase.",CTD_human
1,0,Biomarker,C0036572,Seizures,phenotype,seizures,6529,SLC6A1,GAT-1,CTD_human,11074187,The increase in GAT-1-ir somata in the CRH model and not in the hyperthermia model may reflect the difference in the duration of seizures.,0.2,"The increase in <span class=""gene"" id=""11074187-8-16-21"">GAT-1</span>-ir somata in the CRH model and not in the hyperthermia model may reflect the difference in the duration of <span class=""disease"" id=""11074187-8-129-137"">seizures</span>.",CTD_human
1,0,Biomarker,C0036572,Seizures,phenotype,seizures,6530,SLC6A2,norepinephrine transporter,CTD_human,15911120,Genetic deletion of the norepinephrine transporter decreases vulnerability to seizures.,0.2,"Genetic deletion of the <span class=""gene"" id=""15911120-0-24-50"">norepinephrine transporter</span> decreases vulnerability to <span class=""disease"" id=""15911120-0-78-86"">seizures</span>.",CTD_human
1,0,Biomarker,C0003469,Anxiety Disorders,group,anxiety,6531,SLC6A3,DAT1,CTD_human,19120712,"Association of ADHD, tics, and anxiety with dopamine transporter (DAT1) genotype in autism spectrum disorder.",0.203780662444353,"Association of ADHD, tics, and <span class=""disease"" id=""19120712-0-31-38"">anxiety</span> with <span class=""gene"" id=""19120712-0-44-64"">dopamine transporter</span> (<span class=""gene"" id=""19120712-0-66-70"">DAT1</span>) genotype in autism spectrum disorder.",CTD_human
4,0,Biomarker,C0030567,Parkinson Disease,disease,Parkinson's disease,6531,SLC6A3,Dopamine transporter,CTD_human,19590691,Dopamine transporter genetic variants and pesticides in Parkinson's disease.,0.256248442034184,"<span class=""gene"" id=""19590691-0-0-20"">Dopamine transporter</span> genetic variants and pesticides in <span class=""disease"" id=""19590691-0-56-75"">Parkinson's disease</span>.",CTD_human
4,0,Biomarker,C0030567,Parkinson Disease,disease,Parkinson's disease,6531,SLC6A3,SLC6A3,CTD_human,16963468,"5' and 3' region variability in the dopamine transporter gene (SLC6A3), pesticide exposure and Parkinson's disease risk: a hypothesis-generating study.",0.256248442034184,"5' and 3' region variability in the <span class=""gene"" id=""16963468-0-36-56"">dopamine transporter</span> gene (<span class=""gene"" id=""16963468-0-63-69"">SLC6A3</span>), pesticide exposure and <span class=""disease"" id=""16963468-0-95-114"">Parkinson's disease</span> risk: a hypothesis-generating study.",CTD_human
2,0,Biomarker,C0424295,Hyperactive behavior,phenotype,hyperactivity,6531,SLC6A3,dopamine transporter,CTD_human,18347339,Increased amphetamine-induced hyperactivity and reward in mice overexpressing the dopamine transporter.,0.20954992491282898,"Increased amphetamine-induced <span class=""disease"" id=""18347339-0-30-43"">hyperactivity</span> and reward in mice overexpressing the <span class=""gene"" id=""18347339-0-82-102"">dopamine transporter</span>.",CTD_human
4,0,Biomarker,C1263846,Attention deficit hyperactivity disorder,disease,hyperactivity disorder,6531,SLC6A3,dopamine transporter,CTD_human,22034972,Loss of striatal cannabinoid CB1 receptor function in attention-deficit?/?hyperactivity disorder mice with point-mutation of the dopamine transporter.,0.416550651415947,"Loss of striatal cannabinoid CB1 receptor function in attention-deficit?/?<span class=""disease"" id=""22034972-0-74-96"">hyperactivity disorder</span> mice with point-mutation of the <span class=""gene"" id=""22034972-0-129-149"">dopamine transporter</span>.",CTD_human
4,0,Biomarker,C1263846,Attention deficit hyperactivity disorder,disease,ADHD,6531,SLC6A3,DAT1,CTD_human,19120712,"Association of ADHD, tics, and anxiety with dopamine transporter (DAT1) genotype in autism spectrum disorder.",0.416550651415947,"Association of <span class=""disease"" id=""19120712-0-15-19"">ADHD</span>, tics, and anxiety with <span class=""gene"" id=""19120712-0-44-64"">dopamine transporter</span> (<span class=""gene"" id=""19120712-0-66-70"">DAT1</span>) genotype in autism spectrum disorder.",CTD_human
4,0,Biomarker,C1263846,Attention deficit hyperactivity disorder,disease,attention deficit-hyperactivity disorder,6531,SLC6A3,dopamine transporter,CTD_human,15059031,Polymorphisms of the dopamine transporter gene: influence on response to methylphenidate in attention deficit-hyperactivity disorder.,0.416550651415947,"Polymorphisms of the <span class=""gene"" id=""15059031-0-21-41"">dopamine transporter</span> gene: influence on response to methylphenidate in <span class=""disease"" id=""15059031-0-92-132"">attention deficit-hyperactivity disorder</span>.",CTD_human
1,0,Biomarker,C0003469,Anxiety Disorders,group,anxiety,6532,SLC6A4,5-HTTLPR,CTD_human,18686203,"These findings suggest that within this restricted population increased symptoms of depression, anxiety, and memory are associated with the 5-HTTLPR polymorphism among both males and females.",0.268785238524985,"These findings suggest that within this restricted population increased symptoms of depression, <span class=""disease"" id=""18686203-11-96-103"">anxiety</span>, and memory are associated with the <span class=""gene"" id=""18686203-11-140-148"">5-HTTLPR</span> polymorphism among both males and females.",CTD_human
5,0,Biomarker,C0004352,Autistic Disorder,disease,autism,6532,SLC6A4,SLC6A4,CTD_human,17203304,Evidence for epistasis between SLC6A4 and ITGB3 in autism etiology and in the determination of platelet serotonin levels.,0.34930262387553007,"Evidence for epistasis between <span class=""gene"" id=""17203304-0-31-37"">SLC6A4</span> and ITGB3 in <span class=""disease"" id=""17203304-0-51-57"">autism</span> etiology and in the determination of platelet serotonin levels.",CTD_human
5,0,Biomarker,C0004352,Autistic Disorder,disease,autism,6532,SLC6A4,SLC6A4,CTD_human,16721604,We also show preliminary evidence that genotypes at the ITGB3 and SLC6A4 loci may interact to affect autism susceptibility (P=0.033).,0.34930262387553007,"We also show preliminary evidence that genotypes at the ITGB3 and <span class=""gene"" id=""16721604-7-66-72"">SLC6A4</span> loci may interact to affect <span class=""disease"" id=""16721604-7-101-107"">autism</span> susceptibility (P=0.033).",CTD_human
5,0,Biomarker,C0004352,Autistic Disorder,disease,autistic,6532,SLC6A4,5-HTTLPR,CTD_human,20649385,5-HTTLPR polymorphism: analysis in South African autistic individuals.,0.34930262387553007,"<span class=""gene"" id=""20649385-0-0-8"">5-HTTLPR</span> polymorphism: analysis in South African <span class=""disease"" id=""20649385-0-49-57"">autistic</span> individuals.",CTD_human
7,0,Biomarker,C0005586,Bipolar Disorder,disease,bipolar disorder,6532,SLC6A4,5-HTTLPR,CTD_human,16395126,"The 5-HTTLPR polymorphism could be a useful contributor, among other clinical variables, to predict the risk for manic switches when a patient with bipolar disorder is treated with antidepressant drugs.",0.5087888908331071,"The <span class=""gene"" id=""16395126-9-4-12"">5-HTTLPR</span> polymorphism could be a useful contributor, among other clinical variables, to predict the risk for manic switches when a patient with <span class=""disease"" id=""16395126-9-148-164"">bipolar disorder</span> is treated with antidepressant drugs.",CTD_human;PSYGENET
7,0,Biomarker,C0005586,Bipolar Disorder,disease,bipolar disorder,6532,SLC6A4,5-HTT,CTD_human,11772685,The findings support the hypothesis that comorbid panic disorder identifies a genetic subtype of bipolar disorder and suggest a role for COMT and 5-HTT in vulnerability to these disorders.,0.5087888908331071,"The findings support the hypothesis that comorbid panic disorder identifies a genetic subtype of <span class=""disease"" id=""11772685-10-97-113"">bipolar disorder</span> and suggest a role for COMT and <span class=""gene"" id=""11772685-10-146-151"">5-HTT</span> in vulnerability to these disorders.",CTD_human;PSYGENET
9,0,Biomarker,C0011581,Depressive disorder,disease,depression,6532,SLC6A4,5-HTT,CTD_human,18458677,"The association between the IL-6 polymorphism and reduced risk of depressive symptoms confirms the role of the inflammatory response system in the pathophysiology of IFN-alpha-induced depression; in contrast, the effect of the 5-HTT gene was small and perhaps dependent on the status of the inflammatory response.",0.485465824929628,"The association between the IL-6 polymorphism and reduced risk of depressive symptoms confirms the role of the inflammatory response system in the pathophysiology of IFN-alpha-induced <span class=""disease"" id=""18458677-12-184-194"">depression</span>; in contrast, the effect of the <span class=""gene"" id=""18458677-12-227-232"">5-HTT</span> gene was small and perhaps dependent on the status of the inflammatory response.",CTD_human;PSYGENET
1,0,Biomarker,C0038644,Sudden infant death syndrome,disease,SIDS,6532,SLC6A4,5-HTT,CTD_human,12599191,"These results indicate a relationship between SIDS and the L allele of the 5-HTT gene in African Americans and Caucasians, and if confirmed, will provide an important tool for identifying at-risk individuals and estimating the risk of recurrence.",0.306263513886252,"These results indicate a relationship between <span class=""disease"" id=""12599191-9-46-50"">SIDS</span> and the L allele of the <span class=""gene"" id=""12599191-9-75-80"">5-HTT</span> gene in African Americans and Caucasians, and if confirmed, will provide an important tool for identifying at-risk individuals and estimating the risk of recurrence.",CTD_human
6,0,Biomarker,C0525045,Mood Disorders,group,mood disorders,6532,SLC6A4,5-HTTLPR,CTD_human,19878141,"5-HTTLPR polymorphism, mood disorders and MDMA use in a 3-year follow-up study.",0.4708216382431721,"<span class=""gene"" id=""19878141-0-0-8"">5-HTTLPR</span> polymorphism, <span class=""disease"" id=""19878141-0-23-37"">mood disorders</span> and MDMA use in a 3-year follow-up study.",CTD_human;PSYGENET
6,0,Biomarker,C1269683,Major Depressive Disorder,disease,major depression,6532,SLC6A4,5HTT,CTD_human,16055263,Serotonin transporter (5HTT) is thought to be involved in the pathophysiology of major depression and the target of antidepressants.,0.5165386623003421,"Serotonin transporter (<span class=""gene"" id=""16055263-1-23-27"">5HTT</span>) is thought to be involved in the pathophysiology of <span class=""disease"" id=""16055263-1-81-97"">major depression</span> and the target of antidepressants.",CTD_human;PSYGENET
1,0,Biomarker,C0003873,Rheumatoid Arthritis,disease,RA,653361,NCF1,p47phox,CTD_human,12833524,Immunohistochemistry assigned the Stat1 protein in RA synovial tissue mainly to macrophages and T lymphocytes and the p47phox protein in particular to macrophages.,0.201098907136852,"Immunohistochemistry assigned the Stat1 protein in <span class=""disease"" id=""12833524-8-51-53"">RA</span> synovial tissue mainly to macrophages and T lymphocytes and the <span class=""gene"" id=""12833524-8-118-125"">p47phox</span> protein in particular to macrophages.",CTD_human
1,0,Biomarker,C0162871,"Aortic Aneurysm, Abdominal",disease,abdominal aortic aneurysm,653361,NCF1,p47phox,CTD_human,16864727,Deletion of p47phox attenuates angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E-deficient mice.,0.2,"Deletion of <span class=""gene"" id=""16864727-0-12-19"">p47phox</span> attenuates angiotensin II-induced <span class=""disease"" id=""16864727-0-54-79"">abdominal aortic aneurysm</span> formation in apolipoprotein E-deficient mice.",CTD_human
1,0,Biomarker,C1136249,"Mental Retardation, X-Linked",disease,X-linked mental retardation,6535,SLC6A8,SLC6A8,CTD_human,18350323,"Creatine transporter deficiency is an X-linked mental retardation disorder caused by mutations in the creatine transporter gene, SLC6A8.",0.207388912419119,"Creatine transporter deficiency is an <span class=""disease"" id=""18350323-1-38-65"">X-linked mental retardation</span> disorder caused by mutations in the <span class=""gene"" id=""18350323-1-102-122"">creatine transporter</span> gene, <span class=""gene"" id=""18350323-1-129-135"">SLC6A8</span>.",CTD_human
6,11,Biomarker,C1845862,"Creatine deficiency, X-linked",disease,X-linked creatine-deficiency syndrome,6535,SLC6A8,creatine transporter,CTD_human,11326334,We report the first X-linked creatine-deficiency syndrome caused by a defective creatine transporter.,0.6852198089000489,"We report the first <span class=""disease"" id=""11326334-1-20-57"">X-linked creatine-deficiency syndrome</span> caused by a defective <span class=""gene"" id=""11326334-1-80-100"">creatine transporter</span>.",CTD_human;ORPHANET;UNIPROT
6,11,Biomarker,C1845862,"Creatine deficiency, X-linked",disease,Creatine transporter deficiency,6535,SLC6A8,SLC6A8,CTD_human,17465020,Creatine transporter deficiency is an X-linked mental retardation disorder caused by mutations in the creatine transporter gene (SLC6A8).,0.6852198089000489,"<span class=""disease"" id=""17465020-1-0-31"">Creatine transporter deficiency</span> is an X-linked mental retardation disorder caused by mutations in the <span class=""gene"" id=""17465020-1-102-122"">creatine transporter</span> gene (<span class=""gene"" id=""17465020-1-129-135"">SLC6A8</span>).",CTD_human;ORPHANET;UNIPROT
6,11,Biomarker,C1845862,"Creatine deficiency, X-linked",disease,X-linked creatine deficiency syndrome,6535,SLC6A8,SLC6A8,CTD_human,12210795,X-linked creatine deficiency syndrome: a novel mutation in creatine transporter gene SLC6A8.,0.6852198089000489,"<span class=""disease"" id=""12210795-0-0-37"">X-linked creatine deficiency syndrome</span>: a novel mutation in <span class=""gene"" id=""12210795-0-59-79"">creatine transporter</span> gene <span class=""gene"" id=""12210795-0-85-91"">SLC6A8</span>.",CTD_human;ORPHANET;UNIPROT
2,0,Biomarker,C0018995,Hemochromatosis,disease,Hfe,654,BMP6,BMP6,CTD_human,19252488,"The iron burden in Bmp6 mutant mice is significantly greater than that in mice deficient in the gene associated with classical hemochromatosis (Hfe), suggesting that mutations in BMP6 might cause iron overload in humans with severe juvenile hemochromatosis for which the genetic basis has not yet been characterized.",0.20082418035263896,"The iron burden in <span class=""gene"" id=""19252488-8-19-23"">Bmp6</span> mutant mice is significantly greater than that in mice deficient in the gene associated with classical <span class=""disease"" id=""19252488-8-127-142"">hemochromatosis</span> (<span class=""disease"" id=""19252488-8-144-147"">Hfe</span>), suggesting that mutations in <span class=""gene"" id=""19252488-8-179-183"">BMP6</span> might cause iron overload in humans with severe juvenile hemochromatosis for which the genetic basis has not yet been characterized.",CTD_human
1,0,Biomarker,C0023493,Adult T-Cell Lymphoma/Leukemia,disease,adult T-cell leukemia,654,BMP6,bone morphogenetic protein-6,CTD_human,18688853,Promoter methylation of the bone morphogenetic protein-6 gene in association with adult T-cell leukemia.,0.200274726784213,"Promoter methylation of the <span class=""gene"" id=""18688853-0-28-56"">bone morphogenetic protein-6</span> gene in association with <span class=""disease"" id=""18688853-0-82-103"">adult T-cell leukemia</span>.",CTD_human
1,0,Biomarker,C0036572,Seizures,phenotype,seizures,6546,SLC8A1,NCX1,CTD_human,20888801,"Here we further investigated the role of NCX in the etiology of seizures by quantifying the effects of KB-R7943 and SN-6, potent inhibitors of the reverse mode of NCX subtypes 3 (NCX3) and 1 (NCX1), respectively, on the occurrence of acute seizures and status epilepticus induced by intraperitoneal administration of pilocarpine, a muscarinic acetylcholine receptor agonist.",0.2,"Here we further investigated the role of NCX in the etiology of <span class=""disease"" id=""20888801-2-64-72"">seizures</span> by quantifying the effects of KB-R7943 and SN-6, potent inhibitors of the reverse mode of NCX subtypes 3 (NCX3) and 1 (<span class=""gene"" id=""20888801-2-192-196"">NCX1</span>), respectively, on the occurrence of acute <span class=""disease"" id=""20888801-2-240-248"">seizures</span> and status epilepticus induced by intraperitoneal administration of pilocarpine, a muscarinic acetylcholine receptor agonist.",CTD_human
1,0,Biomarker,C0038220,Status Epilepticus,disease,status epilepticus,6546,SLC8A1,NCX1,CTD_human,20888801,"Here we further investigated the role of NCX in the etiology of seizures by quantifying the effects of KB-R7943 and SN-6, potent inhibitors of the reverse mode of NCX subtypes 3 (NCX3) and 1 (NCX1), respectively, on the occurrence of acute seizures and status epilepticus induced by intraperitoneal administration of pilocarpine, a muscarinic acetylcholine receptor agonist.",0.2,"Here we further investigated the role of NCX in the etiology of seizures by quantifying the effects of KB-R7943 and SN-6, potent inhibitors of the reverse mode of NCX subtypes 3 (NCX3) and 1 (<span class=""gene"" id=""20888801-2-192-196"">NCX1</span>), respectively, on the occurrence of acute seizures and <span class=""disease"" id=""20888801-2-253-271"">status epilepticus</span> induced by intraperitoneal administration of pilocarpine, a muscarinic acetylcholine receptor agonist.",CTD_human
1,0,Biomarker,C0036572,Seizures,phenotype,seizures,6547,SLC8A3,NCX3,CTD_human,20888801,"Here we further investigated the role of NCX in the etiology of seizures by quantifying the effects of KB-R7943 and SN-6, potent inhibitors of the reverse mode of NCX subtypes 3 (NCX3) and 1 (NCX1), respectively, on the occurrence of acute seizures and status epilepticus induced by intraperitoneal administration of pilocarpine, a muscarinic acetylcholine receptor agonist.",0.2,"Here we further investigated the role of NCX in the etiology of <span class=""disease"" id=""20888801-2-64-72"">seizures</span> by quantifying the effects of KB-R7943 and SN-6, potent inhibitors of the reverse mode of NCX subtypes 3 (<span class=""gene"" id=""20888801-2-179-183"">NCX3</span>) and 1 (NCX1), respectively, on the occurrence of acute <span class=""disease"" id=""20888801-2-240-248"">seizures</span> and status epilepticus induced by intraperitoneal administration of pilocarpine, a muscarinic acetylcholine receptor agonist.",CTD_human
1,0,Biomarker,C0038220,Status Epilepticus,disease,status epilepticus,6547,SLC8A3,NCX3,CTD_human,20888801,"Here we further investigated the role of NCX in the etiology of seizures by quantifying the effects of KB-R7943 and SN-6, potent inhibitors of the reverse mode of NCX subtypes 3 (NCX3) and 1 (NCX1), respectively, on the occurrence of acute seizures and status epilepticus induced by intraperitoneal administration of pilocarpine, a muscarinic acetylcholine receptor agonist.",0.2,"Here we further investigated the role of NCX in the etiology of seizures by quantifying the effects of KB-R7943 and SN-6, potent inhibitors of the reverse mode of NCX subtypes 3 (<span class=""gene"" id=""20888801-2-179-183"">NCX3</span>) and 1 (NCX1), respectively, on the occurrence of acute seizures and <span class=""disease"" id=""20888801-2-253-271"">status epilepticus</span> induced by intraperitoneal administration of pilocarpine, a muscarinic acetylcholine receptor agonist.",CTD_human
1,0,Biomarker,C0019163,Hepatitis B,disease,hepatitis B,6554,SLC10A1,NTCP,CTD_human,25550158,Dysregulation of retinoic acid receptor diminishes hepatocyte permissiveness to hepatitis B virus infection through modulation of sodium taurocholate cotransporting polypeptide (NTCP) expression.,0.20357144819477,"Dysregulation of retinoic acid receptor diminishes hepatocyte permissiveness to <span class=""disease"" id=""25550158-0-80-91"">hepatitis B</span> virus infection through modulation of <span class=""gene"" id=""25550158-0-130-176"">sodium taurocholate cotransporting polypeptide</span> (<span class=""gene"" id=""25550158-0-178-182"">NTCP</span>) expression.",CTD_human
1,0,Biomarker,C0041296,Tuberculosis,disease,tuberculosis,6556,SLC11A1,SLC11A1,CTD_human,16597321,Iron and infection: effects of host iron status and the iron-regulatory genes haptoglobin and NRAMP1 (SLC11A1) on host-pathogen interactions in tuberculosis and HIV.,0.502042910890954,"Iron and infection: effects of host iron status and the iron-regulatory genes haptoglobin and <span class=""gene"" id=""16597321-0-94-100"">NRAMP1</span> (<span class=""gene"" id=""16597321-0-102-109"">SLC11A1</span>) on host-pathogen interactions in <span class=""disease"" id=""16597321-0-144-156"">tuberculosis</span> and HIV.",CTD_human;ORPHANET
1,0,Biomarker,C0004775,Bartter Disease,disease,Bartter's syndrome,6557,SLC12A1,NKCC2,CTD_human,10561751,"Mutations of another voltage-gated chloride channel, CLC-Kb, are associated with a form of Bartter's syndrome, whereas other forms of Bartter's syndrome are caused by mutations in the bumetanide-sensitive sodium-potassium-chloride cotransporter (NKCC2) and the potassium channel, ROMK.",0.214517453431343,"Mutations of another voltage-gated chloride channel, CLC-Kb, are associated with a form of <span class=""disease"" id=""10561751-3-91-109"">Bartter's syndrome</span>, whereas other forms of <span class=""disease"" id=""10561751-3-134-152"">Bartter's syndrome</span> are caused by mutations in the bumetanide-sensitive sodium-potassium-chloride cotransporter (<span class=""gene"" id=""10561751-3-246-251"">NKCC2</span>) and the potassium channel, ROMK.",CTD_human
1,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,6558,SLC12A2,NKCC1,CTD_human,17259435,We conclude that NKCC1 influences blood pressure through effects on smooth muscle tone in resistance vessels and that this effect is augmented in hypertension.,0.20054945356842604,"We conclude that <span class=""gene"" id=""17259435-8-17-22"">NKCC1</span> influences blood pressure through effects on smooth muscle tone in resistance vessels and that this effect is augmented in <span class=""disease"" id=""17259435-8-146-158"">hypertension</span>.",CTD_human
15,84,Biomarker,C0268450,Gitelman Syndrome,disease,Gitelman's syndrome,6559,SLC12A3,NCCT,CTD_human,10561751,"Finally, mutations of the thiazide-sensitive sodium-chloride cotransporter (NCCT) are associated with Gitelman's syndrome.",0.732645376196071,"Finally, mutations of the <span class=""gene"" id=""10561751-4-26-74"">thiazide-sensitive sodium-chloride cotransporter</span> (<span class=""gene"" id=""10561751-4-76-80"">NCCT</span>) are associated with <span class=""disease"" id=""10561751-4-102-121"">Gitelman's syndrome</span>.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0020437,Hypercalcemia,disease,hypercalcemia,6569,SLC34A1,Npt2,CTD_human,9560283,"Homozygous mutants (Npt2(-/-)) exhibit increased urinary Pi excretion, hypophosphatemia, an appropriate elevation in the serum concentration of 1,25-dihydroxyvitamin D with attendant hypercalcemia, hypercalciuria and decreased serum parathyroid hormone levels, and increased serum alkaline phosphatase activity.",0.20054945356842604,"Homozygous mutants (<span class=""gene"" id=""9560283-3-20-24"">Npt2</span>(-/-)) exhibit increased urinary Pi excretion, hypophosphatemia, an appropriate elevation in the serum concentration of 1,25-dihydroxyvitamin D with attendant <span class=""disease"" id=""9560283-3-183-196"">hypercalcemia</span>, hypercalciuria and decreased serum parathyroid hormone levels, and increased serum alkaline phosphatase activity.",CTD_human
1,0,Biomarker,C0020438,Hypercalciuria,phenotype,hypercalciuria,6569,SLC34A1,Npt2,CTD_human,9560283,"Targeted inactivation of Npt2 in mice leads to severe renal phosphate wasting, hypercalciuria, and skeletal abnormalities.",0.48109890713685205,"Targeted inactivation of <span class=""gene"" id=""9560283-0-25-29"">Npt2</span> in mice leads to severe renal phosphate wasting, <span class=""disease"" id=""9560283-0-79-93"">hypercalciuria</span>, and skeletal abnormalities.",CTD_human;HPO
1,0,Biomarker,C0085682,Hypophosphatemia,phenotype,hypophosphatemia,6569,SLC34A1,Npt2,CTD_human,9560283,"Homozygous mutants (Npt2(-/-)) exhibit increased urinary Pi excretion, hypophosphatemia, an appropriate elevation in the serum concentration of 1,25-dihydroxyvitamin D with attendant hypercalcemia, hypercalciuria and decreased serum parathyroid hormone levels, and increased serum alkaline phosphatase activity.",0.40137363392106606,"Homozygous mutants (<span class=""gene"" id=""9560283-3-20-24"">Npt2</span>(-/-)) exhibit increased urinary Pi excretion, <span class=""disease"" id=""9560283-3-71-87"">hypophosphatemia</span>, an appropriate elevation in the serum concentration of 1,25-dihydroxyvitamin D with attendant hypercalcemia, hypercalciuria and decreased serum parathyroid hormone levels, and increased serum alkaline phosphatase activity.",CTD_human;HPO
1,0,Biomarker,C0001430,Adenoma,group,adenomas,6573,SLC19A1,reduced folate carrier 1,CTD_human,16963246,"Apc(min/+) mice with heterozygous knockout of the gene for reduced folate carrier 1 (Rfc1(+/-)) developed significantly fewer adenomas compared to Rfc1(+/+)Apc(min/+) mice [30.3+/-4.6 vs. 60.4+/-9.4 on a control diet (CD) and 42.6+/-4.4 vs. 55.8+/-7.6 on a folate-deficient diet, respectively].",0.200274726784213,"Apc(min/+) mice with heterozygous knockout of the gene for <span class=""gene"" id=""16963246-3-59-83"">reduced folate carrier 1</span> (Rfc1(+/-)) developed significantly fewer <span class=""disease"" id=""16963246-3-126-134"">adenomas</span> compared to Rfc1(+/+)Apc(min/+) mice [30.3+/-4.6 vs. 60.4+/-9.4 on a control diet (CD) and 42.6+/-4.4 vs. 55.8+/-7.6 on a folate-deficient diet, respectively].",CTD_human
1,0,Biomarker,C0005695,Bladder Neoplasm,disease,bladder cancer,6573,SLC19A1,SLC19A1,CTD_human,21760912,Expression of RFC/SLC19A1 is associated with tumor type in bladder cancer patients.,0.200274726784213,"Expression of <span class=""gene"" id=""21760912-0-14-17"">RFC</span>/<span class=""gene"" id=""21760912-0-18-25"">SLC19A1</span> is associated with tumor type in <span class=""disease"" id=""21760912-0-59-73"">bladder cancer</span> patients.",CTD_human
6,10,Biomarker,C0393590,Fahr's syndrome (disorder),disease,familial idiopathic basal ganglia calcification,6575,SLC20A2,SLC20A2,CTD_human,22327515,Mutations in SLC20A2 link familial idiopathic basal ganglia calcification with phosphate homeostasis.,0.681923087489492,"Mutations in <span class=""gene"" id=""22327515-0-13-20"">SLC20A2</span> link <span class=""disease"" id=""22327515-0-26-73"">familial idiopathic basal ganglia calcification</span> with phosphate homeostasis.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0028754,Obesity,disease,obese,6580,SLC22A1,OCT1,CTD_human,20956498,OCT1 Expression in adipocytes could contribute to increased metformin action in obese subjects.,0.20054945356842604,"<span class=""gene"" id=""20956498-0-0-4"">OCT1</span> Expression in adipocytes could contribute to increased metformin action in <span class=""disease"" id=""20956498-0-80-85"">obese</span> subjects.",CTD_human
1,0,Biomarker,C0007193,"Cardiomyopathy, Dilated",group,dilated cardiomyopathy,6584,SLC22A5,OCTN2,CTD_human,21641380,Selective regulation of cardiac organic cation transporter novel type 2 (OCTN2) in dilated cardiomyopathy.,0.20054945356842604,"Selective regulation of cardiac organic cation transporter novel type 2 (<span class=""gene"" id=""21641380-0-73-78"">OCTN2</span>) in <span class=""disease"" id=""21641380-0-83-105"">dilated cardiomyopathy</span>.",CTD_human
8,71,Biomarker,C0342788,Renal carnitine transport defect,disease,carnitine deficiency,6584,SLC22A5,SLC22A5,CTD_human,17703373,"Additional molecular investigations identified two mutations (R254X and IVS3 + 1G > A) in the patient's OCTN2 (SLC22A5) gene, consistent with a diagnosis of primary carnitine deficiency due to carnitine transporter defect.",0.6843956285474101,"Additional molecular investigations identified two mutations (R254X and IVS3 + 1G &gt; A) in the patient's <span class=""gene"" id=""17703373-6-104-109"">OCTN2</span> (<span class=""gene"" id=""17703373-6-111-118"">SLC22A5</span>) gene, consistent with a diagnosis of primary <span class=""disease"" id=""17703373-6-165-185"">carnitine deficiency</span> due to carnitine transporter defect.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0206081,Hyperandrogenism,disease,hyperandrogenism,659,BMPR2,BMPR2,CTD_human,22825968,A positive correlation was found between BMPR2 transcripts and hyperandrogenism in FF of PCOS patients.,0.200274726784213,"A positive correlation was found between <span class=""gene"" id=""22825968-6-41-46"">BMPR2</span> transcripts and <span class=""disease"" id=""22825968-6-63-79"">hyperandrogenism</span> in FF of PCOS patients.",CTD_human
2,33,Biomarker,C1303073,Nicolaides Baraitser syndrome,disease,Nicolaides-Baraitser syndrome,6595,SMARCA2,SMARCA2,CTD_human,22366787,Heterozygous missense mutations in SMARCA2 cause Nicolaides-Baraitser syndrome.,0.6010989071368521,"Heterozygous missense mutations in <span class=""gene"" id=""22366787-0-35-42"">SMARCA2</span> cause <span class=""disease"" id=""22366787-0-49-78"">Nicolaides-Baraitser syndrome</span>.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0022665,Kidney Neoplasm,disease,kidney tumors,6596,HLTF,HLTF,CTD_human,16762066,"HLTF expression was conserved in the HKT-1097 cell line established from kidney tumors, but again only 10% of positive cells were found in xenografts produced by HKT-1097 cells in nude mice.",0.20054945356842604,"<span class=""gene"" id=""16762066-8-0-4"">HLTF</span> expression was conserved in the HKT-1097 cell line established from <span class=""disease"" id=""16762066-8-73-86"">kidney tumors</span>, but again only 10% of positive cells were found in xenografts produced by HKT-1097 cells in nude mice.",CTD_human
1,0,Biomarker,C0006413,Burkitt Lymphoma,disease,Burkitt lymphomas,6597,SMARCA4,SMARCA4,CTD_human,23143597,"We identified 70 genes that were recurrently mutated in Burkitt lymphomas, including ID3, GNA13, RET, PIK3R1 and the SWI/SNF genes ARID1A and SMARCA4.",0.20082418035263896,"We identified 70 genes that were recurrently mutated in <span class=""disease"" id=""23143597-4-56-73"">Burkitt lymphomas</span>, including ID3, GNA13, RET, PIK3R1 and the SWI/SNF genes ARID1A and <span class=""gene"" id=""23143597-4-142-149"">SMARCA4</span>.",CTD_human
4,0,Biomarker,C0262584,"Carcinoma, Small Cell",disease,small cell carcinoma,6597,SMARCA4,SMARCA4,CTD_human,24658002,"Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type.",0.202197814273705,"Germline and somatic <span class=""gene"" id=""24658002-0-21-28"">SMARCA4</span> mutations characterize <span class=""disease"" id=""24658002-0-52-72"">small cell carcinoma</span> of the ovary, hypercalcemic type.",CTD_human
4,0,Biomarker,C0262584,"Carcinoma, Small Cell",disease,small-cell carcinomas,6597,SMARCA4,SMARCA4,CTD_human,26343384,"To help define the nosological relationships of these tumors, we compared their transcriptomic profiles with those of SMARCA4-mutated small-cell carcinomas of the ovary, hypercalcemic type (SCCOHTs), SMARCB1-inactivated malignant rhabdoid tumors (MRTs) and lung carcinomas (of which 10% display SMARCA4 mutations).",0.202197814273705,"To help define the nosological relationships of these tumors, we compared their transcriptomic profiles with those of <span class=""gene"" id=""26343384-3-118-125"">SMARCA4</span>-mutated <span class=""disease"" id=""26343384-3-134-155"">small-cell carcinomas</span> of the ovary, hypercalcemic type (SCCOHTs), SMARCB1-inactivated malignant rhabdoid tumors (MRTs) and lung carcinomas (of which 10% display <span class=""gene"" id=""26343384-3-295-302"">SMARCA4</span> mutations).",CTD_human
4,0,Biomarker,C0262584,"Carcinoma, Small Cell",disease,small cell carcinoma,6597,SMARCA4,SMARCA4,CTD_human,24658004,Recurrent SMARCA4 mutations in small cell carcinoma of the ovary.,0.202197814273705,"Recurrent <span class=""gene"" id=""24658004-0-10-17"">SMARCA4</span> mutations in <span class=""disease"" id=""24658004-0-31-51"">small cell carcinoma</span> of the ovary.",CTD_human
4,0,Biomarker,C0262584,"Carcinoma, Small Cell",disease,Small cell carcinoma,6597,SMARCA4,SMARCA4,CTD_human,24658001,"Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4.",0.202197814273705,"<span class=""disease"" id=""24658001-0-0-20"">Small cell carcinoma</span> of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in <span class=""gene"" id=""24658001-0-120-127"">SMARCA4</span>.",CTD_human
4,0,Biomarker,C0919267,ovarian neoplasm,disease,ovarian tumors,6597,SMARCA4,SMARCA4,CTD_human,24658001,We identified germline and somatic inactivating mutations in the SWI/SNF chromatin-remodeling gene SMARCA4 in 75% (9/12) of SCCOHT cases in addition to SMARCA4 protein loss in 82% (14/17) of SCCOHT tumors but in only 0.4% (2/485) of other primary ovarian tumors.,0.200274726784213,"We identified germline and somatic inactivating mutations in the SWI/SNF chromatin-remodeling gene <span class=""gene"" id=""24658001-2-99-106"">SMARCA4</span> in 75% (9/12) of SCCOHT cases in addition to <span class=""gene"" id=""24658001-2-152-159"">SMARCA4</span> protein loss in 82% (14/17) of SCCOHT tumors but in only 0.4% (2/485) of other primary <span class=""disease"" id=""24658001-2-247-261"">ovarian tumors</span>.",CTD_human
1,0,Biomarker,C1261473,Sarcoma,disease,sarcomas,6597,SMARCA4,SMARCA4,CTD_human,26343384,SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas.,0.200274726784213,"<span class=""gene"" id=""26343384-0-0-7"">SMARCA4</span> inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient <span class=""disease"" id=""26343384-0-122-130"">sarcomas</span>.",CTD_human
2,0,Biomarker,C0206743,Rhabdoid Tumor,disease,MRT,6598,SMARCB1,SNF5,CTD_human,25009291,"These data establish that SNF5 loss during MRT development alters the repertoire of available SWI/SNF complexes, generally disrupting those associated with cellular differentiation.",0.278174347398615,"These data establish that <span class=""gene"" id=""25009291-9-26-30"">SNF5</span> loss during <span class=""disease"" id=""25009291-9-43-46"">MRT</span> development alters the repertoire of available SWI/SNF complexes, generally disrupting those associated with cellular differentiation.",CTD_human
2,0,Biomarker,C0206743,Rhabdoid Tumor,disease,MRT,6598,SMARCB1,SMARCB1,CTD_human,26343384,"To help define the nosological relationships of these tumors, we compared their transcriptomic profiles with those of SMARCA4-mutated small-cell carcinomas of the ovary, hypercalcemic type (SCCOHTs), SMARCB1-inactivated malignant rhabdoid tumors (MRTs) and lung carcinomas (of which 10% display SMARCA4 mutations).",0.278174347398615,"To help define the nosological relationships of these tumors, we compared their transcriptomic profiles with those of SMARCA4-mutated small-cell carcinomas of the ovary, hypercalcemic type (SCCOHTs), <span class=""gene"" id=""26343384-3-200-207"">SMARCB1</span>-inactivated <span class=""disease"" id=""26343384-3-220-245"">malignant rhabdoid tumors</span> (<span class=""disease"" id=""26343384-3-247-250"">MRT</span>s) and lung carcinomas (of which 10% display SMARCA4 mutations).",CTD_human
1,0,Biomarker,C0265338,Coffin-Siris syndrome,disease,CSS,6598,SMARCB1,SMARCB1,CTD_human,22426308,"As SMARCB1 encodes a subunit of the SWItch/Sucrose NonFermenting (SWI/SNF) complex, we screened 15 other genes encoding subunits of this complex in 23 individuals with CSS.",0.4010989071368521,"As <span class=""gene"" id=""22426308-2-3-10"">SMARCB1</span> encodes a subunit of the SWItch/Sucrose NonFermenting (SWI/SNF) complex, we screened 15 other genes encoding subunits of this complex in 23 individuals with <span class=""disease"" id=""22426308-2-168-171"">CSS</span>.",CTD_human;ORPHANET
1,0,Biomarker,C1335929,Schwannomatosis,disease,schwannomatosis,6598,SMARCB1,SMARCB1,CTD_human,24362817,Our findings identify LZTR1 as a gene predisposing to an autosomal dominant inherited disorder of multiple schwannomas in ?80% of 22q-related schwannomatosis cases lacking mutation in SMARCB1.,0.409340710663245,"Our findings identify LZTR1 as a gene predisposing to an autosomal dominant inherited disorder of multiple schwannomas in &sim;80% of 22q-related <span class=""disease"" id=""24362817-7-142-157"">schwannomatosis</span> cases lacking mutation in <span class=""gene"" id=""24362817-7-184-191"">SMARCB1</span>.",CTD_human;ORPHANET
4,0,Biomarker,C0026847,Spinal Muscular Atrophy,disease,SMA,6606,SMN1,SMN,CTD_human,19150990,Translational readthrough by the aminoglycoside geneticin (G418) modulates SMN stability in vitro and improves motor function in SMA mice in vivo.,0.569786025321018,"Translational readthrough by the aminoglycoside geneticin (G418) modulates <span class=""gene"" id=""19150990-0-75-78"">SMN</span> stability in vitro and improves motor function in <span class=""disease"" id=""19150990-0-129-132"">SMA</span> mice in vivo.",CTD_human;HPO
4,0,Biomarker,C0026847,Spinal Muscular Atrophy,disease,SMA,6606,SMN1,SMN1,CTD_human,21350916,Spinal Muscular Atrophy (SMA) is an autosomal recessive neurodegenerative disease that is a result of a deletion or mutation of the SMN1 (Survival Motor Neuron) gene.,0.569786025321018,"<span class=""disease"" id=""21350916-1-0-23"">Spinal Muscular Atrophy</span> (<span class=""disease"" id=""21350916-1-25-28"">SMA</span>) is an autosomal recessive neurodegenerative disease that is a result of a deletion or mutation of the <span class=""gene"" id=""21350916-1-132-136"">SMN1</span> (Survival Motor Neuron) gene.",CTD_human;HPO
4,0,Biomarker,C0026847,Spinal Muscular Atrophy,disease,SMA,6606,SMN1,SMN,CTD_human,15862279,"Depletion of SMN protein by RNA interference in control fibroblasts increased caspase-3 activity, whereas transfection of SMA fibroblasts with wild-type SMN decreased caspase-3 activity.",0.569786025321018,"Depletion of <span class=""gene"" id=""15862279-7-13-16"">SMN</span> protein by RNA interference in control fibroblasts increased caspase-3 activity, whereas transfection of <span class=""disease"" id=""15862279-7-122-125"">SMA</span> fibroblasts with wild-type <span class=""gene"" id=""15862279-7-153-156"">SMN</span> decreased caspase-3 activity.",CTD_human;HPO
4,0,Biomarker,C0026847,Spinal Muscular Atrophy,disease,SMA,6606,SMN1,SMN,CTD_human,21819082,We anticipate that a lead candidate chosen from this series may serve as a useful probe for exploring the therapeutic benefits of SMN protein up-regulation in SMA animal models and a starting point for clinical development.,0.569786025321018,"We anticipate that a lead candidate chosen from this series may serve as a useful probe for exploring the therapeutic benefits of <span class=""gene"" id=""21819082-8-130-133"">SMN</span> protein up-regulation in <span class=""disease"" id=""21819082-8-159-162"">SMA</span> animal models and a starting point for clinical development.",CTD_human;HPO
1,0,Therapeutic,C0026847,Spinal Muscular Atrophy,disease,SMA,6607,SMN2,SMN2,CTD_human,21350916,"In the development of a SMA pig model, it was important to demonstrate that the human SMN2 gene would splice appropriately as the model would be based on the presence of the human SMN2 transgene.",0.35293682565800205,"In the development of a <span class=""disease"" id=""21350916-6-24-27"">SMA</span> pig model, it was important to demonstrate that the human <span class=""gene"" id=""21350916-6-86-90"">SMN2</span> gene would splice appropriately as the model would be based on the presence of the human <span class=""gene"" id=""21350916-6-180-184"">SMN2</span> transgene.",CTD_human
1,0,Biomarker,C0025286,Meningioma,disease,meningiomas,6608,SMO,SMO,CTD_human,23334667,Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations.,0.20054945356842604,"Genomic sequencing of <span class=""disease"" id=""23334667-0-22-33"">meningiomas</span> identifies oncogenic <span class=""gene"" id=""23334667-0-55-58"">SMO</span> and AKT1 mutations.",CTD_human
1,0,Biomarker,C0206663,"Neuroectodermal Tumor, Primitive",disease,primitive neuroectodermal tumors of the central nervous system,6608,SMO,SMOH,CTD_human,9581815,Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system.,0.200274726784213,"Missense mutations in <span class=""gene"" id=""9581815-0-22-26"">SMOH</span> in sporadic basal cell carcinomas of the skin and <span class=""disease"" id=""9581815-0-77-139"">primitive neuroectodermal tumors of the central nervous system</span>.",CTD_human
1,0,Biomarker,C0017205,Gaucher Disease,disease,Gaucher disease,6622,SNCA,synuclein (alpha,CTD_human,19576930,"The aim of this study was to determine whether there is a relationship between alpha-synuclein (alpha-syn), a key protein in Parkinson's disease pathogenesis, and abnormalities in glucocerebroside (GC) catabolism that lead to the development of Gaucher disease.",0.200274726784213,"The aim of this study was to determine whether there is a relationship between alpha-<span class=""gene"" id=""19576930-2-85-101"">synuclein (alpha</span>-syn), a key protein in Parkinson's disease pathogenesis, and abnormalities in glucocerebroside (GC) catabolism that lead to the development of <span class=""disease"" id=""19576930-2-245-260"">Gaucher disease</span>.",CTD_human
27,1,Biomarker,C0030567,Parkinson Disease,disease,PD,6622,SNCA,SNCA,CTD_human,19915576,"By comparing results of a GWAS performed on individuals of European ancestry, we identified PARK16, SNCA and LRRK2 as shared risk loci for PD and BST1 and MAPT as loci showing population differences.",0.44,"By comparing results of a GWAS performed on individuals of European ancestry, we identified PARK16, <span class=""gene"" id=""19915576-4-100-104"">SNCA</span> and LRRK2 as shared risk loci for <span class=""disease"" id=""19915576-4-139-141"">PD</span> and BST1 and MAPT as loci showing population differences.",CTD_human
27,1,Biomarker,C0030567,Parkinson Disease,disease,Parkinson's disease,6622,SNCA,?-synuclein,CTD_human,22166454,"In the healthy brain, neuromelanin appears to play a functional role to protect neurons from oxidative load but we have shown that in the Parkinson's disease brain the pigment undergoes structural changes and is associated with aggregation of ?-synuclein protein, even early in the disease process.",0.44,"In the healthy brain, neuromelanin appears to play a functional role to protect neurons from oxidative load but we have shown that in the <span class=""disease"" id=""22166454-4-138-157"">Parkinson's disease</span> brain the pigment undergoes structural changes and is associated with aggregation of <span class=""gene"" id=""22166454-4-243-254"">&alpha;-synuclein</span> protein, even early in the disease process.",CTD_human
27,1,Biomarker,C0030567,Parkinson Disease,disease,Parkinson disease,6622,SNCA,alpha-synuclein,CTD_human,15099020,Mutation A30P in the alpha-synuclein gene is a cause of familial Parkinson disease.,0.44,"Mutation A30P in the <span class=""gene"" id=""15099020-1-21-36"">alpha-synuclein</span> gene is a cause of familial <span class=""disease"" id=""15099020-1-65-82"">Parkinson disease</span>.",CTD_human
27,1,Biomarker,C0030567,Parkinson Disease,disease,PD,6622,SNCA,synuclein (alpha,CTD_human,14535945,Lewy bodies in the brains of patients with Parkinson's disease (PD) contain aggregates of alpha-synuclein (alpha-syn).,0.44,"Lewy bodies in the brains of patients with <span class=""disease"" id=""14535945-1-43-62"">Parkinson's disease</span> (<span class=""disease"" id=""14535945-1-64-66"">PD</span>) contain aggregates of alpha-<span class=""gene"" id=""14535945-1-96-112"">synuclein (alpha</span>-syn).",CTD_human
27,1,Biomarker,C0030567,Parkinson Disease,disease,PD,6622,SNCA,SNCA,CTD_human,19915575,"Association to PD at SNCA was replicated in the Japanese GWAS, confirming this as a major risk locus across populations.",0.44,"Association to <span class=""disease"" id=""19915575-4-15-17"">PD</span> at <span class=""gene"" id=""19915575-4-21-25"">SNCA</span> was replicated in the Japanese GWAS, confirming this as a major risk locus across populations.",CTD_human
27,1,Biomarker,C0030567,Parkinson Disease,disease,PD,6622,SNCA,synuclein (?,CTD_human,21245015,We created a two-hit [neuroinflammation and mutant ?-synuclein (?-syn) overexpression] animal model to investigate mechanisms through which mutant ?-syn and inflammation work in concert to mediate chronic PD neurodegeneration.,0.44,"We created a two-hit [neuroinflammation and mutant &alpha;-<span class=""gene"" id=""21245015-2-53-65"">synuclein (&alpha;</span>-syn) overexpression] animal model to investigate mechanisms through which mutant &alpha;-syn and inflammation work in concert to mediate chronic <span class=""disease"" id=""21245015-2-205-207"">PD</span> neurodegeneration.",CTD_human
27,1,Biomarker,C0030567,Parkinson Disease,disease,PD,6622,SNCA,alpha-synuclein,CTD_human,12151787,"Mutations in the alpha-synuclein gene (A30P and A53T) are reported to cause familial Parkinson's disease (PD), but it is not known how they result in selective dopaminergic cell death.",0.44,"Mutations in the <span class=""gene"" id=""12151787-1-17-32"">alpha-synuclein</span> gene (A30P and A53T) are reported to cause familial <span class=""disease"" id=""12151787-1-85-104"">Parkinson's disease</span> (<span class=""disease"" id=""12151787-1-106-108"">PD</span>), but it is not known how they result in selective dopaminergic cell death.",CTD_human
27,1,Biomarker,C0030567,Parkinson Disease,disease,PD,6622,SNCA,alpha-synuclein,CTD_human,17131421,Patients with additional copies of the alpha-synuclein gene develop PD with a severity proportional to levels of alpha-synuclein overexpression.,0.44,"Patients with additional copies of the <span class=""gene"" id=""17131421-4-39-54"">alpha-synuclein</span> gene develop <span class=""disease"" id=""17131421-4-68-70"">PD</span> with a severity proportional to levels of alpha-synuclein overexpression.",CTD_human
27,1,Biomarker,C0030567,Parkinson Disease,disease,Parkinson disease,6622,SNCA,SNCA,CTD_human,18322262,"Our findings suggest that SNCA REP1 genotype and herbicides have independent effects on risk of Parkinson disease, primarily in younger subjects.",0.44,"Our findings suggest that <span class=""gene"" id=""18322262-12-26-30"">SNCA</span> REP1 genotype and herbicides have independent effects on risk of <span class=""disease"" id=""18322262-12-96-113"">Parkinson disease</span>, primarily in younger subjects.",CTD_human
27,1,Biomarker,C0030567,Parkinson Disease,disease,Parkinson's disease,6622,SNCA,?-Synuclein,CTD_human,20664293,?-Synuclein gene may interact with environmental factors in increasing risk of Parkinson's disease.,0.44,"<span class=""gene"" id=""20664293-0-0-11"">&alpha;-Synuclein</span> gene may interact with environmental factors in increasing risk of <span class=""disease"" id=""20664293-0-79-98"">Parkinson's disease</span>.",CTD_human
27,1,Biomarker,C0030567,Parkinson Disease,disease,Parkinson's disease,6622,SNCA,alpha-synuclein,CTD_human,12732244,"In humans, mutations in the alpha-synuclein gene or exposure to the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produce Parkinson's disease with loss of dopaminergic neurons and depletion of nigrostriatal dopamine. alpha-Synuclein is a vertebrate-specific component of presynaptic nerve terminals that may function in modulating synaptic transmission.",0.44,"In humans, mutations in the <span class=""gene"" id=""12732244-1-28-43"">alpha-synuclein</span> gene or exposure to the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produce <span class=""disease"" id=""12732244-1-139-158"">Parkinson's disease</span> with loss of dopaminergic neurons and depletion of nigrostriatal dopamine. alpha-Synuclein is a vertebrate-specific component of presynaptic nerve terminals that may function in modulating synaptic transmission.",CTD_human
1,0,Biomarker,C0026764,Multiple Myeloma,disease,MM,664,BNIP3,BNIP3,CTD_human,18172295,"Interestingly, methylation of SPARC and BNIP3 was statistically significantly associated with a poor overall survival of MM patients (P = 0.003 and P = 0.017, respectively).",0.20054945356842604,"Interestingly, methylation of SPARC and <span class=""gene"" id=""18172295-7-40-45"">BNIP3</span> was statistically significantly associated with a poor overall survival of <span class=""disease"" id=""18172295-7-121-123"">MM</span> patients (P = 0.003 and P = 0.017, respectively).",CTD_human
1,0,Biomarker,C0033578,Prostatic Neoplasms,group,prostate tumors,664,BNIP3,BNIP3,CTD_human,18163427,These findings suggest that BNIP3 is directly regulated by hypoxia but that there may be a hormonal independent mechanism coordinating the expression of BNIP3 in prostate tumors.,0.200274726784213,"These findings suggest that <span class=""gene"" id=""18163427-11-28-33"">BNIP3</span> is directly regulated by hypoxia but that there may be a hormonal independent mechanism coordinating the expression of <span class=""gene"" id=""18163427-11-153-158"">BNIP3</span> in <span class=""disease"" id=""18163427-11-162-177"">prostate tumors</span>.",CTD_human
24,0,Biomarker,C0002736,Amyotrophic Lateral Sclerosis,disease,amyotrophic lateral sclerosis,6647,SOD1,superoxide dismutase 1,CTD_human,25164820,Identification of a misfolded region in superoxide dismutase 1 that is exposed in amyotrophic lateral sclerosis.,0.7985124563726079,"Identification of a misfolded region in <span class=""gene"" id=""25164820-0-40-62"">superoxide dismutase 1</span> that is exposed in <span class=""disease"" id=""25164820-0-82-111"">amyotrophic lateral sclerosis</span>.",CTD_human;HPO;ORPHANET
24,0,Biomarker,C0002736,Amyotrophic Lateral Sclerosis,disease,amyotrophic lateral sclerosis,6647,SOD1,superoxide dismutase-1,CTD_human,17319283,Protein-bound crotonaldehyde accumulates in the spinal cord of superoxide dismutase-1 mutation-associated familial amyotrophic lateral sclerosis and its transgenic mouse model.,0.7985124563726079,"Protein-bound crotonaldehyde accumulates in the spinal cord of <span class=""gene"" id=""17319283-0-63-85"">superoxide dismutase-1</span> mutation-associated familial <span class=""disease"" id=""17319283-0-115-144"">amyotrophic lateral sclerosis</span> and its transgenic mouse model.",CTD_human;HPO;ORPHANET
24,0,Biomarker,C0002736,Amyotrophic Lateral Sclerosis,disease,amyotrophic lateral sclerosis,6647,SOD1,Cu/Zn superoxide dismutase,CTD_human,7887412,Identification of new mutations in the Cu/Zn superoxide dismutase gene of patients with familial amyotrophic lateral sclerosis.,0.7985124563726079,"Identification of new mutations in the <span class=""gene"" id=""7887412-0-39-65"">Cu/Zn superoxide dismutase</span> gene of patients with familial <span class=""disease"" id=""7887412-0-97-126"">amyotrophic lateral sclerosis</span>.",CTD_human;HPO;ORPHANET
24,0,Biomarker,C0002736,Amyotrophic Lateral Sclerosis,disease,amyotrophic lateral sclerosis,6647,SOD1,SOD1,CTD_human,11590119,Oxidative stress causes abnormal accumulation of familial amyotrophic lateral sclerosis-related mutant SOD1 in transgenic Caenorhabditis elegans.,0.7985124563726079,"Oxidative stress causes abnormal accumulation of familial <span class=""disease"" id=""11590119-0-58-87"">amyotrophic lateral sclerosis</span>-related mutant <span class=""gene"" id=""11590119-0-103-107"">SOD1</span> in transgenic Caenorhabditis elegans.",CTD_human;HPO;ORPHANET
24,0,Biomarker,C0002736,Amyotrophic Lateral Sclerosis,disease,amyotrophic lateral sclerosis,6647,SOD1,superoxide dismutase 1,CTD_human,20177826,Transcriptional profiling in the lumbar spinal cord of a mouse model of amyotrophic lateral sclerosis: a role for wild-type superoxide dismutase 1 in sporadic disease?,0.7985124563726079,"Transcriptional profiling in the lumbar spinal cord of a mouse model of <span class=""disease"" id=""20177826-0-72-101"">amyotrophic lateral sclerosis</span>: a role for wild-type <span class=""gene"" id=""20177826-0-124-146"">superoxide dismutase 1</span> in sporadic disease?",CTD_human;HPO;ORPHANET
24,0,Biomarker,C0002736,Amyotrophic Lateral Sclerosis,disease,amyotrophic lateral sclerosis,6647,SOD1,SOD1,CTD_human,19635794,"We identified a shared property of these familial amyotrophic lateral sclerosis-related SOD1 variants, namely structural and dynamic change affecting the electrostatic loop (loop VII) of SOD1.",0.7985124563726079,"We identified a shared property of these familial <span class=""disease"" id=""19635794-3-50-79"">amyotrophic lateral sclerosis</span>-related <span class=""gene"" id=""19635794-3-88-92"">SOD1</span> variants, namely structural and dynamic change affecting the electrostatic loop (loop VII) of <span class=""gene"" id=""19635794-3-187-191"">SOD1</span>.",CTD_human;HPO;ORPHANET
24,0,Biomarker,C0002736,Amyotrophic Lateral Sclerosis,disease,amyotrophic lateral sclerosis,6647,SOD1,Superoxide dismutase 1,CTD_human,18233996,Superoxide dismutase 1 mutants related to amyotrophic lateral sclerosis induce endoplasmic stress in neuro2a cells.,0.7985124563726079,"<span class=""gene"" id=""18233996-0-0-22"">Superoxide dismutase 1</span> mutants related to <span class=""disease"" id=""18233996-0-42-71"">amyotrophic lateral sclerosis</span> induce endoplasmic stress in neuro2a cells.",CTD_human;HPO;ORPHANET
24,0,Biomarker,C0002736,Amyotrophic Lateral Sclerosis,disease,ALS,6647,SOD1,SOD1,CTD_human,17097207,"To verify this hypothesis, we examined the copper and zinc concentrations and the amounts of lipid peroxides, together with that of the expression of metallothionein (MT) isoforms in a mouse model [superoxide dismutase1 transgenic (SOD1 Tg) mouse] of ALS.",0.7985124563726079,"To verify this hypothesis, we examined the copper and zinc concentrations and the amounts of lipid peroxides, together with that of the expression of metallothionein (MT) isoforms in a mouse model [superoxide dismutase1 transgenic (<span class=""gene"" id=""17097207-2-232-236"">SOD1</span> Tg) mouse] of <span class=""disease"" id=""17097207-2-251-254"">ALS</span>.",CTD_human;HPO;ORPHANET
24,0,Biomarker,C0002736,Amyotrophic Lateral Sclerosis,disease,ALS,6647,SOD1,SOD-1,CTD_human,9065559,"A predilection for disease onset in the lower limbs appears to be a distinguishing feature of familial ALS with SOD-1 mutations, and accords with findings in transgenic mouse models.",0.7985124563726079,"A predilection for disease onset in the lower limbs appears to be a distinguishing feature of familial <span class=""disease"" id=""9065559-6-103-106"">ALS</span> with <span class=""gene"" id=""9065559-6-112-117"">SOD-1</span> mutations, and accords with findings in transgenic mouse models.",CTD_human;HPO;ORPHANET
24,0,Biomarker,C0002736,Amyotrophic Lateral Sclerosis,disease,ALS,6647,SOD1,SOD1,CTD_human,16495328,Mutations in copper/zinc superoxide dismutase 1 (SOD1) are found in approximately 20% of familial and approximately 3% of sporadic ALS cases but are not associated with dementia.,0.7985124563726079,"Mutations in copper/zinc <span class=""gene"" id=""16495328-5-25-47"">superoxide dismutase 1</span> (<span class=""gene"" id=""16495328-5-49-53"">SOD1</span>) are found in approximately 20% of familial and approximately 3% of sporadic <span class=""disease"" id=""16495328-5-131-134"">ALS</span> cases but are not associated with dementia.",CTD_human;HPO;ORPHANET
24,0,Biomarker,C0002736,Amyotrophic Lateral Sclerosis,disease,ALS,6647,SOD1,Cu/Zn superoxide dismutase,CTD_human,19929749,Rapid one-step purification of native dimeric ALS-associated human Cu/Zn superoxide dismutase from transgenic rat tissues.,0.7985124563726079,"Rapid one-step purification of native dimeric <span class=""disease"" id=""19929749-0-46-49"">ALS</span>-associated human <span class=""gene"" id=""19929749-0-67-93"">Cu/Zn superoxide dismutase</span> from transgenic rat tissues.",CTD_human;HPO;ORPHANET
24,0,Biomarker,C0002736,Amyotrophic Lateral Sclerosis,disease,ALS,6647,SOD1,SOD1,CTD_human,17496168,"In SOD1(G93A) transgenic mice, a model of familial ALS, TRO19622 treatment improved motor performance, delayed the onset of the clinical disease, and extended survival.",0.7985124563726079,"In <span class=""gene"" id=""17496168-6-3-7"">SOD1</span>(G93A) transgenic mice, a model of familial <span class=""disease"" id=""17496168-6-51-54"">ALS</span>, TRO19622 treatment improved motor performance, delayed the onset of the clinical disease, and extended survival.",CTD_human;HPO;ORPHANET
24,0,Biomarker,C0002736,Amyotrophic Lateral Sclerosis,disease,ALS,6647,SOD1,SOD1,CTD_human,20515040,"Overall, these findings lend support to the hypothesis that immature mutant SOD1 species contribute to toxicity in SOD1-linked ALS.",0.7985124563726079,"Overall, these findings lend support to the hypothesis that immature mutant <span class=""gene"" id=""20515040-7-76-80"">SOD1</span> species contribute to toxicity in <span class=""gene"" id=""20515040-7-115-119"">SOD1</span>-linked <span class=""disease"" id=""20515040-7-127-130"">ALS</span>.",CTD_human;HPO;ORPHANET
24,0,Biomarker,C0002736,Amyotrophic Lateral Sclerosis,disease,ALS,6647,SOD1,superoxide dismutase 1,CTD_human,23583883,The aim of the work was (1) investigating on gender-dependence of disease progression in the standard model for ALS - the transgenic mouse bearing superoxide dismutase 1 gene mutations - and (2) assessing if a P2X7 receptor antagonist treatment should take into account sexual dimorphism.,0.7985124563726079,"The aim of the work was (1) investigating on gender-dependence of disease progression in the standard model for <span class=""disease"" id=""23583883-6-112-115"">ALS</span> - the transgenic mouse bearing <span class=""gene"" id=""23583883-6-147-169"">superoxide dismutase 1</span> gene mutations - and (2) assessing if a P2X7 receptor antagonist treatment should take into account sexual dimorphism.",CTD_human;HPO;ORPHANET
24,0,Biomarker,C0002736,Amyotrophic Lateral Sclerosis,disease,ALS,6647,SOD1,SOD1,CTD_human,12586733,This study strongly supports a role for COX-2 in the pathophysiology of ALS and provides the first experimental evidence that prophylactic treatment with COX-2 inhibitors can significantly delay the onset of motor dysfunction in the SOD1-G93A transgenic mouse model of ALS.,0.7985124563726079,"This study strongly supports a role for COX-2 in the pathophysiology of <span class=""disease"" id=""12586733-5-72-75"">ALS</span> and provides the first experimental evidence that prophylactic treatment with COX-2 inhibitors can significantly delay the onset of motor dysfunction in the <span class=""gene"" id=""12586733-5-233-237"">SOD1</span>-G93A transgenic mouse model of <span class=""disease"" id=""12586733-5-269-272"">ALS</span>.",CTD_human;HPO;ORPHANET
24,0,Biomarker,C0002736,Amyotrophic Lateral Sclerosis,disease,amyotrophic lateral sclerosis,6647,SOD1,SOD1,CTD_human,10930589,Increased reactive oxygen species in familial amyotrophic lateral sclerosis with mutations in SOD1.,0.7985124563726079,"Increased reactive oxygen species in familial <span class=""disease"" id=""10930589-0-46-75"">amyotrophic lateral sclerosis</span> with mutations in <span class=""gene"" id=""10930589-0-94-98"">SOD1</span>.",CTD_human;HPO;ORPHANET
24,0,Biomarker,C0002736,Amyotrophic Lateral Sclerosis,disease,ALS,6647,SOD1,SOD1,CTD_human,21867702,These results imply that BRC protects motor neurons from the oxidative injury via suppression of astrogliosis in the spinal cord of ALS(SOD1(H46R)) mice.,0.7985124563726079,"These results imply that BRC protects motor neurons from the oxidative injury via suppression of astrogliosis in the spinal cord of <span class=""disease"" id=""21867702-11-132-135"">ALS</span>(<span class=""gene"" id=""21867702-11-136-140"">SOD1</span>(H46R)) mice.",CTD_human;HPO;ORPHANET
24,0,Biomarker,C0002736,Amyotrophic Lateral Sclerosis,disease,amyotrophic lateral sclerosis,6647,SOD1,SOD1,CTD_human,20348957,From transcriptome analysis to therapeutic anti-CD40L treatment in the SOD1 model of amyotrophic lateral sclerosis.,0.7985124563726079,"From transcriptome analysis to therapeutic anti-CD40L treatment in the <span class=""gene"" id=""20348957-0-71-75"">SOD1</span> model of <span class=""disease"" id=""20348957-0-85-114"">amyotrophic lateral sclerosis</span>.",CTD_human;HPO;ORPHANET
1,0,Therapeutic,C0011884,Diabetic Retinopathy,disease,diabetic retinopathy,6647,SOD1,Cu/Zn superoxide dismutase,CTD_human,19074809,Retinal ion regulation in a mouse model of diabetic retinopathy: natural history and the effect of Cu/Zn superoxide dismutase overexpression.,0.202681755307501,"Retinal ion regulation in a mouse model of <span class=""disease"" id=""19074809-0-43-63"">diabetic retinopathy</span>: natural history and the effect of <span class=""gene"" id=""19074809-0-99-125"">Cu/Zn superoxide dismutase</span> overexpression.",CTD_human
1,0,Biomarker,C0013080,Down Syndrome,disease,DS,6647,SOD1,SOD1,CTD_human,11181815,"They also show the potentially deleterious effects of SOD1 overexpression on cellular proliferation, which may be relevant to abnormal development in DS.",0.221660349820883,"They also show the potentially deleterious effects of <span class=""gene"" id=""11181815-7-54-58"">SOD1</span> overexpression on cellular proliferation, which may be relevant to abnormal development in <span class=""disease"" id=""11181815-7-150-152"">DS</span>.",CTD_human
1,0,Biomarker,C0024796,Marfan Syndrome,disease,MV,6647,SOD1,SOD,CTD_human,25101153,"Laminin ?-1 was decreased in MV and increased in M. In conclusion, similarities and differences in oxidative stress in the different aortopathies studied including pathologies with aneurysms were found with alterations in SOD, CAT, GPx, GST, and eNOS activity that modify subendothelial basement membrane proteins.",0.2,"Laminin &gamma;-1 was decreased in <span class=""disease"" id=""25101153-8-29-31"">MV</span> and increased in M. In conclusion, similarities and differences in oxidative stress in the different aortopathies studied including pathologies with aneurysms were found with alterations in <span class=""gene"" id=""25101153-8-222-225"">SOD</span>, CAT, GPx, GST, and eNOS activity that modify subendothelial basement membrane proteins.",CTD_human
1,0,Biomarker,C0025312,Meningomyelocele,disease,myelomeningocele,6647,SOD1,SOD1,CTD_human,22972774,Association of copper-zinc superoxide dismutase (SOD1) and manganese superoxide dismutase (SOD2) genes with nonsyndromic myelomeningocele.,0.20054945356842604,"Association of copper-zinc superoxide dismutase (<span class=""gene"" id=""22972774-0-49-53"">SOD1</span>) and manganese superoxide dismutase (SOD2) genes with nonsyndromic <span class=""disease"" id=""22972774-0-121-137"">myelomeningocele</span>.",CTD_human
1,0,Therapeutic,C0027720,Nephrosis,disease,nephrosis,6647,SOD1,"Cu, Zn-superoxide dismutase",CTD_human,2273594,"[Effects of human Cu, Zn-superoxide dismutase in aminonucleoside nephrosis--evaluation of the morphology and glomerular basement membrane anionic charge sites].",0.2,"[Effects of human <span class=""gene"" id=""2273594-0-18-45"">Cu, Zn-superoxide dismutase</span> in aminonucleoside <span class=""disease"" id=""2273594-0-65-74"">nephrosis</span>--evaluation of the morphology and glomerular basement membrane anionic charge sites].",CTD_human
3,0,Therapeutic,C0030567,Parkinson Disease,disease,Parkinson's Disease,6647,SOD1,Cu/Zn-superoxide dismutase,CTD_human,21318773,"Table 1 Biochemical Alterations in Substantia Nigra of Parkinson's Disease Indicating Oxidative Stress Elevated Decreased Iron (in microglia, astrocytes, oligodendrocytes, and melanized dopamine neurons and mitochondria) GSH (GSSG unchanged); GSH/GSSG ratio decreased Mitochondrial complex I Ferritin Calcium binding protein (calbindin 28) Mitochondrial monoamine oxidase B Transferrin and transferrin receptor Lipofuscin Vitamins E and C Ubiquitin Copper Cu/Zn-superoxide dismutase Cytotoxic cytokines (TNF-a, IL-1, IL-6) Inflammatory transcription factor NFKB Heme oxygenase-1 Ratio of oxidized to reduced glutathione (GSSG/GSH) Nitric oxide Neuromelanin.",0.209586726692824,"Table 1 Biochemical Alterations in Substantia Nigra of <span class=""disease"" id=""21318773-12-55-74"">Parkinson's Disease</span> Indicating Oxidative Stress Elevated Decreased Iron (in microglia, astrocytes, oligodendrocytes, and melanized dopamine neurons and mitochondria) GSH (GSSG unchanged); GSH/GSSG ratio decreased Mitochondrial complex I Ferritin Calcium binding protein (calbindin 28) Mitochondrial monoamine oxidase B Transferrin and transferrin receptor Lipofuscin Vitamins E and C Ubiquitin Copper <span class=""gene"" id=""21318773-12-456-482"">Cu/Zn-superoxide dismutase</span> Cytotoxic cytokines (TNF-a, IL-1, IL-6) Inflammatory transcription factor NFKB Heme oxygenase-1 Ratio of oxidized to reduced glutathione (GSSG/GSH) Nitric oxide Neuromelanin.",CTD_human
3,0,Therapeutic,C0030567,Parkinson Disease,disease,PD,6647,SOD1,SOD1,CTD_human,16353238,They also indicate that SOD1 gene transfer into the nigrostriatal system may be a potential neuroprotective strategy for treating PD.,0.209586726692824,"They also indicate that <span class=""gene"" id=""16353238-10-24-28"">SOD1</span> gene transfer into the nigrostriatal system may be a potential neuroprotective strategy for treating <span class=""disease"" id=""16353238-10-130-132"">PD</span>.",CTD_human
3,0,Biomarker,C0030567,Parkinson Disease,disease,Parkinson's Disease,6647,SOD1,Cu/Zn-superoxide dismutase,CTD_human,21318773,"Table 1 Biochemical Alterations in Substantia Nigra of Parkinson's Disease Indicating Oxidative Stress Elevated Decreased Iron (in microglia, astrocytes, oligodendrocytes, and melanized dopamine neurons and mitochondria) GSH (GSSG unchanged); GSH/GSSG ratio decreased Mitochondrial complex I Ferritin Calcium binding protein (calbindin 28) Mitochondrial monoamine oxidase B Transferrin and transferrin receptor Lipofuscin Vitamins E and C Ubiquitin Copper Cu/Zn-superoxide dismutase Cytotoxic cytokines (TNF-a, IL-1, IL-6) Inflammatory transcription factor NFKB Heme oxygenase-1 Ratio of oxidized to reduced glutathione (GSSG/GSH) Nitric oxide Neuromelanin.",0.209586726692824,"Table 1 Biochemical Alterations in Substantia Nigra of <span class=""disease"" id=""21318773-12-55-74"">Parkinson's Disease</span> Indicating Oxidative Stress Elevated Decreased Iron (in microglia, astrocytes, oligodendrocytes, and melanized dopamine neurons and mitochondria) GSH (GSSG unchanged); GSH/GSSG ratio decreased Mitochondrial complex I Ferritin Calcium binding protein (calbindin 28) Mitochondrial monoamine oxidase B Transferrin and transferrin receptor Lipofuscin Vitamins E and C Ubiquitin Copper <span class=""gene"" id=""21318773-12-456-482"">Cu/Zn-superoxide dismutase</span> Cytotoxic cytokines (TNF-a, IL-1, IL-6) Inflammatory transcription factor NFKB Heme oxygenase-1 Ratio of oxidized to reduced glutathione (GSSG/GSH) Nitric oxide Neuromelanin.",CTD_human
3,0,Biomarker,C0030567,Parkinson Disease,disease,PD,6647,SOD1,SOD1,CTD_human,16353238,They also indicate that SOD1 gene transfer into the nigrostriatal system may be a potential neuroprotective strategy for treating PD.,0.209586726692824,"They also indicate that <span class=""gene"" id=""16353238-10-24-28"">SOD1</span> gene transfer into the nigrostriatal system may be a potential neuroprotective strategy for treating <span class=""disease"" id=""16353238-10-130-132"">PD</span>.",CTD_human
1,0,Biomarker,C0038454,Cerebrovascular accident,group,stroke,6647,SOD1,SOD1,CTD_human,10698074,"The current study used a SOD1 transgenic (SOD1-Tg) murine cortical culture system, derived from the same mouse strain previously used for the stroke models, to identify conditions that determine whether SOD1 overexpression in neurons is protective or detrimental.",0.200274726784213,"The current study used a <span class=""gene"" id=""10698074-2-25-29"">SOD1</span> transgenic (<span class=""gene"" id=""10698074-2-42-46"">SOD1</span>-Tg) murine cortical culture system, derived from the same mouse strain previously used for the <span class=""disease"" id=""10698074-2-142-148"">stroke</span> models, to identify conditions that determine whether <span class=""gene"" id=""10698074-2-203-207"">SOD1</span> overexpression in neurons is protective or detrimental.",CTD_human
1,0,Biomarker,C0041408,Turner Syndrome,disease,Turner's syndrome,6647,SOD1,SOD,CTD_human,25101153,"There was an increase in Mn- and Cu-Zn-SOD activity in SAH, MV, M, and Turner's syndrome.",0.200274726784213,"There was an increase in Mn- and Cu-Zn-<span class=""gene"" id=""25101153-4-39-42"">SOD</span> activity in SAH, MV, M, and <span class=""disease"" id=""25101153-4-71-88"">Turner's syndrome</span>.",CTD_human
1,0,Biomarker,C0085084,Motor Neuron Disease,disease,MND,6647,SOD1,SOD1,CTD_human,16702190,Recent evidence suggests that oxidative stress from aberrant copper chemistry may not play a major part in the pathogenesis of SOD1-related fMND.,0.246574354920372,"Recent evidence suggests that oxidative stress from aberrant copper chemistry may not play a major part in the pathogenesis of <span class=""gene"" id=""16702190-11-127-131"">SOD1</span>-related f<span class=""disease"" id=""16702190-11-141-144"">MND</span>.",CTD_human
51,32,Biomarker,C1862939,AMYOTROPHIC LATERAL SCLEROSIS 1,disease,amyotrophic lateral sclerosis 1,6647,SOD1,SOD-1,CTD_human,11951178,"Mutations in the copper/zinc superoxide dismutase 1 (SOD-1) gene are found in approximately 20% of patients with familial amyotrophic lateral sclerosis (FALS), or amyotrophic lateral sclerosis 1.",0.493736339210655,"Mutations in the copper/zinc <span class=""gene"" id=""11951178-1-29-51"">superoxide dismutase 1</span> (<span class=""gene"" id=""11951178-1-53-58"">SOD-1</span>) gene are found in approximately 20% of patients with familial amyotrophic lateral sclerosis (FALS), or <span class=""disease"" id=""11951178-1-163-194"">amyotrophic lateral sclerosis 1</span>.",CTD_human;UNIPROT
1,0,Biomarker,C0002736,Amyotrophic Lateral Sclerosis,disease,amyotrophic lateral sclerosis,6648,SOD2,superoxide dismutase-2,CTD_human,8866423,Enhanced superoxide dismutase-2 immunoreactivity of astrocytes and occasional neurons in amyotrophic lateral sclerosis.,0.20082418035263896,"Enhanced <span class=""gene"" id=""8866423-0-9-31"">superoxide dismutase-2</span> immunoreactivity of astrocytes and occasional neurons in <span class=""disease"" id=""8866423-0-89-118"">amyotrophic lateral sclerosis</span>.",CTD_human
1,0,Biomarker,C0002871,Anemia,disease,anemia,6648,SOD2,SOD2,CTD_human,20800516,"Impaired SOD2 activity in murine hematopoietic cells affects erythroid development, resulting in anemia characterized by intra-mitochondrial iron deposition, reticulocytosis and shortened red cell life span.",0.200274726784213,"Impaired <span class=""gene"" id=""20800516-2-9-13"">SOD2</span> activity in murine hematopoietic cells affects erythroid development, resulting in <span class=""disease"" id=""20800516-2-97-103"">anemia</span> characterized by intra-mitochondrial iron deposition, reticulocytosis and shortened red cell life span.",CTD_human
2,0,Biomarker,C0002896,Sideroblastic anemia,disease,sideroblastic anemia,6648,SOD2,SOD2,CTD_human,16910769,SOD2-deficiency sideroblastic anemia and red blood cell oxidative stress.,0.200274726784213,"<span class=""gene"" id=""16910769-0-0-4"">SOD2</span>-deficiency <span class=""disease"" id=""16910769-0-16-36"">sideroblastic anemia</span> and red blood cell oxidative stress.",CTD_human
2,0,Biomarker,C0002896,Sideroblastic anemia,disease,SA,6648,SOD2,Sod2,CTD_human,21326867,"To define early events in the pathogenesis of this murine model of SA, we compared erythroid differentiation of Sod2?/? and normal bone marrow cells using flow cytometry and gene expression profiling of erythroblasts.",0.200274726784213,"To define early events in the pathogenesis of this murine model of <span class=""disease"" id=""21326867-3-67-69"">SA</span>, we compared erythroid differentiation of <span class=""gene"" id=""21326867-3-112-116"">Sod2</span>?/? and normal bone marrow cells using flow cytometry and gene expression profiling of erythroblasts.",CTD_human
2,0,Biomarker,C0005695,Bladder Neoplasm,disease,bladder cancer,6648,SOD2,Sod2,CTD_human,18930813,We aimed to identify the role of Sod2 expression and ROS in bladder cancer.,0.201923087489492,"We aimed to identify the role of <span class=""gene"" id=""18930813-4-33-37"">Sod2</span> expression and ROS in <span class=""disease"" id=""18930813-4-60-74"">bladder cancer</span>.",CTD_human
2,0,Biomarker,C0007193,"Cardiomyopathy, Dilated",group,dilated cardiomyopathy,6648,SOD2,SOD2,CTD_human,21195081,"This study examined telomere biology in heart/muscle-specific manganese superoxide dismutase-deficient mice (H/M-SOD2(-/-)), which develop progressive congestive heart failure and exhibit pathology typical of dilated cardiomyopathy.",0.20082418035263896,"This study examined telomere biology in heart/muscle-specific manganese superoxide dismutase-deficient mice (H/M-<span class=""gene"" id=""21195081-2-113-117"">SOD2</span>(-/-)), which develop progressive congestive heart failure and exhibit pathology typical of <span class=""disease"" id=""21195081-2-209-231"">dilated cardiomyopathy</span>.",CTD_human
1,0,Biomarker,C0011881,Diabetic Nephropathy,disease,diabetic nephropathy,6648,SOD2,SOD2,CTD_human,24819633,"SOD2 allelic variations were associated with the incidence and the progression of diabetic nephropathy, with a faster decline in eGFR and with plasma AOPP concentration and SOD activity in subjects with type 1 diabetes.",0.208371149864029,"<span class=""gene"" id=""24819633-13-0-4"">SOD2</span> allelic variations were associated with the incidence and the progression of <span class=""disease"" id=""24819633-13-82-102"">diabetic nephropathy</span>, with a faster decline in eGFR and with plasma AOPP concentration and SOD activity in subjects with type 1 diabetes.",CTD_human
1,0,Therapeutic,C0014866,Esophageal Stenosis,disease,esophageal stricture,6648,SOD2,SOD2,CTD_human,11121210,Modulation of radiation-induced cytokine elevation associated with esophagitis and esophageal stricture by manganese superoxide dismutase-plasmid/liposome (SOD2-PL) gene therapy.,0.200274726784213,"Modulation of radiation-induced cytokine elevation associated with esophagitis and <span class=""disease"" id=""11121210-0-83-103"">esophageal stricture</span> by manganese superoxide dismutase-plasmid/liposome (<span class=""gene"" id=""11121210-0-156-160"">SOD2</span>-PL) gene therapy.",CTD_human
1,0,Therapeutic,C0014868,Esophagitis,disease,esophagitis,6648,SOD2,SOD2,CTD_human,11121210,Modulation of radiation-induced cytokine elevation associated with esophagitis and esophageal stricture by manganese superoxide dismutase-plasmid/liposome (SOD2-PL) gene therapy.,0.200274726784213,"Modulation of radiation-induced cytokine elevation associated with <span class=""disease"" id=""11121210-0-67-78"">esophagitis</span> and esophageal stricture by manganese superoxide dismutase-plasmid/liposome (<span class=""gene"" id=""11121210-0-156-160"">SOD2</span>-PL) gene therapy.",CTD_human
1,0,Biomarker,C0020550,Hyperthyroidism,disease,hyperthyroid,6648,SOD2,SOD2,CTD_human,19914224,"Translated products of AOGs showed differential expression in the liver of hyperthyroid rats, where Cu/Zn SOD (SOD1), CAT and GR were decreased in contrast to Mn SOD (SOD2) and GPx1.",0.2,"Translated products of AOGs showed differential expression in the liver of <span class=""disease"" id=""19914224-6-75-87"">hyperthyroid</span> rats, where Cu/Zn SOD (SOD1), CAT and GR were decreased in contrast to <span class=""gene"" id=""19914224-6-159-165"">Mn SOD</span> (<span class=""gene"" id=""19914224-6-167-171"">SOD2</span>) and GPx1.",CTD_human
1,0,Biomarker,C0021364,Male infertility,phenotype,male infertility,6648,SOD2,SOD2,CTD_human,22206979,The results indicated that the PON1 Arg192Glu (rs662) and SOD2 Val16Ala (rs4880) variant genotypes were associated with a significantly higher risk of male infertility.,0.202681755307501,"The results indicated that the PON1 Arg192Glu (rs662) and <span class=""gene"" id=""22206979-5-58-62"">SOD2</span> Val16Ala (rs4880) variant genotypes were associated with a significantly higher risk of <span class=""disease"" id=""22206979-5-151-167"">male infertility</span>.",CTD_human
1,0,Biomarker,C0023891,"Liver Cirrhosis, Alcoholic",disease,alcoholic cirrhosis,6648,SOD2,superoxide dismutase 2,CTD_human,19731237,Myeloperoxidase and superoxide dismutase 2 polymorphisms comodulate the risk of hepatocellular carcinoma and death in alcoholic cirrhosis.,0.20777053913829002,"Myeloperoxidase and <span class=""gene"" id=""19731237-0-20-42"">superoxide dismutase 2</span> polymorphisms comodulate the risk of hepatocellular carcinoma and death in <span class=""disease"" id=""19731237-0-118-137"">alcoholic cirrhosis</span>.",CTD_human
1,0,Biomarker,C0024115,Lung diseases,group,lung disease,6648,SOD2,MnSOD,CTD_human,8063194,"Thus, elevations of MnSOD mRNA levels in lung or BAL may be predictive of lung disease.",0.20054945356842604,"Thus, elevations of <span class=""gene"" id=""8063194-8-20-25"">MnSOD</span> mRNA levels in lung or BAL may be predictive of <span class=""disease"" id=""8063194-8-74-86"">lung disease</span>.",CTD_human
1,0,Biomarker,C0025312,Meningomyelocele,disease,myelomeningocele,6648,SOD2,SOD2,CTD_human,22972774,Association of copper-zinc superoxide dismutase (SOD1) and manganese superoxide dismutase (SOD2) genes with nonsyndromic myelomeningocele.,0.20054945356842604,"Association of copper-zinc superoxide dismutase (SOD1) and manganese superoxide dismutase (<span class=""gene"" id=""22972774-0-91-95"">SOD2</span>) genes with nonsyndromic <span class=""disease"" id=""22972774-0-121-137"">myelomeningocele</span>.",CTD_human
4,0,Biomarker,C0025500,Mesothelioma,disease,mesothelioma,6648,SOD2,MnSOD,CTD_human,15039138,"Therefore, the intense expression of MnSOD in the mitochondria of mesothelioma cells does not appear be associated with any major chromosomal alterations or the polymorphism of MnSOD gene.",0.20300763924902696,"Therefore, the intense expression of MnSOD in the mitochondria of <span class=""disease"" id=""15039138-8-66-78"">mesothelioma</span> cells does not appear be associated with any major chromosomal alterations or the polymorphism of <span class=""gene"" id=""15039138-8-177-182"">MnSOD</span> gene.",CTD_human
1,0,Biomarker,C0026764,Multiple Myeloma,disease,multiple myeloma,6648,SOD2,SOD-2,CTD_human,15908783,Epigenetic silencing of manganese superoxide dismutase (SOD-2) in KAS 6/1 human multiple myeloma cells increases cell proliferation.,0.20328236603324,"Epigenetic silencing of manganese superoxide dismutase (<span class=""gene"" id=""15908783-0-56-61"">SOD-2</span>) in KAS 6/1 human <span class=""disease"" id=""15908783-0-80-96"">multiple myeloma</span> cells increases cell proliferation.",CTD_human
4,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastasis,6648,SOD2,sod2,CTD_human,12538496,Elevated sod2 activity augments matrix metalloproteinase expression: evidence for the involvement of endogenous hydrogen peroxide in regulating metastasis.,0.206839458850693,"Elevated <span class=""gene"" id=""12538496-0-9-13"">sod2</span> activity augments matrix metalloproteinase expression: evidence for the involvement of endogenous hydrogen peroxide in regulating <span class=""disease"" id=""12538496-0-144-154"">metastasis</span>.",CTD_human
4,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastases,6648,SOD2,SOD2,CTD_human,22580338,"To further evaluate the mechanism of SOD2-mediated metastasis in TSCC, TSCC cell lines with different metastatic potentials (i.e., the highly metastatic UM1 line and the UM2 line, which displays fewer metastases) were used.",0.206839458850693,"To further evaluate the mechanism of <span class=""gene"" id=""22580338-2-37-41"">SOD2</span>-mediated <span class=""disease"" id=""22580338-2-51-61"">metastasis</span> in TSCC, TSCC cell lines with different metastatic potentials (i.e., the highly metastatic UM1 line and the UM2 line, which displays fewer <span class=""disease"" id=""22580338-2-201-211"">metastases</span>) were used.",CTD_human
2,0,Biomarker,C0028754,Obesity,disease,obese,6648,SOD2,MnSOD,CTD_human,23956348,"Electron transport complex-II and manganese superoxide dismutase (MnSOD) enzyme activities were decreased in obese-NGT and obese-GDM, compared with NW women.",0.203780662444353,"Electron transport complex-II and manganese superoxide dismutase (<span class=""gene"" id=""23956348-5-66-71"">MnSOD</span>) enzyme activities were decreased in <span class=""disease"" id=""23956348-5-109-114"">obese</span>-NGT and <span class=""disease"" id=""23956348-5-123-128"">obese</span>-GDM, compared with NW women.",CTD_human
3,0,Biomarker,C0029408,Degenerative polyarthritis,disease,OA,6648,SOD2,SOD2,CTD_human,18784066,"Real time PCR, Western blot, and immunohistofluorescence assays confirmed a significant decrease of the major mitochondrial antioxidant protein manganese-superoxide dismutase (SOD2) in the superficial layer of OA cartilage.",0.20082418035263896,"Real time PCR, Western blot, and immunohistofluorescence assays confirmed a significant decrease of the major mitochondrial antioxidant protein manganese-superoxide dismutase (<span class=""gene"" id=""18784066-7-176-180"">SOD2</span>) in the superficial layer of <span class=""disease"" id=""18784066-7-210-212"">OA</span> cartilage.",CTD_human
3,0,Biomarker,C0029408,Degenerative polyarthritis,disease,OA,6648,SOD2,SOD2,CTD_human,22108257,"The increased levels of SOD2 in OA patients indicate an increased oxidative stress OA-related, therefore this antioxidant enzyme could be a suitable candidate biomarker for diagnosis of OA.",0.20082418035263896,"The increased levels of <span class=""gene"" id=""22108257-11-24-28"">SOD2</span> in <span class=""disease"" id=""22108257-11-32-34"">OA</span> patients indicate an increased oxidative stress OA-related, therefore this antioxidant enzyme could be a suitable candidate biomarker for diagnosis of OA.",CTD_human
3,0,Biomarker,C0030567,Parkinson Disease,disease,Parkinson's disease,6648,SOD2,MnSOD,CTD_human,17188257,Pesticide exposure on southwestern Taiwanese with MnSOD and NQO1 polymorphisms is associated with increased risk of Parkinson's disease.,0.214232956890145,"Pesticide exposure on southwestern Taiwanese with <span class=""gene"" id=""17188257-0-50-55"">MnSOD</span> and NQO1 polymorphisms is associated with increased risk of <span class=""disease"" id=""17188257-0-116-135"">Parkinson's disease</span>.",CTD_human
3,0,Biomarker,C0030567,Parkinson Disease,disease,Parkinson's disease,6648,SOD2,SOD2,CTD_human,25279756,Network analysis identifies SOD2 mRNA as a potential biomarker for Parkinson's disease.,0.214232956890145,"Network analysis identifies <span class=""gene"" id=""25279756-0-28-32"">SOD2</span> mRNA as a potential biomarker for <span class=""disease"" id=""25279756-0-67-86"">Parkinson's disease</span>.",CTD_human
1,0,Biomarker,C0031117,Peripheral Neuropathy,group,peripheral neuropathy,6648,SOD2,SOD2,CTD_human,20864405,"In late-onset bortezomib-induced peripheral neuropathy, the significant genes were SOD2 (upregulated by 1·18 times; p=9·6×10(-3)) and MYO5A (1·93 times; p=3·2×10(-2)), involved in development and function of the nervous system.",0.2,"In late-onset bortezomib-induced <span class=""disease"" id=""20864405-11-33-54"">peripheral neuropathy</span>, the significant genes were <span class=""gene"" id=""20864405-11-83-87"">SOD2</span> (upregulated by 1·18 times; p=9·6&times;10(-3)) and MYO5A (1·93 times; p=3·2&times;10(-2)), involved in development and function of the nervous system.",CTD_human
7,0,Biomarker,C0033578,Prostatic Neoplasms,group,prostate tumor,6648,SOD2,SOD-2,CTD_human,12592389,Increased manganese superoxide dismutase (SOD-2) is part of the mechanism for prostate tumor suppression by Mac25/insulin-like growth factor binding-protein-related protein-1.,0.219353956880597,"Increased manganese superoxide dismutase (<span class=""gene"" id=""12592389-0-42-47"">SOD-2</span>) is part of the mechanism for <span class=""disease"" id=""12592389-0-78-92"">prostate tumor</span> suppression by Mac25/insulin-like growth factor binding-protein-related protein-1.",CTD_human
7,0,Therapeutic,C0033578,Prostatic Neoplasms,group,prostate tumor,6648,SOD2,SOD-2,CTD_human,12592389,Increased manganese superoxide dismutase (SOD-2) is part of the mechanism for prostate tumor suppression by Mac25/insulin-like growth factor binding-protein-related protein-1.,0.219353956880597,"Increased manganese superoxide dismutase (<span class=""gene"" id=""12592389-0-42-47"">SOD-2</span>) is part of the mechanism for <span class=""disease"" id=""12592389-0-78-92"">prostate tumor</span> suppression by Mac25/insulin-like growth factor binding-protein-related protein-1.",CTD_human
7,0,Therapeutic,C0033578,Prostatic Neoplasms,group,prostate tumor,6648,SOD2,SOD2,CTD_human,19074884,"In a low-selenium population, SOD2-Ala16+ men homozygous for SEPP1-Ala234 are at an increased risk of prostate cancer/aggressive prostate cancer especially if ever-smokers, because they are likely to produce more mitochondrial H(2)O(2) that they cannot remove, thereby promoting prostate tumor cell proliferation and migration.",0.219353956880597,"In a low-selenium population, <span class=""gene"" id=""19074884-13-30-34"">SOD2</span>-Ala16+ men homozygous for SEPP1-Ala234 are at an increased risk of prostate cancer/aggressive prostate cancer especially if ever-smokers, because they are likely to produce more mitochondrial H(2)O(2) that they cannot remove, thereby promoting <span class=""disease"" id=""19074884-13-279-293"">prostate tumor</span> cell proliferation and migration.",CTD_human
7,0,Biomarker,C0033578,Prostatic Neoplasms,group,prostate tumor,6648,SOD2,SOD2,CTD_human,19074884,"In a low-selenium population, SOD2-Ala16+ men homozygous for SEPP1-Ala234 are at an increased risk of prostate cancer/aggressive prostate cancer especially if ever-smokers, because they are likely to produce more mitochondrial H(2)O(2) that they cannot remove, thereby promoting prostate tumor cell proliferation and migration.",0.219353956880597,"In a low-selenium population, <span class=""gene"" id=""19074884-13-30-34"">SOD2</span>-Ala16+ men homozygous for SEPP1-Ala234 are at an increased risk of prostate cancer/aggressive prostate cancer especially if ever-smokers, because they are likely to produce more mitochondrial H(2)O(2) that they cannot remove, thereby promoting <span class=""disease"" id=""19074884-13-279-293"">prostate tumor</span> cell proliferation and migration.",CTD_human
2,0,Biomarker,C0162674,Chronic progressive external ophthalmoplegia,disease,CPEO,6648,SOD2,Mn-SOD,CTD_human,14680979,"In the light of these findings, we suggest that the increase in expression of Mn-SOD, ROS production and oxidative damage in affected tissues may play an important role in the pathogenesis and progression of the CPEO syndrome.",0.20054945356842604,"In the light of these findings, we suggest that the increase in expression of <span class=""gene"" id=""14680979-8-78-84"">Mn-SOD</span>, ROS production and oxidative damage in affected tissues may play an important role in the pathogenesis and progression of the <span class=""disease"" id=""14680979-8-212-216"">CPEO</span> syndrome.",CTD_human
1,0,Biomarker,C0268255,Farber Lipogranulomatosis,disease,Farber disease,6648,SOD2,MnSOD,CTD_human,10428046,"Markedly higher expression of mRNA, protein, and activity of MnSOD in skin fibroblasts from patients with Farber disease, a human disorder with pathognomonic accumulation of ceramide due to a deficiency of ceramidase, than in normal skin fibroblasts indicate that ceramide may act as a physiological inducer of MnSOD gene expression.",0.200274726784213,"Markedly higher expression of mRNA, protein, and activity of MnSOD in skin fibroblasts from patients with <span class=""disease"" id=""10428046-8-106-120"">Farber disease</span>, a human disorder with pathognomonic accumulation of ceramide due to a deficiency of ceramidase, than in normal skin fibroblasts indicate that ceramide may act as a physiological inducer of <span class=""gene"" id=""10428046-8-311-316"">MnSOD</span> gene expression.",CTD_human
1,0,Biomarker,C0345967,Malignant mesothelioma,disease,MM,6648,SOD2,Mn-SOD,CTD_human,20617513,We found that most human MM cells overexpressed Mn-SOD protein compared with human mesothelial cells and that NCI-H226 human MM cells highly expressed Mn-SOD and augmented Mn accumulation when loaded with manganese chloride (MnCl(2)).,0.2,"We found that most human <span class=""disease"" id=""20617513-4-25-27"">MM</span> cells overexpressed <span class=""gene"" id=""20617513-4-48-54"">Mn-SOD</span> protein compared with human mesothelial cells and that NCI-H226 human <span class=""disease"" id=""20617513-4-125-127"">MM</span> cells highly expressed Mn-SOD and augmented Mn accumulation when loaded with manganese chloride (MnCl(2)).",CTD_human
1,0,Biomarker,C0752347,Lewy Body Disease,disease,Lewy body disease,6648,SOD2,SOD2,CTD_human,16141792,"Preliminary analyses have identified 2 proteins with lipoxidative damage, alpha-synuclein and manganese superoxide dismutase (SOD2), in incidentally Lewy body disease cortex.",0.2,"Preliminary analyses have identified 2 proteins with lipoxidative damage, alpha-synuclein and manganese superoxide dismutase (<span class=""gene"" id=""16141792-8-126-130"">SOD2</span>), in incidentally <span class=""disease"" id=""16141792-8-149-166"">Lewy body disease</span> cortex.",CTD_human
4,0,Biomarker,C2239176,Liver carcinoma,disease,hepatocellular carcinoma,6648,SOD2,superoxide dismutase 2,CTD_human,19731237,Myeloperoxidase and superoxide dismutase 2 polymorphisms comodulate the risk of hepatocellular carcinoma and death in alcoholic cirrhosis.,0.20886944627514298,"Myeloperoxidase and <span class=""gene"" id=""19731237-0-20-42"">superoxide dismutase 2</span> polymorphisms comodulate the risk of <span class=""disease"" id=""19731237-0-80-104"">hepatocellular carcinoma</span> and death in alcoholic cirrhosis.",CTD_human
2,0,Biomarker,C0024117,Chronic Obstructive Airway Disease,disease,COPD,6649,SOD3,SOD3,CTD_human,16467073,"The 213Gly variant of the SOD3 gene may, through antioxidant or anti-inflammatory effects, confer a degree of resistance in some smokers to the development of COPD.",0.218548717525607,"The 213Gly variant of the <span class=""gene"" id=""16467073-6-26-30"">SOD3</span> gene may, through antioxidant or anti-inflammatory effects, confer a degree of resistance in some smokers to the development of <span class=""disease"" id=""16467073-6-159-163"">COPD</span>.",CTD_human
2,23,Biomarker,C0028326,Noonan Syndrome,disease,Noonan syndrome,6654,SOS1,SOS1,CTD_human,17603483,"Increased RAS signaling owing to PTPN11, SOS1 and KRAS mutations causes approximately 60% of Noonan syndrome cases, and PTPN11 mutations cause 90% of LEOPARD syndrome cases.",0.43361562452537605,"Increased RAS signaling owing to PTPN11, <span class=""gene"" id=""17603483-2-41-45"">SOS1</span> and KRAS mutations causes approximately 60% of <span class=""disease"" id=""17603483-2-93-108"">Noonan syndrome</span> cases, and PTPN11 mutations cause 90% of LEOPARD syndrome cases.",CTD_human;ORPHANET
2,23,Biomarker,C0028326,Noonan Syndrome,disease,Noonan syndrome,6654,SOS1,SOS1,CTD_human,17603482,"Mutations of PTPN11, KRAS and SOS1 in the RAS-MAPK pathway cause approximately 60% of cases of Noonan syndrome.",0.43361562452537605,"Mutations of PTPN11, KRAS and <span class=""gene"" id=""17603482-2-30-34"">SOS1</span> in the RAS-MAPK pathway cause approximately 60% of cases of <span class=""disease"" id=""17603482-2-95-110"">Noonan syndrome</span>.",CTD_human;ORPHANET
1,0,Biomarker,C0152013,Adenocarcinoma of lung (disorder),disease,ADC,6654,SOS1,SOS1,CTD_human,27158780,"Lung ADCs lacking receptor tyrosine kinase-Ras-Raf pathway alterations had mutations in SOS1, VAV1, RASA1, and ARHGAP35.",0.2,"Lung <span class=""disease"" id=""27158780-5-5-8"">ADC</span>s lacking receptor tyrosine kinase-Ras-Raf pathway alterations had mutations in <span class=""gene"" id=""27158780-5-88-92"">SOS1</span>, VAV1, RASA1, and ARHGAP35.",CTD_human
1,0,Biomarker,C0003119,Anophthalmos,disease,anophthalmia,6657,SOX2,SOX2,CTD_human,21532573,"The HMG-box transcription factor Sox2 plays a role throughout neurogenesis and also acts at other stages of development, as illustrated by the multiple organs affected in the anophthalmia syndrome caused by SOX2 mutations.",0.41850733012527896,"The HMG-box <span class=""gene"" id=""21532573-1-12-37"">transcription factor Sox2</span> plays a role throughout neurogenesis and also acts at other stages of development, as illustrated by the multiple organs affected in the <span class=""disease"" id=""21532573-1-175-187"">anophthalmia</span> syndrome caused by <span class=""gene"" id=""21532573-1-207-211"">SOX2</span> mutations.",CTD_human;HPO
1,0,Biomarker,C0007137,Squamous cell carcinoma,disease,squamous cell carcinomas,6657,SOX2,SOX2,CTD_human,19801978,SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas.,0.206318716036901,"<span class=""gene"" id=""19801978-0-0-4"">SOX2</span> is an amplified lineage-survival oncogene in lung and esophageal <span class=""disease"" id=""19801978-0-70-94"">squamous cell carcinomas</span>.",CTD_human
1,0,Biomarker,C0149925,Small cell carcinoma of lung,disease,small-cell lung cancer,6657,SOX2,SOX2,CTD_human,22941189,Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer.,0.201373633921065,"Comprehensive genomic analysis identifies <span class=""gene"" id=""22941189-0-42-46"">SOX2</span> as a frequently amplified gene in <span class=""disease"" id=""22941189-0-81-103"">small-cell lung cancer</span>.",CTD_human
1,0,Biomarker,C0279626,Squamous cell carcinoma of esophagus,disease,esophageal SCC,6657,SOX2,SOX2,CTD_human,19801978,These characteristics identify SOX2 as a lineage-survival oncogene in lung and esophageal SCC.,0.20274726784213098,"These characteristics identify <span class=""gene"" id=""19801978-6-31-35"">SOX2</span> as a lineage-survival oncogene in lung and <span class=""disease"" id=""19801978-6-79-93"">esophageal SCC</span>.",CTD_human
1,0,Biomarker,C0004238,Atrial Fibrillation,disease,atrial fibrillation,6660,SOX5,SOX5,CTD_human,20062060,"Five of the loci, SCN5A, SCN10A, NKX2-5, CAV1-CAV2, and SOX5, were also associated with atrial fibrillation (N = 5,741 cases, P < 0.0056).",0.20054945356842604,"Five of the loci, SCN5A, SCN10A, NKX2-5, CAV1-CAV2, and <span class=""gene"" id=""20062060-6-56-60"">SOX5</span>, were also associated with <span class=""disease"" id=""20062060-6-88-107"">atrial fibrillation</span> (N = 5,741 cases, P &lt; 0.0056).",CTD_human
1,0,Biomarker,C0031900,Pierre Robin Syndrome,disease,Pierre Robin sequence,6662,SOX9,SOX9,CTD_human,19234473,Highly conserved non-coding elements on either side of SOX9 associated with Pierre Robin sequence.,0.40302199462634397,"Highly conserved non-coding elements on either side of <span class=""gene"" id=""19234473-0-55-59"">SOX9</span> associated with <span class=""disease"" id=""19234473-0-76-97"">Pierre Robin sequence</span>.",CTD_human;ORPHANET
1,0,Biomarker,C0265998,ANONYCHIA,disease,anonychia,6662,SOX9,SOX9,CTD_human,19639023,Duplications of noncoding elements 5' of SOX9 are associated with brachydactyly-anonychia.,0.2,"Duplications of noncoding elements 5' of <span class=""gene"" id=""19639023-0-41-45"">SOX9</span> are associated with brachydactyly-<span class=""disease"" id=""19639023-0-80-89"">anonychia</span>.",CTD_human
1,0,Biomarker,C1510586,Autism Spectrum Disorders,disease,ASD,6662,SOX9,SOX9,CTD_human,20868653,"Our analysis identified several novel dysregulated genes and miRNAs in ASD compared with controls, including HEY1, SOX9, miR-486 and miR-181b.",0.2,"Our analysis identified several novel dysregulated genes and miRNAs in <span class=""disease"" id=""20868653-6-71-74"">ASD</span> compared with controls, including HEY1, <span class=""gene"" id=""20868653-6-115-119"">SOX9</span>, miR-486 and miR-181b.",CTD_human
1,0,Biomarker,C0020456,Hyperglycemia,disease,hyperglycemia,6667,SP1,transcription factor Sp1,CTD_human,11696579,"Since hyperglycemia-induced mitochondrial superoxide overproduction increases O-linked N-acetylglucosamine modification and decreases O-linked phosphorylation of the transcription factor Sp1, the effect of hyperglycemia and the hexosamine pathway on eNOS was evaluated.",0.200274726784213,"Since <span class=""disease"" id=""11696579-2-6-19"">hyperglycemia</span>-induced mitochondrial superoxide overproduction increases O-linked N-acetylglucosamine modification and decreases O-linked phosphorylation of the <span class=""gene"" id=""11696579-2-166-190"">transcription factor Sp1</span>, the effect of <span class=""disease"" id=""11696579-2-206-219"">hyperglycemia</span> and the hexosamine pathway on eNOS was evaluated.",CTD_human
2,0,Biomarker,C0005586,Bipolar Disorder,disease,bipolar disorder,6671,SP4,Transcription factor SP4,CTD_human,19401786,Transcription factor SP4 is a susceptibility gene for bipolar disorder.,0.403231208875927,"<span class=""gene"" id=""19401786-0-0-24"">Transcription factor SP4</span> is a susceptibility gene for <span class=""disease"" id=""19401786-0-54-70"">bipolar disorder</span>.",CTD_human;PSYGENET
1,1,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,6671,SP4,Sp4,CTD_human,19401786,Both human genetic and mouse pharmacogenetic studies support Sp4 gene as a susceptibility gene for bipolar disorder or schizophrenia.,0.28082418035263895,"Both human genetic and mouse pharmacogenetic studies support <span class=""gene"" id=""19401786-12-61-64"">Sp4</span> gene as a susceptibility gene for bipolar disorder or <span class=""disease"" id=""19401786-12-119-132"">schizophrenia</span>.",CTD_human
1,0,Biomarker,C0026764,Multiple Myeloma,disease,MM,6678,SPARC,SPARC,CTD_human,18172295,"Moreover, SPARC methylation was associated with loss of SPARC protein expression by immunostaining in a subset of MM patients.",0.20054945356842604,"Moreover, <span class=""gene"" id=""18172295-8-10-15"">SPARC</span> methylation was associated with loss of <span class=""gene"" id=""18172295-8-56-61"">SPARC</span> protein expression by immunostaining in a subset of <span class=""disease"" id=""18172295-8-114-116"">MM</span> patients.",CTD_human
1,0,Biomarker,C0158266,Intervertebral Disc Degeneration,disease,degenerative disc disease,6678,SPARC,SPARC,CTD_human,20714283,We hypothesize that the SPARC-null mouse is useful as a model of chronic back pain due to degenerative disc disease.,0.20054945356842604,"We hypothesize that the <span class=""gene"" id=""20714283-14-24-29"">SPARC</span>-null mouse is useful as a model of chronic back pain due to <span class=""disease"" id=""20714283-14-90-115"">degenerative disc disease</span>.",CTD_human
1,0,Biomarker,C0919267,ovarian neoplasm,disease,ovarian tumors,6678,SPARC,SPARC,CTD_human,19177197,Investigation of primary tumors revealed that the Sparc promoter is methylated in 68% of primary ovarian tumors and that the levels of SPARC protein decrease as the disease progresses from low to high grade.,0.20300763924902696,"Investigation of primary tumors revealed that the <span class=""gene"" id=""19177197-8-50-55"">Sparc</span> promoter is methylated in 68% of primary <span class=""disease"" id=""19177197-8-97-111"">ovarian tumors</span> and that the levels of <span class=""gene"" id=""19177197-8-135-140"">SPARC</span> protein decrease as the disease progresses from low to high grade.",CTD_human
1,0,Biomarker,C0030305,Pancreatitis,disease,pancreatitis,6690,SPINK1,SPINK1,CTD_human,23143602,"Alcohol was long thought to be the primary causative agent, but genetic contributions have been of interest since the discovery that rare PRSS1, CFTR and SPINK1 variants were associated with pancreatitis risk.",0.520986530297745,"Alcohol was long thought to be the primary causative agent, but genetic contributions have been of interest since the discovery that rare PRSS1, CFTR and <span class=""gene"" id=""23143602-2-154-160"">SPINK1</span> variants were associated with <span class=""disease"" id=""23143602-2-191-203"">pancreatitis</span> risk.",CTD_human;HPO
1,0,Biomarker,C0149521,"Pancreatitis, Chronic",disease,chronic pancreatitis,6690,SPINK1,SPINK1,CTD_human,18206817,"Other genes--such as the anionic trypsinogen (PRSS2), the serine protease inhibitor Kazal type 1 (SPINK1), and the cystic fibrosis transmembrane conductance regulator (CFTR)--have also been found to be associated with chronic pancreatitis (idiopathic and hereditary).",0.49971116465928,"Other genes--such as the anionic trypsinogen (PRSS2), the <span class=""gene"" id=""18206817-8-58-96"">serine protease inhibitor Kazal type 1</span> (<span class=""gene"" id=""18206817-8-98-104"">SPINK1</span>), and the cystic fibrosis transmembrane conductance regulator (CFTR)--have also been found to be associated with <span class=""disease"" id=""18206817-8-218-238"">chronic pancreatitis</span> (idiopathic and hereditary).",CTD_human;HPO
1,0,Biomarker,C0017638,Glioma,disease,gliomas,6696,SPP1,Osteopontin,CTD_human,16651633,Osteopontin expression in intratumoral astrocytes marks tumor progression in gliomas induced by prenatal exposure to N-ethyl-N-nitrosourea.,0.206527930286485,"<span class=""gene"" id=""16651633-0-0-11"">Osteopontin</span> expression in intratumoral astrocytes marks tumor progression in <span class=""disease"" id=""16651633-0-77-84"">gliomas</span> induced by prenatal exposure to N-ethyl-N-nitrosourea.",CTD_human
1,0,Biomarker,C0023896,Alcoholic Liver Diseases,group,alcoholic liver disease,6696,SPP1,OPN,CTD_human,18703563,Osteopontin (OPN) up-regulation is known to mediate hepatic inflammation in a rodent model of alcoholic liver disease (ALD) and alcohol ingestion is reported to inhibit hepatic peroxisome proliferator-activated receptor-alpha (PPAR-alpha) activity leading to hepatic steatosis and inflammation.,0.20082418035263896,"<span class=""gene"" id=""18703563-1-0-11"">Osteopontin</span> (<span class=""gene"" id=""18703563-1-13-16"">OPN</span>) up-regulation is known to mediate hepatic inflammation in a rodent model of <span class=""disease"" id=""18703563-1-94-117"">alcoholic liver disease</span> (ALD) and alcohol ingestion is reported to inhibit hepatic peroxisome proliferator-activated receptor-alpha (PPAR-alpha) activity leading to hepatic steatosis and inflammation.",CTD_human
2,0,Biomarker,C0025500,Mesothelioma,disease,mesothelioma,6696,SPP1,osteopontin,CTD_human,16221779,An analysis of serum osteopontin levels comparing the receiver-operating-characteristic curve in the group exposed to asbestos with that of the group with mesothelioma had a sensitivity of 77.6 percent and a specificity of 85.5 percent at a cutoff value of 48.3 ng of osteopontin per milliliter.,0.20929764453129396,"An analysis of serum <span class=""gene"" id=""16221779-8-21-32"">osteopontin</span> levels comparing the receiver-operating-characteristic curve in the group exposed to asbestos with that of the group with <span class=""disease"" id=""16221779-8-155-167"">mesothelioma</span> had a sensitivity of 77.6 percent and a specificity of 85.5 percent at a cutoff value of 48.3 ng of <span class=""gene"" id=""16221779-8-268-279"">osteopontin</span> per milliliter.",CTD_human
1,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastasis,6696,SPP1,OPN,CTD_human,22407340,"Bone sialoprotein (BSP) and osteopontin (OPN) are important factors in the metastasis of breast cancer, which were examined as targets for antineoplastic therapy by siRNA.",0.25104176035436804,"Bone sialoprotein (BSP) and <span class=""gene"" id=""22407340-1-28-39"">osteopontin</span> (<span class=""gene"" id=""22407340-1-41-44"">OPN</span>) are important factors in the <span class=""disease"" id=""22407340-1-75-85"">metastasis</span> of breast cancer, which were examined as targets for antineoplastic therapy by siRNA.",CTD_human
1,0,Biomarker,C0853897,Diabetic Cardiomyopathies,disease,diabetic cardiomyopathy,6696,SPP1,OPN,CTD_human,16980342,"Thus increased expression of OPN may play a deleterious role during streptozotocin-induced diabetic cardiomyopathy with effects on cardiac fibrosis, hypertrophy, and myocyte apoptosis.",0.200274726784213,"Thus increased expression of <span class=""gene"" id=""16980342-15-29-32"">OPN</span> may play a deleterious role during streptozotocin-induced <span class=""disease"" id=""16980342-15-91-114"">diabetic cardiomyopathy</span> with effects on cardiac fibrosis, hypertrophy, and myocyte apoptosis.",CTD_human
2,0,Biomarker,C0014175,Endometriosis,disease,endometriosis,6715,SRD5A1,SRD5A1,CTD_human,23183084,"Altogether, our data in this Z-12 cell model suggest that the beneficial effects of treatment with progestin observed in endometriosis patients might arise from decreased pre-receptor metabolism of the protective progesterone by the SRD5A1 and AKR1C enzymes.",0.2,"Altogether, our data in this Z-12 cell model suggest that the beneficial effects of treatment with progestin observed in <span class=""disease"" id=""23183084-11-121-134"">endometriosis</span> patients might arise from decreased pre-receptor metabolism of the protective progesterone by the <span class=""gene"" id=""23183084-11-233-239"">SRD5A1</span> and AKR1C enzymes.",CTD_human
1,0,Biomarker,C0002170,Alopecia,disease,baldness,6716,SRD5A2,SRD5A2,CTD_human,17136762,"Our study provides evidence that the SRD5A2 A49T A variant is associated with an increased risk of prostate cancer, lower levels of circulating 3alpha-diolG and decreased risk of baldness.",0.201098907136852,"Our study provides evidence that the <span class=""gene"" id=""17136762-10-37-43"">SRD5A2</span> A49T A variant is associated with an increased risk of prostate cancer, lower levels of circulating 3alpha-diolG and decreased risk of <span class=""disease"" id=""17136762-10-179-187"">baldness</span>.",CTD_human
2,203,Biomarker,C0677776,Hereditary Breast and Ovarian Cancer Syndrome,disease,hereditary breast and ovarian cancer,672,BRCA1,BRCA1,CTD_human,8644702,Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden.,0.462362980016374,"Founding <span class=""gene"" id=""8644702-0-9-14"">BRCA1</span> mutations in <span class=""disease"" id=""8644702-0-28-64"">hereditary breast and ovarian cancer</span> in southern Sweden.",CTD_human;ORPHANET
2,203,Biomarker,C0677776,Hereditary Breast and Ovarian Cancer Syndrome,disease,hereditary breast and ovarian cancer,672,BRCA1,BRCA1,CTD_human,21597964,Three founder mutations in BRCA1 and BRCA2 contribute to the risk of hereditary breast and ovarian cancer in Ashkenazi Jews (AJ).,0.462362980016374,"Three founder mutations in <span class=""gene"" id=""21597964-1-27-32"">BRCA1</span> and BRCA2 contribute to the risk of <span class=""disease"" id=""21597964-1-69-105"">hereditary breast and ovarian cancer</span> in Ashkenazi Jews (AJ).",CTD_human;ORPHANET
5,0,Biomarker,C0919267,ovarian neoplasm,disease,ovarian tumours,672,BRCA1,BRCA1,CTD_human,7795652,Somatic mutations in the BRCA1 gene in sporadic ovarian tumours.,0.38252759630547395,"Somatic mutations in the <span class=""gene"" id=""7795652-0-25-30"">BRCA1</span> gene in sporadic <span class=""disease"" id=""7795652-0-48-63"">ovarian tumours</span>.",CTD_human
11,0,Biomarker,C1458155,Mammary Neoplasms,group,mammary tumor,672,BRCA1,BRCA1,CTD_human,15750629,Loss of full-length Brca1 in mammary epithelial cells of the mouse mammary tumor virus (MMTV)-Cre Brca1 conditional exon 11 deletion mouse model results in the development of mammary adenocarcinomas with similar genetic changes to those found in human BRCA1-mutation-related breast cancers.,0.41274754256891494,"Loss of full-length <span class=""gene"" id=""15750629-1-20-25"">Brca1</span> in mammary epithelial cells of the mouse <span class=""disease"" id=""15750629-1-67-80"">mammary tumor</span> virus (MMTV)-Cre Brca1 conditional exon 11 deletion mouse model results in the development of mammary adenocarcinomas with similar genetic changes to those found in human <span class=""gene"" id=""15750629-1-252-257"">BRCA1</span>-mutation-related breast cancers.",CTD_human
11,0,Biomarker,C1458155,Mammary Neoplasms,group,breast tumor,672,BRCA1,BRCA1,CTD_human,26379698,These results validate the concept of using pigs as a model to study BRCA1 defects in breast cancer and establish the first porcine breast tumor cell line.,0.41274754256891494,"These results validate the concept of using pigs as a model to study <span class=""gene"" id=""26379698-9-69-74"">BRCA1</span> defects in breast cancer and establish the first porcine <span class=""disease"" id=""26379698-9-132-144"">breast tumor</span> cell line.",CTD_human
1,0,Biomarker,C0022661,"Kidney Failure, Chronic",disease,CRF,6720,SREBF1,SREBP-1,CTD_human,19878707,"CRF resulted in hypertension, proteinuria, renal tissue lipid accumulation, up-regulation of scavenger receptor A1 (SR-A1), acyl-CoA cholesterol acyltransferase-1 (ACAT1), carbohydrate-responsive element binding protein (ChREBP), fatty acid synthase (FAS), acyl-CoA carboxylase (ACC), liver X receptor (LXR), ATP binding cassette (ABC) A-1, ABCG-1, and SR-B1 and down-regulation of sterol responsive element binding protein-1 (SREBP-1), SREBP-2, HMG-CoA reductase, PPAR-alpha, fatty acid binding protein (L-FABP), and CPT1A.",0.20240702852328799,"<span class=""disease"" id=""19878707-5-0-3"">CRF</span> resulted in hypertension, proteinuria, renal tissue lipid accumulation, up-regulation of scavenger receptor A1 (SR-A1), acyl-CoA cholesterol acyltransferase-1 (ACAT1), carbohydrate-responsive element binding protein (ChREBP), fatty acid synthase (FAS), acyl-CoA carboxylase (ACC), liver X receptor (LXR), ATP binding cassette (ABC) A-1, ABCG-1, and SR-B1 and down-regulation of sterol responsive element binding protein-1 (<span class=""gene"" id=""19878707-5-427-434"">SREBP-1</span>), SREBP-2, HMG-CoA reductase, PPAR-alpha, fatty acid binding protein (L-FABP), and CPT1A.",CTD_human
1,0,Biomarker,C0028754,Obesity,disease,obesity,6720,SREBF1,SREBP-1,CTD_human,10900012,"SREBP-1 overexpression, which is prevented by troglitazone, may play a role in the ectopic lipogenesis and lipotoxicity complicating obesity in Zucker diabetic fatty rats.",0.21189144090148698,"<span class=""gene"" id=""10900012-9-0-7"">SREBP-1</span> overexpression, which is prevented by troglitazone, may play a role in the ectopic lipogenesis and lipotoxicity complicating <span class=""disease"" id=""10900012-9-133-140"">obesity</span> in Zucker diabetic fatty rats.",CTD_human
2,0,Biomarker,C0400966,Non-alcoholic Fatty Liver Disease,disease,NAFLD,6720,SREBF1,SREBP-1,CTD_human,23603006,Amelioration by chicory seed extract of diabetes- and oleic acid-induced non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) via modulation of PPAR? and SREBP-1.,0.202472541057918,"Amelioration by chicory seed extract of diabetes- and oleic acid-induced <span class=""disease"" id=""23603006-0-73-106"">non-alcoholic fatty liver disease</span> (<span class=""disease"" id=""23603006-0-108-113"">NAFLD</span>)/non-alcoholic steatohepatitis (NASH) via modulation of PPAR&alpha; and <span class=""gene"" id=""23603006-0-180-187"">SREBP-1</span>.",CTD_human
2,0,Biomarker,C0400966,Non-alcoholic Fatty Liver Disease,disease,Non-alcoholic fatty liver disease,6720,SREBF1,SREBP-1,CTD_human,24633463,Non-alcoholic fatty liver disease is associated with inhibited AMP-activated kinase (AMPK) and activation of sterol regulatory element binding protein 1 (SREBP-1).,0.202472541057918,"<span class=""disease"" id=""24633463-1-0-33"">Non-alcoholic fatty liver disease</span> is associated with inhibited AMP-activated kinase (AMPK) and activation of <span class=""gene"" id=""24633463-1-109-152"">sterol regulatory element binding protein 1</span> (<span class=""gene"" id=""24633463-1-154-161"">SREBP-1</span>).",CTD_human
2,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,6720,SREBF1,sterol regulatory element-binding protein 1,CTD_human,21147110,"Suppression of the genes adenosine triphosphate citrate lyase, acetyl-CoA carboxylase, fatty acid synthase, stearoyl-CoA desaturase 1, or sterol regulatory element-binding protein 1, which are involved in lipogenesis, reduced proliferation, and survival of HCC cell lines and AKT-dependent cell proliferation.",0.204655999954305,"Suppression of the genes adenosine triphosphate citrate lyase, acetyl-CoA carboxylase, fatty acid synthase, stearoyl-CoA desaturase 1, or <span class=""gene"" id=""21147110-9-138-181"">sterol regulatory element-binding protein 1</span>, which are involved in lipogenesis, reduced proliferation, and survival of <span class=""disease"" id=""21147110-9-257-260"">HCC</span> cell lines and AKT-dependent cell proliferation.",CTD_human
1,0,Biomarker,C0022661,"Kidney Failure, Chronic",disease,CRF,6721,SREBF2,SREBP-2,CTD_human,19878707,"CRF resulted in hypertension, proteinuria, renal tissue lipid accumulation, up-regulation of scavenger receptor A1 (SR-A1), acyl-CoA cholesterol acyltransferase-1 (ACAT1), carbohydrate-responsive element binding protein (ChREBP), fatty acid synthase (FAS), acyl-CoA carboxylase (ACC), liver X receptor (LXR), ATP binding cassette (ABC) A-1, ABCG-1, and SR-B1 and down-regulation of sterol responsive element binding protein-1 (SREBP-1), SREBP-2, HMG-CoA reductase, PPAR-alpha, fatty acid binding protein (L-FABP), and CPT1A.",0.2,"<span class=""disease"" id=""19878707-5-0-3"">CRF</span> resulted in hypertension, proteinuria, renal tissue lipid accumulation, up-regulation of scavenger receptor A1 (SR-A1), acyl-CoA cholesterol acyltransferase-1 (ACAT1), carbohydrate-responsive element binding protein (ChREBP), fatty acid synthase (FAS), acyl-CoA carboxylase (ACC), liver X receptor (LXR), ATP binding cassette (ABC) A-1, ABCG-1, and SR-B1 and down-regulation of sterol responsive element binding protein-1 (SREBP-1), <span class=""gene"" id=""19878707-5-437-444"">SREBP-2</span>, HMG-CoA reductase, PPAR-alpha, fatty acid binding protein (L-FABP), and CPT1A.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,6721,SREBF2,SREBP2,CTD_human,21147110,"In HCC cell lines, the AKT-mammalian target of rapamycin complex 1-ribosomal protein S6 pathway promoted lipogenesis via transcriptional and post-transcriptional mechanisms that included inhibition of fatty acid synthase ubiquitination by the USP2a de-ubiquitinase and disruption of the SREBP1 and SREBP2 degradation complexes.",0.2,"In <span class=""disease"" id=""21147110-8-3-6"">HCC</span> cell lines, the AKT-mammalian target of rapamycin complex 1-ribosomal protein S6 pathway promoted lipogenesis via transcriptional and post-transcriptional mechanisms that included inhibition of fatty acid synthase ubiquitination by the USP2a de-ubiquitinase and disruption of the SREBP1 and <span class=""gene"" id=""21147110-8-298-304"">SREBP2</span> degradation complexes.",CTD_human
1,0,Biomarker,C0002448,Ameloblastoma,disease,ameloblastomas,673,BRAF,BRAF,CTD_human,24859340,Identification of recurrent SMO and BRAF mutations in ameloblastomas.,0.201373633921065,"Identification of recurrent SMO and <span class=""gene"" id=""24859340-0-36-40"">BRAF</span> mutations in <span class=""disease"" id=""24859340-0-54-68"">ameloblastomas</span>.",CTD_human
1,0,Biomarker,C0010276,Craniopharyngioma,disease,craniopharyngiomas,673,BRAF,BRAF,CTD_human,24413733,Targeted genotyping revealed BRAF p.Val600Glu in 95% of papillary craniopharyngiomas (36 of 39 tumors) and mutation of CTNNB1 in 96% of adamantinomatous craniopharyngiomas (51 of 53 tumors).,0.4010989071368521,"Targeted genotyping revealed <span class=""gene"" id=""24413733-4-29-33"">BRAF</span> p.Val600Glu in 95% of papillary craniopharyngiomas (36 of 39 tumors) and mutation of CTNNB1 in 96% of adamantinomatous <span class=""disease"" id=""24413733-4-153-171"">craniopharyngiomas</span> (51 of 53 tumors).",CTD_human;ORPHANET
1,0,Biomarker,C0022665,Kidney Neoplasm,disease,kidney tumors,673,BRAF,B-Raf,CTD_human,21813464,"Western blot analysis of kidney tumors formed following treatment of Tsc-2(EK/+) rats with TGHQ for 8 months revealed increases in B-Raf, Raf-1, pERK, cyclin D1, 4EBP1, and p-4EBP1-Ser65, -Thr70, and -Thr37/46 expression.",0.20082418035263896,"Western blot analysis of <span class=""disease"" id=""21813464-4-25-38"">kidney tumors</span> formed following treatment of Tsc-2(EK/+) rats with TGHQ for 8 months revealed increases in <span class=""gene"" id=""21813464-4-131-136"">B-Raf</span>, Raf-1, pERK, cyclin D1, 4EBP1, and p-4EBP1-Ser65, -Thr70, and -Thr37/46 expression.",CTD_human
21,1,Biomarker,C0025202,melanoma,disease,melanoma,673,BRAF,BRAF,CTD_human,23432625,Current clinical investigations have shown great promise with the combination of trametinib and dabrafenib in patients with BRAF-mutant melanoma; a number of clinical trials of trametinib in combination with other targeted drugs are underway.,0.39129137080274395,"Current clinical investigations have shown great promise with the combination of trametinib and dabrafenib in patients with <span class=""gene"" id=""23432625-9-124-128"">BRAF</span>-mutant <span class=""disease"" id=""23432625-9-136-144"">melanoma</span>; a number of clinical trials of trametinib in combination with other targeted drugs are underway.",CTD_human
21,1,Biomarker,C0025202,melanoma,disease,malignant melanoma,673,BRAF,BRAF,CTD_human,23584600,"A multisite blinded study for the detection of BRAF mutations in formalin-fixed, paraffin-embedded malignant melanoma.",0.39129137080274395,"A multisite blinded study for the detection of <span class=""gene"" id=""23584600-0-47-51"">BRAF</span> mutations in formalin-fixed, paraffin-embedded <span class=""disease"" id=""23584600-0-99-117"">malignant melanoma</span>.",CTD_human
21,1,Biomarker,C0025202,melanoma,disease,melanomas,673,BRAF,B-Raf,CTD_human,20973932,"PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas.",0.39129137080274395,"PLX4032, a potent inhibitor of the <span class=""gene"" id=""20973932-0-35-40"">B-Raf</span> V600E oncogene, selectively inhibits V600E-positive <span class=""disease"" id=""20973932-0-93-102"">melanomas</span>.",CTD_human
21,1,Biomarker,C0025202,melanoma,disease,melanoma,673,BRAF,BRAF,CTD_human,27689874,Hepatocyte growth factor renders BRAF mutant human melanoma cell lines resistant to PLX4032 by downregulating the pro-apoptotic BH3-only proteins PUMA and BIM.,0.39129137080274395,"Hepatocyte growth factor renders <span class=""gene"" id=""27689874-0-33-37"">BRAF</span> mutant human <span class=""disease"" id=""27689874-0-51-59"">melanoma</span> cell lines resistant to PLX4032 by downregulating the pro-apoptotic BH3-only proteins PUMA and BIM.",CTD_human
21,1,Biomarker,C0025202,melanoma,disease,melanoma,673,BRAF,BRAF,CTD_human,21639808,Improved survival with vemurafenib in melanoma with BRAF V600E mutation.,0.39129137080274395,"Improved survival with vemurafenib in <span class=""disease"" id=""21639808-0-38-46"">melanoma</span> with <span class=""gene"" id=""21639808-0-52-56"">BRAF</span> V600E mutation.",CTD_human
21,1,Biomarker,C0025202,melanoma,disease,melanoma,673,BRAF,BRAF,CTD_human,19282848,Mutational activation of BRAF is the earliest and most common genetic alteration in human melanoma.,0.39129137080274395,"Mutational activation of <span class=""gene"" id=""19282848-1-25-29"">BRAF</span> is the earliest and most common genetic alteration in human <span class=""disease"" id=""19282848-1-90-98"">melanoma</span>.",CTD_human
21,1,Biomarker,C0025202,melanoma,disease,melanomas,673,BRAF,BRAF,CTD_human,26214590,"Inactivating NF1 mutations were present in 46% of melanomas expressing wild-type BRAF and RAS, occurred in older patients and showed a distinct pattern of co-mutation with other RASopathy genes, particularly RASA2.",0.39129137080274395,"Inactivating NF1 mutations were present in 46% of <span class=""disease"" id=""26214590-3-50-59"">melanomas</span> expressing wild-type <span class=""gene"" id=""26214590-3-81-85"">BRAF</span> and RAS, occurred in older patients and showed a distinct pattern of co-mutation with other RASopathy genes, particularly RASA2.",CTD_human
21,1,Biomarker,C0025202,melanoma,disease,melanomas,673,BRAF,BRAF,CTD_human,21656352,This article provides a review of GSK2118436 and PLX4032 as potential therapeutics for the treatment of melanomas by inhibiting oncogenic BRAF.,0.39129137080274395,"This article provides a review of GSK2118436 and PLX4032 as potential therapeutics for the treatment of <span class=""disease"" id=""21656352-3-104-113"">melanomas</span> by inhibiting oncogenic <span class=""gene"" id=""21656352-3-138-142"">BRAF</span>.",CTD_human
21,1,Biomarker,C0025202,melanoma,disease,melanomas,673,BRAF,B-Raf,CTD_human,21770473,Inhibitors of c-Kit and mitogen-activated protein kinase (MEK) have also been found to have activity against melanomas and MEK inhibitors are now being examined as a strategy to overcome B-Raf inhibitor resistance.,0.39129137080274395,"Inhibitors of c-Kit and mitogen-activated protein kinase (MEK) have also been found to have activity against <span class=""disease"" id=""21770473-11-109-118"">melanomas</span> and MEK inhibitors are now being examined as a strategy to overcome <span class=""gene"" id=""21770473-11-187-192"">B-Raf</span> inhibitor resistance.",CTD_human
21,1,Biomarker,C0025202,melanoma,disease,melanoma,673,BRAF,BRAF,CTD_human,21606968,BRAF targeted therapy changes the treatment paradigm in melanoma.,0.39129137080274395,"<span class=""gene"" id=""21606968-0-0-4"">BRAF</span> targeted therapy changes the treatment paradigm in <span class=""disease"" id=""21606968-0-56-64"">melanoma</span>.",CTD_human
21,1,Biomarker,C0025202,melanoma,disease,melanoma,673,BRAF,BRAF,CTD_human,18421705,Sunlight ultraviolet irradiation and BRAF V600 mutagenesis in human melanoma.,0.39129137080274395,"Sunlight ultraviolet irradiation and <span class=""gene"" id=""18421705-0-37-41"">BRAF</span> V600 mutagenesis in human <span class=""disease"" id=""18421705-0-68-76"">melanoma</span>.",CTD_human
21,1,Biomarker,C0025202,melanoma,disease,melanoma,673,BRAF,BRAF,CTD_human,22842228,"This activating mutation, the third most frequent in our cohort of sun-exposed melanoma after those of BRAF and NRAS, changes Pro29 to serine (RAC1(P29S)) in the highly conserved switch I domain.",0.39129137080274395,"This activating mutation, the third most frequent in our cohort of sun-exposed <span class=""disease"" id=""22842228-5-79-87"">melanoma</span> after those of <span class=""gene"" id=""22842228-5-103-107"">BRAF</span> and NRAS, changes Pro29 to serine (RAC1(P29S)) in the highly conserved switch I domain.",CTD_human
21,1,Biomarker,C0025202,melanoma,disease,melanoma,673,BRAF,BRAF,CTD_human,23237741,We have treated 45 patients with V600 mutated melanoma including patients with V600R mutation between July 2011 and October 2012 with the selective BRAF inhibitor dabrafenib (n=43) or vemurafenib (n=2) via a compassionate access programme.,0.39129137080274395,"We have treated 45 patients with V600 mutated <span class=""disease"" id=""23237741-5-46-54"">melanoma</span> including patients with V600R mutation between July 2011 and October 2012 with the selective <span class=""gene"" id=""23237741-5-148-152"">BRAF</span> inhibitor dabrafenib (n=43) or vemurafenib (n=2) via a compassionate access programme.",CTD_human
21,1,Biomarker,C0025202,melanoma,disease,melanoma,673,BRAF,BRAF,CTD_human,22535842,"Although the vast majority >90% of melanoma models harbored mutations in either BRAF or NRAS, significant differences in subcutaneous growth aggressiveness became obvious.",0.39129137080274395,"Although the vast majority &gt;90% of <span class=""disease"" id=""22535842-4-35-43"">melanoma</span> models harbored mutations in either <span class=""gene"" id=""22535842-4-80-84"">BRAF</span> or NRAS, significant differences in subcutaneous growth aggressiveness became obvious.",CTD_human
2,2,Biomarker,C0152013,Adenocarcinoma of lung (disorder),disease,adenocarcinoma of the lung,673,BRAF,BRAF,CTD_human,22135231,"We examined epidermal growth factor receptor (EGFR), Kirsten rate sarcoma viral oncogene homolog (KRAS), v-Raf murine sarcoma viral oncogene homolog B1 (BRAF), human epidermal growth factor receptor 2 (HER2), PIK3CA, v-akt murine thymoma vial oncogene homolog 1 (AKT1), v-ras neuroblastoma viral oncogene homolog (NRAS), dual specificity mitogen-activated protein kinase kinase 1 (MEK1), and anaplastic lymphoma kinase (ALK) in patients with adenocarcinoma of the lung to identify driver mutations.",0.205494535684262,"We examined epidermal growth factor receptor (EGFR), Kirsten rate sarcoma viral oncogene homolog (KRAS), <span class=""gene"" id=""22135231-4-105-151"">v-Raf murine sarcoma viral oncogene homolog B1</span> (<span class=""gene"" id=""22135231-4-153-157"">BRAF</span>), human epidermal growth factor receptor 2 (HER2), PIK3CA, v-akt murine thymoma vial oncogene homolog 1 (AKT1), v-ras neuroblastoma viral oncogene homolog (NRAS), dual specificity mitogen-activated protein kinase kinase 1 (MEK1), and anaplastic lymphoma kinase (ALK) in patients with <span class=""disease"" id=""22135231-4-442-468"">adenocarcinoma of the lung</span> to identify driver mutations.",CTD_human
2,2,Biomarker,C0152013,Adenocarcinoma of lung (disorder),disease,LAC,673,BRAF,BRAF,CTD_human,26463840,Pathogenic BRAF mutations were found in two LACs.,0.205494535684262,"Pathogenic <span class=""gene"" id=""26463840-12-11-15"">BRAF</span> mutations were found in two <span class=""disease"" id=""26463840-12-44-47"">LAC</span>s.",CTD_human
1,0,Biomarker,C0596263,Carcinogenesis,phenotype,tumorigenesis,673,BRAF,BRAF,CTD_human,24717435,"Here we show decreasing the levels of CTR1 (Cu transporter 1), or mutations in MEK1 that disrupt Cu binding, decreased BRAF(V600E)-driven signalling and tumorigenesis in mice and human cell settings.",0.232967214105572,"Here we show decreasing the levels of CTR1 (Cu transporter 1), or mutations in MEK1 that disrupt Cu binding, decreased <span class=""gene"" id=""24717435-5-119-123"">BRAF</span>(V600E)-driven signalling and <span class=""disease"" id=""24717435-5-153-166"">tumorigenesis</span> in mice and human cell settings.",CTD_human
6,34,Biomarker,C1275081,Cardio-facio-cutaneous syndrome,disease,CFC syndrome,673,BRAF,BRAF,CTD_human,17703371,"We report the case of a 4-year-old girl who presented a CFC syndrome, confirmed by the presence of a pathogenic R257Q BRAF gene mutation, together with a muscular CoQ10 deficiency.",0.686868169605328,"We report the case of a 4-year-old girl who presented a <span class=""disease"" id=""17703371-6-56-68"">CFC syndrome</span>, confirmed by the presence of a pathogenic R257Q <span class=""gene"" id=""17703371-6-118-122"">BRAF</span> gene mutation, together with a muscular CoQ10 deficiency.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0018054,"Gonadal Dysgenesis, 46,XY",disease,Swyer syndrome,6736,SRY,SRY,CTD_human,27576690,Mutations in human SRY cause gonadal dysgenesis leading to XY female development (Swyer syndrome).,0.208776901717502,"Mutations in human <span class=""gene"" id=""27576690-4-19-22"">SRY</span> cause gonadal dysgenesis leading to XY female development (<span class=""disease"" id=""27576690-4-82-96"">Swyer syndrome</span>).",CTD_human
1,289,Biomarker,C0677776,Hereditary Breast and Ovarian Cancer Syndrome,disease,hereditary breast and ovarian cancer,675,BRCA2,BRCA2,CTD_human,21597964,Three founder mutations in BRCA1 and BRCA2 contribute to the risk of hereditary breast and ovarian cancer in Ashkenazi Jews (AJ).,0.43434084802663797,"Three founder mutations in BRCA1 and <span class=""gene"" id=""21597964-1-37-42"">BRCA2</span> contribute to the risk of <span class=""disease"" id=""21597964-1-69-105"">hereditary breast and ovarian cancer</span> in Ashkenazi Jews (AJ).",CTD_human;ORPHANET
1,0,Biomarker,C0004763,Barrett Esophagus,disease,Barrett esophagus,6750,SST,SST,CTD_human,17999418,SST promoter hypermethylation is a common event in human esophageal carcinomas and is related to early neoplastic progression in Barrett esophagus.,0.200274726784213,"<span class=""gene"" id=""17999418-11-0-3"">SST</span> promoter hypermethylation is a common event in human esophageal carcinomas and is related to early neoplastic progression in <span class=""disease"" id=""17999418-11-129-146"">Barrett esophagus</span>.",CTD_human
3,0,Therapeutic,C0036572,Seizures,phenotype,seizure,6750,SST,somatostatin,CTD_human,7913897,[Effect of intracerebral injections of somatostatin and neurotensin on motor functions in seizure].,0.20054945356842604,"[Effect of intracerebral injections of <span class=""gene"" id=""7913897-0-39-51"">somatostatin</span> and neurotensin on motor functions in <span class=""disease"" id=""7913897-0-90-97"">seizure</span>].",CTD_human
3,0,Biomarker,C0036572,Seizures,phenotype,seizure,6750,SST,somatostatin,CTD_human,7913897,[Effect of intracerebral injections of somatostatin and neurotensin on motor functions in seizure].,0.20054945356842604,"[Effect of intracerebral injections of <span class=""gene"" id=""7913897-0-39-51"">somatostatin</span> and neurotensin on motor functions in <span class=""disease"" id=""7913897-0-90-97"">seizure</span>].",CTD_human
3,0,Therapeutic,C0036572,Seizures,phenotype,seizures,6750,SST,SRIF-14,CTD_human,20134357,"SRA880 did not affect seizure severity and did not reverse the anticonvulsive action of SRIF-14 (1 microM) against pilocarpine-induced seizures, suggesting that hippocampal sst(1) receptors are not involved in the anticonvulsive effects of SRIF-14.",0.20054945356842604,"SRA880 did not affect <span class=""disease"" id=""20134357-4-22-29"">seizure</span> severity and did not reverse the anticonvulsive action of <span class=""gene"" id=""20134357-4-88-95"">SRIF-14</span> (1 microM) against pilocarpine-induced <span class=""disease"" id=""20134357-4-135-143"">seizures</span>, suggesting that hippocampal sst(1) receptors are not involved in the anticonvulsive effects of <span class=""gene"" id=""20134357-4-240-247"">SRIF-14</span>.",CTD_human
3,0,Biomarker,C0036572,Seizures,phenotype,seizures,6750,SST,somatostatin,CTD_human,16771832,Involvement of the somatostatin-2 receptor in the anti-convulsant effect of angiotensin IV against pilocarpine-induced limbic seizures in rats.,0.20054945356842604,"Involvement of the <span class=""gene"" id=""16771832-0-19-31"">somatostatin</span>-2 receptor in the anti-convulsant effect of angiotensin IV against pilocarpine-induced limbic <span class=""disease"" id=""16771832-0-126-134"">seizures</span> in rats.",CTD_human
3,0,Therapeutic,C0036572,Seizures,phenotype,seizures,6750,SST,somatostatin,CTD_human,16771832,Involvement of the somatostatin-2 receptor in the anti-convulsant effect of angiotensin IV against pilocarpine-induced limbic seizures in rats.,0.20054945356842604,"Involvement of the <span class=""gene"" id=""16771832-0-19-31"">somatostatin</span>-2 receptor in the anti-convulsant effect of angiotensin IV against pilocarpine-induced limbic <span class=""disease"" id=""16771832-0-126-134"">seizures</span> in rats.",CTD_human
3,0,Biomarker,C0036572,Seizures,phenotype,seizures,6750,SST,SRIF-14,CTD_human,20134357,"SRA880 did not affect seizure severity and did not reverse the anticonvulsive action of SRIF-14 (1 microM) against pilocarpine-induced seizures, suggesting that hippocampal sst(1) receptors are not involved in the anticonvulsive effects of SRIF-14.",0.20054945356842604,"SRA880 did not affect <span class=""disease"" id=""20134357-4-22-29"">seizure</span> severity and did not reverse the anticonvulsive action of <span class=""gene"" id=""20134357-4-88-95"">SRIF-14</span> (1 microM) against pilocarpine-induced <span class=""disease"" id=""20134357-4-135-143"">seizures</span>, suggesting that hippocampal sst(1) receptors are not involved in the anticonvulsive effects of <span class=""gene"" id=""20134357-4-240-247"">SRIF-14</span>.",CTD_human
1,0,Biomarker,C0038220,Status Epilepticus,disease,SE,6751,SSTR1,SSTR1,CTD_human,18951627,SSTR1 and SSTR4 immunoreactivities were increased in the hippocampus at 1 week after SE.,0.2,"<span class=""gene"" id=""18951627-2-0-5"">SSTR1</span> and SSTR4 immunoreactivities were increased in the hippocampus at 1 week after <span class=""disease"" id=""18951627-2-85-87"">SE</span>.",CTD_human
1,0,Therapeutic,C0036572,Seizures,phenotype,convulsions,6752,SSTR2,somatostatin receptor-2,CTD_human,16771832,"Our study suggests that the ability of Ang IV to inhibit pilocarpine-induced convulsions is dependent on somatostatin receptor-2 activation, and is possibly mediated via the inhibition of IRAP resulting in an elevated concentration of somatostatin-14 in the brain.",0.2,"Our study suggests that the ability of Ang IV to inhibit pilocarpine-induced <span class=""disease"" id=""16771832-5-77-88"">convulsions</span> is dependent on <span class=""gene"" id=""16771832-5-105-128"">somatostatin receptor-2</span> activation, and is possibly mediated via the inhibition of IRAP resulting in an elevated concentration of somatostatin-14 in the brain.",CTD_human
1,0,Biomarker,C0038220,Status Epilepticus,disease,SE,6754,SSTR4,SSTR4,CTD_human,18951627,Both SSTR2B and SSTR4 immunoreactivities were increased within microglia following SE.,0.2,"Both SSTR2B and <span class=""gene"" id=""18951627-7-16-21"">SSTR4</span> immunoreactivities were increased within microglia following <span class=""disease"" id=""18951627-7-83-85"">SE</span>.",CTD_human
1,0,Biomarker,C0038220,Status Epilepticus,disease,SE,6755,SSTR5,SSTR5,CTD_human,18951627,"At 4 weeks after SE, SRIF1-family (SSTR 2A, SSTR2B, and SSTR5) immunoreactivity was increased only in neuropil.",0.2,"At 4 weeks after <span class=""disease"" id=""18951627-3-17-19"">SE</span>, SRIF1-family (SSTR 2A, SSTR2B, and <span class=""gene"" id=""18951627-3-56-61"">SSTR5</span>) immunoreactivity was increased only in neuropil.",CTD_human
1,0,Biomarker,C0039101,synovial sarcoma,disease,synovial sarcomas,6756,SSX1,SSX1,CTD_human,9428816,"There was a significant relation (P=0.003) between histologic subtype (monophasic vs. biphasic) and SSX1 or SSX2 involvement in the fusion transcript: all 12 biphasic synovial sarcomas had a SYT-SSX1 fusion transcript, and all 16 tumors that were positive for SYT-SSX2 were monophasic.",0.630957994352177,"There was a significant relation (P=0.003) between histologic subtype (monophasic vs. biphasic) and <span class=""gene"" id=""9428816-8-100-104"">SSX1</span> or SSX2 involvement in the fusion transcript: all 12 biphasic <span class=""disease"" id=""9428816-8-167-184"">synovial sarcomas</span> had a SYT-<span class=""gene"" id=""9428816-8-195-199"">SSX1</span> fusion transcript, and all 16 tumors that were positive for SYT-SSX2 were monophasic.",CTD_human;HPO;ORPHANET
1,0,Biomarker,C0039101,synovial sarcoma,disease,synovial sarcoma,6757,SSX2,SSX,CTD_human,9428816,SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma.,0.647759394321128,"SYT-<span class=""gene"" id=""9428816-0-4-7"">SSX</span> gene fusion as a determinant of morphology and prognosis in <span class=""disease"" id=""9428816-0-68-84"">synovial sarcoma</span>.",CTD_human;HPO;ORPHANET
1,0,Biomarker,C0039101,synovial sarcoma,disease,synovial sarcoma,6760,SS18,SYT,CTD_human,9428816,SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma.,0.45270447643696293,"<span class=""gene"" id=""9428816-0-0-3"">SYT</span>-SSX gene fusion as a determinant of morphology and prognosis in <span class=""disease"" id=""9428816-0-68-84"">synovial sarcoma</span>.",CTD_human;ORPHANET
1,0,Biomarker,C0265962,Ichthyosis linearis circumflexa,disease,Netherton syndrome,6768,ST14,Matriptase,CTD_human,20657595,Matriptase initiates activation of epidermal pro-kallikrein and disease onset in a mouse model of Netherton syndrome.,0.2,"<span class=""gene"" id=""20657595-0-0-10"">Matriptase</span> initiates activation of epidermal pro-kallikrein and disease onset in a mouse model of <span class=""disease"" id=""20657595-0-98-116"">Netherton syndrome</span>.",CTD_human
2,4,Biomarker,C1835851,"Ichthyosis with hypotrichosis, autosomal recessive",disease,ARIH,6768,ST14,matriptase,CTD_human,18445049,"Autosomal recessive ichthyosis with hypotrichosis (ARIH) syndrome, which is characterized by congenital ichthyosis, abnormal hair and corneal involvement, has recently been shown in one consanguineous Israeli Arab family to be caused by a mutation in the ST14 gene, which encodes serine protease matriptase.",0.6010989071368521,"<span class=""disease"" id=""18445049-1-0-49"">Autosomal recessive ichthyosis with hypotrichosis</span> (<span class=""disease"" id=""18445049-1-51-55"">ARIH</span>) syndrome, which is characterized by congenital ichthyosis, abnormal hair and corneal involvement, has recently been shown in one consanguineous Israeli Arab family to be caused by a mutation in the <span class=""gene"" id=""18445049-1-255-259"">ST14</span> gene, which encodes serine protease <span class=""gene"" id=""18445049-1-296-306"">matriptase</span>.",CTD_human;ORPHANET;UNIPROT
2,4,Biomarker,C1835851,"Ichthyosis with hypotrichosis, autosomal recessive",disease,Autosomal recessive ichthyosis with hypotrichosis,6768,ST14,matriptase,CTD_human,17273967,"Autosomal recessive ichthyosis with hypotrichosis caused by a mutation in ST14, encoding type II transmembrane serine protease matriptase.",0.6010989071368521,"<span class=""disease"" id=""17273967-0-0-49"">Autosomal recessive ichthyosis with hypotrichosis</span> caused by a mutation in <span class=""gene"" id=""17273967-0-74-78"">ST14</span>, encoding type II transmembrane serine protease <span class=""gene"" id=""17273967-0-127-137"">matriptase</span>.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0032460,Polycystic Ovary Syndrome,disease,PCOS,6770,STAR,StAR,CTD_human,21262361,"The mRNA expression corresponding to steroidogenic acute regulatory protein (StAR), and 20alpha-hydroxysteroid dehydrogenase (20?-HSD) was increased, while that corresponding to cytochrome P450 aromatase (P450arom) was decreased in PCOS follicles as compared to controls.",0.201373633921065,"The mRNA expression corresponding to <span class=""gene"" id=""21262361-3-37-75"">steroidogenic acute regulatory protein</span> (<span class=""gene"" id=""21262361-3-77-81"">StAR</span>), and 20alpha-hydroxysteroid dehydrogenase (20&alpha;-HSD) was increased, while that corresponding to cytochrome P450 aromatase (P450arom) was decreased in <span class=""disease"" id=""21262361-3-232-236"">PCOS</span> follicles as compared to controls.",CTD_human
1,0,Biomarker,C0003873,Rheumatoid Arthritis,disease,RA,6772,STAT1,Stat1,CTD_human,12833524,Immunohistochemistry assigned the Stat1 protein in RA synovial tissue mainly to macrophages and T lymphocytes and the p47phox protein in particular to macrophages.,0.20274726784213098,"Immunohistochemistry assigned the <span class=""gene"" id=""12833524-8-34-39"">Stat1</span> protein in <span class=""disease"" id=""12833524-8-51-53"">RA</span> synovial tissue mainly to macrophages and T lymphocytes and the p47phox protein in particular to macrophages.",CTD_human
1,0,Biomarker,C0006845,"Candidiasis, Chronic Mucocutaneous",disease,chronic mucocutaneous candidiasis,6772,STAT1,STAT1,CTD_human,21714643,STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis.,0.40521980890004905,"<span class=""gene"" id=""21714643-0-0-5"">STAT1</span> mutations in autosomal dominant <span class=""disease"" id=""21714643-0-38-71"">chronic mucocutaneous candidiasis</span>.",CTD_human;HPO
1,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,6772,STAT1,STAT1,CTD_human,22488367,"In human samples, 29 HCCs were resected, divided into two groups based on STAT1 activation in tumor and the clinical features were investigated.",0.205703749933845,"In human samples, 29 <span class=""disease"" id=""22488367-7-21-24"">HCC</span>s were resected, divided into two groups based on <span class=""gene"" id=""22488367-7-74-79"">STAT1</span> activation in tumor and the clinical features were investigated.",CTD_human
2,0,Biomarker,C0001418,Adenocarcinoma,group,adenocarcinomas,6774,STAT3,STAT3,CTD_human,26432044,STAT3 nuclear translocation was more frequent in adenocarcinomas and squamous cell carcinomas than that of their noncancerous counterparts.,0.215052551622452,"<span class=""gene"" id=""26432044-8-0-5"">STAT3</span> nuclear translocation was more frequent in <span class=""disease"" id=""26432044-8-49-64"">adenocarcinomas</span> and squamous cell carcinomas than that of their noncancerous counterparts.",CTD_human
2,0,Biomarker,C0001418,Adenocarcinoma,group,adenocarcinomas,6774,STAT3,STAT3,CTD_human,19028472,"MEL exposure modulated the mitotic and apoptotic indices in the colonic adenocarcinomas that developed and lowered the immunohistochemical expression of nuclear factor kappa B, tumor necrosis factor alpha, interleukin-1beta and STAT3 in the epithelial malignancies.",0.215052551622452,"MEL exposure modulated the mitotic and apoptotic indices in the colonic <span class=""disease"" id=""19028472-5-72-87"">adenocarcinomas</span> that developed and lowered the immunohistochemical expression of nuclear factor kappa B, tumor necrosis factor alpha, interleukin-1beta and <span class=""gene"" id=""19028472-5-228-233"">STAT3</span> in the epithelial malignancies.",CTD_human
1,0,Biomarker,C0004364,Autoimmune Diseases,group,autoimmune disease,6774,STAT3,STAT3,CTD_human,25038750,Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease.,0.40384617497898295,"Activating germline mutations in <span class=""gene"" id=""25038750-0-33-38"">STAT3</span> cause early-onset multi-organ <span class=""disease"" id=""25038750-0-69-87"">autoimmune disease</span>.",CTD_human;HPO
1,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,non-small cell lung cancer,6774,STAT3,STAT3,CTD_human,21549414,Prognostic significance of STAT3 expression and its correlation with chemoresistance of non-small cell lung cancer cells.,0.21263743207380303,"Prognostic significance of <span class=""gene"" id=""21549414-0-27-32"">STAT3</span> expression and its correlation with chemoresistance of <span class=""disease"" id=""21549414-0-88-114"">non-small cell lung cancer</span> cells.",CTD_human
2,0,Biomarker,C0007137,Squamous cell carcinoma,disease,squamous cell carcinomas,6774,STAT3,STAT3,CTD_human,26432044,STAT3 nuclear translocation was more frequent in adenocarcinomas and squamous cell carcinomas than that of their noncancerous counterparts.,0.22408982474684902,"<span class=""gene"" id=""26432044-8-0-5"">STAT3</span> nuclear translocation was more frequent in adenocarcinomas and <span class=""disease"" id=""26432044-8-69-93"">squamous cell carcinomas</span> than that of their noncancerous counterparts.",CTD_human
2,0,Biomarker,C0007137,Squamous cell carcinoma,disease,SCC,6774,STAT3,Stat3,CTD_human,17566705,Transfection of constitutively active Stat3 restored survivin expression and partially rescued SCC cells from sulindac-induced antitumorigenic effects.,0.22408982474684902,"Transfection of constitutively active <span class=""gene"" id=""17566705-8-38-43"">Stat3</span> restored survivin expression and partially rescued <span class=""disease"" id=""17566705-8-95-98"">SCC</span> cells from sulindac-induced antitumorigenic effects.",CTD_human
2,1,Biomarker,C0009324,Ulcerative Colitis,disease,ulcerative colitis,6774,STAT3,STAT3,CTD_human,18438405,"Among these loci, we identified variants in 3p21.31, NKX2-3 and CCNY as susceptibility factors for both diseases, whereas variants in PTPN2, HERC2 and STAT3 were associated only with ulcerative colitis in our sample collection.",0.21489908015051398,"Among these loci, we identified variants in 3p21.31, NKX2-3 and CCNY as susceptibility factors for both diseases, whereas variants in PTPN2, HERC2 and <span class=""gene"" id=""18438405-2-151-156"">STAT3</span> were associated only with <span class=""disease"" id=""18438405-2-183-201"">ulcerative colitis</span> in our sample collection.",CTD_human
1,0,Biomarker,C0011854,"Diabetes Mellitus, Insulin-Dependent",disease,type 1 diabetes,6774,STAT3,STAT3,CTD_human,25038750,"We report a new monogenic cause of autoimmunity resulting from de novo germline activating STAT3 mutations in five individuals with a spectrum of early-onset autoimmune disease, including type 1 diabetes.",0.20240702852328799,"We report a new monogenic cause of autoimmunity resulting from de novo germline activating <span class=""gene"" id=""25038750-2-91-96"">STAT3</span> mutations in five individuals with a spectrum of early-onset autoimmune disease, including <span class=""disease"" id=""25038750-2-188-203"">type 1 diabetes</span>.",CTD_human
1,0,Biomarker,C0023493,Adult T-Cell Lymphoma/Leukemia,disease,ATL,6774,STAT3,STAT3,CTD_human,24090995,"In addition, the STAT3 inhibitor S3I-201 not only induced cell growth arrest and cell death but also activated caspase-3 in MT-2 and HUT-102 cells, indicating that STAT3 may be a therapeutic target for ATL.",0.20082418035263896,"In addition, the <span class=""gene"" id=""24090995-8-17-22"">STAT3</span> inhibitor S3I-201 not only induced cell growth arrest and cell death but also activated caspase-3 in MT-2 and HUT-102 cells, indicating that <span class=""gene"" id=""24090995-8-164-169"">STAT3</span> may be a therapeutic target for <span class=""disease"" id=""24090995-8-202-205"">ATL</span>.",CTD_human
1,0,Biomarker,C0023903,Liver neoplasms,group,liver tumours,6774,STAT3,STAT-3,CTD_human,12957465,"STAT-3 is active during the regenerative growth of the liver, but there are hardly any data about its presence in liver tumours.",0.20467035533162303,"<span class=""gene"" id=""12957465-2-0-6"">STAT-3</span> is active during the regenerative growth of the liver, but there are hardly any data about its presence in <span class=""disease"" id=""12957465-2-114-127"">liver tumours</span>.",CTD_human
2,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastasis,6774,STAT3,STAT3,CTD_human,21937440,"Through transcriptional regulation of its target genes, STAT3 controls a wide range of cellular processes, including cellular proliferation, oncogenesis, and cancer metastasis.",0.23431213727200303,"Through transcriptional regulation of its target genes, <span class=""gene"" id=""21937440-3-56-61"">STAT3</span> controls a wide range of cellular processes, including cellular proliferation, oncogenesis, and cancer <span class=""disease"" id=""21937440-3-165-175"">metastasis</span>.",CTD_human
2,0,Biomarker,C0878544,Cardiomyopathies,group,cardiomyopathy,6774,STAT3,Signal transducer and activator of transcription 3,CTD_human,10618415,Signal transducer and activator of transcription 3 in the heart transduces not only a hypertrophic signal but a protective signal against doxorubicin-induced cardiomyopathy.,0.202732912464814,"<span class=""gene"" id=""10618415-0-0-50"">Signal transducer and activator of transcription 3</span> in the heart transduces not only a hypertrophic signal but a protective signal against doxorubicin-induced <span class=""disease"" id=""10618415-0-158-172"">cardiomyopathy</span>.",CTD_human
2,0,Therapeutic,C0878544,Cardiomyopathies,group,cardiomyopathy,6774,STAT3,Signal transducer and activator of transcription 3,CTD_human,10618415,Signal transducer and activator of transcription 3 in the heart transduces not only a hypertrophic signal but a protective signal against doxorubicin-induced cardiomyopathy.,0.202732912464814,"<span class=""gene"" id=""10618415-0-0-50"">Signal transducer and activator of transcription 3</span> in the heart transduces not only a hypertrophic signal but a protective signal against doxorubicin-induced <span class=""disease"" id=""10618415-0-158-172"">cardiomyopathy</span>.",CTD_human
1,0,Biomarker,C1168401,Squamous cell carcinoma of the head and neck,disease,SCCHN,6774,STAT3,STAT3,CTD_human,27064016,"Our results suggest that resveratrol blocks STAT3 signaling pathway through induction of SOCS-1, thus attenuating STAT3 phosphorylation and proliferation in SCCHN cells.",0.209065983879032,"Our results suggest that resveratrol blocks STAT3 signaling pathway through induction of SOCS-1, thus attenuating <span class=""gene"" id=""27064016-14-114-119"">STAT3</span> phosphorylation and proliferation in <span class=""disease"" id=""27064016-14-157-162"">SCCHN</span> cells.",CTD_human
1,0,Biomarker,C3887645,Job Syndrome,disease,hyper IgE syndrome,6774,STAT3,STAT3,CTD_human,25038750,These findings emphasize the critical role of STAT3 in autoimmune disease and contrast with the germline inactivating STAT3 mutations that result in hyper IgE syndrome.,0.230529796096026,"These findings emphasize the critical role of <span class=""gene"" id=""25038750-3-46-51"">STAT3</span> in autoimmune disease and contrast with the germline inactivating <span class=""gene"" id=""25038750-3-118-123"">STAT3</span> mutations that result in <span class=""disease"" id=""25038750-3-149-167"">hyper IgE syndrome</span>.",CTD_human
2,7,Biomarker,C0024141,"Lupus Erythematosus, Systemic",disease,SLE,6775,STAT4,STAT4,CTD_human,18204446,"We also found evidence for association (P < 1 x 10(-5)) at FCGR2A, PTPN22 and STAT4, regions previously associated with SLE and other autoimmune diseases, as well as at > or =9 other loci (P < 2 x 10(-7)).",0.278172070150672,"We also found evidence for association (P &lt; 1 x 10(-5)) at FCGR2A, PTPN22 and <span class=""gene"" id=""18204446-4-78-83"">STAT4</span>, regions previously associated with <span class=""disease"" id=""18204446-4-120-123"">SLE</span> and other autoimmune diseases, as well as at &gt; or =9 other loci (P &lt; 2 x 10(-7)).",CTD_human
1,1,Biomarker,C2239176,Liver carcinoma,disease,HCC,6775,STAT4,STAT4,CTD_human,23242368,We also found significantly lower mRNA expression of STAT4 in HCC tumor tissues compared with paired adjacent nontumor tissues (P = 2.33 × 10(-14)).,0.203021994626344,"We also found significantly lower mRNA expression of <span class=""gene"" id=""23242368-4-53-58"">STAT4</span> in <span class=""disease"" id=""23242368-4-62-65"">HCC</span> tumor tissues compared with paired adjacent nontumor tissues (P = 2.33 &times; 10(-14)).",CTD_human
2,0,Biomarker,C0001418,Adenocarcinoma,group,adenocarcinomas,6776,STAT5A,cS5-F,CTD_human,20235097,Expression of cS5-F also prevented involution and caused the formation of estrogen and progesterone receptor positive (ER(+)PR(+)) adenocarcinomas.,0.20328236603324,"Expression of <span class=""gene"" id=""20235097-10-14-19"">cS5-F</span> also prevented involution and caused the formation of estrogen and progesterone receptor positive (ER(+)PR(+)) <span class=""disease"" id=""20235097-10-131-146"">adenocarcinomas</span>.",CTD_human
1,0,Biomarker,C0206692,"Carcinoma, Lobular",disease,lobular carcinomas,6776,STAT5A,Stat5a,CTD_human,15609129,"Stat5a nuclear expression was detected in ductal and lobular carcinomas and DCIS at a frequency of 48% (15/31), 33% (2/6), and 40% (2/5), respectively.",0.2,"<span class=""gene"" id=""15609129-11-0-6"">Stat5a</span> nuclear expression was detected in ductal and <span class=""disease"" id=""15609129-11-53-71"">lobular carcinomas</span> and DCIS at a frequency of 48% (15/31), 33% (2/6), and 40% (2/5), respectively.",CTD_human
1,0,Biomarker,C1176475,Ductal Carcinoma,disease,ductal carcinomas,6776,STAT5A,Stat5a,CTD_human,15609129,Stat5a nuclear expression was also detected in intraductal proliferations (10 of 21 lesions) and in ductal carcinomas in situ (13 of 15 lesions).,0.2,"<span class=""gene"" id=""15609129-9-0-6"">Stat5a</span> nuclear expression was also detected in intraductal proliferations (10 of 21 lesions) and in <span class=""disease"" id=""15609129-9-100-117"">ductal carcinomas</span> in situ (13 of 15 lesions).",CTD_human
1,0,Therapeutic,C0011615,"Dermatitis, Atopic",disease,atopic dermatitis,6778,STAT6,STAT6,CTD_human,15306842,In vivo transfection of a cis element 'decoy' against signal transducers and activators of transcription 6 (STAT6)-binding site ameliorates IgE-mediated late-phase reaction in an atopic dermatitis mouse model.,0.20575490709115804,"In vivo transfection of a cis element 'decoy' against signal transducers and activators of transcription 6 (<span class=""gene"" id=""15306842-0-108-113"">STAT6</span>)-binding site ameliorates IgE-mediated late-phase reaction in an <span class=""disease"" id=""15306842-0-179-196"">atopic dermatitis</span> mouse model.",CTD_human
2,0,Biomarker,C1266119,Solitary fibrous tumor,disease,solitary fibrous tumor,6778,STAT6,STAT6,CTD_human,23313952,Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing.,0.206318716036901,"Identification of recurrent NAB2-<span class=""gene"" id=""23313952-0-33-38"">STAT6</span> gene fusions in <span class=""disease"" id=""23313952-0-55-77"">solitary fibrous tumor</span> by integrative sequencing.",CTD_human
2,0,Biomarker,C1266119,Solitary fibrous tumor,disease,solitary fibrous tumors,6778,STAT6,STAT6,CTD_human,23313954,Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors.,0.206318716036901,"Whole-exome sequencing identifies a recurrent NAB2-<span class=""gene"" id=""23313954-0-51-56"">STAT6</span> fusion in <span class=""disease"" id=""23313954-0-67-90"">solitary fibrous tumors</span>.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autistic,6779,STATH,statherin,CTD_human,19367726,"Phosphorylation level of four specific salivary phospho-peptides, namely statherin, histatin 1 (both, p < 0.0001) and acidic proline-rich proteins (both entire and truncated isoforms) (p < 0.005) was found significantly lower in autistic patients, with hypo-phosphorylation of at least one peptide observed in 18 ASD subjects (66%).",0.2,"Phosphorylation level of four specific salivary phospho-peptides, namely <span class=""gene"" id=""19367726-2-73-82"">statherin</span>, histatin 1 (both, p &lt; 0.0001) and acidic proline-rich proteins (both entire and truncated isoforms) (p &lt; 0.005) was found significantly lower in <span class=""disease"" id=""19367726-2-229-237"">autistic</span> patients, with hypo-phosphorylation of at least one peptide observed in 18 ASD subjects (66%).",CTD_human
1,0,Biomarker,C0025202,melanoma,disease,melanoma,6790,AURKA,AURKA,CTD_human,22535842,"Genes deregulated at the DNA and mRNA level included well-known cancer genes partly already linked to melanoma (RAS genes, PTEN, AURKA, MAPK inhibitors Sprouty/Spred), but also novel candidates like SIPA1 (a Rap1GAP).",0.201373633921065,"Genes deregulated at the DNA and mRNA level included well-known cancer genes partly already linked to <span class=""disease"" id=""22535842-8-102-110"">melanoma</span> (RAS genes, PTEN, <span class=""gene"" id=""22535842-8-129-134"">AURKA</span>, MAPK inhibitors Sprouty/Spred), but also novel candidates like SIPA1 (a Rap1GAP).",CTD_human
1,0,Biomarker,C0031117,Peripheral Neuropathy,group,peripheral neuropathy,6790,AURKA,AURKA,CTD_human,20864405,"By contrast, early-onset vincristine-induced peripheral neuropathy was characterised by upregulation of genes involved in cell cycle and proliferation, including AURKA (3·31 times; p=1·04×10(-2)) and MKI67 (3·66 times; p=1·82×10(-3)), and the presence of SNPs in genes involved in these processes-eg, GLI1 (rs2228224 [0·13, 0·02-0·97, p=1·18×10(-2)] and rs2242578 [0·14, 0·02-1·12, p=3·00×10(-2)]).",0.2,"By contrast, early-onset vincristine-induced <span class=""disease"" id=""20864405-13-45-66"">peripheral neuropathy</span> was characterised by upregulation of genes involved in cell cycle and proliferation, including <span class=""gene"" id=""20864405-13-162-167"">AURKA</span> (3·31 times; p=1·04&times;10(-2)) and MKI67 (3·66 times; p=1·82&times;10(-3)), and the presence of SNPs in genes involved in these processes-eg, GLI1 (rs2228224 [0·13, 0·02-0·97, p=1·18&times;10(-2)] and rs2242578 [0·14, 0·02-1·12, p=3·00&times;10(-2)]).",CTD_human
1,2,Biomarker,C0035372,Rett Syndrome,disease,Rett syndrome,6792,CDKL5,CDKL5,CTD_human,19241098,"Furthermore, the mutational repertoire of the CDKL5 gene is shown to be expanded by testing patients with phenotypical overlap to Rett syndrome and applying multiplex ligation-dependent probe amplification.",0.446066288752274,"Furthermore, the mutational repertoire of the <span class=""gene"" id=""19241098-7-46-51"">CDKL5</span> gene is shown to be expanded by testing patients with phenotypical overlap to <span class=""disease"" id=""19241098-7-130-143"">Rett syndrome</span> and applying multiplex ligation-dependent probe amplification.",CTD_human;ORPHANET
1,0,Biomarker,C0001418,Adenocarcinoma,group,adenocarcinomas,6794,STK11,LKB1,CTD_human,17676035,"Consistent with these findings, inactivation of LKB1 was found in 34% and 19% of 144 analysed human lung adenocarcinomas and squamous cell carcinomas, respectively.",0.226995149681251,"Consistent with these findings, inactivation of <span class=""gene"" id=""17676035-7-48-52"">LKB1</span> was found in 34% and 19% of 144 analysed human lung <span class=""disease"" id=""17676035-7-105-120"">adenocarcinomas</span> and squamous cell carcinomas, respectively.",CTD_human
1,0,Biomarker,C0007137,Squamous cell carcinoma,disease,squamous cell carcinomas,6794,STK11,LKB1,CTD_human,17676035,"Consistent with these findings, inactivation of LKB1 was found in 34% and 19% of 144 analysed human lung adenocarcinomas and squamous cell carcinomas, respectively.",0.21553649265624802,"Consistent with these findings, inactivation of <span class=""gene"" id=""17676035-7-48-52"">LKB1</span> was found in 34% and 19% of 144 analysed human lung adenocarcinomas and <span class=""disease"" id=""17676035-7-125-149"">squamous cell carcinomas</span>, respectively.",CTD_human
1,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,6794,STK11,LKB1,CTD_human,19289642,"Because oxidative stress inhibits the LKB1/AMPK signaling axis to promote abnormal cell growth in cancer cells, we investigated whether oxidative stress associated with hypertension also results in the inhibition of this kinase circuit to contribute to left ventricular hypertrophy.",0.2,"Because oxidative stress inhibits the <span class=""gene"" id=""19289642-3-38-42"">LKB1</span>/AMPK signaling axis to promote abnormal cell growth in cancer cells, we investigated whether oxidative stress associated with <span class=""disease"" id=""19289642-3-169-181"">hypertension</span> also results in the inhibition of this kinase circuit to contribute to left ventricular hypertrophy.",CTD_human
1,0,Biomarker,C0024121,Lung Neoplasms,group,lung tumours,6794,STK11,LKB1,CTD_human,17676035,"Expression profiling in human lung cancer cell lines and mouse lung tumours identified a variety of metastasis-promoting genes, such as NEDD9, VEGFC and CD24, as targets of LKB1 repression in lung cancer.",0.22177534078120198,"Expression profiling in human lung cancer cell lines and mouse <span class=""disease"" id=""17676035-8-63-75"">lung tumours</span> identified a variety of metastasis-promoting genes, such as NEDD9, VEGFC and CD24, as targets of <span class=""gene"" id=""17676035-8-173-177"">LKB1</span> repression in lung cancer.",CTD_human
1,0,Biomarker,C0149721,Left Ventricular Hypertrophy,disease,left ventricular hypertrophy,6794,STK11,LKB1,CTD_human,19289642,Our data identify a molecular mechanism in the cardiomyocyte involving the oxidative stress-derived lipid peroxidation byproduct HNE and the LKB1/AMPK signaling pathway that contributes to the development of left ventricular hypertrophy.,0.2,"Our data identify a molecular mechanism in the cardiomyocyte involving the oxidative stress-derived lipid peroxidation byproduct HNE and the <span class=""gene"" id=""19289642-9-141-145"">LKB1</span>/AMPK signaling pathway that contributes to the development of <span class=""disease"" id=""19289642-9-208-236"">left ventricular hypertrophy</span>.",CTD_human
1,0,Biomarker,C0152013,Adenocarcinoma of lung (disorder),disease,lung adenocarcinoma,6794,STK11,lkb1,CTD_human,24793789,The MZF1/c-MYC axis mediates lung adenocarcinoma progression caused by wild-type lkb1 loss.,0.20412090176319603,"The MZF1/c-MYC axis mediates <span class=""disease"" id=""24793789-0-29-48"">lung adenocarcinoma</span> progression caused by wild-type <span class=""gene"" id=""24793789-0-81-85"">lkb1</span> loss.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autistic,6804,STX1A,STX1A,CTD_human,18593506,"During early childhood, there is a period of high brain serotonin synthesis that is disrupted in autistic children; STX1A might influence the serotonergic system during this stage of neurodevelopment, as implied by the association with ADI-R_D.",0.202956482091714,"During early childhood, there is a period of high brain serotonin synthesis that is disrupted in <span class=""disease"" id=""18593506-14-97-105"">autistic</span> children; <span class=""gene"" id=""18593506-14-116-121"">STX1A</span> might influence the serotonergic system during this stage of neurodevelopment, as implied by the association with ADI-R_D.",CTD_human
1,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastasis,682,BSG,EMMPRIN,CTD_human,21956400,"Overexpression of EMMPRIN, a member of the immunoglobulin superfamily,             promotes invasion, metastasis, growth and survival of malignant cells.",0.21564507132282898,"Overexpression of <span class=""gene"" id=""21956400-3-18-25"">EMMPRIN</span>, a member of the immunoglobulin superfamily,             promotes invasion, <span class=""disease"" id=""21956400-3-102-112"">metastasis</span>, growth and survival of malignant cells.",CTD_human
1,3,Biomarker,C0030567,Parkinson Disease,disease,PD,683,BST1,BST1,CTD_human,19915576,"By comparing results of a GWAS performed on individuals of European ancestry, we identified PARK16, SNCA and LRRK2 as shared risk loci for PD and BST1 and MAPT as loci showing population differences.",0.21134198733306098,"By comparing results of a GWAS performed on individuals of European ancestry, we identified PARK16, SNCA and LRRK2 as shared risk loci for <span class=""disease"" id=""19915576-4-139-141"">PD</span> and <span class=""gene"" id=""19915576-4-146-150"">BST1</span> and MAPT as loci showing population differences.",CTD_human
1,0,Biomarker,C0020757,Ichthyoses,disease,ichthyosis,6832,SUPV3L1,Supv3L1,CTD_human,19145458,Conditional ablation of Supv3L1 in keratinocytes confirmed atrophic changes in the skin and ichthyosis-like changes.,0.200274726784213,"Conditional ablation of <span class=""gene"" id=""19145458-9-24-31"">Supv3L1</span> in keratinocytes confirmed atrophic changes in the skin and <span class=""disease"" id=""19145458-9-92-102"">ichthyosis</span>-like changes.",CTD_human
1,0,Biomarker,C0872084,Sarcopenia,phenotype,sarcopenia,6832,SUPV3L1,Supv3L1,CTD_human,19145458,"Disruption of Supv3L1 damages the skin and causes sarcopenia, loss of fat, and death.",0.200274726784213,"Disruption of <span class=""gene"" id=""19145458-0-14-21"">Supv3L1</span> damages the skin and causes <span class=""disease"" id=""19145458-0-50-60"">sarcopenia</span>, loss of fat, and death.",CTD_human
2,2,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,type 2 diabetes,6833,ABCC8,ABCC8,CTD_human,22209866,"The common ATP-sensitive potassium (KATP) channel variants E23K and S1369A, found in the KCNJ11 and ABCC8 genes, respectively, form a haplotype that is associated with an increased risk for type 2 diabetes.",0.677469145110308,"The common ATP-sensitive potassium (KATP) channel variants E23K and S1369A, found in the KCNJ11 and <span class=""gene"" id=""22209866-1-100-105"">ABCC8</span> genes, respectively, form a haplotype that is associated with an increased risk for <span class=""disease"" id=""22209866-1-190-205"">type 2 diabetes</span>.",CTD_human;HPO;ORPHANET
2,2,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,NIDDM,6833,ABCC8,SUR1,CTD_human,9568693,"In conclusion, a silent polymorphism in exon 18 of the SUR1 gene is associated with NIDDM in a Danish Caucasian population.",0.677469145110308,"In conclusion, a silent polymorphism in exon 18 of the <span class=""gene"" id=""9568693-11-55-59"">SUR1</span> gene is associated with <span class=""disease"" id=""9568693-11-84-89"">NIDDM</span> in a Danish Caucasian population.",CTD_human;HPO;ORPHANET
2,2,Biomarker,C3888018,Congenital Hyperinsulinism,disease,PHHI,6833,ABCC8,SUR1,CTD_human,10334322,This unique SUR1 mutation explains the majority of PHHI cases in Finland and is strongly associated with a severe form of the disease.,0.234990937178065,"This unique <span class=""gene"" id=""10334322-9-12-16"">SUR1</span> mutation explains the majority of <span class=""disease"" id=""10334322-9-51-55"">PHHI</span> cases in Finland and is strongly associated with a severe form of the disease.",CTD_human
6,10,Biomarker,C0023264,Leigh Disease,disease,Leigh syndrome,6834,SURF1,SURF-1,CTD_human,16765830,Facial dysmorphism in Leigh syndrome with SURF-1 mutation and COX deficiency.,0.7065399194020892,"Facial dysmorphism in <span class=""disease"" id=""16765830-0-22-36"">Leigh syndrome</span> with <span class=""gene"" id=""16765830-0-42-48"">SURF-1</span> mutation and COX deficiency.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0162568,Erythropoietic Protoporphyria,disease,EPP,685,BTC,betacellulin,CTD_human,19267999,"We observed that the expression of amphiregulin, betacellulin and epiregulin was significantly increased in young EPP mice when compared to aged-matched controls in all genetic backgrounds.",0.2,"We observed that the expression of amphiregulin, <span class=""gene"" id=""19267999-6-49-61"">betacellulin</span> and epiregulin was significantly increased in young <span class=""disease"" id=""19267999-6-114-117"">EPP</span> mice when compared to aged-matched controls in all genetic backgrounds.",CTD_human
1,0,Biomarker,C0025202,melanoma,disease,melanoma,6850,SYK,SYK,CTD_human,17145863,"Reexpression of either of two of the silenced genes, HOXB13 and SYK, resulted in reduced colony formation in vitro and diminished tumor formation in vivo, indicating that these genes function as tumor suppressors in melanoma.",0.206015278498054,"Reexpression of either of two of the silenced genes, HOXB13 and <span class=""gene"" id=""17145863-6-64-67"">SYK</span>, resulted in reduced colony formation in vitro and diminished tumor formation in vivo, indicating that these genes function as tumor suppressors in <span class=""disease"" id=""17145863-6-216-224"">melanoma</span>.",CTD_human
1,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,NSCLC,6855,SYP,Syn,CTD_human,21595568,"Expression of NSE was present in 22.4%, ChrA in 15.5% and Syn in 14.8% of patients with NSCLC.",0.200274726784213,"Expression of NSE was present in 22.4%, ChrA in 15.5% and <span class=""gene"" id=""21595568-4-58-61"">Syn</span> in 14.8% of patients with <span class=""disease"" id=""21595568-4-88-93"">NSCLC</span>.",CTD_human
1,0,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,6855,SYP,synaptophysin,CTD_human,11483314,"In schizophrenia, synaptophysin mRNA was decreased, as was complexin II and its mRNA.",0.204106546385879,"In <span class=""disease"" id=""11483314-5-3-16"">schizophrenia</span>, <span class=""gene"" id=""11483314-5-18-31"">synaptophysin</span> mRNA was decreased, as was complexin II and its mRNA.",CTD_human
1,0,Biomarker,C1136249,"Mental Retardation, X-Linked",disease,XLMR,6855,SYP,SYP,CTD_human,19377476,"The screen has discovered nine genes implicated in XLMR, including SYP, ZNF711 and CASK reported here, confirming the power of this strategy.",0.2,"The screen has discovered nine genes implicated in <span class=""disease"" id=""19377476-3-51-55"">XLMR</span>, including <span class=""gene"" id=""19377476-3-67-70"">SYP</span>, ZNF711 and CASK reported here, confirming the power of this strategy.",CTD_human
3,0,Therapeutic,C0002622,Amnesia,disease,amnesia,6863,TAC1,substance P,CTD_human,20600432,Scopolamine- and diazepam-induced amnesia are blocked by systemic and intraseptal administration of substance P and choline chloride.,0.2,"Scopolamine- and diazepam-induced <span class=""disease"" id=""20600432-0-34-41"">amnesia</span> are blocked by systemic and intraseptal administration of <span class=""gene"" id=""20600432-0-100-111"">substance P</span> and choline chloride.",CTD_human
3,0,Therapeutic,C0002622,Amnesia,disease,amnesia,6863,TAC1,substance P,CTD_human,7562510,"In addition, coadministration of JTP-4819 and substance P, arginine-vasopressin or thyrotropin-releasing hormone (at doses at which each drug alone did not prolong the retention time) improved the retention time of rats with scopolamine-induced amnesia.",0.2,"In addition, coadministration of JTP-4819 and <span class=""gene"" id=""7562510-4-46-57"">substance P</span>, arginine-vasopressin or thyrotropin-releasing hormone (at doses at which each drug alone did not prolong the retention time) improved the retention time of rats with scopolamine-induced <span class=""disease"" id=""7562510-4-245-252"">amnesia</span>.",CTD_human
1,0,Biomarker,C0005586,Bipolar Disorder,disease,bipolar disorder,6863,TAC1,PPT,CTD_human,15845098,An inverse relationship between PPT-A mRNA expression levels and lifetime antipsychotic treatment (Fluphenazine) in the schizophrenic and bipolar disorder groups was found.,0.2,"An inverse relationship between <span class=""gene"" id=""15845098-6-32-35"">PPT</span>-A mRNA expression levels and lifetime antipsychotic treatment (Fluphenazine) in the schizophrenic and <span class=""disease"" id=""15845098-6-138-154"">bipolar disorder</span> groups was found.",CTD_human
9,0,Biomarker,C0020429,Hyperalgesia,phenotype,Hyperalgesia,6863,TAC1,substance p,CTD_human,12351280,Hyperalgesia during opioid abstinence: mediation by glutamate and substance p.,0.2,"<span class=""disease"" id=""12351280-0-0-12"">Hyperalgesia</span> during opioid abstinence: mediation by glutamate and <span class=""gene"" id=""12351280-0-66-77"">substance p</span>.",CTD_human
9,0,Biomarker,C0020429,Hyperalgesia,phenotype,hyperalgesia,6863,TAC1,substance P,CTD_human,16259764,"In addition, the ME of B. microstachya (3--300 mg kg(-1), i.p., 30 min earlier) inhibited, in a graded manner, the hyperalgesia induced by bradykinin (3.2 microg/paw), substance P (13.5 microg/paw), carrageenan (300 microg/paw), capsaicin (100 microg/paw) and adrenaline (100 ng/paw) in the rat paw, with mean ID50 values of 20.5, 17.9, 101.8, 54.2 and 99.7 mg kg(-1), respectively.",0.2,"In addition, the ME of B. microstachya (3--300 mg kg(-1), i.p., 30 min earlier) inhibited, in a graded manner, the <span class=""disease"" id=""16259764-5-115-127"">hyperalgesia</span> induced by bradykinin (3.2 microg/paw), <span class=""gene"" id=""16259764-5-168-179"">substance P</span> (13.5 microg/paw), carrageenan (300 microg/paw), capsaicin (100 microg/paw) and adrenaline (100 ng/paw) in the rat paw, with mean ID50 values of 20.5, 17.9, 101.8, 54.2 and 99.7 mg kg(-1), respectively.",CTD_human
9,0,Biomarker,C0020429,Hyperalgesia,phenotype,hyperalgesia,6863,TAC1,substance P,CTD_human,19231294,"In contrast, intrathecal substance P 100 nmol produced hyperalgesia, and intrathecal DAMGO 10 nmol produced antinociception.",0.2,"In contrast, intrathecal <span class=""gene"" id=""19231294-6-25-36"">substance P</span> 100 nmol produced <span class=""disease"" id=""19231294-6-55-67"">hyperalgesia</span>, and intrathecal DAMGO 10 nmol produced antinociception.",CTD_human
9,0,Biomarker,C0020429,Hyperalgesia,phenotype,hyperalgesia,6863,TAC1,substance P,CTD_human,10499367,"GAEE significantly inhibited the hyperalgesia induced by bradykinin or substance P in rat paw, but did not affect the hyperalgesia caused by carrageenan or prostaglandin E2.",0.2,"GAEE significantly inhibited the <span class=""disease"" id=""10499367-2-33-45"">hyperalgesia</span> induced by bradykinin or <span class=""gene"" id=""10499367-2-71-82"">substance P</span> in rat paw, but did not affect the <span class=""disease"" id=""10499367-2-118-130"">hyperalgesia</span> caused by carrageenan or prostaglandin E2.",CTD_human
9,0,Biomarker,C0020429,Hyperalgesia,phenotype,hyperalgesia,6863,TAC1,substance P,CTD_human,9714424,"The HE (3 to 100 mg kg(-1), p.o., 1 h) inhibited in a graded manner, the hyperalgesia induced by bradykinin (3 nmol/paw) or substance P (10 nmol/paw) in rat paw, with mean ED50 values of 54.5 and 53.7 mg kg(-1), respectively.",0.2,"The HE (3 to 100 mg kg(-1), p.o., 1 h) inhibited in a graded manner, the <span class=""disease"" id=""9714424-5-73-85"">hyperalgesia</span> induced by bradykinin (3 nmol/paw) or <span class=""gene"" id=""9714424-5-124-135"">substance P</span> (10 nmol/paw) in rat paw, with mean ED50 values of 54.5 and 53.7 mg kg(-1), respectively.",CTD_human
2,0,Therapeutic,C0020452,Hyperemia,disease,hyperemia,6863,TAC1,Substance P,CTD_human,7507874,Substance P attenuates gastric mucosal hyperemia after stimulation of sensory neurons in the rat stomach.,0.2,"<span class=""gene"" id=""7507874-0-0-11"">Substance P</span> attenuates gastric mucosal <span class=""disease"" id=""7507874-0-39-48"">hyperemia</span> after stimulation of sensory neurons in the rat stomach.",CTD_human
2,0,Therapeutic,C0020452,Hyperemia,disease,hyperemia,6863,TAC1,Substance P,CTD_human,10564113,Substance P may attenuate gastric hyperemia by a mast cell-dependent mechanism in the damaged gastric mucosa.,0.2,"<span class=""gene"" id=""10564113-0-0-11"">Substance P</span> may attenuate gastric <span class=""disease"" id=""10564113-0-34-43"">hyperemia</span> by a mast cell-dependent mechanism in the damaged gastric mucosa.",CTD_human
3,0,Biomarker,C0030193,Pain,phenotype,pain,6863,TAC1,substance P,CTD_human,7694222,Ruthenium red caused a significant inhibition of pain-related behavioral responses induced by i.t. capsaicin but not by i.t. substance P. These results suggest that ruthenium red produces analgesia by inhibiting the release of neuropeptides in the spinal cord.,0.20927519812861603,"Ruthenium red caused a significant inhibition of <span class=""disease"" id=""7694222-2-49-53"">pain</span>-related behavioral responses induced by i.t. capsaicin but not by i.t. <span class=""gene"" id=""7694222-2-125-136"">substance P</span>. These results suggest that ruthenium red produces analgesia by inhibiting the release of neuropeptides in the spinal cord.",CTD_human
1,0,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,6863,TAC1,preprotachykinin,CTD_human,15845098,Down-regulation of amygdala preprotachykinin A mRNA but not 3H-SP receptor binding sites in subjects affected by mood disorders and schizophrenia.,0.20240702852328799,"Down-regulation of amygdala <span class=""gene"" id=""15845098-0-28-44"">preprotachykinin</span> A mRNA but not 3H-SP receptor binding sites in subjects affected by mood disorders and <span class=""disease"" id=""15845098-0-132-145"">schizophrenia</span>.",CTD_human
1,0,Biomarker,C0037036,Sialorrhea,disease,salivation,6863,TAC1,SP,CTD_human,8938667,Injection of substance P (SP) in a rat hindpaw induced extravasation of 125I-labelled albumin in both hindpaws and salivation.,0.2,"Injection of <span class=""gene"" id=""8938667-1-13-24"">substance P</span> (<span class=""gene"" id=""8938667-1-26-28"">SP</span>) in a rat hindpaw induced extravasation of 125I-labelled albumin in both hindpaws and <span class=""disease"" id=""8938667-1-115-125"">salivation</span>.",CTD_human
1,0,Biomarker,C1269683,Major Depressive Disorder,disease,major depression,6863,TAC1,SP,CTD_human,15845098,"Given the important role of the amygdaloid complex in the regulation of emotional behavior, we examined the mRNA levels of preprotachykinin A [PPT-A, a precursor of both SP and neurokinin A (NKA)] and 3H-SP binding sites in the amygdala of patients affected by bipolar disorder, major depression or schizophrenia as compared with matched control individuals.",0.200274726784213,"Given the important role of the amygdaloid complex in the regulation of emotional behavior, we examined the mRNA levels of <span class=""gene"" id=""15845098-2-123-139"">preprotachykinin</span> A [<span class=""gene"" id=""15845098-2-143-146"">PPT</span>-A, a precursor of both <span class=""gene"" id=""15845098-2-170-172"">SP</span> and <span class=""gene"" id=""15845098-2-177-189"">neurokinin A</span> (<span class=""gene"" id=""15845098-2-191-194"">NKA</span>)] and 3H-<span class=""gene"" id=""15845098-2-204-206"">SP</span> binding sites in the amygdala of patients affected by bipolar disorder, <span class=""disease"" id=""15845098-2-279-295"">major depression</span> or schizophrenia as compared with matched control individuals.",CTD_human
1,0,Biomarker,C0009319,Colitis,disease,colon inflammation,6868,ADAM17,TACE,CTD_human,24548422,Involvement of TACE in colon inflammation: a novel mechanism of regulation via SIRT-1 activation.,0.200274726784213,"Involvement of <span class=""gene"" id=""24548422-0-15-19"">TACE</span> in <span class=""disease"" id=""24548422-0-23-41"">colon inflammation</span>: a novel mechanism of regulation via SIRT-1 activation.",CTD_human
5,0,Biomarker,C0001973,"Alcoholic Intoxication, Chronic",disease,alcoholism,6869,TACR1,TACR1,CTD_human,19204064,"Four single-nucleotide polymorphisms (rs3771829, rs3771833, rs3771856, and rs1701137) at the TACR1 gene, previously known to be associated with bipolar disorder or alcoholism, were strongly associated with ADHD.",0.403780662444354,"Four single-nucleotide polymorphisms (rs3771829, rs3771833, rs3771856, and rs1701137) at the <span class=""gene"" id=""19204064-9-93-98"">TACR1</span> gene, previously known to be associated with bipolar disorder or <span class=""disease"" id=""19204064-9-164-174"">alcoholism</span>, were strongly associated with ADHD.",CTD_human;PSYGENET
3,0,Biomarker,C0005586,Bipolar Disorder,disease,bipolar disorder,6869,TACR1,TACR1,CTD_human,19204064,"Four single-nucleotide polymorphisms (rs3771829, rs3771833, rs3771856, and rs1701137) at the TACR1 gene, previously known to be associated with bipolar disorder or alcoholism, were strongly associated with ADHD.",0.400549453568426,"Four single-nucleotide polymorphisms (rs3771829, rs3771833, rs3771856, and rs1701137) at the <span class=""gene"" id=""19204064-9-93-98"">TACR1</span> gene, previously known to be associated with <span class=""disease"" id=""19204064-9-144-160"">bipolar disorder</span> or alcoholism, were strongly associated with ADHD.",CTD_human;PSYGENET
2,0,Biomarker,C0020429,Hyperalgesia,phenotype,hyperalgesia,6869,TACR1,NK-1 receptor,CTD_human,17123731,Spinal NK-1 receptor expressing neurons mediate opioid-induced hyperalgesia and antinociceptive tolerance via activation of descending pathways.,0.2,"Spinal <span class=""gene"" id=""17123731-0-7-20"">NK-1 receptor</span> expressing neurons mediate opioid-induced <span class=""disease"" id=""17123731-0-63-75"">hyperalgesia</span> and antinociceptive tolerance via activation of descending pathways.",CTD_human
2,0,Biomarker,C0020429,Hyperalgesia,phenotype,hyperalgesia,6869,TACR1,NK-1 receptor,CTD_human,15964684,These data support a critical role for the NK-1 receptor in the expression of sustained morphine-induced hyperalgesia.,0.2,"These data support a critical role for the <span class=""gene"" id=""15964684-8-43-56"">NK-1 receptor</span> in the expression of sustained morphine-induced <span class=""disease"" id=""15964684-8-105-117"">hyperalgesia</span>.",CTD_human
1,0,Biomarker,C1263846,Attention deficit hyperactivity disorder,disease,ADHD,6869,TACR1,TACR1,CTD_human,19204064,NK1 (TACR1) receptor gene 'knockout' mouse phenotype predicts genetic association with ADHD.,0.28054945356842603,"NK1 (<span class=""gene"" id=""19204064-0-5-10"">TACR1</span>) receptor gene 'knockout' mouse phenotype predicts genetic association with <span class=""disease"" id=""19204064-0-87-91"">ADHD</span>.",CTD_human
1,0,Biomarker,C0001973,"Alcoholic Intoxication, Chronic",disease,alcohol dependence,6870,TACR3,TACR3,CTD_human,18422838,Seven of the 9 SNPs in the 3' region of TACR3 provided significant evidence of association with alcohol dependence (p <or= 0.05).,0.40508878383078906,"Seven of the 9 SNPs in the 3' region of <span class=""gene"" id=""18422838-7-40-45"">TACR3</span> provided significant evidence of association with <span class=""disease"" id=""18422838-7-96-114"">alcohol dependence</span> (p &lt;or= 0.05).",CTD_human;PSYGENET
1,0,Biomarker,C0279626,Squamous cell carcinoma of esophagus,disease,ESCC,6876,TAGLN,TAGLN,CTD_human,21517111,"Among these identified proteins, 33 proteins including keratin 17 (KRT17), biliverdin reductase B (BLVRB), proteasome activator subunit 1 (PSME1), manganese superoxide dismutase (MnSOD), high-mobility group box-1(HMGB1), heat shock protein 70 (HSP70), peroxiredoxin (PRDX1), keratin 13 (KRT13), and so on were overexpressed, and 14 proteins including cystatin B (CSTB), tropomyosin 2 (TPM2), annexin 1 (ANX1), transgelin (TAGLN), keratin 19 (KRT19), stratifin (SFN), and so on were down-expressed in ESCC.",0.2,"Among these identified proteins, 33 proteins including keratin 17 (KRT17), biliverdin reductase B (BLVRB), proteasome activator subunit 1 (PSME1), manganese superoxide dismutase (MnSOD), high-mobility group box-1(HMGB1), heat shock protein 70 (HSP70), peroxiredoxin (PRDX1), keratin 13 (KRT13), and so on were overexpressed, and 14 proteins including cystatin B (CSTB), tropomyosin 2 (TPM2), annexin 1 (ANX1), <span class=""gene"" id=""21517111-5-410-420"">transgelin</span> (<span class=""gene"" id=""21517111-5-422-427"">TAGLN</span>), keratin 19 (KRT19), stratifin (SFN), and so on were down-expressed in <span class=""disease"" id=""21517111-5-500-504"">ESCC</span>.",CTD_human
1,0,Biomarker,C0152013,Adenocarcinoma of lung (disorder),disease,ADC,688,KLF5,KLF5,CTD_human,27158780,"New significantly mutated genes included PPP3CA, DOT1L, and FTSJD1 in lung ADC, RASA1 in lung SqCC, and KLF5, EP300, and CREBBP in both tumor types.",0.2,"New significantly mutated genes included PPP3CA, DOT1L, and FTSJD1 in lung <span class=""disease"" id=""27158780-3-75-78"">ADC</span>, RASA1 in lung SqCC, and <span class=""gene"" id=""27158780-3-104-108"">KLF5</span>, EP300, and CREBBP in both tumor types.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,6888,TALDO1,Taldo1,CTD_human,19436114,"Here, we show that Taldo1-/- and Taldo1+/- mice spontaneously developed HCC, and Taldo1-/- mice had increased susceptibility to acetaminophen-induced liver failure.",0.2,"Here, we show that <span class=""gene"" id=""19436114-3-19-25"">Taldo1</span>-/- and <span class=""gene"" id=""19436114-3-33-39"">Taldo1</span>+/- mice spontaneously developed <span class=""disease"" id=""19436114-3-72-75"">HCC</span>, and <span class=""gene"" id=""19436114-3-81-87"">Taldo1</span>-/- mice had increased susceptibility to acetaminophen-induced liver failure.",CTD_human
1,0,Biomarker,C0027121,Myositis,disease,myositis,6897,TARS,TARS,CTD_human,23425968,"Threonyl-tRNA synthetase (TARS) is an autoantigen in the autoimmune disorder myositis, and borrelidin, a potent inhibitor of TARS, inhibits angiogenesis.",0.2,"<span class=""gene"" id=""23425968-2-0-24"">Threonyl-tRNA synthetase</span> (<span class=""gene"" id=""23425968-2-26-30"">TARS</span>) is an autoantigen in the autoimmune disorder <span class=""disease"" id=""23425968-2-77-85"">myositis</span>, and borrelidin, a potent inhibitor of <span class=""gene"" id=""23425968-2-125-129"">TARS</span>, inhibits angiogenesis.",CTD_human
4,1,Biomarker,C0012236,DiGeorge Syndrome,disease,DiGeorge syndrome,6899,TBX1,Tbx1,CTD_human,15190012,Full spectrum of malformations in velo-cardio-facial syndrome/DiGeorge syndrome mouse models by altering Tbx1 dosage.,0.704421973040331,"Full spectrum of malformations in <span class=""disease"" id=""15190012-0-34-61"">velo-cardio-facial syndrome</span>/<span class=""disease"" id=""15190012-0-62-79"">DiGeorge syndrome</span> mouse models by altering <span class=""gene"" id=""15190012-0-105-109"">Tbx1</span> dosage.",CTD_human;ORPHANET;UNIPROT
4,1,Biomarker,C0012236,DiGeorge Syndrome,disease,DGS,6899,TBX1,Tbx1,CTD_human,16399080,We can partially rescue one salient feature of DGS in Crkl+/-;Tbx1+/- embryos by genetically reducing the amount of RA produced in the embryo.,0.704421973040331,"We can partially rescue one salient feature of <span class=""disease"" id=""16399080-4-47-50"">DGS</span> in Crkl+/-;<span class=""gene"" id=""16399080-4-62-66"">Tbx1</span>+/- embryos by genetically reducing the amount of RA produced in the embryo.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0039685,Tetralogy of Fallot,disease,TOF,6899,TBX1,TBX1,CTD_human,25093829,"We sequenced the coding, 5'UTR, and 3'UTR regions of twelve transcription factor genes implicated in cardiac outflow tract development (NKX2.5, GATA4, ISL1, TBX20, MEF2C, BOP/SMYD1, HAND2, FOXC1, FOXC2, FOXH, FOXA2 and TBX1) in 93 non-syndromic, non-Mendelian TOF cases.",0.40460484279699294,"We sequenced the coding, 5'UTR, and 3'UTR regions of twelve transcription factor genes implicated in cardiac outflow tract development (NKX2.5, GATA4, ISL1, TBX20, MEF2C, BOP/SMYD1, HAND2, FOXC1, FOXC2, FOXH, FOXA2 and <span class=""gene"" id=""25093829-3-219-223"">TBX1</span>) in 93 non-syndromic, non-Mendelian <span class=""disease"" id=""25093829-3-260-263"">TOF</span> cases.",CTD_human;HPO
6,18,Biomarker,C0574083,3-Methylglutaconic aciduria type 2,disease,BTHS,6901,TAZ,tafazzin,CTD_human,25185984,"Barth syndrome (BTHS) is a genetic, X-linked, rare but often fatal, pediatric skeletal- and cardiomyopathy occurring due to mutations in the tafazzin gene (TAZ).",0.6145605195632939,"<span class=""disease"" id=""25185984-1-0-14"">Barth syndrome</span> (<span class=""disease"" id=""25185984-1-16-20"">BTHS</span>) is a genetic, X-linked, rare but often fatal, pediatric skeletal- and cardiomyopathy occurring due to mutations in the <span class=""gene"" id=""25185984-1-141-149"">tafazzin</span> gene (TAZ).",CTD_human;ORPHANET;UNIPROT
6,18,Biomarker,C0574083,3-Methylglutaconic aciduria type 2,disease,Barth syndrome,6901,TAZ,tafazzin,CTD_human,18430085,"The tafazzin (TAZ) gene is highly conserved from yeast to humans, and the yeast taz1 null mutant shows alterations in cardiolipin (CL) metabolism, mitochondrial dysfunction and stabilization of supercomplexes similar to those found in Barth syndrome, a human disorder resulting from loss of tafazzin.",0.6145605195632939,"The <span class=""gene"" id=""18430085-1-4-12"">tafazzin</span> (<span class=""gene"" id=""18430085-1-14-17"">TAZ</span>) gene is highly conserved from yeast to humans, and the yeast <span class=""gene"" id=""18430085-1-80-84"">taz1</span> null mutant shows alterations in cardiolipin (CL) metabolism, mitochondrial dysfunction and stabilization of supercomplexes similar to those found in <span class=""disease"" id=""18430085-1-235-249"">Barth syndrome</span>, a human disorder resulting from loss of <span class=""gene"" id=""18430085-1-291-299"">tafazzin</span>.",CTD_human;ORPHANET;UNIPROT
1,2,Biomarker,C1855840,HYPOPARATHYROIDISM-RETARDATION-DYSMORPHISM SYNDROME,disease,Sanjad-Sakati syndrome,6905,TBCE,HRD,CTD_human,12389028,"The syndrome of congenital hypoparathyroidism, mental retardation, facial dysmorphism and extreme growth failure (HRD or Sanjad-Sakati syndrome; OMIM 241410) is an autosomal recessive disorder reported almost exclusively in Middle Eastern populations.",0.4010989071368521,"The syndrome of congenital hypoparathyroidism, mental retardation, facial dysmorphism and extreme growth failure (<span class=""gene"" id=""12389028-1-114-117"">HRD</span> or <span class=""disease"" id=""12389028-1-121-143"">Sanjad-Sakati syndrome</span>; OMIM 241410) is an autosomal recessive disorder reported almost exclusively in Middle Eastern populations.",CTD_human;ORPHANET
1,0,Biomarker,C1510586,Autism Spectrum Disorders,disease,autism spectrum disorder,6907,TBL1X,TBL1X,CTD_human,22050706,An X chromosome-wide association study in autism families identifies TBL1X as a novel autism spectrum disorder candidate gene in males.,0.2,"An X chromosome-wide association study in autism families identifies <span class=""gene"" id=""22050706-0-69-74"">TBL1X</span> as a novel <span class=""disease"" id=""22050706-0-86-110"">autism spectrum disorder</span> candidate gene in males.",CTD_human
3,8,Biomarker,C0265264,Holt-Oram syndrome,disease,Holt-Oram syndrome,6910,TBX5,TBX5,CTD_human,15735645,"The cardiac transcription factor TBX5 strongly regulates expression of MYH6, but mutant forms of TBX5, which cause Holt-Oram syndrome, do not.",0.6982756694730179,"The cardiac transcription factor <span class=""gene"" id=""15735645-4-33-37"">TBX5</span> strongly regulates expression of MYH6, but mutant forms of <span class=""gene"" id=""15735645-4-97-101"">TBX5</span>, which cause <span class=""disease"" id=""15735645-4-115-133"">Holt-Oram syndrome</span>, do not.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C1850040,Pelviscapular dysplasia,disease,Cousin syndrome,6913,TBX15,TBX15,CTD_human,19068278,"TBX15 mutations cause craniofacial dysmorphism, hypoplasia of scapula and pelvis, and short stature in Cousin syndrome.",0.400549453568426,"<span class=""gene"" id=""19068278-0-0-5"">TBX15</span> mutations cause <span class=""disease"" id=""19068278-0-22-99"">craniofacial dysmorphism, hypoplasia of scapula and pelvis, and short stature</span> in <span class=""disease"" id=""19068278-0-103-118"">Cousin syndrome</span>.",CTD_human;ORPHANET
2,0,Biomarker,C1319853,"Asthma, Aspirin-Induced",disease,AIA,6915,TBXA2R,TBXA2R,CTD_human,16502481,"Several single nucleotide polymorphisms (SNPs) in the promoters of EP2, TBX21, COX-2, Fc epsilon RIbeta, and TBXA2R were associated with AIA, while an Fc epsilon RIalpha promoter polymorphism was associated with AIU.",0.20054945356842604,"Several single nucleotide polymorphisms (SNPs) in the promoters of EP2, TBX21, COX-2, Fc epsilon RIbeta, and <span class=""gene"" id=""16502481-6-109-115"">TBXA2R</span> were associated with <span class=""disease"" id=""16502481-6-137-140"">AIA</span>, while an Fc epsilon RIalpha promoter polymorphism was associated with AIU.",CTD_human
1,0,Biomarker,C0596263,Carcinogenesis,phenotype,tumorigenesis,692088,SNORD50B,SNORD50B,CTD_human,26595770,"In agreement with this hypothesis, CRISPR-mediated deletion of SNORD50A and SNORD50B in KRAS-mutant tumor cells enhanced tumorigenesis, and SNORD50A and SNORD50B deletion and oncogenic KRAS mutation co-occurred significantly in multiple human tumor types.",0.2,"In agreement with this hypothesis, CRISPR-mediated deletion of SNORD50A and <span class=""gene"" id=""26595770-7-76-84"">SNORD50B</span> in KRAS-mutant tumor cells enhanced <span class=""disease"" id=""26595770-7-121-134"">tumorigenesis</span>, and SNORD50A and <span class=""gene"" id=""26595770-7-153-161"">SNORD50B</span> deletion and oncogenic KRAS mutation co-occurred significantly in multiple human tumor types.",CTD_human
1,0,Biomarker,C0031117,Peripheral Neuropathy,group,PN,6925,TCF4,TCF4,CTD_human,21228734,"Genes associated with immune function (CTLA4, CTSS), reflexive coupling within Schwann cells (GJE1), drug binding (PSMB1), and neuron function (TCF4, DYNC1I1) associated with bortezomib-induced PN in this study.",0.200274726784213,"Genes associated with immune function (CTLA4, CTSS), reflexive coupling within Schwann cells (GJE1), drug binding (PSMB1), and neuron function (<span class=""gene"" id=""21228734-10-144-148"">TCF4</span>, DYNC1I1) associated with bortezomib-induced <span class=""disease"" id=""21228734-10-194-196"">PN</span> in this study.",CTD_human
4,29,Biomarker,C1970431,PITT-HOPKINS SYNDROME,disease,Pitt-Hopkins syndrome,6925,TCF4,TCF4,CTD_human,17436254,"Mutations in TCF4, encoding a class I basic helix-loop-helix transcription factor, are responsible for Pitt-Hopkins syndrome, a severe epileptic encephalopathy associated with autonomic dysfunction.",0.607417623173754,"Mutations in <span class=""gene"" id=""17436254-0-13-17"">TCF4</span>, encoding a class I basic helix-loop-helix transcription factor, are responsible for <span class=""disease"" id=""17436254-0-103-124"">Pitt-Hopkins syndrome</span>, a severe epileptic encephalopathy associated with autonomic dysfunction.",CTD_human;ORPHANET;UNIPROT
4,29,Biomarker,C1970431,PITT-HOPKINS SYNDROME,disease,PTHS,6925,TCF4,TCF4,CTD_human,18728071,TCF4 mutational analysis was performed in 117 patients with PTHS-like features.,0.607417623173754,"<span class=""gene"" id=""18728071-2-0-4"">TCF4</span> mutational analysis was performed in 117 patients with <span class=""disease"" id=""18728071-2-60-64"">PTHS</span>-like features.",CTD_human;ORPHANET;UNIPROT
2,2,Biomarker,C1866994,Ulnar-mammary syndrome,disease,ulnar-mammary syndrome,6926,TBX3,TBX3,CTD_human,9207801,"Mutations in human TBX3 alter limb, apocrine and genital development in ulnar-mammary syndrome.",0.6885165303106059,"Mutations in human <span class=""gene"" id=""9207801-0-19-23"">TBX3</span> alter limb, apocrine and genital development in <span class=""disease"" id=""9207801-0-72-94"">ulnar-mammary syndrome</span>.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0020615,Hypoglycemia,disease,hypoglycaemia,6927,HNF1A,MODY3,CTD_human,15787664,"Diabetic subjects with mutations in the gene encoding hepatocyte nuclear factor (HNF)-1alpha (MODY3) are prone to develop hypoglycaemia at low doses of glibenclamide, interpreted as sulphonylurea hypersensitivity.",0.201648360705279,"Diabetic subjects with mutations in the gene encoding hepatocyte nuclear factor (HNF)-1alpha (<span class=""gene"" id=""15787664-1-94-99"">MODY3</span>) are prone to develop <span class=""disease"" id=""15787664-1-122-135"">hypoglycaemia</span> at low doses of glibenclamide, interpreted as sulphonylurea hypersensitivity.",CTD_human
2,3,Therapeutic,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,type 2 diabetes,6928,HNF1B,TCF2,CTD_human,17603485,"Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes.",0.6839908110448361,"Two variants on chromosome 17 confer prostate cancer risk, and the one in <span class=""gene"" id=""17603485-0-74-78"">TCF2</span> protects against <span class=""disease"" id=""17603485-0-96-111"">type 2 diabetes</span>.",CTD_human;HPO;UNIPROT
2,3,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,type 2 diabetes,6928,HNF1B,TCF2,CTD_human,17603485,"Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes.",0.6839908110448361,"Two variants on chromosome 17 confer prostate cancer risk, and the one in <span class=""gene"" id=""17603485-0-74-78"">TCF2</span> protects against <span class=""disease"" id=""17603485-0-96-111"">type 2 diabetes</span>.",CTD_human;HPO;UNIPROT
1,0,Biomarker,C1961102,Precursor Cell Lymphoblastic Leukemia Lymphoma,disease,acute lymphoblastic leukemia,6929,TCF3,TCF3,CTD_human,26214592,Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options.,0.21395364448559898,"Genomics and drug profiling of fatal <span class=""gene"" id=""26214592-0-37-41"">TCF3</span>-HLF-positive <span class=""disease"" id=""26214592-0-55-83"">acute lymphoblastic leukemia</span> identifies recurrent mutation patterns and therapeutic options.",CTD_human
1,0,Biomarker,C0010346,Crohn Disease,disease,Crohn's disease,6932,TCF7,TCF-1,CTD_human,24994854,TCF-1-mediated Wnt signaling regulates Paneth cell innate immune defense effectors HD-5 and -6: implications for Crohn's disease.,0.200274726784213,"<span class=""gene"" id=""24994854-0-0-5"">TCF-1</span>-mediated Wnt signaling regulates Paneth cell innate immune defense effectors HD-5 and -6: implications for <span class=""disease"" id=""24994854-0-113-128"">Crohn's disease</span>.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,hepatocellular carcinoma,693200,MIR615,miR-615,CTD_human,22819824,miR-615-5p is restrictedly expressed in cirrhotic and cancerous liver tissues and its overexpression alleviates the tumorigenic effects in hepatocellular carcinoma.,0.20082418035263896,"<span class=""gene"" id=""22819824-0-0-7"">miR-615</span>-5p is restrictedly expressed in cirrhotic and cancerous liver tissues and its overexpression alleviates the tumorigenic effects in <span class=""disease"" id=""22819824-0-139-163"">hepatocellular carcinoma</span>.",CTD_human
1,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,NSCLC,693223,MIR638,miR-638,CTD_human,22048643,"Among these miRNAs, downregulation of miR-638 was found in 68% (34/50) of NSCLC tissues.",0.20082418035263896,"Among these miRNAs, downregulation of <span class=""gene"" id=""22048643-5-38-45"">miR-638</span> was found in 68% (34/50) of <span class=""disease"" id=""22048643-5-74-79"">NSCLC</span> tissues.",CTD_human
1,0,Biomarker,C0001418,Adenocarcinoma,group,adenocarcinomas,6934,TCF7L2,TCF7L2,CTD_human,21892161,Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion.,0.200274726784213,"Genomic sequencing of colorectal <span class=""disease"" id=""21892161-0-33-48"">adenocarcinomas</span> identifies a recurrent VTI1A-<span class=""gene"" id=""21892161-0-78-84"">TCF7L2</span> fusion.",CTD_human
2,6,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,T2D,6934,TCF7L2,TCF7L2,CTD_human,17460697,"We conducted a genome-wide association study for type 2 diabetes (T2D) in Icelandic cases and controls, and we found that a previously described variant in the transcription factor 7-like 2 gene (TCF7L2) gene conferred the most significant risk.",0.379130387253696,"We conducted a genome-wide association study for <span class=""disease"" id=""17460697-1-49-64"">type 2 diabetes</span> (<span class=""disease"" id=""17460697-1-66-69"">T2D</span>) in Icelandic cases and controls, and we found that a previously described variant in the <span class=""gene"" id=""17460697-1-160-189"">transcription factor 7-like 2</span> gene (<span class=""gene"" id=""17460697-1-196-202"">TCF7L2</span>) gene conferred the most significant risk.",CTD_human
1,0,Biomarker,C0029172,Oral Submucous Fibrosis,disease,OSF,6935,ZEB1,ZEB1,CTD_human,26934322,"In conclusion, our data suggest that resveratrol epigenetically inhibits ZEB1 expression to suppress the myofibroblast activity of fBMFs and may serve as a dietary supplement for OSF patients.",0.200274726784213,"In conclusion, our data suggest that resveratrol epigenetically inhibits <span class=""gene"" id=""26934322-11-73-77"">ZEB1</span> expression to suppress the myofibroblast activity of fBMFs and may serve as a dietary supplement for <span class=""disease"" id=""26934322-11-179-182"">OSF</span> patients.",CTD_human
1,0,Biomarker,C0010278,Craniosynostosis,disease,craniosynostosis,6938,TCF12,TCF12,CTD_human,23354436,"Using exome sequencing, we identified 38 heterozygous TCF12 mutations in 347 samples from unrelated individuals with craniosynostosis.",0.40082418035263895,"Using exome sequencing, we identified 38 heterozygous <span class=""gene"" id=""23354436-3-54-59"">TCF12</span> mutations in 347 samples from unrelated individuals with <span class=""disease"" id=""23354436-3-117-133"">craniosynostosis</span>.",CTD_human;HPO
1,0,Biomarker,C0036341,Schizophrenia,disease,SZ,694,BTG1,BTG1,CTD_human,16223876,"Implementing this systematic approach, we: (i) discovered 177 putative SZ risk genes in brain, 28 of which map to linked chromosomal loci; (ii) delineated six biological processes and 12 molecular functions that may be particularly disrupted in the illness; (iii) identified 123 putative SZ biomarkers in blood, 6 of which (BTG1, GSK3A, HLA-DRB1, HNRPA3, SELENBP1, and SFRS1) had corresponding differential expression in brain; (iv) verified the differential expression of the strongest candidate SZ biomarker (SELENBP1) in blood; and (v) demonstrated neuronal and glial expression of SELENBP1 protein in brain.",0.200274726784213,"Implementing this systematic approach, we: (i) discovered 177 putative <span class=""disease"" id=""16223876-4-71-73"">SZ</span> risk genes in brain, 28 of which map to linked chromosomal loci; (ii) delineated six biological processes and 12 molecular functions that may be particularly disrupted in the illness; (iii) identified 123 putative SZ biomarkers in blood, 6 of which (<span class=""gene"" id=""16223876-4-324-328"">BTG1</span>, GSK3A, HLA-DRB1, HNRPA3, SELENBP1, and SFRS1) had corresponding differential expression in brain; (iv) verified the differential expression of the strongest candidate SZ biomarker (SELENBP1) in blood; and (v) demonstrated neuronal and glial expression of SELENBP1 protein in brain.",CTD_human
2,12,Biomarker,C0242387,Mandibulofacial Dysostosis,disease,TCS,6949,TCOF1,Tcof1,CTD_human,16938878,"Therefore, Tcof1/Treacle is a unique spatiotemporal regulator of ribosome biogenesis, a deficiency that disrupts neural crest cell formation and proliferation, causing the hypoplasia characteristic of TCS craniofacial anomalies.",0.701110896252457,"Therefore, <span class=""gene"" id=""16938878-9-11-16"">Tcof1</span>/Treacle is a unique spatiotemporal regulator of ribosome biogenesis, a deficiency that disrupts neural crest cell formation and proliferation, causing the hypoplasia characteristic of <span class=""disease"" id=""16938878-9-201-204"">TCS</span> craniofacial anomalies.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0376634,Craniofacial Abnormalities,group,craniofacial abnormalities,6949,TCOF1,Tcof1,CTD_human,16938878,Tcof1/Treacle is required for neural crest cell formation and proliferation deficiencies that cause craniofacial abnormalities.,0.201373633921065,"<span class=""gene"" id=""16938878-0-0-5"">Tcof1</span>/Treacle is required for neural crest cell formation and proliferation deficiencies that cause <span class=""disease"" id=""16938878-0-100-126"">craniofacial abnormalities</span>.",CTD_human
1,0,Biomarker,C0027404,Narcolepsy,disease,Narcolepsy,6955,TRA,T-cell receptor alpha locus,CTD_human,19412176,Narcolepsy is strongly associated with the T-cell receptor alpha locus.,0.203231208875927,"<span class=""disease"" id=""19412176-0-0-10"">Narcolepsy</span> is strongly associated with the <span class=""gene"" id=""19412176-0-43-70"">T-cell receptor alpha locus</span>.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,6999,TDO2,"tryptophan 2,3 dioxygenase",CTD_human,14755447,"Association of tryptophan 2,3 dioxygenase gene polymorphism with autism.",0.20300763924902696,"Association of <span class=""gene"" id=""14755447-0-15-41"">tryptophan 2,3 dioxygenase</span> gene polymorphism with <span class=""disease"" id=""14755447-0-65-71"">autism</span>.",CTD_human
1,0,Biomarker,C0003949,Asbestosis,disease,asbestosis,7001,PRDX2,PRX2,CTD_human,22537621,High plasma levels of tropomyosin 4 (TPM4: p<0.001) and peroxiredoxins 1 and 2 (PRX2: p<0.001) correlated with asbestos exposure or a diagnosis of asbestosis.,0.2,"High plasma levels of tropomyosin 4 (TPM4: p&lt;0.001) and peroxiredoxins 1 and 2 (<span class=""gene"" id=""22537621-8-80-84"">PRX2</span>: p&lt;0.001) correlated with asbestos exposure or a diagnosis of <span class=""disease"" id=""22537621-8-147-157"">asbestosis</span>.",CTD_human
1,0,Biomarker,C0013080,Down Syndrome,disease,DS,7001,PRDX2,thioredoxin peroxidase-I,CTD_human,11771762,"By contrast, a significant reduction was observed in levels of glutathione synthetase (P < 0.01), glutathione-S-transferase mu2 (P < 0.01), glutathione-S-transferase p (P < 0.05), antioxidant protein 2 (P < 0.05), thioredoxin peroxidase-I (P < 0.05) and thioredoxin peroxidase-II (P < 0.01) in DS compared with controls.",0.20874819096286698,"By contrast, a significant reduction was observed in levels of glutathione synthetase (P &lt; 0.01), glutathione-S-transferase mu2 (P &lt; 0.01), glutathione-S-transferase p (P &lt; 0.05), antioxidant protein 2 (P &lt; 0.05), <span class=""gene"" id=""11771762-9-214-238"">thioredoxin peroxidase-I</span> (P &lt; 0.05) and thioredoxin peroxidase-II (P &lt; 0.01) in <span class=""disease"" id=""11771762-9-294-296"">DS</span> compared with controls.",CTD_human
1,0,Therapeutic,C0023470,Myeloid Leukemia,disease,myeloid leukemia,7001,PRDX2,PRDX2,CTD_human,16932348,"Thus, suppression of topo IIbeta and/or PRDX2 levels in myeloid leukemia cells provides a novel approach for improving ATRA-based differentiation therapy.",0.200274726784213,"Thus, suppression of topo IIbeta and/or <span class=""gene"" id=""16932348-10-40-45"">PRDX2</span> levels in <span class=""disease"" id=""16932348-10-56-72"">myeloid leukemia</span> cells provides a novel approach for improving ATRA-based differentiation therapy.",CTD_human
1,0,Biomarker,C0025202,melanoma,disease,malignant melanomas,7001,PRDX2,Peroxiredoxin 2,CTD_human,16778180,Silencing of Peroxiredoxin 2 and aberrant methylation of 33 CpG islands in putative promoter regions in human malignant melanomas.,0.20054945356842604,"Silencing of <span class=""gene"" id=""16778180-0-13-28"">Peroxiredoxin 2</span> and aberrant methylation of 33 CpG islands in putative promoter regions in human <span class=""disease"" id=""16778180-0-110-129"">malignant melanomas</span>.",CTD_human
1,0,Biomarker,C0029463,Osteosarcoma,disease,osteosarcoma,7001,PRDX2,peroxiredoxin 2,CTD_human,23911960,Proteomics study of open biopsy samples identifies peroxiredoxin 2 as a predictive biomarker of response to induction chemotherapy in osteosarcoma.,0.200274726784213,"Proteomics study of open biopsy samples identifies <span class=""gene"" id=""23911960-0-51-66"">peroxiredoxin 2</span> as a predictive biomarker of response to induction chemotherapy in <span class=""disease"" id=""23911960-0-134-146"">osteosarcoma</span>.",CTD_human
1,0,Biomarker,C0206656,"Rhabdomyosarcoma, Embryonal",disease,embryonal rhabdomyosarcoma,701,BUB1B,BUBR1,CTD_human,15475955,"In five families with mosaic variegated aneuploidy, including two with embryonal rhabdomyosarcoma, we identified truncating and missense mutations of BUB1B, which encodes BUBR1, a key protein in the mitotic spindle checkpoint.",0.20300763924902696,"In five families with mosaic variegated aneuploidy, including two with <span class=""disease"" id=""15475955-2-71-97"">embryonal rhabdomyosarcoma</span>, we identified truncating and missense mutations of <span class=""gene"" id=""15475955-2-150-155"">BUB1B</span>, which encodes <span class=""gene"" id=""15475955-2-171-176"">BUBR1</span>, a key protein in the mitotic spindle checkpoint.",CTD_human
1,0,Biomarker,C0279626,Squamous cell carcinoma of esophagus,disease,ESCC,701,BUB1B,BubR1,CTD_human,18691855,"The mitotic checkpoint genes, hsMAD2 and BubR1, were co-ordinately overexpressed in ESCC.",0.20054945356842604,"The mitotic checkpoint genes, hsMAD2 and <span class=""gene"" id=""18691855-13-41-46"">BubR1</span>, were co-ordinately overexpressed in <span class=""disease"" id=""18691855-13-84-88"">ESCC</span>.",CTD_human
1,0,Biomarker,C0265965,Dyskeratosis Congenita,disease,DC,7012,TERC,TERC,CTD_human,17785587,"X-linked DC is due to mutations in DKC1, while heterozygous mutations in TERC (telomerase RNA component) and TERT (telomerase reverse transcriptase) have been found in autosomal dominant DC.",0.431398869254021,"X-linked <span class=""disease"" id=""17785587-2-9-11"">DC</span> is due to mutations in DKC1, while heterozygous mutations in <span class=""gene"" id=""17785587-2-73-77"">TERC</span> (telomerase RNA component) and TERT (telomerase reverse transcriptase) have been found in autosomal dominant <span class=""disease"" id=""17785587-2-187-189"">DC</span>.",CTD_human;ORPHANET
3,1,Biomarker,C1800706,Idiopathic Pulmonary Fibrosis,disease,idiopathic pulmonary fibrosis,7012,TERC,TERC,CTD_human,23535734,"Lead SNPs at two loci (TERC and TERT) associate with several cancers and other diseases, including idiopathic pulmonary fibrosis.",0.4010989071368521,"Lead SNPs at two loci (<span class=""gene"" id=""23535734-5-23-27"">TERC</span> and TERT) associate with several cancers and other diseases, including <span class=""disease"" id=""23535734-5-99-128"">idiopathic pulmonary fibrosis</span>.",CTD_human;ORPHANET
1,0,Biomarker,C0023493,Adult T-Cell Lymphoma/Leukemia,disease,human T-Cell leukemia,7014,TERF2,TRF2,CTD_human,17643074,Telomere attrition and chromosome instability via downregulation of TRF2 contributes to arsenic trioxide-induced apoptosis of human T-Cell leukemia cell line molt-4 cells.,0.20328236603324,"Telomere attrition and chromosome instability via downregulation of <span class=""gene"" id=""17643074-0-68-72"">TRF2</span> contributes to arsenic trioxide-induced apoptosis of <span class=""disease"" id=""17643074-0-126-147"">human T-Cell leukemia</span> cell line molt-4 cells.",CTD_human
4,15,Biomarker,C0002874,Aplastic Anemia,disease,aplastic anemia,7015,TERT,telomerase reverse transcriptase,CTD_human,15814878,"Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia.",0.60761248204602,"Mutations in <span class=""gene"" id=""15814878-0-13-17"">TERT</span>, the gene for <span class=""gene"" id=""15814878-0-32-64"">telomerase reverse transcriptase</span>, in <span class=""disease"" id=""15814878-0-69-84"">aplastic anemia</span>.",CTD_human;HPO;UNIPROT
1,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,NSCLC,7015,TERT,telomerase reverse transcriptase,CTD_human,21252717,Our aim was to prospectively study the association between the catalytic subunit of telomerase (human telomerase reverse transcriptase [hTERT]) in plasma and clinical variables and survival in a large-scale non-small cell lung cancer (NSCLC) study.,0.20982465169704198,"Our aim was to prospectively study the association between the catalytic subunit of telomerase (human <span class=""gene"" id=""21252717-3-102-134"">telomerase reverse transcriptase</span> [hTERT]) in plasma and clinical variables and survival in a large-scale <span class=""disease"" id=""21252717-3-207-233"">non-small cell lung cancer</span> (<span class=""disease"" id=""21252717-3-235-240"">NSCLC</span>) study.",CTD_human
1,0,Biomarker,C0010314,Cri-du-Chat Syndrome,disease,Cri du chat syndrome,7015,TERT,telomerase reverse transcriptase,CTD_human,12629597,Deletion of the telomerase reverse transcriptase gene and haploinsufficiency of telomere maintenance in Cri du chat syndrome.,0.203557092817453,"Deletion of the <span class=""gene"" id=""12629597-0-16-48"">telomerase reverse transcriptase</span> gene and haploinsufficiency of telomere maintenance in <span class=""disease"" id=""12629597-0-104-124"">Cri du chat syndrome</span>.",CTD_human
2,0,Biomarker,C0017638,Glioma,disease,glioma,7015,TERT,TERT,CTD_human,19578367,"We identified five risk loci for glioma at 5p15.33 (rs2736100, TERT; P = 1.50 x 10(-17)), 8q24.21 (rs4295627, CCDC26; P = 2.34 x 10(-18)), 9p21.3 (rs4977756, CDKN2A-CDKN2B; P = 7.24 x 10(-15)), 20q13.33 (rs6010620, RTEL1; P = 2.52 x 10(-12)) and 11q23.3 (rs498872, PHLDB1; P = 1.07 x 10(-8)).",0.225924953299033,"We identified five risk loci for <span class=""disease"" id=""19578367-2-33-39"">glioma</span> at 5p15.33 (rs2736100, <span class=""gene"" id=""19578367-2-63-67"">TERT</span>; P = 1.50 x 10(-17)), 8q24.21 (rs4295627, CCDC26; P = 2.34 x 10(-18)), 9p21.3 (rs4977756, CDKN2A-CDKN2B; P = 7.24 x 10(-15)), 20q13.33 (rs6010620, RTEL1; P = 2.52 x 10(-12)) and 11q23.3 (rs498872, PHLDB1; P = 1.07 x 10(-8)).",CTD_human
1,0,Biomarker,C0027819,Neuroblastoma,disease,neuroblastoma,7015,TERT,TERT,CTD_human,26523776,TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors.,0.204930726738519,"<span class=""gene"" id=""26523776-0-0-4"">TERT</span> rearrangements are frequent in <span class=""disease"" id=""26523776-0-36-49"">neuroblastoma</span> and identify aggressive tumors.",CTD_human
3,0,Biomarker,C0265965,Dyskeratosis Congenita,disease,DC,7015,TERT,TERT,CTD_human,17785587,"Collectively, the findings from this study demonstrate that homozygous TERT mutations, resulting in a pure but severe telomerase deficiency, produce a phenotype of classical AR-DC and its severe variant, the HH syndrome.",0.42402431221221903,"Collectively, the findings from this study demonstrate that homozygous <span class=""gene"" id=""17785587-8-71-75"">TERT</span> mutations, resulting in a pure but severe telomerase deficiency, produce a phenotype of classical AR-<span class=""disease"" id=""17785587-8-177-179"">DC</span> and its severe variant, the HH syndrome.",CTD_human;ORPHANET
3,0,Biomarker,C0265965,Dyskeratosis Congenita,disease,dyskeratosis congenita,7015,TERT,telomerase reverse transcriptase,CTD_human,18042801,Complex inheritance pattern of dyskeratosis congenita in two families with 2 different mutations in the telomerase reverse transcriptase gene.,0.42402431221221903,"Complex inheritance pattern of <span class=""disease"" id=""18042801-0-31-53"">dyskeratosis congenita</span> in two families with 2 different mutations in the <span class=""gene"" id=""18042801-0-104-136"">telomerase reverse transcriptase</span> gene.",CTD_human;ORPHANET
4,16,Biomarker,C1800706,Idiopathic Pulmonary Fibrosis,disease,idiopathic pulmonary fibrosis,7015,TERT,TERT,CTD_human,23535734,"Lead SNPs at two loci (TERC and TERT) associate with several cancers and other diseases, including idiopathic pulmonary fibrosis.",0.410671278452359,"Lead SNPs at two loci (TERC and <span class=""gene"" id=""23535734-5-32-36"">TERT</span>) associate with several cancers and other diseases, including <span class=""disease"" id=""23535734-5-99-128"">idiopathic pulmonary fibrosis</span>.",CTD_human;ORPHANET
4,16,Biomarker,C1800706,Idiopathic Pulmonary Fibrosis,disease,IPF,7015,TERT,TERT,CTD_human,17460043,"Thus, mutations in TERT or TERC that result in telomere shortening over time confer a dramatic increase in susceptibility to adult-onset IPF.",0.410671278452359,"Thus, mutations in <span class=""gene"" id=""17460043-9-19-23"">TERT</span> or TERC that result in telomere shortening over time confer a dramatic increase in susceptibility to adult-onset <span class=""disease"" id=""17460043-9-137-140"">IPF</span>.",CTD_human;ORPHANET
1,0,Biomarker,C1846142,HOYERAAL-HREIDARSSON SYNDROME,disease,Hoyeraal-Hreidarsson syndrome,7015,TERT,Telomerase reverse-transcriptase,CTD_human,17785587,Telomerase reverse-transcriptase homozygous mutations in autosomal recessive dyskeratosis congenita and Hoyeraal-Hreidarsson syndrome.,0.400549453568426,"<span class=""gene"" id=""17785587-0-0-32"">Telomerase reverse-transcriptase</span> homozygous mutations in autosomal recessive dyskeratosis congenita and <span class=""disease"" id=""17785587-0-104-133"">Hoyeraal-Hreidarsson syndrome</span>.",CTD_human;ORPHANET
4,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,7015,TERT,TERT,CTD_human,22634754,"We also identified recurrent HBV integration events (in ? 4 HCCs) that were validated by RNA sequencing (RNA-seq) and Sanger sequencing at the known and putative cancer-related TERT, MLL4 and CCNE1 genes, which showed upregulated gene expression in tumor versus normal tissue.",0.319171087123935,"We also identified recurrent HBV integration events (in &ge; 4 <span class=""disease"" id=""22634754-5-60-63"">HCC</span>s) that were validated by RNA sequencing (RNA-seq) and Sanger sequencing at the known and putative cancer-related <span class=""gene"" id=""22634754-5-177-181"">TERT</span>, MLL4 and CCNE1 genes, which showed upregulated gene expression in tumor versus normal tissue.",CTD_human
4,0,Biomarker,C2239176,Liver carcinoma,disease,hepatocellular carcinoma,7015,TERT,mTERT,CTD_human,16651430,"Here, in a hepatocellular carcinoma-prone model brought about through toxin-induced hepatocyte injury and regeneration, we sought to determine the cooperative interactions of germ line p53 mutation and telomere dysfunction [produced by telomerase reverse transcriptase (mTERT) gene knockout].",0.319171087123935,"Here, in a <span class=""disease"" id=""16651430-5-11-35"">hepatocellular carcinoma</span>-prone model brought about through toxin-induced hepatocyte injury and regeneration, we sought to determine the cooperative interactions of germ line p53 mutation and telomere dysfunction [produced by telomerase reverse transcriptase (<span class=""gene"" id=""16651430-5-270-275"">mTERT</span>) gene knockout].",CTD_human
1,0,Biomarker,C0002395,Alzheimer's Disease,disease,Alzheimer disease,7019,TFAM,TFAM,CTD_human,17192785,"In addition to identifying the epsilon4 allele of APOE and related effects, we pinpointed over a dozen potential Alzheimer disease susceptibility genes (ACE, CHRNB2, CST3, ESR1, GAPDHS, IDE, MTHFR, NCSTN, PRNP, PSEN1, TF, TFAM and TNF) with statistically significant allelic summary odds ratios (ranging from 1.11-1.38 for risk alleles and 0.92-0.67 for protective alleles).",0.223362774572183,"In addition to identifying the epsilon4 allele of APOE and related effects, we pinpointed over a dozen potential <span class=""disease"" id=""17192785-5-113-130"">Alzheimer disease</span> susceptibility genes (ACE, CHRNB2, CST3, ESR1, GAPDHS, IDE, MTHFR, NCSTN, PRNP, PSEN1, TF, <span class=""gene"" id=""17192785-5-222-226"">TFAM</span> and TNF) with statistically significant allelic summary odds ratios (ranging from 1.11-1.38 for risk alleles and 0.92-0.67 for protective alleles).",CTD_human
2,0,Biomarker,C0013274,Patent ductus arteriosus,disease,patent ductus arteriosus,7021,TFAP2B,TFAP2B,CTD_human,10802654,"Mutations in TFAP2B cause Char syndrome, a familial form of patent ductus arteriosus.",0.40438127317009204,"Mutations in <span class=""gene"" id=""10802654-0-13-19"">TFAP2B</span> cause Char syndrome, a familial form of <span class=""disease"" id=""10802654-0-60-84"">patent ductus arteriosus</span>.",CTD_human;HPO
1,0,Therapeutic,C0001883,Airway Obstruction,group,airway obstruction,7035,TFPI,Tissue factor pathway inhibitor,CTD_human,23727623,"Tissue factor pathway inhibitor prevents airway obstruction, respiratory failure and death due to sulfur mustard analog inhalation.",0.2,"<span class=""gene"" id=""23727623-0-0-31"">Tissue factor pathway inhibitor</span> prevents <span class=""disease"" id=""23727623-0-41-59"">airway obstruction</span>, respiratory failure and death due to sulfur mustard analog inhalation.",CTD_human
1,0,Biomarker,C0034155,"Purpura, Thrombotic Thrombocytopenic",disease,thrombotic thrombocytopenic purpura,7035,TFPI,tissue factor pathway inhibitor,CTD_human,7740478,Decreased plasma tissue factor pathway inhibitor levels in patients with thrombotic thrombocytopenic purpura.,0.2,"Decreased plasma <span class=""gene"" id=""7740478-0-17-48"">tissue factor pathway inhibitor</span> levels in patients with <span class=""disease"" id=""7740478-0-73-108"">thrombotic thrombocytopenic purpura</span>.",CTD_human
1,0,Biomarker,C0005283,beta Thalassemia,disease,beta-thalassemia,7036,TFR2,TfR2,CTD_human,16755567,"We found decreased expression of hepcidin and TfR2 and increased expression of TfR1 and NGAL in the beta-thalassemia mouse models, compared with the control mice.",0.200274726784213,"We found decreased expression of hepcidin and <span class=""gene"" id=""16755567-7-46-50"">TfR2</span> and increased expression of TfR1 and NGAL in the <span class=""disease"" id=""16755567-7-100-116"">beta-thalassemia</span> mouse models, compared with the control mice.",CTD_human
1,0,Biomarker,C0005283,beta Thalassemia,disease,beta-thalassemia,7037,TFRC,TfR1,CTD_human,16755567,"We found decreased expression of hepcidin and TfR2 and increased expression of TfR1 and NGAL in the beta-thalassemia mouse models, compared with the control mice.",0.203557092817453,"We found decreased expression of hepcidin and TfR2 and increased expression of <span class=""gene"" id=""16755567-7-79-83"">TfR1</span> and NGAL in the <span class=""disease"" id=""16755567-7-100-116"">beta-thalassemia</span> mouse models, compared with the control mice.",CTD_human
3,0,Biomarker,C0162316,Iron deficiency anemia,disease,iron-deficiency anemia,7037,TFRC,transferrin receptor,CTD_human,16733738,Serum-soluble transferrin receptor concentrations in Helicobacter pylori-associated iron-deficiency anemia.,0.20383181960166602,"Serum-soluble <span class=""gene"" id=""16733738-0-14-34"">transferrin receptor</span> concentrations in Helicobacter pylori-associated <span class=""disease"" id=""16733738-0-84-106"">iron-deficiency anemia</span>.",CTD_human
1,0,Biomarker,C0013336,Dwarfism,disease,dwarfism,7038,TG,thyroglobulin,CTD_human,24582622,A novel mutation in the thyroglobulin gene that causes goiter and dwarfism in Wistar Hannover GALAS rats.,0.200274726784213,"A novel mutation in the <span class=""gene"" id=""24582622-0-24-37"">thyroglobulin</span> gene that causes goiter and <span class=""disease"" id=""24582622-0-66-74"">dwarfism</span> in Wistar Hannover GALAS rats.",CTD_human
1,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,NSCLC,7039,TGFA,TGF-alpha,CTD_human,16230376,Our data suggest that the status of amphiregulin and TGF-alpha in serum can be an important predictor of the resistance to gefitinib among patients with advanced NSCLC.,0.20274726784213098,"Our data suggest that the status of amphiregulin and <span class=""gene"" id=""16230376-9-53-62"">TGF-alpha</span> in serum can be an important predictor of the resistance to gefitinib among patients with advanced <span class=""disease"" id=""16230376-9-162-167"">NSCLC</span>.",CTD_human
1,0,Therapeutic,C0033578,Prostatic Neoplasms,group,prostate tumors,7039,TGFA,TGF-alpha,CTD_human,17136230,"Antisense oligonucleotides (oligos) against transforming growth factor-alpha (TGF-alpha; MR(1)) and its binding site, the epidermal growth factor receptor (EGFR; MR(2)), have proven efficacious against PC-3 and LNCaP prostate tumors when evaluated in both in vitro and in vivo models.",0.201373633921065,"Antisense oligonucleotides (oligos) against <span class=""gene"" id=""17136230-1-44-76"">transforming growth factor-alpha</span> (<span class=""gene"" id=""17136230-1-78-87"">TGF-alpha</span>; MR(1)) and its binding site, the epidermal growth factor receptor (EGFR; MR(2)), have proven efficacious against PC-3 and LNCaP <span class=""disease"" id=""17136230-1-217-232"">prostate tumors</span> when evaluated in both in vitro and in vivo models.",CTD_human
1,0,Therapeutic,C0034063,Pulmonary Edema,phenotype,pulmonary edema,7039,TGFA,TGF-alpha,CTD_human,11919079,"In the TGF-alpha transgenic mouse model, TGF-alpha protects against nickel-induced acute lung injury, at least in part, by attenuating the inflammatory response, reducing pulmonary edema, and preserving levels of SP-B.",0.2,"In the <span class=""gene"" id=""11919079-6-7-16"">TGF-alpha</span> transgenic mouse model, <span class=""gene"" id=""11919079-6-41-50"">TGF-alpha</span> protects against nickel-induced acute lung injury, at least in part, by attenuating the inflammatory response, reducing <span class=""disease"" id=""11919079-6-171-186"">pulmonary edema</span>, and preserving levels of SP-B.",CTD_human
1,0,Biomarker,C0034069,Pulmonary Fibrosis,disease,pulmonary fibrosis,7039,TGFA,transforming growth factor-alpha,CTD_human,18424623,EGF receptor tyrosine kinase inhibitors diminish transforming growth factor-alpha-induced pulmonary fibrosis.,0.201648360705279,"EGF receptor tyrosine kinase inhibitors diminish <span class=""gene"" id=""18424623-0-49-81"">transforming growth factor-alpha</span>-induced <span class=""disease"" id=""18424623-0-90-108"">pulmonary fibrosis</span>.",CTD_human
1,0,Biomarker,C0206624,Hepatoblastoma,disease,hepatoblastomas,7039,TGFA,transforming growth factor alpha,CTD_human,11560253,Greater expression of transforming growth factor alpha and proliferating cell nuclear antigen staining in mouse hepatoblastomas than hepatocellular carcinomas induced by a diethylnitrosamine-sodium phenobarbital regimen.,0.200274726784213,"Greater expression of <span class=""gene"" id=""11560253-0-22-54"">transforming growth factor alpha</span> and proliferating cell nuclear antigen staining in mouse <span class=""disease"" id=""11560253-0-112-127"">hepatoblastomas</span> than hepatocellular carcinomas induced by a diethylnitrosamine-sodium phenobarbital regimen.",CTD_human
2,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,7039,TGFA,TGF-alpha,CTD_human,9029167,"Molecular biological analyses of the induced lesions revealed point mutations in the p53 gene in 60.9% of HCCs, and elevated expression of mRNAs for p53, c-myc, c-fos, TGF-alpha, TGF-beta1, alpha-fetoprotein, GST-P, and GGT, and decreased mRNA expression of EGF and EGFR in HCCs when compared to controls.",0.212333994534955,"Molecular biological analyses of the induced lesions revealed point mutations in the p53 gene in 60.9% of <span class=""disease"" id=""9029167-4-106-109"">HCC</span>s, and elevated expression of mRNAs for p53, c-myc, c-fos, <span class=""gene"" id=""9029167-4-168-177"">TGF-alpha</span>, TGF-beta1, alpha-fetoprotein, GST-P, and GGT, and decreased mRNA expression of EGF and EGFR in <span class=""disease"" id=""9029167-4-274-277"">HCC</span>s when compared to controls.",CTD_human
1,0,Biomarker,C0008925,Cleft Palate,disease,cleft palate,7040,TGFB1,Tgf-?1,CTD_human,25450421,"To test this, we generated Tgf-?1 and Tgf-?2 compound mutant mice and found that approximately 40% of [Tgf-?1(+/-); Tgf-?2(-/-)] compound mutant embryos display cleft palate on C57 background.",0.20481405704657604,"To test this, we generated <span class=""gene"" id=""25450421-5-27-33"">Tgf-&beta;1</span> and Tgf-&beta;2 compound mutant mice and found that approximately 40% of [<span class=""gene"" id=""25450421-5-103-109"">Tgf-&beta;1</span>(+/-); Tgf-&beta;2(-/-)] compound mutant embryos display <span class=""disease"" id=""25450421-5-161-173"">cleft palate</span> on C57 background.",CTD_human
2,0,Biomarker,C0011881,Diabetic Nephropathy,disease,diabetic nephropathy,7040,TGFB1,transforming growth factor-beta 1,CTD_human,19960420,Mangiferin significantly inhibited glomerular extracellular matrix expansion and accumulation and transforming growth factor-beta 1 overexpression in glomeruli of diabetic nephropathy rats.,0.326470361874123,"Mangiferin significantly inhibited glomerular extracellular matrix expansion and accumulation and <span class=""gene"" id=""19960420-5-98-131"">transforming growth factor-beta 1</span> overexpression in glomeruli of <span class=""disease"" id=""19960420-5-163-183"">diabetic nephropathy</span> rats.",CTD_human
1,0,Biomarker,C0024115,Lung diseases,group,lung disease,7040,TGFB1,Transforming growth factor-beta(1,CTD_human,11472967,Transforming growth factor-beta(1) overexpression in tumor necrosis factor-alpha receptor knockout mice induces fibroproliferative lung disease.,0.208920603432455,"<span class=""gene"" id=""11472967-0-0-33"">Transforming growth factor-beta(1</span>) overexpression in tumor necrosis factor-alpha receptor knockout mice induces fibroproliferative <span class=""disease"" id=""11472967-0-131-143"">lung disease</span>.",CTD_human
3,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastasis,7040,TGFB1,TGF-?1,CTD_human,26896736,"In the present study, we showed that Sal reversed transforming growth factor-?1 (TGF-?1) induced invasion and metastasis accompanied with down-regulation of MMP-2 by experiments on human breast cancer cell line MCF-7.",0.231796530082133,"In the present study, we showed that Sal reversed <span class=""gene"" id=""26896736-4-50-79"">transforming growth factor-&beta;1</span> (<span class=""gene"" id=""26896736-4-81-87"">TGF-&beta;1</span>) induced invasion and <span class=""disease"" id=""26896736-4-110-120"">metastasis</span> accompanied with down-regulation of MMP-2 by experiments on human breast cancer cell line MCF-7.",CTD_human
3,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastasis,7040,TGFB1,TGF-?1,CTD_human,23146760,Resveratrol inhibits TGF-?1-induced epithelial-to-mesenchymal transition and suppresses lung cancer invasion and metastasis.,0.231796530082133,"Resveratrol inhibits <span class=""gene"" id=""23146760-0-21-27"">TGF-&beta;1</span>-induced epithelial-to-mesenchymal transition and suppresses lung cancer invasion and <span class=""disease"" id=""23146760-0-113-123"">metastasis</span>.",CTD_human
3,0,Biomarker,C0027726,Nephrotic Syndrome,group,Nephrotic syndrome,7040,TGFB1,TGF-beta 1,CTD_human,8023968,"Nephrotic syndrome induced by puromycin aminonucleoside (PAN) is characterized by tubulointerstitial (TI) inflammation, foci of TI fibrosis, and increased renal mRNA levels for matrix genes, the tissue inhibitor of metalloproteinases (TIMP), and the transforming growth factor-beta 1 (TGF-beta 1).",0.20814758023712898,"<span class=""disease"" id=""8023968-1-0-18"">Nephrotic syndrome</span> induced by puromycin aminonucleoside (PAN) is characterized by tubulointerstitial (TI) inflammation, foci of TI fibrosis, and increased renal mRNA levels for matrix genes, the tissue inhibitor of metalloproteinases (TIMP), and the <span class=""gene"" id=""8023968-1-250-283"">transforming growth factor-beta 1</span> (<span class=""gene"" id=""8023968-1-285-295"">TGF-beta 1</span>).",CTD_human
7,0,Biomarker,C0034069,Pulmonary Fibrosis,disease,lung fibrosis,7040,TGFB1,transforming growth factor-?1,CTD_human,24762191,Arsenic trioxide inhibits transforming growth factor-?1-induced fibroblast to myofibroblast differentiation in vitro and bleomycin induced lung fibrosis in vivo.,0.41750264627769107,"Arsenic trioxide inhibits <span class=""gene"" id=""24762191-0-26-55"">transforming growth factor-&beta;1</span>-induced fibroblast to myofibroblast differentiation in vitro and bleomycin induced <span class=""disease"" id=""24762191-0-139-152"">lung fibrosis</span> in vivo.",CTD_human;HPO
1,0,Biomarker,C0036202,Sarcoidosis,disease,sarcoidosis,7040,TGFB1,TGF-beta 1,CTD_human,17785866,TGF-beta 1 variants in chronic beryllium disease and sarcoidosis.,0.213785817636344,"<span class=""gene"" id=""17785866-0-0-10"">TGF-beta 1</span> variants in chronic beryllium disease and <span class=""disease"" id=""17785866-0-53-64"">sarcoidosis</span>.",CTD_human
1,0,Biomarker,C0040028,"Thrombocythemia, Essential",disease,essential thrombocythemia,7040,TGFB1,TGFbeta,CTD_human,15682418,"PDGF-A, PDGF-B, TGFbeta, and bFGF mRNA levels in patients with essential thrombocythemia treated with anagrelide.",0.200274726784213,"PDGF-A, PDGF-B, <span class=""gene"" id=""15682418-0-16-23"">TGFbeta</span>, and bFGF mRNA levels in patients with <span class=""disease"" id=""15682418-0-63-88"">essential thrombocythemia</span> treated with anagrelide.",CTD_human
1,0,Biomarker,C0008925,Cleft Palate,disease,cleft palate,7042,TGFB2,Tgf-?2,CTD_human,25450421,"In addition, 26% of Tgf-?2(-/-) embryos on 129 background, but not in C57 or Black Swiss, displayed cleft palate.",0.2,"In addition, 26% of <span class=""gene"" id=""25450421-6-20-26"">Tgf-&beta;2</span>(-/-) embryos on 129 background, but not in C57 or Black Swiss, displayed <span class=""disease"" id=""25450421-6-100-112"">cleft palate</span>.",CTD_human
2,0,Biomarker,C0162872,"Aortic Aneurysm, Thoracic",disease,thoracic aortic aneurysms,7042,TGFB2,TGFB2,CTD_human,22772371,TGFB2 mutations cause familial thoracic aortic aneurysms and dissections associated with mild systemic features of Marfan syndrome.,0.201373633921065,"<span class=""gene"" id=""22772371-0-0-5"">TGFB2</span> mutations cause familial <span class=""disease"" id=""22772371-0-31-56"">thoracic aortic aneurysms</span> and dissections associated with mild systemic features of Marfan syndrome.",CTD_human
2,0,Biomarker,C0162872,"Aortic Aneurysm, Thoracic",disease,thoracic aortic aneurysm,7042,TGFB2,TGFB2,CTD_human,22772368,Loss-of-function mutations in TGFB2 cause a syndromic presentation of thoracic aortic aneurysm.,0.201373633921065,"Loss-of-function mutations in <span class=""gene"" id=""22772368-0-30-35"">TGFB2</span> cause a syndromic presentation of <span class=""disease"" id=""22772368-0-70-94"">thoracic aortic aneurysm</span>.",CTD_human
1,3,Biomarker,C2697932,Loeys-Dietz Syndrome,disease,LDS,7042,TGFB2,TGF-?2,CTD_human,22772368,"Here, we report heterozygous mutations or deletions in the gene encoding the TGF-?2 ligand for a phenotype within the LDS spectrum and show upregulation of TGF-? signaling in aortic tissue from affected individuals.",0.201373633921065,"Here, we report heterozygous mutations or deletions in the gene encoding the <span class=""gene"" id=""22772368-2-77-83"">TGF-&beta;2</span> ligand for a phenotype within the <span class=""disease"" id=""22772368-2-118-121"">LDS</span> spectrum and show upregulation of TGF-&beta; signaling in aortic tissue from affected individuals.",CTD_human
1,0,Biomarker,C0008925,Cleft Palate,disease,cleft palate,7043,TGFB3,TGF-beta 3,CTD_human,7493022,Abnormal lung development and cleft palate in mice lacking TGF-beta 3 indicates defects of epithelial-mesenchymal interaction.,0.423637501356396,"Abnormal lung development and <span class=""disease"" id=""7493022-0-30-42"">cleft palate</span> in mice lacking <span class=""gene"" id=""7493022-0-59-69"">TGF-beta 3</span> indicates defects of epithelial-mesenchymal interaction.",CTD_human;HPO
1,0,Biomarker,C0037286,Skin Neoplasms,group,skin tumors,7046,TGFBR1,Multiple self-healing squamous epithelioma,CTD_human,21358634,"Multiple self-healing squamous epithelioma (MSSE), also known as Ferguson-Smith disease (FSD), is an autosomal-dominant skin cancer condition characterized by multiple squamous-carcinoma-like locally invasive skin tumors that grow rapidly for a few weeks before spontaneously regressing, leaving scars.",0.201098907136852,"<span class=""gene"" id=""21358634-1-0-42"">Multiple self-healing squamous epithelioma</span> (MSSE), also known as Ferguson-Smith disease (FSD), is an autosomal-dominant skin cancer condition characterized by multiple squamous-carcinoma-like locally invasive <span class=""disease"" id=""21358634-1-209-220"">skin tumors</span> that grow rapidly for a few weeks before spontaneously regressing, leaving scars.",CTD_human
1,4,Biomarker,C0546476,Multiple self-healing squamous epithelioma,disease,MSSE,7046,TGFBR1,TGFBR1,CTD_human,21358634,This distinguishes MSSE from the Marfan syndrome-related disorders in which missense mutations in TGFBR1 lead to developmental defects with vascular involvement but no reported predisposition to cancer.,0.201098907136852,"This distinguishes <span class=""disease"" id=""21358634-5-19-23"">MSSE</span> from the Marfan syndrome-related disorders in which missense mutations in <span class=""gene"" id=""21358634-5-98-104"">TGFBR1</span> lead to developmental defects with vascular involvement but no reported predisposition to cancer.",CTD_human
2,5,Biomarker,C2697932,Loeys-Dietz Syndrome,disease,Loeys-Dietz syndrome,7046,TGFBR1,TGFBR1,CTD_human,20358619,"Loeys-Dietz syndrome (LDS, OMIM # 609192) caused by heterozygous mutations in TGFBR1 and TGFBR2 has recently been described as an important cause of familial aortic aneurysms.",0.206593442821114,"<span class=""disease"" id=""20358619-1-0-20"">Loeys-Dietz syndrome</span> (LDS, OMIM # 609192) caused by heterozygous mutations in <span class=""gene"" id=""20358619-1-78-84"">TGFBR1</span> and TGFBR2 has recently been described as an important cause of familial aortic aneurysms.",CTD_human
1,9,Biomarker,C0024796,Marfan Syndrome,disease,Marfan syndrome,7048,TGFBR2,TGFBR2,CTD_human,15235604,Heterozygous TGFBR2 mutations in Marfan syndrome.,0.22180405153583602,"Heterozygous <span class=""gene"" id=""15235604-0-13-19"">TGFBR2</span> mutations in <span class=""disease"" id=""15235604-0-33-48"">Marfan syndrome</span>.",CTD_human
1,0,Biomarker,C0162872,"Aortic Aneurysm, Thoracic",disease,thoracic aortic aneurysms,7048,TGFBR2,transforming growth factor-beta receptor type II,CTD_human,16027248,Mutations in transforming growth factor-beta receptor type II cause familial thoracic aortic aneurysms and dissections.,0.213474289072135,"Mutations in <span class=""gene"" id=""16027248-0-13-61"">transforming growth factor-beta receptor type II</span> cause familial <span class=""disease"" id=""16027248-0-77-102"">thoracic aortic aneurysms</span> and dissections.",CTD_human
5,16,Biomarker,C2697932,Loeys-Dietz Syndrome,disease,Loeys-Dietz syndrome,7048,TGFBR2,TGFBR2,CTD_human,20358619,"Loeys-Dietz syndrome (LDS, OMIM # 609192) caused by heterozygous mutations in TGFBR1 and TGFBR2 has recently been described as an important cause of familial aortic aneurysms.",0.21016489101588504,"<span class=""disease"" id=""20358619-1-0-20"">Loeys-Dietz syndrome</span> (LDS, OMIM # 609192) caused by heterozygous mutations in TGFBR1 and <span class=""gene"" id=""20358619-1-89-95"">TGFBR2</span> has recently been described as an important cause of familial aortic aneurysms.",CTD_human
5,16,Biomarker,C2697932,Loeys-Dietz Syndrome,disease,Loeys-Dietz syndrome,7048,TGFBR2,TGFBR2,CTD_human,19006214,Paternal somatic mosaicism of a TGFBR2 mutation transmitting to an affected son with Loeys-Dietz syndrome.,0.21016489101588504,"Paternal somatic mosaicism of a <span class=""gene"" id=""19006214-0-32-38"">TGFBR2</span> mutation transmitting to an affected son with <span class=""disease"" id=""19006214-0-85-105"">Loeys-Dietz syndrome</span>.",CTD_human
5,16,Biomarker,C2697932,Loeys-Dietz Syndrome,disease,Loeys-Dietz syndrome,7048,TGFBR2,TGFBR2,CTD_human,18084123,A Japanese family of typical Loeys-Dietz syndrome with a TGFBR2 mutation.,0.21016489101588504,"A Japanese family of typical <span class=""disease"" id=""18084123-0-29-49"">Loeys-Dietz syndrome</span> with a <span class=""gene"" id=""18084123-0-57-63"">TGFBR2</span> mutation.",CTD_human
1,0,Biomarker,C0079541,Holoprosencephaly,disease,HPE,7050,TGIF1,TGIF,CTD_human,16705179,"Haploinsufficient mutations in the TG-interacting factor (TGIF) gene were previously identified in a subset of HPE families and sporadic patients, and this gene is located within a region of chromosome 18 that is associated with nonrandom chromosomal aberrations in HPE patients.",0.216151458759304,"Haploinsufficient mutations in the TG-interacting factor (<span class=""gene"" id=""16705179-2-58-62"">TGIF</span>) gene were previously identified in a subset of <span class=""disease"" id=""16705179-2-111-114"">HPE</span> families and sporadic patients, and this gene is located within a region of chromosome 18 that is associated with nonrandom chromosomal aberrations in <span class=""disease"" id=""16705179-2-266-269"">HPE</span> patients.",CTD_human
1,0,Biomarker,C0263454,Chloracne,disease,chloracne,7051,TGM1,TGK,CTD_human,21237254,The results demonstrate that in the human skin the activation of mitogen-activated protein kinase pathway and up-regulation of CK17 and TGK may play roles in the pathogenesis of chloracne related to dioxin exposures.,0.20054945356842604,"The results demonstrate that in the human skin the activation of mitogen-activated protein kinase pathway and up-regulation of CK17 and <span class=""gene"" id=""21237254-11-136-139"">TGK</span> may play roles in the pathogenesis of <span class=""disease"" id=""21237254-11-178-187"">chloracne</span> related to dioxin exposures.",CTD_human
2,0,Therapeutic,C0017636,Glioblastoma,disease,glioblastomas,7052,TGM2,Tissue transglutaminase 2,CTD_human,16170020,Tissue transglutaminase 2 inhibition promotes cell death and chemosensitivity in glioblastomas.,0.20054945356842604,"<span class=""gene"" id=""16170020-0-0-25"">Tissue transglutaminase 2</span> inhibition promotes cell death and chemosensitivity in <span class=""disease"" id=""16170020-0-81-94"">glioblastomas</span>.",CTD_human
2,0,Biomarker,C0017636,Glioblastoma,disease,glioblastomas,7052,TGM2,Tissue transglutaminase 2,CTD_human,16170020,Tissue transglutaminase 2 inhibition promotes cell death and chemosensitivity in glioblastomas.,0.20054945356842604,"<span class=""gene"" id=""16170020-0-0-25"">Tissue transglutaminase 2</span> inhibition promotes cell death and chemosensitivity in <span class=""disease"" id=""16170020-0-81-94"">glioblastomas</span>.",CTD_human
2,0,Therapeutic,C0017636,Glioblastoma,disease,glioblastomas,7052,TGM2,Transglutaminase 2,CTD_human,17099729,"Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy.",0.20054945356842604,"<span class=""gene"" id=""17099729-0-0-18"">Transglutaminase 2</span> inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic <span class=""disease"" id=""17099729-0-122-135"">glioblastomas</span> to chemotherapy.",CTD_human
2,0,Biomarker,C0017636,Glioblastoma,disease,glioblastomas,7052,TGM2,Transglutaminase 2,CTD_human,17099729,"Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy.",0.20054945356842604,"<span class=""gene"" id=""17099729-0-0-18"">Transglutaminase 2</span> inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic <span class=""disease"" id=""17099729-0-122-135"">glioblastomas</span> to chemotherapy.",CTD_human
1,0,Biomarker,C1458155,Mammary Neoplasms,group,breast tumors,7052,TGM2,transglutaminase 2,CTD_human,19579870,Increased transglutaminase 2 and GLUT-1 expression in breast tumors not susceptible to chemoprevention with antioxidants.,0.21749638192573498,"Increased <span class=""gene"" id=""19579870-0-10-28"">transglutaminase 2</span> and GLUT-1 expression in <span class=""disease"" id=""19579870-0-54-67"">breast tumors</span> not susceptible to chemoprevention with antioxidants.",CTD_human
1,0,Biomarker,C0031511,Pheochromocytoma,disease,PHEO,7054,TH,tyrosine hydroxylase,CTD_human,22569243,"At both the protein and mRNA levels, MAOA and COMT are detected less often in PHEO compared with adrenal medulla, conversely to tyrosine hydroxylase, L-amino acid decarboxylase, and dopamine ?-hydroxylase, much more expressed in tumor tissue.",0.20357144819477,"At both the protein and mRNA levels, MAOA and COMT are detected less often in <span class=""disease"" id=""22569243-9-78-82"">PHEO</span> compared with adrenal medulla, conversely to <span class=""gene"" id=""22569243-9-128-148"">tyrosine hydroxylase</span>, L-amino acid decarboxylase, and dopamine &beta;-hydroxylase, much more expressed in tumor tissue.",CTD_human
2,0,Biomarker,C0242422,Parkinsonian Disorders,group,parkinsonism,7054,TH,tyrosine hydroxylase,CTD_human,8817341,Recessively inherited L-DOPA-responsive parkinsonism in infancy caused by a point mutation (L205P) in the tyrosine hydroxylase gene.,0.40384617497898295,"Recessively inherited L-DOPA-responsive <span class=""disease"" id=""8817341-0-40-52"">parkinsonism</span> in infancy caused by a point mutation (L205P) in the <span class=""gene"" id=""8817341-0-106-126"">tyrosine hydroxylase</span> gene.",CTD_human;HPO
2,0,Biomarker,C0242422,Parkinsonian Disorders,group,parkinsonism,7054,TH,tyrosine hydroxylase,CTD_human,11246459,Four novel mutations in the tyrosine hydroxylase gene in patients with infantile parkinsonism.,0.40384617497898295,"Four novel mutations in the <span class=""gene"" id=""11246459-0-28-48"">tyrosine hydroxylase</span> gene in patients with infantile <span class=""disease"" id=""11246459-0-81-93"">parkinsonism</span>.",CTD_human;HPO
1,0,Therapeutic,C0012739,Disseminated Intravascular Coagulation,disease,disseminated intravascular coagulation,7056,THBD,MR-33,CTD_human,9134660,Human urinary soluble thrombomodulin (MR-33) improves disseminated intravascular coagulation without affecting bleeding time in rats: comparison with low molecular weight heparin.,0.20082418035263896,"Human urinary soluble <span class=""gene"" id=""9134660-0-22-36"">thrombomodulin</span> (<span class=""gene"" id=""9134660-0-38-43"">MR-33</span>) improves <span class=""disease"" id=""9134660-0-54-92"">disseminated intravascular coagulation</span> without affecting bleeding time in rats: comparison with low molecular weight heparin.",CTD_human
1,0,Biomarker,C0023487,Acute Promyelocytic Leukemia,disease,APL,7056,THBD,TM,CTD_human,16206674,Thrombomodulin (TM) or tissue factor (TF) transcription of mRNA of freshly isolated bone marrow blast from APL patients was detected by semi-quantitative RT-PCR.,0.201373633921065,"<span class=""gene"" id=""16206674-2-0-14"">Thrombomodulin</span> (<span class=""gene"" id=""16206674-2-16-18"">TM</span>) or tissue factor (TF) transcription of mRNA of freshly isolated bone marrow blast from <span class=""disease"" id=""16206674-2-107-110"">APL</span> patients was detected by semi-quantitative RT-PCR.",CTD_human
2,0,Biomarker,C0027051,Myocardial Infarction,disease,myocardial infarction,7056,THBD,thrombomodulin,CTD_human,10627464,Identification and characterization of a thrombomodulin gene mutation coding for an elongated protein with reduced expression in a kindred with myocardial infarction.,0.224685251335936,"Identification and characterization of a <span class=""gene"" id=""10627464-0-41-55"">thrombomodulin</span> gene mutation coding for an elongated protein with reduced expression in a kindred with <span class=""disease"" id=""10627464-0-144-165"">myocardial infarction</span>.",CTD_human
2,0,Biomarker,C0027051,Myocardial Infarction,disease,myocardial infarction,7056,THBD,thrombomodulin,CTD_human,9843165,"A mutation in the thrombomodulin gene, 127G to A coding for Ala25Thr, and the risk of myocardial infarction in men.",0.224685251335936,"A mutation in the <span class=""gene"" id=""9843165-0-18-32"">thrombomodulin</span> gene, 127G to A coding for Ala25Thr, and the risk of <span class=""disease"" id=""9843165-0-86-107"">myocardial infarction</span> in men.",CTD_human
1,0,Biomarker,C0034155,"Purpura, Thrombotic Thrombocytopenic",disease,TTP,7056,THBD,TM,CTD_human,7740478,"Plasma TFPI levels might reflect injury of vascular endothelial cells as do plasma TM levels, and decreased plasma TFPI/TF ratio and vascular endothelial cell injuries might play causative roles in TTP.",0.2,"Plasma TFPI levels might reflect injury of vascular endothelial cells as do plasma <span class=""gene"" id=""7740478-9-83-85"">TM</span> levels, and decreased plasma TFPI/TF ratio and vascular endothelial cell injuries might play causative roles in <span class=""disease"" id=""7740478-9-198-201"">TTP</span>.",CTD_human
1,0,Biomarker,C0398623,Thrombophilia,disease,thrombophilia,7056,THBD,thrombomodulin,CTD_human,12139752,Mutations in the thrombomodulin gene are rare in patients with severe thrombophilia.,0.40914417305935596,"Mutations in the <span class=""gene"" id=""12139752-0-17-31"">thrombomodulin</span> gene are rare in patients with severe <span class=""disease"" id=""12139752-0-70-83"">thrombophilia</span>.",CTD_human;HPO
1,1,Biomarker,C2931788,Atypical Hemolytic Uremic Syndrome,disease,atypical hemolytic-uremic syndrome,7056,THBD,Thrombomodulin,CTD_human,19625716,Thrombomodulin mutations in atypical hemolytic-uremic syndrome.,0.201648360705279,"<span class=""gene"" id=""19625716-0-0-14"">Thrombomodulin</span> mutations in <span class=""disease"" id=""19625716-0-28-62"">atypical hemolytic-uremic syndrome</span>.",CTD_human
1,0,Biomarker,C0011884,Diabetic Retinopathy,disease,diabetic retinopathy,7057,THBS1,TSP1,CTD_human,17117553,[The study of thrombospondin-I (TSP1) expression in the early stages of diabetic retinopathy induced by streptozotocin].,0.2,"[The study of <span class=""gene"" id=""17117553-0-14-30"">thrombospondin-I</span> (<span class=""gene"" id=""17117553-0-32-36"">TSP1</span>) expression in the early stages of <span class=""disease"" id=""17117553-0-72-92"">diabetic retinopathy</span> induced by streptozotocin].",CTD_human
1,0,Biomarker,C0023890,Liver Cirrhosis,disease,cirrhosis,7057,THBS1,Thrombospondin-1,CTD_human,18407596,Thrombospondin-1 expression correlates with angiogenesis in experimental cirrhosis.,0.20240702852328799,"<span class=""gene"" id=""18407596-0-0-16"">Thrombospondin-1</span> expression correlates with angiogenesis in experimental <span class=""disease"" id=""18407596-0-73-82"">cirrhosis</span>.",CTD_human
1,0,Therapeutic,C1458155,Mammary Neoplasms,group,breast tumor,7057,THBS1,TSP,CTD_human,9309585,"Although the conjugated peptides were inactive in vivo, an unconjugated retro-inverso analog of the native TSP peptide inhibited breast tumor growth in a mouse xenograft model.",0.203557092817453,"Although the conjugated peptides were inactive in vivo, an unconjugated retro-inverso analog of the native <span class=""gene"" id=""9309585-8-107-110"">TSP</span> peptide inhibited <span class=""disease"" id=""9309585-8-129-141"">breast tumor</span> growth in a mouse xenograft model.",CTD_human
1,0,Biomarker,C0011849,Diabetes Mellitus,group,diabetes mellitus,7058,THBS2,thrombospondin-2,CTD_human,23723366,Oxidative stress-mediated thrombospondin-2 upregulation impairs bone marrow-derived angiogenic cell function in diabetes mellitus.,0.2,"Oxidative stress-mediated <span class=""gene"" id=""23723366-0-26-42"">thrombospondin-2</span> upregulation impairs bone marrow-derived angiogenic cell function in <span class=""disease"" id=""23723366-0-112-129"">diabetes mellitus</span>.",CTD_human
1,0,Therapeutic,C0878544,Cardiomyopathies,group,cardiomyopathy,7066,THPO,TPO,CTD_human,16651473,"We propose to further explore an integrated program, incorporating TPO with other protocols, for treatment of DOX-induced cardiotoxicity and other forms of cardiomyopathy.",0.2,"We propose to further explore an integrated program, incorporating <span class=""gene"" id=""16651473-10-67-70"">TPO</span> with other protocols, for treatment of DOX-induced cardiotoxicity and other forms of <span class=""disease"" id=""16651473-10-156-170"">cardiomyopathy</span>.",CTD_human
2,0,Biomarker,C2940786,Thyroid Hormone Resistance Syndrome,disease,RTH,7068,THRB,PRTH,CTD_human,9349583,Particular emphasis is given to the clinical and hormonal outcome after 2 years of triiodothyroacetic acid (TRIAC) treatment in an affected child with peripheral thyrotoxic features (pituitary RTH [PRTH]).,0.6391118389412621,"Particular emphasis is given to the clinical and hormonal outcome after 2 years of triiodothyroacetic acid (TRIAC) treatment in an affected child with peripheral thyrotoxic features (pituitary <span class=""disease"" id=""9349583-2-193-196"">RTH</span> [<span class=""gene"" id=""9349583-2-198-202"">PRTH</span>]).",CTD_human;HPO;ORPHANET
2,0,Biomarker,C2940786,Thyroid Hormone Resistance Syndrome,disease,resistance to thyroid hormone,7068,THRB,thyroid hormone receptor beta,CTD_human,10660344,T426I a new mutation in the thyroid hormone receptor beta gene in a sporadic patient with resistance to thyroid hormone and dysmorphism. Mutations in brief no. 192. Online.,0.6391118389412621,"T426I a new mutation in the <span class=""gene"" id=""10660344-0-28-57"">thyroid hormone receptor beta</span> gene in a sporadic patient with <span class=""disease"" id=""10660344-0-90-119"">resistance to thyroid hormone</span> and dysmorphism. Mutations in brief no. 192. Online.",CTD_human;HPO;ORPHANET
1,0,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,Type 2 diabetes,7076,TIMP1,TIMP-1,CTD_human,16023759,"Type 2 diabetes is characterised by reduced monocyte TIMP-1 mRNA levels, and a lower plasma MMP-9 to TIMP-1 protein ratio compared to controls, a pattern that would promote coronary plaque instability if reproduced within vascular plaque.",0.20082418035263896,"<span class=""disease"" id=""16023759-6-0-15"">Type 2 diabetes</span> is characterised by reduced monocyte <span class=""gene"" id=""16023759-6-53-59"">TIMP-1</span> mRNA levels, and a lower plasma MMP-9 to <span class=""gene"" id=""16023759-6-101-107"">TIMP-1</span> protein ratio compared to controls, a pattern that would promote coronary plaque instability if reproduced within vascular plaque.",CTD_human
1,0,Biomarker,C0034069,Pulmonary Fibrosis,disease,pulmonary fibrosis,7076,TIMP1,TIMP-1,CTD_human,21468558,Unbalanced MMP/TIMP-1 expression during the development of experimental pulmonary fibrosis with acute paraquat poisoning.,0.2,"Unbalanced MMP/<span class=""gene"" id=""21468558-0-15-21"">TIMP-1</span> expression during the development of experimental <span class=""disease"" id=""21468558-0-72-90"">pulmonary fibrosis</span> with acute paraquat poisoning.",CTD_human
1,0,Biomarker,C0027051,Myocardial Infarction,disease,MI,7077,TIMP2,TIMP-2,CTD_human,24358288,"TIMP-2 protein levels similarly increased in both MI groups, whereas TIMP-4 protein levels were significantly lower in the infarct region of hKO group.",0.20240702852328799,"<span class=""gene"" id=""24358288-14-0-6"">TIMP-2</span> protein levels similarly increased in both <span class=""disease"" id=""24358288-14-50-52"">MI</span> groups, whereas TIMP-4 protein levels were significantly lower in the infarct region of hKO group.",CTD_human
1,0,Biomarker,C0004096,Asthma,disease,asthma,7078,TIMP3,TIMP3,CTD_human,16926187,"Because remodeling of airway epithelium is a feature of chronic asthma, the up-regulation of MMP10 and TIMP3 by NPS-NPSR1 signaling may be of relevance in the pathogenesis of asthma.",0.20054945356842604,"Because remodeling of airway epithelium is a feature of chronic asthma, the up-regulation of MMP10 and <span class=""gene"" id=""16926187-8-103-108"">TIMP3</span> by NPS-NPSR1 signaling may be of relevance in the pathogenesis of <span class=""disease"" id=""16926187-8-175-181"">asthma</span>.",CTD_human
1,0,Biomarker,C0009319,Colitis,disease,colitis,7078,TIMP3,TIMP-3,CTD_human,24548422,"We aimed to study the expression of TACE, TIMP-3 and SIRT-1 at different stages of colitis and how TACE is regulated in response to SIRT-1 activation.",0.200274726784213,"We aimed to study the expression of TACE, <span class=""gene"" id=""24548422-4-42-48"">TIMP-3</span> and SIRT-1 at different stages of <span class=""disease"" id=""24548422-4-83-90"">colitis</span> and how TACE is regulated in response to SIRT-1 activation.",CTD_human
1,0,Biomarker,C0043121,Wernicke Encephalopathy,disease,Wernicke's encephalopathy,7086,TKT,Transketolase,CTD_human,3762968,Transketolase abnormality in tolazamide-induced Wernicke's encephalopathy.,0.20054945356842604,"<span class=""gene"" id=""3762968-0-0-13"">Transketolase</span> abnormality in tolazamide-induced <span class=""disease"" id=""3762968-0-48-73"">Wernicke's encephalopathy</span>.",CTD_human
1,0,Biomarker,C1458155,Mammary Neoplasms,group,breast tumors,7090,TLE3,TLE3,CTD_human,19075277,"mRNA levels of 10 BCAR genes (AKT1, AKT2, BCAR1, BCAR3, EGFR, ERBB2, GRB7, SRC, TLE3, and TRERF1) were measured in estrogen receptor-positive breast tumors using quantitative reverse-transcriptase polymerase chain reaction.",0.2,"mRNA levels of 10 BCAR genes (AKT1, AKT2, BCAR1, BCAR3, EGFR, ERBB2, GRB7, SRC, <span class=""gene"" id=""19075277-3-80-84"">TLE3</span>, and TRERF1) were measured in estrogen receptor-positive <span class=""disease"" id=""19075277-3-142-155"">breast tumors</span> using quantitative reverse-transcriptase polymerase chain reaction.",CTD_human
1,0,Biomarker,C0014457,Eosinophilia,disease,eosinophilia,7097,TLR2,TLR2,CTD_human,26882889,"Also, the TLR4 ligand LPS and TLR2 ligand like ?-glucan may be strong candidates for exacerbation of lung eosinophilia.",0.20054945356842604,"Also, the TLR4 ligand LPS and <span class=""gene"" id=""26882889-10-30-34"">TLR2</span> ligand like &beta;-glucan may be strong candidates for exacerbation of lung <span class=""disease"" id=""26882889-10-106-118"">eosinophilia</span>.",CTD_human
1,0,Biomarker,C0004153,Atherosclerosis,disease,atherosclerosis,7099,TLR4,TLR4,CTD_human,12124407,"The Asp299Gly TLR4 polymorphism, which attenuates receptor signaling and diminishes the inflammatory response to gram-negative pathogens, is associated with a decreased risk of atherosclerosis.",0.24130797448334304,"The Asp299Gly <span class=""gene"" id=""12124407-7-14-18"">TLR4</span> polymorphism, which attenuates receptor signaling and diminishes the inflammatory response to gram-negative pathogens, is associated with a decreased risk of <span class=""disease"" id=""12124407-7-177-192"">atherosclerosis</span>.",CTD_human
1,0,Biomarker,C0010346,Crohn Disease,disease,Crohn's disease,7099,TLR4,TLR4,CTD_human,17914947,"TLR2, TLR4 and TLR9 polymorphisms and Crohn's disease in a New Zealand Caucasian cohort.",0.26622947209187303,"TLR2, <span class=""gene"" id=""17914947-0-6-10"">TLR4</span> and TLR9 polymorphisms and <span class=""disease"" id=""17914947-0-38-53"">Crohn's disease</span> in a New Zealand Caucasian cohort.",CTD_human
1,0,Biomarker,C0011882,Diabetic Neuropathies,group,diabetic neuropathy,7099,TLR4,TLR4,CTD_human,14693986,Asp299Gly and Thr399Ile genotypes of the TLR4 gene are associated with a reduced prevalence of diabetic neuropathy in patients with type 2 diabetes.,0.28300763924902694,"Asp299Gly and Thr399Ile genotypes of the <span class=""gene"" id=""14693986-0-41-45"">TLR4</span> gene are associated with a reduced prevalence of <span class=""disease"" id=""14693986-0-95-114"">diabetic neuropathy</span> in patients with type 2 diabetes.",CTD_human
1,0,Biomarker,C0014457,Eosinophilia,disease,eosinophilia,7099,TLR4,TLR4,CTD_human,26882889,"Also, the TLR4 ligand LPS and TLR2 ligand like ?-glucan may be strong candidates for exacerbation of lung eosinophilia.",0.200274726784213,"Also, the <span class=""gene"" id=""26882889-10-10-14"">TLR4</span> ligand LPS and TLR2 ligand like &beta;-glucan may be strong candidates for exacerbation of lung <span class=""disease"" id=""26882889-10-106-118"">eosinophilia</span>.",CTD_human
1,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,7099,TLR4,TLR4,CTD_human,27292124,TLR4/MyD88/NF-?B signaling and PPAR-? within the paraventricular nucleus are involved in the effects of telmisartan in hypertension.,0.20433011601278,"<span class=""gene"" id=""27292124-0-0-4"">TLR4</span>/MyD88/NF-&kappa;B signaling and PPAR-&gamma; within the paraventricular nucleus are involved in the effects of telmisartan in <span class=""disease"" id=""27292124-0-119-131"">hypertension</span>.",CTD_human
1,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastasis,7099,TLR4,TLR4,CTD_human,22180778,"Accordingly, simultaneous examination of the expression of TLR4, MD-2 and CXCR7 in cancer tissues of colorectal carcinoma may provide valuable prognostic diagnosis of carcinoma growth and metastasis.",0.20357144819477,"Accordingly, simultaneous examination of the expression of <span class=""gene"" id=""22180778-9-59-63"">TLR4</span>, MD-2 and CXCR7 in cancer tissues of colorectal carcinoma may provide valuable prognostic diagnosis of carcinoma growth and <span class=""disease"" id=""22180778-9-188-198"">metastasis</span>.",CTD_human
1,0,Biomarker,C0242383,Age related macular degeneration,disease,age-related macular degeneration,7099,TLR4,Toll-like receptor 4,CTD_human,15829498,Toll-like receptor 4 variant D299G is associated with susceptibility to age-related macular degeneration.,0.21641641578653198,"<span class=""gene"" id=""15829498-0-0-20"">Toll-like receptor 4</span> variant D299G is associated with susceptibility to <span class=""disease"" id=""15829498-0-72-104"">age-related macular degeneration</span>.",CTD_human
1,0,Biomarker,C0243026,Sepsis,disease,sepsis,7099,TLR4,TLR4,CTD_human,20624996,This indicates that the antimicrobial activities induced though TLR4 are dispensable for survival but contribute to lethality late in the course of sepsis.,0.24315577968122,"This indicates that the antimicrobial activities induced though <span class=""gene"" id=""20624996-9-64-68"">TLR4</span> are dispensable for survival but contribute to lethality late in the course of <span class=""disease"" id=""20624996-9-148-154"">sepsis</span>.",CTD_human
1,0,Biomarker,C0340288,Stable angina,disease,SAP,7099,TLR4,TLR4,CTD_human,20981132,"(1) Expressions of TLR4, levels of TNF-? and MMP-9 were increased and the rate was rising from the control group, to SAP group and then to ACS group.",0.201648360705279,"(1) Expressions of <span class=""gene"" id=""20981132-6-19-23"">TLR4</span>, levels of TNF-&alpha; and MMP-9 were increased and the rate was rising from the control group, to <span class=""disease"" id=""20981132-6-117-120"">SAP</span> group and then to ACS group.",CTD_human
1,0,Biomarker,C0520459,Necrotizing Enterocolitis,disease,necrotizing enterocolitis,7099,TLR4,TLR4,CTD_human,23650378,Endothelial TLR4 activation impairs intestinal microcirculatory perfusion in necrotizing enterocolitis via eNOS-NO-nitrite signaling.,0.28793836598754496,"Endothelial <span class=""gene"" id=""23650378-0-12-16"">TLR4</span> activation impairs intestinal microcirculatory perfusion in <span class=""disease"" id=""23650378-0-77-102"">necrotizing enterocolitis</span> via eNOS-NO-nitrite signaling.",CTD_human
1,0,Biomarker,C0948089,Acute Coronary Syndrome,disease,acute coronary syndromes,7099,TLR4,TLR4,CTD_human,20981132,"The study aims to explore the relationship between expressions of toll-like receptor 4 (TLR4) on peripheral blood monocytes, serum tumor necrosis factor-alpha (TNF-?) and matrix metalloproteinase-9 (MMP-9) in patients with acute coronary syndromes(ACS), and to investigate the possible mechanisms of Benazepril stabilizing atherosclerosis plaques.",0.20974478378509498,"The study aims to explore the relationship between expressions of <span class=""gene"" id=""20981132-1-66-86"">toll-like receptor 4</span> (<span class=""gene"" id=""20981132-1-88-92"">TLR4</span>) on peripheral blood monocytes, serum tumor necrosis factor-alpha (TNF-&alpha;) and matrix metalloproteinase-9 (MMP-9) in patients with <span class=""disease"" id=""20981132-1-223-247"">acute coronary syndromes</span>(ACS), and to investigate the possible mechanisms of Benazepril stabilizing atherosclerosis plaques.",CTD_human
1,0,Biomarker,C1956346,Coronary Artery Disease,disease,coronary artery disease,7099,TLR4,Toll-like receptor 4,CTD_human,20524934,Expression of miR-146a/b is associated with the Toll-like receptor 4 signal in coronary artery disease: effect of renin-angiotensin system blockade and statins on miRNA-146a/b and Toll-like receptor 4 levels.,0.21472666768092602,"Expression of miR-146a/b is associated with the Toll-like receptor 4 signal in <span class=""disease"" id=""20524934-0-79-102"">coronary artery disease</span>: effect of renin-angiotensin system blockade and statins on miRNA-146a/b and <span class=""gene"" id=""20524934-0-180-200"">Toll-like receptor 4</span> levels.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,Hepatocellular Carcinoma,7099,TLR4,Toll-like Receptor 4,CTD_human,27022031,Toll-like Receptor 4 on Macrophage Promotes the Development of Steatohepatitis-related Hepatocellular Carcinoma in Mice.,0.203021994626344,"<span class=""gene"" id=""27022031-0-0-20"">Toll-like Receptor 4</span> on Macrophage Promotes the Development of Steatohepatitis-related <span class=""disease"" id=""27022031-0-87-111"">Hepatocellular Carcinoma</span> in Mice.",CTD_human
6,0,Therapeutic,C0019243,"Angioedemas, Hereditary",disease,HAE,710,SERPING1,C1-INH,CTD_human,23406939,"C1-INH replacement and specific inhibition of plasma kallikrein with ecallantide have been successful in the treatment of hereditary angioedema (HAE), a more common related disorder.",0.24749902291423198,"<span class=""gene"" id=""23406939-2-0-6"">C1-INH</span> replacement and specific inhibition of plasma kallikrein with ecallantide have been successful in the treatment of <span class=""disease"" id=""23406939-2-122-143"">hereditary angioedema</span> (<span class=""disease"" id=""23406939-2-145-148"">HAE</span>), a more common related disorder.",CTD_human
6,0,Therapeutic,C0019243,"Angioedemas, Hereditary",disease,HAE,710,SERPING1,C1-INH,CTD_human,23866957,"Acute attacks, which may occur many hours after a procedure, may be treated with C1-INH; icatibant, a bradykinin B2-receptor antagonist; or ecallantide, a kallikrein inhibitor, all of which have been shown to reduce the duration and severity of HAE attacks.",0.24749902291423198,"Acute attacks, which may occur many hours after a procedure, may be treated with <span class=""gene"" id=""23866957-9-81-87"">C1-INH</span>; icatibant, a bradykinin B2-receptor antagonist; or ecallantide, a kallikrein inhibitor, all of which have been shown to reduce the duration and severity of <span class=""disease"" id=""23866957-9-245-248"">HAE</span> attacks.",CTD_human
6,0,Biomarker,C0019243,"Angioedemas, Hereditary",disease,HAE,710,SERPING1,C1-INH,CTD_human,23406939,"C1-INH replacement and specific inhibition of plasma kallikrein with ecallantide have been successful in the treatment of hereditary angioedema (HAE), a more common related disorder.",0.24749902291423198,"<span class=""gene"" id=""23406939-2-0-6"">C1-INH</span> replacement and specific inhibition of plasma kallikrein with ecallantide have been successful in the treatment of <span class=""disease"" id=""23406939-2-122-143"">hereditary angioedema</span> (<span class=""disease"" id=""23406939-2-145-148"">HAE</span>), a more common related disorder.",CTD_human
6,0,Biomarker,C0019243,"Angioedemas, Hereditary",disease,HAE,710,SERPING1,C1-INH,CTD_human,23866957,"Acute attacks, which may occur many hours after a procedure, may be treated with C1-INH; icatibant, a bradykinin B2-receptor antagonist; or ecallantide, a kallikrein inhibitor, all of which have been shown to reduce the duration and severity of HAE attacks.",0.24749902291423198,"Acute attacks, which may occur many hours after a procedure, may be treated with <span class=""gene"" id=""23866957-9-81-87"">C1-INH</span>; icatibant, a bradykinin B2-receptor antagonist; or ecallantide, a kallikrein inhibitor, all of which have been shown to reduce the duration and severity of <span class=""disease"" id=""23866957-9-245-248"">HAE</span> attacks.",CTD_human
6,0,Therapeutic,C0019243,"Angioedemas, Hereditary",disease,HAE,710,SERPING1,C1-INH,CTD_human,23634741,"In the past, few treatment options were available; however, several new therapies with proven efficacy have recently become available to treat and prevent HAE attacks, such as plasma-derived and recombinant C1-INHs that replace the deficient protein, bradykinin receptor antagonist (icatibant) that blocks bradykinin activity and kallikrein inhibitor (ecallantide) that prevents bradykinin release.",0.24749902291423198,"In the past, few treatment options were available; however, several new therapies with proven efficacy have recently become available to treat and prevent <span class=""disease"" id=""23634741-4-155-158"">HAE</span> attacks, such as plasma-derived and recombinant <span class=""gene"" id=""23634741-4-207-213"">C1-INH</span>s that replace the deficient protein, bradykinin receptor antagonist (icatibant) that blocks bradykinin activity and kallikrein inhibitor (ecallantide) that prevents bradykinin release.",CTD_human
6,0,Biomarker,C0019243,"Angioedemas, Hereditary",disease,HAE,710,SERPING1,C1-INH,CTD_human,23634741,"In the past, few treatment options were available; however, several new therapies with proven efficacy have recently become available to treat and prevent HAE attacks, such as plasma-derived and recombinant C1-INHs that replace the deficient protein, bradykinin receptor antagonist (icatibant) that blocks bradykinin activity and kallikrein inhibitor (ecallantide) that prevents bradykinin release.",0.24749902291423198,"In the past, few treatment options were available; however, several new therapies with proven efficacy have recently become available to treat and prevent <span class=""disease"" id=""23634741-4-155-158"">HAE</span> attacks, such as plasma-derived and recombinant <span class=""gene"" id=""23634741-4-207-213"">C1-INH</span>s that replace the deficient protein, bradykinin receptor antagonist (icatibant) that blocks bradykinin activity and kallikrein inhibitor (ecallantide) that prevents bradykinin release.",CTD_human
2,0,Therapeutic,C2931758,Acquired angioedema,disease,acquired angioedema,710,SERPING1,C1-INH,CTD_human,23406939,Acquired C1 inhibitor (C1-INH) deficiency exposes patients to angioedema recurrences (acquired angioedema [AAE]) mediated by bradykinin pathway activation.,0.203021994626344,"Acquired C1 inhibitor (<span class=""gene"" id=""23406939-1-23-29"">C1-INH</span>) deficiency exposes patients to angioedema recurrences (<span class=""disease"" id=""23406939-1-86-105"">acquired angioedema</span> [AAE]) mediated by bradykinin pathway activation.",CTD_human
2,0,Biomarker,C2931758,Acquired angioedema,disease,acquired angioedema,710,SERPING1,C1-INH,CTD_human,23406939,Acquired C1 inhibitor (C1-INH) deficiency exposes patients to angioedema recurrences (acquired angioedema [AAE]) mediated by bradykinin pathway activation.,0.203021994626344,"Acquired C1 inhibitor (<span class=""gene"" id=""23406939-1-23-29"">C1-INH</span>) deficiency exposes patients to angioedema recurrences (<span class=""disease"" id=""23406939-1-86-105"">acquired angioedema</span> [AAE]) mediated by bradykinin pathway activation.",CTD_human
1,0,Biomarker,C0007193,"Cardiomyopathy, Dilated",group,dilated cardiomyopathy,7112,TMPO,lamina-associated polypeptide 2,CTD_human,16247757,Thymopoietin (lamina-associated polypeptide 2) gene mutation associated with dilated cardiomyopathy.,0.40300763924902705,"<span class=""gene"" id=""16247757-0-0-12"">Thymopoietin</span> (<span class=""gene"" id=""16247757-0-14-45"">lamina-associated polypeptide 2</span>) gene mutation associated with <span class=""disease"" id=""16247757-0-77-99"">dilated cardiomyopathy</span>.",CTD_human;HPO
2,0,Biomarker,C0001418,Adenocarcinoma,group,adenocarcinomas,7124,TNF,tumor necrosis factor alpha,CTD_human,19028472,"MEL exposure modulated the mitotic and apoptotic indices in the colonic adenocarcinomas that developed and lowered the immunohistochemical expression of nuclear factor kappa B, tumor necrosis factor alpha, interleukin-1beta and STAT3 in the epithelial malignancies.",0.224629508558291,"MEL exposure modulated the mitotic and apoptotic indices in the colonic <span class=""disease"" id=""19028472-5-72-87"">adenocarcinomas</span> that developed and lowered the immunohistochemical expression of nuclear factor kappa B, <span class=""gene"" id=""19028472-5-177-204"">tumor necrosis factor alpha</span>, interleukin-1beta and STAT3 in the epithelial malignancies.",CTD_human
2,0,Therapeutic,C0001418,Adenocarcinoma,group,adenocarcinomas,7124,TNF,tumor necrosis factor alpha,CTD_human,19028472,"MEL exposure modulated the mitotic and apoptotic indices in the colonic adenocarcinomas that developed and lowered the immunohistochemical expression of nuclear factor kappa B, tumor necrosis factor alpha, interleukin-1beta and STAT3 in the epithelial malignancies.",0.224629508558291,"MEL exposure modulated the mitotic and apoptotic indices in the colonic <span class=""disease"" id=""19028472-5-72-87"">adenocarcinomas</span> that developed and lowered the immunohistochemical expression of nuclear factor kappa B, <span class=""gene"" id=""19028472-5-177-204"">tumor necrosis factor alpha</span>, interleukin-1beta and STAT3 in the epithelial malignancies.",CTD_human
1,0,Biomarker,C0002395,Alzheimer's Disease,disease,Alzheimer disease,7124,TNF,TNF,CTD_human,17192785,"In addition to identifying the epsilon4 allele of APOE and related effects, we pinpointed over a dozen potential Alzheimer disease susceptibility genes (ACE, CHRNB2, CST3, ESR1, GAPDHS, IDE, MTHFR, NCSTN, PRNP, PSEN1, TF, TFAM and TNF) with statistically significant allelic summary odds ratios (ranging from 1.11-1.38 for risk alleles and 0.92-0.67 for protective alleles).",0.293671761026925,"In addition to identifying the epsilon4 allele of APOE and related effects, we pinpointed over a dozen potential <span class=""disease"" id=""17192785-5-113-130"">Alzheimer disease</span> susceptibility genes (ACE, CHRNB2, CST3, ESR1, GAPDHS, IDE, MTHFR, NCSTN, PRNP, PSEN1, TF, TFAM and <span class=""gene"" id=""17192785-5-231-234"">TNF</span>) with statistically significant allelic summary odds ratios (ranging from 1.11-1.38 for risk alleles and 0.92-0.67 for protective alleles).",CTD_human
1,0,Biomarker,C0002893,Refractory anemias,disease,refractory anemia,7124,TNF,tumor necrosis factor alpha,CTD_human,10870480,Effect of treatment with amifostine used as a single agent in patients with refractory anemia on clinical outcome and serum tumor necrosis factor alpha levels.,0.20762683742333699,"Effect of treatment with amifostine used as a single agent in patients with <span class=""disease"" id=""10870480-0-76-93"">refractory anemia</span> on clinical outcome and serum <span class=""gene"" id=""10870480-0-124-151"">tumor necrosis factor alpha</span> levels.",CTD_human
1,0,Biomarker,C0002895,"Anemia, Sickle Cell",disease,SCD,7124,TNF,TNF-alpha,CTD_human,14965870,These findings suggest that a HU-induced increase in TNF-alpha does not contribute to VOC and sickle cell patients can be counseled that the HU-induced increase in TNF-alpha does not counteract the beneficial effects of HU in SCD.,0.21105290517153,"These findings suggest that a HU-induced increase in <span class=""gene"" id=""14965870-10-53-62"">TNF-alpha</span> does not contribute to VOC and <span class=""disease"" id=""14965870-10-94-105"">sickle cell</span> patients can be counseled that the HU-induced increase in <span class=""gene"" id=""14965870-10-164-173"">TNF-alpha</span> does not counteract the beneficial effects of HU in <span class=""disease"" id=""14965870-10-226-229"">SCD</span>.",CTD_human
1,0,Biomarker,C0003123,Anorexia,disease,anorexia,7124,TNF,tumor necrosis factor-?,CTD_human,25392278,Role of tumor necrosis factor-? and interleukin-1? in anorexia induction following oral exposure to the trichothecene deoxynivalenol (vomitoxin) in the mouse.,0.201923087489492,"Role of <span class=""gene"" id=""25392278-0-8-31"">tumor necrosis factor-&alpha;</span> and interleukin-1&beta; in <span class=""disease"" id=""25392278-0-54-62"">anorexia</span> induction following oral exposure to the trichothecene deoxynivalenol (vomitoxin) in the mouse.",CTD_human
1,0,Biomarker,C0003165,Anthracosis,disease,coal workers' pneumoconiosis,7124,TNF,TNF?,CTD_human,20005085,Possible effect of gene polymorphisms on the release of TNF? and IL1 cytokines in coal workers' pneumoconiosis.,0.20701187132028098,"Possible effect of gene polymorphisms on the release of <span class=""gene"" id=""20005085-0-56-60"">TNF&alpha;</span> and IL1 cytokines in <span class=""disease"" id=""20005085-0-82-110"">coal workers' pneumoconiosis</span>.",CTD_human
2,0,Biomarker,C0003872,"Arthritis, Psoriatic",disease,PsA,7124,TNF,TNF,CTD_human,12746914,"TNF gene polymorphisms may be useful prognostic markers in PsA, and these results support the rationale for using anti-TNF treatment in patients with severe, progressive PsA.",0.238392879791957,"<span class=""gene"" id=""12746914-10-0-3"">TNF</span> gene polymorphisms may be useful prognostic markers in <span class=""disease"" id=""12746914-10-59-62"">PsA</span>, and these results support the rationale for using anti-TNF treatment in patients with severe, progressive <span class=""disease"" id=""12746914-10-170-173"">PsA</span>.",CTD_human
4,0,Biomarker,C0003873,Rheumatoid Arthritis,disease,rheumatoid arthritis,7124,TNF,TNF,CTD_human,8391952,TNF-alpha in rheumatoid arthritis and prospects of anti-TNF therapy.,0.50558989915553,"TNF-alpha in <span class=""disease"" id=""8391952-0-13-33"">rheumatoid arthritis</span> and prospects of anti-<span class=""gene"" id=""8391952-0-56-59"">TNF</span> therapy.",CTD_human
4,0,Biomarker,C0003873,Rheumatoid Arthritis,disease,RA,7124,TNF,TNF,CTD_human,2001072,"TNF thus appears an additional component of RA subclinical alveolitis in RA, but its prognostic value and its precise role in lung damage remain to be determined.",0.50558989915553,"<span class=""gene"" id=""2001072-7-0-3"">TNF</span> thus appears an additional component of <span class=""disease"" id=""2001072-7-44-46"">RA</span> subclinical alveolitis in <span class=""disease"" id=""2001072-7-73-75"">RA</span>, but its prognostic value and its precise role in lung damage remain to be determined.",CTD_human
4,0,Therapeutic,C0003873,Rheumatoid Arthritis,disease,rheumatoid arthritis,7124,TNF,TNFalpha,CTD_human,12566094,"Because interleukin-1beta (IL-1beta) and tumor necrosis factor-alpha (TNFalpha) are central to the progression of inflammation and joint tissue injury in patients with rheumatoid arthritis, we investigated human monocyte IL-1beta and TNFalpha responses after the addition of AjA to cells in vitro.",0.50558989915553,"Because interleukin-1beta (IL-1beta) and <span class=""gene"" id=""12566094-2-41-68"">tumor necrosis factor-alpha</span> (<span class=""gene"" id=""12566094-2-70-78"">TNFalpha</span>) are central to the progression of inflammation and joint tissue injury in patients with <span class=""disease"" id=""12566094-2-168-188"">rheumatoid arthritis</span>, we investigated human monocyte IL-1beta and <span class=""gene"" id=""12566094-2-234-242"">TNFalpha</span> responses after the addition of AjA to cells in vitro.",CTD_human
4,0,Biomarker,C0003873,Rheumatoid Arthritis,disease,rheumatoid arthritis,7124,TNF,TNFalpha,CTD_human,12566094,"Because interleukin-1beta (IL-1beta) and tumor necrosis factor-alpha (TNFalpha) are central to the progression of inflammation and joint tissue injury in patients with rheumatoid arthritis, we investigated human monocyte IL-1beta and TNFalpha responses after the addition of AjA to cells in vitro.",0.50558989915553,"Because interleukin-1beta (IL-1beta) and <span class=""gene"" id=""12566094-2-41-68"">tumor necrosis factor-alpha</span> (<span class=""gene"" id=""12566094-2-70-78"">TNFalpha</span>) are central to the progression of inflammation and joint tissue injury in patients with <span class=""disease"" id=""12566094-2-168-188"">rheumatoid arthritis</span>, we investigated human monocyte IL-1beta and <span class=""gene"" id=""12566094-2-234-242"">TNFalpha</span> responses after the addition of AjA to cells in vitro.",CTD_human
4,0,Therapeutic,C0003873,Rheumatoid Arthritis,disease,rheumatoid arthritis,7124,TNF,TNF,CTD_human,8391952,TNF-alpha in rheumatoid arthritis and prospects of anti-TNF therapy.,0.50558989915553,"TNF-alpha in <span class=""disease"" id=""8391952-0-13-33"">rheumatoid arthritis</span> and prospects of anti-<span class=""gene"" id=""8391952-0-56-59"">TNF</span> therapy.",CTD_human
4,0,Therapeutic,C0003873,Rheumatoid Arthritis,disease,RA,7124,TNF,TNF,CTD_human,2001072,"TNF thus appears an additional component of RA subclinical alveolitis in RA, but its prognostic value and its precise role in lung damage remain to be determined.",0.50558989915553,"<span class=""gene"" id=""2001072-7-0-3"">TNF</span> thus appears an additional component of <span class=""disease"" id=""2001072-7-44-46"">RA</span> subclinical alveolitis in <span class=""disease"" id=""2001072-7-73-75"">RA</span>, but its prognostic value and its precise role in lung damage remain to be determined.",CTD_human
5,0,Biomarker,C0004096,Asthma,disease,asthma,7124,TNF,tumor necrosis factor,CTD_human,14681301,Association of tumor necrosis factor polymorphisms with asthma and serum total IgE.,0.350678535044538,"Association of <span class=""gene"" id=""14681301-0-15-36"">tumor necrosis factor</span> polymorphisms with <span class=""disease"" id=""14681301-0-56-62"">asthma</span> and serum total IgE.",CTD_human
5,0,Biomarker,C0004096,Asthma,disease,asthma,7124,TNF,tumor necrosis factor,CTD_human,12356572,Role of tumor necrosis factor in toluene diisocyanate asthma.,0.350678535044538,"Role of <span class=""gene"" id=""12356572-0-8-29"">tumor necrosis factor</span> in toluene diisocyanate <span class=""disease"" id=""12356572-0-54-60"">asthma</span>.",CTD_human
5,0,Biomarker,C0004096,Asthma,disease,asthma,7124,TNF,TNFA,CTD_human,20049212,"The association between modeled NO(2) and asthma prevalence was significant for carriers of the most common genotypes of NQO1 rs2917666 [odds ratio (OR) = 1.54; 95% confidence interval (CI), 1.10-2.24], TNFA rs2844484 (OR = 2.02; 95% CI, 1.30-3.27).",0.350678535044538,"The association between modeled NO(2) and <span class=""disease"" id=""20049212-6-42-48"">asthma</span> prevalence was significant for carriers of the most common genotypes of NQO1 rs2917666 [odds ratio (OR) = 1.54; 95% confidence interval (CI), 1.10-2.24], <span class=""gene"" id=""20049212-6-203-207"">TNFA</span> rs2844484 (OR = 2.02; 95% CI, 1.30-3.27).",CTD_human
5,0,Biomarker,C0004096,Asthma,disease,asthma,7124,TNF,TNF,CTD_human,16456144,"The TNF-308 GG genotype may have a protective role in asthma pathogenesis, depending on airway oxidative stress levels.",0.350678535044538,"The <span class=""gene"" id=""16456144-11-4-7"">TNF</span>-308 GG genotype may have a protective role in <span class=""disease"" id=""16456144-11-54-60"">asthma</span> pathogenesis, depending on airway oxidative stress levels.",CTD_human
5,0,Biomarker,C0004096,Asthma,disease,asthma,7124,TNF,TNF,CTD_human,17450233,"Similarly, the A allele of the TNF-238 SNP was associated with increased asthma risk among children of nonsmoking parents (RR = 2.21; 95% CI, 1.14-4.30; p for interaction = 0.01).",0.350678535044538,"Similarly, the A allele of the <span class=""gene"" id=""17450233-8-31-34"">TNF</span>-238 SNP was associated with increased <span class=""disease"" id=""17450233-8-73-79"">asthma</span> risk among children of nonsmoking parents (RR = 2.21; 95% CI, 1.14-4.30; p for interaction = 0.01).",CTD_human
2,0,Biomarker,C0009319,Colitis,disease,colitis,7124,TNF,TNF-?,CTD_human,23810507,"Additionally, huperzine A was effective to reverse colitis-induced high lucigenin-enhanced CL values and serum TNF-? levels.",0.21509561775440303,"Additionally, huperzine A was effective to reverse <span class=""disease"" id=""23810507-13-51-58"">colitis</span>-induced high lucigenin-enhanced CL values and serum <span class=""gene"" id=""23810507-13-111-116"">TNF-&alpha;</span> levels.",CTD_human
1,0,Biomarker,C0015625,Fanconi Anemia,disease,FA,7124,TNF,tumour necrosis factor-?,CTD_human,22628295,"Prooxidant states were found in white blood cells and body fluids from FA patients as excess luminol-dependent chemiluminescence, 8-hydroxy-deoxyguanosine, reduced glutathione/oxidized glutathione imbalance, and tumour necrosis factor-?.",0.20821309277175895,"Prooxidant states were found in white blood cells and body fluids from <span class=""disease"" id=""22628295-6-71-73"">FA</span> patients as excess luminol-dependent chemiluminescence, 8-hydroxy-deoxyguanosine, reduced glutathione/oxidized glutathione imbalance, and <span class=""gene"" id=""22628295-6-212-236"">tumour necrosis factor-&alpha;</span>.",CTD_human
1,0,Biomarker,C0017638,Glioma,disease,glioma,7124,TNF,TNF-?,CTD_human,22199285,Resveratrol reduces TNF-?-induced U373MG human glioma cell invasion through regulating NF-?B activation and uPA/uPAR expression.,0.220590153438665,"Resveratrol reduces <span class=""gene"" id=""22199285-0-20-25"">TNF-&alpha;</span>-induced U373MG human <span class=""disease"" id=""22199285-0-47-53"">glioma</span> cell invasion through regulating NF-&kappa;B activation and uPA/uPAR expression.",CTD_human
4,0,Biomarker,C0018801,Heart failure,disease,Heart failure,7124,TNF,TNF-alpha,CTD_human,15135663,Heart failure may in fact be accentuated by a downregulation of myocardial TNF-alpha.,0.30387084074028103,"<span class=""disease"" id=""15135663-15-0-13"">Heart failure</span> may in fact be accentuated by a downregulation of myocardial <span class=""gene"" id=""15135663-15-75-84"">TNF-alpha</span>.",CTD_human
4,0,Biomarker,C0018801,Heart failure,disease,heart failure,7124,TNF,TNF-alpha,CTD_human,17337591,Tumor necrosis factor-alpha (TNF-alpha) is a proinflammatory cytokine that has been implicated in the pathogenesis of heart failure.,0.30387084074028103,"<span class=""gene"" id=""17337591-1-0-27"">Tumor necrosis factor-alpha</span> (<span class=""gene"" id=""17337591-1-29-38"">TNF-alpha</span>) is a proinflammatory cytokine that has been implicated in the pathogenesis of <span class=""disease"" id=""17337591-1-118-131"">heart failure</span>.",CTD_human
1,0,Biomarker,C0018995,Hemochromatosis,disease,hemochromatosis,7124,TNF,TNF-alpha,CTD_human,16793930,"TNF-alpha -308G>A allelic variant modulates iron accumulation in patients with hereditary (homozygous C282Y) hemochromatosis, but the effect of the TNF-alpha -308A allele on clinical manifestations of hemochromatosis was less accentuated than expected from the increased iron load associated with this allele.",0.21072702123000397,"TNF-alpha -308G&gt;A allelic variant modulates iron accumulation in patients with hereditary (homozygous C282Y) <span class=""disease"" id=""16793930-9-109-124"">hemochromatosis</span>, but the effect of the <span class=""gene"" id=""16793930-9-148-157"">TNF-alpha</span> -308A allele on clinical manifestations of <span class=""disease"" id=""16793930-9-201-216"">hemochromatosis</span> was less accentuated than expected from the increased iron load associated with this allele.",CTD_human
2,0,Biomarker,C0019151,Hepatic Encephalopathy,disease,hepatic encephalopathy,7124,TNF,tumor necrosis factor-alpha,CTD_human,16338762,Relationship between tumor necrosis factor-alpha and ammonia in patients with hepatic encephalopathy due to chronic liver failure.,0.2,"Relationship between <span class=""gene"" id=""16338762-0-21-48"">tumor necrosis factor-alpha</span> and ammonia in patients with <span class=""disease"" id=""16338762-0-78-100"">hepatic encephalopathy</span> due to chronic liver failure.",CTD_human
1,0,Biomarker,C0019187,"Hepatitis, Alcoholic",disease,alcoholic hepatitis,7124,TNF,TNF,CTD_human,12586603,"Thus, TNF-alpha-induced RANTES expression may have a critical role in cell-mediated liver injury associated with alcoholic hepatitis.",0.21220296946569503,"Thus, <span class=""gene"" id=""12586603-4-6-9"">TNF</span>-alpha-induced RANTES expression may have a critical role in cell-mediated liver injury associated with <span class=""disease"" id=""12586603-4-113-132"">alcoholic hepatitis</span>.",CTD_human
1,0,Biomarker,C0019202,Hepatolenticular Degeneration,disease,WD,7124,TNF,TNF?,CTD_human,25002079,"The serum IL6 {median (IQRs), 9.42(10.92) vs. 5.2(5.34) pg/ml; P=0.001}, IL8 {12.37(10.92) vs. 5.63(5.52) pg/ml; P<0.001}, IL10 {8.33(8.3) vs. 2.05(1.37) pg/ml; P=0.001} and TNF? {6.14(8.95) vs. 3.61(3.58) pg/ml; P<0.001} were also increased in WD patients compared to controls.",0.20054945356842604,"The serum IL6 {median (IQRs), 9.42(10.92) vs. 5.2(5.34) pg/ml; P=0.001}, IL8 {12.37(10.92) vs. 5.63(5.52) pg/ml; P&lt;0.001}, IL10 {8.33(8.3) vs. 2.05(1.37) pg/ml; P=0.001} and <span class=""gene"" id=""25002079-6-174-178"">TNF&alpha;</span> {6.14(8.95) vs. 3.61(3.58) pg/ml; P&lt;0.001} were also increased in <span class=""disease"" id=""25002079-6-245-247"">WD</span> patients compared to controls.",CTD_human
1,0,Biomarker,C0019284,Diaphragmatic Hernia,phenotype,diaphragmatic hernia,7124,TNF,tumor necrosis factor-alpha,CTD_human,10541330,Antenatal dexamethasone suppresses tumor necrosis factor-alpha expression in hypoplastic lung in nitrofen-induced diaphragmatic hernia in rats.,0.2,"Antenatal dexamethasone suppresses <span class=""gene"" id=""10541330-0-35-62"">tumor necrosis factor-alpha</span> expression in hypoplastic lung in nitrofen-induced <span class=""disease"" id=""10541330-0-114-134"">diaphragmatic hernia</span> in rats.",CTD_human
11,0,Biomarker,C0020429,Hyperalgesia,phenotype,hyperalgesia,7124,TNF,tumour necrosis factor alpha,CTD_human,7881729,"Post-treatment with S14080 dose-dependently antagonized the hyperalgesia induced by prostaglandin E2, bradykinin, dopamine and by the hyperalgesic cytokines reported to be released by carrageenin (tumour necrosis factor alpha, interleukin-1 and interleukin-8).3.",0.28054945356842603,"Post-treatment with S14080 dose-dependently antagonized the <span class=""disease"" id=""7881729-3-60-72"">hyperalgesia</span> induced by prostaglandin E2, bradykinin, dopamine and by the hyperalgesic cytokines reported to be released by carrageenin (<span class=""gene"" id=""7881729-3-197-225"">tumour necrosis factor alpha</span>, interleukin-1 and interleukin-8).3.",CTD_human
11,0,Biomarker,C0020429,Hyperalgesia,phenotype,hyperalgesia,7124,TNF,tumor necrosis factor alpha,CTD_human,16472913,"Neither of these inhibitors, however, affected tumor necrosis factor alpha, prostaglandin E2 or epinephrine hyperalgesia.",0.28054945356842603,"Neither of these inhibitors, however, affected <span class=""gene"" id=""16472913-5-47-74"">tumor necrosis factor alpha</span>, prostaglandin E2 or epinephrine <span class=""disease"" id=""16472913-5-108-120"">hyperalgesia</span>.",CTD_human
11,0,Biomarker,C0020429,Hyperalgesia,phenotype,hyperalgesia,7124,TNF,TNF,CTD_human,18463260,Endogenous tumor necrosis factor alpha (TNFalpha) requires TNF receptor type 2 to generate heat hyperalgesia in a mouse cancer model.,0.28054945356842603,"Endogenous <span class=""gene"" id=""18463260-0-11-38"">tumor necrosis factor alpha</span> (<span class=""gene"" id=""18463260-0-40-48"">TNFalpha</span>) requires <span class=""gene"" id=""18463260-0-59-62"">TNF</span> receptor type 2 to generate heat <span class=""disease"" id=""18463260-0-96-108"">hyperalgesia</span> in a mouse cancer model.",CTD_human
11,0,Biomarker,C0020429,Hyperalgesia,phenotype,hyperalgesia,7124,TNF,TNFalpha,CTD_human,18582539,"Thus, increased sensitization and up-regulation of TRPV1 constitutes a potential mechanism by which TNFalpha mediates inflammatory hyperalgesia and pain.",0.28054945356842603,"Thus, increased sensitization and up-regulation of TRPV1 constitutes a potential mechanism by which <span class=""gene"" id=""18582539-8-100-108"">TNFalpha</span> mediates inflammatory <span class=""disease"" id=""18582539-8-131-143"">hyperalgesia</span> and pain.",CTD_human
11,0,Biomarker,C0020429,Hyperalgesia,phenotype,Hyperalgesia,7124,TNF,tumor necrosis factor,CTD_human,12727271,"Hyperalgesia induced by both PLA(2)s was blocked by the histamine and serotonin receptor antagonists promethazine and methysergide, respectively, by the bradykinin B(2) receptor antagonist HOE 140 and by antibodies to tumor necrosis factor alfa (TNFalpha) and interleukin 1 (IL-1).",0.28054945356842603,"<span class=""disease"" id=""12727271-7-0-12"">Hyperalgesia</span> induced by both PLA(2)s was blocked by the histamine and serotonin receptor antagonists promethazine and methysergide, respectively, by the bradykinin B(2) receptor antagonist HOE 140 and by antibodies to <span class=""gene"" id=""12727271-7-218-239"">tumor necrosis factor</span> alfa (TNFalpha) and interleukin 1 (IL-1).",CTD_human
1,0,Biomarker,C0020437,Hypercalcemia,disease,hypercalcaemia,7124,TNF,tumour necrosis factor alpha,CTD_human,10638776,The patient had hypercalcaemia associated with increased calcitriol serum levels; circulating interleukin-6 and tumour necrosis factor alpha levels were also elevated.,0.20082418035263896,"The patient had <span class=""disease"" id=""10638776-3-16-30"">hypercalcaemia</span> associated with increased calcitriol serum levels; circulating interleukin-6 and <span class=""gene"" id=""10638776-3-112-140"">tumour necrosis factor alpha</span> levels were also elevated.",CTD_human
1,0,Biomarker,C0021390,Inflammatory Bowel Diseases,group,inflammatory bowel disease,7124,TNF,TNF-alpha,CTD_human,15086448,Tumour necrosis factor-alpha (TNF-alpha) plays a central role in the pathophysiology of inflammatory bowel disease.,0.266819084903542,"<span class=""gene"" id=""15086448-1-0-28"">Tumour necrosis factor-alpha</span> (<span class=""gene"" id=""15086448-1-30-39"">TNF-alpha</span>) plays a central role in the pathophysiology of <span class=""disease"" id=""15086448-1-88-114"">inflammatory bowel disease</span>.",CTD_human
1,0,Biomarker,C0022661,"Kidney Failure, Chronic",disease,ESRD,7124,TNF,tumor necrosis factor-alpha,CTD_human,19539174,Subcutaneous and visceral mRNA expressions of tumor necrosis factor-alpha and CD68 were significantly increased in the ESRD versus control group.,0.24125513859440603,"Subcutaneous and visceral mRNA expressions of <span class=""gene"" id=""19539174-8-46-73"">tumor necrosis factor-alpha</span> and CD68 were significantly increased in the <span class=""disease"" id=""19539174-8-119-123"">ESRD</span> versus control group.",CTD_human
2,0,Biomarker,C0023290,"Leishmaniasis, Visceral",disease,visceral leishmaniasis,7124,TNF,cachectin,CTD_human,1901333,Tumor necrosis factor (cachectin) in human visceral leishmaniasis.,0.201373633921065,"<span class=""gene"" id=""1901333-0-0-21"">Tumor necrosis factor</span> (<span class=""gene"" id=""1901333-0-23-32"">cachectin</span>) in human <span class=""disease"" id=""1901333-0-43-65"">visceral leishmaniasis</span>.",CTD_human
1,0,Biomarker,C0023860,Listeriosis,disease,infection by Listeria monocytogenes,7124,TNF,TNF,CTD_human,16751399,"Homozygotes are highly susceptible to infection by Listeria monocytogenes, confirming the essential role of TNF in innate immune defense.",0.20054945356842604,"Homozygotes are highly susceptible to <span class=""disease"" id=""16751399-5-38-73"">infection by Listeria monocytogenes</span>, confirming the essential role of <span class=""gene"" id=""16751399-5-108-111"">TNF</span> in innate immune defense.",CTD_human
1,0,Biomarker,C0024115,Lung diseases,group,lung disease,7124,TNF,TNF,CTD_human,11472967,"Before these experiments, there was no information available that would provide a basis for predicting whether or not TGF-beta(1) expression induces fibroproliferative lung disease in fibrogenic-resistant TNF-alphaRKO mice, an increasingly popular animal model.",0.20433011601278,"Before these experiments, there was no information available that would provide a basis for predicting whether or not TGF-beta(1) expression induces fibroproliferative <span class=""disease"" id=""11472967-8-168-180"">lung disease</span> in fibrogenic-resistant <span class=""gene"" id=""11472967-8-205-208"">TNF</span>-alphaRKO mice, an increasingly popular animal model.",CTD_human
2,0,Biomarker,C0024121,Lung Neoplasms,group,lung tumor,7124,TNF,TNFalpha,CTD_human,14587096,The genes encoding pro-inflammatory tumor necrosis factor-alpha (TNFalpha) and antiinflammatory IL-10 cytokines map within quantitative trait loci that regulate susceptibility to lung tumor development in mice; sensitive A/J and resistant C57BL/6J (B6) mice have different Tnfa and Il-10 alleles.,0.22389328714295997,"The genes encoding pro-inflammatory <span class=""gene"" id=""14587096-3-36-63"">tumor necrosis factor-alpha</span> (<span class=""gene"" id=""14587096-3-65-73"">TNFalpha</span>) and antiinflammatory IL-10 cytokines map within quantitative trait loci that regulate susceptibility to <span class=""disease"" id=""14587096-3-179-189"">lung tumor</span> development in mice; sensitive A/J and resistant C57BL/6J (B6) mice have different Tnfa and Il-10 alleles.",CTD_human
2,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastasis,7124,TNF,TNF?,CTD_human,23431386,"In this study, we showed that TNF? induces EMT in human HCT116 cells and thereby promotes colorectal cancer (CRC) invasion and metastasis.",0.22437081588301896,"In this study, we showed that <span class=""gene"" id=""23431386-4-30-34"">TNF&alpha;</span> induces EMT in human HCT116 cells and thereby promotes colorectal cancer (CRC) invasion and <span class=""disease"" id=""23431386-4-127-137"">metastasis</span>.",CTD_human
1,0,Biomarker,C0027796,Neuralgia,phenotype,neuropathic pain,7124,TNF,TNF-?,CTD_human,20846523,"Administration of spironolactone (10 and 20 mg/kg) significantly attenuated chronic constriction injury-induced pain related behaviour and foot deformity along with attenuation of TNF-? levels, without modulating vincristine-induced neuropathic pain.",0.201373633921065,"Administration of spironolactone (10 and 20 mg/kg) significantly attenuated chronic constriction injury-induced pain related behaviour and foot deformity along with attenuation of <span class=""gene"" id=""20846523-8-180-185"">TNF-&alpha;</span> levels, without modulating vincristine-induced <span class=""disease"" id=""20846523-8-233-249"">neuropathic pain</span>.",CTD_human
3,0,Biomarker,C0028754,Obesity,disease,obesity,7124,TNF,TNF,CTD_human,20141834,Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression.,0.32592628033514803,"Dietary and genetic <span class=""disease"" id=""20141834-0-20-27"">obesity</span> promote liver inflammation and tumorigenesis by enhancing IL-6 and <span class=""gene"" id=""20141834-0-95-98"">TNF</span> expression.",CTD_human
2,0,Biomarker,C0030193,Pain,phenotype,pain,7124,TNF,TNFalpha,CTD_human,18582539,"Thus, increased sensitization and up-regulation of TRPV1 constitutes a potential mechanism by which TNFalpha mediates inflammatory hyperalgesia and pain.",0.20467035533162303,"Thus, increased sensitization and up-regulation of TRPV1 constitutes a potential mechanism by which <span class=""gene"" id=""18582539-8-100-108"">TNFalpha</span> mediates inflammatory hyperalgesia and <span class=""disease"" id=""18582539-8-148-152"">pain</span>.",CTD_human
2,0,Biomarker,C0030193,Pain,phenotype,pain,7124,TNF,TNF-alpha,CTD_human,20383154,Intrathecal RvE1 injection also inhibits spontaneous pain and heat and mechanical hypersensitivity evoked by intrathecal capsaicin and tumor necrosis factor-alpha (TNF-alpha).,0.20467035533162303,"Intrathecal RvE1 injection also inhibits spontaneous <span class=""disease"" id=""20383154-5-53-57"">pain</span> and heat and mechanical hypersensitivity evoked by intrathecal capsaicin and <span class=""gene"" id=""20383154-5-135-162"">tumor necrosis factor-alpha</span> (<span class=""gene"" id=""20383154-5-164-173"">TNF-alpha</span>).",CTD_human
1,0,Biomarker,C0030567,Parkinson Disease,disease,Parkinson's Disease,7124,TNF,TNF-a,CTD_human,21318773,"Table 1 Biochemical Alterations in Substantia Nigra of Parkinson's Disease Indicating Oxidative Stress Elevated Decreased Iron (in microglia, astrocytes, oligodendrocytes, and melanized dopamine neurons and mitochondria) GSH (GSSG unchanged); GSH/GSSG ratio decreased Mitochondrial complex I Ferritin Calcium binding protein (calbindin 28) Mitochondrial monoamine oxidase B Transferrin and transferrin receptor Lipofuscin Vitamins E and C Ubiquitin Copper Cu/Zn-superoxide dismutase Cytotoxic cytokines (TNF-a, IL-1, IL-6) Inflammatory transcription factor NFKB Heme oxygenase-1 Ratio of oxidized to reduced glutathione (GSSG/GSH) Nitric oxide Neuromelanin.",0.234858233377182,"Table 1 Biochemical Alterations in Substantia Nigra of <span class=""disease"" id=""21318773-12-55-74"">Parkinson's Disease</span> Indicating Oxidative Stress Elevated Decreased Iron (in microglia, astrocytes, oligodendrocytes, and melanized dopamine neurons and mitochondria) GSH (GSSG unchanged); GSH/GSSG ratio decreased Mitochondrial complex I Ferritin Calcium binding protein (calbindin 28) Mitochondrial monoamine oxidase B Transferrin and transferrin receptor Lipofuscin Vitamins E and C Ubiquitin Copper Cu/Zn-superoxide dismutase Cytotoxic cytokines (<span class=""gene"" id=""21318773-12-504-509"">TNF-a</span>, IL-1, IL-6) Inflammatory transcription factor NFKB Heme oxygenase-1 Ratio of oxidized to reduced glutathione (GSSG/GSH) Nitric oxide Neuromelanin.",CTD_human
1,0,Therapeutic,C0032227,Pleural effusion disorder,group,pleural effusions,7124,TNF,tumor necrosis factor,CTD_human,2518282,"Rats injected with interleukin-1 (10 micrograms) and tumor necrosis factor (10 micrograms) and then exposed continuously to hyperoxia (greater than 99% O2, 1 atm) survived longer, had increased lung reduced/oxidized glutathione ratios, smaller pleural effusions, less pulmonary hypertension and improved arterial blood gases.",0.202681755307501,"Rats injected with interleukin-1 (10 micrograms) and <span class=""gene"" id=""2518282-1-53-74"">tumor necrosis factor</span> (10 micrograms) and then exposed continuously to hyperoxia (greater than 99% O2, 1 atm) survived longer, had increased lung reduced/oxidized glutathione ratios, smaller <span class=""disease"" id=""2518282-1-244-261"">pleural effusions</span>, less pulmonary hypertension and improved arterial blood gases.",CTD_human
1,0,Therapeutic,C0034063,Pulmonary Edema,phenotype,Pulmonary Edema,7124,TNF,TNF,CTD_human,21188088,The Dual Role of TNF in Pulmonary Edema.,0.2,"The Dual Role of <span class=""gene"" id=""21188088-0-17-20"">TNF</span> in <span class=""disease"" id=""21188088-0-24-39"">Pulmonary Edema</span>.",CTD_human
5,0,Biomarker,C0034069,Pulmonary Fibrosis,disease,PF,7124,TNF,TNF-alpha,CTD_human,17266442,"There were significant differences in cytokine (IL-8, IL-1beta, IL-6, TNF-alpha, IL-12) levels of BAL fluid between patients with PF and healthy controls.",0.21215181230838298,"There were significant differences in cytokine (IL-8, IL-1beta, IL-6, <span class=""gene"" id=""17266442-5-70-79"">TNF-alpha</span>, IL-12) levels of BAL fluid between patients with <span class=""disease"" id=""17266442-5-130-132"">PF</span> and healthy controls.",CTD_human
1,0,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,7124,TNF,TNF,CTD_human,16478754,The relationship between TNF levels and schizophrenia are discussed.,0.259538899092785,"The relationship between <span class=""gene"" id=""16478754-8-25-28"">TNF</span> levels and <span class=""disease"" id=""16478754-8-40-53"">schizophrenia</span> are discussed.",CTD_human
3,0,Biomarker,C0042109,Urticaria,disease,urticaria,7124,TNF,TNF-alpha,CTD_human,19250144,Association of TNF-alpha promoter polymorphisms with aspirin-induced urticaria.,0.202956482091714,"Association of <span class=""gene"" id=""19250144-0-15-24"">TNF-alpha</span> promoter polymorphisms with aspirin-induced <span class=""disease"" id=""19250144-0-69-78"">urticaria</span>.",CTD_human
1,0,Therapeutic,C0079218,"Fibromatosis, Aggressive",disease,desmoid tumor,7124,TNF,TNF,CTD_human,19944662,Common peroneal nerve palsy following TNF-based isolated limb perfusion for irresectable extremity desmoid tumor.,0.2,"Common peroneal nerve palsy following <span class=""gene"" id=""19944662-0-38-41"">TNF</span>-based isolated limb perfusion for irresectable extremity <span class=""disease"" id=""19944662-0-99-112"">desmoid tumor</span>.",CTD_human
1,0,Biomarker,C0085655,Polymyositis,disease,polymyositis,7124,TNF,tumor necrosis factor-alpha,CTD_human,7979221,"To evaluate the possible role of cytokines in human immunodeficiency virus (HIV)-associated muscular disorders, we performed immunocytochemistry for interleukin-1 alpha, -1 beta, and -6 and tumor necrosis factor-alpha on frozen muscle biopsy specimens from HIV-infected patients with various myopathies (HIV polymyositis in 5, HIV-wasting syndrome in 5, zidovudine myopathy in 10) and from seronegative individuals (normal muscle in 2, mitochondrial cytopathies in 10).",0.20575490709115804,"To evaluate the possible role of cytokines in human immunodeficiency virus (HIV)-associated muscular disorders, we performed immunocytochemistry for interleukin-1 alpha, -1 beta, and -6 and <span class=""gene"" id=""7979221-1-190-217"">tumor necrosis factor-alpha</span> on frozen muscle biopsy specimens from HIV-infected patients with various myopathies (HIV <span class=""disease"" id=""7979221-1-308-320"">polymyositis</span> in 5, HIV-wasting syndrome in 5, zidovudine myopathy in 10) and from seronegative individuals (normal muscle in 2, mitochondrial cytopathies in 10).",CTD_human
1,0,Biomarker,C0162557,"Liver Failure, Acute",disease,acute liver failure,7124,TNF,Tumour necrosis factor-alpha,CTD_human,19505222,Tumour necrosis factor-alpha and soluble Fas ligand as biomarkers in non-acetaminophen-induced acute liver failure.,0.20974478378509498,"<span class=""gene"" id=""19505222-0-0-28"">Tumour necrosis factor-alpha</span> and soluble Fas ligand as biomarkers in non-acetaminophen-induced <span class=""disease"" id=""19505222-0-95-114"">acute liver failure</span>.",CTD_human
3,0,Biomarker,C0243026,Sepsis,disease,sepsis,7124,TNF,tumour necrosis factor-alpha,CTD_human,8741040,Pentoxifylline reduces plasma tumour necrosis factor-alpha concentration in premature infants with sepsis.,0.36629720398512294,"Pentoxifylline reduces plasma <span class=""gene"" id=""8741040-0-30-58"">tumour necrosis factor-alpha</span> concentration in premature infants with <span class=""disease"" id=""8741040-0-99-105"">sepsis</span>.",CTD_human
3,0,Biomarker,C0243026,Sepsis,disease,sepsis,7124,TNF,TNF-alpha,CTD_human,9806674,"The proinflammatory cytokines, including tumor necrosis factor-alpha (TNF-alpha) and interferon-gamma (IFN-gamma), are increased in heart failure and sepsis, clinical conditions for which the IV anesthetic ketamine is useful.",0.36629720398512294,"The proinflammatory cytokines, including <span class=""gene"" id=""9806674-1-41-68"">tumor necrosis factor-alpha</span> (<span class=""gene"" id=""9806674-1-70-79"">TNF-alpha</span>) and interferon-gamma (IFN-gamma), are increased in heart failure and <span class=""disease"" id=""9806674-1-150-156"">sepsis</span>, clinical conditions for which the IV anesthetic ketamine is useful.",CTD_human
3,0,Biomarker,C0243026,Sepsis,disease,sepsis,7124,TNF,TNF,CTD_human,15489642,"These results indicate increased activity of TNF-alpha and MAPK following sepsis and demonstrate the beneficial effect of CMT-3 in preventing the increase in TNF-alpha, p38 MAPK, p42/44 MAPK, and the progression of septic shock.",0.36629720398512294,"These results indicate increased activity of <span class=""gene"" id=""15489642-10-45-48"">TNF</span>-alpha and MAPK following <span class=""disease"" id=""15489642-10-74-80"">sepsis</span> and demonstrate the beneficial effect of CMT-3 in preventing the increase in <span class=""gene"" id=""15489642-10-158-161"">TNF</span>-alpha, p38 MAPK, p42/44 MAPK, and the progression of septic shock.",CTD_human
1,0,Biomarker,C0268318,Cholestasis of pregnancy,disease,intrahepatic cholestasis of pregnancy,7124,TNF,tumor necrosis factor-?,CTD_human,23627780,Lithocholic acid-induced placental tumor necrosis factor-? upregulation and syncytiotrophoblast cell apoptosis in intrahepatic cholestasis of pregnancy.,0.200274726784213,"Lithocholic acid-induced placental <span class=""gene"" id=""23627780-0-35-58"">tumor necrosis factor-&alpha;</span> upregulation and syncytiotrophoblast cell apoptosis in <span class=""disease"" id=""23627780-0-114-151"">intrahepatic cholestasis of pregnancy</span>.",CTD_human
1,0,Biomarker,C0340288,Stable angina,disease,SAP,7124,TNF,TNF-?,CTD_human,20981132,"(1) Expressions of TLR4, levels of TNF-? and MMP-9 were increased and the rate was rising from the control group, to SAP group and then to ACS group.",0.20082418035263896,"(1) Expressions of TLR4, levels of <span class=""gene"" id=""20981132-6-35-40"">TNF-&alpha;</span> and MMP-9 were increased and the rate was rising from the control group, to <span class=""disease"" id=""20981132-6-117-120"">SAP</span> group and then to ACS group.",CTD_human
1,0,Biomarker,C0343755,HIV Wasting Syndrome,disease,HIV-wasting syndrome,7124,TNF,tumor necrosis factor-alpha,CTD_human,7979221,"To evaluate the possible role of cytokines in human immunodeficiency virus (HIV)-associated muscular disorders, we performed immunocytochemistry for interleukin-1 alpha, -1 beta, and -6 and tumor necrosis factor-alpha on frozen muscle biopsy specimens from HIV-infected patients with various myopathies (HIV polymyositis in 5, HIV-wasting syndrome in 5, zidovudine myopathy in 10) and from seronegative individuals (normal muscle in 2, mitochondrial cytopathies in 10).",0.200274726784213,"To evaluate the possible role of cytokines in human immunodeficiency virus (HIV)-associated muscular disorders, we performed immunocytochemistry for interleukin-1 alpha, -1 beta, and -6 and <span class=""gene"" id=""7979221-1-190-217"">tumor necrosis factor-alpha</span> on frozen muscle biopsy specimens from HIV-infected patients with various myopathies (HIV polymyositis in 5, <span class=""disease"" id=""7979221-1-327-347"">HIV-wasting syndrome</span> in 5, zidovudine myopathy in 10) and from seronegative individuals (normal muscle in 2, mitochondrial cytopathies in 10).",CTD_human
1,0,Biomarker,C0598608,Hyperhomocysteinemia,disease,hyperhomocysteinemia,7124,TNF,tumor necrosis factor-alpha,CTD_human,12615666,"Increased superoxide production in coronary arteries in hyperhomocysteinemia: role of tumor necrosis factor-alpha, NAD(P)H oxidase, and inducible nitric oxide synthase.",0.2,"Increased superoxide production in coronary arteries in <span class=""disease"" id=""12615666-0-56-76"">hyperhomocysteinemia</span>: role of <span class=""gene"" id=""12615666-0-86-113"">tumor necrosis factor-alpha</span>, NAD(P)H oxidase, and inducible nitric oxide synthase.",CTD_human
1,0,Biomarker,C0853897,Diabetic Cardiomyopathies,disease,diabetic cardiomyopathy,7124,TNF,Tumor necrosis factor-alpha,CTD_human,17909696,Tumor necrosis factor-alpha antagonism protects from myocardial inflammation and fibrosis in experimental diabetic cardiomyopathy.,0.2,"<span class=""gene"" id=""17909696-0-0-27"">Tumor necrosis factor-alpha</span> antagonism protects from myocardial inflammation and fibrosis in experimental <span class=""disease"" id=""17909696-0-106-129"">diabetic cardiomyopathy</span>.",CTD_human
1,0,Biomarker,C0948089,Acute Coronary Syndrome,disease,acute coronary syndromes,7124,TNF,tumor necrosis factor- alpha,CTD_human,20981132,"Expression of toll-like receptor 4, tumor necrosis factor- alpha, matrix metalloproteinase-9 and effects of benazepril in patients with acute coronary syndromes.",0.21220296946569503,"Expression of toll-like receptor 4, <span class=""gene"" id=""20981132-0-36-64"">tumor necrosis factor- alpha</span>, matrix metalloproteinase-9 and effects of benazepril in patients with <span class=""disease"" id=""20981132-0-136-160"">acute coronary syndromes</span>.",CTD_human
4,0,Therapeutic,C1261473,Sarcoma,disease,sarcoma,7124,TNF,TNF,CTD_human,16767912,"Many antineoplastic drugs have been associated to hyperthermia by isolation limb perfusion, the aim of this paper was to describe the results obtained with doxorubicin in association to hyperthermia with or without Tumor Necrosis Factor (TNF) alpha in order to identify the most effective regimen in the multidisciplinary treatment of soft tissue limb sarcoma.",0.203021994626344,"Many antineoplastic drugs have been associated to hyperthermia by isolation limb perfusion, the aim of this paper was to describe the results obtained with doxorubicin in association to hyperthermia with or without <span class=""gene"" id=""16767912-3-215-236"">Tumor Necrosis Factor</span> (<span class=""gene"" id=""16767912-3-238-241"">TNF</span>) alpha in order to identify the most effective regimen in the multidisciplinary treatment of soft tissue limb <span class=""disease"" id=""16767912-3-352-359"">sarcoma</span>.",CTD_human
4,0,Therapeutic,C1261473,Sarcoma,disease,sarcoma,7124,TNF,TNFalpha,CTD_human,17203757,A combination of doxorubicin and tumor necrosis factor alpha (TNFalpha) has been proven to be very effective in the perfusional treatment of advanced soft tissue limb sarcoma both in terms of tumor necrosis and limb conservative surgery rate.,0.203021994626344,"A combination of doxorubicin and <span class=""gene"" id=""17203757-1-33-60"">tumor necrosis factor alpha</span> (<span class=""gene"" id=""17203757-1-62-70"">TNFalpha</span>) has been proven to be very effective in the perfusional treatment of advanced soft tissue limb <span class=""disease"" id=""17203757-1-167-174"">sarcoma</span> both in terms of tumor necrosis and limb conservative surgery rate.",CTD_human
4,2,Biomarker,C0003873,Rheumatoid Arthritis,disease,rheumatoid arthritis,7128,TNFAIP3,TNFAIP3,CTD_human,21841782,A20 (TNFAIP3) deficiency in myeloid cells triggers erosive polyarthritis resembling rheumatoid arthritis.,0.24297359745464803,"A20 (<span class=""gene"" id=""21841782-0-5-12"">TNFAIP3</span>) deficiency in myeloid cells triggers erosive polyarthritis resembling <span class=""disease"" id=""21841782-0-84-104"">rheumatoid arthritis</span>.",CTD_human
4,3,Biomarker,C0024141,"Lupus Erythematosus, Systemic",disease,systemic lupus erythematosus,7128,TNFAIP3,TNFAIP3,CTD_human,21336280,Association of a functional variant downstream of TNFAIP3 with systemic lupus erythematosus.,0.223493799641443,"Association of a functional variant downstream of <span class=""gene"" id=""21336280-0-50-57"">TNFAIP3</span> with <span class=""disease"" id=""21336280-0-63-91"">systemic lupus erythematosus</span>.",CTD_human
4,3,Biomarker,C0024141,"Lupus Erythematosus, Systemic",disease,systemic lupus erythematosus,7128,TNFAIP3,TNFAIP3,CTD_human,19165918,Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus.,0.223493799641443,"Genetic variants near <span class=""gene"" id=""19165918-0-22-29"">TNFAIP3</span> on 6q23 are associated with <span class=""disease"" id=""19165918-0-58-86"">systemic lupus erythematosus</span>.",CTD_human
4,3,Biomarker,C0024141,"Lupus Erythematosus, Systemic",disease,systemic lupus erythematosus,7128,TNFAIP3,TNFAIP3,CTD_human,19165919,Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus.,0.223493799641443,"Multiple polymorphisms in the <span class=""gene"" id=""19165919-0-30-37"">TNFAIP3</span> region are independently associated with <span class=""disease"" id=""19165919-0-79-107"">systemic lupus erythematosus</span>.",CTD_human
1,0,Biomarker,C0004364,Autoimmune Diseases,group,autoimmune diseases,7132,TNFRSF1A,TNFR1,CTD_human,21074606,"Thus, our results suggest that TNFR1 mediates SBS and dysregulation of clock genes in autoimmune diseases.",0.201923087489492,"Thus, our results suggest that <span class=""gene"" id=""21074606-7-31-36"">TNFR1</span> mediates SBS and dysregulation of clock genes in <span class=""disease"" id=""21074606-7-86-105"">autoimmune diseases</span>.",CTD_human
1,0,Biomarker,C0010674,Cystic Fibrosis,disease,cystic fibrosis,7132,TNFRSF1A,TNFRSF1A,CTD_human,16463024,The TNFalpha receptor TNFRSF1A and genes encoding the amiloride-sensitive sodium channel ENaC as modulators in cystic fibrosis.,0.20541466777231498,"The TNFalpha receptor <span class=""gene"" id=""16463024-0-22-30"">TNFRSF1A</span> and genes encoding the amiloride-sensitive sodium channel ENaC as modulators in <span class=""disease"" id=""16463024-0-111-126"">cystic fibrosis</span>.",CTD_human
2,2,Biomarker,C0026769,Multiple Sclerosis,disease,multiple sclerosis,7132,TNFRSF1A,TNFRSF1A,CTD_human,19525953,"Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci.",0.218353858653341,"Meta-analysis of genome scans and replication identify CD6, IRF8 and <span class=""gene"" id=""19525953-0-69-77"">TNFRSF1A</span> as new <span class=""disease"" id=""19525953-0-85-103"">multiple sclerosis</span> susceptibility loci.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,7133,TNFRSF1B,tumor necrosis factor receptor II,CTD_human,16139734,"In sera from 35 persons with autism, among cytokines, only tumor necrosis factor receptor II was elevated compared with controls (P < 0.02).",0.2,"In sera from 35 persons with <span class=""disease"" id=""16139734-4-29-35"">autism</span>, among cytokines, only <span class=""gene"" id=""16139734-4-59-92"">tumor necrosis factor receptor II</span> was elevated compared with controls (P &lt; 0.02).",CTD_human
1,3,Biomarker,C0007193,"Cardiomyopathy, Dilated",group,dilated cardiomyopathy,7137,TNNI3,TNNI3,CTD_human,15070570,We used mutation analysis suitable for identification of both dominant and recessive mutations to investigate the sarcomeric gene for cardiac troponin I (TNNI3) in 235 patients with dilated cardiomyopathy.,0.4182228335840821,"We used mutation analysis suitable for identification of both dominant and recessive mutations to investigate the sarcomeric gene for <span class=""gene"" id=""15070570-3-134-152"">cardiac troponin I</span> (<span class=""gene"" id=""15070570-3-154-159"">TNNI3</span>) in 235 patients with <span class=""disease"" id=""15070570-3-182-204"">dilated cardiomyopathy</span>.",CTD_human;HPO
1,2,Biomarker,C0007196,Restrictive cardiomyopathy,disease,restrictive cardiomyopathy,7137,TNNI3,cardiac troponin I,CTD_human,12531876,Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations.,0.41362776054407296,"Idiopathic <span class=""disease"" id=""12531876-0-11-37"">restrictive cardiomyopathy</span> is part of the clinical expression of <span class=""gene"" id=""12531876-0-76-94"">cardiac troponin I</span> mutations.",CTD_human;HPO
1,0,Biomarker,C0027051,Myocardial Infarction,disease,MI,7137,TNNI3,cTnI,CTD_human,12359538,"Most patients with cTnI elevations meet CK-MB criteria for MI, as well as have a high incidence of underlying significant disease.",0.206015278498054,"Most patients with <span class=""gene"" id=""12359538-11-19-23"">cTnI</span> elevations meet CK-MB criteria for <span class=""disease"" id=""12359538-11-59-61"">MI</span>, as well as have a high incidence of underlying significant disease.",CTD_human
1,0,Biomarker,C0007194,Hypertrophic Cardiomyopathy,disease,HCM,7139,TNNT2,TNNT2,CTD_human,19087273,"Genotyping showed a heterozygous mis-sense mutation (275G>A) in the cardiac troponin T (TNNT2) gene, which is causally associated with HCM.",0.43881130829112297,"Genotyping showed a heterozygous mis-sense mutation (275G&gt;A) in the cardiac troponin T (<span class=""gene"" id=""19087273-7-88-93"">TNNT2</span>) gene, which is causally associated with <span class=""disease"" id=""19087273-7-135-138"">HCM</span>.",CTD_human;HPO
1,0,Biomarker,C0017638,Glioma,disease,gliomas,7153,TOP2A,DNA topoisomerase II-alpha,CTD_human,18402387,DNA topoisomerase II-alpha as a proliferation marker in human gliomas: correlation with PCNA expression and patient survival.,0.20300763924902696,"<span class=""gene"" id=""18402387-0-0-26"">DNA topoisomerase II-alpha</span> as a proliferation marker in human <span class=""disease"" id=""18402387-0-62-69"">gliomas</span>: correlation with PCNA expression and patient survival.",CTD_human
1,0,Biomarker,C0206686,Adrenocortical carcinoma,disease,adrenocortical carcinoma,7153,TOP2A,TOP2A,CTD_human,23533247,TOP2A is overexpressed and is a therapeutic target for adrenocortical carcinoma.,0.200274726784213,"<span class=""gene"" id=""23533247-0-0-5"">TOP2A</span> is overexpressed and is a therapeutic target for <span class=""disease"" id=""23533247-0-55-79"">adrenocortical carcinoma</span>.",CTD_human
4,0,Biomarker,C1458155,Mammary Neoplasms,group,breast tumors,7153,TOP2A,TOP2A,CTD_human,22204715,"We describe an approach for analyzing formalin-fixed, paraffin-embedded breast tumors on tissue microarrays with TOP2A fluorescence in situ hybridization coupled with cytokeratin immunofluorescence to target tumor cells.",0.22461056756064102,"We describe an approach for analyzing formalin-fixed, paraffin-embedded <span class=""disease"" id=""22204715-4-72-85"">breast tumors</span> on tissue microarrays with <span class=""gene"" id=""22204715-4-113-118"">TOP2A</span> fluorescence in situ hybridization coupled with cytokeratin immunofluorescence to target tumor cells.",CTD_human
1,0,Biomarker,C0282612,Prostatic Intraepithelial Neoplasias,disease,prostatic intraepithelial neoplasia,7155,TOP2B,TOP2B,CTD_human,20601956,"Finally, unlike normal prostate epithelium, prostatic intraepithelial neoplasia cells showed strong coexpression of androgen receptor and TOP2B.",0.2,"Finally, unlike normal prostate epithelium, <span class=""disease"" id=""20601956-5-44-79"">prostatic intraepithelial neoplasia</span> cells showed strong coexpression of androgen receptor and <span class=""gene"" id=""20601956-5-138-143"">TOP2B</span>.",CTD_human
3,1,Biomarker,C0001418,Adenocarcinoma,group,adenocarcinoma,7157,TP53,p53,CTD_human,10797276,"In adenocarcinoma, p53 mutation, in addition to stage, emerged as a significant predictor of poor cancer-related survival.",0.471775165972136,"In <span class=""disease"" id=""10797276-9-3-17"">adenocarcinoma</span>, <span class=""gene"" id=""10797276-9-19-22"">p53</span> mutation, in addition to stage, emerged as a significant predictor of poor cancer-related survival.",CTD_human
3,1,Therapeutic,C0001418,Adenocarcinoma,group,adenocarcinomas,7157,TP53,TP53,CTD_human,22484628,"Frequently mutated genes in the adenocarcinomas included TP53 (11/15 tumors), PIK3CA (3/15) and ARID1A (3/15).",0.471775165972136,"Frequently mutated genes in the <span class=""disease"" id=""22484628-3-32-47"">adenocarcinomas</span> included <span class=""gene"" id=""22484628-3-57-61"">TP53</span> (11/15 tumors), PIK3CA (3/15) and ARID1A (3/15).",CTD_human
3,1,Biomarker,C0001418,Adenocarcinoma,group,adenocarcinomas,7157,TP53,TP53,CTD_human,22484628,"Frequently mutated genes in the adenocarcinomas included TP53 (11/15 tumors), PIK3CA (3/15) and ARID1A (3/15).",0.471775165972136,"Frequently mutated genes in the <span class=""disease"" id=""22484628-3-32-47"">adenocarcinomas</span> included <span class=""gene"" id=""22484628-3-57-61"">TP53</span> (11/15 tumors), PIK3CA (3/15) and ARID1A (3/15).",CTD_human
3,1,Therapeutic,C0001418,Adenocarcinoma,group,adenocarcinoma,7157,TP53,p53,CTD_human,10797276,"In adenocarcinoma, p53 mutation, in addition to stage, emerged as a significant predictor of poor cancer-related survival.",0.471775165972136,"In <span class=""disease"" id=""10797276-9-3-17"">adenocarcinoma</span>, <span class=""gene"" id=""10797276-9-19-22"">p53</span> mutation, in addition to stage, emerged as a significant predictor of poor cancer-related survival.",CTD_human
1,0,Biomarker,C0002736,Amyotrophic Lateral Sclerosis,disease,ALS,7157,TP53,p53,CTD_human,17434459,These results indicate that p53 plays a functional role in oxidative stress-induced cell death and supports the possibility that elevated p53 could be involved in motor neuron death in ALS and the wobbler mouse.,0.201648360705279,"These results indicate that <span class=""gene"" id=""17434459-8-28-31"">p53</span> plays a functional role in oxidative stress-induced cell death and supports the possibility that elevated <span class=""gene"" id=""17434459-8-138-141"">p53</span> could be involved in motor neuron death in <span class=""disease"" id=""17434459-8-185-188"">ALS</span> and the wobbler mouse.",CTD_human
4,0,Biomarker,C0005695,Bladder Neoplasm,disease,bladder cancer,7157,TP53,p53,CTD_human,12376482,4-aminobiphenyl is a major etiological agent of human bladder cancer: evidence from its DNA binding spectrum in human p53 gene.,0.39921553818132505,"4-aminobiphenyl is a major etiological agent of human <span class=""disease"" id=""12376482-0-54-68"">bladder cancer</span>: evidence from its DNA binding spectrum in human <span class=""gene"" id=""12376482-0-118-121"">p53</span> gene.",CTD_human
4,0,Biomarker,C0005695,Bladder Neoplasm,disease,bladder tumors,7157,TP53,p53 tumor suppressor,CTD_human,9610789,We examined 19 cyclophosphamide-related bladder tumors to test the hypothesis that they might contain somatic mutations in the p53 tumor suppressor gene that could link a specific metabolite to the etiology of these cancers.,0.39921553818132505,"We examined 19 cyclophosphamide-related <span class=""disease"" id=""9610789-3-40-54"">bladder tumors</span> to test the hypothesis that they might contain somatic mutations in the <span class=""gene"" id=""9610789-3-127-147"">p53 tumor suppressor</span> gene that could link a specific metabolite to the etiology of these cancers.",CTD_human
4,0,Biomarker,C0005695,Bladder Neoplasm,disease,bladder cancer,7157,TP53,TP53,CTD_human,22929185,TP53 alteration associated with bladder cancer progression should be analyzed by both mutational and protein expression analysis.,0.39921553818132505,"<span class=""gene"" id=""22929185-10-0-4"">TP53</span> alteration associated with <span class=""disease"" id=""22929185-10-32-46"">bladder cancer</span> progression should be analyzed by both mutational and protein expression analysis.",CTD_human
4,0,Biomarker,C0005695,Bladder Neoplasm,disease,bladder cancer,7157,TP53,TP53,CTD_human,15906354,TP53 alterations and patterns of carcinogen exposure in a U.S. population-based study of bladder cancer.,0.39921553818132505,"<span class=""gene"" id=""15906354-0-0-4"">TP53</span> alterations and patterns of carcinogen exposure in a U.S. population-based study of <span class=""disease"" id=""15906354-0-89-103"">bladder cancer</span>.",CTD_human
3,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,NSCLC,7157,TP53,TP53,CTD_human,23435014,"While genetic changes in NSCLC are dominated by the effects of tobacco smoke, the increase of transversions in TP53 gene is consistent with a synergistic effect of asbestos.",0.29958211212783004,"While genetic changes in <span class=""disease"" id=""23435014-10-25-30"">NSCLC</span> are dominated by the effects of tobacco smoke, the increase of transversions in <span class=""gene"" id=""23435014-10-111-115"">TP53</span> gene is consistent with a synergistic effect of asbestos.",CTD_human
4,0,Biomarker,C0007134,Renal Cell Carcinoma,disease,renal cell carcinoma,7157,TP53,p53,CTD_human,17275163,Synergy of interferon-alpha and 5-fluorouracil in human renal cell carcinoma requires p53 activity.,0.43093554794949895,"Synergy of interferon-alpha and 5-fluorouracil in human <span class=""disease"" id=""17275163-0-56-76"">renal cell carcinoma</span> requires <span class=""gene"" id=""17275163-0-86-89"">p53</span> activity.",CTD_human;HPO
1,0,Biomarker,C0018923,Hemangiosarcoma,disease,angiosarcomas,7157,TP53,p53,CTD_human,10626228,"The pattern of modification followed the pattern of p53 mutations found in vinyl chloride-associated liver angiosarcomas in humans and rats, but only in regions that showed 100% homology with the human sequence.",0.28439562854740996,"The pattern of modification followed the pattern of <span class=""gene"" id=""10626228-10-52-55"">p53</span> mutations found in vinyl chloride-associated liver <span class=""disease"" id=""10626228-10-107-120"">angiosarcomas</span> in humans and rats, but only in regions that showed 100% homology with the human sequence.",CTD_human
1,0,Biomarker,C0021364,Male infertility,phenotype,male infertility,7157,TP53,TP53,CTD_human,22773013,Genetic variants in TP53 and MDM2 associated with male infertility in Chinese population.,0.20383181960166602,"Genetic variants in <span class=""gene"" id=""22773013-0-20-24"">TP53</span> and MDM2 associated with <span class=""disease"" id=""22773013-0-50-66"">male infertility</span> in Chinese population.",CTD_human
1,0,Biomarker,C0022593,Keratosis,disease,keratosis,7157,TP53,p53,CTD_human,16930632,"Association of specific p53 polymorphisms with keratosis in individuals exposed to arsenic through drinking water in West Bengal, India.",0.21275242303412098,"Association of specific <span class=""gene"" id=""16930632-0-24-27"">p53</span> polymorphisms with <span class=""disease"" id=""16930632-0-47-56"">keratosis</span> in individuals exposed to arsenic through drinking water in West Bengal, India.",CTD_human
1,0,Biomarker,C0023434,Chronic Lymphocytic Leukemia,disease,B-CLL,7157,TP53,p53,CTD_human,16439677,The induction of p53 by nutlin-3 in B-CLL samples was accompanied by alterations of the mitochondrial potential and activation of the caspase-dependent apoptotic pathway.,0.5123663095736479,"The induction of <span class=""gene"" id=""16439677-5-17-20"">p53</span> by nutlin-3 in <span class=""disease"" id=""16439677-5-36-41"">B-CLL</span> samples was accompanied by alterations of the mitochondrial potential and activation of the caspase-dependent apoptotic pathway.",CTD_human;ORPHANET
2,0,Biomarker,C0023903,Liver neoplasms,group,liver tumors,7157,TP53,p53,CTD_human,16410370,"The incidence of KRAS2 mutations in human compared to mouse lung tumors differed significantly, as did the incidence of Hras and p53 gene mutations in human compared to mouse liver tumors.",0.26902957582293996,"The incidence of KRAS2 mutations in human compared to mouse lung tumors differed significantly, as did the incidence of Hras and <span class=""gene"" id=""16410370-8-129-132"">p53</span> gene mutations in human compared to mouse <span class=""disease"" id=""16410370-8-175-187"">liver tumors</span>.",CTD_human
1,0,Biomarker,C0024117,Chronic Obstructive Airway Disease,disease,COPD,7157,TP53,p53,CTD_human,17274270,"These results illustrate the use of p53 immunoreactivity in the characterization of COPD, including mustard lung.",0.21045229444579103,"These results illustrate the use of <span class=""gene"" id=""17274270-8-36-39"">p53</span> immunoreactivity in the characterization of <span class=""disease"" id=""17274270-8-84-88"">COPD</span>, including mustard lung.",CTD_human
5,0,Therapeutic,C0024121,Lung Neoplasms,group,lung tumors,7157,TP53,p53,CTD_human,16410370,"The incidence of KRAS2 mutations in human compared to mouse lung tumors differed significantly, as did the incidence of Hras and p53 gene mutations in human compared to mouse liver tumors.",0.48968538869932793,"The incidence of KRAS2 mutations in human compared to mouse <span class=""disease"" id=""16410370-8-60-71"">lung tumors</span> differed significantly, as did the incidence of Hras and <span class=""gene"" id=""16410370-8-129-132"">p53</span> gene mutations in human compared to mouse liver tumors.",CTD_human
5,0,Biomarker,C0024121,Lung Neoplasms,group,lung tumors,7157,TP53,p53,CTD_human,16410370,"The incidence of KRAS2 mutations in human compared to mouse lung tumors differed significantly, as did the incidence of Hras and p53 gene mutations in human compared to mouse liver tumors.",0.48968538869932793,"The incidence of KRAS2 mutations in human compared to mouse <span class=""disease"" id=""16410370-8-60-71"">lung tumors</span> differed significantly, as did the incidence of Hras and <span class=""gene"" id=""16410370-8-129-132"">p53</span> gene mutations in human compared to mouse liver tumors.",CTD_human
3,0,Biomarker,C0025202,melanoma,disease,malignant melanoma,7157,TP53,p53 tumor-suppressor,CTD_human,21691232,Analysis of the functional integrity of the p53 tumor-suppressor gene in malignant melanoma.,0.314018175683955,"Analysis of the functional integrity of the <span class=""gene"" id=""21691232-0-44-64"">p53 tumor-suppressor</span> gene in <span class=""disease"" id=""21691232-0-73-91"">malignant melanoma</span>.",CTD_human
3,0,Biomarker,C0025202,melanoma,disease,melanoma,7157,TP53,p53,CTD_human,17210701,An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells.,0.314018175683955,"An organometallic protein kinase inhibitor pharmacologically activates <span class=""gene"" id=""17210701-0-71-74"">p53</span> and induces apoptosis in human <span class=""disease"" id=""17210701-0-106-114"">melanoma</span> cells.",CTD_human
1,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastasis,7157,TP53,p53,CTD_human,17949449,"In patients with Dukes'C colorectal cancer who underwent curative surgical resection of the primary tumour, followed by 5-FU-based adjuvant chemotherapy, p53 mutation status as assessed by gene sequencing is a significant predictor of overall and metastasis-free survival.",0.48274894761244297,"In patients with Dukes'C colorectal cancer who underwent curative surgical resection of the primary tumour, followed by 5-FU-based adjuvant chemotherapy, <span class=""gene"" id=""17949449-8-154-157"">p53</span> mutation status as assessed by gene sequencing is a significant predictor of overall and <span class=""disease"" id=""17949449-8-247-257"">metastasis</span>-free survival.",CTD_human
1,2,Biomarker,C0029463,Osteosarcoma,disease,osteosarcoma,7157,TP53,p53,CTD_human,16211088,Adenovirus-mediated p53 gene therapy in osteosarcoma cell lines: sensitization to cisplatin and doxorubicin.,0.548501340500107,"Adenovirus-mediated <span class=""gene"" id=""16211088-0-20-23"">p53</span> gene therapy in <span class=""disease"" id=""16211088-0-40-52"">osteosarcoma</span> cell lines: sensitization to cisplatin and doxorubicin.",CTD_human;HPO
1,2,Therapeutic,C0029463,Osteosarcoma,disease,osteosarcoma,7157,TP53,p53,CTD_human,16211088,Adenovirus-mediated p53 gene therapy in osteosarcoma cell lines: sensitization to cisplatin and doxorubicin.,0.548501340500107,"Adenovirus-mediated <span class=""gene"" id=""16211088-0-20-23"">p53</span> gene therapy in <span class=""disease"" id=""16211088-0-40-52"">osteosarcoma</span> cell lines: sensitization to cisplatin and doxorubicin.",CTD_human;HPO
1,0,Biomarker,C0033860,Psoriasis,disease,psoriasis,7157,TP53,p53,CTD_human,10384915,Expression of p53 protein before and after PUVA treatment in psoriasis.,0.20575490709115804,"Expression of <span class=""gene"" id=""10384915-0-14-17"">p53</span> protein before and after PUVA treatment in <span class=""disease"" id=""10384915-0-61-70"">psoriasis</span>.",CTD_human
2,0,Biomarker,C0036920,Sezary Syndrome,disease,Sézary syndrome,7157,TP53,TP53,CTD_human,26551667,"These analyses identified a distinctive pattern of somatic copy number alterations in Sézary syndrome, including highly prevalent chromosomal deletions involving the TP53, RB1, PTEN, DNMT3A and CDKN1B tumor suppressors.",0.20082418035263896,"These analyses identified a distinctive pattern of somatic copy number alterations in <span class=""disease"" id=""26551667-3-86-101"">S&eacute;zary syndrome</span>, including highly prevalent chromosomal deletions involving the <span class=""gene"" id=""26551667-3-166-170"">TP53</span>, RB1, PTEN, DNMT3A and CDKN1B tumor suppressors.",CTD_human
1,47,Biomarker,C0085390,Li-Fraumeni Syndrome,disease,LFS,7157,TP53,p53,CTD_human,25860607,"Here, we established patient-derived iPSCs from a Li-Fraumeni syndrome (LFS) family and investigated the role of mutant p53 in the development of osteosarcoma (OS).",0.52899238135773,"Here, we established patient-derived iPSCs from a <span class=""disease"" id=""25860607-2-50-70"">Li-Fraumeni syndrome</span> (<span class=""disease"" id=""25860607-2-72-75"">LFS</span>) family and investigated the role of mutant <span class=""gene"" id=""25860607-2-120-123"">p53</span> in the development of osteosarcoma (OS).",CTD_human;ORPHANET
2,0,Biomarker,C0149925,Small cell carcinoma of lung,disease,SCLC,7157,TP53,Tp53,CTD_human,22941188,"Finally, we detected many of the alterations found in humans in SCLC tumors from Tp53 and Rb1 double knockout mice.",0.424421973040331,"Finally, we detected many of the alterations found in humans in <span class=""disease"" id=""22941188-6-64-68"">SCLC</span> tumors from <span class=""gene"" id=""22941188-6-81-85"">Tp53</span> and Rb1 double knockout mice.",CTD_human;ORPHANET
1,0,Biomarker,C0206681,"Adenocarcinoma, Clear Cell",disease,clear cell adenocarcinomas,7157,TP53,p53,CTD_human,9754764,Bcl-2 protein expression associated with resistance to apoptosis in clear cell adenocarcinomas of the vagina and cervix expressing wild-type p53.,0.204055389228567,"Bcl-2 protein expression associated with resistance to apoptosis in <span class=""disease"" id=""9754764-0-68-94"">clear cell adenocarcinomas</span> of the vagina and cervix expressing wild-type <span class=""gene"" id=""9754764-0-141-144"">p53</span>.",CTD_human
1,0,Biomarker,C1168401,Squamous cell carcinoma of the head and neck,disease,HNSCC,7157,TP53,TP53,CTD_human,25086664,The TP53-3p interaction is specific to chromosome 3p and validates in HNSCC and pan-cancer cohorts.,0.255978751444843,"The <span class=""gene"" id=""25086664-4-4-8"">TP53</span>-3p interaction is specific to chromosome 3p and validates in <span class=""disease"" id=""25086664-4-70-75"">HNSCC</span> and pan-cancer cohorts.",CTD_human
6,2,Biomarker,C2239176,Liver carcinoma,disease,hepatocellular carcinomas,7157,TP53,p53,CTD_human,18477611,"We have therefore generated 'knock-in' mouse embryonic stem (ES) cells to investigate the effects of expressing a commonly found hot-spot p53 mutant, R246S -- the mouse equivalent of human R249S, which is associated with hepatocellular carcinomas.",0.672301092922579,"We have therefore generated 'knock-in' mouse embryonic stem (ES) cells to investigate the effects of expressing a commonly found hot-spot <span class=""gene"" id=""18477611-4-138-141"">p53</span> mutant, R246S -- the mouse equivalent of human R249S, which is associated with <span class=""disease"" id=""18477611-4-221-246"">hepatocellular carcinomas</span>.",CTD_human;HPO
6,2,Biomarker,C2239176,Liver carcinoma,disease,hepatocellular carcinomas,7157,TP53,p53,CTD_human,9029167,Highly metastatic hepatocellular carcinomas induced in male F344 rats treated with N-nitrosomorpholine in combination with other hepatocarcinogens show a high incidence of p53 gene mutations along with altered mRNA expression of tumor-related genes.,0.672301092922579,"Highly metastatic <span class=""disease"" id=""9029167-0-18-43"">hepatocellular carcinomas</span> induced in male F344 rats treated with N-nitrosomorpholine in combination with other hepatocarcinogens show a high incidence of <span class=""gene"" id=""9029167-0-172-175"">p53</span> gene mutations along with altered mRNA expression of tumor-related genes.",CTD_human;HPO
6,2,Therapeutic,C2239176,Liver carcinoma,disease,hepatocellular carcinomas,7157,TP53,p53,CTD_human,18477611,"We have therefore generated 'knock-in' mouse embryonic stem (ES) cells to investigate the effects of expressing a commonly found hot-spot p53 mutant, R246S -- the mouse equivalent of human R249S, which is associated with hepatocellular carcinomas.",0.672301092922579,"We have therefore generated 'knock-in' mouse embryonic stem (ES) cells to investigate the effects of expressing a commonly found hot-spot <span class=""gene"" id=""18477611-4-138-141"">p53</span> mutant, R246S -- the mouse equivalent of human R249S, which is associated with <span class=""disease"" id=""18477611-4-221-246"">hepatocellular carcinomas</span>.",CTD_human;HPO
6,2,Biomarker,C2239176,Liver carcinoma,disease,hepatocellular carcinoma,7157,TP53,p53,CTD_human,17191126,Different levels of p53 induced either apoptosis or cell cycle arrest in a doxycycline-regulated hepatocellular carcinoma cell line in vitro.,0.672301092922579,"Different levels of <span class=""gene"" id=""17191126-0-20-23"">p53</span> induced either apoptosis or cell cycle arrest in a doxycycline-regulated <span class=""disease"" id=""17191126-0-97-121"">hepatocellular carcinoma</span> cell line in vitro.",CTD_human;HPO
6,2,Therapeutic,C2239176,Liver carcinoma,disease,hepatocellular carcinoma,7157,TP53,p53,CTD_human,17191126,Different levels of p53 induced either apoptosis or cell cycle arrest in a doxycycline-regulated hepatocellular carcinoma cell line in vitro.,0.672301092922579,"Different levels of <span class=""gene"" id=""17191126-0-20-23"">p53</span> induced either apoptosis or cell cycle arrest in a doxycycline-regulated <span class=""disease"" id=""17191126-0-97-121"">hepatocellular carcinoma</span> cell line in vitro.",CTD_human;HPO
6,2,Therapeutic,C2239176,Liver carcinoma,disease,hepatocellular carcinomas,7157,TP53,p53,CTD_human,9029167,Highly metastatic hepatocellular carcinomas induced in male F344 rats treated with N-nitrosomorpholine in combination with other hepatocarcinogens show a high incidence of p53 gene mutations along with altered mRNA expression of tumor-related genes.,0.672301092922579,"Highly metastatic <span class=""disease"" id=""9029167-0-18-43"">hepatocellular carcinomas</span> induced in male F344 rats treated with N-nitrosomorpholine in combination with other hepatocarcinogens show a high incidence of <span class=""gene"" id=""9029167-0-172-175"">p53</span> gene mutations along with altered mRNA expression of tumor-related genes.",CTD_human;HPO
6,2,Biomarker,C2239176,Liver carcinoma,disease,hepatocellular carcinoma,7157,TP53,TP53,CTD_human,22675488,Aflatoxin-induced TP53 R249S mutation in hepatocellular carcinoma in Thailand: association with tumors developing in the absence of liver cirrhosis.,0.672301092922579,"Aflatoxin-induced <span class=""gene"" id=""22675488-0-18-22"">TP53</span> R249S mutation in <span class=""disease"" id=""22675488-0-41-65"">hepatocellular carcinoma</span> in Thailand: association with tumors developing in the absence of liver cirrhosis.",CTD_human;HPO
6,2,Therapeutic,C2239176,Liver carcinoma,disease,hepatocellular carcinoma,7157,TP53,TP53,CTD_human,22675488,Aflatoxin-induced TP53 R249S mutation in hepatocellular carcinoma in Thailand: association with tumors developing in the absence of liver cirrhosis.,0.672301092922579,"Aflatoxin-induced <span class=""gene"" id=""22675488-0-18-22"">TP53</span> R249S mutation in <span class=""disease"" id=""22675488-0-41-65"">hepatocellular carcinoma</span> in Thailand: association with tumors developing in the absence of liver cirrhosis.",CTD_human;HPO
1,0,Biomarker,C0002878,"Anemia, Hemolytic",disease,hemolytic anemia,7167,TPI1,TPI,CTD_human,2876430,"Triose-phosphate isomerase (TPI; D-glyceraldehyde-3-phosphate ketol-isomerase, EC 5.3.1.1) deficiency is a recessive disorder that results in hemolytic anemia and neuromuscular dysfunction.",0.401923087489492,"<span class=""gene"" id=""2876430-1-0-26"">Triose-phosphate isomerase</span> (<span class=""gene"" id=""2876430-1-28-31"">TPI</span>; D-glyceraldehyde-3-phosphate ketol-isomerase, EC 5.3.1.1) deficiency is a recessive disorder that results in <span class=""disease"" id=""2876430-1-142-158"">hemolytic anemia</span> and neuromuscular dysfunction.",CTD_human;HPO
1,0,Biomarker,C0279626,Squamous cell carcinoma of esophagus,disease,ESCC,7169,TPM2,TPM2,CTD_human,21517111,"Among these identified proteins, 33 proteins including keratin 17 (KRT17), biliverdin reductase B (BLVRB), proteasome activator subunit 1 (PSME1), manganese superoxide dismutase (MnSOD), high-mobility group box-1(HMGB1), heat shock protein 70 (HSP70), peroxiredoxin (PRDX1), keratin 13 (KRT13), and so on were overexpressed, and 14 proteins including cystatin B (CSTB), tropomyosin 2 (TPM2), annexin 1 (ANX1), transgelin (TAGLN), keratin 19 (KRT19), stratifin (SFN), and so on were down-expressed in ESCC.",0.2,"Among these identified proteins, 33 proteins including keratin 17 (KRT17), biliverdin reductase B (BLVRB), proteasome activator subunit 1 (PSME1), manganese superoxide dismutase (MnSOD), high-mobility group box-1(HMGB1), heat shock protein 70 (HSP70), peroxiredoxin (PRDX1), keratin 13 (KRT13), and so on were overexpressed, and 14 proteins including cystatin B (CSTB), <span class=""gene"" id=""21517111-5-370-383"">tropomyosin 2</span> (<span class=""gene"" id=""21517111-5-385-389"">TPM2</span>), annexin 1 (ANX1), transgelin (TAGLN), keratin 19 (KRT19), stratifin (SFN), and so on were down-expressed in <span class=""disease"" id=""21517111-5-500-504"">ESCC</span>.",CTD_human
1,2,Biomarker,C0242383,Age related macular degeneration,disease,age-related macular degeneration,717,C2,C2,CTD_human,16518403,Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration.,0.248308397315015,"Variation in factor B (BF) and complement component 2 (<span class=""gene"" id=""16518403-0-55-57"">C2</span>) genes is associated with <span class=""disease"" id=""16518403-0-84-116"">age-related macular degeneration</span>.",CTD_human
1,0,Biomarker,C0003949,Asbestosis,disease,asbestosis,7171,TPM4,TPM4,CTD_human,22537621,High plasma levels of tropomyosin 4 (TPM4: p<0.001) and peroxiredoxins 1 and 2 (PRX2: p<0.001) correlated with asbestos exposure or a diagnosis of asbestosis.,0.2,"High plasma levels of <span class=""gene"" id=""22537621-8-22-35"">tropomyosin 4</span> (<span class=""gene"" id=""22537621-8-37-41"">TPM4</span>: p&lt;0.001) and peroxiredoxins 1 and 2 (PRX2: p&lt;0.001) correlated with asbestos exposure or a diagnosis of <span class=""disease"" id=""22537621-8-147-157"">asbestosis</span>.",CTD_human
3,0,Biomarker,C0023530,Leukopenia,disease,leukopenia,7172,TPMT,TPMT,CTD_human,25108385,"In Koreans, this variant demonstrated sensitivity and specificity of 89.4% and 93.2%, respectively, for thiopurine-induced early leukopenia (in comparison to 12.1% and 97.6% for TPMT variants).",0.214978948062461,"In Koreans, this variant demonstrated sensitivity and specificity of 89.4% and 93.2%, respectively, for thiopurine-induced early <span class=""disease"" id=""25108385-6-129-139"">leukopenia</span> (in comparison to 12.1% and 97.6% for <span class=""gene"" id=""25108385-6-178-182"">TPMT</span> variants).",CTD_human
3,0,Biomarker,C0023530,Leukopenia,disease,neutropenia,7172,TPMT,thiopurine methyltransferase,CTD_human,18662289,The study confirmed the association of thiopurine methyltransferase heterozygosity with leucopenia and neutropenia in ALL patients and reported a significant association between inosine triphosphatase IVS2+21A-->C variants with thrombocytopenia (P = 0.012).,0.214978948062461,"The study confirmed the association of <span class=""gene"" id=""18662289-8-39-67"">thiopurine methyltransferase</span> heterozygosity with <span class=""disease"" id=""18662289-8-88-98"">leucopenia</span> and <span class=""disease"" id=""18662289-8-103-114"">neutropenia</span> in ALL patients and reported a significant association between inosine triphosphatase IVS2+21A--&gt;C variants with thrombocytopenia (P = 0.012).",CTD_human
3,0,Biomarker,C0023530,Leukopenia,disease,leucopenia,7172,TPMT,thiopurine S-methyltransferase,CTD_human,22535280,The variant genotype thiopurine S-methyltransferase has been associated with the occurrence of leucopenia.,0.214978948062461,"The variant genotype <span class=""gene"" id=""22535280-10-21-51"">thiopurine S-methyltransferase</span> has been associated with the occurrence of <span class=""disease"" id=""22535280-10-95-105"">leucopenia</span>.",CTD_human
1,0,Biomarker,C0027947,Neutropenia,disease,neutropenia,7172,TPMT,thiopurine methyltransferase,CTD_human,18662289,The study confirmed the association of thiopurine methyltransferase heterozygosity with leucopenia and neutropenia in ALL patients and reported a significant association between inosine triphosphatase IVS2+21A-->C variants with thrombocytopenia (P = 0.012).,0.203780662444353,"The study confirmed the association of <span class=""gene"" id=""18662289-8-39-67"">thiopurine methyltransferase</span> heterozygosity with leucopenia and <span class=""disease"" id=""18662289-8-103-114"">neutropenia</span> in ALL patients and reported a significant association between inosine triphosphatase IVS2+21A--&gt;C variants with thrombocytopenia (P = 0.012).",CTD_human
4,1,Biomarker,C0010308,Congenital Hypothyroidism,disease,congenital hypothyroidism,7173,TPO,TPO,CTD_human,17381485,Clinical and genetic characteristics of congenital hypothyroidism due to mutations in the thyroid peroxidase (TPO) gene in Israelis.,0.22056144268403102,"Clinical and genetic characteristics of <span class=""disease"" id=""17381485-0-40-65"">congenital hypothyroidism</span> due to mutations in the <span class=""gene"" id=""17381485-0-90-108"">thyroid peroxidase</span> (<span class=""gene"" id=""17381485-0-110-113"">TPO</span>) gene in Israelis.",CTD_human
4,1,Biomarker,C0010308,Congenital Hypothyroidism,disease,congenital hypothyroidism,7173,TPO,TPO,CTD_human,14751036,The objective of this study was to screen and subsequently identify TPO gene mutations in patients with congenital hypothyroidism with evidence of total iodine organification defects (TIOD) or partial iodine organification defect (PIOD) as defined by the perchlorate discharge test.,0.22056144268403102,"The objective of this study was to screen and subsequently identify <span class=""gene"" id=""14751036-2-68-71"">TPO</span> gene mutations in patients with <span class=""disease"" id=""14751036-2-104-129"">congenital hypothyroidism</span> with evidence of total iodine organification defects (TIOD) or partial iodine organification defect (PIOD) as defined by the perchlorate discharge test.",CTD_human
1,0,Biomarker,C0013363,Dysautonomia,disease,dysautonomia,7177,TPSAB1,TPSAB1,CTD_human,27749843,"Thus, our findings link duplications in TPSAB1 with irritable bowel syndrome, cutaneous complaints, connective tissue abnormalities, and dysautonomia.",0.2,"Thus, our findings link duplications in <span class=""gene"" id=""27749843-6-40-46"">TPSAB1</span> with irritable bowel syndrome, cutaneous complaints, connective tissue abnormalities, and <span class=""disease"" id=""27749843-6-137-149"">dysautonomia</span>.",CTD_human
1,0,Biomarker,C0022104,Irritable Bowel Syndrome,disease,irritable bowel syndrome,7177,TPSAB1,TPSAB1,CTD_human,27749843,"Thus, our findings link duplications in TPSAB1 with irritable bowel syndrome, cutaneous complaints, connective tissue abnormalities, and dysautonomia.",0.2,"Thus, our findings link duplications in <span class=""gene"" id=""27749843-6-40-46"">TPSAB1</span> with <span class=""disease"" id=""27749843-6-52-76"">irritable bowel syndrome</span>, cutaneous complaints, connective tissue abnormalities, and dysautonomia.",CTD_human
1,0,Biomarker,C1956346,Coronary Artery Disease,disease,non-CAD,7189,TRAF6,TRAF6,CTD_human,20524934,"Levels of miR-146a/b, IRAK1 mRNA, TRAF6 mRNA and TLR4 mRNA/TLR4 protein were significantly higher in the CAD group than in the non-CAD group (all P<0.01).",0.20054945356842604,"Levels of miR-146a/b, IRAK1 mRNA, <span class=""gene"" id=""20524934-7-34-39"">TRAF6</span> mRNA and TLR4 mRNA/TLR4 protein were significantly higher in the CAD group than in the <span class=""disease"" id=""20524934-7-127-134"">non-CAD</span> group (all P&lt;0.01).",CTD_human
1,0,Biomarker,C0266833,"Visceral Myopathy, Familial",disease,FVM,72,ACTG2,ACTG2,CTD_human,22960657,We identified the R148S variant in ACTG2 as a cause of FVM in one family.,0.400549453568426,"We identified the R148S variant in <span class=""gene"" id=""22960657-14-35-40"">ACTG2</span> as a cause of <span class=""disease"" id=""22960657-14-55-58"">FVM</span> in one family.",CTD_human;ORPHANET
2,0,Biomarker,C1608393,Megacystis microcolon intestinal hypoperistalsis syndrome,disease,MMIHS,72,ACTG2,ACTG2,CTD_human,24337657,"In conclusion, our study suggests a pathogenic mechanism for MMIHS by identifying causative ACTG2 mutations.",0.40137363392106606,"In conclusion, our study suggests a pathogenic mechanism for <span class=""disease"" id=""24337657-7-61-66"">MMIHS</span> by identifying causative <span class=""gene"" id=""24337657-7-92-97"">ACTG2</span> mutations.",CTD_human;ORPHANET
2,0,Biomarker,C1608393,Megacystis microcolon intestinal hypoperistalsis syndrome,disease,megacystis-microcolon-intestinal hypoperistalsis syndrome,72,ACTG2,ACTG2,CTD_human,24676022,Heterozygous de novo and inherited mutations in the smooth muscle actin (ACTG2) gene underlie megacystis-microcolon-intestinal hypoperistalsis syndrome.,0.40137363392106606,"Heterozygous de novo and inherited mutations in the smooth muscle actin (<span class=""gene"" id=""24676022-0-73-78"">ACTG2</span>) gene underlie <span class=""disease"" id=""24676022-0-94-151"">megacystis-microcolon-intestinal hypoperistalsis syndrome</span>.",CTD_human;ORPHANET
3,0,Therapeutic,C0002622,Amnesia,disease,amnesia,7200,TRH,TRH,CTD_human,7617693,"NS-3 improved amnesia caused by scopolamine, electroconvulsive shock (ECS), and cycloheximide (CXM), but TRH improved only the ECS-induced amnesia.",0.2,"NS-3 improved <span class=""disease"" id=""7617693-2-14-21"">amnesia</span> caused by scopolamine, electroconvulsive shock (ECS), and cycloheximide (CXM), but <span class=""gene"" id=""7617693-2-105-108"">TRH</span> improved only the ECS-induced <span class=""disease"" id=""7617693-2-139-146"">amnesia</span>.",CTD_human
3,0,Therapeutic,C0002622,Amnesia,disease,amnesia,7200,TRH,thyrotropin-releasing hormone,CTD_human,7562510,"In addition, coadministration of JTP-4819 and substance P, arginine-vasopressin or thyrotropin-releasing hormone (at doses at which each drug alone did not prolong the retention time) improved the retention time of rats with scopolamine-induced amnesia.",0.2,"In addition, coadministration of JTP-4819 and substance P, arginine-vasopressin or <span class=""gene"" id=""7562510-4-83-112"">thyrotropin-releasing hormone</span> (at doses at which each drug alone did not prolong the retention time) improved the retention time of rats with scopolamine-induced <span class=""disease"" id=""7562510-4-245-252"">amnesia</span>.",CTD_human
3,0,Therapeutic,C0002622,Amnesia,disease,amnesia,7200,TRH,TRH,CTD_human,8405091,"Repeated administration of TRH for 7 days at doses of 0.2-5 mg/kg s.c. elicited a dose-dependent recovery from amnesia induced by scopolamine, whereas only the group treated with 5 mg/kg/day showed a significant improvement.",0.2,"Repeated administration of <span class=""gene"" id=""8405091-4-27-30"">TRH</span> for 7 days at doses of 0.2-5 mg/kg s.c. elicited a dose-dependent recovery from <span class=""disease"" id=""8405091-4-111-118"">amnesia</span> induced by scopolamine, whereas only the group treated with 5 mg/kg/day showed a significant improvement.",CTD_human
1,0,Therapeutic,C0007370,Catalepsy,disease,catalepsy,7200,TRH,TRH,CTD_human,2547386,"RGH-2202 was 2-5 times more effective than TRH in improving the deficits of active avoidance performance and retention in mice, while it was weaker than TRH in modifying the haloperidol-induced catalepsy in mice and enhancing the spinal reflexes in rats.",0.2,"RGH-2202 was 2-5 times more effective than <span class=""gene"" id=""2547386-8-43-46"">TRH</span> in improving the deficits of active avoidance performance and retention in mice, while it was weaker than <span class=""gene"" id=""2547386-8-153-156"">TRH</span> in modifying the haloperidol-induced <span class=""disease"" id=""2547386-8-194-203"">catalepsy</span> in mice and enhancing the spinal reflexes in rats.",CTD_human
1,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,7200,TRH,TRH,CTD_human,6350720,"In addition, intraventricular administration of TRH, LHRH or LH caused tachycardia, hypertension and a reduction in the epinephrine-induced reflex bradycardia.",0.20082418035263896,"In addition, intraventricular administration of <span class=""gene"" id=""6350720-5-48-51"">TRH</span>, LHRH or LH caused tachycardia, <span class=""disease"" id=""6350720-5-84-96"">hypertension</span> and a reduction in the epinephrine-induced reflex bradycardia.",CTD_human
2,0,Biomarker,C0036572,Seizures,phenotype,seizure,7200,TRH,TRH,CTD_human,15781040,"PRI-2191 alone had no effect on gene expression, but it enhanced the seizure-evoked expression of HSP-70, had an opposite effect on BDNF mRNA level and did not affect prepro-TRH mRNA level.",0.20054945356842604,"PRI-2191 alone had no effect on gene expression, but it enhanced the <span class=""disease"" id=""15781040-7-69-76"">seizure</span>-evoked expression of HSP-70, had an opposite effect on BDNF mRNA level and did not affect prepro-<span class=""gene"" id=""15781040-7-174-177"">TRH</span> mRNA level.",CTD_human
2,0,Biomarker,C0036572,Seizures,phenotype,seizures,7200,TRH,thyrotropin-releasing hormone,CTD_human,10443546,Effects of pilocarpine- and kainate-induced seizures on thyrotropin-releasing hormone biosynthesis and receptors in the rat brain.,0.20054945356842604,"Effects of pilocarpine- and kainate-induced <span class=""disease"" id=""10443546-0-44-52"">seizures</span> on <span class=""gene"" id=""10443546-0-56-85"">thyrotropin-releasing hormone</span> biosynthesis and receptors in the rat brain.",CTD_human
1,0,Biomarker,C0038273,Stereotypic Movement Disorder,phenotype,stereotyped behavior,7200,TRH,TRH,CTD_human,8736133,"In contrast, CRH was anxiogenic and TRH appeared to induce stereotyped behavior.",0.2,"In contrast, CRH was anxiogenic and <span class=""gene"" id=""8736133-12-36-39"">TRH</span> appeared to induce <span class=""disease"" id=""8736133-12-59-79"">stereotyped behavior</span>.",CTD_human
2,0,Biomarker,C0040822,Tremor,phenotype,tremor,7200,TRH,TRH,CTD_human,103733,"20 microgram TRH injected bilaterally into the caudate-putamen, tuberculum olfactorium, nucleus accumbens, amygdala, lateral ventricles, midbrain or cerebral cortex failed to induce any increase in locomotor activity (measured using photocells), although other behavioural changes were observed after each injection, and included body shakes, limb tremor, repetitive head and limb movements, biting, scratching and an alert appearance.",0.2,"20 microgram <span class=""gene"" id=""103733-1-13-16"">TRH</span> injected bilaterally into the caudate-putamen, tuberculum olfactorium, nucleus accumbens, amygdala, lateral ventricles, midbrain or cerebral cortex failed to induce any increase in locomotor activity (measured using photocells), although other behavioural changes were observed after each injection, and included body <span class=""disease"" id=""103733-1-335-341"">shakes</span>, limb <span class=""disease"" id=""103733-1-348-354"">tremor</span>, repetitive head and limb movements, biting, scratching and an alert appearance.",CTD_human
2,0,Biomarker,C0040822,Tremor,phenotype,tremor,7200,TRH,TRH,CTD_human,416961,"Similarly, of these peptides only TRH and MK-771 induced a tremor of the forepaws in pentobarbital-anesthetized mice.",0.2,"Similarly, of these peptides only <span class=""gene"" id=""416961-3-34-37"">TRH</span> and MK-771 induced a <span class=""disease"" id=""416961-3-59-65"">tremor</span> of the forepaws in pentobarbital-anesthetized mice.",CTD_human
2,0,Therapeutic,C0040822,Tremor,phenotype,tremor,7200,TRH,TRH,CTD_human,416961,"Similarly, of these peptides only TRH and MK-771 induced a tremor of the forepaws in pentobarbital-anesthetized mice.",0.2,"Similarly, of these peptides only <span class=""gene"" id=""416961-3-34-37"">TRH</span> and MK-771 induced a <span class=""disease"" id=""416961-3-59-65"">tremor</span> of the forepaws in pentobarbital-anesthetized mice.",CTD_human
2,0,Therapeutic,C0040822,Tremor,phenotype,tremor,7200,TRH,TRH,CTD_human,103733,"20 microgram TRH injected bilaterally into the caudate-putamen, tuberculum olfactorium, nucleus accumbens, amygdala, lateral ventricles, midbrain or cerebral cortex failed to induce any increase in locomotor activity (measured using photocells), although other behavioural changes were observed after each injection, and included body shakes, limb tremor, repetitive head and limb movements, biting, scratching and an alert appearance.",0.2,"20 microgram <span class=""gene"" id=""103733-1-13-16"">TRH</span> injected bilaterally into the caudate-putamen, tuberculum olfactorium, nucleus accumbens, amygdala, lateral ventricles, midbrain or cerebral cortex failed to induce any increase in locomotor activity (measured using photocells), although other behavioural changes were observed after each injection, and included body <span class=""disease"" id=""103733-1-335-341"">shakes</span>, limb <span class=""disease"" id=""103733-1-348-354"">tremor</span>, repetitive head and limb movements, biting, scratching and an alert appearance.",CTD_human
1,0,Biomarker,C0005586,Bipolar Disorder,disease,bipolar disorder,7222,TRPC3,TRPC3,CTD_human,23602965,Chronic oxidative stress modulates TRPC3 and TRPM2 channel expression and function in rat primary cortical neurons: relevance to the pathophysiology of bipolar disorder.,0.200274726784213,"Chronic oxidative stress modulates <span class=""gene"" id=""23602965-0-35-40"">TRPC3</span> and TRPM2 channel expression and function in rat primary cortical neurons: relevance to the pathophysiology of <span class=""disease"" id=""23602965-0-152-168"">bipolar disorder</span>.",CTD_human
1,0,Biomarker,C0005586,Bipolar Disorder,disease,bipolar disorder,7226,TRPM2,TRPM2,CTD_human,23602965,Chronic oxidative stress modulates TRPC3 and TRPM2 channel expression and function in rat primary cortical neurons: relevance to the pathophysiology of bipolar disorder.,0.20974478378509498,"Chronic oxidative stress modulates TRPC3 and <span class=""gene"" id=""23602965-0-45-50"">TRPM2</span> channel expression and function in rat primary cortical neurons: relevance to the pathophysiology of <span class=""disease"" id=""23602965-0-152-168"">bipolar disorder</span>.",CTD_human
2,0,Biomarker,C0376634,Craniofacial Abnormalities,group,craniofacial abnormalities,7227,TRPS1,TRPS1,CTD_human,19759027,"Mutations in the TRPS1 gene are responsible for human tricho-rhino-phalangeal syndrome, which is characterized by skeletal and craniofacial abnormalities.",0.200274726784213,"Mutations in the <span class=""gene"" id=""19759027-2-17-22"">TRPS1</span> gene are responsible for human tricho-rhino-phalangeal syndrome, which is characterized by skeletal and <span class=""disease"" id=""19759027-2-127-153"">craniofacial abnormalities</span>.",CTD_human
1,0,Biomarker,C0007137,Squamous cell carcinoma,disease,squamous cell carcinoma,7248,TSC1,TSC,CTD_human,18538015,Involvement of TSC genes and differential expression of other members of the mTOR signaling pathway in oral squamous cell carcinoma.,0.20767799458065,"Involvement of <span class=""gene"" id=""18538015-0-15-18"">TSC</span> genes and differential expression of other members of the mTOR signaling pathway in oral <span class=""disease"" id=""18538015-0-108-131"">squamous cell carcinoma</span>.",CTD_human
1,0,Biomarker,C0009241,Cognition Disorders,group,Cognitive deficits,7248,TSC1,Tsc1,CTD_human,18067135,Cognitive deficits in Tsc1+/- mice in the absence of cerebral lesions and seizures.,0.2,"<span class=""disease"" id=""18067135-0-0-18"">Cognitive deficits</span> in <span class=""gene"" id=""18067135-0-22-26"">Tsc1</span>+/- mice in the absence of cerebral lesions and seizures.",CTD_human
2,0,Biomarker,C0014544,Epilepsy,disease,epilepsy,7248,TSC1,Tsc1,CTD_human,21062901,Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex.,0.40384617497898295,"Tsc2 gene inactivation causes a more severe <span class=""disease"" id=""21062901-0-44-52"">epilepsy</span> phenotype than <span class=""gene"" id=""21062901-0-68-72"">Tsc1</span> inactivation in a mouse model of tuberous sclerosis complex.",CTD_human;HPO
3,41,Biomarker,C0041341,Tuberous Sclerosis,disease,TSC,7248,TSC1,TSC1,CTD_human,18345974,"Tuberous sclerosis complex (TSC) is an inherited disorder resulting from mutations in one of two genes, TSC1 (Hamartin) and TSC2 (Tuberin).",0.508357491882061,"<span class=""disease"" id=""18345974-1-0-26"">Tuberous sclerosis complex</span> (<span class=""disease"" id=""18345974-1-28-31"">TSC</span>) is an inherited disorder resulting from mutations in one of two genes, <span class=""gene"" id=""18345974-1-104-108"">TSC1</span> (Hamartin) and TSC2 (Tuberin).",CTD_human;ORPHANET
3,41,Biomarker,C0041341,Tuberous Sclerosis,disease,tuberous sclerosis complex,7248,TSC1,Tsc1,CTD_human,21062901,Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex.,0.508357491882061,"Tsc2 gene inactivation causes a more severe epilepsy phenotype than <span class=""gene"" id=""21062901-0-68-72"">Tsc1</span> inactivation in a mouse model of <span class=""disease"" id=""21062901-0-106-132"">tuberous sclerosis complex</span>.",CTD_human;ORPHANET
3,41,Biomarker,C0041341,Tuberous Sclerosis,disease,TSC,7248,TSC1,TSC1,CTD_human,21345208,"Tuberous sclerosis complex (TSC) is an autosomal dominant neurogenetic disorder caused by mutations in one of two genes, TSC1 or TSC2, which encode the proteins hamartin and tuberin, respectively 123.",0.508357491882061,"<span class=""disease"" id=""21345208-1-0-26"">Tuberous sclerosis complex</span> (<span class=""disease"" id=""21345208-1-28-31"">TSC</span>) is an autosomal dominant neurogenetic disorder caused by mutations in one of two genes, <span class=""gene"" id=""21345208-1-121-125"">TSC1</span> or TSC2, which encode the proteins hamartin and tuberin, respectively 123.",CTD_human;ORPHANET
1,0,Biomarker,C1846385,FOCAL CORTICAL DYSPLASIA OF TAYLOR,disease,Focal cortical dysplasia of Taylor,7248,TSC1,TSC1,CTD_human,12112044,Focal cortical dysplasia of Taylor's balloon cell type: mutational analysis of the TSC1 gene indicates a pathogenic relationship to tuberous sclerosis.,0.40027472678421294,"<span class=""disease"" id=""12112044-0-0-34"">Focal cortical dysplasia of Taylor</span>'s balloon cell type: mutational analysis of the <span class=""gene"" id=""12112044-0-83-87"">TSC1</span> gene indicates a pathogenic relationship to tuberous sclerosis.",CTD_human;ORPHANET
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,7249,TSC2,TSC2,CTD_human,14627686,"Association of INPP1, PIK3CG, and TSC2 gene variants with autistic disorder: implications for phosphatidylinositol signalling in autism.",0.484106546385879,"Association of INPP1, PIK3CG, and <span class=""gene"" id=""14627686-0-34-38"">TSC2</span> gene variants with <span class=""disease"" id=""14627686-0-58-75"">autistic disorder</span>: implications for phosphatidylinositol signalling in <span class=""disease"" id=""14627686-0-129-135"">autism</span>.",CTD_human;HPO
1,0,Biomarker,C0014544,Epilepsy,disease,epilepsy,7249,TSC2,Tsc2,CTD_human,21062901,Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex.,0.406253203502271,"<span class=""gene"" id=""21062901-0-0-4"">Tsc2</span> gene inactivation causes a more severe <span class=""disease"" id=""21062901-0-44-52"">epilepsy</span> phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex.",CTD_human;HPO
3,0,Biomarker,C0022665,Kidney Neoplasm,disease,renal tumors,7249,TSC2,Tsc2,CTD_human,12110509,High extracellular signal-regulated kinase (ERK) activity occurred in the OSOM of Tsc2(EK/+) rats at 4 mo and in TGHQ-induced renal tumors.,0.202197814273705,"High extracellular signal-regulated kinase (ERK) activity occurred in the OSOM of <span class=""gene"" id=""12110509-3-82-86"">Tsc2</span>(EK/+) rats at 4 mo and in TGHQ-induced <span class=""disease"" id=""12110509-3-126-138"">renal tumors</span>.",CTD_human
1,0,Biomarker,C0036572,Seizures,phenotype,seizures,7249,TSC2,Tsc2,CTD_human,21062901,"However, Tsc2(GFAP1)CKO mice had an earlier onset and higher frequency of seizures, as well as significantly more severe histological abnormalities, compared with Tsc1(GFAP1)CKO mice.",0.40219781427370505,"However, <span class=""gene"" id=""21062901-6-9-13"">Tsc2</span>(GFAP1)CKO mice had an earlier onset and higher frequency of <span class=""disease"" id=""21062901-6-74-82"">seizures</span>, as well as significantly more severe histological abnormalities, compared with Tsc1(GFAP1)CKO mice.",CTD_human;HPO
4,91,Biomarker,C0041341,Tuberous Sclerosis,disease,tuberous sclerosis complex,7249,TSC2,Tsc2,CTD_human,21062901,Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex.,0.538360280812339,"<span class=""gene"" id=""21062901-0-0-4"">Tsc2</span> gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of <span class=""disease"" id=""21062901-0-106-132"">tuberous sclerosis complex</span>.",CTD_human;ORPHANET
4,91,Biomarker,C0041341,Tuberous Sclerosis,disease,TSC,7249,TSC2,TSC2,CTD_human,10732801,Our laboratory has undertaken the complete mutation analysis of the TSC2 gene in 42 TSC families using single-strand conformation polymorphism analysis and reverse transcription-polymerase chain reaction.,0.538360280812339,"Our laboratory has undertaken the complete mutation analysis of the <span class=""gene"" id=""10732801-3-68-72"">TSC2</span> gene in 42 <span class=""disease"" id=""10732801-3-84-87"">TSC</span> families using single-strand conformation polymorphism analysis and reverse transcription-polymerase chain reaction.",CTD_human;ORPHANET
4,91,Biomarker,C0041341,Tuberous Sclerosis,disease,TSC,7249,TSC2,TSC2,CTD_human,18345974,"Tuberous sclerosis complex (TSC) is an inherited disorder resulting from mutations in one of two genes, TSC1 (Hamartin) and TSC2 (Tuberin).",0.538360280812339,"<span class=""disease"" id=""18345974-1-0-26"">Tuberous sclerosis complex</span> (<span class=""disease"" id=""18345974-1-28-31"">TSC</span>) is an inherited disorder resulting from mutations in one of two genes, TSC1 (Hamartin) and <span class=""gene"" id=""18345974-1-124-128"">TSC2</span> (Tuberin).",CTD_human;ORPHANET
4,91,Biomarker,C0041341,Tuberous Sclerosis,disease,TSC,7249,TSC2,TSC2,CTD_human,21345208,"Tuberous sclerosis complex (TSC) is an autosomal dominant neurogenetic disorder caused by mutations in one of two genes, TSC1 or TSC2, which encode the proteins hamartin and tuberin, respectively 123.",0.538360280812339,"<span class=""disease"" id=""21345208-1-0-26"">Tuberous sclerosis complex</span> (<span class=""disease"" id=""21345208-1-28-31"">TSC</span>) is an autosomal dominant neurogenetic disorder caused by mutations in one of two genes, TSC1 or <span class=""gene"" id=""21345208-1-129-133"">TSC2</span>, which encode the proteins hamartin and tuberin, respectively 123.",CTD_human;ORPHANET
1,2,Biomarker,C0010308,Congenital Hypothyroidism,disease,CH,7253,TSHR,TSHR,CTD_human,12629076,"In conclusion, CH in the siblings is due to the missense mutation, W546X, in their TSHR gene.",0.42264258726579296,"In conclusion, <span class=""disease"" id=""12629076-7-15-17"">CH</span> in the siblings is due to the missense mutation, W546X, in their <span class=""gene"" id=""12629076-7-83-87"">TSHR</span> gene.",CTD_human;HPO
2,1,Biomarker,C0018213,Graves Disease,disease,Graves' disease,7253,TSHR,TSHR,CTD_human,21841780,"Moreover, we identified strong associations of TSHR and major histocompatibility complex class II variants with persistently TRAb-positive Graves' disease.",0.27593790467151097,"Moreover, we identified strong associations of <span class=""gene"" id=""21841780-6-47-51"">TSHR</span> and major histocompatibility complex class II variants with persistently TRAb-positive <span class=""disease"" id=""21841780-6-139-154"">Graves' disease</span>.",CTD_human
1,0,Therapeutic,C0029463,Osteosarcoma,disease,osteosarcoma,7262,PHLDA2,TSSC3,CTD_human,22021909,"TSSC3 overexpression associates with growth inhibition, apoptosis induction and enhances chemotherapeutic effects in human osteosarcoma.",0.201373633921065,"<span class=""gene"" id=""22021909-0-0-5"">TSSC3</span> overexpression associates with growth inhibition, apoptosis induction and enhances chemotherapeutic effects in human <span class=""disease"" id=""22021909-0-123-135"">osteosarcoma</span>.",CTD_human
1,0,Biomarker,C0009319,Colitis,disease,colitis,7263,TST,Rhodanese,CTD_human,19647029,"Rhodanese, but not cystathionine-gamma-lyase, is associated with dextran sulfate sodium-evoked colitis in mice: a sign of impaired colonic sulfide detoxification?",0.2,"<span class=""gene"" id=""19647029-0-0-9"">Rhodanese</span>, but not cystathionine-gamma-lyase, is associated with dextran sulfate sodium-evoked <span class=""disease"" id=""19647029-0-95-102"">colitis</span> in mice: a sign of impaired colonic sulfide detoxification?",CTD_human
3,223,Biomarker,C0007193,"Cardiomyopathy, Dilated",group,dilated cardiomyopathy,7273,TTN,Titin,CTD_human,27869827,Titin-truncating variants (TTNtv) commonly cause dilated cardiomyopathy (DCM).,0.41774866230727004,"<span class=""gene"" id=""27869827-1-0-5"">Titin</span>-truncating variants (TTNtv) commonly cause <span class=""disease"" id=""27869827-1-49-71"">dilated cardiomyopathy</span> (DCM).",CTD_human;HPO
3,223,Biomarker,C0007193,"Cardiomyopathy, Dilated",group,dilated cardiomyopathy,7273,TTN,Titin,CTD_human,11846417,Titin mutations as the molecular basis for dilated cardiomyopathy.,0.41774866230727004,"<span class=""gene"" id=""11846417-0-0-5"">Titin</span> mutations as the molecular basis for <span class=""disease"" id=""11846417-0-43-65"">dilated cardiomyopathy</span>.",CTD_human;HPO
1,4,Biomarker,C0026848,Myopathy,group,muscle disease,7273,TTN,titin,CTD_human,15802564,A human mutation in the titin protein kinase domain causes hereditary muscle disease by disrupting this pathway.,0.405480180306945,"A human mutation in the <span class=""gene"" id=""15802564-5-24-29"">titin</span> protein kinase domain causes hereditary <span class=""disease"" id=""15802564-5-70-84"">muscle disease</span> by disrupting this pathway.",CTD_human;HPO
1,0,Biomarker,C0340427,Familial dilated cardiomyopathy,disease,familial dilated cardiomyopathy,7273,TTN,titin,CTD_human,11788824,"Mutations of TTN, encoding the giant muscle filament titin, cause familial dilated cardiomyopathy.",0.200274726784213,"Mutations of <span class=""gene"" id=""11788824-0-13-16"">TTN</span>, encoding the giant muscle filament <span class=""gene"" id=""11788824-0-53-58"">titin</span>, cause <span class=""disease"" id=""11788824-0-66-97"">familial dilated cardiomyopathy</span>.",CTD_human
1,0,Biomarker,C0004153,Atherosclerosis,disease,atherosclerosis,7274,TTPA,alpha -tocopherol transfer protein,CTD_human,11095717,Increased atherosclerosis in hyperlipidemic mice deficient in alpha -tocopherol transfer protein and vitamin E.,0.2,"Increased <span class=""disease"" id=""11095717-0-10-25"">atherosclerosis</span> in hyperlipidemic mice deficient in <span class=""gene"" id=""11095717-0-62-96"">alpha -tocopherol transfer protein</span> and vitamin E.",CTD_human
7,23,Biomarker,C1848533,Ataxia with vitamin E deficiency,disease,AVED,7274,TTPA,alpha-TTP,CTD_human,11752462,"We produced a model mouse of AVED by deleting the alpha-TTP gene, which showed ataxia and retinal degeneration after 1 year of age.",0.686043989252688,"We produced a model mouse of <span class=""disease"" id=""11752462-3-29-33"">AVED</span> by deleting the <span class=""gene"" id=""11752462-3-50-59"">alpha-TTP</span> gene, which showed ataxia and retinal degeneration after 1 year of age.",CTD_human;ORPHANET;UNIPROT
7,23,Biomarker,C1848533,Ataxia with vitamin E deficiency,disease,Ataxia with isolated vitamin E deficiency,7274,TTPA,TTPA,CTD_human,15300460,"Ataxia with isolated vitamin E deficiency: neurological phenotype, clinical follow-up and novel mutations in TTPA gene in Italian families.",0.686043989252688,"<span class=""disease"" id=""15300460-0-0-41"">Ataxia with isolated vitamin E deficiency</span>: neurological phenotype, clinical follow-up and novel mutations in <span class=""gene"" id=""15300460-0-109-113"">TTPA</span> gene in Italian families.",CTD_human;ORPHANET;UNIPROT
7,23,Biomarker,C1848533,Ataxia with vitamin E deficiency,disease,Ataxia with vitamin E deficiency,7274,TTPA,TTPA,CTD_human,12470185,Ataxia with vitamin E deficiency is a recessive autosomal neurodegenerative disorder resembling the Friedreich ataxia phenotype but is due to mutations in the alpha-tocopherol transfer protein (TTPA) gene.,0.686043989252688,"<span class=""disease"" id=""12470185-1-0-32"">Ataxia with vitamin E deficiency</span> is a recessive autosomal neurodegenerative disorder resembling the Friedreich ataxia phenotype but is due to mutations in the alpha-tocopherol transfer protein (<span class=""gene"" id=""12470185-1-194-198"">TTPA</span>) gene.",CTD_human;ORPHANET;UNIPROT
7,23,Biomarker,C1848533,Ataxia with vitamin E deficiency,disease,ataxia with isolated vitamin E deficiency,7274,TTPA,alpha-TTP,CTD_human,18458655,A novel delins mutation in the alpha-TTP gene in a family segregating ataxia with isolated vitamin E deficiency.,0.686043989252688,"A novel delins mutation in the <span class=""gene"" id=""18458655-0-31-40"">alpha-TTP</span> gene in a family segregating <span class=""disease"" id=""18458655-0-70-111"">ataxia with isolated vitamin E deficiency</span>.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0002726,Amyloidosis,disease,amyloid,7276,TTR,TTR,CTD_human,25595224,"In order to test the hypothesis that sulfate group substituents can improve the efficiencies of such inhibitors, we evaluated the potential of six polychlorinated biphenyl sulfates to inhibit TTR amyloid fibril formation in vitro.",0.498804503312171,"In order to test the hypothesis that sulfate group substituents can improve the efficiencies of such inhibitors, we evaluated the potential of six polychlorinated biphenyl sulfates to inhibit <span class=""gene"" id=""25595224-3-192-195"">TTR</span> <span class=""disease"" id=""25595224-3-196-203"">amyloid</span> fibril formation in vitro.",CTD_human;HPO
2,0,Biomarker,C0024121,Lung Neoplasms,group,lung tumor,7276,TTR,transthyretin,CTD_human,17902193,"Notably, we demonstrate significant regulation of alpha-1-antitrypsin, alpha-2-macroglobulin, hemoglobin subunit alpha, vitamin D-binding protein, major urinary proteins, and transthyretin (up to eight-fold) in serum of lung tumor bearing mice.",0.20546582492962803,"Notably, we demonstrate significant regulation of alpha-1-antitrypsin, alpha-2-macroglobulin, hemoglobin subunit alpha, vitamin D-binding protein, major urinary proteins, and <span class=""gene"" id=""17902193-7-175-188"">transthyretin</span> (up to eight-fold) in serum of <span class=""disease"" id=""17902193-7-220-230"">lung tumor</span> bearing mice.",CTD_human
2,0,Biomarker,C0024121,Lung Neoplasms,group,lung tumor,7276,TTR,transthyretin,CTD_human,19180532,"Notably, expression of alpha-2-macroglobulin, transthyretin, alpha-1-antitrypsin, and properdin was in common in different lung tumor models, but regulation of orosomucoid-8, apolipoprotein-A1, apolipoprotein-C3, apolipoprotein-E, glutathione peroxidase-3, plasma retinol-binding protein, and serum amyloid P component was unique when the serum proteomes of c-myc and c-raf tumor bearing mice were compared.",0.20546582492962803,"Notably, expression of alpha-2-macroglobulin, <span class=""gene"" id=""19180532-8-46-59"">transthyretin</span>, alpha-1-antitrypsin, and properdin was in common in different <span class=""disease"" id=""19180532-8-123-133"">lung tumor</span> models, but regulation of orosomucoid-8, apolipoprotein-A1, apolipoprotein-C3, apolipoprotein-E, glutathione peroxidase-3, plasma retinol-binding protein, and serum amyloid P component was unique when the serum proteomes of c-myc and c-raf tumor bearing mice were compared.",CTD_human
1,0,Biomarker,C0025958,Microcephaly,disease,microcephaly,7283,TUBG1,TUBG1,CTD_human,23603762,"Mutations in TUBG1, DYNC1H1, KIF5C and KIF2A cause malformations of cortical development and microcephaly.",0.2,"Mutations in <span class=""gene"" id=""23603762-0-13-18"">TUBG1</span>, DYNC1H1, KIF5C and KIF2A cause malformations of cortical development and <span class=""disease"" id=""23603762-0-93-105"">microcephaly</span>.",CTD_human
1,0,Biomarker,C1955869,Malformations of Cortical Development,disease,malformations of cortical development,7283,TUBG1,TUBG1,CTD_human,23603762,"Mutations in TUBG1, DYNC1H1, KIF5C and KIF2A cause malformations of cortical development and microcephaly.",0.200274726784213,"Mutations in <span class=""gene"" id=""23603762-0-13-18"">TUBG1</span>, DYNC1H1, KIF5C and KIF2A cause <span class=""disease"" id=""23603762-0-51-88"">malformations of cortical development</span> and microcephaly.",CTD_human
2,2,Biomarker,C0010278,Craniosynostosis,disease,craniosynostosis,7291,TWIST1,Twist,CTD_human,12221714,"Mice heterozygous for a null mutation of the Twist gene replicate certain features of Saethre-Chotzen syndrome, but have not been reported to exhibit craniosynostosis.",0.626134167548616,"Mice heterozygous for a null mutation of the <span class=""gene"" id=""12221714-3-45-50"">Twist</span> gene replicate certain features of Saethre-Chotzen syndrome, but have not been reported to exhibit <span class=""disease"" id=""12221714-3-150-166"">craniosynostosis</span>.",CTD_human;HPO;UNIPROT
1,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,Metastasis,7291,TWIST1,TWIST,CTD_human,19806464,Metastasis-induction and apoptosis-protection by TWIST in gastric cancer cells.,0.231810885459451,"<span class=""disease"" id=""19806464-0-0-10"">Metastasis</span>-induction and apoptosis-protection by <span class=""gene"" id=""19806464-0-49-54"">TWIST</span> in gastric cancer cells.",CTD_human
2,8,Biomarker,C0024141,"Lupus Erythematosus, Systemic",disease,systemic lupus erythematosus,7292,TNFSF4,TNFSF4,CTD_human,18059267,Polymorphism at the TNF superfamily gene TNFSF4 confers susceptibility to systemic lupus erythematosus.,0.220970101426213,"Polymorphism at the TNF superfamily gene <span class=""gene"" id=""18059267-0-41-47"">TNFSF4</span> confers susceptibility to <span class=""disease"" id=""18059267-0-74-102"">systemic lupus erythematosus</span>.",CTD_human
1,0,Biomarker,C0034069,Pulmonary Fibrosis,disease,lung fibrosis,729230,CCR2,CCR2,CTD_human,14609568,"To evaluate the role of CCR2 in lung fibrosis, CCR2 knockout (ko) mice were used in a model of bleomycin-induced lung fibrosis.",0.20054945356842604,"To evaluate the role of <span class=""gene"" id=""14609568-2-24-28"">CCR2</span> in <span class=""disease"" id=""14609568-2-32-45"">lung fibrosis</span>, <span class=""gene"" id=""14609568-2-47-51"">CCR2</span> knockout (ko) mice were used in a model of bleomycin-induced <span class=""disease"" id=""14609568-2-113-126"">lung fibrosis</span>.",CTD_human
2,0,Biomarker,C0038220,Status Epilepticus,disease,status epilepticus,729230,CCR2,CCR2,CTD_human,20034406,Chemokine CCL2 and its receptor CCR2 are increased in the hippocampus following pilocarpine-induced status epilepticus.,0.2,"Chemokine CCL2 and its receptor <span class=""gene"" id=""20034406-0-32-36"">CCR2</span> are increased in the hippocampus following pilocarpine-induced <span class=""disease"" id=""20034406-0-100-118"">status epilepticus</span>.",CTD_human
1,0,Biomarker,C0004364,Autoimmune Diseases,group,autoimmunity,7293,TNFRSF4,CD134,CTD_human,9766631,"We show strongly increased T cell expression of CD134 in a model of T helper 2-mediated systemic autoimmunity, induced by HgCl2.",0.20054945356842604,"We show strongly increased T cell expression of <span class=""gene"" id=""9766631-2-48-53"">CD134</span> in a model of T helper 2-mediated systemic <span class=""disease"" id=""9766631-2-97-109"">autoimmunity</span>, induced by HgCl2.",CTD_human
1,0,Therapeutic,C0006287,Bronchopulmonary Dysplasia,disease,bronchopulmonary dysplasia,7295,TXN,Trx,CTD_human,20812253,"Thioredoxin (Trx) is an antioxidant that prevents oxidative stress-induced cell death, suggesting a potential therapeutic role in bronchopulmonary dysplasia.",0.200274726784213,"<span class=""gene"" id=""20812253-2-0-11"">Thioredoxin</span> (<span class=""gene"" id=""20812253-2-13-16"">Trx</span>) is an antioxidant that prevents oxidative stress-induced cell death, suggesting a potential therapeutic role in <span class=""disease"" id=""20812253-2-130-156"">bronchopulmonary dysplasia</span>.",CTD_human
1,0,Biomarker,C0001430,Adenoma,group,adenoma,7296,TXNRD1,TXNRD1,CTD_human,18483336,"Consistent with the individual SNP results, we observed a significant overall association with adenoma risk for SEPP1 and TXNRD1 (global P = 0.02 and 0.008, respectively) but not for the four GPX genes.",0.20541466777231498,"Consistent with the individual SNP results, we observed a significant overall association with <span class=""disease"" id=""18483336-10-95-102"">adenoma</span> risk for SEPP1 and <span class=""gene"" id=""18483336-10-122-128"">TXNRD1</span> (global P = 0.02 and 0.008, respectively) but not for the four GPX genes.",CTD_human
1,0,Biomarker,C0026769,Multiple Sclerosis,disease,MS,7297,TYK2,TYK2,CTD_human,19525955,"We also replicated several known MS associations (HLA-DR15, P = 7.0 x 10(-184); CD58, P = 9.6 x 10(-8); EVI5-RPL5, P = 2.5 x 10(-6); IL2RA, P = 7.4 x 10(-6); CLEC16A, P = 1.1 x 10(-4); IL7R, P = 1.3 x 10(-3); TYK2, P = 3.5 x 10(-3)) and observed a statistical interaction between SNPs in EVI5-RPL5 and HLA-DR15 (P = 0.001).",0.21450768367435802,"We also replicated several known <span class=""disease"" id=""19525955-5-33-35"">MS</span> associations (HLA-DR15, P = 7.0 x 10(-184); CD58, P = 9.6 x 10(-8); EVI5-RPL5, P = 2.5 x 10(-6); IL2RA, P = 7.4 x 10(-6); CLEC16A, P = 1.1 x 10(-4); IL7R, P = 1.3 x 10(-3); <span class=""gene"" id=""19525955-5-209-213"">TYK2</span>, P = 3.5 x 10(-3)) and observed a statistical interaction between SNPs in EVI5-RPL5 and HLA-DR15 (P = 0.001).",CTD_human
1,0,Biomarker,C0002871,Anemia,disease,anemia,7298,TYMS,thymidylate synthase,CTD_human,19648163,"MTHFR 677C>T also increased the risk of leukopenia and gastrointestinal toxicity, whilst thymidylate synthase 28 bp repeat polymorphism increased the risk of anemia (odds ratio 8.48, 95% confidence interval 2.00-36.09).",0.20054945356842604,"MTHFR 677C&gt;T also increased the risk of leukopenia and gastrointestinal toxicity, whilst <span class=""gene"" id=""19648163-7-89-109"">thymidylate synthase</span> 28 bp repeat polymorphism increased the risk of <span class=""disease"" id=""19648163-7-158-164"">anemia</span> (odds ratio 8.48, 95% confidence interval 2.00-36.09).",CTD_human
1,0,Biomarker,C0006111,Brain Diseases,group,encephalopathy,7298,TYMS,TYMS,CTD_human,20714149,Genetic polymorphisms of the TYMS gene would contribute to the 5-fluorouracil-associated hyperammonemic encephalopathy.,0.200274726784213,"Genetic polymorphisms of the <span class=""gene"" id=""20714149-6-29-33"">TYMS</span> gene would contribute to the 5-fluorouracil-associated hyperammonemic <span class=""disease"" id=""20714149-6-104-118"">encephalopathy</span>.",CTD_human
1,0,Biomarker,C0007137,Squamous cell carcinoma,disease,squamous cell carcinoma,7298,TYMS,TS,CTD_human,16280240,"In 140 patients with primary squamous cell carcinoma (SCC) of the tongue, intratumoural TS expression was evaluated by immunohistochemistry.",0.21149545880499804,"In 140 patients with primary <span class=""disease"" id=""16280240-2-29-52"">squamous cell carcinoma</span> (SCC) of the tongue, intratumoural <span class=""gene"" id=""16280240-2-88-90"">TS</span> expression was evaluated by immunohistochemistry.",CTD_human
6,0,Biomarker,C0009375,Colonic Neoplasms,group,colon tumor,7298,TYMS,TYMS,CTD_human,15355913,"Furthermore, four of them (one each from TYMS and PKG1 and two from AICRT/1) possessed the ability to induce HLA-A2-restricted and peptide-specific CTLs cytotoxic to colon tumor cells in peripheral blood mononuclear cells of colon cancer patients.",0.21997350860398499,"Furthermore, four of them (one each from <span class=""gene"" id=""15355913-8-41-45"">TYMS</span> and PKG1 and two from AICRT/1) possessed the ability to induce HLA-A2-restricted and peptide-specific CTLs cytotoxic to <span class=""disease"" id=""15355913-8-166-177"">colon tumor</span> cells in peripheral blood mononuclear cells of colon cancer patients.",CTD_human
1,0,Biomarker,C0024301,"Lymphoma, Follicular",disease,FL,7298,TYMS,TYMS,CTD_human,16410450,"Individuals with MTR 2756AA had 2-fold higher risk of FL, and subjects not having at least one TYMS 2R allele showed a 2-fold higher risk of FL.",0.202956482091714,"Individuals with MTR 2756AA had 2-fold higher risk of <span class=""disease"" id=""16410450-6-54-56"">FL</span>, and subjects not having at least one <span class=""gene"" id=""16410450-6-95-99"">TYMS</span> 2R allele showed a 2-fold higher risk of <span class=""disease"" id=""16410450-6-141-143"">FL</span>.",CTD_human
1,0,Biomarker,C0024305,"Lymphoma, Non-Hodgkin",disease,NHL,7298,TYMS,TYMS,CTD_human,16365025,We observed no association between NHL and haplotypes for MTHFR or TYMS.,0.20673714453606798,"We observed no association between <span class=""disease"" id=""16365025-8-35-38"">NHL</span> and haplotypes for MTHFR or <span class=""gene"" id=""16365025-8-67-71"">TYMS</span>.",CTD_human
1,0,Biomarker,C0206754,Neuroendocrine Tumors,group,neuroendocrine tumors,7298,TYMS,Thymidylate synthase,CTD_human,18281538,Thymidylate synthase expression in gastroenteropancreatic and pulmonary neuroendocrine tumors.,0.20300763924902696,"<span class=""gene"" id=""18281538-0-0-20"">Thymidylate synthase</span> expression in gastroenteropancreatic and pulmonary <span class=""disease"" id=""18281538-0-72-93"">neuroendocrine tumors</span>.",CTD_human
2,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,7298,TYMS,TS,CTD_human,18019677,The DPD mRNA level was lower and the TS mRNA level was higher in HCC than in adjacent liver.,0.20919533021666797,"The DPD mRNA level was lower and the <span class=""gene"" id=""18019677-12-37-39"">TS</span> mRNA level was higher in <span class=""disease"" id=""18019677-12-65-68"">HCC</span> than in adjacent liver.",CTD_human
2,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,7298,TYMS,TS,CTD_human,18230555,"The relative mRNA level of orotate phosphoribosyltransferase (OPRT), ribonucleotide reductase (RNR), dihydropyrimidine dehydrogenase (DPD) and target enzyme thymidylate synthase (TS), were analyzed in 30 matched samples of HCC (T) and non-tumor tissue (NT) using quantitative RT-PCR.",0.20919533021666797,"The relative mRNA level of orotate phosphoribosyltransferase (OPRT), ribonucleotide reductase (RNR), dihydropyrimidine dehydrogenase (DPD) and target enzyme <span class=""gene"" id=""18230555-3-157-177"">thymidylate synthase</span> (<span class=""gene"" id=""18230555-3-179-181"">TS</span>), were analyzed in 30 matched samples of <span class=""disease"" id=""18230555-3-223-226"">HCC</span> (T) and non-tumor tissue (NT) using quantitative RT-PCR.",CTD_human
4,2,Biomarker,C0025202,melanoma,disease,melanoma,7299,TYR,TYR,CTD_human,19578364,"MC1R and TYR are associated with pigmentation, freckling and cutaneous sun sensitivity, well-recognized melanoma risk factors.",0.30825517756743603,"MC1R and <span class=""gene"" id=""19578364-4-9-12"">TYR</span> are associated with pigmentation, freckling and cutaneous sun sensitivity, well-recognized <span class=""disease"" id=""19578364-4-104-112"">melanoma</span> risk factors.",CTD_human
4,2,Biomarker,C0025202,melanoma,disease,cutaneous melanoma,7299,TYR,TYR,CTD_human,18488027,ASIP and TYR pigmentation variants associate with cutaneous melanoma and basal cell carcinoma.,0.30825517756743603,"ASIP and <span class=""gene"" id=""18488027-0-9-12"">TYR</span> pigmentation variants associate with <span class=""disease"" id=""18488027-0-50-68"">cutaneous melanoma</span> and basal cell carcinoma.",CTD_human
4,2,Biomarker,C0025202,melanoma,disease,MM,7299,TYR,TYR,CTD_human,21559390,"However, three SNPs in TYR, SILV/CDK2 and ADAMTS20 genes (rs17793678, rs2069398 and rs1510521 respectively) had an overall p-value<0.05 when considering the whole DNA collection (1214 MM cases and 1296 controls).",0.30825517756743603,"However, three SNPs in <span class=""gene"" id=""21559390-9-23-26"">TYR</span>, SILV/CDK2 and ADAMTS20 genes (rs17793678, rs2069398 and rs1510521 respectively) had an overall p-value&lt;0.05 when considering the whole DNA collection (1214 <span class=""disease"" id=""21559390-9-184-186"">MM</span> cases and 1296 controls).",CTD_human
2,5,Biomarker,C0078918,"Albinism, Oculocutaneous",disease,oculocutaneous albinism,7299,TYR,tyrosinase,CTD_human,2511845,Human oculocutaneous albinism caused by single base insertion in the tyrosinase gene.,0.266967970755147,"Human <span class=""disease"" id=""2511845-0-6-29"">oculocutaneous albinism</span> caused by single base insertion in the <span class=""gene"" id=""2511845-0-69-79"">tyrosinase</span> gene.",CTD_human
2,0,Biomarker,C0265221,Walker-Warburg congenital muscular dystrophy,disease,Walker-Warburg syndrome,729920,ISPD,ISPD,CTD_human,22522421,Mutations in ISPD cause Walker-Warburg syndrome and defective glycosylation of ?-dystroglycan.,0.4010989071368521,"Mutations in <span class=""gene"" id=""22522421-0-13-17"">ISPD</span> cause <span class=""disease"" id=""22522421-0-24-47"">Walker-Warburg syndrome</span> and defective glycosylation of &alpha;-dystroglycan.",CTD_human;ORPHANET
2,0,Biomarker,C0265221,Walker-Warburg congenital muscular dystrophy,disease,Walker-Warburg syndrome,729920,ISPD,ISPD,CTD_human,22522420,ISPD loss-of-function mutations disrupt dystroglycan O-mannosylation and cause Walker-Warburg syndrome.,0.4010989071368521,"<span class=""gene"" id=""22522420-0-0-4"">ISPD</span> loss-of-function mutations disrupt dystroglycan O-mannosylation and cause <span class=""disease"" id=""22522420-0-79-102"">Walker-Warburg syndrome</span>.",CTD_human;ORPHANET
1,0,Biomarker,C3463824,MYELODYSPLASTIC SYNDROME,group,myelodysplastic syndromes,7307,U2AF1,U2AF1,CTD_human,22158538,Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes.,0.203296721410557,"Recurrent mutations in the <span class=""gene"" id=""22158538-0-27-32"">U2AF1</span> splicing factor in <span class=""disease"" id=""22158538-0-52-77"">myelodysplastic syndromes</span>.",CTD_human
1,0,Biomarker,C0007137,Squamous cell carcinoma,disease,squamous cell carcinomas,7317,UBA1,UBA1,CTD_human,19014429,"Even though UBA1 or UBA7, the early enzymes involved in protein ubiquitination and ubiquitin-like regulation of target proteins, did not underlie the exposure-related deregulation of ubiquitination, a difference was detected in the UBA1 and UBA7 levels between squamous cell carcinomas and respective normal lung tissue (p = 0.02 and p = 0.01) without regard to exposure status.",0.2,"Even though <span class=""gene"" id=""19014429-8-12-16"">UBA1</span> or UBA7, the early enzymes involved in protein ubiquitination and ubiquitin-like regulation of target proteins, did not underlie the exposure-related deregulation of ubiquitination, a difference was detected in the <span class=""gene"" id=""19014429-8-232-236"">UBA1</span> and UBA7 levels between <span class=""disease"" id=""19014429-8-261-285"">squamous cell carcinomas</span> and respective normal lung tissue (p = 0.02 and p = 0.01) without regard to exposure status.",CTD_human
1,0,Biomarker,C0007137,Squamous cell carcinoma,disease,squamous cell carcinomas,7318,UBA7,UBA7,CTD_human,19014429,"Even though UBA1 or UBA7, the early enzymes involved in protein ubiquitination and ubiquitin-like regulation of target proteins, did not underlie the exposure-related deregulation of ubiquitination, a difference was detected in the UBA1 and UBA7 levels between squamous cell carcinomas and respective normal lung tissue (p = 0.02 and p = 0.01) without regard to exposure status.",0.2,"Even though UBA1 or <span class=""gene"" id=""19014429-8-20-24"">UBA7</span>, the early enzymes involved in protein ubiquitination and ubiquitin-like regulation of target proteins, did not underlie the exposure-related deregulation of ubiquitination, a difference was detected in the UBA1 and <span class=""gene"" id=""19014429-8-241-245"">UBA7</span> levels between <span class=""disease"" id=""19014429-8-261-285"">squamous cell carcinomas</span> and respective normal lung tissue (p = 0.02 and p = 0.01) without regard to exposure status.",CTD_human
1,2,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,type 2 diabetes,7325,UBE2E2,UBE2E2,CTD_human,20818381,A genome-wide association study in the Japanese population identifies susceptibility loci for type 2 diabetes at UBE2E2 and C2CD4A-C2CD4B.,0.20350593566014002,"A genome-wide association study in the Japanese population identifies susceptibility loci for <span class=""disease"" id=""20818381-0-94-109"">type 2 diabetes</span> at <span class=""gene"" id=""20818381-0-113-119"">UBE2E2</span> and C2CD4A-C2CD4B.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autistic disorder,7328,UBE2H,UBE2H,CTD_human,14639049,Mutation screening and association study of the UBE2H gene on chromosome 7q32 in autistic disorder.,0.20300763924902696,"Mutation screening and association study of the <span class=""gene"" id=""14639049-0-48-53"">UBE2H</span> gene on chromosome 7q32 in <span class=""disease"" id=""14639049-0-81-98"">autistic disorder</span>.",CTD_human
3,0,Biomarker,C0004352,Autistic Disorder,disease,autism,7337,UBE3A,UBE3A,CTD_human,20609483,Role of UBE3A and ATP10A genes in autism susceptibility region 15q11-q13 in an Italian population: a positive replication for UBE3A.,0.412924835503709,"Role of <span class=""gene"" id=""20609483-0-8-13"">UBE3A</span> and ATP10A genes in <span class=""disease"" id=""20609483-0-34-40"">autism</span> susceptibility region 15q11-q13 in an Italian population: a positive replication for <span class=""gene"" id=""20609483-0-126-131"">UBE3A</span>.",CTD_human;HPO
3,0,Biomarker,C0004352,Autistic Disorder,disease,autism,7337,UBE3A,Angelman syndrome,CTD_human,11543639,Linkage disequilibrium at the Angelman syndrome gene UBE3A in autism families.,0.412924835503709,"Linkage disequilibrium at the <span class=""gene"" id=""11543639-0-30-47"">Angelman syndrome</span> gene UBE3A in <span class=""disease"" id=""11543639-0-62-68"">autism</span> families.",CTD_human;HPO
1,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,7345,UCHL1,UCHL1,CTD_human,18666234,UCHL1 appears to be a functional tumor suppressor involved in the tumorigenesis of HCCs and other digestive cancers.,0.20300763924902696,"<span class=""gene"" id=""18666234-12-0-5"">UCHL1</span> appears to be a functional tumor suppressor involved in the tumorigenesis of <span class=""disease"" id=""18666234-12-83-86"">HCC</span>s and other digestive cancers.",CTD_human
1,0,Biomarker,C0003469,Anxiety Disorders,group,anxiety,7349,UCN,urocortin,CTD_human,16488545,Injections of urocortin 1 into the basolateral amygdala induce anxiety-like behavior and c-Fos expression in brainstem serotonergic neurons.,0.2,"Injections of <span class=""gene"" id=""16488545-0-14-23"">urocortin</span> 1 into the basolateral amygdala induce <span class=""disease"" id=""16488545-0-63-70"">anxiety</span>-like behavior and c-Fos expression in brainstem serotonergic neurons.",CTD_human
1,0,Biomarker,C0011633,Dermatomyositis,disease,dermatomyositis,735,C9,complement,CTD_human,11359403,Hereditary complement (C9) deficiency associated with dermatomyositis.,0.200274726784213,"Hereditary <span class=""gene"" id=""11359403-0-11-21"">complement</span> (C9) deficiency associated with <span class=""disease"" id=""11359403-0-54-69"">dermatomyositis</span>.",CTD_human
1,0,Therapeutic,C0028754,Obesity,disease,obesity,7350,UCP1,Ucp1,CTD_human,15592485,Ectopic expression of mitochondrial uncoupling protein 1 (UCP1) in the white adipose tissue of the aP2-Ucp1 transgenic mice reduced obesity induced by genetic or dietary manipulations.,0.250313031448078,"Ectopic expression of mitochondrial uncoupling protein 1 (<span class=""gene"" id=""15592485-2-58-62"">UCP1</span>) in the white adipose tissue of the aP2-<span class=""gene"" id=""15592485-2-103-107"">Ucp1</span> transgenic mice reduced <span class=""disease"" id=""15592485-2-132-139"">obesity</span> induced by genetic or dietary manipulations.",CTD_human
1,0,Biomarker,C0028754,Obesity,disease,obesity,7350,UCP1,Ucp1,CTD_human,15592485,Ectopic expression of mitochondrial uncoupling protein 1 (UCP1) in the white adipose tissue of the aP2-Ucp1 transgenic mice reduced obesity induced by genetic or dietary manipulations.,0.250313031448078,"Ectopic expression of mitochondrial uncoupling protein 1 (<span class=""gene"" id=""15592485-2-58-62"">UCP1</span>) in the white adipose tissue of the aP2-<span class=""gene"" id=""15592485-2-103-107"">Ucp1</span> transgenic mice reduced <span class=""disease"" id=""15592485-2-132-139"">obesity</span> induced by genetic or dietary manipulations.",CTD_human
2,0,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,type 2 diabetes,7351,UCP2,UCP-2,CTD_human,15562023,The common -866G/A polymorphism in the promoter region of the UCP-2 gene is associated with reduced risk of type 2 diabetes in Caucasians from Italy.,0.353190186254841,"The common -866G/A polymorphism in the promoter region of the <span class=""gene"" id=""15562023-0-62-67"">UCP-2</span> gene is associated with reduced risk of <span class=""disease"" id=""15562023-0-108-123"">type 2 diabetes</span> in Caucasians from Italy.",CTD_human
1,0,Biomarker,C0028754,Obesity,disease,obesity,7351,UCP2,UCP2,CTD_human,11381268,A common polymorphism in the promoter of UCP2 is associated with decreased risk of obesity in middle-aged humans.,0.306923224852884,"A common polymorphism in the promoter of <span class=""gene"" id=""11381268-0-41-45"">UCP2</span> is associated with decreased risk of <span class=""disease"" id=""11381268-0-83-90"">obesity</span> in middle-aged humans.",CTD_human
1,0,Therapeutic,C0038454,Cerebrovascular accident,group,stroke,7351,UCP2,Uncoupling protein-2,CTD_human,12858170,Uncoupling protein-2 prevents neuronal death and diminishes brain dysfunction after stroke and brain trauma.,0.201098907136852,"<span class=""gene"" id=""12858170-0-0-20"">Uncoupling protein-2</span> prevents neuronal death and diminishes brain dysfunction after <span class=""disease"" id=""12858170-0-84-90"">stroke</span> and brain trauma.",CTD_human
1,0,Biomarker,C0017551,Gilbert Disease (disorder),disease,GS,7361,UGT1A,UGT1A,CTD_human,22213127,Seventy-six percent of GS and only 9% of HBD were homozygous for the variant haplotype spanning four UGT1A genes.,0.205494535684262,"Seventy-six percent of <span class=""disease"" id=""22213127-8-23-25"">GS</span> and only 9% of HBD were homozygous for the variant haplotype spanning four <span class=""gene"" id=""22213127-8-101-106"">UGT1A</span> genes.",CTD_human
1,0,Biomarker,C0005695,Bladder Neoplasm,disease,bladder cancer,7364,UGT2B7,UDP-glucuronosyltransferase 2B7,CTD_human,15615884,An association of UDP-glucuronosyltransferase 2B7 C802T (His268Tyr) polymorphism with bladder cancer in benzidine-exposed workers in China.,0.20082418035263896,"An association of <span class=""gene"" id=""15615884-0-18-49"">UDP-glucuronosyltransferase 2B7</span> C802T (His268Tyr) polymorphism with <span class=""disease"" id=""15615884-0-86-100"">bladder cancer</span> in benzidine-exposed workers in China.",CTD_human
2,0,Biomarker,C0022658,Kidney Diseases,group,kidney disease,7369,UMOD,UMOD,CTD_human,19430482,"UMOD encodes the most common protein in human urine, Tamm-Horsfall protein, and rare mutations in UMOD cause mendelian forms of kidney disease.",0.4115098141823161,"<span class=""gene"" id=""19430482-4-0-4"">UMOD</span> encodes the most common protein in human urine, Tamm-Horsfall protein, and rare mutations in <span class=""gene"" id=""19430482-4-98-102"">UMOD</span> cause mendelian forms of <span class=""disease"" id=""19430482-4-128-142"">kidney disease</span>.",CTD_human;HPO
1,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,7372,UMPS,OPRT,CTD_human,18230555,"The relative mRNA level of orotate phosphoribosyltransferase (OPRT), ribonucleotide reductase (RNR), dihydropyrimidine dehydrogenase (DPD) and target enzyme thymidylate synthase (TS), were analyzed in 30 matched samples of HCC (T) and non-tumor tissue (NT) using quantitative RT-PCR.",0.20300763924902696,"The relative mRNA level of <span class=""gene"" id=""18230555-3-27-60"">orotate phosphoribosyltransferase</span> (<span class=""gene"" id=""18230555-3-62-66"">OPRT</span>), ribonucleotide reductase (RNR), dihydropyrimidine dehydrogenase (DPD) and target enzyme thymidylate synthase (TS), were analyzed in 30 matched samples of <span class=""disease"" id=""18230555-3-223-226"">HCC</span> (T) and non-tumor tissue (NT) using quantitative RT-PCR.",CTD_human
1,0,Biomarker,C0005859,Bloom Syndrome,disease,BS,7374,UNG,uracil-DNA glycosylase,CTD_human,2106500,"In Bloom's syndrome (BS) the regulation of uracil-DNA glycosylase, an enzyme involved in the repair of DNA containing 5-FU, is altered.",0.201373633921065,"In <span class=""disease"" id=""2106500-1-3-19"">Bloom's syndrome</span> (<span class=""disease"" id=""2106500-1-21-23"">BS</span>) the regulation of <span class=""gene"" id=""2106500-1-43-65"">uracil-DNA glycosylase</span>, an enzyme involved in the repair of DNA containing 5-FU, is altered.",CTD_human
16,19,Biomarker,C0162566,Porphyria Cutanea Tarda,disease,PCT,7389,UROD,UROD,CTD_human,12030801,"Porphyria cutanea tarda (PCT) is a metabolic disorder of heme biosynthesis, characterized by reduced uroporphyrinogen decarboxylase (UROD) activity and increased urinary excretion of eight and seven carboxyl group porphyrins.",0.628672221141164,"<span class=""disease"" id=""12030801-1-0-23"">Porphyria cutanea tarda</span> (<span class=""disease"" id=""12030801-1-25-28"">PCT</span>) is a metabolic disorder of heme biosynthesis, characterized by reduced <span class=""gene"" id=""12030801-1-101-131"">uroporphyrinogen decarboxylase</span> (<span class=""gene"" id=""12030801-1-133-137"">UROD</span>) activity and increased urinary excretion of eight and seven carboxyl group porphyrins.",CTD_human;ORPHANET;UNIPROT
16,19,Biomarker,C0162566,Porphyria Cutanea Tarda,disease,porphyria cutanea tarda,7389,UROD,uroporphyrinogen decarboxylase,CTD_human,17360334,A porphomethene inhibitor of uroporphyrinogen decarboxylase causes porphyria cutanea tarda.,0.628672221141164,"A porphomethene inhibitor of <span class=""gene"" id=""17360334-0-29-59"">uroporphyrinogen decarboxylase</span> causes <span class=""disease"" id=""17360334-0-67-90"">porphyria cutanea tarda</span>.",CTD_human;ORPHANET;UNIPROT
3,16,Biomarker,C0035334,Retinitis Pigmentosa,disease,retinitis pigmentosa,7399,USH2A,USH2A,CTD_human,10775529,Missense mutation in the USH2A gene: association with recessive retinitis pigmentosa without hearing loss.,0.623372544329168,"Missense mutation in the <span class=""gene"" id=""10775529-0-25-30"">USH2A</span> gene: association with recessive <span class=""disease"" id=""10775529-0-64-84"">retinitis pigmentosa</span> without hearing loss.",CTD_human;HPO;ORPHANET
24,143,Biomarker,C1848634,"USHER SYNDROME, TYPE IIA",disease,Usher syndrome type IIa,7399,USH2A,USH2A,CTD_human,9624053,Three biologically important mutations in Usher syndrome type IIa patients were identified in a gene (USH2A) isolated from this critical region.,0.48219781427370506,"Three biologically important mutations in <span class=""disease"" id=""9624053-2-42-65"">Usher syndrome type IIa</span> patients were identified in a gene (<span class=""gene"" id=""9624053-2-102-107"">USH2A</span>) isolated from this critical region.",CTD_human;UNIPROT
1,0,Biomarker,C0005695,Bladder Neoplasm,disease,bladder cancer,7403,KDM6A,UTX,CTD_human,21822268,"Of these genes, we showed UTX to be altered substantially more frequently in tumors of low stages and grades, highlighting its potential role in the classification and diagnosis of bladder cancer.",0.20082418035263896,"Of these genes, we showed <span class=""gene"" id=""21822268-5-26-29"">UTX</span> to be altered substantially more frequently in tumors of low stages and grades, highlighting its potential role in the classification and diagnosis of <span class=""disease"" id=""21822268-5-181-195"">bladder cancer</span>.",CTD_human
1,0,Biomarker,C0152013,Adenocarcinoma of lung (disorder),disease,ADC,7409,VAV1,VAV1,CTD_human,27158780,"Lung ADCs lacking receptor tyrosine kinase-Ras-Raf pathway alterations had mutations in SOS1, VAV1, RASA1, and ARHGAP35.",0.2,"Lung <span class=""disease"" id=""27158780-5-5-8"">ADC</span>s lacking receptor tyrosine kinase-Ras-Raf pathway alterations had mutations in SOS1, <span class=""gene"" id=""27158780-5-94-98"">VAV1</span>, RASA1, and ARHGAP35.",CTD_human
1,0,Biomarker,C0002895,"Anemia, Sickle Cell",disease,sickle cell disease,7412,VCAM1,vascular cell adhesion molecule-1,CTD_human,16916123,Plasma zinc levels inversely correlate with vascular cell adhesion molecule-1 concentration in children with sickle cell disease.,0.20701187132028098,"Plasma zinc levels inversely correlate with <span class=""gene"" id=""16916123-0-44-77"">vascular cell adhesion molecule-1</span> concentration in children with <span class=""disease"" id=""16916123-0-109-128"">sickle cell disease</span>.",CTD_human
2,0,Biomarker,C0007222,Cardiovascular Diseases,group,cardiovascular disease,7412,VCAM1,VCAM-1,CTD_human,16332659,"Isoflavones have beneficial effects on CRP concentrations, but not on other inflammatory biomarkers of cardiovascular disease risk in postmenopausal women, and may improve VCAM-1 in an ERbeta gene polymorphic subgroup.",0.209795940942407,"Isoflavones have beneficial effects on CRP concentrations, but not on other inflammatory biomarkers of <span class=""disease"" id=""16332659-11-103-125"">cardiovascular disease</span> risk in postmenopausal women, and may improve <span class=""gene"" id=""16332659-11-172-178"">VCAM-1</span> in an ERbeta gene polymorphic subgroup.",CTD_human
2,0,Biomarker,C0007222,Cardiovascular Diseases,group,CVD,7412,VCAM1,VCAM1,CTD_human,25575156,"Of the 170 SNPs tested, multiplicative interactions between well-water arsenic and two SNPs, rs281432 in ICAM1 (padj = 0.0002) and rs3176867 in VCAM1 (padj = 0.035), were significant for CVD after adjustment for multiple testing.",0.209795940942407,"Of the 170 SNPs tested, multiplicative interactions between well-water arsenic and two SNPs, rs281432 in ICAM1 (padj = 0.0002) and rs3176867 in <span class=""gene"" id=""25575156-6-144-149"">VCAM1</span> (padj = 0.035), were significant for <span class=""disease"" id=""25575156-6-187-190"">CVD</span> after adjustment for multiple testing.",CTD_human
1,0,Biomarker,C0009324,Ulcerative Colitis,disease,UC,7412,VCAM1,VCAM-1,CTD_human,15553846,"The results showed that NF-kappaB DNA binding activity, mRNA and protein expression of ICAM-1 and VCAM-1 were increased significantly in patients with UC, compared with normal control (P<0.05).",0.2,"The results showed that NF-kappaB DNA binding activity, mRNA and protein expression of ICAM-1 and <span class=""gene"" id=""15553846-9-98-104"">VCAM-1</span> were increased significantly in patients with <span class=""disease"" id=""15553846-9-151-153"">UC</span>, compared with normal control (P&lt;0.05).",CTD_human
2,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,7412,VCAM1,vascular cell adhesion molecule-1,CTD_human,11834524,Gene transfer of endothelial NO synthase and manganese superoxide dismutase on arterial vascular cell adhesion molecule-1 expression and superoxide production in deoxycorticosterone acetate-salt hypertension.,0.20054945356842604,"Gene transfer of endothelial NO synthase and manganese superoxide dismutase on arterial <span class=""gene"" id=""11834524-0-88-121"">vascular cell adhesion molecule-1</span> expression and superoxide production in deoxycorticosterone acetate-salt <span class=""disease"" id=""11834524-0-195-207"">hypertension</span>.",CTD_human
1,0,Biomarker,C0026769,Multiple Sclerosis,disease,MS,7412,VCAM1,VCAM-1,CTD_human,20175758,"Soluble forms of vascular cell adhesion molecule-1 (VCAM-1), intracellular adhesion molecule-1 (ICAM-1) and E-Selectin play a role in the regulation of blood-brain barrier damage and represent markers of the clinical course of multiple sclerosis (MS) and magnetic resonance imaging activity.",0.202681755307501,"Soluble forms of <span class=""gene"" id=""20175758-1-17-50"">vascular cell adhesion molecule-1</span> (<span class=""gene"" id=""20175758-1-52-58"">VCAM-1</span>), intracellular adhesion molecule-1 (ICAM-1) and E-Selectin play a role in the regulation of blood-brain barrier damage and represent markers of the clinical course of <span class=""disease"" id=""20175758-1-227-245"">multiple sclerosis</span> (<span class=""disease"" id=""20175758-1-247-249"">MS</span>) and magnetic resonance imaging activity.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,7412,VCAM1,VCAM1,CTD_human,22922871,"The results suggest that seven of these genes, including VCAM1 and CDK14, may confer growth and infiltration capacity to HCC cells.",0.200274726784213,"The results suggest that seven of these genes, including <span class=""gene"" id=""22922871-7-57-62"">VCAM1</span> and CDK14, may confer growth and infiltration capacity to <span class=""disease"" id=""22922871-7-121-124"">HCC</span> cells.",CTD_human
1,0,Biomarker,C0948089,Acute Coronary Syndrome,disease,ACS,7414,VCL,vinculin,CTD_human,21751358,"The expression levels of proteins involved in cellular cytoskeleton (F-actin capping, ?-tubulin, ?-tubulin isotypes 1 and 2, vinculin, vimentin and two Ras-related protein Rab-7b isotypes), glycolysis pathway (glyceraldehyde-3-phosphate dehydrogenase, lactate dehydrogenase and two pyruvate kinase isotypes) and cellular-related antioxidant system (manganese superoxide dismutase) and even the expression and activity of glutathione-S-transferase were significantly reduced in platelets from ACS patients compared to CAD patients.",0.2,"The expression levels of proteins involved in cellular cytoskeleton (F-actin capping, &beta;-tubulin, &alpha;-tubulin isotypes 1 and 2, <span class=""gene"" id=""21751358-4-125-133"">vinculin</span>, vimentin and two Ras-related protein Rab-7b isotypes), glycolysis pathway (glyceraldehyde-3-phosphate dehydrogenase, lactate dehydrogenase and two pyruvate kinase isotypes) and cellular-related antioxidant system (manganese superoxide dismutase) and even the expression and activity of glutathione-S-transferase were significantly reduced in platelets from <span class=""disease"" id=""21751358-4-492-495"">ACS</span> patients compared to CAD patients.",CTD_human
2,0,Biomarker,C0002170,Alopecia,disease,alopecia,7421,VDR,VDR,CTD_human,22466564,"HR mutations confer an alopecia phenotype similar to VDR mutations in mice and humans, but the underlying molecular mechanisms have not been elucidated.",0.412883448103381,"HR mutations confer an <span class=""disease"" id=""22466564-5-23-31"">alopecia</span> phenotype similar to <span class=""gene"" id=""22466564-5-53-56"">VDR</span> mutations in mice and humans, but the underlying molecular mechanisms have not been elucidated.",CTD_human;HPO
1,0,Biomarker,C0014556,"Epilepsy, Temporal Lobe",disease,temporal lobe epilepsy,7421,VDR,vitamin D receptor,CTD_human,18534255,Expression of vitamin D receptor mRNA in the hippocampal formation of rats submitted to a model of temporal lobe epilepsy induced by pilocarpine.,0.20054945356842604,"Expression of <span class=""gene"" id=""18534255-0-14-32"">vitamin D receptor</span> mRNA in the hippocampal formation of rats submitted to a model of <span class=""disease"" id=""18534255-0-99-121"">temporal lobe epilepsy</span> induced by pilocarpine.",CTD_human
1,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,7421,VDR,vitamin D receptor,CTD_human,11335187,Associations of blood pressure and hypertension with lead dose measures and polymorphisms in the vitamin D receptor and delta-aminolevulinic acid dehydratase genes.,0.20701187132028098,"Associations of blood pressure and <span class=""disease"" id=""11335187-0-35-47"">hypertension</span> with lead dose measures and polymorphisms in the <span class=""gene"" id=""11335187-0-97-115"">vitamin D receptor</span> and delta-aminolevulinic acid dehydratase genes.",CTD_human
1,0,Biomarker,C0023434,Chronic Lymphocytic Leukemia,disease,B-CLL,7421,VDR,vitamin D receptor,CTD_human,12446453,"The B-CLL cells in the study were shown to highly express vitamin D receptor, but an additional receptor-independent mechanism of cell killing cannot be ruled out at this stage.",0.2,"The <span class=""disease"" id=""12446453-9-4-9"">B-CLL</span> cells in the study were shown to highly express <span class=""gene"" id=""12446453-9-58-76"">vitamin D receptor</span>, but an additional receptor-independent mechanism of cell killing cannot be ruled out at this stage.",CTD_human
1,0,Biomarker,C0002395,Alzheimer's Disease,disease,AD,7422,VEGFA,VEGF,CTD_human,15732116,"These findings suggest that polymorphisms within the promoter region of the VEGF gene confer greater risk for AD, probably by reducing its neuroprotective effect, and confirm the biological role of VEGF in neurodegenerative processes.",0.232949501265007,"These findings suggest that polymorphisms within the promoter region of the <span class=""gene"" id=""15732116-8-76-80"">VEGF</span> gene confer greater risk for <span class=""disease"" id=""15732116-8-110-112"">AD</span>, probably by reducing its neuroprotective effect, and confirm the biological role of <span class=""gene"" id=""15732116-8-198-202"">VEGF</span> in neurodegenerative processes.",CTD_human
1,0,Biomarker,C0003873,Rheumatoid Arthritis,disease,rheumatoid arthritis,7422,VEGFA,VEGF,CTD_human,16368150,Interleukin-18 induces the production of vascular endothelial growth factor (VEGF) in rheumatoid arthritis synovial fibroblasts via AP-1-dependent pathways.,0.22642324971014702,"Interleukin-18 induces the production of <span class=""gene"" id=""16368150-0-41-75"">vascular endothelial growth factor</span> (<span class=""gene"" id=""16368150-0-77-81"">VEGF</span>) in <span class=""disease"" id=""16368150-0-86-106"">rheumatoid arthritis</span> synovial fibroblasts via AP-1-dependent pathways.",CTD_human
3,0,Biomarker,C0004096,Asthma,disease,asthma,7422,VEGFA,VEGF,CTD_human,15201500,Acute and chronic changes of vascular endothelial growth factor (VEGF) in induced sputum of toluene diisocyanate (TDI)-induced asthma patients.,0.22840558538231198,"Acute and chronic changes of <span class=""gene"" id=""15201500-0-29-63"">vascular endothelial growth factor</span> (<span class=""gene"" id=""15201500-0-65-69"">VEGF</span>) in induced sputum of toluene diisocyanate (TDI)-induced <span class=""disease"" id=""15201500-0-127-133"">asthma</span> patients.",CTD_human
3,0,Biomarker,C0004096,Asthma,disease,asthma,7422,VEGFA,vascular endothelial growth factor,CTD_human,11907124,Contribution of vascular endothelial growth factor to airway hyperresponsiveness and inflammation in a murine model of toluene diisocyanate-induced asthma.,0.22840558538231198,"Contribution of <span class=""gene"" id=""11907124-0-16-50"">vascular endothelial growth factor</span> to airway hyperresponsiveness and inflammation in a murine model of toluene diisocyanate-induced <span class=""disease"" id=""11907124-0-148-154"">asthma</span>.",CTD_human
1,0,Biomarker,C0004153,Atherosclerosis,disease,atherosclerosis,7422,VEGFA,VEGF,CTD_human,15937083,VEGF polymorphisms and severity of atherosclerosis.,0.227376776400422,"<span class=""gene"" id=""15937083-0-0-4"">VEGF</span> polymorphisms and severity of <span class=""disease"" id=""15937083-0-35-50"">atherosclerosis</span>.",CTD_human
1,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,non-small cell lung carcinoma,7422,VEGFA,VEGF,CTD_human,15956251,"In the present studies, mice bearing established xenografts (A431 epidermoid carcinoma, H125 non-small cell lung carcinoma, SF767 glioblastoma, and MDA-MB-468 mammary carcinoma) were treated with efficacious and subefficacious doses of CI-1033, and plasma levels and xenograft gene expression of VEGF and IL-8 were evaluated.",0.23262697478672895,"In the present studies, mice bearing established xenografts (A431 epidermoid carcinoma, H125 <span class=""disease"" id=""15956251-4-93-122"">non-small cell lung carcinoma</span>, SF767 glioblastoma, and MDA-MB-468 mammary carcinoma) were treated with efficacious and subefficacious doses of CI-1033, and plasma levels and xenograft gene expression of <span class=""gene"" id=""15956251-4-296-300"">VEGF</span> and IL-8 were evaluated.",CTD_human
2,0,Biomarker,C0007137,Squamous cell carcinoma,disease,epidermoid carcinoma,7422,VEGFA,VEGF,CTD_human,15956251,"In the present studies, mice bearing established xenografts (A431 epidermoid carcinoma, H125 non-small cell lung carcinoma, SF767 glioblastoma, and MDA-MB-468 mammary carcinoma) were treated with efficacious and subefficacious doses of CI-1033, and plasma levels and xenograft gene expression of VEGF and IL-8 were evaluated.",0.271905109787403,"In the present studies, mice bearing established xenografts (A431 <span class=""disease"" id=""15956251-4-66-86"">epidermoid carcinoma</span>, H125 non-small cell lung carcinoma, SF767 glioblastoma, and MDA-MB-468 mammary carcinoma) were treated with efficacious and subefficacious doses of CI-1033, and plasma levels and xenograft gene expression of <span class=""gene"" id=""15956251-4-296-300"">VEGF</span> and IL-8 were evaluated.",CTD_human
1,0,Biomarker,C0011881,Diabetic Nephropathy,disease,DN,7422,VEGFA,VEGF,CTD_human,18630688,"VEGF and Flk-1 play an important role in the pathogenesis of DN, of which over-expression may lead to the damage of kidney.",0.22759576040698998,"<span class=""gene"" id=""18630688-5-0-4"">VEGF</span> and Flk-1 play an important role in the pathogenesis of <span class=""disease"" id=""18630688-5-61-63"">DN</span>, of which over-expression may lead to the damage of kidney.",CTD_human
3,0,Biomarker,C0011884,Diabetic Retinopathy,disease,diabetic retinopathy,7422,VEGFA,VEGF,CTD_human,15788408,Oxidative stress is suggested to occur in retinal tissue during age-related macular degeneration and diabetic retinopathy and is suspected in the mechanism of VEGF expression in these diseases.,0.293611432628947,"Oxidative stress is suggested to occur in retinal tissue during age-related macular degeneration and <span class=""disease"" id=""15788408-2-101-121"">diabetic retinopathy</span> and is suspected in the mechanism of <span class=""gene"" id=""15788408-2-159-163"">VEGF</span> expression in these diseases.",CTD_human
3,0,Biomarker,C0011884,Diabetic Retinopathy,disease,diabetic retinopathy,7422,VEGFA,VEGF,CTD_human,11978667,A common polymorphism in the 5'-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes.,0.293611432628947,"A common polymorphism in the 5'-untranslated region of the <span class=""gene"" id=""11978667-0-59-63"">VEGF</span> gene is associated with <span class=""disease"" id=""11978667-0-88-108"">diabetic retinopathy</span> in type 2 diabetes.",CTD_human
2,0,Biomarker,C0018801,Heart failure,disease,heart failure,7422,VEGFA,vascular endothelial growth factor,CTD_human,15732037,Carvedilol modulates the expression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in a rat model of volume-overload heart failure.,0.207561324888707,"Carvedilol modulates the expression of hypoxia-inducible factor-1alpha and <span class=""gene"" id=""15732037-0-75-109"">vascular endothelial growth factor</span> in a rat model of volume-overload <span class=""disease"" id=""15732037-0-144-157"">heart failure</span>.",CTD_human
1,0,Biomarker,C0023470,Myeloid Leukemia,disease,myeloid leukaemia,7422,VEGFA,vascular endothelial growth factor A,CTD_human,21535412,"Further investigations revealed that knock-down of AGO2 by custom-made AGO2 siRNA in HEK-293 cells resulted in silencing of the expression of target genes vascular endothelial growth factor A and histone deacetylase 2, which are known to be involved in the development of myeloid leukaemia.",0.201098907136852,"Further investigations revealed that knock-down of AGO2 by custom-made AGO2 siRNA in HEK-293 cells resulted in silencing of the expression of target genes <span class=""gene"" id=""21535412-5-155-191"">vascular endothelial growth factor A</span> and histone deacetylase 2, which are known to be involved in the development of <span class=""disease"" id=""21535412-5-272-289"">myeloid leukaemia</span>.",CTD_human
1,0,Biomarker,C0023890,Liver Cirrhosis,disease,cirrhosis,7422,VEGFA,VEGF,CTD_human,11981751,Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis.,0.219042428316388,"Hypoxia-induced <span class=""gene"" id=""11981751-0-16-20"">VEGF</span> and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental <span class=""disease"" id=""11981751-0-114-123"">cirrhosis</span>.",CTD_human
1,0,Biomarker,C0024115,Lung diseases,group,lung disease,7422,VEGFA,VEGF,CTD_human,23618901,The ability of lung fibroblasts to produce VEGF may play a role in pathogenesis of cigarette smoke induced lung disease.,0.201373633921065,"The ability of lung fibroblasts to produce <span class=""gene"" id=""23618901-17-43-47"">VEGF</span> may play a role in pathogenesis of cigarette smoke induced <span class=""disease"" id=""23618901-17-107-119"">lung disease</span>.",CTD_human
3,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastatic tumor,7422,VEGFA,VEGF,CTD_human,15659795,"We have investigated the effect of IFNs/IFO treatment on the expression of vascular endothelial growth factor (VEGF), matrix metalloproteinase 9 (MMP-9), and urokinase plasminogen activator receptor (uPAR), three key mediators of tumor growth and angiogenesis, in tumor xenografts generated either from a primary tumor (EW7) or from a metastatic tumor (COH).",0.342856986690716,"We have investigated the effect of IFNs/IFO treatment on the expression of <span class=""gene"" id=""15659795-5-75-109"">vascular endothelial growth factor</span> (<span class=""gene"" id=""15659795-5-111-115"">VEGF</span>), matrix metalloproteinase 9 (MMP-9), and urokinase plasminogen activator receptor (uPAR), three key mediators of tumor growth and angiogenesis, in tumor xenografts generated either from a primary tumor (EW7) or from a <span class=""disease"" id=""15659795-5-335-351"">metastatic tumor</span> (COH).",CTD_human
1,0,Biomarker,C0029463,Osteosarcoma,disease,osteosarcoma,7422,VEGFA,VEGF,CTD_human,20158913,Neoadjuvant multidrug chemotherapy including high-dose methotrexate modifies VEGF expression in osteosarcoma: an immunohistochemical analysis.,0.219462535547178,"Neoadjuvant multidrug chemotherapy including high-dose methotrexate modifies <span class=""gene"" id=""20158913-0-77-81"">VEGF</span> expression in <span class=""disease"" id=""20158913-0-96-108"">osteosarcoma</span>: an immunohistochemical analysis.",CTD_human
1,0,Biomarker,C0033860,Psoriasis,disease,psoriasis,7422,VEGFA,vascular endothelial growth factor,CTD_human,16385345,Interaction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasis.,0.23201842097741002,"Interaction between genetic control of <span class=""gene"" id=""16385345-0-39-73"">vascular endothelial growth factor</span> production and retinoid responsiveness in <span class=""disease"" id=""16385345-0-116-125"">psoriasis</span>.",CTD_human
1,0,Biomarker,C0035412,Rhabdomyosarcoma,disease,rhabdomyosarcoma,7422,VEGFA,Vascular endothelial growth factor,CTD_human,16116481,Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid.,0.204381273170092,"<span class=""gene"" id=""16116481-0-0-34"">Vascular endothelial growth factor</span> acts in an autocrine manner in <span class=""disease"" id=""16116481-0-66-82"">rhabdomyosarcoma</span> cell lines and can be inhibited with all-trans-retinoic acid.",CTD_human
1,0,Biomarker,C0038358,Gastric ulcer,disease,gastric ulcer healing,7422,VEGFA,vascular endothelial growth factor,CTD_human,11353854,Platelets modulate gastric ulcer healing: role of endostatin and vascular endothelial growth factor release.,0.207114185634906,"Platelets modulate <span class=""disease"" id=""11353854-0-19-40"">gastric ulcer healing</span>: role of endostatin and <span class=""gene"" id=""11353854-0-65-99"">vascular endothelial growth factor</span> release.",CTD_human
1,0,Biomarker,C0085109,Corneal Neovascularization,disease,corneal neovascularization,7422,VEGFA,VEGF,CTD_human,9301478,Experiments examining thalidomide's enantiomers reveal-that the S(-)-enantiomer has the strongest antiangiogenic activity in VEGF-induced and bFGF-induced corneal neovascularization.,0.20521980890004898,"Experiments examining thalidomide's enantiomers reveal-that the S(-)-enantiomer has the strongest antiangiogenic activity in <span class=""gene"" id=""9301478-4-125-129"">VEGF</span>-induced and bFGF-induced <span class=""disease"" id=""9301478-4-155-181"">corneal neovascularization</span>.",CTD_human
5,0,Biomarker,C0151744,Myocardial Ischemia,disease,myocardial ischemia,7422,VEGFA,VEGF,CTD_human,9860779,We initiated a phase 1 clinical study to determine the safety and bioactivity of direct myocardial gene transfer of vascular endothelial growth factor (VEGF) as sole therapy for patients with symptomatic myocardial ischemia.,0.21064883204968102,"We initiated a phase 1 clinical study to determine the safety and bioactivity of direct myocardial gene transfer of <span class=""gene"" id=""9860779-1-116-150"">vascular endothelial growth factor</span> (<span class=""gene"" id=""9860779-1-152-156"">VEGF</span>) as sole therapy for patients with symptomatic <span class=""disease"" id=""9860779-1-204-223"">myocardial ischemia</span>.",CTD_human
5,0,Therapeutic,C0151744,Myocardial Ischemia,disease,myocardial ischemia,7422,VEGFA,VEGF,CTD_human,14503966,These results indicate an arteriogenic effect of VEGF in a large mammalian model of myocardial ischemia and encourage the use of VEGF to promote arteriolar growth in patients with severe coronary artery disease.,0.21064883204968102,"These results indicate an arteriogenic effect of <span class=""gene"" id=""14503966-8-49-53"">VEGF</span> in a large mammalian model of <span class=""disease"" id=""14503966-8-84-103"">myocardial ischemia</span> and encourage the use of <span class=""gene"" id=""14503966-8-129-133"">VEGF</span> to promote arteriolar growth in patients with severe coronary artery disease.",CTD_human
5,0,Biomarker,C0151744,Myocardial Ischemia,disease,myocardial ischemia,7422,VEGFA,VEGF,CTD_human,14503966,These results indicate an arteriogenic effect of VEGF in a large mammalian model of myocardial ischemia and encourage the use of VEGF to promote arteriolar growth in patients with severe coronary artery disease.,0.21064883204968102,"These results indicate an arteriogenic effect of <span class=""gene"" id=""14503966-8-49-53"">VEGF</span> in a large mammalian model of <span class=""disease"" id=""14503966-8-84-103"">myocardial ischemia</span> and encourage the use of <span class=""gene"" id=""14503966-8-129-133"">VEGF</span> to promote arteriolar growth in patients with severe coronary artery disease.",CTD_human
5,0,Therapeutic,C0151744,Myocardial Ischemia,disease,myocardial ischemia,7422,VEGFA,VEGF,CTD_human,9860779,We initiated a phase 1 clinical study to determine the safety and bioactivity of direct myocardial gene transfer of vascular endothelial growth factor (VEGF) as sole therapy for patients with symptomatic myocardial ischemia.,0.21064883204968102,"We initiated a phase 1 clinical study to determine the safety and bioactivity of direct myocardial gene transfer of <span class=""gene"" id=""9860779-1-116-150"">vascular endothelial growth factor</span> (<span class=""gene"" id=""9860779-1-152-156"">VEGF</span>) as sole therapy for patients with symptomatic <span class=""disease"" id=""9860779-1-204-223"">myocardial ischemia</span>.",CTD_human
1,0,Biomarker,C0206726,gliosarcoma,disease,gliosarcomas,7422,VEGFA,VEGF-A,CTD_human,16533777,"The aim of this study was to evaluate the effect of VEGF-A expression on tumor growth, perfusion, and chemotherapeutic efficacy in orthotopic 9L gliosarcomas.",0.200274726784213,"The aim of this study was to evaluate the effect of <span class=""gene"" id=""16533777-2-52-58"">VEGF-A</span> expression on tumor growth, perfusion, and chemotherapeutic efficacy in orthotopic 9L <span class=""disease"" id=""16533777-2-145-157"">gliosarcomas</span>.",CTD_human
1,0,Biomarker,C0242383,Age related macular degeneration,disease,age-related macular degeneration,7422,VEGFA,VEGF,CTD_human,15788408,Oxidative stress is suggested to occur in retinal tissue during age-related macular degeneration and diabetic retinopathy and is suspected in the mechanism of VEGF expression in these diseases.,0.270794606220161,"Oxidative stress is suggested to occur in retinal tissue during <span class=""disease"" id=""15788408-2-64-96"">age-related macular degeneration</span> and diabetic retinopathy and is suspected in the mechanism of <span class=""gene"" id=""15788408-2-159-163"">VEGF</span> expression in these diseases.",CTD_human
2,0,Biomarker,C1956346,Coronary Artery Disease,disease,CAD,7422,VEGFA,VEGF165,CTD_human,14668888,Direct myocardial administration of genes encoding VEGF165 can be an effective method of treatment in patients with chronic and advanced CAD either as a supplementary treatment or as a single therapy.,0.23201032995204898,"Direct myocardial administration of genes encoding <span class=""gene"" id=""14668888-12-51-58"">VEGF165</span> can be an effective method of treatment in patients with chronic and advanced <span class=""disease"" id=""14668888-12-137-140"">CAD</span> either as a supplementary treatment or as a single therapy.",CTD_human
2,0,Therapeutic,C1956346,Coronary Artery Disease,disease,CAD,7422,VEGFA,VEGF165,CTD_human,14668888,Direct myocardial administration of genes encoding VEGF165 can be an effective method of treatment in patients with chronic and advanced CAD either as a supplementary treatment or as a single therapy.,0.23201032995204898,"Direct myocardial administration of genes encoding <span class=""gene"" id=""14668888-12-51-58"">VEGF165</span> can be an effective method of treatment in patients with chronic and advanced <span class=""disease"" id=""14668888-12-137-140"">CAD</span> either as a supplementary treatment or as a single therapy.",CTD_human
1,0,Biomarker,C2717961,Thrombotic Microangiopathies,group,thrombotic microangiopathy,7422,VEGFA,VEGF-A,CTD_human,22808199,Podocyte or endothelial cell VEGF-A knockout causes thrombotic microangiopathy in adult mice.,0.20054945356842604,"Podocyte or endothelial cell <span class=""gene"" id=""22808199-1-29-35"">VEGF-A</span> knockout causes <span class=""disease"" id=""22808199-1-52-78"">thrombotic microangiopathy</span> in adult mice.",CTD_human
1,0,Biomarker,C0025202,melanoma,disease,malignant melanoma,7424,VEGFC,VEGF-C,CTD_human,17562445,Serum VEGF-C is associated with metastatic site in patients with malignant melanoma.,0.20793836598754503,"Serum <span class=""gene"" id=""17562445-0-6-12"">VEGF-C</span> is associated with metastatic site in patients with <span class=""disease"" id=""17562445-0-65-83"">malignant melanoma</span>.",CTD_human
9,0,Biomarker,C0007134,Renal Cell Carcinoma,disease,renal cell cancer,7428,VHL,VHL,CTD_human,15177666,VHL mutations in renal cell cancer: does occupational exposure to trichloroethylene make a difference?,0.525275709484735,"<span class=""gene"" id=""15177666-0-0-3"">VHL</span> mutations in <span class=""disease"" id=""15177666-0-17-34"">renal cell cancer</span>: does occupational exposure to trichloroethylene make a difference?",CTD_human;HPO
9,0,Biomarker,C0007134,Renal Cell Carcinoma,disease,RCC,7428,VHL,VHL,CTD_human,10340905,"Our results suggest that RCC in patients with high, cumulative TRI exposure is associated with a unique mutation pattern in the VHL gene.",0.525275709484735,"Our results suggest that <span class=""disease"" id=""10340905-11-25-28"">RCC</span> in patients with high, cumulative TRI exposure is associated with a unique mutation pattern in the <span class=""gene"" id=""10340905-11-128-131"">VHL</span> gene.",CTD_human;HPO
9,0,Biomarker,C0007134,Renal Cell Carcinoma,disease,RCC,7428,VHL,VHL,CTD_human,9137812,"By comparison to much lower reported VHL mutation frequencies of 33-55% in TRI-unexposed RCC patients, these results indicate a specifically high mutation frequency at the VHL gene in TRI-exposed RCC patients; four of these aberrations have thus far been confirmed as VHL mutations by sequence analysis.",0.525275709484735,"By comparison to much lower reported VHL mutation frequencies of 33-55% in TRI-unexposed <span class=""disease"" id=""9137812-6-89-92"">RCC</span> patients, these results indicate a specifically high mutation frequency at the <span class=""gene"" id=""9137812-6-172-175"">VHL</span> gene in TRI-exposed <span class=""disease"" id=""9137812-6-196-199"">RCC</span> patients; four of these aberrations have thus far been confirmed as VHL mutations by sequence analysis.",CTD_human;HPO
9,0,Biomarker,C0007134,Renal Cell Carcinoma,disease,renal-cell carcinoma,7428,VHL,VHL,CTD_human,19473641,Bilateral renal-cell carcinoma associated with an acquired VHL mutation and long-term trichloroethylene exposure.,0.525275709484735,"Bilateral <span class=""disease"" id=""19473641-0-10-30"">renal-cell carcinoma</span> associated with an acquired <span class=""gene"" id=""19473641-0-59-62"">VHL</span> mutation and long-term trichloroethylene exposure.",CTD_human;HPO
1,0,Biomarker,C0027708,Nephroblastoma,disease,nephroblastomas,7428,VHL,VHL,CTD_human,11880179,"By immunohistochemistry, however, VHL protein level was evidently reduced in six of the eight eosinophilic renal epithelial tumors and in all the ten nephroblastomas.",0.2,"By immunohistochemistry, however, <span class=""gene"" id=""11880179-3-34-37"">VHL</span> protein level was evidently reduced in six of the eight eosinophilic renal epithelial tumors and in all the ten <span class=""disease"" id=""11880179-3-150-165"">nephroblastomas</span>.",CTD_human
1,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastasis,7430,EZR,ezrin,CTD_human,27137931,High expression of ezrin correlates with poor prognosis and metastasis in osteosarcoma.,0.23068326756796398,"High expression of <span class=""gene"" id=""27137931-2-19-24"">ezrin</span> correlates with poor prognosis and <span class=""disease"" id=""27137931-2-60-70"">metastasis</span> in osteosarcoma.",CTD_human
1,0,Biomarker,C0007140,Carcinosarcoma,disease,carcinosarcomas,7431,VIM,vimentin,CTD_human,15132766,"Multiple mammary tumors of adenocarcinoma type were induced in all females, while 83% of treated males developed adenocarcinomas, sarcomas and transitional carcinosarcomas, as evidenced by casein and vimentin immunoreactivity.",0.2,"Multiple mammary tumors of adenocarcinoma type were induced in all females, while 83% of treated males developed adenocarcinomas, sarcomas and transitional <span class=""disease"" id=""15132766-2-156-171"">carcinosarcomas</span>, as evidenced by casein and <span class=""gene"" id=""15132766-2-200-208"">vimentin</span> immunoreactivity.",CTD_human
1,0,Biomarker,C0027720,Nephrosis,disease,nephrosis,7431,VIM,vimentin,CTD_human,16418842,"To gain insight into the role of IF proteins in podocytes, we investigated the expression of nestin, vimentin, and desmin in puromycin aminonucleoside (PAN) nephrosis.",0.28,"To gain insight into the role of IF proteins in podocytes, we investigated the expression of nestin, <span class=""gene"" id=""16418842-2-101-109"">vimentin</span>, and desmin in puromycin aminonucleoside (PAN) <span class=""disease"" id=""16418842-2-157-166"">nephrosis</span>.",CTD_human
2,0,Biomarker,C0029408,Degenerative polyarthritis,disease,osteoarthritis,7431,VIM,vimentin,CTD_human,16876394,"We have demonstrated that an intact vimentin intermediate filament network contributes to the maintenance of the chondrocyte phenotype and thus an imbalance favouring filament disassembly can disturb the integrity of the articular cartilage, and may ultimately lead to the development of pathologies such as osteoarthritis.",0.2,"We have demonstrated that an intact <span class=""gene"" id=""16876394-12-36-44"">vimentin</span> intermediate filament network contributes to the maintenance of the chondrocyte phenotype and thus an imbalance favouring filament disassembly can disturb the integrity of the articular cartilage, and may ultimately lead to the development of pathologies such as <span class=""disease"" id=""16876394-12-308-322"">osteoarthritis</span>.",CTD_human
1,0,Biomarker,C0086543,Cataract,disease,cataract,7431,VIM,vimentin,CTD_human,19126778,Dominant cataract formation in association with a vimentin assembly disrupting mutation.,0.20082418035263896,"Dominant <span class=""disease"" id=""19126778-0-9-17"">cataract</span> formation in association with a <span class=""gene"" id=""19126778-0-50-58"">vimentin</span> assembly disrupting mutation.",CTD_human
1,0,Biomarker,C0345967,Malignant mesothelioma,disease,malignant mesothelioma,7431,VIM,vimentin,CTD_human,22784439,"Immunohistochemical analysis for epithelial membrane antigen, calretinin, vimentin, ?-catenin, melan-A, glucose transporter-1, cytokeratin CAM5.2, Wilms tumor antigen-1, D2-40, CD146, progesterone receptor, estrogen receptor, and cytokeratin 5/6 was indicative of malignant mesothelioma.",0.200274726784213,"Immunohistochemical analysis for epithelial membrane antigen, calretinin, <span class=""gene"" id=""22784439-5-74-82"">vimentin</span>, &beta;-catenin, melan-A, glucose transporter-1, cytokeratin CAM5.2, Wilms tumor antigen-1, D2-40, CD146, progesterone receptor, estrogen receptor, and cytokeratin 5/6 was indicative of <span class=""disease"" id=""22784439-5-264-286"">malignant mesothelioma</span>.",CTD_human
1,0,Biomarker,C0948089,Acute Coronary Syndrome,disease,ACS,7431,VIM,vimentin,CTD_human,21751358,"The expression levels of proteins involved in cellular cytoskeleton (F-actin capping, ?-tubulin, ?-tubulin isotypes 1 and 2, vinculin, vimentin and two Ras-related protein Rab-7b isotypes), glycolysis pathway (glyceraldehyde-3-phosphate dehydrogenase, lactate dehydrogenase and two pyruvate kinase isotypes) and cellular-related antioxidant system (manganese superoxide dismutase) and even the expression and activity of glutathione-S-transferase were significantly reduced in platelets from ACS patients compared to CAD patients.",0.2,"The expression levels of proteins involved in cellular cytoskeleton (F-actin capping, &beta;-tubulin, &alpha;-tubulin isotypes 1 and 2, vinculin, <span class=""gene"" id=""21751358-4-135-143"">vimentin</span> and two Ras-related protein Rab-7b isotypes), glycolysis pathway (glyceraldehyde-3-phosphate dehydrogenase, lactate dehydrogenase and two pyruvate kinase isotypes) and cellular-related antioxidant system (manganese superoxide dismutase) and even the expression and activity of glutathione-S-transferase were significantly reduced in platelets from <span class=""disease"" id=""21751358-4-492-495"">ACS</span> patients compared to CAD patients.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,7432,VIP,VIP,CTD_human,17521630,The current study examined the blockage of VIP during embryogenesis as a model for the behavioral deficits of autism.,0.200274726784213,"The current study examined the blockage of <span class=""gene"" id=""17521630-5-43-46"">VIP</span> during embryogenesis as a model for the behavioral deficits of <span class=""disease"" id=""17521630-5-110-116"">autism</span>.",CTD_human
1,0,Therapeutic,C0009241,Cognition Disorders,group,cognitive deficits,7432,VIP,VIP,CTD_human,8208360,"Thus, VIP appears to have an ameliorating effect on spatial cognitive deficits induced by scopolamine in the rat.",0.2,"Thus, <span class=""gene"" id=""8208360-3-6-9"">VIP</span> appears to have an ameliorating effect on spatial <span class=""disease"" id=""8208360-3-60-78"">cognitive deficits</span> induced by scopolamine in the rat.",CTD_human
1,0,Biomarker,C0013080,Down Syndrome,disease,Down syndrome,7432,VIP,VIP,CTD_human,16289943,"We discuss interrelationships of VIP, NT-3 and IL-8 and their potential relevance to features of the neuropathology of autism or Down syndrome.",0.200274726784213,"We discuss interrelationships of <span class=""gene"" id=""16289943-12-33-36"">VIP</span>, NT-3 and IL-8 and their potential relevance to features of the neuropathology of autism or <span class=""disease"" id=""16289943-12-129-142"">Down syndrome</span>.",CTD_human
2,0,Biomarker,C0035455,Rhinitis,disease,rhinitis,7432,VIP,VIP,CTD_human,14680090,"In comparison to the control, the aspirin-sensitive rhinitis group had a significant increase of VIP-like immunoreactivity in mucosal nerve fibres.",0.2,"In comparison to the control, the aspirin-sensitive <span class=""disease"" id=""14680090-5-52-60"">rhinitis</span> group had a significant increase of <span class=""gene"" id=""14680090-5-97-100"">VIP</span>-like immunoreactivity in mucosal nerve fibres.",CTD_human
2,0,Biomarker,C0035455,Rhinitis,disease,rhinitis,7432,VIP,VIP,CTD_human,12746121,Toxic rhinitis patients had significantly elevated expression scores for VIP (2.83 +/- 0.31 vs 1.27 +/- 0.47 control group) and NPY (3.17 +/- 0.31 vs 0.91 +/- 0.37 control group) revealing an increase of mediators in distinct subpopulations of airway nerves.,0.2,"Toxic <span class=""disease"" id=""12746121-5-6-14"">rhinitis</span> patients had significantly elevated expression scores for <span class=""gene"" id=""12746121-5-73-76"">VIP</span> (2.83 +/- 0.31 vs 1.27 +/- 0.47 control group) and NPY (3.17 +/- 0.31 vs 0.91 +/- 0.37 control group) revealing an increase of mediators in distinct subpopulations of airway nerves.",CTD_human
1,0,Biomarker,C3714756,Intellectual Disability,group,mental retardation,7432,VIP,VIP,CTD_human,11357950,"Neonatal concentrations of VIP, CGRP, BDNF, and NT4/5 were higher (ANOVA, all p values < 0.0001 by Scheffe test for pairwise differences) in children in the autistic spectrum and in those with mental retardation without autism than in control children.",0.2,"Neonatal concentrations of <span class=""gene"" id=""11357950-3-27-30"">VIP</span>, CGRP, BDNF, and NT4/5 were higher (ANOVA, all p values &lt; 0.0001 by Scheffe test for pairwise differences) in children in the autistic spectrum and in those with <span class=""disease"" id=""11357950-3-193-211"">mental retardation</span> without autism than in control children.",CTD_human
1,0,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,7434,VIPR2,VIPR2,CTD_human,21285140,Copy number variants in schizophrenia: confirmation of five previous findings and new evidence for 3q29 microdeletions and VIPR2 duplications.,0.201923087489492,"Copy number variants in <span class=""disease"" id=""21285140-0-24-37"">schizophrenia</span>: confirmation of five previous findings and new evidence for 3q29 microdeletions and <span class=""gene"" id=""21285140-0-123-128"">VIPR2</span> duplications.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,7436,VLDLR,VLDLR,CTD_human,15820235,"Reductions in Reelin protein and mRNA and Dab 1 mRNA and elevations in Reln receptor VLDLR mRNA demonstrate impairments in the Reelin signaling system in autism, accounting for some of the brain structural and cognitive deficits observed in the disorder.",0.20054945356842604,"Reductions in Reelin protein and mRNA and Dab 1 mRNA and elevations in Reln receptor <span class=""gene"" id=""15820235-8-85-90"">VLDLR</span> mRNA demonstrate impairments in the Reelin signaling system in <span class=""disease"" id=""15820235-8-154-160"">autism</span>, accounting for some of the brain structural and cognitive deficits observed in the disorder.",CTD_human
1,0,Biomarker,C0028754,Obesity,disease,obese,7436,VLDLR,VLDLR,CTD_human,20975297,"Similarly, transcripts associated with cholesterol and lipoprotein metabolism showed a differential expression, with APOE and ABCA being decreased and VLDLR being increased in obese versus lean subjects.",0.20082418035263896,"Similarly, transcripts associated with cholesterol and lipoprotein metabolism showed a differential expression, with APOE and ABCA being decreased and <span class=""gene"" id=""20975297-4-151-156"">VLDLR</span> being increased in <span class=""disease"" id=""20975297-4-176-181"">obese</span> versus lean subjects.",CTD_human
1,0,Biomarker,C0004153,Atherosclerosis,disease,atherosclerosis,7442,TRPV1,TRPV1,CTD_human,21908651,Activation of TRPV1 reduces vascular lipid accumulation and attenuates atherosclerosis.,0.2,"Activation of <span class=""gene"" id=""21908651-0-14-19"">TRPV1</span> reduces vascular lipid accumulation and attenuates <span class=""disease"" id=""21908651-0-71-86"">atherosclerosis</span>.",CTD_human
1,0,Biomarker,C0014556,"Epilepsy, Temporal Lobe",disease,temporal lobe epilepsy,7442,TRPV1,TRPV1,CTD_human,20144892,Effects of TRPV1 activation on synaptic excitation in the dentate gyrus of a mouse model of temporal lobe epilepsy.,0.200274726784213,"Effects of <span class=""gene"" id=""20144892-0-11-16"">TRPV1</span> activation on synaptic excitation in the dentate gyrus of a mouse model of <span class=""disease"" id=""20144892-0-92-114"">temporal lobe epilepsy</span>.",CTD_human
1,0,Biomarker,C0014868,Esophagitis,disease,oesophagitis,7442,TRPV1,VR-1,CTD_human,16091555,This suggests that acid induced oesophagitis may act through VR-1 and that inhibition of the receptor may reduce inflammation.,0.2,"This suggests that acid induced <span class=""disease"" id=""16091555-9-32-44"">oesophagitis</span> may act through <span class=""gene"" id=""16091555-9-61-65"">VR-1</span> and that inhibition of the receptor may reduce inflammation.",CTD_human
4,0,Biomarker,C0020429,Hyperalgesia,phenotype,hyperalgesia,7442,TRPV1,TRPV1,CTD_human,23006841,Pretreatment with ketoconazole inhibited the release of TRPV1 agonists in lipid extracts from inflamed skin and significantly reversed CFA-induced heat hyperalgesia by a peripheral mechanism of action.,0.289037273124398,"Pretreatment with ketoconazole inhibited the release of <span class=""gene"" id=""23006841-7-56-61"">TRPV1</span> agonists in lipid extracts from inflamed skin and significantly reversed CFA-induced heat <span class=""disease"" id=""23006841-7-152-164"">hyperalgesia</span> by a peripheral mechanism of action.",CTD_human
4,0,Biomarker,C0020429,Hyperalgesia,phenotype,hyperalgesia,7442,TRPV1,TRPV1,CTD_human,18234885,"Because TRPV1 and TRPA1 channels play important roles in controlling hyperalgesia in inflammatory pain models, we investigated their modulation by WIN and AM1241.",0.289037273124398,"Because <span class=""gene"" id=""18234885-2-8-13"">TRPV1</span> and TRPA1 channels play important roles in controlling <span class=""disease"" id=""18234885-2-69-81"">hyperalgesia</span> in inflammatory pain models, we investigated their modulation by WIN and AM1241.",CTD_human
4,0,Biomarker,C0020429,Hyperalgesia,phenotype,hyperalgesia,7442,TRPV1,TRPV1,CTD_human,18774343,TRPV1 receptor in expression of opioid-induced hyperalgesia.,0.289037273124398,"<span class=""gene"" id=""18774343-0-0-5"">TRPV1</span> receptor in expression of opioid-induced <span class=""disease"" id=""18774343-0-47-59"">hyperalgesia</span>.",CTD_human
1,0,Biomarker,C0028754,Obesity,disease,obesity,7442,TRPV1,TRPV1,CTD_human,17347480,We conclude that the activation of TRPV1 channels by capsaicin prevented adipogenesis and obesity.,0.203231208875927,"We conclude that the activation of <span class=""gene"" id=""17347480-13-35-40"">TRPV1</span> channels by capsaicin prevented adipogenesis and <span class=""disease"" id=""17347480-13-90-97"">obesity</span>.",CTD_human
4,0,Therapeutic,C0030193,Pain,phenotype,pain,7442,TRPV1,TRPV1,CTD_human,17575321,The pain receptor transient receptor potential vanilloid type 1 (TRPV1) has been reported as one of the key components in the pain pathway.,0.21538469991593398,"The pain receptor transient receptor potential vanilloid type 1 (<span class=""gene"" id=""17575321-1-65-70"">TRPV1</span>) has been reported as one of the key components in the <span class=""disease"" id=""17575321-1-126-130"">pain</span> pathway.",CTD_human
4,0,Biomarker,C0030193,Pain,phenotype,pain,7442,TRPV1,TRPV1,CTD_human,17575321,The pain receptor transient receptor potential vanilloid type 1 (TRPV1) has been reported as one of the key components in the pain pathway.,0.21538469991593398,"The pain receptor transient receptor potential vanilloid type 1 (<span class=""gene"" id=""17575321-1-65-70"">TRPV1</span>) has been reported as one of the key components in the <span class=""disease"" id=""17575321-1-126-130"">pain</span> pathway.",CTD_human
1,1,Biomarker,C0002395,Alzheimer's Disease,disease,Alzheimer's Disease,7447,VSNL1,VSNL1,CTD_human,25806004,"VSNL1 Co-Expression Networks in Aging Include Calcium Signaling, Synaptic Plasticity, and Alzheimer's Disease Pathways.",0.204106546385879,"<span class=""gene"" id=""25806004-0-0-5"">VSNL1</span> Co-Expression Networks in Aging Include Calcium Signaling, Synaptic Plasticity, and <span class=""disease"" id=""25806004-0-90-109"">Alzheimer's Disease</span> Pathways.",CTD_human
1,0,Biomarker,C0004238,Atrial Fibrillation,disease,atrial fibrillation,7450,VWF,von Willebrand factor,CTD_human,17890461,"Soluble E-selectin, von Willebrand factor, soluble thrombomodulin, and total body nitrate/nitrite product as indices of endothelial damage/dysfunction in paroxysmal, persistent, and permanent atrial fibrillation.",0.203557092817453,"Soluble E-selectin, <span class=""gene"" id=""17890461-0-20-41"">von Willebrand factor</span>, soluble thrombomodulin, and total body nitrate/nitrite product as indices of endothelial damage/dysfunction in paroxysmal, persistent, and permanent <span class=""disease"" id=""17890461-0-192-211"">atrial fibrillation</span>.",CTD_human
3,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,7450,VWF,von Willebrand factor,CTD_human,12425201,"The objective of the investigation was to assess whether circulating adhesion molecules, von Willebrand factor (vWf) and endothelin-1 are elevated in patients with mild uncomplicated essential hypertension without further risk factors of atherosclerosis and whether they could serve as indicators of endothelial dysfunction in this form of hypertension.",0.203780662444353,"The objective of the investigation was to assess whether circulating adhesion molecules, <span class=""gene"" id=""12425201-1-89-110"">von Willebrand factor</span> (vWf) and endothelin-1 are elevated in patients with mild uncomplicated essential hypertension without further risk factors of atherosclerosis and whether they could serve as indicators of endothelial dysfunction in this form of <span class=""disease"" id=""12425201-1-340-352"">hypertension</span>.",CTD_human
3,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,7450,VWF,vWf,CTD_human,12149661,"The levels of adhesion molecules (intercellular cell adhesion molecule-1 [ICAM-1], E-selectin, P-selectin), von Willebrand factor (vWf) and endothelin-1 were measured in patients with hypertension without any other risk factors of atherosclerosis before and after treatment with quinapril (n = 22) and in normotensive controls (n = 22).",0.203780662444353,"The levels of adhesion molecules (intercellular cell adhesion molecule-1 [ICAM-1], E-selectin, P-selectin), <span class=""gene"" id=""12149661-3-108-129"">von Willebrand factor</span> (<span class=""gene"" id=""12149661-3-131-134"">vWf</span>) and endothelin-1 were measured in patients with <span class=""disease"" id=""12149661-3-184-196"">hypertension</span> without any other risk factors of atherosclerosis before and after treatment with quinapril (n = 22) and in normotensive controls (n = 22).",CTD_human
1,0,Biomarker,C1168401,Squamous cell carcinoma of the head and neck,disease,HNSCC,7465,WEE1,WEE1,CTD_human,25125259,WEE1 kinase is a potential therapeutic drug target for HNSCC.,0.20082418035263896,"<span class=""gene"" id=""25125259-11-0-4"">WEE1</span> kinase is a potential therapeutic drug target for <span class=""disease"" id=""25125259-11-55-60"">HNSCC</span>.",CTD_human
1,3,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,type 2 diabetes,7466,WFS1,WFS1,CTD_human,17603484,Common variants in WFS1 confer risk of type 2 diabetes.,0.286868169605328,"Common variants in <span class=""gene"" id=""17603484-0-19-23"">WFS1</span> confer risk of <span class=""disease"" id=""17603484-0-39-54"">type 2 diabetes</span>.",CTD_human
2,0,Biomarker,C0004352,Autistic Disorder,disease,autism,7472,WNT2,WNT2,CTD_human,19895723,Association between autism and variants in the wingless-type MMTV integration site family member 2 ( WNT2) gene.,0.20706302847759303,"Association between <span class=""disease"" id=""19895723-0-20-26"">autism</span> and variants in the <span class=""gene"" id=""19895723-0-47-98"">wingless-type MMTV integration site family member 2</span> ( <span class=""gene"" id=""19895723-0-101-105"">WNT2</span>) gene.",CTD_human
2,0,Biomarker,C0004352,Autistic Disorder,disease,autism,7472,WNT2,WNT2,CTD_human,11449391,Evidence supporting WNT2 as an autism susceptibility gene.,0.20706302847759303,"Evidence supporting <span class=""gene"" id=""11449391-0-20-24"">WNT2</span> as an <span class=""disease"" id=""11449391-0-31-37"">autism</span> susceptibility gene.",CTD_human
1,0,Biomarker,C0334634,"Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse",disease,MCL,7473,WNT3,Wnt3,CTD_human,18787224,"Using WCP-specific oligonucleotide arrays, we found that MCL highly and consistently expressed Wnt3 and Wnt10. beta-catenin, a transcriptional factor that is a downstream target of WCP, is localized to the nucleus and transcriptionally active in all 3 MCL cell lines examined.",0.20328236603324,"Using WCP-specific oligonucleotide arrays, we found that <span class=""disease"" id=""18787224-4-57-60"">MCL</span> highly and consistently expressed <span class=""gene"" id=""18787224-4-95-99"">Wnt3</span> and Wnt10. beta-catenin, a transcriptional factor that is a downstream target of WCP, is localized to the nucleus and transcriptionally active in all 3 <span class=""disease"" id=""18787224-4-252-255"">MCL</span> cell lines examined.",CTD_human
1,0,Biomarker,C1458155,Mammary Neoplasms,group,breast tumors,7480,WNT10B,WNT10B,CTD_human,12437293,Elevated levels of estrogen and heightened expression of the WNT10B proto-oncogene have been implicated in the development of human malignant breast tumors because they enhance the proliferation of mammary tissue.,0.20054945356842604,"Elevated levels of estrogen and heightened expression of the <span class=""gene"" id=""12437293-3-61-67"">WNT10B</span> proto-oncogene have been implicated in the development of human malignant <span class=""disease"" id=""12437293-3-142-155"">breast tumors</span> because they enhance the proliferation of mammary tissue.",CTD_human
1,0,Biomarker,C0235833,Congenital diaphragmatic hernia,disease,CDH,7481,WNT11,Wnt11,CTD_human,25783350,"The relative mRNA expression levels of pulmonary Wnt11 and RhoA on D21 were significantly increased in the CDH group compared with the control group (p=0.016 and p=0.008, respectively).",0.2,"The relative mRNA expression levels of pulmonary <span class=""gene"" id=""25783350-10-49-54"">Wnt11</span> and RhoA on D21 were significantly increased in the <span class=""disease"" id=""25783350-10-107-110"">CDH</span> group compared with the control group (p=0.016 and p=0.008, respectively).",CTD_human
1,0,Biomarker,C0017636,Glioblastoma,disease,glioblastoma,7490,WT1,Wilms' tumor 1,CTD_human,20820871,Wilms' tumor 1 silencing decreases the viability and chemoresistance of glioblastoma cells in vitro: a potential role for IGF-1R de-repression.,0.20383181960166602,"<span class=""gene"" id=""20820871-0-0-14"">Wilms' tumor 1</span> silencing decreases the viability and chemoresistance of <span class=""disease"" id=""20820871-0-72-84"">glioblastoma</span> cells in vitro: a potential role for IGF-1R de-repression.",CTD_human
6,4,Biomarker,C0027708,Nephroblastoma,disease,Wilms' tumor,7490,WT1,WT1,CTD_human,15591903,Effective use of high-dose chemotherapy and autologous stem cell rescue for relapsed adult Wilms' tumor and a novel alteration in intron 1 of the WT1 gene.,0.688323056363778,"Effective use of high-dose chemotherapy and autologous stem cell rescue for relapsed adult <span class=""disease"" id=""15591903-0-91-103"">Wilms' tumor</span> and a novel alteration in intron 1 of the <span class=""gene"" id=""15591903-0-146-149"">WT1</span> gene.",CTD_human;HPO;ORPHANET;UNIPROT
1,0,Biomarker,C0085215,"Ovarian Failure, Premature",disease,POF,7490,WT1,WT1,CTD_human,26358501,"The coding region of WT1 gene was screened in 384 patients with POF and 6 novel variations were identified, including two missense mutations (p. Pro126Ser in exon1 and p. Arg370His in exon7) and four intronic variants (c.647-27C?>?T, c.647-13G?>?C, c.647-13G?>?A in intron1 and c.950?+?14T?>?C in intron 4).",0.200274726784213,"The coding region of <span class=""gene"" id=""26358501-4-21-24"">WT1</span> gene was screened in 384 patients with <span class=""disease"" id=""26358501-4-64-67"">POF</span> and 6 novel variations were identified, including two missense mutations (p. Pro126Ser in exon1 and p. Arg370His in exon7) and four intronic variants (c.647-27C?&gt;?T, c.647-13G?&gt;?C, c.647-13G?&gt;?A in intron1 and c.950?+?14T?&gt;?C in intron 4).",CTD_human
1,0,Biomarker,C0235833,Congenital diaphragmatic hernia,disease,CDH,7490,WT1,WT1,CTD_human,21072664,Downregulation of diaphragmatic WT1 gene expression may impair diaphragmatic development in the nitrofen CDH model.,0.48082418035263896,"Downregulation of diaphragmatic <span class=""gene"" id=""21072664-17-32-35"">WT1</span> gene expression may impair diaphragmatic development in the nitrofen <span class=""disease"" id=""21072664-17-105-108"">CDH</span> model.",CTD_human;HPO
1,0,Biomarker,C0017638,Glioma,disease,glioma,7494,XBP1,XBP1,CTD_human,21138464,Targeting X box-binding protein-1 (XBP1) enhances sensitivity of glioma cells to oxidative stress.,0.20054945356842604,"Targeting <span class=""gene"" id=""21138464-0-10-33"">X box-binding protein-1</span> (<span class=""gene"" id=""21138464-0-35-39"">XBP1</span>) enhances sensitivity of <span class=""disease"" id=""21138464-0-65-71"">glioma</span> cells to oxidative stress.",CTD_human
2,0,Biomarker,C0393576,Chorea Acanthocytosis Syndrome,disease,neuroacanthocytosis,7504,XK,McLeod syndrome,CTD_human,8619554,A novel point mutation in the McLeod syndrome gene in neuroacanthocytosis.,0.20082418035263896,"A novel point mutation in the <span class=""gene"" id=""8619554-0-30-45"">McLeod syndrome</span> gene in <span class=""disease"" id=""8619554-0-54-73"">neuroacanthocytosis</span>.",CTD_human
1,0,Biomarker,C0021841,Intestinal Neoplasms,group,intestinal tumors,7507,XPA,Xpa,CTD_human,16962818,"In conclusion, the Xpa gene and the NER pathway are involved in repair of bulky PhIP-DNA adducts in the intestines and the liver, and most probably of DNA lesions leading to spontaneous intestinal tumors.",0.2,"In conclusion, the <span class=""gene"" id=""16962818-8-19-22"">Xpa</span> gene and the NER pathway are involved in repair of bulky PhIP-DNA adducts in the intestines and the liver, and most probably of DNA lesions leading to spontaneous <span class=""disease"" id=""16962818-8-186-203"">intestinal tumors</span>.",CTD_human
1,0,Biomarker,C0024121,Lung Neoplasms,group,lung tumors,7508,XPC,XPC,CTD_human,17325666,"Among the analysis of the hypermethylation status of 158 lung tumors, XPC hypermethylation is more common in nonsmokers (39 of 94, 41%) than in smokers (14 of 64, 22%; P=0.010).",0.21361340516675603,"Among the analysis of the hypermethylation status of 158 <span class=""disease"" id=""17325666-7-57-68"">lung tumors</span>, <span class=""gene"" id=""17325666-7-70-73"">XPC</span> hypermethylation is more common in nonsmokers (39 of 94, 41%) than in smokers (14 of 64, 22%; P=0.010).",CTD_human
1,0,Biomarker,C0152013,Adenocarcinoma of lung (disorder),disease,lung adenocarcinoma,7508,XPC,xeroderma pigmentosum complementation group C,CTD_human,21327329,Expression of xeroderma pigmentosum complementation group C protein predicts cisplatin resistance in lung adenocarcinoma patients.,0.20054945356842604,"Expression of <span class=""gene"" id=""21327329-0-14-59"">xeroderma pigmentosum complementation group C</span> protein predicts cisplatin resistance in <span class=""disease"" id=""21327329-0-101-120"">lung adenocarcinoma</span> patients.",CTD_human
1,0,Biomarker,C0017638,Glioma,disease,glioma,7515,XRCC1,XRCC1,CTD_human,25227852,Association between the XRCC1 Arg194Trp polymorphism and glioma risk: an updated meta-analysis.,0.222185678255007,"Association between the <span class=""gene"" id=""25227852-0-24-29"">XRCC1</span> Arg194Trp polymorphism and <span class=""disease"" id=""25227852-0-57-63"">glioma</span> risk: an updated meta-analysis.",CTD_human
1,0,Biomarker,C0038362,Stomatitis,disease,oral mucositis,7515,XRCC1,XRCC1,CTD_human,24594932,"In addition, genetic linkage disequilibrium existed in XRCC1 polymorphisms for >grade 2 oral mucositis and skin reaction indicating the complex inheritance pattern.",0.20054945356842604,"In addition, genetic linkage disequilibrium existed in <span class=""gene"" id=""24594932-7-55-60"">XRCC1</span> polymorphisms for &gt;grade 2 <span class=""disease"" id=""24594932-7-88-102"">oral mucositis</span> and skin reaction indicating the complex inheritance pattern.",CTD_human
1,0,Biomarker,C0279626,Squamous cell carcinoma of esophagus,disease,esophageal squamous cell carcinoma,7515,XRCC1,X-ray repair cross-complementing 1,CTD_human,16639733,"Dietary selenium intake, aldehyde dehydrogenase-2 and X-ray repair cross-complementing 1 genetic polymorphisms, and the risk of esophageal squamous cell carcinoma.",0.203021994626344,"Dietary selenium intake, aldehyde dehydrogenase-2 and <span class=""gene"" id=""16639733-0-54-88"">X-ray repair cross-complementing 1</span> genetic polymorphisms, and the risk of <span class=""disease"" id=""16639733-0-128-162"">esophageal squamous cell carcinoma</span>.",CTD_human
1,0,Biomarker,C0014859,Esophageal Neoplasms,group,esophageal cancer,7517,XRCC3,XRCC3,CTD_human,21347786,"In esophageal cancer patients, none of the polymorphisms studied had conclusive results in multivariate analysis, although XRCC3 variant (rs861539) showed an effect on survival in Kaplan-Meier univariate analysis.",0.207495812354077,"In <span class=""disease"" id=""21347786-11-3-20"">esophageal cancer</span> patients, none of the polymorphisms studied had conclusive results in multivariate analysis, although <span class=""gene"" id=""21347786-11-123-128"">XRCC3</span> variant (rs861539) showed an effect on survival in Kaplan-Meier univariate analysis.",CTD_human
1,0,Biomarker,C0025202,melanoma,disease,melanoma,7517,XRCC3,XRCC3,CTD_human,11059748,"We found the presence of a T allele in exon 7 (position 18067) of the XRCC3 gene was significantly associated with melanoma development (P = 0.004; odds ratio, 2.36; relative risk, 1.74).",0.21373466047903103,"We found the presence of a T allele in exon 7 (position 18067) of the <span class=""gene"" id=""11059748-7-70-75"">XRCC3</span> gene was significantly associated with <span class=""disease"" id=""11059748-7-115-123"">melanoma</span> development (P = 0.004; odds ratio, 2.36; relative risk, 1.74).",CTD_human
1,0,Biomarker,C0085110,Severe Combined Immunodeficiency,disease,SCID,7535,ZAP70,ZAP-70,CTD_human,8202713,"Here, three siblings are described with an autosomal recessive form of severe combined immunodeficiency disease (SCID) in which ZAP-70, a non-Src PTK, is absent as a result of mutations in the ZAP-70 gene.",0.203021994626344,"Here, three siblings are described with an autosomal recessive form of <span class=""disease"" id=""8202713-3-71-111"">severe combined immunodeficiency disease</span> (<span class=""disease"" id=""8202713-3-113-117"">SCID</span>) in which <span class=""gene"" id=""8202713-3-128-134"">ZAP-70</span>, a non-Src PTK, is absent as a result of mutations in the <span class=""gene"" id=""8202713-3-193-199"">ZAP-70</span> gene.",CTD_human
1,0,Biomarker,C0002736,Amyotrophic Lateral Sclerosis,disease,ALS,755,C21orf2,C21orf2,CTD_human,27455348,"Through imputation and mixed-model association analysis in 12,577 cases and 23,475 controls, combined with 2,579 cases and 2,767 controls in an independent replication cohort, we fine-mapped a new risk locus on chromosome 21 and identified C21orf2 as a gene associated with ALS risk.",0.2,"Through imputation and mixed-model association analysis in 12,577 cases and 23,475 controls, combined with 2,579 cases and 2,767 controls in an independent replication cohort, we fine-mapped a new risk locus on chromosome 21 and identified <span class=""gene"" id=""27455348-2-240-247"">C21orf2</span> as a gene associated with <span class=""disease"" id=""27455348-2-274-277"">ALS</span> risk.",CTD_human
1,0,Biomarker,C1136249,"Mental Retardation, X-Linked",disease,XLMR,7552,ZNF711,ZNF711,CTD_human,19377476,"The screen has discovered nine genes implicated in XLMR, including SYP, ZNF711 and CASK reported here, confirming the power of this strategy.",0.200274726784213,"The screen has discovered nine genes implicated in <span class=""disease"" id=""19377476-3-51-55"">XLMR</span>, including SYP, <span class=""gene"" id=""19377476-3-72-78"">ZNF711</span> and CASK reported here, confirming the power of this strategy.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,hepatocellular carcinoma,7571,ZNF23,ZNF23,CTD_human,21965783,"Cisplatin-induced apoptotic effect in HepG2 cells may be mediated via the up-regulation of ZNF23, which suggests that the ZNF23 gene could play an important role in the development of hepatocellular carcinoma.",0.200274726784213,"Cisplatin-induced apoptotic effect in HepG2 cells may be mediated via the up-regulation of <span class=""gene"" id=""21965783-8-91-96"">ZNF23</span>, which suggests that the <span class=""gene"" id=""21965783-8-122-127"">ZNF23</span> gene could play an important role in the development of <span class=""disease"" id=""21965783-8-184-208"">hepatocellular carcinoma</span>.",CTD_human
1,0,Biomarker,C0009241,Cognition Disorders,group,cognitive deficits,7592,ZNF41,ZNF41,CTD_human,14628291,Mutations in the ZNF41 gene are associated with cognitive deficits: identification of a new candidate for X-linked mental retardation.,0.200274726784213,"Mutations in the <span class=""gene"" id=""14628291-0-17-22"">ZNF41</span> gene are associated with <span class=""disease"" id=""14628291-0-48-66"">cognitive deficits</span>: identification of a new candidate for X-linked mental retardation.",CTD_human
1,0,Biomarker,C1136249,"Mental Retardation, X-Linked",disease,X-linked mental retardation,7592,ZNF41,ZNF41,CTD_human,14628291,Mutations in the ZNF41 gene are associated with cognitive deficits: identification of a new candidate for X-linked mental retardation.,0.20054945356842604,"Mutations in the <span class=""gene"" id=""14628291-0-17-22"">ZNF41</span> gene are associated with cognitive deficits: identification of a new candidate for <span class=""disease"" id=""14628291-0-106-133"">X-linked mental retardation</span>.",CTD_human
1,0,Biomarker,C0007124,Noninfiltrating Intraductal Carcinoma,disease,DCIS,768,CA9,CAIX,CTD_human,20526721,"GLUT1 and CAIX were expressed only in DCIS (56.8% and 25.0%) and IDC (44.1% and 30.5%), with higher expression in high grade DCIS than low/intermediate grade DCIS (79.2% vs. 30.0%, p = 0.001 and 37.5% vs. 10.0%, p = 0.036, respectively).",0.20054945356842604,"GLUT1 and <span class=""gene"" id=""20526721-9-10-14"">CAIX</span> were expressed only in <span class=""disease"" id=""20526721-9-38-42"">DCIS</span> (56.8% and 25.0%) and IDC (44.1% and 30.5%), with higher expression in high grade <span class=""disease"" id=""20526721-9-125-129"">DCIS</span> than low/intermediate grade DCIS (79.2% vs. 30.0%, p = 0.001 and 37.5% vs. 10.0%, p = 0.036, respectively).",CTD_human
1,0,Biomarker,C0023473,"Myeloid Leukemia, Chronic",disease,CML,768,CA9,G250,CTD_human,17157168,"Several LAAs are expressed in CML and therefore are candidate structures for specific immunotherapies: bcr-abl (100%), G250 (24%), hTERT (53%), MPP11 (91%), NEWREN60 (94%), PRAME (62%), Proteinase3 (71%), RHAMM/CD168 (83%), and WT1 (53%), but not BAGE, MAGE-A1, SSX2, or NY-ESO-1.",0.200274726784213,"Several LAAs are expressed in <span class=""disease"" id=""17157168-3-30-33"">CML</span> and therefore are candidate structures for specific immunotherapies: bcr-abl (100%), <span class=""gene"" id=""17157168-3-119-123"">G250</span> (24%), hTERT (53%), MPP11 (91%), NEWREN60 (94%), PRAME (62%), Proteinase3 (71%), RHAMM/CD168 (83%), and WT1 (53%), but not BAGE, MAGE-A1, SSX2, or NY-ESO-1.",CTD_human
1,0,Biomarker,C0342543,"Precocious Puberty, Central",disease,Central precocious puberty,7681,MKRN3,MKRN3,CTD_human,23738509,Central precocious puberty caused by mutations in the imprinted gene MKRN3.,0.203021994626344,"<span class=""disease"" id=""23738509-0-0-26"">Central precocious puberty</span> caused by mutations in the imprinted gene <span class=""gene"" id=""23738509-0-69-74"">MKRN3</span>.",CTD_human
1,0,Biomarker,C0023487,Acute Promyelocytic Leukemia,disease,promyelocytic leukemia,7704,ZBTB16,PLZF,CTD_human,23208507,"Acute promyelocytic leukemia (APL) is predominantly characterized by chromosomal translocations between the retinoic acid receptor, alpha (RARA) gene and the promyelocytic leukemia (PML) or promyelocytic leukemia zinc finger (PLZF) gene.",0.420879235600196,"<span class=""disease"" id=""23208507-1-0-28"">Acute promyelocytic leukemia</span> (<span class=""disease"" id=""23208507-1-30-33"">APL</span>) is predominantly characterized by chromosomal translocations between the retinoic acid receptor, alpha (RARA) gene and the promyelocytic leukemia (PML) or <span class=""disease"" id=""23208507-1-190-212"">promyelocytic leukemia</span> zinc finger (<span class=""gene"" id=""23208507-1-226-230"">PLZF</span>) gene.",CTD_human;ORPHANET
1,0,Biomarker,C0014553,Absence Epilepsy,disease,absence epilepsy,773,CACNA1A,Cacna1a,CTD_human,17196942,"Thus, the GRY rat with P/Q-type Ca(2+) channel disorders is a useful model for studying absence epilepsy and Cacna1a-related diseases.",0.281373633921066,"Thus, the GRY rat with P/Q-type Ca(2+) channel disorders is a useful model for studying <span class=""disease"" id=""17196942-9-88-104"">absence epilepsy</span> and <span class=""gene"" id=""17196942-9-109-116"">Cacna1a</span>-related diseases.",CTD_human
1,1,Biomarker,C0206368,Exfoliation Syndrome,disease,exfoliation syndrome,773,CACNA1A,CACNA1A,CTD_human,25706626,A common variant mapping to CACNA1A is associated with susceptibility to exfoliation syndrome.,0.200274726784213,"A common variant mapping to <span class=""gene"" id=""25706626-0-28-35"">CACNA1A</span> is associated with susceptibility to <span class=""disease"" id=""25706626-0-73-93"">exfoliation syndrome</span>.",CTD_human
13,33,Biomarker,C1720416,Episodic ataxia type 2 (disorder),disease,EA2,773,CACNA1A,CACNA1A,CTD_human,11985388,Familial hemiplegic migraine and episodic ataxia type 2 (EA2) are allelic disorders with distinct types of mutations in the CACNA1A gene.,0.697242274870795,"Familial hemiplegic migraine and <span class=""disease"" id=""11985388-1-33-55"">episodic ataxia type 2</span> (<span class=""disease"" id=""11985388-1-57-60"">EA2</span>) are allelic disorders with distinct types of mutations in the <span class=""gene"" id=""11985388-1-124-131"">CACNA1A</span> gene.",CTD_human;ORPHANET;UNIPROT
8,2,Biomarker,C0005586,Bipolar Disorder,disease,bipolar disorder,775,CACNA1C,CACNA1C,CTD_human,21926972,"Finally, a combined GWAS analysis of schizophrenia and bipolar disorder yielded strong association evidence for SNPs in CACNA1C and in the region of NEK4-ITIH1-ITIH3-ITIH4.",0.42501281400908597,"Finally, a combined GWAS analysis of schizophrenia and <span class=""disease"" id=""21926972-5-55-71"">bipolar disorder</span> yielded strong association evidence for SNPs in <span class=""gene"" id=""21926972-5-120-127"">CACNA1C</span> and in the region of NEK4-ITIH1-ITIH3-ITIH4.",CTD_human;PSYGENET
8,2,Biomarker,C0005586,Bipolar Disorder,disease,bipolar disorder,775,CACNA1C,CACNA1C,CTD_human,18711365,Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder.,0.42501281400908597,"Collaborative genome-wide association analysis supports a role for ANK3 and <span class=""gene"" id=""18711365-0-76-83"">CACNA1C</span> in <span class=""disease"" id=""18711365-0-87-103"">bipolar disorder</span>.",CTD_human;PSYGENET
8,2,Biomarker,C0005586,Bipolar Disorder,disease,bipolar disorder,775,CACNA1C,CACNA1C,CTD_human,21926974,"In a joint analysis with a bipolar disorder sample (16,374 affected individuals and 14,044 controls), three loci reached genome-wide significance: CACNA1C (rs4765905, P = 7.0 × 10(-9)), ANK3 (rs10994359, P = 2.5 × 10(-8)) and the ITIH3-ITIH4 region (rs2239547, P = 7.8 × 10(-9)).",0.42501281400908597,"In a joint analysis with a <span class=""disease"" id=""21926974-5-27-43"">bipolar disorder</span> sample (16,374 affected individuals and 14,044 controls), three loci reached genome-wide significance: <span class=""gene"" id=""21926974-5-147-154"">CACNA1C</span> (rs4765905, P = 7.0 &times; 10(-9)), ANK3 (rs10994359, P = 2.5 &times; 10(-8)) and the ITIH3-ITIH4 region (rs2239547, P = 7.8 &times; 10(-9)).",CTD_human;PSYGENET
2,0,Biomarker,C0001430,Adenoma,group,adenomas,776,CACNA1D,CACNA1D,CTD_human,23913001,Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism.,0.201648360705279,"Somatic and germline <span class=""gene"" id=""23913001-0-21-28"">CACNA1D</span> calcium channel mutations in aldosterone-producing <span class=""disease"" id=""23913001-0-80-88"">adenomas</span> and primary aldosteronism.",CTD_human
1,0,Biomarker,C0036572,Seizures,phenotype,EXP1,7779,SLC30A1,ZnT-1,CTD_human,23266720,"Among the total twelve genes, six genes were strongly up- (MT-3, ACAT1, clusterin and ApoE) or down- (ZnT-1 and PRG-3) regulated by developmental seizures (EXP1) compared with that in the CONT1.",0.2,"Among the total twelve genes, six genes were strongly up- (MT-3, ACAT1, clusterin and ApoE) or down- (<span class=""gene"" id=""23266720-8-102-107"">ZnT-1</span> and PRG-3) regulated by developmental <span class=""disease"" id=""23266720-8-146-154"">seizures</span> (<span class=""disease"" id=""23266720-8-156-160"">EXP1</span>) compared with that in the CONT1.",CTD_human
2,1,Biomarker,C0238358,Hypokalemic periodic paralysis,disease,hypokalemic periodic paralysis,779,CACNA1S,CACNA1S,CTD_human,19822448,Severe respiratory phenotype caused by a de novo Arg528Gly mutation in the CACNA1S gene in a patient with hypokalemic periodic paralysis.,0.417264721273474,"Severe respiratory phenotype caused by a de novo Arg528Gly mutation in the <span class=""gene"" id=""19822448-0-75-82"">CACNA1S</span> gene in a patient with <span class=""disease"" id=""19822448-0-106-136"">hypokalemic periodic paralysis</span>.",CTD_human;ORPHANET
2,1,Biomarker,C0238358,Hypokalemic periodic paralysis,disease,hypoPP,779,CACNA1S,CACNA1S,CTD_human,11912116,Previous genetic studies revealed mutations in the voltage-gated calcium channel alpha1-subunit (CACNA1S gene) in families with hypoPP (type I).,0.417264721273474,"Previous genetic studies revealed mutations in the voltage-gated calcium channel alpha1-subunit (<span class=""gene"" id=""11912116-2-97-104"">CACNA1S</span> gene) in families with <span class=""disease"" id=""11912116-2-128-134"">hypoPP</span> (type I).",CTD_human;ORPHANET
1,0,Biomarker,C0040136,Thyroid Neoplasm,disease,thyroid tumor,7799,PRDM2,RIZ1,CTD_human,17103461,"The authors demonstrated that RIZ1 expression is lost in thyroid tumor cell lines and is also significantly reduced in thyroid carcinomas, when compared with normal thyroid tissues (P < .0001) and benign tumors (P = .0003).",0.200274726784213,"The authors demonstrated that <span class=""gene"" id=""17103461-6-30-34"">RIZ1</span> expression is lost in <span class=""disease"" id=""17103461-6-57-70"">thyroid tumor</span> cell lines and is also significantly reduced in thyroid carcinomas, when compared with normal thyroid tissues (P &lt; .0001) and benign tumors (P = .0003).",CTD_human
1,0,Biomarker,C0022336,Creutzfeldt-Jakob disease,disease,CJD,780851,SNORD3A,Snord3A,CTD_human,23349890,"To this effect, we subjected blood mRNA from E200K PrP CJD patients and corresponding family members to global arrays and found that the expression of Snord3A, a non-coding RNA transcript, was elevated several times in CJD patients as compared to controls, while asymptomatic carriers presented intermediate Snord3A levels.",0.2,"To this effect, we subjected blood mRNA from E200K PrP <span class=""disease"" id=""23349890-2-55-58"">CJD</span> patients and corresponding family members to global arrays and found that the expression of <span class=""gene"" id=""23349890-2-151-158"">Snord3A</span>, a non-coding RNA transcript, was elevated several times in <span class=""disease"" id=""23349890-2-219-222"">CJD</span> patients as compared to controls, while asymptomatic carriers presented intermediate <span class=""gene"" id=""23349890-2-308-315"">Snord3A</span> levels.",CTD_human
1,0,Biomarker,C0017668,Focal glomerulosclerosis,disease,FSGS,7827,NPHS2,podocin,CTD_human,15942677,Direct effect of plasma permeability factors from patients with idiopatic FSGS on nephrin and podocin expression in human podocytes.,0.429328574644548,"Direct effect of plasma permeability factors from patients with idiopatic <span class=""disease"" id=""15942677-0-74-78"">FSGS</span> on nephrin and <span class=""gene"" id=""15942677-0-94-101"">podocin</span> expression in human podocytes.",CTD_human;HPO
1,0,Biomarker,C0027720,Nephrosis,disease,nephrosis,7827,NPHS2,podocin,CTD_human,15684566,Nephrin and podocin expression around the onset of puromycin aminonucleoside nephrosis.,0.203231208875927,"Nephrin and <span class=""gene"" id=""15684566-0-12-19"">podocin</span> expression around the onset of puromycin aminonucleoside <span class=""disease"" id=""15684566-0-77-86"">nephrosis</span>.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,7832,BTG2,TIS21,CTD_human,18393292,"These observations were further confirmed in vivo by the reciprocal control of TIS21 expression and FoxM1 phosphorylation in the diethylnitrosamine-induced HCCs and TIS21(-/-) mouse embryonic fibroblast (MEF), in addition to increased expression of cyclin B1 and cdk1 activity.",0.201098907136852,"These observations were further confirmed in vivo by the reciprocal control of <span class=""gene"" id=""18393292-6-79-84"">TIS21</span> expression and FoxM1 phosphorylation in the diethylnitrosamine-induced <span class=""disease"" id=""18393292-6-156-159"">HCC</span>s and <span class=""gene"" id=""18393292-6-165-170"">TIS21</span>(-/-) mouse embryonic fibroblast (MEF), in addition to increased expression of cyclin B1 and cdk1 activity.",CTD_human
1,20,Biomarker,C0268425,Alstrom Syndrome,disease,ALMS,7840,ALMS1,ALMS1,CTD_human,22447358,Alstr?m syndrome (ALMS) is a rare autosomal recessive disorder caused by mutations in the ALMS1 gene.,0.490374105265468,"<span class=""disease"" id=""22447358-1-0-16"">Alstr&ouml;m syndrome</span> (<span class=""disease"" id=""22447358-1-18-22"">ALMS</span>) is a rare autosomal recessive disorder caused by mutations in the <span class=""gene"" id=""22447358-1-90-95"">ALMS1</span> gene.",CTD_human;ORPHANET
1,0,Biomarker,C0009404,Colorectal Neoplasms,group,colorectal tumors,7849,PAX8,PAX8,CTD_human,26075790,"We identified significant expression quantitative trait locus (eQTL) associations for HOXD9 at 2q31.1 in ovarian (P = 4.95 × 10(-4), false discovery rate (FDR) = 0.003) and colorectal (P = 0.01, FDR = 0.09) tumors and for PAX8 at 2q13 in colorectal tumors (P = 0.03, FDR = 0.09).",0.200274726784213,"We identified significant expression quantitative trait locus (eQTL) associations for HOXD9 at 2q31.1 in ovarian (P = 4.95 &times; 10(-4), false discovery rate (FDR) = 0.003) and colorectal (P = 0.01, FDR = 0.09) tumors and for <span class=""gene"" id=""26075790-3-222-226"">PAX8</span> at 2q13 in <span class=""disease"" id=""26075790-3-238-255"">colorectal tumors</span> (P = 0.03, FDR = 0.09).",CTD_human
1,0,Biomarker,C0004134,Ataxia,phenotype,ataxia,785,CACNB4,CACNB4,CTD_human,10762541,"To determine the role of the calcium-channel beta4-subunit gene CACNB4 on chromosome 2q22-23 in related human disorders, we screened for mutations in small pedigrees with familial epilepsy and ataxia.",0.20054945356842604,"To determine the role of the calcium-channel beta4-subunit gene <span class=""gene"" id=""10762541-2-64-70"">CACNB4</span> on chromosome 2q22-23 in related human disorders, we screened for mutations in small pedigrees with familial epilepsy and <span class=""disease"" id=""10762541-2-193-199"">ataxia</span>.",CTD_human
2,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastasis,7852,CXCR4,CXCR4,CTD_human,23743303,"Therefore, identification of nutritional factors which are able to inhibit CXCR4 is important for protection from environmental arsenic-induced carcinogenesis and for abolishing metastasis of malignantly transformed cells.",0.33674413626672306,"Therefore, identification of nutritional factors which are able to inhibit <span class=""gene"" id=""23743303-5-75-80"">CXCR4</span> is important for protection from environmental arsenic-induced carcinogenesis and for abolishing <span class=""disease"" id=""23743303-5-178-188"">metastasis</span> of malignantly transformed cells.",CTD_human
1,4,Biomarker,C0472817,WHIM syndrome,disease,WHIM syndrome,7852,CXCR4,CXCR4,CTD_human,23734232,Hierarchical organization of CXCR4 phosphorylation explains why small deletions at the extreme CXCR4 C terminus typically associated with WHIM syndrome severely alter CXCR4 function.,0.48961543744745895,"Hierarchical organization of <span class=""gene"" id=""23734232-11-29-34"">CXCR4</span> phosphorylation explains why small deletions at the extreme <span class=""gene"" id=""23734232-11-95-100"">CXCR4</span> C terminus typically associated with <span class=""disease"" id=""23734232-11-138-151"">WHIM syndrome</span> severely alter <span class=""gene"" id=""23734232-11-167-172"">CXCR4</span> function.",CTD_human;ORPHANET
1,0,Biomarker,C1458155,Mammary Neoplasms,group,breast tumour,7852,CXCR4,CXCR4,CTD_human,25753200,"Inhibition of CXCR4 expression by TPD7 further correlated with the suppression of SDF-1?-induced migration and invasion in breast tumour cells, knockdown of CXCR4 attenuated TPD7-inhibitory effects.",0.24238167627058896,"Inhibition of <span class=""gene"" id=""25753200-7-14-19"">CXCR4</span> expression by TPD7 further correlated with the suppression of SDF-1&alpha;-induced migration and invasion in <span class=""disease"" id=""25753200-7-123-136"">breast tumour</span> cells, knockdown of <span class=""gene"" id=""25753200-7-157-162"">CXCR4</span> attenuated TPD7-inhibitory effects.",CTD_human
1,0,Biomarker,C0027819,Neuroblastoma,disease,neuroblastoma,7869,SEMA3B,SEMA3B,CTD_human,17452250,The association of SEMA3B expression with neuroblastoma differentiation suggests that this TSG may play a role in neuroblastoma pathobiology.,0.200274726784213,"The association of <span class=""gene"" id=""17452250-10-19-25"">SEMA3B</span> expression with <span class=""disease"" id=""17452250-10-42-55"">neuroblastoma</span> differentiation suggests that this TSG may play a role in <span class=""disease"" id=""17452250-10-114-127"">neuroblastoma</span> pathobiology.",CTD_human
1,0,Biomarker,C0010068,Coronary heart disease,disease,coronary heart disease,79001,VKORC1,VKORC1,CTD_human,16549638,"VKORC1 haplotypes are associated with arterial vascular diseases (stroke, coronary heart disease, and aortic dissection).",0.206238848124954,"<span class=""gene"" id=""16549638-0-0-6"">VKORC1</span> haplotypes are associated with arterial vascular diseases (stroke, <span class=""disease"" id=""16549638-0-74-96"">coronary heart disease</span>, and aortic dissection).",CTD_human
1,0,Biomarker,C0038454,Cerebrovascular accident,group,stroke,79001,VKORC1,VKORC1,CTD_human,16549638,"VKORC1 haplotypes are associated with arterial vascular diseases (stroke, coronary heart disease, and aortic dissection).",0.21100174801421803,"<span class=""gene"" id=""16549638-0-0-6"">VKORC1</span> haplotypes are associated with arterial vascular diseases (<span class=""disease"" id=""16549638-0-66-72"">stroke</span>, coronary heart disease, and aortic dissection).",CTD_human
1,0,Biomarker,C0042373,Vascular Diseases,group,vascular diseases,79001,VKORC1,VKORC1,CTD_human,16549638,"VKORC1 haplotypes are associated with arterial vascular diseases (stroke, coronary heart disease, and aortic dissection).",0.203231208875927,"<span class=""gene"" id=""16549638-0-0-6"">VKORC1</span> haplotypes are associated with arterial <span class=""disease"" id=""16549638-0-47-64"">vascular diseases</span> (stroke, coronary heart disease, and aortic dissection).",CTD_human
1,2,Biomarker,C0149931,Migraine Disorders,group,migraine,79054,TRPM8,TRPM8,CTD_human,21666692,"TRPM8 has been the focus of neuropathic pain models, whereas LRP1 modulates neuronal glutamate signaling, plausibly linking both genes to migraine pathophysiology.",0.201923087489492,"<span class=""gene"" id=""21666692-7-0-5"">TRPM8</span> has been the focus of neuropathic pain models, whereas LRP1 modulates neuronal glutamate signaling, plausibly linking both genes to <span class=""disease"" id=""21666692-7-138-146"">migraine</span> pathophysiology.",CTD_human
1,1,Biomarker,C0025202,melanoma,disease,melanoma,79068,FTO,FTO,CTD_human,23455637,A variant in FTO shows association with melanoma risk not due to BMI.,0.20082418035263896,"A variant in <span class=""gene"" id=""23455637-0-13-16"">FTO</span> shows association with <span class=""disease"" id=""23455637-0-40-48"">melanoma</span> risk not due to BMI.",CTD_human
6,8,Biomarker,C0028754,Obesity,disease,obesity,79068,FTO,FTO,CTD_human,19151714,"In addition to FTO and MC4R, we detected significant association of obesity with three new risk loci in NPC1 (endosomal/lysosomal Niemann-Pick C1 gene, P = 2.9 x 10(-7)), near MAF (encoding the transcription factor c-MAF, P = 3.8 x 10(-13)) and near PTER (phosphotriesterase-related gene, P = 2.1 x 10(-7)).",0.36,"In addition to <span class=""gene"" id=""19151714-3-15-18"">FTO</span> and MC4R, we detected significant association of <span class=""disease"" id=""19151714-3-68-75"">obesity</span> with three new risk loci in NPC1 (endosomal/lysosomal Niemann-Pick C1 gene, P = 2.9 x 10(-7)), near MAF (encoding the transcription factor c-MAF, P = 3.8 x 10(-13)) and near PTER (phosphotriesterase-related gene, P = 2.1 x 10(-7)).",CTD_human
6,8,Biomarker,C0028754,Obesity,disease,obesity,79068,FTO,fat mass and obesity-associated,CTD_human,21076408,"Genome-wide association studies have identified SNPs within FTO, the human fat mass and obesity-associated gene, that are strongly associated with obesity.",0.36,"Genome-wide association studies have identified SNPs within <span class=""gene"" id=""21076408-1-60-63"">FTO</span>, the human <span class=""gene"" id=""21076408-1-75-106"">fat mass and obesity-associated</span> gene, that are strongly associated with <span class=""disease"" id=""21076408-1-147-154"">obesity</span>.",CTD_human
6,8,Biomarker,C0028754,Obesity,disease,obesity,79068,FTO,FTO,CTD_human,19079260,"This includes previously identified variants close to or in the FTO, MC4R, BDNF and SH2B1 genes, in addition to variants at seven loci not previously connected with obesity.",0.36,"This includes previously identified variants close to or in the <span class=""gene"" id=""19079260-5-64-67"">FTO</span>, MC4R, BDNF and SH2B1 genes, in addition to variants at seven loci not previously connected with <span class=""disease"" id=""19079260-5-165-172"">obesity</span>.",CTD_human
6,8,Biomarker,C0028754,Obesity,disease,obesity,79068,FTO,FTO,CTD_human,17496892,Variation in FTO contributes to childhood obesity and severe adult obesity.,0.36,"Variation in <span class=""gene"" id=""17496892-0-13-16"">FTO</span> contributes to childhood obesity and severe adult <span class=""disease"" id=""17496892-0-67-74"">obesity</span>.",CTD_human
2,0,Biomarker,C0033860,Psoriasis,disease,psoriasis,79092,CARD14,CARD14,CTD_human,24212883,"We discovered two independent missense SNVs in IL23R and GJB2 of low frequency and five common missense SNVs in LCE3D, ERAP1, CARD14 and ZNF816A associated with psoriasis at genome-wide significance.",0.205494535684262,"We discovered two independent missense SNVs in IL23R and GJB2 of low frequency and five common missense SNVs in LCE3D, ERAP1, <span class=""gene"" id=""24212883-2-126-132"">CARD14</span> and ZNF816A associated with <span class=""disease"" id=""24212883-2-161-170"">psoriasis</span> at genome-wide significance.",CTD_human
5,11,Biomarker,C0268631,succinic semialdehyde dehydrogenase deficiency,disease,succinic semialdehyde dehydrogenase deficiency,7915,ALDH5A1,ALDH5A1,CTD_human,23825041,A novel ALDH5A1 mutation is associated with succinic semialdehyde dehydrogenase deficiency and severe intellectual disability in an Iranian family.,0.6824725410579179,"A novel <span class=""gene"" id=""23825041-0-8-15"">ALDH5A1</span> mutation is associated with <span class=""disease"" id=""23825041-0-44-90"">succinic semialdehyde dehydrogenase deficiency</span> and severe intellectual disability in an Iranian family.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0345967,Malignant mesothelioma,disease,malignant mesothelioma,794,CALB2,calretinin,CTD_human,22784439,"Immunohistochemical analysis for epithelial membrane antigen, calretinin, vimentin, ?-catenin, melan-A, glucose transporter-1, cytokeratin CAM5.2, Wilms tumor antigen-1, D2-40, CD146, progesterone receptor, estrogen receptor, and cytokeratin 5/6 was indicative of malignant mesothelioma.",0.201373633921065,"Immunohistochemical analysis for epithelial membrane antigen, <span class=""gene"" id=""22784439-5-62-72"">calretinin</span>, vimentin, &beta;-catenin, melan-A, glucose transporter-1, cytokeratin CAM5.2, Wilms tumor antigen-1, D2-40, CD146, progesterone receptor, estrogen receptor, and cytokeratin 5/6 was indicative of <span class=""disease"" id=""22784439-5-264-286"">malignant mesothelioma</span>.",CTD_human
1,0,Biomarker,C0010068,Coronary heart disease,disease,coronary heart disease,7941,PLA2G7,Lp-PLA2,CTD_human,21356620,A meta-analysis of published cohorts has shown that Lp-PLA2 is an independent predictor of coronary heart disease events and stroke.,0.22283744613805898,"A meta-analysis of published cohorts has shown that <span class=""gene"" id=""21356620-2-52-59"">Lp-PLA2</span> is an independent predictor of <span class=""disease"" id=""21356620-2-91-113"">coronary heart disease</span> events and stroke.",CTD_human
1,0,Biomarker,C0038454,Cerebrovascular accident,group,stroke,7941,PLA2G7,Lp-PLA2,CTD_human,21356620,A meta-analysis of published cohorts has shown that Lp-PLA2 is an independent predictor of coronary heart disease events and stroke.,0.201648360705279,"A meta-analysis of published cohorts has shown that <span class=""gene"" id=""21356620-2-52-59"">Lp-PLA2</span> is an independent predictor of coronary heart disease events and <span class=""disease"" id=""21356620-2-125-131"">stroke</span>.",CTD_human
2,0,Biomarker,C0007134,Renal Cell Carcinoma,disease,RCC,79444,BIRC7,BIRC7,CTD_human,25401301,"Finally, we observed upregulation of the anti-apoptotic factor BIRC7 in MiTF-high RCC tumors, suggesting a potential therapeutic role for BIRC7 inhibitors.",0.20902291774708104,"Finally, we observed upregulation of the anti-apoptotic factor <span class=""gene"" id=""25401301-8-63-68"">BIRC7</span> in MiTF-high <span class=""disease"" id=""25401301-8-82-85"">RCC</span> tumors, suggesting a potential therapeutic role for <span class=""gene"" id=""25401301-8-138-143"">BIRC7</span> inhibitors.",CTD_human
2,0,Biomarker,C0007134,Renal Cell Carcinoma,disease,RCC,79444,BIRC7,Livin,CTD_human,17437058,"Livin gene expression was detected in a significant portion of RCC tumor tissue specimens (13/14, 92.9%) and tumor-derived cell lines (12/15, 80.0%).",0.20902291774708104,"<span class=""gene"" id=""17437058-4-0-5"">Livin</span> gene expression was detected in a significant portion of <span class=""disease"" id=""17437058-4-63-66"">RCC</span> tumor tissue specimens (13/14, 92.9%) and tumor-derived cell lines (12/15, 80.0%).",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,796,CALCA,calcitonin,CTD_human,11357950,"In archived neonatal blood of children with autistic spectrum disorders (n = 69), mental retardation without autism (n = 60), or cerebral palsy (CP, n = 63) and of control children (n = 54), we used recycling immunoaffinity chromatography to measure the neuropeptides substance P (SP), vasoactive intestinal peptide (VIP), pituitary adenylate cyclase-activating polypeptide (PACAP), calcitonin gene-related peptide (CGRP), and the neurotrophins nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin 3 (NT3), and neurotrophin 4/5 (NT4/5).",0.2,"In archived neonatal blood of children with <span class=""disease"" id=""11357950-2-44-52"">autistic</span> spectrum disorders (n = 69), mental retardation without <span class=""disease"" id=""11357950-2-109-115"">autism</span> (n = 60), or cerebral palsy (CP, n = 63) and of control children (n = 54), we used recycling immunoaffinity chromatography to measure the neuropeptides substance P (SP), vasoactive intestinal peptide (VIP), pituitary adenylate cyclase-activating polypeptide (PACAP), <span class=""gene"" id=""11357950-2-383-393"">calcitonin</span> gene-related peptide (CGRP), and the neurotrophins nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin 3 (NT3), and neurotrophin 4/5 (NT4/5).",CTD_human
3,0,Biomarker,C0007370,Catalepsy,disease,catalepsy,796,CALCA,calcitonin (1,CTD_human,6686863,"Intracerebroventricular injection of salmon calcitonin (1 micrograms/kg) prevented apomorphine-induced hyperactivity in 2, 7, 18 or 21 month old rats, but potentiated haloperidol-induced catalepsy only in 2 or 7 month old rats.",0.2,"Intracerebroventricular injection of salmon <span class=""gene"" id=""6686863-3-44-57"">calcitonin (1</span> micrograms/kg) prevented apomorphine-induced hyperactivity in 2, 7, 18 or 21 month old rats, but potentiated haloperidol-induced <span class=""disease"" id=""6686863-3-187-196"">catalepsy</span> only in 2 or 7 month old rats.",CTD_human
3,0,Biomarker,C0007370,Catalepsy,disease,catalepsy,796,CALCA,calcitonin,CTD_human,6303368,"Finally, also calcitonin is able to influence haloperidol-induced catalepsy by markedly increasing it.",0.2,"Finally, also <span class=""gene"" id=""6303368-8-14-24"">calcitonin</span> is able to influence haloperidol-induced <span class=""disease"" id=""6303368-8-66-75"">catalepsy</span> by markedly increasing it.",CTD_human
3,0,Biomarker,C0007370,Catalepsy,disease,catalepsy,796,CALCA,Calcitonin,CTD_human,6293644,Calcitonin injection resulted in a potentiation of haloperidol-induced catalepsy and a partial prevention of apomorphine-induced hyperactivity.,0.2,"<span class=""gene"" id=""6293644-2-0-10"">Calcitonin</span> injection resulted in a potentiation of haloperidol-induced <span class=""disease"" id=""6293644-2-71-80"">catalepsy</span> and a partial prevention of apomorphine-induced hyperactivity.",CTD_human
1,0,Biomarker,C0013080,Down Syndrome,disease,Down syndrome,796,CALCA,CGRP,CTD_human,16289943,Concentrations of NT-4/5 and CGRP were correlated in infants with autism but not in Down syndrome or controls.,0.2,"Concentrations of NT-4/5 and <span class=""gene"" id=""16289943-10-29-33"">CGRP</span> were correlated in infants with autism but not in <span class=""disease"" id=""16289943-10-84-97"">Down syndrome</span> or controls.",CTD_human
4,0,Biomarker,C0020429,Hyperalgesia,phenotype,hyperalgesia,796,CALCA,calcitonin,CTD_human,12855330,The role of calcitonin gene-related peptide (CGRP) in the generation and maintenance of mechanical allodynia and hyperalgesia in rats after intradermal injection of capsaicin.,0.280274726784213,"The role of <span class=""gene"" id=""12855330-0-12-22"">calcitonin</span> gene-related peptide (CGRP) in the generation and maintenance of mechanical allodynia and <span class=""disease"" id=""12855330-0-113-125"">hyperalgesia</span> in rats after intradermal injection of capsaicin.",CTD_human
4,0,Therapeutic,C0020429,Hyperalgesia,phenotype,hyperalgesia,796,CALCA,calcitonin,CTD_human,12855330,The role of calcitonin gene-related peptide (CGRP) in the generation and maintenance of mechanical allodynia and hyperalgesia in rats after intradermal injection of capsaicin.,0.280274726784213,"The role of <span class=""gene"" id=""12855330-0-12-22"">calcitonin</span> gene-related peptide (CGRP) in the generation and maintenance of mechanical allodynia and <span class=""disease"" id=""12855330-0-113-125"">hyperalgesia</span> in rats after intradermal injection of capsaicin.",CTD_human
2,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,796,CALCA,calcitonin,CTD_human,1849535,The antihypertensive effect of calcitonin gene-related peptide in rats with norepinephrine- and angiotensin II-induced hypertension.,0.20947005700088103,"The antihypertensive effect of <span class=""gene"" id=""1849535-0-31-41"">calcitonin</span> gene-related peptide in rats with norepinephrine- and angiotensin II-induced <span class=""disease"" id=""1849535-0-119-131"">hypertension</span>.",CTD_human
2,0,Therapeutic,C0020538,Hypertensive disease,group,hypertension,796,CALCA,calcitonin,CTD_human,9887042,We recently reported that calcitonin gene-related peptide (CGRP) reversed the hypertension induced by nitric oxide inhibition in pregnant rats and that this effect appeared to be progesterone dependent.,0.20947005700088103,"We recently reported that <span class=""gene"" id=""9887042-1-26-36"">calcitonin</span> gene-related peptide (CGRP) reversed the <span class=""disease"" id=""9887042-1-78-90"">hypertension</span> induced by nitric oxide inhibition in pregnant rats and that this effect appeared to be progesterone dependent.",CTD_human
1,0,Biomarker,C0033578,Prostatic Neoplasms,group,prostate tumors,796,CALCA,CT,CTD_human,16222118,"Since advanced prostate tumors display chemoresistance, we tested a hypothesis that CT increases apoptosis resistance of prostate cells against cytotoxic drugs.",0.20629000528226699,"Since advanced <span class=""disease"" id=""16222118-2-15-30"">prostate tumors</span> display chemoresistance, we tested a hypothesis that <span class=""gene"" id=""16222118-2-84-86"">CT</span> increases apoptosis resistance of prostate cells against cytotoxic drugs.",CTD_human
2,0,Biomarker,C0149931,Migraine Disorders,group,migraine,796,CALCA,calcitonin,CTD_human,17635592,Activation of trigeminal ganglion nerves and release of calcitonin gene-related peptide (CGRP) are implicated in the pathology of migraine.,0.21446629627403,"Activation of trigeminal ganglion nerves and release of <span class=""gene"" id=""17635592-2-56-66"">calcitonin</span> gene-related peptide (CGRP) are implicated in the pathology of <span class=""disease"" id=""17635592-2-130-138"">migraine</span>.",CTD_human
2,0,Biomarker,C0149931,Migraine Disorders,group,migraine,796,CALCA,CGRP,CTD_human,12574409,"We propose that activation of MAPK pathways may increase CGRP gene expression during migraine, and that sumatriptan can diametrically oppose that activation via a prolonged elevation of intracellular calcium.",0.21446629627403,"We propose that activation of MAPK pathways may increase <span class=""gene"" id=""12574409-10-57-61"">CGRP</span> gene expression during <span class=""disease"" id=""12574409-10-85-93"">migraine</span>, and that sumatriptan can diametrically oppose that activation via a prolonged elevation of intracellular calcium.",CTD_human
2,0,Therapeutic,C0424295,Hyperactive behavior,phenotype,hyperactivity,796,CALCA,Calcitonin,CTD_human,6293644,Calcitonin injection resulted in a potentiation of haloperidol-induced catalepsy and a partial prevention of apomorphine-induced hyperactivity.,0.200274726784213,"<span class=""gene"" id=""6293644-2-0-10"">Calcitonin</span> injection resulted in a potentiation of haloperidol-induced catalepsy and a partial prevention of apomorphine-induced <span class=""disease"" id=""6293644-2-129-142"">hyperactivity</span>.",CTD_human
2,0,Therapeutic,C0424295,Hyperactive behavior,phenotype,hyperactivity,796,CALCA,calcitonin (1,CTD_human,6686863,"Intracerebroventricular injection of salmon calcitonin (1 micrograms/kg) prevented apomorphine-induced hyperactivity in 2, 7, 18 or 21 month old rats, but potentiated haloperidol-induced catalepsy only in 2 or 7 month old rats.",0.200274726784213,"Intracerebroventricular injection of salmon <span class=""gene"" id=""6686863-3-44-57"">calcitonin (1</span> micrograms/kg) prevented apomorphine-induced <span class=""disease"" id=""6686863-3-103-116"">hyperactivity</span> in 2, 7, 18 or 21 month old rats, but potentiated haloperidol-induced catalepsy only in 2 or 7 month old rats.",CTD_human
1,0,Biomarker,C3714756,Intellectual Disability,group,mental retardation,796,CALCA,calcitonin,CTD_human,11357950,"In archived neonatal blood of children with autistic spectrum disorders (n = 69), mental retardation without autism (n = 60), or cerebral palsy (CP, n = 63) and of control children (n = 54), we used recycling immunoaffinity chromatography to measure the neuropeptides substance P (SP), vasoactive intestinal peptide (VIP), pituitary adenylate cyclase-activating polypeptide (PACAP), calcitonin gene-related peptide (CGRP), and the neurotrophins nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin 3 (NT3), and neurotrophin 4/5 (NT4/5).",0.2,"In archived neonatal blood of children with autistic spectrum disorders (n = 69), <span class=""disease"" id=""11357950-2-82-100"">mental retardation</span> without autism (n = 60), or cerebral palsy (CP, n = 63) and of control children (n = 54), we used recycling immunoaffinity chromatography to measure the neuropeptides substance P (SP), vasoactive intestinal peptide (VIP), pituitary adenylate cyclase-activating polypeptide (PACAP), <span class=""gene"" id=""11357950-2-383-393"">calcitonin</span> gene-related peptide (CGRP), and the neurotrophins nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin 3 (NT3), and neurotrophin 4/5 (NT4/5).",CTD_human
1,0,Biomarker,C0431399,Familial aplasia of the vermis,disease,Joubert syndrome,79600,TCTN1,TCTN1,CTD_human,21725307,"Consistent with a shared function for complex components, we identified a mutation in TCTN1 that causes Joubert syndrome.",0.40027472678421294,"Consistent with a shared function for complex components, we identified a mutation in <span class=""gene"" id=""21725307-7-86-91"">TCTN1</span> that causes <span class=""disease"" id=""21725307-7-104-120"">Joubert syndrome</span>.",CTD_human;ORPHANET
1,0,Biomarker,C0038356,Stomach Neoplasms,group,gastric tumors,79633,FAT4,FAT4,CTD_human,22484628,"A prevalence screening confirmed mutations in FAT4, a cadherin family gene, in 5% of gastric cancers (6/110) and FAT4 genomic deletions in 4% (3/83) of gastric tumors.",0.200274726784213,"A prevalence screening confirmed mutations in <span class=""gene"" id=""22484628-5-46-50"">FAT4</span>, a cadherin family gene, in 5% of gastric cancers (6/110) and <span class=""gene"" id=""22484628-5-113-117"">FAT4</span> genomic deletions in 4% (3/83) of <span class=""disease"" id=""22484628-5-152-166"">gastric tumors</span>.",CTD_human
1,0,Biomarker,C1691228,Cystic Kidney Diseases,group,cystic kidney disease,79633,FAT4,Fat4,CTD_human,18604206,Loss of Fat4 disrupts PCP signaling and oriented cell division and leads to cystic kidney disease.,0.2,"Loss of <span class=""gene"" id=""18604206-0-8-12"">Fat4</span> disrupts PCP signaling and oriented cell division and leads to <span class=""disease"" id=""18604206-0-76-97"">cystic kidney disease</span>.",CTD_human
2,0,Biomarker,C0015695,Fatty Liver,disease,fatty liver,79661,NEIL1,neil1,CTD_human,16446448,"In the absence of exogenous oxidative stress, neil1 knockout (neil1-/-) and heterozygotic (neil1+/-) mice develop severe obesity, dyslipidemia, and fatty liver disease and also have a tendency to develop hyperinsulinemia.",0.2,"In the absence of exogenous oxidative stress, <span class=""gene"" id=""16446448-6-46-51"">neil1</span> knockout (<span class=""gene"" id=""16446448-6-62-67"">neil1</span>-/-) and heterozygotic (<span class=""gene"" id=""16446448-6-91-96"">neil1</span>+/-) mice develop severe obesity, dyslipidemia, and <span class=""disease"" id=""16446448-6-148-159"">fatty liver</span> disease and also have a tendency to develop hyperinsulinemia.",CTD_human
2,0,Biomarker,C0015695,Fatty Liver,disease,hepatic steatosis,79661,NEIL1,neil1,CTD_human,21285402,"Following a 5-wk high-fat diet challenge, neil1(-/-) mice gained significantly more body weight than neil1(+/+) littermates and had increased body fat accumulation and moderate to severe hepatic steatosis.",0.2,"Following a 5-wk high-fat diet challenge, <span class=""gene"" id=""21285402-5-42-47"">neil1</span>(-/-) mice gained significantly more body weight than <span class=""gene"" id=""21285402-5-101-106"">neil1</span>(+/+) littermates and had increased body fat accumulation and moderate to severe <span class=""disease"" id=""21285402-5-187-204"">hepatic steatosis</span>.",CTD_human
1,0,Biomarker,C0020459,Hyperinsulinism,disease,hyperinsulinemia,79661,NEIL1,neil1,CTD_human,16446448,"In the absence of exogenous oxidative stress, neil1 knockout (neil1-/-) and heterozygotic (neil1+/-) mice develop severe obesity, dyslipidemia, and fatty liver disease and also have a tendency to develop hyperinsulinemia.",0.2,"In the absence of exogenous oxidative stress, <span class=""gene"" id=""16446448-6-46-51"">neil1</span> knockout (<span class=""gene"" id=""16446448-6-62-67"">neil1</span>-/-) and heterozygotic (<span class=""gene"" id=""16446448-6-91-96"">neil1</span>+/-) mice develop severe obesity, dyslipidemia, and fatty liver disease and also have a tendency to develop <span class=""disease"" id=""16446448-6-204-220"">hyperinsulinemia</span>.",CTD_human
2,0,Biomarker,C0028754,Obesity,disease,obesity,79661,NEIL1,neil1,CTD_human,21285402,"Collectively, these data indicate that NEIL1 deficiency results in an increased susceptibility to obesity and related complications potentially by lowering the threshold for tolerance of cellular oxidative stress in neil1(-/-) mice.",0.28,"Collectively, these data indicate that <span class=""gene"" id=""21285402-9-39-44"">NEIL1</span> deficiency results in an increased susceptibility to <span class=""disease"" id=""21285402-9-98-105"">obesity</span> and related complications potentially by lowering the threshold for tolerance of cellular oxidative stress in <span class=""gene"" id=""21285402-9-216-221"">neil1</span>(-/-) mice.",CTD_human
1,0,Biomarker,C0242339,Dyslipidemias,group,dyslipidemia,79661,NEIL1,neil1,CTD_human,16446448,"In the absence of exogenous oxidative stress, neil1 knockout (neil1-/-) and heterozygotic (neil1+/-) mice develop severe obesity, dyslipidemia, and fatty liver disease and also have a tendency to develop hyperinsulinemia.",0.2,"In the absence of exogenous oxidative stress, <span class=""gene"" id=""16446448-6-46-51"">neil1</span> knockout (<span class=""gene"" id=""16446448-6-62-67"">neil1</span>-/-) and heterozygotic (<span class=""gene"" id=""16446448-6-91-96"">neil1</span>+/-) mice develop severe obesity, <span class=""disease"" id=""16446448-6-130-142"">dyslipidemia</span>, and fatty liver disease and also have a tendency to develop hyperinsulinemia.",CTD_human
1,0,Biomarker,C0271650,Impaired glucose tolerance,phenotype,glucose intolerance,79661,NEIL1,neil1,CTD_human,21285402,A long-term high-fat diet also induced glucose intolerance as well as a significant reduction in mitochondrial DNA and protein content in neil1(-/-) mice.,0.2,"A long-term high-fat diet also induced <span class=""disease"" id=""21285402-8-39-58"">glucose intolerance</span> as well as a significant reduction in mitochondrial DNA and protein content in <span class=""gene"" id=""21285402-8-138-143"">neil1</span>(-/-) mice.",CTD_human
2,0,Biomarker,C0524620,Metabolic Syndrome X,disease,metabolic syndrome,79661,NEIL1,neil1,CTD_human,17389588,Extrapolation of these data suggests that individuals who are heterozygous for these inactive variant neil1 alleles may be at increased risk for metabolic syndrome.,0.200274726784213,"Extrapolation of these data suggests that individuals who are heterozygous for these inactive variant <span class=""gene"" id=""17389588-9-102-107"">neil1</span> alleles may be at increased risk for <span class=""disease"" id=""17389588-9-145-163"">metabolic syndrome</span>.",CTD_human
2,0,Biomarker,C0524620,Metabolic Syndrome X,disease,metabolic syndrome,79661,NEIL1,NEIL1,CTD_human,16446448,The metabolic syndrome resulting from a knockout of the NEIL1 DNA glycosylase.,0.200274726784213,"The <span class=""disease"" id=""16446448-0-4-22"">metabolic syndrome</span> resulting from a knockout of the <span class=""gene"" id=""16446448-0-56-61"">NEIL1</span> DNA glycosylase.",CTD_human
1,1,Biomarker,C0022596,Palmoplantar Keratosis,disease,PPK,79719,AAGAB,?- and ?-adaptin-binding protein p34,CTD_human,23064416,"In 18 families with autosomal dominant punctate PPK, we report heterozygous loss-of-function mutations in AAGAB, encoding ?- and ?-adaptin-binding protein p34, located at a previously linked locus at 15q22.",0.20054945356842604,"In 18 families with autosomal dominant punctate <span class=""disease"" id=""23064416-3-48-51"">PPK</span>, we report heterozygous loss-of-function mutations in <span class=""gene"" id=""23064416-3-106-111"">AAGAB</span>, encoding <span class=""gene"" id=""23064416-3-122-158"">&alpha;- and &gamma;-adaptin-binding protein p34</span>, located at a previously linked locus at 15q22.",CTD_human
1,0,Biomarker,C1136249,"Mental Retardation, X-Linked",disease,XLMR,79742,CXorf36,DIA1R,CTD_human,21264219,Examination of published literature revealed point mutations in DIA1R are associated with X-linked mental retardation (XLMR) and DIA1R deletion is associated with syndromes with ASD-like traits and/or XLMR.,0.200274726784213,"Examination of published literature revealed point mutations in <span class=""gene"" id=""21264219-9-64-69"">DIA1R</span> are associated with <span class=""disease"" id=""21264219-9-90-117"">X-linked mental retardation</span> (<span class=""disease"" id=""21264219-9-119-123"">XLMR</span>) and <span class=""gene"" id=""21264219-9-129-134"">DIA1R</span> deletion is associated with syndromes with ASD-like traits and/or <span class=""disease"" id=""21264219-9-201-205"">XLMR</span>.",CTD_human
2,0,Biomarker,C1510586,Autism Spectrum Disorders,disease,ASD,79742,CXorf36,DIA1R,CTD_human,21283809,Human genes c3orf58 or Deleted In Autism-1 (DIA1) and cXorf36 or Deleted in Autism-1 Related (DIA1R) are implicated in ASD and mental retardation.,0.200274726784213,"Human genes c3orf58 or Deleted In Autism-1 (DIA1) and <span class=""gene"" id=""21283809-2-54-61"">cXorf36</span> or Deleted in Autism-1 Related (<span class=""gene"" id=""21283809-2-94-99"">DIA1R</span>) are implicated in <span class=""disease"" id=""21283809-2-119-122"">ASD</span> and mental retardation.",CTD_human
1,0,Biomarker,C0025202,melanoma,disease,malignant melanomas,7980,TFPI2,tissue factor pathway inhibitor-2,CTD_human,17372906,Silencing of tissue factor pathway inhibitor-2 gene in malignant melanomas.,0.204106546385879,"Silencing of <span class=""gene"" id=""17372906-0-13-46"">tissue factor pathway inhibitor-2</span> gene in <span class=""disease"" id=""17372906-0-55-74"">malignant melanomas</span>.",CTD_human
1,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastasis,7980,TFPI2,TFPI-2,CTD_human,17372906,The results showed that TFPI-2 is silenced in human malignant melanomas by methylation of its promoter CGI and suggested that its silencing is involved in melanoma metastasis.,0.211784540966529,"The results showed that <span class=""gene"" id=""17372906-8-24-30"">TFPI-2</span> is silenced in human malignant melanomas by methylation of its promoter CGI and suggested that its silencing is involved in melanoma <span class=""disease"" id=""17372906-8-164-174"">metastasis</span>.",CTD_human
1,0,Biomarker,C0029408,Degenerative polyarthritis,disease,osteoarthritis,7980,TFPI2,TFPI2,CTD_human,15292528,"While these differences may represent differential behaviour of synovial fibroblasts in in vitro culture, these observations suggest that TFPI2, GRObeta (CXCL2), MnSOD and GCP-2 (CXCL6) may represent new targets for treatments specifically tailored to osteoarthritis.",0.200274726784213,"While these differences may represent differential behaviour of synovial fibroblasts in in vitro culture, these observations suggest that <span class=""gene"" id=""15292528-12-138-143"">TFPI2</span>, GRObeta (CXCL2), MnSOD and GCP-2 (CXCL6) may represent new targets for treatments specifically tailored to <span class=""disease"" id=""15292528-12-252-266"">osteoarthritis</span>.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,hepatocellular carcinoma,7980,TFPI2,Tissue factor pathway inhibitor-2,CTD_human,17464989,Tissue factor pathway inhibitor-2 as a frequently silenced tumor suppressor gene in hepatocellular carcinoma.,0.204930726738519,"<span class=""gene"" id=""17464989-0-0-33"">Tissue factor pathway inhibitor-2</span> as a frequently silenced tumor suppressor gene in <span class=""disease"" id=""17464989-0-84-108"">hepatocellular carcinoma</span>.",CTD_human
1,1,Biomarker,C0265275,Jeune thoracic dystrophy,disease,asphyxiating thoracic dystrophy,79809,TTC21B,IFT139,CTD_human,21258341,"Here we show that mutations in TTC21B, which encodes the retrograde intraflagellar transport protein IFT139, cause both isolated nephronophthisis and syndromic Jeune asphyxiating thoracic dystrophy.",0.4,"Here we show that mutations in <span class=""gene"" id=""21258341-3-31-37"">TTC21B</span>, which encodes the retrograde intraflagellar transport protein <span class=""gene"" id=""21258341-3-101-107"">IFT139</span>, cause both isolated nephronophthisis and syndromic Jeune <span class=""disease"" id=""21258341-3-166-197"">asphyxiating thoracic dystrophy</span>.",CTD_human;ORPHANET
1,0,Biomarker,C0151786,Muscle Weakness,phenotype,muscle weakness,79823,CAMKMT,CaM KMT,CTD_human,26247364,Patients presenting slow growth and muscle weakness that could result from a mitochondrial impairment and mental retardation should be considered for sequence analysis of the CaM KMT gene.,0.2,"Patients presenting slow growth and <span class=""disease"" id=""26247364-15-36-51"">muscle weakness</span> that could result from a mitochondrial impairment and mental retardation should be considered for sequence analysis of the <span class=""gene"" id=""26247364-15-175-182"">CaM KMT</span> gene.",CTD_human
1,0,Biomarker,C0025202,melanoma,disease,melanoma,79852,EPHX3,ABHD9,CTD_human,16778180,"CGIs in putative promoter regions of 34 genes (ABHD9, BARHL1, CLIC5, CNNM1, COL2A1, CPT1C, DDIT4L, DERL3, DHRS3, DPYS, EFEMP2, FAM62C, FAM78A, FLJ33790, GBX2, GPR10, GPRASP1, HOXA9, HOXD11, HOXD12, HOXD13, p14ARF, PAX6, PRDX2, PTPRG, RASD1, RAX, REC8L1, SLC27A3, TGFB2, TLX2, TMEM22, TMEM30B, and UNC5C) were found to be methylated in at least 1 of 13 melanoma cell lines but not in two cultured normal melanocytes.",0.2,"CGIs in putative promoter regions of 34 genes (<span class=""gene"" id=""16778180-3-47-52"">ABHD9</span>, BARHL1, CLIC5, CNNM1, COL2A1, CPT1C, DDIT4L, DERL3, DHRS3, DPYS, EFEMP2, FAM62C, FAM78A, FLJ33790, GBX2, GPR10, GPRASP1, HOXA9, HOXD11, HOXD12, HOXD13, p14ARF, PAX6, PRDX2, PTPRG, RASD1, RAX, REC8L1, SLC27A3, TGFB2, TLX2, TMEM22, TMEM30B, and UNC5C) were found to be methylated in at least 1 of 13 <span class=""disease"" id=""16778180-3-352-360"">melanoma</span> cell lines but not in two cultured normal melanocytes.",CTD_human
1,0,Therapeutic,C0020437,Hypercalcemia,disease,hypercalcemia,799,CALCR,Calcitonin receptor,CTD_human,18627265,Calcitonin receptor plays a physiological role to protect against hypercalcemia in mice.,0.200274726784213,"<span class=""gene"" id=""18627265-0-0-19"">Calcitonin receptor</span> plays a physiological role to protect against <span class=""disease"" id=""18627265-0-66-79"">hypercalcemia</span> in mice.",CTD_human
1,0,Biomarker,C0677886,Epithelial ovarian cancer,disease,EOC,79915,ATAD5,ATAD5,CTD_human,25581431,"Variants at 1p36 (nearest gene, WNT4), 4q26 (SYNPO2), 9q34.2 (ABO) and 17q11.2 (ATAD5) were associated with EOC risk, and at 1p34.3 (RSPO1) and 6p22.1 (GPX6) variants were specifically associated with the serous EOC subtype, all with P < 5 × 10(-8).",0.200274726784213,"Variants at 1p36 (nearest gene, WNT4), 4q26 (SYNPO2), 9q34.2 (ABO) and 17q11.2 (<span class=""gene"" id=""25581431-5-80-85"">ATAD5</span>) were associated with <span class=""disease"" id=""25581431-5-108-111"">EOC</span> risk, and at 1p34.3 (RSPO1) and 6p22.1 (GPX6) variants were specifically associated with the serous <span class=""disease"" id=""25581431-5-212-215"">EOC</span> subtype, all with P &lt; 5 &times; 10(-8).",CTD_human
1,0,Biomarker,C0024121,Lung Neoplasms,group,lung tumor,79930,DOK3,Dok3,CTD_human,20139980,"Here we identify the downstream of tyrosine kinase (Dok) family members Dok1, Dok2 and Dok3 as lung tumor suppressors.",0.200274726784213,"Here we identify the downstream of tyrosine kinase (Dok) family members Dok1, Dok2 and <span class=""gene"" id=""20139980-2-87-91"">Dok3</span> as <span class=""disease"" id=""20139980-2-95-105"">lung tumor</span> suppressors.",CTD_human
3,0,Biomarker,C2746066,Combined D-2- and L-2-hydroxyglutaric aciduria,disease,L-2-Hydroxyglutaric aciduria,79944,L2HGDH,C14orf160,CTD_human,15385440,"L-2-Hydroxyglutaric aciduria: identification of a mutant gene C14orf160, localized on chromosome 14q22.1.",0.202472541057918,"<span class=""disease"" id=""15385440-0-0-28"">L-2-Hydroxyglutaric aciduria</span>: identification of a mutant gene <span class=""gene"" id=""15385440-0-62-71"">C14orf160</span>, localized on chromosome 14q22.1.",CTD_human
3,0,Biomarker,C2746066,Combined D-2- and L-2-hydroxyglutaric aciduria,disease,L-2-hydroxyglutaric aciduria,79944,L2HGDH,L-2-hydroxyglutarate dehydrogenase,CTD_human,15548604,A gene encoding a putative FAD-dependent L-2-hydroxyglutarate dehydrogenase is mutated in L-2-hydroxyglutaric aciduria.,0.202472541057918,"A gene encoding a putative FAD-dependent <span class=""gene"" id=""15548604-0-41-75"">L-2-hydroxyglutarate dehydrogenase</span> is mutated in <span class=""disease"" id=""15548604-0-90-118"">L-2-hydroxyglutaric aciduria</span>.",CTD_human
2,0,Biomarker,C0005695,Bladder Neoplasm,disease,bladder cancer,8000,PSCA,PSCA,CTD_human,20083643,Genetic variation in PSCA and bladder cancer susceptibility in a Chinese population.,0.20412090176319603,"Genetic variation in <span class=""gene"" id=""20083643-0-21-25"">PSCA</span> and <span class=""disease"" id=""20083643-0-30-44"">bladder cancer</span> susceptibility in a Chinese population.",CTD_human
2,0,Biomarker,C0005695,Bladder Neoplasm,disease,bladder cancer,8000,PSCA,PSCA,CTD_human,19648920,A missense variant (rs2294008) in the PSCA gene showed consistent association with bladder cancer in US and European populations.,0.20412090176319603,"A missense variant (rs2294008) in the <span class=""gene"" id=""19648920-3-38-42"">PSCA</span> gene showed consistent association with <span class=""disease"" id=""19648920-3-83-97"">bladder cancer</span> in US and European populations.",CTD_human
1,1,Biomarker,C0013295,Duodenal Ulcer,disease,duodenal ulcer,8000,PSCA,PSCA,CTD_human,22387998,"The C allele of rs2294008 at PSCA was associated with increased risk of duodenal ulcer (odds ratio (OR) = 1.84; P = 3.92 × 10(-33)) in a recessive model but was associated with decreased risk of gastric cancer (OR = 0.79; P = 6.79 × 10(-12)), as reported previously.",0.201098907136852,"The C allele of rs2294008 at <span class=""gene"" id=""22387998-2-29-33"">PSCA</span> was associated with increased risk of <span class=""disease"" id=""22387998-2-72-86"">duodenal ulcer</span> (odds ratio (OR) = 1.84; P = 3.92 &times; 10(-33)) in a recessive model but was associated with decreased risk of gastric cancer (OR = 0.79; P = 6.79 &times; 10(-12)), as reported previously.",CTD_human
1,0,Biomarker,C2931845,Neurodegeneration with brain iron accumulation (NBIA),disease,NBIA,80025,PANK2,PANK2,CTD_human,20629144,"Indian-subcontinent NBIA: unusual phenotypes, novel PANK2 mutations, and undetermined genetic forms.",0.206318716036901,"Indian-subcontinent <span class=""disease"" id=""20629144-0-20-24"">NBIA</span>: unusual phenotypes, novel <span class=""gene"" id=""20629144-0-52-57"">PANK2</span> mutations, and undetermined genetic forms.",CTD_human
1,0,Biomarker,C0025202,melanoma,disease,MM,80070,ADAMTS20,ADAMTS20,CTD_human,21559390,"However, three SNPs in TYR, SILV/CDK2 and ADAMTS20 genes (rs17793678, rs2069398 and rs1510521 respectively) had an overall p-value<0.05 when considering the whole DNA collection (1214 MM cases and 1296 controls).",0.2,"However, three SNPs in TYR, SILV/CDK2 and <span class=""gene"" id=""21559390-9-42-50"">ADAMTS20</span> genes (rs17793678, rs2069398 and rs1510521 respectively) had an overall p-value&lt;0.05 when considering the whole DNA collection (1214 <span class=""disease"" id=""21559390-9-184-186"">MM</span> cases and 1296 controls).",CTD_human
1,0,Biomarker,C0002395,Alzheimer's Disease,disease,Alzheimer's disease,801,CALM1,calmodulin,CTD_human,11470324,Immunostaining of calmodulin and aluminium in Alzheimer's disease-affected brains.,0.20274726784213098,"Immunostaining of <span class=""gene"" id=""11470324-0-18-28"">calmodulin</span> and aluminium in <span class=""disease"" id=""11470324-0-46-65"">Alzheimer's disease</span>-affected brains.",CTD_human
1,0,Biomarker,C0024809,Marijuana Abuse,disease,cannabis,801,CALM1,calmodulin,CTD_human,17205118,"Therefore, humans who abused cocaine, cannabis and/or phencyclidine share a decrease in transcription of calmodulin-related genes and increased transcription related to lipid/cholesterol and Golgi/ER function.",0.200274726784213,"Therefore, humans who abused cocaine, <span class=""disease"" id=""17205118-7-38-46"">cannabis</span> and/or phencyclidine share a decrease in transcription of <span class=""gene"" id=""17205118-7-105-115"">calmodulin</span>-related genes and increased transcription related to lipid/cholesterol and Golgi/ER function.",CTD_human
1,0,Biomarker,C0020443,Hypercholesterolemia,disease,hypercholesterolemia,8013,NR4A3,NOR-1,CTD_human,16005304,Simvastatin inhibited NOR-1 expression induced by LDL in VSMC and by hypercholesterolemia in the abdominal aorta of hyperlipemic pigs.,0.200274726784213,"Simvastatin inhibited <span class=""gene"" id=""16005304-6-22-27"">NOR-1</span> expression induced by LDL in VSMC and by <span class=""disease"" id=""16005304-6-69-89"">hypercholesterolemia</span> in the abdominal aorta of hyperlipemic pigs.",CTD_human
1,0,Biomarker,C0024433,Macrostomia,disease,macrostomia,80144,FRAS1,FRAS1,CTD_human,17163535,Fraser and Ablepharon macrostomia phenotypes: concurrence in one family and association with mutated FRAS1.,0.200274726784213,"Fraser and Ablepharon <span class=""disease"" id=""17163535-0-22-33"">macrostomia</span> phenotypes: concurrence in one family and association with mutated <span class=""gene"" id=""17163535-0-101-106"">FRAS1</span>.",CTD_human
1,14,Biomarker,C0265233,Cryptophthalmos syndrome,disease,FS,80144,FRAS1,FRAS1,CTD_human,17163535,Extensive studies on mRNA expression indicated that this mutation most likely leads to loss of function as most previously reported FRAS1 mutations associated with FS.,0.48467035533162295,"Extensive studies on mRNA expression indicated that this mutation most likely leads to loss of function as most previously reported <span class=""gene"" id=""17163535-5-132-137"">FRAS1</span> mutations associated with <span class=""disease"" id=""17163535-5-164-166"">FS</span>.",CTD_human;ORPHANET
1,1,Biomarker,C0752166,Bardet-Biedl Syndrome,disease,BBS,80184,CEP290,NPHP6,CTD_human,18327255,"Here we show that mutations in MKS1, MKS3 and CEP290 (also known as NPHP6) either can cause Bardet-Biedl syndrome (BBS) or may have a potential epistatic effect on mutations in known BBS-associated loci.",0.404930726738519,"Here we show that mutations in MKS1, MKS3 and <span class=""gene"" id=""18327255-3-46-52"">CEP290</span> (also known as <span class=""gene"" id=""18327255-3-68-73"">NPHP6</span>) either can cause <span class=""disease"" id=""18327255-3-92-113"">Bardet-Biedl syndrome</span> (<span class=""disease"" id=""18327255-3-115-118"">BBS</span>) or may have a potential epistatic effect on mutations in known <span class=""disease"" id=""18327255-3-183-186"">BBS</span>-associated loci.",CTD_human;ORPHANET
1,0,Biomarker,C0010051,Coronary Aneurysm,disease,coronary artery aneurysms,80271,ITPKC,ITPKC,CTD_human,18084290,ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms.,0.200274726784213,"<span class=""gene"" id=""18084290-0-0-5"">ITPKC</span> functional polymorphism associated with Kawasaki disease susceptibility and formation of <span class=""disease"" id=""18084290-0-95-120"">coronary artery aneurysms</span>.",CTD_human
1,1,Biomarker,C0026691,Mucocutaneous Lymph Node Syndrome,disease,Kawasaki disease,80271,ITPKC,ITPKC,CTD_human,18084290,ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms.,0.206304360659584,"<span class=""gene"" id=""18084290-0-0-5"">ITPKC</span> functional polymorphism associated with <span class=""disease"" id=""18084290-0-46-62"">Kawasaki disease</span> susceptibility and formation of coronary artery aneurysms.",CTD_human
1,1,Biomarker,C0025286,Meningioma,disease,meningioma,8028,MLLT10,MLLT10,CTD_human,21804547,Common variation at 10p12.31 near MLLT10 influences meningioma risk.,0.20054945356842604,"Common variation at 10p12.31 near <span class=""gene"" id=""21804547-0-34-40"">MLLT10</span> influences <span class=""disease"" id=""21804547-0-52-62"">meningioma</span> risk.",CTD_human
1,0,Biomarker,C0009404,Colorectal Neoplasms,group,colorectal tumors,80317,ZKSCAN3,ZKSCAN3,CTD_human,18519692," In searching for novel contributing gene products using Unigene cluster data mining, we found overrepresentation of expressed sequence tags corresponding to a previously uncharacterized gene (ZKSCAN3) in colorectal tumors.",0.20300763924902696," In searching for novel contributing gene products using Unigene cluster data mining, we found overrepresentation of expressed sequence tags corresponding to a previously uncharacterized gene (<span class=""gene"" id=""18519692-2-194-201"">ZKSCAN3</span>) in <span class=""disease"" id=""18519692-2-206-223"">colorectal tumors</span>.",CTD_human
1,0,Biomarker,C0015695,Fatty Liver,disease,Hepatic steatosis,80339,PNPLA3,PNPLA3,CTD_human,25678388,Hepatic steatosis in Wilson disease--Role of copper and PNPLA3 mutations.,0.247001954660203,"<span class=""disease"" id=""25678388-0-0-17"">Hepatic steatosis</span> in Wilson disease--Role of copper and <span class=""gene"" id=""25678388-0-56-62"">PNPLA3</span> mutations.",CTD_human
2,1,Biomarker,C0023891,"Liver Cirrhosis, Alcoholic",disease,alcoholic cirrhosis,80339,PNPLA3,PNPLA3,CTD_human,19946271,"We found that rs738409 in PNPLA3 is strongly associated with alcoholic liver disease and clinically evident alcoholic cirrhosis (unadjusted OR= 2.25, P=1.7 x 10(-10); ancestry-adjusted OR=1.79, P=1.9 x 10(-5)).",0.20728659810449399,"We found that rs738409 in <span class=""gene"" id=""19946271-3-26-32"">PNPLA3</span> is strongly associated with alcoholic liver disease and clinically evident <span class=""disease"" id=""19946271-3-108-127"">alcoholic cirrhosis</span> (unadjusted OR= 2.25, P=1.7 x 10(-10); ancestry-adjusted OR=1.79, P=1.9 x 10(-5)).",CTD_human
1,0,Biomarker,C0023896,Alcoholic Liver Diseases,group,alcoholic liver disease,80339,PNPLA3,PNPLA3,CTD_human,19946271,Variant in PNPLA3 is associated with alcoholic liver disease.,0.20866023202555897,"Variant in <span class=""gene"" id=""19946271-0-11-17"">PNPLA3</span> is associated with <span class=""disease"" id=""19946271-0-37-60"">alcoholic liver disease</span>.",CTD_human
3,2,Biomarker,C0400966,Non-alcoholic Fatty Liver Disease,disease,NAFLD,80339,PNPLA3,Pnpla3,CTD_human,27180240,Pnpla3 is a gene whose polymorphism is associated with the pathogenesis of nonalcoholic fatty liver disease (NAFLD) development.,0.23104412661607998,"<span class=""gene"" id=""27180240-7-0-6"">Pnpla3</span> is a gene whose polymorphism is associated with the pathogenesis of <span class=""disease"" id=""27180240-7-75-107"">nonalcoholic fatty liver disease</span> (<span class=""disease"" id=""27180240-7-109-114"">NAFLD</span>) development.",CTD_human
3,2,Biomarker,C0400966,Non-alcoholic Fatty Liver Disease,disease,nonalcoholic fatty liver disease,80339,PNPLA3,PNPLA3,CTD_human,18820647,Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease.,0.23104412661607998,"Genetic variation in <span class=""gene"" id=""18820647-0-21-27"">PNPLA3</span> confers susceptibility to <span class=""disease"" id=""18820647-0-54-86"">nonalcoholic fatty liver disease</span>.",CTD_human
3,2,Biomarker,C0400966,Non-alcoholic Fatty Liver Disease,disease,NAFLD,80339,PNPLA3,PNPLA3,CTD_human,24531328,"Three variants were associated with higher liver fat levels at the exome-wide significance level of 3.6 × 10(-7): two in PNPLA3, an established locus for NAFLD, and one (encoding p.Glu167Lys) in TM6SF2, a gene of unknown function.",0.23104412661607998,"Three variants were associated with higher liver fat levels at the exome-wide significance level of 3.6 &times; 10(-7): two in <span class=""gene"" id=""24531328-3-121-127"">PNPLA3</span>, an established locus for <span class=""disease"" id=""24531328-3-154-159"">NAFLD</span>, and one (encoding p.Glu167Lys) in TM6SF2, a gene of unknown function.",CTD_human
1,0,Therapeutic,C2239176,Liver carcinoma,disease,hepatocellular carcinomas,80381,CD276,B7H3,CTD_human,16217749,Arsenic trioxide synergizes with B7H3-mediated immunotherapy to eradicate hepatocellular carcinomas.,0.20054945356842604,"Arsenic trioxide synergizes with <span class=""gene"" id=""16217749-0-33-37"">B7H3</span>-mediated immunotherapy to eradicate <span class=""disease"" id=""16217749-0-74-99"">hepatocellular carcinomas</span>.",CTD_human
1,0,Biomarker,C0024809,Marijuana Abuse,disease,cannabis,805,CALM2,calmodulin,CTD_human,17205118,"Therefore, humans who abused cocaine, cannabis and/or phencyclidine share a decrease in transcription of calmodulin-related genes and increased transcription related to lipid/cholesterol and Golgi/ER function.",0.200274726784213,"Therefore, humans who abused cocaine, <span class=""disease"" id=""17205118-7-38-46"">cannabis</span> and/or phencyclidine share a decrease in transcription of <span class=""gene"" id=""17205118-7-105-115"">calmodulin</span>-related genes and increased transcription related to lipid/cholesterol and Golgi/ER function.",CTD_human
1,8,Biomarker,C1843807,"Basal ganglia disease, biotin-responsive",disease,Biotin-responsive basal ganglia disease,80704,SLC19A3,SLC19A3,CTD_human,15871139,Biotin-responsive basal ganglia disease maps to 2q36.3 and is due to mutations in SLC19A3.,0.602747267842131,"<span class=""disease"" id=""15871139-0-0-39"">Biotin-responsive basal ganglia disease</span> maps to 2q36.3 and is due to mutations in <span class=""gene"" id=""15871139-0-82-89"">SLC19A3</span>.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0025202,melanoma,disease,melanoma,80723,SLC35G2,TMEM22,CTD_human,16778180,"CGIs in putative promoter regions of 34 genes (ABHD9, BARHL1, CLIC5, CNNM1, COL2A1, CPT1C, DDIT4L, DERL3, DHRS3, DPYS, EFEMP2, FAM62C, FAM78A, FLJ33790, GBX2, GPR10, GPRASP1, HOXA9, HOXD11, HOXD12, HOXD13, p14ARF, PAX6, PRDX2, PTPRG, RASD1, RAX, REC8L1, SLC27A3, TGFB2, TLX2, TMEM22, TMEM30B, and UNC5C) were found to be methylated in at least 1 of 13 melanoma cell lines but not in two cultured normal melanocytes.",0.2,"CGIs in putative promoter regions of 34 genes (ABHD9, BARHL1, CLIC5, CNNM1, COL2A1, CPT1C, DDIT4L, DERL3, DHRS3, DPYS, EFEMP2, FAM62C, FAM78A, FLJ33790, GBX2, GPR10, GPRASP1, HOXA9, HOXD11, HOXD12, HOXD13, p14ARF, PAX6, PRDX2, PTPRG, RASD1, RAX, REC8L1, SLC27A3, TGFB2, TLX2, <span class=""gene"" id=""16778180-3-276-282"">TMEM22</span>, TMEM30B, and UNC5C) were found to be methylated in at least 1 of 13 <span class=""disease"" id=""16778180-3-352-360"">melanoma</span> cell lines but not in two cultured normal melanocytes.",CTD_human
1,0,Biomarker,C0085681,Hyperphosphatemia (disorder),disease,hyperphosphatemia,8074,FGF23,FGF23,CTD_human,17710231,This patient exhibited defects in mineral ion homeostasis with marked hyperphosphatemia and hypercalcemia as well as elevated serum levels of parathyroid hormone and FGF23.,0.20850217493328896,"This patient exhibited defects in mineral ion homeostasis with marked <span class=""disease"" id=""17710231-3-70-87"">hyperphosphatemia</span> and hypercalcemia as well as elevated serum levels of parathyroid hormone and <span class=""gene"" id=""17710231-3-166-171"">FGF23</span>.",CTD_human
1,0,Biomarker,C0010701,Phyllodes Tumor,disease,phyllodes tumor,8085,KMT2D,KMT2D,CTD_human,26437033,"Second, phyllodes tumors exhibited mutations in FLNA, SETD2 and KMT2D, suggesting a role in driving phyllodes tumor development.",0.200274726784213,"Second, <span class=""disease"" id=""26437033-5-8-24"">phyllodes tumors</span> exhibited mutations in FLNA, SETD2 and <span class=""gene"" id=""26437033-5-64-69"">KMT2D</span>, suggesting a role in driving <span class=""disease"" id=""26437033-5-100-115"">phyllodes tumor</span> development.",CTD_human
1,0,Biomarker,C0079744,Diffuse Large B-Cell Lymphoma,disease,DLBCL,8085,KMT2D,MLL2,CTD_human,21804550,"This analysis also revealed mutations in genes not previously implicated in DLBCL pathogenesis, including those regulating chromatin methylation (MLL2; 24% of samples) and immune recognition by T cells.",0.201098907136852,"This analysis also revealed mutations in genes not previously implicated in <span class=""disease"" id=""21804550-4-76-81"">DLBCL</span> pathogenesis, including those regulating chromatin methylation (<span class=""gene"" id=""21804550-4-146-150"">MLL2</span>; 24% of samples) and immune recognition by T cells.",CTD_human
5,128,Biomarker,C0796004,Kabuki make-up syndrome,disease,Kabuki syndrome,8085,KMT2D,MLL2,CTD_human,20711175,Exome sequencing identifies MLL2 mutations as a cause of Kabuki syndrome.,0.6111982856181071,"Exome sequencing identifies <span class=""gene"" id=""20711175-0-28-32"">MLL2</span> mutations as a cause of <span class=""disease"" id=""20711175-0-57-72"">Kabuki syndrome</span>.",CTD_human;ORPHANET;UNIPROT
3,7,Biomarker,C0271742,Glucocorticoid deficiency with achalasia,disease,triple A syndrome,8086,AAAS,ALADIN,CTD_human,23315990,In order to investigate the changes in differential gene expression in ALADIN-deficient or mutated cells under oxidative stress we used fibroblast cell cultures of triple A syndrome patients and compared these to controls.,0.6107143445843111,"In order to investigate the changes in differential gene expression in <span class=""gene"" id=""23315990-3-71-77"">ALADIN</span>-deficient or mutated cells under oxidative stress we used fibroblast cell cultures of <span class=""disease"" id=""23315990-3-164-181"">triple A syndrome</span> patients and compared these to controls.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0023903,Liver neoplasms,group,liver tumor,8100,IFT88,Tg737,CTD_human,9362446,"Ectopic re-expression of the Tg737 gene in a Tg737 deleted mouse liver tumor cell line resulted in suppression of tumorigenic growth, without altering in vitro cell culture growth.",0.20082418035263896,"Ectopic re-expression of the <span class=""gene"" id=""9362446-3-29-34"">Tg737</span> gene in a <span class=""gene"" id=""9362446-3-45-50"">Tg737</span> deleted mouse <span class=""disease"" id=""9362446-3-65-76"">liver tumor</span> cell line resulted in suppression of tumorigenic growth, without altering in vitro cell culture growth.",CTD_human
1,0,Biomarker,C0152427,Polydactyly,disease,polydactyly,8100,IFT88,Tg737,CTD_human,12701101,"Collectively, the data argue for a dosage effect of Tg737 on the limb phenotypes and that the polydactyly is independent of Shh misexpression.",0.2,"Collectively, the data argue for a dosage effect of <span class=""gene"" id=""12701101-8-52-57"">Tg737</span> on the limb phenotypes and that the <span class=""disease"" id=""12701101-8-94-105"">polydactyly</span> is independent of Shh misexpression.",CTD_human
1,0,Biomarker,C0023267,Fibroid Tumor,disease,leiomyoma,81029,WNT5B,Wnt5b,CTD_human,15972578,Overexpression of the Wnt5b gene in leiomyoma cells: implications for a role of the Wnt signaling pathway in the uterine benign tumor.,0.20300763924902696,"Overexpression of the <span class=""gene"" id=""15972578-0-22-27"">Wnt5b</span> gene in <span class=""disease"" id=""15972578-0-36-45"">leiomyoma</span> cells: implications for a role of the Wnt signaling pathway in the uterine benign tumor.",CTD_human
1,0,Biomarker,C1458155,Mammary Neoplasms,group,breast tumors,81031,SLC2A10,SLC2A10,CTD_human,25151356,"The genes identified include eight that are essential for cell proliferation (FGD5, METTL6, CPT1A, DTX3, MRPS23, EIF2S2, EIF6 and SLC2A10) and are uniquely amplified in patients with highly proliferative luminal breast tumors, a clinical subset of patients for which few therapeutic options are effective.",0.200274726784213,"The genes identified include eight that are essential for cell proliferation (FGD5, METTL6, CPT1A, DTX3, MRPS23, EIF2S2, EIF6 and <span class=""gene"" id=""25151356-4-130-137"">SLC2A10</span>) and are uniquely amplified in patients with highly proliferative luminal <span class=""disease"" id=""25151356-4-212-225"">breast tumors</span>, a clinical subset of patients for which few therapeutic options are effective.",CTD_human
1,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,NSCLC,81037,CLPTM1L,CLPTM1L,CTD_human,22675468,"Cleft Lip and Palate Transmembrane Protein 1-Like (CLPTM1L), resides in a region of chromosome 5 for which copy number gain has been found to be the most frequent genetic event in the early stages of non-small cell lung cancer (NSCLC).",0.204055389228567,"Cleft Lip and Palate Transmembrane Protein 1-Like (<span class=""gene"" id=""22675468-1-51-58"">CLPTM1L</span>), resides in a region of chromosome 5 for which copy number gain has been found to be the most frequent genetic event in the early stages of <span class=""disease"" id=""22675468-1-200-226"">non-small cell lung cancer</span> (<span class=""disease"" id=""22675468-1-228-233"">NSCLC</span>).",CTD_human
3,0,Biomarker,C0024121,Lung Neoplasms,group,lung tumor,81037,CLPTM1L,CLPTM1L,CTD_human,24366883,"CLPTM1L expression was required in vitro for morphologic transformation by H-RasV12 or K-RasV12, anchorage-independent growth, and survival of anoikis of lung tumor cells.",0.208096423079816,"<span class=""gene"" id=""24366883-3-0-7"">CLPTM1L</span> expression was required in vitro for morphologic transformation by H-RasV12 or K-RasV12, anchorage-independent growth, and survival of anoikis of <span class=""disease"" id=""24366883-3-154-164"">lung tumor</span> cells.",CTD_human
3,1,Biomarker,C0270952,"Muscular Dystrophy, Oculopharyngeal",disease,OPMD,8106,PABPN1,PABPN1,CTD_human,16239242,Nuclear inclusions formed by the aggregation of a polyalanine expansion mutant of the nuclear poly(A)-binding protein (PABPN1) is a hallmark of oculopharyngeal muscular dystrophy (OPMD).,0.43858483177551394,"Nuclear inclusions formed by the aggregation of a polyalanine expansion mutant of the nuclear poly(A)-binding protein (<span class=""gene"" id=""16239242-1-119-125"">PABPN1</span>) is a hallmark of <span class=""disease"" id=""16239242-1-144-178"">oculopharyngeal muscular dystrophy</span> (<span class=""disease"" id=""16239242-1-180-184"">OPMD</span>).",CTD_human;ORPHANET
1,1,Biomarker,C0029401,Osteitis Deformans,disease,PDB,81501,DCSTAMP,TM7SF4,CTD_human,21623375,"Our data also confirmed the association of TM7SF4 (rs2458413, OR = 1.40, P = 7.38 × 10(-17)) with PDB.",0.20054945356842604,"Our data also confirmed the association of <span class=""gene"" id=""21623375-5-43-49"">TM7SF4</span> (rs2458413, OR = 1.40, P = 7.38 &times; 10(-17)) with <span class=""disease"" id=""21623375-5-98-101"">PDB</span>.",CTD_human
1,0,Biomarker,C0003873,Rheumatoid Arthritis,disease,rheumatoid arthritis,81567,TXNDC5,TXNDC5,CTD_human,23326410,Investigate pathogenic mechanism of TXNDC5 in rheumatoid arthritis.,0.200274726784213,"Investigate pathogenic mechanism of <span class=""gene"" id=""23326410-0-36-42"">TXNDC5</span> in <span class=""disease"" id=""23326410-0-46-66"">rheumatoid arthritis</span>.",CTD_human
2,0,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,816,CAMK2B,CaMKIIbeta,CTD_human,20336626,The elevated levels of CaMKIIbeta mRNA in the striatum suggest that this enzyme may increase D2(High) in animals and possibly in schizophrenia itself.,0.20546582492962803,"The elevated levels of <span class=""gene"" id=""20336626-9-23-33"">CaMKIIbeta</span> mRNA in the striatum suggest that this enzyme may increase D2(High) in animals and possibly in <span class=""disease"" id=""20336626-9-129-142"">schizophrenia</span> itself.",CTD_human
1,0,Biomarker,C0028754,Obesity,disease,obese,8165,AKAP1,AKAP1,CTD_human,20975297,"Several genes and transcripts involved in lipolysis were down-regulated, such as AKAP1, PRKAR2B, Gi and CIDEA, whereas NPY1R and CES1 were up-regulated, when comparing obese to lean subjects.",0.2,"Several genes and transcripts involved in lipolysis were down-regulated, such as <span class=""gene"" id=""20975297-3-81-86"">AKAP1</span>, PRKAR2B, Gi and CIDEA, whereas NPY1R and CES1 were up-regulated, when comparing <span class=""disease"" id=""20975297-3-168-173"">obese</span> to lean subjects.",CTD_human
1,0,Biomarker,C0008073,Developmental Disabilities,group,developmental disabilities,81704,DOCK8,Dedicator of cytokinesis 8,CTD_human,18060736,Dedicator of cytokinesis 8 is disrupted in two patients with mental retardation and developmental disabilities.,0.200274726784213,"<span class=""gene"" id=""18060736-0-0-26"">Dedicator of cytokinesis 8</span> is disrupted in two patients with mental retardation and <span class=""disease"" id=""18060736-0-84-110"">developmental disabilities</span>.",CTD_human
1,0,Biomarker,C0027819,Neuroblastoma,disease,neuroblastoma,81704,DOCK8,DOCK8,CTD_human,26121086,"Recurrent alterations at relapse included mutations in the putative CHD5 neuroblastoma tumor suppressor, chromosome 9p losses, DOCK8 mutations, inactivating mutations in PTPN14 and a relapse-specific activity pattern for the PTPN14 target YAP.",0.2,"Recurrent alterations at relapse included mutations in the putative CHD5 <span class=""disease"" id=""26121086-6-73-86"">neuroblastoma</span> tumor suppressor, chromosome 9p losses, <span class=""gene"" id=""26121086-6-127-132"">DOCK8</span> mutations, inactivating mutations in PTPN14 and a relapse-specific activity pattern for the PTPN14 target YAP.",CTD_human
1,0,Biomarker,C3714756,Intellectual Disability,group,mental retardation,81704,DOCK8,Dedicator of cytokinesis 8,CTD_human,18060736,Dedicator of cytokinesis 8 is disrupted in two patients with mental retardation and developmental disabilities.,0.20300763924902696,"<span class=""gene"" id=""18060736-0-0-26"">Dedicator of cytokinesis 8</span> is disrupted in two patients with <span class=""disease"" id=""18060736-0-61-79"">mental retardation</span> and developmental disabilities.",CTD_human
1,0,Therapeutic,C0009319,Colitis,disease,colitis,8174,MADCAM1,MAdCAM-1,CTD_human,16917232,Antisense therapy of MAdCAM-1 for trinitrobenzenesulfonic acid-induced murine colitis.,0.20054945356842604,"Antisense therapy of <span class=""gene"" id=""16917232-0-21-29"">MAdCAM-1</span> for trinitrobenzenesulfonic acid-induced murine <span class=""disease"" id=""16917232-0-78-85"">colitis</span>.",CTD_human
2,0,Biomarker,C0027794,Neural Tube Defects,group,neural-tube defects,81839,VANGL1,VANGL1,CTD_human,17409324,Mutations in VANGL1 associated with neural-tube defects.,0.20487956958120604,"Mutations in <span class=""gene"" id=""17409324-0-13-19"">VANGL1</span> associated with <span class=""disease"" id=""17409324-0-36-55"">neural-tube defects</span>.",CTD_human
2,0,Biomarker,C0027794,Neural Tube Defects,group,neural tube defects,81839,VANGL1,VANGL1,CTD_human,19319979,Novel mutations in VANGL1 in neural tube defects.,0.20487956958120604,"Novel mutations in <span class=""gene"" id=""19319979-0-19-25"">VANGL1</span> in <span class=""disease"" id=""19319979-0-29-48"">neural tube defects</span>.",CTD_human
1,0,Biomarker,C0023467,"Leukemia, Myelocytic, Acute",disease,AML,81848,SPRY4,SPRY4,CTD_human,25822087,"Thus, SPRY4 is a tumor suppressor at 5q whose disruption contributes to a lethal AML subtype that appears to acquire RAS pathway activation through a loss of negative regulators.",0.2,"Thus, <span class=""gene"" id=""25822087-6-6-11"">SPRY4</span> is a tumor suppressor at 5q whose disruption contributes to a lethal <span class=""disease"" id=""25822087-6-81-84"">AML</span> subtype that appears to acquire RAS pathway activation through a loss of negative regulators.",CTD_human
1,0,Biomarker,C0003873,Rheumatoid Arthritis,disease,rheumatoid arthritis,8200,GDF5,GDF-5,CTD_human,18830904,Modulatory effects of inflammation and therapy on GDF-5 expression in rheumatoid arthritis synovium.,0.20300763924902696,"Modulatory effects of inflammation and therapy on <span class=""gene"" id=""18830904-0-50-55"">GDF-5</span> expression in <span class=""disease"" id=""18830904-0-70-90"">rheumatoid arthritis</span> synovium.",CTD_human
1,0,Biomarker,C0029408,Degenerative polyarthritis,disease,OA,8200,GDF5,GDF-5,CTD_human,18830904,"Stimulation with prednisolone and TNFalpha reduced GDF-5 expression in OA and RA fibroblasts, whereas MTX and IL-1beta revealed minor or no relevant change.",0.231706892413202,"Stimulation with prednisolone and TNFalpha reduced <span class=""gene"" id=""18830904-9-51-56"">GDF-5</span> expression in <span class=""disease"" id=""18830904-9-71-73"">OA</span> and RA fibroblasts, whereas MTX and IL-1beta revealed minor or no relevant change.",CTD_human
1,0,Biomarker,C0001418,Adenocarcinoma,group,adenocarcinoma,8202,NCOA3,SRC-3,CTD_human,20852035,This SRC-3 overexpression frequency was similar to the overexpression frequency observed for squamous cell carcinoma and adenocarcinoma (82.1% vs 90%) and for metastasis and non-metastasis patients (84.6% vs 85.7%).,0.2,"This <span class=""gene"" id=""20852035-6-5-10"">SRC-3</span> overexpression frequency was similar to the overexpression frequency observed for squamous cell carcinoma and <span class=""disease"" id=""20852035-6-121-135"">adenocarcinoma</span> (82.1% vs 90%) and for metastasis and non-metastasis patients (84.6% vs 85.7%).",CTD_human
1,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,non-small cell lung cancer,8202,NCOA3,AIB1,CTD_human,20852035,Overexpression and gender-specific differences of SRC-3 (SRC-3/AIB1) immunoreactivity in human non-small cell lung cancer: an in vivo study.,0.20054945356842604,"Overexpression and gender-specific differences of <span class=""gene"" id=""20852035-0-50-55"">SRC-3</span> (<span class=""gene"" id=""20852035-0-57-62"">SRC-3</span>/<span class=""gene"" id=""20852035-0-63-67"">AIB1</span>) immunoreactivity in human <span class=""disease"" id=""20852035-0-95-121"">non-small cell lung cancer</span>: an in vivo study.",CTD_human
1,0,Biomarker,C0007137,Squamous cell carcinoma,disease,squamous cell carcinoma,8202,NCOA3,SRC-3,CTD_human,20852035,This SRC-3 overexpression frequency was similar to the overexpression frequency observed for squamous cell carcinoma and adenocarcinoma (82.1% vs 90%) and for metastasis and non-metastasis patients (84.6% vs 85.7%).,0.20300763924902696,"This <span class=""gene"" id=""20852035-6-5-10"">SRC-3</span> overexpression frequency was similar to the overexpression frequency observed for <span class=""disease"" id=""20852035-6-93-116"">squamous cell carcinoma</span> and adenocarcinoma (82.1% vs 90%) and for metastasis and non-metastasis patients (84.6% vs 85.7%).",CTD_human
2,0,Biomarker,C0023418,leukemia,disease,leukemia,8202,NCOA3,SRC-3,CTD_human,19433130,Gambogic acid induces G0/G1 arrest and apoptosis involving inhibition of SRC-3 and inactivation of Akt pathway in K562 leukemia cells.,0.200274726784213,"Gambogic acid induces G0/G1 arrest and apoptosis involving inhibition of <span class=""gene"" id=""19433130-0-73-78"">SRC-3</span> and inactivation of Akt pathway in K562 <span class=""disease"" id=""19433130-0-119-127"">leukemia</span> cells.",CTD_human
1,0,Biomarker,C0027051,Myocardial Infarction,disease,MI,8204,NRIP1,RIP140,CTD_human,22503866,"Herein, we reported that the relative protein levels of RIP140/PGC-1? were up-regulated in the failing hearts after chronic myocardial infarction (MI), and correlated negatively with the energy state index phosphocreatine (PCr)/ATP ratios.",0.2,"Herein, we reported that the relative protein levels of <span class=""gene"" id=""22503866-3-56-62"">RIP140</span>/PGC-1&alpha; were up-regulated in the failing hearts after chronic <span class=""disease"" id=""22503866-3-124-145"">myocardial infarction</span> (<span class=""disease"" id=""22503866-3-147-149"">MI</span>), and correlated negatively with the energy state index phosphocreatine (PCr)/ATP ratios.",CTD_human
1,0,Biomarker,C1335929,Schwannomatosis,disease,schwannomatosis,8216,LZTR1,LZTR1,CTD_human,24362817,Our findings identify LZTR1 as a gene predisposing to an autosomal dominant inherited disorder of multiple schwannomas in ?80% of 22q-related schwannomatosis cases lacking mutation in SMARCB1.,0.4010989071368521,"Our findings identify <span class=""gene"" id=""24362817-7-22-27"">LZTR1</span> as a gene predisposing to an autosomal dominant inherited disorder of multiple schwannomas in &sim;80% of 22q-related <span class=""disease"" id=""24362817-7-142-157"">schwannomatosis</span> cases lacking mutation in SMARCB1.",CTD_human;ORPHANET
1,0,Biomarker,C0022548,Keloid,disease,keloid,822,CAPG,gelsolin-like capping protein,CTD_human,20128793,"Various classes of proteins were found either to be present or to be upregulated in keloid tissue: (i) inflammatory/differentiated keratinocyte markers: S100 proteins, peroxiredoxin I; (ii) wound healing proteins: gelsolin-like capping protein; (iii) fibrogenetic proteins: mast cell ?-tryptase, macrophage migration inhibitory factor (MIF); (iv) antifibrotic proteins: asporin; (v) tumour suppressor proteins: stratifin, galectin-1, maspin; and (vi) antiangiogenic proteins: pigment epithelium-derived factor.",0.2,"Various classes of proteins were found either to be present or to be upregulated in <span class=""disease"" id=""20128793-6-84-90"">keloid</span> tissue: (i) inflammatory/differentiated keratinocyte markers: S100 proteins, peroxiredoxin I; (ii) wound healing proteins: <span class=""gene"" id=""20128793-6-214-243"">gelsolin-like capping protein</span>; (iii) fibrogenetic proteins: mast cell &beta;-tryptase, macrophage migration inhibitory factor (MIF); (iv) antifibrotic proteins: asporin; (v) tumour suppressor proteins: stratifin, galectin-1, maspin; and (vi) antiangiogenic proteins: pigment epithelium-derived factor.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,8242,KDM5C,JARID1C,CTD_human,18203167,"The JARID1C-regulated genes SCN2A, CACNA1H, BDNF, and SLC18A1 have previously been associated with autism and cognitive dysfunction.",0.20082418035263896,"The <span class=""gene"" id=""18203167-9-4-11"">JARID1C</span>-regulated genes SCN2A, CACNA1H, BDNF, and SLC18A1 have previously been associated with <span class=""disease"" id=""18203167-9-99-105"">autism</span> and cognitive dysfunction.",CTD_human
1,0,Biomarker,C0001418,Adenocarcinoma,group,adenocarcinomas,8289,ARID1A,ARID1A,CTD_human,22484628,"Frequently mutated genes in the adenocarcinomas included TP53 (11/15 tumors), PIK3CA (3/15) and ARID1A (3/15).",0.203557092817453,"Frequently mutated genes in the <span class=""disease"" id=""22484628-3-32-47"">adenocarcinomas</span> included TP53 (11/15 tumors), PIK3CA (3/15) and <span class=""gene"" id=""22484628-3-96-102"">ARID1A</span> (3/15).",CTD_human
1,0,Biomarker,C0006413,Burkitt Lymphoma,disease,Burkitt lymphomas,8289,ARID1A,ARID1A,CTD_human,23143597,"We identified 70 genes that were recurrently mutated in Burkitt lymphomas, including ID3, GNA13, RET, PIK3R1 and the SWI/SNF genes ARID1A and SMARCA4.",0.2,"We identified 70 genes that were recurrently mutated in <span class=""disease"" id=""23143597-4-56-73"">Burkitt lymphomas</span>, including ID3, GNA13, RET, PIK3R1 and the SWI/SNF genes <span class=""gene"" id=""23143597-4-131-137"">ARID1A</span> and SMARCA4.",CTD_human
1,0,Biomarker,C0027819,Neuroblastoma,disease,neuroblastoma,8289,ARID1A,ARID1A,CTD_human,23202128,Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma.,0.200274726784213,"Integrated genomic analyses identify <span class=""gene"" id=""23202128-0-37-43"">ARID1A</span> and ARID1B alterations in the childhood cancer <span class=""disease"" id=""23202128-0-91-104"">neuroblastoma</span>.",CTD_human
3,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,8289,ARID1A,ARID1A,CTD_human,22922871,"Notably, ARID1A, which encodes a component of the SWI/SNF chromatin remodeling complex, was mutated in 14 of 110 (13%) HBV-associated HCC specimens.",0.20054945356842604,"Notably, <span class=""gene"" id=""22922871-5-9-15"">ARID1A</span>, which encodes a component of the SWI/SNF chromatin remodeling complex, was mutated in 14 of 110 (13%) HBV-associated <span class=""disease"" id=""22922871-5-134-137"">HCC</span> specimens.",CTD_human
3,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,8289,ARID1A,ARID1A,CTD_human,22561517,"We found new recurrent alterations in four genes (ARID1A, RPS6KA3, NFE2L2 and IRF2) not previously described in HCC.",0.20054945356842604,"We found new recurrent alterations in four genes (<span class=""gene"" id=""22561517-4-50-56"">ARID1A</span>, RPS6KA3, NFE2L2 and IRF2) not previously described in <span class=""disease"" id=""22561517-4-112-115"">HCC</span>.",CTD_human
1,0,Biomarker,C0032273,Pneumoconiosis,disease,pneumoconiosis,8290,HIST3H3,HIST3H3,CTD_human,25445010,"By applying ICSNPathway analysis to the pneumoconiosis GWAS data, we identified candidate SNPs, genes such as TICAM1 and HIST3H3, and pathways involved in the positive regulation of TNF production that may contribute to pneumoconiosis susceptibility.",0.200274726784213,"By applying ICSNPathway analysis to the <span class=""disease"" id=""25445010-11-40-54"">pneumoconiosis</span> GWAS data, we identified candidate SNPs, genes such as TICAM1 and <span class=""gene"" id=""25445010-11-121-128"">HIST3H3</span>, and pathways involved in the positive regulation of TNF production that may contribute to <span class=""disease"" id=""25445010-11-220-234"">pneumoconiosis</span> susceptibility.",CTD_human
19,102,Biomarker,C1850808,Miyoshi myopathy,disease,Miyoshi myopathy,8291,DYSF,Dysferlin,CTD_human,15535137,"Dysferlin is a protein of the sarcolemma that is mutated in patients with limb girdle muscular dystrophy 2B, Miyoshi myopathy, and distal anterior myopathy.",0.700055055247556,"<span class=""gene"" id=""15535137-1-0-9"">Dysferlin</span> is a protein of the sarcolemma that is mutated in patients with limb girdle muscular dystrophy 2B, <span class=""disease"" id=""15535137-1-109-125"">Miyoshi myopathy</span>, and distal anterior myopathy.",CTD_human;ORPHANET;UNIPROT
19,102,Biomarker,C1850808,Miyoshi myopathy,disease,Miyoshi myopathy,8291,DYSF,dysferlin,CTD_human,17868276,A novel compound heterozygous dysferlin mutation in Miyoshi myopathy siblings responding to dantrolene.,0.700055055247556,"A novel compound heterozygous <span class=""gene"" id=""17868276-0-30-39"">dysferlin</span> mutation in <span class=""disease"" id=""17868276-0-52-68"">Miyoshi myopathy</span> siblings responding to dantrolene.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0025202,melanoma,disease,melanoma,8295,TRRAP,TRRAP,CTD_human,21499247,"Most importantly, we discovered that TRRAP harbored a recurrent mutation that clustered in one position (p. Ser722Phe) in 6 out of 167 affected individuals (?4%), as well as a previously unidentified gene, GRIN2A, which was mutated in 33% of melanoma samples.",0.200274726784213,"Most importantly, we discovered that <span class=""gene"" id=""21499247-4-37-42"">TRRAP</span> harbored a recurrent mutation that clustered in one position (p. Ser722Phe) in 6 out of 167 affected individuals (&sim;4%), as well as a previously unidentified gene, GRIN2A, which was mutated in 33% of <span class=""disease"" id=""21499247-4-242-250"">melanoma</span> samples.",CTD_human
2,2,Biomarker,C0002395,Alzheimer's Disease,disease,Alzheimer's disease,8301,PICALM,PICALM,CTD_human,19734902,Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease.,0.227354329997744,"Genome-wide association study identifies variants at CLU and <span class=""gene"" id=""19734902-0-61-67"">PICALM</span> associated with <span class=""disease"" id=""19734902-0-84-103"">Alzheimer's disease</span>.",CTD_human
4,0,Biomarker,C0007134,Renal Cell Carcinoma,disease,renal cell carcinoma,8314,BAP1,BAP1,CTD_human,22683710,BAP1 loss defines a new class of renal cell carcinoma.,0.203296721410557,"<span class=""gene"" id=""22683710-0-0-4"">BAP1</span> loss defines a new class of <span class=""disease"" id=""22683710-0-33-53"">renal cell carcinoma</span>.",CTD_human
4,0,Biomarker,C0025500,Mesothelioma,disease,MPM,8314,BAP1,BAP1,CTD_human,21642991,"To identify additional driver genes, we used an integrated genomic analysis of 53 MPM tumor samples to guide a focused sequencing effort that uncovered somatic inactivating mutations in BAP1 in 23% of MPMs.",0.20714289638954103,"To identify additional driver genes, we used an integrated genomic analysis of 53 <span class=""disease"" id=""21642991-2-82-85"">MPM</span> tumor samples to guide a focused sequencing effort that uncovered somatic inactivating mutations in <span class=""gene"" id=""21642991-2-186-190"">BAP1</span> in 23% of MPMs.",CTD_human
4,0,Biomarker,C0025500,Mesothelioma,disease,mesothelioma,8314,BAP1,BAP1,CTD_human,21874000,These results identify a BAP1-related cancer syndrome that is characterized by mesothelioma and uveal melanoma.,0.20714289638954103,"These results identify a <span class=""gene"" id=""21874000-6-25-29"">BAP1</span>-related cancer syndrome that is characterized by <span class=""disease"" id=""21874000-6-79-91"">mesothelioma</span> and uveal melanoma.",CTD_human
4,0,Biomarker,C0025500,Mesothelioma,disease,mesothelioma,8314,BAP1,BAP1,CTD_human,26119930,Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma.,0.20714289638954103,"Minimal asbestos exposure in germline <span class=""gene"" id=""26119930-0-38-42"">BAP1</span> heterozygous mice is associated with deregulated inflammatory response and increased risk of <span class=""disease"" id=""26119930-0-136-148"">mesothelioma</span>.",CTD_human
4,0,Biomarker,C0025500,Mesothelioma,disease,mesothelioma,8314,BAP1,BAP1,CTD_human,26719535,"Collectively, these findings suggest that mesothelioma patients presenting with a family history of cancer should be considered for BAP1 genetic testing to identify those individuals who might benefit from further screening and routine monitoring for the purpose of early detection and intervention.",0.20714289638954103,"Collectively, these findings suggest that <span class=""disease"" id=""26719535-8-42-54"">mesothelioma</span> patients presenting with a family history of cancer should be considered for <span class=""gene"" id=""26719535-8-132-136"">BAP1</span> genetic testing to identify those individuals who might benefit from further screening and routine monitoring for the purpose of early detection and intervention.",CTD_human
3,0,Biomarker,C0220633,Uveal melanoma,disease,uveal melanoma,8314,BAP1,BAP1,CTD_human,21874000,These results identify a BAP1-related cancer syndrome that is characterized by mesothelioma and uveal melanoma.,0.40879125709481895,"These results identify a <span class=""gene"" id=""21874000-6-25-29"">BAP1</span>-related cancer syndrome that is characterized by mesothelioma and <span class=""disease"" id=""21874000-6-96-110"">uveal melanoma</span>.",CTD_human;HPO
4,0,Biomarker,C0345967,Malignant mesothelioma,disease,malignant mesothelioma,8314,BAP1,Bap1,CTD_human,24928783,Germline mutation of Bap1 accelerates development of asbestos-induced malignant mesothelioma.,0.205494535684262,"Germline mutation of <span class=""gene"" id=""24928783-0-21-25"">Bap1</span> accelerates development of asbestos-induced <span class=""disease"" id=""24928783-0-70-92"">malignant mesothelioma</span>.",CTD_human
4,0,Biomarker,C0345967,Malignant mesothelioma,disease,MM,8314,BAP1,BAP1,CTD_human,26463840,BAP1 mutations occurred in asbestos-exposed MM.,0.205494535684262,"<span class=""gene"" id=""26463840-13-0-4"">BAP1</span> mutations occurred in asbestos-exposed <span class=""disease"" id=""26463840-13-44-46"">MM</span>.",CTD_human
4,0,Biomarker,C0345967,Malignant mesothelioma,disease,MM,8314,BAP1,BAP1,CTD_human,25231345,"Our data show that BAP1 mutations are very rare in patients with sporadic MM, and we report a new BAP1 mutation, extend the cancer types associated with these mutations, and suggest the existence of other yet unknown genes in the pathogenesis of familial MM.",0.205494535684262,"Our data show that <span class=""gene"" id=""25231345-10-19-23"">BAP1</span> mutations are very rare in patients with sporadic <span class=""disease"" id=""25231345-10-74-76"">MM</span>, and we report a new <span class=""gene"" id=""25231345-10-98-102"">BAP1</span> mutation, extend the cancer types associated with these mutations, and suggest the existence of other yet unknown genes in the pathogenesis of familial <span class=""disease"" id=""25231345-10-255-257"">MM</span>.",CTD_human
1,1,Biomarker,C0027051,Myocardial Infarction,disease,myocardial infarction,8315,BRAP,BRAP,CTD_human,19198608,SNPs in BRAP associated with risk of myocardial infarction in Asian populations.,0.203780662444353,"SNPs in <span class=""gene"" id=""19198608-0-8-12"">BRAP</span> associated with risk of <span class=""disease"" id=""19198608-0-37-58"">myocardial infarction</span> in Asian populations.",CTD_human
1,0,Biomarker,C0028754,Obesity,disease,obese,834,CASP1,CASPASE-1,CTD_human,22325453,CASPASE-1 mRNA and the proportion of T(h)1 transcripts (TBX21/CD3?) were significantly higher in AT from obese compared with lean subjects.,0.2,"<span class=""gene"" id=""22325453-6-0-9"">CASPASE-1</span> mRNA and the proportion of T(h)1 transcripts (TBX21/CD3?) were significantly higher in AT from <span class=""disease"" id=""22325453-6-105-110"">obese</span> compared with lean subjects.",CTD_human
1,0,Biomarker,C0038220,Status Epilepticus,disease,status epilepticus,834,CASP1,caspase-1,CTD_human,18571097,"We studied the activity of caspase-1, -3 and -8 in the hippocampus of rats exhibiting status epilepticus induced by pilocarpine.All three caspases were activated.",0.2,"We studied the activity of <span class=""gene"" id=""18571097-4-27-36"">caspase-1</span>, -3 and -8 in the hippocampus of rats exhibiting <span class=""disease"" id=""18571097-4-86-104"">status epilepticus</span> induced by pilocarpine.All three caspases were activated.",CTD_human
1,0,Biomarker,C0598608,Hyperhomocysteinemia,disease,hHcy,834,CASP1,caspase 1,CTD_human,22647887,"Pathologically, hHcys-associated albuminuria, foot process effacement of podocytes, loss of podocyte slit diaphragm molecules, and glomerulosclerosis at the late stage were significantly improved by local ASC gene silencing or by caspase 1 inhibition.",0.2,"Pathologically, <span class=""disease"" id=""22647887-7-16-20"">hHcy</span>s-associated albuminuria, foot process effacement of podocytes, loss of podocyte slit diaphragm molecules, and glomerulosclerosis at the late stage were significantly improved by local ASC gene silencing or by <span class=""gene"" id=""22647887-7-230-239"">caspase 1</span> inhibition.",CTD_human
1,0,Biomarker,C0007134,Renal Cell Carcinoma,disease,RCC,835,CASP2,caspase-2,CTD_human,20208132,PIDDosome expression and the role of caspase-2 activation for chemotherapy-induced apoptosis in RCCs.,0.200274726784213,"PIDDosome expression and the role of <span class=""gene"" id=""20208132-0-37-46"">caspase-2</span> activation for chemotherapy-induced apoptosis in <span class=""disease"" id=""20208132-0-96-99"">RCC</span>s.",CTD_human
1,0,Biomarker,C0027819,Neuroblastoma,disease,neuroblastoma,83593,RASSF5,NORE1A,CTD_human,18452173,Assessment of NORE1A as a putative tumor suppressor in human neuroblastoma.,0.20328236603324,"Assessment of <span class=""gene"" id=""18452173-0-14-20"">NORE1A</span> as a putative tumor suppressor in human <span class=""disease"" id=""18452173-0-61-74"">neuroblastoma</span>.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,hepatocellular carcinoma,83597,RTP3,TMEM7,CTD_human,17693185,The interferon-alpha responsive gene TMEM7 suppresses cell proliferation and is downregulated in human hepatocellular carcinoma.,0.20300763924902696,"The interferon-alpha responsive gene <span class=""gene"" id=""17693185-0-37-42"">TMEM7</span> suppresses cell proliferation and is downregulated in human <span class=""disease"" id=""17693185-0-103-127"">hepatocellular carcinoma</span>.",CTD_human
1,0,Biomarker,C0002395,Alzheimer's Disease,disease,AD,836,CASP3,caspase-3,CTD_human,18077176,"The current investigation focused on detection of PtdSer on the outer leaflet of the bilayer in synaptosomes from brain of subjects with AD and amnestic mild cognitive impairment (MCI), as well as expression levels of apoptosis-related proteins Bcl-2, Bax, and caspase-3.",0.21123508739810298,"The current investigation focused on detection of PtdSer on the outer leaflet of the bilayer in synaptosomes from brain of subjects with <span class=""disease"" id=""18077176-6-137-139"">AD</span> and amnestic mild cognitive impairment (MCI), as well as expression levels of apoptosis-related proteins Bcl-2, Bax, and <span class=""gene"" id=""18077176-6-261-270"">caspase-3</span>.",CTD_human
1,0,Biomarker,C0010417,Cryptorchidism,disease,cryptorchidism,836,CASP3,caspase 3,CTD_human,26050606,"In testes, while apoptosis-related caspase 3 and Bcl-xL mRNAs were significantly changed after 14 days, 3 beta-hydroxysteroid dehydrogenase mRNA was greatly reduced immediately after cryptorchidism.",0.2,"In testes, while apoptosis-related <span class=""gene"" id=""26050606-3-35-44"">caspase 3</span> and Bcl-xL mRNAs were significantly changed after 14 days, 3 beta-hydroxysteroid dehydrogenase mRNA was greatly reduced immediately after <span class=""disease"" id=""26050606-3-183-197"">cryptorchidism</span>.",CTD_human
1,0,Biomarker,C0026936,Mycoplasma Infections,group,Mycoplasma,836,CASP3,caspase-3,CTD_human,20179380,Nitric oxide causes anoikis through attenuation of E-cadherin and activation of caspase-3 in human gastric carcinoma AZ-521 cells infected with Mycoplasma hyorhinis.,0.200274726784213,"Nitric oxide causes anoikis through attenuation of E-cadherin and activation of <span class=""gene"" id=""20179380-0-80-89"">caspase-3</span> in human gastric carcinoma AZ-521 cells infected with <span class=""disease"" id=""20179380-0-144-154"">Mycoplasma</span> hyorhinis.",CTD_human
2,0,Biomarker,C0038220,Status Epilepticus,disease,status epilepticus,836,CASP3,caspase-3,CTD_human,16679645,Erythropoietin preconditioning on hippocampus neuronal apoptosis following status epilepticus induced by Li-pilocarpine in rats through anti-caspase-3 expression.,0.28,"Erythropoietin preconditioning on hippocampus neuronal apoptosis following <span class=""disease"" id=""16679645-0-75-93"">status epilepticus</span> induced by Li-pilocarpine in rats through anti-<span class=""gene"" id=""16679645-0-141-150"">caspase-3</span> expression.",CTD_human
1,0,Biomarker,C0243026,Sepsis,disease,sepsis,836,CASP3,caspase-3,CTD_human,16003065,"We have been interested in investigating the role of posttreatment with CMT-3 on hepatic MMP-9, TGF-beta1, and caspase-3 activity following sepsis.",0.200274726784213,"We have been interested in investigating the role of posttreatment with CMT-3 on hepatic MMP-9, TGF-beta1, and <span class=""gene"" id=""16003065-4-111-120"">caspase-3</span> activity following <span class=""disease"" id=""16003065-4-140-146"">sepsis</span>.",CTD_human
1,0,Biomarker,C1336708,Testicular Germ Cell Tumor,disease,TGCT,8379,MAD1L1,MAD1L1,CTD_human,23666239,"In the combined analysis, risk of TGCT was significantly associated with markers at four previously unreported loci: 4q22.2 in HPGDS (per-allele odds ratio (OR) = 1.19, 95% confidence interval (CI) = 1.12-1.26; P = 1.11 × 10(-8)), 7p22.3 in MAD1L1 (OR = 1.21, 95% CI = 1.14-1.29; P = 5.59 × 10(-9)), 16q22.3 in RFWD3 (OR = 1.26, 95% CI = 1.18-1.34; P = 5.15 × 10(-12)) and 17q22 (rs9905704: OR = 1.27, 95% CI = 1.18-1.33; P = 4.32 × 10(-13) and rs7221274: OR = 1.20, 95% CI = 1.12-1.28; P = 4.04 × 10(-9)), a locus that includes TEX14, RAD51C and PPM1E.",0.200274726784213,"In the combined analysis, risk of <span class=""disease"" id=""23666239-4-34-38"">TGCT</span> was significantly associated with markers at four previously unreported loci: 4q22.2 in HPGDS (per-allele odds ratio (OR) = 1.19, 95% confidence interval (CI) = 1.12-1.26; P = 1.11 &times; 10(-8)), 7p22.3 in <span class=""gene"" id=""23666239-4-241-247"">MAD1L1</span> (OR = 1.21, 95% CI = 1.14-1.29; P = 5.59 &times; 10(-9)), 16q22.3 in RFWD3 (OR = 1.26, 95% CI = 1.18-1.34; P = 5.15 &times; 10(-12)) and 17q22 (rs9905704: OR = 1.27, 95% CI = 1.18-1.33; P = 4.32 &times; 10(-13) and rs7221274: OR = 1.20, 95% CI = 1.12-1.28; P = 4.04 &times; 10(-9)), a locus that includes TEX14, RAD51C and PPM1E.",CTD_human
1,1,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,T2D,83795,KCNK16,KCNK16,CTD_human,22158537,"The combined analysis identified eight new T2D loci reaching genome-wide significance, which mapped in or near GLIS3, PEPD, FITM2-R3HDML-HNF4A, KCNK16, MAEA, GCC1-PAX4, PSMD6 and ZFAND3.",0.200274726784213,"The combined analysis identified eight new <span class=""disease"" id=""22158537-3-43-46"">T2D</span> loci reaching genome-wide significance, which mapped in or near GLIS3, PEPD, FITM2-R3HDML-HNF4A, <span class=""gene"" id=""22158537-3-144-150"">KCNK16</span>, MAEA, GCC1-PAX4, PSMD6 and ZFAND3.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,hepatocellular carcinoma,83932,SPRTN,SPRTN,CTD_human,25261934,"Mutations in SPRTN cause early onset hepatocellular carcinoma, genomic instability and progeroid features.",0.200274726784213,"Mutations in <span class=""gene"" id=""25261934-0-13-18"">SPRTN</span> cause early onset <span class=""disease"" id=""25261934-0-37-61"">hepatocellular carcinoma</span>, genomic instability and progeroid features.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,83943,IMMP2L,IMMP2L,CTD_human,19401682,High-density SNP association study and copy number variation analysis of the AUTS1 and AUTS5 loci implicate the IMMP2L-DOCK4 gene region in autism susceptibility.,0.203231208875927,"High-density SNP association study and copy number variation analysis of the AUTS1 and AUTS5 loci implicate the <span class=""gene"" id=""19401682-0-112-118"">IMMP2L</span>-DOCK4 gene region in <span class=""disease"" id=""19401682-0-140-146"">autism</span> susceptibility.",CTD_human
1,1,Biomarker,C0015625,Fanconi Anemia,disease,FA,83990,BRIP1,FANCJ,CTD_human,20639400,The FANCJ-A349P allele failed to rescue cisplatin or telomestatin sensitivity of a FA-J null cell line as detected by cell survival or ?-H2AX foci formation.,0.418088901626113,"The <span class=""gene"" id=""20639400-6-4-9"">FANCJ</span>-A349P allele failed to rescue cisplatin or telomestatin sensitivity of a <span class=""disease"" id=""20639400-6-83-85"">FA</span>-J null cell line as detected by cell survival or &gamma;-H2AX foci formation.",CTD_human;ORPHANET
1,10,Biomarker,C0919267,ovarian neoplasm,disease,Ovarian tumors,83990,BRIP1,BRIP1,CTD_human,21964575,"Ovarian tumors from heterozygous carriers of the Icelandic mutation show loss of the wild-type allele, indicating that BRIP1 behaves like a classical tumor suppressor gene in ovarian cancer.",0.2,"<span class=""disease"" id=""21964575-8-0-14"">Ovarian tumors</span> from heterozygous carriers of the Icelandic mutation show loss of the wild-type allele, indicating that <span class=""gene"" id=""21964575-8-119-124"">BRIP1</span> behaves like a classical tumor suppressor gene in ovarian cancer.",CTD_human
1,0,Biomarker,C0004936,Mental disorders,group,psychiatric disorders,84062,DTNBP1,dysbindin-1,CTD_human,25298178,The present findings in Dys1A-Tg mice support the role of dysbindin-1 in psychiatric disorders.,0.201373633921065,"The present findings in <span class=""gene"" id=""25298178-9-24-32"">Dys1A-Tg</span> mice support the role of <span class=""gene"" id=""25298178-9-58-69"">dysbindin-1</span> in <span class=""disease"" id=""25298178-9-73-94"">psychiatric disorders</span>.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,8407,TAGLN2,transgelin 2,CTD_human,21472284,"These identified proteins, which include stratifin (14-3-3), transgelin 2, heat-shock protein (HSP)70, HSP27, manganese superoxide dismutase, prohibitin, DJ1, ?-enolase, peroxiredoxin 6, aldo-keto reductase family member B10, phosphoglycerate kinase 1, ?-1-antitrypsin and nm23-H1, may play a role in the development of HCC.",0.200274726784213,"These identified proteins, which include stratifin (14-3-3), <span class=""gene"" id=""21472284-9-61-73"">transgelin 2</span>, heat-shock protein (HSP)70, HSP27, manganese superoxide dismutase, prohibitin, DJ1, &alpha;-enolase, peroxiredoxin 6, aldo-keto reductase family member B10, phosphoglycerate kinase 1, &alpha;-1-antitrypsin and nm23-H1, may play a role in the development of <span class=""disease"" id=""21472284-9-320-323"">HCC</span>.",CTD_human
1,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,non-small cell lung cancer,841,CASP8,CASP8,CTD_human,20471133,"A combination of functional polymorphisms in the CASP8, MMP1, IL10 and SEPS1 genes affects risk of non-small cell lung cancer.",0.203021994626344,"A combination of functional polymorphisms in the <span class=""gene"" id=""20471133-0-49-54"">CASP8</span>, MMP1, IL10 and SEPS1 genes affects risk of <span class=""disease"" id=""20471133-0-99-125"">non-small cell lung cancer</span>.",CTD_human
2,0,Biomarker,C0025202,melanoma,disease,cutaneous melanoma,841,CASP8,caspase-8,CTD_human,18563783,Genetic variants and haplotypes of the caspase-8 and caspase-10 genes contribute to susceptibility to cutaneous melanoma.,0.208436662398659,"Genetic variants and haplotypes of the <span class=""gene"" id=""18563783-0-39-48"">caspase-8</span> and caspase-10 genes contribute to susceptibility to <span class=""disease"" id=""18563783-0-102-120"">cutaneous melanoma</span>.",CTD_human
1,0,Biomarker,C1458155,Mammary Neoplasms,group,breast tumors,8412,BCAR3,BCAR3,CTD_human,19075277,"mRNA levels of 10 BCAR genes (AKT1, AKT2, BCAR1, BCAR3, EGFR, ERBB2, GRB7, SRC, TLE3, and TRERF1) were measured in estrogen receptor-positive breast tumors using quantitative reverse-transcriptase polymerase chain reaction.",0.208473464178654,"mRNA levels of 10 BCAR genes (AKT1, AKT2, BCAR1, <span class=""gene"" id=""19075277-3-49-54"">BCAR3</span>, EGFR, ERBB2, GRB7, SRC, TLE3, and TRERF1) were measured in estrogen receptor-positive <span class=""disease"" id=""19075277-3-142-155"">breast tumors</span> using quantitative reverse-transcriptase polymerase chain reaction.",CTD_human
2,2,Biomarker,C0003873,Rheumatoid Arthritis,disease,rheumatoid arthritis,84159,ARID5B,ARID5B,CTD_human,22446963,"Our study identified nine loci newly associated with rheumatoid arthritis at a threshold of P < 5.0 × 10(-8), including B3GNT2, ANXA3, CSF2, CD83, NFKBIE, ARID5B, PDE2A-ARAP1, PLD4 and PTPN2.",0.200274726784213,"Our study identified nine loci newly associated with <span class=""disease"" id=""22446963-3-53-73"">rheumatoid arthritis</span> at a threshold of P &lt; 5.0 &times; 10(-8), including B3GNT2, ANXA3, CSF2, CD83, NFKBIE, <span class=""gene"" id=""22446963-3-155-161"">ARID5B</span>, PDE2A-ARAP1, PLD4 and PTPN2.",CTD_human
1,0,Biomarker,C0018213,Graves Disease,disease,Graves' disease,84159,ARID5B,ARID5B,CTD_human,22446963,"ANXA3 was also associated with susceptibility to systemic lupus erythematosus (P = 0.0040), and B3GNT2 and ARID5B were associated with Graves' disease (P = 3.5 × 10(-4) and 2.9 × 10(-4), respectively).",0.20054945356842604,"ANXA3 was also associated with susceptibility to systemic lupus erythematosus (P = 0.0040), and B3GNT2 and <span class=""gene"" id=""22446963-4-107-113"">ARID5B</span> were associated with <span class=""disease"" id=""22446963-4-135-150"">Graves' disease</span> (P = 3.5 &times; 10(-4) and 2.9 &times; 10(-4), respectively).",CTD_human
1,0,Biomarker,C0005695,Bladder Neoplasm,disease,bladder cancer,84171,LOXL4,LOXL4,CTD_human,17456585,LOXL1 and LOXL4 are epigenetically silenced and can inhibit ras/extracellular signal-regulated kinase signaling pathway in human bladder cancer.,0.20054945356842604,"LOXL1 and <span class=""gene"" id=""17456585-0-10-15"">LOXL4</span> are epigenetically silenced and can inhibit ras/extracellular signal-regulated kinase signaling pathway in human <span class=""disease"" id=""17456585-0-129-143"">bladder cancer</span>.",CTD_human
1,0,Biomarker,C0017636,Glioblastoma,disease,GBM,8425,LTBP4,LTBP4,CTD_human,27270107,"In recurrent GBM with wild-type IDH1, high LTBP4 expression is associated with worse prognosis, highlighting the TGF-? pathway as a potential therapeutic target in GBM.",0.2,"In recurrent <span class=""disease"" id=""27270107-8-13-16"">GBM</span> with wild-type IDH1, high <span class=""gene"" id=""27270107-8-43-48"">LTBP4</span> expression is associated with worse prognosis, highlighting the TGF-&beta; pathway as a potential therapeutic target in <span class=""disease"" id=""27270107-8-164-167"">GBM</span>.",CTD_human
1,0,Biomarker,C1961099,Precursor T-Cell Lymphoblastic Leukemia-Lymphoma,disease,T-cell acute lymphoblastic leukemia,84295,PHF6,PHF6,CTD_human,20228800,PHF6 mutations in T-cell acute lymphoblastic leukemia.,0.201923087489492,"<span class=""gene"" id=""20228800-0-0-4"">PHF6</span> mutations in <span class=""disease"" id=""20228800-0-18-53"">T-cell acute lymphoblastic leukemia</span>.",CTD_human
1,0,Biomarker,C0025202,melanoma,disease,cutaneous melanoma,843,CASP10,caspase-10,CTD_human,18563783,Genetic variants and haplotypes of the caspase-8 and caspase-10 genes contribute to susceptibility to cutaneous melanoma.,0.20541466777231498,"Genetic variants and haplotypes of the caspase-8 and <span class=""gene"" id=""18563783-0-53-63"">caspase-10</span> genes contribute to susceptibility to <span class=""disease"" id=""18563783-0-102-120"">cutaneous melanoma</span>.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,8431,NR0B2,SHP,CTD_human,23811326,"In conclusion, SHP partially protects FXR(-/-) mice from HCC formation by reducing tumor malignancy.",0.203296721410557,"In conclusion, <span class=""gene"" id=""23811326-9-15-18"">SHP</span> partially protects FXR(-/-) mice from <span class=""disease"" id=""23811326-9-57-60"">HCC</span> formation by reducing tumor malignancy.",CTD_human
1,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,non-small cell lung cancer,8434,RECK,RECK,CTD_human,17233834,Downregulation of RECK by promoter methylation correlates with lymph node metastasis in non-small cell lung cancer.,0.202472541057918,"Downregulation of <span class=""gene"" id=""17233834-0-18-22"">RECK</span> by promoter methylation correlates with lymph node metastasis in <span class=""disease"" id=""17233834-0-88-114"">non-small cell lung cancer</span>.",CTD_human
1,0,Biomarker,C0009375,Colonic Neoplasms,group,colon tumor,8434,RECK,RECK,CTD_human,17443689,The mRNA and protein levels of RECK in colon tumor tissues and their normal counterparts were compared.,0.20300763924902696,"The mRNA and protein levels of <span class=""gene"" id=""17443689-4-31-35"">RECK</span> in <span class=""disease"" id=""17443689-4-39-50"">colon tumor</span> tissues and their normal counterparts were compared.",CTD_human
1,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastasis,8434,RECK,RECK,CTD_human,17233834,"Collectively, our results suggest that downregulation of the metastasis suppressor RECK is caused by promoter methylation in non-small cell lung cancer and is associated with K-ras mutation and lymph node metastasis.",0.21535598916129897,"Collectively, our results suggest that downregulation of the <span class=""disease"" id=""17233834-11-61-71"">metastasis</span> suppressor <span class=""gene"" id=""17233834-11-83-87"">RECK</span> is caused by promoter methylation in non-small cell lung cancer and is associated with K-ras mutation and lymph node metastasis.",CTD_human
1,0,Biomarker,C0019569,Hirschsprung Disease,disease,HSCR,8436,SDPR,SDPR,CTD_human,25792468,"The findings suggest that miR-206 may play a significant role in the pathogenesis of HSCR, as well as inhibiting the cell migration and proliferation by targeting SDPR in disease models.",0.200274726784213,"The findings suggest that miR-206 may play a significant role in the pathogenesis of <span class=""disease"" id=""25792468-8-85-89"">HSCR</span>, as well as inhibiting the cell migration and proliferation by targeting <span class=""gene"" id=""25792468-8-163-167"">SDPR</span> in disease models.",CTD_human
1,0,Biomarker,C0011615,"Dermatitis, Atopic",disease,atopic dermatitis,84433,CARD11,CARD11,CTD_human,23042114,"On the basis of data from a genome-wide association study (GWAS) and a validation study comprising a total of 3,328 subjects with atopic dermatitis and 14,992 controls in the Japanese population, we report here 8 new susceptibility loci: IL1RL1-IL18R1-IL18RAP (P(combined) = 8.36 × 10(-18)), the major histocompatibility complex (MHC) region (P = 8.38 × 10(-20)), OR10A3-NLRP10 (P = 1.54 × 10(-22)), GLB1 (P = 2.77 × 10(-16)), CCDC80 (P = 1.56 × 10(-19)), CARD11 (P = 7.83 × 10(-9)), ZNF365 (P = 5.85 × 10(-20)) and CYP24A1-PFDN4 (P = 1.65 × 10(-8)).",0.2,"On the basis of data from a genome-wide association study (GWAS) and a validation study comprising a total of 3,328 subjects with <span class=""disease"" id=""23042114-2-130-147"">atopic dermatitis</span> and 14,992 controls in the Japanese population, we report here 8 new susceptibility loci: IL1RL1-IL18R1-IL18RAP (P(combined) = 8.36 &times; 10(-18)), the major histocompatibility complex (MHC) region (P = 8.38 &times; 10(-20)), OR10A3-NLRP10 (P = 1.54 &times; 10(-22)), GLB1 (P = 2.77 &times; 10(-16)), CCDC80 (P = 1.56 &times; 10(-19)), <span class=""gene"" id=""23042114-2-456-462"">CARD11</span> (P = 7.83 &times; 10(-9)), ZNF365 (P = 5.85 &times; 10(-20)) and CYP24A1-PFDN4 (P = 1.65 &times; 10(-8)).",CTD_human
1,0,Biomarker,C0152013,Adenocarcinoma of lung (disorder),disease,ADC,84444,DOT1L,DOT1L,CTD_human,27158780,"New significantly mutated genes included PPP3CA, DOT1L, and FTSJD1 in lung ADC, RASA1 in lung SqCC, and KLF5, EP300, and CREBBP in both tumor types.",0.2,"New significantly mutated genes included PPP3CA, <span class=""gene"" id=""27158780-3-49-54"">DOT1L</span>, and FTSJD1 in lung <span class=""disease"" id=""27158780-3-75-78"">ADC</span>, RASA1 in lung SqCC, and KLF5, EP300, and CREBBP in both tumor types.",CTD_human
3,1,Biomarker,C0015625,Fanconi Anemia,disease,Fanconi anemia,84464,SLX4,Slx4,CTD_human,21240276,"Disruption of mouse Slx4, a regulator of structure-specific nucleases, phenocopies Fanconi anemia.",0.40329672141055706,"Disruption of mouse <span class=""gene"" id=""21240276-0-20-24"">Slx4</span>, a regulator of structure-specific nucleases, phenocopies <span class=""disease"" id=""21240276-0-83-97"">Fanconi anemia</span>.",CTD_human;ORPHANET
3,1,Biomarker,C0015625,Fanconi Anemia,disease,Fanconi anemia,84464,SLX4,SLX4,CTD_human,21240277,"SLX4, a coordinator of structure-specific endonucleases, is mutated in a new Fanconi anemia subtype.",0.40329672141055706,"<span class=""gene"" id=""21240277-0-0-4"">SLX4</span>, a coordinator of structure-specific endonucleases, is mutated in a new <span class=""disease"" id=""21240277-0-77-91"">Fanconi anemia</span> subtype.",CTD_human;ORPHANET
3,1,Biomarker,C0015625,Fanconi Anemia,disease,Fanconi anemia,84464,SLX4,SLX4,CTD_human,21240275,Mutations of the SLX4 gene in Fanconi anemia.,0.40329672141055706,"Mutations of the <span class=""gene"" id=""21240275-0-17-21"">SLX4</span> gene in <span class=""disease"" id=""21240275-0-30-44"">Fanconi anemia</span>.",CTD_human;ORPHANET
1,0,Biomarker,C0011168,Deglutition Disorders,group,dysphagia,84466,MEGF10,MEGF10,CTD_human,22101682,"Mutations in MEGF10, a regulator of satellite cell myogenesis, cause early onset myopathy, areflexia, respiratory distress and dysphagia (EMARDD).",0.20054945356842604,"Mutations in <span class=""gene"" id=""22101682-0-13-19"">MEGF10</span>, a regulator of satellite cell myogenesis, cause early onset myopathy, areflexia, respiratory distress and <span class=""disease"" id=""22101682-0-127-136"">dysphagia</span> (EMARDD).",CTD_human
1,0,Biomarker,C0026848,Myopathy,group,myopathy,84466,MEGF10,MEGF10,CTD_human,22101682,"Mutations in MEGF10, a regulator of satellite cell myogenesis, cause early onset myopathy, areflexia, respiratory distress and dysphagia (EMARDD).",0.201098907136852,"Mutations in <span class=""gene"" id=""22101682-0-13-19"">MEGF10</span>, a regulator of satellite cell myogenesis, cause early onset <span class=""disease"" id=""22101682-0-81-89"">myopathy</span>, areflexia, respiratory distress and dysphagia (EMARDD).",CTD_human
1,0,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,84547,PGBD1,PGBD1,CTD_human,22037552,"We identified two susceptibility loci for schizophrenia at 6p21-p22.1 (rs1233710 in an intron of ZKSCAN4, P(combined) = 4.76 × 10(-11), odds ratio (OR) = 0.79; rs1635 in an exon of NKAPL, P(combined) = 6.91 × 10(-12), OR = 0.78; rs2142731 in an intron of PGBD1, P(combined) = 5.14 × 10(-10), OR = 0.79) and 11p11.2 (rs11038167 near the 5' UTR of TSPAN18, P(combined) = 1.09 × 10(-11), OR = 1.29; rs11038172, P(combined) = 7.21 × 10(-10), OR = 1.25; rs835784, P(combined) = 2.73 × 10(-11), OR = 1.27).",0.203231208875927,"We identified two susceptibility loci for <span class=""disease"" id=""22037552-2-42-55"">schizophrenia</span> at 6p21-p22.1 (rs1233710 in an intron of ZKSCAN4, P(combined) = 4.76 &times; 10(-11), odds ratio (OR) = 0.79; rs1635 in an exon of NKAPL, P(combined) = 6.91 &times; 10(-12), OR = 0.78; rs2142731 in an intron of <span class=""gene"" id=""22037552-2-255-260"">PGBD1</span>, P(combined) = 5.14 &times; 10(-10), OR = 0.79) and 11p11.2 (rs11038167 near the 5' UTR of TSPAN18, P(combined) = 1.09 &times; 10(-11), OR = 1.29; rs11038172, P(combined) = 7.21 &times; 10(-10), OR = 1.25; rs835784, P(combined) = 2.73 &times; 10(-11), OR = 1.27).",CTD_human
2,1,Biomarker,C0020598,Hypocalcemia,phenotype,hypocalcemia,846,CASR,calcium-sensing receptor,CTD_human,11701698,Activating mutations of the calcium-sensing receptor: management of hypocalcemia.,0.41364211592139105,"Activating mutations of the <span class=""gene"" id=""11701698-0-28-52"">calcium-sensing receptor</span>: management of <span class=""disease"" id=""11701698-0-68-80"">hypocalcemia</span>.",CTD_human;HPO
1,0,Biomarker,C0020626,Hypoparathyroidism,disease,hypoparathyroidism,846,CASR,CaR,CTD_human,11701698,"Thus, mutational analysis of the CaR gene should be considered early in the work-up of isolated hypoparathyroidism.",0.21336738913717804,"Thus, mutational analysis of the <span class=""gene"" id=""11701698-9-33-36"">CaR</span> gene should be considered early in the work-up of isolated <span class=""disease"" id=""11701698-9-96-114"">hypoparathyroidism</span>.",CTD_human
2,0,Biomarker,C0005586,Bipolar Disorder,disease,bipolar disorder,84628,NTNG2,netrin-G2,CTD_human,17507910,Decreased mRNA expression of netrin-G1 and netrin-G2 in the temporal lobe in schizophrenia and bipolar disorder.,0.400549453568426,"Decreased mRNA expression of <span class=""gene"" id=""17507910-0-29-38"">netrin-G1</span> and <span class=""gene"" id=""17507910-0-43-52"">netrin-G2</span> in the temporal lobe in schizophrenia and <span class=""disease"" id=""17507910-0-95-111"">bipolar disorder</span>.",CTD_human;PSYGENET
1,0,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,84628,NTNG2,netrin-G2,CTD_human,17507910,Decreased mRNA expression of netrin-G1 and netrin-G2 in the temporal lobe in schizophrenia and bipolar disorder.,0.204381273170092,"Decreased mRNA expression of <span class=""gene"" id=""17507910-0-29-38"">netrin-G1</span> and <span class=""gene"" id=""17507910-0-43-52"">netrin-G2</span> in the temporal lobe in <span class=""disease"" id=""17507910-0-77-90"">schizophrenia</span> and bipolar disorder.",CTD_human
2,0,Biomarker,C0033860,Psoriasis,disease,psoriasis,84648,LCE3D,LCE3D,CTD_human,24212883,"We discovered two independent missense SNVs in IL23R and GJB2 of low frequency and five common missense SNVs in LCE3D, ERAP1, CARD14 and ZNF816A associated with psoriasis at genome-wide significance.",0.200274726784213,"We discovered two independent missense SNVs in IL23R and GJB2 of low frequency and five common missense SNVs in <span class=""gene"" id=""24212883-2-112-117"">LCE3D</span>, ERAP1, CARD14 and ZNF816A associated with <span class=""disease"" id=""24212883-2-161-170"">psoriasis</span> at genome-wide significance.",CTD_human
1,0,Biomarker,C0004096,Asthma,disease,asthma,847,CAT,CAT,CTD_human,18048809,Functional promoter variants in CAT and HMOX-1 showed ethnicity-specific associations with new-onset asthma.,0.213250719445235,"Functional promoter variants in <span class=""gene"" id=""18048809-10-32-35"">CAT</span> and HMOX-1 showed ethnicity-specific associations with new-onset <span class=""disease"" id=""18048809-10-101-107"">asthma</span>.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autistic,847,CAT,CAT,CTD_human,15205966,"In the autistic group, increased TBARS levels (p < 0.001) and XO (p < 0.001) and SOD (p < 0.001) activity, decreased CAT (p < 0.001) activity and unchanged ADA activity were detected.",0.2,"In the <span class=""disease"" id=""15205966-3-7-15"">autistic</span> group, increased TBARS levels (p &lt; 0.001) and XO (p &lt; 0.001) and SOD (p &lt; 0.001) activity, decreased <span class=""gene"" id=""15205966-3-117-120"">CAT</span> (p &lt; 0.001) activity and unchanged ADA activity were detected.",CTD_human
1,0,Biomarker,C0004943,Behcet Syndrome,disease,Beh?et's disease,847,CAT,CAT,CTD_human,12074830,"It was observed that lipid hydroperoxide and AuAb-oxLDL levels in patients with Beh?et's disease were significantly higher, but erythrocyte SOD, CAT, plasma GSH-Px activities, and TAS were significantly lower than those in healthy subjects.",0.2,"It was observed that lipid hydroperoxide and AuAb-oxLDL levels in patients with <span class=""disease"" id=""12074830-7-80-96"">Beh&Ccedil;et's disease</span> were significantly higher, but erythrocyte SOD, <span class=""gene"" id=""12074830-7-145-148"">CAT</span>, plasma GSH-Px activities, and TAS were significantly lower than those in healthy subjects.",CTD_human
2,0,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,type 2 diabetes,847,CAT,Catalase,CTD_human,15111504,Catalase protects cardiomyocyte function in models of type 1 and type 2 diabetes.,0.21292483550370897,"<span class=""gene"" id=""15111504-0-0-8"">Catalase</span> protects cardiomyocyte function in models of type 1 and <span class=""disease"" id=""15111504-0-65-80"">type 2 diabetes</span>.",CTD_human
2,0,Therapeutic,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,type 2 diabetes,847,CAT,Catalase,CTD_human,15111504,Catalase protects cardiomyocyte function in models of type 1 and type 2 diabetes.,0.21292483550370897,"<span class=""gene"" id=""15111504-0-0-8"">Catalase</span> protects cardiomyocyte function in models of type 1 and <span class=""disease"" id=""15111504-0-65-80"">type 2 diabetes</span>.",CTD_human
1,0,Biomarker,C0011882,Diabetic Neuropathies,group,diabetic neuropathy,847,CAT,Catalase,CTD_human,10780678,Catalase mRNA was significantly increased in experimental diabetic neuropathy at 12 months.,0.202956482091714,"<span class=""gene"" id=""10780678-8-0-8"">Catalase</span> mRNA was significantly increased in experimental <span class=""disease"" id=""10780678-8-58-77"">diabetic neuropathy</span> at 12 months.",CTD_human
1,0,Biomarker,C0017638,Glioma,disease,gliomas,847,CAT,catalase,CTD_human,21138464,"XBP1 confers an important role in protection against oxidative stress in gliomas, potentially via up-regulation of antioxidant molecules such as catalase.",0.20082418035263896,"XBP1 confers an important role in protection against oxidative stress in <span class=""disease"" id=""21138464-9-73-80"">gliomas</span>, potentially via up-regulation of antioxidant molecules such as <span class=""gene"" id=""21138464-9-145-153"">catalase</span>.",CTD_human
1,0,Biomarker,C0019158,Hepatitis,disease,hepatitis,847,CAT,catalase,CTD_human,1937386,These data indicate a loss of catalase activity in most hepatitis livers but also peroxisomal proliferation and shape modifications.,0.2,"These data indicate a loss of <span class=""gene"" id=""1937386-8-30-38"">catalase</span> activity in most <span class=""disease"" id=""1937386-8-56-65"">hepatitis</span> livers but also peroxisomal proliferation and shape modifications.",CTD_human
1,0,Therapeutic,C0020452,Hyperemia,disease,hyperemia,847,CAT,Catalase,CTD_human,10792963,"Hyperemia and the vascular diameter of the main arteriole were significantly reduced by H(2)O(2)-scavenger Catalase, suggesting that endogenous H(2)O(2) may be one of the mediators of hyperemia in the mucosa in this animal model of intestinal inflammation.",0.2,"<span class=""disease"" id=""10792963-10-0-9"">Hyperemia</span> and the vascular diameter of the main arteriole were significantly reduced by H(2)O(2)-scavenger <span class=""gene"" id=""10792963-10-107-115"">Catalase</span>, suggesting that endogenous H(2)O(2) may be one of the mediators of <span class=""disease"" id=""10792963-10-184-193"">hyperemia</span> in the mucosa in this animal model of intestinal inflammation.",CTD_human
1,0,Biomarker,C0020550,Hyperthyroidism,disease,Hyperthyroid,847,CAT,catalase,CTD_human,23391542,"Hyperthyroid rats presented lower sperm motility, higher levels of lipid hydroperoxides and thiobarbituric reactive substances, lower catalase and glutathione peroxidase activities and higher glutathione-S-transferase activity in their testes than control animals.",0.28,"<span class=""disease"" id=""23391542-4-0-12"">Hyperthyroid</span> rats presented lower sperm motility, higher levels of lipid hydroperoxides and thiobarbituric reactive substances, lower <span class=""gene"" id=""23391542-4-134-142"">catalase</span> and glutathione peroxidase activities and higher glutathione-S-transferase activity in their testes than control animals.",CTD_human
2,0,Biomarker,C0022661,"Kidney Failure, Chronic",disease,ESRD,847,CAT,CAT,CTD_human,16518626,"The activity of SOD, GSH-Px, CAT, concentrations of erythrocyte and plasma Se, Cu, Zn were lower in children with ESRD than in controls.",0.28268175530750106,"The activity of SOD, GSH-Px, <span class=""gene"" id=""16518626-8-29-32"">CAT</span>, concentrations of erythrocyte and plasma Se, Cu, Zn were lower in children with <span class=""disease"" id=""16518626-8-114-118"">ESRD</span> than in controls.",CTD_human
1,0,Biomarker,C0024796,Marfan Syndrome,disease,MV,847,CAT,CAT,CTD_human,25101153,"Laminin ?-1 was decreased in MV and increased in M. In conclusion, similarities and differences in oxidative stress in the different aortopathies studied including pathologies with aneurysms were found with alterations in SOD, CAT, GPx, GST, and eNOS activity that modify subendothelial basement membrane proteins.",0.2,"Laminin &gamma;-1 was decreased in <span class=""disease"" id=""25101153-8-29-31"">MV</span> and increased in M. In conclusion, similarities and differences in oxidative stress in the different aortopathies studied including pathologies with aneurysms were found with alterations in SOD, <span class=""gene"" id=""25101153-8-227-230"">CAT</span>, GPx, GST, and eNOS activity that modify subendothelial basement membrane proteins.",CTD_human
1,0,Biomarker,C0025500,Mesothelioma,disease,mesothelioma,847,CAT,catalase,CTD_human,11283936,"Catalase may have multifactorial effects in malignant cells; high catalase and/or coordinated high expression of Mn-SOD and catalase may decrease tumor progression by modulating the cellular redox state, but enhanced antioxidant capacity of mesothelioma cells also may protect tumor cells against exogenous oxidants, at least in vitro.",0.2,"<span class=""gene"" id=""11283936-12-0-8"">Catalase</span> may have multifactorial effects in malignant cells; high <span class=""gene"" id=""11283936-12-66-74"">catalase</span> and/or coordinated high expression of Mn-SOD and <span class=""gene"" id=""11283936-12-124-132"">catalase</span> may decrease tumor progression by modulating the cellular redox state, but enhanced antioxidant capacity of <span class=""disease"" id=""11283936-12-241-253"">mesothelioma</span> cells also may protect tumor cells against exogenous oxidants, at least in vitro.",CTD_human
1,0,Biomarker,C0032927,Precancerous Conditions,phenotype,premalignant,847,CAT,CAT,CTD_human,14580687,"Our findings, although based on small numbers, suggest that the oxidative stress genes MPO and CAT may influence the risk of arsenic-induced premalignant hyperkeratotic skin lesions.",0.200274726784213,"Our findings, although based on small numbers, suggest that the oxidative stress genes MPO and <span class=""gene"" id=""14580687-6-95-98"">CAT</span> may influence the risk of arsenic-induced <span class=""disease"" id=""14580687-6-141-153"">premalignant</span> hyperkeratotic skin lesions.",CTD_human
1,0,Biomarker,C0033626,Protein Deficiency,disease,Protein deficiency,847,CAT,catalase,CTD_human,15865262,"Protein deficiency in normal rats resulted in a significant increase in hepatic activities of catalase, glutathione peroxidase, glutathione reductase, and glutathione-S-transferase and the levels of lipid peroxidation.",0.2,"<span class=""disease"" id=""15865262-5-0-18"">Protein deficiency</span> in normal rats resulted in a significant increase in hepatic activities of <span class=""gene"" id=""15865262-5-94-102"">catalase</span>, glutathione peroxidase, glutathione reductase, and glutathione-S-transferase and the levels of lipid peroxidation.",CTD_human
1,0,Therapeutic,C0034069,Pulmonary Fibrosis,disease,pulmonary fibrosis,847,CAT,catalase,CTD_human,19684199,Modulation of reactive oxygen species by Rac1 or catalase prevents asbestos-induced pulmonary fibrosis.,0.2,"Modulation of reactive oxygen species by Rac1 or <span class=""gene"" id=""19684199-0-49-57"">catalase</span> prevents asbestos-induced <span class=""disease"" id=""19684199-0-84-102"">pulmonary fibrosis</span>.",CTD_human
3,0,Therapeutic,C0036572,Seizures,phenotype,seizures,847,CAT,catalase,CTD_human,18096215,Neuroprotective actions of vitamin C related to decreased lipid peroxidation and increased catalase activity in adult rats after pilocarpine-induced seizures.,0.200274726784213,"Neuroprotective actions of vitamin C related to decreased lipid peroxidation and increased <span class=""gene"" id=""18096215-0-91-99"">catalase</span> activity in adult rats after pilocarpine-induced <span class=""disease"" id=""18096215-0-149-157"">seizures</span>.",CTD_human
3,0,Therapeutic,C0036572,Seizures,phenotype,seizures,847,CAT,catalase,CTD_human,20592767,These results suggest that there is a direct relationship between the lipid peroxidation and nitrite contents during epileptic activity that can be responsible for the superoxide dismutase and catalase enzymatic activity changes observed during the establishment of seizures and SE induced by pilocarpine.,0.200274726784213,"These results suggest that there is a direct relationship between the lipid peroxidation and nitrite contents during epileptic activity that can be responsible for the superoxide dismutase and <span class=""gene"" id=""20592767-11-193-201"">catalase</span> enzymatic activity changes observed during the establishment of <span class=""disease"" id=""20592767-11-266-274"">seizures</span> and SE induced by pilocarpine.",CTD_human
3,0,Therapeutic,C0036572,Seizures,phenotype,seizures,847,CAT,catalase,CTD_human,19616071,Previous studies showed that animals presenting seizures and submitted to 24h of status epilepticus showed normal levels of superoxide dismutase and increased in catalase activities as well as an increase in hippocampal lipid peroxidation and nitrite concentrations.,0.200274726784213,"Previous studies showed that animals presenting <span class=""disease"" id=""19616071-6-48-56"">seizures</span> and submitted to 24h of status epilepticus showed normal levels of superoxide dismutase and increased in <span class=""gene"" id=""19616071-6-162-170"">catalase</span> activities as well as an increase in hippocampal lipid peroxidation and nitrite concentrations.",CTD_human
3,0,Biomarker,C0036572,Seizures,phenotype,seizures,847,CAT,catalase,CTD_human,19616071,Previous studies showed that animals presenting seizures and submitted to 24h of status epilepticus showed normal levels of superoxide dismutase and increased in catalase activities as well as an increase in hippocampal lipid peroxidation and nitrite concentrations.,0.200274726784213,"Previous studies showed that animals presenting <span class=""disease"" id=""19616071-6-48-56"">seizures</span> and submitted to 24h of status epilepticus showed normal levels of superoxide dismutase and increased in <span class=""gene"" id=""19616071-6-162-170"">catalase</span> activities as well as an increase in hippocampal lipid peroxidation and nitrite concentrations.",CTD_human
3,0,Biomarker,C0036572,Seizures,phenotype,seizures,847,CAT,catalase,CTD_human,18096215,Neuroprotective actions of vitamin C related to decreased lipid peroxidation and increased catalase activity in adult rats after pilocarpine-induced seizures.,0.200274726784213,"Neuroprotective actions of vitamin C related to decreased lipid peroxidation and increased <span class=""gene"" id=""18096215-0-91-99"">catalase</span> activity in adult rats after pilocarpine-induced <span class=""disease"" id=""18096215-0-149-157"">seizures</span>.",CTD_human
3,0,Biomarker,C0036572,Seizures,phenotype,seizures,847,CAT,catalase,CTD_human,20592767,These results suggest that there is a direct relationship between the lipid peroxidation and nitrite contents during epileptic activity that can be responsible for the superoxide dismutase and catalase enzymatic activity changes observed during the establishment of seizures and SE induced by pilocarpine.,0.200274726784213,"These results suggest that there is a direct relationship between the lipid peroxidation and nitrite contents during epileptic activity that can be responsible for the superoxide dismutase and <span class=""gene"" id=""20592767-11-193-201"">catalase</span> enzymatic activity changes observed during the establishment of <span class=""disease"" id=""20592767-11-266-274"">seizures</span> and SE induced by pilocarpine.",CTD_human
4,0,Biomarker,C0038220,Status Epilepticus,disease,status epilepticus,847,CAT,catalase,CTD_human,15752349,Our results suggest that GSH and catalase activity play an antioxidant role in the hippocampus during status epilepticus.,0.2,"Our results suggest that GSH and <span class=""gene"" id=""15752349-10-33-41"">catalase</span> activity play an antioxidant role in the hippocampus during <span class=""disease"" id=""15752349-10-102-120"">status epilepticus</span>.",CTD_human
4,0,Biomarker,C0038220,Status Epilepticus,disease,status epilepticus,847,CAT,catalase,CTD_human,18096215,Our results can suggest that neuroprotective effects of vitamin C in adult rats can be the result of reduced lipid peroxidation levels and increase of catalase activity after seizures and status epilepticus induced by pilocarpine.,0.2,"Our results can suggest that neuroprotective effects of vitamin C in adult rats can be the result of reduced lipid peroxidation levels and increase of <span class=""gene"" id=""18096215-9-151-159"">catalase</span> activity after seizures and <span class=""disease"" id=""18096215-9-188-206"">status epilepticus</span> induced by pilocarpine.",CTD_human
4,0,Therapeutic,C0038220,Status Epilepticus,disease,status epilepticus,847,CAT,catalase,CTD_human,17383094,Effects of the vitamin E in catalase activities in hippocampus after status epilepticus induced by pilocarpine in Wistar rats.,0.2,"Effects of the vitamin E in <span class=""gene"" id=""17383094-0-28-36"">catalase</span> activities in hippocampus after <span class=""disease"" id=""17383094-0-69-87"">status epilepticus</span> induced by pilocarpine in Wistar rats.",CTD_human
4,0,Therapeutic,C0038220,Status Epilepticus,disease,status epilepticus,847,CAT,catalase,CTD_human,15752349,Our results suggest that GSH and catalase activity play an antioxidant role in the hippocampus during status epilepticus.,0.2,"Our results suggest that GSH and <span class=""gene"" id=""15752349-10-33-41"">catalase</span> activity play an antioxidant role in the hippocampus during <span class=""disease"" id=""15752349-10-102-120"">status epilepticus</span>.",CTD_human
4,0,Biomarker,C0038220,Status Epilepticus,disease,status epilepticus,847,CAT,catalase,CTD_human,17383094,Effects of the vitamin E in catalase activities in hippocampus after status epilepticus induced by pilocarpine in Wistar rats.,0.2,"Effects of the vitamin E in <span class=""gene"" id=""17383094-0-28-36"">catalase</span> activities in hippocampus after <span class=""disease"" id=""17383094-0-69-87"">status epilepticus</span> induced by pilocarpine in Wistar rats.",CTD_human
4,0,Therapeutic,C0038220,Status Epilepticus,disease,status epilepticus,847,CAT,catalase,CTD_human,18096215,Our results can suggest that neuroprotective effects of vitamin C in adult rats can be the result of reduced lipid peroxidation levels and increase of catalase activity after seizures and status epilepticus induced by pilocarpine.,0.2,"Our results can suggest that neuroprotective effects of vitamin C in adult rats can be the result of reduced lipid peroxidation levels and increase of <span class=""gene"" id=""18096215-9-151-159"">catalase</span> activity after seizures and <span class=""disease"" id=""18096215-9-188-206"">status epilepticus</span> induced by pilocarpine.",CTD_human
4,0,Therapeutic,C0038220,Status Epilepticus,disease,status epilepticus,847,CAT,Catalase,CTD_human,15245787,"Catalase activity in cerebellum, hippocampus, frontal cortex and striatum after status epilepticus induced by pilocarpine in Wistar rats.",0.2,"<span class=""gene"" id=""15245787-0-0-8"">Catalase</span> activity in cerebellum, hippocampus, frontal cortex and striatum after <span class=""disease"" id=""15245787-0-80-98"">status epilepticus</span> induced by pilocarpine in Wistar rats.",CTD_human
4,0,Biomarker,C0038220,Status Epilepticus,disease,status epilepticus,847,CAT,Catalase,CTD_human,15245787,"Catalase activity in cerebellum, hippocampus, frontal cortex and striatum after status epilepticus induced by pilocarpine in Wistar rats.",0.2,"<span class=""gene"" id=""15245787-0-0-8"">Catalase</span> activity in cerebellum, hippocampus, frontal cortex and striatum after <span class=""disease"" id=""15245787-0-80-98"">status epilepticus</span> induced by pilocarpine in Wistar rats.",CTD_human
1,0,Biomarker,C0041408,Turner Syndrome,disease,Turner' syndrome,847,CAT,CAT,CTD_human,25101153,There was also an increase in CAT activity in M and Turner' syndrome.,0.2,"There was also an increase in <span class=""gene"" id=""25101153-5-30-33"">CAT</span> activity in M and <span class=""disease"" id=""25101153-5-52-68"">Turner' syndrome</span>.",CTD_human
1,0,Biomarker,C0079744,Diffuse Large B-Cell Lymphoma,disease,DLBCL,847,CAT,catalase,CTD_human,16081686,"We found that patients with DLBCL with the worst prognosis, according to the outcome predictor score, had decreased expression of catalase, glutathione peroxidase, manganese superoxide dismutase, and VDUP1, a protein that inhibits thioredoxin activity.",0.2,"We found that patients with <span class=""disease"" id=""16081686-5-28-33"">DLBCL</span> with the worst prognosis, according to the outcome predictor score, had decreased expression of <span class=""gene"" id=""16081686-5-130-138"">catalase</span>, glutathione peroxidase, manganese superoxide dismutase, and VDUP1, a protein that inhibits thioredoxin activity.",CTD_human
5,0,Biomarker,C0268419,Acatalasia,disease,acatalasemia,847,CAT,catalase,CTD_human,11001624,Anovel catalase mutation (a GA insertion) causes the Hungarian type of acatalasemia.,0.40357144819477,"Anovel <span class=""gene"" id=""11001624-0-7-15"">catalase</span> mutation (a GA insertion) causes the Hungarian type of <span class=""disease"" id=""11001624-0-71-83"">acatalasemia</span>.",CTD_human;ORPHANET
5,0,Therapeutic,C0268419,Acatalasia,disease,acatalasemia,847,CAT,catalase,CTD_human,11001624,Anovel catalase mutation (a GA insertion) causes the Hungarian type of acatalasemia.,0.40357144819477,"Anovel <span class=""gene"" id=""11001624-0-7-15"">catalase</span> mutation (a GA insertion) causes the Hungarian type of <span class=""disease"" id=""11001624-0-71-83"">acatalasemia</span>.",CTD_human;ORPHANET
1,0,Therapeutic,C0878544,Cardiomyopathies,group,cardiomyopathy,847,CAT,catalase,CTD_human,11800590,The results indicate that catalase elevation in the heart prevents doxorubicin chronic cardiomyopathy.,0.20054945356842604,"The results indicate that <span class=""gene"" id=""11800590-9-26-34"">catalase</span> elevation in the heart prevents doxorubicin chronic <span class=""disease"" id=""11800590-9-87-101"">cardiomyopathy</span>.",CTD_human
3,0,Biomarker,C0011881,Diabetic Nephropathy,disease,diabetic nephropathy,84735,CNDP1,CNDP1,CTD_human,21393041,Association of variants in the carnosine peptidase 1 gene (CNDP1) with diabetic nephropathy in American Indians.,0.22818660137574398,"Association of variants in the carnosine peptidase 1 gene (<span class=""gene"" id=""21393041-0-59-64"">CNDP1</span>) with <span class=""disease"" id=""21393041-0-71-91"">diabetic nephropathy</span> in American Indians.",CTD_human
3,0,Biomarker,C0011881,Diabetic Nephropathy,disease,diabetic nephropathy,84735,CNDP1,carnosinase 1,CTD_human,17942768,"These complimentary approaches have demonstrated that polymorphisms in the carnosinase 1 gene on chromosome 18q, the adiponectin gene on 3q, and the engulfment and cell motility gene on 7p are likely associated with susceptibility to diabetic nephropathy.",0.22818660137574398,"These complimentary approaches have demonstrated that polymorphisms in the <span class=""gene"" id=""17942768-5-75-88"">carnosinase 1</span> gene on chromosome 18q, the adiponectin gene on 3q, and the engulfment and cell motility gene on 7p are likely associated with susceptibility to <span class=""disease"" id=""17942768-5-234-254"">diabetic nephropathy</span>.",CTD_human
3,0,Biomarker,C0011881,Diabetic Nephropathy,disease,diabetic nephropathy,84735,CNDP1,CNDP1,CTD_human,21573905,"Two SNPs, rs2346061 in CNDP1 and rs7577 in CNDP2, were associated with an increased risk of diabetic nephropathy (rs2346061 p = 5.07 × 10(-4); rs7577 p = 0.021).",0.22818660137574398,"Two SNPs, rs2346061 in <span class=""gene"" id=""21573905-5-23-28"">CNDP1</span> and rs7577 in CNDP2, were associated with an increased risk of <span class=""disease"" id=""21573905-5-92-112"">diabetic nephropathy</span> (rs2346061 p = 5.07 &times; 10(-4); rs7577 p = 0.021).",CTD_human
1,0,Biomarker,C1956346,Coronary Artery Disease,disease,CAD,84830,ADTRP,C6orf105,CTD_human,21378986,"We report the first GWAS for CAD in the Chinese Han population and identify a SNP, rs6903956, in C6orf105 associated with susceptibility to CAD in this population.",0.201098907136852,"We report the first GWAS for <span class=""disease"" id=""21378986-6-29-32"">CAD</span> in the Chinese Han population and identify a SNP, rs6903956, in <span class=""gene"" id=""21378986-6-97-105"">C6orf105</span> associated with susceptibility to <span class=""disease"" id=""21378986-6-140-143"">CAD</span> in this population.",CTD_human
1,0,Biomarker,C1458155,Mammary Neoplasms,group,breast tumour,84866,TMEM25,TMEM25,CTD_human,19776672,"TMEM25, REPS2 and Meis 1 expression was investigated by qRT-PCR, in triplicate, in 103 breast tumour biopsies procured in 1993-1994.",0.2,"<span class=""gene"" id=""19776672-4-0-6"">TMEM25</span>, REPS2 and Meis 1 expression was investigated by qRT-PCR, in triplicate, in 103 <span class=""disease"" id=""19776672-4-87-100"">breast tumour</span> biopsies procured in 1993-1994.",CTD_human
2,0,Biomarker,C0025958,Microcephaly,disease,microcephaly,84879,MFSD2A,MFSD2A,CTD_human,26005865,A partially inactivating mutation in the sodium-dependent lysophosphatidylcholine transporter MFSD2A causes a non-lethal microcephaly syndrome.,0.20082418035263896,"A partially inactivating mutation in the sodium-dependent lysophosphatidylcholine transporter <span class=""gene"" id=""26005865-0-94-100"">MFSD2A</span> causes a non-lethal <span class=""disease"" id=""26005865-0-121-133"">microcephaly</span> syndrome.",CTD_human
2,0,Biomarker,C0025958,Microcephaly,disease,microcephaly,84879,MFSD2A,MFSD2A,CTD_human,26005868,"Inactivating mutations in MFSD2A, required for omega-3 fatty acid transport in brain, cause a lethal microcephaly syndrome.",0.20082418035263896,"Inactivating mutations in <span class=""gene"" id=""26005868-0-26-32"">MFSD2A</span>, required for omega-3 fatty acid transport in brain, cause a lethal <span class=""disease"" id=""26005868-0-101-113"">microcephaly</span> syndrome.",CTD_human
1,0,Biomarker,C3714756,Intellectual Disability,group,intellectual disability,84879,MFSD2A,MFSD2A,CTD_human,26005865,"Here we show that a homozygous mutation affecting a highly conserved MFSD2A residue (p.Ser339Leu) is associated with a progressive microcephaly syndrome characterized by intellectual disability, spasticity and absent speech.",0.200274726784213,"Here we show that a homozygous mutation affecting a highly conserved <span class=""gene"" id=""26005865-2-69-75"">MFSD2A</span> residue (p.Ser339Leu) is associated with a progressive microcephaly syndrome characterized by <span class=""disease"" id=""26005865-2-170-193"">intellectual disability</span>, spasticity and absent speech.",CTD_human
1,1,Biomarker,C0270736,Essential Tremor,disease,essential tremor,84894,LINGO1,LINGO1,CTD_human,19182806,Variant in the sequence of the LINGO1 gene confers risk of essential tremor.,0.213055860572969,"Variant in the sequence of the <span class=""gene"" id=""19182806-0-31-37"">LINGO1</span> gene confers risk of <span class=""disease"" id=""19182806-0-59-75"">essential tremor</span>.",CTD_human
1,0,Biomarker,C0017638,Glioma,disease,gliomas,8493,PPM1D,PPM1D,CTD_human,24880341,Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas.,0.201098907136852,"Exome sequencing identifies somatic gain-of-function <span class=""gene"" id=""24880341-0-53-58"">PPM1D</span> mutations in brainstem <span class=""disease"" id=""24880341-0-82-89"">gliomas</span>.",CTD_human
1,9,Biomarker,C0795949,Galloway Mowat syndrome,disease,Galloway-Mowat syndrome,84942,WDR73,WDR73,CTD_human,25466283,Loss-of-function mutations in WDR73 are responsible for microcephaly and steroid-resistant nephrotic syndrome: Galloway-Mowat syndrome.,0.401648360705279,"Loss-of-function mutations in <span class=""gene"" id=""25466283-0-30-35"">WDR73</span> are responsible for microcephaly and steroid-resistant nephrotic syndrome: <span class=""disease"" id=""25466283-0-111-134"">Galloway-Mowat syndrome</span>.",CTD_human;ORPHANET
1,0,Biomarker,C0013421,Dystonia,phenotype,dystonia,84947,SERAC1,SERAC1,CTD_human,22683713,Mutations in the phospholipid remodeling gene SERAC1 impair mitochondrial function and intracellular cholesterol trafficking and cause dystonia and deafness.,0.200274726784213,"Mutations in the phospholipid remodeling gene <span class=""gene"" id=""22683713-0-46-52"">SERAC1</span> impair mitochondrial function and intracellular cholesterol trafficking and cause <span class=""disease"" id=""22683713-0-135-143"">dystonia</span> and deafness.",CTD_human
1,0,Biomarker,C0033578,Prostatic Neoplasms,group,prostate tumours,8495,PPFIBP2,PPFIBP2,CTD_human,26443449,The mRNA levels of PPFIBP2 and ESR2 are differentially expressed in prostate tumours and paired normal tissues.,0.200274726784213,"The mRNA levels of <span class=""gene"" id=""26443449-5-19-26"">PPFIBP2</span> and ESR2 are differentially expressed in <span class=""disease"" id=""26443449-5-68-84"">prostate tumours</span> and paired normal tissues.",CTD_human
1,0,Biomarker,C0043459,Zellweger Syndrome,disease,Zellweger syndrome,8504,PEX3,PEX3,CTD_human,10942428,Identification of PEX3 as the gene mutated in a Zellweger syndrome patient lacking peroxisomal remnant structures.,0.401648360705279,"Identification of <span class=""gene"" id=""10942428-0-18-22"">PEX3</span> as the gene mutated in a <span class=""disease"" id=""10942428-0-48-66"">Zellweger syndrome</span> patient lacking peroxisomal remnant structures.",CTD_human;ORPHANET
1,0,Biomarker,C0014544,Epilepsy,disease,epilepsy,8514,KCNAB2,KCNAB2,CTD_human,11580756,"Loss of the potassium channel beta-subunit gene, KCNAB2, is associated with epilepsy in patients with 1p36 deletion syndrome.",0.40027472678421294,"Loss of the potassium channel beta-subunit gene, <span class=""gene"" id=""11580756-0-49-55"">KCNAB2</span>, is associated with <span class=""disease"" id=""11580756-0-76-84"">epilepsy</span> in patients with 1p36 deletion syndrome.",CTD_human;HPO
1,0,Biomarker,C0028754,Obesity,disease,obesity,8522,GAS7,Gas7,CTD_human,19270708,"Perturbation of eight out of the nine genes, with Gas7, Me1 and Gpx3 being newly confirmed, resulted in significant changes in obesity-related traits.",0.200274726784213,"Perturbation of eight out of the nine genes, with <span class=""gene"" id=""19270708-4-50-54"">Gas7</span>, Me1 and Gpx3 being newly confirmed, resulted in significant changes in <span class=""disease"" id=""19270708-4-127-134"">obesity</span>-related traits.",CTD_human
1,0,Therapeutic,C0027051,Myocardial Infarction,disease,myocardial infarction,8525,DGKZ,diacylglycerol kinase zeta,CTD_human,17071729,Cardiac-specific overexpression of diacylglycerol kinase zeta attenuates left ventricular remodeling and improves survival after myocardial infarction.,0.2,"Cardiac-specific overexpression of <span class=""gene"" id=""17071729-0-35-61"">diacylglycerol kinase zeta</span> attenuates left ventricular remodeling and improves survival after <span class=""disease"" id=""17071729-0-129-150"">myocardial infarction</span>.",CTD_human
2,0,Biomarker,C0004352,Autistic Disorder,disease,Autism,85358,SHANK3,Shank3,CTD_human,26027926,Autism-like Deficits in Shank3-Deficient Mice Are Rescued by Targeting Actin Regulators.,0.29698022473227603,"<span class=""disease"" id=""26027926-0-0-6"">Autism</span>-like Deficits in <span class=""gene"" id=""26027926-0-24-30"">Shank3</span>-Deficient Mice Are Rescued by Targeting Actin Regulators.",CTD_human
2,0,Biomarker,C1510586,Autism Spectrum Disorders,disease,autism spectrum disorders,85358,SHANK3,SHANK3,CTD_human,17173049,Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders.,0.20851653031060602,"Mutations in the gene encoding the synaptic scaffolding protein <span class=""gene"" id=""17173049-0-64-70"">SHANK3</span> are associated with <span class=""disease"" id=""17173049-0-91-116"">autism spectrum disorders</span>.",CTD_human
2,0,Biomarker,C1510586,Autism Spectrum Disorders,disease,ASD,85358,SHANK3,SHANK3,CTD_human,18252227,"Notwithstanding complexities, our results further implicate the SHANK3-NLGN4-NRXN1 postsynaptic density genes and also identify novel loci at DPP6-DPP10-PCDH9 (synapse complex), ANKRD11, DPYD, PTCHD1, 15q24, among others, for a role in ASD susceptibility.",0.20851653031060602,"Notwithstanding complexities, our results further implicate the <span class=""gene"" id=""18252227-8-64-70"">SHANK3</span>-NLGN4-NRXN1 postsynaptic density genes and also identify novel loci at DPP6-DPP10-PCDH9 (synapse complex), ANKRD11, DPYD, PTCHD1, 15q24, among others, for a role in <span class=""disease"" id=""18252227-8-236-239"">ASD</span> susceptibility.",CTD_human
1,1,Biomarker,C3714756,Intellectual Disability,group,mental retardation,85358,SHANK3,SHANK3,CTD_human,16284256,"Three cases with a common breakpoint within SHANK3 share a number of common phenotypic features, such as mental retardation and developmental delay with severely delayed or absent expressive speech.",0.205205453522732,"Three cases with a common breakpoint within <span class=""gene"" id=""16284256-7-44-50"">SHANK3</span> share a number of common phenotypic features, such as <span class=""disease"" id=""16284256-7-105-123"">mental retardation</span> and developmental delay with severely delayed or absent expressive speech.",CTD_human
1,0,Biomarker,C0027794,Neural Tube Defects,group,neural tube defects,85416,ZIC5,Zic5,CTD_human,15136147,Mouse Zic5 deficiency results in neural tube defects and hypoplasia of cephalic neural crest derivatives.,0.20054945356842604,"Mouse <span class=""gene"" id=""15136147-0-6-10"">Zic5</span> deficiency results in <span class=""disease"" id=""15136147-0-33-52"">neural tube defects</span> and hypoplasia of cephalic neural crest derivatives.",CTD_human
1,0,Biomarker,C0029463,Osteosarcoma,disease,bone sarcoma,85417,CCNB3,CCNB3,CTD_human,22387997,A new subtype of bone sarcoma defined by BCOR-CCNB3 gene fusion.,0.200274726784213,"A new subtype of <span class=""disease"" id=""22387997-0-17-29"">bone sarcoma</span> defined by BCOR-<span class=""gene"" id=""22387997-0-46-51"">CCNB3</span> gene fusion.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,85458,DIXDC1,DIXDC1,CTD_human,27752079,"Analysis of DIXDC1 in over 9000 cases of autism, bipolar disorder and schizophrenia reveals higher rates of rare inherited sequence-disrupting single-nucleotide variants (SNVs) in these individuals compared with psychiatrically unaffected controls.",0.2,"Analysis of <span class=""gene"" id=""27752079-4-12-18"">DIXDC1</span> in over 9000 cases of <span class=""disease"" id=""27752079-4-41-47"">autism</span>, bipolar disorder and schizophrenia reveals higher rates of rare inherited sequence-disrupting single-nucleotide variants (SNVs) in these individuals compared with psychiatrically unaffected controls.",CTD_human
1,0,Biomarker,C0005586,Bipolar Disorder,disease,bipolar disorder,85458,DIXDC1,DIXDC1,CTD_human,27752079,"Analysis of DIXDC1 in over 9000 cases of autism, bipolar disorder and schizophrenia reveals higher rates of rare inherited sequence-disrupting single-nucleotide variants (SNVs) in these individuals compared with psychiatrically unaffected controls.",0.2,"Analysis of <span class=""gene"" id=""27752079-4-12-18"">DIXDC1</span> in over 9000 cases of autism, <span class=""disease"" id=""27752079-4-49-65"">bipolar disorder</span> and schizophrenia reveals higher rates of rare inherited sequence-disrupting single-nucleotide variants (SNVs) in these individuals compared with psychiatrically unaffected controls.",CTD_human
1,0,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,85458,DIXDC1,DIXDC1,CTD_human,27752079,"Analysis of DIXDC1 in over 9000 cases of autism, bipolar disorder and schizophrenia reveals higher rates of rare inherited sequence-disrupting single-nucleotide variants (SNVs) in these individuals compared with psychiatrically unaffected controls.",0.200274726784213,"Analysis of <span class=""gene"" id=""27752079-4-12-18"">DIXDC1</span> in over 9000 cases of autism, bipolar disorder and <span class=""disease"" id=""27752079-4-70-83"">schizophrenia</span> reveals higher rates of rare inherited sequence-disrupting single-nucleotide variants (SNVs) in these individuals compared with psychiatrically unaffected controls.",CTD_human
1,0,Biomarker,C0004096,Asthma,disease,asthma,85480,TSLP,TSLP,CTD_human,21804549,"Four were at previously reported loci on 17q21, near IL1RL1, TSLP and IL33, but we report for the first time, to our knowledge, that these loci are associated with asthma risk in three ethnic groups.",0.22613416754861604,"Four were at previously reported loci on 17q21, near IL1RL1, <span class=""gene"" id=""21804549-3-61-65"">TSLP</span> and IL33, but we report for the first time, to our knowledge, that these loci are associated with <span class=""disease"" id=""21804549-3-164-170"">asthma</span> risk in three ethnic groups.",CTD_human
3,0,Biomarker,C0011615,"Dermatitis, Atopic",disease,atopic dermatitis,85480,TSLP,TSLP,CTD_human,23688403,These antimycotics may block the overexpression of TSLP in lesions with atopic dermatitis.,0.296114656979308,"These antimycotics may block the overexpression of <span class=""gene"" id=""23688403-15-51-55"">TSLP</span> in lesions with <span class=""disease"" id=""23688403-15-72-89"">atopic dermatitis</span>.",CTD_human
3,0,Biomarker,C0011615,"Dermatitis, Atopic",disease,AD,85480,TSLP,TSLP,CTD_human,22355542,These studies indicate that IL-13 induces AD and atopic march via a TSLP dependent mechanism.,0.296114656979308,"These studies indicate that IL-13 induces <span class=""disease"" id=""22355542-6-42-44"">AD</span> and atopic march via a <span class=""gene"" id=""22355542-6-68-72"">TSLP</span> dependent mechanism.",CTD_human
3,0,Biomarker,C0011615,"Dermatitis, Atopic",disease,atopic dermatitis,85480,TSLP,thymic stromal lymphopoietin,CTD_human,16880407,Topical vitamin D3 and low-calcemic analogs induce thymic stromal lymphopoietin in mouse keratinocytes and trigger an atopic dermatitis.,0.296114656979308,"Topical vitamin D3 and low-calcemic analogs induce <span class=""gene"" id=""16880407-0-51-79"">thymic stromal lymphopoietin</span> in mouse keratinocytes and trigger an <span class=""disease"" id=""16880407-0-118-135"">atopic dermatitis</span>.",CTD_human
1,0,Biomarker,C0017662,"Glomerulonephritis, Membranoproliferative",disease,MPGN,85480,TSLP,TSLP,CTD_human,17686814,ATRA is not protective but instead aggravates cryoglobulinaemic MPGN and its systemic manifestations in TSLP tg mice.,0.200274726784213,"ATRA is not protective but instead aggravates cryoglobulinaemic <span class=""disease"" id=""17686814-9-64-68"">MPGN</span> and its systemic manifestations in <span class=""gene"" id=""17686814-9-104-108"">TSLP</span> tg mice.",CTD_human
1,2,Biomarker,C0341106,Eosinophilic esophagitis,disease,EoE,85480,TSLP,TSLP,CTD_human,20208534,These data implicate the 5q22 locus in the pathogenesis of EoE and identify TSLP as the most likely candidate gene in the region.,0.201923087489492,"These data implicate the 5q22 locus in the pathogenesis of <span class=""disease"" id=""20208534-4-59-62"">EoE</span> and identify <span class=""gene"" id=""20208534-4-76-80"">TSLP</span> as the most likely candidate gene in the region.",CTD_human
3,0,Biomarker,C0005586,Bipolar Disorder,disease,bipolar disorder,8553,BHLHE40,BHLHE40,CTD_human,25395965,"A group of haplotypes overlapping BHLHE40 was associated with non-24-hour sleep-wake cycles, and less robustly, with delayed sleep and bipolar disorder (e.g., rs34883305, rs34870629, rs74439275, and rs3750275 were associated with n=37, p=4.58E-09, Bonferroni p=2.95E-06).",0.40508878383078906,"A group of haplotypes overlapping <span class=""gene"" id=""25395965-8-34-41"">BHLHE40</span> was associated with non-24-hour sleep-wake cycles, and less robustly, with delayed sleep and <span class=""disease"" id=""25395965-8-135-151"">bipolar disorder</span> (e.g., rs34883305, rs34870629, rs74439275, and rs3750275 were associated with n=37, p=4.58E-09, Bonferroni p=2.95E-06).",CTD_human;PSYGENET
1,0,Biomarker,C0038220,Status Epilepticus,disease,SE,8566,PDXK,pyridoxal kinase,CTD_human,19356691,"To comprehend the role of pyridoxal 5'-phosphate (PLP) in epilepsy or seizure, we investigated whether the expressions of two PLP synthetic enzymes (pyridoxal kinase, PLK; pyridoxine-5'-phosphate oxidase, PNPO) are altered in the hippocampus and whether changes in paired-pulse responses in the hippocampus are associated with altered PLP synthetic enzyme expressions following status epilepticus (SE).",0.2,"To comprehend the role of pyridoxal 5'-phosphate (PLP) in epilepsy or seizure, we investigated whether the expressions of two PLP synthetic enzymes (<span class=""gene"" id=""19356691-1-149-165"">pyridoxal kinase</span>, PLK; pyridoxine-5'-phosphate oxidase, PNPO) are altered in the hippocampus and whether changes in paired-pulse responses in the hippocampus are associated with altered PLP synthetic enzyme expressions following <span class=""disease"" id=""19356691-1-378-396"">status epilepticus</span> (<span class=""disease"" id=""19356691-1-398-400"">SE</span>).",CTD_human
2,1,Biomarker,C0004238,Atrial Fibrillation,disease,atrial fibrillation,857,CAV1,CAV1,CTD_human,20062060,"Five of the loci, SCN5A, SCN10A, NKX2-5, CAV1-CAV2, and SOX5, were also associated with atrial fibrillation (N = 5,741 cases, P < 0.0056).",0.202472541057918,"Five of the loci, SCN5A, SCN10A, NKX2-5, <span class=""gene"" id=""20062060-6-41-45"">CAV1</span>-CAV2, and SOX5, were also associated with <span class=""disease"" id=""20062060-6-88-107"">atrial fibrillation</span> (N = 5,741 cases, P &lt; 0.0056).",CTD_human
1,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastasis,857,CAV1,Cav-1,CTD_human,20562527,"In human breast cancer patients, a loss of stromal Cav-1 is associated with an increased risk of early tumor recurrence, metastasis, tamoxifen-resistance, and poor clinical outcome.",0.22578125158407997,"In human breast cancer patients, a loss of stromal <span class=""gene"" id=""20562527-13-51-56"">Cav-1</span> is associated with an increased risk of early tumor recurrence, <span class=""disease"" id=""20562527-13-121-131"">metastasis</span>, tamoxifen-resistance, and poor clinical outcome.",CTD_human
2,0,Biomarker,C0033578,Prostatic Neoplasms,group,prostate tumors,857,CAV1,CAV-1,CTD_human,15948133,"CAV-1 is located within the prostate cancer aggressiveness locus at 7q31-33, and was identified as being overexpressed in prostate tumors.",0.220229294390549,"<span class=""gene"" id=""15948133-2-0-5"">CAV-1</span> is located within the prostate cancer aggressiveness locus at 7q31-33, and was identified as being overexpressed in <span class=""disease"" id=""15948133-2-122-137"">prostate tumors</span>.",CTD_human
1,0,Biomarker,C0271694,Familial partial lipodystrophy,disease,familial partial lipodystrophy,857,CAV1,caveolin-1,CTD_human,19793595,"Sequencing of candidate genes LMNA, PPARG, AKT2, caveolin-1, as well as the PPARG4 promoter gene, which are known to be associated with familial partial lipodystrophy, revealed no genetic abnormalities, suggesting that this case may involve a novel gene.",0.20054945356842604,"Sequencing of candidate genes LMNA, PPARG, AKT2, <span class=""gene"" id=""19793595-4-49-59"">caveolin-1</span>, as well as the PPARG4 promoter gene, which are known to be associated with <span class=""disease"" id=""19793595-4-136-166"">familial partial lipodystrophy</span>, revealed no genetic abnormalities, suggesting that this case may involve a novel gene.",CTD_human
1,0,Biomarker,C0008925,Cleft Palate,disease,cleft palate,8573,CASK,CASK,CTD_human,9787075,Murine CASK is disrupted in a sex-linked cleft palate mouse mutant.,0.2,"Murine <span class=""gene"" id=""9787075-0-7-11"">CASK</span> is disrupted in a sex-linked <span class=""disease"" id=""9787075-0-41-53"">cleft palate</span> mouse mutant.",CTD_human
1,0,Biomarker,C0025958,Microcephaly,disease,microcephaly,8573,CASK,CASK,CTD_human,19165920,Mutations of CASK cause an X-linked brain malformation phenotype with microcephaly and hypoplasia of the brainstem and cerebellum.,0.201923087489492,"Mutations of <span class=""gene"" id=""19165920-0-13-17"">CASK</span> cause an X-linked brain malformation phenotype with <span class=""disease"" id=""19165920-0-70-82"">microcephaly</span> and hypoplasia of the brainstem and cerebellum.",CTD_human
2,0,Biomarker,C1136249,"Mental Retardation, X-Linked",disease,XLMR,8573,CASK,CASK,CTD_human,19377476,"The screen has discovered nine genes implicated in XLMR, including SYP, ZNF711 and CASK reported here, confirming the power of this strategy.",0.201098907136852,"The screen has discovered nine genes implicated in <span class=""disease"" id=""19377476-3-51-55"">XLMR</span>, including SYP, ZNF711 and <span class=""gene"" id=""19377476-3-83-87"">CASK</span> reported here, confirming the power of this strategy.",CTD_human
1,0,Biomarker,C0242422,Parkinsonian Disorders,group,parkinsonism disorder,8575,PRKRA,PRKRA,CTD_human,18243799,"DYT16, a novel young-onset dystonia-parkinsonism disorder: identification of a segregating mutation in the stress-response protein PRKRA.",0.40137363392106606,"<span class=""gene"" id=""18243799-0-0-5"">DYT16</span>, a novel young-onset dystonia-<span class=""disease"" id=""18243799-0-36-57"">parkinsonism disorder</span>: identification of a segregating mutation in the stress-response protein <span class=""gene"" id=""18243799-0-131-136"">PRKRA</span>.",CTD_human;HPO
1,0,Biomarker,C0393593,Dystonia Disorders,group,dystonia,8575,PRKRA,PRKRA,CTD_human,18243799,"DYT16, a novel young-onset dystonia-parkinsonism disorder: identification of a segregating mutation in the stress-response protein PRKRA.",0.204604842796993,"<span class=""gene"" id=""18243799-0-0-5"">DYT16</span>, a novel young-onset <span class=""disease"" id=""18243799-0-27-35"">dystonia</span>-parkinsonism disorder: identification of a segregating mutation in the stress-response protein <span class=""gene"" id=""18243799-0-131-136"">PRKRA</span>.",CTD_human
1,0,Biomarker,C0003873,Rheumatoid Arthritis,disease,RA,858,CAV2,caveolin 2,CTD_human,17379860,"Treatment with methotrexate resulted in the reversion of the RA-related expression profile of genes associated with growth and apoptosis including insulin-like growth factor binding protein 3, retinoic acid induced 3, and caveolin 2 as well as in the re-expression of the cell adhesion molecule integrin alpha6.",0.200274726784213,"Treatment with methotrexate resulted in the reversion of the <span class=""disease"" id=""17379860-6-61-63"">RA</span>-related expression profile of genes associated with growth and apoptosis including insulin-like growth factor binding protein 3, retinoic acid induced 3, and <span class=""gene"" id=""17379860-6-222-232"">caveolin 2</span> as well as in the re-expression of the cell adhesion molecule integrin alpha6.",CTD_human
1,0,Biomarker,C0004238,Atrial Fibrillation,disease,atrial fibrillation,858,CAV2,CAV2,CTD_human,20062060,"Five of the loci, SCN5A, SCN10A, NKX2-5, CAV1-CAV2, and SOX5, were also associated with atrial fibrillation (N = 5,741 cases, P < 0.0056).",0.20054945356842604,"Five of the loci, SCN5A, SCN10A, NKX2-5, CAV1-<span class=""gene"" id=""20062060-6-46-50"">CAV2</span>, and SOX5, were also associated with <span class=""disease"" id=""20062060-6-88-107"">atrial fibrillation</span> (N = 5,741 cases, P &lt; 0.0056).",CTD_human
1,0,Biomarker,C0018798,Congenital Heart Defects,group,congenital heart defect,859,CAV3,CAV3,CTD_human,21082655,"Selected genes that are present in the hemizygous state and which might be important for the phenotype of this patient as regards the congenital heart defect, autistic behavior and mental retardation (CAV3, OXTR, and SRGAP3/MEGAP, respectively) are discussed in context of the clinical features.",0.2,"Selected genes that are present in the hemizygous state and which might be important for the phenotype of this patient as regards the <span class=""disease"" id=""21082655-6-134-157"">congenital heart defect</span>, autistic behavior and mental retardation (<span class=""gene"" id=""21082655-6-201-205"">CAV3</span>, OXTR, and SRGAP3/MEGAP, respectively) are discussed in context of the clinical features.",CTD_human
1,0,Biomarker,C1838254,RIPPLING MUSCLE DISEASE 1,disease,Rippling muscle disease,859,CAV3,CAV3,CTD_human,21294223,In the present study we examined Ca(2+) homeostasis and excitation-contraction (E-C) coupling in cultured myotubes derived from two patients with Rippling muscle disease with severe reduction in caveolin-3 expression; one patient harboured the heterozygous c.84C>A mutation while the other patient harbored a homozygous splice-site mutation (c.102+ 2T>C) affecting the splice donor site of intron 1 of the CAV3 gene.,0.205494535684262,"In the present study we examined Ca(2+) homeostasis and excitation-contraction (E-C) coupling in cultured myotubes derived from two patients with <span class=""disease"" id=""21294223-3-146-169"">Rippling muscle disease</span> with severe reduction in <span class=""gene"" id=""21294223-3-195-205"">caveolin-3</span> expression; one patient harboured the heterozygous c.84C&gt;A mutation while the other patient harbored a homozygous splice-site mutation (c.102+ 2T&gt;C) affecting the splice donor site of intron 1 of the <span class=""gene"" id=""21294223-3-406-410"">CAV3</span> gene.",CTD_human
12,15,Biomarker,C0008928,Cleidocranial Dysplasia,disease,CCD,860,RUNX2,Runx2,CTD_human,14688224,"Heterozygous mutations in Runx2 cause cleidocranial dysplasia (CCD), an inherited disorder in humans and mice characterized by skeletal defects, supernumerary teeth, and delayed eruption.",0.7309188263104691,"Heterozygous mutations in <span class=""gene"" id=""14688224-2-26-31"">Runx2</span> cause <span class=""disease"" id=""14688224-2-38-61"">cleidocranial dysplasia</span> (<span class=""disease"" id=""14688224-2-63-66"">CCD</span>), an inherited disorder in humans and mice characterized by skeletal defects, supernumerary teeth, and delayed eruption.",CTD_human;ORPHANET;UNIPROT
12,15,Biomarker,C0008928,Cleidocranial Dysplasia,disease,cleidocranial dysplasia,860,RUNX2,RUNX2,CTD_human,17022082,RUNX2 mutations lead to cleidocranial dysplasia in humans.,0.7309188263104691,"<span class=""gene"" id=""17022082-4-0-5"">RUNX2</span> mutations lead to <span class=""disease"" id=""17022082-4-24-47"">cleidocranial dysplasia</span> in humans.",CTD_human;ORPHANET;UNIPROT
2,0,Biomarker,C0029463,Osteosarcoma,disease,OS,860,RUNX2,RUNX2,CTD_human,25307878,We also show that inhibition of RUNX2 expression by JQ1 partly explains the antiproliferative activity of JQ1 in OS cells.,0.21561636056819503,"We also show that inhibition of <span class=""gene"" id=""25307878-13-32-37"">RUNX2</span> expression by JQ1 partly explains the antiproliferative activity of JQ1 in <span class=""disease"" id=""25307878-13-113-115"">OS</span> cells.",CTD_human
2,0,Biomarker,C0004352,Autistic Disorder,disease,autism,8604,SLC25A12,SLC25A12,CTD_human,15056512,Linkage and association of the mitochondrial aspartate/glutamate carrier SLC25A12 gene with autism.,0.220420647857786,"Linkage and association of the mitochondrial aspartate/glutamate carrier <span class=""gene"" id=""15056512-0-73-81"">SLC25A12</span> gene with <span class=""disease"" id=""15056512-0-92-98"">autism</span>.",CTD_human
2,0,Biomarker,C0023467,"Leukemia, Myelocytic, Acute",disease,AML,861,RUNX1,RUNX1,CTD_human,27798625,"Outside of signaling alterations, RUNX1-RUNX1T1 and CBFB-MYH11 AMLs demonstrated remarkably different spectra of cooperating mutations, as RUNX1-RUNX1T1 cases harbored recurrent mutations in DHX15 and ZBTB7A, as well as an enrichment of mutations in epigenetic regulators, including ASXL2 and the cohesin complex.",0.5412275669830879,"Outside of signaling alterations, <span class=""gene"" id=""27798625-4-34-39"">RUNX1</span>-RUNX1T1 and CBFB-MYH11 <span class=""disease"" id=""27798625-4-63-66"">AML</span>s demonstrated remarkably different spectra of cooperating mutations, as <span class=""gene"" id=""27798625-4-139-144"">RUNX1</span>-RUNX1T1 cases harbored recurrent mutations in DHX15 and ZBTB7A, as well as an enrichment of mutations in epigenetic regulators, including ASXL2 and the cohesin complex.",CTD_human;HPO
1,0,Biomarker,C0033578,Prostatic Neoplasms,group,prostate tumors,861,RUNX1,Runx1,CTD_human,17909013,"We found that prostate tumors from the Low-T mutant mice share a similar gene expression profile as androgen-independent prostate tumors from these mutant mice, which includes the deregulated expression of several genes that are up-regulated in human hormone-refractory prostate cancer, such as Vav3 and Runx1.",0.2,"We found that <span class=""disease"" id=""17909013-3-14-29"">prostate tumors</span> from the Low-T mutant mice share a similar gene expression profile as androgen-independent <span class=""disease"" id=""17909013-3-121-136"">prostate tumors</span> from these mutant mice, which includes the deregulated expression of several genes that are up-regulated in human hormone-refractory prostate cancer, such as Vav3 and <span class=""gene"" id=""17909013-3-304-309"">Runx1</span>.",CTD_human
1,0,Biomarker,C1458155,Mammary Neoplasms,group,breast tumours,8614,STC2,STC2,CTD_human,18492817,"Breast tumour gene profiling studies have demonstrated significantly upregulated STC2 expression in hormone-responsive positive breast tumours; therefore, the purpose of this study was to investigate STC2 hormonal regulation and function in breast cancer cells.",0.205740551713841,"<span class=""disease"" id=""18492817-2-0-13"">Breast tumour</span> gene profiling studies have demonstrated significantly upregulated <span class=""gene"" id=""18492817-2-81-85"">STC2</span> expression in hormone-responsive positive <span class=""disease"" id=""18492817-2-128-142"">breast tumours</span>; therefore, the purpose of this study was to investigate <span class=""gene"" id=""18492817-2-200-204"">STC2</span> hormonal regulation and function in breast cancer cells.",CTD_human
2,0,Biomarker,C0023467,"Leukemia, Myelocytic, Acute",disease,AML,862,RUNX1T1,RUNX1T1,CTD_human,27798625,"Outside of signaling alterations, RUNX1-RUNX1T1 and CBFB-MYH11 AMLs demonstrated remarkably different spectra of cooperating mutations, as RUNX1-RUNX1T1 cases harbored recurrent mutations in DHX15 and ZBTB7A, as well as an enrichment of mutations in epigenetic regulators, including ASXL2 and the cohesin complex.",0.283994619082622,"Outside of signaling alterations, RUNX1-<span class=""gene"" id=""27798625-4-40-47"">RUNX1T1</span> and CBFB-MYH11 <span class=""disease"" id=""27798625-4-63-66"">AML</span>s demonstrated remarkably different spectra of cooperating mutations, as RUNX1-<span class=""gene"" id=""27798625-4-145-152"">RUNX1T1</span> cases harbored recurrent mutations in DHX15 and ZBTB7A, as well as an enrichment of mutations in epigenetic regulators, including ASXL2 and the cohesin complex.",CTD_human
1,0,Biomarker,C0001627,Congenital adrenal hyperplasia,disease,adrenal hyperplasia,8622,PDE8B,PDE8B,CTD_human,18272904,"Mutation in PDE8B, a cyclic AMP-specific phosphodiesterase in adrenal hyperplasia.",0.20082418035263896,"Mutation in <span class=""gene"" id=""18272904-0-12-17"">PDE8B</span>, a cyclic AMP-specific phosphodiesterase in <span class=""disease"" id=""18272904-0-62-81"">adrenal hyperplasia</span>.",CTD_human
1,0,Biomarker,C0007137,Squamous cell carcinoma,disease,squamous cell carcinoma,8626,TP63,p63,CTD_human,21527555,Physical association of HDAC1 and HDAC2 with p63 mediates transcriptional repression and tumor maintenance in squamous cell carcinoma.,0.235599638929165,"Physical association of HDAC1 and HDAC2 with <span class=""gene"" id=""21527555-0-45-48"">p63</span> mediates transcriptional repression and tumor maintenance in <span class=""disease"" id=""21527555-0-110-133"">squamous cell carcinoma</span>.",CTD_human
1,0,Biomarker,C0008925,Cleft Palate,disease,cleft palate,8626,TP63,p63,CTD_human,11462173,"We performed p63 mutation analysis in a sample of 43 individuals and families affected with EEC syndrome, in 35 individuals affected with SHFM, and in three families with the EEC-like condition limb-mammary syndrome (LMS), which is characterized by ectrodactyly, cleft palate, and mammary-gland abnormalities.",0.405363510615002,"We performed <span class=""gene"" id=""11462173-2-13-16"">p63</span> mutation analysis in a sample of 43 individuals and families affected with EEC syndrome, in 35 individuals affected with SHFM, and in three families with the EEC-like condition limb-mammary syndrome (LMS), which is characterized by ectrodactyly, <span class=""disease"" id=""11462173-2-263-275"">cleft palate</span>, and mammary-gland abnormalities.",CTD_human;HPO
1,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastases,8626,TP63,p51,CTD_human,15875781,"In patients with melanoma, development of metastases significantly increased the blood levels of p51.",0.203846174978983,"In patients with melanoma, development of <span class=""disease"" id=""15875781-4-42-52"">metastases</span> significantly increased the blood levels of <span class=""gene"" id=""15875781-4-97-100"">p51</span>.",CTD_human
1,3,Biomarker,C0152013,Adenocarcinoma of lung (disorder),disease,lung adenocarcinoma,8626,TP63,TP63,CTD_human,24880342,"We also showed an association between common variation at 3q28 (TP63, rs13314271, OR = 1.13, P = 7.22 × 10(-10)) and lung adenocarcinoma that had been previously reported only in Asians.",0.202197814273705,"We also showed an association between common variation at 3q28 (<span class=""gene"" id=""24880342-3-64-68"">TP63</span>, rs13314271, OR = 1.13, P = 7.22 &times; 10(-10)) and <span class=""disease"" id=""24880342-3-117-136"">lung adenocarcinoma</span> that had been previously reported only in Asians.",CTD_human
1,0,Biomarker,C0406704,Rudiger syndrome 1,disease,EEC syndrome,8626,TP63,p63,CTD_human,11462173,"The combined data show that p63 is the major gene for EEC syndrome, and that it makes a modest contribution to SHFM.",0.404945082115836,"The combined data show that <span class=""gene"" id=""11462173-10-28-31"">p63</span> is the major gene for <span class=""disease"" id=""11462173-10-54-66"">EEC syndrome</span>, and that it makes a modest contribution to SHFM.",CTD_human;ORPHANET
3,3,Biomarker,C0406709,Hay-Wells syndrome,disease,AEC) syndrome,8626,TP63,TP63,CTD_human,19676059,Ankyloblepharon-ectodermal dysplasia-cleft lip/palate (AEC) syndrome and Rapp-Hodgkin syndrome are well-characterized clinical entities caused by mutations in the TP63 gene.,0.487142896389541,"Ankyloblepharon-ectodermal dysplasia-cleft lip/palate (<span class=""disease"" id=""19676059-1-55-68"">AEC) syndrome</span> and Rapp-Hodgkin syndrome are well-characterized clinical entities caused by mutations in the <span class=""gene"" id=""19676059-1-163-167"">TP63</span> gene.",CTD_human;UNIPROT
3,3,Biomarker,C0406709,Hay-Wells syndrome,disease,ankyloblepharon-ectodermal defects-cleft lip and palate,8626,TP63,P63,CTD_human,19239083,The ankyloblepharon-ectodermal defects-cleft lip and palate (Hay-Wells or AEC) and the Rapp-Hodgkin syndrome (RHS) are rare autosomal dominant ectodermal dysplasias due to mutations in the transcription factor gene P63.,0.487142896389541,"The <span class=""disease"" id=""19239083-1-4-59"">ankyloblepharon-ectodermal defects-cleft lip and palate</span> (Hay-Wells or AEC) and the Rapp-Hodgkin syndrome (RHS) are rare autosomal dominant ectodermal dysplasias due to mutations in the transcription factor gene <span class=""gene"" id=""19239083-1-215-218"">P63</span>.",CTD_human;UNIPROT
6,4,Biomarker,C1785148,RAPP-HODGKIN SYNDROME,disease,RHS,8626,TP63,P63,CTD_human,19239083,"To date more than 20 P63 mutations have been described associated with AEC and RHS, the majority of which are missense or nonsense mutations.",0.603296721410557,"To date more than 20 <span class=""gene"" id=""19239083-4-21-24"">P63</span> mutations have been described associated with AEC and <span class=""disease"" id=""19239083-4-79-82"">RHS</span>, the majority of which are missense or nonsense mutations.",CTD_human;ORPHANET;UNIPROT
6,4,Biomarker,C1785148,RAPP-HODGKIN SYNDROME,disease,Rapp-Hodgkin syndrome,8626,TP63,TP63,CTD_human,19676059,Ankyloblepharon-ectodermal dysplasia-cleft lip/palate (AEC) syndrome and Rapp-Hodgkin syndrome are well-characterized clinical entities caused by mutations in the TP63 gene.,0.603296721410557,"Ankyloblepharon-ectodermal dysplasia-cleft lip/palate (AEC) syndrome and <span class=""disease"" id=""19676059-1-73-94"">Rapp-Hodgkin syndrome</span> are well-characterized clinical entities caused by mutations in the <span class=""gene"" id=""19676059-1-163-167"">TP63</span> gene.",CTD_human;ORPHANET;UNIPROT
6,4,Biomarker,C1785148,RAPP-HODGKIN SYNDROME,disease,Rapp-Hodgkin syndrome,8626,TP63,TP63,CTD_human,15748593,"The clinical presentation of ectodermal dysplasia with cleft palate was consistent with Rapp-Hodgkin syndrome, which is one of several allelic diseases associated with mutations in the TP63 gene.",0.603296721410557,"The clinical presentation of ectodermal dysplasia with cleft palate was consistent with <span class=""disease"" id=""15748593-3-88-109"">Rapp-Hodgkin syndrome</span>, which is one of several allelic diseases associated with mutations in the <span class=""gene"" id=""15748593-3-185-189"">TP63</span> gene.",CTD_human;ORPHANET;UNIPROT
1,1,Biomarker,C1863753,LIMB-MAMMARY SYNDROME,disease,LMS,8626,TP63,p63,CTD_human,11462173,"We performed p63 mutation analysis in a sample of 43 individuals and families affected with EEC syndrome, in 35 individuals affected with SHFM, and in three families with the EEC-like condition limb-mammary syndrome (LMS), which is characterized by ectrodactyly, cleft palate, and mammary-gland abnormalities.",0.400549453568426,"We performed <span class=""gene"" id=""11462173-2-13-16"">p63</span> mutation analysis in a sample of 43 individuals and families affected with EEC syndrome, in 35 individuals affected with SHFM, and in three families with the EEC-like condition <span class=""disease"" id=""11462173-2-194-215"">limb-mammary syndrome</span> (<span class=""disease"" id=""11462173-2-217-220"">LMS</span>), which is characterized by ectrodactyly, cleft palate, and mammary-gland abnormalities.",CTD_human;ORPHANET
1,0,Biomarker,C0270853,"Myoclonic Epilepsy, Juvenile",disease,JME,8629,JRK,JRK,CTD_human,11463517,"Polymorphism analysis of JRK/JH8, the human homologue of mouse jerky, and description of a rare mutation in a case of CAE evolving to JME.",0.40027472678421294,"Polymorphism analysis of <span class=""gene"" id=""11463517-0-25-28"">JRK</span>/JH8, the human homologue of mouse jerky, and description of a rare mutation in a case of CAE evolving to <span class=""disease"" id=""11463517-0-134-137"">JME</span>.",CTD_human;ORPHANET
1,0,Biomarker,C0007134,Renal Cell Carcinoma,disease,renal cell carcinoma,8633,UNC5C,UNC5C,CTD_human,21600761,Genetic and epigenetic control of UNC5C expression in human renal cell carcinoma.,0.200274726784213,"Genetic and epigenetic control of <span class=""gene"" id=""21600761-0-34-39"">UNC5C</span> expression in human <span class=""disease"" id=""21600761-0-60-80"">renal cell carcinoma</span>.",CTD_human
1,0,Biomarker,C0011849,Diabetes Mellitus,group,diabetes mellitus,8639,AOC3,SSAO,CTD_human,23154672,"Elevation of SSAO activity is observed in atherosclerosis, diabetes mellitus and obesity.",0.201648360705279,"Elevation of <span class=""gene"" id=""23154672-3-13-17"">SSAO</span> activity is observed in atherosclerosis, <span class=""disease"" id=""23154672-3-59-76"">diabetes mellitus</span> and obesity.",CTD_human
1,0,Biomarker,C0017636,Glioblastoma,disease,glioblastoma,864,RUNX3,RUNX3,CTD_human,16909125,Downregulation of RUNX3 and TES by hypermethylation in glioblastoma.,0.20082418035263896,"Downregulation of <span class=""gene"" id=""16909125-0-18-23"">RUNX3</span> and TES by hypermethylation in <span class=""disease"" id=""16909125-0-55-67"">glioblastoma</span>.",CTD_human
1,0,Biomarker,C0038013,Ankylosing spondylitis,disease,ankylosing spondylitis,864,RUNX3,RUNX3,CTD_human,21743469,"Here we report the identification of three variants in the RUNX3, LTBR-TNFRSF1A and IL12B regions convincingly associated with ankylosing spondylitis (P < 5 × 10(-8) in the combined discovery and replication datasets) and a further four loci at PTGER4, TBKBP1, ANTXR2 and CARD9 that show strong association across all our datasets (P < 5 × 10(-6) overall, with support in each of the three datasets studied).",0.201098907136852,"Here we report the identification of three variants in the <span class=""gene"" id=""21743469-2-59-64"">RUNX3</span>, LTBR-TNFRSF1A and IL12B regions convincingly associated with <span class=""disease"" id=""21743469-2-127-149"">ankylosing spondylitis</span> (P &lt; 5 &times; 10(-8) in the combined discovery and replication datasets) and a further four loci at PTGER4, TBKBP1, ANTXR2 and CARD9 that show strong association across all our datasets (P &lt; 5 &times; 10(-6) overall, with support in each of the three datasets studied).",CTD_human
2,0,Biomarker,C0014175,Endometriosis,disease,endometriosis,8644,AKR1C3,AKR1C3,CTD_human,25446850,These cell models characterized in this study will enable further investigations into the role of PGF2? in the pathophysiology of endometriosis and the involvement of AKR1B1 and AKR1C3.,0.20054945356842604,"These cell models characterized in this study will enable further investigations into the role of PGF2&alpha; in the pathophysiology of <span class=""disease"" id=""25446850-12-130-143"">endometriosis</span> and the involvement of AKR1B1 and <span class=""gene"" id=""25446850-12-178-184"">AKR1C3</span>.",CTD_human
1,0,Biomarker,C0038220,Status Epilepticus,disease,SE,8645,KCNK5,TASK-2,CTD_human,19220408,"In addition, TASK-2 immunoreactivity is gradually increased in perivascular regions following SE.",0.2,"In addition, <span class=""gene"" id=""19220408-5-13-19"">TASK-2</span> immunoreactivity is gradually increased in perivascular regions following <span class=""disease"" id=""19220408-5-94-96"">SE</span>.",CTD_human
3,0,Biomarker,C0008370,Cholestasis,disease,cholestasis,8647,ABCB11,ABCB11,CTD_human,24713091,Drug-induced cholestasis is a frequently observed side effect of drugs and is often caused by an unexpected interaction with the bile salt export pump (BSEP/ABCB11).,0.214704221278248,"Drug-induced <span class=""disease"" id=""24713091-1-13-24"">cholestasis</span> is a frequently observed side effect of drugs and is often caused by an unexpected interaction with the <span class=""gene"" id=""24713091-1-129-150"">bile salt export pump</span> (<span class=""gene"" id=""24713091-1-152-156"">BSEP</span>/<span class=""gene"" id=""24713091-1-157-163"">ABCB11</span>).",CTD_human
1,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastasis,8648,NCOA1,Steroid receptor coactivator 1,CTD_human,21080969,"Steroid receptor coactivator 1 deficiency increases MMTV-neu mediated tumor latency and differentiation specific gene expression, decreases metastasis, and inhibits response to PPAR ligands.",0.201373633921065,"<span class=""gene"" id=""21080969-0-0-30"">Steroid receptor coactivator 1</span> deficiency increases MMTV-neu mediated tumor latency and differentiation specific gene expression, decreases <span class=""disease"" id=""21080969-0-140-150"">metastasis</span>, and inhibits response to PPAR ligands.",CTD_human
2,0,Biomarker,C0023467,"Leukemia, Myelocytic, Acute",disease,AML,865,CBFB,CBFB,CTD_human,27798625,"Outside of signaling alterations, RUNX1-RUNX1T1 and CBFB-MYH11 AMLs demonstrated remarkably different spectra of cooperating mutations, as RUNX1-RUNX1T1 cases harbored recurrent mutations in DHX15 and ZBTB7A, as well as an enrichment of mutations in epigenetic regulators, including ASXL2 and the cohesin complex.",0.21263743207380303,"Outside of signaling alterations, RUNX1-RUNX1T1 and <span class=""gene"" id=""27798625-4-52-56"">CBFB</span>-MYH11 <span class=""disease"" id=""27798625-4-63-66"">AML</span>s demonstrated remarkably different spectra of cooperating mutations, as RUNX1-RUNX1T1 cases harbored recurrent mutations in DHX15 and ZBTB7A, as well as an enrichment of mutations in epigenetic regulators, including ASXL2 and the cohesin complex.",CTD_human
2,0,Biomarker,C0020456,Hyperglycemia,disease,hyperglycemia,8660,IRS2,IRS2,CTD_human,20028942,"Mice with complete deletion of insulin receptor substrate 2 (IRS2) develop hyperglycemia, impaired hepatic insulin signaling, and elevated gluconeogenesis, whereas mice deficient for protein tyrosine phosphatase (PTP)1B display an opposing hepatic phenotype characterized by increased sensitivity to insulin.",0.20054945356842604,"Mice with complete deletion of <span class=""gene"" id=""20028942-1-31-59"">insulin receptor substrate 2</span> (<span class=""gene"" id=""20028942-1-61-65"">IRS2</span>) develop <span class=""disease"" id=""20028942-1-75-88"">hyperglycemia</span>, impaired hepatic insulin signaling, and elevated gluconeogenesis, whereas mice deficient for protein tyrosine phosphatase (PTP)1B display an opposing hepatic phenotype characterized by increased sensitivity to insulin.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,hepatocellular carcinoma,8660,IRS2,insulin receptor substrate-2,CTD_human,16127164,Overexpression of insulin receptor substrate-2 in human and murine hepatocellular carcinoma.,0.20082418035263896,"Overexpression of <span class=""gene"" id=""16127164-0-18-46"">insulin receptor substrate-2</span> in human and murine <span class=""disease"" id=""16127164-0-67-91"">hepatocellular carcinoma</span>.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,hepatocellular carcinomas,8667,EIF3H,EIF3S3,CTD_human,14578863,PTK2 and EIF3S3 genes may be amplification targets at 8q23-q24 and are associated with large hepatocellular carcinomas.,0.200274726784213,"PTK2 and <span class=""gene"" id=""14578863-0-9-15"">EIF3S3</span> genes may be amplification targets at 8q23-q24 and are associated with large <span class=""disease"" id=""14578863-0-93-118"">hepatocellular carcinomas</span>.",CTD_human
1,0,Biomarker,C0008073,Developmental Disabilities,group,developmental disorder,867,CBL,CBL,CTD_human,20694012,"We describe a dominant developmental disorder resulting from germline missense CBL mutations, which is characterized by impaired growth, developmental delay, cryptorchidism and a predisposition to juvenile myelomonocytic leukemia (JMML).",0.2,"We describe a dominant <span class=""disease"" id=""20694012-2-23-45"">developmental disorder</span> resulting from germline missense <span class=""gene"" id=""20694012-2-79-82"">CBL</span> mutations, which is characterized by impaired growth, developmental delay, cryptorchidism and a predisposition to juvenile myelomonocytic leukemia (JMML).",CTD_human
1,0,Biomarker,C0010417,Cryptorchidism,disease,cryptorchidism,867,CBL,CBL,CTD_human,20694012,"We describe a dominant developmental disorder resulting from germline missense CBL mutations, which is characterized by impaired growth, developmental delay, cryptorchidism and a predisposition to juvenile myelomonocytic leukemia (JMML).",0.40027472678421294,"We describe a dominant developmental disorder resulting from germline missense <span class=""gene"" id=""20694012-2-79-82"">CBL</span> mutations, which is characterized by impaired growth, developmental delay, <span class=""disease"" id=""20694012-2-158-172"">cryptorchidism</span> and a predisposition to juvenile myelomonocytic leukemia (JMML).",CTD_human;HPO
3,2,Biomarker,C0349639,Juvenile Myelomonocytic Leukemia,disease,juvenile myelomonocytic leukemia,867,CBL,CBL,CTD_human,20694012,Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia.,0.60439562854741,"Germline <span class=""gene"" id=""20694012-0-9-12"">CBL</span> mutations cause developmental abnormalities and predispose to <span class=""disease"" id=""20694012-0-75-107"">juvenile myelomonocytic leukemia</span>.",CTD_human;HPO;ORPHANET
1,1,Biomarker,C0026769,Multiple Sclerosis,disease,multiple sclerosis,868,CBLB,CBLB,CTD_human,20453840,Variants within the immunoregulatory CBLB gene are associated with multiple sclerosis.,0.20591296418342803,"Variants within the immunoregulatory <span class=""gene"" id=""20453840-0-37-41"">CBLB</span> gene are associated with <span class=""disease"" id=""20453840-0-67-85"">multiple sclerosis</span>.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,hepatocellular carcinoma,873,CBR1,carbonyl reductase 1,CTD_human,21056497,Human carbonyl reductase 1 upregulated by hypoxia renders resistance to apoptosis in hepatocellular carcinoma cells.,0.20054945356842604,"Human <span class=""gene"" id=""21056497-0-6-26"">carbonyl reductase 1</span> upregulated by hypoxia renders resistance to apoptosis in <span class=""disease"" id=""21056497-0-85-109"">hepatocellular carcinoma</span> cells.",CTD_human
1,0,Therapeutic,C0007134,Renal Cell Carcinoma,disease,renal carcinoma,8743,TNFSF10,TRAIL,CTD_human,20403343,The coffee diterpene kahweol sensitizes TRAIL-induced apoptosis in renal carcinoma Caki cells through down-regulation of Bcl-2 and c-FLIP.,0.203846174978983,"The coffee diterpene kahweol sensitizes <span class=""gene"" id=""20403343-0-40-45"">TRAIL</span>-induced apoptosis in <span class=""disease"" id=""20403343-0-67-82"">renal carcinoma</span> Caki cells through down-regulation of Bcl-2 and c-FLIP.",CTD_human
2,0,Therapeutic,C0017638,Glioma,disease,glioma,8743,TNFSF10,TRAIL,CTD_human,16820965,The results of the present study show that the anti-diabetic drug troglitazone sensitizes human glioma and neuroblastoma cells to TRAIL-induced apoptosis.,0.22408982474684902,"The results of the present study show that the anti-diabetic drug troglitazone sensitizes human <span class=""disease"" id=""16820965-3-96-102"">glioma</span> and neuroblastoma cells to <span class=""gene"" id=""16820965-3-130-135"">TRAIL</span>-induced apoptosis.",CTD_human
1,0,Therapeutic,C0023418,leukemia,disease,leukemia,8743,TNFSF10,TRAIL,CTD_human,17204177,[Combined effect of recombinant mutant human TRAIL and daunorubicin in inducing apoptosis of leukemia cell and its mechanism].,0.20822744814907604,"[Combined effect of recombinant mutant human <span class=""gene"" id=""17204177-0-45-50"">TRAIL</span> and daunorubicin in inducing apoptosis of <span class=""disease"" id=""17204177-0-93-101"">leukemia</span> cell and its mechanism].",CTD_human
1,0,Therapeutic,C0027627,Neoplasm Metastasis,phenotype,metastasis,8743,TNFSF10,TRAIL,CTD_human,21209944,"The ability of resveratrol to inhibit tumor growth, metastasis and angiogenesis, and enhance the therapeutic potential of TRAIL suggests that resveratrol alone or in combination with TRAIL can be used for the management of prostate cancer.",0.20412090176319603,"The ability of resveratrol to inhibit tumor growth, <span class=""disease"" id=""21209944-11-52-62"">metastasis</span> and angiogenesis, and enhance the therapeutic potential of <span class=""gene"" id=""21209944-11-122-127"">TRAIL</span> suggests that resveratrol alone or in combination with <span class=""gene"" id=""21209944-11-183-188"">TRAIL</span> can be used for the management of prostate cancer.",CTD_human
1,0,Therapeutic,C0027819,Neuroblastoma,disease,neuroblastoma,8743,TNFSF10,TRAIL,CTD_human,16820965,The results of the present study show that the anti-diabetic drug troglitazone sensitizes human glioma and neuroblastoma cells to TRAIL-induced apoptosis.,0.212319639157638,"The results of the present study show that the anti-diabetic drug troglitazone sensitizes human glioma and <span class=""disease"" id=""16820965-3-107-120"">neuroblastoma</span> cells to <span class=""gene"" id=""16820965-3-130-135"">TRAIL</span>-induced apoptosis.",CTD_human
1,0,Therapeutic,C2239176,Liver carcinoma,disease,hepatoma,8743,TNFSF10,TRAIL,CTD_human,17326159,"RNA interference and TRAIL receptor blockage experiments revealed that in bortezomib-treated hepatoma cells TRAIL-R1/TRAIL-R2 up-regulation, enhanced TRAIL DISC formation and cFLIPL down-regulation in addition to accumulation of Bak cooperatively sensitized for TRAIL.",0.23178217470481602,"RNA interference and <span class=""gene"" id=""17326159-6-21-26"">TRAIL</span> receptor blockage experiments revealed that in bortezomib-treated <span class=""disease"" id=""17326159-6-93-101"">hepatoma</span> cells TRAIL-R1/TRAIL-R2 up-regulation, enhanced TRAIL DISC formation and cFLIPL down-regulation in addition to accumulation of Bak cooperatively sensitized for TRAIL.",CTD_human
1,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,875,CBS,cystathionine beta-synthase,CTD_human,18224302,Simvastatin reverses the hypertension of heterozygous mice lacking cystathionine beta-synthase and apolipoprotein A-I.,0.40268175530750105,"Simvastatin reverses the <span class=""disease"" id=""18224302-0-25-37"">hypertension</span> of heterozygous mice lacking <span class=""gene"" id=""18224302-0-67-94"">cystathionine beta-synthase</span> and apolipoprotein A-I.",CTD_human;HPO
1,0,Biomarker,C0024305,"Lymphoma, Non-Hodgkin",disease,NHL,875,CBS,CBS,CTD_human,17119116,"We observed a decreased risk of NHL over-all with BHMTEx8+453A>T and increased risk with CBS Ex13+41C>T, FPGS Ex15-263T>C, and SHMT1 Ex12+138C>T and Ex12+236C>T.",0.20831999270671597,"We observed a decreased risk of <span class=""disease"" id=""17119116-5-32-35"">NHL</span> over-all with BHMTEx8+453A&gt;T and increased risk with <span class=""gene"" id=""17119116-5-89-92"">CBS</span> Ex13+41C&gt;T, FPGS Ex15-263T&gt;C, and SHMT1 Ex12+138C&gt;T and Ex12+236C&gt;T.",CTD_human
3,0,Biomarker,C0598608,Hyperhomocysteinemia,disease,hyperhomocysteinemia,875,CBS,CBS,CTD_human,19028542,"We have recently demonstrated that the supplementation of catechin, a polyphenol found in the red wine, significantly reduced plasma homocysteine level in cystathionine beta synthase (CBS) deficient mice, a murine model of hyperhomocysteinemia.",0.229248706732601,"We have recently demonstrated that the supplementation of catechin, a polyphenol found in the red wine, significantly reduced plasma homocysteine level in <span class=""gene"" id=""19028542-3-155-182"">cystathionine beta synthase</span> (<span class=""gene"" id=""19028542-3-184-187"">CBS</span>) deficient mice, a murine model of <span class=""disease"" id=""19028542-3-223-243"">hyperhomocysteinemia</span>.",CTD_human
3,0,Biomarker,C0598608,Hyperhomocysteinemia,disease,hyperhomocysteinemia,875,CBS,Cb,CTD_human,19204075,"In humans, severe hyperhomocysteinemia due to genetic alterations in cystathionine beta-synthase (Cbs) or methylenetetrahydrofolate reductase (Mthfr) results in neurological abnormalities and premature death from vascular complications.",0.229248706732601,"In humans, severe <span class=""disease"" id=""19204075-2-18-38"">hyperhomocysteinemia</span> due to genetic alterations in <span class=""gene"" id=""19204075-2-69-96"">cystathionine beta-synthase</span> (<span class=""gene"" id=""19204075-2-98-100"">Cb</span>s) or methylenetetrahydrofolate reductase (Mthfr) results in neurological abnormalities and premature death from vascular complications.",CTD_human
3,0,Biomarker,C0598608,Hyperhomocysteinemia,disease,hyperhomocysteinemia,875,CBS,CBS,CTD_human,17292331,"However, chronic administration of catechin but not quercetin significantly reduced plasma homocysteine levels, attenuated the reduction of the hepatic CBS activity, and restored the decreased paraoxonase-1 gene expression and activity induced by chronic hyperhomocysteinemia.",0.229248706732601,"However, chronic administration of catechin but not quercetin significantly reduced plasma homocysteine levels, attenuated the reduction of the hepatic <span class=""gene"" id=""17292331-4-152-155"">CBS</span> activity, and restored the decreased paraoxonase-1 gene expression and activity induced by chronic <span class=""disease"" id=""17292331-4-255-275"">hyperhomocysteinemia</span>.",CTD_human
1,0,Biomarker,C0009324,Ulcerative Colitis,disease,ulcerative colitis,8767,RIPK2,RIP2,CTD_human,20452301,"The present study was aimed at describing expression of innate immunity genes (NOD2, RIP2, ?-defensins HD5 and HD6) in inflamed colon and in ileum of children with ulcerative colitis.",0.200274726784213,"The present study was aimed at describing expression of innate immunity genes (NOD2, <span class=""gene"" id=""20452301-2-85-89"">RIP2</span>, &alpha;-defensins HD5 and HD6) in inflamed colon and in ileum of children with <span class=""disease"" id=""20452301-2-164-182"">ulcerative colitis</span>.",CTD_human
1,0,Biomarker,C0036572,Seizures,phenotype,seizure,8777,MPDZ,MPDZ,CTD_human,14960011,"Our results show that MPDZ status is genetically correlated with seizure sensitivity to pentylenetetrazol, kainate and other chemiconvulsants.",0.40027472678421294,"Our results show that <span class=""gene"" id=""14960011-7-22-26"">MPDZ</span> status is genetically correlated with <span class=""disease"" id=""14960011-7-65-72"">seizure</span> sensitivity to pentylenetetrazol, kainate and other chemiconvulsants.",CTD_human;HPO
2,0,Therapeutic,C0013386,"Dyskinesia, Drug-Induced",disease,drug-induced dyskinesia,8787,RGS9,RGS9,CTD_human,24663062,These changes are compatible with a Ca2+-induced potentiation of dopamine receptor signaling which may contribute to the drug-induced dyskinesia in RGS9-deficient mice.,0.2,"These changes are compatible with a Ca2+-induced potentiation of dopamine receptor signaling which may contribute to the <span class=""disease"" id=""24663062-12-121-144"">drug-induced dyskinesia</span> in <span class=""gene"" id=""24663062-12-148-152"">RGS9</span>-deficient mice.",CTD_human
2,0,Biomarker,C0013386,"Dyskinesia, Drug-Induced",disease,drug-induced dyskinesia,8787,RGS9,RGS9,CTD_human,24663062,These changes are compatible with a Ca2+-induced potentiation of dopamine receptor signaling which may contribute to the drug-induced dyskinesia in RGS9-deficient mice.,0.2,"These changes are compatible with a Ca2+-induced potentiation of dopamine receptor signaling which may contribute to the <span class=""disease"" id=""24663062-12-121-144"">drug-induced dyskinesia</span> in <span class=""gene"" id=""24663062-12-148-152"">RGS9</span>-deficient mice.",CTD_human
1,0,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,8787,RGS9,RGS9,CTD_human,17318883,"Consistent with dopamine supersensitivity, RGS9 expression is diminished in the amphetamine-treated animal model of schizophrenia and in postmortem schizophrenia brain.",0.203231208875927,"Consistent with dopamine supersensitivity, <span class=""gene"" id=""17318883-0-43-47"">RGS9</span> expression is diminished in the amphetamine-treated animal model of <span class=""disease"" id=""17318883-0-116-129"">schizophrenia</span> and in postmortem <span class=""disease"" id=""17318883-0-148-161"">schizophrenia</span> brain.",CTD_human
1,0,Biomarker,C3463824,MYELODYSPLASTIC SYNDROME,group,myelodysplastic syndrome,8788,DLK1,Dlk1,CTD_human,18575777,"Expression of Dlk1 gene in myelodysplastic syndrome determined by microarray, and its effects on leukemia cells.",0.206839458850693,"Expression of <span class=""gene"" id=""18575777-0-14-18"">Dlk1</span> gene in <span class=""disease"" id=""18575777-0-27-51"">myelodysplastic syndrome</span> determined by microarray, and its effects on leukemia cells.",CTD_human
1,0,Biomarker,C0023434,Chronic Lymphocytic Leukemia,disease,B-CLL,8792,TNFRSF11A,RANK,CTD_human,16270354,Role of the RANKL/RANK system in the induction of interleukin-8 (IL-8) in B chronic lymphocytic leukemia (B-CLL) cells.,0.20541466777231498,"Role of the RANKL/<span class=""gene"" id=""16270354-0-18-22"">RANK</span> system in the induction of interleukin-8 (IL-8) in <span class=""disease"" id=""16270354-0-74-104"">B chronic lymphocytic leukemia</span> (<span class=""disease"" id=""16270354-0-106-111"">B-CLL</span>) cells.",CTD_human
1,0,Biomarker,C0029401,Osteitis Deformans,disease,Paget's disease of bone,8792,TNFRSF11A,TNFRSF11A,CTD_human,20436471,"Genome-wide association study identifies variants at CSF1, OPTN and TNFRSF11A as genetic risk factors for Paget's disease of bone.",0.20845101777597602,"Genome-wide association study identifies variants at CSF1, OPTN and <span class=""gene"" id=""20436471-0-68-77"">TNFRSF11A</span> as genetic risk factors for <span class=""disease"" id=""20436471-0-106-129"">Paget's disease of bone</span>.",CTD_human
1,1,Biomarker,C0242383,Age related macular degeneration,disease,AMD,8797,TNFRSF10A,TNFRSF10A,CTD_human,21909106,"In addition to CFH (rs800292, P = 4.23 × 10(-15)) and ARMS2 (rs3750847, P = 8.67 × 10(-29)) loci, we identified two new susceptibility loci for exudative AMD: TNFRSF10A-LOC389641 on chromosome 8p21 (rs13278062, combined P = 1.03 × 10(-12), odds ratio = 0.73) and REST-C4orf14-POLR2B-IGFBP7 on chromosome 4q12 (rs1713985, combined P = 2.34 × 10(-8), odds ratio = 1.30).",0.20082418035263896,"In addition to CFH (rs800292, P = 4.23 &times; 10(-15)) and ARMS2 (rs3750847, P = 8.67 &times; 10(-29)) loci, we identified two new susceptibility loci for exudative <span class=""disease"" id=""21909106-3-154-157"">AMD</span>: <span class=""gene"" id=""21909106-3-159-168"">TNFRSF10A</span>-LOC389641 on chromosome 8p21 (rs13278062, combined P = 1.03 &times; 10(-12), odds ratio = 0.73) and REST-C4orf14-POLR2B-IGFBP7 on chromosome 4q12 (rs1713985, combined P = 2.34 &times; 10(-8), odds ratio = 1.30).",CTD_human
1,0,Biomarker,C0014175,Endometriosis,disease,endometriosis,8801,SUCLG2,Suclg2,CTD_human,23284138,"Furthermore, we demonstrate a 38.6% differential gene expression overlap with endometrial samples in the midsecretory phase from women with endometriosis, concomitant with similar dysregulation in human disease candidate genes Fos, Nodal, Suclg2, and Kras, among others.",0.2,"Furthermore, we demonstrate a 38.6% differential gene expression overlap with endometrial samples in the midsecretory phase from women with <span class=""disease"" id=""23284138-11-140-153"">endometriosis</span>, concomitant with similar dysregulation in human disease candidate genes Fos, Nodal, <span class=""gene"" id=""23284138-11-239-245"">Suclg2</span>, and Kras, among others.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,8805,TRIM24,Trim24,CTD_human,18026104,"We further show that deletion of a single retinoic acid receptor alpha (Rara) allele in a Trim24-null background suppresses HCC development and restores wild-type expression of retinoic acid-responsive genes in the liver, thus demonstrating that in this genetic background Rara expresses an oncogenic activity correlating with a dysregulation of the retinoic acid signaling pathway.",0.20054945356842604,"We further show that deletion of a single retinoic acid receptor alpha (Rara) allele in a <span class=""gene"" id=""18026104-5-90-96"">Trim24</span>-null background suppresses <span class=""disease"" id=""18026104-5-124-127"">HCC</span> development and restores wild-type expression of retinoic acid-responsive genes in the liver, thus demonstrating that in this genetic background Rara expresses an oncogenic activity correlating with a dysregulation of the retinoic acid signaling pathway.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,hepatocellular carcinoma,8826,IQGAP1,IQGAP1,CTD_human,20977743,IQGAP1 and IQGAP2 are reciprocally altered in hepatocellular carcinoma.,0.201373633921065,"<span class=""gene"" id=""20977743-0-0-6"">IQGAP1</span> and IQGAP2 are reciprocally altered in <span class=""disease"" id=""20977743-0-46-70"">hepatocellular carcinoma</span>.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,8828,NRP2,NRP2,CTD_human,17427189,Association of the neuropilin-2 (NRP2) gene polymorphisms with autism in Chinese Han population.,0.285414667772315,"Association of the <span class=""gene"" id=""17427189-0-19-31"">neuropilin-2</span> (<span class=""gene"" id=""17427189-0-33-37"">NRP2</span>) gene polymorphisms with <span class=""disease"" id=""17427189-0-63-69"">autism</span> in Chinese Han population.",CTD_human
1,0,Biomarker,C0036572,Seizures,phenotype,seizures,8828,NRP2,neuropilin 2,CTD_human,18657176,Decreased number of interneurons and increased seizures in neuropilin 2 deficient mice: implications for autism and epilepsy.,0.2,"Decreased number of interneurons and increased <span class=""disease"" id=""18657176-0-47-55"">seizures</span> in <span class=""gene"" id=""18657176-0-59-71"">neuropilin 2</span> deficient mice: implications for autism and epilepsy.",CTD_human
1,0,Biomarker,C0014544,Epilepsy,disease,epileptic,8831,SYNGAP1,SYNGAP1,CTD_human,23708187,Targeted resequencing in epileptic encephalopathies identifies de novo mutations in CHD2 and SYNGAP1.,0.201373633921065,"Targeted resequencing in <span class=""disease"" id=""23708187-0-25-34"">epileptic</span> encephalopathies identifies de novo mutations in CHD2 and <span class=""gene"" id=""23708187-0-93-100"">SYNGAP1</span>.",CTD_human
1,0,Biomarker,C0003873,Rheumatoid Arthritis,disease,RA,8836,GGH,?-glutamyl hydrolase,CTD_human,23897011,"Concurrent with evidence of an immune-activation gene signature in MTX-naive RA patients, significant up-regulation of the folate-metabolizing enzymes ?-glutamyl hydrolase and dihydrofolate reductase, as well as the MTX/folate efflux transporters ABCC2 and ABCC5, was observed in the MTX-naive RA group compared to healthy controls.",0.21045229444579103,"Concurrent with evidence of an immune-activation gene signature in MTX-naive <span class=""disease"" id=""23897011-6-77-79"">RA</span> patients, significant up-regulation of the folate-metabolizing enzymes <span class=""gene"" id=""23897011-6-151-171"">&gamma;-glutamyl hydrolase</span> and dihydrofolate reductase, as well as the MTX/folate efflux transporters ABCC2 and ABCC5, was observed in the MTX-naive <span class=""disease"" id=""23897011-6-294-296"">RA</span> group compared to healthy controls.",CTD_human
1,0,Biomarker,C0019829,Hodgkin Disease,disease,Hodgkin lymphoma,8837,CFLAR,c-FLIP,CTD_human,17659339,Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: a gene expression profiling study with implications for potential combination therapies.,0.207114185634906,"Bortezomib induces caspase-dependent apoptosis in <span class=""disease"" id=""17659339-0-50-66"">Hodgkin lymphoma</span> cell lines and is associated with reduced <span class=""gene"" id=""17659339-0-109-115"">c-FLIP</span> expression: a gene expression profiling study with implications for potential combination therapies.",CTD_human
1,0,Biomarker,C1955906,"Lymphoma, Extranodal NK-T-Cell",disease,NKTL,8837,CFLAR,c-FLIP,CTD_human,15924153,"Moreover, immunohistochemistry on paraffin-embedded tissue revealed c-FLIP expression in 39% (14 of 36) of NKTL patients.",0.200274726784213,"Moreover, immunohistochemistry on paraffin-embedded tissue revealed <span class=""gene"" id=""15924153-8-68-74"">c-FLIP</span> expression in 39% (14 of 36) of <span class=""disease"" id=""15924153-8-107-111"">NKTL</span> patients.",CTD_human
3,0,Biomarker,C0017636,Glioblastoma,disease,glioblastomas,8842,PROM1,CD133,CTD_human,18679414,"Taken together, our results indicate that DNA hypomethylation is an important determinant of CD133 expression in glioblastomas, and this epigenetic event may be associated with the development of BTICs expressing CD133.",0.22935269977885,"Taken together, our results indicate that DNA hypomethylation is an important determinant of <span class=""gene"" id=""18679414-8-93-98"">CD133</span> expression in <span class=""disease"" id=""18679414-8-113-126"">glioblastomas</span>, and this epigenetic event may be associated with the development of BTICs expressing <span class=""gene"" id=""18679414-8-213-218"">CD133</span>.",CTD_human
3,0,Biomarker,C0017636,Glioblastoma,disease,glioblastoma,8842,PROM1,CD133,CTD_human,18829568,Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors.,0.22935269977885,"Abnormal DNA methylation of <span class=""gene"" id=""18829568-0-28-33"">CD133</span> in colorectal and <span class=""disease"" id=""18829568-0-52-64"">glioblastoma</span> tumors.",CTD_human
2,0,Biomarker,C0003123,Anorexia,disease,anorexia,885,CCK,cholecystokinin,CTD_human,24385417,"Role of cholecystokinin in anorexia induction following oral exposure to the 8-ketotrichothecenes deoxynivalenol, 15-acetyldeoxynivalenol, 3-acetyldeoxynivalenol, fusarenon X, and nivalenol.",0.200274726784213,"Role of <span class=""gene"" id=""24385417-0-8-23"">cholecystokinin</span> in <span class=""disease"" id=""24385417-0-27-35"">anorexia</span> induction following oral exposure to the 8-ketotrichothecenes deoxynivalenol, 15-acetyldeoxynivalenol, 3-acetyldeoxynivalenol, fusarenon X, and nivalenol.",CTD_human
2,0,Biomarker,C0003123,Anorexia,disease,anorexia,885,CCK,CCK,CTD_human,22903826,Orolingual exposure to DON induced plasma PYY and CCK elevation and anorexia comparable with that observed for ip exposure.,0.200274726784213,"Orolingual exposure to DON induced plasma PYY and <span class=""gene"" id=""22903826-9-50-53"">CCK</span> elevation and <span class=""disease"" id=""22903826-9-68-76"">anorexia</span> comparable with that observed for ip exposure.",CTD_human
2,0,Therapeutic,C0007370,Catalepsy,disease,catalepsy,885,CCK,CCK,CTD_human,4040614,"Furthermore, the catalepsy induced by CCK-8-SE was of short duration.With icv. administration only 40 pmole CCK-8-NS induced significant catalepsy.When 0.2, 0.4 and 0.8 mumole/kg sc. doses of CCK-8-NS or 0.4 pmole icv. dose of CCK-8-SE or CCK-8-NS was given in combination with intraperitoneal (ip.) administration of 1.0 mg/kg haloperidol, the total duration of catalepsy was suppressed.Finally, CCK-8-SE sc. when given in combination with haloperidol ip., exerted a biphasic, synergistic-antagonistic effect on the haloperidol-induced catalepsy.",0.2,"Furthermore, the <span class=""disease"" id=""4040614-3-17-26"">catalepsy</span> induced by <span class=""gene"" id=""4040614-3-38-41"">CCK</span>-8-SE was of short duration.With icv. administration only 40 pmole <span class=""gene"" id=""4040614-3-108-111"">CCK</span>-8-NS induced significant <span class=""disease"" id=""4040614-3-137-146"">catalepsy</span>.When 0.2, 0.4 and 0.8 mumole/kg sc. doses of <span class=""gene"" id=""4040614-3-192-195"">CCK</span>-8-NS or 0.4 pmole icv. dose of <span class=""gene"" id=""4040614-3-227-230"">CCK</span>-8-SE or <span class=""gene"" id=""4040614-3-239-242"">CCK</span>-8-NS was given in combination with intraperitoneal (ip.) administration of 1.0 mg/kg haloperidol, the total duration of <span class=""disease"" id=""4040614-3-363-372"">catalepsy</span> was suppressed.Finally, <span class=""gene"" id=""4040614-3-397-400"">CCK</span>-8-SE sc. when given in combination with haloperidol ip., exerted a biphasic, synergistic-antagonistic effect on the haloperidol-induced <span class=""disease"" id=""4040614-3-537-546"">catalepsy</span>.",CTD_human
2,0,Therapeutic,C0007370,Catalepsy,disease,catalepsy,885,CCK,cholecystokinin,CTD_human,2862602,Inhibition of haloperidol-induced catalepsy by cholecystokinin octapeptides after central administration to rats.,0.2,"Inhibition of haloperidol-induced <span class=""disease"" id=""2862602-0-34-43"">catalepsy</span> by <span class=""gene"" id=""2862602-0-47-62"">cholecystokinin</span> octapeptides after central administration to rats.",CTD_human
1,0,Biomarker,C0030305,Pancreatitis,disease,pancreatitis,885,CCK,cholecystokinin,CTD_human,16499907,Beneficial effect of resveratrol on cholecystokinin-induced experimental pancreatitis.,0.20082418035263896,"Beneficial effect of resveratrol on <span class=""gene"" id=""16499907-0-36-51"">cholecystokinin</span>-induced experimental <span class=""disease"" id=""16499907-0-73-85"">pancreatitis</span>.",CTD_human
1,0,Therapeutic,C0036572,Seizures,phenotype,seizures,885,CCK,CCK,CTD_human,6265841,"Anticonvulsant effects of caerulein, cholecystokinin octapeptide (CCK-8) and diazepam against seizures produced in mice by harman, thiosemicarbazide and isoniazid.",0.200274726784213,"Anticonvulsant effects of caerulein, <span class=""gene"" id=""6265841-0-37-52"">cholecystokinin</span> octapeptide (<span class=""gene"" id=""6265841-0-66-69"">CCK</span>-8) and diazepam against <span class=""disease"" id=""6265841-0-94-102"">seizures</span> produced in mice by harman, thiosemicarbazide and isoniazid.",CTD_human
6,0,Biomarker,C0038358,Gastric ulcer,disease,gastric ulcerations,885,CCK,CCK,CTD_human,11787760,"Leptin, a product of ob gene controlling food intake, has recently been detected in the stomach and shown to be released by CCK and implicated in gastroprotection against various noxious agents but it is unknown whether centrally applied leptin influences ischemia-reperfusion (I/R)-induced gastric erosions that progress into deeper gastric ulcerations.",0.2,"Leptin, a product of ob gene controlling food intake, has recently been detected in the stomach and shown to be released by <span class=""gene"" id=""11787760-1-124-127"">CCK</span> and implicated in gastroprotection against various noxious agents but it is unknown whether centrally applied leptin influences ischemia-reperfusion (I/R)-induced gastric erosions that progress into deeper <span class=""disease"" id=""11787760-1-334-353"">gastric ulcerations</span>.",CTD_human
6,0,Therapeutic,C0038358,Gastric ulcer,disease,gastric ulcerations,885,CCK,CCK,CTD_human,11787760,"Leptin, a product of ob gene controlling food intake, has recently been detected in the stomach and shown to be released by CCK and implicated in gastroprotection against various noxious agents but it is unknown whether centrally applied leptin influences ischemia-reperfusion (I/R)-induced gastric erosions that progress into deeper gastric ulcerations.",0.2,"Leptin, a product of ob gene controlling food intake, has recently been detected in the stomach and shown to be released by <span class=""gene"" id=""11787760-1-124-127"">CCK</span> and implicated in gastroprotection against various noxious agents but it is unknown whether centrally applied leptin influences ischemia-reperfusion (I/R)-induced gastric erosions that progress into deeper <span class=""disease"" id=""11787760-1-334-353"">gastric ulcerations</span>.",CTD_human
2,0,Therapeutic,C0424295,Hyperactive behavior,phenotype,hyperactivity,885,CCK,CCK-8,CTD_human,3561887,"Local treatment with the opioid antagonist naloxone antagonized this inhibitory action of CCK-8 (ED50, 18 ng), but did not change the blocking effect of haloperidol on the apomorphine-induced hyperactivity.",0.200274726784213,"Local treatment with the opioid antagonist naloxone antagonized this inhibitory action of <span class=""gene"" id=""3561887-2-90-95"">CCK-8</span> (ED50, 18 ng), but did not change the blocking effect of haloperidol on the apomorphine-induced <span class=""disease"" id=""3561887-2-192-205"">hyperactivity</span>.",CTD_human
2,0,Therapeutic,C0424295,Hyperactive behavior,phenotype,hyperactivity,885,CCK,CCK,CTD_human,3735805,Bilateral injection of CCK-8 (1 microgram per side) into the nucleus caudatus significantly reduced the locomotor hyperactivity induced by methamphetamine.,0.200274726784213,"Bilateral injection of <span class=""gene"" id=""3735805-2-23-26"">CCK</span>-8 (1 microgram per side) into the nucleus caudatus significantly reduced the locomotor <span class=""disease"" id=""3735805-2-114-127"">hyperactivity</span> induced by methamphetamine.",CTD_human
1,0,Biomarker,C0025312,Meningomyelocele,disease,myelomeningocele,8854,ALDH1A2,ALDH1A2,CTD_human,16237707,These results may suggest that polymorphisms in ALDH1A2 may influence the risk for lumbosacral myelomeningocele in humans.,0.20300763924902696,"These results may suggest that polymorphisms in <span class=""gene"" id=""16237707-6-48-55"">ALDH1A2</span> may influence the risk for lumbosacral <span class=""disease"" id=""16237707-6-95-111"">myelomeningocele</span> in humans.",CTD_human
1,0,Biomarker,C0033578,Prostatic Neoplasms,group,prostate tumors,8854,ALDH1A2,ALDH1a2,CTD_human,16166285,"Using bisulfite sequencing, we determined that the ALDH1a2 promoter region was significantly hypermethylated in primary prostate tumors compared with normal prostate specimens (P = 0.01).",0.200274726784213,"Using bisulfite sequencing, we determined that the <span class=""gene"" id=""16166285-6-51-58"">ALDH1a2</span> promoter region was significantly hypermethylated in primary <span class=""disease"" id=""16166285-6-120-135"">prostate tumors</span> compared with normal prostate specimens (P = 0.01).",CTD_human
1,0,Biomarker,C0011849,Diabetes Mellitus,group,diabetes,8856,NR1I2,PXR,CTD_human,20869355,"CAR and PXR are involved in the development of certain diseases, including diabetes, metabolic syndrome and obesity.",0.200274726784213,"CAR and <span class=""gene"" id=""20869355-2-8-11"">PXR</span> are involved in the development of certain diseases, including <span class=""disease"" id=""20869355-2-75-83"">diabetes</span>, metabolic syndrome and obesity.",CTD_human
1,0,Biomarker,C0015695,Fatty Liver,disease,hepatic steatosis,8856,NR1I2,PXR,CTD_human,25182422,"In mice, both ligand-dependent activation and knockout of PXR were previously shown to promote hepatic steatosis.",0.20054945356842604,"In mice, both ligand-dependent activation and knockout of <span class=""gene"" id=""25182422-2-58-61"">PXR</span> were previously shown to promote <span class=""disease"" id=""25182422-2-95-112"">hepatic steatosis</span>.",CTD_human
1,0,Biomarker,C0022353,Neonatal Jaundice,phenotype,neonatal jaundice,8856,NR1I2,PXR,CTD_human,22371261,PXR is a key regulator of pregnancy induced glucuronidation capacity in addition to modulating the severity of neonatal jaundice.,0.200274726784213,"<span class=""gene"" id=""22371261-11-0-3"">PXR</span> is a key regulator of pregnancy induced glucuronidation capacity in addition to modulating the severity of <span class=""disease"" id=""22371261-11-111-128"">neonatal jaundice</span>.",CTD_human
1,0,Biomarker,C0028754,Obesity,disease,obesity,8856,NR1I2,PXR,CTD_human,20869355,"CAR and PXR are involved in the development of certain diseases, including diabetes, metabolic syndrome and obesity.",0.20054945356842604,"CAR and <span class=""gene"" id=""20869355-2-8-11"">PXR</span> are involved in the development of certain diseases, including diabetes, metabolic syndrome and <span class=""disease"" id=""20869355-2-108-115"">obesity</span>.",CTD_human
1,0,Biomarker,C0029463,Osteosarcoma,disease,osteosarcoma,8856,NR1I2,PXR,CTD_human,17279585,Cytotoxicity assays showed that the resistance of the osteosarcoma cell lines to etoposide correlated with PXR protein expression levels and activation of P450 3A4 and could be prevented by ketoconazole.,0.203557092817453,"Cytotoxicity assays showed that the resistance of the <span class=""disease"" id=""17279585-8-54-66"">osteosarcoma</span> cell lines to etoposide correlated with <span class=""gene"" id=""17279585-8-107-110"">PXR</span> protein expression levels and activation of P450 3A4 and could be prevented by ketoconazole.",CTD_human
1,0,Biomarker,C0085682,Hypophosphatemia,phenotype,hypophosphatemia,8856,NR1I2,PXR,CTD_human,19898264,Nuclear xenobiotic receptor PXR-null mouse exhibits hypophosphatemia and represses the Na/Pi-cotransporter SLC34A2.,0.2,"Nuclear xenobiotic receptor <span class=""gene"" id=""19898264-0-28-31"">PXR</span>-null mouse exhibits <span class=""disease"" id=""19898264-0-52-68"">hypophosphatemia</span> and represses the Na/Pi-cotransporter SLC34A2.",CTD_human
1,0,Biomarker,C0524620,Metabolic Syndrome X,disease,metabolic syndrome,8856,NR1I2,PXR,CTD_human,20869355,"CAR and PXR are involved in the development of certain diseases, including diabetes, metabolic syndrome and obesity.",0.20054945356842604,"CAR and <span class=""gene"" id=""20869355-2-8-11"">PXR</span> are involved in the development of certain diseases, including diabetes, <span class=""disease"" id=""20869355-2-85-103"">metabolic syndrome</span> and obesity.",CTD_human
1,0,Biomarker,C0023473,"Myeloid Leukemia, Chronic",disease,chronic myeloid leukemia,8863,PER3,hPER3,CTD_human,16999817,Downregulation of circadian clock genes in chronic myeloid leukemia: alternative methylation pattern of hPER3.,0.20300763924902696,"Downregulation of circadian clock genes in <span class=""disease"" id=""16999817-0-43-67"">chronic myeloid leukemia</span>: alternative methylation pattern of <span class=""gene"" id=""16999817-0-104-109"">hPER3</span>.",CTD_human
1,0,Biomarker,C0023473,"Myeloid Leukemia, Chronic",disease,CML,8864,PER2,hPER2,CTD_human,16999817,The CpG sites of the hPER2 gene were also methylated in 40% of the CML patients.,0.200274726784213,"The CpG sites of the <span class=""gene"" id=""16999817-5-21-26"">hPER2</span> gene were also methylated in 40% of the <span class=""disease"" id=""16999817-5-67-70"">CML</span> patients.",CTD_human
1,0,Biomarker,C0028768,Obsessive-Compulsive Disorder,disease,OCD,887,CCKBR,CCK-B,CTD_human,8878350,"The panic-inducing properties of pentagastrin are not specific for panic disorder patients, which might be indicative of a common neurobiological dysfunction in panic disorder and OCD at the level of CCK-B receptors.",0.2,"The panic-inducing properties of pentagastrin are not specific for panic disorder patients, which might be indicative of a common neurobiological dysfunction in panic disorder and <span class=""disease"" id=""8878350-7-180-183"">OCD</span> at the level of <span class=""gene"" id=""8878350-7-200-205"">CCK-B</span> receptors.",CTD_human
1,0,Biomarker,C0030319,Panic Disorder,disease,panic disorder,887,CCKBR,CCK-B,CTD_human,8878350,"The panic-inducing properties of pentagastrin are not specific for panic disorder patients, which might be indicative of a common neurobiological dysfunction in panic disorder and OCD at the level of CCK-B receptors.",0.210568964137734,"The panic-inducing properties of pentagastrin are not specific for <span class=""disease"" id=""8878350-7-67-81"">panic disorder</span> patients, which might be indicative of a common neurobiological dysfunction in <span class=""disease"" id=""8878350-7-161-175"">panic disorder</span> and OCD at the level of <span class=""gene"" id=""8878350-7-200-205"">CCK-B</span> receptors.",CTD_human
1,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,8870,IER3,IEX-1,CTD_human,20713914,Our results suggest that hypertension in IEX-1 knockout mice may arise primarily from impaired cAMP signaling induced by overproduction of mitochondrial reactive oxygen species in vascular smooth muscle cells and demonstrate a causal relationship between mitochondrial dysfunction and cAMP-dependent vasorelaxation.,0.200274726784213,"Our results suggest that <span class=""disease"" id=""20713914-6-25-37"">hypertension</span> in <span class=""gene"" id=""20713914-6-41-46"">IEX-1</span> knockout mice may arise primarily from impaired cAMP signaling induced by overproduction of mitochondrial reactive oxygen species in vascular smooth muscle cells and demonstrate a causal relationship between mitochondrial dysfunction and cAMP-dependent vasorelaxation.",CTD_human
1,0,Biomarker,C0033860,Psoriasis,disease,psoriasis,8875,VNN2,pantetheinase,CTD_human,19322213,"We hypothesize that increased levels of pantetheinase activity are part of the inflammatory-regenerative epidermal differentiation program, and may contribute to the phenotype observed in psoriasis.",0.200274726784213,"We hypothesize that increased levels of <span class=""gene"" id=""19322213-7-40-53"">pantetheinase</span> activity are part of the inflammatory-regenerative epidermal differentiation program, and may contribute to the phenotype observed in <span class=""disease"" id=""19322213-7-188-197"">psoriasis</span>.",CTD_human
1,0,Therapeutic,C0021390,Inflammatory Bowel Diseases,group,inflammatory bowel disease,8876,VNN1,pantetheinase,CTD_human,17145956,"Thus, the Vanin-1/pantetheinase activity might be a new target for therapeutic intervention in inflammatory bowel disease.",0.200274726784213,"Thus, the <span class=""gene"" id=""17145956-7-10-17"">Vanin-1</span>/<span class=""gene"" id=""17145956-7-18-31"">pantetheinase</span> activity might be a new target for therapeutic intervention in <span class=""disease"" id=""17145956-7-95-121"">inflammatory bowel disease</span>.",CTD_human
1,0,Biomarker,C0033860,Psoriasis,disease,psoriasis,8876,VNN1,pantetheinase,CTD_human,19322213,"We hypothesize that increased levels of pantetheinase activity are part of the inflammatory-regenerative epidermal differentiation program, and may contribute to the phenotype observed in psoriasis.",0.200274726784213,"We hypothesize that increased levels of <span class=""gene"" id=""19322213-7-40-53"">pantetheinase</span> activity are part of the inflammatory-regenerative epidermal differentiation program, and may contribute to the phenotype observed in <span class=""disease"" id=""19322213-7-188-197"">psoriasis</span>.",CTD_human
1,0,Biomarker,C0009324,Ulcerative Colitis,disease,ulcerative colitis,8877,SPHK1,SphK1,CTD_human,24055189,Targeting sphingosine kinase 1 (SphK1) and apoptosis by colon-specific delivery formula of resveratrol in treatment of experimental ulcerative colitis in rats.,0.2,"Targeting <span class=""gene"" id=""24055189-0-10-30"">sphingosine kinase 1</span> (<span class=""gene"" id=""24055189-0-32-37"">SphK1</span>) and apoptosis by colon-specific delivery formula of resveratrol in treatment of experimental <span class=""disease"" id=""24055189-0-132-150"">ulcerative colitis</span> in rats.",CTD_human
1,0,Biomarker,C0023418,leukemia,disease,leukemia,8877,SPHK1,sphingosine kinase 1,CTD_human,18283525,Implications of sphingosine kinase 1 expression level for the cellular sphingolipid rheostat: relevance as a marker for daunorubicin sensitivity of leukemia cells.,0.200274726784213,"Implications of <span class=""gene"" id=""18283525-0-16-36"">sphingosine kinase 1</span> expression level for the cellular sphingolipid rheostat: relevance as a marker for daunorubicin sensitivity of <span class=""disease"" id=""18283525-0-148-156"">leukemia</span> cells.",CTD_human
1,0,Biomarker,C3463824,MYELODYSPLASTIC SYNDROME,group,myelodysplastic syndromes,8877,SPHK1,SPHK1,CTD_human,18283525,We recently reported increased sphingosine kinase 1 (SPHK1) and decreased neutral sphingomyelinase 2 (NSMase2) gene expression in myelodysplastic syndromes and acute leukemia.,0.2,"We recently reported increased <span class=""gene"" id=""18283525-1-31-51"">sphingosine kinase 1</span> (<span class=""gene"" id=""18283525-1-53-58"">SPHK1</span>) and decreased neutral sphingomyelinase 2 (NSMase2) gene expression in <span class=""disease"" id=""18283525-1-130-155"">myelodysplastic syndromes</span> and acute leukemia.",CTD_human
1,0,Biomarker,C0002736,Amyotrophic Lateral Sclerosis,disease,ALS,8878,SQSTM1,Sequestosome 1,CTD_human,19765191,Sequestosome 1/p62 links familial ALS mutant SOD1 to LC3 via an ubiquitin-independent mechanism.,0.60439562854741,"<span class=""gene"" id=""19765191-0-0-14"">Sequestosome 1</span>/p62 links familial <span class=""disease"" id=""19765191-0-34-37"">ALS</span> mutant SOD1 to LC3 via an ubiquitin-independent mechanism.",CTD_human;HPO;ORPHANET
1,0,Biomarker,C0242383,Age related macular degeneration,disease,AMD,8878,SQSTM1,SQSTM1,CTD_human,23922739,"Interestingly, when compared to human controls, AMD donor samples show strong SQSTM1/p62 rather than ELAVL1/HuR accumulation in the drusen rich macular area suggesting impaired autophagy in the pathology of AMD.",0.2,"Interestingly, when compared to human controls, <span class=""disease"" id=""23922739-11-48-51"">AMD</span> donor samples show strong <span class=""gene"" id=""23922739-11-78-84"">SQSTM1</span>/p62 rather than ELAVL1/HuR accumulation in the drusen rich macular area suggesting impaired autophagy in the pathology of <span class=""disease"" id=""23922739-11-207-210"">AMD</span>.",CTD_human
1,0,Biomarker,C1458155,Mammary Neoplasms,group,breast tumors,8894,EIF2S2,EIF2S2,CTD_human,25151356,"The genes identified include eight that are essential for cell proliferation (FGD5, METTL6, CPT1A, DTX3, MRPS23, EIF2S2, EIF6 and SLC2A10) and are uniquely amplified in patients with highly proliferative luminal breast tumors, a clinical subset of patients for which few therapeutic options are effective.",0.2,"The genes identified include eight that are essential for cell proliferation (FGD5, METTL6, CPT1A, DTX3, MRPS23, <span class=""gene"" id=""25151356-4-113-119"">EIF2S2</span>, EIF6 and SLC2A10) and are uniquely amplified in patients with highly proliferative luminal <span class=""disease"" id=""25151356-4-212-225"">breast tumors</span>, a clinical subset of patients for which few therapeutic options are effective.",CTD_human
3,6,Biomarker,C0796254,"DANDY-WALKER MALFORMATION WITH MENTAL RETARDATION, BASAL GANGLIA DISEASE, AND SEIZURES",disease,Pettigrew syndrome,8905,AP1S2,AP1S2,CTD_human,23756445,"AP1S2 is mutated in X-linked Dandy-Walker malformation with intellectual disability, basal ganglia disease and seizures (Pettigrew syndrome).",0.48027472678421296,"<span class=""gene"" id=""23756445-0-0-5"">AP1S2</span> is mutated in X-linked Dandy-Walker malformation with intellectual disability, basal ganglia disease and seizures (<span class=""disease"" id=""23756445-0-121-139"">Pettigrew syndrome</span>).",CTD_human;ORPHANET
1,0,Biomarker,C0032460,Polycystic Ovary Syndrome,disease,PCOS,891,CCNB1,cyclin B1,CTD_human,21411543,"Progesterone-regulated genes, including mitogen-inducible gene 6 (MIG6), leukemia inhibitory factor (LIF), GRB2-associated binding protein 1 (GAB1), S100P, and claudin-4 were significantly lower in PCOS endometrium; whereas cell proliferation genes, such as Anillin and cyclin B1, were up-regulated.",0.200274726784213,"Progesterone-regulated genes, including mitogen-inducible gene 6 (MIG6), leukemia inhibitory factor (LIF), GRB2-associated binding protein 1 (GAB1), S100P, and claudin-4 were significantly lower in <span class=""disease"" id=""21411543-11-198-202"">PCOS</span> endometrium; whereas cell proliferation genes, such as Anillin and <span class=""gene"" id=""21411543-11-270-279"">cyclin B1</span>, were up-regulated.",CTD_human
1,0,Biomarker,C0009324,Ulcerative Colitis,disease,ulcerative colitis,8924,HERC2,HERC2,CTD_human,18438405,"Among these loci, we identified variants in 3p21.31, NKX2-3 and CCNY as susceptibility factors for both diseases, whereas variants in PTPN2, HERC2 and STAT3 were associated only with ulcerative colitis in our sample collection.",0.21022872481889102,"Among these loci, we identified variants in 3p21.31, NKX2-3 and CCNY as susceptibility factors for both diseases, whereas variants in PTPN2, <span class=""gene"" id=""18438405-2-141-146"">HERC2</span> and STAT3 were associated only with <span class=""disease"" id=""18438405-2-183-201"">ulcerative colitis</span> in our sample collection.",CTD_human
3,1,Biomarker,C1275808,Congenital central hypoventilation,disease,congenital central hypoventilation syndrome,8929,PHOX2B,PHOX2b,CTD_human,14608649,Idiopathic congenital central hypoventilation syndrome: analysis of genes pertinent to early autonomic nervous system embryologic development and identification of mutations in PHOX2b.,0.710363647978394,"Idiopathic <span class=""disease"" id=""14608649-0-11-54"">congenital central hypoventilation syndrome</span>: analysis of genes pertinent to early autonomic nervous system embryologic development and identification of mutations in <span class=""gene"" id=""14608649-0-177-183"">PHOX2b</span>.",CTD_human;ORPHANET;UNIPROT
3,1,Biomarker,C1275808,Congenital central hypoventilation,disease,congenital central hypoventilation syndrome,8929,PHOX2B,PHOX2B,CTD_human,12640453,Polyalanine expansion and frameshift mutations of the paired-like homeobox gene PHOX2B in congenital central hypoventilation syndrome.,0.710363647978394,"Polyalanine expansion and frameshift mutations of the paired-like homeobox gene <span class=""gene"" id=""12640453-0-80-86"">PHOX2B</span> in <span class=""disease"" id=""12640453-0-90-133"">congenital central hypoventilation syndrome</span>.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0004352,Autistic Disorder,disease,autistic,8930,MBD4,MBD4,CTD_human,19921286,"We evaluated 226 autistic individuals for alterations in the four genes most homologous to MECP2: MBD1, MBD2, MBD3, and MBD4.",0.2,"We evaluated 226 <span class=""disease"" id=""19921286-3-17-25"">autistic</span> individuals for alterations in the four genes most homologous to MECP2: MBD1, MBD2, MBD3, and <span class=""gene"" id=""19921286-3-120-124"">MBD4</span>.",CTD_human
1,0,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,T2D,894,CCND2,CCND2,CTD_human,24464100,"A low-frequency (1.47%) variant in intron 1 of CCND2, rs76895963[G], reduces risk of T2D by half (odds ratio (OR) = 0.53, P = 5.0 × 10(-21)) and is correlated with increased CCND2 expression.",0.202956482091714,"A low-frequency (1.47%) variant in intron 1 of <span class=""gene"" id=""24464100-2-47-52"">CCND2</span>, rs76895963[G], reduces risk of <span class=""disease"" id=""24464100-2-85-88"">T2D</span> by half (odds ratio (OR) = 0.53, P = 5.0 &times; 10(-21)) and is correlated with increased <span class=""gene"" id=""24464100-2-174-179"">CCND2</span> expression.",CTD_human
1,1,Biomarker,C0268474,Hydroxykynureninuria,phenotype,Xanthurenic aciduria,8942,KYNU,kynureninase,CTD_human,17334708,Xanthurenic aciduria due to a mutation in KYNU encoding kynureninase.,0.600274726784213,"<span class=""disease"" id=""17334708-0-0-20"">Xanthurenic aciduria</span> due to a mutation in <span class=""gene"" id=""17334708-0-42-46"">KYNU</span> encoding <span class=""gene"" id=""17334708-0-56-68"">kynureninase</span>.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0005695,Bladder Neoplasm,disease,bladder cancer,898,CCNE1,CCNE1,CTD_human,20972438,"In a combined analysis, we identified three new regions associated with bladder cancer on chromosomes 22q13.1, 19q12 and 2q37.1: rs1014971, (P = 8 × 10?¹²) maps to a non-genic region of chromosome 22q13.1, rs8102137 (P = 2 × 10?¹¹) on 19q12 maps to CCNE1 and rs11892031 (P = 1 × 10??) maps to the UGT1A cluster on 2q37.1.",0.201098907136852,"In a combined analysis, we identified three new regions associated with <span class=""disease"" id=""20972438-2-72-86"">bladder cancer</span> on chromosomes 22q13.1, 19q12 and 2q37.1: rs1014971, (P = 8 &times; 10?¹²) maps to a non-genic region of chromosome 22q13.1, rs8102137 (P = 2 &times; 10?¹¹) on 19q12 maps to <span class=""gene"" id=""20972438-2-249-254"">CCNE1</span> and rs11892031 (P = 1 &times; 10??) maps to the UGT1A cluster on 2q37.1.",CTD_human
2,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,898,CCNE1,CCNE1,CTD_human,22634754,"We also identified recurrent HBV integration events (in ? 4 HCCs) that were validated by RNA sequencing (RNA-seq) and Sanger sequencing at the known and putative cancer-related TERT, MLL4 and CCNE1 genes, which showed upregulated gene expression in tumor versus normal tissue.",0.20383181960166602,"We also identified recurrent HBV integration events (in &ge; 4 <span class=""disease"" id=""22634754-5-60-63"">HCC</span>s) that were validated by RNA sequencing (RNA-seq) and Sanger sequencing at the known and putative cancer-related TERT, MLL4 and <span class=""gene"" id=""22634754-5-192-197"">CCNE1</span> genes, which showed upregulated gene expression in tumor versus normal tissue.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,89885,FATE1,FATE,CTD_human,15580283,"FATE/BJ-HCC-2 mRNA transcript was detected in the peripheral blood mononuclear cells (PBMCs) of 46.67% patients whose resected HCC tissue samples were positive for FATE/BJ-HCC-2 mRNA, which implicated tumor cell dissemination in blood circulation and may relate to the metastasis of HCC.",0.2,"<span class=""gene"" id=""15580283-13-0-4"">FATE</span>/BJ-HCC-2 mRNA transcript was detected in the peripheral blood mononuclear cells (PBMCs) of 46.67% patients whose resected <span class=""disease"" id=""15580283-13-127-130"">HCC</span> tissue samples were positive for <span class=""gene"" id=""15580283-13-164-168"">FATE</span>/BJ-HCC-2 mRNA, which implicated tumor cell dissemination in blood circulation and may relate to the metastasis of <span class=""disease"" id=""15580283-13-283-286"">HCC</span>.",CTD_human
1,0,Biomarker,C0004096,Asthma,disease,asthma,8989,TRPA1,TRPA1,CTD_human,19458046,TRPA1 may represent a promising pharmacological target for the treatment of asthma and other allergic inflammatory conditions.,0.2,"<span class=""gene"" id=""19458046-13-0-5"">TRPA1</span> may represent a promising pharmacological target for the treatment of <span class=""disease"" id=""19458046-13-76-82"">asthma</span> and other allergic inflammatory conditions.",CTD_human
3,0,Biomarker,C0020429,Hyperalgesia,phenotype,hyperalgesia,8989,TRPA1,TRPA1,CTD_human,18234885,"Because TRPV1 and TRPA1 channels play important roles in controlling hyperalgesia in inflammatory pain models, we investigated their modulation by WIN and AM1241.",0.28,"Because TRPV1 and <span class=""gene"" id=""18234885-2-18-23"">TRPA1</span> channels play important roles in controlling <span class=""disease"" id=""18234885-2-69-81"">hyperalgesia</span> in inflammatory pain models, we investigated their modulation by WIN and AM1241.",CTD_human
1,0,Biomarker,C0030193,Pain,phenotype,pain,8989,TRPA1,TRPA1,CTD_human,20601631,"Animal studies using TRPA1 antagonists or TRPA1-deficient mice confirmed the role of TRPA1 in chemically induced respiratory reflexes, pain, and inflammation in vivo.",0.40714289638954104,"Animal studies using <span class=""gene"" id=""20601631-9-21-26"">TRPA1</span> antagonists or <span class=""gene"" id=""20601631-9-42-47"">TRPA1</span>-deficient mice confirmed the role of <span class=""gene"" id=""20601631-9-85-90"">TRPA1</span> in chemically induced respiratory reflexes, <span class=""disease"" id=""20601631-9-135-139"">pain</span>, and inflammation in vivo.",CTD_human;HPO
2,0,Biomarker,C0878773,Overactive Bladder,disease,OAB,8989,TRPA1,TRPA1,CTD_human,21367919,The present data show that the TRPA1 activation and upregulation seem to exert an important role in OAB following SCI.,0.28,"The present data show that the <span class=""gene"" id=""21367919-10-31-36"">TRPA1</span> activation and upregulation seem to exert an important role in <span class=""disease"" id=""21367919-10-100-103"">OAB</span> following SCI.",CTD_human
2,0,Therapeutic,C0878773,Overactive Bladder,disease,OAB,8989,TRPA1,TRPA1,CTD_human,21367919,The present data show that the TRPA1 activation and upregulation seem to exert an important role in OAB following SCI.,0.28,"The present data show that the <span class=""gene"" id=""21367919-10-31-36"">TRPA1</span> activation and upregulation seem to exert an important role in <span class=""disease"" id=""21367919-10-100-103"">OAB</span> following SCI.",CTD_human
2,0,Biomarker,C0001418,Adenocarcinoma,group,adenocarcinomas,8991,SELENBP1,selenium-binding protein 1,CTD_human,14991897,Reduced selenium-binding protein 1 expression is associated with poor outcome in lung adenocarcinomas.,0.20054945356842604,"Reduced <span class=""gene"" id=""14991897-0-8-34"">selenium-binding protein 1</span> expression is associated with poor outcome in lung <span class=""disease"" id=""14991897-0-86-101"">adenocarcinomas</span>.",CTD_human
1,0,Biomarker,C0009404,Colorectal Neoplasms,group,colorectal tumors,8991,SELENBP1,selenium-binding protein 1,CTD_human,18435490,We identified approximately 3.5-fold significant downregulation of selenium-binding protein 1 (SBP1) in colorectal tumors compared to normal mucosa (p = 0.003).,0.205740551713841,"We identified approximately 3.5-fold significant downregulation of <span class=""gene"" id=""18435490-2-67-93"">selenium-binding protein 1</span> (SBP1) in <span class=""disease"" id=""18435490-2-104-121"">colorectal tumors</span> compared to normal mucosa (p = 0.003).",CTD_human
1,0,Biomarker,C0033975,Psychotic Disorders,group,psychosis,8991,SELENBP1,SELENBP1,CTD_human,18163446,The utility of SELENBP1 gene expression as a biomarker for major psychotic disorders: replication in schizophrenia and extension to bipolar disorder with psychosis.,0.200274726784213,"The utility of <span class=""gene"" id=""18163446-0-15-23"">SELENBP1</span> gene expression as a biomarker for major <span class=""disease"" id=""18163446-0-65-84"">psychotic disorders</span>: replication in schizophrenia and extension to bipolar disorder with <span class=""disease"" id=""18163446-0-154-163"">psychosis</span>.",CTD_human
2,0,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,8991,SELENBP1,SELENBP1,CTD_human,16223876,Comparative gene expression analysis of blood and brain provides concurrent validation of SELENBP1 up-regulation in schizophrenia.,0.20350593566014002,"Comparative gene expression analysis of blood and brain provides concurrent validation of <span class=""gene"" id=""16223876-0-90-98"">SELENBP1</span> up-regulation in <span class=""disease"" id=""16223876-0-116-129"">schizophrenia</span>.",CTD_human
2,0,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,8991,SELENBP1,SELENBP1,CTD_human,18163446,The utility of SELENBP1 gene expression as a biomarker for major psychotic disorders: replication in schizophrenia and extension to bipolar disorder with psychosis.,0.20350593566014002,"The utility of <span class=""gene"" id=""18163446-0-15-23"">SELENBP1</span> gene expression as a biomarker for major psychotic disorders: replication in <span class=""disease"" id=""18163446-0-101-114"">schizophrenia</span> and extension to bipolar disorder with psychosis.",CTD_human
2,0,Biomarker,C0919267,ovarian neoplasm,disease,ovarian tumors,8991,SELENBP1,Selenium-Binding Protein 1,CTD_human,18272210,"Selenium-Binding Protein 1 expression in ovaries and ovarian tumors in the laying hen, a spontaneous model of human ovarian cancer.",0.20300763924902696,"<span class=""gene"" id=""18272210-0-0-26"">Selenium-Binding Protein 1</span> expression in ovaries and <span class=""disease"" id=""18272210-0-53-67"">ovarian tumors</span> in the laying hen, a spontaneous model of human ovarian cancer.",CTD_human
1,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastasis,8999,CDKL2,CDKL2,CTD_human,25333262,"Furthermore, CDKL2 enhanced primary tumor formation and metastasis in a breast cancer xenograft model.",0.2,"Furthermore, <span class=""gene"" id=""25333262-5-13-18"">CDKL2</span> enhanced primary tumor formation and <span class=""disease"" id=""25333262-5-56-66"">metastasis</span> in a breast cancer xenograft model.",CTD_human
1,0,Biomarker,C0005695,Bladder Neoplasm,disease,bladder cancer,9,NAT1,NAT1,CTD_human,16003747,"Individuals carrying NAT1wt/*10 and NAT1*10/*10 showed higher relative risks of bladder cancer (OR = 2.8, 95% CI = 0.8-10.1 and OR = 2.2, 95% CI = 0.6-8.3, respectively).",0.218456172967967,"Individuals carrying NAT1wt/*10 and <span class=""gene"" id=""16003747-7-36-40"">NAT1</span>*10/*10 showed higher relative risks of <span class=""disease"" id=""16003747-7-80-94"">bladder cancer</span> (OR = 2.8, 95% CI = 0.8-10.1 and OR = 2.2, 95% CI = 0.6-8.3, respectively).",CTD_human
1,0,Biomarker,C0004114,Astrocytoma,disease,astrocytoma,90,ACVR1,ACVR1,CTD_human,24705250,Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma.,0.20054945356842604,"Recurrent somatic mutations in <span class=""gene"" id=""24705250-0-31-36"">ACVR1</span> in pediatric midline high-grade <span class=""disease"" id=""24705250-0-69-80"">astrocytoma</span>.",CTD_human
3,0,Biomarker,C0017638,Glioma,disease,gliomas,90,ACVR1,ACVR1,CTD_human,24705254,Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations.,0.200274726784213,"Genomic analysis of diffuse intrinsic pontine <span class=""disease"" id=""24705254-0-46-53"">gliomas</span> identifies three molecular subgroups and recurrent activating <span class=""gene"" id=""24705254-0-116-121"">ACVR1</span> mutations.",CTD_human
1,1,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,90139,TSPAN18,TSPAN18,CTD_human,22037552,"We identified two susceptibility loci for schizophrenia at 6p21-p22.1 (rs1233710 in an intron of ZKSCAN4, P(combined) = 4.76 × 10(-11), odds ratio (OR) = 0.79; rs1635 in an exon of NKAPL, P(combined) = 6.91 × 10(-12), OR = 0.78; rs2142731 in an intron of PGBD1, P(combined) = 5.14 × 10(-10), OR = 0.79) and 11p11.2 (rs11038167 near the 5' UTR of TSPAN18, P(combined) = 1.09 × 10(-11), OR = 1.29; rs11038172, P(combined) = 7.21 × 10(-10), OR = 1.25; rs835784, P(combined) = 2.73 × 10(-11), OR = 1.27).",0.20082418035263896,"We identified two susceptibility loci for <span class=""disease"" id=""22037552-2-42-55"">schizophrenia</span> at 6p21-p22.1 (rs1233710 in an intron of ZKSCAN4, P(combined) = 4.76 &times; 10(-11), odds ratio (OR) = 0.79; rs1635 in an exon of NKAPL, P(combined) = 6.91 &times; 10(-12), OR = 0.78; rs2142731 in an intron of PGBD1, P(combined) = 5.14 &times; 10(-10), OR = 0.79) and 11p11.2 (rs11038167 near the 5' UTR of <span class=""gene"" id=""22037552-2-346-353"">TSPAN18</span>, P(combined) = 1.09 &times; 10(-11), OR = 1.29; rs11038172, P(combined) = 7.21 &times; 10(-10), OR = 1.25; rs835784, P(combined) = 2.73 &times; 10(-11), OR = 1.27).",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,9021,SOCS3,SOCS3,CTD_human,16831601,SOCS3 expression was reduced in the HCC regions compared with the non-HCC regions.,0.20712854101222303,"<span class=""gene"" id=""16831601-8-0-5"">SOCS3</span> expression was reduced in the <span class=""disease"" id=""16831601-8-36-39"">HCC</span> regions compared with the non-<span class=""disease"" id=""16831601-8-70-73"">HCC</span> regions.",CTD_human
1,0,Biomarker,C0003123,Anorexia,disease,anorexia,90226,UCN2,Urocortin 2,CTD_human,17627984,"Urocortin 2 was less potent in DIO rats, ineffective at the 0.3 microg dose, but produced CRF(2) antagonist-reversible anorexia at higher doses.",0.2,"<span class=""gene"" id=""17627984-6-0-11"">Urocortin 2</span> was less potent in DIO rats, ineffective at the 0.3 microg dose, but produced CRF(2) antagonist-reversible <span class=""disease"" id=""17627984-6-119-127"">anorexia</span> at higher doses.",CTD_human
1,0,Therapeutic,C0018801,Heart failure,disease,heart failure,90226,UCN2,urocortin 2,CTD_human,16330704,"Integrated hemodynamic, hormonal, and renal actions of urocortin 2 in normal and paced sheep: beneficial effects in heart failure.",0.200274726784213,"Integrated hemodynamic, hormonal, and renal actions of <span class=""gene"" id=""16330704-0-55-66"">urocortin 2</span> in normal and paced sheep: beneficial effects in <span class=""disease"" id=""16330704-0-116-129"">heart failure</span>.",CTD_human
1,0,Biomarker,C0175702,Williams Syndrome,disease,Williams-Beuren syndrome,9031,BAZ1B,WSTF,CTD_human,16448863,The gene WSTF is deleted in the autosomal dominant hereditary disorder Williams-Beuren syndrome.,0.48219781427370506,"The gene <span class=""gene"" id=""16448863-1-9-13"">WSTF</span> is deleted in the autosomal dominant hereditary disorder <span class=""disease"" id=""16448863-1-71-95"">Williams-Beuren syndrome</span>.",CTD_human;ORPHANET
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,9037,SEMA5A,SEMA5A,CTD_human,17028446,Constitutional downregulation of SEMA5A expression in autism.,0.20383181960166602,"Constitutional downregulation of <span class=""gene"" id=""17028446-0-33-39"">SEMA5A</span> expression in <span class=""disease"" id=""17028446-0-54-60"">autism</span>.",CTD_human
1,0,Biomarker,C0007137,Squamous cell carcinoma,disease,SCC,90417,KNSTRN,KNSTRN,CTD_human,25194279,These findings suggest a role for KNSTRN mutagenesis in SCC development.,0.200274726784213,"These findings suggest a role for <span class=""gene"" id=""25194279-3-34-40"">KNSTRN</span> mutagenesis in <span class=""disease"" id=""25194279-3-56-59"">SCC</span> development.",CTD_human
1,0,Biomarker,C0024121,Lung Neoplasms,group,lung tumor,9046,DOK2,DOK2,CTD_human,20139980,"Given the genomic localization of DOK2, we propose it as an 8p21.3 haploinsufficient human lung tumor suppressor.",0.200274726784213,"Given the genomic localization of <span class=""gene"" id=""20139980-6-34-38"">DOK2</span>, we propose it as an 8p21.3 haploinsufficient human <span class=""disease"" id=""20139980-6-91-101"">lung tumor</span> suppressor.",CTD_human
1,0,Biomarker,C0003873,Rheumatoid Arthritis,disease,RA,9052,GPRC5A,retinoic acid induced 3,CTD_human,17379860,"Treatment with methotrexate resulted in the reversion of the RA-related expression profile of genes associated with growth and apoptosis including insulin-like growth factor binding protein 3, retinoic acid induced 3, and caveolin 2 as well as in the re-expression of the cell adhesion molecule integrin alpha6.",0.200274726784213,"Treatment with methotrexate resulted in the reversion of the <span class=""disease"" id=""17379860-6-61-63"">RA</span>-related expression profile of genes associated with growth and apoptosis including insulin-like growth factor binding protein 3, <span class=""gene"" id=""17379860-6-193-216"">retinoic acid induced 3</span>, and caveolin 2 as well as in the re-expression of the cell adhesion molecule integrin alpha6.",CTD_human
1,2,Biomarker,C0007959,Charcot-Marie-Tooth Disease,disease,Charcot-Marie-Tooth disease,90678,LRSAM1,LRSAM1,CTD_human,20865121,Mutation in the gene encoding ubiquitin ligase LRSAM1 in patients with Charcot-Marie-Tooth disease.,0.201098907136852,"Mutation in the gene encoding ubiquitin ligase <span class=""gene"" id=""20865121-0-47-53"">LRSAM1</span> in patients with <span class=""disease"" id=""20865121-0-71-98"">Charcot-Marie-Tooth disease</span>.",CTD_human
1,0,Biomarker,C0030305,Pancreatitis,disease,pancreatitis,9075,CLDN2,CLDN2,CTD_human,23143602,Common genetic variants in the CLDN2 and PRSS1-PRSS2 loci alter risk for alcohol-related and sporadic pancreatitis.,0.200274726784213,"Common genetic variants in the <span class=""gene"" id=""23143602-0-31-36"">CLDN2</span> and PRSS1-PRSS2 loci alter risk for alcohol-related and sporadic <span class=""disease"" id=""23143602-0-102-114"">pancreatitis</span>.",CTD_human
1,0,Biomarker,C0011616,Contact Dermatitis,disease,contact dermatitis,9076,CLDN1,CLDN1,CTD_human,23136956,"The CLDN1 polymorphisms rs9290927, rs893051 and rs17501010 were associated, respectively, with nickel contact sensitization in individuals without ear piercings, contact sensitization to fragrances, and with both organic compounds and nickel contact dermatitis.",0.200274726784213,"The <span class=""gene"" id=""23136956-11-4-9"">CLDN1</span> polymorphisms rs9290927, rs893051 and rs17501010 were associated, respectively, with nickel contact sensitization in individuals without ear piercings, contact sensitization to fragrances, and with both organic compounds and nickel <span class=""disease"" id=""23136956-11-242-260"">contact dermatitis</span>.",CTD_human
4,0,Biomarker,C0004096,Asthma,disease,asthma,90865,IL33,IL33,CTD_human,21804549,"Four were at previously reported loci on 17q21, near IL1RL1, TSLP and IL33, but we report for the first time, to our knowledge, that these loci are associated with asthma risk in three ethnic groups.",0.21683652301732298,"Four were at previously reported loci on 17q21, near IL1RL1, TSLP and <span class=""gene"" id=""21804549-3-70-74"">IL33</span>, but we report for the first time, to our knowledge, that these loci are associated with <span class=""disease"" id=""21804549-3-164-170"">asthma</span> risk in three ethnic groups.",CTD_human
4,0,Biomarker,C0004096,Asthma,disease,asthma,90865,IL33,IL33,CTD_human,24241537,"Four of these, GSDMB, IL33, RAD50 and IL1RL1, were previously reported as asthma susceptibility loci, but the effect sizes for these loci in our cohort were considerably larger than in the previous genome-wide association studies of asthma.",0.21683652301732298,"Four of these, GSDMB, <span class=""gene"" id=""24241537-5-22-26"">IL33</span>, RAD50 and IL1RL1, were previously reported as <span class=""disease"" id=""24241537-5-74-80"">asthma</span> susceptibility loci, but the effect sizes for these loci in our cohort were considerably larger than in the previous genome-wide association studies of <span class=""disease"" id=""24241537-5-233-239"">asthma</span>.",CTD_human
1,1,Biomarker,C0035334,Retinitis Pigmentosa,disease,cone-rod dystrophy,9094,UNC119,UNC119,CTD_human,11006213,HRG4 (UNC119) mutation found in cone-rod dystrophy causes retinal degeneration in a transgenic model.,0.40082418035263895,"<span class=""gene"" id=""11006213-0-0-4"">HRG4</span> (<span class=""gene"" id=""11006213-0-6-12"">UNC119</span>) mutation found in <span class=""disease"" id=""11006213-0-32-50"">cone-rod dystrophy</span> causes retinal degeneration in a transgenic model.",CTD_human;ORPHANET
1,4,Biomarker,C0221406,Pituitary-dependent Cushing's disease,disease,Cushing's disease,9101,USP8,USP8,CTD_human,25485838,Mutations in the deubiquitinase gene USP8 cause Cushing's disease.,0.40219781427370505,"Mutations in the deubiquitinase gene <span class=""gene"" id=""25485838-0-37-41"">USP8</span> cause <span class=""disease"" id=""25485838-0-48-65"">Cushing's disease</span>.",CTD_human;ORPHANET
1,0,Biomarker,C0004114,Astrocytoma,disease,astrocytoma,9113,LATS1,LATS1,CTD_human,17049657,Promoter hypermethylation-mediated down-regulation of LATS1 and LATS2 in human astrocytoma.,0.200274726784213,"Promoter hypermethylation-mediated down-regulation of <span class=""gene"" id=""17049657-0-54-59"">LATS1</span> and LATS2 in human <span class=""disease"" id=""17049657-0-79-90"">astrocytoma</span>.",CTD_human
1,0,Biomarker,C0029124,Optic Atrophy,disease,optic atrophy,91137,SLC25A46,SLC25A46,CTD_human,26168012,"Mutations in SLC25A46, encoding a UGO1-like protein, cause an optic atrophy spectrum disorder.",0.200274726784213,"Mutations in <span class=""gene"" id=""26168012-0-13-21"">SLC25A46</span>, encoding a UGO1-like protein, cause an <span class=""disease"" id=""26168012-0-62-75"">optic atrophy</span> spectrum disorder.",CTD_human
1,0,Biomarker,C0752166,Bardet-Biedl Syndrome,disease,BBS,91147,TMEM67,MKS3,CTD_human,18327255,"Here we show that mutations in MKS1, MKS3 and CEP290 (also known as NPHP6) either can cause Bardet-Biedl syndrome (BBS) or may have a potential epistatic effect on mutations in known BBS-associated loci.",0.20300763924902696,"Here we show that mutations in MKS1, <span class=""gene"" id=""18327255-3-37-41"">MKS3</span> and CEP290 (also known as NPHP6) either can cause <span class=""disease"" id=""18327255-3-92-113"">Bardet-Biedl syndrome</span> (<span class=""disease"" id=""18327255-3-115-118"">BBS</span>) or may have a potential epistatic effect on mutations in known <span class=""disease"" id=""18327255-3-183-186"">BBS</span>-associated loci.",CTD_human
1,0,Biomarker,C0524851,Neurodegenerative Disorders,group,neurodegenerative disease,9118,INA,?-internexin,CTD_human,22430071,"After validation by Western blot and quantitative real-time PCR, the expressions of three proteins related to neurodegenerative disease, septin 5, ?-internexin, and ?-synuclein, were identified to be altered by MCLR exposure.",0.2,"After validation by Western blot and quantitative real-time PCR, the expressions of three proteins related to <span class=""disease"" id=""22430071-4-110-135"">neurodegenerative disease</span>, septin 5, <span class=""gene"" id=""22430071-4-147-159"">&alpha;-internexin</span>, and &alpha;-synuclein, were identified to be altered by MCLR exposure.",CTD_human
1,0,Biomarker,C0013720,Ehlers-Danlos Syndrome,disease,EDS,91252,SLC39A13,Slc39a13,CTD_human,18985159,Homozygosity for a SLC39A13 loss of function mutation was detected in sibs affected by a unique variant of EDS that recapitulates the phenotype observed in Slc39a13-KO mice.,0.20082418035263896,"Homozygosity for a <span class=""gene"" id=""18985159-5-19-27"">SLC39A13</span> loss of function mutation was detected in sibs affected by a unique variant of <span class=""disease"" id=""18985159-5-107-110"">EDS</span> that recapitulates the phenotype observed in <span class=""gene"" id=""18985159-5-156-164"">Slc39a13</span>-KO mice.",CTD_human
5,3,Biomarker,C0004096,Asthma,disease,asthma,9173,IL1RL1,IL1RL1,CTD_human,21150878,"Association between ORMDL3, IL1RL1 and a deletion on chromosome 17q21 with asthma risk in Australia.",0.22507664781209197,"Association between ORMDL3, <span class=""gene"" id=""21150878-0-28-34"">IL1RL1</span> and a deletion on chromosome 17q21 with <span class=""disease"" id=""21150878-0-75-81"">asthma</span> risk in Australia.",CTD_human
5,3,Biomarker,C0004096,Asthma,disease,asthma,9173,IL1RL1,IL1RL1,CTD_human,21804549,"Four were at previously reported loci on 17q21, near IL1RL1, TSLP and IL33, but we report for the first time, to our knowledge, that these loci are associated with asthma risk in three ethnic groups.",0.22507664781209197,"Four were at previously reported loci on 17q21, near <span class=""gene"" id=""21804549-3-53-59"">IL1RL1</span>, TSLP and IL33, but we report for the first time, to our knowledge, that these loci are associated with <span class=""disease"" id=""21804549-3-164-170"">asthma</span> risk in three ethnic groups.",CTD_human
5,3,Biomarker,C0004096,Asthma,disease,asthma,9173,IL1RL1,IL1RL1,CTD_human,19198610,"A SNP at IL1RL1 associated with asthma (P = 5.5 x 10(-12)) in a collection of ten different populations (7,996 cases and 44,890 controls).",0.22507664781209197,"A SNP at <span class=""gene"" id=""19198610-5-9-15"">IL1RL1</span> associated with <span class=""disease"" id=""19198610-5-32-38"">asthma</span> (P = 5.5 x 10(-12)) in a collection of ten different populations (7,996 cases and 44,890 controls).",CTD_human
5,3,Biomarker,C0004096,Asthma,disease,asthma,9173,IL1RL1,IL1RL1,CTD_human,24241537,"Four of these, GSDMB, IL33, RAD50 and IL1RL1, were previously reported as asthma susceptibility loci, but the effect sizes for these loci in our cohort were considerably larger than in the previous genome-wide association studies of asthma.",0.22507664781209197,"Four of these, GSDMB, IL33, RAD50 and <span class=""gene"" id=""24241537-5-38-44"">IL1RL1</span>, were previously reported as <span class=""disease"" id=""24241537-5-74-80"">asthma</span> susceptibility loci, but the effect sizes for these loci in our cohort were considerably larger than in the previous genome-wide association studies of <span class=""disease"" id=""24241537-5-233-239"">asthma</span>.",CTD_human
1,0,Biomarker,C1458155,Mammary Neoplasms,group,breast tumour,9185,REPS2,REPS2,CTD_human,19776672,"TMEM25, REPS2 and Meis 1 expression was investigated by qRT-PCR, in triplicate, in 103 breast tumour biopsies procured in 1993-1994.",0.2,"TMEM25, <span class=""gene"" id=""19776672-4-8-13"">REPS2</span> and Meis 1 expression was investigated by qRT-PCR, in triplicate, in 103 <span class=""disease"" id=""19776672-4-87-100"">breast tumour</span> biopsies procured in 1993-1994.",CTD_human
1,1,Biomarker,C0036421,Systemic Scleroderma,disease,systemic sclerosis,919,CD247,CD247,CTD_human,20383147,Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus.,0.20082418035263896,"Genome-wide association study of <span class=""disease"" id=""20383147-0-33-51"">systemic sclerosis</span> identifies <span class=""gene"" id=""20383147-0-63-68"">CD247</span> as a new susceptibility locus.",CTD_human
1,0,Biomarker,C0032460,Polycystic Ovary Syndrome,disease,polycystic ovary syndrome,9210,BMP15,BMP15,CTD_human,22825968,Single-cell expression analysis of BMP15 and GDF9 in mature oocytes and BMPR2 in cumulus cells of women with polycystic ovary syndrome undergoing controlled ovarian hyperstimulation.,0.21001951056930804,"Single-cell expression analysis of <span class=""gene"" id=""22825968-0-35-40"">BMP15</span> and GDF9 in mature oocytes and BMPR2 in cumulus cells of women with <span class=""disease"" id=""22825968-0-109-134"">polycystic ovary syndrome</span> undergoing controlled ovarian hyperstimulation.",CTD_human
1,0,Therapeutic,C0027627,Neoplasm Metastasis,phenotype,metastasis,92140,MTDH,MTDH,CTD_human,19111877,MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer.,0.21456051956329397,"<span class=""gene"" id=""19111877-0-0-4"">MTDH</span> activation by 8q22 genomic gain promotes chemoresistance and <span class=""disease"" id=""19111877-0-66-76"">metastasis</span> of poor-prognosis breast cancer.",CTD_human
1,0,Biomarker,C0042842,Vitamin A Deficiency,disease,vitamin A deficiency,9227,LRAT,LRAT,CTD_human,16174770,We produced an LRAT gene knock-out mouse strain and assessed whether LRAT-/- mice were more susceptible to vitamin A deficiency than wild type (WT) mice.,0.2,"We produced an <span class=""gene"" id=""16174770-2-15-19"">LRAT</span> gene knock-out mouse strain and assessed whether LRAT-/- mice were more susceptible to <span class=""disease"" id=""16174770-2-107-127"">vitamin A deficiency</span> than wild type (WT) mice.",CTD_human
1,0,Biomarker,C0339527,Leber Congenital Amaurosis,disease,Leber congenital amaurosis,9227,LRAT,LRAT,CTD_human,19339306,"Inactivating mutations in the retinoid isomerase (RPE65) or lecithin:retinol acyltransferase (LRAT) genes cause Leber congenital amaurosis (LCA), a severe visual impairment in humans.",0.40137363392106606,"Inactivating mutations in the retinoid isomerase (RPE65) or lecithin:retinol acyltransferase (<span class=""gene"" id=""19339306-1-94-98"">LRAT</span>) genes cause <span class=""disease"" id=""19339306-1-112-138"">Leber congenital amaurosis</span> (LCA), a severe visual impairment in humans.",CTD_human;ORPHANET
1,0,Biomarker,C0033860,Psoriasis,disease,psoriasis,9232,PTTG1,PTTG1,CTD_human,20953187,"We identified six new susceptibility loci associated with psoriasis in the Chinese study containing the candidate genes ERAP1, PTTG1, CSMD1, GJB2, SERPINB8 and ZNF816A (combined P < 5 × 10??) and replicated one locus, 5q33.1 (TNIP1-ANXA6), previously reported (combined P = 3.8 × 10?²¹) in the European studies.",0.202681755307501,"We identified six new susceptibility loci associated with <span class=""disease"" id=""20953187-2-58-67"">psoriasis</span> in the Chinese study containing the candidate genes ERAP1, <span class=""gene"" id=""20953187-2-127-132"">PTTG1</span>, CSMD1, GJB2, SERPINB8 and ZNF816A (combined P &lt; 5 &times; 10??) and replicated one locus, 5q33.1 (TNIP1-ANXA6), previously reported (combined P = 3.8 &times; 10?²¹) in the European studies.",CTD_human
1,0,Biomarker,C0025149,Medulloblastoma,disease,medulloblastoma,92335,STRADA,LYK5,CTD_human,21652733,An analysis of the expression of the 6 target genes in primary medulloblastoma tumor samples and cell lines revealed overexpression of LYK5 and PIK3CG.,0.200274726784213,"An analysis of the expression of the 6 target genes in primary <span class=""disease"" id=""21652733-7-63-78"">medulloblastoma</span> tumor samples and cell lines revealed overexpression of <span class=""gene"" id=""21652733-7-135-139"">LYK5</span> and PIK3CG.",CTD_human
1,0,Biomarker,C0029456,Osteoporosis,disease,osteoporosis,92344,GORAB,Gerodermia osteodysplastica,CTD_human,18997784,Gerodermia osteodysplastica is an autosomal recessive disorder characterized by wrinkly skin and osteoporosis.,0.20054945356842604,"<span class=""gene"" id=""18997784-1-0-27"">Gerodermia osteodysplastica</span> is an autosomal recessive disorder characterized by wrinkly skin and <span class=""disease"" id=""18997784-1-97-109"">osteoporosis</span>.",CTD_human
1,3,Biomarker,C0432255,Geroderma osteodysplastica,disease,gerodermia osteodysplastica,92344,GORAB,SCYL1BP1,CTD_human,18997784,"Here we demonstrate that gerodermia osteodysplastica is caused by loss-of-function mutations in SCYL1BP1, which is highly expressed in skin and osteoblasts.",0.40137363392106606,"Here we demonstrate that <span class=""disease"" id=""18997784-2-25-52"">gerodermia osteodysplastica</span> is caused by loss-of-function mutations in <span class=""gene"" id=""18997784-2-96-104"">SCYL1BP1</span>, which is highly expressed in skin and osteoblasts.",CTD_human;ORPHANET
1,0,Biomarker,C1510586,Autism Spectrum Disorders,disease,ASD,9248,GPR50,GPR50,CTD_human,20657642,"Concerning GPR50, we detected a significant association between ASD and two variations, Delta502-505 and T532A, in affected males, but it did not hold up after Bonferonni correction for multiple testing.",0.20054945356842604,"Concerning <span class=""gene"" id=""20657642-11-11-16"">GPR50</span>, we detected a significant association between <span class=""disease"" id=""20657642-11-64-67"">ASD</span> and two variations, Delta502-505 and T532A, in affected males, but it did not hold up after Bonferonni correction for multiple testing.",CTD_human
1,0,Biomarker,C0013911,Emaciation,phenotype,emaciation,92667,MGME1,C20orf72,CTD_human,23313956,"Here, we identify homozygous nonsense and missense mutations in the orphan gene C20orf72 in three families with a mitochondrial syndrome characterized by external ophthalmoplegia, emaciation and respiratory failure.",0.2,"Here, we identify homozygous nonsense and missense mutations in the orphan gene <span class=""gene"" id=""23313956-3-80-88"">C20orf72</span> in three families with a mitochondrial syndrome characterized by external ophthalmoplegia, <span class=""disease"" id=""23313956-3-180-190"">emaciation</span> and respiratory failure.",CTD_human
1,0,Biomarker,C0751651,Mitochondrial Diseases,group,mitochondrial disease,92667,MGME1,MGME1,CTD_human,23313956,Loss-of-function mutations in MGME1 impair mtDNA replication and cause multisystemic mitochondrial disease.,0.20054945356842604,"Loss-of-function mutations in <span class=""gene"" id=""23313956-0-30-35"">MGME1</span> impair mtDNA replication and cause multisystemic <span class=""disease"" id=""23313956-0-85-106"">mitochondrial disease</span>.",CTD_human
1,2,Biomarker,C0022521,Kartagener Syndrome,disease,PCD,92749,DRC1,CCDC164,CTD_human,23354437,"Here, we identify the DRC1 subunit of the nexin-dynein regulatory complex (N-DRC), an axonemal structure critical for the regulation of dynein motors, and show that mutations in the gene encoding DRC1, CCDC164, are involved in PCD pathogenesis.",0.40027472678421294,"Here, we identify the <span class=""gene"" id=""23354437-2-22-26"">DRC1</span> subunit of the nexin-dynein regulatory complex (N-DRC), an axonemal structure critical for the regulation of dynein motors, and show that mutations in the gene encoding <span class=""gene"" id=""23354437-2-196-200"">DRC1</span>, <span class=""gene"" id=""23354437-2-202-209"">CCDC164</span>, are involved in <span class=""disease"" id=""23354437-2-227-230"">PCD</span> pathogenesis.",CTD_human;ORPHANET
1,0,Biomarker,C0017636,Glioblastoma,disease,glioblastoma,928,CD9,CD9,CTD_human,26573230,We validated CD9 gene and protein expression showing selective up-regulation in glioblastoma stem cells isolated from primary biopsies and in primary organotypic glioblastoma spheroids as well as in U87-MG and U373 glioblastoma cell lines.,0.20082418035263896,"We validated <span class=""gene"" id=""26573230-6-13-16"">CD9</span> gene and protein expression showing selective up-regulation in <span class=""disease"" id=""26573230-6-80-92"">glioblastoma</span> stem cells isolated from primary biopsies and in primary organotypic <span class=""disease"" id=""26573230-6-162-174"">glioblastoma</span> spheroids as well as in U87-MG and U373 <span class=""disease"" id=""26573230-6-215-227"">glioblastoma</span> cell lines.",CTD_human
1,0,Biomarker,C0004096,Asthma,disease,asthma,929,CD14,CD14,CTD_human,17607003,"CD14, endotoxin, and asthma risk: actions and interactions.",0.298695032323084,"<span class=""gene"" id=""17607003-0-0-4"">CD14</span>, endotoxin, and <span class=""disease"" id=""17607003-0-21-27"">asthma</span> risk: actions and interactions.",CTD_human
1,0,Biomarker,C0013595,Eczema,disease,eczema,929,CD14,CD14,CTD_human,19759553,The results also demonstrate a susceptibility effect of the combination of CD14 and IL4Ralpha SNPs with eczema.,0.202197814273705,"The results also demonstrate a susceptibility effect of the combination of <span class=""gene"" id=""19759553-11-75-79"">CD14</span> and IL4Ralpha SNPs with <span class=""disease"" id=""19759553-11-104-110"">eczema</span>.",CTD_human
1,0,Biomarker,C0003873,Rheumatoid Arthritis,disease,rheumatoid arthritis,9308,CD83,CD83,CTD_human,22446963,"Our study identified nine loci newly associated with rheumatoid arthritis at a threshold of P < 5.0 × 10(-8), including B3GNT2, ANXA3, CSF2, CD83, NFKBIE, ARID5B, PDE2A-ARAP1, PLD4 and PTPN2.",0.20300763924902696,"Our study identified nine loci newly associated with <span class=""disease"" id=""22446963-3-53-73"">rheumatoid arthritis</span> at a threshold of P &lt; 5.0 &times; 10(-8), including B3GNT2, ANXA3, CSF2, <span class=""gene"" id=""22446963-3-141-145"">CD83</span>, NFKBIE, ARID5B, PDE2A-ARAP1, PLD4 and PTPN2.",CTD_human
1,0,Biomarker,C0007137,Squamous cell carcinoma,disease,ARLC-SCC,931,MS4A1,MS4A1,CTD_human,22514692,"We conclude that differential expression of MS4A1 in this comparative gene expression study of ARLC-SCC versus NARLC-SCC is a stromal signal of uncertain significance, and an example of the rationale for tumor cell enrichment in preparation for gene expression studies where the aim is to identify markers of particular tumor phenotypes.",0.2,"We conclude that differential expression of <span class=""gene"" id=""22514692-9-44-49"">MS4A1</span> in this comparative gene expression study of <span class=""disease"" id=""22514692-9-95-103"">ARLC-SCC</span> versus NARLC-SCC is a stromal signal of uncertain significance, and an example of the rationale for tumor cell enrichment in preparation for gene expression studies where the aim is to identify markers of particular tumor phenotypes.",CTD_human
1,0,Biomarker,C0014556,"Epilepsy, Temporal Lobe",disease,TLE,9353,SLIT2,Slit2,CTD_human,20153733,These results suggest that Slit2 may play an important role in the pathogenesis of TLE.,0.200274726784213,"These results suggest that <span class=""gene"" id=""20153733-12-27-32"">Slit2</span> may play an important role in the pathogenesis of <span class=""disease"" id=""20153733-12-83-86"">TLE</span>.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,hepatocellular carcinomas,9353,SLIT2,SLIT2,CTD_human,19100240,Epigenetic inactivation of SLIT2 in human hepatocellular carcinomas.,0.20300763924902696,"Epigenetic inactivation of <span class=""gene"" id=""19100240-0-27-32"">SLIT2</span> in human <span class=""disease"" id=""19100240-0-42-67"">hepatocellular carcinomas</span>.",CTD_human
1,0,Biomarker,C0003873,Rheumatoid Arthritis,disease,RA,9355,LHX2,LIM homeobox 2,CTD_human,17568789,"HOXD10, HOXD11, HOXD13, CCL8 and LIM homeobox 2 were highly and exclusively expressed in RA and CLU, sarcoglycan-gamma, GPR64, POU3F3, peroxisome proliferative activated receptor-gamma and tripartite motif-containing 2 were expressed only in OA.",0.200274726784213,"HOXD10, HOXD11, HOXD13, CCL8 and <span class=""gene"" id=""17568789-4-33-47"">LIM homeobox 2</span> were highly and exclusively expressed in <span class=""disease"" id=""17568789-4-89-91"">RA</span> and CLU, sarcoglycan-gamma, GPR64, POU3F3, peroxisome proliferative activated receptor-gamma and tripartite motif-containing 2 were expressed only in OA.",CTD_human
1,0,Biomarker,C0003850,Arteriosclerosis,disease,arteriosclerosis,9365,KL,klotho,CTD_human,9363890,"A defect in klotho gene expression in the mouse results in a syndrome that resembles human ageing, including a short lifespan, infertility, arteriosclerosis, skin atrophy, osteoporosis and emphysema.",0.20357144819477,"A defect in <span class=""gene"" id=""9363890-2-12-18"">klotho</span> gene expression in the mouse results in a syndrome that resembles human ageing, including a short lifespan, infertility, <span class=""disease"" id=""9363890-2-140-156"">arteriosclerosis</span>, skin atrophy, osteoporosis and emphysema.",CTD_human
1,0,Biomarker,C0029456,Osteoporosis,disease,osteoporosis,9365,KL,klotho,CTD_human,9363890,"A defect in klotho gene expression in the mouse results in a syndrome that resembles human ageing, including a short lifespan, infertility, arteriosclerosis, skin atrophy, osteoporosis and emphysema.",0.201098907136852,"A defect in <span class=""gene"" id=""9363890-2-12-18"">klotho</span> gene expression in the mouse results in a syndrome that resembles human ageing, including a short lifespan, infertility, arteriosclerosis, skin atrophy, <span class=""disease"" id=""9363890-2-172-184"">osteoporosis</span> and emphysema.",CTD_human
1,0,Biomarker,C1956346,Coronary Artery Disease,disease,coronary artery disease,9365,KL,KLOTHO,CTD_human,12669274,KLOTHO allele status and the risk of early-onset occult coronary artery disease.,0.20274726784213098,"<span class=""gene"" id=""12669274-0-0-6"">KLOTHO</span> allele status and the risk of early-onset occult <span class=""disease"" id=""12669274-0-56-79"">coronary artery disease</span>.",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autistic,93664,CADPS2,CADPS2,CTD_human,17380209,Autistic-like phenotypes in Cadps2-knockout mice and aberrant CADPS2 splicing in autistic patients.,0.281648360705279,"<span class=""disease"" id=""17380209-0-0-8"">Autistic</span>-like phenotypes in <span class=""gene"" id=""17380209-0-28-34"">Cadps2</span>-knockout mice and aberrant <span class=""gene"" id=""17380209-0-62-68"">CADPS2</span> splicing in <span class=""disease"" id=""17380209-0-81-89"">autistic</span> patients.",CTD_human
3,0,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,type 2 diabetes,9370,ADIPOQ,APM1,CTD_human,12354786,Single-nucleotide polymorphism haplotypes in the both proximal promoter and exon 3 of the APM1 gene modulate adipocyte-secreted adiponectin hormone levels and contribute to the genetic risk for type 2 diabetes in French Caucasians.,0.324723044317466,"Single-nucleotide polymorphism haplotypes in the both proximal promoter and exon 3 of the <span class=""gene"" id=""12354786-0-90-94"">APM1</span> gene modulate adipocyte-secreted adiponectin hormone levels and contribute to the genetic risk for <span class=""disease"" id=""12354786-0-194-209"">type 2 diabetes</span> in French Caucasians.",CTD_human
3,0,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,NIDDM,9370,ADIPOQ,adiponectin,CTD_human,15734870,The common polymorphisms (single nucleotide polymorphism [SNP] +45 and SNP +276) of the adiponectin gene predict the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial.,0.324723044317466,"The common polymorphisms (single nucleotide polymorphism [SNP] +45 and SNP +276) of the <span class=""gene"" id=""15734870-0-88-99"">adiponectin</span> gene predict the conversion from impaired glucose tolerance to <span class=""disease"" id=""15734870-0-163-178"">type 2 diabetes</span>: the STOP-<span class=""disease"" id=""15734870-0-189-194"">NIDDM</span> trial.",CTD_human
1,0,Biomarker,C0011881,Diabetic Nephropathy,disease,diabetic nephropathy,9370,ADIPOQ,adiponectin,CTD_human,17942768,"These complimentary approaches have demonstrated that polymorphisms in the carnosinase 1 gene on chromosome 18q, the adiponectin gene on 3q, and the engulfment and cell motility gene on 7p are likely associated with susceptibility to diabetic nephropathy.",0.213525446229448,"These complimentary approaches have demonstrated that polymorphisms in the carnosinase 1 gene on chromosome 18q, the <span class=""gene"" id=""17942768-5-117-128"">adiponectin</span> gene on 3q, and the engulfment and cell motility gene on 7p are likely associated with susceptibility to <span class=""disease"" id=""17942768-5-234-254"">diabetic nephropathy</span>.",CTD_human
2,0,Biomarker,C0028754,Obesity,disease,obesity,9370,ADIPOQ,Acrp30,CTD_human,14617771,The long-term expression of recombinant adeno-associated virus-Acrp30 vectors was tested after intramuscular or intraportal injection in female Sprague-Dawley rats with diet-induced obesity.,0.389121039126589,"The long-term expression of recombinant adeno-associated virus-<span class=""gene"" id=""14617771-5-63-69"">Acrp30</span> vectors was tested after intramuscular or intraportal injection in female Sprague-Dawley rats with diet-induced <span class=""disease"" id=""14617771-5-182-189"">obesity</span>.",CTD_human
2,0,Therapeutic,C0028754,Obesity,disease,obesity,9370,ADIPOQ,Acrp30,CTD_human,14617771,The long-term expression of recombinant adeno-associated virus-Acrp30 vectors was tested after intramuscular or intraportal injection in female Sprague-Dawley rats with diet-induced obesity.,0.389121039126589,"The long-term expression of recombinant adeno-associated virus-<span class=""gene"" id=""14617771-5-63-69"">Acrp30</span> vectors was tested after intramuscular or intraportal injection in female Sprague-Dawley rats with diet-induced <span class=""disease"" id=""14617771-5-182-189"">obesity</span>.",CTD_human
1,0,Biomarker,C0400966,Non-alcoholic Fatty Liver Disease,disease,NAFLD,9370,ADIPOQ,Adiponectin,CTD_human,20415685,"Adiponectin generally predicts steatosis grade and severity of NAFLD, but it remains to be addressed to what extent this is a direct effect or related to the presence of more severe IR.",0.283296721410557,"<span class=""gene"" id=""20415685-7-0-11"">Adiponectin</span> generally predicts steatosis grade and severity of <span class=""disease"" id=""20415685-7-63-68"">NAFLD</span>, but it remains to be addressed to what extent this is a direct effect or related to the presence of more severe IR.",CTD_human
1,0,Biomarker,C0021400,Influenza,disease,influenza,9376,SLC22A8,organic anion transporter 3,CTD_human,23129053,Targeting organic anion transporter 3 with probenecid as a novel anti-influenza a virus strategy.,0.200274726784213,"Targeting <span class=""gene"" id=""23129053-0-10-37"">organic anion transporter 3</span> with probenecid as a novel anti-<span class=""disease"" id=""23129053-0-70-79"">influenza</span> a virus strategy.",CTD_human
4,0,Biomarker,C0004352,Autistic Disorder,disease,autism,9378,NRXN1,NRXN1,CTD_human,20157312,"At a gene level, CAM genes associated in all three samples (NRXN1 and CNTNAP2), which were previously implicated in specific language disorder, autism and schizophrenia.",0.29763199261532697,"At a gene level, CAM genes associated in all three samples (<span class=""gene"" id=""20157312-8-60-65"">NRXN1</span> and CNTNAP2), which were previously implicated in specific language disorder, <span class=""disease"" id=""20157312-8-144-150"">autism</span> and schizophrenia.",CTD_human
3,0,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,9378,NRXN1,NRXN1,CTD_human,21424692,Truncating mutations in NRXN2 and NRXN1 in autism spectrum disorders and schizophrenia.,0.30974700314371506,"Truncating mutations in NRXN2 and <span class=""gene"" id=""21424692-0-34-39"">NRXN1</span> in autism spectrum disorders and <span class=""disease"" id=""21424692-0-73-86"">schizophrenia</span>.",CTD_human
3,0,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,9378,NRXN1,NRXN1,CTD_human,21285140,"The data strongly confirm the association of schizophrenia with 1q21.1, 15q13.3, and 22q11.21 deletions, 16p11.2 duplications, and exonic NRXN1 deletions.",0.30974700314371506,"The data strongly confirm the association of <span class=""disease"" id=""21285140-9-45-58"">schizophrenia</span> with 1q21.1, 15q13.3, and 22q11.21 deletions, 16p11.2 duplications, and exonic <span class=""gene"" id=""21285140-9-138-143"">NRXN1</span> deletions.",CTD_human
3,0,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,9378,NRXN1,NRXN1,CTD_human,20157312,"At a gene level, CAM genes associated in all three samples (NRXN1 and CNTNAP2), which were previously implicated in specific language disorder, autism and schizophrenia.",0.30974700314371506,"At a gene level, CAM genes associated in all three samples (<span class=""gene"" id=""20157312-8-60-65"">NRXN1</span> and CNTNAP2), which were previously implicated in specific language disorder, autism and <span class=""disease"" id=""20157312-8-155-168"">schizophrenia</span>.",CTD_human
1,0,Biomarker,C1510586,Autism Spectrum Disorders,disease,ASD,9378,NRXN1,NRXN1,CTD_human,18252227,"Notwithstanding complexities, our results further implicate the SHANK3-NLGN4-NRXN1 postsynaptic density genes and also identify novel loci at DPP6-DPP10-PCDH9 (synapse complex), ANKRD11, DPYD, PTCHD1, 15q24, among others, for a role in ASD susceptibility.",0.206318716036901,"Notwithstanding complexities, our results further implicate the SHANK3-NLGN4-<span class=""gene"" id=""18252227-8-77-82"">NRXN1</span> postsynaptic density genes and also identify novel loci at DPP6-DPP10-PCDH9 (synapse complex), ANKRD11, DPYD, PTCHD1, 15q24, among others, for a role in <span class=""disease"" id=""18252227-8-236-239"">ASD</span> susceptibility.",CTD_human
1,0,Biomarker,C1970431,PITT-HOPKINS SYNDROME,disease,Pitt-Hopkins syndrome,9378,NRXN1,NRXN1,CTD_human,19896112,"We now identified homozygous and compound-heterozygous deletions and mutations via molecular karyotyping and mutational screening in CNTNAP2 and NRXN1 in four patients with severe mental retardation (MR) and variable features, such as autistic behavior, epilepsy, and breathing anomalies, phenotypically overlapping with Pitt-Hopkins syndrome.",0.201098907136852,"We now identified homozygous and compound-heterozygous deletions and mutations via molecular karyotyping and mutational screening in CNTNAP2 and <span class=""gene"" id=""19896112-2-145-150"">NRXN1</span> in four patients with severe mental retardation (MR) and variable features, such as autistic behavior, epilepsy, and breathing anomalies, phenotypically overlapping with <span class=""disease"" id=""19896112-2-321-342"">Pitt-Hopkins syndrome</span>.",CTD_human
1,0,Biomarker,C1510586,Autism Spectrum Disorders,disease,autism spectrum disorders,9379,NRXN2,NRXN2,CTD_human,21424692,Truncating mutations in NRXN2 and NRXN1 in autism spectrum disorders and schizophrenia.,0.20082418035263896,"Truncating mutations in <span class=""gene"" id=""21424692-0-24-29"">NRXN2</span> and NRXN1 in <span class=""disease"" id=""21424692-0-43-68"">autism spectrum disorders</span> and schizophrenia.",CTD_human
2,0,Biomarker,C0004352,Autistic Disorder,disease,autistic disorder,93986,FOXP2,FOXP2,CTD_human,15108192,Association between the FOXP2 gene and autistic disorder in Chinese population.,0.20838550524134603,"Association between the <span class=""gene"" id=""15108192-0-24-29"">FOXP2</span> gene and <span class=""disease"" id=""15108192-0-39-56"">autistic disorder</span> in Chinese population.",CTD_human
1,0,Biomarker,C0175693,Russell-Silver syndrome,disease,SRS,93986,FOXP2,FOXP2,CTD_human,17033973,Our results indicate that absence of paternal FOXP2 is the cause of DVD in patients with SRS with maternal UPD7.,0.200274726784213,"Our results indicate that absence of paternal <span class=""gene"" id=""17033973-8-46-51"">FOXP2</span> is the cause of DVD in patients with <span class=""disease"" id=""17033973-8-89-92"">SRS</span> with maternal UPD7.",CTD_human
3,0,Biomarker,C0003873,Rheumatoid Arthritis,disease,rheumatoid arthritis,940,CD28,CD28,CTD_human,19898481,"Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk.",0.21847052834528402,"Genetic variants at <span class=""gene"" id=""19898481-0-20-24"">CD28</span>, PRDM1 and CD2/CD58 are associated with <span class=""disease"" id=""19898481-0-65-85"">rheumatoid arthritis</span> risk.",CTD_human
2,0,Biomarker,C0004364,Autoimmune Diseases,group,autoimmunity,940,CD28,CD28,CTD_human,15494542,Absence of CTLA-4 expression in CD40L-/- mice suggests that signaling via both CD28 and CD40L is important for T cell activation and subsequent autoimmunity in mHgIA.,0.20439562854741,"Absence of CTLA-4 expression in CD40L-/- mice suggests that signaling via both <span class=""gene"" id=""15494542-9-79-83"">CD28</span> and CD40L is important for T cell activation and subsequent <span class=""disease"" id=""15494542-9-144-156"">autoimmunity</span> in mHgIA.",CTD_human
2,0,Biomarker,C0004364,Autoimmune Diseases,group,autoimmunity,940,CD28,CD28,CTD_human,19077085,Gold- and silver-induced murine autoimmunity--requirement for cytokines and CD28 in murine heavy metal-induced autoimmunity.,0.20439562854741,"Gold- and silver-induced murine <span class=""disease"" id=""19077085-0-32-44"">autoimmunity</span>--requirement for cytokines and <span class=""gene"" id=""19077085-0-76-80"">CD28</span> in murine heavy metal-induced <span class=""disease"" id=""19077085-0-111-123"">autoimmunity</span>.",CTD_human
1,14,Biomarker,C0032339,Rothmund-Thomson syndrome,disease,RTS,9401,RECQL4,RECQL4,CTD_human,18616953,"Primary RTS fibroblasts from these RTS patients show no sensitivity to a wide variety of genotoxic agents including ionizing or ultraviolet irradiation, nitrogen mustard, 4NQO, 8-MOP, Cis-Pt, MMC, H2O2, HU, or UV plus caffeine which could be related to the RECQL4 alterations identified here.",0.313588592502365,"Primary <span class=""disease"" id=""18616953-6-8-11"">RTS</span> fibroblasts from these <span class=""disease"" id=""18616953-6-35-38"">RTS</span> patients show no sensitivity to a wide variety of genotoxic agents including ionizing or ultraviolet irradiation, nitrogen mustard, 4NQO, 8-MOP, Cis-Pt, MMC, H2O2, HU, or UV plus caffeine which could be related to the <span class=""gene"" id=""18616953-6-257-263"">RECQL4</span> alterations identified here.",CTD_human
1,0,Biomarker,C0043459,Zellweger Syndrome,disease,Zellweger syndrome,9409,PEX16,PEX16,CTD_human,11890679,A novel aberrant splicing mutation of the PEX16 gene in two patients with Zellweger syndrome.,0.40383181960166603,"A novel aberrant splicing mutation of the <span class=""gene"" id=""11890679-0-42-47"">PEX16</span> gene in two patients with <span class=""disease"" id=""11890679-0-74-92"">Zellweger syndrome</span>.",CTD_human;ORPHANET
2,0,Biomarker,C1832200,Peroxisome biogenesis disorders,group,peroxisome biogenesis disorders,9409,PEX16,PEX16,CTD_human,11890679,A nonsense mutation (R176ter) in the PEX16 gene has been reported in the case of only one patient (D-01) belonging to complementation group D of the peroxisome biogenesis disorders.,0.20054945356842604,"A nonsense mutation (R176ter) in the <span class=""gene"" id=""11890679-2-37-42"">PEX16</span> gene has been reported in the case of only one patient (D-01) belonging to complementation group D of the <span class=""disease"" id=""11890679-2-149-180"">peroxisome biogenesis disorders</span>.",CTD_human
2,0,Biomarker,C0004096,Asthma,disease,asthmatics,94103,ORMDL3,ORMDL3,CTD_human,25256354,"In summary, this study supports that there are differences in DNA methylation at this locus between asthmatics and controls; and both SNPs and CpG sites are independently associated with ORMDL3 expression.",0.249822826062325,"In summary, this study supports that there are differences in DNA methylation at this locus between <span class=""disease"" id=""25256354-11-100-110"">asthmatics</span> and controls; and both SNPs and CpG sites are independently associated with <span class=""gene"" id=""25256354-11-187-193"">ORMDL3</span> expression.",CTD_human
2,0,Biomarker,C0004096,Asthma,disease,asthma,94103,ORMDL3,ORMDL3,CTD_human,21150878,"Association between ORMDL3, IL1RL1 and a deletion on chromosome 17q21 with asthma risk in Australia.",0.249822826062325,"Association between <span class=""gene"" id=""21150878-0-20-26"">ORMDL3</span>, IL1RL1 and a deletion on chromosome 17q21 with <span class=""disease"" id=""21150878-0-75-81"">asthma</span> risk in Australia.",CTD_human
1,0,Biomarker,C0009324,Ulcerative Colitis,disease,ulcerative colitis,94103,ORMDL3,ORMDL3,CTD_human,20228799,"After testing an independent cohort of 2,009 cases of ulcerative colitis and 1,580 controls, we identified 13 loci that were significantly associated with ulcerative colitis (P < 5 x 10(-8)), including the immunoglobulin receptor gene FCGR2A, 5p15, 2p16 and ORMDL3 (orosomucoid1-like 3).",0.20082418035263896,"After testing an independent cohort of 2,009 cases of <span class=""disease"" id=""20228799-5-54-72"">ulcerative colitis</span> and 1,580 controls, we identified 13 loci that were significantly associated with <span class=""disease"" id=""20228799-5-155-173"">ulcerative colitis</span> (P &lt; 5 x 10(-8)), including the immunoglobulin receptor gene FCGR2A, 5p15, 2p16 and <span class=""gene"" id=""20228799-5-258-264"">ORMDL3</span> (orosomucoid1-like 3).",CTD_human
1,0,Biomarker,C0334634,"Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse",disease,mantle-cell lymphomas,9411,ARHGAP29,PARG1,CTD_human,17488656,"Promoter methylation of PARG1, a novel candidate tumor suppressor gene in mantle-cell lymphomas.",0.200274726784213,"Promoter methylation of <span class=""gene"" id=""17488656-0-24-29"">PARG1</span>, a novel candidate tumor suppressor gene in <span class=""disease"" id=""17488656-0-74-95"">mantle-cell lymphomas</span>.",CTD_human
1,0,Biomarker,C0026764,Multiple Myeloma,disease,myeloma,942,CD86,CD86,CTD_human,16611307,Circulating levels and clinical significance of soluble CD86 in myeloma patients.,0.20082418035263896,"Circulating levels and clinical significance of soluble <span class=""gene"" id=""16611307-0-56-60"">CD86</span> in <span class=""disease"" id=""16611307-0-64-71"">myeloma</span> patients.",CTD_human
1,0,Biomarker,C0001418,Adenocarcinoma,group,adenocarcinomas,9420,CYP7B1,CYP7B1,CTD_human,17639508,The immunohistochemical results demonstrate that high expression of CYP7B1 protein occurs in high-grade prostatic intraepithelial neoplasia (PIN) and adenocarcinomas.,0.200274726784213,"The immunohistochemical results demonstrate that high expression of <span class=""gene"" id=""17639508-6-68-74"">CYP7B1</span> protein occurs in high-grade prostatic intraepithelial neoplasia (PIN) and <span class=""disease"" id=""17639508-6-150-165"">adenocarcinomas</span>.",CTD_human
1,0,Biomarker,C0033578,Prostatic Neoplasms,group,prostate tumors,9420,CYP7B1,CYP7B1,CTD_human,17639508,We hypothesized that CYP7B1 expression is increased in prostate tumors and that promoter methylation contributes to the regulation of CYP7B1 expression in human prostate tissue.,0.20300763924902696,"We hypothesized that <span class=""gene"" id=""17639508-3-21-27"">CYP7B1</span> expression is increased in <span class=""disease"" id=""17639508-3-55-70"">prostate tumors</span> and that promoter methylation contributes to the regulation of <span class=""gene"" id=""17639508-3-134-140"">CYP7B1</span> expression in human prostate tissue.",CTD_human
1,0,Biomarker,C0025500,Mesothelioma,disease,mesothelioma,94274,PPP1R14A,CPI-17,CTD_human,18835652,"Our hypothesis was that in human mesothelioma without detectable NF2 mutations, regulators of NF2/merlin activity such as CPI-17 would be altered.",0.2,"Our hypothesis was that in human <span class=""disease"" id=""18835652-4-33-45"">mesothelioma</span> without detectable NF2 mutations, regulators of NF2/merlin activity such as <span class=""gene"" id=""18835652-4-122-128"">CPI-17</span> would be altered.",CTD_human
1,0,Biomarker,C0001430,Adenoma,group,adenomas,9429,ABCG2,breast cancer resistance protein,CTD_human,21544799,Downregulation of breast cancer resistance protein in colon adenomas reduces cellular xenobiotic resistance and leads to accumulation of a food-derived carcinogen.,0.200274726784213,"Downregulation of <span class=""gene"" id=""21544799-0-18-50"">breast cancer resistance protein</span> in colon <span class=""disease"" id=""21544799-0-60-68"">adenomas</span> reduces cellular xenobiotic resistance and leads to accumulation of a food-derived carcinogen.",CTD_human
1,0,Biomarker,C0023892,Biliary cirrhosis,disease,biliary cirrhosis,9429,ABCG2,breast cancer resistance protein,CTD_human,15542527,Significant downregulation of the transport proteins multidrug resistance associated protein 2 and breast cancer resistance protein was observed in biliary cirrhosis.,0.2,"Significant downregulation of the transport proteins multidrug resistance associated protein 2 and <span class=""gene"" id=""15542527-6-99-131"">breast cancer resistance protein</span> was observed in <span class=""disease"" id=""15542527-6-148-165"">biliary cirrhosis</span>.",CTD_human
1,0,Biomarker,C0079744,Diffuse Large B-Cell Lymphoma,disease,diffuse large B-cell lymphoma,9429,ABCG2,ABCG2,CTD_human,21625222,ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma.,0.20350593566014002,"<span class=""gene"" id=""21625222-0-0-5"">ABCG2</span> is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in <span class=""disease"" id=""21625222-0-112-141"">diffuse large B-cell lymphoma</span>.",CTD_human
1,0,Biomarker,C1168401,Squamous cell carcinoma of the head and neck,disease,HNSCC,9429,ABCG2,ABCG2,CTD_human,25275603,"Cluster analysis however revealed that simultaneous high expression of SLC31A1, ABCC2, and ABCG2 indicates poor survival of HNSCC patients.",0.20054945356842604,"Cluster analysis however revealed that simultaneous high expression of SLC31A1, ABCC2, and <span class=""gene"" id=""25275603-8-91-96"">ABCG2</span> indicates poor survival of <span class=""disease"" id=""25275603-8-124-129"">HNSCC</span> patients.",CTD_human
1,0,Biomarker,C1961099,Precursor T-Cell Lymphoblastic Leukemia-Lymphoma,disease,T-ALL,9429,ABCG2,ABCG2,CTD_human,20019844,"Furthermore, drug selection with sulfasalazine and topotecan induced a complete demethylation of the ABCG2 promoter in the T-ALL and ovarian carcinoma model cell lines CCRF-CEM and IGROV1, respectively.",0.200274726784213,"Furthermore, drug selection with sulfasalazine and topotecan induced a complete demethylation of the <span class=""gene"" id=""20019844-5-101-106"">ABCG2</span> promoter in the <span class=""disease"" id=""20019844-5-123-128"">T-ALL</span> and ovarian carcinoma model cell lines CCRF-CEM and IGROV1, respectively.",CTD_human
2,0,Biomarker,C0019829,Hodgkin Disease,disease,Hodgkin's lymphoma,943,TNFRSF8,CD30,CTD_human,12453859,Serum levels of soluble CD30 improve International Prognostic Score in predicting the outcome of advanced Hodgkin's lymphoma.,0.236466885413756,"Serum levels of soluble <span class=""gene"" id=""12453859-0-24-28"">CD30</span> improve International Prognostic Score in predicting the outcome of advanced <span class=""disease"" id=""12453859-0-106-124"">Hodgkin's lymphoma</span>.",CTD_human
1,0,Biomarker,C0017638,Glioma,disease,gliomas,9444,QKI,QKI,CTD_human,26829751,We identified MYB-QKI fusions as a specific and single candidate driver event in angiocentric gliomas.,0.20054945356842604,"We identified MYB-<span class=""gene"" id=""26829751-3-18-21"">QKI</span> fusions as a specific and single candidate driver event in angiocentric <span class=""disease"" id=""26829751-3-94-101"">gliomas</span>.",CTD_human
1,0,Biomarker,C0024115,Lung diseases,group,lung disease,9446,GSTO1,GSTO1-1,CTD_human,22293942,"The polymorphism A140D of GSTO1-1 has been not only associated with distinct urinary profile of arsenic metabolites in populations chronically exposed to iAs in drinking water, but also with higher risk of childhood leukemia and lung disease in non-exposed populations, suggesting that GSTO1-1 involvement in other physiologic processes different from toxics metabolism could be more relevant than is thought.",0.200274726784213,"The polymorphism A140D of <span class=""gene"" id=""22293942-4-26-33"">GSTO1-1</span> has been not only associated with distinct urinary profile of arsenic metabolites in populations chronically exposed to iAs in drinking water, but also with higher risk of childhood leukemia and <span class=""disease"" id=""22293942-4-229-241"">lung disease</span> in non-exposed populations, suggesting that <span class=""gene"" id=""22293942-4-286-293"">GSTO1-1</span> involvement in other physiologic processes different from toxics metabolism could be more relevant than is thought.",CTD_human
2,2,Biomarker,C0002395,Alzheimer's Disease,disease,Alzheimer's disease,945,CD33,CD33,CTD_human,21460840,"Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease.",0.20494508211583604,"Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, <span class=""gene"" id=""21460840-0-48-52"">CD33</span> and CD2AP are associated with <span class=""disease"" id=""21460840-0-83-102"">Alzheimer's disease</span>.",CTD_human
1,1,Biomarker,C0038868,Progressive supranuclear palsy,disease,PSP,9451,EIF2AK3,EIF2AK3,CTD_human,21685912,"We found significant previously unidentified signals (P < 5 × 10(-8)) associated with PSP risk at STX6, EIF2AK3 and MOBP.",0.200274726784213,"We found significant previously unidentified signals (P &lt; 5 &times; 10(-8)) associated with <span class=""disease"" id=""21685912-5-86-89"">PSP</span> risk at STX6, <span class=""gene"" id=""21685912-5-104-111"">EIF2AK3</span> and MOBP.",CTD_human
1,0,Biomarker,C0039685,Tetralogy of Fallot,disease,TOF,9464,HAND2,HAND2,CTD_human,25093829,"We sequenced the coding, 5'UTR, and 3'UTR regions of twelve transcription factor genes implicated in cardiac outflow tract development (NKX2.5, GATA4, ISL1, TBX20, MEF2C, BOP/SMYD1, HAND2, FOXC1, FOXC2, FOXH, FOXA2 and TBX1) in 93 non-syndromic, non-Mendelian TOF cases.",0.200274726784213,"We sequenced the coding, 5'UTR, and 3'UTR regions of twelve transcription factor genes implicated in cardiac outflow tract development (NKX2.5, GATA4, ISL1, TBX20, MEF2C, BOP/SMYD1, <span class=""gene"" id=""25093829-3-182-187"">HAND2</span>, FOXC1, FOXC2, FOXH, FOXA2 and TBX1) in 93 non-syndromic, non-Mendelian <span class=""disease"" id=""25093829-3-260-263"">TOF</span> cases.",CTD_human
1,0,Biomarker,C0020538,Hypertensive disease,group,hypertension,948,CD36,Cd36,CTD_human,18587397,Identification of renal Cd36 as a determinant of blood pressure and risk for hypertension.,0.20919533021666797,"Identification of renal <span class=""gene"" id=""18587397-0-24-28"">Cd36</span> as a determinant of blood pressure and risk for <span class=""disease"" id=""18587397-0-77-89"">hypertension</span>.",CTD_human
1,0,Biomarker,C0021051,Immunologic Deficiency Syndromes,group,immunodeficiency,948,CD36,Cd36,CTD_human,15690042,Here we show that an N-ethyl-N-nitrosourea-induced nonsense mutation of Cd36 (oblivious) causes a recessive immunodeficiency phenotype in which macrophages are insensitive to the R-enantiomer of MALP-2 (a diacylated bacterial lipopeptide) and to lipoteichoic acid.,0.200274726784213,"Here we show that an N-ethyl-N-nitrosourea-induced nonsense mutation of <span class=""gene"" id=""15690042-4-72-76"">Cd36</span> (oblivious) causes a recessive <span class=""disease"" id=""15690042-4-108-124"">immunodeficiency</span> phenotype in which macrophages are insensitive to the R-enantiomer of MALP-2 (a diacylated bacterial lipopeptide) and to lipoteichoic acid.",CTD_human
1,0,Biomarker,C0271650,Impaired glucose tolerance,phenotype,glucose intolerance,948,CD36,Cd36,CTD_human,14640889,"Transgenic expression of Cd36 in the new lines was associated with significantly decreased serum fatty acids, amelioration of insulin resistance and glucose intolerance but failed to induce any consistent changes in blood pressure as measured by radiotelemetry.",0.203557092817453,"Transgenic expression of <span class=""gene"" id=""14640889-5-25-29"">Cd36</span> in the new lines was associated with significantly decreased serum fatty acids, amelioration of insulin resistance and <span class=""disease"" id=""14640889-5-149-168"">glucose intolerance</span> but failed to induce any consistent changes in blood pressure as measured by radiotelemetry.",CTD_human
1,0,Biomarker,C0016427,Follicular cyst,disease,follicular cysts,949,SCARB1,SCARB1,CTD_human,20404351,"Mice bearing null mutation of the Scarb1 gene (SCARB1(-/-)) had ovaries with small corpora lutea, large follicles with hypertrophied theca cells, and follicular cysts with blood-filled cavities.",0.2,"Mice bearing null mutation of the <span class=""gene"" id=""20404351-4-34-40"">Scarb1</span> gene (<span class=""gene"" id=""20404351-4-47-53"">SCARB1</span>(-/-)) had ovaries with small corpora lutea, large follicles with hypertrophied theca cells, and <span class=""disease"" id=""20404351-4-150-166"">follicular cysts</span> with blood-filled cavities.",CTD_human
1,0,Biomarker,C0400966,Non-alcoholic Fatty Liver Disease,disease,NAFLD,949,SCARB1,SR-BI,CTD_human,23127599,"These data indicate that the alleviative effects of Res on NAFLD are associated with up regulation of hepatic LDLr and SR-BI gene expressions, which provide new insights into the pharmacological targets of Res in the prevention of NAFLD.",0.2,"These data indicate that the alleviative effects of Res on <span class=""disease"" id=""23127599-7-59-64"">NAFLD</span> are associated with up regulation of hepatic LDLr and <span class=""gene"" id=""23127599-7-119-124"">SR-BI</span> gene expressions, which provide new insights into the pharmacological targets of Res in the prevention of <span class=""disease"" id=""23127599-7-231-236"">NAFLD</span>.",CTD_human
1,0,Biomarker,C0031117,Peripheral Neuropathy,group,peripheral neuropathy,9499,MYOT,MYOT,CTD_human,15111675,"1) Mutations in myotilin cause MFM; 2) exon 2 of MYOT is a hotspot for mutations; 3) peripheral neuropathy, cardiomyopathy, and distal weakness greater than proximal weakness are part of the spectrum of myotilinopathy; 4) not all cases of myotilinopathy have a limb-girdle phenotype; and 5) the molecular basis of the majority of MFM cases remains to be discovered.",0.40300763924902705,"1) Mutations in <span class=""gene"" id=""15111675-10-16-24"">myotilin</span> cause MFM; 2) exon 2 of <span class=""gene"" id=""15111675-10-49-53"">MYOT</span> is a hotspot for mutations; 3) <span class=""disease"" id=""15111675-10-85-106"">peripheral neuropathy</span>, cardiomyopathy, and distal weakness greater than proximal weakness are part of the spectrum of myotilinopathy; 4) not all cases of myotilinopathy have a limb-girdle phenotype; and 5) the molecular basis of the majority of MFM cases remains to be discovered.",CTD_human;HPO
1,0,Biomarker,C0878544,Cardiomyopathies,group,cardiomyopathy,9499,MYOT,MYOT,CTD_human,15111675,"1) Mutations in myotilin cause MFM; 2) exon 2 of MYOT is a hotspot for mutations; 3) peripheral neuropathy, cardiomyopathy, and distal weakness greater than proximal weakness are part of the spectrum of myotilinopathy; 4) not all cases of myotilinopathy have a limb-girdle phenotype; and 5) the molecular basis of the majority of MFM cases remains to be discovered.",0.40273291246481396,"1) Mutations in <span class=""gene"" id=""15111675-10-16-24"">myotilin</span> cause MFM; 2) exon 2 of <span class=""gene"" id=""15111675-10-49-53"">MYOT</span> is a hotspot for mutations; 3) peripheral neuropathy, <span class=""disease"" id=""15111675-10-108-122"">cardiomyopathy</span>, and distal weakness greater than proximal weakness are part of the spectrum of myotilinopathy; 4) not all cases of myotilinopathy have a limb-girdle phenotype; and 5) the molecular basis of the majority of MFM cases remains to be discovered.",CTD_human;HPO
1,3,Biomarker,C1836607,MYOTILINOPATHY,disease,myotilinopathy,9499,MYOT,MYOT,CTD_human,15111675,"1) Mutations in myotilin cause MFM; 2) exon 2 of MYOT is a hotspot for mutations; 3) peripheral neuropathy, cardiomyopathy, and distal weakness greater than proximal weakness are part of the spectrum of myotilinopathy; 4) not all cases of myotilinopathy have a limb-girdle phenotype; and 5) the molecular basis of the majority of MFM cases remains to be discovered.",0.201373633921065,"1) Mutations in <span class=""gene"" id=""15111675-10-16-24"">myotilin</span> cause MFM; 2) exon 2 of <span class=""gene"" id=""15111675-10-49-53"">MYOT</span> is a hotspot for mutations; 3) peripheral neuropathy, cardiomyopathy, and distal weakness greater than proximal weakness are part of the spectrum of <span class=""disease"" id=""15111675-10-203-217"">myotilinopathy</span>; 4) not all cases of <span class=""disease"" id=""15111675-10-239-253"">myotilinopathy</span> have a limb-girdle phenotype; and 5) the molecular basis of the majority of MFM cases remains to be discovered.",CTD_human
1,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,non-small cell lung cancer,9510,ADAMTS1,ADAMTS1,CTD_human,19027488,Aberrant methylation of ADAMTS1 in non-small cell lung cancer.,0.20054945356842604,"Aberrant methylation of <span class=""gene"" id=""19027488-0-24-31"">ADAMTS1</span> in <span class=""disease"" id=""19027488-0-35-61"">non-small cell lung cancer</span>.",CTD_human
1,0,Biomarker,C1458155,Mammary Neoplasms,group,breast tumors,9510,ADAMTS1,ADAMTS-1,CTD_human,23289900,Decreased expression of ADAMTS-1 in human breast tumors stimulates migration and invasion.,0.20054945356842604,"Decreased expression of <span class=""gene"" id=""23289900-0-24-32"">ADAMTS-1</span> in human <span class=""disease"" id=""23289900-0-42-55"">breast tumors</span> stimulates migration and invasion.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,9510,ADAMTS1,ADAMTS1,CTD_human,19514085,"17-AAG, a heat shock protein 90 (HSP-90) inhibitor, was shown to modulate the expression of several diverse cancer-associated genes, including ADAMTS1, part of the query signature, and maspin, an HSP-90-associated protein with a tumor suppressor role in HCC.",0.201098907136852,"17-AAG, a heat shock protein 90 (HSP-90) inhibitor, was shown to modulate the expression of several diverse cancer-associated genes, including <span class=""gene"" id=""19514085-9-143-150"">ADAMTS1</span>, part of the query signature, and maspin, an HSP-90-associated protein with a tumor suppressor role in <span class=""disease"" id=""19514085-9-254-257"">HCC</span>.",CTD_human
1,0,Biomarker,C0018801,Heart failure,disease,Heart Failure,9518,GDF15,growth-differentiation factor-15,CTD_human,20855664,Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial.,0.20054945356842604,"Serial measurement of <span class=""gene"" id=""20855664-0-22-54"">growth-differentiation factor-15</span> in <span class=""disease"" id=""20855664-0-58-71"">heart failure</span>: relation to disease severity and prognosis in the Valsartan <span class=""disease"" id=""20855664-0-133-146"">Heart Failure</span> Trial.",CTD_human
1,0,Biomarker,C0027627,Neoplasm Metastasis,phenotype,metastasis,9518,GDF15,GDF15,CTD_human,23996089,"Morphological effects on expression of growth differentiation factor 15 (GDF15), a marker of metastasis.",0.20274726784213098,"Morphological effects on expression of <span class=""gene"" id=""23996089-0-39-71"">growth differentiation factor 15</span> (<span class=""gene"" id=""23996089-0-73-78"">GDF15</span>), a marker of <span class=""disease"" id=""23996089-0-93-103"">metastasis</span>.",CTD_human
1,0,Biomarker,C0149721,Left Ventricular Hypertrophy,disease,left ventricular hypertrophy,9518,GDF15,growth-differentiation factor 15,CTD_human,19505289,The haplotype of the growth-differentiation factor 15 gene is associated with left ventricular hypertrophy in human essential hypertension.,0.202681755307501,"The haplotype of the <span class=""gene"" id=""19505289-0-21-53"">growth-differentiation factor 15</span> gene is associated with <span class=""disease"" id=""19505289-0-78-106"">left ventricular hypertrophy</span> in human essential hypertension.",CTD_human
1,0,Biomarker,C1956346,Coronary Artery Disease,disease,coronary artery disease,9518,GDF15,GDF-15,CTD_human,20855664,Growth-differentiation factor-15 (GDF-15) is emerging as a prognostic biomarker in patients with coronary artery disease.,0.200274726784213,"<span class=""gene"" id=""20855664-1-0-32"">Growth-differentiation factor-15</span> (<span class=""gene"" id=""20855664-1-34-40"">GDF-15</span>) is emerging as a prognostic biomarker in patients with <span class=""disease"" id=""20855664-1-97-120"">coronary artery disease</span>.",CTD_human
1,0,Biomarker,C0242387,Mandibulofacial Dysostosis,disease,TCS,9533,POLR1C,POLR1C,CTD_human,21131976,"Furthermore, we discovered mutations in both alleles of POLR1C in three individuals with TCS.",0.6013736339210661,"Furthermore, we discovered mutations in both alleles of <span class=""gene"" id=""21131976-3-56-62"">POLR1C</span> in three individuals with <span class=""disease"" id=""21131976-3-89-92"">TCS</span>.",CTD_human;HPO;ORPHANET
2,0,Biomarker,C0020295,Hydronephrosis,disease,hydronephrosis,9536,PTGES,microsomal prostaglandin E synthase-1,CTD_human,22430074,Critical role of microsomal prostaglandin E synthase-1 in the hydronephrosis caused by lactational exposure to dioxin in mice.,0.2,"Critical role of <span class=""gene"" id=""22430074-0-17-54"">microsomal prostaglandin E synthase-1</span> in the <span class=""disease"" id=""22430074-0-62-76"">hydronephrosis</span> caused by lactational exposure to dioxin in mice.",CTD_human
2,0,Biomarker,C0020295,Hydronephrosis,disease,hydronephrosis,9536,PTGES,mPGES-1,CTD_human,25015655,"Although these mouse strains possess AhR alleles tightly bound to TCDD, their difference in incidence and severity of hydronephrosis can be explained, in part, by differences in the expression of mPGES-1 and Egr-1.",0.2,"Although these mouse strains possess AhR alleles tightly bound to TCDD, their difference in incidence and severity of <span class=""disease"" id=""25015655-9-118-132"">hydronephrosis</span> can be explained, in part, by differences in the expression of <span class=""gene"" id=""25015655-9-196-203"">mPGES-1</span> and Egr-1.",CTD_human
1,0,Biomarker,C0032617,Polyuria,phenotype,polyuria,9536,PTGES,mPGES-1,CTD_human,19692487,Mice lacking mPGES-1 are resistant to lithium-induced polyuria.,0.2,"Mice lacking <span class=""gene"" id=""19692487-0-13-20"">mPGES-1</span> are resistant to lithium-induced <span class=""disease"" id=""19692487-0-54-62"">polyuria</span>.",CTD_human
1,0,Therapeutic,C0024121,Lung Neoplasms,group,lung tumor,9547,CXCL14,CXCL14,CTD_human,20562917,"Forced expression of CXCL14 in H23 cells, where this gene is silenced by methylation, increased cell death in vitro and dramatically reduced the in vivo growth of lung tumor xenografts through necrosis of up to 90% of the tumor mass.",0.200274726784213,"Forced expression of <span class=""gene"" id=""20562917-5-21-27"">CXCL14</span> in H23 cells, where this gene is silenced by methylation, increased cell death in vitro and dramatically reduced the in vivo growth of <span class=""disease"" id=""20562917-5-163-173"">lung tumor</span> xenografts through necrosis of up to 90% of the tumor mass.",CTD_human
1,0,Biomarker,C0036631,Seminoma,disease,seminoma,955,ENTPD6,ENTPD6,CTD_human,21519793,"In addition, ENTPD6 expression in seminoma was higher than that in other testicular tumors.",0.2,"In addition, <span class=""gene"" id=""21519793-6-13-19"">ENTPD6</span> expression in <span class=""disease"" id=""21519793-6-34-42"">seminoma</span> was higher than that in other testicular tumors.",CTD_human
1,1,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,T2D,9559,VPS26A,VPS26A,CTD_human,21874001,"In the combined analysis, we identified common genetic variants at six loci (GRB14, ST6GAL1, VPS26A, HMG20A, AP3S2 and HNF4A) newly associated with T2D (P = 4.1 × 10(-8) to P = 1.9 × 10(-11)).",0.200274726784213,"In the combined analysis, we identified common genetic variants at six loci (GRB14, ST6GAL1, <span class=""gene"" id=""21874001-4-93-99"">VPS26A</span>, HMG20A, AP3S2 and HNF4A) newly associated with <span class=""disease"" id=""21874001-4-148-151"">T2D</span> (P = 4.1 &times; 10(-8) to P = 1.9 &times; 10(-11)).",CTD_human
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,9568,GABBR2,GABBR2,CTD_human,19002745,"We compared levels of GABA(B) receptor subunits GABA(B) receptor 1 (GABBR1) and GABA(B) receptor 2 (GABBR2) in cerebellum, Brodmann's area 9 (BA9), and BA40 of subjects with autism and matched controls.",0.200274726784213,"We compared levels of GABA(B) receptor subunits GABA(B) receptor 1 (GABBR1) and <span class=""gene"" id=""19002745-4-80-98"">GABA(B) receptor 2</span> (<span class=""gene"" id=""19002745-4-100-106"">GABBR2</span>) in cerebellum, Brodmann's area 9 (BA9), and BA40 of subjects with <span class=""disease"" id=""19002745-4-174-180"">autism</span> and matched controls.",CTD_human
1,0,Biomarker,C1510586,Autism Spectrum Disorders,disease,autism spectrum disorders,95681,CEP41,TSGA14,CTD_human,21438139,Mutations in the TSGA14 gene in families with autism spectrum disorders.,0.200274726784213,"Mutations in the <span class=""gene"" id=""21438139-0-17-23"">TSGA14</span> gene in families with <span class=""disease"" id=""21438139-0-46-71"">autism spectrum disorders</span>.",CTD_human
1,0,Biomarker,C0175702,Williams Syndrome,disease,Williams-Beuren syndrome,9569,GTF2IRD1,GTF2IRD1,CTD_human,20007321,Negative autoregulation of GTF2IRD1 in Williams-Beuren syndrome via a novel DNA binding mechanism.,0.48576926246847496,"Negative autoregulation of <span class=""gene"" id=""20007321-0-27-35"">GTF2IRD1</span> in <span class=""disease"" id=""20007321-0-39-63"">Williams-Beuren syndrome</span> via a novel DNA binding mechanism.",CTD_human;ORPHANET
1,0,Biomarker,C0376634,Craniofacial Abnormalities,group,craniofacial abnormalities,9569,GTF2IRD1,Gtf2ird1,CTD_human,20007321,Mice with mutations of the Gtf2ird1 allele show evidence of craniofacial abnormalities and behavioral changes.,0.200274726784213,"Mice with mutations of the <span class=""gene"" id=""20007321-5-27-35"">Gtf2ird1</span> allele show evidence of <span class=""disease"" id=""20007321-5-60-86"">craniofacial abnormalities</span> and behavioral changes.",CTD_human
3,2,Biomarker,C0003873,Rheumatoid Arthritis,disease,rheumatoid arthritis,958,CD40,CD40,CTD_human,18794853,Common variants at CD40 and other loci confer risk of rheumatoid arthritis.,0.235854826199409,"Common variants at <span class=""gene"" id=""18794853-0-19-23"">CD40</span> and other loci confer risk of <span class=""disease"" id=""18794853-0-54-74"">rheumatoid arthritis</span>.",CTD_human
2,0,Biomarker,C0026691,Mucocutaneous Lymph Node Syndrome,disease,Kawasaki disease,958,CD40,CD40,CTD_human,22446961,"We report two new loci, one at BLK (encoding B-lymphoid tyrosine kinase) and one at CD40, that are associated with Kawasaki disease at genome-wide significance (P < 5 × 10(-8)).",0.20350593566014002,"We report two new loci, one at BLK (encoding B-lymphoid tyrosine kinase) and one at <span class=""gene"" id=""22446961-2-84-88"">CD40</span>, that are associated with <span class=""disease"" id=""22446961-2-115-131"">Kawasaki disease</span> at genome-wide significance (P &lt; 5 &times; 10(-8)).",CTD_human
1,0,Biomarker,C0038220,Status Epilepticus,disease,status epilepticus,958,CD40,CD40,CTD_human,18455351,"Peroxisome proliferator-activated receptor gamma agonist, rosiglitazone, suppresses CD40 expression and attenuates inflammatory responses after lithium pilocarpine-induced status epilepticus in rats.",0.2,"Peroxisome proliferator-activated receptor gamma agonist, rosiglitazone, suppresses <span class=""gene"" id=""18455351-0-84-88"">CD40</span> expression and attenuates inflammatory responses after lithium pilocarpine-induced <span class=""disease"" id=""18455351-0-172-190"">status epilepticus</span> in rats.",CTD_human
2,0,Biomarker,C0005695,Bladder Neoplasm,disease,bladder cancer,9582,APOBEC3B,APOBEC3B,CTD_human,27643540,"In vitro, APOBEC3B expression was predominantly induced by treatment with a DNA-damaging drug in bladder cancer cell lines, and APOBEC3A expression was induced as part of the antiviral interferon-stimulated response in breast cancer cell lines.",0.2,"In vitro, <span class=""gene"" id=""27643540-5-10-18"">APOBEC3B</span> expression was predominantly induced by treatment with a DNA-damaging drug in <span class=""disease"" id=""27643540-5-97-111"">bladder cancer</span> cell lines, and APOBEC3A expression was induced as part of the antiviral interferon-stimulated response in breast cancer cell lines.",CTD_human
1,0,Biomarker,C0152013,Adenocarcinoma of lung (disorder),disease,lung (adenocarcinoma,9582,APOBEC3B,APOBEC3B,CTD_human,23852168,"Notably, APOBEC3B is upregulated, and its preferred target sequence is frequently mutated and clustered in at least six distinct cancers: bladder, cervix, lung (adenocarcinoma and squamous cell carcinoma), head and neck, and breast.",0.200274726784213,"Notably, <span class=""gene"" id=""23852168-5-9-17"">APOBEC3B</span> is upregulated, and its preferred target sequence is frequently mutated and clustered in at least six distinct cancers: bladder, cervix, <span class=""disease"" id=""23852168-5-155-175"">lung (adenocarcinoma</span> and squamous cell carcinoma), head and neck, and breast.",CTD_human
4,0,Biomarker,C1458155,Mammary Neoplasms,group,breast tumours,9582,APOBEC3B,APOBEC3B,CTD_human,23389445,APOBEC3B messenger RNA is upregulated in most primary breast tumours and breast cancer cell lines.,0.200274726784213,"<span class=""gene"" id=""23389445-4-0-8"">APOBEC3B</span> messenger RNA is upregulated in most primary <span class=""disease"" id=""23389445-4-54-68"">breast tumours</span> and breast cancer cell lines.",CTD_human
4,0,Biomarker,C1458155,Mammary Neoplasms,group,breast tumors,9582,APOBEC3B,APOBEC3B,CTD_human,27643540,"In contrast, a 30-kb deletion that eliminates APOBEC3B and creates an APOBEC3A-APOBEC3B chimera was not important in bladder cancer, whereas it was associated with breast cancer risk and enrichment with APOBEC-signature mutations in breast tumors.",0.200274726784213,"In contrast, a 30-kb deletion that eliminates <span class=""gene"" id=""27643540-4-46-54"">APOBEC3B</span> and creates an APOBEC3A-<span class=""gene"" id=""27643540-4-79-87"">APOBEC3B</span> chimera was not important in bladder cancer, whereas it was associated with breast cancer risk and enrichment with APOBEC-signature mutations in <span class=""disease"" id=""27643540-4-233-246"">breast tumors</span>.",CTD_human
1,0,Biomarker,C0013080,Down Syndrome,disease,DS,9588,PRDX6,antioxidant protein 2,CTD_human,11771762,"By contrast, a significant reduction was observed in levels of glutathione synthetase (P < 0.01), glutathione-S-transferase mu2 (P < 0.01), glutathione-S-transferase p (P < 0.05), antioxidant protein 2 (P < 0.05), thioredoxin peroxidase-I (P < 0.05) and thioredoxin peroxidase-II (P < 0.01) in DS compared with controls.",0.202732912464814,"By contrast, a significant reduction was observed in levels of glutathione synthetase (P &lt; 0.01), glutathione-S-transferase mu2 (P &lt; 0.01), glutathione-S-transferase p (P &lt; 0.05), <span class=""gene"" id=""11771762-9-180-201"">antioxidant protein 2</span> (P &lt; 0.05), thioredoxin peroxidase-I (P &lt; 0.05) and thioredoxin peroxidase-II (P &lt; 0.01) in <span class=""disease"" id=""11771762-9-294-296"">DS</span> compared with controls.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,9588,PRDX6,peroxiredoxin 6,CTD_human,21472284,"These identified proteins, which include stratifin (14-3-3), transgelin 2, heat-shock protein (HSP)70, HSP27, manganese superoxide dismutase, prohibitin, DJ1, ?-enolase, peroxiredoxin 6, aldo-keto reductase family member B10, phosphoglycerate kinase 1, ?-1-antitrypsin and nm23-H1, may play a role in the development of HCC.",0.2,"These identified proteins, which include stratifin (14-3-3), transgelin 2, heat-shock protein (HSP)70, HSP27, manganese superoxide dismutase, prohibitin, DJ1, &alpha;-enolase, <span class=""gene"" id=""21472284-9-170-185"">peroxiredoxin 6</span>, aldo-keto reductase family member B10, phosphoglycerate kinase 1, &alpha;-1-antitrypsin and nm23-H1, may play a role in the development of <span class=""disease"" id=""21472284-9-320-323"">HCC</span>.",CTD_human
1,0,Therapeutic,C0002736,Amyotrophic Lateral Sclerosis,disease,ALS,959,CD40LG,CD40L,CTD_human,20348957,"A therapy using a monoclonal antibody to CD40L was developed that slows weight loss, delays paralysis and extends survival in an ALS mouse model.",0.200274726784213,"A therapy using a monoclonal antibody to <span class=""gene"" id=""20348957-4-41-46"">CD40L</span> was developed that slows weight loss, delays paralysis and extends survival in an <span class=""disease"" id=""20348957-4-129-132"">ALS</span> mouse model.",CTD_human
1,0,Biomarker,C0004364,Autoimmune Diseases,group,autoimmunity,959,CD40LG,CD40L,CTD_human,15494542,Absence of CTLA-4 expression in CD40L-/- mice suggests that signaling via both CD28 and CD40L is important for T cell activation and subsequent autoimmunity in mHgIA.,0.20795272136486298,"Absence of CTLA-4 expression in <span class=""gene"" id=""15494542-9-32-37"">CD40L</span>-/- mice suggests that signaling via both CD28 and <span class=""gene"" id=""15494542-9-88-93"">CD40L</span> is important for T cell activation and subsequent <span class=""disease"" id=""15494542-9-144-156"">autoimmunity</span> in mHgIA.",CTD_human
1,0,Biomarker,C1956346,Coronary Artery Disease,disease,coronary artery disease,959,CD40LG,CD40 ligand,CTD_human,16368305,"Effect of atorvastatin on circulating proinflammatory T-lymphocyte subsets and soluble CD40 ligand in patients with stable coronary artery disease--a randomized, placebo-controlled study.",0.28601527849805397,"Effect of atorvastatin on circulating proinflammatory T-lymphocyte subsets and soluble <span class=""gene"" id=""16368305-0-87-98"">CD40 ligand</span> in patients with stable <span class=""disease"" id=""16368305-0-123-146"">coronary artery disease</span>--a randomized, placebo-controlled study.",CTD_human
2,0,Biomarker,C0023487,Acute Promyelocytic Leukemia,disease,acute promyelocytic leukemia,960,CD44,CD44,CTD_human,16208414,CD44 ligation induces apoptosis via caspase- and serine protease-dependent pathways in acute promyelocytic leukemia cells.,0.20300763924902696,"<span class=""gene"" id=""16208414-0-0-4"">CD44</span> ligation induces apoptosis via caspase- and serine protease-dependent pathways in <span class=""disease"" id=""16208414-0-87-115"">acute promyelocytic leukemia</span> cells.",CTD_human
2,0,Therapeutic,C0023487,Acute Promyelocytic Leukemia,disease,acute promyelocytic leukemia,960,CD44,CD44,CTD_human,16208414,CD44 ligation induces apoptosis via caspase- and serine protease-dependent pathways in acute promyelocytic leukemia cells.,0.20300763924902696,"<span class=""gene"" id=""16208414-0-0-4"">CD44</span> ligation induces apoptosis via caspase- and serine protease-dependent pathways in <span class=""disease"" id=""16208414-0-87-115"">acute promyelocytic leukemia</span> cells.",CTD_human
1,0,Biomarker,C0003469,Anxiety Disorders,group,anxiety,9607,CARTPT,Cocaine- and amphetamine-regulated transcript,CTD_human,12600694,Cocaine- and amphetamine-regulated transcript peptide produces anxiety-like behavior in rodents.,0.201098907136852,"<span class=""gene"" id=""12600694-0-0-45"">Cocaine- and amphetamine-regulated transcript</span> peptide produces <span class=""disease"" id=""12600694-0-63-70"">anxiety</span>-like behavior in rodents.",CTD_human
1,0,Therapeutic,C0020429,Hyperalgesia,phenotype,hyperalgesia,9607,CARTPT,cocaine- and amphetamine-regulated transcript,CTD_human,21167239,Evidence for the participation of cocaine- and amphetamine-regulated transcript peptide (CART) in the fluoxetine-induced anti-hyperalgesia in neuropathic rats.,0.2,"Evidence for the participation of <span class=""gene"" id=""21167239-0-34-79"">cocaine- and amphetamine-regulated transcript</span> peptide (CART) in the fluoxetine-induced anti-<span class=""disease"" id=""21167239-0-126-138"">hyperalgesia</span> in neuropathic rats.",CTD_human
1,0,Biomarker,C0020550,Hyperthyroidism,disease,hyperthyroidism,9607,CARTPT,cocaine- and amphetamine-regulated transcript,CTD_human,12395121,"These data indicate that the increments in food intake in hyperthyroidism could be mediated, at least in some extent, by a decreased expression, at the paraventricular nucleus of the hypothalamus, of the anorexigenic cocaine- and amphetamine-regulated transcript peptides.",0.2,"These data indicate that the increments in food intake in <span class=""disease"" id=""12395121-6-58-73"">hyperthyroidism</span> could be mediated, at least in some extent, by a decreased expression, at the paraventricular nucleus of the hypothalamus, of the anorexigenic <span class=""gene"" id=""12395121-6-217-262"">cocaine- and amphetamine-regulated transcript</span> peptides.",CTD_human
1,0,Biomarker,C0022661,"Kidney Failure, Chronic",disease,CRF,9619,ABCG1,ABCG-1,CTD_human,19878707,"CRF resulted in hypertension, proteinuria, renal tissue lipid accumulation, up-regulation of scavenger receptor A1 (SR-A1), acyl-CoA cholesterol acyltransferase-1 (ACAT1), carbohydrate-responsive element binding protein (ChREBP), fatty acid synthase (FAS), acyl-CoA carboxylase (ACC), liver X receptor (LXR), ATP binding cassette (ABC) A-1, ABCG-1, and SR-B1 and down-regulation of sterol responsive element binding protein-1 (SREBP-1), SREBP-2, HMG-CoA reductase, PPAR-alpha, fatty acid binding protein (L-FABP), and CPT1A.",0.2,"<span class=""disease"" id=""19878707-5-0-3"">CRF</span> resulted in hypertension, proteinuria, renal tissue lipid accumulation, up-regulation of scavenger receptor A1 (SR-A1), acyl-CoA cholesterol acyltransferase-1 (ACAT1), carbohydrate-responsive element binding protein (ChREBP), fatty acid synthase (FAS), acyl-CoA carboxylase (ACC), liver X receptor (LXR), ATP binding cassette (ABC) A-1, <span class=""gene"" id=""19878707-5-341-347"">ABCG-1</span>, and SR-B1 and down-regulation of sterol responsive element binding protein-1 (SREBP-1), SREBP-2, HMG-CoA reductase, PPAR-alpha, fatty acid binding protein (L-FABP), and CPT1A.",CTD_human
1,0,Biomarker,C1847114,"SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 5",disease,"Cerebellar Ataxia with Mental retardation, Optic atrophy and Skin abnormalities",9640,ZNF592,CAMOS,CTD_human,20531441,"CAMOS (Cerebellar Ataxia with Mental retardation, Optic atrophy and Skin abnormalities) is a rare autosomal recessive syndrome characterized by a nonprogressive congenital cerebellar ataxia associated with mental retardation, optic atrophy, and skin abnormalities.",0.200274726784213,"<span class=""gene"" id=""20531441-1-0-5"">CAMOS</span> (<span class=""disease"" id=""20531441-1-7-86"">Cerebellar Ataxia with Mental retardation, Optic atrophy and Skin abnormalities</span>) is a rare autosomal recessive syndrome characterized by a nonprogressive congenital cerebellar ataxia associated with mental retardation, optic atrophy, and skin abnormalities.",CTD_human
2,3,Biomarker,C0026769,Multiple Sclerosis,disease,MS,965,CD58,CD58,CTD_human,19525955,"We also replicated several known MS associations (HLA-DR15, P = 7.0 x 10(-184); CD58, P = 9.6 x 10(-8); EVI5-RPL5, P = 2.5 x 10(-6); IL2RA, P = 7.4 x 10(-6); CLEC16A, P = 1.1 x 10(-4); IL7R, P = 1.3 x 10(-3); TYK2, P = 3.5 x 10(-3)) and observed a statistical interaction between SNPs in EVI5-RPL5 and HLA-DR15 (P = 0.001).",0.23218106369001298,"We also replicated several known <span class=""disease"" id=""19525955-5-33-35"">MS</span> associations (HLA-DR15, P = 7.0 x 10(-184); <span class=""gene"" id=""19525955-5-80-84"">CD58</span>, P = 9.6 x 10(-8); EVI5-RPL5, P = 2.5 x 10(-6); IL2RA, P = 7.4 x 10(-6); CLEC16A, P = 1.1 x 10(-4); IL7R, P = 1.3 x 10(-3); TYK2, P = 3.5 x 10(-3)) and observed a statistical interaction between SNPs in EVI5-RPL5 and HLA-DR15 (P = 0.001).",CTD_human
1,0,Biomarker,C0079774,Peripheral T-Cell Lymphoma,disease,PTCL,965,CD58,CD58,CTD_human,24413734,"In addition, we describe new and recurrent, albeit less frequent, genetic defects including mutations in FYN, ATM, B2M and CD58 implicating SRC signaling, impaired DNA damage response and escape from immune surveillance mechanisms in the pathogenesis of PTCL.",0.200274726784213,"In addition, we describe new and recurrent, albeit less frequent, genetic defects including mutations in FYN, ATM, B2M and <span class=""gene"" id=""24413734-5-123-127"">CD58</span> implicating SRC signaling, impaired DNA damage response and escape from immune surveillance mechanisms in the pathogenesis of <span class=""disease"" id=""24413734-5-254-258"">PTCL</span>.",CTD_human
1,0,Biomarker,C0022661,"Kidney Failure, Chronic",disease,ESRD,968,CD68,CD68,CTD_human,19539174,Increased infiltration of subcutaneous and visceral adipose tissue with CD68-positive immunocompetent cells was found in the ESRD group by histologic examination.,0.200274726784213,"Increased infiltration of subcutaneous and visceral adipose tissue with <span class=""gene"" id=""19539174-11-72-76"">CD68</span>-positive immunocompetent cells was found in the <span class=""disease"" id=""19539174-11-125-129"">ESRD</span> group by histologic examination.",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,hepatocellular carcinoma,9681,DEPDC5,DEPDC5,CTD_human,21725309,Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers.,0.201648360705279,"Variation in the <span class=""gene"" id=""21725309-0-17-23"">DEPDC5</span> locus is associated with progression to <span class=""disease"" id=""21725309-0-64-88"">hepatocellular carcinoma</span> in chronic hepatitis C virus carriers.",CTD_human
1,1,Biomarker,C0014175,Endometriosis,disease,endometriosis,9687,GREB1,GREB1,CTD_human,23104006,"In addition, we establish an association of rs13394619 in GREB1 at 2p25.1 with endometriosis and identify a newly associated locus at 12q22 near VEZT (rs10859871).",0.201098907136852,"In addition, we establish an association of rs13394619 in <span class=""gene"" id=""23104006-3-58-63"">GREB1</span> at 2p25.1 with <span class=""disease"" id=""23104006-3-79-92"">endometriosis</span> and identify a newly associated locus at 12q22 near VEZT (rs10859871).",CTD_human
1,0,Therapeutic,C0003864,Arthritis,disease,arthritis,969,CD69,CD69,CTD_human,12882836,CD69-null mice protected from arthritis induced with anti-type II collagen antibodies.,0.20082418035263896,"<span class=""gene"" id=""12882836-0-0-4"">CD69</span>-null mice protected from <span class=""disease"" id=""12882836-0-30-39"">arthritis</span> induced with anti-type II collagen antibodies.",CTD_human
1,0,Biomarker,C1850343,MOSAIC VARIEGATED ANEUPLOIDY SYNDROME,disease,mosaic variegated aneuploidy syndrome,9702,CEP57,CEP57,CTD_human,21552266,Mutations in CEP57 cause mosaic variegated aneuploidy syndrome.,0.400549453568426,"Mutations in <span class=""gene"" id=""21552266-0-13-18"">CEP57</span> cause <span class=""disease"" id=""21552266-0-25-62"">mosaic variegated aneuploidy syndrome</span>.",CTD_human;ORPHANET
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,9732,DOCK4,DOCK4,CTD_human,19401682,High-density SNP association study and copy number variation analysis of the AUTS1 and AUTS5 loci implicate the IMMP2L-DOCK4 gene region in autism susceptibility.,0.206187690967642,"High-density SNP association study and copy number variation analysis of the AUTS1 and AUTS5 loci implicate the IMMP2L-<span class=""gene"" id=""19401682-0-119-124"">DOCK4</span> gene region in <span class=""disease"" id=""19401682-0-140-146"">autism</span> susceptibility.",CTD_human
1,2,Biomarker,C0038454,Cerebrovascular accident,group,stroke,9734,HDAC9,histone deacetylase 9,CTD_human,22306652,"We identified a new association for large vessel stroke within HDAC9 (encoding histone deacetylase 9) on chromosome 7p21.1 (including further replication in an additional 735 affected individuals and 28,583 controls) (rs11984041; combined P = 1.87 × 10(-11); odds ratio (OR) = 1.42, 95% confidence interval (CI) = 1.28-1.57).",0.203296721410557,"We identified a new association for large vessel <span class=""disease"" id=""22306652-5-49-55"">stroke</span> within <span class=""gene"" id=""22306652-5-63-68"">HDAC9</span> (encoding <span class=""gene"" id=""22306652-5-79-100"">histone deacetylase 9</span>) on chromosome 7p21.1 (including further replication in an additional 735 affected individuals and 28,583 controls) (rs11984041; combined P = 1.87 &times; 10(-11); odds ratio (OR) = 1.42, 95% confidence interval (CI) = 1.28-1.57).",CTD_human
1,0,Biomarker,C0038013,Ankylosing spondylitis,disease,ankylosing spondylitis,9755,TBKBP1,TBKBP1,CTD_human,21743469,"Here we report the identification of three variants in the RUNX3, LTBR-TNFRSF1A and IL12B regions convincingly associated with ankylosing spondylitis (P < 5 × 10(-8) in the combined discovery and replication datasets) and a further four loci at PTGER4, TBKBP1, ANTXR2 and CARD9 that show strong association across all our datasets (P < 5 × 10(-6) overall, with support in each of the three datasets studied).",0.20082418035263896,"Here we report the identification of three variants in the RUNX3, LTBR-TNFRSF1A and IL12B regions convincingly associated with <span class=""disease"" id=""21743469-2-127-149"">ankylosing spondylitis</span> (P &lt; 5 &times; 10(-8) in the combined discovery and replication datasets) and a further four loci at PTGER4, <span class=""gene"" id=""21743469-2-253-259"">TBKBP1</span>, ANTXR2 and CARD9 that show strong association across all our datasets (P &lt; 5 &times; 10(-6) overall, with support in each of the three datasets studied).",CTD_human
1,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,9757,KMT2B,MLL4,CTD_human,22634754,"We also identified recurrent HBV integration events (in ? 4 HCCs) that were validated by RNA sequencing (RNA-seq) and Sanger sequencing at the known and putative cancer-related TERT, MLL4 and CCNE1 genes, which showed upregulated gene expression in tumor versus normal tissue.",0.201648360705279,"We also identified recurrent HBV integration events (in &ge; 4 <span class=""disease"" id=""22634754-5-60-63"">HCC</span>s) that were validated by RNA sequencing (RNA-seq) and Sanger sequencing at the known and putative cancer-related TERT, <span class=""gene"" id=""22634754-5-183-187"">MLL4</span> and CCNE1 genes, which showed upregulated gene expression in tumor versus normal tissue.",CTD_human
1,0,Biomarker,C0005695,Bladder Neoplasm,disease,bladder cancer,9759,HDAC4,HDAC4,CTD_human,21507255,The results of our immunohistochemistry (IHC) staining studies further revealed a strong correlation between the over-expression of HDAC4 and increased bladder cancer occurrence (p < 0.001) as well as a marginal significance of increasing incidence of HDAC4 positivity seen with an increase in severity of bladder cancer (p = 0.08).,0.200274726784213,"The results of our immunohistochemistry (IHC) staining studies further revealed a strong correlation between the over-expression of <span class=""gene"" id=""21507255-9-132-137"">HDAC4</span> and increased <span class=""disease"" id=""21507255-9-152-166"">bladder cancer</span> occurrence (p &lt; 0.001) as well as a marginal significance of increasing incidence of <span class=""gene"" id=""21507255-9-252-257"">HDAC4</span> positivity seen with an increase in severity of <span class=""disease"" id=""21507255-9-306-320"">bladder cancer</span> (p = 0.08).",CTD_human
1,0,Biomarker,C0221357,Brachydactyly,disease,brachydactyly,9759,HDAC4,HDAC4,CTD_human,20691407,"Haploinsufficiency of HDAC4 causes brachydactyly mental retardation syndrome, with brachydactyly type E, developmental delays, and behavioral problems.",0.4010989071368521,"Haploinsufficiency of <span class=""gene"" id=""20691407-0-22-27"">HDAC4</span> causes brachydactyly mental retardation syndrome, with <span class=""disease"" id=""20691407-0-83-96"">brachydactyly</span> type E, developmental delays, and behavioral problems.",CTD_human;HPO
1,0,Biomarker,C2931817,Chromosome 2q37 deletion syndrome,disease,brachydactyly mental retardation syndrome,9759,HDAC4,HDAC4,CTD_human,20691407,"Haploinsufficiency of HDAC4 causes brachydactyly mental retardation syndrome, with brachydactyly type E, developmental delays, and behavioral problems.",0.401923087489492,"Haploinsufficiency of <span class=""gene"" id=""20691407-0-22-27"">HDAC4</span> causes <span class=""disease"" id=""20691407-0-35-76"">brachydactyly mental retardation syndrome</span>, with brachydactyly type E, developmental delays, and behavioral problems.",CTD_human;ORPHANET
1,0,Biomarker,C0152427,Polydactyly,disease,polydactyly,9786,KIAA0586,talpid(3,CTD_human,15554946,"Limb polydactyly in talpid(3) suggests a gain of Hedgehog (Hh) signaling, whereas, paradoxically, absence of midline facial structures suggests a loss of Hh function.",0.200274726784213,"Limb <span class=""disease"" id=""15554946-2-5-16"">polydactyly</span> in <span class=""gene"" id=""15554946-2-20-28"">talpid(3</span>) suggests a gain of Hedgehog (Hh) signaling, whereas, paradoxically, absence of midline facial structures suggests a loss of Hh function.",CTD_human
1,0,Biomarker,C0376634,Craniofacial Abnormalities,group,craniofacial abnormalities,9786,KIAA0586,talpid(3,CTD_human,15554946,The talpid(3) chicken mutant has a pleiotropic phenotype including polydactyly and craniofacial abnormalities.,0.2,"The <span class=""gene"" id=""15554946-1-4-12"">talpid(3</span>) chicken mutant has a pleiotropic phenotype including polydactyly and <span class=""disease"" id=""15554946-1-83-109"">craniofacial abnormalities</span>.",CTD_human
1,3,Biomarker,C0432269,Lenz Majewski hyperostotic dwarfism,disease,Lenz-Majewski syndrome,9791,PTDSS1,PTDSS1,CTD_human,24241535,Gain-of-function mutations in the phosphatidylserine synthase 1 (PTDSS1) gene cause Lenz-Majewski syndrome.,0.600549453568426,"Gain-of-function mutations in the <span class=""gene"" id=""24241535-0-34-63"">phosphatidylserine synthase 1</span> (<span class=""gene"" id=""24241535-0-65-71"">PTDSS1</span>) gene cause <span class=""disease"" id=""24241535-0-84-106"">Lenz-Majewski syndrome</span>.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0007131,Non-Small Cell Lung Carcinoma,disease,non-small-cell lung carcinoma,9817,KEAP1,KEAP1,CTD_human,22684020,Regulatory role of KEAP1 and NRF2 in PPAR? expression and chemoresistance in human non-small-cell lung carcinoma cells.,0.203846174978983,"Regulatory role of <span class=""gene"" id=""22684020-0-19-24"">KEAP1</span> and NRF2 in PPAR&gamma; expression and chemoresistance in human <span class=""disease"" id=""22684020-0-83-112"">non-small-cell lung carcinoma</span> cells.",CTD_human
1,0,Biomarker,C0079744,Diffuse Large B-Cell Lymphoma,disease,diffuse large B-cell lymphoma,983,CDK1,cdk1,CTD_human,19223503,Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy.,0.20054945356842604,"Phospho-p70S6K/p85S6K and <span class=""gene"" id=""19223503-0-26-30"">cdc2</span>/<span class=""gene"" id=""19223503-0-31-35"">cdk1</span> are novel targets for <span class=""disease"" id=""19223503-0-58-87"">diffuse large B-cell lymphoma</span> combination therapy.",CTD_human
5,83,Biomarker,C1856113,Mowat-Wilson syndrome,disease,Mowat-Wilson syndrome,9839,ZEB2,Zfhx1b,CTD_human,17478475,Neural crest-specific removal of Zfhx1b in mouse leads to a wide range of neurocristopathies reminiscent of Mowat-Wilson syndrome.,0.489340710663245,"Neural crest-specific removal of <span class=""gene"" id=""17478475-0-33-39"">Zfhx1b</span> in mouse leads to a wide range of neurocristopathies reminiscent of <span class=""disease"" id=""17478475-0-108-129"">Mowat-Wilson syndrome</span>.",CTD_human;UNIPROT
5,83,Biomarker,C1856113,Mowat-Wilson syndrome,disease,"Mowat-Wilson"" syndrome",9839,ZEB2,ZFHX1B,CTD_human,15006694,"Pleiotropic and diverse expression of ZFHX1B gene transcripts during mouse and human development supports the various clinical manifestations of the ""Mowat-Wilson"" syndrome.",0.489340710663245,"Pleiotropic and diverse expression of <span class=""gene"" id=""15006694-0-38-44"">ZFHX1B</span> gene transcripts during mouse and human development supports the various clinical manifestations of the ""<span class=""disease"" id=""15006694-0-150-172"">Mowat-Wilson"" syndrome</span>.",CTD_human;UNIPROT
1,0,Biomarker,C0004352,Autistic Disorder,disease,autism,9855,FARP2,FARP2,CTD_human,19365831,"FARP2, HDLBP and PASK are downregulated in a patient with autism and 2q37.3 deletion syndrome.",0.200274726784213,"<span class=""gene"" id=""19365831-0-0-5"">FARP2</span>, HDLBP and PASK are downregulated in a patient with <span class=""disease"" id=""19365831-0-58-64"">autism</span> and 2q37.3 deletion syndrome.",CTD_human
1,1,Biomarker,C0023434,Chronic Lymphocytic Leukemia,disease,CLL,9855,FARP2,FARP2,CTD_human,20062064,"We identified four new risk loci for CLL at 2q37.3 (rs757978, FARP2; odds ratio (OR) = 1.39; P = 2.11 x 10(-9)), 8q24.21 (rs2456449; OR = 1.26; P = 7.84 x 10(-10)), 15q21.3 (rs7169431; OR = 1.36; P = 4.74 x 10(-7)) and 16q24.1 (rs305061; OR = 1.22; P = 3.60 x 10(-7)).",0.200274726784213,"We identified four new risk loci for <span class=""disease"" id=""20062064-2-37-40"">CLL</span> at 2q37.3 (rs757978, <span class=""gene"" id=""20062064-2-62-67"">FARP2</span>; odds ratio (OR) = 1.39; P = 2.11 x 10(-9)), 8q24.21 (rs2456449; OR = 1.26; P = 7.84 x 10(-10)), 15q21.3 (rs7169431; OR = 1.36; P = 4.74 x 10(-7)) and 16q24.1 (rs305061; OR = 1.22; P = 3.60 x 10(-7)).",CTD_human
1,1,Biomarker,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",disease,T2D,9861,PSMD6,PSMD6,CTD_human,22158537,"The combined analysis identified eight new T2D loci reaching genome-wide significance, which mapped in or near GLIS3, PEPD, FITM2-R3HDML-HNF4A, KCNK16, MAEA, GCC1-PAX4, PSMD6 and ZFAND3.",0.200274726784213,"The combined analysis identified eight new <span class=""disease"" id=""22158537-3-43-46"">T2D</span> loci reaching genome-wide significance, which mapped in or near GLIS3, PEPD, FITM2-R3HDML-HNF4A, KCNK16, MAEA, GCC1-PAX4, <span class=""gene"" id=""22158537-3-169-174"">PSMD6</span> and ZFAND3.",CTD_human
3,1,Biomarker,C0036341,Schizophrenia,disease,SZ,9863,MAGI2,MAGI-2,CTD_human,25653350,"One of the rare CNVs found in SZ cohorts is the duplication of Synaptic Scaffolding Molecule (S-SCAM, also called MAGI-2), which encodes a postsynaptic scaffolding protein controlling synaptic AMPA receptor levels, and thus the strength of excitatory synaptic transmission.",0.48109890713685205,"One of the rare CNVs found in <span class=""disease"" id=""25653350-3-30-32"">SZ</span> cohorts is the duplication of Synaptic Scaffolding Molecule (S-SCAM, also called <span class=""gene"" id=""25653350-3-114-120"">MAGI-2</span>), which encodes a postsynaptic scaffolding protein controlling synaptic AMPA receptor levels, and thus the strength of excitatory synaptic transmission.",CTD_human;PSYGENET
1,0,Biomarker,C0025202,melanoma,disease,melanoma,9869,SETDB1,SETDB1,CTD_human,21983785,"The associated variants at the 1q21.3 locus span a region with ten genes, and plausible candidate genes for melanoma susceptibility include ARNT and SETDB1.",0.20082418035263896,"The associated variants at the 1q21.3 locus span a region with ten genes, and plausible candidate genes for <span class=""disease"" id=""21983785-6-108-116"">melanoma</span> susceptibility include ARNT and <span class=""gene"" id=""21983785-6-149-155"">SETDB1</span>.",CTD_human
1,0,Biomarker,C0026764,Multiple Myeloma,disease,Multiple Myeloma,9891,NUAK1,ARK5,CTD_human,26873845,Dual Targeting of CDK4 and ARK5 Using a Novel Kinase Inhibitor ON123300 Exerts Potent Anticancer Activity against Multiple Myeloma.,0.200274726784213,"Dual Targeting of CDK4 and <span class=""gene"" id=""26873845-0-27-31"">ARK5</span> Using a Novel Kinase Inhibitor ON123300 Exerts Potent Anticancer Activity against <span class=""disease"" id=""26873845-0-114-130"">Multiple Myeloma</span>.",CTD_human
1,0,Biomarker,C0037771,"Paraparesis, Spastic",phenotype,spastic paraparesis,9895,TECPR2,TECPR2,CTD_human,23176824,Mutation in TECPR2 reveals a role for autophagy in hereditary spastic paraparesis.,0.200274726784213,"Mutation in <span class=""gene"" id=""23176824-0-12-18"">TECPR2</span> reveals a role for autophagy in hereditary <span class=""disease"" id=""23176824-0-62-81"">spastic paraparesis</span>.",CTD_human
1,0,Biomarker,C0338473,Neuroaxonal Dystrophies,group,Neuroaxonal Dystrophy,9895,TECPR2,TECPR2,CTD_human,26555167,TECPR2 Associated Neuroaxonal Dystrophy in Spanish Water Dogs.,0.200274726784213,"<span class=""gene"" id=""26555167-0-0-6"">TECPR2</span> Associated <span class=""disease"" id=""26555167-0-18-39"">Neuroaxonal Dystrophy</span> in Spanish Water Dogs.",CTD_human
1,0,Biomarker,C0007959,Charcot-Marie-Tooth Disease,disease,Charcot-Marie-Tooth,9896,FIG4,CMT4J,CTD_human,17572665,This novel form of autosomal recessive Charcot-Marie-Tooth disorder is designated CMT4J.,0.202472541057918,"This novel form of autosomal recessive <span class=""disease"" id=""17572665-11-39-58"">Charcot-Marie-Tooth</span> disorder is designated <span class=""gene"" id=""17572665-11-82-87"">CMT4J</span>.",CTD_human
1,0,Biomarker,C0022658,Kidney Diseases,group,nephropathy,9899,SV2B,SV2B,CTD_human,16943307,"The mRNA expression of SV2B clearly is altered not only in PAN nephropathy but also in another proteinuric state that is caused by an antibody against nephrin, a functional molecule of the slit diaphragm.",0.200274726784213,"The mRNA expression of <span class=""gene"" id=""16943307-6-23-27"">SV2B</span> clearly is altered not only in PAN <span class=""disease"" id=""16943307-6-63-74"">nephropathy</span> but also in another proteinuric state that is caused by an antibody against nephrin, a functional molecule of the slit diaphragm.",CTD_human
1,0,Biomarker,C3714756,Intellectual Disability,group,mental retardation,9901,SRGAP3,MEGAP,CTD_human,21082655,"Selected genes that are present in the hemizygous state and which might be important for the phenotype of this patient as regards the congenital heart defect, autistic behavior and mental retardation (CAV3, OXTR, and SRGAP3/MEGAP, respectively) are discussed in context of the clinical features.",0.204930726738519,"Selected genes that are present in the hemizygous state and which might be important for the phenotype of this patient as regards the congenital heart defect, autistic behavior and <span class=""disease"" id=""21082655-6-181-199"">mental retardation</span> (CAV3, OXTR, and <span class=""gene"" id=""21082655-6-217-223"">SRGAP3</span>/<span class=""gene"" id=""21082655-6-224-229"">MEGAP</span>, respectively) are discussed in context of the clinical features.",CTD_human
1,0,Biomarker,C0008924,Cleft Lip,disease,cleft lip,9935,MAFB,MAFB,CTD_human,20436469,A genome-wide association study of cleft lip with and without cleft palate identifies risk variants near MAFB and ABCA4.,0.202681755307501,"A genome-wide association study of <span class=""disease"" id=""20436469-0-35-44"">cleft lip</span> with and without cleft palate identifies risk variants near <span class=""gene"" id=""20436469-0-105-109"">MAFB</span> and ABCA4.",CTD_human
1,4,Biomarker,C0175703,Thrombocytopenia-Absent Radius Syndrome,disease,TAR syndrome,9939,RBM8A,RBM8A,CTD_human,22366785,Compound inheritance of a low-frequency regulatory SNP and a rare null mutation in exon-junction complex subunit RBM8A causes TAR syndrome.,0.40137363392106606,"Compound inheritance of a low-frequency regulatory SNP and a rare null mutation in exon-junction complex subunit <span class=""gene"" id=""22366785-0-113-118"">RBM8A</span> causes <span class=""disease"" id=""22366785-0-126-138"">TAR syndrome</span>.",CTD_human;ORPHANET
1,0,Biomarker,C0008370,Cholestasis,disease,cholestasis,9962,SLC23A2,SVCT2,CTD_human,18706437,"When cholestasis was induced in pregnant rats, BVR alpha, SVCT1 and SVCT2 expression in maternal and fetal livers was stimulated, and this was further enhanced by UDCA treatment.",0.200274726784213,"When <span class=""disease"" id=""18706437-10-5-16"">cholestasis</span> was induced in pregnant rats, BVR alpha, SVCT1 and <span class=""gene"" id=""18706437-10-68-73"">SVCT2</span> expression in maternal and fetal livers was stimulated, and this was further enhanced by UDCA treatment.",CTD_human
1,0,Biomarker,C0008370,Cholestasis,disease,cholestasis,9963,SLC23A1,SVCT1,CTD_human,18706437,"When cholestasis was induced in pregnant rats, BVR alpha, SVCT1 and SVCT2 expression in maternal and fetal livers was stimulated, and this was further enhanced by UDCA treatment.",0.2,"When <span class=""disease"" id=""18706437-10-5-16"">cholestasis</span> was induced in pregnant rats, BVR alpha, <span class=""gene"" id=""18706437-10-58-63"">SVCT1</span> and SVCT2 expression in maternal and fetal livers was stimulated, and this was further enhanced by UDCA treatment.",CTD_human
1,0,Biomarker,C0010701,Phyllodes Tumor,disease,phyllodes tumors,9968,MED12,MED12,CTD_human,26437033,"First, we frequently observed MED12 and RARA mutations in both fibroadenomas and phyllodes tumors, emphasizing the importance of these mutations in fibroepithelial tumorigenesis.",0.20357144819477,"First, we frequently observed <span class=""gene"" id=""26437033-4-30-35"">MED12</span> and RARA mutations in both fibroadenomas and <span class=""disease"" id=""26437033-4-81-97"">phyllodes tumors</span>, emphasizing the importance of these mutations in fibroepithelial tumorigenesis.",CTD_human
2,0,Biomarker,C0206650,Fibroadenoma,disease,fibroadenomas,9968,MED12,MED12,CTD_human,26437033,"First, we frequently observed MED12 and RARA mutations in both fibroadenomas and phyllodes tumors, emphasizing the importance of these mutations in fibroepithelial tumorigenesis.",0.202197814273705,"First, we frequently observed <span class=""gene"" id=""26437033-4-30-35"">MED12</span> and RARA mutations in both <span class=""disease"" id=""26437033-4-63-76"">fibroadenomas</span> and phyllodes tumors, emphasizing the importance of these mutations in fibroepithelial tumorigenesis.",CTD_human
2,0,Biomarker,C0206650,Fibroadenoma,disease,fibroadenoma,9968,MED12,MED12,CTD_human,25038752,Exome sequencing identifies highly recurrent MED12 somatic mutations in breast fibroadenoma.,0.202197814273705,"Exome sequencing identifies highly recurrent <span class=""gene"" id=""25038752-0-45-50"">MED12</span> somatic mutations in breast <span class=""disease"" id=""25038752-0-79-91"">fibroadenoma</span>.",CTD_human
1,8,Biomarker,C0220769,FG syndrome,disease,Opitz-Kaveggia syndrome,9968,MED12,MED12,CTD_human,17334363,A recurrent mutation in MED12 leading to R961W causes Opitz-Kaveggia syndrome.,0.603296721410557,"A recurrent mutation in <span class=""gene"" id=""17334363-0-24-29"">MED12</span> leading to R961W causes <span class=""disease"" id=""17334363-0-54-77"">Opitz-Kaveggia syndrome</span>.",CTD_human;ORPHANET;UNIPROT
1,0,Biomarker,C0011849,Diabetes Mellitus,group,diabetes,9970,NR1I3,CAR,CTD_human,20869355,"CAR and PXR are involved in the development of certain diseases, including diabetes, metabolic syndrome and obesity.",0.2,"<span class=""gene"" id=""20869355-2-0-3"">CAR</span> and PXR are involved in the development of certain diseases, including <span class=""disease"" id=""20869355-2-75-83"">diabetes</span>, metabolic syndrome and obesity.",CTD_human
4,0,Biomarker,C0023903,Liver neoplasms,group,hepatic tumors,9970,NR1I3,CAR,CTD_human,22293087,"Hepatic cytochrome p450 (Cyp) 2b10 mRNA induction and increased Cyp2b10 enzyme activity signify activation of hepatic nuclear receptor constitutive androstane receptor (CAR), a widely established promoter of rodent-specific hepatic tumors.",0.20082418035263896,"Hepatic cytochrome p450 (Cyp) 2b10 mRNA induction and increased Cyp2b10 enzyme activity signify activation of hepatic nuclear receptor <span class=""gene"" id=""22293087-4-135-167"">constitutive androstane receptor</span> (<span class=""gene"" id=""22293087-4-169-172"">CAR</span>), a widely established promoter of rodent-specific <span class=""disease"" id=""22293087-4-224-238"">hepatic tumors</span>.",CTD_human
4,0,Biomarker,C0023903,Liver neoplasms,group,liver tumors,9970,NR1I3,CAR,CTD_human,24449422,Phenobarbital (PB) is a prototypical nongenotoxic carcinogen that activates the constitutive androstane receptor (CAR) resulting in rodent liver tumors.,0.20082418035263896,"Phenobarbital (PB) is a prototypical nongenotoxic carcinogen that activates the <span class=""gene"" id=""24449422-2-80-112"">constitutive androstane receptor</span> (<span class=""gene"" id=""24449422-2-114-117"">CAR</span>) resulting in rodent <span class=""disease"" id=""24449422-2-139-151"">liver tumors</span>.",CTD_human
1,0,Biomarker,C0028754,Obesity,disease,obesity,9970,NR1I3,CAR,CTD_human,20869355,"CAR and PXR are involved in the development of certain diseases, including diabetes, metabolic syndrome and obesity.",0.20054945356842604,"<span class=""gene"" id=""20869355-2-0-3"">CAR</span> and PXR are involved in the development of certain diseases, including diabetes, metabolic syndrome and <span class=""disease"" id=""20869355-2-108-115"">obesity</span>.",CTD_human
1,0,Biomarker,C0524620,Metabolic Syndrome X,disease,metabolic syndrome,9970,NR1I3,CAR,CTD_human,20869355,"CAR and PXR are involved in the development of certain diseases, including diabetes, metabolic syndrome and obesity.",0.2,"<span class=""gene"" id=""20869355-2-0-3"">CAR</span> and PXR are involved in the development of certain diseases, including diabetes, <span class=""disease"" id=""20869355-2-85-103"">metabolic syndrome</span> and obesity.",CTD_human
2,0,Biomarker,C0008370,Cholestasis,disease,cholestasis,9971,NR1H4,FXR,CTD_human,23178280,"FXR deficiency in mice results in cholestasis, metabolic disorders, and tumorigenesis in liver and intestine.",0.206029633875371,"<span class=""gene"" id=""23178280-2-0-3"">FXR</span> deficiency in mice results in <span class=""disease"" id=""23178280-2-34-45"">cholestasis</span>, metabolic disorders, and tumorigenesis in liver and intestine.",CTD_human
1,0,Biomarker,C0010346,Crohn Disease,disease,Crohn's disease,9971,NR1H4,FXR,CTD_human,21829567,"Mesenteric adipose tissue from rodent colitis and Crohn's disease is metabolically active and shows inflammation-driven regulation of PPAR?, FXR and leptin.",0.201098907136852,"Mesenteric adipose tissue from rodent colitis and <span class=""disease"" id=""21829567-11-50-65"">Crohn's disease</span> is metabolically active and shows inflammation-driven regulation of PPAR&gamma;, <span class=""gene"" id=""21829567-11-141-144"">FXR</span> and leptin.",CTD_human
3,0,Biomarker,C0023903,Liver neoplasms,group,liver tumors,9971,NR1H4,FXR,CTD_human,24091600,"FXR is essential in maintaining bile acid (BA) homeostasis, and FXR(-/-) mice develop cholestasis, inflammation, and spontaneous liver tumors.",0.202197814273705,"<span class=""gene"" id=""24091600-2-0-3"">FXR</span> is essential in maintaining bile acid (BA) homeostasis, and <span class=""gene"" id=""24091600-2-64-67"">FXR</span>(-/-) mice develop cholestasis, inflammation, and spontaneous <span class=""disease"" id=""24091600-2-129-141"">liver tumors</span>.",CTD_human
3,0,Biomarker,C0023903,Liver neoplasms,group,liver tumor,9971,NR1H4,FXR,CTD_human,24189133,"In conclusion, BAs suppress autophagic flux in hepatocytes by impairing autophagosomal-lysosomal fusion, which may be implicated in bile acid-induced liver tumor promotion observed in FXR KO mice.",0.202197814273705,"In conclusion, BAs suppress autophagic flux in hepatocytes by impairing autophagosomal-lysosomal fusion, which may be implicated in bile acid-induced <span class=""disease"" id=""24189133-8-150-161"">liver tumor</span> promotion observed in <span class=""gene"" id=""24189133-8-184-187"">FXR</span> KO mice.",CTD_human
2,0,Biomarker,C2239176,Liver carcinoma,disease,HCC,9971,NR1H4,FXR,CTD_human,23811326,"In conclusion, SHP partially protects FXR(-/-) mice from HCC formation by reducing tumor malignancy.",0.28412090176319704,"In conclusion, SHP partially protects <span class=""gene"" id=""23811326-9-38-41"">FXR</span>(-/-) mice from <span class=""disease"" id=""23811326-9-57-60"">HCC</span> formation by reducing tumor malignancy.",CTD_human
1,0,Biomarker,C0019693,HIV Infections,group,HIV,998,CDC42,cdc42,CTD_human,15308739,"Notable among them were cdc42 and lyn, which were downregulated and are required for HIV Nef binding and viral replication.",0.202956482091714,"Notable among them were <span class=""gene"" id=""15308739-10-24-29"">cdc42</span> and lyn, which were downregulated and are required for <span class=""disease"" id=""15308739-10-85-88"">HIV</span> Nef binding and viral replication.",CTD_human
1,0,Biomarker,C0025202,melanoma,disease,melanoma,9985,REC8,REC8L1,CTD_human,16778180,"CGIs in putative promoter regions of 34 genes (ABHD9, BARHL1, CLIC5, CNNM1, COL2A1, CPT1C, DDIT4L, DERL3, DHRS3, DPYS, EFEMP2, FAM62C, FAM78A, FLJ33790, GBX2, GPR10, GPRASP1, HOXA9, HOXD11, HOXD12, HOXD13, p14ARF, PAX6, PRDX2, PTPRG, RASD1, RAX, REC8L1, SLC27A3, TGFB2, TLX2, TMEM22, TMEM30B, and UNC5C) were found to be methylated in at least 1 of 13 melanoma cell lines but not in two cultured normal melanocytes.",0.2,"CGIs in putative promoter regions of 34 genes (ABHD9, BARHL1, CLIC5, CNNM1, COL2A1, CPT1C, DDIT4L, DERL3, DHRS3, DPYS, EFEMP2, FAM62C, FAM78A, FLJ33790, GBX2, GPR10, GPRASP1, HOXA9, HOXD11, HOXD12, HOXD13, p14ARF, PAX6, PRDX2, PTPRG, RASD1, RAX, <span class=""gene"" id=""16778180-3-246-252"">REC8L1</span>, SLC27A3, TGFB2, TLX2, TMEM22, TMEM30B, and UNC5C) were found to be methylated in at least 1 of 13 <span class=""disease"" id=""16778180-3-352-360"">melanoma</span> cell lines but not in two cultured normal melanocytes.",CTD_human
2,0,Biomarker,C0005695,Bladder Neoplasm,disease,bladder cancer,999,CDH1,CDH1,CTD_human,26901067,Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer.,0.21307830697564697,"Frequent somatic <span class=""gene"" id=""26901067-0-17-21"">CDH1</span> loss-of-function mutations in plasmacytoid variant <span class=""disease"" id=""26901067-0-73-87"">bladder cancer</span>.",CTD_human
1,0,Biomarker,C0009324,Ulcerative Colitis,disease,ulcerative colitis,999,CDH1,CDH1,CTD_human,19915572,"Of note, CDH1 has recently been associated with susceptibility to colorectal cancer, an established complication of longstanding ulcerative colitis.",0.20274726784213098,"Of note, <span class=""gene"" id=""19915572-5-9-13"">CDH1</span> has recently been associated with susceptibility to colorectal cancer, an established complication of longstanding <span class=""disease"" id=""19915572-5-129-147"">ulcerative colitis</span>.",CTD_human
2,0,Biomarker,C2931456,"Prostate cancer, familial",disease,hereditary prostate cancer,999,CDH1,CDH1,CTD_human,14961571,Our data indicate that the -160 single nucleotide polymorphism in CDH1 is a low-penetrant prostate cancer susceptibility gene that might explain a proportion of familial and notably hereditary prostate cancer.,0.200274726784213,"Our data indicate that the -160 single nucleotide polymorphism in <span class=""gene"" id=""14961571-8-66-70"">CDH1</span> is a low-penetrant prostate cancer susceptibility gene that might explain a proportion of familial and notably <span class=""disease"" id=""14961571-8-182-208"">hereditary prostate cancer</span>.",CTD_human
1,0,Biomarker,C0004238,Atrial Fibrillation,disease,atrial fibrillation,9992,KCNE2,KCNE2,CTD_human,15368194,Identification of a KCNE2 gain-of-function mutation in patients with familial atrial fibrillation.,0.40355709281745294,"Identification of a <span class=""gene"" id=""15368194-0-20-25"">KCNE2</span> gain-of-function mutation in patients with familial <span class=""disease"" id=""15368194-0-78-97"">atrial fibrillation</span>.",CTD_human;HPO
3,2,Biomarker,C0023976,Long QT Syndrome,disease,LQTS,9992,KCNE2,MiRP1,CTD_human,10984545,We conclude that allelic variants of MiRP1 contribute to a significant fraction of cases of drug-induced LQTS through multiple mechanisms and that common sequence variations that increase the risk of life-threatening drug reactions can be clinically silent before drug exposure.,0.233410995896125,"We conclude that allelic variants of <span class=""gene"" id=""10984545-5-37-42"">MiRP1</span> contribute to a significant fraction of cases of drug-induced <span class=""disease"" id=""10984545-5-105-109"">LQTS</span> through multiple mechanisms and that common sequence variations that increase the risk of life-threatening drug reactions can be clinically silent before drug exposure.",CTD_human
3,2,Biomarker,C0023976,Long QT Syndrome,disease,long QT syndrome,9992,KCNE2,MiRP1,CTD_human,10219239,Three missense mutations associated with long QT syndrome and ventricular fibrillation are identified in the gene for MiRP1.,0.233410995896125,"Three missense mutations associated with <span class=""disease"" id=""10219239-4-41-57"">long QT syndrome</span> and ventricular fibrillation are identified in the gene for <span class=""gene"" id=""10219239-4-118-123"">MiRP1</span>.",CTD_human
1,0,Biomarker,C0042510,Ventricular Fibrillation,disease,ventricular fibrillation,9992,KCNE2,MiRP1,CTD_human,10219239,Three missense mutations associated with long QT syndrome and ventricular fibrillation are identified in the gene for MiRP1.,0.40027472678421294,"Three missense mutations associated with long QT syndrome and <span class=""disease"" id=""10219239-4-62-86"">ventricular fibrillation</span> are identified in the gene for <span class=""gene"" id=""10219239-4-118-123"">MiRP1</span>.",CTD_human;HPO
1,0,Biomarker,C0036341,Schizophrenia,disease,schizophrenia,9993,DGCR2,DGCR2,CTD_human,21822266,"We identified 40 de novo mutations in 27 cases affecting 40 genes, including a potentially disruptive mutation in DGCR2, a gene located in the schizophrenia-predisposing 22q11.2 microdeletion region.",0.208096423079816,"We identified 40 de novo mutations in 27 cases affecting 40 genes, including a potentially disruptive mutation in <span class=""gene"" id=""21822266-3-114-119"">DGCR2</span>, a gene located in the <span class=""disease"" id=""21822266-3-143-156"">schizophrenia</span>-predisposing 22q11.2 microdeletion region.",CTD_human
2,0,Biomarker,C0007194,Hypertrophic Cardiomyopathy,disease,hypertrophic cardiomyopathy,9997,SCO2,Sco2,CTD_human,14970747,Reversion of hypertrophic cardiomyopathy in a patient with deficiency of the mitochondrial copper binding protein Sco2: is there a potential effect of copper?,0.40793836598754496,"Reversion of <span class=""disease"" id=""14970747-0-13-40"">hypertrophic cardiomyopathy</span> in a patient with deficiency of the mitochondrial copper binding protein <span class=""gene"" id=""14970747-0-114-118"">Sco2</span>: is there a potential effect of copper?",CTD_human;HPO
2,1,Biomarker,C0268237,Cytochrome-c Oxidase Deficiency,disease,COX-deficiency,9997,SCO2,SCO2,CTD_human,11027508,"Recently, we and others have shown that mutations in SCO2 are associated with a lethal infantile hypertrophic cardiomyopathy (HCMP) with COX-deficiency.",0.288502174933289,"Recently, we and others have shown that mutations in <span class=""gene"" id=""11027508-2-53-57"">SCO2</span> are associated with a lethal infantile hypertrophic cardiomyopathy (HCMP) with <span class=""disease"" id=""11027508-2-137-151"">COX-deficiency</span>.",CTD_human
2,1,Biomarker,C0268237,Cytochrome-c Oxidase Deficiency,disease,COX deficiency,9997,SCO2,SCO2,CTD_human,16326995,Marked prevalence of two nuclear DNA mutations (845-846delCT in the SURF1 gene and 1541G>A in the SCO2 gene) associated with COX deficiency in a Slavonic population suggests the existence of regional differences in the genetic basis of COX deficiency.,0.288502174933289,"Marked prevalence of two nuclear DNA mutations (845-846delCT in the SURF1 gene and 1541G&gt;A in the <span class=""gene"" id=""16326995-10-98-102"">SCO2</span> gene) associated with <span class=""disease"" id=""16326995-10-125-139"">COX deficiency</span> in a Slavonic population suggests the existence of regional differences in the genetic basis of <span class=""disease"" id=""16326995-10-236-250"">COX deficiency</span>.",CTD_human
1,0,Biomarker,C0878544,Cardiomyopathies,group,cardiomyopathy,9997,SCO2,SCO2,CTD_human,16326995,Mutations in a mitochondrial copper-binding protein (SCO2) gene were found in nine children with encephalomyopathy and/or cardiomyopathy; all of them were homozygotes or heterozygotes for 1541G>A mutation.,0.202197814273705,"Mutations in a mitochondrial copper-binding protein (<span class=""gene"" id=""16326995-7-53-57"">SCO2</span>) gene were found in nine children with encephalomyopathy and/or <span class=""disease"" id=""16326995-7-122-136"">cardiomyopathy</span>; all of them were homozygotes or heterozygotes for 1541G&gt;A mutation.",CTD_human
